>HUM10001# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HPLC eluted self peptides/cytotoxicity/competitive as./direct bind.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HIV reverse transcriptase (460-485)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1MN,POL_HV1ND,POL_HV1BR,POL_HV1B1,# & POL_HV1MA,POL_HV1B5,POL_HV1Y2,POL_HV1N5,POL_HV1EL,# & POL_HV1JR,POL_HV1H2,POL_HV1PV,POL_HV1OY,POL_HV1RH)# & PIR1: (GNLJND,B44001,GNVWVL,GNVWH3,GNVWLV)# & PIR2: (S54378,B47175)# ANCHOR POSITIONS: 2,9# REFERENCES: tsomides91a,rammensee93a,ruppert93a,tanigaki94a,del_guercio95a,# & rammensee95a,sette94a,fruci93a,pogue95a,theobald95a,barouch95a,# & van_der_burg95a,van_der_burg96a,diehl96a,hivdb97a,goulder97a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM10002# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC, cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV reverse transcriptase (460-485)# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1PV,POL_HV1H2,POL_HV1EL,POL_HV1JR,# & POL_HV1B1,POL_HV1N5,POL_HV1OY,POL_HV1Y2,POL_HV1MN,# & POL_HV1Z2,POL_HV1BR,POL_HV1ND,POL_HV1MA,POL_HV1B5)# & PIR1: (GNVWLV,GNLJND,GNVWVL,GNVWH3,B44001)# & PIR2: (B47175,S54378)# REFERENCES: tsomides91a,kageyama95a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,EILKEPVHGV*# SEQUENCE: EILKEPVHGV*# ...# >HUM10003# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC, cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV reverse transcriptase (460-485)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1Y2,POL_HV1EL,POL_HV1MA,POL_HV1B5,# & POL_HV1RH,POL_HV1OY,POL_HV1N5,POL_HV1Z2,POL_HV1BR,# & POL_HV1ND,POL_HV1B1,POL_HV1JR,POL_HV1H2,POL_HV1PV)# & PIR1: (B44001,GNLJND,GNVWH3,GNVWVL,GNVWLV)# & PIR2: (S54378,B47175)# REFERENCES: tsomides91a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,LKEPVHGV*# SEQUENCE: LKEPVHGV*# ...# >HUM10004# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC, cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV reverse transcriptase (460-485)# DB REFERENCE: SWISS: (POL_HV1ND,POL_HV1BR,POL_HV1OY,POL_HV1N5,POL_HV1MA,# & POL_HV1B5,POL_HV1Z2,POL_HV1B1,POL_HV1Y2,POL_HV1EL,# & POL_HV1MN,POL_HV1RH,POL_HV1H2,POL_HV1PV,POL_HV1JR)# & PIR1: (GNVWLV,GNVWVL,B44001,GNVWH3,GNLJND)# & PIR2: (B47175,S54378)# REFERENCES: tsomides91a,kageyama95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ILKEPVHGVY*# SEQUENCE: ILKEPVHGVY*# ...# >HUM10005# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: elution/cytotoxicity as./direct bind./Stabilization/Half-time# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Influenza matrix protein (58-66)# DB REFERENCE: SWISS: (VMT1_IAUDO,VMT1_IAPUE,VMT1_IAUSS,VMT1_IAWIL,VMT1_IALE1,# & VMT1_IALE2,VMT1_IACKB,VMT1_IAZI1,VMT1_IAANN,VMT1_IABAN,# & VMT1_IAMAN,VMT1_IAFOW)# & PIR1: (MFIV1K,MFIV61,MFIV,MFIVWS,JN0392,MFIV1M,MFIVC)# & PIR2: (S04050,S07429,S14616,S04056,S04058,S04054,S04052)# ANCHOR POSITIONS: 2,9# REFERENCES: falk91a,bednarek91a,gotch88a,parker92a,nijman93a,tanigaki94a,# & rammensee95a,falk94b,sette94a,fruci93a,rivoltini95b,barouch95a,# & van_der_burg95a,van_der_burg96a,engelhard96a,rivoltini96a,# & van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM10006# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGFLGFVFTLTV*# SEQUENCE: KGFLGFVFTLTV*# ...# >HUM10007# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,KGKLGFVFTLTV*# SEQUENCE: KGKLGFVFTLTV*# ...# >HUM10008# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KGALGFVFTLTV*# SEQUENCE: KGALGFVFTLTV*# ...# >HUM10009# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,KGYLGFVFTLTV*# SEQUENCE: KGYLGFVFTLTV*# ...# >HUM1000A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGELGFVFTLTV*# SEQUENCE: KGELGFVFTLTV*# ...# >HUM1000B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGISGFVFTLTV*# SEQUENCE: KGISGFVFTLTV*# ...# >HUM1000C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGINGFVFTLTV*# SEQUENCE: KGINGFVFTLTV*# ...# >HUM1000D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,KGITGFVFTLTV*# SEQUENCE: KGITGFVFTLTV*# ...# >HUM1000E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KGILGIVFTLTV*# SEQUENCE: KGILGIVFTLTV*# ...# >HUM1000F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGVVFTLTV*# SEQUENCE: KGILGVVFTLTV*# ...# >HUM10010# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KGILGYVFTLTV*# SEQUENCE: KGILGYVFTLTV*# ...# >HUM10011# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE:Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGDVFTLTV*# SEQUENCE: KGILGDVFTLTV*# ...# >HUM10012# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,KGILGFRFTLTV*# SEQUENCE: KGILGFRFTLTV*# ...# >HUM10013# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGFVNTLTV*# SEQUENCE: KGILGFVNTLTV*# ...# >HUM10014# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,KGILGFVITLTV*# SEQUENCE: KGILGFVITLTV*# ...# >HUM10015# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGFVSTLTV*# SEQUENCE: KGILGFVSTLTV*# ...# >HUM10016# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,KGILGFVYTLTV*# SEQUENCE: KGILGFVYTLTV*# ...# >HUM10017# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding/cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a,frelinger90a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,KGILGFVFKLTV*# SEQUENCE: KGILGFVFKLTV*# ...# >HUM10018# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGFVFGLTV*# SEQUENCE: KGILGFVFGLTV*# ...# >HUM10019# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGFVFTSTV*# SEQUENCE: KGILGFVFTSTV*# ...# >HUM1001A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGFVFTFTV*# SEQUENCE: KGILGFVFTFTV*# ...# >HUM1001B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGFVFTRTV*# SEQUENCE: KGILGFVFTRTV*# ...# >HUM1001C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KGILGFVFTETV*# SEQUENCE: KGILGFVFTETV*# ...# >HUM1001D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KGILGFVFTLDV*# SEQUENCE: KGILGFVFTLDV*# ...# >HUM1001E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KGILGFVFTLAV*# SEQUENCE: KGILGFVFTLAV*# ...# >HUM1001F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KGILGFVFTLTK*# SEQUENCE: KGILGFVFTLTK*# ...# >HUM10020# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,RGILGFVFTLTV*# SEQUENCE: RGILGFVFTLTV*# ...# >HUM10021# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GGILGFVFTLTV*# SEQUENCE: GGILGFVFTLTV*# ...# >HUM10022# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,EGILGFVFTLTV*# SEQUENCE: EGILGFVFTLTV*# ...# >HUM10023# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,HGILGFVFTLTV*# SEQUENCE: HGILGFVFTLTV*# ...# >HUM10024# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,FGILGFVFTLTV*# SEQUENCE: FGILGFVFTLTV*# ...# >HUM10025# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KAILGFVFTLTV*# SEQUENCE: KAILGFVFTLTV*# ...# >HUM10026# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KSILGFVFTLTV*# SEQUENCE: KSILGFVFTLTV*# ...# >HUM10027# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KDILGFVFTLTV*# SEQUENCE: KDILGFVFTLTV*# ...# >HUM10028# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KKILGFVFTLTV*# SEQUENCE: KKILGFVFTLTV*# ...# >HUM10029# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KEILGFVFTLTV*# SEQUENCE: KEILGFVFTLTV*# ...# >HUM1002A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KQILGFVFTLTV*# SEQUENCE: KQILGFVFTLTV*# ...# >HUM1002B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KLILGFVFTLTV*# SEQUENCE: KLILGFVFTLTV*# ...# >HUM1002C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (57-68) homologue# ANCHOR POSITIONS: 4,10# REFERENCES: gotch88a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KFILGFVFTLTV*# SEQUENCE: KFILGFVFTLTV*# ...# >HUM1002D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Influenza matrix protein (58-68)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IAANN,VMT1_IAUSS,VMT1_IABAN,VMT1_IAWIL,# & VMT1_IALE1,VMT1_IACKB,VMT1_IAFOW,VMT1_IAUDO,VMT1_IAMAN,# & VMT1_IAPUE,VMT1_IAZI1)# & PIR1: (JN0392,MFIVWS,MFIV,MFIV61,MFIV1K,MFIV1M,MFIVC)# & PIR2: (S04056,S04054,S04052,S07429,S14616,S04050,S04058)# REFERENCES: bednarek91a,bodmer89a,parker92a,garboczi92a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,GILGFVFTLTV*# SEQUENCE: GILGFVFTLTV*# ...# >HUM1002E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Influenza matrix protein (58-65)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IAZI1,VMT1_IAFOW,VMT1_IALE1,VMT1_IAMAN,# & VMT1_IAPUE,VMT1_IAUSS,VMT1_IAWIL,VMT1_IAUDO,VMT1_IACKB,# & VMT1_IABAN,VMT1_IAANN)# & PIR1: (MFIV61,JN0392,MFIV1M,MFIVC,MFIV1K,MFIV,MFIVWS)# & PIR2: (S14616,S04054,S04050,S07429,S04058,S04056,S04052)# REFERENCES: bednarek91a,parker92a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,GILGFVFT*# SEQUENCE: GILGFVFT*# ...# >HUM1002F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Influenza matrix protein (58-67)# DB REFERENCE: SWISS: (VMT1_IAANN,VMT1_IAUDO,VMT1_IAWIL,VMT1_IACKB,VMT1_IAUSS,# & VMT1_IAPUE,VMT1_IALE2,VMT1_IAZI1,VMT1_IAFOW,VMT1_IALE1,# & VMT1_IABAN,VMT1_IAMAN)# & PIR1: (JN0392,MFIV,MFIV61,MFIVC,MFIV1M,MFIVWS,MFIV1K)# & PIR2: (S04050,S04058,S07429,S04052,S04056,S14616,S04054)# REFERENCES: bednarek91a,parker92a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesm,GILGFVFTLT*# SEQUENCE: GILGFVFTLT*# ...# >HUM10030# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./binding as./HLA assembly# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Influenza matrix protein (59-67)# DB REFERENCE: SWISS: (VMT1_IAFOW,VMT1_IAUDO,VMT1_IAANN,VMT1_IABAN,VMT1_IAMAN,# & VMT1_IAUSS,VMT1_IAPUE,VMT1_IACKB,VMT1_IAWIL,VMT1_IAZI1,# & VMT1_IALE2,VMT1_IALE1)# & PIR1: (MFIV1K,JN0392,MFIV61,MFIVC,MFIV,MFIVWS,MFIV1M)# & PIR2: (S14616,S04052,S04056,S07429,S04050,S04054,S04058)# REFERENCES: bednarek91a,connan94a,parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actyesm,bindyesh,ILGFVFTLT*# SEQUENCE: ILGFVFTLT*# ...# >HUM10031# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct binding/cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Influenza matrix protein (59-68)# DB REFERENCE: SWISS: (VMT1_IABAN,VMT1_IAPUE,VMT1_IAUSS,VMT1_IACKB,VMT1_IAZI1,# & VMT1_IAANN,VMT1_IAMAN,VMT1_IAWIL,VMT1_IALE1,VMT1_IALE2,# & VMT1_IAFOW,VMT1_IAUDO)# & PIR1: (MFIV1M,MFIV1K,MFIVC,JN0392,MFIVWS,MFIV,MFIV61)# & PIR2: (S04050,S04054,S14616,S04058,S07429,S04052,S04056)# REFERENCES: bednarek91a,bodmer89a,connan94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesm,ILGFVFTLTV*# SEQUENCE: ILGFVFTLTV*# ...# >HUM10032# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a,chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SIPSGGIGV*# SEQUENCE: SIPSGGIGV*# ...# >HUM10033# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted sef peptides/competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human IP 30 signal peptide# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708,S21727)# REFERENCES: rammensee93a,hunt92a,henderson92a,wei92a,chen94a,sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,LLDVPTAAV*# SEQUENCE: LLDVPTAAV*# ...# >HUM10034# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands/competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a,chen94a# COMMENT: Position 2 (I or L), position 6 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesm,GIVPFIVSV*# SEQUENCE: GIVPFIVSV*# ...# >HUM10035# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a,chen94a# COMMENT: Position 2 (I or L), position 6 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesm,GIVPFLVSV*# SEQUENCE: GIVPFLVSV*# ...# >HUM10036# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a,chen94a# COMMENT: Position 2 (I or L), position 6 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesm,GLVPFIVSV*# SEQUENCE: GLVPFIVSV*# ...# >HUM10037# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands/eluted self peptides# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (IMA2_HUMAN,IMO1_HUMAN)# & PIR2: (A56516)# REFERENCES: rammensee93a,hunt92a,chen94a,sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GLVPFLVSV*# SEQUENCE: GLVPFLVSV*# ...# >HUM10038# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides/competitive binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P 61, regulatory subunit of protein phospatase 2A (389-397)# DB REFERENCE: SWISS: (2AAB_PIG,2AAA_PEA,2AAA_HUMAN,2AAA_PIG,2AAB_HUMAN,# & 2AAA_DROME)# & PIR2: (S43776,D34541,S40171,S72499,A34541,S69215,B34541,C34541,# & A43767,S51809,I51631,S51807,S51808,A36180)# REFERENCES: rammensee93a,hunt92a,chen94a,sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,SLLPAIVEL*# SEQUENCE: SLLPAIVEL*# ...# >HUM10039# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT:Position 2 (I or L), position 3 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,SIIVRALEV*# SEQUENCE: SIIVRALEV*# ...# >HUM1003A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT:Position 2 (I or L), position 3 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,SLIVRALEV*# SEQUENCE: SLIVRALEV*# ...# >HUM1003B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT:Position 2 (I or L), position 3 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,SILVRALEV*# SEQUENCE: SILVRALEV*# ...# >HUM1003C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Position 2 (I or L), position 3 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,SLLVRALEV*# SEQUENCE: SLLVRALEV*# ...# >HUM1003D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVIII*# SEQUENCE: KINEPVIII*# ...# >HUM1003E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVIIL*# SEQUENCE: KINEPVIIL*# ...# >HUM1003F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVILI*# SEQUENCE: KINEPVILI*# ...# >HUM10040# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVILL*# SEQUENCE: KINEPVILL*# ...# >HUM10041# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVLII*# SEQUENCE: KINEPVLII*# ...# >HUM10042# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVLIL*# SEQUENCE: KINEPVLIL*# ...# >HUM10043# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVLLI*# SEQUENCE: KINEPVLLI*# ...# >HUM10044# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVLLL*# SEQUENCE: KINEPVLLL*# ...# >HUM10045# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVIII*# SEQUENCE: KLNEPVIII*# ...# >HUM10046# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVIIL*# SEQUENCE: KLNEPVIIL*# ...# >HUM10047# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVILI*# SEQUENCE: KLNEPVILI*# ...# >HUM10048# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVILL*# SEQUENCE: KLNEPVILL*# ...# >HUM10049# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVLII*# SEQUENCE: KLNEPVLII*# ...# >HUM1004A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVLIL*# SEQUENCE: KLNEPVLIL*# ...# >HUM1004B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVLLI*# SEQUENCE: KLNEPVLLI*# ...# >HUM1004C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee93a,hunt92a# COMMENT: Pos 2 (I or L), pos 7 (I or L), pos 8 (I or L), pos 9 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVLLL*# SEQUENCE: KLNEPVLLL*# ...# >HUM1004D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human nuclear p68, ATP# DB REFERENCE: SWISS: (P68_HUMAN,P68_MOUSE,P68_HUMAN)# & PIR2: (I48385,JC1087)# REFERENCES: rammensee93a,hunt92a,chen94a,sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YLLPAIVHI*# SEQUENCE: YLLPAIVHI*# ...# >HUM1004E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands/eluted self peptides# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TIS-21, B-cell transloc. gene I protein (103-111)# DB REFERENCE: SWISS: (BTG1_RAT,BTG2_RAT,BTG1_BOVIN,BTG1_HUMAN,BTG1_CHICK,# & PC3_RAT,BTG2_MOUSE,TS21_MOUSE)# & PIR2: (I48272,I53276,S19961,A40443,S20947,A40761)# REFERENCES: rammensee93a,hunt92a,sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,TLWVDPYEV*# SEQUENCE: TLWVDPYEV*# ...# >HUM1004F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73)# DB REFERENCE: SWISS: (VMT1_IABAN,VMT1_IAANN,VMT1_IAFOW,VMT1_IALE1,VMT1_IALE2,# & VMT1_IAMAN,VMT1_IACKB,VMT1_IAUSS,VMT1_IAPUE,VMT1_IAUDO,# & VMT1_IAWIL)# & PIR1: (MFIVC,JN0392,MFIV1M,MFIV,MFIVWS,MFIV61,MFIV1K)# & PIR2: (S04050,S04054,S14616,S04058,S04056,S07429,S04052)# REFERENCES: shimojo89a,falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,LTKGILGFVFTLTVPSERG*# SEQUENCE: LTKGILGFVFTLTVPSERG*# ...# >HUM10050# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73) homologue# ANCHOR POSITIONS: 5,12# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,LTKAILGFVFTLTVPSERG*# SEQUENCE: LTKAILGFVFTLTVPSERG*# ...# >HUM10051# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73) homologue# ANCHOR POSITIONS: 5,12# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,LTKSILGFVFTLTVPSERG*# SEQUENCE: LTKSILGFVFTLTVPSERG*# ...# >HUM10052# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73) homologue# ANCHOR POSITIONS: 5,12# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LTKGILSFVFTLTVPSERG*# SEQUENCE: LTKGILSFVFTLTVPSERG*# ...# >HUM10053# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73) homologue# ANCHOR POSITIONS: 5,12# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LTKGILGSVFTLTVPSERG*# SEQUENCE: LTKGILGSVFTLTVPSERG*# ...# >HUM10054# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73) homologue# ANCHOR POSITIONS: 5,12# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,LTKGISGFVFTLTVPSERG*# SEQUENCE: LTKGISGFVFTLTVPSERG*# ...# >HUM10055# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73) homologue# ANCHOR POSITIONS: 5,12# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,LTKGILAFVFTLTVPSERG*# SEQUENCE: LTKGILAFVFTLTVPSERG*# ...# >HUM10056# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73) homologue# ANCHOR POSITIONS: 5,12# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,LTKGILGFVFKLTVPSERG*# SEQUENCE: LTKGILGFVFKLTVPSERG*# ...# >HUM20057# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Rotavirus VP4 (86-100)# ANCHOR POSITIONS:# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,CPTNQQVVLEGTNKTD*# SEQUENCE: CPTNQQVVLEGTNKTD*# ...# >HUM10058# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HAV VP4 (1-23)# ANCHOR POSITIONS:# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MNMSKQGIFQTVGSGLDHILSLAC*# SEQUENCE: MNMSKQGIFQTVGSGLDHILSLAC*# ...# >HUM10059# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AT III (281-298)# ANCHOR POSITIONS:# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CMVLILPKPEKSLAKVEKE*# SEQUENCE: CMVLILPKPEKSLAKVEKE*# ...# >HUM1005A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293)# DB REFERENCE: SWISS: (VGLY_LYCVW,VGLY_LYCVA)# & PIR1: (VGXPLM,VGXPLA,VGXPLC)# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LSDSSGVENPGGYCLTKWMILA*# SEQUENCE: LSDSSGVENPGGYCLTKWMILA*# ...# >HUM1005B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: RV VP4 (86-100)# ANCHOR POSITIONS:# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,CPTNQQVVLEGTNKTD*# SEQUENCE: CPTNQQVVLEGTNKTD*# ...# >MUS1005C# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza nucleoprotein (366-379)# DB REFERENCE: SWISS: (VNUC_IALEN,VNUC_IAZCA,VNUC_IAWIL,VNUC_IAPUE)# & PIR1: (VHIVXL,VHIV34)# & PIR2: (B36754)# REFERENCES: bastin87a,townsend86a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,ASNENMETMESSTL*# SEQUENCE: ASNENMETMESSTL*# ...# >MUS1005D# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza nucleoprotein (365-379)# DB REFERENCE: SWISS: (VNUC_IAWIL,VNUC_IAPUE,VNUC_IALEN,VNUC_IAZCA)# & PIR1: (VHIVXL,VHIV34)# & PIR2: (B36754)# REFERENCES: bastin87a,townsend86a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesu,IASNENMETMESSTL*# SEQUENCE: IASNENMETMESSTL*# ...# >MUS1005E# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza nucleoprotein (367-379)# DB REFERENCE: SWISS: (VNUC_IAZCA,VNUC_IAPUE,VNUC_IAWIL,VNUC_IALEN)# & PIR1: (VHIV34,VHIVXL)# & PIR2: (B36754)# REFERENCES: townsend86a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,SNENMETMESSTL*# SEQUENCE: SNENMETMESSTL*# ...# >HUM1005F# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu NP (335-350)# ANCHOR POSITIONS:# REFERENCES: carreno90a,townsend86a,choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,SAAFEDLRVLSFIRGY*# SEQUENCE: SAAFEDLRVLSFIRGY*# ...# >HUM10060# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (335-350)# ANCHOR POSITIONS:# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SAAFEDLRVLSFIRGY*# SEQUENCE: SAAFEDLRVLSFIRGY*# ...# >HUM10061# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Flu PB1 (246-257)# DB REFERENCE: SWISS: (RRP1_IAWIL,RRP1_IABEI,RRP1_IAZH3,RRP1_IASIN,RRP1_IALE3,# & RRP1_IAZON,RRP1_IAANN,RRP1_IADUN,RRP1_IAKIE,RRP1_IANT6,# & RRP1_IAGU2,RRP1_IATKM,RRP1_IAZTF,RRP1_IAME8,RRP1_IAVI7,# & RRP1_IALE1,RRP1_IAHLO,RRP1_IAWIS,RRP1_IALE2,RRP1_IAMAN,# & RRP1_IAPUE,RRP1_IAHTE)# & PIR1: (P1IV33,B60011,P1IV34,P1IV61,A60008,P1IV68)# & PIR2: (S06212)# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,MQIRGFVYFVET*# SEQUENCE: MQIRGFVYFVET*# ...# >HUM10062# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: FLU PB1 (403-414)# DB REFERENCE: SWISS: (RRP1_IAME8,RRP1_IAHLO,RRP1_IAVI7,RRP1_IAWIS,RRP1_IAKOR,# & RRP1_IAHTE,RRP1_INBAC,RRP1_IAZON,RRP1_IALE3,RRP1_IADUN,# & RRP1_IATKM,RRP1_IAGU2,RRP1_IAWIL,RRP1_IAKOR,RRP1_IAZH3,# & RRP1_IASIN,RRP1_IAZTF,RRP1_IABEI,RRP1_IAANN,RRP1_IAMAN,# & RRP1_IAPUE,RRP1_IANT6,RRP1_INBAD,RRP1_INBLE,RRP1_IALE1,# & RRP1_IALE2,RRP1_IAKIE)# & PIR1: (P1IVBC,P1IV61,P1IV34,B60011,A60008,P1IV68,P1IVBL,P1IV33,# & P1IVBW)# & PIR2: (S06212)# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LSPGMMMGMFNM*# SEQUENCE: LSPGMMMGMFNM*# ...# >HUM10063# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: PY CS 6-REPEAT# DB REFERENCE: SWISS: (CSP_PLAYO)# & PIR1: (OZZQMY)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,QGPGAPQGPGAPQGPGAPQGPGAP*# SEQUENCE: QGPGAPQGPGAPQGPGAPQGPGAP*# ...# >HUM10064# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Influenza nucleoprotein (50-63)# DB REFERENCE: SWISS: (VNUC_IAMEG,VNUC_IALEN,VNUC_IANT6,VNUC_IAHO2,VNUC_IAVI6,# & VNUC_IAMEB,VNUC_IAZH1,VNUC_IAME6,VNUC_IAANN,VNUC_IAUSS,# & VNUC_IAUDO,VNUC_IAWIL,VNUC_IAKIE,VNUC_IAME3,VNUC_IASIN,# & VNUC_IAPUE,VNUC_IACAL,VNUC_IAANN,VNUC_IAS31,VNUC_IAMEE,# & VNUC_IAFOW,VNUC_IAME4,VNUC_IAHIC,VNUC_IATX7,VNUC_IAME5,# & VNUC_IAB39,VNUC_IAMEA,VNUC_IAMEC,VNUC_IABRA,VNUC_IAHO1,# & VNUC_IAZCA,VNUC_IAZDA,VNUC_IAMEF,VNUC_IAEN5,# & VNUC_IAFOM)# & PIR1: (VHIVAK,VHIVA7,VHIV68,VHIVX4,VHIVN5,VHIV34,VHIVX2,VHIV8H,# & VHIVX3,VHIVX6,VHIV61,VHIVX5,VHIVN7,VHIVXL)# & PIR2: (B36754)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM10065# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TRY REPEAT# ANCHOR POSITIONS:# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,CDKKESGDSEDKKESGDSE*# SEQUENCE: CDKKESGDSEDKKESGDSE*# ...# >HUM10066# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: PF HRP-II (1-15)# DB REFERENCE: SWISS: (HRP1_PLAFA)# & PIR2: (A25942,S31773,S31774,S31771,S31782,S31781)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,AHHAHHAADAHHAAD*# SEQUENCE: AHHAHHAADAHHAAD*# ...# >HUM10067# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: RNAP (1557-1577)# DB REFERENCE: SWISS: (RPB1_MOUSE,RPB1_CAEEL,RPB0_ARATH,RPB1_HUMAN,RPB1_YEAST,# & RPB1_DICDI,RPB1_ARATH,RPB1_CRIGR,RPB1_YEAST,# & RPB1_SCHPO)# & PIR1: (JDMU2,JDMU1,RNBY2L)# & PIR2: (S26849,A34092,A27677,S14182,S14183,A28490,A56823,S21054,# & S14181)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,SPTSPSYSPTSPSYSPTSPSY*# SEQUENCE: SPTSPSYSPTSPSYSPTSPSY*# ...# >HUM10068# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: FLU PB1 (537-548)# DB REFERENCE: SWISS: (RRP1_IAZTF,RRP1_IAKOR,RRP1_IAPUE,RRP1_IALE2,RRP1_IAHLO,# & RRP1_IAWIL,RRP1_IAZH3,RRP1_IASIN,RRP1_IAKOR,RRP1_IAZON,# & RRP1_IALE3,RRP1_IADUN,RRP1_IAGU2,RRP1_IAWIS,RRP1_IATKM,# & RRP1_IAME8,RRP1_IAHTE,RRP1_IAKIE,RRP1_IALE1,RRP1_IAMAN,# & RRP1_IANT6,RRP1_IAVI7,RRP1_IABEI)# & PIR1: (A60008,P1IV33,P1IV68,B60011,P1IV34)# & PIR2: (S06212)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,NDLGPATAQMAL*# SEQUENCE: NDLGPATAQMAL*# ...# >HUM10069# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: FLU M1 (17-31)# DB REFERENCE: SWISS: (VMT1_IAUSS,VMT1_IAFPW,VMT1_IAFPR,VMT1_IAFOW,VMT1_IAPUE,# & VMT1_IALE1,VMT1_IAUDO,VMT1_IABAN,VMT1_IAANN,VMT1_IAWIL,# & VMT1_IACKB,VMT1_IAMAN,VMT1_IALE2)# & PIR1: (MFIV,MFIVC,MFIV1M,MFIVWS,MFIV61,MFIV1K,MFIV1F,B45539,# & JN0392)# & PIR2: (S04058,S04054,S14616,S04050,S07945,S07429,S04052,# & S04056)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,SGPLKAEIAQRLEDV*# SEQUENCE: SGPLKAEIAQRLEDV*# ...# >HUM1006A# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: PY CS 4-repeat# ANCHOR POSITIONS:# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,YPPQQPPQQPPQQPPQQ*# SEQUENCE: YPPQQPPQQPPQQPPQQ*# ...# >HUM1006B# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: FLU B/Lee/40 MI (57-68)# DB REFERENCE: SWISS: (VMT1_INBAD,VMT1_INBAC,VMT1_INBSI,VMT1_INBLE)# & PIR1: (MFIV1,MFIVB1,MFIVBW,MFIVBC)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,KALIGASICFLK*# SEQUENCE: KALIGASICFLK*# ...# >HUM1006C# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: FLU HA (127-140)# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,NTTKGVTAACSHAG*# SEQUENCE: NTTKGVTAACSHAG*# ...# >HUM1006D# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: FLU HA PR8 (518-528)# DB REFERENCE: SWISS: (HEMA_IAWIL,HEMA_IAPUE,HEMA_IAZIN,HEMA_IADA4,HEMA_IATKW,# & HEMA_IALEN,HEMA_IAZNJ,HEMA_IAUSS)# & PIR1: (HMIV,HMIV5,HMIVUR,HMIV17,HMIVN1,HMIVD1,HMIVTW)# & PIR3: (S69887,S69888)# REFERENCES: carreno90a# COMMENT:# SUMMARY: HLA-B37,actyesn,bindyesu,IYSTVASSLVL*# SEQUENCE: IYSTVASSLVL*# ...# >HUM1006E# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FLU HA PR8 (518-528)# DB REFERENCE: SWISS: (HEMA_IAPUE,HEMA_IALEN,HEMA_IAZIN,HEMA_IAUSS,HEMA_IAZNJ,# & HEMA_IATKW,HEMA_IAWIL,HEMA_IADA4)# & PIR1: (HMIV5,HMIVTW,HMIVUR,HMIV,HMIVD1,HMIVN1,HMIV17)# & PIR3: (S69887,S69888)# REFERENCES: carreno92a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,IYSTVASSLVL*# SEQUENCE: IYSTVASSLVL*# ...# >HUM1006F# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (335-349)# DB REFERENCE: SWISS: (VNUC_IANT6,VNUC_IADE1,VNUC_IAVI6,VNUC_IAZH1,# & VNUC_IAHO1)# & PIR1: (VHIV8H,VHIV68,VHIVN7)# REFERENCES: carreno92a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SAAFEDLRVLSFIRG*# SEQUENCE: SAAFEDLRVLSFIRG*# ...# >HUM10070# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FLU B/Lee/40 MI (57-68)# DB REFERENCE: SWISS: (VMT1_INBAC,VMT1_INBAD,VMT1_INBLE,VMT1_INBSI)# & PIR1: (MFIVBW,MFIVBC,MFIV1,MFIVB1)# REFERENCES: carreno92a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KALIGASICFLK*# SEQUENCE: KALIGASICFLK*# ...# >HUM10071# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: gp160 (315-329)# ANCHOR POSITIONS:# REFERENCES: carreno92a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,RIQRGRGRAFVTIGK*# SEQUENCE: RIQRGRGRAFVTIGK*# ...# >HUM10072# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV GAG p24 protein (265-276)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_HV1MA,GAG_HV1B5,GAG_HV1H2,GAG_HV1C4,# & GAG_HV1W2,GAG_HV1N5,GAG_HV1RH,GAG_HV1ND,GAG_HV1OY,# & GAG_HV1Z2,GAG_HV1Y2,GAG_HV1J3,GAG_HV1JR,GAG_HV1PV,# & GAG_HV1BR,GAG_HV1A2,GAG_HV1B1)# & PIR1: (FOVWLV,FOVWH3,FOVWH4,FOLJND,A38068,FOVWA2,FOVWVL,# & A44001)# & PIR2: (S60697,S60704,S60698,S60699,S60702,S54377,S60703,# & S60708)# & PIR3: (S19598,S33979)# REFERENCES: carreno92a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KRWIILGLNK*# SEQUENCE: KRWIILGLNK*# ...# >HUM10073# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FLU HA (307-318)# ANCHOR POSITIONS:# REFERENCES: carreno92a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,PRYVRQNTLRLA*# SEQUENCE: PRYVRQNTLRLA*# ...# >HUM10074# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: gp160 (315-329)# ANCHOR POSITIONS:# REFERENCES: carreno92a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RIQRGRGRAFVTIGK*# SEQUENCE: RIQRGRGRAFVTIGK*# ...# >HUM10075# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: competitive inhibition as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV GAG p24 protein (265-276)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1BR,GAG_HV1A2,GAG_HV1B1,GAG_HV1N5,# & GAG_HV1W2,GAG_HV1H2,GAG_HV1MA,GAG_HV1MN,GAG_HV1OY,# & GAG_HV1Z2,GAG_HV1RH,GAG_HV1B5,GAG_HV1C4,GAG_HV1Y2,# & GAG_HV1JR,GAG_HV1J3,GAG_HV1ND)# & PIR1: (FOLJND,A38068,FOVWVL,FOVWLV,A44001,FOVWH3,FOVWH4,# & FOVWA2)# & PIR2: (S60703,S60697,S60704,S54377,S60698,S60702,S60699,# & S60708)# & PIR3: (S33979,S19598)# REFERENCES: rammensee93a,carreno92a,jardetzky91a,huet90a,parker92b,buseyne93a,# & brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRWIILGLNK*# SEQUENCE: KRWIILGLNK*# ...# >HUM20076# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as./ proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: FLU M1 (17-29)# DB REFERENCE: SWISS: (VMT1_IAFPW,VMT1_IAUDO,VMT1_IALE1,VMT1_IAPUE,VMT1_IAFPR,# & VMT1_IAFOW,VMT1_IAWIL,VMT1_IAMAN,VMT1_IAANN,VMT1_IACKB,# & VMT1_IABAN,VMT1_IAUSS,VMT1_IALE2)# & PIR1: (MFIV1F,JN0392,B45539,MFIVWS,MFIV61,MFIV1K,MFIVC,MFIV1M,# & MFIV)# & PIR2: (S04058,S14616,S04052,S04056,S04050,S07945,S07429,# & S04054)# REFERENCES: hill91a,rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,SGPLKAEIAQRLE*# SEQUENCE: SGPLKAEIAQRLE*# ...# >HUM20077# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: M. tuberculosis (3-14) homologue# ANCHOR POSITIONS:# REFERENCES: hill91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RYKRGLTVAVAG*# SEQUENCE: RYKRGLTVAVAG*# ...# >HUM20078# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: M. tuberculosis (3-14) homologue# ANCHOR POSITIONS:# REFERENCES: hill91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RFKRGLTVAVAG*# SEQUENCE: RFKRGLTVAVAG*# ...# >HUM20079# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M1 (17-29) homologue# ANCHOR POSITIONS:# REFERENCES: hill91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,SGPYRAEIAQRLE*# SEQUENCE: SGPYRAEIAQRLE*# ...# >HUM2007A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M1 (17-29) homologue# ANCHOR POSITIONS:# REFERENCES: hill91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,SGPLRREIAQRLE*# SEQUENCE: SGPLRREIAQRLE*# ...# >HUM2007B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FLU M1 (17-29) homologue# ANCHOR POSITIONS:# REFERENCES: hill91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SGPYRREIAQRLE*# SEQUENCE: SGPYRREIAQRLE*# ...# >HUM2007C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as./competition as./direct binding# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: FLU M1 (17-31)# DB REFERENCE: SWISS: (VMT1_IAUSS,VMT1_IAFPR,VMT1_IAUDO,VMT1_IALE1,VMT1_IABAN,# & VMT1_IALE2,VMT1_IACKB,VMT1_IAFPW,VMT1_IAWIL,VMT1_IAPUE,# & VMT1_IAFOW,VMT1_IAANN,VMT1_IAMAN)# & PIR1: (MFIVC,MFIV1K,MFIVWS,MFIV,MFIV1M,JN0392,MFIV61,MFIV1F,# & B45539)# & PIR2: (S04052,S07429,S14616,S04054,S07945,S04050,S04056,# & S04058)# REFERENCES: rothbard88a,o'sullivan90a,jardetzky90a,sherman94a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,SGPLKAEIAQRLEDV*# SEQUENCE: SGPLKAEIAQRLEDV*# ...# >HUM2007D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: FLU M1 (18-31)# DB REFERENCE: SWISS: (VMT1_IABAN,VMT1_IALE2,VMT1_IAWIL,VMT1_IAFPW,VMT1_IACKB,# & VMT1_IAFOW,VMT1_IAANN,VMT1_IAMAN,VMT1_IAUSS,VMT1_IAUDO,# & VMT1_IAFPR,VMT1_IALE1,VMT1_IAPUE)# & PIR1: (MFIV1M,MFIV61,B45539,MFIV1K,JN0392,MFIVWS,MFIV,MFIVC,# & MFIV1F)# & PIR2: (S04054,S14616,S07945,S04050,S07429,S04056,S04058,# & S04052)# REFERENCES: rothbard88a,kropshofer92a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,GPLKAEIAQRLEDV*# SEQUENCE: GPLKAEIAQRLEDV*# ...# >HUM2007E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as./competitive binding# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: FLU M1 (19-31)# DB REFERENCE: SWISS: (VMT1_IALE1,VMT1_IAPUE,VMT1_IACKB,VMT1_IAFPW,VMT1_IAMAN,# & VMT1_IAFPR,VMT1_IAUSS,VMT1_IAFOW,VMT1_IAANN,VMT1_IAUDO,# & VMT1_IABAN,VMT1_IAWIL,VMT1_IALE2)# & PIR1: (MFIVC,MFIV1F,MFIV,MFIV1M,MFIV61,MFIVWS,JN0392,B45539,# & MFIV1K)# & PIR2: (S07945,S14616,S04050,S04058,S04054,S04052,S07429,# & S04056)# REFERENCES: rothbard88a,sidney92a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesh,PLKAEIAQRLEDV*# SEQUENCE: PLKAEIAQRLEDV*# ...# >HUM2007F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A hemagglutanin (306-324)# DB REFERENCE: SWISS: (HEMA_IADHM,HEMA_IADH2,HEMA_IAVI7,HEMA_IAME2,HEMA_IAUDO,# & HEMA_IABAN,HEMA_IAEN6,HEMA_IADH3,HEMA_IADH7,HEMA_IAZH2,# & HEMA_IADU3,HEMA_IADH6,HEMA_IAAIC,HEMA_IAQU7,HEMA_IADH1,# & HEMA_IAEN7,HEMA_IAZCO,HEMA_IANT6,HEMA_IADH4)# & PIR1: (HMIV33,HMIVHA,HMIVH,HMIVDU,HMIV98,HMIV15,HMIV80,HMIV89,# & HMIVHM,HMIV77,HMIV6,HMIVV,HMIVS3)# & PIR2: (A92979,JQ1156)# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,CPKYVKQNTLKLATGMRNV*# SEQUENCE: CPKYVKQNTLKLATGMRNV*# ...# >HUM20080# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A hemagglutanin (307-324)# DB REFERENCE: SWISS: (HEMA_IABAN,HEMA_IAZCO,HEMA_IAZH2,HEMA_IADHM,HEMA_IADH1,# & HEMA_IAEN7,HEMA_IADH4,HEMA_IAUDO,HEMA_IAEN6,HEMA_IANT6,# & HEMA_IAAIC,HEMA_IAQU7,HEMA_IAVI7,HEMA_IAME2,HEMA_IADH2,# & HEMA_IADH6,HEMA_IADU3,HEMA_IADH7,HEMA_IADH3)# & PIR1: (HMIVHM,HMIVDU,HMIVS3,HMIVV,HMIV98,HMIV15,HMIV89,HMIV6,# & HMIVH,HMIV33,HMIVHA,HMIV80,HMIV77)# & PIR2: (A92979,JQ1156)# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,PKYVKQNTLKLATGMRNV*# SEQUENCE: PKYVKQNTLKLATGMRNV*# ...# >HUM20081# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A hemagglutanin (308-324)# DB REFERENCE: SWISS: (HEMA_IAAIC,HEMA_IAQU7,HEMA_IADU3,HEMA_IADH6,HEMA_IADH2,# & HEMA_IADHM,HEMA_IAZCO,HEMA_IAEN7,HEMA_IAEN6,HEMA_IAUDO,# & HEMA_IADH4,HEMA_IAVI7,HEMA_IADH3,HEMA_IADH7,HEMA_IADH1,# & HEMA_IANT6,HEMA_IAME2,HEMA_IAZH2,HEMA_IABAN)# & PIR1: (HMIV98,HMIV80,HMIVH,HMIV33,HMIVHA,HMIVV,HMIVS3,HMIV77,# & HMIV6,HMIV89,HMIVHM,HMIV15,HMIVDU)# & PIR2: (A92979,JQ1156)# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,KYVKQNTLKLATGMRNV*# SEQUENCE: KYVKQNTLKLATGMRNV*# ...# >HUM20082# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza A hemagglutanin (307-317)# DB REFERENCE: SWISS: (HEMA_IAZH2,HEMA_IAME2,HEMA_IAUDO,HEMA_IAZUK,HEMA_IAVI7,# & HEMA_IAZCO,HEMA_IAEN6,HEMA_IADHM,HEMA_IAEN7,HEMA_IADU3,# & HEMA_IADH7,HEMA_IADH3,HEMA_IADH1,HEMA_IABAN,HEMA_IAGHK,# & HEMA_IANT6,HEMA_IADH6,HEMA_IADH2,HEMA_IAME1,HEMA_IAQU7,# & HEMA_IAAIC,HEMA_IADHL,HEMA_IADH4)# & PIR1: (HMIV77,HMIV6,HMIV15,HMIV80,HMIVH,HMIVHM,HMIV89,HMIVDU,# & HMIV33,HMIVV,HMIVS3,HMIV98,HMIVHA)# & PIR2: (JQ1155,JQ1156,JQ1154,A92979)# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,PKYVKQNTLKL*# SEQUENCE: PKYVKQNTLKL*# ...# >HUM20083# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A hemagglutanin (307-318)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IAGHK,HEMA_IAME1,HEMA_IAAIC,HEMA_IADHL,# & HEMA_IADH7,HEMA_IADH3,HEMA_IADH1,HEMA_IADU3,HEMA_IADH6,# & HEMA_IAZUK,HEMA_IAVI7,HEMA_IAZH2,HEMA_IAME2,HEMA_IADHM,# & HEMA_IAEN7,HEMA_IAQU7,HEMA_IANT6,HEMA_IABAN,HEMA_IAUDO,# & HEMA_IAZCO,HEMA_IAEN6,HEMA_IADH2)# & PIR1: (HMIVHA,HMIVS3,HMIV89,HMIV33,HMIVH,HMIV15,HMIV77,HMIV98,# & HMIVV,HMIVHM,HMIVDU,HMIV80,HMIV6)# & PIR2: (A92979,JQ1156,JQ1155,JQ1154)# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,PKYVKQNTLKLA*# SEQUENCE: PKYVKQNTLKLA*# ...# >HUM20084# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: synthetic hybrid between FLU M1 (17-31) and FLU HA (307-319)# ANCHOR POSITIONS:# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,SKYLKQNIAKLLE*# SEQUENCE: SKYLKQNIAKLLE*# ...# >HUM20085# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: synthetic hybrid between FLU M1 (17-31) and FLU HA (307-319)# ANCHOR POSITIONS:# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,PKYVKQNTAKLLT*# SEQUENCE: PKYVKQNTAKLLT*# ...# >HUM20086# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: synthetic hybrid between FLU M1 (17-31) and FLU HA (307-319)# ANCHOR POSITIONS:# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,PKYVKQNTLKLLT*# SEQUENCE: PKYVKQNTLKLLT*# ...# >HUM20087# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: synthetic hybrid between FLU M1 (17-31) and FLU HA (307-319)# ANCHOR POSITIONS:# REFERENCES: rothbard88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,AGPLKAETLQRAT*# SEQUENCE: AGPLKAETLQRAT*# ...# >MUS20088# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: moth cytochrome c (81-103)# DB REFERENCE: SWISS: (CYC_SAMCY,CYC_MACMA,CYC_MANSE)# & PIR1: (CCMT,CCWOT,CCMM)# REFERENCES: heber-katz82a# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesu,GTKMVFAGLKKANERADLIAYLK*# SEQUENCE: GTKMVFAGLKKANERADLIAYLK*# ...# >MUS20089# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: fly cytochrome c (81-103)# DB REFERENCE: SWISS: (CYC_LUCCU,CYC_HAEIR,CYC_BOEPE,CYC2_DROME,CYC2_DROME,# & CYC_BOEPE)# & PIR1: (CCFFCM,CCFHHF,CCHFGB,CCFFDM)# & PIR2: (B25506)# REFERENCES: heber-katz82a# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesu,GTKMIFAGLKKPNERGDLIAYLK*# SEQUENCE: GTKMIFAGLKKPNERGDLIAYLK*# ...# >MUS2008A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (81-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: heber-katz82a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,GTKMIFAGIKKKAERADLIAYLKQ*# SEQUENCE: GTKMIFAGIKKKAERADLIAYLKQ*# ...# >MUS2008B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tuna cytochrome c (81-103)# DB REFERENCE: SWISS: (CYC_KATPE)# & PIR1: (CCBN)# REFERENCES: heber-katz82a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,GTKMIFAGIKKKGERQDLVAYLK*# SEQUENCE: GTKMIFAGIKKKGERQDLVAYLK*# ...# >MUS2008C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: SPERM WHALE MYOGLOB. (132-146)# DB REFERENCE: SWISS: (MYG_MEGNO,MYG_CASFI,MYG_PHYCA,MYG_BALPH,MYG_ESCGI,# & MYG_INIGE,MYG_BALAC,MYG_TURTR,MYG_GLOME,MYG_PHYCA,# & MYG_ORCOR)# & PIR1: (MYWHH,MYWHC,MYWHT,MYDDAR,MYWHK,MYDDBS,MYDD,MYWHF,MYWHP,# & MYWHL)# & PIR2: (JN0410)# REFERENCES: berkower86a,kurata90a,schild95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,NKALELFRKDIAAKY*# SEQUENCE: NKALELFRKDIAAKY*# ...# >MUS2008D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: SPERM WHALE MYOGLOB. (133-146)# DB REFERENCE: SWISS: (MYG_GLOME,MYG_TURTR,MYG_INIGE,MYG_ESCGI,MYG_MESCA,# & MYG_MEGNO,MYG_PHYCA,MYG_BALAC,MYG_KOGSI,MYG_ZIPCA,# & MYG_PHYCA,MYG_CASFI,MYG_BALPH,MYG_ORCOR)# & PIR1: (MYWHK,MYDDAR,MYWHF,MYWHH,MYDDBS,MYWHC,MYWHL,MYWHP,MYWHU,# & MYWHW,MYWHT,MYWHZ,MYDD)# & PIR2: (JN0410)# REFERENCES: berkower86a,altuvia94a,kurata90a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KALELFRKDIAAKY*# SEQUENCE: KALELFRKDIAAKY*# ...# >MUS2008E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: SPERM WHALE MYOGLOB. (134-146)# DB REFERENCE: SWISS: (MYG_GLOME,MYG_KOGSI,MYG_ESCGI,MYG_MEGNO,MYG_ZIPCA,# & MYG_BALAC,MYG_INIGE,MYG_MESCA,MYG_ORCOR,MYG_CASFI,# & MYG_BALPH,MYG_TURTR,MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHC,MYWHT,MYDD,MYWHP,MYWHL,MYWHW,MYDDBS,MYWHF,MYWHH,# & MYWHK,MYDDAR,MYWHU,MYWHZ)# & PIR2: (JN0410)# REFERENCES: berkower86a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,ALELFRKDIAAKY*# SEQUENCE: ALELFRKDIAAKY*# ...# >MUS2008F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: SPERM WHALE MYOGLOB. (135-146)# DB REFERENCE: SWISS: (MYG_MEGNO,MYG_BALAC,MYG_PHYCA,MYG_PHYCA,MYG_TURTR,# & MYG_KOGSI,MYG_CASFI,MYG_ORCOR,MYG_BALPH,MYG_MESCA,# & MYG_INIGE,MYG_ESCGI,MYG_GLOME,MYG_ZIPCA)# & PIR1: (MYWHZ,MYWHW,MYWHT,MYDDAR,MYWHK,MYWHU,MYWHF,MYDDBS,MYWHH,# & MYWHC,MYWHL,MYWHP,MYDD)# & PIR2: (JN0410)# REFERENCES: berkower86a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,LELFRKDIAAKY*# SEQUENCE: LELFRKDIAAKY*# ...# >MUS20090# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: SPERM WHALE MYOGLOB. (136-146)# DB REFERENCE: SWISS: (MYG_BALAC,MYG_ZIPCA,MYG_ESCGI,MYG_PHYCA,MYG_ORCOR,# & MYG_KOGSI,MYG_TURTR,MYG_GLOME,MYG_BALPH,MYG_MESCA,# & MYG_INIGE,MYG_MEGNO,MYG_PHYCA,MYG_CASFI)# & PIR1: (MYWHL,MYWHP,MYDD,MYWHK,MYWHH,MYDDBS,MYWHF,MYWHC,MYDDAR,# & MYWHT,MYWHZ,MYWHU,MYWHW)# & PIR2: (JN0410)# REFERENCES: berkower86a,kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,ELFRKDIAAKY*# SEQUENCE: ELFRKDIAAKY*# ...# >MUS20091# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibitory binding# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Sperm whale myoglobin (106-118)# DB REFERENCE: SWISS: (MYG_PHOPH,MYG_INIGE,MYG_TURTR,MYG_KOGSI,MYG_PHYCA,# & MYG_PHYCA,MYG_ORCOR,MYG_GLOME)# & PIR1: (MYWHP,MYPED,MYWHT,MYDD,MYWHW,MYPE,MYDDBS,MYDDAR,MYWHL)# REFERENCES: berkower85a,berkower84a,buus87a,altuvia94a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesh,FISEAIIHVLHSR*# SEQUENCE: FISEAIIHVLHSR*# ...# >MUS20092# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: harbour seal myoglobin (106-118)# DB REFERENCE: SWISS: (MYG_HALGR,MYG_RABIT,MYG_PHOSI)# & PIR1: (MYRB,MYSLG,MYSLH)# & PIR2: (JN0344)# REFERENCES: berkower84a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,FISEAIIHVLHSK*# SEQUENCE: FISEAIIHVLHSK*# ...# >MUS20093# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: STAPH. NUCLEASE (91-110)# ANCHOR POSITIONS:# REFERENCES: finnegan86a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,YIRADFKMVNEALVRQGLAK*# SEQUENCE: YIRADFKMVNEALVRQGLAK*# ...# >MUS20094# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: STAPH. NUCLEASE (51-70)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: finnegan86a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,VEKYGPEASAFTKKMVENAK*# SEQUENCE: VEKYGPEASAFTKKMVENAK*# ...# >MUS20095# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: STAPH. NUCLEASE (81-100)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: finnegan86a,guillet86a,altuvia94a,nikcevich94a,liu93a# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesu,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >MUS20096# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SPERM WHALE MYOGLOB. (111-118)# DB REFERENCE: SWISS: (MYG_TURTR,MYG_ORCOR,MYG_PHYCA,MYG_PHYCA,MYG_GLOME,# & MYG_ESCGI,MYG_KOGSI,MYG_ZIPCA,MYG_BALPH,MYG_BALAC,# & MYG_MEGNO,MYG_PHOPH,MYG_INIGE)# & PIR1: (MYDDBS,MYWHK,MYWHL,MYWHZ,MYWHW,MYPE,MYWHP,MYDDAR,MYWHH,# & MYPED,MYWHC,MYDD,MYWHF,MYWHT)# REFERENCES: livingstone87a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,IIHVLHSR*# SEQUENCE: IIHVLHSR*# ...# >MUS20097# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SPERM WHALE MYOGLOB. (70-78)# DB REFERENCE: SWISS: (MYG_KOGSI,MYG_ORCOR,MYG_TURTR,MYG_GLOME,MYG_PHYCA,# & MYG_PHYCA,MYG_RABIT)# & PIR1: (MYWHL,MYWHT,MYWHP,MYRB,MYWHW,MYDD,MYDDBS)# REFERENCES: livingstone87a,altuvia94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,TALGAILKK*# SEQUENCE: TALGAILKK*# ...# >MUS20098# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (81-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: hedrick82a# COMMENT:# SUMMARY: I-As,actyesl,bindyesu,GTKMIFAGIKKKAERADLIAYLKQ*# SEQUENCE: GTKMIFAGIKKKAERADLIAYLKQ*# ...# >MUS20099# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (1-15)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,GKVYLVGGPELGGWK*# SEQUENCE: GKVYLVGGPELGGWK*# ...# >MUS2009A# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (11-25)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,LGGWKLQSDPRAYAL*# SEQUENCE: LGGWKLQSDPRAYAL*# ...# >MUS2009B# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (51-65), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a,smilek90a# COMMENT:# SUMMARY: H-2d,actyesh,bindyesu,EVWREEAYHAADIKD*# SEQUENCE: EVWREEAYHAADIKD*# ...# >MUS2009C# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (71-85)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,PGGPDRFTLLTPGSH*# SEQUENCE: PGGPDRFTLLTPGSH*# ...# >MUS2009D# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (81-95), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,TPGSHFIATKDQKFV*# SEQUENCE: TPGSHFIATKDQKFV*# ...# >MUS2009E# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (91-101), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,DQKFVAAVPGR*# SEQUENCE: DQKFVAAVPGR*# ...# >MUS2009F# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (1-15)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,GKVYLVGGPELGGWK*# SEQUENCE: GKVYLVGGPELGGWK*# ...# >MUS200A0# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (11-25)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,LGGWKLQSDPRAYAL*# SEQUENCE: LGGWKLQSDPRAYAL*# ...# >MUS200A1# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (51-65), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a,smilek90a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,EVWREEAYHAADIKD*# SEQUENCE: EVWREEAYHAADIKD*# ...# >MUS200A2# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (1-15)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2q,actyesl,bindyesu,GKVYLVGGPELGGWK*# SEQUENCE: GKVYLVGGPELGGWK*# ...# >MUS200A3# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (11-25)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2q,actyesm,bindyesu,LGGWKLQSDPRAYAL*# SEQUENCE: LGGWKLQSDPRAYAL*# ...# >MUS200A4# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (51-65), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a,smilek90a# COMMENT:# SUMMARY: H-2q,actyesm,bindyesu,EVWREEAYHAADIKD*# SEQUENCE: EVWREEAYHAADIKD*# ...# >MUS200A5# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (81-95), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2q,actyesl,bindyesu,TPGSHFIATKDQKFV*# SEQUENCE: TPGSHFIATKDQKFV*# ...# >MUS200A6# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (91-101), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2q,actyesl,bindyesu,DQKFVAAVPGR*# SEQUENCE: DQKFVAAVPGR*# ...# >MUS200A7# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (1-15)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2s,actyesm,bindyesu,GKVYLVGGPELGGWK*# SEQUENCE: GKVYLVGGPELGGWK*# ...# >MUS200A8# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (11-25)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2s,actyesm,bindyesu,LGGWKLQSDPRAYAL*# SEQUENCE: LGGWKLQSDPRAYAL*# ...# >MUS200A9# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (51-65), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a,smilek90a# COMMENT:# SUMMARY: H-2s,actyesh,bindyesu,EVWREEAYHAADIKD*# SEQUENCE: EVWREEAYHAADIKD*# ...# >MUS200AA# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (91-101), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2s,actyesl,bindyesu,DQKFVAAVPGR*# SEQUENCE: DQKFVAAVPGR*# ...# >MUS200AB# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (7-16)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,GGPELGGWKL*# SEQUENCE: GGPELGGWKL*# ...# >MUS200AC# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (8-18)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2s,actyesm,bindyesu,GPELGGWKLQS*# SEQUENCE: GPELGGWKLQS*# ...# >MUS200AD# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (10-19)# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,ELGGWKLKLQSD*# SEQUENCE: ELGGWKLKLQSD*# ...# >MUS200AE# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (10-19)# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2q,actyesm,bindyesu,ELGGWKLKLQSD*# SEQUENCE: ELGGWKLKLQSD*# ...# >MUS200AF# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (52-64), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesh,bindyesu,VWREEAYHAADIK*# SEQUENCE: VWREEAYHAADIK*# ...# >MUS200B0# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (52-64), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2q,actyesh,bindyesu,VWREEAYHAADIK*# SEQUENCE: VWREEAYHAADIK*# ...# >MUS200B1# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (52-64), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2s,actyesh,bindyesu,VWREEAYHAADIK*# SEQUENCE: VWREEAYHAADIK*# ...# >MUS200B2# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (73-83)# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,GPDRFTLLTPG*# SEQUENCE: GPDRFTLLTPG*# ...# >MUS200B3# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (87-99), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,IATKDQKFVACVP*# SEQUENCE: IATKDQKFVACVP*# ...# >MUS200B4# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (87-99), homologue# ANCHOR POSITIONS:# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2q,actyesm,bindyesu,IATKDQKFVACVP*# SEQUENCE: IATKDQKFVACVP*# ...# >MUS200B5# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (92-101), homologue# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,QKFVACVPGR*# SEQUENCE: QKFVACVPGR*# ...# >MUS200B6# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Ragweed allergen Ra3 (92-101), homologue# DB REFERENCE: SWISS: (MPA3_AMBEL,MPA3_AMBEL)# & PIR1: (ARRA3)# REFERENCES: kurisaki86a,atassi86a# COMMENT:# SUMMARY: H-2q,actyesm,bindyesu,QKFVACVPGR*# SEQUENCE: QKFVACVPGR*# ...# >MUS200B7# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU HA (111-119)# DB REFERENCE: SWISS: (HEMA_IAUSS,HEMA_IAZNJ,HEMA_IAPUE,HEMA_IALEN,HEMA_IACAO,# & HEMA_IAHAR,HEMA_IAXIA,HEMA_IATAI,HEMA_IAKIE,# & HEMA_IAZIN)# & PIR1: (HMIVN1,HMIVUR,HMIVTA,HMIV17,HMIV)# & PIR2: (JQ2371,JQ2372,A35788,PQ0321,JQ1437,JQ1643,PQ0319,# & JQ2370)# & PIR3: (S69886,S69889,S69888)# REFERENCES: carreno92a,eisenlohr88a,altuvia94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,FERFEIFPK*# SEQUENCE: FERFEIFPK*# ...# >MUS200B8# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU HA1 (302-313)# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: eisenlohr88a,altuvia94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,CPKYVRSAKLRM*# SEQUENCE: CPKYVRSAKLRM*# ...# >MUS200B9# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU HA1 (128-138)# ANCHOR POSITIONS:# REFERENCES: hill91a,rothbard88b,eisenlohr88a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,TNGVTAACSHE*# SEQUENCE: TNGVTAACSHE*# ...# >MUS100BA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza nucleoprotein NP (147-161)# DB REFERENCE: SWISS: (VNUC_IAFOW,VNUC_IAANA,VNUC_IADBE,VNUC_IAHPR,VNUC_IAZNE,# & VNUC_IASH2,VNUC_IARUD,VNUC_IAME3,VNUC_IASIN,VNUC_IAPUE,# & VNUC_IAGU2,VNUC_IAZON,VNUC_IAB37,VNUC_IADE1,VNUC_IAZJ3,# & VNUC_IAZH4,VNUC_IATX7,VNUC_IAZI2,VNUC_IAWIS,VNUC_IAZOH,# & VNUC_IAMAA,VNUC_IAME4,VNUC_IATKO,VNUC_IAHLO,VNUC_IAMEE,# & VNUC_IABRA,VNUC_IAMEA,VNUC_IAGUA,VNUC_IAEN5,VNUC_IAFOM,# & VNUC_IAHJI,VNUC_IADM2,VNUC_IAZW1,VNUC_IADAU,VNUC_IAMEF,# & VNUC_IAZGE,VNUC_IAGRE,VNUC_IAS06,VNUC_IAZTE,VNUC_IASE0,# & VNUC_IAME5,VNUC_IAMEC,VNUC_IAB39,VNUC_IANT6,VNUC_IACAL,# & VNUC_IAMAN,VNUC_IAMIN,VNUC_IAANN,VNUC_IAWIL,VNUC_IAUDO,# & VNUC_IAZJ1,VNUC_IAANN,VNUC_IAUSS,VNUC_IAKIE,VNUC_IAMEB,# & VNUC_IAWHP,VNUC_IAZW2,VNUC_IAVI6,VNUC_IATEI,VNUC_IADHK,# & VNUC_IATRT,VNUC_IAFPR,VNUC_IAGU4,VNUC_IATKN,VNUC_IALEN,# & VNUC_IAGU3,VNUC_IAHO2,VNUC_IADNZ,VNUC_IADMA,VNUC_IAHO1,# & VNUC_IAMEG,VNUC_IATRS,VNUC_IAZJ4,VNUC_IAZCA,VNUC_IAFPD,# & VNUC_IAME6,VNUC_IABUD,VNUC_IAS31,VNUC_IAHMI,VNUC_IAZ29,# & VNUC_IADCZ,VNUC_IANEJ,VNUC_IAGU1,VNUC_IADE2,VNUC_IAZDA,# & VNUC_IAOHI,VNUC_IAHIC,VNUC_IAS11,VNUC_IAZMA,VNUC_IADU2,# & VNUC_IAWHN,VNUC_IAZI3,VNUC_IACKP,VNUC_IACKG,VNUC_IAPAR,# & VNUC_IAZJ2,VNUC_IAZ41,VNUC_IAZJA,VNUC_IAGD7,VNUC_IAZI1,# & VNUC_IAZH3,VNUC_IAZH1)# & PIR1: (A60028,VHIVAK,VHIVX5,VHIV8H,VHIVX6,VHIV61,VHIV68,VHIVN6,# & VHIVA7,VHIVX1,VHIVX4,VHIVA3,VHIVN3,VHIVA6,VHIVN5,VHIVN1,# & VHIVN2,VHIVN7,VHIVX3,VHIVN4,VHIVN9,VHIVX2,VHIVXL,VHIVN8,# & VHIV34,VHIVM1,VHIVC1)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# REFERENCES: taylor87a,perkins89a,bodmer88a,zaghouani93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,TYQRTRALVRTGMDP*# SEQUENCE: TYQRTRALVRTGMDP*# ...# >MUS100BB# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./HPLC# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza nucleoprotein (50-63)# DB REFERENCE: SWISS: (VNUC_IAEN5,VNUC_IASIN,VNUC_IAME3,VNUC_IAHIC,VNUC_IAFOM,# & VNUC_IAZCA,VNUC_IAKIE,VNUC_IAS31,VNUC_IAZH1,VNUC_IAME6,# & VNUC_IAZDA,VNUC_IAANN,VNUC_IAUSS,VNUC_IAHO2,VNUC_IAMEG,# & VNUC_IAVI6,VNUC_IAPUE,VNUC_IAFOW,VNUC_IAMEA,VNUC_IATX7,# & VNUC_IAME4,VNUC_IAMEE,VNUC_IABRA,VNUC_IAMEB,VNUC_IAUDO,# & VNUC_IAWIL,VNUC_IAANN,VNUC_IAMEC,VNUC_IAME5,VNUC_IAB39,# & VNUC_IACAL,VNUC_IANT6,VNUC_IAMEF,VNUC_IALEN,# & VNUC_IAHO1)# & PIR1: (VHIVX6,VHIVN7,VHIVX2,VHIV8H,VHIV34,VHIVA7,VHIV61,VHIVX5,# & VHIV68,VHIVN5,VHIVXL,VHIVX4,VHIVAK,VHIVX3)# & PIR2: (B36754)# REFERENCES: taylor87a,gould91a,rotzschke90b,perkins89a,hickling90a# COMMENT:# SUMMARY: H-2Kk,actyesl,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM100BC# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza nucleoprotein NP (335-349)# DB REFERENCE: SWISS: (VNUC_IAPUE,VNUC_IALEN)# & PIR1: (VHIV34,VHIVXL)# & PIR2: (B36754)# REFERENCES: taylor87a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,SAAFEDLRVLSFIKG*# SEQUENCE: SAAFEDLRVLSFIKG*# ...# >MUS100BD# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Plasmodium yoelii CSP (280-288)# DB REFERENCE: SWISS: (CSP_PLAYO)# & PIR1: (OZZQMY)# & PIR2: (A44969)# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,SYVPSAEQI*# SEQUENCE: SYVPSAEQI*# ...# >MUS100BE# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Plasmodium yoelii CSP (277-288)# DB REFERENCE: SWISS: (CSP_PLAYO)# & PIR1: (OZZQMY)# & PIR2: (A44969)# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,NEDSYVPSAEQI*# SEQUENCE: NEDSYVPSAEQI*# ...# >MUS100BF# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Plasmodium yoelii CSP (278-288)# DB REFERENCE: SWISS: (CSP_PLAYO)# & PIR1: (OZZQMY)# & PIR2: (A44969)# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,EDSYVPSAEQI*# SEQUENCE: EDSYVPSAEQI*# ...# >MUS100C0# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Plasmodium yoelii CSP (279-288)# DB REFERENCE: SWISS: (CSP_PLAYO)# & PIR1: (OZZQMY)# & PIR2: (A44969)# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,DSYVPSAEQI*# SEQUENCE: DSYVPSAEQI*# ...# >MUS100C1# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Plasmodium berghei CSP (252-260)# DB REFERENCE: SWISS: (CSP_PLABE,CSP_PLABA)# & PIR1: (OZZQMB,OZZQBK)# REFERENCES: romero91a,eberl93a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,SYIPSAEKI*# SEQUENCE: SYIPSAEKI*# ...# >MUS100C2# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Plasmodium berghei CSP (249-260)# DB REFERENCE: SWISS: (CSP_PLABA,CSP_PLABE)# & PIR1: (OZZQBK,OZZQMB)# REFERENCES: romero91a,maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,NDDSYIPSAEKI*# SEQUENCE: NDDSYIPSAEKI*# ...# >MUS100C3# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: Plasmodium berghei CSP (250-260)# DB REFERENCE: SWISS: (CSP_PLABA,CSP_PLABE)# & PIR1: (OZZQBK,OZZQMB)# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesl,DDSYIPSAEKI*# SEQUENCE: DDSYIPSAEKI*# ...# >MUS100C4# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: Plasmodium berghei CSP (251-260)# DB REFERENCE: SWISS: (CSP_PLABA,CSP_PLABE)# & PIR1: (OZZQBK,OZZQMB)# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesl,DSYIPSAEKI*# SEQUENCE: DSYIPSAEKI*# ...# >MUS100C5# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Plasmodium berghei CSP (253-260)# DB REFERENCE: SWISS: (CSP_PLABA,CSP_PLABE)# & PIR1: (OZZQMB,OZZQBK)# REFERENCES: romero91a,abastado93a,eberl93a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,YIPSAEKI*# SEQUENCE: YIPSAEKI*# ...# >MUS100C6# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Plasmodium berghei CSP (252-262)# DB REFERENCE: SWISS: (CSP_PLABA,CSP_PLABE)# & PIR1: (OZZQBK,OZZQMB)# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,SYIPSAEKILE*# SEQUENCE: SYIPSAEKILE*# ...# >MUS100C7# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Plasmodium berghei CSP (252-261)# DB REFERENCE: SWISS: (CSP_PLABE,CSP_PLABA)# & PIR1: (OZZQMB,OZZQBK)# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,SYIPSAEKIL*# SEQUENCE: SYIPSAEKIL*# ...# >MUS100C8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: Plasmodium berghei CSP (252-259)# DB REFERENCE: SWISS: (CSP_PLABA,CSP_PLABE)# & PIR1: (OZZQBK,OZZQMB)# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actyesn,bindyesl,SYIPSAEK*# SEQUENCE: SYIPSAEK*# ...# >MUS100C9# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HLA-A24 (170-179)# DB REFERENCE: SWISS: (VNUC_IAFOW,VNUC_IAANA,VNUC_IADBE,VNUC_IAHPR,VNUC_IAZNE,# & VNUC_IASH2,VNUC_IARUD,VNUC_IAME3,VNUC_IASIN,VNUC_IAPUE,# & VNUC_IAGU2,VNUC_IAZON,VNUC_IAB37,VNUC_IADE1,VNUC_IAZJ3,# & VNUC_IAZH4,VNUC_IATX7,VNUC_IAZI2,VNUC_IAWIS,VNUC_IAZOH,# & VNUC_IAMAA,VNUC_IAME4,VNUC_IATKO,VNUC_IAHLO,VNUC_IAMEE,# & VNUC_IABRA,VNUC_IAMEA,VNUC_IAGUA,VNUC_IAEN5,VNUC_IAFOM,# & VNUC_IAHJI,VNUC_IADM2,VNUC_IAZW1,VNUC_IADAU,VNUC_IAMEF,# & VNUC_IAZGE,VNUC_IAGRE,VNUC_IAS06,VNUC_IAZTE,VNUC_IASE0,# & VNUC_IAME5,VNUC_IAMEC,VNUC_IAB39,VNUC_IANT6,VNUC_IACAL,# & VNUC_IAMAN,VNUC_IAMIN,VNUC_IAANN,VNUC_IAWIL,VNUC_IAUDO,# & VNUC_IAZJ1,VNUC_IAANN,VNUC_IAUSS,VNUC_IAKIE,VNUC_IAMEB,# & VNUC_IAWHP,VNUC_IAZW2,VNUC_IAVI6,VNUC_IATEI,VNUC_IADHK,# & VNUC_IATRT,VNUC_IAFPR,VNUC_IAGU4,VNUC_IATKN,VNUC_IALEN,# & VNUC_IAGU3,VNUC_IAHO2,VNUC_IADNZ,VNUC_IADMA,VNUC_IAHO1,# & VNUC_IAMEG,VNUC_IATRS,VNUC_IAZJ4,VNUC_IAZCA,VNUC_IAFPD,# & VNUC_IAME6,VNUC_IABUD,VNUC_IAS31,VNUC_IAHMI,VNUC_IAZ29,# & VNUC_IADCZ,VNUC_IANEJ,VNUC_IAGU1,VNUC_IADE2,VNUC_IAZDA,# & VNUC_IAOHI,VNUC_IAHIC,VNUC_IAS11,VNUC_IAZMA,VNUC_IADU2,# & VNUC_IAWHN,VNUC_IAZI3,VNUC_IACKP,VNUC_IACKG,VNUC_IAPAR,# & VNUC_IAZJ2,VNUC_IAZ41,VNUC_IAZJA,VNUC_IAGD7,VNUC_IAZI1,# & VNUC_IAZH3,VNUC_IAZH1,1C02_GORGO,1A11_HUMAN,1A04_PANTR,# & 1B56_HUMAN,1A03_HUMAN,1A32_HUMAN,1A02_HUMAN,1C03_GORGO,# & 1B29_HUMAN,1B27_HUMAN)# & PIR1: (HLHU69,HLHUA2,HLHU32,HLHUB2,HLHUC4,HLHU10,HLHU12,HLHUA3,# & HLHUB8,HLHUAW,HLHUB4)# & PIR2: (I67482,I80171,JH0542,I56009,JH0543,I38610,I37529,I37482,# & I36957,JH0537,A35997,I84448,I37515,S11134,I37485,I68748,# & I59654,I61907,S44994,I56130,I38439,I38509,S11135,S10934,# & S03535,I37528,I80165,I54493,A47636,I54442,S11133,I37520,# & I80168,I84432,I72755,I59655,I80167,I37544,G01230,I54463,# & I37526,JH0535,I61863,A45880,D35997,I38518,JH0546,I72113,# & S42823,I56149,JL0135,I72754,S11143,I37483,A60384,I36966,# & I38505,I62041,I36962,I61861,S51102,I37519,I62042,I68750,# & I54551,I72217,I80166,I69002,I59308,JH0544,I62045,S03538,# & C37028,I59622,I56116,I61905,I68774,S11137,I61857,S11136,# & I68700,I84488,JS0262,I61902,C35997,I37521,I38443,S24433,# & S24436,I84486,I37542,I72752,S11139,I61866,I37516,I54449,# & I37476,I37475,A49411,I38507,I84487,I38436,I84490,S24435,# & I36959,A45850,A45834,I62044,I54289,I81233,S03537,I83063,# & I36958,I61904,I54416,S24440,I37527,I72170,JH0547,S52486,# & S16769,I54505,I68749,I54314,I54308,S25415,I59633,S24027,# & I68699,A37028,I61906,B37028,I38441,I36960,I80170,I37477,# & S11138,I56053,I36956,I68724,I68850,JH0536,I80169,S18198,# & I72753,I56133,I38519,A45847,S48134,I36961,S24439,I38421,# & S11141,I37478,I61856,I37523,I37470,S16789,I38442,S01171,# & JH0545,I54298,S11140,I54307,I37480,I62043,S24437,I37479,# & JH0526,I36965,S29990,I56039,I59645)# & PIR3: (S07114,S07115,S07113,G02922,S06424)# REFERENCES: romero91a,eberl93a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,RYLENGKETL*# SEQUENCE: RYLENGKETL*# ...# >MUS100CA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: HLA-A24 (170-182)# DB REFERENCE: SWISS: (1B40_HUMAN,1C02_GORGO,HLAH_HUMAN,1C04_GORGO,1B05_HUMAN,# & 1B10_HUMAN,1B28_HUMAN,1CXX_HUMAN,1B12_HUMAN,1C28_PANTR,# & 1B01_PANTR,1A02_PANTR,1B23_HUMAN,1C02_HUMAN,1B26_HUMAN,# & 1C02_HUMAN,1C02_GORGO,1B36_HUMAN,1B43_HUMAN,HLAF_HUMAN,# & 1B56_HUMAN,1B27_HUMAN,1B31_HUMAN,1C03_GORGO,HLAH_HUMAN,# & 1B41_HUMAN,1B59_HUMAN,1B01_SAGOE,1B20_HUMAN,HLAF_MACMU,# & 1B32_HUMAN,1B60_HUMAN,1B45_HUMAN,1B04_GORGO,1C01_GORGO,# & 1B44_HUMAN,1B62_HUMAN,1B18_HUMAN,1B22_HUMAN,1A24_HUMAN,# & 1C15_HUMAN,1C07_HUMAN,1B29_HUMAN,1B15_HUMAN,1C16_HUMAN,# & 1B02_PANTR,1B25_HUMAN,1B55_HUMAN,1B61_HUMAN,1B21_HUMAN,# & 1B24_HUMAN,1B19_HUMAN,1B48_HUMAN,1B12_HUMAN,1C18_HUMAN,# & 1B42_HUMAN,1B57_HUMAN,1B14_HUMAN,1A01_SAGOE,1B11_HUMAN,# & 1B58_HUMAN,1B35_HUMAN,HLAF_HUMAN,1B54_HUMAN,1B34_HUMAN,# & 1B16_HUMAN,1C04_HUMAN,1B47_HUMAN)# & PIR1: (HLHUB2,HLHUC4,HLHU12,HLHUB8,HLHUB4)# & PIR2: (S11136,S24440,JH0547,I36958,I38507,I37475,I54449,S52486,# & JH0546,S42823,S11135,S10934,I54505,I68724,S11141,I37516,# & I84488,I54463,C35997,I54416,S24433,I54289,S24436,A49411,# & S44994,I37515,I37485,I38505,A60384,I37529,I37528,S11133,# & D35997,I36956,JH0545,S24439,S16789,I59633,S24027,S11138,# & B37028,S03538,I56116,I61905,I72217,I68750,I61861,S24435,# & S48134,I80169,G01230,JH0543,I37521,JS0262,I72752,S11139,# & I84486,S03537,I81233,I61866,I84490,I37527,I61904,I62044,# & A45834,A45850,I37544,I37526,I80167,I72113,A45880,I61863,# & I37520,I80168,I72755,I59655,I80165,I54442,I54298,S11140,# & I59645,S29990,JH0526,S24437,I62043,I80170,I36960,I56053,# & I54314,I54308,S25415,I61906,I36957,I59654,I61907,I68748,# & S11134,I80171,JH0542,I56130,I38509,I59308,I80166,I62042,# & I62041,I36962,I37519,S11143,I72754,I56149,I62045,JH0544,# & I59622,I68774,S11137,C37028,I37523,I38421,I72753,I56133,# & I68850,I68749)# & PIR3: (S07115,S07113,S07114,G02922)# REFERENCES: romero91a,maryanski88a,maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesm,RYLENGKETLQRA*# SEQUENCE: RYLENGKETLQRA*# ...# >MUS100CB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HLA-A24 (170-178)# DB REFERENCE: SWISS: (1C15_HUMAN,1A24_HUMAN,1B21_HUMAN,1B25_HUMAN,1B55_HUMAN,# & 1B44_HUMAN,1B62_HUMAN,1B18_HUMAN,1B29_HUMAN,1B15_HUMAN,# & 1B27_HUMAN,1C16_HUMAN,1B61_HUMAN,1C07_HUMAN,1A25_HUMAN,# & 1B42_HUMAN,1A03_GORGO,1B57_HUMAN,1A29_HUMAN,1B14_HUMAN,# & 1B24_HUMAN,1A31_HUMAN,1B19_HUMAN,1A23_HUMAN,1C18_HUMAN,# & 1C04_HUMAN,1A01_HUMAN,1C01_PANTR,1B45_HUMAN,1B04_GORGO,# & 1A66_HUMAN,HLAF_HUMAN,1A36_HUMAN,1B16_HUMAN,1A01_PONPY,# & 1B54_HUMAN,1A03_PANTR,1B32_HUMAN,1B59_HUMAN,1B01_SAGOE,# & 1B20_HUMAN,1C03_GORGO,HLAH_HUMAN,1A34_HUMAN,1A04_GORGO,# & 1B31_HUMAN,1A80_HUMAN,HLAF_HUMAN,1A26_HUMAN,1A43_HUMAN,# & 1AXX_HUMAN,1B43_HUMAN,1B36_HUMAN,1B56_HUMAN,1B22_HUMAN,# & 1B02_PANTR,1A74_HUMAN,1B34_HUMAN,1B47_HUMAN,1B12_HUMAN,# & 1C01_GORGO,1B60_HUMAN,1B35_HUMAN,1A31_HUMAN,1A26_HUMAN,# & 1B41_HUMAN,1B40_HUMAN,1A03_HUMAN,1A32_HUMAN,1C02_GORGO,# & 1A69_HUMAN,1C02_HUMAN,1A02_GORGO,1A02_HUMAN,1B10_HUMAN,# & 1C02_GORGO,HLAH_HUMAN,1C04_GORGO,1B11_HUMAN,1C28_PANTR,# & 1A01_PANTR,1A30_HUMAN,1A01_SAGOE,1B58_HUMAN,1B23_HUMAN,# & 1B01_PANTR,1A02_PANTR,1B12_HUMAN,1A68_HUMAN,1B05_HUMAN,# & 1A11_HUMAN,1CXX_HUMAN,1C02_HUMAN,1A02_HUMAN,HLAF_MACMU,# & 1A04_PANTR,1B28_HUMAN,1B26_HUMAN)# & PIR1: (HLHU10,HLHU12,HLHUB2,HLHUC4,HLHUA2,HLHUAW,HLHU32,HLHU69,# & HLHUB4,HLHUA3,HLHUB8)# & PIR2: (A60384,S44994,I36961,I37485,JH0536,I37528,A45847,I38519,# & S11133,D35997,I61856,C35997,I54416,I54463,I38442,I84488,# & A49411,I54298,S25415,JL0135,I61906,S51102,I56053,I59645,# & I69002,S29990,JH0526,S24437,I62043,I38439,I59622,S11137,# & C37028,I67482,I68749,I54308,I37483,I37482,I38610,I56133,# & I84448,A35997,I72753,A37028,I68699,I72217,I68750,I61861,# & S03538,I56116,I36956,I38441,S24027,B37028,I37479,JH0547,# & I56039,I54449,I36958,JH0546,S52486,S11141,S11135,S10934,# & S42823,I54307,I37480,I68724,I54505,I80169,JH0543,S48134,# & S16769,S24435,I62041,I36962,I72754,S03535,S11143,I80166,# & I59308,I84432,I56149,JH0542,I68748,I59654,I38509,I36959,# & JS0262,I37526,I37476,S03537,I84487,I81233,I84486,A45834,# & I37542,A45850,I37520,I80168,I59655,I61857,A45880,I61902,# & I61863,I80167,I37544,I80165,S01171,I36960,I80170,I54551,# & S11140,S16789,S24439,I37477,I59633,I61905,S24433,I54289,# & S24436,I37529,I38505,I37515,I38518,I80171,S11134,I61907,# & I36957,I56130,I37519,A47636,JH0544,I62045,I36966,I56009,# & I38421,I37523,I68850,JH0537,I68774,I38436,I61904,I37527,# & I62044,I72170,I83063,I72113,I54442,I72755,I68700,I61866,# & I37516,I37470,I37478,S18198,JH0545,S11138,I54493,I62042,# & JH0535,I54314,G01230,I84490,I72752,S11139,I38443,I37521,# & I37475,I38507,S24440,S11136,I36965)# & PIR3: (S07115,S06424,G02922,S07114,S07113)# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesn,bindyesm,RYLENGKET*# SEQUENCE: RYLENGKET*# ...# >MUS100CC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: HLA-A24 (171-189)# DB REFERENCE: SWISS: (1B58_HUMAN,1C04_HUMAN,1A02_HUMAN,1C04_GORGO,1C16_HUMAN,# & HLAH_HUMAN,1B23_HUMAN,1A02_PANTR,1B12_HUMAN,1C28_PANTR,# & 1A01_PANTR,1A01_SAGOE,1B24_HUMAN,1A30_HUMAN,1B14_HUMAN,# & 1A03_GORGO,1B57_HUMAN,1B42_HUMAN,1A29_HUMAN,1A68_HUMAN,# & 1B12_HUMAN,1B05_HUMAN,1A11_HUMAN,1B11_HUMAN,1B01_PANTR,# & 1B19_HUMAN,1C02_GORGO,1C02_HUMAN,1CXX_HUMAN,HLAF_MACMU,# & 1B28_HUMAN,1A04_PANTR,1B26_HUMAN,1A31_HUMAN,1B10_HUMAN,# & 1A02_GORGO,1C02_GORGO,1B61_HUMAN,1A36_HUMAN,1A01_PONPY,# & 1B54_HUMAN,1A03_PANTR,HLAH_HUMAN,1A32_HUMAN,1A03_HUMAN,# & 1B40_HUMAN,1A69_HUMAN,1C02_HUMAN,1A02_HUMAN,1B48_HUMAN,# & 1B34_HUMAN,1B47_HUMAN,1A26_HUMAN,1B41_HUMAN,1B35_HUMAN,# & 1B60_HUMAN,1C01_GORGO,1B02_PANTR,1A74_HUMAN,1B22_HUMAN,# & 1B44_HUMAN,1B62_HUMAN,1B18_HUMAN,1B21_HUMAN,1B25_HUMAN,# & 1A24_HUMAN,1B55_HUMAN,1C07_HUMAN,1A25_HUMAN,1B29_HUMAN,# & 1B27_HUMAN,1B15_HUMAN,1B56_HUMAN,1C15_HUMAN,1A01_HUMAN,# & 1C01_PANTR,1B04_GORGO,1B45_HUMAN,1A66_HUMAN,HLAF_HUMAN,# & 1B16_HUMAN,1A31_HUMAN,1A23_HUMAN,1C18_HUMAN,1A34_HUMAN,# & 1A04_GORGO,1B31_HUMAN,1A80_HUMAN,1B20_HUMAN,1B01_SAGOE,# & 1C03_GORGO,1AXX_HUMAN,1A43_HUMAN,1B36_HUMAN,1B43_HUMAN,# & 1A26_HUMAN,1B32_HUMAN,1B59_HUMAN,HLAF_HUMAN)# & PIR1: (HLHUB2,HLHUB8,HLHUA3,HLHU10,HLHUC4,HLHUAW,HLHU12,HLHUB4,# & HLHU32,HLHU69,HLHUA2)# & PIR2: (I37475,S24440,I37521,S11139,I37516,JH0545,I84432,I80165,# & S01171,D35997,I59622,I38610,I67482,I54449,S11134,I36957,# & I38436,I36962,I80166,I59654,I56149,A45880,I61863,I38509,# & JS0262,I37544,I37526,A45834,JH0536,C35997,I54463,I84488,# & A49411,S44994,I37485,I61861,I37528,A45847,S29990,I59645,# & S51102,I56053,JH0526,S11137,A35997,I54308,JH0537,I72029,# & I38518,A47636,I62044,I68699,I56116,S24027,I68850,I37515,# & I54416,I68748,JH0542,I72754,S03535,S11143,I62041,I59308,# & I38439,I36959,I80167,A45850,I37542,I84487,I84486,S03537,# & I81233,I37520,I80168,I59655,I61857,I61902,C37028,I56133,# & I37482,I68749,S25415,I37483,I72753,I84448,I69002,I62043,# & S24437,I61906,JL0135,I37476,I37470,I37478,S18198,S11138,# & I54314,I54493,I62042,G01230,JH0535,I38443,I84490,I72752,# & S11136,I38507,I36965,I59633,I61905,S16789,I37477,S24439,# & I37529,I38505,I54289,S24433,S24436,I80170,I36960,I54551,# & S11140,S11133,I38519,I68750,A60384,I36961,I61856,I38442,# & I54298,I37479,S52486,JH0547,I36958,I56039,JH0546,S42823,# & I36956,I38441,B37028,A37028,I72217,S03538,I54505,I54307,# & S10934,S11135,I37480,S11141,I68724,S16769,S24435,JH0543,# & S48134,I80169,I61866,I37527,I56130,I54442,I72755,I68700,# & I72170,I83063,I61904,I72113,I80171,I37519,I61907,JH0544,# & I62045,I68774,I37523,I38421,I36966,I56009)# & PIR3: (G02922,S07115,S07113,S06424,S07114)# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesm,YLENGKETL*# SEQUENCE: YLENGKETL*# ...# >MUS100CD# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference/Competition/Stabilization/CTL induction/HPLC# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Influenza nucleoprotein NP (147-155)# DB REFERENCE: SWISS: (VNUC_IASH2,VNUC_IAZNE,VNUC_IAB37,VNUC_IAWHP,VNUC_IAMEC,# & VNUC_IAGU2,VNUC_IACAL,VNUC_IADE1,VNUC_IAZW1,VNUC_IAZOH,# & VNUC_IADM2,VNUC_IADBE,VNUC_IAHPR,VNUC_IAHLO,VNUC_IAGRE,# & VNUC_IAMEA,VNUC_IAHO2,VNUC_IAMAN,VNUC_IAMEG,VNUC_IAZJ1,# & VNUC_IAUSS,VNUC_IAHTE,VNUC_IADNZ,VNUC_IAZJ4,VNUC_IAGU3,# & VNUC_IAZH1,VNUC_IAME6,VNUC_IATKN,VNUC_IATEI,VNUC_IADHK,# & VNUC_IAZJ3,VNUC_IATRT,VNUC_IAZDA,VNUC_IARUD,VNUC_IAPUE,# & VNUC_IAME5,VNUC_IAZON,VNUC_IAMEF,VNUC_IABRA,VNUC_IAHJI,# & VNUC_IAWIS,VNUC_IAANA,VNUC_IAMEB,VNUC_IAS31,VNUC_IAFPR,# & VNUC_IATRS,VNUC_IATX7,VNUC_IAANN,VNUC_IAHIC,VNUC_IACKG,# & VNUC_IASE0,VNUC_IACKP,VNUC_IAFOM,VNUC_IAS11,VNUC_IADCZ,# & VNUC_IAZI1,VNUC_IAZH3,VNUC_IAHMI,VNUC_IAPAR,VNUC_IASIN,# & VNUC_IAZ41,VNUC_IAEN5,VNUC_IADAU,VNUC_IAZJ2,VNUC_IAME3,# & VNUC_IALEN,VNUC_IAB39,VNUC_IADMA,VNUC_IAMAA,VNUC_IADE2,# & VNUC_IAFPD,VNUC_IAKIE,VNUC_IANT6,VNUC_IAMIN,VNUC_IAGUA,# & VNUC_IAZH4,VNUC_IATKO,VNUC_IAZI2,VNUC_IAHO1,VNUC_IAANN,# & VNUC_IAUDO,VNUC_IAWIL,VNUC_IAGU4,VNUC_IAZW2,VNUC_IAZTE,# & VNUC_IAS06,VNUC_IAFOW,VNUC_IAZGE,VNUC_IAME4,VNUC_IAVI6,# & VNUC_IABUD,VNUC_IAGU1,VNUC_IAZCA,VNUC_IAZMA,VNUC_IAWHN,# & VNUC_IAZI3,VNUC_IADU2,VNUC_IAOHI,VNUC_IAZ29,VNUC_IANEJ,# & VNUC_IAMEE,VNUC_IAGD7,VNUC_IAZJA)# & PIR1: (VHIVXL,VHIVN6,VHIVN5,VHIVC1,VHIVX6,VHIVM1,VHIVN8,VHIVN3,# & A60028,VHIVA3,VHIVN1,VHIV8H,VHIV61,VHIVA7,VHIVA6,VHIVX5,# & VHIV68,VHIVN4,VHIVN7,VHIVN9,VHIVX3,VHIVX4,VHIVAK,VHIVX1,# & VHIV34,VHIVN2,VHIVX2)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS: 2,9# REFERENCES: romero91a,rotzschke90a,abastado93a,eberl93a,maryanski93a,deng97a,# & huang96a,zaghouani93a,sauzet96a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,TYQRTRALV*# SEQUENCE: TYQRTRALV*# ...# >MUS100CE# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive inhibition as./cytotoxicity as./HPLC# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Influenza nucleoprotein NP (147-158)# DB REFERENCE: SWISS: (VNUC_IAANN,VNUC_IAWIL,VNUC_IAGUA,VNUC_IAZH4,VNUC_IATRT,# & VNUC_IATX7,VNUC_IAANN,VNUC_IAMEB,VNUC_IAMEF,VNUC_IAME5,# & VNUC_IAFOM,VNUC_IAS11,VNUC_IAUSS,VNUC_IAGU2,VNUC_IACAL,# & VNUC_IAZW1,VNUC_IADAU,VNUC_IAZTE,VNUC_IAS06,VNUC_IATKO,# & VNUC_IAEN5,VNUC_IAGRE,VNUC_IATEI,VNUC_IAZGE,VNUC_IAOHI,# & VNUC_IANT6,VNUC_IAMIN,VNUC_IADM2,VNUC_IAMAA,VNUC_IADMA,# & VNUC_IAB39,VNUC_IALEN,VNUC_IAVI6,VNUC_IADE2,VNUC_IAKIE,# & VNUC_IAFPD,VNUC_IAUDO,VNUC_IAZW2,VNUC_IAFOW,VNUC_IAME4,# & VNUC_IAGU4,VNUC_IAHO1,VNUC_IAMEE,VNUC_IAZI2,VNUC_IABUD,# & VNUC_IANEJ,VNUC_IAGU1,VNUC_IAGD7,VNUC_IAZJA,VNUC_IAPUE,# & VNUC_IADU2,VNUC_IAZCA,VNUC_IAHIC,VNUC_IAHJI,VNUC_IAANA,# & VNUC_IAZJ2,VNUC_IAME3,VNUC_IAZH3,VNUC_IADHK,VNUC_IAMEC,# & VNUC_IAB37,VNUC_IAWHP,VNUC_IAHPR,VNUC_IADBE,VNUC_IAZNE,# & VNUC_IASH2,VNUC_IAZJ4,VNUC_IAMEA,VNUC_IAMAN,VNUC_IADCZ,# & VNUC_IAHMI,VNUC_IASIN,VNUC_IAZ41,VNUC_IAZI1,VNUC_IAPAR,# & VNUC_IAWIS,VNUC_IABRA,VNUC_IASE0,VNUC_IACKG,VNUC_IAZMA,# & VNUC_IAZ29,VNUC_IAZI3,VNUC_IAWHN,VNUC_IATRS,VNUC_IAS31,# & VNUC_IAFPR,VNUC_IAZDA,VNUC_IAZJ3,VNUC_IARUD,VNUC_IAZON,# & VNUC_IADE1,VNUC_IAHLO,VNUC_IAZOH,VNUC_IAMEG,VNUC_IAHO2,# & VNUC_IACKP,VNUC_IAZJ1,VNUC_IADNZ,VNUC_IATKN,VNUC_IAME6,# & VNUC_IAGU3,VNUC_IAZH1)# & PIR1: (VHIV34,VHIVC1,VHIVN2,VHIVA6,VHIV61,VHIVX6,VHIVN8,VHIVX3,# & A60028,VHIVM1,VHIV8H,VHIVN4,VHIVN6,VHIVN5,VHIVXL,VHIVX2,# & VHIV68,VHIVX5,VHIVA7,VHIVX1,VHIVN9,VHIVX4,VHIVAK,VHIVN7,# & VHIVN1,VHIVN3,VHIVA3)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS: 2,9# REFERENCES: romero91a,rotzschke90b,bodmer88a,blum-tirouvanziam94a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesm,TYQRTRALVRTG*# SEQUENCE: TYQRTRALVRTG*# ...# >MUS100CF# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: Influenza nucleoprotein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romero91a# COMMENT:# SUMMARY: H-2Kd,actyesl,bindyesm,TYQRTRAL*# SEQUENCE: TYQRTRAL*# ...# >MUS100D0# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Influenza nucleoprotein NP (147-155)# DB REFERENCE: SWISS: (VNUC_IABRA,VNUC_IAZMA,VNUC_IATRT,VNUC_IADM2,VNUC_IAZDA,# & VNUC_IAMEG,VNUC_IATEI,VNUC_IAMEF,VNUC_IAME3,VNUC_IAMEC,# & VNUC_IAZJ1,VNUC_IAZON,VNUC_IAZH3,VNUC_IAS11,VNUC_IAWIL,# & VNUC_IAZI3,VNUC_IAHMI,VNUC_IAZ41,VNUC_IAUDO,VNUC_IABUD,# & VNUC_IAME4,VNUC_IAZNE,VNUC_IASH2,VNUC_IAMEA,VNUC_IAGU2,# & VNUC_IAHJI,VNUC_IAPUE,VNUC_IARUD,VNUC_IAZOH,VNUC_IASE0,# & VNUC_IATKN,VNUC_IAGU3,VNUC_IAZI2,VNUC_IAWIS,VNUC_IAPAR,# & VNUC_IAHLO,VNUC_IAZCA,VNUC_IAMAN,VNUC_IAGRE,VNUC_IAHPR,# & VNUC_IADE1,VNUC_IAUSS,VNUC_IATKO,VNUC_IAFPD,VNUC_IASIN,# & VNUC_IAZJ3,VNUC_IAGU1,VNUC_IAZJ4,VNUC_IAEN5,VNUC_IAZGE,# & VNUC_IAOHI,VNUC_IAZTE,VNUC_IAKIE,VNUC_IAGU4,VNUC_IAVI6,# & VNUC_IAGD7,VNUC_IAHTE,VNUC_IANEJ,VNUC_IAZ29,VNUC_IAWHN,# & VNUC_IAFPR,VNUC_IAMIN,VNUC_IADHK,VNUC_IAZJ2,VNUC_IAANA,# & VNUC_IAFOM,VNUC_IAS06,VNUC_IAME5,VNUC_IAMEB,VNUC_IATX7,# & VNUC_IAANN,VNUC_IAZW1,VNUC_IADAU,VNUC_IAME6,VNUC_IAZH1,# & VNUC_IADBE,VNUC_IAB37,VNUC_IAHIC,VNUC_IAZH4,VNUC_IACAL,# & VNUC_IADE2,VNUC_IAB39,VNUC_IAMEE,VNUC_IAFOW,VNUC_IAZJA,# & VNUC_IACKG,VNUC_IADCZ,VNUC_IAZI1,VNUC_IAZW2,VNUC_IAHO1,# & VNUC_IATRS,VNUC_IAS31,VNUC_IACKP,VNUC_IADNZ,VNUC_IAHO2,# & VNUC_IAANN,VNUC_IAGUA,VNUC_IADU2,VNUC_IADMA,VNUC_IALEN,# & VNUC_IANT6,VNUC_IAMAA,VNUC_IAWHP)# & PIR1: (VHIVA6,VHIVA3,A60028,VHIV68,VHIVN3,VHIVX5,VHIVN5,VHIVX4,# & VHIVN8,VHIVN9,VHIVX2,VHIVX6,VHIVX3,VHIV61,VHIVN2,VHIV8H,# & VHIVXL,VHIVA7,VHIVM1,VHIVN4,VHIVAK,VHIVN7,VHIVN1,VHIV34,# & VHIVC1,VHIVN6,VHIVX1)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS: 1,8# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesm,YQRTRALV*# SEQUENCE: YQRTRALV*# ...# >MUS100D1# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: HPLC/competitive inhibition/cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Tumor antigen of P815/P198 (14-22)# DB REFERENCE: PIR2: (JL0149)# REFERENCES: romero91a,wallny92a,falk93a,wallny92b,eberl93a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,KYQAVTTTL*# SEQUENCE: KYQAVTTTL*# ...# >MUS100D2# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive inhibition/cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Tumor antigen of P815/P198 (14-24)# DB REFERENCE: PIR2: (JL0149)# REFERENCES: romero91a,falk93a,wallny92b,abastado93a,maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesm,KYQAVTTTLEE*# SEQUENCE: KYQAVTTTLEE*# ...# >MUS100D3# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Tumor antigen of P815/P198 (14-23)# DB REFERENCE: PIR2: (JL0149)# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesm,KYQAVTTTLE*# SEQUENCE: KYQAVTTTLE*# ...# >MUS100D4# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: Tumor antigen of P815/P198 (14-21)# DB REFERENCE: PIR2: (JL0149)# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesl,KYQAVTTT*# SEQUENCE: KYQAVTTT*# ...# >MUS100D5# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/Stabilization/Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176)# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: romero91a,maryanski91a,maryanski93a,cook96a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,YPHFMPTNL*# SEQUENCE: YPHFMPTNL*# ...# >MUS100D6# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Y___TL homologue# ANCHOR POSITIONS: 2,9# REFERENCES: romero91a,maryanski90a,maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,AYPPPPPTLA*# SEQUENCE: AYPPPPPTLA*# ...# >MUS100D7# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Y___L homologue# ANCHOR POSITIONS: 1,?# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,YPPPPPL*# SEQUENCE: YPPPPPL*# ...# >MUS100D8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Y___L homologue# ANCHOR POSITIONS: 2,?# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,AYPPPPPL*# SEQUENCE: AYPPPPPL*# ...# >MUS100D9# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Y___L homologue# ANCHOR POSITIONS: 1,8# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YPPPPPPL*# SEQUENCE: YPPPPPPL*# ...# >MUS100DA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive inhibition as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Y___ homologue# ANCHOR POSITIONS: 2,9# REFERENCES: romero91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesm,AYPPPPPPL*# SEQUENCE: AYPPPPPPL*# ...# >MUS100DB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Y___L homologue# ANCHOR POSITIONS: 1,9# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,YPPPPPPPL*# SEQUENCE: YPPPPPPPL*# ...# >MUS100DC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Y___L homologue# ANCHOR POSITIONS: 2,10# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,AYPPPPPPPL*# SEQUENCE: AYPPPPPPPL*# ...# >MUS100DD# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Plasmon res./Competition/CTL induction/Reference/Stabil./Half-time# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: MCMV pp89 (168-176)# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: maryanski86a,reddehase89a,townsend89a,del_val88a,catipovic92a,# & corr92a,udaka92a,kageyama95a,khilko93a,lipford94a,maryanski91a,# & maryanski93a,lie91a,cook96a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesh,YPHFMPTNL*# SEQUENCE: YPHFMPTNL*# ...# >MUS100DE# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Y___L homologue# ANCHOR POSITIONS:# REFERENCES: romero91a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,YPPPPPPPL*# SEQUENCE: YPPPPPPPL*# ...# >MUS100DF# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./Stabilization# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Influenza A/JAP/305 Hemagglutinin (202-221)# DB REFERENCE: SWISS: (HEMA_IAJAP,HEMA_IACKS,HEMA_IADIR,HEMA_IATKI,# & HEMA_IATKO)# & PIR1: (HMIVC2,HMIVAT,HMIVT8,HMIV2,HMIVD8)# & PIR2: (PL0161)# REFERENCES: hahn92a,cao94a,cao95a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesh,bindyesm,TYVSVGTSTL*# SEQUENCE: TYVSVGTSTL*# ...# >MUS100E0# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,TTLYQNVGTYVSVGTSTLNK*# SEQUENCE: TTLYQNVGTYVSVGTSTLNK*# ...# >MUS100E1# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,STLYQNVGTYVSVGTSTLNK*# SEQUENCE: STLYQNVGTYVSVGTSTLNK*# ...# >MUS100E2# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,CTLYQNVGTYVSVGTSTLNK*# SEQUENCE: CTLYQNVGTYVSVGTSTLNK*# ...# >MUS100E3# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,GTLYQNVGTYVSVGTSTLNK*# SEQUENCE: GTLYQNVGTYVSVGTSTLNK*# ...# >MUS100E4# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RALYQNVGTYVSVGTSTLNK*# SEQUENCE: RALYQNVGTYVSVGTSTLNK*# ...# >MUS100E5# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RLLYQNVGTYVSVGTSTLNK*# SEQUENCE: RLLYQNVGTYVSVGTSTLNK*# ...# >MUS100E6# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RKLYQNVGTYVSVGTSTLNK*# SEQUENCE: RKLYQNVGTYVSVGTSTLNK*# ...# >MUS100E7# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTFYQNVGTYVSVGTSTLNK*# SEQUENCE: RTFYQNVGTYVSVGTSTLNK*# ...# >MUS100E8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTWYQNVGTYVSVGTSTLNK*# SEQUENCE: RTWYQNVGTYVSVGTSTLNK*# ...# >MUS100E9# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTWYLNVGTYVSVGTSTLNK*# SEQUENCE: RTWYLNVGTYVSVGTSTLNK*# ...# >MUS100EA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLDQNVGTYVSVGTSTLNK*# SEQUENCE: RTLDQNVGTYVSVGTSTLNK*# ...# >MUS100EB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLNQNVGTYVSVGTSTLNK*# SEQUENCE: RTLNQNVGTYVSVGTSTLNK*# ...# >MUS100EC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLSENVGTYVSVGTSTLNK*# SEQUENCE: RTLSENVGTYVSVGTSTLNK*# ...# >MUS100ED# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLIENVGTYVSVGTSTLNK*# SEQUENCE: RTLIENVGTYVSVGTSTLNK*# ...# >MUS100EE# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLGENVGTYVSVGTSTLNK*# SEQUENCE: RTLGENVGTYVSVGTSTLNK*# ...# >MUS100EF# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYENVGTYVSVGTSTLNK*# SEQUENCE: RTLYENVGTYVSVGTSTLNK*# ...# >MUS100F0# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYLNVGTYVSVGTSTLNK*# SEQUENCE: RTLYLNVGTYVSVGTSTLNK*# ...# >MUS100F1# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYHNVGTYVSVGTSTLNK*# SEQUENCE: RTLYHNVGTYVSVGTSTLNK*# ...# >MUS100F2# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQTVGTYVSVGTSTLNK*# SEQUENCE: RTLYQTVGTYVSVGTSTLNK*# ...# >MUS100F3# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQKVGTYVSVGTSTLNK*# SEQUENCE: RTLYQKVGTYVSVGTSTLNK*# ...# >MUS100F4# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQYLGTYVSVGTSTLNK*# SEQUENCE: RTLYQYLGTYVSVGTSTLNK*# ...# >MUS100F5# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQTAGTYVSVGTSTLNK*# SEQUENCE: RTLYQTAGTYVSVGTSTLNK*# ...# >MUS100F6# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNEGTYVSVGTSTLNK*# SEQUENCE: RTLYQNEGTYVSVGTSTLNK*# ...# >MUS100F7# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNGGTYVSVGTSTLNK*# SEQUENCE: RTLYQNGGTYVSVGTSTLNK*# ...# >MUS100F8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,STLYQNGGTYVSVGTSTLNK*# SEQUENCE: STLYQNGGTYVSVGTSTLNK*# ...# >MUS100F9# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RRLYQNAGTYVSVGTSTLNK*# SEQUENCE: RRLYQNAGTYVSVGTSTLNK*# ...# >MUS100FA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVSTYVSVGTSTLNK*# SEQUENCE: RTLYQNVSTYVSVGTSTLNK*# ...# >MUS100FB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVCTYVSVGTSTLNK*# SEQUENCE: RTLYQNVCTYVSVGTSTLNK*# ...# >MUS100FC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RKLYQNVCTYVSVGTSTLNK*# SEQUENCE: RKLYQNVCTYVSVGTSTLNK*# ...# >MUS100FD# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGNYVSVGTSTLNK*# SEQUENCE: RTLYQNVGNYVSVGTSTLNK*# ...# >MUS100FE# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGGYVSVGTSTLNK*# SEQUENCE: RTLYQNVGGYVSVGTSTLNK*# ...# >MUS100FF# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A JAP/305 HA (202-221)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# REFERENCES: hahn92a,braciale89a,falk93a,cao94a# COMMENT: Not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,LYQNVGTYV*# SEQUENCE: LYQNVGTYV*# ...# >MUS10100# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a,hahn96a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesl,RTLYQNVGTDVSVGTSTLNK*# SEQUENCE: RTLYQNVGTDVSVGTSTLNK*# ...# >MUS10101# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: Pos 16 (E or Q); Not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTHVSVGTE*# SEQUENCE: RTLYQNVGTHVSVGTE*# ...# >MUS10102# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: Pos 16 (E or Q); Not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTHVSVGTQ*# SEQUENCE: RTLYQNVGTHVSVGTQ*# ...# >MUS10103# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTHVSVDTSTLNK*# SEQUENCE: RTLYQNVGTHVSVDTSTLNK*# ...# >MUS10104# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYLSVGTSTLNK*# SEQUENCE: RTLYQNVGTYLSVGTSTLNK*# ...# >MUS10105# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVAVGTSTLNK*# SEQUENCE: RTLYQNVGTYVAVGTSTLNK*# ...# >MUS10106# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVCVGTSTLNK*# SEQUENCE: RTLYQNVGTYVCVGTSTLNK*# ...# >MUS10107# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVPVGTSTLNK*# SEQUENCE: RTLYQNVGTYVPVGTSTLNK*# ...# >MUS10108# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSLGTSTLNK*# SEQUENCE: RTLYQNVGTYVSLGTSTLNK*# ...# >MUS10109# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSIGTSTLKK*# SEQUENCE: RTLYQNVGTYVSIGTSTLKK*# ...# >MUS1010A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: Pos 20 (E or Q); Not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSEGTSTCNE*# SEQUENCE: RTLYQNVGTYVSEGTSTCNE*# ...# >MUS1010B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: Pos 20 (E or Q); Not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSEGTSTCNQ*# SEQUENCE: RTLYQNVGTYVSEGTSTCNQ*# ...# >MUS1010C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSEGTSKLNK*# SEQUENCE: RTLYQNVGTYVSEGTSKLNK*# ...# >MUS1010D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSKVTSTLNK*# SEQUENCE: RTLYQNVGTYVSKVTSTLNK*# ...# >MUS1010E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVRTSTVYK*# SEQUENCE: RTLYQNVGTYVSVRTSTVYK*# ...# >MUS1010F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGPSTLNK*# SEQUENCE: RTLYQNVGTYVSVGPSTLNK*# ...# >MUS10110# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTATLNK*# SEQUENCE: RTLYQNVGTYVSVGTATLNK*# ...# >MUS10111# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSSLNK*# SEQUENCE: RTLYQNVGTYVSVGTSSLNK*# ...# >MUS10112# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSNLNK*# SEQUENCE: RTLYQNVGTYVSVGTSNLNK*# ...# >MUS10113# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSKLNK*# SEQUENCE: RTLYQNVGTYVSVGTSKLNK*# ...# >MUS10114# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSTWNK*# SEQUENCE: RTLYQNVGTYVSVGTSTWNK*# ...# >MUS10115# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSTFKR*# SEQUENCE: RTLYQNVGTYVSVGTSTFKR*# ...# >MUS10116# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSTLDK*# SEQUENCE: RTLYQNVGTYVSVGTSTLDK*# ...# >MUS10117# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSTLYK*# SEQUENCE: RTLYQNVGTYVSVGTSTLYK*# ...# >MUS10118# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSTLTT*# SEQUENCE: RTLYQNVGTYVSVGTSTLTT*# ...# >MUS10119# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSTLNR*# SEQUENCE: RTLYQNVGTYVSVGTSTLNR*# ...# >MUS1011A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSTLNQ*# SEQUENCE: RTLYQNVGTYVSVGTSTLNQ*# ...# >MUS1011B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (202-221) homologue# ANCHOR POSITIONS:# REFERENCES: hahn92a# COMMENT: Pos 20 (E or Q); Not recognized by all Kd restricted clones# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYVSVGTSTLNE*# SEQUENCE: RTLYQNVGTYVSVGTSTLNE*# ...# >MUS1011C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-CW3 (171-186)# DB REFERENCE: SWISS: (1C06_HUMAN)# & PIR2: (I81231)# ANCHOR POSITIONS:# REFERENCES: maryanski86a# COMMENT: recognized by 2 of 3 Kb restricted clones# SUMMARY: H-2Kd,actyesm,bindyesu,YLKNGKETLQRAEHPK*# SEQUENCE: YLKNGKETLQRAEHPK*# ...# >MUS1011D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-A3 (171-186)# DB REFERENCE: SWISS: (1A04_PANTR,1A03_HUMAN,1A31_HUMAN,1A30_HUMAN,1A36_HUMAN,# & 1A03_PANTR,1A31_HUMAN,1A01_HUMAN,1A80_HUMAN,1A11_HUMAN,# & 1A23_HUMAN,1A01_PANTR)# & PIR1: (HLHUA3)# & PIR2: (I83063,I72170,I54493,I36965,I37478,S01171,A47636,I38518,# & I38610,I38439,S03535,I36961,I61856,I54307,I37476,I36959,# & I38519,I56039,I36966)# & PIR3: (S06424)# REFERENCES: maryanski86a# COMMENT: recognized by 2 of 3 Kb restricted clones# SUMMARY: H-2Kd,actyesm,bindyesu,YLENGKETLQRTDPPK*# SEQUENCE: YLENGKETLQRTDPPK*# ...# >MUS1011E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-A24 (171-186)# DB REFERENCE: SWISS: (1A02_PANTR,1B23_HUMAN,1B57_HUMAN,1B42_HUMAN,1B14_HUMAN,# & 1B24_HUMAN,1B16_HUMAN,1C28_PANTR,HLAH_HUMAN,1B32_HUMAN,# & 1B20_HUMAN,1B43_HUMAN,1B40_HUMAN,1B04_GORGO,1B45_HUMAN,# & 1B21_HUMAN,1B25_HUMAN,1A24_HUMAN,1B62_HUMAN,1B18_HUMAN,# & 1B27_HUMAN,1B29_HUMAN,HLAF_HUMAN,1B60_HUMAN,1C01_GORGO,# & 1B22_HUMAN,1B02_PANTR,1B35_HUMAN,1B34_HUMAN,1B48_HUMAN,# & 1B47_HUMAN,1B41_HUMAN,1B10_HUMAN,1B61_HUMAN,1B54_HUMAN,# & 1B11_HUMAN,1B19_HUMAN,1B05_HUMAN,1B28_HUMAN,1B12_HUMAN,# & HLAF_HUMAN,HLAH_HUMAN,1B12_HUMAN,1B58_HUMAN,1B31_HUMAN,# & 1B59_HUMAN,1B36_HUMAN,1B15_HUMAN,1B56_HUMAN,1B44_HUMAN,# & 1B55_HUMAN,1B26_HUMAN,HLAF_MACMU,1B01_PANTR)# & PIR1: (HLHU12,HLHUB2,HLHUB4,HLHUB8)# & PIR2: (I38421,I36960,I72755,I54442,I56130,I80171,I80167,JH0542,# & I72754,I62041,I61906,S24437,A45850,I81233,I72752,A45834,# & I59654,I80166,S29990,I59645,C35997,S24027,S24440,I84486,# & I72753,I68748,I59655,I37520,I37516,I36957,I61863,I38509,# & I62044,I61904,I84490,S24436,A60384,I54298,S03538,I36956,# & S52486,I59308,I80168,I62043,S25415,I56133,S03537,D35997,# & I54416,I68850,I37515,I56116,I80165,I37475,I37521,I54314,# & I37485,I61861,I54463,I84488,I54308,A45880,I36962,I56149,# & S16789,S24439,I59633,I61905,I54289,S24433,I62042,G01230,# & I61907,I37519,JH0544,I62045,I68774,I80170,S24435,I80169,# & JH0543,I68724,I54505)# & PIR3: (S07115,S07114,S07113)# REFERENCES: maryanski86a# COMMENT: recognized by 2 of 3 Kb restricted clones# SUMMARY: H-2Kd,actyesm,bindyesu,YLENGKETLQRADPPK*# SEQUENCE: YLENGKETLQRADPPK*# ...# >MUS1011F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-CW3 (168-182)# DB REFERENCE: SWISS: (1C06_HUMAN)# & PIR2: (I81231)# ANCHOR POSITIONS:# REFERENCES: maryanski88a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,LRRYLKNGKETLQRA*# SEQUENCE: LRRYLKNGKETLQRA*# ...# >MUS10120# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-CW3 (169-182)# DB REFERENCE: SWISS: (1C06_HUMAN)# & PIR2: (I81231)# ANCHOR POSITIONS:# REFERENCES: maryanski88a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,RRYLKNGKETLQRA*# SEQUENCE: RRYLKNGKETLQRA*# ...# >MUS10121# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-Cw3 (170-182)# DB REFERENCE: SWISS: (1C06_HUMAN)# & PIR2: (I81231)# ANCHOR POSITIONS:# REFERENCES: maryanski88a,maryanski91a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,RYLKNGKETLQRA*# SEQUENCE: RYLKNGKETLQRA*# ...# >MUS10122# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-CW3 (171-182)# DB REFERENCE: SWISS: (1C06_HUMAN)# & PIR2: (I81231)# ANCHOR POSITIONS:# REFERENCES: maryanski88a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,YLKNGKETLQRA*# SEQUENCE: YLKNGKETLQRA*# ...# >MUS10123# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-A24 (168-182)# DB REFERENCE: SWISS: (1B10_HUMAN,1B54_HUMAN,1B19_HUMAN,1B05_HUMAN,1B61_HUMAN,# & 1C02_HUMAN,1C07_HUMAN,1B40_HUMAN,1C15_HUMAN,1B20_HUMAN,# & 1B32_HUMAN,1B29_HUMAN,1B27_HUMAN,1B34_HUMAN,1B35_HUMAN,# & 1B47_HUMAN,1B48_HUMAN,1B60_HUMAN,1C01_GORGO,1B22_HUMAN,# & 1B02_PANTR,1B59_HUMAN,1B31_HUMAN,1B26_HUMAN,1B01_PANTR,# & 1B58_HUMAN,1B12_HUMAN,1B44_HUMAN,1B55_HUMAN,1B15_HUMAN,# & 1B36_HUMAN,1C02_GORGO,HLAH_HUMAN,1CXX_HUMAN,1C02_HUMAN,# & HLAF_HUMAN,1B41_HUMAN,1B28_HUMAN,1B56_HUMAN,HLAF_HUMAN,# & 1B12_HUMAN,1C02_GORGO,1C04_HUMAN,1C16_HUMAN,HLAH_HUMAN,# & 1C28_PANTR,1B16_HUMAN,1B45_HUMAN,1B04_GORGO,1B23_HUMAN,# & 1B42_HUMAN,1B24_HUMAN,1A24_HUMAN,1B62_HUMAN,1B18_HUMAN,# & 1B21_HUMAN,1B25_HUMAN,1C18_HUMAN,1B57_HUMAN,1A02_PANTR,# & 1B14_HUMAN,HLAF_MACMU,1B11_HUMAN,1C03_GORGO,1C04_GORGO,# & 1B43_HUMAN)# & PIR1: (HLHUB8,HLHUC4,HLHUB4,HLHU12,HLHUB2)# & PIR2: (I59308,S25415,I62043,I54298,C37028,A60384,I68749,S03538,# & S24435,I80169,JH0543,I68724,I54505,I80170,I62045,JH0544,# & G01230,I62042,I36958,JH0547,S24433,S16789,S24439,I59633,# & B37028,I37527,I72113,I54314,S48134,I56116,I61861,I84488,# & I54308,I56149,A45880,I61866,I80165,I38507,I38505,I37529,# & I61906,JH0542,JS0262,I37544,I37526,I80167,A45850,JH0526,# & I56130,I80171,I72755,S44994,D35997,I68850,I54416,I37515,# & I37516,JH0545,I36957,I59655,I37520,I72753,I59622,I72752,# & I80166,A45834,I59654,S24027,C35997,S29990,S24440,I61904,# & I61863,I84490,I62044,I38509,I37521,I37523,I37519,I61907,# & I54289,I37528,I54449,I68748,S24436,I84486,S52486,I59645,# & I54442,A49411,I36960,I38421,S24437,I62041,I72754,I81233,# & I37475,S03537,I36956,I56133,I80168,I36962,I37485,JH0546,# & S42823,I61905,I68750)# & PIR3: (G02922,S07115,S07114,S07113)# REFERENCES: maryanski88a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,LRRYLENGKETLQRA*# SEQUENCE: LRRYLENGKETLQRA*# ...# >MUS10124# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-A24 (169-182)# DB REFERENCE: SWISS: (1B22_HUMAN,1B62_HUMAN,1B18_HUMAN,1B40_HUMAN,1B57_HUMAN,# & 1B10_HUMAN,1B05_HUMAN,1B12_HUMAN,1A02_PANTR,1B14_HUMAN,# & 1C18_HUMAN,1B27_HUMAN,1B21_HUMAN,1B25_HUMAN,1A24_HUMAN,# & 1B32_HUMAN,1B20_HUMAN,1C15_HUMAN,1C02_GORGO,HLAF_HUMAN,# & 1B29_HUMAN,1C03_GORGO,1B43_HUMAN,1B11_HUMAN,HLAF_MACMU,# & 1B56_HUMAN,1C04_GORGO,1B28_HUMAN,1B23_HUMAN,1B42_HUMAN,# & 1B45_HUMAN,1B47_HUMAN,1B34_HUMAN,1B54_HUMAN,1B36_HUMAN,# & 1C02_GORGO,1B55_HUMAN,1B44_HUMAN,1B01_PANTR,1C28_PANTR,# & HLAH_HUMAN,1B24_HUMAN,1B16_HUMAN,1B04_GORGO,1C04_HUMAN,# & 1C16_HUMAN,HLAF_HUMAN,1B12_HUMAN,1B41_HUMAN,1B61_HUMAN,# & 1B19_HUMAN,1B58_HUMAN,1C07_HUMAN,1B02_PANTR,1B60_HUMAN,# & 1C01_GORGO,1B48_HUMAN,1B35_HUMAN,1C02_HUMAN,1CXX_HUMAN,# & 1C02_HUMAN,HLAH_HUMAN,1B59_HUMAN,1B31_HUMAN,1B15_HUMAN,# & 1B26_HUMAN)# & PIR1: (HLHUB4,HLHUB2,HLHU12,HLHUC4,HLHUB8)# & PIR2: (I61861,S44994,I56130,I54463,I61906,I37544,A60384,I68749,# & I68724,S24439,G01230,I36958,I62042,I80170,S24435,I80169,# & I72752,I61904,I80168,I56133,I36956,I37485,I68750,I38421,# & I36960,JH0547,I61907,S24436,I68748,I54308,A45850,I59654,# & I37520,I84490,I37528,I54449,I37521,I37523,I37519,I54289,# & I72113,I37527,I59645,I54442,A49411,I72754,I62041,I81233,# & S24437,I37475,S52486,I84486,I61863,I38509,I62044,I36962,# & I61905,S42823,JH0546,S03537,C35997,S24027,I80166,S29990,# & I37516,S24440,A45834,I36957,JH0545,I59622,I59655,I72753,# & I80167,JH0542,JS0262,I37526,JH0526,I72755,I80171,I68850,# & I37515,I54416,D35997,I59308,I38505,I37529,I80165,I38507,# & I84488,I68774,I56116,I61866,A45880,I56149,S48134,JH0544,# & I62045,JH0543,B37028,I59633,S16789,S24433,I54314,I54505,# & S03538,C37028,I54298,I62043,S25415)# & PIR3: (S07114,G02922,S07115,S07113)# REFERENCES: maryanski88a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,RRYLENGKETLQRA*# SEQUENCE: RRYLENGKETLQRA*# ...# >MUS10125# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-A24 (171-182)# DB REFERENCE: SWISS: (1B12_HUMAN,1B16_HUMAN,1B24_HUMAN,1B04_GORGO,1B41_HUMAN,# & HLAH_HUMAN,1C28_PANTR,1B58_HUMAN,1B19_HUMAN,1C02_HUMAN,# & 1C04_HUMAN,1C16_HUMAN,1B59_HUMAN,1B31_HUMAN,1B26_HUMAN,# & 1B36_HUMAN,1B55_HUMAN,1C02_GORGO,1B01_PANTR,1B42_HUMAN,# & 1B45_HUMAN,1B56_HUMAN,1C04_GORGO,1C03_GORGO,1B43_HUMAN,# & 1B11_HUMAN,HLAF_MACMU,1B29_HUMAN,1B34_HUMAN,1B47_HUMAN,# & 1B15_HUMAN,1CXX_HUMAN,HLAH_HUMAN,1C02_HUMAN,1B61_HUMAN,# & 1B01_SAGOE,1B28_HUMAN,1B23_HUMAN,1B44_HUMAN,1B22_HUMAN,# & 1B40_HUMAN,1B18_HUMAN,1B57_HUMAN,1B10_HUMAN,1B05_HUMAN,# & 1B20_HUMAN,1B48_HUMAN,1A01_SAGOE,1C02_GORGO,HLAF_HUMAN,# & 1B12_HUMAN,1B02_PANTR,1B60_HUMAN,1C01_GORGO,1B35_HUMAN,# & 1C07_HUMAN,1B27_HUMAN,1C15_HUMAN,1A24_HUMAN,1B25_HUMAN,# & 1B21_HUMAN,1B14_HUMAN,1A02_PANTR,1B62_HUMAN,1B54_HUMAN,# & 1C18_HUMAN,1B32_HUMAN,HLAF_HUMAN)# & PIR1: (HLHU12,HLHUB8,HLHUB4,HLHUC4,HLHUB2)# & PIR2: (JH0543,C37028,I62043,S11143,JH0544,I62045,S16789,B37028,# & D35997,I80165,I37529,I38505,S48134,A45880,I61866,I68774,# & I56116,I84488,I37515,JH0542,JH0526,I72755,I36957,JH0545,# & I59655,S10934,S11135,I72753,I59622,C35997,S24027,S24440,# & I37516,S29990,A45834,S11133,I81233,S03537,G01230,I38509,# & I61863,I36962,I61905,S42823,JH0546,S52486,I37519,S11136,# & I72754,I62041,S11140,I37475,I59645,I54442,A60384,I68749,# & I80169,S24435,S11137,I62042,I61861,I56053,I61906,I56130,# & I54463,S44994,I72752,I37528,I54449,I37523,I37521,I72113,# & I37527,S24436,I68748,JH0547,I61904,I68750,I80168,I56133,# & I37485,I36960,I59308,I54308,I59654,I37520,I84490,S11134,# & I54289,A49411,I84486,I62044,S11141,JS0262,S11139,S24439,# & A45850,I61907,I38507,I56149,I54505,S24433,I36956,I38421,# & I37544,I36958,I68724,I80170,S11138,S24437,I54314,I59633,# & I54298,S25415,S03538,I80171,I72217,I68850,I80167,I37526,# & I54416,I80166)# & PIR3: (S07115,G02922,S07114,S07113)# REFERENCES: maryanski88a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,YLENGKETLQRA*# SEQUENCE: YLENGKETLQRA*# ...# >MUS10126# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: pp89 IE murine cytomegalovirus (167-177)# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: reddehase89a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesl,MYPHFMPTNLG*# SEQUENCE: MYPHFMPTNLG*# ...# >MUS10127# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./Competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: pp89 IE murine cytomegalovirus (167-176)# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: reddehase89a,hickling90a,maryanski91a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesm,MYPHFMPTNL*# SEQUENCE: MYPHFMPTNL*# ...# >MUS10128# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: pp89 IE murine cytomegalovirus (168-177)# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: reddehase89a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesl,YPHFMPTNLG*# SEQUENCE: YPHFMPTNLG*# ...# >MUS10129# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: pp89 IE murine cytomegalovirus (169-176)# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: reddehase89a# COMMENT:# SUMMARY: H-2Ld,actyesl,bindyesl,PHFMPTNL*# SEQUENCE: PHFMPTNL*# ...# >MUS1012A# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza A HA (354-365)# DB REFERENCE: SWISS: (HEMA_IAKIE,HEMA_IAPUE,HEMA_IAWIL,HEMA_IALEN,HEMA_IAZIN,# & HEMA_IASH2,HEMA_IAZNJ,HEMA_IAUSS,HEMA_IADA4)# & PIR1: (HMIVD1,HMIVN1,HMIVUR,HMIVSA,HMIV,HMIV17,HMIV5)# & PIR3: (S69889,S69888)# REFERENCES: gould91a# COMMENT:# SUMMARY: H-2Kk,actyesl,bindyesu,IEGGWTGMIDGW*# SEQUENCE: IEGGWTGMIDGW*# ...# >MUS1012B# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza A HA (354-362)# DB REFERENCE: SWISS: (HEMA_IALEN,HEMA_IAPUE,HEMA_IAZNJ,HEMA_IASH2,HEMA_IAWIL,# & HEMA_IAKIE,HEMA_IADA4,HEMA_IAUSS,HEMA_IAZIN)# & PIR1: (HMIV,HMIVUR,HMIVN1,HMIV5,HMIVSA,HMIVD1,HMIV17)# & PIR3: (S69888,S69889)# REFERENCES: gould91a# COMMENT:# SUMMARY: H-2Kk,actyesh,bindyesu,IEGGWTGMI*# SEQUENCE: IEGGWTGMI*# ...# >MUS1012C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza A HA (355-362)# DB REFERENCE: SWISS: (HEMA_IAUSS,HEMA_IASH2,HEMA_IAZNJ,HEMA_IAWIL,HEMA_IAKIE,# & HEMA_IALEN,HEMA_IAPUE,HEMA_IADA4,HEMA_IAZIN)# & PIR1: (HMIV17,HMIVUR,HMIVSA,HMIVD1,HMIV5,HMIV,HMIVN1)# & PIR3: (S69888,S69889)# REFERENCES: gould91a# COMMENT:# SUMMARY: H-2Kk,actyesl,bindyesu,EGGWTGMI*# SEQUENCE: EGGWTGMI*# ...# >MUS1012D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza A HA (255-262)# DB REFERENCE: SWISS: (HEMA_IAUSS,HEMA_IAHAR,HEMA_IAPUE,HEMA_IATAI,HEMA_IAKIE,# & HEMA_IALEN,HEMA_IAXIA)# & PIR1: (HMIVUR,HMIVTA,HMIV)# & PIR2: (A35788,S16785,PQ0319,JQ1643,JQ2372,JQ2371,JQ1437,PQ0321,# & JQ2370)# REFERENCES: gould91a# COMMENT:# SUMMARY: H-2Kk,actyesh,bindyesu,FEANGNLI*# SEQUENCE: FEANGNLI*# ...# >MUS1012E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A HA (255-266)# ANCHOR POSITIONS:# REFERENCES: gould91a# COMMENT:# SUMMARY: H-2Kk,actyesm,bindyesu,FEANGNLIAPMY*# SEQUENCE: FEANGNLIAPMY*# ...# >MUS1012F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A HA (255-271)# ANCHOR POSITIONS:# REFERENCES: gould91a# COMMENT:# SUMMARY: H-2Kk,actyesm,bindyesu,FEANGNLIAPMYAFALS*# SEQUENCE: FEANGNLIAPMYAFALS*# ...# >MUS10130# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./competitive binding/direct binding# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Influenza virus nucleoprotein (50-57)# DB REFERENCE: SWISS: (VNUC_IADNZ,VNUC_IAFOM,VNUC_IADHK,VNUC_IAZON,VNUC_IADBE,# & VNUC_IACKG,VNUC_IAZH4,VNUC_IATKO,VNUC_IAZJ3,VNUC_IAWIS,# & VNUC_IAZH1,VNUC_IAANN,VNUC_IATX7,VNUC_IAANN,VNUC_IADMA,# & VNUC_IABRA,VNUC_IAMEA,VNUC_IARUD,VNUC_IAME4,VNUC_IAHO2,# & VNUC_IAS31,VNUC_IASIN,VNUC_IAFPD,VNUC_IAZGE,VNUC_IATEI,# & VNUC_IAZJ4,VNUC_IAZ29,VNUC_IANEJ,VNUC_IAFPR,VNUC_IAZJ2,# & VNUC_IAZTE,VNUC_IAZI2,VNUC_IAPAR,VNUC_IAGRE,VNUC_IAMAN,# & VNUC_IADE1,VNUC_IATKN,VNUC_IASE0,VNUC_IATRS,VNUC_IAMAA,# & VNUC_IALEN,VNUC_IANT6,VNUC_IAZW2,VNUC_IACAL,VNUC_IAB39,# & VNUC_IAB37,VNUC_IAMEE,VNUC_IAFOW,VNUC_IAZW1,VNUC_IAME5,# & VNUC_IAS06,VNUC_IADCZ,VNUC_IAZI1,VNUC_IADAU,VNUC_IAZDA,# & VNUC_IAMEG,VNUC_IAEN5,VNUC_IAVI6,VNUC_IAKIE,VNUC_IAANA,# & VNUC_IAGD7,VNUC_IAZOH,VNUC_IAZCA,VNUC_IAZJA,VNUC_IAME6,# & VNUC_IADE2,VNUC_IAHIC,VNUC_IAUSS,VNUC_IAHO1,VNUC_IAWHP,# & VNUC_IAMEB,VNUC_IADU2,VNUC_IAPUE,VNUC_IAZNE,VNUC_IAZH3,# & VNUC_IAS11,VNUC_IAWIL,VNUC_IAZJ1,VNUC_IAMEC,VNUC_IAME3,# & VNUC_IAMEF,VNUC_IAZ41,VNUC_IAZI3,VNUC_IABUD,VNUC_IAUDO,# & VNUC_IATRT,VNUC_IADM2,VNUC_IAZMA)# & PIR1: (VHIVX3,VHIVX6,VHIVX1,VHIVA3,VHIV68,VHIVX4,VHIVN5,VHIVN8,# & VHIV34,VHIVN6,VHIV61,VHIVC1,VHIVN2,VHIVX2,VHIVN9,VHIVX5,# & VHIV8H,VHIVN7,VHIVN1,VHIVAK,VHIVXL,VHIVA7,VHIVA6)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# REFERENCES: gould91a,olsen94a,pedersen94a# COMMENT:# SUMMARY: H-2Kk,actyesm,bindyesh,SDYEGRLI*# SEQUENCE: SDYEGRLI*# ...# >MUS10131# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SV 40 T antigen (560-568)# DB REFERENCE: SWISS: (TALA_SV40,TALA_POVBK,TALA_POVBA)# & PIR1: (TVVPTB,TVVPAS,TVVPT4)# REFERENCES: rammensee93a,rawle89a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,SEFLLEKRI*# SEQUENCE: SEFLLEKRI*# ...# >MUS10132# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza Haemagglutinin 2 (255-262)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: rammensee93a,gould91a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,FESTGNLI*# SEQUENCE: FESTGNLI*# ...# >MUS10133# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (252-271)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: H-2Kk,actyesl,bindyesu,TINFESTGNLIAPEYGFKIS*# SEQUENCE: TINFESTGNLIAPEYGFKIS*# ...# >MUS10134# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (250-271)# ANCHOR POSITIONS:# REFERENCES: sweetser89a# COMMENT:# SUMMARY: H-2Kk,actyesl,bindyesu,MDTINFESTGNLIAPEYGFKIS*# SEQUENCE: MDTINFESTGNLIAPEYGFKIS*# ...# >MUS10135# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (255-271)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: H-2Kk,actyesm,bindyesu,FESTGNLIAPEYGFKIS*# SEQUENCE: FESTGNLIAPEYGFKIS*# ...# >MUS10136# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (254-265)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: H-2Kk,actyesm,bindyesu,NFESTGNLIAPE*# SEQUENCE: NFESTGNLIAPE*# ...# >MUS10137# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (252-268)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: H-2Kk,actyesm,bindyesu,TINFESTGNLIAPEYGF*# SEQUENCE: TINFESTGNLIAPEYGF*# ...# >MUS10138# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (252-263)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: H-2Kk,actyesl,bindyesu,TINFESTGNLIA*# SEQUENCE: TINFESTGNLIA*# ...# >MUS20139# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (252-271)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,TINFESTGNLIAPEYGFKIS*# SEQUENCE: TINFESTGNLIAPEYGFKIS*# ...# >MUS2013A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (250-271)# ANCHOR POSITIONS:# REFERENCES: sweetser89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,MDTINFESTGNLIAPEYGFKIS*# SEQUENCE: MDTINFESTGNLIAPEYGFKIS*# ...# >MUS2013B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (257-271)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,STGNLIAPEYGFKIS*# SEQUENCE: STGNLIAPEYGFKIS*# ...# >MUS2013C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (255-271)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,FESTGNLIAPEYGFKIS*# SEQUENCE: FESTGNLIAPEYGFKIS*# ...# >MUS2013D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (258-269)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,TGNLIAPEYGFK*# SEQUENCE: TGNLIAPEYGFK*# ...# >MUS2013E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (256-267)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,ESTGNLIAPEYG*# SEQUENCE: ESTGNLIAPEYG*# ...# >MUS2013F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A/Japan/305/57 HA (252-268)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: sweetser89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,TINFESTGNLIAPEYGF*# SEQUENCE: TINFESTGNLIAPEYGF*# ...# >MUS10140# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Plasmodium falciparum CSP (371-390)# ANCHOR POSITIONS:# REFERENCES: rammensee93a,gould91a,kumar88a# COMMENT: Two possible allignments, not definite, but strong evidence for H-2Kk# SUMMARY: H-2Kk,actyesm,bindyesu,DELDYENDIEKKICKMEKCSC*# SEQUENCE: DELDYENDIEKKICKMEKCSC*# ...# >MUS10141# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Plasmodium falciparum CSP (368-390)# ANCHOR POSITIONS:# REFERENCES: rammensee93a,gould91a,kumar88a# COMMENT: Two possible allignments, not definite, but strong evidence for H-2Kk# SUMMARY: H-2Kk,actyesm,bindyesu,KPKDELDYENDIEKKICKMEKCSC*# SEQUENCE: KPKDELDYENDIEKKICKMEKCSC*# ...# >MUS10142# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: HPLC eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Protein tyrosin kinase JAK1# DB REFERENCE: SWISS: (JAK1_MOUSE,JAK1_MOUSE)# & PIR2: (S15407)# REFERENCES: rammensee93a,falk91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,SYFPEITHI*# SEQUENCE: SYFPEITHI*# ...# >MUS10143# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: HPLC, competitive peptide inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Listeriolysin (L. monocytogenes) LLO (91-99)# DB REFERENCE: SWISS: (TACY_LISMO)# & PIR2: (S24231,A43505)# REFERENCES: rammensee93a,pamer91a,lipford94a,verma95a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,GYKDGNEYI*# SEQUENCE: GYKDGNEYI*# ...# >MUS10144# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.s/binding as./Reference/Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Influenza nucleoprotein (366-374)# DB REFERENCE: SWISS: (VNUC_IAANA,VNUC_IAZJA,VNUC_IAZH3,VNUC_IAGU4,VNUC_IADCZ,# & VNUC_IAZI1,VNUC_IAMAN,VNUC_IADE1,VNUC_IAZGE,VNUC_IAPAR,# & VNUC_IASE0,VNUC_IADMA,VNUC_IAHMI,VNUC_IATKO,VNUC_IADBE,# & VNUC_IAGU2,VNUC_IACKG,VNUC_IADHK,VNUC_IASH2,VNUC_IAZCA,# & VNUC_IADE2,VNUC_IADU2,VNUC_IAWHN,VNUC_IAMIN,VNUC_IAZOH,# & VNUC_IAGU1,VNUC_IAWIL,VNUC_IAZI3,VNUC_IAZMA,VNUC_IAPUE,# & VNUC_IAZNE,VNUC_IAGRE,VNUC_IATEI,VNUC_IAFPD,VNUC_IAZJ4,# & VNUC_IATRT,VNUC_IAZ41,VNUC_IADAU,VNUC_IAGUN,VNUC_IAGUM,# & VNUC_IAHJI,VNUC_IARUD,VNUC_IAMAA,VNUC_IAZI2,VNUC_IATKN,# & VNUC_IAGU3,VNUC_IADM2,VNUC_IAZ29,VNUC_IAFPR,VNUC_IAGUA,# & VNUC_IALEN,VNUC_IADNZ)# & PIR1: (VHIVA3,VHIVN3,VHIVX1,VHIVN6,VHIVC1,VHIVN2,A60028,VHIVA6,# & VHIVXL,VHIVN1,VHIVN4,VHIVM1,VHIV34,VHIVN9)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# REFERENCES: rammensee93a,falk91a,townsend86a,rotzschke90a,christinck91a,# & abastado93a,marshall94a,correa95a,feltkamp94a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesh,ASNENMETM*# SEQUENCE: ASNENMETM*# ...# >MUS10145# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: HPLC and cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Influenza nucleoprotein (365-380)# ANCHOR POSITIONS: 7,11# REFERENCES: christinck91a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesh,YIASNENMETMESSTLE*# SEQUENCE: YIASNENMETMESSTLE*# ...# >MUS10146# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: HPLC/cytotoxicity as./direct binding/Reference/Competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Influenza nucleoprotein NP (147-158)# ANCHOR POSITIONS:# REFERENCES: rotzschke90a,choppin90a,bouillot89a,bodmer88a,sambhara94a,# & maryanski91a,lie91a,sauzet96a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,TYQRTRALVTG*# SEQUENCE: TYQRTRALVTG*# ...# >MUS10147# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Respiratory syncytial virus RSV M2 (82-90)# DB REFERENCE: SWISS: (VMA2_HRSVA)# & PIR1: (WMNZ22)# REFERENCES: kulkarni93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,SYIGSINNI*# SEQUENCE: SYIGSINNI*# ...# >MUS10148# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Respiratory syncytial virus RSV M2 (82-90)# DB REFERENCE: SWISS: (VMA2_HRSVA)# & PIR1: (WMNZ22)# REFERENCES: kulkarni93a# COMMENT:# SUMMARY: H-2Kd,actyesl,bindyesu,EYALGVVGV*# SEQUENCE: EYALGVVGV*# ...# >HUM10149# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (55-73)# DB REFERENCE: SWISS: (VMT1_IAWIL,VMT1_IAFOW,VMT1_IAPUE,VMT1_IAMAN,VMT1_IAANN,# & VMT1_IALE2,VMT1_IABAN,VMT1_IALE1,VMT1_IACKB,VMT1_IAUDO,# & VMT1_IAUSS)# & PIR1: (MFIV,MFIVWS,MFIV1K,JN0392,MFIV1M,MFIVC,MFIV61)# & PIR2: (S04056,S04050,S04054,S04052,S04058,S07429,S14616)# REFERENCES: bodmer89a,perkins89a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,LTKGILGFVFTLTVPSERG*# SEQUENCE: LTKGILGFVFTLTVPSERG*# ...# >HUM1014A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (53-68)# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IAANN,VMT1_IAFOW,VMT1_IAWIL,VMT1_IAMAN,# & VMT1_IABAN,VMT1_IALE1,VMT1_IAUSS,VMT1_IAUDO,VMT1_IAPUE,# & VMT1_IALE2,VMT1_IAZI1)# & PIR1: (JN0392,MFIV61,MFIV,MFIV1M,MFIVC,MFIV1K,MFIVWS)# & PIR2: (S04052,S04056,S14616,S04054,S04050,S07429,S04058)# REFERENCES: bodmer89a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,SPLTKGILGFVFTLTV*# SEQUENCE: SPLTKGILGFVFTLTV*# ...# >HUM1014B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./direct binding/HLA assembly# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Influenza matrix protein (57-68)# DB REFERENCE: SWISS: (VMT1_IAUDO,VMT1_IAANN,VMT1_IALE2,VMT1_IAZI1,VMT1_IAFOW,# & VMT1_IACKB,VMT1_IABAN,VMT1_IAMAN,VMT1_IAPUE,VMT1_IALE1,# & VMT1_IAUSS,VMT1_IAWIL)# & PIR1: (MFIV1K,MFIVC,JN0392,MFIV61,MFIVWS,MFIV,MFIV1M)# & PIR2: (S04058,S04050,S04054,S14616,S04056,S07429,S04052)# REFERENCES: bodmer89a,parker92a,choppin90a,bouillot89a,connan94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesh,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM1014C# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza matrix protein (58-68)# DB REFERENCE: SWISS: (VMT1_IABAN,VMT1_IACKB,VMT1_IAWIL,VMT1_IAZI1,VMT1_IAFOW,# & VMT1_IAPUE,VMT1_IAUSS,VMT1_IALE1,VMT1_IALE2,VMT1_IAUDO,# & VMT1_IAANN,VMT1_IAMAN)# & PIR1: (MFIVC,MFIV,MFIV1M,MFIV61,MFIVWS,JN0392,MFIV1K)# & PIR2: (S04058,S14616,S04054,S04052,S04056,S04050,S07429)# REFERENCES: bodmer89a# COMMENT:# SUMMARY: HLA-A69,actyesm,bindyesu,GILGFVFTLTV*# SEQUENCE: GILGFVFTLTV*# ...# >HUM1014D# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza matrix protein (59-68)# DB REFERENCE: SWISS: (VMT1_IABAN,VMT1_IAANN,VMT1_IAWIL,VMT1_IALE2,VMT1_IAFOW,# & VMT1_IAZI1,VMT1_IAUSS,VMT1_IALE1,VMT1_IAPUE,VMT1_IAUDO,# & VMT1_IAMAN,VMT1_IACKB)# & PIR1: (MFIV,MFIV1M,MFIVC,MFIVWS,JN0392,MFIV1K,MFIV61)# & PIR2: (S04052,S04056,S04058,S04050,S04054,S14616,S07429)# REFERENCES: bodmer89a# COMMENT:# SUMMARY: HLA-A69,actyesl,bindyesu,ILGFVFTLTV*# SEQUENCE: ILGFVFTLTV*# ...# >MUS1014E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Peptide pulsing and cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Poliovirus (Mahoney) VP1 capsid protein (1111-1118)# DB REFERENCE: SWISS: (POLH_POL1M,POLG_POL1M,POLG_POL2W,POLG_POL2L,POLG_POL1S,# & POLG_POL32,POLG_POL3L)# & PIR1: (GNNY4P,GNNY3P,GNNY5P,GNNY27,GNNY1P,GNNY2P,GNNY2W)# & PIR2: (S09553,S03822)# & PIR3: (S42524)# REFERENCES: kutubuddin92a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,TYKDTVQL*# SEQUENCE: TYKDTVQL*# ...# >MUS1014F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Peptide pulsing/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Poliovirus (Mahoney) VP1 capsid protein (1208-1217)# DB REFERENCE: SWISS: (POLG_POL1M,POLH_POL1M,POLG_POL1S)# & PIR1: (GNNY3P,GNNY2P,GNNY1P)# REFERENCES: bodmer89a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,FYDGFSKVPL*# SEQUENCE: FYDGFSKVPL*# ...# >MUS10150# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: flow cytometry/Reference/Stabilization/CTL assays# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Adenovirus E1A (234-243)# DB REFERENCE: SWISS: (E1A_ADE02,E1A_ADE05)# & PIR1: (Q2AD2,Q2AD5)# REFERENCES: rammensee93a,falk91a,kast91a,falk93a,feltkamp93a,feltkamp94a,# & toes95a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesh,SGPSNTPPEI*# SEQUENCE: SGPSNTPPEI*# ...# >MUS10151# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: flow cytometry and cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Adenovirus E1A# DB REFERENCE: SWISS: (E1A_ADE02,E1A_ADE05)# & PIR1: (Q2AD2,Q2AD5)# REFERENCES: kast91a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesl,PSNTPPEI*# SEQUENCE: PSNTPPEI*# ...# >MUS10152# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competitive binding as./stabilisation as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Lymphocyte choriomeningitis virus GP (272-293)# DB REFERENCE: SWISS: (VGLY_LYCVW,VGLY_LYCVA)# & PIR1: (VGXPLC,VGXPLA,VGXPLM)# REFERENCES: rammensee93a,falk91a,oldstone88a,horwitz94a,gairin95a,feltkamp94a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesm,SGVENPGGYCL*# SEQUENCE: SGVENPGGYCL*# ...# >MUS10153# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (277-293)# DB REFERENCE: SWISS: (VGLY_LYCVA,VGLY_LYCVW)# & PIR1: (VGXPLA,VGXPLM,VGXPLC)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,GVENPGGYCLTKWMILA*# SEQUENCE: GVENPGGYCLTKWMILA*# ...# >MUS10154# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (277-290)# DB REFERENCE: SWISS: (VGLY_LYCVW,VGLY_LYCVA)# & PIR1: (VGXPLM,VGXPLA,VGXPLC)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,GVENPGGYCLTKWM*# SEQUENCE: GVENPGGYCLTKWM*# ...# >MUS10155# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (277-289)# DB REFERENCE: SWISS: (VGLY_LYCVW,VGLY_LYCVA)# & PIR1: (VGXPLC,VGXPLA,VGXPLM)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,GVENPGGYCLTKW*# SEQUENCE: GVENPGGYCLTKW*# ...# >MUS10156# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (277-288)# DB REFERENCE: SWISS: (VGLY_LYCVA,VGLY_LYCVW)# & PIR1: (VGXPLA,VGXPLM,VGXPLC)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,GVENPGGYCLTK*# SEQUENCE: GVENPGGYCLTK*# ...# >MUS10157# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (276-290)# DB REFERENCE: SWISS: (VGLY_LYCVA,VGLY_LYCVW)# & PIR1: (VGXPLM,VGXPLC,VGXPLA)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,SGVENPGGYCLTKWM*# SEQUENCE: SGVENPGGYCLTKWM*# ...# >MUS10158# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (275-290)# DB REFERENCE: SWISS: (VGLY_LYCVA,VGLY_LYCVW)# & PIR1: (VGXPLC,VGXPLM,VGXPLA)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,SSGVENPGGYCLTKWM*# SEQUENCE: SSGVENPGGYCLTKWM*# ...# >MUS10159# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (274-290)# DB REFERENCE: SWISS: (VGLY_LYCVW,VGLY_LYCVA)# & PIR1: (VGXPLC,VGXPLM,VGXPLA)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,DSSGVENPGGYCLTKWM*# SEQUENCE: DSSGVENPGGYCLTKWM*# ...# >MUS1015A# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-290)# DB REFERENCE: SWISS: (VGLY_LYCVA,VGLY_LYCVW)# & PIR1: (VGXPLM,VGXPLA,VGXPLC)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGVENPGGYCLTKWM*# SEQUENCE: LSDSSGVENPGGYCLTKWM*# ...# >MUS1015B# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (278-286)# DB REFERENCE: SWISS: (VGLY_LYCVW,VGLY_LYCVA)# & PIR1: (VGXPLM,VGXPLC,VGXPLA)# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,VENPGGYCL*# SEQUENCE: VENPGGYCL*# ...# >MUS1015C# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGLENPGGYCLTKWMILA*# SEQUENCE: LSDSSGLENPGGYCLTKWMILA*# ...# >MUS1015D# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGIENPGGYCLTKWMILA*# SEQUENCE: LSDSSGIENPGGYCLTKWMILA*# ...# >MUS1015E# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGAENPGGYCLTKWMILA*# SEQUENCE: LSDSSGAENPGGYCLTKWMILA*# ...# >MUS1015F# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT: not all clones# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGSENPGGYCLTKWMILA*# SEQUENCE: LSDSSGSENPGGYCLTKWMILA*# ...# >MUS10160# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT: not all clones# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGTENPGGYCLTKWMILA*# SEQUENCE: LSDSSGTENPGGYCLTKWMILA*# ...# >MUS10161# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT: not all clones# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGFENPGGYCLTKWMILA*# SEQUENCE: LSDSSGFENPGGYCLTKWMILA*# ...# >MUS10162# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT: not all clones# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGYENPGGYCLTKWMILA*# SEQUENCE: LSDSSGYENPGGYCLTKWMILA*# ...# >MUS10163# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT:not all clones# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGKENPGGYCLTKWMILA*# SEQUENCE: LSDSSGKENPGGYCLTKWMILA*# ...# >MUS10164# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus GP (272-293) homologue# ANCHOR POSITIONS:# REFERENCES: oldstone88a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,LSDSSGNENPGGYCLTKWMILA*# SEQUENCE: LSDSSGNENPGGYCLTKWMILA*# ...# >MUS10165# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competitive binding as./stabilisation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Lymphocyte choriomeningitis virus# DB REFERENCE: SWISS: (NCAP_LYCVW,NCAP_LYCVA)# & PIR1: (VHXPLM,VHXPLC)# REFERENCES: rammensee93a,schulz89a,horwitz94a,gairin95a,feltkamp94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesh,FQPQNGQFI*# SEQUENCE: FQPQNGQFI*# ...# >MUS10166# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (112-126)# DB REFERENCE: SWISS: (NCAP_LYCVW)# & PIR1: (VHXPLC)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,KIMRTERPQASGVYM*# SEQUENCE: KIMRTERPQASGVYM*# ...# >MUS10167# MHC MOLECULE: H-2Dq, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (112-126)# DB REFERENCE: SWISS: (NCAP_LYCVW)# & PIR1: (VHXPLC)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Dq,actyesu,bindyesu,KIMRTERPQASGVYM*# SEQUENCE: KIMRTERPQASGVYM*# ...# >MUS10168# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (115-129)# DB REFERENCE: SWISS: (NCAP_LYCVW)# & PIR1: (VHXPLC)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RTERPQASGVYMGNL*# SEQUENCE: RTERPQASGVYMGNL*# ...# >MUS10169# MHC MOLECULE: H-2Dq, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (115-129)# DB REFERENCE: SWISS: (NCAP_LYCVW)# & PIR1: (VHXPLC)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Dq,actyesu,bindyesu,RTERPQASGVYMGNL*# SEQUENCE: RTERPQASGVYMGNL*# ...# >MUS1016A# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (118-132)# DB REFERENCE: SWISS: (NCAP_LYCVW)# & PIR1: (VHXPLC)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RPQASGVYMGNLTAQ*# SEQUENCE: RPQASGVYMGNLTAQ*# ...# >MUS1016B# MHC MOLECULE: H-2Dq, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (118-132)# DB REFERENCE: SWISS: (NCAP_LYCVW)# & PIR1: (VHXPLC)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Dq,actyesu,bindyesu,RPQASGVYMGNLTAQ*# SEQUENCE: RPQASGVYMGNLTAQ*# ...# >MUS1016C# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (118-126)# DB REFERENCE: SWISS: (NCAP_LYCVW,NCAP_LYCVA)# & PIR1: (VHXPLC,VHXPLM)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RPQASGVYM*# SEQUENCE: RPQASGVYM*# ...# >MUS1016D# MHC MOLECULE: H-2Dq, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (118-126)# DB REFERENCE: SWISS: (NCAP_LYCVA,NCAP_LYCVW)# & PIR1: (VHXPLC,VHXPLM)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Dq,actyesu,bindyesu,RPQASGVYM*# SEQUENCE: RPQASGVYM*# ...# >MUS1016E# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (391-405)# DB REFERENCE: SWISS: (NCAP_LYCVA,NCAP_LYCVW)# & PIR1: (VHXPLC,VHXPLM)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,VEIAIFQPQNGQFIH*# SEQUENCE: VEIAIFQPQNGQFIH*# ...# >MUS1016F# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (394-408)# DB REFERENCE: SWISS: (NCAP_LYCVW,NCAP_LYCVA)# & PIR1: (VHXPLM,VHXPLC)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,AIFQPQNGQFIHFYR*# SEQUENCE: AIFQPQNGQFIHFYR*# ...# >MUS10170# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lymphocyte choriomeningitis virus (397-411)# DB REFERENCE: SWISS: (NCAP_LYCVW)# & PIR1: (VHXPLC)# REFERENCES: schulz89a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,QPQNGQFIHFYREPT*# SEQUENCE: QPQNGQFIHFYREPT*# ...# >HUM10171# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV EBNA-2A (64-83)# DB REFERENCE: SWISS: (EBN2_EBV)# & PIR2: (S32988)# & PIR3: (S42442,S42447)# REFERENCES: schmidt91a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,QLSDTPLIPLTIFVGENTGV*# SEQUENCE: QLSDTPLIPLTIFVGENTGV*# ...# >HUM10172# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: EBV EBNA-3A (6-20)# DB REFERENCE: PIR2: (E49253,D49253)# REFERENCES: schmidt91a,apolloni92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesm,AWNAGFLRGRAYGLD*# SEQUENCE: AWNAGFLRGRAYGLD*# ...# >MUS10173# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as./Reference/Stabilization# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Simian virus 40 T (206-215)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: rammensee93a,deckhut92a,feltkamp94a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesh,SAINNYAQKL*# SEQUENCE: SAINNYAQKL*# ...# >MUS10174# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Simian virus 40 T (223-231)# ANCHOR POSITIONS: 5,9# REFERENCES: rammensee93a,deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesu,CKGVNEEYL*# SEQUENCE: CKGVNEEYL*# ...# >MUS10175# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: antibody blocking as./CTL assays/Reference/Stabilization# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Simian virus 40 T (489-497)# DB REFERENCE: SWISS: (TALA_POVMK,TALA_SV40)# & PIR1: (TVVPMK,TVVPT4)# & PIR3: (PH1377)# REFERENCES: rammensee93a,deckhut92a,alsheikly94a,feltkamp94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,QGINNLDNL*# SEQUENCE: QGINNLDNL*# ...# >MUS10176# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (205-219)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a,tevethia90a,alsheikly94a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,VSAINNYAQKLCTFS*# SEQUENCE: VSAINNYAQKLCTFS*# ...# >MUS10177# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (205-218)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,VSAINNYAQKLCTF*# SEQUENCE: VSAINNYAQKLCTF*# ...# >MUS10178# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (205-217)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,VSAINNYAQKLCT*# SEQUENCE: VSAINNYAQKLCT*# ...# >MUS10179# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (205-216)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,VSAINNYAQKLC*# SEQUENCE: VSAINNYAQKLC*# ...# >MUS1017A# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Simian virus 40 T (205-215)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,VSAINNYAQKL*# SEQUENCE: VSAINNYAQKL*# ...# >MUS1017B# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Simian virus 40 T (206-217)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesu,SAINNYAQKLCT*# SEQUENCE: SAINNYAQKLCT*# ...# >MUS1017C# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (207-217)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,AINNYAQKLCT*# SEQUENCE: AINNYAQKLCT*# ...# >MUS1017D# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as./Stabilization# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Simian virus 40 T (207-215)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a,alsheikly94a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesl,AINNYAQKL*# SEQUENCE: AINNYAQKL*# ...# >MUS1017E# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (220-233)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a,tevethia90a,alsheikly94a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,FLICKGVNKEYLMY*# SEQUENCE: FLICKGVNKEYLMY*# ...# >MUS1017F# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (221-233)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,LICKGVNKEYLMY*# SEQUENCE: LICKGVNKEYLMY*# ...# >MUS10180# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (222-233)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,ICKGVNKEYLMY*# SEQUENCE: ICKGVNKEYLMY*# ...# >MUS10181# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Simian virus 40 T (223-233)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesu,CKGVNKEYLMY*# SEQUENCE: CKGVNKEYLMY*# ...# >MUS10182# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (220-231)# DB REFERENCE: SWISS: (TALA_POVJC,TALA_SV40,TALA_POVBA,TALA_POVBK)# & PIR1: (TVVPTB,TVVPAS,TVVPTJ,TVVPT4)# REFERENCES: deckhut92a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,FLICKGVNKEYL*# SEQUENCE: FLICKGVNKEYL*# ...# >MUS10183# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: antibody blocking as./CTL assays/Reference/Stabilization# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Simian virus 40 T (223-231)# DB REFERENCE: SWISS: (TALA_POVBK,TALA_POVJC,TALA_SV40,TALA_POVBA)# & PIR1: (TVVPTJ,TVVPAS,TVVPTB,TVVPT4)# REFERENCES: deckhut92a,lill92a,alsheikly94a,feltkamp94a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesh,CKGVNKEYL*# SEQUENCE: CKGVNKEYL*# ...# >MUS10184# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./antibody blocking as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Simian virus 40 T (489-503)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# & PIR3: (PH1377)# REFERENCES: deckhut92a,lill92a,tevethia90a,alsheikly94a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,QGINNLDNLRDYLDG*# SEQUENCE: QGINNLDNLRDYLDG*# ...# >MUS10185# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: HPLC/competition/Reference/Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59)# DB REFERENCE: SWISS: (NCAP_VSVSJ,NCAP_VSVIG)# & PIR1: (VHVNN,VHVNV4)# REFERENCES: rammensee93a,falk91a,van_bleek90a,chen90a,anderson93a,olsen94a,# & feltkamp94a,hogquist93a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesh,RGYVYQGL*# SEQUENCE: RGYVYQGL*# ...# >HUM10186# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides/direct binding# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human histone H3, H3.3# DB REFERENCE: SWISS: (H33_HUMAN,H32_XENLA,H3_NEUCR,H33_CAEEL,H31_HUMAN,# & H3_PSAMI,H31_SCHPO,H3_PSAMI,H33_SCHPO,H3_ACRFO,H3_EMENI,# & H3_STRPU,H3_DROME,H3_CAEEL,H32_BOVIN,YB21_CAEEL,# & H3_ENCAL)# & PIR1: (HSZP3,HSXL31,HSCH3,HSUR3P,HSRK3,HSXL32,HSUR3M,HSEAH3,# & HSHU33,HSKW3,HSHU3,HSBO3,HSFI3,HSTR3)# & PIR2: (A56654,S09655,JH0304,I50460,S01198,I50244,S04186,I51448,# & JQ1343,S10097,S06755,S61220,I48092,S01196,I49397,I57019,# & S10168,S61215,S01197,S32621,S32638,JQ0757,S06743,S61218,# & S57473,S34185,S50140,I49395,A56618,JQ1983,I50245,I49398,# & S20678,S61214,S07350,S20669,JS0690,JQ1984,S20109,JN0687,# & A02630,A56580,S11315)# & PIR3: (A45941,S42065,S42066,S11938)# REFERENCES: rammensee93a,jardetzky91a,barber93a,anderson93a,fukazawa94a,# & sette94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSTEL*# SEQUENCE: RRYQKSTEL*# ...# >HUM10187# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human Hsp89 alpha# DB REFERENCE: SWISS: (HS9A_HUMAN,HS9A_CRIGR,HS9A_CHICK,HS9A_MOUSE,# & HS9A_MOUSE)# & PIR1: (HHCH90,HHHU86,HHMS86)# REFERENCES: rammensee93a,jardetzky91a,barber93a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRIKEIVKK*# SEQUENCE: RRIKEIVKK*# ...# >HUM10188# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human Hsp89 beta# DB REFERENCE: SWISS: (HS9B_MOUSE,HS9B_HUMAN,HS9B_RAT,HS9B_HUMAN,HS9B_CHICK)# & PIR1: (HHHU84,HHMS84)# & PIR2: (JC1468)# REFERENCES: rammensee93a,jardetzky91a,barber93a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRVKEVVKK*# SEQUENCE: RRVKEVVKK*# ...# >HUM10189# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human elongation factor 2# DB REFERENCE: SWISS: (EF2_CRIGR,EF2_MESAU,EF2_RAT,EF2_CRIGR,EF2_CHICK,# & EF2_MESAU,EF2_RAT,EF2_HUMAN)# & PIR1: (EFRT2,EFHU2)# & PIR2: (A28660,A25440)# REFERENCES: rammensee93a,jardetzky91a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRWLPAGDA*# SEQUENCE: RRWLPAGDA*# ...# >HUM1018A# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human ATP-dependant rna helicase# DB REFERENCE: SWISS: (P68_HUMAN,P68_HUMAN,P68_MOUSE)# & PIR2: (I48385,JC1087)# REFERENCES: rammensee93a,jardetzky91a,barber93a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRSKEITVR*# SEQUENCE: RRSKEITVR*# ...# >HUM1018B# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ribosomal protein (yeast/slime mould)# DB REFERENCE: SWISS: (RL8_HUMAN,RL8_HUMAN,RL8_AEDAL,RL8_XENLA)# & PIR1: (R5RTL8)# & PIR2: (JN0923,S42725)# REFERENCES: rammensee93a,jardetzky91a,anderson93a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,GRIDKPILK*# SEQUENCE: GRIDKPILK*# ...# >HUM1018C# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rat 60S ribosomal protein L28# DB REFERENCE: SWISS: (RL28_MOUSE,RL28_RAT,RL28_RAT,RL28_HUMAN)# & PIR1: (R5RT28)# & PIR2: (I48738,S55915)# REFERENCES: rammensee93a,jardetzky91a,parker92b,barber93a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,FRYNGLIHR*# SEQUENCE: FRYNGLIHR*# ...# >HUM1018D# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2# REFERENCES: rammensee93a,jardetzky91a,anderson93a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRFEGLTQR*# SEQUENCE: KRFEGLTQR*# ...# >HUM1018E# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2# REFERENCES: rammensee93a,jardetzky91a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRFTRPEH*# SEQUENCE: RRFTRPEH*# ...# >HUM1018F# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2# REFERENCES: rammensee93a,jardetzky91a,parker92b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRISGVDRY*# SEQUENCE: RRISGVDRY*# ...# >HUM10190# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (RL13_CHICK,RL13_RAT,RL13_HUMAN,RL13_CHICK)# & PIR2: (JC2368,S23753)# REFERENCES: rammensee93a,jardetzky91a,parker92b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,ARLFGIRAK*# SEQUENCE: ARLFGIRAK*# ...# >HUM10191# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Eluted self peptides/competitive inhibition of lysis/direct binding# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A nucleoprotein (383-391)# DB REFERENCE: SWISS: (VNUC_IAZJ3,VNUC_IAMAA,VNUC_IAZI2,VNUC_IAFOM,VNUC_IALEN,# & VNUC_IAZH4,VNUC_IATKN,VNUC_IAME4,VNUC_IAMEA,VNUC_IAANN,# & VNUC_IAANN,VNUC_IADAU,VNUC_IAGRE,VNUC_IAFOW,VNUC_IAB39,# & VNUC_IAFPD,VNUC_IAZTE,VNUC_IAZOH,VNUC_IASIN,VNUC_IAHMI,# & VNUC_IAPUE,VNUC_IAZJ2,VNUC_IADE2,VNUC_IAMIN,VNUC_IAMEC,# & VNUC_IABUD,VNUC_IADBE,VNUC_IATKO,VNUC_IAZI1,VNUC_IAHO1,# & VNUC_IAZDA,VNUC_IAZJA,VNUC_IADU2,VNUC_IAWHN,VNUC_IATEI,# & VNUC_IATRT,VNUC_IAZI3,VNUC_IAZMA,VNUC_IAS06,VNUC_IATRS,# & VNUC_IACKP,VNUC_IASH2,VNUC_IAHLO,VNUC_IAS11,VNUC_IADMA,# & VNUC_IAUDO,VNUC_IACKG,VNUC_IAMEF,VNUC_IAME3,VNUC_IAMEG,# & VNUC_IAANA,VNUC_IARUD,VNUC_IAEN5,VNUC_IAKIE,VNUC_IAVI6,# & VNUC_IAOHI,VNUC_IAHIC,VNUC_IAUSS,VNUC_IASE0,VNUC_IAPAR,# & VNUC_IAMAN,VNUC_IANEJ,VNUC_IAZJ1,VNUC_IAME5,VNUC_IAZW1,# & VNUC_IACAL,VNUC_IAWIL,VNUC_IAMEB,VNUC_IADE1,VNUC_IAWHP,# & VNUC_IAZH3,VNUC_IAGD7,VNUC_IABRA,VNUC_IAZON,VNUC_IADNZ,# & VNUC_IAS31,VNUC_IATX7,VNUC_IAZH1,VNUC_IAZ41,VNUC_IAHO2,# & VNUC_IAZ29,VNUC_IADM2,VNUC_IANT6,VNUC_IAZW2,VNUC_IAME6,# & VNUC_IAHTE,VNUC_IAB37,VNUC_IAWIS,VNUC_IAFPR,VNUC_IAMEE)# & PIR1: (VHIV68,A60028,VHIVX2,VHIVXL,VHIVN9,VHIVAK,VHIVA3,VHIV8H,# & VHIVX5,VHIVC1,VHIVM1,VHIVN5,VHIVN1,VHIV61,VHIVN8,VHIVX6,# & VHIVX1,VHIVX4,VHIVN3,VHIVA6,VHIVX3,VHIVN7,VHIVA7,# & VHIV34)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS: 2# REFERENCES: rammensee93a,carreno92a,jardetzky91a,huet90a,dibrino93a,gao94a,# & sette94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,SRYWAIRTR*# SEQUENCE: SRYWAIRTR*# ...# >HUM10192# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: eluted self peptides/beta2m dissociation/Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (314-322)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1BR,ENV_HV1MF,ENV_HV1B1,ENV_HV1H3,# & ENV_HV1B8,ENV_HV1H2)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S13288,S33985)# REFERENCES: rammensee93a,jardetzky91a,parker92b,parker94b,hivdb97a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRAFVTIGK*# SEQUENCE: GRAFVTIGK*# ...# >MUS10193# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: HPLC/stabilisation# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: FLU NP 1968 (366-374)# DB REFERENCE: SWISS: (VNUC_IANT6,VNUC_IAHO2,VNUC_IAHO1)# & PIR1: (VHIV68,VHIVN5,VHIV8H)# REFERENCES: rammensee93a,cerundolo91a,elvin93a,feltkamp94a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesm,ASNENMDAM*# SEQUENCE: ASNENMDAM*# ...# >MUS10194# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: HPLC# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: FLU NP 1934 (367-374)# ANCHOR POSITIONS: 5,9# REFERENCES: cerundolo91a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesm,YSNENMETM*# SEQUENCE: YSNENMETM*# ...# >MUS10195# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: HPLC/binding as./cytotoxicity as./Reference/Stabilization# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Chicken ovalbumin (258-265)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: rammensee93a,falk91a,rotzschke91a,chen90a,kageyama95a,chen94b,# & correa95a,feltkamp94a,hogquist93a# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesh,SIINFEKL*# SEQUENCE: SIINFEKL*# ...# >MUS10196# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Self protein of P815# DB REFERENCE: SWISS: (U119_CAEEL,U119_CAEBR,U119_CAEEL)# & PIR2: (A38976)# REFERENCES: rammensee93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,HIYEFPQL*# SEQUENCE: HIYEFPQL*# ...# >MUS10197# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./competitive binding/stimulation as./Stabilization# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Sendai virus NP (324-332)# DB REFERENCE: SWISS: (NCAP_SEND5,NCAP_SENDE,NCAP_PI1HW,NCAP_PI1HA,NCAP_SENDF,# & NCAP_PI3B,NCAP_SENDZ,NCAP_PI1HC)# & PIR1: (VHNZB3,VHNZT1,VHNZSV,A48341,VHNZP1)# & PIR2: (S13778,S72316,S72317)# REFERENCES: rammensee93a,falk91a,schumacher91a,chen90a,cole95b,feltkamp94a,# & hogquist93a# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesh,FAPGNYPAL*# SEQUENCE: FAPGNYPAL*# ...# >MUS10198# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Sendai virus (321-336)# DB REFERENCE: SWISS: (NCAP_SENDE,NCAP_PI1HC,NCAP_PI3B,NCAP_SEND5,NCAP_PI1HW,# & NCAP_SENDF,NCAP_SENDZ)# & PIR1: (VHNZT1,VHNZP1,VHNZB3,VHNZSV)# & PIR2: (S72316,S13778,S72317)# REFERENCES: schumacher91a# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,GEFAPGNYPALWSY*# SEQUENCE: GEFAPGNYPALWSY*# ...# >MUS10199# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV-I glycoprotein B# ANCHOR POSITIONS: 5,8# REFERENCES: rammensee93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,SIIEFARL*# SEQUENCE: SIIEFARL*# ...# >MUS1019A# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza NS1 (152-160)# DB REFERENCE: SWISS: (VNS1_IATRS,VNS1_IAZI1,VNS1_IAPI0,VNS1_IAFOW,VNS1_IAFOM,# & VNS1_IAMYN,VNS1_IAMAN,VNS1_IAUSS,VNS1_IACKJ,VNS1_IAUDO,# & VNS1_IAPI2,VNS1_IACKB,VNS1_IALEN,VNS1_IAAIC,VNS1_IALE1,# & VNS1_IADE1,VNS1_IAMAO,VNS1_IAALA,VNS1_IACHI,# & VNS1_IAPUE)# & PIR1: (MNIV1A,MNIVX3,MNIVX1,MNIVA4,MNIV47,MNIVC1,MNIVA2,MNIV1,# & MNIVX5,MNIV77,MNIV1K,D45539,MNIV14,MNIVA3,MNIVX9,# & MNIVA1)# & PIR2: (S09648)# REFERENCES: cossins93a# COMMENT:# SUMMARY: H-2Kk,actyesh,bindyesu,EEGAIVGEI*# SEQUENCE: EEGAIVGEI*# ...# >MUS1019B# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: Influenza NS1 (153-160)# DB REFERENCE: SWISS: (VNS1_IAMAO,VNS1_IALE1,VNS1_IADE1,VNS1_IAZI1,VNS1_IAALA,# & VNS1_IAPI2,VNS1_IAUSS,VNS1_IAMYN,VNS1_IAMAN,VNS1_IAAIC,# & VNS1_IACKB,VNS1_IAPI0,VNS1_IATRS,VNS1_IAFPR,VNS1_IAFOM,# & VNS1_IAFOW,VNS1_IALEN,VNS1_IACHI,VNS1_IAUDO,VNS1_IACKJ,# & VNS1_IAPUE)# & PIR1: (MNIVX1,MNIVA3,MNIVA2,MNIV1K,MNIVX5,MNIV1F,MNIVX9,MNIVA4,# & MNIV47,D45539,MNIV14,MNIVA1,MNIV77,MNIV1,MNIV1A,MNIVX3,# & MNIVC1)# & PIR2: (S09648)# REFERENCES: cossins93a# COMMENT:# SUMMARY: H-2Kk,actyesl,bindyesm,EGAIVGEI*# SEQUENCE: EGAIVGEI*# ...# >MUS1019C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: competitive inhibition of lysis and cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rabies NS (191-206)# DB REFERENCE: SWISS: (RRPP_RABVE)# & PIR3: (S13707)# REFERENCES: cossins93a,larson91a# COMMENT: Two possible allignments# SUMMARY: H-2Kk,actyesu,bindyesu,EKDDLSVEAEIAHQIA*# SEQUENCE: EKDDLSVEAEIAHQIA*# ...# >MUS2019D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation asasys# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Rabies NS (191-206)# DB REFERENCE: SWISS: (RRPP_RABVE)# & PIR3: (S13707)# REFERENCES: larson91a# COMMENT:# SUMMARY: I-Ak,actyesh,bindyesu,EKDDLSVEAEIAHQIA*# SEQUENCE: EKDDLSVEAEIAHQIA*# ...# >MUS1019E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV1 RT (205-219)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1RH,POL_HV1N5,POL_HV1B1,POL_HV1BR,# & POL_HV1MN,POL_HV1JR,POL_HV1PV,POL_HV1Y2,POL_HV1A2,# & POL_HV1B5)# & PIR1: (GNVWH3,GNVWVL,GNVWLV,B44001,GNVWA2)# & PIR2: (S32065,S32140,S32134,S32151,S32063,S32056,A47175,S32122,# & S32055,S32061,S32136,S32127,B47330,S32095,S32060,S32062,# & F47330,S32058,S32139,S32057,B47175,S32126,S32059,S32053,# & S32118,S32117,S32119,S32135,S32052,S32054,S32064,# & S32120)# & PIR3: (S33980)# REFERENCES: hosmalin90a# COMMENT: not definite, but strong evidence for H-2Kk# SUMMARY: H-2Kk,actyesl,bindyesu,CTEMEKEGKISKIGP*# SEQUENCE: CTEMEKEGKISKIGP*# ...# >MUS1019F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV1 RT (203-219)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1JR,POL_HV1PV,POL_HV1BR,POL_HV1H2,# & POL_HV1A2,POL_HV1B5,POL_HV1Y2,POL_HV1B1,POL_HV1N5,# & POL_HV1RH)# & PIR1: (GNVWVL,GNVWH3,GNVWA2,B44001,GNVWLV)# & PIR2: (S32134,S32139,S32136,S32064,S32054,S32120,A47175,S32055,# & S32061,S32126,B47175,B47330,S32095,S32060,S32056,S32063,# & S32118,S32059,S32053,S32062,S32122,S32127,F47330,S32058,# & S32119,S32135,S32052,S32065,S32151,S32057,S32117)# & PIR3: (S33980)# REFERENCES: hosmalin90a# COMMENT: not definite, but strong evidence for H-2Kk# SUMMARY: H-2Kk,actyesm,bindyesu,EICTEMEKEGKISKIGP*# SEQUENCE: EICTEMEKEGKISKIGP*# ...# >HUM101A0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HPLC/competitive binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Calreticulin# DB REFERENCE: SWISS: (CRTC_HUMAN,CRTC_RAT,CRTC_HUMAN,CRTC_MOUSE)# & PIR2: (S06763,A37047,JH0819)# REFERENCES: henderson92a,chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MLLSVPLLLG*# SEQUENCE: MLLSVPLLLG*# ...# >MUS201A1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation/Reference/Proliferation# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Mouse apolipo protein Apo-E (268-284)# DB REFERENCE: SWISS: (APE_MOUSE,APE_MOUSE)# & PIR2: (JU0036)# REFERENCES: hunt92b,barber93a,rider96a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesl,WANLMEKIQASVATNPI*# SEQUENCE: WANLMEKIQASVATNPI*# ...# >MUS201A2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation/Reference# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Cys-C (40-55)# DB REFERENCE: SWISS: (CYTC_RAT,CYTC_MOUSE)# & PIR2: (S07085,S10587,A36163)# REFERENCES: hunt92b,barber93a,rider96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,DAYHSRAIQVVRARKQ*# SEQUENCE: DAYHSRAIQVVRARKQ*# ...# >MUS201A3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation/Reference/Competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: I-Ed alpha (52-68)# DB REFERENCE: SWISS: (HA21_MOUSE,HA21_MOUSE,HA23_MOUSE,HA22_MOUSE,# & HA2R_HUMAN)# & PIR1: (HLMSED,HLMSEA,HLHUDA)# & PIR2: (S06316,I72480,I55971,A46505,I54426,I56085)# REFERENCES: hunt92b,barber93a,feng94a,rider96a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesm,ASFEAQGALANIAVDKA*# SEQUENCE: ASFEAQGALANIAVDKA*# ...# >MUS201A4# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation/Reference/Proliferation# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Mouse apolipo protein Apo-E (236-252)# DB REFERENCE: SWISS: (APE_MOUSE,APE_MOUSE,APE_RAT,APE_RAT)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b,rider96a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesm,EEQTQQIRLQAEIFQAR*# SEQUENCE: EEQTQQIRLQAEIFQAR*# ...# >MUS201A5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation/inhibitory binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Li (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: hunt92b,barber93a,sette95a,rider96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >MUS201A6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Lambda repressor (12-26)# ANCHOR POSITIONS:# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,LEDARRLKAYEKKK*# SEQUENCE: LEDARRLKAYEKKK*# ...# >MUS201A7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TF receptor (442-459)# DB REFERENCE: PIR2: (S29548)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,VPQLNQMVRTAAEVAGQL*# SEQUENCE: VPQLNQMVRTAAEVAGQL*# ...# >MUS201A8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TF receptor (442-457)# DB REFERENCE: PIR2: (A34549,S29548)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,VPQLNQMVRTAAEVAG*# SEQUENCE: VPQLNQMVRTAAEVAG*# ...# >MUS201A9# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TF receptor (442-456)# DB REFERENCE: PIR2: (S29548,A34549)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,VPQLNQMVRTAAEVA*# SEQUENCE: VPQLNQMVRTAAEVA*# ...# >MUS201AA# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: TF receptor (442-455)# DB REFERENCE: PIR2: (A34549,S29548)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,VPQLNQMVRTAAEV*# SEQUENCE: VPQLNQMVRTAAEV*# ...# >MUS201AB# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: TF receptor (442-453)# DB REFERENCE: PIR2: (S29548,A34549)# REFERENCES: hunt92b,feng94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesl,VPQLNQMVRTAA*# SEQUENCE: VPQLNQMVRTAA*# ...# >MUS201AC# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TF receptor (446-459)# DB REFERENCE: PIR2: (S29548)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,NQMVRTAAEVAGQL*# SEQUENCE: NQMVRTAAEVAGQL*# ...# >MUS201AD# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TF receptor (447-459)# DB REFERENCE: PIR2: (S29548)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,QMVRTAAEVAGQL*# SEQUENCE: QMVRTAAEVAGQL*# ...# >MUS201AE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TF receptor (447-456)# DB REFERENCE: PIR2: (S29548,A34549)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,QMVRTAAEVA*# SEQUENCE: QMVRTAAEVA*# ...# >MUS201AF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation/Competition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: TF receptor (448-459)# DB REFERENCE: PIR2: (S29548)# REFERENCES: hunt92b,feng94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesl,MVRTAAEVAGQL*# SEQUENCE: MVRTAAEVAGQL*# ...# >MUS201B0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mouse apolipo protein Apo-E (236-250)# DB REFERENCE: SWISS: (APE_RAT,APE_RAT,APE_MOUSE,APE_MOUSE)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,EEQTQQIRLQAEIFQ*# SEQUENCE: EEQTQQIRLQAEIFQ*# ...# >MUS201B1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mouse apolipo protein Apo-E (236-249)# DB REFERENCE: SWISS: (APE_RAT,APE_RAT,APE_MOUSE,APE_MOUSE)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,EEQTQQIRLQAEIF*# SEQUENCE: EEQTQQIRLQAEIF*# ...# >MUS201B2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mouse apolipo protein Apo-E (236-248)# DB REFERENCE: SWISS: (APE_MOUSE,APE_MOUSE,APE_RAT,APE_RAT)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,EEQTQQIRLQAEI*# SEQUENCE: EEQTQQIRLQAEI*# ...# >MUS201B3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mouse apolipo protein Apo-E (236-246)# DB REFERENCE: SWISS: (APE_RAT,APE_MOUSE,APE_MOUSE,APE_RAT)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,EEQTQQIRLQA*# SEQUENCE: EEQTQQIRLQA*# ...# >MUS201B4# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse apolipo protein Apo-E (239-252)# DB REFERENCE: SWISS: (APE_RAT,APE_MOUSE,APE_MOUSE,APE_RAT)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,TQQIRLQAEIFQAR*# SEQUENCE: TQQIRLQAEIFQAR*# ...# >MUS201B5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mouse apolipo protein Apo-E (242-252)# DB REFERENCE: SWISS: (APE_MOUSE,APE_RAT,APE_RAT,APE_MOUSE)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,IRLQAEIFQAR*# SEQUENCE: IRLQAEIFQAR*# ...# >MUS201B6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mouse apolipo protein Apo-E (243-252)# DB REFERENCE: SWISS: (APE_RAT,APE_MOUSE,APE_RAT,APE_MOUSE)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,RLQAEIFQAR*# SEQUENCE: RLQAEIFQAR*# ...# >MUS201B7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mouse apolipo protein Apo-E (244-252)# DB REFERENCE: SWISS: (APE_MOUSE,APE_RAT,APE_RAT,APE_MOUSE)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: hunt92b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,LQAEIFQAR*# SEQUENCE: LQAEIFQAR*# ...# >MUS201B8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse apolipo-protein E (238-252)# DB REFERENCE: SWISS: (APE_RAT,APE_RAT,APE_MOUSE,APE_MOUSE)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: rammensee93b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,QTQQIRLQAEIFQAR*# SEQUENCE: QTQQIRLQAEIFQAR*# ...# >MUS101B9# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A/JAP/305 Hemagglutinin (523-545)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR3: (S12270)# REFERENCES: falk91a,falk91b,braciale89a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,VYQILAIYATVAGSLSLAIMMAG*# SEQUENCE: VYQILAIYATVAGSLSLAIMMAG*# ...# >MUS101BA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A/PR/8 Hemagglutinin (518-528)# DB REFERENCE: SWISS: (HEMA_IATKW,HEMA_IAZNJ,HEMA_IADA4,HEMA_IAUSS,HEMA_IAZIN,# & HEMA_IAPUE,HEMA_IALEN,HEMA_IAWIL)# & PIR1: (HMIVUR,HMIVTW,HMIV5,HMIVN1,HMIVD1,HMIV17,HMIV)# & PIR3: (S69887,S69888)# REFERENCES: falk91a,falk91b# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,IYSTVASSLVL*# SEQUENCE: IYSTVASSLVL*# ...# >MUS101BB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse tumor (P815)# ANCHOR POSITIONS: 2,9# REFERENCES: falk91b# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,LYQAVTTTLEE*# SEQUENCE: LYQAVTTTLEE*# ...# >MUS101BC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza A/JAP/305 Hemagglutinin (202-221)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# REFERENCES: braciale89a,perkins89a,hahn96a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,RTLYQNVGTYVSVGTSTLNK*# SEQUENCE: RTLYQNVGTYVSVGTSTLNK*# ...# >MUS101BD# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A JAP/305 HA (529-537)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR3: (S12270)# REFERENCES: braciale89a,falk93a,rammensee95a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,IYATVAGSL*# SEQUENCE: IYATVAGSL*# ...# >HUM101BE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: synthetic homologues to influenza matrix protein# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,dibrino93a,parker94a# COMMENT: Minimum (engineered) binding peptide# SUMMARY: HLA-A2,actunkn,bindyesh,GLFGGGGGV*# SEQUENCE: GLFGGGGGV*# ...# >HUM101BF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV pol (968-976)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1B1,POL_HV1BR,POL_SIVMK,POL_HV1PV,# & POL_HV1JR,POL_SIVM1,POL_HV2BE,POL_SIVSP,POL_SIVGB,# & POL_HV2RO,POL_HV2D2,POL_HV1Z6,POL_SIVM1,POL_HV1U4,# & POL_HV1N5,POL_HV1EL,POL_SIVS4,POL_HV1B5,POL_HV1A2,# & POL_HV1Z2,POL_HV1RH,POL_HV1OY,POL_HV1H2,POL_HV1MA,# & POL_HV1ND,POL_HV1MN,POL_SIVCZ)# & PIR1: (GNVWLV,B44001,GNVWA2,GNLJG5,GNLJG3,GNLJSI,GNVWVL,GNVWH3,# & GNLJND,GNLJG2)# & PIR2: (A26192,S08436,S28081,S54378)# & PIR3: (S33980)# REFERENCES: parker92a,parker94a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLWKGEGAV*# SEQUENCE: LLWKGEGAV*# ...# >HUM101C0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV pol (747-755)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1MF,ENV_HV1B1,ENV_HV1H2,ENV_HV1B8,# & ENV_HV1H3,ENV_HV1PV)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S33985,S13288)# REFERENCES: parker92a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,RLVNGSLAL*# SEQUENCE: RLVNGSLAL*# ...# >HUM101C1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV gag (151-159)# DB REFERENCE: SWISS: (GAG_HV1U4,GAG_HV1MN,GAG_HV1N5,GAG_HV1RH,GAG_HV1PV,# & GAG_HV1A2,GAG_HV1BR,GAG_HV1B1,GAG_HV1H2,GAG_HV1W2,# & GAG_HV1OY,GAG_HV1B5,GAG_HV1J3,GAG_SIVCZ,GAG_HV1Y2)# & PIR1: (FOVWVL,FOLJSI,A38068,A44001,FOVWA2,FOVWH3,FOVWLV)# & PIR3: (S33979)# REFERENCES: parker92a,parker94a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,TLNAWVKVV*# SEQUENCE: TLNAWVKVV*# ...# >HUM101C2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV gag (77-85)# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1H2,GAG_HV1OY,GAG_HV1A2,GAG_HV1BR,# & GAG_HV1B1,GAG_HV1Y2,GAG_HV1JR,GAG_HV1MN,GAG_HV1EL,# & GAG_HV1C4,GAG_HV1ND,GAG_HV1PV,GAG_HV1MA,GAG_HV1B5)# & PIR1: (FOLJND,FOVWVL,A44001,A38068,FOVWH3,FOVWLV,FOVWH4,# & FOVWA2)# & PIR3: (S33979)# REFERENCES: parker92a,johnson91a,parker94a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,SLYNTVATL*# SEQUENCE: SLYNTVATL*# ...# >HUM101C3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as./HLA assembly/cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (510-518)# DB REFERENCE: SWISS: (POL_HV1PV,POL_HV1JR,POL_HV1B5,POL_HV1BR,POL_HV1ND,# & POL_HV1RH,POL_HV1Y2,POL_HV1B1,POL_HV1N5,POL_HV1EL,# & POL_HV1H2,POL_HV1OY,POL_HV1MN,POL_HV1MA,POL_HV1Z2)# & PIR1: (GNVWVL,GNVWLV,GNLJND,B44001,GNVWH3)# & PIR2: (S54378,B47175)# REFERENCES: parker92a,connan94a,kageyama95a,parker94a,fruci93a,brander95a,# & hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM101C4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: peptide-pulsed target cells/binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HTLV-1 Tax (11-19)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# REFERENCES: parker92a,utz92a,parker92b,del_guercio95a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLFGYPVYV*# SEQUENCE: LLFGYPVYV*# ...# >HUM101C5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: peptide-pulsed target cells and cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HCMV gB (618-628)# DB REFERENCE: SWISS: (VGLB_HCMVA,VGLB_HCMVT)# & PIR1: (VGBETE,VGBEC1)# & PIR2: (PQ0309,PQ0308,PQ0305)# REFERENCES: parker92a# COMMENT: Other peptides overlapping the region are not good binders# SUMMARY: HLA-A2,actyesh,bindyesh,FIAGNSAYEYV*# SEQUENCE: FIAGNSAYEYV*# ...# >HUM101C6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: peptide-pulsed target cells and cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: HCMV gB (614-628)# DB REFERENCE: SWISS: (VGLB_HCMVA,VGLB_HCMVT)# & PIR1: (VGBEC1,VGBETE)# & PIR2: (PQ0309,PQ0305,PQ0308)# REFERENCES: parker92a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesl,IAGNSAYEYV*# SEQUENCE: IAGNSAYEYV*# ...# >HUM101C7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSP 84 (571-579)# DB REFERENCE: SWISS: (HS9B_RAT,HS9B_CHICK,HS9B_HUMAN,HS9B_HUMAN,HS9B_MOUSE)# & PIR1: (HHHU84,HHMS84)# & PIR2: (JC1468)# REFERENCES: parker92a,parker92b,dibrino93a,barber93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ILDKKVEKV*# SEQUENCE: ILDKKVEKV*# ...# >HUM101C8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: phosphor imager/cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Influenza matrix protein (58-66) homologue# DB REFERENCE: PIR1: (B45539)# REFERENCES: parker92a,falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,GLLGFVFTL*# SEQUENCE: GLLGFVFTL*# ...# >HUM101C9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: spectrometry natural ligands/competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human IP 30 signal peptide# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708,S21727)# REFERENCES: wei92a,chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLLDVPTAAV*# SEQUENCE: LLLDVPTAAV*# ...# >HUM101CA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: endogenous peptide/ HPLC analysis# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Leader alpha-subunit signal sequence receptor# DB REFERENCE: PIR3: (S36679)# REFERENCES: parker92a,wei92a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,VLFRGGPRGLLAV*# SEQUENCE: VLFRGGPRGLLAV*# ...# >HUM101CB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: endogenous peptide/ HPLC analysis# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Leader alpha-subunit signal sequence receptor# ANCHOR POSITIONS: 2,[10,11]# REFERENCES: parker92a,wei92a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GLFRGGPRGLLAV*# SEQUENCE: GLFRGGPRGLLAV*# ...# >HUM101CC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,AILGFVFTL*# SEQUENCE: AILGFVFTL*# ...# >HUM101CD# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./cytotoxicity as./binding as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,sauma93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,GALGFVFTL*# SEQUENCE: GALGFVFTL*# ...# >HUM101CE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./cytotoxicity as./binding as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,sauma93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesh,GIAGFVFTL*# SEQUENCE: GIAGFVFTL*# ...# >HUM101CF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: none# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GILAFVFTL*# SEQUENCE: GILAFVFTL*# ...# >HUM101D0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: none# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GILGAVFTL*# SEQUENCE: GILGAVFTL*# ...# >HUM101D1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as.# ACTIVITY: none# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GILGFAFTL*# SEQUENCE: GILGFAFTL*# ...# >HUM101D2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as.# ACTIVITY: none# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GILGFVATL*# SEQUENCE: GILGFVATL*# ...# >HUM101D3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesh,GILGFVFAL*# SEQUENCE: GILGFVFAL*# ...# >HUM101D4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesh,GILGFVFTA*# SEQUENCE: GILGFVFTA*# ...# >HUM101D5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./cytotoxicity as./binding as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,sauma93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,KILGFVFTL*# SEQUENCE: KILGFVFTL*# ...# >HUM101D6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesh,GKLGFVFTL*# SEQUENCE: GKLGFVFTL*# ...# >HUM101D7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./bionding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesh,GIKGFVFTL*# SEQUENCE: GIKGFVFTL*# ...# >HUM101D8# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actyesm,bindyesh,GILKFVFTL*# SEQUENCE: GILKFVFTL*# ...# >HUM101D9# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as./stabilisation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a,elvin93a,stuber95a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesh,GILGKVFTL*# SEQUENCE: GILGKVFTL*# ...# >HUM101DA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as.# ACTIVITY: none# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GILGFKFTL*# SEQUENCE: GILGFKFTL*# ...# >HUM101DB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as.# ACTIVITY: none# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GILGFVKTL*# SEQUENCE: GILGFVKTL*# ...# >HUM101DC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as./binding as.# ACTIVITY: none# BINDING: yes, high# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GILGFVFKL*# SEQUENCE: GILGFVFKL*# ...# >HUM101DD# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Phosphor imager NIEF as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: flu matrix protein homologue# ANCHOR POSITIONS: 2,9# REFERENCES: parker92a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesl,GILGFVFTK*# SEQUENCE: GILGFVFTK*# ...# >HUM101DE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/cytotoxicity as./competitive inhibition/binding/IEF as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: FLUB NP(82-94)# DB REFERENCE: SWISS: (VNUC_INBLE,VNUC_INBAA,VNUC_INBSI,VNUC_INBAD,# & VNUC_INBAC)# & PIR1: (VHIVBA,VHIVBW,VHIVBC)# REFERENCES: carreno92a,parker92a,parker92b,robbins89a,garboczi92a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesh,KLGEFYNQMM*# SEQUENCE: KLGEFYNQMM*# ...# >HUM101DF# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (305-314)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1B1,GAG_HV1MN,GAG_HV1BR,GAG_HV1H2,# & GAG_SIVCZ,GAG_HV1J3,GAG_HV1N5,GAG_HV1C4,GAG_HV1Z2,# & GAG_HV1B5,GAG_HV1Y2)# & PIR1: (A38068,A44001,FOLJSI,FOVWH3,FOVWH4,FOVWVL,FOVWLV)# & PIR2: (S60708,S54377,S60697,S60699,S60700)# & PIR3: (S33979)# REFERENCES: johnson91a,buseyne93a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,RAEQASQEVK*# SEQUENCE: RAEQASQEVK*# ...# >HUM101E0# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Elicitation of CTL responses synthetic peptide as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (298-314)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1MN,GAG_HV1B5,GAG_HV1PV,GAG_HV1C4,# & GAG_HV1N5,GAG_HV1BR,GAG_HV1J3,GAG_SIVCZ,GAG_HV1H2,# & GAG_HV1Z2,GAG_HV1Y2)# & PIR1: (FOVWVL,A44001,A38068,FOVWH4,FOVWH3,FOLJSI,FOVWLV)# & PIR2: (S60697,S60699,S60700,S54377,S60708)# & PIR3: (S33979)# REFERENCES: johnson91a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,DRFYKTLRAEQASQEVK*# SEQUENCE: DRFYKTLRAEQASQEVK*# ...# >HUM101E1# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Elicitation of CTL responses synthetic peptide as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (300-314)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1MN,GAG_HV1J3,GAG_HV1H2,GAG_HV1C4,# & GAG_HV1PV,GAG_HV1Y2,GAG_HV1Z2,GAG_HV1BR,GAG_SIVCZ,# & GAG_HV1N5,GAG_HV1B1)# & PIR1: (FOVWVL,FOLJSI,FOVWH3,A38068,FOVWLV,A44001,FOVWH4)# & PIR2: (S60700,S60697,S54377,S60699,S60708)# & PIR3: (S33979)# REFERENCES: johnson91a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,FYKTLRAEQASQEVK*# SEQUENCE: FYKTLRAEQASQEVK*# ...# >HUM101E2# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Elicitation of CTL responses synthetic peptide as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (301-314)# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1B5,GAG_HV1MN,GAG_HV1PV,GAG_HV1Y2,# & GAG_HV1Z2,GAG_HV1J3,GAG_HV1BR,GAG_HV1C4,GAG_HV1N5,# & GAG_SIVCZ,GAG_HV1B1)# & PIR1: (A44001,FOLJSI,FOVWH4,FOVWVL,FOVWLV,A38068,FOVWH3)# & PIR2: (S60699,S60700,S60708,S54377,S60697)# & PIR3: (S33979)# REFERENCES: johnson91a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,YKTLRAEQASQEVK*# SEQUENCE: YKTLRAEQASQEVK*# ...# >HUM101E3# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Elicitation of CTL responses synthetic peptide as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (302-314)# DB REFERENCE: SWISS: (GAG_HV1Y2,GAG_HV1B1,GAG_HV1B5,GAG_HV1MN,GAG_HV1Z2,# & GAG_HV1PV,GAG_HV1BR,GAG_HV1J3,GAG_HV1C4,GAG_HV1N5,# & GAG_SIVCZ,GAG_HV1H2)# & PIR1: (FOLJSI,A44001,FOVWH3,FOVWLV,FOVWH4,FOVWVL,A38068)# & PIR2: (S54377,S60700,S60708,S60697,S60699)# & PIR3: (S33979)# REFERENCES: johnson91a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,KTLRAEQASQEVK*# SEQUENCE: KTLRAEQASQEVK*# ...# >HUM101E4# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Elicitation of CTL responses synthetic peptide as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (303-314)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1MN,GAG_HV1PV,GAG_HV1Z2,GAG_HV1B1,# & GAG_HV1J3,GAG_HV1N5,GAG_HV1BR,GAG_SIVCZ,GAG_HV1B5,# & GAG_HV1Y2,GAG_HV1H2)# & PIR1: (FOVWH3,FOVWH4,A44001,FOLJSI,FOVWLV,FOVWVL,A38068)# & PIR2: (S60699,S60708,S60697,S60700,S54377)# & PIR3: (S33979)# REFERENCES: johnson91a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,TLRAEQASQEVK*# SEQUENCE: TLRAEQASQEVK*# ...# >HUM101E5# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Elicitation of CTL responses synthetic peptide as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (304-314)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_HV1PV,GAG_HV1B5,GAG_HV1H2,GAG_HV1BR,# & GAG_HV1N5,GAG_HV1B1,GAG_HV1Y2,GAG_SIVCZ,GAG_HV1J3,# & GAG_HV1C4,GAG_HV1Z2)# & PIR1: (FOVWH4,FOVWH3,A38068,FOVWVL,FOLJSI,A44001,FOVWLV)# & PIR2: (S54377,S60700,S60708,S60697,S60699)# & PIR3: (S33979)# REFERENCES: johnson91a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,LRAEQASQEVK*# SEQUENCE: LRAEQASQEVK*# ...# >HUM101E6# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Elicitation of CTL responses synthetic peptide as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (298-313)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1J3,GAG_HV1H2,GAG_HV1B5,GAG_HV1C4,# & GAG_HV1MN,GAG_SIVCZ,GAG_HV1Y2,GAG_HV1BR,GAG_HV1N5,# & GAG_HV1PV,GAG_HV1Z2)# & PIR1: (FOVWH3,FOVWVL,FOVWH4,FOLJSI,A44001,A38068,FOVWLV)# & PIR2: (S60700,S60697,S60708,S54377,S60699)# & PIR3: (S33979)# REFERENCES: johnson91a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,DRFYKTLRAEQASQEV*# SEQUENCE: DRFYKTLRAEQASQEV*# ...# >HUM101E7# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: flow cytometry/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (18-42)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1BR,GAG_HV1J3,GAG_HV1A2,GAG_HV1H2,# & GAG_HV1B5,GAG_HV1PV)# & PIR1: (FOVWH3,FOVWLV,FOVWVL,FOVWA2)# & PIR3: (S33979)# REFERENCES: johnson91a,hivdb97a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,KIRLRPGGKKKYKLKHIVWASRELE*# SEQUENCE: KIRLRPGGKKKYKLKHIVWASRELE*# ...# >HUM101E8# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: flow cytometry/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (263-284)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1B5,GAG_HV1A2,GAG_HV1BR,GAG_HV1N5,# & GAG_HV1Y2,GAG_HV1B1,GAG_HV1W2,GAG_HV1H2,GAG_HV1OY)# & PIR1: (FOVWH3,FOVWA2,FOVWVL,FOVWLV,A44001)# & PIR2: (S60703,S60702,S60699,S60704)# & PIR3: (S33979)# REFERENCES: johnson91a,hivdb97a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,KRWIILGLNKIVRMYSPTSILD*# SEQUENCE: KRWIILGLNKIVRMYSPTSILD*# ...# >HUM101E9# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: flow cytometry/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (143-164)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_SIVCZ,GAG_HV1PV,GAG_HV1RH,GAG_HV1H2,# & GAG_HV1B5,GAG_HV1A2,GAG_HV1B1,GAG_HV1N5,GAG_HV1Y2,# & GAG_HV1BR,GAG_HV1J3,GAG_HV1W2)# & PIR1: (A38068,FOVWVL,FOVWA2,FOVWLV,A44001,FOVWH3,FOLJSI)# REFERENCES: johnson91a,buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,VHQAISPRTLNAWVKVVEEKAF*# SEQUENCE: VHQAISPRTLNAWVKVVEEKAF*# ...# >HUM101EA# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: flow cytometry/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (153-174)# DB REFERENCE: SWISS: (GAG_HV1OY,GAG_HV1H2,GAG_HV1A2,GAG_HV1RH,GAG_HV1J3,# & GAG_HV1BR,GAG_HV1Y2,GAG_HV1PV,GAG_HV1W2,GAG_HV1B5,# & GAG_SIVCZ,GAG_HV1MN,GAG_HV1N5,GAG_HV1B1)# & PIR1: (A38068,FOVWVL,FOLJSI,A44001,FOVWLV,FOVWA2,FOVWH3)# & PIR3: (S33979)# REFERENCES: johnson91a,buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,NAWVKVVEEKAFSPEVIPMFSA*# SEQUENCE: NAWVKVVEEKAFSPEVIPMFSA*# ...# >HUM101EB# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: flow cytometry/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (173-194)# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1B1,GAG_HV1W2,GAG_HV1ND,GAG_HV1H2,# & GAG_HV1A2,GAG_HV1Z2,GAG_HV1N5,GAG_HV1EL,GAG_HV1BR,# & GAG_HV1J3,GAG_HV1JR,GAG_HV1PV,GAG_HV1Y2,GAG_HV1B5,# & GAG_HV1MN)# & PIR1: (FOLJND,A38068,FOVWH3,A44001,FOVWA2,FOVWLV,FOVWVL)# & PIR2: (S54377)# & PIR3: (S33979)# REFERENCES: johnson91a,buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,SALSEGATPQDLNTMLNTVGGH*# SEQUENCE: SALSEGATPQDLNTMLNTVGGH*# ...# >HUM101EC# MHC MOLECULE: HLA-B52, CLASS-1, (HUMAN)# METHOD: flow cytometry/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (193-214)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1Y2,GAG_HV1B5,GAG_HV1EL,GAG_HV1PV,# & GAG_HV1J3,GAG_HV1B1,GAG_HV1A2,GAG_HV1OY,GAG_HV1MN,# & GAG_HV1BR,GAG_HV1JR,GAG_HV1H2,GAG_HV1RH,GAG_HV1W2,# & GAG_HV1Z2,GAG_HV1N5)# & PIR1: (FOVWH3,FOVWLV,FOVWH4,FOVWA2,A38068,A44001,FOVWVL)# & PIR2: (S44993,S54377)# & PIR3: (S33979)# REFERENCES: johnson91a,hivdb97a# COMMENT:# SUMMARY: HLA-B52,actyesu,bindyesu,GHQAAMQMLKETINEEAAEWDR*# SEQUENCE: GHQAAMQMLKETINEEAAEWDR*# ...# >HUM101ED# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: IEF as. - determining rate of dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (308-322)# ANCHOR POSITIONS:# REFERENCES: parker92b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RIQRGSGRAFVTIGK*# SEQUENCE: RIQRGSGRAFVTIGK*# ...# >HUM101EE# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: IEF as. - determining rate of dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (311-322)# ANCHOR POSITIONS:# REFERENCES: parker92b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RGSGRAFVTIGK*# SEQUENCE: RGSGRAFVTIGK*# ...# >HUM101EF# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competitive inhibition of lysis/direct binding# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: NP (380-393)# DB REFERENCE: SWISS: (VNUC_IAUSS,VNUC_IAKIE,VNUC_IARUD,VNUC_IAGU1,VNUC_IAANA,# & VNUC_IAUDO,VNUC_IAS11,VNUC_IAWHN,VNUC_IADU2,VNUC_IATRT,# & VNUC_IAMEC,VNUC_IADBE,VNUC_IAHMI,VNUC_IAZOH,VNUC_IAZTE,# & VNUC_IAB39,VNUC_IAFPD,VNUC_IAHPR,VNUC_IALEN,VNUC_IATRS,# & VNUC_IACKP,VNUC_IAME6,VNUC_IAGD7,VNUC_IABRA,VNUC_IAWIS,# & VNUC_IADE1,VNUC_IAWHP,VNUC_IAZJ1,VNUC_IAZ41,VNUC_IAZON,# & VNUC_IADM2,VNUC_IADNZ,VNUC_IAZ29,VNUC_IAME4,VNUC_IANT6,# & VNUC_IADAU,VNUC_IAANN,VNUC_IAZH4,VNUC_IAGRE,VNUC_IAMAA,# & VNUC_IAZJ3,VNUC_IATKN,VNUC_IAFOM,VNUC_IAZI2,VNUC_IAZJA,# & VNUC_IAZDA,VNUC_IATX7,VNUC_IADE2,VNUC_IAMIN,VNUC_IAPUE,# & VNUC_IABUD,VNUC_IATKO,VNUC_IAZMA,VNUC_IATEI,VNUC_IAEN5,# & VNUC_IAMEG,VNUC_IAMEA,VNUC_IAHIC,VNUC_IAZCA,VNUC_IAOHI,# & VNUC_IAME3,VNUC_IAMEF,VNUC_IACKG,VNUC_IASH2,VNUC_IAPAR,# & VNUC_IAFPR,VNUC_IAZI3,VNUC_IADMA,VNUC_IAVI6,VNUC_IAZI1,# & VNUC_IAHO2,VNUC_IAME5,VNUC_IAZW1,VNUC_IACAL,VNUC_IAWIL,# & VNUC_IANEJ,VNUC_IAZW2,VNUC_IAMEB,VNUC_IAZH3,VNUC_IAHO1,# & VNUC_IAS06,VNUC_IAMEE,VNUC_IAHTE,VNUC_IAB37,VNUC_IAANN,# & VNUC_IAMAN,VNUC_IASE0,VNUC_IAHLO,VNUC_IAS31,VNUC_IAZH1,# & VNUC_IAFOW,VNUC_IADCZ,VNUC_IASIN,VNUC_IAZJ2)# & PIR1: (VHIVA3,VHIV61,VHIVX5,VHIVX2,VHIV68,VHIVM1,VHIVX3,VHIVC1,# & VHIVA6,VHIV8H,VHIVN1,VHIVN8,VHIV34,VHIVN7,VHIVA7,VHIVN9,# & VHIVXL,VHIVX4,VHIVN3,VHIVX1,VHIVX6,A60028,VHIVAK,VHIVN4,# & VHIVN5)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS: 3,5# REFERENCES: sutton93a,rowland-jones93a,suhrbier93a,dibrino94a,sette94a,# & goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,ELRSRYWAI*# SEQUENCE: ELRSRYWAI*# ...# >HUM101F0# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competitive inhibition of lysis# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: NP (380-393)# ANCHOR POSITIONS: 3,5# REFERENCES: sutton93a,rowland-jones93a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,ELKSRYWAI*# SEQUENCE: ELKSRYWAI*# ...# >HUM101F1# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competitive inhibition of lysis/HLA assembly# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gag (24-32)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV2NZ,GAG_HV1B1,GAG_HV1J3,GAG_HV1PV,# & GAG_HV1H2,GAG_HV1MN,GAG_HV2CA,GAG_HV1B5,GAG_HV1A2)# & PIR1: (FOVWH3,A38068,FOLJCA,FOVWA2,FOVWVL,FOVWLV)# & PIR3: (S33979,S19598)# REFERENCES: sutton93a,rowland-jones93a,mcadam95a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,GGKKKYKLK*# SEQUENCE: GGKKKYKLK*# ...# >HUM101F2# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competitive inhibition of lysis# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gag (25-33)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1B1,GAG_HV1J3,GAG_HV2NZ,GAG_HV1B5,# & GAG_HV1A2,GAG_HV1MN,GAG_HV2CA,GAG_HV1H2,GAG_HV1PV)# & PIR1: (FOVWH3,FOVWVL,FOVWLV,FOLJCA,FOVWA2,A38068)# & PIR3: (S33979,S19598)# REFERENCES: sutton93a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,GKKKYKLKH*# SEQUENCE: GKKKYKLKH*# ...# >HUM101F3# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competitive inhibition of lysis# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gag (26-34)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1A2,GAG_HV2CA,GAG_HV1B1,GAG_HV1BR,# & GAG_HV2NZ,GAG_HV1H2,GAG_HV1B5,GAG_HV1J3)# & PIR1: (FOVWA2,FOVWVL,FOVWLV,FOLJCA,FOVWH3)# & PIR3: (S19598,S33979)# REFERENCES: sutton93a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,KKKYKLKHI*# SEQUENCE: KKKYKLKHI*# ...# >HUM101F4# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competitive inhibition/Reference/Stabilisation# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: HIV gag (24-31)# DB REFERENCE: SWISS: (GAG_HV2CA,GAG_HV1A2,GAG_HV1PV,GAG_HV1H2,GAG_HV1B5,# & GAG_HV2NZ,GAG_HV1B1,GAG_HV1MN,GAG_HV1BR,GAG_HV1J3)# & PIR1: (FOVWH3,A38068,FOLJCA,FOVWVL,FOVWLV,FOVWA2)# & PIR3: (S19598,S33979)# REFERENCES: sutton93a,price97a,brander95b,hivdb97a,goulder97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesm,GGKKKYKL*# SEQUENCE: GGKKKYKL*# ...# >HUM101F5# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV EBNA-3 (334-353)# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: sutton93a,johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AWNAGFLRGRAYGIDLLRTE*# SEQUENCE: AWNAGFLRGRAYGIDLLRTE*# ...# >HUM101F6# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV EBNA-3 (339-347)# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: sutton93a,burrows90a,dibrino94a,burrows92a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,FLRGRAYGI*# SEQUENCE: FLRGRAYGI*# ...# >HUM101F7# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: flow cytometry/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag (255-269)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1Y2,GAG_HV1OY,GAG_HV1ND,GAG_HV1JR,# & GAG_HV1B5,GAG_HV1BR,GAG_HV1MN,GAG_HV1H2,GAG_HV1A2,# & GAG_HV1Z2,GAG_HV1PV,GAG_HV1W2,GAG_HV1J3,GAG_HV1RH,# & GAG_HV1EL,GAG_HV1B1)# & PIR1: (FOVWA2,FOVWLV,A38068,FOVWH3,A44001,FOVWVL,FOLJND)# & PIR2: (S60702,S54377,S60697,S60698,S60699,S60703,S60704,# & S60708)# & PIR3: (S19598,S33979)# REFERENCES: johnson91a,sutton93a,suhrbier93a,johnson92a,buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,NPPIPVGEIYKRWII*# SEQUENCE: NPPIPVGEIYKRWII*# ...# >HUM101F8# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./HLA assembly# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gag (261-269)# DB REFERENCE: SWISS: (GAG_HV1Z2,GAG_HV1PV,GAG_HV1BR,GAG_HV1C4,GAG_HV1RH,# & GAG_HV1EL,GAG_HV1MN,GAG_HV1B1,GAG_HV1N5,GAG_HV1JR,# & GAG_HV1OY,GAG_HV1B5,GAG_HV1H2,GAG_HV1ND,GAG_HV1Y2,# & GAG_HV1J3,GAG_HV1W2,GAG_HV1A2)# & PIR1: (FOVWLV,FOVWH4,FOVWA2,A38068,FOVWH3,A44001,FOLJND,# & FOVWVL)# & PIR2: (S60697,S60703,S60702,S54377,S60699,S60704,S60698,S60700,# & S60708)# & PIR3: (S19598,S33979)# REFERENCES: sutton93a,dibrino94a,mcadam95a,brander95b,hivdb97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,GEIYKRWII*# SEQUENCE: GEIYKRWII*# ...# >HUM101F9# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag 325-340# ANCHOR POSITIONS: 9,11# REFERENCES: sutton93a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,VQNANPDCKTILKALY*# SEQUENCE: VQNANPDCKTILKALY*# ...# >HUM101FA# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./HLA assembly# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag 331-339# DB REFERENCE: SWISS: (GAG_HV1JR,GAG_HV1OY,GAG_HV1RH,GAG_HV1MN,GAG_HV1EL,# & GAG_HV1B1,GAG_HV1W2,GAG_HV1A2,GAG_HV1J3,GAG_HV1Y2,# & GAG_HV1B5,GAG_HV1N5,GAG_HV1C4,GAG_HV1MA,GAG_HV1Z2,# & GAG_HV1PV,GAG_HV1BR,GAG_HV1H2,GAG_HV1ND)# & PIR1: (FOVWLV,FOVWVL,FOVWA2,FOVWH4,FOVWH3,A44001,FOLJND,# & A38068)# & PIR2: (S60700,S60708,S60698,S60697,S60703,S54377,S60702,S60704,# & S60699)# & PIR3: (S33979,S19598)# REFERENCES: sutton93a,mcadam95a,brander95b,hivdb97a,goulder97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,DCKTILKAL*# SEQUENCE: DCKTILKAL*# ...# >HUM101FB# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIVgp41 (576-600)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1PV,ENV_HV1Z2,ENV_HV1J3,ENV_HV1BR,# & ENV_HV1Z6,ENV_HV1B1,ENV_HV1B8,ENV_HV1H2,ENV_HV1H3,# & ENV_HV1MF,ENV_HV1EL)# & PIR1: (A44963,VCLJLV,VCLJZR,VCLJVL,VCLJH3)# & PIR2: (S21998,S54384,S70422,S70425,S21996)# & PIR3: (S13288,S33985)# REFERENCES: sutton93a,johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,QLQARILAVERYLKDQQLLGIWGCS*# SEQUENCE: QLQARILAVERYLKDQQLLGIWGCS*# ...# >HUM101FC# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIVgp41 (587-594)# DB REFERENCE: SWISS: (ENV_HV1Z2,ENV_HV1C4,ENV_HV1MN,ENV_HV1PV,ENV_HV1ZH,# & ENV_HV1Z6,ENV_HV1BN,ENV_HV1B1,ENV_HV1B8,ENV_HV1H2,# & ENV_HV1OY,ENV_HV1H3,ENV_HV1Z8,ENV_HV1MF,ENV_HV1EL,# & ENV_HV1S1,ENV_HV1BR,ENV_HV1J3)# & PIR1: (A44963,VCLJH4,VCLJH3,VCLJZR,VCLJVL,VCLJBR,VCLJLV,# & VCLJMN)# & PIR2: (S22002,S70418,S21994,S70424,S70425,S70423,S21990,S70422,# & S22000,S22006,S21992,S70420,B41621,S54384,S21996,S22004,# & S70417,S70419,S21998,S70421)# & PIR3: (S33985,S13288)# REFERENCES: sutton93a,suhrbier93a,johnson92a,dai92a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,YLKDQQLL*# SEQUENCE: YLKDQQLL*# ...# >HUM101FD# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: competitive inhibition of lysis# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 RT (172-196)# ANCHOR POSITIONS: 16,18# REFERENCES: sutton93a,walker89a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,IETVPVKLKPGMGDPKVKQWPLTEE*# SEQUENCE: IETVPVKLKPGMGDPKVKQWPLTEE*# ...# >HUM101FE# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: predicted from the longer cytotoxic peptide# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 RT (185-193)# ANCHOR POSITIONS:# REFERENCES: walker89a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,DPKVKQWPL*# SEQUENCE: DPKVKQWPL*# ...# >HUM101FF# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 RT (325-349)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1BR,POL_HV1PV,POL_HV1H2,POL_HV1OY,# & POL_HV1B5,POL_HV1A2)# & PIR1: (GNVWVL,GNVWA2,GNVWLV)# & PIR2: (B47330,S32079,D47330,S32137,A47330,S32075,S32068,B47175,# & S32070,S32069,S32066,S32160,S32096,S32159,S32072,S32078,# & S32138,S32074,S32136,S32157,S32067,S32080,S32076,S32135,# & E47330,S32139,S32071,S32134,S32126)# REFERENCES: walker89a,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,AIFQSSMTKILEPFRKQNPDIVIYQ*# SEQUENCE: AIFQSSMTKILEPFRKQNPDIVIYQ*# ...# >HUM10200# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 RT (342-366)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1B5,POL_HV1PV,POL_HV1BR,POL_HV1OY,# & POL_HV1H2,POL_HV1B1,POL_HV1MN,POL_HV1A2)# & PIR1: (GNVWA2,GNVWH3,GNVWLV,GNVWVL)# & PIR2: (A47330,C47330,S32140,F47330,S32052,S32117,S32135,E47330,# & S32134,S32129,D47330,S32151,S32138,S32136,S32137,S32079,# & S32122,S32157,S32080,S32065,S32073,S32078,S32072,S32064,# & S32054,S32120,S32058,S32126,S32127,S32139,S32160,S32159,# & S32055,S32053,S32118,S32056,S32069,B47175,S32119,S32060,# & S32075,S32068,B47330,S32097,S32077,S32063)# REFERENCES: walker89a,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,NPDIVIYQYMDDLYVGSDLEIGQHR*# SEQUENCE: NPDIVIYQYMDDLYVGSDLEIGQHR*# ...# >HUM10201# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 RT (342-366)# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1BR,POL_HV1A2,POL_HV1H2,POL_HV1RH,# & POL_HV1B1,POL_HV1Y2,POL_HV1PV,POL_HV1N5)# & PIR1: (GNVWH3,GNVWLV,GNVWVL,B44001,GNVWA2)# & PIR2: (A47175,B47175)# REFERENCES: walker89a,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,EIQKQGQGQWTYQIYQEPFKNLKTG*# SEQUENCE: EIQKQGQGQWTYQIYQEPFKNLKTG*# ...# >HUM10202# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 RT (461-485)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1Y2,POL_HV1PV,POL_HV1OY,POL_HV1H2,# & POL_HV1B1,POL_HV1ND,POL_HV1N5,POL_HV1MN,POL_HV1BR,# & POL_HV1EL,POL_HV1B5)# & PIR1: (GNVWH3,GNVWVL,GNLJND,B44001,GNVWLV)# & PIR2: (S54378,B47175)# REFERENCES: walker89a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,PLTEEAELELAENREILKEPVHGVY*# SEQUENCE: PLTEEAELELAENREILKEPVHGVY*# ...# >HUM10203# MHC MOLECULE: HLA-B60, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 RT (359-383)# DB REFERENCE: SWISS: (POL_HV1PV,POL_HV1B1,POL_HV1BR,POL_HV1H2)# & PIR1: (GNVWVL,GNVWH3,GNVWLV)# & PIR2: (B47175)# REFERENCES: walker89a,hivdb97a# COMMENT:# SUMMARY: HLA-B60,actyesu,bindyesu,DLEIGQHRTKIEELRQHLLRWGLTT*# SEQUENCE: DLEIGQHRTKIEELRQHLLRWGLTT*# ...# >HUM10204# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef7F (74-82)# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_HV1Z6,NEF_HV1SC,NEF_HV1OY,NEF_HV1S1,# & NEF_HV1B8,NEF_HV1BR,NEF_HV1H2,NEF_HV1EL,NEF_HV1ND,# & NEF_HV1U4,NEF_HV1BN,NEF_HV1S3,NEF_HV1B1,NEF_HV2D2,# & NEF_HV1A2,NEF_HV1MN,NEF_HV1MA,NEF_HV1Z2,NEF_HV1PV,# & NEF_HV112)# & PIR1: (ASLJO2,ASLJH3,ASLJVL,QQLJZR,ASLJ12,QQLJND,ASLJBR,# & ASLJFV)# & PIR2: (S03244,S03245,S25937,S54385,S43467,S24572,S24985)# & PIR3: (S33986)# REFERENCES: carreno92a,koenig90a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,VPLRPMTYK*# SEQUENCE: VPLRPMTYK*# ...# >MUS10205# MHC MOLECULE: H-2Dk, CLASS-1, (MOUSE)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: H-2Ld (61-85)# DB REFERENCE: SWISS: (HA1L_MOUSE)# & PIR1: (HLMSLD)# & PIR2: (I54069,JL0059,I60188,B60854)# REFERENCES: song88a,townsend89a# COMMENT:# SUMMARY: H-2Dk,actyesu,bindyesu,ERITQIAKGQEQWFRVNLRTLLGYY*# SEQUENCE: ERITQIAKGQEQWFRVNLRTLLGYY*# ...# >MUS10206# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: competition as./cytotoxicity as./binding as./Stabilization# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Murine citomegalovirus p89 (168-176)# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: del_val88a,catipovic92a,kageyama95a,hogquist93a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,YPHFMPTNL*# SEQUENCE: YPHFMPTNL*# ...# >MUS10207# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Flow microfluorometry/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59) 52A# ANCHOR POSITIONS: 5,8# REFERENCES: catipovic92a,imarai95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,AGYVYQGL*# SEQUENCE: AGYVYQGL*# ...# >MUS10208# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Flow microfluorometry/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59) 53A# ANCHOR POSITIONS: 5,8# REFERENCES: catipovic92a,imarai95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,RAYVYQGL*# SEQUENCE: RAYVYQGL*# ...# >MUS10209# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Flow microfluorometry/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59) 54A# ANCHOR POSITIONS: 5,8# REFERENCES: catipovic92a,imarai95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,RGAVYQGL*# SEQUENCE: RGAVYQGL*# ...# >MUS1020A# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Flow microfluorometry/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59) 55A# ANCHOR POSITIONS: 5,8# REFERENCES: catipovic92a,imarai95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,RGYAYQGL*# SEQUENCE: RGYAYQGL*# ...# >MUS1020B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Flow microfluorometry/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59) 56A# ANCHOR POSITIONS: 5,8# REFERENCES: catipovic92a,imarai95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,RGYVAQGL*# SEQUENCE: RGYVAQGL*# ...# >MUS1020C# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Flow microfluorometry/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59) 57A# ANCHOR POSITIONS: 5,8# REFERENCES: catipovic92a,imarai95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,RGYVYAGL*# SEQUENCE: RGYVYAGL*# ...# >MUS1020D# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Flow microfluorometry/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59) 58A# ANCHOR POSITIONS: 5,8# REFERENCES: catipovic92a,imarai95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,RGYVYQAL*# SEQUENCE: RGYVYQAL*# ...# >MUS1020E# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Flow microfluorometry/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Vesicular stomatitis virus NP (52-59) 59A# ANCHOR POSITIONS: 5,8# REFERENCES: catipovic92a,imarai95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,RGYVYQGA*# SEQUENCE: RGYVYQGA*# ...# >MUS1020F# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides/competitive binding/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Murine pLCMV NP (118-126)# DB REFERENCE: SWISS: (NCAP_LYCVA,NCAP_LYCVW)# & PIR1: (VHXPLC,VHXPLM)# REFERENCES: falk93a,corr92a,udaka92a,lie91a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesm,RPQASGVYM*# SEQUENCE: RPQASGVYM*# ...# >MUS10210# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: S. erythraeus rRNA adenine N-6-methyltransferase# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,QPQRGRENF*# SEQUENCE: QPQRGRENF*# ...# >MUS10211# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse proline-rich protein# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,APQPNLYQL*# SEQUENCE: APQPNLYQL*# ...# >MUS10212# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE:# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,YPNYNIHNF*# SEQUENCE: YPNYNIHNF*# ...# >MUS10213# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: Bovine endozepine# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,APQPGMENFK*# SEQUENCE: APQPGMENFK*# ...# >MUS10214# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Bovine endozepine# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,APQPGMENF*# SEQUENCE: APQPGMENF*# ...# >MUS10215# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE:# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,APQRGRENF*# SEQUENCE: APQRGRENF*# ...# >MUS10216# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse phosphoglycerate kinase# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,APQKAGGFLM*# SEQUENCE: APQKAGGFLM*# ...# >MUS10217# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE:# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT: Minimum binding peptide# SUMMARY: H-2Ld,actunkn,bindyesm,APAAAAAAL*# SEQUENCE: APAAAAAAL*# ...# >MUS10218# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides and competitive binding# ACTIVITY: ?# BINDING: yes, little# SOURCE:# ANCHOR POSITIONS:# REFERENCES: corr92a# COMMENT: Minimum binding peptide# SUMMARY: H-2Ld,actunkn,bindyesl,APLEANYQAF*# SEQUENCE: APLEANYQAF*# ...# >MUS10219# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: eluted self peptides/competitive binding/Competition/Half-time# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ld-self# DB REFERENCE: SWISS: (SPCO_MOUSE,SPCO_HUMAN)# & PIR2: (A44159)# REFERENCES: corr92a,khilko93a,cook96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,YPNVNIHNF*# SEQUENCE: YPNVNIHNF*# ...# >MUS1021A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RFLENGKETLQRA*# SEQUENCE: RFLENGKETLQRA*# ...# >MUS1021B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-A24 (170-182) homologue# DB REFERENCE: SWISS: (1B33_HUMAN,1B46_HUMAN,1B02_HUMAN)# & PIR1: (HLHU40,HLHUB7)# & PIR2: (I38437,I68701,S60601,I54418,I61903,I59651,S24438)# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RYLENGKDKLERA*# SEQUENCE: RYLENGKDKLERA*# ...# >MUS1021C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYLENGKDTLQRA*# SEQUENCE: RYLENGKDTLQRA*# ...# >MUS1021D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-A24 (170-182) homologue# DB REFERENCE: SWISS: (1C03_HUMAN)# & PIR2: (I68712)# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RYLENGKEKLQRA*# SEQUENCE: RYLENGKEKLQRA*# ...# >MUS1021E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYLENGKETLERA*# SEQUENCE: RYLENGKETLERA*# ...# >MUS1021F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RYLENGKETAQRA*# SEQUENCE: RYLENGKETAQRA*# ...# >MUS10220# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RYLENGKETKQRA*# SEQUENCE: RYLENGKETKQRA*# ...# >MUS10221# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RYLENGKEDLQRA*# SEQUENCE: RYLENGKEDLQRA*# ...# >MUS10222# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RYLENGKEKAQRA*# SEQUENCE: RYLENGKEKAQRA*# ...# >MUS10223# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYAENGKETLQRA*# SEQUENCE: RYAENGKETLQRA*# ...# >MUS10224# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A24 (170-182) homologue# ANCHOR POSITIONS: 2,10# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYLENTKETLQRA*# SEQUENCE: RYLENTKETLQRA*# ...# >MUS10225# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A24 (170-182) homologue# DB REFERENCE: SWISS: (1B03_GORGO,1B01_GORGO,1B02_GORGO)# & PIR2: (JH0540,JH0539,JH0541)# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYLENGRETLQRA*# SEQUENCE: RYLENGRETLQRA*# ...# >MUS10226# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A24 (170-182) homologue# DB REFERENCE: SWISS: (HA1D_MOUSE,HA1D_MOUSE)# & PIR1: (HLMSKD)# & PIR2: (A21198,B45876)# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYLELGNETLLRT*# SEQUENCE: RYLELGNETLLRT*# ...# >MUS10227# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A24 (170-182) homologue# DB REFERENCE: SWISS: (HA1Y_MOUSE,HA11_MOUSE,HA11_MOUSE,HA1L_MOUSE,HA1B_MOUSE,# & HA1B_MOUSE,HA12_MOUSE,HA1Z_MOUSE,HA12_MOUSE)# & PIR1: (HLMSDB,HLMSKB,HLMS2,HLMS1,HLMSLD)# & PIR2: (I54069,B60854,I59068,JL0059,I49713,JL0058,C60854,I58989,# & I57611,I55665,I49712,I70694,I48658,I56002,I60188)# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYLKNGNATLLRT*# SEQUENCE: RYLKNGNATLLRT*# ...# >MUS10228# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: AY___TLA homologue# ANCHOR POSITIONS:# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,AYPPTLA*# SEQUENCE: AYPPTLA*# ...# >MUS10229# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: AY___TLA homologue# ANCHOR POSITIONS:# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,AYPPPPTLA*# SEQUENCE: AYPPPPTLA*# ...# >MUS1022A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: AY___TLA homologue# ANCHOR POSITIONS:# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,AYPPPPPPTLA*# SEQUENCE: AYPPPPPPTLA*# ...# >MUS1022B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: AY___TLA homologue# ANCHOR POSITIONS:# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,AAPPPPPTLA*# SEQUENCE: AAPPPPPTLA*# ...# >MUS1022C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: AY___TLA homologue# ANCHOR POSITIONS:# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,YPPPPPTLA*# SEQUENCE: YPPPPPTLA*# ...# >MUS1022D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: AY___TLA homologue# ANCHOR POSITIONS:# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,AYGGGGTLA*# SEQUENCE: AYGGGGTLA*# ...# >MUS1022E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: AY___TLA homologue# ANCHOR POSITIONS:# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,AYGGGGGTLA*# SEQUENCE: AYGGGGGTLA*# ...# >MUS1022F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: AY___TLA homologue# ANCHOR POSITIONS:# REFERENCES: maryanski90a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,AYGGGGGGTLA*# SEQUENCE: AYGGGGGGTLA*# ...# >HUM10230# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./direct binding/Reference# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: gp160 (768-778)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1KB,ENV_HV1BN,ENV_HV1J3,ENV_HV1W1,# & ENV_HV1Y2,ENV_HV1SC,ENV_HV1B8,ENV_HV1H3,ENV_HV1PV,# & ENV_HV1B1,ENV_HV1H2,ENV_HV1BR)# & PIR1: (VCLJH3,VCLJSC,VCLJBR,H44001,VCLJ3W,VCLJKB,VCLJLV,# & VCLJVL)# & PIR2: (S21998,S70421,S21994,S70425,S70422,S21996)# & PIR3: (S33985,S13288)# REFERENCES: takahashi91a,safrit94a,sette94a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesh,RLRDLLLIVTR*# SEQUENCE: RLRDLLLIVTR*# ...# >HUM10231# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: gp160 (760-784)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1SC,ENV_HV1Y2,ENV_HV1H3,ENV_HV1J3,# & ENV_HV1B1,ENV_HV1PV,ENV_HV1H2,ENV_HV1BR,ENV_HV1MF,# & ENV_HV1W1)# & PIR1: (VCLJ3W,VCLJH3,VCLJSC,VCLJLV,H44001,VCLJVL)# & PIR2: (S70425,S21994,S21998,S70421,S70422,S21996)# & PIR3: (S33985,S13288)# REFERENCES: takahashi91a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,SLCLFSYHRLRDLLLIVTRIVELLG*# SEQUENCE: SLCLFSYHRLRDLLLIVTRIVELLG*# ...# >HUM10232# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: gp160 (765-778)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1H2,ENV_HV1BR,ENV_HV1H3,# & ENV_HV1SC,ENV_HV1BN,ENV_HV1MF,ENV_HV1KB,ENV_HV1W1,# & ENV_HV1Y2,ENV_HV1J3,ENV_HV1B8)# & PIR1: (VCLJBR,VCLJLV,H44001,VCLJVL,VCLJKB,VCLJH3,VCLJSC,# & VCLJ3W)# & PIR2: (S21994,S70421,S70422,S70425,S21998,S21996)# & PIR3: (S33985,S13288)# REFERENCES: takahashi91a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,SYHRLRDLLLIVTR*# SEQUENCE: SYHRLRDLLLIVTR*# ...# >HUM10233# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: gp160 (767-778)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1H3,ENV_HV1H2,ENV_HV1J3,ENV_HV1PV,# & ENV_HV1MF,ENV_HV1SC,ENV_HV1B8,ENV_HV1B1,ENV_HV1BR,# & ENV_HV1Y2,ENV_HV1KB,ENV_HV1W1)# & PIR1: (VCLJH3,VCLJKB,VCLJ3W,VCLJSC,H44001,VCLJLV,VCLJBR,# & VCLJVL)# & PIR2: (S21996,S70425,S21994,S70421,S70422,S21998)# & PIR3: (S13288,S33985)# REFERENCES: takahashi91a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,HRLRDLLLIVTR*# SEQUENCE: HRLRDLLLIVTR*# ...# >HUM10234# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: gp160 (769-778)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1BR,ENV_HV1B1,ENV_HV1H3,ENV_HV1H2,# & ENV_HV1Y2,ENV_HV1W1,ENV_HV1J3,ENV_HV1PV,ENV_HV1MF,# & ENV_HV1SC,ENV_HV1BN,ENV_HV1KB)# & PIR1: (VCLJKB,VCLJLV,VCLJH3,H44001,VCLJBR,VCLJSC,VCLJ3W,# & VCLJVL)# & PIR2: (S21998,S21996,S70421,S21994,S70425,S70422)# & PIR3: (S13288,S33985)# REFERENCES: takahashi91a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,LRDLLLIVTR*# SEQUENCE: LRDLLLIVTR*# ...# >HUM10235# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: gp160 (768-778) homologue# DB REFERENCE: SWISS: (ENV_HV1RH)# REFERENCES: takahashi91a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,RLRDLLLIVVR*# SEQUENCE: RLRDLLLIVVR*# ...# >HUM10236# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: gp160 (768-778) homologue# DB REFERENCE: SWISS: (ENV_HV1C4)# & PIR1: (VCLJH4)# & PIR2: (S70419,S22006,S70423,S21992,S70424,S21990,S70420,# & S22004)# REFERENCES: takahashi91a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,RLRDLLLIVAR*# SEQUENCE: RLRDLLLIVAR*# ...# >HUM10237# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: gp160 (760-788) homologue# DB REFERENCE: SWISS: (ENV_HV1MA)# & PIR2: (S70417,S22002,S22000,S70418)# REFERENCES: takahashi91a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,RLRDLLLIATR*# SEQUENCE: RLRDLLLIATR*# ...# >HUM20238# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Plasmodium falciparum NNX (83-91)# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,NALYKMNAVAAAA*# SEQUENCE: NALYKMNAVAAAA*# ...# >HUM20239# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin TT (763-775)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,SGPDKEQIADEIN*# SEQUENCE: SGPDKEQIADEIN*# ...# >HUM2023A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,MFQRMAVDA*# SEQUENCE: MFQRMAVDA*# ...# >HUM2023B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,WQMAMSRLH*# SEQUENCE: WQMAMSRLH*# ...# >HUM2023C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,NYQMMGTMR*# SEQUENCE: NYQMMGTMR*# ...# >HUM2023D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,FTMLMNQVM*# SEQUENCE: FTMLMNQVM*# ...# >HUM2023E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRMQSNHVS*# SEQUENCE: YRMQSNHVS*# ...# >HUM2023F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YQQMGARLM*# SEQUENCE: YQQMGARLM*# ...# >HUM20240# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,FMRLGGGHL*# SEQUENCE: FMRLGGGHL*# ...# >HUM20241# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YGKLRGGTL*# SEQUENCE: YGKLRGGTL*# ...# >HUM20242# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,TWNSLRGRL*# SEQUENCE: TWNSLRGRL*# ...# >HUM20243# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PWQAMRGWL*# SEQUENCE: PWQAMRGWL*# ...# >HUM20244# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRQMSAPTL*# SEQUENCE: YRQMSAPTL*# ...# >HUM20245# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,SIMMMGAVR*# SEQUENCE: SIMMMGAVR*# ...# >HUM20246# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,FERARSRLL*# SEQUENCE: FERARSRLL*# ...# >HUM20247# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VYRAQGPQM*# SEQUENCE: VYRAQGPQM*# ...# >HUM20248# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,DRSMEWRMM*# SEQUENCE: DRSMEWRMM*# ...# >HUM20249# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,SWRHIQTRV*# SEQUENCE: SWRHIQTRV*# ...# >HUM2024A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,IWHMQNARV*# SEQUENCE: IWHMQNARV*# ...# >HUM2024B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,QVGKYLGLG*# SEQUENCE: QVGKYLGLG*# ...# >HUM2024C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,QRYNAMRAA*# SEQUENCE: QRYNAMRAA*# ...# >HUM2024D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,KKIMSYHAL*# SEQUENCE: KKIMSYHAL*# ...# >HUM2024E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,WFGQLQAAQ*# SEQUENCE: WFGQLQAAQ*# ...# >HUM2024F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,WYTLLKSRL*# SEQUENCE: WYTLLKSRL*# ...# >HUM20250# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YLRMLQILK*# SEQUENCE: YLRMLQILK*# ...# >HUM20251# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,MMSRMLGQT*# SEQUENCE: MMSRMLGQT*# ...# >HUM20252# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,FSAIRNRIL*# SEQUENCE: FSAIRNRIL*# ...# >HUM20253# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,MYGLMLAQR*# SEQUENCE: MYGLMLAQR*# ...# >HUM20254# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YKLLRATQM*# SEQUENCE: YKLLRATQM*# ...# >HUM20255# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,TYRGMAGFR*# SEQUENCE: TYRGMAGFR*# ...# >HUM20256# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YIMQMNRVV*# SEQUENCE: YIMQMNRVV*# ...# >HUM20257# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRGMSAFRA*# SEQUENCE: YRGMSAFRA*# ...# >HUM20258# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRHAQAYGV*# SEQUENCE: YRHAQAYGV*# ...# >HUM20259# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YKPMLASVG*# SEQUENCE: YKPMLASVG*# ...# >HUM2025A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,NWRALRGAL*# SEQUENCE: NWRALRGAL*# ...# >HUM2025B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,SSGRYARLG*# SEQUENCE: SSGRYARLG*# ...# >HUM2025C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRAMQTTLS*# SEQUENCE: YRAMQTTLS*# ...# >HUM2025D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YQALRAYWQ*# SEQUENCE: YQALRAYWQ*# ...# >HUM2025E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,LWQSFMQMA*# SEQUENCE: LWQSFMQMA*# ...# >HUM2025F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,RVFQNLRAS*# SEQUENCE: RVFQNLRAS*# ...# >HUM20260# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,LTLMQAKRL*# SEQUENCE: LTLMQAKRL*# ...# >HUM20261# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,MFHRMSGLQ*# SEQUENCE: MFHRMSGLQ*# ...# >HUM20262# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,MPRQYTQMI*# SEQUENCE: MPRQYTQMI*# ...# >HUM20263# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YAAMRGGQI*# SEQUENCE: YAAMRGGQI*# ...# >HUM20264# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRQMWVNRA*# SEQUENCE: YRQMWVNRA*# ...# >HUM20265# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,TFYRMGTQM*# SEQUENCE: TFYRMGTQM*# ...# >HUM20266# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,NYLGMKPRV*# SEQUENCE: NYLGMKPRV*# ...# >HUM20267# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,RFTQMMAVA*# SEQUENCE: RFTQMMAVA*# ...# >HUM20268# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,FHQLRGGSL*# SEQUENCE: FHQLRGGSL*# ...# >HUM20269# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,WRQMYRAQL*# SEQUENCE: WRQMYRAQL*# ...# >HUM2026A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,RFTQMGALA*# SEQUENCE: RFTQMGALA*# ...# >HUM2026B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GQRSYSSMQ*# SEQUENCE: GQRSYSSMQ*# ...# >HUM2026C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,FHKVYRGLL*# SEQUENCE: FHKVYRGLL*# ...# >HUM2026D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YKPLWGQMT*# SEQUENCE: YKPLWGQMT*# ...# >HUM2026E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,FMAMRAVRL*# SEQUENCE: FMAMRAVRL*# ...# >HUM2026F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,WIGQMYAAK*# SEQUENCE: WIGQMYAAK*# ...# >HUM20270# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,RGFRHMMAA*# SEQUENCE: RGFRHMMAA*# ...# >HUM20271# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,WKGLQGALS*# SEQUENCE: WKGLQGALS*# ...# >HUM20272# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRGMQRRTL*# SEQUENCE: YRGMQRRTL*# ...# >HUM20273# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,RSYSLAPGR*# SEQUENCE: RSYSLAPGR*# ...# >HUM20274# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YYGKMPALV*# SEQUENCE: YYGKMPALV*# ...# >HUM10275# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV LMP p63 (43-53)# DB REFERENCE: SWISS: (LMP1_EBV,LMP1_EBVC)# & PIR1: (LABECA,QQBE50)# & PIR2: (G00065,S21660)# REFERENCES: carreno92a,rothbard88b,thorley-lawson87a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,VMSDWTGGALL*# SEQUENCE: VMSDWTGGALL*# ...# >MUS10276# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU PB2 (187-195)# DB REFERENCE: SWISS: (RRP3_IALE2,RRP3_IACHI,RRP3_IAHLO,RRP3_IAHK6,RRP3_IAKOR,# & RRP3_IAZI1,RRP3_IAVI7,RRP3_IAZTE,RRP3_IAHPR,RRP3_IAKIE,# & RRP3_IARUD,RRP3_IASE2,RRP3_IAPUE,RRP3_IAGU2,RRP3_IAFPR,# & RRP3_IAME8,RRP3_IAWIL,RRP3_IASIN,RRP3_IAGUA,RRP3_IAANN,# & RRP3_IATKM,RRP3_IABUD,RRP3_IAMAN,RRP3_IALE1,RRP3_IANT6,# & RRP3_IAFPW,RRP3_IALE3)# & PIR1: (A60011,P3IV34,P3IVAK,P3IV2A,P3IV33,P3IV61,P3IV68,# & B60008)# & PIR2: (S04930,JN0435)# REFERENCES: carreno92a,maloy89a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,ERELVRKTR*# SEQUENCE: ERELVRKTR*# ...# >MUS10277# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU PB2 (303-313)# DB REFERENCE: SWISS: (RRP3_IALE3,RRP3_IARUD,RRP3_IASIN,RRP3_IAKIE,RRP3_IAVI7,# & RRP3_IAFPR,RRP3_IANT6,RRP3_IALE2,RRP3_IAHK6,RRP3_IAHLO,# & RRP3_IACHI,RRP3_IAHPR,RRP3_IAZI1,RRP3_IAKOR,RRP3_IAPUE,# & RRP3_IASE2,RRP3_IAGUA,RRP3_IAANN,RRP3_IATKM,RRP3_IAZTE,# & RRP3_IAWIL,RRP3_IALE1,RRP3_IAFPW,RRP3_IAMAN,RRP3_IABUD,# & RRP3_IAME8,RRP3_IAGU2)# & PIR1: (P3IV68,P3IV61,A60011,P3IVAK,P3IV34,P3IV33,P3IV2A,# & B60008)# & PIR2: (S04930,JN0435)# REFERENCES: carreno92a,maloy89a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,SFGGFTFKRTS*# SEQUENCE: SFGGFTFKRTS*# ...# >MUS20278# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU HA (127-140)# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: carreno92a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NTTKGVTAACSHAG*# SEQUENCE: NTTKGVTAACSHAG*# ...# >MUS10279# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV (HTLV IIIB) gp160 (308-322)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1B8,ENV_HV1MF,ENV_HV1BR,ENV_HV1PV,# & ENV_HV1H2,ENV_HV1B1)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S13288,S33985)# REFERENCES: takahashi88a# COMMENT:# SUMMARY: H-2Dd,actyesm,bindyesu,QRGPGRAFVTIG*# SEQUENCE: QRGPGRAFVTIG*# ...# >MUS1027A# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV (HTLV IIIB) gp160 (308-322)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1B1,ENV_HV1H3,ENV_HV1MF,ENV_HV1BR,# & ENV_HV1PV,ENV_HV1H2)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR3: (S13288,S33985)# REFERENCES: takahashi88a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,QRGPGRAFVTIG*# SEQUENCE: QRGPGRAFVTIG*# ...# >HUM1027B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: none# BINDING: yes, ?# SOURCE: HLA-A2 (98-113)# DB REFERENCE: SWISS: (1B15_HUMAN,1B07_HUMAN,1B10_HUMAN,1B40_HUMAN,HA15_MOUSE,# & 1B41_HUMAN,1B16_HUMAN,1C06_HUMAN,1A74_HUMAN,1B08_HUMAN,# & 1A32_HUMAN,1B18_HUMAN,1B42_HUMAN,1C05_HUMAN,1B14_HUMAN,# & 1B19_HUMAN)# & PIR1: (HLHUB2,HLHUW3,HLHU32,HLHUB4,HLMS37)# & PIR2: (I37482,I81231,I56198,I59654,I80166,I62045,I80175,I37516,# & I37515,I80173,I61859,I37485,I80172,I61861,I59308,S33355,# & S25415,I61862,I80170,I54289,I84486)# REFERENCES: townsend89a,clayberger87a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,YGCDVGPDGRLLRGY*# SEQUENCE: YGCDVGPDGRLLRGY*# ...# >HUM1027C# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-A2 (56-69)# ANCHOR POSITIONS:# REFERENCES: clayberger87a# COMMENT:# SUMMARY: HLA-A69,actyesm,bindyesu,EYWDGETRKVKAQS*# SEQUENCE: EYWDGETRKVKAQS*# ...# >HUM1027D# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: competition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HLA-B17 (56-69)# DB REFERENCE: SWISS: (1B61_HUMAN,1B60_HUMAN,1B62_HUMAN)# & PIR1: (HLHUB8)# & PIR2: (I84490,D35997,I37521)# REFERENCES: clayberger87a# COMMENT:# SUMMARY: HLA-A69,actyesm,bindyesu,EYWDGETRNMKASA*# SEQUENCE: EYWDGETRNMKASA*# ...# >MUS1027E# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza NP (Y-345-360)# ANCHOR POSITIONS:# REFERENCES: catipovic92a,townsend90a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,YSFIRGTKVSPRGKLST*# SEQUENCE: YSFIRGTKVSPRGKLST*# ...# >MUS1027F# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Simian virus 40 T (223-231) homologue# DB REFERENCE: PIR3: (PH1375)# REFERENCES: lill92a# COMMENT:# SUMMARY: H-2Db,actyesn,bindyesu,CKGVNNEYL*# SEQUENCE: CKGVNNEYL*# ...# >MUS10280# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Simian virus 40 T (223-231) homologue# DB REFERENCE: PIR3: (PH1376)# REFERENCES: lill92a# COMMENT:# SUMMARY: H-2Db,actyesn,bindyesu,CKGVNKEFL*# SEQUENCE: CKGVNKEFL*# ...# >MUS10281# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Simian virus 40 T (223-231) homologue# DB REFERENCE: PIR3: (PH1378)# REFERENCES: lill92a# COMMENT:# SUMMARY: H-2Db,actyesn,bindyesu,QGFNNLDNLRDYLDG*# SEQUENCE: QGFNNLDNLRDYLDG*# ...# >MUS10282# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Simian virus 40 T (223-231) homologue# ANCHOR POSITIONS:# REFERENCES: lill92a# COMMENT:# SUMMARY: H-2Db,actyesn,bindyesu,QGINNLDILRDYLDG*# SEQUENCE: QGINNLDILRDYLDG*# ...# >HUM20283# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCS.T3 (378-392)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesu,bindyesu,DIEKKIAKMEKAS*# SEQUENCE: DIEKKIAKMEKAS*# ...# >HUM20284# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: Malaria HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,o'sullivan90a,sinigaglia88a,sidney92a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesh,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM20285# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesm,bindyesl,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM20286# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM20287# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Malaria HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM20288# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: Malaria HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesm,bindyesl,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM20289# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM2028A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesl,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM2028B# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesl,bindyesl,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM2028C# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM2028D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (381-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesl,KKIAKMEKASSVFNVVNS*# SEQUENCE: KKIAKMEKASSVFNVVNS*# ...# >HUM2028E# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (381-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,KKIAKMEKASSVFNVVNS*# SEQUENCE: KKIAKMEKASSVFNVVNS*# ...# >HUM2028F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Malaria HCS.T3 (382-398)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,KIAKMEKASSVFNVVNS*# SEQUENCE: KIAKMEKASSVFNVVNS*# ...# >HUM20290# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Malaria HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM20291# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesm,bindyesl,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM20292# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM20293# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Malaria HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM20294# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesm,bindyesl,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM20295# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM20296# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Malaria HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM20297# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesm,bindyesl,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM20298# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM20299# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Malaria HCS.T3 (378-394)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,DIEKKIAKMEKASSVFN*# SEQUENCE: DIEKKIAKMEKASSVFN*# ...# >HUM2029A# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-394)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesl,bindyesl,DIEKKIAKMEKASSVFN*# SEQUENCE: DIEKKIAKMEKASSVFN*# ...# >HUM2029B# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-394)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,DIEKKIAKMEKASSVFN*# SEQUENCE: DIEKKIAKMEKASSVFN*# ...# >HUM2029C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-393)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesl,DIEKKIAKMEKASSVF*# SEQUENCE: DIEKKIAKMEKASSVF*# ...# >HUM2029D# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-393)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesl,bindyesl,DIEKKIAKMEKASSVF*# SEQUENCE: DIEKKIAKMEKASSVF*# ...# >HUM2029E# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-393)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,DIEKKIAKMEKASSVF*# SEQUENCE: DIEKKIAKMEKASSVF*# ...# >HUM2029F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-392)# ANCHOR POSITIONS:# REFERENCES: kilgus91a,sinigaglia88a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesl,DIEKKIAKMEKASSV*# SEQUENCE: DIEKKIAKMEKASSV*# ...# >HUM202A0# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-392)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesl,bindyesl,DIEKKIAKMEKASSV*# SEQUENCE: DIEKKIAKMEKASSV*# ...# >HUM202A1# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-392)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actyesl,bindyesl,DIEKKIAKMEKASSV*# SEQUENCE: DIEKKIAKMEKASSV*# ...# >HUM202A2# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Malaria HCS.T3 (378-391)# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actyesl,bindyesl,DIEKKIAKMEKASS*# SEQUENCE: DIEKKIAKMEKASS*# ...# >HUM202A3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVFNVV*# SEQUENCE: EKKIAKMEKASSVFNVV*# ...# >HUM202A4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,KKKIAKMEKASSVFNVV*# SEQUENCE: KKKIAKMEKASSVFNVV*# ...# >HUM202A5# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,FKKIAKMEKASSVFNVV*# SEQUENCE: FKKIAKMEKASSVFNVV*# ...# >HUM202A6# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,GKKIAKMEKASSVFNVV*# SEQUENCE: GKKIAKMEKASSVFNVV*# ...# >HUM202A7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EGKIAKMEKASSVFNVV*# SEQUENCE: EGKIAKMEKASSVFNVV*# ...# >HUM202A8# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EDKIAKMEKASSVFNVV*# SEQUENCE: EDKIAKMEKASSVFNVV*# ...# >HUM202A9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EVKIAKMEKASSVFNVV*# SEQUENCE: EVKIAKMEKASSVFNVV*# ...# >HUM202AA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKDIAKMEKASSVFNVV*# SEQUENCE: EKDIAKMEKASSVFNVV*# ...# >HUM202AB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKGIAKMEKASSVFNVV*# SEQUENCE: EKGIAKMEKASSVFNVV*# ...# >HUM202AC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKYIAKMEKASSVFNVV*# SEQUENCE: EKYIAKMEKASSVFNVV*# ...# >HUM202AD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKGAKMEKASSVFNVV*# SEQUENCE: EKKGAKMEKASSVFNVV*# ...# >HUM202AE# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKDAKMEKASSVFNVV*# SEQUENCE: EKKDAKMEKASSVFNVV*# ...# >HUM202AF# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKKAKMEKASSVFNVV*# SEQUENCE: EKKKAKMEKASSVFNVV*# ...# >HUM202B0# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIVKMEKASSVFNVV*# SEQUENCE: EKKIVKMEKASSVFNVV*# ...# >HUM202B1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIIKMEKASSVFNVV*# SEQUENCE: EKKIIKMEKASSVFNVV*# ...# >HUM202B2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIYKMEKASSVFNVV*# SEQUENCE: EKKIYKMEKASSVFNVV*# ...# >HUM202B3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIADMEKASSVFNVV*# SEQUENCE: EKKIADMEKASSVFNVV*# ...# >HUM202B4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAFMEKASSVFNVV*# SEQUENCE: EKKIAFMEKASSVFNVV*# ...# >HUM202B5# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAGMEKASSVFNVV*# SEQUENCE: EKKIAGMEKASSVFNVV*# ...# >HUM202B6# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKGEKASSVFNVV*# SEQUENCE: EKKIAKGEKASSVFNVV*# ...# >HUM202B7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKKEKASSVFNVV*# SEQUENCE: EKKIAKKEKASSVFNVV*# ...# >HUM202B8# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKDEKASSVFNVV*# SEQUENCE: EKKIAKDEKASSVFNVV*# ...# >HUM202B9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMFKASSVFNVV*# SEQUENCE: EKKIAKMFKASSVFNVV*# ...# >HUM202BA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMGKASSVFNVV*# SEQUENCE: EKKIAKMGKASSVFNVV*# ...# >HUM202BB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMKKASSVFNVV*# SEQUENCE: EKKIAKMKKASSVFNVV*# ...# >HUM202BC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEGASSVFNVV*# SEQUENCE: EKKIAKMEGASSVFNVV*# ...# >HUM202BD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEDASSVFNVV*# SEQUENCE: EKKIAKMEDASSVFNVV*# ...# >HUM202BE# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEFASSVFNVV*# SEQUENCE: EKKIAKMEFASSVFNVV*# ...# >HUM202BF# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKAFSVFNVV*# SEQUENCE: EKKIAKMEKAFSVFNVV*# ...# >HUM202C0# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKAKSVFNVV*# SEQUENCE: EKKIAKMEKAKSVFNVV*# ...# >HUM202C1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKAESVFNVV*# SEQUENCE: EKKIAKMEKAESVFNVV*# ...# >HUM202C2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASFVFNVV*# SEQUENCE: EKKIAKMEKASFVFNVV*# ...# >HUM202C3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASKVFNVV*# SEQUENCE: EKKIAKMEKASKVFNVV*# ...# >HUM202C4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASEVFNVV*# SEQUENCE: EKKIAKMEKASEVFNVV*# ...# >HUM202C5# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVGNVV*# SEQUENCE: EKKIAKMEKASSVGNVV*# ...# >HUM202C6# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVDNVV*# SEQUENCE: EKKIAKMEKASSVDNVV*# ...# >HUM202C7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVKNVV*# SEQUENCE: EKKIAKMEKASSVKNVV*# ...# >HUM202C8# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVFKVV*# SEQUENCE: EKKIAKMEKASSVFKVV*# ...# >HUM202C9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVFEVV*# SEQUENCE: EKKIAKMEKASSVFEVV*# ...# >HUM202CA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVFFVV*# SEQUENCE: EKKIAKMEKASSVFFVV*# ...# >HUM202CB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVFNGV*# SEQUENCE: EKKIAKMEKASSVFNGV*# ...# >HUM202CC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVFNKV*# SEQUENCE: EKKIAKMEKASSVFNKV*# ...# >HUM202CD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EKKIAKMEKASSVFNDV*# SEQUENCE: EKKIAKMEKASSVFNDV*# ...# >HUM202CE# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVFNVV*# SEQUENCE: EKKIAKMEKASSVFNVV*# ...# >HUM202CF# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KKKIAKMEKASSVFNVV*# SEQUENCE: KKKIAKMEKASSVFNVV*# ...# >HUM202D0# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,FKKIAKMEKASSVFNVV*# SEQUENCE: FKKIAKMEKASSVFNVV*# ...# >HUM202D1# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,GKKIAKMEKASSVFNVV*# SEQUENCE: GKKIAKMEKASSVFNVV*# ...# >HUM202D2# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EGKIAKMEKASSVFNVV*# SEQUENCE: EGKIAKMEKASSVFNVV*# ...# >HUM202D3# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EDKIAKMEKASSVFNVV*# SEQUENCE: EDKIAKMEKASSVFNVV*# ...# >HUM202D4# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EVKIAKMEKASSVFNVV*# SEQUENCE: EVKIAKMEKASSVFNVV*# ...# >HUM202D5# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKDIAKMEKASSVFNVV*# SEQUENCE: EKDIAKMEKASSVFNVV*# ...# >HUM202D6# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKGIAKMEKASSVFNVV*# SEQUENCE: EKGIAKMEKASSVFNVV*# ...# >HUM202D7# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKYIAKMEKASSVFNVV*# SEQUENCE: EKYIAKMEKASSVFNVV*# ...# >HUM202D8# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIVKMEKASSVFNVV*# SEQUENCE: EKKIVKMEKASSVFNVV*# ...# >HUM202D9# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIIKMEKASSVFNVV*# SEQUENCE: EKKIIKMEKASSVFNVV*# ...# >HUM202DA# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIYKMEKASSVFNVV*# SEQUENCE: EKKIYKMEKASSVFNVV*# ...# >HUM202DB# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIADMEKASSVFNVV*# SEQUENCE: EKKIADMEKASSVFNVV*# ...# >HUM202DC# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAFMEKASSVFNVV*# SEQUENCE: EKKIAFMEKASSVFNVV*# ...# >HUM202DD# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAGMEKASSVFNVV*# SEQUENCE: EKKIAGMEKASSVFNVV*# ...# >HUM202DE# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKGEKASSVFNVV*# SEQUENCE: EKKIAKGEKASSVFNVV*# ...# >HUM202DF# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKKEKASSVFNVV*# SEQUENCE: EKKIAKKEKASSVFNVV*# ...# >HUM202E0# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,EKKIAKMGKASSVFNVV*# SEQUENCE: EKKIAKMGKASSVFNVV*# ...# >HUM202E1# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,EKKIAKMKKASSVFNVV*# SEQUENCE: EKKIAKMKKASSVFNVV*# ...# >HUM202E2# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKESSVFNVV*# SEQUENCE: EKKIAKMEKESSVFNVV*# ...# >HUM202E3# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKDSSVFNVV*# SEQUENCE: EKKIAKMEKDSSVFNVV*# ...# >HUM202E4# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKYSSVFNVV*# SEQUENCE: EKKIAKMEKYSSVFNVV*# ...# >HUM202E5# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKVSSVFNVV*# SEQUENCE: EKKIAKMEKVSSVFNVV*# ...# >HUM202E6# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKAFSVFNVV*# SEQUENCE: EKKIAKMEKAFSVFNVV*# ...# >HUM202E7# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKAKSVFNVV*# SEQUENCE: EKKIAKMEKAKSVFNVV*# ...# >HUM202E8# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKAESVFNVV*# SEQUENCE: EKKIAKMEKAESVFNVV*# ...# >HUM202E9# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASFVFNVV*# SEQUENCE: EKKIAKMEKASFVFNVV*# ...# >HUM202EA# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASKVFNVV*# SEQUENCE: EKKIAKMEKASKVFNVV*# ...# >HUM202EB# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASEVFNVV*# SEQUENCE: EKKIAKMEKASEVFNVV*# ...# >HUM202EC# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSGFNVV*# SEQUENCE: EKKIAKMEKASSGFNVV*# ...# >HUM202ED# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSKFNVV*# SEQUENCE: EKKIAKMEKASSKFNVV*# ...# >HUM202EE# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSDFNVV*# SEQUENCE: EKKIAKMEKASSDFNVV*# ...# >HUM202EF# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVGNVV*# SEQUENCE: EKKIAKMEKASSVGNVV*# ...# >HUM202F0# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVDNVV*# SEQUENCE: EKKIAKMEKASSVDNVV*# ...# >HUM202F1# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVKNVV*# SEQUENCE: EKKIAKMEKASSVKNVV*# ...# >HUM202F2# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVFKVV*# SEQUENCE: EKKIAKMEKASSVFKVV*# ...# >HUM202F3# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVFEVV*# SEQUENCE: EKKIAKMEKASSVFEVV*# ...# >HUM202F4# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVFFVV*# SEQUENCE: EKKIAKMEKASSVFFVV*# ...# >HUM202F5# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVFNGV*# SEQUENCE: EKKIAKMEKASSVFNGV*# ...# >HUM202F6# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVFNKV*# SEQUENCE: EKKIAKMEKASSVFNKV*# ...# >HUM202F7# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVFNDV*# SEQUENCE: EKKIAKMEKASSVFNDV*# ...# >HUM202F8# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASSVFNVV*# SEQUENCE: EKKIAKMEKASSVFNVV*# ...# >HUM202F9# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,KKKIAKMEKASSVFNVV*# SEQUENCE: KKKIAKMEKASSVFNVV*# ...# >HUM202FA# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,GKKIAKMEKASSVFNVV*# SEQUENCE: GKKIAKMEKASSVFNVV*# ...# >HUM202FB# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EGKIAKMEKASSVFNVV*# SEQUENCE: EGKIAKMEKASSVFNVV*# ...# >HUM202FC# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EDKIAKMEKASSVFNVV*# SEQUENCE: EDKIAKMEKASSVFNVV*# ...# >HUM202FD# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EVKIAKMEKASSVFNVV*# SEQUENCE: EVKIAKMEKASSVFNVV*# ...# >HUM202FE# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKDIAKMEKASSVFNVV*# SEQUENCE: EKDIAKMEKASSVFNVV*# ...# >HUM202FF# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKGIAKMEKASSVFNVV*# SEQUENCE: EKGIAKMEKASSVFNVV*# ...# >HUM20300# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKYIAKMEKASSVFNVV*# SEQUENCE: EKYIAKMEKASSVFNVV*# ...# >HUM20301# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKGAKMEKASSVFNVV*# SEQUENCE: EKKGAKMEKASSVFNVV*# ...# >HUM20302# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKDAKMEKASSVFNVV*# SEQUENCE: EKKDAKMEKASSVFNVV*# ...# >HUM20303# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKKAKMEKASSVFNVV*# SEQUENCE: EKKKAKMEKASSVFNVV*# ...# >HUM20304# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKLAKMEKASSVFNVV*# SEQUENCE: EKKLAKMEKASSVFNVV*# ...# >HUM20305# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesm,EKKIVKMEKASSVFNVV*# SEQUENCE: EKKIVKMEKASSVFNVV*# ...# >HUM20306# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesm,EKKIIKMEKASSVFNVV*# SEQUENCE: EKKIIKMEKASSVFNVV*# ...# >HUM20307# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIYKMEKASSVFNVV*# SEQUENCE: EKKIYKMEKASSVFNVV*# ...# >HUM20308# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIKKMEKASSVFNVV*# SEQUENCE: EKKIKKMEKASSVFNVV*# ...# >HUM20309# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIADMEKASSVFNVV*# SEQUENCE: EKKIADMEKASSVFNVV*# ...# >HUM2030A# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAFMEKASSVFNVV*# SEQUENCE: EKKIAFMEKASSVFNVV*# ...# >HUM2030B# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAGMEKASSVFNVV*# SEQUENCE: EKKIAGMEKASSVFNVV*# ...# >HUM2030C# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKGEKASSVFNVV*# SEQUENCE: EKKIAKGEKASSVFNVV*# ...# >HUM2030D# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKKEKASSVFNVV*# SEQUENCE: EKKIAKKEKASSVFNVV*# ...# >HUM2030E# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKDEKASSVFNVV*# SEQUENCE: EKKIAKDEKASSVFNVV*# ...# >HUM2030F# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMFKASSVFNVV*# SEQUENCE: EKKIAKMFKASSVFNVV*# ...# >HUM20310# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesm,EKKIAKMGKASSVFNVV*# SEQUENCE: EKKIAKMGKASSVFNVV*# ...# >HUM20311# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMKKASSVFNVV*# SEQUENCE: EKKIAKMKKASSVFNVV*# ...# >HUM20312# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEDASSVFNVV*# SEQUENCE: EKKIAKMEDASSVFNVV*# ...# >HUM20313# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEFASSVFNVV*# SEQUENCE: EKKIAKMEFASSVFNVV*# ...# >HUM20314# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKDSSVFNVV*# SEQUENCE: EKKIAKMEKDSSVFNVV*# ...# >HUM20315# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKYSSVFNVV*# SEQUENCE: EKKIAKMEKYSSVFNVV*# ...# >HUM20316# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKVSSVFNVV*# SEQUENCE: EKKIAKMEKVSSVFNVV*# ...# >HUM20317# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKAKSVFNVV*# SEQUENCE: EKKIAKMEKAKSVFNVV*# ...# >HUM20318# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKAESVFNVV*# SEQUENCE: EKKIAKMEKAESVFNVV*# ...# >HUM20319# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASKVFNVV*# SEQUENCE: EKKIAKMEKASKVFNVV*# ...# >HUM2031A# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASEVFNVV*# SEQUENCE: EKKIAKMEKASEVFNVV*# ...# >HUM2031B# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASSVGNVV*# SEQUENCE: EKKIAKMEKASSVGNVV*# ...# >HUM2031C# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesm,EKKIAKMEKASSVDNVV*# SEQUENCE: EKKIAKMEKASSVDNVV*# ...# >HUM2031D# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesm,EKKIAKMEKASSVKNVV*# SEQUENCE: EKKIAKMEKASSVKNVV*# ...# >HUM2031E# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASSVFKVV*# SEQUENCE: EKKIAKMEKASSVFKVV*# ...# >HUM2031F# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASSVFEVV*# SEQUENCE: EKKIAKMEKASSVFEVV*# ...# >HUM20320# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASSVFFVV*# SEQUENCE: EKKIAKMEKASSVFFVV*# ...# >HUM20321# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASSVFNGV*# SEQUENCE: EKKIAKMEKASSVFNGV*# ...# >HUM20322# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASSVFNKV*# SEQUENCE: EKKIAKMEKASSVFNKV*# ...# >HUM20323# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Malaria HCS.T3 (380-396) homologue# ANCHOR POSITIONS:# REFERENCES: kilgus91a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesl,EKKIAKMEKASSVFNDV*# SEQUENCE: EKKIAKMEKASSVFNDV*# ...# >MUS20324# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding/proliferation as./competitive inhibition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61)# DB REFERENCE: SWISS: (LYC_MELGA,LYC_CHICK,LYC1_TACAC,LYC_ORTVE,LYC_PHAVE,# & LYC_CHRAM,LYC_SYRRE,LYC_LOPLE,LYC1_ANAPL,LYC_CHICK,# & LYC_PAVCR,LYC_PHACO)# & PIR1: (LZFER,LZOVE,LZDK,LZCH,LZQJE,LZTK)# & PIR2: (A61281,JQ1033,JT0526,JQ1041,JU0178,JH0211,JU0237,JH0212,# & A45660,JC2144)# REFERENCES: rothbard88b,rammensee93b,jorgensen92a,allen87a,altuvia94a,# & vignali94a,cavani95a# COMMENT: T-cell contact residue: 1,7,10 not I-Ad# SUMMARY: I-Ak,actyesu,bindyesu,DYGILQINSR*# SEQUENCE: DYGILQINSR*# ...# >MUS20325# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: allen87a# COMMENT: T-cell contact residue: 1,7,10# SUMMARY: I-Ak,actyesu,bindyesu,DYAILQINSR*# SEQUENCE: DYAILQINSR*# ...# >MUS20326# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: allen87a# COMMENT: T-cell contact residue: 1,7,10# SUMMARY: I-Ak,actyesu,bindyesu,DYGALQINSR*# SEQUENCE: DYGALQINSR*# ...# >MUS20327# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: allen87a# COMMENT: T-cell contact residue: 1,7,10# SUMMARY: I-Ak,actyesn,bindyesu,DYGILAINSR*# SEQUENCE: DYGILAINSR*# ...# >MUS20328# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: allen87a# COMMENT: T-cell contact residue: 1,7,10# SUMMARY: I-Ak,actyesu,bindyesu,DYGILQIASR*# SEQUENCE: DYGILQIASR*# ...# >MUS20329# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: allen87a# COMMENT: T-cell contact residue: 1,7,10# SUMMARY: I-Ak,actyesn,bindyesu,DYGILQINAR*# SEQUENCE: DYGILQINAR*# ...# >MUS2032A# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYCM_MOUSE,LYC_CAMDR,LYC_COLGU,LYC2_PIG,LYC2_RAT,# & LYC_NASLA,LYC_PREEN,LYC1_PIG,LYC_RABIT,LYC_HUMAN,# & LYC3_PIG,LYC3_PIG,LYC_PYGNE,LYC2_ONCMY,LYC_PONPY,# & LYC2_PIG,LYC_COLAN,LYC_RABIT,LYC1_RAT,LYC1_PIG,# & LYC_HYLLA,LYCP_MOUSE,LYC_HUMAN,LYC_GORGO,LYC_PREEN)# & PIR1: (LZHU,LZRT)# & PIR2: (B40729,A31239,S09229,JX0104,A40729,I51047,A29736,# & I61852)# & PIR3: (JC2506,JX0367,S10046,S10047)# REFERENCES: allen87a# COMMENT: T-cell contact residue: 1,7,10# SUMMARY: I-Ak,actyesu,bindyesu,DYGIFQINSR*# SEQUENCE: DYGIFQINSR*# ...# >MUS2032B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: allen87a# COMMENT: T-cell contact residue: 1,7,10# SUMMARY: I-Ak,actyesn,bindyesu,DYGIVQINSR*# SEQUENCE: DYGIVQINSR*# ...# >MUS2032C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (52-61) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: allen87a# COMMENT: T-cell contact residue: 1,7,10# SUMMARY: I-Ak,actyesn,bindyesu,DYGIIQINSR*# SEQUENCE: DYGIIQINSR*# ...# >MUS2032D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MCC (95-103)# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: jorgensen92a,fox87a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,IAYLKQATK*# SEQUENCE: IAYLKQATK*# ...# >MUS2032E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibition as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MCC (93-103)# ANCHOR POSITIONS: 3,8,11# REFERENCES: fox87a,harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,ELIAYLKQATK*# SEQUENCE: ELIAYLKQATK*# ...# >MUS2032F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: MCC (93-103) homologue# ANCHOR POSITIONS:# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,ELIAYNKQATK*# SEQUENCE: ELIAYNKQATK*# ...# >MUS20330# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MCC (93-103) homologue# ANCHOR POSITIONS:# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,ELIAYAKQATK*# SEQUENCE: ELIAYAKQATK*# ...# >MUS20331# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MCC (93-103) homologue# ANCHOR POSITIONS:# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,ELIAYLKQSTK*# SEQUENCE: ELIAYLKQSTK*# ...# >MUS20332# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: MCC (93-103) homologue# ANCHOR POSITIONS:# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,ELIAYLKQATA*# SEQUENCE: ELIAYLKQATA*# ...# >MUS20333# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MCC (93-103) homologue# ANCHOR POSITIONS:# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,ELIAYLKQATR*# SEQUENCE: ELIAYLKQATR*# ...# >MUS20334# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MCC (93-103) homologue# ANCHOR POSITIONS:# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,ELIAYLKQATAK*# SEQUENCE: ELIAYLKQATAK*# ...# >MUS20335# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MCC (93-103) homologue# ANCHOR POSITIONS:# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,ELIAYLKQATAR*# SEQUENCE: ELIAYLKQATAR*# ...# >MUS20336# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: MCC (93-103) homologue# ANCHOR POSITIONS:# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,ELIAYLKQATAE*# SEQUENCE: ELIAYLKQATAE*# ...# >MUS20337# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MCC (81-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: fox87a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,IFAGIKKKAERADLIAYLKQATAK*# SEQUENCE: IFAGIKKKAERADLIAYLKQATAK*# ...# >HUM10338# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV EBNA-3 (334-348)# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: apolloni92a# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,AWNAGFLRGRAYGID*# SEQUENCE: AWNAGFLRGRAYGID*# ...# >HUM10339# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV EBNA-3 (339-353)# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: apolloni92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,FLRGRAYGIDLLRTE*# SEQUENCE: FLRGRAYGIDLLRTE*# ...# >HUM1033A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV EBNA-3# DB REFERENCE: PIR2: (S27920)# REFERENCES: apolloni92a# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,AWNAGLLRGRAYGQD*# SEQUENCE: AWNAGLLRGRAYGQD*# ...# >HUM1033B# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV EBNA-3# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (S33015,A31666)# REFERENCES: apolloni92a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,EENLLDFVRFMGVMSSCNNP*# SEQUENCE: EENLLDFVRFMGVMSSCNNP*# ...# >HUM2033C# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319)# DB REFERENCE: SWISS: (HEMA_IADH7,HEMA_IADU3,HEMA_IAAIC,HEMA_IADH4,HEMA_IAVI7,# & HEMA_IAZH2,HEMA_IAQU7,HEMA_IAUDO,HEMA_IAZCO,HEMA_IANT6,# & HEMA_IADH3,HEMA_IADH1,HEMA_IAZUK,HEMA_IAEN6,HEMA_IABAN,# & HEMA_IAME1,HEMA_IADH2,HEMA_IADH6,HEMA_IAME2,HEMA_IADHM,# & HEMA_IAEN7)# & PIR1: (HMIVV,HMIVHM,HMIV15,HMIV80,HMIV98,HMIV33,HMIV77,HMIVH,# & HMIV89,HMIVDU,HMIV6,HMIVHA,HMIVS3)# & PIR2: (A92979,JQ1156)# REFERENCES: jorgensen92a,o'sullivan91a,o'sullivan91b,sidney92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesm,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM2033D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competitive binding/blocking as./proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Hemagglutinin (307-319)# DB REFERENCE: SWISS: (HEMA_IADU3,HEMA_IADH2,HEMA_IADH4,HEMA_IAAIC,HEMA_IAME1,# & HEMA_IAEN6,HEMA_IAQU7,HEMA_IAVI7,HEMA_IADH6,HEMA_IAME2,# & HEMA_IAEN7,HEMA_IADHM,HEMA_IABAN,HEMA_IANT6,HEMA_IADH1,# & HEMA_IADH3,HEMA_IAZUK,HEMA_IADH7,HEMA_IAZH2,HEMA_IAUDO,# & HEMA_IAZCO)# & PIR1: (HMIV98,HMIV89,HMIV6,HMIVV,HMIVHM,HMIV80,HMIVS3,HMIVHA,# & HMIV15,HMIV33,HMIVH,HMIV77,HMIVDU)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a,o'sullivan91b,o'sullivan90a,lamb88a,jardetzky90a,# & sidney92a,celis94a,sette95a,vogt95a,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesh,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM2033E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AKYVKQNTLKLAT*# SEQUENCE: AKYVKQNTLKLAT*# ...# >HUM2033F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,KKYVKQNTLKLAT*# SEQUENCE: KKYVKQNTLKLAT*# ...# >HUM20340# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,EKYVKQNTLKLAT*# SEQUENCE: EKYVKQNTLKLAT*# ...# >HUM20341# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52174,S52180,JQ2375,S52183,S52188,S52195,S52187,JQ2378,# & S52178,S52176,JQ2374,S52179,S52197,S52199,JQ2377,S52173,# & S52189,S52175,S52198,S52182,S52186,S52191,S52185)# & PIR3: (S38637)# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesh,PRYVKQNTLKLAT*# SEQUENCE: PRYVKQNTLKLAT*# ...# >HUM20342# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PEYVKQNTLKLAT*# SEQUENCE: PEYVKQNTLKLAT*# ...# >HUM20343# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PSYVKQNTLKLAT*# SEQUENCE: PSYVKQNTLKLAT*# ...# >HUM20344# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PAYVKQNTLKLAT*# SEQUENCE: PAYVKQNTLKLAT*# ...# >HUM20345# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKFVKQNTLKLAT*# SEQUENCE: PKFVKQNTLKLAT*# ...# >HUM20346# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYLKQNTLKLAT*# SEQUENCE: PKYLKQNTLKLAT*# ...# >HUM20347# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYKKQNTLKLAT*# SEQUENCE: PKYKKQNTLKLAT*# ...# >HUM20348# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYQKQNTLKLAT*# SEQUENCE: PKYQKQNTLKLAT*# ...# >HUM20349# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYAKQNTLKLAT*# SEQUENCE: PKYAKQNTLKLAT*# ...# >HUM2034A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYEKQNTLKLAT*# SEQUENCE: PKYEKQNTLKLAT*# ...# >HUM2034B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesm,PKYVRQNTLKLAT*# SEQUENCE: PKYVRQNTLKLAT*# ...# >HUM2034C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVEQNTLKLAT*# SEQUENCE: PKYVEQNTLKLAT*# ...# >HUM2034D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVSQNTLKLAT*# SEQUENCE: PKYVSQNTLKLAT*# ...# >HUM2034E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVAQNTLKLAT*# SEQUENCE: PKYVAQNTLKLAT*# ...# >HUM2034F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKYVVQNTLKLAT*# SEQUENCE: PKYVVQNTLKLAT*# ...# >HUM20350# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKYVKNNTLKLAT*# SEQUENCE: PKYVKNNTLKLAT*# ...# >HUM20351# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesm,PKYVKLNTLKLAT*# SEQUENCE: PKYVKLNTLKLAT*# ...# >HUM20352# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKYVKTNTLKLAT*# SEQUENCE: PKYVKTNTLKLAT*# ...# >HUM20353# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKYVKANTLKLAT*# SEQUENCE: PKYVKANTLKLAT*# ...# >HUM20354# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKYVKENTLKLAT*# SEQUENCE: PKYVKENTLKLAT*# ...# >HUM20355# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKYVKKNTLKLAT*# SEQUENCE: PKYVKKNTLKLAT*# ...# >HUM20356# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQQTLKLAT*# SEQUENCE: PKYVKQQTLKLAT*# ...# >HUM20357# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQTTLKLAT*# SEQUENCE: PKYVKQTTLKLAT*# ...# >HUM20358# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQLTLKLAT*# SEQUENCE: PKYVKQLTLKLAT*# ...# >HUM20359# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesm,PKYVKQATLKLAT*# SEQUENCE: PKYVKQATLKLAT*# ...# >HUM2035A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQETLKLAT*# SEQUENCE: PKYVKQETLKLAT*# ...# >HUM2035B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesm,PKYVKQKTLKLAT*# SEQUENCE: PKYVKQKTLKLAT*# ...# >HUM2035C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IADHK,HEMA_IAZH3)# & PIR1: (HMIVS2)# & PIR2: (JQ1153)# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesm,PKYVKQNSLKLAT*# SEQUENCE: PKYVKQNSLKLAT*# ...# >HUM2035D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesh,PKYVKQNELKLAT*# SEQUENCE: PKYVKQNELKLAT*# ...# >HUM2035E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKYVKQNVLKLAT*# SEQUENCE: PKYVKQNVLKLAT*# ...# >HUM2035F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKYVKQNALKLAT*# SEQUENCE: PKYVKQNALKLAT*# ...# >HUM20360# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKYVKQNYLKLAT*# SEQUENCE: PKYVKQNYLKLAT*# ...# >HUM20361# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKYVKQNQLKLAT*# SEQUENCE: PKYVKQNQLKLAT*# ...# >HUM20362# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTIKLAT*# SEQUENCE: PKYVKQNTIKLAT*# ...# >HUM20363# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTKKLAT*# SEQUENCE: PKYVKQNTKKLAT*# ...# >HUM20364# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTQKLAT*# SEQUENCE: PKYVKQNTQKLAT*# ...# >HUM20365# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesm,PKYVKQNTAKLAT*# SEQUENCE: PKYVKQNTAKLAT*# ...# >HUM20366# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTEKLAT*# SEQUENCE: PKYVKQNTEKLAT*# ...# >HUM20367# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLRLAT*# SEQUENCE: PKYVKQNTLRLAT*# ...# >HUM20368# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLELAT*# SEQUENCE: PKYVKQNTLELAT*# ...# >HUM20369# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLSLAT*# SEQUENCE: PKYVKQNTLSLAT*# ...# >HUM2036A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLALAT*# SEQUENCE: PKYVKQNTLALAT*# ...# >HUM2036B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLLLAT*# SEQUENCE: PKYVKQNTLLLAT*# ...# >HUM2036C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKYVKQNTLKIAT*# SEQUENCE: PKYVKQNTLKIAT*# ...# >HUM2036D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKYVKQNTLKKAT*# SEQUENCE: PKYVKQNTLKKAT*# ...# >HUM2036E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKYVKQNTLKQAT*# SEQUENCE: PKYVKQNTLKQAT*# ...# >HUM2036F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competition/proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b,alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesm,PKYVKQNTLKAAT*# SEQUENCE: PKYVKQNTLKAAT*# ...# >HUM20370# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKYVKQNTLKFAT*# SEQUENCE: PKYVKQNTLKFAT*# ...# >HUM20371# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLKLST*# SEQUENCE: PKYVKQNTLKLST*# ...# >HUM20372# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLKLFT*# SEQUENCE: PKYVKQNTLKLFT*# ...# >HUM20373# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLKLKT*# SEQUENCE: PKYVKQNTLKLKT*# ...# >HUM20374# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLKLAS*# SEQUENCE: PKYVKQNTLKLAS*# ...# >HUM20375# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLKLAK*# SEQUENCE: PKYVKQNTLKLAK*# ...# >HUM20376# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLKLAY*# SEQUENCE: PKYVKQNTLKLAY*# ...# >HUM20377# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVKQNTLKLAA*# SEQUENCE: PKYVKQNTLKLAA*# ...# >HUM20378# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as./competitive binding/blocking as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Hemagglutinin (307-319)# DB REFERENCE: SWISS: (HEMA_IADH3,HEMA_IADH1,HEMA_IAZUK,HEMA_IANT6,HEMA_IAZCO,# & HEMA_IAZH2,HEMA_IAEN6,HEMA_IAVI7,HEMA_IADH6,HEMA_IAME2,# & HEMA_IABAN,HEMA_IAEN7,HEMA_IADHM,HEMA_IAUDO,HEMA_IADH2,# & HEMA_IAQU7,HEMA_IADU3,HEMA_IADH7,HEMA_IAME1,HEMA_IADH4,# & HEMA_IAAIC)# & PIR1: (HMIV15,HMIV89,HMIV98,HMIV6,HMIVHM,HMIV77,HMIVH,HMIVDU,# & HMIV33,HMIVHA,HMIV80,HMIVS3,HMIVV)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a,o'sullivan91b,sidney92a,celis94a,vogt95a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesh,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM20379# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,AKYVKQNTLKLAT*# SEQUENCE: AKYVKQNTLKLAT*# ...# >HUM2037A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,KKYVKQNTLKLAT*# SEQUENCE: KKYVKQNTLKLAT*# ...# >HUM2037B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,EKYVKQNTLKLAT*# SEQUENCE: EKYVKQNTLKLAT*# ...# >HUM2037C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52174,S52187,S52195,S52198,S52182,S52180,S52189,JQ2377,# & S52173,S52186,S52188,S52178,S52179,S52197,JQ2374,JQ2375,# & S52185,S52191,S52199,S52183,JQ2378,S52176,S52175)# & PIR3: (S38637)# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PRYVKQNTLKLAT*# SEQUENCE: PRYVKQNTLKLAT*# ...# >HUM2037D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PEYVKQNTLKLAT*# SEQUENCE: PEYVKQNTLKLAT*# ...# >HUM2037E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PSYVKQNTLKLAT*# SEQUENCE: PSYVKQNTLKLAT*# ...# >HUM2037F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PAYVKQNTLKLAT*# SEQUENCE: PAYVKQNTLKLAT*# ...# >HUM20380# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKFVKQNTLKLAT*# SEQUENCE: PKFVKQNTLKLAT*# ...# >HUM20381# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYLKQNTLKLAT*# SEQUENCE: PKYLKQNTLKLAT*# ...# >HUM20382# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYKKQNTLKLAT*# SEQUENCE: PKYKKQNTLKLAT*# ...# >HUM20383# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYQKQNTLKLAT*# SEQUENCE: PKYQKQNTLKLAT*# ...# >HUM20384# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYAKQNTLKLAT*# SEQUENCE: PKYAKQNTLKLAT*# ...# >HUM20385# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYEKQNTLKLAT*# SEQUENCE: PKYEKQNTLKLAT*# ...# >HUM20386# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVRQNTLKLAT*# SEQUENCE: PKYVRQNTLKLAT*# ...# >HUM20387# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVEQNTLKLAT*# SEQUENCE: PKYVEQNTLKLAT*# ...# >HUM20388# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVSQNTLKLAT*# SEQUENCE: PKYVSQNTLKLAT*# ...# >HUM20389# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVAQNTLKLAT*# SEQUENCE: PKYVAQNTLKLAT*# ...# >HUM2038A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVVQNTLKLAT*# SEQUENCE: PKYVVQNTLKLAT*# ...# >HUM2038B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKNNTLKLAT*# SEQUENCE: PKYVKNNTLKLAT*# ...# >HUM2038C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKLNTLKLAT*# SEQUENCE: PKYVKLNTLKLAT*# ...# >HUM2038D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKTNTLKLAT*# SEQUENCE: PKYVKTNTLKLAT*# ...# >HUM2038E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKANTLKLAT*# SEQUENCE: PKYVKANTLKLAT*# ...# >HUM2038F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKENTLKLAT*# SEQUENCE: PKYVKENTLKLAT*# ...# >HUM20390# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKKNTLKLAT*# SEQUENCE: PKYVKKNTLKLAT*# ...# >HUM20391# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQQTLKLAT*# SEQUENCE: PKYVKQQTLKLAT*# ...# >HUM20392# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQTTLKLAT*# SEQUENCE: PKYVKQTTLKLAT*# ...# >HUM20393# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQLTLKLAT*# SEQUENCE: PKYVKQLTLKLAT*# ...# >HUM20394# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQATLKLAT*# SEQUENCE: PKYVKQATLKLAT*# ...# >HUM20395# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQETLKLAT*# SEQUENCE: PKYVKQETLKLAT*# ...# >HUM20396# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQKTLKLAT*# SEQUENCE: PKYVKQKTLKLAT*# ...# >HUM20397# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IADHK,HEMA_IAZH3)# & PIR1: (HMIVS2)# & PIR2: (JQ1153)# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNSLKLAT*# SEQUENCE: PKYVKQNSLKLAT*# ...# >HUM20398# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNVLKLAT*# SEQUENCE: PKYVKQNVLKLAT*# ...# >HUM20399# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNALKLAT*# SEQUENCE: PKYVKQNALKLAT*# ...# >HUM2039A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNYLKLAT*# SEQUENCE: PKYVKQNYLKLAT*# ...# >HUM2039B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNKLKLAT*# SEQUENCE: PKYVKQNKLKLAT*# ...# >HUM2039C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNQLKLAT*# SEQUENCE: PKYVKQNQLKLAT*# ...# >HUM2039D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTIKLAT*# SEQUENCE: PKYVKQNTIKLAT*# ...# >HUM2039E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTKKLAT*# SEQUENCE: PKYVKQNTKKLAT*# ...# >HUM2039F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTQKLAT*# SEQUENCE: PKYVKQNTQKLAT*# ...# >HUM203A0# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTAKLAT*# SEQUENCE: PKYVKQNTAKLAT*# ...# >HUM203A1# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTEKLAT*# SEQUENCE: PKYVKQNTEKLAT*# ...# >HUM203A2# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLRLAT*# SEQUENCE: PKYVKQNTLRLAT*# ...# >HUM203A3# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLELAT*# SEQUENCE: PKYVKQNTLELAT*# ...# >HUM203A4# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLSLAT*# SEQUENCE: PKYVKQNTLSLAT*# ...# >HUM203A5# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLALAT*# SEQUENCE: PKYVKQNTLALAT*# ...# >HUM203A6# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLLLAT*# SEQUENCE: PKYVKQNTLLLAT*# ...# >HUM203A7# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKIAT*# SEQUENCE: PKYVKQNTLKIAT*# ...# >HUM203A8# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,PKYVKQNTLKKAT*# SEQUENCE: PKYVKQNTLKKAT*# ...# >HUM203A9# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKQAT*# SEQUENCE: PKYVKQNTLKQAT*# ...# >HUM203AA# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKAAT*# SEQUENCE: PKYVKQNTLKAAT*# ...# >HUM203AB# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKEAT*# SEQUENCE: PKYVKQNTLKEAT*# ...# >HUM203AC# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKFAT*# SEQUENCE: PKYVKQNTLKFAT*# ...# >HUM203AD# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKLST*# SEQUENCE: PKYVKQNTLKLST*# ...# >HUM203AE# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKLFT*# SEQUENCE: PKYVKQNTLKLFT*# ...# >HUM203AF# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKLKT*# SEQUENCE: PKYVKQNTLKLKT*# ...# >HUM203B0# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKLAS*# SEQUENCE: PKYVKQNTLKLAS*# ...# >HUM203B1# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKLAK*# SEQUENCE: PKYVKQNTLKLAK*# ...# >HUM203B2# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKLAY*# SEQUENCE: PKYVKQNTLKLAY*# ...# >HUM203B3# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PKYVKQNTLKLAA*# SEQUENCE: PKYVKQNTLKLAA*# ...# >HUM203B4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as./competitive binding# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319)# DB REFERENCE: SWISS: (HEMA_IAZUK,HEMA_IAZCO,HEMA_IANT6,HEMA_IAZH2,HEMA_IAEN6,# & HEMA_IABAN,HEMA_IADU3,HEMA_IADH1,HEMA_IADH3,HEMA_IADH6,# & HEMA_IAME2,HEMA_IADHM,HEMA_IAME1,HEMA_IADH2,HEMA_IAQU7,# & HEMA_IAUDO,HEMA_IADH4,HEMA_IAEN7,HEMA_IAVI7,HEMA_IAAIC,# & HEMA_IADH7)# & PIR1: (HMIV89,HMIV80,HMIV77,HMIV6,HMIVHM,HMIVHA,HMIV15,HMIV98,# & HMIVH,HMIVDU,HMIV33,HMIVS3,HMIVV)# & PIR2: (JQ1156,A92979)# REFERENCES: o'sullivan91a,o'sullivan91b,sidney92a,alexander94a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesm,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM203B5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,AKYVKQNTLKLAT*# SEQUENCE: AKYVKQNTLKLAT*# ...# >HUM203B6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,KKYVKQNTLKLAT*# SEQUENCE: KKYVKQNTLKLAT*# ...# >HUM203B7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,EKYVKQNTLKLAT*# SEQUENCE: EKYVKQNTLKLAT*# ...# >HUM203B8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52189,S52175,S52187,S52178,S52186,JQ2375,S52191,S52185,# & S52197,JQ2374,S52179,S52174,S52195,S52183,JQ2377,S52176,# & JQ2378,S52198,S52180,S52182,S52173,S52188,S52199)# & PIR3: (S38637)# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PRYVKQNTLKLAT*# SEQUENCE: PRYVKQNTLKLAT*# ...# >HUM203B9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PEYVKQNTLKLAT*# SEQUENCE: PEYVKQNTLKLAT*# ...# >HUM203BA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PSYVKQNTLKLAT*# SEQUENCE: PSYVKQNTLKLAT*# ...# >HUM203BB# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PAYVKQNTLKLAT*# SEQUENCE: PAYVKQNTLKLAT*# ...# >HUM203BC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKFVKQNTLKLAT*# SEQUENCE: PKFVKQNTLKLAT*# ...# >HUM203BD# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYLKQNTLKLAT*# SEQUENCE: PKYLKQNTLKLAT*# ...# >HUM203BE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYKKQNTLKLAT*# SEQUENCE: PKYKKQNTLKLAT*# ...# >HUM203BF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYQKQNTLKLAT*# SEQUENCE: PKYQKQNTLKLAT*# ...# >HUM203C0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYAKQNTLKLAT*# SEQUENCE: PKYAKQNTLKLAT*# ...# >HUM203C1# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYEKQNTLKLAT*# SEQUENCE: PKYEKQNTLKLAT*# ...# >HUM203C2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVRQNTLKLAT*# SEQUENCE: PKYVRQNTLKLAT*# ...# >HUM203C3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVEQNTLKLAT*# SEQUENCE: PKYVEQNTLKLAT*# ...# >HUM203C4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVSQNTLKLAT*# SEQUENCE: PKYVSQNTLKLAT*# ...# >HUM203C5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVAQNTLKLAT*# SEQUENCE: PKYVAQNTLKLAT*# ...# >HUM203C6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVVQNTLKLAT*# SEQUENCE: PKYVVQNTLKLAT*# ...# >HUM203C7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKNNTLKLAT*# SEQUENCE: PKYVKNNTLKLAT*# ...# >HUM203C8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKLNTLKLAT*# SEQUENCE: PKYVKLNTLKLAT*# ...# >HUM203C9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKTNTLKLAT*# SEQUENCE: PKYVKTNTLKLAT*# ...# >HUM203CA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKANTLKLAT*# SEQUENCE: PKYVKANTLKLAT*# ...# >HUM203CB# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKENTLKLAT*# SEQUENCE: PKYVKENTLKLAT*# ...# >HUM203CC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKKNTLKLAT*# SEQUENCE: PKYVKKNTLKLAT*# ...# >HUM203CD# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQQTLKLAT*# SEQUENCE: PKYVKQQTLKLAT*# ...# >HUM203CE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQTTLKLAT*# SEQUENCE: PKYVKQTTLKLAT*# ...# >HUM203CF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQLTLKLAT*# SEQUENCE: PKYVKQLTLKLAT*# ...# >HUM203D0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQATLKLAT*# SEQUENCE: PKYVKQATLKLAT*# ...# >HUM203D1# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQETLKLAT*# SEQUENCE: PKYVKQETLKLAT*# ...# >HUM203D2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQKTLKLAT*# SEQUENCE: PKYVKQKTLKLAT*# ...# >HUM203D3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IAZH3,HEMA_IADHK)# & PIR1: (HMIVS2)# & PIR2: (JQ1153)# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNSLKLAT*# SEQUENCE: PKYVKQNSLKLAT*# ...# >HUM203D4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNVLKLAT*# SEQUENCE: PKYVKQNVLKLAT*# ...# >HUM203D5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNALKLAT*# SEQUENCE: PKYVKQNALKLAT*# ...# >HUM203D6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNYLKLAT*# SEQUENCE: PKYVKQNYLKLAT*# ...# >HUM203D7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQNKLKLAT*# SEQUENCE: PKYVKQNKLKLAT*# ...# >HUM203D8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNQLKLAT*# SEQUENCE: PKYVKQNQLKLAT*# ...# >HUM203D9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTIKLAT*# SEQUENCE: PKYVKQNTIKLAT*# ...# >HUM203DA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQNTKKLAT*# SEQUENCE: PKYVKQNTKKLAT*# ...# >HUM203DB# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTQKLAT*# SEQUENCE: PKYVKQNTQKLAT*# ...# >HUM203DC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTAKLAT*# SEQUENCE: PKYVKQNTAKLAT*# ...# >HUM203DD# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQNTLRLAT*# SEQUENCE: PKYVKQNTLRLAT*# ...# >HUM203DE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLELAT*# SEQUENCE: PKYVKQNTLELAT*# ...# >HUM203DF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLSLAT*# SEQUENCE: PKYVKQNTLSLAT*# ...# >HUM203E0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLALAT*# SEQUENCE: PKYVKQNTLALAT*# ...# >HUM203E1# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLLLAT*# SEQUENCE: PKYVKQNTLLLAT*# ...# >HUM203E2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKIAT*# SEQUENCE: PKYVKQNTLKIAT*# ...# >HUM203E3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKKAT*# SEQUENCE: PKYVKQNTLKKAT*# ...# >HUM203E4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQNTLKQAT*# SEQUENCE: PKYVKQNTLKQAT*# ...# >HUM203E5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQNTLKAAT*# SEQUENCE: PKYVKQNTLKAAT*# ...# >HUM203E6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKEAT*# SEQUENCE: PKYVKQNTLKEAT*# ...# >HUM203E7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKFAT*# SEQUENCE: PKYVKQNTLKFAT*# ...# >HUM203E8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKLST*# SEQUENCE: PKYVKQNTLKLST*# ...# >HUM203E9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKLFT*# SEQUENCE: PKYVKQNTLKLFT*# ...# >HUM203EA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQNTLKLKT*# SEQUENCE: PKYVKQNTLKLKT*# ...# >HUM203EB# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQNTLKLAS*# SEQUENCE: PKYVKQNTLKLAS*# ...# >HUM203EC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKLAK*# SEQUENCE: PKYVKQNTLKLAK*# ...# >HUM203ED# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKLAY*# SEQUENCE: PKYVKQNTLKLAY*# ...# >HUM203EE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PKYVKQNTLKLAA*# SEQUENCE: PKYVKQNTLKLAA*# ...# >HUM203EF# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as./competitive binding# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319)# DB REFERENCE: SWISS: (HEMA_IAME2,HEMA_IADHM,HEMA_IADH2,HEMA_IAQU7,HEMA_IAME1,# & HEMA_IAUDO,HEMA_IAZCO,HEMA_IAZUK,HEMA_IABAN,HEMA_IAEN6,# & HEMA_IANT6,HEMA_IAEN7,HEMA_IADH7,HEMA_IADH6,HEMA_IADH3,# & HEMA_IADH1,HEMA_IAVI7,HEMA_IADU3,HEMA_IADH4,HEMA_IAZH2,# & HEMA_IAAIC)# & PIR1: (HMIV89,HMIV80,HMIV33,HMIVH,HMIV98,HMIVDU,HMIVHA,HMIVHM,# & HMIV77,HMIV6,HMIV15,HMIVS3,HMIVV)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91b,sidney92a,alexander94a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesm,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM203F0# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AKYVKQNTLKLAT*# SEQUENCE: AKYVKQNTLKLAT*# ...# >HUM203F1# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,KKYVKQNTLKLAT*# SEQUENCE: KKYVKQNTLKLAT*# ...# >HUM203F2# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,EKYVKQNTLKLAT*# SEQUENCE: EKYVKQNTLKLAT*# ...# >HUM203F3# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52198,S52182,JQ2378,S52183,S52174,S52178,S52186,S52185,# & JQ2375,S52195,JQ2377,S52199,S52189,S52188,S52173,S52191,# & S52179,S52180,S52176,S52197,JQ2374,S52175,S52187)# & PIR3: (S38637)# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PRYVKQNTLKLAT*# SEQUENCE: PRYVKQNTLKLAT*# ...# >HUM203F4# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PEYVKQNTLKLAT*# SEQUENCE: PEYVKQNTLKLAT*# ...# >HUM203F5# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PSYVKQNTLKLAT*# SEQUENCE: PSYVKQNTLKLAT*# ...# >HUM203F6# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PAYVKQNTLKLAT*# SEQUENCE: PAYVKQNTLKLAT*# ...# >HUM203F7# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKFVKQNTLKLAT*# SEQUENCE: PKFVKQNTLKLAT*# ...# >HUM203F8# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYLKQNTLKLAT*# SEQUENCE: PKYLKQNTLKLAT*# ...# >HUM203F9# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYKKQNTLKLAT*# SEQUENCE: PKYKKQNTLKLAT*# ...# >HUM203FA# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYQKQNTLKLAT*# SEQUENCE: PKYQKQNTLKLAT*# ...# >HUM203FB# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYAKQNTLKLAT*# SEQUENCE: PKYAKQNTLKLAT*# ...# >HUM203FC# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYEKQNTLKLAT*# SEQUENCE: PKYEKQNTLKLAT*# ...# >HUM203FD# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVRQNTLKLAT*# SEQUENCE: PKYVRQNTLKLAT*# ...# >HUM203FE# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVEQNTLKLAT*# SEQUENCE: PKYVEQNTLKLAT*# ...# >HUM203FF# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVSQNTLKLAT*# SEQUENCE: PKYVSQNTLKLAT*# ...# >HUM20400# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVAQNTLKLAT*# SEQUENCE: PKYVAQNTLKLAT*# ...# >HUM20401# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVVQNTLKLAT*# SEQUENCE: PKYVVQNTLKLAT*# ...# >HUM20402# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKNNTLKLAT*# SEQUENCE: PKYVKNNTLKLAT*# ...# >HUM20403# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKLNTLKLAT*# SEQUENCE: PKYVKLNTLKLAT*# ...# >HUM20404# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKANTLKLAT*# SEQUENCE: PKYVKANTLKLAT*# ...# >HUM20405# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKENTLKLAT*# SEQUENCE: PKYVKENTLKLAT*# ...# >HUM20406# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKKNTLKLAT*# SEQUENCE: PKYVKKNTLKLAT*# ...# >HUM20407# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQQTLKLAT*# SEQUENCE: PKYVKQQTLKLAT*# ...# >HUM20408# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQTTLKLAT*# SEQUENCE: PKYVKQTTLKLAT*# ...# >HUM20409# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQLTLKLAT*# SEQUENCE: PKYVKQLTLKLAT*# ...# >HUM2040A# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQATLKLAT*# SEQUENCE: PKYVKQATLKLAT*# ...# >HUM2040B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQETLKLAT*# SEQUENCE: PKYVKQETLKLAT*# ...# >HUM2040C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQKTLKLAT*# SEQUENCE: PKYVKQKTLKLAT*# ...# >HUM2040D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IAZH3,HEMA_IADHK)# & PIR1: (HMIVS2)# & PIR2: (JQ1153)# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNSLKLAT*# SEQUENCE: PKYVKQNSLKLAT*# ...# >HUM2040E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNELKLAT*# SEQUENCE: PKYVKQNELKLAT*# ...# >HUM2040F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNVLKLAT*# SEQUENCE: PKYVKQNVLKLAT*# ...# >HUM20410# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNALKLAT*# SEQUENCE: PKYVKQNALKLAT*# ...# >HUM20411# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNYLKLAT*# SEQUENCE: PKYVKQNYLKLAT*# ...# >HUM20412# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNKLKLAT*# SEQUENCE: PKYVKQNKLKLAT*# ...# >HUM20413# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNQLKLAT*# SEQUENCE: PKYVKQNQLKLAT*# ...# >HUM20414# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNTIKLAT*# SEQUENCE: PKYVKQNTIKLAT*# ...# >HUM20415# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTKKLAT*# SEQUENCE: PKYVKQNTKKLAT*# ...# >HUM20416# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTQKLAT*# SEQUENCE: PKYVKQNTQKLAT*# ...# >HUM20417# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTAKLAT*# SEQUENCE: PKYVKQNTAKLAT*# ...# >HUM20418# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTEKLAT*# SEQUENCE: PKYVKQNTEKLAT*# ...# >HUM20419# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNTLRLAT*# SEQUENCE: PKYVKQNTLRLAT*# ...# >HUM2041A# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLELAT*# SEQUENCE: PKYVKQNTLELAT*# ...# >HUM2041B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLSLAT*# SEQUENCE: PKYVKQNTLSLAT*# ...# >HUM2041C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLALAT*# SEQUENCE: PKYVKQNTLALAT*# ...# >HUM2041D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLLLAT*# SEQUENCE: PKYVKQNTLLLAT*# ...# >HUM2041E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNTLKIAT*# SEQUENCE: PKYVKQNTLKIAT*# ...# >HUM2041F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKKAT*# SEQUENCE: PKYVKQNTLKKAT*# ...# >HUM20420# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKQAT*# SEQUENCE: PKYVKQNTLKQAT*# ...# >HUM20421# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKAAT*# SEQUENCE: PKYVKQNTLKAAT*# ...# >HUM20422# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKEAT*# SEQUENCE: PKYVKQNTLKEAT*# ...# >HUM20423# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKFAT*# SEQUENCE: PKYVKQNTLKFAT*# ...# >HUM20424# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKLST*# SEQUENCE: PKYVKQNTLKLST*# ...# >HUM20425# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKLFT*# SEQUENCE: PKYVKQNTLKLFT*# ...# >HUM20426# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKLKT*# SEQUENCE: PKYVKQNTLKLKT*# ...# >HUM20427# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKLAS*# SEQUENCE: PKYVKQNTLKLAS*# ...# >HUM20428# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKLAK*# SEQUENCE: PKYVKQNTLKLAK*# ...# >HUM20429# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNTLKLAY*# SEQUENCE: PKYVKQNTLKLAY*# ...# >HUM2042A# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKLAA*# SEQUENCE: PKYVKQNTLKLAA*# ...# >HUM2042B# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as./competitive binding# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Tetanus toxin (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a,o'sullivan91b,demotz89a,kropshofer92a,sidney92a# COMMENT:# SUMMARY: HLA-DR5,actyesm,bindyesh,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM2042C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as./competitive binding/inhibition as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a,o'sullivan91b,sidney92a,sette95a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesh,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM2042D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,TYIKANSKFIGITE*# SEQUENCE: TYIKANSKFIGITE*# ...# >HUM2042E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,LYIKANSKFIGITE*# SEQUENCE: LYIKANSKFIGITE*# ...# >HUM2042F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,NYIKANSKFIGITE*# SEQUENCE: NYIKANSKFIGITE*# ...# >HUM20430# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,QEIKANSKFIGITE*# SEQUENCE: QEIKANSKFIGITE*# ...# >HUM20431# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,QSIKANSKFIGITE*# SEQUENCE: QSIKANSKFIGITE*# ...# >HUM20432# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QFIKANSKFIGITE*# SEQUENCE: QFIKANSKFIGITE*# ...# >HUM20433# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYQKANSKFIGITE*# SEQUENCE: QYQKANSKFIGITE*# ...# >HUM20434# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYKKANSKFIGITE*# SEQUENCE: QYKKANSKFIGITE*# ...# >HUM20435# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYVKANSKFIGITE*# SEQUENCE: QYVKANSKFIGITE*# ...# >HUM20436# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYISANSKFIGITE*# SEQUENCE: QYISANSKFIGITE*# ...# >HUM20437# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIIANSKFIGITE*# SEQUENCE: QYIIANSKFIGITE*# ...# >HUM20438# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIRANSKFIGITE*# SEQUENCE: QYIRANSKFIGITE*# ...# >HUM20439# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKKNSKFIGITE*# SEQUENCE: QYIKKNSKFIGITE*# ...# >HUM2043A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKFNSKFIGITE*# SEQUENCE: QYIKFNSKFIGITE*# ...# >HUM2043B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKSNSKFIGITE*# SEQUENCE: QYIKSNSKFIGITE*# ...# >HUM2043C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKAASKFIGITE*# SEQUENCE: QYIKAASKFIGITE*# ...# >HUM2043D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKALSKFIGITE*# SEQUENCE: QYIKALSKFIGITE*# ...# >HUM2043E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKAQSKFIGITE*# SEQUENCE: QYIKAQSKFIGITE*# ...# >HUM2043F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANYKFIGITE*# SEQUENCE: QYIKANYKFIGITE*# ...# >HUM20440# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,QYIKANQKFIGITE*# SEQUENCE: QYIKANQKFIGITE*# ...# >HUM20441# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANAKFIGITE*# SEQUENCE: QYIKANAKFIGITE*# ...# >HUM20442# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSSFIGITE*# SEQUENCE: QYIKANSSFIGITE*# ...# >HUM20443# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSEFIGITE*# SEQUENCE: QYIKANSEFIGITE*# ...# >HUM20444# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSRFIGITE*# SEQUENCE: QYIKANSRFIGITE*# ...# >HUM20445# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKEIGITE*# SEQUENCE: QYIKANSKEIGITE*# ...# >HUM20446# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKSIGITE*# SEQUENCE: QYIKANSKSIGITE*# ...# >HUM20447# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFKGITE*# SEQUENCE: QYIKANSKFKGITE*# ...# >HUM20448# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFQGITE*# SEQUENCE: QYIKANSKFQGITE*# ...# >HUM20449# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFVGITE*# SEQUENCE: QYIKANSKFVGITE*# ...# >HUM2044A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIQITE*# SEQUENCE: QYIKANSKFIQITE*# ...# >HUM2044B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIYITE*# SEQUENCE: QYIKANSKFIYITE*# ...# >HUM2044C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIAITE*# SEQUENCE: QYIKANSKFIAITE*# ...# >HUM2044D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGQTE*# SEQUENCE: QYIKANSKFIGQTE*# ...# >HUM2044E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGKTE*# SEQUENCE: QYIKANSKFIGKTE*# ...# >HUM2044F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGLTE*# SEQUENCE: QYIKANSKFIGLTE*# ...# >HUM20450# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGIKE*# SEQUENCE: QYIKANSKFIGIKE*# ...# >HUM20451# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGIFE*# SEQUENCE: QYIKANSKFIGIFE*# ...# >HUM20452# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGISE*# SEQUENCE: QYIKANSKFIGISE*# ...# >HUM20453# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGITK*# SEQUENCE: QYIKANSKFIGITK*# ...# >HUM20454# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGITD*# SEQUENCE: QYIKANSKFIGITD*# ...# >HUM20455# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QYIKANSKFIGITV*# SEQUENCE: QYIKANSKFIGITV*# ...# >HUM20456# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as./competitive binding# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a,o'sullivan91b,sidney92a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesm,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM20457# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,TYIKANSKFIGITE*# SEQUENCE: TYIKANSKFIGITE*# ...# >HUM20458# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,LYIKANSKFIGITE*# SEQUENCE: LYIKANSKFIGITE*# ...# >HUM20459# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,NYIKANSKFIGITE*# SEQUENCE: NYIKANSKFIGITE*# ...# >HUM2045A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QEIKANSKFIGITE*# SEQUENCE: QEIKANSKFIGITE*# ...# >HUM2045B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QSIKANSKFIGITE*# SEQUENCE: QSIKANSKFIGITE*# ...# >HUM2045C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QFIKANSKFIGITE*# SEQUENCE: QFIKANSKFIGITE*# ...# >HUM2045D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYQKANSKFIGITE*# SEQUENCE: QYQKANSKFIGITE*# ...# >HUM2045E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYKKANSKFIGITE*# SEQUENCE: QYKKANSKFIGITE*# ...# >HUM2045F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYVKANSKFIGITE*# SEQUENCE: QYVKANSKFIGITE*# ...# >HUM20460# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYISANSKFIGITE*# SEQUENCE: QYISANSKFIGITE*# ...# >HUM20461# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIIANSKFIGITE*# SEQUENCE: QYIIANSKFIGITE*# ...# >HUM20462# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIRANSKFIGITE*# SEQUENCE: QYIRANSKFIGITE*# ...# >HUM20463# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,QYIKKNSKFIGITE*# SEQUENCE: QYIKKNSKFIGITE*# ...# >HUM20464# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKSNSKFIGITE*# SEQUENCE: QYIKSNSKFIGITE*# ...# >HUM20465# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKAASKFIGITE*# SEQUENCE: QYIKAASKFIGITE*# ...# >HUM20466# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKALSKFIGITE*# SEQUENCE: QYIKALSKFIGITE*# ...# >HUM20467# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKAQSKFIGITE*# SEQUENCE: QYIKAQSKFIGITE*# ...# >HUM20468# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANYKFIGITE*# SEQUENCE: QYIKANYKFIGITE*# ...# >HUM20469# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANQKFIGITE*# SEQUENCE: QYIKANQKFIGITE*# ...# >HUM2046A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANAKFIGITE*# SEQUENCE: QYIKANAKFIGITE*# ...# >HUM2046B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSSFIGITE*# SEQUENCE: QYIKANSSFIGITE*# ...# >HUM2046C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSRFIGITE*# SEQUENCE: QYIKANSRFIGITE*# ...# >HUM2046D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKEIGITE*# SEQUENCE: QYIKANSKEIGITE*# ...# >HUM2046E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKSIGITE*# SEQUENCE: QYIKANSKSIGITE*# ...# >HUM2046F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFKGITE*# SEQUENCE: QYIKANSKFKGITE*# ...# >HUM20470# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFQGITE*# SEQUENCE: QYIKANSKFQGITE*# ...# >HUM20471# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFVGITE*# SEQUENCE: QYIKANSKFVGITE*# ...# >HUM20472# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIQITE*# SEQUENCE: QYIKANSKFIQITE*# ...# >HUM20473# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIYITE*# SEQUENCE: QYIKANSKFIYITE*# ...# >HUM20474# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIAITE*# SEQUENCE: QYIKANSKFIAITE*# ...# >HUM20475# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGQTE*# SEQUENCE: QYIKANSKFIGQTE*# ...# >HUM20476# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGKTE*# SEQUENCE: QYIKANSKFIGKTE*# ...# >HUM20477# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGLTE*# SEQUENCE: QYIKANSKFIGLTE*# ...# >HUM20478# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGIKE*# SEQUENCE: QYIKANSKFIGIKE*# ...# >HUM20479# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGIFE*# SEQUENCE: QYIKANSKFIGIFE*# ...# >HUM2047A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGISE*# SEQUENCE: QYIKANSKFIGISE*# ...# >HUM2047B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGITK*# SEQUENCE: QYIKANSKFIGITK*# ...# >HUM2047C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGITD*# SEQUENCE: QYIKANSKFIGITD*# ...# >HUM2047D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,QYIKANSKFIGITV*# SEQUENCE: QYIKANSKFIGITV*# ...# >HUM2047E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as./competitive binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842) homologue# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91b,sidney92a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM2047F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,TYIKANSKFIGITE*# SEQUENCE: TYIKANSKFIGITE*# ...# >HUM20480# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,LYIKANSKFIGITE*# SEQUENCE: LYIKANSKFIGITE*# ...# >HUM20481# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,NYIKANSKFIGITE*# SEQUENCE: NYIKANSKFIGITE*# ...# >HUM20482# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,QEIKANSKFIGITE*# SEQUENCE: QEIKANSKFIGITE*# ...# >HUM20483# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,QSIKANSKFIGITE*# SEQUENCE: QSIKANSKFIGITE*# ...# >HUM20484# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QFIKANSKFIGITE*# SEQUENCE: QFIKANSKFIGITE*# ...# >HUM20485# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYQKANSKFIGITE*# SEQUENCE: QYQKANSKFIGITE*# ...# >HUM20486# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYKKANSKFIGITE*# SEQUENCE: QYKKANSKFIGITE*# ...# >HUM20487# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYVKANSKFIGITE*# SEQUENCE: QYVKANSKFIGITE*# ...# >HUM20488# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYISANSKFIGITE*# SEQUENCE: QYISANSKFIGITE*# ...# >HUM20489# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIIANSKFIGITE*# SEQUENCE: QYIIANSKFIGITE*# ...# >HUM2048A# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIRANSKFIGITE*# SEQUENCE: QYIRANSKFIGITE*# ...# >HUM2048B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKKNSKFIGITE*# SEQUENCE: QYIKKNSKFIGITE*# ...# >HUM2048C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKFNSKFIGITE*# SEQUENCE: QYIKFNSKFIGITE*# ...# >HUM2048D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKSNSKFIGITE*# SEQUENCE: QYIKSNSKFIGITE*# ...# >HUM2048E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKAASKFIGITE*# SEQUENCE: QYIKAASKFIGITE*# ...# >HUM2048F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKALSKFIGITE*# SEQUENCE: QYIKALSKFIGITE*# ...# >HUM20490# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKAQSKFIGITE*# SEQUENCE: QYIKAQSKFIGITE*# ...# >HUM20491# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANYKFIGITE*# SEQUENCE: QYIKANYKFIGITE*# ...# >HUM20492# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANQKFIGITE*# SEQUENCE: QYIKANQKFIGITE*# ...# >HUM20493# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANAKFIGITE*# SEQUENCE: QYIKANAKFIGITE*# ...# >HUM20494# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSSFIGITE*# SEQUENCE: QYIKANSSFIGITE*# ...# >HUM20495# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSEFIGITE*# SEQUENCE: QYIKANSEFIGITE*# ...# >HUM20496# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSRFIGITE*# SEQUENCE: QYIKANSRFIGITE*# ...# >HUM20497# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKEIGITE*# SEQUENCE: QYIKANSKEIGITE*# ...# >HUM20498# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKSIGITE*# SEQUENCE: QYIKANSKSIGITE*# ...# >HUM20499# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,QYIKANSKFKGITE*# SEQUENCE: QYIKANSKFKGITE*# ...# >HUM2049A# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFQGITE*# SEQUENCE: QYIKANSKFQGITE*# ...# >HUM2049B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFVGITE*# SEQUENCE: QYIKANSKFVGITE*# ...# >HUM2049C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIQITE*# SEQUENCE: QYIKANSKFIQITE*# ...# >HUM2049D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIYITE*# SEQUENCE: QYIKANSKFIYITE*# ...# >HUM2049E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIAITE*# SEQUENCE: QYIKANSKFIAITE*# ...# >HUM2049F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGQTE*# SEQUENCE: QYIKANSKFIGQTE*# ...# >HUM204A0# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGKTE*# SEQUENCE: QYIKANSKFIGKTE*# ...# >HUM204A1# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGLTE*# SEQUENCE: QYIKANSKFIGLTE*# ...# >HUM204A2# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGIKE*# SEQUENCE: QYIKANSKFIGIKE*# ...# >HUM204A3# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGIFE*# SEQUENCE: QYIKANSKFIGIFE*# ...# >HUM204A4# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGISE*# SEQUENCE: QYIKANSKFIGISE*# ...# >HUM204A5# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGITK*# SEQUENCE: QYIKANSKFIGITK*# ...# >HUM204A6# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGITD*# SEQUENCE: QYIKANSKFIGITD*# ...# >HUM204A7# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxin (830-842) homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QYIKANSKFIGITV*# SEQUENCE: QYIKANSKFIGITV*# ...# >HUM204A8# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (75-98)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91b# COMMENT:# SUMMARY: HLA-DR?,actunkn,bindyesu,FKNNVTPRT*# SEQUENCE: FKNNVTPRT*# ...# >HUM204A9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p Cyt c (88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a,o'sullivan90a,chicz92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,KAERADLIAYLKQATAK*# SEQUENCE: KAERADLIAYLKQATAK*# ...# >HUM204AA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p Cyt c (90-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,ERADLIAYLKQATAK*# SEQUENCE: ERADLIAYLKQATAK*# ...# >HUM204AB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p Cyt c (92-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,ADLIAYLKQATAK*# SEQUENCE: ADLIAYLKQATAK*# ...# >HUM204AC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p Cyt c (93-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,DLIAYLKQATAK*# SEQUENCE: DLIAYLKQATAK*# ...# >HUM204AD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p Cyt c (94-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,LIAYLKQATAK*# SEQUENCE: LIAYLKQATAK*# ...# >HUM204AE# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p Cyt c (95-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,IAYLKQATAK*# SEQUENCE: IAYLKQATAK*# ...# >HUM204AF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p Cyt c (88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,KAERADLIAYLKQATAK*# SEQUENCE: KAERADLIAYLKQATAK*# ...# >HUM204B0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p Cyt c (90-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,ERADLIAYLKQATAK*# SEQUENCE: ERADLIAYLKQATAK*# ...# >HUM204B1# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p Cyt c (92-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,ADLIAYLKQATAK*# SEQUENCE: ADLIAYLKQATAK*# ...# >HUM204B2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p Cyt c (93-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,DLIAYLKQATAK*# SEQUENCE: DLIAYLKQATAK*# ...# >HUM204B3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p Cyt c (94-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,LIAYLKQATAK*# SEQUENCE: LIAYLKQATAK*# ...# >HUM204B4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p Cyt c (95-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,IAYLKQATAK*# SEQUENCE: IAYLKQATAK*# ...# >HUM204B5# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p Cyt c (88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,KAERADLIAYLKQATAK*# SEQUENCE: KAERADLIAYLKQATAK*# ...# >HUM204B6# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Dynorphin (1-13)# DB REFERENCE: SWISS: (NDDB_HUMAN,NDDB_HUMAN,NDDB_PIG,NDDB_BOVIN,NDDB_RAT,# & NDDB_CAVPO,NDDB_RAT,NDDB_PIG)# & PIR1: (DFPG,DFHU,DFRTP)# REFERENCES: o'sullivan91a,o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,YGGFLRRIRPKLK*# SEQUENCE: YGGFLRRIRPKLK*# ...# >HUM204B7# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Dynorphin (3-13)# DB REFERENCE: SWISS: (NDDB_HUMAN,NDDB_RAT,NDDB_PIG,NDDB_CAVPO,NDDB_BOVIN,# & NDDB_PIG,NDDB_RAT,NDDB_HUMAN)# & PIR1: (DFRTP,DFPG,DFHU)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,GFLRRIRPKLK*# SEQUENCE: GFLRRIRPKLK*# ...# >HUM204B8# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Dynorphin (4-13)# DB REFERENCE: SWISS: (NDDB_RAT,NDDB_CAVPO,NDDB_BOVIN,NDDB_HUMAN,NDDB_PIG,# & NDDB_RAT,NDDB_HUMAN,NDDB_PIG)# & PIR1: (DFRTP,DFHU,DFPG)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,FLRRIRPKLK*# SEQUENCE: FLRRIRPKLK*# ...# >HUM204B9# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Dynorphin (5-13)# DB REFERENCE: SWISS: (NDDB_HUMAN,NDDB_HUMAN,NDDB_BOVIN,NDDB_RAT,NDDB_PIG,# & NDDB_CAVPO,NDDB_RAT,NDDB_PIG)# & PIR1: (DFRTP,DFHU,DFPG)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,LRRIRPKLK*# SEQUENCE: LRRIRPKLK*# ...# >HUM204BA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Dynorphin (1-13)# DB REFERENCE: SWISS: (NDDB_HUMAN,NDDB_PIG,NDDB_RAT,NDDB_BOVIN,NDDB_CAVPO,# & NDDB_HUMAN,NDDB_RAT,NDDB_PIG)# & PIR1: (DFRTP,DFHU,DFPG)# REFERENCES: o'sullivan91a,o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,YGGFLRRIRPKLK*# SEQUENCE: YGGFLRRIRPKLK*# ...# >HUM204BB# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Dynorphin (3-13)# DB REFERENCE: SWISS: (NDDB_CAVPO,NDDB_RAT,NDDB_PIG,NDDB_PIG,NDDB_HUMAN,# & NDDB_HUMAN,NDDB_RAT,NDDB_BOVIN)# & PIR1: (DFRTP,DFPG,DFHU)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,GFLRRIRPKLK*# SEQUENCE: GFLRRIRPKLK*# ...# >HUM204BC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Dynorphin (4-13)# DB REFERENCE: SWISS: (NDDB_PIG,NDDB_PIG,NDDB_HUMAN,NDDB_RAT,NDDB_RAT,# & NDDB_BOVIN,NDDB_CAVPO,NDDB_HUMAN)# & PIR1: (DFHU,DFPG,DFRTP)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,FLRRIRPKLK*# SEQUENCE: FLRRIRPKLK*# ...# >HUM204BD# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Dynorphin (5-13)# DB REFERENCE: SWISS: (NDDB_BOVIN,NDDB_HUMAN,NDDB_PIG,NDDB_PIG,NDDB_CAVPO,# & NDDB_HUMAN,NDDB_RAT,NDDB_RAT)# & PIR1: (DFHU,DFPG,DFRTP)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,LRRIRPKLK*# SEQUENCE: LRRIRPKLK*# ...# >HUM204BE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Dynorphin (1-11)# DB REFERENCE: SWISS: (NDDB_HUMAN,NDDB_PIG,NDDB_PIG,NDDB_HUMAN,NDDB_CAVPO,# & NDDB_RAT,NDDB_BOVIN,NDDB_RAT)# & PIR1: (DFPG,DFRTP,DFHU)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,YGGFLRRIRPK*# SEQUENCE: YGGFLRRIRPK*# ...# >HUM204BF# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-153)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,NKALELFRKDIAAKYKELGYGK*# SEQUENCE: NKALELFRKDIAAKYKELGYGK*# ...# >HUM204C0# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-147)# DB REFERENCE: SWISS: (MYG_BALAC,MYG_CASFI,MYG_BALPH,MYG_PHYCA,MYG_ESCGI,# & MYG_MEGNO,MYG_PHYCA,MYG_GLOME,MYG_ORCOR,MYG_TURTR,# & MYG_INIGE)# & PIR1: (MYWHK,MYWHT,MYDD,MYWHP,MYWHC,MYWHL,MYDDAR,MYWHF,MYDDBS,# & MYWHH)# & PIR2: (JN0410)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,NKALELFRKDIAAKYK*# SEQUENCE: NKALELFRKDIAAKYK*# ...# >HUM204C1# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-151)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP)# REFERENCES: o'sullivan91a,o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,NKALELFRKDIAAKYKELGY*# SEQUENCE: NKALELFRKDIAAKYKELGY*# ...# >HUM204C2# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (134-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ALELFRKDIAAKYKELGYGK*# SEQUENCE: ALELFRKDIAAKYKELGYGK*# ...# >HUM204C3# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (136-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ELFRKDIAAKYKELGYGK*# SEQUENCE: ELFRKDIAAKYKELGYGK*# ...# >HUM204C4# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (137-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,LFRKDIAAKYKELGYGK*# SEQUENCE: LFRKDIAAKYKELGYGK*# ...# >HUM204C5# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (138-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,FRKDIAAKYKELGYGK*# SEQUENCE: FRKDIAAKYKELGYGK*# ...# >HUM204C6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-153)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,NKALELFRKDIAAKYKELGYGK*# SEQUENCE: NKALELFRKDIAAKYKELGYGK*# ...# >HUM204C7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-147)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_INIGE,MYG_BALPH,MYG_MEGNO,MYG_ORCOR,# & MYG_TURTR,MYG_GLOME,MYG_CASFI,MYG_ESCGI,MYG_PHYCA,# & MYG_BALAC)# & PIR1: (MYWHC,MYWHT,MYDDAR,MYWHP,MYDD,MYWHH,MYWHF,MYWHL,MYWHK,# & MYDDBS)# & PIR2: (JN0410)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,NKALELFRKDIAAKYK*# SEQUENCE: NKALELFRKDIAAKYK*# ...# >HUM204C8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-146)# DB REFERENCE: SWISS: (MYG_TURTR,MYG_PHYCA,MYG_PHYCA,MYG_ESCGI,MYG_CASFI,# & MYG_ORCOR,MYG_BALPH,MYG_MEGNO,MYG_BALAC,MYG_GLOME,# & MYG_INIGE)# & PIR1: (MYWHP,MYWHT,MYDDBS,MYWHL,MYWHK,MYDD,MYDDAR,MYWHC,MYWHF,# & MYWHH)# & PIR2: (JN0410)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,NKALELFRKDIAAKY*# SEQUENCE: NKALELFRKDIAAKY*# ...# >HUM204C9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-145)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_ORCOR,MYG_GLOME,MYG_TURTR,MYG_CASFI,# & MYG_ESCGI,MYG_BALAC,MYG_MEGNO,MYG_PHYCA,MYG_BALPH,# & MYG_INIGE)# & PIR1: (MYWHK,MYDDBS,MYWHH,MYWHC,MYWHF,MYWHT,MYWHP,MYDD,MYDDAR,# & MYWHL)# & PIR2: (JN0410)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,NKALELFRKDIAAK*# SEQUENCE: NKALELFRKDIAAK*# ...# >HUM204CA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (132-143)# DB REFERENCE: SWISS: (MYG_ORCOR,MYG_MEGNO,MYG_CASFI,MYG_PHYCA,MYG_PHOPH,# & MYG_BALAC,MYG_TURTR,MYG_ESCGI,MYG_INIGE,MYG_BALPH,# & MYG_GLOME,MYG_PHYCA)# & PIR1: (MYDDBS,MYWHF,MYWHL,MYDDAR,MYWHK,MYWHC,MYPE,MYDD,MYWHH,# & MYWHT,MYPED,MYWHP)# & PIR2: (JN0410)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,NKALELFRKDIA*# SEQUENCE: NKALELFRKDIA*# ...# >HUM204CB# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-151)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP)# REFERENCES: o'sullivan91a,o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,NKALELFRKDIAAKYKELGY*# SEQUENCE: NKALELFRKDIAAKYKELGY*# ...# >HUM204CC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (134-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,ALELFRKDIAAKYKELGYGK*# SEQUENCE: ALELFRKDIAAKYKELGYGK*# ...# >HUM204CD# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (136-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,ELFRKDIAAKYKELGYGK*# SEQUENCE: ELFRKDIAAKYKELGYGK*# ...# >HUM204CE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (137-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,LFRKDIAAKYKELGYGK*# SEQUENCE: LFRKDIAAKYKELGYGK*# ...# >HUM204CF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (138-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,FRKDIAAKYKELGYGK*# SEQUENCE: FRKDIAAKYKELGYGK*# ...# >HUM204D0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (139-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,RKDIAAKYKELGYGK*# SEQUENCE: RKDIAAKYKELGYGK*# ...# >HUM204D1# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-153)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,NKALELFRKDIAAKYKELGYGK*# SEQUENCE: NKALELFRKDIAAKYKELGYGK*# ...# >HUM204D2# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-147)# DB REFERENCE: SWISS: (MYG_ESCGI,MYG_GLOME,MYG_PHYCA,MYG_CASFI,MYG_PHYCA,# & MYG_MEGNO,MYG_ORCOR,MYG_BALAC,MYG_INIGE,MYG_TURTR,# & MYG_BALPH)# & PIR1: (MYWHT,MYWHL,MYDDAR,MYDDBS,MYWHP,MYWHK,MYDD,MYWHH,MYWHF,# & MYWHC)# & PIR2: (JN0410)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,NKALELFRKDIAAKYK*# SEQUENCE: NKALELFRKDIAAKYK*# ...# >HUM204D3# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-146)# DB REFERENCE: SWISS: (MYG_BALAC,MYG_INIGE,MYG_PHYCA,MYG_CASFI,MYG_MEGNO,# & MYG_ORCOR,MYG_PHYCA,MYG_BALPH,MYG_TURTR,MYG_GLOME,# & MYG_ESCGI)# & PIR1: (MYWHT,MYWHP,MYDDBS,MYDD,MYWHL,MYDDAR,MYWHC,MYWHF,MYWHH,# & MYWHK)# & PIR2: (JN0410)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,NKALELFRKDIAAKY*# SEQUENCE: NKALELFRKDIAAKY*# ...# >HUM204D4# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (132-145)# DB REFERENCE: SWISS: (MYG_BALPH,MYG_GLOME,MYG_ORCOR,MYG_CASFI,MYG_BALAC,# & MYG_PHYCA,MYG_INIGE,MYG_MEGNO,MYG_PHYCA,MYG_TURTR,# & MYG_ESCGI)# & PIR1: (MYDDAR,MYDDBS,MYWHP,MYWHT,MYWHK,MYDD,MYWHH,MYWHC,MYWHF,# & MYWHL)# & PIR2: (JN0410)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesm,NKALELFRKDIAAK*# SEQUENCE: NKALELFRKDIAAK*# ...# >HUM204D5# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-151)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,NKALELFRKDIAAKYKELGY*# SEQUENCE: NKALELFRKDIAAKYKELGY*# ...# >HUM204D6# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (134-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,ALELFRKDIAAKYKELGYGK*# SEQUENCE: ALELFRKDIAAKYKELGYGK*# ...# >HUM204D7# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (136-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,ELFRKDIAAKYKELGYGK*# SEQUENCE: ELFRKDIAAKYKELGYGK*# ...# >HUM204D8# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (137-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,LFRKDIAAKYKELGYGK*# SEQUENCE: LFRKDIAAKYKELGYGK*# ...# >HUM204D9# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (138-151)# ANCHOR POSITIONS:# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,FRKDIAAKYKELGYGK*# SEQUENCE: FRKDIAAKYKELGYGK*# ...# >HUM204DA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,ILMQYIKANSKFIGITELKK*# SEQUENCE: ILMQYIKANSKFIGITELKK*# ...# >HUM204DB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,ILMQYIKANSKFIGITE*# SEQUENCE: ILMQYIKANSKFIGITE*# ...# >HUM204DC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-841)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,ILMQYIKANSKFIGI*# SEQUENCE: ILMQYIKANSKFIGI*# ...# >HUM204DD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,ILMQYIKANSKFIG*# SEQUENCE: ILMQYIKANSKFIG*# ...# >HUM204DE# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-839)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,ILMQYIKANSKFI*# SEQUENCE: ILMQYIKANSKFI*# ...# >HUM204DF# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (827-838)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,ILMQYIKANSKF*# SEQUENCE: ILMQYIKANSKF*# ...# >HUM204E0# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-837)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,ILMQYIKANSK*# SEQUENCE: ILMQYIKANSK*# ...# >HUM204E1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (830-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,QYIKANSKFIGITELKK*# SEQUENCE: QYIKANSKFIGITELKK*# ...# >HUM204E2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a,panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesl,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM204E3# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (827-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,ILMQYIKANSKFIGITELKK*# SEQUENCE: ILMQYIKANSKFIGITELKK*# ...# >HUM204E4# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (827-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,ILMQYIKANSKFIGITE*# SEQUENCE: ILMQYIKANSKFIGITE*# ...# >HUM204E5# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (827-841)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,ILMQYIKANSKFIGI*# SEQUENCE: ILMQYIKANSKFIGI*# ...# >HUM204E6# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ILMQYIKANSKFIG*# SEQUENCE: ILMQYIKANSKFIG*# ...# >HUM204E7# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-839)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ILMQYIKANSKFI*# SEQUENCE: ILMQYIKANSKFI*# ...# >HUM204E8# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-838)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ILMQYIKANSKF*# SEQUENCE: ILMQYIKANSKF*# ...# >HUM204E9# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (827-837)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,ILMQYIKANSK*# SEQUENCE: ILMQYIKANSK*# ...# >HUM204EA# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (830-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,QYIKANSKFIGITELKK*# SEQUENCE: QYIKANSKFIGITELKK*# ...# >HUM204EB# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (830-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,IKANSKFIGITELKK*# SEQUENCE: IKANSKFIGITELKK*# ...# >HUM204EC# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (830-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,ANSKFIGITELKK*# SEQUENCE: ANSKFIGITELKK*# ...# >HUM204ED# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as./proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a,panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR2,actyesm,bindyesm,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM204EE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,ILMQYIKANSKFIGITELKK*# SEQUENCE: ILMQYIKANSKFIGITELKK*# ...# >HUM204EF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,ILMQYIKANSKFIGITE*# SEQUENCE: ILMQYIKANSKFIGITE*# ...# >HUM204F0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (827-841)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,ILMQYIKANSKFIGI*# SEQUENCE: ILMQYIKANSKFIGI*# ...# >HUM204F1# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (827-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,ILMQYIKANSKFIG*# SEQUENCE: ILMQYIKANSKFIG*# ...# >HUM204F2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tetanus toxin tt (827-838)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,ILMQYIKANSKF*# SEQUENCE: ILMQYIKANSKF*# ...# >HUM204F3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (830-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,QYIKANSKFIGITELKK*# SEQUENCE: QYIKANSKFIGITELKK*# ...# >HUM204F4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tetanus toxin tt (830-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,IKANSKFIGITELKK*# SEQUENCE: IKANSKFIGITELKK*# ...# >HUM204F5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as./proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a,panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesl,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM204F6# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: tetanus toxin tt (830-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan91a,sidney92a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesl,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM204F7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (304-322)# DB REFERENCE: SWISS: (HEMA_IADHM,HEMA_IADH2,HEMA_IAME2,HEMA_IAEN6,HEMA_IAZUK,# & HEMA_IABAN,HEMA_IAUDO,HEMA_IADH3,HEMA_IAVI7,HEMA_IAEN7,# & HEMA_IAZCO,HEMA_IADU3,HEMA_IADH1,HEMA_IADH7,HEMA_IADH4,# & HEMA_IAZH2,HEMA_IAAIC,HEMA_IANT6,HEMA_IADH6,# & HEMA_IAQU7)# & PIR1: (HMIV33,HMIVHM,HMIVH,HMIV98,HMIV6,HMIV15,HMIVV,HMIVS3,# & HMIVDU,HMIV89,HMIV80,HMIVHA,HMIV77)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,GACPKYVKQNTLKLATGMR*# SEQUENCE: GACPKYVKQNTLKLATGMR*# ...# >HUM204F8# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (304-319)# DB REFERENCE: SWISS: (HEMA_IADH3,HEMA_IAZCO,HEMA_IAZH2,HEMA_IADH4,HEMA_IABAN,# & HEMA_IAZUK,HEMA_IADHM,HEMA_IAEN7,HEMA_IAUDO,HEMA_IAAIC,# & HEMA_IAQU7,HEMA_IANT6,HEMA_IADH6,HEMA_IADU3,HEMA_IADH1,# & HEMA_IADH7,HEMA_IAME2,HEMA_IAEN6,HEMA_IADH2,HEMA_IAME1,# & HEMA_IAVI7)# & PIR1: (HMIVH,HMIV98,HMIVDU,HMIVV,HMIVS3,HMIV15,HMIVHM,HMIV33,# & HMIV77,HMIV6,HMIVHA,HMIV80,HMIV89)# & PIR2: (JQ1156,A92979)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,GACPKYVKQNTLKLAT*# SEQUENCE: GACPKYVKQNTLKLAT*# ...# >HUM204F9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (304-318)# DB REFERENCE: SWISS: (HEMA_IADH1,HEMA_IADU3,HEMA_IAGHK,HEMA_IADH2,HEMA_IAME2,# & HEMA_IADHM,HEMA_IAEN7,HEMA_IAZH2,HEMA_IADH6,HEMA_IAQU7,# & HEMA_IANT6,HEMA_IAAIC,HEMA_IAUDO,HEMA_IADH3,HEMA_IAZUK,# & HEMA_IAME1,HEMA_IAVI7,HEMA_IADH4,HEMA_IAEN6,HEMA_IABAN,# & HEMA_IAZCO,HEMA_IADHL,HEMA_IADH7)# & PIR1: (HMIVH,HMIVHA,HMIV15,HMIVDU,HMIV6,HMIV77,HMIV89,HMIVHM,# & HMIV33,HMIV98,HMIV80,HMIVV,HMIVS3)# & PIR2: (JQ1154,JQ1156,JQ1155,A92979)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,GACPKYVKQNTLKLA*# SEQUENCE: GACPKYVKQNTLKLA*# ...# >HUM204FA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (304-317)# DB REFERENCE: SWISS: (HEMA_IAUDO,HEMA_IADH3,HEMA_IAZUK,HEMA_IABAN,HEMA_IADH2,# & HEMA_IAEN6,HEMA_IAME2,HEMA_IADH1,HEMA_IAZH2,HEMA_IADHM,# & HEMA_IADH7,HEMA_IADHL,HEMA_IAZCO,HEMA_IAME1,HEMA_IADH4,# & HEMA_IAVI7,HEMA_IAGHK,HEMA_IADU3,HEMA_IAQU7,HEMA_IAAIC,# & HEMA_IADH6,HEMA_IANT6,HEMA_IAEN7)# & PIR1: (HMIVS3,HMIVHA,HMIV98,HMIVH,HMIV33,HMIV77,HMIV6,HMIV15,# & HMIVHM,HMIVDU,HMIV80,HMIVV,HMIV89)# & PIR2: (JQ1154,A92979,JQ1156,JQ1155)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,GACPKYVKQNTLKL*# SEQUENCE: GACPKYVKQNTLKL*# ...# >HUM204FB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-322)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IAEN7,HEMA_IAAIC,HEMA_IAQU7,HEMA_IADU3,# & HEMA_IADH7,HEMA_IABAN,HEMA_IADH3,HEMA_IADH2,HEMA_IAME2,# & HEMA_IAVI7,HEMA_IAZCO,HEMA_IADH6,HEMA_IANT6,HEMA_IADHM,# & HEMA_IAZUK,HEMA_IAEN6,HEMA_IAUDO,HEMA_IADH1,# & HEMA_IAZH2)# & PIR1: (HMIVH,HMIV77,HMIV15,HMIVDU,HMIV33,HMIV80,HMIVV,HMIVHM,# & HMIV6,HMIVHA,HMIV98,HMIVS3,HMIV89)# & PIR2: (JQ1156,A92979)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PKYVKQNTLKLATGMR*# SEQUENCE: PKYVKQNTLKLATGMR*# ...# >HUM204FC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (308-322)# DB REFERENCE: SWISS: (HEMA_IANT6,HEMA_IADH1,HEMA_IAEN7,HEMA_IABAN,HEMA_IADU3,# & HEMA_IAZCO,HEMA_IAZUK,HEMA_IAQU7,HEMA_IAZH2,HEMA_IAEN6,# & HEMA_IADH3,HEMA_IAME2,HEMA_IADH6,HEMA_IADH2,HEMA_IAVI7,# & HEMA_IAUDO,HEMA_IADHM,HEMA_IAAIC,HEMA_IADH7,# & HEMA_IADH4)# & PIR1: (HMIVS3,HMIV80,HMIV6,HMIVHM,HMIVV,HMIV15,HMIVH,HMIVDU,# & HMIV77,HMIVHA,HMIV98,HMIV33,HMIV89)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,KYVKQNTLKLATGMR*# SEQUENCE: KYVKQNTLKLATGMR*# ...# >HUM204FD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (309-322)# DB REFERENCE: SWISS: (HEMA_IADH3,HEMA_IADH7,HEMA_IADH4,HEMA_IAEN6,HEMA_IAVI7,# & HEMA_IAZCO,HEMA_IAQU7,HEMA_IAZUK,HEMA_IAME6,HEMA_IAZH2,# & HEMA_IADH1,HEMA_IAEN7,HEMA_IADU3,HEMA_IAUDO,HEMA_IADH6,# & HEMA_IADH2,HEMA_IAAIC,HEMA_IABAN,HEMA_IANT6,HEMA_IADHM,# & HEMA_IAME2)# & PIR1: (HMIV77,HMIVHM,HMIVS3,HMIVV,HMIVH,HMIVDU,HMIV33,HMIV86,# & HMIVHA,HMIV89,HMIV15,HMIV6,HMIV80,HMIV98)# & PIR2: (S52185,JQ2374,S52199,S52188,S52182,S52174,JQ2378,S52189,# & JQ2375,S52197,S52195,S52176,S52186,S52173,A92979,S52183,# & S52191,S52180,S52179,JQ1156,S52187,S52175,S52178,JQ2377,# & S52198)# & PIR3: (S38637)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,YVKQNTLKLATGMR*# SEQUENCE: YVKQNTLKLATGMR*# ...# >HUM204FE# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (304-322)# DB REFERENCE: SWISS: (HEMA_IADU3,HEMA_IAAIC,HEMA_IADH2,HEMA_IAEN6,HEMA_IAZUK,# & HEMA_IAEN7,HEMA_IADH3,HEMA_IAME2,HEMA_IANT6,HEMA_IABAN,# & HEMA_IADHM,HEMA_IADH6,HEMA_IAUDO,HEMA_IAQU7,HEMA_IAZH2,# & HEMA_IADH1,HEMA_IAZCO,HEMA_IADH4,HEMA_IADH7,# & HEMA_IAVI7)# & PIR1: (HMIVH,HMIV89,HMIV77,HMIVS3,HMIVHM,HMIVHA,HMIV33,HMIV80,# & HMIV6,HMIV15,HMIV98,HMIVV,HMIVDU)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,GACPKYVKQNTLKLATGMR*# SEQUENCE: GACPKYVKQNTLKLATGMR*# ...# >HUM204FF# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (304-319)# DB REFERENCE: SWISS: (HEMA_IAZCO,HEMA_IAZH2,HEMA_IANT6,HEMA_IABAN,HEMA_IAME1,# & HEMA_IADH6,HEMA_IAEN7,HEMA_IAZUK,HEMA_IADU3,HEMA_IAEN6,# & HEMA_IADH1,HEMA_IAUDO,HEMA_IADH3,HEMA_IAVI7,HEMA_IAQU7,# & HEMA_IAAIC,HEMA_IADH4,HEMA_IADHM,HEMA_IAME2,HEMA_IADH2,# & HEMA_IADH7)# & PIR1: (HMIVHM,HMIVDU,HMIV89,HMIV77,HMIVV,HMIVS3,HMIV15,HMIV80,# & HMIV6,HMIV98,HMIVHA,HMIVH,HMIV33)# & PIR2: (JQ1156,A92979)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,GACPKYVKQNTLKLAT*# SEQUENCE: GACPKYVKQNTLKLAT*# ...# >HUM20500# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (304-318)# DB REFERENCE: SWISS: (HEMA_IAGHK,HEMA_IAZCO,HEMA_IAVI7,HEMA_IADH7,HEMA_IADHL,# & HEMA_IAEN7,HEMA_IAAIC,HEMA_IANT6,HEMA_IADH6,HEMA_IABAN,# & HEMA_IAQU7,HEMA_IADH4,HEMA_IADHM,HEMA_IAME2,HEMA_IADH2,# & HEMA_IAUDO,HEMA_IADH1,HEMA_IADH3,HEMA_IAEN6,HEMA_IADU3,# & HEMA_IAZUK,HEMA_IAZH2,HEMA_IAME1)# & PIR1: (HMIVHM,HMIV33,HMIV89,HMIVH,HMIV77,HMIV98,HMIV80,HMIV6,# & HMIVV,HMIV15,HMIVS3,HMIVHA,HMIVDU)# & PIR2: (JQ1156,JQ1154,JQ1155,A92979)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,GACPKYVKQNTLKLA*# SEQUENCE: GACPKYVKQNTLKLA*# ...# >HUM20501# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (304-317)# DB REFERENCE: SWISS: (HEMA_IAZUK,HEMA_IAME1,HEMA_IAEN6,HEMA_IADH3,HEMA_IAUDO,# & HEMA_IADHM,HEMA_IAME2,HEMA_IADH2,HEMA_IABAN,HEMA_IAGHK,# & HEMA_IAZCO,HEMA_IAVI7,HEMA_IADHL,HEMA_IAEN7,HEMA_IANT6,# & HEMA_IADH7,HEMA_IAZH2,HEMA_IAAIC,HEMA_IADH4,HEMA_IADU3,# & HEMA_IAQU7,HEMA_IADH6,HEMA_IADH1)# & PIR1: (HMIV98,HMIV80,HMIV77,HMIVDU,HMIV6,HMIV15,HMIVHA,HMIVS3,# & HMIVV,HMIVH,HMIVHM,HMIV33,HMIV89)# & PIR2: (A92979,JQ1154,JQ1155,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,GACPKYVKQNTLKL*# SEQUENCE: GACPKYVKQNTLKL*# ...# >HUM20502# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (304-316)# DB REFERENCE: SWISS: (HEMA_IAZH2,HEMA_IAGHK,HEMA_IAME1,HEMA_IADH4,HEMA_IAEN7,# & HEMA_IADHM,HEMA_IAUDO,HEMA_IADH3,HEMA_IAVI7,HEMA_IADH1,# & HEMA_IAAIC,HEMA_IADU3,HEMA_IAQU7,HEMA_IADH6,HEMA_IANT6,# & HEMA_IADH7,HEMA_IAZCO,HEMA_IADHL,HEMA_IABAN,HEMA_IAZUK,# & HEMA_IAEN6,HEMA_IAME2,HEMA_IADH2)# & PIR1: (HMIVHM,HMIV98,HMIV77,HMIV80,HMIVHA,HMIV15,HMIV6,HMIVDU,# & HMIVS3,HMIVV,HMIVH,HMIV33,HMIV89)# & PIR2: (JQ1154,JQ1155,A92979,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,GACPKYVKQNTLK*# SEQUENCE: GACPKYVKQNTLK*# ...# >HUM20503# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-322)# DB REFERENCE: SWISS: (HEMA_IAZCO,HEMA_IABAN,HEMA_IAME2,HEMA_IADH2,HEMA_IAEN6,# & HEMA_IANT6,HEMA_IADH1,HEMA_IADH6,HEMA_IAQU7,HEMA_IAAIC,# & HEMA_IADHM,HEMA_IAUDO,HEMA_IAVI7,HEMA_IADH4,HEMA_IADH7,# & HEMA_IADU3,HEMA_IADH3,HEMA_IAEN7,HEMA_IAZUK,# & HEMA_IAZH2)# & PIR1: (HMIV77,HMIV80,HMIVHA,HMIV15,HMIV98,HMIV33,HMIVV,HMIVH,# & HMIV89,HMIVS3,HMIVHM,HMIVDU,HMIV6)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,PKYVKQNTLKLATGMR*# SEQUENCE: PKYVKQNTLKLATGMR*# ...# >HUM20504# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (308-322)# DB REFERENCE: SWISS: (HEMA_IAZCO,HEMA_IAZH2,HEMA_IADH7,HEMA_IAVI7,HEMA_IAUDO,# & HEMA_IADHM,HEMA_IADH1,HEMA_IAEN6,HEMA_IAME2,HEMA_IAZUK,# & HEMA_IADU3,HEMA_IAEN7,HEMA_IADH3,HEMA_IADH4,HEMA_IAAIC,# & HEMA_IAQU7,HEMA_IADH6,HEMA_IADH2,HEMA_IABAN,# & HEMA_IANT6)# & PIR1: (HMIVHM,HMIVV,HMIV89,HMIV77,HMIVHA,HMIV6,HMIV98,HMIV15,# & HMIV33,HMIVDU,HMIVS3,HMIVH,HMIV80)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,KYVKQNTLKLATGMR*# SEQUENCE: KYVKQNTLKLATGMR*# ...# >HUM20505# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hemagglutinin (309-322)# DB REFERENCE: SWISS: (HEMA_IAAIC,HEMA_IADH6,HEMA_IAQU7,HEMA_IADH4,HEMA_IAME6,# & HEMA_IAEN7,HEMA_IADU3,HEMA_IAEN6,HEMA_IADH7,HEMA_IADHM,# & HEMA_IABAN,HEMA_IADH3,HEMA_IAZUK,HEMA_IAVI7,HEMA_IAUDO,# & HEMA_IAZH2,HEMA_IADH1,HEMA_IAME2,HEMA_IAZCO,HEMA_IANT6,# & HEMA_IADH2)# & PIR1: (HMIVDU,HMIV33,HMIVH,HMIV80,HMIV77,HMIV89,HMIVHA,HMIV86,# & HMIVV,HMIV15,HMIV6,HMIVS3,HMIVHM,HMIV98)# & PIR2: (JQ2378,S52199,S52186,S52173,A92979,S52189,JQ1156,S52183,# & S52188,S52195,S52198,JQ2377,S52176,S52179,S52185,JQ2374,# & S52174,S52178,JQ2375,S52197,S52187,S52175,S52180,S52182,# & S52191)# & PIR3: (S38637)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,YVKQNTLKLATGMR*# SEQUENCE: YVKQNTLKLATGMR*# ...# >HUM20506# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (304-322)# DB REFERENCE: SWISS: (HEMA_IANT6,HEMA_IADH6,HEMA_IAEN6,HEMA_IAUDO,HEMA_IAZUK,# & HEMA_IADHM,HEMA_IADH2,HEMA_IADH3,HEMA_IADH1,HEMA_IAVI7,# & HEMA_IAME2,HEMA_IAZCO,HEMA_IAZH2,HEMA_IABAN,HEMA_IADH7,# & HEMA_IADH4,HEMA_IAAIC,HEMA_IAQU7,HEMA_IADU3,# & HEMA_IAEN7)# & PIR1: (HMIV15,HMIVV,HMIVS3,HMIV6,HMIV80,HMIV77,HMIV33,HMIVH,# & HMIVDU,HMIVHM,HMIV98,HMIVHA,HMIV89)# & PIR2: (JQ1156,A92979)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,GACPKYVKQNTLKLATGMR*# SEQUENCE: GACPKYVKQNTLKLATGMR*# ...# >HUM20507# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (304-319)# DB REFERENCE: SWISS: (HEMA_IADH7,HEMA_IADH4,HEMA_IADU3,HEMA_IAEN7,HEMA_IAVI7,# & HEMA_IADH3,HEMA_IAZH2,HEMA_IAME1,HEMA_IADH6,HEMA_IAEN6,# & HEMA_IAZUK,HEMA_IAZCO,HEMA_IADH1,HEMA_IADH2,HEMA_IADHM,# & HEMA_IAME2,HEMA_IANT6,HEMA_IAUDO,HEMA_IABAN,HEMA_IAQU7,# & HEMA_IAAIC)# & PIR1: (HMIVHM,HMIV98,HMIVS3,HMIVHA,HMIV89,HMIV6,HMIVDU,HMIVV,# & HMIV15,HMIV77,HMIV33,HMIV80,HMIVH)# & PIR2: (JQ1156,A92979)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,GACPKYVKQNTLKLAT*# SEQUENCE: GACPKYVKQNTLKLAT*# ...# >HUM20508# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (304-318)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IAAIC,HEMA_IADH2,HEMA_IAME2,HEMA_IAEN7,# & HEMA_IAGHK,HEMA_IABAN,HEMA_IADHL,HEMA_IAME1,HEMA_IAEN6,# & HEMA_IADH6,HEMA_IADH3,HEMA_IAUDO,HEMA_IANT6,HEMA_IAQU7,# & HEMA_IADH7,HEMA_IADU3,HEMA_IAVI7,HEMA_IAZH2,HEMA_IAZUK,# & HEMA_IADHM,HEMA_IADH1,HEMA_IAZCO)# & PIR1: (HMIVHM,HMIV89,HMIVH,HMIVHA,HMIV77,HMIV15,HMIV33,HMIV80,# & HMIV98,HMIVDU,HMIVS3,HMIV6,HMIVV)# & PIR2: (JQ1154,JQ1156,A92979,JQ1155)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,GACPKYVKQNTLKLA*# SEQUENCE: GACPKYVKQNTLKLA*# ...# >HUM20509# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (307-322)# DB REFERENCE: SWISS: (HEMA_IADH6,HEMA_IAZH2,HEMA_IANT6,HEMA_IADHM,HEMA_IADH7,# & HEMA_IADH2,HEMA_IABAN,HEMA_IAEN7,HEMA_IAZUK,HEMA_IAVI7,# & HEMA_IAUDO,HEMA_IAZCO,HEMA_IAQU7,HEMA_IADH3,HEMA_IAEN6,# & HEMA_IAME2,HEMA_IADH1,HEMA_IADU3,HEMA_IADH4,# & HEMA_IAAIC)# & PIR1: (HMIV33,HMIV6,HMIVS3,HMIVV,HMIVH,HMIVHA,HMIV77,HMIV98,# & HMIVDU,HMIV15,HMIVHM,HMIV80,HMIV89)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,PKYVKQNTLKLATGMR*# SEQUENCE: PKYVKQNTLKLATGMR*# ...# >HUM2050A# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (308-322)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IAAIC,HEMA_IAEN6,HEMA_IADH3,HEMA_IAQU7,# & HEMA_IADHM,HEMA_IAZCO,HEMA_IADH2,HEMA_IAEN7,HEMA_IADH7,# & HEMA_IAVI7,HEMA_IADU3,HEMA_IAME2,HEMA_IADH1,HEMA_IADH6,# & HEMA_IABAN,HEMA_IAZH2,HEMA_IANT6,HEMA_IAUDO,# & HEMA_IAZUK)# & PIR1: (HMIV33,HMIVS3,HMIV77,HMIVV,HMIVH,HMIVHM,HMIV89,HMIV80,# & HMIVDU,HMIV98,HMIV15,HMIVHA,HMIV6)# & PIR2: (A92979,JQ1156)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,KYVKQNTLKLATGMR*# SEQUENCE: KYVKQNTLKLATGMR*# ...# >HUM2050B# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (309-322)# DB REFERENCE: SWISS: (HEMA_IAVI7,HEMA_IAME2,HEMA_IADU3,HEMA_IANT6,HEMA_IAUDO,# & HEMA_IAZUK,HEMA_IADH2,HEMA_IAZCO,HEMA_IADHM,HEMA_IADH3,# & HEMA_IAQU7,HEMA_IADH4,HEMA_IAEN7,HEMA_IADH7,HEMA_IAEN6,# & HEMA_IAME6,HEMA_IABAN,HEMA_IADH6,HEMA_IADH1,HEMA_IAAIC,# & HEMA_IAZH2)# & PIR1: (HMIV6,HMIVDU,HMIV80,HMIV89,HMIV15,HMIVHA,HMIV33,HMIV86,# & HMIV77,HMIVS3,HMIVH,HMIV98,HMIVHM,HMIVV)# & PIR2: (S52188,S52183,S52189,S52173,A92979,S52186,S52199,S52185,# & S52174,JQ2375,S52178,S52195,S52182,JQ2374,S52197,S52187,# & S52175,S52179,JQ2377,S52180,S52198,JQ2378,JQ1156,S52191,# & S52176)# & PIR3: (S38637)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,YVKQNTLKLATGMR*# SEQUENCE: YVKQNTLKLATGMR*# ...# >HUM2050C# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hemagglutinin (310-322)# DB REFERENCE: SWISS: (HEMA_IAZH2,HEMA_IAAIC,HEMA_IADH4,HEMA_IANT6,HEMA_IAQU7,# & HEMA_IAVI7,HEMA_IAUDO,HEMA_IADU3,HEMA_IADH7,HEMA_IABAN,# & HEMA_IADH6,HEMA_IADH1,HEMA_IAME2,HEMA_IADH3,HEMA_IAZUK,# & HEMA_IADHM,HEMA_IADH2,HEMA_IAZCO,HEMA_IAME6,HEMA_IAEN7,# & HEMA_IAEN6)# & PIR1: (HMIV80,HMIVHA,HMIV89,HMIV98,HMIV77,HMIVH,HMIVV,HMIVHM,# & HMIVS3,HMIVDU,HMIV6,HMIV86,HMIV33,HMIV15)# & PIR2: (JQ2374,S52182,S52197,JQ2375,S52188,S52189,JQ1156,S52198,# & S52180,S52195,S52173,A92979,S52175,S52174,S52185,S52187,# & S52191,S52176,S52186,S52199,S52183,S52178,S52179,JQ2377,# & JQ2378)# & PIR3: (S38637)# REFERENCES: o'sullivan91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,VKQNTLKLATGMR*# SEQUENCE: VKQNTLKLATGMR*# ...# >MUS2050D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding/stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Ova(323-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: hunt92b,buus87a,sette87a,marrack93a,altuvia94a,sette89b,# & alexander94a,feng94a,lock91a,smilek90a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesh,ISQAVHAAHAEINEAGR*# SEQUENCE: ISQAVHAAHAEINEAGR*# ...# >MUS2050E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding/direct binding# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Ha(130-142)# ANCHOR POSITIONS:# REFERENCES: buus87a,choppin90a,altuvia94a,sette89b# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesh,HNTNGVTAACSHE*# SEQUENCE: HNTNGVTAACSHE*# ...# >MUS2050F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding/direct binding# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Lambda repr(12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: buus87a,choppin90a,altuvia94a,sette89b,lock91a,sauzet96a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesm,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >MUS20510# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as./binding as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: HEL(46-61)# DB REFERENCE: SWISS: (LYC1_ANAPL,LYC_CHICK,LYC_SYRRE,LYC_CHRAM,LYC1_TACAC,# & LYC_PHAVE,LYC_CHICK,LYC_MELGA,LYC_PHACO,LYC_LOPLE,# & LYC_PAVCR)# & PIR1: (LZCH,LZDK,LZFER,LZTK,LZQJE)# & PIR2: (A61281,JQ1041,JU0178,A45660,JH0211,JH0212,JU0237,JT0526,# & JQ1033,JC2144)# REFERENCES: buus87a,sette89b,alexander94a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesl,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >MUS20511# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HEL(74-86)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPCA,LYC_PAVCR,LYC_COLVI,LYC_MELGA,# & LYC_CHICK)# & PIR1: (LZTK,LZQJEC,LZQJE,LZCH)# & PIR2: (JC2144,JU0237,JT0526)# REFERENCES: buus87a,sette89b# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesm,NLCNIPCSALLSS*# SEQUENCE: NLCNIPCSALLSS*# ...# >MUS20512# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: HEL(81-96)# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_CHICK,LYC_SYRRE,LYC_PHACO,LYC_CHICK,# & LYC_MELGA,LYC_PHAVE,LYC_CHRAM,LYC_LOPLE)# & PIR1: (LZTK,LZCH,LZFER,LZQJE)# & PIR2: (JT0526,JU0237,JQ1041,JU0178,JH0211,JQ1033,JH0212)# REFERENCES: buus87a,sette89b# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesl,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >MUS20513# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: p Cytc(88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: buus87a,sette89b# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesm,KAERADLIAYLKQATAK*# SEQUENCE: KAERADLIAYLKQATAK*# ...# >MUS20514# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Lambda repr(12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: buus87a,sette89b,rammensee95a,villadangos95a,vaysburd95a,# & schild95a,lock91,schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesh,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >MUS20515# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding/competitive binding/binding as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: HEL(46-61)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_SYRRE,LYC_PAVCR,LYC1_TACAC,LYC_PHACO,# & LYC_CHICK,LYC_CHRAM,LYC_CHICK,LYC_MELGA,LYC1_ANAPL,# & LYC_LOPLE)# & PIR1: (LZQJE,LZDK,LZTK,LZFER,LZCH)# & PIR2: (JH0212,JH0211,JU0178,JQ1041,A45660,JU0237,JT0526,A61281,# & JC2144,JQ1033)# REFERENCES: buus87a,sette89b,alexander94a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesl,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >MUS20516# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Ha(111-122)# DB REFERENCE: SWISS: (HEMA_IATAI,HEMA_IAHAR,HEMA_IAPUE,HEMA_IAXIA)# & PIR1: (HMIV,HMIVTA)# & PIR2: (JQ2370,JQ1643,PQ0319,JQ2371,JQ2372,JQ1437,A35788,# & PQ0321)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesm,FERFEIFPKESS*# SEQUENCE: FERFEIFPKESS*# ...# >MUS20517# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Myo(132-153)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP)# REFERENCES: buus87a,sette89b# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesh,NKALELFRKDIAAKYKELGYQG*# SEQUENCE: NKALELFRKDIAAKYKELGYQG*# ...# >MUS20518# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: HSV(8-23)# DB REFERENCE: SWISS: (VGLD_HSV11,VGLD_HSV1H,VLGD_HSV1A)# & PIR1: (A47627,VGBED1,VGBE17,VGBEDZ)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesm,SLKMADPNRFRGKDLP*# SEQUENCE: SLKMADPNRFRGKDLP*# ...# >MUS20519# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: p Cytc(88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesl,KAERADLIAYLKQATAK*# SEQUENCE: KAERADLIAYLKQATAK*# ...# >MUS2051A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: m Cytc(88-103)# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: buus87a,sette89b# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesm,ANERADLIAYLKQATK*# SEQUENCE: ANERADLIAYLKQATK*# ...# >MUS2051B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: Ova(323-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesm,ISQAVHAAHAEINEAGR*# SEQUENCE: ISQAVHAAHAEINEAGR*# ...# >MUS2051C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: none# BINDING: yes, high# SOURCE: Ha(130-142)# ANCHOR POSITIONS:# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesh,HNTNGVTAACSHE*# SEQUENCE: HNTNGVTAACSHE*# ...# >MUS2051D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: Myo(106-118)# DB REFERENCE: SWISS: (MYG_KOGSI,MYG_PHOPH,MYG_GLOME,MYG_PHYCA,MYG_INIGE,# & MYG_ORCOR,MYG_PHYCA,MYG_TURTR)# & PIR1: (MYWHT,MYWHP,MYPE,MYWHL,MYPED,MYDDAR,MYDDBS,MYDD,MYWHW)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesm,FISEAIIHVLHSR*# SEQUENCE: FISEAIIHVLHSR*# ...# >MUS2051E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competition/direct binding/Reference/Recognition/Proliferation# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HEL (46-61)# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_CHICK,LYC_CHRAM,LYC_PHACO,LYC1_ANAPL,# & LYC_MELGA,LYC_CHICK,LYC_PHAVE,LYC_SYRRE,LYC1_TACAC,# & LYC_LOPLE)# & PIR1: (LZFER,LZTK,LZCH,LZQJE,LZDK)# & PIR2: (A61281,JH0211,JQ1033,JC2144,JQ1041,A45660,JU0237,JT0526,# & JU0178,JH0212)# REFERENCES: buus87a,choppin90a,marrack93a,vignali94a,bauer95a,alexander94a# & adorini93a,feng94a,guery92a,smilek90a# COMMENT:# SUMMARY: I-Ak,actyesm,bindyesh,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >MUS2051F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding/proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (46-61)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPCA,LYC_PAVCR,LYC_CHICK,LYC_COLVI,# & LYC_MELGA)# & PIR1: (LZCH,LZTK,LZQJE,LZQJEC)# & PIR2: (JT0526,JU0237,JC2144)# REFERENCES: buus87a,shastri85a,altuvia94a,bauer95a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,NLCNIPCSALLSS*# SEQUENCE: NLCNIPCSALLSS*# ...# >MUS20520# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HEL(81-96)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_MELGA,LYC_PHACO,LYC_LOPLE,LYC_PHAVE,# & LYC_PAVCR,LYC_CHICK,LYC_CHRAM,LYC_SYRRE)# & PIR1: (LZTK,LZCH,LZQJE,LZFER)# & PIR2: (JU0237,JH0211,JQ1033,JH0212,JU0178,JQ1041,JT0526)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesm,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >MUS20521# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: p Cytc(88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesm,KAERADLIAYLKQATAK*# SEQUENCE: KAERADLIAYLKQATAK*# ...# >MUS20522# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Ova(323-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesl,ISQAVHAAHAEINEAGR*# SEQUENCE: ISQAVHAAHAEINEAGR*# ...# >MUS20523# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: Myo(106-118)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_INIGE,MYG_PHOPH,MYG_KOGSI,MYG_PHYCA,# & MYG_GLOME,MYG_TURTR,MYG_ORCOR)# & PIR1: (MYWHL,MYDDAR,MYWHW,MYPED,MYPE,MYWHT,MYWHP,MYDDBS,MYDD)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesl,FISEAIIHVLHSR*# SEQUENCE: FISEAIIHVLHSR*# ...# >MUS20524# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Lambda repr (12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: buus87a,marrack93a,altuvia94a,lock91a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesm,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >MUS20525# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HEL(46-61)# DB REFERENCE: SWISS: (LYC_MELGA,LYC_CHICK,LYC1_ANAPL,LYC_CHICK,LYC_PHACO,# & LYC_SYRRE,LYC_PAVCR,LYC_CHRAM,LYC1_TACAC,LYC_PHAVE,# & LYC_LOPLE)# & PIR1: (LZDK,LZQJE,LZFER,LZTK,LZCH)# & PIR2: (JC2144,JH0211,JQ1033,JT0526,JQ1041,A61281,A45660,JH0212,# & JU0237,JU0178)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesl,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >MUS20526# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HEL(81-96)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_MELGA,LYC_CHICK,LYC_CHICK,LYC_PHACO,# & LYC_SYRRE,LYC_PAVCR,LYC_CHRAM,LYC_LOPLE)# & PIR1: (LZCH,LZQJE,LZFER,LZTK)# & PIR2: (JQ1041,JU0237,JH0211,JQ1033,JH0212,JU0178,JT0526)# REFERENCES: buus87a,marrack93a,altuvia94a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesh,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >MUS20527# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: Ha(111-122)# DB REFERENCE: SWISS: (HEMA_IAPUE,HEMA_IAHAR,HEMA_IATAI,HEMA_IAXIA)# & PIR1: (HMIV,HMIVTA)# & PIR2: (JQ1437,JQ2370,PQ0321,JQ2371,JQ1643,PQ0319,A35788,# & JQ2372)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesl,FERFEIFPKESS*# SEQUENCE: FERFEIFPKESS*# ...# >MUS20528# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: Myo(132-153)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesm,NKALELFRKDIAAKYKELGYQG*# SEQUENCE: NKALELFRKDIAAKYKELGYQG*# ...# >MUS20529# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: HSV gD (8-23)# DB REFERENCE: SWISS: (VGLD_HSV1H,VLGD_HSV1A,VGLD_HSV11)# & PIR1: (VGBE17,VGBED1,A47627,VGBEDZ)# REFERENCES: buus87a,altuvia94a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesl,SLKMADPNRFRGKDLP*# SEQUENCE: SLKMADPNRFRGKDLP*# ...# >MUS2052A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding/stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: p Cytc(88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: buus87a,marrack93a,la-face97a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesh,KAERADLIAYLKQATAK*# SEQUENCE: KAERADLIAYLKQATAK*# ...# >MUS2052B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive inhibitory binding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: m Cytc(88-103)# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: buus87a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesh,ANERADLIAYLKQATK*# SEQUENCE: ANERADLIAYLKQATK*# ...# >MUS2052C# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: competitive binding/proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HEL(81-96)# DB REFERENCE: SWISS: (LYC_MELGA,LYC_PAVCR,LYC_PHACO,LYC_CHICK,LYC_LOPLE,# & LYC_CHRAM,LYC_CHICK,LYC_SYRRE,LYC_PHAVE)# & PIR1: (LZFER,LZCH,LZTK,LZQJE)# & PIR2: (JQ1041,JH0212,JT0526,JH0211,JQ1033,JU0237,JU0178)# REFERENCES: buus87a,shastri85a,altuvia94a,sette89b# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesh,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >HUM2052D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Ragweed allergen Ra3 (51-65)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a,sidney92a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesm,EVWREEAYHAADIKD*# SEQUENCE: EVWREEAYHAADIKD*# ...# >HUM2052E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Tet tox TT (947-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,FNNFTVSFWLRVPKVSASHLE*# SEQUENCE: FNNFTVSFWLRVPKVSASHLE*# ...# >HUM2052F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ML (240-259)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,TLLQAAPALDKY*# SEQUENCE: TLLQAAPALDKY*# ...# >HUM20530# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV (245-260)# DB REFERENCE: SWISS: (VLGD_HSV1A,VGLD_HSV11)# & PIR1: (A47627,VGBED1,VGBE17)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,APYTSTLLPPELSETP*# SEQUENCE: APYTSTLLPPELSETP*# ...# >HUM20531# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: OVA homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YTYTVHAAHAYTYT*# SEQUENCE: YTYTVHAAHAYTYT*# ...# >HUM20532# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza hemagglutinin (187-206)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RTLYQNVGTYVSVGTSTLNK*# SEQUENCE: RTLYQNVGTYVSVGTSTLNK*# ...# >HUM20533# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chicken OVA (15-29)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,DVFKELKVHHANENI*# SEQUENCE: DVFKELKVHHANENI*# ...# >HUM20534# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza hemagglutinin (302-313)# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,CPKYVRSAKLRM*# SEQUENCE: CPKYVRSAKLRM*# ...# >HUM20535# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bacteriophage A (12-26)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,YLEDARRLKAIYEKKK*# SEQUENCE: YLEDARRLKAIYEKKK*# ...# >HUM20536# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: OVA homologue# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,YTYTVHAAHAYTYT*# SEQUENCE: YTYTVHAAHAYTYT*# ...# >HUM20537# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myelin basic protein (75-98)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_MOUSE)# & PIR1: (MBMSB,MBHUB)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,GRTQDENPVVHFFKNIVTPRTPPP*# SEQUENCE: GRTQDENPVVHFFKNIVTPRTPPP*# ...# >HUM20538# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chicken OVA (15-29)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DVFKELKVHHANENI*# SEQUENCE: DVFKELKVHHANENI*# ...# >HUM20539# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV gd (8-23)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SLKMADPNRFKGKDLP*# SEQUENCE: SLKMADPNRFKGKDLP*# ...# >HUM2053A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza hemagglutinin (302-313)# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,CPKYVRSAKLRM*# SEQUENCE: CPKYVRSAKLRM*# ...# >HUM2053B# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myelin basic protein (75-98)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_MOUSE)# & PIR1: (MBHUB,MBMSB)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,GRTQDENPVVHFFKNIVTPRTPPP*# SEQUENCE: GRTQDENPVVHFFKNIVTPRTPPP*# ...# >HUM2053C# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chicken OVA (15-29)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DVFKELKVHHANENI*# SEQUENCE: DVFKELKVHHANENI*# ...# >HUM2053D# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza hemagglutinin (302-313)# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,CPKYVRSAKLRM*# SEQUENCE: CPKYVRSAKLRM*# ...# >HUM2053E# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sperm whale myoglobin (132-151)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,NKALELFRKDIAAKYKELGY*# SEQUENCE: NKALELFRKDIAAKYKELGY*# ...# >HUM2053F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (1-18)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_NUMME,LYC_CHICK,LYC_LOPCA,LYC_COLVI)# & PIR1: (LZCH,LZUH,LZQJEC)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KVFGRCELAAAMKRHGLD*# SEQUENCE: KVFGRCELAAAMKRHGLD*# ...# >HUM20540# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (20-41)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,DNYRGYSLGNWVCAAKFESNFTQ*# SEQUENCE: DNYRGYSLGNWVCAAKFESNFTQ*# ...# >HUM20541# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (112-129)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZCH)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RNRCKGTDVQAWIRGCRL*# SEQUENCE: RNRCKGTDVQAWIRGCRL*# ...# >HUM20542# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (1-18)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_NUMME,LYC_CHICK,LYC_COLVI,LYC_LOPCA)# & PIR1: (LZUH,LZQJEC,LZCH)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,KVFGRCELAAAMKRHGLD*# SEQUENCE: KVFGRCELAAAMKRHGLD*# ...# >HUM20543# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (8-29)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_NUMME,LYC_CHICK,LYC_CHICK,LYC_LOPCA)# & PIR1: (LZQJEC,LZUH,LZCH)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,LAAAMKRHGLDNYRGYSLGNWV*# SEQUENCE: LAAAMKRHGLDNYRGYSLGNWV*# ...# >HUM20544# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (20-41)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DNYRGYSLGNWVCAAKFESNFTQ*# SEQUENCE: DNYRGYSLGNWVCAAKFESNFTQ*# ...# >HUM20545# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (107-116)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPCA,LYC_MELGA,LYC_LOPLE,LYC_CHICK,# & LYC_COTJA,LYC_SYRRE,LYC_CHRAM,LYC_PAVCR,LYC_COLVI,# & LYC3_ANAPL)# & PIR1: (LZTK,LZQJEC,LZDK3,LZQJE,LZCH)# & PIR2: (JT0526,JQ1033,JU0237,JQ1041)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,AWVAWRNRCK*# SEQUENCE: AWVAWRNRCK*# ...# >HUM20546# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (112-129)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZCH)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,RNRCKGTDVQAWIRGCRL*# SEQUENCE: RNRCKGTDVQAWIRGCRL*# ...# >HUM20547# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (1-18)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_CHICK,LYC_LOPCA,LYC_CHICK,LYC_COLVI)# & PIR1: (LZUH,LZCH,LZQJEC)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,KVFGRCELAAAMKRHGLD*# SEQUENCE: KVFGRCELAAAMKRHGLD*# ...# >HUM20548# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (8-29)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_NUMME,LYC_LOPCA,LYC_COLVI,LYC_CHICK)# & PIR1: (LZQJEC,LZCH,LZUH)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,LAAAMKRHGLDNYRGYSLGNWV*# SEQUENCE: LAAAMKRHGLDNYRGYSLGNWV*# ...# >HUM20549# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (91-106)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR2: (JU0178)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,SVNCAKKIVSDGDGMN*# SEQUENCE: SVNCAKKIVSDGDGMN*# ...# >HUM2054A# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (51-66)# DB REFERENCE: SWISS: (LYC_PHACO,LYC_ORTVE,LYC_SYRRE,LYC_CHRAM,LYC_CHICK,# & LYC_PAVCR,LYC_PHAVE,LYC_CHICK,LYC_LOPLE,LYC_MELGA)# & PIR1: (LZTK,LZOVE,LZQJE,LZCH)# & PIR2: (JU0237,JT0526,JQ1033,JU0178,JQ1041,JC2144)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,TDYGILQINSRWWCND*# SEQUENCE: TDYGILQINSRWWCND*# ...# >HUM2054B# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (81-96)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_PHAVE,LYC_LOPLE,LYC_CHRAM,LYC_MELGA,# & LYC_PAVCR,LYC_CHICK,LYC_CHICK,LYC_PHACO)# & PIR1: (LZQJE,LZTK,LZCH,LZFER)# & PIR2: (JH0212,JU0237,JQ1033,JH0211,JQ1041,JT0526,JU0178)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >HUM2054C# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (91-106)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR2: (JU0178)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,SVNCAKKIVSDGDGMN*# SEQUENCE: SVNCAKKIVSDGDGMN*# ...# >HUM2054D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2Mm microglobulin (7-22)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,IQWSRHPPENGKPNI*# SEQUENCE: IQWSRHPPENGKPNI*# ...# >HUM2054E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2Mm microglobulin (25-40)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: o'sullivan90a,sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,CYVTQFHPPHIEIQML*# SEQUENCE: CYVTQFHPPHIEIQML*# ...# >HUM2054F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2Mm microglobulin (31-46)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,HPPHIEIQMLKNGKKI*# SEQUENCE: HPPHIEIQMLKNGKKI*# ...# >HUM20550# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding/binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B2Mm microglobulin (61-76)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE,B2MG_RAT,B2MG_RAT,B2MG_MUSSP)# & PIR1: (MGMSB2,A26842)# & PIR2: (I84730)# REFERENCES: o'sullivan90a,sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,SFYILAHTEFTPTETD*# SEQUENCE: SFYILAHTEFTPTETD*# ...# >HUM20551# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2Mm microglobulin (31-46)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,HPPHIEIQMLKNGKKI*# SEQUENCE: HPPHIEIQMLKNGKKI*# ...# >HUM20552# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding/binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B2Mm microglobulin (37-52)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: o'sullivan90a,sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,IQMLKNGKKIPKVEMS*# SEQUENCE: IQMLKNGKKIPKVEMS*# ...# >HUM20553# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding /binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B2Mm microglobulin (1-16)# DB REFERENCE: SWISS: (B2MG_RAT,B2MG_RAT,B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (A26842,MGMSB2)# REFERENCES: o'sullivan90a,sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,IQKTPQIQVYSRHPPE*# SEQUENCE: IQKTPQIQVYSRHPPE*# ...# >HUM20554# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2Mm microglobulin (31-46)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,HPPHIEIQMLKNGKKI*# SEQUENCE: HPPHIEIQMLKNGKKI*# ...# >HUM20555# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding /binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2Mm microglobulin (37-52)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: o'sullivan90a,sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,IQMLKNGKKIPKVEMS*# SEQUENCE: IQMLKNGKKIPKVEMS*# ...# >HUM20556# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2Mm microglobulin (49-64)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,VEMSDMSFSKDWSFYI*# SEQUENCE: VEMSDMSFSKDWSFYI*# ...# >HUM20557# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2Mm microglobulin (55-70)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE,B2MG_RAT,B2MG_MUSSP,B2MG_RAT,# & B2MG_MUSCR)# & PIR1: (A26842,MGMSB2)# & PIR2: (I84730)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,SFSKDWSFYILAHTEF*# SEQUENCE: SFSKDWSFYILAHTEF*# ...# >HUM20558# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (19-34)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,NELGRFKHTDACCRTH*# SEQUENCE: NELGRFKHTDACCRTH*# ...# >HUM20559# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (73-88)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SSYFVGKMYFNLINTK*# SEQUENCE: SSYFVGKMYFNLINTK*# ...# >HUM2055A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (79-94)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KMYFNLINTKCYKLEH*# SEQUENCE: KMYFNLINTKCYKLEH*# ...# >HUM2055B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (115-128)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SKPKVYQWFDLRKY*# SEQUENCE: SKPKVYQWFDLRKY*# ...# >HUM2055C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (19-34)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,NELGRFKHTDACCRTH*# SEQUENCE: NELGRFKHTDACCRTH*# ...# >HUM2055D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (73-88)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SSYFVGKMYFNLINTK*# SEQUENCE: SSYFVGKMYFNLINTK*# ...# >HUM2055E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (79-94)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,KMYFNLINTKCYKLEH*# SEQUENCE: KMYFNLINTKCYKLEH*# ...# >HUM2055F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (109-124)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,HYTVDKSKPKWQWFD*# SEQUENCE: HYTVDKSKPKWQWFD*# ...# >HUM20560# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (115-128)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SKPKVYQWFDLRKY*# SEQUENCE: SKPKVYQWFDLRKY*# ...# >HUM20561# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (19-34)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,NELGRFKHTDACCRTH*# SEQUENCE: NELGRFKHTDACCRTH*# ...# >HUM20562# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (73-88)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,SSYFVGKMYFNLINTK*# SEQUENCE: SSYFVGKMYFNLINTK*# ...# >HUM20563# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (79-94)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,KMYFNLINTKCYKLEH*# SEQUENCE: KMYFNLINTKCYKLEH*# ...# >HUM20564# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (115-128)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,SKPKVYQWFDLRKY*# SEQUENCE: SKPKVYQWFDLRKY*# ...# >HUM20565# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (7-22)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,LWCGHGNKSSGPNELG*# SEQUENCE: LWCGHGNKSSGPNELG*# ...# >HUM20566# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (61-76)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,NNDFYKNSADTISSYF*# SEQUENCE: NNDFYKNSADTISSYF*# ...# >HUM20567# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (103-118)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,TEGRCLHYTVDKSKPK*# SEQUENCE: TEGRCLHYTVDKSKPK*# ...# >HUM20568# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (109-124)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,HYTVDKSKPKWQWFD*# SEQUENCE: HYTVDKSKPKWQWFD*# ...# >HUM20569# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLA2 (115-128)# DB REFERENCE: SWISS: (PA2_APIME,PA2_APIME)# & PIR1: (PSHBA)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,SKPKVYQWFDLRKY*# SEQUENCE: SKPKVYQWFDLRKY*# ...# >HUM2056A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (1-20)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,ATSTKKLHKEPATLIKAIDG*# SEQUENCE: ATSTKKLHKEPATLIKAIDG*# ...# >HUM2056B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (11-30)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PATLIKAIDGDTVKLMYKGQ*# SEQUENCE: PATLIKAIDGDTVKLMYKGQ*# ...# >HUM2056C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (21-40)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,DTVKLMYKGQPMTFRLLLVD*# SEQUENCE: DTVKLMYKGQPMTFRLLLVD*# ...# >HUM2056D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (31-50)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PMTFRLLLVDTPETKHPKKG*# SEQUENCE: PMTFRLLLVDTPETKHPKKG*# ...# >HUM2056E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (81-100)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >HUM2056F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (91-110)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YIYADGKMVNEALVRQGLAK*# SEQUENCE: YIYADGKMVNEALVRQGLAK*# ...# >HUM20570# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (111-130)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VAYWKPNNTHEQHLRKSEA*# SEQUENCE: VAYWKPNNTHEQHLRKSEA*# ...# >HUM20571# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (1-20)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,ATSTKKLHKEPATLIKAIDG*# SEQUENCE: ATSTKKLHKEPATLIKAIDG*# ...# >HUM20572# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (21-40)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DTVKLMYKGQPMTFRLLLVD*# SEQUENCE: DTVKLMYKGQPMTFRLLLVD*# ...# >HUM20573# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (51-70)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,VEKYGPEASAFTKKMVENAK*# SEQUENCE: VEKYGPEASAFTKKMVENAK*# ...# >HUM20574# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (61-80)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,FTKKMVENAKKIEVEFDKGQ*# SEQUENCE: FTKKMVENAKKIEVEFDKGQ*# ...# >HUM20575# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (81-100)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >HUM20576# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (101-120)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,EALVRQGLAKVAYVYKPNNT*# SEQUENCE: EALVRQGLAKVAYVYKPNNT*# ...# >HUM20577# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (111-130)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,VAYWKPNNTHEQHLRKSEA*# SEQUENCE: VAYWKPNNTHEQHLRKSEA*# ...# >HUM20578# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (121-140)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,HEQHLRKSEAQAKKEKLNIW*# SEQUENCE: HEQHLRKSEAQAKKEKLNIW*# ...# >HUM20579# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (21-40)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DTVKLMYKGQPMTFRLLLVD*# SEQUENCE: DTVKLMYKGQPMTFRLLLVD*# ...# >HUM2057A# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (101-120)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,EALVRQGLAKVAYVYKPNNT*# SEQUENCE: EALVRQGLAKVAYVYKPNNT*# ...# >HUM2057B# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (111-130)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,VAYWKPNNTHEQHLRKSEA*# SEQUENCE: VAYWKPNNTHEQHLRKSEA*# ...# >HUM2057C# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (1-20)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,ATSTKKLHKEPATLIKAIDG*# SEQUENCE: ATSTKKLHKEPATLIKAIDG*# ...# >HUM2057D# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (11-30)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,PATLIKAIDGDTVKLMYKGQ*# SEQUENCE: PATLIKAIDGDTVKLMYKGQ*# ...# >HUM2057E# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (21-40)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,DTVKLMYKGQPMTFRLLLVD*# SEQUENCE: DTVKLMYKGQPMTFRLLLVD*# ...# >HUM2057F# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (71-90)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,KIEVEFDKGQRTDKYGRGLA*# SEQUENCE: KIEVEFDKGQRTDKYGRGLA*# ...# >HUM20580# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (81-100)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >HUM20581# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (111-130)# ANCHOR POSITIONS:# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,VAYWKPNNTHEQHLRKSEA*# SEQUENCE: VAYWKPNNTHEQHLRKSEA*# ...# >HUM20582# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p13 (97-112)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1B5,GAG_HV1A2,GAG_HV1B1,GAG_HV1H2,# & GAG_HV1JR,GAG_HV1PV)# & PIR1: (FOVWA2,FOVWLV,FOVWH3)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,QKQEPIDKELYPLTSL*# SEQUENCE: QKQEPIDKELYPLTSL*# ...# >HUM20583# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p17 (1-16)# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1OY,GAG_HV1A2,GAG_HV1N5)# & PIR1: (FOVWA2)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,GARASVLSGGELDKWE*# SEQUENCE: GARASVLSGGELDKWE*# ...# >HUM20584# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p17 (41-56)# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1B1,GAG_HV1BR,GAG_HV1B5,GAG_HV1N5,# & GAG_HV1PV,GAG_HV1A2,GAG_HV1H2)# & PIR1: (FOVWLV,FOVWVL,FOVWA2,FOVWH3)# & PIR3: (S33979)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,ERFAVNPGLLETSEGC*# SEQUENCE: ERFAVNPGLLETSEGC*# ...# >HUM20585# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p25 (1-16)# DB REFERENCE: SWISS: (GAG_HV1JR,GAG_HV1ND,GAG_HV1W2,GAG_HV1N5,GAG_HV1C4,# & GAG_HV1RH,GAG_HV1EL,GAG_HV1Y2,GAG_HV1A2,GAG_HV1Z2)# & PIR1: (A44001,FOVWA2,FOLJND,FOVWH4)# & PIR2: (S54377)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PIVQNLQGQMVHQAIS*# SEQUENCE: PIVQNLQGQMVHQAIS*# ...# >HUM20586# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p25 (41-56)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1PV,GAG_HV1B5,GAG_HV1W2,GAG_HV1N5,# & GAG_HV1J3,GAG_HV1EL,GAG_HV1RH,GAG_HV1MN,GAG_HV1Z2,# & GAG_HV1H2,GAG_HV1JR,GAG_HV1A2,GAG_HV1BR,GAG_HV1Y2,# & GAG_HV1B1)# & PIR1: (FOVWA2,A44001,FOVWH3,FOLJND,FOVWLV,FOVWVL,A38068)# & PIR2: (S54377)# & PIR3: (S33979)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SALSEGATPQDLNTML*# SEQUENCE: SALSEGATPQDLNTML*# ...# >HUM20587# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p25 (73-88)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1A2,GAG_HV1BR,GAG_HV1B1,GAG_HV1PV,# & GAG_HV1H2)# & PIR1: (FOVWVL,FOVWLV,FOVWA2,FOVWH3)# & PIR2: (S49086)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,INEEAAEWDRVHPVHA*# SEQUENCE: INEEAAEWDRVHPVHA*# ...# >HUM20588# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p17 (9-24)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1W2,GAG_HV1OY,GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,GGELDKWEKIRLRPGG*# SEQUENCE: GGELDKWEKIRLRPGG*# ...# >HUM20589# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p25 (41-56)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_HV1W2,GAG_HV1B5,GAG_HV1Y2,GAG_HV1N5,# & GAG_HV1BR,GAG_HV1A2,GAG_HV1H2,GAG_HV1ND,GAG_HV1PV,# & GAG_HV1EL,GAG_HV1RH,GAG_HV1J3,GAG_HV1B1,GAG_HV1JR,# & GAG_HV1Z2)# & PIR1: (FOVWA2,FOVWH3,FOVWVL,FOVWLV,FOLJND,A38068,A44001)# & PIR2: (S54377)# & PIR3: (S33979)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SALSEGATPQDLNTML*# SEQUENCE: SALSEGATPQDLNTML*# ...# >HUM2058A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p25 (129-144)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1Y2,GAG_HV1B5,GAG_HV1A2,GAG_HV1PV,# & GAG_HV1ND,GAG_HV1C4,GAG_HV1JR,GAG_HV1RH,GAG_HV1W2,# & GAG_HV1OY,GAG_HV1MA,GAG_HV1Z2,GAG_HV1MN,GAG_HV1N5,# & GAG_HV1H2,GAG_HV1B1,GAG_HV1J3)# & PIR1: (FOVWH4,FOVWH3,A44001,A38068,FOLJND,FOVWA2,FOVWVL,# & FOVWLV)# & PIR2: (S60698,S60708,S60699,S60704,S54377,S60703,S60697,# & S60702)# & PIR3: (S33979)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,IYKRWIILGLNKIVRM*# SEQUENCE: IYKRWIILGLNKIVRM*# ...# >HUM2058B# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p13 (57-72)# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1B1,GAG_HV1H2,GAG_HV1PV,GAG_HV1BR,# & GAG_HV1B5,GAG_HV1JR)# & PIR1: (FOVWA2,FOVWH3,FOVWLV)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,LGKIWPSYKGRPGNFL*# SEQUENCE: LGKIWPSYKGRPGNFL*# ...# >HUM2058C# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p17 (33-48)# DB REFERENCE: SWISS: (GAG_HV1JR,GAG_HV1PV,GAG_HV1H2,GAG_HV1B1,GAG_HV1A2,# & GAG_HV1N5,GAG_HV1B5,GAG_HV1BR,GAG_HV1W2)# & PIR1: (FOVWA2,FOVWLV,FOVWH3,FOVWVL)# & PIR3: (S33979)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,IVWASRELERFAVNPG*# SEQUENCE: IVWASRELERFAVNPG*# ...# >HUM2058D# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p17 (41-56)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1BR,GAG_HV1B5,GAG_HV1W2,GAG_HV1H2,# & GAG_HV1B1,GAG_HV1A2,GAG_HV1PV)# & PIR1: (FOVWH3,FOVWVL,FOVWA2,FOVWLV)# & PIR3: (S33979)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,ERFAVNPGLLETSEGC*# SEQUENCE: ERFAVNPGLLETSEGC*# ...# >HUM2058E# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p25 (41-56)# DB REFERENCE: SWISS: (GAG_HV1EL,GAG_HV1H2,GAG_HV1B1,GAG_HV1J3,GAG_HV1MN,# & GAG_HV1B5,GAG_HV1Y2,GAG_HV1W2,GAG_HV1A2,GAG_HV1Z2,# & GAG_HV1BR,GAG_HV1RH,GAG_HV1N5,GAG_HV1JR,GAG_HV1ND,# & GAG_HV1PV)# & PIR1: (A38068,FOLJND,FOVWVL,FOVWH3,A44001,FOVWLV,FOVWA2)# & PIR2: (S54377)# & PIR3: (S33979)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,SALSEGATPQDLNTML*# SEQUENCE: SALSEGATPQDLNTML*# ...# >HUM2058F# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p25 (73-88)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1H2,GAG_HV1B5,GAG_HV1PV,GAG_HV1A2,# & GAG_HV1BR)# & PIR1: (FOVWH3,FOVWLV,FOVWA2,FOVWVL)# & PIR2: (S49086)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,INEEAAEWDRVHPVHA*# SEQUENCE: INEEAAEWDRVHPVHA*# ...# >HUM20590# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV (218-232)# DB REFERENCE: SWISS: (LMP1_EBVC,LMP1_EBV)# & PIR1: (QQBE50,LABECA)# & PIR2: (G00065,S21660,S24611)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,NSNEGRHHLLVSGAG*# SEQUENCE: NSNEGRHHLLVSGAG*# ...# >HUM20591# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV (260-274)# DB REFERENCE: SWISS: (LMP1_EBVR,LMP1_EBVC,LMP1_EBV)# & PIR1: (LABERJ,LABECA,QQBE50)# & PIR2: (G00065,S24611,S21660)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DDNGPQDPDNTDDNG*# SEQUENCE: DDNGPQDPDNTDDNG*# ...# >HUM20592# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV (225-239)# DB REFERENCE: SWISS: (LMP1_EBVC,LMP1_EBV)# & PIR1: (LABECA,QQBE50)# & PIR2: (S24611,G00065,S21660)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,HLLVSGAGDGPPLCS*# SEQUENCE: HLLVSGAGDGPPLCS*# ...# >HUM20593# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV (5-24)# DB REFERENCE: SWISS: (LMP1_EBVR,LMP1_EBV)# & PIR1: (LABERJ,QQBE50)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,LERGPPGPRRPPRGPPLSSS*# SEQUENCE: LERGPPGPRRPPRGPPLSSS*# ...# >HUM20594# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV (239-253)# DB REFERENCE: SWISS: (LMP1_EBVC,LMP1_EBV)# & PIR1: (QQBE50,LABECA)# & PIR2: (G00065,S21660,S24611)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,SQNLGAPGGGPDNGP*# SEQUENCE: SQNLGAPGGGPDNGP*# ...# >HUM20595# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibitory binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV (5-24)# DB REFERENCE: SWISS: (LMP1_EBVR,LMP1_EBV)# & PIR1: (QQBE50,LABERJ)# REFERENCES: o'sullivan90a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,LERGPPGPRRPPRGPPLSSS*# SEQUENCE: LERGPPGPRRPPRGPPLSSS*# ...# >HUM20596# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: mass spectrometry/Edman microsequencing/binding inhibition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A2 invariant chain (105-118), CLIP# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee93b,chicz92a,chicz93a,barber93a,malcherek95a,geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,KMRMATPLLMQALP*# SEQUENCE: KMRMATPLLMQALP*# ...# >HUM20597# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (105-117)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38443,I61902,I84448,I38442,I61857,I37542)# REFERENCES: chicz92a,chicz93a,rotzschke94b,barber93a,hammer94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SDWRFLRGYHQYA*# SEQUENCE: SDWRFLRGYHQYA*# ...# >HUM20598# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (Na+ or K+) ATPase (199-216)# DB REFERENCE: SWISS: (ATN1_HUMAN,ATN1_PIG,ATN1_SHEEP,ATN1_CANFA,ATN1_HORSE,# & ATN3_PIG,ATN1_RAT,ATN1_HUMAN)# & PIR1: (PWSHNA,S04630)# & PIR2: (S20970,B24862,A24639,A24414)# REFERENCES: chicz92a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,IPADLRIISANGCKVDNS*# SEQUENCE: IPADLRIISANGCKVDNS*# ...# >HUM20599# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (680-696)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: chicz92a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RVEYHFLSPYVSPKESP*# SEQUENCE: RVEYHFLSPYVSPKESP*# ...# >HUM2059A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine Fetuin (56-73)# DB REFERENCE: SWISS: (A2HS_BOVIN,A2HS_SHEEP,A2HS_BOVIN,A2HS_SHEEP)# & PIR2: (A35714,S22394)# REFERENCES: chicz92a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YKHTLNQIDSVKVWPRRP*# SEQUENCE: YKHTLNQIDSVKVWPRRP*# ...# >HUM2059B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (249-263)# DB REFERENCE: SWISS: (MSP1_PLAFC,MSP1_PLAFK,MSP1_PLAFD,MSP1_PLAFP,MSP1_PLAFW,# & MSP1_PLAFN)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (A24594,S05603,S16752,A44865,B54498,S28793,A25814,# & A45948)# REFERENCES: chicz92a,guttinger91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LKKLVFGYRKPLDNI*# SEQUENCE: LKKLVFGYRKPLDNI*# ...# >HUM2059C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum CS (329-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: chicz92a,guttinger88a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KHIEQYLKKIKNS*# SEQUENCE: KHIEQYLKKIKNS*# ...# >HUM2059D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: RP-HLPC IC50(microM)# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DR1 beta-chain (1-20)# DB REFERENCE: SWISS: (HB2F_HUMAN,HB2E_HUMAN)# & PIR1: (HLHU1B)# & PIR2: (I56072)# REFERENCES: chicz92a,harris92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,GDTRPRFLWQLKFECHFFNG*# SEQUENCE: GDTRPRFLWQLKFECHFFNG*# ...# >HUM2059E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: RP-HLPC IC50(microM)# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DR1 beta-chain (21-42)# DB REFERENCE: SWISS: (HB2F_HUMAN,HB2E_HUMAN)# & PIR1: (HLHU1B)# & PIR2: (PH0147,I56072)# REFERENCES: chicz92a,harris92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,TERVRLLERCIYNQEESVRFDS*# SEQUENCE: TERVRLLERCIYNQEESVRFDS*# ...# >HUM2059F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: RP-HLPC IC50(microM)# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DR1 beta-chain (66-90)# DB REFERENCE: SWISS: (HB2F_HUMAN)# & PIR1: (HLHU1B)# & PIR2: (B30575,I79422)# REFERENCES: chicz92a,harris92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,DLLEQRRAAVDTYCRHNYGVGESFT*# SEQUENCE: DLLEQRRAAVDTYCRHNYGVGESFT*# ...# >HUM205A0# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HLPC/binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta2m (7-22)# DB REFERENCE: SWISS: (B2MG_MUSSP,B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# & PIR2: (I84730)# REFERENCES: o'sullivan90a,chicz92a,sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,IQVYSRHPPENGKPNI*# SEQUENCE: IQVYSRHPPENGKPNI*# ...# >HUM205A1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (211-224)# DB REFERENCE: SWISS: (MSP1_PLAFW,MSP1_PLAFC,MSP1_PLAF3,MSP1_PLAFP,MSP1_PLAFD,# & MSP1_PLAFK)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A44865,A45948,A25814,S16752,A24594,S05603,S06286)# REFERENCES: chicz92a,guttinger91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YKLNFYFDLLRAKL*# SEQUENCE: YKLNFYFDLLRAKL*# ...# >HUM205A2# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (211-224)# DB REFERENCE: SWISS: (MSP1_PLAFP,MSP1_PLAFD,MSP1_PLAFW,MSP1_PLAFC,MSP1_PLAF3,# & MSP1_PLAFK)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (A24594,S16752,A44865,A25814,A45948,S06286,S05603)# REFERENCES: guttinger91a,celis94a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,YKLNFYFDLLRAKL*# SEQUENCE: YKLNFYFDLLRAKL*# ...# >HUM205A3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (338-350)# DB REFERENCE: SWISS: (MSP1_PLAFK,MSP1_PLAFW,MSP1_PLAFC,MSP1_PLAFP)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A24594,S05603,A45948)# REFERENCES: chicz92a,guttinger91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,IDTLKKNENIKEL*# SEQUENCE: IDTLKKNENIKEL*# ...# >HUM205A4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: RP-HLPC IC50(microM)# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DR1 beta-chain (43-62)# DB REFERENCE: SWISS: (HB2K_MOUSE,HB2H_HUMAN,HB2F_HUMAN,HB2C_HUMAN,HB2D_MOUSE,# & HB2D_HUMAN,HB2J_MOUSE,HB2Q_MOUSE)# & PIR1: (HLHU1B,HLMSAB,HLHU4D,HLMSQB,HLMSBK)# & PIR2: (I68827,I59629,PT0171,S38691,I54287,S38699,G02161,I38411,# & S38683,S37119,C27060,I54509,D39797,I56072,I79652,B28756,# & I54309,A25239,C25239,A45873,I79661,PH0147,PH0158,I38899,# & D32526,PL0285,I59643,I54291,PT0169,A53278,I79659,C33287,# & I79421,I54294,I48422,F27060,B30575,PT0170,S38688,I79419,# & I79648,I80418,S38684,B27060,I54304,I59630,S70749,B27618,# & A29310,I67726,B28043,A45856,S38700,A27618,S01441,I51875,# & I68733)# REFERENCES: chicz92a,harris92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,DVGEYRAVTELGRPDAEYWN*# SEQUENCE: DVGEYRAVTELGRPDAEYWN*# ...# >HUM205A5# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (1273-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: demotz89a,demotz89b# COMMENT:# SUMMARY: HLA-DR52,actyesm,bindyesu,GQIGNDPNRDIL*# SEQUENCE: GQIGNDPNRDIL*# ...# >HUM205A6# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (1274-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: demotz89a# COMMENT:# SUMMARY: HLA-DR52,actyesl,bindyesu,QIGNDPNRDIL*# SEQUENCE: QIGNDPNRDIL*# ...# >HUM205A7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ragweed allergen (51-61)# ANCHOR POSITIONS: 2,9# REFERENCES: kropshofer92a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,EVWREEAYHAA*# SEQUENCE: EVWREEAYHAA*# ...# >HUM205A8# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ribonuclease (101-112)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: kropshofer92a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,EALVRQGLAKVA*# SEQUENCE: EALVRQGLAKVA*# ...# >HUM205A9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. tuberculosis (3-14)# ANCHOR POSITIONS: 2,9# REFERENCES: hill91a,kropshofer92a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,RVKRGLTVAVAG*# SEQUENCE: RVKRGLTVAVAG*# ...# >HUM205AA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae (65 kD) (412-425)# ANCHOR POSITIONS: 3,9# REFERENCES: kropshofer92a# COMMENT: not stimulating DR2# SUMMARY: HLA-DR1,actyesu,bindyesu,AKLAKLAGGVAVIK*# SEQUENCE: AKLAKLAGGVAVIK*# ...# >HUM205AB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Self-peptide SP3# ANCHOR POSITIONS: 3,11# REFERENCES: rammensee93b,kropshofer92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,AILEFRAMAQFSRKDT*# SEQUENCE: AILEFRAMAQFSRKDT*# ...# >HUM205AC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCS.T3 (381-393)# ANCHOR POSITIONS:# REFERENCES: kropshofer92a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,KKIAKMEKASSVF*# SEQUENCE: KKIAKMEKASSVF*# ...# >HUM205AD# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: Pepscan system# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (241-249)# DB REFERENCE: SWISS: (MSP1_PLAFM,MSP1_PLAFW,MSP1_PLAFC,MSP1_PLAF3,MSP1_PLAFK,# & MSP1_PLAFP,MSP1_PLAFF,MSP1_PLAFN,MSP1_PLAFD)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (A26868,S05603,S28793,A25814,A44865,S16752,A45948,B54498,# & S06286,A24594,A54498)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,IRANELDVL*# SEQUENCE: IRANELDVL*# ...# >HUM205AE# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Pepscan system/proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: P. falciparum p190 (245-253)# DB REFERENCE: SWISS: (MSP1_PLAF3,MSP1_PLAFP,MSP1_PLAFN,MSP1_PLAFD,MSP1_PLAFK,# & MSP1_PLAFW,MSP1_PLAFC)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A24594,B54498,S16752,A45948,S28793,S05603,S06286,A25814,# & A44865)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,ELDVLKKLV*# SEQUENCE: ELDVLKKLV*# ...# >HUM205AF# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: Pepscan system/proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: P. falciparum p190 (340-348)# DB REFERENCE: SWISS: (MSP1_PLAF3,MSP1_PLAFF,MSP1_PLAFW,MSP1_PLAFK,MSP1_PLAFM,# & MSP1_PLAFC,MSP1_PLAFP)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (S16752,A26868,S05603,C44866,A44866,B44866,A45948,A54498,# & A44865,S06286,A24594)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR52,actyesm,bindyesu,TLKKNENIK*# SEQUENCE: TLKKNENIK*# ...# >HUM205B0# MHC MOLECULE: HLA-DR18, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (188-208)# DB REFERENCE: SWISS: (MSP1_PLAF3,MSP1_PLAFW,MSP1_PLAFN,MSP1_PLAFD,MSP1_PLAFC,# & MSP1_PLAFK,MSP1_PLAFP)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A44865,A45948,A24594,A25814,B54498,S06286,S05603,# & S16752)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR18,actyesu,bindyesu,TLCDNIHGFKYLIDGYEEINE*# SEQUENCE: TLCDNIHGFKYLIDGYEEINE*# ...# >HUM205B1# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (239-249)# DB REFERENCE: SWISS: (MSP1_PLAFP,MSP1_PLAFK,MSP1_PLAFC,MSP1_PLAFD,MSP1_PLAFF,# & MSP1_PLAFM,MSP1_PLAFN,MSP1_PLAFW,MSP1_PLAF3)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (S05603,S16752,A26868,S06286,A24594,A44865,A54498,A45948,# & B54498,A25814,S28793)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,LKIRANELDVL*# SEQUENCE: LKIRANELDVL*# ...# >HUM205B2# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (249-271)# DB REFERENCE: SWISS: (MSP1_PLAFW,MSP1_PLAFN,MSP1_PLAFP,MSP1_PLAFC,MSP1_PLAFD,# & MSP1_PLAFK)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (A25814,A45948,S28793,A44865,B54498,S16752,A24594,# & S05603)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesu,LKKLVFGYRKPLDNIKDNVGKME*# SEQUENCE: LKKLVFGYRKPLDNIKDNVGKME*# ...# >HUM205B3# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (260-273)# DB REFERENCE: SWISS: (MSP1_PLAFF,MSP1_PLAFK,MSP1_PLAFD,MSP1_PLAFN,MSP1_PLAFP,# & MSP1_PLAFC,MSP1_PLAFM,MSP1_PLAFW)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A26868,S16752,A24594,A25814,A45948,A44865,A54498,S05603,# & B54498)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR14,actyesu,bindyesu,LDNIKDNVGKMEDY*# SEQUENCE: LDNIKDNVGKMEDY*# ...# >HUM205B4# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (311-327)# DB REFERENCE: PIR1: (SAZQK1)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,YQAQYDLFIYNKQLEEA*# SEQUENCE: YQAQYDLFIYNKQLEEA*# ...# >HUM205B5# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive inhibition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (338-350)# DB REFERENCE: SWISS: (MSP1_PLAFK,MSP1_PLAFP,MSP1_PLAFC,MSP1_PLAFW)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A24594,A45948,S05603)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesu,IDTLKKNENIKEL*# SEQUENCE: IDTLKKNENIKEL*# ...# >HUM205B6# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (249-263)# DB REFERENCE: SWISS: (MSP1_PLAFK,MSP1_PLAFP,MSP1_PLAFD,MSP1_PLAFC,MSP1_PLAFW,# & MSP1_PLAFN)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A25814,S28793,A44865,A45948,A24594,S16752,S05603,# & B54498)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LKKLVFGYRKPLDNI*# SEQUENCE: LKKLVFGYRKPLDNI*# ...# >HUM205B7# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (278-294)# DB REFERENCE: SWISS: (MSP1_PLAFW,MSP1_PLAFK)# & PIR1: (SAZQK1)# & PIR2: (S05603,A24594)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KKTIENINELIEESKKT*# SEQUENCE: KKTIENINELIEESKKT*# ...# >HUM205B8# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (338-350)# DB REFERENCE: SWISS: (MSP1_PLAFK,MSP1_PLAFC,MSP1_PLAFP,MSP1_PLAFW)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (S05603,A24594,A45948)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IDTLKKNENIKEL*# SEQUENCE: IDTLKKNENIKEL*# ...# >HUM205B9# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (268-294)# DB REFERENCE: SWISS: (MSP1_PLAFK,MSP1_PLAFW)# & PIR1: (SAZQK1)# & PIR2: (S05603,A24594)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,GKMEDYIKKNKKTIE*# SEQUENCE: GKMEDYIKKNKKTIE*# ...# >HUM205BA# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (311-327)# DB REFERENCE: PIR1: (SAZQK1)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,YQAQYDLFIYNKQLEEA*# SEQUENCE: YQAQYDLFIYNKQLEEA*# ...# >HUM205BB# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (338-350)# DB REFERENCE: SWISS: (MSP1_PLAFP,MSP1_PLAFC,MSP1_PLAFW,MSP1_PLAFK)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (S05603,A45948,A24594)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,IDTLKKNENIKEL*# SEQUENCE: IDTLKKNENIKEL*# ...# >HUM205BC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (241-255)# DB REFERENCE: SWISS: (MSP1_PLAFC,MSP1_PLAFN,MSP1_PLAFW,MSP1_PLAFK,MSP1_PLAF3,# & MSP1_PLAFP,MSP1_PLAFD)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (A44865,S05603,A25814,S06286,S28793,A45948,S16752,A24594,# & B54498)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,IRANELDVLKKLVFG*# SEQUENCE: IRANELDVLKKLVFG*# ...# >HUM205BD# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (249-263)# DB REFERENCE: SWISS: (MSP1_PLAFC,MSP1_PLAFN,MSP1_PLAFW,MSP1_PLAFK,MSP1_PLAFD,# & MSP1_PLAFP)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (S28793,B54498,S16752,A44865,S05603,A25814,A24594,# & A45948)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR6,actunkn,bindyesu,LKKLVFGYRKPLDNI*# SEQUENCE: LKKLVFGYRKPLDNI*# ...# >HUM205BE# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (260-273)# DB REFERENCE: SWISS: (MSP1_PLAFM,MSP1_PLAFP,MSP1_PLAFC,MSP1_PLAFF,MSP1_PLAFW,# & MSP1_PLAFD,MSP1_PLAFK,MSP1_PLAFN)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (S16752,B54498,A44865,A24594,A26868,S05603,A25814,A45948,# & A54498)# REFERENCES: guttinger91a,crisanti88a# COMMENT:# SUMMARY: HLA-DR6,actyesu,bindyesu,LDNIKDNVGKMEDY*# SEQUENCE: LDNIKDNVGKMEDY*# ...# >HUM205BF# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (268-294)# DB REFERENCE: SWISS: (MSP1_PLAFK,MSP1_PLAFW)# & PIR1: (SAZQK1)# & PIR2: (A24594,S05603)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR6,actunkn,bindyesu,GKMEDYIKKNKKTIE*# SEQUENCE: GKMEDYIKKNKKTIE*# ...# >HUM205C0# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (278-294)# DB REFERENCE: SWISS: (MSP1_PLAFW,MSP1_PLAFK)# & PIR1: (SAZQK1)# & PIR2: (S05603,A24594)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR6,actunkn,bindyesu,KKTIENINELIEESKKT*# SEQUENCE: KKTIENINELIEESKKT*# ...# >HUM205C1# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (311-327)# DB REFERENCE: PIR1: (SAZQK1)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR6,actunkn,bindyesu,YQAQYDLFIYNKQLEEA*# SEQUENCE: YQAQYDLFIYNKQLEEA*# ...# >HUM205C2# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (249-263)# DB REFERENCE: SWISS: (MSP1_PLAFK,MSP1_PLAFC,MSP1_PLAFP,MSP1_PLAFW,MSP1_PLAFD,# & MSP1_PLAFN)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (B54498,A44865,S05603,A25814,A45948,A24594,S16752,# & S28793)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,LKKLVFGYRKPLDNI*# SEQUENCE: LKKLVFGYRKPLDNI*# ...# >HUM205C3# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (338-350)# DB REFERENCE: SWISS: (MSP1_PLAFW,MSP1_PLAFK,MSP1_PLAFP,MSP1_PLAFC)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (S05603,A24594,A45948)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,IDTLKKNENIKEL*# SEQUENCE: IDTLKKNENIKEL*# ...# >HUM205C4# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (249-263)# DB REFERENCE: SWISS: (MSP1_PLAFC,MSP1_PLAFP,MSP1_PLAFW,MSP1_PLAFN,MSP1_PLAFK,# & MSP1_PLAFD)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (S05603,S16752,A24594,B54498,A44865,A25814,A45948,# & S28793)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,LKKLVFGYRKPLDNI*# SEQUENCE: LKKLVFGYRKPLDNI*# ...# >HUM205C5# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (268-294)# DB REFERENCE: SWISS: (MSP1_PLAFK,MSP1_PLAFW)# & PIR1: (SAZQK1)# & PIR2: (S05603,A24594)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,GKMEDYIKKNKKTIE*# SEQUENCE: GKMEDYIKKNKKTIE*# ...# >HUM205C6# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (278-294)# DB REFERENCE: SWISS: (MSP1_PLAFW,MSP1_PLAFK)# & PIR1: (SAZQK1)# & PIR2: (S05603,A24594)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,KKTIENINELIEESKKT*# SEQUENCE: KKTIENINELIEESKKT*# ...# >HUM205C7# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (241-255)# DB REFERENCE: SWISS: (MSP1_PLAFC,MSP1_PLAFK,MSP1_PLAFD,MSP1_PLAFP,MSP1_PLAFW,# & MSP1_PLAFN,MSP1_PLAF3)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (B54498,S05603,A25814,A24594,S16752,S06286,A44865,A45948,# & S28793)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,IRANELDVLKKLVFG*# SEQUENCE: IRANELDVLKKLVFG*# ...# >HUM205C8# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: functional competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (311-327)# DB REFERENCE: PIR1: (SAZQK1)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,YQAQYDLFIYNKQLEEA*# SEQUENCE: YQAQYDLFIYNKQLEEA*# ...# >HUM205C9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: P. falciparum p190 (339-350)# DB REFERENCE: SWISS: (MSP1_PLAFW,MSP1_PLAFP,MSP1_PLAFK,MSP1_PLAFC)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A45948,S05603,A24594)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,NENIKELLDKIN*# SEQUENCE: NENIKELLDKIN*# ...# >HUM205CA# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: proliferation as./Pepscan system# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: P. falciparum p190 (314-324)# DB REFERENCE: SWISS: (MSP1_PLAF3)# & PIR1: (SAZQK1)# & PIR2: (S06286,A44866)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DR15,actyesl,bindyesu,QYDLFIYNKQL*# SEQUENCE: QYDLFIYNKQL*# ...# >HUM205CB# MHC MOLECULE: HLA-DQ6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: P. falciparum p190 (325-336)# DB REFERENCE: SWISS: (MSP1_PLAFP,MSP1_PLAFW,MSP1_PLAF3,MSP1_PLAFK,MSP1_PLAFC,# & MSP1_PLAFF,MSP1_PLAFM)# & PIR1: (SAZQGM,SAZQK1)# & PIR2: (A54498,C44866,A45948,A44865,A24594,S06286,S05603,S16752,# & A26868,B44866,A44866)# REFERENCES: guttinger91a# COMMENT:# SUMMARY: HLA-DQ6,actyesm,bindyesu,LISVLEKRIDTL*# SEQUENCE: LISVLEKRIDTL*# ...# >HUM205CC# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: DR1 beta-chain (43-62)# DB REFERENCE: SWISS: (HB2D_HUMAN,HB2Q_MOUSE,HB2D_MOUSE,HB2K_MOUSE,HB2H_HUMAN,# & HB2C_HUMAN,HB2F_HUMAN,HB2J_MOUSE)# & PIR1: (HLHU1B,HLMSAB,HLMSBK,HLHU4D,HLMSQB)# & PIR2: (A25239,I79661,I48422,I54291,A29310,B27618,I80418,B27060,# & I59630,B28043,S38691,I54287,I68827,C27060,PH0158,PL0285,# & C25239,I38411,I54304,S38684,A45873,D39797,I54309,B28756,# & I38899,S70749,I67726,A45856,S38700,PH0147,I56072,I79652,# & I68733,A27618,I51875,S01441,I54509,S37119,S38683,S38699,# & G02161,I59629,PT0171,I79419,I79648,S38688,B30575,D32526,# & I59643,C33287,A53278,I79659,PT0169,I54294,I79421,PT0170,# & F27060)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,DVGEYRAVTELGRPDAEYWN*# SEQUENCE: DVGEYRAVTELGRPDAEYWN*# ...# >HUM205CD# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: DR1 beta-chain (1-20)# DB REFERENCE: SWISS: (HB2E_HUMAN,HB2F_HUMAN)# & PIR1: (HLHU1B)# & PIR2: (I56072)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,GDTRPRFLWQLKFECHFFNG*# SEQUENCE: GDTRPRFLWQLKFECHFFNG*# ...# >HUM205CE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: DR1 beta-chain (21-42)# DB REFERENCE: SWISS: (HB2F_HUMAN,HB2E_HUMAN)# & PIR1: (HLHU1B)# & PIR2: (PH0147,I56072)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,TERVRLLERCIYNQEESVRFDS*# SEQUENCE: TERVRLLERCIYNQEESVRFDS*# ...# >HUM205CF# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: DR1 beta-chain (43-62)# DB REFERENCE: SWISS: (HB2C_HUMAN,HB2J_MOUSE,HB2K_MOUSE,HB2H_HUMAN,HB2F_HUMAN,# & HB2D_MOUSE,HB2Q_MOUSE,HB2D_HUMAN)# & PIR1: (HLMSQB,HLHU4D,HLHU1B,HLMSAB,HLMSBK)# & PIR2: (I79419,I79648,I59629,A53278,C33287,I67726,A45856,S70749,# & B28043,A27618,I54509,S38683,PH0147,I59630,A29310,PT0169,# & PT0171,PL0285,I79652,I51875,S01441,I68733,B27618,B27060,# & I80418,I56072,A25239,I79661,I48422,I54291,S37119,G02161,# & S38699,S38688,B30575,I68827,I54287,S38691,C27060,PH0158,# & I54304,S38684,A45873,D39797,I38411,C25239,I54309,B28756,# & I38899,S38700,I59643,D32526,I79659,I79421,I54294,PT0170,# & F27060)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,DVGEYRAVTELGRPDAEYWN*# SEQUENCE: DVGEYRAVTELGRPDAEYWN*# ...# >HUM205D0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: DR1 beta-chain (66-90)# DB REFERENCE: SWISS: (HB2F_HUMAN)# & PIR1: (HLHU1B)# & PIR2: (I79422,B30575)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,DLLEQRRAAVDTYCRHNYGVGESFT*# SEQUENCE: DLLEQRRAAVDTYCRHNYGVGESFT*# ...# >HUM205D1# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as./competitive binding# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Malaria HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: guttinger88a,sinigaglia88a,sidney92a# COMMENT:# SUMMARY: HLA-DR2,actyesh,bindyesu,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM205D2# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as./competitive binding# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Malaria HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: guttinger88a,sinigaglia88a,sidney92a# COMMENT:# SUMMARY: HLA-DR9,actyesh,bindyesu,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM205D3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P. falciparum CS (325-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# REFERENCES: guttinger88a# COMMENT:# SUMMARY: HLA-DR5,actyesh,bindyesu,EPSDKHIEQYLKKIKNS*# SEQUENCE: EPSDKHIEQYLKKIKNS*# ...# >HUM205D4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P. falciparum CS (326-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: guttinger88a# COMMENT:# SUMMARY: HLA-DR5,actyesh,bindyesu,PSDKHIEQYLKKIKNS*# SEQUENCE: PSDKHIEQYLKKIKNS*# ...# >HUM205D5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P. falciparum CS (329-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: guttinger88a# COMMENT:# SUMMARY: HLA-DR5,actyesh,bindyesu,KHIEQYLKKIKNS*# SEQUENCE: KHIEQYLKKIKNS*# ...# >HUM205D6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P. falciparum CS (330-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: guttinger88a# COMMENT:# SUMMARY: HLA-DR5,actyesh,bindyesu,HIEQYLKKIKNS*# SEQUENCE: HIEQYLKKIKNS*# ...# >HUM205D7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: P. falciparum CS (331-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: guttinger88a# COMMENT:# SUMMARY: HLA-DR5,actyesm,bindyesu,IEQYLKKIKNS*# SEQUENCE: IEQYLKKIKNS*# ...# >HUM205D8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: P. falciparum CS (332-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: guttinger88a# COMMENT:# SUMMARY: HLA-DR5,actyesm,bindyesu,EQYLKKIKNS*# SEQUENCE: EQYLKKIKNS*# ...# >HUM205D9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: P. falciparum CS (333-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: guttinger88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,QYLKKIKNS*# SEQUENCE: QYLKKIKNS*# ...# >HUM205DA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P. falciparum CS (330-341) homologue# ANCHOR POSITIONS:# REFERENCES: guttinger88a# COMMENT:# SUMMARY: HLA-DR5,actyesh,bindyesu,HIEKYLKKIKNS*# SEQUENCE: HIEKYLKKIKNS*# ...# >HUM205DB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR1,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205DC# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205DD# MHC MOLECULE: HLA-DR18, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR18,actyesu,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205DE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205DF# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205E0# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205E1# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR7,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205E2# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR8,actyesu,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205E3# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR9,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205E4# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205E5# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR52,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205E6# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR11,actyesm,bindyesu,FNNFTVSFWLRVPKVSASHLE*# SEQUENCE: FNNFTVSFWLRVPKVSASHLE*# ...# >HUM205E7# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR7,actyesm,bindyesu,FNNFTVSFWLRVPKVSASHLE*# SEQUENCE: FNNFTVSFWLRVPKVSASHLE*# ...# >HUM205E8# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,FNNFTVSFWLRVPKVSASHLE*# SEQUENCE: FNNFTVSFWLRVPKVSASHLE*# ...# >HUM205E9# MHC MOLECULE: HLA-DPw2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DPw2,actyesm,bindyesu,FNNFTVSFWLRVPKVSASHLE*# SEQUENCE: FNNFTVSFWLRVPKVSASHLE*# ...# >HUM205EA# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DPw4,actyesm,bindyesu,FNNFTVSFWLRVPKVSASHLE*# SEQUENCE: FNNFTVSFWLRVPKVSASHLE*# ...# >HUM205EB# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (1273-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: demotz89a,panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesu,GQIGNDPNRDIL*# SEQUENCE: GQIGNDPNRDIL*# ...# >HUM205EC# MHC MOLECULE: HLA-DR52c, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (1273-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: demotz89a,panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR52c,actyesu,bindyesu,GQIGNDPNRDIL*# SEQUENCE: GQIGNDPNRDIL*# ...# >HUM205ED# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (953-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR5,actyesm,bindyesu,SFWLRVPKVSASHLE*# SEQUENCE: SFWLRVPKVSASHLE*# ...# >HUM205EE# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-960)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,FNNFTVSFWLRVPK*# SEQUENCE: FNNFTVSFWLRVPK*# ...# >HUM205EF# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-960)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,FNNFTVSFWLRVPK*# SEQUENCE: FNNFTVSFWLRVPK*# ...# >HUM205F0# MHC MOLECULE: HLA-DP2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (949-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DP2,actyesl,bindyesu,NFTVSFWLRVPKVSASHLE*# SEQUENCE: NFTVSFWLRVPKVSASHLE*# ...# >HUM205F1# MHC MOLECULE: HLA-DP2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-960)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DP2,actyesm,bindyesu,FNNFTVSFWLRVPK*# SEQUENCE: FNNFTVSFWLRVPK*# ...# >HUM205F2# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (949-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DP4,actyesl,bindyesu,NFTVSFWLRVPKVSASHLE*# SEQUENCE: NFTVSFWLRVPKVSASHLE*# ...# >HUM205F3# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-960)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DP4,actyesm,bindyesu,FNNFTVSFWLRVPK*# SEQUENCE: FNNFTVSFWLRVPK*# ...# >HUM205F4# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR6,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205F5# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM205F6# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM205F7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR5,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205F8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM205F9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,QYIKAASKFIGITEL*# SEQUENCE: QYIKAASKFIGITEL*# ...# >HUM205FA# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR3,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM205FB# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR3,actyesl,bindyesu,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM205FC# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR3,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM205FD# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM205FE# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM205FF# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR52,actyesl,bindyesu,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM20600# MHC MOLECULE: HLA-DR52(DRB3*02), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR52,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM20601# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR1,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM20602# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR2,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM20603# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM20604# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-844)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR4,actyesm,bindyesu,QYIKANSKFIGITEL*# SEQUENCE: QYIKANSKFIGITEL*# ...# >HUM20605# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM20606# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM20607# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tetanus toxin tt (831-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR7,actyesm,bindyesu,YIKANSKFIGITE*# SEQUENCE: YIKANSKFIGITE*# ...# >HUM20608# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-842)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: panina-bordignon89a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,QYIKANSKFIGIT*# SEQUENCE: QYIKANSKFIGIT*# ...# >HUM20609# MHC MOLECULE: HLA-DQ?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum p190 (260-273)# ANCHOR POSITIONS:# REFERENCES: crisanti88a# COMMENT:# SUMMARY: HLA-DQ?,actyesu,bindyesu,YKLNFYDLLRAKL*# SEQUENCE: YKLNFYDLLRAKL*# ...# >HUM2060A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae (439-448)# DB REFERENCE: SWISS: (CH60_MYCPA,CH60_MYCPA,CH62_MYCLE,CH62_STRAL,CH62_MYCTU,# & CH60_MYCTU)# & PIR2: (C41325,S40245,A26950,A43509,A25902)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,HRIEDAVRNA*# SEQUENCE: HRIEDAVRNA*# ...# >HUM2060B# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: Proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: M. leprae (437-459)# DB REFERENCE: SWISS: (CH62_STRAL,CH60_MYCPA,CH62_MYCTU,CH62_MYCLE,CH60_MYCPA,# & CH60_MYCTU)# & PIR2: (A25902,A43509,S40245,A26950,C41325)# REFERENCES: lamb87a# COMMENT:# SUMMARY: HLA-?,actyesm,bindyesu,RKHRIEDAVRNAKAAVEEGIVAG*# SEQUENCE: RKHRIEDAVRNAKAAVEEGIVAG*# ...# >HUM2060C# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae (112-132)# DB REFERENCE: SWISS: (CH62_STRAL,CH60_MYCSC,CH60_MYCMA,CH60_MYCPA,CH62_MYCTU,# & CH60_MYCFO,CH60_MYCGS,CH60_MYCVA,CH60_MYCPH,CH60_MYCAS,# & CH60_MYCAV,CH60_MYCCH,CH60_MYCSH,CH60_MYCTU,CH60_MYCCI,# & CH60_MYCKA,CH60_MYCNO,CH60_MYCRH,CH60_MYCAG,CH60_MYCPA,# & CH60_MYCPV,CH60_MYCMR,CH62_MYCLE,CH60_MYCGO,CH60_MYCFA,# & CH60_MYCXE,CH60_MYCIT,CH60_MYCGN)# & PIR2: (C41325,A26950,S05294,A25902,S05293,S05292,S40245,S05295,# & A43509)# REFERENCES: lamb87a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,YEKIGAELVKEVAKKTDDVAG*# SEQUENCE: YEKIGAELVKEVAKKTDDVAG*# ...# >HUM2060D# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae 65 KD antigen (2-12)# DB REFERENCE: PIR2: (A25902)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesu,PGRDGETQPAS*# SEQUENCE: PGRDGETQPAS*# ...# >HUM2060E# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae 65 KD antigen (17-61)# DB REFERENCE: PIR2: (A25902)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,SRALHPASVSNGGCRHPVTLASFLIRRNHFAMAKTIAYDEE___# SEQUENCE: SRALHPASVSNGGCRHPVTLASFLIRRNHFAMAKTIAYDEEARRG*# ...# >HUM2060F# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae 65 KD antigen (85-108)# DB REFERENCE: SWISS: (CH60_MYCTU,CH60_MYCPA,CH62_MYCTU,CH62_STRAL,CH60_MYCPA,# & CH62_MYCLE)# & PIR2: (A25902,C41325,A26950,S40245,A43509)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,VLEKKWGAPTITNDGVSIAKEIEL*# SEQUENCE: VLEKKWGAPTITNDGVSIAKEIEL*# ...# >HUM20610# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae 65 KD antigen (418-427)# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCTU,CH62_MYCLE,CH60_MYCPA,CH62_STRAL,# & CH60_MYCPA)# & PIR2: (A26950,A43509,C41325,A25902,S40245)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,AGGVAVIKAG*# SEQUENCE: AGGVAVIKAG*# ...# >HUM20611# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae 65 KD antigen (480-540)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,EATGANIVKVALEAPLKQIAFNSGMEPGVVAEKVRNLSVGH___# SEQUENCE: EATGANIVKVALEAPLKQIAFNSGMEPGVVAEKVRNLSVGHGLNAATGEYEDLLKAGVADP*# ...# >HUM20612# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae 65 KD antigen (412-439)# DB REFERENCE: SWISS: (CH62_MYCTU,CH62_MYCLE,CH60_MYCPA,CH60_MYCTU,# & CH60_MYCPA)# & PIR2: (S40245,A43509,A25902,A26950)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,ERLAKLAGGVAVIKAGAATEVELKERKH*# SEQUENCE: ERLAKLAGGVAVIKAGAATEVELKERKH*# ...# >HUM20613# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae 65 KD antigen (390-412)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCPA,CH60_MYCPA)# & PIR2: (A25902,S40245)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,RVAQIRTEIENSDSDYDREKLQE*# SEQUENCE: RVAQIRTEIENSDSDYDREKLQE*# ...# >HUM20614# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae 65 KD antigen (412-425)# DB REFERENCE: SWISS: (CH60_CHRVI,CH60_MYCTU,CH60_BACSU,CH60_COXBU,CH60_PYRSA,# & CH60_PSEPU,CH60_MYCPA,CH61_SYNY3,CH62_MYCTU,CH60_PSEAE,# & CH60_CYAPA,CH60_THEP3,CH60_STAAU,CH60_BACST,CH61_MYCTU,# & CH60_BACP3,CH60_PSEPU,CH60_MYCPA,CH61_SYNY3,# & CH62_MYCLE)# & PIR2: (S51563,A26950,B47292,B49855,A25902,S40245,JQ1195,B44425,# & JN0601,S39765,B47073,A43509,S49253,B43606,B41884)# REFERENCES: van_schooten89a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,ERLAKLAGGVAVIK*# SEQUENCE: ERLAKLAGGVAVIK*# ...# >HUM20615# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. bovis 65 KD antigen (1-14)# DB REFERENCE: PIR2: (A26950,S40245,A25902,A43509)# REFERENCES: thole88a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesu,MAKTIAYDEEARRG*# SEQUENCE: MAKTIAYDEEARRG*# ...# >HUM20616# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. bovis 65 KD antigen (17-61)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCPA,CH60_MYCTU,CH60_MYCPA)# & PIR2: (A26950,S40245,A43509)# REFERENCES: thole88a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,RGLNALADAVKVTLGPKGRNVVLEKKWGAPTITNDGVSIAKE*# SEQUENCE: RGLNALADAVKVTLGPKGRNVVLEKKWGAPTITNDGVSIAKE*# ...# >HUM20617# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. bovis 65 KD antigen (85-108)# DB REFERENCE: SWISS: (CH60_MYCTU,CH60_MYCPA,CH60_MYCFO,CH60_MYCVA,CH60_MYCPH,# & CH60_MYCPA,CH60_MYCCI,CH61_STRAL,CH60_MYCPV,CH60_MYCRH,# & CH62_STRAL,CH60_MYCFA,CH62_MYCTU,CH60_MYCAG,CH60_MYCIT,# & CH60_MYCAV)# & PIR2: (C41325,S40245,S05295,S05292,S05294,B41325,A43509,A26950,# & S05293)# REFERENCES: thole88a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,GDGTTTATVLAQALVREGLRNVAA*# SEQUENCE: GDGTTTATVLAQALVREGLRNVAA*# ...# >HUM20618# MHC MOLECULE: HLA-DQ?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. bovis 65 KD antigen (235-279)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU)# & PIR2: (A43509,A26950)# REFERENCES: thole88a# COMMENT:# SUMMARY: HLA-DQ?,actyesu,bindyesu,LEKVIGAGKPLLIIAEDVEGEALSTLVVNKIRGTFKSVAVK___# SEQUENCE: LEKVIGAGKPLLIIAEDVEGEALSTLVVNKIRGTFKSVAVKAPGF*# ...# >HUM20619# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. bovis 65 KD antigen (65-85)# DB REFERENCE: SWISS: (CH60_MYCCH,CH60_MYCPH,CH60_MYCVA,CH60_MYCFA,CH60_MYCAS,# & CH62_STRAL,CH60_MYCGS,CH60_MYCPV,CH60_MYCRH,CH60_MYCCI,# & CH60_MYCSH,CH60_MYCSC,CH60_MYCMA,CH60_MYCGN,CH60_MYCGO,# & CH60_MYCIT,CH60_MYCXE,CH62_MYCLE,CH60_MYCAG,CH60_MYCTU,# & CH60_MYCKA,CH60_MYCPA,CH60_MYCFO,CH62_MYCTU,CH60_MYCPA,# & CH60_MYCAV,CH60_MYCMR,CH60_MYCNO)# & PIR2: (S05293,A43509,S05292,S05294,A25902,S40245,C41325,A26950,# & S05295)# REFERENCES: thole88a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,YEKIGAELVKEVAKKTDDVAG*# SEQUENCE: YEKIGAELVKEVAKKTDDVAG*# ...# >HUM2061A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bordetella pertussis BPS1 (27-39)# DB REFERENCE: SWISS: (TOX1_BORPE,TOX1_BORPE)# & PIR1: (WEBR11,WEBR1P)# REFERENCES: de_magistris89a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,GNNDNVLDHLTGR*# SEQUENCE: GNNDNVLDHLTGR*# ...# >HUM2061B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bordetella pertussis BPS1 (171-194)# DB REFERENCE: SWISS: (TOX1_BORPE,TOX1_BORPE)# & PIR1: (WEBR1P)# & PIR2: (A25973)# REFERENCES: de_magistris89a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,TRANPNPYTSRRSVASIVGTLVRMA*# SEQUENCE: TRANPNPYTSRRSVASIVGTLVRMA*# ...# >MUS2061C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as./recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZQJE,LZCH)# & PIR2: (JU0237,A61281)# REFERENCES: lambert89a,altuvia94a,adorini93a# COMMENT:# SUMMARY: I-Ak,actyesh,bindyesu,FESNFNTQATNR*# SEQUENCE: FESNFNTQATNR*# ...# >MUS2061D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (35-45)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZQJE,LZCH)# & PIR2: (JU0237,A61281)# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,ESNFNTQATNR*# SEQUENCE: ESNFNTQATNR*# ...# >MUS2061E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (36-45)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH,LZQJE)# & PIR2: (A61281,JU0237)# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesu,SNFNTQATNR*# SEQUENCE: SNFNTQATNR*# ...# >MUS2061F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (37-45)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH,LZQJE)# & PIR2: (A61281,JU0237)# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesu,NFNTQATNR*# SEQUENCE: NFNTQATNR*# ...# >MUS20620# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-44)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH,LZQJE)# & PIR2: (JU0237,A61281)# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,FESNFNTQATN*# SEQUENCE: FESNFNTQATN*# ...# >MUS20621# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,AESNFNTQATNR*# SEQUENCE: AESNFNTQATNR*# ...# >MUS20622# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,FASNFNTQATNR*# SEQUENCE: FASNFNTQATNR*# ...# >MUS20623# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,FEANFNTQATNR*# SEQUENCE: FEANFNTQATNR*# ...# >MUS20624# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesu,FESAFNTQATNR*# SEQUENCE: FESAFNTQATNR*# ...# >MUS20625# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesu,FESNANTQATNR*# SEQUENCE: FESNANTQATNR*# ...# >MUS20626# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,FESNFATQATNR*# SEQUENCE: FESNFATQATNR*# ...# >MUS20627# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesn,bindyesu,FESNFNAQATNR*# SEQUENCE: FESNFNAQATNR*# ...# >MUS20628# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,FESNFNTAATNR*# SEQUENCE: FESNFNTAATNR*# ...# >MUS20629# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,FESNFNTQAANR*# SEQUENCE: FESNFNTQAANR*# ...# >MUS2062A# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,FESNFNTQATAR*# SEQUENCE: FESNFNTQATAR*# ...# >MUS2062B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,FESNFNTQATNA*# SEQUENCE: FESNFNTQATNA*# ...# >MUS2062C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,FESNYNTQATNR*# SEQUENCE: FESNYNTQATNR*# ...# >MUS2062D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,FESNFNVQATNR*# SEQUENCE: FESNFNVQATNR*# ...# >MUS2062E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (34-45) homologue# ANCHOR POSITIONS:# REFERENCES: lambert89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,FESNFNTRATNY*# SEQUENCE: FESNFNTRATNY*# ...# >HUM2062F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13lib library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YMMQKSVRA*# SEQUENCE: YMMQKSVRA*# ...# >HUM20630# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,APQQLLHQM*# SEQUENCE: APQQLLHQM*# ...# >HUM20631# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AYWQVMTNM*# SEQUENCE: AYWQVMTNM*# ...# >HUM20632# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FRPIQTVLS*# SEQUENCE: FRPIQTVLS*# ...# >HUM20633# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GWGMMRTLR*# SEQUENCE: GWGMMRTLR*# ...# >HUM20634# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KAWSRMGSM*# SEQUENCE: KAWSRMGSM*# ...# >HUM20635# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,NWRGVLSQM*# SEQUENCE: NWRGVLSQM*# ...# >HUM20636# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SYARGRTLH*# SEQUENCE: SYARGRTLH*# ...# >HUM20637# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TMQQGFREA*# SEQUENCE: TMQQGFREA*# ...# >HUM20638# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WNYISSVQS*# SEQUENCE: WNYISSVQS*# ...# >HUM20639# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WRIAQTNHA*# SEQUENCE: WRIAQTNHA*# ...# >HUM2063A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WSTARTLWQ*# SEQUENCE: WSTARTLWQ*# ...# >HUM2063B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YHAHRTLLQ*# SEQUENCE: YHAHRTLLQ*# ...# >HUM2063C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YRHAVGQLG*# SEQUENCE: YRHAVGQLG*# ...# >HUM2063D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AWAHMTTLR*# SEQUENCE: AWAHMTTLR*# ...# >HUM2063E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FGWVSTLLQ*# SEQUENCE: FGWVSTLLQ*# ...# >HUM2063F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FRYMQVLTS*# SEQUENCE: FRYMQVLTS*# ...# >HUM20640# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GWLGLRTLR*# SEQUENCE: GWLGLRTLR*# ...# >HUM20641# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LYSWLPTQM*# SEQUENCE: LYSWLPTQM*# ...# >HUM20642# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PWRTMKNQI*# SEQUENCE: PWRTMKNQI*# ...# >HUM20643# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SYGAQLSMR*# SEQUENCE: SYGAQLSMR*# ...# >HUM20644# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TWRMAITQL*# SEQUENCE: TWRMAITQL*# ...# >HUM20645# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WQNMVTTLQ*# SEQUENCE: WQNMVTTLQ*# ...# >HUM20646# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WRIWGTQRA*# SEQUENCE: WRIWGTQRA*# ...# >HUM20647# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WWASVANAR*# SEQUENCE: WWASVANAR*# ...# >HUM20648# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YRAFATTWQ*# SEQUENCE: YRAFATTWQ*# ...# >HUM20649# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YRTGHVLQA*# SEQUENCE: YRTGHVLQA*# ...# >HUM2064A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AWHVVATLH*# SEQUENCE: AWHVVATLH*# ...# >HUM2064B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FMRMQTMTQ*# SEQUENCE: FMRMQTMTQ*# ...# >HUM2064C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FSRAGSMWS*# SEQUENCE: FSRAGSMWS*# ...# >HUM2064D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GYQQVRTLL*# SEQUENCE: GYQQVRTLL*# ...# >HUM2064E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,MLAMRTLLQ*# SEQUENCE: MLAMRTLLQ*# ...# >HUM2064F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,RIQTIRTLL*# SEQUENCE: RIQTIRTLL*# ...# >HUM20650# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SYYAAKAIQ*# SEQUENCE: SYYAAKAIQ*# ...# >HUM20651# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TYRVGATLR*# SEQUENCE: TYRVGATLR*# ...# >HUM20652# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WQTAFTQRQ*# SEQUENCE: WQTAFTQRQ*# ...# >HUM20653# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WRSWMTSTQ*# SEQUENCE: WRSWMTSTQ*# ...# >HUM20654# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WWRAQTLLQ*# SEQUENCE: WWRAQTLLQ*# ...# >HUM20655# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YRGFGNNPG*# SEQUENCE: YRGFGNNPG*# ...# >HUM20656# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YSAIQTMRA*# SEQUENCE: YSAIQTMRA*# ...# >HUM20657# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AWRTAGNML*# SEQUENCE: AWRTAGNML*# ...# >HUM20658# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FRFVYTAMQ*# SEQUENCE: FRFVYTAMQ*# ...# >HUM20659# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GALGGWWWT*# SEQUENCE: GALGGWWWT*# ...# >HUM2065A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,IRYWSTLAQ*# SEQUENCE: IRYWSTLAQ*# ...# >HUM2065B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,MWRGLNTVR*# SEQUENCE: MWRGLNTVR*# ...# >HUM2065C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,RWSAMQSNL*# SEQUENCE: RWSAMQSNL*# ...# >HUM2065D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TFARWKMKG*# SEQUENCE: TFARWKMKG*# ...# >HUM2065E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WMPLRTLAE*# SEQUENCE: WMPLRTLAE*# ...# >HUM2065F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WRAISVRLQ*# SEQUENCE: WRAISVRLQ*# ...# >HUM20660# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WRTWGTARQ*# SEQUENCE: WRTWGTARQ*# ...# >HUM20661# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WYEGFGNNR*# SEQUENCE: WYEGFGNNR*# ...# >HUM20662# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YRGGVTLRQ*# SEQUENCE: YRGGVTLRQ*# ...# >HUM20663# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YYSQAVTQI*# SEQUENCE: YYSQAVTQI*# ...# >HUM20664# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,VWGEGYGGE*# SEQUENCE: VWGEGYGGE*# ...# >HUM20665# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,MRQMQRAVA*# SEQUENCE: MRQMQRAVA*# ...# >HUM20666# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,GLVQVDRES*# SEQUENCE: GLVQVDRES*# ...# >HUM20667# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,TWGGLGRLL*# SEQUENCE: TWGGLGRLL*# ...# >HUM20668# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,LWAQVSRAI*# SEQUENCE: LWAQVSRAI*# ...# >HUM20669# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,VVTWWMGRG*# SEQUENCE: VVTWWMGRG*# ...# >HUM2066A# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WRWMSRVSS*# SEQUENCE: WRWMSRVSS*# ...# >HUM2066B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,KYWQAMERG*# SEQUENCE: KYWQAMERG*# ...# >HUM2066C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,RWKLMQKQL*# SEQUENCE: RWKLMQKQL*# ...# >HUM2066D# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,TWRTLWRQV*# SEQUENCE: TWRTLWRQV*# ...# >HUM2066E# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,GERLGGSRS*# SEQUENCE: GERLGGSRS*# ...# >HUM2066F# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,FWSLGRWTQ*# SEQUENCE: FWSLGRWTQ*# ...# >HUM20670# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,GWQLTAKRT*# SEQUENCE: GWQLTAKRT*# ...# >HUM20671# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,GNQWGNYVR*# SEQUENCE: GNQWGNYVR*# ...# >HUM20672# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,VLQMSHRMM*# SEQUENCE: VLQMSHRMM*# ...# >HUM20673# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WVSLGRLAA*# SEQUENCE: WVSLGRLAA*# ...# >HUM20674# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,YTFNRVMRL*# SEQUENCE: YTFNRVMRL*# ...# >HUM20675# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WWAGVGRAR*# SEQUENCE: WWAGVGRAR*# ...# >HUM20676# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,FMFWSARSD*# SEQUENCE: FMFWSARSD*# ...# >HUM20677# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WWHIGRMRG*# SEQUENCE: WWHIGRMRG*# ...# >HUM20678# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WYQMVARGR*# SEQUENCE: WYQMVARGR*# ...# >HUM20679# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,LHLMQRNWG*# SEQUENCE: LHLMQRNWG*# ...# >HUM2067A# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,MWEMLWRPR*# SEQUENCE: MWEMLWRPR*# ...# >HUM2067B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WLGSMRKQV*# SEQUENCE: WLGSMRKQV*# ...# >HUM2067C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WGWYGMSRW*# SEQUENCE: WGWYGMSRW*# ...# >HUM2067D# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,GWRLLSRWG*# SEQUENCE: GWRLLSRWG*# ...# >HUM2067E# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WGDEEWAWW*# SEQUENCE: WGDEEWAWW*# ...# >HUM2067F# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,KAPMFQMRE*# SEQUENCE: KAPMFQMRE*# ...# >HUM20680# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,EWVSLFRMQ*# SEQUENCE: EWVSLFRMQ*# ...# >HUM20681# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WAQMFRGAQ*# SEQUENCE: WAQMFRGAQ*# ...# >HUM20682# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WGWVTRAAP*# SEQUENCE: WGWVTRAAP*# ...# >HUM20683# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,RNWWANWDR*# SEQUENCE: RNWWANWDR*# ...# >HUM20684# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WWRMPRPLQ*# SEQUENCE: WWRMPRPLQ*# ...# >HUM20685# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WWWQMKDWR*# SEQUENCE: WWWQMKDWR*# ...# >HUM20686# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,LWHWTQRHL*# SEQUENCE: LWHWTQRHL*# ...# >HUM20687# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,GMLMNMMRR*# SEQUENCE: GMLMNMMRR*# ...# >HUM20688# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,MIWWGMGRW*# SEQUENCE: MIWWGMGRW*# ...# >HUM20689# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,GLGWWQKWE*# SEQUENCE: GLGWWQKWE*# ...# >HUM2068A# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,DWEGVKKRR*# SEQUENCE: DWEGVKKRR*# ...# >HUM2068B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,LWMLQGKGQ*# SEQUENCE: LWMLQGKGQ*# ...# >HUM2068C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,MWQELVRIQ*# SEQUENCE: MWQELVRIQ*# ...# >HUM2068D# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,GGFGWMSRM*# SEQUENCE: GGFGWMSRM*# ...# >HUM2068E# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,YAAISRGAQ*# SEQUENCE: YAAISRGAQ*# ...# >HUM2068F# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,YTQMMRSFH*# SEQUENCE: YTQMMRSFH*# ...# >HUM20690# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,VWRFLTKVR*# SEQUENCE: VWRFLTKVR*# ...# >HUM20691# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WWRSSPRLS*# SEQUENCE: WWRSSPRLS*# ...# >HUM20692# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WWHLMGHRV*# SEQUENCE: WWHLMGHRV*# ...# >HUM20693# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,VWGQVFKQV*# SEQUENCE: VWGQVFKQV*# ...# >HUM20694# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,RWTEALRRP*# SEQUENCE: RWTEALRRP*# ...# >HUM20695# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,EWWGLGRWR*# SEQUENCE: EWWGLGRWR*# ...# >HUM20696# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,TIWGMQRWQ*# SEQUENCE: TIWGMQRWQ*# ...# >HUM20697# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: Phage from M13 library# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,WKAMRKWTS*# SEQUENCE: WKAMRKWTS*# ...# >MUS20698# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: hen egg-white lysozyme HEL (107-116)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_CHICK,LYC_MELGA,LYC_CHICK,LYC_COLVI,# & LYC_SYRRE,LYC_CHRAM,LYC3_ANAPL,LYC_LOPLE,LYC_COTJA,# & LYC_PAVCR)# & PIR1: (LZTK,LZQJE,LZQJEC,LZCH,LZDK3)# & PIR2: (JQ1041,JT0526,JU0237,JQ1033)# REFERENCES: jorgensen92a,leighton91a,altuvia94a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesl,AWVAWRNRCK*# SEQUENCE: AWVAWRNRCK*# ...# >MUS20699# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_COTJA,LYC_MELGA,LYC_COLVI,LYC_CHRAM,# & LYC3_ANAPL,LYC_LOPLE,LYC_PAVCR,LYC_LOPCA,LYC_CHICK,# & LYC_CHICK)# & PIR1: (LZCH,LZQJEC,LZTK,LZQJE,LZDK3)# & PIR2: (JU0237,JQ1041,JT0526,JQ1033)# REFERENCES: sette89a,altuvia94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AWVAWRNRCK*# SEQUENCE: AWVAWRNRCK*# ...# >MUS2069A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding/proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (98-115)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPLE,LYC_CHRAM,LYC_CHICK,LYC_LOPCA)# & PIR1: (LZCH,LZQJEC)# & PIR2: (JQ1033)# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,IVSDGNGMNAWVAWRNRC*# SEQUENCE: IVSDGNGMNAWVAWRNRC*# ...# >MUS2069B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding/competitive inhibition/proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-124)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: sette89a,leighton91a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,AWVAWRNRCKGTDVQAWI*# SEQUENCE: AWVAWRNRCKGTDVQAWI*# ...# >MUS2069C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (110-124)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,AWRNRCKGTDVQAWI*# SEQUENCE: AWRNRCKGTDVQAWI*# ...# >MUS2069D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,EWVAWRNRCK*# SEQUENCE: EWVAWRNRCK*# ...# >MUS2069E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,VWVAWRNRCK*# SEQUENCE: VWVAWRNRCK*# ...# >MUS2069F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,SWVAWRNRCK*# SEQUENCE: SWVAWRNRCK*# ...# >MUS206A0# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AAVAWRNRCK*# SEQUENCE: AAVAWRNRCK*# ...# >MUS206A1# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AFVAWRNRCK*# SEQUENCE: AFVAWRNRCK*# ...# >MUS206A2# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AQVAWRNRCK*# SEQUENCE: AQVAWRNRCK*# ...# >MUS206A3# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AWAAWRNRCK*# SEQUENCE: AWAAWRNRCK*# ...# >MUS206A4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AWLAWRNRCK*# SEQUENCE: AWLAWRNRCK*# ...# >MUS206A5# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AWEAWRNRCK*# SEQUENCE: AWEAWRNRCK*# ...# >MUS206A6# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AWVSWRNRCK*# SEQUENCE: AWVSWRNRCK*# ...# >MUS206A7# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVEWRNRCK*# SEQUENCE: AWVEWRNRCK*# ...# >MUS206A8# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVVWRNRCK*# SEQUENCE: AWVVWRNRCK*# ...# >MUS206A9# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAQRNRCK*# SEQUENCE: AWVAQRNRCK*# ...# >MUS206AA# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAARNRCK*# SEQUENCE: AWVAARNRCK*# ...# >MUS206AB# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AWVAFRNRCK*# SEQUENCE: AWVAFRNRCK*# ...# >MUS206AC# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWENRCK*# SEQUENCE: AWVAWENRCK*# ...# >MUS206AD# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWKNRCK*# SEQUENCE: AWVAWKNRCK*# ...# >MUS206AE# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWANRCK*# SEQUENCE: AWVAWANRCK*# ...# >MUS206AF# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWRQRCK*# SEQUENCE: AWVAWRQRCK*# ...# >MUS206B0# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWRVRCK*# SEQUENCE: AWVAWRVRCK*# ...# >MUS206B1# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWRARCK*# SEQUENCE: AWVAWRARCK*# ...# >MUS206B2# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWRNECK*# SEQUENCE: AWVAWRNECK*# ...# >MUS206B3# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWRNKCK*# SEQUENCE: AWVAWRNKCK*# ...# >MUS206B4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWRNACK*# SEQUENCE: AWVAWRNACK*# ...# >MUS206B5# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWRNRQK*# SEQUENCE: AWVAWRNRQK*# ...# >MUS206B6# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesu,AWVAWRNREK*# SEQUENCE: AWVAWRNREK*# ...# >MUS206B7# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AWVAWRNRKK*# SEQUENCE: AWVAWRNRKK*# ...# >MUS206B8# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./ proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-116) homologue# DB REFERENCE: SWISS: (LYC1_ANAPL)# & PIR1: (LZDK)# REFERENCES: sette89a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AWVAWRNRCR*# SEQUENCE: AWVAWRNRCR*# ...# >HUM206B9# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ alpha chain (97-112)# DB REFERENCE: SWISS: (HA24_HUMAN,HA21_HUMAN)# & PIR1: (HLHUDQ,HLHUDC)# & PIR2: (A29312)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,NIVIKRSNSTAATNEV*# SEQUENCE: NIVIKRSNSTAATNEV*# ...# >HUM206BA# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ alpha chain (97-119)# DB REFERENCE: SWISS: (HA24_HUMAN,HA21_HUMAN)# & PIR1: (HLHUDQ,HLHUDC)# & PIR2: (A29312)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,NIVIKRSNSTAATNEVPEVTVFS*# SEQUENCE: NIVIKRSNSTAATNEVPEVTVFS*# ...# >HUM206BB# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ beta chain (43-57)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I72481,I68723,I59528,I61839,D35054,I59623,I84420,I61835,# & I36974,I68817,I68813,I68732)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DVGVYRAVTPQGRPD*# SEQUENCE: DVGVYRAVTPQGRPD*# ...# >HUM206BC# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ beta chain (42-59)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I84420,I68732,I68723,I36974,I59623,I61835,D35054,I61839,# & I68817,I68813,I59528,I72481)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SDVGVYRAVTPQGRPDAE*# SEQUENCE: SDVGVYRAVTPQGRPDAE*# ...# >HUM206BD# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ beta chain (43-59)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I68817,I68732,I84420,I36974,I61839,I68723,I59623,I59528,# & I72481,I61835,I68813,D35054)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DVGVYRAVTPQGRPDAE*# SEQUENCE: DVGVYRAVTPQGRPDAE*# ...# >HUM206BE# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR2b beta chain (94-108)# DB REFERENCE: SWISS: (HB2G_HUMAN,HB2K_HUMAN,HB2C_HUMAN)# & PIR1: (HLHUWB,HLHU4D)# & PIR2: (B27618,I54509,I54427,I68734,F27060,I59092,B28031)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,RVQPKVTVYPSKTQP*# SEQUENCE: RVQPKVTVYPSKTQP*# ...# >HUM206BF# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR2b beta chain (94-108)# DB REFERENCE: SWISS: (HB2C_HUMAN,HB2K_HUMAN,HB2G_HUMAN)# & PIR1: (HLHUWB,HLHU4D)# & PIR2: (I54427,I59092,F27060,I68734,I54509,B28031,B27618)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,RVQPKVTVYPSKTQPLQH*# SEQUENCE: RVQPKVTVYPSKTQPLQH*# ...# >HUM206C0# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FnR alpha chain (586-616)# DB REFERENCE: SWISS: (ITA5_HUMAN,ITA5_HUMAN)# & PIR2: (A27079)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,LSPIHIALNFSLDPQAPVDSHGLRPALHYQ*# SEQUENCE: LSPIHIALNFSLDPQAPVDSHGLRPALHYQ*# ...# >HUM206C1# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: K+ channel protein (173-189)# DB REFERENCE: SWISS: (CIK5_RABIT,CIK5_RAT,CIK5_RABIT,CIK5_MOUSE,CIK5_RAT,# & CIK5_HUMAN,CIK5_HUMAN)# & PIR2: (JH0166,S66669,A49507,S51212,A56031,C49507)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DGILYYYQSGGRLRRPV*# SEQUENCE: DGILYYYQSGGRLRRPV*# ...# >HUM206C2# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: K+ channel protein (173-190)# DB REFERENCE: SWISS: (CIK5_MOUSE,CIK5_RAT,CIK5_RABIT,CIK5_HUMAN,CIK5_RAT,# & CIK5_HUMAN,CIK5_RABIT)# & PIR2: (S66669,JH0166,A49507,S51212,A56031,C49507)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DGILYYYQSGGRLRRPVN*# SEQUENCE: DGILYYYQSGGRLRRPVN*# ...# >HUM206C3# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mannose binding potein (174-193)# DB REFERENCE: SWISS: (MABC_HUMAN)# & PIR1: (LNHUMC)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,IQNLIKEEAFLGITDEKTEG*# SEQUENCE: IQNLIKEEAFLGITDEKTEG*# ...# >HUM206C4# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MET (59-81)# DB REFERENCE: SWISS: (MET_HUMAN,MET_HUMAN)# & PIR1: (TVHUME)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,EHHIFLGATNYIYVLNEEDLQKV*# SEQUENCE: EHHIFLGATNYIYVLNEEDLQKV*# ...# >HUM206C5# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: GBP-2 (434-450)# DB REFERENCE: SWISS: (GBP2_HUMAN)# & PIR2: (B41268,S70524)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,QELKNKYYQVPRKGIQA*# SEQUENCE: QELKNKYYQVPRKGIQA*# ...# >HUM206C6# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1200-1218)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,FPKSLHTYANILLDRRVPQ*# SEQUENCE: FPKSLHTYANILLDRRVPQ*# ...# >HUM206C7# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1200-1220)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,FPKSLHTYANILLDRRVPQDT*# SEQUENCE: FPKSLHTYANILLDRRVPQDT*# ...# >HUM206C8# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine factor VIII (1775-1790)# DB REFERENCE: SWISS: (FA8_HUMAN,FA8_HUMAN)# & PIR1: (EZHU)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,LWDYGMSSSPHVLRNR*# SEQUENCE: LWDYGMSSSPHVLRNR*# ...# >HUM206C9# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A30 (28-43)# DB REFERENCE: SWISS: (1A02_GORGO,1A03_HUMAN,1A01_PONPY,1A31_HUMAN,1A30_HUMAN,# & 1A36_HUMAN,1A02_HUMAN,1A03_PANTR,1A33_HUMAN,1A66_HUMAN,# & 1A25_HUMAN,1A69_HUMAN,1A26_HUMAN,1A43_HUMAN,1A74_HUMAN,# & 1A34_HUMAN,1A31_HUMAN,1A04_GORGO,1A02_HUMAN,1A32_HUMAN,# & 1A04_PANTR,1A24_HUMAN,1A29_HUMAN,1A11_HUMAN,1A26_HUMAN,# & 1A68_HUMAN,1A23_HUMAN,1A03_GORGO,1A01_PANTR,1A01_GORGO,# & 1A01_HUMAN)# & PIR1: (HLHU32,HLHU69,HLHUAW,HLHUA2,HLHU28,HLHUA3)# & PIR2: (I56039,I84448,I84432,I84487,I61857,I38518,S01171,I37478,# & I36965,I38441,S03535,I36961,JH0534,I36959,I38443,JH0537,# & S51099,I38436,I54307,I37542,I37476,I61856,S18198,I37470,# & A35997,I38519,I54416,A45847,JH0536,I36966,I61902,I37482,# & A47636,I37477,I38610,JH0535,S16769,I72171,I37480,I72170,# & I83063,A37028,I54493,I37479,JL0135,I37483)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,VDDTQFVRFDSDAASQ*# SEQUENCE: VDDTQFVRFDSDAASQ*# ...# >HUM206CA# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (111-128)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,PPEVTVLTNSPVELREPN*# SEQUENCE: PPEVTVLTNSPVELREPN*# ...# >HUM206CB# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (111-129)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,PPEVTVLTNSPVELREPNV*# SEQUENCE: PPEVTVLTNSPVELREPNV*# ...# >HUM206CC# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (131-149)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,ATKYGNMTEDHVMHLLQNA*# SEQUENCE: ATKYGNMTEDHVMHLLQNA*# ...# >HUM206CD# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Acetylholine receptor (289-304)# DB REFERENCE: SWISS: (ACHB_BOVIN,ACHB_TORCA,ACHB_HUMAN)# & PIR1: (ACRYB1)# & PIR2: (S04607,S07227)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,VFLLLLADKVPETSLS*# SEQUENCE: VFLLLLADKVPETSLS*# ...# >HUM206CE# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glucose transporter (459-474)# DB REFERENCE: SWISS: (GTR1_BOVIN,GTR1_HUMAN,GTR1_BOVIN,GTR1_RABIT,GTR1_MOUSE,# & GTR1_MOUSE,GTR1_RAT,GTR1_RABIT,GTR1_PIG,GTR1_RAT,# & GTR1_PIG)# & PIR2: (A25949,I45902,S09705,A27217,A30797,S04223)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,TFDEIASGFRQGGASQ*# SEQUENCE: TFDEIASGFRQGGASQ*# ...# >HUM206CF# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Na+ channel protein (384-397)# DB REFERENCE: SWISS: (CIN4_RAT,CIN4_HUMAN)# & PIR1: (CHRTM1)# & PIR2: (I51964,JS0648,I64893,I54323)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,YGYTSYDTFSWAFL*# SEQUENCE: YGYTSYDTFSWAFL*# ...# >HUM206D0# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD45 (1071-1084)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GQVKKNNHQEQDKIE*# SEQUENCE: GQVKKNNHQEQDKIE*# ...# >HUM206D1# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ICAM-2 (64-76)# DB REFERENCE: SWISS: (ICA2_HUMAN,ICA2_HUMAN)# & PIR2: (S03967)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,LNKILLDEQAQWK*# SEQUENCE: LNKILLDEQAQWK*# ...# >HUM206D2# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IFN-gamma receptor (128-147)# DB REFERENCE: SWISS: (INGR_HUMAN,INGR_HUMAN)# & PIR2: (A31555)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GPPKLDIRKEEKQIMIDIFH*# SEQUENCE: GPPKLDIRKEEKQIMIDIFH*# ...# >HUM206D3# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IFN-gamma receptor (128-148)# DB REFERENCE: SWISS: (INGR_HUMAN,INGR_HUMAN)# & PIR2: (A31555)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GPPKLDIRKEEKQIMIDIFHP*# SEQUENCE: GPPKLDIRKEEKQIMIDIFHP*# ...# >HUM206D4# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV gp220 (592-606)# DB REFERENCE: SWISS: (VGP3_EBVA8,VGP3_EBV)# & PIR1: (QQBE21,QQBE22)# & PIR2: (S29605)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,TGHGARTSTEPTTDY*# SEQUENCE: TGHGARTSTEPTTDY*# ...# >HUM206D5# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV tegument p140 (1395-1407)# DB REFERENCE: SWISS: (TEGU_EBV)# & PIR1: (QQBE8)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,KELKRQYEKKLRQ*# SEQUENCE: KELKRQYEKKLRQ*# ...# >HUM206D6# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IP-30 (38-57)# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,SPLQALDFFGNGPPVNYKTG*# SEQUENCE: SPLQALDFFGNGPPVNYKTG*# ...# >HUM206D7# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IP-30 (38-59)# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,SPLQALDFFGNGPPVNYKTGNL*# SEQUENCE: SPLQALDFFGNGPPVNYKTGNL*# ...# >HUM206D8# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cyt-b5 (155-172)# DB REFERENCE: SWISS: (NC5R_HUMAN,NC5R_HUMAN)# & PIR1: (RDHUB5)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GKFAIRPDKKSNPIIRTV*# SEQUENCE: GKFAIRPDKKSNPIIRTV*# ...# >HUM206D9# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1276-1290)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NLFLKSDGRIKYTLN*# SEQUENCE: NLFLKSDGRIKYTLN*# ...# >HUM206DA# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1273-1292)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,IPDNLFLKSDGRIKYTLNKN*# SEQUENCE: IPDNLFLKSDGRIKYTLNKN*# ...# >HUM206DB# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1273-1291)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,IPDNLFLKSDGRIKYTLNK*# SEQUENCE: IPDNLFLKSDGRIKYTLNK*# ...# >HUM206DC# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1273-1290)# ANCHOR POSITIONS:# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,IPDNLFLKSDGRIKYTLN*# SEQUENCE: IPDNLFLKSDGRIKYTLN*# ...# >HUM206DD# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1273-1289)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,IPDNLFLKSDGRIKYTL*# SEQUENCE: IPDNLFLKSDGRIKYTL*# ...# >HUM206DE# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1276-1291)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NLFLKSDGRIKYTLNK*# SEQUENCE: NLFLKSDGRIKYTLNK*# ...# >HUM206DF# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1207-1224)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,YANILLDRRVPQTDMTF*# SEQUENCE: YANILLDRRVPQTDMTF*# ...# >HUM206E0# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1794-1810)# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,VTTLNSDLKYNALDLTN*# SEQUENCE: VTTLNSDLKYNALDLTN*# ...# >HUM206E1# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (31-42)# DB REFERENCE: SWISS: (1A01_SAGOE,1A29_HUMAN,1B08_HUMAN,1B60_HUMAN,1A24_HUMAN,# & 1CXX_HUMAN,1C02_HUMAN,1A02_HUMAN,1C02_GORGO,1B62_HUMAN,# & 1A11_HUMAN,1B22_HUMAN,1B57_HUMAN,1B28_HUMAN,1A32_HUMAN,# & 1B44_HUMAN,1A04_PANTR,1C17_HUMAN,1A04_GORGO,1B01_SAGOE,# & 1A30_HUMAN,1B63_HUMAN,1B29_HUMAN,1A31_HUMAN,1B55_HUMAN,# & 1C02_GORGO,1B56_HUMAN,1C04_GORGO,1B01_PANTR,1A02_GORGO,# & 1B13_HUMAN,1A69_HUMAN,1A25_HUMAN,1A26_HUMAN,1A43_HUMAN,# & 1B31_HUMAN,1B26_HUMAN,1A74_HUMAN,1C06_HUMAN,1C01_SAGOE,# & 1A34_HUMAN,1C04_HUMAN,1C16_HUMAN,1C03_GORGO,1B10_HUMAN,# & 1B03_GORGO,1B11_HUMAN,1B53_HUMAN,1B01_GORGO,1A03_PANTR,# & 1A33_HUMAN,1A36_HUMAN,1B32_HUMAN,1A23_HUMAN,1C18_HUMAN,# & 1B49_HUMAN,HA1B_RABIT,1C01_HUMAN,1A68_HUMAN,1B12_HUMAN,# & 1B54_HUMAN,HA1A_RABIT,1A01_PANTR,1C01_PANTR,1B02_GORGO,# & 1A02_HUMAN,1A01_PONPY,1B46_HUMAN,1B07_HUMAN,1A03_HUMAN,# & 1B23_HUMAN,1A31_HUMAN,1B39_HUMAN,1B58_HUMAN,1B59_HUMAN,# & 1B25_HUMAN,1A26_HUMAN,1B02_HUMAN,1B61_HUMAN,1B24_HUMAN,# & 1B52_HUMAN,1A66_HUMAN,1C02_HUMAN,1A01_GORGO,1B04_HUMAN,# & 1B27_HUMAN,1B21_HUMAN,1A01_HUMAN,1C03_HUMAN,1C15_HUMAN,# & 1A03_GORGO,1C07_HUMAN,1B12_HUMAN,1C11_HUMAN)# & PIR1: (HLHUB7,HLHU28,HLHUA3,HLHUA2,HLHU32,HLHUC4,HLHU69,HLHUAW,# & HLRB,S42102,HLHUB8)#& & PIR2: (I84448,S24439,I68747,I67482,I62044,S11141,A49411,G01230,# & I81233,I72170,S11133,S03537,I61859,I80166,I72218,I37544,# & S11142,I38421,S01171,S24437,S11138,I54457,I54505,I62045,# & I61857,I84487,JH0539,I38507,JS0262,I84432,I61907,I84486,# & I61856,I54307,I68850,I80167,I37526,I37522,I80171,I37521,# & I37478,I38441,B30345,S24434,I59633,I54430,S03535,D35997,# & I54314,S24438,I54298,I81231,I68712,I72113,I37523,I84490,# & I37470,S18198,I37528,I59308,I54449,S33355,A35997,I61860,# & A45847,I56130,I36966,S52290,I61862,JH0541,I62042,I54416,# & I80169,I37482,I68749,I68748,S51099,S24436,JH0537,S60601,# & I38443,I72171,I38509,S16769,JH0546,I61865,I37475,S11136,# & I38610,JH0535,I46858,I37078,I62041,A47636,I37477,I59645,# & I83063,I72755,I84431,A37028,JH0526,I37120,S24027,C35997,# & S24440,JH0545,I37480,I72753,I59622,I54493,S10934,S11135,# & I68774,I38505,I54418,I37483,I84488,A30345,I59188,I62043,# & I56034,C37028,I61903,B37028,I56133,I61866,I37529,I36961,# & JH0534,S24433,I38436,I72754,I61902,JH0536,I56039,JL0135,# & A45857,S16789,I80168,I61904,I36959,I54308,JH0547,I37476,# & I37542,S11134,JH0540,I36958,I59654,I38518,I38442,I72217,# & I36965,A45834,I36957,I37479,I61863,I59651,S48134,A45880,# & I80165,S42823,I37527,S24435,I38519,I56053,I72752,S44994,# & I54463)# & PIR3: (S07113,S06424,G02922)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAAS*# SEQUENCE: TQFVRFDSDAAS*# ...# >HUM206E2# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-50)# DB REFERENCE: SWISS: (1A66_HUMAN,1A03_GORGO,1A69_HUMAN,1A74_HUMAN,1A26_HUMAN,# & 1A25_HUMAN,1A29_HUMAN,1A11_HUMAN,1A43_HUMAN,1A01_GORGO,# & 1A26_HUMAN,1A31_HUMAN,1A30_HUMAN,1A02_GORGO,1A03_PANTR,# & 1A33_HUMAN,1A34_HUMAN,1A04_PANTR,1A32_HUMAN,1A68_HUMAN,# & 1A04_GORGO,1A02_HUMAN,1A24_HUMAN,1A02_HUMAN,1A03_HUMAN,# & 1A31_HUMAN,1A23_HUMAN,1A01_PANTR)# & PIR1: (HLHU32,HLHU28,HLHUA3,HLHUAW,HLHUA2,HLHU69)# & PIR2: (S03535,I54493,I37483,I38610,S16769,I37476,I84487,JH0534,# & I38436,I61902,I37480,A37028,I83063,JH0535,I37477,A47636,# & I72171,S51099,JH0537,I38443,I36966,A45847,I37482,A35997,# & I54416,I37470,S18198,S01171,I61857,I38441,I54307,I37479,# & I38519,I72170,I84448,I56039,JL0135,I37542,I36959,I36965,# & JH0536,I36961)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQRMEPRAP*# SEQUENCE: VDDTQFVRFDSDAASQRMEPRAP*# ...# >HUM206E3# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-48)# DB REFERENCE: SWISS: (1A01_GORGO,1A43_HUMAN,1A01_PONPY,1A29_HUMAN,1A11_HUMAN,# & 1A01_PANTR,1A02_HUMAN,1A03_HUMAN,1A26_HUMAN,1A33_HUMAN,# & 1A30_HUMAN,1A31_HUMAN,1A02_GORGO,1A32_HUMAN,1A04_GORGO,# & 1A23_HUMAN,1A04_PANTR,1A66_HUMAN,1A74_HUMAN,1A68_HUMAN,# & 1A24_HUMAN,1A02_HUMAN,1A31_HUMAN,1A34_HUMAN,1A26_HUMAN,# & 1A03_PANTR,1A03_GORGO,1A25_HUMAN,1A69_HUMAN)# & PIR1: (HLHUA3,HLHUAW,HLHU28,HLHU32,HLHU69,HLHUA2)# & PIR2: (I61902,I37476,JH0534,I38436,I36961,JH0536,S03535,I54493,# & S16769,I84448,I38519,I37479,JL0135,I56039,I84432,I36959,# & I37542,I36965,I54307,I38441,S01171,I37482,A35997,I54416,# & A45847,I36966,JH0537,A47636,JH0535,S18198,A37028,I37480,# & I72171,I83063,I38610,I84487,I72170,I61857,I37477,I37470,# & I38443,I37483,S51099)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQRMEPR*# SEQUENCE: VDDTQFVRFDSDAASQRMEPR*# ...# >HUM206E4# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-47)# DB REFERENCE: SWISS: (1A69_HUMAN,1A26_HUMAN,1A03_GORGO,1A25_HUMAN,1A31_HUMAN,# & 1A03_PANTR,1A33_HUMAN,1A31_HUMAN,1A30_HUMAN,1A43_HUMAN,# & 1A02_HUMAN,1A34_HUMAN,1A26_HUMAN,1A01_PANTR,1A03_HUMAN,# & 1A32_HUMAN,1A04_PANTR,1A23_HUMAN,1A04_GORGO,1A02_GORGO,# & 1A01_PONPY,1A29_HUMAN,1A11_HUMAN,1A01_GORGO,1A68_HUMAN,# & 1A02_HUMAN,1A74_HUMAN,1A66_HUMAN,1A24_HUMAN)# & PIR1: (HLHUA3,HLHU28,HLHUAW,HLHU32,HLHU69,HLHUA2)# & PIR2: (I38441,I72171,A37028,A47636,S18198,I36966,I38519,I84448,# & I37480,I83063,I61857,I84487,I37470,S03535,I54493,I37483,# & I37482,I36959,JH0535,JH0537,A45847,I54416,A35997,S01171,# & I54307,I37479,I37542,I36965,JL0135,I84432,I56039,I37476,# & JH0534,I38436,S16769,I36961,JH0536,S51099,I61902,I37477,# & I38443,I38610,I72170)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQRMEP*# SEQUENCE: VDDTQFVRFDSDAASQRMEP*# ...# >HUM206E5# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-46)# DB REFERENCE: SWISS: (1A34_HUMAN,1A43_HUMAN,1A66_HUMAN,1A74_HUMAN,1A68_HUMAN,# & 1A24_HUMAN,1A32_HUMAN,1A04_PANTR,1A23_HUMAN,1A01_PANTR,# & 1A03_HUMAN,1A01_PONPY,1A29_HUMAN,1A01_GORGO,1A11_HUMAN,# & 1A33_HUMAN,1A26_HUMAN,1A03_GORGO,1A25_HUMAN,1A31_HUMAN,# & 1A02_HUMAN,1A26_HUMAN,1A30_HUMAN,1A02_HUMAN,1A02_GORGO,# & 1A04_GORGO,1A69_HUMAN,1A03_PANTR,1A31_HUMAN)# & PIR1: (HLHUA3,HLHUA2,HLHUAW,HLHU28,HLHU69,HLHU32)# & PIR2: (I54493,I37483,I36959,I37482,I84448,I37480,I83063,I84487,# & I37470,I61857,I72170,I38610,I38441,S18198,I72171,I61902,# & I37477,I38443,I38436,JH0534,I37476,S16769,I36961,I37479,# & I56039,I84432,JH0536,JL0135,S01171,JH0537,A45847,JH0535,# & S51099,S03535,I54307,I54416,A35997,I37542,I36965,A47636,# & A37028,I36966,I38519)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQRME*# SEQUENCE: VDDTQFVRFDSDAASQRME*# ...# >HUM206E6# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (30-48)# DB REFERENCE: SWISS: (1A31_HUMAN,1A03_PANTR,1A69_HUMAN,1A03_HUMAN,1A01_PANTR,# & 1A32_HUMAN,1A04_PANTR,1A04_GORGO,1A02_HUMAN,1A34_HUMAN,# & 1A66_HUMAN,1A01_GORGO,1A02_GORGO,1A23_HUMAN,1A26_HUMAN,# & 1A68_HUMAN,1A24_HUMAN,1A74_HUMAN,1A01_PONPY,1A29_HUMAN,# & 1A11_HUMAN,1A43_HUMAN,1A02_HUMAN,1A30_HUMAN,1A33_HUMAN,# & 1A03_GORGO,1A26_HUMAN,1A25_HUMAN,1A31_HUMAN)# & PIR1: (HLHU69,HLHU28,HLHUA3,HLHU32,HLHUAW,HLHUA2)# & PIR2: (A35997,I54307,JH0537,A45847,JH0536,I36961,JH0535,I61902,# & I38443,I72171,S18198,I38441,JL0135,I54416,S01171,I37479,# & I56039,I84432,JH0534,I38436,I37476,S16769,I37477,I72170,# & I37480,I84448,I84487,I83063,I37470,I61857,I38610,I37542,# & I36965,I54493,I37483,I36959,I37482,S03535,I38519,A37028,# & A47636,I36966,S51099)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DTQFVRFDSDAASQRMEPR*# SEQUENCE: DTQFVRFDSDAASQRMEPR*# ...# >HUM206E7# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (31-49)# DB REFERENCE: SWISS: (1A02_GORGO,1A23_HUMAN,1A66_HUMAN,1A01_GORGO,1A34_HUMAN,# & 1A02_HUMAN,1A33_HUMAN,1A25_HUMAN,1A30_HUMAN,1A68_HUMAN,# & 1A74_HUMAN,1A43_HUMAN,1A01_PANTR,1A03_PANTR,1A24_HUMAN,# & 1A03_GORGO,1A26_HUMAN,1A31_HUMAN,1A03_HUMAN,1A29_HUMAN,# & 1A11_HUMAN,1A69_HUMAN,1A04_GORGO,1A04_PANTR,1A32_HUMAN,# & 1A02_HUMAN,1A26_HUMAN,1A31_HUMAN)# & PIR1: (HLHU28,HLHU32,HLHUA3,HLHUAW,HLHU69,HLHUA2)# & PIR2: (I54307,A35997,S51099,I61902,JH0536,I36961,JH0537,I72171,# & S18198,I38441,I38443,I37483,I54493,I36959,I37542,S03535,# & I38519,A47636,I37480,I84487,I37470,I61857,I83063,I38610,# & I72170,I38436,S16769,I37476,S01171,I36965,I36966,I54416,# & JL0135,I37482,I84448,JH0534,I37479,I56039,I37477,A45847,# & JH0535,A37028)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAASQRMEPRA*# SEQUENCE: TQFVRFDSDAASQRMEPRA*# ...# >HUM206E8# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-44)# DB REFERENCE: SWISS: (1A03_HUMAN,1A32_HUMAN,1A04_PANTR,1A04_GORGO,1A01_PONPY,# & 1A68_HUMAN,1A74_HUMAN,1A11_HUMAN,1A69_HUMAN,1A66_HUMAN,# & 1A25_HUMAN,1A03_GORGO,1A29_HUMAN,1A02_HUMAN,1A26_HUMAN,# & 1A31_HUMAN,1A31_HUMAN,1A26_HUMAN,1A02_HUMAN,1A33_HUMAN,# & 1A30_HUMAN,1A43_HUMAN,1A02_GORGO,1A23_HUMAN,1A01_GORGO,# & 1A34_HUMAN,1A24_HUMAN,1A01_PANTR,1A03_PANTR)# & PIR1: (HLHU28,HLHU69,HLHUAW,HLHUA2,HLHU32,HLHUA3)# & PIR2: (A35997,I54307,A37028,I72170,S01171,S51099,I38519,I37483,# & I36961,JH0537,S18198,I38441,I38443,I54493,I37480,S16769,# & I37476,I38436,I84432,I38610,I83063,I84487,I61857,I37470,# & I36959,I37542,S03535,A47636,I37479,JH0536,I61902,I72171,# & I84448,I37482,JH0534,I56039,I37477,A45847,JH0535,I54416,# & JL0135,I36965,I36966)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQR*# SEQUENCE: VDDTQFVRFDSDAASQR*# ...# >HUM206E9# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (31-47)# DB REFERENCE: SWISS: (1A29_HUMAN,1A02_HUMAN,1A26_HUMAN,1A31_HUMAN,1A66_HUMAN,# & 1A03_GORGO,1A24_HUMAN,1A01_PANTR,1A02_HUMAN,1A30_HUMAN,# & 1A02_GORGO,1A23_HUMAN,1A01_GORGO,1A69_HUMAN,1A74_HUMAN,# & 1A31_HUMAN,1A26_HUMAN,1A33_HUMAN,1A34_HUMAN,1A03_PANTR,# & 1A68_HUMAN,1A01_PONPY,1A43_HUMAN,1A03_HUMAN,1A04_PANTR,# & 1A04_GORGO,1A32_HUMAN,1A11_HUMAN,1A25_HUMAN)# & PIR1: (HLHUA2,HLHU28,HLHUA3,HLHU32,HLHU69,HLHUAW)# & PIR2: (I54493,A35997,I54307,I37483,I72170,S01171,JH0537,I36961,# & I38443,S18198,S51099,I38519,I36966,I84448,I37482,I37477,# & JH0534,A45847,JL0135,I54416,S16769,JH0536,I61902,I72171,# & S03535,I36959,I37542,I61857,I84487,I83063,I38610,I37476,# & I38436,I84432,A47636,I37479,I37480,I56039,I37470,I38441,# & A37028,JH0535,I36965)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAASQRMEP*# SEQUENCE: TQFVRFDSDAASQRMEP*# ...# >HUM206EA# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (31-45)# DB REFERENCE: SWISS: (1A68_HUMAN,1A01_PONPY,1A03_HUMAN,1A11_HUMAN,1A02_HUMAN,# & 1A43_HUMAN,1A26_HUMAN,1A31_HUMAN,1A04_GORGO,1A04_PANTR,# & 1A32_HUMAN,1A25_HUMAN,1A24_HUMAN,1A01_PANTR,1A02_GORGO,# & 1A23_HUMAN,1A01_GORGO,1A30_HUMAN,1A29_HUMAN,1A66_HUMAN,# & 1A31_HUMAN,1A02_HUMAN,1A03_GORGO,1A03_PANTR,1A34_HUMAN,# & 1A26_HUMAN,1A69_HUMAN,1A74_HUMAN,1A33_HUMAN)# & PIR1: (HLHUAW,HLHUA2,HLHUA3,HLHU32,HLHU69,HLHU28)# & PIR2: (I54493,I37470,I83063,JH0536,I84432,S01171,I54307,A45847,# & I36966,S16769,I38610,I37477,I36959,I61857,I84487,S03535,# & I37542,I61902,I84448,I37482,JH0534,JL0135,I54416,I37476,# & I38436,I72171,S18198,I72170,I37483,S51099,I38519,JH0537,# & I38443,I36961,A35997,I56039,JH0535,I36965,I38441,A37028,# & A47636,I37479,I37480)# & PIR3: (S06424)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAASQRM*# SEQUENCE: TQFVRFDSDAASQRM*# ...# >HUM206EB# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-50)# DB REFERENCE: SWISS: (1C18_HUMAN,1C01_HUMAN,1C02_GORGO,1C02_HUMAN,1CXX_HUMAN,# & 1C17_HUMAN,1C16_HUMAN,1C04_HUMAN,1C03_GORGO,1C02_GORGO,# & 1B55_HUMAN,1C04_GORGO,1C01_PANTR,1C06_HUMAN,1C15_HUMAN,# & 1C02_HUMAN,1C11_HUMAN)# & PIR1: (HLHUC4)# & PIR2: (I37529,I37527,S44994,S42823,S48134,A49411,I38507,I37526,# & C37028,I54449,I72113,JH0546,JH0545,I38505,B37028,I68749,# & I56130,I37544,I56034,I37528,I61866,A45857,I81231,I54430,# & I37078,I37523,I59622,JH0547)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASPRGEPRAP*# SEQUENCE: VDDTQFVRFDSDAASPRGEPRAP*# ...# >HUM206EC# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (31-52)# DB REFERENCE: SWISS: (1C11_HUMAN,1C06_HUMAN,1C15_HUMAN,1C02_HUMAN,1C04_HUMAN,# & 1C16_HUMAN,1C01_PANTR,1C18_HUMAN,1C02_GORGO,1C01_HUMAN,# & 1C17_HUMAN,1CXX_HUMAN,1C02_HUMAN,1C04_GORGO,1C03_GORGO,# & 1B55_HUMAN,1C02_GORGO)# & PIR1: (HLHUC4)# & PIR2: (I72113,S48134,I68749,I37544,I38505,I54430,B37028,JH0545,# & JH0546,I54449,I38507,C37028,S44994,S42823,I37527,A49411,# & I37529,I59622,I37523,I37078,I81231,I37526,I56130,A45857,# & I61866,I37528,I56034,JH0547,I36958)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAASPRGEPRAP*# SEQUENCE: TQFVRFDSDAASPRGEPRAP*# ...# >HUM206ED# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-48)# DB REFERENCE: SWISS: (1CXX_HUMAN,1C02_HUMAN,1C04_GORGO,1C01_PANTR,1C17_HUMAN,# & 1C01_HUMAN,1C02_GORGO,1C15_HUMAN,1C06_HUMAN,1C02_HUMAN,# & 1C03_GORGO,1B55_HUMAN,1C02_GORGO,1C03_HUMAN,1C07_HUMAN,# & 1C04_HUMAN,1C16_HUMAN,1C18_HUMAN,1C11_HUMAN)# & PIR1: (HLHUC4)# & PIR2: (I38505,I68749,I37544,S48134,I72113,I37526,I37529,I37523,# & I37078,I68712,I37528,JS0262,I56130,I61866,A45857,JH0547,# & B37028,I37527,S44994,I38507,A49411,JH0546,I54449,JH0545,# & I81231,C37028,I59622,I54430,S42823,JH0526,I56034)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASPRGEPR*# SEQUENCE: VDDTQFVRFDSDAASPRGEPR*# ...# >HUM206EE# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-47)# DB REFERENCE: SWISS: (1C16_HUMAN,1C04_HUMAN,1C03_HUMAN,1CXX_HUMAN,1C02_GORGO,# & 1C04_GORGO,1C02_HUMAN,1C07_HUMAN,1C18_HUMAN,1C11_HUMAN,# & 1C17_HUMAN,1C02_GORGO,1C06_HUMAN,1C15_HUMAN,1C01_HUMAN,# & 1C03_GORGO,1B55_HUMAN,1C02_HUMAN,1C01_PANTR)# & PIR1: (HLHUC4)# & PIR2: (I68749,JH0546,S44994,I37529,I56130,S48134,I59622,I54449,# & JS0262,B37028,JH0545,I38507,A49411,I37527,I37078,I68712,# & I37523,I37528,A45857,I61866,JH0547,I37544,I38505,I72113,# & I37526,JH0526,S42823,I54430,I56034,C37028,I81231)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASPRGEP*# SEQUENCE: VDDTQFVRFDSDAASPRGEP*# ...# >HUM206EF# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-46)# DB REFERENCE: SWISS: (1C03_GORGO,1C02_HUMAN,1C01_HUMAN,1C01_PANTR,1C07_HUMAN,# & 1C18_HUMAN,1C02_GORGO,1C04_HUMAN,1C17_HUMAN,1B55_HUMAN,# & 1C11_HUMAN,1C16_HUMAN,1CXX_HUMAN,1C03_HUMAN,1C02_GORGO,# & 1C04_GORGO,1C02_HUMAN,1C15_HUMAN,1C06_HUMAN)# & PIR1: (HLHUC4)# & PIR2: (JS0262,I68749,I59622,I54449,I56130,S44994,I37529,JH0546,# & I81231,S42823,I54430,I37544,I38505,I72113,I37526,I37528,# & I61866,JH0547,I37527,A49411,I68712,I38507,S48134,B37028,# & JH0526,I37523,I37078,A45857,JH0545,I56034,C37028)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASPRGE*# SEQUENCE: VDDTQFVRFDSDAASPRGE*# ...# >HUM206F0# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-45)# DB REFERENCE: SWISS: (1C02_GORGO,1C02_GORGO,1CXX_HUMAN,1C04_GORGO,1C03_HUMAN,# & 1C06_HUMAN,1C15_HUMAN,1C02_HUMAN,1C03_GORGO,1C11_HUMAN,# & 1B55_HUMAN,1C16_HUMAN,1C01_HUMAN,1C02_HUMAN,1C01_PANTR,# & 1C07_HUMAN,1C18_HUMAN,1C04_HUMAN,1C17_HUMAN)# & PIR1: (HLHUC4)# & PIR2: (I37523,A45857,JH0545,I56034,JH0526,I37544,I61866,I37527,# & S48134,B37028,A49411,JH0547,I37528,I38505,I37526,I72113,# & S42823,I54430,I59622,I54449,I68749,I37529,S44994,JH0546,# & I56130,I81231,JS0262,I37078,C37028,I38507,I68712)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASPRG*# SEQUENCE: VDDTQFVRFDSDAASPRG*# ...# >HUM206F1# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (31-48)# DB REFERENCE: SWISS: (1C11_HUMAN,1C16_HUMAN,1B55_HUMAN,1C18_HUMAN,1C01_HUMAN,# & 1C17_HUMAN,1C04_HUMAN,1C15_HUMAN,1C06_HUMAN,1C02_HUMAN,# & 1C03_GORGO,1C01_PANTR,1CXX_HUMAN,1C03_HUMAN,1C02_GORGO,# & 1C02_HUMAN,1C04_GORGO,1C02_GORGO,1C07_HUMAN)# & PIR1: (HLHUC4)# & PIR2: (B37028,I56034,JH0526,JH0545,I37523,A45857,I37527,S48134,# & I61866,I37544,I38507,I68712,C37028,I36958,JS0262,I56130,# & I81231,A49411,JH0547,I59622,S44994,I37078,I37528,S42823,# & I38505,I72113,I37526,I54430,I54449,JH0546,I37529,# & I68749)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAASPRGEPR*# SEQUENCE: TQFVRFDSDAASPRGEPR*# ...# >HUM206F2# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-44)# DB REFERENCE: SWISS: (1C16_HUMAN,1B11_HUMAN,1C02_GORGO,1B25_HUMAN,1CXX_HUMAN,# & 1B58_HUMAN,1B21_HUMAN,1C17_HUMAN,1B04_HUMAN,1B31_HUMAN,# & 1C01_HUMAN,1B02_HUMAN,1B61_HUMAN,1C04_GORGO,1B59_HUMAN,# & 1B52_HUMAN,1C07_HUMAN,1B24_HUMAN,1B27_HUMAN,1C02_HUMAN,# & 1B12_HUMAN,1C02_HUMAN,1B01_PANTR,1C02_GORGO,1C01_PANTR,# & 1C03_HUMAN,1B54_HUMAN,1B12_HUMAN,1B32_HUMAN,1B49_HUMAN,# & HA1B_RABIT,HA1A_RABIT,1B46_HUMAN,1B07_HUMAN,1B02_GORGO,# & 1B39_HUMAN,1B23_HUMAN,1B56_HUMAN,1B57_HUMAN,1B22_HUMAN,# & 1C11_HUMAN,1B55_HUMAN,1B29_HUMAN,1B63_HUMAN,1B01_GORGO,# & 1B26_HUMAN,1C18_HUMAN,1C01_SAGOE,1C04_HUMAN,1B10_HUMAN,# & 1B03_GORGO,1B53_HUMAN,1C03_GORGO,1B01_SAGOE,1B60_HUMAN,# & 1B08_HUMAN,1A01_SAGOE,1B62_HUMAN,1C15_HUMAN,1C06_HUMAN,# & 1B44_HUMAN,1B28_HUMAN)# & PIR1: (HLHUB7,HLHUB8,S42102,HLHUC4,HLRB)# & PIR2: (S52290,JH0541,I80169,S24438,I54298,I54314,D35997,I80171,# & I68712,I46858,I56130,I62041,I59188,A30345,JH0547,I72755,# & S24027,S11135,I54463,I37529,JH0546,I59651,I61863,I38505,# & A45880,JH0526,I62045,S10934,I72753,C35997,I62043,I37528,# & JH0545,I61859,A45834,I68774,I84488,I54418,I38509,S24440,# & I84431,I37120,I81231,I61865,I37475,JS0262,I84490,I59645,# & S11136,I59308,S33355,S60601,I61862,I62042,I68748,S24436,# & C37028,A49411,I61903,S24434,I80167,I61907,I38421,S11142,# & I72218,I56034,I37523,A45857,I80166,S11138,I37527,I54457,# & I54505,I67482,JH0539,S48134,I84486,I38507,I37521,I37522,# & B30345,S24437,I61866,I59633,I37544,I68850,S11133,I81233,# & G01230,S03537,I68747,S11141,I62044,S24439,B37028,I36957,# & I54430,I80165,I72113,I37526,I54449,I68749,I72752,I61904,# & I56053,S24435,S16789,S42823,I72217,I59654,JH0540,S11134,# & I80168,I54308,S24433,S44994,I59622,I72754,I37078,# & I56133)# & PIR3: (S07113,G02922)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASPR*# SEQUENCE: VDDTQFVRFDSDAASPR*# ...# >HUM206F3# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (30-46)# DB REFERENCE: SWISS: (1C03_HUMAN,1C01_PANTR,1C15_HUMAN,1C06_HUMAN,1C03_GORGO,# & 1C02_GORGO,1C07_HUMAN,1C02_HUMAN,1C02_HUMAN,1B55_HUMAN,# & 1C04_GORGO,1C04_HUMAN,1C16_HUMAN,1C17_HUMAN,1CXX_HUMAN,# & 1C02_GORGO,1C01_HUMAN,1C18_HUMAN,1C11_HUMAN)# & PIR1: (HLHUC4)# & PIR2: (JH0526,I37529,I68712,I56130,JH0547,I59622,I54430,I37526,# & I68749,B37028,S44994,S42823,I54449,I72113,A45857,I56034,# & I36958,S48134,I37544,I61866,I38507,C37028,I81231,JS0262,# & I37523,I37527,I37528,JH0545,I37078,I38505,JH0546,# & A49411)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DTQFVRFDSDAASPRGE*# SEQUENCE: DTQFVRFDSDAASPRGE*# ...# >HUM206F4# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (31-44)# DB REFERENCE: SWISS: (1C03_GORGO,1B13_HUMAN,1B26_HUMAN,1C01_SAGOE,1B04_HUMAN,# & 1C18_HUMAN,1C02_GORGO,1CXX_HUMAN,1B31_HUMAN,1B21_HUMAN,# & 1B02_HUMAN,1B57_HUMAN,1B25_HUMAN,1B11_HUMAN,1B01_GORGO,# & 1B03_GORGO,1C15_HUMAN,1C01_HUMAN,1C11_HUMAN,HA1A_RABIT,# & 1B12_HUMAN,1B61_HUMAN,1C16_HUMAN,1C17_HUMAN,1B59_HUMAN,# & 1B52_HUMAN,1B24_HUMAN,1C04_HUMAN,1B27_HUMAN,1B55_HUMAN,# & 1B58_HUMAN,1C02_HUMAN,1B01_PANTR,1C04_GORGO,1B01_SAGOE,# & 1B60_HUMAN,1B08_HUMAN,1A01_SAGOE,1C01_PANTR,1C03_HUMAN,# & 1B44_HUMAN,1B49_HUMAN,HA1B_RABIT,1C07_HUMAN,1B32_HUMAN,# & 1B28_HUMAN,1B62_HUMAN,1B22_HUMAN,1B56_HUMAN,1C06_HUMAN,# & 1B10_HUMAN,1B53_HUMAN,1B63_HUMAN,1B29_HUMAN,1B02_GORGO,# & 1B46_HUMAN,1B54_HUMAN,1B12_HUMAN,1C02_HUMAN,1C02_GORGO,# & 1B23_HUMAN,1B39_HUMAN,1B07_HUMAN)# & PIR1: (HLRB,HLHUB7,HLHUC4,HLHUB8,S42102)# & PIR2: (I59308,I81231,I84431,S60601,I37544,I36958,I56130,I36957,# & JH0526,I59633,I37526,I68749,S44994,S11141,I80166,I54463,# & I62045,S11135,I62041,I46858,I59188,A30345,A49411,S52290,# & S24438,I54314,I54308,S11134,S10934,I54418,I84488,I38509,# & S24437,I84490,S33355,I59645,S11136,I61865,I37475,C37028,# & S24440,JS0262,I68774,I37120,A45857,I56034,S48134,S24436,# & I84486,I68748,I61862,I61866,I38507,B37028,I54430,I68850,# & I37522,I61860,B30345,I37521,I68747,I59622,I62044,JH0539,# & S42823,I67482,I54457,I54505,I72218,I61907,S11142,I38421,# & S11138,G01230,I80168,I62042,I61903,S16789,I72754,I72217,# & I37529,I59654,JH0540,S24439,S03537,I81233,S11133,I68712,# & I72752,I61904,S24435,I56053,JH0547,I80165,S24433,I56133,# & I72755,S24027,I54298,D35997,I80171,JH0541,I80169,I61863,# & A45880,I59651,JH0546,I38505,I37078,C35997,I72753,I62043,# & JH0545,I37528,S24434,I54449,I72113,I80167,I37523,I37527,# & I61859,A45834)# & PIR3: (G02922,S07113)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAASPR*# SEQUENCE: TQFVRFDSDAASPR*# ...# >HUM206F5# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9 (31-42)# DB REFERENCE: SWISS: (1C02_HUMAN,1B36_HUMAN,1C04_HUMAN,1B34_HUMAN,1C03_HUMAN,# & 1C14_HUMAN,1C07_HUMAN,1C02_HUMAN,1C12_HUMAN,1C16_HUMAN,# & 1C17_HUMAN,1B39_HUMAN,1C15_HUMAN,1B20_HUMAN,1C01_HUMAN,# & 1C11_HUMAN,1C01_PANTR,1C03_GORGO,1CXX_HUMAN,1C18_HUMAN,# & 1B04_HUMAN,1B02_HUMAN,1B38_HUMAN,HA19_CANFA,1C01_GORGO,# & 1B35_HUMAN,1C06_HUMAN)# & PIR1: (S42102,HLHUB7,HLHUC4)# & PIR2: (I46603,A45897,I46604,I46030,I59188,A49411,I37526,I68749,# & I67483,B45831,S44994,JH0526,I37544,I81231,I72113,I54449,# & I37527,I61906,I37492,JH0546,I38505,I37528,JH0290,I37078,# & I37523,I61864,JH0292,I61866,I37529,A60369,S52486,I68712,# & I61905,I54430,I59655,I59622,I68747,I67482,S42823,I81232,# & JH0288,JH0543,JH0291,I38507,I61865,JH0544,C37028,I56034,# & A45857,A45849,I56116,S48134,B37028,JH0289,S11143,A45845,# & I54418,I56149,I59651,I68750,I68701,I84431,I36958,S60601,# & I72808,I37135,JS0262)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLRSWTAADTAAQIT*# SEQUENCE: DLRSWTAADTAAQIT*# ...# >HUM206F6# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9 (130-150)# DB REFERENCE: SWISS: (1C14_HUMAN,1C03_HUMAN,1C06_HUMAN,1B04_HUMAN,1B38_HUMAN,# & 1C01_GORGO,HA19_CANFA,1B35_HUMAN,1C02_HUMAN,1C17_HUMAN,# & 1B39_HUMAN,1C18_HUMAN,1C01_HUMAN,1C01_PANTR,1CXX_HUMAN,# & 1B02_HUMAN,1C02_HUMAN,1B36_HUMAN,1C04_HUMAN,1B34_HUMAN,# & 1C16_HUMAN,1C07_HUMAN,1C12_HUMAN,1C15_HUMAN,# & 1B20_HUMAN)# & PIR1: (HLHUB7,HLHUC4,S42102)# & PIR2: (I38507,A45857,I68747,I81232,I68749,I81231,I72113,I61864,# & I59651,I68701,I84431,I54418,I56149,S48134,I37544,S44994,# & I59622,S42823,I54430,I56116,I56034,B37028,JH0544,C37028,# & JH0543,S52486,I61905,I68712,I61906,I37492,I37523,I37527,# & I38505,I37528,I59655,I61865,I37135,I59188,JH0526,I37526,# & I54449,JS0262,S60601,A45845,I61866)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LRSWTAADTAAQITQRKWEAA*# SEQUENCE: LRSWTAADTAAQITQRKWEAA*# ...# >HUM206F7# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9 (129-147)# DB REFERENCE: SWISS: (1C01_PANTR,1CXX_HUMAN,1C04_HUMAN,1C16_HUMAN,1C15_HUMAN,# & 1B02_HUMAN,HA19_CANFA,1C02_HUMAN,1B39_HUMAN,1C17_HUMAN,# & 1C18_HUMAN,1C01_HUMAN,1B35_HUMAN,1B34_HUMAN,1B36_HUMAN,# & 1B20_HUMAN,1C01_GORGO,1B38_HUMAN,1B04_HUMAN,1C14_HUMAN,# & 1C03_HUMAN,1C06_HUMAN,1C12_HUMAN,1C07_HUMAN,# & 1C02_HUMAN)# & PIR1: (S42102,HLHUB7,HLHUC4)# & PIR2: (I59655,I37135,S44994,I56149,I84431,I68701,I68747,I81232,# & A45857,I68749,I81231,I61864,JS0262,S60601,I56116,I59188,# & JH0526,I54449,I37523,I38505,B37028,I54430,I61905,S52486,# & JH0543,C37028,I37526,I59651,I37544,S42823,I61906,I61865,# & S48134,I54418,I72113,I38507,I61866,A45845,I68712,I59622,# & I56034,I37528,I37527,I37492,JH0544)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLRSWTAADTAAQITQRKW*# SEQUENCE: DLRSWTAADTAAQITQRKW*# ...# >HUM206F8# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9 (130-147)# DB REFERENCE: SWISS: (1C04_HUMAN,1C03_HUMAN,1C12_HUMAN,1C07_HUMAN,1C14_HUMAN,# & HA19_CANFA,1C06_HUMAN,1C02_HUMAN,1B20_HUMAN,1C01_PANTR,# & 1C01_GORGO,1B04_HUMAN,1C16_HUMAN,1B38_HUMAN,1C18_HUMAN,# & 1B34_HUMAN,1B35_HUMAN,1B36_HUMAN,1C15_HUMAN,1CXX_HUMAN,# & 1B02_HUMAN,1C02_HUMAN,1B39_HUMAN,1C17_HUMAN,# & 1C01_HUMAN)# & PIR1: (HLHUC4,HLHUB7,S42102)# & PIR2: (C37028,JH0526,I37523,JS0262,A45857,I81232,I81231,I68749,# & I68701,I56149,I37528,I37526,I61905,I38505,I59622,S60601,# & JH0543,I54430,B37028,S52486,I54449,I84431,I68747,I61864,# & I68712,I37492,I37527,I56034,JH0544,S44994,I37135,I59655,# & I54418,I38507,I72113,I61866,A45845,S48134,S42823,I61906,# & I61865,I59651,I37544,I56116,I59188)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LRSWTAADTAAQITQRKW*# SEQUENCE: LRSWTAADTAAQITQRKW*# ...# >HUM206F9# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9 (129-145)# DB REFERENCE: SWISS: (1B04_HUMAN,1B35_HUMAN,1B36_HUMAN,1B02_HUMAN,1CXX_HUMAN,# & 1C01_HUMAN,1C02_HUMAN,1C17_HUMAN,1C16_HUMAN,1C03_GORGO,# & 1C11_HUMAN,1B38_HUMAN,1B34_HUMAN,1B39_HUMAN,1C07_HUMAN,# & HA19_CANFA,1C02_HUMAN,1C06_HUMAN,1C01_PANTR,1B20_HUMAN,# & 1C01_GORGO,1C18_HUMAN,1C14_HUMAN,1C04_HUMAN,1C03_HUMAN,# & 1C12_HUMAN,1C15_HUMAN)# & PIR1: (HLHUB7,HLHUC4,S42102)# & PIR2: (S60601,I38505,I37526,I68750,I68701,I56149,I37528,I36958,# & I59188,I37544,I59651,JH0526,I37523,JS0262,A45857,I81232,# & I37492,I37527,I68712,I59655,I37135,S44994,I54418,I72113,# & I38507,I61866,A45845,S48134,I61865,I54449,I61864,JH0546,# & C37028,I37078,I56034,JH0544,A49411,I61906,I72808,I37529,# & S52486,I61905,S11143,I59622,I81231,I68749,S42823,I56116,# & I68747,I84431,B37028,JH0543,I54430)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLRSWTAADTAAQITQR*# SEQUENCE: DLRSWTAADTAAQITQR*# ...# >HUM206FA# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9 (129-144)# DB REFERENCE: SWISS: (1CXX_HUMAN,1B02_HUMAN,1C12_HUMAN,1C03_HUMAN,1C15_HUMAN,# & 1C17_HUMAN,1C07_HUMAN,1C02_HUMAN,1C18_HUMAN,1C14_HUMAN,# & 1C04_HUMAN,1C02_HUMAN,1C01_HUMAN,1B35_HUMAN,1C11_HUMAN,# & 1C06_HUMAN,1B39_HUMAN,1B34_HUMAN,HA19_CANFA,1C01_GORGO,# & 1B20_HUMAN,1C01_PANTR,1B36_HUMAN,1B04_HUMAN,1C16_HUMAN,# & 1C03_GORGO,1B38_HUMAN)# & PIR1: (HLHUB7,S42102,HLHUC4)# & PIR2: (I54449,I61864,I38507,I61865,I37492,A45857,I68750,JS0262,# & I38505,S60601,I68747,I84431,I68749,I81231,I61905,S52486,# & I81232,S48134,I54418,I72113,I61866,A45845,I37527,I68712,# & I59655,I37135,JH0546,S44994,I37526,I68701,I56149,I37528,# & I36958,I59651,I37544,I59188,JH0526,I37523,B37028,JH0543,# & I54430,S42823,I56116,S11143,I59622,I37529,I37078,A49411,# & I56034,JH0544,I61906,I72808,C37028)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLRSWTAADTAAQITQ*# SEQUENCE: DLRSWTAADTAAQITQ*# ...# >HUM206FB# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw62 (129-145)# DB REFERENCE: SWISS: (1B45_HUMAN,1B58_HUMAN,1B61_HUMAN,1B55_HUMAN,1B47_HUMAN,# & 1B01_PANTR,1B15_HUMAN,1B23_HUMAN,1B52_HUMAN,1B40_HUMAN,# & 1B43_HUMAN,1B04_GORGO,1B02_GORGO,1B22_HUMAN,1B56_HUMAN,# & 1B08_HUMAN,1B41_HUMAN,1B54_HUMAN,1B12_HUMAN,1B32_HUMAN,# & 1B28_HUMAN,1B11_HUMAN,1B25_HUMAN,1B01_GORGO,1B48_HUMAN,# & 1B03_GORGO,1B21_HUMAN,1B18_HUMAN,1B42_HUMAN,1B12_HUMAN,# & 1B27_HUMAN,1B07_HUMAN,1B59_HUMAN,1B24_HUMAN,1B44_HUMAN,# & 1B49_HUMAN,1B16_HUMAN,1B19_HUMAN,1B02_PANTR,1B29_HUMAN,# & 1B62_HUMAN,1B31_HUMAN,1B57_HUMAN,1B60_HUMAN,1B63_HUMAN,# & 1B14_HUMAN,1A02_PANTR,1B26_HUMAN,1B13_HUMAN,1B10_HUMAN,# & 1B53_HUMAN)# & PIR1: (HLHUB2,HLHUB8,HLHUB4)# & PIR2: (I80168,I80173,I62042,I38860,I38509,A30345,I68724,I54314,# & I54463,I62045,I36956,I59308,S03538,I38874,I38875,I56130,# & I36957,I54308,I38876,A45834,I61859,I54289,I37520,S24434,# & I80167,S24027,JH0541,S25415,I56133,S24433,I61863,I80170,# & I36960,C35997,I72753,I62044,I61907,I37521,B30345,I68850,# & I37515,I84490,I80174,I59645,I37475,I84486,I37516,S24436,# & S03537,I80165,I80172,I61861,I72752,I36962,S24435,I59654,# & I37485,I72754,I37519,S16789,I54298,I68774,I61862,I80171,# & I62043,I80175,I59633,I84488,S24437,S24440,I37120,G01230,# & I62041,A45880,I80169,I72755,D35997,I61904,I81233,JH0540,# & I61860,I37522,JH0542,JH0539,I54457,I54505,S24439,I38421,# & I80176,I68748)# & PIR3: (S07115,S07113)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLSSWTAADTAAQITQR*# SEQUENCE: DLSSWTAADTAAQITQR*# ...# >HUM206FC# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw62 (129-150)# DB REFERENCE: SWISS: (1B22_HUMAN,1B56_HUMAN,1B08_HUMAN,1B10_HUMAN,1B13_HUMAN,# & 1B26_HUMAN,1B53_HUMAN,1B12_HUMAN,1B19_HUMAN,1B14_HUMAN,# & 1B42_HUMAN,1B29_HUMAN,1B63_HUMAN,1B60_HUMAN,1B54_HUMAN,# & 1B32_HUMAN,1B41_HUMAN,1A02_PANTR,1B43_HUMAN,1B55_HUMAN,# & 1B25_HUMAN,1B31_HUMAN,1B27_HUMAN,1B49_HUMAN,1B07_HUMAN,# & 1B59_HUMAN,1B24_HUMAN,1B62_HUMAN,1B16_HUMAN,1B44_HUMAN,# & 1B02_PANTR,1B57_HUMAN,1B23_HUMAN,1B40_HUMAN,1B52_HUMAN,# & 1B61_HUMAN,1B02_GORGO,1B04_GORGO,1B28_HUMAN,1B12_HUMAN,# & 1B01_PANTR,1B15_HUMAN,1B47_HUMAN,1B45_HUMAN,1B11_HUMAN,# & 1B58_HUMAN,1B03_GORGO,1B48_HUMAN,1B01_GORGO,1B21_HUMAN,# & 1B18_HUMAN)# & PIR1: (HLHUB2,HLHUB4,HLHUB8)# & PIR2: (I68850,I37521,I37475,I84490,I37515,I72754,I61861,I36962,# & I72753,I54308,I38874,A30345,I80173,I38860,I62041,I72755,# & S24439,I61860,JH0542,I54298,I68774,I61862,I59645,I37120,# & I62043,I54457,I59308,I80172,I80174,S25415,S24027,S24435,# & C35997,I36960,I61863,I80170,JH0541,I56133,S24433,I61907,# & I62044,B30345,I37516,S24436,I84486,I72752,I80165,S03537,# & I59654,I37485,I37519,S16789,I38509,I54463,I36956,I62045,# & I54314,I68724,I38876,I37520,I54289,A45834,I61859,S24434,# & I80167,S03538,I38875,I36957,I56130,I80168,I62042,D35997,# & I80169,I61904,JH0540,JH0539,I54505,I81233,I38421,I37522,# & I68748,I80176,A45880,S24440,G01230,I84488,S24437,I59633,# & I80175,I80171)# & PIR3: (S07115,S07113)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLSSWTAADTAAQITQRKWEAA*# SEQUENCE: DLSSWTAADTAAQITQRKWEAA*# ...# >HUM206FD# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw62 (129-148)# DB REFERENCE: SWISS: (1B62_HUMAN,1B02_PANTR,1B07_HUMAN,1B59_HUMAN,1B24_HUMAN,# & 1B21_HUMAN,1B57_HUMAN,1B18_HUMAN,1B03_GORGO,1B01_GORGO,# & 1B40_HUMAN,1B52_HUMAN,1B61_HUMAN,1B23_HUMAN,1B47_HUMAN,# & 1B01_PANTR,1B15_HUMAN,1B11_HUMAN,1B45_HUMAN,1B58_HUMAN,# & 1B60_HUMAN,1B41_HUMAN,1B54_HUMAN,1B43_HUMAN,1B25_HUMAN,# & 1B55_HUMAN,1B31_HUMAN,1B14_HUMAN,1B49_HUMAN,1B32_HUMAN,# & 1A02_PANTR,1B27_HUMAN,1B63_HUMAN,1B16_HUMAN,1B44_HUMAN,# & 1B48_HUMAN,1B56_HUMAN,1B22_HUMAN,1B53_HUMAN,1B12_HUMAN,# & 1B19_HUMAN,1B42_HUMAN,1B29_HUMAN,1B08_HUMAN,1B13_HUMAN,# & 1B26_HUMAN,1B10_HUMAN,1B12_HUMAN,1B04_GORGO,1B02_GORGO,# & 1B28_HUMAN)# & PIR1: (HLHUB2,HLHUB8,HLHUB4)# & PIR2: (I59308,I54457,S25415,S24027,I80174,S24435,I62043,I54298,# & I61862,I80173,I38860,I62041,I61861,I72754,I72753,I54308,# & I59633,D35997,A45880,JH0540,I61904,JH0539,I81233,I68748,# & I37522,I80168,S24440,S24437,I84488,G01230,C35997,I37520,# & I54289,I61863,I56133,JH0541,I61907,I37516,I84486,I80165,# & S03537,I72752,I38876,A45834,I61859,S24434,I80167,I36957,# & I68724,I54314,I38875,I80169,I80176,I54505,S03538,I37521,# & I59645,I37120,I68774,S24436,I37519,S16789,I80172,I36962,# & I68850,I84490,I37515,I37475,I38874,A30345,I61860,S24439,# & JH0542,I72755,I80171,I80175,I38421,I62042,I38509,I54463,# & I36956,I62045,I56130,I80170,I36960,B30345,I62044,I59654,# & I37485,S24433)# & PIR3: (S07115,S07113)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLSSWTAADTAAQITQRKWE*# SEQUENCE: DLSSWTAADTAAQITQRKWE*# ...# >HUM206FE# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw62 (129-146)# DB REFERENCE: SWISS: (1B23_HUMAN,1B02_GORGO,1B40_HUMAN,1B52_HUMAN,1B61_HUMAN,# & 1B01_PANTR,1B15_HUMAN,1B12_HUMAN,1B10_HUMAN,1B26_HUMAN,# & 1B47_HUMAN,1B08_HUMAN,1B13_HUMAN,1B28_HUMAN,1B04_GORGO,# & 1B45_HUMAN,1B02_PANTR,1B21_HUMAN,1B03_GORGO,1B01_GORGO,# & 1B60_HUMAN,1B43_HUMAN,1B31_HUMAN,1B16_HUMAN,1A02_PANTR,# & 1B22_HUMAN,1B48_HUMAN,1B32_HUMAN,1B27_HUMAN,1B63_HUMAN,# & 1B44_HUMAN,1B56_HUMAN,1B19_HUMAN,1B29_HUMAN,1B42_HUMAN,# & 1B12_HUMAN,1B53_HUMAN,1B57_HUMAN,1B18_HUMAN,1B58_HUMAN,# & 1B11_HUMAN,1B62_HUMAN,1B07_HUMAN,1B24_HUMAN,1B59_HUMAN,# & 1B55_HUMAN,1B25_HUMAN,1B54_HUMAN,1B41_HUMAN,1B49_HUMAN,# & 1B14_HUMAN)# & PIR1: (HLHUB4,HLHUB2,HLHUB8)# & PIR2: (I61907,I36957,I84486,I37522,I61904,I84488,S24440,I59633,# & I61861,S24027,A30345,I68850,JH0542,I80175,I84490,I56130,# & I38509,S24434,I54314,I80172,I68774,S24436,I36962,D35997,# & I80165,I37475,S24437,G01230,A45880,JH0540,JH0539,I81233,# & I68748,I80168,I61863,JH0541,C35997,I38876,I37520,I54289,# & I61859,A45834,S03537,I37516,I72752,I56133,I80167,I68724,# & I54298,I61862,I62043,I80173,I38860,I62041,I72754,I72753,# & I54308,I54457,I59308,S25415,I80174,S24435,I38421,I62042,# & I54463,I36956,I62045,I36960,I80170,S24433,I62044,I59654,# & I37485,B30345,I72755,I61860,S24439,I38874,I37515,I80171,# & I37519,S16789,S03538,I59645,I37120,I38875,I80169,I80176,# & I54505,I37521)# & PIR3: (S07115,S07113)# REFERENCES: harris92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLSSWTAADTAAQITQRK*# SEQUENCE: DLSSWTAADTAAQITQRK*# ...# >HUM206FF# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VLA-4 (229-244)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSLFVYNITTNVPVKYKAF*# SEQUENCE: GSLFVYNITTNVPVKYKAF*# ...# >HUM20700# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VLA-4 (229-248)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSLFVYNITTNVPVKYKAFLDQ*# SEQUENCE: GSLFVYNITTNVPVKYKAFLDQ*# ...# >HUM20701# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ3.2 beta chain (24-38)# DB REFERENCE: SWISS: (HB23_HUMAN,HB21_HUMAN,HB24_HUMAN)# & PIR1: (HLHUDB,HLHU1C)# & PIR2: (A31459,I68718,I37543,I54480,I59466,I72481,B32527,I55994,# & S49322)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SPEDFVYQFKGMCYF*# SEQUENCE: SPEDFVYQFKGMCYF*# ...# >HUM20702# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PAI-1 (261-278)# DB REFERENCE: SWISS: (PAI1_HUMAN,PAI1_HUMAN)# & PIR1: (ITHUP1)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,AAPYEKEVPLSALTNILS*# SEQUENCE: AAPYEKEVPLSALTNILS*# ...# >HUM20703# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PAI-1 (261-278)# DB REFERENCE: SWISS: (PAI1_HUMAN,PAI1_HUMAN)# & PIR1: (ITHUP1)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,AAPYEKEVPLSALTNILSAQL*# SEQUENCE: AAPYEKEVPLSALTNILSAQL*# ...# >HUM20704# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin C (151-166)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YDHNFVKAINADQKSW*# SEQUENCE: YDHNFVKAINADQKSW*# ...# >HUM20705# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin C (151-167)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YDHNFVKAINADQKSWT*# SEQUENCE: YDHNFVKAINADQKSWT*# ...# >HUM20706# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG heavy chain (121-137)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GVYFYLQWGRSTLVSVS*# SEQUENCE: GVYFYLQWGRSTLVSVS*# ...# >HUM20707# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine hemoglobin (26-41)# DB REFERENCE: SWISS: (HBA_TUPGL,HBA_RHIUN,HBA_MYOVE,HBA_SPECI,HBA_CTEGU,# & HBA_MEGLY,HBA_HUMAN,HBA1_TADBR,HBA_EULFU,HBA_PAPCY,# & HBA_CALAR,HBA1_GALCR,HBA_CEBAP,HBA_PROHA,HBA_BISBO,# & HBA_THEGE,HBA2_GALCR,HBA_HIPAM,HBA1_BOSMU,HBA_PTEPO,# & HBA_MACNE,HBA_PREEN,HBA_SAGFU,HBA_TAPGE,HBA_MACSI,# & HBA_MACAS,HBA_CERTO,HBA_MACGG,HBA_BOVIN,HBA_MACAS,# & HBA3_GORGO,HBA_BOSGF,HBA_ALCAA,HBA3_PANTR,HBA_CAPHI,# & HBA_CERSI,HBA_TARBA,HBA_PTEAL,HBA_MACSP,HBA_NYCCO,# & HBA_ATEGE,HBA_RANTA,HBA_SPEPA,HBA_CERAE,HBA2_BOSMU,# & HBA_MACMU,HBA_BOVIN,HBA_CYNSP,HBA_PONPY,HBA_MACCA,# & HBA_ROUAE,HBA_TRAST,HBA_MARMA,HBA_MANSP,HBA_ANTPA,# & HBA_SPETO,HBA_MACFA,HBA_COLBA,HBA_LORTA,HBA_GORGO,# & HBA_HUMAN)# & PIR1: (HAGT2,HACZ,HAMKS,HAMQIP,HARNW,HABAG,HALRS,HAMQA,HAMQB,# & HACZP,HAHU,HAFXG,HASH,HASHR2,HALRN,HAGO,HABO,HACJB,HAGT,# & HAHXR,HARTNG,HAYA2,HAMQJ,HABOG,HAMQ2P,HABAIM,HABAY,# & HAMQP,HASHR1,HABOKA,HAMQC,HAMQF,HAEKN,HAFXB,HAYA1,HABTV,# & HAMQR,HAMKP)# & PIR2: (A24693,JU0165,I78575,A29392,S31852,S31851,I58217,A24690,# & JC1099,D60515,A26640,C27792,B28865,A25359,B25597,A26543,# & S31853,B27792,A25597,B25126,B25727,A29702,A25729,A29391,# & A25357)# & PIR3: (B49141,S28934,S13481,S20278,S59496,S20277)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,AEALERMFLSFPTTKT*# SEQUENCE: AEALERMFLSFPTTKT*# ...# >HUM20708# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-29 (234-249)# DB REFERENCE: SWISS: (1A31_HUMAN,HA1B_MOUSE,HA1L_MOUSE,HA11_MOUSE,1A26_HUMAN,# & HA12_RAT,1A32_HUMAN,HA1B_MOUSE,HA13_MOUSE,1A25_HUMAN,# & HA12_MOUSE,1A34_HUMAN,HA18_MOUSE,1A33_HUMAN,1A26_HUMAN,# & HA1Z_MOUSE,1A29_HUMAN,1A31_HUMAN,HA1Q_MOUSE,HA17_MOUSE,# & 1A66_HUMAN,1A74_HUMAN,HA1K_MOUSE,HA1W_MOUSE,HA10_MOUSE,# & HA11_MOUSE,1A43_HUMAN,HA1K_MOUSE,HA13_MOUSE,HA11_RAT,# & HA1Y_MOUSE,HA17_MOUSE,HA12_MOUSE)# & PIR1: (HLHU32,HLMSDB,HLMS1,HLMSTR,HLMSKB,HLMSLD,HLMS2,HLMSKK)# & PIR2: (B60854,S13766,S16769,A60854,I38610,I72171,I38436,I60188,# & I54554,S31651,I37477,I69008,I68771,A45847,A45851,S52367,# & I54069,I57814,I71998,A24582,B35090,I49712,I37479,I60331,# & A37028,I54414,I55665,JL0135,I54531,I37482,I54491,I56077,# & I72170,I37483,A35997,C60854,I68705,I54462,I54548,I57806,# & A53277,I70694,A35090,I69009,I37480,A21125,I49713,I56002,# & B24582,I84487)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RPAGDGTFQKWASVVV*# SEQUENCE: RPAGDGTFQKWASVVV*# ...# >HUM20709# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-29 (234-253)# DB REFERENCE: SWISS: (1A32_HUMAN,1A43_HUMAN,1A31_HUMAN,1A26_HUMAN,1A33_HUMAN,# & 1A29_HUMAN,1A31_HUMAN,1A34_HUMAN,1A26_HUMAN,1A25_HUMAN,# & 1A74_HUMAN,1A66_HUMAN)# & PIR1: (HLHU32)# & PIR2: (A35997,I37479,A45847,I38436,I72170,A37028,I37483,I37482,# & JL0135,S16769,I37477,I38610,I84487,I72171,I37480)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RPAGDGTFQKWASVVVPSGQ*# SEQUENCE: RPAGDGTFQKWASVVVPSGQ*# ...# >HUM2070A# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-29 (237-258)# DB REFERENCE: SWISS: (1A33_HUMAN,1A26_HUMAN,1A43_HUMAN,1A74_HUMAN,1A66_HUMAN,# & 1A26_HUMAN,1A25_HUMAN,1A34_HUMAN,1A31_HUMAN,1A32_HUMAN,# & 1A31_HUMAN,1A29_HUMAN)# & PIR1: (HLHU32)# & PIR2: (I72170,A35997,A45847,I37479,I37480,I72171,I84487,I37483,# & A37028,I37477,S16769,JL0135,I38436,I38610,I37482)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GDGTFQKWASVVVPSGQEQRYT*# SEQUENCE: GDGTFQKWASVVVPSGQEQRYT*# ...# >HUM2070B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-29 (237-254)# DB REFERENCE: SWISS: (1A26_HUMAN,1A29_HUMAN,1A31_HUMAN,1A32_HUMAN,1A43_HUMAN,# & 1A25_HUMAN,1A26_HUMAN,1A66_HUMAN,1A74_HUMAN,1A33_HUMAN,# & 1A31_HUMAN,1A34_HUMAN)# & PIR1: (HLHU32)# & PIR2: (I37483,S16769,I84487,I37480,I72171,I37477,A37028,A35997,# & I37479,A45847,I72170,I37482,JL0135,I38436,I38610)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GDGTFQKWASVVVPSGQE*# SEQUENCE: GDGTFQKWASVVVPSGQE*# ...# >HUM2070C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-29 (239-253)# DB REFERENCE: SWISS: (1A43_HUMAN,1A32_HUMAN,1A31_HUMAN,1A34_HUMAN,1A31_HUMAN,# & 1A33_HUMAN,1A74_HUMAN,1A66_HUMAN,1A29_HUMAN,1A26_HUMAN,# & 1A26_HUMAN,1A25_HUMAN)# & PIR1: (HLHU32)# & PIR2: (S16769,JL0135,I38436,I37482,A37028,I37479,A35997,A45847,# & I37480,I72171,I37477,I38610,I37483,I72170,I84487)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GTFQKWASVVVPSG*# SEQUENCE: GTFQKWASVVVPSG*# ...# >HUM2070D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-29 (239-253)# DB REFERENCE: SWISS: (1A26_HUMAN,1A25_HUMAN,1A74_HUMAN,1A66_HUMAN,1A33_HUMAN,# & 1A31_HUMAN,1A34_HUMAN,1A43_HUMAN,1A32_HUMAN,1A31_HUMAN,# & 1A29_HUMAN,1A26_HUMAN)# & PIR1: (HLHU32)# & PIR2: (I37483,I84487,A37028,I38436,JL0135,A35997,I37479,I37482,# & S16769,I37480,I72171,I37477,A45847,I72170,I38610)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GTFQKWASVVVPSGQ*# SEQUENCE: GTFQKWASVVVPSGQ*# ...# >HUM2070E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-29 (239-261)# DB REFERENCE: SWISS: (1A66_HUMAN,1A43_HUMAN,1A32_HUMAN,1A31_HUMAN,1A34_HUMAN,# & 1A74_HUMAN,1A29_HUMAN,1A31_HUMAN,1A25_HUMAN,1A26_HUMAN,# & 1A33_HUMAN,1A26_HUMAN)# & PIR1: (HLHU32)# & PIR2: (I84487,I37483,I37482,A37028,I72170,I37477,I72171,A45847,# & I38610,I38436,I37479,S16769,A35997,JL0135,I37480)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GTFQKWASVVVPSGQEQRYTCHV*# SEQUENCE: GTFQKWASVVVPSGQEQRYTCHV*# ...# >HUM2070F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (83-97)# DB REFERENCE: SWISS: (1B11_HUMAN,1B12_HUMAN,1B40_HUMAN,1B46_HUMAN,1B41_HUMAN,# & 1B05_HUMAN,1B33_HUMAN,1B36_HUMAN,1B35_HUMAN,1B47_HUMAN,# & 1B38_HUMAN,1B42_HUMAN,1B34_HUMAN,1B29_HUMAN,1B53_HUMAN,# & 1B12_HUMAN,1B45_HUMAN,1B48_HUMAN,1B43_HUMAN)# & PIR1: (HLHUB4,HLHU40)# & PIR2: (I38421,S25415,I38437,I56149,G01230,I68724,I37520,C35997,# & I37516,I61861,S24027,S16789,A45850,I68748,I62044,I62043,# & I54442,S24437,I37519,S24433,B30345,I61906,I61864,I37492,# & I61905,S52486,I61903,S24434,S24438)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RETQISKTNTQTYRE*# SEQUENCE: RETQISKTNTQTYRE*# ...# >HUM20710# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (83-99)# DB REFERENCE: SWISS: (1B05_HUMAN,1B47_HUMAN,1B53_HUMAN,1B42_HUMAN,1B41_HUMAN,# & 1B40_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (I61861,A45850,S25415,I37516,S24434,I54442,B30345)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RETQISKTNTQTYRENL*# SEQUENCE: RETQISKTNTQTYRENL*# ...# >HUM20711# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (83-98)# DB REFERENCE: SWISS: (1B40_HUMAN,1B53_HUMAN,1B41_HUMAN,1B42_HUMAN,1B47_HUMAN,# & 1B05_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (I54442,B30345,I61861,A45850,S25415,S24434,I37516)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RETQISKTNTQTYREN*# SEQUENCE: RETQISKTNTQTYREN*# ...# >HUM20712# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (101-126)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RSNYTPITNPPEVTVLTNSPVELREP*# SEQUENCE: RSNYTPITNPPEVTVLTNSPVELREP*# ...# >HUM20713# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (58-78)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I72480,I56085)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GALANIAVDKANLEIMTKRSN*# SEQUENCE: GALANIAVDKANLEIMTKRSN*# ...# >HUM20714# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ alpha chain (179-208)# DB REFERENCE: SWISS: (HB2X_HUMAN,HB21_HUMAN)# & PIR1: (HLHUDB)# & PIR2: (D29312)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,SLQSPITVEWRAQSESAQSKMLSGIGGFVL*# SEQUENCE: SLQSPITVEWRAQSESAQSKMLSGIGGFVL*# ...# >HUM20715# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 4F2 (318-334)# DB REFERENCE: SWISS: (4F2_HUMAN,4F2_HUMAN)# & PIR1: (SAHU4F)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VTQYLNATGNRWCSWSL*# SEQUENCE: VTQYLNATGNRWCSWSL*# ...# >HUM20716# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 4F2 (318-338)# DB REFERENCE: SWISS: (4F2_HUMAN,4F2_HUMAN)# & PIR1: (SAHU4F)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VTQYLNATGNRWCSWSLSQAR*# SEQUENCE: VTQYLNATGNRWCSWSLSQAR*# ...# >HUM20717# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LIF receptor (854-866)# DB REFERENCE: SWISS: (LIFR_HUMAN,LIFR_MOUSE)# & PIR2: (S17308,JX0312)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,TSILCYRKREWIK*# SEQUENCE: TSILCYRKREWIK*# ...# >HUM20718# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thromboxane-A synthase (406-420)# DB REFERENCE: SWISS: (THAS_MOUSE,THAS_RAT,THAS_RAT,THAS_MOUSE,THAS_HUMAN)# & PIR2: (JN0683,A41766,B41766,S48161,S42404)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,PAFRFTREAAQDCEV*# SEQUENCE: PAFRFTREAAQDCEV*# ...# >HUM20719# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: K+ channel protein (492-516)# DB REFERENCE: PIR2: (S19552,S13919)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GDMYPKTWSGMLVGALCALAGVLTI*# SEQUENCE: GDMYPKTWSGMLVGALCALAGVLTI*# ...# >HUM2071A# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 70 (38-52)# DB REFERENCE: SWISS: (HS70_THEAN,HS7T_MOUSE,HS7D_DROME,HS7C_RAT,HS7C_HUMAN,# & HS7C_BOVIN,HS70_HYDMA,HS72_RAT,HS71_BOVIN,HS71_PUCGR,# & HS72_HUMAN,HS71_RAT,HS7C_DICDI,HS72_MOUSE,HS7C_CRIGR,# & HS7H_HUMAN,HS71_MOUSE,HS70_BRELC,HS72_BOVIN,HS70_CHICK,# & HS70_PLACB,HS74_YEAST,HS73_RAT,HS70_SOYBN,HS7C_BRARE,# & HS73_BOVIN,HS73_YEAST,HS71_SCHPO,HS7T_MOUSE,HS7C_RAT,# & HS72_PARLI,HS72_HUMAN,HS72_MOUSE,HS7A_CAEEL,HS7C_BOVIN,# & HS71_HUMAN,HS70_PLEWA,HS70_ONCTS,HS7C_DICDI,HS73_BOVIN,# & HS70_PLAFA,HS70_CHLRE,HS71_MOUSE,HS71_RAT,HS70_BRUMA,# & HS70_XENLA)# & PIR1: (HHXL70,HHKW7A,HHUM7B)# & PIR2: (A55719,JQ1515,S53498,A27077,A45635,PQ0138,B36590,I49761,# & A44979,S25649,S21365,S37394,S14992,S10859,I51129,A29160,# & S31766,S67431,S41415,I54542,S08211,B45871,S36753,A48439,# & A45871,S27004,S11456,JC4786,JH0095,JC4853,A36333,A44985,# & S07197,S31716,A45935,PC1156,A48872,A49242,S43388,A35922,# & I56574,A25646,JU0164)# & PIR3: (JC2215)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,TPSYVAFTDTERLIG*# SEQUENCE: TPSYVAFTDTERLIG*# ...# >HUM2071B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 70 (38-54)# DB REFERENCE: SWISS: (HS70_THEAN,HS70_ONCTS,HS70_CHLRE,HS70_HYDMA,HS71_MOUSE,# & HS71_RAT,HS70_BRUMA,HS70_PLAFA,HS7C_DICDI,HS70_XENLA,# & HS72_BOVIN,HS71_MOUSE,HS72_MOUSE,HS72_HUMAN,HS71_HUMAN,# & HS7A_CAEEL,HS7C_HUMAN,HS7H_HUMAN,HS72_HUMAN,HS7C_DICDI,# & HS70_PLACB,HS7C_BRARE,HS73_RAT,HS74_YEAST,HS7C_BOVIN,# & HS71_RAT,HS7C_CRIGR,HS72_MOUSE,HS70_SOYBN,HS70_BRELC,# & HS70_CHICK,HS72_RAT,HS71_BOVIN,HS7C_RAT,HS7T_MOUSE,# & HS7C_BOVIN,HS7D_DROME,HS71_SCHPO,HS72_PARLI,HS7C_RAT,# & HS73_YEAST,HS7T_MOUSE)# & PIR1: (HHUM7B,HHXL70,HHKW7A)# & PIR2: (A45871,A48439,S36753,S11456,JU0164,I56574,A25646,S27004,# & A29160,S10859,A49242,S67431,A55719,PQ0138,A27077,JC4853,# & A36333,JH0095,A44985,A45935,S07197,S31716,I54542,S41415,# & S37394,S25649,S21365,I49761,B36590,PC1156,S14992,S31766,# & A35922,S08211,B45871,JC4786,S43388,A48872,A44979,A45635,# & JQ1515,S53498)# & PIR3: (JC2215)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,TPSYVAFTDTERLIGDA*# SEQUENCE: TPSYVAFTDTERLIGDA*# ...# >HUM2071C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV MCP (1264-1277)# DB REFERENCE: SWISS: (VCAP_EBV)# & PIR1: (QQBE45)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VPGLYSPCRAFFNK*# SEQUENCE: VPGLYSPCRAFFNK*# ...# >HUM2071D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV MCP (1264-1282)# DB REFERENCE: SWISS: (VCAP_EBV)# & PIR1: (QQBE45)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VPGLYSPCRAFFNKEELL*# SEQUENCE: VPGLYSPCRAFFNKEELL*# ...# >HUM2071E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1586-1600)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,KVDLTFSKQHALLCS*# SEQUENCE: KVDLTFSKQHALLCS*# ...# >HUM2071F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1586-1608)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,KVDLTFSKQHALLCSDYQADYES*# SEQUENCE: KVDLTFSKQHALLCSDYQADYES*# ...# >HUM20720# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1942-1954)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,FSHDYRGSTSHRL*# SEQUENCE: FSHDYRGSTSHRL*# ...# >HUM20721# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (2077-2089)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,LPKYFEKKRNTII*# SEQUENCE: LPKYFEKKRNTII*# ...# >HUM20722# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Complement C9 (465-483)# DB REFERENCE: SWISS: (CO9_HUMAN,CO9_HUMAN)# & PIR1: (C9HU)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,APVLISQKLSPIYNLVPVK*# SEQUENCE: APVLISQKLSPIYNLVPVK*# ...# >HUM20723# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (158-180)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,SETVFLPREDHLFRKFHYLPFLP*# SEQUENCE: SETVFLPREDHLFRKFHYLPFLP*# ...# >HUM20724# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DP beta chain (80-92)# DB REFERENCE: SWISS: (HB2S_HUMAN)# & PIR1: (HLHUS1)# & PIR2: (I68796,I68793,I59642,A30537,F30536,G30536,C39247,D39247,# & I81235,H30536,D30537,I37541,I81238,I54303,S49382,I68788,# & I59648,I59636,E30536,I68799,I68795,I68562,I68794,I68800,# & I54506,I59621,I54458,I84461,A39247)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RHNYELDEAVTLQ*# SEQUENCE: RHNYELDEAVTLQ*# ...# >HUM20725# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAM blast-1 (92-108)# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,GALYISKVQKEDNSTYI*# SEQUENCE: GALYISKVQKEDNSTYI*# ...# >HUM20726# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAM blast-1 (88-108)# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DPQSGALYISKVQKEDNSTYI*# SEQUENCE: DPQSGALYISKVQKEDNSTYI*# ...# >HUM20727# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAM blast-1 (129-143)# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DPVPKPVIKIEKIED*# SEQUENCE: DPVPKPVIKIEKIED*# ...# >HUM20728# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAM blast-1 (129-146)# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DPVPKPVIKIEKIEDMDD*# SEQUENCE: DPVPKPVIKIEKIEDMDD*# ...# >HUM20729# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig kappa chain (63-77)# DB REFERENCE: PIR2: (S16823)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,FTFTISRLEPEDFAV*# SEQUENCE: FTFTISRLEPEDFAV*# ...# >HUM2072A# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig kappa chain (63-80)# DB REFERENCE: PIR2: (S16823)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,FTFTISRLEPEDFAVYYC*# SEQUENCE: FTFTISRLEPEDFAVYYC*# ...# >HUM2072B# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAR (1302-1316)# DB REFERENCE: SWISS: (PTPF_HUMAN)# & PIR1: (TDHULK)# & PIR2: (A56493,S46216)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DPVEMRRLNYQTPG*# SEQUENCE: DPVEMRRLNYQTPG*# ...# >HUM2072C# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LIF receptor (709-726)# DB REFERENCE: SWISS: (LIFR_HUMAN)# & PIR2: (S17308)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,YQLLRSMIGYIEELAPIV*# SEQUENCE: YQLLRSMIGYIEELAPIV*# ...# >HUM2072D# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IFN-alpha receptor (271-287)# DB REFERENCE: SWISS: (INR1_HUMAN,INR1_HUMAN)# & PIR2: (S17112,A32694)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,GNHLYKWKQIPDCENVK*# SEQUENCE: GNHLYKWKQIPDCENVK*# ...# >HUM2072E# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IL-8 receptor (169-188)# DB REFERENCE: SWISS: (IL8A_GORGO,IL8A_PANTR,IL8A_PONPY,IL8A_HUMAN)# & PIR2: (A39445)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,LPFFLFRQAYHPNNSSPVCY*# SEQUENCE: LPFFLFRQAYHPNNSSPVCY*# ...# >HUM2072F# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ca2+ release channel (2614-2623)# DB REFERENCE: SWISS: (RYNR_RABIT,RYNR_HUMAN,RYNR_PIG,RYNR_PIG)# & PIR2: (I47133,S18135,I46646,A35041,I46645,B35041,S31395,# & A54161)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RPSMLQHLLR*# SEQUENCE: RPSMLQHLLR*# ...# >HUM20730# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD35 (359-380)# DB REFERENCE: SWISS: (CR1_HUMAN,CR1_HUMAN)# & PIR2: (I73012,S03291,I36937,A28507,I36936)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DDFMGQLLNGRVLFPVNLQLGA*# SEQUENCE: DDFMGQLLNGRVLFPVNLQLGA*# ...# >HUM20731# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD75 (106-122)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,IPRLKIWKNYLSMNKY*# SEQUENCE: IPRLKIWKNYLSMNKY*# ...# >HUM20732# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Calcitonin receptor (38-53)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,EPFLYILGKSRVLEAQ*# SEQUENCE: EPFLYILGKSRVLEAQ*# ...# >HUM20733# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-1 (103-117)# DB REFERENCE: SWISS: (TIM1_PAPCY,TIM1_HUMAN,TIM1_HUMAN)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,SEEFLIAGKLQDGLL*# SEQUENCE: SEEFLIAGKLQDGLL*# ...# >HUM20734# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-1 (101-118)# DB REFERENCE: SWISS: (TIM1_PAPCY,TIM1_HUMAN,TIM1_HUMAN)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,NRSEEFLIAGKLQDGLLH*# SEQUENCE: NRSEEFLIAGKLQDGLLH*# ...# >HUM20735# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-1 (102-117)# DB REFERENCE: SWISS: (TIM1_HUMAN,TIM1_PAPCY,TIM1_HUMAN)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RSEEFLIAGKLQDGLL*# SEQUENCE: RSEEFLIAGKLQDGLL*# ...# >HUM20736# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-1 (101-112)# DB REFERENCE: SWISS: (TIM1_PAPCY,TIM1_HUMAN,TIM1_HUMAN)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,NRSEEFLIAGKL*# SEQUENCE: NRSEEFLIAGKL*# ...# >HUM20737# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-2 (187-205)# DB REFERENCE: SWISS: (TIM2_BOVIN,TIM2_MOUSE,TIM2_HUMAN,TIM2_RAT,TIM2_HUMAN)# & PIR1: (S38624,A35996,A37128)# & PIR2: (I53415,JH0683,S45683)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,QAKFFACIKRSDGSCAWYR*# SEQUENCE: QAKFFACIKRSDGSCAWYR*# ...# >HUM20738# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-2 (187-214)# DB REFERENCE: SWISS: (TIM2_BOVIN,TIM2_MOUSE,TIM2_RAT,TIM2_HUMAN,TIM2_HUMAN)# & PIR1: (A37128,A35996,S38624)# & PIR2: (I53415,JH0683,S45683)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,QAKFFACIKRSDGSCAWYRGAAPPKQEF*# SEQUENCE: QAKFFACIKRSDGSCAWYRGAAPPKQEF*# ...# >HUM20739# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PAI-1 (378-396)# DB REFERENCE: SWISS: (PAI1_HUMAN,PAI1_HUMAN,PAI1_MUSVI,PAI1_BOVIN)# & PIR1: (S06745,ITHUP1)# & PIR2: (JC4265)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DRPFLFVVRHNPTGTVLFM*# SEQUENCE: DRPFLFVVRHNPTGTVLFM*# ...# >HUM2073A# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PAI-1 (133-148)# DB REFERENCE: SWISS: (PAI1_HUMAN,PAI1_HUMAN)# & PIR1: (ITHUP1)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,MPHFFRLFRSTVKQVD*# SEQUENCE: MPHFFRLFRSTVKQVD*# ...# >HUM2073B# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin E (89-104)# DB REFERENCE: SWISS: (CATE_CAVPO,CATE_MOUSE,CATE_RAT,CATE_CAVPO,ASPR_ORYSA,# & CATE_HUMAN)# & PIR2: (A34401,JS0732,S66465,A43356,S66466,JC5077)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,QNFTVIFDTGSSNLWV*# SEQUENCE: QNFTVIFDTGSSNLWV*# ...# >HUM2073C# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin E (89-112)# DB REFERENCE: SWISS: (CATE_CAVPO,CATE_CAVPO,CATE_MOUSE,CATE_HUMAN)# & PIR2: (A43356,S66465,A34401)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,QNFTVIFDTGSSNLWVPSVYCTSP*# SEQUENCE: QNFTVIFDTGSSNLWVPSVYCTSP*# ...# >HUM2073D# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin S (189-205)# DB REFERENCE: SWISS: (CATS_HUMAN)# & PIR2: (A42482)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,TAFQYIIDNKGIDSDAS*# SEQUENCE: TAFQYIIDNKGIDSDAS*# ...# >HUM2073E# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cystatin SN (41-58)# DB REFERENCE: SWISS: (CYTT_HUMAN)# & PIR2: (B29632)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DEYYRRLLRVLRAREQIV*# SEQUENCE: DEYYRRLLRVLRAREQIV*# ...# >HUM2073F# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Tubulin alpha-1 chain (207-219)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,EIAYDICRRNLDI*# SEQUENCE: EIAYDICRRNLDI*# ...# >HUM20740# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Tubulin alpha-1 chain (207-223)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,EIAYDICRRNLDIERPT*# SEQUENCE: EIAYDICRRNLDIERPT*# ...# >HUM20741# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myosin beta heavy chain (1027-1047)# DB REFERENCE: SWISS: (MYSP_HUMAN)# & PIR2: (I38055,S12459,A30220)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,HELEKIKKQVEQEKCEIQAAL*# SEQUENCE: HELEKIKKQVEQEKCEIQAAL*# ...# >HUM20742# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Alpha-enolase (23-35)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,AEVYHDVAASEFF*# SEQUENCE: AEVYHDVAASEFF*# ...# >HUM20743# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: c-myc (371-385)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,KRSFFALRDQIPDL*# SEQUENCE: KRSFFALRDQIPDL*# ...# >HUM20744# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: K-ras (164-180)# DB REFERENCE: SWISS: (RASK_HUMAN,RASK_MSVKI,RASK_MSVKI,RASK_MOUSE)# & PIR1: (TVMSK,TVHUK,TVMV2K)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RQYRLKKISKEEKTPGC*# SEQUENCE: RQYRLKKISKEEKTPGC*# ...# >HUM20745# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1724-1739)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,KNIFHFKVNQEGLKLS*# SEQUENCE: KNIFHFKVNQEGLKLS*# ...# >HUM20746# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1724-1743)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,KNIFHFKVNQEGLKLSNDMM*# SEQUENCE: KNIFHFKVNQEGLKLSNDMM*# ...# >HUM20747# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (1780-1799)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,YKQTVSLDIQPYSLVTTLNS*# SEQUENCE: YKQTVSLDIQPYSLVTTLNS*# ...# >HUM20748# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (2647-2662)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,TPEFTILNTLHIPSFT*# SEQUENCE: TPEFTILNTLHIPSFT*# ...# >HUM20749# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (2646-2662)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,STPEFTILNTLHIPSFT*# SEQUENCE: STPEFTILNTLHIPSFT*# ...# >HUM2074A# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (2647-2664)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,TPEFTILNTLHIPSFTID*# SEQUENCE: TPEFTILNTLHIPSFTID*# ...# >HUM2074B# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (2885-2900)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,SNTKYFHKLNIPQLDF*# SEQUENCE: SNTKYFHKLNIPQLDF*# ...# >HUM2074C# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (2072-2086)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,LPFFKFLPKYFEKKR*# SEQUENCE: LPFFKFLPKYFEKKR*# ...# >HUM2074D# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (2072-2088)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,LPFFKFLPKYFEKKRNT*# SEQUENCE: LPFFKFLPKYFEKKRNT*# ...# >HUM2074E# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine apolipoprotein B-100 (4022-4036)# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,WNFYYSPQSSPDKKL*# SEQUENCE: WNFYYSPQSSPDKKL*# ...# >HUM2074F# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine transferrin (261-273)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DVIWELLNHAQEH*# SEQUENCE: DVIWELLNHAQEH*# ...# >HUM20750# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine transferrin (261-281)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DVIWELLNHAQEHFGKDKSKE*# SEQUENCE: DVIWELLNHAQEHFGKDKSKE*# ...# >HUM20751# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine transferrin (261-275)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DVIWELLNHAQEHFG*# SEQUENCE: DVIWELLNHAQEHFG*# ...# >HUM20752# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: von Willebrand factor (617-630)# DB REFERENCE: SWISS: (VWF_HUMAN,VWF_HUMAN)# & PIR1: (VWHU)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,IALLLMASQEPQRM*# SEQUENCE: IALLLMASQEPQRM*# ...# >HUM20753# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: von Willebrand factor (617-636)# DB REFERENCE: SWISS: (VWF_HUMAN,VWF_HUMAN)# & PIR1: (VWHU)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,IALLLMASQEPQRMSRNFVR*# SEQUENCE: IALLLMASQEPQRMSRNFVR*# ...# >HUM20754# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (105-124)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38442,I84448,I61857,I61902,I37542,I38443)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,SDWRFLRGYHQYAYDGKDYI*# SEQUENCE: SDWRFLRGYHQYAYDGKDYI*# ...# >HUM20755# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-120)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I61902,I61857,I84448,I37542,I38442,I38443)# REFERENCES: chicz93a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VGSDWRFLRGYHQYAYDG*# SEQUENCE: VGSDWRFLRGYHQYAYDG*# ...# >HUM20756# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-120)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I38443,I61857,I84448,I61902,I37542,I38442)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,VGSDWRFLRGYHQYAYDG*# SEQUENCE: VGSDWRFLRGYHQYAYDG*# ...# >HUM20757# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-120)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38443,I61902,I37542,I61857,I38442,I84448)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VGSDWRFLRGYHQYAYDG*# SEQUENCE: VGSDWRFLRGYHQYAYDG*# ...# >HUM20758# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-119)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I61902,I37542,I38442,I61857,I84448,I38443)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,VGSDWRFLRGYHQYAYD*# SEQUENCE: VGSDWRFLRGYHQYAYD*# ...# >HUM20759# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (104-119)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I61902,I84448,I38442,I37542,I61857,I38443)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,GSDWRFLRGYHQYAYD*# SEQUENCE: GSDWRFLRGYHQYAYD*# ...# >HUM2075A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-117)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I84448,I38443,I61857,I61902,I37542,I38442)# REFERENCES: chicz93a,rotzschke94b,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VGSDWRFLRGYHQYA*# SEQUENCE: VGSDWRFLRGYHQYA*# ...# >HUM2075B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-117)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I61857,I38443,I37542,I84448,I61902,I38442)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,VGSDWRFLRGYHQYA*# SEQUENCE: VGSDWRFLRGYHQYA*# ...# >HUM2075C# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-117)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I37542,I61857,I38443,I61902,I84448,I38442)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,VGSDWRFLRGYHQYA*# SEQUENCE: VGSDWRFLRGYHQYA*# ...# >HUM2075D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-117)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I38443,I37542,I61902,I84448,I61857,I38442)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VGSDWRFLRGYHQYA*# SEQUENCE: VGSDWRFLRGYHQYA*# ...# >HUM2075E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-116)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38443,I37542,I61902,I61857,I38442,I84448)# REFERENCES: chicz93a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VGSDWRFLRGYHQY*# SEQUENCE: VGSDWRFLRGYHQY*# ...# >HUM2075F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (103-116)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I84448,I37542,I61902,I61857,I38442,I38443)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,VGSDWRFLRGYHQY*# SEQUENCE: VGSDWRFLRGYHQY*# ...# >HUM20760# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (104-117)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38442,I38443,I37542,I84448,I61857,I61902)# REFERENCES: chicz93a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,GSDWRFLRGYHQYA*# SEQUENCE: GSDWRFLRGYHQYA*# ...# >HUM20761# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (104-117)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I38443,I84448,I61857,I61902,I37542,I38442)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,GSDWRFLRGYHQYA*# SEQUENCE: GSDWRFLRGYHQYA*# ...# >HUM20762# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (104-117)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38443,I61857,I84448,I37542,I61902,I38442)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GSDWRFLRGYHQYA*# SEQUENCE: GSDWRFLRGYHQYA*# ...# >HUM20763# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (104-116)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I61857,I37542,I61902,I38442,I38443,I84448)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GSDWRFLRGYHQY*# SEQUENCE: GSDWRFLRGYHQY*# ...# >HUM20764# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (105-117)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38442,I61902,I37542,I61857,I84448,I38443)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SDWRFLRGYHQYA*# SEQUENCE: SDWRFLRGYHQYA*# ...# >HUM20765# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 like membrane (105-117)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I84448,I37542,I38443,I61857,I61902,I38442)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,SDWRFLRGYHQYA*# SEQUENCE: SDWRFLRGYHQYA*# ...# >HUM20766# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (97-121)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALPMG*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPMG*# ...# >HUM20767# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing/binding inhibition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain membrane (81-104)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b,barber93a,geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPM*# ...# >HUM20768# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing/binding inhibition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (97-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b,geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPM*# ...# >HUM20769# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (98-121)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALPMG*# SEQUENCE: PKPPKPVSKMRMATPLLMQALPMG*# ...# >HUM2076A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (97-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALP*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALP*# ...# >HUM2076B# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (97-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,riberdy92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALP*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALP*# ...# >HUM2076C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (98-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: PKPPKPVSKMRMATPLLMQALPM*# ...# >HUM2076D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (98-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: PKPPKPVSKMRMATPLLMQALPM*# ...# >HUM2076E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (99-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALPM*# SEQUENCE: KPPKPVSKMRMATPLLMQALPM*# ...# >HUM2076F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (99-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALPM*# SEQUENCE: KPPKPVSKMRMATPLLMQALPM*# ...# >HUM20770# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (98-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALP*# SEQUENCE: PKPPKPVSKMRMATPLLMQALP*# ...# >HUM20771# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (98-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALP*# SEQUENCE: PKPPKPVSKMRMATPLLMQALP*# ...# >HUM20772# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (98-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALP*# SEQUENCE: PKPPKPVSKMRMATPLLMQALP*# ...# >HUM20773# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (98-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALP*# SEQUENCE: PKPPKPVSKMRMATPLLMQALP*# ...# >HUM20774# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (99-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALP*# SEQUENCE: KPPKPVSKMRMATPLLMQALP*# ...# >HUM20775# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (99-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALP*# SEQUENCE: KPPKPVSKMRMATPLLMQALP*# ...# >HUM20776# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (99-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALP*# SEQUENCE: KPPKPVSKMRMATPLLMQALP*# ...# >HUM20777# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (99-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALP*# SEQUENCE: KPPKPVSKMRMATPLLMQALP*# ...# >HUM20778# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (100-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PPKPVSKMRMATPLLMQALP*# SEQUENCE: PPKPVSKMRMATPLLMQALP*# ...# >HUM20779# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain membrane (100-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,PPKPVSKMRMATPLLMQALP*# SEQUENCE: PPKPVSKMRMATPLLMQALP*# ...# >HUM2077A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing/direct binding/blocking as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain membrane (106-124)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,vogt95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,KMRMATPLLMQALPMGALP*# SEQUENCE: KMRMATPLLMQALPMGALP*# ...# >HUM2077B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing/binding inhibition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain membrane (106-120), CLIP# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b,barber93a,malcherek95a,geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,KMRMATPLLMQALPM*# SEQUENCE: KMRMATPLLMQALPM*# ...# >HUM2077C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing/binding inhibition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain membrane (106-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz93a,rotzschke94b,geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,KMRMATPLLMQALPM*# SEQUENCE: KMRMATPLLMQALPM*# ...# >HUM2077D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (182-200)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I72480,I56085)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,APSPLPETTENVVCALGLTV*# SEQUENCE: APSPLPETTENVVCALGLTV*# ...# >HUM2077E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (182-198)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I72480,I56085)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,APSPLPETTENVVCALG*# SEQUENCE: APSPLPETTENVVCALG*# ...# >HUM2077F# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (182-198)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,APSPLPETTENVVCALG*# SEQUENCE: APSPLPETTENVVCALG*# ...# >HUM20780# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (182-198)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,APSPLPETTENVVCALG*# SEQUENCE: APSPLPETTENVVCALG*# ...# >HUM20781# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (182-194)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,APSPLPETTENVV*# SEQUENCE: APSPLPETTENVV*# ...# >HUM20782# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (188-208)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KHKVYACEVTHQGLSSPVTKS*# SEQUENCE: KHKVYACEVTHQGLSSPVTKS*# ...# >HUM20783# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (188-207)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KHKVYACEVTHQGLSSPVTK*# SEQUENCE: KHKVYACEVTHQGLSSPVTK*# ...# >HUM20784# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (189-206)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,HKVYACEVTHQGLSSPVT*# SEQUENCE: HKVYACEVTHQGLSSPVT*# ...# >HUM20785# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (188-204)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KHKVYACEVTHQGLSSP*# SEQUENCE: KHKVYACEVTHQGLSSP*# ...# >HUM20786# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (187-203)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EKHKVYACEVTHQGLSS*# SEQUENCE: EKHKVYACEVTHQGLSS*# ...# >HUM20787# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (188-203)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KHKVYACEVTHQGLSS*# SEQUENCE: KHKVYACEVTHQGLSS*# ...# >HUM20788# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (189-204)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,HKVYACEVTHQGLSSP*# SEQUENCE: HKVYACEVTHQGLSSP*# ...# >HUM20789# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (187-202)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EKHKVYACEVTHQGLS*# SEQUENCE: EKHKVYACEVTHQGLS*# ...# >HUM2078A# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (188-202)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KHKVYACEVTHQGLS*# SEQUENCE: KHKVYACEVTHQGLS*# ...# >HUM2078B# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (189-203)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,HKVYACEVTHQGLSS*# SEQUENCE: HKVYACEVTHQGLSS*# ...# >HUM2078C# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (187-200)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EKHKVYACEVTHQG*# SEQUENCE: EKHKVYACEVTHQG*# ...# >HUM2078D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (188-201)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,KHKVYACEVTHQGL*# SEQUENCE: KHKVYACEVTHQGL*# ...# >HUM2078E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Mass spectrometry/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IG kappa chain (188-200)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: chicz93a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,KHKVYACEVTHQG*# SEQUENCE: KHKVYACEVTHQG*# ...# >MUS2078F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU HA (127-140)# DB REFERENCE: SWISS: (CYC_CHICK,CYC_EQUAS,CYC_ESCGI,CYC_DRONO,CYC_MINSC,# & CYC_STRCA,CYC_RANCA,CYC_RABIT,CYC_MOUSE,CYC_MIRLE,# & CYC_COLLI,CYC_COLLI,CYC_BOVIN,CYC_DRONO,CYC_HIPAM,# & CYC_CANFA,CYC_CHICK,CYC_CANFA,CYC_APTPA,CYC_EQUAS,# & CYC_APTPA,CYC_ANAPL,CYC_ESCGI,CYC_ANAPL)# & PIR1: (CCSH,CCHP,CCRB,CCWHC,CCDG,CCDK,CCEU,CCPN,CCPY,CCCH,# & CCHOZ,CCOS,CCCM,CCMS,CCRT,CCBO,CCHOD,CCPG,CCTK,CCFG,# & CCSLE,CCGW,CCBTS)# & PIR2: (C04604)# REFERENCES: rothbard88b# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,GFSYTDANKNKGIT*# SEQUENCE: GFSYTDANKNKGIT*# ...# >MUS20790# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_APTPA,CYC_ANAPL,CYC_ANAPL,CYC_DRONO,# & CYC_DRONO,CYC_COLLI,CYC_STRCA,CYC_CHICK,CYC_APTPA,# & CYC_CHICK)# & PIR1: (CCPY,CCTK,CCPN,CCDK,CCEU,CCOS,CCCH)# REFERENCES: ogasawara89a,ogasawara87a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNKGIT*# SEQUENCE: AEGFSYTDANKNKGIT*# ...# >MUS20791# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEAFSYTDANKNKGIT*# SEQUENCE: AEAFSYTDANKNKGIT*# ...# >MUS20792# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AETFSYTDANKNKGIT*# SEQUENCE: AETFSYTDANKNKGIT*# ...# >MUS20793# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGYSYTDANKNKGIT*# SEQUENCE: AEGYSYTDANKNKGIT*# ...# >MUS20794# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGASYTDANKNKGIT*# SEQUENCE: AEGASYTDANKNKGIT*# ...# >MUS20795# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFTYTDANKNKGIT*# SEQUENCE: AEGFTYTDANKNKGIT*# ...# >MUS20796# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFEYTDANKNKGIT*# SEQUENCE: AEGFEYTDANKNKGIT*# ...# >MUS20797# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSFTDANKNKGIT*# SEQUENCE: AEGFSFTDANKNKGIT*# ...# >MUS20798# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYSDANKNKGIT*# SEQUENCE: AEGFSYSDANKNKGIT*# ...# >MUS20799# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTNANKNKGIT*# SEQUENCE: AEGFSYTNANKNKGIT*# ...# >MUS2079A# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# DB REFERENCE: SWISS: (CYC_CHESE,CYC_CHESE)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTEANKNKGIT*# SEQUENCE: AEGFSYTEANKNKGIT*# ...# >MUS2079B# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTQANKNKGIT*# SEQUENCE: AEGFSYTQANKNKGIT*# ...# >MUS2079C# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# DB REFERENCE: SWISS: (CYC_VARVA)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTAANKNKGIT*# SEQUENCE: AEGFSYTAANKNKGIT*# ...# >MUS2079D# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTVANKNKGIT*# SEQUENCE: AEGFSYTVANKNKGIT*# ...# >MUS2079E# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTLANKNKGIT*# SEQUENCE: AEGFSYTLANKNKGIT*# ...# >MUS2079F# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTKANKNKGIT*# SEQUENCE: AEGFSYTKANKNKGIT*# ...# >MUS207A0# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTMANKNKGIT*# SEQUENCE: AEGFSYTMANKNKGIT*# ...# >MUS207A1# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDLNKNKGIT*# SEQUENCE: AEGFSYTDLNKNKGIT*# ...# >MUS207A2# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDPNKNKGIT*# SEQUENCE: AEGFSYTDPNKNKGIT*# ...# >MUS207A3# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTDADKNKGIT*# SEQUENCE: AEGFSYTDADKNKGIT*# ...# >MUS207A4# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTDAEKNKGIT*# SEQUENCE: AEGFSYTDAEKNKGIT*# ...# >MUS207A5# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTDAQKNKGIT*# SEQUENCE: AEGFSYTDAQKNKGIT*# ...# >MUS207A6# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTDAYKNKGIT*# SEQUENCE: AEGFSYTDAYKNKGIT*# ...# >MUS207A7# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTDATKNKGIT*# SEQUENCE: AEGFSYTDATKNKGIT*# ...# >MUS207A8# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANQNKGIT*# SEQUENCE: AEGFSYTDANQNKGIT*# ...# >MUS207A9# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANRNKGIT*# SEQUENCE: AEGFSYTDANRNKGIT*# ...# >MUS207AA# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKAKGIT*# SEQUENCE: AEGFSYTDANKAKGIT*# ...# >MUS207AB# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKEKGIT*# SEQUENCE: AEGFSYTDANKEKGIT*# ...# >MUS207AC# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,AEGFSYTDANKGKGIT*# SEQUENCE: AEGFSYTDANKGKGIT*# ...# >MUS207AD# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,AEGFSYTDANKHKGIT*# SEQUENCE: AEGFSYTDANKHKGIT*# ...# >MUS207AE# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,AEGFSYTDANKLKGIT*# SEQUENCE: AEGFSYTDANKLKGIT*# ...# >MUS207AF# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,AEGFSYTDANKPKGIT*# SEQUENCE: AEGFSYTDANKPKGIT*# ...# >MUS207B0# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,AEGFSYTDANKQKGIT*# SEQUENCE: AEGFSYTDANKQKGIT*# ...# >MUS207B1# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKSKGIT*# SEQUENCE: AEGFSYTDANKSKGIT*# ...# >MUS207B2# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTDANKTKGIT*# SEQUENCE: AEGFSYTDANKTKGIT*# ...# >MUS207B3# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKYKGIT*# SEQUENCE: AEGFSYTDANKYKGIT*# ...# >MUS207B4# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNQGIT*# SEQUENCE: AEGFSYTDANKNQGIT*# ...# >MUS207B5# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNRGIT*# SEQUENCE: AEGFSYTDANKNRGIT*# ...# >MUS207B6# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNKAIT*# SEQUENCE: AEGFSYTDANKNKAIT*# ...# >MUS207B7# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNKTIT*# SEQUENCE: AEGFSYTDANKNKTIT*# ...# >MUS207B8# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNKGLT*# SEQUENCE: AEGFSYTDANKNKGLT*# ...# >MUS207B9# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNKGTT*# SEQUENCE: AEGFSYTDANKNKGTT*# ...# >MUS207BA# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNKGIV*# SEQUENCE: AEGFSYTDANKNKGIV*# ...# >MUS207BB# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (44-58)# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,EGFSYTDANKNKGIV*# SEQUENCE: EGFSYTDANKNKGIV*# ...# >MUS207BC# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-57)# DB REFERENCE: SWISS: (CYC_CHICK,CYC_APTPA,CYC_APTPA,CYC_STRCA,CYC_DRONO,# & CYC_COLLI,CYC_ANAPL,CYC_ANAPL,CYC_DRONO,CYC_CHICK,# & CYC_COLLI)# & PIR1: (CCPN,CCOS,CCPY,CCEU,CCTK,CCDK,CCCH)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNKGI*# SEQUENCE: AEGFSYTDANKNKGI*# ...# >MUS207BD# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-56)# DB REFERENCE: SWISS: (CYC_STRCA,CYC_DRONO,CYC_CHICK,CYC_DRONO,CYC_APTPA,# & CYC_CHICK,CYC_ANAPL,CYC_COLLI,CYC_ANAPL,CYC_APTPA,# & CYC_COLLI)# & PIR1: (CCDK,CCEU,CCTK,CCPY,CCPN,CCOS,CCCH)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNKG*# SEQUENCE: AEGFSYTDANKNKG*# ...# >MUS207BE# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-55)# DB REFERENCE: SWISS: (CYC_CHICK,CYC_DRONO,CYC_DRONO,CYC_APTPA,CYC_ANAPL,# & CYC_COLLI,CYC_CHICK,CYC_ANAPL,CYC_APTPA,CYC_COLLI,# & CYC_STRCA)# & PIR1: (CCCH,CCPY,CCOS,CCEU,CCTK,CCDK,CCPN)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKNK*# SEQUENCE: AEGFSYTDANKNK*# ...# >MUS207BF# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-54)# DB REFERENCE: SWISS: (CYC_STRCA,CYC_CHICK,CYC_CHICK,CYC_DRONO,CYC_APTPA,# & CYC_COLLI,CYC_ANAPL,CYC_COLLI,CYC_ANAPL,CYC_APTPA,# & CYC_DRONO)# & PIR1: (CCDK,CCEU,CCTK,CCCH,CCOS,CCPN,CCPY)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTDANKN*# SEQUENCE: AEGFSYTDANKN*# ...# >MUS207C0# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AEGFSYTLANKTKGIT*# SEQUENCE: AEGFSYTLANKTKGIT*# ...# >MUS207C1# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ab,actyesl,bindyesu,AEGFSYTLANKYKGIT*# SEQUENCE: AEGFSYTLANKYKGIT*# ...# >MUS207C2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58)# DB REFERENCE: SWISS: (CYC_ANAPL,CYC_COLLI,CYC_COLLI,CYC_APTPA,CYC_STRCA,# & CYC_APTPA,CYC_CHICK,CYC_ANAPL,CYC_DRONO,CYC_CHICK,# & CYC_DRONO)# & PIR1: (CCPY,CCCH,CCPN,CCOS,CCTK,CCEU,CCDK)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNKGIT*# SEQUENCE: AEGFSYTDANKNKGIT*# ...# >MUS207C3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEAFSYTDANKNKGIT*# SEQUENCE: AEAFSYTDANKNKGIT*# ...# >MUS207C4# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AETFSYTDANKNKGIT*# SEQUENCE: AETFSYTDANKNKGIT*# ...# >MUS207C5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGYSYTDANKNKGIT*# SEQUENCE: AEGYSYTDANKNKGIT*# ...# >MUS207C6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGASYTDANKNKGIT*# SEQUENCE: AEGASYTDANKNKGIT*# ...# >MUS207C7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFTYTDANKNKGIT*# SEQUENCE: AEGFTYTDANKNKGIT*# ...# >MUS207C8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFEYTDANKNKGIT*# SEQUENCE: AEGFEYTDANKNKGIT*# ...# >MUS207C9# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSFTDANKNKGIT*# SEQUENCE: AEGFSFTDANKNKGIT*# ...# >MUS207CA# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYSDANKNKGIT*# SEQUENCE: AEGFSYSDANKNKGIT*# ...# >MUS207CB# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTNANKNKGIT*# SEQUENCE: AEGFSYTNANKNKGIT*# ...# >MUS207CC# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# DB REFERENCE: SWISS: (CYC_CHESE,CYC_CHESE)# REFERENCES: ogasawara89a,itoh94a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTEANKNKGIT*# SEQUENCE: AEGFSYTEANKNKGIT*# ...# >MUS207CD# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTQANKNKGIT*# SEQUENCE: AEGFSYTQANKNKGIT*# ...# >MUS207CE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# DB REFERENCE: SWISS: (CYC_VARVA)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTAANKNKGIT*# SEQUENCE: AEGFSYTAANKNKGIT*# ...# >MUS207CF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a,itoh94a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTVANKNKGIT*# SEQUENCE: AEGFSYTVANKNKGIT*# ...# >MUS207D0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTLANKNKGIT*# SEQUENCE: AEGFSYTLANKNKGIT*# ...# >MUS207D1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTKANKNKGIT*# SEQUENCE: AEGFSYTKANKNKGIT*# ...# >MUS207D2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTMANKNKGIT*# SEQUENCE: AEGFSYTMANKNKGIT*# ...# >MUS207D3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDLNKNKGIT*# SEQUENCE: AEGFSYTDLNKNKGIT*# ...# >MUS207D4# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDPNKNKGIT*# SEQUENCE: AEGFSYTDPNKNKGIT*# ...# >MUS207D5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTDADKNKGIT*# SEQUENCE: AEGFSYTDADKNKGIT*# ...# >MUS207D6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTDAEKNKGIT*# SEQUENCE: AEGFSYTDAEKNKGIT*# ...# >MUS207D7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTDAQKNKGIT*# SEQUENCE: AEGFSYTDAQKNKGIT*# ...# >MUS207D8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTDAYKNKGIT*# SEQUENCE: AEGFSYTDAYKNKGIT*# ...# >MUS207D9# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTDATKNKGIT*# SEQUENCE: AEGFSYTDATKNKGIT*# ...# >MUS207DA# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANQNKGIT*# SEQUENCE: AEGFSYTDANQNKGIT*# ...# >MUS207DB# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANRNKGIT*# SEQUENCE: AEGFSYTDANRNKGIT*# ...# >MUS207DC# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKAKGIT*# SEQUENCE: AEGFSYTDANKAKGIT*# ...# >MUS207DD# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKEKGIT*# SEQUENCE: AEGFSYTDANKEKGIT*# ...# >MUS207DE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,AEGFSYTDANKGKGIT*# SEQUENCE: AEGFSYTDANKGKGIT*# ...# >MUS207DF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,AEGFSYTDANKHKGIT*# SEQUENCE: AEGFSYTDANKHKGIT*# ...# >MUS207E0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,AEGFSYTDANKLKGIT*# SEQUENCE: AEGFSYTDANKLKGIT*# ...# >MUS207E1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,AEGFSYTDANKPKGIT*# SEQUENCE: AEGFSYTDANKPKGIT*# ...# >MUS207E2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,AEGFSYTDANKQKGIT*# SEQUENCE: AEGFSYTDANKQKGIT*# ...# >MUS207E3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKSKGIT*# SEQUENCE: AEGFSYTDANKSKGIT*# ...# >MUS207E4# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTDANKTKGIT*# SEQUENCE: AEGFSYTDANKTKGIT*# ...# >MUS207E5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKYKGIT*# SEQUENCE: AEGFSYTDANKYKGIT*# ...# >MUS207E6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNQGIT*# SEQUENCE: AEGFSYTDANKNQGIT*# ...# >MUS207E7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNRGIT*# SEQUENCE: AEGFSYTDANKNRGIT*# ...# >MUS207E8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNKAIT*# SEQUENCE: AEGFSYTDANKNKAIT*# ...# >MUS207E9# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNKTIT*# SEQUENCE: AEGFSYTDANKNKTIT*# ...# >MUS207EA# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNKGLT*# SEQUENCE: AEGFSYTDANKNKGLT*# ...# >MUS207EB# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNKGTT*# SEQUENCE: AEGFSYTDANKNKGTT*# ...# >MUS207EC# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNKGIV*# SEQUENCE: AEGFSYTDANKNKGIV*# ...# >MUS207ED# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (44-58)# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,EGFSYTDANKNKGIV*# SEQUENCE: EGFSYTDANKNKGIV*# ...# >MUS207EE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-57)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI,CYC_ANAPL,CYC_CHICK,CYC_ANAPL,# & CYC_STRCA,CYC_APTPA,CYC_DRONO,CYC_DRONO,CYC_CHICK,# & CYC_APTPA)# & PIR1: (CCEU,CCDK,CCTK,CCCH,CCOS,CCPN,CCPY)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNKGI*# SEQUENCE: AEGFSYTDANKNKGI*# ...# >MUS207EF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-56)# DB REFERENCE: SWISS: (CYC_ANAPL,CYC_CHICK,CYC_APTPA,CYC_CHICK,CYC_COLLI,# & CYC_COLLI,CYC_ANAPL,CYC_DRONO,CYC_DRONO,CYC_APTPA,# & CYC_STRCA)# & PIR1: (CCPN,CCPY,CCOS,CCCH,CCTK,CCEU,CCDK)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNKG*# SEQUENCE: AEGFSYTDANKNKG*# ...# >MUS207F0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-55)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_CHICK,CYC_DRONO,CYC_APTPA,CYC_STRCA,# & CYC_COLLI,CYC_DRONO,CYC_CHICK,CYC_APTPA,CYC_ANAPL,# & CYC_ANAPL)# & PIR1: (CCTK,CCCH,CCOS,CCPN,CCPY,CCEU,CCDK)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKNK*# SEQUENCE: AEGFSYTDANKNK*# ...# >MUS207F1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-54)# DB REFERENCE: SWISS: (CYC_ANAPL,CYC_COLLI,CYC_ANAPL,CYC_CHICK,CYC_CHICK,# & CYC_DRONO,CYC_APTPA,CYC_APTPA,CYC_COLLI,CYC_DRONO,# & CYC_STRCA)# & PIR1: (CCDK,CCCH,CCPN,CCPY,CCOS,CCTK,CCEU)# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTDANKN*# SEQUENCE: AEGFSYTDANKN*# ...# >MUS207F2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTLANKTKGIT*# SEQUENCE: AEGFSYTLANKTKGIT*# ...# >MUS207F3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p cyt c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: ogasawara89a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGFSYTLANKYKGIT*# SEQUENCE: AEGFSYTLANKYKGIT*# ...# >MUS207F4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (81-96)# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_CHRAM,LYC_LOPLE,LYC_CHICK,LYC_SYRRE,# & LYC_PHACO,LYC_MELGA,LYC_PHAVE,LYC_CHICK)# & PIR1: (LZTK,LZFER,LZCH,LZQJE)# & PIR2: (JT0526,JQ1041,JH0211,JQ1033,JH0212,JU0237,JU0178)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,DITASVNCAK*# SEQUENCE: DITASVNCAK*# ...# >MUS207F5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p Cyt c (88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: leighton91a,harris93e.kelner92a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,IAYLKQATAK*# SEQUENCE: IAYLKQATAK*# ...# >MUS207F6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: m Cyt c (88-104)# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,DLIAYLQATK*# SEQUENCE: DLIAYLQATK*# ...# >MUS207F7# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Myo (132-153)# DB REFERENCE: SWISS: (MYG_KOGSI,MYG_TURTR,MYG_ORCOR,MYG_GLOME,MYG_BALPH,# & MYG_CASFI,MYG_ESCGI,MYG_PHYCA,MYG_INIGE,MYG_BALAC,# & MYG_MESCA,MYG_MEGNO,MYG_ZIPCA,MYG_PHYCA)# & PIR1: (MYWHZ,MYWHP,MYWHH,MYWHF,MYWHC,MYWHK,MYWHW,MYWHT,MYDDBS,# & MYWHU,MYWHL,MYDD,MYDDAR)# & PIR2: (JN0410)# REFERENCES: leighton91a,kelner92a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,ELFRKDIAAK*# SEQUENCE: ELFRKDIAAK*# ...# >MUS207F8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: lambda Rep (12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: leighton91a,kelner92a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,RLKAIYEKKK*# SEQUENCE: RLKAIYEKKK*# ...# >MUS207F9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (88-97)# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,GLAYTYADGK*# SEQUENCE: GLAYTYADGK*# ...# >MUS207FA# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nase (101-120)# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,EALVRQGCAK*# SEQUENCE: EALVRQGCAK*# ...# >MUS207FB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nonnatural sequence# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,KRLKRLKRLKRLKRL*# SEQUENCE: KRLKRLKRLKRLKRL*# ...# >MUS207FC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nonnatural sequence# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,AWRNRAKAWRNRAKGTD*# SEQUENCE: AWRNRAKAWRNRAKGTD*# ...# >MUS207FD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV (140-154)# DB REFERENCE: SWISS: (CORA_HPBVZ,CORA_HPBVT,CORA_HPBVY,CORA_HPBVJ,CORA_HPBVO,# & CORA_HPBVF,CORA_HPBVL,CORA_HPBVA,CORA_HPBV4)# & PIR1: (NKVLJ1,NKVLCP,NKVLAH,NKVLBH,NKVLA4,NKVLA1,NKVLA2,NKVLJ2,# & NKVLH3)# & PIR2: (S53257,S53281,S53260,S53238,S53198,S53232,S53163,S53140,# & S53223,S53236,S53279,S20750,S53229,S53157,S53242,S53272,# & S53255,S53146,S53152,S53204,S53200,S53240,S53194,S53155,# & S53159,S53225,S53202,S53216,JQ2227,S32204,S53181,S53211,# & S04570,S53207,S35530,S53251,S53227,S20746,S53178,S53184,# & S53172,S47405,S53253,S53221)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,LSTLPETTVVRRRGRS*# SEQUENCE: LSTLPETTVVRRRGRS*# ...# >MUS207FE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myelin basic protein (75-98)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_MOUSE)# & PIR1: (MBMSB,MBHUB)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,GRTQDENPVVHFFKNIVTPRTPPP*# SEQUENCE: GRTQDENPVVHFFKNIVTPRTPPP*# ...# >MUS207FF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: OVA homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,YTYTVHAAHAYTYT*# SEQUENCE: YTYTVHAAHAYTYT*# ...# >MUS20800# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (1-18)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_LOPCA,LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZQJEC,LZUH,LZCH)# REFERENCES: leighton91a,altuvia94a,rammensee95a,bauer95a,guery92a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,KVFGRCELAAAMKRHGLD*# SEQUENCE: KVFGRCELAAAMKRHGLD*# ...# >MUS20801# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Dynorphin (1-13)# DB REFERENCE: SWISS: (NDDB_RAT,NDDB_RAT,NDDB_PIG,NDDB_CAVPO,NDDB_HUMAN,# & NDDB_HUMAN,NDDB_PIG,NDDB_BOVIN)# & PIR1: (DFPG,DFHU,DFRTP)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,YGGFLRRIRPKLK*# SEQUENCE: YGGFLRRIRPKLK*# ...# >MUS20802# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nonnatural sequence# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,EFVAAKAAQK*# SEQUENCE: EFVAAKAAQK*# ...# >MUS20803# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: BPT (214-228)# DB REFERENCE: SWISS: (TOX1_BORPE,TOX1_BORPE)# & PIR1: (WEBR1P)# & PIR2: (A25973)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,SRRSVASIVGTLVRM*# SEQUENCE: SRRSVASIVGTLVRM*# ...# >MUS20804# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ACHR (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >MUS20805# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nonnatural sequence# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,YYVRAVRAYLTT*# SEQUENCE: YYVRAVRAYLTT*# ...# >MUS20806# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p I# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (A37881,B37881)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,EQNVRSAGELELQFRRVKCK*# SEQUENCE: EQNVRSAGELELQFRRVKCK*# ...# >MUS20807# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HA (187-206)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,RTLYQNVGTYVSVGTSTLNK*# SEQUENCE: RTLYQNVGTYVSVGTSTLNK*# ...# >MUS20808# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HEL (98-116)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_CHRAM,LYC_CHICK,LYC_LOPLE,LYC_CHICK)# & PIR1: (LZQJEC,LZCH)# & PIR2: (JQ1033)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,IVSDGNGMNAWVAWRNRCK*# SEQUENCE: IVSDGNGMNAWVAWRNRCK*# ...# >MUS20809# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (98-115)# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_CHICK,LYC_CHICK,LYC_LOPCA,LYC_CHRAM)# & PIR1: (LZQJEC,LZCH)# & PIR2: (JQ1033)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,IVSDGNGMNAWVAWRNRC*# SEQUENCE: IVSDGNGMNAWVAWRNRC*# ...# >MUS2080A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-124)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZCH)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRNRCKGTDVQAWI*# SEQUENCE: AWVAWRNRCKGTDVQAWI*# ...# >MUS2080B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (108-124)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,WVAWRNRCKGTDVQAWI*# SEQUENCE: WVAWRNRCKGTDVQAWI*# ...# >MUS2080C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (109-124)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZCH)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,VAWRNRCKGTDVQAWI*# SEQUENCE: VAWRNRCKGTDVQAWI*# ...# >MUS2080D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HEL (98-116)# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_CHRAM,LYC_CHICK,LYC_CHICK,LYC_LOPCA)# & PIR1: (LZQJEC,LZCH)# & PIR2: (JQ1033)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,IVSDGNGMNAWVAWRNRCK*# SEQUENCE: IVSDGNGMNAWVAWRNRCK*# ...# >MUS2080E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HEL (108-124)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,WVAWRNRCKGTDVQAWI*# SEQUENCE: WVAWRNRCKGTDVQAWI*# ...# >MUS2080F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (109-124)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,VAWRNRCKGTDVQAWI*# SEQUENCE: VAWRNRCKGTDVQAWI*# ...# >MUS20810# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,SWVAWRNRCK*# SEQUENCE: SWVAWRNRCK*# ...# >MUS20811# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,VWVAWRNRCK*# SEQUENCE: VWVAWRNRCK*# ...# >MUS20812# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,EWVAWRNRCK*# SEQUENCE: EWVAWRNRCK*# ...# >MUS20813# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AFVAWRNRCK*# SEQUENCE: AFVAWRNRCK*# ...# >MUS20814# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AAVAWRNRCK*# SEQUENCE: AAVAWRNRCK*# ...# >MUS20815# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AQVAWRNRCK*# SEQUENCE: AQVAWRNRCK*# ...# >MUS20816# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWLAWRNRCK*# SEQUENCE: AWLAWRNRCK*# ...# >MUS20817# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWAAWRNRCK*# SEQUENCE: AWAAWRNRCK*# ...# >MUS20818# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVSWRNRCK*# SEQUENCE: AWVSWRNRCK*# ...# >MUS20819# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVVWRNRCK*# SEQUENCE: AWVVWRNRCK*# ...# >MUS2081A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesl,AWVAFRNRCK*# SEQUENCE: AWVAFRNRCK*# ...# >MUS2081B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesl,AWVAARNRCK*# SEQUENCE: AWVAARNRCK*# ...# >MUS2081C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWKNRCK*# SEQUENCE: AWVAWKNRCK*# ...# >MUS2081D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRQRCK*# SEQUENCE: AWVAWRQRCK*# ...# >MUS2081E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRARCK*# SEQUENCE: AWVAWRARCK*# ...# >MUS2081F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRNKCK*# SEQUENCE: AWVAWRNKCK*# ...# >MUS20820# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRNACK*# SEQUENCE: AWVAWRNACK*# ...# >MUS20821# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRNRVK*# SEQUENCE: AWVAWRNRVK*# ...# >MUS20822# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRNRQK*# SEQUENCE: AWVAWRNRQK*# ...# >MUS20823# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRNREK*# SEQUENCE: AWVAWRNREK*# ...# >MUS20824# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# ANCHOR POSITIONS:# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRNRKK*# SEQUENCE: AWVAWRNRKK*# ...# >MUS20825# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HEL (107-116) homologue# DB REFERENCE: SWISS: (LYC1_ANAPL)# & PIR1: (LZDK)# REFERENCES: leighton91a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,AWVAWRNRCR*# SEQUENCE: AWVAWRNRCR*# ...# >MUS10826# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU PB2 (146-159)# DB REFERENCE: SWISS: (RRP3_IASIN,RRP3_IARUD,RRP3_IAPUE,RRP3_IACAO,RRP3_IAHK6,# & RRP3_IAFPR,RRP3_IAKIE,RRP3_IAVI7,RRP3_IANT6,RRP3_IAZI1,# & RRP3_IALE1,RRP3_IAME8,RRP3_IAWIL,RRP3_IALE2,RRP3_IAKOR,# & RRP3_IASE2,RRP3_IATKM,RRP3_IAANN,RRP3_IAGUA,RRP3_IAHLO,# & RRP3_IACHI,RRP3_IAMAN,RRP3_IAFPW,RRP3_IAZTE,# & RRP3_IALE3)# & PIR1: (P3IV68,B60008,P3IV34,P3IVAK,P3IV61,P3IV2A,P3IV33,# & A60011)# & PIR2: (S04930,JN0435)# REFERENCES: shimojo89a,maloy89a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,VFPNEVGARILTSE*# SEQUENCE: VFPNEVGARILTSE*# ...# >MUS20827# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA I (325-335)# DB REFERENCE: SWISS: (OVAL_COTJA,OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: rothbard88b,jorgensen92a,sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAEIN*# SEQUENCE: QAVHAAHAEIN*# ...# >MUS20828# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-335)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHAEIN*# SEQUENCE: ISQAVHAAHAEIN*# ...# >MUS20829# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-333)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHAE*# SEQUENCE: ISQAVHAAHAE*# ...# >MUS2082A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-332)# DB REFERENCE: SWISS: (OVAL_COTJA,OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHA*# SEQUENCE: ISQAVHAAHA*# ...# >MUS2082B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (325-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,QAVHAAHAEINEAGR*# SEQUENCE: QAVHAAHAEINEAGR*# ...# >MUS2082C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (326-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,AVHAAHAEINEAGR*# SEQUENCE: AVHAAHAEINEAGR*# ...# >MUS2082D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (327-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,VHAAHAEINEAGR*# SEQUENCE: VHAAHAEINEAGR*# ...# >MUS2082E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NAVHAAHAEIN*# SEQUENCE: NAVHAAHAEIN*# ...# >MUS2082F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,EAVHAAHAEIN*# SEQUENCE: EAVHAAHAEIN*# ...# >MUS20830# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,SAVHAAHAEIN*# SEQUENCE: SAVHAAHAEIN*# ...# >MUS20831# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,YAVHAAHAEIN*# SEQUENCE: YAVHAAHAEIN*# ...# >MUS20832# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,LAVHAAHAEIN*# SEQUENCE: LAVHAAHAEIN*# ...# >MUS20833# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QGVHAAHAEIN*# SEQUENCE: QGVHAAHAEIN*# ...# >MUS20834# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QSVHAAHAEIN*# SEQUENCE: QSVHAAHAEIN*# ...# >MUS20835# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QVVHAAHAEIN*# SEQUENCE: QVVHAAHAEIN*# ...# >MUS20836# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QRVHAAHAEIN*# SEQUENCE: QRVHAAHAEIN*# ...# >MUS20837# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QYVHAAHAEIN*# SEQUENCE: QYVHAAHAEIN*# ...# >MUS20838# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QALHAAHAEIN*# SEQUENCE: QALHAAHAEIN*# ...# >MUS20839# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAIHAAHAEIN*# SEQUENCE: QAIHAAHAEIN*# ...# >MUS2083A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QATHAAHAEIN*# SEQUENCE: QATHAAHAEIN*# ...# >MUS2083B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QADHAAHAEIN*# SEQUENCE: QADHAAHAEIN*# ...# >MUS2083C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QARHAAHAEIN*# SEQUENCE: QARHAAHAEIN*# ...# >MUS2083D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVRAAHAEIN*# SEQUENCE: QAVRAAHAEIN*# ...# >MUS2083E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVQAAHAEIN*# SEQUENCE: QAVQAAHAEIN*# ...# >MUS2083F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVKAAHAEIN*# SEQUENCE: QAVKAAHAEIN*# ...# >MUS20840# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVEAAHAEIN*# SEQUENCE: QAVEAAHAEIN*# ...# >MUS20841# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVLAAHAEIN*# SEQUENCE: QAVLAAHAEIN*# ...# >MUS20842# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHGAHAEIN*# SEQUENCE: QAVHGAHAEIN*# ...# >MUS20843# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHSAHAEIN*# SEQUENCE: QAVHSAHAEIN*# ...# >MUS20844# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHVAHAEIN*# SEQUENCE: QAVHVAHAEIN*# ...# >MUS20845# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHYAHAEIN*# SEQUENCE: QAVHYAHAEIN*# ...# >MUS20846# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAGHAEIN*# SEQUENCE: QAVHAGHAEIN*# ...# >MUS20847# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHASHAEIN*# SEQUENCE: QAVHASHAEIN*# ...# >MUS20848# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAVHAEIN*# SEQUENCE: QAVHAVHAEIN*# ...# >MUS20849# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHARHAEIN*# SEQUENCE: QAVHARHAEIN*# ...# >MUS2084A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAYHAEIN*# SEQUENCE: QAVHAYHAEIN*# ...# >MUS2084B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAARAEIN*# SEQUENCE: QAVHAARAEIN*# ...# >MUS2084C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAQAEIN*# SEQUENCE: QAVHAAQAEIN*# ...# >MUS2084D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAKAEIN*# SEQUENCE: QAVHAAKAEIN*# ...# >MUS2084E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAEAEIN*# SEQUENCE: QAVHAAEAEIN*# ...# >MUS2084F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAALAEIN*# SEQUENCE: QAVHAALAEIN*# ...# >MUS20850# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHGEIN*# SEQUENCE: QAVHAAHGEIN*# ...# >MUS20851# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHSEIN*# SEQUENCE: QAVHAAHSEIN*# ...# >MUS20852# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHVEIN*# SEQUENCE: QAVHAAHVEIN*# ...# >MUS20853# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHADIN*# SEQUENCE: QAVHAAHADIN*# ...# >MUS20854# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAHAQIN*# SEQUENCE: QAVHAAHAQIN*# ...# >MUS20855# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAHARIN*# SEQUENCE: QAVHAAHARIN*# ...# >MUS20856# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAHAIIN*# SEQUENCE: QAVHAAHAIIN*# ...# >MUS20857# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAHAYIN*# SEQUENCE: QAVHAAHAYIN*# ...# >MUS20858# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAELN*# SEQUENCE: QAVHAAHAELN*# ...# >MUS20859# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAEYN*# SEQUENCE: QAVHAAHAEYN*# ...# >MUS2085A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAETN*# SEQUENCE: QAVHAAHAETN*# ...# >MUS2085B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAHAERN*# SEQUENCE: QAVHAAHAERN*# ...# >MUS2085C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,QAVHAAHAEDN*# SEQUENCE: QAVHAAHAEDN*# ...# >MUS2085D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAEID*# SEQUENCE: QAVHAAHAEID*# ...# >MUS2085E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAEIQ*# SEQUENCE: QAVHAAHAEIQ*# ...# >MUS2085F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAEIT*# SEQUENCE: QAVHAAHAEIT*# ...# >MUS20860# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAEIY*# SEQUENCE: QAVHAAHAEIY*# ...# >MUS20861# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./ binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (325-335) homologue# ANCHOR POSITIONS:# REFERENCES: sette87a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,QAVHAAHAEII*# SEQUENCE: QAVHAAHAEII*# ...# >MUS20862# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLV env (255-269)# DB REFERENCE: SWISS: (ENV_MLVRK,ENV_MLVAV,ENV_MLVRD)# & PIR1: (VCMVVR,VCVWEK,VCMVKA)# & PIR2: (A46511)# REFERENCES: rudensky92a,barber93a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,IRLKITDSGPRVPIGPN*# SEQUENCE: IRLKITDSGPRVPIGPN*# ...# >MUS20863# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgG2a (194-210)# DB REFERENCE: SWISS: (GCAA_MOUSE,GCAM_MOUSE)# & PIR1: (G2MSA,G2MSAM)# & PIR2: (A35944,S37483,S40295,S38950)# REFERENCES: rudensky92a,barber93a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,WPSQSITCNVAHPASST*# SEQUENCE: WPSQSITCNVAHPASST*# ...# >MUS20864# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgG2a (281-296)# DB REFERENCE: SWISS: (GCB_MOUSE,GCB_MOUSE,GCAB_MOUSE,GCAA_MOUSE,GCAM_MOUSE,# & GCBM_MOUSE)# & PIR1: (G2MSBM,G2MSAM,G2MS11,G2MSAB,G2MSA)# & PIR2: (A30503,S37483,B30503)# & PIR3: (S25057)# REFERENCES: rudensky92a,barber93a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,NVEVHTAQTQTHREDY*# SEQUENCE: NVEVHTAQTQTHREDY*# ...# >MUS20865# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TfR (203-218)# DB REFERENCE: PIR2: (S29548)# REFERENCES: rudensky92a,barber93a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,KPTEVSGKLVHANFGT*# SEQUENCE: KPTEVSGKLVHANFGT*# ...# >MUS20866# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 5,6,11# REFERENCES: rudensky92a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,XPYMFADKVVHLPGSQ*# SEQUENCE: XPYMFADKVVHLPGSQ*# ...# >MUS20867# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLV env (145-158)# ANCHOR POSITIONS: 2,9# REFERENCES: rudensky92a,rudensky91a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,HNEGFYVCPGHHRP*# SEQUENCE: HNEGFYVCPGHHRP*# ...# >MUS20868# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides/proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: I-E alpha (52-68)# DB REFERENCE: SWISS: (HA2R_HUMAN,HA22_MOUSE,HA21_MOUSE,HA21_MOUSE,# & HA23_MOUSE)# & PIR1: (HLHUDA,HLMSED,HLMSEA)# & PIR2: (I56085,I54426,A46505,I55971,S06316,I72480)# REFERENCES: rudensky92a,rudensky91a,barber93a,rider96# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,ASFEAQGALANIAVDKA*# SEQUENCE: ASFEAQGALANIAVDKA*# ...# >MUS20869# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ii (85-99)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: rudensky92a,rudensky91a,barber93a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,KPVSQMRMATPLLMR*# SEQUENCE: KPVSQMRMATPLLMR*# ...# >MUS2086A# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides/reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: I-A beta (55-66)# DB REFERENCE: SWISS: (HB2Q_MOUSE,HB2A_MOUSE,HB2D_MOUSE,HB2J_MOUSE)# & PIR1: (HLMSAB,HLMSQB)# & PIR2: (I48422,I59665,A53278,I48656,I59495)# REFERENCES: rudensky92a,barber93a,hsu96a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,RPDAEYWNSQPE*# SEQUENCE: RPDAEYWNSQPE*# ...# >MUS2086B# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgGVH (59-74)# ANCHOR POSITIONS: 2,8# REFERENCES: rudensky92a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,XNADFKTPATLTVD*# SEQUENCE: XNADFKTPATLTVD*# ...# >MUS2086C# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 3,9# REFERENCES: rudensky92a,rudensky91a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,NYNAYNATPATLAVD*# SEQUENCE: NYNAYNATPATLAVD*# ...# >MUS2086D# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLV env (454-469)# DB REFERENCE: SWISS: (ENV_MLVAV)# & PIR1: (VCVWEK)# & PIR2: (A46511,S22805,B43491,A43491)# REFERENCES: rammensee93b,rudensky92a,rudensky91a,barber93a,schild95a# COMMENT:# SUMMARY: I-Eb,actunkn,bindyesu,SPSYVYHQFERRAK*# SEQUENCE: SPSYVYHQFERRAK*# ...# >MUS2086E# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: BSA (141-157)# DB REFERENCE: SWISS: (ALBU_BOVIN,ALBU_PIG,ALBU_FELCA)# & PIR1: (ABBOS,ABPGS)# & PIR2: (S57632,JC4660)# REFERENCES: rudensky92a,rudensky91a# COMMENT:# SUMMARY: I-Eb,actunkn,bindyesu,GKYLYEIARRHPYF*# SEQUENCE: GKYLYEIARRHPYF*# ...# >MUS2086F# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 5,6,7,..,..# REFERENCES: rudensky92a,rudensky91a,schild95a# COMMENT:# SUMMARY: I-Eb,actunkn,bindyesu,XPQSYLIHEXXXIS*# SEQUENCE: XPQSYLIHEXXXIS*# ...# >MUS20870# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: E alpha (52-66)# DB REFERENCE: SWISS: (HA21_MOUSE,HA23_MOUSE,HA21_MOUSE,HA2R_HUMAN,# & HA22_MOUSE)# & PIR1: (HLMSED,HLHUDA,HLMSEA)# & PIR2: (S06316,PL0127,I72480,I55971,I54426,A45881,A46505,# & I56085)# REFERENCES: rudensky92a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,ASFEAQGALANIAVD*# SEQUENCE: ASFEAQGALANIAVD*# ...# >MUS20871# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: HPLC eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: E alpha (54-67)# DB REFERENCE: SWISS: (HA21_MOUSE,HA21_MOUSE,HA2R_HUMAN,HA22_MOUSE,# & HA23_MOUSE)# & PIR1: (HLHUDA,HLMSEA,HLMSED)# & PIR2: (S06316,A46505,I56085,I54426,I55971,A53273,I72480)# REFERENCES: rudensky92a,rudensky91a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,FEAQGALANIAVDK*# SEQUENCE: FEAQGALANIAVDK*# ...# >MUS20872# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MCC (45-56)# DB REFERENCE: SWISS: (CYC_ESCGI,CYC_CHICK,CYC_APTPA,CYC2_MOUSE,CYC_COLLI,# & CYC_ANAPL,CYC_HIPAM,CYC_CANFA,CYC_BOVIN,CYC_CHICK,# & CYC_CANFA,CYC_RANCA,CYC_MOUSE,CYC_MIRLE,CYC_RABIT,# & CYC_APTPA,CYC2_MOUSE,CYC_ESCGI,CYC_EQUAS,CYC_STRCA,# & CYC2_RAT,CYC_DRONO,CYC_MINSC,CYC_COLLI,CYC_DRONO,# & CYC_EQUAS,CYC_ANAPL,CYC2_RAT)# & PIR1: (CCRB,CCPN,CCPY,CCPG,CCDK,CCRT,CCCH,CCRTT,CCWHC,CCDG,# & CCCM,CCOS,CCHOD,CCBO,CCFG,CCSLE,CCGW,CCMST,CCEU,CCMS,# & CCHOZ,CCBTS,CCTK,CCSH,CCHP)# & PIR2: (C04604)# REFERENCES: jorgensen92a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,GFSYTDANKNKG*# SEQUENCE: GFSYTDANKNKG*# ...# >HUM10873# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gp120 (197-205)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1H3,ENV_HV1PV,ENV_HV1BR,ENV_HV1B1)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S33985)# REFERENCES: garboczi92a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,TLTSCNTSV*# SEQUENCE: TLTSCNTSV*# ...# >MUS20874# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin mouse (1-16)# DB REFERENCE: SWISS: (B2MG_RAT,B2MG_MOUSE,B2MG_MOUSE,B2MG_RAT)# & PIR1: (MGMSB2,A26842)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,IQKTPQIQVYSRHPPE*# SEQUENCE: IQKTPQIQVYSRHPPE*# ...# >MUS20875# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (7-22)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE,B2MG_MUSSP)# & PIR1: (MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,IQVYSRHPPENGKPNI*# SEQUENCE: IQVYSRHPPENGKPNI*# ...# >MUS20876# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Beta 2 microglobulin mouse (25-40)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,CYVTQFHPPHIEIQML*# SEQUENCE: CYVTQFHPPHIEIQML*# ...# >MUS20877# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (37-52)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,IQMLKNGKKIPKVEMS*# SEQUENCE: IQMLKNGKKIPKVEMS*# ...# >MUS20878# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (43-58)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,GKKIPKVEMSDMSFSK*# SEQUENCE: GKKIPKVEMSDMSFSK*# ...# >MUS20879# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (55-70)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MUSCR,B2MG_MUSSP,B2MG_MOUSE,B2MG_RAT,# & B2MG_RAT)# & PIR1: (A26842,MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,SFSKDWSFYILAHTEF*# SEQUENCE: SFSKDWSFYILAHTEF*# ...# >MUS2087A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (61-76)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_RAT,B2MG_MOUSE,B2MG_MUSSP,B2MG_RAT)# & PIR1: (A26842,MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,SFYILAHTEFTPTETD*# SEQUENCE: SFYILAHTEFTPTETD*# ...# >MUS2087B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (97-112)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ASMAEPKTVYWDRDM*# SEQUENCE: ASMAEPKTVYWDRDM*# ...# >MUS2087C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin human (1-16)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,IQRTPKIQVYSRHPAE*# SEQUENCE: IQRTPKIQVYSRHPAE*# ...# >MUS2087D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin human (7-22)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,IQVYSRHPAENGKSNF*# SEQUENCE: IQVYSRHPAENGKSNF*# ...# >MUS2087E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (19-34)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963,I61868)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,KSNFLNCYVSGFHPSD*# SEQUENCE: KSNFLNCYVSGFHPSD*# ...# >MUS2087F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (25-40)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY,B2MG_SAGOE)# & PIR1: (MGHUB2)# & PIR2: (I37063,I54312,I61868,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,CYVSGFHPSDIEVDLL*# SEQUENCE: CYVSGFHPSDIEVDLL*# ...# >MUS20880# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin human (31-46)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,HPSDIEVDLLKNGERI*# SEQUENCE: HPSDIEVDLLKNGERI*# ...# >MUS20881# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (43-58)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,GERIEKVEHSDLSFSY*# SEQUENCE: GERIEKVEHSDLSFSY*# ...# >MUS20882# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (79-94)# DB REFERENCE: SWISS: (B2MG_PONPY,B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963,I61868)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,TEKDEYACRVNHVTLS*# SEQUENCE: TEKDEYACRVNHVTLS*# ...# >MUS20883# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Beta 2 microglobulin human (91-106)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,ACRVNHVTLSQPKIVK*# SEQUENCE: ACRVNHVTLSQPKIVK*# ...# >MUS20884# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin mouse (19-34)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,KPNILNCYVTQFHPPH*# SEQUENCE: KPNILNCYVTQFHPPH*# ...# >MUS20885# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin mouse (25-40)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,CYVTQFHPPHIEIQML*# SEQUENCE: CYVTQFHPPHIEIQML*# ...# >MUS20886# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (43-58)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,GKKIPKVEMSDMSFSK*# SEQUENCE: GKKIPKVEMSDMSFSK*# ...# >MUS20887# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (55-70)# DB REFERENCE: SWISS: (B2MG_MUSCR,B2MG_MOUSE,B2MG_RAT,B2MG_MUSSP,B2MG_MOUSE,# & B2MG_RAT)# & PIR1: (MGMSB2,A26842)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,SFSKDWSFYILAHTEF*# SEQUENCE: SFSKDWSFYILAHTEF*# ...# >MUS20888# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin mouse (61-76)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_RAT,B2MG_RAT,B2MG_MOUSE,B2MG_MUSSP)# & PIR1: (MGMSB2,A26842)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,SFYILAHTEFTPTETD*# SEQUENCE: SFYILAHTEFTPTETD*# ...# >MUS20889# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (97-112)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,ASMAEPKTVYWDRDM*# SEQUENCE: ASMAEPKTVYWDRDM*# ...# >MUS2088A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin mouse (1-16)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_RAT,B2MG_MOUSE,B2MG_RAT)# & PIR1: (MGMSB2,A26842)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,IQKTPQIQVYSRHPPE*# SEQUENCE: IQKTPQIQVYSRHPPE*# ...# >MUS2088B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (7-22)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MUSSP,B2MG_MOUSE)# & PIR1: (MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,IQVYSRHPPENGKPNI*# SEQUENCE: IQVYSRHPPENGKPNI*# ...# >MUS2088C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (13-28)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MUSSP,B2MG_MOUSE)# & PIR1: (MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,HPPENGKPNILNCYVT*# SEQUENCE: HPPENGKPNILNCYVT*# ...# >MUS2088D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (19-34)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,KPNILNCYVTQFHPPH*# SEQUENCE: KPNILNCYVTQFHPPH*# ...# >MUS2088E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (25-40)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,CYVTQFHPPHIEIQML*# SEQUENCE: CYVTQFHPPHIEIQML*# ...# >MUS2088F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin mouse (31-46)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,HPPHIEIQMLKDGKKI*# SEQUENCE: HPPHIEIQMLKDGKKI*# ...# >MUS20890# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Beta 2 microglobulin mouse (37-52)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesh,IQMLKNGKKIPKVEMS*# SEQUENCE: IQMLKNGKKIPKVEMS*# ...# >MUS20891# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (43-58)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,GKKIPKVEMSDMSFSK*# SEQUENCE: GKKIPKVEMSDMSFSK*# ...# >MUS20892# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (49-64)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,VEMSDMSFSKDWSFYL*# SEQUENCE: VEMSDMSFSKDWSFYL*# ...# >MUS20893# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (55-70)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_RAT,B2MG_MUSSP,B2MG_MUSCR,B2MG_MOUSE,# & B2MG_RAT)# & PIR1: (A26842,MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,SFSKDWSFYILAHTEF*# SEQUENCE: SFSKDWSFYILAHTEF*# ...# >MUS20894# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (61-76)# DB REFERENCE: SWISS: (B2MG_MUSSP,B2MG_RAT,B2MG_MOUSE,B2MG_RAT,B2MG_MOUSE)# & PIR1: (MGMSB2,A26842)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,SFYILAHTEFTPTETD*# SEQUENCE: SFYILAHTEFTPTETD*# ...# >MUS20895# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (67-82)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,HTEFTPTETDTYACRV*# SEQUENCE: HTEFTPTETDTYACRV*# ...# >MUS20896# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (79-94)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,TETDTYACRVKHDSMA*# SEQUENCE: TETDTYACRVKHDSMA*# ...# >MUS20897# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (91-106)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,ACRVKHDSMAEPKTVY*# SEQUENCE: ACRVKHDSMAEPKTVY*# ...# >MUS20898# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (97-112)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,ASMAEPKTVYWDRDM*# SEQUENCE: ASMAEPKTVYWDRDM*# ...# >MUS20899# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Beta 2 microglobulin human (1-16)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesh,IQRTPKIQVYSRHPAE*# SEQUENCE: IQRTPKIQVYSRHPAE*# ...# >MUS2089A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (7-22)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,IQVYSRHPAENGKSNF*# SEQUENCE: IQVYSRHPAENGKSNF*# ...# >MUS2089B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (19-34)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I61868,I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,KSNFLNCYVSGFHPSD*# SEQUENCE: KSNFLNCYVSGFHPSD*# ...# >MUS2089C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (31-46)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,HPSDIEVDLLKNGERI*# SEQUENCE: HPSDIEVDLLKNGERI*# ...# >MUS2089D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (37-52)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,VDLLKDGERIEKVEHS*# SEQUENCE: VDLLKDGERIEKVEHS*# ...# >MUS2089E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (43-58)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,GERIEKVEHSDLSFSY*# SEQUENCE: GERIEKVEHSDLSFSY*# ...# >MUS2089F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (55-70)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,SFSNDWSFYLLYYTEF*# SEQUENCE: SFSNDWSFYLLYYTEF*# ...# >MUS208A0# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin human (61-76)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063,I61868)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,SFYLLYYTEFTPTEKD*# SEQUENCE: SFYLLYYTEFTPTEKD*# ...# >MUS208A1# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (91-106)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,ACRVNHVTLSQPKIVK*# SEQUENCE: ACRVNHVTLSQPKIVK*# ...# >MUS208A2# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (97-112)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,VTLSQPKIVKWDRDM*# SEQUENCE: VTLSQPKIVKWDRDM*# ...# >HUM208A3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (31-46)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HPPHIEIQMLKDGKKI*# SEQUENCE: HPPHIEIQMLKDGKKI*# ...# >HUM208A4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (49-64)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,VEMSDMSFSKDWSFYL*# SEQUENCE: VEMSDMSFSKDWSFYL*# ...# >HUM208A5# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (55-70)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_RAT,B2MG_RAT,B2MG_MUSCR,B2MG_MUSSP,# & B2MG_MOUSE)# & PIR1: (A26842,MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,SFSKDWSFYILAHTEF*# SEQUENCE: SFSKDWSFYILAHTEF*# ...# >HUM208A6# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (1-16)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,IQRTPKIQVYSRHPAE*# SEQUENCE: IQRTPKIQVYSRHPAE*# ...# >HUM208A7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin human (7-22)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,IQVYSRHPAENGKSNF*# SEQUENCE: IQVYSRHPAENGKSNF*# ...# >HUM208A8# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (13-28)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063,I61868)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HPAENGKSNFLNCYVS*# SEQUENCE: HPAENGKSNFLNCYVS*# ...# >HUM208A9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (19-34)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I36963,I61868,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,KSNFLNCYVSGFHPSD*# SEQUENCE: KSNFLNCYVSGFHPSD*# ...# >HUM208AA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (91-106)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,ACRVNHVTLSQPKIVK*# SEQUENCE: ACRVNHVTLSQPKIVK*# ...# >HUM208AB# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Beta 2 microglobulin mouse (31-46)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,HPPHIEIQMLKDGKKI*# SEQUENCE: HPPHIEIQMLKDGKKI*# ...# >HUM208AC# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (91-106)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ACRVKHDSMAEPKTVY*# SEQUENCE: ACRVKHDSMAEPKTVY*# ...# >HUM208AD# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (97-112)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ASMAEPKTVYWDRDM*# SEQUENCE: ASMAEPKTVYWDRDM*# ...# >HUM208AE# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (1-16)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,IQRTPKIQVYSRHPAE*# SEQUENCE: IQRTPKIQVYSRHPAE*# ...# >HUM208AF# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin human (7-22)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,IQVYSRHPAENGKSNF*# SEQUENCE: IQVYSRHPAENGKSNF*# ...# >HUM208B0# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (19-34)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I61868,I36963,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,KSNFLNCYVSGFHPSD*# SEQUENCE: KSNFLNCYVSGFHPSD*# ...# >HUM208B1# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (43-58)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,GERIEKVEHSDLSFSY*# SEQUENCE: GERIEKVEHSDLSFSY*# ...# >HUM208B2# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin human (55-70)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,SFSNDWSFYLLYYTEF*# SEQUENCE: SFSNDWSFYLLYYTEF*# ...# >HUM208B3# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (91-106)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ACRVNHVTLSQPKIVK*# SEQUENCE: ACRVNHVTLSQPKIVK*# ...# >HUM208B4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (7-22)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MUSSP,B2MG_MOUSE)# & PIR1: (MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,IQVYSRHPPENGKPNI*# SEQUENCE: IQVYSRHPPENGKPNI*# ...# >HUM208B5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin mouse (31-46)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,HPPHIEIQMLKDGKKI*# SEQUENCE: HPPHIEIQMLKDGKKI*# ...# >HUM208B6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (49-64)# ANCHOR POSITIONS:# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,VEMSDMSFSKDWSFYL*# SEQUENCE: VEMSDMSFSKDWSFYL*# ...# >HUM208B7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin mouse (55-70)# DB REFERENCE: SWISS: (B2MG_RAT,B2MG_MOUSE,B2MG_RAT,B2MG_MUSSP,B2MG_MOUSE,# & B2MG_MUSCR)# & PIR1: (A26842,MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,SFSKDWSFYILAHTEF*# SEQUENCE: SFSKDWSFYILAHTEF*# ...# >HUM208B8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta 2 microglobulin human (1-16)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,IQRTPKIQVYSRHPAE*# SEQUENCE: IQRTPKIQVYSRHPAE*# ...# >HUM208B9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (7-22)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,IQVYSRHPAENGKSNF*# SEQUENCE: IQVYSRHPAENGKSNF*# ...# >HUM208BA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta 2 microglobulin human (19-34)# DB REFERENCE: SWISS: (B2MG_PONPY,B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I61868,I36963)# REFERENCES: sette93a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,KSNFLNCYVSGFHPSD*# SEQUENCE: KSNFLNCYVSGFHPSD*# ...# >HUM108BB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp160 (313-327)# ANCHOR POSITIONS:# REFERENCES: dadaglio91a,clerici91a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,RIQRGRGRAFVTIGK*# SEQUENCE: RIQRGRGRAFVTIGK*# ...# >HUM108BC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./reference# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp160 (421-440)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1BR,ENV_HV1PV,ENV_HV1H3)# & PIR1: (VCLJVL,VCLJLV)# & PIR3: (S13289,S13288)# REFERENCES: dadaglio91a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,LPCRIKQFINMWQEVGKAMY*# SEQUENCE: LPCRIKQFINMWQEVGKAMY*# ...# >HUM108BD# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp160 (25-46)# DB REFERENCE: SWISS: (ENV_HV1Z8,ENV_HV1Y2,ENV_HV1MA,ENV_HV1EL,ENV_HV1MF,# & ENV_HV1N5,ENV_HV1OY,ENV_HV1A2,ENV_HV1RH,ENV_HV1PV,# & ENV_HV1H2,ENV_HV1MN,ENV_HV1Z2,ENV_HV1W2,ENV_HV1B1,# & ENV_HV1Z6,ENV_HV1BR,ENV_HV1H3,ENV_HV1W1,ENV_HV1S1,# & ENV_HV1KB,ENV_HV1SC,ENV_HV1C4)# & PIR1: (VCLJKX,VCLJLV,VCLJSC,VCLJ3W,VCLJH3,VCLJZR,VCLJKB,VCLJMN,# & VCLJVL,H44001,VCLJA2,VCLJH4)# & PIR2: (A40218,S54384)# & PIR3: (S13288,S33985,S13289)# REFERENCES: dadaglio91a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,LWVTVYYGVPVWKEATTTLFCA*# SEQUENCE: LWVTVYYGVPVWKEATTTLFCA*# ...# >HUM108BE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp160 (295-312)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1MF,ENV_HV1PV,ENV_HV1S1,ENV_HV1BR)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR2: (A46410,C46410)# & PIR3: (S13289,S13288)# REFERENCES: dadaglio91a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,SVEINCTRPNNNTRKSI*# SEQUENCE: SVEINCTRPNNNTRKSI*# ...# >HUM108BF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp160 (494-513)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1SC,ENV_HV1W1,ENV_HV1B1,ENV_HV1H3,# & ENV_HV1H2,ENV_HV1PV,ENV_HV1S3,ENV_HV1Y2,ENV_HV1S1,# & ENV_HV1C4,ENV_HV1BN,ENV_HV1JR,ENV_HV1BR)# & PIR1: (VCLJLV,VCLJBR,VCLJH3,H44001,VCLJSC,VCLJ3W,VCLJVL,# & VCLJH4)# & PIR2: (A40218,C41621,S60538)# & PIR3: (S33985,S13288,S13289)# REFERENCES: dadaglio91a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,VKIEPLGVAPTKAKRRVVQR*# SEQUENCE: VKIEPLGVAPTKAKRRVVQR*# ...# >HUM108C0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp160 (374-380)# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1PV,ENV_HV1BR,ENV_HV1H3,ENV_HV1B1,# & ENV_HV1W2,ENV_HV1W1,ENV_HV1H2,ENV_HV1MF,ENV_HV1B8)# & PIR1: (VCLJLV,VCLJ3W,VCLJVL,H44001,VCLJH3)# & PIR2: (A40218)# & PIR3: (S13288,S33985)# REFERENCES: dadaglio91a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,PEIVTHS*# SEQUENCE: PEIVTHS*# ...# >HUM108C1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp160 (381-392)# ANCHOR POSITIONS:# REFERENCES: dadaglio91a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,KNCGGEFFYCNS*# SEQUENCE: KNCGGEFFYCNS*# ...# >HUM108C2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p25 gag (265-280)# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1B5,GAG_HV1N5,GAG_HV1OY,GAG_HV1H2,# & GAG_HV1B1,GAG_HV1BR,GAG_HV1Y2,GAG_HV1PV,GAG_HV1A2)# & PIR1: (A44001,FOVWH3,FOVWVL,FOVWA2,FOVWLV)# & PIR2: (S60703,S60699,S60704,S60702)# & PIR3: (S33979)# REFERENCES: dadaglio91a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,YKRWIILGLNKIVRMYSPT*# SEQUENCE: YKRWIILGLNKIVRMYSPT*# ...# >RHE108C3# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SIV mac gag 11C p11C (182-190)# DB REFERENCE: SWISS: (GAG_HV2RO,GAG_SIVS4,GAG_HV2SB,GAG_SIVMS,GAG_HV2CA,# & GAG_SIVMK,GAG_HV2BE,GAG_SIVA1,GAG_HV2NZ,GAG_HV2D2,# & GAG_HV2ST,GAG_SIVAT,GAG_SIVSP,GAG_SIVAG,GAG_HV2G1,# & GAG_HV2D1,GAG_HV2KR)# & PIR1: (FOLJGG,FOLJG2,FOLJTM,FOLJG4,FOLJCA,FOLJG5,FOLJST)# & PIR2: (S12152,S03070,S08435,S04237,S53091)# REFERENCES: chen92a,shen94a# COMMENT:# SUMMARY: Mamu-A1,actyesu,bindyesu,TPYDINQML*# SEQUENCE: TPYDINQML*# ...# >RHE108C4# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SIV mac gag 11C p11C (182-190) variant# ANCHOR POSITIONS:# REFERENCES: chen92a,shen94a# COMMENT:# SUMMARY: Mamu-A1,actyesu,bindyesu,APYDINQML*# SEQUENCE: APYDINQML*# ...# >RHE108C5# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SIV mac gag 11C p11C (182-190) variant# ANCHOR POSITIONS:# REFERENCES: chen92a,shen94a# COMMENT:# SUMMARY: Mamu-A1,actyesu,bindyesu,TPYNINQML*# SEQUENCE: TPYNINQML*# ...# >RHE108C6# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SIV mac gag 11C p11C (182-190) variant# ANCHOR POSITIONS:# REFERENCES: chen92a,shen94a# COMMENT:# SUMMARY: Mamu-A1,actyesu,bindyesu,TPYDIDQML*# SEQUENCE: TPYDIDQML*# ...# >RHE108C7# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SIV mac gag 11C p11C (182-190) variant# ANCHOR POSITIONS:# REFERENCES: chen92a,shen94a# COMMENT:# SUMMARY: Mamu-A1,actyesu,bindyesu,APYNINQML*# SEQUENCE: APYNINQML*# ...# >MUS108C8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: direct peptide binding as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HLA-A2 (170-185)# DB REFERENCE: SWISS: (1A01_PONPY,1A26_HUMAN,1A02_GORGO,1A34_HUMAN,1A02_HUMAN,# & 1A66_HUMAN,1A32_HUMAN,1AXX_HUMAN,1A29_HUMAN,1A74_HUMAN,# & 1A04_GORGO,1A43_HUMAN,1A02_HUMAN,1A69_HUMAN,1A68_HUMAN,# & 1A25_HUMAN,1A26_HUMAN)# & PIR1: (HLHUA2,HLHU69,HLHU10,HLHU32,HLHUAW)# & PIR2: (I68699,JL0135,I84432,I38442,A37028,I37542,I37477,A45847,# & JH0537,JH0535,I38443,I37482,I37483,A35997,I37480,I38441,# & I84448,I84487,I68700,I37470,I61902,I61857,S16769,I38436,# & I37479)# REFERENCES: choppin90a,bouillot89a,sauzet96a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,RYLENGKETLQRTDAP*# SEQUENCE: RYLENGKETLQRTDAP*# ...# >HUM108C9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 gag (265-279)# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1N5,GAG_HV1JR,GAG_HV1A2,GAG_HV1ND,# & GAG_HV1MA,GAG_HV1PV,GAG_HV1BR,GAG_HV1MN,GAG_HV1B1,# & GAG_HV1W2,GAG_HV1C4,GAG_HV1B5,GAG_HV1OY,GAG_HV1Z2,# & GAG_HV1J3,GAG_HV1Y2,GAG_HV1H2)# & PIR1: (FOVWLV,A38068,FOVWH3,FOLJND,FOVWA2,FOVWH4,A44001,# & FOVWVL)# & PIR2: (S60699,S60702,S60708,S60698,S60703,S60697,S54377,# & S60704)# & PIR3: (S19598,S33979)# REFERENCES: choppin90a,hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRWIILGLNKIVRMY*# SEQUENCE: KRWIILGLNKIVRMY*# ...# >HUM108CA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as./cytotoxicity as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 gag (418-433)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1BR,GAG_HV1U4,GAG_HV1MA,GAG_HV1MN,# & GAG_HV1PV,GAG_HV1N5,GAG_HV1B5,GAG_HV1H2,GAG_HV1Y2)# & PIR1: (A38068,FOVWVL,A44001,FOVWLV,FOVWH3)# & PIR2: (S24471,S24478)# & PIR3: (S33979)# REFERENCES: choppin90a,claverie88a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,KEGHQMKDCTERQANF*# SEQUENCE: KEGHQMKDCTERQANF*# ...# >MUS108CB# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: direct peptide binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 env (312-327)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1BR,ENV_HV1H3,ENV_HV1B1,ENV_HV1PV,# & ENV_HV1B8,ENV_HV1H2)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,IRIQRGPGRAFVTIGK*# SEQUENCE: IRIQRGPGRAFVTIGK*# ...# >HUM108CC# MHC MOLECULE: HLA-B17, CLASS-1, (HUMAN)# METHOD: direct peptide binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 nef (113-128)# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_HV1BR,NEF_HV1A2,NEF_HV1PV,NEF_HV1S3,# & NEF_HV112)# & PIR1: (ASLJ12,ASLJO2,ASLJFV,ASLJVL)# & PIR2: (S03245,S43467,S03247)# & PIR3: (S33986)# REFERENCES: choppin90a,culmann89a# COMMENT:# SUMMARY: HLA-B17,actyesu,bindyesu,WIYHTQGYFPDWQNYT*# SEQUENCE: WIYHTQGYFPDWQNYT*# ...# >HUM108CD# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 nef (113-128)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1S3,NEF_HV112,NEF_HV1A2,NEF_HV1JR,# & NEF_HV1BR)# & PIR1: (ASLJO2,ASLJVL,ASLJFV,ASLJ12)# & PIR2: (S43467,S03245,S03247)# & PIR3: (S33986)# REFERENCES: choppin90a,culmann89a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,WIYHTQGYFPDWQNYT*# SEQUENCE: WIYHTQGYFPDWQNYT*# ...# >HUM108CE# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: direct peptide binding as./cytotoxicity as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 nef (132-147)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1B8)# & PIR1: (ASLJFV)# & PIR2: (S03244,S43467,S03247)# REFERENCES: choppin90a,culmann91a/hivdb97a# COMMENT:# SUMMARY: HLA-B18,actyesu,bindyesu,GVRYPLTFGWCYKLVP*# SEQUENCE: GVRYPLTFGWCYKLVP*# ...# >HUM108CF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A matrix M (57-68)# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IALE2,VMT1_IAWIL,VMT1_IAANN,VMT1_IAZI1,# & VMT1_IALE1,VMT1_IAUSS,VMT1_IAPUE,VMT1_IAUDO,VMT1_IABAN,# & VMT1_IAFOW,VMT1_IAMAN)# & PIR1: (MFIV1K,MFIVWS,MFIVC,MFIV1M,MFIV,JN0392,MFIV61)# & PIR2: (S14616,S04054,S04058,S04056,S04050,S07429,S04052)# REFERENCES: choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM108D0# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A matrix M (57-68)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IAUSS,VMT1_IAWIL,VMT1_IAANN,VMT1_IAPUE,# & VMT1_IAUDO,VMT1_IAMAN,VMT1_IAFOW,VMT1_IABAN,VMT1_IACKB,# & VMT1_IALE1,VMT1_IAZI1)# & PIR1: (MFIV61,MFIVC,MFIV1M,MFIV,JN0392,MFIV1K,MFIVWS)# & PIR2: (S04052,S14616,S04050,S04054,S04058,S04056,S07429)# REFERENCES: choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesl,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM108D1# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A matrix M (57-68)# ANCHOR POSITIONS:# REFERENCES: choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,YKGILGFVFTLTV*# SEQUENCE: YKGILGFVFTLTV*# ...# >HUM108D2# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A matrix M (57-68)# ANCHOR POSITIONS:# REFERENCES: choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesl,YKGILGFVFTLTV*# SEQUENCE: YKGILGFVFTLTV*# ...# >HUM108D3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A nucleoprotein N (335-349)# ANCHOR POSITIONS:# REFERENCES: choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,SAAFEDLRVLSFIRGY*# SEQUENCE: SAAFEDLRVLSFIRGY*# ...# >HUM108D4# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A nucleoprotein N (335-349)# ANCHOR POSITIONS:# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,SAAFEDLRVLSFIRGY*# SEQUENCE: SAAFEDLRVLSFIRGY*# ...# >HUM108D5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 gag (265-279)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1J3,GAG_HV1B1,GAG_HV1BR,GAG_HV1W2,# & GAG_HV1C4,GAG_HV1OY,GAG_HV1Z2,GAG_HV1MA,GAG_HV1PV,# & GAG_HV1MN,GAG_HV1Y2,GAG_HV1H2,GAG_HV1A2,GAG_HV1JR,# & GAG_HV1RH,GAG_HV1B5,GAG_HV1ND)# & PIR1: (FOVWVL,A38068,FOVWA2,A44001,FOVWLV,FOLJND,FOVWH4,# & FOVWH3)# & PIR2: (S60698,S60699,S54377,S60704,S60703,S60702,S60708,# & S60697)# & PIR3: (S33979,S19598)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KRWIILGLNKIVRMY*# SEQUENCE: KRWIILGLNKIVRMY*# ...# >HUM108D6# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 gag (265-279)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1A2,GAG_HV1B5,GAG_HV1ND,GAG_HV1OY,# & GAG_HV1C4,GAG_HV1N5,GAG_HV1B1,GAG_HV1H2,GAG_HV1MN,# & GAG_HV1PV,GAG_HV1Y2,GAG_HV1RH,GAG_HV1J3,GAG_HV1W2,# & GAG_HV1JR,GAG_HV1Z2,GAG_HV1MA)# & PIR1: (FOLJND,FOVWH3,FOVWLV,A38068,FOVWA2,FOVWVL,FOVWH4,# & A44001)# & PIR2: (S54377,S60699,S60698,S60708,S60702,S60697,S60704,# & S60703)# & PIR3: (S33979,S19598)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,KRWIILGLNKIVRMY*# SEQUENCE: KRWIILGLNKIVRMY*# ...# >HUM108D7# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 gag (418-433)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1MA,GAG_HV1BR,GAG_HV1B5,GAG_HV1N5,# & GAG_HV1MN,GAG_HV1H2,GAG_HV1Y2,GAG_HV1PV,GAG_HV1U4)# & PIR1: (FOVWH3,FOVWLV,A38068,FOVWVL,A44001)# & PIR2: (S24478,S24471)# & PIR3: (S33979)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,KEGHQMKDCTERQANF*# SEQUENCE: KEGHQMKDCTERQANF*# ...# >HUM108D8# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (312-327)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1PV,ENV_HV1BR,ENV_HV1H3,ENV_HV1B1,# & ENV_HV1B8,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S13288,S33985)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,IRIQRGPGRAFVTIGK*# SEQUENCE: IRIQRGPGRAFVTIGK*# ...# >HUM108D9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (312-327)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1H3,ENV_HV1B1,ENV_HV1BR,# & ENV_HV1MF,ENV_HV1PV)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,IRIQRGPGRAFVTIGK*# SEQUENCE: IRIQRGPGRAFVTIGK*# ...# >HUM108DA# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (312-327)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1B1,ENV_HV1BR,ENV_HV1H3,# & ENV_HV1PV,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,IRIQRGPGRAFVTIGK*# SEQUENCE: IRIQRGPGRAFVTIGK*# ...# >HUM108DB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (584-604)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B1,ENV_HV1H3,ENV_HV1MF,ENV_HV1PV,# & ENV_HV1Z2,ENV_HV1ZH,ENV_HV1BR,ENV_HV1Z6,ENV_HV1J3,# & ENV_HV1B8,ENV_HV1EL)# & PIR1: (VCLJZR,A44963,VCLJLV,VCLJH3,VCLJVL)# & PIR2: (S70422,S21998,S54384,S21996,S70425)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RILAVERYLKDQQLLGIWGCS*# SEQUENCE: RILAVERYLKDQQLLGIWGCS*# ...# >HUM108DC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (584-604)# DB REFERENCE: SWISS: (ENV_HV1Z2,ENV_HV1EL,ENV_HV1H3,ENV_HV1PV,ENV_HV1MF,# & ENV_HV1B1,ENV_HV1Z6,ENV_HV1H2,ENV_HV1ZH,ENV_HV1J3,# & ENV_HV1BR,ENV_HV1B8)# & PIR1: (VCLJVL,A44963,VCLJH3,VCLJLV,VCLJZR)# & PIR2: (S70425,S21996,S54384,S21998,S70422)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RILAVERYLKDQQLLGIWGCS*# SEQUENCE: RILAVERYLKDQQLLGIWGCS*# ...# >HUM108DD# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (584-604)# DB REFERENCE: SWISS: (ENV_HV1Z2,ENV_HV1EL,ENV_HV1H2,ENV_HV1B1,ENV_HV1H3,# & ENV_HV1MF,ENV_HV1PV,ENV_HV1Z6,ENV_HV1BR,ENV_HV1B8,# & ENV_HV1J3,ENV_HV1ZH)# & PIR1: (VCLJLV,VCLJH3,VCLJZR,VCLJVL,A44963)# & PIR2: (S70422,S54384,S21996,S70425,S21998)# & PIR3: (S13288,S33985)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,RILAVERYLKDQQLLGIWGCS*# SEQUENCE: RILAVERYLKDQQLLGIWGCS*# ...# >HUM108DE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A haemagglutinin HA (305-329)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IAAIC,HEMA_IAVI7,HEMA_IADU3,HEMA_IAUDO,# & HEMA_IABAN,HEMA_IADH7,HEMA_IADH1,HEMA_IADHM,HEMA_IADH3,# & HEMA_IAEN7,HEMA_IAZCO,HEMA_IADH6,HEMA_IANT6,# & HEMA_IAZH2)# & PIR1: (HMIVH,HMIVV,HMIV6,HMIV77,HMIVDU,HMIVHA,HMIV89,HMIV15,# & HMIV33,HMIV98,HMIVS3)# & PIR2: (JQ1156,A92979)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CPKYVKQNTLKLATGMRNVPEKQTR*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQTR*# ...# >HUM108DF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A haemagglutinin HA (305-329)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IAAIC,HEMA_IAVI7,HEMA_IADU3,HEMA_IADH7,# & HEMA_IAUDO,HEMA_IAZCO,HEMA_IABAN,HEMA_IADH1,HEMA_IADHM,# & HEMA_IANT6,HEMA_IAZH2,HEMA_IADH6,HEMA_IAEN7,# & HEMA_IADH3)# & PIR1: (HMIVV,HMIV98,HMIV15,HMIV6,HMIVS3,HMIV89,HMIVHA,HMIVDU,# & HMIV33,HMIVH,HMIV77)# & PIR2: (JQ1156,A92979)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,CPKYVKQNTLKLATGMRNVPEKQTR*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQTR*# ...# >HUM108E0# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A haemagglutinin HA (305-329)# DB REFERENCE: SWISS: (HEMA_IADHM,HEMA_IAUDO,HEMA_IAZCO,HEMA_IADH4,HEMA_IADH1,# & HEMA_IABAN,HEMA_IADH6,HEMA_IAZH2,HEMA_IANT6,HEMA_IAAIC,# & HEMA_IAVI7,HEMA_IADH7,HEMA_IADU3,HEMA_IADH3,# & HEMA_IAEN7)# & PIR1: (HMIVHA,HMIV89,HMIV77,HMIVDU,HMIV98,HMIV6,HMIVV,HMIV15,# & HMIV33,HMIVS3,HMIVH)# & PIR2: (A92979,JQ1156)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,CPKYVKQNTLKLATGMRNVPEKQTR*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQTR*# ...# >HUM108E1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lambda repressor R (12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >HUM108E2# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lambda repressor R (12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >HUM108E3# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lambda repressor R (12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >HUM108E4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as./reference# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: HIV1 env (105-117)# DB REFERENCE: SWISS: (ENV_HV1S1,ENV_HV1B8,ENV_HV1BN,ENV_HV1H3,ENV_HV1Z6,# & ENV_HV1MA,ENV_HV1Y2,ENV_HV1N5,ENV_HV1SC,ENV_HV1BR,# & ENV_HV1ND,ENV_HV1EL,ENV_HV1J3,ENV_HV1W1,ENV_HV1MN,# & ENV_HV1MF,ENV_HV1PV,ENV_HV1RH,ENV_SIVCZ,ENV_HV1B1,# & ENV_HV1C4,ENV_HV1W2,ENV_HV1Z2,ENV_HV1Z3,ENV_HV1H2)# & PIR1: (VCLJZR,VCLJSI,VCLJND,VCLJH3,VCLJBR,VCLJH4,VCLJVL,VCLJSC,# & VCLJMN,H44001,VCLJLV,VCLJ3W)# & PIR2: (S31493,S25938,S54384,S25939)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a,clerici91a,bouillot89a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >HUM108E5# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (105-117)# DB REFERENCE: SWISS: (ENV_HV1MA,ENV_HV1H3,ENV_HV1N5,ENV_HV1Y2,ENV_HV1ND,# & ENV_HV1J3,ENV_HV1EL,ENV_HV1SC,ENV_HV1W1,ENV_HV1MN,# & ENV_HV1RH,ENV_SIVCZ,ENV_HV1B1,ENV_HV1H2,ENV_HV1W2,# & ENV_HV1Z2,ENV_HV1BN,ENV_HV1S1,ENV_HV1B8,ENV_HV1Z3,# & ENV_HV1MF,ENV_HV1PV,ENV_HV1BR,ENV_HV1C4,ENV_HV1Z6)# & PIR1: (VCLJ3W,VCLJH3,VCLJND,VCLJSC,VCLJH4,VCLJVL,VCLJLV,H44001,# & VCLJMN,VCLJBR,VCLJZR,VCLJSI)# & PIR2: (S25939,S25938,S54384,S31493)# & PIR3: (S13288,S33985)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >HUM108E6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (428-445)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1PV,ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJLV)# & PIR3: (S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FINMWQEVGKAMYAPPIS*# SEQUENCE: FINMWQEVGKAMYAPPIS*# ...# >HUM108E7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (428-445)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1PV,ENV_HV1MF,ENV_HV1BR)# & PIR1: (VCLJLV,VCLJVL)# & PIR3: (S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,FINMWQEVGKAMYAPPIS*# SEQUENCE: FINMWQEVGKAMYAPPIS*# ...# >HUM108E8# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lysosyme (46-61)# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_CHICK,LYC_CHICK,LYC_PAVCR,LYC1_TACAC,# & LYC_LOPLE,LYC_PHACO,LYC_SYRRE,LYC_PHAVE,LYC_MELGA,# & LYC1_ANAPL)# & PIR1: (LZCH,LZFER,LZTK,LZDK,LZQJE)# & PIR2: (JU0237,A61281,JH0211,JC2144,JU0178,JQ1041,JT0526,JQ1033,# & JH0212,A45660)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >HUM108E9# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lysosyme (46-61)# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_CHICK,LYC_PHAVE,LYC1_TACAC,LYC_MELGA,# & LYC_PHACO,LYC_LOPLE,LYC_PAVCR,LYC_SYRRE,LYC1_ANAPL,# & LYC_CHICK)# & PIR1: (LZFER,LZDK,LZQJE,LZCH,LZTK)# & PIR2: (JH0211,JC2144,JQ1033,JH0212,JT0526,JQ1041,A61281,JU0178,# & JU0237,A45660)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >HUM108EA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 nef (132-147)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1B8)# & PIR1: (ASLJFV)# & PIR2: (S03244,S43467,S03247)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GVRYPLTFGWCYKLVP*# SEQUENCE: GVRYPLTFGWCYKLVP*# ...# >HUM108EB# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 nef (132-147)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1BR)# & PIR1: (ASLJFV)# & PIR2: (S43467,S03244,S03247)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,GVRYPLTFGWCYKLVP*# SEQUENCE: GVRYPLTFGWCYKLVP*# ...# >HUM108EC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding/HLA assembly# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 nef (137-145)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1B8,NEF_HV1PV,NEF_HV1U4,NEF_HV112)# & PIR1: (ASLJVL,ASLJFV,ASLJH3,ASLJ12)# & PIR2: (S43467,S03244,S03247)# REFERENCES: choppin90a,connan94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LTFGWCYKL*# SEQUENCE: LTFGWCYKL*# ...# >HUM108ED# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 nef (137-145)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV112,NEF_HV1PV,NEF_HV1B8,NEF_HV1U4)# & PIR1: (ASLJFV,ASLJ12,ASLJH3,ASLJVL)# & PIR2: (S03244,S43467,S03247)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,LTFGWCYKL*# SEQUENCE: LTFGWCYKL*# ...# >HUM108EE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 vif (1-15)# DB REFERENCE: SWISS: (VIF_HV1OY,VIF_HV1MA,VIF_HV1Y2,VIF_HV1JR,VIF_SIVCZ,# & VIF_HV1Z2,VIF_HV1Z6,VIF_HV1EL,VIF_HV1A2,VIF_HV1RH,# & VIF_HV1B1,VIF_HV1B5,VIF_HV1U4,VIF_HV1ND,VIF_HV1NA,# & VIF_HV1N5)# & PIR1: (ASLJO1,ASLJNA,C44001,ASLJND,ASLJZR,ASLJSI,ASLJS3)# & PIR2: (S42995,S42999,S42972,S42997,S43000,S42969,S42952,S42970,# & S42962,S42957,S43001,S42961,S43006,S42980,S42946,S42993,# & S42956,S42988,S42975,S42960,S42947,S42967,S42990,S43004,# & S42996,S42994,S42968,S42964,S42998,S42950,S42976,S42977,# & S54379,S42973,S43003,S42981,S42951,S42974,S42954,S42959,# & S42965,S42966,S42992,S42979,S42941,S43007,S42940,S42978,# & S43002,B41308,S42963,S42958,S42949,S42942,S42945)# & PIR3: (S33981)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MENRWQVMIVWQVDR*# SEQUENCE: MENRWQVMIVWQVDR*# ...# >HUM108EF# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 vif (1-15)# DB REFERENCE: SWISS: (VIF_HV1ND,VIF_HV1NA,VIF_HV1N5,VIF_HV1RH,VIF_HV1B1,# & VIF_HV1B5,VIF_HV1U4,VIF_HV1Z2,VIF_SIVCZ,VIF_HV1Z6,# & VIF_HV1EL,VIF_HV1JR,VIF_HV1Y2,VIF_HV1MA,VIF_HV1A2,# & VIF_HV1OY)# & PIR1: (ASLJZR,ASLJNA,ASLJO1,ASLJS3,ASLJSI,ASLJND,C44001)# & PIR2: (S42994,S42956,S42967,S43006,S42952,S42958,S42963,S42978,# & S42999,S42988,S42942,S42966,S42954,S42979,S42940,S43007,# & S42968,S42961,S42998,S43003,S42976,S42949,S43001,S42947,# & S42975,S42960,S42946,S42993,S42980,S42964,S42945,S42970,# & S42962,S42957,S42995,S42972,S42997,S42969,S43000,S42990,# & S43004,S42996,S42992,S42941,S42965,S42974,S42959,S42973,# & S54379,S42977,S42950,S42951,S42981,S43002,B41308)# & PIR3: (S33981)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,MENRWQVMIVWQVDR*# SEQUENCE: MENRWQVMIVWQVDR*# ...# >HUM108F0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 vif (25-40)# DB REFERENCE: SWISS: (VIF_HV1NA,VIF_HV1B1)# & PIR1: (ASLJNA,ASLJS3)# & PIR2: (S42964,S42946)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,VKHHMYVSGKARGWFY*# SEQUENCE: VKHHMYVSGKARGWFY*# ...# >HUM108F1# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 vif (25-40)# DB REFERENCE: SWISS: (VIF_HV1NA,VIF_HV1B1)# & PIR1: (ASLJS3,ASLJNA)# & PIR2: (S42964,S42946)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,VKHHMYVSGKARGWFY*# SEQUENCE: VKHHMYVSGKARGWFY*# ...# >HUM108F2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 vif (60-72)# DB REFERENCE: SWISS: (VIF_HV1B1,VIF_HV1NA,VIF_HV1B5,VIF_HV1JR,VIF_HV1MN)# & PIR1: (ASLJS3,ASLJNA)# & PIR2: (S42998,S42979,S42940,S42975,S43002,S42973,S42959,S42967,# & S42997,S42949,S42964,S42955,S42963,S42994,S43006,S42946,# & S42950,S42996,S42960)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GDARLVITTYWGL*# SEQUENCE: GDARLVITTYWGL*# ...# >HUM108F3# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 vif (60-72)# DB REFERENCE: SWISS: (VIF_HV1B5,VIF_HV1B1,VIF_HV1JR,VIF_HV1MN,VIF_HV1NA)# & PIR1: (ASLJS3,ASLJNA)# & PIR2: (S42997,S42975,S42940,S42979,S42960,S42994,S43006,S42950,# & S42996,S42964,S42949,S43002,S42998,S42973,S42959,S42967,# & S42955,S42963,S42946)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,GDARLVITTYWGL*# SEQUENCE: GDARLVITTYWGL*# ...# >HUM108F4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 rev (37-50)# DB REFERENCE: SWISS: (REV_HV1OY,REV_HV1W2,REV_HV1Y2,REV_HV1H2,REV_HV1B8,# & REV_HV1SC,REV_HV1A2,REV_HV112,REV_HV1S1,REV_HV1MN,# & REV_HV1BR,REV_HV1PV,REV_HV1RH,REV_HV1S3,REV_HV1JR,# & REV_HV1B1,REV_HV1C4)# & PIR1: (F44001,VKLJH3)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ARRNRRRRWRERQR*# SEQUENCE: ARRNRRRRWRERQR*# ...# >HUM108F5# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 rev (37-50)# DB REFERENCE: SWISS: (REV_HV112,REV_HV1B8,REV_HV1PV,REV_HV1H2,REV_HV1W2,# & REV_HV1MN,REV_HV1B1,REV_HV1JR,REV_HV1S3,REV_HV1OY,# & REV_HV1Y2,REV_HV1A2,REV_HV1RH,REV_HV1BR,REV_HV1SC,# & REV_HV1S1,REV_HV1C4)# & PIR1: (F44001,VKLJH3)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,ARRNRRRRWRERQR*# SEQUENCE: ARRNRRRRWRERQR*# ...# >HUM108F6# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 vpr (55-68# DB REFERENCE: SWISS: (VPR_HV1MN,VPR_HV1RH,VPR_HV1A2,VPR_HV1N5,VPR_HV1B5,# & VPR_HV1B1,VPR_HV1SC,VPR_HV1Y2,VPR_HV1BR,VPR_HV1JR)# & PIR1: (D44001)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,AGVEAIIRILQQLL*# SEQUENCE: AGVEAIIRILQQLL*# ...# >HUM108F7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV1 vpr (68-80)# DB REFERENCE: SWISS: (VPR_HV1MN,VPR_HV1SC,VPR_HV1BR,VPR_HV1JR,VPR_HV1N5)# REFERENCES: choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,LFIHFRIGCRHSR*# SEQUENCE: LFIHFRIGCRHSR*# ...# >HUM108F8# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV1 vpr (68-80)# DB REFERENCE: SWISS: (VPR_HV1JR,VPR_HV1BR,VPR_HV1MN,VPR_HV1N5,VPR_HV1SC)# REFERENCES: choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesh,LFIHFRIGCRHSR*# SEQUENCE: LFIHFRIGCRHSR*# ...# >HUM108F9# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 gag (378-391)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1BR,GAG_HV1H2)# & PIR1: (FOVWLV)# & PIR2: (S24476)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MQRGNFRNQRKIVK*# SEQUENCE: MQRGNFRNQRKIVK*# ...# >HUM108FA# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 gag (378-391)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1H2,GAG_HV1B5)# & PIR1: (FOVWLV)# & PIR2: (S24476)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,MQRGNFRNQRKIVK*# SEQUENCE: MQRGNFRNQRKIVK*# ...# >HUM108FB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (846-860)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1PV,ENV_HV1H3,ENV_HV1H2,ENV_HV1BR,# & ENV_HV1MF,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S13288,S33985)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RHIPRRIRQGLERIL*# SEQUENCE: RHIPRRIRQGLERIL*# ...# >HUM108FC# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (846-860)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1H3,ENV_HV1B8,ENV_HV1BR,ENV_HV1MF,# & ENV_HV1PV,ENV_HV1H2)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,RHIPRRIRQGLERIL*# SEQUENCE: RHIPRRIRQGLERIL*# ...# >HUM208FD# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A haemagglutinin HA (305-329)# DB REFERENCE: SWISS: (HEMA_IADH6,HEMA_IAUDO,HEMA_IADH4,HEMA_IAEN7,HEMA_IAAIC,# & HEMA_IADU3,HEMA_IANT6,HEMA_IADH7,HEMA_IAVI7,HEMA_IAZH2,# & HEMA_IABAN,HEMA_IADH3,HEMA_IAZCO,HEMA_IADHM,# & HEMA_IADH1)# & PIR1: (HMIVDU,HMIV33,HMIVS3,HMIV15,HMIVV,HMIVH,HMIV89,HMIV98,# & HMIVHA,HMIV77,HMIV6)# & PIR2: (A92979,JQ1156)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR?,actyesu,bindyesu,CPKYVKQNTLKLATGMRNVPEKQTR*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQTR*# ...# >MUS208FE# MHC MOLECULE: I-A?, CLASS-2, (MOUSE)# METHOD: direct peptide binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 env (105-117)# DB REFERENCE: SWISS: (ENV_HV1SC,ENV_HV1W1,ENV_HV1Z6,ENV_HV1B1,ENV_HV1PV,# & ENV_HV1Z2,ENV_HV1Z3,ENV_HV1C4,ENV_HV1B8,ENV_HV1H3,# & ENV_HV1BR,ENV_HV1S1,ENV_HV1BN,ENV_HV1N5,ENV_HV1MA,# & ENV_HV1Y2,ENV_HV1EL,ENV_HV1J3,ENV_HV1MN,ENV_HV1RH,# & ENV_SIVCZ,ENV_HV1H2,ENV_HV1ND,ENV_HV1W2,ENV_HV1MF)# & PIR1: (VCLJMN,VCLJLV,H44001,VCLJH3,VCLJBR,VCLJVL,VCLJH4,VCLJSI,# & VCLJZR,VCLJSC,VCLJ3W,VCLJND)# & PIR2: (S25939,S54384,S25938,S31493)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: I-A?,actyesu,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >MUS208FF# MHC MOLECULE: I-A?, CLASS-2, (MOUSE)# METHOD: direct peptide binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 env (428-445)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1BR,ENV_HV1PV,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJLV)# & PIR3: (S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: I-A?,actyesu,bindyesu,FINMWQEVGKAMYAPPIS*# SEQUENCE: FINMWQEVGKAMYAPPIS*# ...# >HUM20900# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV1 env (584-604)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1H3,ENV_HV1ZH,ENV_HV1MF,ENV_HV1B1,# & ENV_HV1PV,ENV_HV1B8,ENV_HV1EL,ENV_HV1BR,ENV_HV1Z6,# & ENV_HV1Z2,ENV_HV1J3)# & PIR1: (VCLJZR,A44963,VCLJVL,VCLJLV,VCLJH3)# & PIR2: (S70422,S21998,S54384,S70425,S21996)# & PIR3: (S13288,S33985)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,RILAVERYLKDQQLLGIWGCS*# SEQUENCE: RILAVERYLKDQQLLGIWGCS*# ...# >HUM20901# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A haemagglutinin HA (305-329)# DB REFERENCE: SWISS: (HEMA_IADH6,HEMA_IADHM,HEMA_IAUDO,HEMA_IANT6,HEMA_IADH1,# & HEMA_IADH3,HEMA_IAZCO,HEMA_IAVI7,HEMA_IAEN7,HEMA_IADH4,# & HEMA_IADH7,HEMA_IAAIC,HEMA_IABAN,HEMA_IAZH2,# & HEMA_IADU3)# & PIR1: (HMIVDU,HMIV6,HMIV89,HMIV98,HMIVS3,HMIV33,HMIVHA,HMIV15,# & HMIVV,HMIVH,HMIV77)# & PIR2: (A92979,JQ1156)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,CPKYVKQNTLKLATGMRNVPEKQTR*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQTR*# ...# >HUM20902# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A haemagglutinin HA (305-329)# DB REFERENCE: SWISS: (HEMA_IAZCO,HEMA_IAEN7,HEMA_IADH7,HEMA_IADH6,HEMA_IAUDO,# & HEMA_IADH3,HEMA_IAVI7,HEMA_IADH1,HEMA_IADH4,HEMA_IAAIC,# & HEMA_IAZH2,HEMA_IABAN,HEMA_IADU3,HEMA_IADHM,# & HEMA_IANT6)# & PIR1: (HMIV77,HMIVV,HMIVH,HMIV33,HMIV6,HMIV98,HMIVS3,HMIVDU,# & HMIV15,HMIV89,HMIVHA)# & PIR2: (JQ1156,A92979)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,CPKYVKQNTLKLATGMRNVPEKQTR*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQTR*# ...# >HUM20903# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (584-604)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B1,ENV_HV1ZH,ENV_HV1H2,ENV_HV1H3,# & ENV_HV1Z2,ENV_HV1EL,ENV_HV1J3,ENV_HV1BR,ENV_HV1B8,# & ENV_HV1Z6,ENV_HV1PV)# & PIR1: (VCLJH3,A44963,VCLJVL,VCLJLV,VCLJZR)# & PIR2: (S21996,S70425,S70422,S54384,S21998)# & PIR3: (S13288,S33985)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,RILAVERYLKDQQLLGIWGCS*# SEQUENCE: RILAVERYLKDQQLLGIWGCS*# ...# >HUM20904# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (584-604)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1H3,ENV_HV1B1,ENV_HV1MF,ENV_HV1Z2,# & ENV_HV1H2,ENV_HV1BR,ENV_HV1EL,ENV_HV1Z6,ENV_HV1B8,# & ENV_HV1PV,ENV_HV1J3)# & PIR1: (VCLJZR,VCLJH3,A44963,VCLJLV,VCLJVL)# & PIR2: (S70425,S54384,S70422,S21996,S21998)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,RILAVERYLKDQQLLGIWGCS*# SEQUENCE: RILAVERYLKDQQLLGIWGCS*# ...# >HUM20905# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (428-445)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1H3,ENV_HV1PV,ENV_HV1BR)# & PIR1: (VCLJLV,VCLJVL)# & PIR3: (S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,FINMWQEVGKAMYAPPIS*# SEQUENCE: FINMWQEVGKAMYAPPIS*# ...# >HUM20906# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lambda repressor R (12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >HUM20907# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (312-327)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B8,ENV_HV1BR,ENV_HV1H2,ENV_HV1H3,# & ENV_HV1PV,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,IRIQRGPGRAFVTIGK*# SEQUENCE: IRIQRGPGRAFVTIGK*# ...# >HUM20908# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 env (312-327)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1H3,ENV_HV1MF,ENV_HV1BR,ENV_HV1B1,# & ENV_HV1PV,ENV_HV1H2)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,IRIQRGPGRAFVTIGK*# SEQUENCE: IRIQRGPGRAFVTIGK*# ...# >HUM20909# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A matrix M (57-68)# ANCHOR POSITIONS:# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,YKGILGFVFTLTV*# SEQUENCE: YKGILGFVFTLTV*# ...# >HUM2090A# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A matrix M (57-68)# ANCHOR POSITIONS:# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,YKGILGFVFTLTV*# SEQUENCE: YKGILGFVFTLTV*# ...# >HUM2090B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A nucleoprotein N (335-349)# ANCHOR POSITIONS:# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SAAFEDLRVLSFIRGY*# SEQUENCE: SAAFEDLRVLSFIRGY*# ...# >HUM2090C# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A nucleoprotein N (335-349)# ANCHOR POSITIONS:# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,SAAFEDLRVLSFIRGY*# SEQUENCE: SAAFEDLRVLSFIRGY*# ...# >HUM2090D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 gag (265-279)# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1H2,GAG_HV1JR,GAG_HV1ND,GAG_HV1MA,# & GAG_HV1W2,GAG_HV1BR,GAG_HV1N5,GAG_HV1B5,GAG_HV1OY,# & GAG_HV1B1,GAG_HV1A2,GAG_HV1Y2,GAG_HV1PV,GAG_HV1J3,# & GAG_HV1C4,GAG_HV1MN,GAG_HV1Z2)# & PIR1: (FOVWH4,A44001,FOLJND,FOVWLV,FOVWVL,FOVWH3,FOVWA2,# & A38068)# & PIR2: (S60708,S60702,S60697,S60698,S54377,S60703,S60699,# & S60704)# & PIR3: (S19598,S33979)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,KRWIILGLNKIVRMY*# SEQUENCE: KRWIILGLNKIVRMY*# ...# >HUM2090E# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV1 gag (265-279)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1JR,GAG_HV1ND,GAG_HV1W2,GAG_HV1MA,# & GAG_HV1Y2,GAG_HV1PV,GAG_HV1A2,GAG_HV1J3,GAG_HV1MN,# & GAG_HV1Z2,GAG_HV1C4,GAG_HV1BR,GAG_HV1RH,GAG_HV1B5,# & GAG_HV1H2,GAG_HV1B1,GAG_HV1OY)# & PIR1: (FOVWVL,FOVWLV,FOLJND,A44001,FOVWH4,FOVWH3,FOVWA2,# & A38068)# & PIR2: (S60703,S60702,S60697,S60698,S60699,S60708,S54377,# & S60704)# & PIR3: (S19598,S33979)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,KRWIILGLNKIVRMY*# SEQUENCE: KRWIILGLNKIVRMY*# ...# >HUM2090F# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 nef (132-147)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1BR)# & PIR1: (ASLJFV)# & PIR2: (S03247,S03244,S43467)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,GVRYPLTFGWCYKLVP*# SEQUENCE: GVRYPLTFGWCYKLVP*# ...# >HUM20910# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 nef (137-145)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1B8,NEF_HV112,NEF_HV1U4,NEF_HV1BR)# & PIR1: (ASLJH3,ASLJVL,ASLJFV,ASLJ12)# & PIR2: (S03247,S43467,S03244)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,LTFGWCYKL*# SEQUENCE: LTFGWCYKL*# ...# >HUM20911# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 vif (1-15)# DB REFERENCE: SWISS: (VIF_HV1Z2,VIF_HV1Y2,VIF_HV1B1,VIF_HV1N5,VIF_HV1B5,# & VIF_HV1MA,VIF_HV1U4,VIF_HV1ND,VIF_HV1JR,VIF_HV1EL,# & VIF_SIVCZ,VIF_HV1RH,VIF_HV1Z6,VIF_HV1OY,VIF_HV1A2,# & VIF_HV1NA)# & PIR1: (ASLJND,ASLJZR,ASLJSI,ASLJNA,ASLJS3,C44001,ASLJO1)# & PIR2: (S42963,S42946,S42957,S42970,S42969,S42998,S42967,S42995,# & S42975,S42994,S42980,S42959,S42954,S42949,S43003,S42966,# & S42973,S42958,S42950,S42978,S42979,S42981,S42965,S43002,# & S42947,S43001,S42942,S42996,S42999,S42988,S42964,S43006,# & S42940,S42952,S43007,S42961,S42976,B41308,S42951,S42962,# & S42956,S42997,S42977,S54379,S42974,S42941,S42992,S43000,# & S42972,S42993,S42968,S42960,S43004,S42990,S42945)# & PIR3: (S33981)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,MENRWQVMIVWQVDR*# SEQUENCE: MENRWQVMIVWQVDR*# ...# >HUM20912# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 vif (25-40)# DB REFERENCE: SWISS: (VIF_HV1B1,VIF_HV1NA)# & PIR1: (ASLJS3,ASLJNA)# & PIR2: (S42946,S42964)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,VKHHMYVSGKARGWFY*# SEQUENCE: VKHHMYVSGKARGWFY*# ...# >HUM20913# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 vif (60-72)# DB REFERENCE: SWISS: (VIF_HV1B1,VIF_HV1MN,VIF_HV1NA,VIF_HV1JR,VIF_HV1B5)# & PIR1: (ASLJNA,ASLJS3)# & PIR2: (S42940,S42964,S42994,S42959,S42967,S43006,S42955,S42996,# & S43002,S42973,S42997,S42949,S42950,S42979,S42998,S42963,# & S42975,S42946,S42960)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,GDARLVITTYWGL*# SEQUENCE: GDARLVITTYWGL*# ...# >HUM20914# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 rev (37-50)# DB REFERENCE: SWISS: (REV_HV1BR,REV_HV1B8,REV_HV1Y2,REV_HV1B1,REV_HV1A2,# & REV_HV1PV,REV_HV1W2,REV_HV1RH,REV_HV1S1,REV_HV1C4,# & REV_HV1OY,REV_HV1SC,REV_HV1S3,REV_HV1H2,REV_HV1MN,# & REV_HV112,REV_HV1JR)# & PIR1: (F44001,VKLJH3)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,ARRNRRRRWRERQR*# SEQUENCE: ARRNRRRRWRERQR*# ...# >HUM20915# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 vpr (55-68# DB REFERENCE: SWISS: (VPR_HV1SC,VPR_HV1N5,VPR_HV1MN,VPR_HV1B5,VPR_HV1JR,# & VPR_HV1RH,VPR_HV1B1,VPR_HV1A2,VPR_HV1BR,VPR_HV1Y2)# & PIR1: (D44001)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,AGVEAIIRILQQLL*# SEQUENCE: AGVEAIIRILQQLL*# ...# >HUM20916# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 vpr (68-80)# DB REFERENCE: SWISS: (VPR_HV1SC,VPR_HV1BR,VPR_HV1MN,VPR_HV1N5,VPR_HV1JR)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,LFIHFRIGCRHSR*# SEQUENCE: LFIHFRIGCRHSR*# ...# >HUM20917# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 gag (378-391)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1B5,GAG_HV1H2)# & PIR1: (FOVWLV)# & PIR2: (S24476)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,MQRGNFRNQRKIVK*# SEQUENCE: MQRGNFRNQRKIVK*# ...# >HUM20918# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: direct peptide binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV1 env (846-860)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1MF,ENV_HV1B8,ENV_HV1H3,ENV_HV1BR,# & ENV_HV1B1,ENV_HV1H2)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S33985,S13288)# REFERENCES: choppin90a# COMMENT:# SUMMARY: HLA-DR13,actyesn,bindyesu,RHIPRRIRQGLERIL*# SEQUENCE: RHIPRRIRQGLERIL*# ...# >HUM10919# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: gp120 (428-443)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1J3,ENV_HV1S3,ENV_HV1JR,ENV_HV1B8,# & ENV_HV1Y2,ENV_HV1A2,ENV_HV1B1,ENV_HV1MN)# & PIR1: (VCLJMN,H44001,VCLJA2,VCLJBR,VCLJH3)# & PIR2: (C41621,A40218,S25940,S60538)# & PIR3: (S33985)# REFERENCES: clerici91a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >HUM1091A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: gp160 (834-848)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1MF,ENV_HV1PV)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# REFERENCES: clerici91a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >MUS2091B# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: gp120 (428-443)# DB REFERENCE: SWISS: (ENV_HV1MN,ENV_HV1S3,ENV_HV1BN,ENV_HV1B8,ENV_HV1J3,# & ENV_HV1B1,ENV_HV1A2,ENV_HV1JR,ENV_HV1Y2)# & PIR1: (VCLJBR,VCLJA2,VCLJMN,H44001,VCLJH3)# & PIR2: (S60538,C41621,S25940,A40218)# & PIR3: (S33985)# REFERENCES: cease87a,hale89a,altuvia94a,hivdb97a# COMMENT: I-Ek or I-Ak# SUMMARY: H-2k,actyesh,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS2091C# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: gp120 (428-443)# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1B8,ENV_HV1A2,ENV_HV1B1,ENV_HV1S3,# & ENV_HV1JR,ENV_HV1BN,ENV_HV1J3,ENV_HV1MN)# & PIR1: (VCLJBR,VCLJA2,VCLJMN,H44001,VCLJH3)# & PIR2: (A40218,S25940,S60538,C41621)# & PIR3: (S33985)# REFERENCES: cease87a,hale89a,altuvia94a,hivdb97a# COMMENT: I-Ad or I-Ed# SUMMARY: H-2d,actyesl,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS2091D# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferative as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV envT2 (112-124)# DB REFERENCE: SWISS: (ENV_HV1C4,ENV_HV1PV,ENV_HV1Z6,ENV_HV1H3,ENV_HV1Z2,# & ENV_HV1MA,ENV_HV1S1,ENV_HV1BN,ENV_HV1Y2,ENV_HV1Z3,# & ENV_HV1B1,ENV_HV1W2,ENV_HV1B8,ENV_HV1SC,ENV_HV1N5,# & ENV_HV1EL,ENV_HV1J3,ENV_HV1RH,ENV_HV1BR,ENV_HV1ND,# & ENV_SIVCZ,ENV_HV1W1,ENV_HV1MF,ENV_HV1MN,ENV_HV1H2)# & PIR1: (VCLJSI,VCLJSC,VCLJZR,VCLJVL,H44001,VCLJH4,VCLJH3,VCLJND,# & VCLJ3W,VCLJMN,VCLJBR,VCLJLV)# & PIR2: (S25938,S31493,S25939,S54384)# & PIR3: (S13288,S33985)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >MUS2091E# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: gp120 (428-443)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1A2,ENV_HV1JR,ENV_HV1MN,ENV_HV1S3,# & ENV_HV1J3,ENV_HV1B8,ENV_HV1BN,ENV_HV1Y2)# & PIR1: (H44001,VCLJH3,VCLJA2,VCLJMN,VCLJBR)# & PIR2: (A40218,C41621,S60538,S25940)# & PIR3: (S33985)# REFERENCES: cease87a,hale89a,altuvia94a# COMMENT:# SUMMARY: I-As,actyesh,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS2091F# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (437-451)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1OY,ENV_HV1PV,ENV_HV1H3,ENV_HV1H2,# & ENV_HV1B1,ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ad or I-Ed# SUMMARY: H-2d,actyesu,bindyesu,VGKAMYAPPISGQIR*# SEQUENCE: VGKAMYAPPISGQIR*# ...# >MUS20920# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (437-451)# DB REFERENCE: SWISS: (ENV_HV1OY,ENV_HV1PV,ENV_HV1BR,ENV_HV1MF,ENV_HV1B1,# & ENV_HV1H3,ENV_HV1B8,ENV_HV1H2)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ak or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,VGKAMYAPPISGQIR*# SEQUENCE: VGKAMYAPPISGQIR*# ...# >MUS20921# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (437-451)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B1,ENV_HV1H2,ENV_HV1BR,ENV_HV1H3,# & ENV_HV1B8,ENV_HV1OY,ENV_HV1PV)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S13288,S33985)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,VGKAMYAPPISGQIR*# SEQUENCE: VGKAMYAPPISGQIR*# ...# >MUS20922# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (437-451)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1B8,ENV_HV1PV,ENV_HV1H2,ENV_HV1MF,# & ENV_HV1OY,ENV_HV1B1,ENV_HV1BR)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,VGKAMYAPPISGQIR*# SEQUENCE: VGKAMYAPPISGQIR*# ...# >MUS20923# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (432-446)# DB REFERENCE: SWISS: (ENV_HV1S3,ENV_HV1J3,ENV_HV1BN,ENV_HV1B1,ENV_HV1BR,# & ENV_HV1MF,ENV_HV1KB,ENV_HV1Y2,ENV_HV1OY,ENV_HV1PV,# & ENV_HV1B8,ENV_HV1JR,ENV_HV1H3,ENV_HV1MN,ENV_HV1RH,# & ENV_HV1SC,ENV_HV1A2)# & PIR1: (VCLJLV,VCLJSC,VCLJKB,VCLJVL,VCLJMN,VCLJH3,H44001,VCLJA2,# & VCLJBR,VCLJKX)# & PIR2: (B41621,C41621,A40218,S60538,A41621,S25940)# & PIR3: (S33985,S13289,S13288)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,NMWQEVGKAMYAPPI*# SEQUENCE: NMWQEVGKAMYAPPI*# ...# >MUS20924# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (492-506)# ANCHOR POSITIONS:# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ak or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,CKYKVVKIEPLGVAPT*# SEQUENCE: CKYKVVKIEPLGVAPT*# ...# >MUS20925# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (492-506)# ANCHOR POSITIONS:# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ad or I-Ed# SUMMARY: H-2d,actyesu,bindyesu,CKYKVVKIEPLGVAPT*# SEQUENCE: CKYKVVKIEPLGVAPT*# ...# >MUS20926# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (492-506)# ANCHOR POSITIONS:# REFERENCES: hale89a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,CKYKVVKIEPLGVAPT*# SEQUENCE: CKYKVVKIEPLGVAPT*# ...# >MUS20927# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (492-506)# ANCHOR POSITIONS:# REFERENCES: hale89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,CKYKVVKIEPLGVAPT*# SEQUENCE: CKYKVVKIEPLGVAPT*# ...# >MUS10928# MHC MOLECULE: H-2k, CLASS-1, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV envT2 (112-124)# DB REFERENCE: SWISS: (ENV_SIVCZ,ENV_HV1BN,ENV_HV1Z2,ENV_HV1N5,ENV_HV1ND,# & ENV_HV1B1,ENV_HV1W1,ENV_HV1SC,ENV_HV1H3,ENV_HV1MN,# & ENV_HV1RH,ENV_HV1EL,ENV_HV1Z6,ENV_HV1C4,ENV_HV1B8,# & ENV_HV1W2,ENV_HV1H2,ENV_HV1Y2,ENV_HV1J3,ENV_HV1MA,# & ENV_HV1BR,ENV_HV1S1,ENV_HV1Z3,ENV_HV1PV,ENV_HV1MF)# & PIR1: (VCLJH3,H44001,VCLJSI,VCLJSC,VCLJBR,VCLJLV,VCLJND,VCLJ3W,# & VCLJZR,VCLJVL,VCLJMN,VCLJH4)# & PIR2: (S31493,S54384,S25939,S25938)# & PIR3: (S33985,S13288)# REFERENCES: hale89a# COMMENT: I-Ak or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >MUS20929# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV envT2 (109-123)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1H3,ENV_HV1MN,ENV_HV1RH,# & ENV_HV1J3,ENV_HV1S1,ENV_HV1MF,ENV_HV1Z3,ENV_HV1B1,# & ENV_HV1ND,ENV_HV1SC,ENV_HV1PV,ENV_HV1W2,ENV_HV1EL,# & ENV_HV1W1,ENV_HV1C4,ENV_HV1BR,ENV_HV1MA,ENV_HV1Y2,# & ENV_HV1Z2,ENV_HV1BN,ENV_HV1N5)# & PIR1: (VCLJBR,VCLJVL,VCLJLV,H44001,VCLJH3,VCLJ3W,VCLJH4,VCLJND,# & VCLJSC,VCLJMN)# & PIR2: (S25938,S25939,S54384,S31493)# & PIR3: (S33985,S13288)# REFERENCES: hale89a# COMMENT: I-Ak or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,EQMHEDIISLWDQSL*# SEQUENCE: EQMHEDIISLWDQSL*# ...# >MUS2092A# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV envT2 (109-123)# DB REFERENCE: SWISS: (ENV_HV1W2,ENV_HV1J3,ENV_HV1Z2,ENV_HV1BN,ENV_HV1C4,# & ENV_HV1S1,ENV_HV1N5,ENV_HV1Y2,ENV_HV1EL,ENV_HV1H3,# & ENV_HV1B8,ENV_HV1MA,ENV_HV1BR,ENV_HV1PV,ENV_HV1W1,# & ENV_HV1RH,ENV_HV1MN,ENV_HV1H2,ENV_HV1MF,ENV_HV1Z3,# & ENV_HV1SC,ENV_HV1ND,ENV_HV1B1)# & PIR1: (VCLJH4,VCLJND,H44001,VCLJ3W,VCLJLV,VCLJH3,VCLJSC,VCLJMN,# & VCLJBR,VCLJVL)# & PIR2: (S25939,S25938,S54384,S31493)# & PIR3: (S33985,S13288)# REFERENCES: hale89a# COMMENT: I-Ad or I-Ed# SUMMARY: H-2d,actyesu,bindyesu,EQMHEDIISLWDQSL*# SEQUENCE: EQMHEDIISLWDQSL*# ...# >MUS2092B# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV envT2 (109-123)# DB REFERENCE: SWISS: (ENV_HV1MN,ENV_HV1H2,ENV_HV1Z3,ENV_HV1H3,ENV_HV1EL,# & ENV_HV1B8,ENV_HV1N5,ENV_HV1Y2,ENV_HV1ND,ENV_HV1B1,# & ENV_HV1RH,ENV_HV1BR,ENV_HV1PV,ENV_HV1W1,ENV_HV1C4,# & ENV_HV1MF,ENV_HV1Z2,ENV_HV1W2,ENV_HV1BN,ENV_HV1S1,# & ENV_HV1SC,ENV_HV1J3,ENV_HV1MA)# & PIR1: (VCLJH3,VCLJBR,VCLJSC,H44001,VCLJLV,VCLJ3W,VCLJVL,VCLJH4,# & VCLJMN,VCLJND)# & PIR2: (S54384,S31493,S25938,S25939)# & PIR3: (S13288,S33985)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,EQMHEDIISLWDQSL*# SEQUENCE: EQMHEDIISLWDQSL*# ...# >MUS2092C# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (324-338)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1MF,ENV_HV1B1,ENV_HV1PV,# & ENV_HV1BR,ENV_HV1H3)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S13288,S33985)# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ad or I-Ed# SUMMARY: H-2d,actyesu,bindyesu,FVTIGKIGNMRQAHC*# SEQUENCE: FVTIGKIGNMRQAHC*# ...# >MUS2092D# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (324-338)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H3,ENV_HV1B1,ENV_HV1H2,ENV_HV1B8,# & ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ak or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,FVTIGKIGNMRQAHC*# SEQUENCE: FVTIGKIGNMRQAHC*# ...# >MUS2092E# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (342-356)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1H2)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# REFERENCES: hale89a# COMMENT: I-Ak or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,RAKWNNTLKQIDSKL*# SEQUENCE: RAKWNNTLKQIDSKL*# ...# >MUS2092F# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (342-356)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1H2)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,RAKWNNTLKQIDSKL*# SEQUENCE: RAKWNNTLKQIDSKL*# ...# >MUS20930# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (342-356)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H2,ENV_HV1B1)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,RAKWNNTLKQIDSKL*# SEQUENCE: RAKWNNTLKQIDSKL*# ...# >MUS20931# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (828-842)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B1,ENV_HV1BR,ENV_HV1MF,ENV_HV1PV)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S33985)# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ak or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,AVAEGTDRVIEVVQG*# SEQUENCE: AVAEGTDRVIEVVQG*# ...# >MUS20932# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (834-848)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1B1,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ak or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >MUS20933# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (834-848)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1MF,ENV_HV1PV)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >MUS20934# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (841-855)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1MF)# & PIR1: (VCLJH3,VCLJVL)# & PIR3: (S33985)# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ad or I-Ed# SUMMARY: H-2d,actyesu,bindyesu,QGAYRAIRHIPRRIR*# SEQUENCE: QGAYRAIRHIPRRIR*# ...# >MUS20935# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (841-855)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1MF,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJVL)# & PIR3: (S33985)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,QGAYRAIRHIPRRIR*# SEQUENCE: QGAYRAIRHIPRRIR*# ...# >MUS20936# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (841-855)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1MF,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJVL)# & PIR3: (S33985)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,QGAYRAIRHIPRRIR*# SEQUENCE: QGAYRAIRHIPRRIR*# ...# >MUS20937# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (846-860)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1BR,ENV_HV1H3,ENV_HV1MF,ENV_HV1B8,# & ENV_HV1B1,ENV_HV1H2)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR2: (S22002,S70418)# & PIR3: (S13288,S33985)# REFERENCES: hale89a,hivdb97a# COMMENT: I-Ad or I-Ed# SUMMARY: H-2d,actyesu,bindyesu,AIRHIPRRIRQGLER*# SEQUENCE: AIRHIPRRIRQGLER*# ...# >MUS20938# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp160 (846-860)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1H3,ENV_HV1MF,ENV_HV1PV,ENV_HV1BR,# & ENV_HV1B8,ENV_HV1H2)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR2: (S70418,S22002)# & PIR3: (S33985,S13288)# REFERENCES: hale89a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,AIRHIPRRIRQGLER*# SEQUENCE: AIRHIPRRIRQGLER*# ...# >MUS10939# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HSV gB (498-505)# DB REFERENCE: SWISS: (VGLB_HSV1K,VGLB_HSV1P,VGLB_HSV1F,VGLB_HSV23,VGLB_HSV11,# & VGLB_HSV2H)# & PIR1: (VGBEK2,VGBEB1,VGBEK1,VGBEW7,VGBEB2)# REFERENCES: bonneau93a# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,SSIEFARL*# SEQUENCE: SSIEFARL*# ...# >MUS1093A# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HSV gB (497-507)# DB REFERENCE: SWISS: (VGLB_HSV1F,VGLB_HSV2H,VGLB_HSV1P,VGLB_HSV1K,VGLB_HSV23,# & VGLB_HSV11)# & PIR1: (VGBEW7,VGBEB2,VGBEB1,VGBEK1,VGBEK2)# REFERENCES: bonneau93a,udhayakumar94a# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,TSSIEFARLQF*# SEQUENCE: TSSIEFARLQF*# ...# >MUS2093B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bovine insulin B-chain (5-15)# DB REFERENCE: SWISS: (INS_PSAOB,INS_LEPSP,INS_KATPE,INS_PETMA,INS_CERAE,# & INS_SELRF,INS_PIG,INS_HUMAN,INS_SELRF,INS_MACFA,# & INS_ACOCA,INS_PSESC,INS_CANFA,INS2_MOUSE,INS1_XENLA,# & INS_TORMA,INS_AMICA,INS2_XENLA,INS_ACOCA,INS_PIG,# & INS_SHEEP,INS_BALPH,INS_CAMDR,INS_RODSP,INS_HUMAN,# & INS_RABIT,INS_HORSE,INS_CRILO,INS_BOVIN,INS_BALBO,# & INS_ANGRO,INS_ANSAN,INS_SQUAC,INS_CHICK,INS_FELCA,# & INS_ANAPL,INS_HYSCR,INS_ELEMA,INS_DIDMA,INS_PANTR,# & INS2_MOUSE,INS_CAPHI,INS2_RAT)# & PIR1: (INCT,INWH1S,INGT,IPPG,INRB,IPCH,INHY,INSH,IPXL2,IPDG,# & A61125,IPHU,INGXA,IPBO,INWHP,INMS2,INGS,IPHO,INLMS,# & IPXL1,IPRYM,A61129,INPQ,INTK,INDF,IPRT2,INWHF,INOS,# & INCMA,INEL)# & PIR2: (JQ0178,B42179,S09278,A53438,JQ0362,S63591,A60414,I48166,# & A42179)# & PIR3: (S15426,JQ0363,I51221,S44470)# REFERENCES: rothbard88b# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,HLCGSHLVEAL*# SEQUENCE: HLCGSHLVEAL*# ...# >MUS2093C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Cytochrome human (13-25)# DB REFERENCE: SWISS: (CYC_ANAPL,CYC_ATESP,CYC_HUMAN,CYC_APTPA,CYC_STRCA,# & CYC_DRONO,CYC_ATESP,CYC_VARVA,CYC_MACMU,CYC_DRONO,# & CYC_COLLI,CYC_CHICK,CYC_ANAPL,CYC_COLLI,CYC_APTPA,# & CYC_CHICK)# & PIR1: (CCTK,CCDK,CCMQR,CCPN,CCCH,CCMKP,CCOS,CCPY,CCHU,CCCZ,# & CCEU)# REFERENCES: corradin83a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,KCSQCHTVEKGGK*# SEQUENCE: KCSQCHTVEKGGK*# ...# >MUS2093D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Cytochrome tuna (13-25)# DB REFERENCE: SWISS: (CYC_SQUSU,CYC_KATPE)# & PIR1: (CCDF)# REFERENCES: corradin83a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,KCAQCHTVENGGK*# SEQUENCE: KCAQCHTVENGGK*# ...# >MUS2093E# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Cytochrome horse (45-58)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_HORSE)# & PIR1: (CCHO)# REFERENCES: hill91a,rothbard88b# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,GFTYTDANKNKGIT*# SEQUENCE: GFTYTDANKNKGIT*# ...# >MUS2093F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Cytochrome horse (45-58)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_HORSE)# & PIR1: (CCHO)# REFERENCES: hill91a,rothbard88b# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,GFTYTDANKNKGIT*# SEQUENCE: GFTYTDANKNKGIT*# ...# >MUS20940# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu hemagglutinin A X31 (48-70)# DB REFERENCE: SWISS: (HEMA_IAUDO,HEMA_IAAIC,HEMA_IAME2,HEMA_IAX31,HEMA_IANT6,# & HEMA_IAME1,HEMA_IAQU7)# & PIR1: (HMIVHM,HMIVHA,HMIVH,HMIVH3)# & PIR2: (A93233)# REFERENCES: mills86a# COMMENT:# SUMMARY: I-Ak,actyesh,bindyesu,TGKICNNPHRILDGIDCTLID*# SEQUENCE: TGKICNNPHRILDGIDCTLID*# ...# >MUS20941# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu hemagglutinin A X47 (52-85)# ANCHOR POSITIONS:# REFERENCES: mills86a# COMMENT:# SUMMARY: I-Ak,actyesh,bindyesu,CNNPHRILDGIDCTLIDALLGDPHCDGFQNEKWDL*# SEQUENCE: CNNPHRILDGIDCTLIDALLGDPHCDGFQNEKWDL*# ...# >MUS20942# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu hemagglutinin A duck63 (48-85)# DB REFERENCE: SWISS: (HEMA_IADU3)# & PIR1: (HMIVDU)# REFERENCES: mills86a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TGKICNNPHRILDGRACTLIDALLGDPHCDVFQNETWDL*# SEQUENCE: TGKICNNPHRILDGRACTLIDALLGDPHCDVFQNETWDL*# ...# >MUS20943# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rat/Human myelin base protein MBP (1-9)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_HUMAN,MBP_RAT,MBP_PANTR,MBP_MOUSE)# & PIR1: (MBHUB,MBCZB,MBRTS,MBPGB,MBMSB)# & PIR2: (A37246)# REFERENCES: zamvil86a,bhardwaj93a# COMMENT: Acetylation of first residue essential for recognition# SUMMARY: I-Au,actyesu,bindyesu,ASQKRPSQR*# SEQUENCE: ASQKRPSQR*# ...# >MUS20944# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bovine myelin base protein MBP (1-9)# DB REFERENCE: SWISS: (MBP_BOVIN)# & PIR1: (MBBOB)# REFERENCES: zamvil86a# COMMENT: Acetylation of first residue essential for recognition# SUMMARY: I-Au,actyesu,bindyesu,AAQKRPSQR*# SEQUENCE: AAQKRPSQR*# ...# >MUS20945# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as./Induction of EAE/Reference# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Rat/Human myelin base protein MBP Ac(1-11)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_RAT,MBP_PANTR,MBP_CAVPO)# & PIR1: (MBRTS,MBHUB,MBCZB,MBPGB)# & PIR2: (A37246)# REFERENCES: zamvil86a,mcDevitt,acha-orbea88a,bell91a,smilek90a# COMMENT: Acetylation of first residue essential for recognition# SUMMARY: I-Au,actyesh,bindyesm,ASQKRPSQRHG*# SEQUENCE: ASQKRPSQRHG*# ...# >MUS20946# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Rat/Human myelin base protein MBP (1-16)# DB REFERENCE: SWISS: (MBP_RAT,MBP_PANTR,MBP_HUMAN,MBP_CAVPO)# & PIR1: (MBHUB,MBPGB,MBCZB,MBRTS)# & PIR2: (A37246)# REFERENCES: zamvil86a# COMMENT: Acetylation of first residue essential for recognition# SUMMARY: I-Au,actyesh,bindyesu,ASQKRPSQRHGSKYLA*# SEQUENCE: ASQKRPSQRHGSKYLA*# ...# >MUS20947# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rat/Human myelin base protein MBP (1-20)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_RAT,MBP_PANTR)# & PIR1: (MBCZB,MBHUB,MBRTS)# & PIR2: (A37246)# REFERENCES: zamvil86a# COMMENT: Acetylation of first residue essential for recognition# SUMMARY: I-Au,actyesu,bindyesu,ASQKRPSQRHGSKYLATAST*# SEQUENCE: ASQKRPSQRHGSKYLATAST*# ...# >MUS20948# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HEL (81-93)# DB REFERENCE: SWISS: (LYC_MELGA,LYC_PAVCR,LYC_LOPLE,LYC_SYRRE,LYC_PHAVE,# & LYC_CHRAM,LYC_PHACO,LYC_CHICK,LYC_CHICK)# & PIR1: (LZFER,LZQJE,LZCH,LZTK)# & PIR2: (JU0178,JU0237,JQ1033,JH0212,JT0526,JQ1041,JH0211)# REFERENCES: manca84a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,SALLSSDITASVN*# SEQUENCE: SALLSSDITASVN*# ...# >MUS20949# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: BEL (81-93)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_COLVI)# & PIR1: (LZQJEC)# REFERENCES: manca84a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,SALLSSDITATVN*# SEQUENCE: SALLSSDITATVN*# ...# >MUS2094A# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: BEL (81-93)# DB REFERENCE: SWISS: (LYC_NUMME)# & PIR1: (LZUH)# REFERENCES: manca84a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,SALQSSDITATAN*# SEQUENCE: SALQSSDITATAN*# ...# >MUS2094B# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Herpes glycoprotein HSV D (1-23)# DB REFERENCE: SWISS: (VGLD_HSV1H,VGLD_HSV11,VLGD_HSV1A)# & PIR1: (A47627,VGBEDZ,VGBED1)# REFERENCES: heber-katz85a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,KYALADASLKMADPNRFRGKDLP*# SEQUENCE: KYALADASLKMADPNRFRGKDLP*# ...# >MUS2094C# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Herpes glycoprotein HSV D (1-23) homologue# ANCHOR POSITIONS:# REFERENCES: heber-katz85a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,KYALADPSLKMADPNRFRGKDLP*# SEQUENCE: KYALADPSLKMADPNRFRGKDLP*# ...# >MUS2094D# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Herpes glycoprotein HSV D (1-23) homologue# DB REFERENCE: SWISS: (VGLD_HSV2)# & PIR1: (VGBE33,VGBED2)# & PIR2: (E43674)# REFERENCES: heber-katz85a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,KYALADPSLKMADPNRFRGKNLP*# SEQUENCE: KYALADPSLKMADPNRFRGKNLP*# ...# >MUS2094E# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Herpes glycoprotein HSV D (8-23)# DB REFERENCE: SWISS: (VLGD_HSV1A,VGLD_HSV1H,VGLD_HSV11)# & PIR1: (VGBEDZ,VGBE17,VGBED1,A47627)# REFERENCES: heber-katz85a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,SLKMADPNRFRGKDLP*# SEQUENCE: SLKMADPNRFRGKDLP*# ...# >MUS2094F# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Herpes glycoprotein HSV D (8-23) homologue# DB REFERENCE: SWISS: (VGLD_HSV2)# & PIR1: (VGBE33,VGBED2)# & PIR2: (E43674)# REFERENCES: heber-katz85a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,SLKMADPNRFRGKNLP*# SEQUENCE: SLKMADPNRFRGKNLP*# ...# >MUS20950# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lambda repressor (15-24)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: guillet86a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,DARRLKAIYEK*# SEQUENCE: DARRLKAIYEK*# ...# >MUS20951# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lambda repressor (12-24)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: guillet86a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,LEDARRLKAIYEK*# SEQUENCE: LEDARRLKAIYEK*# ...# >MUS20952# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ova (323-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: guillet86a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,SQAVHAAHAEINE*# SEQUENCE: SQAVHAAHAEINE*# ...# >MUS20953# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Nase (66-78) homologue 73-K,75-I# ANCHOR POSITIONS:# REFERENCES: guillet86a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,VENAKKIKYGEVEFDK*# SEQUENCE: VENAKKIKYGEVEFDK*# ...# >MUS20954# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Hepatitis B pre-S (120-132) ayw# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVJ,VMSA_HPBVA,VMSA_HPBVY,VMSA_HPBVI,# & VMSA_HPBVO)# & PIR1: (SAVLAH,SAVLJ3,SAVLBH,SAVLJ2,SAVLA1,SAVLJ1)# & PIR2: (S20745,S32202,S47407,S41869,S41870,S20753,S41871)# REFERENCES: milich86a# COMMENT: I-Aq or I-Eq or I-Cq# SUMMARY: H-2q,actyesh,bindyesu,MQWNSTTFHQTLQ*# SEQUENCE: MQWNSTTFHQTLQ*# ...# >MUS20955# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Hepatitis B pre-S (120-132) ayw# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVO,VMSA_HPBVA,VMSA_HPBVJ,# & VMSA_HPBVI)# & PIR1: (SAVLJ1,SAVLA1,SAVLJ2,SAVLBH,SAVLAH,SAVLJ3)# & PIR2: (S41871,S41869,S47407,S41870,S20745,S32202,S20753)# REFERENCES: milich86a,altuvia94a# COMMENT: I-Ak or I-Ck or I-Ek# SUMMARY: H-2k,actyesm,bindyesu,MQWNSTTFHQTLQ*# SEQUENCE: MQWNSTTFHQTLQ*# ...# >MUS20956# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Hepatitis B pre-S (120-132) ayw# DB REFERENCE: SWISS: (VMSA_HPBVJ,VMSA_HPBVO,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVI,# & VMSA_HPBVA)# & PIR1: (SAVLJ1,SAVLJ2,SAVLA1,SAVLBH,SAVLAH,SAVLJ3)# & PIR2: (S20745,S32202,S47407,S20753,S41871,S41869,S41870)# REFERENCES: milich86a,altuvia94a# COMMENT: I-As or I-Cs or I-Es# SUMMARY: H-2s,actyesm,bindyesu,MQWNSTTFHQTLQ*# SEQUENCE: MQWNSTTFHQTLQ*# ...# >MUS20957# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rabies glycoprotein (32-44)# DB REFERENCE: SWISS: (VGLG_RABVP,VGLG_RABVS,VGLG_RABVV,VGLG_RABVH,VGLG_RABVT,# & VGLG_RABVE)# & PIR1: (VGVNRB,VGVNDB,VGVNRV,VGVNSB,VGVNG)# & PIR2: (JC1098,S30575,S33419)# REFERENCES: macfarlan84a# COMMENT: I-Ad or I-Cd or I-Ed# SUMMARY: H-2d,actyesu,bindyesu,DEGCTNLSGFSYM*# SEQUENCE: DEGCTNLSGFSYM*# ...# >MUS20958# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface antigen (95-109)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVJ,VMSA_HPBVO,VMSA_HPBVZ,VMSA_HPBV0,# & VMSA_HPBVR,VMSA_HPBVL,VMSA_HPBVD,VMSA_HPBV2,VMSA_HPBVT,# & VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBV9,VMSA_HPBVP,VMSA_HPBVY,# & VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVI,VMSA_HPBVA,# & VMSA_HPBV4)# & PIR1: (SAVLHV,SAVLAH,SAVLVE,JQ1571,SAVLA,JQ1575,JQ1570,JQ1578,# & SAVLVD,JQ1574,SAVLAD,JQ1580,JQ1572,SAVLBH,JQ1581,JQ1576,# & JQ1573,SAVLKS,JQ1579,SAVLAJ,SAVLJ3,SAVLA1,SAVLJ2,SAVLJ1,# & SAVLCP)# & PIR2: (S47407,JQ2104,JQ2077,JQ2052,JQ2081,JQ2070,JQ2060,JQ2067,# & JQ2105,JQ2119,JQ2057,JQ2058,JQ2110,S32202,JQ2055,JQ2225,# & S20745,JQ2047,JQ2121,JQ2078,JQ2103,JQ2075,S41871,JQ2065,# & JQ2098,JQ2061,JQ2123,JQ2054,JQ2056,S41869,S41870,JQ2096,# & JQ2108,S20753,JQ2115,JQ2069,JQ2114,JQ2097,JQ2112,JQ2051,# & JQ2091,JQ2101,S35528,JQ2087,JQ2095,JQ2062,JQ2088,JQ2092,# & JQ2102,JQ2100,JQ2073,JQ2226,JQ2083,JQ2089,JQ2109,JQ2106,# & JQ2094,JQ2079,JQ2076,S47411,JQ2116,JQ2080,JQ2230,JQ2063,# & JQ2045,JQ2111,JQ2099,JQ2050,JQ2053,JQ2059,JQ2066,JQ2068,# & JQ2085,JQ2122,JQ2090,JQ2072,JQ2120)# REFERENCES: rothbard88b,milich85a# COMMENT: I-Aq or I-Eq or I-Cq# SUMMARY: H-2q,actyesu,bindyesu,LVLLDYQGMLPVCPL*# SEQUENCE: LVLLDYQGMLPVCPL*# ...# >MUS20959# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface antigen (38-52)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBVA)# & PIR1: (SAVLA1,JQ1571,SAVLAH,JQ1572,SAVLAJ,SAVLBH)# & PIR2: (JQ2072,S20745,JQ2080,JQ2067,S32202,JQ2077,JQ2069,S20753,# & JQ2068,JQ2063,JQ2066,JQ2079,JQ2073,JQ2083,S41869,S41870,# & JQ2076,S47407,JQ2070,JQ2081,JQ2075,S41871,JQ2065,# & JQ2078)# REFERENCES: milich85a# COMMENT: I-Aq or I-Eq or I-Cq# SUMMARY: H-2q,actyesu,bindyesu,SLNFLGGTTVCLGQN*# SEQUENCE: SLNFLGGTTVCLGQN*# ...# >MUS2095A# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface antigen (140-154)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVD,VMSA_HPBVY,VMSA_HPBVZ,# & VMSA_HPBVA,VMSA_HPBV4,VMSA_HPBVN,VMSA_HPBVL,# & VMSA_HPBVY)# & PIR1: (JQ1576,SAVLBH,SAVLN1,JQ1571,SAVLAH,SAVLA,SAVLCP,JQ1572,# & JQ1581,SAVLAJ,SAVLA1,JQ1574,SAVLAD)# & PIR2: (JQ2103,S41869,JQ2083,JQ2073,JQ2075,JQ2104,S41871,JQ2078,# & JQ2105,JQ2070,JQ2110,JQ2068,JQ2098,JQ2123,JQ2079,JQ2108,# & JQ2115,JQ2112,JQ2102,S32202,JQ2106,JQ2069,S20753,JQ2097,# & JQ2114,JQ2066,JQ2101,JQ2113,JQ2076,JQ2099,JQ2080,JQ2072,# & JQ2063,JQ2096,S47407,JQ2081,JQ2116,JQ2111,JQ2094,JQ2077,# & JQ2067,JQ2100,JQ2095,S43492,JQ2065,JQ2054,JQ2056,JQ2109,# & S35528,S20745)# REFERENCES: rothbard88b,milich85a# COMMENT: I-Ak or I-Ck or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,TKPSDGNCTCIPIPS*# SEQUENCE: TKPSDGNCTCIPIPS*# ...# >MUS2095B# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface antigen (110-137)# ANCHOR POSITIONS:# REFERENCES: milich85a# COMMENT: I-Ak or I-Ck or I-Ek# SUMMARY: H-2k,actyesu,bindyesu,FPGSSTTSTGPCRTCMTTAQGTSMYPSC*# SEQUENCE: FPGSSTTSTGPCRTCMTTAQGTSMYPSC*# ...# >MUS2095C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum 7G8 CS (326-343)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: rothbard88b,good87a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,PSDKHIEQYLKKIKNSIS*# SEQUENCE: PSDKHIEQYLKKIKNSIS*# ...# >MUS2095D# MHC MOLECULE: H-2?, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rat myelin basic protein (35-47)# DB REFERENCE: SWISS: (MBP_RAT,MBP_MOUSE)# & PIR1: (MBRTS,MBMSB)# REFERENCES: rothbard88b# COMMENT: I-Eu or I-Es# SUMMARY: H-2?,actyesu,bindyesu,TGILDSIGRFFSG*# SEQUENCE: TGILDSIGRFFSG*# ...# >MUS2095E# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rat myelin basic protein (89-101)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_MOUSE,MBP_HUMAN,MBP_BOVIN,MBP_PANTR,# & MBP_RAT)# & PIR1: (MBHUB,MBCZB,MBRTS,MBPGB,MBBOB,MBMSB)# & PIR2: (A37246)# REFERENCES: rothbard88b# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >MUS1095F# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse complement C9# DB REFERENCE: SWISS: (CO9_MOUSE,CO9_MOUSE)# & PIR2: (A29677)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,DLNDVKHCL*# SEQUENCE: DLNDVKHCL*# ...# >MUS10960# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse retrovirus-related pol polyprotein (reverse transcriptase)# DB REFERENCE: SWISS: (POL2_MOUSE)# & PIR1: (GNMSLL)# & PIR2: (I49130)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,DLIPILHKL*# SEQUENCE: DLIPILHKL*# ...# >MUS10961# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse c-ets-2 protein (proto-oncogene)# DB REFERENCE: SWISS: (ETS2_MOUSE)# & PIR1: (TVMSE2)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,HLNAVPHWI*# SEQUENCE: HLNAVPHWI*# ...# >MUS10962# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse VDJ recombination-activating protein rag-1# DB REFERENCE: SWISS: (RAG1_MOUSE,RAG1_HUMAN,RAG1_MOUSE,RAG1_HUMAN,RAG1_RABIT,# & RAG1_CHICK,RAG1_CHICK,RAG1_RABIT)# & PIR2: (A33754,B33754,S42509,S44379,S42511)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,SQNLVFHSI*# SEQUENCE: SQNLVFHSI*# ...# >MUS10963# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse epidermal growth factor precursor# DB REFERENCE: SWISS: (EGF_MOUSE,EGF_MOUSE)# & PIR1: (EGMSMG)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,IQNDVGHPF*# SEQUENCE: IQNDVGHPF*# ...# >MUS10964# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse NADH-ubiquinone oxidoreductase chain 4# DB REFERENCE: SWISS: (NU4M_MOUSE,NU4M_RAT,NU4M_RAT,NU4M_MOUSE)# & PIR1: (QXMS4M)# & PIR2: (S04756)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,TMLMIAHGL*# SEQUENCE: TMLMIAHGL*# ...# >MUS10965# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse interferon-gamma-precursor# DB REFERENCE: SWISS: (ING_MOUSE)# & PIR1: (IVMSG)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,ELIRVVHQL*# SEQUENCE: ELIRVVHQL*# ...# >MUS10966# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse galactosyl transferase associated protein kinase# DB REFERENCE: SWISS: (KP58_RAT,KP58_MOUSE,KP58_RAT,KP58_HUMAN)# & PIR2: (B54024,E54024,S47628,H54024,A42823,A54024,A55817,F54024,# & G54024,I50463,A38282,A53227)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,VMNYVEHDL*# SEQUENCE: VMNYVEHDL*# ...# >MUS10967# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Schistosoma mansoni haemoglobinase precursor# DB REFERENCE: SWISS: (HGLB_SCHMA)# & PIR2: (A60145)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,FLISILHIL*# SEQUENCE: FLISILHIL*# ...# >MUS10968# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Schistosoma mansoni 3-hydroxy-3-methyl-glutaryl-coenzyme# DB REFERENCE: SWISS: (HMDH_SCHMA,HMDH_SCHMA)# & PIR2: (A34416)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,NQLFVDHML*# SEQUENCE: NQLFVDHML*# ...# >MUS10969# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Salmonela typhimurium DNAb proyein# DB REFERENCE: SWISS: (DNAB_SALTY)# & PIR2: (A32011)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,DMIAVAHEI*# SEQUENCE: DMIAVAHEI*# ...# >MUS1096A# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Salmonela typhimurium acetate operon repressor# DB REFERENCE: SWISS: (ICLR_ECOLI,ICLR_ECOLI,ICLR_SALTY)# & PIR1: (RPECIR)# & PIR2: (S12729)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,NLLAIVHPI*# SEQUENCE: NLLAIVHPI*# ...# >MUS1096B# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Salmonela typhimurium oligopeptide# DB REFERENCE: SWISS: (OPPF_SALTY,OPPF_ECOLI,OPPF_HAEIN)# & PIR1: (QREBOF)# & PIR2: (B64184)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,SLIFIAHDL*# SEQUENCE: SLIFIAHDL*# ...# >MUS1096C# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Clostridium tetani tetanus toxin precursor# DB REFERENCE: SWISS: (BXB_CLOBO,BXB_CLOBO,BXG_CLOBO,TETX_CLOTE)# & PIR1: (BTCLTN)# & PIR2: (I40631,S21575,A48940,S39791,S33411,A42871)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,ELIHVLHGL*# SEQUENCE: ELIHVLHGL*# ...# >MUS1096D# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Klebsiella aerogenes urease alpha subunit# DB REFERENCE: SWISS: (URE2_HELPY,URE1_MYCTU,URE1_BACPA,URE2_HELPY,URE1_KLEAE,# & URE1_PROMI,URE1_SYNY3,URE2_HELFE,URE1_BACSB,URE1_MYCTU,# & URE1_KLEAE,UREA_SCHPO,UREA_CANEN,URE1_CLOPE,URE1_HAEIN,# & URE1_UREUR,URE1_RHIME,URE1_PROVU)# & PIR1: (S10032,URKCBP,URJB,C36138,S08480,S35291,D43719)# & PIR2: (H64075,C36950,S42607,S75169)# & PIR3: (S47104)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,DMLMVCHHL*# SEQUENCE: DMLMVCHHL*# ...# >MUS1096E# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human papillomavirus type 1a# DB REFERENCE: SWISS: (VL1_HPV1A)# & PIR1: (P1WL)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,RLLLVGHPL*# SEQUENCE: RLLLVGHPL*# ...# >MUS1096F# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human papillomavirus type 41# DB REFERENCE: SWISS: (VL1_HPV17,VL1_HPV41)# & PIR1: (P1WL41)# & PIR2: (S36484)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,RLLTVGHPF*# SEQUENCE: RLLTVGHPF*# ...# >MUS10970# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human cytomegalovirus# DB REFERENCE: SWISS: (US15_HCMVA)# & PIR1: (QQBEF7)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,RQIVVVHAL*# SEQUENCE: RQIVVVHAL*# ...# >MUS10971# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Vaccinia virus# ANCHOR POSITIONS: 7,9# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,TLITVRHKL*# SEQUENCE: TLITVRHKL*# ...# >MUS10972# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Newcastle disease virus# DB REFERENCE: SWISS: (RRPL_NDVB)# & PIR1: (RRNZNV)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,ELIHVNHLI*# SEQUENCE: ELIHVNHLI*# ...# >MUS10973# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine viral diarrhoea virus# DB REFERENCE: SWISS: (POLG_BVDVS,POLG_BVDVN)# & PIR1: (A44217,GNWVBV)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,KLLEIFHTI*# SEQUENCE: KLLEIFHTI*# ...# >MUS10974# MHC MOLECULE: H-2Qa-2a, CLASS-1, (MOUSE)# METHOD: HPLC and pattern matching# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Varicella zoster virus strain Dumas# DB REFERENCE: SWISS: (UL20_VZVD)# & PIR1: (WZBE39)# REFERENCES: rotzschke93a# COMMENT: unconventional glycophosphatidyl-anchored class I molecule# SUMMARY: H-2Qa-2a,actunkn,bindyesu,LLLTILHHF*# SEQUENCE: LLLTILHHF*# ...# >MUS10975# MHC MOLECULE: H-2b, CLASS-1, (MOUSE)# METHOD: HPLC /reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: beta2-microglobulin, a allele (77-89)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: rotzschke90b# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,TYACRVKHDSMAE*# SEQUENCE: TYACRVKHDSMAE*# ...# >MUS10976# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: HPLC /reference/Stabilization# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Influenza nucleoprotein (365-380)# DB REFERENCE: SWISS: (VNUC_IAWIL,VNUC_IALEN,VNUC_IAZCA,VNUC_IAPUE)# & PIR1: (VHIVXL,VHIV34)# & PIR2: (B36754)# REFERENCES: rotzschke90b,reinholdsson-ljunggren93a,lie91a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesm,IASNENMETMESSTLE*# SEQUENCE: IASNENMETMESSTLE*# ...# >HUM10977# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: HPLC /reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza nucleoprotein (384-393)# ANCHOR POSITIONS:# REFERENCES: rotzschke90b# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RYWAIRTRSGFYNQMM*# SEQUENCE: RYWAIRTRSGFYNQMM*# ...# >HUM10978# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC /reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza nucleoprotein (82-94)# DB REFERENCE: SWISS: (VNUC_INBAD,VNUC_INBAA,VNUC_INBSI,VNUC_INBAC,# & VNUC_INBLE)# & PIR1: (VHIVBC,VHIVBW,VHIVBA)# REFERENCES: rotzschke90b# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,MVVKLGEFYNQMM*# SEQUENCE: MVVKLGEFYNQMM*# ...# >HUM10979# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive peptide inhibition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LCMV GP (272-293)# DB REFERENCE: SWISS: (VGLY_LYCVA,VGLY_LYCVW)# & PIR1: (VGXPLM,VGXPLC,VGXPLA)# REFERENCES: shimojo89a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CLTKWMILA*# SEQUENCE: CLTKWMILA*# ...# >HUM1097A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (446-460)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1MA,GAG_HV1Z2,GAG_HV1EL)# & PIR1: (FOLJND)# & PIR2: (S54377)# REFERENCES: claverie88a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GNFLQSRPEPTAPPA*# SEQUENCE: GNFLQSRPEPTAPPA*# ...# >HUM1097B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (193-203)# ANCHOR POSITIONS:# REFERENCES: claverie88a,buseyne93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GHQAAMEMLKE*# SEQUENCE: GHQAAMEMLKE*# ...# >HUM1097C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (219-233)# DB REFERENCE: SWISS: (GAG_HV1EL,GAG_HV1H2,GAG_HV1MN,GAG_HV1PV,GAG_HV1N5,# & GAG_HV1B5,GAG_HV1W2,GAG_HV1BR,GAG_HV1Z2,GAG_HV1A2,# & GAG_HV1B1,GAG_HV1RH,GAG_HV1JR,GAG_HV1C4,GAG_HV1OY,# & GAG_HV1Y2)# & PIR1: (FOVWH4,FOVWA2,FOVWVL,FOVWH3,FOVWLV,A44001,A38068)# & PIR2: (S54377)# REFERENCES: claverie88a,buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,HAGPIAPGQMREPRG*# SEQUENCE: HAGPIAPGQMREPRG*# ...# >HUM2097D# MHC MOLECULE: HLA-DPw3, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: DR3 BI chain (67-85)# DB REFERENCE: SWISS: (HB2B_HUMAN,HB2B_HUMAN)# & PIR1: (HLHU3D)# & PIR2: (S03442,I59625,I37537,I38020,I68555,I68710,I68554,# & I54294)# REFERENCES: de_koster89a# COMMENT:# SUMMARY: HLA-DPw3,actyesu,bindyesu,LLEQKRGRVDNYCRHNYGV*# SEQUENCE: LLEQKRGRVDNYCRHNYGV*# ...# >MUS2097E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza nucleoprotein (50-63)# DB REFERENCE: SWISS: (VNUC_IAHO2,VNUC_IAVI6,VNUC_IAMEB,VNUC_IAMEE,VNUC_IASIN,# & VNUC_IAZH1,VNUC_IAFOW,VNUC_IATX7,VNUC_IAMEA,VNUC_IAMEF,# & VNUC_IAME5,VNUC_IAHO1,VNUC_IAHIC,VNUC_IAEN5,VNUC_IAME4,# & VNUC_IAANN,VNUC_IAZCA,VNUC_IAME3,VNUC_IAZDA,VNUC_IAFOM,# & VNUC_IAUSS,VNUC_IAKIE,VNUC_IAB39,VNUC_IAWIL,VNUC_IAME6,# & VNUC_IABRA,VNUC_IAMEG,VNUC_IALEN,VNUC_IAUDO,VNUC_IACAL,# & VNUC_IAMEC,VNUC_IANT6,VNUC_IAPUE,VNUC_IAANN,# & VNUC_IAS31)# & PIR1: (VHIVAK,VHIVX5,VHIV68,VHIVN5,VHIVXL,VHIV61,VHIV8H,VHIV34,# & VHIVA7,VHIVX4,VHIVX3,VHIVX6,VHIVX2,VHIVN7)# & PIR2: (B36754)# REFERENCES: perkins89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >MUS2097F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza nucleoprotein NP (147-158)# DB REFERENCE: SWISS: (VNUC_IAS06,VNUC_IAMAN,VNUC_IAHLO,VNUC_IATEI,VNUC_IAGUA,# & VNUC_IAMEG,VNUC_IAZDA,VNUC_IAME6,VNUC_IAB39,VNUC_IABUD,# & VNUC_IAGRE,VNUC_IAWHP,VNUC_IAZJ1,VNUC_IAHJI,VNUC_IATRS,# & VNUC_IADCZ,VNUC_IADE1,VNUC_IACKG,VNUC_IAHIC,VNUC_IAZCA,# & VNUC_IAZI1,VNUC_IAZMA,VNUC_IADNZ,VNUC_IAGD7,VNUC_IASIN,# & VNUC_IAFOW,VNUC_IAWIS,VNUC_IAVI6,VNUC_IAMEE,VNUC_IADHK,# & VNUC_IAHO2,VNUC_IATRT,VNUC_IAMEF,VNUC_IANEJ,VNUC_IAZW1,# & VNUC_IAHO1,VNUC_IAFPD,VNUC_IADBE,VNUC_IAZTE,VNUC_IAZOH,# & VNUC_IAGU1,VNUC_IAZGE,VNUC_IARUD,VNUC_IAWHN,VNUC_IADU2,# & VNUC_IAMEA,VNUC_IAZI2,VNUC_IAMAA,VNUC_IAZNE,VNUC_IAZJ3,# & VNUC_IABRA,VNUC_IAWIL,VNUC_IAZ41,VNUC_IADM2,VNUC_IATKO,# & VNUC_IAUSS,VNUC_IAMIN,VNUC_IAFOM,VNUC_IAME4,VNUC_IAEN5,# & VNUC_IADAU,VNUC_IAPAR,VNUC_IAZH3,VNUC_IAZW2,VNUC_IAGU4,# & VNUC_IAHMI,VNUC_IAME5,VNUC_IATX7,VNUC_IAANA,VNUC_IAHPR,# & VNUC_IAGU2,VNUC_IAZH1,VNUC_IAS11,VNUC_IACKP,VNUC_IAANN,# & VNUC_IASH2,VNUC_IAZJ4,VNUC_IAOHI,VNUC_IAMEB,VNUC_IAZ29,# & VNUC_IAZON,VNUC_IAZJA,VNUC_IATKN,VNUC_IAZH4,VNUC_IAKIE,# & VNUC_IADE2,VNUC_IASE0,VNUC_IACAL,VNUC_IAZJ2,VNUC_IAMEC,# & VNUC_IAFPR,VNUC_IAB37,VNUC_IAANN,VNUC_IAS31,VNUC_IAPUE,# & VNUC_IANT6,VNUC_IALEN,VNUC_IADMA,VNUC_IAZI3,VNUC_IAGU3,# & VNUC_IAUDO,VNUC_IAME3)# & PIR1: (VHIVX5,VHIVN8,VHIVX1,VHIVX3,VHIV8H,VHIVX2,VHIVN1,VHIVC1,# & VHIVN7,VHIV61,VHIVXL,VHIV68,VHIVA6,VHIVAK,VHIVA7,VHIVN4,# & VHIVN9,VHIV34,VHIVX6,VHIVX4,VHIVM1,VHIVA3,VHIVN6,A60028,# & VHIVN2,VHIVN3,VHIVN5)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS:# REFERENCES: perkins89a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,TYQRTRALVRTGMDP*# SEQUENCE: TYQRTRALVRTGMDP*# ...# >MUS10980# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU NP 1968 (366-374)# DB REFERENCE: SWISS: (VNUC_IAPUE,VNUC_IAWIL,VNUC_IALEN,VNUC_IAZCA)# & PIR1: (VHIV34,VHIVXL)# & PIR2: (B36754)# REFERENCES: perkins89a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,IASNENMETMESSTL*# SEQUENCE: IASNENMETMESSTL*# ...# >MUS20981# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU NP 1968 (366-374)# DB REFERENCE: SWISS: (VNUC_IAZCA,VNUC_IAWIL,VNUC_IAPUE,VNUC_IALEN)# & PIR1: (VHIV34,VHIVXL)# & PIR2: (B36754)# REFERENCES: perkins89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,IASNENMETMESSTL*# SEQUENCE: IASNENMETMESSTL*# ...# >MUS20982# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A/JAP/305 Hemagglutinin (202-221)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# REFERENCES: perkins89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,RTLYQNVGTYVSVGTSTLNK*# SEQUENCE: RTLYQNVGTYVSVGTSTLNK*# ...# >MUS20983# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A/JAP/305 Hemagglutinin (202-221)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# REFERENCES: perkins89a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,RTLYQNVGTYVSVGTSTLNK*# SEQUENCE: RTLYQNVGTYVSVGTSTLNK*# ...# >MUS20984# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Influenza A/JAP/305 Hemagglutinin (202-221)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# REFERENCES: perkins89a,sette89b# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesm,RTLYQNVGTYVSVGTSTLNK*# SEQUENCE: RTLYQNVGTYVSVGTSTLNK*# ...# >MUS20985# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A/JAP/305 Hemagglutinin (523-545)# ANCHOR POSITIONS:# REFERENCES: perkins89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,VYQILAIYATVGSLSLAIMMAG*# SEQUENCE: VYQILAIYATVGSLSLAIMMAG*# ...# >MUS10986# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A/JAP/305 Hemagglutinin (523-545)# ANCHOR POSITIONS:# REFERENCES: perkins89a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,VYQILAIYATVGSLSLAIMMAG*# SEQUENCE: VYQILAIYATVGSLSLAIMMAG*# ...# >MUS20987# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu NP (335-350)# DB REFERENCE: SWISS: (VNUC_IADE1,VNUC_IAVI6,VNUC_IAZH1,VNUC_IAHO1,# & VNUC_IANT6)# & PIR1: (VHIV68,VHIV8H,VHIVN7)# REFERENCES: perkins89a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,SAAFEDLRVLSFIRG*# SEQUENCE: SAAFEDLRVLSFIRG*# ...# >HUM10988# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu NP (335-350)# DB REFERENCE: SWISS: (VNUC_IADE1,VNUC_IAZH1,VNUC_IAVI6,VNUC_IANT6,# & VNUC_IAHO1)# & PIR1: (VHIV68,VHIVN7,VHIV8H)# REFERENCES: perkins89a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,SAAFEDLRVLSFIRG*# SEQUENCE: SAAFEDLRVLSFIRG*# ...# >MUS20989# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza nucleoprotein NP (55-73)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IAUSS,VMT1_IAFOW,VMT1_IAUDO,VMT1_IAANN,# & VMT1_IAWIL,VMT1_IAMAN,VMT1_IACKB,VMT1_IAPUE,VMT1_IABAN,# & VMT1_IALE1)# & PIR1: (MFIVC,MFIVWS,MFIV1M,MFIV61,MFIV,MFIV1K,JN0392)# & PIR2: (S04050,S04052,S07429,S14616,S04058,S04054,S04056)# REFERENCES: perkins89a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,LTKGILGFVFTLTVPSERG*# SEQUENCE: LTKGILGFVFTLTVPSERG*# ...# >HUM1098A# MHC MOLECULE: HLA-Cw3, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag (140-152)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1W2,GAG_HV1B1,GAG_HV1MN,GAG_HV1H2,# & GAG_HV1C4,GAG_HV1N5,GAG_SIVCZ,GAG_HV1JR,GAG_HV1Y2,# & GAG_HV1J3,GAG_HV1BR,GAG_HV1RH,GAG_HV1Z2,GAG_HV1A2,# & GAG_HV1ND,GAG_HV1PV,GAG_HV1EL)# & PIR1: (A44001,FOVWLV,A38068,FOVWA2,FOLJSI,FOVWVL,FOVWH3,FOLJND,# & FOVWH4)# & PIR2: (S54377,S52929)# REFERENCES: littaua91a,hivdb97a# COMMENT:# SUMMARY: HLA-Cw3,actyesu,bindyesu,GQMVHQAISPRTL*# SEQUENCE: GQMVHQAISPRTL*# ...# >HUM2098B# MHC MOLECULE: HLA-DPw4(DPB1*0402), CLASS-2, (HUMAN)# METHOD: functional as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (577-595)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1MF,ENV_HV1B1,ENV_HV1Z6,ENV_HV1EL,# & ENV_HV1BR,ENV_HV1B8,ENV_HV1ZH,ENV_HV1PV,ENV_HV1C4,# & ENV_HV1H2,ENV_HV1Z2,ENV_HV1J3)# & PIR1: (A44963,VCLJLV,VCLJVL,VCLJZR,VCLJH3,VCLJH4)# & PIR2: (S21998,S54384,S70422,S21996,S70425)# & PIR3: (S33985,S13288)# REFERENCES: hammond91a# COMMENT:# SUMMARY: HLA-DPw4,actyesu,bindyesu,GIKQLQARILAVERYLKDQ*# SEQUENCE: GIKQLQARILAVERYLKDQ*# ...# >HUM2098C# MHC MOLECULE: HLA-DPw4(DPB1*0402), CLASS-2, (HUMAN)# METHOD: functional as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rabies NS (101-120)# DB REFERENCE: SWISS: (RRPP_RABVP)# & PIR1: (MNVNRV)# REFERENCES: hammond91a# COMMENT:# SUMMARY: HLA-DPw4,actyesu,bindyesu,GVQIVRQIRSGERFLKIWSQ*# SEQUENCE: GVQIVRQIRSGERFLKIWSQ*# ...# >HUM2098D# MHC MOLECULE: HLA-DPw4(DPB1*0402), CLASS-2, (HUMAN)# METHOD: functional as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HepBSAg (19-28)# DB REFERENCE: SWISS: (VMSA_HPBVD,VMSA_HPBV2,VMSA_HPBV0,VMSA_HPBVR,VMSA_HPBVR,# & VMSA_HPBVZ,VMSA_HPBV9,VMSA_HPBVS,VMSA_HPBVW,VMSA_HPBVN,# & VMSA_HPBVP,VMSA_HPBV4,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVW,# & VMSA_HPBVY)# & PIR1: (SAVLN1,SAVLAJ,SAVLVD,SAVLBH,JQ1577,JQ1575,SAVLAR,SAVLHV,# & SAVLVE,SAVLAD,SAVLA,SAVLKS,SAVLAH)# & PIR2: (JQ2077,S47411,JQ2081,S20749,JQ2108,S41870,JQ2098,JQ2079,# & JQ2097,JQ2114,JQ2103,JQ2104,JQ2054,JQ2066,JQ2109,JQ2050,# & JQ2115,JQ2070,S43492,S32202,JQ2083,S41871,JQ2078,JQ2047,# & JQ2102,JQ2112,S41869,JQ2052,JQ2073,JQ2055,JQ2105,JQ2075,# & JQ2094,JQ2067,JQ2111,S36654,JQ2045,JQ2095,JQ2100,JQ2065,# & JQ2068,JQ2053,S20745,S35528,JQ2056,JQ2046,S47407,JQ2096,# & JQ2063,JQ2051,JQ2076,JQ2113,JQ2069,JQ2048,S20753,JQ2080,# & JQ2099,JQ2072)# & PIR4: (S42226)# REFERENCES: hammond91a# COMMENT:# SUMMARY: HLA-DPw4,actyesu,bindyesu,FFLLTRILTI*# SEQUENCE: FFLLTRILTI*# ...# >HUM2098E# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: functional as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp41 (581-595)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1J3,ENV_HV1ZH,ENV_HV1PV,ENV_HV1H2,# & ENV_HV1C4,ENV_HV1Z2,ENV_HV1B1,ENV_HV1Z6,ENV_HV1BR,# & ENV_HV1EL,ENV_HV1MF,ENV_HV1H3)# & PIR1: (VCLJLV,VCLJVL,VCLJZR,VCLJH3,VCLJH4,A44963)# & PIR2: (S54384,S70425,S70422,S21996,S21998)# & PIR3: (S33985,S13288)# REFERENCES: hammond91a# COMMENT:# SUMMARY: HLA-DPw4,actyesm,bindyesu,LQARILAVERYLKDQ*# SEQUENCE: LQARILAVERYLKDQ*# ...# >HUM2098F# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: functional as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp41 (582-595)# DB REFERENCE: SWISS: (ENV_HV1Z6,ENV_HV1Z2,ENV_HV1C4,ENV_HV1PV,ENV_HV1H3,# & ENV_HV1B8,ENV_HV1ZH,ENV_HV1B1,ENV_HV1BR,ENV_HV1EL,# & ENV_HV1H2,ENV_HV1J3,ENV_HV1MF)# & PIR1: (VCLJH4,VCLJZR,VCLJH3,VCLJVL,VCLJLV,A44963)# & PIR2: (S70422,S21998,S70425,S54384,S21996)# & PIR3: (S33985,S13288)# REFERENCES: hammond91a# COMMENT:# SUMMARY: HLA-DPw4,actyesm,bindyesu,QARILAVERYLKDQ*# SEQUENCE: QARILAVERYLKDQ*# ...# >HUM20990# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: functional as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV gp41 (583-595)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1H2,ENV_HV1EL,ENV_HV1BR,ENV_HV1ZH,# & ENV_HV1C4,ENV_HV1Z2,ENV_HV1B8,ENV_HV1J3,ENV_HV1Z6,# & ENV_HV1H3,ENV_HV1PV,ENV_HV1B1)# & PIR1: (A44963,VCLJLV,VCLJH4,VCLJH3,VCLJVL,VCLJZR)# & PIR2: (S21998,S54384,S21996,S70425,S70422)# & PIR3: (S13288,S33985)# REFERENCES: hammond91a# COMMENT:# SUMMARY: HLA-DPw4,actyesl,bindyesu,ARILAVERYLKDQ*# SEQUENCE: ARILAVERYLKDQ*# ...# >HUM20991# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: functional as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (577-595)# ANCHOR POSITIONS:# REFERENCES: hammond91a# COMMENT:# SUMMARY: HLA-DPw4,actyesu,bindyesu,GIKQLQARIVAVERYLKDQ*# SEQUENCE: GIKQLQARIVAVERYLKDQ*# ...# >HUM20992# MHC MOLECULE: HLA-DPw4(DPB1*0402), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HepBSAg (4-33)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBV0,# & VMSA_HPBVP,VMSA_HPBVZ,VMSA_HPBVD,VMSA_HPBVW,# & VMSA_HPBVW)# & PIR1: (SAVLAJ,SAVLVD,SAVLAH,JQ1577,SAVLBH,SAVLHV,JQ1575,SAVLAD,# & SAVLVE)# & PIR2: (JQ2054,S32202,JQ2067,S41870,S20749,JQ2081,S41869,JQ2073,# & JQ2076,S47407,JQ2080,JQ2079,JQ2068,JQ2056,S20745,JQ2053,# & JQ2063,JQ2051,JQ2078,JQ2083,JQ2050,JQ2070,JQ2077,S47411,# & JQ2055,JQ2047,JQ2052,JQ2075,JQ2072,JQ2048,JQ2069,# & S20753)# & PIR4: (S42226)# REFERENCES: celis88a# COMMENT:# SUMMARY: HLA-DPw4,actyesm,bindyesu,ITSGFLGPLLVLQAGFFLLTRILTIPQSLD*# SEQUENCE: ITSGFLGPLLVLQAGFFLLTRILTIPQSLD*# ...# >HUM20993# MHC MOLECULE: HLA-DPw4(DPB1*0402), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HepBSAg (14-33)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBV9,VMSA_HPBVS,VMSA_HPBVZ,VMSA_HPBVP,# & VMSA_HPBVN,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVY,VMSA_HPBV2,# & VMSA_HPBVW,VMSA_HPBVW,VMSA_HPBV4,VMSA_HPBVD,VMSA_HPBVY,# & VMSA_HPBV0)# & PIR1: (SAVLBH,SAVLA,SAVLN1,SAVLVD,SAVLAJ,SAVLAR,JQ1577,SAVLKS,# & JQ1575,SAVLVE,SAVLAD,SAVLAH,SAVLHV)# & PIR2: (JQ2105,JQ2102,JQ2069,JQ2072,JQ2051,JQ2052,JQ2079,JQ2115,# & S32202,JQ2054,S43492,JQ2066,JQ2056,S20745,JQ2046,JQ2070,# & JQ2065,JQ2050,JQ2094,JQ2100,JQ2045,S47411,S35528,JQ2098,# & JQ2108,JQ2080,JQ2097,JQ2114,S47407,JQ2076,JQ2104,JQ2103,# & JQ2099,JQ2053,JQ2112,S20749,JQ2073,JQ2077,JQ2111,JQ2083,# & S41871,JQ2055,JQ2047,S20753,JQ2048,JQ2075,JQ2109,JQ2095,# & JQ2068,JQ2063,JQ2078,S36654,S41869,JQ2067,JQ2081,# & S41870)# & PIR4: (S42226)# REFERENCES: celis88a# COMMENT:# SUMMARY: HLA-DPw4,actyesm,bindyesu,VLQAGFFLLTRILTIPQSLD*# SEQUENCE: VLQAGFFLLTRILTIPQSLD*# ...# >HUM20994# MHC MOLECULE: HLA-DPw4(DPB1*0402), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HepBSAg (19-33)# DB REFERENCE: SWISS: (VMSA_HPBVW,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVD,# & VMSA_HPBV4,VMSA_HPBV0,VMSA_HPBVN,VMSA_HPBVZ,VMSA_HPBV9,# & VMSA_HPBVS,VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVR,# & VMSA_HPBVP)# & PIR1: (SAVLKS,SAVLN1,SAVLHV,SAVLA,SAVLVD,SAVLAR,SAVLAJ,SAVLAH,# & JQ1575,JQ1577,SAVLAD,SAVLVE,SAVLBH)# & PIR2: (S20749,JQ2112,JQ2067,JQ2075,JQ2046,JQ2047,JQ2063,JQ2095,# & JQ2079,JQ2066,JQ2073,JQ2069,JQ2102,S35528,JQ2098,JQ2080,# & JQ2097,JQ2100,JQ2065,JQ2053,JQ2099,S43492,JQ2054,JQ2115,# & S32202,JQ2108,JQ2096,JQ2076,JQ2114,JQ2068,JQ2078,S41869,# & S36654,S41870,JQ2081,JQ2052,JQ2109,S41871,JQ2055,S20753,# & JQ2048,JQ2083,JQ2111,JQ2104,S47411,JQ2077,S47407,JQ2103,# & JQ2056,JQ2072,JQ2051,JQ2045,S20745,JQ2094,JQ2070,JQ2050,# & JQ2105)# & PIR4: (S42226)# REFERENCES: celis88a# COMMENT:# SUMMARY: HLA-DPw4,actyesm,bindyesu,FFLLTRILTIPQSLD*# SEQUENCE: FFLLTRILTIPQSLD*# ...# >HUM20995# MHC MOLECULE: HLA-DPw4(DPB1*0402), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HepBSAg (24-33)# DB REFERENCE: SWISS: (VMSA_HPBVN,VMSA_HPBVR,VMSA_HPBVZ,VMSA_HPBV2,VMSA_HPBVW,# & VMSA_HPBVY,VMSA_HPBV4,VMSA_HPBV0,VMSA_HPBV9,VMSA_HPBVR,# & VMSA_HPBVS,VMSA_HPBVW,VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVD,# & VMSA_HPBVY)# & PIR1: (JQ1572,SAVLA,SAVLAH,SAVLVD,SAVLAR,SAVLAD,JQ1571,SAVLHV,# & SAVLVE,JQ1577,JQ1575,JQ1576,SAVLBH,JQ1574,SAVLN1,SAVLKS,# & SAVLAJ)# & PIR2: (JQ2105,JQ2054,JQ2115,JQ2056,S20745,JQ2072,JQ2055,S41869,# & JQ2069,JQ2070,JQ2066,JQ2073,JQ2079,JQ2063,S47407,JQ2077,# & JQ2104,S20749,JQ2067,JQ2053,JQ2111,S43492,JQ2101,S20753,# & JQ2083,JQ2109,JQ2078,S36654,JQ2068,JQ2081,JQ2100,JQ2098,# & JQ2097,JQ2080,S32202,JQ2076,JQ2108,JQ2114,JQ2099,JQ2050,# & JQ2045,JQ2094,JQ2102,S35528,JQ2065,S41871,S41870,S47411,# & JQ2103,JQ2051,JQ2112,JQ2075,JQ2046,JQ2095,JQ2047,JQ2096,# & JQ2106,JQ2048,JQ2052)# & PIR4: (S42226)# REFERENCES: celis88a# COMMENT:# SUMMARY: HLA-DPw4,actyesl,bindyesu,RILTIPQSLD*# SEQUENCE: RILTIPQSLD*# ...# >HUM10996# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (113-128)# ANCHOR POSITIONS:# REFERENCES: hadida92a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,WIYHTQGYFPDWQNT*# SEQUENCE: WIYHTQGYFPDWQNT*# ...# >HUM10997# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (113-128)# ANCHOR POSITIONS:# REFERENCES: hadida92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,WIYHTQGYFPDWQNT*# SEQUENCE: WIYHTQGYFPDWQNT*# ...# >HUM10998# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (192-206)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1PV,NEF_HV112)# & PIR1: (ASLJVL,ASLJFV,ASLJ12)# & PIR2: (S03244,S03245,S43467)# & PIR3: (S33986,JQ1620)# REFERENCES: hadida92a,hivdb97a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,HHVARELHPEYFKNC*# SEQUENCE: HHVARELHPEYFKNC*# ...# >HUM10999# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (182-198)# DB REFERENCE: SWISS: (NEF_HV1Y2,NEF_HV1BR,NEF_HV112,NEF_HV1PV)# & PIR1: (ASLJFV,I44001,ASLJVL,ASLJ12)# & PIR2: (S43467,S03245,S03244)# & PIR3: (JQ1620,S33986)# REFERENCES: hadida92a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,EWRFDSRLAFHHVAREL*# SEQUENCE: EWRFDSRLAFHHVAREL*# ...# >HUM1099A# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (66-80)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1B1,NEF_HV1PV,NEF_HV1B8,NEF_HV1BR,# & NEF_HV1H2)# & PIR1: (ASLJVL,ASLJH3,ASLJFV,ASLJ12)# & PIR2: (S43467,S03245,S03244,S24985)# & PIR3: (S33986)# REFERENCES: hadida92a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,VGFPVTPQVPLRPMT*# SEQUENCE: VGFPVTPQVPLRPMT*# ...# >HUM1099B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (66-80)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1PV,NEF_HV1B1,NEF_HV1B8,NEF_HV1BR,# & NEF_HV1H2)# & PIR1: (ASLJH3,ASLJVL,ASLJFV,ASLJ12)# & PIR2: (S03245,S24985,S03244,S43467)# & PIR3: (S33986)# REFERENCES: hadida92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,VGFPVTPQVPLRPMT*# SEQUENCE: VGFPVTPQVPLRPMT*# ...# >HUM1099C# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (93-106)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1B1,NEF_HV1BR,NEF_HV1H2,NEF_HV1PV,# & NEF_HV112)# & PIR1: (ASLJVL,ASLJFV,ASLJH3,ASLJ12)# & PIR2: (S03247,S03245,S03244,S43467)# & PIR3: (S33986)# REFERENCES: hadida92a,hivdb97a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,EKGGLEGLIHSQRR*# SEQUENCE: EKGGLEGLIHSQRR*# ...# >HUM1099D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (93-106)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1B1,NEF_HV1B8,NEF_HV1BR,NEF_HV1H2,# & NEF_HV112)# & PIR1: (ASLJFV,ASLJ12,ASLJH3,ASLJVL)# & PIR2: (S03247,S03244,S43467,S03245)# & PIR3: (S33986)# REFERENCES: hadida92a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,EKGGLEGLIHSQRR*# SEQUENCE: EKGGLEGLIHSQRR*# ...# >HUM1099E# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (132-147)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1B8)# & PIR1: (ASLJFV)# & PIR2: (S03244,S43467,S03247)# REFERENCES: hadida92a,hivdb97a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,GVRYPLTFGWCYKLVP*# SEQUENCE: GVRYPLTFGWCYKLVP*# ...# >HUM1099F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (132-147)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1B8)# & PIR1: (ASLJFV)# & PIR2: (S03244,S43467,S03247)# REFERENCES: hadida92a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GVRYPLTFGWCYKLVP*# SEQUENCE: GVRYPLTFGWCYKLVP*# ...# >HUM109A0# MHC MOLECULE: HLA-B17, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (113-128)# ANCHOR POSITIONS:# REFERENCES: culmann91a# COMMENT:# SUMMARY: HLA-B17,actyesu,bindyesu,WIYHTQGYFPDWQNT*# SEQUENCE: WIYHTQGYFPDWQNT*# ...# >HUM109A1# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (113-128)# ANCHOR POSITIONS:# REFERENCES: culmann91a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,WIYHTQGYFPDWQNT*# SEQUENCE: WIYHTQGYFPDWQNT*# ...# >HUM109A2# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Stabilization/Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV Nef (73-82)# DB REFERENCE: SWISS: (NEF_HV1U4,NEF_HV1PV,NEF_HV1JR,NEF_HV1EL,NEF_HV1S3,# & NEF_HV1MA,NEF_HV1S1,NEF_HV1BN,NEF_HV1ND,NEF_HV1B8,# & NEF_HV1Z2,NEF_HV1BR,NEF_HV112,NEF_HV1MN,NEF_HV1A2,# & NEF_HV1H2,NEF_HV1OY,NEF_HV1B1,NEF_HV1Z6,NEF_HV1SC)# & PIR1: (ASLJFV,ASLJO2,QQLJND,ASLJBR,QQLJZR,ASLJH3,ASLJ12,# & ASLJVL)# & PIR2: (S25937,S43467,S03244,S24985,S03245,S54385)# & PIR3: (S33986)# REFERENCES: culmann91a,couillin95a,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,QVPLRPMTYK*# SEQUENCE: QVPLRPMTYK*# ...# >HUM109A3# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./binding as./stabilisation as./reconstitution# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: HIV Nef (73-82)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1BR,NEF_HV1MA,NEF_HV1BN,NEF_HV1PV,# & NEF_HV1S1,NEF_HV1U4,NEF_HV1EL,NEF_HV1S3,NEF_HV1Z2,# & NEF_HV112,NEF_HV1MN,NEF_HV1JR,NEF_HV1ND,NEF_HV1H2,# & NEF_HV1A2,NEF_HV1OY,NEF_HV1Z6,NEF_HV1B1,NEF_HV1SC)# & PIR1: (ASLJ12,ASLJBR,ASLJO2,ASLJH3,ASLJVL,QQLJND,QQLJZR,# & ASLJFV)# & PIR2: (S03244,S03245,S43467,S25937,S24985,S54385)# & PIR3: (S33986)# REFERENCES: culmann91a,dibrino93a,dibrino93b,anderson93a,castelli95a,maier94a# & zeh94a,hivdb97a,goulder97a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesh,QVPLRPMTYK*# SEQUENCE: QVPLRPMTYK*# ...# >HUM109A4# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (73-82)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1MA,NEF_HV1BN,NEF_HV1PV,NEF_HV1H2,# & NEF_HV1EL,NEF_HV112,NEF_HV1MN,NEF_HV1JR,NEF_HV1U4,# & NEF_HV1ND,NEF_HV1OY,NEF_HV1Z6,NEF_HV1A2,NEF_HV1B1,# & NEF_HV1SC,NEF_HV1BR,NEF_HV1S1,NEF_HV1S3,NEF_HV1Z2)# & PIR1: (QQLJND,ASLJH3,ASLJFV,ASLJBR,ASLJVL,ASLJ12,ASLJO2,# & QQLJZR)# & PIR2: (S03245,S25937,S03244,S43467,S24985,S54385)# & PIR3: (S33986)# REFERENCES: culmann91a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,QVPLRPMTYK*# SEQUENCE: QVPLRPMTYK*# ...# >HUM109A5# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (126-138)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1BR,NEF_HV1BN)# & PIR1: (ASLJFV,ASLJBR)# & PIR2: (S03244,S43467,S03247)# REFERENCES: culmann91a,hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,NYTPGPGVRYPLT*# SEQUENCE: NYTPGPGVRYPLT*# ...# >HUM109A6# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (79-94)# DB REFERENCE: SWISS: (NEF_HV1B1,NEF_HV1B8,NEF_HV1H2,NEF_HV1BN,NEF_HV1PV,# & NEF_HV112,NEF_HV1BR)# & PIR1: (ASLJFV,ASLJ12,ASLJVL,ASLJH3,ASLJBR)# & PIR2: (S43467,S03245,S03247,S03244,S24985)# & PIR3: (S33986)# REFERENCES: culmann91a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,MTYKAAVDLSHFLKEK*# SEQUENCE: MTYKAAVDLSHFLKEK*# ...# >HUM109A7# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (83-94)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1H2,NEF_HV1PV,NEF_HV1BN,NEF_HV1RH,# & NEF_HV1B1,NEF_HV1B8,NEF_HV1BR)# & PIR1: (ASLJH3,ASLJVL,ASLJBR,ASLJ12,ASLJFV)# & PIR2: (S43467,S24985,S03245,S03246,S03244,S03247)# & PIR3: (S33986)# REFERENCES: culmann91a,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,AAVDLSHFLKEK*# SEQUENCE: AAVDLSHFLKEK*# ...# >HUM109A8# MHC MOLECULE: HLA-B17, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (115-125)# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_HV1MN,NEF_HV1Y2,NEF_HV1A2,NEF_HV112,# & NEF_HV1PV,NEF_HV1MA,NEF_HV1BR,NEF_HV1BN,NEF_HV1OY,# & NEF_HV1RH,NEF_HV1S3)# & PIR1: (ASLJBR,I44001,ASLJFV,ASLJO2,ASLJ12,ASLJVL)# & PIR2: (S24985,S03246,S03247,S03245,S43467)# & PIR3: (S33986)# REFERENCES: culmann91a# COMMENT:# SUMMARY: HLA-B17,actyesu,bindyesu,YHTQGYFPDWQ*# SEQUENCE: YHTQGYFPDWQ*# ...# >HUM109A9# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV Nef (117-128)# ANCHOR POSITIONS:# REFERENCES: culmann91a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,TQGYFPDWQNT*# SEQUENCE: TQGYFPDWQNT*# ...# >HUM109AA# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: mass spectrometry, eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: NT/60/68 nucleo protein (91-99)# DB REFERENCE: SWISS: (VNUC_IAME6,VNUC_IAEN5,VNUC_IAFOM,VNUC_IAS06,VNUC_IAUDO,# & VNUC_IAANN,VNUC_IAMEE,VNUC_IANEJ,VNUC_IASIN,VNUC_IAGD7,# & VNUC_IAGU1,VNUC_IAB39,VNUC_IAUSS,VNUC_IAME4,VNUC_IAPAR,# & VNUC_IAHIC,VNUC_IAMEB,VNUC_IAOHI,VNUC_IAS11,VNUC_IAVI6,# & VNUC_IAMEC,VNUC_IACAL,VNUC_IAHO1,VNUC_IANT6,VNUC_IABRA,# & VNUC_IAZH1,VNUC_IAB37,VNUC_IAANN,VNUC_IAMEF,VNUC_IAMEA,# & VNUC_IAFOW,VNUC_IAHO2,VNUC_IAME3,VNUC_IATX7,VNUC_IAME5,# & VNUC_IAKIE,VNUC_IAMEG)# & PIR1: (VHIVX4,VHIVAK,VHIVX5,VHIVN7,VHIVA3,VHIVX6,VHIV68,VHIVX3,# & VHIV61,VHIVX2,VHIVA7,VHIVN5,VHIV8H)# REFERENCES: falk93a,guo92a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,KTGGPIYKR*# SEQUENCE: KTGGPIYKR*# ...# >HUM109AB# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: mass spectrometry, eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal 60S homologue# ANCHOR POSITIONS:# REFERENCES: falk93a,guo92a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,DVFRDPALKL*# SEQUENCE: DVFRDPALKL*# ...# >HUM109AC# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: mass spectrometry, eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human Hsp70 B/hsc70# DB REFERENCE: SWISS: (HS71_DROME,HS70_PLEWA,HS71_PIG,HS71_HANPO,HS71_MOUSE,# & HS71_RAT,HS76_YEAST,HS70_ONCTS,HS7E_SPIOL,HS70_HYDMA,# & HS70_CLAHE,HS70_SCHMA,HS7C_HUMAN,HS75_CANAL,GR78_HUMAN,# & HS72_YEAST,HS73_RAT,HS77_HUMAN,GR78_RAT,HS72_ANOAL,# & HS7C_DICDI,HS70_XENLA,HS72_PICAN,HS7C_DROME,GR78_MOUSE,# & HS75_YEAST,HS7C_BOVIN,HS71_YEAST,HS7T_MOUSE,HS70_LEIMA,# & HS76_YEAST,HS71_ANOAL,HS70_LEIDO,HS71_DROME,HS70_TRYCR,# & HS71_PIG,HS7C_RAT,HS73_YEAST,HS71_CANAL,GR78_RAT,# & GR78_MESAU,GR78_HUMAN,HS7C_BOVIN,HS72_USTMA,HS71_BOVIN,# & HS70_ACHKL,HS71_RAT,HS70_CLAHE,HS72_DROME,HS72_LYCES,# & HS71_MOUSE,HS74_YEAST,HS70_PLACB,GR78_MESAU,HS70_MAIZE,# & HS71_LYCES,HS70_PLAFA,HS70_ONCMY,HS74_CANAL,HS76_HUMAN,# & HS72_ARATH,HS71_PICAN,HS70_PYRSA,HS76_PIG,HS7A_CAEEL,# & HS7C_DICDI,HS70_LEIAM,HS70_CHLRE,HS70_DAUCA,HS71_ARATH,# & HS75_YEAST,HS74_ANOAL,HS74_TRYBB,GR78_MOUSE,HS7C_PETHY,# & HS7C_RAT,HS7T_MOUSE,HS71_PUCGR,HS72_BOVIN,HS7H_HUMAN,# & HS71_HUMAN,HS7C_CRIGR,HS70_SOYBN,HS75_KLUMA,HS70_BLAEM,# & HS75_SCHPO,HS72_DROME,HS72_PICAN)# & PIR1: (HHFF72,HHKW7A,HHRTGB,HHXL70,HHBYA1)# & PIR2: (A49242,S41403,B45871,S35718,S30562,A53163,S20139,S06443,# & S42488,S37394,S21365,S51712,JA0170,JN0666,S31766,S06158,# & A25089,S14992,A27414,A35922,S50721,S53500,A44979,JQ1515,# & S53498,A25398,S37165,I50242,I49761,JC4786,JC4853,A29821,# & S36753,S31716,S07197,A37048,JH0095,S41415,S14949,A48469,# & I54542,JC4610,A48439,S20149,A25773,S05375,S27004,A45871,# & S18349,I51129,S46302,A42582,A29160,S44168,S52727,S03250,# & S25585,S09036,S14950,S41372,A45935,S53126,A27077,B36590,# & A34041,S11448,S11456,JU0164,I56574)# & PIR3: (S49303,JC2215,S21175)# REFERENCES: falk93a,guo92a,barber93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,TVFDAKRLIGR*# SEQUENCE: TVFDAKRLIGR*# ...# >HUM109AD# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: mass spectrometry, eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE:# ANCHOR POSITIONS:# REFERENCES: falk93a,guo92a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,EVAPPEYHR*# SEQUENCE: EVAPPEYHR*# ...# >HUM109AE# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: mass spectrometry, eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE:# ANCHOR POSITIONS:# REFERENCES: falk93a,guo92a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,EVAPPEYHRK*# SEQUENCE: EVAPPEYHRK*# ...# >HUM109AF# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: mass spectrometry, eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE:# ANCHOR POSITIONS:# REFERENCES: falk93a,guo92a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,AVAAVAARR*# SEQUENCE: AVAAVAARR*# ...# >HUM109B0# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: mass spectrometry, eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE:# DB REFERENCE: SWISS: (RL15_RAT,RL15_HUMAN,RL15_CHICK)# & PIR2: (JC2369,I50725)# REFERENCES: falk93a,guo92a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,EVILIDPFHK*# SEQUENCE: EVILIDPFHK*# ...# >MUS109B1# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/CTL assays# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: tum+ P815-cell P198 (148-158)# DB REFERENCE: SWISS: (R13A_RAT,R13A_MOUSE,R13A_HUMAN)# & PIR2: (A53204,S29539)# & PIR3: (A44367)# REFERENCES: falk93a,wallny92b,maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesl,bindyesm,KYQAVTATLEE*# SEQUENCE: KYQAVTATLEE*# ...# >MUS109B2# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive as./Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MCMV pp89 (167-176)# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: romero91a,eberl93a,maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesh,MYPHFMPTNL*# SEQUENCE: MYPHFMPTNL*# ...# >HUM109B3# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein (437-448)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASY,VGLF_MEASE,VGLF_MEASA)# & PIR1: (E48556,JU0274,VGNZMV)# & PIR2: (PQ0388,PQ0376)# REFERENCES: falk93a,van_binnendijk92a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,SRRYPDAVYLHR*# SEQUENCE: SRRYPDAVYLHR*# ...# >HUM209B4# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein (452-463)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASE,VGLF_MEASE,VGLF_MEASY)# & PIR1: (VGNZMV,JU0274)# & PIR2: (PQ0376,PQ0388)# REFERENCES: van_binnendijk92a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,GPPISLERLDVG*# SEQUENCE: GPPISLERLDVG*# ...# >HUM209B5# MHC MOLECULE: HLA-DQ?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein (452-463)# DB REFERENCE: SWISS: (VGLF_MEASY,VGLF_MEASE,VGLF_MEASE,VGLF_MEASI)# & PIR1: (JU0274,VGNZMV)# & PIR2: (PQ0376,PQ0388)# REFERENCES: van_binnendijk92a# COMMENT: HLA-DQ5 or HLA-DQ6# SUMMARY: HLA-DQ?,actyesu,bindyesu,GPPISLERLDVG*# SEQUENCE: GPPISLERLDVG*# ...# >HUM109B6# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competition/Reconstitution/Reference# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Melanoma expressed MAGE 1 (161-169)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: falk93a,traversari92a,dibrino94a,dibrino93b,chen94a,falk94c,# & gaugler94a,zeh94a,rosenberg96a,robbins96a,romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A1,actyesh,bindyesm,EADPTGHSY*# SEQUENCE: EADPTGHSY*# ...# >HUM109B7# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A NP (89-101)# DB REFERENCE: SWISS: (VNUC_IAUSS,VNUC_IAMEF,VNUC_IAFOM,VNUC_IAZH1,VNUC_IATX7,# & VNUC_IAKIE,VNUC_IAFOW,VNUC_IAMEA,VNUC_IAHO2,VNUC_IAME6,# & VNUC_IAVI6,VNUC_IAMEG,VNUC_IANT6,VNUC_IACAL,VNUC_IAMEB,# & VNUC_IAOHI,VNUC_IAHO1,VNUC_IAANN,VNUC_IAME5,VNUC_IAUDO,# & VNUC_IAANN,VNUC_IAMEE,VNUC_IAEN5,VNUC_IAME4,VNUC_IAB39,# & VNUC_IABRA)# & PIR1: (VHIV8H,VHIVN5,VHIVA7,VHIVX4,VHIVX5,VHIVN7,VHIVX6,VHIVAK,# & VHIVX2,VHIVX3,VHIV61,VHIV68)# REFERENCES: traversari92a,kelly92a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,PKKTGGPIYKRVD*# SEQUENCE: PKKTGGPIYKRVD*# ...# >MUS109B8# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./binding as./Stabilization/Half-time# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: (endogenous)Alpha-ketoglutarate dehydrogenase# DB REFERENCE: SWISS: (ODO1_HUMAN,ODO1_MOUSE)# & PIR2: (A41911,B38234)# REFERENCES: falk93a,udaka92a,kageyama95a,dutz94a,sykulev94a,wu95a,# & sykulev95a,gillanders96a,cook96a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesm,LSPFPFDL*# SEQUENCE: LSPFPFDL*# ...# >MUS109B9# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./Reference/Stabilization# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tum- P91A (12-24)# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# REFERENCES: udaka92a,lurquin89a,maryanski91a,gillanders96a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,ISTQNHRALDLVA*# SEQUENCE: ISTQNHRALDLVA*# ...# >MUS109BA# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: inhibitory as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MCMVR PP89 (168-176)# ANCHOR POSITIONS:# REFERENCES: udaka92a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,YPRFMPTNL*# SEQUENCE: YPRFMPTNL*# ...# >MUS109BB# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tum- P91A (12-26)# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# REFERENCES: lurquin89a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,ISTQNHRALDLVAAK*# SEQUENCE: ISTQNHRALDLVAAK*# ...# >MUS109BC# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tum- P91A (12-25)# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# REFERENCES: lurquin89a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,ISTQNHRALDLVAA*# SEQUENCE: ISTQNHRALDLVAA*# ...# >MUS109BD# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: tum- P91A (12-23)# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# REFERENCES: lurquin89a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,ISTQNHRALDLV*# SEQUENCE: ISTQNHRALDLV*# ...# >MUS109BE# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: tum- P91A (12-22)# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# REFERENCES: lurquin89a# COMMENT:# SUMMARY: H-2Ld,actyesl,bindyesu,ISTQNHRALDL*# SEQUENCE: ISTQNHRALDL*# ...# >MUS109BF# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 5,8# REFERENCES: falk93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,SNYLFTKL*# SEQUENCE: SNYLFTKL*# ...# >MUS109C0# MHC MOLECULE: H-2M3, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MTAalpha: NADH-DH subunit ND1 (1-10)# ANCHOR POSITIONS:# REFERENCES: falk93a,loveland90a# COMMENT: Maternaly transmitted histocompatibility complex# SUMMARY: H-2M3,actunkn,bindyesu,MFFINILTLL*# SEQUENCE: MFFINILTLL*# ...# >MUS109C1# MHC MOLECULE: H-2M3, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MTAbeta: NADH-DH subunit ND1 (1-10)# ANCHOR POSITIONS:# REFERENCES: falk93a,loveland90a# COMMENT: Maternaly transmitted histocompatibility complex# SUMMARY: H-2M3,actunkn,bindyesu,MFFINALTLL*# SEQUENCE: MFFINALTLL*# ...# >MUS109C2# MHC MOLECULE: H-2M3, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MTAgamma: NADH-DH subunit ND1 (1-10)# ANCHOR POSITIONS:# REFERENCES: falk93a,loveland90a# COMMENT: Maternaly transmitted histocompatibility complex# SUMMARY: H-2M3,actunkn,bindyesu,MFFINVLTLL*# SEQUENCE: MFFINVLTLL*# ...# >MUS109C3# MHC MOLECULE: H-2M3, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MTAdelta: NADH-DH subunit ND1 (1-10)# ANCHOR POSITIONS:# REFERENCES: falk93a,loveland90a# COMMENT: Maternaly transmitted histocompatibility complex# SUMMARY: H-2M3,actunkn,bindyesu,MFFINTLTLL*# SEQUENCE: MFFINTLTLL*# ...# >HUM209C4# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: M. leprae 65kDa (418-427)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: anderson88a# COMMENT:# SUMMARY: HLA-DR2,actyesm,bindyesu,LQAAPALDKL*# SEQUENCE: LQAAPALDKL*# ...# >HUM209C5# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: B3 chain of DR2 molecule# DB REFERENCE: SWISS: (HB2G_HUMAN)# & PIR1: (HLHUWB)# & PIR2: (I59652,I54287,A27618,D32526,S37122,C27060,I68734,S37121,# & I59647)# REFERENCES: berkower86a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,EQARAAVDTY*# SEQUENCE: EQARAAVDTY*# ...# >HUM209C6# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM209C7# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM209C8# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (381-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,KKIAKMEKASSVFNVVNS*# SEQUENCE: KKIAKMEKASSVFNVVNS*# ...# >HUM209C9# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (382-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,KIAKMEKASSVFNVVNS*# SEQUENCE: KIAKMEKASSVFNVVNS*# ...# >HUM209CA# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (383-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,IAKMEKASSVFNVVNS*# SEQUENCE: IAKMEKASSVFNVVNS*# ...# >HUM209CB# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (384-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,AKMEKASSVFNVVNS*# SEQUENCE: AKMEKASSVFNVVNS*# ...# >HUM209CC# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (385-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,KMEKASSVFNVVNS*# SEQUENCE: KMEKASSVFNVVNS*# ...# >HUM209CD# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM209CE# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM209CF# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR2,actyesl,bindyesu,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM209D0# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as./competitive binding# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a,sidney92a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM209D1# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as./competitive binding# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a,sidney92a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM209D2# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM209D3# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (381-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,KKIAKMEKASSVFNVVNS*# SEQUENCE: KKIAKMEKASSVFNVVNS*# ...# >HUM209D4# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (382-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,KIAKMEKASSVFNVVNS*# SEQUENCE: KIAKMEKASSVFNVVNS*# ...# >HUM209D5# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (383-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,IAKMEKASSVFNVVNS*# SEQUENCE: IAKMEKASSVFNVVNS*# ...# >HUM209D6# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM209D7# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM209D8# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM209D9# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-394)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,DIEKKIAKMEKASSVFN*# SEQUENCE: DIEKKIAKMEKASSVFN*# ...# >HUM209DA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as./competitive binding/binding as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a,sidney92a,alexander94a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesm,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM209DB# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM209DC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM209DD# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM209DE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM209DF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM209E0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-394)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,DIEKKIAKMEKASSVFN*# SEQUENCE: DIEKKIAKMEKASSVFN*# ...# >HUM209E1# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-393)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,DIEKKIAKMEKASSVF*# SEQUENCE: DIEKKIAKMEKASSVF*# ...# >HUM209E2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-392)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,DIEKKIAKMEKASSV*# SEQUENCE: DIEKKIAKMEKASSV*# ...# >HUM209E3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-391)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,DIEKKIAKMEKASS*# SEQUENCE: DIEKKIAKMEKASS*# ...# >HUM209E4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-390)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR5,actyesl,bindyesu,DIEKKIAKMEKAS*# SEQUENCE: DIEKKIAKMEKAS*# ...# >HUM209E5# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM209E6# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM209E7# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM209E8# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (381-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,KKIAKMEKASSVFNVVNS*# SEQUENCE: KKIAKMEKASSVFNVVNS*# ...# >HUM209E9# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM209EA# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM209EB# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM209EC# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-394)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,DIEKKIAKMEKASSVFN*# SEQUENCE: DIEKKIAKMEKASSVFN*# ...# >HUM209ED# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-393)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,DIEKKIAKMEKASSVF*# SEQUENCE: DIEKKIAKMEKASSVF*# ...# >HUM209EE# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-392)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR6,actyesl,bindyesu,DIEKKIAKMEKASSV*# SEQUENCE: DIEKKIAKMEKASSV*# ...# >HUM209EF# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as./competitive binding/binding as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HCS.T3 (378-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a,sidney92a,alexander94a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesm,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM209F0# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM209F1# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM209F2# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (381-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,KKIAKMEKASSVFNVVNS*# SEQUENCE: KKIAKMEKASSVFNVVNS*# ...# >HUM209F3# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM209F4# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM209F5# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM209F6# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-394)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesu,DIEKKIAKMEKASSVFN*# SEQUENCE: DIEKKIAKMEKASSVFN*# ...# >HUM209F7# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (379-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,IEKKIAKMEKASSVFNVVNS*# SEQUENCE: IEKKIAKMEKASSVFNVVNS*# ...# >HUM209F8# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (380-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,EKKIAKMEKASSVFNVVNS*# SEQUENCE: EKKIAKMEKASSVFNVVNS*# ...# >HUM209F9# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (383-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,IAKMEKASSVFNVVNS*# SEQUENCE: IAKMEKASSVFNVVNS*# ...# >HUM209FA# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (384-398)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,AKMEKASSVFNVVNS*# SEQUENCE: AKMEKASSVFNVVNS*# ...# >HUM209FB# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-397)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,DIEKKIAKMEKASSVFNVVN*# SEQUENCE: DIEKKIAKMEKASSVFNVVN*# ...# >HUM209FC# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-396)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,DIEKKIAKMEKASSVFNVV*# SEQUENCE: DIEKKIAKMEKASSVFNVV*# ...# >HUM209FD# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCS.T3 (378-395)# ANCHOR POSITIONS:# REFERENCES: sinigaglia88a# COMMENT:# SUMMARY: HLA-DR9,actyesl,bindyesu,DIEKKIAKMEKASSVFNV*# SEQUENCE: DIEKKIAKMEKASSVFNV*# ...# >HUM209FE# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as./Reference# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp 120 (410-429)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1H3,ENV_HV1PV,ENV_HV1BR)# & PIR1: (VCLJLV,VCLJVL)# & PIR3: (S13288)# REFERENCES: siliciano88a,hivdb97a# COMMENT:# SUMMARY: HLA-DR4,actyesm,bindyesu,GSDTITLPCRIKQFINMWQE*# SEQUENCE: GSDTITLPCRIKQFINMWQE*# ...# >HUM209FF# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp 120 (410-429) isolate# DB REFERENCE: SWISS: (ENV_HV1H2)# REFERENCES: siliciano88a# COMMENT:# SUMMARY: HLA-DR4,actyesm,bindyesu,GSDTITLPCRIKQIINMWQK*# SEQUENCE: GSDTITLPCRIKQIINMWQK*# ...# >HUM20A00# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV gp 120 (410-429) isolate# DB REFERENCE: SWISS: (ENV_HV1RH)# REFERENCES: siliciano88a# COMMENT:# SUMMARY: HLA-DR4,actyesm,bindyesu,GNDTITLPCRIKQIVNMWQE*# SEQUENCE: GNDTITLPCRIKQIVNMWQE*# ...# >HUM20A01# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV gp 120 (410-429) isolate# ANCHOR POSITIONS:# REFERENCES: siliciano88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,NNETIIIPCRIKQIINMWQE*# SEQUENCE: NNETIIIPCRIKQIINMWQE*# ...# >HUM20A02# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV gp 120 (410-429) isolate# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1B1)# & PIR1: (VCLJH3)# & PIR3: (S33985)# REFERENCES: siliciano88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,GSDTITLPCRIKQIINMWQE*# SEQUENCE: GSDTITLPCRIKQIINMWQE*# ...# >HUM20A03# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV gp 120 (410-429) isolate# ANCHOR POSITIONS:# REFERENCES: siliciano88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,GNDTITIPCRIKQIINMWQE*# SEQUENCE: GNDTITIPCRIKQIINMWQE*# ...# >HUM20A04# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV gp 120 (410-429) isolate# DB REFERENCE: SWISS: (ENV_HV1W2)# REFERENCES: siliciano88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,NSTLITLPCRIKQIINMWQG*# SEQUENCE: NSTLITLPCRIKQIINMWQG*# ...# >HUM20A05# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV gp 120 (410-429) isolate# DB REFERENCE: SWISS: (ENV_HV1MA)# REFERENCES: siliciano88a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,STGSITLPCRIKQIINMWQK*# SEQUENCE: STGSITLPCRIKQIINMWQK*# ...# >MUS10A06# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: references# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM10A07# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (377-387)# ANCHOR POSITIONS:# REFERENCES: hickling90a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,NSGGEFFYSNS*# SEQUENCE: NSGGEFFYSNS*# ...# >HUM10A08# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: references# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IASIN,VNUC_IANEJ,VNUC_IACKG,VNUC_IAHIC,VNUC_IAZMA,# & VNUC_IAMEF,VNUC_IADNZ,VNUC_IATEI,VNUC_IAMEA,VNUC_IAHTE,# & VNUC_IAFOW,VNUC_IAGRE,VNUC_IAKIE,VNUC_IATX7,VNUC_IABRA,# & VNUC_IAZI3,VNUC_IASE0,VNUC_IAZW2,VNUC_IAHLO,VNUC_IAME3,# & VNUC_IAZ29,VNUC_IAMEB,VNUC_IADE2,VNUC_IAHO2,VNUC_IARUD,# & VNUC_IADE1,VNUC_IAME6,VNUC_IALEN,VNUC_IAZI2,VNUC_IADAU,# & VNUC_IATKO,VNUC_IAMIN,VNUC_IADM2,VNUC_IAB39,VNUC_IASH2,# & VNUC_IAME4,VNUC_IAFPR,VNUC_IAUDO,VNUC_IAMEE,VNUC_IAHO1,# & VNUC_IAANN,VNUC_IATKN,VNUC_IAZH4,VNUC_IAOHI,VNUC_IAZON,# & VNUC_IAHMI,VNUC_IAME5,VNUC_IAMAN,VNUC_IAFOM,VNUC_IAWIS,# & VNUC_IAMEC,VNUC_IATRT,VNUC_IADBE,VNUC_IAZW1,VNUC_IAZTE,# & VNUC_IAZOH,VNUC_IANT6,VNUC_IAMEG,VNUC_IAZDA,VNUC_IAS06,# & VNUC_IAWIL,VNUC_IAWHP,VNUC_IAPAR,VNUC_IAZI1,VNUC_IAUSS,# & VNUC_IAS11,VNUC_IAS31,VNUC_IACAL,VNUC_IAZJ3,VNUC_IAMAA,# & VNUC_IAB37,VNUC_IAZ41,VNUC_IADMA,VNUC_IAANA,VNUC_IAZH3,# & VNUC_IAGD7,VNUC_IAZH1,VNUC_IABUD,VNUC_IAZJ1,VNUC_IAVI6,# & VNUC_IAPUE,VNUC_IADU2,VNUC_IAANN,VNUC_IAZJ2,VNUC_IACKP,# & VNUC_IAZJA,VNUC_IATRS,VNUC_IAEN5,VNUC_IAWHN)# & PIR1: (VHIVN7,VHIVM1,VHIVN8,VHIV68,VHIVX4,VHIVN5,VHIV61,VHIVXL,# & VHIVN1,VHIV34,VHIVA6,VHIVX6,VHIVC1,VHIVN9,VHIVAK,VHIVX1,# & VHIVX2,VHIVX3,VHIVA3,VHIV8H,VHIVA7,VHIVN3,VHIVX5,# & A60028)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A09# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (50-63)# DB REFERENCE: SWISS: (VNUC_IAZDA,VNUC_IAFOW,VNUC_IAHO1,VNUC_IACAL,VNUC_IAMEG,# & VNUC_IANT6,VNUC_IAEN5,VNUC_IAMEE,VNUC_IAMEC,VNUC_IAFOM,# & VNUC_IAME5,VNUC_IAANN,VNUC_IABRA,VNUC_IAME6,VNUC_IAHO2,# & VNUC_IAKIE,VNUC_IATX7,VNUC_IALEN,VNUC_IAHIC,VNUC_IAMEF,# & VNUC_IAUDO,VNUC_IAME4,VNUC_IAMEA,VNUC_IAB39,VNUC_IAME3,# & VNUC_IAMEB,VNUC_IASIN,VNUC_IAZH1,VNUC_IAZCA,VNUC_IAS31,# & VNUC_IAUSS,VNUC_IAWIL,VNUC_IAPUE,VNUC_IAANN,# & VNUC_IAVI6)# & PIR1: (VHIVX3,VHIVX2,VHIVA7,VHIV34,VHIVX4,VHIVX6,VHIVN7,VHIV61,# & VHIV68,VHIV8H,VHIVXL,VHIVAK,VHIVN5,VHIVX5)# & PIR2: (B36754)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM20A0A# MHC MOLECULE: HLA-DR10, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (50-63)# DB REFERENCE: SWISS: (VNUC_IAMEC,VNUC_IAEN5,VNUC_IAMEG,VNUC_IANT6,VNUC_IAHO1,# & VNUC_IAFOW,VNUC_IAZDA,VNUC_IAPUE,VNUC_IAZCA,VNUC_IAMEB,# & VNUC_IAME3,VNUC_IASIN,VNUC_IATX7,VNUC_IAVI6,VNUC_IAS31,# & VNUC_IAB39,VNUC_IAUDO,VNUC_IACAL,VNUC_IAKIE,VNUC_IAHIC,# & VNUC_IAUSS,VNUC_IAWIL,VNUC_IABRA,VNUC_IAHO2,VNUC_IAME6,# & VNUC_IAMEE,VNUC_IAFOM,VNUC_IAME5,VNUC_IAANN,VNUC_IALEN,# & VNUC_IAMEF,VNUC_IAANN,VNUC_IAME4,VNUC_IAMEA,# & VNUC_IAZH1)# & PIR1: (VHIVXL,VHIVX5,VHIVA7,VHIV34,VHIVX6,VHIVX3,VHIVN5,VHIV8H,# & VHIVAK,VHIVX4,VHIV61,VHIV68,VHIVN7,VHIVX2)# & PIR2: (B36754)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR10,actunkn,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM20A0B# MHC MOLECULE: HLA-DR16, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (50-63)# DB REFERENCE: SWISS: (VNUC_IAVI6,VNUC_IAANN,VNUC_IALEN,VNUC_IAME6,VNUC_IAFOM,# & VNUC_IAMEC,VNUC_IAME3,VNUC_IAHO2,VNUC_IABRA,VNUC_IAUDO,# & VNUC_IAMEA,VNUC_IAS31,VNUC_IAME5,VNUC_IAKIE,VNUC_IACAL,# & VNUC_IASIN,VNUC_IATX7,VNUC_IAZCA,VNUC_IAHO1,VNUC_IAFOW,# & VNUC_IAWIL,VNUC_IAUSS,VNUC_IAHIC,VNUC_IAB39,VNUC_IAMEG,# & VNUC_IANT6,VNUC_IAEN5,VNUC_IAPUE,VNUC_IAMEB,VNUC_IAZDA,# & VNUC_IAANN,VNUC_IAMEF,VNUC_IAMEE,VNUC_IAME4,# & VNUC_IAZH1)# & PIR1: (VHIV68,VHIVAK,VHIV8H,VHIVX5,VHIVN7,VHIVX2,VHIVA7,VHIVN5,# & VHIVX3,VHIV34,VHIVXL,VHIV61,VHIVX6,VHIVX4)# & PIR2: (B36754)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR16,actunkn,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM20A0C# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (50-63)# DB REFERENCE: SWISS: (VNUC_IAVI6,VNUC_IAME6,VNUC_IAFOM,VNUC_IAMEA,VNUC_IAMEC,# & VNUC_IAUDO,VNUC_IAMEF,VNUC_IAZH1,VNUC_IANT6,VNUC_IAMEG,# & VNUC_IACAL,VNUC_IAANN,VNUC_IAME4,VNUC_IAHIC,VNUC_IAEN5,# & VNUC_IAB39,VNUC_IAPUE,VNUC_IAMEB,VNUC_IASIN,VNUC_IAZCA,# & VNUC_IAS31,VNUC_IAFOW,VNUC_IAKIE,VNUC_IAHO2,VNUC_IAANN,# & VNUC_IALEN,VNUC_IAME3,VNUC_IATX7,VNUC_IAZDA,VNUC_IAMEE,# & VNUC_IAUSS,VNUC_IAWIL,VNUC_IABRA,VNUC_IAME5,# & VNUC_IAHO1)# & PIR1: (VHIVX6,VHIVX5,VHIVN5,VHIVX2,VHIVXL,VHIV68,VHIV61,VHIVX4,# & VHIV8H,VHIVA7,VHIVX3,VHIV34,VHIVN7,VHIVAK)# & PIR2: (B36754)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM20A0D# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (50-63)# DB REFERENCE: SWISS: (VNUC_IAMEC,VNUC_IANT6,VNUC_IAMEG,VNUC_IAKIE,VNUC_IAMEE,# & VNUC_IAME5,VNUC_IAHO2,VNUC_IAANN,VNUC_IAMEB,VNUC_IAWIL,# & VNUC_IATX7,VNUC_IAS31,VNUC_IAHO1,VNUC_IAANN,VNUC_IASIN,# & VNUC_IAZCA,VNUC_IAEN5,VNUC_IAMEA,VNUC_IAME4,VNUC_IAHIC,# & VNUC_IACAL,VNUC_IAZH1,VNUC_IAFOM,VNUC_IAVI6,VNUC_IAFOW,# & VNUC_IAPUE,VNUC_IAB39,VNUC_IAMEF,VNUC_IALEN,VNUC_IAUDO,# & VNUC_IAME6,VNUC_IAUSS,VNUC_IAZDA,VNUC_IAME3,# & VNUC_IABRA)# & PIR1: (VHIVA7,VHIVX3,VHIVX4,VHIV61,VHIV8H,VHIVX5,VHIVN5,VHIVX6,# & VHIVXL,VHIVAK,VHIV68,VHIVX2,VHIVN7,VHIV34)# & PIR2: (B36754)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM20A0E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (50-63)# DB REFERENCE: SWISS: (VNUC_IAMEG,VNUC_IAME5,VNUC_IAWIL,VNUC_IAHO1,VNUC_IAS31,# & VNUC_IAHO2,VNUC_IAMEE,VNUC_IAMEB,VNUC_IAFOW,VNUC_IATX7,# & VNUC_IACAL,VNUC_IAHIC,VNUC_IAUSS,VNUC_IAZDA,VNUC_IABRA,# & VNUC_IAUDO,VNUC_IAPUE,VNUC_IAB39,VNUC_IALEN,VNUC_IAMEF,# & VNUC_IAME6,VNUC_IAFOM,VNUC_IAVI6,VNUC_IAME3,VNUC_IAZH1,# & VNUC_IAEN5,VNUC_IAME4,VNUC_IAMEA,VNUC_IAANN,VNUC_IAZCA,# & VNUC_IAMEC,VNUC_IANT6,VNUC_IASIN,VNUC_IAKIE,# & VNUC_IAANN)# & PIR1: (VHIV34,VHIVX2,VHIVAK,VHIVX5,VHIV61,VHIVX4,VHIVA7,VHIVN5,# & VHIV68,VHIVN7,VHIVX6,VHIVXL,VHIV8H,VHIVX3)# & PIR2: (B36754)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM20A0F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A10# MHC MOLECULE: HLA-DR10, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR10,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A11# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A12# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A13# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A14# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A15# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A16# MHC MOLECULE: HLA-DR12, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A17# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (147-158)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,TYQRTRAKVTG*# SEQUENCE: TYQRTRAKVTG*# ...# >HUM20A18# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (398-413)# DB REFERENCE: SWISS: (VNUC_IAHO2,VNUC_IAUDO,VNUC_IAME4,VNUC_IAMEF,VNUC_IAMEG,# & VNUC_IAMEA,VNUC_IAZH1,VNUC_IAB39,VNUC_IAHO1,# & VNUC_IANT6)# & PIR1: (VHIVN5,VHIV8H,VHIVN7,VHIVA7,VHIV68)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,QQRASAGQISVQPAFS*# SEQUENCE: QQRASAGQISVQPAFS*# ...# >HUM20A19# MHC MOLECULE: HLA-DR16, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (398-413)# DB REFERENCE: SWISS: (VNUC_IAHO2,VNUC_IAMEG,VNUC_IAHO1,VNUC_IAZH1,VNUC_IANT6,# & VNUC_IAMEA,VNUC_IAB39,VNUC_IAME4,VNUC_IAMEF,# & VNUC_IAUDO)# & PIR1: (VHIV68,VHIV8H,VHIVN5,VHIVA7,VHIVN7)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR16,actunkn,bindyesu,QQRASAGQISVQPAFS*# SEQUENCE: QQRASAGQISVQPAFS*# ...# >HUM20A1A# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (398-413)# DB REFERENCE: SWISS: (VNUC_IAMEA,VNUC_IAMEF,VNUC_IAZH1,VNUC_IANT6,VNUC_IAMEG,# & VNUC_IAHO1,VNUC_IAHO2,VNUC_IAUDO,VNUC_IAME4,# & VNUC_IAB39)# & PIR1: (VHIVA7,VHIV68,VHIVN5,VHIVN7,VHIV8H)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,QQRASAGQISVQPAFS*# SEQUENCE: QQRASAGQISVQPAFS*# ...# >HUM20A1B# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (398-413)# DB REFERENCE: SWISS: (VNUC_IAMEF,VNUC_IAB39,VNUC_IAHO2,VNUC_IAME4,VNUC_IANT6,# & VNUC_IAUDO,VNUC_IAHO1,VNUC_IAMEA,VNUC_IAMEG,# & VNUC_IAZH1)# & PIR1: (VHIVN7,VHIV8H,VHIV68,VHIVN5,VHIVA7)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,QQRASAGQISVQPAFS*# SEQUENCE: QQRASAGQISVQPAFS*# ...# >HUM20A1C# MHC MOLECULE: HLA-DR12, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (398-413)# DB REFERENCE: SWISS: (VNUC_IAME4,VNUC_IAMEA,VNUC_IAMEF,VNUC_IAUDO,VNUC_IAHO1,# & VNUC_IAHO2,VNUC_IAB39,VNUC_IAZH1,VNUC_IANT6,# & VNUC_IAMEG)# & PIR1: (VHIV68,VHIVN7,VHIV8H,VHIVN5,VHIVA7)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,QQRASAGQISVQPAFS*# SEQUENCE: QQRASAGQISVQPAFS*# ...# >HUM20A1D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thy 1.1 (80-98)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,DEGDYFSELRVSGANPM*# SEQUENCE: DEGDYFSELRVSGANPM*# ...# >HUM20A1E# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thy 1.1 (80-98)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DEGDYFSELRVSGANPM*# SEQUENCE: DEGDYFSELRVSGANPM*# ...# >HUM20A1F# MHC MOLECULE: HLA-DR12, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thy 1.1 (80-98)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,DEGDYFSELRVSGANPM*# SEQUENCE: DEGDYFSELRVSGANPM*# ...# >HUM20A20# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A21# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A22# MHC MOLECULE: HLA-DR9, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IADMA,VNUC_IAZJ1,VNUC_IAGD7,VNUC_IAZH3,VNUC_IAWHP,# & VNUC_IAANN,VNUC_IAB37,VNUC_IASIN,VNUC_IAZJ3,VNUC_IAME4,# & VNUC_IAZJ2,VNUC_IAZJA,VNUC_IAFOW,VNUC_IADE1,VNUC_IACAL,# & VNUC_IAKIE,VNUC_IAS06,VNUC_IAHO2,VNUC_IAMIN,VNUC_IADAU,# & VNUC_IANT6,VNUC_IANEJ,VNUC_IAME5,VNUC_IAMEB,VNUC_IAUSS,# & VNUC_IAVI6,VNUC_IAOHI,VNUC_IAZON,VNUC_IAZH4,VNUC_IATKN,# & VNUC_IAWIL,VNUC_IATEI,VNUC_IAMEF,VNUC_IAME6,VNUC_IAHLO,# & VNUC_IATX7,VNUC_IAZW2,VNUC_IAZ29,VNUC_IAB39,VNUC_IARUD,# & VNUC_IATKO,VNUC_IAHO1,VNUC_IADM2,VNUC_IAUDO,VNUC_IASE0,# & VNUC_IACKG,VNUC_IAMEE,VNUC_IAMEG,VNUC_IAGRE,VNUC_IAZMA,# & VNUC_IADNZ,VNUC_IAZI2,VNUC_IAPUE,VNUC_IAHTE,VNUC_IAMAN,# & VNUC_IAMEA,VNUC_IASH2,VNUC_IABRA,VNUC_IAFPR,VNUC_IAZDA,# & VNUC_IAEN5,VNUC_IAZOH,VNUC_IAZW1,VNUC_IAME3,VNUC_IAFOM,# & VNUC_IATRT,VNUC_IADU2,VNUC_IAMAA,VNUC_IABUD,VNUC_IADE2,# & VNUC_IAS31,VNUC_IAZH1,VNUC_IAHMI,VNUC_IALEN,VNUC_IADBE,# & VNUC_IAZTE,VNUC_IAWIS,VNUC_IAZI3,VNUC_IAHIC,VNUC_IAMEC,# & VNUC_IAPAR,VNUC_IAZI1,VNUC_IAZ41,VNUC_IAS11,VNUC_IAANA,# & VNUC_IACKP,VNUC_IATRS,VNUC_IAANN,VNUC_IAWHN)# & PIR1: (VHIVA7,VHIV61,VHIVA6,VHIVC1,VHIV68,VHIVX4,A60028,VHIVX1,# & VHIVAK,VHIVX2,VHIV34,VHIVN1,VHIVM1,VHIVX5,VHIVN9,VHIVN5,# & VHIVN8,VHIVX3,VHIVN3,VHIVX6,VHIVA3,VHIV8H,VHIVN7,# & VHIVXL)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A23# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IAFOM,VNUC_IAHIC,VNUC_IACKP,VNUC_IAMEF,VNUC_IATEI,# & VNUC_IACAL,VNUC_IAZ41,VNUC_IAZDA,VNUC_IASH2,VNUC_IAMEA,# & VNUC_IAPUE,VNUC_IAGRE,VNUC_IAMEE,VNUC_IAUDO,VNUC_IAB37,# & VNUC_IASIN,VNUC_IAMAN,VNUC_IAZMA,VNUC_IAFOW,VNUC_IAMIN,# & VNUC_IADAU,VNUC_IAUSS,VNUC_IAANN,VNUC_IAZTE,VNUC_IAOHI,# & VNUC_IAZW1,VNUC_IAHTE,VNUC_IAMEG,VNUC_IAME3,VNUC_IAZOH,# & VNUC_IAFPR,VNUC_IACKG,VNUC_IADNZ,VNUC_IAZI2,VNUC_IAHO1,# & VNUC_IADM2,VNUC_IAHLO,VNUC_IATX7,VNUC_IAB39,VNUC_IAZW2,# & VNUC_IAANN,VNUC_IARUD,VNUC_IASE0,VNUC_IAME4,VNUC_IAZJ3,# & VNUC_IAZJ1,VNUC_IAGD7,VNUC_IAMEB,VNUC_IANEJ,VNUC_IAZON,# & VNUC_IAME6,VNUC_IATKN,VNUC_IAZH4,VNUC_IADE1,VNUC_IAHO2,# & VNUC_IAMEC,VNUC_IAZI1,VNUC_IAZ29,VNUC_IAWHP,VNUC_IATKO,# & VNUC_IABRA,VNUC_IADMA,VNUC_IAZH3,VNUC_IAZJ2,VNUC_IAZJA,# & VNUC_IAVI6,VNUC_IAPAR,VNUC_IAKIE,VNUC_IAS06,VNUC_IAWIL,# & VNUC_IANT6,VNUC_IAME5,VNUC_IADE2,VNUC_IAS31,VNUC_IAZH1,# & VNUC_IATRT,VNUC_IADU2,VNUC_IAEN5,VNUC_IAWIS,VNUC_IADBE,# & VNUC_IAWHN,VNUC_IAANA,VNUC_IAS11,VNUC_IATRS,VNUC_IAZI3,# & VNUC_IABUD,VNUC_IAMAA,VNUC_IALEN,VNUC_IAHMI)# & PIR1: (VHIVN9,VHIVX5,VHIV34,VHIVM1,VHIVN7,VHIV8H,VHIV68,VHIVX4,# & VHIVN3,VHIVC1,VHIVX1,A60028,VHIVA7,VHIVX2,VHIVN1,VHIVX6,# & VHIVN5,VHIVAK,VHIVXL,VHIVN8,VHIVX3,VHIVA3,VHIVA6,# & VHIV61)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A24# MHC MOLECULE: HLA-DR10, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IAB37,VNUC_IAUDO,VNUC_IATEI,VNUC_IAMEF,VNUC_IAZ41,# & VNUC_IAFOM,VNUC_IAMEA,VNUC_IAMEE,VNUC_IAZDA,VNUC_IAME3,# & VNUC_IADAU,VNUC_IAFOW,VNUC_IAZH3,VNUC_IADMA,VNUC_IAVI6,# & VNUC_IAWHP,VNUC_IAWIL,VNUC_IAEN5,VNUC_IAZH1,VNUC_IADE2,# & VNUC_IABUD,VNUC_IALEN,VNUC_IAHO1,VNUC_IADM2,VNUC_IAMEG,# & VNUC_IAZJ1,VNUC_IAMEB,VNUC_IAANA,VNUC_IAWIS,VNUC_IACKP,# & VNUC_IAS06,VNUC_IAKIE,VNUC_IAPAR,VNUC_IAME5,VNUC_IATKO,# & VNUC_IAZJ2,VNUC_IAZJA,VNUC_IAS31,VNUC_IAMAA,VNUC_IAZI3,# & VNUC_IAWHN,VNUC_IAHMI,VNUC_IADU2,VNUC_IABRA,VNUC_IATRT,# & VNUC_IAZON,VNUC_IAZH4,VNUC_IAME6,VNUC_IADE1,VNUC_IANEJ,# & VNUC_IAS11,VNUC_IATRS,VNUC_IAHO2,VNUC_IAMEC,VNUC_IAZI1,# & VNUC_IAME4,VNUC_IAGD7,VNUC_IADNZ,VNUC_IAFPR,VNUC_IAANN,# & VNUC_IAB39,VNUC_IAHLO,VNUC_IARUD,VNUC_IAZOH,VNUC_IASE0,# & VNUC_IASH2,VNUC_IAGRE,VNUC_IAHTE,VNUC_IANT6,VNUC_IATX7,# & VNUC_IADBE,VNUC_IATKN,VNUC_IAZJ3,VNUC_IAZW2,VNUC_IAZI2,# & VNUC_IACKG,VNUC_IAHIC,VNUC_IAZ29,VNUC_IASIN,VNUC_IAPUE,# & VNUC_IACAL,VNUC_IAZTE,VNUC_IAANN,VNUC_IAZW1,VNUC_IAOHI,# & VNUC_IAMIN,VNUC_IAUSS,VNUC_IAZMA,VNUC_IAMAN)# & PIR1: (VHIVA6,VHIV61,VHIV68,VHIVAK,VHIVA3,A60028,VHIVX4,VHIV34,# & VHIVX2,VHIVN1,VHIVN8,VHIVX3,VHIV8H,VHIVX6,VHIVXL,VHIVN5,# & VHIVM1,VHIVN7,VHIVX1,VHIVC1,VHIVA7,VHIVN3,VHIVN9,# & VHIVX5)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR10,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A25# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IANT6,VNUC_IAZOH,VNUC_IARUD,VNUC_IASH2,VNUC_IACKG,# & VNUC_IAZI2,VNUC_IAMEB,VNUC_IAHO1,VNUC_IAMAN,VNUC_IAWHP,# & VNUC_IAVI6,VNUC_IAHO2,VNUC_IAS11,VNUC_IAZI3,VNUC_IATKO,# & VNUC_IAUDO,VNUC_IATEI,VNUC_IAS31,VNUC_IAEN5,VNUC_IAMEG,# & VNUC_IAZH4,VNUC_IADBE,VNUC_IAHLO,VNUC_IAZON,VNUC_IANEJ,# & VNUC_IAME4,VNUC_IAMEC,VNUC_IAZI1,VNUC_IAHMI,VNUC_IATRS,# & VNUC_IAWHN,VNUC_IADNZ,VNUC_IAB39,VNUC_IAMAA,VNUC_IADU2,# & VNUC_IABRA,VNUC_IACKP,VNUC_IAME5,VNUC_IAS06,VNUC_IAPAR,# & VNUC_IAZJ2,VNUC_IAMEE,VNUC_IAB37,VNUC_IAMEA,VNUC_IAZ41,# & VNUC_IADE2,VNUC_IABUD,VNUC_IAANA,VNUC_IAZH3,VNUC_IAWIL,# & VNUC_IAZDA,VNUC_IAFOM,VNUC_IAKIE,VNUC_IAZJA,VNUC_IATRT,# & VNUC_IADE1,VNUC_IAME6,VNUC_IAGD7,VNUC_IAANN,VNUC_IAMEF,# & VNUC_IAFOW,VNUC_IADAU,VNUC_IAME3,VNUC_IADM2,VNUC_IADMA,# & VNUC_IAPUE,VNUC_IAZTE,VNUC_IAZJ1,VNUC_IAZH1,VNUC_IALEN,# & VNUC_IAWIS,VNUC_IASE0,VNUC_IATX7,VNUC_IAHTE,VNUC_IAFPR,# & VNUC_IAZW2,VNUC_IAZJ3,VNUC_IAOHI,VNUC_IAMIN,VNUC_IAANN,# & VNUC_IAZW1,VNUC_IAUSS,VNUC_IAZMA,VNUC_IASIN,VNUC_IACAL,# & VNUC_IAHIC,VNUC_IAZ29,VNUC_IAGRE,VNUC_IATKN)# & PIR1: (VHIVC1,VHIV8H,VHIVN8,VHIVX3,VHIVX2,VHIVN1,VHIVXL,VHIVN9,# & VHIVA3,VHIVX1,VHIVA7,VHIVM1,VHIVN7,VHIVN5,VHIV68,A60028,# & VHIVX4,VHIV61,VHIVN3,VHIVX5,VHIVA6,VHIVAK,VHIV34,# & VHIVX6)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A26# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IATEI,VNUC_IADBE,VNUC_IAWHP,VNUC_IAMAN,VNUC_IAVI6,# & VNUC_IASH2,VNUC_IANT6,VNUC_IAHO2,VNUC_IAZI3,VNUC_IADNZ,# & VNUC_IAS31,VNUC_IAHLO,VNUC_IAZDA,VNUC_IAMEF,VNUC_IADAU,# & VNUC_IAME3,VNUC_IACKG,VNUC_IAZH1,VNUC_IADE1,VNUC_IAGD7,# & VNUC_IAFPR,VNUC_IAZW2,VNUC_IAWHN,VNUC_IAZI1,VNUC_IAMEC,# & VNUC_IAZ41,VNUC_IAMEA,VNUC_IAZW1,VNUC_IACAL,VNUC_IADMA,# & VNUC_IAPUE,VNUC_IAZTE,VNUC_IAWIS,VNUC_IALEN,VNUC_IAZJ1,# & VNUC_IADM2,VNUC_IAZJA,VNUC_IAKIE,VNUC_IAFOW,VNUC_IAFOM,# & VNUC_IATRT,VNUC_IAME6,VNUC_IAGRE,VNUC_IAHIC,VNUC_IAHTE,# & VNUC_IATX7,VNUC_IAZJ3,VNUC_IAOHI,VNUC_IAANN,VNUC_IASE0,# & VNUC_IAZH3,VNUC_IABUD,VNUC_IAWIL,VNUC_IAUSS,VNUC_IAZMA,# & VNUC_IATRS,VNUC_IAMAA,VNUC_IAHMI,VNUC_IAME4,VNUC_IAB39,# & VNUC_IACKP,VNUC_IAS06,VNUC_IAME5,VNUC_IADU2,VNUC_IABRA,# & VNUC_IAZJ2,VNUC_IAZON,VNUC_IAZH4,VNUC_IAHO1,VNUC_IAEN5,# & VNUC_IANEJ,VNUC_IARUD,VNUC_IATKO,VNUC_IAZI2,VNUC_IAB37,# & VNUC_IATKN,VNUC_IAANN,VNUC_IAMIN,VNUC_IAZ29,VNUC_IASIN,# & VNUC_IAANA,VNUC_IADE2,VNUC_IAMEE,VNUC_IAPAR,VNUC_IAS11,# & VNUC_IAZOH,VNUC_IAMEB,VNUC_IAUDO,VNUC_IAMEG)# & PIR1: (VHIVA3,VHIVX4,VHIVA6,VHIVX5,VHIVN3,VHIV8H,VHIVX2,A60028,# & VHIVC1,VHIVX3,VHIV34,VHIVAK,VHIVX6,VHIVA7,VHIVX1,VHIVN8,# & VHIVXL,VHIVM1,VHIVN9,VHIV68,VHIV61,VHIVN7,VHIVN5,# & VHIVN1)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A27# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu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hickling90a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A28# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IAPUE,VNUC_IASH2,VNUC_IAZOH,VNUC_IAMEG,VNUC_IAZW1,# & VNUC_IAZW2,VNUC_IAMEE,VNUC_IAHO1,VNUC_IAGRE,VNUC_IAZI2,# & VNUC_IAZH4,VNUC_IAB37,VNUC_IAEN5,VNUC_IASIN,VNUC_IATRS,# & VNUC_IACKP,VNUC_IAVI6,VNUC_IAWIS,VNUC_IADM2,VNUC_IAMAA,# & VNUC_IAZON,VNUC_IARUD,VNUC_IAZJ3,VNUC_IAHMI,VNUC_IAHIC,# & VNUC_IAUDO,VNUC_IAMEF,VNUC_IAME4,VNUC_IAANA,VNUC_IATKO,# & VNUC_IANEJ,VNUC_IAZJ1,VNUC_IAZJA,VNUC_IAKIE,VNUC_IATRT,# & VNUC_IAMAN,VNUC_IATX7,VNUC_IAMEC,VNUC_IAMEB,VNUC_IACKG,# & VNUC_IACAL,VNUC_IAMEA,VNUC_IAWHN,VNUC_IAHLO,VNUC_IAUSS,# & VNUC_IAOHI,VNUC_IAWIL,VNUC_IABUD,VNUC_IASE0,VNUC_IATEI,# & VNUC_IAANN,VNUC_IAMIN,VNUC_IADE2,VNUC_IAZ29,VNUC_IAPAR,# & VNUC_IATKN,VNUC_IAS31,VNUC_IAWHP,VNUC_IAGD7,VNUC_IADAU,# & VNUC_IAZMA,VNUC_IAME5,VNUC_IALEN,VNUC_IADMA,VNUC_IANT6,# & VNUC_IAFOW,VNUC_IAME6,VNUC_IAZDA,VNUC_IADU2,VNUC_IAFPR,# & VNUC_IADNZ,VNUC_IAFOM,VNUC_IADE1,VNUC_IAZI3,VNUC_IAB39,# & VNUC_IAZTE,VNUC_IAHTE,VNUC_IAME3,VNUC_IAS11,VNUC_IAZH1,# & VNUC_IAZ41,VNUC_IAZI1,VNUC_IADBE,VNUC_IAZH3,VNUC_IAZJ2,# & VNUC_IAHO2,VNUC_IAS06,VNUC_IABRA,VNUC_IAANN)# & PIR1: (VHIVA3,VHIVN7,VHIV8H,VHIVA6,A60028,VHIVC1,VHIVX6,VHIVN3,# & VHIVX2,VHIV61,VHIVX5,VHIVN9,VHIVX4,VHIVN1,VHIVX1,VHIVN8,# & VHIVXL,VHIVA7,VHIVM1,VHIVN5,VHIV68,VHIVX3,VHIVAK,# & VHIV34)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A29# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IAFOM,VNUC_IADU2,VNUC_IADMA,VNUC_IANT6,VNUC_IAME3,# & VNUC_IAFPR,VNUC_IAS06,VNUC_IAUSS,VNUC_IABUD,VNUC_IAZW2,# & VNUC_IAUDO,VNUC_IAME4,VNUC_IATRS,VNUC_IAZJA,VNUC_IAMEE,# & VNUC_IAHMI,VNUC_IACKP,VNUC_IABRA,VNUC_IAME6,VNUC_IADNZ,# & VNUC_IAME5,VNUC_IALEN,VNUC_IAWIL,VNUC_IADE2,VNUC_IADAU,# & VNUC_IAFOW,VNUC_IAWHP,VNUC_IACKG,VNUC_IAZI2,VNUC_IAZH4,# & VNUC_IAEN5,VNUC_IASIN,VNUC_IAWHN,VNUC_IAMEA,VNUC_IAANN,# & VNUC_IAOHI,VNUC_IAVI6,VNUC_IAWIS,VNUC_IADM2,VNUC_IAPUE,# & VNUC_IASH2,VNUC_IAZJ3,VNUC_IARUD,VNUC_IAMAA,VNUC_IAZOH,# & VNUC_IAZW1,VNUC_IAMEG,VNUC_IAMEC,VNUC_IAKIE,VNUC_IATRT,# & VNUC_IAMAN,VNUC_IATKO,VNUC_IAHIC,VNUC_IAZH3,VNUC_IATKN,# & VNUC_IAMIN,VNUC_IATEI,VNUC_IASE0,VNUC_IAMEB,VNUC_IACAL,# & VNUC_IAHLO,VNUC_IAB37,VNUC_IAS31,VNUC_IAZ29,VNUC_IAPAR,# & VNUC_IAGD7,VNUC_IAHO1,VNUC_IAZON,VNUC_IAGRE,VNUC_IAZJ1,# & VNUC_IATX7,VNUC_IAMEF,VNUC_IAZJ2,VNUC_IANEJ,VNUC_IAANA,# & VNUC_IAZDA,VNUC_IAB39,VNUC_IAZI3,VNUC_IADE1,VNUC_IAZMA,# & VNUC_IAHO2,VNUC_IAANN,VNUC_IADBE,VNUC_IAZTE,VNUC_IAS11,# & VNUC_IAZH1,VNUC_IAZ41,VNUC_IAZI1,VNUC_IAHTE)# & PIR1: (VHIVX3,VHIVX1,VHIVN8,VHIVA7,VHIVN5,VHIVX5,VHIVXL,A60028,# & VHIVA3,VHIVN7,VHIVX6,VHIVN3,VHIVX2,VHIVAK,VHIV34,VHIV68,# & VHIV61,VHIVC1,VHIVN1,VHIVN9,VHIVX4,VHIVM1,VHIVA6,# & VHIV8H)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A2A# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (384-394)# DB REFERENCE: SWISS: (VNUC_IATRS,VNUC_IAMEE,VNUC_IAHMI,VNUC_IAUSS,VNUC_IAUDO,# & VNUC_IADMA,VNUC_IANT6,VNUC_IAFOM,VNUC_IAFPR,VNUC_IAWIL,# & VNUC_IABRA,VNUC_IADNZ,VNUC_IALEN,VNUC_IAHO1,VNUC_IATX7,# & VNUC_IATKN,VNUC_IAMEB,VNUC_IACAL,VNUC_IAS06,VNUC_IAME3,# & VNUC_IAANA,VNUC_IANEJ,VNUC_IAGD7,VNUC_IAZ41,VNUC_IAS11,# & VNUC_IAZI3,VNUC_IAWHN,VNUC_IAPUE,VNUC_IAZI2,VNUC_IAEN5,# & VNUC_IAMAA,VNUC_IAOHI,VNUC_IADAU,VNUC_IAANN,VNUC_IAZH3,# & VNUC_IATKO,VNUC_IAHIC,VNUC_IAZJ3,VNUC_IAMEF,VNUC_IAZJ2,# & VNUC_IAMIN,VNUC_IAGRE,VNUC_IAZON,VNUC_IAHLO,VNUC_IATEI,# & VNUC_IAB37,VNUC_IAZTE,VNUC_IAHTE,VNUC_IADE1,VNUC_IAZH1,# & VNUC_IADBE,VNUC_IAZDA,VNUC_IAS31,VNUC_IATRT,VNUC_IAMAN,# & VNUC_IAWIS,VNUC_IADM2,VNUC_IAVI6,VNUC_IAZOH,VNUC_IAMEG,# & VNUC_IAZW1,VNUC_IAANN,VNUC_IAZH4,VNUC_IAME4,VNUC_IAZ29,# & VNUC_IAPAR,VNUC_IAZJA,VNUC_IAMEC,VNUC_IAB39,VNUC_IAMEA,# & VNUC_IADE2,VNUC_IAWHP,VNUC_IABUD,VNUC_IACKP,VNUC_IAZMA,# & VNUC_IASE0,VNUC_IAZJ1,VNUC_IADU2,VNUC_IAZI1,VNUC_IAHO2,# & VNUC_IAKIE,VNUC_IASH2,VNUC_IASIN,VNUC_IARUD,VNUC_IACKG,# & VNUC_IAZW2,VNUC_IAFOW,VNUC_IAME6,VNUC_IAME5)# & PIR1: (VHIVX4,VHIVX2,VHIVN1,VHIVN3,VHIVX5,VHIVC1,VHIV34,VHIVX3,# & VHIVN8,VHIVM1,VHIV8H,VHIVA6,VHIVN9,VHIVA7,VHIVAK,VHIV68,# & VHIV61,VHIVX1,VHIVN5,VHIVX6,VHIVA3,VHIVN7,A60028,# & VHIVXL)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesu,RYWAIRTRSGGN*# SEQUENCE: RYWAIRTRSGGN*# ...# >HUM20A2B# MHC MOLECULE: HLA-DR10, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR10,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A2C# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A2D# MHC MOLECULE: HLA-DR16, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR16,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A2E# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A2F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A30# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A31# MHC MOLECULE: HLA-DR12, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A32# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A33# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A34# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu HA (307-319)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesu,PRYVRQNTLRLAT*# SEQUENCE: PRYVRQNTLRLAT*# ...# >HUM20A35# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (377-387)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,NSGGEFFYSNS*# SEQUENCE: NSGGEFFYSNS*# ...# >HUM20A36# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (377-387)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,NSGGEFFYSNS*# SEQUENCE: NSGGEFFYSNS*# ...# >HUM20A37# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (377-387)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,NSGGEFFYSNS*# SEQUENCE: NSGGEFFYSNS*# ...# >HUM20A38# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (377-387)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,NSGGEFFYSNS*# SEQUENCE: NSGGEFFYSNS*# ...# >HUM20A39# MHC MOLECULE: HLA-DR12, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (377-387)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,NSGGEFFYSNS*# SEQUENCE: NSGGEFFYSNS*# ...# >HUM20A3A# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (377-387)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,NSGGEFFYSNS*# SEQUENCE: NSGGEFFYSNS*# ...# >HUM20A3B# MHC MOLECULE: HLA-DR14, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (377-387)# ANCHOR POSITIONS:# REFERENCES: hickling90a# COMMENT:# SUMMARY: HLA-DR14,actunkn,bindyesu,NSGGEFFYSNS*# SEQUENCE: NSGGEFFYSNS*# ...# >HUM20A3C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Borrelia burgdorferi HSP60 (260-274)# DB REFERENCE: SWISS: (CH60_BORBU)# & PIR2: (A49209,S16428)# REFERENCES: shanafelt91a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,ALVLNSVRGALKVCA*# SEQUENCE: ALVLNSVRGALKVCA*# ...# >HUM20A3D# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (830-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: demotz89b# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,QYIKANSKFIGI*# SEQUENCE: QYIKANSKFIGI*# ...# >HUM20A3E# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin tt (947-960)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: demotz89b# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,FNNFTVSFWLRVPK*# SEQUENCE: FNNFTVSFWLRVPK*# ...# >MUS20A3F# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: flu HA1 P7/X31 (53-68)# DB REFERENCE: SWISS: (HEMA_IAQU7,HEMA_IAME1,HEMA_IAUDO,HEMA_IANT6,HEMA_IAX31,# & HEMA_IAAIC,HEMA_IAME2)# & PIR1: (HMIVHA,HMIVH3,HMIVH,HMIVHM)# & PIR2: (A93233)# REFERENCES: mills86a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,CNNPHRILDGIDCTLID*# SEQUENCE: CNNPHRILDGIDCTLID*# ...# >MUS20A40# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: duck HA1# DB REFERENCE: SWISS: (HEMA_IADU3)# & PIR1: (HMIVDU)# REFERENCES: mills86a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,CNNPHRILDGRACTLID*# SEQUENCE: CNNPHRILDGRACTLID*# ...# >MUS10A41# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HEL (49-56)# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_PHAVE,LYC_ORTVE,LYC_SYRRE,LYC1_TACAC,# & LYC_CHICK,LYC_CHICK,LYC1_ANAPL,LYC_PHACO,LYC3_ANAPL,# & LYC_LOPLE,LYC_MELGA,LYC_PAVCR)# & PIR1: (LZTK,LZFER,LZOVE,LZDK,LZQJE,LZDK3,LZCH)# & PIR2: (JT0526,A61281,JH0211,JQ1033,JQ1041,JH0212,JC2144,JU0237,# & JU0178,A45660)# REFERENCES: calin-laurens93a# COMMENT:# SUMMARY: H-2Kb,actyesn,bindyesu,GSTDYGIL*# SEQUENCE: GSTDYGIL*# ...# >MUS10A42# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (70-78)# ANCHOR POSITIONS:# REFERENCES: calin-laurens93a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,PGSRNLCNL*# SEQUENCE: PGSRNLCNL*# ...# >MUS10A43# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (1-18)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_CHICK,LYC_CHICK,LYC_COLVI,LYC_LOPCA)# & PIR1: (LZCH,LZQJEC,LZUH)# REFERENCES: calin-laurens93a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,KVFGRCELAAAMKRHGLD*# SEQUENCE: KVFGRCELAAAMKRHGLD*# ...# >MUS10A44# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (1-17)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_CHICK,LYC_CHICK,LYC_LOPCA,LYC_COLVI)# & PIR1: (LZCH,LZUH,LZQJEC)# REFERENCES: calin-laurens93a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,KVFGRCELAAAMKRHGL*# SEQUENCE: KVFGRCELAAAMKRHGL*# ...# >HUM20A45# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu MA (17-29)# DB REFERENCE: SWISS: (VMT1_IAPUE,VMT1_IACKB,VMT1_IALE1,VMT1_IAMAN,VMT1_IAFPW,# & VMT1_IALE2,VMT1_IAUDO,VMT1_IAUSS,VMT1_IAWIL,VMT1_IAANN,# & VMT1_IAFPR,VMT1_IABAN,VMT1_IAFOW)# & PIR1: (MFIVC,MFIVWS,MFIV1K,MFIV1F,MFIV61,MFIV1M,B45539,JN0392,# & MFIV)# & PIR2: (S04056,S07945,S04052,S04058,S04050,S14616,S04054,# & S07429)# REFERENCES: lamb88a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,SGPLKAEIAQRLE*# SEQUENCE: SGPLKAEIAQRLE*# ...# >HUM20A46# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. tuberculosis (1-15)# ANCHOR POSITIONS:# REFERENCES: lamb88a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,EHRVKRGLTVAVAGA*# SEQUENCE: EHRVKRGLTVAVAGA*# ...# >HUM20A47# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. tuberculosis (1-15)# ANCHOR POSITIONS:# REFERENCES: lamb88a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,EHRVKRGLTVAVAGA*# SEQUENCE: EHRVKRGLTVAVAGA*# ...# >HUM10A48# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./(LDA)/CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: PIR2: (D49253,E49253)# REFERENCES: suhrbier93a,burrows92a,khanna92a,burrows94a# COMMENT:# SUMMARY: HLA-B8,actyesh,bindyesu,FLRGRAYGL*# SEQUENCE: FLRGRAYGL*# ...# >HUM10A49# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV/EBNA4# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: suhrbier93a# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,IVKQRRWKL*# SEQUENCE: IVKQRRWKL*# ...# >HUM10A4A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./binding as./HLA assambly/Reconstitution# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Flu MA (58-66)# DB REFERENCE: SWISS: (VMT1_IAWIL,VMT1_IAZI1,VMT1_IALE1,VMT1_IACKB,VMT1_IAANN,# & VMT1_IALE2,VMT1_IABAN,VMT1_IAFOW,VMT1_IAMAN,VMT1_IAUSS,# & VMT1_IAUDO,VMT1_IAPUE)# & PIR1: (MFIV61,MFIVWS,MFIV,MFIV1M,MFIVC,JN0392,MFIV1K)# & PIR2: (S04056,S04058,S04050,S04054,S04052,S07429,S14616)# REFERENCES: sauma93a,connan94a,parker94a,zeh94a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM10A4B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,AILGFVFTA*# SEQUENCE: AILGFVFTA*# ...# >HUM10A4C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,AALGFVFTA*# SEQUENCE: AALGFVFTA*# ...# >HUM10A4D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,AALGFVFAA*# SEQUENCE: AALGFVFAA*# ...# >HUM10A4E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,AAAGFVFTA*# SEQUENCE: AAAGFVFTA*# ...# >HUM10A4F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,EILGFVFTL*# SEQUENCE: EILGFVFTL*# ...# >HUM10A50# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,GGLGFVFTL*# SEQUENCE: GGLGFVFTL*# ...# >HUM10A51# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# DB REFERENCE: SWISS: (VMT1_IAFPW,VMT1_IAFPR)# & PIR1: (PN0083,MFIV1F,PN0086)# & PIR2: (S07945)# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GVLGFVFTL*# SEQUENCE: GVLGFVFTL*# ...# >HUM10A52# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GMLGFVFTL*# SEQUENCE: GMLGFVFTL*# ...# >HUM10A53# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,GFLGFVFTL*# SEQUENCE: GFLGFVFTL*# ...# >HUM10A54# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,GIGGFVFTL*# SEQUENCE: GIGGFVFTL*# ...# >HUM10A55# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./binding as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,GIVGFVFTL*# SEQUENCE: GIVGFVFTL*# ...# >HUM10A56# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MA (58-66) homologue# ANCHOR POSITIONS:# REFERENCES: sauma93a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GIMGFVFTL*# SEQUENCE: GIMGFVFTL*# ...# >HUM10A57# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ribosomal protein s16 (41-49)# DB REFERENCE: SWISS: (RS16_PIG,RS16_HUMAN)# & PIR1: (R3RT16,R3HU16)# REFERENCES: dibrino94a,falk94c,dibrino94b# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,MIEPRTLQY*# SEQUENCE: MIEPRTLQY*# ...# >HUM10A58# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ornithine decarboxylase (309-317)# DB REFERENCE: SWISS: (DCOR_HUMAN,DCOR_CRIGR)# & PIR1: (DCHYOC,DCHUO)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,SSEQTFMYY*# SEQUENCE: SSEQTFMYY*# ...# >HUM10A59# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,STEPVNILY*# SEQUENCE: STEPVNILY*# ...# >HUM10A5A# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,GTDPGVLIY*# SEQUENCE: GTDPGVLIY*# ...# >HUM10A5B# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,STEPPMLNY*# SEQUENCE: STEPPMLNY*# ...# >HUM10A5C# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,SLEPQRTQY*# SEQUENCE: SLEPQRTQY*# ...# >HUM10A5D# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,FTEVSIRKY*# SEQUENCE: FTEVSIRKY*# ...# >HUM10A5E# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,ITEDMGHLKY*# SEQUENCE: ITEDMGHLKY*# ...# >HUM10A5F# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,KFDPVNLVY*# SEQUENCE: KFDPVNLVY*# ...# >HUM10A60# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,AVDPGGMYS*# SEQUENCE: AVDPGGMYS*# ...# >HUM10A61# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,FGSGARDXY*# SEQUENCE: FGSGARDXY*# ...# >HUM10A62# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,YXEPQFLTY*# SEQUENCE: YXEPQFLTY*# ...# >HUM10A63# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,SIEPXTLY*# SEQUENCE: SIEPXTLY*# ...# >HUM10A64# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,AXIPAFINY*# SEQUENCE: AXIPAFINY*# ...# >HUM10A65# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endoginous) human fibrillarin (177-188)# DB REFERENCE: SWISS: (FBRL_HUMAN,FBRL_MOUSE,FBRL_MOUSE)# & PIR2: (S38342,A38712)# REFERENCES: dibrino94a,falk94c# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,VSDIVGPDGLVY*# SEQUENCE: VSDIVGPDGLVY*# ...# >HUM10A66# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,FAKPRVHG*# SEQUENCE: FAKPRVHG*# ...# >HUM10A67# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,SPKLKYMQ*# SEQUENCE: SPKLKYMQ*# ...# >HUM10A68# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,ELKKKTNL*# SEQUENCE: ELKKKTNL*# ...# >HUM10A69# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# DB REFERENCE: SWISS: (DHE4_AGABI,DHE4_AGABI)# & PIR2: (S63608)# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,ELKLKG*# SEQUENCE: ELKLKG*# ...# >HUM10A6A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) human Il-6 precursor (161-169)# DB REFERENCE: SWISS: (IL6_BOVIN)# & PIR2: (A56610)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,ILKQKIADL*# SEQUENCE: ILKQKIADL*# ...# >HUM10A6B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,SPKEKIXY*# SEQUENCE: SPKEKIXY*# ...# >HUM10A6C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,XAKEKLAD*# SEQUENCE: XAKEKLAD*# ...# >HUM10A6D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Position 8 (Q or L)# SUMMARY: HLA-B8,actunkn,bindyesu,SPKEKYEQ*# SEQUENCE: SPKEKYEQ*# ...# >HUM10A6E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Position 8 (Q or L)# SUMMARY: HLA-B8,actunkn,bindyesu,SPKEKYEL*# SEQUENCE: SPKEKYEL*# ...# >HUM10A6F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) human tristetraproline (148-155)# DB REFERENCE: SWISS: (TTP_RAT,TISB_HUMAN,TTP_BOVIN,TISD_MOUSE,TISD_HUMAN,# & TTP_HUMAN,TISB_MOUSE,TISB_RAT,TTP_MOUSE)# & PIR2: (S10471,S49147,B39590,S34854,A36600,C39590,JC1255,S34427,# & S04743)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,HPKYKTEL*# SEQUENCE: HPKYKTEL*# ...# >HUM10A70# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) yeast phosphoribosyl aminomidazole s.s.(95-102)# DB REFERENCE: SWISS: (PUR7_YEAST)# & PIR1: (JQ1395)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,EPKYKTQL*# SEQUENCE: EPKYKTQL*# ...# >HUM10A71# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) human restin (1273-1281)# DB REFERENCE: SWISS: (REST_HUMAN,REST_HUMAN)# & PIR2: (S22695,A43336)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,ELKVKNLEL*# SEQUENCE: ELKVKNLEL*# ...# >HUM10A72# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) rat ribosomal protein I18 (95-103)# DB REFERENCE: SWISS: (RL18_HUMAN,RL18_MOUSE,RL18_RAT)# & PIR1: (R5RT81,JN0779)# & PIR2: (S38352)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,VPKLKVCAL*# SEQUENCE: VPKLKVCAL*# ...# >HUM10A73# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,ELKEKTQL*# SEQUENCE: ELKEKTQL*# ...# >HUM10A74# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# DB REFERENCE: SWISS: (POL_EIAV9,POL_EIAVC,POL_EIAVY)# & PIR1: (GNLJEV,GNLJEW,GNLJ22)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,TLKEKIQ*# SEQUENCE: TLKEKIQ*# ...# >HUM10A75# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,LPKVKLAL*# SEQUENCE: LPKVKLAL*# ...# >HUM10A76# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKDVI*# SEQUENCE: IPKQKDVI*# ...# >HUM10A77# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKPVI*# SEQUENCE: IPKQKPVI*# ...# >HUM10A78# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKVVI*# SEQUENCE: IPKQKVVI*# ...# >HUM10A79# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKDVL*# SEQUENCE: IPKQKDVL*# ...# >HUM10A7A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKPVL*# SEQUENCE: IPKQKPVL*# ...# >HUM10A7B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKVVL*# SEQUENCE: IPKQKVVL*# ...# >HUM10A7C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKDLI*# SEQUENCE: IPKQKDLI*# ...# >HUM10A7D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKPLI*# SEQUENCE: IPKQKPLI*# ...# >HUM10A7E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKVLI*# SEQUENCE: IPKQKVLI*# ...# >HUM10A7F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKDLL*# SEQUENCE: IPKQKDLL*# ...# >HUM10A80# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKPLL*# SEQUENCE: IPKQKPLL*# ...# >HUM10A81# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,IPKQKVLL*# SEQUENCE: IPKQKVLL*# ...# >HUM10A82# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKDVI*# SEQUENCE: LPKQKDVI*# ...# >HUM10A83# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKPVI*# SEQUENCE: LPKQKPVI*# ...# >HUM10A84# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKVVI*# SEQUENCE: LPKQKVVI*# ...# >HUM10A85# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKDVL*# SEQUENCE: LPKQKDVL*# ...# >HUM10A86# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKPVL*# SEQUENCE: LPKQKPVL*# ...# >HUM10A87# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKVVL*# SEQUENCE: LPKQKVVL*# ...# >HUM10A88# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKDLI*# SEQUENCE: LPKQKDLI*# ...# >HUM10A89# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKPLI*# SEQUENCE: LPKQKPLI*# ...# >HUM10A8A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKVLI*# SEQUENCE: LPKQKVLI*# ...# >HUM10A8B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKDLL*# SEQUENCE: LPKQKDLL*# ...# >HUM10A8C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKPLL*# SEQUENCE: LPKQKPLL*# ...# >HUM10A8D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT: Pos 1 (I or L), pos 6 (D or P or V), pos 7 (V or L), pos 8 (I or L)# SUMMARY: HLA-B8,actunkn,bindyesu,LPKQKVLL*# SEQUENCE: LPKQKVLL*# ...# >HUM10A8E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,VLDLKIVAF*# SEQUENCE: VLDLKIVAF*# ...# >HUM10A8F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,GPKEKXAM*# SEQUENCE: GPKEKXAM*# ...# >HUM10A90# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,GLKVKGNEF*# SEQUENCE: GLKVKGNEF*# ...# >HUM10A91# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,FLKPKFVAL*# SEQUENCE: FLKPKFVAL*# ...# >HUM10A92# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,ELKIKVYXL*# SEQUENCE: ELKIKVYXL*# ...# >HUM10A93# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,SLKEKVXL*# SEQUENCE: SLKEKVXL*# ...# >HUM10A94# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,ELKEKXYEL*# SEQUENCE: ELKEKXYEL*# ...# >HUM10A95# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,DLKGKIG*# SEQUENCE: DLKGKIG*# ...# >HUM10A96# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,IPKLKNVKR*# SEQUENCE: IPKLKNVKR*# ...# >HUM10A97# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,SLKIKXL*# SEQUENCE: SLKIKXL*# ...# >HUM10A98# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,DLKQKNEL*# SEQUENCE: DLKQKNEL*# ...# >HUM10A99# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC-Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (endogenous) ?# ANCHOR POSITIONS:# REFERENCES: dibrino94a,dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLYEKVYTYK*# SEQUENCE: KLYEKVYTYK*# ...# >HUM10A9A# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,ATEPAAAAY*# SEQUENCE: ATEPAAAAY*# ...# >HUM10A9B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: homologue# DB REFERENCE: SWISS: (NCAP_BUNSH,TPIS_CORGL,TPIS_CORGL,NCAP_BUNLC)# & PIR1: (VHVULV,VHVUNH)# & PIR2: (C43260)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,AAKAKAAL*# SEQUENCE: AAKAKAAL*# ...# >HUM10A9C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,APKAKAAL*# SEQUENCE: APKAKAAL*# ...# >HUM10A9D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference and binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu A NP (380-388) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,ELKSKYWAI*# SEQUENCE: ELKSKYWAI*# ...# >HUM10A9E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference and binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p24 (262-270)# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1RH,GAG_HV1B1,GAG_HV1BR,GAG_HV1Y2,# & GAG_HV1Z2,GAG_HV1A2,GAG_HV1H2,GAG_HV1N5,GAG_HV1C4,# & GAG_HV1MN,GAG_HV1B5,GAG_HV1OY,GAG_HV1ND,GAG_HV1PV,# & GAG_HV1JR,GAG_HV1J3)# & PIR1: (FOVWH3,A38068,FOLJND,FOVWH4,FOVWLV,FOVWA2,A44001,# & FOVWVL)# & PIR2: (S60708,S60697,S60698,S60699,S54377,S60703,S60704,# & S60702)# & PIR3: (S33979)# REFERENCES: dibrino94a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,EIYKRWIIL*# SEQUENCE: EIYKRWIIL*# ...# >HUM10A9F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17 (93-101)# DB REFERENCE: SWISS: (GAG_HV1JR,GAG_HV1B5,GAG_HV1H2,GAG_HV1B1,GAG_HV1BR,# & GAG_HV1PV)# & PIR1: (FOVWH3,FOVWLV,FOVWVL)# & PIR3: (S33979)# REFERENCES: dibrino94a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,EIKDTKEAL*# SEQUENCE: EIKDTKEAL*# ...# >HUM10AA0# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human nucleotide binding protein# DB REFERENCE: SWISS: (GBLP_HUMAN,GBLP_HUMAN)# & PIR2: (I49700,S45054,B33928,A33928,S38398,A36986)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,SRDKTIIMW*# SEQUENCE: SRDKTIIMW*# ...# >HUM10AA1# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: rat ribosomal protein L36# DB REFERENCE: SWISS: (RL36_RAT)# & PIR2: (JN0483)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRLTKHTKF*# SEQUENCE: GRLTKHTKF*# ...# >HUM10AA2# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human fau-protein# DB REFERENCE: SWISS: (RS30_HUMAN,RS30_HUMAN)# & PIR2: (A47416,S38383,JC1278,I48346)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRFVNVVPTF*# SEQUENCE: RRFVNVVPTF*# ...# >HUM10AA3# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human fasyl pyrophosphate synthetase (191-199)# DB REFERENCE: SWISS: (FPPS_RAT,FPPS_HUMAN)# & PIR1: (A35726,A34713,B34713)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KRYKSIVKY*# SEQUENCE: KRYKSIVKY*# ...# >HUM10AA4# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human cytochrome C oxidase# DB REFERENCE: SWISS: (COXH_BOVIN)# & PIR1: (OGBO6C)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KRKKAYADF*# SEQUENCE: KRKKAYADF*# ...# >HUM10AA5# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human actin# DB REFERENCE: SWISS: (ACT1_ARATH,ACT2_DIPDE,ACT7_SOLTU,ACT1_BOMMO,ACT_SPOLI,# & ACT7_ARATH,ACT1_AEDAE,ACT2_ORYSA,ACT_HYDAT,ACT2_SCHMA,# & ACT3_DROME,ACT6_DROME,ACT2_PEA,ACT3_BOMMO,ACT2_DAUCA,# & ACTC_FUGRU,ACT1_STRFN,ACT1_SOLTU,ACT4_ARATH,ACTM_STYPL,# & ACT_ENTHI,ACT3_BACDO,ACTC_STRPU,ACT3_DIPDE,ACT_TOXGO,# & ACT1_NAEFO,ACT_CRYPV,ACT_CRYNE,ACT2_DIPDE,ACTC_STYPL,# & ACTC_ARATH,ACT1_XENLA,ACT1_PEA,ACT4_ARATH,ACT2_ARTSX,# & ACTB_RABIT,ACT1_SORVU,ACT1_PLAFA,ACT2_PLAFA,ACT4_CAEEL,# & ACT2_LYTPI,ACTS_HUMAN,ACTS_CYPCA,ACT1_SCHMA,ACT2_ONCVO,# & ACT1_ORYSA,ACTY_LIMPO,ACT1_DROME,ACT2_CAEEL,ACTY_LIMPO,# & ACTT_FUGRU,ACT1_LYTPI,ACT1_FUGRU,ACT1_MAIZE,ACTB_CYPCA,# & ACT2_XENLA,ACT5_SOLTU,ACTC_HUMAN,ACT2_ARATH,ACTB_CRIGR,# & ACT7_ARATH,ACTN_STYCL,ACTH_HUMAN,ACTS_FUGRU,ACTS_CARAU,# & ACT2_SOLTU,ACT_PROCL,ACT_TOBAC,ACT_SCHPO,ACT1_ARTSX,# & ACT2_FUGRU,ACT3_PEA,ACTM_MOLOC,ACT8_DICDI,ACT2_DROME,# & ACT2_LYTPI,ACT_PUCGR,ACT1_PNECA,ACT1_HELER,ACT_PHARH,# & ACT1_LYTPI,ACT8_XENLA,ACT4_SOLTU,ACTF_STRPU,ACTE_STRPU,# & ACTB_XENBO,ACTM_HELTB,ACTM_APLCA,ACTY_DROME,ACT3_LIMPO,# & ACT1_ONCVO,ACT1_HALRO,ACT5_BACDO,ACTC_HALRO,ACT1_CAEEL,# & ACT3_LIMPO,ACT_TAESO,ACT4_ARTSX,ACT3_XENLA,ACT4_CAEEL,# & ACT5_DIPDE,ACT8_DICDI,ACTB_ARATH,ACT2_BACDO,ACTC_ARATH,# & ACT2_ECHGR,ACT5_DROME,ACTB_ARATH,ACTA_HUMAN,ACT3_ARATH,# & ACT2_BOMMO,ACTM_HELER,ACT3_PODCA,ACT3_ORYSA,ACTA_LIMPO,# & ACTB_STRPU,ACTA_CHICK,ACTM_STYCL,ACT2_DICDI,ACTA_PHYPO,# & ACT3_SOYBN,ACT6_SOLTU,ACTA_LIMPO,ACT1_NAEFO,ACTM_HELER,# & ACT1_PODCA,ACT_SCHPO,ACTM_MOLOC,ACTA_STRPU,ACT_MANSE,# & ACTG_HUMAN,ACTM_STRPU,ACT5_CHICK,ACT5_XENLA,ACTB_HUMAN,# & ACTD_STRPU,ACT2_XENTR,ACT5_DIPDE,ACT3_DIPDE,ACT1_HELER,# & FGR_FSVGR,ACTC_PISOC,ACT2_HALRO,ACT3_FUGRU,ACT1_ECHGR,# & ACTH_HUMAN,ACT3_ARTSX,ACTM_PISOC,ACT1_DICDI,ACT1_ACACA,# & ACTM_HELTB,ACT_TOXGO)# & PIR1: (ATRBSM,ATRZ3,ATRB,ATDO,ATHUC,ATZM1,A43552,ATRT,A24904,# & ATMUM1,ATBOSM,ATHU,B29686,ATFY,ATFF8,ATHUG,ATMSB,ATMSG,# & A25719,A48324,A22224,ATRZ2,ATBOB,ATURS,ATRZ1,ATRBB,# & TVMVRR,A23022,ATBOG,ATAX,ATHUSM,ATRTC,ATCH,ATCHB,ATAXE,# & S11222,ATSY3,ATHUB,ATCHSM)# & PIR2: (S38782,JS0189,JC5227,S07382,S20098,S20097,A31375,S12730,# & S33386,A37431,S68089,S20094,B25819,S07003,S43509,S11450,# & S07288,S01077,S68109,A48449,S25488,S20093,S04538,JQ0154,# & A32788,JC1246,S07251,A45634,A43911,A54728,S47090,S20092,# & A29664,S68112,JC2008,S68108,S49479,A03000,S49480,S08596,# & JN0833,A29686,B23412,A26559,A55001,S58316,I49465,S11452,# & C43616,S16710,JN0832,A26836,A24848,JS0190,A54509,S09578,# & A40261,A54496,S68110,S05430,S11453,A61043,A25084,S21907,# & B24848,S47897,S12628,S26435,S16709,S33387,S27135,S47986,# & S42103,A25135,S31933,JC5228,S11451,S09059,S68090,A28258,# & S68107,S49481)# & PIR3: (S71119,A44940,S71125,S70377,S71124,S71118,S71126,# & S71120)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KRGILTLKY*# SEQUENCE: KRGILTLKY*# ...# >HUM10AA6# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRFGVGNKY*# SEQUENCE: GRFGVGNKY*# ...# >HUM10AA7# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRFKLIVLY*# SEQUENCE: GRFKLIVLY*# ...# >HUM10AA8# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: rat ribosomal protein L36# DB REFERENCE: SWISS: (RL36_RAT)# & PIR2: (JN0483)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRLTKHTKF*# SEQUENCE: GRLTKHTKF*# ...# >HUM10AA9# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human breast basic conserved protein (190-198)# DB REFERENCE: SWISS: (RL13_CHICK,RL13_HUMAN,RL13_RAT,RL13_CHICK)# & PIR2: (S23753,JC2368)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,ARLFGIRAK*# SEQUENCE: ARLFGIRAK*# ...# >HUM10AAA# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Position 4 (G or F), position 5 ?# SUMMARY: HLA-B27,actunkn,bindyesu,RRLGXQYRR*# SEQUENCE: RRLGXQYRR*# ...# >HUM10AAB# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Position 4 (G or F) position 5 ?# SUMMARY: HLA-B27,actunkn,bindyesu,RRLFXQYRR*# SEQUENCE: RRLFXQYRR*# ...# >HUM10AAC# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human immediate early-response gene# DB REFERENCE: PIR2: (I37018,I84441)# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRFGDKLNF*# SEQUENCE: RRFGDKLNF*# ...# >HUM10AAD# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Position 3 (V or F), position 8 (E or S)# SUMMARY: HLA-B27,actunkn,bindyesu,GRVFIIKEN*# SEQUENCE: GRVFIIKEN*# ...# >HUM10AAE# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Position 3 (V or F), position 8 (E or S)# SUMMARY: HLA-B27,actunkn,bindyesu,GRVFIIKSN*# SEQUENCE: GRVFIIKSN*# ...# >HUM10AAF# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Position 3 (V or F), position 8 (E or S)# SUMMARY: HLA-B27,actunkn,bindyesu,GRFFIIKEN*# SEQUENCE: GRFFIIKEN*# ...# >HUM10AB0# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Position 3 (V or F), position 8 (E or S)# SUMMARY: HLA-B27,actunkn,bindyesu,GRFFIIKSN*# SEQUENCE: GRFFIIKSN*# ...# >HUM10AB1# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXIFXRFGYH*# SEQUENCE: GRXXIFXRFGYH*# ...# >HUM10AB2# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXLFXRFGYH*# SEQUENCE: GRXXLFXRFGYH*# ...# >HUM10AB3# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXVFXRFGYH*# SEQUENCE: GRXXVFXRFGYH*# ...# >HUM10AB4# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXILXRFGYH*# SEQUENCE: GRXXILXRFGYH*# ...# >HUM10AB5# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXLLXRFGYH*# SEQUENCE: GRXXLLXRFGYH*# ...# >HUM10AB6# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXVLXRFGYH*# SEQUENCE: GRXXVLXRFGYH*# ...# >HUM10AB7# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXIFXNFGYH*# SEQUENCE: GRXXIFXNFGYH*# ...# >HUM10AB8# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXLFXNFGYH*# SEQUENCE: GRXXLFXNFGYH*# ...# >HUM10AB9# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXVFXNFGYH*# SEQUENCE: GRXXVFXNFGYH*# ...# >HUM10ABA# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXILXNFGYH*# SEQUENCE: GRXXILXNFGYH*# ...# >HUM10ABB# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXLLXNFGYH*# SEQUENCE: GRXXLLXNFGYH*# ...# >HUM10ABC# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXVLXNFGYH*# SEQUENCE: GRXXVLXNFGYH*# ...# >HUM10ABD# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXIFXRYGYH*# SEQUENCE: GRXXIFXRYGYH*# ...# >HUM10ABE# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXLFXRYGYH*# SEQUENCE: GRXXLFXRYGYH*# ...# >HUM10ABF# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXVFXRYGYH*# SEQUENCE: GRXXVFXRYGYH*# ...# >HUM10AC0# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXILXRYGYH*# SEQUENCE: GRXXILXRYGYH*# ...# >HUM10AC1# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXLLXRYGYH*# SEQUENCE: GRXXLLXRYGYH*# ...# >HUM10AC2# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXVLXRYGYH*# SEQUENCE: GRXXVLXRYGYH*# ...# >HUM10AC3# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXIFXNYGYH*# SEQUENCE: GRXXIFXNYGYH*# ...# >HUM10AC4# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXLFXNYGYH*# SEQUENCE: GRXXLFXNYGYH*# ...# >HUM10AC5# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXVFXNYGYH*# SEQUENCE: GRXXVFXNYGYH*# ...# >HUM10AC6# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXILXNYGYH*# SEQUENCE: GRXXILXNYGYH*# ...# >HUM10AC7# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXLLXNYGYH*# SEQUENCE: GRXXLLXNYGYH*# ...# >HUM10AC8# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Pos 5(I or L or V), pos 6 (F or L), pos 8 (R or N), pos 9 (F or Y)# SUMMARY: HLA-B27,actunkn,bindyesu,GRXXVLXNYGYH*# SEQUENCE: GRXXVLXNYGYH*# ...# >HUM10AC9# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human cytochrome P450# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,TRYPILAGH*# SEQUENCE: TRYPILAGH*# ...# >HUM10ACA# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRISGVDRY*# SEQUENCE: RRISGVDRY*# ...# >HUM10ACB# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: cattle myristoilated alanine-rich C-kinase substrate (155-163)# DB REFERENCE: SWISS: (MACS_RAT,MACS_CHICK,MACS_BOVIN,MACS_HUMAN,MACS_MOUSE)# & PIR2: (A38873,A41400,A39773,S08341,A39169)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KRFSFKKSF*# SEQUENCE: KRFSFKKSF*# ...# >HUM10ACC# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: rat core histone# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,ARLQTALL*# SEQUENCE: ARLQTALL*# ...# >HUM10ACD# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIS 11 B protein (325-333)# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRXPIFSRL*# SEQUENCE: RRXPIFSRL*# ...# >HUM10ACE# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homologous to proteasome subunit C5 (127-135)# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Position 5 (Q or P)# SUMMARY: HLA-B27,actunkn,bindyesu,RRFMQYYVY*# SEQUENCE: RRFMQYYVY*# ...# >HUM10ACF# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rotzschke94a# COMMENT: Position 5 (Q or P)# SUMMARY: HLA-B27,actunkn,bindyesu,RRFMPYYVY*# SEQUENCE: RRFMPYYVY*# ...# >HUM10AD0# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human HSP 86 (200-209)# DB REFERENCE: SWISS: (HS9A_HUMAN,HS9A_CHICK,HS9A_MOUSE,HS9A_CRIGR,# & HS9A_MOUSE)# & PIR1: (HHCH90,HHHU86,HHMS86)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRIKEIVKKH*# SEQUENCE: RRIKEIVKKH*# ...# >HUM10AD1# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human ribonucleoprotein L (312-322)# DB REFERENCE: SWISS: (ROL_HUMAN)# & PIR2: (A33616)# REFERENCES: rotzschke94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRMGPPVGGHR*# SEQUENCE: RRMGPPVGGHR*# ...# >HUM20AD2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin receptor (142-155)# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,TGTIKLLNENSYVP*# SEQUENCE: TGTIKLLNENSYVP*# ...# >HUM20AD3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin receptor (144-155)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,TIKLLNENSYVPR*# SEQUENCE: TIKLLNENSYVPR*# ...# >HUM20AD4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin receptor (141-156)# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,FTGTIKLLNENSYVPR*# SEQUENCE: FTGTIKLLNENSYVPR*# ...# >HUM20AD5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin receptor (141-156) reverse# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,RPVYSNENLLKITGTF*# SEQUENCE: RPVYSNENLLKITGTF*# ...# >HUM20AD6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin receptor (140-156)# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DFTGTIKLLNENSYVPR*# SEQUENCE: DFTGTIKLLNENSYVPR*# ...# >HUM20AD7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA class I B-38 (104-121)# DB REFERENCE: SWISS: (1C11_HUMAN)# & PIR2: (I37078)# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,GPDGRLLRGYDQFAYDGK*# SEQUENCE: GPDGRLLRGYDQFAYDGK*# ...# >HUM20AD8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA class I (104-119)# DB REFERENCE: SWISS: (1C11_HUMAN)# & PIR2: (I37078)# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,GPDGRLLRGYDQFAYD*# SEQUENCE: GPDGRLLRGYDQFAYD*# ...# >HUM20AD9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: valosin-containing protein p97 (78-93)# DB REFERENCE: SWISS: (TERA_MOUSE,TERA_RAT,TERA_XENLA,TERA_PIG)# & PIR1: (S25197,S19738,VPPG,A55190)# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,SDEKIRMNRVVRNNLR*# SEQUENCE: SDEKIRMNRVVRNNLR*# ...# >HUM20ADA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,EALIHQLKINPYVLS*# SEQUENCE: EALIHQLKINPYVLS*# ...# >HUM20ADB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA class I A2# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VGDDWRFLRGYHQYA*# SEQUENCE: VGDDWRFLRGYHQYA*# ...# >HUM20ADC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Na+K+ ATPase (199-216)# DB REFERENCE: SWISS: (ATN1_HUMAN,ATN1_RAT,ATN1_SHEEP,ATN1_PIG,ATN3_PIG,# & ATN1_HUMAN,ATN1_CANFA,ATN1_HORSE)# & PIR1: (PWSHNA,S04630)# & PIR2: (A24414,B24862,S20970,A24639)# REFERENCES: falk94a,rotzschke94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,IPADLRIISANGCK*# SEQUENCE: IPADLRIISANGCK*# ...# >HUM20ADD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RVEYHFLSPYVSP*# SEQUENCE: RVEYHFLSPYVSP*# ...# >HUM20ADE# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: bovine fetuin# DB REFERENCE: SWISS: (A2HS_SHEEP,A2HS_BOVIN,A2HS_SHEEP,A2HS_BOVIN)# & PIR2: (A35714,S22394)# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LNQIDSVKVW*# SEQUENCE: LNQIDSVKVW*# ...# >HUM20ADF# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,AILEFRAMAQFSRKTD*# SEQUENCE: AILEFRAMAQFSRKTD*# ...# >HUM20AE0# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DPw4,actunkn,bindyesu,EKKYFAATQFEPLAARL*# SEQUENCE: EKKYFAATQFEPLAARL*# ...# >HUM20AE1# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DPw4,actunkn,bindyesu,KKYFAATQFEPLAARL*# SEQUENCE: KKYFAATQFEPLAARL*# ...# >HUM20AE2# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DPw4,actunkn,bindyesu,EKKYFAATQFEPL*# SEQUENCE: EKKYFAATQFEPL*# ...# >HUM20AE3# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IL-3 receptor alpha-chain (127-146)# DB REFERENCE: SWISS: (IL3R_HUMAN,IL3R_HUMAN)# & PIR2: (A40266)# REFERENCES: falk94a,rotzschke94b# COMMENT:# SUMMARY: HLA-DPw4,actunkn,bindyesu,GPGAPADVQYDLYLNVANRR*# SEQUENCE: GPGAPADVQYDLYLNVANRR*# ...# >HUM20AE4# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: invariant chain (111-125)/CLIP# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: falk94a,rotzschke94b,malcherek95a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,TPLLMQALPMGALPQ*# SEQUENCE: TPLLMQALPMGALPQ*# ...# >HUM20AE5# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: invariant chain (111-126)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,TPLLMQALPMGALPQG*# SEQUENCE: TPLLMQALPMGALPQG*# ...# >HUM20AE6# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: invariant chain (99-117)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,KPPKPVSKMRMATPLLMQA*# SEQUENCE: KPPKPVSKMRMATPLLMQA*# ...# >HUM20AE7# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: invariant chain (97-115), CLIP# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: falk94a,malcherek95a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,LPKPPKPVSKMRMATPLLM*# SEQUENCE: LPKPPKPVSKMRMATPLLM*# ...# >HUM20AE8# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin receptor (579-597)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,IPELNKVARAAAEVAGQF*# SEQUENCE: IPELNKVARAAAEVAGQF*# ...# >HUM20AE9# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DQ beta chain (43-55)# DB REFERENCE: PIR2: (A32339,A35056,I55996,I79496,A35055,F30575,I54288,# & I54454)# REFERENCES: falk94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,DVEVYRAVTPLGP*# SEQUENCE: DVEVYRAVTPLGP*# ...# >HUM10AEA# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesu,AYIDNVYKF*# SEQUENCE: AYIDNVYKF*# ...# >HUM10AEB# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,ATAKAAAAY*# SEQUENCE: ATAKAAAAY*# ...# >HUM10AEC# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,AADKAAAAY*# SEQUENCE: AADKAAAAY*# ...# >HUM10AED# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,ATDKAAAAY*# SEQUENCE: ATDKAAAAY*# ...# >HUM10AEE# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,ATAKAAAAAY*# SEQUENCE: ATAKAAAAAY*# ...# >HUM10AEF# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,AADKAAAAAY*# SEQUENCE: AADKAAAAAY*# ...# >HUM10AF0# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,ATDKAAAAAY*# SEQUENCE: ATDKAAAAAY*# ...# >HUM10AF1# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ATAKAAAAY*# SEQUENCE: ATAKAAAAY*# ...# >HUM10AF2# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ATDKAAAAY*# SEQUENCE: ATDKAAAAY*# ...# >HUM10AF3# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ALAAAAAAK*# SEQUENCE: ALAAAAAAK*# ...# >HUM10AF4# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ATAAAAAAK*# SEQUENCE: ATAAAAAAK*# ...# >HUM10AF5# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ATAKAAAAAY*# SEQUENCE: ATAKAAAAAY*# ...# >HUM10AF6# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ATDKAAAAAY*# SEQUENCE: ATDKAAAAAY*# ...# >HUM10AF7# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ALAAAAAAAK*# SEQUENCE: ALAAAAAAAK*# ...# >HUM10AF8# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ATAKAAAAAK*# SEQUENCE: ATAKAAAAAK*# ...# >HUM10AF9# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ATAKAAAAY*# SEQUENCE: ATAKAAAAY*# ...# >HUM10AFA# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,ATDKAAAAAY*# SEQUENCE: ATDKAAAAAY*# ...# >HUM10AFB# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ALAAAAAAK*# SEQUENCE: ALAAAAAAK*# ...# >HUM10AFC# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ATAKAAAAK*# SEQUENCE: ATAKAAAAK*# ...# >HUM10AFD# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,ATAKAAAAAY*# SEQUENCE: ATAKAAAAAY*# ...# >HUM10AFE# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ALAAAAAAAK*# SEQUENCE: ALAAAAAAAK*# ...# >HUM10AFF# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AYAKAAAAF*# SEQUENCE: AYAKAAAAF*# ...# >HUM10B00# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AYAKAAAAAF*# SEQUENCE: AYAKAAAAAF*# ...# >HUM10B01# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,AMAAAAAAK*# SEQUENCE: AMAAAAAAK*# ...# >HUM10B02# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,AVAAAAAAK*# SEQUENCE: AVAAAAAAK*# ...# >HUM10B03# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ASAAAAAAK*# SEQUENCE: ASAAAAAAK*# ...# >HUM10B04# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (RL14_RAT)# & PIR2: (JC4808)# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,AIAAAAAAK*# SEQUENCE: AIAAAAAAK*# ...# >HUM10B05# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (RL14_HUMAN,HME1_HUMAN,ELS_BOVIN,FMRA_ANTEL,YFC4_YEAST,# & ELS_HUMAN,ELS_BOVIN,VPHE_NPVLD,ELS_MOUSE,RL14_HUMAN,# & ELS_HUMAN,ELS_RAT)# & PIR1: (EAMS,JQ1559,EART,EAHU,EABO)# & PIR2: (B48423,JC5273,S43568,A44308,S59623,S56230)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,AAAAAAAAK*# SEQUENCE: AAAAAAAAK*# ...# >HUM10B06# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,AFAAAAAAK*# SEQUENCE: AFAAAAAAK*# ...# >HUM10B07# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (ELS_CHICK)# & PIR2: (A26601)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,AGAAAAAAK*# SEQUENCE: AGAAAAAAK*# ...# >HUM10B08# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ACAAAAAAK*# SEQUENCE: ACAAAAAAK*# ...# >HUM10B09# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (ANP5_MYOAE)# & PIR1: (FDFI5G)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ADAAAAAAK*# SEQUENCE: ADAAAAAAK*# ...# >HUM10B0A# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ALAAAAAAR*# SEQUENCE: ALAAAAAAR*# ...# >HUM10B0B# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ALAAAAAAY*# SEQUENCE: ALAAAAAAY*# ...# >HUM10B0C# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (SP20_YEAST,SP20_YEAST)# & PIR2: (S58643)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ALAAAAAAA*# SEQUENCE: ALAAAAAAA*# ...# >HUM10B0D# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AMAAAAAAK*# SEQUENCE: AMAAAAAAK*# ...# >HUM10B0E# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (ELS_BOVIN,FMRA_ANTEL,RL14_HUMAN,ELS_MOUSE,ELS_BOVIN,# & VPHE_NPVLD,HME1_HUMAN,ELS_HUMAN,ELS_RAT,RL14_HUMAN,# & ELS_HUMAN,YFC4_YEAST)# & PIR1: (JQ1559,EART,EAHU,EAMS,EABO)# & PIR2: (S43568,A44308,B48423,JC5273,S59623,S56230)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AAAAAAAAK*# SEQUENCE: AAAAAAAAK*# ...# >HUM10B0F# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (RL14_RAT)# & PIR2: (JC4808)# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AIAAAAAAK*# SEQUENCE: AIAAAAAAK*# ...# >HUM10B10# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ATAAAAAAK*# SEQUENCE: ATAAAAAAK*# ...# >HUM10B11# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AVAAAAAAK*# SEQUENCE: AVAAAAAAK*# ...# >HUM10B12# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ASAAAAAAK*# SEQUENCE: ASAAAAAAK*# ...# >HUM10B13# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (ELS_CHICK)# & PIR2: (A26601)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AGAAAAAAK*# SEQUENCE: AGAAAAAAK*# ...# >HUM10B14# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ANAAAAAAK*# SEQUENCE: ANAAAAAAK*# ...# >HUM10B15# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,ACAAAAAAK*# SEQUENCE: ACAAAAAAK*# ...# >HUM10B16# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,AFAAAAAAK*# SEQUENCE: AFAAAAAAK*# ...# >HUM10B17# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (ANP5_MYOAE)# & PIR1: (FDFI5G)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,ADAAAAAAK*# SEQUENCE: ADAAAAAAK*# ...# >HUM10B18# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# DB REFERENCE: SWISS: (FDH_NEUCR)# & PIR2: (A47117)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,AKAAAAAAK*# SEQUENCE: AKAAAAAAK*# ...# >HUM10B19# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,ALAAAAAAR*# SEQUENCE: ALAAAAAAR*# ...# >HUM10B1A# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,AFAKAAAAF*# SEQUENCE: AFAKAAAAF*# ...# >HUM10B1B# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,AMAKAAAAF*# SEQUENCE: AMAKAAAAF*# ...# >HUM10B1C# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,APAKAAAAF*# SEQUENCE: APAKAAAAF*# ...# >HUM10B1D# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AYAKAAAAW*# SEQUENCE: AYAKAAAAW*# ...# >HUM10B1E# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,AYAKAAAAI*# SEQUENCE: AYAKAAAAI*# ...# >HUM10B1F# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,AYAKAAAAL*# SEQUENCE: AYAKAAAAL*# ...# >HUM10B20# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,ASAKAAAAY*# SEQUENCE: ASAKAAAAY*# ...# >HUM10B21# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,AMAKAAAAY*# SEQUENCE: AMAKAAAAY*# ...# >HUM10B22# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,AAAKAAAAY*# SEQUENCE: AAAKAAAAY*# ...# >HUM10B23# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,AIAKAAAAY*# SEQUENCE: AIAKAAAAY*# ...# >HUM10B24# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,ALAKAAAAY*# SEQUENCE: ALAKAAAAY*# ...# >HUM10B25# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,AVAKAAAAY*# SEQUENCE: AVAKAAAAY*# ...# >HUM10B26# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,AKAKAAAAY*# SEQUENCE: AKAKAAAAY*# ...# >HUM10B27# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,ATAKAAAAA*# SEQUENCE: ATAKAAAAA*# ...# >HUM10B28# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,ATAKAAAAF*# SEQUENCE: ATAKAAAAF*# ...# >HUM10B29# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,ATAKAAAAH*# SEQUENCE: ATAKAAAAH*# ...# >HUM10B2A# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,AAEKAAAAY*# SEQUENCE: AAEKAAAAY*# ...# >HUM10B2B# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,AASKAAAAY*# SEQUENCE: AASKAAAAY*# ...# >HUM10B2C# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,AANKAAAAY*# SEQUENCE: AANKAAAAY*# ...# >HUM10B2D# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,AAQKAAAAY*# SEQUENCE: AAQKAAAAY*# ...# >HUM10B2E# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,AADKAAAAA*# SEQUENCE: AADKAAAAA*# ...# >HUM10B2F# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,AADKAAAAW*# SEQUENCE: AADKAAAAW*# ...# >HUM10B30# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) Cytochrome C oxidase C# DB REFERENCE: SWISS: (COX2_GORBE,COX2_CERGA,COX2_PAPAN,COX2_CERAE,COX2_MACMU,# & COX2_PANPA,COX2_MACFA,COX2_PANTR,COX2_PONPY,COX2_HUMAN,# & COX2_GORGO,COX2_HYLLA,COX2_HYLSY,COX2_THEGE,# & COX2_MANLE)# & PIR1: (OBHU2)# & PIR2: (I37046,I37050,A27420,I84443,I61892,I84421,I37028,I61891,# & I61893)# & PIR3: (I36905,I61849,I61850,I36932,I36925,I84424)# REFERENCES: kubo94a,falk94c# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,YTDYGGLIFNSY*# SEQUENCE: YTDYGGLIFNSY*# ...# >HUM10B31# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) Cytosine methyl transpherase# DB REFERENCE: SWISS: (MTDM_HUMAN)# & PIR2: (JC5145,S22610)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,YLDDPDLKY*# SEQUENCE: YLDDPDLKY*# ...# >HUM10B32# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) Prolif. Cell Nucl. factor# DB REFERENCE: SWISS: (PCNA_MOUSE,PCNA_RAT,PCNA_HUMAN)# & PIR1: (WMMS,WMHUET,WMRTET)# & PIR2: (I48707)# REFERENCES: kubo94a,falk94c# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,IADMGHLKY*# SEQUENCE: IADMGHLKY*# ...# >HUM10B33# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Transforming prot. (ets-1)# DB REFERENCE: SWISS: (ETS1_RAT,ETSA_CHICK,ETSB_CHICK,ETSA_XENLA,MYBE_AVILE,# & ETS1_MOUSE,ETS1_HUMAN)# & PIR1: (A53988,TVFVES,TVHUET,TVCHTE,A35875,S11225,TVCHET)# REFERENCES: kubo94a,falk94c# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,YTSDYFISY*# SEQUENCE: YTSDYFISY*# ...# >HUM10B34# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) Fructose-6-p-amino transfer.# DB REFERENCE: SWISS: (GFAT_MOUSE,GFAT_HUMAN)# & PIR2: (A45055)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,STDHIPILY*# SEQUENCE: STDHIPILY*# ...# >HUM10B35# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) Human J-chain (102-110)# DB REFERENCE: SWISS: (IGJ_HUMAN,IGJ_HUMAN)# & PIR1: (JIHU)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,YTAVVPLVY*# SEQUENCE: YTAVVPLVY*# ...# >HUM10B36# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) Ig gamma-4 (279-287)# DB REFERENCE: SWISS: (GC1_HUMAN,GC2_HUMAN,GC4_HUMAN,GC3_HUMAN)# & PIR1: (GHHU,G2HU,G4HU,G3HUWI)# & PIR2: (PT0207,A23511,S72664,A60764,S69340,A36040)# & PIR3: (S69339)# & PIR4: (S31866)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,DSDGSFFLY*# SEQUENCE: DSDGSFFLY*# ...# >HUM10B37# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) Cyclin Prot. D Type# DB REFERENCE: SWISS: (CGD2_RAT,CGD2_HUMAN,CGD2_MOUSE,CGD2_HUMAN)# & PIR2: (A42822,A41984,I58372,JC4011)# REFERENCES: kubo94a,falk94c# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesh,ATDFKFAMY*# SEQUENCE: ATDFKFAMY*# ...# >HUM10B38# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 5 (I or L), position 8 (Ior L)# SUMMARY: HLA-A1,actunkn,bindyesh,GTDEIRNIY*# SEQUENCE: GTDEIRNIY*# ...# >HUM10B39# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 5 (I or L), position 8 (Ior L)# SUMMARY: HLA-A1,actunkn,bindyesh,GTDEIRNLY*# SEQUENCE: GTDEIRNLY*# ...# >HUM10B3A# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 5 (I or L), position 8 (Ior L)# SUMMARY: HLA-A1,actunkn,bindyesh,GTDELRNIY*# SEQUENCE: GTDELRNIY*# ...# >HUM10B3B# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 5 (I or L), position 8 (Ior L)# SUMMARY: HLA-A1,actunkn,bindyesh,GTDELRNLY*# SEQUENCE: GTDELRNLY*# ...# >HUM10B3C# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L), position 5 (I or L), position 6 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETDIIIDRSEY*# SEQUENCE: ETDIIIDRSEY*# ...# >HUM10B3D# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L), position 5 (I or L), position 6 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETDIILDRSEY*# SEQUENCE: ETDIILDRSEY*# ...# >HUM10B3E# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L), position 5 (I or L), position 6 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETDILIDRSEY*# SEQUENCE: ETDILIDRSEY*# ...# >HUM10B3F# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L), position 5 (I or L), position 6 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETDILLDRSEY*# SEQUENCE: ETDILLDRSEY*# ...# >HUM10B40# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L), position 5 (I or L), position 6 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETDLIIDRSEY*# SEQUENCE: ETDLIIDRSEY*# ...# >HUM10B41# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L), position 5 (I or L), position 6 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETDLILDRSEY*# SEQUENCE: ETDLILDRSEY*# ...# >HUM10B42# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L), position 5 (I or L), position 6 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETDLLIDRSEY*# SEQUENCE: ETDLLIDRSEY*# ...# >HUM10B43# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L), position 5 (I or L), position 6 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETDLLLDRSEY*# SEQUENCE: ETDLLLDRSEY*# ...# >HUM10B44# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesh,FTDVNSIIRY*# SEQUENCE: FTDVNSIIRY*# ...# >HUM10B45# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesh,FTDVNSILRY*# SEQUENCE: FTDVNSILRY*# ...# >HUM10B46# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesh,FTDVNSLIRY*# SEQUENCE: FTDVNSLIRY*# ...# >HUM10B47# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesh,FTDVNSLLRY*# SEQUENCE: FTDVNSLLRY*# ...# >HUM10B48# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,YTNPQFNVY*# SEQUENCE: YTNPQFNVY*# ...# >HUM10B49# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 2 (I or L), position 7 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,VIDPYNIKY*# SEQUENCE: VIDPYNIKY*# ...# >HUM10B4A# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 2 (I or L), position 7 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,VIDPYNLKY*# SEQUENCE: VIDPYNLKY*# ...# >HUM10B4B# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 2 (I or L), position 7 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,VLDPYNIKY*# SEQUENCE: VLDPYNIKY*# ...# >HUM10B4C# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 2 (I or L), position 7 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,VLDPYNLKY*# SEQUENCE: VLDPYNLKY*# ...# >HUM10B4D# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,VADKVHIMY*# SEQUENCE: VADKVHIMY*# ...# >HUM10B4E# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# DB REFERENCE: PIR2: (A49656)# REFERENCES: kubo94a# COMMENT: Position 7 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,VADKVHLMY*# SEQUENCE: VADKVHLMY*# ...# >HUM10B4F# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 3 (I or L), position 4 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETIIPDWSY*# SEQUENCE: ETIIPDWSY*# ...# >HUM10B50# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 3 (I or L), position 4 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETILPDWSY*# SEQUENCE: ETILPDWSY*# ...# >HUM10B51# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 3 (I or L), position 4 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETLIPDWSY*# SEQUENCE: ETLIPDWSY*# ...# >HUM10B52# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 3 (I or L), position 4 (I or L)# SUMMARY: HLA-A1,actunkn,bindyesm,ETLLPDWSY*# SEQUENCE: ETLLPDWSY*# ...# >HUM10B53# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Ribosomal protein S3# DB REFERENCE: SWISS: (RS3B_XENLA,RS3_HUMAN,RS3A_XENLA,RS3_AMBME,RS3_RAT)# & PIR1: (R3HUS3,R3RT3,R3XL3A)# & PIR2: (I51635,S41170)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,RTQNVLGEK*# SEQUENCE: RTQNVLGEK*# ...# >HUM10B54# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Ribosomal protein S6# DB REFERENCE: SWISS: (RS6_TOBAC,RS6_CHICK,RS6_CHICK,RS6_TOBAC,RS6_HUMAN)# & PIR1: (R3MS6,R3RTS6,R3HU6)# & PIR2: (S25550,JC4145)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,SVLNLVIVK*# SEQUENCE: SVLNLVIVK*# ...# >HUM10B55# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Thymosin B-10# DB REFERENCE: SWISS: (TYB0_HUMAN,TYB0_HUMAN)# & PIR2: (A27704,A27266)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ASFDKAKLK*# SEQUENCE: ASFDKAKLK*# ...# >HUM10B56# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Ribosomal protein L7A-Rat# DB REFERENCE: SWISS: (RL7A_HUMAN,RL7A_CHICK,RL7A_MOUSE)# & PIR1: (R5HU7A,R5RT7A,S18159)# & PIR2: (A30241)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,KVVNPLFEK*# SEQUENCE: KVVNPLFEK*# ...# >HUM10B57# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Rat prohibitin# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A11,actunkn,bindyesm,ATAGDGIIELRK*# SEQUENCE: ATAGDGIIELRK*# ...# >HUM10B58# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Rat prohibitin# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A11,actunkn,bindyesm,ATAGDGILELRK*# SEQUENCE: ATAGDGILELRK*# ...# >HUM10B59# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Rat prohibitin# DB REFERENCE: SWISS: (PHB_RAT,PHB_HUMAN)# & PIR2: (A39682,I52690)# REFERENCES: kubo94a,falk94c# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A11,actunkn,bindyesm,ATAGDGLIELRK*# SEQUENCE: ATAGDGLIELRK*# ...# >HUM10B5A# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Rat prohibitin# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A11,actunkn,bindyesm,ATAGDGLLELRK*# SEQUENCE: ATAGDGLLELRK*# ...# >HUM10B5B# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L)# SUMMARY: HLA-A11,actunkn,bindyesm,AAMIDTVVFK*# SEQUENCE: AAMIDTVVFK*# ...# >HUM10B5C# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L)# SUMMARY: HLA-A11,actunkn,bindyesm,AAMLDTVVFK*# SEQUENCE: AAMLDTVVFK*# ...# >HUM10B5D# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L)# SUMMARY: HLA-A11,actunkn,bindyesh,GTMTTSIYK*# SEQUENCE: GTMTTSIYK*# ...# >HUM10B5E# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L)# SUMMARY: HLA-A11,actunkn,bindyesh,GTMTTSLYK*# SEQUENCE: GTMTTSLYK*# ...# >HUM10B5F# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,RVEQAVESMVK*# SEQUENCE: RVEQAVESMVK*# ...# >HUM10B60# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Ribosomal protein S6# DB REFERENCE: SWISS: (RS6_CHICK,RS6_TOBAC,RS6_TOBAC,RS6_CHICK,RS6_HUMAN)# & PIR1: (R3MS6,R3RTS6,R3HU6)# & PIR2: (JC4145,S25550)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,SVLNLVIVK*# SEQUENCE: SVLNLVIVK*# ...# >HUM10B61# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Thymosin B-10# DB REFERENCE: SWISS: (TYB0_HUMAN,TYB0_HUMAN)# & PIR2: (A27266,A27704)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ASFDKAKLK*# SEQUENCE: ASFDKAKLK*# ...# >HUM10B62# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Ribosomal protein L7A-Rat# DB REFERENCE: SWISS: (RL7A_CHICK,RL7A_HUMAN,RL7A_MOUSE)# & PIR1: (R5HU7A,R5RT7A,S18159)# & PIR2: (A30241)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,KVVNPLFEK*# SEQUENCE: KVVNPLFEK*# ...# >HUM10B63# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: (nat) Rat prohibitin# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A3,actunkn,bindyesl,ATAGDGIIELRK*# SEQUENCE: ATAGDGIIELRK*# ...# >HUM10B64# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: (nat) Rat prohibitin# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A3,actunkn,bindyesl,ATAGDGILELRK*# SEQUENCE: ATAGDGILELRK*# ...# >HUM10B65# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: (nat) Rat prohibitin# DB REFERENCE: SWISS: (PHB_RAT,PHB_HUMAN)# & PIR2: (I52690,A39682)# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A3,actunkn,bindyesl,ATAGDGLIELRK*# SEQUENCE: ATAGDGLIELRK*# ...# >HUM10B66# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: (nat) Rat prohibitin# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L), position 8 (I or L)# SUMMARY: HLA-A3,actunkn,bindyesl,ATAGDGLLELRK*# SEQUENCE: ATAGDGLLELRK*# ...# >HUM10B67# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L)# SUMMARY: HLA-A3,actunkn,bindyesm,AAMIDTVVFK*# SEQUENCE: AAMIDTVVFK*# ...# >HUM10B68# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 4 (I or L)# SUMMARY: HLA-A3,actunkn,bindyesm,AAMLDTVVFK*# SEQUENCE: AAMLDTVVFK*# ...# >HUM10B69# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L)# SUMMARY: HLA-A3,actunkn,bindyesh,GTMTTSIYK*# SEQUENCE: GTMTTSIYK*# ...# >HUM10B6A# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 7 (I or L)# SUMMARY: HLA-A3,actunkn,bindyesh,GTMTTSLYK*# SEQUENCE: GTMTTSLYK*# ...# >HUM10B6B# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, little# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,RVEQAVESMVK*# SEQUENCE: RVEQAVESMVK*# ...# >HUM10B6C# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) Phospho prot. phosphatatse-1 (91-99)# DB REFERENCE: SWISS: (PP11_ARATH,PP1A_HUMAN,PP1_ORYSA,PP12_ARATH,PP1G_XENLA,# & PPZ1_YEAST,PPZ2_YEAST,PP15_ARATH,PP1G_RAT,PP1B_DROME,# & PP1G_RAT,PP1B_HUMAN,PP12_SCHPO,PP1_MAIZE,PP12_RABIT,# & YME1_CAEEL,PP1_BRAOL,PP1G_HUMAN,PP1A_HUMAN,PP1B_HUMAN)# & PIR1: (PABY12,PARB11)# & PIR2: (JX0157,S31089,I76571,I73630,C32550,S35699,I76572,B32550,# & D32550,I76573,S35700,S24264,S41052,S13828,I56556,S31086,# & S26225,S29310,S35674,A46240,S13829,JN0723,S29317,# & S20882)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,KYPENFFLL*# SEQUENCE: KYPENFFLL*# ...# >HUM10B6D# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) Unk. Prot. Act. K+ T cell# DB REFERENCE: SWISS: (NK4_HUMAN)# & PIR2: (I56140)# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,YYEEQHPEL*# SEQUENCE: YYEEQHPEL*# ...# >HUM10B6E# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: (nat) ?# DB REFERENCE: SWISS: (TEGT_HUMAN,TEGT_HUMAN)# & PIR2: (I38334)# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AYVHMVTHF*# SEQUENCE: AYVHMVTHF*# ...# >HUM10B6F# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 3 (I or L), position 9 (I or L)# SUMMARY: HLA-A24,actunkn,bindyesh,VYIKHPVSI*# SEQUENCE: VYIKHPVSI*# ...# >HUM10B70# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# DB REFERENCE: SWISS: (PP31_HUMAN)# & PIR2: (S56108)# REFERENCES: kubo94a# COMMENT: Position 3 (I or L), position 9 (I or L)# SUMMARY: HLA-A24,actunkn,bindyesh,VYIKHPVSL*# SEQUENCE: VYIKHPVSL*# ...# >HUM10B71# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 3 (I or L), position 9 (I or L)# SUMMARY: HLA-A24,actunkn,bindyesh,VYLKHPVSI*# SEQUENCE: VYLKHPVSI*# ...# >HUM10B72# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: (nat) ?# ANCHOR POSITIONS:# REFERENCES: kubo94a# COMMENT: Position 3 (I or L), position 9 (I or L)# SUMMARY: HLA-A24,actunkn,bindyesh,VYLKHPVSL*# SEQUENCE: VYLKHPVSL*# ...# >HUM10B73# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a,kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,YLEPAIAKY*# SEQUENCE: YLEPAIAKY*# ...# >HUM10B74# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./Competition/Refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV Core (18-27) homologue# ANCHOR POSITIONS:# REFERENCES: kast94a,del_guercio95a,parkhurst96a,rivoltini96a,tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM10B75# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,KVFPYALINK*# SEQUENCE: KVFPYALINK*# ...# >HUM10B76# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a,kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AVDLYHFLK*# SEQUENCE: AVDLYHFLK*# ...# >HUM10B77# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: putative motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a,kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AYIDNYNKF*# SEQUENCE: AYIDNYNKF*# ...# >HUM10B78# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1ND,GAG_HV1B5,GAG_HV1J3,GAG_HV1JR,# & GAG_HV1Y2,GAG_HV1Z2,GAG_HV1A2,GAG_HV1EL,GAG_HV1C4,# & GAG_HV1PV,GAG_HV1B1,GAG_HV1N5,GAG_HV1BR,GAG_HV1MA,# & GAG_HV1RH)# & PIR1: (FOVWH4,FOVWA2,FOVWH3,FOVWLV,FOLJND,A44001)# & PIR2: (S54377)# & PIR3: (S33979)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLQSRPEPT*# SEQUENCE: FLQSRPEPT*# ...# >HUM10B79# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: human papillomavirus 16 E6 (85-95)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,HYCYSLYGTTL*# SEQUENCE: HYCYSLYGTTL*# ...# >HUM10B7A# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: human papillomavirus 16 E6 (66-76)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,PYAVCDKCLKF*# SEQUENCE: PYAVCDKCLKF*# ...# >HUM10B7B# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: human papillomavirus 16 E6 (89-99)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,SLYGTTLEQQY*# SEQUENCE: SLYGTTLEQQY*# ...# >HUM10B7C# MHC MOLECULE: HLA-A1(A*0101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (80-88)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,ISEYRHYCY*# SEQUENCE: ISEYRHYCY*# ...# >HUM10B7D# MHC MOLECULE: HLA-A1(A*0101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E7 (44-52)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,QAEPDRAHY*# SEQUENCE: QAEPDRAHY*# ...# >HUM10B7E# MHC MOLECULE: HLA-A1(A*0101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E7 (37-45)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,EIDGPAGQA*# SEQUENCE: EIDGPAGQA*# ...# >HUM10B7F# MHC MOLECULE: HLA-A1(A*0101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E7 (73-81)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,HVDIRTLED*# SEQUENCE: HVDIRTLED*# ...# >HUM10B80# MHC MOLECULE: HLA-A1(A*0101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E7 (19-27)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,TTDLYCYEQ*# SEQUENCE: TTDLYCYEQ*# ...# >HUM10B81# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: human papillomavirus 16 E7 (82-90)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,sette94b,ressing95a,wentworth96a,van_der_burg95a,# & van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLMGTLGIV*# SEQUENCE: LLMGTLGIV*# ...# >HUM10B82# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (11-19)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YMLDLQPET*# SEQUENCE: YMLDLQPET*# ...# >HUM10B83# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (52-60)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,sette94b,frumento93a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FAFRDLCIV*# SEQUENCE: FAFRDLCIV*# ...# >HUM10B84# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competitive binding as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (86-94)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,wentworth96a,van_der_burg95a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesm,TLGIVCPIC*# SEQUENCE: TLGIVCPIC*# ...# >HUM10B85# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (7-15)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,sette94b,ressing95a,wentworth96a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,TLHEYMLDL*# SEQUENCE: TLHEYMLDL*# ...# >HUM10B86# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (85-93)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GTLGIVCPI*# SEQUENCE: GTLGIVCPI*# ...# >HUM10B87# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response/competitive binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (18-26)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,sette94b,ressing95a,van_der_burg95a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KLPQLCTEL*# SEQUENCE: KLPQLCTEL*# ...# >HUM10B88# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (12-20)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,MLDLQPETT*# SEQUENCE: MLDLQPETT*# ...# >HUM10B89# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response/competitive binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (7-15)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,ressing95a,van_der_burg95a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AMFQDPQER*# SEQUENCE: AMFQDPQER*# ...# >HUM10B8A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response/competitive binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (26-34)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,ressing95a,van_der_burg95a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LQTTIHDII*# SEQUENCE: LQTTIHDII*# ...# >HUM10B8B# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: human papillomavirus 16 E6 (59-67)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,IVYRDGNPY*# SEQUENCE: IVYRDGNPY*# ...# >HUM10B8C# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (125-133)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,HLDKKQRFH*# SEQUENCE: HLDKKQRFH*# ...# >HUM10B8D# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (7-15)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,AMFQDPQER*# SEQUENCE: AMFQDPQER*# ...# >HUM10B8E# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (93-101)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,TTLEQQYNK*# SEQUENCE: TTLEQQYNK*# ...# >HUM10B8F# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E7 (89-97)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,IVCPICSQK*# SEQUENCE: IVCPICSQK*# ...# >HUM10B90# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (75-83)# DB REFERENCE: SWISS: (VE6_HPV35,VE6_HPV16)# & PIR1: (W6WL35,W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,KFYSKISEY*# SEQUENCE: KFYSKISEY*# ...# >HUM10B91# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (33-41)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,IILECVYCK*# SEQUENCE: IILECVYCK*# ...# >HUM10B92# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (89-97)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,SLYGTTLEQ*# SEQUENCE: SLYGTTLEQ*# ...# >HUM10B93# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (143-151)# ANCHOR POSITIONS:# REFERENCES: kast94a,van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,AMSAARSSR*# SEQUENCE: AMSAARSSR*# ...# >HUM10B94# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (42-50)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,QQLLRREVY*# SEQUENCE: QQLLRREVY*# ...# >HUM10B95# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (93-101)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,TTLEQQYNK*# SEQUENCE: TTLEQQYNK*# ...# >HUM10B96# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (7-15)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AMFQDPQER*# SEQUENCE: AMFQDPQER*# ...# >HUM10B97# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (59-67)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,IVYRDGNPY*# SEQUENCE: IVYRDGNPY*# ...# >HUM10B98# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: binding as./refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (33-41)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,IILECVYCK*# SEQUENCE: IILECVYCK*# ...# >HUM10B99# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (80-88)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ISEYRHYCY*# SEQUENCE: ISEYRHYCY*# ...# >HUM10B9A# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: binding as./refolding# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E7 (89-97)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,IVCPICSQK*# SEQUENCE: IVCPICSQK*# ...# >HUM10B9B# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (42-50)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,QQLLRREVY*# SEQUENCE: QQLLRREVY*# ...# >HUM10B9C# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (87-95)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,van_der_burg95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,CYSLYGTTL*# SEQUENCE: CYSLYGTTL*# ...# >HUM10B9D# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (131-139)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,RFHNIRGRW*# SEQUENCE: RFHNIRGRW*# ...# >HUM10B9E# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (49-57)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,RAHYNIVTF*# SEQUENCE: RAHYNIVTF*# ...# >HUM10B9F# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (49-57)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,VYDFAFRDL*# SEQUENCE: VYDFAFRDL*# ...# >HUM10BA0# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (26-34)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,LQTTIHDII*# SEQUENCE: LQTTIHDII*# ...# >HUM10BA1# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (1-9)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,MHQKRTAMF*# SEQUENCE: MHQKRTAMF*# ...# >HUM10BA2# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus 16 E6 (44-52)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,LLRREVYDF*# SEQUENCE: LLRREVYDF*# ...# >HUM10BA3# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (18-25)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,ETTDLYCY*# SEQUENCE: ETTDLYCY*# ...# >HUM10BA4# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (77-86)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,YSKISEYRHY*# SEQUENCE: YSKISEYRHY*# ...# >HUM10BA5# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (2-11)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,HGDTPTLHEY*# SEQUENCE: HGDTPTLHEY*# ...# >HUM10BA6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: human papillomavirus 16 E7 (86-93)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,ressing95a,wentworth96a,van_der_burg95a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,TLGIVCPI*# SEQUENCE: TLGIVCPI*# ...# >HUM10BA7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response/competitive binding# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: human papillomavirus 16 E7 (11-20)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a,sette94b,ressing95a,van_der_burg95a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,YMLDLQPETT*# SEQUENCE: YMLDLQPETT*# ...# >HUM10BA8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./in vivo response# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (29-38)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a,sette94b,ressing95a,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,TIHDIILECV*# SEQUENCE: TIHDIILECV*# ...# >HUM10BA9# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (106-115)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,LLIRCINCQK*# SEQUENCE: LLIRCINCQK*# ...# >HUM10BAA# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (68-75)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AVCDKCLK*# SEQUENCE: AVCDKCLK*# ...# >HUM10BAB# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (9-18)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,FQDPQERPRK*# SEQUENCE: FQDPQERPRK*# ...# >HUM10BAC# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (32-41)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,DIILECVYCK*# SEQUENCE: DIILECVYCK*# ...# >HUM10BAD# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (92-101)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,GTTLEQQYNK*# SEQUENCE: GTTLEQQYNK*# ...# >HUM10BAE# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (106-115)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,LLIRCINCQK*# SEQUENCE: LLIRCINCQK*# ...# >HUM10BAF# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E7 (88-97)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,GIVCPICSQK*# SEQUENCE: GIVCPICSQK*# ...# >HUM10BB0# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human papillomavirus 16 E6 (71-78)# DB REFERENCE: SWISS: (VE6_HPV45,VE6_HPV18)# & PIR1: (W6WL18)# & PIR2: (S36561)# REFERENCES: kast94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,FYSRIREL*# SEQUENCE: FYSRIREL*# ...# >HUM10BB1# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBNA 4 (416-424)# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: zhang93a,de_campos-lima94a,falk94c,gavioli96a,levitsky96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,IVTDFSVIK*# SEQUENCE: IVTDFSVIK*# ...# >HUM10BB2# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,IDTDFSVIK*# SEQUENCE: IDTDFSVIK*# ...# >HUM10BB3# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,IKTDFSVIK*# SEQUENCE: IKTDFSVIK*# ...# >HUM10BB4# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesu,IVRDFSVIK*# SEQUENCE: IVRDFSVIK*# ...# >HUM10BB5# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,IVDDFSVIK*# SEQUENCE: IVDDFSVIK*# ...# >HUM10BB6# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,IVTDYSVIK*# SEQUENCE: IVTDYSVIK*# ...# >HUM10BB7# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,IVTDLSVIK*# SEQUENCE: IVTDLSVIK*# ...# >HUM10BB8# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesn,bindyesu,IVTDFLVIK*# SEQUENCE: IVTDFLVIK*# ...# >HUM10BB9# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,IVTDFSIIK*# SEQUENCE: IVTDFSIIK*# ...# >HUM10BBA# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,IVTDFSVID*# SEQUENCE: IVTDFSVID*# ...# >HUM10BBB# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,IVTDFSVIT*# SEQUENCE: IVTDFSVIT*# ...# >HUM10BBC# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBNA 4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: zhang93a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,IVTDFSVIR*# SEQUENCE: IVTDFSVIR*# ...# >HUM10BBD# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag (325-333)# DB REFERENCE: SWISS: (POL_HV1JR,POL_HV1B5,POL_HV1RH,POL_HV1ND,POL_HV1B1,# & POL_HV1A2,POL_HV1MN,POL_HV1PV,POL_HV1BR,POL_HV1H2,# & POL_HV1OY,POL_HV1MA,POL_HV1Z2,POL_HV1EL)# & PIR1: (GNVWLV,GNVWA2,GNLJND,GNVWVL,GNVWH3)# & PIR2: (S32048,S32050,S32089,S32069,S32067,S32134,B47175,S54378,# & S32074,D47330,S32137,S32096,S32079,S32136,S32138,S32126,# & S32078,S32072,S32080,S32093,S32157,B47330,S32068,S32159,# & A47175,S32092,S32160,S32051,S32090,S32047,S43127,A47330,# & S32071,S32135,S32076,S32066,S32070,S32139,S32098,S32075,# & E47330,S32049,S32091)# REFERENCES: zhang93a,brander95b,hivdb97a,gavioli96a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,AIFQSSMTK*# SEQUENCE: AIFQSSMTK*# ...# >HUM10BBE# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (74-82)# DB REFERENCE: SWISS: (NEF_HV1ND,NEF_HV1BN,NEF_HV1JR,NEF_HV2D2,NEF_HV1U4,# & NEF_HV112,NEF_HV1EL,NEF_HV1S1,NEF_HV1OY,NEF_HV1S3,# & NEF_HV1Z2,NEF_HV1Z6,NEF_HV1BR,NEF_HV1SC,NEF_HV1A2,# & NEF_HV1PV,NEF_HV1MA,NEF_HV1H2,NEF_HV1MN,NEF_HV1B8,# & NEF_HV1B1)# & PIR1: (QQLJZR,ASLJO2,ASLJFV,ASLJBR,QQLJND,ASLJ12,ASLJVL,# & ASLJH3)# & PIR2: (S24572,S25937,S03244,S03245,S43467,S54385,S24985)# & PIR3: (S33986)# REFERENCES: zhang93a,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,VPLRPMTYK*# SEQUENCE: VPLRPMTYK*# ...# >HUM10BBF# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as./Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: celular protein p53 (343-351)# DB REFERENCE: SWISS: (P53_MESAU,P53_RAT,P53_HUMAN,P53_MESAU,P53_CERAE,# & P53_FELCA,P53_CRIGR,P53_RAT,P53_MOUSE,P53_FELCA,# & P53_CERAE,P53_HUMAN,P53_MOUSE)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S02192,JH0633,S38824,S06594,JC6176,JC6193)# REFERENCES: zhang93a,gavioli96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,ELNEALELK*# SEQUENCE: ELNEALELK*# ...# >HUM10BC0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a,ruppert93a,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAAV*# SEQUENCE: ALAKAAAAV*# ...# >HUM10BC1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,AMAKAAAAV*# SEQUENCE: AMAKAAAAV*# ...# >HUM10BC2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AIAKAAAAV*# SEQUENCE: AIAKAAAAV*# ...# >HUM10BC3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,AVAKAAAAV*# SEQUENCE: AVAKAAAAV*# ...# >HUM10BC4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AAAKAAAAV*# SEQUENCE: AAAKAAAAV*# ...# >HUM10BC5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ATAKAAAAV*# SEQUENCE: ATAKAAAAV*# ...# >HUM10BC6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAAI*# SEQUENCE: ALAKAAAAI*# ...# >HUM10BC7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAAAL*# SEQUENCE: ALAKAAAAL*# ...# >HUM10BC8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAAAA*# SEQUENCE: ALAKAAAAA*# ...# >HUM10BC9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALAKAAAAM*# SEQUENCE: ALAKAAAAM*# ...# >HUM10BCA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAAAT*# SEQUENCE: ALAKAAAAT*# ...# >HUM10BCB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLAKAAAAV*# SEQUENCE: FLAKAAAAV*# ...# >HUM10BCC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KLAKAAAAV*# SEQUENCE: KLAKAAAAV*# ...# >HUM10BCD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,VLAKAAAAV*# SEQUENCE: VLAKAAAAV*# ...# >HUM10BCE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALFKAAAAV*# SEQUENCE: ALFKAAAAV*# ...# >HUM10BCF# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALEKAAAAV*# SEQUENCE: ALEKAAAAV*# ...# >HUM10BD0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALMKAAAAV*# SEQUENCE: ALMKAAAAV*# ...# >HUM10BD1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALSKAAAAV*# SEQUENCE: ALSKAAAAV*# ...# >HUM10BD2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALKKAAAAV*# SEQUENCE: ALKKAAAAV*# ...# >HUM10BD3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALACAAAAV*# SEQUENCE: ALACAAAAV*# ...# >HUM10BD4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAVAAAAV*# SEQUENCE: ALAVAAAAV*# ...# >HUM10BD5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAPAAAAV*# SEQUENCE: ALAPAAAAV*# ...# >HUM10BD6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALATAAAAV*# SEQUENCE: ALATAAAAV*# ...# >HUM10BD7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALADAAAAV*# SEQUENCE: ALADAAAAV*# ...# >HUM10BD8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKNAAAV*# SEQUENCE: ALAKNAAAV*# ...# >HUM10BD9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKLAAAV*# SEQUENCE: ALAKLAAAV*# ...# >HUM10BDA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKYAAAV*# SEQUENCE: ALAKYAAAV*# ...# >HUM10BDB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKGAAAV*# SEQUENCE: ALAKGAAAV*# ...# >HUM10BDC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKEAAAV*# SEQUENCE: ALAKEAAAV*# ...# >HUM10BDD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAIAAV*# SEQUENCE: ALAKAIAAV*# ...# >HUM10BDE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAPAAV*# SEQUENCE: ALAKAPAAV*# ...# >HUM10BDF# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAYAAV*# SEQUENCE: ALAKAYAAV*# ...# >HUM10BE0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAGAAV*# SEQUENCE: ALAKAGAAV*# ...# >HUM10BE1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKARAAV*# SEQUENCE: ALAKARAAV*# ...# >HUM10BE2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAYAV*# SEQUENCE: ALAKAAYAV*# ...# >HUM10BE3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAANAV*# SEQUENCE: ALAKAANAV*# ...# >HUM10BE4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAALAV*# SEQUENCE: ALAKAALAV*# ...# >HUM10BE5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAPAV*# SEQUENCE: ALAKAAPAV*# ...# >HUM10BE6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAEAV*# SEQUENCE: ALAKAAEAV*# ...# >HUM10BE7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAALV*# SEQUENCE: ALAKAAALV*# ...# >HUM10BE8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAGV*# SEQUENCE: ALAKAAAGV*# ...# >HUM10BE9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAPV*# SEQUENCE: ALAKAAAPV*# ...# >HUM10BEA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAFV*# SEQUENCE: ALAKAAAFV*# ...# >HUM10BEB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAAEV*# SEQUENCE: ALAKAAAEV*# ...# >HUM10BEC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: hepatitis B virus SAg (335-343)# DB REFERENCE: SWISS: (VMSA_HPBV4,VMSA_HPBVA,VMSA_HPBVS,VMSA_HPBVO,VMSA_HPBVY,# & VMSA_HPBVW,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBVN,VMSA_HPBVZ,# & VMSA_HPBV9,VMSA_HPBV2,VMSA_HPBVJ,VMSA_HPBVY,VMSA_HPBV2,# & VMSA_HPBVI,VMSA_HPBVW,VMSA_HPBV0,VMSA_HPBVR,# & VMSA_HPBVD)# & PIR1: (SAVLJ2,JQ1578,JQ1576,SAVLKS,SAVLN1,SAVLVD,JQ1575,SAVLAR,# & SAVLAH,SAVLAD,JQ1571,SAVLVE,SAVLHV,SAVLA,SAVLBH,SAVLA1,# & SAVLJ1,SAVLAJ,JQ1570,JQ1577,JQ1574,JQ1572,SAVLJ3,# & JQ1573)# & PIR2: (JQ2048,JQ2046,JQ2090,JQ2112,JQ2098,S36654,S20749,JQ2063,# & JQ2116,JQ2075,JQ2065,S41870,JQ2076,JQ2114,JQ2062,JQ2104,# & S47407,JQ2091,JQ2053,JQ2100,JQ2061,JQ2092,JQ2081,JQ2078,# & JQ2054,JQ2105,JQ2109,JQ2083,JQ2068,JQ2111,JQ2101,S43492,# & JQ2113,JQ2115,S20745,JQ2058,JQ2060,JQ2057,JQ2069,JQ2056,# & JQ2110,JQ2072,S20753,JQ2089,JQ2108,S32202,JQ2050,JQ2045,# & JQ2067,JQ2077,JQ2097,JQ2080,JQ2073,JQ2087,JQ2066,JQ2079,# & JQ2103,S47411,JQ2085,JQ2051,JQ2047,S35528,JQ2102,JQ2055,# & S41869,JQ2070,JQ2052,JQ2059,JQ2106)# REFERENCES: ruppert93a,sette94b,del_guercio95a,rammensee95a,sette94a,# & wentworth96a,van_der_burg96a,nayersina93a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,WLSLLVPFV*# SEQUENCE: WLSLLVPFV*# ...# >HUM10BED# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: hepatitis C virus NS4# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVH,POLG_HCVBK,POLG_HCV1,POLG_HCVTW,# & POLG_HCVJT)# & PIR1: (GNWVTC,GNWVCH,GNWVTW,GNWVC3,GNWVCJ)# & PIR2: (PS0326,JQ1366,A45573,A54317,S40770,S18030,PC2219,S32748,# & S06067,A61196)# REFERENCES: ruppert93a,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,YLVAYQATV*# SEQUENCE: YLVAYQATV*# ...# >HUM10BEE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (DPOL_HPBV9,DPOL_HPBVR,DPOL_HPBVL,DPOL_HPBV2,# & DPOL_HPBVM)# & PIR1: (JDVLVD,JDVLVS,S20757,JDVLVR,JDVLCP,S43491,JDVLKS)# & PIR2: (S35527)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,SLYAVSPSV*# SEQUENCE: SLYAVSPSV*# ...# >HUM10BEF# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./Stabilization/CTL induction# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: c-erb2# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# REFERENCES: ruppert93a,fisk95a,disis94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,HLYQGCQVV*# SEQUENCE: HLYQGCQVV*# ...# >HUM10BF0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HIV# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1RH,POL_HV1Y2,POL_HV1PV,POL_HV1MN,# & POL_HV1BR,POL_SIVM1,POL_HV1U4,POL_HV1OY,POL_HV1MA,# & POL_HV1Z2,POL_SIVSP,POL_SIVM1,POL_HV1EL,POL_SIVGB,# & POL_HV1N5,POL_HV2RO,POL_HV1Z6,POL_SIVCZ,POL_SIVS4,# & POL_HV1JR,POL_SIVMK,POL_HV1B1,POL_HV1H2,POL_HV1A2,# & POL_HV2D2,POL_HV1ND,POL_HV2BE)# & PIR1: (GNLJG5,GNLJG3,GNLJND,B44001,GNVWLV,GNVWH3,GNVWVL,GNLJSI,# & GNVWA2,GNLJG2)# & PIR2: (S08436,A26192,S54378,S28081)# & PIR3: (S33980)# REFERENCES: ruppert93a,van_der_burg96a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,LLWKGEGAV*# SEQUENCE: LLWKGEGAV*# ...# >HUM10BF1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./stabilisation as./cytotoxicity as./inhibition as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: p53 tumor supressor gene (264-272)# DB REFERENCE: SWISS: (P53_HUMAN,P53_CERAE,P53_FELCA,P53_MESAU,P53_CERAE,# & P53_BOVIN,P53_CRIGR,P53_FELCA,P53_MESAU,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (JH0633,JC6193,S06594,JC6176,S51648)# REFERENCES: ruppert93a,houbiers93a,stuber94a,castelli95a,del_guercio95a,# & sette94a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,LLGRNSFEV*# SEQUENCE: LLGRNSFEV*# ...# >HUM10BF2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hepatitis C virus# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVTW,POLG_HCVJA,POLG_HCVH,POLG_HCVJT,# & POLG_HCVBK)# & PIR1: (GNWVCJ,GNWVC3,GNWVTC,GNWVCH,GNWVTW)# & PIR2: (S18030,S40770,A45573)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YLVTRHADV*# SEQUENCE: YLVTRHADV*# ...# >HUM10BF3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hepatitis C virus# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVBK,POLG_HCVJ6,POLG_HCV1,POLG_HCVJT,# & POLG_HCVH,POLG_HCVTW)# & PIR1: (GNWVTC,GNWVC3,GNWVCJ,GNWVCH,GNWVTW)# & PIR2: (A45573,JQ1303,S40770)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GLRDLAVAV*# SEQUENCE: GLRDLAVAV*# ...# >HUM10BF4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: c-erb2# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: ruppert93a,fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,PLTSIISAV*# SEQUENCE: PLTSIISAV*# ...# >HUM10BF5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1BR,POL_HV1PV,POL_HV1N5,POL_HV1EL,# & POL_HV1Z2,POL_HV1ND,POL_HV1B1,POL_HV1H2,POL_HV1U4,# & POL_HV1MN,POL_HV1Y2)# & PIR1: (B44001,GNVWLV,GNVWH3,GNLJND,GNVWVL)# & PIR2: (S54378)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,HLEGKVILV*# SEQUENCE: HLEGKVILV*# ...# >HUM10BF6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (X_HPBVL,X_HPBVI,X_HPBV9,X_HPBV2,X_HPBVJ,X_HPBV2,X_HPBVY,# & X_HPBVT,X_HPBVO,X_HPBVA)# & PIR1: (QQVLKS,QQVLBH,A48345,B48345,QQVLA1,QQVLD1,QQVLAW,# & QQVLCP)# & PIR2: (S12542,JS0604,S20747,S47408,JS0256,S22319,S04570,S53130,# & A58456,S35529,JS0603,JQ2228,S32203,S12598,S47404,S33687,# & S20751,S20756)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,HLSLRGLPV*# SEQUENCE: HLSLRGLPV*# ...# >HUM10BF7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papillomavirus# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RLCVQSTHV*# SEQUENCE: RLCVQSTHV*# ...# >HUM10BF8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVI,DPOL_HPBVA,DPOL_HPBVJ,DPOL_HPBVO,# & DPOL_HPBVT,DPOM_HPBVY)# & PIR1: (JQ2229,JDVLVA,JDVLJ1,JDVLJ2,JDVLA1,S20752,S47406,JDVLVB,# & JDVLJ3)# & PIR2: (S71785)# REFERENCES: ruppert93a,sette94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLYADSPSV*# SEQUENCE: SLYADSPSV*# ...# >HUM10BF9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVA,VMSA_HPBVY)# & PIR1: (SAVLA1,SAVLAJ,SAVLBH,JQ1572,SAVLAH,JQ1571)# & PIR2: (JQ2079,S20745,JQ2068,JQ2080,JQ2081,JQ2078,JQ2070,JQ2077,# & JQ2067,S32202,S41870,JQ2076,S41871,S47407,JQ2075,JQ2063,# & JQ2072,JQ2069,JQ2073,JQ2066,S20753,JQ2083,JQ2065,# & S41869)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLGGTTVCL*# SEQUENCE: FLGGTTVCL*# ...# >HUM10BFA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hepatitis B virus pol (678-686)# DB REFERENCE: SWISS: (DPOL_HPBVZ,DPOM_HPBVY,DPOL_HPBV4,DPOL_HPBVY,DPOL_HPBVA,# & DPOL_HPBVR)# & PIR1: (S47406,JDVLA1,S43491,JDVLVR,JDVLVA,JDVLVB,JDVLVH,# & S20752)# & PIR2: (S71785)# REFERENCES: ruppert93a,sette94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLCKQYLNL*# SEQUENCE: FLCKQYLNL*# ...# >HUM10BFB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVJ,DPOL_HPBVZ,DPOL_HPBVI,DPOL_HPBVT,# & DPOL_HPBVW,DPOL_HPBVY,DPOL_HPBVO,DPOL_HPBV9,DPOL_HPBVL,# & DPOL_HPBV2,DPOL_HPBVA,DPOL_HPBVP)# & PIR1: (JDVLCP,JDVLVB,JDVLKS,JDVLVH,S47406,S20757,JDVLVD,JDVLJ3,# & JDVLA1,JDVLJ2,JDVLVA,JDVLJ1,JQ2229)# REFERENCES: ruppert93a,sette94b,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,GLSRYVARL*# SEQUENCE: GLSRYVARL*# ...# >HUM10BFC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1C4)# & PIR1: (FOVWH4)# & PIR2: (S60697)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,RMYSPISIL*# SEQUENCE: RMYSPISIL*# ...# >HUM10BFD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE melanoma associated gene expression antigen# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALSRKVAEL*# SEQUENCE: ALSRKVAEL*# ...# >HUM10BFE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./competition/direct binding/cytotoxicity as./Half-time# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: hepatitis B virus HBC (18-27)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVA,CORA_HPBVO,CORA_HPBVW,CORA_HPBVZ,# & CORA_HPBVT,CORA_HPBVJ,CORA_HPBV2,CORA_HPBVF,CORA_HPBVL,# & CORA_HPBV9)# & PIR1: (NKVLA2,NKVLJ2,NKVLA6,NKVLKS,NKVLAH,NKVLJ1,NKVLBH,NKVLCP,# & NKVLA1,NKVLH3,NKVLA3)# & PIR2: (S53159,S53216,JQ2227,S53211,S53251,S53207,S53274,S01405,# & S53189,S53260,S53281,S53221,S47405,S53286,S53272,S53255,# & S53152,S53163,S53232,S53223,S25651,S47409,S53270,S53175,# & S53204,S53227,S53253,S53184,S53137,S53214,S53240,S53257,# & S20746,S53169,S53200,S53129,S53178,S43490,S53225,S53143,# & S53181,S32204,S53236,S53288,S53267,S53229,S53242,S53279,# & S20750,S53155,S53202,S33686,S53238)# REFERENCES: ruppert93a,sette94b,del_guercio95a,rammensee95a,bertoletti94a,# & chen94a,sette94a,wrightham95a,wentworth96a,van_der_burg95a,# & nayersina93a,engelhard96a,van-elsas96a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesh,FLPSDFFPSV*# SEQUENCE: FLPSDFFPSV*# ...# >HUM10BFF# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (CORA_HPBVY)# & PIR1: (NKVLAH)# & PIR2: (S53198,S20746,S53137,S53181,S53140,S53163,S53260,S53274,# & S53211,S53194,S53216,S53159,S20755,S20750,S53247,S32204,# & S53202,S53257,S53204,S53200,S53129,S53225,S47405,S53272,# & S53270,S53186,S53207,S53189,S53281)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,LMTLATWVGV*# SEQUENCE: LMTLATWVGV*# ...# >HUM10C00# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (CORA_HPBV4)# & PIR1: (NKVLA4)# & PIR2: (S08645,S04570,S35530,S53140,S08647,S08646)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLPSDFFPSI*# SEQUENCE: FLPSDFFPSI*# ...# >HUM10C01# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (CORA_HPBVW,CORA_HPBVY,CORA_HPBV2,CORA_HPBVL,CORA_HPBVT,# & CORA_HPBVJ,CORA_HPBV9)# & PIR1: (NKVLJ1,NKVLA3,NKVLA6,NKVLKS,NKVLCP,NKVLBH,NKVLAH)# & PIR2: (S53202,S25651,S47409,S53181,S53169,S53149,S53272,S47405,# & S20755,S53227,S53286,S53204,S53207,JQ2227,S20750,S53281,# & S53163,S53242,S53157,S53267,S20746,S53238,S22318,S53152,# & S53274,S53216,S01405,S53200,S53161,S53247,S32204,# & S53140)# REFERENCES: ruppert93a,sette94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ILCWGELMTL*# SEQUENCE: ILCWGELMTL*# ...# >HUM10C02# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV# DB REFERENCE: SWISS: (ENV_HV1C4,ENV_HV1ZH,ENV_HV1Z2,ENV_HV1MF,ENV_HV1Z6,# & ENV_HV1EL,ENV_HV1OY,ENV_HV1S3)# & PIR1: (VCLJH4,VCLJZR,A44963)# & PIR2: (S54384)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,NLWVTVYYGV*# SEQUENCE: NLWVTVYYGV*# ...# >HUM10C03# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1A2,ENV_HV1S1,ENV_HV1H2,ENV_HV1BN,# & ENV_HV1JR,ENV_HV1B1,ENV_HV1PV,ENV_HV1H3,ENV_HV1MN)# & PIR1: (VCLJVL,VCLJMN,VCLJBR,VCLJLV,VCLJA2,VCLJH3)# & PIR2: (A40218)# & PIR3: (S33985,S13288,S13289)# REFERENCES: ruppert93a,dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,KLWVTVYYGV*# SEQUENCE: KLWVTVYYGV*# ...# >HUM10C04# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (DPOL_HPBVY)# & PIR1: (S20752,JDVLVA)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,RMRGTFSAPL*# SEQUENCE: RMRGTFSAPL*# ...# >HUM10C05# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE melanoma associated gene expression antigen# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN,MAG6_HUMAN,MAG6_HUMAN)# & PIR2: (G01445,JC2360,JC2361)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,SLQLVFGIEL*# SEQUENCE: SLQLVFGIEL*# ...# >HUM10C06# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (VMSA_HPBVJ,VMSA_HPBVO,VMSA_HPBVI)# & PIR1: (JQ1570,SAVLJ1,SAVLJ3,SAVLJ2)# & PIR2: (JQ2060,JQ2059,JQ2061,JQ2057,JQ2058,JQ2062)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,FLCILLLCLI*# SEQUENCE: FLCILLLCLI*# ...# >HUM10C07# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVA,DPOM_HPBVY,DPOL_HPBVZ)# & PIR1: (S20752,JDVLVB,JDVLVA,S20757,JDVLA1,JDVLVH,S47406)# & PIR2: (S71785)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,HLESLFTAV*# SEQUENCE: HLESLFTAV*# ...# >HUM10C08# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hepatitis B virus# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVY)# & PIR1: (JDVLVA,JDVLCP)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RLSSNSRIL*# SEQUENCE: RLSSNSRIL*# ...# >HUM10C09# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hepatitis B virus# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,DLVHFASPL*# SEQUENCE: DLVHFASPL*# ...# >HUM10C0A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP prostatic acid phospathase# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,DLFGIWSKV*# SEQUENCE: DLFGIWSKV*# ...# >HUM10C0B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: kubo94a,ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAAAAV*# SEQUENCE: ALAKAAAAAV*# ...# >HUM10C0C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLYCYFALV*# SEQUENCE: FLYCYFALV*# ...# >HUM10C0D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A2 binding motif homologue# ANCHOR POSITIONS:# REFERENCES: ruppert93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,SLVGFGILCV*# SEQUENCE: SLVGFGILCV*# ...# >MUS10C0E# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: insulin receptor precursor murine# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPKTDAQTL*# SEQUENCE: SGPKTDAQTL*# ...# >MUS10C0F# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: fiber protein adenovirus 2# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,KGPITVQI*# SEQUENCE: KGPITVQI*# ...# >MUS10C10# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: elution/reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin receptor rat# ANCHOR POSITIONS:# REFERENCES: corr93a,correa95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,VGPQKNENL*# SEQUENCE: VGPQKNENL*# ...# >MUS10C11# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mRNA CD40 mouse# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPRKAIAL*# SEQUENCE: SGPRKAIAL*# ...# >MUS10C12# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation/Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: fibronectin precursor human# ANCHOR POSITIONS:# REFERENCES: corr93a,correa95a# COMMENT: 2,3,9# SUMMARY: H-2Dd,actunkn,bindyesu,AGPDRTEKL*# SEQUENCE: AGPDRTEKL*# ...# >MUS10C13# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: fibronectin precursor human# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,AGPDRTEKAL*# SEQUENCE: AGPDRTEKAL*# ...# >MUS10C14# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation/Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: metalloproteinase 2 inhibitor mouse# ANCHOR POSITIONS: 2,3,9# REFERENCES: corr93a,correa95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,KGPDKGNEF*# SEQUENCE: KGPDKGNEF*# ...# >MUS10C15# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hypoxantine phosphoribosyltransferase human# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,IGPERGHNL*# SEQUENCE: IGPERGHNL*# ...# >MUS10C16# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: urease Canavalia ensiformis# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,DGPVREHNL*# SEQUENCE: DGPVREHNL*# ...# >MUS10C17# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: pyruvate kinase rat# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,KGPERANGL*# SEQUENCE: KGPERANGL*# ...# >MUS10C18# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: proliferating cell nucleolar antigen P40 human# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPERGEKL*# SEQUENCE: SGPERGEKL*# ...# >MUS10C19# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation/Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ribosomal protein S17 rat# ANCHOR POSITIONS: 2,3,9# REFERENCES: corr93a,correa95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,DGPVRGISI*# SEQUENCE: DGPVRGISI*# ...# >MUS10C1A# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: alpha 1 macroglobulin rat# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,NGPQRIYNL*# SEQUENCE: NGPQRIYNL*# ...# >MUS10C1B# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: superoxidase dismutase horse# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPVALVNFI*# SEQUENCE: SGPVALVNFI*# ...# >MUS10C1C# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: superoxidase dismutase horse# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPVALVNF*# SEQUENCE: SGPVALVNF*# ...# >MUS10C1D# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV 1 envelope protein# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,IGPNRAFNF*# SEQUENCE: IGPNRAFNF*# ...# >MUS10C1E# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: heterogenous nuclear ribonucleoprotein complex K# DB REFERENCE: SWISS: (ROK_HUMAN,ROK_HUMAN)# & PIR2: (S41224,S41495,A42058,S43363,A54143)# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPERILSI*# SEQUENCE: SGPERILSI*# ...# >MUS10C1F# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: heterogenous nuclear ribonucleoprotein complex K# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPERILSL*# SEQUENCE: SGPERILSL*# ...# >MUS10C20# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: heterogenous nuclear ribonucleoprotein complex K# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPERILSAY*# SEQUENCE: SGPERILSAY*# ...# >MUS10C21# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: T complex associated testes peptide mouse# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,VGPSGKYFIL*# SEQUENCE: VGPSGKYFIL*# ...# >MUS10C22# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: T complex associated testes peptide mouse# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,VGPSGKYFI*# SEQUENCE: VGPSGKYFI*# ...# >MUS10C23# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: feline leukemia virus envelope protein# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,FGPYKLNRL*# SEQUENCE: FGPYKLNRL*# ...# >MUS10C24# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ran Canis familiaris# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,FGPIKFNVL*# SEQUENCE: FGPIKFNVL*# ...# >MUS10C25# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LasA protein Pseudomonas aeruginosa# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,FGPYRFYVL*# SEQUENCE: FGPYRFYVL*# ...# >MUS10C26# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LasA protein Pseudomonas aeruginosa# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,FGPYRFYVLT*# SEQUENCE: FGPYRFYVLT*# ...# >MUS10C27# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: motif homologue# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,AGPARAAAL*# SEQUENCE: AGPARAAAL*# ...# >MUS10C28# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: motif homologue# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,AGPAAAAAL*# SEQUENCE: AGPAAAAAL*# ...# >MUS10C29# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: elongation factor rat# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SEQDLNF*# SEQUENCE: SEQDLNF*# ...# >MUS10C2A# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transforming protein spi-1 human# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SXHKEQPAT*# SEQUENCE: SXHKEQPAT*# ...# >MUS10C2B# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: amidotransferase II Streptomyces griesus# ANCHOR POSITIONS:# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,AGPDRFIXXM*# SEQUENCE: AGPDRFIXXM*# ...# >MUS10C2C# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides Edman degradation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tum- P35B# DB REFERENCE: PIR2: (S12516)# REFERENCES: corr93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,NGPPHSNNFGY*# SEQUENCE: NGPPHSNNFGY*# ...# >MUS10C2D# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: eluted self-peptides/cytotoxicity as./Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HIV gp160 (318-327)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1H3,ENV_HV1BR,ENV_HV1MF,ENV_HV1B1,# & ENV_HV1PV,ENV_HV1H2)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR2: (S65399)# & PIR3: (S13288,S33985)# REFERENCES: corr93a,bergmann93a,alexander-miller96a,hivdb97a,correa95a,# & takeshita95a# COMMENT:# SUMMARY: H-2Dd,actyesh,bindyesu,RGPGRAFVTI*# SEQUENCE: RGPGRAFVTI*# ...# >MUS10C2E# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LCMV NP (119-127)# DB REFERENCE: SWISS: (NCAP_LYCVA,NCAP_LYCVW)# & PIR1: (VHXPLC,VHXPLM)# REFERENCES: horwitz94a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,PQASGVYMG*# SEQUENCE: PQASGVYMG*# ...# >MUS10C2F# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LCMV NP (119-127)# ANCHOR POSITIONS:# REFERENCES: horwitz94a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,LKTSGVYMG*# SEQUENCE: LKTSGVYMG*# ...# >MUS10C30# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LCMV NP (122-127)# DB REFERENCE: SWISS: (NCAP_LYCVW,NCAP_LYCVA,NCAP_LASSG)# & PIR1: (VHXPL2,VHXPLM,VHXPLC)# REFERENCES: horwitz94a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,SGVYMG*# SEQUENCE: SGVYMG*# ...# >MUS10C31# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LCMV GP1 (33-42)# DB REFERENCE: SWISS: (VGLY_LYCVA,VGLY_LYCVW)# & PIR1: (VGXPLA,VGXPLC,VGXPLM)# REFERENCES: horwitz94a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,KAVYNFATCG*# SEQUENCE: KAVYNFATCG*# ...# >HUM10C32# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV gp41 (584-594)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1Z2,ENV_HV1BR,ENV_HV1J3,ENV_HV1OY,# & ENV_HV1MN,ENV_HV1H2,ENV_HV1Z6,ENV_HV1S1,ENV_HV1C4,# & ENV_HV1ZH,ENV_HV1MF,ENV_HV1B1,ENV_HV1EL,ENV_HV1B8,# & ENV_HV1H3,ENV_HV1PV)# & PIR1: (VCLJZR,VCLJMN,VCLJH4,VCLJBR,VCLJH3,A44963,VCLJLV,# & VCLJVL)# & PIR2: (S22004,S21996,S70417,S70421,S70422,S21998,S54384,S70420,# & S70425,S21994,S70424,S22002,S21992,S22000,S70418,S70419,# & B41621,S21990,S70423,S22006)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,ERYLKDQQLLG*# SEQUENCE: ERYLKDQQLLG*# ...# >HUM10C33# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (584-594)# DB REFERENCE: SWISS: (ENV_HV1Z2,ENV_HV1J3,ENV_HV1PV,ENV_HV1MN,ENV_HV1H2,# & ENV_HV1OY,ENV_HV1C4,ENV_HV1MF,ENV_HV1B8,ENV_HV1H3,# & ENV_HV1B1,ENV_HV1BN,ENV_HV1BR,ENV_HV1ZH,ENV_HV1Z6,# & ENV_HV1S1,ENV_HV1EL)# & PIR1: (VCLJH3,A44963,VCLJBR,VCLJZR,VCLJH4,VCLJMN,VCLJVL,# & VCLJLV)# & PIR2: (S21994,S70417,S22006,B41621,S21990,S70425,S70424,S21996,# & S22004,S22002,S22000,S54384,S70420,S21992,S70418,S21998,# & S70421,S70423,S70419,S70422)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,ERYLKDQQLLG*# SEQUENCE: ERYLKDQQLLG*# ...# >HUM10C34# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (584-592)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1EL,ENV_HV1BR,ENV_HV1Z6,ENV_HV1Z2,# & ENV_HV1MN,ENV_HV1OY,ENV_HV1KB,ENV_HV1JR,ENV_HV1PV,# & ENV_HV1J3,ENV_HV1MF,ENV_HV1BN,ENV_HV1S1,ENV_HV1C4,# & ENV_HV1B8,ENV_HV1H2,ENV_HV1B1,ENV_HV1ZH)# & PIR1: (VCLJMN,A44963,VCLJKX,VCLJLV,VCLJKB,VCLJBR,VCLJVL,VCLJH4,# & VCLJH3,VCLJZR)# & PIR2: (B41621,S21990,S22006,S21994,S70417,S22002,S70422,S21996,# & S70421,S70423,S54384,S21992,S70424,S22000,S70419,S21998,# & S70420,S70418,S22004,S70425)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,ERYLKDQQL*# SEQUENCE: ERYLKDQQL*# ...# >HUM10C35# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-598)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1ZH,ENV_HV1H3,ENV_HV1Z6,ENV_HV1OY,# & ENV_HV1J3,ENV_HV1BN,ENV_HV1BR,ENV_HV1EL,ENV_HV1Z2,# & ENV_HV1PV,ENV_HV1S1,ENV_HV1B1,ENV_HV1B8,ENV_HV1H2)# & PIR1: (VCLJBR,A44963,VCLJLV,VCLJH3,VCLJVL,VCLJZR)# & PIR2: (S70424,S22000,S22006,S21996,S70419,S70421,S22002,S21990,# & S21994,S70417,S70422,S70420,S70418,S70425,S22004,S21998,# & S54384,S70423,S21992)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AVERYLKDQQLLGIWGC*# SEQUENCE: AVERYLKDQQLLGIWGC*# ...# >HUM10C36# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (580-595)# ANCHOR POSITIONS:# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,ILAVERYLKDQQLLGC*# SEQUENCE: ILAVERYLKDQQLLGC*# ...# >HUM10C37# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (584-605)# ANCHOR POSITIONS:# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,ERYLKDQQLLGIWGCSGKLICG*# SEQUENCE: ERYLKDQQLLGIWGCSGKLICG*# ...# >HUM10C38# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-596)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1BR,ENV_HV1Z6,ENV_HV1H3,ENV_HV1BN,# & ENV_HV1OY,ENV_HV1J3,ENV_HV1EL,ENV_HV1PV,ENV_HV1S1,# & ENV_HV1H2,ENV_HV1B1,ENV_HV1B8,ENV_HV1MF,ENV_HV1Z2)# & PIR1: (VCLJBR,A44963,VCLJH3,VCLJVL,VCLJLV,VCLJZR)# & PIR2: (S21990,S22002,S22004,S70419,S70424,S22000,S22006,S54384,# & S21996,S21998,S70422,S70418,S70421,S70417,S70423,S21992,# & S70425,S70420,S21994)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AVERYLKDQQLLGIW*# SEQUENCE: AVERYLKDQQLLGIW*# ...# >HUM10C39# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-595)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1OY,ENV_HV1J3,ENV_HV1BN,ENV_HV1Z6,# & ENV_HV1B8,ENV_HV1H2,ENV_HV1PV,ENV_HV1S1,ENV_HV1EL,# & ENV_HV1ZH,ENV_HV1BR,ENV_HV1B1,ENV_HV1H3,ENV_HV1Z2)# & PIR1: (VCLJLV,A44963,VCLJBR,VCLJH3,VCLJVL,VCLJZR)# & PIR2: (S70423,S70425,S22002,S21998,S22006,S70424,S70417,S70421,# & S21992,S22000,S54384,S22004,S70420,S21994,S70418,S70419,# & S21996,S70422,S21990)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AVERYLKDQQLLGI*# SEQUENCE: AVERYLKDQQLLGI*# ...# >HUM10C3A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-594)# DB REFERENCE: SWISS: (ENV_HV1C4,ENV_HV1MN,ENV_HV1B8,ENV_HV1H3,ENV_HV1ZH,# & ENV_HV1EL,ENV_HV1S1,ENV_HV1PV,ENV_HV1Z6,ENV_HV1H2,# & ENV_HV1BN,ENV_HV1Z2,ENV_HV1B1,ENV_HV1BR,ENV_HV1J3,# & ENV_HV1MF,ENV_HV1OY)# & PIR1: (VCLJLV,VCLJMN,VCLJBR,VCLJZR,VCLJH3,VCLJH4,VCLJVL,# & A44963)# & PIR2: (S70422,S21994,S22000,S21992,S70424,S70423,S70419,S70420,# & S22002,S21998,S70417,S70421,S22004,S70418,S22006,S21996,# & S21990,S70425,S54384)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AVERYLKDQQLLG*# SEQUENCE: AVERYLKDQQLLG*# ...# >HUM10C3B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-593)# DB REFERENCE: SWISS: (ENV_HV1C4,ENV_HV1BN,ENV_HV1Z6,ENV_HV1H3,ENV_HV1H2,# & ENV_HV1S1,ENV_HV1EL,ENV_HV1BR,ENV_HV1MN,ENV_HV1B8,# & ENV_HV1ZH,ENV_HV1PV,ENV_HV1B1,ENV_HV1Z2,ENV_HV1OY,# & ENV_HV1J3,ENV_HV1MF)# & PIR1: (A44963,VCLJMN,VCLJLV,VCLJH4,VCLJBR,VCLJZR,VCLJH3,# & VCLJVL)# & PIR2: (S21998,S70421,S70423,S70418,S70422,S21994,S70420,S70417,# & S21990,S22002,S21996,S70419,S22000,S21992,S54384,S22004,# & S22006,S70425,S70424)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AVERYLKDQQLL*# SEQUENCE: AVERYLKDQQLL*# ...# >HUM10C3C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (583-596)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1H2,ENV_HV1EL,ENV_HV1S1,ENV_HV1Z6,# & ENV_HV1PV,ENV_HV1Z2,ENV_HV1BR,ENV_HV1B8,ENV_HV1B1,# & ENV_HV1MF,ENV_HV1J3,ENV_HV1ZH,ENV_HV1OY,ENV_HV1H3)# & PIR1: (VCLJZR,A44963,VCLJBR,VCLJVL,VCLJH3,VCLJLV)# & PIR2: (S22002,S70422,S21994,S70423,S70418,S70424,S22000,S21992,# & S54384,S70417,S70420,S21996,S22006,S22004,S70425,S70421,# & S21998,S21990,S70419)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,VERYLKDQQLLGIW*# SEQUENCE: VERYLKDQQLLGIW*# ...# >HUM10C3D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (584-596)# DB REFERENCE: SWISS: (ENV_HV1Z6,ENV_HV1BN,ENV_HV1H3,ENV_HV1J3,ENV_HV1Z2,# & ENV_HV1BR,ENV_HV1B8,ENV_HV1ZH,ENV_HV1PV,ENV_HV1EL,# & ENV_HV1H2,ENV_HV1S1,ENV_HV1MF,ENV_HV1B1,ENV_HV1OY)# & PIR1: (VCLJLV,VCLJVL,VCLJH3,VCLJBR,A44963,VCLJZR)# & PIR2: (S54384,S70422,S70421,S21998,S70419,S21990,S70418,S21996,# & S22000,S22002,S21994,B41621,S70417,S21992,S70424,S22004,# & S70425,S70420,S22006,S70423)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,ERYLKDQQLLGIW*# SEQUENCE: ERYLKDQQLLGIW*# ...# >HUM10C3E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (585-596)# DB REFERENCE: SWISS: (ENV_HV1OY,ENV_HV1H3,ENV_HV1BN,ENV_HV1Z6,ENV_HV1BR,# & ENV_HV1J3,ENV_HV1Z2,ENV_HV1ZH,ENV_HV1B8,ENV_HV1EL,# & ENV_HV1H2,ENV_HV1B1,ENV_HV1MF,ENV_HV1PV,ENV_HV1S1)# & PIR1: (VCLJLV,VCLJBR,A44963,VCLJH3,VCLJVL,VCLJZR)# & PIR2: (S21990,B41621,S70417,S70418,S70419,S70420,S22006,S70423,# & S21998,S54384,S22000,S70424,S22004,S70425,S21994,S21996,# & S70422,S70421,S22002,S21992)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,RYLKDQQLLGIW*# SEQUENCE: RYLKDQQLLGIW*# ...# >HUM10C3F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (586-596)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1OY,ENV_HV1BN,ENV_HV1BR,ENV_HV1Z2,# & ENV_HV1ZH,ENV_HV1EL,ENV_HV1H3,ENV_HV1Z8,ENV_HV1MF,# & ENV_HV1S1,ENV_HV1PV,ENV_HV1J3,ENV_HV1Z6,ENV_HV1B8,# & ENV_HV1H2)# & PIR1: (VCLJH3,VCLJBR,A44963,VCLJVL,VCLJZR,VCLJLV)# & PIR2: (S70424,S22000,S70418,S70422,S21992,S21994,S70425,S70420,# & S70419,B41621,S70417,S22004,S70423,S22006,S54384,S21998,# & S22002,S70421,S21990,S21996)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,YLKDQQLLGIW*# SEQUENCE: YLKDQQLLGIW*# ...# >HUM10C40# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (583-593)# DB REFERENCE: SWISS: (ENV_HV1OY,ENV_HV1Z2,ENV_HV1H2,ENV_HV1MN,ENV_HV1J3,# & ENV_HV1Z6,ENV_HV1B1,ENV_HV1C4,ENV_HV1BR,ENV_HV1BN,# & ENV_HV1MF,ENV_HV1H3,ENV_HV1B8,ENV_HV1S1,ENV_HV1PV,# & ENV_HV1EL,ENV_HV1ZH)# & PIR1: (VCLJZR,VCLJLV,VCLJBR,VCLJH3,VCLJH4,A44963,VCLJVL,# & VCLJMN)# & PIR2: (S70425,S21994,S70420,S70419,S21992,S70424,S70422,S70418,# & S70421,S22002,S21990,S70417,S70423,S21996,S22000,S22004,# & S22006,S21998,S54384)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,VERYLKDQQLL*# SEQUENCE: VERYLKDQQLL*# ...# >HUM10C41# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (575-599)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1Z2,ENV_HV1H2,ENV_HV1J3,ENV_HV1Z6,# & ENV_HV1BR,ENV_HV1MF,ENV_HV1H3,ENV_HV1PV,ENV_HV1EL,# & ENV_HV1B1,ENV_HV1B8)# & PIR1: (VCLJZR,VCLJVL,VCLJLV,VCLJH3,A44963)# & PIR2: (S21998,S70422,S70425,S54384,S21996)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a,hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,QLQARILAVERYLKDQQLLGIWGCS*# SEQUENCE: QLQARILAVERYLKDQQLLGIWGCS*# ...# >HUM10C42# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (576-592)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1PV,ENV_HV1B8,ENV_HV1Z2,ENV_HV1J3,# & ENV_HV1Z6,ENV_HV1H3,ENV_HV1B1,ENV_HV1C4,ENV_HV1EL,# & ENV_HV1MF,ENV_HV1BR,ENV_HV1ZH)# & PIR1: (VCLJVL,A44963,VCLJH3,VCLJZR,VCLJH4,VCLJLV)# & PIR2: (S21998,S70422,S21996,S70425,S54384)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,LQARILAVERYLKDQQL*# SEQUENCE: LQARILAVERYLKDQQL*# ...# >HUM10C43# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (576-594)# ANCHOR POSITIONS:# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,LQARILAVERYLKDQQLGC*# SEQUENCE: LQARILAVERYLKDQQLGC*# ...# >HUM10C44# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-598)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1BR,ENV_HV1S1,ENV_HV1BN,ENV_HV1PV,# & ENV_HV1OY,ENV_HV1B8,ENV_HV1J3,ENV_HV1Z6,ENV_HV1B1,# & ENV_HV1H2,ENV_HV1Z2,ENV_HV1EL,ENV_HV1ZH,ENV_HV1MF)# & PIR1: (A44963,VCLJVL,VCLJBR,VCLJH3,VCLJLV,VCLJZR)# & PIR2: (S70424,S21992,S70417,S70421,S21990,S21994,S70420,S70419,# & S21998,S70418,S70423,S22006,S22000,S21996,S22002,S70422,# & S70425,S22004,S54384)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,AVERYLKDQQLLGIWGC*# SEQUENCE: AVERYLKDQQLLGIWGC*# ...# >HUM10C45# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (580-595)# ANCHOR POSITIONS:# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,ILAVERYLKDQQLLGC*# SEQUENCE: ILAVERYLKDQQLLGC*# ...# >HUM10C46# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (584-605)# ANCHOR POSITIONS:# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,ERYLKDQQLLGIWGCSGKLICG*# SEQUENCE: ERYLKDQQLLGIWGCSGKLICG*# ...# >HUM10C47# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-596)# DB REFERENCE: SWISS: (ENV_HV1S1,ENV_HV1BN,ENV_HV1H3,ENV_HV1B1,ENV_HV1MF,# & ENV_HV1OY,ENV_HV1B8,ENV_HV1PV,ENV_HV1Z6,ENV_HV1J3,# & ENV_HV1H2,ENV_HV1EL,ENV_HV1ZH,ENV_HV1BR,ENV_HV1Z2)# & PIR1: (VCLJBR,A44963,VCLJZR,VCLJLV,VCLJH3,VCLJVL)# & PIR2: (S70421,S21990,S70417,S54384,S70425,S22004,S21992,S70424,# & S22000,S70423,S21994,S70418,S70419,S70420,S22006,S21998,# & S21996,S22002,S70422)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,AVERYLKDQQLLGIW*# SEQUENCE: AVERYLKDQQLLGIW*# ...# >HUM10C48# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-595)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1S1,ENV_HV1B1,ENV_HV1MF,ENV_HV1Z6,# & ENV_HV1J3,ENV_HV1ZH,ENV_HV1OY,ENV_HV1EL,ENV_HV1H2,# & ENV_HV1B8,ENV_HV1PV,ENV_HV1H3,ENV_HV1Z2,ENV_HV1BR)# & PIR1: (VCLJBR,VCLJZR,VCLJLV,VCLJVL,A44963,VCLJH3)# & PIR2: (S22004,S70425,S70424,S21998,S70422,S70420,S70419,S70417,# & S54384,S21996,S22002,S22000,S22006,S70423,S70418,S21994,# & S70421,S21990,S21992)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,AVERYLKDQQLLGI*# SEQUENCE: AVERYLKDQQLLGI*# ...# >HUM10C49# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-594)# DB REFERENCE: SWISS: (ENV_HV1J3,ENV_HV1ZH,ENV_HV1OY,ENV_HV1B8,ENV_HV1B1,# & ENV_HV1BN,ENV_HV1S1,ENV_HV1C4,ENV_HV1EL,ENV_HV1H2,# & ENV_HV1PV,ENV_HV1H3,ENV_HV1BR,ENV_HV1MN,ENV_HV1Z6,# & ENV_HV1MF,ENV_HV1Z2)# & PIR1: (VCLJLV,VCLJVL,VCLJH3,VCLJMN,A44963,VCLJH4,VCLJZR,# & VCLJBR)# & PIR2: (S70421,S70422,S70417,S21992,S22004,S70425,S21998,S70420,# & S22002,S70418,S70419,S21990,S22000,S54384,S22006,S21994,# & S70423,S70424,S21996)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,AVERYLKDQQLLG*# SEQUENCE: AVERYLKDQQLLG*# ...# >HUM10C4A# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-593)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1J3,ENV_HV1H3,ENV_HV1H2,ENV_HV1S1,# & ENV_HV1BN,ENV_HV1BR,ENV_HV1OY,ENV_HV1ZH,ENV_HV1B8,# & ENV_HV1EL,ENV_HV1B1,ENV_HV1C4,ENV_HV1PV,ENV_HV1Z2,# & ENV_HV1MN,ENV_HV1Z6)# & PIR1: (VCLJH3,VCLJH4,VCLJBR,VCLJZR,A44963,VCLJLV,VCLJMN,# & VCLJVL)# & PIR2: (S70417,S70419,S22004,S70425,S21998,S70421,S70422,S21994,# & S70424,S21992,S21996,S70420,S22000,S21990,S22006,S54384,# & S70423,S22002,S70418)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,AVERYLKDQQLL*# SEQUENCE: AVERYLKDQQLL*# ...# >HUM10C4B# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (582-592)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1KB,ENV_HV1JR,ENV_HV1BR,ENV_HV1H2,# & ENV_HV1S1,ENV_HV1BN,ENV_HV1MN,ENV_HV1C4,ENV_HV1EL,# & ENV_HV1Z2,ENV_HV1B1,ENV_HV1PV,ENV_HV1OY,ENV_HV1ZH,# & ENV_HV1B8,ENV_HV1Z6,ENV_HV1MF,ENV_HV1J3)# & PIR1: (VCLJKB,VCLJH3,A44963,VCLJH4,VCLJBR,VCLJZR,VCLJLV,VCLJMN,# & VCLJVL,VCLJKX)# & PIR2: (S70420,S70418,S22004,S22000,S70417,S54384,S21998,S21994,# & S70424,S70421,S70422,S22002,S70423,S22006,S70419,S21990,# & S70425,S21992,S21996)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,AVERYLKDQQL*# SEQUENCE: AVERYLKDQQL*# ...# >HUM10C4C# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (583-596)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1BN,ENV_HV1S1,ENV_HV1EL,ENV_HV1MF,# & ENV_HV1Z2,ENV_HV1B1,ENV_HV1ZH,ENV_HV1B8,ENV_HV1OY,# & ENV_HV1H3,ENV_HV1Z6,ENV_HV1J3,ENV_HV1H2,ENV_HV1BR)# & PIR1: (VCLJH3,A44963,VCLJBR,VCLJZR,VCLJLV,VCLJVL)# & PIR2: (S22004,S21990,S22000,S70422,S70423,S70418,S21992,S21996,# & S70425,S22002,S21994,S70424,S21998,S22006,S70419,S54384,# & S70417,S70420,S70421)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,VERYLKDQQLLGIW*# SEQUENCE: VERYLKDQQLLGIW*# ...# >HUM10C4D# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (584-596)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1EL,ENV_HV1Z2,ENV_HV1B8,ENV_HV1MF,# & ENV_HV1ZH,ENV_HV1H3,ENV_HV1OY,ENV_HV1BR,ENV_HV1J3,# & ENV_HV1Z6,ENV_HV1S1,ENV_HV1BN,ENV_HV1H2,ENV_HV1B1)# & PIR1: (VCLJLV,VCLJH3,A44963,VCLJZR,VCLJBR,VCLJVL)# & PIR2: (S21990,S70421,S70423,S70422,S22004,B41621,S22002,S70424,# & S70425,S21996,S22000,S70420,S21994,S21998,S22006,S70419,# & S21992,S70418,S54384,S70417)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,ERYLKDQQLLGIW*# SEQUENCE: ERYLKDQQLLGIW*# ...# >HUM10C4E# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (583-593)# DB REFERENCE: SWISS: (ENV_HV1S1,ENV_HV1OY,ENV_HV1EL,ENV_HV1PV,ENV_HV1Z2,# & ENV_HV1B8,ENV_HV1MF,ENV_HV1H3,ENV_HV1C4,ENV_HV1BR,# & ENV_HV1MN,ENV_HV1Z6,ENV_HV1J3,ENV_HV1ZH,ENV_HV1B1,# & ENV_HV1BN,ENV_HV1H2)# & PIR1: (VCLJBR,VCLJH3,VCLJLV,A44963,VCLJVL,VCLJMN,VCLJZR,# & VCLJH4)# & PIR2: (S70424,S70425,S22002,S22006,S21992,S70418,S21990,S22004,# & S70422,S70423,S70417,S54384,S70421,S70419,S22000,S70420,# & S21998,S21994,S21996)# & PIR3: (S13288,S33985)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,VERYLKDQQLL*# SEQUENCE: VERYLKDQQLL*# ...# >HUM10C4F# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (583-592)# DB REFERENCE: SWISS: (ENV_HV1OY,ENV_HV1EL,ENV_HV1B8,ENV_HV1Z6,ENV_HV1PV,# & ENV_HV1Z2,ENV_HV1H3,ENV_HV1C4,ENV_HV1BR,ENV_HV1JR,# & ENV_HV1MN,ENV_HV1MF,ENV_HV1J3,ENV_HV1KB,ENV_HV1BN,# & ENV_HV1H2,ENV_HV1B1,ENV_HV1ZH,ENV_HV1S1)# & PIR1: (VCLJKB,VCLJBR,VCLJLV,VCLJKX,A44963,VCLJZR,VCLJH4,VCLJH3,# & VCLJVL,VCLJMN)# & PIR2: (S70423,S70422,S22002,S21990,S21992,S70418,S21994,S70424,# & S70420,S70419,S70417,S70421,S22000,S22004,S54384,S70425,# & S22006,S21998,S21996)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a,hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,VERYLKDQQL*# SEQUENCE: VERYLKDQQL*# ...# >HUM10C50# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (584-593)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1S1,ENV_HV1OY,ENV_HV1B8,ENV_HV1Z6,# & ENV_HV1PV,ENV_HV1MN,ENV_HV1MF,ENV_HV1H3,ENV_HV1C4,# & ENV_HV1BR,ENV_HV1J3,ENV_HV1H2,ENV_HV1B1,ENV_HV1EL,# & ENV_HV1BN,ENV_HV1Z2)# & PIR1: (VCLJLV,VCLJH3,A44963,VCLJVL,VCLJMN,VCLJBR,VCLJZR,# & VCLJH4)# & PIR2: (S70424,S21992,S22006,S54384,S22004,S70419,S70417,B41621,# & S21994,S21990,S21998,S22000,S70425,S22002,S70421,S70422,# & S70423,S21996,S70420,S70418)# & PIR3: (S33985,S13288)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,ERYLKDQQLL*# SEQUENCE: ERYLKDQQLL*# ...# >HUM10C51# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV gp41 (584-594)# DB REFERENCE: SWISS: (ENV_HV1W1,ENV_HV1SC,ENV_HV1S3,ENV_HV1W2,ENV_HV1Y2,# & ENV_HV1RH,ENV_HV1A2,ENV_HV1ND)# & PIR1: (VCLJA2,VCLJND,VCLJSC,H44001,VCLJ3W)# & PIR2: (A41621,C41621)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,ERYLRDQQLLG*# SEQUENCE: ERYLRDQQLLG*# ...# >HUM10C52# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p17 (21-35)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1B1,GAG_HV1H2,GAG_HV1J3,GAG_HV2NZ,# & GAG_HV2CA,GAG_HV1A2,GAG_HV1BR,GAG_HV1B5)# & PIR1: (FOVWA2,FOVWLV,FOVWH3,FOVWVL,FOLJCA)# & PIR3: (S33979,S19598)# REFERENCES: suhrbier93a,johnson92a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,LRPGGKKKYKLKHIV*# SEQUENCE: LRPGGKKKYKLKHIV*# ...# >HUM10C53# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 (253-268)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_HV1BR,GAG_HV1W2,GAG_HV1J3,GAG_HV1Z2,# & GAG_HV1B1,GAG_HV1OY,GAG_HV1ND,GAG_HV1PV,GAG_HV1A2,# & GAG_HV1N5,GAG_HV1B5,GAG_HV1RH,GAG_HV1H2,GAG_HV1Y2,# & GAG_HV1JR)# & PIR1: (FOVWH3,FOVWLV,FOVWVL,FOLJND,FOVWA2,A44001,A38068)# & PIR2: (S54377,S60698,S60708,S60699,S60702,S60704,S60697,# & S60703)# & PIR3: (S33979)# REFERENCES: johnson92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,NPPIPVGEIYKRWIIL*# SEQUENCE: NPPIPVGEIYKRWIIL*# ...# >HUM10C54# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 (323-337)# DB REFERENCE: SWISS: (GAG_HV1EL,GAG_HV1BR,GAG_HV1JR,GAG_HV1MA,GAG_HV1W2,# & GAG_HV1MN,GAG_HV1Z2,GAG_HV1B1,GAG_HV1C4,GAG_HV1OY,# & GAG_HV1ND,GAG_HV1A2,GAG_HV1PV,GAG_HV1N5,GAG_HV1Y2,# & GAG_HV1H2,GAG_HV1J3,GAG_HV1RH,GAG_HV1B5)# & PIR1: (FOVWLV,FOVWH3,A38068,FOVWVL,A44001,FOVWA2,FOVWH4,# & FOLJND)# & PIR2: (S60708,S54377,S60699,S60704,S60700,S60698,S60703)# & PIR3: (S33979,S19598)# REFERENCES: suhrbier93a,johnson92a,buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,VQNANPDCKTILKAL*# SEQUENCE: VQNANPDCKTILKAL*# ...# >HUM10C55# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 RT (160-184)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1PV,POL_HV1OY,POL_HV1ND,POL_HV1MN,# & POL_HV1A2,POL_HV1Y2,POL_HV1N5,POL_HV1EL,POL_HV1B5,# & POL_HV1RH,POL_HV1JR,POL_HV1H2,POL_HV1B1,POL_HV1Z2)# & PIR1: (GNVWLV,GNLJND,GNVWA2,B44001,GNVWH3,GNVWVL)# & PIR2: (S32119,S32092,S32118,S32075,S32093,S32122,S54378,S32089,# & S32098,B47175,S32067,S32065,S32069,A47175,S32097,S63731,# & S32096,S32157,S32080,S32072,S32071,S32076,S32047,S32090,# & S32091,S32049,S32073,S63746,S32079,S32074,S32048,S32050,# & S32066,S63732,S32126,S32078,S63734,S32160,S32159,S32077,# & S32070,S32094,S32068,S32051)# & PIR3: (S33980)# REFERENCES: suhrbier93a,johnson92a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,IETVPVKLKPGMDGPKVKQWPLTEE*# SEQUENCE: IETVPVKLKPGMDGPKVKQWPLTEE*# ...# >HUM10C56# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (21-31)# DB REFERENCE: SWISS: (P53_CERAE,P53_CERAE,P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,DLWKLLPENNV*# SEQUENCE: DLWKLLPENNV*# ...# >HUM10C57# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./stabilisation as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 tumor supressor gene (24-32)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN,P53_CERAE,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: houbiers93a,stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KLLPENNVL*# SEQUENCE: KLLPENNVL*# ...# >HUM10C58# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./inhibition as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: p53 tumor supressor gene (25-35)# DB REFERENCE: SWISS: (P53_CERAE,P53_CERAE,P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: houbiers93a,theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesh,LLPENNVLSPL*# SEQUENCE: LLPENNVLSPL*# ...# >HUM10C59# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (65-74)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RMPEAAPPVA*# SEQUENCE: RMPEAAPPVA*# ...# >HUM10C5A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./stabilisation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: p53 tumor supressor gene (65-73)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# REFERENCES: houbiers93a,stuber94a,theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,RMPEAAPPV*# SEQUENCE: RMPEAAPPV*# ...# >HUM10C5B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (113-122)# DB REFERENCE: SWISS: (P53_CANFA,P53_SHEEP,P53_CRIGR,P53_CERAE,P53_HUMAN,# & P53_MESAU,P53_HUMAN,P53_SHEEP,P53_CERAE,P53_MESAU)# & PIR1: (DNHU53)# & PIR2: (S06594,JC6176,JC6193,JH0633)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,FLHSGTAKSV*# SEQUENCE: FLHSGTAKSV*# ...# >HUM10C5C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (129-138)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALNKMFCQLA*# SEQUENCE: ALNKMFCQLA*# ...# >HUM10C5D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./stabilisation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 tumor supressor gene (129-137)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: houbiers93a,stuber94a,theobald95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ALNKMFCQL*# SEQUENCE: ALNKMFCQL*# ...# >HUM10C5E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./stabilisation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (132-140)# DB REFERENCE: SWISS: (P53_CERAE,P53_HUMAN,P53_CERAE,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: houbiers93a,stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KMFCQLAKT*# SEQUENCE: KMFCQLAKT*# ...# >HUM10C5F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (136-145)# DB REFERENCE: SWISS: (P53_CRIGR,P53_MESAU,P53_HUMAN,P53_MOUSE,P53_FELCA,# & P53_MOUSE,P53_BOVIN,P53_SHEEP,P53_MESAU,P53_HUMAN,# & P53_SHEEP,P53_CERAE,P53_CERAE,P53_FELCA,P53_CANFA,# & P53_RAT,P53_RAT)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S38824,JH0633,S02192,JC6193,S06594,JC6176,S51648)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QLAKTCPVQL*# SEQUENCE: QLAKTCPVQL*# ...# >HUM10C60# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (168-176)# DB REFERENCE: SWISS: (P53_RAT,P53_HUMAN,P53_HUMAN,P53_CERAE,P53_CERAE,P53_RAT,# & P53_BOVIN,P53_MOUSE,P53_MOUSE)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S38824,S51648,S06594,S02192,JC6193)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,HMTEVVRRC*# SEQUENCE: HMTEVVRRC*# ...# >HUM10C61# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 tumor supressor gene (187-197)# DB REFERENCE: SWISS: (P53_RAT,P53_BOVIN,P53_MOUSE,P53_MESAU,P53_MESAU,# & P53_SHEEP,P53_HUMAN,P53_CERAE,P53_SHEEP,P53_CANFA,# & P53_HUMAN,P53_FELCA,P53_MOUSE,P53_FELCA,P53_CERAE,# & P53_RAT)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S06594,JH0633,S38824,S51648,S02192,JC6193,I46226)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLAPPQHLIRV*# SEQUENCE: GLAPPQHLIRV*# ...# >HUM10C62# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (193-203)# DB REFERENCE: SWISS: (P53_HUMAN,P53_CERAE,P53_HUMAN,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,HLIRVEGNLRV*# SEQUENCE: HLIRVEGNLRV*# ...# >HUM10C63# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./stabilisation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (256-265)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN,P53_CERAE,P53_RAT,P53_CERAE,# & P53_MOUSE,P53_RAT,P53_MOUSE)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S02192,JC6193,S38824,S06594)# REFERENCES: houbiers93a,stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,TLEDSSGNLL*# SEQUENCE: TLEDSSGNLL*# ...# >HUM10C64# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./stabilisation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 tumor supressor gene (263-272)# DB REFERENCE: SWISS: (P53_HUMAN,P53_CERAE,P53_CRIGR,P53_CERAE,P53_BOVIN,# & P53_HUMAN,P53_MESAU,P53_MESAU)# & PIR1: (DNHU53)# & PIR2: (JC6176,S51648,S06594,JC6193,JH0633)# REFERENCES: houbiers93a,stuber94a,theobald95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,NLLGRNSFEV*# SEQUENCE: NLLGRNSFEV*# ...# >HUM10C65# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 tumor supressor gene (264-274)# DB REFERENCE: SWISS: (P53_CERAE,P53_BOVIN,P53_FELCA,P53_CERAE,P53_HUMAN,# & P53_HUMAN,P53_FELCA)# & PIR1: (DNHU53)# & PIR2: (JC6193,S06594,S51648)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLGRNSFEVRV*# SEQUENCE: LLGRNSFEVRV*# ...# >HUM10C66# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 tumor supressor gene (339-407)# DB REFERENCE: SWISS: (P53_RAT,P53_MOUSE,P53_FELCA,P53_MOUSE,P53_CERAE,# & P53_FELCA,P53_SHEEP,P53_RAT,P53_HUMAN,P53_SHEEP,# & P53_CERAE,P53_HUMAN)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S38824,S06594,S02192,JC6193)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,EMFRELNEA*# SEQUENCE: EMFRELNEA*# ...# >HUM10C67# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 mutant (129-137)# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALNKMLCQL*# SEQUENCE: ALNKMLCQL*# ...# >HUM10C68# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 mutant (129-137)# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALNKMFYKL*# SEQUENCE: ALNKMFYKL*# ...# >HUM10C69# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 mutant (132-140)# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,NMFCQLAKT*# SEQUENCE: NMFCQLAKT*# ...# >HUM10C6A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 mutant (132-140)# DB REFERENCE: SWISS: (P53_SALIR,P53_SHEEP,P53_SHEEP,P53_MESAU,P53_FELCA,# & P53_XENLA,P53_XENLA,P53_BOVIN,P53_CRIGR,P53_SALIR,# & P53_MOUSE,P53_RAT,P53_CANFA,P53_MOUSE,P53_FELCA,# & P53_MESAU,P53_RAT)# & PIR1: (DNMS53)# & PIR2: (S02192,JH0633,JC6193,A29376,JC6176,JH0631,S51648)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KLFCQLAKT*# SEQUENCE: KLFCQLAKT*# ...# >HUM10C6B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 mutant (132-140)# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KMFYQLAKT*# SEQUENCE: KMFYQLAKT*# ...# >HUM10C6C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: P53 mutant (168-176)# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,HMTEVVRHC*# SEQUENCE: HMTEVVRHC*# ...# >HUM10C6D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 mutant (187-197)# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GLAPPQHFIRV*# SEQUENCE: GLAPPQHFIRV*# ...# >HUM10C6E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 mutant (264-273)# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLGRNSFEVCV*# SEQUENCE: LLGRNSFEVCV*# ...# >HUM10C6F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 mutant (264-274)# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLGRNSFEVC*# SEQUENCE: LLGRNSFEVC*# ...# >HUM10C70# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ALGRNSFEV*# SEQUENCE: ALGRNSFEV*# ...# >HUM10C71# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LLARNSFEV*# SEQUENCE: LLARNSFEV*# ...# >HUM10C72# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LLGANSFEV*# SEQUENCE: LLGANSFEV*# ...# >HUM10C73# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LLGRASFEV*# SEQUENCE: LLGRASFEV*# ...# >HUM10C74# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LLGRNAFEV*# SEQUENCE: LLGRNAFEV*# ...# >HUM10C75# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LLGRNSAEV*# SEQUENCE: LLGRNSAEV*# ...# >HUM10C76# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LLGRNSFAV*# SEQUENCE: LLGRNSFAV*# ...# >HUM10C77# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,RLGRNSFEV*# SEQUENCE: RLGRNSFEV*# ...# >HUM10C78# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: p53 (264-272) homologue# DB REFERENCE: SWISS: (P53_SALIR,P53_SALIR)# & PIR2: (JH0631)# REFERENCES: houbiers93a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LLGRRSFEV*# SEQUENCE: LLGRRSFEV*# ...# >HUM10C79# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza matrix (41-51)# DB REFERENCE: SWISS: (VMT1_IAWIL,VMT1_IAPUE,VMT1_IAFPW,VMT1_IAFPR)# & PIR1: (MFIVWS,MFIV,MFIV1F)# & PIR2: (S07945,S04054,S07429,S04050)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,VLMEWLKTRPI*# SEQUENCE: VLMEWLKTRPI*# ...# >HUM10C7A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza matrix (3-11)# DB REFERENCE: SWISS: (VMT1_IAMAN,VMT1_IALE1,VMT1_IAANN,VMT1_IAFOW,VMT1_IAFPW,# & VMT1_IAWIL,VMT1_IAUSS,VMT1_IALE2,VMT1_IACKB,VMT1_IAPUE,# & VMT1_IABAN,VMT1_IAUDO,VMT1_IAFPR)# & PIR1: (PN0086,JN0392,MFIVC,MFIVWS,MFIV,MFIV1K,MFIV1F,PN0083,# & B45539,MFIV61,MFIV1M)# & PIR2: (S04050,S04058,S07945,S14616,S04052,S04056,S07429,# & S04054)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,LLTEVETYV*# SEQUENCE: LLTEVETYV*# ...# >HUM10C7B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza matrix (3-12)# DB REFERENCE: SWISS: (VMT1_IAANN,VMT1_IAWIL,VMT1_IAUDO,VMT1_IAFPW,VMT1_IAFOW,# & VMT1_IABAN,VMT1_IAPUE,VMT1_IAFPR,VMT1_IAMAN,VMT1_IALE1,# & VMT1_IALE2,VMT1_IAUSS,VMT1_IACKB)# & PIR1: (MFIV61,MFIVC,MFIV,PN0083,PN0086,MFIV1M,MFIVWS,B45539,# & MFIV1K,JN0392,MFIV1F)# & PIR2: (S07945,S04054,S07429,S04056,S04052,S14616,S04050,# & S04058)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LLTEVETYVL*# SEQUENCE: LLTEVETYVL*# ...# >HUM10C7C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza matrix (51-59)# DB REFERENCE: SWISS: (VMT1_IAPUE,VMT1_IACKB,VMT1_IAUSS,VMT1_IALE1,VMT1_IABAN,# & VMT1_IALE2,VMT1_IAMAN,VMT1_IAZI1,VMT1_IAUDO,VMT1_IAWIL,# & VMT1_IAANN,VMT1_IAFOW)# & PIR1: (MFIV1K,JN0392,MFIVWS,MFIV1M,MFIV,MFIVC,MFIV61)# & PIR2: (S04056,S04054,S04050,S04052,S14616,S04058,S07429)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ILSPLTKGI*# SEQUENCE: ILSPLTKGI*# ...# >HUM10C7D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza matrix (51-60)# DB REFERENCE: SWISS: (VMT1_IAMAN,VMT1_IAWIL,VMT1_IABAN,VMT1_IACKB,VMT1_IAFOW,# & VMT1_IALE2,VMT1_IAUDO,VMT1_IAZI1,VMT1_IAANN,VMT1_IAPUE,# & VMT1_IALE1,VMT1_IAUSS)# & PIR1: (MFIV,MFIV1M,JN0392,MFIV1K,MFIV61,MFIVWS,MFIVC)# & PIR2: (S04058,S04052,S07429,S04054,S04056,S14616,S04050)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILSPLTKGIL*# SEQUENCE: ILSPLTKGIL*# ...# >HUM10C7E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza matrix (58-68)# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IAMAN,VMT1_IAWIL,VMT1_IAUDO,VMT1_IALE1,# & VMT1_IAUSS,VMT1_IAPUE,VMT1_IAANN,VMT1_IAZI1,VMT1_IABAN,# & VMT1_IAFOW,VMT1_IALE2)# & PIR1: (MFIV1K,MFIV61,MFIV,MFIVWS,MFIVC,MFIV1M,JN0392)# & PIR2: (S04056,S04050,S14616,S04052,S04058,S04054,S07429)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GILGFVFTLTV*# SEQUENCE: GILGFVFTLTV*# ...# >HUM10C7F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza matrix (2-11)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IALE1,VMT1_IAFPR,VMT1_IAFPW,VMT1_IAMAN,# & VMT1_IAUSS,VMT1_IABAN,VMT1_IAFOW,VMT1_IAPUE,VMT1_IACKB,# & VMT1_IAUDO,VMT1_IAWIL,VMT1_IAANN)# & PIR1: (MFIVC,MFIVWS,B45539,MFIV1K,MFIV,MFIV1F,PN0083,MFIV1M,# & MFIV61,JN0392,PN0086)# & PIR2: (S04058,S07429,S04050,S04056,S04052,S07945,S14616,# & S04054)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,SLLTEVETYV*# SEQUENCE: SLLTEVETYV*# ...# >HUM10C80# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza matrix (2-12)# DB REFERENCE: SWISS: (VMT1_IAMAN,VMT1_IAFPR,VMT1_IABAN,VMT1_IAFOW,VMT1_IAUDO,# & VMT1_IAWIL,VMT1_IACKB,VMT1_IALE2,VMT1_IAPUE,VMT1_IAFPW,# & VMT1_IAANN,VMT1_IALE1,VMT1_IAUSS)# & PIR1: (MFIV1K,JN0392,MFIV1M,PN0083,PN0086,MFIV1F,MFIV61,B45539,# & MFIVC,MFIV,MFIVWS)# & PIR2: (S04056,S14616,S04054,S04050,S07429,S04058,S07945,# & S04052)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLLTEVETYVL*# SEQUENCE: SLLTEVETYVL*# ...# >HUM10C81# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza matrix (50-59)# DB REFERENCE: SWISS: (VMT1_IALE1,VMT1_IAUDO,VMT1_IAWIL,VMT1_IAZI1,VMT1_IAPUE,# & VMT1_IACKB,VMT1_IAFOW,VMT1_IABAN,VMT1_IAUSS,VMT1_IAANN,# & VMT1_IAMAN,VMT1_IALE2)# & PIR1: (MFIVC,MFIV61,MFIV,MFIV1M,MFIV1K,JN0392,MFIVWS)# & PIR2: (S04054,S04056,S04052,S04058,S04050,S07429,S14616)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,PILSPLTKGI*# SEQUENCE: PILSPLTKGI*# ...# >HUM10C82# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza matrix (134-142)# DB REFERENCE: SWISS: (VMT1_IAFOW,VMT1_IABAN,VMT1_IALE2,VMT1_IAWIL,VMT1_IAUDO,# & VMT1_IALE1,VMT1_IAANN,VMT1_IAPUE)# & PIR1: (MFIVWS,MFIV,MFIV1K,MFIVC,MFIV61)# & PIR2: (S04056,S04058,S07429,S14616,S04050,S04052,S04054)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,RMGAVTTEV*# SEQUENCE: RMGAVTTEV*# ...# >HUM10C83# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza matrix (59-68)# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IAPUE,VMT1_IAMAN,VMT1_IALE2,VMT1_IAUDO,# & VMT1_IAWIL,VMT1_IAZI1,VMT1_IAFOW,VMT1_IABAN,VMT1_IAANN,# & VMT1_IAUSS,VMT1_IALE1)# & PIR1: (MFIV,MFIV61,MFIVWS,MFIVC,MFIV1M,MFIV1K,JN0392)# & PIR2: (S07429,S04056,S04054,S04050,S14616,S04052,S04058)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILGFVFTLTV*# SEQUENCE: ILGFVFTLTV*# ...# >HUM10C84# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza matrix (145-155)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IAZI1,VMT1_IAFPW,VMT1_IALE1,VMT1_IAANN,# & VMT1_IAPUE,VMT1_IAFOW,VMT1_IAUDO,VMT1_IACKB,VMT1_IAWIL,# & VMT1_IAMAN,VMT1_IAFPR,VMT1_IABAN,VMT1_IACAO)# & PIR1: (MFIV1K,MFIV61,PN0086,MFIVWS,B45539,PN0083,MFIV1F,MFIV,# & MFIVC,MFIV1M)# & PIR2: (S04050,S07429,S14616,S04052,S04058,S04054,S04056,# & S07945)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GLVCATCEQIA*# SEQUENCE: GLVCATCEQIA*# ...# >HUM10C85# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza matrix (164-172)# DB REFERENCE: SWISS: (VMT1_IAUSS,VMT1_IACAO,VMT1_IAANN,VMT1_IACKB,VMT1_IAWIL,# & VMT1_IAFPW,VMT1_IAZI1,VMT1_IAFOW,VMT1_IAPUE)# & PIR1: (MFIV,JN0392,MFIVWS,PN0086,PN0083,MFIV61,B45539)# & PIR2: (S07945,S14616,S04052,S07429,S04050,S04056)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,QMVTTTNPL*# SEQUENCE: QMVTTTNPL*# ...# >HUM10C86# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza matrix (164-173)# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IAPUE,VMT1_IAANN,VMT1_IAZI1,VMT1_IAFOW,# & VMT1_IAFPW,VMT1_IAUSS,VMT1_IAWIL,VMT1_IACAO)# & PIR1: (JN0392,PN0083,B45539,MFIV61,PN0086,MFIVWS,MFIV)# & PIR2: (S04056,S14616,S04050,S07945,S04052,S07429)# REFERENCES: nijman93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QMVTTTNPLI*# SEQUENCE: QMVTTTNPLI*# ...# >HUM10C87# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry/binding as./Reconstitution/Reference# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA DP signal sequence# DB REFERENCE: SWISS: (HB2P_HUMAN,HB2Q_HUMAN,HB2Q_HUMAN)# & PIR1: (HLHUS2,HLHUPB)# & PIR2: (I54458,I38197,I38195,I59621,I54285)# REFERENCES: huczko93a,smith96a,skipper96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,APRTVALTA*# SEQUENCE: APRTVALTA*# ...# >HUM10C88# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 4 (I or L), position 6 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRIPITGI*# SEQUENCE: APRIPITGI*# ...# >HUM10C89# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 4 (I or L), position 6 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRIPITGL*# SEQUENCE: APRIPITGL*# ...# >HUM10C8A# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 4 (I or L), position 6 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRIPLTGI*# SEQUENCE: APRIPLTGI*# ...# >HUM10C8B# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 4 (I or L), position 6 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRIPLTGL*# SEQUENCE: APRIPLTGL*# ...# >HUM10C8C# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 4 (I or L), position 6 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRLPITGI*# SEQUENCE: APRLPITGI*# ...# >HUM10C8D# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 4 (I or L), position 6 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRLPITGL*# SEQUENCE: APRLPITGL*# ...# >HUM10C8E# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 4 (I or L), position 6 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRLPLTGI*# SEQUENCE: APRLPLTGI*# ...# >HUM10C8F# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 4 (I or L), position 6 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRLPLTGL*# SEQUENCE: APRLPLTGL*# ...# >HUM10C90# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRASRPSI*# SEQUENCE: APRASRPSI*# ...# >HUM10C91# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRASRPSL*# SEQUENCE: APRASRPSL*# ...# >HUM10C92# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry/binding as./Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA A*0201 signal sequence# DB REFERENCE: SWISS: (1A26_HUMAN,1A43_HUMAN,1A25_HUMAN,1A68_HUMAN,1A04_PANTR,# & 1A02_HUMAN,1A66_HUMAN,1A03_GORGO,1A26_HUMAN,1A34_HUMAN,# & 1A01_GORGO,1A23_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2)# & PIR2: (I37483,A35997,I38441,I37479,I61902,I37477,I61857,S01171,# & I38442,I84448,I84487,JH0534,I38436,S16769,I37542,JH0536,# & I37470,I37480,I38443,I54493,JL0135)# REFERENCES: huczko93a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,APRTLVLLL*# SEQUENCE: APRTLVLLL*# ...# >HUM10C93# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APAPTVAVI*# SEQUENCE: APAPTVAVI*# ...# >HUM10C94# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APAPTVAVL*# SEQUENCE: APAPTVAVL*# ...# >HUM10C95# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,MPRGVVVTI*# SEQUENCE: MPRGVVVTI*# ...# >HUM10C96# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,MPRGVVVTL*# SEQUENCE: MPRGVVVTL*# ...# >HUM10C97# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry/binding as.Reconstitution# ACTIVITY: ?# BINDING: yes, high# SOURCE: CD20# DB REFERENCE: SWISS: (CD20_HUMAN,CD2R_HUMAN)# & PIR1: (A30586)# REFERENCES: huczko93a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,RPKSNIVLL*# SEQUENCE: RPKSNIVLL*# ...# >HUM10C98# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,RPSGPGPEI*# SEQUENCE: RPSGPGPEI*# ...# >HUM10C99# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (SN22_HUMAN)# & PIR2: (S39580,S45251)# REFERENCES: huczko93a# COMMENT: Position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,RPSGPGPEL*# SEQUENCE: RPSGPGPEL*# ...# >HUM10C9A# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry/binding as./reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Topoisomerase II# DB REFERENCE: SWISS: (TOP2_MOUSE,TOPB_HUMAN,TOP2_RAT,TOP2_CRIGR,TOPA_HUMAN,# & TOP2_MOUSE)# & PIR2: (JN0598,A48536,B48536,JS0703,A39242,A44406,S54154,A40493,# & S59969)# REFERENCES: huczko93a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,SPRYIFTML*# SEQUENCE: SPRYIFTML*# ...# >HUM10C9B# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry/binding as./reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA B7 signal sequence# DB REFERENCE: SWISS: (1B02_HUMAN,1B31_HUMAN,1B32_HUMAN,1B39_HUMAN,1B04_HUMAN,# & 1B07_HUMAN,1B08_HUMAN,1B46_HUMAN)# & PIR1: (HLHUB7,S42102)# & PIR2: (I68850,I59651,I61862,I54418,I61859,I54314,I84431,S60601,# & I59645,I61903,I54505,I61865,I84488)# REFERENCES: huczko93a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,LVMAPRTVL*# SEQUENCE: LVMAPRTVL*# ...# >HUM10C9C# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 8 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,RVMAPRAII*# SEQUENCE: RVMAPRAII*# ...# >HUM10C9D# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 8 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,RVMAPRAIL*# SEQUENCE: RVMAPRAIL*# ...# >HUM10C9E# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 8 (I or L), position 9 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,RVMAPRALI*# SEQUENCE: RVMAPRALI*# ...# >HUM10C9F# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC - mass spectrometry/binding as./competitive binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mage-1# DB REFERENCE: SWISS: (1C11_HUMAN)# & PIR2: (I37529,I37078)# ANCHOR POSITIONS:# REFERENCES: huczko93a,chen94a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,RVMAPRALL*# SEQUENCE: RVMAPRALL*# ...# >HUM10CA0# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry/binding as./reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA DP signal sequence# DB REFERENCE: SWISS: (HB2Q_HUMAN,HB2Q_HUMAN,HB2P_HUMAN)# & PIR1: (HLHUPB,HLHUS2)# & PIR2: (I38197,I54458,I54285,I59621,I38195)# REFERENCES: huczko93a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,APRTVALTAL*# SEQUENCE: APRTVALTAL*# ...# >HUM10CA1# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 6 (I or L), position 8 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRAFIPIPV*# SEQUENCE: APRAFIPIPV*# ...# >HUM10CA2# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 6 (I or L), position 8 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRAFIPLPV*# SEQUENCE: APRAFIPLPV*# ...# >HUM10CA3# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 6 (I or L), position 8 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRAFLPIPV*# SEQUENCE: APRAFLPIPV*# ...# >HUM10CA4# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 6 (I or L), position 8 (I or L)# SUMMARY: HLA-B7,actunkn,bindyesu,APRAFLPLPV*# SEQUENCE: APRAFLPLPV*# ...# >HUM10CA5# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HPLC/mass spectrometry/binding as./reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: Histone H1 (49-59)# DB REFERENCE: SWISS: (H12_MOUSE,H1_SALTR,H11_MOUSE,H1D_HUMAN,H14_MOUSE,# & H1B_HUMAN,H12_RAT,H15_MOUSE,H13_MOUSE,H12_MOUSE,# & H1C_HUMAN,H11_BOVIN,H14_RABIT)# & PIR1: (HSHU11,HSHU1B,HSBO11,HSTR1)# & PIR2: (S49482,I49742,A02579,JX0086,B40335,A28470,JH0159)# REFERENCES: huczko93a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,AASKERSGVSL*# SEQUENCE: AASKERSGVSL*# ...# >HUM10CA6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YLLPAIVEL*# SEQUENCE: YLLPAIVEL*# ...# >HUM10CA7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 6 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,AVVPFIVSV*# SEQUENCE: AVVPFIVSV*# ...# >HUM10CA8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT: Position 6 (I or L)# SUMMARY: HLA-A2,actunkn,bindyesu,AVVPFLVSV*# SEQUENCE: AVVPFLVSV*# ...# >HUM10CA9# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly Ala homologue# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRAAAAAL*# SEQUENCE: APRAAAAAL*# ...# >HUM10CAA# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly Ala homologue# DB REFERENCE: SWISS: (EVX1_MOUSE)# & PIR2: (S12541)# REFERENCES: huczko93a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRAAAAAA*# SEQUENCE: APRAAAAAA*# ...# >HUM10CAB# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly Ala homologue# DB REFERENCE: SWISS: (RLA1_TRYCR,V33P_ADE02,V33P_ADE05,IE18_PRVIF,HMEV_DROME,# & HMEV_DROME)# & PIR1: (WMAD51,EDBEIF,R6UTP1)# & PIR2: (A26066)# REFERENCES: huczko93a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APAAAAAAA*# SEQUENCE: APAAAAAAA*# ...# >HUM10CAC# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly Ala homologue# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,AARAAAAAA*# SEQUENCE: AARAAAAAA*# ...# >HUM10CAD# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly Ala homologue# DB REFERENCE: SWISS: (GSH2_MOUSE,HMCU_DROME,KIR4_HUMAN,EVX2_MOUSE,YHI0_YEAST,# & GSH1_MOUSE,GSHI_MOUSE,BAF1_KLUMA,KPCM_HUMAN)# & PIR2: (S03170,S33791,A53215,A49432,A55929,A43915,A39065,I57039,# & S46774,A41726,S27806,S63604)# REFERENCES: huczko93a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,AAAAAAAAL*# SEQUENCE: AAAAAAAAL*# ...# >HUM10CAE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DP signal sequence homologue# ANCHOR POSITIONS:# REFERENCES: huczko93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ACRTVALTA*# SEQUENCE: ACRTVALTA*# ...# >HUM10CAF# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KXFKMILRK*# SEQUENCE: KXFKMILRK*# ...# >HUM10CB0# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLFKNILYK*# SEQUENCE: KLFKNILYK*# ...# >HUM10CB1# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,YLXVRXAXIV*# SEQUENCE: YLXVRXAXIV*# ...# >HUM10CB2# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLHKQRAKS*# SEQUENCE: KLHKQRAKS*# ...# >HUM10CB3# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SLFKQVVTK*# SEQUENCE: SLFKQVVTK*# ...# >HUM10CB4# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KXFVKXLXY*# SEQUENCE: KXFVKXLXY*# ...# >HUM10CB5# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SLFNTHLXK*# SEQUENCE: SLFNTHLXK*# ...# >HUM10CB6# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,TLANDXVVP*# SEQUENCE: TLANDXVVP*# ...# >HUM10CB7# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,GIFAXXXVKA*# SEQUENCE: GIFAXXXVKA*# ...# >HUM10CB8# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,TXFVKXLXY*# SEQUENCE: TXFVKXLXY*# ...# >HUM10CB9# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SLFDHILXKH*# SEQUENCE: SLFDHILXKH*# ...# >HUM10CBA# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLFKVVXNY*# SEQUENCE: KLFKVVXNY*# ...# >HUM10CBB# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLFNIMVTY*# SEQUENCE: KLFNIMVTY*# ...# >HUM10CBC# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLFKVTFSY*# SEQUENCE: KLFKVTFSY*# ...# >HUM10CBD# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,GLFPXQFAY*# SEQUENCE: GLFPXQFAY*# ...# >HUM10CBE# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SLFELVFXY*# SEQUENCE: SLFELVFXY*# ...# >HUM10CBF# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SLXEKTFDY*# SEQUENCE: SLXEKTFDY*# ...# >HUM10CC0# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SLHKYXFEY*# SEQUENCE: SLHKYXFEY*# ...# >HUM10CC1# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KMFNITVTY*# SEQUENCE: KMFNITVTY*# ...# >HUM10CC2# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLFVKVYNY*# SEQUENCE: KLFVKVYNY*# ...# >HUM10CC3# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KIVRKPGMA*# SEQUENCE: KIVRKPGMA*# ...# >HUM10CC4# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation and binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLYEKVYTY*# SEQUENCE: KLYEKVYTY*# ...# >HUM10CC5# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,GLFPGQFAY*# SEQUENCE: GLFPGQFAY*# ...# >HUM10CC6# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HPLC-Edman degradation/binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: eluted peptide# ANCHOR POSITIONS:# REFERENCES: dibrino94a,dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLFEKVYNY*# SEQUENCE: KLFEKVYNY*# ...# >HUM10CC7# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,GLFGGGGGY*# SEQUENCE: GLFGGGGGY*# ...# >HUM10CC8# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,GLFGGGGGK*# SEQUENCE: GLFGGGGGK*# ...# >HUM10CC9# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: dibrino93a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,GLGGGGFGY*# SEQUENCE: GLGGGGFGY*# ...# >HUM10CCA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CLKHIVWASRELERFA*# SEQUENCE: CLKHIVWASRELERFA*# ...# >HUM10CCB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CLGQLQPSLQTGSEEL*# SEQUENCE: CLGQLQPSLQTGSEEL*# ...# >HUM10CCC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CGSEELRSLYNTVATL*# SEQUENCE: CGSEELRSLYNTVATL*# ...# >HUM10CCD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,AFPPEVIPMFSALSEC*# SEQUENCE: AFPPEVIPMFSALSEC*# ...# >HUM10CCE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LQEQIGWMTNNPPIPC*# SEQUENCE: LQEQIGWMTNNPPIPC*# ...# >HUM10CCF# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CAEAMSQVTNPANIMM*# SEQUENCE: CAEAMSQVTNPANIMM*# ...# >HUM10CD0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CLGKIWPSYKGRPGNF*# SEQUENCE: CLGKIWPSYKGRPGNF*# ...# >HUM10CD1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (50-63)# DB REFERENCE: SWISS: (VNUC_IAME4,VNUC_IAMEA,VNUC_IAMEC,VNUC_IAB39,VNUC_IAHO2,# & VNUC_IAME5,VNUC_IAFOW,VNUC_IAMEB,VNUC_IAHIC,VNUC_IAANN,# & VNUC_IAPUE,VNUC_IAUSS,VNUC_IAUDO,VNUC_IAANN,VNUC_IAEN5,# & VNUC_IACAL,VNUC_IAHO1,VNUC_IATX7,VNUC_IAME3,VNUC_IAMEE,# & VNUC_IAWIL,VNUC_IABRA,VNUC_IAFOM,VNUC_IAMEF,VNUC_IAS31,# & VNUC_IAZDA,VNUC_IAZH1,VNUC_IAMEG,VNUC_IAVI6,VNUC_IALEN,# & VNUC_IANT6,VNUC_IAME6,VNUC_IAZCA,VNUC_IASIN,# & VNUC_IAKIE)# & PIR1: (VHIVX3,VHIV68,VHIVX5,VHIV34,VHIVN5,VHIVX6,VHIVX2,VHIVA7,# & VHIVX4,VHIVN7,VHIVXL,VHIV61,VHIVAK,VHIV8H)# & PIR2: (B36754)# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >HUM10CD2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu MP (57-68)# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KGILGFTLTV*# SEQUENCE: KGILGFTLTV*# ...# >MUS10CD3# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CMGARASVLSGGELDK*# SEQUENCE: CMGARASVLSGGELDK*# ...# >MUS10CD4# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CLGQLQPSLQTGSEEL*# SEQUENCE: CLGQLQPSLQTGSEEL*# ...# >MUS10CD5# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CGSEELRSLYNTVATL*# SEQUENCE: CGSEELRSLYNTVATL*# ...# >MUS10CD6# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CAAGTGNGSQVSQNY*# SEQUENCE: CAAGTGNGSQVSQNY*# ...# >MUS10CD7# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,VHQAISPRTLNAWVKC*# SEQUENCE: VHQAISPRTLNAWVKC*# ...# >MUS10CD8# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,SALSEGATPQDLNTMC*# SEQUENCE: SALSEGATPQDLNTMC*# ...# >MUS10CD9# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,GHQAAMQMLKETINEC*# SEQUENCE: GHQAAMQMLKETINEC*# ...# >MUS10CDA# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,IAPGQMREPRGSDIAC*# SEQUENCE: IAPGQMREPRGSDIAC*# ...# >MUS10CDB# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CAEAMSQVTNPANIMM*# SEQUENCE: CAEAMSQVTNPANIMM*# ...# >MUS10CDC# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CRFGEETTTPSQKQEPI*# SEQUENCE: CRFGEETTTPSQKQEPI*# ...# >MUS10CDD# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CPQKQEPIDKELYPLTS*# SEQUENCE: CPQKQEPIDKELYPLTS*# ...# >MUS10CDE# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CYPLTSLRSLFGNDPSSQ*# SEQUENCE: CYPLTSLRSLFGNDPSSQ*# ...# >MUS10CDF# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as./stabilisation of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: Flu NP (50-63)# DB REFERENCE: SWISS: (VNUC_IAZH1,VNUC_IAFOW,VNUC_IAMEA,VNUC_IAUSS,VNUC_IAZCA,# & VNUC_IAME5,VNUC_IACAL,VNUC_IAEN5,VNUC_IAMEC,VNUC_IAHIC,# & VNUC_IAMEG,VNUC_IAMEE,VNUC_IAS31,VNUC_IABRA,VNUC_IAHO1,# & VNUC_IAME3,VNUC_IAME4,VNUC_IAB39,VNUC_IAANN,VNUC_IAHO2,# & VNUC_IAME6,VNUC_IAMEB,VNUC_IAANN,VNUC_IAPUE,VNUC_IAUDO,# & VNUC_IAVI6,VNUC_IAZDA,VNUC_IAMEF,VNUC_IAFOM,VNUC_IAWIL,# & VNUC_IATX7,VNUC_IANT6,VNUC_IALEN,VNUC_IAKIE,# & VNUC_IASIN)# & PIR1: (VHIV34,VHIVX5,VHIVA7,VHIVN7,VHIV68,VHIVX3,VHIV61,VHIV8H,# & VHIVXL,VHIVN5,VHIVAK,VHIVX2,VHIVX4,VHIVX6)# & PIR2: (B36754)# REFERENCES: elvin91a,elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,SDYEGRLIQNSLTI*# SEQUENCE: SDYEGRLIQNSLTI*# ...# >MUS10CE0# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu NP (365-379)# DB REFERENCE: SWISS: (VNUC_IAHO2,VNUC_IANT6,VNUC_IAHO1)# & PIR1: (VHIV68,VHIV8H,VHIVN5)# REFERENCES: elvin91a,sauzet96a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,IASNENMDAMESSTL*# SEQUENCE: IASNENMDAMESSTL*# ...# >MUS10CE1# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,CLKHIVWASRELERFA*# SEQUENCE: CLKHIVWASRELERFA*# ...# >MUS10CE2# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,VHQAISPRTLNAWVKC*# SEQUENCE: VHQAISPRTLNAWVKC*# ...# >MUS10CE3# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,NAWVKVVEEKAFPEVC*# SEQUENCE: NAWVKVVEEKAFPEVC*# ...# >MUS10CE4# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,AFPPEVIPMFSALSEC*# SEQUENCE: AFPPEVIPMFSALSEC*# ...# >MUS10CE5# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,DLNTMLNTVGGHQAAC*# SEQUENCE: DLNTMLNTVGGHQAAC*# ...# >MUS10CE6# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# ANCHOR POSITIONS:# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,LQEQIGWMTNNPPIPC*# SEQUENCE: LQEQIGWMTNNPPIPC*# ...# >MUS10CE7# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 Gag# DB REFERENCE: SWISS: (GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: elvin91a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,NCRAPRKKGCWRCGR*# SEQUENCE: NCRAPRKKGCWRCGR*# ...# >MUS10CE8# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu NP (345-360)# DB REFERENCE: SWISS: (VNUC_IAMEA,VNUC_IAMEC,VNUC_IAKIE,VNUC_IAVI6,VNUC_IAS06,# & VNUC_IAME3,VNUC_IAB37,VNUC_IAME6,VNUC_IAMEB,VNUC_IAUDO,# & VNUC_IAB39,VNUC_IANT6,VNUC_IAS11,VNUC_IATX7,VNUC_IAHO2,# & VNUC_IAZDA,VNUC_IAMEG,VNUC_IAHO1,VNUC_IAZH1,# & VNUC_IACAL)# & PIR1: (VHIVA7,VHIVN5,VHIVN7,VHIVX5,VHIVX6,VHIV68,VHIV8H,# & VHIVAK)# REFERENCES: elvin91a,reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,SFIRGTKVSPRGKLST*# SEQUENCE: SFIRGTKVSPRGKLST*# ...# >HUM10CE9# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, little# SOURCE: P.falciparum CSP (300-308)# DB REFERENCE: SWISS: (CSP_PLAFL,CSP_PLAFA,CSP_PLAFO,CSP_PLAFW,CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (A54533,B29795,S05428,A54529,A29795)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,MPNDPNRNV*# SEQUENCE: MPNDPNRNV*# ...# >HUM10CEA# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, little# SOURCE: P.falciparum CSP (300-308)# ANCHOR POSITIONS:# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,MPNYPNRNV*# SEQUENCE: MPNYPNRNV*# ...# >HUM10CEB# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, little# SOURCE: P.falciparum CSP (300-308)# ANCHOR POSITIONS:# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,MPNNPNRNV*# SEQUENCE: MPNNPNRNV*# ...# >HUM10CEC# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, little# SOURCE: P.falciparum sporozoite hepatocyte binding antigen (7-15)# DB REFERENCE: SWISS: (SSSP_PLAFO)# & PIR2: (S30129,A45607)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,IPSLALMLI*# SEQUENCE: IPSLALMLI*# ...# >HUM10CED# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, little# SOURCE: P.falciparum sporozoite hepatocyte binding antigen (77-85)# DB REFERENCE: SWISS: (SSSP_PLAFO,SSSP_PLAFO)# & PIR2: (S30129,S10313)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,MPLETQLAI*# SEQUENCE: MPLETQLAI*# ...# >HUM10CEE# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: HPLC/X-ray cristallography/Reference# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: P.falciparum liver stage specific antigen (1786-1794)# DB REFERENCE: PIR2: (A45592)# REFERENCES: hill92a,smith96b# COMMENT:# SUMMARY: HLA-B53,actyesu,bindyesl,KPIVQYDNF*# SEQUENCE: KPIVQYDNF*# ...# >HUM10CEF# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, little# SOURCE: P.falciparum trombospondin related protein (529-537)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,EPAPFDETL*# SEQUENCE: EPAPFDETL*# ...# >HUM10CF0# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: HPLC/competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P.falciparum trombospondin related protein (206-214)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# REFERENCES: hill92a,doolan97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,HPSDGKCNL*# SEQUENCE: HPSDGKCNL*# ...# >HUM10CF1# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: HIV-2# DB REFERENCE: SWISS: (GAG_HV2G1,GAG_SIVAG,GAG_HV2ST,GAG_SIVAT,GAG_SIVMS,# & GAG_HV2RO,GAG_HV2CA,GAG_HV2D2,GAG_SIVSP,GAG_SIVMK,# & GAG_HV2BE,GAG_HV2D1,GAG_HV2SB,GAG_HV2NZ,GAG_HV2KR,# & GAG_SIVS4,GAG_SIVA1)# & PIR1: (FOLJG2,FOLJST,FOLJG4,FOLJTM,FOLJCA,FOLJG5,FOLJGG)# & PIR2: (S53091,S12152,S04237,S08435,S03070)# REFERENCES: hill92a,brander95a# COMMENT:# SUMMARY: HLA-B53,actyesu,bindyesl,TPYDINQML*# SEQUENCE: TPYDINQML*# ...# >HUM10CF2# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, little# SOURCE: eluted self peptide# DB REFERENCE: SWISS: (1B52_HUMAN,1B11_HUMAN,1A23_HUMAN,1C01_SAGOE,1CXX_HUMAN,# & 1B02_HUMAN,1A01_HUMAN,1A02_HUMAN,1B23_HUMAN,1B12_HUMAN,# & 1A03_HUMAN,1A01_PONPY,1A11_HUMAN,1A31_HUMAN,1B07_HUMAN,# & 1A01_GORGO,1A33_HUMAN,1B01_PANTR,1B42_HUMAN,1A30_HUMAN,# & 1C15_HUMAN,1B04_GORGO,1A26_HUMAN,1C14_HUMAN,1C16_HUMAN,# & HLAF_HUMAN,1A31_HUMAN,1B15_HUMAN,1B10_HUMAN,1A29_HUMAN,# & 1B31_HUMAN,1B63_HUMAN,1B27_HUMAN,1B44_HUMAN,1B43_HUMAN,# & 1A25_HUMAN,1A68_HUMAN,1A04_PANTR,1A43_HUMAN,1B19_HUMAN,# & 1A26_HUMAN,HLAE_PONPY,1C11_HUMAN,1B20_HUMAN,1B12_HUMAN,# & HLAH_HUMAN,1C28_PANTR,1C03_GORGO,1B29_HUMAN,HLAE_HUMAN,# & 1A03_GORGO,1A80_HUMAN,1B57_HUMAN,1A32_HUMAN,1B04_HUMAN,# & 1B01_SAGOE,1B62_HUMAN,1A36_HUMAN,1A24_HUMAN,1A01_PANTR,# & 1B38_HUMAN,1B24_HUMAN,1B59_HUMAN,1B14_HUMAN,1B34_HUMAN,# & 1C01_GORGO,1C01_PANTR,1A74_HUMAN,1B39_HUMAN,1B25_HUMAN,# & 1B49_HUMAN,1B05_HUMAN,1B46_HUMAN,1B40_HUMAN,1B13_HUMAN,# & 1C18_HUMAN,1OKO_GORGO,1A69_HUMAN,1B28_HUMAN,HLAH_HUMAN,# & 1B02_PANTR,1B53_HUMAN,1C02_HUMAN,1B03_GORGO,1B36_HUMAN,# & 1B01_GORGO,1B21_HUMAN,1B16_HUMAN,1B35_HUMAN,1B22_HUMAN,# & 1A04_GORGO,1A02_PANTR,1B08_HUMAN,1B41_HUMAN,1B60_HUMAN,# & 1B33_HUMAN,1B55_HUMAN,1B54_HUMAN,1A66_HUMAN,1AXX_HUMAN,# & 1B47_HUMAN,1C02_GORGO,1B32_HUMAN,1A02_HUMAN,1B45_HUMAN,# & 1B56_HUMAN,HA19_CANFA,1C04_GORGO,1B48_HUMAN,1C06_HUMAN,# & 1C01_HUMAN,1C07_HUMAN,1C05_HUMAN,1C02_HUMAN,1C13_HUMAN,# & 1C17_HUMAN,1B26_HUMAN,1C02_GORGO,HLAF_HUMAN,1B18_HUMAN,# & 1B58_HUMAN,1A02_GORGO,1B61_HUMAN,1B02_GORGO,1A34_HUMAN,# & 1C12_HUMAN)# & PIR1: (HLHUB2,HLHUB7,HLHUB8,HLHU12,HLHUB4,HLHUC4,HLHUW3,HLHU28,# & HLHU40,HLHU10,HLHUA3,HLHU69,HLHU32,HLHUA2,HLHUAW,# & PIR2: (A45850,I62041,I72217,JH0290,I36958,I37470,S11140,I38610,# & I54298,I37526,JH0292,I72170,I37519,I61867,I37544,JH0526,# & I37523,I36961,I37480,I72753,S25415,I54308,I68701,I72113,# & I72218,S11142,I62043,I84487,I84448,JH0540,JH0539,I37527,# & A45880,S11138,A45845,I37135,I80168,I59655,I54289,I61859,# & I56133,I36959,S16769,JH0288,S03537,JH0534,I59651,S44994,# & I54418,JH0546,JH0543,S24438,S52486,I37516,S35940,I38436,# & I37476,I37479,G01230,S18197,I61856,I37482,S24435,I54430,# & I54505,I59308,S11137,I37492,I37485,JH0536,I61864,JH0538,# & I56039,I62042,I37478,I37542,I62045,I54463,I36956,I61865,# & JH0545,I59622,I54314,JL0135,I84431,I37120,S24439,I36965,# & S42823,I54493,I36966,I54412,I37483,S11141,I61904,A45847,# & I37522,I80166,I38441,I38437,I56149,A35997,A37028,S11134,# & I68750,A45857,I61902,I37520,C35997,I83063,I36957,I37078,# & I54449,I61905,I80169,C37028,B45897,I62044,I81232,JH0535,# & A28834,B30345,S11139,I36962,I81231,S18198,D35997,I80165,# & I37475,S16789,I38505,I84490,S24027,I68850,JH0542,I68749,# & I68774,I37477,I56130,I54442,S11135,I84432,I38518,I61857,# & I68748,S24436,S48134,I38442,S01171,I38439,JH0541,I61863,# & I72752,I68745,B37028,I59645,JH0544,I54307,JH0537,I68724,# & A30345,I38509,I68747,I59633,S24440,I38507,JS0262,I38421,# & I84486,I61907,I37521,I38443,I56034,A45897,I61860,I72755,# & I80171,S60601,I56116,A47636,S03538,I72754,I68700,I72171,# & S24433,I38519,JH0547,I61861,A60384,I59654,I36960,I80170,# & I84488,I54457,I61906,I61903,I81233,S24434,I54416,I61862,# & I67482,S24437,JH0291,S33355,I80167,A45834,S11136)# & PIR3: (G02922,S07113,S07115,S07114,S06424)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,YPAEITLTW*# SEQUENCE: YPAEITLTW*# ...# >HUM10CF3# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P.falciparum sporozoite hepatocyte binding antigen (7-15)# DB REFERENCE: SWISS: (SSSP_PLAFO)# & PIR2: (S30129,A45607)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPSLALMLI*# SEQUENCE: IPSLALMLI*# ...# >HUM10CF4# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: HPLC/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: P.falciparum sporozoite hepatocyte binding antigen (77-85)# DB REFERENCE: SWISS: (SSSP_PLAFO,SSSP_PLAFO)# & PIR2: (S30129,S10313)# REFERENCES: hill92a,connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,MPLETQLAI*# SEQUENCE: MPLETQLAI*# ...# >HUM10CF5# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P.falciparum CSP (300-308)# DB REFERENCE: SWISS: (CSP_PLAFL,CSP_PLAFA,CSP_PLAFW,CSP_PLAFO,CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (S05428,A54529,A54533,B29795,A29795)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,MPNDPNRNV*# SEQUENCE: MPNDPNRNV*# ...# >HUM10CF6# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, little# SOURCE: P.falciparum CSP (300-308)# ANCHOR POSITIONS:# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,MPNYPNRNV*# SEQUENCE: MPNYPNRNV*# ...# >HUM10CF7# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P.falciparum CSP (368-375)# DB REFERENCE: SWISS: (CSP_PLAFT,CSP_PLAFO,CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (S05428,C60657,B60657,A38869,A54533)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,KPKDELDY*# SEQUENCE: KPKDELDY*# ...# >HUM10CF8# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P.falciparum CSP (368-375)# ANCHOR POSITIONS:# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,KSKDELDY*# SEQUENCE: KSKDELDY*# ...# >HUM10CF9# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P.falciparum liver stage specific antigen (1850-1857)# DB REFERENCE: PIR2: (A45592)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,KPNDKSLY*# SEQUENCE: KPNDKSLY*# ...# >HUM10CFA# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P.falciparum CSP# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLAFW,CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (A54529,A54533)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,ENDIEKKICKMEKCS*# SEQUENCE: ENDIEKKICKMEKCS*# ...# >HUM10CFB# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P.falciparum CSP# DB REFERENCE: SWISS: (CSP_PLAFO)# & PIR2: (S05428)# REFERENCES: hill92a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,ELDYANDIEKKICKM*# SEQUENCE: ELDYANDIEKKICKM*# ...# >MUS20CFC# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p cyt c (88-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Es,actyesu,bindyesu,KAERADLIAYLKQATAK*# SEQUENCE: KAERADLIAYLKQATAK*# ...# >MUS20CFD# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,XQLGAQNEMLXPV*# SEQUENCE: XQLGAQNEMLXPV*# ...# >MUS20CFE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin (100-115)# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,AVVKKGTDFQLNQLE*# SEQUENCE: AVVKKGTDFQLNQLE*# ...# >MUS20CFF# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin (103-118)# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,KKGTDFQLNQLEGKKG*# SEQUENCE: KKGTDFQLNQLEGKKG*# ...# >MUS20D00# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ak beta (37-51)# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,EYVRFDSFVGEYRAVT*# SEQUENCE: EYVRFDSFVGEYRAVT*# ...# >MUS20D01# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: D10# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,XPLALQFAELPVNKG*# SEQUENCE: XPLALQFAELPVNKG*# ...# >MUS20D02# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,XPIDDGGIEA*# SEQUENCE: XPIDDGGIEA*# ...# >MUS20D03# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ek beta (33-48)# DB REFERENCE: SWISS: (HB23_MOUSE,HB2I_MOUSE,HB24_MOUSE)# & PIR1: (HLMSE2)# & PIR2: (A30529,I56056,S11650,S03117,A21200,A46561,I55654,I48657,# & S38676,A45836)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,EENLRFDSDVGEFRAV*# SEQUENCE: EENLRFDSDVGEFRAV*# ...# >MUS20D04# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MB1 (177-195)# DB REFERENCE: SWISS: (C79A_HUMAN,C79A_HUMAN,C79A_BOVIN,C79A_MOUSE,C79A_BOVIN,# & C79A_MOUSE)# & PIR2: (A46477,A43540,I57851)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,YEDENLYEGLNLDDCSMYE*# SEQUENCE: YEDENLYEGLNLDDCSMYE*# ...# >MUS20D05# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: cathepsin H (77-93)# DB REFERENCE: SWISS: (CATH_RAT)# & PIR1: (KHRTH)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,EYILYNKGIMGEDSYPY*# SEQUENCE: EYILYNKGIMGEDSYPY*# ...# >MUS20D06# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Fc e receptor II (298-311)# DB REFERENCE: SWISS: (FCE2_MOUSE,FCE2_MOUSE)# & PIR1: (LNMSER)# & PIR2: (S34198)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,RSYLDAWVCEQLAT*# SEQUENCE: RSYLDAWVCEQLAT*# ...# >MUS20D07# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ak beta (3-18)# DB REFERENCE: SWISS: (HB2K_MOUSE)# & PIR1: (HLMSBK)# & PIR2: (PL0286,PL0285)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,NSERHFVHQFQPFCYF*# SEQUENCE: NSERHFVHQFQPFCYF*# ...# >MUS20D08# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ak beta (10-21)# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,HQFQPFCYFTNT*# SEQUENCE: HQFQPFCYFTNT*# ...# >MUS20D09# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta 2 m (31-44)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,HPPHIEIQMLKNGK*# SEQUENCE: HPPHIEIQMLKNGK*# ...# >MUS20D0A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: c cyt inh (41-54)# DB REFERENCE: SWISS: (CLUS_RAT)# & PIR2: (A27205)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,YVNKEIQNAVQGVK*# SEQUENCE: YVNKEIQNAVQGVK*# ...# >MUS20D0B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta 2 m (31-47)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,FHPPHIEIQMLKNGKKIP*# SEQUENCE: FHPPHIEIQMLKNGKKIP*# ...# >MUS20D0C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: cognate HSP70 (234-249)# DB REFERENCE: SWISS: (HS7C_RAT,HS7C_BOVIN,HS70_ONCMY,HS7C_RAT,HS7C_HUMAN,# & HS7C_BOVIN,HS7C_ICTPU,HS7C_ICTPU)# & PIR2: (S07197,JC4853,A45935,S11456,S31716,A27077)# & PIR3: (S21175)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,FDNRMVNHFIAEFKRK*# SEQUENCE: FDNRMVNHFIAEFKRK*# ...# >MUS20D0D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: serum albumin (347-362)# DB REFERENCE: SWISS: (ALBU_MOUSE,ALBU_MOUSE,ALBU_RAT,ALBU_RAT)# & PIR1: (ABRTS)# & PIR2: (A05139)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,STPTLVEAARNLGRVG*# SEQUENCE: STPTLVEAARNLGRVG*# ...# >MUS20D0E# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,XXXLKIXXKG*# SEQUENCE: XXXLKIXXKG*# ...# >MUS20D0F# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta 2 m (31-44)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,HPPHIEIQMLKNGK*# SEQUENCE: HPPHIEIQMLKNGK*# ...# >MUS20D10# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ld (160-175)# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,EGECVEWLHRYKNGNA*# SEQUENCE: EGECVEWLHRYKNGNA*# ...# >MUS20D11# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,XXQILXLXGK*# SEQUENCE: XXQILXLXGK*# ...# >MUS20D12# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,XIMPFLKLFPG*# SEQUENCE: XIMPFLKLFPG*# ...# >MUS20D13# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: histone 2B (1-11)# ANCHOR POSITIONS:# REFERENCES: marrack93a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,PEPAKXAPAPK*# SEQUENCE: PEPAKXAPAPK*# ...# >MUS10D14# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: alkali hydrolisis and cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Beta galactosidose (876-884)# DB REFERENCE: SWISS: (BGAL_ECOLI,BGAL_ECOLI)# & PIR1: (GBEC)# REFERENCES: gavin93a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesu,TPHPARIGL*# SEQUENCE: TPHPARIGL*# ...# >HUM10D15# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: alkali hydrolisis and cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: CMV pp65 MP (123-131)# DB REFERENCE: SWISS: (PP65_HCMVT,PP65_HCMVA)# & PIR1: (WMBE65,WMBETW)# REFERENCES: gavin93a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,IPSINVHHY*# SEQUENCE: IPSINVHHY*# ...# >HUM10D16# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: alkali hydrolisis and cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: CMV major immediate-early protein (378-389)# DB REFERENCE: SWISS: (VIE1_HCMVT,VIE1_HCMVA)# & PIR1: (EDBEIC,EDBEM5)# REFERENCES: gavin93a# COMMENT:# SUMMARY: HLA-B18,actyesu,bindyesu,SDEEEAIVAYTL*# SEQUENCE: SDEEEAIVAYTL*# ...# >MUS10D17# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Insulin B chain bovine/mouse II (7-15)# DB REFERENCE: SWISS: (INS_ACOCA,INS_PETMA,INS_PIG,INS_ZAODH,INS_RODSP,# & INS_HYSCR,INS2_MOUSE,INS_ANSAN,INS_CANFA,INS_PSESC,# & INS1_XENLA,INS_AMICA,INS_PSAOB,INS_TORMA,INS_CROAT,# & INS_ACOCA,INS_RABIT,INS_HUMAN,INS_CAMDR,INS_ANGRO,# & INS_BALBO,INS_SHEEP,INS_BALPH,INS_PIG,INS2_XENLA,# & INS_KATPE,INS_LEPSP,INS_SELRF,INS_CERAE,INS_HUMAN,# & INS_MACFA,INS2_RAT,INS_SQUAC,INS_PANTR,INS_CAPHI,# & INS_SELRF,INS2_MOUSE,INS_CHICK,INS_BOVIN,INS_FELCA,# & INS_ANAPL,INS_ELEMA,INS_HORSE,INS_CRILO,INS_DIDMA)# & PIR1: (IPRT2,INDF,INPQ,INEL,A61129,IPRYM,INRB,A61125,IPXL2,# & IPPG,INHY,INCT,IPHU,IPHO,INLMS,INGT,INMS2,INWHP,IPBO,# & IPCH,INWH1S,INRS,INSH,IPDG,INCMA,INOS,INTK,INWHF,IPXL1,# & INGXA,INGS)# & PIR2: (A42179,JQ0178,S09278,JQ0359,B42179,A60414,A53438,JQ0362,# & S63591,I48166)# & PIR3: (S15426,I51221,JQ0363,S61361,JQ0360,S44470)# REFERENCES: sheil92a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,CGSHLVEAL*# SEQUENCE: CGSHLVEAL*# ...# >MUS10D18# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Insulin B chain bovine/mouse II (8-15)# DB REFERENCE: SWISS: (INS_BALBO,INS_FELCA,INS_HORSE,INS2_XENLA,INS_HUMAN,# & INS_SHEEP,INS_DIDMA,INS_ACOCA,INS_CERAE,INS_PSAOB,# & INS2_RAT,INS_PANTR,INS_ANAPL,INS_PIG,INS_ZAODH,# & INS_HYSCR,INS_RODSP,INS2_MOUSE,INS_ANSAN,INS_CANFA,# & INS_PSESC,INS_AMICA,INS1_XENLA,INS_KATPE,INS_HUMAN,# & INS_CAMDR,INS_ACOCA,INS_CROAT,INS_PIG,INS_BALPH,# & INS_MACFA,INS_SELRF,INS_LEPSP,INS_CAPHI,INS_SQUAC,# & INS_SELRF,INS2_MOUSE,INS_BOVIN,INS_CHICK,INS_ELEMA,# & INS_ANGRO,INS_CRILO,INS_RABIT,INS_TORMA,INS_PETMA)# & PIR1: (A61129,INWHP,IPBO,INMS2,INPQ,INOS,INCT,IPPG,INRB,A61125,# & IPXL2,IPDG,INSH,INGS,IPCH,INWH1S,IPHO,INGT,IPDK,INLMS,# & INEL,INDF,IPRT2,IPRYM,INRS,INHY,IPXL1,IPHU,INGXA,INTK,# & INWHF,INCMA)# & PIR2: (A53438,JQ0178,B42179,S09278,JQ0359,A60414,JQ0362,I48166,# & A42179,S63591)# & PIR3: (S15426,S44470,JQ0360,JQ0363,I51221,S61361)# REFERENCES: sheil92a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,GSHLVEAL*# SEQUENCE: GSHLVEAL*# ...# >MUS10D19# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Insulin B chain bovine/mouse II (9-15)# DB REFERENCE: SWISS: (INS_ZAODH,INS_CAPHI,INS_ACOCA,INS_HUMAN,INS_SHEEP,# & INS_DIDMA,INS_CERAE,INS_ACOCA,INS2_RAT,INS2_MOUSE,# & INS_PIG,INS_SQUAC,INS_AMICA,INS1_XENLA,INS_PSESC,# & INS_CANFA,INS_BALPH,INS_LEPSP,INS_KATPE,INS_ANSAN,# & INS2_MOUSE,INS_CHICK,INS_SELRF,INS_BOVIN,INS_ANGRO,# & INS_RABIT,INS_TORMA,INS_PSAOB,INS_HYSCR,INS_RODSP,# & INS_CRILO,INS2_XENLA,INS_PANTR,INS_SELRF,INS_ANAPL,# & INS_PETMA,INS_BALBO,INS_HORSE,INS_FELCA,INS_HUMAN,# & INS_PIG,INS_CROAT,INS_CAMDR,INS_MACFA,INS_ELEMA)# & PIR1: (IPDG,INOS,IPPG,INRB,INCT,A61129,INMS2,INSH,INGS,A61125,# & INRS,INLMS,IPHU,INEL,IPXL1,INTK,INWHF,INCMA,INGXA,INHY,# & IPDK,INDF,IPRT2,IPHO,IPCH,INGT,INWH1S,IPBO,INWHP,IPRYM,# & IPXL2,INPQ)# & PIR2: (S63591,JQ0362,A42179,I48166,B42179,A60414,JQ0178,JQ0359,# & A53438,S09278)# & PIR3: (S15426,JQ0363,S44470,JQ0360,S61361,I51221)# REFERENCES: sheil92a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,SHLVEAL*# SEQUENCE: SHLVEAL*# ...# >MUS10D1A# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Insulin B chain bovine/mouse II (10-15)# DB REFERENCE: SWISS: (INS_AOTTR,INS1_RAT,INS1_XENLA,INS_BALPH,INS_BALBO,# & INS_CROAT,INS_FELCA,NDI1_YEAST,INS_PSESC,INS_SELRF,# & INS_CANFA,INS_CHICK,INS_ANAPL,INS_PANTR,INS_SQUAC,# & INS_ACOCA,INS_ACOCA,INS2_RAT,INS_DIDMA,INS_SHEEP,# & INS_CERAE,INS2_MOUSE,INS_PIG,INS2_MOUSE,INS_ANSAN,# & INS_AMICA,INS_LEPSP,INS1_MOUSE,INS_BOVIN,INS_SELRF,# & INS_RABIT,INS_ANGRO,INS_PSAOB,INS_CRILO,INS_RODSP,# & INS_HYSCR,INS2_XENLA,INS_PETMA,INS_MACFA,INS_CAMDR,# & INS_PIG,INS_KATPE,INS_HUMAN,INS_HORSE,INS_ELEMA,# & THDF_ECOLI,INS_TORMA,INS_CAPHI,INS_ZAODH,INS_HUMAN,# & THDF_ECOLI,NDI1_YEAST)# & PIR1: (INRS,IPHU,INSH,A61129,INWHP,IPCH,INDF,IPXL1,INTK,INWHF,# & INMKSQ,INGXA,INMS2,INGS,IPDG,INOS,INCT,IPPG,INRB,INCMA,# & A61125,INHY,IPDK,IPRT2,IPHO,IPRT1,INPQ,INLMS,INEL,# & INWH1S,INGT,IPRYM,INMS1,IPXL2,IPBO)# & PIR2: (JQ0359,A60414,JQ0178,B42179,S26704,I48166,A42179,A53438,# & S09278,S63591,JQ0362,A39883,S74435)# & PIR3: (JQ0363,S15426,JQ0360,S61361,I51221,S44470)# REFERENCES: sheil92a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,HLVEAL*# SEQUENCE: HLVEAL*# ...# >MUS10D1B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Insulin B chain bovine/mouse I (7-15)# DB REFERENCE: SWISS: (INS1_RAT,INS1_MOUSE,INS_AOTTR)# & PIR1: (INMS1,IPRT1,INMKSQ)# & PIR2: (A39883)# REFERENCES: sheil92a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,CGPHLVEAL*# SEQUENCE: CGPHLVEAL*# ...# >HUM10D1C# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV2 ROD gag/SIVmac gag (182-190)# ANCHOR POSITIONS:# REFERENCES: gotch93a# COMMENT:# SUMMARY: HLA-B53,actyesu,bindyesu,TPYDLNQML*# SEQUENCE: TPYDLNQML*# ...# >RHE10D1D# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV2 ROD gag/SIVmac gag (182-190)# ANCHOR POSITIONS:# REFERENCES: gotch93a# COMMENT:# SUMMARY: Mamu-A1,actyesu,bindyesu,TPYDLNQML*# SEQUENCE: TPYDLNQML*# ...# >HUM10D1E# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA3C (258-266)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015)# REFERENCES: brooks93a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRIYDLIEL*# SEQUENCE: RRIYDLIEL*# ...# >HUM10D1F# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA3C (258-266)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (S33015,A31666)# REFERENCES: brooks93a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,LRGKWQRRYR*# SEQUENCE: LRGKWQRRYR*# ...# >HUM10D20# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LMP2 (236-244)# DB REFERENCE: SWISS: (LMP2_EBV)# & PIR1: (WMBELM)# REFERENCES: brooks93a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRRWRRLTV*# SEQUENCE: RRRWRRLTV*# ...# >HUM10D21# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity asays/competitive binding/binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBcAG (18-27)# DB REFERENCE: SWISS: (CORA_HPBVO,CORA_HPBVA,CORA_HPBVJ,CORA_HPBVF,CORA_HPBV9,# & CORA_HPBVL,CORA_HPBV2,CORA_HPBVW,CORA_HPBVY,CORA_HPBVZ,# & CORA_HPBVT)# & PIR1: (NKVLAH,NKVLJ2,NKVLBH,NKVLA1,NKVLA3,NKVLJ1,NKVLA6,NKVLKS,# & NKVLA2,NKVLCP,NKVLH3)# & PIR2: (S32204,S53152,S53251,S53216,S53274,S53225,S53207,S53175,# & S53232,S53242,S53223,S47405,S53211,S53236,S53272,S53288,# & S53181,S20746,S53227,S53240,JQ2227,S53270,S53189,S53200,# & S01405,S53159,S53214,S53255,S53281,S53267,S53129,S53163,# & S53221,S53178,S53257,S53238,S43490,S53260,S53143,S53202,# & S47409,S25651,S53169,S53229,S53279,S53137,S53253,S20750,# & S33686,S53184,S53155,S53286,S53204)# REFERENCES: missale93a,bertoletti94b,parker94a,cerny95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLPSDFFPSV*# SEQUENCE: FLPSDFFPSV*# ...# >HUM10D22# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-155)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVF,CORA_HPBVT,CORA_HPBVA,CORA_HPBVO,# & CORA_HPBV4,CORA_HPBVL,CORA_HPBVZ,CORA_HPBVY)# & PIR1: (NKVLAH,NKVLJ2,NKVLBH,NKVLA1,NKVLH3,NKVLA4,NKVLJ1,NKVLCP,# & NKVLA2)# & PIR2: (S53146,S53181,S53198,S53255,S53281,JQ2227,S53240,S53227,# & S47405,S53236,S53223,S53242,S53251,S53216,S53152,S32204,# & S53207,S53253,S20750,S53178,S53257,S35530,S53157,S53200,# & S53260,S53172,S53163,S53140,S53272,S53202,S53238,S53194,# & S20746,S53211,S53232,S53225,S53229,S53279,S53155,S53204,# & S53184,S53159,S53221,S04570)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,LSTLPETTVVRRRGRS*# SEQUENCE: LSTLPETTVVRRRGRS*# ...# >HUM10D23# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-154)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBV4,CORA_HPBVY,CORA_HPBVO,CORA_HPBVZ,# & CORA_HPBVT,CORA_HPBVJ,CORA_HPBVF,CORA_HPBVA)# & PIR1: (NKVLH3,NKVLA1,NKVLBH,NKVLJ2,NKVLAH,NKVLA4,NKVLA2,NKVLJ1,# & NKVLCP)# & PIR2: (S53257,S53157,S53207,S53163,S53270,S53227,S53236,S47405,# & S53221,S53204,S53184,S53216,S53223,S35530,S53198,S53260,# & S53178,S53140,S53152,S53169,S53159,JQ2227,S53240,S53242,# & S20750,S53253,S53251,S32204,S53255,S53281,S53146,S53181,# & S04570,S53279,S53175,S53229,S53155,S53211,S53225,S53232,# & S53272,S53166,S53200,S53194,S53172,S20746,S53238,# & S53202)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,LSTLPETTVVRRRGR*# SEQUENCE: LSTLPETTVVRRRGR*# ...# >HUM10D24# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-153)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVF,CORA_HPBVY,CORA_HPBVA,CORA_HPBV4,# & CORA_HPBVL,CORA_HPBVO,CORA_HPBVT,CORA_HPBVZ)# & PIR1: (NKVLA2,NKVLAH,NKVLA1,NKVLA4,NKVLJ2,NKVLCP,NKVLJ1,NKVLBH,# & NKVLH3)# & PIR2: (S53223,S53216,S53184,S53159,S53260,S35530,S53221,S53227,# & S47405,S53163,S53257,S53157,S20746,S53172,S53194,S53238,# & S53200,S53181,S53255,S53281,S53175,S53232,S53166,S53169,# & S53178,S53140,S20750,S53253,S53242,S53251,S32204,JQ2227,# & S53240,S53152,S53198,S53155,S53236,S53204,S53207,S53270,# & S53225,S53211,S53279,S53272,S53202,S04570,S53229,# & S53146)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,LSTLPETTVVRRRG*# SEQUENCE: LSTLPETTVVRRRG*# ...# >HUM10D25# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-152)# DB REFERENCE: SWISS: (CORA_HPBVW,CORA_HPBVZ,CORA_HPBVL,CORA_HPBV9,CORA_HPBVT,# & CORA_HPBVA,CORA_HPBV4,CORA_HPBVF,CORA_HPBVY,CORA_HPBVO,# & CORA_HPBVJ,CORA_HPBV2)# & PIR1: (NKVLA4,NKVLJ2,NKVLKS,NKVLCP,NKVLJ1,NKVLA6,NKVLBH,NKVLA3,# & NKVLH3,NKVLA2,NKVLA1,NKVLAH)# & PIR2: (S53157,S53257,S53240,S53242,S01405,S53223,S53159,S53279,# & S53270,S53207,S53225,S53172,S53200,S53211,S53155,S53169,# & JQ2227,S53238,S53166,S53232,S53181,S53255,S53129,S53281,# & S53178,S20750,S53253,S32204,S53251,S53140,S53175,S53260,# & S35530,S53221,S53227,S25651,S47409,S20746,S53194,S47405,# & S53163,S53216,S33686,S53184,S04570,S53229,S53146,S53202,# & S53272,S53236,S53204,S53152,S53198)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,LSTLPETTVVRRR*# SEQUENCE: LSTLPETTVVRRR*# ...# >HUM10D26# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-151)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVL,CORA_HPBVO,CORA_HPBV4,CORA_HPBV2,# & CORA_HPBVJ,CORA_HPBVZ,CORA_HPBVW,CORA_HPBVT,CORA_HPBVA,# & CORA_HPBVF,CORA_HPBVY)# & PIR1: (NKVLA6,NKVLJ2,NKVLA2,NKVLAH,NKVLA1,NKVLH3,NKVLKS,NKVLJ1,# & NKVLCP,NKVLA4,NKVLBH,NKVLA3)# & PIR2: (S53155,S53169,S53270,S53225,S53279,S53223,S53159,S53211,# & S53200,S53172,S53257,S53242,S01405,S53229,S53184,S53272,# & S53202,S53204,S53152,S53163,S53140,S32204,S53207,JQ2227,# & S53281,S53255,S53129,S20750,S53181,S53253,S53194,S20746,# & S53227,S25651,S47409,S35530,S53260,S53240,S53238,S53178,# & S53175,S04570,S53146,S53216,S53157,S53198,S53236,S53251,# & S53166,S53232,S33686,S53221,S47405)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,LSTLPETTVVRR*# SEQUENCE: LSTLPETTVVRR*# ...# >HUM10D27# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-155)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVA,CORA_HPBVT,CORA_HPBVY,CORA_HPBVO,# & CORA_HPBVF,CORA_HPBV4,CORA_HPBVZ,CORA_HPBVL)# & PIR1: (NKVLA2,NKVLJ2,NKVLCP,NKVLAH,NKVLH3,NKVLA1,NKVLJ1,NKVLA4,# & NKVLBH)# & PIR2: (S53202,S53229,S53204,S53242,S53260,S20750,S53255,S53281,# & S53225,S53223,S53159,S53155,S53172,S53211,S53232,S53272,# & S47405,S32204,S53181,S53140,S53238,S53152,S53184,S53253,# & S20746,S53227,S35530,S53251,S53163,S53194,S53279,S53257,# & S53221,S53200,S53216,S04570,S53146,S53240,JQ2227,S53207,# & S53236,S53198,S53157,S53178)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,STLPETTVVRRRGRS*# SEQUENCE: STLPETTVVRRRGRS*# ...# >HUM10D28# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-154)# DB REFERENCE: SWISS: (CORA_HPBVF,CORA_HPBVO,CORA_HPBVA,CORA_HPBVT,CORA_HPBVJ,# & CORA_HPBVZ,CORA_HPBVL,CORA_HPBV4,CORA_HPBVY)# & PIR1: (NKVLH3,NKVLA1,NKVLA2,NKVLJ2,NKVLCP,NKVLBH,NKVLJ1,NKVLA4,# & NKVLAH)# & PIR2: (S53181,S53175,S32204,S53140,S53238,S53155,S53159,S53172,# & S53211,S53194,S53272,S53163,S53146,S53240,S53207,JQ2227,# & S53229,S53255,S53281,S53166,S53260,S53236,S53270,S53198,# & S53169,S53227,S04570,S53232,S53251,S53184,S35530,S53257,# & S53279,S47405,S53202,S53204,S53242,S20750,S53223,S53225,# & S53216,S53178,S53157,S20746,S53152,S53253,S53221,# & S53200)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,STLPETTVVRRRGR*# SEQUENCE: STLPETTVVRRRGR*# ...# >HUM10D29# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-153)# DB REFERENCE: SWISS: (CORA_HPBV4,CORA_HPBVO,CORA_HPBVJ,CORA_HPBVT,CORA_HPBVA,# & CORA_HPBVL,CORA_HPBVF,CORA_HPBVY,CORA_HPBVZ)# & PIR1: (NKVLA1,NKVLA4,NKVLA2,NKVLJ2,NKVLCP,NKVLBH,NKVLAH,NKVLH3,# & NKVLJ1)# & PIR2: (S53198,S53159,S53281,S53255,S53172,S32204,S53140,S53163,# & S53194,S53152,S53253,S53270,S53229,S53169,S53236,S35530,# & S53178,S53257,S53184,S20746,S53221,S53157,S53279,S53175,# & S53238,S53272,S53181,S53155,S53211,S53166,S53260,S53146,# & S53240,S53207,JQ2227,S53200,S53242,S53204,S53202,S20750,# & S53227,S04570,S53232,S53251,S53216,S53223,S53225,# & S47405)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,STLPETTVVRRRG*# SEQUENCE: STLPETTVVRRRG*# ...# >HUM10D2A# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-152)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVF,CORA_HPBVY,CORA_HPBV2,CORA_HPBVZ,# & CORA_HPBVO,CORA_HPBVA,CORA_HPBVT,CORA_HPBVL,CORA_HPBV4,# & CORA_HPBVW,CORA_HPBV9)# & PIR1: (NKVLA4,NKVLA2,NKVLJ2,NKVLA6,NKVLKS,NKVLA1,NKVLA3,NKVLJ1,# & NKVLBH,NKVLCP,NKVLH3,NKVLAH)# & PIR2: (S53152,S53140,S32204,S53194,S53163,S53221,S53157,S53178,# & S53184,S20746,S53279,S53229,S33686,S53198,S53159,S53232,# & S04570,S53202,S53204,S53200,S53223,S25651,S53236,S20750,# & S01405,S53281,S35530,S53146,S53169,S47409,JQ2227,S53207,# & S53240,S53175,S53211,S53238,S53181,S53155,S53242,S53227,# & S53225,S53253,S53270,S53172,S53255,S53251,S47405,S53216,# & S53166,S53260,S53272,S53257,S53129)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,STLPETTVVRRR*# SEQUENCE: STLPETTVVRRR*# ...# >HUM10D2B# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-151)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVT,CORA_HPBVL,CORA_HPBV4,CORA_HPBVW,# & CORA_HPBVY,CORA_HPBVF,CORA_HPBV2,CORA_HPBVZ,CORA_HPBVJ,# & CORA_HPBVA,CORA_HPBVO)# & PIR1: (NKVLA2,NKVLH3,NKVLA1,NKVLKS,NKVLA4,NKVLA6,NKVLAH,NKVLA3,# & NKVLCP,NKVLBH,NKVLJ2,NKVLJ1)# & PIR2: (S33686,S53204,S53232,S53194,S53279,S53229,S53216,S53272,# & S53129,S47405,S53255,S53198,S53202,S04570,S53242,S53227,# & S53240,JQ2227,S47409,S53169,S25651,S01405,S20750,S53223,# & S53200,S53211,S53207,S53175,S53166,S53172,S53181,S53253,# & S53281,S53152,S53140,S32204,S53163,S53159,S53221,S53157,# & S20746,S53178,S53184,S53260,S53257,S53155,S53238,S53225,# & S53270,S53236,S35530,S53146,S53251)# REFERENCES: missale93a,falk94c,bertoni97a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,STLPETTVVRR*# SEQUENCE: STLPETTVVRR*# ...# >HUM10D2C# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-150)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBV4,CORA_HPBVW,CORA_HPBVO,CORA_HPBVA,# & CORA_HPBVJ,CORA_HPBV2,CORA_HPBVF,CORA_HPBVL,CORA_HPBVT,# & CORA_HPBVZ,CORA_HPBV9)# & PIR1: (NKVLAH,NKVLH3,NKVLA1,NKVLJ1,NKVLA4,NKVLA3,NKVLJ2,NKVLCP,# & NKVLBH,NKVLA6,NKVLKS,NKVLA2)# & PIR2: (S53279,S53194,S53129,S53216,S53227,S53242,S25651,S01405,# & S20750,S53240,S53169,S47409,S53172,S53253,S53181,S53281,# & S53166,S47405,S53198,S04570,S53232,S35530,S53236,S53225,# & S53270,S43490,S53157,S20746,S53178,S53257,S53251,S53211,# & S53175,S53200,S53207,S53140,S53159,S53260,S53223,S53202,# & S53255,S53288,JQ2227,S53229,S53204,S33686,S53272,S53146,# & S53238,S53155,S53221,S53184,S53152,S53163,S32204)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesl,bindyesu,STLPETTVVR*# SEQUENCE: STLPETTVVR*# ...# >HUM10D2D# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (142-154)# DB REFERENCE: SWISS: (CORA_HPBVT,CORA_HPBVY,CORA_HPBVJ,CORA_HPBVZ,CORA_HPBVF,# & CORA_HPBVA,CORA_HPBVO,CORA_HPBV4,CORA_HPBVL)# & PIR1: (NKVLA2,NKVLJ1,NKVLA1,NKVLA4,NKVLH3,NKVLCP,NKVLBH,NKVLAH,# & NKVLJ2)# & PIR2: (S53257,S53157,S53225,S53207,S53260,S53279,S04570,S47405,# & S53238,S53274,S53223,S53232,S53194,S20746,S53216,S53198,# & S53200,S53178,S53251,S53140,S53159,S53240,S53169,S20750,# & S53242,S53227,S35530,S53236,S53270,S53281,S53166,S53172,# & S53181,S53253,S53221,S53184,S32204,S53152,S53163,S53229,# & S53211,S53175,S53255,JQ2227,S53202,S53204,S53272,S53155,# & S53146)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesl,bindyesu,TLPETTVVRRRGR*# SEQUENCE: TLPETTVVRRRGR*# ...# >HUM10D2E# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (142-151)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBV9,CORA_HPBVW,CORA_HPBVL,CORA_HPBV4,# & CORA_HPBV2,CORA_HPBVJ,CORA_HPBVA,CORA_HPBVO,CORA_HPBVT,# & CORA_HPBVF,CORA_HPBVZ)# & PIR1: (NKVLA4,NKVLA6,NKVLH3,NKVLJ1,NKVLKS,NKVLA3,NKVLCP,NKVLBH,# & NKVLAH,NKVLA1,NKVLJ2,NKVLA2)# & PIR2: (S47405,S04570,S53238,S33686,S53274,S20746,S53200,S53223,# & S53232,S53194,S53216,S53257,S53157,S53225,S53260,S53175,# & S53229,S53281,S53181,S53253,S53221,S53163,S25651,JQ2227,# & S53129,S53272,S53236,S01405,S53152,S53178,S53251,S53140,# & S20750,S53242,S53169,S53159,S53198,S47409,S53255,S35530,# & S53166,S53172,S53279,S53207,S53211,S53155,S53146,S53204,# & S53202,S53240,S53227,S53270,S53184,S32204)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,TLPETTVVRR*# SEQUENCE: TLPETTVVRR*# ...# >HUM10D2F# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-155)# DB REFERENCE: SWISS: (CORA_HPBVA,CORA_HPBVJ,CORA_HPBVF,CORA_HPBVO,CORA_HPBVL,# & CORA_HPBVZ,CORA_HPBV4,CORA_HPBVT,CORA_HPBVY)# & PIR1: (NKVLJ2,NKVLJ1,NKVLA4,NKVLAH,NKVLCP,NKVLBH,NKVLA1,NKVLA2,# & NKVLH3)# & PIR2: (S53257,S53229,S53163,S53272,S53242,S53232,S53223,S53184,# & S53240,S53204,S53279,S53225,S53221,S53200,S04570,S53207,# & S53211,S53155,S35530,S53140,JQ2227,S53181,S53253,S53281,# & S53251,S53178,S20750,S53238,S47405,S20746,S53157,S53260,# & S53216,S53194,S53227,S32204,S53255,S53172,S53236,S53152,# & S53159,S53198,S53146,S53202)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,LSTLPETTVVRRRGRS*# SEQUENCE: LSTLPETTVVRRRGRS*# ...# >HUM10D30# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-154)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVJ,CORA_HPBVF,CORA_HPBVL,CORA_HPBV4,# & CORA_HPBVZ,CORA_HPBVA,CORA_HPBVO,CORA_HPBVT)# & PIR1: (NKVLA4,NKVLCP,NKVLAH,NKVLA1,NKVLA2,NKVLH3,NKVLJ2,NKVLJ1,# & NKVLBH)# & PIR2: (S53232,S53223,S53184,S53279,S35530,S53140,S53225,S53221,# & S53200,S53155,S53257,S53242,S53255,S53236,S53152,S53227,# & S53146,S53175,S53194,S53216,S53202,S53181,S53253,S53281,# & S20750,S53251,S53260,S20746,S47405,S53238,S53240,S32204,# & S53169,S53178,JQ2227,S53166,S04570,S53163,S53211,S53207,# & S53157,S53204,S53229,S53272,S53270,S53172,S53198,# & S53159)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,LSTLPETTVVRRRGR*# SEQUENCE: LSTLPETTVVRRRGR*# ...# >HUM10D31# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-153)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBVF,CORA_HPBVY,CORA_HPBV4,CORA_HPBVZ,# & CORA_HPBVO,CORA_HPBVA,CORA_HPBVT,CORA_HPBVJ)# & PIR1: (NKVLJ2,NKVLJ1,NKVLA1,NKVLA2,NKVLAH,NKVLCP,NKVLH3,NKVLA4,# & NKVLBH)# & PIR2: (S53223,S53272,S53270,S53238,S53216,S20750,S53227,S53202,# & S53146,S53255,S53236,S53242,S53200,S53159,JQ2227,S53178,# & S20746,S47405,S53181,S53194,S53251,S53140,S53175,S53253,# & S53281,S53260,S53232,S53184,S53279,S53221,S35530,S53152,# & S53257,S53225,S53155,S53163,S53207,S53211,S53157,S53240,# & S53169,S32204,S53166,S04570,S53204,S53229,S53172,# & S53198)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,LSTLPETTVVRRRG*# SEQUENCE: LSTLPETTVVRRRG*# ...# >HUM10D32# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-152)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBV4,CORA_HPBVZ,CORA_HPBVO,CORA_HPBV2,# & CORA_HPBVF,CORA_HPBVW,CORA_HPBVY,CORA_HPBVA,CORA_HPBVT,# & CORA_HPBV9,CORA_HPBVL)# & PIR1: (NKVLJ1,NKVLCP,NKVLH3,NKVLA3,NKVLA4,NKVLA2,NKVLA1,NKVLKS,# & NKVLBH,NKVLJ2,NKVLAH,NKVLA6)# & PIR2: (S53270,S53181,S20746,S01405,S53194,S53140,S53175,S53200,# & S53159,S53207,S53211,S32204,S53223,S53236,S53255,S53146,# & S53225,S53166,S53229,S53172,S53198,S53260,S53279,S35530,# & S25651,S53129,S53251,S47405,S53178,JQ2227,S53227,S53216,# & S20750,S53242,S53202,S47409,S53163,S53204,S04570,S53232,# & S53155,S53257,S53152,S53184,S53221,S53253,S53281,S53272,# & S53238,S33686,S53157,S53169,S53240)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,LSTLPETTVVRRR*# SEQUENCE: LSTLPETTVVRRR*# ...# >HUM10D33# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (140-151)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBV2,CORA_HPBVJ,CORA_HPBVO,CORA_HPBVT,# & CORA_HPBVF,CORA_HPBVY,CORA_HPBVA,CORA_HPBVW,CORA_HPBVL,# & CORA_HPBV4,CORA_HPBVZ)# & PIR1: (NKVLCP,NKVLA4,NKVLA3,NKVLJ1,NKVLA1,NKVLA2,NKVLA6,NKVLBH,# & NKVLH3,NKVLKS,NKVLAH,NKVLJ2)# & PIR2: (S53194,S53152,S53155,S53157,S53225,S53129,S53146,S53198,# & S53184,S53253,S53238,S47405,S53251,S53232,S20750,S53166,# & S53172,S53229,S53260,S35530,S53178,S53257,S25651,S53279,# & S20746,S53270,S53181,S53207,S53211,S32204,S53223,S53236,# & S53255,S53221,S53281,S01405,S53140,S53175,S53159,S53200,# & S53242,S53227,S53202,S53216,S47409,S53163,S04570,S53204,# & JQ2227,S53272,S33686,S53169,S53240)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,LSTLPETTVVRR*# SEQUENCE: LSTLPETTVVRR*# ...# >HUM10D34# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-155)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVJ,CORA_HPBVO,CORA_HPBVT,CORA_HPBVA,# & CORA_HPBVL,CORA_HPBV4,CORA_HPBVZ,CORA_HPBVF)# & PIR1: (NKVLA4,NKVLA2,NKVLJ1,NKVLCP,NKVLJ2,NKVLA1,NKVLBH,NKVLH3,# & NKVLAH)# & PIR2: (S53194,S53152,S53232,S53178,S53279,S20746,S53257,S53163,# & S53216,S53204,S53200,S53159,JQ2227,S53272,S53240,S53242,# & S53221,S53229,S53225,S53146,S35530,S53172,S53211,S53207,# & S53223,S53255,S53236,S53253,S53238,S53184,S53198,S20750,# & S53251,S53181,S53202,S04570,S53281,S53140,S32204,S53260,# & S47405,S53155,S53157,S53227)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,STLPETTVVRRRGRS*# SEQUENCE: STLPETTVVRRRGRS*# ...# >HUM10D35# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-154)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVO,CORA_HPBVY,CORA_HPBVT,CORA_HPBVL,# & CORA_HPBVZ,CORA_HPBV4,CORA_HPBVA,CORA_HPBVF)# & PIR1: (NKVLA1,NKVLJ1,NKVLA2,NKVLA4,NKVLCP,NKVLAH,NKVLJ2,NKVLH3,# & NKVLBH)# & PIR2: (S53279,S53232,S53194,S47405,S53155,S53200,S53223,S53255,# & S53207,S53270,S53163,S53216,JQ2227,S53253,S53227,S20750,# & S32204,S53236,S53159,S53240,S53272,S53211,S53166,S53281,# & S53172,S53181,S53229,S53169,S53152,S53204,S53175,S53178,# & S20746,S53257,S53260,S53140,S53225,S53242,S53221,S53146,# & S35530,S53202,S04570,S53251,S53198,S53184,S53238,# & S53157)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,STLPETTVVRRRGR*# SEQUENCE: STLPETTVVRRRGR*# ...# >HUM10D36# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-153)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVO,CORA_HPBVY,CORA_HPBVL,CORA_HPBVZ,# & CORA_HPBV4,CORA_HPBVA,CORA_HPBVF,CORA_HPBVT)# & PIR1: (NKVLJ1,NKVLJ2,NKVLAH,NKVLA1,NKVLBH,NKVLA4,NKVLCP,NKVLA2,# & NKVLH3)# & PIR2: (S53155,S47405,S53194,S53232,S20750,S32204,S53227,S53229,# & S53172,S53281,S53181,S53216,S53200,S53207,S53146,S53225,# & S53242,S53221,S35530,S53251,S20746,S53178,S53140,S53260,# & S53198,S53255,S53240,S53166,S53159,S53152,S53175,S53204,# & S53236,S53253,S53270,JQ2227,S53257,S53169,S53211,S53272,# & S53279,S53163,S53223,S53157,S53184,S53238,S53202,# & S04570)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,STLPETTVVRRRG*# SEQUENCE: STLPETTVVRRRG*# ...# >HUM10D37# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-152)# DB REFERENCE: SWISS: (CORA_HPBVT,CORA_HPBVW,CORA_HPBVJ,CORA_HPBVY,CORA_HPBVZ,# & CORA_HPBVL,CORA_HPBVF,CORA_HPBV9,CORA_HPBV2,CORA_HPBVA,# & CORA_HPBV4,CORA_HPBVO)# & PIR1: (NKVLA2,NKVLA6,NKVLH3,NKVLAH,NKVLJ2,NKVLBH,NKVLCP,NKVLA1,# & NKVLJ1,NKVLA4,NKVLKS,NKVLA3)# & PIR2: (S47409,S53181,S53232,S53272,S53169,S53157,S53238,S53223,# & S53175,S53166,S53240,S20746,S53146,S53221,S53200,S33686,# & S53194,S32204,S53155,S53270,S53159,S53255,S53178,S53140,# & S53152,S53260,S53216,S53198,S47405,S53207,S53225,S53242,# & S01405,S35530,S53251,S20750,S53227,S53229,S53172,S53281,# & S53211,S53129,S25651,JQ2227,S53257,S53184,S04570,S53202,# & S53279,S53163,S53253,S53236,S53204)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,STLPETTVVRRR*# SEQUENCE: STLPETTVVRRR*# ...# >HUM10D38# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-151)# DB REFERENCE: SWISS: (CORA_HPBVF,CORA_HPBVW,CORA_HPBVJ,CORA_HPBVL,CORA_HPBVZ,# & CORA_HPBVY,CORA_HPBV4,CORA_HPBV9,CORA_HPBVO,CORA_HPBV2,# & CORA_HPBVA,CORA_HPBVT)# & PIR1: (NKVLA6,NKVLH3,NKVLJ2,NKVLAH,NKVLBH,NKVLCP,NKVLKS,NKVLA1,# & NKVLJ1,NKVLA4,NKVLA3,NKVLA2)# & PIR2: (S53255,S53270,S53157,S53238,S53272,S47409,S53181,S32204,# & S53155,S53216,S53240,S53221,S53232,S53200,S25651,JQ2227,# & S53257,S20750,S53229,S53129,S53163,S53202,S53253,S53204,# & S35530,S53166,S53178,S53140,S53152,S53242,S53251,S53198,# & S53279,S53236,S53172,S53281,S53184,S53211,S53159,S53175,# & S53223,S53227,S01405,S53225,S53207,S47405,S53260,S53169,# & S33686,S53194,S53146,S20746,S04570)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,STLPETTVVRR*# SEQUENCE: STLPETTVVRR*# ...# >HUM10D39# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (141-150)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBVT,CORA_HPBVZ,CORA_HPBVW,CORA_HPBVF,# & CORA_HPBVJ,CORA_HPBV9,CORA_HPBVO,CORA_HPBVA,CORA_HPBV2,# & CORA_HPBV4,CORA_HPBVY)# & PIR1: (NKVLA4,NKVLJ2,NKVLBH,NKVLA3,NKVLA6,NKVLA1,NKVLKS,NKVLH3,# & NKVLCP,NKVLJ1,NKVLA2,NKVLAH)# & PIR2: (S53155,S32204,S53232,S53221,S53240,S33686,S53225,S53207,# & S04570,S53288,S53211,S53272,S53223,S53198,S20750,S53229,# & S53129,S43490,S53202,S53253,S53257,S53140,S53251,S53178,# & S53242,S53152,S53166,S53204,S53163,S53255,S53270,S47409,# & S53181,S53157,S53238,S25651,JQ2227,S53200,S53216,S53227,# & S47405,S01405,S53260,S35530,S53279,S53236,S53172,S53281,# & S53184,S53159,S53175,S20746,S53194,S53146,S53169)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,STLPETTVVR*# SEQUENCE: STLPETTVVR*# ...# >HUM10D3A# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (142-155)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBVT,CORA_HPBVY,CORA_HPBVF,CORA_HPBVJ,# & CORA_HPBVO,CORA_HPBVA,CORA_HPBV4,CORA_HPBVZ)# & PIR1: (NKVLA1,NKVLA2,NKVLAH,NKVLA4,NKVLBH,NKVLCP,NKVLJ2,NKVLJ1,# & NKVLH3)# & PIR2: (S53155,S53223,S53198,S53225,S53207,S04570,S53272,S53163,# & S53204,S53152,S53232,S53240,S35530,S53281,S53279,S53236,# & S53184,S53159,S53227,S47405,S53260,S53216,S53274,S53194,# & S20746,S53200,S53202,S53253,S53257,S53242,S53251,S53255,# & S53181,S53238,S53178,S53140,S53146,S53157,S53211,JQ2227,# & S53229,S20750,S53172,S53221,S32204)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,TLPETTVVRRRGRS*# SEQUENCE: TLPETTVVRRRGRS*# ...# >HUM10D3B# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (142-154)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVJ,CORA_HPBVZ,CORA_HPBVL,CORA_HPBVT,# & CORA_HPBVO,CORA_HPBVA,CORA_HPBV4,CORA_HPBVF)# & PIR1: (NKVLA1,NKVLA2,NKVLAH,NKVLJ1,NKVLCP,NKVLJ2,NKVLA4,NKVLH3,# & NKVLBH)# & PIR2: (S53229,S04570,S53204,S53223,S53242,S53181,S53216,S53279,# & S53270,S53232,S53236,S47405,S53207,S53255,S53202,S53157,# & S53274,S20746,S53281,S53227,S53260,S53257,S53253,S53238,# & S53251,S53200,S53194,S53240,S53178,S53140,S53169,S53155,# & S53198,S35530,S53159,S53184,S53272,S53175,S53225,S53163,# & S53152,JQ2227,S20750,S53166,S53146,S53211,S53172,S32204,# & S53221)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,TLPETTVVRRRGR*# SEQUENCE: TLPETTVVRRRGR*# ...# >HUM10D3C# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (142-153)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVJ,CORA_HPBVA,CORA_HPBVL,CORA_HPBVZ,# & CORA_HPBVF,CORA_HPBVO,CORA_HPBVT,CORA_HPBV4)# & PIR1: (NKVLA1,NKVLA2,NKVLJ1,NKVLCP,NKVLH3,NKVLA4,NKVLBH,NKVLJ2,# & NKVLAH)# & PIR2: (S53229,S53223,S04570,S53157,S53202,S53200,S53207,S53236,# & S53194,S53178,S53181,S53232,S53279,S53146,S53211,S53225,# & S53175,S53163,S53172,S53221,S32204,S53242,S53240,S53274,# & S53184,S53281,S53260,S53227,S35530,S53198,S53255,S47405,# & S53251,S53140,S53159,S53257,S53238,S53166,JQ2227,S53152,# & S20750,S53272,S53169,S53155,S20746,S53253,S53216,S53270,# & S53204)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,TLPETTVVRRRG*# SEQUENCE: TLPETTVVRRRG*# ...# >HUM10D3D# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (142-152)# DB REFERENCE: SWISS: (CORA_HPBVZ,CORA_HPBVL,CORA_HPBVW,CORA_HPBVA,CORA_HPBV4,# & CORA_HPBVJ,CORA_HPBVY,CORA_HPBVF,CORA_HPBV9,CORA_HPBVO,# & CORA_HPBVT,CORA_HPBV2)# & PIR1: (NKVLH3,NKVLCP,NKVLA1,NKVLBH,NKVLKS,NKVLA4,NKVLJ1,NKVLA3,# & NKVLAH,NKVLA2,NKVLA6,NKVLJ2)# & PIR2: (S53270,S53272,S53155,S20746,S53157,S53229,S53194,S53129,# & S53225,S53163,S53221,S53146,S53232,S53279,S53178,S53238,# & S20750,S53169,S53184,S53227,S53159,S53257,S47405,S32204,# & S53172,S47409,S25651,S53175,S35530,S53198,S53281,S53260,# & S53253,S53274,S04570,S53223,S53202,S53211,S53181,S01405,# & S53200,S53236,S53207,S53242,S53240,S53152,JQ2227,S53166,# & S33686,S53251,S53140,S53255,S53216,S53204)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,TLPETTVVRRR*# SEQUENCE: TLPETTVVRRR*# ...# >HUM10D3E# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV nucleocapsid core antigen HBcAG (142-151)# DB REFERENCE: SWISS: (CORA_HPBV4,CORA_HPBV2,CORA_HPBVL,CORA_HPBVA,CORA_HPBVW,# & CORA_HPBV9,CORA_HPBVF,CORA_HPBVJ,CORA_HPBVY,CORA_HPBVO,# & CORA_HPBVT,CORA_HPBVZ)# & PIR1: (NKVLA4,NKVLH3,NKVLKS,NKVLA1,NKVLA2,NKVLJ2,NKVLA6,NKVLBH,# & NKVLJ1,NKVLAH,NKVLA3,NKVLCP)# & PIR2: (S53270,S53155,S53272,S53194,S53159,S47405,S53169,S53238,# & S53178,S53253,S53274,S53166,S53152,S53240,S53129,S53255,# & S53216,S53204,S53225,S53227,S53172,S53175,S53198,S35530,# & S53281,S47409,S53211,S53236,S53184,S20750,S25651,S32204,# & S20746,S53257,S53242,S53251,JQ2227,S04570,S53207,S53202,# & S53200,S53223,S53181,S01405,S53260,S33686,S53140,S53163,# & S53221,S53146,S53279,S53232,S53157,S53229)# REFERENCES: missale93a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,TLPETTVVRR*# SEQUENCE: TLPETTVVRR*# ...# >HUM10D3F# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (580-591)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1S1,ENV_HV1H2,ENV_HV1MN,ENV_HV1C4,# & ENV_HV1BN,ENV_HV1J3,ENV_HV1H3,ENV_HV1ZH,ENV_HV1MF,# & ENV_HV1EL,ENV_HV1Z2,ENV_HV1B1,ENV_HV1PV,ENV_HV1OY,# & ENV_HV1B8,ENV_HV1Z6)# & PIR1: (VCLJH3,A44963,VCLJH4,VCLJVL,VCLJMN,VCLJZR,VCLJBR,# & VCLJLV)# & PIR2: (S21992,S70425,S22002,S70422,S21994,S21998,S22004,S70423,# & S21990,S70421,S70424,S22000,S21996,S70420,S70418,S70419,# & S54384,S70417,S22006)# & PIR3: (S13288,S33985)# REFERENCES: dai92a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,AVERYLKDQQLL*# SEQUENCE: AVERYLKDQQLL*# ...# >HUM10D40# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (581-591)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1B1,ENV_HV1H3,ENV_HV1MN,ENV_HV1H2,# & ENV_HV1S1,ENV_HV1J3,ENV_HV1ZH,ENV_HV1B8,ENV_HV1OY,# & ENV_HV1Z6,ENV_HV1EL,ENV_HV1Z2,ENV_HV1MF,ENV_HV1PV,# & ENV_HV1BR,ENV_HV1C4)# & PIR1: (VCLJMN,VCLJLV,VCLJH4,VCLJVL,VCLJBR,VCLJH3,VCLJZR,# & A44963)# & PIR2: (S22002,S22004,S21998,S54384,S21996,S70418,S70422,S21994,# & S70417,S22000,S21990,S70421,S70423,S70425,S21992,S70424,# & S70420,S70419,S22006)# & PIR3: (S13288,S33985)# REFERENCES: dai92a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,VERYLKDQQLL*# SEQUENCE: VERYLKDQQLL*# ...# >HUM10D41# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (582-591)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1C4,ENV_HV1H3,ENV_HV1H2,ENV_HV1S1,# & ENV_HV1B1,ENV_HV1BN,ENV_HV1EL,ENV_HV1Z6,ENV_HV1Z2,# & ENV_HV1MF,ENV_HV1OY,ENV_HV1ZH,ENV_HV1J3,ENV_HV1BR,# & ENV_HV1MN,ENV_HV1PV)# & PIR1: (VCLJVL,VCLJLV,VCLJZR,VCLJH4,VCLJBR,VCLJMN,VCLJH3,# & A44963)# & PIR2: (S22004,S22006,S70419,S21990,S70417,S70418,S21996,S21994,# & S54384,S22000,S70425,S70423,S70421,B41621,S70422,S22002,# & S21998,S70424,S21992,S70420)# & PIR3: (S33985,S13288)# REFERENCES: dai92a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,ERYLKDQQLL*# SEQUENCE: ERYLKDQQLL*# ...# >HUM10D42# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (583-591)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1MF,ENV_HV1MN,ENV_HV1C4,ENV_HV1EL,# & ENV_HV1H2,ENV_HV1OY,ENV_HV1Z6,ENV_HV1Z2,ENV_HV1S1,# & ENV_HV1B1,ENV_HV1BN,ENV_HV1PV,ENV_HV1J3,ENV_HV1BR,# & ENV_HV1H3,ENV_HV1B8)# & PIR1: (VCLJVL,VCLJLV,VCLJBR,VCLJH4,VCLJH3,A44963,VCLJMN,# & VCLJZR)# & PIR2: (S22004,S22000,S70421,S54384,S21992,S21990,S70417,S70420,# & B41621,S70422,S70425,S70423,S21994,S21998,S22002,S70424,# & S70419,S22006,S70418,S21996)# & PIR3: (S13288,S33985)# REFERENCES: dai92a,maier94a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,RYLKDQQLL*# SEQUENCE: RYLKDQQLL*# ...# >HUM10D43# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (584-591)# DB REFERENCE: SWISS: (ENV_HV1Z2,ENV_HV1Z6,ENV_HV1PV,ENV_HV1Z8,ENV_HV1C4,# & ENV_HV1MF,ENV_HV1ZH,ENV_HV1B8,ENV_HV1BR,ENV_HV1BN,# & ENV_HV1OY,ENV_HV1S1,ENV_HV1EL,ENV_HV1H2,ENV_HV1H3,# & ENV_HV1MN,ENV_HV1B1,ENV_HV1J3)# & PIR1: (VCLJVL,VCLJH4,VCLJBR,VCLJH3,VCLJMN,A44963,VCLJZR,# & VCLJLV)# & PIR2: (S21996,S22006,S54384,S70421,S21992,S70417,S21990,S70420,# & S70423,S21998,S70424,S21994,B41621,S22000,S22004,S22002,# & S70419,S70422,S70425,S70418)# & PIR3: (S13288,S33985)# REFERENCES: dai92a,brander95a,hivdb97a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,YLKDQQLL*# SEQUENCE: YLKDQQLL*# ...# >HUM10D44# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (585-591)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1PV,ENV_HV1Z8,ENV_HV1Z6,ENV_HV1BN,# & ENV_HV1EL,ENV_HV1H2,ENV_HV1S1,ENV_HV1C4,ENV_HV1MF,# & ENV_HV1ZH,ENV_HV1B8,ENV_HV1B1,ENV_HV1BR,ENV_HV1OY,# & ENV_HV1Z2,ENV_HV1MN,ENV_HV1J3)# & PIR1: (VCLJBR,VCLJH4,VCLJZR,A44963,VCLJMN,VCLJH3,VCLJLV,# & VCLJVL)# & PIR2: (S22006,S21996,S54384,S21998,B41621,S70423,S70418,S22002,# & S70425,S70422,S70420,S70417,S70421,S22000,S21994,S70424,# & S21992,S70419,S22004,S21990)# & PIR3: (S13288,S33985)# REFERENCES: dai92a,hivdb97a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,LKDQQLL*# SEQUENCE: LKDQQLL*# ...# >HUM10D45# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (584-590)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1JR,ENV_HV1S1,ENV_HV1H2,ENV_HV1EL,# & ENV_HV1PV,ENV_HV1Z2,ENV_HV1H3,ENV_HV1Z6,ENV_HV1B1,# & ENV_HV1C4,ENV_HV1B8,ENV_HV1OY,ENV_HV1BR,ENV_HV1MN,# & ENV_HV1J3,ENV_HV1KB,ENV_HV1Z8,ENV_HV1ZH,ENV_HV1MF)# & PIR1: (VCLJKB,VCLJH4,VCLJKX,VCLJZR,A44963,VCLJBR,VCLJVL,VCLJLV,# & VCLJMN,VCLJH3)# & PIR2: (S21994,S21998,S22002,S70424,S21992,S70421,S70418,S70425,# & S21990,S70423,S22004,B41621,S21996,S22006,S54384,S70422,# & S70419,S70420,S70417,S22000)# & PIR3: (S33985,S13288)# REFERENCES: dai92a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,YLKDQQL*# SEQUENCE: YLKDQQL*# ...# >HUM10D46# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (584-591)# DB REFERENCE: SWISS: (ENV_HV1ND,ENV_HV1A2,ENV_HV1Y2,ENV_HV1W2,ENV_HV1RH,# & ENV_HV1SC,ENV_HV1S3,ENV_HV1W1)# & PIR1: (VCLJ3W,VCLJSC,H44001,VCLJND,VCLJA2)# & PIR2: (C41621,A41621)# REFERENCES: dai92a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,YLRDQQLL*# SEQUENCE: YLRDQQLL*# ...# >HUM10D47# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (584-591)# ANCHOR POSITIONS:# REFERENCES: dai92a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,YLQDQQLL*# SEQUENCE: YLQDQQLL*# ...# >HUM10D48# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 NL43 env (584-591)# DB REFERENCE: SWISS: (ENV_HV1KB,ENV_HV1JR)# & PIR1: (VCLJKX,VCLJKB)# REFERENCES: dai92a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,YLKDQQLM*# SEQUENCE: YLKDQQLM*# ...# >HUM10D49# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 (60-84)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2)# & PIR2: (I61902,I61857,I38443,I37542,I37470,I38442)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,WDGETRKVKAHSQTHRVDLGTLRGY*# SEQUENCE: WDGETRKVKAHSQTHRVDLGTLRGY*# ...# >HUM10D4A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (87-102)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I37542,I84448,I61902,I61857,I38443)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QSEAGSHTVQRMYGCD*# SEQUENCE: QSEAGSHTVQRMYGCD*# ...# >HUM10D4B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Aw24 (60-84)# DB REFERENCE: SWISS: (1A23_HUMAN,1A24_HUMAN)# & PIR2: (I54416,I54493)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,WDEETGKVKAHSQTDRENLRIALRY*# SEQUENCE: WDEETGKVKAHSQTDRENLRIALRY*# ...# >HUM10D4C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Aw32 (60-84)# DB REFERENCE: SWISS: (1A32_HUMAN)# & PIR1: (HLHU32)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,WDQETRNVKAHSQTDRESLRIALRY*# SEQUENCE: WDQETRNVKAHSQTDRESLRIALRY*# ...# >HUM10D4D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: A68.1 (141-160)# DB REFERENCE: SWISS: (1A68_HUMAN)# & PIR1: (HLHUAW)# & PIR2: (I68700,I38441,I68699,I38442)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,QTTKHKWEAAHVAEQWRAYL*# SEQUENCE: QTTKHKWEAAHVAEQWRAYL*# ...# >HUM10D4E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A68.1 (98-113)# DB REFERENCE: SWISS: (1A03_HUMAN,1A03_PANTR,1A03_GORGO,1A80_HUMAN,1AXX_HUMAN,# & 1A02_GORGO,1A01_PANTR,1A01_GORGO,1A30_HUMAN,1A31_HUMAN,# & 1A33_HUMAN,1A31_HUMAN,1A04_GORGO)# & PIR1: (HLHUAW,HLHU10,HLHUA3)# & PIR2: (I38439,I72029,I37476,JH0537,I54307,I37483,I36966,S51100,# & I72171,JH0535,S18198,JH0536,S03535,I38610,I56039,I72170,# & I36961,I36959,S51102,I38519,JH0534)# & PIR3: (S06424)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,MYGCDVGSDGRFLRG*# SEQUENCE: MYGCDVGSDGRFLRG*# ...# >HUM10D4F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A68.1 (87-102)# DB REFERENCE: SWISS: (1A68_HUMAN)# & PIR2: (I38441,JL0135)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QSEAGSHTIQRMYGCD*# SEQUENCE: QSEAGSHTIQRMYGCD*# ...# >HUM10D50# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Bw58 (56-69)# DB REFERENCE: SWISS: (1B62_HUMAN,1B61_HUMAN,1B60_HUMAN)# & PIR1: (HLHUB8)# & PIR2: (D35997,I84490,I37521)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GPEYWDGETRNMKA*# SEQUENCE: GPEYWDGETRNMKA*# ...# >HUM10D51# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B15_HUMAN)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,WDRETQICKAKAQTDRENLRIALRY*# SEQUENCE: WDRETQICKAKAQTDRENLRIALRY*# ...# >HUM10D52# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B19_HUMAN)# & PIR2: (I37515)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,WDRETQICKAKAQTDRESLRTLLRY*# SEQUENCE: WDRETQICKAKAQTDRESLRTLLRY*# ...# >HUM10D53# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B13 (60-84)# DB REFERENCE: SWISS: (1B05_HUMAN,1B41_HUMAN,1B42_HUMAN)# & PIR2: (I54442,I37516,I61861,S25415,A45850)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,WDRETQISKTNTQTYRENLRTALRY*# SEQUENCE: WDRETQISKTNTQTYRENLRTALRY*# ...# >HUM10D54# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B41 (60-84)# DB REFERENCE: SWISS: (1B34_HUMAN,1B43_HUMAN,1B46_HUMAN,1B35_HUMAN,1B33_HUMAN,# & 1B36_HUMAN,1B38_HUMAN,1B12_HUMAN,1B48_HUMAN,1B11_HUMAN,# & 1B12_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I37519,I62043,S24433,I61906,I61903,I62044,S24027,S16789,# & I38437,I56149,I37520,I61905,S52486,S24438,I38421,I68748,# & S24437,G01230,I37492,I61864)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,WDRETQISKTNTQTYRESLRNLRGY*# SEQUENCE: WDRETQISKTNTQTYRESLRNLRGY*# ...# >HUM10D55# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B44.1 (141-160)# DB REFERENCE: SWISS: (1B38_HUMAN,1B04_HUMAN,1B43_HUMAN,1B29_HUMAN,1B39_HUMAN,# & 1B40_HUMAN,1B41_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (C35997,I61864,I68747,I37519,I61861,I37492,I84431,I61865,# & I59188)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,QITQRKWEAARVAEQDRAYL*# SEQUENCE: QITQRKWEAARVAEQDRAYL*# ...# >HUM10D56# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B47 (60-84)# DB REFERENCE: SWISS: (1B45_HUMAN,1B29_HUMAN)# & PIR2: (C35997,I68724)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,WDRETQISKTNTQTYREDLRTLLRY*# SEQUENCE: WDRETQISKTNTQTYREDLRTLLRY*# ...# >HUM10D57# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding/cytotoxicity as./competitive inhibitory# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Flu M (57-68)# DB REFERENCE: SWISS: (VMT1_IAFOW,VMT1_IALE1,VMT1_IAMAN,VMT1_IAUDO,VMT1_IAZI1,# & VMT1_IAPUE,VMT1_IALE2,VMT1_IACKB,VMT1_IAUSS,VMT1_IAANN,# & VMT1_IABAN,VMT1_IAWIL)# & PIR1: (MFIVC,MFIV1M,MFIV,MFIVWS,JN0392,MFIV61,MFIV1K)# & PIR2: (S14616,S04056,S04054,S07429,S04052,S04058,S04050)# REFERENCES: chen90a,bednarek91b# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesm,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM10D58# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag (265-279)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,KRWILGLNKIVRMYC*# SEQUENCE: KRWILGLNKIVRMYC*# ...# >HUM10D59# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu NP (335-349)# DB REFERENCE: SWISS: (VNUC_IAHO1,VNUC_IANT6,VNUC_IAVI6,VNUC_IAZH1,# & VNUC_IADE1)# & PIR1: (VHIV8H,VHIVN7,VHIV68)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SAAFEDLRVLSFIRG*# SEQUENCE: SAAFEDLRVLSFIRG*# ...# >HUM10D5A# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (60-84)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2)# & PIR2: (I61857,I38443,I37542,I37470,I61902,I38442)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,WDGETRKVKAHSQTHRVDLGTLRGY*# SEQUENCE: WDGETRKVKAHSQTHRVDLGTLRGY*# ...# >HUM10D5B# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (87-102)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I61857,I38443,I37542,I84448,I61902)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,QSEAGSHTVQRMYGCD*# SEQUENCE: QSEAGSHTVQRMYGCD*# ...# >HUM10D5C# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (137-148)# DB REFERENCE: SWISS: (1A02_HUMAN,1AXX_HUMAN,1A02_HUMAN,1A69_HUMAN,# & 1A68_HUMAN)# & PIR1: (HLHU69,HLHUAW,HLHUA2,HLHU10)# & PIR2: (I61902,I38441,I38443,I37470,I56009,I61857,I38442,I84448,# & I37542,I68699,I68700,I54412)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,DMAAQTTKHKWE*# SEQUENCE: DMAAQTTKHKWE*# ...# >HUM10D5D# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Aw24 (60-84)# DB REFERENCE: SWISS: (1A23_HUMAN,1A24_HUMAN)# & PIR2: (I54416,I54493)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,WDEETGKVKAHSQTDRENLRIALRY*# SEQUENCE: WDEETGKVKAHSQTDRENLRIALRY*# ...# >HUM10D5E# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Aw32 (60-84)# DB REFERENCE: SWISS: (1A32_HUMAN)# & PIR1: (HLHU32)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,WDQETRNVKAHSQTDRESLRIALRY*# SEQUENCE: WDQETRNVKAHSQTDRESLRIALRY*# ...# >HUM10D5F# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A68.1 (141-160)# DB REFERENCE: SWISS: (1A68_HUMAN)# & PIR1: (HLHUAW)# & PIR2: (I68699,I68700,I38442,I38441)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,QTTKHKWEAAHVAEQWRAYL*# SEQUENCE: QTTKHKWEAAHVAEQWRAYL*# ...# >HUM10D60# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A68.1 (98-113)# DB REFERENCE: SWISS: (1A03_HUMAN,1A02_GORGO,1AXX_HUMAN,1A30_HUMAN,1A31_HUMAN,# & 1A33_HUMAN,1A04_GORGO,1A03_PANTR,1A01_PANTR,1A01_GORGO,# & 1A03_GORGO,1A80_HUMAN,1A31_HUMAN)# & PIR1: (HLHUAW,HLHUA3,HLHU10)# & PIR2: (I36959,S51102,S51100,S03535,JH0536,JH0534,I36961,I37476,# & I38610,I36966,I37483,I72170,JH0537,I54307,I72171,S18198,# & JH0535,I72029,I38439,I38519,I56039)# & PIR3: (S06424)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,MYGCDVGSDGRFLRG*# SEQUENCE: MYGCDVGSDGRFLRG*# ...# >HUM10D61# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A68.1 (87-102)# DB REFERENCE: SWISS: (1A68_HUMAN)# & PIR2: (I38441,JL0135)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,QSEAGSHTIQRMYGCD*# SEQUENCE: QSEAGSHTIQRMYGCD*# ...# >HUM10D62# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Bw58 (60-84)# DB REFERENCE: SWISS: (1B61_HUMAN,1B60_HUMAN,1B62_HUMAN)# & PIR1: (HLHUB8)# & PIR2: (I84490,I37521,D35997)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,WDGETRNMKASAQTYRENLRIALRY*# SEQUENCE: WDGETRNMKASAQTYRENLRIALRY*# ...# >HUM10D63# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B15_HUMAN)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,WDRETQICKAKAQTDRENLRIALRY*# SEQUENCE: WDRETQICKAKAQTDRENLRIALRY*# ...# >HUM10D64# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B19_HUMAN)# & PIR2: (I37515)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,WDRETQICKAKAQTDRESLRTLLRY*# SEQUENCE: WDRETQICKAKAQTDRESLRTLLRY*# ...# >HUM10D65# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B13 (60-84)# DB REFERENCE: SWISS: (1B05_HUMAN,1B41_HUMAN,1B42_HUMAN)# & PIR2: (I37516,I61861,I54442,S25415,A45850)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,WDRETQISKTNTQTYRENLRTALRY*# SEQUENCE: WDRETQISKTNTQTYRENLRTALRY*# ...# >HUM10D66# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B41 (60-84)# DB REFERENCE: SWISS: (1B36_HUMAN,1B33_HUMAN,1B43_HUMAN,1B48_HUMAN,1B34_HUMAN,# & 1B46_HUMAN,1B35_HUMAN,1B38_HUMAN,1B11_HUMAN,1B12_HUMAN,# & 1B12_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I62043,I38437,I56149,I37520,I61905,S24027,S16789,I62044,# & S24437,G01230,I61864,I37519,S24438,S52486,I61906,I61903,# & S24433,I38421,I68748,I37492)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,WDRETQISKTNTQTYRESLRNLRGY*# SEQUENCE: WDRETQISKTNTQTYRESLRNLRGY*# ...# >HUM10D67# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B44.1 (141-160)# DB REFERENCE: SWISS: (1B04_HUMAN,1B41_HUMAN,1B40_HUMAN,1B43_HUMAN,1B38_HUMAN,# & 1B29_HUMAN,1B39_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (I68747,I61861,I37519,I61864,C35997,I37492,I84431,I61865,# & I59188)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,QITQRKWEAARVAEQDRAYL*# SEQUENCE: QITQRKWEAARVAEQDRAYL*# ...# >HUM10D68# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B47 (60-84)# DB REFERENCE: SWISS: (1B45_HUMAN,1B29_HUMAN)# & PIR2: (C35997,I68724)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,WDRETQISKTNTQTYREDLRTLLRY*# SEQUENCE: WDRETQISKTNTQTYREDLRTLLRY*# ...# >HUM10D69# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Beta2m (51-66)# DB REFERENCE: SWISS: (B2MG_PONPY,B2MG_SAGOE,B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963,I61868,I54312)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,HSDLSFSKDWSFYLLY*# SEQUENCE: HSDLSFSKDWSFYLLY*# ...# >HUM10D6A# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding/cytotoxic as./competitive inhibition# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Flu M (57-68)# DB REFERENCE: SWISS: (VMT1_IAFOW,VMT1_IALE1,VMT1_IAZI1,VMT1_IAMAN,VMT1_IALE2,# & VMT1_IACKB,VMT1_IAANN,VMT1_IAUSS,VMT1_IABAN,VMT1_IAWIL,# & VMT1_IAPUE,VMT1_IAUDO)# & PIR1: (JN0392,MFIV,MFIVC,MFIV1M,MFIVWS,MFIV61,MFIV1K)# & PIR2: (S04054,S04056,S14616,S04052,S04058,S04050,S07429)# REFERENCES: bodmer89a,chen90a# COMMENT:# SUMMARY: HLA-A69,actyesm,bindyesm,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM10D6B# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag (265-279)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KRWILGLNKIVRMYC*# SEQUENCE: KRWILGLNKIVRMYC*# ...# >HUM10D6C# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu NP (335-349)# DB REFERENCE: SWISS: (VNUC_IAHO1,VNUC_IAZH1,VNUC_IANT6,VNUC_IAVI6,# & VNUC_IADE1)# & PIR1: (VHIVN7,VHIV68,VHIV8H)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,SAAFEDLRVLSFIRG*# SEQUENCE: SAAFEDLRVLSFIRG*# ...# >HUM10D6D# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Aw24 (60-84)# DB REFERENCE: SWISS: (1A23_HUMAN,1A24_HUMAN)# & PIR2: (I54416,I54493)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,WDEETGKVKAHSQTDRENLRIALRY*# SEQUENCE: WDEETGKVKAHSQTDRENLRIALRY*# ...# >HUM10D6E# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Aw32 (60-84)# DB REFERENCE: SWISS: (1A32_HUMAN)# & PIR1: (HLHU32)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,WDQETRNVKAHSQTDRESLRIALRY*# SEQUENCE: WDQETRNVKAHSQTDRESLRIALRY*# ...# >HUM10D6F# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A68.1 (141-160)# DB REFERENCE: SWISS: (1A68_HUMAN)# & PIR1: (HLHUAW)# & PIR2: (I68699,I38442,I68700,I38441)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,QTTKHKWEAAHVAEQWRAYL*# SEQUENCE: QTTKHKWEAAHVAEQWRAYL*# ...# >HUM10D70# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Bw58 (60-84)# DB REFERENCE: SWISS: (1B61_HUMAN,1B60_HUMAN,1B62_HUMAN)# & PIR1: (HLHUB8)# & PIR2: (I84490,D35997,I37521)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,WDGETRNMKASAQTYRENLRIALRY*# SEQUENCE: WDGETRNMKASAQTYRENLRIALRY*# ...# >HUM10D71# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B15_HUMAN)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,WDRETQICKAKAQTDRENLRIALRY*# SEQUENCE: WDRETQICKAKAQTDRENLRIALRY*# ...# >HUM10D72# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B19_HUMAN)# & PIR2: (I37515)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,WDRETQICKAKAQTDRESLRTLLRY*# SEQUENCE: WDRETQICKAKAQTDRESLRTLLRY*# ...# >HUM10D73# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B41 (60-84)# DB REFERENCE: SWISS: (1B12_HUMAN,1B48_HUMAN,1B33_HUMAN,1B46_HUMAN,1B35_HUMAN,# & 1B43_HUMAN,1B36_HUMAN,1B38_HUMAN,1B34_HUMAN,1B12_HUMAN,# & 1B11_HUMAN)# & PIR1: (HLHU40)# & PIR2: (S24433,I37520,I56149,I62044,I37519,I38437,I62043,I61906,# & I61864,G01230,S24437,I61903,I61905,S16789,S24027,I38421,# & I68748,I37492,S24438,S52486)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,WDRETQISKTNTQTYRESLRNLRGY*# SEQUENCE: WDRETQISKTNTQTYRESLRNLRGY*# ...# >HUM10D74# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: B44.1 (141-160)# DB REFERENCE: SWISS: (1B38_HUMAN,1B43_HUMAN,1B39_HUMAN,1B29_HUMAN,1B41_HUMAN,# & 1B04_HUMAN,1B40_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (I61864,I68747,I37519,C35997,I61865,I61861,I37492,I59188,# & I84431)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,QITQRKWEAARVAEQDRAYL*# SEQUENCE: QITQRKWEAARVAEQDRAYL*# ...# >HUM10D75# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: B47 (60-84)# DB REFERENCE: SWISS: (1B45_HUMAN,1B29_HUMAN)# & PIR2: (C35997,I68724)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,WDRETQISKTNTQTYREDLRTLLRY*# SEQUENCE: WDRETQISKTNTQTYREDLRTLLRY*# ...# >HUM10D76# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Beta2m (51-66)# DB REFERENCE: SWISS: (B2MG_PONPY,B2MG_SAGOE,B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I54312,I37063,I36963,I61868)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,HSDLSFSKDWSFYLLY*# SEQUENCE: HSDLSFSKDWSFYLLY*# ...# >HUM10D77# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Flu M (57-68)# DB REFERENCE: SWISS: (VMT1_IAFOW,VMT1_IALE1,VMT1_IACKB,VMT1_IAUSS,VMT1_IALE2,# & VMT1_IAWIL,VMT1_IAPUE,VMT1_IAUDO,VMT1_IABAN,VMT1_IAANN,# & VMT1_IAMAN,VMT1_IAZI1)# & PIR1: (MFIVC,MFIV1K,MFIV61,MFIV1M,MFIV,MFIVWS,JN0392)# & PIR2: (S04050,S04058,S14616,S07429,S04054,S04052,S04056)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM10D78# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Flu NP (335-349)# DB REFERENCE: SWISS: (VNUC_IAHO1,VNUC_IAZH1,VNUC_IANT6,VNUC_IADE1,# & VNUC_IAVI6)# & PIR1: (VHIV8H,VHIV68,VHIVN7)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,SAAFEDLRVLSFIRG*# SEQUENCE: SAAFEDLRVLSFIRG*# ...# >HUM10D79# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A2 (60-84)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2)# & PIR2: (I37542,I38443,I61857,I37470,I61902,I38442)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,WDGETRKVKAHSQTHRVDLGTLRGY*# SEQUENCE: WDGETRKVKAHSQTHRVDLGTLRGY*# ...# >HUM10D7A# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (87-102)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I61857,I37542,I38443,I84448,I61902)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,QSEAGSHTVQRMYGCD*# SEQUENCE: QSEAGSHTVQRMYGCD*# ...# >HUM10D7B# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (137-148)# DB REFERENCE: SWISS: (1A68_HUMAN,1A02_HUMAN,1AXX_HUMAN,1A69_HUMAN,# & 1A02_HUMAN)# & PIR1: (HLHU69,HLHUAW,HLHU10,HLHUA2)# & PIR2: (I68700,I37470,I61857,I38442,I68699,I54412,I37542,I38443,# & I38441,I61902,I84448,I56009)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,DMAAQTTKHKWE*# SEQUENCE: DMAAQTTKHKWE*# ...# >HUM10D7C# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Aw24 (60-84)# DB REFERENCE: SWISS: (1A24_HUMAN,1A23_HUMAN)# & PIR2: (I54416,I54493)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,WDEETGKVKAHSQTDRENLRIALRY*# SEQUENCE: WDEETGKVKAHSQTDRENLRIALRY*# ...# >HUM10D7D# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Aw32 (60-84)# DB REFERENCE: SWISS: (1A32_HUMAN)# & PIR1: (HLHU32)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,WDQETRNVKAHSQTDRESLRIALRY*# SEQUENCE: WDQETRNVKAHSQTDRESLRIALRY*# ...# >HUM10D7E# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: A68.1 (141-160)# DB REFERENCE: SWISS: (1A68_HUMAN)# & PIR1: (HLHUAW)# & PIR2: (I68700,I68699,I38441,I38442)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,QTTKHKWEAAHVAEQWRAYL*# SEQUENCE: QTTKHKWEAAHVAEQWRAYL*# ...# >HUM10D7F# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A68.1 (98-113)# DB REFERENCE: SWISS: (1A01_GORGO,1A01_PANTR,1A80_HUMAN,1A03_GORGO,1A03_HUMAN,# & 1A31_HUMAN,1A02_GORGO,1A03_PANTR,1A33_HUMAN,1A04_GORGO,# & 1A30_HUMAN,1A31_HUMAN,1AXX_HUMAN)# & PIR1: (HLHU10,HLHUA3,HLHUAW)# & PIR2: (I72170,I72029,I38610,S51102,S51100,I36961,I56039,S03535,# & JH0537,I54307,I38519,I37476,JH0534,JH0536,I36959,I36966,# & I37483,JH0535,I72171,S18198,I38439)# & PIR3: (S06424)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,MYGCDVGSDGRFLRG*# SEQUENCE: MYGCDVGSDGRFLRG*# ...# >HUM10D80# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A68.1 (87-102)# DB REFERENCE: SWISS: (1A68_HUMAN)# & PIR2: (I38441,JL0135)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,QSEAGSHTIQRMYGCD*# SEQUENCE: QSEAGSHTIQRMYGCD*# ...# >HUM10D81# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Bw58 (60-84)# DB REFERENCE: SWISS: (1B60_HUMAN,1B61_HUMAN,1B62_HUMAN)# & PIR1: (HLHUB8)# & PIR2: (I84490,I37521,D35997)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,WDGETRNMKASAQTYRENLRIALRY*# SEQUENCE: WDGETRNMKASAQTYRENLRIALRY*# ...# >HUM10D82# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B15_HUMAN)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,WDRETQICKAKAQTDRENLRIALRY*# SEQUENCE: WDRETQICKAKAQTDRENLRIALRY*# ...# >HUM10D83# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B19_HUMAN)# & PIR2: (I37515)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,WDRETQICKAKAQTDRESLRTLLRY*# SEQUENCE: WDRETQICKAKAQTDRESLRTLLRY*# ...# >HUM10D84# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B13 (60-84)# DB REFERENCE: SWISS: (1B05_HUMAN,1B41_HUMAN,1B42_HUMAN)# & PIR2: (I37516,I54442,A45850,S25415,I61861)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,WDRETQISKTNTQTYRENLRTALRY*# SEQUENCE: WDRETQISKTNTQTYRENLRTALRY*# ...# >HUM10D85# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B41 (60-84)# DB REFERENCE: SWISS: (1B43_HUMAN,1B34_HUMAN,1B11_HUMAN,1B48_HUMAN,1B46_HUMAN,# & 1B35_HUMAN,1B36_HUMAN,1B12_HUMAN,1B33_HUMAN,1B12_HUMAN,# & 1B38_HUMAN)# & PIR1: (HLHU40)# & PIR2: (S16789,I37492,I38437,I68748,S24433,I56149,I62043,G01230,# & I61905,S24027,I61903,S24438,S52486,I61864,I37519,I61906,# & I38421,I37520,I62044,S24437)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,WDRETQISKTNTQTYRESLRNLRGY*# SEQUENCE: WDRETQISKTNTQTYRESLRNLRGY*# ...# >HUM10D86# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B44.1 (141-160)# DB REFERENCE: SWISS: (1B38_HUMAN,1B04_HUMAN,1B39_HUMAN,1B40_HUMAN,1B29_HUMAN,# & 1B43_HUMAN,1B41_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (I37492,I84431,I61861,C35997,I68747,I61864,I59188,I61865,# & I37519)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,QITQRKWEAARVAEQDRAYL*# SEQUENCE: QITQRKWEAARVAEQDRAYL*# ...# >HUM10D87# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B47 (60-84)# DB REFERENCE: SWISS: (1B45_HUMAN,1B29_HUMAN)# & PIR2: (I68724,C35997)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,WDRETQISKTNTQTYREDLRTLLRY*# SEQUENCE: WDRETQISKTNTQTYREDLRTLLRY*# ...# >HUM10D88# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Beta2m (51-66)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_SAGOE,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I61868,I37063,I54312,I36963)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,HSDLSFSKDWSFYLLY*# SEQUENCE: HSDLSFSKDWSFYLLY*# ...# >HUM10D89# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu M (57-68)# DB REFERENCE: SWISS: (VMT1_IALE1,VMT1_IAFOW,VMT1_IAPUE,VMT1_IABAN,VMT1_IAANN,# & VMT1_IAZI1,VMT1_IAMAN,VMT1_IACKB,VMT1_IAUSS,VMT1_IAWIL,# & VMT1_IAUDO,VMT1_IALE2)# & PIR1: (MFIV,MFIV1M,MFIV1K,MFIV61,MFIVC,MFIVWS,JN0392)# & PIR2: (S04050,S04056,S04054,S07429,S04052,S14616,S04058)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM10D8A# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag (265-279)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KRWILGLNKIVRMYC*# SEQUENCE: KRWILGLNKIVRMYC*# ...# >HUM10D8B# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu NP (335-349)# DB REFERENCE: SWISS: (VNUC_IAVI6,VNUC_IAHO1,VNUC_IAZH1,VNUC_IANT6,# & VNUC_IADE1)# & PIR1: (VHIVN7,VHIV68,VHIV8H)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,SAAFEDLRVLSFIRG*# SEQUENCE: SAAFEDLRVLSFIRG*# ...# >HUM10D8C# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (60-84)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2)# & PIR2: (I37542,I37470,I61857,I61902,I38442,I38443)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,WDGETRKVKAHSQTHRVDLGTLRGY*# SEQUENCE: WDGETRKVKAHSQTHRVDLGTLRGY*# ...# >HUM10D8D# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (87-102)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38443,I61902,I61857,I84448,I37542)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,QSEAGSHTVQRMYGCD*# SEQUENCE: QSEAGSHTVQRMYGCD*# ...# >HUM10D8E# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: A2 (137-148)# DB REFERENCE: SWISS: (1AXX_HUMAN,1A02_HUMAN,1A69_HUMAN,1A02_HUMAN,# & 1A68_HUMAN)# & PIR1: (HLHUAW,HLHUA2,HLHU69,HLHU10)# & PIR2: (I68700,I61902,I38442,I38443,I56009,I37542,I37470,I54412,# & I61857,I68699,I38441,I84448)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,DMAAQTTKHKWE*# SEQUENCE: DMAAQTTKHKWE*# ...# >HUM10D8F# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Aw24 (60-84)# DB REFERENCE: SWISS: (1A24_HUMAN,1A23_HUMAN)# & PIR2: (I54416,I54493)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,WDEETGKVKAHSQTDRENLRIALRY*# SEQUENCE: WDEETGKVKAHSQTDRENLRIALRY*# ...# >HUM10D90# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: A68.1 (141-160)# DB REFERENCE: SWISS: (1A68_HUMAN)# & PIR1: (HLHUAW)# & PIR2: (I38441,I68699,I68700,I38442)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,QTTKHKWEAAHVAEQWRAYL*# SEQUENCE: QTTKHKWEAAHVAEQWRAYL*# ...# >HUM10D91# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Bw58 (60-84)# DB REFERENCE: SWISS: (1B60_HUMAN,1B61_HUMAN,1B62_HUMAN)# & PIR1: (HLHUB8)# & PIR2: (D35997,I37521,I84490)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,WDGETRNMKASAQTYRENLRIALRY*# SEQUENCE: WDGETRNMKASAQTYRENLRIALRY*# ...# >HUM10D92# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B15_HUMAN)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,WDRETQICKAKAQTDRENLRIALRY*# SEQUENCE: WDRETQICKAKAQTDRENLRIALRY*# ...# >HUM10D93# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: B27 (60-84)# DB REFERENCE: SWISS: (1B19_HUMAN)# & PIR2: (I37515)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,WDRETQICKAKAQTDRESLRTLLRY*# SEQUENCE: WDRETQICKAKAQTDRESLRTLLRY*# ...# >HUM10D94# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: B13 (60-84)# DB REFERENCE: SWISS: (1B05_HUMAN,1B41_HUMAN,1B42_HUMAN)# & PIR2: (I37516,A45850,S25415,I61861,I54442)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,WDRETQISKTNTQTYRENLRTALRY*# SEQUENCE: WDRETQISKTNTQTYRENLRTALRY*# ...# >HUM10D95# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: B41 (60-84)# DB REFERENCE: SWISS: (1B12_HUMAN,1B34_HUMAN,1B11_HUMAN,1B35_HUMAN,1B36_HUMAN,# & 1B12_HUMAN,1B43_HUMAN,1B46_HUMAN,1B33_HUMAN,1B48_HUMAN,# & 1B38_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I61905,S24027,I37492,I37519,I56149,I37520,I61903,S52486,# & S24438,I61864,I62044,I38421,I61906,S24437,S16789,S24433,# & I38437,I68748,I62043,G01230)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,WDRETQISKTNTQTYRESLRNLRGY*# SEQUENCE: WDRETQISKTNTQTYRESLRNLRGY*# ...# >HUM10D96# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B44.1 (141-160)# DB REFERENCE: SWISS: (1B38_HUMAN,1B39_HUMAN,1B43_HUMAN,1B40_HUMAN,1B41_HUMAN,# & 1B04_HUMAN,1B29_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (I37492,I37519,I61865,I84431,I61864,I68747,I61861,I59188,# & C35997)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,QITQRKWEAARVAEQDRAYL*# SEQUENCE: QITQRKWEAARVAEQDRAYL*# ...# >HUM10D97# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: B47 (60-84)# DB REFERENCE: SWISS: (1B45_HUMAN,1B29_HUMAN)# & PIR2: (I68724,C35997)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,WDRETQISKTNTQTYREDLRTLLRY*# SEQUENCE: WDRETQISKTNTQTYREDLRTLLRY*# ...# >HUM10D98# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Beta2m (51-66)# DB REFERENCE: SWISS: (B2MG_SAGOE,B2MG_PONPY,B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I54312,I36963,I61868,I37063)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,HSDLSFSKDWSFYLLY*# SEQUENCE: HSDLSFSKDWSFYLLY*# ...# >HUM10D99# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu M (57-68)# DB REFERENCE: SWISS: (VMT1_IAZI1,VMT1_IALE2,VMT1_IALE1,VMT1_IAFOW,VMT1_IAPUE,# & VMT1_IAMAN,VMT1_IAANN,VMT1_IABAN,VMT1_IACKB,VMT1_IAUSS,# & VMT1_IAUDO,VMT1_IAWIL)# & PIR1: (MFIV1K,MFIVC,MFIV61,MFIV1M,JN0392,MFIV,MFIVWS)# & PIR2: (S04050,S07429,S04054,S14616,S04058,S04052,S04056)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM10D9A# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag (265-279)# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KRWILGLNKIVRMYC*# SEQUENCE: KRWILGLNKIVRMYC*# ...# >HUM10D9B# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu NP (335-349)# DB REFERENCE: SWISS: (VNUC_IAZH1,VNUC_IADE1,VNUC_IAVI6,VNUC_IANT6,# & VNUC_IAHO1)# & PIR1: (VHIV8H,VHIVN7,VHIV68)# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,SAAFEDLRVLSFIRG*# SEQUENCE: SAAFEDLRVLSFIRG*# ...# >HUM10D9C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AGILGFVFTLTV*# SEQUENCE: AGILGFVFTLTV*# ...# >HUM10D9D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KSILGFVFTLTV*# SEQUENCE: KSILGFVFTLTV*# ...# >HUM10D9E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KQILGFVFTLTV*# SEQUENCE: KQILGFVFTLTV*# ...# >HUM10D9F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KAILGFVFTLTV*# SEQUENCE: KAILGFVFTLTV*# ...# >HUM10DA0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KLILGFVFTLTV*# SEQUENCE: KLILGFVFTLTV*# ...# >HUM10DA1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KFILGFVFTLTV*# SEQUENCE: KFILGFVFTLTV*# ...# >HUM10DA2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KKILGFVFTLTV*# SEQUENCE: KKILGFVFTLTV*# ...# >HUM10DA3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGKLGFVFTLTV*# SEQUENCE: KGKLGFVFTLTV*# ...# >HUM10DA4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGFLGFVFTLTV*# SEQUENCE: KGFLGFVFTLTV*# ...# >HUM10DA5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGYLGFVFTLTV*# SEQUENCE: KGYLGFVFTLTV*# ...# >HUM10DA6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGINMFVFTLTV*# SEQUENCE: KGINMFVFTLTV*# ...# >HUM10DA7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGISGFVFTLTV*# SEQUENCE: KGISGFVFTLTV*# ...# >HUM10DA8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGITGFVFTLTV*# SEQUENCE: KGITGFVFTLTV*# ...# >HUM10DA9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGIAGFVFTLTV*# SEQUENCE: KGIAGFVFTLTV*# ...# >HUM10DAA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGIPGFVFTLTV*# SEQUENCE: KGIPGFVFTLTV*# ...# >HUM10DAB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILSFVFTLTV*# SEQUENCE: KGILSFVFTLTV*# ...# >HUM10DAC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGQVFTLTV*# SEQUENCE: KGILGQVFTLTV*# ...# >HUM10DAD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGAVFTLTV*# SEQUENCE: KGILGAVFTLTV*# ...# >HUM10DAE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGVVFTLTV*# SEQUENCE: KGILGVVFTLTV*# ...# >HUM10DAF# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGIVFTLTV*# SEQUENCE: KGILGIVFTLTV*# ...# >HUM10DB0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGILGYVFTLTV*# SEQUENCE: KGILGYVFTLTV*# ...# >HUM10DB1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGFAFTLTV*# SEQUENCE: KGILGFAFTLTV*# ...# >HUM10DB2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGILGFYFTLTV*# SEQUENCE: KGILGFYFTLTV*# ...# >HUM10DB3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGILGFFFTLTV*# SEQUENCE: KGILGFFFTLTV*# ...# >HUM10DB4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGILGFVQTLTV*# SEQUENCE: KGILGFVQTLTV*# ...# >HUM10DB5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGILGFVNTLTV*# SEQUENCE: KGILGFVNTLTV*# ...# >HUM10DB6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGILGFVYTLTV*# SEQUENCE: KGILGFVYTLTV*# ...# >HUM10DB7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding/cytotoxicity as./competitive inhibition# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a,bednarek91b# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesh,KGILGFVFKLTV*# SEQUENCE: KGILGFVFKLTV*# ...# >HUM10DB8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGILGFVFALTV*# SEQUENCE: KGILGFVFALTV*# ...# >HUM10DB9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGFVFGLTV*# SEQUENCE: KGILGFVFGLTV*# ...# >HUM10DBA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGFVFQLTV*# SEQUENCE: KGILGFVFQLTV*# ...# >HUM10DBB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KGILGFVFTRTV*# SEQUENCE: KGILGFVFTRTV*# ...# >HUM10DBC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGFVFTFTV*# SEQUENCE: KGILGFVFTFTV*# ...# >HUM10DBD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KGILGFVFTSTV*# SEQUENCE: KGILGFVFTSTV*# ...# >HUM10DBE# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,HGILGFVFTLTV*# SEQUENCE: HGILGFVFTLTV*# ...# >HUM10DBF# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,RGILGFVFTLTV*# SEQUENCE: RGILGFVFTLTV*# ...# >HUM10DC0# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,AGILGFVFTLTV*# SEQUENCE: AGILGFVFTLTV*# ...# >HUM10DC1# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KSILGFVFTLTV*# SEQUENCE: KSILGFVFTLTV*# ...# >HUM10DC2# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KQILGFVFTLTV*# SEQUENCE: KQILGFVFTLTV*# ...# >HUM10DC3# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KAILGFVFTLTV*# SEQUENCE: KAILGFVFTLTV*# ...# >HUM10DC4# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KLILGFVFTLTV*# SEQUENCE: KLILGFVFTLTV*# ...# >HUM10DC5# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KFILGFVFTLTV*# SEQUENCE: KFILGFVFTLTV*# ...# >HUM10DC6# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KKILGFVFTLTV*# SEQUENCE: KKILGFVFTLTV*# ...# >HUM10DC7# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGALGFVFTLTV*# SEQUENCE: KGALGFVFTLTV*# ...# >HUM10DC8# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGKLGFVFTLTV*# SEQUENCE: KGKLGFVFTLTV*# ...# >HUM10DC9# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,KGFLGFVFTLTV*# SEQUENCE: KGFLGFVFTLTV*# ...# >HUM10DCA# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGELGFVFTLTV*# SEQUENCE: KGELGFVFTLTV*# ...# >HUM10DCB# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGYLGFVFTLTV*# SEQUENCE: KGYLGFVFTLTV*# ...# >HUM10DCC# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGINMFVFTLTV*# SEQUENCE: KGINMFVFTLTV*# ...# >HUM10DCD# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGISGFVFTLTV*# SEQUENCE: KGISGFVFTLTV*# ...# >HUM10DCE# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGITGFVFTLTV*# SEQUENCE: KGITGFVFTLTV*# ...# >HUM10DCF# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGIAGFVFTLTV*# SEQUENCE: KGIAGFVFTLTV*# ...# >HUM10DD0# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGIPGFVFTLTV*# SEQUENCE: KGIPGFVFTLTV*# ...# >HUM10DD1# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILSFVFTLTV*# SEQUENCE: KGILSFVFTLTV*# ...# >HUM10DD2# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGKVFTLTV*# SEQUENCE: KGILGKVFTLTV*# ...# >HUM10DD3# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGQVFTLTV*# SEQUENCE: KGILGQVFTLTV*# ...# >HUM10DD4# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGAVFTLTV*# SEQUENCE: KGILGAVFTLTV*# ...# >HUM10DD5# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGVVFTLTV*# SEQUENCE: KGILGVVFTLTV*# ...# >HUM10DD6# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGIVFTLTV*# SEQUENCE: KGILGIVFTLTV*# ...# >HUM10DD7# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,KGILGYVFTLTV*# SEQUENCE: KGILGYVFTLTV*# ...# >HUM10DD8# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGFAFTLTV*# SEQUENCE: KGILGFAFTLTV*# ...# >HUM10DD9# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFEFTLTV*# SEQUENCE: KGILGFEFTLTV*# ...# >HUM10DDA# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGFYFTLTV*# SEQUENCE: KGILGFYFTLTV*# ...# >HUM10DDB# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGFFFTLTV*# SEQUENCE: KGILGFFFTLTV*# ...# >HUM10DDC# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFRFTLTV*# SEQUENCE: KGILGFRFTLTV*# ...# >HUM10DDD# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFVATLTV*# SEQUENCE: KGILGFVATLTV*# ...# >HUM10DDE# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,KGILGFVQTLTV*# SEQUENCE: KGILGFVQTLTV*# ...# >HUM10DDF# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGFVNTLTV*# SEQUENCE: KGILGFVNTLTV*# ...# >HUM10DE0# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFVSTLTV*# SEQUENCE: KGILGFVSTLTV*# ...# >HUM10DE1# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGFVYTLTV*# SEQUENCE: KGILGFVYTLTV*# ...# >HUM10DE2# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFVITLTV*# SEQUENCE: KGILGFVITLTV*# ...# >HUM10DE3# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,KGILGFVFKLTV*# SEQUENCE: KGILGFVFKLTV*# ...# >HUM10DE4# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFVFALTV*# SEQUENCE: KGILGFVFALTV*# ...# >HUM10DE5# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFVFGLTV*# SEQUENCE: KGILGFVFGLTV*# ...# >HUM10DE6# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGFVFQLTV*# SEQUENCE: KGILGFVFQLTV*# ...# >HUM10DE7# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFVFDLTV*# SEQUENCE: KGILGFVFDLTV*# ...# >HUM10DE8# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFVFTATV*# SEQUENCE: KGILGFVFTATV*# ...# >HUM10DE9# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGFVFTRTV*# SEQUENCE: KGILGFVFTRTV*# ...# >HUM10DEA# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesl,KGILGFVFTETV*# SEQUENCE: KGILGFVFTETV*# ...# >HUM10DEB# MHC MOLECULE: HLA-A69, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,KGILGFVFTFTV*# SEQUENCE: KGILGFVFTFTV*# ...# >HUM10DEC# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,RGILGFVFTLTV*# SEQUENCE: RGILGFVFTLTV*# ...# >HUM10DED# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,AGILGFVFTLTV*# SEQUENCE: AGILGFVFTLTV*# ...# >HUM10DEE# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,KLILGFVFTLTV*# SEQUENCE: KLILGFVFTLTV*# ...# >HUM10DEF# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,KGILGFYFTLTV*# SEQUENCE: KGILGFYFTLTV*# ...# >HUM10DF0# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,KGILGFVYTLTV*# SEQUENCE: KGILGFVYTLTV*# ...# >HUM10DF1# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,KGILGFVFKLTV*# SEQUENCE: KGILGFVFKLTV*# ...# >HUM10DF2# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,KGILGFVFTFTV*# SEQUENCE: KGILGFVFTFTV*# ...# >HUM10DF3# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,HGILGFVFTLTV*# SEQUENCE: HGILGFVFTLTV*# ...# >HUM10DF4# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,RGILGFVFTLTV*# SEQUENCE: RGILGFVFTLTV*# ...# >HUM10DF5# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,AGILGFVFTLTV*# SEQUENCE: AGILGFVFTLTV*# ...# >HUM10DF6# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KSILGFVFTLTV*# SEQUENCE: KSILGFVFTLTV*# ...# >HUM10DF7# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KQILGFVFTLTV*# SEQUENCE: KQILGFVFTLTV*# ...# >HUM10DF8# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KAILGFVFTLTV*# SEQUENCE: KAILGFVFTLTV*# ...# >HUM10DF9# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KLILGFVFTLTV*# SEQUENCE: KLILGFVFTLTV*# ...# >HUM10DFA# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KFILGFVFTLTV*# SEQUENCE: KFILGFVFTLTV*# ...# >HUM10DFB# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KEILGFVFTLTV*# SEQUENCE: KEILGFVFTLTV*# ...# >HUM10DFC# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KKILGFVFTLTV*# SEQUENCE: KKILGFVFTLTV*# ...# >HUM10DFD# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGALGFVFTLTV*# SEQUENCE: KGALGFVFTLTV*# ...# >HUM10DFE# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGKLGFVFTLTV*# SEQUENCE: KGKLGFVFTLTV*# ...# >HUM10DFF# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGFLGFVFTLTV*# SEQUENCE: KGFLGFVFTLTV*# ...# >HUM10E00# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGELGFVFTLTV*# SEQUENCE: KGELGFVFTLTV*# ...# >HUM10E01# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGYLGFVFTLTV*# SEQUENCE: KGYLGFVFTLTV*# ...# >HUM10E02# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGINMFVFTLTV*# SEQUENCE: KGINMFVFTLTV*# ...# >HUM10E03# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGISGFVFTLTV*# SEQUENCE: KGISGFVFTLTV*# ...# >HUM10E04# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGITGFVFTLTV*# SEQUENCE: KGITGFVFTLTV*# ...# >HUM10E05# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGIAGFVFTLTV*# SEQUENCE: KGIAGFVFTLTV*# ...# >HUM10E06# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGIPGFVFTLTV*# SEQUENCE: KGIPGFVFTLTV*# ...# >HUM10E07# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILSFVFTLTV*# SEQUENCE: KGILSFVFTLTV*# ...# >HUM10E08# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGILGKVFTLTV*# SEQUENCE: KGILGKVFTLTV*# ...# >HUM10E09# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGAVFTLTV*# SEQUENCE: KGILGAVFTLTV*# ...# >HUM10E0A# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGVVFTLTV*# SEQUENCE: KGILGVVFTLTV*# ...# >HUM10E0B# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGIVFTLTV*# SEQUENCE: KGILGIVFTLTV*# ...# >HUM10E0C# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGILGYVFTLTV*# SEQUENCE: KGILGYVFTLTV*# ...# >HUM10E0D# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGFAFTLTV*# SEQUENCE: KGILGFAFTLTV*# ...# >HUM10E0E# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGILGFEFTLTV*# SEQUENCE: KGILGFEFTLTV*# ...# >HUM10E0F# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGFYFTLTV*# SEQUENCE: KGILGFYFTLTV*# ...# >HUM10E10# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGFFFTLTV*# SEQUENCE: KGILGFFFTLTV*# ...# >HUM10E11# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGFRFTLTV*# SEQUENCE: KGILGFRFTLTV*# ...# >HUM10E12# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGILGFVATLTV*# SEQUENCE: KGILGFVATLTV*# ...# >HUM10E13# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGILGFVQTLTV*# SEQUENCE: KGILGFVQTLTV*# ...# >HUM10E14# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGILGFVNTLTV*# SEQUENCE: KGILGFVNTLTV*# ...# >HUM10E15# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGILGFVYTLTV*# SEQUENCE: KGILGFVYTLTV*# ...# >HUM10E16# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGILGFVITLTV*# SEQUENCE: KGILGFVITLTV*# ...# >HUM10E17# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGILGFVFKLTV*# SEQUENCE: KGILGFVFKLTV*# ...# >HUM10E18# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGFVFALTV*# SEQUENCE: KGILGFVFALTV*# ...# >HUM10E19# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGFVFQLTV*# SEQUENCE: KGILGFVFQLTV*# ...# >HUM10E1A# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGILGFVFDLTV*# SEQUENCE: KGILGFVFDLTV*# ...# >HUM10E1B# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGILGFVFTATV*# SEQUENCE: KGILGFVFTATV*# ...# >HUM10E1C# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesh,KGILGFVFTRTV*# SEQUENCE: KGILGFVFTRTV*# ...# >HUM10E1D# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGILGFVFTETV*# SEQUENCE: KGILGFVFTETV*# ...# >HUM10E1E# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesm,KGILGFVFTFTV*# SEQUENCE: KGILGFVFTFTV*# ...# >HUM10E1F# MHC MOLECULE: HLA-B5, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B5,actunkn,bindyesl,KGILGFVFTSTV*# SEQUENCE: KGILGFVFTSTV*# ...# >HUM10E20# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,HGILGFVFTLTV *# SEQUENCE: HGILGFVFTLTV *# ...# >HUM10E21# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,RGILGFVFTLTV*# SEQUENCE: RGILGFVFTLTV*# ...# >HUM10E22# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,AGILGFVFTLTV*# SEQUENCE: AGILGFVFTLTV*# ...# >HUM10E23# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KSILGFVFTLTV*# SEQUENCE: KSILGFVFTLTV*# ...# >HUM10E24# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KQILGFVFTLTV*# SEQUENCE: KQILGFVFTLTV*# ...# >HUM10E25# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KAILGFVFTLTV*# SEQUENCE: KAILGFVFTLTV*# ...# >HUM10E26# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KLILGFVFTLTV*# SEQUENCE: KLILGFVFTLTV*# ...# >HUM10E27# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KFILGFVFTLTV*# SEQUENCE: KFILGFVFTLTV*# ...# >HUM10E28# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KKILGFVFTLTV*# SEQUENCE: KKILGFVFTLTV*# ...# >HUM10E29# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGALGFVFTLTV*# SEQUENCE: KGALGFVFTLTV*# ...# >HUM10E2A# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGKLGFVFTLTV*# SEQUENCE: KGKLGFVFTLTV*# ...# >HUM10E2B# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGFLGFVFTLTV*# SEQUENCE: KGFLGFVFTLTV*# ...# >HUM10E2C# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGELGFVFTLTV*# SEQUENCE: KGELGFVFTLTV*# ...# >HUM10E2D# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGYLGFVFTLTV*# SEQUENCE: KGYLGFVFTLTV*# ...# >HUM10E2E# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGINMFVFTLTV*# SEQUENCE: KGINMFVFTLTV*# ...# >HUM10E2F# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGISGFVFTLTV*# SEQUENCE: KGISGFVFTLTV*# ...# >HUM10E30# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGITGFVFTLTV*# SEQUENCE: KGITGFVFTLTV*# ...# >HUM10E31# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGIAGFVFTLTV*# SEQUENCE: KGIAGFVFTLTV*# ...# >HUM10E32# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGIPGFVFTLTV*# SEQUENCE: KGIPGFVFTLTV*# ...# >HUM10E33# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILSFVFTLTV*# SEQUENCE: KGILSFVFTLTV*# ...# >HUM10E34# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGQVFTLTV*# SEQUENCE: KGILGQVFTLTV*# ...# >HUM10E35# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGAVFTLTV*# SEQUENCE: KGILGAVFTLTV*# ...# >HUM10E36# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILGVVFTLTV*# SEQUENCE: KGILGVVFTLTV*# ...# >HUM10E37# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILGIVFTLTV*# SEQUENCE: KGILGIVFTLTV*# ...# >HUM10E38# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,KGILGYVFTLTV*# SEQUENCE: KGILGYVFTLTV*# ...# >HUM10E39# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFAFTLTV*# SEQUENCE: KGILGFAFTLTV*# ...# >HUM10E3A# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFEFTLTV*# SEQUENCE: KGILGFEFTLTV*# ...# >HUM10E3B# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFYFTLTV*# SEQUENCE: KGILGFYFTLTV*# ...# >HUM10E3C# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFFFTLTV*# SEQUENCE: KGILGFFFTLTV*# ...# >HUM10E3D# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFRFTLTV*# SEQUENCE: KGILGFRFTLTV*# ...# >HUM10E3E# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILGFVQTLTV*# SEQUENCE: KGILGFVQTLTV*# ...# >HUM10E3F# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFVNTLTV*# SEQUENCE: KGILGFVNTLTV*# ...# >HUM10E40# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFVSTLTV*# SEQUENCE: KGILGFVSTLTV*# ...# >HUM10E41# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILGFVYTLTV*# SEQUENCE: KGILGFVYTLTV*# ...# >HUM10E42# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,KGILGFVFKLTV*# SEQUENCE: KGILGFVFKLTV*# ...# >HUM10E43# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFVFGLTV*# SEQUENCE: KGILGFVFGLTV*# ...# >HUM10E44# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILGFVFQLTV*# SEQUENCE: KGILGFVFQLTV*# ...# >HUM10E45# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFVFDLTV*# SEQUENCE: KGILGFVFDLTV*# ...# >HUM10E46# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILGFVFALTV*# SEQUENCE: KGILGFVFALTV*# ...# >HUM10E47# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFVFTATV*# SEQUENCE: KGILGFVFTATV*# ...# >HUM10E48# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,KGILGFVFTRTV*# SEQUENCE: KGILGFVFTRTV*# ...# >HUM10E49# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: solid phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU M (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,KGILGFVFTFTV*# SEQUENCE: KGILGFVFTFTV*# ...# >MUS10E4A# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (325-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,AAGNYPAL*# SEQUENCE: AAGNYPAL*# ...# >MUS10E4B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (325-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,AGGNYPAL*# SEQUENCE: AGGNYPAL*# ...# >MUS10E4C# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (325-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,AIGNYPAL*# SEQUENCE: AIGNYPAL*# ...# >MUS10E4D# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (325-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,ANGNYPAL*# SEQUENCE: ANGNYPAL*# ...# >MUS10E4E# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (325-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,AVGNYPAL*# SEQUENCE: AVGNYPAL*# ...# >MUS10E4F# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as./competitive binding/stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: Sendai virus NP (324-332)# DB REFERENCE: SWISS: (NCAP_PI3B,NCAP_SENDZ,NCAP_SENDF,NCAP_PI1HA,NCAP_PI1HC,# & NCAP_SENDE,NCAP_PI1HW,NCAP_SEND5)# & PIR1: (VHNZP1,VHNZB3,VHNZSV,VHNZT1,A48341)# & PIR2: (S72317,S72316,S13778)# REFERENCES: chen90a,olsen94a,feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,FAPGNYPAL*# SEQUENCE: FAPGNYPAL*# ...# >MUS10E50# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (324-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,FAAGNYPAL*# SEQUENCE: FAAGNYPAL*# ...# >MUS10E51# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (324-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,FAGGNYPAL*# SEQUENCE: FAGGNYPAL*# ...# >MUS10E52# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (324-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,FAIGNYPAL*# SEQUENCE: FAIGNYPAL*# ...# >MUS10E53# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (324-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,FANGNYPAL*# SEQUENCE: FANGNYPAL*# ...# >MUS10E54# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (324-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,FAVGNYPAL*# SEQUENCE: FAVGNYPAL*# ...# >MUS10E55# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sendai virus NP (324-332) homologue# ANCHOR POSITIONS:# REFERENCES: chen90a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,FANGNYPAL*# SEQUENCE: FANGNYPAL*# ...# >MUS10E56# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Plasmodium Berghei homologue# ANCHOR POSITIONS:# REFERENCES: abastado93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,SYIPSAEYI*# SEQUENCE: SYIPSAEYI*# ...# >MUS10E57# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: binding as./Reference/Competition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HLA Cw3 (170-179)# DB REFERENCE: SWISS: (1C06_HUMAN,1C05_HUMAN)# & PIR1: (HLHUW3)# & PIR2: (I81231)# REFERENCES: abastado93a,rammensee95a,eberl93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,RYLKNGKETL*# SEQUENCE: RYLKNGKETL*# ...# >MUS10E58# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: binding as./Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: VSV NP (52-59)# DB REFERENCE: SWISS: (NCAP_VSVIG,NCAP_VSVSJ)# & PIR1: (VHVNV4,VHVNN)# REFERENCES: abastado93a,ojcius94a,jackson93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesh,RGYVYQGL*# SEQUENCE: RGYVYQGL*# ...# >MUS20E59# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesl,bindyesu,SSQKRPSQRHG*# SEQUENCE: SSQKRPSQRHG*# ...# >MUS20E5A# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesm,bindyesu,AAQKRPSQRHG*# SEQUENCE: AAQKRPSQRHG*# ...# >MUS20E5B# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition/Reference# ACTIVITY: none# BINDING: yes, little# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a,bell91a,smilek90a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesn,bindyesl,ASAKRPSQRHG*# SEQUENCE: ASAKRPSQRHG*# ...# >MUS20E5C# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as./Induction of EAE/Reference# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Rat/Bovine myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a,bell91a,smilek90a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesh,bindyesh,ASQARPSQRHG*# SEQUENCE: ASQARPSQRHG*# ...# >MUS20E5D# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesl,bindyesu,ASQKAPSQRHG*# SEQUENCE: ASQKAPSQRHG*# ...# >MUS20E5E# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive inhibition/Reference# ACTIVITY: none# BINDING: yes, moderate# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a,bell91a,smilek90a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesn,bindyesm,ASQKRASQRHG*# SEQUENCE: ASQKRASQRHG*# ...# >MUS20E5F# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesm,bindyesu,ASQKRPAQRHG*# SEQUENCE: ASQKRPAQRHG*# ...# >MUS20E60# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesm,bindyesu,ASQKRPSARHG*# SEQUENCE: ASQKRPSARHG*# ...# >MUS20E61# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesm,bindyesu,ASQKRPSQAHG*# SEQUENCE: ASQKRPSQAHG*# ...# >MUS20E62# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: Rat myelin basic protein Ac(1-11) homologue# ANCHOR POSITIONS:# REFERENCES: mcDevitt,acha-orbea88a# COMMENT: acetylated N-terminal# SUMMARY: I-Au,actyesn,bindyesh,ASAARPSQAHG*# SEQUENCE: ASAARPSQAHG*# ...# >MUS20E63# MHC MOLECULE: I-Eu, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rat myelin basic protein (35-47)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_RAT)# & PIR1: (MBRTS,MBMSB)# REFERENCES: mcDevitt,villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Eu,actyesu,bindyesu,TGILDSIGRFFSG*# SEQUENCE: TGILDSIGRFFSG*# ...# >MUS20E64# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rat myelin basic protein (89-101)# ANCHOR POSITIONS:# REFERENCES: mcDevitt# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,VHFFKNVTPRTP*# SEQUENCE: VHFFKNVTPRTP*# ...# >HUM10E65# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, high# SOURCE: Protein phosphatase 2A# DB REFERENCE: SWISS: (2AAB_PIG,2AAA_PEA,2AAB_HUMAN,2AAA_DROME,2AAA_PIG,# & 2AAA_HUMAN)# & PIR2: (A34541,S69215,C34541,D34541,S51808,A36180,B34541,S51809,# & I51631,A43767,S72499,S51807,S43776,S40171)# REFERENCES: harris93a,barber93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLLPAIVEL*# SEQUENCE: SLLPAIVEL*# ...# >HUM10E66# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLLGLLVEV*# SEQUENCE: SLLGLLVEV*# ...# >HUM10E67# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALLPPINIL*# SEQUENCE: ALLPPINIL*# ...# >HUM10E68# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,TLIKIQHTL*# SEQUENCE: TLIKIQHTL*# ...# >HUM10E69# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALIVGXNDD*# SEQUENCE: ALIVGXNDD*# ...# >HUM10E6A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Carboxypeptidase M# DB REFERENCE: SWISS: (CBPM_HUMAN)# & PIR2: (A32619)# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,HLIDYLVTS*# SEQUENCE: HLIDYLVTS*# ...# >HUM10E6B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KLIKPIVMK*# SEQUENCE: KLIKPIVMK*# ...# >HUM10E6C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ILAPPVVKLLV*# SEQUENCE: ILAPPVVKLLV*# ...# >HUM10E6D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALFPQLVIL*# SEQUENCE: ALFPQLVIL*# ...# >HUM10E6E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RLFPVLXFQ*# SEQUENCE: RLFPVLXFQ*# ...# >HUM10E6F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,AAAPPPVRR*# SEQUENCE: AAAPPPVRR*# ...# >HUM10E70# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SWVSKHXWS*# SEQUENCE: SWVSKHXWS*# ...# >HUM10E71# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,XVLKXIAKR*# SEQUENCE: XVLKXIAKR*# ...# >HUM10E72# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,PVKQVVYHR*# SEQUENCE: PVKQVVYHR*# ...# >HUM10E73# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta-Actin# DB REFERENCE: SWISS: (ACT1_DICDI,ACT2_DICDI,ACTM_HELTB,ACTC_STRPU,ACT3_PODCA,# & ACT3_ORYSA,ACT5_CHICK,ACT_AJECA,ACTM_HELER,ACT3_LIMPO,# & ACT8_XENLA,ACTG_EMENI,ACT1_ORYSA,ACT_CHLRE,ACTB_CRIGR,# & ACT4_ARATH,ACT4_CAEEL,ACT1_SOLTU,ACT7_SOLTU,ACT2_TETPY,# & ACT4_ARATH,ACT2_LYTPI,ACT7_ARATH,ACT2_DROME,ACT_PUCGR,# & ACT_HYDAT,ACT_TOXGO,ACTM_LYTPI,ACTM_STYPL,ACT_CRYNE,# & ACT_FUCDI,ACT3_ECHGR,ACTC_STYPL,ACT_CRYPV,ACT1_ONCVO,# & ACT4_DICDI,ACT_CHLRE,ACT8_DICDI,ACT4_CAEEL,ACT1_HELER,# & ACT1_LYTPI,ACTC_HALRO,ACT1_CAEEL,ACTE_STRPU,ACTF_STRPU,# & ACTM_APLCA,ACTM_HELTB,ACTB_XENBO,ACT5_SOLTU,ACT2_ARATH,# & ACT3_SOLTU,ACT7_ARATH,ACT2_ONCVO,ACT_TOBAC,ACT3_DICDI,# & ACT2_SOLTU,ACT2_FUGRU,ACT_PHYME,ACT3_PEA,ACT1_DROME,# & ACT2_CAEEL,ACT1_FUGRU,ACT1_LYTPI,ACT1_PLAFA,ACT1_SORVU,# & ACT2_LYTPI,ACTB_RABIT,ACT_PINCO,ACTC_ARATH,ACT1_DAUCA,# & ACT_DICVI,ACT_COSCS,ACT4_ARTSX,ACT3_FUGRU,ACTC_PISOC,# & ACT1_ECHGR,ACTB_STRPU,ACT1_ACACA,ACT1_TETTH,ACT3_ARTSX,# & ACT_FUCVE,ACTD_STRPU,ACTB_HUMAN,ACT_ACHBI,ACT_FUCDI,# & ACT3_ARATH,ACTA_LIMPO,ACT3_SOYBN,ACT6_SOLTU,ACT1_PHYIN,# & ACTA_PHYPO,ACT2_ABSGL,ACT5_XENLA,ACTG_HUMAN,ACTA_STRPU,# & ACT6_DIPDE,ACTM_HELER,ACT1_PODCA,ACTB_CYPCA,ACTY_LIMPO,# & ACTY_LIMPO,ACT_VOLCA,ACTB_ARATH,ACTB_ARATH,ACT6_DIPDE,# & ACT_THELA,ACT1_HELER,ACT_NEUCR,ACT_TOXGO,ACT1_ARATH,# & ACT2_DAUCA,ACT1_STRFN,ACT2_PHYIN,ACT3_LYTPI,ACT8_DICDI,# & ACT3_BOMMO,ACTA_LIMPO,ACTC_ARATH,ACT3_LIMPO,ACTM_PISOC)# & PIR1: (S11222,ATSY3,ATAX,ATRTC,ATBOG,ATCHB,ATHUB,ATRZ3,ATDO,# & ATJN,ATFY,ATBOB,ATMUM1,ATURS,ATRBB,ATMSB,ATHUG,A43552,# & ATFF8,ATRZ1,ATMSG,A48324)# & PIR2: (S68107,A28258,S20093,JQ0154,S26039,A29407,S38782,S14120,# & A37431,S33386,C23412,D23412,S20092,S24409,S12628,S33387,# & S16709,A25135,S42103,JC5228,S31933,S58316,B23412,JN0833,# & S14851,S49480,A55001,S20096,A03000,S49479,S68108,S39777,# & S20094,JT0385,S43509,S07003,S07288,S01077,S68109,JE0415,# & S07002,S16710,JN0832,JS0190,S11453,A45634,S68112,JE0414,# & S24408,A61043,S11452,S03126,A25084,S27135,S49481,S47090,# & S12730,JC5227,JC4612,S07284,A54496,S09578,B33761,S68110,# & S20098,JS0189,A48449)# & PIR3: (S71126,S71124,S71125,S49007)# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,ESGPSIVHRK*# SEQUENCE: ESGPSIVHRK*# ...# >HUM10E74# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,TTXTTTNAR*# SEQUENCE: TTXTTTNAR*# ...# >HUM10E75# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,ATLKTXMQT*# SEQUENCE: ATLKTXMQT*# ...# >HUM10E76# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,DTTPTXXR*# SEQUENCE: DTTPTXXR*# ...# >HUM10E77# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,AVLGXNVLL*# SEQUENCE: AVLGXNVLL*# ...# >HUM10E78# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,IVIRVXYXL*# SEQUENCE: IVIRVXYXL*# ...# >HUM10E79# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,SVIGQKNVT*# SEQUENCE: SVIGQKNVT*# ...# >HUM10E7A# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,NVMPVIXXD*# SEQUENCE: NVMPVIXXD*# ...# >HUM10E7B# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,TVKPVKPRL*# SEQUENCE: TVKPVKPRL*# ...# >HUM10E7C# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,TEFPKERHLRL*# SEQUENCE: TEFPKERHLRL*# ...# >HUM10E7D# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFPNKNXL*# SEQUENCE: GEFPNKNXL*# ...# >HUM10E7E# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFPNKNXLYA*# SEQUENCE: GEFPNKNXLYA*# ...# >HUM10E7F# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFPGKIFLYAM*# SEQUENCE: GEFPGKIFLYAM*# ...# >HUM10E80# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,WEFLQPILL*# SEQUENCE: WEFLQPILL*# ...# >HUM10E81# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFIPGNDLHR*# SEQUENCE: GEFIPGNDLHR*# ...# >HUM10E82# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFPPXDNW*# SEQUENCE: GEFPPXDNW*# ...# >HUM10E83# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ alpha-chain# DB REFERENCE: SWISS: (HA24_HUMAN,HA22_HUMAN,HA21_HUMAN)# & PIR1: (HLHUD7,HLHUDQ,HLHUDC)# & PIR2: (C34514,I37038,A29312,D34512,I61806,I61796,I68551,I37040,# & I61799,I37039,I36971,I37064,I37041,I61803,A34513,B27628,# & I36920,I61786,F34513,G34514,I54290,I61792)# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,EEFYVDLER*# SEQUENCE: EEFYVDLER*# ...# >HUM10E84# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,NEFPDIDIR*# SEQUENCE: NEFPDIDIR*# ...# >HUM10E85# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,AEFPKXEAR*# SEQUENCE: AEFPKXEAR*# ...# >HUM10E86# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,AEIGEVIVLWXW*# SEQUENCE: AEIGEVIVLWXW*# ...# >HUM10E87# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,AEIPGEIAL*# SEQUENCE: AEIPGEIAL*# ...# >HUM10E88# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histone H3# DB REFERENCE: SWISS: (H32_XENLA,H3_HORVU,H3_MAIZE,H33_CAEEL,H32_BOVIN,# & H32_ORYSA,H32_MEDSA,YB21_CAEEL,H3_CHLRE,H3_ACRFO,# & H33_HUMAN,H3_VOLCA,H3_YEAST,H33_SCHPO,H31_SCHPO,H3_PEA,# & H34_CAIMO,H31_HUMAN,H3_ENCAL,H3_YEAST,H3_CAEEL,# & H3_DROME)# & PIR1: (HSFI3,HSBH3,HSTR3,HSCH3,HSXL32,HSEAH3,HSRK3,HSBY3,# & HSXL31,HSDK34,HSKW3,HSHU33,HSBO3,HSVK3L,HSZP3,HSHU3)# & PIR2: (I48092,S10097,JQ1343,I51448,S04186,S59592,S61215,S04099,# & I51443,A56618,JQ1983,S06743,S32638,JQ0757,S34185,S57473,# & S61218,I50460,JH0304,A56654,S11315,I49397,S00940,I57019,# & A26014,S10168,I50244,I49398,I50245,S57626,S61214,JS0690,# & A56580,S00373,S06250,S59123,A25564,S24346,S04521,S09655,# & S56707,S61220,S06755,A02630,JN0687,S20109,S04520,JQ1984,# & S59581,I49395)# & PIR3: (S42065,A45941,S42066)# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,REIAQDFKTD*# SEQUENCE: REIAQDFKTD*# ...# >HUM10E89# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IRE-BP# DB REFERENCE: SWISS: (IRE1_HUMAN,IRE1_HUMAN)# & PIR2: (A36203,S26403)# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEILDVFDA*# SEQUENCE: GEILDVFDA*# ...# >HUM10E8A# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,FEIPXLDVA*# SEQUENCE: FEIPXLDVA*# ...# >HUM10E8B# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,AEIKKKNK*# SEQUENCE: AEIKKKNK*# ...# >HUM10E8C# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,NEARIAXE*# SEQUENCE: NEARIAXE*# ...# >HUM10E8D# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,DEVTPQPQLV*# SEQUENCE: DEVTPQPQLV*# ...# >HUM10E8E# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,KEVGVDVALYA*# SEQUENCE: KEVGVDVALYA*# ...# >HUM10E8F# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: c-myc# DB REFERENCE: SWISS: (MYC_HUMAN,MYC_MOUSE,MYC_CALJA,MYC_FLVTT,MYC_FELCA,# & MYC_SHEEP,MYC_RAT,MYC_PANTR,MYC_PIG,MYC_HYLLA,MYC_HUMAN,# & MYC1_MARMO,MYC_CANFA,MYC_MOUSE)# & PIR1: (TVHUM,TVRTMC,TVCTMC,TVMVFT,TVMS)# & PIR2: (S03325,JC1179,A26268,JU0449,I59064,I37244,JC1178,I61947,# & I53224)# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,HEETPPTTS*# SEQUENCE: HEETPPTTS*# ...# >HUM10E90# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ubiquitin# DB REFERENCE: SWISS: (UBIQ_ACECL,UBIQ_TRYCR,UBIQ_HUMAN,UBIQ_HUMAN,UBIQ_TRYBB,# & UBIQ_YEAST,UBIQ_LEIMA,UBIQ_ACACA,UBIQ_LEITA,UBIQ_TETPY,# & UBIQ_EUPEU,UBIQ_AGLNE,UBIQ_NEUCR,UBIQ_CAEEL,UBIQ_YEAST,# & UBIQ_EIMBO,UBIQ_STRPU,UBIQ_CHLRE,UBIQ_DICDI,UBIQ_COPCO,# & UBIQ_SOYBN,UBIQ_CHLRE,UBIQ_PHYIN)# & PIR1: (UQTO7A,UQJNI,UQHU,UQHUB,UQPM,UQUTC,UQUYSF,UQHY,UQFFR7,# & UQUTRC,UQNCR,UQDOR7,UQBO,UQFFM,UQWO7A,UQSY,UQUT,UQBYR7,# & UQHUC,UQOA,UQNC,UQBY,UQMUM,S29853,UQHUR,UQDOR,S20925,# & UQHUR7,UQKM,UQFS)# & PIR2: (S19802,C36571,S55242,S49332,S19800,A29456,A29584,S12161,# & S25164,I50438,S30151,C34080,S42643,D36571,S12114,S43121,# & S28420,A26087,S45359,S34662,A49768,S33633,JC5226,I52220,# & S25154,S28203,JN0790,B27806,JT0492,S55243,PS0380,S55244,# & JS0657,S11248,I50437,S25305,A25062,C48111,D34080,S34332,# & A36571,S53719,JQ1728,S28426,S25001,S20863,S10319,A30126,# & S43306,S34655,A34080,JT0491,B34080,S11296,S42750,S17435,# & S62908,S40611,S17436,S12583,S45304,S16263,S34334,JH0227,# & A27806,S18535,S34333,D29456,I45964,JH0302,S62740,S32020,# & S38669,S01884,JH0226,S29238,S62909,S13928,S55245,I50728,# & A56582,B48470,A31560,PS0428,S25848,I51568,I52328,# & S21083)# & PIR3: (S40240,S40239,S34285,S46214)# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,KESTLHLVL*# SEQUENCE: KESTLHLVL*# ...# >HUM10E91# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cyclin B# DB REFERENCE: SWISS: (CGB1_RAT,CGB1_CRILO,CGB1_MESAU,CGB2_MESAU,CGB2_MOUSE,# & CGB1_MOUSE,CGB1_HUMAN,CGB1_CRILO)# & PIR2: (S34224,A43285,A32992,S34226,S21529,I48316)# REFERENCES: harris93a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEVDVEQHT*# SEQUENCE: GEVDVEQHT*# ...# >HUM10E92# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA B40# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,KLERADPXKT*# SEQUENCE: KLERADPXKT*# ...# >HUM10E93# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,GLKPIKQNLYSR*# SEQUENCE: GLKPIKQNLYSR*# ...# >HUM10E94# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,ALHQMDVEV*# SEQUENCE: ALHQMDVEV*# ...# >HUM10E95# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,GLPGQKXYWW*# SEQUENCE: GLPGQKXYWW*# ...# >HUM10E96# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA A2# DB REFERENCE: SWISS: (1B11_HUMAN,1B61_HUMAN,1B35_HUMAN,1B59_HUMAN,1B24_HUMAN,# & 1A36_HUMAN,1B01_SAGOE,1B57_HUMAN,1B07_HUMAN,1B23_HUMAN,# & 1A03_GORGO,1A01_PANTR,1A68_HUMAN,1A01_PONPY,1A11_HUMAN,# & 1A01_GORGO,1A01_HUMAN,1B02_HUMAN,1B01_PANTR,1B41_HUMAN,# & 1A24_HUMAN,1B45_HUMAN,1B12_HUMAN,1A03_HUMAN,1A80_HUMAN,# & 1B52_HUMAN,1C01_SAGOE,1B04_HUMAN,1B10_HUMAN,HA1B_BOVIN,# & 1B04_GORGO,1B42_HUMAN,HA1A_BOVIN,1B20_HUMAN,1A04_PANTR,# & 1B60_HUMAN,1B44_HUMAN,1B31_HUMAN,1B26_HUMAN,1B22_HUMAN,# & 1B02_PANTR,1B58_HUMAN,1B56_HUMAN,1A02_HUMAN,1A23_HUMAN,# & 1B63_HUMAN,1B34_HUMAN,1B27_HUMAN,1A04_GORGO,1B13_HUMAN,# & 1B49_HUMAN,1A01_SAGOE,1B25_HUMAN,HLAH_HUMAN,1B15_HUMAN,# & 1B21_HUMAN,1B01_GORGO,1B03_GORGO,1B53_HUMAN,1A30_HUMAN,# & 1B28_HUMAN,1OKO_GORGO,1B19_HUMAN,1B05_HUMAN,1B43_HUMAN,# & 1A03_PANTR,HLAH_HUMAN,1B36_HUMAN,1B39_HUMAN,1B40_HUMAN,# & 1B62_HUMAN,1B16_HUMAN,1B08_HUMAN,1A02_PANTR,1B54_HUMAN,# & 1A02_GORGO,1B47_HUMAN,1B46_HUMAN,1B48_HUMAN,1B18_HUMAN,# & 1B02_GORGO,1B29_HUMAN,1B38_HUMAN,1B32_HUMAN,1B55_HUMAN,# & 1AXX_HUMAN,HA19_CANFA,1A02_HUMAN,1B12_HUMAN)# & PIR1: (HLHUB7,HLHUB2,HLHU10,HLHU12,HLHUB8,S42102,HLHUA3,HLHUB4,# & HLHUA2)# & PIR2: (A45845,A45880,JH0540,JH0539,I80168,I59651,I59308,I68747,# & I37542,I56133,A45850,I38519,I84431,I46921,I54493,I36956,# & I62042,I68748,I56130,I38437,I38518,I68850,I38443,I62043,# & S11139,I38442,I84486,I61862,S11136,I56116,I36960,I59654,# & S24436,S24440,I57454,I54442,I61863,I61865,I37522,I61904,# & I56053,I46604,S11135,I84432,I59645,I72753,S18198,S11138,# & A45849,I54289,I36965,I37120,I54314,I62044,A45831,I37521,# & I37515,JH0537,S11133,I61856,S18197,S24435,I37478,I61906,# & I62045,S11137,JH0538,I37485,I68701,S11140,I84490,B40730,# & I38421,I54505,I54298,I38439,I62041,A60369,I72217,S11142,# & E45831,JH0535,I36966,I72218,I61859,I59655,S52486,S24438,# & I68724,I61903,I61864,I54418,S03537,S24437,I80167,A45834,# & S24434,I81233,I61905,S25415,I80170,I84488,A27638,I80171,# & S60601,I72754,I54457,I37470,G01230,I36962,JH0534,I38441,# & B30345,I37476,I46603,I80165,I37475,C35997,I36957,I83063,# & S16789,S03535,B27638,I80166,S11141,I37492,S11134,I61902,# & I80169,I54420,I56039,C45831,JH0536,B53250,I37519,S24433,# & I46030,JH0542,I61907,I61857,I70665,I59633,I61861,A30345,# & S03538,A47636,I72755,I61860,JH0541,D35997,I54416,I72752,# & S10934,I56149,I36961,S01171,F45831,I84448,I37520)# & PIR3: (S07115,S07113,G02922)# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,SAQGSDVSLT*# SEQUENCE: SAQGSDVSLT*# ...# >HUM10E97# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,TAQTXDVHL*# SEQUENCE: TAQTXDVHL*# ...# >HUM10E98# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,KAQPQTMEM*# SEQUENCE: KAQPQTMEM*# ...# >HUM10E99# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: BCL-2# DB REFERENCE: SWISS: (BCL2_RAT,BC2A_HUMAN,BCL2_RAT,BC2B_HUMAN,BCL2_HUMAN)# & PIR1: (TVHUA1,TVHUB1)# & PIR2: (I67432,D37332,I58194)# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,SPVPPVVHL*# SEQUENCE: SPVPPVVHL*# ...# >HUM10E9A# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,DXIGAIRQL*# SEQUENCE: DXIGAIRQL*# ...# >HUM10E9B# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93a# COMMENT: HLA-A2 or HLA-A68 or HLA-B40# SUMMARY: HLA-?,actunkn,bindyesu,SXVPDDXNXN*# SEQUENCE: SXVPDDXNXN*# ...# >HUM20E9C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DTPAVYYAAKWXRW*# SEQUENCE: DTPAVYYAAKWXRW*# ...# >HUM20E9D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig V Region H Chain# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,XSAVYYXAKRRQ*# SEQUENCE: XSAVYYXAKRRQ*# ...# >HUM20E9E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SNKAVYXAAKRX*# SEQUENCE: SNKAVYXAAKRX*# ...# >HUM20E9F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DNLIVYYYHKA*# SEQUENCE: DNLIVYYYHKA*# ...# >HUM20EA0# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SPIPMNXVKXN*# SEQUENCE: SPIPMNXVKXN*# ...# >HUM20EA1# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DPYAPIMAVK*# SEQUENCE: DPYAPIMAVK*# ...# >HUM20EA2# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LD78 alpha (MIP)# DB REFERENCE: SWISS: (MI1A_HUMAN)# & PIR2: (A30574)# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,KPGVIFLTKRSRQV*# SEQUENCE: KPGVIFLTKRSRQV*# ...# >HUM20EA3# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,RPYVYFVMKRPTAVXPXR*# SEQUENCE: RPYVYFVMKRPTAVXPXR*# ...# >HUM20EA4# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,VPYIIFLXKXP*# SEQUENCE: VPYIIFLXKXP*# ...# >HUM20EA5# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,IPYIIFLXKKYXI*# SEQUENCE: IPYIIFLXKKYXI*# ...# >HUM20EA6# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DPLYIXMNKLQ*# SEQUENCE: DPLYIXMNKLQ*# ...# >HUM20EA7# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,GPLYFKLKGYEQYN*# SEQUENCE: GPLYFKLKGYEQYN*# ...# >HUM20EA8# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DPTLWVFARKLAIV*# SEQUENCE: DPTLWVFARKLAIV*# ...# >HUM20EA9# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,TPTLVEVSRXLKV*# SEQUENCE: TPTLVEVSRXLKV*# ...# >HUM20EAA# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,DPWAIAKNGDLMEYPY*# SEQUENCE: DPWAIAKNGDLMEYPY*# ...# >HUM20EAB# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,WVYVYAKARXDN*# SEQUENCE: WVYVYAKARXDN*# ...# >HUM20EAC# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DTPAVYYAAKWXRW*# SEQUENCE: DTPAVYYAAKWXRW*# ...# >HUM20EAD# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig V Region H Chain# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,XSAVYYXAKRRQ*# SEQUENCE: XSAVYYXAKRRQ*# ...# >HUM20EAE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,SNKAVYXAAKRX*# SEQUENCE: SNKAVYXAAKRX*# ...# >HUM20EAF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DNLIVYYYHKA*# SEQUENCE: DNLIVYYYHKA*# ...# >HUM20EB0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,SPIPMNXVKXN*# SEQUENCE: SPIPMNXVKXN*# ...# >HUM20EB1# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DPYAPIMAVK*# SEQUENCE: DPYAPIMAVK*# ...# >HUM20EB2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LD78 alpha (MIP)# DB REFERENCE: SWISS: (MI1A_HUMAN)# & PIR2: (A30574)# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,KPGVIFLTKRSRQV*# SEQUENCE: KPGVIFLTKRSRQV*# ...# >HUM20EB3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,RPYVYFVMKRPTAVXPXR*# SEQUENCE: RPYVYFVMKRPTAVXPXR*# ...# >HUM20EB4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,VPYIIFLXKXP*# SEQUENCE: VPYIIFLXKXP*# ...# >HUM20EB5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,IPYIIFLXKKYXI*# SEQUENCE: IPYIIFLXKKYXI*# ...# >HUM20EB6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DPLYIXMNKLQ*# SEQUENCE: DPLYIXMNKLQ*# ...# >HUM20EB7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,GPLYFKLKGYEQYN*# SEQUENCE: GPLYFKLKGYEQYN*# ...# >HUM20EB8# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DPTLWVFARKLAIV*# SEQUENCE: DPTLWVFARKLAIV*# ...# >HUM20EB9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,TPTLVEVSRXLKV*# SEQUENCE: TPTLVEVSRXLKV*# ...# >HUM20EBA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,DPWAIAKNGDLMEYPY*# SEQUENCE: DPWAIAKNGDLMEYPY*# ...# >HUM20EBB# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: HPLC/Edman degradation naturally processed# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,WVYVYAKARXDN*# SEQUENCE: WVYVYAKARXDN*# ...# >HUM10EBC# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Flu NP (32-40)# DB REFERENCE: SWISS: (VNUC_IATX7,VNUC_IAMEB,VNUC_IAMEG,VNUC_IAGD7,VNUC_IAS31,# & VNUC_IAS11,VNUC_IABRA,VNUC_IAKIE,VNUC_IAS06,VNUC_IACAL,# & VNUC_IAME5,VNUC_IAEN5,VNUC_IAFOW,VNUC_IAB39,VNUC_IAME4,# & VNUC_IAANN,VNUC_IANT6,VNUC_IAME3,VNUC_IAB37,VNUC_IASIN,# & VNUC_IAMEC,VNUC_IAMEE,VNUC_IAUDO,VNUC_IAME6,VNUC_IAZDA,# & VNUC_IAHO2,VNUC_IAMEF,VNUC_IAMEA,VNUC_IAVI6,VNUC_IAHO1,# & VNUC_IAUSS)# & PIR1: (VHIVX3,VHIVN5,VHIV8H,VHIVX5,VHIVX2,VHIV61,VHIVA7,VHIV68,# & VHIVAK,VHIVX6,VHIVX4)# REFERENCES: dibrino93b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesu,MIDGIGRFY*# SEQUENCE: MIDGIGRFY*# ...# >HUM10EBD# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu NP (44-52)# DB REFERENCE: SWISS: (VNUC_IAZ29,VNUC_IAZJA,VNUC_IADCZ,VNUC_IATX7,VNUC_IAWHP,# & VNUC_IACAL,VNUC_IAZW2,VNUC_IAME5,VNUC_IABRA,VNUC_IACKG,# & VNUC_IARUD,VNUC_IASE0,VNUC_IAKIE,VNUC_IAHIC,VNUC_IAZMA,# & VNUC_IALEN,VNUC_IAMAA,VNUC_IAZJ3,VNUC_IAZH3,VNUC_IAZCA,# & VNUC_IAMEF,VNUC_IATKN,VNUC_IAANA,VNUC_IADE1,VNUC_IAB37,# & VNUC_IATEI,VNUC_IAZGE,VNUC_IADHK,VNUC_IAZTE,VNUC_IASIN,# & VNUC_IAWIS,VNUC_IADM2,VNUC_IAZH4,VNUC_IADMA,VNUC_IAMEE,# & VNUC_IAHO1,VNUC_IADNZ,VNUC_IAUSS,VNUC_IAZH1,VNUC_IATKO,# & VNUC_IAZ41,VNUC_IAZI3,VNUC_IAMEA,VNUC_IAUDO,VNUC_IAME6,# & VNUC_IAZI2,VNUC_IAWIL,VNUC_IAZDA,VNUC_IAEN5,VNUC_IAZON,# & VNUC_IAVI6,VNUC_IAFPR,VNUC_IAME3,VNUC_IAZOH,VNUC_IAZW1,# & VNUC_IAB39,VNUC_IAMEC,VNUC_IADBE,VNUC_IAANN,VNUC_IAME4,# & VNUC_IAMAN,VNUC_IADE2,VNUC_IAMEB,VNUC_IAGD7,VNUC_IAS31,# & VNUC_IAMEG,VNUC_IAS11,VNUC_IAS06,VNUC_IAZJ1,VNUC_IANEJ,# & VNUC_IAFOW,VNUC_IADAU,VNUC_IAFOM,VNUC_IAHO2,VNUC_IAZNE,# & VNUC_IATRT,VNUC_IAPUE,VNUC_IAFPD,VNUC_IAZJ2,VNUC_IANT6,# & VNUC_IATRS,VNUC_IAANN,VNUC_IADU2,VNUC_IAPAR,# & VNUC_IAZI1)# & PIR1: (VHIVX5,VHIVN2,VHIVX3,VHIVXL,VHIVX1,VHIVN1,VHIVX6,VHIVX2,# & VHIVN5,VHIV34,VHIV8H,VHIVN8,VHIVC1,VHIVX4,VHIV68,VHIVAK,# & VHIVA7,VHIVA3,VHIV61,VHIVN9,VHIVN7,VHIVA6,VHIVN6)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# REFERENCES: dibrino93b# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,CTELKLSDY*# SEQUENCE: CTELKLSDY*# ...# >HUM10EBE# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu basic polimerase PB1 (591-599)# DB REFERENCE: SWISS: (RRP1_IAHLO,RRP1_IADUN,RRP1_IAHTE,RRP1_IAME8,RRP1_IAGU2,# & RRP1_IASIN,RRP1_IAZH3,RRP1_IABEI,RRP1_IAANN,RRP1_IANT6,# & RRP1_IAMAN,RRP1_IAVI7,RRP1_IAKIE,RRP1_IALE1,RRP1_IATKM,# & RRP1_IAWIS,RRP1_IAZON,RRP1_IAZTF,RRP1_IAPUE,# & RRP1_IAWIL)# & PIR1: (B60011,P1IV34,P1IV33,P1IV68,A60008,P1IV61)# & PIR2: (S06212)# REFERENCES: dibrino93b,falk94c# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,VSDGGPNLY*# SEQUENCE: VSDGGPNLY*# ...# >HUM10EBF# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu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dibrino93b# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesu,ILRGSVAHK*# SEQUENCE: ILRGSVAHK*# ...# >HUM20EC0# MHC MOLECULE: HLA-DPw3, CLASS-2, (HUMAN)# METHOD: binding as./ HPLC/Edman degradation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HLA DR3 (71-83)# DB REFERENCE: SWISS: (HB2B_HUMAN,HB2B_HUMAN)# & PIR1: (HLHU3D)# & PIR2: (I54294,I68710,I38020,I59625,I37537,S03442,I68554,# & I68555)# REFERENCES: verreck94a# COMMENT:# SUMMARY: HLA-DPw3,actyesu,bindyesu,KRGRVDNYCRHNY*# SEQUENCE: KRGRVDNYCRHNY*# ...# >HUM20EC1# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: binding as./ HPLC/Edman degradation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HLA DR3 (71-83)# DB REFERENCE: SWISS: (HB2B_HUMAN,HB2B_HUMAN)# & PIR1: (HLHU3D)# & PIR2: (I37537,I68554,I54294,I68555,I59625,S03442,I68710,# & I38020)# REFERENCES: verreck94a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,KRGRVDNYCRHNY*# SEQUENCE: KRGRVDNYCRHNY*# ...# >HUM20EC2# MHC MOLECULE: HLA-DPw3, CLASS-2, (HUMAN)# METHOD: binding as./ HPLC/Edman degradation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: GAPDH (12-26)# DB REFERENCE: SWISS: (G3P_BOVIN,G3P_RABIT,G3P_BOVIN,G3P2_JACOR,G3P_RABIT,# & G3P1_HUMAN,G3P1_JACOR,G3P1_JACOR,G3P_PIG,G3P_PIG,# & G3P2_JACOR,G3P2_HUMAN)# & PIR1: (DEPGG3,DEHUG3)# & PIR2: (JC4309,A12055)# & PIR3: (S62673,S62674)# REFERENCES: verreck94a# COMMENT:# SUMMARY: HLA-DPw3,actyesu,bindyesu,RIGRLVTRAAFNSGK*# SEQUENCE: RIGRLVTRAAFNSGK*# ...# >HUM20EC3# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: binding as./ HPLC/Edman degradation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: GAPDH (12-26)# DB REFERENCE: SWISS: (G3P_PIG,G3P2_JACOR,G3P2_HUMAN,G3P1_HUMAN,G3P_BOVIN,# & G3P_BOVIN,G3P1_JACOR,G3P2_JACOR,G3P_RABIT,G3P_PIG,# & G3P_RABIT,G3P1_JACOR)# & PIR1: (DEHUG3,DEPGG3)# & PIR2: (A12055,JC4309)# & PIR3: (S62674,S62673)# REFERENCES: verreck94a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,RIGRLVTRAAFNSGK*# SEQUENCE: RIGRLVTRAAFNSGK*# ...# >MUS20EC4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive inhibition/HPLC/Edman sequencing# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Hen egg lysozyme (48-62)# DB REFERENCE: SWISS: (LYC_CHICK,LYC1_ANAPL,LYC_PAVCR,LYC_CHICK,LYC_PHACO,# & LYC_PHAVE,LYC_CHRAM,LYC_SYRRE,LYC_LOPLE,LYC_MELGA)# & PIR1: (LZTK,LZCH,LZQJE,LZDK)# & PIR2: (JU0237,JU0178,JQ1033,JC2144,JT0526,JQ1041)# REFERENCES: rotzschke94b,barber93a,vignali94a,nelson92a,greer96a# COMMENT: naturally processed peptide# SUMMARY: I-Ak,actyesl,bindyesu,DGSTDYGILQINSRW*# SEQUENCE: DGSTDYGILQINSRW*# ...# >MUS20EC5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Hen egg lysozyme 49-64# DB REFERENCE: SWISS: (LYC_ORTVE,LYC1_ANAPL,LYC_MELGA,LYC_LOPLE,LYC_PAVCR,# & LYC_CHRAM,LYC_SYRRE,LYC_CHICK,LYC_CHICK,LYC_PHACO,# & LYC_PHAVE)# & PIR1: (LZQJE,LZTK,LZDK,LZOVE,LZCH)# & PIR2: (JU0237,JQ1041,JT0526,JC2144,JQ1033,JU0178)# REFERENCES: rotzschke94b,vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,GSTDYGILQINSRWWC*# SEQUENCE: GSTDYGILQINSRWWC*# ...# >MUS20EC6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hen egg lysozyme 45-68# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZQJE,LZCH)# & PIR2: (JU0237)# REFERENCES: rotzschke94b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,QATNRNTDGSTDYGILQINSRWWCNDGR*# SEQUENCE: QATNRNTDGSTDYGILQINSRWWCNDGR*# ...# >HUM20EC7# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B100 2877-2892# ANCHOR POSITIONS:# REFERENCES: rotzschke94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,ISNQLTLDSNTKYFHK*# SEQUENCE: ISNQLTLDSNTKYFHK*# ...# >HUM20EC8# MHC MOLECULE: HLA-DPw2, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine serumalbumin 152-170# DB REFERENCE: SWISS: (ALBU_BOVIN)# & PIR1: (ABBOS)# REFERENCES: rotzschke94b# COMMENT:# SUMMARY: HLA-DPw2,actunkn,bindyesu,ADEKKFWGKYLYEIARRHP*# SEQUENCE: ADEKKFWGKYLYEIARRHP*# ...# >HUM20EC9# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC class 1 (Cw4) 104-121# DB REFERENCE: SWISS: (1C14_HUMAN,1C07_HUMAN,1C13_HUMAN,1B08_HUMAN,1B29_HUMAN,# & 1C12_HUMAN,1B07_HUMAN)# & PIR1: (S42102)# & PIR2: (I79640,I61862,I37135,I61859,C35997,JS0262,JH0526,# & I81232)# & PIR3: (G02922)# REFERENCES: rotzschke94b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,GPDGRLLRGYNQFAYDGK*# SEQUENCE: GPDGRLLRGYNQFAYDGK*# ...# >HUM20ECA# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC class 1 (B) 104-119# DB REFERENCE: SWISS: (1B52_HUMAN,1B24_HUMAN,1B35_HUMAN,1B04_HUMAN,1B46_HUMAN,# & 1B38_HUMAN,1B49_HUMAN,1B34_HUMAN,1B63_HUMAN,1B33_HUMAN,# & 1B20_HUMAN,1B53_HUMAN,1B39_HUMAN,1B61_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I59655,I61903,I38509,I38437,B30345,I61906,I61864,S52486,# & I37120,I37521,I37492,I56116,I59188,I37522,I61865,I84431,# & I68747,I59651,I54457,I56149,A30345)# REFERENCES: rotzschke94b# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesu,GPDGRLLRGHNQYAYD*# SEQUENCE: GPDGRLLRGHNQYAYD*# ...# >HUM20ECB# MHC MOLECULE: HLA-DPw2, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor 5-31# ANCHOR POSITIONS:# REFERENCES: rotzschke94b# COMMENT:# SUMMARY: HLA-DPw2,actunkn,bindyesu,GEPLSYTRFSLARQVDR*# SEQUENCE: GEPLSYTRFSLARQVDR*# ...# >HUM20ECC# MHC MOLECULE: HLA-DPw2, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin H 185-198# DB REFERENCE: SWISS: (CATH_HUMAN,CATH_MOUSE,CATH_RAT)# & PIR1: (KHHUH,KHRTH)# REFERENCES: rotzschke94b# COMMENT:# SUMMARY: HLA-DPw2,actunkn,bindyesu,LPSQAFEYILYNKG*# SEQUENCE: LPSQAFEYILYNKG*# ...# >HUM20ECD# MHC MOLECULE: HLA-DPw2, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PGK 1 339-354# DB REFERENCE: SWISS: (PGK2_RAT,PGK1_HUMAN,PGK_CRIGR,PGK_HORSE,PGK1_MOUSE)# & PIR1: (KIHUG,KIHOG)# & PIR2: (I48074,A25567,A33792)# REFERENCES: rotzschke94b# COMMENT:# SUMMARY: HLA-DPw2,actunkn,bindyesu,GPVGVFEWEAFARGTK*# SEQUENCE: GPVGVFEWEAFARGTK*# ...# >HUM20ECE# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human hsp70 (hsp70/hsc70) (296-310)# DB REFERENCE: SWISS: (HS72_PICAN,HS7T_MOUSE,HS72_BOVIN,HS7H_HUMAN,HS71_HUMAN,# & HS7C_RAT,HS71_RAT,HS7C_DICDI,HS70_ONCMY,HS71_MOUSE,# & HS70_PLEWA,HS71_MOUSE,HS70_HYDMA,HS72_YEAST,HS73_RAT,# & HS7C_DICDI,HS72_PICAN,HS71_YEAST,HS71_RAT,HS71_PIG,# & HS71_HANPO,HS7C_RAT,HS71_CANAL,HS71_BOVIN,HS71_PIG,# & HS7T_MOUSE,HS7C_HUMAN,HS74_CANAL,HS71_PICAN,HS71_SCHPO,# & HS74_YEAST,HS7C_BOVIN,HS7C_CRIGR,HS7C_BOVIN,HS7C_BRARE,# & HS70_CHICK,HS70_BLAEM,HS70_ONCTS)# & PIR1: (HHBYA1)# & PIR2: (S37394,S20139,JH0095,S11456,A45935,B45871,S35718,S67431,# & I56574,I51344,B36590,JC4853,A27077,A29160,A48872,I51129,# & S27004,I54542,A48439,S41372,S31716,A34041,S43388,S31766,# & A25646,S07197,S41415,I49761,A45871,A35922,S51712)# & PIR3: (S21175)# REFERENCES: rotzschke94b,newcomb93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,IDFYTSITRARFEE*# SEQUENCE: IDFYTSITRARFEE*# ...# >HUM20ECF# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human hsp70 (hsp70/hsc70) (296-310)# DB REFERENCE: SWISS: (HS71_BOVIN,HS71_CANAL,HS72_PICAN,HS7C_DICDI,HS72_PICAN,# & HS7C_BRARE,HS7T_MOUSE,HS70_BLAEM,HS70_ONCTS,HS71_YEAST,# & HS71_SCHPO,HS71_PICAN,HS74_CANAL,HS71_HANPO,HS71_PIG,# & HS71_RAT,HS71_PIG,HS7C_RAT,HS7T_MOUSE,HS72_BOVIN,# & HS71_HUMAN,HS7H_HUMAN,HS70_ONCMY,HS71_RAT,HS7C_RAT,# & HS70_PLEWA,HS70_HYDMA,HS72_YEAST,HS73_RAT,HS71_MOUSE,# & HS71_MOUSE,HS7C_BOVIN,HS7C_CRIGR,HS7C_DICDI,HS74_YEAST,# & HS7C_BOVIN,HS7C_HUMAN,HS70_CHICK)# & PIR1: (HHBYA1)# & PIR2: (I51344,S51712,A25646,A45871,S11456,S20139,I51129,A29160,# & I56574,S35718,I49761,S41415,S07197,S31766,S31716,A34041,# & S41372,S43388,A35922,JH0095,S27004,A27077,A48872,B36590,# & JC4853,B45871,A48439,S67431,A45935,S37394,I54542)# & PIR3: (S21175)# REFERENCES: rotzschke94b,newcomb93a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,IDFYTSITRARFEE*# SEQUENCE: IDFYTSITRARFEE*# ...# >HUM20ED0# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Elution and Sequencing/Half-time# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain DR 97-120# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rotzschke94b,barber93a,riberdy92a,van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,LPKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPM*# ...# >HUM20ED1# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Elution and Sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain DR (99-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rotzschke94b,riberdy92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALPM*# SEQUENCE: KPPKPVSKMRMATPLLMQALPM*# ...# >MUS20ED2# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 70-78# DB REFERENCE: SWISS: (MYG_RABIT,MYG_PHYCA,MYG_KOGSI,MYG_TURTR,MYG_ORCOR,# & MYG_GLOME,MYG_PHYCA)# & PIR1: (MYDD,MYWHL,MYWHW,MYRB,MYWHT,MYWHP,MYDDBS)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,TALGAILKK*# SEQUENCE: TALGAILKK*# ...# >MUS20ED3# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 106-118# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHOPH,MYG_GLOME,MYG_ORCOR,MYG_KOGSI,# & MYG_INIGE,MYG_PHYCA,MYG_TURTR)# & PIR1: (MYWHL,MYWHP,MYDDBS,MYPE,MYPED,MYWHT,MYWHW,MYDD,MYDDAR)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,FISEAIIHVLHSR*# SEQUENCE: FISEAIIHVLHSR*# ...# >MUS20ED4# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 106-118# DB REFERENCE: SWISS: (MYG_KOGSI,MYG_TURTR,MYG_ORCOR,MYG_GLOME,MYG_PHYCA,# & MYG_PHYCA,MYG_INIGE,MYG_PHOPH)# & PIR1: (MYDDBS,MYDDAR,MYWHW,MYDD,MYWHL,MYPE,MYPED,MYWHP,MYWHT)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,FISEAIIHVLHSR*# SEQUENCE: FISEAIIHVLHSR*# ...# >MUS20ED5# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 106-118# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_INIGE,MYG_ORCOR,MYG_GLOME,MYG_TURTR,# & MYG_PHYCA,MYG_KOGSI,MYG_PHOPH)# & PIR1: (MYWHL,MYWHW,MYDDBS,MYWHT,MYPED,MYPE,MYDDAR,MYDD,MYWHP)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,FISEAIIHVLHSR*# SEQUENCE: FISEAIIHVLHSR*# ...# >MUS20ED6# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 133-146# DB REFERENCE: SWISS: (MYG_ORCOR,MYG_ZIPCA,MYG_GLOME,MYG_PHYCA,MYG_INIGE,# & MYG_ESCGI,MYG_TURTR,MYG_PHYCA,MYG_KOGSI,MYG_CASFI,# & MYG_BALPH,MYG_BALAC,MYG_MEGNO,MYG_MESCA)# & PIR1: (MYWHU,MYWHK,MYWHZ,MYWHC,MYWHL,MYWHP,MYDD,MYWHH,MYDDBS,# & MYDDAR,MYWHF,MYWHT,MYWHW)# & PIR2: (JN0410)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,KALELFRKDIAAKY*# SEQUENCE: KALELFRKDIAAKY*# ...# >MUS20ED7# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 26-40# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,QDILIRLFKSHPETL*# SEQUENCE: QDILIRLFKSHPETL*# ...# >MUS20ED8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 26-40# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,QDILIRLFKSHPETL*# SEQUENCE: QDILIRLFKSHPETL*# ...# >MUS20ED9# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 111-120# DB REFERENCE: SWISS: (MYG_BALAC,MYG_KOGSI,MYG_GLOME,MYG_ORCOR,MYG_INIGE,# & MYG_PHOPH,MYG_ESCGI,MYG_TURTR,MYG_PHYCA,MYG_MEGNO,# & MYG_BALPH,MYG_PHYCA,MYG_ZIPCA)# & PIR1: (MYWHP,MYPED,MYWHK,MYWHC,MYDD,MYWHF,MYDDAR,MYDDBS,MYPE,# & MYWHL,MYWHZ,MYWHT,MYWHW,MYWHH)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,IIHVLHSRHP*# SEQUENCE: IIHVLHSRHP*# ...# >MUS20EDA# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sperm whale myog. 111-120# DB REFERENCE: SWISS: (MYG_ORCOR,MYG_BALPH,MYG_PHYCA,MYG_BALAC,MYG_ESCGI,# & MYG_PHOPH,MYG_INIGE,MYG_ZIPCA,MYG_PHYCA,MYG_MEGNO,# & MYG_GLOME,MYG_KOGSI,MYG_TURTR)# & PIR1: (MYDDAR,MYWHW,MYDD,MYWHP,MYPED,MYPE,MYWHC,MYWHK,MYWHH,# & MYWHT,MYWHZ,MYWHL,MYDDBS,MYWHF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,IIHVLHSRHP*# SEQUENCE: IIHVLHSRHP*# ...# >MUS20EDB# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Equine myog. 106-118# DB REFERENCE: SWISS: (MYG_HORSE,MYG_HORSE,MYG_MESCA)# & PIR1: (MYHO,MYWHU,MYHOZ)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,FISDAIIHVLHSK*# SEQUENCE: FISDAIIHVLHSK*# ...# >MUS20EDC# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Equine myog. 106-118# DB REFERENCE: SWISS: (MYG_MESCA,MYG_HORSE,MYG_HORSE)# & PIR1: (MYWHU,MYHOZ,MYHO)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,FISDAIIHVLHSK*# SEQUENCE: FISDAIIHVLHSK*# ...# >MUS20EDD# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Equine myog. 106-118# DB REFERENCE: SWISS: (MYG_HORSE,MYG_HORSE,MYG_MESCA)# & PIR1: (MYHOZ,MYWHU,MYHO)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,FISDAIIHVLHSK*# SEQUENCE: FISDAIIHVLHSK*# ...# >MUS20EDE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Equine myog. 106-118# DB REFERENCE: SWISS: (MYG_MESCA,MYG_HORSE,MYG_HORSE)# & PIR1: (MYHOZ,MYWHU,MYHO)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,FISDAIIHVLHSK*# SEQUENCE: FISDAIIHVLHSK*# ...# >MUS20EDF# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Equine myog. 102-117# DB REFERENCE: SWISS: (MYG_MEGNO,MYG_HORSE,MYG_ZIPCA,MYG_ESCGI,MYG_BALAC,# & MYG_HORSE,MYG_BALPH,MYG_MESCA)# & PIR1: (MYHOZ,MYWHH,MYWHZ,MYHO,MYWHF,MYWHU,MYWHK,MYWHC)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,KYLEFISDAIIHVLHS*# SEQUENCE: KYLEFISDAIIHVLHS*# ...# >MUS20EE0# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Equine myog. 102-117# DB REFERENCE: SWISS: (MYG_HORSE,MYG_MEGNO,MYG_ZIPCA,MYG_BALAC,MYG_MESCA,# & MYG_HORSE,MYG_ESCGI,MYG_BALPH)# & PIR1: (MYWHC,MYWHZ,MYHOZ,MYWHK,MYWHU,MYWHF,MYHO,MYWHH)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,KYLEFISDAIIHVLHS*# SEQUENCE: KYLEFISDAIIHVLHS*# ...# >MUS20EE1# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pigeon Cyt. c 45-58# DB REFERENCE: SWISS: (CYC_EQUAS,CYC_MINSC,CYC_DRONO,CYC_ESCGI,CYC_MOUSE,# & CYC_MIRLE,CYC_HIPAM,CYC_CANFA,CYC_COLLI,CYC_BOVIN,# & CYC_CANFA,CYC_ESCGI,CYC_RABIT,CYC_RANCA,CYC_DRONO,# & CYC_STRCA,CYC_APTPA,CYC_CHICK,CYC_ANAPL,CYC_COLLI,# & CYC_CHICK,CYC_EQUAS,CYC_APTPA,CYC_ANAPL)# & PIR1: (CCHOD,CCRB,CCCM,CCSH,CCMS,CCHOZ,CCTK,CCBTS,CCEU,CCFG,# & CCSLE,CCBO,CCGW,CCPG,CCRT,CCDK,CCPN,CCDG,CCWHC,CCCH,# & CCHP,CCPY,CCOS)# & PIR2: (C04604)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,GFSYTDANKNKGIT*# SEQUENCE: GFSYTDANKNKGIT*# ...# >MUS20EE2# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pigeon Cyt. c 45-58# DB REFERENCE: SWISS: (CYC_ESCGI,CYC_RABIT,CYC_MOUSE,CYC_RANCA,CYC_DRONO,# & CYC_MINSC,CYC_COLLI,CYC_CANFA,CYC_CHICK,CYC_EQUAS,# & CYC_ANAPL,CYC_ESCGI,CYC_BOVIN,CYC_CANFA,CYC_HIPAM,# & CYC_CHICK,CYC_APTPA,CYC_ANAPL,CYC_COLLI,CYC_STRCA,# & CYC_EQUAS,CYC_APTPA,CYC_MIRLE,CYC_DRONO)# & PIR1: (CCCM,CCCH,CCOS,CCDG,CCWHC,CCPG,CCDK,CCRT,CCBO,CCFG,# & CCSLE,CCGW,CCEU,CCBTS,CCTK,CCHOZ,CCMS,CCSH,CCRB,CCHOD,# & CCPY,CCHP,CCPN)# & PIR2: (C04604)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,GFSYTDANKNKGIT*# SEQUENCE: GFSYTDANKNKGIT*# ...# >MUS20EE3# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pigeon Cyt. c 93-104# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,DLIAYLKQATAK*# SEQUENCE: DLIAYLKQATAK*# ...# >MUS20EE4# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pigeon Cyt. c 93-104# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,DLIAYLKQATAK*# SEQUENCE: DLIAYLKQATAK*# ...# >MUS20EE5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pigeon Cyt. c 93-104# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,DLIAYLKQATAK*# SEQUENCE: DLIAYLKQATAK*# ...# >MUS20EE6# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pigeon Cyt. c 93-104# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Es,actyesu,bindyesu,DLIAYLKQATAK*# SEQUENCE: DLIAYLKQATAK*# ...# >MUS20EE7# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Moth Cyt. c 93-103# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,DLIAYLKQATK*# SEQUENCE: DLIAYLKQATK*# ...# >MUS20EE8# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Moth Cyt. c 93-103# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,DLIAYLKQATK*# SEQUENCE: DLIAYLKQATK*# ...# >MUS20EE9# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Moth Cyt. c 93-103# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,DLIAYLKQATK*# SEQUENCE: DLIAYLKQATK*# ...# >MUS20EEA# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Moth Cyt. c 93-103# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Eb,actyesu,bindyesu,DLIAYLKQATK*# SEQUENCE: DLIAYLKQATK*# ...# >MUS20EEB# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Moth Cyt. c 93-103# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Es,actyesu,bindyesu,DLIAYLKQATK*# SEQUENCE: DLIAYLKQATK*# ...# >MUS20EEC# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Horse Cyt. c 47-53# DB REFERENCE: SWISS: (CYC_HORSE,CYC_HORSE,CYC_MACGI)# & PIR1: (CCKGG,CCHO)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,TYTDANK*# SEQUENCE: TYTDANK*# ...# >MUS20EED# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Horse Cyt. c 47-53# DB REFERENCE: SWISS: (CYC_MACGI,CYC_HORSE,CYC_HORSE)# & PIR1: (CCHO,CCKGG)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,TYTDANK*# SEQUENCE: TYTDANK*# ...# >MUS20EEE# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Beef Cyt. c 13-25# DB REFERENCE: SWISS: (CYC_ESCGI,CYC2_MOUSE,CYC_EQUAS,CYC_HIPAM,CYC_MOUSE,# & CYC_HORSE,CYC_MINSC,CYC2_RAT,CYC_HORSE,CYC_ESCGI,# & CYC_CHESE,CYC_EQUAS,CYC_BOVIN,CYC_CANFA,CYC2_MOUSE,# & CYC2_RAT,CYC_MACGI,CYC_RABIT,CYC_CHESE,CYC_CANFA,# & CYC_MIRLE)# & PIR1: (CCWHC,CCRTT,CCBO,CCPG,CCRT,CCGW,CCSLE,CCHP,CCMS,CCBTS,# & CCSH,CCHO,CCRB,CCHOD,CCCM,CCKGG,CCHOZ,CCST,CCMST)# & PIR2: (C04604)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,KCAQCHTVEKGGK*# SEQUENCE: KCAQCHTVEKGGK*# ...# >MUS20EEF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Beef Cyt. c 13-25# DB REFERENCE: SWISS: (CYC_EQUAS,CYC_MIRLE,CYC_MACGI,CYC2_MOUSE,CYC_CANFA,# & CYC_BOVIN,CYC2_RAT,CYC2_RAT,CYC_HORSE,CYC_EQUAS,# & CYC_ESCGI,CYC_HORSE,CYC_CHESE,CYC_MOUSE,CYC_ESCGI,# & CYC_HIPAM,CYC2_MOUSE,CYC_MINSC,CYC_CHESE,CYC_CANFA,# & CYC_RABIT)# & PIR1: (CCRTT,CCPG,CCRT,CCST,CCKGG,CCHOZ,CCHP,CCHO,CCRB,CCHOD,# & CCCM,CCBO,CCSLE,CCGW,CCMS,CCBTS,CCSH,CCWHC,CCMST)# & PIR2: (C04604)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,KCAQCHTVEKGGK*# SEQUENCE: KCAQCHTVEKGGK*# ...# >MUS20EF0# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Beef Cyt. c 66-80# DB REFERENCE: SWISS: (CYC_USTSP,CYC_NEUCR,CYC_APTPA,CYC_EQUAS,CYC_SAMCY,# & CYC_COLLI,CYC_MIRLE,CYC_BOEPE,CYC2_DROME,CYC_MANSE,# & CYC2_MOUSE,CYC_KATPE,CYC_COLLI,CYC_CHESE,CYC_ESCGI,# & CYC_APTPA,CYC_ANAPL,CYC_MOUSE,CYC_CROAT,CYC_RANCA,# & CYC_MINSC,CYC_ASTRU,CYC2_DROME,CYC_CANFA,CYC_CHESE,# & CYC_ASTRU,CYC_DRONO,CYC_RABIT,CYC_NEUCR,CYC_BOEPE,# & CYC_CHICK,CYC_EISFO,CYC_MACMU,CYC_HELAS,CYC_HIPAM,# & CYC_ESCGI,CYC_APIME,CYC_ANAPL,CYC_ATESP,CYC_LUCCU,# & CYC_CROAT,CYC_VARVA,CYC_ATESP,CYC_EQUAS,CYC_HORSE,# & CYC2_RAT,CYC_HUMAN,CYC_BOVIN,CYC_CANFA,CYC_STRCA,# & CYC2_MOUSE,CYC_APIME,CYC_STELP,CYC_CHICK,CYC_ARATH,# & CYC_MACGI,CYC_EISFO,CYC_DRONO,CYC_HAEIR,CYC2_RAT,# & CYC_HORSE,CYC_ARATH)# & PIR1: (CCUS,CCHO,CCKGG,CCMKP,CCWHC,CCBO,CCMQR,CCWB,CCDK,CCSLE,# & CCHP,CCCZ,CCRB,CCHOD,CCSF,CCBN,CCGW,CCFFDM,CCBTS,CCRSW,# & CCSH,CCMT,CCEU,CCNC,CCMS,CCHA,CCFFCM,CCPY,CCHB,CCTK,# & CCCM,CCHOZ,CCWOT,CCRS,CCRTT,CCPN,CCPG,CCRT,CCFHHF,# & CCHFGB,CCCH,CCOS,CCMST,CCDG,CCHU)# & PIR2: (C04604,B25506)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,EYLENPKKYIPGTKM*# SEQUENCE: EYLENPKKYIPGTKM*# ...# >MUS20EF1# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Beef Cyt. c 66-80# DB REFERENCE: SWISS: (CYC_BOEPE,CYC_COLLI,CYC2_DROME,CYC_NEUCR,CYC_HORSE,# & CYC_MACGI,CYC_BOVIN,CYC_EISFO,CYC_DRONO,CYC_HIPAM,# & CYC2_RAT,CYC_HUMAN,CYC2_MOUSE,CYC_EQUAS,CYC_LUCCU,# & CYC_VARVA,CYC_HELAS,CYC_APIME,CYC_ANAPL,CYC_ATESP,# & CYC_HORSE,CYC_ASTRU,CYC_ESCGI,CYC_DRONO,CYC_CHESE,# & CYC_RABIT,CYC2_DROME,CYC_NEUCR,CYC_ANAPL,CYC_CHESE,# & CYC_COLLI,CYC_MANSE,CYC_CROAT,CYC_ASTRU,CYC_RANCA,# & CYC_MINSC,CYC_ESCGI,CYC_SAMCY,CYC_EQUAS,CYC_MIRLE,# & CYC_MOUSE,CYC_KATPE,CYC2_MOUSE,CYC_USTSP,CYC_APTPA,# & CYC_APTPA,CYC_BOEPE,CYC_MACMU,CYC_CROAT,CYC_CHICK,# & CYC_CANFA,CYC_EISFO,CYC2_RAT,CYC_ARATH,CYC_STELP,# & CYC_HAEIR,CYC_CHICK,CYC_ARATH,CYC_ATESP,CYC_STRCA,# & CYC_CANFA,CYC_APIME)# & PIR1: (CCBO,CCMS,CCPN,CCHFGB,CCUS,CCHO,CCKGG,CCDG,CCHU,CCFFCM,# & CCPG,CCRT,CCFHHF,CCRTT,CCRS,CCHOZ,CCMST,CCOS,CCCZ,CCRB,# & CCHOD,CCHP,CCRSW,CCMT,CCEU,CCSH,CCSF,CCFFDM,CCBTS,CCNC,# & CCHB,CCPY,CCTK,CCCM,CCWOT,CCBN,CCGW,CCMKP,CCDK,CCSLE,# & CCMQR,CCHA,CCWHC,CCWB,CCCH)# & PIR2: (C04604,B25506)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,EYLENPKKYIPGTKM*# SEQUENCE: EYLENPKKYIPGTKM*# ...# >MUS20EF2# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu. Hemag. A/PR/8 79-91# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,IVETPNSENGICY*# SEQUENCE: IVETPNSENGICY*# ...# >MUS20EF3# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu. Hemag. A/PR/8 79-91# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,IVETPNSENGICY*# SEQUENCE: IVETPNSENGICY*# ...# >MUS20EF4# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu. Hemag. A/PR8/34 111-119# DB REFERENCE: SWISS: (HEMA_IAKIE,HEMA_IAXIA,HEMA_IACAO,HEMA_IAPUE,HEMA_IALEN,# & HEMA_IAZNJ,HEMA_IAZIN,HEMA_IAUSS,HEMA_IATAI,# & HEMA_IAHAR)# & PIR1: (HMIVUR,HMIV17,HMIVN1,HMIV,HMIVTA)# & PIR2: (JQ2371,PQ0319,JQ1643,JQ1437,JQ2370,PQ0321,JQ2372,# & A35788)# & PIR3: (S69889,S69886,S69888)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,FERFEIFPK*# SEQUENCE: FERFEIFPK*# ...# >MUS20EF5# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu Hemag A/PR/8/34 126-138# ANCHOR POSITIONS:# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,HNTNGVTAACSHE*# SEQUENCE: HNTNGVTAACSHE*# ...# >MUS20EF6# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu Hemag A/PR8/34 302-313# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,CPKYVRSAKLRM*# SEQUENCE: CPKYVRSAKLRM*# ...# >MUS20EF7# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu. Hemag. A/Aichi 54-62# DB REFERENCE: SWISS: (HEMA_IAZCO,HEMA_IAX31,HEMA_IAVI7,HEMA_IANT6,HEMA_IAEN6,# & HEMA_IAQU7,HEMA_IAUDO,HEMA_IAME1,HEMA_IAAIC,# & HEMA_IAME2)# & PIR1: (HMIVV,HMIVHM,HMIVH,HMIVH3,HMIVHA)# & PIR2: (A93233)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,NPHRILDGI*# SEQUENCE: NPHRILDGI*# ...# >MUS20EF8# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu. Hemag. A/Aichi 54-62# DB REFERENCE: SWISS: (HEMA_IAME2,HEMA_IAZCO,HEMA_IANT6,HEMA_IAVI7,HEMA_IAUDO,# & HEMA_IAAIC,HEMA_IAQU7,HEMA_IAEN6,HEMA_IAX31,# & HEMA_IAME1)# & PIR1: (HMIVHM,HMIVHA,HMIVV,HMIVH,HMIVH3)# & PIR2: (A93233)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,NPHRILDGI*# SEQUENCE: NPHRILDGI*# ...# >MUS20EF9# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu. Hemag. A/Aichi 118-138# DB REFERENCE: SWISS: (HEMA_IANT6,HEMA_IAEN6,HEMA_IAX31,HEMA_IADM2,HEMA_IAZH2,# & HEMA_IAME1,HEMA_IADH7,HEMA_IADH6,HEMA_IADH1,HEMA_IADH3,# & HEMA_IADHL,HEMA_IADHM,HEMA_IADH4,HEMA_IAAIC,HEMA_IADA3,# & HEMA_IAGHK)# & PIR1: (HMIVH,HMIVHA,HMIV77,HMIV89,HMIV15,HMIV98,HMIVS3,# & HMIV33)# & PIR2: (JQ1154,A93233,JQ1156,JQ1155)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,LEFITEGFTWTGVTQNGGSNA*# SEQUENCE: LEFITEGFTWTGVTQNGGSNA*# ...# >MUS20EFA# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu. Hemag. A/Aichi 118-138# DB REFERENCE: SWISS: (HEMA_IADH1,HEMA_IADM2,HEMA_IAX31,HEMA_IADA3,HEMA_IADH4,# & HEMA_IAEN6,HEMA_IAAIC,HEMA_IADHL,HEMA_IADH3,HEMA_IADH7,# & HEMA_IADHM,HEMA_IANT6,HEMA_IAZH2,HEMA_IAME1,HEMA_IADH6,# & HEMA_IAGHK)# & PIR1: (HMIV98,HMIV77,HMIVH,HMIVHA,HMIV15,HMIV33,HMIVS3,# & HMIV89)# & PIR2: (A93233,JQ1154,JQ1156,JQ1155)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,LEFITEGFTWTGVTQNGGSNA*# SEQUENCE: LEFITEGFTWTGVTQNGGSNA*# ...# >MUS20EFB# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pork insulin 5-16# DB REFERENCE: SWISS: (INS_CAPHI,INS_TORMA,INS_PIG,INS_ELEMA,INS_CAMDR,# & INS_MACFA,INS_PETMA,INS_RODSP,INS2_XENLA,INS_RABIT,# & INS_ANSAN,INS2_MOUSE,INS_BOVIN,INS_SELRF,INS2_RAT,# & INS_SHEEP,INS_DIDMA,INS_KATPE,INS_PIG,INS2_MOUSE,# & INS_ACOCA,INS_PSAOB,INS_SELRF,INS_CHICK,INS_LEPSP,# & INS_FELCA,INS_PANTR,INS_BALBO,INS_ANGRO,INS_HORSE,# & INS_CRILO,INS_HUMAN,INS_CERAE,INS_BALPH,INS1_XENLA,# & INS_CANFA,INS_ANAPL,INS_SQUAC,INS_PSESC,INS_ACOCA,# & INS_HUMAN,INS_HYSCR)# & PIR1: (INOS,IPDG,IPCH,INWHP,IPHU,INCMA,A61129,INHY,IPRT2,INRB,# & INCT,INGS,INGXA,INLMS,INPQ,INWH1S,INGT,INEL,INWHF,INTK,# & IPXL1,INDF,A61125,INSH,IPXL2,IPBO,IPRYM,IPHO,IPPG,# & INMS2)# & PIR2: (S09278,A53438,S63591,JQ0362,JQ0178,A42179,I48166,B42179,# & A60414)# & PIR3: (I51221,JQ0363,S44470)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,HLCGSHLVEALY*# SEQUENCE: HLCGSHLVEALY*# ...# >MUS20EFC# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pork insulin 66-78# DB REFERENCE: SWISS: (INS_CANFA,INS_BALPH,INS_RABIT,INS_HUMAN,INS_CERAE,# & INS_HUMAN,INS_PANTR,INS_PIG,INS_MACFA,INS_PIG)# & PIR1: (INRB,INWHF,IPHU,INWHP,IPDG,IPPG)# & PIR2: (B42179,A53438,JQ0178,A42179)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,EQCCTSICSLY*# SEQUENCE: EQCCTSICSLY*# ...# >MUS20EFD# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pork insulin 66-78# DB REFERENCE: SWISS: (INS_HUMAN,INS_CERAE,INS_PIG,INS_PANTR,INS_PIG,INS_MACFA,# & INS_HUMAN,INS_CANFA,INS_BALPH,INS_RABIT)# & PIR1: (INRB,IPPG,IPDG,INWHP,IPHU,INWHF)# & PIR2: (A42179,B42179,A53438,JQ0178)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,EQCCTSICSLY*# SEQUENCE: EQCCTSICSLY*# ...# >MUS20EFE# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 52-61# DB REFERENCE: SWISS: (LYC_CHICK,LYC_ORTVE,LYC_SYRRE,LYC_PAVCR,LYC_MELGA,# & LYC_CHICK,LYC_PHAVE,LYC_CHRAM,LYC_LOPLE,LYC1_ANAPL,# & LYC_PHACO,LYC1_TACAC)# & PIR1: (LZQJE,LZTK,LZOVE,LZDK,LZFER,LZCH)# & PIR2: (JH0212,JH0211,A45660,JU0237,JQ1041,JC2144,JU0178,A61281,# & JT0526,JQ1033)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,DYGILQINSR*# SEQUENCE: DYGILQINSR*# ...# >MUS20EFF# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 74-86# DB REFERENCE: SWISS: (LYC_MELGA,LYC_CHICK,LYC_LOPCA,LYC_COLVI,LYC_PAVCR,# & LYC_CHICK)# & PIR1: (LZQJE,LZQJEC,LZCH,LZTK)# & PIR2: (JT0526,JU0237,JC2144)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,NLCNIPCSALLSS*# SEQUENCE: NLCNIPCSALLSS*# ...# >MUS20F00# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 81-96# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_SYRRE,LYC_PAVCR,LYC_PHACO,# & LYC_CHRAM,LYC_LOPLE,LYC_MELGA,LYC_PHAVE)# & PIR1: (LZFER,LZQJE,LZTK,LZCH)# & PIR2: (JQ1041,JH0212,JT0526,JU0178,JQ1033,JH0211,JU0237)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >MUS20F01# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 81-96# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_CHRAM,LYC_PAVCR,LYC_PHAVE,LYC_CHICK,# & LYC_MELGA,LYC_LOPLE,LYC_CHICK,LYC_PHACO)# & PIR1: (LZFER,LZTK,LZCH,LZQJE)# & PIR2: (JQ1041,JU0237,JH0211,JH0212,JU0178,JQ1033,JT0526)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >MUS20F02# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 107-116# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPLE,LYC_COTJA,LYC_MELGA,LYC_CHRAM,# & LYC_SYRRE,LYC_PAVCR,LYC3_ANAPL,LYC_LOPCA,LYC_CHICK,# & LYC_COLVI)# & PIR1: (LZTK,LZCH,LZDK3,LZQJEC,LZQJE)# & PIR2: (JT0526,JU0237,JQ1041,JQ1033)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,AWVAWRNRCK*# SEQUENCE: AWVAWRNRCK*# ...# >MUS20F03# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 107-116# DB REFERENCE: SWISS: (LYC_MELGA,LYC_COTJA,LYC_SYRRE,LYC_PAVCR,LYC3_ANAPL,# & LYC_CHICK,LYC_COLVI,LYC_CHRAM,LYC_CHICK,LYC_LOPLE,# & LYC_LOPCA)# & PIR1: (LZQJEC,LZCH,LZTK,LZDK3,LZQJE)# & PIR2: (JQ1033,JT0526,JU0237,JQ1041)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,AWVAWRNRCK*# SEQUENCE: AWVAWRNRCK*# ...# >MUS20F04# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 1-18# DB REFERENCE: SWISS: (LYC_NUMME,LYC_LOPCA,LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZUH,LZCH,LZQJEC)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KVFGRCELAAAMKRHGLD*# SEQUENCE: KVFGRCELAAAMKRHGLD*# ...# >MUS20F05# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 34-45# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH,LZQJE)# & PIR2: (JU0237,A61281)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,FESNFNTQATNR*# SEQUENCE: FESNFNTQATNR*# ...# >MUS20F06# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 112-129# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,RNRCKGTDVQAWIRGCRL*# SEQUENCE: RNRCKGTDVQAWIRGCRL*# ...# >MUS20F07# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen egg Lysozyme 112-129# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,RNRCKGTDVQAWIRGCRL*# SEQUENCE: RNRCKGTDVQAWIRGCRL*# ...# >MUS20F08# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mouse H-2 Class 1 59-71# DB REFERENCE: SWISS: (HA1B_MOUSE,HA1B_MOUSE)# & PIR1: (HLMSKB)# & PIR2: (I54531,I68771,A32273,I54554)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,YWERETQKAKGNE*# SEQUENCE: YWERETQKAKGNE*# ...# >MUS20F09# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mouse H-2 Class 1 59-71# DB REFERENCE: SWISS: (HA1B_MOUSE,HA1B_MOUSE)# & PIR1: (HLMSKB)# & PIR2: (I68771,I54554,A32273,I54531)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,YWERETQKAKGNE*# SEQUENCE: YWERETQKAKGNE*# ...# >MUS20F0A# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bovine Ribonuclease 43-56# DB REFERENCE: SWISS: (RNP_DAMDA,RNP_ORYLE,RNP_BOVIN,RNP_AEPME,RNP_PIG,# & RNP_SHEEP,RNP_CAPCA,RNP_AEPME,RNP_SHEEP,RNP_GAZTH,# & RNP_ALCAA,RNP_CEREL,RNP_ANTAM,RNP_BUBAR,RNP_GAZTH,# & RNP_ANTAM,RNP_DAMDA,RNP_RANTA,RNP_CEREL,RNP_ALCAA,# & RNP_BOVIN,RNP_GIRCA,RNP_GIRCA,RNP_PIG,RNPB_CAVPO,# & RNP_BUBAR,RNP_RANTA,RNP_CAPCA)# & PIR1: (NREKN,NRSH,NRGPB,NRWB,NRDEO,NRBO,NRGF,NRDEF,NRDEN,NRBOB,# & NRDER,NRPG)# & PIR2: (S08546,I45998,S08549,S07141)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,VNTFVHESLADVQA*# SEQUENCE: VNTFVHESLADVQA*# ...# >MUS20F0B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bovine Ribonuclease 43-56# DB REFERENCE: SWISS: (RNP_AEPME,RNP_GIRCA,RNP_CAPCA,RNP_SHEEP,RNP_SHEEP,# & RNP_DAMDA,RNP_PIG,RNP_GAZTH,RNP_CEREL,RNP_ALCAA,# & RNP_BUBAR,RNP_RANTA,RNPB_CAVPO,RNP_GIRCA,RNP_BOVIN,# & RNP_ANTAM,RNP_ALCAA,RNP_ORYLE,RNP_CEREL,RNP_CAPCA,# & RNP_BOVIN,RNP_DAMDA,RNP_AEPME,RNP_PIG,RNP_RANTA,# & RNP_GAZTH,RNP_BUBAR,RNP_ANTAM)# & PIR1: (NRSH,NRBO,NRGF,NRPG,NRDEF,NRDEO,NRWB,NRDEN,NRDER,NRGPB,# & NRBOB,NREKN)# & PIR2: (S08549,S08546,I45998,S07141)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,VNTFVHESLADVQA*# SEQUENCE: VNTFVHESLADVQA*# ...# >MUS20F0C# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP 328-334# DB REFERENCE: SWISS: (CSP_PLAFT,LTE1_YEAST,LTE1_YEAST,CSP_PLAFW,CSP_PLAFA)# & PIR1: (BVBYL1,OZZQAF)# & PIR2: (A54533,A38869,A54529,D60657,C60657,B60657,A29795)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,DKHIEQY*# SEQUENCE: DKHIEQY*# ...# >MUS20F0D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP 328-334# DB REFERENCE: SWISS: (CSP_PLAFA,LTE1_YEAST,CSP_PLAFW,LTE1_YEAST,CSP_PLAFT)# & PIR1: (OZZQAF,BVBYL1)# & PIR2: (B60657,D60657,A54529,A54533,C60657,A29795,A38869)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,DKHIEQY*# SEQUENCE: DKHIEQY*# ...# >MUS20F0E# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP 386-400# DB REFERENCE: SWISS: (CSP_PLAFO,CSP_PLAFW,CSP_PLARE,CSP_PLAFA,CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (S05428,A39756,A54529,A54533)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,MEKCSSVFNVVNSSI*# SEQUENCE: MEKCSSVFNVVNSSI*# ...# >MUS20F0F# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP 386-400# DB REFERENCE: SWISS: (CSP_PLARE,CSP_PLAFA,CSP_PLAFT,CSP_PLAFW,CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (A54529,A39756,A54533,S05428)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,MEKCSSVFNVVNSSI*# SEQUENCE: MEKCSSVFNVVNSSI*# ...# >MUS20F10# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP 386-400# DB REFERENCE: SWISS: (CSP_PLARE,CSP_PLAFA,CSP_PLAFW,CSP_PLAFT,CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (S05428,A54529,A39756,A54533)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,MEKCSSVFNVVNSSI*# SEQUENCE: MEKCSSVFNVVNSSI*# ...# >MUS20F11# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Plas. falc CSP 330-343# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,HIEQYLKKIKNSIS*# SEQUENCE: HIEQYLKKIKNSIS*# ...# >MUS20F12# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Plas. falc CSP 330-343# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (C60657)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,HIEQYLKKIKNSIS*# SEQUENCE: HIEQYLKKIKNSIS*# ...# >MUS20F13# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP 361-380# DB REFERENCE: SWISS: (CSP_PLAFT,CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (A54533,C60657)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,IKPGSANKPKDELDYENDIE*# SEQUENCE: IKPGSANKPKDELDYENDIE*# ...# >MUS20F14# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre S2 120-132# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVO,VMSA_HPBVJ,VMSA_HPBVA,# & VMSA_HPBVI)# & PIR1: (SAVLBH,SAVLJ1,SAVLJ2,SAVLAH,SAVLJ3,SAVLA1)# & PIR2: (S47407,S41871,S41870,S41869,S20753,S32202,S20745)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,MQWNSTTFHQTLQ*# SEQUENCE: MQWNSTTFHQTLQ*# ...# >MUS20F15# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre S2 120-132# DB REFERENCE: SWISS: (VMSA_HPBVI,VMSA_HPBVJ,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVA,# & VMSA_HPBVO)# & PIR1: (SAVLBH,SAVLJ1,SAVLJ2,SAVLA1,SAVLAH,SAVLJ3)# & PIR2: (S32202,S47407,S41869,S20753,S41870,S20745,S41871)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,MQWNSTTFHQTLQ*# SEQUENCE: MQWNSTTFHQTLQ*# ...# >MUS20F16# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre Sl 12-21# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVJ,VMSA_HPBVP,VMSA_HPBVR,# & VMSA_HPBV9,VMSA_HPBVO,VMSA_HPBV2,VMSA_HPBVI,VMSA_HPBVW,# & VMSA_HPBVR,VMSA_HPBV4)# & PIR1: (SAVLJ3,SAVLKS,SAVLA,SAVLJ2,SAVLVE,SAVLJ1,SAVLVD)# & PIR2: (S43492,S35528,S47411,S36654)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,MGTNLSVPNP*# SEQUENCE: MGTNLSVPNP*# ...# >MUS20F17# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre Sl 12-21# DB REFERENCE: SWISS: (VMSA_HPBV4,VMSA_HPBVR,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBVW,# & VMSA_HPBV9,VMSA_HPBVI,VMSA_HPBVO,VMSA_HPBV2,VMSA_HPBV2,# & VMSA_HPBVW,VMSA_HPBVJ)# & PIR1: (SAVLA,SAVLKS,SAVLJ2,SAVLJ3,SAVLVD,SAVLJ1,SAVLVE)# & PIR2: (S36654,S47411,S35528,S43492)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,MGTNLSVPNP*# SEQUENCE: MGTNLSVPNP*# ...# >MUS20F18# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre Sl 57-67# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBV2)# & PIR1: (SAVLVD)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,QVGVGAFGPRL*# SEQUENCE: QVGVGAFGPRL*# ...# >MUS20F19# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre Sl 57-67# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBV2)# & PIR1: (SAVLVD)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,QVGVGAFGPRL*# SEQUENCE: QVGVGAFGPRL*# ...# >MUS20F1A# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre Sl 94-117# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBV4,VMSA_HPBVW,# & VMSA_HPBVP,VMSA_HPBVW,VMSA_HPBV2)# & PIR1: (SAVLVD,SAVLA,SAVLVE)# & PIR2: (S35528,S36654,S43492)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,PASTNRQSGRQPTPISPPLRDSHP*# SEQUENCE: PASTNRQSGRQPTPISPPLRDSHP*# ...# >MUS20F1B# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre Sl 94-117# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVP,VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVR,# & VMSA_HPBVW,VMSA_HPBV4,VMSA_HPBV2)# & PIR1: (SAVLA,SAVLVD,SAVLVE)# & PIR2: (S36654,S43492,S35528)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,PASTNRQSGRQPTPISPPLRDSHP*# SEQUENCE: PASTNRQSGRQPTPISPPLRDSHP*# ...# >MUS20F1C# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBsAg pre Sl 94-117# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBV4,VMSA_HPBV2,VMSA_HPBVR,VMSA_HPBVP,# & VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBVW)# & PIR1: (SAVLVE,SAVLA,SAVLVD)# & PIR2: (S36654,S43492,S35528)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,PASTNRQSGRQPTPISPPLRDSHP*# SEQUENCE: PASTNRQSGRQPTPISPPLRDSHP*# ...# >MUS20F1D# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBcAg 129-140# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVT,CORA_HPBV4,CORA_HPBV2,CORA_HPBVZ,# & CORA_HPBVA,CORA_HPBVW,CORA_HPBVF,CORA_HPBVJ,CORA_HPBV9,# & CORA_HPBVO,CORA_HPBVL)# & PIR1: (NKVLJ1,NKVLAH,NKVLA1,NKVLCP,NKVLBH,NKVLA3,NKVLA4,NKVLH3,# & NKVLJ2,NKVLA6,NKVLA2,NKVLKS)# & PIR2: (S53221,S53232,S04570,S20750,S53216,S53186,S47405,S47409,# & S53236,S53202,S53242,S53257,S53129,S53198,S53281,S20755,# & S53229,S53163,S53146,S53194,S53169,S53253,S53274,S53272,# & S53270,S53159,S53166,S53240,S53223,S01405,S53260,S53238,# & S53279,S53140,S33686,S25651,S32204,S53207,JQ2227,S53251,# & S20746,S53225,S53172,S53175,S53204,S53247,S53152,S53161,# & S53211,S53189,S53214,S53181,S35530,S53227,S53255)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,PPAYRPPNAPIL*# SEQUENCE: PPAYRPPNAPIL*# ...# >MUS20F1E# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBcAg 120-131# DB REFERENCE: SWISS: (CORA_HPBVF,CORA_HPBV9,CORA_HPBVW,CORA_HPBV4,CORA_HPBV2,# & CORA_HPBVZ,CORA_HPBVA,CORA_HPBVY,CORA_HPBVT,CORA_HPBVO,# & CORA_HPBVL,CORA_HPBVJ)# & PIR1: (NKVLKS,NKVLJ1,NKVLA1,NKVLA2,NKVLA4,NKVLH3,NKVLBH,NKVLAH,# & NKVLA3,NKVLCP,NKVLA6,NKVLJ2)# & PIR2: (S53189,S53281,S53152,S53247,S53204,S53166,S53159,S53227,# & S53255,S53221,S53232,S04570,S47405,S53216,S53236,S53242,# & S53169,S53253,S53274,S53149,S20755,S53146,S53207,S53175,# & S53225,S53129,S53200,S53137,S53279,S53140,S53172,JQ2227,# & S53251,S33686,S53229,S53163,S53198,S53211,S53223,S53260,# & S53238,S53270,S53240,S47409,S53202,S53161,S53214,S53181,# & S35530,S25651,S32204,S20746,S53272,S53267,S01405,S53257,# & S53186)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,VSFGVWIRTPPA*# SEQUENCE: VSFGVWIRTPPA*# ...# >MUS20F1F# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBcAg 120-140# DB REFERENCE: SWISS: (CORA_HPBVF,CORA_HPBVJ,CORA_HPBVO,CORA_HPBVL,CORA_HPBVY,# & CORA_HPBVT,CORA_HPBVZ,CORA_HPBV2,CORA_HPBV4,CORA_HPBVW,# & CORA_HPBV9,CORA_HPBVA)# & PIR1: (NKVLA4,NKVLJ2,NKVLBH,NKVLAH,NKVLCP,NKVLJ1,NKVLA1,NKVLA3,# & NKVLA6,NKVLH3,NKVLA2,NKVLKS)# & PIR2: (S35530,S53198,S53279,S53216,S53253,S53214,S53161,S53181,# & S32204,S53207,S53175,S53225,S53129,S53247,S53166,S53152,# & S53211,S53270,S53238,JQ2227,S53169,S53274,S53146,S04570,# & S53255,S20755,S53236,S53242,S53223,S33686,S53240,S47405,# & S53227,S53232,S53221,S53163,S53229,S53172,S53251,S47409,# & S53202,S53272,S25651,S20746,S53186,S53257,S53281,S53189,# & S53140,S01405,S53260,S53159,S53204)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,VSFGVWIRTPPAYRPPNAPIL*# SEQUENCE: VSFGVWIRTPPAYRPPNAPIL*# ...# >MUS20F20# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV/HBcAg 85-100# DB REFERENCE: SWISS: (CORA_HPBVA,CORA_HPBVY)# & PIR1: (NKVLAH,NKVLBH,NKVLA1)# & PIR2: (S53281,S53129,S53242,S53140,S20750,S53267,S53253,S53181,# & S53214,S53194,S53274,S53146,S53255,S53270,S53157,S53238,# & S53186,S53286,S53189,S53152,S53247,S53272,S53143,S53251,# & S53227,S47405,S20746,S53163,S53229,S53149,S53211,S53175,# & S53223,S53200,S53232,S22318,S53137,S53216,S32204,S20755,# & S53207,S53169,S53161,S53198)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,VVSYVNTNMGLKFRQL*# SEQUENCE: VVSYVNTNMGLKFRQL*# ...# >MUS20F21# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSV/gD 1-16# DB REFERENCE: SWISS: (VLGD_HSV1A,VGLD_HSV1H,VGLD_HSV11)# & PIR1: (VGBEDZ,A47627,VGBED1)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KYALADASLKMADPNR*# SEQUENCE: KYALADASLKMADPNR*# ...# >MUS20F22# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSV/gD 1-16# DB REFERENCE: SWISS: (VGLD_HSV11,VLGD_HSV1A,VGLD_HSV1H)# & PIR1: (VGBED1,VGBEDZ,A47627)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,KYALADASLKMADPNR*# SEQUENCE: KYALADASLKMADPNR*# ...# >MUS20F23# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSV/gD 8-23# DB REFERENCE: SWISS: (VLGD_HSV1A,VGLD_HSV1H,VGLD_HSV11)# & PIR1: (VGBE17,A47627,VGBED1,VGBEDZ)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,SLKMADPNRFRGKDLP*# SEQUENCE: SLKMADPNRFRGKDLP*# ...# >MUS20F24# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Porcine lactate dehyd. 211-223# DB REFERENCE: PIR1: (DEPGLH)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,QLNPEMGTDNDSE*# SEQUENCE: QLNPEMGTDNDSE*# ...# >MUS20F25# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Porcine lactate dehyd. 211-223# DB REFERENCE: PIR1: (DEPGLH)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,QLNPEMGTDNDSE*# SEQUENCE: QLNPEMGTDNDSE*# ...# >MUS20F26# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 91-110# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,YIYADGKMVNEALVRQGLAK*# SEQUENCE: YIYADGKMVNEALVRQGLAK*# ...# >MUS20F27# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 91-110# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,YIYADGKMVNEALVRQGLAK*# SEQUENCE: YIYADGKMVNEALVRQGLAK*# ...# >MUS20F28# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 81-100# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >MUS20F29# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 81-100# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >MUS20F2A# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 81-100# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a,schild95a# COMMENT:# SUMMARY: I-Eb,actyesu,bindyesu,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >MUS20F2B# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 51-70# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,VEKYGPEASAFTKKMVENAK*# SEQUENCE: VEKYGPEASAFTKKMVENAK*# ...# >MUS20F2C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 51-70# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,VEKYGPEASAFTKKMVENAK*# SEQUENCE: VEKYGPEASAFTKKMVENAK*# ...# >MUS20F2D# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 61-80# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,FTKKMVENAKKIEVEFDKGQ*# SEQUENCE: FTKKMVENAKKIEVEFDKGQ*# ...# >MUS20F2E# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 21-40# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,DTVKLMYKGQPMTFRLLLVD*# SEQUENCE: DTVKLMYKGQPMTFRLLLVD*# ...# >MUS20F2F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 21-40# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,DTVKLMYKGQPMTFRLLLVD*# SEQUENCE: DTVKLMYKGQPMTFRLLLVD*# ...# >MUS20F30# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 112-130# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,AYVYKPNNTHEQHLRKSEA*# SEQUENCE: AYVYKPNNTHEQHLRKSEA*# ...# >MUS20F31# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 121-140# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,HEQHLRKSEAQAKKEKLNIW*# SEQUENCE: HEQHLRKSEAQAKKEKLNIW*# ...# >MUS20F32# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staph. nuclease 121-140# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a,schild95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,HEQHLRKSEAQAKKEKLNIW*# SEQUENCE: HEQHLRKSEAQAKKEKLNIW*# ...# >MUS20F33# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bee Venom/apamin 1-18# DB REFERENCE: SWISS: (APAM_APIME)# & PIR1: (AMHB)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,CNCKAPETALCARRCQQH*# SEQUENCE: CNCKAPETALCARRCQQH*# ...# >MUS20F34# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bee Venom/apamin 1-18# DB REFERENCE: SWISS: (APAM_APIME)# & PIR1: (AMHB)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,CNCKAPETALCARRCQQH*# SEQUENCE: CNCKAPETALCARRCQQH*# ...# >MUS20F35# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bee Venom/apamin 1-18# DB REFERENCE: SWISS: (APAM_APIME)# & PIR1: (AMHB)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,CNCKAPETALCARRCQQH*# SEQUENCE: CNCKAPETALCARRCQQH*# ...# >MUS20F36# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bee Venom/apamin 1-18# DB REFERENCE: SWISS: (APAM_APIME)# & PIR1: (AMHB)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,CNCKAPETALCARRCQQH*# SEQUENCE: CNCKAPETALCARRCQQH*# ...# >MUS20F37# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lambda Repressor 12-26# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: altuvia94a,smilek90a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >MUS20F38# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lambda Repressor 12-26# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >MUS20F39# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIVI/IIIB gpl20 421-436# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1MN,ENV_HV1Y2,ENV_HV1B8,ENV_HV1B1,# & ENV_HV1S3,ENV_HV1J3,ENV_HV1JR,ENV_HV1BN)# & PIR1: (VCLJH3,VCLJBR,H44001,VCLJMN,VCLJA2)# & PIR2: (C41621,S25940,S60538,A40218)# & PIR3: (S33985)# REFERENCES: altuvia94a,hivdb97a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS20F3A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIVI/IIIB gpl20 421-436# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1BN,ENV_HV1B1,ENV_HV1JR,ENV_HV1MN,# & ENV_HV1A2,ENV_HV1S3,ENV_HV1B8,ENV_HV1J3)# & PIR1: (VCLJH3,H44001,VCLJMN,VCLJA2,VCLJBR)# & PIR2: (C41621,S25940,S60538,A40218)# & PIR3: (S33985)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS20F3B# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIVI/IIIB gpl20 308-322# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1B8,ENV_HV1B1,ENV_HV1PV,ENV_HV1MF,# & ENV_HV1H3,ENV_HV1H2)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >MUS20F3C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HIVI/IIIB gpl20 308-322# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B8,ENV_HV1H2,ENV_HV1B1,ENV_HV1PV,# & ENV_HV1H3,ENV_HV1BR)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: altuvia94a,takeshita95a# COMMENT:# SUMMARY: I-Ad,actyesh,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >MUS20F3D# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIVI/IIIB gpl20 105.117# DB REFERENCE: SWISS: (ENV_HV1SC,ENV_HV1PV,ENV_HV1RH,ENV_HV1W2,ENV_HV1MN,# & ENV_HV1BR,ENV_HV1N5,ENV_HV1W1,ENV_HV1J3,ENV_HV1ND,# & ENV_HV1MA,ENV_HV1Y2,ENV_HV1Z2,ENV_HV1MF,ENV_HV1H2,# & ENV_HV1B8,ENV_HV1H3,ENV_HV1Z6,ENV_HV1C4,ENV_HV1B1,# & ENV_HV1Z3,ENV_HV1EL,ENV_HV1BN,ENV_HV1S1,ENV_SIVCZ)# & PIR1: (H44001,VCLJSI,VCLJLV,VCLJH3,VCLJH4,VCLJBR,VCLJND,VCLJZR,# & VCLJ3W,VCLJSC,VCLJVL,VCLJMN)# & PIR2: (S25938,S54384,S25939,S31493)# & PIR3: (S33985,S13288)# REFERENCES: altuvia94a,hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >MUS20F3E# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen ovalbumin 323-339# DB REFERENCE: SWISS: (OVAL_COTJA,OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,ISQAVHAAHAEINEAGR*# SEQUENCE: ISQAVHAAHAEINEAGR*# ...# >MUS20F3F# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP pig 11 48# DB REFERENCE: SWISS: (FLGL_SALTY,ITA2_BOVIN,RPSW_STRCO,NTCB_SYNY3,N358_HUMAN,# & RANG_MOUSE,NOLO_RHISN,MBP_CAVPO,ITA2_BOVIN,NTCB_SYNP7,# & N358_HUMAN,FLGL_ECOLI,FLGL_ECOLI,PCCA_RAT,YN9B_YEAST,# & RANG_HUMAN,RANG_MOUSE)# & PIR1: (CGHU2A)# & PIR2: (S58984,A37246,S10362,S54056,S40475,S63462,S54290,S44022,# & A34337,S76393,JQ1973,S57968,S58884,S21369,A33332,S29615,# & A48725,A57545,S09646,I45914,S54286)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,GSDRA*# SEQUENCE: GSDRA*# ...# >MUS20F40# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP pig 11 48# DB REFERENCE: SWISS: (RANG_MOUSE,FLGL_ECOLI,RANG_HUMAN,ITA2_BOVIN,NTCB_SYNP7,# & N358_HUMAN,FLGL_ECOLI,N358_HUMAN,NTCB_SYNY3,FLGL_SALTY,# & RPSW_STRCO,MBP_CAVPO,NOLO_RHISN,ITA2_BOVIN,RANG_MOUSE,# & PCCA_RAT,YN9B_YEAST)# & PIR1: (CGHU2A)# & PIR2: (S09646,A57545,A33332,S29615,S10362,S58984,S21369,S44022,# & S54290,A34337,S58884,S54286,I45914,S54056,S63462,A48725,# & S40475,JQ1973,S76393,S57968,A37246)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,GSDRA*# SEQUENCE: GSDRA*# ...# >MUS20F41# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP mouse 87-98# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_RAT,MBP_BOVIN,MBP_CAVPO,MBP_MOUSE,# & MBP_PANTR)# & PIR1: (MBCZB,MBPGB,MBMSB,MBHUB,MBBOB,MBRTS)# & PIR2: (A37246)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,FKNIVTPRTPPP*# SEQUENCE: FKNIVTPRTPPP*# ...# >MUS20F42# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP mouse 87-98# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_BOVIN,MBP_RAT,MBP_HUMAN,MBP_CAVPO,# & MBP_PANTR)# & PIR1: (MBCZB,MBPGB,MBMSB,MBHUB,MBRTS,MBBOB)# & PIR2: (A37246)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,FKNIVTPRTPPP*# SEQUENCE: FKNIVTPRTPPP*# ...# >MUS20F43# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP mouse 91-104# DB REFERENCE: SWISS: (MBP_RAT,MBP_PANTR,MBP_CAVPO,MBP_HUMAN,MBP_BOVIN,# & MBP_MOUSE)# & PIR1: (MBPGB,MBMSB,MBRTS,MBHUB,MBBOB,MBCZB)# & PIR2: (A37246)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,VTPRTPPPSQGKGR*# SEQUENCE: VTPRTPPPSQGKGR*# ...# >MUS20F44# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP mouse 91-104# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_BOVIN,MBP_RAT,MBP_PANTR,# & MBP_MOUSE)# & PIR1: (MBHUB,MBRTS,MBBOB,MBCZB,MBPGB,MBMSB)# & PIR2: (A37246)# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,VTPRTPPPSQGKGR*# SEQUENCE: VTPRTPPPSQGKGR*# ...# >MUS20F45# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ig Lambda-2 chain 91-108# ANCHOR POSITIONS:# REFERENCES: altuvia94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,ALWYSTHFVFGGGTKVTV*# SEQUENCE: ALWYSTHFVFGGGTKVTV*# ...# >MUS20F46# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ig Lambda-2 chain 91-108# ANCHOR POSITIONS:# REFERENCES: altuvia94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,ALWYSTHFVFGGGTKVTV*# SEQUENCE: ALWYSTHFVFGGGTKVTV*# ...# >MUS20F47# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAAHAAHAEINEAGR*# SEQUENCE: ISQAAHAAHAEINEAGR*# ...# >MUS20F48# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVAAAHAEINEAGR*# SEQUENCE: ISQAVAAAHAEINEAGR*# ...# >MUS20F49# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAAAAEINEAGR*# SEQUENCE: ISQAVHAAAAEINEAGR*# ...# >MUS20F4A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQACHAAHAEINEAGR*# SEQUENCE: ISQACHAAHAEINEAGR*# ...# >MUS20F4B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVCAAHAEINEAGR*# SEQUENCE: ISQAVCAAHAEINEAGR*# ...# >MUS20F4C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHCAHAEINEAGR*# SEQUENCE: ISQAVHCAHAEINEAGR*# ...# >MUS20F4D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHACHAEINEAGR*# SEQUENCE: ISQAVHACHAEINEAGR*# ...# >MUS20F4E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAACAEINEAGR*# SEQUENCE: ISQAVHAACAEINEAGR*# ...# >MUS20F4F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHCEINEAGR*# SEQUENCE: ISQAVHAAHCEINEAGR*# ...# >MUS20F50# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVDAAHAEINEAGR*# SEQUENCE: ISQAVDAAHAEINEAGR*# ...# >MUS20F51# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHDAHAEINEAGR*# SEQUENCE: ISQAVHDAHAEINEAGR*# ...# >MUS20F52# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHADHAEINEAGR*# SEQUENCE: ISQAVHADHAEINEAGR*# ...# >MUS20F53# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAADAEINEAGR*# SEQUENCE: ISQAVHAADAEINEAGR*# ...# >MUS20F54# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVEAAHAEINEAGR*# SEQUENCE: ISQAVEAAHAEINEAGR*# ...# >MUS20F55# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHEAHAEINEAGR*# SEQUENCE: ISQAVHEAHAEINEAGR*# ...# >MUS20F56# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAEHAEINEAGR*# SEQUENCE: ISQAVHAEHAEINEAGR*# ...# >MUS20F57# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAEAEINEAGR*# SEQUENCE: ISQAVHAAEAEINEAGR*# ...# >MUS20F58# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHFAHAEINEAGR*# SEQUENCE: ISQAVHFAHAEINEAGR*# ...# >MUS20F59# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAFHAEINEAGR*# SEQUENCE: ISQAVHAFHAEINEAGR*# ...# >MUS20F5A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAFAEINEAGR*# SEQUENCE: ISQAVHAAFAEINEAGR*# ...# >MUS20F5B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVGAAHAEINEAGR*# SEQUENCE: ISQAVGAAHAEINEAGR*# ...# >MUS20F5C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHGAHAEINEAGR*# SEQUENCE: ISQAVHGAHAEINEAGR*# ...# >MUS20F5D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAGHAEINEAGR*# SEQUENCE: ISQAVHAGHAEINEAGR*# ...# >MUS20F5E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHGEINEAGR*# SEQUENCE: ISQAVHAAHGEINEAGR*# ...# >MUS20F5F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHHAHAEINEAGR*# SEQUENCE: ISQAVHHAHAEINEAGR*# ...# >MUS20F60# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAHHAEINEAGR*# SEQUENCE: ISQAVHAHHAEINEAGR*# ...# >MUS20F61# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAIHAAHAEINEAGR*# SEQUENCE: ISQAIHAAHAEINEAGR*# ...# >MUS20F62# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVIAAHAEINEAGR*# SEQUENCE: ISQAVIAAHAEINEAGR*# ...# >MUS20F63# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHIAHAEINEAGR*# SEQUENCE: ISQAVHIAHAEINEAGR*# ...# >MUS20F64# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAIHAEINEAGR*# SEQUENCE: ISQAVHAIHAEINEAGR*# ...# >MUS20F65# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAAIAEINEAGR*# SEQUENCE: ISQAVHAAIAEINEAGR*# ...# >MUS20F66# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHIEINEAGR*# SEQUENCE: ISQAVHAAHIEINEAGR*# ...# >MUS20F67# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVKAAHAEINEAGR*# SEQUENCE: ISQAVKAAHAEINEAGR*# ...# >MUS20F68# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAKHAEINEAGR*# SEQUENCE: ISQAVHAKHAEINEAGR*# ...# >MUS20F69# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAAKAEINEAGR*# SEQUENCE: ISQAVHAAKAEINEAGR*# ...# >MUS20F6A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQALHAAHAEINEAGR*# SEQUENCE: ISQALHAAHAEINEAGR*# ...# >MUS20F6B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVLAAHAEINEAGR*# SEQUENCE: ISQAVLAAHAEINEAGR*# ...# >MUS20F6C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHLAHAEINEAGR*# SEQUENCE: ISQAVHLAHAEINEAGR*# ...# >MUS20F6D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHALHAEINEAGR*# SEQUENCE: ISQAVHALHAEINEAGR*# ...# >MUS20F6E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAALAEINEAGR*# SEQUENCE: ISQAVHAALAEINEAGR*# ...# >MUS20F6F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHLEINEAGR*# SEQUENCE: ISQAVHAAHLEINEAGR*# ...# >MUS20F70# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAMHAAHAEINEAGR*# SEQUENCE: ISQAMHAAHAEINEAGR*# ...# >MUS20F71# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHMAHAEINEAGR*# SEQUENCE: ISQAVHMAHAEINEAGR*# ...# >MUS20F72# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAMHAEINEAGR*# SEQUENCE: ISQAVHAMHAEINEAGR*# ...# >MUS20F73# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAMAEINEAGR*# SEQUENCE: ISQAVHAAMAEINEAGR*# ...# >MUS20F74# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHMEINEAGR*# SEQUENCE: ISQAVHAAHMEINEAGR*# ...# >MUS20F75# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVNAAHAEINEAGR*# SEQUENCE: ISQAVNAAHAEINEAGR*# ...# >MUS20F76# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHNAHAEINEAGR*# SEQUENCE: ISQAVHNAHAEINEAGR*# ...# >MUS20F77# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHANHAEINEAGR*# SEQUENCE: ISQAVHANHAEINEAGR*# ...# >MUS20F78# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAPHAAHAEINEAGR*# SEQUENCE: ISQAPHAAHAEINEAGR*# ...# >MUS20F79# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHPAHAEINEAGR*# SEQUENCE: ISQAVHPAHAEINEAGR*# ...# >MUS20F7A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAPHAEINEAGR*# SEQUENCE: ISQAVHAPHAEINEAGR*# ...# >MUS20F7B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAPAEINEAGR*# SEQUENCE: ISQAVHAAPAEINEAGR*# ...# >MUS20F7C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHPEINEAGR*# SEQUENCE: ISQAVHAAHPEINEAGR*# ...# >MUS20F7D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVQAAHAEINEAGR*# SEQUENCE: ISQAVQAAHAEINEAGR*# ...# >MUS20F7E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHQAHAEINEAGR*# SEQUENCE: ISQAVHQAHAEINEAGR*# ...# >MUS20F7F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAQHAEINEAGR*# SEQUENCE: ISQAVHAQHAEINEAGR*# ...# >MUS20F80# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAAQAEINEAGR*# SEQUENCE: ISQAVHAAQAEINEAGR*# ...# >MUS20F81# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVRAAHAEINEAGR*# SEQUENCE: ISQAVRAAHAEINEAGR*# ...# >MUS20F82# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHRAHAEINEAGR*# SEQUENCE: ISQAVHRAHAEINEAGR*# ...# >MUS20F83# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHARHAEINEAGR*# SEQUENCE: ISQAVHARHAEINEAGR*# ...# >MUS20F84# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAARAEINEAGR*# SEQUENCE: ISQAVHAARAEINEAGR*# ...# >MUS20F85# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQASHAAHAEINEAGR*# SEQUENCE: ISQASHAAHAEINEAGR*# ...# >MUS20F86# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVSAAHAEINEAGR*# SEQUENCE: ISQAVSAAHAEINEAGR*# ...# >MUS20F87# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHSAHAEINEAGR*# SEQUENCE: ISQAVHSAHAEINEAGR*# ...# >MUS20F88# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHASHAEINEAGR*# SEQUENCE: ISQAVHASHAEINEAGR*# ...# >MUS20F89# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAASAEINEAGR*# SEQUENCE: ISQAVHAASAEINEAGR*# ...# >MUS20F8A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAAHSEINEAGR*# SEQUENCE: ISQAVHAAHSEINEAGR*# ...# >MUS20F8B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQATHAAHAEINEAGR*# SEQUENCE: ISQATHAAHAEINEAGR*# ...# >MUS20F8C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVTAAHAEINEAGR*# SEQUENCE: ISQAVTAAHAEINEAGR*# ...# >MUS20F8D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHTAHAEINEAGR*# SEQUENCE: ISQAVHTAHAEINEAGR*# ...# >MUS20F8E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHATHAEINEAGR*# SEQUENCE: ISQAVHATHAEINEAGR*# ...# >MUS20F8F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAATAEINEAGR*# SEQUENCE: ISQAVHAATAEINEAGR*# ...# >MUS20F90# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAAHTEINEAGR*# SEQUENCE: ISQAVHAAHTEINEAGR*# ...# >MUS20F91# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVVAAHAEINEAGR*# SEQUENCE: ISQAVVAAHAEINEAGR*# ...# >MUS20F92# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHVAHAEINEAGR*# SEQUENCE: ISQAVHVAHAEINEAGR*# ...# >MUS20F93# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAVHAEINEAGR*# SEQUENCE: ISQAVHAVHAEINEAGR*# ...# >MUS20F94# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAAVAEINEAGR*# SEQUENCE: ISQAVHAAVAEINEAGR*# ...# >MUS20F95# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAHVEINEAGR*# SEQUENCE: ISQAVHAAHVEINEAGR*# ...# >MUS20F96# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHWAHAEINEAGR*# SEQUENCE: ISQAVHWAHAEINEAGR*# ...# >MUS20F97# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAWHAEINEAGR*# SEQUENCE: ISQAVHAWHAEINEAGR*# ...# >MUS20F98# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVHAAWAEINEAGR*# SEQUENCE: ISQAVHAAWAEINEAGR*# ...# >MUS20F99# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,ISQAVYAAHAEINEAGR*# SEQUENCE: ISQAVYAAHAEINEAGR*# ...# >MUS20F9A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHYAHAEINEAGR*# SEQUENCE: ISQAVHYAHAEINEAGR*# ...# >MUS20F9B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAYHAEINEAGR*# SEQUENCE: ISQAVHAYHAEINEAGR*# ...# >MUS20F9C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova (323-336) homologue# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ISQAVHAAYAEINEAGR*# SEQUENCE: ISQAVHAAYAEINEAGR*# ...# >MUS20F9D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Chicken ovalbumin Ova(312-322)# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,LSCISSAESLK*# SEQUENCE: LSCISSAESLK*# ...# >MUS20F9E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Chicken ovalbumin Ova(317-327)# DB REFERENCE: SWISS: (OVAX_CHICK,OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH,DXCH)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,SAESLKISQAV*# SEQUENCE: SAESLKISQAV*# ...# >MUS20F9F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hen egg white Lysozyme HEL(105-120)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_SYRRE,LYC_COLVI,LYC_CHRAM,LYC3_ANAPL,# & LYC_PAVCR,LYC_COTJA,LYC_MELGA,LYC_LOPLE,LYC_LOPCA,# & LYC_CHICK)# & PIR1: (LZQJE,LZTK,LZQJEC,LZDK3,LZCH)# & PIR2: (JT0526,JU0237,JQ1041,JQ1033)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,MNAWVAWRNRCKGTDV*# SEQUENCE: MNAWVAWRNRCKGTDV*# ...# >MUS20FA0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hen egg white Lysozyme HEL(107-129)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,AWVAWRNRCKGTDVQAWIRGCRL*# SEQUENCE: AWVAWRNRCKGTDVQAWIRGCRL*# ...# >MUS20FA1# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hen egg white Lysozyme HEL(116-129)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZCH)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,KGTDVQAWIRGCRL*# SEQUENCE: KGTDVQAWIRGCRL*# ...# >MUS20FA2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Cytochromes h. cyt(11-27)# DB REFERENCE: SWISS: (CYC2_MOUSE,CYC_HORSE,CYC_CHESE,CYC_EQUAS,CYC_MIRLE,# & CYC_RABIT,CYC_ESCGI,CYC_MINSC,CYC_MOUSE,CYC_MACGI,# & CYC_EQUAS,CYC_HIPAM,CYC2_MOUSE,CYC_ESCGI,CYC_CANFA,# & CYC_BOVIN,CYC_HORSE,CYC_CANFA,CYC_CHESE)# & PIR1: (CCKGG,CCHO,CCMST,CCPG,CCRT,CCCM,CCSH,CCBTS,CCHOD,CCHP,# & CCHOZ,CCGW,CCSLE,CCWHC,CCBO,CCMS,CCRB)# & PIR2: (C04604)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,VQKCAQCHTVEKGGKHK*# SEQUENCE: VQKCAQCHTVEKGGKHK*# ...# >MUS20FA3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin Myo(63-78)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_KOGSI,MYG_PHYCA)# & PIR1: (MYWHW,MYWHP)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,KHGVTVLTALGAILKK*# SEQUENCE: KHGVTVLTALGAILKK*# ...# >MUS20FA4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin Myo(63-78)# DB REFERENCE: SWISS: (MYG_KOGSI,MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHW,MYWHP)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,KHGVTVLTALGAILKK*# SEQUENCE: KHGVTVLTALGAILKK*# ...# >MUS20FA5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Sperm whale myoglobin Myo(108-118)# DB REFERENCE: SWISS: (MYG_ORCOR,MYG_TURTR,MYG_KOGSI,MYG_PHOPH,MYG_INIGE,# & MYG_PHYCA,MYG_PHYCA,MYG_GLOME)# & PIR1: (MYWHL,MYWHT,MYWHW,MYWHP,MYDDAR,MYPE,MYPED,MYDDBS,MYDD)# REFERENCES: sette89b,sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,SEAIIHVLHSR*# SEQUENCE: SEAIIHVLHSR*# ...# >MUS20FA6# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin Myo(108-118)# DB REFERENCE: SWISS: (MYG_PHOPH,MYG_TURTR,MYG_INIGE,MYG_KOGSI,MYG_PHYCA,# & MYG_GLOME,MYG_PHYCA,MYG_ORCOR)# & PIR1: (MYDDBS,MYWHP,MYPED,MYDD,MYDDAR,MYPE,MYWHL,MYWHW,MYWHT)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,SEAIIHVLHSR*# SEQUENCE: SEAIIHVLHSR*# ...# >MUS20FA7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MHC class 2 IAk(6-20)# DB REFERENCE: SWISS: (HA2K_MOUSE)# & PIR1: (HLMSAA)# & PIR2: (I54447)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ADHVGSYGITVYQSP*# SEQUENCE: ADHVGSYGITVYQSP*# ...# >MUS20FA8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MHC class 2 lAd alpha (60-76)# DB REFERENCE: SWISS: (HA2D_MOUSE)# & PIR1: (HLMSA2)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,PQGGLQNIAAEKHNLGI*# SEQUENCE: PQGGLQNIAAEKHNLGI*# ...# >MUS20FA9# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria proteins CS(325-341)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,EPSDKHIEQYLKKIKNS*# SEQUENCE: EPSDKHIEQYLKKIKNS*# ...# >MUS20FAA# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Malaria proteins CS(382-394)# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,KIAKMEKASSVFNVVNS*# SEQUENCE: KIAKMEKASSVFNVVNS*# ...# >MUS20FAB# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza proteins Ha(111-120)# DB REFERENCE: SWISS: (HEMA_IAHAR,HEMA_IATAI,HEMA_IAUSS,HEMA_IALEN,HEMA_IACAO,# & HEMA_IAPUE,HEMA_IAXIA,HEMA_IAKIE)# & PIR1: (HMIV,HMIVTA,HMIVUR)# & PIR2: (JQ2370,JQ2371,JQ1437,PQ0319,PQ0321,JQ1643,JQ2372,# & A35788)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,FERFEIFPKE*# SEQUENCE: FERFEIFPKE*# ...# >MUS20FAC# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Influenza proteins NP(147-158) Arg-# ANCHOR POSITIONS:# REFERENCES: sette89b,sauzet96a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesl,TYQRTRALVTG*# SEQUENCE: TYQRTRALVTG*# ...# >MUS20FAD# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Herpes simplex virus HSVgd(186-210)# DB REFERENCE: SWISS: (VLGD_HSV1A,VGLD_HSV1H,VGLD_HSV11)# & PIR1: (VGBED1,VGBE17,A47627,VGBEDZ)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,IPPSACLSPQAYQQG*# SEQUENCE: IPPSACLSPQAYQQG*# ...# >MUS20FAE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Herpes simplex virus HSVgd(245-260)# DB REFERENCE: SWISS: (VGLD_HSV11,VLGD_HSV1A)# & PIR1: (A47627,VGBED1,VGBE17)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,APYTSTLLPPELSETP*# SEQUENCE: APYTSTLLPPELSETP*# ...# >MUS20FAF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Herpes simplex virus HSVgd(204-219)# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,PQAYQQGVTDSIGML*# SEQUENCE: PQAYQQGVTDSIGML*# ...# >MUS20FB0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV ps pl3(97-112)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1JR,GAG_HV1BR,GAG_HV1PV,GAG_HV1B1,# & GAG_HV1A2,GAG_HV1H2)# & PIR1: (FOVWH3,FOVWLV,FOVWA2)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,QKQEPIDKELYPLTSL*# SEQUENCE: QKQEPIDKELYPLTSL*# ...# >MUS20FB1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV ps pl3(105-123)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1H2,GAG_HV1JR,GAG_HV1PV,GAG_HV1B1,# & GAG_HV1B5,GAG_HV1A2)# & PIR1: (FOVWA2,FOVWH3,FOVWLV)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ELYPLTSLRSLFGNDPSSQ*# SEQUENCE: ELYPLTSLRSLFGNDPSSQ*# ...# >MUS20FB2# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV ps pl7(9-24)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1A2,GAG_HV1W2,GAG_HV1OY)# & PIR1: (FOVWA2)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,GGELDKWEKIRLRPGG*# SEQUENCE: GGELDKWEKIRLRPGG*# ...# >MUS20FB3# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV ps pl7(17-32)# DB REFERENCE: SWISS: (GAG_HV2NZ,GAG_HV1PV,GAG_HV1BR,GAG_HV1H2,GAG_HV1B1,# & GAG_HV1B5,GAG_HV1A2,GAG_HV1J3,GAG_HV1MN)# & PIR1: (A38068,FOVWH3,FOVWVL,FOVWLV,FOVWA2)# & PIR3: (S33979)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,KIRLRPGGKKKYKLKH*# SEQUENCE: KIRLRPGGKKKYKLKH*# ...# >MUS20FB4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV ps pl7(33-48)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1H2,GAG_HV1PV,GAG_HV1N5,GAG_HV1W2,# & GAG_HV1BR,GAG_HV1B1,GAG_HV1A2,GAG_HV1JR)# & PIR1: (FOVWH3,FOVWVL,FOVWLV,FOVWA2)# & PIR3: (S33979)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,IVWASRELERFAVNPG*# SEQUENCE: IVWASRELERFAVNPG*# ...# >MUS20FB5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV ps pl7(57-73)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1A2,GAG_HV1J3,GAG_HV1N5,GAG_HV1C4,# & GAG_HV1BR,GAG_HV1W2,GAG_HV1MN,GAG_HV1H2,GAG_HV1Y2,# & GAG_HV1B5,GAG_HV1PV)# & PIR1: (FOVWLV,FOVWA2,A44001,A38068,FOVWVL,FOVWH4,FOVWH3)# & PIR3: (S33979)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,RQILGQLQPSLQTGSE*# SEQUENCE: RQILGQLQPSLQTGSE*# ...# >MUS20FB6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV ps pl7(115-135)# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,KAQQAAAAGTGNSSQVSQNY*# SEQUENCE: KAQQAAAAGTGNSSQVSQNY*# ...# >MUS20FB7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV ps p25(33-48)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1N5,GAG_HV1Z2,GAG_HV1B1,GAG_HV1ND,# & GAG_HV1BR,GAG_HV1A2,GAG_HV1U4,GAG_HV1JR,GAG_HV1B5,# & GAG_HV1MA,GAG_HV1Y2,GAG_HV1J3,GAG_HV1MN,GAG_HV1W2,# & GAG_HV1RH,GAG_HV1H2,GAG_HV1EL)# & PIR1: (FOVWVL,A38068,FOVWA2,FOVWLV,FOLJND,FOVWH3,A44001)# & PIR2: (S54377)# & PIR3: (S33979)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,SPEVIPMFSALSEGAT*# SEQUENCE: SPEVIPMFSALSEGAT*# ...# >MUS20FB8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Miscellaneous Angiotensin# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,DRVYHIPFHLLVYS*# SEQUENCE: DRVYHIPFHLLVYS*# ...# >MUS20FB9# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Miscellaneous Dynorphin(1-13)# DB REFERENCE: SWISS: (NDDB_BOVIN,NDDB_HUMAN,NDDB_CAVPO,NDDB_HUMAN,NDDB_PIG,# & NDDB_RAT,NDDB_PIG,NDDB_RAT)# & PIR1: (DFRTP,DFPG,DFHU)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,YGGFLRRIRPKLK*# SEQUENCE: YGGFLRRIRPKLK*# ...# >MUS20FBA# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Miscellaneous (YT)4VHAAH# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,YTYTYTYTVHAAH*# SEQUENCE: YTYTYTYTVHAAH*# ...# >MUS20FBB# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Miscellaneous JF39# ANCHOR POSITIONS:# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,AHRVQLGPRSLQVLLIP*# SEQUENCE: AHRVQLGPRSLQVLLIP*# ...# >MUS20FBC# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Nase(1-20)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,ATSTKKLHKEPATLIKAIDG*# SEQUENCE: ATSTKKLHKEPATLIKAIDG*# ...# >MUS20FBD# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Nase(11-30)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,PATLIKAIDGDTVKLMYKGQ*# SEQUENCE: PATLIKAIDGDTVKLMYKGQ*# ...# >MUS20FBE# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Nase(31-50)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,PMTFRLLLVDTPETKHPKKG*# SEQUENCE: PMTFRLLLVDTPETKHPKKG*# ...# >MUS20FBF# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./Reference# ACTIVITY: none# BINDING: yes, little# SOURCE: Nase(51-70)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a,sette89b,schild95a# COMMENT:# SUMMARY: I-Ed,actyesn,bindyesl,VEKYGPEASAFTKKMVENAK*# SEQUENCE: VEKYGPEASAFTKKMVENAK*# ...# >MUS20FC0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Nase(61-80)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a,sette89b# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesl,FTKKMVENAKKIEVEFDKGQ*# SEQUENCE: FTKKMVENAKKIEVEFDKGQ*# ...# >MUS20FC1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Nase(81-100)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >MUS20FC2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Nase(91-110)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,YIYADGKMVNEALVRQGLAK*# SEQUENCE: YIYADGKMVNEALVRQGLAK*# ...# >MUS20FC3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Nase(101-120)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,EALVRQGLAKVAYVYKPNNT*# SEQUENCE: EALVRQGLAKVAYVYKPNNT*# ...# >MUS20FC4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Nase(101-120)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette89b# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,EALVRQGLAKVAYVYKPNNT*# SEQUENCE: EALVRQGLAKVAYVYKPNNT*# ...# >MUS20FC5# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Nase (112-130)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: altuvia94a,sette89b# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesm,AYVYKPNNTHEQHLRKSEA*# SEQUENCE: AYVYKPNNTHEQHLRKSEA*# ...# >MUS20FC6# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: competitive binding as./Reference/Elution# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Nase(121-140)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette89b,schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesl,HEQHLRKSEAQAKKEKLNIW*# SEQUENCE: HEQHLRKSEAQAKKEKLNIW*# ...# >MUS20FC7# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLV envelope protein 454-469# DB REFERENCE: SWISS: (ENV_MLVAV)# & PIR1: (VCVWEK)# & PIR2: (A43491,A46511,S22805,B43491)# REFERENCES: barber93a,schild95a# COMMENT:# SUMMARY: I-Eb,actunkn,bindyesu,SPSYVYHQFERRAKYK*# SEQUENCE: SPSYVYHQFERRAKYK*# ...# >MUS20FC8# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLV envelope protein 454-468# DB REFERENCE: SWISS: (ENV_MLVAV)# & PIR1: (VCVWEK)# & PIR2: (A46511,S22805,B43491,A43491)# REFERENCES: barber93a# COMMENT:# SUMMARY: I-Eb,actunkn,bindyesu,SPSYVYHQFERRAKY*# SEQUENCE: SPSYVYHQFERRAKY*# ...# >MUS20FC9# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine serum albumin 141-157# DB REFERENCE: SWISS: (ALBU_FELCA,ALBU_BOVIN,ALBU_PIG)# & PIR1: (ABBOS,ABPGS)# & PIR2: (S57632,JC4660)# REFERENCES: barber93a# COMMENT:# SUMMARY: I-Eb,actunkn,bindyesu,GKYLYEIARRHPYFYAP*# SEQUENCE: GKYLYEIARRHPYFYAP*# ...# >HUM20FCA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human invariant chain 82-105# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKPPKPVSKMRMATPLIMQALPMG*# SEQUENCE: PKPPKPVSKMRMATPLIMQALPMG*# ...# >HUM20FCB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human invariant chain 82-104# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKPPKPVSKMRMATPLIMQALPM*# SEQUENCE: PKPPKPVSKMRMATPLIMQALPM*# ...# >HUM20FCC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human invariant chain 83-103# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KPPKPVSKMRMATPLIMQALP*# SEQUENCE: KPPKPVSKMRMATPLIMQALP*# ...# >HUM20FCD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine fetuin 56-74# DB REFERENCE: SWISS: (A2HS_SHEEP,A2HS_BOVIN,A2HS_SHEEP,A2HS_BOVIN)# & PIR2: (A35714,S22394)# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YKHTLNQIDSVKVWPRRPT*# SEQUENCE: YKHTLNQIDSVKVWPRRPT*# ...# >HUM20FCE# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human invariant chain 81-103# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,LPKPPKPVSKNRYATPLLMQALP*# SEQUENCE: LPKPPKPVSKNRYATPLLMQALP*# ...# >HUM20FCF# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human invariant chain 83-104# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,KPPKPVSKNRMATPLLMQALPM*# SEQUENCE: KPPKPVSKNRMATPLLMQALPM*# ...# >HUM20FD0# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human invariant chain 83-103# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,KPPKPVSKNRMATPLLMQALP*# SEQUENCE: KPPKPVSKNRMATPLLMQALP*# ...# >HUM20FD1# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human invariant chain 83-100# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,KPPKPVSKMRNATPLLMQ*# SEQUENCE: KPPKPVSKMRNATPLLMQ*# ...# >MUS20FD2# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLVC envelope protein 145-158# DB REFERENCE: SWISS: (ENV_MLVRK,ENV_MLVRD)# & PIR1: (VCMVVR,VCMVKA)# & PIR2: (A46511,B43491,A43491)# REFERENCES: barber93a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,HNEGFYVCPGPHRP*# SEQUENCE: HNEGFYVCPGPHRP*# ...# >MUS20FD3# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLV envelope protein 145-157# DB REFERENCE: SWISS: (ENV_MLVRD,ENV_MLVRK)# & PIR1: (VCMVKA,VCMVVR)# & PIR2: (A43491,A46511,B43491)# REFERENCES: barber93a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,HNEGFYVCPGPHR*# SEQUENCE: HNEGFYVCPGPHR*# ...# >MUS20FD4# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Immunoglobulin G heavy chain 59-74# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,XNADFKTPATLTVDKP*# SEQUENCE: XNADFKTPATLTVDKP*# ...# >MUS20FD5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse apolipoprotein-E 268-283# DB REFERENCE: SWISS: (APE_MOUSE,APE_MOUSE)# & PIR2: (JU0036)# REFERENCES: barber93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,WANLMEKIQASVATNP*# SEQUENCE: WANLMEKIQASVATNP*# ...# >MUS20FD6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse class II I-E alpha chain 52-67# DB REFERENCE: SWISS: (HA2R_HUMAN,HA23_MOUSE,HA21_MOUSE,HA21_MOUSE,# & HA22_MOUSE)# & PIR1: (HLHUDA,HLMSEA,HLMSED)# & PIR2: (I72480,S06316,I54426,A46505,I56085,I55971)# REFERENCES: barber93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,ASFEAQGALANIAVDK*# SEQUENCE: ASFEAQGALANIAVDK*# ...# >MUS20FD7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse apolipoprotein-E 237-252# DB REFERENCE: SWISS: (APE_MOUSE,APE_RAT,APE_RAT,APE_MOUSE)# & PIR1: (LPRTE)# & PIR2: (JU0036)# REFERENCES: barber93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,EQTQQIRLQAEIFQAR*# SEQUENCE: EQTQQIRLQAEIFQAR*# ...# >MUS20FD8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference/Competition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rat tranrerrin receptor 442-459# DB REFERENCE: PIR2: (S29548,A34549)# REFERENCES: barber93a,feng94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,VPQLNQMVRTAAEVAGQ*# SEQUENCE: VPQLNQMVRTAAEVAGQ*# ...# >MUS20FD9# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC/Edman sequencing/binding assays/Compettition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HSP70 (28-41)# DB REFERENCE: SWISS: (HS7D_DROME,HS73_YEAST,HS71_ANOAL,HS70_ACHKL,HS71_SCHPO,# & HS70_TRYCR,HS71_DROME,HS7A_CAEEL,HS72_ARATH,HS71_RAT,# & HS72_PARLI,HS71_HUMAN,HS70_PLAFA,HS71_LYCES,HS71_DROME,# & HS7E_SPIOL,HS7C_CRIGR,HS71_MOUSE,HS7A_DROME,HS72_HUMAN,# & HS7C_HUMAN,HS73_BOVIN,HS70_XENLA,HS7C_DICDI,HS73_BOVIN,# & HS71_ARATH,HS70_ONCTS,HS70_BLAEM,HS70_BRUMA,HS74_TRYBB,# & HS70_LEIAM,HS70_CHLRE,HS71_BOVIN,HS7C_RAT,HS74_ANOAL,# & HS74_PARLI,HS71_RAT,HS72_RAT,HS70_LEIDO,HS7C_RAT,# & HS70_PLACB,HS70_ONCMY,HS7C_BOVIN,HS71_MOUSE,HS70_SCHMA,# & HS7C_TRYBB,HS7C_BRARE,HS72_ANOAL,HS70_DAUCA,HS72_LYCES,# & HS70_BRELC,HS70_CHICK,HS74_LEIMA,HS72_HUMAN,HS72_MOUSE,# & HS7T_MOUSE,HS72_BOVIN,HS7A_DROSI,HS72_MOUSE,HS7T_MOUSE,# & HS7C_PETHY,HS71_PUCGR,HS7B_DROME,HS70_MAIZE,HS7H_HUMAN,# & HS70_LEIMA,HS7C_ICTPU,HS73_RAT,HS7C_BOVIN,HS7C_ICTPU,# & HS7C_DICDI,HS74_YEAST)# & PIR1: (HHUM7B,HHXL70,HHKW7A)# & PIR2: (A48469,JC4853,A36333,A27077,JA0170,B36590,S31766,S43388,# & S37394,S08211,S21364,B45871,A45635,S52727,S03250,S14950,# & A42582,S11456,S46302,A25646,A29160,I56574,S53126,JQ0314,# & JU0164,JN0668,S11448,S10859,A35922,S21363,A25398,S37165,# & JH0095,S41403,S06158,I49761,A25089,S41415,S53500,JQ1515,# & A45935,B03309,S14949,S36753,I54542,A53163,S05439,JC1391,# & S25649,A49242,A55719,S31716,A44979,PQ0138,S07197,S44168,# & A45871,S06443,A03309,A45515,S18349,S67431,A48439,# & JC4786)# & PIR3: (JC2215,S21175)# REFERENCES: barber93a,nelson92a,greer96a,nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,IIANDQGNRTTPSY*# SEQUENCE: IIANDQGNRTTPSY*# ...# >MUS20FDA# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse class II I-Ak beta chain 165-179# DB REFERENCE: SWISS: (HB2A_MOUSE,HB2U_MOUSE,HB2K_MOUSE,HB2S_MOUSE)# & PIR1: (HLMSBS,HLMSBK,HLMSBU)# & PIR2: (A61389,I68209,I68208,I80418,I59495,I54100,I48656)# REFERENCES: barber93a,nelson92a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,TPRRGEVYTCHVEHP*# SEQUENCE: TPRRGEVYTCHVEHP*# ...# >MUS20FDB# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rat S30 ribosomal protein 75-96# DB REFERENCE: SWISS: (RS30_HUMAN,RS30_HUMAN)# & PIR2: (I48346,JC1278,A47416)# REFERENCES: barber93a,nelson92a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,KVHGSLARAGKVRGQTPKVAKQ*# SEQUENCE: KVHGSLARAGKVRGQTPKVAKQ*# ...# >MUS20FDC# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rat S30 ribosomal protein 83-103# DB REFERENCE: SWISS: (RS30_HUMAN,RS30_HUMAN)# & PIR2: (JC1278,A47416,I48346)# REFERENCES: barber93a,nelson92a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,AGKVRGQTPKVAKQEKKKKKT*# SEQUENCE: AGKVRGQTPKVAKQEKKKKKT*# ...# >MUS20FDD# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse ryudocan 84-100# ANCHOR POSITIONS:# REFERENCES: barber93a,nelson92a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,EPLVPLDNHIPENAQPG*# SEQUENCE: EPLVPLDNHIPENAQPG*# ...# >MUS20FDE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: HPLC/Edman sequencing/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hen egg lysozyme (48-60)# DB REFERENCE: SWISS: (LYC_PHACO,LYC_CHICK,LYC_PAVCR,LYC_SYRRE,LYC_MELGA,# & LYC1_ANAPL,LYC_LOPLE,LYC1_TACAC,LYC_CHRAM,LYC_PHAVE,# & LYC_CHICK)# & PIR1: (LZFER,LZDK,LZQJE,LZTK,LZCH)# & PIR2: (A61281,JU0237,JQ1041,JT0526,JH0211,JH0212,JC2144,A45660,# & JU0178,JQ1033)# REFERENCES: barber93a,nelson92a,nelson96b# COMMENT: naturally processed peptide# SUMMARY: I-Ak,actunkn,bindyesu,DGSTDYGILQINS*# SEQUENCE: DGSTDYGILQINS*# ...# >MUS10FDF# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse phosphoglycerate kinase# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,XPQKAGGFLM*# SEQUENCE: XPQKAGGFLM*# ...# >HUM10FE0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human ATP-dependent RNA helicase# DB REFERENCE: SWISS: (P68_MOUSE,P68_HUMAN,P68_HUMAN)# & PIR2: (I48385,JC1087)# REFERENCES: barber93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,YLLPAIVHI*# SEQUENCE: YLLPAIVHI*# ...# >HUM10FE1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TIS21# DB REFERENCE: SWISS: (BTG1_CHICK,BTG1_BOVIN,PC3_RAT,BTG2_MOUSE,BTG1_HUMAN,# & BTG1_RAT,BTG2_RAT,TS21_MOUSE)# & PIR2: (S19961,S20947,A40761,I53276,I48272,A40443)# REFERENCES: barber93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,TLWVDPYEV*# SEQUENCE: TLWVDPYEV*# ...# >HUM10FE2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Human IP-30 leader peptide# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708,S21727)# REFERENCES: barber93a,anderson93a,parker94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLDVPTAAV*# SEQUENCE: LLDVPTAAV*# ...# >HUM10FE3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human IP-30 leader peptide# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708)# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLLDVPTAAVQA*# SEQUENCE: LLLDVPTAAVQA*# ...# >HUM10FE4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human IP-30 leader peptide# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (S21727,A43708)# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLLDVPTAAVQ*# SEQUENCE: LLLDVPTAAVQ*# ...# >HUM10FE5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human IP-30 leader peptide# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (S21727,A43708)# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLLDVPTAAV*# SEQUENCE: LLLDVPTAAV*# ...# >HUM10FE6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Calreticulin leader peptide# DB REFERENCE: SWISS: (CRTC_HUMAN,CRTC_HUMAN,CRTC_RAT,CRTC_MOUSE)# & PIR2: (A37047,JH0819,S06763)# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MLLSVPLLLG*# SEQUENCE: MLLSVPLLLG*# ...# >HUM10FE7# MHC MOLECULE: HLA-A68, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal 60S homologue# DB REFERENCE: SWISS: (RL27_HUMAN)# & PIR1: (R5RT27)# & PIR2: (S43505,S22288)# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,DVFRDPALK*# SEQUENCE: DVFRDPALK*# ...# >HUM10FE8# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human class I alpha3 domain# ANCHOR POSITIONS:# REFERENCES: barber93a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesu,YPAEITLYW*# SEQUENCE: YPAEITLYW*# ...# >HUM20FE9# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct,Binding-competitive# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova reiterative# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,AHAAHAAHAAHAAHAA*# SEQUENCE: AHAAHAAHAAHAAHAA*# ...# >HUM20FEA# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct,Binding-competitive# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova reiterative# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,VHAAHAVHAAHAEIN*# SEQUENCE: VHAAHAVHAAHAEIN*# ...# >HUM20FEB# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct,Binding-competitive# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 145-165# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: sidney94a# COMMENT: -CONH2 at C-terminus# SUMMARY: HLA-DQ7,actunkn,bindyesm,INSWVESQTNGIIRNVLQPSS*# SEQUENCE: INSWVESQTNGIIRNVLQPSS*# ...# >HUM20FEC# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct,Binding-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 307-326# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,SSSANLSGISSAESLKISQA*# SEQUENCE: SSSANLSGISSAESLKISQA*# ...# >HUM20FED# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct,Binding-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova combinatorial# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,YYVRAVRAYLTT*# SEQUENCE: YYVRAVRAYLTT*# ...# >HUM20FEE# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 20-39# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: sidney94a# COMMENT: peptide did not compete for binding to HLA-DQ3.1# SUMMARY: HLA-DQ7,actunkn,bindyesl,VHHANENIFYCPIAIMSALA*# SEQUENCE: VHHANENIFYCPIAIMSALA*# ...# >HUM20FEF# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323- 339# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT: Core region HAAHA# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAHAEINEAGR*# SEQUENCE: ISQAVHAAHAEINEAGR*# ...# >HUM20FF0# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 324-339# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,SQAVHAAHAEINEAGR*# SEQUENCE: SQAVHAAHAEINEAGR*# ...# >HUM20FF1# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 325-339# DB REFERENCE: SWISS: (OVAL_COTJA,OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,QAVHAAHAEINEAGR*# SEQUENCE: QAVHAAHAEINEAGR*# ...# >HUM20FF2# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 326-339# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,AVHAAHAEINEAGR*# SEQUENCE: AVHAAHAEINEAGR*# ...# >HUM20FF3# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 327-339# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,VHAAHAEINEAGR*# SEQUENCE: VHAAHAEINEAGR*# ...# >HUM20FF4# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 328-339# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,HAAHAEINEAGR*# SEQUENCE: HAAHAEINEAGR*# ...# >HUM20FF5# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 329-339# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,AAHAEINEAGR*# SEQUENCE: AAHAEINEAGR*# ...# >HUM20FF6# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGADGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGADGVGKSALTIQLIQ*# ...# >HUM20FF7# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-337# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAHAEINEA*# SEQUENCE: ISQAVHAAHAEINEA*# ...# >HUM20FF8# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-336# DB REFERENCE: SWISS: (OVAL_COTJA,OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAHAEINE*# SEQUENCE: ISQAVHAAHAEINE*# ...# >HUM20FF9# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-335# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAAEIN*# SEQUENCE: ISQAVHAAAEIN*# ...# >HUM20FFA# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-333# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAHAE*# SEQUENCE: ISQAVHAAHAE*# ...# >HUM20FFB# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-332# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAHA*# SEQUENCE: ISQAVHAAHA*# ...# >HUM20FFC# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct/competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Ova (101-120)# DB REFERENCE: SWISS: (MPH1_HOLLA,MPH1_HOLLA,MPL1_LOLPR,MPL1_LOLPR,# & MPA1_PHAAQ)# & PIR2: (A37881,B37881,S38581)# & PIR3: (S13614)# REFERENCES: sidney94a,sidney92a# COMMENT: Core region LSGHA# SUMMARY: HLA-DQ7,actyesu,bindyesm,APYHFDLSGHAFGSMAKKGE*# SEQUENCE: APYHFDLSGHAFGSMAKKGE*# ...# >HUM20FFD# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 103-120# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR,MPH1_HOLLA,MPA1_PHAAQ,# & MPH1_HOLLA)# & PIR2: (S38581,B37881,A37881)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,YHFDLSGHAFGSMAKKGE*# SEQUENCE: YHFDLSGHAFGSMAKKGE*# ...# >HUM20FFE# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 105-120# DB REFERENCE: SWISS: (MPA1_PHAAQ,MPH1_HOLLA,MPL1_LOLPR,MPL1_LOLPR,# & MPH1_HOLLA)# & PIR2: (A37881,S38581,B37881)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,FDLSGHAFGSMAKKGE*# SEQUENCE: FDLSGHAFGSMAKKGE*# ...# >HUM20FFF# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 107-120# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR,MPA1_PHAAQ,MPH1_HOLLA,# & MPH1_HOLLA)# & PIR2: (A37881,B37881,S38581)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,LSGHAFGSMAKKGE*# SEQUENCE: LSGHAFGSMAKKGE*# ...# >HUM21000# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 101-119# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,APYHFDLSGHAFGSMARRG*# SEQUENCE: APYHFDLSGHAFGSMARRG*# ...# >HUM21001# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 101-116# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,APYHFDLSGHAFSGMA*# SEQUENCE: APYHFDLSGHAFSGMA*# ...# >HUM21002# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 101-114# DB REFERENCE: SWISS: (MPA1_PHAAQ,MPL1_LOLPR,MPH1_HOLLA,MPL1_LOLPR,# & MPH1_HOLLA)# & PIR2: (B37881,A37881,S38581)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,APYHFDLSGHAFGS*# SEQUENCE: APYHFDLSGHAFGS*# ...# >HUM21003# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 101-112# DB REFERENCE: SWISS: (MPA1_PHAAQ,MPH1_HOLLA,MPH1_HOLLA,MPL1_LOLPR,MPL1_LOLPR,# & MPP1_PHLPR,MPP1_PHLPR)# & PIR2: (S44182,A37881,S38581,B37881)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,APYHFDLSGHAF*# SEQUENCE: APYHFDLSGHAF*# ...# >HUM21004# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 101-111# DB REFERENCE: SWISS: (MPH1_HOLLA,MPL1_LOLPR,MPP1_PHLPR,MPL1_LOLPR,MPP1_PHLPR,# & MPH1_HOLLA,MPA1_PHAAQ)# & PIR2: (S38581,A37881,S44182,B37881)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,APYHFDLSGHA*# SEQUENCE: APYHFDLSGHA*# ...# >HUM21005# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Nase 101-120# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,EALVRQGLARVAYVYKPNNT*# SEQUENCE: EALVRQGLARVAYVYKPNNT*# ...# >HUM21006# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ROIV - artificial peptide# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YAHAAHAAHAAHAAHAA*# SEQUENCE: YAHAAHAAHAAHAAHAA*# ...# >HUM21007# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Stp. dt. 18 kd Y1-16# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YGAVDSILGGVATYGAA*# SEQUENCE: YGAVDSILGGVATYGAA*# ...# >HUM21008# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p l 101-120# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,APYHFDLSGlIAFGSMAKKGE*# SEQUENCE: APYHFDLSGlIAFGSMAKKGE*# ...# >HUM21009# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Wiley poly(A)DR binder# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,AAYAAAAAAKAAA*# SEQUENCE: AAYAAAAAAKAAA*# ...# >HUM2100A# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Staphylococcus nuclease 101-120# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,EALVRQGLARVAYVYRPNNT*# SEQUENCE: EALVRQGLARVAYVYRPNNT*# ...# >HUM2100B# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CS 382-398# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,KIAKMEKASSVFNVVNS*# SEQUENCE: KIAKMEKASSVFNVVNS*# ...# >HUM2100C# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ova 297-316# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,LMAMGITDVFSSSANLSGIS*# SEQUENCE: LMAMGITDVFSSSANLSGIS*# ...# >HUM2100D# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 19K MT 1-15# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YEHRVKRGLTVAVAGA*# SEQUENCE: YEHRVKRGLTVAVAGA*# ...# >HUM2100E# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p l 151-170# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,VEXGSNPNYLAILVKYVDGD*# SEQUENCE: VEXGSNPNYLAILVKYVDGD*# ...# >HUM2100F# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p l 191-210# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (A37881,B37881)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,ESWGAVWRIDTPDKLTGPFT*# SEQUENCE: ESWGAVWRIDTPDKLTGPFT*# ...# >HUM21010# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MT231-245# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCTU)# & PIR2: (A26950,A43509)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,LLPLLEKVIGAGKPL*# SEQUENCE: LLPLLEKVIGAGKPL*# ...# >HUM21011# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B6(TPO Y632-645)# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YIDVWLGGLAENFLP*# SEQUENCE: YIDVWLGGLAENFLP*# ...# >HUM21012# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol pl 181-200# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (A37881)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,KGKDKWIELKESWGAVWRID*# SEQUENCE: KGKDKWIELKESWGAVWRID*# ...# >HUM21013# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HA 130-141, site 2# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,HNTNGVTAASSH*# SEQUENCE: HNTNGVTAASSH*# ...# >HUM21014# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Non-natural sequence# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YTYTVHAAHAYTYT*# SEQUENCE: YTYTVHAAHAYTYT*# ...# >HUM21015# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp17 1-16# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1OY,GAG_HV1W2,GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,GARASVLSGGELDKWE*# SEQUENCE: GARASVLSGGELDKWE*# ...# >HUM21016# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hepatitis B core 1-20# DB REFERENCE: SWISS: (CORA_HPBVA,CORA_HPBVY,CORA_HPBV2,CORA_HPBVZ,CORA_HPBVL,# & CORA_HPBV9,CORA_HPBVJ,CORA_HPBVW)# & PIR1: (NKVLAH,NKVLA1,NKVLJ1,NKVLCP,NKVLA3,NKVLA2,NKVLBH,NKVLKS,# & NKVLA6)# & PIR2: (S53225,S53200,S53257,S20750,S25651,S53253,S53255,S53202,# & S53181,S53240,S53186,S53159,S53204,S53281,S53207,S20746,# & S53229,S32204,S53216,S53242,S53140,S53227,S53251,S53223,# & S53272,S53274,S47405,S01405,S53238,S47409,S53232,S53184,# & S53279,S53198,S53169,S53260,S53211,S53163,S53267,S53172,# & S53270,S53155,S53247,S33686,S53236)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,MDIDPYKEFGATVELLSFLP*# SEQUENCE: MDIDPYKEFGATVELLSFLP*# ...# >HUM21017# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Non-natural sequence# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YQFVRANARSIGITK*# SEQUENCE: YQFVRANARSIGITK*# ...# >HUM21018# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV core 50-69# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVJ,CORA_HPBVW,CORA_HPBV2,# & CORA_HPBV9)# & PIR1: (NKVLKS,NKVLA6,NKVLBH,NKVLA3,NKVLJ1,NKVLAH)# & PIR2: (S53204,S53149,S47409,S53161,S53247,S53267,S22318,S53272,# & S32204,S53286,S53152,S53140,S25651,S53181,S53202,S53227,# & S53169,S53238,S53163,S20755,S20750,S53200,S53216,S53157,# & S20746,S53207,S53274,S47405,S01405)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM21019# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DQ peptide from amylin 16-37# DB REFERENCE: SWISS: (IAPP_HUMAN)# & PIR1: (TCHUIA)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,LVHSSNNFGAILSSTNVGSNTY*# SEQUENCE: LVHSSNNFGAILSSTNVGSNTY*# ...# >HUM2101A# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gpl3 57-72# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1BR,GAG_HV1JR,GAG_HV1A2,GAG_HV1B5,# & GAG_HV1H2,GAG_HV1B1)# & PIR1: (FOVWA2,FOVWH3,FOVWLV)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,LGKIWPSYKGRPGNFL*# SEQUENCE: LGKIWPSYKGRPGNFL*# ...# >HUM2101B# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV LMP 372-386# DB REFERENCE: SWISS: (LMP1_EBVC,LMP1_EBV,LMP1_EBVR)# & PIR1: (LABECA,LABERJ,QQBE50)# & PIR2: (G00065,S24611,S21660)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,DDDDPHGPVQLSYYD*# SEQUENCE: DDDDPHGPVQLSYYD*# ...# >HUM2101C# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Non-natural sequence# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,QFVIANASSVAKTD*# SEQUENCE: QFVIANASSVAKTD*# ...# >HUM2101D# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p l 141-160# DB REFERENCE: PIR2: (A37881)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YPDDTKPTFHVEKGSNPNYL*# SEQUENCE: YPDDTKPTFHVEKGSNPNYL*# ...# >HUM2101E# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: gp110p# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,EQNQEQRRAAQRAAG*# SEQUENCE: EQNQEQRRAAQRAAG*# ...# >HUM2101F# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL 98-115# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_CHICK,LYC_LOPLE,LYC_CHICK,LYC_CHRAM)# & PIR1: (LZQJEC,LZCH)# & PIR2: (JQ1033)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,IVSDGNGMNAWVAWRNRC*# SEQUENCE: IVSDGNGMNAWVAWRNRC*# ...# >HUM21020# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV LMP 41-51# DB REFERENCE: SWISS: (LMP1_EBV,LMP1_EBVC)# & PIR1: (LABECA,QQBE50)# & PIR2: (S21660,G00065)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YIVMSDWTGGA*# SEQUENCE: YIVMSDWTGGA*# ...# >HUM21021# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Gliadin# DB REFERENCE: SWISS: (GDA0_WHEAT,GDA8_WHEAT,GDA1_WHEAT)# & PIR1: (EEWTA)# & PIR2: (S07923,B22364)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,FRPSQQNPQAQGSVQPQQLP*# SEQUENCE: FRPSQQNPQAQGSVQPQQLP*# ...# >HUM21022# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Beta 2 microglobulin 91-106# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,ACRVKHDSMAEPKTVY*# SEQUENCE: ACRVKHDSMAEPKTVY*# ...# >HUM21023# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p l 21-40# DB REFERENCE: SWISS: (MPL1_LOLPR,MPA1_PHAAQ,MPH1_HOLLA,MPH1_HOLLA,MPP1_PHLPR,# & MPL1_LOLPR,MPP1_PHLPR)# & PIR2: (S44182,B37881,A37881,S38581)# & PIR3: (S13614)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,AKSTWYGKPTGAGPKDNGGA*# SEQUENCE: AKSTWYGKPTGAGPKDNGGA*# ...# >HUM21024# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HA 187-206# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,RTLYQNVGTYVSVGTSTLNK*# SEQUENCE: RTLYQNVGTYVSVGTSTLNK*# ...# >HUM21025# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gpl 7 41-56# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1BR,GAG_HV1PV,GAG_HV1B5,GAG_HV1A2,# & GAG_HV1N5,GAG_HV1B1,GAG_HV1H2)# & PIR1: (FOVWA2,FOVWVL,FOVWLV,FOVWH3)# & PIR3: (S33979)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,ERFAVNPGLLETSEGC*# SEQUENCE: ERFAVNPGLLETSEGC*# ...# >HUM21026# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Non-natural sequence# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,AWRNRAKAWRNRAKAWRNRAK*# SEQUENCE: AWRNRAKAWRNRAKAWRNRAK*# ...# >HUM21027# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gpl7 113-133# DB REFERENCE: SWISS: (GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,KAQQAAAAAGTGNSSQVSQNY*# SEQUENCE: KAQQAAAAAGTGNSSQVSQNY*# ...# >HUM21028# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DNAJ p# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,QKRAAYDQYGHAAFEC*# SEQUENCE: QKRAAYDQYGHAAFEC*# ...# >HUM21029# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bordetella pertussis 151-161# DB REFERENCE: SWISS: (TOX1_BORPE,TOX1_BORPE)# & PIR1: (WEBR11,WEBR1P)# & PIR2: (A25973,B25973)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,RILAGALATYQ*# SEQUENCE: RILAGALATYQ*# ...# >HUM2102A# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bordetella pertussis 247-261# DB REFERENCE: SWISS: (TOX1_BORPE,TOX1_BORPE)# & PIR1: (WEBR11,WEBR1P)# & PIR2: (A25973)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,AAWSERAGEAMVLV*# SEQUENCE: AAWSERAGEAMVLV*# ...# >HUM2102B# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL 81-96# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_PHACO,LYC_PAVCR,LYC_LOPLE,LYC_CHICK,# & LYC_CHICK,LYC_PHAVE,LYC_MELGA,LYC_CHRAM)# & PIR1: (LZCH,LZFER,LZQJE,LZTK)# & PIR2: (JQ1041,JU0237,JH0212,JH0211,JQ1033,JT0526,JU0178)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >HUM2102C# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV Pre S (2) ayw 16-33# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVR,VMSA_HPBV4,VMSA_HPBVR,# & VMSA_HPBV9,VMSA_HPBVY)# & PIR1: (SAVLKS,SAVLBH,SAVLAH,SAVLA,SAVLAJ)# & PIR2: (S41869,S43492,S47407,S36654,S20753,S08142,S41871,S20749,# & S35528,S32202,S20745)# & PIR4: (S42226)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,RVRGLYFPAGGSSSGTVN*# SEQUENCE: RVRGLYFPAGGSSSGTVN*# ...# >HUM2102D# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Rheumatoid factor variable region# DB REFERENCE: SWISS: (KV1_CANFA,KV2E_HUMAN,KV2A_HUMAN,KV2D_HUMAN)# & PIR1: (K2HUCM,K2HUTW,K2HUGM)# & PIR2: (S58206,S40356,S40372,S40371,S34091,PT0219,S40337,S40342,# & S24681,S40357,S40319,S34093,S02576,S40323,S24205,S26882,# & B34153,S40375,S58207,S24208)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,RASGVPDRFSGSGSGTDFT*# SEQUENCE: RASGVPDRFSGSGSGTDFT*# ...# >HUM2102E# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV Pre S (2) ayw 33-49# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY)# & PIR1: (SAVLAH)# & PIR2: (S41869)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,NPVLTTASPLSSIFSRI*# SEQUENCE: NPVLTTASPLSSIFSRI*# ...# >HUM2102F# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Rheumatoid factor variable region# DB REFERENCE: PIR2: (S25752,S36047,D44151,S23627)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,TISCSGSSSNIGSNTVN*# SEQUENCE: TISCSGSSSNIGSNTVN*# ...# >HUM21030# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Rheumatoid factor variable region# DB REFERENCE: SWISS: (HV1G_HUMAN)# & PIR1: (HVHU35)# & PIR2: (S18551,S46393,S49530,S26912,S26938,PH1668,PH1669,# & S36265)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,KVSCKASGYTFTGYYMH*# SEQUENCE: KVSCKASGYTFTGYYMH*# ...# >HUM21031# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV Pre S (1) ayw 63-77# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVA)# & PIR1: (SAVLAH,SAVLA1)# & PIR2: (S20745)# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,LLGWSPQAQGILQTL*# SEQUENCE: LLGWSPQAQGILQTL*# ...# >HUM21032# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVRAAHAEINEAGR*# SEQUENCE: ISQAVRAAHAEINEAGR*# ...# >HUM21033# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVQAAHAEINEAGR*# SEQUENCE: ISQAVQAAHAEINEAGR*# ...# >HUM21034# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVEAAHAEINEAGR*# SEQUENCE: ISQAVEAAHAEINEAGR*# ...# >HUM21035# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVKAAHAEINEAGR*# SEQUENCE: ISQAVKAAHAEINEAGR*# ...# >HUM21036# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVLAAHAEINEAGR*# SEQUENCE: ISQAVLAAHAEINEAGR*# ...# >HUM21037# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHVAHAEINEAGR*# SEQUENCE: ISQAVHVAHAEINEAGR*# ...# >HUM21038# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHRAHAEINEAGR*# SEQUENCE: ISQAVHRAHAEINEAGR*# ...# >HUM21039# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHYAHAEINEAGR*# SEQUENCE: ISQAVHYAHAEINEAGR*# ...# >HUM2103A# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHASHAEINEAGR*# SEQUENCE: ISQAVHASHAEINEAGR*# ...# >HUM2103B# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAVHAEINEAGR*# SEQUENCE: ISQAVHAVHAEINEAGR*# ...# >HUM2103C# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHARHAEINEAGR*# SEQUENCE: ISQAVHARHAEINEAGR*# ...# >HUM2103D# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHAARAEINEAGR*# SEQUENCE: ISQAVHAARAEINEAGR*# ...# >HUM2103E# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHAAQAEINEAGR*# SEQUENCE: ISQAVHAAQAEINEAGR*# ...# >HUM2103F# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHAAKAEINEAGR*# SEQUENCE: ISQAVHAAKAEINEAGR*# ...# >HUM21040# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAEAEINEAGR*# SEQUENCE: ISQAVHAAEAEINEAGR*# ...# >HUM21041# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHAALAEINEAGR*# SEQUENCE: ISQAVHAALAEINEAGR*# ...# >HUM21042# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHAANAEINEAGR*# SEQUENCE: ISQAVHAANAEINEAGR*# ...# >HUM21043# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHAAHSEINEAGR*# SEQUENCE: ISQAVHAAHSEINEAGR*# ...# >HUM21044# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAHREINEAGR*# SEQUENCE: ISQAVHAAHREINEAGR*# ...# >HUM21045# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ova 323-339 homologue# ANCHOR POSITIONS:# REFERENCES: sidney94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,ISQAVHAAHYEINEAGR*# SEQUENCE: ISQAVHAAHYEINEAGR*# ...# >HUM21046# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Prolifiration-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: alpha-gliadin 30-49# DB REFERENCE: SWISS: (GDA9_WHEAT)# & PIR2: (S10015)# REFERENCES: gjertsen94a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,FPGQQQPFPPQQPYPQPQPF*# SEQUENCE: FPGQQQPFPPQQPYPQPQPF*# ...# >HUM21047# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Prolifiration-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: alpha-gliadin# DB REFERENCE: SWISS: (GDA0_WHEAT,GDA1_WHEAT)# & PIR1: (EEWTA)# & PIR2: (B22364,S07923)# REFERENCES: gjertsen94a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,LGQQQPFPPQQPYPQPQPF*# SEQUENCE: LGQQQPFPPQQPYPQPQPF*# ...# >HUM21048# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Prolifiration-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: alpha-gliadin# DB REFERENCE: SWISS: (GDA0_WHEAT,GDA1_WHEAT)# & PIR1: (EEWTA)# & PIR2: (B22364,S07923)# REFERENCES: gjertsen94a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,LGQQQPFPPQQPYPQPQ*# SEQUENCE: LGQQQPFPPQQPYPQPQ*# ...# >HUM21049# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Prolifiration-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: alpha-gliadin# DB REFERENCE: SWISS: (GDA1_WHEAT,GDA0_WHEAT)# & PIR1: (EEWTA)# & PIR2: (B22364,S07923)# REFERENCES: gjertsen94a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,QFLGQQQPFPPQQPYPQPQ*# SEQUENCE: QFLGQQQPFPPQQPYPQPQ*# ...# >HUM2104A# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Prolifiration-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: alpha-gliadin# DB REFERENCE: SWISS: (GDA0_WHEAT,GDA1_WHEAT)# & PIR1: (EEWTA)# & PIR2: (S07923,B22364)# REFERENCES: gjertsen94a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,FLGQQQPFPPQQPYPQPQ*# SEQUENCE: FLGQQQPFPPQQPYPQPQ*# ...# >MUS2104B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC1_ANAPL,LYC_SYRRE,LYC_ORTVE,LYC_PAVCR,LYC_PHACO,# & LYC_CHICK,LYC_PHAVE,LYC_CHICK,LYC_CHRAM,LYC1_TACAC,# & LYC_MELGA,LYC_LOPLE)# & PIR1: (LZTK,LZDK,LZQJE,LZCH,LZFER,LZOVE)# & PIR2: (JU0178,A61281,JC2144,A45660,JU0237,JQ1041,JT0526,JH0212,# & JH0211,JQ1033)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,STDYGILQINSR*# SEQUENCE: STDYGILQINSR*# ...# >MUS2104C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_MELGA,LYC_LOPLE,LYC_SYRRE,LYC1_ANAPL,LYC_CHICK,# & LYC_CHICK,LYC_CHRAM,LYC_ORTVE,LYC_PHACO,LYC_PAVCR,# & LYC_PHAVE)# & PIR1: (LZCH,LZTK,LZOVE,LZDK,LZQJE)# & PIR2: (JC2144,JT0526,JQ1033,JU0237,JQ1041,JU0178)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDYGILQINSRW*# SEQUENCE: TDYGILQINSRW*# ...# >MUS2104D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive/HPLC/Edman sequencing# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_CHICK,LYC_PHACO,LYC_MELGA,LYC_LOPLE,# & LYC_ORTVE,LYC_CHICK,LYC1_ANAPL,LYC_PHAVE,LYC_PAVCR,# & LYC_SYRRE)# & PIR1: (LZTK,LZQJE,LZOVE,LZCH,LZDK)# & PIR2: (JU0178,JT0526,JQ1033,JQ1041,JU0237,JC2144)# REFERENCES: barber93a,vignali94a,nelson92a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DYGILQINSRWW*# SEQUENCE: DYGILQINSRWW*# ...# >MUS2104E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC1_ANAPL,LYC_SYRRE,LYC1_TACAC,LYC_CHRAM,LYC_CHICK,# & LYC_LOPLE,LYC_ORTVE,LYC_CHICK,LYC_PAVCR,LYC_PHAVE,# & LYC_PHACO,LYC_MELGA)# & PIR1: (LZCH,LZDK,LZFER,LZQJE,LZOVE,LZTK)# & PIR2: (JU0237,JQ1041,JH0211,JH0212,JT0526,JC2144,A45660,JU0178,# & JQ1033,A61281)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,GSTDYGILQINSR*# SEQUENCE: GSTDYGILQINSR*# ...# >MUS2104F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_ORTVE,LYC_CHRAM,LYC_CHICK,LYC_PAVCR,LYC_PHAVE,# & LYC_MELGA,LYC_SYRRE,LYC_PHACO,LYC_CHICK,LYC_LOPLE,# & LYC1_ANAPL)# & PIR1: (LZOVE,LZDK,LZQJE,LZCH,LZTK)# & PIR2: (JU0237,JQ1041,JT0526,JQ1033,JU0178,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,STDYGILQINSRW*# SEQUENCE: STDYGILQINSRW*# ...# >MUS21050# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_PHAVE,LYC_ORTVE,LYC_PAVCR,# & LYC_PHACO,LYC_MELGA,LYC_CHRAM,LYC_LOPLE,LYC1_ANAPL,# & LYC_SYRRE)# & PIR1: (LZOVE,LZDK,LZTK,LZCH,LZQJE)# & PIR2: (JQ1033,JQ1041,JU0237,JT0526,JC2144,JU0178)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDYGILQINSRWW*# SEQUENCE: TDYGILQINSRWW*# ...# >MUS21051# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive/elution# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-64) homologue# DB REFERENCE: SWISS: (LYC1_ANAPL,LYC_CHICK,LYC_PHAVE,LYC_PAVCR,LYC_PHACO,# & LYC_MELGA,LYC_CHRAM,LYC_ORTVE,LYC_LOPLE,LYC_SYRRE,# & LYC_CHICK)# & PIR1: (LZOVE,LZQJE,LZTK,LZCH,LZDK)# & PIR2: (JU0178,JC2144,JT0526,JU0237,JQ1041,JQ1033)# REFERENCES: vignali94a,nelson96b# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DYGILQINSRWWC*# SEQUENCE: DYGILQINSRWWC*# ...# >MUS21052# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive/HPLC/Edman sequencing/elution# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (48-61) homologue# DB REFERENCE: SWISS: (LYC_CHRAM,LYC1_ANAPL,LYC1_TACAC,LYC_PHAVE,LYC_MELGA,# & LYC_PAVCR,LYC_CHICK,LYC_CHICK,LYC_SYRRE,LYC_LOPLE,# & LYC_PHACO)# & PIR1: (LZQJE,LZCH,LZTK,LZFER,LZDK)# & PIR2: (JQ1033,JU0178,JC2144,JT0526,JU0237,JQ1041,A61281,JH0212,# & JH0211,A45660)# REFERENCES: barber93a,vignali94a,nelson92a,nelson96b,nelson96c# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DGSTDYGILQINSR*# SEQUENCE: DGSTDYGILQINSR*# ...# >MUS21053# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_ORTVE,LYC_SYRRE,LYC_PAVCR,LYC_MELGA,LYC1_ANAPL,# & LYC_CHICK,LYC_CHICK,LYC_LOPLE,LYC_CHRAM,LYC_PHACO,# & LYC_PHAVE)# & PIR1: (LZTK,LZQJE,LZDK,LZOVE,LZCH)# & PIR2: (JC2144,JU0178,JQ1041,JT0526,JQ1033,JU0237)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,GSTDYGILQINSRW*# SEQUENCE: GSTDYGILQINSRW*# ...# >MUS21054# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHRAM,LYC_SYRRE,LYC_PAVCR,LYC_CHICK,# & LYC_LOPLE,LYC1_ANAPL,LYC_MELGA,LYC_PHACO,LYC_PHAVE,# & LYC_ORTVE)# & PIR1: (LZTK,LZOVE,LZDK,LZQJE,LZCH)# & PIR2: (JQ1033,JT0526,JC2144,JU0178,JQ1041,JU0237)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,STDYGILQINSRWW*# SEQUENCE: STDYGILQINSRWW*# ...# >MUS21055# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_MELGA,LYC1_ANAPL,LYC_CHICK,LYC_CHRAM,LYC_CHICK,# & LYC_LOPLE,LYC_PAVCR,LYC_SYRRE,LYC_PHACO,LYC_PHAVE,# & LYC_ORTVE)# & PIR1: (LZTK,LZDK,LZQJE,LZOVE,LZCH)# & PIR2: (JU0237,JC2144,JU0178,JQ1033,JT0526,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDYGILQINSRWWC*# SEQUENCE: TDYGILQINSRWWC*# ...# >MUS21056# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_ORTVE,LYC_MELGA,LYC_CHRAM,LYC_PHACO,LYC_CHICK,# & LYC_LOPLE,LYC_PAVCR,LYC_SYRRE,LYC_PHAVE,LYC_CHICK)# & PIR1: (LZTK,LZOVE,LZQJE,LZCH)# & PIR2: (JQ1041,JU0178,JC2144,JU0237,JQ1033,JT0526)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DYGILQINSRWWCN*# SEQUENCE: DYGILQINSRWWCN*# ...# >MUS21057# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_PHACO,LYC_CHICK,LYC_CHRAM,LYC_LOPLE,# & LYC1_ANAPL,LYC_PAVCR,LYC_PHAVE,LYC_CHICK,LYC1_TACAC,# & LYC_MELGA)# & PIR1: (LZTK,LZCH,LZDK,LZFER,LZQJE)# & PIR2: (JH0212,JH0211,A45660,JT0526,JQ1033,A61281,JU0178,JC2144,# & JQ1041,JU0237)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDGSTDYGILQINSR*# SEQUENCE: TDGSTDYGILQINSR*# ...# >MUS21058# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_MELGA,LYC_PAVCR,LYC_SYRRE,LYC1_ANAPL,# & LYC_LOPLE,LYC_CHICK,LYC_CHRAM,LYC_PHACO,LYC_ORTVE,# & LYC_CHICK)# & PIR1: (LZDK,LZTK,LZCH,LZOVE,LZQJE)# & PIR2: (JU0178,JC2144,JT0526,JU0237,JQ1033,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,GSTDYGILQINSRWW*# SEQUENCE: GSTDYGILQINSRWW*# ...# >MUS21059# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_MELGA,LYC_CHICK,LYC_SYRRE,LYC_ORTVE,# & LYC1_ANAPL,LYC_CHICK,LYC_PHACO,LYC_CHRAM,LYC_LOPLE,# & LYC_PAVCR)# & PIR1: (LZDK,LZCH,LZOVE,LZQJE,LZTK)# & PIR2: (JU0237,JQ1041,JC2144,JQ1033,JT0526,JU0178)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,STDYGILQINSRWWC*# SEQUENCE: STDYGILQINSRWWC*# ...# >MUS2105A# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_CHICK,LYC_MELGA,LYC_SYRRE,LYC_ORTVE,# & LYC_CHICK,LYC_PHACO,LYC_CHRAM,LYC_PHAVE,LYC_LOPLE)# & PIR1: (LZQJE,LZOVE,LZTK,LZCH)# & PIR2: (JC2144,JQ1033,JT0526,JU0237,JQ1041,JU0178)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDYGILQINSRWWCN*# SEQUENCE: TDYGILQINSRWWCN*# ...# >MUS2105B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_MELGA,LYC_ORTVE,LYC_CHRAM,LYC_PHAVE,# & LYC_PAVCR,LYC_CHICK,LYC_CHICK,LYC_SYRRE,LYC_PHACO)# & PIR1: (LZQJE,LZCH,LZTK,LZOVE)# & PIR2: (JU0178,JQ1033,JU0237,JQ1041,JT0526,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DYGILQINSRWWCND*# SEQUENCE: DYGILQINSRWWCND*# ...# >MUS2105C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_MELGA,LYC_CHRAM,LYC_PHAVE,LYC_PAVCR,# & LYC_LOPLE,LYC1_ANAPL,LYC_CHICK,LYC_CHICK,LYC_PHACO)# & PIR1: (LZQJE,LZDK,LZTK,LZCH)# & PIR2: (JC2144,JU0178,JQ1033,JU0237,JT0526,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDGSTDYGILQINSRW*# SEQUENCE: TDGSTDYGILQINSRW*# ...# >MUS2105D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive/elution# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_SYRRE,LYC_MELGA,LYC_PHAVE,LYC_PAVCR,# & LYC_LOPLE,LYC_CHICK,LYC1_ANAPL,LYC_CHRAM,LYC_PHACO)# & PIR1: (LZQJE,LZCH,LZDK,LZTK)# & PIR2: (JU0237,JQ1041,JT0526,JC2144,JQ1033,JU0178)# REFERENCES: vignali94a,nelson96b# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DGSTDYGILQINSRWW*# SEQUENCE: DGSTDYGILQINSRWW*# ...# >MUS2105E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_MELGA,LYC_SYRRE,LYC_CHICK,LYC_ORTVE,# & LYC_PAVCR,LYC_LOPLE,LYC_CHICK,LYC_CHRAM,LYC_PHACO)# & PIR1: (LZQJE,LZTK,LZCH,LZOVE)# & PIR2: (JU0237,JT0526,JQ1041,JQ1033,JU0178,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,STDYGILQINSRWWCN*# SEQUENCE: STDYGILQINSRWWCN*# ...# >MUS2105F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive/competitive binding as./proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_ORTVE,LYC_CHRAM,LYC_SYRRE,LYC_CHICK,LYC_CHICK,# & LYC_PHACO,LYC_MELGA,LYC_PHAVE,LYC_PAVCR,LYC_LOPLE)# & PIR1: (LZCH,LZOVE,LZQJE,LZTK)# & PIR2: (JU0178,JQ1033,JC2144,JU0237,JT0526,JQ1041)# REFERENCES: vignali94a,bauer95a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDYGILQINSRWWCND*# SEQUENCE: TDYGILQINSRWWCND*# ...# >MUS21060# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_MELGA,LYC_CHRAM,LYC_PHACO,LYC_SYRRE,LYC_CHICK,# & LYC_ORTVE,LYC_CHICK,LYC_LOPLE,LYC_PAVCR,LYC_PHAVE)# & PIR1: (LZTK,LZCH,LZOVE,LZQJE)# & PIR2: (JC2144,JT0526,JU0237,JQ1041,JU0178,JQ1033)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DYGILQINSRWWCNDG*# SEQUENCE: DYGILQINSRWWCNDG*# ...# >MUS21061# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_MELGA,LYC_PHACO,LYC_PHAVE,LYC_SYRRE,LYC_CHICK,# & LYC_CHRAM,LYC_PAVCR,LYC_LOPLE,LYC_CHICK,LYC1_ANAPL)# & PIR1: (LZQJE,LZDK,LZCH,LZTK)# & PIR2: (JC2144,JQ1041,JU0178,JT0526,JU0237,JQ1033)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,RNTDGSTDYGILQINSR*# SEQUENCE: RNTDGSTDYGILQINSR*# ...# >MUS21062# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PAVCR,LYC1_ANAPL,LYC_PHAVE,LYC_CHRAM,LYC_LOPLE,# & LYC_PHACO,LYC_MELGA,LYC_CHICK,LYC_SYRRE,LYC_CHICK)# & PIR1: (LZCH,LZTK,LZQJE,LZDK)# & PIR2: (JQ1041,JC2144,JU0178,JQ1033,JT0526,JU0237)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,NTDGSTDYGILQINSRW*# SEQUENCE: NTDGSTDYGILQINSRW*# ...# >MUS21063# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_MELGA,LYC_PHAVE,LYC_PHACO,LYC_CHICK,# & LYC_SYRRE,LYC_PAVCR,LYC1_ANAPL,LYC_LOPLE,LYC_CHICK)# & PIR1: (LZDK,LZCH,LZTK,LZQJE)# & PIR2: (JT0526,JU0178,JC2144,JQ1041,JQ1033,JU0237)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDGSTDYGILQINSRWW*# SEQUENCE: TDGSTDYGILQINSRWW*# ...# >MUS21064# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_SYRRE,LYC_CHRAM,LYC_MELGA,LYC1_ANAPL,# & LYC_PHACO,LYC_CHICK,LYC_PHAVE,LYC_LOPLE,LYC_PAVCR)# & PIR1: (LZDK,LZTK,LZQJE,LZCH)# & PIR2: (JT0526,JQ1033,JU0237,JC2144,JU0178,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DGSTDYGILQINSRWWC*# SEQUENCE: DGSTDYGILQINSRWWC*# ...# >MUS21065# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_ORTVE,LYC_PHACO,LYC_PAVCR,LYC_CHRAM,# & LYC_PHAVE,LYC_MELGA,LYC_LOPLE,LYC_CHICK,LYC_SYRRE)# & PIR1: (LZOVE,LZQJE,LZCH,LZTK)# & PIR2: (JU0178,JC2144,JT0526,JQ1033,JU0237,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,GSTDYGILQINSRWWCN*# SEQUENCE: GSTDYGILQINSRWWCN*# ...# >MUS21066# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_ORTVE,LYC_CHICK,LYC_PAVCR,LYC_PHACO,LYC_CHRAM,# & LYC_LOPLE,LYC_MELGA,LYC_CHICK,LYC_PHAVE,LYC_SYRRE)# & PIR1: (LZOVE,LZCH,LZTK,LZQJE)# & PIR2: (JQ1041,JT0526,JQ1033,JU0237,JC2144,JU0178)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,STDYGILQINSRWWCND*# SEQUENCE: STDYGILQINSRWWCND*# ...# >MUS21067# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_CHICK,LYC_MELGA,LYC_PAVCR,LYC_CHICK,# & LYC_PHAVE,LYC_SYRRE,LYC_PHACO,LYC_LOPLE,LYC_ORTVE)# & PIR1: (LZCH,LZQJE,LZTK,LZOVE)# & PIR2: (JU0178,JC2144,JQ1041,JQ1033,JU0237,JT0526)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDYGILQINSRWWCNDG*# SEQUENCE: TDYGILQINSRWWCNDG*# ...# >MUS21068# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DYGILQINSRWWCNDGA*# SEQUENCE: DYGILQINSRWWCNDGA*# ...# >MUS21069# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PHAVE,LYC1_ANAPL,LYC_MELGA,LYC_CHICK,LYC_PAVCR,# & LYC_SYRRE,LYC_CHICK,LYC_CHRAM,LYC_PHACO,LYC_LOPLE)# & PIR1: (LZQJE,LZTK,LZCH,LZDK)# & PIR2: (JU0237,JQ1033,JT0526,JU0178,JC2144,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,NRNTDGSTDYGILQINSR*# SEQUENCE: NRNTDGSTDYGILQINSR*# ...# >MUS2106A# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_PAVCR,LYC1_ANAPL,LYC_PHACO,LYC_CHICK,# & LYC_SYRRE,LYC_CHRAM,LYC_PHAVE,LYC_MELGA,LYC_LOPLE)# & PIR1: (LZCH,LZTK,LZQJE,LZDK)# & PIR2: (JT0526,JU0237,JU0178,JC2144,JQ1041,JQ1033)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,RNTDGSTDYGILQINSRW*# SEQUENCE: RNTDGSTDYGILQINSRW*# ...# >MUS2106B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_MELGA,LYC_CHRAM,LYC_PAVCR,LYC1_ANAPL,# & LYC_PHACO,LYC_CHICK,LYC_SYRRE,LYC_LOPLE,LYC_PHAVE)# & PIR1: (LZTK,LZQJE,LZDK,LZCH)# & PIR2: (JQ1033,JT0526,JU0237,JQ1041,JU0178,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,NTDGSTDYGILQINSRWW*# SEQUENCE: NTDGSTDYGILQINSRWW*# ...# >MUS2106C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_MELGA,LYC_PHAVE,LYC_PAVCR,LYC_PHACO,# & LYC1_ANAPL,LYC_SYRRE,LYC_CHICK,LYC_LOPLE,LYC_CHICK)# & PIR1: (LZDK,LZCH,LZTK,LZQJE)# & PIR2: (JU0178,JU0237,JT0526,JC2144,JQ1033,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDGSTDYGILQINSRWWC*# SEQUENCE: TDGSTDYGILQINSRWWC*# ...# >MUS2106D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHRAM,LYC_MELGA,LYC_PHAVE,LYC_PAVCR,# & LYC_LOPLE,LYC_SYRRE,LYC_PHACO,LYC_CHICK)# & PIR1: (LZTK,LZQJE,LZCH)# & PIR2: (JU0237,JT0526,JQ1041,JQ1033,JU0178,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DGSTDYGILQINSRWWCN*# SEQUENCE: DGSTDYGILQINSRWWCN*# ...# >MUS2106E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_ORTVE,LYC_CHICK,LYC_SYRRE,LYC_PAVCR,LYC_CHRAM,# & LYC_PHACO,LYC_LOPLE,LYC_PHAVE,LYC_CHICK,LYC_MELGA)# & PIR1: (LZTK,LZQJE,LZOVE,LZCH)# & PIR2: (JU0178,JQ1033,JU0237,JT0526,JQ1041,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,GSTDYGILQINSRWWCND*# SEQUENCE: GSTDYGILQINSRWWCND*# ...# >MUS2106F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_PAVCR,LYC_CHRAM,LYC_PHACO,LYC_ORTVE,# & LYC_CHICK,LYC_PHAVE,LYC_SYRRE,LYC_CHICK,LYC_MELGA)# & PIR1: (LZQJE,LZCH,LZOVE,LZTK)# & PIR2: (JU0178,JT0526,JQ1041,JC2144,JU0237,JQ1033)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,STDYGILQINSRWWCNDG*# SEQUENCE: STDYGILQINSRWWCNDG*# ...# >MUS21070# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_SYRRE,LYC_PHACO,LYC_ORTVE,LYC_PHAVE,# & LYC_CHRAM,LYC_CHICK,LYC_MELGA,LYC_CHICK)# & PIR1: (LZCH,LZOVE,LZTK,LZQJE)# & PIR2: (JU0178,JT0526,JQ1041,JC2144,JU0237)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDYGILQINSRWWCNDGR*# SEQUENCE: TDYGILQINSRWWCNDGR*# ...# >MUS21071# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_PHACO,LYC_CHICK,LYC_PAVCR,LYC_SYRRE,# & LYC_MELGA,LYC_CHICK,LYC_PHAVE,LYC_ORTVE)# & PIR1: (LZTK,LZCH,LZQJE,LZOVE)# & PIR2: (JU0237,JU0178,JT0526,JC2144,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DYGILQINSRWWCNDGRT*# SEQUENCE: DYGILQINSRWWCNDGRT*# ...# >MUS21072# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_MELGA,LYC_CHICK,LYC_CHICK,LYC_CHRAM,LYC_LOPLE,# & LYC_PAVCR,LYC_PHACO,LYC_PHAVE,LYC1_ANAPL,LYC_SYRRE)# & PIR1: (LZDK,LZTK,LZQJE,LZCH)# & PIR2: (JC2144,JU0178,JT0526,JQ1033,JU0237,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TNRNTDGSTDYGILQINSR*# SEQUENCE: TNRNTDGSTDYGILQINSR*# ...# >MUS21073# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC1_ANAPL,LYC_SYRRE,LYC_PHAVE,LYC_PHACO,LYC_CHICK,# & LYC_LOPLE,LYC_CHRAM,LYC_PAVCR,LYC_MELGA,LYC_CHICK)# & PIR1: (LZDK,LZQJE,LZCH,LZTK)# & PIR2: (JU0237,JQ1033,JQ1041,JT0526,JU0178,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,NRNTDGSTDYGILQINSRW*# SEQUENCE: NRNTDGSTDYGILQINSRW*# ...# >MUS21074# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPLE,LYC_CHICK,LYC_PHACO,LYC1_ANAPL,# & LYC_MELGA,LYC_SYRRE,LYC_CHRAM,LYC_PHAVE,LYC_PAVCR)# & PIR1: (LZTK,LZDK,LZQJE,LZCH)# & PIR2: (JU0178,JT0526,JQ1033,JU0237,JC2144,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,RNTDGSTDYGILQINSRWW*# SEQUENCE: RNTDGSTDYGILQINSRWW*# ...# >MUS21075# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_PHAVE,LYC_CHICK,LYC1_ANAPL,LYC_MELGA,# & LYC_PAVCR,LYC_SYRRE,LYC_LOPLE,LYC_CHICK,LYC_PHACO)# & PIR1: (LZTK,LZCH,LZDK,LZQJE)# & PIR2: (JC2144,JQ1033,JU0178,JU0237,JT0526,JQ1041)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,NTDGSTDYGILQINSRWWC*# SEQUENCE: NTDGSTDYGILQINSRWWC*# ...# >MUS21076# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_PHACO,LYC_PAVCR,LYC_MELGA,LYC_CHRAM,# & LYC_CHICK,LYC_LOPLE,LYC_PHAVE,LYC_CHICK)# & PIR1: (LZCH,LZQJE,LZTK)# & PIR2: (JQ1033,JU0178,JU0237,JQ1041,JT0526,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDGSTDYGILQINSRWWCN*# SEQUENCE: TDGSTDYGILQINSRWWCN*# ...# >MUS21077# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_CHICK,LYC_PHAVE,LYC_CHICK,LYC_CHRAM,# & LYC_MELGA,LYC_SYRRE,LYC_PHACO,LYC_PAVCR)# & PIR1: (LZQJE,LZCH,LZTK)# & PIR2: (JT0526,JQ1041,JU0237,JQ1033,JU0178,JC2144)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DGSTDYGILQINSRWWCND*# SEQUENCE: DGSTDYGILQINSRWWCND*# ...# >MUS21078# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_ORTVE,LYC_PAVCR,LYC_PHAVE,LYC_CHICK,LYC_SYRRE,# & LYC_CHICK,LYC_CHRAM,LYC_PHACO,LYC_MELGA,LYC_LOPLE)# & PIR1: (LZOVE,LZTK,LZCH,LZQJE)# & PIR2: (JC2144,JQ1041,JT0526,JQ1033,JU0237,JU0178)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,GSTDYGILQINSRWWCNDG*# SEQUENCE: GSTDYGILQINSRWWCNDG*# ...# >MUS21079# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_PHACO,LYC_ORTVE,LYC_MELGA,LYC_CHICK,# & LYC_CHRAM,LYC_CHICK,LYC_PHAVE,LYC_SYRRE)# & PIR1: (LZCH,LZQJE,LZTK,LZOVE)# & PIR2: (JC2144,JU0237,JU0178,JQ1041,JT0526)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,STDYGILQINSRWWCNDGR*# SEQUENCE: STDYGILQINSRWWCNDGR*# ...# >MUS2107A# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHRAM,LYC_PHAVE,LYC_CHICK,LYC_MELGA,# & LYC_PHACO,LYC_PAVCR,LYC_ORTVE,LYC_SYRRE)# & PIR1: (LZOVE,LZCH,LZQJE,LZTK)# & PIR2: (JU0178,JC2144,JU0237,JQ1041,JT0526)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,TDYGILQINSRWWCNDGRT*# SEQUENCE: TDYGILQINSRWWCNDGRT*# ...# >MUS2107B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: hen egg lysozyme HEL (52-61) homologue# DB REFERENCE: SWISS: (LYC_PHACO,LYC_ORTVE,LYC_CHICK,LYC_SYRRE,LYC_CHICK,# & LYC_PHAVE,LYC_CHRAM,LYC_MELGA,LYC_PAVCR)# & PIR1: (LZOVE,LZCH,LZTK,LZQJE)# & PIR2: (JU0178,JQ1041,JT0526,JC2144,JU0237)# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,DYGILQINSRWWCNDGRTP*# SEQUENCE: DYGILQINSRWWCNDGRTP*# ...# >MUS2107C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRWWA*# SEQUENCE: DGSTDYGILQINSRWWA*# ...# >MUS2107D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRWWAA*# SEQUENCE: DGSTDYGILQINSRWWAA*# ...# >MUS2107E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRA*# SEQUENCE: DGSTDYGILQINSRA*# ...# >MUS2107F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRAA*# SEQUENCE: DGSTDYGILQINSRAA*# ...# >MUS21080# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRWA*# SEQUENCE: DGSTDYGILQINSRWA*# ...# >MUS21081# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRAW*# SEQUENCE: DGSTDYGILQINSRAW*# ...# >MUS21082# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRF*# SEQUENCE: DGSTDYGILQINSRF*# ...# >MUS21083# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRFF*# SEQUENCE: DGSTDYGILQINSRFF*# ...# >MUS21084# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRWF*# SEQUENCE: DGSTDYGILQINSRWF*# ...# >MUS21085# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRFW*# SEQUENCE: DGSTDYGILQINSRFW*# ...# >MUS21086# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRFA*# SEQUENCE: DGSTDYGILQINSRFA*# ...# >MUS21087# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRAF*# SEQUENCE: DGSTDYGILQINSRAF*# ...# >MUS21088# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, little# SOURCE: hen egg lysozyme HEL (48-61) homologue# ANCHOR POSITIONS:# REFERENCES: vignali94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTDYGILQINSRQQ*# SEQUENCE: DGSTDYGILQINSRQQ*# ...# >HUM11089# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,FLRGRAYGID*# SEQUENCE: FLRGRAYGID*# ...# >HUM1108A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGFLRGRAYGI*# SEQUENCE: AGFLRGRAYGI*# ...# >HUM1108B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,FLRGRAYGIDL*# SEQUENCE: FLRGRAYGIDL*# ...# >HUM1108C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,NAGFLRGRAYGI*# SEQUENCE: NAGFLRGRAYGI*# ...# >HUM1108D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,FLRGRAYGIDLL*# SEQUENCE: FLRGRAYGIDLL*# ...# >HUM1108E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,MLRGRAYGL*# SEQUENCE: MLRGRAYGL*# ...# >HUM1108F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,YLRGRAYGL*# SEQUENCE: YLRGRAYGL*# ...# >HUM11090# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,FIRGRAYGL*# SEQUENCE: FIRGRAYGL*# ...# >HUM11091# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,FVRGRAYGL*# SEQUENCE: FVRGRAYGL*# ...# >HUM11092# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,FLRGRAYAL*# SEQUENCE: FLRGRAYAL*# ...# >HUM11093# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,FLRGRAYSL*# SEQUENCE: FLRGRAYSL*# ...# >HUM11094# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,ELRGRAYGL*# SEQUENCE: ELRGRAYGL*# ...# >HUM11095# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,HLRGRAYGL*# SEQUENCE: HLRGRAYGL*# ...# >HUM11096# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,HIRGRAYSL*# SEQUENCE: HIRGRAYSL*# ...# >HUM11097# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGALRGRAYGL*# SEQUENCE: AGALRGRAYGL*# ...# >HUM11098# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGCLRGRAYGL*# SEQUENCE: AGCLRGRAYGL*# ...# >HUM11099# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGDLRGRAYGL*# SEQUENCE: AGDLRGRAYGL*# ...# >HUM1109A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGELRGRAYGL*# SEQUENCE: AGELRGRAYGL*# ...# >HUM1109B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# DB REFERENCE: PIR2: (D49253,E49253)# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGFLRGRAYGL*# SEQUENCE: AGFLRGRAYGL*# ...# >HUM1109C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGGLRGRAYGL*# SEQUENCE: AGGLRGRAYGL*# ...# >HUM1109D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGHLRGRAYGL*# SEQUENCE: AGHLRGRAYGL*# ...# >HUM1109E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGILRGRAYGL*# SEQUENCE: AGILRGRAYGL*# ...# >HUM1109F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGKLRGRAYGL*# SEQUENCE: AGKLRGRAYGL*# ...# >HUM110A0# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGLLRGRAYGL*# SEQUENCE: AGLLRGRAYGL*# ...# >HUM110A1# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGMLRGRAYGL*# SEQUENCE: AGMLRGRAYGL*# ...# >HUM110A2# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGNLRGRAYGL*# SEQUENCE: AGNLRGRAYGL*# ...# >HUM110A3# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGPLRGRAYGL*# SEQUENCE: AGPLRGRAYGL*# ...# >HUM110A4# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGQLRGRAYGL*# SEQUENCE: AGQLRGRAYGL*# ...# >HUM110A5# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGRLRGRAYGL*# SEQUENCE: AGRLRGRAYGL*# ...# >HUM110A6# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGSLRGRAYGL*# SEQUENCE: AGSLRGRAYGL*# ...# >HUM110A7# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGTLRGRAYGL*# SEQUENCE: AGTLRGRAYGL*# ...# >HUM110A8# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGVLRGRAYGL*# SEQUENCE: AGVLRGRAYGL*# ...# >HUM110A9# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGWLRGRAYGL*# SEQUENCE: AGWLRGRAYGL*# ...# >HUM110AA# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3 EBV# ANCHOR POSITIONS:# REFERENCES: burrows92a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,AGYLRGRAYGL*# SEQUENCE: AGYLRGRAYGL*# ...# >HUM210AB# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Elution and Sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC Invariant Chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: barber93a,riberdy92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,LPKPPKPVSKMRMATPL*# SEQUENCE: LPKPPKPVSKMRMATPL*# ...# >HUM210AC# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Elution and Sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC Invariant Chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: riberdy92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,PKPPKPVSKMRMATPL*# SEQUENCE: PKPPKPVSKMRMATPL*# ...# >HUM210AD# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Elution and Sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC Invariant Chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: riberdy92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQA*# SEQUENCE: PKPPKPVSKMRMATPLLMQA*# ...# >HUM210AE# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Elution and Sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC Invariant Chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: riberdy92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,KPPKPVSKMRMATPLLMQ*# SEQUENCE: KPPKPVSKMRMATPLLMQ*# ...# >HUM110AF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Influenza A virus matrix M.55-71# DB REFERENCE: SWISS: (VMT1_IAANN,VMT1_IALE1,VMT1_IALE2,VMT1_IAMAN,VMT1_IABAN,# & VMT1_IAFOW,VMT1_IAUDO,VMT1_IAWIL,VMT1_IAUSS,VMT1_IAPUE,# & VMT1_IACKB)# & PIR1: (MFIVC,MFIV61,MFIV,MFIV1K,MFIVWS,MFIV1M,JN0392)# & PIR2: (S04056,S14616,S04054,S07429,S04050,S04058,S04052)# REFERENCES: bouillot89a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,LTKGILGFVFTLTVPSE*# SEQUENCE: LTKGILGFVFTLTVPSE*# ...# >HUM110B0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Influenza A virus matrix (56-68)# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IALE1,VMT1_IAUDO,VMT1_IAPUE,VMT1_IAWIL,# & VMT1_IAFOW,VMT1_IALE2,VMT1_IAANN,VMT1_IAUSS,VMT1_IAZI1,# & VMT1_IAMAN,VMT1_IABAN)# & PIR1: (MFIV1M,MFIV61,MFIV,MFIV1K,JN0392,MFIVWS,MFIVC)# & PIR2: (S04056,S04058,S04054,S14616,S04050,S07429,S04052)# REFERENCES: bouillot89a,connan94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,TKGILGFVFTLTV*# SEQUENCE: TKGILGFVFTLTV*# ...# >HUM110B1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Influenza A virus matrix M.Y+57-68# ANCHOR POSITIONS:# REFERENCES: choppin90a,bouillot89a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,YKGILGFVFTLTV*# SEQUENCE: YKGILGFVFTLTV*# ...# >HUM110B2# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A virus matrix M.55-71# DB REFERENCE: SWISS: (VMT1_IAUSS,VMT1_IAWIL,VMT1_IALE1,VMT1_IAMAN,VMT1_IABAN,# & VMT1_IAANN,VMT1_IALE2,VMT1_IAFOW,VMT1_IAPUE,VMT1_IACKB,# & VMT1_IAUDO)# & PIR1: (MFIV1K,JN0392,MFIVC,MFIV,MFIV1M,MFIV61,MFIVWS)# & PIR2: (S04052,S04050,S04054,S04056,S04058,S14616,S07429)# REFERENCES: bouillot89a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,LTKGILGFVFTLTVPSE*# SEQUENCE: LTKGILGFVFTLTVPSE*# ...# >HUM110B3# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A virus matrix M.56-68# DB REFERENCE: SWISS: (VMT1_IAANN,VMT1_IALE1,VMT1_IAZI1,VMT1_IAPUE,VMT1_IAUSS,# & VMT1_IAFOW,VMT1_IACKB,VMT1_IAUDO,VMT1_IAWIL,VMT1_IALE2,# & VMT1_IAMAN,VMT1_IABAN)# & PIR1: (MFIV1M,MFIV61,MFIV1K,JN0392,MFIVWS,MFIVC,MFIV)# & PIR2: (S04052,S04056,S04058,S07429,S14616,S04054,S04050)# REFERENCES: bouillot89a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,TKGILGFVFTLTV*# SEQUENCE: TKGILGFVFTLTV*# ...# >HUM110B4# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A virus matrix M.55-71# DB REFERENCE: SWISS: (VMT1_IAMAN,VMT1_IAWIL,VMT1_IABAN,VMT1_IAUDO,VMT1_IACKB,# & VMT1_IALE1,VMT1_IAPUE,VMT1_IAUSS,VMT1_IALE2,VMT1_IAANN,# & VMT1_IAFOW)# & PIR1: (MFIVWS,MFIVC,MFIV1M,JN0392,MFIV,MFIV61,MFIV1K)# & PIR2: (S04056,S04058,S04052,S04054,S07429,S04050,S14616)# REFERENCES: bouillot89a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesl,LTKGILGFVFTLTVPSE*# SEQUENCE: LTKGILGFVFTLTVPSE*# ...# >HUM110B5# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza A virus matrix M.56-68# DB REFERENCE: SWISS: (VMT1_IALE1,VMT1_IAUSS,VMT1_IAFOW,VMT1_IAUDO,VMT1_IAZI1,# & VMT1_IABAN,VMT1_IACKB,VMT1_IAANN,VMT1_IAMAN,VMT1_IAWIL,# & VMT1_IAPUE,VMT1_IALE2)# & PIR1: (MFIVWS,MFIV61,MFIV1K,MFIV,MFIVC,MFIV1M,JN0392)# & PIR2: (S04056,S04054,S04050,S04058,S04052,S14616,S07429)# REFERENCES: bouillot89a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesl,TKGILGFVFTLTV*# SEQUENCE: TKGILGFVFTLTV*# ...# >HUM110B6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Binding-Direct/solid-phase binding as./Reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 Gag G.265-279C+# ANCHOR POSITIONS:# REFERENCES: bouillot89a,frelinger90a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,KRWIILGLNKIVRMYC*# SEQUENCE: KRWIILGLNKIVRMYC*# ...# >HUM110B7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Binding-Direct/solid-phase binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV-1 Gag G.265-279C+# ANCHOR POSITIONS:# REFERENCES: bouillot89a,frelinger90a,buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesh,KRWIILGLNKIVRMYC*# SEQUENCE: KRWIILGLNKIVRMYC*# ...# >HUM110B8# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: Binding-Direct/Reference# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 Gag G.265-279C+# ANCHOR POSITIONS:# REFERENCES: bouillot89a,hivdb97a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesm,KRWIILGLNKIVRMYC*# SEQUENCE: KRWIILGLNKIVRMYC*# ...# >HUM110B9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Vpr R.68-80# DB REFERENCE: SWISS: (VPR_HV1MN,VPR_HV1JR,VPR_HV1N5,VPR_HV1BR,VPR_HV1SC)# REFERENCES: bouillot89a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,LFIHFRIGCRHSR*# SEQUENCE: LFIHFRIGCRHSR*# ...# >HUM110BA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: anderson93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GILGKVFTLTV*# SEQUENCE: GILGKVFTLTV*# ...# >HUM110BB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: PIR3: (S36679)# REFERENCES: anderson93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,VLFRGGPRGLLAV*# SEQUENCE: VLFRGGPRGLLAV*# ...# >HUM210BC# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ld pI rye grass# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (A37881,B37881)# & PIR3: (S13614)# REFERENCES: bungy_poor_fard93a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,WGAVWRIDTPDKLT*# SEQUENCE: WGAVWRIDTPDKLT*# ...# >MUS210BD# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP# DB REFERENCE: SWISS: (MBP_MOUSE)# & PIR1: (MBMSB)# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,ASQKRPSQRSK*# SEQUENCE: ASQKRPSQRSK*# ...# >MUS210BE# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRSKILDSIGRFFS*# SEQUENCE: SQRSKILDSIGRFFS*# ...# >MUS210BF# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRSKILDSIGRFFSGDR*# SEQUENCE: SQRSKILDSIGRFFSGDR*# ...# >MUS210C0# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRSKILDSIGRFF*# SEQUENCE: SQRSKILDSIGRFF*# ...# >MUS210C1# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SARSKILDSIGRFF*# SEQUENCE: SARSKILDSIGRFF*# ...# >MUS210C2# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQESKILDSIGRFF*# SEQUENCE: SQESKILDSIGRFF*# ...# >MUS210C3# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRKKILDSIGRFF*# SEQUENCE: SQRKKILDSIGRFF*# ...# >MUS210C4# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRSLILDSIGRFF*# SEQUENCE: SQRSLILDSIGRFF*# ...# >MUS210C5# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRSKYLDSIGRFF*# SEQUENCE: SQRSKYLDSIGRFF*# ...# >MUS210C6# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRSKIMDSIGRFF*# SEQUENCE: SQRSKIMDSIGRFF*# ...# >MUS210C7# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRSKILPSIGRFF*# SEQUENCE: SQRSKILPSIGRFF*# ...# >MUS210C8# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,QQRSKILDSIGRFF*# SEQUENCE: QQRSKILDSIGRFF*# ...# >MUS210C9# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,RQRSKILDSIGRFF*# SEQUENCE: RQRSKILDSIGRFF*# ...# >MUS210CA# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,SQRSKILHSIGRFF*# SEQUENCE: SQRSKILHSIGRFF*# ...# >MUS210CB# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP homologue# ANCHOR POSITIONS:# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,KQRSKILDSIGRFF*# SEQUENCE: KQRSKILDSIGRFF*# ...# >MUS210CC# MHC MOLECULE: I-Eu, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (35-47)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_RAT)# & PIR1: (MBMSB,MBRTS)# REFERENCES: bhardwaj93a# COMMENT:# SUMMARY: I-Eu,actyesu,bindyesu,ILDSIGRFFSGDR*# SEQUENCE: ILDSIGRFFSGDR*# ...# >MUS110CD# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct/competition/Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1PV,ENV_HV1H3,ENV_HV1B8,ENV_HV1H2,# & ENV_HV1BR,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a,takeshita95a,hivdb97a# COMMENT:# SUMMARY: H-2Dd,actyesh,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >MUS110CE# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1B1,ENV_HV1MF,ENV_HV1PV,# & ENV_HV1H3,ENV_HV1BR)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,IQRGPGRAFVTIGK*# SEQUENCE: IQRGPGRAFVTIGK*# ...# >MUS110CF# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1H2,ENV_HV1MF,ENV_HV1H3,ENV_HV1B1,# & ENV_HV1PV,ENV_HV1BR)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,QRGPGRAFVTIGK*# SEQUENCE: QRGPGRAFVTIGK*# ...# >MUS110D0# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1B1,ENV_HV1MF,ENV_HV1B8,ENV_HV1H2,# & ENV_HV1PV,ENV_HV1BR)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S13288,S33985)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RGPGRAFVTIGK*# SEQUENCE: RGPGRAFVTIGK*# ...# >MUS110D1# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1BR,ENV_HV1PV,ENV_HV1H2,ENV_HV1H3,# & ENV_HV1MF,ENV_HV1B8)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,GPGRAFVTIGK*# SEQUENCE: GPGRAFVTIGK*# ...# >MUS110D2# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B8,ENV_HV1H2,ENV_HV1B1,ENV_HV1H3,# & ENV_HV1PV,ENV_HV1BR)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,PGRAFVTIGK*# SEQUENCE: PGRAFVTIGK*# ...# >MUS110D3# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct/Recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1PV,ENV_HV1BR,ENV_HV1H2,ENV_HV1MF,# & ENV_HV1B8,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a,takeshita95a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesl,RIQRGPGRAFVTI*# SEQUENCE: RIQRGPGRAFVTI*# ...# >MUS110D4# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1PV,ENV_HV1H3,ENV_HV1MF,ENV_HV1B1,# & ENV_HV1B8,ENV_HV1H2)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RIQRGPGRAFVTIG*# SEQUENCE: RIQRGPGRAFVTIG*# ...# >MUS110D5# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H2,ENV_HV1B8,ENV_HV1B1,ENV_HV1MF,# & ENV_HV1H3,ENV_HV1BR)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RGPGRAFVTIGKIG*# SEQUENCE: RGPGRAFVTIGKIG*# ...# >MUS110D6# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1H3,ENV_HV1B1,ENV_HV1B8,ENV_HV1MF,# & ENV_HV1PV,ENV_HV1H2)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,GPGRAFVTIGKIG*# SEQUENCE: GPGRAFVTIGKIG*# ...# >MUS110D7# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1H3,ENV_HV1PV,ENV_HV1MF,ENV_HV1B8,# & ENV_HV1BR,ENV_HV1B1)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,PGRAFVTIGKIG*# SEQUENCE: PGRAFVTIGKIG*# ...# >MUS110D8# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1H2,ENV_HV1B8,ENV_HV1B1,ENV_HV1PV,# & ENV_HV1H3,ENV_HV1BR)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RGPGRAFVTIGKI*# SEQUENCE: RGPGRAFVTIGKI*# ...# >MUS110D9# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1B8,ENV_HV1H2,ENV_HV1MF,ENV_HV1H3,# & ENV_HV1B1,ENV_HV1PV)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,GPGRAFVTIGKI*# SEQUENCE: GPGRAFVTIGKI*# ...# >MUS110DA# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1B1,ENV_HV1H3,ENV_HV1PV,# & ENV_HV1MF,ENV_HV1BR)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,PGRAFVTIGKI*# SEQUENCE: PGRAFVTIGKI*# ...# >MUS110DB# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct/competition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1B1,ENV_HV1H3,ENV_HV1PV,# & ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a,takeshita95a# COMMENT:# SUMMARY: H-2Dd,actyesl,bindyesu,RGPGRAFVTIG*# SEQUENCE: RGPGRAFVTIG*# ...# >MUS110DC# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1B8,ENV_HV1H2,ENV_HV1H3,ENV_HV1PV,# & ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,GPGRAFVTIG*# SEQUENCE: GPGRAFVTIG*# ...# >MUS110DD# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1MF,ENV_HV1PV,ENV_HV1B1,# & ENV_HV1H3,ENV_HV1BR)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,PGRAFVTIG*# SEQUENCE: PGRAFVTIG*# ...# >MUS110DE# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct/competition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1BR,ENV_HV1PV,ENV_HV1MF,ENV_HV1H2,# & ENV_HV1B8,ENV_HV1B1)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR2: (S65399)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a,takeshita95a# COMMENT:# SUMMARY: H-2Dd,actyesh,bindyesu,GPGRAFVTI*# SEQUENCE: GPGRAFVTI*# ...# >MUS110DF# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1MF,ENV_HV1H3,ENV_HV1PV,ENV_HV1H2,# & ENV_HV1B8,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR2: (S65399)# & PIR3: (S33985,S13288)# REFERENCES: bergmann93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,PGRAFVTI*# SEQUENCE: PGRAFVTI*# ...# >HUM210E0# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNKKKLAT*# SEQUENCE: PKYVKQNKKKLAT*# ...# >HUM210E1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,EKYVKQNTLKA*# SEQUENCE: EKYVKQNTLKA*# ...# >HUM210E2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,DKYVKQNTLKA*# SEQUENCE: DKYVKQNTLKA*# ...# >HUM210E3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RKYVKQNTLKA*# SEQUENCE: RKYVKQNTLKA*# ...# >HUM210E4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KKYVKQNTLKA*# SEQUENCE: KKYVKQNTLKA*# ...# >HUM210E5# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PRYVKQNTLKA*# SEQUENCE: PRYVKQNTLKA*# ...# >HUM210E6# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PFYVKQNTLKA*# SEQUENCE: PFYVKQNTLKA*# ...# >HUM210E7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PGYVKQNTLKA*# SEQUENCE: PGYVKQNTLKA*# ...# >HUM210E8# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKFVKQNTLKA*# SEQUENCE: PKFVKQNTLKA*# ...# >HUM210E9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYRKQNTLKA*# SEQUENCE: PKYRKQNTLKA*# ...# >HUM210EA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYEKQNTLKA*# SEQUENCE: PKYEKQNTLKA*# ...# >HUM210EB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYFKQNTLKA*# SEQUENCE: PKYFKQNTLKA*# ...# >HUM210EC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYQKQNTLKA*# SEQUENCE: PKYQKQNTLKA*# ...# >HUM210ED# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVEQNTLKA*# SEQUENCE: PKYVEQNTLKA*# ...# >HUM210EE# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVRQNTLKA*# SEQUENCE: PKYVRQNTLKA*# ...# >HUM210EF# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVFQNTLKA*# SEQUENCE: PKYVFQNTLKA*# ...# >HUM210F0# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVQQNTLKA*# SEQUENCE: PKYVQQNTLKA*# ...# >HUM210F1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKENTLKA*# SEQUENCE: PKYVKENTLKA*# ...# >HUM210F2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKDNTLKA*# SEQUENCE: PKYVKDNTLKA*# ...# >HUM210F3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKKNTLKA*# SEQUENCE: PKYVKKNTLKA*# ...# >HUM210F4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKRNTLKA*# SEQUENCE: PKYVKRNTLKA*# ...# >HUM210F5# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQKTLKA*# SEQUENCE: PKYVKQKTLKA*# ...# >HUM210F6# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQSTLKA*# SEQUENCE: PKYVKQSTLKA*# ...# >HUM210F7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQDTLKA*# SEQUENCE: PKYVKQDTLKA*# ...# >HUM210F8# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNELKA*# SEQUENCE: PKYVKQNELKA*# ...# >HUM210F9# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNYLKA*# SEQUENCE: PKYVKQNYLKA*# ...# >HUM210FA# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTKKA*# SEQUENCE: PKYVKQNTKKA*# ...# >HUM210FB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTSKA*# SEQUENCE: PKYVKQNTSKA*# ...# >HUM210FC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTEKA*# SEQUENCE: PKYVKQNTEKA*# ...# >HUM210FD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTLSA*# SEQUENCE: PKYVKQNTLSA*# ...# >HUM210FE# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTLIA*# SEQUENCE: PKYVKQNTLIA*# ...# >HUM210FF# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTLFA*# SEQUENCE: PKYVKQNTLFA*# ...# >HUM21100# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTLDA*# SEQUENCE: PKYVKQNTLDA*# ...# >HUM21101# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTLKE*# SEQUENCE: PKYVKQNTLKE*# ...# >HUM21102# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTLKD*# SEQUENCE: PKYVKQNTLKD*# ...# >HUM21103# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTLKK*# SEQUENCE: PKYVKQNTLKK*# ...# >HUM21104# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A Hemagglutinin homologue# ANCHOR POSITIONS:# REFERENCES: jardetzky90a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,PKYVKQNTLKR*# SEQUENCE: PKYVKQNTLKR*# ...# >MUS21105# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_RABIT,MYPR_HUMAN,# & MYPR_BOVIN)# & PIR1: (S34792,MPBOPL,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: amor93a,amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DYEYLINVIHAFQYV*# SEQUENCE: DYEYLINVIHAFQYV*# ...# >MUS21106# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: in vivo induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP 103-116# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_BOVIN,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (S34792,MPRTPL,MPHUPL,MPBOPL)# & PIR2: (A43548)# REFERENCES: amor93a# COMMENT:# SUMMARY: H-2q,actyesu,bindyesu,YKTTICGKGLSATV*# SEQUENCE: YKTTICGKGLSATV*# ...# >MUS21107# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: in vivo induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP 139-151# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_RABIT,MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA,# & MYPR_POEGU)# & PIR1: (MPHUPL,S34792,MPRTPL)# & PIR2: (A43548)# & PIR3: (I51270)# REFERENCES: amor93a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,HCLGKWLGHPDKF*# SEQUENCE: HCLGKWLGHPDKF*# ...# >MUS21108# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: in vivo induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP 1215-232# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_BOVIN,MYPR_HUMAN,MYPR_CHICK,MYPR_HUMAN,# & MYPR_POEGU,MYPR_RABIT)# & PIR1: (S34792,MPRTPL,MPBOPL,MPHUPL)# & PIR2: (A43548,S17600)# & PIR3: (I51270)# REFERENCES: amor93a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,PGKVCGSNL*# SEQUENCE: PGKVCGSNL*# ...# >HUM11109# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxic-competitive/Cytotoxic-Direct# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza A virus matrix protein homologue# ANCHOR POSITIONS:# REFERENCES: bednarek91b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,KKALGFVFTLDK*# SEQUENCE: KKALGFVFTLDK*# ...# >HUM1110A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxic-competitive/Cytotoxic-Direct# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza A virus matrix protein homologue# ANCHOR POSITIONS:# REFERENCES: bednarek91b# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,KDALGFVFTLDK*# SEQUENCE: KDALGFVFTLDK*# ...# >HUM1110B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxic-competitive/Cytotoxic-Direct# ACTIVITY: none# BINDING: yes, ?# SOURCE: Influenza A virus matrix protein homologue# ANCHOR POSITIONS:# REFERENCES: bednarek91b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,KKALGFVFKLDK*# SEQUENCE: KKALGFVFKLDK*# ...# >HUM1110C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxic-competitive/Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A virus matrix protein homologue# ANCHOR POSITIONS:# REFERENCES: bednarek91b# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,YKKALGFVFTLDK*# SEQUENCE: YKKALGFVFTLDK*# ...# >HUM1110D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxic-competitive/Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza A virus matrix protein homologue# ANCHOR POSITIONS:# REFERENCES: bednarek91b# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,YKKALGFVFKLDK*# SEQUENCE: YKKALGFVFKLDK*# ...# >MUS2110E# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: AChr Torpedo californica 195-212# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: brocke90a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >MUS2110F# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AChr Torpedo californica 198-212# DB REFERENCE: SWISS: (ACHA_HUMAN,ACHA_MOUSE,ACHA_MOUSE,ACHA_RAT,ACHA_BOVIN)# & PIR1: (ACHUA1,ACBOA1)# & PIR2: (A24383,I49458)# & PIR3: (S13872)# REFERENCES: brocke90a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,YLDITYHFVMQRLPL*# SEQUENCE: YLDITYHFVMQRLPL*# ...# >MUS21110# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AChr Torpedo californica 199-212# DB REFERENCE: SWISS: (ACHA_MOUSE,ACHA_RAT,ACHA_HUMAN,ACHA_MOUSE,ACHA_BOVIN)# & PIR1: (ACHUA1,ACBOA1)# & PIR2: (A24383,I49458)# & PIR3: (S13872)# REFERENCES: brocke90a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,LDITYHFVMQRLPL*# SEQUENCE: LDITYHFVMQRLPL*# ...# >MUS21111# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AChr Torpedo californica 200-212# DB REFERENCE: SWISS: (ACHA_MOUSE,ACHA_BOVIN,ACHA_RAT,ACHA_HUMAN,ACHA_MOUSE)# & PIR1: (ACBOA1,ACHUA1)# & PIR2: (A24383,I49458)# & PIR3: (S13872)# REFERENCES: brocke90a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,DITYHFVMQRLPL*# SEQUENCE: DITYHFVMQRLPL*# ...# >MUS21112# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AChr Torpedo californica 195-210# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: brocke90a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,DTPYLDITYHFVMQRL*# SEQUENCE: DTPYLDITYHFVMQRL*# ...# >MUS21113# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AChr Torpedo californica 199-210# DB REFERENCE: SWISS: (ACHA_MOUSE,ACHA_HUMAN,ACHA_MOUSE,ACHA_RAT,ACHA_BOVIN)# & PIR1: (ACHUA1,ACBOA1)# & PIR2: (A24383,I49458)# & PIR3: (S13872)# REFERENCES: brocke90a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,LDITYHFVMQRL*# SEQUENCE: LDITYHFVMQRL*# ...# >MUS21114# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AChr Torpedo californica 257-271# DB REFERENCE: SWISS: (ACHA_TORMA,ACHA_TORCA,ACH1_XENLA,ACHA_RAT,ACHA_BOVIN,# & ACHA_HUMAN,ACHA_MOUSE,ACH2_XENLA,ACHA_MOUSE,# & ACHA_CHICK)# & PIR1: (ACRYA1,ACCHAN,ACHUA1,ACBOA1)# & PIR2: (I50548,S08162,I50150,A28529,I49458,A24383)# & PIR3: (S13872)# REFERENCES: brocke90a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,LLVIVELIPSTSSAV*# SEQUENCE: LLVIVELIPSTSSAV*# ...# >MUS21115# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AChr Torpedo californica 259-271# ANCHOR POSITIONS:# REFERENCES: brocke90a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,VIVELIPSTSSAVAV*# SEQUENCE: VIVELIPSTSSAVAV*# ...# >MUS11116# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza virus nucleoprotein (141-161) homologue# DB REFERENCE: SWISS: (VNUC_IAMAN,VNUC_IAZOH,VNUC_IAGRE,VNUC_IATRT,VNUC_IADBE,# & VNUC_IAWHN,VNUC_IAZJ4,VNUC_IAZMA,VNUC_IAZJ3,VNUC_IATEI,# & VNUC_IASE0,VNUC_IAZGE,VNUC_IAFPD,VNUC_IAZJ2,VNUC_IADE2,# & VNUC_IAWHP,VNUC_IAGU3,VNUC_IAZJA,VNUC_IACKP,VNUC_IAZDA,# & VNUC_IAZH4,VNUC_IAZTE,VNUC_IADHK,VNUC_IALEN,VNUC_IAHPR,# & VNUC_IATKN,VNUC_IAANA,VNUC_IAZJ1,VNUC_IARUD,VNUC_IACKG,# & VNUC_IAZI2,VNUC_IAMIN,VNUC_IAFPR,VNUC_IADNZ,VNUC_IAZON,# & VNUC_IAZ29,VNUC_IAGU2,VNUC_IASH2,VNUC_IAS31,VNUC_IADU2,# & VNUC_IAZNE,VNUC_IAPAR,VNUC_IAGU1,VNUC_IANEJ,VNUC_IAHJI,# & VNUC_IAZW1,VNUC_IATRS,VNUC_IAMAA,VNUC_IAGUA,VNUC_IAZI1,# & VNUC_IAZW2,VNUC_IADM2,VNUC_IADE1,VNUC_IADCZ,VNUC_IAZCA,# & VNUC_IAZH3,VNUC_IAPUE,VNUC_IADAU,VNUC_IABUD,VNUC_IADMA,# & VNUC_IAZ41,VNUC_IAZI3,VNUC_IAWIL,VNUC_IAWIS,# & VNUC_IAGU4)# & PIR1: (VHIVN4,VHIVXL,A60028,VHIVN2,VHIVM1,VHIVN1,VHIVX1,VHIVA3,# & VHIV34,VHIVA6,VHIVN8,VHIVN6,VHIVC1,VHIVN9)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# REFERENCES: bodmer88a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,SNLNDATYQRTRALVRTGMDP*# SEQUENCE: SNLNDATYQRTRALVRTGMDP*# ...# >MUS11117# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct/Reference/Stabilization# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Influenza virus nucleoprotein (147-158) homologue# ANCHOR POSITIONS:# REFERENCES: bodmer88a,feltkamp94a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,TYQRTRALVTTG*# SEQUENCE: TYQRTRALVTTG*# ...# >MUS11118# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct/Stabilization# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: Influenza virus nucleoprotein (147-158) homologue# ANCHOR POSITIONS:# REFERENCES: bodmer88a,feltkamp94a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesl,TYQRTRALVTGG*# SEQUENCE: TYQRTRALVTGG*# ...# >MUS11119# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Influenza virus nucleoprotein (147-157) homologue# ANCHOR POSITIONS:# REFERENCES: bodmer88a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,TYQRTRALVRG*# SEQUENCE: TYQRTRALVRG*# ...# >MUS1111A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Cytotoxic-Direct# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza virus nucleoprotein (147-158) homologue# ANCHOR POSITIONS:# REFERENCES: bodmer88a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,TYQRTRALVRGA*# SEQUENCE: TYQRTRALVRGA*# ...# >MUS2111B# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hen Egg-White lysozyme (HEL) 46-61# DB REFERENCE: SWISS: (LYC1_ANAPL,LYC_CHRAM,LYC_LOPLE,LYC1_TACAC,LYC_CHICK,# & LYC_CHICK,LYC_MELGA,LYC_PHACO,LYC_SYRRE,LYC_PAVCR,# & LYC_PHAVE)# & PIR1: (LZFER,LZDK,LZCH,LZQJE,LZTK)# & PIR2: (A45660,JH0211,JH0212,JU0237,JC2144,JQ1041,JT0526,JU0178,# & A61281,JQ1033)# REFERENCES: allen84a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >MUS2111C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,KLRVQKSTWERGSLF*# SEQUENCE: KLRVQKSTWERGSLF*# ...# >MUS2111D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,SKLRVQKSTWERGSLF*# SEQUENCE: SKLRVQKSTWERGSLF*# ...# >MUS2111E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,MYSKLRVQKSTWERG*# SEQUENCE: MYSKLRVQKSTWERG*# ...# >MUS2111F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesh,bindyesu,FMYSKLRVQKSTWERG*# SEQUENCE: FMYSKLRVQKSTWERG*# ...# >MUS21120# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesh,bindyesu,YFMYSKLRVQKSTWERG*# SEQUENCE: YFMYSKLRVQKSTWERG*# ...# >MUS21121# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesh,bindyesu,YFMYSKLRVQKST*# SEQUENCE: YFMYSKLRVQKST*# ...# >MUS21122# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesh,bindyesu,YFMYSKLRVQKS*# SEQUENCE: YFMYSKLRVQKS*# ...# >MUS21123# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,YSKLRVQKST*# SEQUENCE: YSKLRVQKST*# ...# >MUS21124# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,YSKLRVQKSTWE*# SEQUENCE: YSKLRVQKSTWE*# ...# >MUS21125# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,YSKLRVQKSTWER*# SEQUENCE: YSKLRVQKSTWER*# ...# >MUS21126# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,YSKLRVQKSTWERG*# SEQUENCE: YSKLRVQKSTWERG*# ...# >MUS21127# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,YSKLRVQKSTWERGS*# SEQUENCE: YSKLRVQKSTWERGS*# ...# >MUS21128# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,YSKLRVQKSTWERGSL*# SEQUENCE: YSKLRVQKSTWERGSL*# ...# >MUS21129# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# DB REFERENCE: SWISS: (GCAB_MOUSE)# & PIR1: (G2MSAB)# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,YSKLRVQKSTWERGSLF*# SEQUENCE: YSKLRVQKSTWERGSLF*# ...# >MUS2112A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,YFMYSALRVQKST*# SEQUENCE: YFMYSALRVQKST*# ...# >MUS2112B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,YFMYSKARVQKST*# SEQUENCE: YFMYSKARVQKST*# ...# >MUS2112C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,YFMYSKLKVQKST*# SEQUENCE: YFMYSKLKVQKST*# ...# >MUS2112D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesh,bindyesu,YFMYSKLRAQKST*# SEQUENCE: YFMYSKLRAQKST*# ...# >MUS2112E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,YFMYSKLRVAKST*# SEQUENCE: YFMYSKLRVAKST*# ...# >MUS2112F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,YFMYSKLRVNKST*# SEQUENCE: YFMYSKLRVNKST*# ...# >MUS21130# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,YFMYSKLRVQKAT*# SEQUENCE: YFMYSKLRVQKAT*# ...# >MUS21131# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,YFMYSKLRVQKKT*# SEQUENCE: YFMYSKLRVQKKT*# ...# >MUS21132# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: T-cell hybridoma specificity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: IGgamma2ab (BALB/c mouse)# ANCHOR POSITIONS:# REFERENCES: bartnes93a# COMMENT:# SUMMARY: I-Ad,actyesn,bindyesu,GLHNHLTTKTYSRSLGK*# SEQUENCE: GLHNHLTTKTYSRSLGK*# ...# >HUM21133# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human Acetylholine receptor# DB REFERENCE: SWISS: (ACHA_MOUSE,ACHA_BOVIN,ACHA_FELCA,ACHA_ERICO,ACHA_RAT,# & ACHA_MOUSE,ACHA_HUMAN)# & PIR1: (ACHUA1,ACBOA1)# & PIR2: (I49458,A24383)# & PIR3: (S13872)# REFERENCES: ong91a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,MKLGTWTYDGSVV*# SEQUENCE: MKLGTWTYDGSVV*# ...# >HUM21134# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human Acetylholine receptor# ANCHOR POSITIONS:# REFERENCES: ong91a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,MKLGIWTYDGSVV*# SEQUENCE: MKLGIWTYDGSVV*# ...# >HUM21135# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct/Proliferation-competitive# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp120# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1MF,ENV_HV1H3,ENV_HV1BR)# & PIR1: (VCLJVL,VCLJLV)# & PIR3: (S13288)# REFERENCES: callahan90a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GSDTITLPCRIKQFINMWQE*# SEQUENCE: GSDTITLPCRIKQFINMWQE*# ...# >HUM21136# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct/Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 gp120# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1B8)# & PIR1: (VCLJH3)# & PIR3: (S33985)# REFERENCES: callahan90a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,GSDTITLPCRIKQIINMWQE*# SEQUENCE: GSDTITLPCRIKQIINMWQE*# ...# >HUM21137# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct/Proliferation-competitive# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp120# DB REFERENCE: SWISS: (ENV_HV1H2)# REFERENCES: callahan90a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GSDTITLPCRIKQIINMWQK*# SEQUENCE: GSDTITLPCRIKQIINMWQK*# ...# >HUM21138# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct/Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 gp120# DB REFERENCE: SWISS: (ENV_HV1JR,ENV_HV1A2)# & PIR1: (VCLJA2)# REFERENCES: callahan90a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,GNDTIILPCRIKQIINMWQE*# SEQUENCE: GNDTIILPCRIKQIINMWQE*# ...# >HUM21139# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct/Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 gp120# DB REFERENCE: SWISS: (ENV_HV1RH)# REFERENCES: callahan90a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,GNDTITLPCRIKQIVNMWQE*# SEQUENCE: GNDTITLPCRIKQIVNMWQE*# ...# >HUM2113A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct/Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 gp120# DB REFERENCE: SWISS: (ENV_HV1W2)# REFERENCES: callahan90a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,NSTLITLPCRIKQIINMWQG*# SEQUENCE: NSTLITLPCRIKQIINMWQG*# ...# >HUM2113B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct/Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 gp120# ANCHOR POSITIONS:# REFERENCES: callahan90a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,NNETIIIPCRIKQIINMWQE*# SEQUENCE: NNETIIIPCRIKQIINMWQE*# ...# >HUM2113C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation-Direct/Proliferation-competitive# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 gp120# DB REFERENCE: SWISS: (ENV_HV1MA)# REFERENCES: callahan90a# COMMENT:# SUMMARY: HLA-DR4,actyesl,bindyesu,STGSITLPCRIKQIINMWQK*# SEQUENCE: STGSITLPCRIKQIINMWQK*# ...# >MUS2113D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse mammary tumor virus (76-119)# DB REFERENCE: PIR2: (JH0554,S26174,S24574,JH0551,S20889)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,DSFNNSSVQDYNLNDSENSTFLLGQGPQPTSSYKPHRLCPSEIE*# SEQUENCE: DSFNNSSVQDYNLNDSENSTFLLGQGPQPTSSYKPHRLCPSEIE*# ...# >MUS2113E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mouse mammary tumor virus (76-119)# DB REFERENCE: PIR2: (S26174,S24574,S20889,JH0554,JH0551)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,DSFNNSSVQDYNLNDSENSTFLLGQGPQPTSSYKPHRLCPSEIE*# SEQUENCE: DSFNNSSVQDYNLNDSENSTFLLGQGPQPTSSYKPHRLCPSEIE*# ...# >HUM2113F# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (12-22)# DB REFERENCE: SWISS: (NEF_HV1A2)# & PIR1: (ASLJO2)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DR6,actyesu,bindyesu,GWSAIRERMRR*# SEQUENCE: GWSAIRERMRR*# ...# >HUM21140# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (13-23)# DB REFERENCE: SWISS: (NEF_HV1A2)# & PIR1: (ASLJO2)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DR6,actyesu,bindyesu,WSAIRERMRRA*# SEQUENCE: WSAIRERMRRA*# ...# >HUM21141# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (14-24)# DB REFERENCE: SWISS: (NEF_HV1A2)# & PIR1: (ASLJO2)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DR6,actyesu,bindyesu,SAIRERMRRAE*# SEQUENCE: SAIRERMRRAE*# ...# >HUM21142# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (44-54)# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_HV1BN,NEF_HV1H2,NEF_HV1BR,NEF_HV1S1,# & NEF_HV1B1,NEF_HV1B8,NEF_HV1Y2,NEF_HV1OY,NEF_HV1A2,# & NEF_HV112,NEF_HV1PV)# & PIR1: (ASLJ12,I44001,ASLJFV,ASLJH3,ASLJVL,ASLJBR,ASLJO2)# & PIR2: (S43467,S25937,S24985,S03247,S03245,S03244)# & PIR3: (S33986)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,HGAITSSNTAA*# SEQUENCE: HGAITSSNTAA*# ...# >HUM21143# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (45-55)# DB REFERENCE: SWISS: (NEF_HV1H2,NEF_HV1JR,NEF_HV1BN,NEF_HV1Y2,NEF_HV1A2,# & NEF_HV1OY,NEF_HV1BR,NEF_HV1B8)# & PIR1: (ASLJBR,ASLJO2,I44001,ASLJFV)# & PIR2: (S03244,S24985,S03247)# & PIR3: (S33986)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,GAITSSNTAAT*# SEQUENCE: GAITSSNTAAT*# ...# >HUM21144# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (46-56)# DB REFERENCE: SWISS: (NEF_HV1BN,NEF_HV1BR,NEF_HV1Y2,NEF_HV1JR,NEF_HV1B8,# & NEF_HV1OY,NEF_HV1A2,NEF_HV1H2)# & PIR1: (ASLJFV,I44001,ASLJBR,ASLJO2)# & PIR2: (S03247,S03244,S24985)# & PIR3: (S33986)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,AITSSNTAATN*# SEQUENCE: AITSSNTAATN*# ...# >HUM21145# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (47-57)# DB REFERENCE: SWISS: (NEF_HV1BN,NEF_HV1Y2,NEF_HV1BR,NEF_HV1B8,NEF_HV1JR,# & NEF_HV1H2,NEF_HV1OY,NEF_HV1A2)# & PIR1: (ASLJFV,ASLJBR,I44001,ASLJO2)# & PIR2: (S24985,S03244,S03247)# & PIR3: (S33986)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,ITSSNTAATNA*# SEQUENCE: ITSSNTAATNA*# ...# >HUM21146# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (193-203)# DB REFERENCE: SWISS: (NEF_HV1S1,NEF_HV1A2,NEF_HV1B8,NEF_HV1BN)# & PIR1: (ASLJO2,ASLJH3,ASLJBR)# & PIR2: (S03247)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,LAFHHMARELH*# SEQUENCE: LAFHHMARELH*# ...# >HUM21147# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (194-204)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1S1,NEF_HV1A2,NEF_HV1BN)# & PIR1: (ASLJO2,ASLJH3,ASLJBR)# & PIR2: (S03247)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,AFHHMARELHP*# SEQUENCE: AFHHMARELHP*# ...# >HUM21148# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (195-205)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1BN,NEF_HV1S1,NEF_HV1A2)# & PIR1: (ASLJBR,ASLJH3,ASLJO2)# & PIR2: (S03247)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,FHHMARELHPE*# SEQUENCE: FHHMARELHPE*# ...# >HUM21149# MHC MOLECULE: HLA-DP5, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (182-192)# DB REFERENCE: SWISS: (NEF_HV1A2)# & PIR1: (ASLJO2)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DP5,actyesu,bindyesu,KEVLVWRFDSK*# SEQUENCE: KEVLVWRFDSK*# ...# >HUM2114A# MHC MOLECULE: HLA-DP5, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (183-193)# DB REFERENCE: SWISS: (NEF_HV1A2)# & PIR1: (ASLJO2)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DP5,actyesu,bindyesu,EVLVWRFDSKL*# SEQUENCE: EVLVWRFDSKL*# ...# >HUM2114B# MHC MOLECULE: HLA-DP5, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (184-194)# DB REFERENCE: SWISS: (NEF_HV1A2)# & PIR1: (ASLJO2)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DP5,actyesu,bindyesu,VLVWRFDSKLA*# SEQUENCE: VLVWRFDSKLA*# ...# >HUM2114C# MHC MOLECULE: HLA-DP5, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (185-195)# DB REFERENCE: SWISS: (NEF_HV1A2)# & PIR1: (ASLJO2)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DP5,actyesu,bindyesu,LVWRFDSKLAF*# SEQUENCE: LVWRFDSKLAF*# ...# >HUM2114D# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (67-77)# DB REFERENCE: SWISS: (NEF_HV1A2,NEF_HV1MA,NEF_HV1SC,NEF_HV1Y2)# & PIR1: (ASLJO2,I44001)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,EEEVGFPVRPQ*# SEQUENCE: EEEVGFPVRPQ*# ...# >HUM2114E# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-SF2 (68-78)# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_SIVCZ,NEF_HV1ZH,NEF_HV1RH,NEF_HV1Z6,# & NEF_HV1SC,NEF_HV1Z2,NEF_HV1A2,NEF_HV1Y2,NEF_HV1ND,# & NEF_HV1MA,NEF_HV1OY)# & PIR1: (QQLJND,QQLJZR,ASLJO2,I44001,ASLJIK,B44963)# & PIR2: (S54385,S03246)# REFERENCES: wentworth94a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,EEVGFPVRPQV*# SEQUENCE: EEVGFPVRPQV*# ...# >HUM2114F# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,SGPLKAEIAQRLEY*# SEQUENCE: SGPLKAEIAQRLEY*# ...# >HUM21150# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,YVVVGAAGVGKSA*# SEQUENCE: YVVVGAAGVGKSA*# ...# >HUM21151# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASK_RAT,RASK_MELGA,RASN_HUMAN,RASH_RAT,RASH_CHICK,# & RASH_RAT,RASL_HUMAN,RASN_MOUSE,RASL_RAT,RASL_HUMAN,# & RASN_MOUSE,RASH_MOUSE,RASN_CAVPO,RAS1_DROME,RASH_HUMAN,# & RASL_RAT,RASN_HUMAN,RASK_RAT,RASK_MOUSE,RASN_RAT,# & RASH_MESAU,RASH_HUMAN,RASK_MONDO,RAS_CARAU,RASL_MOUSE,# & RASL_MOUSE,RAS1_DROME,RASK_HUMAN)# & PIR1: (TVCHRS,TVGPRS,TVHU2K,TVMSK,TVHUH,TVHURA,TVHUK,TVFF85,# & TVMSNS,TVGPRT)# & PIR2: (PC4098,S02054,A46134,S26621,A54321,PC4097,A43816,I59500,# & I58402,A48088,B25229,A43808,S05483,A25229,A37355,S31720,# & S06217,B54321,S57718,I52205,I37096,I59498,JC5154)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGAGGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAGGVGKSALTIQLIQ*# ...# >HUM21152# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASK_XENLA,RASX_XENLA)# & PIR2: (S34138,I52688,I52219,A60192)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGAVGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAVGVGKSALTIQLIQ*# ...# >HUM21153# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASH_MSV)# & PIR1: (TVMVB)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGAKGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAKGVGKSALTIQLIQ*# ...# >HUM21154# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_RRASV,RASH_MSVNS,RASH_MSVHA)# & PIR1: (TVMVNS,TVMVRS,TVMV3H)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGARGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGARGVGKSALTIQLIQ*# ...# >HUM21155# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGAAGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAAGVGKSALTIQLIQ*# ...# >HUM21156# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASK_MSVKI,RASK_MSVKI)# & PIR1: (TVMV2K)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGASGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGASGVGKSALTIQLIQ*# ...# >HUM21157# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: PIR2: (I53221,I51971)# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGACGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGACGVGKSALTIQLIQ*# ...# >HUM21158# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGADGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGADGVGKSALTIQLIQ*# ...# >HUM21159# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesu,MTEYKLVVVGAGVVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAGVVGKSALTIQLIQ*# ...# >HUM2115A# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,SGPLKAEIAQRLEY*# SEQUENCE: SGPLKAEIAQRLEY*# ...# >HUM2115B# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,YVVVGAAGVGKSA*# SEQUENCE: YVVVGAAGVGKSA*# ...# >HUM2115C# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASL_RAT,RASH_MESAU,RASL_MOUSE,RASL_HUMAN,RASN_MOUSE,# & RASN_MOUSE,RASH_RAT,RASK_MELGA,RASN_HUMAN,RASK_RAT,# & RASH_HUMAN,RASN_HUMAN,RASK_MOUSE,RASK_MONDO,RASK_HUMAN,# & RASL_MOUSE,RASL_RAT,RASH_MOUSE,RASL_HUMAN,RASH_HUMAN,# & RAS1_DROME,RASN_RAT,RAS1_DROME,RASN_CAVPO,RAS_CARAU,# & RASK_RAT,RASH_RAT,RASH_CHICK)# & PIR1: (TVGPRS,TVCHRS,TVGPRT,TVFF85,TVHUH,TVHUK,TVMSNS,TVHU2K,# & TVMSK,TVHURA)# & PIR2: (B54321,S06217,A37355,S05483,A43808,S57718,I52205,S31720,# & A25229,I37096,I59498,JC5154,B25229,A48088,A54321,S26621,# & PC4098,S02054,A46134,PC4097,A43816,I59500,I58402)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGAGGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAGGVGKSALTIQLIQ*# ...# >HUM2115D# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASK_XENLA,RASX_XENLA)# & PIR2: (I52219,I52688,S34138,A60192)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGAVGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAVGVGKSALTIQLIQ*# ...# >HUM2115E# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASH_MSV)# & PIR1: (TVMVB)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGAKGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAKGVGKSALTIQLIQ*# ...# >HUM2115F# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASH_RRASV,RASH_MSVNS,RASH_MSVHA,RASH_MSVHA)# & PIR1: (TVMV3H,TVMVNS,TVMVRS)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGARGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGARGVGKSALTIQLIQ*# ...# >HUM21160# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGAAGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAAGVGKSALTIQLIQ*# ...# >HUM21161# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: SWISS: (RASK_MSVKI,RASK_MSVKI)# & PIR1: (TVMV2K)# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGASGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGASGVGKSALTIQLIQ*# ...# >HUM21162# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: PIR2: (I51971,I53221)# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGACGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGACGVGKSALTIQLIQ*# ...# >HUM21163# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actunkn,bindyesu,MTEYKLVVVGAGVVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAGVVGKSALTIQLIQ*# ...# >HUM21164# MHC MOLECULE: HLA-DQ1(DQB1*0101), CLASS-2, (HUMAN)# METHOD: Binding-competitive# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV# ANCHOR POSITIONS:# REFERENCES: johansen94a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,KLVVVGADGVGKS*# SEQUENCE: KLVVVGADGVGKS*# ...# >MUS21165# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (102-116)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPCA,LYC_LOPLE,LYC_MELGA,LYC_CHRAM,# & LYC_CHICK)# & PIR1: (LZCH,LZTK,LZQJEC)# & PIR2: (JQ1033)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,GNGMNAWVAWRNRCK*# SEQUENCE: GNGMNAWVAWRNRCK*# ...# >MUS21166# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (103-117)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_CHICK,LYC_CHRAM,LYC_CHICK,LYC_MELGA,# & LYC_PAVCR,LYC_LOPLE,LYC_SYRRE)# & PIR1: (LZTK,LZCH,LZQJEC)# & PIR2: (JQ1041,JT0526,JQ1033)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,NGMNAWVAWRNRCKG*# SEQUENCE: NGMNAWVAWRNRCKG*# ...# >MUS21167# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (104-118)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_PAVCR,LYC3_ANAPL,LYC_CHRAM,LYC_COLVI,# & LYC_LOPCA,LYC_SYRRE,LYC_LOPLE,LYC_COTJA,LYC_CHICK,# & LYC_MELGA)# & PIR1: (LZTK,LZCH,LZDK3,LZQJE,LZQJEC)# & PIR2: (JQ1041,JQ1033,JT0526,JU0237)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,GMNAWVAWRNRCKGT*# SEQUENCE: GMNAWVAWRNRCKGT*# ...# >MUS21168# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (105-119)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_LOPLE,LYC_COTJA,LYC_CHICK,LYC_LOPCA,# & LYC_CHICK,LYC_PAVCR,LYC_CHRAM,LYC_MELGA,LYC_COLVI,# & LYC3_ANAPL)# & PIR1: (LZQJE,LZDK3,LZTK,LZCH,LZQJEC)# & PIR2: (JQ1041,JT0526,JQ1033,JU0237)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,MNAWVAWRNRCKGTD*# SEQUENCE: MNAWVAWRNRCKGTD*# ...# >MUS21169# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (106-120)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COTJA,LYC_MELGA,LYC_CHRAM,LYC_CHICK,# & LYC3_ANAPL,LYC_LOPLE,LYC_SYRRE,LYC_LOPCA,LYC_PAVCR,# & LYC_COLVI)# & PIR1: (LZDK3,LZQJEC,LZTK,LZCH,LZQJE)# & PIR2: (JT0526,JU0237,JQ1033,JQ1041)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,NAWVAWRNRCKGTDV*# SEQUENCE: NAWVAWRNRCKGTDV*# ...# >MUS2116A# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (107-121)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_CHICK)# & PIR1: (LZCH)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,AWVAWRNRCKGTDVQ*# SEQUENCE: AWVAWRNRCKGTDVQ*# ...# >MUS2116B# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (108-122)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZCH)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,WVAWRNRCKGTDVQA*# SEQUENCE: WVAWRNRCKGTDVQA*# ...# >MUS2116C# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation-Direct# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hen egg-white lysozyme HEL (108-116)# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_CHICK,LYC_LOPCA,LYC_LOPLE,LYC_SYRRE,# & LYC_CHRAM,LYC_MELGA,LYC_CHICK,LYC_COTJA,LYC_COLVI,# & LYC3_ANAPL)# & PIR1: (LZTK,LZQJE,LZDK3,LZQJEC,LZCH)# & PIR2: (JT0526,JQ1041,JU0237,JQ1033)# REFERENCES: cabaniols94a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,WVAWRNRCK*# SEQUENCE: WVAWRNRCK*# ...# >MUS2116D# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (48-67)# DB REFERENCE: SWISS: (HEMA_IANT6,HEMA_IAX31,HEMA_IADM2,HEMA_IAME2,HEMA_IAZH3,# & HEMA_IADH4,HEMA_IAEN6,HEMA_IADH5,HEMA_IADU3,HEMA_IADHM,# & HEMA_IAZH2,HEMA_IAQU7,HEMA_IAME1,HEMA_IADH2,HEMA_IADHK,# & HEMA_IAMAO,HEMA_IADH6,HEMA_IADHL,HEMA_IAUDO,HEMA_IADH7,# & HEMA_IADH3,HEMA_IAAIC,HEMA_IAVI7,HEMA_IADA3)# & PIR1: (HMIVV,HMIV33,HMIVS2,HMIVHA,HMIVH,HMIV80,HMIV21,HMIVHM,# & HMIVDU,HMIVS3,HMIV15,HMIVH3,HMIV98,HMIV89)# & PIR2: (JQ1153,JQ1156,JQ1155,A93233)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,DQIEVTNATELVQSSSTGKICNN*# SEQUENCE: DQIEVTNATELVQSSSTGKICNN*# ...# >MUS2116E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (56-76)# DB REFERENCE: SWISS: (HEMA_IADU3,HEMA_IAEN6,HEMA_IADHM,HEMA_IADHL,HEMA_IAUDO,# & HEMA_IAVI7,HEMA_IAMAO,HEMA_IADH6,HEMA_IAZH2,HEMA_IADH2,# & HEMA_IADH3,HEMA_IADH1,HEMA_IAME2,HEMA_IAZH3,HEMA_IAME1,# & HEMA_IAQU7,HEMA_IADM2,HEMA_IANT6,HEMA_IADHK,HEMA_IADA3,# & HEMA_IAAIC,HEMA_IADH7,HEMA_IADH5,HEMA_IADH4,HEMA_IAX31,# & HEMA_IAZCO)# & PIR1: (HMIVS3,HMIVV,HMIV33,HMIVHA,HMIV98,HMIVDU,HMIVHM,HMIV21,# & HMIV15,HMIV77,HMIVH,HMIVH3,HMIV89,HMIV80,HMIVS2)# & PIR2: (JQ1156,JQ1155,A93233,JQ1153)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,TELVQSSSTGKI*# SEQUENCE: TELVQSSSTGKI*# ...# >MUS2116F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (120-139)# DB REFERENCE: SWISS: (HEMA_IAEN6,HEMA_IAZH2,HEMA_IAX31,HEMA_IAAIC,HEMA_IADHK,# & HEMA_IADH4,HEMA_IADH7,HEMA_IADHL,HEMA_IADH6,HEMA_IAQU7,# & HEMA_IAME1,HEMA_IADH1,HEMA_IAMAO,HEMA_IADHM,HEMA_IAGHK,# & HEMA_IADU3,HEMA_IADH3,HEMA_IADM2,HEMA_IANT6,# & HEMA_IAZH3)# & PIR1: (HMIV15,HMIV77,HMIVH,HMIVDU,HMIV89,HMIVHA,HMIV98,HMIVS2,# & HMIVS3,HMIV33)# & PIR2: (JQ1155,JQ1156,A93233,JQ1153,JQ1154)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,DYASLRSLVASSGTLEFITE*# SEQUENCE: DYASLRSLVASSGTLEFITE*# ...# >MUS21170# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (177-199)# DB REFERENCE: SWISS: (HEMA_IAAIC,HEMA_IADHM,HEMA_IAX31)# & PIR1: (HMIVHA)# & PIR2: (JQ1156,A93233)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,YPVLNVTMPNNDNFDKLYIWGIH*# SEQUENCE: YPVLNVTMPNNDNFDKLYIWGIH*# ...# >MUS21171# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (186-205)# DB REFERENCE: SWISS: (HEMA_IAAIC,HEMA_IAX31)# & PIR1: (HMIVHA)# & PIR2: (A93233)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NNDNFDKLYIWGIHHPSTNQ*# SEQUENCE: NNDNFDKLYIWGIHHPSTNQ*# ...# >MUS21172# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (206-227)# DB REFERENCE: SWISS: (HEMA_IAEN6,HEMA_IAAIC,HEMA_IAX31,HEMA_IAQU7,HEMA_IAME1,# & HEMA_IANT6)# & PIR1: (HMIVHA,HMIVH)# & PIR2: (A93233)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,EQTSLYVQASGRVTVSTRRSQ*# SEQUENCE: EQTSLYVQASGRVTVSTRRSQ*# ...# >MUS21173# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (226-245)# DB REFERENCE: SWISS: (HEMA_IAZUK,HEMA_IAME1,HEMA_IABAN,HEMA_IAX31,HEMA_IAUDO,# & HEMA_IAAIC,HEMA_IAEN6)# & PIR1: (HMIVHA)# & PIR2: (A93233,A92979)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,QQTIIPNIGSRPWVRGLSSR*# SEQUENCE: QQTIIPNIGSRPWVRGLSSR*# ...# >MUS21174# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (245-265)# DB REFERENCE: SWISS: (HEMA_IAAIC,HEMA_IADH1,HEMA_IAQU7,HEMA_IADHK,HEMA_IANT6,# & HEMA_IAGHK,HEMA_IADM2,HEMA_IAHAL,HEMA_IAZH3,HEMA_IAEN6,# & HEMA_IADHL,HEMA_IADH4,HEMA_IADU3,HEMA_IADH5,# & HEMA_IADA3)# & PIR1: (HMIVS2,HMIV21,HMIVH,HMIVHA,HMIVE4,HMIV77,HMIV89,# & HMIVDU)# & PIR2: (JQ1154,JQ1153,JQ1155)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,RISIYWTIVKPGDVLVINSNG*# SEQUENCE: RISIYWTIVKPGDVLVINSNG*# ...# >MUS21175# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza haemagglutinin H3 (269-288)# DB REFERENCE: SWISS: (HEMA_IAME1,HEMA_IAHFO,HEMA_IADHM,HEMA_IAVI7,HEMA_IAHRO,# & HEMA_IAEN6,HEMA_IAQU7,HEMA_IADH6,HEMA_IAHUR,HEMA_IADHK,# & HEMA_IADH1,HEMA_IADA3,HEMA_IANT6,HEMA_IAME2,HEMA_IADHL,# & HEMA_IADH3,HEMA_IAMAO,HEMA_IADH2,HEMA_IAGHK,HEMA_IAUDO,# & HEMA_IAHMI,HEMA_IAZH2,HEMA_IADH5,HEMA_IADU3,HEMA_IAZH3,# & HEMA_IAAIC,HEMA_IADH7)# & PIR1: (HMIVE6,HMIV77,HMIVE2,HMIVHM,HMIVS2,HMIV80,HMIV21,HMIVH,# & HMIV98,HMIVS3,HMIV33,HMIVDU,HMIVHA,HMIVV,HMIVE7,HMIV15,# & HMIVE1)# & PIR2: (JQ1156,JQ1153,JQ1155,JQ1154)# REFERENCES: smith94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,APRGYFKMRTGKSSIMRSDA*# SEQUENCE: APRGYFKMRTGKSSIMRSDA*# ...# >MUS11176# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Simian Virus 40 T Antigen (223-231)# ANCHOR POSITIONS: 5,9# REFERENCES: tevethia90a,elliott93a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,CKGVNKFYL*# SEQUENCE: CKGVNKFYL*# ...# >MUS11177# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Cytotoxicity as./direct binding# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Papilloma Virus E7 protein (47-57)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: neisig95a,elliott93a,sadovnikova94a,sadovnikova94b,feltkamp93a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,RAHYNIVTF*# SEQUENCE: RAHYNIVTF*# ...# >MUS11178# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Cytotoxicity as./binding as./stabilisation as./CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Papilloma Virus E7 protein (21-28)# DB REFERENCE: SWISS: (VE7_HPV35,VE7_HPV16,VE7_HPV42,VE7_HPV33)# & PIR1: (W7WLHS,W7WL33,W7WL42,W7WL35)# & PIR3: (S12367)# REFERENCES: elliott93a,sadovnikova94a,bauer95a# COMMENT: binds only in vitro# SUMMARY: H-2Kb,actyesu,bindyesu,DLYCYEQL*# SEQUENCE: DLYCYEQL*# ...# >MUS11179# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LCMVGP2# ANCHOR POSITIONS: 5,11# REFERENCES: elliott93a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,SGVENFGGYCL*# SEQUENCE: SGVENFGGYCL*# ...# >MUS1117A# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LCMVNP# ANCHOR POSITIONS: 5,9# REFERENCES: elliott93a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,FQPQNGCFI*# SEQUENCE: FQPQNGCFI*# ...# >MUS1117B# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: corr92a,elliott93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,XPQGPREQ*# SEQUENCE: XPQGPREQ*# ...# >MUS1117C# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: corr92a,rammensee95a,elliott93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,XPQPNLYQL*# SEQUENCE: XPQPNLYQL*# ...# >MUS1117D# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: corr92a,elliott93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,XPAXAYPY*# SEQUENCE: XPAXAYPY*# ...# >HUM1117E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HTLV1 Tax# ANCHOR POSITIONS: 2,9# REFERENCES: elliott93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLFGYPVYV*# SEQUENCE: SLFGYPVYV*# ...# >HUM1117F# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Stabilization/CTL assays# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: HIV-1 nef (74-81)# DB REFERENCE: SWISS: (NEF_HV2D2,NEF_HV1OY,NEF_HV1ND,NEF_HV112,NEF_HV1S1,# & NEF_HV1B8,NEF_HV1U4,NEF_HV1H2,NEF_HV1MN,NEF_HV1S3,# & NEF_HV1BR,NEF_HV1BN,NEF_HV1B1,NEF_HV1JR,NEF_HV1Z6,# & NEF_HV1EL,NEF_HV1SC,NEF_HV1Z2,NEF_HV1PV,NEF_HV1A2,# & NEF_HV1MA)# & PIR1: (ASLJ12,ASLJH3,QQLJND,QQLJZR,ASLJBR,ASLJVL,ASLJFV,# & ASLJO2)# & PIR2: (S03245,S03244,S43467,S25937,S24572,S24985,S54385)# & PIR3: (S33986)# REFERENCES: elliott93a,feltkamp94a# COMMENT:# SUMMARY: HLA-B35,actyesl,bindyesl,VPLRPMTY*# SEQUENCE: VPLRPMTY*# ...# >HUM11180# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-2 gag (245-253)# DB REFERENCE: SWISS: (GAG_HV2D1,GAG_HV2SB,GAG_HV2CA,GAG_HV2G1,GAG_HV2D2,# & GAG_HV2BE,GAG_HV2RO,GAG_HV2NZ)# & PIR1: (FOLJGG,FOLJCA,FOLJG2)# & PIR2: (S53091,S12152,S08435)# REFERENCES: elliott93a,brander95a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,NPVPVGNIY*# SEQUENCE: NPVPVGNIY*# ...# >HUM11181# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: Eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Proteas. C3# DB REFERENCE: SWISS: (PRC3_HUMAN,PRC3_DROME,PRC3_HUMAN,PRC3_MOUSE,PRC3_XENLA,# & PRC3_MOUSE,PRC3_RAT,PRC3_RAT)# & PIR1: (SNRTC3,SNHUC3)# & PIR2: (JH0421,S36116)# REFERENCES: elliott93a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesu,DPSGAYFAW*# SEQUENCE: DPSGAYFAW*# ...# >HUM11182# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: Eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CKSh 1# DB REFERENCE: SWISS: (CKS2_HUMAN,CKS1_PATVU,CKS1_HUMAN,CKS2_XENLA)# & PIR2: (B36670,A36670,S42789)# REFERENCES: elliott93a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesu,EPEPHILLF*# SEQUENCE: EPEPHILLF*# ...# >HUM11183# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17# DB REFERENCE: SWISS: (GAG_HV1Z2,GAG_HV2ST,GAG_SIVMK,GAG_HV1B5,GAG_HV2D2,# & GAG_HV2KR,GAG_SIVM1,GAG_HV2SB,GAG_HV2CA,GAG_HV1MA,# & GAG_HV2NZ,GAG_SIVMS,GAG_HV1B1,GAG_HV1MN,GAG_HV1H2,# & GAG_HV1JR,GAG_HV1PV,GAG_HV1EL,GAG_HV1W2,GAG_HV2BE,# & GAG_HV2RO,GAG_HV1OY,GAG_HV1A2,GAG_HV1ND,GAG_HV1J3,# & GAG_HV1BR)# & PIR1: (FOLJCA,FOVWH3,FOLJST,A38068,FOLJTM,FOVWVL,FOLJG3,FOVWA2,# & FOLJND,FOLJG5,FOVWLV,FOLJG2)# & PIR2: (S03070,S54377,S08435,S53091)# & PIR3: (S33979)# REFERENCES: elliott93a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,RLRPGGKKKY*# SEQUENCE: RLRPGGKKKY*# ...# >HUM11184# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive inhibition of CTL# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV NP (18-27) mutant# ANCHOR POSITIONS: 2,9# REFERENCES: bertoletti94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLPNDFFPSA*# SEQUENCE: FLPNDFFPSA*# ...# >HUM11185# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive inhibition of CTL# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV NP (18-27) mutant# ANCHOR POSITIONS: 2,9# REFERENCES: bertoletti94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPNDFFPSV*# SEQUENCE: FLPNDFFPSV*# ...# >HUM11186# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive inhibition of CTL# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV NP (18-27) mutant# ANCHOR POSITIONS: 2,9# REFERENCES: bertoletti94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLPADFFPSI*# SEQUENCE: FLPADFFPSI*# ...# >HUM11187# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive inhibition of CTL# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV NP (18-27) mutant# ANCHOR POSITIONS: 2,9# REFERENCES: bertoletti94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPADFFPSV*# SEQUENCE: FLPADFFPSV*# ...# >HUM11188# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive inhibition of CTL# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV NP (18-27) mutant# ANCHOR POSITIONS: 2,9# REFERENCES: bertoletti94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLPVDFFPSI*# SEQUENCE: FLPVDFFPSI*# ...# >HUM11189# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive inhibition of CTL# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV NP (18-27) mutant# DB REFERENCE: PIR2: (S53149,S53161)# REFERENCES: bertoletti94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPVDFFPSV*# SEQUENCE: FLPVDFFPSV*# ...# >MUS2118A# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mMBP (Ac1-20)# DB REFERENCE: SWISS: (MBP_MOUSE)# & PIR1: (MBMSB)# REFERENCES: bhardwaj94a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,ASQKRPSQRSKYLATASTMD*# SEQUENCE: ASQKRPSQRSKYLATASTMD*# ...# >MUS2118B# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: mMBP (61-80)# DB REFERENCE: SWISS: (MBP_MOUSE)# & PIR1: (MBMSB)# REFERENCES: bhardwaj94a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesl,RTTHYGSLPQKSQHGRTQDE*# SEQUENCE: RTTHYGSLPQKSQHGRTQDE*# ...# >MUS2118C# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mMBP (101-120)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_BOVIN,MBP_MOUSE)# & PIR1: (MBMSB,MBPGB,MBBOB)# & PIR2: (A37246)# REFERENCES: bhardwaj94a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,GKGRGLSLSRFSWGAEGQKP*# SEQUENCE: GKGRGLSLSRFSWGAEGQKP*# ...# >MUS2118D# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mMBP (121-140)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB,MBMSB)# REFERENCES: bhardwaj94a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,GFGYGGRASDYKSAHKGFKG*# SEQUENCE: GFGYGGRASDYKSAHKGFKG*# ...# >MUS2118E# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mMBP (81-100)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_CAVPO,MBP_RAT,MBP_HUMAN,MBP_MOUSE,# & MBP_PANTR)# & PIR1: (MBPGB,MBHUB,MBBOB,MBMSB,MBRTS,MBCZB)# & PIR2: (A37246)# REFERENCES: bhardwaj94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,NPVVHFFKNIVTPRTPPPSQ*# SEQUENCE: NPVVHFFKNIVTPRTPPPSQ*# ...# >MUS2118F# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mMBP (121-140)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_PANTR)# & PIR1: (MBMSB,MBCZB,MBHUB)# REFERENCES: bhardwaj94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,GFGYGGRASDYKSAHKGFKG*# SEQUENCE: GFGYGGRASDYKSAHKGFKG*# ...# >MUS21190# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mMBP (131-150)# DB REFERENCE: SWISS: (MBP_MOUSE)# & PIR1: (MBMSB)# REFERENCES: bhardwaj94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,YKSAHKGFKGAYDAQGTLSK*# SEQUENCE: YKSAHKGFKGAYDAQGTLSK*# ...# >HUM11191# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TIS-21# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT: position 2 (L or I)# SUMMARY: HLA-A2,actunkn,bindyesm,TIWVDPYEV*# SEQUENCE: TIWVDPYEV*# ...# >HUM11192# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT: position 2 (L or I), position 7 (L or I)# SUMMARY: HLA-A2,actunkn,bindyesl,SIPSGGLGV*# SEQUENCE: SIPSGGLGV*# ...# >HUM11193# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT: position 2 (L or I), position 7 (L or I)# SUMMARY: HLA-A2,actunkn,bindyesl,SLPSGGIGV*# SEQUENCE: SLPSGGIGV*# ...# >HUM11194# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT: position 2 (L or I), position 7 (L or I)# SUMMARY: HLA-A2,actunkn,bindyesl,SLPSGGLGV*# SEQUENCE: SLPSGGLGV*# ...# >HUM11195# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A*0201 signal sequence analogue# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,APRTLVYLL*# SEQUENCE: APRTLVYLL*# ...# >HUM11196# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: IP-30 signal sequence# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (S21727,A43708)# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesl,LLDVPTAAV*# SEQUENCE: LLDVPTAAV*# ...# >HUM11197# MHC MOLECULE: HLA-A3(A*0302), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (1C11_HUMAN)# & PIR2: (I37529,I37078)# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,RVMAPRALL*# SEQUENCE: RVMAPRALL*# ...# >HUM11198# MHC MOLECULE: HLA-A3(A*0302), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gp41# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1BN,ENV_HV1H2,ENV_HV1PV,ENV_HV1W1,# & ENV_HV1J3,ENV_HV1BR,ENV_HV1SC,ENV_HV1H3,ENV_HV1KB,# & ENV_HV1Y2,ENV_HV1B1,ENV_HV1B8)# & PIR1: (VCLJBR,VCLJKB,VCLJH3,VCLJLV,VCLJVL,VCLJ3W,VCLJSC,# & H44001)# & PIR2: (S21998,S21996,S70422,S70425,S70421,S21994)# & PIR3: (S33985,S13288)# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,RLRDLLLIVTR*# SEQUENCE: RLRDLLLIVTR*# ...# >HUM11199# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: IP-30 signal sequence# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708)# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,LLLDVPTAAVQA*# SEQUENCE: LLLDVPTAAVQA*# ...# >HUM1119A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: IP-30 signal sequence homologue# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLDDVPTAAVQA*# SEQUENCE: LLDDVPTAAVQA*# ...# >HUM1119B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: IP-30 signal sequence homologue# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,LLLDVPTADVQA*# SEQUENCE: LLLDVPTADVQA*# ...# >HUM1119C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: IP-30 signal sequence homologue# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLLDVPTAADQA*# SEQUENCE: LLLDVPTAADQA*# ...# >HUM1119D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: IP-30 signal sequence homologue# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLLDVPTAAVQD*# SEQUENCE: LLLDVPTAAVQD*# ...# >HUM1119E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: IP-30 signal sequence homologue# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLLDVPTADDDD*# SEQUENCE: LLLDVPTADDDD*# ...# >HUM1119F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: calreticulin# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,MLDSVPLLLG*# SEQUENCE: MLDSVPLLLG*# ...# >HUM111A0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: calreticulin# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,MLLSVPLLDG*# SEQUENCE: MLLSVPLLDG*# ...# >HUM111A1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: calreticulin# ANCHOR POSITIONS:# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,MLLSVPLLLD*# SEQUENCE: MLLSVPLLLD*# ...# >HUM111A2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: calreticulin# DB REFERENCE: SWISS: (CRTC_RAT,CRTC_MOUSE,CRTC_HUMAN,CRTC_HUMAN)# & PIR2: (JH0819,A37047,S06763)# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLSVPLLLG*# SEQUENCE: LLSVPLLLG*# ...# >HUM111A3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: calreticulin# DB REFERENCE: SWISS: (CRTC_MOUSE,CRTC_RAT,CRTC_HUMAN,CRTC_HUMAN)# & PIR2: (S06763,JH0819,A37047)# REFERENCES: chen94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,MLLSVPLLL*# SEQUENCE: MLLSVPLLL*# ...# >MUS211A4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: S70-Hb (64-76)# DB REFERENCE: SWISS: (HBB2_MOUSE,HBB2_MOUSE)# & PIR1: (HBMSN1)# REFERENCES: evavold93a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,GKKVITAFNEGLK*# SEQUENCE: GKKVITAFNEGLK*# ...# >MUS211A5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: S70-Hb (64-76) analogue# ANCHOR POSITIONS:# REFERENCES: evavold93a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,GKKVLTAFNEGLK*# SEQUENCE: GKKVLTAFNEGLK*# ...# >MUS211A6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: S70-Hb (64-76) analogue# ANCHOR POSITIONS:# REFERENCES: evavold93a# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesu,GKKVITSFNEGLK*# SEQUENCE: GKKVITSFNEGLK*# ...# >HUM111A7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu MP (59-67) analogue# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IAZI1,VMT1_IABAN,VMT1_IAPUE,VMT1_IAMAN,# & VMT1_IALE2,VMT1_IAANN,VMT1_IAWIL,VMT1_IAUDO,VMT1_IAUSS,# & VMT1_IALE1,VMT1_IAFOW)# & PIR1: (JN0392,MFIV61,MFIV1K,MFIV1M,MFIV,MFIVC,MFIVWS)# & PIR2: (S04056,S07429,S04058,S04052,S04050,S04054,S14616)# REFERENCES: falk94b# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,ILGFVFTLT*# SEQUENCE: ILGFVFTLT*# ...# >HUM111A8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MP (58-66) analogue# DB REFERENCE: SWISS: (VMT1_IAFPW,VMT1_IAFPR)# & PIR1: (PN0086,MFIV1F,PN0083)# & PIR2: (S07945)# REFERENCES: falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GVLGFVFTL*# SEQUENCE: GVLGFVFTL*# ...# >HUM111A9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MP (58-66) analogue# ANCHOR POSITIONS: 2,9# REFERENCES: falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GMLGFVFTL*# SEQUENCE: GMLGFVFTL*# ...# >HUM111AA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MP (58-66) analogue# ANCHOR POSITIONS: 2,9# REFERENCES: falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GTLGFVFTL*# SEQUENCE: GTLGFVFTL*# ...# >HUM111AB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MP (58-66) analogue# ANCHOR POSITIONS: 2,9# REFERENCES: falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GQLGFVFTL*# SEQUENCE: GQLGFVFTL*# ...# >HUM111AC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MP (58-66) analogue# ANCHOR POSITIONS: 2,9# REFERENCES: falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GELGFVFTL*# SEQUENCE: GELGFVFTL*# ...# >HUM111AD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MP (58-66) analogue# ANCHOR POSITIONS: 2,9# REFERENCES: falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GILGFVFTV*# SEQUENCE: GILGFVFTV*# ...# >HUM111AE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu MP (58-66) analogue# ANCHOR POSITIONS: 2,9# REFERENCES: falk94b# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,GILGFVFTM*# SEQUENCE: GILGFVFTM*# ...# >HUM111AF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RQYQKSTEL*# SEQUENCE: RQYQKSTEL*# ...# >HUM111B0# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYAKSTEL*# SEQUENCE: RRYAKSTEL*# ...# >HUM111B1# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYCKSTEL*# SEQUENCE: RRYCKSTEL*# ...# >HUM111B2# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYDKSTEL*# SEQUENCE: RRYDKSTEL*# ...# >HUM111B3# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYEKSTEL*# SEQUENCE: RRYEKSTEL*# ...# >HUM111B4# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYFKSTEL*# SEQUENCE: RRYFKSTEL*# ...# >HUM111B5# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYGKSTEL*# SEQUENCE: RRYGKSTEL*# ...# >HUM111B6# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYHKSTEL*# SEQUENCE: RRYHKSTEL*# ...# >HUM111B7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYIKSTEL*# SEQUENCE: RRYIKSTEL*# ...# >HUM111B8# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYKKSTEL*# SEQUENCE: RRYKKSTEL*# ...# >HUM111B9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYLKSTEL*# SEQUENCE: RRYLKSTEL*# ...# >HUM111BA# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYMKSTEL*# SEQUENCE: RRYMKSTEL*# ...# >HUM111BB# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYNKSTEL*# SEQUENCE: RRYNKSTEL*# ...# >HUM111BC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYPKSTEL*# SEQUENCE: RRYPKSTEL*# ...# >HUM111BD# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYRKSTEL*# SEQUENCE: RRYRKSTEL*# ...# >HUM111BE# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYSKSTEL*# SEQUENCE: RRYSKSTEL*# ...# >HUM111BF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYTKSTEL*# SEQUENCE: RRYTKSTEL*# ...# >HUM111C0# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYVKSTEL*# SEQUENCE: RRYVKSTEL*# ...# >HUM111C1# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYWKSTEL*# SEQUENCE: RRYWKSTEL*# ...# >HUM111C2# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYYKSTEL*# SEQUENCE: RRYYKSTEL*# ...# >HUM111C3# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQASTEL*# SEQUENCE: RRYQASTEL*# ...# >HUM111C4# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQCSTEL*# SEQUENCE: RRYQCSTEL*# ...# >HUM111C5# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQDSTEL*# SEQUENCE: RRYQDSTEL*# ...# >HUM111C6# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQESTEL*# SEQUENCE: RRYQESTEL*# ...# >HUM111C7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQFSTEL*# SEQUENCE: RRYQFSTEL*# ...# >HUM111C8# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQGSTEL*# SEQUENCE: RRYQGSTEL*# ...# >HUM111C9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQHSTEL*# SEQUENCE: RRYQHSTEL*# ...# >HUM111CA# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQISTEL*# SEQUENCE: RRYQISTEL*# ...# >HUM111CB# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQLSTEL*# SEQUENCE: RRYQLSTEL*# ...# >HUM111CC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQMSTEL*# SEQUENCE: RRYQMSTEL*# ...# >HUM111CD# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQNSTEL*# SEQUENCE: RRYQNSTEL*# ...# >HUM111CE# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQPSTEL*# SEQUENCE: RRYQPSTEL*# ...# >HUM111CF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQQSTEL*# SEQUENCE: RRYQQSTEL*# ...# >HUM111D0# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQRSTEL*# SEQUENCE: RRYQRSTEL*# ...# >HUM111D1# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQSSTEL*# SEQUENCE: RRYQSSTEL*# ...# >HUM111D2# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQTSTEL*# SEQUENCE: RRYQTSTEL*# ...# >HUM111D3# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQVSTEL*# SEQUENCE: RRYQVSTEL*# ...# >HUM111D4# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQWSTEL*# SEQUENCE: RRYQWSTEL*# ...# >HUM111D5# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQYSTEL*# SEQUENCE: RRYQYSTEL*# ...# >HUM111D6# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKATEL*# SEQUENCE: RRYQKATEL*# ...# >HUM111D7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKCTEL*# SEQUENCE: RRYQKCTEL*# ...# >HUM111D8# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKDTEL*# SEQUENCE: RRYQKDTEL*# ...# >HUM111D9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKETEL*# SEQUENCE: RRYQKETEL*# ...# >HUM111DA# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKFTEL*# SEQUENCE: RRYQKFTEL*# ...# >HUM111DB# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKGTEL*# SEQUENCE: RRYQKGTEL*# ...# >HUM111DC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKHTEL*# SEQUENCE: RRYQKHTEL*# ...# >HUM111DD# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKITEL*# SEQUENCE: RRYQKITEL*# ...# >HUM111DE# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKKTEL*# SEQUENCE: RRYQKKTEL*# ...# >HUM111DF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKLTEL*# SEQUENCE: RRYQKLTEL*# ...# >HUM111E0# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKMTEL*# SEQUENCE: RRYQKMTEL*# ...# >HUM111E1# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKNTEL*# SEQUENCE: RRYQKNTEL*# ...# >HUM111E2# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKPTEL*# SEQUENCE: RRYQKPTEL*# ...# >HUM111E3# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKQTEL*# SEQUENCE: RRYQKQTEL*# ...# >HUM111E4# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKRTEL*# SEQUENCE: RRYQKRTEL*# ...# >HUM111E5# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKTTEL*# SEQUENCE: RRYQKTTEL*# ...# >HUM111E6# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKVTEL*# SEQUENCE: RRYQKVTEL*# ...# >HUM111E7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKWTEL*# SEQUENCE: RRYQKWTEL*# ...# >HUM111E8# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKYTEL*# SEQUENCE: RRYQKYTEL*# ...# >HUM111E9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSAEL*# SEQUENCE: RRYQKSAEL*# ...# >HUM111EA# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSCEL*# SEQUENCE: RRYQKSCEL*# ...# >HUM111EB# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSDEL*# SEQUENCE: RRYQKSDEL*# ...# >HUM111EC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSEEL*# SEQUENCE: RRYQKSEEL*# ...# >HUM111ED# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSFEL*# SEQUENCE: RRYQKSFEL*# ...# >HUM111EE# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSGEL*# SEQUENCE: RRYQKSGEL*# ...# >HUM111EF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSHEL*# SEQUENCE: RRYQKSHEL*# ...# >HUM111F0# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSIEL*# SEQUENCE: RRYQKSIEL*# ...# >HUM111F1# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSKEL*# SEQUENCE: RRYQKSKEL*# ...# >HUM111F2# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSLEL*# SEQUENCE: RRYQKSLEL*# ...# >HUM111F3# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSMEL*# SEQUENCE: RRYQKSMEL*# ...# >HUM111F4# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSNEL*# SEQUENCE: RRYQKSNEL*# ...# >HUM111F5# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSPEL*# SEQUENCE: RRYQKSPEL*# ...# >HUM111F6# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSQEL*# SEQUENCE: RRYQKSQEL*# ...# >HUM111F7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSREL*# SEQUENCE: RRYQKSREL*# ...# >HUM111F8# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSSEL*# SEQUENCE: RRYQKSSEL*# ...# >HUM111F9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSVEL*# SEQUENCE: RRYQKSVEL*# ...# >HUM111FA# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSWEL*# SEQUENCE: RRYQKSWEL*# ...# >HUM111FB# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSYEL*# SEQUENCE: RRYQKSYEL*# ...# >HUM111FC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTAL*# SEQUENCE: RRYQKSTAL*# ...# >HUM111FD# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTCL*# SEQUENCE: RRYQKSTCL*# ...# >HUM111FE# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSTDL*# SEQUENCE: RRYQKSTDL*# ...# >HUM111FF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTFL*# SEQUENCE: RRYQKSTFL*# ...# >HUM11200# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTGL*# SEQUENCE: RRYQKSTGL*# ...# >HUM11201# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTHL*# SEQUENCE: RRYQKSTHL*# ...# >HUM11202# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTIL*# SEQUENCE: RRYQKSTIL*# ...# >HUM11203# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTKL*# SEQUENCE: RRYQKSTKL*# ...# >HUM11204# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTLL*# SEQUENCE: RRYQKSTLL*# ...# >HUM11205# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTML*# SEQUENCE: RRYQKSTML*# ...# >HUM11206# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTNL*# SEQUENCE: RRYQKSTNL*# ...# >HUM11207# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTPL*# SEQUENCE: RRYQKSTPL*# ...# >HUM11208# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTQL*# SEQUENCE: RRYQKSTQL*# ...# >HUM11209# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTRL*# SEQUENCE: RRYQKSTRL*# ...# >HUM1120A# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTSL*# SEQUENCE: RRYQKSTSL*# ...# >HUM1120B# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTTL*# SEQUENCE: RRYQKSTTL*# ...# >HUM1120C# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTVL*# SEQUENCE: RRYQKSTVL*# ...# >HUM1120D# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTWL*# SEQUENCE: RRYQKSTWL*# ...# >HUM1120E# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTYL*# SEQUENCE: RRYQKSTYL*# ...# >HUM1120F# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSTEA*# SEQUENCE: RRYQKSTEA*# ...# >HUM11210# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEC*# SEQUENCE: RRYQKSTEC*# ...# >HUM11211# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTED*# SEQUENCE: RRYQKSTED*# ...# >HUM11212# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEE*# SEQUENCE: RRYQKSTEE*# ...# >HUM11213# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEF*# SEQUENCE: RRYQKSTEF*# ...# >HUM11214# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEG*# SEQUENCE: RRYQKSTEG*# ...# >HUM11215# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEH*# SEQUENCE: RRYQKSTEH*# ...# >HUM11216# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEI*# SEQUENCE: RRYQKSTEI*# ...# >HUM11217# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSTEK*# SEQUENCE: RRYQKSTEK*# ...# >HUM11218# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSTEM*# SEQUENCE: RRYQKSTEM*# ...# >HUM11219# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEN*# SEQUENCE: RRYQKSTEN*# ...# >HUM1121A# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEP*# SEQUENCE: RRYQKSTEP*# ...# >HUM1121B# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEQ*# SEQUENCE: RRYQKSTEQ*# ...# >HUM1121C# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSTER*# SEQUENCE: RRYQKSTER*# ...# >HUM1121D# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTES*# SEQUENCE: RRYQKSTES*# ...# >HUM1121E# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTET*# SEQUENCE: RRYQKSTET*# ...# >HUM1121F# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYQKSTEV*# SEQUENCE: RRYQKSTEV*# ...# >HUM11220# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEW*# SEQUENCE: RRYQKSTEW*# ...# >HUM11221# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: none# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,RRYQKSTEY*# SEQUENCE: RRYQKSTEY*# ...# >HUM11222# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,ARYQKSTEL*# SEQUENCE: ARYQKSTEL*# ...# >HUM11223# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,CRYQKSTEL*# SEQUENCE: CRYQKSTEL*# ...# >HUM11224# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,ERYQKSTEL*# SEQUENCE: ERYQKSTEL*# ...# >HUM11225# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,FRYQKSTEL*# SEQUENCE: FRYQKSTEL*# ...# >HUM11226# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,GRYQKSTEL*# SEQUENCE: GRYQKSTEL*# ...# >HUM11227# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# DB REFERENCE: SWISS: (H34_CAIMO)# & PIR1: (HSDK34)# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,HRYQKSTEL*# SEQUENCE: HRYQKSTEL*# ...# >HUM11228# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,IRYQKSTEL*# SEQUENCE: IRYQKSTEL*# ...# >HUM11229# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRYQKSTEL*# SEQUENCE: KRYQKSTEL*# ...# >HUM1122A# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,LRYQKSTEL*# SEQUENCE: LRYQKSTEL*# ...# >HUM1122B# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,MRYQKSTEL*# SEQUENCE: MRYQKSTEL*# ...# >HUM1122C# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,NRYQKSTEL*# SEQUENCE: NRYQKSTEL*# ...# >HUM1122D# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,QRYQKSTEL*# SEQUENCE: QRYQKSTEL*# ...# >HUM1122E# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,SRYQKSTEL*# SEQUENCE: SRYQKSTEL*# ...# >HUM1122F# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,TRYQKSTEL*# SEQUENCE: TRYQKSTEL*# ...# >HUM11230# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,VRYQKSTEL*# SEQUENCE: VRYQKSTEL*# ...# >HUM11231# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,YRYQKSTEL*# SEQUENCE: YRYQKSTEL*# ...# >HUM11232# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: direct binding/stabilisation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Histone H3.3 homologue# ANCHOR POSITIONS: 2# REFERENCES: fukazawa94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,WRYQKSTEL*# SEQUENCE: WRYQKSTEL*# ...# >HUM11233# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: procollagen alpha1(I)/alpha1(II)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA11_HUMAN,CA11_MOUSE,# & CA11_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (S21626)# REFERENCES: gao94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,IRSPEGSRK*# SEQUENCE: IRSPEGSRK*# ...# >HUM11234# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: procollagen alpha1(II)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_MOUSE)# & PIR1: (CGHU6C)# & PIR2: (A41182,B41182,A61396)# REFERENCES: gao94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,SRFTYTALK*# SEQUENCE: SRFTYTALK*# ...# >HUM11235# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: procollagen alpha2(XI)# DB REFERENCE: SWISS: (CA2B_HUMAN)# & PIR1: (CGHU2E)# REFERENCES: gao94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRSVDGSRL*# SEQUENCE: RRSVDGSRL*# ...# >HUM11236# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: procollagen alpha2(XI)# DB REFERENCE: SWISS: (CA2B_HUMAN)# & PIR1: (CGHU2E)# REFERENCES: gao94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,RRPTGTQDS*# SEQUENCE: RRPTGTQDS*# ...# >HUM11237# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MART-1# DB REFERENCE: PIR2: (A55253)# REFERENCES: kawakami94a,rosenberg96a# COMMENT: natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM11238# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MART-1# DB REFERENCE: PIR2: (A55253)# REFERENCES: kawakami94a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A2,actyesu,bindyesu,EAAGIGILTV*# SEQUENCE: EAAGIGILTV*# ...# >HUM11239# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MART-1# DB REFERENCE: PIR2: (A55253)# REFERENCES: kawakami94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,AAGIGILTVI*# SEQUENCE: AAGIGILTVI*# ...# >HUM2123A# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190)# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKEKGKDKWIELK*# SEQUENCE: GDVVAVVDIKEKGKDKWIELK*# ...# >HUM2123B# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVLAVVDIKEKGKDKWIELK*# SEQUENCE: GDVLAVVDIKEKGKDKWIELK*# ...# >HUM2123C# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVRAVVDIKEKGKDKWIELK*# SEQUENCE: GDVRAVVDIKEKGKDKWIELK*# ...# >HUM2123D# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVEAVVDIKEKGKDKWIELK*# SEQUENCE: GDVEAVVDIKEKGKDKWIELK*# ...# >HUM2123E# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVDVVDIKEKGKDKWIELK*# SEQUENCE: GDVVDVVDIKEKGKDKWIELK*# ...# >HUM2123F# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVRVVDIKEKGKDKWIELK*# SEQUENCE: GDVVRVVDIKEKGKDKWIELK*# ...# >HUM21240# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVGVVDIKEKGKDKWIELK*# SEQUENCE: GDVVGVVDIKEKGKDKWIELK*# ...# >HUM21241# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVALVDIKEKGKDKWIELK*# SEQUENCE: GDVVALVDIKEKGKDKWIELK*# ...# >HUM21242# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVARVDIKEKGKDKWIELK*# SEQUENCE: GDVVARVDIKEKGKDKWIELK*# ...# >HUM21243# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAEVDIKEKGKDKWIELK*# SEQUENCE: GDVVAEVDIKEKGKDKWIELK*# ...# >HUM21244# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVLDIKEKGKDKWIELK*# SEQUENCE: GDVVAVLDIKEKGKDKWIELK*# ...# >HUM21245# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVRDIKEKGKDKWIELK*# SEQUENCE: GDVVAVRDIKEKGKDKWIELK*# ...# >HUM21246# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVEDIKEKGKDKWIELK*# SEQUENCE: GDVVAVEDIKEKGKDKWIELK*# ...# >HUM21247# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDLKEKGKDKWIELK*# SEQUENCE: GDVVAVVDLKEKGKDKWIELK*# ...# >HUM21248# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDRKEKGKDKWIELK*# SEQUENCE: GDVVAVVDRKEKGKDKWIELK*# ...# >HUM21249# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDEKEKGKDKWIELK*# SEQUENCE: GDVVAVVDEKEKGKDKWIELK*# ...# >HUM2124A# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIREKGKDKWIELK*# SEQUENCE: GDVVAVVDIREKGKDKWIELK*# ...# >HUM2124B# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKDKGKDKWIELK*# SEQUENCE: GDVVAVVDIKDKGKDKWIELK*# ...# >HUM2124C# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKLKGKDKWIELK*# SEQUENCE: GDVVAVVDIKLKGKDKWIELK*# ...# >HUM2124D# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKRKGKDKWIELK*# SEQUENCE: GDVVAVVDIKRKGKDKWIELK*# ...# >HUM2124E# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKERGKDKWIELK*# SEQUENCE: GDVVAVVDIKERGKDKWIELK*# ...# >HUM2124F# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKELGKDKWIELK*# SEQUENCE: GDVVAVVDIKELGKDKWIELK*# ...# >HUM21250# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKEEGKDKWIELK*# SEQUENCE: GDVVAVVDIKEEGKDKWIELK*# ...# >HUM21251# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKEKRKDKWIELK*# SEQUENCE: GDVVAVVDIKEKRKDKWIELK*# ...# >HUM21252# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKEKAKDKWIELK*# SEQUENCE: GDVVAVVDIKEKAKDKWIELK*# ...# >HUM21253# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKEKGRDKWIELK*# SEQUENCE: GDVVAVVDIKEKGRDKWIELK*# ...# >HUM21254# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKEKGLDKWIELK*# SEQUENCE: GDVVAVVDIKEKGLDKWIELK*# ...# >HUM21255# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p. (71-190) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,GDVVAVVDIKEKGEDKWIELK*# SEQUENCE: GDVVAVVDIKEKGEDKWIELK*# ...# >HUM21256# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151)# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAAKYKEGY*# SEQUENCE: NKALELFRKDIAAKYKEGY*# ...# >HUM21257# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELERKDIAAKYKEGY*# SEQUENCE: NKALELERKDIAAKYKEGY*# ...# >HUM21258# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELVRKDIAAKYKEGY*# SEQUENCE: NKALELVRKDIAAKYKEGY*# ...# >HUM21259# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFKKDIAAKYKEGY*# SEQUENCE: NKALELFKKDIAAKYKEGY*# ...# >HUM2125A# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFIKDIAAKYKEGY*# SEQUENCE: NKALELFIKDIAAKYKEGY*# ...# >HUM2125B# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFEKDIAAKYKEGY*# SEQUENCE: NKALELFEKDIAAKYKEGY*# ...# >HUM2125C# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRRDIAAKYKEGY*# SEQUENCE: NKALELFRRDIAAKYKEGY*# ...# >HUM2125D# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRIDIAAKYKEGY*# SEQUENCE: NKALELFRIDIAAKYKEGY*# ...# >HUM2125E# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFREDIAAKYKEGY*# SEQUENCE: NKALELFREDIAAKYKEGY*# ...# >HUM2125F# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDKAAKYKEGY*# SEQUENCE: NKALELFRKDKAAKYKEGY*# ...# >HUM21260# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDEAAKYKEGY*# SEQUENCE: NKALELFRKDEAAKYKEGY*# ...# >HUM21261# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDLAAKYKEGY*# SEQUENCE: NKALELFRKDLAAKYKEGY*# ...# >HUM21262# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDILAKYKEGY*# SEQUENCE: NKALELFRKDILAKYKEGY*# ...# >HUM21263# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIKAKYKEGY*# SEQUENCE: NKALELFRKDIKAKYKEGY*# ...# >HUM21264# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIEAKYKEGY*# SEQUENCE: NKALELFRKDIEAKYKEGY*# ...# >HUM21265# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIALKYKEGY*# SEQUENCE: NKALELFRKDIALKYKEGY*# ...# >HUM21266# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAEKYKEGY*# SEQUENCE: NKALELFRKDIAEKYKEGY*# ...# >HUM21267# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAARYKEGY*# SEQUENCE: NKALELFRKDIAARYKEGY*# ...# >HUM21268# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAAEYKEGY*# SEQUENCE: NKALELFRKDIAAEYKEGY*# ...# >HUM21269# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAALYKEGY*# SEQUENCE: NKALELFRKDIAALYKEGY*# ...# >HUM2126A# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAAKFKEGY*# SEQUENCE: NKALELFRKDIAAKFKEGY*# ...# >HUM2126B# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAAKEKEGY*# SEQUENCE: NKALELFRKDIAAKEKEGY*# ...# >HUM2126C# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAAKAKEGY*# SEQUENCE: NKALELFRKDIAAKAKEGY*# ...# >HUM2126D# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAAKYREGY*# SEQUENCE: NKALELFRKDIAAKYREGY*# ...# >HUM2126E# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myo (132-151) homologue# ANCHOR POSITIONS:# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,NKALELFRKDIAAKYEEGY*# SEQUENCE: NKALELFRKDIAAKYEEGY*# ...# >HUM2126F# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (3-13)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCTU,CH60_MYCPA,CH60_MYCSM,CH60_MYCPA,# & CH62_MYCTU)# & PIR2: (A43509,A25902,A37335,S40245,A26950)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesu,KTIAYDEEARR*# SEQUENCE: KTIAYDEEARR*# ...# >HUM21270# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (1-15)# DB REFERENCE: PIR2: (A26950,S40245,A25902,A43509)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesu,MAKTIAYDEEARRGL*# SEQUENCE: MAKTIAYDEEARRGL*# ...# >HUM21271# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (41-55)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCTU,CH60_MYCPA,CH62_STRAL,CH60_MYCTU,# & CH62_MYCLE)# & PIR2: (A26950,C41325,A25902,A43509,S40245)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,KKWGAPTITNDGVSI*# SEQUENCE: KKWGAPTITNDGVSI*# ...# >HUM21272# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (81-95)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCTU,CH60_MYCPH,CH62_MYCTU,CH60_MYCAS,# & CH60_MYCPA,CH60_MYCXE,CH60_MYCGN,CH60_MYCGO,CH60_MYCPA,# & CH60_MYCSH,CH60_MYCSC,CH60_MYCGS,CH60_MYCRH,CH60_MYCMA,# & CH60_MYCCI,CH60_MYCUL,CH60_MYCAG,CH60_MYCIT,CH60_MYCFO,# & CH60_MYCMR,CH60_MYCAV,CH60_MYCNO,CH62_STRAL,CH60_MYCFA,# & CH60_MYCPV,CH60_MYCVA,CH60_MYCKA,CH60_MYCCH)# & PIR2: (C41325,A43509,S05292,A26950,S05295,A25902,S40245,S05293,# & S05294)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,DDVAGDGTTTATVLA*# SEQUENCE: DDVAGDGTTTATVLA*# ...# >HUM21273# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hsp 65 M.tuberculosis (91-105)# DB REFERENCE: SWISS: (CH60_MYCPV,CH62_STRAL,CH60_MYCFA,CH60_MYCVA,CH60_MYCRH,# & CH60_MYCAG,CH60_MYCIT,CH60_MYCPA,CH60_MYCTU,CH60_MYCPH,# & CH61_STRAL,CH60_MYCCI,CH60_MYCAV,CH60_MYCFO,CH62_MYCTU,# & CH60_MYCPA)# & PIR2: (S05294,C41325,S40245,S05295,B41325,A26950,A43509,S05292,# & S05293)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,ATVLAQALVREGLRN*# SEQUENCE: ATVLAQALVREGLRN*# ...# >HUM21274# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hsp 65 M.tuberculosis (171-195)# DB REFERENCE: SWISS: (CH60_MYCAV,CH60_MYCMR,CH60_MYCTU,CH60_MYCPA,CH62_MYCTU,# & CH60_MYCFO,CH60_MYCCH,CH60_MYCPA,CH62_MYCLE)# & PIR2: (A25902,A26950,A43509,S40245)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,GVITVEESNTFGLQL*# SEQUENCE: GVITVEESNTFGLQL*# ...# >HUM21275# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (181-205)# DB REFERENCE: SWISS: (CH60_MYCMR,CH60_MYCFO,CH60_MYCPA,CH62_MYCLE,CH60_MYCPA,# & CH60_MYCTU,CH60_MYCAV,CH62_MYCTU,CH60_MYCCH)# & PIR2: (S40245,A43509,A25902,A26950)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,FGLQLELTEGMRFDK*# SEQUENCE: FGLQLELTEGMRFDK*# ...# >HUM21276# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (191-205)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCPA,CH60_MYCTU,CH60_MYCPA,# & CH62_MYCTU)# & PIR2: (A25902,A26950,S40245,A43509)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,MRFDKGYISGYFVTD*# SEQUENCE: MRFDKGYISGYFVTD*# ...# >HUM21277# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (201-215)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU)# & PIR2: (A26950,A43509)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,YFVTDPERQEAVLED*# SEQUENCE: YFVTDPERQEAVLED*# ...# >HUM21278# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (211-225)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU)# & PIR2: (A43509,A26950)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,AVLEDPYILLVSSKV*# SEQUENCE: AVLEDPYILLVSSKV*# ...# >HUM21279# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (241-255)# DB REFERENCE: SWISS: (CH60_HAEIN,CH60_YEREN,CH60_PASMU,CH60_MYCPA,CH60_CHRVI,# & CH60_XANMA,CH60_MYCTU,CH62_MYCTU,CH60_HAEDU,CH60_ECOLI,# & CH60_SALTI,CH60_MYCPA,CH60_ECOLI,CH60_ACTAC)# & PIR1: (BVECGL)# & PIR2: (S56371,S40245,JC4519,S26423,B49203,S52901,C64076,A26950,# & A43509,B47073)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,AGKPLLIIAEDVEGE*# SEQUENCE: AGKPLLIIAEDVEGE*# ...# >HUM2127A# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (261-275)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCTU,CH60_MYCTU,CH60_MYCPA,CH62_MYCLE,# & CH62_STRAL)# & PIR2: (A25902,A43509,S40245,C41325,A26950)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,VVNKIRGTFKSVAVK*# SEQUENCE: VVNKIRGTFKSVAVK*# ...# >HUM2127B# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (281-295)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCLE,CH60_MYCPA,CH62_MYCTU,# & CH60_MYCTU)# & PIR2: (A26950,A43509,A25902,S40245)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,DRRKAMLQDMAILTG*# SEQUENCE: DRRKAMLQDMAILTG*# ...# >HUM2127C# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hsp 65 M.tuberculosis (291-305)# DB REFERENCE: SWISS: (CH60_MYCPA,CH60_MYCPA,CH62_MYCTU,CH60_MYCTU)# & PIR2: (A26950,A43509,S40245)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,AILTGGQVISEEVGL*# SEQUENCE: AILTGGQVISEEVGL*# ...# >HUM2127D# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (321-345)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU,CH60_MYCPA,CH60_MYCPA)# & PIR2: (A43509,A26950,S40245)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,VVVTKDETTIVEGAG*# SEQUENCE: VVVTKDETTIVEGAG*# ...# >HUM2127E# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hsp 65 M.tuberculosis (331-355)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU,CH62_MYCLE)# & PIR2: (A26950,A25902,A43509)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,VEGAGDTDAIAGRVA*# SEQUENCE: VEGAGDTDAIAGRVA*# ...# >HUM2127F# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hsp 65 M.tuberculosis (391-405)# DB REFERENCE: SWISS: (CH62_STRAL,CH60_MYCTU,CH62_MYCTU,CH62_MYCLE,CH60_MYCPA,# & CH60_MYCPA)# & PIR2: (A25902,C41325,A43509,S40245,A26950)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,KHRIEDAVRNAKAAV*# SEQUENCE: KHRIEDAVRNAKAAV*# ...# >HUM21280# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hsp 65 M.tuberculosis (441-455)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCTU,CH62_MYCTU)# & PIR2: (A25902,A43509,A26950)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,KVALEAPLKQIAFNS*# SEQUENCE: KVALEAPLKQIAFNS*# ...# >HUM21281# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (481-495)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU)# & PIR2: (A43509,A26950)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,VYEDLLAAGVADPVK*# SEQUENCE: VYEDLLAAGVADPVK*# ...# >HUM21282# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hsp 65 M.tuberculosis (491-505)# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCLE,CH62_MYCTU,CH60_MYCPA,# & CH60_MYCPA)# & PIR2: (A25902,S40245,A26950,A43509)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,ADPVKVTRSALQNAA*# SEQUENCE: ADPVKVTRSALQNAA*# ...# >HUM21283# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hsp 65 M.tuberculosis (501-515)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCPA,CH60_MYCPA,CH60_MYCTU,# & CH62_MYCLE)# & PIR2: (A43509,S40245,A26950,A25902)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,LQNAASIAGLFLTTE*# SEQUENCE: LQNAASIAGLFLTTE*# ...# >HUM21284# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 65 M.tuberculosis (511-525)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU)# & PIR2: (A26950,A43509)# REFERENCES: geluk94a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,FLTTEAVVADKPEKE*# SEQUENCE: FLTTEAVVADKPEKE*# ...# >HUM21285# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ach Rec. (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >HUM21286# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (830-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM21287# MHC MOLECULE: HLA-DQ?, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human MBP (144-163)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DQ?,actyesu,bindyesu,VDAQGTLSKIFKLGGRDSRS*# SEQUENCE: VDAQGTLSKIFKLGGRDSRS*# ...# >HUM21288# MHC MOLECULE: HLA-DP?, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human MBP (144-163)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DP?,actyesu,bindyesu,VDAQGTLSKIFKLGGRDSRS*# SEQUENCE: VDAQGTLSKIFKLGGRDSRS*# ...# >HUM21289# MHC MOLECULE: HLA-DR52c, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (1272-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52c,actyesu,bindyesu,NGQIGNDPNRDIL*# SEQUENCE: NGQIGNDPNRDIL*# ...# >HUM2128A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ML 65kD (Y464-487) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,YTLLQAAPALDKLKLTGDEATGANI*# SEQUENCE: YTLLQAAPALDKLKLTGDEATGANI*# ...# >HUM2128B# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lol pl (101-120)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR,MPH1_HOLLA,MPA1_PHAAQ,# & MPH1_HOLLA)# & PIR2: (S38581,B37881,A37881)# & PIR3: (S13614)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DQ8,actyesu,bindyesu,APYHFDLSGHAFGSMAKKGE*# SEQUENCE: APYHFDLSGHAFGSMAKKGE*# ...# >HUM2128C# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hep Pre S1 (21-47)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBV2,# & VMSA_HPBVR)# & PIR1: (SAVLA,SAVLVD)# & PIR2: (S43492,S36654,S35528,S47411)# REFERENCES: sidney92a,celis94a,serra93a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,PLGFFPDHQLDPAFGANSNNPDWDFNP*# SEQUENCE: PLGFFPDHQLDPAFGANSNNPDWDFNP*# ...# >HUM2128D# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV core (50-69)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVJ,CORA_HPBVY,CORA_HPBV2,# & CORA_HPBVW)# & PIR1: (NKVLKS,NKVLBH,NKVLAH,NKVLJ1,NKVLA6,NKVLA3)# & PIR2: (S53202,S53140,S53247,S47409,S53157,S53272,S53181,S53238,# & S47405,S53207,S53163,S53286,S53274,S01405,S53161,S53169,# & S53152,S25651,S53204,S53267,S53149,S22318,S32204,S20755,# & S53227,S53200,S20750,S53216,S20746)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DPw4,actyesu,bindyesu,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM2128E# MHC MOLECULE: HLA-DPw2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (947-969)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DPw2,actyesu,bindyesu,FNNFTVSFWLRVPKVSASHLEQY*# SEQUENCE: FNNFTVSFWLRVPKVSASHLEQY*# ...# >HUM2128F# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Malaria Y B1# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR6,actyesu,bindyesu,YLDNIKDNVGKMED*# SEQUENCE: YLDNIKDNVGKMED*# ...# >HUM21290# MHC MOLECULE: HLA-DQ?, CLASS-2, (HUMAN)# METHOD: competitive binding/proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Malaria A1 p19L (211-224)# DB REFERENCE: SWISS: (MSP1_PLAFW,MSP1_PLAFK,MSP1_PLAFC,MSP1_PLAFP,MSP1_PLAF3,# & MSP1_PLAFD)# & PIR1: (SAZQK1,SAZQGM)# & PIR2: (S05603,S16752,A45948,A25814,S06286,A44865,A24594)# REFERENCES: sidney92a,serra93a# COMMENT:# SUMMARY: HLA-DQ?,actyesu,bindyesu,YKLNFYFDLLRAKL*# SEQUENCE: YKLNFYFDLLRAKL*# ...# >HUM21291# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: CS (378-398)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR8,actyesu,bindyesu,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM21292# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HV gp 120# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,YGSDTITLPCRIKLQFINMWQE*# SEQUENCE: YGSDTITLPCRIKLQFINMWQE*# ...# >HUM21293# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MT (231-245# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU)# & PIR2: (A26950,A43509)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,LLPLLEKVIGAGKPL*# SEQUENCE: LLPLLEKVIGAGKPL*# ...# >HUM21294# MHC MOLECULE: HLA-DP2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: NP7 TPO (Y535-551)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DP2,actyesu,bindyesu,YLDPLIRGLLARPAKLQV*# SEQUENCE: YLDPLIRGLLARPAKLQV*# ...# >HUM21295# MHC MOLECULE: HLA-DQ6, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: NP7 TPO (Y535-551)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DQ6,actyesu,bindyesu,YLDPLIRGLLARPAKLQV*# SEQUENCE: YLDPLIRGLLARPAKLQV*# ...# >HUM21296# MHC MOLECULE: HLA-DP?, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: DR3 BI Y (67-85)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DP?,actyesu,bindyesu,YLLEQKRGRVDNYCRHNYGV*# SEQUENCE: YLLEQKRGRVDNYCRHNYGV*# ...# >HUM21297# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ach Rec. (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >HUM21298# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: MT 65 kD (Y3-13) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesm,YKTIAYDEEARR*# SEQUENCE: YKTIAYDEEARR*# ...# >HUM21299# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Lol pl (171-190)# ANCHOR POSITIONS:# REFERENCES: sidney92a,celis94a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesl,GDVVAVVDIKEKGKDKWIELK*# SEQUENCE: GDVVAVVDIKEKGKDKWIELK*# ...# >HUM2129A# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: TT (830-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesl,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM2129B# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ML 18K (38-5)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,EFWEFDLPGIKA*# SEQUENCE: EFWEFDLPGIKA*# ...# >HUM2129C# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human MBP (144-163)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,VDAQGTLSKIFKLGGRDSRS*# SEQUENCE: VDAQGTLSKIFKLGGRDSRS*# ...# >HUM2129D# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (1272-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,NGQIGNDPNRDIL*# SEQUENCE: NGQIGNDPNRDIL*# ...# >HUM2129E# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ML 65kD (Y464-487) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,YTLLQAAPALDKLKLTGDEATGANI*# SEQUENCE: YTLLQAAPALDKLKLTGDEATGANI*# ...# >HUM2129F# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Lol pl (191-210)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (B37881,A37881)# & PIR3: (S13614)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,ESWGAVWRIDTPDKLTGPFT*# SEQUENCE: ESWGAVWRIDTPDKLTGPFT*# ...# >HUM212A0# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ach Rec. (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >HUM212A1# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human MBP (144-163)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,VDAQGTLSKIFKLGGRDSRS*# SEQUENCE: VDAQGTLSKIFKLGGRDSRS*# ...# >HUM212A2# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: TT (1272-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesm,NGQIGNDPNRDIL*# SEQUENCE: NGQIGNDPNRDIL*# ...# >HUM212A3# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ML 65kD (Y464-487) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,YTLLQAAPALDKLKLTGDEATGANI*# SEQUENCE: YTLLQAAPALDKLKLTGDEATGANI*# ...# >HUM212A4# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Lol pl (191-210)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (B37881,A37881)# & PIR3: (S13614)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesh,ESWGAVWRIDTPDKLTGPFT*# SEQUENCE: ESWGAVWRIDTPDKLTGPFT*# ...# >HUM212A5# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Lol pl (101-120)# DB REFERENCE: SWISS: (MPH1_HOLLA,MPL1_LOLPR,MPH1_HOLLA,MPL1_LOLPR,# & MPA1_PHAAQ)# & PIR2: (A37881,S38581,B37881)# & PIR3: (S13614)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesm,APYHFDLSGHAFGSMAKKGE*# SEQUENCE: APYHFDLSGHAFGSMAKKGE*# ...# >HUM212A6# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hep Pre S1 (21-47)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBV2,# & VMSA_HPBVR)# & PIR1: (SAVLA,SAVLVD)# & PIR2: (S43492,S47411,S35528,S36654)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,PLGFFPDHQLDPAFGANSNNPDWDFNP*# SEQUENCE: PLGFFPDHQLDPAFGANSNNPDWDFNP*# ...# >HUM212A7# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as./binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV core (50-69)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVJ,CORA_HPBVY,CORA_HPBV2,# & CORA_HPBVW)# & PIR1: (NKVLKS,NKVLJ1,NKVLA3,NKVLAH,NKVLBH,NKVLA6)# & PIR2: (S53286,S53204,S53247,S53202,S53140,S53216,S53161,S20750,# & S53238,S47405,S22318,S53149,S47409,S20755,S53157,S53272,# & S53152,S25651,S53207,S53181,S53267,S32204,S53163,S53200,# & S20746,S53227,S53169,S01405,S53274)# REFERENCES: sidney92a,alexander94a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM212A8# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAT (19-31)# DB REFERENCE: SWISS: (VMT1_IAWIL,VMT1_IAFPW,VMT1_IAFPR,VMT1_IALE1,VMT1_IAUSS,# & VMT1_IAPUE,VMT1_IACKB,VMT1_IAUDO,VMT1_IAFOW,VMT1_IAANN,# & VMT1_IALE2,VMT1_IABAN,VMT1_IAMAN)# & PIR1: (MFIV1F,JN0392,B45539,MFIVWS,MFIVC,MFIV61,MFIV1K,MFIV1M,# & MFIV)# & PIR2: (S14616,S04058,S04050,S07429,S04056,S04052,S07945,# & S04054)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,PLKAEIAQRLEDV*# SEQUENCE: PLKAEIAQRLEDV*# ...# >HUM212A9# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (947-969)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,FNNFTVSFWLRVPKVSASHLEQY*# SEQUENCE: FNNFTVSFWLRVPKVSASHLEQY*# ...# >HUM212AA# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IADU3,HEMA_IAEN7,HEMA_IAAIC,HEMA_IADH6,HEMA_IADH4,# & HEMA_IABAN,HEMA_IAEN6,HEMA_IAQU7,HEMA_IAZCO,HEMA_IAME1,# & HEMA_IAUDO,HEMA_IADH2,HEMA_IANT6,HEMA_IADH1,HEMA_IAZH2,# & HEMA_IADH7,HEMA_IADH3,HEMA_IAME2,HEMA_IAVI7,HEMA_IADHM,# & HEMA_IAZUK)# & PIR1: (HMIVV,HMIV15,HMIVHA,HMIV89,HMIVDU,HMIV6,HMIVS3,HMIV33,# & HMIV98,HMIV77,HMIVH,HMIVHM,HMIV80)# & PIR2: (JQ1156,A92979)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM212AB# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ach Rec. (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >HUM212AC# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human MBP (144-163)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VDAQGTLSKIFKLGGRDSRS*# SEQUENCE: VDAQGTLSKIFKLGGRDSRS*# ...# >HUM212AD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML 65kD (Y464-487) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a,sette95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YTLLQAAPALDKLKLTGDEATGANI*# SEQUENCE: YTLLQAAPALDKLKLTGDEATGANI*# ...# >HUM212AE# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV core (50-69)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBV2,CORA_HPBVW,CORA_HPBV9,# & CORA_HPBVY)# & PIR1: (NKVLJ1,NKVLKS,NKVLA6,NKVLAH,NKVLBH,NKVLA3)# & PIR2: (S47405,S53238,S22318,S53149,S53216,S53247,S53202,S53286,# & S53204,S20755,S53161,S20750,S25651,S47409,S53157,S20746,# & S53200,S53274,S32204,S01405,S53169,S53152,S53140,S53227,# & S53163,S53267,S53207,S53181,S53272)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM212AF# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (947-969)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,FNNFTVSFWLRVPKVSASHLEQY*# SEQUENCE: FNNFTVSFWLRVPKVSASHLEQY*# ...# >HUM212B0# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MT (211-225)# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCTU)# & PIR2: (A26950,A43509)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesh,AVLEDPYILLVSSKV*# SEQUENCE: AVLEDPYILLVSSKV*# ...# >HUM212B1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Rabies virus glycoprotein# DB REFERENCE: SWISS: (VGLG_RABVP,VGLG_RABVV,VGLG_RABVH,VGLG_RABVS,# & VGLG_RABVE)# & PIR1: (VGVNDB,VGVNSB,VGVNG,VGVNRB,VGVNRV)# & PIR2: (JC1098,S30575,S33419)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,DALESIMTTKSVSFR*# SEQUENCE: DALESIMTTKSVSFR*# ...# >HUM212B2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: NP7 TPO (Y535-551)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YLDPLIRGLLARPAKLQV*# SEQUENCE: YLDPLIRGLLARPAKLQV*# ...# >HUM212B3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: B. pertussis (30-41)# DB REFERENCE: SWISS: (TOX1_BORPE,TOX1_BORPE)# & PIR1: (WEBR11,WEBR1P)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesm,DNVLDHLTGRSC*# SEQUENCE: DNVLDHLTGRSC*# ...# >HUM212B4# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ach Rec. (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >HUM212B5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: ML 18K (38-5)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesm,EFWEFDLPGIKA*# SEQUENCE: EFWEFDLPGIKA*# ...# >HUM212B6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ML 65kD (Y464-487) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YTLLQAAPALDKLKLTGDEATGANI*# SEQUENCE: YTLLQAAPALDKLKLTGDEATGANI*# ...# >HUM212B7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as./direct binding# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Lol pl (101-120)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPH1_HOLLA,MPH1_HOLLA,MPA1_PHAAQ,# & MPL1_LOLPR)# & PIR2: (S38581,A37881,B37881)# & PIR3: (S13614)# REFERENCES: sidney92a,sette93b# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesh,APYHFDLSGHAFGSMAKKGE*# SEQUENCE: APYHFDLSGHAFGSMAKKGE*# ...# >HUM212B8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV core (50-69)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVW,CORA_HPBVJ,CORA_HPBV2,# & CORA_HPBV9)# & PIR1: (NKVLA3,NKVLJ1,NKVLA6,NKVLKS,NKVLAH,NKVLBH)# & PIR2: (S53161,S20755,S53216,S53149,S53163,S53181,S53204,S53247,# & S53272,S53274,S53152,S53200,S53140,S01405,S25651,S47409,# & S53227,S53169,S22318,S20750,S47405,S53202,S32204,S20746,# & S53157,S53286,S53238,S53207,S53267)# REFERENCES: sidney92a,alexander94a,sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM212B9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (947-969)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,FNNFTVSFWLRVPKVSASHLEQY*# SEQUENCE: FNNFTVSFWLRVPKVSASHLEQY*# ...# >HUM212BA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding/binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IAME2,HEMA_IAUDO,HEMA_IADU3,HEMA_IAEN7,HEMA_IAZUK,# & HEMA_IADHM,HEMA_IADH2,HEMA_IAZCO,HEMA_IABAN,HEMA_IAEN6,# & HEMA_IANT6,HEMA_IAZH2,HEMA_IADH3,HEMA_IADH6,HEMA_IAQU7,# & HEMA_IADH4,HEMA_IAAIC,HEMA_IAVI7,HEMA_IADH7,HEMA_IAME1,# & HEMA_IADH1)# & PIR1: (HMIVH,HMIV89,HMIVHM,HMIV77,HMIV6,HMIVV,HMIV15,HMIVDU,# & HMIV98,HMIV33,HMIVS3,HMIV80,HMIVHA)# & PIR2: (JQ1156,A92979)# REFERENCES: hill94a,marshall95a,sidney92a,marshall94a,hammer95a,alexander94a,# & woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM212BB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: RAG (51-65)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,EVWREEAYHAADIKD*# SEQUENCE: EVWREEAYHAADIKD*# ...# >HUM212BC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CS (378-398)# ANCHOR POSITIONS:# REFERENCES: sidney92a,alexander94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM212BD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HV gp 120# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YGSDTITLPCRIKLQFINMWQE*# SEQUENCE: YGSDTITLPCRIKLQFINMWQE*# ...# >HUM212BE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Rabies virus glycoprotein# DB REFERENCE: SWISS: (VGLG_RABVH,VGLG_RABVS,VGLG_RABVE,VGLG_RABVV,# & VGLG_RABVP)# & PIR1: (VGVNDB,VGVNG,VGVNRB,VGVNRV,VGVNSB)# & PIR2: (S30575,JC1098,S33419)# REFERENCES: sidney92a,sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DALESIMTTKSVSFR*# SEQUENCE: DALESIMTTKSVSFR*# ...# >HUM212BF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: NP7 TPO (Y535-551)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YLDPLIRGLLARPAKLQV*# SEQUENCE: YLDPLIRGLLARPAKLQV*# ...# >HUM212C0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human MBP (144-163)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesh,VDAQGTLSKIFKLGGRDSRS*# SEQUENCE: VDAQGTLSKIFKLGGRDSRS*# ...# >HUM212C1# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML 65kD (Y464-487) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,YTLLQAAPALDKLKLTGDEATGANI*# SEQUENCE: YTLLQAAPALDKLKLTGDEATGANI*# ...# >HUM212C2# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Lol pl (191-210)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (B37881,A37881)# & PIR3: (S13614)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,ESWGAVWRIDTPDKLTGPFT*# SEQUENCE: ESWGAVWRIDTPDKLTGPFT*# ...# >HUM212C3# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Lol pl (101-120)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR,MPH1_HOLLA,MPA1_PHAAQ,# & MPH1_HOLLA)# & PIR2: (A37881,B37881,S38581)# & PIR3: (S13614)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,APYHFDLSGHAFGSMAKKGE*# SEQUENCE: APYHFDLSGHAFGSMAKKGE*# ...# >HUM212C4# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV core (50-69)# DB REFERENCE: SWISS: (CORA_HPBV2,CORA_HPBVW,CORA_HPBVJ,CORA_HPBVY,# & CORA_HPBV9)# & PIR1: (NKVLAH,NKVLJ1,NKVLBH,NKVLA3,NKVLA6,NKVLKS)# & PIR2: (S53169,S47405,S25651,S53238,S53157,S53163,S53286,S53207,# & S53140,S53274,S53149,S53216,S53161,S01405,S47409,S53181,# & S20755,S53227,S53272,S53204,S53247,S53200,S53152,S53202,# & S22318,S20750,S53267,S32204,S20746)# REFERENCES: sidney92a,alexander94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM212C5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: TT (947-969)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesh,FNNFTVSFWLRVPKVSASHLEQY*# SEQUENCE: FNNFTVSFWLRVPKVSASHLEQY*# ...# >HUM212C6# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HV gp 120# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,YGSDTITLPCRIKLQFINMWQE*# SEQUENCE: YGSDTITLPCRIKLQFINMWQE*# ...# >HUM212C7# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: NP7 TPO (Y535-551)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,YLDPLIRGLLARPAKLQV*# SEQUENCE: YLDPLIRGLLARPAKLQV*# ...# >HUM212C8# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ach Rec. (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >HUM212C9# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human MBP (144-163)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,VDAQGTLSKIFKLGGRDSRS*# SEQUENCE: VDAQGTLSKIFKLGGRDSRS*# ...# >HUM212CA# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV core (50-69)# DB REFERENCE: SWISS: (CORA_HPBVW,CORA_HPBV9,CORA_HPBV2,CORA_HPBVJ,# & CORA_HPBVY)# & PIR1: (NKVLAH,NKVLA3,NKVLBH,NKVLA6,NKVLJ1,NKVLKS)# & PIR2: (S47405,S25651,S53286,S53207,S53140,S53274,S20755,S53227,# & S53157,S53238,S53202,S22318,S53267,S53181,S53204,S53272,# & S53152,S53247,S53200,S53161,S47409,S53216,S20750,S32204,# & S20746,S53149,S01405,S53163,S53169)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM212CB# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAT (19-31)# DB REFERENCE: SWISS: (VMT1_IALE1,VMT1_IAWIL,VMT1_IAANN,VMT1_IALE2,VMT1_IABAN,# & VMT1_IAMAN,VMT1_IAFPW,VMT1_IAUSS,VMT1_IAFPR,VMT1_IAPUE,# & VMT1_IAFOW,VMT1_IAUDO,VMT1_IACKB)# & PIR1: (MFIV1K,B45539,JN0392,MFIV1M,MFIVC,MFIVWS,MFIV61,MFIV1F,# & MFIV)# & PIR2: (S14616,S04050,S04052,S04058,S07945,S04054,S04056,# & S07429)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PLKAEIAQRLEDV*# SEQUENCE: PLKAEIAQRLEDV*# ...# >HUM212CC# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (947-969)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,FNNFTVSFWLRVPKVSASHLEQY*# SEQUENCE: FNNFTVSFWLRVPKVSASHLEQY*# ...# >HUM212CD# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lol pl (71-90)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (B37881,A37881)# & PIR3: (S13614)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,SCFEIKCTKPESCSGEAVTV*# SEQUENCE: SCFEIKCTKPESCSGEAVTV*# ...# >HUM212CE# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MT (211-225)# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCTU)# & PIR2: (A26950,A43509)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AVLEDPYILLVSSKV*# SEQUENCE: AVLEDPYILLVSSKV*# ...# >HUM212CF# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Rabies virus glycoprotein# DB REFERENCE: SWISS: (VGLG_RABVS,VGLG_RABVP,VGLG_RABVH,VGLG_RABVE,# & VGLG_RABVV)# & PIR1: (VGVNG,VGVNSB,VGVNDB,VGVNRV,VGVNRB)# & PIR2: (S33419,JC1098,S30575)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,DALESIMTTKSVSFR*# SEQUENCE: DALESIMTTKSVSFR*# ...# >HUM212D0# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,NYIKANSKFIGITE*# SEQUENCE: NYIKANSKFIGITE*# ...# >HUM212D1# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,TYIKANSKFIGITE*# SEQUENCE: TYIKANSKFIGITE*# ...# >HUM212D2# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QFIKANSKFIGITE*# SEQUENCE: QFIKANSKFIGITE*# ...# >HUM212D3# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QSIKANSKFIGITE*# SEQUENCE: QSIKANSKFIGITE*# ...# >HUM212D4# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QEIKANSKFIGITE*# SEQUENCE: QEIKANSKFIGITE*# ...# >HUM212D5# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIRANSKFIGITE*# SEQUENCE: QYIRANSKFIGITE*# ...# >HUM212D6# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYISANSKFIGITE*# SEQUENCE: QYISANSKFIGITE*# ...# >HUM212D7# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIIANSKFIGITE*# SEQUENCE: QYIIANSKFIGITE*# ...# >HUM212D8# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKSNSKFIGITE*# SEQUENCE: QYIKSNSKFIGITE*# ...# >HUM212D9# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKAASKFIGITE*# SEQUENCE: QYIKAASKFIGITE*# ...# >HUM212DA# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANAKFIGITE*# SEQUENCE: QYIKANAKFIGITE*# ...# >HUM212DB# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesl,QYIKANQKFIGITE*# SEQUENCE: QYIKANQKFIGITE*# ...# >HUM212DC# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSSFIGITE*# SEQUENCE: QYIKANSSFIGITE*# ...# >HUM212DD# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKYIGITE*# SEQUENCE: QYIKANSKYIGITE*# ...# >HUM212DE# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKSIGITE*# SEQUENCE: QYIKANSKSIGITE*# ...# >HUM212DF# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKEIGITE*# SEQUENCE: QYIKANSKEIGITE*# ...# >HUM212E0# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFVGITE*# SEQUENCE: QYIKANSKFVGITE*# ...# >HUM212E1# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFQGITE*# SEQUENCE: QYIKANSKFQGITE*# ...# >HUM212E2# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFKGITE*# SEQUENCE: QYIKANSKFKGITE*# ...# >HUM212E3# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIYITE*# SEQUENCE: QYIKANSKFIYITE*# ...# >HUM212E4# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGLTE*# SEQUENCE: QYIKANSKFIGLTE*# ...# >HUM212E5# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGQTE*# SEQUENCE: QYIKANSKFIGQTE*# ...# >HUM212E6# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGKTE*# SEQUENCE: QYIKANSKFIGKTE*# ...# >HUM212E7# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGISE*# SEQUENCE: QYIKANSKFIGISE*# ...# >HUM212E8# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGIFE*# SEQUENCE: QYIKANSKFIGIFE*# ...# >HUM212E9# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGIKE*# SEQUENCE: QYIKANSKFIGIKE*# ...# >HUM212EA# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGITD*# SEQUENCE: QYIKANSKFIGITD*# ...# >HUM212EB# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGITV*# SEQUENCE: QYIKANSKFIGITV*# ...# >HUM212EC# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,QYIKANSKFIGITK*# SEQUENCE: QYIKANSKFIGITK*# ...# >HUM212ED# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (132-150)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,NKALELFRKDIAAKYKEGY*# SEQUENCE: NKALELFRKDIAAKYKEGY*# ...# >HUM212EE# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (132-147)# DB REFERENCE: SWISS: (MYG_BALAC,MYG_MEGNO,MYG_GLOME,MYG_ORCOR,MYG_PHYCA,# & MYG_TURTR,MYG_PHYCA,MYG_INIGE,MYG_BALPH,MYG_ESCGI,# & MYG_CASFI)# & PIR1: (MYWHK,MYWHP,MYDDBS,MYWHC,MYDDAR,MYWHF,MYWHT,MYWHH,MYDD,# & MYWHL)# & PIR2: (JN0410)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,NKALELFRKDIAAKYK*# SEQUENCE: NKALELFRKDIAAKYK*# ...# >HUM212EF# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (132-146)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_ESCGI,MYG_INIGE,MYG_CASFI,MYG_BALPH,# & MYG_PHYCA,MYG_TURTR,MYG_MEGNO,MYG_BALAC,MYG_GLOME,# & MYG_ORCOR)# & PIR1: (MYWHK,MYWHC,MYDDBS,MYWHF,MYDDAR,MYWHP,MYWHT,MYDD,MYWHL,# & MYWHH)# & PIR2: (JN0410)# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,NKALELFRKDIAAKY*# SEQUENCE: NKALELFRKDIAAKY*# ...# >HUM212F0# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (134-150)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,ALELFRKDIAAKYKEGY*# SEQUENCE: ALELFRKDIAAKYKEGY*# ...# >HUM212F1# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Sperm whale myoglobin (136-150)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,ELFRKDIAAKYKEGY*# SEQUENCE: ELFRKDIAAKYKEGY*# ...# >HUM212F2# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (137-150)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,LFRKDIAAKYKEGY*# SEQUENCE: LFRKDIAAKYKEGY*# ...# >HUM212F3# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Sperm whale myoglobin (138-150)# ANCHOR POSITIONS:# REFERENCES: sidney92a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,FRKDIAAKYKEGY*# SEQUENCE: FRKDIAAKYKEGY*# ...# >HUM212F4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (103-115)# DB REFERENCE: SWISS: (HEMA_IADHM,HEMA_IADHK,HEMA_IAEN7,HEMA_IAME6,HEMA_IADH2,# & HEMA_IAX31,HEMA_IAEN6,HEMA_IADH1,HEMA_IADH6,HEMA_IADH4,# & HEMA_IAME1,HEMA_IADH7,HEMA_IAAIC,HEMA_IAVI7,HEMA_IAHMI,# & HEMA_IAZH3,HEMA_IAHUR,HEMA_IAMAO,HEMA_IAGHK,HEMA_IADU3,# & HEMA_IANT6,HEMA_IADH3,HEMA_IAUDO,HEMA_IAQU7,HEMA_IADHL,# & HEMA_IAZCO,HEMA_IAZH2,HEMA_IABAN,HEMA_IADM2)# & PIR1: (HMIVE2,HMIV89,HMIV77,HMIV80,HMIVHA,HMIVE1,HMIVH,HMIVS2,# & HMIV15,HMIV86,HMIVDU,HMIV98,HMIVS3,HMIVV,HMIV33,HMIV6)# & PIR2: (S52199,S52176,S52191,S52187,S52188,JQ1156,S52180,JQ2375,# & S52189,JQ1153,S52174,A93233,JQ2378,JQ2377,S52179,S52182,# & S52197,JQ2374,S52195,S52173,S52175,A92979,S52186,S52183,# & JQ1155,S52178,JQ1154,S52185)# & PIR3: (S38637)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PDYASLRSLVASS*# SEQUENCE: PDYASLRSLVASS*# ...# >HUM212F5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding/direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IADHM,HEMA_IAZUK,HEMA_IADH2,HEMA_IAEN7,HEMA_IAEN6,# & HEMA_IAAIC,HEMA_IAVI7,HEMA_IABAN,HEMA_IAZH2,HEMA_IAQU7,# & HEMA_IAZCO,HEMA_IAUDO,HEMA_IANT6,HEMA_IAME2,HEMA_IADU3,# & HEMA_IADH3,HEMA_IADH1,HEMA_IADH6,HEMA_IADH4,HEMA_IAME1,# & HEMA_IADH7)# & PIR1: (HMIV80,HMIVHA,HMIV77,HMIV89,HMIVH,HMIVHM,HMIV15,HMIV98,# & HMIVS3,HMIV6,HMIVV,HMIVDU,HMIV33)# & PIR2: (JQ1156,A92979)# REFERENCES: hill94a,marshall94a,hedley94a,alexander94a,woulfe95a,# & raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM212F6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (591-603)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,KIYSYFPSVISKV*# SEQUENCE: KIYSYFPSVISKV*# ...# >HUM212F7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (90-102)# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HFFKNIVTPRTPA*# SEQUENCE: HFFKNIVTPRTPA*# ...# >HUM212F8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu NP (383-395)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,SRYWAIRTRSGGI*# SEQUENCE: SRYWAIRTRSGGI*# ...# >HUM212F9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (828-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,MQYIKANSKFIGI*# SEQUENCE: MQYIKANSKFIGI*# ...# >HUM212FA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Matrix (18-13)# DB REFERENCE: SWISS: (VMT1_IAUSS,VMT1_IAUDO,VMT1_IAFOW,VMT1_IAWIL,VMT1_IALE1,# & VMT1_IABAN,VMT1_IAMAN,VMT1_IAANN,VMT1_IAFPW,VMT1_IAFPR,# & VMT1_IALE2,VMT1_IACKB,VMT1_IAPUE)# & PIR1: (MFIVC,MFIV,JN0392,MFIV61,MFIV1K,MFIVWS,MFIV1F,MFIV1M,# & B45539)# & PIR2: (S07429,S14616,S04054,S04058,S04052,S04050,S07945,# & S04056)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,GPLKAEIAQRLED*# SEQUENCE: GPLKAEIAQRLED*# ...# >HUM212FB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Pertussis toxin (31-43)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,NVLDHLTGRSSQV*# SEQUENCE: NVLDHLTGRSSQV*# ...# >HUM212FC# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Myoglobin (67-79)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA,MYG_RABIT,MYG_TURTR,MYG_GLOME,# & MYG_KOGSI,MYG_ORCOR)# & PIR1: (MYWHL,MYWHW,MYRB,MYWHT,MYWHP,MYDDBS,MYDD)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,TVLTALGAILKKK*# SEQUENCE: TVLTALGAILKKK*# ...# >HUM212FD# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: M. leprae 65kDa (416-428)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,TLLQAAPALDKLK*# SEQUENCE: TLLQAAPALDKLK*# ...# >HUM212FE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tuberculosis 19 kDa (2-14)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HRVKRGLTVAVAG*# SEQUENCE: HRVKRGLTVAVAG*# ...# >HUM212FF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (103-115)# DB REFERENCE: SWISS: (HEMA_IAX31,HEMA_IADH1,HEMA_IADH4,HEMA_IAME1,HEMA_IADH7,# & HEMA_IADH6,HEMA_IAZH3,HEMA_IAHMI,HEMA_IADH3,HEMA_IADU3,# & HEMA_IAUDO,HEMA_IAQU7,HEMA_IABAN,HEMA_IAZH2,HEMA_IAZCO,# & HEMA_IAHUR,HEMA_IAVI7,HEMA_IAME6,HEMA_IAEN7,HEMA_IADHL,# & HEMA_IAEN6,HEMA_IAAIC,HEMA_IADHM,HEMA_IADM2,HEMA_IADH2,# & HEMA_IANT6,HEMA_IAMAO,HEMA_IAGHK,HEMA_IADHK)# & PIR1: (HMIV77,HMIV89,HMIVHA,HMIV15,HMIV33,HMIV6,HMIVDU,HMIVS3,# & HMIVH,HMIV86,HMIVE1,HMIVV,HMIV98,HMIV80,HMIVS2,HMIVE2)# & PIR2: (S52174,S52188,JQ1156,A92979,S52180,S52189,JQ2375,S52179,# & JQ2374,S52197,S52173,S52195,S52187,S52176,A93233,JQ2378,# & S52178,S52199,JQ2377,JQ1155,JQ1153,S52185,JQ1154,S52182,# & S52175,S52191,S52183,S52186)# & PIR3: (S38637)# REFERENCES: marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PDYASLRSLVASS*# SEQUENCE: PDYASLRSLVASS*# ...# >HUM21300# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (591-603)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KIYSYFPSVISKV*# SEQUENCE: KIYSYFPSVISKV*# ...# >HUM21301# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (90-102)# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HFFKNIVTPRTPA*# SEQUENCE: HFFKNIVTPRTPA*# ...# >HUM21302# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (23-35)# DB REFERENCE: SWISS: (HEMA_IAHMI,HEMA_IAHK6,HEMA_IADH3,HEMA_IAHTE,HEMA_IAHSA,# & HEMA_IAHUR,HEMA_IAAIC,HEMA_IANT6,HEMA_IAZUK,HEMA_IAHRO,# & HEMA_IAHFO,HEMA_IADH7,HEMA_IAHK7,HEMA_IAHSU,HEMA_IADH1,# & HEMA_IADH6,HEMA_IAHNM,HEMA_IAX31)# & PIR1: (HMIV33,HMIVEE,HMIVE6,HMIVE8,HMIVHA,HMIV77,HMIVE2,HMIVE7,# & HMIVE9,HMIV98,HMIVE5,HMIVH,HMIVET,HMIV15,HMIVE1)# & PIR2: (A93233)# & PIR3: (S33703)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,GTLVKTITDDQIE*# SEQUENCE: GTLVKTITDDQIE*# ...# >HUM21303# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flu NP (383-395)# ANCHOR POSITIONS:# REFERENCES: marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SRYWAIRTRSGGI*# SEQUENCE: SRYWAIRTRSGGI*# ...# >HUM21304# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (828-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,MQYIKANSKFIGI*# SEQUENCE: MQYIKANSKFIGI*# ...# >HUM21305# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Myoglobin (67-79)# DB REFERENCE: SWISS: (MYG_KOGSI,MYG_PHYCA,MYG_TURTR,MYG_PHYCA,MYG_RABIT,# & MYG_ORCOR,MYG_GLOME)# & PIR1: (MYDD,MYWHT,MYWHW,MYWHP,MYDDBS,MYWHL,MYRB)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,TVLTALGAILKKK*# SEQUENCE: TVLTALGAILKKK*# ...# >HUM21306# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (828-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,MQYIKANSKFIGI*# SEQUENCE: MQYIKANSKFIGI*# ...# >HUM21307# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. leprae 65kDa (416-428)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,TLLQAAPALDKLK*# SEQUENCE: TLLQAAPALDKLK*# ...# >HUM21308# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC/competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IAUDO,HEMA_IAAIC,HEMA_IAZH2,HEMA_IABAN,HEMA_IAQU7,# & HEMA_IAME2,HEMA_IAEN7,HEMA_IADHM,HEMA_IANT6,HEMA_IAZUK,# & HEMA_IAZCO,HEMA_IAME1,HEMA_IADH4,HEMA_IADH3,HEMA_IAVI7,# & HEMA_IAEN6,HEMA_IADH2,HEMA_IADH6,HEMA_IADH1,HEMA_IADH7,# & HEMA_IADU3)# & PIR1: (HMIVV,HMIV6,HMIVHA,HMIV15,HMIV80,HMIVH,HMIVDU,HMIVS3,# & HMIV89,HMIVHM,HMIV33,HMIV98,HMIV77)# & PIR2: (JQ1156,A92979)# REFERENCES: vogt94a,marshall94a,alexander94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM21309# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (591-603)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,KIYSYFPSVISKV*# SEQUENCE: KIYSYFPSVISKV*# ...# >HUM2130A# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (90-102)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,HFFKNIVTPRTPA*# SEQUENCE: HFFKNIVTPRTPA*# ...# >HUM2130B# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (103-115)# DB REFERENCE: SWISS: (HEMA_IAME1,HEMA_IAEN7,HEMA_IANT6,HEMA_IADH7,HEMA_IAMAO,# & HEMA_IADHK,HEMA_IAX31,HEMA_IADU3,HEMA_IAGHK,HEMA_IAQU7,# & HEMA_IADH2,HEMA_IAME6,HEMA_IADH6,HEMA_IADHL,HEMA_IADM2,# & HEMA_IADH4,HEMA_IADH3,HEMA_IAVI7,HEMA_IAZCO,HEMA_IAEN6,# & HEMA_IADH1,HEMA_IADHM,HEMA_IAZH3,HEMA_IAHUR,HEMA_IAHMI,# & HEMA_IAUDO,HEMA_IAAIC,HEMA_IAZH2,HEMA_IABAN)# & PIR1: (HMIVHA,HMIV6,HMIV77,HMIV89,HMIV98,HMIVDU,HMIV80,HMIV15,# & HMIV86,HMIVE2,HMIVH,HMIVE1,HMIV33,HMIVV,HMIVS2,HMIVS3)# & PIR2: (S52174,S52187,S52176,JQ2375,S52180,S52189,S52182,S52199,# & JQ1155,S52175,S52191,JQ1154,JQ1153,S52188,S52186,JQ2378,# & A92979,JQ2374,S52197,S52183,A93233,JQ1156,JQ2377,S52173,# & S52179,S52195,S52178,S52185)# & PIR3: (S38637)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,PDYASLRSLVASS*# SEQUENCE: PDYASLRSLVASS*# ...# >HUM2130C# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu NP (383-395)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,SRYWAIRTRSGGI*# SEQUENCE: SRYWAIRTRSGGI*# ...# >HUM2130D# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tuberculosis 19 kDa (2-14)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,HRVKRGLTVAVAG*# SEQUENCE: HRVKRGLTVAVAG*# ...# >HUM2130E# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Matrix (18-13)# DB REFERENCE: SWISS: (VMT1_IAFOW,VMT1_IAANN,VMT1_IAUDO,VMT1_IAWIL,VMT1_IABAN,# & VMT1_IAMAN,VMT1_IALE2,VMT1_IAFPR,VMT1_IALE1,VMT1_IACKB,# & VMT1_IAPUE,VMT1_IAUSS,VMT1_IAFPW)# & PIR1: (MFIV1M,MFIVWS,MFIV1F,MFIV1K,JN0392,MFIVC,B45539,MFIV61,# & MFIV)# & PIR2: (S04056,S07429,S04052,S04054,S04058,S14616,S07945,# & S04050)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,GPLKAEIAQRLED*# SEQUENCE: GPLKAEIAQRLED*# ...# >HUM2130F# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Myoglobin (67-79)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_ORCOR,MYG_RABIT,MYG_GLOME,MYG_PHYCA,# & MYG_KOGSI,MYG_TURTR)# & PIR1: (MYDD,MYWHT,MYWHP,MYWHL,MYWHW,MYDDBS,MYRB)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,TVLTALGAILKKK*# SEQUENCE: TVLTALGAILKKK*# ...# >HUM21310# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tuberculosis 19 kDa (2-14)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,HRVKRGLTVAVAG*# SEQUENCE: HRVKRGLTVAVAG*# ...# >HUM21311# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Pertussis toxin (31-43)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,NVLDHLTGRSSQV*# SEQUENCE: NVLDHLTGRSSQV*# ...# >HUM21312# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Myoglobin (110-122)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA,MYG_INIGE,MYG_ESCGI)# & PIR1: (MYWHC,MYWHP,MYDDAR)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AIIHVLHSRHPGD*# SEQUENCE: AIIHVLHSRHPGD*# ...# >HUM21313# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (103-115)# DB REFERENCE: SWISS: (HEMA_IAMAO,HEMA_IAME1,HEMA_IADHK,HEMA_IAX31,HEMA_IADH3,# & HEMA_IAVI7,HEMA_IAZCO,HEMA_IADH1,HEMA_IADH6,HEMA_IADHM,# & HEMA_IAGHK,HEMA_IADH7,HEMA_IADU3,HEMA_IAQU7,HEMA_IADH2,# & HEMA_IAME6,HEMA_IADHL,HEMA_IAZH2,HEMA_IABAN,HEMA_IAAIC,# & HEMA_IAHUR,HEMA_IAZH3,HEMA_IADM2,HEMA_IADH4,HEMA_IAEN6,# & HEMA_IAHMI,HEMA_IAUDO,HEMA_IAEN7,HEMA_IANT6)# & PIR1: (HMIV80,HMIV77,HMIVDU,HMIV6,HMIVS2,HMIV33,HMIVH,HMIVE1,# & HMIV15,HMIV86,HMIVE2,HMIVV,HMIVHA,HMIVS3,HMIV98,# & HMIV89)# & PIR2: (S52175,JQ1154,JQ1153,S52180,S52182,S52199,JQ2377,S52179,# & S52185,S52188,JQ2375,S52183,S52187,S52174,A92979,JQ2374,# & S52197,JQ1155,JQ1156,S52176,S52189,S52178,JQ2378,S52186,# & S52191,A93233,S52173,S52195)# & PIR3: (S38637)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,PDYASLRSLVASS*# SEQUENCE: PDYASLRSLVASS*# ...# >HUM21314# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (591-603)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,KIYSYFPSVISKV*# SEQUENCE: KIYSYFPSVISKV*# ...# >HUM21315# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IAAIC,HEMA_IAME1,HEMA_IADH2,HEMA_IAQU7,HEMA_IAME2,# & HEMA_IADH4,HEMA_IANT6,HEMA_IAEN7,HEMA_IADH7,HEMA_IAVI7,# & HEMA_IAZCO,HEMA_IADH3,HEMA_IADHM,HEMA_IADH6,HEMA_IADH1,# & HEMA_IAEN6,HEMA_IADU3,HEMA_IAZUK,HEMA_IAZH2,HEMA_IABAN,# & HEMA_IAUDO)# & PIR1: (HMIV15,HMIV98,HMIVDU,HMIVS3,HMIVHA,HMIV33,HMIV6,HMIV80,# & HMIV89,HMIVHM,HMIVV,HMIV77,HMIVH)# & PIR2: (A92979,JQ1156)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM21316# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: M. leprae 65kDa (416-428)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,TLLQAAPALDKLK*# SEQUENCE: TLLQAAPALDKLK*# ...# >HUM21317# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (828-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,MQYIKANSKFIGI*# SEQUENCE: MQYIKANSKFIGI*# ...# >HUM21318# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (90-102)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,HFFKNIVTPRTPA*# SEQUENCE: HFFKNIVTPRTPA*# ...# >HUM21319# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Matrix (18-13)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IAUDO,VMT1_IAFPR,VMT1_IALE1,VMT1_IAPUE,# & VMT1_IAFPW,VMT1_IABAN,VMT1_IAMAN,VMT1_IAANN,VMT1_IAFOW,# & VMT1_IAWIL,VMT1_IAUSS,VMT1_IACKB)# & PIR1: (MFIV1M,MFIV61,MFIV1F,JN0392,MFIVC,B45539,MFIV1K,MFIVWS,# & MFIV)# & PIR2: (S04052,S07429,S07945,S14616,S04050,S04056,S04054,# & S04058)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,GPLKAEIAQRLED*# SEQUENCE: GPLKAEIAQRLED*# ...# >HUM2131A# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (591-603)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KIYSYFPSVISKV*# SEQUENCE: KIYSYFPSVISKV*# ...# >HUM2131B# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (90-102)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HFFKNIVTPRTPA*# SEQUENCE: HFFKNIVTPRTPA*# ...# >HUM2131C# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (103-115)# DB REFERENCE: SWISS: (HEMA_IADH6,HEMA_IADH1,HEMA_IAEN6,HEMA_IADU3,HEMA_IADHK,# & HEMA_IAUDO,HEMA_IADM2,HEMA_IADH2,HEMA_IADHM,HEMA_IADH3,# & HEMA_IAZCO,HEMA_IAVI7,HEMA_IANT6,HEMA_IAEN7,HEMA_IAMAO,# & HEMA_IADH7,HEMA_IAME1,HEMA_IAAIC,HEMA_IAZH3,HEMA_IAME6,# & HEMA_IAQU7,HEMA_IABAN,HEMA_IAZH2,HEMA_IAHUR,HEMA_IAHMI,# & HEMA_IAX31,HEMA_IADH4,HEMA_IAGHK,HEMA_IADHL)# & PIR1: (HMIVE2,HMIVH,HMIVDU,HMIV86,HMIVS3,HMIVV,HMIV15,HMIV98,# & HMIVHA,HMIVE1,HMIVS2,HMIV6,HMIV33,HMIV89,HMIV77,# & HMIV80)# & PIR2: (S52173,A93233,S52178,S52186,JQ2378,JQ1156,S52189,S52176,# & S52188,JQ2377,S52185,S52179,S52183,S52187,JQ2374,S52197,# & JQ1154,JQ1153,S52182,JQ2375,S52174,S52191,S52195,S52180,# & S52175,S52199,JQ1155,A92979)# & PIR3: (S38637)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PDYASLRSLVASS*# SEQUENCE: PDYASLRSLVASS*# ...# >HUM2131D# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IAZCO,HEMA_IAUDO,HEMA_IAAIC,HEMA_IAEN6,HEMA_IAVI7,# & HEMA_IADH3,HEMA_IAQU7,HEMA_IAME1,HEMA_IAZH2,HEMA_IABAN,# & HEMA_IADHM,HEMA_IADH7,HEMA_IAEN7,HEMA_IADH4,HEMA_IADH6,# & HEMA_IADH1,HEMA_IADU3,HEMA_IANT6,HEMA_IADH2,HEMA_IAME2,# & HEMA_IAZUK)# & PIR1: (HMIV33,HMIV80,HMIV77,HMIVHA,HMIVDU,HMIVS3,HMIV98,HMIVH,# & HMIVV,HMIV6,HMIV15,HMIVHM,HMIV89)# & PIR2: (JQ1156,A92979)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM2131E# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Flu NP (383-395)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,SRYWAIRTRSGGI*# SEQUENCE: SRYWAIRTRSGGI*# ...# >HUM2131F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: M. leprae 65kDa (416-428)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,TLLQAAPALDKLK*# SEQUENCE: TLLQAAPALDKLK*# ...# >HUM21320# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (828-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,MQYIKANSKFIGI*# SEQUENCE: MQYIKANSKFIGI*# ...# >HUM21321# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (591-603)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,KIYSYFPSVISKV*# SEQUENCE: KIYSYFPSVISKV*# ...# >HUM21322# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as./proliferation# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IADH1,HEMA_IADH6,HEMA_IANT6,HEMA_IAME2,HEMA_IADH2,# & HEMA_IAZUK,HEMA_IADH7,HEMA_IAQU7,HEMA_IAZH2,HEMA_IAZCO,# & HEMA_IAUDO,HEMA_IAAIC,HEMA_IAVI7,HEMA_IAEN6,HEMA_IADU3,# & HEMA_IAME1,HEMA_IABAN,HEMA_IADHM,HEMA_IAEN7,HEMA_IADH3,# & HEMA_IADH4)# & PIR1: (HMIV77,HMIV33,HMIVDU,HMIV6,HMIVHA,HMIV15,HMIVS3,HMIVV,# & HMIVH,HMIV89,HMIV98,HMIVHM,HMIV80)# & PIR2: (A92979,JQ1156)# REFERENCES: marshall94a,krieger91a,raddrizzani97a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesl,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM21323# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Flu NP (383-395)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,SRYWAIRTRSGGI*# SEQUENCE: SRYWAIRTRSGGI*# ...# >HUM21324# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (90-102)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,HFFKNIVTPRTPA*# SEQUENCE: HFFKNIVTPRTPA*# ...# >HUM21325# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (103-115)# DB REFERENCE: SWISS: (HEMA_IAQU7,HEMA_IAZH2,HEMA_IAHMI,HEMA_IADH2,HEMA_IAX31,# & HEMA_IADHL,HEMA_IADU3,HEMA_IAUDO,HEMA_IAVI7,HEMA_IADHM,# & HEMA_IAME6,HEMA_IAMAO,HEMA_IADH1,HEMA_IADH6,HEMA_IADH7,# & HEMA_IADH4,HEMA_IAHUR,HEMA_IANT6,HEMA_IADH3,HEMA_IAGHK,# & HEMA_IABAN,HEMA_IAME1,HEMA_IAEN7,HEMA_IAZH3,HEMA_IAZCO,# & HEMA_IAAIC,HEMA_IAEN6,HEMA_IADHK,HEMA_IADM2)# & PIR1: (HMIV98,HMIVH,HMIV77,HMIV89,HMIVV,HMIVE2,HMIV33,HMIV15,# & HMIVS3,HMIV6,HMIV86,HMIVS2,HMIVE1,HMIV80,HMIVHA,# & HMIVDU)# & PIR2: (S52191,JQ1153,A92979,JQ2375,JQ1155,S52175,JQ2378,S52173,# & S52187,JQ1154,S52174,S52178,S52185,JQ2377,S52197,JQ2374,# & A93233,S52186,S52189,S52176,S52188,S52199,S52180,S52195,# & JQ1156,S52182,S52183,S52179)# & PIR3: (S38637)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PDYASLRSLVASS*# SEQUENCE: PDYASLRSLVASS*# ...# >HUM21326# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (828-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesh,MQYIKANSKFIGI*# SEQUENCE: MQYIKANSKFIGI*# ...# >HUM21327# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Myoglobin (67-79)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_TURTR,MYG_ORCOR,MYG_PHYCA,MYG_RABIT,# & MYG_KOGSI,MYG_GLOME)# & PIR1: (MYWHW,MYDD,MYWHP,MYDDBS,MYWHL,MYWHT,MYRB)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,TVLTALGAILKKK*# SEQUENCE: TVLTALGAILKKK*# ...# >HUM21328# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tuberculosis 19 kDa (2-14)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,HRVKRGLTVAVAG*# SEQUENCE: HRVKRGLTVAVAG*# ...# >HUM21329# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: M. leprae 65kDa (416-428)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,TLLQAAPALDKLK*# SEQUENCE: TLLQAAPALDKLK*# ...# >HUM2132A# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IAME1,HEMA_IADH4,HEMA_IADH3,HEMA_IADH1,HEMA_IADH6,# & HEMA_IADH7,HEMA_IAVI7,HEMA_IANT6,HEMA_IAUDO,HEMA_IADU3,# & HEMA_IADHM,HEMA_IAEN7,HEMA_IAZUK,HEMA_IAQU7,HEMA_IAZH2,# & HEMA_IAME2,HEMA_IADH2,HEMA_IABAN,HEMA_IAZCO,HEMA_IAAIC,# & HEMA_IAEN6)# & PIR1: (HMIVHM,HMIV89,HMIV80,HMIV33,HMIVDU,HMIVV,HMIV98,HMIVH,# & HMIVS3,HMIV15,HMIVHA,HMIV77,HMIV6)# & PIR2: (JQ1156,A92979)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM2132B# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (90-102)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,HFFKNIVTPRTPA*# SEQUENCE: HFFKNIVTPRTPA*# ...# >HUM2132C# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (23-35)# DB REFERENCE: SWISS: (HEMA_IAHRO,HEMA_IAHNM,HEMA_IAHMI,HEMA_IAHK6,HEMA_IAX31,# & HEMA_IAAIC,HEMA_IADH7,HEMA_IADH6,HEMA_IADH1,HEMA_IAHK7,# & HEMA_IAZUK,HEMA_IANT6,HEMA_IAHSU,HEMA_IAHUR,HEMA_IAHFO,# & HEMA_IADH3,HEMA_IAHTE,HEMA_IAHSA)# & PIR1: (HMIVE8,HMIVE6,HMIVE7,HMIVHA,HMIVE1,HMIVET,HMIVE2,HMIVEE,# & HMIV15,HMIV77,HMIV98,HMIVH,HMIVE5,HMIV33,HMIVE9)# & PIR2: (A93233)# & PIR3: (S33703)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,GTLVKTITDDQIE*# SEQUENCE: GTLVKTITDDQIE*# ...# >HUM2132D# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (103-115)# DB REFERENCE: SWISS: (HEMA_IAME1,HEMA_IADHK,HEMA_IADH4,HEMA_IAHUR,HEMA_IANT6,# & HEMA_IAX31,HEMA_IAZH2,HEMA_IAQU7,HEMA_IAAIC,HEMA_IADU3,# & HEMA_IADHL,HEMA_IAUDO,HEMA_IAMAO,HEMA_IADH7,HEMA_IAEN7,# & HEMA_IAVI7,HEMA_IADH3,HEMA_IADHM,HEMA_IAME6,HEMA_IAGHK,# & HEMA_IAEN6,HEMA_IABAN,HEMA_IAHMI,HEMA_IADM2,HEMA_IADH6,# & HEMA_IAZH3,HEMA_IADH2,HEMA_IADH1,HEMA_IAZCO)# & PIR1: (HMIVV,HMIV6,HMIVDU,HMIV80,HMIV89,HMIV86,HMIV33,HMIVH,# & HMIVE1,HMIVHA,HMIV15,HMIV77,HMIV98,HMIVS2,HMIVE2,# & HMIVS3)# & PIR2: (S52185,S52197,S52191,S52189,S52182,S52183,S52179,S52195,# & S52175,JQ1156,S52187,S52178,S52174,S52199,S52176,JQ1153,# & JQ2375,A93233,JQ1155,S52173,JQ2374,JQ1154,S52180,A92979,# & JQ2377,S52188,S52186,JQ2378)# & PIR3: (S38637)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,PDYASLRSLVASS*# SEQUENCE: PDYASLRSLVASS*# ...# >HUM2132E# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Myoglobin (110-122)# DB REFERENCE: SWISS: (MYG_ESCGI,MYG_PHYCA,MYG_PHYCA,MYG_INIGE)# & PIR1: (MYDDAR,MYWHP,MYWHC)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,AIIHVLHSRHPGD*# SEQUENCE: AIIHVLHSRHPGD*# ...# >HUM2132F# MHC MOLECULE: HLA-DR4(DRB1*04012), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Myoglobin (110-122)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_ESCGI,MYG_PHYCA,MYG_INIGE)# & PIR1: (MYWHC,MYWHP,MYDDAR)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AIIHVLHSRHPGD*# SEQUENCE: AIIHVLHSRHPGD*# ...# >HUM21330# MHC MOLECULE: HLA-DR4(DRB1*04012), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (591-603)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KIYSYFPSVISKV*# SEQUENCE: KIYSYFPSVISKV*# ...# >HUM21331# MHC MOLECULE: HLA-DR4(DRB1*04012), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu NP (383-395)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SRYWAIRTRSGGI*# SEQUENCE: SRYWAIRTRSGGI*# ...# >HUM21332# MHC MOLECULE: HLA-DR4(DRB1*04012), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (103-115)# DB REFERENCE: SWISS: (HEMA_IAHMI,HEMA_IAZH3,HEMA_IADHK,HEMA_IADH6,HEMA_IADH1,# & HEMA_IADH2,HEMA_IAME1,HEMA_IANT6,HEMA_IADU3,HEMA_IAZH2,# & HEMA_IAEN6,HEMA_IADM2,HEMA_IADH3,HEMA_IABAN,HEMA_IAGHK,# & HEMA_IAVI7,HEMA_IAZCO,HEMA_IADHM,HEMA_IAME6,HEMA_IAUDO,# & HEMA_IADH7,HEMA_IAEN7,HEMA_IADHL,HEMA_IAMAO,HEMA_IAQU7,# & HEMA_IAX31,HEMA_IADH4,HEMA_IAAIC,HEMA_IAHUR)# & PIR1: (HMIV33,HMIVH,HMIV15,HMIVS3,HMIVE1,HMIVHA,HMIVV,HMIV6,# & HMIV80,HMIV89,HMIV86,HMIVDU,HMIVS2,HMIV77,HMIVE2,# & HMIV98)# & PIR2: (S52176,S52197,A92979,JQ2375,JQ1153,A93233,JQ1155,JQ1154,# & S52178,S52174,JQ2378,S52183,S52179,JQ1156,S52175,S52187,# & S52185,S52191,S52180,S52188,S52199,S52195,S52173,JQ2374,# & S52182,S52189,S52186,JQ2377)# & PIR3: (S38637)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PDYASLRSLVASS*# SEQUENCE: PDYASLRSLVASS*# ...# >HUM21333# MHC MOLECULE: HLA-DR4(DRB1*04012), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (90-102)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HFFKNIVTPRTPA*# SEQUENCE: HFFKNIVTPRTPA*# ...# >HUM21334# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IAEN7,HEMA_IABAN,HEMA_IAUDO,HEMA_IAQU7,HEMA_IAAIC,# & HEMA_IADH3,HEMA_IADHM,HEMA_IADU3,HEMA_IAEN6,HEMA_IAZH2,# & HEMA_IADH1,HEMA_IAME1,HEMA_IADH6,HEMA_IAVI7,HEMA_IAZCO,# & HEMA_IADH4,HEMA_IAZUK,HEMA_IADH2,HEMA_IAME2,HEMA_IADH7,# & HEMA_IANT6)# & PIR1: (HMIV77,HMIV15,HMIVS3,HMIVDU,HMIVHA,HMIV6,HMIV89,HMIV33,# & HMIVH,HMIVV,HMIV80,HMIVHM,HMIV98)# & PIR2: (JQ1156,A92979)# REFERENCES: marshall94a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM21335# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Pertussis toxin (31-43)# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,NVLDHLTGRSSQV*# SEQUENCE: NVLDHLTGRSSQV*# ...# >HUM21336# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Myoglobin (67-79)# DB REFERENCE: SWISS: (MYG_GLOME,MYG_PHYCA,MYG_PHYCA,MYG_KOGSI,MYG_RABIT,# & MYG_ORCOR,MYG_TURTR)# & PIR1: (MYDDBS,MYWHP,MYDD,MYWHL,MYRB,MYWHW,MYWHT)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,TVLTALGAILKKK*# SEQUENCE: TVLTALGAILKKK*# ...# >HUM21337# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: M. leprae 65kDa (416-428)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,TLLQAAPALDKLK*# SEQUENCE: TLLQAAPALDKLK*# ...# >HUM21338# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (828-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,MQYIKANSKFIGI*# SEQUENCE: MQYIKANSKFIGI*# ...# >HUM21339# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (23-35)# DB REFERENCE: SWISS: (HEMA_IAHNM,HEMA_IAHMI,HEMA_IANT6,HEMA_IAHRO,HEMA_IAZUK,# & HEMA_IADH1,HEMA_IADH3,HEMA_IAHFO,HEMA_IAHSA,HEMA_IAX31,# & HEMA_IAHTE,HEMA_IAAIC,HEMA_IAHSU,HEMA_IAHK6,HEMA_IADH6,# & HEMA_IADH7,HEMA_IAHK7,HEMA_IAHUR)# & PIR1: (HMIVHA,HMIV15,HMIVE9,HMIVE6,HMIV33,HMIVE8,HMIVE7,HMIV98,# & HMIVEE,HMIVE2,HMIV77,HMIVH,HMIVE5,HMIVET,HMIVE1)# & PIR2: (A93233)# & PIR3: (S33703)# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,GTLVKTITDDQIE*# SEQUENCE: GTLVKTITDDQIE*# ...# >HUM2133A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAAAAA*# SEQUENCE: AAYAAAKAAAAAA*# ...# >HUM2133B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM2133C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAWAAAKAAAAAA*# SEQUENCE: AAWAAAKAAAAAA*# ...# >HUM2133D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAVAAAKAAAAAA*# SEQUENCE: AAVAAAKAAAAAA*# ...# >HUM2133E# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AALAAAKAAAAAA*# SEQUENCE: AALAAAKAAAAAA*# ...# >HUM2133F# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM21340# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAVAAAKAAAAAA*# SEQUENCE: AAVAAAKAAAAAA*# ...# >HUM21341# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AALAAAKAAAAAA*# SEQUENCE: AALAAAKAAAAAA*# ...# >HUM21342# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAAAAA*# SEQUENCE: AAYAAAKAAAAAA*# ...# >HUM21343# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM21344# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAWAAAKAAAAAA*# SEQUENCE: AAWAAAKAAAAAA*# ...# >HUM21345# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAVAAAKAAAAAA*# SEQUENCE: AAVAAAKAAAAAA*# ...# >HUM21346# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AALAAAKAAAAAA*# SEQUENCE: AALAAAKAAAAAA*# ...# >HUM21347# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAAAA*# SEQUENCE: AAYAAAKAAAAAA*# ...# >HUM21348# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM21349# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAYAAAKAAAAAA*# SEQUENCE: AAYAAAKAAAAAA*# ...# >HUM2134A# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM2134B# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAWAAAKAAAAAA*# SEQUENCE: AAWAAAKAAAAAA*# ...# >HUM2134C# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AALAAAKAAAAAA*# SEQUENCE: AALAAAKAAAAAA*# ...# >HUM2134D# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM2134E# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,AALAAAKAAAAAA*# SEQUENCE: AALAAAKAAAAAA*# ...# >HUM2134F# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAYAAAKAAAAAA*# SEQUENCE: AAYAAAKAAAAAA*# ...# >HUM21350# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM21351# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAWAAAKAAAAAA*# SEQUENCE: AAWAAAKAAAAAA*# ...# >HUM21352# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAVAAAKAAAAAA*# SEQUENCE: AAVAAAKAAAAAA*# ...# >HUM21353# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AALAAAKAAAAAA*# SEQUENCE: AALAAAKAAAAAA*# ...# >HUM21354# MHC MOLECULE: HLA-DR5(DRB1*11011), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,AAYAAAKAAAAAA*# SEQUENCE: AAYAAAKAAAAAA*# ...# >HUM21355# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAAAA*# SEQUENCE: AAYAAAKAAAAAA*# ...# >HUM21356# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM21357# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAWAAAKAAAAAA*# SEQUENCE: AAWAAAKAAAAAA*# ...# >HUM21358# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAVAAAKAAAAAA*# SEQUENCE: AAVAAAKAAAAAA*# ...# >HUM21359# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AALAAAKAAAAAA*# SEQUENCE: AALAAAKAAAAAA*# ...# >HUM2135A# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAAAA*# SEQUENCE: AAYAAAKAAAAAA*# ...# >HUM2135B# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAFAAAKAAAAAA*# SEQUENCE: AAFAAAKAAAAAA*# ...# >HUM2135C# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAWAAAKAAAAAA*# SEQUENCE: AAWAAAKAAAAAA*# ...# >HUM2135D# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAVAAAKAAAAAA*# SEQUENCE: AAVAAAKAAAAAA*# ...# >HUM2135E# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AALAAAKAAAAAA*# SEQUENCE: AALAAAKAAAAAA*# ...# >HUM2135F# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AASAAAKAAAAAA*# SEQUENCE: AASAAAKAAAAAA*# ...# >HUM21360# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAAKAA*# SEQUENCE: AAYAAAKAAAKAA*# ...# >HUM21361# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAAEAA*# SEQUENCE: AAYAAAKAAAEAA*# ...# >HUM21362# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAALAA*# SEQUENCE: AAYAAAKAAALAA*# ...# >HUM21363# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAAFAA*# SEQUENCE: AAYAAAKAAAFAA*# ...# >HUM21364# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAAVAA*# SEQUENCE: AAYAAAKAAAVAA*# ...# >HUM21365# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAASAA*# SEQUENCE: AAYAAAKAAASAA*# ...# >HUM21366# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAARAA*# SEQUENCE: AAYAAAKAAARAA*# ...# >HUM21367# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAADAA*# SEQUENCE: AAYAAAKAAADAA*# ...# >HUM21368# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAAGAA*# SEQUENCE: AAYAAAKAAAGAA*# ...# >HUM21369# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAKKAAAAAA*# SEQUENCE: AAYAAKKAAAAAA*# ...# >HUM2136A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAEKAAAAAA*# SEQUENCE: AAYAAEKAAAAAA*# ...# >HUM2136B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAASKAAAAAA*# SEQUENCE: AAYAASKAAAAAA*# ...# >HUM2136C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAALKAAAAAA*# SEQUENCE: AAYAALKAAAAAA*# ...# >HUM2136D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAQKAAAAAA*# SEQUENCE: AAYAAQKAAAAAA*# ...# >HUM2136E# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAFKAAAAAA*# SEQUENCE: AAYAAFKAAAAAA*# ...# >HUM2136F# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKADAAAA*# SEQUENCE: AAYAAAKADAAAA*# ...# >HUM21370# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAKAAAA*# SEQUENCE: AAYAAAKAKAAAA*# ...# >HUM21371# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAEAAAA*# SEQUENCE: AAYAAAKAEAAAA*# ...# >HUM21372# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKALAAAA*# SEQUENCE: AAYAAAKALAAAA*# ...# >HUM21373# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAFAAAA*# SEQUENCE: AAYAAAKAFAAAA*# ...# >HUM21374# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,AAYAAAKAAAKAA*# SEQUENCE: AAYAAAKAAAKAA*# ...# >HUM21375# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,AAYAAAKAAAEAA*# SEQUENCE: AAYAAAKAAAEAA*# ...# >HUM21376# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAYAAAKAAALAA*# SEQUENCE: AAYAAAKAAALAA*# ...# >HUM21377# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,AAYAAAKAAAFAA*# SEQUENCE: AAYAAAKAAAFAA*# ...# >HUM21378# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAYAAAKAAAVAA*# SEQUENCE: AAYAAAKAAAVAA*# ...# >HUM21379# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAASAA*# SEQUENCE: AAYAAAKAAASAA*# ...# >HUM2137A# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAYAAAKAAARAA*# SEQUENCE: AAYAAAKAAARAA*# ...# >HUM2137B# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAYAAAKAAADAA*# SEQUENCE: AAYAAAKAAADAA*# ...# >HUM2137C# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAAAGAA*# SEQUENCE: AAYAAAKAAAGAA*# ...# >HUM2137D# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,AAYAAKKAAAAAA*# SEQUENCE: AAYAAKKAAAAAA*# ...# >HUM2137E# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAEKAAAAAA*# SEQUENCE: AAYAAEKAAAAAA*# ...# >HUM2137F# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAASKAAAAAA*# SEQUENCE: AAYAASKAAAAAA*# ...# >HUM21380# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAALKAAAAAA*# SEQUENCE: AAYAALKAAAAAA*# ...# >HUM21381# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAQKAAAAAA*# SEQUENCE: AAYAAQKAAAAAA*# ...# >HUM21382# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAFKAAAAAA*# SEQUENCE: AAYAAFKAAAAAA*# ...# >HUM21383# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAYAAAKADAAAA*# SEQUENCE: AAYAAAKADAAAA*# ...# >HUM21384# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAYAAAKAKAAAA*# SEQUENCE: AAYAAAKAKAAAA*# ...# >HUM21385# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAEAAAA*# SEQUENCE: AAYAAAKAEAAAA*# ...# >HUM21386# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKALAAAA*# SEQUENCE: AAYAAAKALAAAA*# ...# >HUM21387# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAKAFAAAA*# SEQUENCE: AAYAAAKAFAAAA*# ...# >HUM21388# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAKAA*# SEQUENCE: AAYAAAKAAAKAA*# ...# >HUM21389# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAEAA*# SEQUENCE: AAYAAAKAAAEAA*# ...# >HUM2138A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAAKAAALAA*# SEQUENCE: AAYAAAKAAALAA*# ...# >HUM2138B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAFAA*# SEQUENCE: AAYAAAKAAAFAA*# ...# >HUM2138C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAAKAAAVAA*# SEQUENCE: AAYAAAKAAAVAA*# ...# >HUM2138D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAASAA*# SEQUENCE: AAYAAAKAAASAA*# ...# >HUM2138E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAAKAAARAA*# SEQUENCE: AAYAAAKAAARAA*# ...# >HUM2138F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAAKAAADAA*# SEQUENCE: AAYAAAKAAADAA*# ...# >HUM21390# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAAGAA*# SEQUENCE: AAYAAAKAAAGAA*# ...# >HUM21391# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAKKAAAAAA*# SEQUENCE: AAYAAKKAAAAAA*# ...# >HUM21392# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAEKAAAAAA*# SEQUENCE: AAYAAEKAAAAAA*# ...# >HUM21393# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAASKAAAAAA*# SEQUENCE: AAYAASKAAAAAA*# ...# >HUM21394# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAALKAAAAAA*# SEQUENCE: AAYAALKAAAAAA*# ...# >HUM21395# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAQKAAAAAA*# SEQUENCE: AAYAAQKAAAAAA*# ...# >HUM21396# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAFKAAAAAA*# SEQUENCE: AAYAAFKAAAAAA*# ...# >HUM21397# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAAKADAAAA*# SEQUENCE: AAYAAAKADAAAA*# ...# >HUM21398# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAAKAKAAAA*# SEQUENCE: AAYAAAKAKAAAA*# ...# >HUM21399# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAEAAAA*# SEQUENCE: AAYAAAKAEAAAA*# ...# >HUM2139A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall95a,marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKALAAAA*# SEQUENCE: AAYAAAKALAAAA*# ...# >HUM2139B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAFAAAA*# SEQUENCE: AAYAAAKAFAAAA*# ...# >HUM2139C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAALAA*# SEQUENCE: AAYAAAKAAALAA*# ...# >HUM2139D# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAVAA*# SEQUENCE: AAYAAAKAAAVAA*# ...# >HUM2139E# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAASAA*# SEQUENCE: AAYAAAKAAASAA*# ...# >HUM2139F# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAARAA*# SEQUENCE: AAYAAAKAAARAA*# ...# >HUM213A0# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAGAA*# SEQUENCE: AAYAAAKAAAGAA*# ...# >HUM213A1# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAKKAAAAAA*# SEQUENCE: AAYAAKKAAAAAA*# ...# >HUM213A2# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAASKAAAAAA*# SEQUENCE: AAYAASKAAAAAA*# ...# >HUM213A3# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAALKAAAAAA*# SEQUENCE: AAYAALKAAAAAA*# ...# >HUM213A4# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAQKAAAAAA*# SEQUENCE: AAYAAQKAAAAAA*# ...# >HUM213A5# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAFKAAAAAA*# SEQUENCE: AAYAAFKAAAAAA*# ...# >HUM213A6# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAAKAKAAAA*# SEQUENCE: AAYAAAKAKAAAA*# ...# >HUM213A7# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAEAAAA*# SEQUENCE: AAYAAAKAEAAAA*# ...# >HUM213A8# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKALAAAA*# SEQUENCE: AAYAAAKALAAAA*# ...# >HUM213A9# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAAAKAFAAAA*# SEQUENCE: AAYAAAKAFAAAA*# ...# >HUM213AA# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAAEAA*# SEQUENCE: AAYAAAKAAAEAA*# ...# >HUM213AB# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAALAA*# SEQUENCE: AAYAAAKAAALAA*# ...# >HUM213AC# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAARAA*# SEQUENCE: AAYAAAKAAARAA*# ...# >HUM213AD# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAADAA*# SEQUENCE: AAYAAAKAAADAA*# ...# >HUM213AE# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAAAGAA*# SEQUENCE: AAYAAAKAAAGAA*# ...# >HUM213AF# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAEKAAAAAA*# SEQUENCE: AAYAAEKAAAAAA*# ...# >HUM213B0# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAASKAAAAAA*# SEQUENCE: AAYAASKAAAAAA*# ...# >HUM213B1# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAALKAAAAAA*# SEQUENCE: AAYAALKAAAAAA*# ...# >HUM213B2# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAQKAAAAAA*# SEQUENCE: AAYAAQKAAAAAA*# ...# >HUM213B3# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKADAAAA*# SEQUENCE: AAYAAAKADAAAA*# ...# >HUM213B4# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKALAAAA*# SEQUENCE: AAYAAAKALAAAA*# ...# >HUM213B5# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAYAAAKAFAAAA*# SEQUENCE: AAYAAAKAFAAAA*# ...# >HUM213B6# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,AAYAAAKAAAEAA*# SEQUENCE: AAYAAAKAAAEAA*# ...# >HUM213B7# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,AAYAAAKAAALAA*# SEQUENCE: AAYAAAKAAALAA*# ...# >HUM213B8# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAYAAAKAAAFAA*# SEQUENCE: AAYAAAKAAAFAA*# ...# >HUM213B9# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAYAAAKAAAVAA*# SEQUENCE: AAYAAAKAAAVAA*# ...# >HUM213BA# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,AAYAAAKAAASAA*# SEQUENCE: AAYAAAKAAASAA*# ...# >HUM213BB# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,AAYAAAKAAARAA*# SEQUENCE: AAYAAAKAAARAA*# ...# >HUM213BC# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,AAYAAAKAAADAA*# SEQUENCE: AAYAAAKAAADAA*# ...# >HUM213BD# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,AAYAAAKAAAGAA*# SEQUENCE: AAYAAAKAAAGAA*# ...# >HUM213BE# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAYAASKAAAAAA*# SEQUENCE: AAYAASKAAAAAA*# ...# >HUM213BF# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,AAYAALKAAAAAA*# SEQUENCE: AAYAALKAAAAAA*# ...# >HUM213C0# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAYAAFKAAAAAA*# SEQUENCE: AAYAAFKAAAAAA*# ...# >HUM213C1# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAYAAAKAKAAAA*# SEQUENCE: AAYAAAKAKAAAA*# ...# >HUM213C2# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,AAYAAAKAEAAAA*# SEQUENCE: AAYAAAKAEAAAA*# ...# >HUM213C3# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAYAAAKALAAAA*# SEQUENCE: AAYAAAKALAAAA*# ...# >HUM213C4# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,AAYAAAKAFAAAA*# SEQUENCE: AAYAAAKAFAAAA*# ...# >HUM213C5# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,AAYAAAKAAASAA*# SEQUENCE: AAYAAAKAAASAA*# ...# >HUM213C6# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,AAYAAAKAAARAA*# SEQUENCE: AAYAAAKAAARAA*# ...# >HUM213C7# MHC MOLECULE: HLA-DR9(DRB1*0911), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,AAYAASKAAAAAA*# SEQUENCE: AAYAASKAAAAAA*# ...# >HUM213C8# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAAAKAA*# SEQUENCE: AAYAAAKAAAKAA*# ...# >HUM213C9# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,AAYAAAKAAAEAA*# SEQUENCE: AAYAAAKAAAEAA*# ...# >HUM213CA# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAAALAA*# SEQUENCE: AAYAAAKAAALAA*# ...# >HUM213CB# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAAAFAA*# SEQUENCE: AAYAAAKAAAFAA*# ...# >HUM213CC# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAAAVAA*# SEQUENCE: AAYAAAKAAAVAA*# ...# >HUM213CD# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAAASAA*# SEQUENCE: AAYAAAKAAASAA*# ...# >HUM213CE# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAAARAA*# SEQUENCE: AAYAAAKAAARAA*# ...# >HUM213CF# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAAADAA*# SEQUENCE: AAYAAAKAAADAA*# ...# >HUM213D0# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAAAGAA*# SEQUENCE: AAYAAAKAAAGAA*# ...# >HUM213D1# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAKKAAAAAA*# SEQUENCE: AAYAAKKAAAAAA*# ...# >HUM213D2# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAEKAAAAAA*# SEQUENCE: AAYAAEKAAAAAA*# ...# >HUM213D3# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAASKAAAAAA*# SEQUENCE: AAYAASKAAAAAA*# ...# >HUM213D4# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAALKAAAAAA*# SEQUENCE: AAYAALKAAAAAA*# ...# >HUM213D5# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAQKAAAAAA*# SEQUENCE: AAYAAQKAAAAAA*# ...# >HUM213D6# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAFKAAAAAA*# SEQUENCE: AAYAAFKAAAAAA*# ...# >HUM213D7# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,AAYAAAKADAAAA*# SEQUENCE: AAYAAAKADAAAA*# ...# >HUM213D8# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAKAAAA*# SEQUENCE: AAYAAAKAKAAAA*# ...# >HUM213D9# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,AAYAAAKAEAAAA*# SEQUENCE: AAYAAAKAEAAAA*# ...# >HUM213DA# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKALAAAA*# SEQUENCE: AAYAAAKALAAAA*# ...# >HUM213DB# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: marshall94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AAYAAAKAFAAAA*# SEQUENCE: AAYAAAKAFAAAA*# ...# >HUM113DC# MHC MOLECULE: HLA-A1(A*0101), CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: MAGE-1# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesm,EADPTGHSY*# SEQUENCE: EADPTGHSY*# ...# >HUM113DD# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Direct binding as./binding as./competitive binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV nef (73-82)# DB REFERENCE: SWISS: (NEF_HV1A2,NEF_HV1S3,NEF_HV1Z6,NEF_HV1SC,NEF_HV112,# & NEF_HV1BR,NEF_HV1MN,NEF_HV1BN,NEF_HV1B1,NEF_HV1ND,# & NEF_HV1EL,NEF_HV1Z2,NEF_HV1JR,NEF_HV1B8,NEF_HV1S1,# & NEF_HV1H2,NEF_HV1U4,NEF_HV1OY,NEF_HV1PV,NEF_HV1MA)# & PIR1: (ASLJBR,ASLJ12,ASLJH3,ASLJVL,ASLJFV,ASLJO2,QQLJND,# & QQLJZR)# & PIR2: (S43467,S03244,S03245,S25937,S54385,S24985)# & PIR3: (S33986)# REFERENCES: marshall95a,sette94a,van_der_burg95a,brander95a,hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,QVPLRPMTYK*# SEQUENCE: QVPLRPMTYK*# ...# >HUM113DE# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-94)# DB REFERENCE: SWISS: (NEF_HV1Z6,NEF_HV1BN,NEF_HV1PV,NEF_HV1BR,NEF_HV1RH,# & NEF_HV1SC,NEF_HV1H2,NEF_HV1B1,NEF_HV112,NEF_HV1B8,# & NEF_HV1ND)# & PIR1: (ASLJ12,QQLJZR,ASLJVL,ASLJFV,ASLJH3,QQLJND,ASLJBR)# & PIR2: (S03244,S03245,S03246,S03247,S24985,S43467)# & PIR3: (S33986)# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,AVDLSHFLK*# SEQUENCE: AVDLSHFLK*# ...# >HUM113DF# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBNA4 (416-424)# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,IVTDFSVIK*# SEQUENCE: IVTDFSVIK*# ...# >HUM113E0# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV nef (73-82)# DB REFERENCE: SWISS: (NEF_HV1U4,NEF_HV1B8,NEF_HV1ND,NEF_HV1A2,NEF_HV1OY,# & NEF_HV1H2,NEF_HV1Z2,NEF_HV1MN,NEF_HV1SC,NEF_HV1S1,# & NEF_HV112,NEF_HV1S3,NEF_HV1BN,NEF_HV1Z6,NEF_HV1MA,# & NEF_HV1PV,NEF_HV1BR,NEF_HV1JR,NEF_HV1B1,NEF_HV1EL)# & PIR1: (QQLJZR,ASLJ12,ASLJH3,ASLJBR,ASLJO2,ASLJFV,ASLJVL,# & QQLJND)# & PIR2: (S03245,S24985,S43467,S25937,S54385,S03244)# & PIR3: (S33986)# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,QVPLRPMTYK*# SEQUENCE: QVPLRPMTYK*# ...# >HUM113E1# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Direct binding as./refolding# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HIV nef (84-94)# DB REFERENCE: SWISS: (NEF_HV1SC,NEF_HV1B1,NEF_HV1BR,NEF_HV1ND,NEF_HV1RH,# & NEF_HV1BN,NEF_HV1Z6,NEF_HV1PV,NEF_HV1H2,NEF_HV112,# & NEF_HV1B8)# & PIR1: (ASLJBR,ASLJH3,ASLJFV,ASLJ12,ASLJVL,QQLJND,QQLJZR)# & PIR2: (S43467,S03245,S03247,S03244,S03246,S24985)# & PIR3: (S33986)# REFERENCES: sette94a,zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesm,AVDLSHFLK*# SEQUENCE: AVDLSHFLK*# ...# >HUM113E2# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Direct binding as./refolding/CTL assays# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: EBNA4 (416-424)# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: sette94a,zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesm,IVTDFSVIK*# SEQUENCE: IVTDFSVIK*# ...# >HUM113E3# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 NL43 env gp41 (768-778)# DB REFERENCE: SWISS: (ENV_HV1KB,ENV_HV1BR,ENV_HV1SC,ENV_HV1J3,ENV_HV1W1,# & ENV_HV1H3,ENV_HV1B8,ENV_HV1MF,ENV_HV1Y2,ENV_HV1B1,# & ENV_HV1BN,ENV_HV1H2,ENV_HV1PV)# & PIR1: (H44001,VCLJKB,VCLJVL,VCLJBR,VCLJH3,VCLJ3W,VCLJLV,# & VCLJSC)# & PIR2: (S21994,S70421,S21998,S70422,S70425,S21996)# & PIR3: (S33985,S13288)# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,RLRDLLLIVTR*# SEQUENCE: RLRDLLLIVTR*# ...# >HUM113E4# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PEP (1-14)# ANCHOR POSITIONS:# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRYEGLTQR*# SEQUENCE: KRYEGLTQR*# ...# >HUM113E5# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PEP 2-62a# ANCHOR POSITIONS:# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,ARLYGIRAK*# SEQUENCE: ARLYGIRAK*# ...# >HUM113E6# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum liver Ag (1786-1794)# DB REFERENCE: PIR2: (A45592)# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-B53,actyesu,bindyesu,KPIVQYDNF*# SEQUENCE: KPIVQYDNF*# ...# >HUM113E7# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Direct binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBc (18-28)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVJ,CORA_HPBVW,CORA_HPBVY,CORA_HPBV2,# & CORA_HPBVF,CORA_HPBVO,CORA_HPBVA,CORA_HPBVL,CORA_HPBVZ,# & CORA_HPBVT)# & PIR1: (NKVLJ2,NKVLA3,NKVLA1,NKVLH3,NKVLJ1,NKVLA2,NKVLBH,NKVLAH,# & NKVLA6,NKVLCP,NKVLKS)# & PIR2: (S53286,S53225,S53202,S53216,S47409,S53211,S32204,S53279,# & S53236,S53272,S53129,S53240,S53229,S53189,S53184,S53200,# & S53274,S25651,S53227,S53251,S43490,S53152,S53242,S53204,# & S53267,S53143,S53255,S53214,S53175,S53232,JQ2227,S53260,# & S01405,S53163,S53169,S20746,S20750,S33686,S53270,S53155,# & S53288,S53223,S53181,S47405,S53207,S53253,S53221,S53257,# & S53238,S53178,S53159,S53281,S53137)# REFERENCES: sette94a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,FLPSDFFPSVR*# SEQUENCE: FLPSDFFPSVR*# ...# >MUS113E8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Protein tyrosine kinase JAK1 (355-363)# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,TYFPEITHI*# SEQUENCE: TYFPEITHI*# ...# >MUS113E9# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,GYLGQVTXI*# SEQUENCE: GYLGQVTXI*# ...# >MUS113EA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Collagen 1 alpha 2 (mouse)# DB REFERENCE: SWISS: (CA21_MOUSE,CA21_HUMAN,CA21_HUMAN,CA21_MOUSE)# & PIR1: (CGHU2S)# & PIR2: (A43291,S31210)# REFERENCES: reich94a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,SFVDTRTLL*# SEQUENCE: SFVDTRTLL*# ...# >MUS213EB# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding/proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (560-574)# ANCHOR POSITIONS:# REFERENCES: reich94a,amor96a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,KPKATAEQLKTVMDD*# SEQUENCE: KPKATAEQLKTVMDD*# ...# >MUS213EC# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding/reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (55-68)# DB REFERENCE: PIR2: (B28438)# REFERENCES: reich94a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,GHNYVTAIRNQQEG*# SEQUENCE: GHNYVTAIRNQQEG*# ...# >MUS213ED# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hnRNP B1/A2 (31-43)# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,ETTEESLRNYYEG*# SEQUENCE: ETTEESLRNYYEG*# ...# >MUS213EE# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding/Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hnRNP A2/B1 (51-66)# DB REFERENCE: SWISS: (RO21_XENLA,RO22_XENLA,ROA2_HUMAN,ROA2_HUMAN)# & PIR2: (S40775,S40776,B34504)# REFERENCES: reich94a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,VVMRDPASKRSRGFGF*# SEQUENCE: VVMRDPASKRSRGFGF*# ...# >MUS213EF# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding/proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hnRNP A1 (44-59)# DB REFERENCE: SWISS: (RO31_XENLA,RO32_XENLA)# & PIR2: (S40777,S40778)# REFERENCES: reich94a,amor96a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,VVMRDPQTKRSRGFGF*# SEQUENCE: VVMRDPQTKRSRGFGF*# ...# >MUS213F0# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (88-102)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_CHICK,LYC_CHICK,LYC_CHRAM,LYC_PHACO,# & LYC_LOPLE)# & PIR1: (LZCH)# & PIR2: (JQ1033,JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,ITASVNCAKKIVSDG*# SEQUENCE: ITASVNCAKKIVSDG*# ...# >MUS213F1# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (89-103)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR2: (JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,TASVNCAKKIVSDGD*# SEQUENCE: TASVNCAKKIVSDGD*# ...# >MUS213F2# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (90-104)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR2: (JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,ASVNCAKKIVSDGDG*# SEQUENCE: ASVNCAKKIVSDGDG*# ...# >MUS213F3# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (91-105)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR2: (JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,SVNCAKKIVSDGDGM*# SEQUENCE: SVNCAKKIVSDGDGM*# ...# >MUS213F4# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (92-106)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR2: (JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,VNCAKKIVSDGDGMN*# SEQUENCE: VNCAKKIVSDGDGMN*# ...# >MUS213F5# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (93-107)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR1: (LZUH)# & PIR2: (JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,NCAKKIVSDGDGMNA*# SEQUENCE: NCAKKIVSDGDGMNA*# ...# >MUS213F6# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (94-108)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR1: (LZUH)# & PIR2: (JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,CAKKIVSDGDGMNAW*# SEQUENCE: CAKKIVSDGDGMNAW*# ...# >MUS213F7# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (95-109)# DB REFERENCE: SWISS: (LYC_PHAVE)# & PIR1: (LZUH)# & PIR2: (JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,AKKIVSDGDGMNAWV*# SEQUENCE: AKKIVSDGDGMNAWV*# ...# >MUS213F8# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (6-20)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_COLVI,LYC_CHICK,LYC_NUMME,LYC_CHICK)# & PIR1: (LZUH,LZCH,LZQJEC)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,RCELAAAMKRHGLDN*# SEQUENCE: RCELAAAMKRHGLDN*# ...# >MUS213F9# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (7-21)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_LOPCA,LYC_NUMME,LYC_CHICK)# & PIR1: (LZUH,LZQJEC,LZCH)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,CELAAAMKRHGLDNY*# SEQUENCE: CELAAAMKRHGLDNY*# ...# >MUS213FA# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (8-22)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_NUMME,LYC_COLVI,LYC_LOPCA,LYC_CHICK)# & PIR1: (LZUH,LZCH,LZQJEC)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,ELAAAMKRHGLDNYR*# SEQUENCE: ELAAAMKRHGLDNYR*# ...# >MUS213FB# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (9-23)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_CHICK,LYC_COLVI,LYC_NUMME,LYC_CHICK)# & PIR1: (LZCH,LZQJEC,LZUH)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,LAAAMKRHGLDNYRG*# SEQUENCE: LAAAMKRHGLDNYRG*# ...# >MUS213FC# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HEL (10-24)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_NUMME,LYC_CHICK,LYC_LOPCA,LYC_COLVI)# & PIR1: (LZUH,LZCH,LZQJEC)# REFERENCES: deng93a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesh,AAAMKRHGLDNYRGY*# SEQUENCE: AAAMKRHGLDNYRGY*# ...# >MUS213FD# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (11-25)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_NUMME,LYC_LOPCA,LYC_CHICK)# & PIR1: (LZCH,LZUH,LZQJEC)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,AAMKRHGLDNYRGYS*# SEQUENCE: AAMKRHGLDNYRGYS*# ...# >MUS213FE# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (12-26)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_CHICK,LYC_LOPCA,LYC_COLVI,LYC_CHICK)# & PIR1: (LZUH,LZQJEC,LZCH)# REFERENCES: deng93a,carrasco-marin96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,AMKRHGLDNYRGYSL*# SEQUENCE: AMKRHGLDNYRGYSL*# ...# >MUS213FF# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (13-27)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_CHICK,LYC_COLVI,LYC_CHICK,LYC_LOPCA)# & PIR1: (LZQJEC,LZUH,LZCH)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,MKRHGLDNYRGYSLG*# SEQUENCE: MKRHGLDNYRGYSLG*# ...# >MUS21400# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (14-28)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPCA,LYC_COLVI,LYC_NUMME,LYC_CHICK)# & PIR1: (LZUH,LZQJEC,LZCH)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,RHGLDNYRGYSLGNW*# SEQUENCE: RHGLDNYRGYSLGNW*# ...# >MUS21401# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-574)# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KATAEQLKTVMDD*# SEQUENCE: KATAEQLKTVMDD*# ...# >MUS21402# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAEQLKTVMD*# SEQUENCE: KPKATAEQLKTVMD*# ...# >MUS21403# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAEQLKTVMDK*# SEQUENCE: KPKATAEQLKTVMDK*# ...# >MUS21404# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAEQLKTVMA*# SEQUENCE: KPKATAEQLKTVMA*# ...# >MUS21405# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAEQLKAVMD*# SEQUENCE: KPKATAEQLKAVMD*# ...# >MUS21406# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAEQLRTVMD*# SEQUENCE: KPKATAEQLRTVMD*# ...# >MUS21407# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAEQLATVMD*# SEQUENCE: KPKATAEQLATVMD*# ...# >MUS21408# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAEALKTVMD*# SEQUENCE: KPKATAEALKTVMD*# ...# >MUS21409# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAAQLKTVMD*# SEQUENCE: KPKATAAQLKTVMD*# ...# >MUS2140A# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKAAAEQLKTVMD*# SEQUENCE: KPKAAAEQLKTVMD*# ...# >MUS2140B# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKAYAEQLKTVMD*# SEQUENCE: KPKAYAEQLKTVMD*# ...# >MUS2140C# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKARAEQLKTVMD*# SEQUENCE: KPKARAEQLKTVMD*# ...# >MUS2140D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKANAEQLKTVMD*# SEQUENCE: KPKANAEQLKTVMD*# ...# >MUS2140E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKAEAEQLKTVMD*# SEQUENCE: KPKAEAEQLKTVMD*# ...# >MUS2140F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKASAEQLKTVMD*# SEQUENCE: KPKASAEQLKTVMD*# ...# >MUS21410# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKALAEQLKTVMD*# SEQUENCE: KPKALAEQLKTVMD*# ...# >MUS21411# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin MSA (562-573) homologue# ANCHOR POSITIONS:# REFERENCES: reich94a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKAKAEQLKTVMD*# SEQUENCE: KPKAKAEQLKTVMD*# ...# >MUS21412# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (14-20)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_LOPCA,LYC_COLVI,LYC_NUMME)# & PIR1: (LZCH,LZUH,LZQJEC)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,RHGLDNY*# SEQUENCE: RHGLDNY*# ...# >MUS21413# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (95-102)# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_PHAVE,LYC_CHICK,LYC_CHRAM,LYC_PHACO,# & LYC_LOPCA,LYC_CHICK,LYC_NUMME,LYC_COLVI)# & PIR1: (LZQJEC,LZUH,LZCH)# & PIR2: (JQ1033,JC2144,JU0178)# REFERENCES: deng93a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,AKKIVSDG*# SEQUENCE: AKKIVSDG*# ...# >HUM11414# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,falk94c# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,LTDPGVLDY*# SEQUENCE: LTDPGVLDY*# ...# >HUM11415# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA class I alpha chain# DB REFERENCE: SWISS: (1A11_HUMAN,1A01_PANTR,1A01_HUMAN,1A36_HUMAN,1A03_PANTR,# & 1A80_HUMAN)# & PIR2: (I83063,S03535,I37478,I37483,I36961,A47636,I38518,I36966,# & I38439,I61856,I36959)# & PIR3: (S06424)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,QSEDGSHTIQIMY*# SEQUENCE: QSEDGSHTIQIMY*# ...# >HUM11416# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,AVMKPEAEKRK*# SEQUENCE: AVMKPEAEKRK*# ...# >HUM11417# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSB 66 EST# ANCHOR POSITIONS:# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,AVILPPLSPYFK*# SEQUENCE: AVILPPLSPYFK*# ...# >HUM11418# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thymosin beta-10# ANCHOR POSITIONS:# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,ASEDKAKLKK*# SEQUENCE: ASEDKAKLKK*# ...# >HUM11419# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine metalloproteinase# DB REFERENCE: PIR2: (S66129)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,GQYGNPLNK*# SEQUENCE: GQYGNPLNK*# ...# >HUM1141A# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S19# DB REFERENCE: SWISS: (RS19_PIG,RS19_HUMAN)# & PIR2: (I52692)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,GVMPSHFSR*# SEQUENCE: GVMPSHFSR*# ...# >HUM1141B# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor 2# DB REFERENCE: SWISS: (EF2_MESAU,EF2_CRIGR,EF2_RAT,EF2_HUMAN,EF2_RAT,EF2_MESAU,# & EF2_CRIGR)# & PIR1: (EFHU2,EFRT2)# & PIR2: (A28660,A25440)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,YFDPANGKFSK*# SEQUENCE: YFDPANGKFSK*# ...# >HUM1141C# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,STYYGSFVTR*# SEQUENCE: STYYGSFVTR*# ...# >HUM1141D# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histon H2 a 5# DB REFERENCE: SWISS: (H2A2_XENLA,H2AL_STRPU,H2A_BUFBG,H2A_PARLI,H2A_CAIMO,# & H2A3_STRPU,H2A2_MOUSE,H2A1_MOUSE,H2A3_LYTPI,H2A1_XENLA,# & H2A4_MOUSE,H2AX_HUMAN,H2A3_MOUSE,H2A4_PSAMI,H2A4_CHICK,# & H2AX_HUMAN,H2A5_HUMAN,H2AT_RAT,H2A_ONCMY,H2A1_HUMAN,# & H2A3_PSAMI,H2A1_RAT,H2A_ASTRU,H2A2_HUMAN,H2AX_MOUSE,# & H2A_STRPU,H2A3_CHICK,H2A2_PSAMI,H2A1_PSAMI,H2A3_CHICK)# & PIR1: (HSCH2A,HSUR9M,HSURA1,HSHUA5,HSUR9P,HSHUA1,HSUR7M,HSURH2,# & HSURA2,HSRT2A,HSURH9,HSXLA1,HSSF2,HSBO2A,HSTR21)# & PIR2: (S26188,I48091,JC1523,I50657,S45110,S04565,I51445,S07631,# & I48406,G40335,JH0303,S19241,I49394,I37466,A25077,A36322,# & I79341,S06754,I50651,I50457,S06742)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,LQFPVGRVHR*# SEQUENCE: LQFPVGRVHR*# ...# >HUM1141E# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S29 (rat)# DB REFERENCE: SWISS: (RS29_HUMAN,RS29_HUMAN)# & PIR2: (S55919,S30298)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,QQLYWSHPR*# SEQUENCE: QQLYWSHPR*# ...# >HUM1141F# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CCAAT-binding transcription factor# DB REFERENCE: SWISS: (YB1_CHICK,CBFX_HUMAN,CBFX_MOUSE,YB1_HUMAN,CBFX_RAT,# & YB1_MOUSE,CBFX_MOUSE,YB1_MOUSE)# & PIR2: (PS0015,A49594,A55971,I39382,I52910,I58195,A48136,A40498,# & JQ2292,A23677)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,RGYRPRFRR*# SEQUENCE: RGYRPRFRR*# ...# >HUM11420# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: [GlcNac]-P-transferase# DB REFERENCE: SWISS: (GPT_MOUSE,GPT_MOUSE)# & PIR2: (S24326)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,KVFGPIHER*# SEQUENCE: KVFGPIHER*# ...# >HUM11421# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,KIMKWNYER*# SEQUENCE: KIMKWNYER*# ...# >HUM11422# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lamin B2# ANCHOR POSITIONS:# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,RYMDAWNTYSR*# SEQUENCE: RYMDAWNTYSR*# ...# >HUM11423# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA class I alpha chain# DB REFERENCE: SWISS: (1A34_HUMAN,1A32_HUMAN,1A66_HUMAN,1A31_HUMAN,1A43_HUMAN,# & 1A30_HUMAN,1A29_HUMAN,1A33_HUMAN,1A23_HUMAN,1A74_HUMAN,# & 1A25_HUMAN,1A31_HUMAN,1A04_PANTR,1A26_HUMAN,1OKO_GORGO,# & 1A03_GORGO,1A01_PONPY,1A26_HUMAN)# & PIR1: (HLHU32)# & PIR2: (S51102,S18198,S51100,I38436,I37479,I37476,A45847,JL0135,# & S01171,I37477,I72170,JH0536,I56039,I54307,I37480,S18197,# & JH0538,I84487,S16769,I37483,I84432,I72171,I38519,I38610,# & I36966,I36965,I37482,A37028,A35997)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,DMAAQITQR*# SEQUENCE: DMAAQITQR*# ...# >HUM11424# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Actin# DB REFERENCE: SWISS: (ACT1_ONCVO,ACTC_PISOC,ACT5_XENLA,ACT_PUCGR,ACT7_ARATH,# & ACTY_LIMPO,ACT_VOLCA,ACT2_DAUCA,ACT2_PHYIN,ACT8_DICDI,# & ACT2_SOLTU,ACT_TOBAC,ACT3_DICDI,ACT_CHLRE,ACT8_DICDI,# & ACT2_LYTPI,ACT3_BOMMO,ACT_NEUCR,ACT1_ACACA,ACT_TOXGO,# & ACT1_HELER,ACT_THELA,ACTB_ARATH,ACT1_ARATH,ACT1_STRFN,# & ACT3_LYTPI,ACTB_ARATH,ACT6_DIPDE,ACTY_LIMPO,ACTB_CYPCA,# & ACT3_SOLTU,ACT_PHYME,ACT2_FUGRU,ACT3_PEA,ACTC_ARATH,# & ACT3_LIMPO,ACTA_LIMPO,ACTM_PISOC,ACT4_ARATH,ACT1_SOLTU,# & ACT7_ARATH,ACTC_STYPL,ACT3_LIMPO,ACT3_PODCA,ACT5_CHICK,# & ACT1_TETTH,ACT_FUCDI,ACTB_HUMAN,ACTA_PHYPO,ACTA_STRPU,# & ACT4_CAEEL,ACT1_FUGRU,ACT_PINCO,ACT1_PLAFA,ACT1_DROME,# & ACTM_HELTB,ACTB_XENBO,ACT1_ECHGR,ACT_DICVI,ACT_COSCS,# & ACTC_ARATH,ACT1_DAUCA,ACT4_ARTSX,ACTB_RABIT,ACT1_SORVU,# & ACT2_LYTPI,ACT1_LYTPI,ACT2_CAEEL,ACT5_SOLTU,ACT2_ARATH,# & ACT2_ONCVO,ACT3_FUGRU,ACTM_APLCA,ACTF_STRPU,ACTE_STRPU,# & ACT1_CAEEL,ACTC_HALRO,ACT1_HELER,ACT1_LYTPI,ACT4_DICDI,# & ACT_TOXGO,ACT6_DIPDE,ACTM_HELER,ACT1_PODCA,ACT_ACHBI,# & ACT3_ARATH,ACTD_STRPU,ACT2_ABSGL,ACTG_HUMAN,ACT1_PHYIN,# & ACT3_SOYBN,ACT6_SOLTU,ACTA_LIMPO,ACT_FUCVE,ACTB_STRPU,# & ACT3_ARTSX,ACTB_CRIGR,ACT_HYDAT,ACT2_DROME,ACT2_TETPY,# & ACT7_SOLTU,ACT4_ARATH,ACT_FUCDI,ACT3_ECHGR,ACT_CRYNE,# & ACT_CRYPV,ACTM_STYPL,ACTM_LYTPI,ACT4_CAEEL,ACT1_ORYSA,# & ACT_CHLRE,ACT8_XENLA,ACTG_EMENI,ACT3_ORYSA,ACTM_HELER,# & ACT_AJECA,ACT2_DICDI,ACT1_DICDI,ACTM_HELTB,ACTC_STRPU)# & PIR1: (ATFF8,ATDO,ATFY,A48324,ATRZ1,ATHUB,ATMSG,ATJN,ATRBB,# & ATMUM1,ATURS,ATBOB,ATBOG,ATMSB,ATSY3,ATRTC,A43552,ATHUG,# & ATCHB,S11222,ATAX,ATRZ3)# & PIR2: (S68107,C23412,JT0385,JE0415,JN0832,A48449,S20098,JC5228,# & S12628,S39777,S11453,JE0414,S49481,S33387,S49479,S07002,# & JS0190,S16710,S43509,S07003,S20094,S07288,S68109,S38782,# & S14120,A37431,S33386,S20092,D23412,A28258,A25084,S01077,# & JS0189,B33761,S68110,S09578,A54496,JN0833,B23412,S14851,# & A55001,S49480,A03000,S68108,S20096,S58316,S31933,A25135,# & S42103,S24409,S16709,S20093,A29407,S26039,JQ0154,A45634,# & S27135,S47090,S12730,JC5227,S11452,S24408,A61043,S68112,# & S03126,JC4612,S07284)# & PIR3: (S71126,S71124,S71125,S49007)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,ESGPSIVHR*# SEQUENCE: ESGPSIVHR*# ...# >HUM11425# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,TYYGSFVTR*# SEQUENCE: TYYGSFVTR*# ...# >HUM11426# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human cDNA HSB15F102# DB REFERENCE: SWISS: (SUI1_HUMAN)# & PIR2: (JC2042)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,DYIHIRIQQR*# SEQUENCE: DYIHIRIQQR*# ...# >HUM11427# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,EIMKWNRER*# SEQUENCE: EIMKWNRER*# ...# >HUM11428# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: pool sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histon 3.1/3.3# DB REFERENCE: SWISS: (H32_MEDSA,H3_VOLCA,H3_PSAMI,H33_CAEEL,H32_XENLA,# & H31_HUMAN,H3_CAEEL,H3_DROME,H3_PEA,H3_ENCAL,H3_ACRFO,# & YB21_CAEEL,H3_CHLRE,H3_HORVU,H3_PSAMI,H32_ORYSA,# & H32_BOVIN,H3_STRPU,H33_HUMAN,H3_MAIZE)# & PIR1: (HSKW3,HSBO3,HSXL32,HSUR3P,HSHU3,HSTR3,HSEAH3,HSCH3,# & HSFI3,HSBH3,HSUR3M,HSRK3,HSPM3,HSHU33,HSXL31)# & PIR2: (I49397,S00940,A26014,S10168,I57019,S32621,I50244,S61215,# & S59592,S50140,S04186,S10097,JH0304,I50460,S11315,JN0687,# & S59581,S61220,S06755,S01198,S09655,S24346,S59123,A25564,# & S45111,S57626,S01196,S06250,S61218,S34185,S32638,S57780,# & A56618,S20678,I51443,S00373,I48092,S20109,S04521,I49398,# & I50245,A56654,S01197,S04520,A56580,S61214,JS0690,JQ0757,# & S57473,S06743,S20669,I51448,S04099)# & PIR3: (A45941)# REFERENCES: falk94c# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,TIMPKDIQLARR*# SEQUENCE: TIMPKDIQLARR*# ...# >HUM11429# MHC MOLECULE: HLA-B27(B*2701), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (378-386)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,SRHKKLMFK*# SEQUENCE: SRHKKLMFK*# ...# >HUM1142A# MHC MOLECULE: HLA-B27(B*2701), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (8-16)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_RAT,MBP_PANTR)# & PIR1: (MBRTS,MBPGB,MBCZB,MBHUB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,QRHGSKYLA*# SEQUENCE: QRHGSKYLA*# ...# >HUM1142B# MHC MOLECULE: HLA-B27(B*2701), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (24-32)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_PANTR,MBP_RAT,MBP_MOUSE,# & MBP_BOVIN)# & PIR1: (MBBOB,MBMSB,MBPGB,MBCZB,MBRTS,MBHUB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,ARHGFLPRH*# SEQUENCE: ARHGFLPRH*# ...# >HUM1142C# MHC MOLECULE: HLA-B27(B*2701), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (64-72)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBHUB,MBCZB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,ARTAHYGSL*# SEQUENCE: ARTAHYGSL*# ...# >HUM1142D# MHC MOLECULE: HLA-B27(B*2701), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (112-120)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_MOUSE,MBP_CAVPO,MBP_BOVIN,MBP_HUMAN)# & PIR1: (MBBOB,MBMSB,MBHUB,MBCZB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,SRFSWGAEG*# SEQUENCE: SRFSWGAEG*# ...# >HUM1142E# MHC MOLECULE: HLA-B27(B*2701), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (106-114)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_HUMAN,MBP_BOVIN,MBP_CAVPO,# & MBP_RAT)# & PIR1: (MBHUB,MBRTS,MBMSB,MBCZB,MBPGB,MBBOB)# & PIR2: (A60222,A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,GRGLSLSRF*# SEQUENCE: GRGLSLSRF*# ...# >HUM1142F# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HSP89alpha (201-209)# DB REFERENCE: SWISS: (HS9A_MOUSE,HS9A_CRIGR,HS9A_HUMAN,HS9A_CHICK,# & HS9A_MOUSE)# & PIR1: (HHHU86,HHMS86,HHCH90)# REFERENCES: tanigaki94b,villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,RRIKEIVKK*# SEQUENCE: RRIKEIVKK*# ...# >HUM11430# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (362-370)# DB REFERENCE: SWISS: (P53_SHEEP,P53_SHEEP,P53_FELCA,P53_BOVIN,P53_CERAE,# & P53_HUMAN,P53_HUMAN,P53_CERAE,P53_FELCA)# & PIR1: (DNHU53)# & PIR2: (S06594,S51648)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,SRAHSSHLK*# SEQUENCE: SRAHSSHLK*# ...# >HUM11431# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (378-386)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,SRHKKLMFK*# SEQUENCE: SRHKKLMFK*# ...# >HUM11432# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (173-181)# DB REFERENCE: SWISS: (P53_MESAU,P53_MOUSE,P53_MOUSE,P53_HUMAN,P53_MESAU,# & P53_BOVIN,P53_CERAE,P53_RAT,P53_CERAE,P53_RAT,P53_CHICK,# & P53_FELCA,P53_HUMAN,P53_FELCA,P53_CANFA,P53_CHICK,# & P53_CRIGR)# & PIR1: (DNHU53,DNMS53)# & PIR2: (JC6193,S51648,JH0633,S06594,S38824,S02193,I46226,JC6176,# & S02192)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,VRRCPHHER*# SEQUENCE: VRRCPHHER*# ...# >HUM11433# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (272-280)# DB REFERENCE: SWISS: (P53_BOVIN,P53_SHEEP,P53_SALIR,P53_XENLA,P53_XENLA,# & P53_CHICK,P53_MOUSE,P53_MOUSE,P53_FELCA,P53_CANFA,# & P53_SALIR,P53_RAT,P53_HUMAN,P53_CHICK,P53_SHEEP,# & P53_FELCA,P53_RAT,P53_CERAE,P53_HUMAN,P53_CERAE)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S02192,JC6193,JH0631,S51648,A29376,S02193,S38824,# & S06594)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,VRVCACPGR*# SEQUENCE: VRVCACPGR*# ...# >HUM11434# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (282-290)# DB REFERENCE: SWISS: (P53_BOVIN,P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S51648)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,RRTEEENLR*# SEQUENCE: RRTEEENLR*# ...# >HUM11435# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (334-342)# ANCHOR POSITIONS: 2,9# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,GRERFEMER*# SEQUENCE: GRERFEMER*# ...# >HUM11436# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (161-169)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_RAT,MBP_HUMAN,MBP_PANTR,MBP_CAVPO,# & MBP_BOVIN)# & PIR1: (MBPGB,MBBOB,MBHUB,MBRTS,MBCZB,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,SRSGSPMAR*# SEQUENCE: SRSGSPMAR*# ...# >HUM11437# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (25-33)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_PANTR,MBP_HUMAN,MBP_BOVIN,MBP_MOUSE,# & MBP_RAT)# & PIR1: (MBMSB,MBCZB,MBRTS,MBBOB,MBHUB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,RHGFLPRHR*# SEQUENCE: RHGFLPRHR*# ...# >HUM11438# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (8-16)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_PANTR,MBP_HUMAN,MBP_RAT)# & PIR1: (MBHUB,MBRTS,MBPGB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,QRHGSKYLA*# SEQUENCE: QRHGSKYLA*# ...# >HUM11439# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (24-32)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_HUMAN,MBP_RAT,MBP_BOVIN,MBP_PANTR,# & MBP_MOUSE)# & PIR1: (MBRTS,MBCZB,MBBOB,MBPGB,MBHUB,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,ARHGFLPRH*# SEQUENCE: ARHGFLPRH*# ...# >HUM1143A# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (64-72)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARTAHYGSL*# SEQUENCE: ARTAHYGSL*# ...# >HUM1143B# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (42-50)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRFFGGDRG*# SEQUENCE: GRFFGGDRG*# ...# >HUM1143C# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (112-120)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_BOVIN,MBP_HUMAN,MBP_CAVPO)# & PIR1: (MBMSB,MBPGB,MBHUB,MBBOB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,SRFSWGAEG*# SEQUENCE: SRFSWGAEG*# ...# >HUM1143D# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (106-114)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_BOVIN,MBP_RAT,MBP_PANTR,# & MBP_CAVPO)# & PIR1: (MBBOB,MBHUB,MBCZB,MBPGB,MBRTS,MBMSB)# & PIR2: (A60222,A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,GRGLSLSRF*# SEQUENCE: GRGLSLSRF*# ...# >HUM1143E# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HSP89alpha (201-209)# DB REFERENCE: SWISS: (HS9A_CRIGR,HS9A_MOUSE,HS9A_HUMAN,HS9A_MOUSE,# & HS9A_CHICK)# & PIR1: (HHCH90,HHHU86,HHMS86)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,RRIKEIVKK*# SEQUENCE: RRIKEIVKK*# ...# >HUM1143F# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (362-370)# DB REFERENCE: SWISS: (P53_SHEEP,P53_BOVIN,P53_FELCA,P53_CERAE,P53_CERAE,# & P53_HUMAN,P53_SHEEP,P53_HUMAN,P53_FELCA)# & PIR1: (DNHU53)# & PIR2: (S06594,S51648)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,SRAHSSHLK*# SEQUENCE: SRAHSSHLK*# ...# >HUM11440# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (378-386)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,SRHKKLMFK*# SEQUENCE: SRHKKLMFK*# ...# >HUM11441# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (173-181)# DB REFERENCE: SWISS: (P53_RAT,P53_CANFA,P53_CERAE,P53_MESAU,P53_MOUSE,# & P53_CHICK,P53_FELCA,P53_CRIGR,P53_FELCA,P53_CHICK,# & P53_HUMAN,P53_MESAU,P53_BOVIN,P53_RAT,P53_MOUSE,# & P53_CERAE,P53_HUMAN)# & PIR1: (DNHU53,DNMS53)# & PIR2: (JC6193,S02192,JC6176,I46226,S06594,S38824,JH0633,S51648,# & S02193)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,VRRCPHHER*# SEQUENCE: VRRCPHHER*# ...# >HUM11442# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (272-280)# DB REFERENCE: SWISS: (P53_MOUSE,P53_FELCA,P53_CERAE,P53_MOUSE,P53_XENLA,# & P53_HUMAN,P53_BOVIN,P53_RAT,P53_SALIR,P53_CANFA,# & P53_CERAE,P53_SALIR,P53_FELCA,P53_CHICK,P53_HUMAN,# & P53_XENLA,P53_SHEEP,P53_CHICK,P53_SHEEP,P53_RAT)# & PIR1: (DNHU53,DNMS53)# & PIR2: (A29376,S02193,JC6193,S02192,S51648,S38824,JH0631,# & S06594)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,VRVCACPGR*# SEQUENCE: VRVCACPGR*# ...# >HUM11443# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (161-169)# DB REFERENCE: SWISS: (MBP_RAT,MBP_PANTR,MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,# & MBP_CAVPO)# & PIR1: (MBHUB,MBRTS,MBMSB,MBBOB,MBPGB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,SRSGSPMAR*# SEQUENCE: SRSGSPMAR*# ...# >HUM11444# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (25-33)# DB REFERENCE: SWISS: (MBP_RAT,MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,MBP_CAVPO,# & MBP_PANTR)# & PIR1: (MBCZB,MBMSB,MBHUB,MBRTS,MBBOB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,RHGFLPRHR*# SEQUENCE: RHGFLPRHR*# ...# >HUM11445# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (8-16)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_PANTR,MBP_CAVPO)# & PIR1: (MBCZB,MBHUB,MBRTS,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,QRHGSKYLA*# SEQUENCE: QRHGSKYLA*# ...# >HUM11446# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (129-137)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_MOUSE,MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBBOB,MBMSB,MBHUB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRASDYKSA*# SEQUENCE: GRASDYKSA*# ...# >HUM11447# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (24-32)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_BOVIN,MBP_RAT,MBP_PANTR,# & MBP_MOUSE)# & PIR1: (MBPGB,MBRTS,MBMSB,MBCZB,MBBOB,MBHUB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARHGFLPRH*# SEQUENCE: ARHGFLPRH*# ...# >HUM11448# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (64-72)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARTAHYGSL*# SEQUENCE: ARTAHYGSL*# ...# >HUM11449# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (42-50)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,GRFFGGDRG*# SEQUENCE: GRFFGGDRG*# ...# >HUM1144A# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (112-120)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_CAVPO,MBP_BOVIN,MBP_MOUSE,MBP_HUMAN)# & PIR1: (MBCZB,MBBOB,MBHUB,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,SRFSWGAEG*# SEQUENCE: SRFSWGAEG*# ...# >HUM1144B# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (106-114)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_RAT,MBP_MOUSE,MBP_HUMAN,MBP_PANTR,# & MBP_BOVIN)# & PIR1: (MBMSB,MBCZB,MBPGB,MBBOB,MBHUB,MBRTS)# & PIR2: (A37246,A60222)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,GRGLSLSRF*# SEQUENCE: GRGLSLSRF*# ...# >HUM1144C# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HSP89alpha (201-209)# DB REFERENCE: SWISS: (HS9A_CHICK,HS9A_MOUSE,HS9A_MOUSE,HS9A_HUMAN,# & HS9A_CRIGR)# & PIR1: (HHMS86,HHCH90,HHHU86)# REFERENCES: tanigaki94b,pogue95a,fruci93b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,RRIKEIVKK*# SEQUENCE: RRIKEIVKK*# ...# >HUM1144D# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (362-370)# DB REFERENCE: SWISS: (P53_BOVIN,P53_HUMAN,P53_FELCA,P53_HUMAN,P53_FELCA,# & P53_SHEEP,P53_SHEEP,P53_CERAE,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594,S51648)# REFERENCES: tanigaki94b,fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,SRAHSSHLK*# SEQUENCE: SRAHSSHLK*# ...# >HUM1144E# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (378-386)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: tanigaki94b,fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,SRHKKLMFK*# SEQUENCE: SRHKKLMFK*# ...# >HUM1144F# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (173-181)# DB REFERENCE: SWISS: (P53_CHICK,P53_FELCA,P53_CHICK,P53_MESAU,P53_RAT,# & P53_HUMAN,P53_MESAU,P53_CRIGR,P53_FELCA,P53_CERAE,# & P53_CERAE,P53_MOUSE,P53_HUMAN,P53_BOVIN,P53_RAT,# & P53_CANFA,P53_MOUSE)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S02192,S02193,S51648,JC6176,I46226,JH0633,S38824,JC6193,# & S06594)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,VRRCPHHER*# SEQUENCE: VRRCPHHER*# ...# >HUM11450# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (201-209)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,LRVEYLDDR*# SEQUENCE: LRVEYLDDR*# ...# >HUM11451# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (272-280)# DB REFERENCE: SWISS: (P53_MOUSE,P53_CHICK,P53_CHICK,P53_XENLA,P53_SHEEP,# & P53_RAT,P53_MOUSE,P53_CERAE,P53_CERAE,P53_BOVIN,# & P53_SHEEP,P53_SALIR,P53_HUMAN,P53_RAT,P53_FELCA,# & P53_HUMAN,P53_SALIR,P53_XENLA,P53_CANFA,P53_FELCA)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S38824,JC6193,S02192,S51648,S02193,A29376,S06594,# & JH0631)# REFERENCES: tanigaki94b,fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,VRVCACPGR*# SEQUENCE: VRVCACPGR*# ...# >HUM11452# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (282-290)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN,P53_BOVIN)# & PIR1: (DNHU53)# & PIR2: (S51648)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,RRTEEENLR*# SEQUENCE: RRTEEENLR*# ...# >HUM11453# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (334-342)# ANCHOR POSITIONS: 2,9# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,GRERFEMER*# SEQUENCE: GRERFEMER*# ...# >HUM11454# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (161-169)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_BOVIN,MBP_PANTR,MBP_HUMAN,MBP_CAVPO,# & MBP_RAT)# & PIR1: (MBCZB,MBRTS,MBBOB,MBHUB,MBPGB,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,SRSGSPMAR*# SEQUENCE: SRSGSPMAR*# ...# >HUM11455# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (25-33)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_RAT,MBP_CAVPO,MBP_BOVIN,MBP_HUMAN,# & MBP_PANTR)# & PIR1: (MBRTS,MBCZB,MBBOB,MBHUB,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RHGFLPRHR*# SEQUENCE: RHGFLPRHR*# ...# >HUM11456# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (8-16)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_RAT,MBP_HUMAN,MBP_CAVPO)# & PIR1: (MBRTS,MBHUB,MBCZB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,QRHGSKYLA*# SEQUENCE: QRHGSKYLA*# ...# >HUM11457# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (129-137)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_HUMAN,MBP_PANTR,MBP_MOUSE)# & PIR1: (MBMSB,MBCZB,MBHUB,MBBOB)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRASDYKSA*# SEQUENCE: GRASDYKSA*# ...# >HUM11458# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (24-32)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_BOVIN,MBP_CAVPO,MBP_MOUSE,MBP_RAT,# & MBP_PANTR)# & PIR1: (MBHUB,MBBOB,MBCZB,MBRTS,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,ARHGFLPRH*# SEQUENCE: ARHGFLPRH*# ...# >HUM11459# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (64-72)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,ARTAHYGSL*# SEQUENCE: ARTAHYGSL*# ...# >HUM1145A# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (42-50)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBHUB,MBCZB)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,GRFFGGDRG*# SEQUENCE: GRFFGGDRG*# ...# >HUM1145B# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (112-120)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_BOVIN,MBP_HUMAN,MBP_CAVPO)# & PIR1: (MBHUB,MBPGB,MBMSB,MBCZB,MBBOB)# & PIR2: (A37246)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,SRFSWGAEG*# SEQUENCE: SRFSWGAEG*# ...# >HUM1145C# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (78-96)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_MOUSE)# & PIR1: (MBHUB,MBMSB)# & PIR2: (I53256)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRTQDENPV*# SEQUENCE: GRTQDENPV*# ...# >HUM1145D# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Binding as./refolding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (106-114)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_CAVPO,MBP_HUMAN,MBP_MOUSE,MBP_RAT,# & MBP_PANTR)# & PIR1: (MBMSB,MBRTS,MBCZB,MBBOB,MBHUB,MBPGB)# & PIR2: (A37246,A60222)# REFERENCES: tanigaki94b,tanigaki94c# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,GRGLSLSRF*# SEQUENCE: GRGLSLSRF*# ...# >HUM1145E# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HSP89alpha (201-209)# DB REFERENCE: SWISS: (HS9A_HUMAN,HS9A_CHICK,HS9A_MOUSE,HS9A_MOUSE,# & HS9A_CRIGR)# & PIR1: (HHMS86,HHHU86,HHCH90)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,RRIKEIVKK*# SEQUENCE: RRIKEIVKK*# ...# >HUM1145F# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (362-370)# DB REFERENCE: SWISS: (P53_BOVIN,P53_SHEEP,P53_CERAE,P53_HUMAN,P53_FELCA,# & P53_SHEEP,P53_FELCA,P53_CERAE,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S06594,S51648)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,SRAHSSHLK*# SEQUENCE: SRAHSSHLK*# ...# >HUM11460# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (378-386)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,SRHKKLMFK*# SEQUENCE: SRHKKLMFK*# ...# >HUM11461# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (201-209)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,LRVEYLDDR*# SEQUENCE: LRVEYLDDR*# ...# >HUM11462# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (282-290)# DB REFERENCE: SWISS: (P53_HUMAN,P53_BOVIN,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S51648)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,RRTEEENLR*# SEQUENCE: RRTEEENLR*# ...# >HUM11463# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (334-342)# ANCHOR POSITIONS: 2,9# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRERFEMER*# SEQUENCE: GRERFEMER*# ...# >HUM11464# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (161-169)# DB REFERENCE: SWISS: (MBP_RAT,MBP_BOVIN,MBP_CAVPO,MBP_HUMAN,MBP_MOUSE,# & MBP_PANTR)# & PIR1: (MBCZB,MBHUB,MBBOB,MBMSB,MBRTS,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,SRSGSPMAR*# SEQUENCE: SRSGSPMAR*# ...# >HUM11465# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (25-33)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_BOVIN,MBP_CAVPO,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBMSB,MBRTS,MBCZB,MBHUB,MBBOB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,RHGFLPRHR*# SEQUENCE: RHGFLPRHR*# ...# >HUM11466# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (48-56)# DB REFERENCE: SWISS: (MBP_RAT,MBP_MOUSE,MBP_PANTR,MBP_RABIT,MBP_HUMAN,# & MBP_BOVIN)# & PIR1: (MBHUB,MBBOB,MBCZB,MBRTS,MBMSB,MBPGB)# & PIR2: (B92087)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,DRGAPKRGS*# SEQUENCE: DRGAPKRGS*# ...# >HUM11467# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (8-16)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_RAT,MBP_CAVPO,MBP_HUMAN)# & PIR1: (MBHUB,MBRTS,MBPGB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,QRHGSKYLA*# SEQUENCE: QRHGSKYLA*# ...# >HUM11468# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (129-137)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_PANTR,MBP_HUMAN,MBP_MOUSE)# & PIR1: (MBHUB,MBBOB,MBMSB,MBCZB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,GRASDYKSA*# SEQUENCE: GRASDYKSA*# ...# >HUM11469# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (24-32)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_RAT,MBP_HUMAN,MBP_BOVIN,MBP_MOUSE,# & MBP_CAVPO)# & PIR1: (MBRTS,MBBOB,MBHUB,MBMSB,MBPGB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,ARHGFLPRH*# SEQUENCE: ARHGFLPRH*# ...# >HUM1146A# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (53-61)# DB REFERENCE: SWISS: (MBP_RAT,MBP_PANTR,MBP_CAVPO)# & PIR1: (MBRTS,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,KRGSGKDSH*# SEQUENCE: KRGSGKDSH*# ...# >HUM1146B# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (30-38)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_PANTR,MBP_MOUSE,MBP_BOVIN,MBP_RAT,# & MBP_HUMAN)# & PIR1: (MBRTS,MBHUB,MBCZB,MBBOB,MBMSB)# & PIR2: (A37246,S66383)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,PRHRDTGIL*# SEQUENCE: PRHRDTGIL*# ...# >HUM1146C# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (64-72)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBCZB,MBHUB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,ARTAHYGSL*# SEQUENCE: ARTAHYGSL*# ...# >HUM1146D# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (96-104)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_PANTR,MBP_CAVPO,MBP_RAT,# & MBP_BOVIN)# & PIR1: (MBBOB,MBCZB,MBHUB,MBRTS,MBPGB,MBMSB)# & PIR2: (A37246)# & PIR3: (S12904)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,PRTPPPSQG*# SEQUENCE: PRTPPPSQG*# ...# >HUM1146E# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (121-129)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,QRPGFGYGG*# SEQUENCE: QRPGFGYGG*# ...# >HUM1146F# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (78-96)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN)# & PIR1: (MBHUB,MBMSB)# & PIR2: (I53256)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRTQDENPV*# SEQUENCE: GRTQDENPV*# ...# >HUM11470# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (106-114)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_RAT,MBP_BOVIN,MBP_HUMAN,MBP_CAVPO,# & MBP_PANTR)# & PIR1: (MBHUB,MBMSB,MBCZB,MBPGB,MBRTS,MBBOB)# & PIR2: (A60222,A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRGLSLSRF*# SEQUENCE: GRGLSLSRF*# ...# >HUM11471# MHC MOLECULE: HLA-B27(B*2706), CLASS-1, (HUMAN)# METHOD: Binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (158-166)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_RAT,MBP_MOUSE,MBP_BOVIN,MBP_CAVPO,# & MBP_HUMAN)# & PIR1: (MBHUB,MBBOB,MBMSB,MBRTS,MBPGB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRDSRSGSP*# SEQUENCE: GRDSRSGSP*# ...# >HUM21472# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: synthetic universal DR4 binding peptide# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT: universal DR4 binder# SUMMARY: HLA-DR4,actunkn,bindyesh,YPKFVKQNTLKAA*# SEQUENCE: YPKFVKQNTLKAA*# ...# >HUM21473# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: link (61-73)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AKFYRDPTAFGSG*# SEQUENCE: AKFYRDPTAFGSG*# ...# >HUM21474# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: link (170-182)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YNLNFHEAQQAAL*# SEQUENCE: YNLNFHEAQQAAL*# ...# >HUM21475# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: link (249-261)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,DVFAFTSNFNGRF*# SEQUENCE: DVFAFTSNFNGRF*# ...# >HUM21476# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: link (268-280)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TKLTYDEAVQAAL*# SEQUENCE: TKLTYDEAVQAAL*# ...# >HUM21477# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (13-25)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LTLLVAAVLRAQG*# SEQUENCE: LTLLVAAVLRAQG*# ...# >HUM21478# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1165-1177)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,DPLQYMRADQAAG*# SEQUENCE: DPLQYMRADQAAG*# ...# >HUM21479# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1168-1180)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,QYMRADQAAGGLR*# SEQUENCE: QYMRADQAAGGLR*# ...# >HUM2147A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1306-1318)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_MOUSE,CA12_BOVIN,CA12_BOVIN,# & CA12_CHICK)# & PIR1: (CGHU6C,CGBO6C,CGCH6C)# & PIR2: (A57032,A61396,B41182,A41182)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,MTFLRLLSTEGSQ*# SEQUENCE: MTFLRLLSTEGSQ*# ...# >HUM2147B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1307-1319)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_CHICK,CA12_BOVIN,CA12_MOUSE,CA12_HUMAN,# & CA12_HUMAN)# & PIR1: (CGBO6C,CGCH6C,CGHU6C)# & PIR2: (B41182,A61396,A57032,A41182)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TFLRLLSTEGSQN*# SEQUENCE: TFLRLLSTEGSQN*# ...# >HUM2147C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1340-1352)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_BOVIN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGHU6C,CGBO6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KALLIQGSNDVEI*# SEQUENCE: KALLIQGSNDVEI*# ...# >HUM2147D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1350-1362)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_CHICK,CA12_BOVIN,# & CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C,CGCH6C)# & PIR2: (A40333,A57032,B40333)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VEIRAEGNSRFTY*# SEQUENCE: VEIRAEGNSRFTY*# ...# >HUM2147E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hsp65 (181-193)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCPA,CH60_MYCTU,CH60_MYCMR,CH60_MYCPA,# & CH60_MYCFO,CH60_MYCCH,CH62_MYCTU,CH60_MYCAV)# & PIR2: (A25902,A43509,A26950,S40245)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,FGLQLELTEGMRF*# SEQUENCE: FGLQLELTEGMRF*# ...# >HUM2147F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: hsp65 (189-201)# DB REFERENCE: SWISS: (CH60_MYCPA,CH60_MYCTU,CH62_MYCTU,CH60_MYCPA,# & CH62_MYCLE)# & PIR2: (A26950,S40245,A43509,A25902)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EGMRFDKGYISGY*# SEQUENCE: EGMRFDKGYISGY*# ...# >HUM21480# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: hsp65 (216-228)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCTU,CH62_MYCTU)# & PIR2: (A43509,A26950,A25902)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PYILLVSSKVSTV*# SEQUENCE: PYILLVSSKVSTV*# ...# >HUM21481# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: hsp65 (284-296)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCTU,CH60_MYCPA,CH60_MYCTU)# & PIR2: (A26950,A43509,S40245)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KAMLQDMAILTGG*# SEQUENCE: KAMLQDMAILTGG*# ...# >HUM21482# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: hsp65 (509-521)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCPA,CH60_MYCPA,CH62_MYCTU,# & CH60_MYCTU)# & PIR2: (A43509,S40245,A26950,A25902)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GLFLTTEAVVADK*# SEQUENCE: GLFLTTEAVVADK*# ...# >HUM21483# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (9-21)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YILFAHLVNKVHI*# SEQUENCE: YILFAHLVNKVHI*# ...# >HUM21484# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (34-46)# DB REFERENCE: PIR2: (A48118)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FAIINLFNEYSKK*# SEQUENCE: FAIINLFNEYSKK*# ...# >HUM21485# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (491-503)# DB REFERENCE: SWISS: (FILA_HUMAN)# & PIR2: (A35938,A32947)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GSFLYQVSTHEQS*# SEQUENCE: GSFLYQVSTHEQS*# ...# >HUM21486# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (492-504)# DB REFERENCE: SWISS: (FILA_HUMAN)# & PIR2: (A32947,A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SFLYQVSTHEQSE*# SEQUENCE: SFLYQVSTHEQSE*# ...# >HUM21487# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (644-656)# DB REFERENCE: PIR2: (A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SSFSQDRDSQAQS*# SEQUENCE: SSFSQDRDSQAQS*# ...# >HUM21488# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (1139-1151)# DB REFERENCE: PIR2: (A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GSFIYQVSTHEQS*# SEQUENCE: GSFIYQVSTHEQS*# ...# >HUM21489# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (1140-1152)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SFIYQVSTHEQSS*# SEQUENCE: SFIYQVSTHEQSS*# ...# >HUM2148A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: link (61-73)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AKFYRDPTAFGSG*# SEQUENCE: AKFYRDPTAFGSG*# ...# >HUM2148B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: link (170-182)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YNLNFHEAQQAAL*# SEQUENCE: YNLNFHEAQQAAL*# ...# >HUM2148C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: link (249-261)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,DVFAFTSNFNGRF*# SEQUENCE: DVFAFTSNFNGRF*# ...# >HUM2148D# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: link (268-280)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,TKLTYDEAVQAAL*# SEQUENCE: TKLTYDEAVQAAL*# ...# >HUM2148E# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (13-25)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LTLLVAAVLRAQG*# SEQUENCE: LTLLVAAVLRAQG*# ...# >HUM2148F# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1165-1177)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,DPLQYMRADQAAG*# SEQUENCE: DPLQYMRADQAAG*# ...# >HUM21490# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen (1168-1180)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QYMRADQAAGGLR*# SEQUENCE: QYMRADQAAGGLR*# ...# >HUM21491# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1306-1318)# DB REFERENCE: SWISS: (CA12_MOUSE,CA12_BOVIN,CA12_HUMAN,CA12_BOVIN,CA12_HUMAN,# & CA12_CHICK)# & PIR1: (CGHU6C,CGCH6C,CGBO6C)# & PIR2: (A41182,B41182,A61396,A57032)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,MTFLRLLSTEGSQ*# SEQUENCE: MTFLRLLSTEGSQ*# ...# >HUM21492# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (1307-1319)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_CHICK,CA12_HUMAN,CA12_BOVIN,CA12_MOUSE,# & CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C,CGCH6C)# & PIR2: (A61396,B41182,A57032,A41182)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TFLRLLSTEGSQN*# SEQUENCE: TFLRLLSTEGSQN*# ...# >HUM21493# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen (1340-1352)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_HUMAN,CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KALLIQGSNDVEI*# SEQUENCE: KALLIQGSNDVEI*# ...# >HUM21494# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen (1350-1362)# DB REFERENCE: SWISS: (CA12_CHICK,CA12_HUMAN,CA12_BOVIN,CA12_HUMAN,# & CA12_BOVIN)# & PIR1: (CGCH6C,CGHU6C,CGBO6C)# & PIR2: (A40333,B40333,A57032)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,VEIRAEGNSRFTY*# SEQUENCE: VEIRAEGNSRFTY*# ...# >HUM21495# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hsp65 (181-193)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCLE,CH60_MYCCH,CH60_MYCFO,CH60_MYCPA,# & CH60_MYCTU,CH60_MYCAV,CH60_MYCMR,CH62_MYCTU)# & PIR2: (S40245,A43509,A26950,A25902)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,FGLQLELTEGMRF*# SEQUENCE: FGLQLELTEGMRF*# ...# >HUM21496# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hsp65 (189-201)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCPA,CH60_MYCTU,CH62_MYCTU,# & CH60_MYCPA)# & PIR2: (S40245,A25902,A26950,A43509)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EGMRFDKGYISGY*# SEQUENCE: EGMRFDKGYISGY*# ...# >HUM21497# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: hsp65 (216-228)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU,CH62_MYCLE)# & PIR2: (A25902,A26950,A43509)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PYILLVSSKVSTV*# SEQUENCE: PYILLVSSKVSTV*# ...# >HUM21498# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: hsp65 (284-296)# DB REFERENCE: SWISS: (CH60_MYCTU,CH60_MYCPA,CH62_MYCTU,CH60_MYCPA)# & PIR2: (A43509,S40245,A26950)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KAMLQDMAILTGG*# SEQUENCE: KAMLQDMAILTGG*# ...# >HUM21499# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hsp65 (509-521)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCPA,CH60_MYCTU,CH60_MYCPA,# & CH62_MYCTU)# & PIR2: (A26950,A25902,A43509,S40245)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,GLFLTTEAVVADK*# SEQUENCE: GLFLTTEAVVADK*# ...# >HUM2149A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (9-21)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YILFAHLVNKVHI*# SEQUENCE: YILFAHLVNKVHI*# ...# >HUM2149B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (34-46)# DB REFERENCE: PIR2: (A48118)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FAIINLFNEYSKK*# SEQUENCE: FAIINLFNEYSKK*# ...# >HUM2149C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (491-503)# DB REFERENCE: SWISS: (FILA_HUMAN)# & PIR2: (A35938,A32947)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GSFLYQVSTHEQS*# SEQUENCE: GSFLYQVSTHEQS*# ...# >HUM2149D# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (492-504)# DB REFERENCE: SWISS: (FILA_HUMAN)# & PIR2: (A32947,A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SFLYQVSTHEQSE*# SEQUENCE: SFLYQVSTHEQSE*# ...# >HUM2149E# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: fillagrin (644-656)# DB REFERENCE: PIR2: (A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,SSFSQDRDSQAQS*# SEQUENCE: SSFSQDRDSQAQS*# ...# >HUM2149F# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (1139-1151)# DB REFERENCE: PIR2: (A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GSFIYQVSTHEQS*# SEQUENCE: GSFIYQVSTHEQS*# ...# >HUM214A0# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (1140-1152)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SFIYQVSTHEQSS*# SEQUENCE: SFIYQVSTHEQSS*# ...# >HUM214A1# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: link (61-73)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AKFYRDPTAFGSG*# SEQUENCE: AKFYRDPTAFGSG*# ...# >HUM214A2# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: link (170-182)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,YNLNFHEAQQAAL*# SEQUENCE: YNLNFHEAQQAAL*# ...# >HUM214A3# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: link (249-261)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DVFAFTSNFNGRF*# SEQUENCE: DVFAFTSNFNGRF*# ...# >HUM214A4# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: link (268-280)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,TKLTYDEAVQAAL*# SEQUENCE: TKLTYDEAVQAAL*# ...# >HUM214A5# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen (13-25)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LTLLVAAVLRAQG*# SEQUENCE: LTLLVAAVLRAQG*# ...# >HUM214A6# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen (1165-1177)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DPLQYMRADQAAG*# SEQUENCE: DPLQYMRADQAAG*# ...# >HUM214A7# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen (1168-1180)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,QYMRADQAAGGLR*# SEQUENCE: QYMRADQAAGGLR*# ...# >HUM214A8# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen (1306-1318)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_MOUSE,CA12_BOVIN,CA12_HUMAN,CA12_CHICK,# & CA12_BOVIN)# & PIR1: (CGCH6C,CGHU6C,CGBO6C)# & PIR2: (A41182,A61396,B41182,A57032)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,MTFLRLLSTEGSQ*# SEQUENCE: MTFLRLLSTEGSQ*# ...# >HUM214A9# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen (1307-1319)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_CHICK,CA12_BOVIN,CA12_HUMAN,# & CA12_MOUSE)# & PIR1: (CGCH6C,CGHU6C,CGBO6C)# & PIR2: (A57032,A41182,B41182,A61396)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,TFLRLLSTEGSQN*# SEQUENCE: TFLRLLSTEGSQN*# ...# >HUM214AA# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen (1340-1352)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KALLIQGSNDVEI*# SEQUENCE: KALLIQGSNDVEI*# ...# >HUM214AB# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen (1350-1362)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_HUMAN,CA12_CHICK,# & CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C,CGCH6C)# & PIR2: (B40333,A40333,A57032)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,VEIRAEGNSRFTY*# SEQUENCE: VEIRAEGNSRFTY*# ...# >HUM214AC# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hsp65 (181-193)# DB REFERENCE: SWISS: (CH60_MYCAV,CH62_MYCTU,CH60_MYCTU,CH62_MYCLE,CH60_MYCCH,# & CH60_MYCFO,CH60_MYCPA,CH60_MYCPA,CH60_MYCMR)# & PIR2: (A26950,S40245,A25902,A43509)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,FGLQLELTEGMRF*# SEQUENCE: FGLQLELTEGMRF*# ...# >HUM214AD# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hsp65 (189-201)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCPA,CH62_MYCLE,CH60_MYCPA,# & CH60_MYCTU)# & PIR2: (A25902,A43509,S40245,A26950)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,EGMRFDKGYISGY*# SEQUENCE: EGMRFDKGYISGY*# ...# >HUM214AE# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hsp65 (216-228)# DB REFERENCE: SWISS: (CH62_MYCLE,CH62_MYCTU,CH60_MYCTU)# & PIR2: (A25902,A43509,A26950)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PYILLVSSKVSTV*# SEQUENCE: PYILLVSSKVSTV*# ...# >HUM214AF# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: hsp65 (284-296)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCTU,CH60_MYCTU,CH60_MYCPA)# & PIR2: (A26950,S40245,A43509)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KAMLQDMAILTGG*# SEQUENCE: KAMLQDMAILTGG*# ...# >HUM214B0# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: hsp65 (509-521)# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCLE,CH62_MYCTU,CH60_MYCPA,# & CH60_MYCPA)# & PIR2: (A25902,A43509,S40245,A26950)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,GLFLTTEAVVADK*# SEQUENCE: GLFLTTEAVVADK*# ...# >HUM214B1# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: fillagrin (9-21)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,YILFAHLVNKVHI*# SEQUENCE: YILFAHLVNKVHI*# ...# >HUM214B2# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: fillagrin (34-46)# DB REFERENCE: PIR2: (A48118)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,FAIINLFNEYSKK*# SEQUENCE: FAIINLFNEYSKK*# ...# >HUM214B3# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (492-504)# DB REFERENCE: SWISS: (FILA_HUMAN)# & PIR2: (A32947,A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SFLYQVSTHEQSE*# SEQUENCE: SFLYQVSTHEQSE*# ...# >HUM214B4# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: fillagrin (644-656)# DB REFERENCE: PIR2: (A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,SSFSQDRDSQAQS*# SEQUENCE: SSFSQDRDSQAQS*# ...# >HUM214B5# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: fillagrin (1139-1151)# DB REFERENCE: PIR2: (A35938)# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GSFIYQVSTHEQS*# SEQUENCE: GSFIYQVSTHEQS*# ...# >HUM214B6# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: fillagrin (1140-1152)# ANCHOR POSITIONS:# REFERENCES: hammer95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SFIYQVSTHEQSS*# SEQUENCE: SFIYQVSTHEQSS*# ...# >HUM214B7# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (279-294)# DB REFERENCE: SWISS: (VL1_HPV16,VL1_HPV35,VL1_HPV34)# & PIR1: (P1WLHS,P1WL35)# & PIR2: (S36526,S36520)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,EQMFVRHLFNRAGTVG*# SEQUENCE: EQMFVRHLFNRAGTVG*# ...# >HUM214B8# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (91-106)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesu,VSGLQYRVFRIHLPDP*# SEQUENCE: VSGLQYRVFRIHLPDP*# ...# >HUM214B9# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (5-18)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,TPTLHEYMLDLQPE*# SEQUENCE: TPTLHEYMLDLQPE*# ...# >HUM214BA# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (17-38)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,PETTDLYCYEQLNDSSEEEDEI*# SEQUENCE: PETTDLYCYEQLNDSSEEEDEI*# ...# >HUM214BB# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (21-34)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,DLYCYEQLNDSSEE*# SEQUENCE: DLYCYEQLNDSSEE*# ...# >HUM214BC# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (25-38)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,YEQLNDSSEEEDEI*# SEQUENCE: YEQLNDSSEEEDEI*# ...# >HUM214BD# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (69-86)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,VQSTHVDIRTLEDLLMGT*# SEQUENCE: VQSTHVDIRTLEDLLMGT*# ...# >HUM214BE# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (73-86)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,HVDIRTLEDLLMGT*# SEQUENCE: HVDIRTLEDLLMGT*# ...# >HUM214BF# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E6 (42-57)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,VPVSKVVSTDEYVART*# SEQUENCE: VPVSKVVSTDEYVART*# ...# >HUM214C0# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (40-63)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,PPVPVSKVVSTDEYVARTNIYYHA*# SEQUENCE: PPVPVSKVVSTDEYVARTNIYYHA*# ...# >HUM214C1# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (219-244)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,TVIQDGDMVHTGFGAMDFTTLQANKS*# SEQUENCE: TVIQDGDMVHTGFGAMDFTTLQANKS*# ...# >MUS214C2# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (20-29)# ANCHOR POSITIONS:# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,TLDLYCYEQLN*# SEQUENCE: TLDLYCYEQLN*# ...# >MUS214C3# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (45-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,AEPDRAHYNI*# SEQUENCE: AEPDRAHYNI*# ...# >MUS214C4# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (60-79)# ANCHOR POSITIONS:# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,STLRLCVQSTHVIRTL*# SEQUENCE: STLRLCVQSTHVIRTL*# ...# >MUS214C5# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (85-94)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,GTLGIVCPIC*# SEQUENCE: GTLGIVCPIC*# ...# >MUS214C6# MHC MOLECULE: I-Aa, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Aa,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214C7# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214C8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214C9# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214CA# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214CB# MHC MOLECULE: I-Ea, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ea,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214CC# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214CD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214CE# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (48-54)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Es,actyesu,bindyesu,DRAHYNI*# SEQUENCE: DRAHYNI*# ...# >MUS214CF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (40-63)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,PPVPVSKVVSTDEYVARTNIYYHA*# SEQUENCE: PPVPVSKVVSTDEYVARTNIYYHA*# ...# >MUS214D0# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (40-63)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,PPVPVSKVVSTDEYVARTNIYYHA*# SEQUENCE: PPVPVSKVVSTDEYVARTNIYYHA*# ...# >MUS214D1# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (40-63)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,PPVPVSKVVSTDEYVARTNIYYHA*# SEQUENCE: PPVPVSKVVSTDEYVARTNIYYHA*# ...# >MUS214D2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (40-63)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,PPVPVSKVVSTDEYVARTNIYYHA*# SEQUENCE: PPVPVSKVVSTDEYVARTNIYYHA*# ...# >MUS214D3# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (91-106)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,VSGLQYRVFRIHLPDP*# SEQUENCE: VSGLQYRVFRIHLPDP*# ...# >MUS214D4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (91-106)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,VSGLQYRVFRIHLPDP*# SEQUENCE: VSGLQYRVFRIHLPDP*# ...# >MUS214D5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (91-106)# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,VSGLQYRVFRIHLPDP*# SEQUENCE: VSGLQYRVFRIHLPDP*# ...# >MUS214D6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (279-294)# DB REFERENCE: SWISS: (VL1_HPV34,VL1_HPV35,VL1_HPV16)# & PIR1: (P1WLHS,P1WL35)# & PIR2: (S36526,S36520)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,EQMFVRHLFNRAGTVG*# SEQUENCE: EQMFVRHLFNRAGTVG*# ...# >MUS214D7# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (279-294)# DB REFERENCE: SWISS: (VL1_HPV35,VL1_HPV34,VL1_HPV16)# & PIR1: (P1WL35,P1WLHS)# & PIR2: (S36520,S36526)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,EQMFVRHLFNRAGTVG*# SEQUENCE: EQMFVRHLFNRAGTVG*# ...# >MUS214D8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 L1 (279-294)# DB REFERENCE: SWISS: (VL1_HPV16,VL1_HPV34,VL1_HPV35)# & PIR1: (P1WL35,P1WLHS)# & PIR2: (S36520,S36526)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,EQMFVRHLFNRAGTVG*# SEQUENCE: EQMFVRHLFNRAGTVG*# ...# >MUS214D9# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E6 (41-50)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,EVYDFAFRDL*# SEQUENCE: EVYDFAFRDL*# ...# >MUS214DA# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E6 (91-100)# ANCHOR POSITIONS:# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,QYNKPLCDDL*# SEQUENCE: QYNKPLCDDL*# ...# >MUS214DB# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E6 (146-151)# DB REFERENCE: PIR2: (S66916)# ANCHOR POSITIONS:# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,RRQTQL*# SEQUENCE: RRQTQL*# ...# >HUM114DC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E7 (4-12)# DB REFERENCE: SWISS: (VE7_HPV11)# & PIR1: (W7WL11)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,RLVTLKDIV*# SEQUENCE: RLVTLKDIV*# ...# >MUS114DD# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E6 (131-140)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,RWTGRCMSCC*# SEQUENCE: RWTGRCMSCC*# ...# >MUS114DE# MHC MOLECULE: H-2d, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E6 (86-95)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,TTLEQQYNKP*# SEQUENCE: TTLEQQYNKP*# ...# >MUS114DF# MHC MOLECULE: H-2d, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV11 E6 (116-125)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: sadovnikova94b# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,QRHLDKKQRF*# SEQUENCE: QRHLDKKQRF*# ...# >HUM214E0# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_PANTR,MBP_RAT,MBP_MOUSE,# & MBP_BOVIN)# & PIR1: (MBMSB,MBRTS,MBPGB,MBHUB,MBCZB,MBBOB)# & PIR2: (A37246)# REFERENCES: vogt94a,martin94a# COMMENT:# SUMMARY: HLA-DR51,actyesu,bindyesu,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >HUM214E1# MHC MOLECULE: HLA-DR2(DRB1*1501), CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_BOVIN,MBP_PANTR,MBP_CAVPO,MBP_RAT,# & MBP_HUMAN)# & PIR1: (MBCZB,MBBOB,MBMSB,MBRTS,MBPGB,MBHUB)# & PIR2: (A37246)# REFERENCES: martin94a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >HUM214E2# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface Ag HBV(S) (19-28)# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_HPBVR,VMSA_HPBVY,VMSA_HPBVP,VMSA_HPBVS,# & VMSA_HPBV4,VMSA_HPBV2,VMSA_HPBV0,VMSA_HPBVW,VMSA_HPBVN,# & VMSA_HPBVY,VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBV9,# & VMSA_HPBVD)# & PIR1: (SAVLA,SAVLAD,SAVLAH,SAVLN1,SAVLVD,JQ1575,SAVLHV,SAVLKS,# & JQ1577,SAVLVE,SAVLBH,SAVLAR,SAVLAJ)# & PIR2: (S20745,S41871,S47411,JQ2047,S20753,JQ2050,JQ2078,JQ2081,# & S43492,JQ2070,JQ2055,S20749,JQ2052,JQ2063,JQ2069,JQ2075,# & JQ2053,JQ2099,JQ2054,S32202,JQ2048,JQ2095,JQ2112,JQ2114,# & JQ2065,JQ2104,JQ2096,JQ2066,JQ2056,JQ2051,JQ2072,JQ2115,# & S47407,JQ2067,JQ2077,JQ2079,JQ2113,JQ2094,JQ2083,JQ2097,# & S36654,JQ2073,JQ2098,JQ2080,JQ2111,JQ2109,JQ2068,S41869,# & JQ2105,JQ2045,JQ2108,JQ2103,JQ2102,JQ2076,JQ2100,S41870,# & S35528,JQ2046)# & PIR4: (S42226)# REFERENCES: celis90a# COMMENT:# SUMMARY: HLA-DPw4,actyesu,bindyesu,FFLLTRILTI*# SEQUENCE: FFLLTRILTI*# ...# >HUM214E3# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rabies virus NS (101-120)# DB REFERENCE: SWISS: (RRPP_RABVP)# & PIR1: (MNVNRV)# REFERENCES: celis90a# COMMENT:# SUMMARY: HLA-DPw4,actyesu,bindyesu,GVQIVRQIRSGERFLKIWSQ*# SEQUENCE: GVQIVRQIRSGERFLKIWSQ*# ...# >HUM214E4# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Hepatitis B surface Ag HBV(S) (19-28) homologue# ANCHOR POSITIONS:# REFERENCES: celis90a# COMMENT:# SUMMARY: HLA-DPw4,actyesl,bindyesu,FFLLTRFLKI*# SEQUENCE: FFLLTRFLKI*# ...# >HUM214E5# MHC MOLECULE: HLA-DPw4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Rabies virus NS (101-120) homologue# ANCHOR POSITIONS:# REFERENCES: celis90a# COMMENT:# SUMMARY: HLA-DPw4,actyesl,bindyesu,GVQIVRQIRSGERILTIWSQ*# SEQUENCE: GVQIVRQIRSGERILTIWSQ*# ...# >HUM214E6# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (10-19)# DB REFERENCE: SWISS: (VMSA_HPBV4,VMSA_HPBVJ,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVY,# & VMSA_HPBVR,VMSA_HPBVP,VMSA_HPBVO,VMSA_HPBVA,VMSA_HPBV2,# & VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBVT,VMSA_HPBV9,# & VMSA_HPBVZ)# & PIR1: (SAVLKS,SAVLA1,SAVLBH,SAVLAJ,SAVLJ2,SAVLAH,SAVLJ3,SAVLA,# & SAVLVD,SAVLJ1)# & PIR2: (S41870,S35528,S41869,S47407,S36654,S43492,S20753,S20745,# & S41871,S47411,S32202,JQ2230,S20749)# REFERENCES: celis94a,serra93a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,PLGFFPDHQL*# SEQUENCE: PLGFFPDHQL*# ...# >HUM214E7# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (10-21)# DB REFERENCE: SWISS: (VMSA_HPBVI,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVA,VMSA_HPBV2,# & VMSA_HPBVO,VMSA_HPBVT,VMSA_HPBVR,VMSA_HPBV9,VMSA_HPBVZ,# & VMSA_HPBVR,VMSA_HPBVJ,VMSA_HPBVY,VMSA_HPBVP,# & VMSA_HPBV4)# & PIR1: (SAVLAJ,SAVLKS,SAVLBH,SAVLAH,SAVLA,SAVLA1,SAVLVD,SAVLJ1,# & SAVLJ3,SAVLJ2)# & PIR2: (S41870,S35528,S41869,S36654,S43492,S41871,S47411,S20749,# & S20745,JQ2230,S20753,S32202,S47407)# REFERENCES: celis94a,serra93a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,PLGFFPDHQLDP*# SEQUENCE: PLGFFPDHQLDP*# ...# >HUM214E8# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (10-25)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBV4,# & VMSA_HPBVR)# & PIR1: (SAVLVD,SAVLA)# & PIR2: (S43492,S47411,S35528,S36654)# REFERENCES: celis94a,serra93a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,PLGFFPDHQLDPAFGA*# SEQUENCE: PLGFFPDHQLDPAFGA*# ...# >HUM214E9# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (11-27)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBVA,VMSA_HPBVY)# & PIR1: (SAVLAH,SAVLA1,SAVLAJ,SAVLBH)# & PIR2: (S41870,S41869,S20753,S20745,S32202,S41871,S47407)# REFERENCES: celis94a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,LGFFPDHQLDPAFRANT*# SEQUENCE: LGFFPDHQLDPAFRANT*# ...# >HUM214EA# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HAChR (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: celis94a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >HUM214EB# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IANT6,HEMA_IADH4,HEMA_IAZUK,HEMA_IAME1,HEMA_IADH6,# & HEMA_IADU3,HEMA_IAEN6,HEMA_IAZH2,HEMA_IADHM,HEMA_IADH3,# & HEMA_IAUDO,HEMA_IAME2,HEMA_IADH2,HEMA_IADH7,HEMA_IAQU7,# & HEMA_IABAN,HEMA_IAVI7,HEMA_IAZCO,HEMA_IADH1,HEMA_IAAIC,# & HEMA_IAEN7)# & PIR1: (HMIV98,HMIV15,HMIVHA,HMIVHM,HMIV6,HMIVH,HMIVS3,HMIV77,# & HMIVDU,HMIV89,HMIV33,HMIVV,HMIV80)# & PIR2: (JQ1156,A92979)# REFERENCES: celis94a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesu,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM214EC# MHC MOLECULE: HLA-DQ5(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (10-19)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVJ,VMSA_HPBVT,VMSA_HPBV4,VMSA_HPBVO,# & VMSA_HPBV2,VMSA_HPBV2,VMSA_HPBV9,VMSA_HPBVR,VMSA_HPBVI,# & VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVP,VMSA_HPBVA,# & VMSA_HPBVY)# & PIR1: (SAVLJ2,SAVLKS,SAVLA,SAVLVD,SAVLBH,SAVLAH,SAVLA1,SAVLJ3,# & SAVLJ1,SAVLAJ)# & PIR2: (S20745,S35528,S41869,S47407,S47411,S20753,S41871,JQ2230,# & S43492,S32202,S36654,S41870,S20749)# REFERENCES: celis94a,serra93a# COMMENT:# SUMMARY: HLA-DQ5,actunkn,bindyesu,PLGFFPDHQL*# SEQUENCE: PLGFFPDHQL*# ...# >HUM214ED# MHC MOLECULE: HLA-DQ5(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (10-21)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVA,VMSA_HPBVZ,VMSA_HPBVP,# & VMSA_HPBVJ,VMSA_HPBV4,VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBV9,# & VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVR,VMSA_HPBVT,# & VMSA_HPBVO)# & PIR1: (SAVLJ1,SAVLAJ,SAVLJ3,SAVLAH,SAVLA,SAVLVD,SAVLKS,SAVLA1,# & SAVLJ2,SAVLBH)# & PIR2: (S41871,S41869,S47407,S47411,S36654,S41870,JQ2230,S43492,# & S32202,S20749,S20745,S35528,S20753)# REFERENCES: celis94a,serra93a# COMMENT:# SUMMARY: HLA-DQ5,actyesu,bindyesu,PLGFFPDHQLDP*# SEQUENCE: PLGFFPDHQLDP*# ...# >HUM214EE# MHC MOLECULE: HLA-DQ5(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (10-25)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBV4,VMSA_HPBV2,VMSA_HPBVR,# & VMSA_HPBVR)# & PIR1: (SAVLVD,SAVLA)# & PIR2: (S35528,S43492,S47411,S36654)# REFERENCES: celis94a,serra93a# COMMENT:# SUMMARY: HLA-DQ5,actyesm,bindyesu,PLGFFPDHQLDPAFGA*# SEQUENCE: PLGFFPDHQLDPAFGA*# ...# >HUM214EF# MHC MOLECULE: HLA-DQ5(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (10-36)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBV2,# & VMSA_HPBVP)# & PIR1: (SAVLA,SAVLVD)# & PIR2: (S47411,S43492,S36654,S35528)# REFERENCES: celis94a# COMMENT:# SUMMARY: HLA-DQ5,actyesu,bindyesu,PLGFFPDHQLDPAFGANSNNPDWDFNP*# SEQUENCE: PLGFFPDHQLDPAFGANSNNPDWDFNP*# ...# >HUM214F0# MHC MOLECULE: HLA-DQ5(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (11-27)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVA,VMSA_HPBVZ)# & PIR1: (SAVLAH,SAVLA1,SAVLBH,SAVLAJ)# & PIR2: (S41871,S41869,S32202,S41870,S20745,S47407,S20753)# REFERENCES: celis94a# COMMENT:# SUMMARY: HLA-DQ5,actyesu,bindyesu,LGFFPDHQLDPAFRANT*# SEQUENCE: LGFFPDHQLDPAFRANT*# ...# >HUM214F1# MHC MOLECULE: HLA-DQ6(DQA1*01021xDQB1*0604), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Hepatitis B surface HBS (10-25)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBV4,VMSA_HPBV2,# & VMSA_HPBV2)# & PIR1: (SAVLVD,SAVLA)# & PIR2: (S47411,S36654,S35528,S43492)# REFERENCES: celis94a,serra93a# COMMENT:# SUMMARY: HLA-DQ6,actyesl,bindyesu,PLGFFPDHQLDPAFGA*# SEQUENCE: PLGFFPDHQLDPAFGA*# ...# >HUM214F2# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LolPl (171-190)# ANCHOR POSITIONS:# REFERENCES: celis94a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,GDVVAVVDIKEKGKDKWIELK*# SEQUENCE: GDVVAVVDIKEKGKDKWIELK*# ...# >HUM214F3# MHC MOLECULE: HLA-DQ5(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LolPl (171-190)# ANCHOR POSITIONS:# REFERENCES: celis94a# COMMENT:# SUMMARY: HLA-DQ5,actyesu,bindyesu,GDVVAVVDIKEKGKDKWIELK*# SEQUENCE: GDVVAVVDIKEKGKDKWIELK*# ...# >MUS114F4# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (55-62)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,KVVRFDKL*# SEQUENCE: KVVRFDKL*# ...# >MUS114F5# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (55-62) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,SVVRFDKL*# SEQUENCE: SVVRFDKL*# ...# >MUS114F6# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (55-62) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,KIVRFDKL*# SEQUENCE: KIVRFDKL*# ...# >MUS114F7# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (55-62) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,KVIRFDKL*# SEQUENCE: KVIRFDKL*# ...# >MUS114F8# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (55-62) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,KVVNFDKL*# SEQUENCE: KVVNFDKL*# ...# >MUS114F9# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (55-62) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,KVVRFEKL*# SEQUENCE: KVVRFEKL*# ...# >MUS114FA# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,KIINFEKL*# SEQUENCE: KIINFEKL*# ...# >MUS114FB# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,SVINFEKL*# SEQUENCE: SVINFEKL*# ...# >MUS114FC# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,SIVNFEKL*# SEQUENCE: SIVNFEKL*# ...# >MUS114FD# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,SIIRFEKL*# SEQUENCE: SIIRFEKL*# ...# >MUS114FE# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS: 5,8# REFERENCES: chen94b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,SIINFDKL*# SEQUENCE: SIINFDKL*# ...# >HUM114FF# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MAGE-3# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# REFERENCES: celis94b,rosenberg96a,robbins96a,romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A1,actyesu,bindyesh,EVDPIGHLY*# SEQUENCE: EVDPIGHLY*# ...# >HUM11500# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: MAGE-3# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG6_HUMAN,MAG3_HUMAN,MAG6_HUMAN)# & PIR2: (JC2361,JC2360,G01445)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesm,ASSLPTTMNY*# SEQUENCE: ASSLPTTMNY*# ...# >HUM11501# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: MAGE-2# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesm,ASSFSTTINY*# SEQUENCE: ASSFSTTINY*# ...# >HUM11502# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MAGE-3# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG6_HUMAN,MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (G01445,JC2361,JC2360)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesl,SSLPTTMNY*# SEQUENCE: SSLPTTMNY*# ...# >HUM11503# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MAGE-3# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG6_HUMAN,MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (G01445,JC2360,JC2361)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesl,GSVVGNWQY*# SEQUENCE: GSVVGNWQY*# ...# >HUM11504# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MAGE-2# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesl,SSFSTTINY*# SEQUENCE: SSFSTTINY*# ...# >HUM11505# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MAGE-3# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG6_HUMAN,MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (G01445,JC2361,JC2360)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesl,FATCLGLSY*# SEQUENCE: FATCLGLSY*# ...# >HUM11506# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MAGE-2# DB REFERENCE: SWISS: (MAG1_HUMAN,MAGC_HUMAN,MAG4_HUMAN,MAG1_HUMAN,MAG2_HUMAN,# & MAGC_HUMAN,MAG2_HUMAN,MAG8_HUMAN,MAG4_HUMAN,# & MAG8_HUMAN)# & PIR2: (I54519,I38667,JC2358,JC2362,JC2359,G01446,I68889,# & I38661)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesl,LVTCLGLSY*# SEQUENCE: LVTCLGLSY*# ...# >HUM11507# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MAGE-3# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG6_HUMAN,MAG3_HUMAN,MAG6_HUMAN)# & PIR2: (G01445,JC2361,JC2360)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesl,LGSVVGNWQY*# SEQUENCE: LGSVVGNWQY*# ...# >HUM11508# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./ binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MAGE-3# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG6_HUMAN,MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (G01445,JC2360,JC2361)# REFERENCES: celis94b# COMMENT:# SUMMARY: HLA-A1,actyesn,bindyesl,IFATCLGLSY*# SEQUENCE: IFATCLGLSY*# ...# >HUM21509# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CS (380-396)# ANCHOR POSITIONS: 4,7# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EKKIAKMEKASSVFNVV*# SEQUENCE: EKKIAKMEKASSVFNVV*# ...# >HUM2150A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CS (380-396)# ANCHOR POSITIONS: 4,7# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,EKKIAKMEKASSVFNVV*# SEQUENCE: EKKIAKMEKASSVFNVV*# ...# >HUM2150B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, little# SOURCE: CS (380-396)# ANCHOR POSITIONS: 4,7,9# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,EKKIAKMEKASSVFNVV*# SEQUENCE: EKKIAKMEKASSVFNVV*# ...# >HUM2150C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YAALAAAAL*# SEQUENCE: YAALAAAAL*# ...# >HUM2150D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YAALATAAL*# SEQUENCE: YAALATAAL*# ...# >HUM2150E# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YAALARAAL*# SEQUENCE: YAALARAAL*# ...# >HUM2150F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YAALATAAL*# SEQUENCE: YAALATAAL*# ...# >HUM21510# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: hammer93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,YAALARAAL*# SEQUENCE: YAALARAAL*# ...# >HUM21511# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? (eluted self peptide)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VPIQRAVYQNVVVNN*# SEQUENCE: VPIQRAVYQNVVVNN*# ...# >HUM21512# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: eluted self peptide# ANCHOR POSITIONS:# REFERENCES: matsushita94a,matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPGTGAYYVLLN*# SEQUENCE: SPGTGAYYVLLN*# ...# >HUM21513# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as./Reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: eluted self peptide# ANCHOR POSITIONS:# REFERENCES: matsushita94a,chen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GSTVFDNLPNPEIDGDYYGW*# SEQUENCE: GSTVFDNLPNPEIDGDYYGW*# ...# >HUM21514# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PKM2p (99-117) (eluted self peptide)# DB REFERENCE: SWISS: (KPY1_HUMAN,KPY2_RAT,KPY2_MOUSE,KPY1_RABIT,KPY2_HUMAN,# & KPY1_RABIT,KPY1_RAT,KPY2_MOUSE)# & PIR2: (A54113,S30038,S55921,B26186,S64635,A26186,JT0486)# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SDPILYRPVAVALDTKGPE*# SEQUENCE: SDPILYRPVAVALDTKGPE*# ...# >HUM21515# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD20p (26-45) (eluted self peptide)# DB REFERENCE: SWISS: (CD2R_HUMAN,CD20_HUMAN)# & PIR1: (A30586)# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GPKPLFRRMSSLVGPTQSFF*# SEQUENCE: GPKPLFRRMSSLVGPTQSFF*# ...# >HUM21516# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD23p (195-214) (eluted self peptide)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EGQLVSIHSPEEQDFLTKHA*# SEQUENCE: EGQLVSIHSPEEQDFLTKHA*# ...# >HUM21517# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MIFp (32-51) (eluted self peptide)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GKPPQYIAVHVVPDQTMAFG*# SEQUENCE: GKPPQYIAVHVVPDQTMAFG*# ...# >HUM21518# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? (eluted self peptide)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VPIQRAVYQNVVVNN*# SEQUENCE: VPIQRAVYQNVVVNN*# ...# >HUM21519# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? (eluted self peptide)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SPGTGAYYVLLN*# SEQUENCE: SPGTGAYYVLLN*# ...# >HUM2151A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as./Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? (eluted self peptide)# ANCHOR POSITIONS:# REFERENCES: matsushita94a,chen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLPNPEIDGDYYGW*# SEQUENCE: GSTVFDNLPNPEIDGDYYGW*# ...# >HUM2151B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PKM2p (99-117) (eluted self peptide)# DB REFERENCE: SWISS: (KPY1_RABIT,KPY1_RAT,KPY2_MOUSE,KPY1_RABIT,KPY1_HUMAN,# & KPY2_RAT,KPY2_MOUSE,KPY2_HUMAN)# & PIR2: (A26186,A54113,JT0486,S30038,S55921,B26186,S64635)# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SDPILYRPVAVALDTKGPE*# SEQUENCE: SDPILYRPVAVALDTKGPE*# ...# >HUM2151C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: CD20p (26-45) (eluted self peptide)# DB REFERENCE: SWISS: (CD2R_HUMAN,CD20_HUMAN)# & PIR1: (A30586)# REFERENCES: matsushita94a,chen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GPKPLFRRMSSLVGPTQSFF*# SEQUENCE: GPKPLFRRMSSLVGPTQSFF*# ...# >HUM2151D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD23p (195-214) (eluted self peptide)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EGQLVSIHSPEEQDFLTKHA*# SEQUENCE: EGQLVSIHSPEEQDFLTKHA*# ...# >HUM2151E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MIFp (32-51) (eluted self peptide)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GKPPQYIAVHVVPDQTMAFG*# SEQUENCE: GKPPQYIAVHVVPDQTMAFG*# ...# >HUM2151F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLPNPE*# SEQUENCE: GSTVFDNLPNPE*# ...# >HUM21520# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,ASTVFDNLPNPE*# SEQUENCE: ASTVFDNLPNPE*# ...# >HUM21521# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SSTVFDNLPNPE*# SEQUENCE: SSTVFDNLPNPE*# ...# >HUM21522# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GATVFDNLPNPE*# SEQUENCE: GATVFDNLPNPE*# ...# >HUM21523# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GVTVFDNLPNPE*# SEQUENCE: GVTVFDNLPNPE*# ...# >HUM21524# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSAVFDNLPNPE*# SEQUENCE: GSAVFDNLPNPE*# ...# >HUM21525# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTSFDNLPNPE*# SEQUENCE: GSTSFDNLPNPE*# ...# >HUM21526# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFANLPNPE*# SEQUENCE: GSTVFANLPNPE*# ...# >HUM21527# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDALPNPE*# SEQUENCE: GSTVFDALPNPE*# ...# >HUM21528# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLSNPE*# SEQUENCE: GSTVFDNLSNPE*# ...# >HUM21529# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,GSTVFDNLPAPE*# SEQUENCE: GSTVFDNLPAPE*# ...# >HUM2152A# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLPNSE*# SEQUENCE: GSTVFDNLPNSE*# ...# >HUM2152B# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLPNPA*# SEQUENCE: GSTVFDNLPNPA*# ...# >HUM2152C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLPNPE*# SEQUENCE: GSTVFDNLPNPE*# ...# >HUM2152D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,ASTVFDNLPNPE*# SEQUENCE: ASTVFDNLPNPE*# ...# >HUM2152E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SSTVFDNLPNPE*# SEQUENCE: SSTVFDNLPNPE*# ...# >HUM2152F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GATVFDNLPNPE*# SEQUENCE: GATVFDNLPNPE*# ...# >HUM21530# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GVTVFDNLPNPE*# SEQUENCE: GVTVFDNLPNPE*# ...# >HUM21531# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSAVFDNLPNPE*# SEQUENCE: GSAVFDNLPNPE*# ...# >HUM21532# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTSFDNLPNPE*# SEQUENCE: GSTSFDNLPNPE*# ...# >HUM21533# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFANLPNPE*# SEQUENCE: GSTVFANLPNPE*# ...# >HUM21534# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDALPNPE*# SEQUENCE: GSTVFDALPNPE*# ...# >HUM21535# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLSNPE*# SEQUENCE: GSTVFDNLSNPE*# ...# >HUM21536# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,GSTVFDNLPAPE*# SEQUENCE: GSTVFDNLPAPE*# ...# >HUM21537# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLPNSE*# SEQUENCE: GSTVFDNLPNSE*# ...# >HUM21538# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSTVFDNLPNPA*# SEQUENCE: GSTVFDNLPNPA*# ...# >HUM21539# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAAAALANAA*# SEQUENCE: AAAAALANAA*# ...# >HUM2153A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAVAALANAA*# SEQUENCE: AAVAALANAA*# ...# >HUM2153B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AALAALANAA*# SEQUENCE: AALAALANAA*# ...# >HUM2153C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a,chen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAIAALANAA*# SEQUENCE: AAIAALANAA*# ...# >HUM2153D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAFAALANAA*# SEQUENCE: AAFAALANAA*# ...# >HUM2153E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAMAALANAA*# SEQUENCE: AAMAALANAA*# ...# >HUM2153F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAWAALANAA*# SEQUENCE: AAWAALANAA*# ...# >HUM21540# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAALANAA*# SEQUENCE: AAYAALANAA*# ...# >HUM21541# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAARANAA*# SEQUENCE: AAFAARANAA*# ...# >HUM21542# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAEANAA*# SEQUENCE: AAFAAEANAA*# ...# >HUM21543# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAADANAA*# SEQUENCE: AAFAADANAA*# ...# >HUM21544# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAQANAA*# SEQUENCE: AAFAAQANAA*# ...# >HUM21545# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAANANAA*# SEQUENCE: AAFAANANAA*# ...# >HUM21546# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAATANAA*# SEQUENCE: AAFAATANAA*# ...# >HUM21547# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAASANAA*# SEQUENCE: AAFAASANAA*# ...# >HUM21548# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAACANAA*# SEQUENCE: AAFAACANAA*# ...# >HUM21549# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAGANAA*# SEQUENCE: AAFAAGANAA*# ...# >HUM2154A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAAANAA*# SEQUENCE: AAFAAAANAA*# ...# >HUM2154B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAVANAA*# SEQUENCE: AAFAAVANAA*# ...# >HUM2154C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAIANAA*# SEQUENCE: AAFAAIANAA*# ...# >HUM2154D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAFANAA*# SEQUENCE: AAFAAFANAA*# ...# >HUM2154E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAMANAA*# SEQUENCE: AAFAAMANAA*# ...# >HUM2154F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAWANAA*# SEQUENCE: AAFAAWANAA*# ...# >HUM21550# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAYANAA*# SEQUENCE: AAFAAYANAA*# ...# >HUM21551# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAPANAA*# SEQUENCE: AAFAAPANAA*# ...# >HUM21552# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALARAA*# SEQUENCE: AAFAALARAA*# ...# >HUM21553# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAKAA*# SEQUENCE: AAFAALAKAA*# ...# >HUM21554# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAHAA*# SEQUENCE: AAFAALAHAA*# ...# >HUM21555# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAEAA*# SEQUENCE: AAFAALAEAA*# ...# >HUM21556# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALADAA*# SEQUENCE: AAFAALADAA*# ...# >HUM21557# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAALAQAA*# SEQUENCE: AAFAALAQAA*# ...# >HUM21558# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALATAA*# SEQUENCE: AAFAALATAA*# ...# >HUM21559# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAFAALASAA*# SEQUENCE: AAFAALASAA*# ...# >HUM2155A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALACAA*# SEQUENCE: AAFAALACAA*# ...# >HUM2155B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAGAA*# SEQUENCE: AAFAALAGAA*# ...# >HUM2155C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAAAA*# SEQUENCE: AAFAALAAAA*# ...# >HUM2155D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAVAA*# SEQUENCE: AAFAALAVAA*# ...# >HUM2155E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAALALAA*# SEQUENCE: AAFAALALAA*# ...# >HUM2155F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAIAA*# SEQUENCE: AAFAALAIAA*# ...# >HUM21560# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAFAA*# SEQUENCE: AAFAALAFAA*# ...# >HUM21561# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAMAA*# SEQUENCE: AAFAALAMAA*# ...# >HUM21562# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAWAA*# SEQUENCE: AAFAALAWAA*# ...# >HUM21563# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAYAA*# SEQUENCE: AAFAALAYAA*# ...# >HUM21564# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAPAA*# SEQUENCE: AAFAALAPAA*# ...# >HUM21565# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AACAALANAA*# SEQUENCE: AACAALANAA*# ...# >HUM21566# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAAAALANAA*# SEQUENCE: AAAAALANAA*# ...# >HUM21567# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAVAALANAA*# SEQUENCE: AAVAALANAA*# ...# >HUM21568# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AALAALANAA*# SEQUENCE: AALAALANAA*# ...# >HUM21569# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAIAALANAA*# SEQUENCE: AAIAALANAA*# ...# >HUM2156A# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAFAALANAA*# SEQUENCE: AAFAALANAA*# ...# >HUM2156B# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAMAALANAA*# SEQUENCE: AAMAALANAA*# ...# >HUM2156C# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAWAALANAA*# SEQUENCE: AAWAALANAA*# ...# >HUM2156D# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAYAALANAA*# SEQUENCE: AAYAALANAA*# ...# >HUM2156E# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAEANAA*# SEQUENCE: AAFAAEANAA*# ...# >HUM2156F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAADANAA*# SEQUENCE: AAFAADANAA*# ...# >HUM21570# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAAQANAA*# SEQUENCE: AAFAAQANAA*# ...# >HUM21571# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAANANAA*# SEQUENCE: AAFAANANAA*# ...# >HUM21572# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAATANAA*# SEQUENCE: AAFAATANAA*# ...# >HUM21573# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAASANAA*# SEQUENCE: AAFAASANAA*# ...# >HUM21574# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAACANAA*# SEQUENCE: AAFAACANAA*# ...# >HUM21575# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAAANAA*# SEQUENCE: AAFAAAANAA*# ...# >HUM21576# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAVANAA*# SEQUENCE: AAFAAVANAA*# ...# >HUM21577# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAFAAIANAA*# SEQUENCE: AAFAAIANAA*# ...# >HUM21578# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAFAAFANAA*# SEQUENCE: AAFAAFANAA*# ...# >HUM21579# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAMANAA*# SEQUENCE: AAFAAMANAA*# ...# >HUM2157A# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAWANAA*# SEQUENCE: AAFAAWANAA*# ...# >HUM2157B# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAYANAA*# SEQUENCE: AAFAAYANAA*# ...# >HUM2157C# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALARAA*# SEQUENCE: AAFAALARAA*# ...# >HUM2157D# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAKAA*# SEQUENCE: AAFAALAKAA*# ...# >HUM2157E# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAHAA*# SEQUENCE: AAFAALAHAA*# ...# >HUM2157F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAEAA*# SEQUENCE: AAFAALAEAA*# ...# >HUM21580# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAALADAA*# SEQUENCE: AAFAALADAA*# ...# >HUM21581# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAQAA*# SEQUENCE: AAFAALAQAA*# ...# >HUM21582# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAALATAA*# SEQUENCE: AAFAALATAA*# ...# >HUM21583# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAALASAA*# SEQUENCE: AAFAALASAA*# ...# >HUM21584# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALACAA*# SEQUENCE: AAFAALACAA*# ...# >HUM21585# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAGAA*# SEQUENCE: AAFAALAGAA*# ...# >HUM21586# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAAAA*# SEQUENCE: AAFAALAAAA*# ...# >HUM21587# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAALAVAA*# SEQUENCE: AAFAALAVAA*# ...# >HUM21588# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALALAA*# SEQUENCE: AAFAALALAA*# ...# >HUM21589# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAALAIAA*# SEQUENCE: AAFAALAIAA*# ...# >HUM2158A# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAFAA*# SEQUENCE: AAFAALAFAA*# ...# >HUM2158B# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAMAA*# SEQUENCE: AAFAALAMAA*# ...# >HUM2158C# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAWAA*# SEQUENCE: AAFAALAWAA*# ...# >HUM2158D# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAYAA*# SEQUENCE: AAFAALAYAA*# ...# >HUM2158E# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAFAALAPAA*# SEQUENCE: AAFAALAPAA*# ...# >HUM2158F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAMASAA*# SEQUENCE: AAFAAMASAA*# ...# >HUM21590# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# DB REFERENCE: SWISS: (FM2_BORPE)# & PIR2: (S03754,S36449)# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AALAAIASAA*# SEQUENCE: AALAAIASAA*# ...# >HUM21591# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KAAYAAVAVAA*# SEQUENCE: KAAYAAVAVAA*# ...# >HUM21592# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAFAAMASAA*# SEQUENCE: AAFAAMASAA*# ...# >HUM21593# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding motif homologue# DB REFERENCE: SWISS: (FM2_BORPE)# & PIR2: (S03754,S36449)# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AALAAIASAA*# SEQUENCE: AALAAIASAA*# ...# >HUM21594# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding motif homologue# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,KAAYAAVAVAA*# SEQUENCE: KAAYAAVAVAA*# ...# >HUM21595# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Kk- Insulin alpha (8-17)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,KKTSICSLYQLE*# SEQUENCE: KKTSICSLYQLE*# ...# >HUM21596# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: K- Insulin alpha (12-21)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,KSLYQLENYCN*# SEQUENCE: KSLYQLENYCN*# ...# >HUM21597# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: K- Insulin beta (11-30)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,KLVEALYLVCGERGFFYTPKT*# SEQUENCE: KLVEALYLVCGERGFFYTPKT*# ...# >HUM21598# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: KK- Insulin alpha (8-17)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesm,KKTSICSLYQLE*# SEQUENCE: KKTSICSLYQLE*# ...# >HUM21599# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: KK- Insulin alpha (8-21)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,KKTSICSLYQLENYCN*# SEQUENCE: KKTSICSLYQLENYCN*# ...# >HUM2159A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: KK- Insulin alpha (8-19)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,KKTSICSLYQLENY*# SEQUENCE: KKTSICSLYQLENY*# ...# >HUM2159B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: K- Insulin alpha (12-21)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesl,KSLYQLENYCN*# SEQUENCE: KSLYQLENYCN*# ...# >HUM2159C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: K- Insulin beta (11-30)# ANCHOR POSITIONS:# REFERENCES: matsushita94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesl,KLVEALYLVCGERGFFYTPKT*# SEQUENCE: KLVEALYLVCGERGFFYTPKT*# ...# >MUS1159D# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./binding as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Alpha-ketoglutarate dehydrogenase# DB REFERENCE: SWISS: (ODO1_HUMAN,ODO1_MOUSE)# & PIR2: (A41911,B38234)# REFERENCES: kageyama95a,dutz94a# COMMENT:# SUMMARY: H-2Kb,actyesl,bindyesu,LSPFPFDL*# SEQUENCE: LSPFPFDL*# ...# >MUS1159E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Measles virus nucleoprotein MVNP (52-59)# DB REFERENCE: SWISS: (NCAP_MEASY,NCAP_MEASA,NCAP_MEASE,NCAP_MEASH)# & PIR1: (VHNZMH,VHNZMV,JU0272,A48556)# & PIR2: (A49601)# & PIR3: (S03685)# REFERENCES: beauverger94a# COMMENT:# SUMMARY: H-2Kk,actyesh,bindyesu,LDRLVRLI*# SEQUENCE: LDRLVRLI*# ...# >MUS1159F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Measles virus nucleoprotein MVNP (81-88)# DB REFERENCE: SWISS: (NCAP_MEASH,NCAP_MEASI,NCAP_MEASE,NCAP_PHODV,NCAP_MEASY,# & NCAP_CDVO,NCAP_RINDU,NCAP_MEASA,NCAP_CDVO,NCAP_RINDL,# & NCAP_PPRV,NCAP_RINDR)# & PIR1: (VHNZCV,A48556,VHNZMV,JU0272,VHNZMH)# & PIR2: (JQ1608,S47308,A49601,A49277,S24791,S36405)# & PIR3: (S03685)# REFERENCES: beauverger94a# COMMENT:# SUMMARY: H-2Kk,actyesh,bindyesu,VESPGQLI*# SEQUENCE: VESPGQLI*# ...# >HUM115A0# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesh,bindyesu,ARYWAIRTR*# SEQUENCE: ARYWAIRTR*# ...# >HUM115A1# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesh,bindyesu,LRYWAIRTR*# SEQUENCE: LRYWAIRTR*# ...# >HUM115A2# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesm,bindyesu,KRYWAIRTR*# SEQUENCE: KRYWAIRTR*# ...# >HUM115A3# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesm,bindyesu,FRYWAIRTR*# SEQUENCE: FRYWAIRTR*# ...# >HUM115A4# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesh,bindyesu,SRFWAIRTR*# SEQUENCE: SRFWAIRTR*# ...# >HUM115A5# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRLWAIRTR*# SEQUENCE: SRLWAIRTR*# ...# >HUM115A6# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,SRYAAIRTR*# SEQUENCE: SRYAAIRTR*# ...# >HUM115A7# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,SRYLAIRTR*# SEQUENCE: SRYLAIRTR*# ...# >HUM115A8# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,SRYEAIRTR*# SEQUENCE: SRYEAIRTR*# ...# >HUM115A9# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,SRYKAIRTR*# SEQUENCE: SRYKAIRTR*# ...# >HUM115AA# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRYFAIRTR*# SEQUENCE: SRYFAIRTR*# ...# >HUM115AB# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRYYAIRTR*# SEQUENCE: SRYYAIRTR*# ...# >HUM115AC# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,SRYHAIRTR*# SEQUENCE: SRYHAIRTR*# ...# >HUM115AD# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRYWAIATR*# SEQUENCE: SRYWAIATR*# ...# >HUM115AE# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRYWAIDTR*# SEQUENCE: SRYWAIDTR*# ...# >HUM115AF# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesn,bindyesu,SRYWAIETR*# SEQUENCE: SRYWAIETR*# ...# >HUM115B0# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRYWAIITR*# SEQUENCE: SRYWAIITR*# ...# >HUM115B1# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRYWAIRAR*# SEQUENCE: SRYWAIRAR*# ...# >HUM115B2# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRYWAIRER*# SEQUENCE: SRYWAIRER*# ...# >HUM115B3# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesm,bindyesu,SRYWAIRKR*# SEQUENCE: SRYWAIRKR*# ...# >HUM115B4# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesl,bindyesu,SRYWAIRFR*# SEQUENCE: SRYWAIRFR*# ...# >HUM115B5# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# ANCHOR POSITIONS:# REFERENCES: bowness94a# COMMENT:# SUMMARY: HLA-B27,actyesm,bindyesu,SRYWAIRTL*# SEQUENCE: SRYWAIRTL*# ...# >HUM215B6# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Thyroid peroxidase (632-645Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesh,IDVWLGGLAENFLPY*# SEQUENCE: IDVWLGGLAENFLPY*# ...# >HUM215B7# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rabies virus nucleoprotein (11-25Y)# DB REFERENCE: SWISS: (NCAP_RABVU,NCAP_RABVS,NCAP_RABVP,NCAP_RABVF,# & NCAP_RABVA)# & PIR1: (VHVNSB,VHVNAV,VHVNRV)# & PIR2: (JQ2016,JQ2015)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ8,actyesu,bindyesu,NNQVVSLKPEIIVDQY*# SEQUENCE: NNQVVSLKPEIIVDQY*# ...# >HUM215B8# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MB 65kDa (243-255Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,KPLLIIAEDVEGEY*# SEQUENCE: KPLLIIAEDVEGEY*# ...# >HUM215B9# MHC MOLECULE: HLA-DQ6, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum glycoprotein 190 (330-341Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ6,actyesu,bindyesu,LISVLEKRIDTLY*# SEQUENCE: LISVLEKRIDTLY*# ...# >HUM215BA# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P8# DB REFERENCE: PIR2: (S22035,S38393,S03495,PT0733,S57882)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,LIYFQGTGAADDSGL*# SEQUENCE: LIYFQGTGAADDSGL*# ...# >HUM215BB# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P13# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,IGQYYEEEERQRGNF*# SEQUENCE: IGQYYEEEERQRGNF*# ...# >HUM215BC# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (100-117)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_PANTR,MBP_CAVPO,MBP_HUMAN,MBP_RAT,# & MBP_MOUSE)# & PIR1: (MBCZB,MBBOB,MBRTS,MBMSB,MBPGB,MBHUB)# & PIR2: (A37246)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,PPSQGKGRGLSLSRFSWG*# SEQUENCE: PPSQGKGRGLSLSRFSWG*# ...# >HUM215BD# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: DQalpha1*0301(153-168)# DB REFERENCE: SWISS: (HA22_HUMAN,HA21_HUMAN,HA26_HUMAN,HA26_HUMAN,# & HA25_HUMAN)# & PIR1: (HLHUDC,HLHUDX,HLHUD7,HLHUD1)# & PIR2: (I54444,I54290,A29312,I54439,I54437,A37044,I68717,# & I58988)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,YLTFLPSADEIYDCKV*# SEQUENCE: YLTFLPSADEIYDCKV*# ...# >HUM215BE# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: DQalpha1*0302(153-168)# DB REFERENCE: SWISS: (HA24_HUMAN)# & PIR1: (HLHUDQ)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,YLTFLPSDDEIYDCKV*# SEQUENCE: YLTFLPSDDEIYDCKV*# ...# >HUM215BF# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu matrix (17-29Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,SGPLKAEIAQRLEY*# SEQUENCE: SGPLKAEIAQRLEY*# ...# >HUM215C0# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P54# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,RGNFPDRFSARQFPEFISEAIIHVLHSRHPGC*# SEQUENCE: RGNFPDRFSARQFPEFISEAIIHVLHSRHPGC*# ...# >HUM215C1# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p21 ras (54-67,61L)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,DILDTAGLEEYSAM*# SEQUENCE: DILDTAGLEEYSAM*# ...# >HUM215C2# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: RV nucleoprotein (11-25Y)# DB REFERENCE: SWISS: (NCAP_RABVU,NCAP_RABVS,NCAP_RABVP,NCAP_RABVF,# & NCAP_RABVA)# & PIR1: (VHVNAV,VHVNSB,VHVNRV)# & PIR2: (JQ2015,JQ2016)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,NNQVVSLKPEIIVDQY*# SEQUENCE: NNQVVSLKPEIIVDQY*# ...# >HUM215C3# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MB 65kDa (243-255Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,KPLLIIAEDVEGEY*# SEQUENCE: KPLLIIAEDVEGEY*# ...# >HUM215C4# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MT 65kDa (3-13)# DB REFERENCE: SWISS: (CH62_MYCTU,CH62_MYCLE,CH60_MYCTU,CH60_MYCPA,CH60_MYCPA,# & CH60_MYCSM)# & PIR2: (A37335,A43509,S40245,A25902,A26950)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,KTIAYDEEARR*# SEQUENCE: KTIAYDEEARR*# ...# >HUM215C5# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: OVA (258-276Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,IINFEKLTEWTSSNVMEERY*# SEQUENCE: IINFEKLTEWTSSNVMEERY*# ...# >HUM215C6# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu hemagglutinin (255-271Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,FESTGNLIAPEYGFKISY*# SEQUENCE: FESTGNLIAPEYGFKISY*# ...# >HUM215C7# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Flu nucleoprotein (50-63Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,SDYEGRLIQNSLTIY*# SEQUENCE: SDYEGRLIQNSLTIY*# ...# >HUM215C8# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu nucleoprotein (265-280Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,IASNENMDAMESSTLY*# SEQUENCE: IASNENMDAMESSTLY*# ...# >HUM215C9# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: DQ(beta1*0302) (57-70)# DB REFERENCE: SWISS: (HB24_HUMAN)# & PIR1: (HLHU1C)# & PIR2: (B35056,A35056,S46648,I36976,I35055)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,AAEYWNSQKEVLER*# SEQUENCE: AAEYWNSQKEVLER*# ...# >HUM215CA# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML 18kDa (40-52)# DB REFERENCE: SWISS: (18KD_MYCLE)# & PIR2: (A27586)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,VVEFDLPGIKADS*# SEQUENCE: VVEFDLPGIKADS*# ...# >HUM215CB# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML 18kDa (31-43)# DB REFERENCE: SWISS: (18KD_MYCLE)# & PIR2: (A27586)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,DAWREGEEFVVEF*# SEQUENCE: DAWREGEEFVVEF*# ...# >HUM215CC# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P5# DB REFERENCE: PIR2: (S03496,B26524)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,LLHFVKESKQDESGM*# SEQUENCE: LLHFVKESKQDESGM*# ...# >HUM215CD# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: DQ(alpha1*0301) (153-168)# DB REFERENCE: SWISS: (HA26_HUMAN,HA26_HUMAN,HA21_HUMAN,HA25_HUMAN,# & HA22_HUMAN)# & PIR1: (HLHUDC,HLHUDX,HLHUD1,HLHUD7)# & PIR2: (I68717,I54444,I54437,A37044,I58988,I54290,I54439,# & A29312)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,YLTFLPSADEIYDCKV*# SEQUENCE: YLTFLPSADEIYDCKV*# ...# >HUM215CE# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: DQ(alpha1*0302) (153-168)# DB REFERENCE: SWISS: (HA24_HUMAN)# & PIR1: (HLHUDQ)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,YLTFLPSDDEIYDCKV*# SEQUENCE: YLTFLPSDDEIYDCKV*# ...# >HUM215CF# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu matrix (17-29Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,SGPLKAEIAQRLEY*# SEQUENCE: SGPLKAEIAQRLEY*# ...# >HUM215D0# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PF cp (379-395Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,IEKKIAKMEKASSVFNVY*# SEQUENCE: IEKKIAKMEKASSVFNVY*# ...# >HUM215D1# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: P139# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,EHPSLQSPITVEWRLLH*# SEQUENCE: EHPSLQSPITVEWRLLH*# ...# >HUM215D2# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: EGF receptor# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,SRALEEKKGNYVVTHG*# SEQUENCE: SRALEEKKGNYVVTHG*# ...# >HUM215D3# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: DQ(beta1*D0602) (21-36)# DB REFERENCE: SWISS: (HB23_HUMAN,HB25_HUMAN,HB25_HUMAN,HB24_HUMAN)# & PIR1: (HLHU1C,HLHUC3)# & PIR2: (F35056,B35056,I36973,B32527,I55994,A31459,I61828,I36974,# & E35056,F35055,I36976,I68806,B35057,I54480,G35055,I68819,# & E35055,C35057,A35058,I35055,I68732,I36975,I59639,I61836,# & I72482)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,TERVRLVTRYIYNREE*# SEQUENCE: TERVRLVTRYIYNREE*# ...# >HUM215D4# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: RV nucleoprotein (11-25Y)# DB REFERENCE: SWISS: (NCAP_RABVU,NCAP_RABVP,NCAP_RABVS,NCAP_RABVA,# & NCAP_RABVF)# & PIR1: (VHVNRV,VHVNSB,VHVNAV)# & PIR2: (JQ2015,JQ2016)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,NNQVVSLKPEIIVDQY*# SEQUENCE: NNQVVSLKPEIIVDQY*# ...# >HUM215D5# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MB 65kDa (243-255Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,KPLLIIAEDVEGEY*# SEQUENCE: KPLLIIAEDVEGEY*# ...# >HUM215D6# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MT 65kDa (3-13)# DB REFERENCE: SWISS: (CH60_MYCSM,CH62_MYCTU,CH62_MYCLE,CH60_MYCTU,CH60_MYCPA,# & CH60_MYCPA)# & PIR2: (A25902,A43509,A37335,S40245,A26950)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,KTIAYDEEARR*# SEQUENCE: KTIAYDEEARR*# ...# >HUM215D7# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-Cw3 (170-182Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesl,RYLKNGKETLQRAY*# SEQUENCE: RYLKNGKETLQRAY*# ...# >HUM215D8# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu hemagglutinin (255-271Y)# ANCHOR POSITIONS:# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,FESTGNLIAPEYGFKISY*# SEQUENCE: FESTGNLIAPEYGFKISY*# ...# >HUM215D9# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML 18kDa (40-52)# DB REFERENCE: SWISS: (18KD_MYCLE)# & PIR2: (A27586)# REFERENCES: johansen94b# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,VVEFDLPGIKADS*# SEQUENCE: VVEFDLPGIKADS*# ...# >MUS215DA# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Human GAD65 (524-543)# DB REFERENCE: SWISS: (DCE2_HUMAN,DCE2_MOUSE,DCE2_RAT)# & PIR1: (A41292,JH0423,S38533)# REFERENCES: chen94c,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesh,bindyesu,SRLSKVAPVIKARMMEYGTT*# SEQUENCE: SRLSKVAPVIKARMMEYGTT*# ...# >MUS115DB# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: p29 endogenous peptide# ANCHOR POSITIONS:# REFERENCES: talken94a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,YPNVNIHF*# SEQUENCE: YPNVNIHF*# ...# >MUS115DC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HLA Cw3 (170-182)# ANCHOR POSITIONS:# REFERENCES: talken94a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,RYLKNETLQRA*# SEQUENCE: RYLKNETLQRA*# ...# >HUM215DD# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ApoB (2877-2892)# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,ISNQLTLDSNIKYFHK*# SEQUENCE: ISNQLTLDSNIKYFHK*# ...# >HUM215DE# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: LDL-R (518-532)# DB REFERENCE: SWISS: (LDLR_HUMAN,LDLR_HUMAN)# & PIR1: (QRHULD)# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,KPRAIVVDPVHGFMY*# SEQUENCE: KPRAIVVDPVHGFMY*# ...# >HUM215DF# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ApoB (4483-4496)# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,AVNEIISDYHQQFT*# SEQUENCE: AVNEIISDYHQQFT*# ...# >HUM215E0# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ApoB (1273-1290)# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,IPDNLFLKSDGRVKYTLN*# SEQUENCE: IPDNLFLKSDGRVKYTLN*# ...# >HUM215E1# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TF-R (620-634)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,LLSFVRDLNQYRADI*# SEQUENCE: LLSFVRDLNQYRADI*# ...# >HUM215E2# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: IFNR-gamma (128-146)# DB REFERENCE: SWISS: (INGR_HUMAN,INGR_HUMAN)# & PIR2: (A31555)# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,GPPKLDIRKEEKQIMIDIF*# SEQUENCE: GPPKLDIRKEEKQIMIDIF*# ...# >HUM215E3# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: IgG2a# DB REFERENCE: SWISS: (GCAM_MOUSE)# & PIR1: (G2MSAM)# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,KQTISPDYRNMI*# SEQUENCE: KQTISPDYRNMI*# ...# >HUM215E4# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: alpha1 AT (149-164)# DB REFERENCE: SWISS: (A1AT_BOVIN,A1AT_BOVIN)# & PIR2: (S21097)# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VDTFLEDVKNLYHSEA*# SEQUENCE: VDTFLEDVKNLYHSEA*# ...# >HUM215E5# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ApoB (2881-2890)# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,LTLDSNIKYF*# SEQUENCE: LTLDSNIKYF*# ...# >HUM215E6# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ApoB (2881-2890) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,AALTLDSNIKYFA*# SEQUENCE: AALTLDSNIKYFA*# ...# >HUM215E7# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ApoB (2881-2890) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,AAAALTLDSNIKYFAA*# SEQUENCE: AAAALTLDSNIKYFAA*# ...# >HUM215E8# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: alpha1 AT (149-161) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,VDTALEDVKNLYHSEA*# SEQUENCE: VDTALEDVKNLYHSEA*# ...# >HUM215E9# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: alpha1 AT (149-164) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,VDTFLEAVKNLYHSEA*# SEQUENCE: VDTFLEAVKNLYHSEA*# ...# >HUM215EA# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: alpha1 AT (149-164) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VDTFLEDVANLYHSEA*# SEQUENCE: VDTFLEDVANLYHSEA*# ...# >HUM215EB# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: alpha1 AT (149-164) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VDTFLEDVKNLAHSEA*# SEQUENCE: VDTFLEDVKNLAHSEA*# ...# >HUM215EC# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: alpha1 AT (149-164) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,VDTFLEAVANLYHSEA*# SEQUENCE: VDTFLEAVANLYHSEA*# ...# >HUM215ED# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: alpha1 AT (149-164) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,VDTFAEAVKNLYHSEA*# SEQUENCE: VDTFAEAVKNLYHSEA*# ...# >HUM215EE# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: alpha1 AT (149-161) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VDTFLAAVKNLYHSEA*# SEQUENCE: VDTFLAAVKNLYHSEA*# ...# >HUM215EF# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: alpha1 AT (149-164) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,VDTFLEAAKNLYHSEA*# SEQUENCE: VDTFLEAAKNLYHSEA*# ...# >HUM215F0# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: alpha1 AT (149-l64) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,VDTFLEAVKALYHSEA*# SEQUENCE: VDTFLEAVKALYHSEA*# ...# >HUM215F1# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: alpha1 AT (149-164) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,VDTFLEAVKNAYHSEA*# SEQUENCE: VDTFLEAVKNAYHSEA*# ...# >HUM215F2# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A2 (103-117) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,VGSDWRFDRGYHQYA*# SEQUENCE: VGSDWRFDRGYHQYA*# ...# >HUM215F3# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TF-R (140-156)# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,DFTGTIKLLNENSYVPR*# SEQUENCE: DFTGTIKLLNENSYVPR*# ...# >HUM215F4# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TF-R (140-156) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,DFTGTIKLDNENSYVPR*# SEQUENCE: DFTGTIKLDNENSYVPR*# ...# >HUM215F5# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TF-R (140-156) homologue# ANCHOR POSITIONS:# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,DFTGTIKDDDENSYVPR*# SEQUENCE: DFTGTIKDDDENSYVPR*# ...# >HUM215F6# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HSP65 (3-13)# DB REFERENCE: SWISS: (CH60_MYCPA,CH60_MYCTU,CH60_MYCSM,CH62_MYCTU,CH62_MYCLE,# & CH60_MYCPA)# & PIR2: (A43509,A37335,S40245,A26950,A25902)# REFERENCES: malcherek94a,geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesm,KTIAYDEEARR*# SEQUENCE: KTIAYDEEARR*# ...# >HUM215F7# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HAChRalpha (310-323)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,NWVRKVFIDTIPNI*# SEQUENCE: NWVRKVFIDTIPNI*# ...# >HUM215F8# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HAChRalpha (310-325)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,NWVRKVFIDTIPNIMF*# SEQUENCE: NWVRKVFIDTIPNIMF*# ...# >HUM215F9# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (1272-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: malcherek94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,NGQIGNDPNRDIL*# SEQUENCE: NGQIGNDPNRDIL*# ...# >HUM115FA# MHC MOLECULE: HLA-Cw16(Cw*1601), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MAGE-1 (229-237)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: van_der_bruggen94a# COMMENT:# SUMMARY: HLA-Cw16,actyesm,bindyesu,SAYGEPRKL*# SEQUENCE: SAYGEPRKL*# ...# >HUM215FB# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (106-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: malcherek95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,KMRMATPLLMQALP*# SEQUENCE: KMRMATPLLMQALP*# ...# >HUM215FC# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (99-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: malcherek95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALP*# SEQUENCE: KPPKPVSKMRMATPLLMQALP*# ...# >HUM115FD# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHKPXAIXYR*# SEQUENCE: XHKPXAIXYR*# ...# >HUM115FE# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HCK tyrosine kynase P59 (25-33)# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHKPVYVPRY*# SEQUENCE: XHKPVYVPRY*# ...# >HUM115FF# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHLPVMVKY*# SEQUENCE: XHLPVMVKY*# ...# >HUM11600# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,KHDPYDVSY*# SEQUENCE: KHDPYDVSY*# ...# >HUM11601# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHFKFVESF*# SEQUENCE: XHFKFVESF*# ...# >HUM11602# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHKPAVAKF*# SEQUENCE: XHKPAVAKF*# ...# >HUM11603# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,KHEKLIXXY*# SEQUENCE: KHEKLIXXY*# ...# >HUM11604# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,KHIPIFLKY*# SEQUENCE: KHIPIFLKY*# ...# >HUM11605# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHEPLFLKY*# SEQUENCE: XHEPLFLKY*# ...# >HUM11606# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,GHFPIILKY*# SEQUENCE: GHFPIILKY*# ...# >HUM11607# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHIPDAXKY*# SEQUENCE: XHIPDAXKY*# ...# >HUM11608# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHMPIVFYF*# SEQUENCE: XHMPIVFYF*# ...# >HUM11609# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Kell blood group protein (202-210)# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,GHFPFFRXY*# SEQUENCE: GHFPFFRXY*# ...# >HUM1160A# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHDPLLXKY*# SEQUENCE: XHDPLLXKY*# ...# >HUM1160B# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHFLXVRAY*# SEQUENCE: XHFLXVRAY*# ...# >HUM1160C# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,XHIPIXXY*# SEQUENCE: XHIPIXXY*# ...# >HUM1160D# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,VHMPVYLKY*# SEQUENCE: VHMPVYLKY*# ...# >HUM1160E# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: New Castle disease virus hemagglutinin-neuraminidase (472-480)# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Probable HLA allele A31, possible A1,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPYPLIVYR*# SEQUENCE: XPYPLIVYR*# ...# >HUM1160F# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Probable HLA allele A31, possible A1,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPKPXEXERF*# SEQUENCE: XPKPXEXERF*# ...# >HUM11610# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Probable HLA allele A31, possible A1,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,KPKPKVXKR*# SEQUENCE: KPKPKVXKR*# ...# >HUM11611# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,A31,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPLPALVEY*# SEQUENCE: XPLPALVEY*# ...# >HUM11612# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Complement receptor type 2 precursor (25-34)# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Probable HLA allele A31, possible A1,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPPPILNKR*# SEQUENCE: XPPPILNKR*# ...# >HUM11613# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Probable HLA allele A31, possible A1,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPERFKRQR*# SEQUENCE: XPERFKRQR*# ...# >HUM11614# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Probable HLA allele A31, possible A1,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPDPYEVKR*# SEQUENCE: XPDPYEVKR*# ...# >HUM11615# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,A31,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPFEVELFR*# SEQUENCE: XPFEVELFR*# ...# >HUM11616# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,A31,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,GPMNXVVXF*# SEQUENCE: GPMNXVVXF*# ...# >HUM11617# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,A31,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPFKIMNGR*# SEQUENCE: XPFKIMNGR*# ...# >HUM11618# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,A31,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPLELFYXF*# SEQUENCE: XPLELFYXF*# ...# >HUM11619# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin A precursor (5-13)# DB REFERENCE: SWISS: (PRTP_HUMAN)# & PIR2: (A31589)# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,A31,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,APPPLFLLL*# SEQUENCE: APPPLFLLL*# ...# >HUM1161A# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,A31,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPIEVFXQY*# SEQUENCE: XPIEVFXQY*# ...# >HUM1161B# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,A31,B38,B58# SUMMARY: HLA-?,actunkn,bindyesu,XPFELLFMR*# SEQUENCE: XPFELLFMR*# ...# >HUM1161C# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,KVKEXIXXXFH*# SEQUENCE: KVKEXIXXXFH*# ...# >HUM1161D# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,XVKPIRATR*# SEQUENCE: XVKPIRATR*# ...# >HUM1161E# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,XVNPEYXXR*# SEQUENCE: XVNPEYXXR*# ...# >HUM1161F# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,RVYGVIXQR*# SEQUENCE: RVYGVIXQR*# ...# >HUM11620# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,XVEVMIEK*# SEQUENCE: XVEVMIEK*# ...# >HUM11621# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,XVFAVLLLF*# SEQUENCE: XVFAVLLLF*# ...# >HUM11622# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: eluted peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,KXDTKIIKR*# SEQUENCE: KXDTKIIKR*# ...# >HUM11623# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide-putative binding motif# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,KHDPLYAKF*# SEQUENCE: KHDPLYAKF*# ...# >HUM11624# MHC MOLECULE: HLA-B58, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide-putative binding motif# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,KPFPLYAKR*# SEQUENCE: KPFPLYAKR*# ...# >HUM11625# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide-putative binding motif# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,KPFPLYAKR*# SEQUENCE: KPFPLYAKR*# ...# >HUM11626# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide-putative binding motif# ANCHOR POSITIONS:# REFERENCES: colovai94a# COMMENT: Possible HLA alleles A1,B8# SUMMARY: HLA-?,actunkn,bindyesu,KPFPLYAKR*# SEQUENCE: KPFPLYAKR*# ...# >MUS21627# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: antigen presentation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B S-preS(2) (156-170)# ANCHOR POSITIONS:# REFERENCES: scheerlinck91a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NIASHISSSSARTGD*# SEQUENCE: NIASHISSSSARTGD*# ...# >MUS21628# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: antigen presentation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B S-preS(2) (156-170) homologue# ANCHOR POSITIONS:# REFERENCES: scheerlinck92a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NIASHISSSSARTGDIAC*# SEQUENCE: NIASHISSSSARTGDIAC*# ...# >MUS21629# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: antigen presentation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B S-preS(2) (156-170) homologue# ANCHOR POSITIONS:# REFERENCES: scheerlinck92a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NIASHISSSSARIAC*# SEQUENCE: NIASHISSSSARIAC*# ...# >MUS2162A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: antigen presentation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B S-preS(2) (156-170) homologue# ANCHOR POSITIONS:# REFERENCES: scheerlinck92a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NIASHISSSSAIAC*# SEQUENCE: NIASHISSSSAIAC*# ...# >MUS2162B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: antigen presentation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B S-preS(2) (156-170) homologue# ANCHOR POSITIONS:# REFERENCES: scheerlinck92a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NIASHISSSSIAC*# SEQUENCE: NIASHISSSSIAC*# ...# >MUS1162C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides/competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Beta-actin# DB REFERENCE: SWISS: (ACTG_HUMAN,ACT8_XENLA,ACT3_ECHGR,ACTB_CRIGR,ACTB_HUMAN,# & ACTB_XENBO,ACT5_CHICK,ACT1_NAEFO,ACT_THELA,ACT2_FUGRU,# & ACT3_PEA,ACTB_CYPCA,ACT1_PNECA,ACTA_LIMPO,ACT2_NAEFO,# & ACT1_NAEFO,ACT5_XENLA,ACTA_LIMPO,ACTB_RABIT,# & ACT2_SCHMA)# & PIR1: (ATBOB,ATMSB,ATBOG,ATMSG,ATRBB,ATCHB,S11222,ATHUB,A48324,# & ATRTC,ATHUG,A43552)# & PIR2: (JC5227,A26559,S03126,S58316,A55001,I39393,S47897,S49481,# & S01077,S05430,S43509,S38782)# & PIR3: (S71125)# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,HETTFNSI*# SEQUENCE: HETTFNSI*# ...# >MUS1162D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides/competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: S24 Ribosomal protein# DB REFERENCE: SWISS: (RS1A_HUMAN)# & PIR2: (JC2234,S22051,S52339)# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,DDHRAGKI*# SEQUENCE: DDHRAGKI*# ...# >MUS1162E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT: Position 4 T or P# SUMMARY: H-2Kk,actunkn,bindyesu,YEDTGKTI*# SEQUENCE: YEDTGKTI*# ...# >MUS1162F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT: Position 4 T or P# SUMMARY: H-2Kk,actunkn,bindyesu,YEDPGKTI*# SEQUENCE: YEDPGKTI*# ...# >MUS11630# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides/competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: T cell transcription factor# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,KEMKAKVI*# SEQUENCE: KEMKAKVI*# ...# >MUS11631# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HmRNP C protein# DB REFERENCE: SWISS: (ROC_RAT)# & PIR2: (S09017,A54601,I49070,A44192)# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,EEEPVKKI*# SEQUENCE: EEEPVKKI*# ...# >MUS11632# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: S7/S8 ribosomal protein# DB REFERENCE: SWISS: (RS7_HUMAN,RS7_FUGRU)# & PIR1: (R3RT7)# & PIR2: (JC4388)# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,SEIVGKRI*# SEQUENCE: SEIVGKRI*# ...# >MUS11633# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: H-2Dk# DB REFERENCE: SWISS: (HA12_RAT,HA13_MOUSE,HA13_MOUSE,HA11_RAT,1OKO_GORGO)# & PIR2: (I54531,I69008,I68771,S52367,I54548,S18197,JH0538,B35090,# & I54554,I71998,I60331,S31651,S25536,A45851,A35090)# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,SEGGSHTI*# SEQUENCE: SEGGSHTI*# ...# >MUS11634# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides/competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (PRC6_RAT)# & PIR2: (S60038)# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,DERTVRKI*# SEQUENCE: DERTVRKI*# ...# >MUS11635# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CarG motif binding protein# DB REFERENCE: SWISS: (CABA_MOUSE)# & PIR2: (S53710,S56751,S56750,JQ0448)# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,EEDPVKKV*# SEQUENCE: EEDPVKKV*# ...# >MUS11636# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides/competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: BiP# DB REFERENCE: SWISS: (HS74_PARLI,GR78_HUMAN,GR78_RAT,GR78_MOUSE,GR78_MESAU,# & GR78_RAT,GR78_HUMAN,HS70_CHICK,HS7C_DROME,GR78_MOUSE,# & GR78_MESAU)# & PIR1: (HHRTGB)# & PIR2: (JN0666,I50242,A29821,A25646,A27414,A37048,JC1391)# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,EAYLGKKV*# SEQUENCE: EAYLGKKV*# ...# >MUS11637# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT: Position 4 Tor P, position 6 K or R# SUMMARY: H-2Kk,actunkn,bindyesu,XEKTAKRI*# SEQUENCE: XEKTAKRI*# ...# >MUS11638# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT: Position 4 Tor P, position 6 K or R# SUMMARY: H-2Kk,actunkn,bindyesu,XEKPAKRI*# SEQUENCE: XEKPAKRI*# ...# >MUS11639# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT: Position 4 Tor P, position 6 K or R# SUMMARY: H-2Kk,actunkn,bindyesu,XEKTARRI*# SEQUENCE: XEKTARRI*# ...# >MUS1163A# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT: Position 4 Tor P, position 6 K or R# SUMMARY: H-2Kk,actunkn,bindyesu,XEKPARRI*# SEQUENCE: XEKPARRI*# ...# >MUS1163B# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT: Position 4 Tor P, position 6 K or R# SUMMARY: H-2Kk,actunkn,bindyesu,XENXAKAL*# SEQUENCE: XENXAKAL*# ...# >MUS1163C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: T cell transcription factor homologue# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,KEAKAKVI*# SEQUENCE: KEAKAKVI*# ...# >MUS1163D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: T cell transcription factor homologue# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,KEMKAKAI*# SEQUENCE: KEMKAKAI*# ...# >MUS1163E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: T cell transcription factor homologue# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,KEMKAAVI*# SEQUENCE: KEMKAAVI*# ...# >MUS1163F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: T cell transcription factor homologue# ANCHOR POSITIONS:# REFERENCES: brown94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesu,AEMKAKVI*# SEQUENCE: AEMKAKVI*# ...# >HUM21640# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (1273-1284)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,GQIGNDPNRDIL*# SEQUENCE: GQIGNDPNRDIL*# ...# >HUM21641# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (3-13)# DB REFERENCE: SWISS: (CH61_MYCLE)# & PIR2: (S25181)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,SKLIEYDETARH*# SEQUENCE: SKLIEYDETARH*# ...# >HUM21642# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp70 (259-269)# DB REFERENCE: SWISS: (DNAK_MYCLE)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,KNPLFLDEQLI*# SEQUENCE: KNPLFLDEQLI*# ...# >HUM21643# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp18 (61-70)# DB REFERENCE: SWISS: (18KD_MYCLE)# & PIR2: (A27586)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,VVTVRAERPG*# SEQUENCE: VVTVRAERPG*# ...# >HUM21644# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: proliferation as./competitive binding# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (4-13)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCLE,CH62_MYCTU,CH60_MYCSM,CH60_MYCPA,# & CH60_MYCTU)# & PIR2: (A43509,A37335,A25902,A26950,S40245)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,TIAYDEEARR*# SEQUENCE: TIAYDEEARR*# ...# >HUM21645# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,IIAYDEEARR*# SEQUENCE: IIAYDEEARR*# ...# >HUM21646# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TLAYDEEARR*# SEQUENCE: TLAYDEEARR*# ...# >HUM21647# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TILYDEEARR*# SEQUENCE: TILYDEEARR*# ...# >HUM21648# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIRYDEEARR*# SEQUENCE: TIRYDEEARR*# ...# >HUM21649# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIDYDEEARR*# SEQUENCE: TIDYDEEARR*# ...# >HUM2164A# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIHYDEEARR*# SEQUENCE: TIHYDEEARR*# ...# >HUM2164B# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIQYDEEARR*# SEQUENCE: TIQYDEEARR*# ...# >HUM2164C# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIGYDEEARR*# SEQUENCE: TIGYDEEARR*# ...# >HUM2164D# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIASDEEARR*# SEQUENCE: TIASDEEARR*# ...# >HUM2164E# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIARDEEARR*# SEQUENCE: TIARDEEARR*# ...# >HUM2164F# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAPDEEARR*# SEQUENCE: TIAPDEEARR*# ...# >HUM21650# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAHDEEARR*# SEQUENCE: TIAHDEEARR*# ...# >HUM21651# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAFDEEARR*# SEQUENCE: TIAFDEEARR*# ...# >HUM21652# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDDEARR*# SEQUENCE: TIAYDDEARR*# ...# >HUM21653# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDREARR*# SEQUENCE: TIAYDREARR*# ...# >HUM21654# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDLEARR*# SEQUENCE: TIAYDLEARR*# ...# >HUM21655# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDVEARR*# SEQUENCE: TIAYDVEARR*# ...# >HUM21656# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEFARR*# SEQUENCE: TIAYDEFARR*# ...# >HUM21657# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDETARR*# SEQUENCE: TIAYDETARR*# ...# >HUM21658# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDELARR*# SEQUENCE: TIAYDELARR*# ...# >HUM21659# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEIARR*# SEQUENCE: TIAYDEIARR*# ...# >HUM2165A# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEEERR*# SEQUENCE: TIAYDEEERR*# ...# >HUM2165B# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEELRR*# SEQUENCE: TIAYDEELRR*# ...# >HUM2165C# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEEHRR*# SEQUENCE: TIAYDEEHRR*# ...# >HUM2165D# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEESRR*# SEQUENCE: TIAYDEESRR*# ...# >HUM2165E# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEENRR*# SEQUENCE: TIAYDEENRR*# ...# >HUM2165F# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEEAKR*# SEQUENCE: TIAYDEEAKR*# ...# >HUM21660# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEEARY*# SEQUENCE: TIAYDEEARY*# ...# >HUM21661# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp65 (4-13) homologue# ANCHOR POSITIONS: 2,5# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,TIAYDEEARF*# SEQUENCE: TIAYDEEARF*# ...# >HUM21662# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-20)# DB REFERENCE: SWISS: (CH60_MYCSM,CH60_MYCPA,CH60_MYCTU,CH60_MYCPA,CH62_MYCLE,# & CH62_MYCTU)# & PIR2: (S40245,A37335,A25902,A43509,A26950)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEARRGLERGLN*# SEQUENCE: AKTIAYDEEARRGLERGLN*# ...# >HUM21663# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-19)# DB REFERENCE: SWISS: (CH60_MYCPA,CH60_MYCTU,CH62_MYCTU,CH62_MYCLE,CH60_MYCPA,# & CH60_MYCSM)# & PIR2: (A43509,A26950,S40245,A37335,A25902)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEARRGLERGL*# SEQUENCE: AKTIAYDEEARRGLERGL*# ...# >HUM21664# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-18)# DB REFERENCE: SWISS: (CH60_MYCPA,CH60_MYCTU,CH62_MYCLE,CH60_MYCPA,CH62_MYCTU,# & CH60_MYCSM)# & PIR2: (A26950,A37335,S40245,A25902,A43509)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEARRGLERG*# SEQUENCE: AKTIAYDEEARRGLERG*# ...# >HUM21665# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-17)# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCTU,CH60_MYCPA,CH60_MYCSM,CH60_MYCPA,# & CH62_MYCLE)# & PIR2: (A25902,S40245,A37335,A26950,A43509)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEARRGLER*# SEQUENCE: AKTIAYDEEARRGLER*# ...# >HUM21666# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-16)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCTU,CH60_MYCPA,CH60_MYCSM,CH60_MYCTU,# & CH62_MYCLE)# & PIR2: (A25902,A43509,S40245,A37335,A26950)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEARRGLE*# SEQUENCE: AKTIAYDEEARRGLE*# ...# >HUM21667# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-15)# DB REFERENCE: SWISS: (CH60_MYCSM,CH60_MYCPA,CH62_MYCTU,CH60_MYCTU,CH62_MYCLE,# & CH60_MYCPA)# & PIR2: (S40245,A26950,A37335,A25902,A43509)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEARRGL*# SEQUENCE: AKTIAYDEEARRGL*# ...# >HUM21668# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-14)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCTU,CH60_MYCSM,CH60_MYCTU,CH62_MYCLE,# & CH60_MYCPA)# & PIR2: (A25902,S40245,A26950,A37335,A43509)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEARRG*# SEQUENCE: AKTIAYDEEARRG*# ...# >HUM21669# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-13)# DB REFERENCE: SWISS: (CH60_MYCPA,CH60_MYCPA,CH62_MYCLE,CH60_MYCSM,CH62_MYCTU,# & CH60_MYCTU)# & PIR2: (A43509,A37335,S40245,A26950,A25902)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEARR*# SEQUENCE: AKTIAYDEEARR*# ...# >HUM2166A# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-12)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCSM,CH60_MYCPA,CH60_MYCPA,CH60_MYCTU,# & CH62_MYCTU)# & PIR2: (A37335,A26950,A25902,S40245,A43509)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEAR*# SEQUENCE: AKTIAYDEEAR*# ...# >HUM2166B# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (2-11)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCSM,CH60_MYCTU,CH60_MYCPA,CH62_MYCLE,# & CH60_MYCPA)# & PIR2: (A26950,S40245,A25902,A43509,A37335)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,AKTIAYDEEA*# SEQUENCE: AKTIAYDEEA*# ...# >HUM2166C# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (3-12)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCTU,CH60_MYCTU,CH60_MYCSM,CH62_MYCLE,# & CH60_MYCPA)# & PIR2: (A43509,A37335,A25902,S40245,A26950)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,KTIAYDEEAR*# SEQUENCE: KTIAYDEEAR*# ...# >HUM2166D# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hsp65 (2-10)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCPA,CH60_MYCPA,CH62_MYCLE,CH60_MYCTU,# & CH60_MYCSM)# & PIR2: (S40245,A25902,A26950,A37335,A43509)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesn,bindyesu,AKTIAYDEE*# SEQUENCE: AKTIAYDEE*# ...# >HUM2166E# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (3-11)# DB REFERENCE: SWISS: (CH60_MYCTU,CH60_MYCPA,CH60_MYCPA,CH60_MYCSM,CH62_MYCLE,# & CH62_MYCTU)# & PIR2: (A25902,A37335,A26950,A43509,S40245)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,KTIAYDEEA*# SEQUENCE: KTIAYDEEA*# ...# >HUM2166F# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (4-12)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCSM,CH62_MYCLE,CH60_MYCPA,CH60_MYCTU,# & CH60_MYCPA)# & PIR2: (A37335,A43509,S40245,A25902,A26950)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,TIAYDEEAR*# SEQUENCE: TIAYDEEAR*# ...# >HUM21670# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (5-13)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCPA,CH60_MYCTU,CH60_MYCPA,CH62_MYCTU,# & CH60_MYCSM)# & PIR2: (A26950,A25902,S40245,A43509,A37335)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,IAYDEEARR*# SEQUENCE: IAYDEEARR*# ...# >HUM21671# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hsp65 (3-10)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCPA,CH60_MYCTU,CH60_MYCSM,CH62_MYCLE,# & CH60_MYCPA)# & PIR2: (A43509,A37335,A25902,S40245,A26950)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesn,bindyesu,KTIAYDEE*# SEQUENCE: KTIAYDEE*# ...# >HUM21672# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (4-11)# DB REFERENCE: SWISS: (CH60_MYCSM,CH62_MYCTU,CH60_MYCPA,CH60_MYCPA,CH62_MYCLE,# & CH60_MYCTU)# & PIR2: (A43509,A37335,S40245,A25902,A26950)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,TIAYDEEA*# SEQUENCE: TIAYDEEA*# ...# >HUM21673# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: hsp65 (4-10)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCPA,CH62_MYCTU,CH60_MYCTU,CH60_MYCSM,# & CH60_MYCPA)# & PIR2: (A26950,A25902,A43509,A37335,S40245)# REFERENCES: geluk92a# COMMENT:# SUMMARY: HLA-DR17,actyesn,bindyesu,TIAYDEE*# SEQUENCE: TIAYDEE*# ...# >MUS11674# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Moloney MuLV gag (126-134)# DB REFERENCE: SWISS: (GAG_MSVMO,GAG_MLVF5,GAG_MLVFP,GAG_MSVMT,GAG_MLVFF)# & PIR1: (FOMVM,FOMVMU)# & PIR3: (S70394,S35474)# REFERENCES: sijts94a# COMMENT:# SUMMARY: H-2Kb,actyesn,bindyesu,PQSSLYPAL*# SEQUENCE: PQSSLYPAL*# ...# >MUS11675# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Moloney MuLV env (189-196)# DB REFERENCE: SWISS: (ENV_MLVMO)# & PIR1: (VCVWEM)# REFERENCES: sijts94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,SSWDFITV*# SEQUENCE: SSWDFITV*# ...# >MUS11676# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Moloney MuLV env (317-325)# DB REFERENCE: SWISS: (ENV_MLVMO,ENV1_MOUSE,ENV2_FRSFV,ENV_MCFF,ENV_RSFFV,# & ENV_RMCFV,ENV1_MOUSE,ENV2_FRSFV)# & PIR1: (VCVW2S,VCMVRV,VCMVSR,VCVWFS,VCVWEM,VCVWM2)# & PIR2: (B29350,A21170)# REFERENCES: sijts94a# COMMENT:# SUMMARY: H-2Kb,actyesn,bindyesu,LVDGAYQAL*# SEQUENCE: LVDGAYQAL*# ...# >MUS11677# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Moloney MuLV env (453-461)# DB REFERENCE: SWISS: (ENV_MLVMO)# & PIR1: (VCVWEM)# REFERENCES: sijts94a# COMMENT:# SUMMARY: H-2Kb,actyesn,bindyesu,SPSYVYGLF*# SEQUENCE: SPSYVYGLF*# ...# >MUS11678# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Moloney MuLV env (602-610)# DB REFERENCE: SWISS: (ENV1_FRSFV,ENV_MLVF5,ENV_RMCFV,ENV_MLVMO,ENV_MCFF,# & ENV_MLVFP,ENV_MLVCB,ENV2_FRSFV,ENV2_MOUSE,ENV2_FRSFV,# & ENV_MLVFF)# & PIR1: (VCVWEM,VCVW2S,VCMVRV,VCVW5S,VCVWM2,VCMVCB,VCMVPV,# & VCVWFS)# & PIR2: (S15464,B43491,A21170,A25483)# & PIR3: (S70395)# REFERENCES: sijts94a# COMMENT:# SUMMARY: H-2Kb,actyesn,bindyesu,NRSPWFTTL*# SEQUENCE: NRSPWFTTL*# ...# >MUS11679# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Moloney MuLV env (189-196)# DB REFERENCE: SWISS: (ENV_MLVMO)# & PIR1: (VCVWEM)# REFERENCES: sijts94a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,SSWDFITV*# SEQUENCE: SSWDFITV*# ...# >MUS1167A# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as./Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: Friend MuLV env (189-196)# DB REFERENCE: SWISS: (ENV_FSVGB,ENV_FLVCA,ENV_MLVFR,ENV_FSVGA,ENV_FLVC6,# & ENV_MLVFP,ENV_FLVC1,ENV_MLVCB,ENV_MLVAV,ENV_MLVFF,# & ENV_FSVSM,ENV_FLVGL,ENV_MLVRK,ENV_MLVF5,ENV_FLVCS,# & ENV_FLVSA,ENV_FSVST,ENV2_MOUSE,ENV_FLVLB,ENV_MLVRD)# & PIR1: (VCVWSF,VCVWEK,VCMVSS,VCVWGF,VCMVVR,VCMVPV,VCMVS2,VCMVCB,# & VCFMLV,VCMVLB,VCMVKA,VCMVSA,VCMVFP,VCMVFG)# & PIR2: (S20285,B43491,A25982,C46165,B46165,A25483,A46511,B31479,# & A46165,A43491)# & PIR3: (S70395)# REFERENCES: sijts94a,feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,SSWDYITV*# SEQUENCE: SSWDYITV*# ...# >MUS1167B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MCF1233 MuLV env (189-196)# DB REFERENCE: SWISS: (ENV2_FRSFV,ENV_RMCFV,ENV_MCFF,ENV2_FRSFV,ENV1_MOUSE,# & ENV_FRSFB,ENV_RSFFV,ENV1_MOUSE,ENV1_FRSFV,ENV_MCFF3)# & PIR1: (VCVW5S,VCVWB6,VCVWFS,VCVWM1,VCMVSR,VCVWM2,VCVW2S,# & VCMVRV)# & PIR2: (B29350,PL0196,A21170,S15464,S31428)# REFERENCES: sijts94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,SSWDLISL*# SEQUENCE: SSWDLISL*# ...# >HUM1167C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBc (18-27)# ANCHOR POSITIONS: 2,10# REFERENCES: bertoletti94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLPNDFFPSA*# SEQUENCE: FLPNDFFPSA*# ...# >HUM1167D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBc (18-27)# ANCHOR POSITIONS: 2,10# REFERENCES: bertoletti94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLPNDFFPSV*# SEQUENCE: FLPNDFFPSV*# ...# >HUM1167E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBc (18-27)# ANCHOR POSITIONS: 2,10# REFERENCES: bertoletti94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLPSDFFPSA*# SEQUENCE: FLPSDFFPSA*# ...# >HUM1167F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBc (18-27)# ANCHOR POSITIONS: 2,10# REFERENCES: bertoletti94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLPADFFPSI*# SEQUENCE: FLPADFFPSI*# ...# >HUM11680# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBc (18-27)# ANCHOR POSITIONS: 2,10# REFERENCES: bertoletti94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLPADFFPSV*# SEQUENCE: FLPADFFPSV*# ...# >HUM11681# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBc (18-27)# ANCHOR POSITIONS: 2,10# REFERENCES: bertoletti94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLPVDFFPSI*# SEQUENCE: FLPVDFFPSI*# ...# >HUM11682# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBc (18-27)# DB REFERENCE: PIR2: (S53161,S53149)# REFERENCES: bertoletti94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLPVDFFPSV*# SEQUENCE: FLPVDFFPSV*# ...# >HUM11683# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBc (18-27)# DB REFERENCE: SWISS: (CORA_HPBV4)# & PIR1: (NKVLA4)# & PIR2: (S35530,S04570,S53140,S08645,S08647,S08646)# REFERENCES: bertoletti94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLPSDFFPSI*# SEQUENCE: FLPSDFFPSI*# ...# >HUM11684# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV 1 env# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1MF,ENV_HV1Y2,ENV_HV1B1,ENV_HV1BR,# & ENV_HV1PV,ENV_HV1S1,ENV_HV1RH)# & PIR1: (VCLJA2,H44001,VCLJVL,VCLJH3,VCLJLV)# & PIR2: (S35867,S42895,S35829,A46410,S42912,S35818,S42900,PC2295,# & S35852,S42916,S42898,S42897,S35869,S35836,S42909,S42902,# & S42911,S25940,S35823,S35832,S42915,S42904,S35841,S35859,# & PC2294,S35820,S35868,S60538,S42910,S35834,S42913,S35862,# & S35806,S35850,S35854,PC2296,PC2293,S42906,S42917,S42899,# & S42901,S35804,S35830,S42918,S35835,S35865,C46410,S42903,# & S42905,S35853,S35828,B46410,S42914,S42908,S35819)# & PIR3: (S13289,S13288)# REFERENCES: safrit94b# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,TRPNNNTRKSI*# SEQUENCE: TRPNNNTRKSI*# ...# >HUM11685# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV 1 env# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1Y2,ENV_HV1S1,ENV_HV1RH,ENV_HV1ZH,# & ENV_HV1BR,ENV_HV1PV,ENV_HV1B1,ENV_HV1MF)# & PIR1: (VCLJVL,H44001,A44963,VCLJLV,VCLJH3,VCLJA2)# & PIR2: (S35841,S42915,S35832,S35869,S42909,S42897,S42898,S42916,# & S42900,S35852,S42911,S35823,S42895,S35867,S35829,S42912,# & D46410,A46410,S42908,S35853,S42901,S35804,S42903,S42914,# & S35806,S35854,PC2296,S35862,PC2293,S35868,S35834,C41621,# & S60538,S42910,S35820,S35865,S25940,S35836,S42902,PC2295,# & PC2294,S35859,S42904,S35830,S42913,S35850,S42906,C46410,# & S35828,S35818,S35835,S42918,S42899,S42917,S42905,B46410,# & S35819)# & PIR3: (S13289,S13288)# REFERENCES: safrit94b,brander95a,hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,RPNNNTRKSI*# SEQUENCE: RPNNNTRKSI*# ...# >HUM11686# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, high# SOURCE: synthetic binding motif homologue# ANCHOR POSITIONS: 2,9# REFERENCES: ruppert94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,KLAEYVAKV*# SEQUENCE: KLAEYVAKV*# ...# >HUM21687# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (3345-3360)# ANCHOR POSITIONS:# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR11,actunkn,bindyesu,SXVITLNTNVGLYXQS*# SEQUENCE: SXVITLNTNVGLYXQS*# ...# >HUM21688# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human heat shock cognate protein hsc70 (238-250)# ANCHOR POSITIONS:# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR11,actunkn,bindyesu,XNHFIAEFKRKHK*# SEQUENCE: XNHFIAEFKRKHK*# ...# >HUM21689# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR11,actunkn,bindyesu,DPXQDELQKLNAXDP*# SEQUENCE: DPXQDELQKLNAXDP*# ...# >HUM2168A# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human transferrin receptor (580-595)# ANCHOR POSITIONS:# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR11,actunkn,bindyesu,XPELNKVARAAAEVAG*# SEQUENCE: XPELNKVARAAAEVAG*# ...# >HUM2168B# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human granulin D (41-56)# DB REFERENCE: SWISS: (GRN_CAVPO,GRN_HUMAN)# & PIR1: (GYHU)# & PIR2: (I48141)# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR11,actunkn,bindyesu,CPAGYTCNVKARSCEK*# SEQUENCE: CPAGYTCNVKARSCEK*# ...# >HUM2168C# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human heat shock cognate protein hsc70 (238-252)# DB REFERENCE: SWISS: (HS7C_BOVIN,HS7C_RAT,HS7C_ICTPU,HS7C_ICTPU,HS7C_HUMAN,# & HS7C_RAT,HS7C_BOVIN)# & PIR2: (JC4853,S11456,A45935,S07197,S31716,A27077)# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR11,actunkn,bindyesu,VNHFIAEFKRKHKKD*# SEQUENCE: VNHFIAEFKRKHKKD*# ...# >HUM2168D# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw61 (5-20)# DB REFERENCE: SWISS: (1B34_HUMAN,1B35_HUMAN,1B36_HUMAN,1B18_HUMAN,1B20_HUMAN,# & 1B15_HUMAN,1B19_HUMAN,1B16_HUMAN,1B14_HUMAN,1B29_HUMAN,# & 1B13_HUMAN)# & PIR1: (S42102,HLHUB2)# & PIR2: (I37485,I59655,I54289,I61906,C35997,I56116,I61860,I61905,# & I37515,S52486,I56149)# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR11,actunkn,bindyesu,MRYFHTSVSRPGRGEP*# SEQUENCE: MRYFHTSVSRPGRGEP*# ...# >HUM2168E# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human IG kappa chain (190-204)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR11,actunkn,bindyesu,KHKVYACEVTHQGLS*# SEQUENCE: KHKVYACEVTHQGLS*# ...# >HUM2168F# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (3345-3360)# ANCHOR POSITIONS:# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR52,actunkn,bindyesu,SXVITLNTNVGLYXQS*# SEQUENCE: SXVITLNTNVGLYXQS*# ...# >HUM21690# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human heat shock cognate protein hsc70 (238-250)# ANCHOR POSITIONS:# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR52,actunkn,bindyesu,XNHFIAEFKRKHK*# SEQUENCE: XNHFIAEFKRKHK*# ...# >HUM21691# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR52,actunkn,bindyesu,DPXQDELQKLNAXDP*# SEQUENCE: DPXQDELQKLNAXDP*# ...# >HUM21692# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human transferrin receptor (580-595)# ANCHOR POSITIONS:# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR52,actunkn,bindyesu,XPELNKVARAAAEVAG*# SEQUENCE: XPELNKVARAAAEVAG*# ...# >HUM21693# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human granulin D (41-56)# DB REFERENCE: SWISS: (GRN_CAVPO,GRN_HUMAN)# & PIR1: (GYHU)# & PIR2: (I48141)# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR52,actunkn,bindyesu,CPAGYTCNVKARSCEK*# SEQUENCE: CPAGYTCNVKARSCEK*# ...# >HUM21694# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human heat shock cognate protein hsc70 (238-252)# DB REFERENCE: SWISS: (HS7C_ICTPU,HS7C_RAT,HS7C_HUMAN,HS7C_RAT,HS7C_BOVIN,# & HS7C_ICTPU,HS7C_BOVIN)# & PIR2: (S11456,JC4853,S07197,S31716,A27077,A45935)# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR52,actunkn,bindyesu,VNHFIAEFKRKHKKD*# SEQUENCE: VNHFIAEFKRKHKKD*# ...# >HUM21695# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw61 (5-20)# DB REFERENCE: SWISS: (1B35_HUMAN,1B36_HUMAN,1B34_HUMAN,1B13_HUMAN,1B20_HUMAN,# & 1B18_HUMAN,1B16_HUMAN,1B15_HUMAN,1B19_HUMAN,1B14_HUMAN,# & 1B29_HUMAN)# & PIR1: (S42102,HLHUB2)# & PIR2: (C35997,I61905,I56149,I54289,I37485,I61860,I61906,I59655,# & I37515,I56116,S52486)# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR52,actunkn,bindyesu,MRYFHTSVSRPGRGEP*# SEQUENCE: MRYFHTSVSRPGRGEP*# ...# >HUM21696# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: eluted naturally processed peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human IG kappa chain (190-204)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: newcomb93a# COMMENT: It was not possible to determine if peptide binds to DR11 or DR52# SUMMARY: HLA-DR52,actunkn,bindyesu,KHKVYACEVTHQGLS*# SEQUENCE: KHKVYACEVTHQGLS*# ...# >HUM21697# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YRSMAAAAA*# SEQUENCE: YRSMAAAAA*# ...# >HUM21698# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,VRSMAAAAA*# SEQUENCE: VRSMAAAAA*# ...# >HUM21699# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FRSMAAAAA*# SEQUENCE: FRSMAAAAA*# ...# >HUM2169A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,MRSMAAAAA*# SEQUENCE: MRSMAAAAA*# ...# >HUM2169B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,IRSMAAAAA*# SEQUENCE: IRSMAAAAA*# ...# >HUM2169C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,LRSMAAAAA*# SEQUENCE: LRSMAAAAA*# ...# >HUM2169D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WRSMAAAAA*# SEQUENCE: WRSMAAAAA*# ...# >HUM2169E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YASAAAAAA*# SEQUENCE: YASAAAAAA*# ...# >HUM2169F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YASATAAAA*# SEQUENCE: YASATAAAA*# ...# >HUM216A0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YASAATAAA*# SEQUENCE: YASAATAAA*# ...# >HUM216A1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YASAAATAA*# SEQUENCE: YASAAATAA*# ...# >HUM216A2# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YRSMRAAAA*# SEQUENCE: YRSMRAAAA*# ...# >HUM216A3# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala binding homologue# ANCHOR POSITIONS:# REFERENCES: hammer94b,hammer94c# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,YRSMAARAA*# SEQUENCE: YRSMAARAA*# ...# >HUM216A4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Self-peptide SP3# ANCHOR POSITIONS:# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LEFRAMAQFSRKT*# SEQUENCE: LEFRAMAQFSRKT*# ...# >HUM216A5# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: NA+/K+ ATPase# DB REFERENCE: SWISS: (ATN1_HORSE,ATN1_CANFA,ATN1_HUMAN,ATN1_SHEEP,ATN1_HUMAN,# & ATN1_PIG,ATN1_RAT,ATN3_PIG)# & PIR1: (S04630,PWSHNA)# & PIR2: (A24639,A24414,B24862,S20970)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,ADLRIISANGCKV*# SEQUENCE: ADLRIISANGCKV*# ...# >HUM216A6# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VEYHFLSPYVSPK*# SEQUENCE: VEYHFLSPYVSPK*# ...# >HUM216A7# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine fetuin# DB REFERENCE: SWISS: (A2HS_BOVIN,A2HS_BOVIN,A2HS_SHEEP,A2HS_SHEEP)# & PIR2: (A35714,S22394)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,HTLNQIDSVKVWP*# SEQUENCE: HTLNQIDSVKVWP*# ...# >HUM216A8# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2# DB REFERENCE: SWISS: (1A34_HUMAN,1A11_HUMAN,1A24_HUMAN,1A36_HUMAN,1A01_PANTR,# & 1A03_GORGO,1A01_PONPY,1A32_HUMAN,1A26_HUMAN,1A68_HUMAN,# & 1A01_HUMAN,1A01_GORGO,1A23_HUMAN,1A66_HUMAN,1A30_HUMAN,# & 1A31_HUMAN,1A25_HUMAN,1A26_HUMAN,1A03_HUMAN,1A04_PANTR,# & 1A31_HUMAN,1A33_HUMAN,1A04_GORGO,1A74_HUMAN,1A02_HUMAN,# & 1A43_HUMAN,1A03_PANTR,1A29_HUMAN,1A69_HUMAN,1A02_GORGO,# & 1A02_HUMAN)# & PIR1: (HLHUA3,HLHUA2,HLHU69,HLHU28,HLHUAW,HLHU32)# & PIR2: (I84432,I38519,I38610,I36966,I38443,S18198,I61857,I38441,# & JH0534,A35997,I37542,I37482,I61856,I84448,I38436,I37479,# & A47636,I37477,S01171,I61902,A45847,I37476,JH0537,I37483,# & JH0535,I84487,I56039,S03535,S16769,I54307,I37478,JH0536,# & JL0135,S51099,I36961,I37470,I38518,I72170,I54416,I54493,# & I36965,I36959,A37028,I83063,I37480,I72171)# & PIR3: (S06424)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAASQ*# SEQUENCE: TQFVRFDSDAASQ*# ...# >HUM216A9# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9# DB REFERENCE: SWISS: (HA19_CANFA,1C18_HUMAN,1B38_HUMAN,1B20_HUMAN,1C03_GORGO,# & 1C01_PANTR,1B39_HUMAN,1C01_HUMAN,1C06_HUMAN,1C02_HUMAN,# & 1B35_HUMAN,HA1B_BOVIN,1C17_HUMAN,1B36_HUMAN,1B34_HUMAN,# & 1C14_HUMAN,1C04_HUMAN,1C07_HUMAN,1C01_GORGO,1C03_HUMAN,# & 1B04_HUMAN,1C15_HUMAN,1C16_HUMAN,1B02_HUMAN,1CXX_HUMAN,# & 1C11_HUMAN,1C12_HUMAN,1C02_HUMAN)# & PIR1: (HLHUC4,HLHUB7,S42102)# & PIR2: (I37527,I46049,JH0291,B37028,A45857,I59622,S11143,I61905,# & I37078,I68749,I61865,I59651,I46030,B27638,I37529,JH0290,# & I37492,I36958,I37544,I37135,I61864,I68712,I37523,I61866,# & I37526,JH0292,I56116,JH0546,S44994,I54418,I68701,I72113,# & A60369,I54430,I59655,I37528,S42823,JH0289,JH0288,A49411,# & I72808,I67482,A45845,I56149,I81231,I46603,C37028,I68750,# & S60601,I67483,I84431,B45831,I54449,I68747,I59188,I38505,# & I56034,A45897,I38507,JS0262,A45849,JH0526,S48134,JH0544,# & I81232,I61906,I46604,JH0543,S52486)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,RSWTAADTAAQIT*# SEQUENCE: RSWTAADTAAQIT*# ...# >HUM216AA# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VLA-4# DB REFERENCE: SWISS: (ITA4_HUMAN,ITA4_HUMAN)# & PIR2: (S06046)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SLFVYNITTNKYK*# SEQUENCE: SLFVYNITTNKYK*# ...# >HUM216AB# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine hemoglobulin# DB REFERENCE: SWISS: (HBA_CERTO,HBA_MACAS,HBA_BOSGF,HBA3_GORGO,HBA_ODOVI,# & HBA_MACSI,HBA_PREEN,HBA_SAGFU,HBA3_PANTR,HBA_ALCAA,# & HBA_CAPHI,HBA_TAPGE,HBA_MACNE,HBA_HIPAM,HBA_SPEPA,# & HBA_MACMU,HBA2_BOSMU,HBA_CYNSP,HBA_PONPY,HBA_ATEGE,# & HBA_RANTA,HBA_NYCCO,HBA_PTEAL,HBA_MACCA,HBA_MARMA,# & HBA_ROUAE,HBA_TRAST,HBA_LORTA,HBA_COLBA,HBA_GORGO,# & HBA1_BOSMU,HBA_HUMAN,HBA_RHIUN,HBA_MYOVE,HBA_MACSP,# & HBA_CEBAP,HBA1_GALCR,HBA_PROHA,HBA_CALAR,HBA_CEBCA,# & HBA_MEGLY,HBA_HUMAN,HBA_CERAE,HBA_BOVIN,HBA_SPETO,# & HBA_MANSP,HBA_ANTPA,HBA2_GALCR,HBA_MACGG,HBA_PTEPO,# & HBA_THEGE,HBA_BISBO,HBA_MACFA,HBA_CERSI,HBA_SPECI,# & HBA1_TADBR,HBA_TRIIN,HBA_TARBA,HBA_TUPGL,HBA_PAPCY,# & HBA_BOVIN,HBA_MACAS,HBA_CTEGU,HBA_EULFU)# & PIR1: (HASH,HAGO,HALRN,HAMQJ,HAGT2,HAMKS,HARTNG,HAYA2,HAHU,# & HABO,HACJB,HAGT,HAMQIP,HABAG,HABTV,HAMQR,HAMQC,HAFXB,# & HAMQF,HAEKN,HABAY,HAMQB,HAMQA,HAEMA,HAHXR,HAFXG,HASHR2,# & HAMQ2P,HABOG,HAMQP,HASHR1,HABOKA,HABAIM,HAMKP,HALRS,# & HACZP,HARNW,HAYA1,HACZ)# & PIR2: (A25359,A25477,A25357,B25597,A26543,S31853,C27792,A26640,# & B28865,I58217,S31852,A24690,A29392,JC1099,D60515,A24693,# & I78575,A25729,A29391,A29702,B25126,A25597,JU0165,B27792,# & B25727,S31851)# & PIR3: (S28934,S20277,S20278,S13481,B49141,S59496)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,RMFLSFPTTKT*# SEQUENCE: RMFLSFPTTKT*# ...# >HUM216AC# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human hsp# DB REFERENCE: SWISS: (HS72_BOVIN,HS72_MOUSE,HS7C_RAT,HS73_BOVIN,HS72_HUMAN,# & HS71_SCHPO,HS74_YEAST,HS7H_HUMAN,HS7C_HUMAN,HS71_BOVIN,# & HS7T_MOUSE,HS7C_BRARE,HS76_HUMAN,HS7C_BOVIN,HS73_BOVIN,# & HS72_RAT,HS71_MOUSE,HS7C_BOVIN,HS70_BLAEM,HS72_YEAST,# & HS71_MOUSE,HS7C_CRIGR,HS7C_ICTPU,HS71_PIG,HS7D_DROME,# & HS7X_PIG,HS72_PICAN,HS72_PICAN,HS73_RAT,HS7C_DICDI,# & HS71_PIG,HS71_CANAL,HS70_CHICK,HS7T_MOUSE,HS72_MOUSE,# & HS72_HUMAN,HS70_ONCTS,HS70_PLEWA,HS70_HYDMA,HS76_PIG,# & HS71_YEAST,HS71_RAT,HS71_HUMAN,HS71_PICAN,HS74_CANAL,# & HS71_HANPO,HS7C_DICDI,HS71_RAT,HS7C_RAT,HS70_ONCMY,# & HS7C_ICTPU)# & PIR1: (HHBYA1)# & PIR2: (A27077,A36333,S37394,I49761,S31716,A45935,JC4853,S11456,# & A48872,A25646,S41415,A29160,A35922,S10859,B45871,A34041,# & S41372,S35718,A55719,I51129,I54542,S08211,JH0095,I46588,# & A45871,S09036,S20139,S67431,A48439,S51712,I51344,S43388,# & S31766,B36590,S27004,I56574,S07197,S25585)# & PIR3: (S21175)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,DFYTSITRARFEE*# SEQUENCE: DFYTSITRARFEE*# ...# >HUM216AD# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human granulin D# DB REFERENCE: SWISS: (GRN_CAVPO,GRN_HUMAN)# & PIR1: (GYHU)# & PIR2: (I48141)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,AGYTCNVKARSCE*# SEQUENCE: AGYTCNVKARSCE*# ...# >HUM216AE# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human hsp# DB REFERENCE: SWISS: (HS7C_RAT,HS7C_BOVIN,HS7C_BOVIN,HS7C_ICTPU,HS7C_HUMAN,# & HS7C_RAT,HS7C_ICTPU)# & PIR2: (S31716,S07197,A27077,S11456,JC4853,A45935)# REFERENCES: hammer94b# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,NHFIAEFKRKHKK*# SEQUENCE: NHFIAEFKRKHKK*# ...# >HUM116AF# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV reverse transcriptase# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1U4,POL_HV1RH,POL_HV1PV,POL_SIVCZ,# & POL_HV1N5,POL_HV1OY,POL_HV1B1,POL_HV1Z2,POL_HV1ND,# & POL_HV1BR,POL_HV1Y2,POL_HV1MN,POL_HV1A2,POL_HV1JR,# & POL_HV1H2,POL_HV1EL)# & PIR1: (GNLJSI,GNLJND,GNVWH3,GNVWA2,GNVWVL,B44001,GNVWLV)# & PIR2: (S32092,S32119,S32075,S32094,S63743,S63734,S32160,S63731,# & S32157,S32072,S32129,S32133,S63735,S32152,S32066,S32097,# & A47175,S32096,S32065,S32098,S32140,S32049,S32090,S32120,# & S32127,S32078,B47175,S32080,S32091,S32047,S63745,S32076,# & S32071,S32048,S32050,S32131,S63732,S32118,S32067,S32069,# & S32132,S32070,S32122,S32128,S54378,S32089,S32093,S32051,# & S32151,S32068,S32126,S63750,S32159,S32074,S63746,S32079,# & S63737,S32073,S32077,S63753)# & PIR3: (S33980)# REFERENCES: rammensee94a,brander95b,hivdb97a,goulder97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GPKVKQWPL*# SEQUENCE: GPKVKQWPL*# ...# >HUM116B0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HER-2 (968-981)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# REFERENCES: fisk94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,RFRELVSEFSRMAR*# SEQUENCE: RFRELVSEFSRMAR*# ...# >HUM116B1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HER-2 (971-979)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# REFERENCES: fisk94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ELVSEFSRM*# SEQUENCE: ELVSEFSRM*# ...# >HUM116B2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HER-2 (971-979)# ANCHOR POSITIONS:# REFERENCES: fisk94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ELVSEFSRV*# SEQUENCE: ELVSEFSRV*# ...# >MUS216B3# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus hemagglutinin-neuraminidase glycoprotein HN (163-178)# DB REFERENCE: SWISS: (HEMA_SENDF)# & PIR2: (S12135)# REFERENCES: cole94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,VGEPYLSSDPKISLLPG*# SEQUENCE: VGEPYLSSDPKISLLPG*# ...# >MUS216B4# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus hemagglutinin-neuraminidase glycoprotein HN (199-215)# DB REFERENCE: SWISS: (HEMA_SENDF,HEMA_SENDZ,HEMA_SENDJ,HEMA_SENDH,# & HEMA_SEND5)# & PIR1: (HNNZSZ,HNNZS,HNNZSH)# & PIR2: (S12135,S14532)# REFERENCES: cole94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,SIGEAIYAYSSNLITQG*# SEQUENCE: SIGEAIYAYSSNLITQG*# ...# >MUS216B5# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus hemagglutinin-neuraminidase glycoprotein HN (205-221)# ANCHOR POSITIONS:# REFERENCES: cole94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,YAYSSNLITQGCADIGG*# SEQUENCE: YAYSSNLITQGCADIGG*# ...# >MUS216B6# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus hemagglutinin-neuraminidase glycoprotein HN (415-436)# ANCHOR POSITIONS:# REFERENCES: cole94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,LKLGDRVYIYTRSSGWG*# SEQUENCE: LKLGDRVYIYTRSSGWG*# ...# >MUS216B7# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus hemagglutinin-neuraminidase glycoprotein HN (421-436)# DB REFERENCE: SWISS: (HEMA_SENDF,HEMA_SEND5,HEMA_SENDZ,HEMA_SENDH,# & HEMA_SENDJ)# & PIR1: (HNNZS,HNNZSH,HNNZSZ)# & PIR2: (S14532,S12135)# REFERENCES: cole94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,VYIYTRSSGWHSQLQIG*# SEQUENCE: VYIYTRSSGWHSQLQIG*# ...# >MUS216B8# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus hemagglutinin-neuraminidase glycoprotein HN (475-490)# ANCHOR POSITIONS:# REFERENCES: cole94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,SGVYTDAYPLSPDAANG*# SEQUENCE: SGVYTDAYPLSPDAANG*# ...# >MUS216B9# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus hemagglutinin-neuraminidase glycoprotein HN (481-496)# ANCHOR POSITIONS:# REFERENCES: cole94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,AYPLSPDAANVATVTLG*# SEQUENCE: AYPLSPDAANVATVTLG*# ...# >MUS216BA# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus hemagglutinin-neuraminidase glycoprotein HN (559-574)# ANCHOR POSITIONS:# REFERENCES: cole94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,QPMLFKTSIPKLCKAEG*# SEQUENCE: QPMLFKTSIPKLCKAEG*# ...# >MUS116BB# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./ stabilisation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P1A (35-43)# DB REFERENCE: SWISS: (TUR8_MOUSE)# & PIR2: (JH0456)# REFERENCES: van_den_eynde94a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesu,LPYLGWLVF*# SEQUENCE: LPYLGWLVF*# ...# >MUS116BC# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./ stabilisation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P1A (35-43) homologue# ANCHOR POSITIONS: 2,6,9# REFERENCES: van_den_eynde94a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesu,APYLGWLVF*# SEQUENCE: APYLGWLVF*# ...# >MUS116BD# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./ stabilisation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: P1A (35-43) homologue# ANCHOR POSITIONS: 2,6,9# REFERENCES: van_den_eynde94a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,LAYLGWLVF*# SEQUENCE: LAYLGWLVF*# ...# >MUS116BE# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./ stabilisation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P1A (35-43) homologue# ANCHOR POSITIONS: 2,6,9# REFERENCES: van_den_eynde94a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,LPALGWLVF*# SEQUENCE: LPALGWLVF*# ...# >MUS116BF# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./ stabilisation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P1A (35-43) homologue# ANCHOR POSITIONS: 2,6,9# REFERENCES: van_den_eynde94a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,LPYAGWLVF*# SEQUENCE: LPYAGWLVF*# ...# >MUS116C0# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./ stabilisation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P1A (35-43) homologue# ANCHOR POSITIONS: 2,6,9# REFERENCES: van_den_eynde94a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesu,LPYLAWLVF*# SEQUENCE: LPYLAWLVF*# ...# >MUS116C1# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./ stabilisation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P1A (35-43) homologue# ANCHOR POSITIONS: 2,6,9# REFERENCES: van_den_eynde94a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,LPYLGWAVF*# SEQUENCE: LPYLGWAVF*# ...# >MUS116C2# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./ stabilisation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P1A (35-43) homologue# ANCHOR POSITIONS: 2,6,9# REFERENCES: van_den_eynde94a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,LPYLGWLAF*# SEQUENCE: LPYLGWLAF*# ...# >MUS116C3# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,NGLWNLDLI*# SEQUENCE: NGLWNLDLI*# ...# >MUS116C4# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,SLLYNLDLM*# SEQUENCE: SLLYNLDLM*# ...# >MUS116C5# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,GSPHNMDLI*# SEQUENCE: GSPHNMDLI*# ...# >MUS116C6# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,ANVPNCDLM*# SEQUENCE: ANVPNCDLM*# ...# >MUS116C7# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,ALIWNMDLI*# SEQUENCE: ALIWNMDLI*# ...# >MUS116C8# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,MVWFNMDLM*# SEQUENCE: MVWFNMDLM*# ...# >MUS116C9# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,MGPFNIDLM*# SEQUENCE: MGPFNIDLM*# ...# >MUS116CA# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,GGPINMDLI*# SEQUENCE: GGPINMDLI*# ...# >MUS116CB# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,AVMINCDLI*# SEQUENCE: AVMINCDLI*# ...# >MUS116CC# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,GAGYNLDLI*# SEQUENCE: GAGYNLDLI*# ...# >MUS116CD# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,ATGFNLDLM*# SEQUENCE: ATGFNLDLM*# ...# >MUS116CE# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,SLGVNIDLM*# SEQUENCE: SLGVNIDLM*# ...# >MUS116CF# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,WMGHNAIVI*# SEQUENCE: WMGHNAIVI*# ...# >MUS116D0# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,FQGHNDRVM*# SEQUENCE: FQGHNDRVM*# ...# >MUS116D1# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,GMSWNMDFI*# SEQUENCE: GMSWNMDFI*# ...# >MUS116D2# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,FSLHNEMYI*# SEQUENCE: FSLHNEMYI*# ...# >MUS116D3# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,WTGHNGDVM*# SEQUENCE: WTGHNGDVM*# ...# >MUS116D4# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,CAGHNMDHI*# SEQUENCE: CAGHNMDHI*# ...# >MUS116D5# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,WASHNMDPI*# SEQUENCE: WASHNMDPI*# ...# >MUS116D6# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,FMPHNAFWM*# SEQUENCE: FMPHNAFWM*# ...# >MUS116D7# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: random peptide library# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,FMGHNANTM*# SEQUENCE: FMGHNANTM*# ...# >MUS116D8# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./peptide libraries# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: synthetic peptide# ANCHOR POSITIONS: 5,9# REFERENCES: gavin94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,FAGHNMDLM*# SEQUENCE: FAGHNMDLM*# ...# >HUM116D9# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (29-37)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_RAT,MBP_CAVPO,MBP_HUMAN,MBP_PANTR,# & MBP_MOUSE)# & PIR1: (MBPGB,MBMSB,MBHUB,MBRTS,MBBOB,MBCZB)# & PIR2: (A37246,S66383)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPRHRDTGI*# SEQUENCE: LPRHRDTGI*# ...# >HUM116DA# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (86-94)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_MOUSE,MBP_PANTR,MBP_CHICK,MBP_HUMAN,# & MBP_RAT,MBP_CAVPO)# & PIR1: (MBHUB,MBBOB,MBPGB,MBCZB,MBMSB,MBRTS)# & PIR2: (S08535,A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,VVHFFKNIV*# SEQUENCE: VVHFFKNIV*# ...# >HUM116DB# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (98-106)# DB REFERENCE: SWISS: (MBP_RAT,MBP_CAVPO,MBP_HUMAN,MBP_BOVIN,MBP_MOUSE,# & MBP_PANTR)# & PIR1: (MBRTS,MBPGB,MBBOB,MBCZB,MBHUB,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,TPPPSQGKG*# SEQUENCE: TPPPSQGKG*# ...# >HUM116DC# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (136-144)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,SAHKGFKGV*# SEQUENCE: SAHKGFKGV*# ...# >HUM116DD# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (145-153)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,MBP_PANTR)# & PIR1: (MBCZB,MBPGB,MBHUB,MBBOB,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,DAQGTLSKI*# SEQUENCE: DAQGTLSKI*# ...# >HUM116DE# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CHB38 gliadin peptide# DB REFERENCE: SWISS: (GDA9_WHEAT,GDA4_WHEAT,GDA6_WHEAT,GDA2_WHEAT,GDA3_WHEAT,# & GDA7_WHEAT,GDA1_WHEAT,GDA5_WHEAT)# & PIR2: (A22364,E22364,D22364,S10015,C22364,S07361,B22364,S07924,# & A27319)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,QPFPSQQPY*# SEQUENCE: QPFPSQQPY*# ...# >HUM116DF# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (29-37)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_CAVPO,MBP_MOUSE,MBP_PANTR,# & MBP_BOVIN)# & PIR1: (MBPGB,MBHUB,MBMSB,MBCZB,MBBOB,MBRTS)# & PIR2: (S66383,A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPRHRDTGI*# SEQUENCE: LPRHRDTGI*# ...# >HUM116E0# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (62-70)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBCZB,MBHUB)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,HPARTAHYG*# SEQUENCE: HPARTAHYG*# ...# >HUM116E1# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-92)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_MOUSE,MBP_BOVIN,MBP_CHICK,MBP_RAT,# & MBP_HUMAN,MBP_CAVPO)# & PIR1: (MBRTS,MBBOB,MBCZB,MBMSB,MBHUB,MBPGB)# & PIR2: (I53256,S08535,A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,NPVVHFFKN*# SEQUENCE: NPVVHFFKN*# ...# >HUM116E2# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (86-94)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN,MBP_CAVPO,MBP_MOUSE,MBP_BOVIN,# & MBP_CHICK,MBP_RAT)# & PIR1: (MBBOB,MBCZB,MBPGB,MBMSB,MBHUB,MBRTS)# & PIR2: (A37246,S08535)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,VVHFFKNIV*# SEQUENCE: VVHFFKNIV*# ...# >HUM116E3# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (145-153)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_BOVIN,MBP_HUMAN,MBP_CAVPO,MBP_PANTR)# & PIR1: (MBPGB,MBMSB,MBHUB,MBBOB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,DAQGTLSKI*# SEQUENCE: DAQGTLSKI*# ...# >HUM116E4# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (2-10)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_RAT,MBP_PANTR,MBP_HUMAN)# & PIR1: (MBHUB,MBCZB,MBPGB,MBRTS)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,SQKRPSQRH*# SEQUENCE: SQKRPSQRH*# ...# >HUM116E5# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (6-14)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_PANTR,MBP_RAT,MBP_HUMAN)# & PIR1: (MBCZB,MBRTS,MBHUB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,PSQRHGSKY*# SEQUENCE: PSQRHGSKY*# ...# >HUM116E6# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (7-15)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_HUMAN,MBP_PANTR,MBP_RAT)# & PIR1: (MBPGB,MBRTS,MBCZB,MBHUB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,SQRHGSKYL*# SEQUENCE: SQRHGSKYL*# ...# >HUM116E7# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (11-19)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_HUMAN,MBP_RAT,MBP_PANTR)# & PIR1: (MBCZB,MBRTS,MBHUB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,GSKYLATAS*# SEQUENCE: GSKYLATAS*# ...# >HUM116E8# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (13-21)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_PANTR,MBP_RAT,MBP_MOUSE,MBP_HUMAN)# & PIR1: (MBHUB,MBCZB,MBRTS,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,KYLATASTM*# SEQUENCE: KYLATASTM*# ...# >HUM116E9# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (14-22)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_CAVPO,MBP_RAT,MBP_MOUSE,MBP_HUMAN)# & PIR1: (MBRTS,MBHUB,MBMSB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,YLATASTMD*# SEQUENCE: YLATASTMD*# ...# >HUM116EA# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (15-23)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN,MBP_CAVPO,MBP_MOUSE,MBP_RAT)# & PIR1: (MBHUB,MBRTS,MBCZB,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,LATASTMDH*# SEQUENCE: LATASTMDH*# ...# >HUM116EB# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (20-28)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_MOUSE,MBP_RAT,MBP_PANTR,# & MBP_BOVIN)# & PIR1: (MBMSB,MBCZB,MBPGB,MBBOB,MBHUB,MBRTS)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,TMDHARHGF*# SEQUENCE: TMDHARHGF*# ...# >HUM116EC# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (37-45)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN,MBP_RAT,MBP_MOUSE,MBP_CAVPO)# & PIR1: (MBHUB,MBRTS,MBCZB,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,ILDSIGRFF*# SEQUENCE: ILDSIGRFF*# ...# >HUM116ED# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (60-68)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,SHHPARTAH*# SEQUENCE: SHHPARTAH*# ...# >HUM116EE# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (119-127)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,EGQRPGFGY*# SEQUENCE: EGQRPGFGY*# ...# >HUM116EF# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (120-128)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,GQRPGFGYG*# SEQUENCE: GQRPGFGYG*# ...# >HUM116F0# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (126-134)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_BOVIN,MBP_PANTR)# & PIR1: (MBBOB,MBMSB,MBCZB,MBHUB)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,GYGGRASDY*# SEQUENCE: GYGGRASDY*# ...# >HUM116F1# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (146-154)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_BOVIN,MBP_MOUSE,MBP_HUMAN,MBP_CAVPO)# & PIR1: (MBCZB,MBHUB,MBBOB,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,AQGTLSKIF*# SEQUENCE: AQGTLSKIF*# ...# >HUM116F2# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (159-167)# DB REFERENCE: SWISS: (MBP_RAT,MBP_PANTR,MBP_CAVPO,MBP_MOUSE,MBP_HUMAN,# & MBP_BOVIN)# & PIR1: (MBMSB,MBHUB,MBPGB,MBRTS,MBCZB,MBBOB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesh,RDSRSGSPM*# SEQUENCE: RDSRSGSPM*# ...# >HUM116F3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (13-21)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_MOUSE,MBP_RAT,MBP_CAVPO,MBP_HUMAN)# & PIR1: (MBRTS,MBMSB,MBHUB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KYLATASTM*# SEQUENCE: KYLATASTM*# ...# >HUM116F4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (14-22)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_MOUSE,MBP_PANTR,MBP_RAT,MBP_HUMAN)# & PIR1: (MBCZB,MBMSB,MBHUB,MBRTS)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,YLATASTMD*# SEQUENCE: YLATASTMD*# ...# >HUM116F5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (20-28)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_CAVPO,MBP_BOVIN,MBP_MOUSE,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBCZB,MBPGB,MBHUB,MBRTS,MBBOB,MBMSB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,TMDHARHGF*# SEQUENCE: TMDHARHGF*# ...# >HUM116F6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (21-29)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_RAT,MBP_HUMAN,MBP_PANTR,MBP_CAVPO,# & MBP_MOUSE)# & PIR1: (MBPGB,MBHUB,MBMSB,MBRTS,MBBOB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,MDHARHGFL*# SEQUENCE: MDHARHGFL*# ...# >HUM116F7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (79-87)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_MOUSE,MBP_PANTR)# & PIR1: (MBRTS,MBMSB,MBHUB,MBCZB)# & PIR2: (I53256)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,RTQDENPVV*# SEQUENCE: RTQDENPVV*# ...# >HUM116F8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (86-94)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_PANTR,MBP_CHICK,MBP_MOUSE,MBP_HUMAN,# & MBP_CAVPO,MBP_RAT)# & PIR1: (MBHUB,MBPGB,MBBOB,MBMSB,MBRTS,MBCZB)# & PIR2: (A37246,S08535)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,VVHFFKNIV*# SEQUENCE: VVHFFKNIV*# ...# >HUM116F9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (90-98)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_MOUSE,MBP_PANTR,MBP_BOVIN,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBHUB,MBRTS,MBCZB,MBBOB,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,FKNIVTPRT*# SEQUENCE: FKNIVTPRT*# ...# >HUM116FA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (110-118)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_MOUSE,MBP_HUMAN,MBP_BOVIN,MBP_PANTR)# & PIR1: (MBBOB,MBMSB,MBPGB,MBCZB,MBHUB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLSRFSWGA*# SEQUENCE: SLSRFSWGA*# ...# >HUM116FB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (136-144)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SAHKGFKGV*# SEQUENCE: SAHKGFKGV*# ...# >HUM116FC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (148-156)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_HUMAN,MBP_CHICK,MBP_PANTR,MBP_MOUSE,# & MBP_CAVPO)# & PIR1: (MBBOB,MBCZB,MBHUB,MBPGB,MBMSB)# & PIR2: (A37246,S08535)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GTLSKIFKL*# SEQUENCE: GTLSKIFKL*# ...# >HUM116FD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (149-157)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN,MBP_CAVPO,MBP_CHICK,MBP_MOUSE,# & MBP_BOVIN)# & PIR1: (MBMSB,MBHUB,MBCZB,MBBOB,MBPGB)# & PIR2: (A37246,S08535)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,TLSKIFKLG*# SEQUENCE: TLSKIFKLG*# ...# >HUM116FE# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (13-21)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_CAVPO,MBP_RAT,MBP_PANTR,MBP_HUMAN)# & PIR1: (MBMSB,MBCZB,MBHUB,MBRTS)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KYLATASTM*# SEQUENCE: KYLATASTM*# ...# >HUM116FF# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (14-22)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_RAT,MBP_CAVPO,MBP_PANTR,MBP_MOUSE)# & PIR1: (MBMSB,MBHUB,MBRTS,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,YLATASTMD*# SEQUENCE: YLATASTMD*# ...# >HUM11700# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (20-28)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_MOUSE,MBP_BOVIN,MBP_HUMAN,MBP_RAT,# & MBP_CAVPO)# & PIR1: (MBHUB,MBPGB,MBMSB,MBCZB,MBBOB,MBRTS)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,TMDHARHGF*# SEQUENCE: TMDHARHGF*# ...# >HUM11701# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (21-29)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_CAVPO,MBP_BOVIN,MBP_PANTR,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBBOB,MBMSB,MBCZB,MBHUB,MBPGB,MBRTS)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,MDHARHGFL*# SEQUENCE: MDHARHGFL*# ...# >HUM11702# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (79-87)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR,MBP_RAT,MBP_MOUSE)# & PIR1: (MBHUB,MBRTS,MBCZB,MBMSB)# & PIR2: (I53256)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,RTQDENPVV*# SEQUENCE: RTQDENPVV*# ...# >HUM11703# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (90-98)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_RAT,MBP_HUMAN,MBP_CAVPO,MBP_PANTR,# & MBP_BOVIN)# & PIR1: (MBBOB,MBHUB,MBCZB,MBRTS,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FKNIVTPRT*# SEQUENCE: FKNIVTPRT*# ...# >HUM11704# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (110-118)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_MOUSE,MBP_BOVIN,MBP_PANTR)# & PIR1: (MBBOB,MBHUB,MBMSB,MBPGB,MBCZB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLSRFSWGA*# SEQUENCE: SLSRFSWGA*# ...# >HUM11705# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (112-120)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_BOVIN,MBP_CAVPO,MBP_HUMAN)# & PIR1: (MBHUB,MBCZB,MBBOB,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SRFSWGAEG*# SEQUENCE: SRFSWGAEG*# ...# >HUM11706# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (136-144)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SAHKGFKGV*# SEQUENCE: SAHKGFKGV*# ...# >HUM11707# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (148-156)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR,MBP_CAVPO,MBP_BOVIN,MBP_MOUSE,# & MBP_CHICK)# & PIR1: (MBCZB,MBHUB,MBBOB,MBPGB,MBMSB)# & PIR2: (A37246,S08535)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GTLSKIFKL*# SEQUENCE: GTLSKIFKL*# ...# >HUM11708# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (149-157)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_CHICK,MBP_PANTR,MBP_BOVIN,# & MBP_CAVPO)# & PIR1: (MBBOB,MBPGB,MBHUB,MBMSB,MBCZB)# & PIR2: (A37246,S08535)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,TLSKIFKLG*# SEQUENCE: TLSKIFKLG*# ...# >HUM11709# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (150-158)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_HUMAN,MBP_CHICK,MBP_BOVIN,MBP_MOUSE,# & MBP_PANTR)# & PIR1: (MBCZB,MBHUB,MBMSB,MBPGB,MBBOB)# & PIR2: (S08535,A37246)# REFERENCES: tanigaki94c# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LSKIFKLGG*# SEQUENCE: LSKIFKLGG*# ...# >HUM1170A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MBP (110-118)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,MBP_PANTR,MBP_CAVPO)# & PIR1: (MBMSB,MBPGB,MBBOB,MBHUB,MBCZB)# & PIR2: (A37246)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,SLSRFSWGA*# SEQUENCE: SLSRFSWGA*# ...# >HUM1170B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLP (253-261)# DB REFERENCE: SWISS: (MYPR_CHICK,MYPR_RABIT,MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA,# & MYPR_BOVIN)# & PIR1: (S34792,MPRTPL,MPHUPL)# & PIR2: (S17600,A43548)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLLTFMIAA*# SEQUENCE: SLLTFMIAA*# ...# >HUM1170C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: PLP (80-88)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_POEGU,MYPR_CANFA,MYPR_RABIT,# & MYPR_CHICK,MYPR_BOVIN)# & PIR1: (MPBOPL,MPHUPL,MPRTPL,S34792)# & PIR2: (S17600,A43548)# & PIR3: (I51270)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,FLYGALLLA*# SEQUENCE: FLYGALLLA*# ...# >HUM1170D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MAG (556-564)# DB REFERENCE: SWISS: (MAG_HUMAN)# & PIR1: (A61084)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,VLFSSDFRI*# SEQUENCE: VLFSSDFRI*# ...# >HUM1170E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAG (406-414)# DB REFERENCE: SWISS: (MAG_HUMAN)# & PIR1: (A61084)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,NLSVEFAPV*# SEQUENCE: NLSVEFAPV*# ...# >HUM1170F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAG (234-242)# DB REFERENCE: SWISS: (MAG_HUMAN)# & PIR1: (A61084)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SMDVKYPPV*# SEQUENCE: SMDVKYPPV*# ...# >HUM11710# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAG (8-16)# DB REFERENCE: SWISS: (MAGL_MOUSE,MAGS_MOUSE,MAGL_RAT,MAG_HUMAN,MAGS_RAT)# & PIR1: (BNRT3,BNRT3S,A61084)# & PIR2: (B33785)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,PLFWIMISA*# SEQUENCE: PLFWIMISA*# ...# >HUM11711# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: MAG (509-517)# DB REFERENCE: SWISS: (MAG_HUMAN,MAGS_RAT,MAGL_MOUSE,BNC3_RAT,MAGS_MOUSE,# & MAGL_RAT)# & PIR1: (BNRT3S,BNRT3,A61084)# & PIR2: (B33785,I56564)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,LMWAKIGPV*# SEQUENCE: LMWAKIGPV*# ...# >HUM11712# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: MAG (287-295)# DB REFERENCE: SWISS: (MAG_HUMAN)# & PIR1: (A61084)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,SLLLELEEV*# SEQUENCE: SLLLELEEV*# ...# >HUM11713# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MOG (157-165)# DB REFERENCE: SWISS: (OMGP_HUMAN,OMGP_HUMAN,OMGP_MOUSE)# & PIR2: (A39613,A47530,I46918)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KLWTVPTNM*# SEQUENCE: KLWTVPTNM*# ...# >HUM11714# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MOG (113-121)# DB REFERENCE: SWISS: (OMGP_MOUSE,OMGP_HUMAN,OMGP_HUMAN)# & PIR2: (A47530,A39613)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KLLDKSDTA*# SEQUENCE: KLLDKSDTA*# ...# >HUM11715# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MOG (7-15)# DB REFERENCE: SWISS: (OMGP_HUMAN,OMGP_HUMAN)# & PIR2: (A39613)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KMSLCLFIL*# SEQUENCE: KMSLCLFIL*# ...# >HUM11716# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MOG (240-248)# DB REFERENCE: SWISS: (OMGP_HUMAN,OMGP_HUMAN)# & PIR2: (I46918,A39613)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LKWMMETKA*# SEQUENCE: LKWMMETKA*# ...# >HUM11717# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MOG (164-172)# DB REFERENCE: SWISS: (OMGP_HUMAN,OMGP_MOUSE,OMGP_HUMAN)# & PIR2: (A47530,A39613)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,NMPSKLHIV*# SEQUENCE: NMPSKLHIV*# ...# >HUM11718# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MOG (133-141)# DB REFERENCE: SWISS: (OMGP_HUMAN,OMGP_HUMAN,OMGP_MOUSE)# & PIR2: (A39613,A47530)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,NMLEKVVLI*# SEQUENCE: NMLEKVVLI*# ...# >HUM11719# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MOG (422-430)# DB REFERENCE: SWISS: (OMGP_HUMAN,OMGP_HUMAN)# & PIR2: (A39613)# REFERENCES: tsuchida94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,WKVNASFLL*# SEQUENCE: WKVNASFLL*# ...# >HUM1171A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KALGFVFTL*# SEQUENCE: KALGFVFTL*# ...# >HUM1171B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KILGKVFTL*# SEQUENCE: KILGKVFTL*# ...# >HUM1171C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KLFGGGGGV*# SEQUENCE: KLFGGGGGV*# ...# >HUM1171D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KLFGGVGGV*# SEQUENCE: KLFGGVGGV*# ...# >HUM1171E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLFGGVGGV*# SEQUENCE: GLFGGVGGV*# ...# >HUM1171F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: PIR1: (B45539)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLLGFVFTL*# SEQUENCE: GLLGFVFTL*# ...# >HUM11720# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,ILASLFAAV*# SEQUENCE: ILASLFAAV*# ...# >HUM11721# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLFGGGFGV*# SEQUENCE: GLFGGGFGV*# ...# >HUM11722# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLFGGFGGV*# SEQUENCE: GLFGGFGGV*# ...# >HUM11723# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLFGGGVGV*# SEQUENCE: GLFGGGVGV*# ...# >HUM11724# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GQLGFVFTL*# SEQUENCE: GQLGFVFTL*# ...# >HUM11725# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,LQFGYPVYV*# SEQUENCE: LQFGYPVYV*# ...# >HUM11726# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,LMFGYPVYV*# SEQUENCE: LMFGYPVYV*# ...# >HUM11727# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLFKGGGGV*# SEQUENCE: GLFKGGGGV*# ...# >HUM11728# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLFGGGAGV*# SEQUENCE: GLFGGGAGV*# ...# >HUM11729# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,ALFAAAAAV*# SEQUENCE: ALFAAAAAV*# ...# >HUM1172A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLFGGGEGV*# SEQUENCE: GLFGGGEGV*# ...# >HUM1172B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLFKGVGGV*# SEQUENCE: GLFKGVGGV*# ...# >HUM1172C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GLYGGGGGV*# SEQUENCE: GLYGGGGGV*# ...# >HUM1172D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GELGFVFTL*# SEQUENCE: GELGFVFTL*# ...# >HUM1172E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GILGEVFTL*# SEQUENCE: GILGEVFTL*# ...# >HUM1172F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GILFGAFTL*# SEQUENCE: GILFGAFTL*# ...# >HUM11730# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GILGFEFTL*# SEQUENCE: GILGFEFTL*# ...# >HUM11731# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GILGFVFEL*# SEQUENCE: GILGFVFEL*# ...# >HUM11732# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GILGFVFVL*# SEQUENCE: GILGFVFVL*# ...# >HUM11733# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GILPFVFTL*# SEQUENCE: GILPFVFTL*# ...# >HUM11734# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,CLFGYPVYV*# SEQUENCE: CLFGYPVYV*# ...# >HUM11735# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VGLB_HCMVT,VGLB_HCMVA)# & PIR1: (VGBEC1,VGBETE)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,FIFPNYTIV*# SEQUENCE: FIFPNYTIV*# ...# >HUM11736# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KLGEFFNQM*# SEQUENCE: KLGEFFNQM*# ...# >HUM11737# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VNUC_INBAC,VNUC_INBLE,VNUC_INBAA,VNUC_INBSI,# & VNUC_INBAD)# & PIR1: (VHIVBC,VHIVBA,VHIVBW)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KLGEFYNQM*# SEQUENCE: KLGEFYNQM*# ...# >HUM11738# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KMFGYPVYV*# SEQUENCE: KMFGYPVYV*# ...# >HUM11739# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VGLB_HCMVT,VGLB_HCMVA)# & PIR1: (VGBETE,VGBEC1)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,NIVAHTFKV*# SEQUENCE: NIVAHTFKV*# ...# >HUM1173A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (PP65_HCMVT,PP65_HCMVA)# & PIR1: (WMBETW,WMBE65)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,NLVPMVATV*# SEQUENCE: NLVPMVATV*# ...# >HUM1173B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,QMLLAIARL*# SEQUENCE: QMLLAIARL*# ...# >HUM1173C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (PP65_HCMVT,PP65_HCMVA)# & PIR1: (WMBETW,WMBE65)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,QMWQARLTV*# SEQUENCE: QMWQARLTV*# ...# >HUM1173D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (PP65_HCMVT,PP65_HCMVA)# & PIR1: (WMBE65)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,RLLQTGIHV*# SEQUENCE: RLLQTGIHV*# ...# >HUM1173E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VGLB_HCMVT,VGLB_HCMVA)# & PIR1: (VGBETE,VGBEC1)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,YLFKRMIDL*# SEQUENCE: YLFKRMIDL*# ...# >HUM1173F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KLFGFVFTV*# SEQUENCE: KLFGFVFTV*# ...# >HUM11740# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,GIGFGGGGL*# SEQUENCE: GIGFGGGGL*# ...# >HUM11741# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KILGFVFTK*# SEQUENCE: KILGFVFTK*# ...# >HUM11742# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,KKLGFVFTL*# SEQUENCE: KKLGFVFTL*# ...# >HUM11743# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actunkn,bindyesh,LRFGYPVYV*# SEQUENCE: LRFGYPVYV*# ...# >HUM11744# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HTLV-1 tax# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actyesu,bindyesh,LLFGYPVYV*# SEQUENCE: LLFGYPVYV*# ...# >HUM11745# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HCMV gB# DB REFERENCE: SWISS: (VGLB_HCMVT,VGLB_HCMVA)# & PIR1: (VGBEC1,VGBETE)# & PIR2: (PQ0308,PQ0305,PQ0309)# REFERENCES: parker94a# COMMENT: peptides with t1/2 gt 100 good binders, t1/2 < 5 non-binders# SUMMARY: HLA-A2,actyesu,bindyesh,FIAGNSAYEYV*# SEQUENCE: FIAGNSAYEYV*# ...# >HUM11746# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: molecular modeling# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA6# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015,S27922,H49034)# REFERENCES: thorpe94a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,EENLLDFVR*# SEQUENCE: EENLLDFVR*# ...# >HUM11747# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: molecular modeling# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24gag# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1W2,GAG_HV1Z2,GAG_HV1B5,GAG_HV1MN,# & GAG_HV1PV,GAG_HV1JR,GAG_HV1H2,GAG_HV1Y2,GAG_HV1B1,# & GAG_HV1MA,GAG_HV1EL,GAG_HV1U4,GAG_HV1A2,GAG_HV1ND,# & GAG_HV1BR,GAG_HV1RH,GAG_HV1C4,GAG_HV1J3)# & PIR1: (FOVWVL,A44001,FOVWH4,A38068,FOLJND,FOVWLV,FOVWA2,# & FOVWH3)# & PIR2: (S54377)# & PIR3: (S33979)# REFERENCES: thorpe94a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,SEGATPQDL*# SEQUENCE: SEGATPQDL*# ...# >HUM11748# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 env# ANCHOR POSITIONS: 2,11# REFERENCES: maier94a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,RLRDLLLILTR*# SEQUENCE: RLRDLLLILTR*# ...# >HUM11749# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 env# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1W1,ENV_HV1Z3,ENV_HV1EL,ENV_HV1ZH,# & ENV_HV1KB,ENV_HV1H3,ENV_HV1Z6,ENV_HV1MA,ENV_HV1PV,# & ENV_HV1B1,ENV_HV1MF,ENV_HV1N5,ENV_HV1S3,ENV_HV1MN,# & ENV_HV1J3,ENV_HV1C4,ENV_HV1RH,ENV_HV1Z2,ENV_HV1OY,# & ENV_HV1H2,ENV_HV1BN,ENV_HV1Z8,ENV_HV1BR,ENV_HV1S1,# & ENV_HV1SC,ENV_HV1A2,ENV_HV1JR,ENV_HV1W2)# & PIR1: (H44001,VCLJ3W,VCLJBR,VCLJMN,VCLJLV,VCLJKB,VCLJSC,VCLJKX,# & A44963,VCLJVL,VCLJH3,VCLJA2,VCLJH4,VCLJZR)# & PIR2: (A40218,S54384)# & PIR3: (S33985,S13289,S13288)# REFERENCES: maier94a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,TVYYGVPVWK*# SEQUENCE: TVYYGVPVWK*# ...# >HUM1174A# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: reference/CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 gag# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1MN,GAG_HV1H2,GAG_HV1OY,GAG_SIVMK,# & GAG_HV2ST,GAG_HV1BR,GAG_SIVM1,GAG_HV2KR,GAG_HV1J3,# & GAG_HV1PV,GAG_HV1JR,GAG_HV1B1,GAG_HV1MA,GAG_HV1EL,# & GAG_HV2NZ,GAG_HV2SB,GAG_HV1B5,GAG_HV2BE,GAG_HV1ND,# & GAG_HV1A2,GAG_HV2D2,GAG_SIVMS,GAG_HV2RO,GAG_HV2CA,# & GAG_HV1Z2)# & PIR1: (FOLJTM,A38068,FOVWVL,FOLJST,FOLJG2,FOLJG5,FOLJCA,FOVWH3,# & FOVWA2,FOLJG3,FOLJND,FOVWLV)# & PIR2: (S03070,S08435,S54377,S53091)# & PIR3: (S33979)# REFERENCES: maier94a,goulder97a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,RLRPGGKKK*# SEQUENCE: RLRPGGKKK*# ...# >HUM1174B# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 nef# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1BR,NEF_HV1BN)# & PIR1: (ASLJBR,ASLJFV)# & PIR2: (S43467,S03244,S24985,S03247)# REFERENCES: rammensee95a,maier94a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,TPGPGVRYPL*# SEQUENCE: TPGPGVRYPL*# ...# >HUM2174C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae HSP70 (410-421)# DB REFERENCE: SWISS: (DNAK_MYCLE,DNAK_MYCTU,DNAK_STRCO,DNAK_MYCPA)# & PIR2: (JN0830,S34440,S29698,A32144,A30544)# REFERENCES: oftung94a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,SVQIQVYQGERE*# SEQUENCE: SVQIQVYQGERE*# ...# >HUM2174D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae HSP70 (411-422)# DB REFERENCE: SWISS: (DNAK_MYCLE,DNAK_STRCO,DNAK_MYCPA,DNAK_MYCTU)# & PIR2: (A32144,S29698,S34440,JN0830,A30544)# REFERENCES: oftung94a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,VQIQVYQGEREI*# SEQUENCE: VQIQVYQGEREI*# ...# >HUM2174E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae HSP70 (412-423)# DB REFERENCE: SWISS: (DNAK_MYCLE,DNAK_MYCTU,DNAK_MYCPA,DNAK_STRCO)# & PIR2: (A32144,A30544,S34440,JN0830,S29698)# REFERENCES: oftung94a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,QIQVYQGEREIA*# SEQUENCE: QIQVYQGEREIA*# ...# >HUM2174F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae HSP70 (413-424)# DB REFERENCE: SWISS: (DNAK_MYCLE)# & PIR2: (A30544)# REFERENCES: oftung94a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,IQVYQGEREIAS*# SEQUENCE: IQVYQGEREIAS*# ...# >HUM21750# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae HSP70 (413-421)# DB REFERENCE: SWISS: (DNAK_MYCTU,DNAK_MYCPA,DNAK_MYCLE,DNAK_STRCO)# & PIR2: (S34440,S29698,A30544,JN0830,A32144)# REFERENCES: oftung94a# COMMENT: core peptide# SUMMARY: HLA-DR2,actyesu,bindyesu,IQVYQGERE*# SEQUENCE: IQVYQGERE*# ...# >HUM21751# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae HSP70 (66-82)# DB REFERENCE: SWISS: (DNAK_MYCLE)# REFERENCES: oftung94a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,IRSVKRHMGSDWSIEID*# SEQUENCE: IRSVKRHMGSDWSIEID*# ...# >HUM21752# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae HSP70 (216-226)# ANCHOR POSITIONS:# REFERENCES: oftung94a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,FKGTRGIDLTK*# SEQUENCE: FKGTRGIDLTK*# ...# >HUM21753# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae HSP70 (262-274)# DB REFERENCE: SWISS: (DNAK_MYCLE)# REFERENCES: oftung94a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesu,SDKNPLFLDEQLI*# SEQUENCE: SDKNPLFLDEQLI*# ...# >HUM11754# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEs HSP57 (43-51)# DB REFERENCE: PIR2: (B60273)# REFERENCES: daser94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,DRAEVVALG*# SEQUENCE: DRAEVVALG*# ...# >HUM11755# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (12-20)# DB REFERENCE: SWISS: (CH60_CHLTR)# & PIR2: (B41479,A60273,I40731)# REFERENCES: daser94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,ARKKIQKGV*# SEQUENCE: ARKKIQKGV*# ...# >HUM11756# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (117-125)# DB REFERENCE: PIR2: (A60273)# REFERENCES: daser94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KRGIDKAAK*# SEQUENCE: KRGIDKAAK*# ...# >HUM11757# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (283-291)# DB REFERENCE: PIR2: (A60273)# REFERENCES: daser94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,DRRKAMFED*# SEQUENCE: DRRKAMFED*# ...# >HUM11758# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (284-292)# DB REFERENCE: PIR2: (A60273)# REFERENCES: rammensee95a,daser94a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRKAMFEDI*# SEQUENCE: RRKAMFEDI*# ...# >HUM11759# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (379-387)# DB REFERENCE: SWISS: (CH60_CHLTR,CH60_CHLPN,CH60_CHLPS)# & PIR2: (A60273,B41479,S19023,JL0117)# REFERENCES: daser94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,IRVGAATEI*# SEQUENCE: IRVGAATEI*# ...# >HUM1175A# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (283-291) homologue# DB REFERENCE: PIR2: (A60273)# REFERENCES: daser94a,rognan94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRKAMFED*# SEQUENCE: RRKAMFED*# ...# >HUM1175B# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (283-291) homologue# ANCHOR POSITIONS:# REFERENCES: daser94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RIKAMFED*# SEQUENCE: RIKAMFED*# ...# >HUM1175C# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: binding-direct/assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Chlamydia trachomatis groEl HSP57 (283-291) homologue# ANCHOR POSITIONS:# REFERENCES: daser94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,RKKAMFEDI*# SEQUENCE: RKKAMFEDI*# ...# >HUM1175D# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HLA assembly as./molecular modeling# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (284-292)# DB REFERENCE: PIR2: (A60273)# REFERENCES: rognan94a,rognan95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRKAMFEDI*# SEQUENCE: RRKAMFEDI*# ...# >HUM1175E# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: molecular modeling# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis groEl HSP57 (283-291) homologue# DB REFERENCE: PIR2: (A60273)# REFERENCES: rognan94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRKAMFED*# SEQUENCE: RRKAMFED*# ...# >HUM1175F# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HLA assembly as./reference/molecular modeling# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: E. coli HSP75# DB REFERENCE: SWISS: (DNAK_ECOLI,DNAK_BORBU,DNAK_AGRTU,DNAK_RHIME,DNAK_ERYRH,# & DNAK_SALTY,DNAK_BURCE,RPOB_RICTY,DNAK_ECOLI,DNAK_CLOAB,# & HS7E_DROME)# & PIR1: (IQECDK)# & PIR2: (B41873,A49230,I39585,A55551,JN0667,A44789)# REFERENCES: rognan94a,rognan95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,QRLKEAAEK*# SEQUENCE: QRLKEAAEK*# ...# >HUM21760# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae fusion protein antigen# ANCHOR POSITIONS:# REFERENCES: mustafa94a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,HHLVRASIDLGSGSIQL*# SEQUENCE: HHLVRASIDLGSGSIQL*# ...# >HUM21761# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae fusion protein antigen# ANCHOR POSITIONS:# REFERENCES: mustafa94a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,LVRASIDLGSGS*# SEQUENCE: LVRASIDLGSGS*# ...# >HUM21762# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae fusion protein antigen# ANCHOR POSITIONS:# REFERENCES: mustafa94a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,HLVRASIDLGSG*# SEQUENCE: HLVRASIDLGSG*# ...# >HUM21763# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae fusion protein antigen# ANCHOR POSITIONS:# REFERENCES: mustafa94a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,HHLVRASIDLGS*# SEQUENCE: HHLVRASIDLGS*# ...# >HUM21764# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: M. leprae fusion protein antigen# ANCHOR POSITIONS:# REFERENCES: mustafa94a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,SHHLVRASIDLG*# SEQUENCE: SHHLVRASIDLG*# ...# >HUM21765# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: M. leprae fusion protein antigen# ANCHOR POSITIONS:# REFERENCES: mustafa94a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesl,GSHHLVRASIDL*# SEQUENCE: GSHHLVRASIDL*# ...# >MUS11766# MHC MOLECULE: H-2b, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TCR-V beta 8.2 variable region# DB REFERENCE: SWISS: (TVB5_MOUSE)# & PIR1: (RWMSC5)# & PIR2: (E27664,PL0223,A30603,JH0349,A49027,F27577,D27664,# & S00857)# REFERENCES: kuhrober94a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,KASRPSQENFSLILE*# SEQUENCE: KASRPSQENFSLILE*# ...# >MUS11767# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: murine alpha-ketoglutarate dehydrogenase alpha-KGDH# DB REFERENCE: SWISS: (ODO1_MOUSE,ODO1_HUMAN)# & PIR2: (A41911)# REFERENCES: sykulev94a,huang96a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesu,QLSPFPFDL*# SEQUENCE: QLSPFPFDL*# ...# >MUS11768# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: murine alpha-ketoglutarate dehydrogenase alpha-KGDH# DB REFERENCE: SWISS: (ODO1_HUMAN,ODO1_MOUSE)# & PIR2: (B38234,A41911)# REFERENCES: sykulev94a,connolly94a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,LSPFPFDLL*# SEQUENCE: LSPFPFDLL*# ...# >MUS11769# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: murine alpha-ketoglutarate dehydrogenase alpha-KGDH# DB REFERENCE: SWISS: (ODO1_HUMAN,ODO1_MOUSE)# & PIR2: (A41911,B38234,A38234)# REFERENCES: sykulev94a,sykulev95a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,SPFPFDLLL*# SEQUENCE: SPFPFDLLL*# ...# >RAT2176A# MHC MOLECULE: I-Au, CLASS-2, (RAT)# METHOD: proliferation as./ lymphokine as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rat S100beta (76-91)# DB REFERENCE: SWISS: (S10B_RAT)# & PIR2: (A26557)# REFERENCES: kojima94a# COMMENT:# SUMMARY: I-Au,actyesu,bindyesu,FVSMVTTACHEFFEHE*# SEQUENCE: FVSMVTTACHEFFEHE*# ...# >HUM2176B# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSV-1 fusion protein (425-439)# DB REFERENCE: SWISS: (ATIN_HSV2H,ATIN_HSV23)# & PIR1: (IXBE33)# & PIR2: (JS0689)# REFERENCES: koelle94a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,LRLDGEEVDMTPADA*# SEQUENCE: LRLDGEEVDMTPADA*# ...# >HUM2176C# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSV-1 fusion protein (430-444)# DB REFERENCE: SWISS: (ATIN_HSV23,ATIN_HSV2H)# & PIR1: (IXBE33)# & PIR2: (JS0689)# REFERENCES: koelle94a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,EEVDMTPADALDDFD*# SEQUENCE: EEVDMTPADALDDFD*# ...# >MUS1176D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P. falciparum CS (39-47)# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLAFW,CSP_PLAFT,CSP_PLAFO,CSP_PLAFL,# & CSP_PLARE)# & PIR1: (OZZQAF)# & PIR2: (B29795,A54533,A39756,A54529,A29795,S05428)# REFERENCES: blum-tirouvanziam94a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,NYDNAGTNL*# SEQUENCE: NYDNAGTNL*# ...# >MUS1176E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: P. falciparum CS (40-47)# DB REFERENCE: SWISS: (CSP_PLAFT,CSP_PLAFW,CSP_PLAFA,CSP_PLAFL,CSP_PLAFO,# & CSP_PLARE)# & PIR1: (OZZQAF)# & PIR2: (B29795,A29795,A54529,A39756,A54533,S05428)# REFERENCES: blum-tirouvanziam94a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,YDNAGTNL*# SEQUENCE: YDNAGTNL*# ...# >MUS1176F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P. falciparum CS (333-342)# ANCHOR POSITIONS:# REFERENCES: blum-tirouvanziam94a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,KYLKKIKNSL*# SEQUENCE: KYLKKIKNSL*# ...# >MUS11770# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: P. falciparum CS (334-342)# ANCHOR POSITIONS:# REFERENCES: blum-tirouvanziam94a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,YLKKIKNSL*# SEQUENCE: YLKKIKNSL*# ...# >RAT21771# MHC MOLECULE: I-?, CLASS-2, (RAT)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Toxoplasma gondii P30 (SAG-1) (48-67)# DB REFERENCE: SWISS: (P30_TOXGO)# & PIR2: (A46478,A30527)# REFERENCES: godard94a# COMMENT: Fischer rat# SUMMARY: I-?,actyesu,bindyesu,SDPPLVANQVVTCPDKKSTA*# SEQUENCE: SDPPLVANQVVTCPDKKSTA*# ...# >RAT21772# MHC MOLECULE: I-?, CLASS-2, (RAT)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Toxoplasma gondii P30 (SAG-1) (238-256)# DB REFERENCE: SWISS: (P30_TOXGO)# & PIR2: (A30527)# REFERENCES: godard94a# COMMENT: Fischer rat# SUMMARY: I-?,actyesu,bindyesu,CNEKSFKDILPKLTENPWQ*# SEQUENCE: CNEKSFKDILPKLTENPWQ*# ...# >HUM21773# MHC MOLECULE: HLA-DQ?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (140-152)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1EL,GAG_HV1B5,GAG_HV1J3,GAG_HV1ND,# & GAG_HV1A2,GAG_HV1C4,GAG_HV1N5,GAG_HV1W2,GAG_HV1H2,# & GAG_SIVCZ,GAG_HV1RH,GAG_HV1Z2,GAG_HV1JR,GAG_HV1PV,# & GAG_HV1MN,GAG_HV1Y2,GAG_HV1BR)# & PIR1: (FOVWVL,FOLJSI,FOLJND,FOVWH3,FOVWH4,FOVWLV,A38068,FOVWA2,# & A44001)# & PIR2: (S52929,S54377)# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-DQ?,actyesu,bindyesu,GQMVHQAISPRTL*# SEQUENCE: GQMVHQAISPRTL*# ...# >HUM11774# MHC MOLECULE: HLA-Cw3, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (145-150)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1ND,GAG_HV1B1,CTPT_CRIGR,GAG_HV1MN,# & GAG_HV1Z2,GAG_HV1N5,GAG_HV1Y2,GAG_HV1MA,GAG_HV1JR,# & GAG_HV1PV,GAG_HV1BR,GAG_HV1H2,CTPT_CRIGR,GAG_HV1W2,# & GAG_HV1RH,GAG_SIVCZ,GAG_HV1C4,GAG_HV1A2,GAG_HV1J3,# & GAG_HV1EL)# & PIR1: (FOLJSI,FOVWH4,FOVWH3,FOVWLV,A44001,FOVWA2,FOLJND,FOVWVL,# & A38068)# & PIR2: (S52929,S44385,S54377)# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-Cw3,actyesu,bindyesu,QAISPR*# SEQUENCE: QAISPR*# ...# >HUM11775# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: reference/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (169-184)# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1H2,GAG_HV1W2,GAG_HV1U4,GAG_HV1N5,# & GAG_HV1BR,GAG_HV1MA,GAG_HV1B5,GAG_HV1MN,GAG_HV1Z2,# & GAG_HV1J3,GAG_HV1EL,GAG_HV1B1,GAG_HV1JR,GAG_HV1A2,# & GAG_HV1Y2,GAG_HV1PV,GAG_HV1ND)# & PIR1: (FOVWH3,FOVWLV,A38068,FOVWA2,FOVWVL,A44001,FOLJND)# & PIR2: (S54377)# & PIR3: (S33979)# REFERENCES: buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,IPMFSALSEGATPQDL*# SEQUENCE: IPMFSALSEGATPQDL*# ...# >HUM11776# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (181-189)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1OY,GAG_HV1B1,GAG_HV1EL,GAG_HV1H2,# & GAG_HV1C4,GAG_HV1N5,GAG_HV1B5,GAG_HV1MN,GAG_HV1JR,# & GAG_HV1A2,GAG_HV1ND,GAG_HV1Y2,GAG_HV1J3,GAG_HV1Z2,# & GAG_HV1W2,GAG_HV1RH,GAG_HV1BR)# & PIR1: (FOVWH3,A44001,A38068,FOVWA2,FOVWH4,FOVWVL,FOVWLV,# & FOLJND)# & PIR2: (S49086,S54377)# & PIR3: (S33979)# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,PQDLNTMLN*# SEQUENCE: PQDLNTMLN*# ...# >HUM11777# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (181-193)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1W2,GAG_HV1RH,GAG_HV1ND,GAG_HV1B5,# & GAG_HV1N5,GAG_HV1C4,GAG_HV1Y2,GAG_HV1OY,GAG_HV1EL,# & GAG_HV1H2,GAG_HV1A2,GAG_HV1JR,GAG_HV1MN,GAG_HV1J3,# & GAG_HV1Z2,GAG_HV1B1,GAG_HV1PV)# & PIR1: (FOVWH3,A38068,FOVWLV,FOLJND,FOVWH4,FOVWA2,FOVWVL,# & A44001)# & PIR2: (S49086,S54377)# & PIR3: (S33979)# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,PQDLNTMLNTVGG*# SEQUENCE: PQDLNTMLNTVGG*# ...# >HUM11778# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (183-197)# ANCHOR POSITIONS:# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,DLNTMNLNTVGGHQAA*# SEQUENCE: DLNTMNLNTVGGHQAA*# ...# >HUM11779# MHC MOLECULE: HLA-B52, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (193-214)# ANCHOR POSITIONS:# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-B52,actyesu,bindyesu,GHQAAMEMLKITINEEAAEWDR*# SEQUENCE: GHQAAMEMLKITINEEAAEWDR*# ...# >HUM1177A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (253-274)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1W2,GAG_HV1B1,GAG_HV1B5,GAG_HV1Y2,# & GAG_HV1JR,GAG_HV1OY,GAG_HV1Z2,GAG_HV1A2,GAG_HV1J3,# & GAG_HV1H2,GAG_HV1MN,GAG_HV1N5,GAG_HV1BR,GAG_HV1RH,# & GAG_HV1ND)# & PIR1: (A44001,FOVWLV,A38068,FOVWA2,FOVWVL,FOLJND,FOVWH3)# & PIR2: (S60698,S54377,S60708,S60703,S60699,S60704,S60702,# & S60697)# & PIR3: (S33979)# REFERENCES: buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,NPPIPVGEIYKRWIILGLNKIV*# SEQUENCE: NPPIPVGEIYKRWIILGLNKIV*# ...# >HUM1177B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (256-270)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1Z2,GAG_HV1A2,GAG_HV1H2,GAG_HV1MN,# & GAG_HV1J3,GAG_HV1Y2,GAG_HV1B5,GAG_HV1JR,GAG_HV1OY,# & GAG_HV1ND,GAG_HV1BR,GAG_HV1PV,GAG_HV1W2,GAG_HV1RH,# & GAG_HV1B1)# & PIR1: (A44001,FOVWA2,A38068,FOLJND,FOVWH3,FOVWLV,FOVWVL)# & PIR2: (S60704,S60699,S60698,S54377,S60697,S60708,S60703,# & S60702)# & PIR3: (S33979)# REFERENCES: buseyne93a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,IPVGEIYKRWIILGL*# SEQUENCE: IPVGEIYKRWIILGL*# ...# >HUM1177C# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (263-277)# DB REFERENCE: SWISS: (GAG_HV1EL)# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesu,KRWIIVGLNKIVRMY*# SEQUENCE: KRWIIVGLNKIVRMY*# ...# >HUM1177D# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (263-278)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1OY,GAG_HV1JR,GAG_HV1Y2,GAG_HV1C4,# & GAG_HV1PV,GAG_HV1B5,GAG_HV1J3,GAG_HV1H2,GAG_HV1N5,# & GAG_HV1B1,GAG_HV1Z2,GAG_HV1A2,GAG_HV1MN,GAG_HV1W2,# & GAG_HV1MA,GAG_HV1BR,GAG_HV1RH)# & PIR1: (FOVWLV,FOVWVL,FOVWA2,A44001,FOVWH4,A38068,FOVWH3,# & FOLJND)# & PIR2: (S60702,S54377,S60703,S60698,S60697,S60708,S60699,# & S60704)# & PIR3: (S33979)# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRWIILGLNKIVRMYS*# SEQUENCE: KRWIILGLNKIVRMYS*# ...# >HUM1177E# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (263-284)# ANCHOR POSITIONS:# REFERENCES: buseyne93a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,KRWIILGNKIVRMYSPTSILD*# SEQUENCE: KRWIILGNKIVRMYSPTSILD*# ...# >HUM2177F# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P21 ras homologue# ANCHOR POSITIONS:# REFERENCES: gedde-dahl92a# COMMENT:# SUMMARY: HLA-DQ8,actyesu,bindyesu,CLLDILDTAGLEEYSAMRD*# SEQUENCE: CLLDILDTAGLEEYSAMRD*# ...# >HUM21780# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P21 ras (55-64) homologue# ANCHOR POSITIONS:# REFERENCES: gedde-dahl92a# COMMENT:# SUMMARY: HLA-DR8,actyesu,bindyesu,ILDTAGLEEY*# SEQUENCE: ILDTAGLEEY*# ...# >HUM21781# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P21 ras (57-68) homologue# ANCHOR POSITIONS:# REFERENCES: gedde-dahl92a# COMMENT:# SUMMARY: HLA-DR8,actyesu,bindyesu,DTAGLEEYSAMRD*# SEQUENCE: DTAGLEEYSAMRD*# ...# >MUS21782# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Staphylococcus aureus nuclease NASE (86-100)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: nikcevich94a# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesu,GRGLAYIYADGKMVN*# SEQUENCE: GRGLAYIYADGKMVN*# ...# >MUS21783# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Staphylococcus aureus nuclease NASE (111-130)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: nikcevich94a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesl,VAYVYKPNNTHEQHLRKSEA*# SEQUENCE: VAYVYKPNNTHEQHLRKSEA*# ...# >MUS21784# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Staphylococcus aureus nuclease NASE (116-135)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: nikcevich94a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesl,KPNNTHEQHLRKSEAQAKKE*# SEQUENCE: KPNNTHEQHLRKSEAQAKKE*# ...# >HUM21785# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: in vitro assembly# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ii15# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: hedley94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KMRMATPLLMQALPM*# SEQUENCE: KMRMATPLLMQALPM*# ...# >HUM21786# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: in vitro assembly# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ii24# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: hedley94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPM*# ...# >HUM21787# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: in vitro assembly# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgKappa# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: hedley94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,KHKVYACEVTHQGLS*# SEQUENCE: KHKVYACEVTHQGLS*# ...# >HUM21788# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: in vitro assembly# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B ApoB# ANCHOR POSITIONS:# REFERENCES: hedley94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,IPDNLFLKSDGRIKYTLNK*# SEQUENCE: IPDNLFLKSDGRIKYTLNK*# ...# >HUM21789# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: in vitro assembly# ACTIVITY: ?# BINDING: yes, ?# SOURCE: bovine fetuin# DB REFERENCE: SWISS: (A2HS_SHEEP,A2HS_BOVIN,A2HS_BOVIN,A2HS_SHEEP)# & PIR2: (S22394,A35714)# REFERENCES: sinigaglia94a,hedley94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YKHTLNQIDSVKVWPRRP*# SEQUENCE: YKHTLNQIDSVKVWPRRP*# ...# >HUM2178A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: in vitro assembly# ACTIVITY: ?# BINDING: yes, ?# SOURCE: A2-like protein# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I61857,I61902,I38443,I37542,I84448,I38442)# REFERENCES: hedley94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VGSDWRFLRGYHQYAYDG*# SEQUENCE: VGSDWRFLRGYHQYAYDG*# ...# >HUM1178B# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CMV transmembrane glycoprotein# ANCHOR POSITIONS:# REFERENCES: harris93d# COMMENT: binding to either HLA-A3, HLA-B18 or HLA-B51# SUMMARY: HLA-?,actunkn,bindyesu,SEYRVKEYK*# SEQUENCE: SEYRVKEYK*# ...# >HUM1178C# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IL-1 beta# DB REFERENCE: SWISS: (IL1B_MACNE,IL1B_CERTO,IL1B_MACMU,IL1B_HUMAN)# & PIR1: (ICHU1B)# REFERENCES: harris93d# COMMENT: binding to either HLA-A3, HLA-B18 or HLA-B51# SUMMARY: HLA-?,actunkn,bindyesu,SVDPKNYPK*# SEQUENCE: SVDPKNYPK*# ...# >HUM1178D# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93d# COMMENT: binding to either HLA-A3, HLA-B18 or HLA-B51# SUMMARY: HLA-?,actunkn,bindyesu,ALYGVAA*# SEQUENCE: ALYGVAA*# ...# >HUM1178E# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93d# COMMENT: binding to either HLA-A3, HLA-B18 or HLA-B51# SUMMARY: HLA-?,actunkn,bindyesu,KVYPSXAS*# SEQUENCE: KVYPSXAS*# ...# >HUM1178F# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris93d# COMMENT: binding to either HLA-A3, HLA-B18 or HLA-B51# SUMMARY: HLA-?,actunkn,bindyesu,XIXKVGNQK*# SEQUENCE: XIXKVGNQK*# ...# >HUM11790# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV EBNA4 (101-115)# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# & PIR2: (S27921)# REFERENCES: gavioli93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,NPTQAPVIQLVHAVY*# SEQUENCE: NPTQAPVIQLVHAVY*# ...# >HUM11791# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBV EBNA4 (396-410)# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: gavioli93a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesu,GRPAVFDRKSDAKST*# SEQUENCE: GRPAVFDRKSDAKST*# ...# >HUM11792# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV EBNA4 (411-425)# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: gavioli93a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,KKCRAIVTDFSVIKA*# SEQUENCE: KKCRAIVTDFSVIKA*# ...# >HUM11793# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBV EBNA4 (416-429)# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: gavioli93a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesu,IVTDFSVIKAIEEE*# SEQUENCE: IVTDFSVIKAIEEE*# ...# >HUM11794# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Drosofila protooncogene DRAF-1# DB REFERENCE: SWISS: (KRAF_DROME,KRAF_DROME)# & PIR1: (TVFFDF)# REFERENCES: frumento93a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,ERLNSQDQQEDSSLVE*# SEQUENCE: ERLNSQDQQEDSSLVE*# ...# >HUM21795# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Proteolipid protein PLP (40-60)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_RABIT,MYPR_CANFA,MYPR_HUMAN,# & MYPR_HUMAN)# & PIR1: (MPBOPL,S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: pelfrey93a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,TGTEKLIETYFSKNYQDYEYL*# SEQUENCE: TGTEKLIETYFSKNYQDYEYL*# ...# >HUM21796# MHC MOLECULE: HLA-DR6, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Proteolipid protein PLP (40-60)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_BOVIN,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (MPRTPL,MPHUPL,S34792,MPBOPL)# & PIR2: (A43548)# REFERENCES: pelfrey93a# COMMENT:# SUMMARY: HLA-DR6,actyesu,bindyesu,TGTEKLIETYFSKNYQDYEYL*# SEQUENCE: TGTEKLIETYFSKNYQDYEYL*# ...# >HUM21797# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Proteolipid protein PLP (89-106)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT,# & MYPR_BOVIN)# & PIR1: (MPBOPL,MPRTPL,MPHUPL,S34792)# & PIR2: (A43548)# REFERENCES: pelfrey94a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,GFYTTGAVRQIFGDYKTT*# SEQUENCE: GFYTTGAVRQIFGDYKTT*# ...# >HUM21798# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Proteolipid protein PLP (89-106)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_BOVIN,MYPR_RABIT,# & MYPR_CANFA)# & PIR1: (MPRTPL,S34792,MPBOPL,MPHUPL)# & PIR2: (A43548)# REFERENCES: pelfrey94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,GFYTTGAVRQIFGDYKTT*# SEQUENCE: GFYTTGAVRQIFGDYKTT*# ...# >HUM21799# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Proteolipid protein PLP (89-106)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_HUMAN,MYPR_RABIT,MYPR_CANFA,# & MYPR_HUMAN)# & PIR1: (MPHUPL,S34792,MPRTPL,MPBOPL)# & PIR2: (A43548)# REFERENCES: pelfrey94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,GFYTTGAVRQIFGDYKTT*# SEQUENCE: GFYTTGAVRQIFGDYKTT*# ...# >HUM2179A# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Proteolipid protein PLP (89-106)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,# & MYPR_CANFA)# & PIR1: (MPBOPL,MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: pelfrey94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GFYTTGAVRQIFGDYKTT*# SEQUENCE: GFYTTGAVRQIFGDYKTT*# ...# >HUM2179B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: Proteolipid protein PLP (40-60)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_BOVIN,MYPR_RABIT,MYPR_HUMAN,# & MYPR_CANFA)# & PIR1: (S34792,MPBOPL,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: pelfrey94a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,TGTEKLIETYFSKNYQDYEYL*# SEQUENCE: TGTEKLIETYFSKNYQDYEYL*# ...# >HUM2179C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: Proteolipid protein PLP (172-191)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT)# & PIR1: (MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: pelfrey94a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,PVYIYFNTWTTCQSIAFPS*# SEQUENCE: PVYIYFNTWTTCQSIAFPS*# ...# >HUM2179D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: Proteolipid protein PLP (181-200)# ANCHOR POSITIONS:# REFERENCES: pelfrey94a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,TTCQSIAFPSKTSASIGSCL*# SEQUENCE: TTCQSIAFPSKTSASIGSCL*# ...# >HUM2179E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: Proteolipid protein PLP (31-50)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_BOVIN,MYPR_HUMAN,# & MYPR_CANFA)# & PIR1: (MPHUPL,S34792,MPRTPL)# & PIR2: (A43548)# REFERENCES: pelfrey94a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,FCGCGHEALTGTEKLIETYF*# SEQUENCE: FCGCGHEALTGTEKLIETYF*# ...# >MUS1179F# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: direct binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV oncogene E6 (37-45)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: feltkamp93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,CVYCKQQLL*# SEQUENCE: CVYCKQQLL*# ...# >MUS117A0# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: direct binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV oncogene E6 (72-80)# DB REFERENCE: SWISS: (VE6_HPV35,VE6_HPV16)# & PIR1: (W6WL35,W6WLHS)# REFERENCES: feltkamp93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,KCLKFYSKI*# SEQUENCE: KCLKFYSKI*# ...# >MUS117A1# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: direct binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV oncogene E6 (37-45)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: feltkamp93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,CVYCKQQLL*# SEQUENCE: CVYCKQQLL*# ...# >MUS117A2# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: direct binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV oncogene E6 (109-117)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: feltkamp93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,RCINCQKPL*# SEQUENCE: RCINCQKPL*# ...# >MUS117A3# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: direct binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human papilloma virus HPV oncogene E7 (57-65)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: feltkamp93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,FCCKCDSTL*# SEQUENCE: FCCKCDSTL*# ...# >HUM217A4# MHC MOLECULE: HLA-DQ?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hAChR (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# REFERENCES: serra93a# COMMENT:# SUMMARY: HLA-DQ?,actyesu,bindyesu,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >HUM117A5# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./binding as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu A NP (383-391)# DB REFERENCE: SWISS: (VNUC_IARUD,VNUC_IATKO,VNUC_IAMEA,VNUC_IAME6,VNUC_IAZJ1,# & VNUC_IAME5,VNUC_IABRA,VNUC_IAZ29,VNUC_IAS31,VNUC_IAS06,# & VNUC_IAZI1,VNUC_IAGD7,VNUC_IAZON,VNUC_IADU2,VNUC_IAPAR,# & VNUC_IANEJ,VNUC_IAFOW,VNUC_IATRS,VNUC_IAMAA,VNUC_IAZW1,# & VNUC_IAPUE,VNUC_IABUD,VNUC_IACAL,VNUC_IAZW2,VNUC_IADM2,# & VNUC_IAWIL,VNUC_IAZI3,VNUC_IAWIS,VNUC_IACKP,VNUC_IAMEG,# & VNUC_IADE2,VNUC_IAZJ2,VNUC_IAZJA,VNUC_IADBE,VNUC_IAFOM,# & VNUC_IAHO2,VNUC_IATRT,VNUC_IAVI6,VNUC_IANT6,VNUC_IAMEC,# & VNUC_IAME3,VNUC_IAZJ3,VNUC_IAZOH,VNUC_IAMAN,VNUC_IAZMA,# & VNUC_IAHLO,VNUC_IADE1,VNUC_IAUDO,VNUC_IAHTE,VNUC_IAHIC,# & VNUC_IAZ41,VNUC_IAZH1,VNUC_IAZH4,VNUC_IAHO1,VNUC_IALEN,# & VNUC_IATKN,VNUC_IAANA,VNUC_IAKIE,VNUC_IASH2,VNUC_IAS11,# & VNUC_IAMEB,VNUC_IAEN5,VNUC_IAUSS,VNUC_IAHMI,VNUC_IATX7,# & VNUC_IAZH3,VNUC_IAANN,VNUC_IAB37,VNUC_IAGRE,VNUC_IASE0,# & VNUC_IADNZ,VNUC_IAZI2,VNUC_IAFPR,VNUC_IASIN,VNUC_IAMEF,# & VNUC_IAANN,VNUC_IAZDA,VNUC_IAME4,VNUC_IAOHI,VNUC_IAB39,# & VNUC_IACKG,VNUC_IATEI,VNUC_IAMIN,VNUC_IAZTE,VNUC_IAMEE,# & VNUC_IAWHP,VNUC_IAFPD,VNUC_IAWHN,VNUC_IADMA,VNUC_IADAU)# & PIR1: (A60028,VHIVX6,VHIVM1,VHIVN7,VHIVA7,VHIVC1,VHIVA6,VHIVN1,# & VHIVX4,VHIV34,VHIVX1,VHIVX3,VHIVN3,VHIVX2,VHIVN8,VHIVAK,# & VHIVA3,VHIV8H,VHIVN9,VHIVXL,VHIVX5,VHIV61,VHIVN5,# & VHIV68)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS: 2,9# REFERENCES: colbert93a,villadangos95a,fruci95a# COMMENT:# SUMMARY: HLA-B27,actyesm,bindyesu,SRYWAIRTR*# SEQUENCE: SRYWAIRTR*# ...# >HUM117A6# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu A NP (383-391) homologue# DB REFERENCE: SWISS: (VNUC_IAZCA,VNUC_IAHPR,VNUC_IADCZ)# & PIR1: (VHIVN4)# REFERENCES: colbert93a# COMMENT:# SUMMARY: HLA-B27,actyesm,bindyesu,SRYWAIRTK*# SEQUENCE: SRYWAIRTK*# ...# >MUS117A7# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: NP (366-379) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,YSNENMDAMESSTL*# SEQUENCE: YSNENMDAMESSTL*# ...# >MUS117A8# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: NP (364-379) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,YIASNENMDAMESSTL*# SEQUENCE: YIASNENMDAMESSTL*# ...# >MUS117A9# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, high# SOURCE: NP (366-374) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,YSNENMDAM*# SEQUENCE: YSNENMDAM*# ...# >MUS117AA# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: NP (366-374) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,ASNENMDAA*# SEQUENCE: ASNENMDAA*# ...# >MUS117AB# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: NP (366-374) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,YSNEAMDAM*# SEQUENCE: YSNEAMDAM*# ...# >MUS117AC# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: NP (366-374) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,YSNENMDAA*# SEQUENCE: YSNENMDAA*# ...# >MUS117AD# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: NP (366-374) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,ALNENMDAM*# SEQUENCE: ALNENMDAM*# ...# >MUS117AE# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: NP (366-374) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,YSNQNYTAM*# SEQUENCE: YSNQNYTAM*# ...# >MUS117AF# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: PA (346-354) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,YDIENEEKI*# SEQUENCE: YDIENEEKI*# ...# >MUS117B0# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: PA (515-523)# DB REFERENCE: SWISS: (RRP2_IAVI7,RRP2_IAZH2,RRP2_IAHTE,RRP2_IAGU2,RRP2_IALE1,# & RRP2_IAPUE,RRP2_IAWIL,RRP2_IAPI0,RRP2_IANT6,RRP2_IADH2,# & RRP2_IAHLO,RRP2_IAZTF,RRP2_IASIN,RRP2_IAZH3,RRP2_IARUD,# & RRP2_IAANN,RRP2_IAFPR,RRP2_IATKM,RRP2_IAKOR,RRP2_IALE2,# & RRP2_IAZI1)# & PIR1: (P2IV68,P2IV61,P2IVWS,P2IV34,C60008)# & PIR2: (S07418)# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,TDVVNFVSM*# SEQUENCE: TDVVNFVSM*# ...# >MUS117B1# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: NP (55-63)# DB REFERENCE: SWISS: (VNUC_IAME6,VNUC_IAMEE,VNUC_IAME4,VNUC_IANT6,VNUC_IAPUE,# & VNUC_IAWIL,VNUC_IAME3,VNUC_IAEN5,VNUC_IATX7,VNUC_IAANN,# & VNUC_IAUSS,VNUC_IASIN,VNUC_IAMEF,VNUC_IAANN,VNUC_IAZCA,# & VNUC_IAB39,VNUC_IAOHI,VNUC_IACAL,VNUC_IAMEG,VNUC_IAZDA,# & VNUC_IAVI6,VNUC_IAS31,VNUC_IABRA,VNUC_IAME5,VNUC_IAMEA,# & VNUC_IAFOW,VNUC_IAMEC,VNUC_IAFOM,VNUC_IAHO2,VNUC_IAZH1,# & VNUC_IAHO1,VNUC_IAUDO,VNUC_IAHIC,VNUC_IAKIE,VNUC_IALEN,# & VNUC_IAMEB)# & PIR1: (VHIV34,VHIVX4,VHIVX6,VHIVX3,VHIVN7,VHIVX2,VHIV61,VHIVXL,# & VHIVX5,VHIVN5,VHIV68,VHIV8H,VHIVA7,VHIVAK)# & PIR2: (B36754)# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,RLIQNSLTI*# SEQUENCE: RLIQNSLTI*# ...# >MUS117B2# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: NP (55-63) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,RSIQNSLTI*# SEQUENCE: RSIQNSLTI*# ...# >MUS117B3# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, ?# SOURCE: NP (55-63) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,RLNQNSLTI*# SEQUENCE: RLNQNSLTI*# ...# >MUS117B4# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, ?# SOURCE: NP (55-63) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,RLIENSLTI*# SEQUENCE: RLIENSLTI*# ...# >MUS117B5# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: NP (55-63) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,RLIQNMLTI*# SEQUENCE: RLIQNMLTI*# ...# >MUS117B6# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag (390-398)# DB REFERENCE: SWISS: (GAG_HV1A2)# & PIR1: (FOVWA2)# & PIR3: (S33979)# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,SQVTNPANI*# SEQUENCE: SQVTNPANI*# ...# >MUS117B7# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag (390-398) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,SSVTNPANI*# SEQUENCE: SSVTNPANI*# ...# >MUS117B8# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag (390-398) homologue# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,SLVTNPANI*# SEQUENCE: SLVTNPANI*# ...# >MUS117B9# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, high# SOURCE: MP (58-66)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IALE1,VMT1_IABAN,VMT1_IAMAN,VMT1_IAZI1,# & VMT1_IAFOW,VMT1_IAUSS,VMT1_IAPUE,VMT1_IAANN,VMT1_IAWIL,# & VMT1_IACKB,VMT1_IAUDO)# & PIR1: (MFIV1K,MFIV61,MFIV1M,JN0392,MFIV,MFIVC,MFIVWS)# & PIR2: (S04056,S14616,S04050,S04058,S04054,S04052,S07429)# REFERENCES: elvin93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM117BA# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA Bw53 (207-215)# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,YPAEITLW*# SEQUENCE: YPAEITLW*# ...# >HUM117BB# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: stabilization of class I molecules# ACTIVITY: ?# BINDING: yes, ?# SOURCE: JE 11 artificial peptide# ANCHOR POSITIONS:# REFERENCES: elvin93a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VPLRPMRNV*# SEQUENCE: VPLRPMRNV*# ...# >HUM117BC# MHC MOLECULE: HLA-A26, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1EL,POL_HV1RH,POL_HV1B5,POL_HV1MA,# & POL_HV1PV,POL_HV1N5,POL_HV1ND,POL_HV1H2,POL_HV1MN,# & POL_HV1JR,POL_HV1Y2,POL_HV1Z2,POL_HV1B1,POL_HV1OY)# & PIR1: (GNVWVL,GNVWLV,GNLJND,GNVWH3,B44001)# & PIR2: (B47175,S54378)# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A26,actunkn,bindyesu,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM117BD# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM117BE# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM117BF# MHC MOLECULE: HLA-A26, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A26,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM117C0# MHC MOLECULE: HLA-A28, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A28,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM117C1# MHC MOLECULE: HLA-A29, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM117C2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM117C3# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM117C4# MHC MOLECULE: HLA-A26, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A26,actunkn,bindyesl,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM117C5# MHC MOLECULE: HLA-A28, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A28,actunkn,bindyesl,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM117C6# MHC MOLECULE: HLA-A29, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesl,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM117C7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM117C8# MHC MOLECULE: HLA-A26, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A26,actunkn,bindyesu,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM117C9# MHC MOLECULE: HLA-A28, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A28,actunkn,bindyesu,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM117CA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RLSELEAALQRA*# SEQUENCE: RLSELEAALQRA*# ...# >HUM117CB# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: direct binding/refolding# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (334-342)# DB REFERENCE: SWISS: (P53_CERAE,P53_RAT,P53_FELCA,P53_RAT,P53_HUMAN,P53_CERAE,# & P53_HUMAN,P53_FELCA)# & PIR1: (DNHU53)# & PIR2: (S02192,S06594,JC6193)# REFERENCES: fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,GRERFEMFR*# SEQUENCE: GRERFEMFR*# ...# >HUM117CC# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: direct binding/refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (362-370)# DB REFERENCE: SWISS: (P53_SHEEP,P53_FELCA,P53_HUMAN,P53_HUMAN,P53_FELCA,# & P53_BOVIN,P53_CERAE,P53_SHEEP,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594,S51648)# REFERENCES: fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,SRAHSSHLK*# SEQUENCE: SRAHSSHLK*# ...# >HUM117CD# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: direct binding/refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (378-386)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,SRHKKLMFK*# SEQUENCE: SRHKKLMFK*# ...# >HUM117CE# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: direct binding/refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (173-181)# DB REFERENCE: SWISS: (P53_CANFA,P53_RAT,P53_RAT,P53_CRIGR,P53_CERAE,P53_CERAE,# & P53_BOVIN,P53_MESAU,P53_HUMAN,P53_HUMAN,P53_MOUSE,# & P53_CHICK,P53_CHICK,P53_MOUSE,P53_FELCA,P53_MESAU,# & P53_FELCA)# & PIR1: (DNMS53,DNHU53)# & PIR2: (JC6176,S38824,I46226,S51648,S02192,S06594,S02193,JH0633,# & JC6193)# REFERENCES: fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,VRRCPHHER*# SEQUENCE: VRRCPHHER*# ...# >HUM117CF# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: direct binding/refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (334-342)# DB REFERENCE: SWISS: (P53_FELCA,P53_HUMAN,P53_HUMAN,P53_FELCA,P53_CERAE,# & P53_RAT,P53_RAT,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594,JC6193,S02192)# REFERENCES: fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,GRERFEMFR*# SEQUENCE: GRERFEMFR*# ...# >HUM117D0# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: direct binding/refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (362-370)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN,P53_SHEEP,P53_FELCA,P53_CERAE,# & P53_BOVIN,P53_FELCA,P53_CERAE,P53_SHEEP)# & PIR1: (DNHU53)# & PIR2: (S51648,S06594)# REFERENCES: fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,SRAHSSHLK*# SEQUENCE: SRAHSSHLK*# ...# >HUM117D1# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: direct binding/refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P53 (378-386)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: fruci93a,fruci93b# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,SRHKKLMFK*# SEQUENCE: SRHKKLMFK*# ...# >HUM117D2# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: direct binding/refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (272-280)# DB REFERENCE: SWISS: (P53_RAT,P53_FELCA,P53_CERAE,P53_CHICK,P53_FELCA,# & P53_SHEEP,P53_CANFA,P53_XENLA,P53_HUMAN,P53_MOUSE,# & P53_MOUSE,P53_CHICK,P53_BOVIN,P53_SALIR,P53_CERAE,# & P53_RAT,P53_HUMAN,P53_SHEEP,P53_XENLA,P53_SALIR)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S06594,S02193,A29376,S02192,JC6193,JH0631,S38824,# & S51648)# REFERENCES: fruci93a,fruci93b,# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,VRVCACPGR*# SEQUENCE: VRVCACPGR*# ...# >MUS217D3# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a,alexander94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesh,HSLGKWLGHPDKF*# SEQUENCE: HSLGKWLGHPDKF*# ...# >MUS217D4# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLAKWLGHPDKF*# SEQUENCE: HSLAKWLGHPDKF*# ...# >MUS217D5# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesn,bindyesu,HSLKKWLGHPDKF*# SEQUENCE: HSLKKWLGHPDKF*# ...# >MUS217D6# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesn,bindyesm,HSLFKWLGHPDKF*# SEQUENCE: HSLFKWLGHPDKF*# ...# >MUS217D7# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesm,HSLGRWLGHPDKF*# SEQUENCE: HSLGRWLGHPDKF*# ...# >MUS217D8# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGAWLGHPDKF*# SEQUENCE: HSLGAWLGHPDKF*# ...# >MUS217D9# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesm,HSLGFWLGHPDKF*# SEQUENCE: HSLGFWLGHPDKF*# ...# >MUS217DA# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKFLGHPDKF*# SEQUENCE: HSLGKFLGHPDKF*# ...# >MUS217DB# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesn,bindyesu,HSLGKALGHPDKF*# SEQUENCE: HSLGKALGHPDKF*# ...# >MUS217DC# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesn,bindyesu,HSLGKKLGHPDKF*# SEQUENCE: HSLGKKLGHPDKF*# ...# >MUS217DD# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWAGHPDKF*# SEQUENCE: HSLGKWAGHPDKF*# ...# >MUS217DE# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWFGHPDKF*# SEQUENCE: HSLGKWFGHPDKF*# ...# >MUS217DF# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesl,HSLGKWKGHPDKF*# SEQUENCE: HSLGKWKGHPDKF*# ...# >MUS217E0# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWLAHPDKF*# SEQUENCE: HSLGKWLAHPDKF*# ...# >MUS217E1# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWLKHPDKF*# SEQUENCE: HSLGKWLKHPDKF*# ...# >MUS217E2# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWLFHPDKF*# SEQUENCE: HSLGKWLFHPDKF*# ...# >MUS217E3# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWLGAPDKF*# SEQUENCE: HSLGKWLGAPDKF*# ...# >MUS217E4# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWLGKPDKF*# SEQUENCE: HSLGKWLGKPDKF*# ...# >MUS217E5# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWLGFPDKF*# SEQUENCE: HSLGKWLGFPDKF*# ...# >MUS217E6# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,HSLGKWLGHADKF*# SEQUENCE: HSLGKWLGHADKF*# ...# >MUS217E7# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesl,HSLGKWLGHKDKF*# SEQUENCE: HSLGKWLGHKDKF*# ...# >MUS217E8# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actyesu,bindyesl,HSLGKWLGHFDKF*# SEQUENCE: HSLGKWLGHFDKF*# ...# >MUS217E9# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,HSLGKYLGHPDKF*# SEQUENCE: HSLGKYLGHPDKF*# ...# >MUS217EA# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,HSLGKRLGHPDKF*# SEQUENCE: HSLGKRLGHPDKF*# ...# >MUS217EB# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,HSLGKLLGHPDKF*# SEQUENCE: HSLGKLLGHPDKF*# ...# >MUS217EC# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,HSLGKSLGHPDKF*# SEQUENCE: HSLGKSLGHPDKF*# ...# >MUS217ED# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as./inhibitory proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PLP (139-151) homologue# ANCHOR POSITIONS:# REFERENCES: franco94a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,HSLGKNLGHPDKF*# SEQUENCE: HSLGKNLGHPDKF*# ...# >MUS217EE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin# DB REFERENCE: SWISS: (HEMA_IAEN7,HEMA_IAME2,HEMA_IAZUK,HEMA_IADU3,HEMA_IAAIC,# & HEMA_IAUDO,HEMA_IAHNM,HEMA_IADH3,HEMA_IAHTE,HEMA_IADHL,# & HEMA_IAHSU,HEMA_IADH6,HEMA_IAZH2,HEMA_IAHFO,HEMA_IAME1,# & HEMA_IAGHK,HEMA_IAME6,HEMA_IADH5,HEMA_IANT6,HEMA_IADH4,# & HEMA_IAVI7,HEMA_IAZCO,HEMA_IADM2,HEMA_IAHRO,HEMA_IAHTO,# & HEMA_IABAN,HEMA_IADH2,HEMA_IAHK7,HEMA_IADHK,HEMA_IAZH3,# & HEMA_IADH7,HEMA_IADA3,HEMA_IAHK6,HEMA_IADHM)# & PIR1: (HMIVHA,HMIVHM,HMIV15,HMIV6,HMIV86,HMIVH,HMIVS3,HMIV21,# & HMIVDU,HMIVE7,HMIVE3,HMIV98,HMIVS2,HMIVET,HMIV33,HMIVE9,# & HMIVE6,HMIV89,HMIV80,HMIVEE,HMIVV,HMIVE5)# & PIR2: (JQ1154,JQ1156,A92979,JQ1153,JQ1155)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,ALNNRFQIKGVEL*# SEQUENCE: ALNNRFQIKGVEL*# ...# >MUS217EF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin# DB REFERENCE: SWISS: (HEMA_IADHL,HEMA_IAME1,HEMA_IAME6,HEMA_IADH2,HEMA_IADHK,# & HEMA_IAHK7,HEMA_IAHK6,HEMA_IADH1,HEMA_IAEN7,HEMA_IAZUK,# & HEMA_IADU3,HEMA_IADH3,HEMA_IAHNM,HEMA_IAUDO,HEMA_IADHM,# & HEMA_IAZH3,HEMA_IADA3,HEMA_IADH7,HEMA_IAHTO,HEMA_IADM2,# & HEMA_IAVI7,HEMA_IAZCO,HEMA_IAHSU,HEMA_IAHFO,HEMA_IADH6,# & HEMA_IAZH2,HEMA_IANT6,HEMA_IADH4,HEMA_IAGHK,HEMA_IADH5,# & HEMA_IAHRO,HEMA_IAHTE,HEMA_IAAIC,HEMA_IAME2)# & PIR1: (HMIVS2,HMIV33,HMIV77,HMIVE9,HMIV98,HMIVE6,HMIVE3,HMIVE5,# & HMIVV,HMIVEE,HMIV80,HMIV86,HMIV21,HMIVDU,HMIVET,HMIV89,# & HMIVHM,HMIVE7,HMIVHA,HMIVS3,HMIVH,HMIV6,HMIV15)# & PIR2: (JQ1155,JQ1156,JQ1153,JQ1154)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,NNRFQIKGVELKS*# SEQUENCE: NNRFQIKGVELKS*# ...# >MUS217F0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin# DB REFERENCE: SWISS: (HEMA_IAAIC,HEMA_IAHTE,HEMA_IAZH2,HEMA_IAHFO,HEMA_IADH5,# & HEMA_IAUDO,HEMA_IADH3,HEMA_IADHL,HEMA_IADH4,HEMA_IAVI7,# & HEMA_IADM2,HEMA_IAHTO,HEMA_IAGHK,HEMA_IADH6,HEMA_IAHRO,# & HEMA_IADH7,HEMA_IADA3,HEMA_IAEN7,HEMA_IADHM,HEMA_IAHK7,# & HEMA_IADHK,HEMA_IADH2,HEMA_IAME1,HEMA_IADH1,HEMA_IAZUK,# & HEMA_IADU3,HEMA_IAHSU,HEMA_IAHK6,HEMA_IAME2,HEMA_IAHNM,# & HEMA_IAME6,HEMA_IAZCO,HEMA_IAZH3,HEMA_IANT6)# & PIR1: (HMIVS3,HMIV89,HMIVE5,HMIVV,HMIVE7,HMIV6,HMIV15,HMIV98,# & HMIVHA,HMIVE3,HMIVET,HMIV86,HMIV21,HMIVDU,HMIV77,HMIVE6,# & HMIVHM,HMIVS2,HMIVH,HMIVE9,HMIV80,HMIVEE,HMIV33)# & PIR2: (JQ1153,JQ1156,JQ1155,JQ1154)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,RFQIKGVELKSGY*# SEQUENCE: RFQIKGVELKSGY*# ...# >MUS217F1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin# DB REFERENCE: SWISS: (HEMA_IAZUK,HEMA_IADU3,HEMA_IAME1,HEMA_IAHK7,HEMA_IAGRE,# & HEMA_IAME6,HEMA_IAMAB,HEMA_IAHSA,HEMA_IAHRO,HEMA_IAHAL,# & HEMA_IADH5,HEMA_IAUDO,HEMA_IAMAA,HEMA_IANT6,HEMA_IAHSU,# & HEMA_IAHMI,HEMA_IAHK6,HEMA_IAAIC,HEMA_IAHNM,HEMA_IABAN,# & HEMA_IABUD,HEMA_IASE2,HEMA_IACKA,HEMA_IATKM,HEMA_IADM2,# & HEMA_IARUD,HEMA_IADCZ,HEMA_IAEN7,HEMA_IAVI7,HEMA_IAHUR,# & HEMA_IAHFO,HEMA_IAHTE)# & PIR1: (HMIVE1,HMIVF6,HMIVE4,HMIVF1,HMIVH,HMIVF9,HMIV21,A46339,# & HMIVE8,HMIVET,HMIVEE,HMIVHA,HMIVF7,HMIVE9,HMIVE6,HMIVE2,# & HMIVDU,HMIV86,HMIVF2,HMIVF8,HMIVV,HMIV6,HMIVE7,HMIVF3,# & HMIVE5)# & PIR2: (A92979,A33157)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,WSYNAELLVALEN*# SEQUENCE: WSYNAELLVALEN*# ...# >MUS217F2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin# DB REFERENCE: SWISS: (HEMA_IAHSU,HEMA_IABAN,HEMA_IAMAB,HEMA_IAME1,HEMA_IAHK6,# & HEMA_IAMAA,HEMA_IASE2,HEMA_IACKA,HEMA_IATKM,HEMA_IAHNM,# & HEMA_IAHMI,HEMA_IAHK7,HEMA_IADU3,HEMA_IAZUK,HEMA_IAHTE,# & HEMA_IAME6,HEMA_IAGRE,HEMA_IAHSA,HEMA_IAHAL,HEMA_IAHRO,# & HEMA_IADH5,HEMA_IAVI7,HEMA_IADCZ,HEMA_IAEN7,HEMA_IAHUR,# & HEMA_IADM2,HEMA_IARUD,HEMA_IAHFO,HEMA_IAUDO,HEMA_IANT6,# & HEMA_IAAIC,HEMA_IABUD)# & PIR1: (HMIVF3,HMIVE9,HMIVF7,HMIVE7,HMIV6,HMIVHA,HMIVEE,HMIVE8,# & HMIVF6,HMIV21,HMIVE6,HMIVF1,HMIVF8,HMIVE4,HMIVDU,HMIVH,# & HMIVF9,HMIVE1,HMIVV,HMIV86,HMIVE5,HMIVET,A46339,HMIVE2,# & HMIVF2)# & PIR2: (A92979,A33157)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,YNAELLVALENQH*# SEQUENCE: YNAELLVALENQH*# ...# >MUS217F3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin# DB REFERENCE: SWISS: (HEMA_IAMAA,HEMA_IACKA,HEMA_IAVI7,HEMA_IAHRO,HEMA_IAHSA,# & HEMA_IAZUK,HEMA_IAEN7,HEMA_IADCZ,HEMA_IADM2,HEMA_IAHFO,# & HEMA_IAAIC,HEMA_IAUDO,HEMA_IAME1,HEMA_IAHK6,HEMA_IAMAB,# & HEMA_IAHUR,HEMA_IABUD,HEMA_IANT6,HEMA_IAGRE,HEMA_IAHK7,# & HEMA_IAME6,HEMA_IASE2,HEMA_IAHMI,HEMA_IATKM,HEMA_IADA3,# & HEMA_IAHNM,HEMA_IADH5,HEMA_IAHTE,HEMA_IAHSU,HEMA_IARUD,# & HEMA_IAHAL,HEMA_IADU3,HEMA_IABAN)# & PIR1: (HMIVE2,HMIVF9,HMIVV,A46339,HMIVF7,HMIV21,HMIVE5,HMIVEE,# & HMIVHA,HMIVE8,HMIVET,HMIVDU,HMIVE7,HMIVE1,HMIVH,HMIV86,# & HMIVF1,HMIV6,HMIVF3,HMIVF2,HMIVF6,HMIVF8,HMIVE4,HMIVE9,# & HMIVE6)# & PIR2: (A92979,A33157)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,AELLVALENQHTI*# SEQUENCE: AELLVALENQHTI*# ...# >MUS217F4# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin (90-106)# DB REFERENCE: SWISS: (HEMA_IAHAL,HEMA_IARUD,HEMA_IAHSU,HEMA_IATKM,HEMA_IAHUR,# & HEMA_IAGRE,HEMA_IAHMI,HEMA_IASE2,HEMA_IAHNM,HEMA_IADH5,# & HEMA_IABUD,HEMA_IANT6,HEMA_IAHRO,HEMA_IADM2,HEMA_IAVI7,# & HEMA_IAEN7,HEMA_IADCZ,HEMA_IAAIC,HEMA_IAUDO,HEMA_IAHFO,# & HEMA_IABAN,HEMA_IAME1,HEMA_IAHK6,HEMA_IADU3,HEMA_IAHTE,# & HEMA_IAHSA,HEMA_IAZUK,HEMA_IAMAB,HEMA_IAMAA,HEMA_IACKA,# & HEMA_IAME6,HEMA_IAHK7)# & PIR1: (HMIVE8,HMIVF6,HMIVE6,HMIVF8,HMIVEE,HMIVE1,HMIVH,HMIVET,# & HMIV86,HMIVE5,HMIVF2,HMIVF7,HMIVE2,A46339,HMIVV,HMIVDU,# & HMIV6,HMIVE7,HMIVF1,HMIVHA,HMIVE9,HMIV21,HMIVE4,HMIVF3,# & HMIVF9)# & PIR2: (A33157,A92979)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,DLWSYNAELLVALENQH*# SEQUENCE: DLWSYNAELLVALENQH*# ...# >MUS217F5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin (170-178)# DB REFERENCE: SWISS: (HEMA_IADH7,HEMA_IAHTO,HEMA_IAVI7,HEMA_IADH1,HEMA_IADM2,# & HEMA_IAHSU,HEMA_IADH4,HEMA_IADHL,HEMA_IADH6,HEMA_IAHTE,# & HEMA_IADU3,HEMA_IAME2,HEMA_IAZUK,HEMA_IAZH3,HEMA_IAME6,# & HEMA_IAZCO,HEMA_IADH2,HEMA_IAME1,HEMA_IAHK6,HEMA_IABAN,# & HEMA_IADHK,HEMA_IAEN7,HEMA_IAAIC,HEMA_IAUDO,HEMA_IAHNM,# & HEMA_IAGHK,HEMA_IANT6,HEMA_IADH5,HEMA_IAZH2,HEMA_IAHRO,# & HEMA_IAHFO,HEMA_IADHM,HEMA_IAHK7,HEMA_IADH3,# & HEMA_IADA3)# & PIR1: (HMIVHM,HMIVE5,HMIVE3,HMIVV,HMIV15,HMIVE9,HMIV89,HMIVH,# & HMIV98,HMIV80,HMIV33,HMIVHA,HMIV86,HMIV21,HMIVS2,HMIVS3,# & HMIV77,HMIV6,HMIVET,HMIVEE,HMIVDU,HMIVE6,HMIVE7)# & PIR2: (JQ1153,JQ1156,JQ1155,A92979,JQ1154)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,RFQIKGVEL*# SEQUENCE: RFQIKGVEL*# ...# >MUS217F6# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin (165-180)# DB REFERENCE: SWISS: (HEMA_IAHRO,HEMA_IANT6,HEMA_IAVI7,HEMA_IADH4,HEMA_IAZH2,# & HEMA_IAME1,HEMA_IAZUK,HEMA_IAME6,HEMA_IADH5,HEMA_IAGHK,# & HEMA_IAEN7,HEMA_IAAIC,HEMA_IAUDO,HEMA_IAME2,HEMA_IAHTE,# & HEMA_IAZH3,HEMA_IAZCO,HEMA_IADH7,HEMA_IAHSU,HEMA_IADHL,# & HEMA_IAHNM,HEMA_IADA3,HEMA_IAHFO,HEMA_IAHK7,HEMA_IADH3,# & HEMA_IADHM,HEMA_IADM2,HEMA_IAHTO,HEMA_IADH6,HEMA_IAHK6,# & HEMA_IADH2,HEMA_IADHK,HEMA_IADU3)# & PIR1: (HMIVE7,HMIVHA,HMIV33,HMIVE6,HMIVEE,HMIV80,HMIVE9,HMIV98,# & HMIV89,HMIVH,HMIVHM,HMIV6,HMIV86,HMIV21,HMIVS3,HMIVE5,# & HMIV15,HMIVS2,HMIVV,HMIVE3,HMIVDU,HMIVET)# & PIR2: (JQ1155,JQ1156,JQ1153,JQ1154)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,EALNNRFQIKGVELKS*# SEQUENCE: EALNNRFQIKGVELKS*# ...# >MUS217F7# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza virus hemagglutinin (96-104)# DB REFERENCE: SWISS: (HEMA_IAHTE,HEMA_IAEN7,HEMA_IAMAA,HEMA_IADH5,HEMA_IAHSA,# & HEMA_IADM2,HEMA_IAME1,HEMA_IATKM,HEMA_IARUD,HEMA_IAZUK,# & HEMA_IAME6,HEMA_IANT6,HEMA_IASE2,HEMA_IAHK6,HEMA_IAHFO,# & HEMA_IADA3,HEMA_IAHAL,HEMA_IACKA,HEMA_IADU3,HEMA_IAMAB,# & HEMA_IAHSU,HEMA_IADCZ,HEMA_IABUD,HEMA_IAGRE,HEMA_IAHUR,# & HEMA_IAAIC,HEMA_IAUDO,HEMA_IAHRO,HEMA_IAVI7,HEMA_IABAN,# & HEMA_IAHNM,HEMA_IAHMI,HEMA_IAHK7)# & PIR1: (HMIVV,HMIVE9,HMIVF2,HMIVF3,HMIVE5,HMIVF8,HMIVDU,HMIVET,# & HMIVF9,HMIVEE,HMIVE4,HMIV21,HMIVE1,HMIVF6,HMIVE6,HMIVE7,# & HMIVE2,A46339,HMIVF1,HMIV6,HMIVH,HMIVF7,HMIVE8,HMIV86,# & HMIVHA)# & PIR2: (A92979,A33157)# & PIR3: (S33703)# REFERENCES: jackson94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AELLVALEN*# SEQUENCE: AELLVALEN*# ...# >HUM117F8# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (761-780)# DB REFERENCE: SWISS: (ENV_HV1SC,ENV_HV1J3,ENV_HV1B8,ENV_HV1BR,ENV_HV1MF,# & ENV_HV1PV,ENV_HV1H2,ENV_HV1Y2,ENV_HV1W1,ENV_HV1KB,# & ENV_HV1H3,ENV_HV1B1)# & PIR1: (H44001,VCLJSC,VCLJH3,VCLJKB,VCLJ3W,VCLJLV,VCLJVL)# & PIR2: (S70425,S21998,S21994,S70421,S21996,S70422)# & PIR3: (S13288,S33985)# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,RSLCLFSYHRLRDLLLIVTR*# SEQUENCE: RSLCLFSYHRLRDLLLIVTR*# ...# >HUM117F9# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (763-780)# DB REFERENCE: SWISS: (ENV_HV1KB,ENV_HV1J3,ENV_HV1SC,ENV_HV1MF,ENV_HV1B1,# & ENV_HV1H3,ENV_HV1BR,ENV_HV1H2,ENV_HV1PV,ENV_HV1Y2,# & ENV_HV1B8,ENV_HV1W1)# & PIR1: (VCLJH3,VCLJLV,VCLJVL,VCLJ3W,VCLJKB,H44001,VCLJSC)# & PIR2: (S21998,S70425,S21994,S70421,S70422,S21996)# & PIR3: (S13288,S33985)# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,LCLFSYHRLRDLLLIVTR*# SEQUENCE: LCLFSYHRLRDLLLIVTR*# ...# >HUM117FA# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (765-780)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1BR,ENV_HV1Y2,ENV_HV1B8,ENV_HV1KB,# & ENV_HV1SC,ENV_HV1MF,ENV_HV1W1,ENV_HV1PV,ENV_HV1H2,# & ENV_HV1J3,ENV_HV1BN,ENV_HV1B1)# & PIR1: (H44001,VCLJBR,VCLJH3,VCLJSC,VCLJLV,VCLJKB,VCLJVL,# & VCLJ3W)# & PIR2: (S70421,S70422,S21994,S21998,S70425,S21996)# & PIR3: (S13288,S33985)# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,LFSYHRLRDLLLIVTR*# SEQUENCE: LFSYHRLRDLLLIVTR*# ...# >HUM117FB# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (767-780)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1W1,ENV_HV1J3,ENV_HV1H2,ENV_HV1BN,# & ENV_HV1B1,ENV_HV1Y2,ENV_HV1MF,ENV_HV1H3,ENV_HV1B8,# & ENV_HV1KB,ENV_HV1SC,ENV_HV1PV)# & PIR1: (VCLJKB,VCLJH3,H44001,VCLJVL,VCLJSC,VCLJ3W,VCLJBR,# & VCLJLV)# & PIR2: (S70421,S70425,S21994,S21998,S21996,S70422)# & PIR3: (S13288,S33985)# REFERENCES: safrit94a,hivdb97a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,SYHRLRDLLLIVTR*# SEQUENCE: SYHRLRDLLLIVTR*# ...# >HUM117FC# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (768-778)# DB REFERENCE: SWISS: (ENV_HV1RH,ENV_HV1B1,ENV_HV1C4,ENV_HV1H2,ENV_HV1BN,# & ENV_HV1KB,ENV_HV1B8,ENV_HV1SC,ENV_HV1MF,ENV_HV1W1,# & ENV_HV1J3,ENV_HV1BR,ENV_HV1H3,ENV_HV1Y2,ENV_HV1W2,# & ENV_HV1PV)# & PIR1: (VCLJLV,VCLJBR,VCLJH4,VCLJVL,VCLJSC,VCLJ3W,VCLJH3,VCLJKB,# & H44001)# & PIR2: (S70422,S70421,S70424,S21992,S70425,S70423,S21996,S21998,# & S21994,S21990)# & PIR3: (S13288,S33985)# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,YHRLRDLLLIV*# SEQUENCE: YHRLRDLLLIV*# ...# >HUM117FD# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (768-777)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B8,ENV_HV1H3,ENV_HV1RH,ENV_HV1BN,# & ENV_HV1C4,ENV_HV1H2,ENV_HV1J3,ENV_HV1BR,ENV_HV1MA,# & ENV_HV1W1,ENV_HV1Y2,ENV_HV1PV,ENV_HV1W2,ENV_HV1B1,# & ENV_HV1KB,ENV_HV1SC)# & PIR1: (VCLJ3W,VCLJBR,VCLJH4,VCLJSC,VCLJLV,H44001,VCLJKB,VCLJH3,# & VCLJVL)# & PIR2: (S21996,S70417,S21990,S70425,S70424,S22002,S70421,S21992,# & S22000,S21994,S70418,S70422,S21998,S70423)# & PIR3: (S13288,S33985)# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,YHRLRDLLLI*# SEQUENCE: YHRLRDLLLI*# ...# >HUM117FE# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (769-780)# DB REFERENCE: SWISS: (ENV_HV1KB,ENV_HV1B1,ENV_HV1MF,ENV_HV1BN,ENV_HV1H2,# & ENV_HV1BR,ENV_HV1PV,ENV_HV1B8,ENV_HV1H3,ENV_HV1Y2,# & ENV_HV1J3,ENV_HV1W1,ENV_HV1SC)# & PIR1: (H44001,VCLJVL,VCLJBR,VCLJLV,VCLJSC,VCLJ3W,VCLJH3,# & VCLJKB)# & PIR2: (S21998,S70425,S21994,S70422,S21996,S70421)# & PIR3: (S13288,S33985)# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,HRLRDLLLIVTR*# SEQUENCE: HRLRDLLLIVTR*# ...# >HUM117FF# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (770-780)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1BN,ENV_HV1MF,ENV_HV1B8,ENV_HV1J3,# & ENV_HV1PV,ENV_HV1BR,ENV_HV1SC,ENV_HV1H3,ENV_HV1KB,# & ENV_HV1W1,ENV_HV1H2,ENV_HV1Y2)# & PIR1: (VCLJLV,VCLJH3,VCLJBR,VCLJVL,H44001,VCLJKB,VCLJSC,# & VCLJ3W)# & PIR2: (S21998,S21994,S70422,S70425,S21996,S70421)# & PIR3: (S13288,S33985)# REFERENCES: safrit94a,brander95a,hivdb97a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,RLRDLLLIVTR*# SEQUENCE: RLRDLLLIVTR*# ...# >HUM11800# MHC MOLECULE: HLA-A32, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41# ANCHOR POSITIONS:# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A32,actyesu,bindyesu,VLSIVNRVRQGYSPLSFQHT*# SEQUENCE: VLSIVNRVRQGYSPLSFQHT*# ...# >HUM11801# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (770-780)# ANCHOR POSITIONS:# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,RLRDLLLIVVVR*# SEQUENCE: RLRDLLLIVVVR*# ...# >HUM11802# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41 (770-780) homologue# DB REFERENCE: SWISS: (ENV_HV1MN)# & PIR1: (VCLJMN)# REFERENCES: safrit94a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,HRDLLLI*# SEQUENCE: HRDLLLI*# ...# >MUS11803# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: direct binding# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Plasmodium bereghei# ANCHOR POSITIONS:# REFERENCES: ojcius94a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesm,SYYPSAEI*# SEQUENCE: SYYPSAEI*# ...# >MUS11804# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: direct binding# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Plasmodium bereghei# ANCHOR POSITIONS:# REFERENCES: ojcius94a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesm,SYIPSAEYILE*# SEQUENCE: SYIPSAEYILE*# ...# >MUS11805# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: direct binding# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Plasmodium bereghei# ANCHOR POSITIONS:# REFERENCES: ojcius94a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesl,NDDSYIPSAEYI*# SEQUENCE: NDDSYIPSAEYI*# ...# >MUS11806# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160 (421-444)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1B8)# & PIR1: (VCLJH3)# & PIR3: (S33985)# REFERENCES: shirai94a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,KQIINMWQEVGKAMYAPPISGQIR*# SEQUENCE: KQIINMWQEVGKAMYAPPISGQIR*# ...# >MUS11807# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160 (476-499)# DB REFERENCE: SWISS: (ENV_HV1Z6,ENV_HV1BR,ENV_HV1OY,ENV_HV1Z2,ENV_HV1H2,# & ENV_HV1S1,ENV_HV1BN,ENV_HV1B8,ENV_HV1SC,ENV_HV1B1,# & ENV_HV1W1,ENV_HV1H3,ENV_HV1KB,ENV_HV1ZH,ENV_HV1Y2,# & ENV_HV1PV,ENV_HV1C4,ENV_HV1JR)# & PIR1: (VCLJKB,VCLJ3W,VCLJH3,VCLJSC,VCLJH4,VCLJBR,VCLJLV,VCLJZR,# & A44963,H44001,VCLJVL,VCLJKX)# & PIR2: (S60535,S60524,S60546,S54384,A40218,S60545,S60529,S60547,# & S60552,S60528,C41621,S60555,S60553,S60548,S60551,S60554,# & S25940)# & PIR3: (S13289,S33985,S13288)# REFERENCES: shirai94a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RDNWRSELYKYKVVKIEPLGVAPT*# SEQUENCE: RDNWRSELYKYKVVKIEPLGVAPT*# ...# >MUS11808# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp160 (821-853)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1MF)# & PIR1: (VCLJH3,VCLJVL)# & PIR3: (S33985)# REFERENCES: shirai94a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLER*# SEQUENCE: AVAEGTDRVIEVVQGAYRAIRHIPRRIRQGLER*# ...# >HUM11809# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (42-50)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,DLMLSPDDI*# SEQUENCE: DLMLSPDDI*# ...# >HUM1180A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (43-52)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LMLSPDDIEQ*# SEQUENCE: LMLSPDDIEQ*# ...# >HUM1180B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as./inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: p53 (92-100)# DB REFERENCE: SWISS: (P53_CERAE,P53_HUMAN,P53_RAT,P53_CERAE,P53_RAT,# & P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S02192,JC6193,S06594)# REFERENCES: stuber94a,theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,PLSSSVPSQ*# SEQUENCE: PLSSSVPSQ*# ...# >HUM1180C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (110-118)# DB REFERENCE: SWISS: (P53_HUMAN,P53_SHEEP,P53_CRIGR,P53_MESAU,P53_CANFA,# & P53_CERAE,P53_CERAE,P53_MESAU,P53_HUMAN,P53_SHEEP)# & PIR1: (DNHU53)# & PIR2: (JH0633,S06594,JC6176,JC6193)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RLGFLHSGT*# SEQUENCE: RLGFLHSGT*# ...# >HUM1180D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (132-140) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QMFCQLAKT*# SEQUENCE: QMFCQLAKT*# ...# >HUM1180E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (136-144)# DB REFERENCE: SWISS: (P53_HUMAN,P53_SHEEP,P53_CANFA,P53_CRIGR,P53_CERAE,# & P53_RAT,P53_SHEEP,P53_BOVIN,P53_FELCA,P53_CERAE,# & P53_MESAU,P53_MOUSE,P53_MOUSE,P53_SALIR,P53_MESAU,# & P53_RAT,P53_HUMAN,P53_SALIR,P53_FELCA)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S51648,JC6193,JH0631,JC6176,S38824,S06594,JH0633,# & S02192)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,QLAKTCPVQ*# SEQUENCE: QLAKTCPVQ*# ...# >HUM1180F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (159-167) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AMAIHKQSQ*# SEQUENCE: AMAIHKQSQ*# ...# >HUM11810# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (186-196)# DB REFERENCE: SWISS: (P53_MESAU,P53_FELCA,P53_MOUSE,P53_SHEEP,P53_SHEEP,# & P53_CANFA,P53_CERAE,P53_RAT,P53_CERAE,P53_MOUSE,P53_RAT,# & P53_HUMAN,P53_FELCA,P53_HUMAN,P53_BOVIN,P53_MESAU)# & PIR1: (DNMS53,DNHU53)# & PIR2: (I46226,JH0633,S38824,S51648,S06594,JC6193,S02192)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,DGLAPPQHLIR*# SEQUENCE: DGLAPPQHLIR*# ...# >HUM11811# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as./inhibition as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (187-195)# DB REFERENCE: SWISS: (P53_FELCA,P53_MOUSE,P53_MOUSE,P53_MESAU,P53_MESAU,# & P53_CANFA,P53_RAT,P53_RAT,P53_BOVIN,P53_FELCA,P53_HUMAN,# & P53_HUMAN,P53_SHEEP,P53_SHEEP,P53_CERAE,P53_CERAE)# & PIR1: (DNHU53,DNMS53)# & PIR2: (I46226,S02192,S06594,JH0633,JC6193,S51648,S38824)# REFERENCES: stuber94a,theobald95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLAPPQHLI*# SEQUENCE: GLAPPQHLI*# ...# >HUM11812# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (187-195) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLAPPQHEI*# SEQUENCE: GLAPPQHEI*# ...# >HUM11813# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (193-201)# DB REFERENCE: SWISS: (P53_FELCA,P53_CERAE,P53_MOUSE,P53_CANFA,P53_SHEEP,# & P53_SHEEP,P53_CERAE,P53_HUMAN,P53_HUMAN,P53_BOVIN,# & P53_MOUSE,P53_CRIGR,P53_FELCA)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S38824,I46226,S51648,S06594,JC6193,JC6176)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,HLIRVEGNL*# SEQUENCE: HLIRVEGNL*# ...# >HUM11814# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (193-201) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RLIRVEGNL*# SEQUENCE: RLIRVEGNL*# ...# >HUM11815# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (193-201) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,HLIKVEGNL*# SEQUENCE: HLIKVEGNL*# ...# >HUM11816# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (193-201) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ELIRVEGNL*# SEQUENCE: ELIRVEGNL*# ...# >HUM11817# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (193-201) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,HEIRVEGNL*# SEQUENCE: HEIRVEGNL*# ...# >HUM11818# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (245-253)# DB REFERENCE: SWISS: (P53_MESAU,P53_SALIR,P53_MOUSE,P53_RAT,P53_MOUSE,# & P53_CERAE,P53_HUMAN,P53_SHEEP,P53_BOVIN,P53_CRIGR,# & P53_XENLA,P53_SALIR,P53_CHICK,P53_HUMAN,P53_CHICK,# & P53_MESAU,P53_SHEEP,P53_CERAE,P53_XENLA,P53_CANFA,# & P53_RAT)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S51648,S02192,S06594,JH0633,S02193,S38824,JH0631,A29376,# & JC6176,JC6193)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GMNRRPILT*# SEQUENCE: GMNRRPILT*# ...# >HUM11819# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (245-253) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GMNCRPILT*# SEQUENCE: GMNCRPILT*# ...# >HUM1181A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (245-253) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GMNKRPILT*# SEQUENCE: GMNKRPILT*# ...# >HUM1181B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (245-253) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GMNERPILT*# SEQUENCE: GMNERPILT*# ...# >HUM1181C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (245-253) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GMNRHPILT*# SEQUENCE: GMNRHPILT*# ...# >HUM1181D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (250-258)# DB REFERENCE: SWISS: (P53_HUMAN,P53_SHEEP,P53_CERAE,P53_CRIGR,P53_XENLA,# & P53_XENLA,P53_RAT,P53_CERAE,P53_SHEEP,P53_MESAU,# & P53_MOUSE,P53_RAT,P53_BOVIN,P53_SALIR,P53_CANFA,# & P53_HUMAN,P53_MOUSE,P53_SALIR,P53_MESAU)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S06594,S38824,A29376,JH0631,JH0633,S51648,JC6176,JC6193,# & S02192)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,PILTIITLE*# SEQUENCE: PILTIITLE*# ...# >HUM1181E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LLGRNSFEM*# SEQUENCE: LLGRNSFEM*# ...# >HUM1181F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (264-272) homologue# ANCHOR POSITIONS:# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,LLGRNSEEM*# SEQUENCE: LLGRNSEEM*# ...# >HUM11820# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as./inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: p53 (322-330)# DB REFERENCE: SWISS: (P53_SHEEP,P53_RAT,P53_FELCA,P53_FELCA,P53_CERAE,# & P53_MOUSE,P53_CERAE,P53_HUMAN,P53_SHEEP,P53_MOUSE,# & P53_RAT,P53_HUMAN,P53_BOVIN)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S51648,S02192,S06594,S38824)# REFERENCES: stuber94a,theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,PLDGEYFTL*# SEQUENCE: PLDGEYFTL*# ...# >HUM11821# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./reconstitution as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (331-339)# DB REFERENCE: SWISS: (P53_CERAE,P53_HUMAN,P53_FELCA,P53_CERAE,P53_FELCA,# & P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: stuber94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QIRGRERFE*# SEQUENCE: QIRGRERFE*# ...# >HUM21822# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: Binding-Direct# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HAP 128-145 (immunogenic haemagglutinic peptide)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# REFERENCES: nygard94a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,KVKILPKDRWTQHTTTGG*# SEQUENCE: KVKILPKDRWTQHTTTGG*# ...# >MUS11823# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (255-271)# ANCHOR POSITIONS:# REFERENCES: olsen94a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGNLIAEPYGFKIS*# SEQUENCE: FESTGNLIAEPYGFKIS*# ...# >HUM21824# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Poa p IX (162-174)# ANCHOR POSITIONS:# REFERENCES: mohapatra94a# COMMENT: allergen epitope# SUMMARY: HLA-?,actyesu,bindyesu,PAGELQVIDKYDA*# SEQUENCE: PAGELQVIDKYDA*# ...# >HUM21825# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: (NA+/K+) ATPase# DB REFERENCE: SWISS: (ATN1_HUMAN,ATN1_CANFA,ATN1_SHEEP,ATN1_PIG,ATN1_RAT,# & ATN1_HORSE,ATN1_HUMAN,ATN3_PIG)# & PIR1: (S04630,PWSHNA)# & PIR2: (A24639,A24414,B24862,S20970)# REFERENCES: sinigaglia94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,IPADLRIISANGCKVDNS*# SEQUENCE: IPADLRIISANGCKVDNS*# ...# >HUM21826# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I38442,I84448,I61857,I37542,I38443,I61902)# REFERENCES: sinigaglia94a,sinigaglia94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SDWRFLRGYHQYA*# SEQUENCE: SDWRFLRGYHQYA*# ...# >HUM21827# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (680-696)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: sinigaglia94a,rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,RVEYHFLSPYVSPKESP*# SEQUENCE: RVEYHFLSPYVSPKESP*# ...# >HUM21828# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Self peptide SP3# ANCHOR POSITIONS: 5,8# REFERENCES: sinigaglia94a,rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,AILEFRAMAQFSRKTD*# SEQUENCE: AILEFRAMAQFSRKTD*# ...# >HUM21829# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2# DB REFERENCE: SWISS: (1A25_HUMAN,1A34_HUMAN,1A11_HUMAN,1A02_HUMAN,1A01_PANTR,# & 1A32_HUMAN,1A29_HUMAN,1A33_HUMAN,1A03_GORGO,1A04_PANTR,# & 1A31_HUMAN,1A03_HUMAN,1A02_GORGO,1A04_GORGO,1A26_HUMAN,# & 1A23_HUMAN,1A68_HUMAN,1A01_GORGO,1A30_HUMAN,1A24_HUMAN,# & 1A26_HUMAN,1A31_HUMAN,1A66_HUMAN,1A03_PANTR,1A43_HUMAN,# & 1A69_HUMAN,1A74_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA3,HLHU69,HLHU28,HLHUA2,HLHU32,HLHUAW)# & PIR2: (I56039,JH0535,I84487,A47636,I38441,S18198,I38519,I54307,# & JL0135,I37483,I37477,S03535,I83063,I37480,I54416,I61902,# & I36966,I38436,JH0534,S01171,I38443,A45847,I37542,I61857,# & I37476,I84448,JH0537,I38610,I37479,I37482,A35997,JH0536,# & I36961,S51099,I37470,I72170,I36959,A37028,S16769,I72171,# & I54493,I36965)# & PIR3: (S06424)# REFERENCES: sinigaglia94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQRMEPRA*# SEQUENCE: VDDTQFVRFDSDAASQRMEPRA*# ...# >HUM2182A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9# DB REFERENCE: SWISS: (1C11_HUMAN,1C03_GORGO,1CXX_HUMAN,1C02_GORGO,1C04_HUMAN,# & 1C15_HUMAN,1C16_HUMAN,1C01_PANTR,1C18_HUMAN,1C17_HUMAN,# & 1C02_HUMAN,1B55_HUMAN,1C01_HUMAN,1C06_HUMAN,1C02_HUMAN,# & 1C04_GORGO,1C02_GORGO)# & PIR1: (HLHUC4)# & PIR2: (I37078,I56130,I68749,I37527,B37028,A45857,I59622,I37529,# & I37544,A49411,I56034,I38507,S48134,I72113,I54430,I37528,# & I81231,I38505,JH0545,I54449,C37028,JH0547,S42823,S44994,# & JH0546,I37523,I61866,I37526)# REFERENCES: sinigaglia94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASPRGEPRA*# SEQUENCE: VDDTQFVRFDSDAASPRGEPRA*# ...# >HUM2182B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9# DB REFERENCE: SWISS: (1C02_HUMAN,1C02_HUMAN,HA19_CANFA,1B34_HUMAN,1C12_HUMAN,# & 1C01_PANTR,1C04_HUMAN,1B39_HUMAN,1C15_HUMAN,1B36_HUMAN,# & 1C16_HUMAN,1B35_HUMAN,1C06_HUMAN,1C01_HUMAN,1C17_HUMAN,# & 1C18_HUMAN,1B38_HUMAN,1B04_HUMAN,1C01_GORGO,1C14_HUMAN,# & 1C07_HUMAN,1B20_HUMAN,1C03_HUMAN,1CXX_HUMAN,# & 1B02_HUMAN)# & PIR1: (HLHUC4,S42102,HLHUB7)# & PIR2: (I81231,I54418,S48134,I84431,I56034,I37523,S42823,I61865,# & S52486,I37492,I54449,I37528,I38507,S60601,I68747,I59655,# & I72113,I56116,I54430,I61864,I61905,I68701,I38505,I59188,# & JH0526,I37527,JS0262,I68749,I37544,I56149,A45845,I37526,# & I61866,I37135,S44994,I59651,B37028,I61906,I59622,A45857,# & I81232,JH0544,JH0543,I68712,C37028)# REFERENCES: sinigaglia94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LRSWTAADTAAQITQRKWEA*# SEQUENCE: LRSWTAADTAAQITQRKWEA*# ...# >HUM2182C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw62# DB REFERENCE: SWISS: (1B01_PANTR,1B41_HUMAN,1B02_PANTR,1B25_HUMAN,1B19_HUMAN,# & 1B29_HUMAN,1B14_HUMAN,1B49_HUMAN,1B56_HUMAN,1B58_HUMAN,# & 1B13_HUMAN,1B45_HUMAN,1B22_HUMAN,1B26_HUMAN,1B44_HUMAN,# & 1B31_HUMAN,1B53_HUMAN,1B60_HUMAN,1B10_HUMAN,1B04_GORGO,# & 1B42_HUMAN,1B61_HUMAN,1B18_HUMAN,1B63_HUMAN,1B16_HUMAN,# & 1B27_HUMAN,1B62_HUMAN,1B40_HUMAN,1B55_HUMAN,1B43_HUMAN,# & 1B21_HUMAN,1B03_GORGO,1B01_GORGO,1B28_HUMAN,1A02_PANTR,# & 1B54_HUMAN,1B32_HUMAN,1B48_HUMAN,1B02_GORGO,1B12_HUMAN,# & 1B59_HUMAN,1B15_HUMAN,1B23_HUMAN,1B57_HUMAN,1B24_HUMAN,# & 1B11_HUMAN,1B12_HUMAN,1B07_HUMAN,1B52_HUMAN,1B47_HUMAN,# & 1B08_HUMAN)# & PIR1: (HLHUB4,HLHUB8,HLHUB2)# & PIR2: (I72753,I59645,I80172,I68850,I36960,I84486,I80175,I38509,# & S24437,I61860,I37485,I61863,S24440,S24436,I38875,I37520,# & I37522,I68748,C35997,I62042,I36956,B30345,I56133,A45880,# & JH0539,JH0540,I80168,S24027,I80167,A45834,I81233,I72754,# & I80171,I56130,I84488,G01230,I36962,I80165,I80174,I37475,# & I72755,S03538,I68774,I59633,I61862,I38874,I72752,D35997,# & I36957,S24434,I61907,I38421,I37521,I84490,I54298,I37515,# & I38876,I62044,I54314,S24435,I37516,I62045,I54308,S16789,# & I80169,I37519,I38860,I80173,JH0542,A30345,S24433,S24439,# & I37120,I61859,I61904,I54289,I62043,S25415,I80176,I61861,# & JH0541,I59654,I59308,I54457,I54463,I80170,S03537,I54505,# & I62041,I68724)# & PIR3: (S07115,S07113)# REFERENCES: sinigaglia94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLSSWTAADTAAQITQRKWEA*# SEQUENCE: DLSSWTAADTAAQITQRKWEA*# ...# >HUM2182D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VLA-4# DB REFERENCE: SWISS: (ITA4_HUMAN,ITA4_HUMAN)# & PIR2: (S06046)# REFERENCES: sinigaglia94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSLFVYNITTNKYKAFLDKQ*# SEQUENCE: GSLFVYNITTNKYKAFLDKQ*# ...# >HUM2182E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine hemoglobin# ANCHOR POSITIONS: 4,7,9# REFERENCES: sinigaglia94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,AEALERMFLSFPTTKTHLA*# SEQUENCE: AEALERMFLSFPTTKTHLA*# ...# >HUM2182F# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human Hsp (Hsp70/hsc70) (291-305)# DB REFERENCE: SWISS: (HS71_CANAL,HS70_CHICK,HS71_PIG,HS73_RAT,HS72_PICAN,# & HS72_PICAN,HS70_BLAEM,HS7C_CRIGR,HS71_MOUSE,HS72_YEAST,# & HS7H_HUMAN,HS71_MOUSE,HS7C_BOVIN,HS7C_BOVIN,HS70_ONCMY,# & HS7C_RAT,HS70_ONCTS,HS70_HYDMA,HS71_YEAST,HS71_RAT,# & HS71_RAT,HS70_PLEWA,HS7C_DICDI,HS74_YEAST,HS7C_HUMAN,# & HS72_BOVIN,HS7T_MOUSE,HS7C_RAT,HS74_CANAL,HS71_PICAN,# & HS71_SCHPO,HS71_PIG,HS7T_MOUSE,HS7C_DICDI,HS7C_BRARE,# & HS71_BOVIN,HS71_HANPO,HS71_HUMAN)# & PIR1: (HHBYA1)# & PIR2: (I49761,I51129,JC4853,A34041,B45871,A45935,S20139,S67431,# & A48439,A27077,A45871,I54542,S41415,A48872,I51344,S51712,# & S31766,B36590,S07197,S27004,I56574,S11456,A35922,A29160,# & S43388,S31716,JH0095,S35718,A25646,S41372,S37394)# & PIR3: (S21175)# REFERENCES: sinigaglia94a,rammensee95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,IDFYTSITRARFEE*# SEQUENCE: IDFYTSITRARFEE*# ...# >HUM21830# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human granulin D (41-56)# DB REFERENCE: SWISS: (GRN_CAVPO,GRN_HUMAN)# & PIR1: (GYHU)# & PIR2: (I48141)# REFERENCES: sinigaglia94a,rammensee95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,CPAGYTCNVKARSCEK*# SEQUENCE: CPAGYTCNVKARSCEK*# ...# >HUM21831# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human Hscp 70 (238-252)# DB REFERENCE: SWISS: (HS7C_BOVIN,HS7C_BOVIN,HS7C_HUMAN,HS7C_RAT,HS7C_ICTPU,# & HS7C_ICTPU,HS7C_RAT)# & PIR2: (JC4853,S11456,S07197,A45935,S31716,A27077)# REFERENCES: sinigaglia94a,steward93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,VNHFIAEFKRKHKKD*# SEQUENCE: VNHFIAEFKRKHKKD*# ...# >HUM21832# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw61 (5-20)# DB REFERENCE: SWISS: (1B35_HUMAN,1B34_HUMAN,1B18_HUMAN,1B20_HUMAN,1B16_HUMAN,# & 1B29_HUMAN,1B15_HUMAN,1B13_HUMAN,1B36_HUMAN,1B19_HUMAN,# & 1B14_HUMAN)# & PIR1: (S42102,HLHUB2)# & PIR2: (I56149,I59655,I54289,I61905,I61860,C35997,I37485,S52486,# & I56116,I37515,I61906)# REFERENCES: sinigaglia94a,rammensee95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,MRYFHTSVSRPGRGEP*# SEQUENCE: MRYFHTSVSRPGRGEP*# ...# >HUM21833# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human Ig kappa-chain (190-204)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: sinigaglia94a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,KHKVYACEVTHQGLS*# SEQUENCE: KHKVYACEVTHQGLS*# ...# >MUS11834# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: OVA (11-122)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: sambhara94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,YPILPEYLQCVK*# SEQUENCE: YPILPEYLQCVK*# ...# >MUS11835# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference/Stabilization# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tum-# ANCHOR POSITIONS:# REFERENCES: sambhara94a,lie91a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,ISTQNHRALPLVA*# SEQUENCE: ISTQNHRALPLVA*# ...# >HUM21836# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Thyroid peroxidase (535-551)# DB REFERENCE: SWISS: (PERT_HUMAN)# & PIR1: (OPHUIT)# REFERENCES: dayan91a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,LDPLIRGLLARPAKLQV*# SEQUENCE: LDPLIRGLLARPAKLQV*# ...# >HUM21837# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Thyroid peroxidase (632-645)# DB REFERENCE: SWISS: (PERT_HUMAN)# & PIR1: (OPHUIT)# REFERENCES: dayan91a# COMMENT: HLA-DQ2 or HLA-DP6# SUMMARY: HLA-?,actyesu,bindyesu,IDVWLGGLAENFLP*# SEQUENCE: IDVWLGGLAENFLP*# ...# >HUM11838# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu matrix (59-66)# DB REFERENCE: SWISS: (VMT1_IAZI1,VMT1_IAFOW,VMT1_IAUDO,VMT1_IACKB,VMT1_IAWIL,# & VMT1_IAPUE,VMT1_IAMAN,VMT1_IALE2,VMT1_IAUSS,VMT1_IAANN,# & VMT1_IABAN,VMT1_IALE1)# & PIR1: (MFIV61,MFIVC,MFIVWS,MFIV1M,MFIV1K,JN0392,MFIV)# & PIR2: (S14616,S04054,S07429,S04052,S04050,S04056,S04058)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ILGFVFTL*# SEQUENCE: ILGFVFTL*# ...# >HUM11839# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hiv Nef (83-91)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1H2,NEF_HV1BR,NEF_HV1B8,NEF_HV112,# & NEF_HV1RH,NEF_HV1B1,NEF_HV1SC,NEF_HV1BN)# & PIR1: (ASLJH3,ASLJ12,ASLJBR,ASLJFV,ASLJVL)# & PIR2: (S03245,S03247,S03244,S03246,S24985,S43467)# & PIR3: (S33986)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AAVDLSHFL*# SEQUENCE: AAVDLSHFL*# ...# >HUM1183A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hiv Nef (144-153)# DB REFERENCE: SWISS: (NEF_HV1RH,NEF_HV1BR,NEF_HV1PV)# & PIR1: (ASLJFV,ASLJVL)# & PIR2: (S03247,S43467,S03246)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KLVPVEPDKV*# SEQUENCE: KLVPVEPDKV*# ...# >HUM1183B# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu matrix (56-68)# DB REFERENCE: SWISS: (VMT1_IABAN,VMT1_IAANN,VMT1_IAUSS,VMT1_IAMAN,VMT1_IALE2,# & VMT1_IAUDO,VMT1_IACKB,VMT1_IAPUE,VMT1_IAZI1,VMT1_IAFOW,# & VMT1_IALE1,VMT1_IAWIL)# & PIR1: (MFIVWS,MFIV61,MFIVC,MFIV1K,JN0392,MFIV,MFIV1M)# & PIR2: (S04054,S14616,S04058,S07429,S04056,S04052,S04050)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,TKGILGFVFTLTV*# SEQUENCE: TKGILGFVFTLTV*# ...# >HUM1183C# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu matrix (57-68)# DB REFERENCE: SWISS: (VMT1_IAUDO,VMT1_IALE1,VMT1_IAANN,VMT1_IAFOW,VMT1_IAUSS,# & VMT1_IAMAN,VMT1_IAWIL,VMT1_IAZI1,VMT1_IABAN,VMT1_IAPUE,# & VMT1_IALE2,VMT1_IACKB)# & PIR1: (MFIV61,MFIV1K,MFIV,MFIV1M,MFIVC,JN0392,MFIVWS)# & PIR2: (S04050,S04056,S04052,S04058,S07429,S14616,S04054)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,KGILGFVFTLTV*# SEQUENCE: KGILGFVFTLTV*# ...# >HUM1183D# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu matrix (60-68)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IACKB,VMT1_IAPUE,VMT1_IALE1,VMT1_IAFPW,# & VMT1_IAANN,VMT1_IAUSS,VMT1_IAUDO,VMT1_IAMAN,VMT1_IAFPR,# & VMT1_IAWIL,VMT1_IAZI1,VMT1_IABAN,VMT1_IAFOW)# & PIR1: (PN0086,JN0392,MFIVWS,PN0083,MFIV1M,MFIV,MFIV61,MFIV1K,# & B45539,MFIVC,MFIV1F)# & PIR2: (S04052,S14616,S04058,S07429,S04054,S04056,S04050,# & S07945)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LGFVFTLTV*# SEQUENCE: LGFVFTLTV*# ...# >HUM1183E# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu matrix (59-68)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IAMAN,VMT1_IABAN,VMT1_IAZI1,VMT1_IAANN,# & VMT1_IAUDO,VMT1_IALE1,VMT1_IAFOW,VMT1_IAUSS,VMT1_IAWIL,# & VMT1_IACKB,VMT1_IAPUE)# & PIR1: (MFIVC,MFIV,MFIV61,MFIV1M,MFIVWS,JN0392,MFIV1K)# & PIR2: (S04054,S04050,S14616,S07429,S04052,S04058,S04056)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,ILGFVFTLTV*# SEQUENCE: ILGFVFTLTV*# ...# >HUM1183F# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hiv Nef (120-128)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1BR,NEF_HV1RH,NEF_HV112,NEF_HV1OY,# & NEF_HV1A2,NEF_HV1MA,NEF_HV1S1,NEF_HV1S3,NEF_HV1Y2,# & NEF_HV1BN,NEF_HV1JR,NEF_HV1B8,NEF_HV1MN)# & PIR1: (ASLJVL,ASLJFV,ASLJO2,I44001,ASLJBR,ASLJ12)# & PIR2: (S03245,S03247,S03246,S43467)# & PIR3: (S33986)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,YFPDWQNYT*# SEQUENCE: YFPDWQNYT*# ...# >HUM11840# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hiv Nef (140-148)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1BR,NEF_HV1B8,NEF_HV112,NEF_HV1U4)# & PIR1: (ASLJFV,ASLJH3,ASLJ12,ASLJVL)# & PIR2: (S03247,S03244,S43467)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,GWCYKLVPV*# SEQUENCE: GWCYKLVPV*# ...# >HUM11841# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hiv Nef (184-195)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1BR,NEF_HV1PV,NEF_HV1Y2)# & PIR1: (ASLJFV,ASLJ12,I44001,ASLJVL)# & PIR2: (S03245,S43467,S03244)# & PIR3: (JQ1620,S33986)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,RFDSRLAFHHVA*# SEQUENCE: RFDSRLAFHHVA*# ...# >HUM11842# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)/Reference# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Hiv Nef (186-194)# DB REFERENCE: SWISS: (NEF_HV1Y2,NEF_HV1RH,NEF_HV112,NEF_HV1BR,NEF_HV1PV)# & PIR1: (I44001,ASLJ12,ASLJVL,ASLJFV)# & PIR2: (S03245,S03244,S43467,S03246)# & PIR3: (JQ1620,S33986)# REFERENCES: connan94a,hivdb97a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesm,DSRLAFHHV*# SEQUENCE: DSRLAFHHV*# ...# >HUM11843# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hiv Nef (186-195)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1PV,NEF_HV1Y2,NEF_HV1BR,NEF_HV1RH)# & PIR1: (ASLJVL,I44001,ASLJFV,ASLJ12)# & PIR2: (S43467,S03244,S03245,S03246)# & PIR3: (S33986,JQ1620)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,DSRLAFHHVA*# SEQUENCE: DSRLAFHHVA*# ...# >HUM11844# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Direct binding (HLA assembly)# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hiv Nef (190-198)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1BR,NEF_HV1PV,NEF_HV1Y2)# & PIR1: (ASLJFV,ASLJVL,ASLJ12,I44001)# & PIR2: (S43467,S03245,S03244)# & PIR3: (S33986,JQ1620)# REFERENCES: connan94a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,AFHHVAREL*# SEQUENCE: AFHHVAREL*# ...# >HUM11845# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA4 (399-408)# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: de_campos-lima94a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,AVFDRKSDAK*# SEQUENCE: AVFDRKSDAK*# ...# >HUM11846# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: de_campos-lima94a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,ILTDFSVIK*# SEQUENCE: ILTDFSVIK*# ...# >HUM11847# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: de_campos-lima94a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,ILTDFSVIR*# SEQUENCE: ILTDFSVIR*# ...# >HUM11848# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA4 (416-424) homologue# ANCHOR POSITIONS:# REFERENCES: de_campos-lima94a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,IVTDFSVIN*# SEQUENCE: IVTDFSVIN*# ...# >MUS11849# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: MOPC 21 V heavy chain myeloma (49-58)# DB REFERENCE: SWISS: (HV16_MOUSE)# & PIR1: (G1MS21)# & PIR2: (D25913)# REFERENCES: cao94a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,AYISSGSSTL*# SEQUENCE: AYISSGSSTL*# ...# >MUS1184A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Flu HA (210-219) homologue# ANCHOR POSITIONS:# REFERENCES: cao94a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,TYVSVSTSTL*# SEQUENCE: TYVSVSTSTL*# ...# >MUS1184B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: direct binding/cytotoxicity/competition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ras p21 protooncogene (56-67) homologue# ANCHOR POSITIONS:# REFERENCES: peace94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,LDTAGLEEYSAM*# SEQUENCE: LDTAGLEEYSAM*# ...# >MUS1184C# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: direct binding/cytotoxicity/competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ras p21 protooncogene (57-67) homologue# ANCHOR POSITIONS:# REFERENCES: peace94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,DTAGLEEYSAM*# SEQUENCE: DTAGLEEYSAM*# ...# >MUS1184D# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: direct binding/cytotoxicity/competition as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ras p21 protooncogene (58-67) homologue# ANCHOR POSITIONS:# REFERENCES: peace94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,TAGLEEYSAM*# SEQUENCE: TAGLEEYSAM*# ...# >MUS1184E# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: direct binding/cytotoxicity/competition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ras p21 protooncogene (59-67) homologue# ANCHOR POSITIONS:# REFERENCES: peace94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,AGLEEYSAM*# SEQUENCE: AGLEEYSAM*# ...# >MUS1184F# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: direct binding/cytotoxicity/competition as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: ras p21 protooncogene (60-67) homologue# ANCHOR POSITIONS:# REFERENCES: peace94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesl,GLEEYSAM*# SEQUENCE: GLEEYSAM*# ...# >MUS11850# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: direct binding/cytotoxicity/competition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ras p21 protooncogene (61-67) homologue# ANCHOR POSITIONS:# REFERENCES: peace94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,LEEYSAM*# SEQUENCE: LEEYSAM*# ...# >HUM21851# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rubella virus envelope protein E1 (268-291)# ANCHOR POSITIONS:# REFERENCES: ou94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,APGPGEVWVTPVIGSARKCGLHI*# SEQUENCE: APGPGEVWVTPVIGSARKCGLHI*# ...# >HUM21852# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rubella virus envelope protein E1 (273-291)# ANCHOR POSITIONS:# REFERENCES: ou94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,EVWVTPVIGSARKCGLHI*# SEQUENCE: EVWVTPVIGSARKCGLHI*# ...# >HUM21853# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rubella virus envelope protein E1 (272-285)# ANCHOR POSITIONS:# REFERENCES: ou94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GEVWVTPVIGSAR*# SEQUENCE: GEVWVTPVIGSAR*# ...# >HUM21854# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rubella virus envelope protein E1 (273-284)# ANCHOR POSITIONS:# REFERENCES: ou94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,EVWVTPVIGSA*# SEQUENCE: EVWVTPVIGSA*# ...# >HUM21855# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rubella virus envelope protein E1 (272-282)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVR,POLS_RUBVT,POLS_RUBVM)# & PIR1: (GNWV77,GNWVR4,GNWVR3,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# REFERENCES: ou94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GEVWVTPVIGS*# SEQUENCE: GEVWVTPVIGS*# ...# >HUM21856# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rubella virus envelope protein E1 (273-284) homologue# ANCHOR POSITIONS:# REFERENCES: ou94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,AVWVTPVIGSQA*# SEQUENCE: AVWVTPVIGSQA*# ...# >HUM21857# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rubella virus envelope protein E1 (273-284) homologue# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVM,POLS_RUBVR,POLS_RUBVT)# & PIR1: (GNWVRA,GNWVR4,GNWVR3,GNWV77)# & PIR2: (A24309)# & PIR3: (A32270)# REFERENCES: ou94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,EVWVTPVIGSQA*# SEQUENCE: EVWVTPVIGSQA*# ...# >HUM21858# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rubella virus envelope protein E1 (273-284) homologue# ANCHOR POSITIONS:# REFERENCES: ou94a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,EVWVTPVIGTQA*# SEQUENCE: EVWVTPVIGTQA*# ...# >MUS11859# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Listeria monocytogenes LLO (91-99)# DB REFERENCE: SWISS: (P60_LISMO,P60_LISIN,P60_LISMO,P60_LISIN)# & PIR2: (A41487)# REFERENCES: pamer94a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,KYGVSVQDI*# SEQUENCE: KYGVSVQDI*# ...# >MUS2185A# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Schistosoma mansoni triose-phosphate isomerase TPI (194-210)# DB REFERENCE: SWISS: (TPIS_SCHMA)# & PIR2: (A38233)# REFERENCES: reynolds94a# COMMENT:# SUMMARY: I-?,actyesu,bindyesu,KWFKTNAPNGVDEKIRI*# SEQUENCE: KWFKTNAPNGVDEKIRI*# ...# >MUS2185B# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Schistosoma mansoni triose-phosphate isomerase TPI (142-154)# DB REFERENCE: SWISS: (TPIS_SCHMA)# & PIR2: (A38233)# REFERENCES: reynolds94a# COMMENT:# SUMMARY: I-?,actyesu,bindyesu,EVCVRQLKAIANK*# SEQUENCE: EVCVRQLKAIANK*# ...# >MUS2185C# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Schistosoma mansoni triose-phosphate isomerase TPI (193-202)# DB REFERENCE: SWISS: (TPIS_SCHMA)# & PIR2: (A38233)# REFERENCES: reynolds94a# COMMENT:# SUMMARY: I-?,actyesu,bindyesu,RKWFKTNAPN*# SEQUENCE: RKWFKTNAPN*# ...# >MUS1185D# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competitive binding as./stabilisation as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: LCMV GP1 (33-41)# DB REFERENCE: SWISS: (VGLY_LYCVW,VGLY_LYCVA)# & PIR1: (VGXPLA,VGXPLM,VGXPLC)# REFERENCES: sebzda94a,gairin95a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesh,KAVYNFATC*# SEQUENCE: KAVYNFATC*# ...# >HUM1185E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM1185F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM11860# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM11861# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RLSELEAALQRA*# SEQUENCE: RLSELEAALQRA*# ...# >HUM11862# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,TIAPFGIFGTNY*# SEQUENCE: TIAPFGIFGTNY*# ...# >HUM11863# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as./CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IALE1,VMT1_IAUDO,VMT1_IAFOW,VMT1_IAUSS,# & VMT1_IAANN,VMT1_IAZI1,VMT1_IALE2,VMT1_IAMAN,VMT1_IABAN,# & VMT1_IAWIL,VMT1_IAPUE)# & PIR1: (MFIV1M,MFIVWS,MFIV,MFIV1K,JN0392,MFIV61,MFIVC)# & PIR2: (S04052,S04058,S04050,S04054,S04056,S14616,S07429)# REFERENCES: tanigaki94a,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM11864# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1B1,POL_HV1Z2,POL_HV1RH,POL_HV1H2,# & POL_HV1EL,POL_HV1BR,POL_HV1MA,POL_HV1B5,POL_HV1OY,# & POL_HV1Y2,POL_HV1ND,POL_HV1JR,POL_HV1N5,POL_HV1PV)# & PIR1: (GNVWLV,GNVWVL,GNVWH3,GNLJND,B44001)# & PIR2: (S54378,B47175)# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM11865# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM11866# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM11867# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM11868# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RLSELEAALQRA*# SEQUENCE: RLSELEAALQRA*# ...# >HUM11869# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM1186A# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM1186B# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,TIAPFGIFGTNY*# SEQUENCE: TIAPFGIFGTNY*# ...# >HUM1186C# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as./CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VMT1_IAUDO,VMT1_IALE2,VMT1_IAWIL,VMT1_IAPUE,VMT1_IACKB,# & VMT1_IAZI1,VMT1_IAANN,VMT1_IABAN,VMT1_IAUSS,VMT1_IALE1,# & VMT1_IAFOW,VMT1_IAMAN)# & PIR1: (MFIVWS,MFIV,MFIV1K,MFIV1M,JN0392,MFIV61,MFIVC)# & PIR2: (S04058,S04052,S14616,S07429,S04054,S04056,S04050)# REFERENCES: tanigaki94a,fruci93a,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM1186D# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1PV,POL_HV1ND,POL_HV1B5,POL_HV1OY,# & POL_HV1MA,POL_HV1EL,POL_HV1Z2,POL_HV1RH,POL_HV1H2,# & POL_HV1B1,POL_HV1BR,POL_HV1N5,POL_HV1JR,POL_HV1Y2)# & PIR1: (GNVWVL,GNVWLV,B44001,GNLJND,GNVWH3)# & PIR2: (S54378,B47175)# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM1186E# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM1186F# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM11870# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM11871# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a,fruci93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RLSELEAALQRA*# SEQUENCE: RLSELEAALQRA*# ...# >HUM11872# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,TIAPFGIFGTNY*# SEQUENCE: TIAPFGIFGTNY*# ...# >HUM11873# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM11874# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1OY,POL_HV1JR,POL_HV1MN,POL_HV1H2,POL_HV1B5,# & POL_HV1MA,POL_HV1ND,POL_HV1EL,POL_HV1Z2,POL_HV1BR,# & POL_HV1B1,POL_HV1N5,POL_HV1Y2,POL_HV1PV,POL_HV1RH)# & PIR1: (B44001,GNVWH3,GNVWLV,GNVWVL,GNLJND)# & PIR2: (B47175,S54378)# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A26 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesu,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM11875# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A26 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM11876# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A26 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM11877# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A26 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesu,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM11878# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A26 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesu,TIAPFGIFGTNY*# SEQUENCE: TIAPFGIFGTNY*# ...# >HUM11879# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A28 or HLA-B53# SUMMARY: HLA-?,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM1187A# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A28 or HLA-B53# SUMMARY: HLA-?,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM1187B# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A28 or HLA-B53# SUMMARY: HLA-?,actunkn,bindyesu,ELAQYLDLVRALEAA*# SEQUENCE: ELAQYLDLVRALEAA*# ...# >HUM1187C# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A29 or HLA-B61# SUMMARY: HLA-?,actunkn,bindyesu,YDIMPPLLFV*# SEQUENCE: YDIMPPLLFV*# ...# >HUM1187D# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A29 or HLA-B61# SUMMARY: HLA-?,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM1187E# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Direct binding - alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: tanigaki94a# COMMENT: Binding to HLA-A30 or HLA-B18# SUMMARY: HLA-?,actunkn,bindyesu,EVAPPLLFV*# SEQUENCE: EVAPPLLFV*# ...# >HUM2187F# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p21 ras (6-21)# ANCHOR POSITIONS:# REFERENCES: spurkland94a# COMMENT:# SUMMARY: HLA-DQ6,actyesu,bindyesu,LVVVGAGVVGKSALAL*# SEQUENCE: LVVVGAGVVGKSALAL*# ...# >HUM21880# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p21 ras (7-21)# ANCHOR POSITIONS:# REFERENCES: spurkland94a# COMMENT:# SUMMARY: HLA-DQ6,actyesu,bindyesu,VVVGAGVVGKSALAL*# SEQUENCE: VVVGAGVVGKSALAL*# ...# >HUM21881# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p21 ras (8-21)# ANCHOR POSITIONS:# REFERENCES: spurkland94a# COMMENT:# SUMMARY: HLA-DQ6,actyesu,bindyesu,VVGAGVVGKSALAL*# SEQUENCE: VVGAGVVGKSALAL*# ...# >HUM21882# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p21 ras (6-19)# ANCHOR POSITIONS:# REFERENCES: spurkland94a# COMMENT:# SUMMARY: HLA-DQ6,actyesu,bindyesu,LVVVGAGVVGKSAL*# SEQUENCE: LVVVGAGVVGKSAL*# ...# >HUM21883# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p21 ras (6-18)# ANCHOR POSITIONS:# REFERENCES: spurkland94a# COMMENT:# SUMMARY: HLA-DQ6,actyesu,bindyesu,LVVVGAGVVGKSA*# SEQUENCE: LVVVGAGVVGKSA*# ...# >HUM21884# MHC MOLECULE: HLA-DQ6(DQA1*0102xDQB1*0602), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p21 ras (6-17)# ANCHOR POSITIONS:# REFERENCES: spurkland94a# COMMENT:# SUMMARY: HLA-DQ6,actyesu,bindyesu,LVVVGAGVVGKS*# SEQUENCE: LVVVGAGVVGKS*# ...# >HUM11885# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag p17# DB REFERENCE: SWISS: (GAG_HV1OY,GAG_HV1A2,GAG_HV1Y2,GAG_HV1W2,GAG_HV1N5)# & PIR1: (A44001,FOVWA2)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GELDKWEKIRLRPGG*# SEQUENCE: GELDKWEKIRLRPGG*# ...# >HUM11886# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p17# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,CLRPGGKKKYKLKHIV*# SEQUENCE: CLRPGGKKKYKLKHIV*# ...# >HUM11887# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag p17# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,CLGQLQPSLQTGSEEL*# SEQUENCE: CLGQLQPSLQTGSEEL*# ...# >HUM11888# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p17# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,CGSEELRSLYNTVATL*# SEQUENCE: CGSEELRSLYNTVATL*# ...# >HUM11889# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p17# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1MA)# & PIR1: (FOVWA2)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,TVATLYCVHQRIDVK*# SEQUENCE: TVATLYCVHQRIDVK*# ...# >HUM1188A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p24# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,VHQAISPRTLNAWVKC*# SEQUENCE: VHQAISPRTLNAWVKC*# ...# >HUM1188B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag p24# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,CVGGPGHKARVL*# SEQUENCE: CVGGPGHKARVL*# ...# >HUM1188C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag p15# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,CAEAMSQVTNPANIMM*# SEQUENCE: CAEAMSQVTNPANIMM*# ...# >HUM1188D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag p15# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,CANIMMQRGNFRNQRK*# SEQUENCE: CANIMMQRGNFRNQRK*# ...# >HUM1188E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag p15# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1B1)# & PIR1: (FOVWH3,FOVWVL)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RNQRKMVKCFNCGKE*# SEQUENCE: RNQRKMVKCFNCGKE*# ...# >HUM1188F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# DB REFERENCE: SWISS: (GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,CRAPRKKGCWRCGR*# SEQUENCE: CRAPRKKGCWRCGR*# ...# >HUM11890# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,CLGKIWPSYKGRPGNF*# SEQUENCE: CLGKIWPSYKGRPGNF*# ...# >HUM11891# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,CEPTAPPEESFRFGEE*# SEQUENCE: CEPTAPPEESFRFGEE*# ...# >HUM11892# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1PV,POL_HV1BR,POL_HV1H2,POL_HV1B5,# & POL_HV1Z2,POL_HV1RH,POL_HV1OY)# & PIR1: (GNVWH3,GNVWVL,GNVWLV)# & PIR2: (S63735,S54378,S63739,S63742,S63733,S63755,S02760,# & S63716)# & PIR3: (S34484)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FIKVRQYDQILIEICGHKAIGTVLV*# SEQUENCE: FIKVRQYDQILIEICGHKAIGTVLV*# ...# >HUM11893# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1B1,POL_HV1Y2,POL_HV1Z2,POL_HV1ND,# & POL_HV1BR,POL_HV1N5,POL_HV1PV,POL_HV1A2,POL_HV1RH,# & POL_HV1B5,POL_HV1JR,POL_HV1EL)# & PIR1: (GNVWA2,GNVWVL,GNVWH3,GNVWLV,B44001,GNLJND)# & PIR2: (S63733,S63742,S63752,S63751,S63753,S63737,S63747,S63741,# & S63735,S63754,S63731,S63750,S63736,S63748,S63734,S63732,# & S63745,S63755,S54378)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RNLLTQIGCTLNFPISPIETVPVKL*# SEQUENCE: RNLLTQIGCTLNFPISPIETVPVKL*# ...# >HUM11894# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1Z2,POL_HV1BR,POL_HV1PV,POL_HV1B1,# & POL_HV1H2)# & PIR1: (GNVWLV,GNVWH3,GNVWVL)# & PIR2: (S54378,B47175)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LVGKLNWASQIYPGIKVRQLCKLLR*# SEQUENCE: LVGKLNWASQIYPGIKVRQLCKLLR*# ...# >HUM11895# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1PV,POL_HV1B5,POL_HV1Y2,POL_HV1H2,# & POL_HV1BR)# & PIR1: (GNVWH3,B44001,GNVWVL,GNVWLV)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SIVIWGKTPKFKLPIQKETWETWWT*# SEQUENCE: SIVIWGKTPKFKLPIQKETWETWWT*# ...# >HUM11896# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1JR,POL_HV1PV,POL_HV1A2,POL_HV1ND,POL_HV1MN,# & POL_HV1OY,POL_HV1MA,POL_HV1EL,POL_HV1H2,POL_HV1Z2,# & POL_HV1BR,POL_HV1N5,POL_HV1RH,POL_HV1B5,POL_HV1B1,# & POL_HV1Y2)# & PIR1: (B44001,GNVWH3,GNLJND,GNVWVL,GNVWLV,GNVWA2)# & PIR2: (S54378)# & PIR3: (S33980)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,CDKCQLKGEAMHGQVDCSPGIWQLD*# SEQUENCE: CDKCQLKGEAMHGQVDCSPGIWQLD*# ...# >HUM11897# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1ND,POL_HV1PV,POL_HV1OY,POL_HV1JR,# & POL_HV1U4,POL_HV1A2,POL_HV1RH,POL_HV1H2,POL_HV1Y2,# & POL_HV1B1,POL_HV1B5,POL_HV1MN,POL_HV1Z2,POL_HV1N5,# & POL_HV1BR)# & PIR1: (GNVWH3,GNVWLV,B44001,GNVWA2,GNLJND,GNVWVL)# & PIR2: (S54378)# & PIR3: (S33980)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LVAVHVASGYIEAEVIPAETGQETA*# SEQUENCE: LVAVHVASGYIEAEVIPAETGQETA*# ...# >HUM11898# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1BR,POL_SIVCZ,POL_HV1H2,POL_HV1A2,POL_HV1MN,# & POL_HV1B1,POL_HV1B5,POL_HV1PV)# & PIR1: (GNLJSI,GNVWH3,GNVWLV,GNVWVL,GNVWA2)# & PIR3: (S33980)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,AETGQETAYFLLKLAGRWPVKTIHT*# SEQUENCE: AETGQETAYFLLKLAGRWPVKTIHT*# ...# >HUM11899# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1B5,POL_HV1PV)# & PIR1: (GNVWVL,GNVWH3)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,TKELQKQITKIQNFRVYYRDSRNPL*# SEQUENCE: TKELQKQITKIQNFRVYYRDSRNPL*# ...# >HUM1189A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YRDSRNPLWKGPSKLLWKGEGAVVI*# SEQUENCE: YRDSRNPLWKGPSKLLWKGEGAVVI*# ...# >HUM1189B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1OY,POL_HV1RH,POL_HV1U4,POL_HV1B5,# & POL_HV1MA,POL_HV1Y2,POL_HV1N5,POL_HV1BR,POL_HV1PV,# & POL_HV1H2,POL_HV1B1)# & PIR1: (GNVWA2,GNVWLV,GNVWH3,GNVWVL,B44001)# & PIR3: (S33980)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KGEGAVVIQDNSDIKVVPRRKAKII*# SEQUENCE: KGEGAVVIQDNSDIKVVPRRKAKII*# ...# >HUM1189C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1H2,POL_HV1A2,POL_HV1BR,POL_HV1N5,# & POL_HV1B1,POL_HV1B5,POL_HV1PV,POL_SIVCZ,POL_HV1OY)# & PIR1: (GNLJSI,GNVWA2,GNVWH3,GNVWLV,GNVWVL)# & PIR3: (S33980)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,PRRKAKIIRDYGKQMAGDDCVASRQ*# SEQUENCE: PRRKAKIIRDYGKQMAGDDCVASRQ*# ...# >HUM1189D# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p17# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesm,CLRPGGKKKYKLKHIV*# SEQUENCE: CLRPGGKKKYKLKHIV*# ...# >HUM1189E# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p17# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesm,CLGQLQPSLQTGSEEL*# SEQUENCE: CLGQLQPSLQTGSEEL*# ...# >HUM1189F# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag p24# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesl,PPIPVGEIYKRWIIC*# SEQUENCE: PPIPVGEIYKRWIIC*# ...# >HUM118A0# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag p24# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesl,VQNANPDCKTILKALY*# SEQUENCE: VQNANPDCKTILKALY*# ...# >HUM118A1# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p24# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesm,CVGGPGHKARVL*# SEQUENCE: CVGGPGHKARVL*# ...# >HUM118A2# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesm,CANIMMQRGNFRNQRK*# SEQUENCE: CANIMMQRGNFRNQRK*# ...# >HUM118A3# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1B1)# & PIR1: (FOVWH3,FOVWVL)# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesm,RNQRKMVKCFNCGKE*# SEQUENCE: RNQRKMVKCFNCGKE*# ...# >HUM118A4# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# DB REFERENCE: SWISS: (GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesm,CRAPRKKGCWRCGR*# SEQUENCE: CRAPRKKGCWRCGR*# ...# >HUM118A5# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu M1# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT: binding to HLA-A1 or HLA-B8# SUMMARY: HLA-?,actunkn,bindyesm,KGILGFVFKLTV*# SEQUENCE: KGILGFVFKLTV*# ...# >HUM118A6# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p17# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,CLRPGGKKKYKLKHIV*# SEQUENCE: CLRPGGKKKYKLKHIV*# ...# >HUM118A7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag p17# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,CLGQLQPSLQTGSEEL*# SEQUENCE: CLGQLQPSLQTGSEEL*# ...# >HUM118A8# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag p17# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,CGSEELRSLYNTVATL*# SEQUENCE: CGSEELRSLYNTVATL*# ...# >HUM118A9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p17# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1MA)# & PIR1: (FOVWA2)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,TVATLYCVHQRIDVK*# SEQUENCE: TVATLYCVHQRIDVK*# ...# >HUM118AA# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p24# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,VHQAISPRTLNAWVKC*# SEQUENCE: VHQAISPRTLNAWVKC*# ...# >HUM118AB# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag p15# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,CAEAMSQVTNPANIMM*# SEQUENCE: CAEAMSQVTNPANIMM*# ...# >HUM118AC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag p15# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,CANIMMQRGNFRNQRK*# SEQUENCE: CANIMMQRGNFRNQRK*# ...# >HUM118AD# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1PV)# & PIR1: (FOVWVL,FOVWH3)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,RNQRKMVKCFNCGKE*# SEQUENCE: RNQRKMVKCFNCGKE*# ...# >HUM118AE# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# DB REFERENCE: SWISS: (GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,CRAPRKKGCWRCGR*# SEQUENCE: CRAPRKKGCWRCGR*# ...# >HUM118AF# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag p15# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,CEPTAPPEESFRFGEE*# SEQUENCE: CEPTAPPEESFRFGEE*# ...# >HUM118B0# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: solid-phase binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu M1# ANCHOR POSITIONS:# REFERENCES: frelinger90a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,KGILGFVFKLTV*# SEQUENCE: KGILGFVFKLTV*# ...# >HUM118B1# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA 3A (458-466)# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: lee95a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesu,YPLHEQHGM*# SEQUENCE: YPLHEQHGM*# ...# >HUM118B2# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA 3A (458-466)# ANCHOR POSITIONS:# REFERENCES: lee95a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesu,HPLHEQHGM*# SEQUENCE: HPLHEQHGM*# ...# >HUM118B3# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBV EBNA 3A (458-466)# ANCHOR POSITIONS:# REFERENCES: lee95a# COMMENT:# SUMMARY: HLA-B35,actyesm,bindyesu,YPLHQQHGM*# SEQUENCE: YPLHQQHGM*# ...# >HUM118B4# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA 3A (458-466)# ANCHOR POSITIONS:# REFERENCES: lee95a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesu,YPLHEQHSM*# SEQUENCE: YPLHEQHSM*# ...# >MUS118B5# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: pMCMV# DB REFERENCE: SWISS: (VIE1_MCMVS)# & PIR1: (EDBEMC)# REFERENCES: kageyama95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,YPHFMPTNL*# SEQUENCE: YPHFMPTNL*# ...# >MUS118B6# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: murine alpha-ketoglutarate dehydrogenase homologue# ANCHOR POSITIONS:# REFERENCES: kageyama95a,wu95a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesu,LSPYPFDL*# SEQUENCE: LSPYPFDL*# ...# >MUS118B7# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stabilisation as./stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: malarkannan95a# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,MSIINFEKL*# SEQUENCE: MSIINFEKL*# ...# >MUS118B8# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stabilisation as./stimulation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: malarkannan95a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,KSIINFEKL*# SEQUENCE: KSIINFEKL*# ...# >MUS118B9# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: stabilisation as./stimulation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: malarkannan95a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesu,MSIINFEKL*# SEQUENCE: MSIINFEKL*# ...# >HUM218BA# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ6 (43-58)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I61835,I68723,I59623,I84420,D35054,I68732,I68813,I61839,# & I72481,I59528,I36974,I68817)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,DVGVYRAVTPQGRPDA*# SEQUENCE: DVGVYRAVTPQGRPDA*# ...# >HUM218BB# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A3 (134-149)# DB REFERENCE: SWISS: (1A24_HUMAN,1A03_HUMAN,1A01_HUMAN,1A11_HUMAN,1A01_PANTR,# & 1A80_HUMAN,1A36_HUMAN,HLAH_HUMAN,HLAH_HUMAN)# & PIR1: (HLHUA3,HLHU12)# & PIR2: (I36959,I38518,I72029,I37478,A47636,I61856,I54416,I38439,# & I54493,I83063,I36961)# & PIR3: (S06424)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,TAADMAAQITKRKWEA*# SEQUENCE: TAADMAAQITKRKWEA*# ...# >HUM218BC# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR15 (43-61)# ANCHOR POSITIONS: 5# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,DVGEFRAVTELGRPDAEYV*# SEQUENCE: DVGEFRAVTELGRPDAEYV*# ...# >HUM218BD# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: SP3 (1-16)# ANCHOR POSITIONS: 5# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,AILEFRAMAQFSRKTD*# SEQUENCE: AILEFRAMAQFSRKTD*# ...# >HUM218BE# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSP65 (418-427)# DB REFERENCE: SWISS: (CH62_MYCLE)# & PIR2: (A25902)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,LQAAPALDKL*# SEQUENCE: LQAAPALDKL*# ...# >HUM218BF# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (85-105)# DB REFERENCE: SWISS: (MBP_RAT,MBP_BOVIN,MBP_HUMAN,MBP_PANTR,MBP_MOUSE,# & MBP_CAVPO)# & PIR1: (MBMSB,MBCZB,MBRTS,MBBOB,MBPGB,MBHUB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,PVVHFFKNIVTPRTPPPSQGK*# SEQUENCE: PVVHFFKNIVTPRTPPPSQGK*# ...# >HUM218C0# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (131-145)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: vogt94a,rammensee95a# COMMENT:# SUMMARY: HLA-DR51,actyesu,bindyesu,ASDYKSAHKGFKGVD*# SEQUENCE: ASDYKSAHKGFKGVD*# ...# >HUM218C1# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC/reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (139-153)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: vogt94a,rammensee95a# COMMENT:# SUMMARY: HLA-DR51,actyesu,bindyesu,KGFKGVDAQGTLSKI*# SEQUENCE: KGFKGVDAQGTLSKI*# ...# >HUM218C2# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A3 (152-166)# ANCHOR POSITIONS: 5# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,EAEQLRAYLDGTGVE*# SEQUENCE: EAEQLRAYLDGTGVE*# ...# >HUM218C3# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DRA (45-58)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I72480,I56085)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,LEEFGRFASFEAQG*# SEQUENCE: LEEFGRFASFEAQG*# ...# >HUM218C4# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ6 (43-58)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I68813,I59623,I61839,I68732,I84420,I72481,I68723,I68817,# & I36974,I59528,I61835,D35054)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,DVGVYRAVTPQGRPDA*# SEQUENCE: DVGVYRAVTPQGRPDA*# ...# >HUM218C5# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: SP3 (1-16)# ANCHOR POSITIONS: 2# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,AILEFRAMAQFSRKTD*# SEQUENCE: AILEFRAMAQFSRKTD*# ...# >HUM218C6# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (85-105)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_BOVIN,MBP_RAT,MBP_CAVPO,# & MBP_HUMAN)# & PIR1: (MBBOB,MBCZB,MBMSB,MBRTS,MBHUB,MBPGB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,PVVHFFKNIVTPRTPPPSQGK*# SEQUENCE: PVVHFFKNIVTPRTPPPSQGK*# ...# >HUM218C7# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC/competitive binding as./reference# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: MBP (85-95)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_RAT,MBP_BOVIN,MBP_PANTR,# & MBP_MOUSE)# & PIR1: (MBMSB,MBHUB,MBPGB,MBRTS,MBCZB,MBBOB)# & PIR2: (A37246)# REFERENCES: vogt94a,rammensee95a,wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesm,PVVHFFKNIVT*# SEQUENCE: PVVHFFKNIVT*# ...# >HUM218C8# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Eluted self peptides/HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (148-162)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN,MBP_BOVIN,MBP_CAVPO,MBP_MOUSE)# & PIR1: (MBCZB,MBHUB,MBBOB,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,GTLSKIFKLGGRDSRSG*# SEQUENCE: GTLSKIFKLGGRDSRSG*# ...# >HUM218C9# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (88-98)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_RAT,MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,# & MBP_CAVPO)# & PIR1: (MBBOB,MBCZB,MBMSB,MBRTS,MBHUB,MBPGB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,HFFKNIVTPRT*# SEQUENCE: HFFKNIVTPRT*# ...# >HUM218CA# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-98)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_CAVPO,MBP_MOUSE,MBP_HUMAN,MBP_RAT,# & MBP_PANTR)# & PIR1: (MBBOB,MBHUB,MBPGB,MBRTS,MBMSB,MBCZB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFKNIVTPRT*# SEQUENCE: VHFFKNIVTPRT*# ...# >HUM218CB# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (86-98)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_PANTR,MBP_BOVIN,MBP_CAVPO,# & MBP_MOUSE)# & PIR1: (MBBOB,MBMSB,MBCZB,MBRTS,MBHUB,MBPGB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VVHFFKNIVTPRT*# SEQUENCE: VVHFFKNIVTPRT*# ...# >HUM218CC# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (85-98)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_RAT,MBP_MOUSE,MBP_BOVIN,# & MBP_PANTR)# & PIR1: (MBRTS,MBHUB,MBBOB,MBPGB,MBCZB,MBMSB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,PVVHFFKNIVTPRT*# SEQUENCE: PVVHFFKNIVTPRT*# ...# >HUM218CD# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (84-98)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_CAVPO,MBP_PANTR,MBP_RAT,MBP_MOUSE,# & MBP_HUMAN)# & PIR1: (MBPGB,MBMSB,MBHUB,MBRTS,MBBOB,MBCZB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,NPVVHFFKNIVTPRT*# SEQUENCE: NPVVHFFKNIVTPRT*# ...# >HUM218CE# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-98)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_RAT,MBP_MOUSE,MBP_PANTR,MBP_CAVPO,# & MBP_BOVIN)# & PIR1: (MBBOB,MBPGB,MBCZB,MBMSB,MBRTS,MBHUB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,VHFFKNIVTPRT*# SEQUENCE: VHFFKNIVTPRT*# ...# >HUM218CF# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (86-98)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,MBP_PANTR,MBP_CAVPO,# & MBP_RAT)# & PIR1: (MBPGB,MBMSB,MBHUB,MBBOB,MBRTS,MBCZB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,VVHFFKNIVTPRT*# SEQUENCE: VVHFFKNIVTPRT*# ...# >HUM218D0# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (85-98)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_MOUSE,MBP_PANTR,MBP_BOVIN,MBP_CAVPO,# & MBP_RAT)# & PIR1: (MBPGB,MBRTS,MBCZB,MBMSB,MBBOB,MBHUB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,PVVHFFKNIVTPRT*# SEQUENCE: PVVHFFKNIVTPRT*# ...# >HUM218D1# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (84-98)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_RAT,MBP_PANTR,MBP_BOVIN,# & MBP_MOUSE)# & PIR1: (MBBOB,MBRTS,MBCZB,MBPGB,MBHUB,MBMSB)# & PIR2: (A37246)# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,NPVVHFFKNIVTPRT*# SEQUENCE: NPVVHFFKNIVTPRT*# ...# >HUM218D3# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MBP (84-95)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_RAT,MBP_BOVIN,MBP_HUMAN,# & MBP_CAVPO)# & PIR1: (MBRTS,MBPGB,MBHUB,MBCZB,MBBOB,MBMSB)# & PIR2: (A37246)# REFERENCES: vogt94a,wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesh,NPVVHFFKNIVT*# SEQUENCE: NPVVHFFKNIVT*# ...# >HUM218D4# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_CAVPO,MBP_MOUSE,MBP_BOVIN,# & MBP_PANTR)# & PIR1: (MBCZB,MBBOB,MBMSB,MBPGB,MBHUB,MBRTS)# & PIR2: (A37246)# REFERENCES: vogt94a,martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >HUM218D5# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHAFKNIVTPRTP*# SEQUENCE: VHAFKNIVTPRTP*# ...# >HUM218D6# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFANIVTPRTP*# SEQUENCE: VHFFANIVTPRTP*# ...# >HUM218D7# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFKAIVTPRTP*# SEQUENCE: VHFFKAIVTPRTP*# ...# >HUM218D8# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFKNAVTPRTP*# SEQUENCE: VHFFKNAVTPRTP*# ...# >HUM218D9# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFKNIATPRTP*# SEQUENCE: VHFFKNIATPRTP*# ...# >HUM218DA# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFKNIVAPRTP*# SEQUENCE: VHFFKNIVAPRTP*# ...# >HUM218DB# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFKNIVTARTP*# SEQUENCE: VHFFKNIVTARTP*# ...# >HUM218DC# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFKNIVTPATP*# SEQUENCE: VHFFKNIVTPATP*# ...# >HUM218DD# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,VHFFKNIVTPRAP*# SEQUENCE: VHFFKNIVTPRAP*# ...# >HUM218DE# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a,martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,VHAFKNIVTPRTP*# SEQUENCE: VHAFKNIVTPRTP*# ...# >HUM218DF# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,VHFFANIVTPRTP*# SEQUENCE: VHFFANIVTPRTP*# ...# >HUM218E0# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,VHFFKAIVTPRTP*# SEQUENCE: VHFFKAIVTPRTP*# ...# >HUM218E1# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a,martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesn,bindyesu,VHFFKNAVTPRTP*# SEQUENCE: VHFFKNAVTPRTP*# ...# >HUM218E2# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a,martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesn,bindyesu,VHFFKNIATPRTP*# SEQUENCE: VHFFKNIATPRTP*# ...# >HUM218E3# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a,martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,VHFFKNIVAPRTP*# SEQUENCE: VHFFKNIVAPRTP*# ...# >HUM218E4# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a,martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,VHFFKNIVTARTP*# SEQUENCE: VHFFKNIVTARTP*# ...# >HUM218E5# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a,martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,VHFFKNIVTPATP*# SEQUENCE: VHFFKNIVTPATP*# ...# >HUM218E6# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99) homologue# ANCHOR POSITIONS:# REFERENCES: vogt94a,martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,VHFFKNIVTPRAP*# SEQUENCE: VHFFKNIVTPRAP*# ...# >HUM218E7# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B*2705 (108-122)# DB REFERENCE: SWISS: (1B14_HUMAN,1B16_HUMAN,1B18_HUMAN,1B45_HUMAN,# & 1B15_HUMAN)# & PIR1: (HLHUB2)# & PIR2: (I68724,I62045,I54289)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,GPDGRLLRGYHQDAYDGKD*# SEQUENCE: GPDGRLLRGYHQDAYDGKD*# ...# >HUM218E8# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B*2705 (108-122)# DB REFERENCE: SWISS: (1B18_HUMAN,1B16_HUMAN,1B15_HUMAN,1B45_HUMAN,# & 1B14_HUMAN)# & PIR1: (HLHUB2)# & PIR2: (I62045,I68724,I54289)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,GPDGRLLRGYHQDAYDGK*# SEQUENCE: GPDGRLLRGYHQDAYDGK*# ...# >HUM218E9# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B*2705 (108-122)# DB REFERENCE: SWISS: (1B18_HUMAN,1B16_HUMAN,1B15_HUMAN,1B45_HUMAN,# & 1B14_HUMAN)# & PIR1: (HLHUB2)# & PIR2: (I68724,I54289,I62045)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,RLLRGYHQDAYDGKD*# SEQUENCE: RLLRGYHQDAYDGKD*# ...# >HUM218EA# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B*2705 (108-121)# DB REFERENCE: SWISS: (1B18_HUMAN,1B15_HUMAN,1B16_HUMAN,1B45_HUMAN,# & 1B14_HUMAN)# & PIR1: (HLHUB2)# & PIR2: (I68724,I62045,I54289)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,RLLRGYHQDAYDGK*# SEQUENCE: RLLRGYHQDAYDGK*# ...# >HUM218EB# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgG (44-59)# ANCHOR POSITIONS:# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,DTLRSYYADWYQQKPG*# SEQUENCE: DTLRSYYADWYQQKPG*# ...# >HUM218EC# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Carboxypeptidase E CBE(142-158)# DB REFERENCE: SWISS: (CBPH_RAT,CBPH_HUMAN,CBPH_MOUSE)# & PIR2: (S09489,S16383,S12461,A40469)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,GIDLNRNFPDLDRIVYV*# SEQUENCE: GIDLNRNFPDLDRIVYV*# ...# >HUM218ED# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Carboxypeptidase E CBE (143-158)# DB REFERENCE: SWISS: (CBPH_RAT,CBPH_HUMAN,CBPH_MOUSE)# & PIR2: (S09489,S12461,S16383,A40469)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,IDLNRNFPDLDRIVYV*# SEQUENCE: IDLNRNFPDLDRIVYV*# ...# >HUM218EE# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (102-122)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,LKSQDLELSWNLNGLQADLSS*# SEQUENCE: LKSQDLELSWNLNGLQADLSS*# ...# >HUM218EF# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (104-124)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,LKSQDLELSWNLNGLQADLSSFK*# SEQUENCE: LKSQDLELSWNLNGLQADLSSFK*# ...# >HUM218F0# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (102-121)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,LKSQDLELSWNLNGLQADLS*# SEQUENCE: LKSQDLELSWNLNGLQADLS*# ...# >HUM218F1# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (103-122)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,KSQDLELSWNLNGLQADLSS*# SEQUENCE: KSQDLELSWNLNGLQADLSS*# ...# >HUM218F2# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (103-121)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,KSQDLELSWNLNGLQADLS*# SEQUENCE: KSQDLELSWNLNGLQADLS*# ...# >HUM218F3# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (104-122)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,SQDLELSWNLNGLQADLSS*# SEQUENCE: SQDLELSWNLNGLQADLSS*# ...# >HUM218F4# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (104-121)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,SQDLELSWNLNGLQADLS*# SEQUENCE: SQDLELSWNLNGLQADLS*# ...# >HUM218F5# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (105-120)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,QDLELSWNLNGLQADL*# SEQUENCE: QDLELSWNLNGLQADL*# ...# >HUM218F6# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (104-118)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,SQDLELSWNLNGLQA*# SEQUENCE: SQDLELSWNLNGLQA*# ...# >HUM218F7# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (105-118)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,QDLELSWNLNGLQA*# SEQUENCE: QDLELSWNLNGLQA*# ...# >HUM218F8# MHC MOLECULE: HLA-DQ1(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FceR (105-116)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ1,actunkn,bindyesu,QDLELSWNLNGLQ*# SEQUENCE: QDLELSWNLNGLQ*# ...# >HUM218F9# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ8 alpha (75-87)# DB REFERENCE: SWISS: (HA21_HUMAN,HA24_HUMAN)# & PIR1: (HLHUDC,HLHUDQ)# & PIR2: (I68551,A29312)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,IVIKRSNSTAATN*# SEQUENCE: IVIKRSNSTAATN*# ...# >HUM218FA# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (332-347)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# & PIR2: (S29548)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,IPVQTISRAAAEKLFG*# SEQUENCE: IPVQTISRAAAEKLFG*# ...# >HUM218FB# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: li chain - invariant chain (98-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALP*# SEQUENCE: PKPPKPVSKMRMATPLLMQALP*# ...# >HUM218FC# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Basic proline rich protein BPRP (1-20)# ANCHOR POSITIONS:# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,GPPEKPQGPPQQEGNNPQGP*# SEQUENCE: GPPEKPQGPPQQEGNNPQGP*# ...# >HUM218FD# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Basic proline rich protein BPRP (1-16)# ANCHOR POSITIONS:# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,GPPEKPQGPPQQEGNN*# SEQUENCE: GPPEKPQGPPQQEGNN*# ...# >HUM218FE# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal L18 protein (17-42)# DB REFERENCE: SWISS: (RL18_HUMAN,RL18_RAT,RL18_MOUSE)# & PIR1: (JN0779,R5RT81)# & PIR2: (S38352)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,EPKSQDIYLRLLVKLYRFLARRTNST*# SEQUENCE: EPKSQDIYLRLLVKLYRFLARRTNST*# ...# >HUM218FF# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: SSBP (18-74)# DB REFERENCE: SWISS: (SSB_HUMAN)# & PIR2: (JN0568)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,SETTTSLVLERSLNRVHLLGRVGQDPVLRQVEGKNPVTIFS___# SEQUENCE: SETTTSLVLERSLNRVHLLGRVGQDPVLRQVEGKNPVTIFSLATNEMWRSGDSEVYQ*# ...# >HUM21900# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: SSBP (24-74)# DB REFERENCE: SWISS: (SSB_HUMAN)# & PIR2: (JN0568)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,LVLERSLNRVHLLGRVGQDPVLRQVEGKNPVTIFSLATNEM___# SEQUENCE: LVLERSLNRVHLLGRVGQDPVLRQVEGKNPVTIFSLATNEMWRSGDSEVYQ*# ...# >HUM21901# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: SSBP (18-46)# DB REFERENCE: SWISS: (SSB_HUMAN)# & PIR2: (JN0568)# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,SETTTSLVLERSLNRVHLLGRVGQDPVLR*# SEQUENCE: SETTTSLVLERSLNRVHLLGRVGQDPVLR*# ...# >HUM21902# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: eluted self peptides/HPLC/mass spectrometry/Edman sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: SSBP (75-184)# DB REFERENCE: SWISS: (SSB_HUMAN)# & PIR2: (JN0568)# ANCHOR POSITIONS:# REFERENCES: chicz94a# COMMENT: IDDM related alleles# SUMMARY: HLA-DQ8,actunkn,bindyesu,LGDVSQKTTWHRISVFRPGLRDVAYQYVKKGSRIYLEGKID___# SEQUENCE: LGDVSQKTTWHRISVFRPGLRDVAYQYVKKGSRIYLEGKIDYGEYMDKNNVRRQATTIIADNIIFLS*# ...# >MUS11903# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: surface induction/cytotoxicity as./Stabilization# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P91A tum- (14-22) homologue# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# REFERENCES: alexander-miller94a,gillanders96a# COMMENT: synthetic peptides# SUMMARY: H-2Ld,actyesu,bindyesu,TQNHRALDL*# SEQUENCE: TQNHRALDL*# ...# >MUS11904# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: surface induction/cytotoxicity as./Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P91A tum- (14-22) homologue# ANCHOR POSITIONS: 6,8,9# REFERENCES: alexander-miller94a,robinson96a# COMMENT: synthetic peptides# SUMMARY: H-2Ld,actyesu,bindyesh,AQNHRALDL*# SEQUENCE: AQNHRALDL*# ...# >MUS11905# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: surface induction/cytotoxicity as./Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P91A tum- (14-22) homologue# ANCHOR POSITIONS: 6,8,9# REFERENCES: alexander-miller94a,robinson96a# COMMENT: synthetic peptides# SUMMARY: H-2Ld,actyesu,bindyesh,TANHRALDL*# SEQUENCE: TANHRALDL*# ...# >MUS11906# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: surface induction/cytotoxicity as./Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P91A tum- (14-22) homologue# ANCHOR POSITIONS: 6,8,9# REFERENCES: alexander-miller94a,robinson96a# COMMENT: synthetic peptides# SUMMARY: H-2Ld,actyesu,bindyesh,TFNHRALDL*# SEQUENCE: TFNHRALDL*# ...# >MUS11907# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: surface induction/cytotoxicity as./Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P91A tum- (14-22) homologue# ANCHOR POSITIONS: 6,8,9# REFERENCES: alexander-miller94a,robinson96a# COMMENT: synthetic peptides# SUMMARY: H-2Ld,actyesu,bindyesh,TQAHRALDL*# SEQUENCE: TQAHRALDL*# ...# >MUS11908# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: surface induction/cytotoxicity as./Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P91A tum- (14-22) homologue# ANCHOR POSITIONS: 6,8,9# REFERENCES: alexander-miller94a,robinson96a# COMMENT: synthetic peptides# SUMMARY: H-2Ld,actyesu,bindyesh,TQNARALDL*# SEQUENCE: TQNARALDL*# ...# >MUS11909# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: surface induction/cytotoxicity as./Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P91A tum- (14-22) homologue# ANCHOR POSITIONS: 6,8,9# REFERENCES: alexander-miller94a,robinson96a# COMMENT: synthetic peptides# SUMMARY: H-2Ld,actyesu,bindyesh,TQNHAALDL*# SEQUENCE: TQNHAALDL*# ...# >MUS1190A# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: surface induction/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P91A tum- (14-22) homologue# ANCHOR POSITIONS: 6,8,9# REFERENCES: alexander-miller94a# COMMENT: synthetic peptides# SUMMARY: H-2Ld,actyesu,bindyesu,TQNHRAADL*# SEQUENCE: TQNHRAADL*# ...# >HUM2190B# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bluegrass pollen allergen# DB REFERENCE: SWISS: (MP92_POAPR,MP93_POAPR,MP93_POAPR,MP92_POAPR,MP91_POAPR,# & MP5A_PHLPR,MP91_POAPR)# & PIR2: (C39098,A60373,S32101,A39098,B39098,S37400)# REFERENCES: mohapatra94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,VKYTVFETALKKAIT*# SEQUENCE: VKYTVFETALKKAIT*# ...# >HUM2190C# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ryegrass pollen allergen# DB REFERENCE: SWISS: (MPL2_LOLPR,MPL2_LOLPR)# & PIR2: (A48595,A34291)# REFERENCES: mohapatra94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,HGSNEWLALKKNGD*# SEQUENCE: HGSNEWLALKKNGD*# ...# >HUM2190D# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ragweed pollen allergen# DB REFERENCE: SWISS: (MPA5_AMBEL,MPA5_AMBEL)# & PIR1: (ARRA5)# REFERENCES: mohapatra94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,VCYESSEICSKKCGK*# SEQUENCE: VCYESSEICSKKCGK*# ...# >HUM2190E# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bluegrass pollen allergen# DB REFERENCE: SWISS: (MP93_POAPR,MP92_POAPR,MP92_POAPR,MP93_POAPR,MP91_POAPR,# & MP91_POAPR)# & PIR2: (B39098,A39098,C39098)# REFERENCES: mohapatra94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,PAGELQVIDKVDA*# SEQUENCE: PAGELQVIDKVDA*# ...# >HUM2190F# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: redtop pollen allergen# ANCHOR POSITIONS:# REFERENCES: mohapatra94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,AAELQVIDKVDF*# SEQUENCE: AAELQVIDKVDF*# ...# >HUM21910# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: smooth brome pollen allergen# ANCHOR POSITIONS:# REFERENCES: mohapatra94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,AAELQVIDKADA*# SEQUENCE: AAELQVIDKADA*# ...# >HUM21911# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: birch tree pollen allergen# ANCHOR POSITIONS:# REFERENCES: mohapatra94b# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,PAAELQVIDKADA*# SEQUENCE: PAAELQVIDKADA*# ...# >MUS11912# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: MMTV env (103-111)# DB REFERENCE: SWISS: (ENV_MMTVG,ENV_MMTVB)# & PIR1: (VCMVM,VCMVMM)# & PIR2: (S26388)# REFERENCES: gill94a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actyesu,bindyesm,AYLPKPPIL*# SEQUENCE: AYLPKPPIL*# ...# >MUS11913# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MMTV gag (425-433)# DB REFERENCE: SWISS: (GAG_MMTVC,GAG_MMTVB)# & PIR1: (FOMVMM)# & PIR2: (A29029)# REFERENCES: gill94a,wei96a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actyesu,bindyesh,SYETFISRL*# SEQUENCE: SYETFISRL*# ...# >MUS11914# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MMTV gag (504-512)# DB REFERENCE: SWISS: (GAG_MMTVC,GAG_MMTVB)# & PIR1: (FOMVMM)# & PIR2: (A29029)# REFERENCES: gill94a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actyesn,bindyesl,KYSTFVKQT*# SEQUENCE: KYSTFVKQT*# ...# >MUS11915# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MMTV env (372-381)# DB REFERENCE: SWISS: (ENV_MMTVB,ENV_MMTVG)# & PIR1: (VCMVMM,VCMVM)# REFERENCES: gill94a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actunkn,bindyesm,TYPYAILLGL*# SEQUENCE: TYPYAILLGL*# ...# >MUS11916# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MMTV env (474-482)# DB REFERENCE: SWISS: (ENV_MMTVG,ENV_MMTVB)# & PIR1: (VCMVMM,VCMVM)# & PIR2: (S26388)# REFERENCES: gill94a,wei96a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actyesu,bindyesh,SFAVATTAL*# SEQUENCE: SFAVATTAL*# ...# >MUS11917# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MMTV env (626-634)# DB REFERENCE: SWISS: (ENV_MMTVB,ENV_MMTVG)# & PIR1: (VCMVM,VCMVMM)# & PIR2: (S26388)# REFERENCES: gill94a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actunkn,bindyesh,IFIGVGALL*# SEQUENCE: IFIGVGALL*# ...# >MUS11918# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MMTV env (645-653)# DB REFERENCE: SWISS: (ENV_MMTVG,ENV_MMTVB)# & PIR1: (VCMVMM,VCMVM)# & PIR2: (S26388)# REFERENCES: gill94a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actunkn,bindyesl,VFQCLAKSL*# SEQUENCE: VFQCLAKSL*# ...# >MUS11919# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MMTV env (624-633)# DB REFERENCE: SWISS: (ENV_MMTVG,ENV_MMTVB)# & PIR1: (VCMVM,VCMVMM)# & PIR2: (S26388)# REFERENCES: gill94a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actunkn,bindyesh,YFIFIGVGAL*# SEQUENCE: YFIFIGVGAL*# ...# >MUS1191A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MMTV gag (45-54)# DB REFERENCE: SWISS: (GAG_MMTVB,GAG_MMTVC)# & PIR1: (FOMVMM)# REFERENCES: gill94a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actunkn,bindyesl,WFPEEGGLNL*# SEQUENCE: WFPEEGGLNL*# ...# >MUS1191B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MMTV env (456-465)# DB REFERENCE: SWISS: (ENV_MMTVB,ENV_MMTVG)# & PIR1: (VCMVMM,VCMVM)# & PIR2: (S26388)# REFERENCES: gill94a# COMMENT: synthetic peptides# SUMMARY: H-2Kd,actunkn,bindyesl,RFVAAIILGI*# SEQUENCE: RFVAAIILGI*# ...# >RHE1191C# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SIV mac gag 11C p11C (182-190) variant# ANCHOR POSITIONS:# REFERENCES: shen94a# COMMENT: synthetic peptides# SUMMARY: Mamu-A1,actyesu,bindyesu,TPYDINRML*# SEQUENCE: TPYDINRML*# ...# >RHE1191D# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SIV mac gag 11C p11C (182-190) variant# ANCHOR POSITIONS:# REFERENCES: shen94a# COMMENT: synthetic peptides# SUMMARY: Mamu-A1,actyesu,bindyesu,TPYDINQRL*# SEQUENCE: TPYDINQRL*# ...# >RHE1191E# MHC MOLECULE: Mamu-A1(MamuA*01), CLASS-1, (RHESUS MACAQUE)# METHOD: Cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SIV mac gag 11C p11C (182-190) variant# ANCHOR POSITIONS:# REFERENCES: shen94a# COMMENT: synthetic peptides# SUMMARY: Mamu-A1,actyesu,bindyesu,TPYDINQMR*# SEQUENCE: TPYDINQMR*# ...# >HUM1191F# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: self peptide# ANCHOR POSITIONS: 2,9# REFERENCES: takamiya94a,schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,LPFDFTPGY*# SEQUENCE: LPFDFTPGY*# ...# >HUM11920# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,LPFDFTPGS*# SEQUENCE: LPFDFTPGS*# ...# >HUM11921# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,RPFDFTPGYN*# SEQUENCE: RPFDFTPGYN*# ...# >HUM11922# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,RPFDFTPGY*# SEQUENCE: RPFDFTPGY*# ...# >HUM11923# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? self peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,LPGPKFLQY*# SEQUENCE: LPGPKFLQY*# ...# >HUM11924# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,LPFDFTPY*# SEQUENCE: LPFDFTPY*# ...# >HUM11925# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,LPFDFTPGGY*# SEQUENCE: LPFDFTPGGY*# ...# >HUM11926# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,LPFDFTPGGGY*# SEQUENCE: LPFDFTPGGGY*# ...# >HUM11927# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,LPFDFTPGGGGY*# SEQUENCE: LPFDFTPGGGGY*# ...# >HUM11928# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: takamiya94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,LPFDFTPGGGGGY*# SEQUENCE: LPFDFTPGGGGGY*# ...# >HUM11929# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV Pol (1147-1155)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBVM,DPOL_HPBV4,DPOL_HPBVJ,DPOL_HPBVY,# & DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBVL,DPOL_HPBVA,DPOL_HPBVP,# & DPOL_HPBV2,DPOL_HPBV9,DPOL_HPBVZ,DPOL_HPBVO)# & PIR1: (JDVLVH,JDVLVR,JDVLJ2,S20752,JDVLVS,JDVLVB,JDVLCP,S47406,# & JDVLJ3,JDVLVD,JDVLKS,S20757,JDVLJ1,JDVLA1,JDVLVA)# & PIR2: (S71785,S35527)# REFERENCES: sette94b,wentworth96a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLLSLGIHL*# SEQUENCE: FLLSLGIHL*# ...# >HUM1192A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV Pol (635-643)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVY,DPOL_HPBV4,DPOL_HPBVZ,DPOL_HPBVR,# & DPOL_HPBVM,DPOL_HPBVA,DPOL_HPBVJ)# & PIR1: (S20757,S43491,JDVLJ1,JDVLVS,JDVLVB,S47406,JDVLVA,JDVLA1,# & JDVLVH,JDVLVR)# & PIR2: (S71785,S35527)# REFERENCES: sette94b,wentworth96a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLYSSTVPV*# SEQUENCE: GLYSSTVPV*# ...# >HUM1192B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV Pol (1076-1084)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBVZ,DPOL_HPBVJ,DPOL_HPBVI,DPOL_HPBVA,# & DPOL_HPBVM,DPOL_HPBV4,DPOL_HPBVO,DPOL_HPBVP,DPOL_HPBVR,# & DPOM_HPBVY,DPOL_HPBVY)# & PIR1: (S20757,JDVLVS,JDVLVR,JDVLVB,JDVLJ3,JDVLVH,S43491,S47406,# & JDVLJ1,JQ2229,JDVLVA,JDVLA1,JDVLJ2)# & PIR2: (S71785,S35527)# REFERENCES: sette94b,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,HLYSHPIIL*# SEQUENCE: HLYSHPIIL*# ...# >HUM1192C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HPV 16 E7 (86-93)# ANCHOR POSITIONS:# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,TLIDVCPI*# SEQUENCE: TLIDVCPI*# ...# >HUM1192D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV Pol (1344-1352)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBV9,DPOL_HPBVT,DPOL_HPBV2,DPOM_HPBVY,# & DPOL_HPBVY,DPOL_HPBVJ,DPOL_HPBVL,DPOL_HPBVA,DPOL_HPBVI,# & DPOL_HPBVO)# & PIR1: (S43491,JDVLJ3,JDVLCP,JDVLKS,S20752,JDVLVD,S47406,S20757,# & JDVLVB,JDVLVR,JDVLVA,JDVLA1,JDVLJ2,JDVLJ1,JQ2229)# & PIR2: (S35527,S71785)# REFERENCES: sette94b,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,WILRGTSFV*# SEQUENCE: WILRGTSFV*# ...# >HUM1192E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV Pol (996-1004)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVP,DPOL_HPBVL,DPOL_HPBVW,DPOL_HPBV2,# & DPOL_HPBV9,DPOL_HPBVT,DPOL_HPBVZ,DPOL_HPBVM,DPOL_HPBVR,# & DPOL_HPBVJ,DPOM_HPBVY,DPOL_HPBVY,DPOL_HPBVO,# & DPOL_HPBVA)# & PIR1: (S47406,JDVLVS,JDVLVD,S20757,S43491,JDVLJ1,JQ2229,JDVLVR,# & JDVLA1,JDVLVA,JDVLJ2,JDVLVH,JDVLVB,S20752,JDVLCP,# & JDVLKS)# & PIR2: (S71785,S35527)# REFERENCES: sette94b,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,NLSWLSLDV*# SEQUENCE: NLSWLSLDV*# ...# >HUM1192F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV Pol (992-1000)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVZ,DPOL_HPBVT,DPOL_HPBVM,DPOL_HPBVW,# & DPOL_HPBVA,DPOL_HPBVY,DPOL_HPBVO,DPOL_HPBVR,DPOL_HPBVJ,# & DPOM_HPBVY,DPOL_HPBV4,DPOL_HPBVP,DPOL_HPBV2,# & DPOL_HPBV9)# & PIR1: (JDVLJ2,S43491,JDVLCP,JDVLJ1,JDVLVS,JDVLVD,S47406,JDVLVB,# & S20752,JDVLA1,JDVLVA,JDVLVR,JQ2229,JDVLVH,S20757,# & JDVLKS)# & PIR2: (S71785,S35527)# REFERENCES: sette94b,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LLSSNLSWL*# SEQUENCE: LLSSNLSWL*# ...# >HUM11930# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV Pol (985-993)# DB REFERENCE: SWISS: (DPOL_HPBVJ,DPOM_HPBVY,DPOL_HPBVR,DPOL_HPBV2,DPOL_HPBVP,# & DPOL_HPBV4,DPOL_HPBV9,DPOL_HPBVT,DPOL_HPBVM,DPOL_HPBVO,# & DPOL_HPBVY,DPOL_HPBVW,DPOL_HPBVZ,DPOL_HPBVL,DPOL_HPBVA,# & DPOL_HPBVI)# & PIR1: (JDVLJ2,S43491,S20757,JDVLA1,JDVLVB,JDVLVR,S20752,JDVLVA,# & JQ2229,JDVLJ1,JDVLVH,JDVLVS,JDVLVD,S47406,JDVLKS,JDVLCP,# & JDVLJ3)# & PIR2: (S71785,S35527)# REFERENCES: sette94b,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,NLQSLTNLL*# SEQUENCE: NLQSLTNLL*# ...# >HUM11931# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV Pol (43-51)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBVM,DPOM_HPBVY,DPOL_HPBVA,DPOL_HPBVT,# & DPOL_HPBV4,DPOL_HPBVL,DPOL_HPBVZ,DPOL_HPBVR,DPOL_HPBVY,# & DPOL_HPBVO,DPOL_HPBVJ)# & PIR1: (JDVLJ2,S43491,JDVLVB,JDVLVA,JDVLJ1,JQ2229,JDVLVH,JDVLVS,# & S47406,JDVLVR,S20757,JDVLA1,JDVLJ3,JDVLCP)# & PIR2: (S35527)# REFERENCES: sette94b,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,HLLVGSSGL*# SEQUENCE: HLLVGSSGL*# ...# >HUM11932# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: HBV POL (527-535)# DB REFERENCE: SWISS: (DPOL_WHV59,DPOL_HPBVZ,DPOL_HPBVO,DPOL_HPBV9,DPOL_HPBVA,# & DPOL_HPBVI,DPOL_HPBVT,DPOL_HPBVM,DPOM_HPBVY,DPOL_HPBVL,# & DPOL_HPBVR,DPOL_HPBVJ,DPOL_HPBVY,DPOL_HPBV4,DPOL_HPBV2,# & DPOL_HPBVP)# & PIR1: (JDVLVR,S47406,S20757,JDVLVD,JDVLVB,JDVLVA,JQ2229,JDVLJ1,# & S20752,JDVLVH,JDVL59,JDVLVS,JDVLCP,JDVLJ3,S43491,JDVLA1,# & JDVLKS,JDVLJ2)# & PIR2: (S71785,S35527)# REFERENCES: sette94b,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,LLAQFTSAI*# SEQUENCE: LLAQFTSAI*# ...# >HUM11933# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: HBV CORE (118-126)# DB REFERENCE: SWISS: (CORA_HPBVO,CORA_HPBVY,CORA_HPBVJ,CORA_HPBV9,CORA_HPBVZ,# & CORA_HPBVW,CORA_HPBVT,CORA_HPBVL,CORA_HPBV4,CORA_HPBVA,# & CORA_HPBVF,CORA_HPBV2)# & PIR1: (NKVLAH,NKVLA2,NKVLA6,NKVLBH,NKVLA1,NKVLCP,NKVLKS,NKVLJ1,# & NKVLA3,NKVLJ2,NKVLH3,NKVLA4)# & PIR2: (S53257,S53186,S53140,S47405,S53253,S53189,S53204,S53207,# & S53159,S22318,S53281,S53178,JQ2227,S01405,S53240,S53229,# & S53166,S53129,S20746,S33686,S53149,S35530,S53288,S20755,# & S53184,S53227,S53279,S53236,S53198,S53202,S53225,S53172,# & S53286,S47409,S32204,S53211,S53175,S53137,S53146,S53238,# & S53152,S53242,S25651,S53200,S53247,S53270,S53157,S53181,# & S53223,S53232,S53169,S53163,S53260,S53251,S43490,S53267,# & S53143,S53255,S53221,S53214,S53216,S53194,S04570,S53155,# & S53272,S53274,S53161)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,YLVSFGVWI*# SEQUENCE: YLVSFGVWI*# ...# >HUM11934# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV ENV (338-347)# DB REFERENCE: SWISS: (VMSA_HPBVP,VMSA_HPBV4,VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBVW,# & VMSA_HPBV2,VMSA_HPBVJ,VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBVO,# & VMSA_HPBVY,VMSA_HPBV9,VMSA_HPBV0,VMSA_HPBVA,VMSA_HPBVW,# & VMSA_HPBVN,VMSA_HPBV2,VMSA_HPBVR)# & PIR1: (SAVLJ3,SAVLA,SAVLJ2,SAVLKS,SAVLHV,JQ1571,JQ1577,JQ1575,# & SAVLVE,SAVLA1,SAVLBH,SAVLAJ,SAVLVD,SAVLJ1,JQ1574,JQ1570,# & SAVLN1,JQ1572,SAVLAH)# & PIR2: (JQ2111,JQ2058,JQ2100,JQ2056,JQ2059,JQ2047,JQ2050,JQ2057,# & JQ2073,JQ2110,JQ2048,JQ2065,JQ2114,JQ2068,JQ2045,S47407,# & JQ2046,JQ2103,JQ2067,JQ2077,S20745,JQ2069,JQ2099,JQ2061,# & JQ2078,JQ2072,JQ2051,S20749,JQ2115,JQ2116,JQ2097,JQ2098,# & JQ2062,S47411,S20753,JQ2109,JQ2108,JQ2066,S41869,JQ2112,# & JQ2063,JQ2052,JQ2075,JQ2055,JQ2054,JQ2053,S36654,JQ2060,# & JQ2113,JQ2076,JQ2101,S32202,JQ2081)# REFERENCES: sette94b,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLVPFVQWFV*# SEQUENCE: LLVPFVQWFV*# ...# >HUM11935# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competition# ACTIVITY: none# BINDING: yes, high# SOURCE: HBV ENV (62-70)# DB REFERENCE: SWISS: (VMSA_HPBVA,VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVJ,VMSA_HPBV4,# & VMSA_HPBVR,VMSA_HPBVO,VMSA_HPBVY,VMSA_HPBVT,VMSA_HPBVR,# & VMSA_HPBVI)# & PIR1: (SAVLAJ,SAVLBH,SAVLAH,SAVLJ3,SAVLJ2,SAVLA,SAVLJ1,# & SAVLA1)# & PIR2: (S41869,S32202,S20753,S41871,S20745,S20749,JQ2230,S47407,# & S41870,S35528,S43492)# REFERENCES: sette94b,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GLLGWSPQA*# SEQUENCE: GLLGWSPQA*# ...# >HUM11936# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV ENV (183-191)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVD,VMSA_HPBV9,VMSA_HPBV0,# & VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBV4,VMSA_HPBVR,# & VMSA_HPBVR,VMSA_HPBVN,VMSA_HPBVW,VMSA_HPBVP,VMSA_HPBVS,# & VMSA_HPBVZ)# & PIR1: (JQ1577,SAVLAH,SAVLHV,SAVLAJ,JQ1575,SAVLKS,SAVLAR,SAVLAD,# & SAVLVE,SAVLA,SAVLVD,SAVLBH,SAVLN1)# & PIR2: (JQ2098,S47411,JQ2072,JQ2115,JQ2048,JQ2114,JQ2045,S35528,# & JQ2099,JQ2067,S20745,JQ2054,JQ2070,JQ2052,JQ2080,JQ2050,# & JQ2100,JQ2094,S41871,JQ2066,JQ2051,JQ2096,JQ2068,JQ2113,# & S36654,JQ2076,JQ2047,JQ2056,JQ2083,JQ2111,JQ2046,JQ2103,# & JQ2065,S43492,JQ2073,S41870,JQ2105,JQ2077,JQ2069,JQ2078,# & JQ2097,JQ2095,S47407,JQ2104,S20749,JQ2109,JQ2063,S41869,# & JQ2081,S32202,JQ2079,JQ2112,JQ2075,JQ2055,S20753,JQ2102,# & JQ2053,JQ2108)# & PIR4: (S42226)# REFERENCES: sette94b,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLLTRILTI*# SEQUENCE: FLLTRILTI*# ...# >HUM11937# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: HBV ENV (360-368)# DB REFERENCE: SWISS: (VMSA_HPBVJ,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVZ,# & VMSA_HPBVR,VMSA_HPBV4,VMSA_HPBVR,VMSA_HPBV9,VMSA_HPBVD,# & VMSA_HPBVN,VMSA_HPBVW,VMSA_HPBVS,VMSA_HPBVW,VMSA_HPBVY,# & VMSA_HPBV2)# & PIR1: (SAVLA,SAVLVE,SAVLJ1,JQ1574,SAVLKS,SAVLAD,SAVLN1,SAVLAH,# & SAVLAJ,JQ1571,JQ1581,JQ1576,JQ1575,SAVLBH,JQ1572,SAVLVD,# & JQ1573,JQ1577,SAVLAR,JQ1578)# & PIR2: (JQ2078,JQ2097,JQ2053,JQ2109,JQ2104,S47407,S41869,JQ2075,# & JQ2063,S32202,JQ2079,JQ2055,S20753,JQ2105,JQ2069,JQ2065,# & JQ2103,JQ2073,JQ2047,JQ2085,JQ2070,S20745,JQ2061,JQ2092,# & JQ2052,JQ2083,JQ2106,JQ2080,JQ2090,JQ2094,JQ2110,JQ2098,# & S47411,JQ2072,JQ2091,JQ2048,JQ2067,JQ2051,JQ2096,JQ2066,# & JQ2089,JQ2045,JQ2054,S36654,JQ2111,JQ2087,JQ2059,JQ2050,# & JQ2108,JQ2112,JQ2081,JQ2101,S20749,JQ2095,S41870,JQ2099,# & S35528,JQ2114,JQ2115,JQ2113,JQ2116,JQ2056,JQ2088)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,MMWYWGPSL*# SEQUENCE: MMWYWGPSL*# ...# >HUM11938# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ENV (249-258)# DB REFERENCE: SWISS: (VMSA_HPBVN,VMSA_HPBV0,VMSA_HPBVL,VMSA_HPBVO,VMSA_HPBV2,# & VMSA_HPBV9,VMSA_HPBVD,VMSA_HPBVW,VMSA_HPBVJ,VMSA_HPBV2,# & VMSA_HPBVA,VMSA_HPBVY,VMSA_HPBVI,VMSA_HPBVT,VMSA_HPBVW,# & VMSA_HPBVR,VMSA_HPBV4,VMSA_HPBVP,VMSA_HPBVY,VMSA_HPBVZ,# & VMSA_HPBVR,VMSA_HPBVS)# & PIR1: (SAVLJ2,SAVLHV,SAVLBH,SAVLVD,JQ1573,JQ1571,JQ1578,SAVLA,# & JQ1580,SAVLN1,JQ1576,SAVLCP,JQ1575,SAVLA1,SAVLAR,JQ1577,# & JQ1572,SAVLVE,SAVLJ3,SAVLAD,JQ1579,SAVLAJ,SAVLAH,JQ1581,# & JQ1574,JQ1570,SAVLKS,SAVLJ1)# & PIR2: (JQ2066,JQ2096,JQ2089,JQ2113,JQ2088,JQ2056,S20749,JQ2077,# & JQ2070,JQ2061,S47411,JQ2073,JQ2065,JQ2055,S41869,JQ2063,# & JQ2225,JQ2109,JQ2102,JQ2060,S47407,JQ2079,JQ2057,JQ2108,# & JQ2068,JQ2106,JQ2083,JQ2099,JQ2050,JQ2058,JQ2078,JQ2097,# & S41871,JQ2087,JQ2111,JQ2054,JQ2045,JQ2053,JQ2115,S35528,# & JQ2114,JQ2116,JQ2122,JQ2100,JQ2120,JQ2059,JQ2051,JQ2076,# & JQ2112,JQ2081,JQ2101,S41870,JQ2095,JQ2094,JQ2226,JQ2110,# & JQ2080,JQ2090,JQ2046,JQ2048,JQ2062,JQ2098,S43492,JQ2067,# & JQ2072,JQ2091,S20745,JQ2092,JQ2052,JQ2230,JQ2104,JQ2075,# & S20753,JQ2119,JQ2103,JQ2047,JQ2085,JQ2123,JQ2069,JQ2105,# & JQ2121,S32202)# & PIR4: (S42226)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ILLLCLIFLL*# SEQUENCE: ILLLCLIFLL*# ...# >HUM11939# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: HBV POL (502-510)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVR,DPOL_HPBV2,DPOL_HPBVO,DPOL_HPBVJ,# & DPOL_HPBVT,DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBV4,DPOL_HPBVP,# & DPOL_HPBV9,DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBVL,# & DPOL_HPBVZ)# & PIR1: (JDVLA1,JDVLKS,JDVLCP,JDVLJ3,JQ2229,S20752,JDVLJ1,JDVLVH,# & S20757,S47406,JDVLVR,JDVLVD,JDVLVB,JDVLVA,S43491,JDVLJ2,# & JDVLVS)# & PIR2: (S35527,S71785)# REFERENCES: sette94b,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,KLHLYSHPI*# SEQUENCE: KLHLYSHPI*# ...# >HUM1193A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./Refolding# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV ENV (348-357)# DB REFERENCE: SWISS: (VMSA_HPBVN,VMSA_HPBVO,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVS,# & VMSA_HPBVY,VMSA_HPBVJ,VMSA_HPBV4,VMSA_HPBV0,VMSA_HPBVY,# & VMSA_HPBVI,VMSA_HPBVD)# & PIR1: (SAVLAD,JQ1573,SAVLJ2,JQ1576,SAVLA,SAVLJ1,JQ1581,SAVLJ3,# & JQ1578,SAVLN1,JQ1571,SAVLHV,SAVLBH,JQ1570,SAVLAH,JQ1574,# & JQ1572,JQ1577,SAVLAR)# & PIR2: (JQ2069,JQ2104,JQ2075,S20745,JQ2092,S43492,JQ2098,JQ2090,# & JQ2091,JQ2095,JQ2116,S35528,JQ2065,JQ2061,JQ2077,JQ2078,# & JQ2111,JQ2108,JQ2068,JQ2079,JQ2102,JQ2089,JQ2099,JQ2050,# & JQ2106,JQ2113,JQ2109,JQ2101,JQ2110,JQ2094,JQ2058,JQ2083,# & S47407,JQ2060,S20753,S32202,JQ2105,JQ2085,JQ2062,JQ2067,# & JQ2112,JQ2076,JQ2063,S41869,JQ2070,JQ2073,JQ2096,JQ2066,# & JQ2057,JQ2097,JQ2087,JQ2100,JQ2114)# REFERENCES: sette94b,van_der_burg96a,nayersina93a,tan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,GLSPTVWLSV*# SEQUENCE: GLSPTVWLSV*# ...# >HUM1193B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: HBV ENV (175-184)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVL,VMSA_HPBV0,VMSA_HPBVD,# & VMSA_HPBVW,VMSA_HPBVP,VMSA_HPBVJ,VMSA_HPBVR,VMSA_HPBV2,# & VMSA_HPBVR,VMSA_HPBVO,VMSA_HPBV2,VMSA_HPBVZ,VMSA_HPBV4,# & VMSA_HPBVS,VMSA_HPBVA,VMSA_HPBVW,VMSA_HPBVN)# & PIR1: (SAVLHV,JQ1578,JQ1577,SAVLAJ,JQ1575,SAVLAH,JQ1570,SAVLVE,# & SAVLN1,SAVLJ2,JQ1573,SAVLAD,JQ1581,SAVLA,SAVLBH,SAVLCP,# & SAVLA1,SAVLAR,SAVLVD,SAVLJ1)# & PIR2: (JQ2115,JQ2054,JQ2066,JQ2073,S20749,JQ2087,JQ2085,JQ2111,# & JQ2065,JQ2077,JQ2095,JQ2047,JQ2103,JQ2123,JQ2098,JQ2092,# & JQ2104,JQ2069,JQ2075,JQ2083,JQ2060,S32202,JQ2094,JQ2110,# & JQ2081,JQ2061,JQ2068,JQ2055,S47411,JQ2067,JQ2063,S47407,# & S36654,JQ2113,JQ2109,JQ2097,JQ2114,JQ2100,JQ2057,JQ2056,# & S41869,JQ2088,JQ2070,S20753,JQ2058,JQ2053,JQ2050,JQ2099,# & JQ2045,S08142,JQ2112,JQ2076,JQ2105,JQ2108,JQ2059,JQ2079,# & JQ2102,S41870,JQ2051,JQ2078,JQ2072,JQ2116,JQ2080,JQ2046,# & JQ2048,S35528,JQ2052,S20745,JQ2091,S43492,JQ2090)# & PIR4: (S42226)# REFERENCES: sette94b,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,LLVLQAGFFL*# SEQUENCE: LLVLQAGFFL*# ...# >HUM1193C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV ENV (250-258)# DB REFERENCE: SWISS: (VMSA_HPBVN,VMSA_HPBVS,VMSA_WHV8I,VMSA_HPBV9,VMSA_HPBV4,# & VMSA_HPBV2,VMSA_HPBVO,VMSA_HPBVZ,VMSA_HPBVP,VMSA_HPBVR,# & VMSA_HPBVD,VMSA_HPBVW,VMSA_HPBV0,VMSA_HPBVI,VMSA_HPBVY,# & VMSA_HPBVY,VMSA_HPBVW,VMSA_WHV59,VMSA_HPBVA,VMSA_WHV7,# & VMSA_HPBVT,VMSA_HPBVR,VMSA_HPBVJ,VMSA_HPBV2,VMSA_WHVW6,# & VMSA_HPBVL,VMSA_WHV8,VMSA_WHV1)# & PIR1: (SAVLJ1,SAVLCP,SAVLC2,SAVL59,SAVLJ2,JQ1571,JQ1581,JQ1579,# & SAVL7,JQ1580,SAVLVE,SAVLAR,SAVLHV,JQ1578,SAVLAJ,SAVLKS,# & SAVLAH,SAVLN1,JQ1576,SAVLA1,SAVLVD,SAVLA,SAVLJ3,SAVLBH,# & JQ1570,JQ1577,JQ1574,JQ1572,SAVL64,JQ1575,SAVLW8,SAVLAD,# & JQ1573,SAVLC)# & PIR2: (S35528,JQ2072,JQ2052,JQ2121,S20745,S43492,JQ2090,JQ2230,# & JQ2051,JQ2108,JQ2226,JQ2102,JQ2225,S41869,JQ2075,JQ2085,# & JQ2079,JQ2050,JQ2045,JQ2053,JQ2076,JQ2105,S20753,JQ2058,# & JQ2088,JQ2056,JQ2100,JQ2114,JQ2104,JQ2069,JQ2103,JQ2098,# & JQ2092,JQ2095,JQ2062,JQ2113,JQ2106,S41871,JQ2083,JQ2094,# & JQ2110,S32202,JQ2096,JQ2087,S20749,JQ2073,JQ2066,JQ2115,# & S47411,S47407,JQ2055,JQ2068,JQ2061,JQ2065,JQ2077,JQ2059,# & S41870,JQ2081,JQ2101,JQ2063,JQ2067,JQ2091,JQ2119,JQ2116,# & JQ2048,JQ2080,JQ2046,JQ2078,JQ2112,JQ2099,JQ2047,JQ2123,# & JQ2111,JQ2054,JQ2060,JQ2109,JQ2070,JQ2057,JQ2120,JQ2097,# & JQ2089,JQ2122)# & PIR4: (S42226)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLLCLIFLL*# SEQUENCE: LLLCLIFLL*# ...# >HUM1193D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: HBV ENV (371-379)# DB REFERENCE: SWISS: (VMSA_HPBVJ,VMSA_HPBVI,VMSA_HPBVO)# & PIR1: (SAVLJ3,JQ1570,SAVLJ2,SAVLJ1)# & PIR2: (JQ2061,JQ2058,JQ2059,JQ2057,JQ2060,JQ2062)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,ILSPFMPLL*# SEQUENCE: ILSPFMPLL*# ...# >HUM1193E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: HBV ENV (259-267)# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBVT,VMSA_HPBVJ,# & VMSA_HPBVA,VMSA_HPBV0,VMSA_HPBVW,VMSA_HPBVW,VMSA_HPBVR,# & VMSA_HPBVI,VMSA_HPBVO,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBV2,# & VMSA_HPBVY,VMSA_HPBV4,VMSA_HPBV9,VMSA_HPBVD,# & VMSA_HPBVL)# & PIR1: (SAVLHV,JQ1578,JQ1571,SAVLAH,SAVLAJ,SAVLVE,JQ1570,JQ1575,# & JQ1574,SAVLA,SAVLAD,JQ1572,SAVLJ3,JQ1573,SAVLVD,SAVLJ1,# & SAVLJ2,SAVLA1,JQ1576,SAVLKS,SAVLBH,JQ1581,JQ1580,JQ1579,# & SAVLCP)# & PIR2: (JQ2098,JQ2113,JQ2057,JQ2115,JQ2096,JQ2087,JQ2073,JQ2066,# & JQ2060,JQ2083,JQ2094,JQ2110,JQ2059,JQ2068,S47407,JQ2058,# & JQ2116,JQ2046,JQ2080,JQ2078,JQ2119,JQ2054,JQ2111,JQ2047,# & JQ2120,JQ2097,JQ2089,JQ2063,JQ2067,S41870,JQ2065,JQ2085,# & JQ2095,JQ2092,JQ2075,S35528,S20745,JQ2122,S41871,JQ2088,# & JQ2056,JQ2050,JQ2045,JQ2105,JQ2100,JQ2076,JQ2051,JQ2072,# & JQ2121,JQ2052,JQ2226,JQ2106,S20753,JQ2053,JQ2114,JQ2103,# & JQ2102,JQ2108,JQ2090,JQ2230,JQ2225,JQ2055,S47411,S32202,# & JQ2123,JQ2061,JQ2070,JQ2099,S41869,JQ2079,JQ2062,JQ2069,# & JQ2104,JQ2112,JQ2091,JQ2109,JQ2101,JQ2081,JQ2077)# REFERENCES: sette94b,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,VLLDYQGML*# SEQUENCE: VLLDYQGML*# ...# >HUM1193F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV ENV (378-387)# DB REFERENCE: SWISS: (VMSA_HPBVI,VMSA_HPBV9,VMSA_HPBV2,VMSA_HPBVN,VMSA_HPBV4,# & VMSA_HPBVD,VMSA_HPBVY,VMSA_HPBVA,VMSA_HPBVP,VMSA_HPBVW,# & VMSA_HPBVL,VMSA_HPBV2,VMSA_HPBVO,VMSA_HPBVY,VMSA_HPBVW,# & VMSA_HPBVR,VMSA_HPBVJ,VMSA_HPBV0,VMSA_HPBVR,# & VMSA_HPBVS)# & PIR1: (JQ1574,JQ1570,SAVLA1,SAVLJ1,SAVLJ2,SAVLA,SAVLVE,JQ1578,# & JQ1571,SAVLVD,JQ1576,SAVLHV,JQ1575,SAVLJ3,JQ1573,SAVLKS,# & SAVLAR,JQ1577,JQ1572,SAVLAD,SAVLAH,SAVLN1,SAVLCP,JQ1581,# & SAVLBH)# & PIR2: (JQ2104,JQ2069,JQ2123,JQ2116,JQ2098,JQ2059,JQ2072,JQ2101,# & JQ2106,JQ2103,JQ2048,JQ2070,JQ2063,JQ2045,JQ2051,JQ2088,# & S41871,JQ2100,JQ2046,JQ2066,JQ2076,JQ2050,JQ2115,JQ2057,# & JQ2113,JQ2096,JQ2073,JQ2060,JQ2083,JQ2110,JQ2094,S20753,# & JQ2052,S20745,JQ2047,JQ2095,JQ2092,S35528,JQ2075,JQ2112,# & JQ2109,JQ2091,JQ2077,JQ2079,S32202,S47411,JQ2099,JQ2061,# & JQ2053,JQ2102,JQ2108,JQ2090,JQ2114,JQ2065,S36654,JQ2085,# & JQ2067,S20749,JQ2054,JQ2111,S47407,JQ2068,JQ2058,JQ2089,# & JQ2097)# REFERENCES: sette94b,del_guercio95a,wentworth96a,nayersina93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLPIFFCLWV*# SEQUENCE: LLPIFFCLWV*# ...# >HUM11940# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV ENV (250-259)# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_WHV8I,VMSA_HPBVS,VMSA_HPBVR,VMSA_HPBVJ,# & VMSA_HPBVY,VMSA_HPBVL,VMSA_WHV7,VMSA_HPBV2,VMSA_WHV59,# & VMSA_HPBVA,VMSA_HPBVY,VMSA_HPBVD,VMSA_HPBVP,VMSA_WHV8,# & VMSA_HPBV0,VMSA_HPBVR,VMSA_WHV1,VMSA_HPBVI,VMSA_HPBV2,# & VMSA_HPBVO,VMSA_HPBVW,VMSA_HPBV4,VMSA_HPBVT,VMSA_HPBVW,# & VMSA_HPBVN,VMSA_HPBV9,VMSA_WHVW6)# & PIR1: (SAVLA1,SAVLJ1,SAVL7,SAVLA,JQ1574,JQ1579,JQ1580,SAVLAD,# & SAVLW8,JQ1573,SAVLVE,SAVLVD,SAVLJ3,JQ1575,SAVLN1,SAVLC,# & JQ1571,SAVLHV,JQ1578,SAVL64,JQ1576,SAVLCP,JQ1581,SAVLAR,# & SAVL59,SAVLKS,JQ1572,SAVLAJ,SAVLC2,SAVLBH,JQ1570,JQ1577,# & SAVLAH,SAVLJ2)# & PIR2: (JQ2114,JQ2108,JQ2085,JQ2099,JQ2061,S32202,JQ2120,S47411,# & JQ2079,S35528,JQ2091,JQ2077,JQ2051,JQ2230,JQ2045,JQ2088,# & JQ2225,JQ2106,JQ2048,JQ2055,JQ2063,S41869,JQ2072,JQ2101,# & S20745,JQ2104,JQ2069,JQ2081,JQ2123,JQ2062,JQ2059,JQ2047,# & S20753,JQ2119,JQ2103,JQ2067,JQ2111,JQ2089,JQ2058,JQ2113,# & JQ2057,JQ2105,JQ2068,JQ2056,JQ2060,JQ2094,JQ2110,S20749,# & JQ2080,JQ2102,JQ2053,JQ2090,JQ2065,JQ2115,JQ2096,JQ2073,# & JQ2083,JQ2050,S43492,JQ2121,S41870,JQ2112,JQ2109,JQ2075,# & JQ2092,JQ2070,S41871,JQ2100,JQ2066,JQ2116,JQ2098,JQ2076,# & JQ2226,S47407,JQ2052,JQ2122,JQ2054,JQ2087,JQ2097,JQ2078,# & JQ2095,JQ2046)# & PIR4: (S42226)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,LLLCLIFLLV*# SEQUENCE: LLLCLIFLLV*# ...# >HUM11941# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBV ENV (260-269)# DB REFERENCE: SWISS: (VMSA_HPBVO,VMSA_HPBVJ,VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBV0,# & VMSA_HPBVW,VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBV4,VMSA_HPBVT,# & VMSA_HPBVI,VMSA_HPBV9,VMSA_HPBVR,VMSA_HPBVP,VMSA_HPBV2,# & VMSA_HPBVL,VMSA_HPBVD,VMSA_HPBVA,VMSA_HPBVY,# & VMSA_HPBVR)# & PIR1: (SAVLJ2,SAVLVD,SAVLAH,SAVLVE,JQ1574,JQ1578,JQ1576,JQ1571,# & SAVLA1,SAVLJ1,SAVLA,JQ1579,JQ1580,JQ1581,SAVLCP,SAVLAD,# & SAVLJ3,JQ1575,SAVLHV,SAVLAJ,JQ1572,JQ1573,SAVLBH,JQ1570,# & SAVLKS)# & PIR2: (JQ2090,JQ2096,JQ2116,JQ2098,JQ2055,JQ2051,JQ2230,JQ2091,# & S35528,JQ2067,JQ2056,JQ2080,JQ2102,JQ2083,JQ2073,JQ2100,# & JQ2092,S20745,JQ2104,JQ2062,JQ2072,JQ2057,JQ2111,JQ2099,# & S47411,JQ2114,JQ2089,JQ2058,JQ2068,JQ2110,JQ2060,S32202,# & JQ2120,JQ2108,JQ2085,JQ2061,JQ2079,S41871,JQ2115,JQ2105,# & JQ2088,JQ2094,JQ2119,JQ2103,JQ2097,JQ2087,JQ2054,JQ2078,# & JQ2095,JQ2076,JQ2226,S47407,JQ2052,JQ2122,S41870,JQ2112,# & JQ2109,JQ2075,JQ2066,JQ2070,JQ2121,JQ2050,JQ2065,JQ2053,# & JQ2069,JQ2123,JQ2081,JQ2059,JQ2047,S20753,JQ2101,S41869,# & JQ2063,JQ2106,JQ2077,JQ2045,JQ2225)# REFERENCES: sette94b,nayersina93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,LLDYQGMLPV*# SEQUENCE: LLDYQGMLPV*# ...# >HUM11942# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV ENV (359-368)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBVW,VMSA_HPBVY,# & VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVY,VMSA_HPBVD,VMSA_HPBV9,# & VMSA_HPBVZ,VMSA_HPBVJ,VMSA_HPBVR,VMSA_HPBVN,VMSA_HPBVS,# & VMSA_HPBV4)# & PIR1: (SAVLVD,SAVLAH,SAVLVE,JQ1572,JQ1578,SAVLN1,JQ1581,SAVLJ1,# & SAVLA,SAVLAR,SAVLAD,SAVLKS,SAVLAJ,JQ1575,SAVLBH,JQ1573,# & JQ1574,JQ1577,JQ1576,JQ1571)# & PIR2: (JQ2053,S36654,JQ2047,S20753,JQ2070,JQ2112,JQ2109,S41870,# & JQ2075,JQ2052,JQ2054,JQ2097,S47407,JQ2103,JQ2078,JQ2095,# & JQ2099,S47411,JQ2092,JQ2067,JQ2091,S35528,JQ2116,JQ2098,# & JQ2096,JQ2115,JQ2088,JQ2045,JQ2048,JQ2072,JQ2101,S41869,# & JQ2106,JQ2063,JQ2108,S32202,JQ2079,JQ2059,JQ2081,JQ2069,# & JQ2050,JQ2065,JQ2061,JQ2089,JQ2113,JQ2087,JQ2066,S20745,# & JQ2104,JQ2083,JQ2080,JQ2111,S20749,JQ2085,JQ2110,JQ2105,# & JQ2094,JQ2056,JQ2051,JQ2055,JQ2090,JQ2114,JQ2073)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,WMMWYWGPSL*# SEQUENCE: WMMWYWGPSL*# ...# >HUM11943# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV POL (526-535)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVA,DPOL_HPBV9,DPOL_HPBV4,DPOL_HPBV2,# & DPOL_HPBVL,DPOL_HPBVY,DPOL_WHV59,DPOL_HPBVR,DPOL_HPBVO,# & DPOL_HPBVT,DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBVJ,DPOL_HPBVP,# & DPOL_HPBVZ)# & PIR1: (JQ2229,S20757,S47406,JDVLCP,JDVLJ3,JDVLA1,JDVLJ1,JDVL59,# & S20752,JDVLKS,JDVLVH,JDVLVD,JDVLVB,JDVLVA,JDVLJ2,S43491,# & JDVLVR,JDVLVS)# & PIR2: (S35527,S71785)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,FLLAQFTSAI*# SEQUENCE: FLLAQFTSAI*# ...# >HUM11944# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV POL (149-158)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVJ,DPOL_HPBVR,DPOL_HPBVO,DPOL_HPBV9,# & DPOL_HPBV2,DPOL_HPBV4,DPOL_HPBVY,DPOL_HPBVM,DPOL_HPBVT,# & DPOL_HPBVI,DPOL_HPBVP,DPOL_HPBVW)# & PIR1: (JQ2229,JDVLKS,S20752,S47406,JDVLJ3,JDVLJ1,JDVLVD,JDVLVA,# & JDVLVB,S43491,JDVLJ2,S20757,JDVLVR,JDVLVS)# & PIR2: (S71785,S35527)# REFERENCES: sette94b,del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,YLHTLWKAGI*# SEQUENCE: YLHTLWKAGI*# ...# >HUM11945# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBV ENV (251-259)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBV9,VMSA_HPBVW,VMSA_HPBVO,VMSA_HPBV0,# & VMSA_HPBV4,VMSA_HPBVJ,VMSA_WHV1,VMSA_HPBVS,VMSA_WHV8I,# & VMSA_WHV8,VMSA_HPBVZ,VMSA_HPBVI,VMSA_HPBVT,VMSA_HPBVD,# & VMSA_HPBV2,VMSA_HPBVW,VMSA_WHV59,VMSA_HPBV2,VMSA_HPBVP,# & VMSA_HPBVL,VMSA_WHVW6,VMSA_HPBVN,VMSA_HPBVA,VMSA_HPBVY,# & VMSA_HPBVR,VMSA_HPBVR,VMSA_WHV7)# & PIR1: (SAVLVD,SAVL7,SAVLVE,JQ1570,JQ1580,JQ1579,SAVLAR,JQ1572,# & SAVLAJ,JQ1581,SAVLAD,SAVLCP,SAVLC,SAVLHV,SAVLJ3,SAVLKS,# & SAVLA1,SAVL59,SAVLC2,SAVLN1,JQ1576,JQ1571,JQ1577,SAVLJ2,# & SAVL64,JQ1573,SAVLBH,JQ1574,SAVLW8,SAVLAH,JQ1578,SAVLJ1,# & SAVLA,JQ1575)# & PIR2: (JQ2079,JQ2101,S41869,JQ2120,JQ2063,S20753,JQ2075,JQ2109,# & JQ2112,JQ2054,JQ2097,S47407,JQ2108,S43492,JQ2060,JQ2048,# & JQ2088,JQ2045,JQ2072,JQ2073,JQ2230,JQ2085,JQ2094,JQ2105,# & JQ2055,JQ2051,S20745,JQ2104,JQ2083,JQ2080,JQ2102,JQ2111,# & JQ2087,JQ2066,JQ2065,JQ2069,JQ2081,JQ2061,JQ2096,JQ2098,# & JQ2067,JQ2076,JQ2122,JQ2095,JQ2123,JQ2062,JQ2059,JQ2056,# & JQ2114,S47411,S41870,JQ2052,S35528,JQ2046,JQ2110,JQ2090,# & JQ2058,JQ2106,JQ2050,JQ2057,JQ2089,JQ2113,S20749,JQ2100,# & JQ2092,JQ2091,JQ2226,JQ2116,JQ2115,JQ2119,JQ2068,S32202,# & S41871,JQ2099,JQ2121,JQ2103,JQ2078,JQ2070,JQ2053,JQ2077,# & JQ2047,JQ2225)# & PIR4: (S42226)# REFERENCES: sette94b,nayersina93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,LLCLIFLLV*# SEQUENCE: LLCLIFLLV*# ...# >HUM11946# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV PRECORE (2-10)# DB REFERENCE: SWISS: (CORA_HPBVA,CORA_HPBV9,CORA_HPBVT)# & PIR1: (NKVLJ2,NKVLBH,NKVLA6,NKVLA3,NKVLA4,NKVLKS,NKVLAH,# & NKVLA1)# & PIR2: (JQ2227,S33686,S20746,S53229,S53257,S53253,S47405,S20750,# & S53279,S53157,S53238,S53161,S53251,S53242,S53163,S35530,# & S53198,S53236,S53227,S53211,S32204,S47409,S53202,S53225,# & S53223,S53200,S25651,S53216,S53272,S53274,S53204,S53240,# & S01405,S53281,S53159)# & PIR4: (S53139,S20754,S53151,S53133)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,QLFHLCLII*# SEQUENCE: QLFHLCLII*# ...# >HUM11947# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV ENV (249-257)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVN,VMSA_HPBVS,VMSA_HPBVL,# & VMSA_HPBVO,VMSA_HPBV0,VMSA_HPBV4,VMSA_HPBV9,VMSA_HPBVY,# & VMSA_HPBVW,VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVT,VMSA_HPBVD,# & VMSA_HPBVI,VMSA_HPBVJ,VMSA_HPBV2,VMSA_HPBVA,VMSA_HPBVP,# & VMSA_HPBVZ,VMSA_HPBVY)# & PIR1: (SAVLN1,SAVLVD,JQ1570,SAVLVE,SAVLJ2,JQ1577,JQ1576,JQ1571,# & SAVLAD,SAVLBH,JQ1574,SAVLJ1,SAVLA,SAVLKS,SAVLHV,JQ1581,# & JQ1580,SAVLAR,JQ1575,SAVLCP,JQ1573,JQ1578,SAVLJ3,SAVLAH,# & SAVLA1,JQ1579,JQ1572,SAVLAJ)# & PIR2: (JQ2095,JQ2067,JQ2122,JQ2075,S20753,S41869,JQ2079,JQ2096,# & JQ2089,JQ2076,JQ2097,JQ2060,S43492,JQ2059,JQ2056,JQ2114,# & S47411,JQ2052,S41870,S35528,JQ2110,JQ2058,JQ2106,S20749,# & JQ2115,JQ2119,JQ2116,JQ2092,JQ2226,JQ2091,JQ2088,S41871,# & JQ2048,JQ2072,JQ2045,JQ2047,JQ2077,JQ2068,JQ2103,JQ2099,# & JQ2053,JQ2225,JQ2078,JQ2104,S20745,JQ2055,JQ2094,JQ2105,# & JQ2098,JQ2066,JQ2069,JQ2081,JQ2057,JQ2100,S32202,JQ2121,# & JQ2230,JQ2051,JQ2102,JQ2111,JQ2083,JQ2061,JQ2065,JQ2087,# & S47407,JQ2063,JQ2120,JQ2046,JQ2090,JQ2062,JQ2070,JQ2113,# & JQ2050,JQ2080,JQ2085,JQ2073,JQ2054,JQ2112,JQ2109,JQ2101,# & JQ2108,JQ2123)# & PIR4: (S42226)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ILLLCLIFL*# SEQUENCE: ILLLCLIFL*# ...# >HUM11948# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV ENV (377-385)# DB REFERENCE: SWISS: (VMSA_HPBVA,VMSA_HPBVI,VMSA_HPBV0,VMSA_HPBVY,VMSA_HPBVY,# & VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVN,VMSA_HPBVW,VMSA_HPBVO,# & VMSA_HPBV2,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVW,VMSA_HPBVD,# & VMSA_HPBV4,VMSA_HPBV9,VMSA_HPBVL,VMSA_HPBVS,VMSA_HPBVZ,# & VMSA_HPBVJ)# & PIR1: (SAVLAR,SAVLVD,JQ1577,JQ1581,JQ1573,SAVLBH,SAVLCP,SAVLAD,# & SAVLJ2,SAVLHV,JQ1572,SAVLAJ,JQ1575,JQ1578,SAVLAH,SAVLA1,# & SAVLJ3,JQ1570,SAVLVE,JQ1574,SAVLKS,SAVLA,SAVLJ1,JQ1571,# & JQ1576,SAVLN1)# & PIR2: (JQ2066,JQ2077,JQ2088,JQ2095,S36654,JQ2056,S47411,S20749,# & JQ2057,S32202,JQ2063,S20753,JQ2079,JQ2089,JQ2099,JQ2078,# & JQ2048,JQ2094,JQ2110,JQ2058,JQ2080,JQ2112,JQ2054,JQ2050,# & JQ2103,JQ2047,S41871,JQ2072,JQ2106,JQ2115,JQ2091,JQ2116,# & JQ2092,JQ2101,JQ2123,JQ2109,JQ2108,JQ2114,JQ2052,JQ2059,# & S35528,JQ2085,JQ2073,JQ2113,JQ2090,JQ2070,S47407,JQ2046,# & JQ2051,JQ2102,JQ2083,JQ2061,JQ2065,JQ2087,JQ2111,JQ2060,# & JQ2100,JQ2096,JQ2097,JQ2076,JQ2053,JQ2068,JQ2045,JQ2075,# & JQ2067,JQ2055,JQ2104,S20745,JQ2098,JQ2069,JQ2081)# REFERENCES: sette94b,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,PLLPIFFCL*# SEQUENCE: PLLPIFFCL*# ...# >HUM11949# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV ENV (248-257)# DB REFERENCE: SWISS: (VMSA_HPBVP,VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVY,# & VMSA_HPBV0,VMSA_HPBVA,VMSA_HPBVS,VMSA_HPBVW,VMSA_HPBVZ,# & VMSA_HPBVR,VMSA_HPBVW,VMSA_HPBV9,VMSA_HPBV4,VMSA_HPBVN,# & VMSA_HPBVR,VMSA_HPBVT,VMSA_HPBVL,VMSA_HPBVD)# & PIR1: (SAVLKS,JQ1574,SAVLHV,SAVLAJ,JQ1575,SAVLAH,JQ1571,SAVLN1,# & SAVLVE,JQ1573,SAVLCP,SAVLAD,SAVLBH,SAVLA,JQ1576,JQ1581,# & SAVLAR,SAVLVD,JQ1577,JQ1578,JQ1572,JQ1580,JQ1579,# & SAVLA1)# & PIR2: (JQ2047,JQ2072,JQ2091,JQ2116,JQ2115,JQ2052,JQ2105,JQ2122,# & JQ2055,S20745,JQ2081,JQ2098,JQ2120,JQ2113,JQ2066,JQ2121,# & JQ2226,JQ2045,JQ2068,JQ2053,JQ2050,JQ2112,JQ2054,JQ2080,# & JQ2078,JQ2094,JQ2048,JQ2110,JQ2079,S20753,JQ2089,S20749,# & JQ2087,JQ2051,JQ2100,JQ2076,JQ2096,JQ2095,JQ2088,JQ2073,# & JQ2070,JQ2090,JQ2046,JQ2108,S35528,JQ2225,JQ2123,JQ2101,# & JQ2063,S32202,S47407,JQ2097,JQ2106,JQ2230,JQ2099,S43492,# & JQ2119,JQ2085,S41870,JQ2065,JQ2111,JQ2102,JQ2083,JQ2056,# & S47411,JQ2077,JQ2104,JQ2069,JQ2067,S41869,JQ2075,JQ2114,# & JQ2109,JQ2092,JQ2103,S41871)# & PIR4: (S42226)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,FILLLCLIFL*# SEQUENCE: FILLLCLIFL*# ...# >HUM1194A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV CORE (100-108)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBV4,CORA_HPBVW,CORA_HPBV2,CORA_HPBVA,# & CORA_HPBVY,CORA_HPBVO,CORA_HPBVZ,CORA_HPBVT,# & CORA_HPBVF)# & PIR1: (NKVLA3,NKVLA6,NKVLJ2,NKVLCP,NKVLBH,NKVLH3,NKVLA4,NKVLAH,# & NKVLA2,NKVLA1)# & PIR2: (S53236,S53166,S32204,S53186,S53229,S53152,S53169,S53157,# & S53172,S53221,S53255,S01405,S53240,S53184,S43490,S53267,# & S53146,S53225,S53288,S53211,S20755,S53216,S53200,S53223,# & S53137,S33686,S20746,JQ2227,S53253,S53257,S47405,S53175,# & S53274,S53286,S53279,S53232,S53270,S53260,S20750,S53181,# & S53238,S53247,S53214,S53143,S53155,S53242,S53194,S04570,# & S53163,S53251,S53207,S53189,S25651,S47409,S53140,S53159,# & S53281,S53198,S53227,S35530)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,LLWFHISCL*# SEQUENCE: LLWFHISCL*# ...# >HUM1194B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV ENV (177-185)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVO,VMSA_HPBV2,VMSA_HPBVS,VMSA_HPBVW,# & VMSA_HPBVZ,VMSA_HPBVD,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVJ,# & VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBVW,VMSA_HPBVA,VMSA_HPBVN,# & VMSA_HPBVL,VMSA_HPBV4,VMSA_HPBV9,VMSA_HPBV0,# & VMSA_HPBVY)# & PIR1: (SAVLHV,SAVLAJ,JQ1575,JQ1573,SAVLCP,SAVLAD,JQ1577,SAVLVD,# & JQ1570,SAVLKS,SAVLA1,SAVLJ2,SAVLA,JQ1578,SAVLN1,SAVLAH,# & SAVLBH,SAVLAR,JQ1581,SAVLJ1,SAVLVE)# & PIR2: (JQ2090,JQ2046,JQ2072,JQ2052,S35528,S20745,JQ2081,JQ2079,# & JQ2055,JQ2066,S32202,JQ2097,S43492,JQ2099,JQ2077,JQ2056,# & JQ2111,JQ2102,JQ2065,S41870,JQ2078,JQ2094,JQ2048,JQ2112,# & JQ2080,JQ2050,JQ2060,JQ2045,JQ2068,JQ2069,JQ2104,S41871,# & JQ2103,JQ2092,JQ2114,S20749,S20753,JQ2089,S08142,JQ2051,# & JQ2059,JQ2095,JQ2088,JQ2067,JQ2075,JQ2061,JQ2054,JQ2110,# & JQ2087,JQ2076,JQ2113,JQ2091,JQ2057,JQ2063,S47407,JQ2058,# & JQ2053,S47411,JQ2083,S36654,S41869,JQ2085,JQ2109,JQ2098,# & JQ2116,JQ2115,JQ2047,JQ2105,JQ2100,JQ2073,JQ2070,JQ2108,# & JQ2123)# & PIR4: (S42226)# REFERENCES: sette94b,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,VLQAGFFLL*# SEQUENCE: VLQAGFFLL*# ...# >HUM1194C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV CORE (139-148)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBVA,CORA_HPBV4,CORA_HPBV2,CORA_HPBVO,# & CORA_HPBVT,CORA_HPBVZ,CORA_HPBVY,CORA_HPBVJ,CORA_HPBVF,# & CORA_HPBVW,CORA_HPBV9)# & PIR1: (NKVLA6,NKVLKS,NKVLAH,NKVLJ1,NKVLH3,NKVLCP,NKVLJ2,NKVLA3,# & NKVLA2,NKVLA1,NKVLBH,NKVLA4)# & PIR2: (S20755,S53279,S33686,S53178,S53225,S35530,S53140,S53236,# & S53229,S53204,S53194,S53155,S53272,S53251,S53181,S53238,# & S53240,S47409,JQ2227,S53253,S53270,S20746,S53232,S53137,# & S53257,S47405,S53129,S53175,S53260,S20750,S32204,S53189,# & S53207,S53163,S53242,S04570,S53172,S53157,S53169,S53255,# & S53221,S01405,S53184,S43490,S53161,S53146,S25651,S53159,# & S53166,S53152,S53281,S53198,S53227,S53200,S53223,S53216,# & S53202,S53288,S53211)# REFERENCES: sette94b,wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,ILSTLPETTV*# SEQUENCE: ILSTLPETTV*# ...# >HUM1194D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV ENV (204-212)# DB REFERENCE: SWISS: (VMSA_HPBVO,VMSA_HPBVJ)# & PIR1: (SAVLJ2,SAVLJ1,JQ1570)# & PIR2: (JQ2061,JQ2058,JQ2062,JQ2060,JQ2057,JQ2059)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,FLGGTPVCL*# SEQUENCE: FLGGTPVCL*# ...# >HUM1194E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HBV PRECORE (9-17)# DB REFERENCE: SWISS: (CORA_HPBV9)# & PIR1: (NKVLA6,NKVLA3,NKVLKS)# & PIR2: (S33686,S47409,S01405,S20750)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,IISCTCPTV*# SEQUENCE: IISCTCPTV*# ...# >HUM1194F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HBV CORE (114-124)# DB REFERENCE: SWISS: (CORA_HPBVF,CORA_HPBV9,CORA_HPBVJ,CORA_HPBVZ,CORA_HPBVT,# & CORA_HPBVO,CORA_HPBVW,CORA_HPBVL,CORA_HPBV2,# & CORA_HPBV4)# & PIR1: (NKVLA6,NKVLA2,NKVLJ2,NKVLKS,NKVLJ1,NKVLH3,NKVLA4,NKVLCP,# & NKVLA3)# & PIR2: (S01405,S47409,S25651,S35530,JQ2227,S33686,S53152,S53137,# & S43490,S53175,S04570,S53140)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,TVLEYLVSFGV*# SEQUENCE: TVLEYLVSFGV*# ...# >HUM11950# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HBV POL (773-782)# ANCHOR POSITIONS:# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,ILRGTSFVYV'*# SEQUENCE: ILRGTSFVYV'*# ...# >HUM11951# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HBV POL (765-774)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVA,DPOL_HPBVI,DPOL_HPBVO,DPOL_HPBVJ,# & DPOL_HPBV9,DPOM_HPBVY,DPOL_HPBVY,DPOL_HPBVR,DPOL_HPBVT,# & DPOL_HPBVM)# & PIR1: (JDVLJ1,JQ2229,JDVLVB,JDVLVA,S43491,JDVLJ2,JDVLVS,JDVLKS,# & JDVLA1,JDVLCP,JDVLJ3,JDVLVR,S47406,S20752)# & PIR2: (S35527,S71785)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,LLGCAANWIL*# SEQUENCE: LLGCAANWIL*# ...# >HUM11952# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HBV CORE (99-108)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBVW,CORA_HPBVY,CORA_HPBVO,CORA_HPBVZ,# & CORA_HPBVF,CORA_HPBV2,CORA_HPBV4,CORA_HPBVA,# & CORA_HPBVT)# & PIR1: (NKVLA2,NKVLA3,NKVLH3,NKVLA1,NKVLA4,NKVLBH,NKVLJ2,NKVLA6,# & NKVLAH,NKVLCP)# & PIR2: (S53288,S53198,S53211,S01405,S47409,S53260,S53200,S53242,# & S53166,S53159,S53270,S53137,S43490,S53240,S53236,S53229,# & S53238,S53181,S53155,S53251,S53279,S53152,S53184,S33686,# & S53255,S53221,S53214,S53143,S53172,S53157,S53169,S53189,# & S53207,S25651,S53274,S53163,S53286,S32204,S20755,S53140,# & S53194,S53146,S20746,S35530,S53223,S20750,S53227,S53247,# & JQ2227,S53232,S47405,S53257,S04570,S53186,S53225,S53175,# & S53253,S53267,S53216,S53281)# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,QLLWFHISCL*# SEQUENCE: QLLWFHISCL*# ...# >HUM11953# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV ENV (251-260)# ANCHOR POSITIONS:# REFERENCES: sette94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILCLIFLLVL*# SEQUENCE: ILCLIFLLVL*# ...# >HUM11954# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./binding as./reference/Half-time# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: p939/MART-1 (32-40)# DB REFERENCE: PIR2: (A55253)# REFERENCES: castelli95a,rivoltini95a,anichini96a,kawakami96a,van-elsas96a,# & romero97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,ILTVILGVL*# SEQUENCE: ILTVILGVL*# ...# >HUM11955# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation/competition/cytotoxicity as./reference/Half-time# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: gp100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A53668,A41234)# REFERENCES: castelli95a,rammensee95a,kawakami95b,rivoltini95b,anichini96a# & parkhurst96a,kawakami96a,engelhard96a,romero96a,rivoltini96a,# & van-elsas96a,tan97a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesh,bindyesh,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >MUS21956# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (52-61) homologue# ANCHOR POSITIONS:# REFERENCES: cavani95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DKGILQINSR*# SEQUENCE: DKGILQINSR*# ...# >MUS21957# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (52-61) homologue# ANCHOR POSITIONS:# REFERENCES: cavani95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DYGIKQINSR*# SEQUENCE: DYGIKQINSR*# ...# >MUS21958# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (52-61) homologue# ANCHOR POSITIONS:# REFERENCES: cavani95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DYGILQIKSR*# SEQUENCE: DYGILQIKSR*# ...# >MUS21959# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: cavani95a,fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,AAAAYRAAAAAAA*# SEQUENCE: AAAAYRAAAAAAA*# ...# >MUS2195A# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: cavani95a# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,AAAKYRAAAAAAA*# SEQUENCE: AAAKYRAAAAAAA*# ...# >MUS2195B# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: cavani95a# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,AAAAYRKAAAAAA*# SEQUENCE: AAAAYRKAAAAAA*# ...# >MUS2195C# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: cavani95a# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,AAAAYRAAAKAAA*# SEQUENCE: AAAAYRAAAKAAA*# ...# >HUM2195D# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: ?# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human Ii (131-149)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: hitzel95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,ATKYGNMTEDHVMHLLQNA*# SEQUENCE: ATKYGNMTEDHVMHLLQNA*# ...# >MUS1195E# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: reference/Stabilization/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Adenovirus early protein Ad5 E1B (192-200)# DB REFERENCE: SWISS: (E1BL_ADE05,E1BL_ADE02)# & PIR1: (Q1AD55,Q1AD52)# REFERENCES: neisig95a,feltkamp94a,toes95a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesh,VNIRNCCYI*# SEQUENCE: VNIRNCCYI*# ...# >MUS1195F# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: reference/Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MCF1233 MuLV# DB REFERENCE: SWISS: (ENV_MLVAV,ENV_MCFF3,ENV_FLVC6,ENV_FSVGA,ENV_FLVLB,# & ENV_MLVKI,ENV_FSVSM,ENV_FLVSA,ENV_MSVFB,ENV_FENV1,# & ENV_FLVGL,ENV_FSVGB)# & PIR1: (VCMVFP,VCMVSA,VCMVLB,VCVWM1,VCVWEK,VCVWGF,VCMVSS,VCMVS2,# & VCMVFG,VCMVCE)# & PIR2: (A46511,A03985,S22805,A25982,A03986,A43491)# REFERENCES: neisig95a,rammensee95a,feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesh,KSPWFTTL*# SEQUENCE: KSPWFTTL*# ...# >HUM11960# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus DV NS3 (500-508)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# REFERENCES: livingston95a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,TPEGIIPTL*# SEQUENCE: TPEGIIPTL*# ...# >HUM11961# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ALAKAAAAV*# SEQUENCE: ALAKAAAAV*# ...# >HUM11962# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,AIAKAAAAV*# SEQUENCE: AIAKAAAAV*# ...# >HUM11963# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AVAKAAAAV*# SEQUENCE: AVAKAAAAV*# ...# >HUM11964# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AAAKAAAAV*# SEQUENCE: AAAKAAAAV*# ...# >HUM11965# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAAI*# SEQUENCE: ALAKAAAAI*# ...# >HUM11966# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAAAA*# SEQUENCE: ALAKAAAAA*# ...# >HUM11967# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ALAKAAAAL*# SEQUENCE: ALAKAAAAL*# ...# >HUM11968# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAAM*# SEQUENCE: ALAKAAAAM*# ...# >HUM11969# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAAAN*# SEQUENCE: ALAKAAAAN*# ...# >HUM1196A# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALAKAAAAR*# SEQUENCE: ALAKAAAAR*# ...# >HUM1196B# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAAV*# SEQUENCE: ALAKAAAAV*# ...# >HUM1196C# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,AIAKAAAAV*# SEQUENCE: AIAKAAAAV*# ...# >HUM1196D# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,AVAKAAAAV*# SEQUENCE: AVAKAAAAV*# ...# >HUM1196E# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AAAKAAAAV*# SEQUENCE: AAAKAAAAV*# ...# >HUM1196F# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAAI*# SEQUENCE: ALAKAAAAI*# ...# >HUM11970# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAAA*# SEQUENCE: ALAKAAAAA*# ...# >HUM11971# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ALAKAAAAL*# SEQUENCE: ALAKAAAAL*# ...# >HUM11972# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAKAAAAM*# SEQUENCE: ALAKAAAAM*# ...# >HUM11973# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV Pol# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1JR,POL_HV1OY,POL_HV1BR,POL_HV1MA,# & POL_HV1PV,POL_HV1B1,POL_HV1B5,POL_HV1H2,POL_HV1MN)# & PIR1: (GNVWVL,GNVWH3,GNVWLV,GNVWA2)# & PIR2: (A47175,B47175)# & PIR3: (S11523,S33980)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,IVGAETFYV*# SEQUENCE: IVGAETFYV*# ...# >HUM11974# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV Pol (185-193)# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,DPKVKQWPL*# SEQUENCE: DPKVKQWPL*# ...# >HUM11975# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV (141-151)# DB REFERENCE: SWISS: (CORA_HPBVZ,CORA_HPBVA,CORA_HPBVO,CORA_HPBV2,CORA_HPBVF,# & CORA_HPBV4,CORA_HPBVW,CORA_HPBVJ,CORA_HPBVL,CORA_HPBV9,# & CORA_HPBVY,CORA_HPBVT)# & PIR1: (NKVLA1,NKVLH3,NKVLAH,NKVLCP,NKVLA2,NKVLKS,NKVLA6,NKVLJ2,# & NKVLA4,NKVLBH,NKVLJ1,NKVLA3)# & PIR2: (S53253,S53216,S53140,S53204,S53242,S53175,JQ2227,S47405,# & S53155,S53240,S53181,S53184,S53270,S53159,S53227,S20750,# & S53223,S53178,S47409,S01405,S53211,S25651,S53172,S53169,# & S53255,S53281,S53257,S20746,S53152,S53238,S53166,S53260,# & S53200,S04570,S53225,S53232,S33686,S53279,S32204,S53207,# & S53163,S53129,S53221,S53157,S53198,S53202,S53236,S53229,# & S53251,S53272,S53146,S53194,S35530)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,STLPETTVVRR*# SEQUENCE: STLPETTVVRR*# ...# >HUM11976# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as./Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV Core (18-27)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVL,CORA_HPBVW,CORA_HPBV9,CORA_HPBVJ,# & CORA_HPBVF,CORA_HPBV2,CORA_HPBVT,CORA_HPBVO,CORA_HPBVA,# & CORA_HPBVZ)# & PIR1: (NKVLAH,NKVLJ2,NKVLA6,NKVLKS,NKVLH3,NKVLA1,NKVLCP,NKVLBH,# & NKVLA2,NKVLA3,NKVLJ1)# & PIR2: (S53251,S32204,S53272,S53236,S53229,S53242,S53175,S43490,# & S53288,S53211,S53240,S53181,S53155,S53260,S53232,S53255,# & S25651,S47409,S47405,S53204,S53202,S33686,S53221,S53227,# & S20750,S53137,JQ2227,S53253,S01405,S53286,S53214,S53143,# & S53274,S53189,S53184,S53169,S53163,S53207,S53279,S53129,# & S53270,S53159,S53178,S53223,S53216,S53238,S53152,S20746,# & S53281,S53257,S53200,S53225,S53267)# REFERENCES: del_guercio95a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLPSDFFPSV*# SEQUENCE: FLPSDFFPSV*# ...# >HUM11977# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: pS3 (264-272)# DB REFERENCE: SWISS: (P53_CERAE,P53_MESAU,P53_CERAE,P53_BOVIN,P53_CRIGR,# & P53_HUMAN,P53_FELCA,P53_HUMAN,P53_FELCA,P53_MESAU)# & PIR1: (DNHU53)# & PIR2: (JC6193,S06594,JH0633,JC6176,S51648)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,LLGRNSFEV*# SEQUENCE: LLGRNSFEV*# ...# >HUM11978# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV Pol# DB REFERENCE: SWISS: (DPOL_HPBV9,DPOL_HPBVP,DPOL_HPBVY,DPOL_HPBVT,DPOL_HPBV4,# & DPOL_HPBV2,DPOL_HPBVR,DPOL_HPBVM,DPOL_HPBVI,DPOL_HPBVJ,# & DPOL_HPBVO,DPOL_HPBVW,DPOM_HPBVY)# & PIR1: (JDVLKS,S47406,JDVLVS,S20757,JDVLJ2,S43491,JDVLVA,JDVLVR,# & S20752,JDVLJ1,JDVLVD,JDVLVB,JDVLJ3,JQ2229)# & PIR2: (S71785,S35527)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YLHTLWKAGI*# SEQUENCE: YLHTLWKAGI*# ...# >HUM11979# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV Pol# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1BR,POL_HV1A2,POL_HV1JR,POL_HV1OY,# & POL_HV1MA,POL_HV1B1,POL_HV1PV,POL_HV1MN,POL_HV1B5)# & PIR1: (GNVWLV,GNVWA2,GNVWVL,GNVWH3)# & PIR2: (B47175,A47175)# & PIR3: (S11523,S33980)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,IVGAETFYV*# SEQUENCE: IVGAETFYV*# ...# >HUM1197A# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as./competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV Env (335-343)# DB REFERENCE: SWISS: (VMSA_HPBV4,VMSA_HPBVY,VMSA_HPBVI,VMSA_HPBVA,VMSA_HPBVJ,# & VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBVN,VMSA_HPBVO,# & VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBVP,VMSA_HPBVY,VMSA_HPBV2,# & VMSA_HPBVZ,VMSA_HPBVS,VMSA_HPBV9,VMSA_HPBVD,# & VMSA_HPBV0)# & PIR1: (JQ1573,SAVLAJ,SAVLAD,JQ1577,SAVLA1,JQ1578,JQ1575,JQ1574,# & SAVLVE,SAVLJ3,SAVLA,SAVLVD,SAVLHV,JQ1572,SAVLAR,SAVLBH,# & SAVLAH,SAVLJ1,SAVLJ2,JQ1571,SAVLKS,JQ1570,SAVLN1,# & JQ1576)# & PIR2: (JQ2092,JQ2068,S20749,JQ2085,JQ2109,S20745,JQ2067,JQ2065,# & JQ2111,JQ2102,JQ2077,JQ2053,JQ2073,JQ2059,JQ2115,JQ2105,# & JQ2116,JQ2047,S20753,JQ2078,JQ2089,JQ2114,JQ2103,JQ2112,# & JQ2048,JQ2072,S35528,JQ2052,JQ2090,JQ2046,JQ2051,JQ2081,# & JQ2075,JQ2101,JQ2066,JQ2061,JQ2097,S32202,JQ2108,JQ2070,# & JQ2100,JQ2098,JQ2058,S43492,JQ2062,S41870,JQ2056,JQ2104,# & JQ2069,JQ2045,JQ2080,JQ2050,JQ2063,S47407,JQ2113,JQ2091,# & JQ2083,S47411,JQ2057,S36654,S41869,JQ2076,JQ2060,JQ2106,# & JQ2087,JQ2110,JQ2054,JQ2079,JQ2055)# REFERENCES: del_guercio95a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,WLSLLVPFV*# SEQUENCE: WLSLLVPFV*# ...# >HUM1197B# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 Pol (476-484)# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1MA,POL_HV1ND,POL_HV1Y2,POL_HV1PV,# & POL_HV1B1,POL_HV1MN,POL_HV1B5,POL_HV1OY,POL_HV1N5,# & POL_HV1Z2,POL_HV1JR,POL_HV1H2,POL_HV1EL,POL_HV1BR)# & PIR1: (GNLJND,GNVWLV,GNVWH3,B44001,GNVWVL)# & PIR2: (S54378,B47175)# REFERENCES: del_guercio95a,barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM1197C# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV-1 Tax (12-19)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LLFGYPVYV*# SEQUENCE: LLFGYPVYV*# ...# >HUM1197D# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as./CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV Core (18-27)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVL,CORA_HPBVO,CORA_HPBVZ,CORA_HPBVA,# & CORA_HPBVT,CORA_HPBVY,CORA_HPBVF,CORA_HPBV2,CORA_HPBVJ,# & CORA_HPBVW)# & PIR1: (NKVLAH,NKVLH3,NKVLA6,NKVLA2,NKVLBH,NKVLKS,NKVLJ2,NKVLA3,# & NKVLJ1,NKVLCP,NKVLA1)# & PIR2: (S53272,S53175,S53155,S53181,S53225,S53129,S47405,S53221,# & S47409,S53184,S53270,S53227,S53211,S53202,S53223,S53207,# & S53163,S53279,S53238,S53281,S53257,S43490,S53242,S32204,# & S53229,S53236,S53251,S25651,S53255,S53232,S53260,S53204,# & S33686,S01405,S53137,JQ2227,S53253,S20750,S53286,S53267,# & S53200,S53288,S53240,S20746,S53152,S53143,S53159,S53274,# & S53214,S53189,S53169,S53216,S53178)# REFERENCES: del_guercio95a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLPSDFFPSV*# SEQUENCE: FLPSDFFPSV*# ...# >HUM1197E# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: pS3 (264-272)# DB REFERENCE: SWISS: (P53_CRIGR,P53_FELCA,P53_BOVIN,P53_FELCA,P53_HUMAN,# & P53_MESAU,P53_CERAE,P53_MESAU,P53_CERAE,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (JH0633,S51648,JC6176,JC6193,S06594)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LLGRNSFEV*# SEQUENCE: LLGRNSFEV*# ...# >HUM1197F# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV Pol# DB REFERENCE: SWISS: (DPOL_HPBV2,DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBVT,DPOL_HPBVJ,# & DPOL_HPBVW,DPOL_HPBVO,DPOL_HPBVI,DPOL_HPBV4,DPOL_HPBVR,# & DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBV9)# & PIR1: (JDVLKS,JDVLVS,S20757,JDVLJ3,JDVLVD,JDVLVB,JQ2229,S47406,# & JDVLVR,JDVLJ1,S43491,JDVLJ2,JDVLVA,S20752)# & PIR2: (S35527,S71785)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YLHTLWKAGI*# SEQUENCE: YLHTLWKAGI*# ...# >HUM11980# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV Pol# DB REFERENCE: SWISS: (POL_HV1JR,POL_HV1MN,POL_HV1B1,POL_HV1H2,POL_HV1OY,# & POL_HV1BR,POL_HV1MA,POL_HV1B5,POL_HV1PV,POL_HV1A2)# & PIR1: (GNVWH3,GNVWLV,GNVWA2,GNVWVL)# & PIR2: (B47175,A47175)# & PIR3: (S11523,S33980)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,IVGAETFYV*# SEQUENCE: IVGAETFYV*# ...# >HUM11981# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as./CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV Env (335-343)# DB REFERENCE: SWISS: (VMSA_HPBVW,VMSA_HPBVN,VMSA_HPBVW,VMSA_HPBV0,VMSA_HPBVD,# & VMSA_HPBV9,VMSA_HPBVJ,VMSA_HPBVA,VMSA_HPBVO,VMSA_HPBVY,# & VMSA_HPBVZ,VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVS,# & VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBV4,VMSA_HPBVY,# & VMSA_HPBVI)# & PIR1: (SAVLAJ,SAVLAD,JQ1572,SAVLAH,JQ1571,SAVLKS,JQ1570,JQ1576,# & SAVLA,SAVLJ3,SAVLHV,JQ1577,JQ1578,SAVLA1,SAVLBH,JQ1575,# & JQ1574,SAVLAR,JQ1573,SAVLVE,SAVLN1,SAVLVD,SAVLJ1,# & SAVLJ2)# & PIR2: (JQ2092,JQ2109,S20745,S20749,JQ2067,JQ2101,JQ2051,JQ2072,# & JQ2070,JQ2069,JQ2061,JQ2112,JQ2090,JQ2048,JQ2062,JQ2058,# & JQ2104,JQ2050,JQ2063,JQ2091,JQ2055,JQ2079,S41869,JQ2083,# & S36654,S47411,JQ2057,S47407,JQ2113,S32202,JQ2097,JQ2066,# & JQ2108,JQ2098,JQ2100,JQ2078,JQ2089,JQ2065,JQ2102,JQ2111,# & JQ2114,JQ2103,JQ2076,JQ2106,JQ2087,JQ2060,JQ2054,JQ2110,# & JQ2068,JQ2085,JQ2075,JQ2073,JQ2059,JQ2105,JQ2115,JQ2116,# & JQ2053,JQ2077,JQ2046,JQ2045,JQ2080,S43492,JQ2056,S41870,# & JQ2047,S20753,JQ2052,S35528,JQ2081)# REFERENCES: del_guercio95a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,WLSLLVPFV*# SEQUENCE: WLSLLVPFV*# ...# >HUM11982# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as./bindind as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 Pol (476-484)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1EL,POL_HV1OY,POL_HV1BR,POL_HV1H2,# & POL_HV1MN,POL_HV1JR,POL_HV1N5,POL_HV1Y2,POL_HV1B5,# & POL_HV1ND,POL_HV1RH,POL_HV1B1,POL_HV1Z2,POL_HV1PV)# & PIR1: (GNVWH3,B44001,GNLJND,GNVWVL,GNVWLV)# & PIR2: (B47175,S54378)# REFERENCES: del_guercio95a,barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM11983# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV-1 Tax (12-19)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547)# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LLFGYPVYV*# SEQUENCE: LLFGYPVYV*# ...# >HUM11984# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV Core (18-27) homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM11985# MHC MOLECULE: HLA-A69(A*6901), CLASS-1, (HUMAN)# METHOD: cell binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV Core (18-27) homologue# ANCHOR POSITIONS:# REFERENCES: del_guercio95a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesm,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM21986# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: mass spectrometry/peptide sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP invariant chain (81-103)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: avva94a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALP*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALP*# ...# >HUM21987# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: mass spectrometry/peptide sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP invariant chain# ANCHOR POSITIONS:# REFERENCES: avva94a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,XPKPPKPVXKM*# SEQUENCE: XPKPPKPVXKM*# ...# >HUM21988# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: mass spectrometry/peptide sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP invariant chain# ANCHOR POSITIONS:# REFERENCES: avva94a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,XXXPPKPVXKMIXA*# SEQUENCE: XXXPPKPVXKMIXA*# ...# >HUM21989# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (308-319)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IADH3,HEMA_IADU3,HEMA_IAME1,HEMA_IANT6,# & HEMA_IADH1,HEMA_IADH2,HEMA_IADH6,HEMA_IAAIC,HEMA_IAZCO,# & HEMA_IAME2,HEMA_IABAN,HEMA_IAUDO,HEMA_IAVI7,HEMA_IAZH2,# & HEMA_IAEN6,HEMA_IADH7,HEMA_IADHM,HEMA_IAQU7,HEMA_IAEN7,# & HEMA_IAZUK)# & PIR1: (HMIVV,HMIV15,HMIVHA,HMIVHM,HMIV89,HMIVH,HMIV6,HMIV77,# & HMIV33,HMIVS3,HMIV80,HMIVDU,HMIV98)# & PIR2: (A92979,JQ1156)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,KYVKQNTLKLAT*# SEQUENCE: KYVKQNTLKLAT*# ...# >HUM2198A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (309-319)# DB REFERENCE: SWISS: (HEMA_IAME6,HEMA_IAZH2,HEMA_IAEN7,HEMA_IAQU7,HEMA_IAUDO,# & HEMA_IADH2,HEMA_IADH3,HEMA_IADH4,HEMA_IADU3,HEMA_IAME1,# & HEMA_IAME2,HEMA_IAVI7,HEMA_IADH1,HEMA_IANT6,HEMA_IAEN6,# & HEMA_IADH7,HEMA_IAZUK,HEMA_IABAN,HEMA_IAAIC,HEMA_IAZCO,# & HEMA_IADHM,HEMA_IADH6)# & PIR1: (HMIVV,HMIV15,HMIVDU,HMIV80,HMIV89,HMIVS3,HMIVHM,HMIVH,# & HMIV6,HMIV77,HMIVHA,HMIV86,HMIV33,HMIV98)# & PIR2: (JQ2374,JQ2375,A92979,S52199,S52195,S52189,S52198,S52186,# & JQ1156,JQ2378,S52173,S52188,S52178,S52174,S52185,S52191,# & S52175,S52183,S52187,S52180,S52179,S52197,S52176,S52182,# & JQ2377)# & PIR3: (S38637)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YVKQNTLKLAT*# SEQUENCE: YVKQNTLKLAT*# ...# >HUM2198B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: RMBP (89-102)# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VHFFKNIVTPRTPA*# SEQUENCE: VHFFKNIVTPRTPA*# ...# >HUM2198C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: RMBP (91-102)# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,FFKNIVTPRTPA*# SEQUENCE: FFKNIVTPRTPA*# ...# >HUM2198D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: RMBP (92-102)# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,FKNIVTPRTPA*# SEQUENCE: FKNIVTPRTPA*# ...# >HUM2198E# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: RMBP (89-101)# DB REFERENCE: SWISS: (MBP_RAT,MBP_PANTR,MBP_HUMAN,MBP_CAVPO,MBP_BOVIN,# & MBP_MOUSE)# & PIR1: (MBCZB,MBRTS,MBMSB,MBHUB,MBPGB,MBBOB)# & PIR2: (A37246)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >HUM2198F# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: RMBP (89-100)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_CAVPO,MBP_BOVIN,MBP_RAT,# & MBP_PANTR)# & PIR1: (MBRTS,MBCZB,MBPGB,MBHUB,MBMSB,MBBOB)# & PIR2: (A37246)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,VHFFKNIVTPRT*# SEQUENCE: VHFFKNIVTPRT*# ...# >HUM21990# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: RMBP (89-99)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN,MBP_MOUSE,MBP_BOVIN,MBP_CAVPO,# & MBP_RAT)# & PIR1: (MBCZB,MBMSB,MBPGB,MBHUB,MBRTS,MBBOB)# & PIR2: (A37246)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,VHFFKNIVTPR*# SEQUENCE: VHFFKNIVTPR*# ...# >HUM21991# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: RMBP (89-97)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_RAT,MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,# & MBP_PANTR)# & PIR1: (MBBOB,MBHUB,MBRTS,MBCZB,MBMSB,MBPGB)# & PIR2: (A37246)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,VHFFKNIVT*# SEQUENCE: VHFFKNIVT*# ...# >HUM21992# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAAAAKAAA*# SEQUENCE: AAYAAAAAAKAAA*# ...# >HUM21993# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYKAAAAAAAAA*# SEQUENCE: AAYKAAAAAAAAA*# ...# >HUM21994# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAAAAAAAKA*# SEQUENCE: AAYAAAAAAAAKA*# ...# >HUM21995# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAYAAADAAAAAA*# SEQUENCE: AAYAAADAAAAAA*# ...# >HUM21996# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAAYAAAAAAAKA*# SEQUENCE: AAAYAAAAAAAKA*# ...# >HUM21997# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAAAYAAAAAAKA*# SEQUENCE: AAAAYAAAAAAKA*# ...# >HUM21998# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,AAAAAYAAAAAKA*# SEQUENCE: AAAAAYAAAAAKA*# ...# >HUM21999# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AYAAAKAAAAAAA*# SEQUENCE: AYAAAKAAAAAAA*# ...# >HUM2199A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YAAAKAAAAAAAA*# SEQUENCE: YAAAKAAAAAAAA*# ...# >HUM2199B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAAYAAAKAAAAA*# SEQUENCE: AAAYAAAKAAAAA*# ...# >HUM2199C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAAAYAAAKAAAA*# SEQUENCE: AAAAYAAAKAAAA*# ...# >HUM2199D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAAAAYAAAKAAA*# SEQUENCE: AAAAAYAAAKAAA*# ...# >HUM2199E# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAAAAAYAAAKAA*# SEQUENCE: AAAAAAYAAAKAA*# ...# >HUM2199F# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AAAAAAAYAAAKA*# SEQUENCE: AAAAAAAYAAAKA*# ...# >HUM219A0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,AAAAAAAAYAAAK*# SEQUENCE: AAAAAAAAYAAAK*# ...# >HUM219A1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ser homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,SSYSSSKSSSSSS*# SEQUENCE: SSYSSSKSSSSSS*# ...# >HUM219A2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,RRFAAAAAAAAAR*# SEQUENCE: RRFAAAAAAAAAR*# ...# >HUM219A3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,RRAAAAAAAAAAR*# SEQUENCE: RRAAAAAAAAAAR*# ...# >HUM219A4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,AAAAAAKAAAYAA*# SEQUENCE: AAAAAAKAAAYAA*# ...# >HUM219A5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (308-319)# DB REFERENCE: SWISS: (HEMA_IAEN6,HEMA_IADH6,HEMA_IADHM,HEMA_IAAIC,HEMA_IAME1,# & HEMA_IADH4,HEMA_IADH7,HEMA_IAME2,HEMA_IABAN,HEMA_IAVI7,# & HEMA_IADH1,HEMA_IAEN7,HEMA_IADH3,HEMA_IADU3,HEMA_IAZUK,# & HEMA_IANT6,HEMA_IADH2,HEMA_IAUDO,HEMA_IAZH2,HEMA_IAQU7,# & HEMA_IAZCO)# & PIR1: (HMIVS3,HMIV33,HMIV98,HMIV77,HMIVDU,HMIV15,HMIVHA,HMIVV,# & HMIV89,HMIV80,HMIVHM,HMIV6,HMIVH)# & PIR2: (A92979,JQ1156)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KYVKQNTLKLAT*# SEQUENCE: KYVKQNTLKLAT*# ...# >HUM219A6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (309-319)# DB REFERENCE: SWISS: (HEMA_IAEN6,HEMA_IADHM,HEMA_IAAIC,HEMA_IAME1,HEMA_IAUDO,# & HEMA_IADH6,HEMA_IAME6,HEMA_IABAN,HEMA_IADH7,HEMA_IAZCO,# & HEMA_IANT6,HEMA_IAQU7,HEMA_IAZH2,HEMA_IADH2,HEMA_IAZUK,# & HEMA_IADH4,HEMA_IADH3,HEMA_IAVI7,HEMA_IADU3,HEMA_IAEN7,# & HEMA_IAME2,HEMA_IADH1)# & PIR1: (HMIV6,HMIV80,HMIVHM,HMIVV,HMIVS3,HMIVH,HMIV15,HMIV98,# & HMIV77,HMIVDU,HMIV86,HMIVHA,HMIV33,HMIV89)# & PIR2: (S52174,S52188,S52173,A92979,JQ2374,S52176,S52182,S52180,# & S52195,S52189,S52178,S52183,S52191,S52185,JQ2375,S52187,# & S52198,S52175,JQ2378,S52199,S52186,S52179,JQ1156,S52197,# & JQ2377)# & PIR3: (S38637)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YVKQNTLKLAT*# SEQUENCE: YVKQNTLKLAT*# ...# >HUM219A7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: RMBP (89-102)# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,VHFFKNIVTPRTPA*# SEQUENCE: VHFFKNIVTPRTPA*# ...# >HUM219A8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: RMBP (91-102)# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,FFKNIVTPRTPA*# SEQUENCE: FFKNIVTPRTPA*# ...# >HUM219A9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: RMBP (92-102)# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,FKNIVTPRTPA*# SEQUENCE: FKNIVTPRTPA*# ...# >HUM219AA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as./binding inhibition as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: RMBP (89-101)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_MOUSE,MBP_CAVPO,MBP_BOVIN,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBCZB,MBPGB,MBMSB,MBHUB,MBBOB,MBRTS)# & PIR2: (A37246)# REFERENCES: hill94a,marshall95a,martin92a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >HUM219AB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: RMBP (89-100)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_RAT,MBP_MOUSE,MBP_CAVPO,MBP_BOVIN,# & MBP_PANTR)# & PIR1: (MBMSB,MBRTS,MBPGB,MBBOB,MBHUB,MBCZB)# & PIR2: (A37246)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,VHFFKNIVTPRT*# SEQUENCE: VHFFKNIVTPRT*# ...# >HUM219AC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: RMBP (89-99)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_CAVPO,MBP_HUMAN,MBP_MOUSE,MBP_RAT,# & MBP_PANTR)# & PIR1: (MBHUB,MBRTS,MBCZB,MBPGB,MBBOB,MBMSB)# & PIR2: (A37246)# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,VHFFKNIVTPR*# SEQUENCE: VHFFKNIVTPR*# ...# >HUM219AD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAAAAKAAA*# SEQUENCE: AAYAAAAAAKAAA*# ...# >HUM219AE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYKAAAAAAAAA*# SEQUENCE: AAYKAAAAAAAAA*# ...# >HUM219AF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAAAAAAKA*# SEQUENCE: AAYAAAAAAAAKA*# ...# >HUM219B0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAADAAAAAA*# SEQUENCE: AAYAAADAAAAAA*# ...# >HUM219B1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAAYAAAAAAKAA*# SEQUENCE: AAAYAAAAAAKAA*# ...# >HUM219B2# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAAAYAAAAAAKA*# SEQUENCE: AAAAYAAAAAAKA*# ...# >HUM219B3# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AYAAAKAAAAAAA*# SEQUENCE: AYAAAKAAAAAAA*# ...# >HUM219B4# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YAAAKAAAAAAAA*# SEQUENCE: YAAAKAAAAAAAA*# ...# >HUM219B5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAAYAAAKAAAAA*# SEQUENCE: AAAYAAAKAAAAA*# ...# >HUM219B6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AAAAYAAAKAAAA*# SEQUENCE: AAAAYAAAKAAAA*# ...# >HUM219B7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AAAAAYAAAKAAA*# SEQUENCE: AAAAAYAAAKAAA*# ...# >HUM219B8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ser homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SSYSSSKSSSSSS*# SEQUENCE: SSYSSSKSSSSSS*# ...# >HUM219B9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: hill94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,RRFAAAAAAAAAR*# SEQUENCE: RRFAAAAAAAAAR*# ...# >MUS119BA# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: OVA (176-183)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: bellone94a# COMMENT: Rate of dissociation is relatively high - 4h to dissociate# SUMMARY: H-2Kb,actyesu,bindyesh,NAIVFKGL*# SEQUENCE: NAIVFKGL*# ...# >MUS219BB# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus MVF (258-277)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASY,VGLF_MEASE,VGLF_MEASI,# & VGLF_MEASE)# & PIR1: (VGNZMV,JU0274,E48556)# REFERENCES: shaw93a# COMMENT:# SUMMARY: I-?,actyesu,bindyesu,GILESRGIKARITHVDTESY*# SEQUENCE: GILESRGIKARITHVDTESY*# ...# >MUS219BC# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus MVF (288-302)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_RINDB,VGLF_MEASY,# & VGLF_MEASE)# & PIR1: (E48556,JU0274,VGNZMV)# & PIR2: (S47300,PQ0376,PQ0388)# REFERENCES: shaw93a# COMMENT:# SUMMARY: I-?,actyesu,bindyesu,LSEIKGVIVHRLEGV*# SEQUENCE: LSEIKGVIVHRLEGV*# ...# >MUS219BD# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus MVH (49-72)# DB REFERENCE: SWISS: (HEMA_MEASA,HEMA_MEASE,HEMA_MEASH)# & PIR1: (HMNZHA,F48556,HMNZED)# REFERENCES: shaw93a# COMMENT:# SUMMARY: I-?,actyesu,bindyesu,LIGLLAIAGIRLHRAAIYTAEIHK*# SEQUENCE: LIGLLAIAGIRLHRAAIYTAEIHK*# ...# >MUS219BE# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus MVH (253-267)# DB REFERENCE: SWISS: (HEMA_MEASY,HEMA_MEASE,HEMA_MEASI,HEMA_MEASA)# & PIR1: (HMNZED,F48556)# & PIR2: (PQ0377,JU0273,PQ0381)# REFERENCES: shaw93a# COMMENT:# SUMMARY: I-?,actyesu,bindyesu,RVFEVGVIRNPGLGA*# SEQUENCE: RVFEVGVIRNPGLGA*# ...# >MUS219BF# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Respiratory syncytial virus RS1A (45-60)# DB REFERENCE: SWISS: (VSH_HRSVA)# & PIR1: (P1NZAR)# REFERENCES: shaw93a# COMMENT:# SUMMARY: I-?,actyesu,bindyesu,CEYNVFHNKTFELPRA*# SEQUENCE: CEYNVFHNKTFELPRA*# ...# >HUM219C0# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: MHC restriction as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human MBP (139-153)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: saruhan_direskene93a# COMMENT:# SUMMARY: HLA-DR51,actyesu,bindyesu,HKGFKGVDAQGTLSK*# SEQUENCE: HKGFKGVDAQGTLSK*# ...# >HUM219C1# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: MHC restriction as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TcR beta1 CDR3 region (82-96)# DB REFERENCE: PIR2: (S17379,S36133,S26275,S57880,S36942,I38313,S17378,# & S25416)# REFERENCES: saruhan_direskene93a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,DRFSAERLKGVDSTL*# SEQUENCE: DRFSAERLKGVDSTL*# ...# >HUM219C2# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: MHC restriction as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TcR beta2 Vbeta (114-128)# DB REFERENCE: PIR2: (S57880)# REFERENCES: saruhan_direskene93a# COMMENT: MHC restriction to HLA-DRw6 or to HLA-DRw52# SUMMARY: HLA-DR?,actyesu,bindyesu,SLLRSWEQFFGPGTR*# SEQUENCE: SLLRSWEQFFGPGTR*# ...# >MUS219C3# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV HBsAg (23-34)# DB REFERENCE: SWISS: (VMSA_HPBVD,VMSA_HPBV0,VMSA_HPBVN,VMSA_HPBVW,VMSA_HPBVP,# & VMSA_HPBV2,VMSA_HPBV2,VMSA_HPBVR,VMSA_HPBVZ,VMSA_HPBV9,# & VMSA_HPBVY,VMSA_HPBVR,VMSA_HPBVY,VMSA_HPBV4,VMSA_HPBVS,# & VMSA_HPBVW)# & PIR1: (SAVLA,SAVLAR,SAVLAJ,SAVLAD,SAVLAH,JQ1572,JQ1576,JQ1571,# & SAVLBH,SAVLHV,JQ1575,SAVLVD,SAVLN1,JQ1574,JQ1577,SAVLKS,# & SAVLVE)# & PIR2: (JQ2078,JQ2065,JQ2111,JQ2114,JQ2103,S41871,JQ2096,JQ2054,# & JQ2105,JQ2073,JQ2053,JQ2050,JQ2055,JQ2063,S20749,JQ2067,# & JQ2109,JQ2051,JQ2101,JQ2112,S35528,JQ2081,JQ2047,JQ2108,# & JQ2100,JQ2076,S36654,S47411,JQ2045,JQ2056,S43492,S41869,# & JQ2069,JQ2095,JQ2048,JQ2079,JQ2115,JQ2099,JQ2068,JQ2075,# & JQ2046,JQ2102,S32202,JQ2066,JQ2106,JQ2094,JQ2083,S41870,# & JQ2097,JQ2080,JQ2052,S20753,JQ2070,JQ2072,S20745,JQ2104,# & JQ2077,JQ2098,S47407)# & PIR4: (S42226)# REFERENCES: steward93a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,TRILTIPQSLDS*# SEQUENCE: TRILTIPQSLDS*# ...# >MUS219C4# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV HBsAg (160-171)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVO,VMSA_HPBV9,VMSA_HPBV2,VMSA_HPBVP,# & VMSA_HPBVW,VMSA_HPBVJ,VMSA_HPBVI,VMSA_HPBVW)# & PIR1: (SAVLJ2,SAVLJ3,JQ1570,SAVLJ1,JQ1577,SAVLVD,JQ1575,SAVLKS,# & SAVLVE)# & PIR2: (JQ2059,JQ2052,S47411,JQ2053,JQ2056,JQ2054,JQ2062,S36654,# & JQ2046,JQ2045,JQ2057,JQ2060,JQ2061,JQ2048,JQ2058,JQ2047,# & JQ2055,JQ2051,S20749,JQ2050)# REFERENCES: steward93a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,KYLWEWASVRFS*# SEQUENCE: KYLWEWASVRFS*# ...# >MUS219C5# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV HBsAg (23-34)# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBV4,VMSA_HPBV9,VMSA_HPBVD,VMSA_HPBVW,# & VMSA_HPBVN,VMSA_HPBV0,VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBVY,# & VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVR,# & VMSA_HPBVS)# & PIR1: (JQ1572,JQ1571,SAVLN1,JQ1574,JQ1575,SAVLVE,SAVLAR,SAVLKS,# & SAVLVD,SAVLAD,JQ1576,SAVLHV,SAVLBH,SAVLAH,SAVLAJ,SAVLA,# & JQ1577)# & PIR2: (JQ2109,JQ2063,JQ2112,JQ2053,JQ2094,JQ2102,S32202,JQ2054,# & JQ2056,JQ2079,JQ2068,JQ2075,S20753,S47411,JQ2097,JQ2052,# & S47407,S20745,JQ2069,JQ2095,JQ2105,JQ2073,JQ2111,JQ2114,# & S41871,JQ2096,JQ2045,S43492,JQ2076,JQ2108,JQ2115,JQ2098,# & JQ2103,S41869,JQ2106,JQ2083,JQ2066,JQ2099,S35528,JQ2067,# & S20749,JQ2065,JQ2047,JQ2100,JQ2046,S36654,JQ2070,JQ2072,# & JQ2080,S41870,JQ2077,JQ2104,JQ2048,JQ2101,JQ2081,JQ2051,# & JQ2050,JQ2055,JQ2078)# & PIR4: (S42226)# REFERENCES: steward93a# COMMENT:# SUMMARY: H-2q,actyesu,bindyesu,TRILTIPQSLDS*# SEQUENCE: TRILTIPQSLDS*# ...# >MUS219C6# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV HBsAg (160-171)# DB REFERENCE: SWISS: (VMSA_HPBVO,VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVP,VMSA_HPBVI,# & VMSA_HPBVW,VMSA_HPBV2,VMSA_HPBV9,VMSA_HPBVJ)# & PIR1: (SAVLJ2,JQ1575,SAVLJ3,SAVLVD,SAVLKS,SAVLVE,SAVLJ1,JQ1577,# & JQ1570)# & PIR2: (JQ2056,S47411,JQ2052,JQ2051,JQ2048,JQ2055,JQ2050,JQ2053,# & S20749,JQ2047,JQ2045,JQ2060,JQ2057,JQ2059,JQ2046,S36654,# & JQ2062,JQ2061,JQ2054,JQ2058)# REFERENCES: steward93a# COMMENT:# SUMMARY: H-2q,actyesu,bindyesu,KYLWEWASVRFS*# SEQUENCE: KYLWEWASVRFS*# ...# >HUM119C7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HPLC and sequencing/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: storkus93a# COMMENT: possibly ELGHPGAFI cytochrome oxidase subunit 1 (38-46)# SUMMARY: HLA-A2,actyesu,bindyesu,XXGHPGAFV*# SEQUENCE: XXGHPGAFV*# ...# >HUM119C8# MHC MOLECULE: HLA-A69(A*6901), CLASS-1, (HUMAN)# METHOD: HPLC and sequencing/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: storkus93a# COMMENT: possibly ELGHPGAFI cytochrome oxidase subunit 1 (38-46)# SUMMARY: HLA-A69,actyesu,bindyesu,XXGHPGAFV*# SEQUENCE: XXGHPGAFV*# ...# >HUM219C9# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxoid tt (141-171)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: reece93a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,EQDPSGATTKSAMLTNLIIFGPGPVLNKNEV*# SEQUENCE: EQDPSGATTKSAMLTNLIIFGPGPVLNKNEV*# ...# >HUM219CA# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxoid tt (257-268)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: reece93a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,QEIYMQHTYPIS*# SEQUENCE: QEIYMQHTYPIS*# ...# >HUM219CB# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxoid tt (616-631)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: reece93a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,VRDIIDDFTNESSQKT*# SEQUENCE: VRDIIDDFTNESSQKT*# ...# >HUM219CC# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxoid tt (640-651)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: reece93a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,STIVPYIGPALN*# SEQUENCE: STIVPYIGPALN*# ...# >HUM219CD# MHC MOLECULE: HLA-?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxoid tt (652-663)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: reece93a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,IVKQGYEGNFIG*# SEQUENCE: IVKQGYEGNFIG*# ...# >HUM219CE# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19000 MW antigen (11-30)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S11234,S02753)# REFERENCES: rees93a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,GAAILVAGLSGCSSNKSTTG*# SEQUENCE: GAAILVAGLSGCSSNKSTTG*# ...# >HUM219CF# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19000 MW antigen (21-40)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# REFERENCES: rees93a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,GCSSNKSTTGSGETTTAAGT*# SEQUENCE: GCSSNKSTTGSGETTTAAGT*# ...# >HUM219D0# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19000 MW antigen (15-35)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S11234,S02753)# REFERENCES: rees93a# COMMENT:# SUMMARY: HLA-DR5,actyesu,bindyesu,LVAGLSGCSSNKSTTGSGETT*# SEQUENCE: LVAGLSGCSSNKSTTGSGETT*# ...# >HUM219D1# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19000 MW antigen (1-20)# DB REFERENCE: PIR2: (S11234)# REFERENCES: rees93a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,VKRGLTVAVAGAAILVAGLS*# SEQUENCE: VKRGLTVAVAGAAILVAGLS*# ...# >HUM219D2# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19000 MW antigen (11-30)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S11234,S02753)# REFERENCES: rees93a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,GAAILVAGLSGCSSNKSTTG*# SEQUENCE: GAAILVAGLSGCSSNKSTTG*# ...# >HUM219D3# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19000 MW antigen (21-40)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# REFERENCES: rees93a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GCSSNKSTTGSGETTTAAGT*# SEQUENCE: GCSSNKSTTGSGETTTAAGT*# ...# >HUM119D4# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./Reconstitution# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: EBNA 3C (881-889)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015,S27922)# REFERENCES: hill95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesm,QPRAPIRPI*# SEQUENCE: QPRAPIRPI*# ...# >HUM119D5# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./Reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBNA 3C (881-891)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (S33015,S27922,A31666)# REFERENCES: hill95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,QPRAPIRPIPT*# SEQUENCE: QPRAPIRPIPT*# ...# >HUM119D6# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./Reconstitution# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: EBNA 3A (379-387)# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: hill95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesm,RPPIFIRRL*# SEQUENCE: RPPIFIRRL*# ...# >HUM119D7# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBNA 3C (881-889)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015,S27922)# REFERENCES: hill95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,QPRAPIRPI*# SEQUENCE: QPRAPIRPI*# ...# >MUS119D8# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competitive binding as./stabilisation as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: LCMV NP (397-404)# DB REFERENCE: SWISS: (NCAP_LYCVA,NCAP_LYCVW)# & PIR1: (VHXPLM,VHXPLC)# REFERENCES: gairin95a# COMMENT:# SUMMARY: H-2Db,actyesn,bindyesl,QPQNGQFI*# SEQUENCE: QPQNGQFI*# ...# >MUS119D9# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: competitive binding as./stabilisation as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: LCMV GP1 (33-43)# DB REFERENCE: SWISS: (VGLY_LYCVA,VGLY_LYCVW)# & PIR1: (VGXPLA,VGXPLM,VGXPLC)# REFERENCES: gairin95a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesh,KAVYNFATCGI*# SEQUENCE: KAVYNFATCGI*# ...# >MUS119DA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A HA (518-526)# DB REFERENCE: SWISS: (HEMA_IACKP,HEMA_IADIR,HEMA_IATKW,HEMA_IACKS,HEMA_IAZIN,# & HEMA_IAZNJ,HEMA_IACKQ,HEMA_IAPUE,HEMA_IAKIE,HEMA_IATKI,# & HEMA_IAUSS,HEMA_IALEN,HEMA_IADA4,HEMA_IATKO,# & HEMA_IAWIL)# & PIR1: (HMIVN1,HMIV17,HMIVT8,HMIVD8,HMIVD1,HMIV,HMIVTW,HMIVC2,# & HMIVUR,HMIV5)# & PIR3: (S69887,S69888)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,YSTVASSL*# SEQUENCE: YSTVASSL*# ...# >MUS119DB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSV-1 ICP27 (448-456)# DB REFERENCE: SWISS: (IE63_HSV11,IE63_HSV11,IE63_HSV1E)# & PIR1: (A48560,WMBEY4)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,DYATLGVGV*# SEQUENCE: DYATLGVGV*# ...# >MUS119DC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSV-1 ICP27 (322-332)# DB REFERENCE: SWISS: (IE63_HSV11,IE63_HSV1E,IE63_HSV11)# & PIR1: (WMBEY4,A48560)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,LYRTFAGNPRA*# SEQUENCE: LYRTFAGNPRA*# ...# >MUS119DD# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP (333-342)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,KYLKKIKNSL*# SEQUENCE: KYLKKIKNSL*# ...# >MUS119DE# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: APC frameshift# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,KYLKIKHLL*# SEQUENCE: KYLKIKHLL*# ...# >MUS119DF# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. mRNA CD40 mouse ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPRKXIXL*# SEQUENCE: SGPRKXIXL*# ...# >MUS119E0# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,AGPDRTEKXL*# SEQUENCE: AGPDRTEKXL*# ...# >MUS119E1# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. hypoxanthine phosphoribosyl-transferase# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,GPERGHNL*# SEQUENCE: GPERGHNL*# ...# >MUS119E2# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,KGPERXNGL*# SEQUENCE: KGPERXNGL*# ...# >MUS119E3# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,GPNRAFNF*# SEQUENCE: GPNRAFNF*# ...# >MUS119E4# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. heterog. nucl. RNP complex K# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SGPERLLSXY*# SEQUENCE: SGPERLLSXY*# ...# >MUS119E5# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,FGPLKFNVLT*# SEQUENCE: FGPLKFNVLT*# ...# >MUS119E6# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. insulin receptor precursor# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesu,SXPKTDXQTL*# SEQUENCE: SXPKTDXQTL*# ...# >MUS119E7# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tum-P35B (4-13)# DB REFERENCE: PIR2: (S12516)# REFERENCES: rammensee95a,correa95a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,GPPHSNNFGY*# SEQUENCE: GPPHSNNFGY*# ...# >MUS119E8# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV core (133-142)# DB REFERENCE: SWISS: (POLG_HCVE1,POLG_HCV1,POLG_HCVBK,POLG_HCVH4,POLG_HCVH,# & POLG_HCVH7,POLG_HCVJ2,POLG_HCVJT,POLG_HCVTH,POLG_HCVH8,# & POLG_HCVJA,POLG_HCVHK,POLG_HCVTW)# & PIR1: (GNWVTW,GNWVC3,GNWVTC,GNWVCJ,GNWVCH)# & PIR2: (S18032,S18030,PN0677,PC2061,JQ1925,A44150,S21471,PC2060,# & JH0711,S40770,JQ1926,JN0265,S41288,PC1284,S19875,A45573,# & S18031,S12707,PS0388)# & PIR3: (S32740)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,LMGYIPLVGA*# SEQUENCE: LMGYIPLVGA*# ...# >MUS119E9# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,XPLEANYQXF*# SEQUENCE: XPLEANYQXF*# ...# >MUS119EA# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesu,XPQPGREQ*# SEQUENCE: XPQPGREQ*# ...# >MUS119EB# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OGDH (97-112)# DB REFERENCE: SWISS: (ODO1_HUMAN,ODO1_MOUSE)# & PIR2: (A41911)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,VAITRIEQLSPFPFDL*# SEQUENCE: VAITRIEQLSPFPFDL*# ...# >MUS119EC# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tumor antigen P91A (12-20)# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,STQNHRAL*# SEQUENCE: STQNHRAL*# ...# >MUS119ED# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: JHMV Nucleocapsid (318-326)# DB REFERENCE: SWISS: (NCA2_CVMA5,NCAP_CVTKE,NCAP_CVHOC,NCAP_CVBF,NCAP_CVBM,# & NCAP_CVMJH)# & PIR1: (A60003,VHIHBC,VHIHMJ,C45340,VHIHN1)# & PIR2: (JQ1173)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,APTAGAFFF*# SEQUENCE: APTAGAFFF*# ...# >MUS119EE# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles NP (281-289)# DB REFERENCE: SWISS: (NCAP_MEASH,NCAP_PHODV,NCAP_RINDU,NCAP_MEASE,NCAP_MEASY,# & NCAP_MEASA,NCAP_CDVO,NCAP_RINDR,NCAP_PPRV,NCAP_CDVO,# & NCAP_RINDL,NCAP_MEASI)# & PIR1: (A48556,VHNZMV,VHNZMH,JU0272,VHNZCV)# & PIR2: (S24791,S36405,S47308,A49601,JQ1608,A49277)# & PIR3: (S52473)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,YPALGLHEF*# SEQUENCE: YPALGLHEF*# ...# >MUS119EF# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles HA (343-351)# DB REFERENCE: SWISS: (HEMA_MEASA,HEMA_MEASH,HEMA_MEASY,HEMA_MEASI,# & HEMA_MEASE)# & PIR1: (HMNZED,HMNZHA,F48556)# & PIR2: (PQ0381,JU0273)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,DPVIDRLYL*# SEQUENCE: DPVIDRLYL*# ...# >MUS119F0# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles HA (544-552)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,SPGRSFSCYF*# SEQUENCE: SPGRSFSCYF*# ...# >MUS119F1# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rotavirus VP7 (33-40)# DB REFERENCE: SWISS: (VS09_ROTBU,VS09_ROTHO,VS09_ROTH4,VS09_ROTBT,VS09_ROTHU,# & VS09_ROTHW,VS09_ROTB4,VS09_ROTHP,VS09_ROTBU,# & VS09_ROTBN)# & PIR1: (VGXR49,VGXRDB,VGXRH4,VGXRB6,VGXRCB,VGXRWA,VGXRMD,VGXR7H,# & VGXRP)# & PIR3: (S25546)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,IIYRFLLI*# SEQUENCE: IIYRFLLI*# ...# >MUS119F2# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rotavirus VP6 (376-384)# DB REFERENCE: SWISS: (VS06_ROTBR,VS06_ROTBU,VS06_ROTHS,VS06_ROTPY,VS06_ROTS1,# & VS06_ROTEH,VS06_ROTE1,VS06_ROTPG,VS06_ROTHW,# & VS06_ROTH1)# & PIR1: (VPXR15,VPXR14,VPXR76,VPXR6S,VPXRS2,VPXR11,VPXRGT,VPXRBR,# & VPXR6H)# & PIR2: (JQ2020,S31412,S11209)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,VGPVFPPGM*# SEQUENCE: VGPVFPPGM*# ...# >MUS119F3# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rotavirus VP3 (585-593)# DB REFERENCE: SWISS: (VP3_ROTS1)# & PIR1: (P3XRSR)# & PIR2: (S06085)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,YSGYIFRDL*# SEQUENCE: YSGYIFRDL*# ...# >MUS119F4# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: HPLC/cytotoxicity as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MUT 2 tumor antigen# DB REFERENCE: PIR2: (S43972)# REFERENCES: rammensee95a,mandelboim94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,FEQNTAQA*# SEQUENCE: FEQNTAQA*# ...# >MUS119F5# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: HPLC/cytotoxicity as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MUT I tumor antigen# DB REFERENCE: PIR2: (S43971)# REFERENCES: rammensee95a,mandelboim94a,malarkannan95b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,FEQNTAQP*# SEQUENCE: FEQNTAQP*# ...# >MUS119F6# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Yersinia YOP 51 (249-257)# DB REFERENCE: SWISS: (YOPH_YERPS,YOPH_YEREN)# & PIR2: (A53889,S01054)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,QVGNTRTI*# SEQUENCE: QVGNTRTI*# ...# >MUS119F7# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SV 40 T (492-501)# DB REFERENCE: SWISS: (TALA_SV40,TALA_POVHA)# & PIR1: (TVVPT4,TVVPTH)# & PIR3: (PH1377,PH1378)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesu,NNLDNLRDYL*# SEQUENCE: NNLDNLRDYL*# ...# >MUS119F8# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP (375-383)# DB REFERENCE: SWISS: (CSP_PLAFW,CSP_PLAFA,CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (A54529,A54533)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,YENDIEKKI*# SEQUENCE: YENDIEKKI*# ...# >MUS119F9# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP (371-379)# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (C60657,A54533)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,DELDYENDI*# SEQUENCE: DELDYENDI*# ...# >MUS119FA# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-I RT (206-214)# DB REFERENCE: SWISS: (POL_HV1JR,POL_HV1ND,POL_HV1B5,POL_HV1H2,POL_HV1Z2,# & POL_HV1A2,POL_HV1RH,POL_HV1Y2,POL_HV1N5,POL_HV1OY,# & POL_HV1BR,POL_HV1B1,POL_HV1PV,POL_HV1MN)# & PIR1: (GNVWVL,GNLJND,B44001,GNVWA2,GNVWLV,GNVWH3)# & PIR2: (S32140,S32065,S32119,S32126,S32127,S32139,S32120,S32064,# & S32136,S32134,S32055,S32095,B47330,S32058,S32053,S32117,# & F47330,S32135,S32057,S54378,S32052,S32151,S32122,B47175,# & S32063,S32054,S32059,S32062,S32061,S32118,S32056,S32060,# & A47175)# & PIR3: (S33980)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,TEMEKEGKI*# SEQUENCE: TEMEKEGKI*# ...# >MUS119FB# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rabies NS (197-205)# DB REFERENCE: SWISS: (RRPP_RABVE,RRPP_RABVA,RRPP_RABVS,RRPP_RABVC,# & RRPP_RABVP)# & PIR1: (MNVNAV,MNVNSB,MNVNRV)# & PIR2: (B58460,S47164)# & PIR3: (S13706,S13707)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,VEAEIAHQI*# SEQUENCE: VEAEIAHQI*# ...# >MUS119FC# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KQNPEAHQL*# SEQUENCE: KQNPEAHQL*# ...# >MUS119FD# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,ALAELPHEL*# SEQUENCE: ALAELPHEL*# ...# >MUS119FE# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KQNPTVHHL*# SEQUENCE: KQNPTVHHL*# ...# >MUS119FF# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,AGLLGMRSGL*# SEQUENCE: AGLLGMRSGL*# ...# >MUS11A00# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KLIKVYHSL*# SEQUENCE: KLIKVYHSL*# ...# >MUS11A01# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,VQXTMHPI*# SEQUENCE: VQXTMHPI*# ...# >MUS11A02# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,RSNGQVHML*# SEQUENCE: RSNGQVHML*# ...# >MUS11A03# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cofilin (127-135)# DB REFERENCE: SWISS: (COF1_PIG,COF1_MOUSE,COF1_HUMAN,COF1_RAT,COF1_PIG,# & COF1_HUMAN)# & PIR1: (S12584,S12632,A29240)# & PIR2: (S49101)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KLTGIKHEL*# SEQUENCE: KLTGIKHEL*# ...# >MUS11A04# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,AMLATYHKL*# SEQUENCE: AMLATYHKL*# ...# >MUS11A05# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,GQLXVXHKL*# SEQUENCE: GQLXVXHKL*# ...# >MUS11A06# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein L19 (137-145)# DB REFERENCE: SWISS: (RL19_HUMAN,RL19_MOUSE)# & PIR1: (R5RT19)# & PIR2: (A36554,A48992)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,ILMEHIHKL*# SEQUENCE: ILMEHIHKL*# ...# >MUS11A07# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,AQNPVLYQI*# SEQUENCE: AQNPVLYQI*# ...# >MUS11A08# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,SLIKTVREM*# SEQUENCE: SLIKTVREM*# ...# >MUS11A09# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KMLPVEHNL*# SEQUENCE: KMLPVEHNL*# ...# >MUS11A0A# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KQLIVTYHL*# SEQUENCE: KQLIVTYHL*# ...# >MUS11A0B# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,SVLDDLALL*# SEQUENCE: SVLDDLALL*# ...# >MUS11A0C# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,YESPLMXFL*# SEQUENCE: YESPLMXFL*# ...# >MUS11A0D# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,DLLGTLHNL*# SEQUENCE: DLLGTLHNL*# ...# >MUS11A0E# MHC MOLECULE: H-2Dk, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LEC-A# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2Dk,actyesu,bindyesu,RRKGKYTGL*# SEQUENCE: RRKGKYTGL*# ...# >MUS11A0F# MHC MOLECULE: H-2M3, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ND1alpha (1-17)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2M3,actyesu,bindyesu,FFINILTLLVP*# SEQUENCE: FFINILTLLVP*# ...# >MUS11A10# MHC MOLECULE: H-2M3, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ND1alpha (1-17)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: H-2M3,actyesu,bindyesu,FFINALTLLVP*# SEQUENCE: FFINALTLLVP*# ...# >HUM11A11# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,GTDEXRNXY*# SEQUENCE: GTDEXRNXY*# ...# >HUM11A12# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,VSDPYNXKY*# SEQUENCE: VSDPYNXKY*# ...# >HUM11A13# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,VADKVHXMY*# SEQUENCE: VADKVHXMY*# ...# >HUM11A14# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,ETXXPDWSY*# SEQUENCE: ETXXPDWSY*# ...# >HUM11A15# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,FTDVNSXXRY*# SEQUENCE: FTDVNSXXRY*# ...# >HUM11A16# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,TEDMGHLKY*# SEQUENCE: TEDMGHLKY*# ...# >HUM11A17# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,ETDXXXDRSEY*# SEQUENCE: ETDXXXDRSEY*# ...# >HUM11A18# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SXPSGGXGV*# SEQUENCE: SXPSGGXGV*# ...# >HUM11A19# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GXVPFXVSV*# SEQUENCE: GXVPFXVSV*# ...# >HUM11A1A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SXXVRAXEV*# SEQUENCE: SXXVRAXEV*# ...# >HUM11A1B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KXNEPVXXX*# SEQUENCE: KXNEPVXXX*# ...# >HUM11A1C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IP-30 signal sequence (26-36)# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (S21727,A43708)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLLDVPTAAVQ*# SEQUENCE: LLLDVPTAAVQ*# ...# >HUM11A1D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: SSR alpha signal sequence (12-25)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,VLFRGGPRGLLAVA*# SEQUENCE: VLFRGGPRGLLAVA*# ...# >HUM11A1E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-E signal sequence (1-9)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MVDGTTLLL*# SEQUENCE: MVDGTTLLL*# ...# >HUM11A1F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLLGLLVEV*# SEQUENCE: SLLGLLVEV*# ...# >HUM11A20# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALLPPINIL*# SEQUENCE: ALLPPINIL*# ...# >HUM11A21# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,TLIKIQHTL*# SEQUENCE: TLIKIQHTL*# ...# >HUM11A22# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALIVGXNDD*# SEQUENCE: ALIVGXNDD*# ...# >HUM11A23# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Carboxypeptidase M (91-99)# DB REFERENCE: SWISS: (CBPM_HUMAN)# & PIR2: (A32619)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,HLIDYLVTS*# SEQUENCE: HLIDYLVTS*# ...# >HUM11A24# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ILAPPVVKLLV*# SEQUENCE: ILAPPVVKLLV*# ...# >HUM11A25# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALFPQLVIL*# SEQUENCE: ALFPQLVIL*# ...# >HUM11A26# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? mouse protein# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALWGFFPVX*# SEQUENCE: ALWGFFPVX*# ...# >HUM11A27# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competition/CTL as./Stabilization/Half-time/Refolding/Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Tyrosinase (369-377)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: rammensee95a,kawakami95b,van_der_burg95a,van_der_burg96a,# & wolfel94a,diehl96a,kawakami96a,skipper96b,van-elsas96a,tan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,YMNGTMSQV*# SEQUENCE: YMNGTMSQV*# ...# >HUM11A28# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference/Refolding with competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Influenza B NP (85-94)# DB REFERENCE: SWISS: (VNUC_INBSI,VNUC_INBAA,VNUC_INBLE,VNUC_INBAC,# & VNUC_INBAD)# & PIR1: (VHIVBC,VHIVBA,VHIVBW)# REFERENCES: rammensee95a,van_der_burg96a,tan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,KLGEFYNQMM*# SEQUENCE: KLGEFYNQMM*# ...# >HUM11A29# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference/Refolding with competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HCV-1 (1406-1415)# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCV1)# & PIR1: (GNWVC3,GNWVCH)# REFERENCES: rammensee95a,van_der_burg96a,tan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,KLVALGINAV*# SEQUENCE: KLVALGINAV*# ...# >HUM11A2A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tyrosinase (1-9)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,MLLALLYCL*# SEQUENCE: MLLALLYCL*# ...# >HUM11A2B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays/Reference/Half-time/Competition/Stabilization/Recognition# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Melan A/Mart 1# DB REFERENCE: PIR2: (A55253)# REFERENCES: rammensee95a,kawakami95b,rivoltini95a,rivoltini95b# & fleischauer96a,kawakami96a,engelhard96a,romero96a,rivoltini96a,# & van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM11A2C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: pmel 17/gp100# ANCHOR POSITIONS:# REFERENCES: rammensee95a,anichini96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ILDGTATLRL*# SEQUENCE: ILDGTATLRL*# ...# >HUM11A2D# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-I env gp41 (768-778)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1J3,ENV_HV1PV,ENV_HV1BR,ENV_HV1KB,# & ENV_HV1H3,ENV_HV1W1,ENV_HV1SC,ENV_HV1B1,ENV_HV1BN,# & ENV_HV1B8,ENV_HV1H2,ENV_HV1Y2)# & PIR1: (VCLJVL,VCLJSC,VCLJKB,VCLJBR,VCLJLV,VCLJH3,H44001,# & VCLJ3W)# & PIR2: (S21994,S70422,S21998,S21996,S70425,S70421)# & PIR3: (S13288,S33985)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,RLRDLLLIVTR*# SEQUENCE: RLRDLLLIVTR*# ...# >HUM11A2E# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,AVMKPEAEKRK*# SEQUENCE: AVMKPEAEKRK*# ...# >HUM11A2F# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSB 66 EST (18-29)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,AVILPPLSPYFK*# SEQUENCE: AVILPPLSPYFK*# ...# >HUM11A30# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thymosin beta-10 (11-20)# DB REFERENCE: SWISS: (TYB0_HUMAN,TYB0_HUMAN)# & PIR2: (A27266,A27704)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,ASFDKAKLKK*# SEQUENCE: ASFDKAKLKK*# ...# >HUM11A31# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle metalloproteinase (19-27)# DB REFERENCE: PIR2: (S66129)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,GQYGNPLNK*# SEQUENCE: GQYGNPLNK*# ...# >HUM11A32# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein Sl9 (93-101)# DB REFERENCE: SWISS: (RS19_HUMAN,RS19_PIG)# & PIR2: (I52692)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,GVMPSHFSR*# SEQUENCE: GVMPSHFSR*# ...# >HUM11A33# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor 2 (265-275)# DB REFERENCE: SWISS: (EF2_RAT,EF2_MESAU,EF2_CRIGR,EF2_RAT,EF2_HUMAN,EF2_MESAU,# & EF2_CRIGR)# & PIR1: (EFRT2,EFHU2)# & PIR2: (A25440,A28660)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,YFDPANGKFSK*# SEQUENCE: YFDPANGKFSK*# ...# >HUM11A34# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Prohibitin (rat) 229-240)# DB REFERENCE: SWISS: (PHB_RAT,PHB_HUMAN)# & PIR2: (I52690,A39682)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,ATAGDGLIELRK*# SEQUENCE: ATAGDGLIELRK*# ...# >HUM11A35# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,STYYGSFVTR*# SEQUENCE: STYYGSFVTR*# ...# >HUM11A36# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S6 (107-115)# DB REFERENCE: SWISS: (RS6_CHICK,RS6_CHICK,RS6_TOBAC,RS6_HUMAN,RS6_TOBAC)# & PIR1: (R3RTS6,R3MS6,R3HU6)# & PIR2: (JC4145,S25550)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,SVLNLVIVK*# SEQUENCE: SVLNLVIVK*# ...# >HUM11A37# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein L7A (25-33)# DB REFERENCE: SWISS: (RL7A_MOUSE,RL7A_HUMAN,RL7A_CHICK)# & PIR1: (R5HU7A,R5RT7A,S18159)# & PIR2: (A30241)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,KVVNPLFEK*# SEQUENCE: KVVNPLFEK*# ...# >HUM11A38# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S3 (54-62)# DB REFERENCE: SWISS: (RS3A_XENLA,RS3_HUMAN,RS3B_XENLA,RS3_RAT,RS3_AMBME)# & PIR1: (R3RT3,R3XL3A,R3HUS3)# & PIR2: (S41170,I51635)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,RTQNVLGEK*# SEQUENCE: RTQNVLGEK*# ...# >HUM11A39# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,GTMTTSXYK*# SEQUENCE: GTMTTSXYK*# ...# >HUM11A3A# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thymosin beta-10 (11-19)# DB REFERENCE: SWISS: (TYB0_HUMAN,TYB0_HUMAN)# & PIR2: (A27704,A27266)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,ASFDKAKLK*# SEQUENCE: ASFDKAKLK*# ...# >HUM11A3B# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,AAMXDTVVFK*# SEQUENCE: AAMXDTVVFK*# ...# >HUM11A3C# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,RVEQAVESMVK*# SEQUENCE: RVEQAVESMVK*# ...# >HUM11A3D# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,STYYGSFVTR*# SEQUENCE: STYYGSFVTR*# ...# >HUM11A3E# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesu,VYXKHPVSX*# SEQUENCE: VYXKHPVSX*# ...# >HUM11A3F# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histon H2 a (23-32)# DB REFERENCE: SWISS: (H2A1_RAT,H2A4_PSAMI,H2AX_HUMAN,H2A5_HUMAN,H2A4_CHICK,# & H2A_ONCMY,H2A3_CHICK,H2A2_PSAMI,H2A2_XENLA,H2AX_MOUSE,# & H2A_BUFBG,H2AL_STRPU,H2A_PARLI,H2A3_STRPU,H2A1_XENLA,# & H2A1_MOUSE,H2A2_MOUSE,H2A3_LYTPI,H2A4_MOUSE,H2AX_HUMAN,# & H2A3_MOUSE,H2AT_RAT,H2A2_HUMAN,H2A1_HUMAN,H2A_ASTRU,# & H2A_CAIMO,H2A3_PSAMI,H2A1_PSAMI,H2A_STRPU,H2A3_CHICK)# & PIR1: (HSCH2A,HSURA1,HSUR9M,HSURA2,HSURH2,HSXLA1,HSRT2A,HSUR9P,# & HSHUA1,HSBO2A,HSHUA5,HSURH9,HSUR7M,HSTR21,HSSF2)# & PIR2: (A36322,I49394,I48091,S19241,I37466,A25077,I50457,I50651,# & S07631,JH0303,I50657,S26188,S06742,S06754,I51445,G40335,# & I48406,I79341,S04565,S45110,JC1523)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,LQFPVGRVHR*# SEQUENCE: LQFPVGRVHR*# ...# >HUM11A40# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S29 (rat) (3-11)# DB REFERENCE: SWISS: (RS29_HUMAN,RS29_HUMAN)# & PIR2: (S55919,S30298)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,QQLYWSHPR*# SEQUENCE: QQLYWSHPR*# ...# >HUM11A41# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CCAAT-binding transcription factor (240-248)# DB REFERENCE: SWISS: (CBFX_MOUSE,CBFX_RAT,YB1_MOUSE,YB1_CHICK,CBFX_HUMAN,# & YB1_HUMAN,YB1_MOUSE,CBFX_MOUSE)# & PIR2: (PS0015,A49594,A40498,A48136,I39382,I52910,A55971,JQ2292,# & A23677,I58195)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,RGYRPRFRR*# SEQUENCE: RGYRPRFRR*# ...# >HUM11A42# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: [GlcNac]-P-transferase (371-379)# DB REFERENCE: SWISS: (GPT_MOUSE,GPT_MOUSE)# & PIR2: (S24326)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,KVFGPIHER*# SEQUENCE: KVFGPIHER*# ...# >HUM11A43# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,KIMKWNYER*# SEQUENCE: KIMKWNYER*# ...# >HUM11A44# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lamin B2# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesu,RYMDAWNTYSR*# SEQUENCE: RYMDAWNTYSR*# ...# >HUM11A45# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: reference/competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Hepatitis B cAg (141-151)# DB REFERENCE: SWISS: (CORA_HPBVF,CORA_HPBVL,CORA_HPBVO,CORA_HPBVW,CORA_HPBVZ,# & CORA_HPBV4,CORA_HPBVT,CORA_HPBVY,CORA_HPBVA,CORA_HPBV9,# & CORA_HPBVJ,CORA_HPBV2)# & PIR1: (NKVLKS,NKVLA3,NKVLA6,NKVLH3,NKVLAH,NKVLA1,NKVLA4,NKVLJ2,# & NKVLA2,NKVLCP,NKVLJ1,NKVLBH)# & PIR2: (S20746,S53260,S32204,S35530,S53227,S53223,S53163,S53159,# & S53169,S53279,S53207,S53257,S53281,S04570,S53184,S33686,# & S53181,S53155,S53175,S53198,S53216,S53200,S53178,S53152,# & S53172,S25651,S53140,S53242,S53236,S53251,S53229,S53232,# & S53255,S53240,S01405,S20750,S53253,JQ2227,S53204,S53129,# & S53157,S53202,S53166,S53211,S53238,S53194,S53272,S53146,# & S53225,S47409,S53221,S47405,S53270)# REFERENCES: rammensee95a,bertoni97a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesm,STLPETTVVRR*# SEQUENCE: STLPETTVVRR*# ...# >HUM11A46# MHC MOLECULE: HLA-A33(A*3302), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA class I alpha-chain (161-169)# DB REFERENCE: SWISS: (1A43_HUMAN,1A25_HUMAN,1A29_HUMAN,1A03_GORGO,1A34_HUMAN,# & 1A32_HUMAN,1A26_HUMAN,1A31_HUMAN,1A66_HUMAN,1A23_HUMAN,# & 1A30_HUMAN,1A31_HUMAN,1A04_PANTR,1A74_HUMAN,1A01_PONPY,# & 1A26_HUMAN,1A33_HUMAN,1OKO_GORGO)# & PIR1: (HLHU32)# & PIR2: (I37477,I37480,JL0135,I54307,I36966,I38436,S18198,I56039,# & S51100,I84432,A37028,S16769,I72170,JH0536,I72171,S51102,# & I36965,I37482,A35997,I37479,S01171,S18197,JH0538,I37476,# & A45847,I84487,I38519,I37483,I38610)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,DMAAQITQR*# SEQUENCE: DMAAQITQR*# ...# >HUM11A47# MHC MOLECULE: HLA-A33(A*3302), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Actin (364-372)# DB REFERENCE: SWISS: (ACT5_XENLA,ACT1_HELER,ACT_TOXGO,ACT3_SOLTU,ACT1_DROME,# & ACT1_FUGRU,ACT1_ECHGR,ACTA_LIMPO,ACTC_ARATH,ACT_THELA,# & ACTM_STYPL,ACTD_STRPU,ACT2_ABSGL,ACT_TOXGO,ACT6_DIPDE,# & ACT1_PODCA,ACT1_HELER,ACTE_STRPU,ACT5_CHICK,ACT_HYDAT,# & ACT2_FUGRU,ACT2_DROME,ACT1_ORYSA,ACT_COSCS,ACTB_RABIT,# & ACT2_ARATH,ACT2_LYTPI,ACT3_BOMMO,ACT_CHLRE,ACT_PUCGR,# & ACT_NEUCR,ACT7_ARATH,ACT1_ONCVO,ACT3_ARATH,ACT_ACHBI,# & ACT8_XENLA,ACTB_CRIGR,ACT6_SOLTU,ACT1_PHYIN,ACTB_STRPU,# & ACT_FUCVE,ACTM_LYTPI,ACT_CRYPV,ACT4_DICDI,ACTC_HALRO,# & ACT1_CAEEL,ACT4_ARTSX,ACT2_LYTPI,ACTC_ARATH,ACT1_DAUCA,# & ACT1_LYTPI,ACTG_HUMAN,ACTF_STRPU,ACT3_ECHGR,ACT3_PEA,# & ACTB_XENBO,ACT4_CAEEL,ACT_CHLRE,ACT_CRYNE,ACT7_SOLTU,# & ACT2_TETPY,ACTG_EMENI,ACTB_HUMAN,ACT_AJECA,ACTM_HELER,# & ACT3_ORYSA,ACTM_HELTB,ACT2_DICDI,ACT1_DICDI,ACTC_STRPU,# & ACT1_ARATH,ACTB_ARATH,ACT6_DIPDE,ACTY_LIMPO,ACT3_LYTPI,# & ACT1_PLAFA,ACT_PINCO,ACTM_PISOC,ACT3_LIMPO,ACT3_PODCA,# & ACTY_LIMPO,ACT2_DAUCA,ACT2_PHYIN,ACT_VOLCA,ACT7_ARATH,# & ACT4_ARATH,ACT1_SOLTU,ACT3_LIMPO,ACT1_TETTH,ACTA_PHYPO,# & ACTM_HELTB,ACTC_STYPL,ACTB_CYPCA,ACT_FUCDI,ACTA_STRPU,# & ACT2_CAEEL,ACTM_APLCA,ACT1_ACACA,ACT8_DICDI,ACTA_LIMPO,# & ACTC_PISOC,ACT1_STRFN,ACTB_ARATH,ACT3_SOYBN,ACTM_HELER,# & ACT3_FUGRU,ACT3_ARTSX,ACT_FUCDI,ACT4_ARATH,ACT_PHYME,# & ACT4_CAEEL,ACT1_SORVU,ACT1_LYTPI,ACT2_ONCVO,ACT2_SOLTU,# & ACT_TOBAC,ACT3_DICDI,ACT5_SOLTU,ACT8_DICDI,ACT_DICVI)# & PIR1: (ATHUG,ATMUM1,ATSY3,ATFF8,A43552,S11222,ATHUB,ATRBB,# & ATBOB,ATURS,ATRTC,ATJN,ATMSB,ATBOG,ATDO,ATRZ1,ATMSG,# & A48324,ATCHB,ATRZ3,ATFY,ATAX)# & PIR2: (S16709,S26039,S24408,S39777,JS0190,S07003,S38782,S33386,# & JC5227,JE0415,C23412,S49481,A61043,S20094,S16710,D23412,# & S20092,S14120,S03126,JS0189,S14851,S68109,S07288,A37431,# & JQ0154,A29407,S20093,S58316,A25135,S42103,S24409,S31933,# & S11453,JN0832,B33761,S09578,A55001,S43509,S07002,JC4612,# & S07284,S11452,S68112,S68110,A54496,S68108,A03000,B23412,# & S20096,JN0833,S49480,A45634,S01077,S27135,S47090,S12730,# & JT0385,S68107,S33387,S49479,A28258,A25084,S20098,A48449,# & JC5228,S12628,JE0414)# & PIR3: (S71126,S71124,S49007,S71125)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,ESGPSIVHR*# SEQUENCE: ESGPSIVHR*# ...# >HUM11A48# MHC MOLECULE: HLA-A33(A*3302), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,TYYGSFVTR*# SEQUENCE: TYYGSFVTR*# ...# >HUM11A49# MHC MOLECULE: HLA-A33(A*3302), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSB15F102 (65-74)# DB REFERENCE: SWISS: (SUI1_HUMAN)# & PIR2: (JC2042)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,DYIHIRIQQR*# SEQUENCE: DYIHIRIQQR*# ...# >HUM11A4A# MHC MOLECULE: HLA-A33(A*3302), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,EIMKWNRER*# SEQUENCE: EIMKWNRER*# ...# >HUM11A4B# MHC MOLECULE: HLA-A33(A*3302), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histon 3.1/3.3 (118-129)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesu,TAMPKDIQLARR*# SEQUENCE: TAMPKDIQLARR*# ...# >HUM11A4C# MHC MOLECULE: HLA-A33(A*3302), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 gag (267-275)# DB REFERENCE: SWISS: (GAG_HV1EL)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesu,IVGLNKIVR*# SEQUENCE: IVGLNKIVR*# ...# >HUM11A4D# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,AVAAVAARR*# SEQUENCE: AVAAVAARR*# ...# >HUM11A4E# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,EVAPPEYHR*# SEQUENCE: EVAPPEYHR*# ...# >HUM11A4F# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,EVAPPEYHRK*# SEQUENCE: EVAPPEYHRK*# ...# >HUM11A50# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homologous ribosomal 60S# DB REFERENCE: SWISS: (RL27_HUMAN)# & PIR1: (R5RT27)# & PIR2: (S22288,S43505)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,DVFRDPALK*# SEQUENCE: DVFRDPALK*# ...# >HUM11A51# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (RL15_HUMAN,RL15_CHICK,RL15_RAT)# & PIR2: (JC2369,I50725)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,EVILIDPFHK*# SEQUENCE: EVILIDPFHK*# ...# >HUM11A52# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSP 70B/HSC70 (66-76)# DB REFERENCE: SWISS: (HS71_CANAL,HS73_RAT,HS71_DROME,HS71_RAT,GR78_RAT,# & HS71_PIG,HS73_YEAST,HS71_DROME,HS71_RAT,HS72_LYCES,# & HS70_ACHKL,HS70_CLAHE,HS71_YEAST,HS7C_RAT,HS77_HUMAN,# & HS71_BOVIN,HS70_SOYBN,HS70_MAIZE,HS75_YEAST,HS75_YEAST,# & HS7C_PETHY,HS75_SCHPO,HS7T_MOUSE,HS74_ANOAL,HS70_PYRSA,# & HS7C_HUMAN,HS71_MOUSE,HS72_YEAST,HS71_PIG,HS7E_SPIOL,# & HS7C_BOVIN,HS72_USTMA,HS70_TRYCR,HS70_PLAFA,HS76_PIG,# & HS76_YEAST,GR78_MESAU,HS70_LEIMA,GR78_MESAU,HS7C_DICDI,# & HS71_HUMAN,HS71_HANPO,HS75_KLUMA,HS7C_DROME,HS76_HUMAN,# & HS7T_MOUSE,HS72_ANOAL,HS71_PICAN,GR78_HUMAN,HS70_DAUCA,# & HS7C_DICDI,HS70_PLEWA,HS70_PLACB,HS70_CLAHE,HS75_CANAL,# & HS72_DROME,HS71_PUCGR,GR78_MOUSE,HS70_SCHMA,HS74_YEAST,# & HS70_LEIAM,HS70_LEIDO,HS70_CHLRE,HS74_CANAL,HS74_TRYBB,# & HS72_BOVIN,HS71_ARATH,HS76_YEAST,HS7H_HUMAN,HS71_MOUSE,# & GR78_HUMAN,HS70_XENLA,GR78_RAT,HS7C_CRIGR,HS70_BLAEM,# & GR78_MOUSE,HS7C_RAT,HS71_LYCES,HS70_ONCTS,HS72_DROME,# & HS70_HYDMA,HS71_ANOAL,HS72_PICAN,HS72_PICAN,HS7C_BOVIN,# & HS70_ONCMY,HS7A_CAEEL,HS72_ARATH)# & PIR1: (HHKW7A,HHBYA1,HHXL70,HHRTGB,HHFF72)# & PIR2: (JC4853,A25089,S06158,A48439,A27414,S07197,I54542,A49242,# & A53163,JN0666,S27004,S36753,I56574,I49761,S31766,A25398,# & S11448,S11456,S14992,S50721,A42582,S31716,S03250,S52727,# & I51129,S53498,S37394,JH0095,JC4786,A44979,I50242,A35922,# & A29160,S44168,S05375,S06443,A25773,S41372,S35718,B45871,# & JQ1515,A34041,S53126,A48469,JA0170,S25585,S18349,S20149,# & A27077,S42488,JC4610,A37048,B36590,S51712,S37165,S30562,# & S41415,JU0164,A45871,A45935,S20139,S21365,S41403,S53500,# & S46302,S09036,S14950,A29821,S14949)# & PIR3: (JC2215,S49303,S21175)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,TVFDAKRLIGR*# SEQUENCE: TVFDAKRLIGR*# ...# >HUM11A53# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,XVLKXIAKR*# SEQUENCE: XVLKXIAKR*# ...# >HUM11A54# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,PVKQVVYHR*# SEQUENCE: PVKQVVYHR*# ...# >HUM11A55# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta-Actin (364-373)# DB REFERENCE: SWISS: (ACTM_HELTB,ACT2_DICDI,ACT1_DICDI,ACTB_HUMAN,ACTG_EMENI,# & ACTB_XENBO,ACT4_CAEEL,ACTC_STRPU,ACT3_ORYSA,ACT1_ARATH,# & ACTB_ARATH,ACTY_LIMPO,ACTB_STRPU,ACT6_SOLTU,ACT1_PHYIN,# & ACTB_CRIGR,ACT8_XENLA,ACT3_ARATH,ACT_ACHBI,ACT1_CAEEL,# & ACTG_HUMAN,ACTF_STRPU,ACT3_ECHGR,ACT_CRYPV,ACT_CRYNE,# & ACT7_SOLTU,ACT2_TETPY,ACTM_HELTB,ACTA_PHYPO,ACT1_PLAFA,# & ACT_PINCO,ACTC_STYPL,ACT_FUCDI,ACT7_ARATH,ACT3_PODCA,# & ACT2_DAUCA,ACTY_LIMPO,ACT_NEUCR,ACTB_RABIT,ACT1_HELER,# & ACT_COSCS,ACT_CHLRE,ACTC_PISOC,ACT1_ECHGR,ACTA_LIMPO,# & ACT3_SOLTU,ACT1_DROME,ACT1_PODCA,ACTD_STRPU,ACTM_STYPL,# & ACT6_DIPDE,ACT_TOXGO,ACT_THELA,ACT_TOXGO,ACT1_HELER,# & ACT5_XENLA,ACT5_CHICK,ACT8_DICDI,ACT2_SOLTU,ACT4_DICDI,# & ACT4_ARTSX,ACT1_LYTPI,ACT_DICVI,ACTB_ARATH,ACT_PHYME,# & ACT_FUCDI,ACT4_ARATH,ACTM_APLCA,ACT3_FUGRU,ACT3_SOYBN,# & ACT3_ARTSX,ACT8_DICDI,ACTA_LIMPO,ACT_CHLRE,ACTM_LYTPI,# & ACTM_HELER,ACT_AJECA,ACTM_PISOC,ACTA_STRPU,ACTB_CYPCA,# & ACT1_TETTH,ACT2_PHYIN,ACT1_SOLTU,ACT3_LIMPO,ACT_VOLCA,# & ACT1_ONCVO,ACT3_BOMMO,ACT_PUCGR,ACT2_LYTPI,ACT2_ARATH,# & ACT2_ABSGL,ACTE_STRPU,ACT1_FUGRU,ACT1_ORYSA,ACT_HYDAT,# & ACT2_DROME,ACT4_CAEEL,ACTM_HELER,ACT7_ARATH,ACTC_HALRO,# & ACT1_DAUCA,ACT1_SORVU,ACTC_ARATH,ACT2_LYTPI,ACT2_ONCVO,# & ACT1_LYTPI,ACT5_SOLTU,ACT3_DICDI,ACT_FUCVE,ACT_TOBAC,# & ACT1_STRFN,ACT1_ACACA,ACT2_CAEEL,ACT2_FUGRU,ACTC_ARATH,# & ACT6_DIPDE,ACT3_LYTPI,ACT3_LIMPO,ACT3_PEA,ACT4_ARATH)# & PIR1: (S11222,ATHUB,ATBOG,ATMUM1,ATFF8,ATHUG,ATDO,ATURS,ATAX,# & ATRZ3,ATRBB,ATMSB,ATRZ1,ATJN,ATRTC,ATMSG,A48324,ATSY3,# & ATFY,ATCHB,A43552,ATBOB)# & PIR2: (S20094,S03126,S14851,S49481,JE0415,S33387,A54496,S07284,# & S01077,S20093,S68109,S07288,A29407,S26039,S11453,S09578,# & A25135,S27135,S20096,JS0189,A61043,S16709,S24408,JN0832,# & B33761,S07002,S43509,A55001,JC5227,C23412,S33386,S07003,# & S38782,JS0190,S39777,A48449,JC5228,S12628,JE0414,S68107,# & JT0385,S47090,S12730,A45634,S49479,A25084,A28258,S20092,# & S14120,S68108,A03000,B23412,JN0833,S49480,S68110,S11452,# & S68112,JC4612,S58316,JQ0154,S42103,S31933,S24409,S16710,# & D23412,A37431,S20098)# & PIR3: (S71126,S71124,S71125,S49007)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,ESGPSIVHRK*# SEQUENCE: ESGPSIVHRK*# ...# >HUM11A56# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,TTXTTTNAR*# SEQUENCE: TTXTTTNAR*# ...# >HUM11A57# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesu,DTTPTXXR*# SEQUENCE: DTTPTXXR*# ...# >HUM11A58# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza NP (91-99)# DB REFERENCE: SWISS: (VNUC_IAMEB,VNUC_IAGD7,VNUC_IAME4,VNUC_IAFOM,VNUC_IAMEE,# & VNUC_IABRA,VNUC_IAME5,VNUC_IAS11,VNUC_IACAL,VNUC_IAEN5,# & VNUC_IATX7,VNUC_IAUSS,VNUC_IAANN,VNUC_IAKIE,VNUC_IAZH1,# & VNUC_IAGU1,VNUC_IAHO2,VNUC_IAME3,VNUC_IANT6,VNUC_IAB37,# & VNUC_IAME6,VNUC_IAMEG,VNUC_IAVI6,VNUC_IAB39,VNUC_IAOHI,# & VNUC_IAANN,VNUC_IASIN,VNUC_IAMEF,VNUC_IAHIC,VNUC_IAUDO,# & VNUC_IAHO1,VNUC_IAMEC,VNUC_IANEJ,VNUC_IAFOW,VNUC_IAPAR,# & VNUC_IAMEA,VNUC_IAS06)# & PIR1: (VHIVX3,VHIVX4,VHIVX2,VHIV8H,VHIVX6,VHIV68,VHIVAK,VHIV61,# & VHIVX5,VHIVN5,VHIVA3,VHIVN7,VHIVA7)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,KTGGPIYKR*# SEQUENCE: KTGGPIYKR*# ...# >HUM11A59# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: reference/competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Hepatitis B cAg (141-151)# DB REFERENCE: SWISS: (CORA_HPBVZ,CORA_HPBVT,CORA_HPBVL,CORA_HPBVA,CORA_HPBV2,# & CORA_HPBVJ,CORA_HPBVW,CORA_HPBVY,CORA_HPBVO,CORA_HPBV4,# & CORA_HPBV9,CORA_HPBVF)# & PIR1: (NKVLJ1,NKVLA3,NKVLKS,NKVLH3,NKVLAH,NKVLA1,NKVLA4,NKVLCP,# & NKVLA6,NKVLA2,NKVLBH,NKVLJ2)# & PIR2: (S01405,S53178,S53211,S53169,S53152,S53242,S53229,S53255,# & S53240,S53198,S53216,S53238,S53166,S53202,S53253,JQ2227,# & S53204,S47409,S47405,S53221,S53272,S04570,S53281,S53257,# & S53207,S53159,S53181,S53175,S33686,S53172,S25651,S20746,# & S32204,S53163,S53227,S53184,S53279,S35530,S53232,S53270,# & S53140,S53260,S53223,S20750,S53157,S53129,S53251,S53236,# & S53146,S53194,S53225,S53155,S53200)# REFERENCES: rammensee95a,bertoni97a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesh,STLPETTVVRR*# SEQUENCE: STLPETTVVRR*# ...# >HUM11A5A# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference/Reconstitution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRAXXXXX*# SEQUENCE: APRAXXXXX*# ...# >HUM11A5B# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference/Reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,APRXPXTGX*# SEQUENCE: APRXPXTGX*# ...# >HUM11A5C# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference/Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,APRASRPSX*# SEQUENCE: APRASRPSX*# ...# >HUM11A5D# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference/Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,MPRGVVVTX*# SEQUENCE: MPRGVVVTX*# ...# >HUM11A5E# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference/Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,APAPTVAVX*# SEQUENCE: APAPTVAVX*# ...# >HUM11A5F# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference/Reconstitution# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,RPSGPGPEX*# SEQUENCE: RPSGPGPEX*# ...# >HUM11A60# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference/Reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,RVMAPRAXX*# SEQUENCE: RVMAPRAXX*# ...# >HUM11A61# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRAFXPXPV*# SEQUENCE: APRAFXPXPV*# ...# >HUM11A62# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRSNGMVX*# SEQUENCE: APRSNGMVX*# ...# >HUM11A63# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRQPGXMA*# SEQUENCE: APRQPGXMA*# ...# >HUM11A64# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal S26 protein (107-115)# DB REFERENCE: SWISS: (RS26_HUMAN)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APAPPPKPM*# SEQUENCE: APAPPPKPM*# ...# >HUM11A65# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: reference/Reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,APYGGPXAX*# SEQUENCE: APYGGPXAX*# ...# >HUM11A66# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rat ribosomal prot. L18 (94-102)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,VPKLKVXAL*# SEQUENCE: VPKLKVXAL*# ...# >HUM11A67# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,FAKPRVGG*# SEQUENCE: FAKPRVGG*# ...# >HUM11A68# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,SPKEKYEX*# SEQUENCE: SPKEKYEX*# ...# >HUM11A69# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRFGVGNRY*# SEQUENCE: GRFGVGNRY*# ...# >HUM11A6A# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homologous to Il-1 receptor antagonist# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRVFIIKE*# SEQUENCE: GRVFIIKE*# ...# >HUM11A6B# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KRFEGLTQR*# SEQUENCE: KRFEGLTQR*# ...# >HUM11A6C# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor 2 (341-349)# DB REFERENCE: SWISS: (EF2_MESAU,EF2_RAT,EF2_CRIGR,EF2_HUMAN,EF2_MESAU,EF2_RAT,# & EF2_CHICK,EF2_CRIGR)# & PIR1: (EFHU2,EFRT2)# & PIR2: (A28660,A25440)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRWLPAGDA*# SEQUENCE: RRWLPAGDA*# ...# >HUM11A6D# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRFTRPEH*# SEQUENCE: RRFTRPEH*# ...# >HUM11A6E# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KKYQKSTEL*# SEQUENCE: KKYQKSTEL*# ...# >HUM11A6F# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Draft-1 protooncogene (1-16)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,XXLNSQDQQCDSSLVE*# SEQUENCE: XXLNSQDQQCDSSLVE*# ...# >HUM11A70# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles F protein (438-446)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASE,VGLF_MEASY)# & PIR1: (E48556,JU0274,VGNZMV)# & PIR2: (PQ0388,PQ0376)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRYPDAVYL*# SEQUENCE: RRYPDAVYL*# ...# >HUM11A71# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV E1 (235-242)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVTH)# & PIR1: (GNWVC3)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,ASRCWVAM*# SEQUENCE: ASRCWVAM*# ...# >HUM11A72# MHC MOLECULE: HLA-B37(B*3701), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza NP (339-347)# DB REFERENCE: SWISS: (VNUC_IAPUE,VNUC_IAVI6,VNUC_IALEN,VNUC_IAHO1,VNUC_IADE1,# & VNUC_IANT6,VNUC_IAZH1)# & PIR1: (VHIV8H,VHIV34,VHIVXL,VHIV68,VHIVN7)# & PIR2: (B36754)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,EDLRVLSFI*# SEQUENCE: EDLRVLSFI*# ...# >HUM11A73# MHC MOLECULE: HLA-B38(B*3801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,EHAGVISVL*# SEQUENCE: EHAGVISVL*# ...# >HUM11A74# MHC MOLECULE: HLA-B38(B*3801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,THDELEDKL*# SEQUENCE: THDELEDKL*# ...# >HUM11A75# MHC MOLECULE: HLA-B38(B*3801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histone binding protein (627-635)# DB REFERENCE: SWISS: (NASP_HUMAN,NASP_RABIT)# & PIR2: (A48819,A43800)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,QYDEAVAQF*# SEQUENCE: QYDEAVAQF*# ...# >HUM11A76# MHC MOLECULE: HLA-B38(B*3801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor 2 (265-273)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,YPDPANGKF*# SEQUENCE: YPDPANGKF*# ...# >HUM11A77# MHC MOLECULE: HLA-B38(B*3801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cyclin (152-159)# DB REFERENCE: SWISS: (PCNA_MOUSE,PCNA_RAT,PCNA_HUMAN)# & PIR1: (WMHUET,WMRTET,WMMS)# & PIR2: (I48707)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,SHIGDAVV*# SEQUENCE: SHIGDAVV*# ...# >HUM11A78# MHC MOLECULE: HLA-B38(B*3801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cyclin A (178-186)# DB REFERENCE: SWISS: (CG2A_BOVIN,CG2A_HUMAN,CG2A_MESAU)# & PIR2: (S24788,S08277)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,YHEDIHTYL*# SEQUENCE: YHEDIHTYL*# ...# >HUM11A79# MHC MOLECULE: HLA-B38(B*3801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PmS protein (270-278)# DB REFERENCE: PIR2: (S21977)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B38,actunkn,bindyesu,TFDVAPSRL*# SEQUENCE: TFDVAPSRL*# ...# >HUM11A7A# MHC MOLECULE: HLA-B39(B*39011), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cyclin (152-159)# DB REFERENCE: SWISS: (PCNA_MOUSE,PCNA_HUMAN,PCNA_RAT)# & PIR1: (WMMS,WMHUET,WMRTET)# & PIR2: (I48707)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B39,actunkn,bindyesu,SHIGDAVV*# SEQUENCE: SHIGDAVV*# ...# >HUM11A7B# MHC MOLECULE: HLA-B39(B*39011), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CKShs1 protein (59-66)# DB REFERENCE: SWISS: (CKS2_XENLA,CKS2_HUMAN,CKS1_HUMAN)# & PIR2: (A36670,B36670)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B39,actunkn,bindyesu,IHEPEPHI*# SEQUENCE: IHEPEPHI*# ...# >HUM11A7C# MHC MOLECULE: HLA-B39(B*39011), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: GBLP (35-42)# DB REFERENCE: SWISS: (GBLP_HUMAN,GBLP_HUMAN)# & PIR2: (B33928,S45054,A36986,A33928,I49700,S38398)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B39,actunkn,bindyesu,SRDKTIIM*# SEQUENCE: SRDKTIIM*# ...# >HUM11A7D# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFPGKIFLYA*# SEQUENCE: GEFPGKIFLYA*# ...# >HUM11A7E# MHC MOLECULE: HLA-B44(B*4403), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSP 90 (427-436)# DB REFERENCE: SWISS: (HS9A_CHICK,HS9A_HUMAN,HS9A_MOUSE,HS9B_HUMAN,HS9A_MOUSE,# & HS9B_RAT,HS9B_HUMAN,HS9B_CHICK,HS9A_CRIGR,HS9B_MOUSE)# & PIR1: (HHMS84,HHMS86,HHCH90,HHHU84,HHHU86)# & PIR2: (A45529,JC1468)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesu,AEDKENYKKF*# SEQUENCE: AEDKENYKKF*# ...# >HUM11A7F# MHC MOLECULE: HLA-B44(B*4403), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor 2 (48-57)# DB REFERENCE: SWISS: (EF12_HUMAN,EF12_XENLA,STTN_HUMAN,EF1A_PLAFK,EF11_CRIGR,# & EF1A_MOUSE,EF12_HUMAN,STTN_RAT,EF1C_PORPU,EF1A_CRIGR,# & EF11_MOUSE,EF1A_ENTHI,EF10_XENLA,EF1A_STYLE,EF12_MOUSE,# & EF11_HUMAN,EF11_HUMAN,EF13_XENLA)# & PIR1: (EFMS1,EFRB1,EFHU1,EFHUA2)# & PIR2: (S21055,A60491,JU0133,S16308,I50226,S50143,JC2445,S21909,# & A40389,JH0530,S13806)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesu,AEMGKGSFKY*# SEQUENCE: AEMGKGSFKY*# ...# >HUM11A80# MHC MOLECULE: HLA-B44(B*4403), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 6 (130-139)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (S33015,H49034,A31666,S27922)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,EENLLDFVRF*# SEQUENCE: EENLLDFVRF*# ...# >HUM11A81# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: UBC5, yeast (61-68)# DB REFERENCE: SWISS: (UBC6_MOUSE,UBC6_HUMAN,UBCB_ARATH,UBC2_DROME,UB5B_HUMAN,# & UB6B_MOUSE,UBC9_ARATH,UBC4_SCHPO,UBC5_YEAST,UBC8_ARATH,# & UBC6_HUMAN,UB5C_HUMAN,UBC1_DROME,UB5B_HUMAN,UB5D_RAT,# & UB6B_MOUSE,UB5C_HUMAN,UBC2_CAEEL,UBC4_LYCES,UBC5_YEAST,# & UBCA_ARATH)# & PIR2: (S32672,A48145,S19157,S53359,S32673,S22858,S53358,S32674,# & I59365)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPFKPPKV*# SEQUENCE: YPFKPPKV*# ...# >HUM11A82# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thymidylate syntnase (253-261)# DB REFERENCE: SWISS: (TYSY_VZVD,TYSY_MOUSE,TYSY_MOUSE,TYSY_HUMAN,TYSY_RAT)# & PIR1: (SYBE13,YXMST,YXHUT)# & PIR2: (S53715)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,DAHIYLNHI*# SEQUENCE: DAHIYLNHI*# ...# >HUM11A83# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: GBLP (192-200)# DB REFERENCE: SWISS: (GBLP_HUMAN,GBLP_HUMAN)# & PIR2: (A33928,B33928,S45054,A36986,I49700,S38398)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,TGYLNTVTV*# SEQUENCE: TGYLNTVTV*# ...# >HUM11A84# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: PIR2: (A55652)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,DAYALNHTL*# SEQUENCE: DAYALNHTL*# ...# >HUM11A85# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPEVNRQL*# SEQUENCE: LPPEVNRQL*# ...# >HUM11A86# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC I a chain (140-148)# DB REFERENCE: SWISS: (1B52_HUMAN,1C02_HUMAN,1B20_HUMAN,1B24_HUMAN,1C01_SAGOE,# & 1C02_HUMAN,1B34_HUMAN,1B04_HUMAN,1B61_HUMAN,1B53_HUMAN,# & 1C01_HUMAN,1A02_PANTR,1B38_HUMAN,1B46_HUMAN,1A23_HUMAN,# & 1A69_HUMAN,1B02_PANTR,1B01_PANTR,1A02_HUMAN,1B02_HUMAN,# & 1A02_HUMAN,1B39_HUMAN,1A24_HUMAN,1B33_HUMAN,1B22_HUMAN,# & 1B35_HUMAN,1B63_HUMAN,1B19_HUMAN,1A68_HUMAN,# & 1B49_HUMAN)# & PIR1: (HLHU69,HLHU40,HLHUB7,HLHUA2)# & PIR2: (I36960,S11136,I80176,I61906,I84431,I38441,I54418,S03537,# & I80169,S60601,I37521,I72218,I38443,I37522,S03538,I37470,# & S11133,I68747,I68701,I59655,I61902,I80174,I72808,I61903,# & I37515,I56116,I37120,I37528,I61865,I38437,S52486,I37492,# & I54493,I59188,S24434,I61864,I36957,I54457,I54412,S24436,# & I54416,B30345,I36956,I59651,I80172,I38509,I80175,I61857,# & I84448,I54298,S11142,I54430,S24438,I37542,S11140,I54308,# & A30345,I56149,I80171,I36962,I59622,I38442)# & PIR3: (S07115,S07113)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YAYDGKDYI*# SEQUENCE: YAYDGKDYI*# ...# >HUM11A87# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: UBC5, yeast (61-68)# DB REFERENCE: SWISS: (UB6B_MOUSE,UBC4_LYCES,UB5D_RAT,UBC2_CAEEL,UBC6_HUMAN,# & UBC8_ARATH,UBC6_HUMAN,UBCB_ARATH,UBC2_DROME,UBC6_MOUSE,# & UB6B_MOUSE,UB5B_HUMAN,UB5C_HUMAN,UBC5_YEAST,UBCA_ARATH,# & UB5C_HUMAN,UB5B_HUMAN,UBC1_DROME,UBC5_YEAST,UBC4_SCHPO,# & UBC9_ARATH)# & PIR2: (S32673,S32672,A48145,S53358,S22858,S53359,S32674,S19157,# & I59365)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPFKPPKV*# SEQUENCE: YPFKPPKV*# ...# >HUM11A88# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPGRIIKX*# SEQUENCE: LPPGRIIKX*# ...# >HUM11A89# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CDC25 homol. (560-567)# DB REFERENCE: SWISS: (GNRP_MOUSE,GNRP_MOUSE)# & PIR2: (S28407)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPFTVILV*# SEQUENCE: LPFTVILV*# ...# >HUM11A8A# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: GBLP (192-200)# DB REFERENCE: SWISS: (GBLP_HUMAN,GBLP_HUMAN)# & PIR2: (A36986,S38398,A33928,I49700,S45054,B33928)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,TGYLNTVTV*# SEQUENCE: TGYLNTVTV*# ...# >HUM11A8B# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC I alpha chain (140-148)# DB REFERENCE: SWISS: (1B23_HUMAN,1C03_GORGO,1B29_HUMAN,1B08_HUMAN,1C04_GORGO,# & 1C11_HUMAN,1C02_GORGO,1C14_HUMAN,1C07_HUMAN,1C12_HUMAN,# & 1B31_HUMAN,1C02_GORGO,1B32_HUMAN,1C13_HUMAN,1B26_HUMAN,# & 1B07_HUMAN)# & PIR1: (S42102)# & PIR2: (C35997,I84488,I80166,I37544,I80167,JS0262,I68774,I61862,# & JH0545,S24439,I81232,I38875,I79640,I80168,I37135,I37078,# & I59645,S24440,JH0546,I80170,JH0547,I61859,I61904,I54505,# & I54463,I68850,I80165,JH0526,I38874,I54314,I56133)# & PIR3: (G02922)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,FAYDGKDYI*# SEQUENCE: FAYDGKDYI*# ...# >HUM11A8C# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S7/S8A (135-144)# DB REFERENCE: SWISS: (RS7_HUMAN,RS7_FUGRU)# & PIR1: (R3RT7)# & PIR2: (JC4388)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,FPSEIVGKRI*# SEQUENCE: FPSEIVGKRI*# ...# >HUM11A8D# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor 1 a (208-216)# DB REFERENCE: SWISS: (EF1A_MOUSE,EF11_MOUSE,EF12_HUMAN,STTN_HUMAN,EF12_HUMAN,# & EF1A_CRIGR,EF11_HUMAN,STTN_RAT,EF12_MOUSE,EF11_HUMAN,# & EF11_CRIGR)# & PIR1: (EFHU1,EFRB1,EFMS1,EFHUA2)# & PIR2: (I59399,JU0133,A40389,JC2445,I50226,S21055)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,MPWFKGWKV*# SEQUENCE: MPWFKGWKV*# ...# >HUM11A8E# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: GBLP (192-l99)# DB REFERENCE: SWISS: (GBLP_HUMAN,GBLP_HUMAN)# & PIR2: (I49700,B33928,S38398,S45054,A33928,A36986)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,TGYLNTVTV*# SEQUENCE: TGYLNTVTV*# ...# >HUM11A8F# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thyrnidilate synthase (253-261)# DB REFERENCE: SWISS: (TYSY_HUMAN,TYSY_RAT,TYSY_MOUSE,TYSY_MOUSE,TYSY_VZVD)# & PIR1: (YXHUT,YXMST,SYBE13)# & PIR2: (S53715)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,DAHIYLNHI*# SEQUENCE: DAHIYLNHI*# ...# >HUM11A90# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YFDDTLEDF*# SEQUENCE: YFDDTLEDF*# ...# >HUM11A91# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: GBLP (192-200)# DB REFERENCE: SWISS: (GBLP_HUMAN,GBLP_HUMAN)# & PIR2: (I49700,S38398,A33928,A36986,S45054,B33928)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,TGYLNTVTV*# SEQUENCE: TGYLNTVTV*# ...# >HUM11A92# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribos. prot. S21 (60-67)# DB REFERENCE: SWISS: (RS21_HUMAN)# & PIR2: (S34108)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,GQFKTYAI*# SEQUENCE: GQFKTYAI*# ...# >HUM11A93# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Pl-CDC21 (259-266)# DB REFERENCE: SWISS: (C21H_HUMAN,C21H_MOUSE,MCM4_HUMAN,MCM4_MOUSE)# & PIR2: (S56766,S65954)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,HSTIMPRL*# SEQUENCE: HSTIMPRL*# ...# >HUM11A94# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC II beta chain (150-158)# DB REFERENCE: SWISS: (HB2D_HUMAN,HB2B_HUMAN,HB2B_HUMAN,HB2A_HUMAN,HB2G_HUMAN,# & HB2F_HUMAN,HB2C_HUMAN,HB2E_HUMAN,HB2H_HUMAN,HB2I_HUMAN,# & HB2J_HUMAN,HB2K_HUMAN)# & PIR1: (HLHU1B,HLHU3D,HLHU5D,HLHU4D)# & PIR2: (I54287,E60748,E39797,I68710,B28031,I54295,A60748,A29310,# & B27618,C27060,F27060,I54509,I68734,I55966,B39797,I54427,# & A27618,I37469,B42621,I59092,S01441,A25925,I56072,I67726,# & F60748,I54294,D39797,B60748,A25324,D32526,I71904,D60748,# & C60748,I54448,I68733,A39797,C32526,A42621,A45856,C39797,# & A28031)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,GFYPGSIEV*# SEQUENCE: GFYPGSIEV*# ...# >HUM11A95# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: RBAP-2 (266-273)# DB REFERENCE: SWISS: (RBB1_HUMAN)# & PIR2: (B42997,I58383,I78883,I58390)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,VQIFGNKM*# SEQUENCE: VQIFGNKM*# ...# >HUM11A96# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Flongation factor 2 (265-273)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,YPDPANGKF*# SEQUENCE: YPDPANGKF*# ...# >HUM11A97# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histone 2a Z (25-32)# DB REFERENCE: SWISS: (H2A_CHITH,H2A4_VOLCA,H2A3_WHEAT,H2A_PETCR,H2AO_CHITH,# & H2A_PICAB,H2AV_STRPU,H2A2_PEA,H2A2_TETTH,H2AV_CHICK,# & H2A_DROME,H2A_PLAFA,H2AV_YEAST,H2A_URECA,H2AV_DROME,# & H2A2_WHEAT,H2A2_PEA,H2A_SEPOF,H2A_SIPNU,H2A1_TETTH,# & H2A2_TETPY,H2A_CHLRE,H2A_ACRFO,H2A_LYCES,H2A_PLADU,# & H2A3_VOLCA,H2AZ_HUMAN,H2AV_TETTH,H2AZ_HUMAN,H2A1_TETPY,# & H2A1_WHEAT,H2A_MAIZE)# & PIR1: (HSFF2,HSOO2,HSTE92,HSWT2A,HSCH2F,HSTE91,HSIN21,HSWT91,# & HSWT93)# & PIR2: (S08210,S53518,S41471,S18004,S60474,C56612,B56618,A35881,# & A45564,JQ1182,S11314,S53521,S41472,JQ0796,S08118,S59590,# & S59126,S21938,S66694,JQ0794,S03642,S40435,S21849,S03282,# & S59584,S11498,S53519,S53520,C56580,S03644,S30155,# & S07392)# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,LQFPVGRI*# SEQUENCE: LQFPVGRI*# ...# >HUM11A98# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: reference/Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,HMYIFLHTV*# SEQUENCE: HMYIFLHTV*# ...# >HUM11A99# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lamin C (490-498)# DB REFERENCE: SWISS: (LAMA_MOUSE,LAMC_MOUSE,LAMA_MOUSE,LAMA_RAT,LAMC_MOUSE,# & LAMA_RAT,LAMC_HUMAN,LAMA_HUMAN)# & PIR1: (VEHULC,VEHULA)# & PIR2: (S28182,S30573,I53414,S04333,S27267)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,KAGQVVTIW*# SEQUENCE: KAGQVVTIW*# ...# >HUM11A9A# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC class I (260-268)# DB REFERENCE: SWISS: (1B57_HUMAN,1B56_HUMAN,1B60_HUMAN,1B02_HUMAN,1B20_HUMAN,# & 1B23_HUMAN,1B16_HUMAN,1B25_HUMAN,1B04_GORGO,1B44_HUMAN,# & 1B45_HUMAN,1B08_HUMAN,1B29_HUMAN,1B34_HUMAN,1B58_HUMAN,# & 1B12_HUMAN,1B13_HUMAN,1B54_HUMAN,1B53_HUMAN,1B31_HUMAN,# & 1B48_HUMAN,1B12_HUMAN,1B42_HUMAN,1B10_HUMAN,1A02_PANTR,# & 1B27_HUMAN,1B62_HUMAN,1B40_HUMAN,1B36_HUMAN,1B21_HUMAN,# & 1B43_HUMAN,1B28_HUMAN,1B04_HUMAN,1B61_HUMAN,1B26_HUMAN,# & 1B07_HUMAN,1B39_HUMAN,1B22_HUMAN,1B33_HUMAN,1B15_HUMAN,# & 1B41_HUMAN,1B02_PANTR,1B11_HUMAN,1B18_HUMAN,1B59_HUMAN,# & 1B14_HUMAN,1B35_HUMAN,1B19_HUMAN,1B63_HUMAN,1B49_HUMAN,# & 1B38_HUMAN,1B05_HUMAN,1B46_HUMAN,1B32_HUMAN,1B55_HUMAN,# & 1B52_HUMAN,1B24_HUMAN,1B47_HUMAN)# & PIR1: (HLHU40,HLHUB7,HLHUB2,HLHUB4,HLHUB8)# & PIR2: (I80168,I36956,I72755,B30345,I61860,I59645,I38509,JH0542,# & I68774,I37519,I61862,I54289,C35997,I84488,I80167,I56149,# & I36962,A30345,I37516,I54308,S24027,I81233,I62041,S60601,# & A45850,I68850,I37522,S03538,I37492,S52486,I61863,S24434,# & S24437,I61905,A45880,I80170,I68748,I54457,I62042,I37520,# & S24436,S24440,I37120,I56116,I61859,I84486,I38437,I61865,# & I61861,I54505,I54463,I84431,I59308,I61906,I59654,I68701,# & I59655,I68747,I56133,I62043,I54442,I61903,I38421,S24439,# & I84490,S24435,I54298,S24433,I80166,S16789,I37485,I59651,# & I56130,I72754,I37475,G01230,A45834,I59633,I72752,D35997,# & I37521,I80165,I36960,I37515,I72753,I61904,I62045,I61864,# & I68724,I62044,S24438,I61907,I54314,S25415)# & PIR3: (S07115)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,AGDRTFQKW*# SEQUENCE: AGDRTFQKW*# ...# >HUM11A9B# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,ITTKAISRF*# SEQUENCE: ITTKAISRF*# ...# >HUM11A9C# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein L30 (23-31)# DB REFERENCE: SWISS: (RL24_HUMAN)# & PIR2: (JC2444,JN0549)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,RTDGKVFQF*# SEQUENCE: RTDGKVFQF*# ...# >HUM11A9D# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cytochrome C oxidase (154-163)# DB REFERENCE: SWISS: (COX2_MANLE,COX2_CERGA,COX2_GORBE,COX2_PANPA,COX2_PONPY,# & COX2_GORGO,COX2_HYLLA,COX2_HYLSY,COX2_CERAE,COX2_MACMU,# & COX2_PAPAN,COX2_THEGE,COX2_HUMAN,COX2_MACFA,# & COX2_PANTR)# & PIR1: (OBHU2)# & PIR2: (I61891,I61893,I37046,I37050,I84421,I37028,I61892,I84443,# & A27420)# & PIR3: (I36925,I61850,I84424,I61849,I36932,I36905)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,ITSQDVLHSW*# SEQUENCE: ITSQDVLHSW*# ...# >HUM11A9E# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,ISDSNPFLTQ*# SEQUENCE: ISDSNPFLTQ*# ...# >HUM11A9F# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,KTDEVVTLF*# SEQUENCE: KTDEVVTLF*# ...# >HUM11AA0# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC class II beta (209-217)# DB REFERENCE: SWISS: (HB2I_HUMAN,HB2E_HUMAN,HB2B_HUMAN,HB2A_HUMAN,HB2F_HUMAN,# & HB2B_HUMAN,HB2G_HUMAN)# & PIR1: (HLHU5D,HLHU3D,HLHU1B,HLHUWB)# & PIR2: (G28043,I37469,A27618,E39797,I54287,D60748,C60748,I68733,# & A60748,I68734,F27060,C27060,I55966,F60748,D39797,D32526,# & I71904,E28043,H28043,A45856,C39797,I68710,I54509,I54295,# & B28043,I54448,I56072,I67726,A25324,E60748,I54294,B27618,# & C32526)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,VTSPLTVEW*# SEQUENCE: VTSPLTVEW*# ...# >HUM11AA1# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glucose transporter 5 (322-330)# DB REFERENCE: SWISS: (GTR5_HUMAN)# & PIR2: (G02864,A36629)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B58,actunkn,bindyesu,GAVNVVMTF*# SEQUENCE: GAVNVVMTF*# ...# >HUM11AA2# MHC MOLECULE: HLA-B60(B*40012), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ubiquitin (63-71)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B60,actunkn,bindyesu,KESTLHKVL*# SEQUENCE: KESTLHKVL*# ...# >HUM11AA3# MHC MOLECULE: HLA-B60(B*40012), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC class I (221-230)# DB REFERENCE: SWISS: (1B23_HUMAN,1B55_HUMAN,1B05_HUMAN,1C01_PANTR,1A74_HUMAN,# & 1B14_HUMAN,1C11_HUMAN,1B19_HUMAN,1B01_PANTR,1AXX_HUMAN,# & 1A32_HUMAN,1C01_SAGOE,1B48_HUMAN,1C16_HUMAN,1B10_HUMAN,# & 1B45_HUMAN,1B34_HUMAN,1A66_HUMAN,1C03_HUMAN,1B01_SAGOE,# & 1B43_HUMAN,1C17_HUMAN,1B60_HUMAN,1B20_HUMAN,1B56_HUMAN,# & 1B02_HUMAN,1B57_HUMAN,1A43_HUMAN,1B32_HUMAN,1B38_HUMAN,# & 1A69_HUMAN,1A01_PONPY,1A36_HUMAN,1A02_HUMAN,1B63_HUMAN,# & 1B35_HUMAN,HLAF_HUMAN,1B47_HUMAN,1A33_HUMAN,1B52_HUMAN,# & 1A24_HUMAN,1B24_HUMAN,1A80_HUMAN,1A02_HUMAN,1OKO_GORGO,# & 1B61_HUMAN,1A03_HUMAN,1C01_HUMAN,1A23_HUMAN,1B01_GORGO,# & 1B31_HUMAN,1B53_HUMAN,1C28_PANTR,1B04_HUMAN,1A31_HUMAN,# & 1B04_GORGO,HLAE_PONPY,1C15_HUMAN,1C06_HUMAN,1B12_HUMAN,# & 1B13_HUMAN,1C13_HUMAN,1B08_HUMAN,1C02_GORGO,1A30_HUMAN,# & 1B29_HUMAN,1B02_GORGO,1B58_HUMAN,1C04_HUMAN,1A26_HUMAN,# & 1C14_HUMAN,1A01_PANTR,1B18_HUMAN,1C12_HUMAN,1A34_HUMAN,# & 1C07_HUMAN,1B12_HUMAN,1B33_HUMAN,1B39_HUMAN,1C01_GORGO,# & 1A29_HUMAN,1B59_HUMAN,1A01_HUMAN,1B02_PANTR,1C05_HUMAN,# & 1A11_HUMAN,1B11_HUMAN,1B26_HUMAN,1B22_HUMAN,1C02_HUMAN,# & 1B07_HUMAN,1B15_HUMAN,1C02_GORGO,1C04_GORGO,1A25_HUMAN,# & 1B44_HUMAN,1B49_HUMAN,1A26_HUMAN,1B46_HUMAN,HLAH_HUMAN,# & 1B16_HUMAN,1CXX_HUMAN,HLAH_HUMAN,1A68_HUMAN,1B03_GORGO,# & 1B62_HUMAN,1B28_HUMAN,1A03_PANTR,1B27_HUMAN,1A02_PANTR,# & 1B36_HUMAN,1C18_HUMAN,1B21_HUMAN,1A01_SAGOE,1B25_HUMAN,# & 1C03_GORGO,1C02_HUMAN,1B54_HUMAN,HLAE_HUMAN,1A31_HUMAN,# & HLAF_HUMAN)# & PIR1: (HLHU12,HLHU28,HLHU32,HLHUC4,HLHUB7,HLHU69,HLHU10,HLHUAW,# & HLHU40,HLHUW3,HLHUB2,HLHUA2,HLHUA3,S42102,HLHUB8)# & PIR2: (I37475,I72754,A45834,A27797,I56034,I56130,JH0526,D35997,# & S48134,A60384,I37485,I37470,I36961,I80166,I36958,S24433,# & I38443,I84490,I72218,I81231,I80169,S16789,I38436,A28834,# & I54493,I54442,I62043,I68712,I38421,I61905,S24437,JH0543,# & S16769,B37028,I84432,JH0544,A45857,I36959,A37028,I54416,# & S52486,S03538,I37522,I38518,I68850,I61866,JH0540,I37478,# & I56039,JH0539,JH0546,I37526,A47636,I37480,I68699,I68701,# & I59655,I68747,I37477,C37028,I54551,I54505,I59654,I84431,# & JL0135,I59308,I61857,I54308,I38505,S24027,I37483,I38439,# & I68745,S11135,I56053,I84487,I37521,I38441,I80165,S42823,# & I38519,S11136,I62045,I61904,I72753,JH0541,S11139,I83063,# & I54314,I61902,S11138,I62044,S11133,I68700,I61907,I38442,# & I38509,JS0262,I59645,I59622,I69002,I81232,I37520,I80168,# & I37479,I80171,I72755,S11137,I37482,B30345,I36962,I37476,# & S18197,I54430,I68774,JH0545,I80167,I84488,I54289,I72217,# & I37519,I61865,I38437,I37078,I37120,I72171,I68749,I80170,# & I68748,I72170,S11141,I37135,I61856,I62042,I54457,S24436,# & S24440,I84448,I37542,I72113,JH0538,G01230,S03537,I37523,# & S03535,I56133,I61863,S44994,S60601,I54412,I37527,I61859,# & I36956,C35997,A30345,I56149,I81233,I68724,S24438,I54449,# & I38610,I62041,A45850,I37492,S24434,A45880,I68750,S11134,# & I56116,I84486,I37544,A35997,I38507,I61867,I61860,S11142,# & S11140,JH0542,I61862,I59651,I59633,I72752,A45847,S24435,# & S24439,I54298,I36960,I37515,I61864,I54418,I61903,I36957,# & I61906,I54307,I54463,JH0547,S10934)# & PIR3: (G02922,S06424,S07114,S07113,S07115)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B60,actunkn,bindyesu,HEATLRCWAL*# SEQUENCE: HEATLRCWAL*# ...# >HUM11AA4# MHC MOLECULE: HLA-B60(B*40012), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSHMO2C05# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B60,actunkn,bindyesu,YEIHDGMNL*# SEQUENCE: YEIHDGMNL*# ...# >HUM11AA5# MHC MOLECULE: HLA-B60(B*40012), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Signal peptidase (45-54)# DB REFERENCE: SWISS: (SPC4_CANFA,SPC3_CANFA,SPC4_RAT)# & PIR2: (A35309,A34229)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B60,actunkn,bindyesu,SESPIVVVL*# SEQUENCE: SESPIVVVL*# ...# >HUM11AA6# MHC MOLECULE: HLA-B60(B*40012), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S17 (95-105)# DB REFERENCE: SWISS: (RS17_RAT,RS17_CRIGR,RS17_HUMAN,RS17_CHICK,RS17_CRIGR)# & PIR1: (R4HU17,R4RT17)# & PIR2: (PC4160,S00760)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B60,actunkn,bindyesu,IEVDPDTKEML*# SEQUENCE: IEVDPDTKEML*# ...# >HUM11AA7# MHC MOLECULE: HLA-B61(B*4006), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IEF (mRNA) 9306 (127-135)# DB REFERENCE: SWISS: (RB46_HUMAN,RB48_MOUSE,MSIH_HUMAN,RB48_HUMAN,RB46_MOUSE,# & RB48_HUMAN)# & PIR2: (I49366,S33446,S36112,I39181,I49367)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFGGFGSV*# SEQUENCE: GEFGGFGSV*# ...# >HUM11AA8# MHC MOLECULE: HLA-B61(B*4006), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Associated-microfibril. protein (72-80)# DB REFERENCE: SWISS: (MFA1_CHICK,MFA1_CHICK,MFA1_HUMAN,MFA1_HUMAN)# & PIR2: (A42670,A55565)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,EEFQFIKKA*# SEQUENCE: EEFQFIKKA*# ...# >HUM11AA9# MHC MOLECULE: HLA-B61(B*4006), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S21 (6-13)# DB REFERENCE: SWISS: (RS21_HUMAN,RS21_RAT)# & PIR1: (R3RT21)# & PIR2: (S51027,S34108)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFVDLYV*# SEQUENCE: GEFVDLYV*# ...# >HUM11AAA# MHC MOLECULE: HLA-B61(B*4006), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S17 (77-84)# DB REFERENCE: SWISS: (RS17_CHICK,RS17_CRIGR,RS17_RAT,RS17_CRIGR,RS17_HUMAN,# & RS17_DROME)# & PIR1: (R4RT17,R4FF17,R4HU17)# & PIR2: (PC4160,S00760)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,RERRDNYV*# SEQUENCE: RERRDNYV*# ...# >HUM11AAB# MHC MOLECULE: HLA-B61(B*4006), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribonucl. reductase (290-297)# DB REFERENCE: SWISS: (RIR2_HUMAN)# & PIR2: (S25854)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,REIIINAV*# SEQUENCE: REIIINAV*# ...# >HUM11AAC# MHC MOLECULE: HLA-B61(B*4006), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S15 (116-123)# DB REFERENCE: SWISS: (RS15_HUMAN,RS15_XENLA,RS15_XIPMA,RS15_HUMAN,# & RS15_XENLA)# & PIR1: (R3HU15,R3RT15,R3HY15)# & PIR2: (B34823,C34823,A34823)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEFSITYK*# SEQUENCE: GEFSITYK*# ...# >HUM11AAD# MHC MOLECULE: HLA-B61(B*4006), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (NRDC_RAT)# & PIR2: (I59311)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,GEHGLIIRV*# SEQUENCE: GEHGLIIRV*# ...# >HUM11AAE# MHC MOLECULE: HLA-B61(B*4006), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,REMIPFADI*# SEQUENCE: REMIPFADI*# ...# >HUM11AAF# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor 1 a (271-280)# DB REFERENCE: SWISS: (EF11_HUMAN,EF1A_TOBAC,EF1A_NEUCR,EF11_MOUSE,EF11_CRIGR,# & EF11_HUMAN,EF1A_TRIRE,EF1A_CRIGR,EF1A_MOUSE,# & EF1A_SOYBN)# & PIR1: (EFRB1,EFMS1,EFHU1)# & PIR2: (I50226,S50143,S17434,S21055,S35772,JU0133,I59399,# & I54251)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,VLKPGMVVTF*# SEQUENCE: VLKPGMVVTF*# ...# >HUM11AB0# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S15 (114-122)# DB REFERENCE: SWISS: (RS15_XENLA,RS15_YEAST,RS15_XENLA,RS15_HUMAN,RS15_YEAST,# & RS15_HUMAN,RS15_XIPMA)# & PIR1: (R3HU15,R3HY15,R3RT15)# & PIR2: (C34823,S24053,B34823,A34823)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,YLGEFSITY*# SEQUENCE: YLGEFSITY*# ...# >HUM11AB1# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein L8 (rat) (7-15)# DB REFERENCE: SWISS: (RL8_HUMAN,RL8_XENLA,RL8_HUMAN)# & PIR1: (R5RTL8)# & PIR2: (S42725,JN0923)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,GQRKGAGSV*# SEQUENCE: GQRKGAGSV*# ...# >HUM11AB2# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein L27 (66-74)# DB REFERENCE: SWISS: (RL27_HUMAN)# & PIR1: (R5RT27)# & PIR2: (S43505,S22288)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,KIKSFVKVY*# SEQUENCE: KIKSFVKVY*# ...# >HUM11AB3# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (RPB7_HUMAN,RPB7_HUMAN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,IQPGRGFVLY*# SEQUENCE: IQPGRGFVLY*# ...# >HUM11AB4# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,barber96a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,SQFGGGSQY*# SEQUENCE: SQFGGGSQY*# ...# >HUM11AB5# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein L28 (rat) 68-76)# DB REFERENCE: SWISS: (RL28_HUMAN,RL28_RAT,RL28_MOUSE,RL28_RAT)# & PIR1: (R5RT28)# & PIR2: (I48738,S55915)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,GQRKPATSY*# SEQUENCE: GQRKPATSY*# ...# >HUM11AB6# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Collagen alpha 1 (1106-1112)# DB REFERENCE: SWISS: (CA1B_MOUSE,YMT8_YEAST,CA2B_HUMAN,CA1B_HUMAN)# & PIR1: (CGHU1E,CGHU2E)# & PIR2: (S18251,I57012,S28791,S54548)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,VQGPVGL*# SEQUENCE: VQGPVGL*# ...# >HUM11AB7# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag (267-276)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,ILGNKIVRMY*# SEQUENCE: ILGNKIVRMY*# ...# >HUM11AB8# MHC MOLECULE: HLA-Cw3(Cw*0301), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag (144-152)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1J3,GAG_HV1Y2,GAG_HV1B1,GAG_HV1H2,# & GAG_HV1JR,GAG_HV1MN,GAG_HV1A2,GAG_HV1EL,GAG_HV1RH,# & GAG_HV1Z2,GAG_SIVCZ,GAG_HV1ND,GAG_HV1W2,GAG_HV1N5,# & GAG_HV1BR,GAG_HV1PV,GAG_HV1MA,GAG_HV1C4)# & PIR1: (A44001,FOVWH3,FOVWLV,FOVWH4,A38068,FOLJSI,FOLJND,FOVWA2,# & FOVWVL)# & PIR2: (S54377,S52929)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-Cw3,actyesu,bindyesu,HQAISPRTL*# SEQUENCE: HQAISPRTL*# ...# >HUM11AB9# MHC MOLECULE: HLA-Cw3(Cw*0301), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LHIV gag (141-152)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1B1,GAG_HV1Y2,GAG_HV1PV,GAG_HV1RH,# & GAG_HV1J3,GAG_HV1EL,GAG_HV1H2,GAG_HV1W2,GAG_HV1N5,# & GAG_HV1BR,GAG_SIVCZ,GAG_HV1ND,GAG_HV1Z2,GAG_HV1A2,# & GAG_HV1MN,GAG_HV1B5,GAG_HV1JR)# & PIR1: (FOVWLV,FOVWA2,FOVWVL,A38068,FOVWH3,A44001,FOVWH4,FOLJSI,# & FOLJND)# & PIR2: (S54377,S52929)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-Cw3,actyesu,bindyesu,QMVHQAISPRT*# SEQUENCE: QMVHQAISPRT*# ...# >HUM11ABA# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: reference/stabilization/HLA assembly# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV-1 gp 120 (380-388)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1PV,ENV_HV1RH,ENV_HV1N5,ENV_HV1H3,# & ENV_HV1BR,ENV_HV1Y2,ENV_HV1MF,ENV_HV1J3,ENV_HV1EL,# & ENV_HV1Z6,ENV_HV1Z2,ENV_HV1H2,ENV_HV1C4,ENV_HV1JR,# & ENV_HV1SC,ENV_HV1B1,ENV_HV1OY,ENV_HV1W1,ENV_HV1W2,# & ENV_HV1BN,ENV_HV1MN,ENV_HV1ZH,ENV_HV1Z8,ENV_HV1S1)# & PIR1: (VCLJVL,VCLJ3W,VCLJMN,A44963,VCLJZR,VCLJLV,H44001,VCLJH3,# & VCLJSC,VCLJBR,VCLJH4)# & PIR2: (S60556,S60528,S60555,S60522,S60548,S60541,S54384,S60546,# & S60524,S60557,S60547,A41621,S60549,S60525,S60521,S60523,# & S60550,S60535,S60545,S31493,A40218,S60529)# & PIR3: (S13289,S33985,S13288)# REFERENCES: rammensee95a,rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actyesu,bindyesh,SFNCGGEFF*# SEQUENCE: SFNCGGEFF*# ...# >HUM11ABB# MHC MOLECULE: HLA-Cw6(Cw*0602), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-Cw6,actunkn,bindyesu,YQFTGIKKY*# SEQUENCE: YQFTGIKKY*# ...# >HUM11ABC# MHC MOLECULE: HLA-Cw6(Cw*0602), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-Cw6,actunkn,bindyesu,VRHDGGNVL*# SEQUENCE: VRHDGGNVL*# ...# >HUM11ABD# MHC MOLECULE: HLA-Cw6(Cw*0602), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-Cw6,actunkn,bindyesu,FAFPLIQRV*# SEQUENCE: FAFPLIQRV*# ...# >HUM11ABE# MHC MOLECULE: HLA-Cw6(Cw*0602), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-Cw6,actunkn,bindyesu,XQRTPKAGLYY*# SEQUENCE: XQRTPKAGLYY*# ...# >HUM11ABF# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homologous hnRNP A2 or B1 (277-288)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,NYGGGNYGSGSY*# SEQUENCE: NYGGGNYGSGSY*# ...# >HUM11AC0# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,FYPPYPFLDG*# SEQUENCE: FYPPYPFLDG*# ...# >HUM21AC1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (103-117)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHUA2,HLHU69)# & PIR2: (I38442,I61857,I84448,I38443,I61902,I37542)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VGSDWRFLRGYHQYA*# SEQUENCE: VGSDWRFLRGYHQYA*# ...# >HUM21AC2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (103-120)# DB REFERENCE: SWISS: (1A02_HUMAN,1A69_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I37542,I61902,I84448,I38443,I61857,I38442)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VGSDWRFLRGYHQYAYDG*# SEQUENCE: VGSDWRFLRGYHQYAYDG*# ...# >HUM21AC3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (103-116)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I38442,I61857,I38443,I37542,I61902,I84448)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VGSDWRFLRGYHQY*# SEQUENCE: VGSDWRFLRGYHQY*# ...# >HUM21AC4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (104-117)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I84448,I38442,I61902,I37542,I38443,I61857)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,GSDWRFLRGYHQYA*# SEQUENCE: GSDWRFLRGYHQYA*# ...# >HUM21AC5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (97-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPM*# ...# >HUM21AC6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Na+-K+-ATPase (199-216)# DB REFERENCE: SWISS: (ATN1_RAT,ATN1_SHEEP,ATN1_HUMAN,ATN1_CANFA,ATN1_PIG,# & ATN1_HORSE,ATN3_PIG,ATN1_HUMAN)# & PIR1: (PWSHNA,S04630)# & PIR2: (A24639,A24414,B24862,S20970)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,IPADLRIISANGCK*# SEQUENCE: IPADLRIISANGCK*# ...# >HUM21AC7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle fetuin (56-74)# DB REFERENCE: SWISS: (A2HS_SHEEP,A2HS_BOVIN,A2HS_BOVIN,A2HS_SHEEP)# & PIR2: (S22394,A35714)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YKHTLNQIDSVKVWPRRPT*# SEQUENCE: YKHTLNQIDSVKVWPRRPT*# ...# >HUM21AC8# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (2877-2894)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,ISNQLTLDSNTKYFHKLN*# SEQUENCE: ISNQLTLDSNTKYFHKLN*# ...# >HUM21AC9# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (2877-2893)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,ISNQLTLDSNTKYFHKL*# SEQUENCE: ISNQLTLDSNTKYFHKL*# ...# >HUM21ACA# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (2877-2892)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,ISNQLTLDSNTKYFHK*# SEQUENCE: ISNQLTLDSNTKYFHK*# ...# >HUM21ACB# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Alpha-1-Antitrypsin (149-164)# DB REFERENCE: SWISS: (A1AT_BOVIN,A1AT_BOVIN)# & PIR2: (S21097)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,VDTFLEDVKNLYHSEA*# SEQUENCE: VDTFLEDVKNLYHSEA*# ...# >HUM21ACC# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LDL-Receptor (518-532)# DB REFERENCE: SWISS: (LDLR_HUMAN,LDLR_HUMAN)# & PIR1: (QRHULD)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,KPRAIVVDPVHGFMY*# SEQUENCE: KPRAIVVDPVHGFMY*# ...# >HUM21ACD# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgG2a, membrane domain# DB REFERENCE: SWISS: (GCAM_MOUSE)# & PIR1: (G2MSAM)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,KQTISPDYRNMI*# SEQUENCE: KQTISPDYRNMI*# ...# >HUM21ACE# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,YPDFIMDPKEKDKV*# SEQUENCE: YPDFIMDPKEKDKV*# ...# >HUM21ACF# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,NIQLINDQEVARFD*# SEQUENCE: NIQLINDQEVARFD*# ...# >HUM21AD0# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (618-632)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,LLSFVRDLNQYRADI*# SEQUENCE: LLSFVRDLNQYRADI*# ...# >HUM21AD1# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (97-113)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,LPKPPKPVSKMRMATPL*# SEQUENCE: LPKPPKPVSKMRMATPL*# ...# >HUM21AD2# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (97-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALP*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALP*# ...# >HUM21AD3# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (97-120)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPM*# ...# >HUM21AD4# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (98-113)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,PKPPKPVSKMRMATPL*# SEQUENCE: PKPPKPVSKMRMATPL*# ...# >HUM21AD5# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (98-117)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQA*# SEQUENCE: PKPPKPVSKMRMATPLLMQA*# ...# >HUM21AD6# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (99-116)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,KPPKPVSKMRMATPLLMQ*# SEQUENCE: KPPKPVSKMRMATPLLMQ*# ...# >HUM21AD7# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (99-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,KPPKPVSKMRMATPLLMQALPM*# SEQUENCE: KPPKPVSKMRMATPLLMQALPM*# ...# >HUM21AD8# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A30 (28-?)# DB REFERENCE: SWISS: (1A04_GORGO,1A23_HUMAN,1A03_HUMAN,1A02_HUMAN,1A03_PANTR,# & 1A69_HUMAN,1A02_HUMAN,1A26_HUMAN,1A43_HUMAN,1A74_HUMAN,# & 1A66_HUMAN,1A32_HUMAN,1A25_HUMAN,1A29_HUMAN,1A02_GORGO,# & 1A26_HUMAN,1A01_PANTR,1A34_HUMAN,1A04_PANTR,1A11_HUMAN,# & 1A33_HUMAN,1A03_GORGO,1A01_GORGO,1A24_HUMAN,1A31_HUMAN,# & 1A31_HUMAN,1A68_HUMAN,1A30_HUMAN,1A01_HUMAN,1A36_HUMAN,# & 1A01_PONPY)# & PIR1: (HLHUA3,HLHU69,HLHUAW,HLHU32,HLHUA2,HLHU28)# & PIR2: (S16769,I37478,I56039,I38518,I72170,I61856,I37482,JH0534,# & JH0537,I37480,I61857,S03535,I54307,I84448,A45847,I38610,# & I36961,I61902,I37470,S18198,S51099,I54493,I37542,I84487,# & I83063,I38441,I38519,A35997,JH0535,I37483,I36966,I37479,# & I37476,S01171,I72171,JH0536,A47636,I84432,I36959,A37028,# & I54416,I37477,I38436,I36965,JL0135,I38443)# & PIR3: (S06424)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,VDDTQFVRFDSDAASQ*# SEQUENCE: VDDTQFVRFDSDAASQ*# ...# >HUM21AD9# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (131-149)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,ATKYGNMTEDHVMHLLQNA*# SEQUENCE: ATKYGNMTEDHVMHLLQNA*# ...# >HUM21ADA# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ACh receptor (289-304)# DB REFERENCE: SWISS: (ACHB_TORCA,ACHB_BOVIN,ACHB_HUMAN)# & PIR1: (ACRYB1)# & PIR2: (S04607,S07227)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,VFLLLLADKVPETSLS*# SEQUENCE: VFLLLLADKVPETSLS*# ...# >HUM21ADB# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ICAM-2 (64-76)# DB REFERENCE: SWISS: (ICA2_HUMAN,ICA2_HUMAN)# & PIR2: (S03967)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,LNKILLDEQAQWK*# SEQUENCE: LNKILLDEQAQWK*# ...# >HUM21ADC# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IFN-gamma receptor (128-147)# DB REFERENCE: SWISS: (INGR_HUMAN,INGR_HUMAN)# & PIR2: (A31555)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,GPPKLDIRKEEKQIMIDIFH*# SEQUENCE: GPPKLDIRKEEKQIMIDIFH*# ...# >HUM21ADD# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IFN-gamma receptor (128-148)# DB REFERENCE: SWISS: (INGR_HUMAN,INGR_HUMAN)# & PIR2: (A31555)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,GPPKLDIRKEEKQIMIDIFHP*# SEQUENCE: GPPKLDIRKEEKQIMIDIFHP*# ...# >HUM21ADE# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cyt-bS (155-172)# DB REFERENCE: SWISS: (NC5R_HUMAN,NC5R_HUMAN)# & PIR1: (RDHUB5)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,GKFAIRPDKKSNPIIRTV*# SEQUENCE: GKFAIRPDKKSNPIIRTV*# ...# >HUM21ADF# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1207-1224)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,YANILLDRRVPQTDMTF*# SEQUENCE: YANILLDRRVPQTDMTF*# ...# >HUM21AE0# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1276-1295)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,NLFLKSDGRIKYTLNKNSLK*# SEQUENCE: NLFLKSDGRIKYTLNKNSLK*# ...# >HUM21AE1# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1273-1292)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,IPDNLFLKSDGRIKYTLNKN*# SEQUENCE: IPDNLFLKSDGRIKYTLNKN*# ...# >HUM21AE2# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1273-1291)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,IPDNLFLKSDGRIKYTLNK*# SEQUENCE: IPDNLFLKSDGRIKYTLNK*# ...# >HUM21AE3# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1273-1290)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,IPDNLFLKSDGRIKYTLN*# SEQUENCE: IPDNLFLKSDGRIKYTLN*# ...# >HUM21AE4# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1273-1289)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,IPDNLFLKSDGRIKYTL*# SEQUENCE: IPDNLFLKSDGRIKYTL*# ...# >HUM21AE5# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1276-1291)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,NLFLKSDGRIKYTLNK*# SEQUENCE: NLFLKSDGRIKYTLNK*# ...# >HUM21AE6# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1276-1290)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,NLFLKSDGRIKYTLN*# SEQUENCE: NLFLKSDGRIKYTLN*# ...# >HUM21AE7# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (1294-1810)# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,VTTLNSDLKYNALDLTN*# SEQUENCE: VTTLNSDLKYNALDLTN*# ...# >HUM21AE8# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (103-117)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_HUMAN,1A02_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I61857,I61902,I37542,I84448,I38443,I38442)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesu,VGSDWRFLRGYHQYA*# SEQUENCE: VGSDWRFLRGYHQYA*# ...# >HUM21AE9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (33-47)# DB REFERENCE: SWISS: (1A04_GORGO,1A03_HUMAN,1A23_HUMAN,1A03_PANTR,1A03_GORGO,# & 1A26_HUMAN,1A02_HUMAN,1A01_PANTR,1A34_HUMAN,1A02_GORGO,# & 1A02_HUMAN,1A69_HUMAN,1A01_GORGO,1A24_HUMAN,1A33_HUMAN,# & 1A43_HUMAN,1A25_HUMAN,1A29_HUMAN,1A04_PANTR,1A26_HUMAN,# & 1A11_HUMAN,1A66_HUMAN,1A32_HUMAN,1A74_HUMAN,1A68_HUMAN,# & 1A31_HUMAN,1A30_HUMAN,1A31_HUMAN,1A01_PONPY)# & PIR1: (HLHU32,HLHU28,HLHUA2,HLHUAW,HLHUA3,HLHU69)# & PIR2: (I84487,S18198,I36965,JH0536,I38436,I72170,S51099,I36966,# & I37483,I54307,I54416,A47636,I37470,I36961,I38441,I38519,# & I83063,JL0135,I54493,I37477,I84432,I61902,S01171,I37479,# & I72171,I36959,A37028,I37476,I38443,I84448,I37480,A45847,# & I61857,I38610,JH0535,A35997,S03535,JH0537,JH0534,I37482,# & I37542,I56039,S16769)# & PIR3: (S06424)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FVRFDSDAASQRMEP*# SEQUENCE: FVRFDSDAASQRMEP*# ...# >HUM21AEA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (28-45)# DB REFERENCE: SWISS: (1A69_HUMAN,1A02_GORGO,1A02_HUMAN,1A34_HUMAN,1A01_PANTR,# & 1A02_HUMAN,1A01_PONPY,1A30_HUMAN,1A31_HUMAN,1A25_HUMAN,# & 1A01_GORGO,1A24_HUMAN,1A33_HUMAN,1A43_HUMAN,1A68_HUMAN,# & 1A74_HUMAN,1A32_HUMAN,1A66_HUMAN,1A03_PANTR,1A03_GORGO,# & 1A26_HUMAN,1A04_GORGO,1A03_HUMAN,1A23_HUMAN,1A11_HUMAN,# & 1A29_HUMAN,1A26_HUMAN,1A04_PANTR,1A31_HUMAN)# & PIR1: (HLHUA2,HLHUAW,HLHUA3,HLHU32,HLHU28,HLHU69)# & PIR2: (S51099,I36966,I54307,I37483,I54416,A47636,I37480,JH0534,# & S16769,JH0537,I37482,I37542,I84448,S03535,I38443,I84487,# & I72170,I38436,JH0536,I36965,I37477,I61902,I37479,I72171,# & I84432,I36959,A37028,I37470,I36961,I38519,I83063,A45847,# & I61857,I38610,A35997,JH0535,I37476,JL0135,S01171,I38441,# & I54493,S18198,I56039)# & PIR3: (S06424)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQRM*# SEQUENCE: VDDTQFVRFDSDAASQRM*# ...# >HUM21AEB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (33-45)# DB REFERENCE: SWISS: (1A25_HUMAN,1A24_HUMAN,1A26_HUMAN,1A04_PANTR,1A29_HUMAN,# & 1A11_HUMAN,1A03_HUMAN,1A04_GORGO,1A26_HUMAN,1A66_HUMAN,# & 1A23_HUMAN,1A01_GORGO,1A43_HUMAN,1A31_HUMAN,1A31_HUMAN,# & 1A30_HUMAN,1A01_PONPY,1A68_HUMAN,1A74_HUMAN,1A32_HUMAN,# & 1A33_HUMAN,1A02_GORGO,1A01_PANTR,1A34_HUMAN,1A02_HUMAN,# & 1A02_HUMAN,1A69_HUMAN,1A03_GORGO,1A03_PANTR)# & PIR1: (HLHU69,HLHU28,HLHUA2,HLHU32,HLHUA3,HLHUAW)# & PIR2: (I54307,I36965,I37470,I61902,I38519,I83063,I36961,I72171,# & I37477,A45847,A47636,I37482,JH0537,JH0534,S16769,I37542,# & I84448,S03535,I38443,I37480,I38610,I61857,A35997,JH0535,# & I84432,I36959,A37028,I37479,I38441,I54493,S18198,I56039,# & I37476,JH0536,I38436,I84487,I72170,I36966,I37483,S51099,# & I54416,JL0135,S01171)# & PIR3: (S06424)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FVRFDSDAASQRM*# SEQUENCE: FVRFDSDAASQRM*# ...# >HUM21AEC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-C2 (8-?)# DB REFERENCE: SWISS: (1C17_HUMAN,1C16_HUMAN,1C11_HUMAN,1C01_PANTR,1B55_HUMAN,# & 1CXX_HUMAN,1C06_HUMAN,1C02_GORGO,1C04_HUMAN,1C07_HUMAN,# & 1C02_HUMAN,1C04_GORGO,1C02_HUMAN,1C02_GORGO,1C15_HUMAN,# & 1C03_HUMAN,1C03_GORGO,1C18_HUMAN,1C01_HUMAN)# & PIR1: (HLHUC4)# & PIR2: (I38507,I38505,I81231,JH0526,I56034,I56130,S48134,S42823,# & I72113,S44994,I37527,I37523,I54449,JH0547,I54430,JH0545,# & JS0262,I68749,A49411,A45857,I37078,C37028,B37028,I61866,# & JH0546,I37526,I59622,I37528,I37529,I68712,I37544)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASPRGEP*# SEQUENCE: VDDTQFVRFDSDAASPRGEP*# ...# >HUM21AED# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (143-156)# DB REFERENCE: SWISS: (1B21_HUMAN,1B31_HUMAN,1B40_HUMAN,1B61_HUMAN,1B27_HUMAN,# & 1B59_HUMAN,1B53_HUMAN,1B28_HUMAN,1B43_HUMAN,1B48_HUMAN,# & 1B19_HUMAN,1B05_HUMAN,1B02_GORGO,1B58_HUMAN,1B55_HUMAN,# & 1B52_HUMAN,1B24_HUMAN,1B01_GORGO,1B25_HUMAN,1B54_HUMAN,# & 1B44_HUMAN,1B03_GORGO,1B62_HUMAN,1B16_HUMAN,1B49_HUMAN,# & 1B63_HUMAN,1B07_HUMAN,1B26_HUMAN,1B22_HUMAN,1B15_HUMAN,# & 1B12_HUMAN,1B18_HUMAN,1B42_HUMAN,1B02_PANTR,1B11_HUMAN,# & 1B29_HUMAN,1B08_HUMAN,1B12_HUMAN,1B13_HUMAN,1B47_HUMAN,# & 1B41_HUMAN,1B32_HUMAN,1B23_HUMAN,1B01_PANTR,1B14_HUMAN,# & 1B45_HUMAN,1B10_HUMAN,1B56_HUMAN,1B60_HUMAN,# & 1B57_HUMAN)# & PIR1: (HLHUB4,HLHUB8,HLHUB2)# & PIR2: (I84486,S16789,D35997,I62045,I62044,I38509,I84488,G01230,# & A30345,I56130,I38875,S24437,I59654,I59308,I72754,I38876,# & I80168,I59645,I61862,I61860,A45850,I54463,JH0541,I37521,# & I54308,S24027,JH0539,JH0540,S03538,I68850,I37522,I54505,# & I80172,I37120,I68748,I38860,I80173,I54457,I62042,S24440,# & S24436,I37520,I80171,I72755,B30345,I68774,I54289,I37519,# & I37516,I80167,I84490,I36957,I59633,S24435,S24439,I54298,# & I72752,I37515,I68724,S25415,C35997,I81233,I61859,I61863,# & I56133,S03537,I80165,I61904,I72753,I61907,I54314,I37485,# & I61861,I80169,I80166,S24433,A45834,I37475,I62043,I54442,# & I38421,S24434,I62041,A45880,I38874)# & PIR3: (S07113)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DGKDYIALNEDLSS*# SEQUENCE: DGKDYIALNEDLSS*# ...# >HUM21AEE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (154-168)# DB REFERENCE: SWISS: (1B49_HUMAN,1B44_HUMAN,1B03_GORGO,1B62_HUMAN,1B54_HUMAN,# & 1B02_GORGO,1B58_HUMAN,1B25_HUMAN,1B01_GORGO,1B24_HUMAN,# & 1B52_HUMAN,1B55_HUMAN,1B05_HUMAN,1B19_HUMAN,1B10_HUMAN,# & 1B45_HUMAN,1B57_HUMAN,1B23_HUMAN,1B16_HUMAN,1B01_PANTR,# & 1B14_HUMAN,1B11_HUMAN,1B02_PANTR,1B04_GORGO,1B22_HUMAN,# & 1B26_HUMAN,1B15_HUMAN,1B47_HUMAN,1B32_HUMAN,1B56_HUMAN,# & 1B41_HUMAN,1B53_HUMAN,1B59_HUMAN,1B29_HUMAN,1B61_HUMAN,# & 1B42_HUMAN,1B18_HUMAN,1B07_HUMAN,1B60_HUMAN,1B48_HUMAN,# & 1B43_HUMAN,1B28_HUMAN,1B31_HUMAN,1B27_HUMAN,1B63_HUMAN,# & 1B12_HUMAN,1A02_PANTR,1B21_HUMAN,1B40_HUMAN,1B08_HUMAN,# & 1B13_HUMAN,1B12_HUMAN)# & PIR1: (HLHUB2,HLHUB8,HLHUB4)# & PIR2: (I59308,I56130,I59654,JH0541,S24437,JH0542,I59645,S03537,# & I61859,I61863,A45880,I62041,S24434,I68724,I81233,C35997,# & S24435,I36957,I72752,I59633,I80167,I84490,I62044,I62045,# & D35997,I84486,G01230,I38509,I36956,I80174,A30345,I80176,# & I36960,I54463,I61860,S24027,I54308,I37521,A45834,I80168,# & I68774,I80171,S24440,I37520,S24436,I62042,I54457,I80173,# & I37522,I80172,I80175,I80165,I61907,I37485,I61904,I37475,# & I80169,I62043,I54442,I38421,I56133,S24439,S25415,I72754,# & I38875,I38876,I38860,I37120,I36962,I54289,I37519,I72755,# & B30345,I68850,S03538,I37516,I54314,S24433,I61861,I72753,# & I84488,S16789,I68748,I54505,JH0540,JH0539,I80170,I54298,# & I37515,I38874,A45850,I61862)# & PIR3: (S07113,S07115)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LSSWTAADTAAQITQ*# SEQUENCE: LSSWTAADTAAQITQ*# ...# >HUM21AEF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (154-167)# DB REFERENCE: SWISS: (1B08_HUMAN,1B02_PANTR,1B04_GORGO,1B22_HUMAN,1B26_HUMAN,# & 1B11_HUMAN,1B40_HUMAN,1B13_HUMAN,1B12_HUMAN,1A02_PANTR,# & 1B58_HUMAN,1B29_HUMAN,1B21_HUMAN,1B31_HUMAN,1B48_HUMAN,# & 1B43_HUMAN,1B14_HUMAN,1B32_HUMAN,1B24_HUMAN,1B25_HUMAN,# & 1B02_GORGO,1B12_HUMAN,1B27_HUMAN,1B63_HUMAN,1B16_HUMAN,# & 1B23_HUMAN,1B44_HUMAN,1B62_HUMAN,1B03_GORGO,1B45_HUMAN,# & 1B10_HUMAN,1B01_PANTR,1B47_HUMAN,1B41_HUMAN,1B57_HUMAN,# & 1B56_HUMAN,1B15_HUMAN,1B55_HUMAN,1B52_HUMAN,1B19_HUMAN,# & 1B05_HUMAN,1B49_HUMAN,1B54_HUMAN,1B01_GORGO,1B28_HUMAN,# & 1B60_HUMAN,1B61_HUMAN,1B07_HUMAN,1B18_HUMAN,1B42_HUMAN,# & 1B59_HUMAN,1B53_HUMAN)# & PIR1: (HLHUB2,HLHUB4,HLHUB8)# & PIR2: (I38876,I54442,S24440,I62041,S24434,A45880,I59633,I72752,# & I81233,S24437,I59645,I59654,I80169,I37485,I61904,I80173,# & I80171,I37520,I37522,I37519,I37120,I68850,S24439,I36956,# & I80174,I61860,S24027,I54463,D35997,I68724,I61859,I61863,# & C35997,S24435,I36957,I80175,I80165,I61907,I37475,I38421,# & I62043,I80172,I68774,S24436,I54457,I62042,S25415,I56133,# & I38875,I72754,I84488,S16789,JH0540,JH0539,I54505,I80170,# & I68748,I61862,A45850,I54298,I38874,I37515,I80168,A45834,# & I80176,I36960,I54308,I38509,G01230,A30345,I59308,I37521,# & JH0541,I56130,JH0542,S03537,I62045,I84486,I62044,I80167,# & I84490,I38860,S03538,I36962,I72755,B30345,I54289,I37516,# & I54314,S24433,I72753,I61861)# & PIR3: (S07113,S07115)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LSSWTAADTAAQIT*# SEQUENCE: LSSWTAADTAAQIT*# ...# >HUM21AF0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR4 beta (252-270)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IYFRNQKGSHSGLQPTGFL*# SEQUENCE: IYFRNQKGSHSGLQPTGFL*# ...# >HUM21AF1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle (transferin68-82)# DB REFERENCE: SWISS: (TRFE_BOVIN)# & PIR2: (A39684,A60166)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DVAFVKDQTVIQNTD*# SEQUENCE: DVAFVKDQTVIQNTD*# ...# >HUM21AF2# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin C (170-185)# DB REFERENCE: SWISS: (CATC_HUMAN)# & PIR2: (S66504)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YDHNFVKAINAIQKSW*# SEQUENCE: YDHNFVKAINAIQKSW*# ...# >HUM21AF3# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgK chain C region (80-?)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KHKVYACEVTHQG*# SEQUENCE: KHKVYACEVTHQG*# ...# >HUM21AF4# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgK chain C region (81-?)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,HKVYACEVTHQGL*# SEQUENCE: HKVYACEVTHQGL*# ...# >HUM21AF5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DGPFRIITVPAALDY*# SEQUENCE: DGPFRIITVPAALDY*# ...# >HUM21AF6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sphingolipid activator protein 3 (165-176)# DB REFERENCE: SWISS: (SAP3_HUMAN,SAP3_HUMAN)# & PIR2: (S05036,S22411,JQ1037,S13195,I54178)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TGNYRIESVLSS*# SEQUENCE: TGNYRIESVLSS*# ...# >HUM21AF7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSC 70 (445-?)# DB REFERENCE: SWISS: (HS7C_HUMAN,HS73_BOVIN,HS71_HUMAN,HS73_PLAFA,HS7C_DICDI,# & HS76_HUMAN,HS72_MOUSE,HS7C_ICTPU,HS7C_ICTPU,HS7C_BOVIN,# & HS7D_DROME,HS72_HUMAN,HS70_ONCVO,HS70_CHICK,HS7C_DICDI,# & HS7A_CAEEL,HS7C_RAT,HS70_XENLA,HS7H_HUMAN,HS72_MOUSE,# & HS70_ONCTS,HS7C_RAT,HS73_BOVIN,HS7C_BRARE,HS74_ANOAL,# & HS72_ANOAL,HS7C_BOVIN,HS72_HUMAN,HS72_RAT,HS7C_CRIGR,# & HS70_ONCMY,HS71_ANOAL)# & PIR1: (HHKW7A,HHXL70)# & PIR2: (A36333,A27077,S07197,S31716,S31766,A48872,A29160,A55719,# & A35922,S37394,S08211,A45871,A45935,S10859,S37165,S05436,# & S09036,S51682,JC4853,B45871,A25646,S11456,A44985)# & PIR3: (S21175)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GERAMTKDNNLLG*# SEQUENCE: GERAMTKDNNLLG*# ...# >HUM21AF8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,XXXYEXALSLPSK*# SEQUENCE: XXXYEXALSLPSK*# ...# >HUM21AF9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VLA-4 (229-247)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSLFVYNITTNKYKAFLKQ*# SEQUENCE: GSLFVYNITTNKYKAFLKQ*# ...# >HUM21AFA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ beta 3.2 chain (24-38)# DB REFERENCE: SWISS: (HB23_HUMAN,HB24_HUMAN,HB21_HUMAN)# & PIR1: (HLHUDB,HLHU1C)# & PIR2: (I37543,I59466,S49322,I72481,I68718,I55994,B32527,A31459,# & I54480)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SPEDFVYQFKGMCYF*# SEQUENCE: SPEDFVYQFKGMCYF*# ...# >HUM21AFB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PAI-1 (261-281)# DB REFERENCE: SWISS: (PAI1_HUMAN,PAI1_HUMAN)# & PIR1: (ITHUP1)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,AAPYEKEVPLSALTNILSAQL*# SEQUENCE: AAPYEKEVPLSALTNILSAQL*# ...# >HUM21AFC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig heavy chain (121-?)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GVYFYLQWGRSTLVSVS*# SEQUENCE: GVYFYLQWGRSTLVSVS*# ...# >HUM21AFD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle hemoglobin (26-41)# DB REFERENCE: SWISS: (HBA_EULFU,HBA_CTEGU,HBA_BISBO,HBA_MACFA,HBA1_TADBR,# & HBA_SPECI,HBA_CYNSP,HBA_ATEGE,HBA_MACMU,HBA_NYCCO,# & HBA_PAPCY,HBA_BOVIN,HBA_MACAS,HBA_BOSGF,HBA_ALCAA,# & HBA_HUMAN,HBA_HIPAM,HBA_COLBA,HBA_BOVIN,HBA_MEGLY,# & HBA_TAPGE,HBA_MACNE,HBA3_PANTR,HBA_CAPHI,HBA_PREEN,# & HBA_CERTO,HBA_MACSI,HBA3_GORGO,HBA_CALAR,HBA1_BOSMU,# & HBA_GORGO,HBA_ROUAE,HBA_MARMA,HBA_TRAST,HBA_MACCA,# & HBA_PONPY,HBA_RANTA,HBA_SPEPA,HBA2_BOSMU,HBA_CERAE,# & HBA_MYOVE,HBA_HUMAN,HBA_PROHA,HBA_PTEPO,HBA_SPETO,# & HBA_ANTPA,HBA_MACGG,HBA_LORTA,HBA_TUPGL,HBA_CERSI,# & HBA_THEGE,HBA_MACSP,HBA_TARBA,HBA_SAGFU,HBA_MACAS,# & HBA_CEBAP,HBA1_GALCR,HBA2_GALCR,HBA_MANSP,HBA_RHIUN,# & HBA_PTEAL)# & PIR1: (HALRS,HAHXR,HAMQ2P,HABOG,HARNW,HAMKP,HABAY,HABOKA,HASH,# & HASHR2,HAFXG,HACZP,HABAIM,HAYA1,HACZ,HARTNG,HAMKS,HAMQJ,# & HAMQA,HABTV,HAGT,HABO,HACJB,HAHU,HALRN,HAGO,HASHR1,# & HAMQP,HAMQR,HAMQF,HAMQC,HAEKN,HAFXB,HAMQB,HABAG,HAMQIP,# & HAGT2,HAYA2)# & PIR2: (A26640,S31853,A29702,A24690,I78575,B25597,B28865,B27792,# & A25597,D60515,JC1099,A24693,JU0165,I58217,S31852,A29392,# & S31851,B25727,A25359,A25357,C27792,A29391,A25729,B25126,# & A26543)# & PIR3: (S20277,S59496,S13481,B49141,S28934,S20278)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,AEALERMFLSFPTTKT*# SEQUENCE: AEALERMFLSFPTTKT*# ...# >HUM21AFE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Cw9 (130-150)# DB REFERENCE: SWISS: (1CXX_HUMAN,1B36_HUMAN,1B04_HUMAN,1C06_HUMAN,HA19_CANFA,# & 1B34_HUMAN,1C03_HUMAN,1B20_HUMAN,1B02_HUMAN,1C15_HUMAN,# & 1C02_HUMAN,1C07_HUMAN,1C14_HUMAN,1C12_HUMAN,1C01_GORGO,# & 1B39_HUMAN,1C01_PANTR,1B38_HUMAN,1C16_HUMAN,1C17_HUMAN,# & 1B35_HUMAN,1C02_HUMAN,1C04_HUMAN,1C18_HUMAN,# & 1C01_HUMAN)# & PIR1: (S42102,HLHUC4,HLHUB7)# & PIR2: (JH0526,A45845,I56034,S48134,JH0543,S52486,I61905,S42823,# & I84431,I59655,I68701,A45857,I68749,B37028,C37028,JH0544,# & I61865,I54430,I68712,S60601,I37528,I59622,I61864,I61906,# & I37523,I37527,S44994,I59188,I72113,I56116,I37526,I38507,# & I38505,I54449,I56149,I37544,I59651,I54418,I37492,I68747,# & I81231,I61866,I37135,JS0262,I81232)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LRSWTAADTAAQITQRKWEAA*# SEQUENCE: LRSWTAADTAAQITQRKWEAA*# ...# >HUM21AFF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Bw62 (129-150)# DB REFERENCE: SWISS: (1B08_HUMAN,1B57_HUMAN,1B58_HUMAN,1B45_HUMAN,1B60_HUMAN,# & 1B25_HUMAN,1B59_HUMAN,1B18_HUMAN,1B42_HUMAN,1B07_HUMAN,# & 1B61_HUMAN,1B28_HUMAN,1B01_GORGO,1B55_HUMAN,1B52_HUMAN,# & 1B19_HUMAN,1B53_HUMAN,1B16_HUMAN,1B44_HUMAN,1B03_GORGO,# & 1B62_HUMAN,1B23_HUMAN,1B49_HUMAN,1B54_HUMAN,1B01_PANTR,# & 1B10_HUMAN,1B47_HUMAN,1B41_HUMAN,1B56_HUMAN,1B32_HUMAN,# & 1B27_HUMAN,1B63_HUMAN,1B14_HUMAN,1B02_GORGO,1B24_HUMAN,# & 1B48_HUMAN,1B43_HUMAN,1B31_HUMAN,1B15_HUMAN,1B26_HUMAN,# & 1B22_HUMAN,1B02_PANTR,1B04_GORGO,1B11_HUMAN,1B12_HUMAN,# & 1B13_HUMAN,1B40_HUMAN,1A02_PANTR,1B12_HUMAN,1B21_HUMAN,# & 1B29_HUMAN)# & PIR1: (HLHUB4,HLHUB2,HLHUB8)# & PIR2: (I56130,I37521,JH0541,A30345,S24433,I38860,I72755,I54289,# & I37516,I59645,I61904,I80169,I68850,I37120,I61860,I54463,# & I36956,I37519,A45880,I80171,I54314,I36962,I54298,I54457,# & I68774,S24435,I38421,I38875,I72754,S25415,I56133,S16789,# & I84488,I80170,JH0540,JH0539,I68748,I54505,I84490,I80167,# & I62045,I62044,I84486,S03538,B30345,I72753,I61861,S24434,# & I62041,I59633,I72752,I81233,I59654,S24437,I37485,I37522,# & I80173,I37520,A45834,I80168,I38874,I37515,I61862,S24027,# & I80174,D35997,S24440,I38876,I62042,I68724,I61859,I61863,# & C35997,I36957,I80175,I80165,I37475,I61907,I80172,I62043,# & S24436,I38509,I54308,I80176,I36960,S03537,I59308,JH0542,# & G01230,S24439)# & PIR3: (S07115,S07113)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLSSWTAADTAAQITQRKWEAA*# SEQUENCE: DLSSWTAADTAAQITQRKWEAA*# ...# >HUM21B00# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (182-198)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,APSPLPETTENVVCALG*# SEQUENCE: APSPLPETTENVVCALG*# ...# >HUM21B01# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha (238-252)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IIKGVRKSNAAERRG*# SEQUENCE: IIKGVRKSNAAERRG*# ...# >HUM21B02# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DR4 beta (248-266)# DB REFERENCE: SWISS: (HB2J_HUMAN,HB2A_HUMAN,HB2D_HUMAN,HB2F_HUMAN,HB2H_HUMAN,# & HB2E_HUMAN)# & PIR1: (HLHU1B,HLHU5D,HLHUWB)# & PIR2: (I37469,A25925,I68734,I55966,F27060,B27618,I54509,A28031,# & A29310,I56072,A45856,E28043,I71904)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IYFRNQKGHSGLQPTGFLS*# SEQUENCE: IYFRNQKGHSGLQPTGFLS*# ...# >HUM21B03# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DR4 beta (250-261)# DB REFERENCE: SWISS: (HB2J_HUMAN,HB2A_HUMAN,HB2H_HUMAN,HB2I_HUMAN,HB2D_HUMAN,# & HB2D_CANFA,HB2B_HUMAN,HB2B_HUMAN,HB2E_HUMAN,HB2F_HUMAN,# & HB2K_HUMAN)# & PIR1: (HLHU5D,HLHU1B,HLHU3D,HLHUWB)# & PIR2: (H28043,A28031,I71904,A42621,A39797,I56072,I54509,A29310,# & S01441,I59092,A25925,G28043,I54448,A45856,B27618,B28031,# & A45844,E28043,I54295,A25324,I54294,B42621,D39797,I55966,# & I68734,F27060,I37469,E39797)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FRNQKGHSGLQP*# SEQUENCE: FRNQKGHSGLQP*# ...# >HUM21B04# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DR4 beta (249-266)# DB REFERENCE: SWISS: (HB2E_HUMAN,HB2J_HUMAN,HB2A_HUMAN,HB2H_HUMAN,HB2F_HUMAN,# & HB2D_HUMAN)# & PIR1: (HLHU1B,HLHU5D,HLHUWB)# & PIR2: (I37469,F27060,A45856,I71904,E28043,B27618,I56072,I54509,# & A25925,I68734,I55966,A29310,A28031)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FIYFRNQKGHSGLQPTGFLS*# SEQUENCE: FIYFRNQKGHSGLQPTGFLS*# ...# >HUM21B05# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DR4Dw10 beta (37-47)# DB REFERENCE: SWISS: (HB2H_HUMAN,HB2D_HUMAN,HB2K_MOUSE,HB2J_MOUSE)# & PIR1: (HLMSBK)# & PIR2: (S70749,I79653,I54304,S38700,I79422,I54516,I68899,I79663,# & A45544,I68778,I48422,PH0160,S01441,S03440,I59629,I79419,# & S38684,I51875,I54500,I72483,S57512,I79656,I54291,I68909,# & S38691,A45856,PL0285,S37121,A29310,A39797,S38683,PL0286,# & PT0161,PH0156,G02057,I54309,I47170,I54473,I79421,I37539,# & S38705,I79650,S38699,I80418,A39260,I79667)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YVRFDSDVGEY*# SEQUENCE: YVRFDSDVGEY*# ...# >HUM21B06# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (97-?)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LPKPPKPVSKMRMATPLLQ*# SEQUENCE: LPKPPKPVSKMRMATPLLQ*# ...# >HUM21B07# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Pyruvate kinase (264-278)# DB REFERENCE: SWISS: (KPY2_MOUSE,KPY2_RAT,KPY1_RAT,KPY2_HUMAN,KPYK_CHICK,# & KPY1_RABIT,KPY2_MOUSE,KPY1_FELCA,KPY1_RABIT,KPY1_HUMAN,# & KPYK_XENLA)# & PIR1: (KICHPM)# & PIR2: (B26186,S30038,S55921,S64635,A25091,A54113,A33983,A26186,# & S51374,JT0486)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IKIISKIENHEGVRR*# SEQUENCE: IKIISKIENHEGVRR*# ...# >HUM21B08# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Pyruvate-kinase (264-277)# DB REFERENCE: SWISS: (KPY2_HUMAN,KPY1_RAT,KPYK_CHICK,KPY2_MOUSE,KPY1_RABIT,# & KPY2_MOUSE,KPY1_HUMAN,KPYK_XENLA,KPY2_RAT,KPY1_FELCA,# & KPY1_RABIT)# & PIR1: (KICHPM)# & PIR2: (S51374,A26186,A33983,S55921,S30038,B26186,S64635,A25091,# & A54113,JT0486)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IKIISKIENHEGVR*# SEQUENCE: IKIISKIENHEGVR*# ...# >HUM21B09# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSC 70 (574-585)# DB REFERENCE: SWISS: (HS7C_BOVIN,HS7C_HUMAN,HS7C_BOVIN)# & PIR2: (S11456,A27077)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,CNEIINWLDKNQ*# SEQUENCE: CNEIINWLDKNQ*# ...# >HUM21B0A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Leucine-rich a 2-glyco-protein (200-211)# DB REFERENCE: SWISS: (A2GL_HUMAN)# & PIR1: (NBHUA2)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,QPDLRYLFLNGN*# SEQUENCE: QPDLRYLFLNGN*# ...# >HUM21B0B# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B60 (1-?)# DB REFERENCE: SWISS: (1B04_GORGO,1B47_HUMAN,1B33_HUMAN,1B38_HUMAN,1B43_HUMAN,# & 1B48_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I37492,I37519,I61864,I37520,JH0542,I38437)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSHSMRYFHTAMSRPGRGE*# SEQUENCE: GSHSMRYFHTAMSRPGRGE*# ...# >HUM21B0C# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B60 (2-?)# DB REFERENCE: SWISS: (1B48_HUMAN,1B43_HUMAN,1B47_HUMAN,1B33_HUMAN,1B38_HUMAN,# & 1B04_GORGO)# & PIR1: (HLHU40)# & PIR2: (I37519,I37520,JH0542,I61864,I37492,I38437)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SHSMRYFHTAMSRPGRGE*# SEQUENCE: SHSMRYFHTAMSRPGRGE*# ...# >HUM21B0D# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: GAPDH (139-154)# DB REFERENCE: SWISS: (G3P2_HUMAN)# & PIR1: (DEHUG3)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YDNSLKIISNASCTTN*# SEQUENCE: YDNSLKIISNASCTTN*# ...# >HUM21B0E# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PGSG (1-19)# DB REFERENCE: SWISS: (PGSG_HUMAN)# & PIR2: (A28058)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YPTQRARYQWVRCNPDSNS*# SEQUENCE: YPTQRARYQWVRCNPDSNS*# ...# >HUM21B0F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PGSG 4- (19)# DB REFERENCE: SWISS: (PGSG_HUMAN)# & PIR2: (A28058)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,QRARYQWVRCNPDSNS*# SEQUENCE: QRARYQWVRCNPDSNS*# ...# >HUM21B10# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PGSG (5-19)# DB REFERENCE: SWISS: (PGSG_HUMAN)# & PIR2: (A28058)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,RARYQWVRCNPDSNS*# SEQUENCE: RARYQWVRCNPDSNS*# ...# >HUM21B11# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MIF (32-45)# DB REFERENCE: SWISS: (MIF_HUMAN)# & PIR2: (A48793)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KPPQYIAVHVVPDQ*# SEQUENCE: KPPQYIAVHVVPDQ*# ...# >HUM21B12# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (173-186)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FREFKLSKVWRDQH*# SEQUENCE: FREFKLSKVWRDQH*# ...# >HUM21B13# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (173-185)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FREFKLSKVWRDQ*# SEQUENCE: FREFKLSKVWRDQ*# ...# >HUM21B14# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (174-186)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,REFKLSKVWRDQH*# SEQUENCE: REFKLSKVWRDQH*# ...# >HUM21B15# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (174-185)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,REFKLSKVWRDQ*# SEQUENCE: REFKLSKVWRDQ*# ...# >HUM21B16# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (397-411)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VEPDHYVVVGAQRDA*# SEQUENCE: VEPDHYVVVGAQRDA*# ...# >HUM21B17# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (398-411)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EPDHYVVVGAQRDA*# SEQUENCE: EPDHYVVVGAQRDA*# ...# >HUM21B18# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (92-107)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,THYYAVAVVKKDTDFK*# SEQUENCE: THYYAVAVVKKDTDFK*# ...# >HUM21B19# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 90-beta (68-81)# DB REFERENCE: SWISS: (HS9B_HUMAN,HS9B_HUMAN)# & PIR1: (HHMS84,HHHU84)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KELKIDIIPNPQER*# SEQUENCE: KELKIDIIPNPQER*# ...# >HUM21B1A# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta 2-microglobulin (83-96)# DB REFERENCE: SWISS: (B2MG_PONPY,B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963,I61868)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YLLYYTEFTPTEKD*# SEQUENCE: YLLYYTEFTPTEKD*# ...# >HUM21B1B# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta 2-microglobulin (84-98)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963,I61868)# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LLYYTEFTPTEKDEY*# SEQUENCE: LLYYTEFTPTEKDEY*# ...# >HUM21B1C# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histone H3 (110-?)# DB REFERENCE: SWISS: (H3_PSAMI,H3_PSAMI,H3_MAIZE,H32_XENLA,H32_MEDSA,H3_PEA,# & H3_HORVU,H33_HUMAN,H3_STRPU,YB21_CAEEL,H3_ACRFO,# & H32_ORYSA,H32_BOVIN,H3_CAEEL,H31_HUMAN,H3_ENCAL,# & H33_CAEEL,H3_VOLCA)# & PIR1: (HSRK3,HSFI3,HSBH3,HSEAH3,HSTR3,HSHU33,HSUR3M,HSCH3,# & HSBO3,HSUR3P,HSXL32,HSKW3,HSHU3,HSXL31)# & PIR2: (S20678,S10168,JN0687,I50460,JH0304,S04099,I51448,S04186,# & S32621,S59581,S04520,A56580,I49398,A25564,S45111,S24346,# & JS0690,S61214,JQ1984,S20669,JQ0757,S11315,S09655,S01198,# & S06755,S61220,S57626,S01196,S06250,S20109,I48092,I50245,# & S04521,A56654,S01197,S50140,I49397,I57019,S00940,A26014,# & I50244,A56618,S57780,S34185,S59592,S61218,I51443,S00373,# & S61215)# & PIR3: (A45941)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,CAIHAKRVTIMPKDIQLA*# SEQUENCE: CAIHAKRVTIMPKDIQLA*# ...# >HUM21B1D# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ras-related protein RAB-7 rat (86-98)# DB REFERENCE: SWISS: (RAB7_CANFA,RAB7_HUMAN,RAB7_RAT,RAB7_MOUSE)# & PIR2: (S62733,B30413,S01934)# & PIR3: (JC5268)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,APNTFKTLDSWRD*# SEQUENCE: APNTFKTLDSWRD*# ...# >HUM21B1E# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Phosphoglycerate kinase (216-228)# DB REFERENCE: SWISS: (PGK1_MACEU,PGK2_RAT,PGK1_HUMAN,PGK_CRIGR,PGK1_MOUSE,# & PGK_HORSE)# & PIR1: (KIHUG,KIHOG)# & PIR2: (A33792,PC1118,A25567,I48074)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VADKIQLINNMLD*# SEQUENCE: VADKIQLINNMLD*# ...# >HUM21B1F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. MIF (32-46)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,XXXQYIAVHVVPDQT*# SEQUENCE: XXXQYIAVHVVPDQT*# ...# >HUM21B20# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PKM2 (99-112)# DB REFERENCE: SWISS: (KPY1_RAT,KPY1_RABIT,KPY2_HUMAN,KPY1_HUMAN,KPY2_MOUSE,# & KPY2_RAT,KPY1_RABIT,KPY2_MOUSE)# & PIR2: (S55921,S30038,B26186,JT0486,A54113,S64635,A26186)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SDPILYRPVAVALD*# SEQUENCE: SDPILYRPVAVALD*# ...# >HUM21B21# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VPIQRAVYQNVVVNNPXD*# SEQUENCE: VPIQRAVYQNVVVNNPXD*# ...# >HUM21B22# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MIF (32-47)# DB REFERENCE: SWISS: (MIF_HUMAN)# & PIR2: (A48793)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KPPQYIAVHVVPDQLM*# SEQUENCE: KPPQYIAVHVVPDQLM*# ...# >HUM21B23# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MIF (32-46)# DB REFERENCE: SWISS: (MIF_HUMAN)# & PIR2: (A48793)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KPPQYIAVHVVPDQL*# SEQUENCE: KPPQYIAVHVVPDQL*# ...# >HUM21B24# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PKM2 (101-118)# DB REFERENCE: SWISS: (KPY1_HUMAN,KPY2_HUMAN,KPY2_MOUSE,KPY1_RABIT,KPY2_RAT,# & KPY1_RAT,KPY2_MOUSE,KPY1_RABIT)# & PIR2: (S55921,B26186,S64635,A26186,A54113,JT0486,S30038)# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DPILYRPVAVALDTKGPE*# SEQUENCE: DPILYRPVAVALDTKGPE*# ...# >HUM21B25# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution/flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PKM2 (101-117)# DB REFERENCE: SWISS: (KPY2_MOUSE,KPY2_HUMAN,KPY2_RAT,KPY1_RABIT,KPY1_RAT,# & KPY2_MOUSE,KPY1_RABIT,KPY1_HUMAN)# & PIR2: (JT0486,B26186,S64635,A54113,A26186,S55921,S30038)# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DPILYRPVAVALDTKGP*# SEQUENCE: DPILYRPVAVALDTKGP*# ...# >HUM21B26# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (88-108)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DNPQTHYYAVAVVKKDTDFKL*# SEQUENCE: DNPQTHYYAVAVVKKDTDFKL*# ...# >HUM21B27# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (88-107)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DNPQTHYYAVAVVKKDTDFK*# SEQUENCE: DNPQTHYYAVAVVKKDTDFK*# ...# >HUM21B28# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (89-108)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,NPQTHYYAVAVVKKDTDFKL*# SEQUENCE: NPQTHYYAVAVVKKDTDFKL*# ...# >HUM21B29# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (89-107)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,NPQTHYYAVAVVKKDTDFK*# SEQUENCE: NPQTHYYAVAVVKKDTDFK*# ...# >HUM21B2A# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (88-103)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DNPQTHYYAVAVVKKD*# SEQUENCE: DNPQTHYYAVAVVKKD*# ...# >HUM21B2B# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution/flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (92-106)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,THYYAVAVVKKDTDF*# SEQUENCE: THYYAVAVVKKDTDF*# ...# >HUM21B2C# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta 2m (85-26)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I61868,I37063,I36963)# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LYYTEFTPTEKD*# SEQUENCE: LYYTEFTPTEKD*# ...# >HUM21B2D# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin C (58-73)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,XXXXKKVVVYLQKLDT*# SEQUENCE: XXXXKKVVVYLQKLDT*# ...# >HUM21B2E# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution/flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin C (62-76)# DB REFERENCE: SWISS: (CATC_HUMAN)# & PIR2: (S66504)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KKVVVYLQKLDTAYD*# SEQUENCE: KKVVVYLQKLDTAYD*# ...# >HUM21B2F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin C (63-76)# DB REFERENCE: SWISS: (CATC_HUMAN)# & PIR2: (S66504)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KVVVYLQKLDTAYD*# SEQUENCE: KVVVYLQKLDTAYD*# ...# >HUM21B30# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: reference/elution/flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (3218-3230)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KPYNEAKTXFDKY*# SEQUENCE: KPYNEAKTXFDKY*# ...# >HUM21B31# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. HSC 70 (238-250)# DB REFERENCE: SWISS: (HS7C_RAT,HS7C_ICTPU,HS7C_ICTPU,HS7C_RAT,HS7C_HUMAN,# & HS7C_BOVIN,HS7C_BOVIN)# & PIR2: (S07197,A45935,S31716,A27077,JC4853,S11456)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,VNHFIAEFKRKHK*# SEQUENCE: VNHFIAEFKRKHK*# ...# >HUM21B32# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B38 (104-121)# DB REFERENCE: SWISS: (1C11_HUMAN)# & PIR2: (I37078)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,GPDGRLLRGYDQFAYDGK*# SEQUENCE: GPDGRLLRGYDQFAYDGK*# ...# >HUM21B33# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA class I (104-129)# DB REFERENCE: SWISS: (1B33_HUMAN,1B61_HUMAN,1B38_HUMAN,1B46_HUMAN,1B49_HUMAN,# & 1B34_HUMAN,1B24_HUMAN,1B39_HUMAN,1B52_HUMAN,1B53_HUMAN,# & 1B35_HUMAN,1B63_HUMAN,1B20_HUMAN,1B04_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I37522,I56116,I37492,I68747,I37521,I37120,I38509,I54457,# & B30345,I61865,S52486,I84431,I61864,I59655,A30345,I61906,# & I38437,I59188,I61903,I59651,I56149)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,GPDGRLLRGHNQYAYD*# SEQUENCE: GPDGRLLRGHNQYAYD*# ...# >HUM21B34# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (142-155)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,TGTIKLLNENSYVP*# SEQUENCE: TGTIKLLNENSYVP*# ...# >HUM21B35# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (144-156)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,TIKLLNENSYVPR*# SEQUENCE: TIKLLNENSYVPR*# ...# >HUM21B36# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (141-156)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,FTGTIKLLNENSYVPR*# SEQUENCE: FTGTIKLLNENSYVPR*# ...# >HUM21B37# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (140-156)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,DFTGTIKLLNENSYVPR*# SEQUENCE: DFTGTIKLLNENSYVPR*# ...# >HUM21B38# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Valosin-cont. protein p97 (78-93)# DB REFERENCE: SWISS: (TERA_RAT,TERA_MOUSE,TERA_PIG,TERA_XENLA)# & PIR1: (VPPG,S19738,S25197,A55190)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,SDEKIRMNRVVRNNLR*# SEQUENCE: SDEKIRMNRVVRNNLR*# ...# >HUM21B39# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. to apolipoprotein# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,SSVITLNTNVGLYXQT*# SEQUENCE: SSVITLNTNVGLYXQT*# ...# >HUM21B3A# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,EALIHQLKINPYVLS*# SEQUENCE: EALIHQLKINPYVLS*# ...# >HUM21B3B# MHC MOLECULE: HLA-DR12(DRB1*1201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Dihydrolipoamide dehydrogenase (138-152)# DB REFERENCE: SWISS: (DLDH_CANFA,DLDH_HUMAN)# & PIR1: (DEHULP)# & PIR2: (JC4241)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR12,actunkn,bindyesu,AHLFKQNKVVHVNG*# SEQUENCE: AHLFKQNKVVHVNG*# ...# >HUM21B3C# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A3 (152-166)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesu,AEQLRAYLDGTGVE*# SEQUENCE: AEQLRAYLDGTGVE*# ...# >HUM21B3D# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ6 (43-56)# DB REFERENCE: SWISS: (HB25_HUMAN,HB22_HUMAN,HB22_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3,HLHU2C)# & PIR2: (D35054,I54296,I37071,I61835,I36975,I68811,I36973,I61839,# & I36974,I68819,I59639,I54440,I72481,I68813,I68723,I59528,# & I84420,I68817,E35055,I68718,F35055,I72482,I68812,I68732,# & I59623)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,DVGVYRAVTPQGRP*# SEQUENCE: DVGVYRAVTPQGRP*# ...# >HUM21B3E# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ6 (41-57)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I68723,I72481,I68817,I68813,D35054,I68732,I59528,I61835,# & I84420,I61839,I59623)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,DSDVGVYRAVTPQGRPD*# SEQUENCE: DSDVGVYRAVTPQGRPD*# ...# >HUM21B3F# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ6 (41-58)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I59623,I59528,I68723,I61839,I84420,I61835,I68732,D35054,# & I72481,I68817,I68813)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,DSDVGVYRAVTPQGRPDA*# SEQUENCE: DSDVGVYRAVTPQGRPDA*# ...# >HUM21B40# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ6 (41-60)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I72481,I68813,D35054,I68817,I61835,I68732,I61839,I68723,# & I59528,I59623,I84420)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,DSDVGVYRAVTPQGRPDAEY*# SEQUENCE: DSDVGVYRAVTPQGRPDAEY*# ...# >HUM21B41# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A3 (135-151)# DB REFERENCE: SWISS: (1A11_HUMAN,1A03_HUMAN,1A24_HUMAN,1A01_PANTR)# & PIR1: (HLHUA3)# & PIR2: (A47636,I36959,I54416,I36961,I83063,I72029,I54493)# & PIR3: (S06424)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,AADMAAQITKRKWEAAH*# SEQUENCE: AADMAAQITKRKWEAAH*# ...# >HUM21B42# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR2b (43-61)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesu,DVGEFAAVTEKRRPDAEYW*# SEQUENCE: DVGEFAAVTEKRRPDAEYW*# ...# >HUM21B43# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (111-126)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,TPLLMQALPMGALPQG*# SEQUENCE: TPLLMQALPMGALPQG*# ...# >HUM21B44# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (111-125)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,TPLLMQALPMGA LPQ*# SEQUENCE: TPLLMQALPMGA LPQ*# ...# >HUM21B45# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (99-117)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,KPPKPVSKMRMATPLLMQA*# SEQUENCE: KPPKPVSKMRMATPLLMQA*# ...# >HUM21B46# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (579-597)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,IPELNKVARAAA *# SEQUENCE: IPELNKVARAAA *# ...# >HUM21B47# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DQ beta chain (43-55)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,DVEVYRAVTPLGPEVAGQF*# SEQUENCE: DVEVYRAVTPLGPEVAGQF*# ...# >HUM21B48# MHC MOLECULE: HLA-DPw4(DPA1*0501xDPB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DPw4,actunkn,bindyesu,EKKYFAATQFEPLAARL*# SEQUENCE: EKKYFAATQFEPLAARL*# ...# >HUM21B49# MHC MOLECULE: HLA-DPw4(DPA1*0501xDPB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DPw4,actunkn,bindyesu,KKYFAATQFEPLAARL*# SEQUENCE: KKYFAATQFEPLAARL*# ...# >HUM21B4A# MHC MOLECULE: HLA-DPw4(DPA1*0501xDPB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DPw4,actunkn,bindyesu,EKKYFAATQFEPL*# SEQUENCE: EKKYFAATQFEPL*# ...# >HUM21B4B# MHC MOLECULE: HLA-DPw4(DPA1*0501xDPB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IL-3 Receptor alpha chain (127-146)# DB REFERENCE: SWISS: (IL3R_HUMAN,IL3R_HUMAN)# & PIR2: (A40266)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DPw4,actunkn,bindyesu,GPGAPADVQYDLYLNVANRR*# SEQUENCE: GPGAPADVQYDLYLNVANRR*# ...# >HUM21B4C# MHC MOLECULE: HLA-DPw2(DPA1*0102xDPB1*0201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle serum albumin (152-170)# DB REFERENCE: SWISS: (ALBU_BOVIN)# & PIR1: (ABBOS)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DPw2,actunkn,bindyesu,ADEKKFWGKYLYEIARRHP*# SEQUENCE: ADEKKFWGKYLYEIARRHP*# ...# >HUM21B4D# MHC MOLECULE: HLA-DPw2(DPA1*0102xDPB1*0201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (15-31)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# & PIR2: (A48592,S29548)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DPw2,actunkn,bindyesu,GEPLSYTRFSLARQVDG*# SEQUENCE: GEPLSYTRFSLARQVDG*# ...# >HUM21B4E# MHC MOLECULE: HLA-DPw2(DPA1*0102xDPB1*0201), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin H (185-198)# DB REFERENCE: SWISS: (CATH_RAT,CATH_HUMAN,CATH_MOUSE)# & PIR1: (KHHUH,KHRTH)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DPw2,actunkn,bindyesu,LPSQAFEYILYNKG*# SEQUENCE: LPSQAFEYILYNKG*# ...# >HUM21B4F# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQa (97-119)# DB REFERENCE: SWISS: (HA21_HUMAN,HA24_HUMAN)# & PIR1: (HLHUDC,HLHUDQ)# & PIR2: (A29312)# REFERENCES: rammensee95a# COMMENT: HLA-DR51(DRB5*0101) or HLA-DR15(DRB1*1501) binder# SUMMARY: HLA-DR?,actunkn,bindyesu,NIVIKRSNSTAATNEVPEVTVFS*# SEQUENCE: NIVIKRSNSTAATNEVPEVTVFS*# ...# >HUM21B50# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQa (97-112)# DB REFERENCE: SWISS: (HA21_HUMAN,HA24_HUMAN)# & PIR1: (HLHUDQ,HLHUDC)# & PIR2: (A29312)# REFERENCES: rammensee95a# COMMENT: HLA-DR51(DRB5*0101) or HLA-DR15(DRB1*1501) binder# SUMMARY: HLA-DR?,actunkn,bindyesu,NIVIKRSNSTAATNEV*# SEQUENCE: NIVIKRSNSTAATNEV*# ...# >HUM21B51# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQb (42-59)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I61839,I61835,I72481,I68813,I36974,I59528,I84420,I59623,# & I68723,I68732,D35054,I68817)# REFERENCES: rammensee95a# COMMENT: HLA-DR51(DRB5*0101) or HLA-DR15(DRB1*1501) binder# SUMMARY: HLA-DR?,actunkn,bindyesu,SDVGVYRAVTPQGRPDAE*# SEQUENCE: SDVGVYRAVTPQGRPDAE*# ...# >HUM21B52# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQb (43-59)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (D35054,I59623,I84420,I68813,I72481,I61835,I61839,I59528,# & I68817,I36974,I68732,I68723)# REFERENCES: rammensee95a# COMMENT: HLA-DR51(DRB5*0101) or HLA-DR15(DRB1*1501) binder# SUMMARY: HLA-DR?,actunkn,bindyesu,DVGVYRAVTPQGRPDAE*# SEQUENCE: DVGVYRAVTPQGRPDAE*# ...# >HUM21B53# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQb (43-57)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I61839,I68813,I68732,I59528,I36974,I68817,I68723,I72481,# & I61835,I84420,D35054,I59623)# REFERENCES: rammensee95a# COMMENT: HLA-DR51(DRB5*0101) or HLA-DR15(DRB1*1501) binder# SUMMARY: HLA-DR?,actunkn,bindyesu,DVGVYRAVTPQGRPD*# SEQUENCE: DVGVYRAVTPQGRPD*# ...# >HUM21B54# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A29 (234-253)# DB REFERENCE: SWISS: (1A34_HUMAN,1A31_HUMAN,1A31_HUMAN,1A43_HUMAN,1A66_HUMAN,# & 1A26_HUMAN,1A74_HUMAN,1A29_HUMAN,1A33_HUMAN,1A32_HUMAN,# & 1A26_HUMAN,1A25_HUMAN)# & PIR1: (HLHU32)# & PIR2: (I37480,S16769,A37028,I38610,I37483,I37479,JL0135,I72171,# & A45847,I37477,I37482,I72170,I38436,I84487,A35997)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RPAGDGTFQKWASVVVPSGQ*# SEQUENCE: RPAGDGTFQKWASVVVPSGQ*# ...# >HUM21B55# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A29 (234-249)# DB REFERENCE: SWISS: (1A33_HUMAN,1A25_HUMAN,1A26_HUMAN,HA1Q_MOUSE,1A32_HUMAN,# & HA13_MOUSE,HA1K_MOUSE,HA1Y_MOUSE,HA1B_MOUSE,HA1W_MOUSE,# & HA12_MOUSE,1A31_HUMAN,1A31_HUMAN,HA17_MOUSE,HA12_MOUSE,# & 1A74_HUMAN,HA1K_MOUSE,HA1B_MOUSE,HA18_MOUSE,1A29_HUMAN,# & 1A26_HUMAN,HA11_RAT,1A66_HUMAN,HA10_MOUSE,HA13_MOUSE,# & HA11_MOUSE,HA12_RAT,HA17_MOUSE,1A34_HUMAN,HA1Z_MOUSE,# & 1A43_HUMAN,HA11_MOUSE,HA1L_MOUSE)# & PIR1: (HLMS1,HLMSKK,HLMSLD,HLMSTR,HLMSDB,HLMSKB,HLMS2,HLHU32)# & PIR2: (I54554,I71998,I54462,I37479,I54414,A24582,I55665,I72171,# & A45847,I56002,A35997,I37477,A21125,B60854,I68705,I38610,# & I56077,B24582,I72170,I38436,I49713,I84487,A45851,I60188,# & I54069,I57814,S13766,I54531,A60854,I70694,I69009,A53277,# & I37482,S31651,A35090,I57806,JL0135,I54548,I54491,A37028,# & S52367,I68771,I69008,I49712,I37480,S16769,I37483,C60854,# & B35090,I60331)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RPAGDGTFQKWASVVV*# SEQUENCE: RPAGDGTFQKWASVVV*# ...# >HUM21B56# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A29 (237-258)# DB REFERENCE: SWISS: (1A29_HUMAN,1A66_HUMAN,1A74_HUMAN,1A43_HUMAN,1A26_HUMAN,# & 1A31_HUMAN,1A25_HUMAN,1A31_HUMAN,1A33_HUMAN,1A34_HUMAN,# & 1A26_HUMAN,1A32_HUMAN)# & PIR1: (HLHU32)# & PIR2: (I37483,S16769,I37480,I37479,A35997,I37477,I38610,I84487,# & JL0135,A45847,I72171,A37028,I72170,I37482,I38436)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GDGTFQKWASVVVPSGQEQRYT*# SEQUENCE: GDGTFQKWASVVVPSGQEQRYT*# ...# >HUM21B57# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A29 (237-254)# DB REFERENCE: SWISS: (1A34_HUMAN,1A26_HUMAN,1A32_HUMAN,1A33_HUMAN,1A29_HUMAN,# & 1A31_HUMAN,1A26_HUMAN,1A31_HUMAN,1A25_HUMAN,1A43_HUMAN,# & 1A66_HUMAN,1A74_HUMAN)# & PIR1: (HLHU32)# & PIR2: (I37477,I38610,I37482,I72171,A37028,I38436,A45847,JL0135,# & A35997,I37479,I72170,I37483,I37480,S16769,I84487)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GDGTFQKWASVVVPSGQE*# SEQUENCE: GDGTFQKWASVVVPSGQE*# ...# >HUM21B58# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A29 (239-252)# DB REFERENCE: SWISS: (1A31_HUMAN,1A26_HUMAN,1A43_HUMAN,1A66_HUMAN,1A74_HUMAN,# & 1A29_HUMAN,1A33_HUMAN,1A31_HUMAN,1A25_HUMAN,1A32_HUMAN,# & 1A34_HUMAN,1A26_HUMAN)# & PIR1: (HLHU32)# & PIR2: (A45847,JL0135,I37480,I84487,S16769,I37482,I37477,I37479,# & I72170,A37028,I37483,I38436,I72171,I38610,A35997)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GTFQKWASVVVPSG*# SEQUENCE: GTFQKWASVVVPSG*# ...# >HUM21B59# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A29 (239-253)# DB REFERENCE: SWISS: (1A26_HUMAN,1A66_HUMAN,1A26_HUMAN,1A32_HUMAN,1A34_HUMAN,# & 1A31_HUMAN,1A25_HUMAN,1A31_HUMAN,1A43_HUMAN,1A33_HUMAN,# & 1A74_HUMAN,1A29_HUMAN)# & PIR1: (HLHU32)# & PIR2: (JL0135,I84487,I38610,A35997,I37477,I37482,I37479,I72170,# & I37483,A37028,I38436,I72171,S16769,I37480,A45847)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GTFQKWASVVVPSGQ*# SEQUENCE: GTFQKWASVVVPSGQ*# ...# >HUM21B5A# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A29 (239-261)# DB REFERENCE: SWISS: (1A31_HUMAN,1A33_HUMAN,1A74_HUMAN,1A43_HUMAN,1A31_HUMAN,# & 1A25_HUMAN,1A66_HUMAN,1A32_HUMAN,1A26_HUMAN,1A26_HUMAN,# & 1A29_HUMAN,1A34_HUMAN)# & PIR1: (HLHU32)# & PIR2: (I72170,A45847,I37479,I37482,I37480,A35997,A37028,JL0135,# & I38436,I72171,S16769,I38610,I84487,I37483,I37477)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GTFQKWASVVVPSGQEQRYTCHV*# SEQUENCE: GTFQKWASVVVPSGQEQRYTCHV*# ...# >HUM21B5B# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (83-99)# DB REFERENCE: SWISS: (1B41_HUMAN,1B40_HUMAN,1B53_HUMAN,1B42_HUMAN,1B05_HUMAN,# & 1B47_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (B30345,A45850,I37516,S24434,I54442,S25415,I61861)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RETQISKTNTQTYRENL*# SEQUENCE: RETQISKTNTQTYRENL*# ...# >HUM21B5C# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (83-98)# DB REFERENCE: SWISS: (1B47_HUMAN,1B42_HUMAN,1B53_HUMAN,1B05_HUMAN,1B40_HUMAN,# & 1B41_HUMAN)# & PIR1: (HLHUB4)# & PIR2: (S25415,B30345,I37516,A45850,I54442,S24434,I61861)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RETQISKTNTQTYREN*# SEQUENCE: RETQISKTNTQTYREN*# ...# >HUM21B5D# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B44 (83-97)# DB REFERENCE: SWISS: (1B11_HUMAN,1B12_HUMAN,1B41_HUMAN,1B12_HUMAN,1B40_HUMAN,# & 1B47_HUMAN,1B34_HUMAN,1B42_HUMAN,1B36_HUMAN,1B29_HUMAN,# & 1B05_HUMAN,1B45_HUMAN,1B46_HUMAN,1B38_HUMAN,1B33_HUMAN,# & 1B35_HUMAN,1B48_HUMAN,1B43_HUMAN,1B53_HUMAN)# & PIR1: (HLHUB4,HLHU40)# & PIR2: (C35997,I38437,I68748,S24433,S24438,I38421,I61861,B30345,# & I61903,S24437,S24027,I37492,S24434,I56149,I37520,I37519,# & G01230,I61905,I62044,S25415,I61864,I68724,I62043,S52486,# & I61906,A45850,I54442,S16789,I37516)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RETQISKTNTQTYRE*# SEQUENCE: RETQISKTNTQTYRE*# ...# >HUM21B5E# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR a chain (101-126)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,RSNYTPITNPPEVTVLTNSPVELREP*# SEQUENCE: RSNYTPITNPPEVTVLTNSPVELREP*# ...# >HUM21B5F# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR a chain (58-78)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GALANIAVDKANLEIMTKRSN*# SEQUENCE: GALANIAVDKANLEIMTKRSN*# ...# >HUM21B60# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DQ a chain (179-?)# DB REFERENCE: SWISS: (HB2X_HUMAN,HB21_HUMAN)# & PIR1: (HLHUDB)# & PIR2: (D29312)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,SLQSPITVEWRAQSESAQSKMLSGIGGFVL*# SEQUENCE: SLQSPITVEWRAQSESAQSKMLSGIGGFVL*# ...# >HUM21B61# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 4F2 (318-338)# DB REFERENCE: SWISS: (4F2_HUMAN,4F2_HUMAN)# & PIR1: (SAHU4F)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VTQYLNATGNRWCSWSLSQAR*# SEQUENCE: VTQYLNATGNRWCSWSLSQAR*# ...# >HUM21B62# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 4F2 (318-334)# DB REFERENCE: SWISS: (4F2_HUMAN,4F2_HUMAN)# & PIR1: (SAHU4F)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VTQYLNATGNRWCSWSL*# SEQUENCE: VTQYLNATGNRWCSWSL*# ...# >HUM21B63# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LIF receptor (854-866)# DB REFERENCE: SWISS: (LIFR_HUMAN,LIFR_MOUSE)# & PIR2: (S17308,JX0312)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,TSILCYRKREWIK*# SEQUENCE: TSILCYRKREWIK*# ...# >HUM21B64# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Thromboxane-A synthase (406-420)# DB REFERENCE: SWISS: (THAS_MOUSE,THAS_MOUSE,THAS_HUMAN,THAS_RAT,THAS_RAT)# & PIR2: (S48161,S42404,JN0683,B41766,A41766)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,PAFRFTREAAQDCEV*# SEQUENCE: PAFRFTREAAQDCEV*# ...# >HUM21B65# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: K+ channel protein (492-516)# DB REFERENCE: PIR2: (S19552,S13919)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,GDMYPKTWSGMLVGALCALAGVLTI*# SEQUENCE: GDMYPKTWSGMLVGALCALAGVLTI*# ...# >HUM21B66# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hsp 70 (38-54)# DB REFERENCE: SWISS: (HS7H_HUMAN,HS71_BOVIN,HS71_HUMAN,HS72_BOVIN,HS7C_BOVIN,# & HS71_RAT,HS71_MOUSE,HS72_RAT,HS7C_BRARE,HS70_BRUMA,# & HS74_YEAST,HS70_CHLRE,HS70_HYDMA,HS70_CHICK,HS7C_DICDI,# & HS7C_DICDI,HS71_MOUSE,HS7T_MOUSE,HS7C_BOVIN,HS7C_RAT,# & HS7C_HUMAN,HS72_MOUSE,HS70_ONCTS,HS72_MOUSE,HS72_PARLI,# & HS70_XENLA,HS70_PLACB,HS7D_DROME,HS72_HUMAN,HS70_PLAFA,# & HS7T_MOUSE,HS7C_CRIGR,HS73_RAT,HS73_YEAST,HS72_HUMAN,# & HS70_SOYBN,HS70_BRELC,HS7A_CAEEL,HS7C_RAT,HS71_SCHPO,# & HS71_RAT,HS70_THEAN)# & PIR1: (HHUM7B,HHKW7A,HHXL70)# & PIR2: (S14992,S67431,I49761,S37394,A35922,A44985,S36753,PC1156,# & JC4853,S31716,A45871,S10859,S27004,I56574,A45635,S07197,# & JH0095,JC4786,S31766,S21365,JU0164,B36590,A48872,PQ0138,# & B45871,A25646,A36333,S11456,JQ1515,A29160,A55719,S41415,# & S43388,I54542,A48439,A49242,A27077,S08211,S25649,A44979,# & S53498,A45935)# & PIR3: (JC2215)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,TPSYVAFTDTERLIGDA*# SEQUENCE: TPSYVAFTDTERLIGDA*# ...# >HUM21B67# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSP 70 (38-52)# DB REFERENCE: SWISS: (HS7C_BOVIN,HS72_RAT,HS71_MOUSE,HS70_HYDMA,HS71_RAT,# & HS71_BOVIN,HS7H_HUMAN,HS70_SOYBN,HS73_RAT,HS7A_CAEEL,# & HS70_PLACB,HS70_PLAFA,HS7C_RAT,HS7C_RAT,HS71_SCHPO,# & HS70_XENLA,HS73_BOVIN,HS71_RAT,HS70_THEAN,HS72_HUMAN,# & HS7C_CRIGR,HS73_YEAST,HS7T_MOUSE,HS7D_DROME,HS74_YEAST,# & HS7C_BRARE,HS70_BRUMA,HS70_CHLRE,HS70_CHICK,HS72_MOUSE,# & HS71_MOUSE,HS73_BOVIN,HS7T_MOUSE,HS7C_HUMAN,HS7C_DICDI,# & HS72_HUMAN,HS70_BRELC,HS70_ONCTS,HS7C_DICDI,HS7C_BOVIN,# & HS70_PLEWA,HS71_PUCGR,HS72_PARLI,HS72_MOUSE,HS71_HUMAN,# & HS72_BOVIN)# & PIR1: (HHKW7A,HHXL70,HHUM7B)# & PIR2: (S31716,JU0164,A44979,S25649,A29160,S31766,JH0095,S27004,# & A45871,S14992,S37394,S67431,I49761,S41415,A27077,JQ1515,# & S43388,S08211,S53498,A45935,A36333,S11456,A49242,A48439,# & I54542,A55719,S21365,PQ0138,A48872,B36590,B45871,A25646,# & A35922,A44985,A45635,I51129,S07197,JC4786,I56574,S36753,# & JC4853,PC1156,S10859)# & PIR3: (JC2215)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,TPSYVAFTDTERLIG*# SEQUENCE: TPSYVAFTDTERLIG*# ...# >HUM21B68# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV MCP (1264-1282)# DB REFERENCE: SWISS: (VCAP_EBV)# & PIR1: (QQBE45)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VPGLYSPCRAFFNKEELL*# SEQUENCE: VPGLYSPCRAFFNKEELL*# ...# >HUM21B69# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV MCP (1264-1277)# DB REFERENCE: SWISS: (VCAP_EBV)# & PIR1: (QQBE45)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VPGLYSPCRAFFNK*# SEQUENCE: VPGLYSPCRAFFNK*# ...# >HUM21B6A# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B 100 (1586-1608)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,KVDLTFSKQHALLCSDYQADYES*# SEQUENCE: KVDLTFSKQHALLCSDYQADYES*# ...# >HUM21B6B# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B 100 (1586-1600)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,KVDLTFSKQHALLCS*# SEQUENCE: KVDLTFSKQHALLCS*# ...# >HUM21B6C# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B 100 1942 (-1954)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,FSHDYRGSTSHRL*# SEQUENCE: FSHDYRGSTSHRL*# ...# >HUM21B6D# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B 100 (2077-2089)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,LPKYFEKKRNTII*# SEQUENCE: LPKYFEKKRNTII*# ...# >HUM21B6E# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Complement C9 (465-483)# DB REFERENCE: SWISS: (CO9_HUMAN,CO9_HUMAN)# & PIR1: (C9HU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,APVLISQKLSPIYNLVPVK*# SEQUENCE: APVLISQKLSPIYNLVPVK*# ...# >HUM21B6F# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A2 (103-120)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I61857,I84448,I37542,I61902,I38443,I38442)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,VGSDWRFLRGYHQYAYDG*# SEQUENCE: VGSDWRFLRGYHQYAYDG*# ...# >HUM21B70# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (98-119)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,PKPPKPVSKMRMATPLLMQALP*# SEQUENCE: PKPPKPVSKMRMATPLLMQALP*# ...# >HUM21B71# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DRa chain (182-200)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I72480,I56085)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,APSPLPETTENVVCALGLTV*# SEQUENCE: APSPLPETTENVVCALGLTV*# ...# >HUM21B72# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig kappa chain (188-201)# DB REFERENCE: SWISS: (KAC_HUMAN)# & PIR1: (K3HU)# & PIR2: (S02577)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,KHKVYACEVTHQGL*# SEQUENCE: KHKVYACEVTHQGL*# ...# >HUM21B73# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (182-198)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,APSPLPETTENVVCALG*# SEQUENCE: APSPLPETTENVVCALG*# ...# >HUM21B74# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha chain (158-180)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I72480,I56085)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,SETVFLPREDHLFRKFHYLPFLP*# SEQUENCE: SETVFLPREDHLFRKFHYLPFLP*# ...# >HUM21B75# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DP beta chain (80-92)# DB REFERENCE: SWISS: (HB2S_HUMAN)# & PIR1: (HLHUS1)# & PIR2: (E30536,H30536,I68795,A39247,I84461,I59636,F30536,G30536,# & C39247,D39247,I81235,I81238,D30537,I59621,I68562,I68794,# & I68800,I68796,I59642,S49382,I68788,I59648,I54303,I54458,# & I68799,I37541,I54506,I68793,A30537)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RHNYELDEAVTLQ*# SEQUENCE: RHNYELDEAVTLQ*# ...# >HUM21B76# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAM Blast-1 (88-108)# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DPQSGALYISKVQKEDNSTYI*# SEQUENCE: DPQSGALYISKVQKEDNSTYI*# ...# >HUM21B77# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAM Blast-1 (92-108)# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,GALYISKVQKEDNSTYI*# SEQUENCE: GALYISKVQKEDNSTYI*# ...# >HUM21B78# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAM Blast-1 (129-146)# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DPVPKPVIKIEKIEDMDD*# SEQUENCE: DPVPKPVIKIEKIEDMDD*# ...# >HUM21B79# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAM Blast-1 (129-143)# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DPVPKPVIKIEKIED*# SEQUENCE: DPVPKPVIKIEKIED*# ...# >HUM21B7A# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig k chain (63-80)# DB REFERENCE: PIR2: (S16823)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,FTFTISRLEPEDFAVYYC*# SEQUENCE: FTFTISRLEPEDFAVYYC*# ...# >HUM21B7B# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig k chain (63-77)# DB REFERENCE: PIR2: (S16823)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,FTFTISRLEPEDFAV*# SEQUENCE: FTFTISRLEPEDFAV*# ...# >HUM21B7C# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LAR (1302-1316)# DB REFERENCE: SWISS: (PTPF_HUMAN)# & PIR1: (TDHULK)# & PIR2: (A56493,S46216)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DPVEMRRLNYQTPG*# SEQUENCE: DPVEMRRLNYQTPG*# ...# >HUM21B7D# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LIF receptor (709-726)# DB REFERENCE: SWISS: (LIFR_HUMAN)# & PIR2: (S17308)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,YQLLRSMIGYIEELAPIV*# SEQUENCE: YQLLRSMIGYIEELAPIV*# ...# >HUM21B7E# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IFN-a receptor (271-287)# DB REFERENCE: SWISS: (INR1_HUMAN,INR1_HUMAN)# & PIR2: (S17112,A32694)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,GNHLYKWKQIPDCENVK*# SEQUENCE: GNHLYKWKQIPDCENVK*# ...# >HUM21B7F# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IL-8 receptor (169-188)# DB REFERENCE: SWISS: (IL8A_PANTR,IL8A_HUMAN,IL8A_PONPY,IL8A_GORGO)# & PIR2: (A39445)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,LPFFLFRQAYHPNNSSPVCY*# SEQUENCE: LPFFLFRQAYHPNNSSPVCY*# ...# >HUM21B80# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ca2+ release channel (2614-2623)# DB REFERENCE: SWISS: (RYNR_RABIT,RYNR_PIG,RYNR_HUMAN,RYNR_PIG)# & PIR2: (I46646,S31395,A54161,I47133,A35041,S18135,I46645,# & B35041)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RPSMLQHLLR*# SEQUENCE: RPSMLQHLLR*# ...# >HUM21B81# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD35 (359-380)# DB REFERENCE: SWISS: (CR1_HUMAN,CR1_HUMAN)# & PIR2: (S03291,I36937,A28507,I36936,I73012)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DDFMGQLLNGRVLFPVNLQLGA*# SEQUENCE: DDFMGQLLNGRVLFPVNLQLGA*# ...# >HUM21B82# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD75 (106-122)# DB REFERENCE: SWISS: (CAG1_HUMAN,CAG1_HUMAN)# & PIR2: (A41734)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,IPRLQKIWKNYLSMNKY*# SEQUENCE: IPRLQKIWKNYLSMNKY*# ...# >HUM21B83# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Calcitonin receptor (38-53)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,EPFLYILGKSRVLEAQ*# SEQUENCE: EPFLYILGKSRVLEAQ*# ...# >HUM21B84# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-1 (101-118)# DB REFERENCE: SWISS: (TIM1_HUMAN,TIM1_PAPCY,TIM1_HUMAN)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,NRSEEFLIAGKLQDGLLH*# SEQUENCE: NRSEEFLIAGKLQDGLLH*# ...# >HUM21B85# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-1 (102-117)# DB REFERENCE: SWISS: (TIM1_HUMAN,TIM1_PAPCY,TIM1_HUMAN)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RSEEFLIAGKLQDGLL*# SEQUENCE: RSEEFLIAGKLQDGLL*# ...# >HUM21B86# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-1 (103-117)# DB REFERENCE: SWISS: (TIM1_HUMAN,TIM1_PAPCY,TIM1_HUMAN)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,SEEFLIAGKLQDGLL*# SEQUENCE: SEEFLIAGKLQDGLL*# ...# >HUM21B87# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-1 (101-112)# DB REFERENCE: SWISS: (TIM1_HUMAN,TIM1_PAPCY,TIM1_HUMAN)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,NRSEEFLIAGKL*# SEQUENCE: NRSEEFLIAGKL*# ...# >HUM21B88# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-2 (187-214)# DB REFERENCE: SWISS: (TIM2_MOUSE,TIM2_RAT,TIM2_BOVIN,TIM2_HUMAN,TIM2_HUMAN)# & PIR1: (A35996,A37128,S38624)# & PIR2: (S45683,JH0683,I53415)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,QAKFFACIKRSDGSCAWYRGAAPPKQEF*# SEQUENCE: QAKFFACIKRSDGSCAWYRGAAPPKQEF*# ...# >HUM21B89# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TIMP-2 (187-205)# DB REFERENCE: SWISS: (TIM2_RAT,TIM2_HUMAN,TIM2_HUMAN,TIM2_BOVIN,TIM2_MOUSE)# & PIR1: (A37128,A35996,S38624)# & PIR2: (JH0683,S45683,I53415)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,QAKFFACIKRSDGSCAWYR*# SEQUENCE: QAKFFACIKRSDGSCAWYR*# ...# >HUM21B8A# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PAI-1 (378-396)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DRPFLFWRHNPTGTVLFM*# SEQUENCE: DRPFLFWRHNPTGTVLFM*# ...# >HUM21B8B# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PAI-1 (133-148)# DB REFERENCE: SWISS: (PAI1_HUMAN,PAI1_HUMAN)# & PIR1: (ITHUP1)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,MPHFFRLFRSTVKQVD*# SEQUENCE: MPHFFRLFRSTVKQVD*# ...# >HUM21B8C# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin E (89-112)# DB REFERENCE: SWISS: (CATE_MOUSE,CATE_CAVPO,CATE_CAVPO,CATE_HUMAN)# & PIR2: (A34401,S66465,A43356)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,QNFTVIFDTGSSNLWVPSVYCTSP*# SEQUENCE: QNFTVIFDTGSSNLWVPSVYCTSP*# ...# >HUM21B8D# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin E (89-104)# DB REFERENCE: SWISS: (CATE_HUMAN,ASPR_ORYSA,CATE_RAT,CATE_CAVPO,CATE_CAVPO,# & CATE_MOUSE)# & PIR2: (JC5077,S66465,S66466,JS0732,A34401,A43356)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,QNFTVIFDTGSSNLWV*# SEQUENCE: QNFTVIFDTGSSNLWV*# ...# >HUM21B8E# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin S (189-205)# DB REFERENCE: SWISS: (CATS_HUMAN)# & PIR2: (A42482)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,TAFQYIIDNKGIDSDAS*# SEQUENCE: TAFQYIIDNKGIDSDAS*# ...# >HUM21B8F# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cystatin SN (41-58)# DB REFERENCE: SWISS: (CYTT_HUMAN)# & PIR2: (B29632)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DEYYRRLLRVLRAREQIV*# SEQUENCE: DEYYRRLLRVLRAREQIV*# ...# >HUM21B90# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Tubulin alpha-1 chain (207-223)# DB REFERENCE: SWISS: (TBA1_CHICK,TBA_EUGGR,TBA8_CHICK,TBA_PIG,TBA_TETTH,# & TBA2_DROME,TBA1_HUMAN,TBA_XENLA,TBA6_MOUSE,TBA4_HUMAN,# & TBA2_MOUSE,TBA3_DROME,TBA_TETPY,TBA_TORMA,TBA3_MOUSE,# & TBA1_CRIGR,TBA5_CHICK,TBA1_RAT,TBA1_DROME,TBAT_ONCMY,# & TBA_PLAFK,TBA2_PATVU,TBA_TOXGO,TBA1_PARLI)# & PIR1: (UBCHA8,UBCHA,UBCHA5,UBRTA,UBPGA)# & PIR2: (I77425,C26488,A23035,I77427,S01767,I77424,B26488,A56622,# & I77403,B24903,S33512,S33517,I77428,C24903,A26488,JC4133,# & S07459,A61275,S42033,A24903,A48433,I77426,S00253,A25873,# & I57568,A60671,S16339,S11207)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,EAIYDICRRNLDIERPT*# SEQUENCE: EAIYDICRRNLDIERPT*# ...# >HUM21B91# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Tubulin alpha-1 chain (207-219)# DB REFERENCE: SWISS: (TBA3_DROME,TBA2_MOUSE,TBA1_CHICK,TBA_TETTH,TBA_PIG,# & TBA8_CHICK,TBA5_CHICK,TBAT_ONCMY,TBA2_PATVU,TBA_EUGGR,# & TBA_TORMA,TBA1_HUMAN,TBA1_CRIGR,TBA1_RAT,TBA_HAECO,# & TBA1_PARLI,TBA_TOXGO,TBA_PLAFK,TBA3_MOUSE,TBA1_DROME,# & TBA_XENLA,TBA6_MOUSE,TBA_ONCKE,TBA_TETPY,TBA4_HUMAN,# & TBA1_PNECA,TBA2_DROME,TBA_BOMMO)# & PIR1: (UBCHA5,UBCHA8,UBPGA,UBRTA,UBCHA)# & PIR2: (S07459,A48466,B26488,A56622,I77424,S01767,A24903,A48433,# & A61275,S42033,I57568,A56635,C26488,A23035,S52152,A60671,# & S00253,S25004,I77426,S43138,JC4133,C24903,S33512,JU0154,# & A26488,I77428,I77403,I77427,I77425,A25873,S16339,S11207,# & B24903,S33517)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,EAIYDICRRNLDI*# SEQUENCE: EAIYDICRRNLDI*# ...# >HUM21B92# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Myosin B heavy chain (1027-1047)# DB REFERENCE: SWISS: (MYSP_HUMAN)# & PIR2: (I38055,S12459,A30220)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,HELEKIKKQVEQEKCEIQAAL*# SEQUENCE: HELEKIKKQVEQEKCEIQAAL*# ...# >HUM21B93# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: alpha-enolase (23-?)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,AEVYHDVAASEFF*# SEQUENCE: AEVYHDVAASEFF*# ...# >HUM21B94# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: c-myc (371-385)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,KRSFFALRDQIPDL*# SEQUENCE: KRSFFALRDQIPDL*# ...# >HUM21B95# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: K-ras (164-180)# DB REFERENCE: SWISS: (RASK_HUMAN,RASK_MSVKI,RASK_MSVKI,RASK_MOUSE)# & PIR1: (TVMSK,TVMV2K,TVHUK)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,RQYRLKKISKEEKTPGC*# SEQUENCE: RQYRLKKISKEEKTPGC*# ...# >HUM21B96# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (1724-1743)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,KNIFHFKVNQEGLKLSNDMM*# SEQUENCE: KNIFHFKVNQEGLKLSNDMM*# ...# >HUM21B97# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (1724-1739)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,KNIFHFKVNQEGLKLS*# SEQUENCE: KNIFHFKVNQEGLKLS*# ...# >HUM21B98# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (1780-1799)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,YKQTVSLDIQPYSLVTTLNS*# SEQUENCE: YKQTVSLDIQPYSLVTTLNS*# ...# >HUM21B99# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (2646-2662)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,STPEFTILNTLHIPSFT*# SEQUENCE: STPEFTILNTLHIPSFT*# ...# >HUM21B9A# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (2647-2664)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,TPEFTILNTLHIPSFTID*# SEQUENCE: TPEFTILNTLHIPSFTID*# ...# >HUM21B9B# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (2647-2662)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,TPEFTILNTLHIPSFT*# SEQUENCE: TPEFTILNTLHIPSFT*# ...# >HUM21B9C# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (2885-2900)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,SNTKYFHKLNIPQLDF*# SEQUENCE: SNTKYFHKLNIPQLDF*# ...# >HUM21B9D# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (2072-2088)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,LPFFKFLPKYFEKKRNT*# SEQUENCE: LPFFKFLPKYFEKKRNT*# ...# >HUM21B9E# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (2072-2086)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,LPFFKFLPKYFEKKR*# SEQUENCE: LPFFKFLPKYFEKKR*# ...# >HUM21B9F# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (4022-4036)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,WNFYYSPQS SPDKKL*# SEQUENCE: WNFYYSPQS SPDKKL*# ...# >HUM21BA0# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle transferrin (261-281)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DVIWELLNHAQEHFGKDKSKE*# SEQUENCE: DVIWELLNHAQEHFGKDKSKE*# ...# >HUM21BA1# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle transferrin (261-275)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DVIWELLNHAQEHFG*# SEQUENCE: DVIWELLNHAQEHFG*# ...# >HUM21BA2# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle transferrin (261-273)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,DVIWELLNHAQEH*# SEQUENCE: DVIWELLNHAQEH*# ...# >HUM21BA3# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: von Willebrand factor (617-636)# DB REFERENCE: SWISS: (VWF_HUMAN,VWF_HUMAN)# & PIR1: (VWHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,IALLLMASQEPQRMSRNFVR*# SEQUENCE: IALLLMASQEPQRMSRNFVR*# ...# >HUM21BA4# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: von Willebrand factor (617-630)# DB REFERENCE: SWISS: (VWF_HUMAN,VWF_HUMAN)# & PIR1: (VWHU)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,IALLLMASQEPQRM*# SEQUENCE: IALLLMASQEPQRM*# ...# >HUM21BA5# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. Apolipoprotein (3345-3360)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR11 or HLA-DRw52# SUMMARY: HLA-DR?,actunkn,bindyesu,SXVITLNTNVGLYXQS*# SEQUENCE: SXVITLNTNVGLYXQS*# ...# >HUM21BA6# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR11 or HLA-DRw52# SUMMARY: HLA-DR?,actunkn,bindyesu,DPXQDELQKLNAXDP*# SEQUENCE: DPXQDELQKLNAXDP*# ...# >HUM21BA7# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homol. Transferrin receptor (580-595)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR11 or HLA-DRw52# SUMMARY: HLA-DR?,actunkn,bindyesu,XPELNKVARAAAEVAG*# SEQUENCE: XPELNKVARAAAEVAG*# ...# >HUM21BA8# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glucose transporter (459-474)# DB REFERENCE: SWISS: (GTR1_RABIT,GTR1_RABIT,GTR1_MOUSE,GTR1_BOVIN,GTR1_HUMAN,# & GTR1_BOVIN,GTR1_PIG,GTR1_RAT,GTR1_MOUSE,GTR1_PIG,# & GTR1_RAT)# & PIR2: (A25949,S09705,I45902,A27217,S04223,A30797)# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR17 or HLA-DRw52# SUMMARY: HLA-DR?,actunkn,bindyesu,TFDEIASGFRQGGASQ*# SEQUENCE: TFDEIASGFRQGGASQ*# ...# >HUM21BA9# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Na+ channel protein (384-397)# DB REFERENCE: SWISS: (CIN4_HUMAN,CIN4_RAT)# & PIR1: (CHRTM1)# & PIR2: (I54323,JS0648,I51964,I64893)# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR17 or HLA-DRw52# SUMMARY: HLA-DR?,actunkn,bindyesu,YGYTSYDTFSWAFL*# SEQUENCE: YGYTSYDTFSWAFL*# ...# >HUM21BAA# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD45 (1071-1084)# DB REFERENCE: SWISS: (CD45_HUMAN,CD45_HUMAN)# & PIR2: (A46546)# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR17 or HLA-DRw52# SUMMARY: HLA-DR8,actunkn,bindyesu,GQVKKNNHQEDKIE*# SEQUENCE: GQVKKNNHQEDKIE*# ...# >HUM21BAB# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV gp220 (592-606)# DB REFERENCE: SWISS: (VGP3_EBV,VGP3_EBVA8)# & PIR1: (QQBE21,QQBE22)# & PIR2: (S29605)# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR17 or HLA-DRw52# SUMMARY: HLA-DR?,actunkn,bindyesu,TGHGARTSTEPTTDY*# SEQUENCE: TGHGARTSTEPTTDY*# ...# >HUM21BAC# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV tegument p140 (1395-1407)# DB REFERENCE: SWISS: (TEGU_EBV)# & PIR1: (QQBE8)# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR17 or HLA-DRw52# SUMMARY: HLA-DR?,actunkn,bindyesu,KELKRQYEKKLRQ*# SEQUENCE: KELKRQYEKKLRQ*# ...# >HUM21BAD# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IP 30 (38-59)# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708)# REFERENCES: rammensee95a# COMMENT: binder to HLA-DR17 or HLA-DRw52# SUMMARY: HLA-DR?,actunkn,bindyesu,SPLQALDFFGNGPPVNYKTGNL*# SEQUENCE: SPLQALDFFGNGPPVNYKTGNL*# ...# >MUS21BAE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta2m (42-56)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,HPPHIEIQMLKNGKK*# SEQUENCE: HPPHIEIQMLKNGKK*# ...# >MUS21BAF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSC70 (234-248)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,DNRMVHFIAEFKRK*# SEQUENCE: DNRMVHFIAEFKRK*# ...# >MUS21BB0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serum albumin (347-361)# DB REFERENCE: SWISS: (ALBU_RAT,ALBU_MOUSE,ALBU_RAT,ALBU_MOUSE)# & PIR1: (ABRTS)# & PIR2: (A05139)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,TPTLVEAARNLGRVG*# SEQUENCE: TPTLVEAARNLGRVG*# ...# >MUS21BB1# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: C cyt inhib. (41-55)# DB REFERENCE: SWISS: (CLUS_RAT)# & PIR2: (A27205)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,VNKEIQNAVQGVKHI*# SEQUENCE: VNKEIQNAVQGVKHI*# ...# >MUS21BB2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ER60 (448-461)# DB REFERENCE: SWISS: (ER60_MOUSE,ER60_HUMAN,ER60_MOUSE,ER60_RAT,ER60_RAT,# & ER60_HUMAN)# & PIR1: (A28807)# & PIR2: (S55507,S63994,S68363,S41661,G02888)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,GFPTIYFSPANKKL*# SEQUENCE: GFPTIYFSPANKKL*# ...# >MUS21BB3# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,IPLIMLINKARNKAE*# SEQUENCE: IPLIMLINKARNKAE*# ...# >MUS21BB4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: alpha1-antitryp. (397-410)# DB REFERENCE: SWISS: (A1AT_BOVIN,A1AT_BOVIN,A1AT_SHEEP)# & PIR1: (ITSH)# & PIR2: (S21097)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,YDRNTKSPLFVGKV*# SEQUENCE: YDRNTKSPLFVGKV*# ...# >MUS21BB5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,FAEFGTLKKAAVHYDRSG*# SEQUENCE: FAEFGTLKKAAVHYDRSG*# ...# >MUS21BB6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human dead box protein?# ANCHOR POSITIONS:# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,LHLGYLPNQLFR*# SEQUENCE: LHLGYLPNQLFR*# ...# >MUS21BB7# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference/eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle fetuin (342-)# DB REFERENCE: SWISS: (A2HS_BOVIN,A2HS_BOVIN)# & PIR2: (A35714)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,IPGGPVRLCPGRIR*# SEQUENCE: IPGGPVRLCPGRIR*# ...# >MUS21BB8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MCC (91-103)# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,RADLIAYLKQATK*# SEQUENCE: RADLIAYLKQATK*# ...# >MUS21BB9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PCC (91-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,RADLIAYLKQATAK*# SEQUENCE: RADLIAYLKQATAK*# ...# >MUS21BBA# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SWMb (66-78)# DB REFERENCE: SWISS: (MYG_KOGSI,MYG_PHYCA,MYG_PHYCA)# & PIR1: (MYWHP,MYWHW)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,VTVLTALGAILKK*# SEQUENCE: VTVLTALGAILKK*# ...# >MUS21BBB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EqMb (69-77)# DB REFERENCE: SWISS: (MYG_LUTLU,MYG_LAGMA,MYG_HUMAN,MYG_ERIEU,MYG_ORYAF,# & MYG_LYCPI,MYG_PROGU,MYG_SHEEP,MYG_PERPO,MYG_BALAC,# & MYG_BOVIN,MYG_VULCH,MYG_BOVIN,MYG_PIG,MYG_INIGE,# & MYG_ELEMA,MYG_ZALCA,MYG_CEBAP,MYG_GALCR,MYG_AOTTR,# & MYG_HYLAG,MYG_ESCGI,MYG_BALPH,MYG_CALJA,MYG_SPAEH,# & MYG_PAPAN,MYG_PHOSI,MYG_NYCCO,MYG_HORSE,MYG_ZIPCA,# & MYG_SAISC,MYG_HORSE,MYG_MACFA,MYG_ONDZI,MYG_PHOPH,# & MYG_ROUAE,MYG_LEPMU,MYG_LAGLA,MYG_MEGNO,MYG_MELME,# & MYG_GORBE,MYG_PANTR,MYG_MESCA,MYG_CEREL,MYG_LOXAF,# & MYG_CANFA,MYG_PONPY,MYG_HALGR)# & PIR1: (MYGO,MYHO,MYOT,MYMQHL,MYCZ,MYMQIM,MYBO,MYSH,MYMQW,MYMQN,# & MYGI,MYDE,MYWHH,MYWHF,MYMQS,MYHOZ,MYMQC,MYMQRG,MYPG,# & MYHU,MYZC,MYHH,MYPED,MYLR,MYSLH,MYOY,MYDDAR,MYLP,MYBD,# & MYKS,MYELA,MYPE,MYELI,MYCJ,MYOL,MYWHC,MYSLG,MYWHZ,MYBAO,# & PN0126,MYVJ,MYOG,MYWHK,MYWHU)# & PIR2: (JN0344)# & PIR3: (A61366)# REFERENCES: rammensee95a,harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LTALGGILK*# SEQUENCE: LTALGGILK*# ...# >MUS21BBC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MoMb (69-77)# DB REFERENCE: SWISS: (MYG_MOUSE,MYG_MOUSE)# & PIR1: (MYMS)# REFERENCES: rammensee95a,harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LTALGTILK*# SEQUENCE: LTALGTILK*# ...# >MUS21BBD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MoHb (68-76)# DB REFERENCE: SWISS: (HBB2_MOUSE,HBB2_MOUSE)# & PIR1: (HBMSN1)# REFERENCES: rammensee95a,harris93e,schild95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,ITAFNEGLK*# SEQUENCE: ITAFNEGLK*# ...# >MUS21BBE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (108-119)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPCA,LYC_SYRRE,LYC_COTJA,LYC_CHRAM,# & LYC_PAVCR,LYC_MELGA,LYC_CHICK,LYC_COLVI,LYC3_ANAPL,# & LYC_LOPLE)# & PIR1: (LZQJEC,LZDK3,LZCH,LZQJE,LZTK)# & PIR2: (JU0237,JT0526,JQ1033,JQ1041)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,WVAWRNRCKGTD*# SEQUENCE: WVAWRNRCKGTD*# ...# >MUS21BBF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SNase (121-140)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,HEHQLRKSEAQAKKEKLNIW*# SEQUENCE: HEHQLRKSEAQAKKEKLNIW*# ...# >MUS21BC0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LLO (218-226)# DB REFERENCE: SWISS: (TACY_LISMO,TACY_LISSE)# & PIR2: (S24231,A43505,S22340)# REFERENCES: rammensee95a,harris93e,schild95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,IAKFGTAFK*# SEQUENCE: IAKFGTAFK*# ...# >MUS21BC1# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ig lambda (91-108)# DB REFERENCE: SWISS: (LV2B_MOUSE)# & PIR1: (L2MS35)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,ALWFRNHFVFGGGTKVTV*# SEQUENCE: ALWFRNHFVFGGGTKVTV*# ...# >MUS21BC2# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SWM (102-118)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_ORCOR,MYG_PHOPH,MYG_GLOME,MYG_INIGE,# & MYG_PHYCA,MYG_KOGSI,MYG_TURTR)# & PIR1: (MYPE,MYDD,MYPED,MYDDBS,MYWHL,MYDDAR,MYWHW,MYWHP,MYWHT)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,KYLEFISEAIIHVLHSR*# SEQUENCE: KYLEFISEAIIHVLHSR*# ...# >MUS21BC3# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (108-119)# DB REFERENCE: SWISS: (LYC_COTJA,LYC3_ANAPL,LYC_CHICK,LYC_LOPCA,LYC_CHICK,# & LYC_SYRRE,LYC_COLVI,LYC_MELGA,LYC_LOPLE,LYC_CHRAM,# & LYC_PAVCR)# & PIR1: (LZQJEC,LZCH,LZQJE,LZTK,LZDK3)# & PIR2: (JQ1033,JT0526,JU0237,JQ1041)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,WVAWRNRCKGTD*# SEQUENCE: WVAWRNRCKGTD*# ...# >MUS21BC4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SNase (112-129)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,AYVYKPNNTHEQHLRKSE*# SEQUENCE: AYVYKPNNTHEQHLRKSE*# ...# >MUS21BC5# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: FLU PR/8 HA (109-119)# DB REFERENCE: SWISS: (HEMA_IAUSS,HEMA_IAHAR,HEMA_IACAO,HEMA_IALEN,HEMA_IAKIE,# & HEMA_IAXIA,HEMA_IAPUE,HEMA_IATAI,HEMA_IAZNJ,# & HEMA_IAZIN)# & PIR1: (HMIVUR,HMIVTA,HMIVN1,HMIV17,HMIV)# & PIR2: (JQ1437,A35788,JQ1643,PQ0321,PQ0319,JQ2370,JQ2372,# & JQ2371)# & PIR3: (S69886,S69889,S69888)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,SSFERFEIFPK*# SEQUENCE: SSFERFEIFPK*# ...# >MUS21BC6# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gag p17 (17-28)# DB REFERENCE: SWISS: (GAG_HV1JR,GAG_HV1MN,GAG_HV2ST,GAG_HV1A2,GAG_HV1H2,# & GAG_HV1EL,GAG_HV1W2,GAG_HV1BR,GAG_HV2KR,GAG_HV1Z2,# & GAG_SIVMK,GAG_HV1PV,GAG_HV2SB,GAG_SIVM1,GAG_HV1OY,# & GAG_HV1J3,GAG_HV1MA,GAG_HV2NZ,GAG_HV1B5,GAG_HV1B1)# & PIR1: (FOLJST,FOLJG3,FOVWA2,A38068,FOVWH3,FOLJG5,FOVWLV,# & FOVWVL)# & PIR2: (S54377,S03070)# & PIR3: (S33979)# REFERENCES: rammensee95a,schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,EKIRLRPGGKKK*# SEQUENCE: EKIRLRPGGKKK*# ...# >MUS21BC7# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLVenv (255-269)# DB REFERENCE: SWISS: (ENV_MLVRK,ENV_MLVRD,ENV_MLVAV)# & PIR1: (VCMVKA,VCMVVR,VCVWEK)# & PIR2: (A46511)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,IRLKITDSGPRVPIGPN*# SEQUENCE: IRLKITDSGPRVPIGPN*# ...# >MUS21BC8# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLVenv (255-267)# DB REFERENCE: SWISS: (ENV_MLVAV,ENV_MLVRK,ENV_MLVRD)# & PIR1: (VCMVVR,VCMVKA,VCVWEK)# & PIR2: (A46511)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,IRLKITDSGPRVPIG*# SEQUENCE: IRLKITDSGPRVPIG*# ...# >MUS21BC9# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgG2a (194-210)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,WQSQSITCNVAHPASST*# SEQUENCE: WQSQSITCNVAHPASST*# ...# >MUS21BCA# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgG2a (281-296)# DB REFERENCE: SWISS: (GCB_MOUSE,GCAB_MOUSE,GCB_MOUSE,GCAM_MOUSE,GCBM_MOUSE,# & GCAA_MOUSE)# & PIR1: (G2MSBM,G2MS11,G2MSAM,G2MSAB,G2MSA)# & PIR2: (B30503,A30503,S37483)# & PIR3: (S25057)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,NVEVHTAQTQTHREDY*# SEQUENCE: NVEVHTAQTQTHREDY*# ...# >MUS21BCB# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (203-218)# DB REFERENCE: PIR2: (S29548)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,KPTEVSGKLVHANFGT*# SEQUENCE: KPTEVSGKLVHANFGT*# ...# >MUS21BCC# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesu,XPYMFADKWHLPGSQ*# SEQUENCE: XPYMFADKWHLPGSQ*# ...# >MUS21BCD# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cys-C (40-55)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,DAYHSRAIQWRARKQ*# SEQUENCE: DAYHSRAIQWRARKQ*# ...# >MUS21BCE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apo-E (237-252)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,EQTQQIRLQAE I FQAR*# SEQUENCE: EQTQQIRLQAE I FQAR*# ...# >MUS21BCF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Tf recp. (442-459)# ANCHOR POSITIONS:# REFERENCES: rammensee95a,rider96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,VPQLNQMVRTAAEVAGQX*# SEQUENCE: VPQLNQMVRTAAEVAGQX*# ...# >MUS21BD0# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hen egg lysozyme (48-62)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHRAM,LYC_PAVCR,LYC_LOPLE,LYC1_ANAPL,# & LYC_MELGA,LYC_PHAVE,LYC_PHACO,LYC_SYRRE,LYC_CHICK)# & PIR1: (LZQJE,LZCH,LZDK,LZTK)# & PIR2: (JU0237,JC2144,JQ1041,JU0178,JT0526,JQ1033)# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,DGSTDYGILQINSRW*# SEQUENCE: DGSTDYGILQINSRW*# ...# >MUS21BD1# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,XQLGAQNEMLXPL*# SEQUENCE: XQLGAQNEMLXPL*# ...# >MUS21BD2# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin (100-113)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,XXKKGTDFQLNQLE*# SEQUENCE: XXKKGTDFQLNQLE*# ...# >MUS21BD3# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: H-2A beta k (37-51)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,YVRFDSFVGEYRAVT*# SEQUENCE: YVRFDSFVGEYRAVT*# ...# >MUS21BD4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: H-2E beta k (33-47)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,XNLRFDSDVGEFRAV*# SEQUENCE: XNLRFDSDVGEFRAV*# ...# >MUS21BD5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBI (177-194)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,EDENLYEGLNLDDXSMYE*# SEQUENCE: EDENLYEGLNLDDXSMYE*# ...# >MUS21BD6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin H (77-92)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,XXLYNKGINGEDSYPY*# SEQUENCE: XXLYNKGINGEDSYPY*# ...# >MUS21BD7# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Fce-Receptor II (298-310)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,SYLDAXVXEQLAT*# SEQUENCE: SYLDAXVXEQLAT*# ...# >MUS21BD8# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: H-2A beta k (3-17)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,XXXHFVHQFQPFCYF*# SEQUENCE: XXXHFVHQFQPFCYF*# ...# >MUS21BD9# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: H-2A beta k (10-20)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,QFQPFXYFTNT*# SEQUENCE: QFQPFXYFTNT*# ...# >MUS21BDA# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hnRNP B1/A2 (31-43)# DB REFERENCE: SWISS: (RO21_XENLA,ROA2_HUMAN,ROA2_HUMAN)# & PIR2: (B34504,S40775)# REFERENCES: rammensee95a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,ETTEESLRNYYEQ*# SEQUENCE: ETTEESLRNYYEQ*# ...# >MUS21BDB# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hnRNPA2/Bl (51-66)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,WMRDPASKRSRGFGF*# SEQUENCE: WMRDPASKRSRGFGF*# ...# >MUS21BDC# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hnRNP Al (44-59)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,WMRDPQTKRSRGFGF*# SEQUENCE: WMRDPQTKRSRGFGF*# ...# >MUS21BDD# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta globin major (33-45)# ANCHOR POSITIONS:# REFERENCES: rammensee95a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,WYPWTQRYFDSF*# SEQUENCE: WYPWTQRYFDSF*# ...# >HUM11BDE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reference/Stabilization/Competition/Half-time/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: gp100 (457-466)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,I38400,A41234)# REFERENCES: kawakami94b,kawakami95b,van_der_burg96a,kawakami96a,romero96a,# & van-elsas96a,maccalli97a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesm,LLDGTATLRL*# SEQUENCE: LLDGTATLRL*# ...# >HUM11BDF# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as./cytotoxicity as./Reference# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: gp100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A53668,I38400)# REFERENCES: kawakami95b,rivoltini95b, kawakami96a,romero96a,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM11BE0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: gp100 (154-163)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A53668,A41234)# REFERENCES: kawakami95b# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,KTWGQYWQVL*# SEQUENCE: KTWGQYWQVL*# ...# >HUM11BE1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/Recognition/Reference/CTL assays# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: gp100 (209-217)# DB REFERENCE: SWISS: (PM17_BOVIN,PM17_MOUSE,PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A49179,S53871,I38400,A53668)# REFERENCES: kawakami95b,parkhurst96a,kawakami96a,romero96a,maccalli97a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesh,bindyesm,ITDQVPFSV*# SEQUENCE: ITDQVPFSV*# ...# >HUM11BE2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: gp100 (208-217)# DB REFERENCE: SWISS: (PM17_BOVIN,PM17_MOUSE,PM17_HUMAN,PM17_HUMAN)# & PIR2: (S53871,A41234,A49179,A53668,I38400)# REFERENCES: kawakami95b# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,TITDQVPFSV*# SEQUENCE: TITDQVPFSV*# ...# >HUM11BE3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as./cytotoxicity as./Reference# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: gp100 (476-485)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,A41234,I38400)# REFERENCES: kawakami95b,rivoltini95b,kawakami96a,romero96a,rivoltini96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesh,bindyesh,VLYRYGSFSV*# SEQUENCE: VLYRYGSFSV*# ...# >HUM11BE4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays/Competition/Stabilization/Recognition# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: MART-1# DB REFERENCE: PIR2: (A55253)# REFERENCES: kawakami95b,romero97a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,EAAGIGILTV*# SEQUENCE: EAAGIGILTV*# ...# >HUM11BE5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays/Competition# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: MART-1# DB REFERENCE: PIR2: (A55253)# REFERENCES: kawakami95b,romero97a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesl,AAGIGILTVI*# SEQUENCE: AAGIGILTVI*# ...# >HUM11BE6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as./cytotoxicity as./reference# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: tyrosinase (1-9)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: kawakami95b,wolfel94a,kawakami96a,romero96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,MLLAVLYCL*# SEQUENCE: MLLAVLYCL*# ...# >HUM11BE7# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRASRPSL*# SEQUENCE: APRASRPSL*# ...# >HUM11BE8# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: histone H1# DB REFERENCE: SWISS: (H12_MOUSE,H11_MOUSE,H1_SALTR,H12_MOUSE,H14_RABIT,# & H1D_HUMAN,H15_MOUSE,H1B_HUMAN,H11_BOVIN,H1C_HUMAN,# & H14_MOUSE,H12_RAT,H13_MOUSE)# & PIR1: (HSTR1,HSBO11,HSHU1B,HSHU11)# & PIR2: (JX0086,S49482,A28470,I49742,A02579,B40335,JH0159)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,AASKERSGVSL*# SEQUENCE: AASKERSGVSL*# ...# >HUM11BE9# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta-actin# DB REFERENCE: SWISS: (ACTC_PISOC,ACTA_LIMPO,ACT_PHARH,ACT1_DROME,ACTA_LIMPO,# & ACT5_CHICK,ACT5_BACDO,ACT1_HELER,ACT5_XENLA,ACT1_HALRO,# & ACT1_PODCA,ACTM_STYPL,ACT2_BACDO,ACTC_HUMAN,ACTC_STRPU,# & ACTS_FUGRU,ACTS_CARAU,ACTH_HUMAN,ACTN_STYCL,ACTS_CYPCA,# & ACT_CRYNE,ACT8_XENLA,ACT1_ARTSX,ACTB_HUMAN,ACTB_XENBO,# & ACT4_CAEEL,ACTY_LIMPO,ACT3_PODCA,ACT1_XENLA,ACT3_XENLA,# & ACTM_HELTB,ACT2_XENLA,ACTC_STYPL,ACTS_HUMAN,ACTT_FUGRU,# & ACT2_DROME,ACT_HYDAT,ACTM_MOLOC,ACTE_STRPU,ACT_MANSE,# & ACT2_CAEEL,ACTA_STRPU,ACTM_PISOC,ACTM_HELER,ACT1_ONCVO,# & ACTB_CYPCA,ACT3_LIMPO,ACT2_XENTR,ACT5_DIPDE,ACTM_APLCA,# & ACT2_HALRO,ACTM_STYCL,ACTA_CHICK,ACT4_DROME,ACT4_ARTSX,# & ACT_TAESO,ACTD_STRPU,ACT1_HELER,ACT5_DROME,ACTB_RABIT,# & ACT2_ECHGR,ACTA_HUMAN,ACT3_FUGRU,FGR_FSVGR,ACT5_DIPDE,# & ACT1_SCHMA,ACTM_HELTB,ACTH_HUMAN,ACT3_DIPDE,ACT2_BOMMO,# & ACT1_FUGRU,ACT2_FUGRU,ACT2_DIPDE,ACT4_CAEEL,ACT3_LIMPO,# & ACT1_STRFN,ACT3_BACDO,ACT3_DIPDE,ACTM_HELER,ACT2_SCHMA,# & ACT3_DROME,ACTM_MOLOC,ACTB_CRIGR,ACTB_STRPU,ACT1_CAEEL,# & ACT2_DIPDE,ACT2_ONCVO,ACT1_AEDAE,ACT2_LYTPI,ACTC_HALRO,# & ACT1_LYTPI,ACTY_LIMPO,ACT6_DROME,ACT_SPOLI,ACTG_HUMAN,# & ACTF_STRPU,ACTC_FUGRU,ACT2_LYTPI,ACT1_LYTPI,ACT2_ARTSX)# & PIR1: (A22224,ATFF8,ATHUG,A23022,ATURS,ATMSB,ATMSG,A48324,# & A25719,ATRTC,TVMVRR,ATCHB,ATHU,ATBOSM,ATRBB,ATRT,ATRBSM,# & ATFF7,B29686,A24904,ATRB,ATHUC,ATCHSM,ATBOG,S11222,# & ATHUB,ATHUSM,A43552,ATBOB,ATCH)# & PIR2: (JS0189,S16709,S27135,S16710,S49481,S33387,S11453,A26559,# & S09578,A31375,A28258,JC5227,JC1246,A54728,S38782,JS0190,# & S01077,A32788,JN0832,A55001,S43509,S04538,JC5228,S11450,# & B25819,A48449,A24848,JN0833,JQ0154,A29686,S07288,S07251,# & A61043,B24848,S21907,C43616,S05430,S08596,S11451,S33386,# & A43911,I49465,A03000,S12730,S49480,A40261,S49479,# & S07382)# & PIR3: (A44940,S71124,S71119,S71125,S71120,S70377,S71118,# & S71126)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,RPRHQGVMV*# SEQUENCE: RPRHQGVMV*# ...# >HUM11BEA# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DP signal sequence# DB REFERENCE: SWISS: (HB2P_HUMAN,HB2Q_HUMAN,HB2Q_HUMAN)# & PIR1: (HLHUPB,HLHUS2)# & PIR2: (I54285,I59621,I38197,I38195,I54458)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRTVALTA*# SEQUENCE: APRTVALTA*# ...# >HUM11BEB# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (1C11_HUMAN)# & PIR2: (I37078,I37529)# ANCHOR POSITIONS:# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,RVMAPRALL*# SEQUENCE: RVMAPRALL*# ...# >HUM11BEC# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD20# DB REFERENCE: SWISS: (CD2R_HUMAN,CD20_HUMAN)# & PIR1: (A30586)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,RPKSNIVLL*# SEQUENCE: RPKSNIVLL*# ...# >HUM11BED# MHC MOLECULE: HLA-B55(B*5501), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B55,actunkn,bindyesu,APRQPGLMA*# SEQUENCE: APRQPGLMA*# ...# >HUM11BEE# MHC MOLECULE: HLA-B55(B*5501), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DP signal sequence# DB REFERENCE: SWISS: (HB2Q_HUMAN,HB2Q_HUMAN,HB2P_HUMAN)# & PIR1: (HLHUS2,HLHUPB)# & PIR2: (I38195,I59621,I54285,I54458,I38197)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B55,actunkn,bindyesu,APRTVALTA*# SEQUENCE: APRTVALTA*# ...# >HUM11BEF# MHC MOLECULE: HLA-B55(B*5502), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B55,actunkn,bindyesu,APRQPGLMA*# SEQUENCE: APRQPGLMA*# ...# >HUM11BF0# MHC MOLECULE: HLA-B55(B*5502), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DP signal sequence# DB REFERENCE: SWISS: (HB2Q_HUMAN,HB2Q_HUMAN,HB2P_HUMAN)# & PIR1: (HLHUPB,HLHUS2)# & PIR2: (I54458,I38195,I54285,I59621,I38197)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B55,actunkn,bindyesu,APRTVALTA*# SEQUENCE: APRTVALTA*# ...# >HUM11BF1# MHC MOLECULE: HLA-B55(B*5502), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta-actin# DB REFERENCE: SWISS: (ACT3_BACDO,ACT1_STRFN,ACT2_CAEEL,ACT1_ONCVO,ACT3_LIMPO,# & ACTB_CYPCA,ACTA_STRPU,ACTM_MOLOC,ACT_MANSE,ACTA_CHICK,# & ACTM_STYCL,ACT4_ARTSX,ACTM_HELER,ACTM_PISOC,ACTN_STYCL,# & ACTH_HUMAN,ACTS_CYPCA,ACTC_STRPU,ACTC_HUMAN,ACT2_XENLA,# & ACTS_HUMAN,ACTC_STYPL,ACT3_XENLA,ACTY_LIMPO,ACT3_PODCA,# & ACT1_XENLA,ACTM_APLCA,ACTC_PISOC,ACTA_LIMPO,ACT1_HALRO,# & ACT1_HELER,ACT5_XENLA,ACT5_BACDO,ACT5_CHICK,ACT1_DROME,# & ACTA_LIMPO,ACT1_PODCA,ACT2_BACDO,ACT1_SCHMA,ACT1_CAEEL,# & ACTB_CRIGR,ACTM_HELER,ACT2_DIPDE,ACT3_FUGRU,FGR_FSVGR,# & ACT3_DIPDE,ACT5_DROME,ACT_TAESO,ACT2_ECHGR,ACTA_HUMAN,# & ACTD_STRPU,ACT2_BOMMO,ACT4_DROME,ACT3_DIPDE,ACTE_STRPU,# & ACT2_DROME,ACTM_HELTB,ACT2_XENTR,ACT5_DIPDE,ACT_PHARH,# & ACTB_RABIT,ACT1_HELER,ACT1_FUGRU,ACT3_LIMPO,ACT4_CAEEL,# & ACT2_FUGRU,ACT3_DROME,ACTB_STRPU,ACT_SPOLI,ACTF_STRPU,# & ACTG_HUMAN,ACT2_ARTSX,ACT2_LYTPI,ACT1_LYTPI,ACT4_CAEEL,# & ACTB_HUMAN,ACTS_CARAU,ACT1_AEDAE,ACTY_LIMPO,ACT6_DROME,# & ACT2_DIPDE,ACTC_FUGRU,ACT2_LYTPI,ACTS_FUGRU,ACTT_FUGRU,# & ACTM_STYPL,ACT2_HALRO,ACT5_DIPDE,ACT2_SCHMA,ACTH_HUMAN,# & ACT8_XENLA,ACT1_ARTSX,ACT_CRYNE,ACTB_XENBO,ACTC_HALRO,# & ACT2_ONCVO,ACT1_LYTPI,ACTM_MOLOC,ACTM_HELTB,ACT_HYDAT)# & PIR1: (ATHUSM,A43552,ATCHSM,ATBOG,ATHUB,S11222,ATBOSM,ATMSG,# & A48324,TVMVRR,ATCH,ATBOB,ATRBB,B29686,ATHUC,ATHUG,ATFF8,# & A23022,ATMSB,ATCHB,ATRT,ATHU,ATFF7,A22224,ATURS,ATRBSM,# & A25719,ATRB,ATRTC,A24904)# & PIR2: (S01077,JN0832,JC5227,JS0190,JC5228,A03000,S12730,S11451,# & S33387,S08596,S05430,S43509,S33386,A43911,C43616,B24848,# & S21907,A29686,S07288,S07251,A61043,S07382,S49479,A40261,# & S49480,I49465,S27135,S16709,JS0189,S16710,S11453,A26559,# & S09578,S49481,A32788,A55001,S04538,A24848,JN0833,JQ0154,# & B25819,S11450,A48449,JC1246,S38782,A54728,A28258,# & A31375)# & PIR3: (S71126,S71118,S70377,S71120,A44940,S71124,S71119,# & S71125)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B55,actunkn,bindyesu,RPRHQGVMV*# SEQUENCE: RPRHQGVMV*# ...# >HUM11BF2# MHC MOLECULE: HLA-B55(B*5502), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (SYS_HUMAN,SYS_CRIGR)# & PIR2: (S35441,G01026)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B55,actunkn,bindyesu,IPYHIVNIV*# SEQUENCE: IPYHIVNIV*# ...# >HUM11BF3# MHC MOLECULE: HLA-B55(B*5502), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LMP2# DB REFERENCE: SWISS: (PRC7_HUMAN,PRC7_HUMAN)# & PIR2: (S27332)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B55,actunkn,bindyesu,APTGDLPRA*# SEQUENCE: APTGDLPRA*# ...# >HUM11BF4# MHC MOLECULE: HLA-B56(B*5601), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DP signal sequence# DB REFERENCE: SWISS: (HB2P_HUMAN,HB2Q_HUMAN,HB2Q_HUMAN)# & PIR1: (HLHUS2,HLHUPB)# & PIR2: (I38197,I54458,I54285,I59621,I38195)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B56,actunkn,bindyesu,APRTVALTA*# SEQUENCE: APRTVALTA*# ...# >HUM11BF5# MHC MOLECULE: HLA-B56(B*5601), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B56,actunkn,bindyesu,APRQPGLMA*# SEQUENCE: APRQPGLMA*# ...# >HUM11BF6# MHC MOLECULE: HLA-B56(B*5601), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LMP2# DB REFERENCE: SWISS: (PRC7_HUMAN,PRC7_HUMAN)# & PIR2: (S27332)# REFERENCES: barber95a# COMMENT:# SUMMARY: HLA-B56,actunkn,bindyesu,APTGDLPRA*# SEQUENCE: APTGDLPRA*# ...# >HUM21BF7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AKYAAAKAAAAAA*# SEQUENCE: AKYAAAKAAAAAA*# ...# >HUM21BF8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYVAAKAAAAAA*# SEQUENCE: AAYVAAKAAAAAA*# ...# >HUM21BF9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAKAKAAAAAA*# SEQUENCE: AAYAKAKAAAAAA*# ...# >HUM21BFA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAANAAKAAA*# SEQUENCE: AAYAAANAAKAAA*# ...# >HUM21BFB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKTAAAAA*# SEQUENCE: AAYAAAKTAAAAA*# ...# >HUM21BFC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAKAAA*# SEQUENCE: AAYAAAKAAKAAA*# ...# >HUM21BFD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AQYAAAKAAAAAA*# SEQUENCE: AQYAAAKAAAAAA*# ...# >HUM21BFE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYIAAKAAAAAA*# SEQUENCE: AAYIAAKAAAAAA*# ...# >HUM21BFF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKSAAAAA*# SEQUENCE: AAYAAAKSAAAAA*# ...# >HUM21C00# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAFAAA*# SEQUENCE: AAYAAAKAAFAAA*# ...# >HUM21C01# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAAIAA*# SEQUENCE: AAYAAAKAAAIAA*# ...# >HUM21C02# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AAYAAAKAAAAGA*# SEQUENCE: AAYAAAKAAAAGA*# ...# >HUM21C03# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: RMBP 90-102# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_RAT,MBP_BOVIN,MBP_HUMAN,MBP_PANTR,# & MBP_CAVPO)# & PIR1: (MBCZB,MBRTS,MBMSB,MBPGB,MBBOB,MBHUB)# & PIR2: (A37246)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HFFKNIVTPRTPP*# SEQUENCE: HFFKNIVTPRTPP*# ...# >HUM21C04# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP 12-24# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_RAT,MBP_PANTR,MBP_HUMAN,MBP_CAVPO)# & PIR1: (MBHUB,MBRTS,MBCZB,MBMSB)# & PIR2: (A37246)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SKYLATASTMDHA*# SEQUENCE: SKYLATASTMDHA*# ...# >HUM21C05# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP 13-25# DB REFERENCE: SWISS: (MBP_PANTR,MBP_CAVPO,MBP_MOUSE,MBP_RAT,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB,MBRTS,MBMSB)# & PIR2: (A37246)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KYLATASTMDHAR*# SEQUENCE: KYLATASTMDHAR*# ...# >HUM21C06# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP 35-47# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,TGILDSIGRFFGG*# SEQUENCE: TGILDSIGRFFGG*# ...# >HUM21C07# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP 43-55# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,RFFGGDRGAPKRG*# SEQUENCE: RFFGGDRGAPKRG*# ...# >HUM21C08# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP 86-98# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_BOVIN,MBP_CAVPO,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBHUB,MBPGB,MBMSB,MBBOB,MBCZB,MBRTS)# & PIR2: (A37246)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PVVHFFKNIVTPR*# SEQUENCE: PVVHFFKNIVTPR*# ...# >HUM21C09# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP 107-119# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_CAVPO,MBP_PANTR,MBP_BOVIN)# & PIR1: (MBHUB,MBBOB,MBPGB,MBCZB,MBMSB)# & PIR2: (A37246)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,RGLSLSRFSWGAE*# SEQUENCE: RGLSLSRFSWGAE*# ...# >HUM21C0A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP 114-126# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,FSWGAEGQRPGFG*# SEQUENCE: FSWGAEGQRPGFG*# ...# >HUM21C0B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP 142-154# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KGFKGVDAQGTLS*# SEQUENCE: KGFKGVDAQGTLS*# ...# >HUM21C0C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hum. albumin 423-435# DB REFERENCE: SWISS: (ALB_MACMU,ALBU_HUMAN)# & PIR1: (ABHUS)# & PIR2: (G01747,A47391)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GEYKFQNALLVRY*# SEQUENCE: GEYKFQNALLVRY*# ...# >HUM21C0D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hum. albumin 183-195# ANCHOR POSITIONS: 3# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KRYKAAFTESSQA*# SEQUENCE: KRYKAAFTESSQA*# ...# >HUM21C0E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hum. albumin 64-76# DB REFERENCE: SWISS: (ALBU_HUMAN,ALB_MACMU)# & PIR1: (ABHUS)# & PIR2: (G01747,A47391)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VKLVNEVTEFAKT*# SEQUENCE: VKLVNEVTEFAKT*# ...# >HUM21C0F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hum. albumin 369-381# DB REFERENCE: SWISS: (ALBU_HUMAN)# & PIR1: (ABHUS)# & PIR2: (G01747)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LLLRLAKTYETTL*# SEQUENCE: LLLRLAKTYETTL*# ...# >HUM21C10# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hum. albumin 531-543# DB REFERENCE: SWISS: (ALBU_HUMAN)# & PIR1: (ABHUS)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FTFHADICTLSEK*# SEQUENCE: FTFHADICTLSEK*# ...# >HUM21C11# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hum. albumin 160-172# DB REFERENCE: SWISS: (ALBU_HUMAN)# & PIR1: (ABHUS)# & PIR2: (G01747)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KKYLYEIARRHPY*# SEQUENCE: KKYLYEIARRHPY*# ...# >HUM21C12# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hum. albumin 484-496# DB REFERENCE: SWISS: (ALBU_HUMAN)# & PIR1: (ABHUS)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LCVLHEKTPVSDR*# SEQUENCE: LCVLHEKTPVSDR*# ...# >HUM21C13# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hum. albumin 478-490# DB REFERENCE: SWISS: (ALBU_HUMAN)# & PIR1: (ABHUS)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SVVLNQLCVLHEK*# SEQUENCE: SVVLNQLCVLHEK*# ...# >HUM21C14# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hum. albumin 263-275# DB REFERENCE: SWISS: (ALBU_HUMAN,ALB_MACMU)# & PIR1: (ABHUS)# & PIR2: (A47391,G01747)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,TKVHTECCHGDLL*# SEQUENCE: TKVHTECCHGDLL*# ...# >HUM21C15# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hum. albumin 513-525# DB REFERENCE: SWISS: (ALBU_HUMAN)# & PIR1: (ABHUS)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,SALEVDETYVPKE*# SEQUENCE: SALEVDETYVPKE*# ...# >HUM21C16# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hum. albumin 260-272# DB REFERENCE: SWISS: (ALB_MACMU,ALBU_HUMAN)# & PIR1: (ABHUS)# & PIR2: (G01747,A47391)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,TDLTKVHTECCHG*# SEQUENCE: TDLTKVHTECCHG*# ...# >HUM21C17# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hum. albumin 142-156# DB REFERENCE: SWISS: (ALB_MACMU,ALBU_HUMAN)# & PIR1: (ABHUS)# & PIR2: (A47391,G01747)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,PEVDVMCTAFHDN*# SEQUENCE: PEVDVMCTAFHDN*# ...# >HUM21C18# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Hum. albumin 53-65# DB REFERENCE: SWISS: (ALBU_HUMAN)# & PIR1: (ABHUS)# & PIR2: (G01747)# REFERENCES: marshall95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,AQYLQQCPFEDHV*# SEQUENCE: AQYLQQCPFEDHV*# ...# >HUM11C19# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: thomson95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,QAKWRLQTL*# SEQUENCE: QAKWRLQTL*# ...# >HUM11C1A# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938,S27920)# REFERENCES: thomson95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,SVRDRLARL*# SEQUENCE: SVRDRLARL*# ...# >HUM11C1B# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 6# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015)# REFERENCES: thomson95a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,KEHVIQNAF*# SEQUENCE: KEHVIQNAF*# ...# >HUM11C1C# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: thomson95a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,HLAAQGMAY*# SEQUENCE: HLAAQGMAY*# ...# >HUM11C1D# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 2# DB REFERENCE: SWISS: (EBN2_EBV)# & PIR2: (S32988)# & PIR3: (S42447,S42442)# REFERENCES: thomson95a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesu,DTPLIPLTIF*# SEQUENCE: DTPLIPLTIF*# ...# >HUM21C1E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: dnaJp1# DB REFERENCE: SWISS: (DNAJ_HAEDU,DNAJ_SALTY,DNAJ_HAEIN,DNAJ_ECOLI,# & DNAJ_ECOLI)# & PIR1: (HHECDJ)# & PIR2: (C64112)# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QKRAAYDQYGHAAFE*# SEQUENCE: QKRAAYDQYGHAAFE*# ...# >HUM21C1F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: dnaJp2# DB REFERENCE: SWISS: (DNAJ_ECOLI,DNAJ_ECOLI)# & PIR1: (HHECDJ)# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,VLTDSQKRAAYDQYG*# SEQUENCE: VLTDSQKRAAYDQYG*# ...# >HUM21C20# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: dnaJpV# ANCHOR POSITIONS:# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,DERAAYDQYGHAAFE*# SEQUENCE: DERAAYDQYGHAAFE*# ...# >HUM21C21# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA DR4 beta chain# DB REFERENCE: SWISS: (HB2H_HUMAN)# & PIR2: (I59629,A29310)# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,QKRAAVDTYCRHNYG*# SEQUENCE: QKRAAVDTYCRHNYG*# ...# >HUM21C22# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA DR4 beta chain# DB REFERENCE: SWISS: (HB2H_HUMAN)# & PIR2: (I59629,A29310)# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,KDLLEQKRAAVDTYC*# SEQUENCE: KDLLEQKRAAVDTYC*# ...# >HUM21C23# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: dnaJp1# DB REFERENCE: SWISS: (DNAJ_ECOLI,DNAJ_HAEDU,DNAJ_SALTY,DNAJ_ECOLI,# & DNAJ_HAEIN)# & PIR1: (HHECDJ)# & PIR2: (C64112)# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QKRAAYDQYGHAAFE*# SEQUENCE: QKRAAYDQYGHAAFE*# ...# >HUM21C24# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: dnaJp2# DB REFERENCE: SWISS: (DNAJ_ECOLI,DNAJ_ECOLI)# & PIR1: (HHECDJ)# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,VLTDSQKRAAYDQYG*# SEQUENCE: VLTDSQKRAAYDQYG*# ...# >HUM21C25# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: dnaJpV# ANCHOR POSITIONS:# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,DERAAYDQYGHAAFE*# SEQUENCE: DERAAYDQYGHAAFE*# ...# >HUM21C26# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA DR4 beta chain# DB REFERENCE: SWISS: (HB2H_HUMAN)# & PIR2: (I59629,A29310)# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,QKRAAVDTYCRHNYG*# SEQUENCE: QKRAAVDTYCRHNYG*# ...# >HUM21C27# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA DR4 beta chain# DB REFERENCE: SWISS: (HB2H_HUMAN)# & PIR2: (I59629,A29310)# REFERENCES: albani95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,KDLLEQKRAAVDTYC*# SEQUENCE: KDLLEQKRAAVDTYC*# ...# >HUM11C28# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (196-205)# DB REFERENCE: SWISS: (P53_HUMAN,P53_CERAE,P53_HUMAN,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,RVEGNLRVEY*# SEQUENCE: RVEGNLRVEY*# ...# >HUM11C29# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (226-234)# DB REFERENCE: SWISS: (P53_CERAE,P53_CRIGR,P53_MESAU,P53_HUMAN,P53_CERAE,# & P53_FELCA,P53_HUMAN,P53_FELCA,P53_MESAU)# & PIR1: (DNHU53)# & PIR2: (JH0633,S06594,JC6176,JC6193)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesm,GSDCTTIHY*# SEQUENCE: GSDCTTIHY*# ...# >HUM11C2A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as./reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: p53 (25-35)# DB REFERENCE: SWISS: (P53_CERAE,P53_CERAE,P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: gnjatic95a,parker96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLPENNVLSPL*# SEQUENCE: LLPENNVLSPL*# ...# >HUM11C2B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as./reference/reconstitution# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: p53 (65-73)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# REFERENCES: gnjatic95a,parker96a,zeh94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,RMPEAAPPV*# SEQUENCE: RMPEAAPPV*# ...# >HUM11C2C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (65-73) homologue# DB REFERENCE: PIR1: (DNHU53)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,RMPEAAPRV*# SEQUENCE: RMPEAAPRV*# ...# >HUM11C2D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (129-137)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ALNKMFCQL*# SEQUENCE: ALNKMFCQL*# ...# >HUM11C2E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as./reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: p53 (187-197)# DB REFERENCE: SWISS: (P53_RAT,P53_MOUSE,P53_CERAE,P53_BOVIN,P53_CERAE,# & P53_CANFA,P53_RAT,P53_MESAU,P53_MESAU,P53_HUMAN,# & P53_SHEEP,P53_FELCA,P53_HUMAN,P53_SHEEP,P53_MOUSE,# & P53_FELCA)# & PIR1: (DNMS53,DNHU53)# & PIR2: (JC6193,S02192,S38824,S51648,I46226,S06594,JH0633)# REFERENCES: gnjatic95a,parker96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,GLAPPQHLIRV*# SEQUENCE: GLAPPQHLIRV*# ...# >HUM11C2F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (263-272)# DB REFERENCE: SWISS: (P53_CERAE,P53_MESAU,P53_MESAU,P53_HUMAN,P53_HUMAN,# & P53_CRIGR,P53_CERAE,P53_BOVIN)# & PIR1: (DNHU53)# & PIR2: (JH0633,JC6176,S51648,S06594,JC6193)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,NLLGRNSFEV*# SEQUENCE: NLLGRNSFEV*# ...# >HUM11C30# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as./reference/reconstitution# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: p53 (264-272)# DB REFERENCE: SWISS: (P53_BOVIN,P53_FELCA,P53_CERAE,P53_MESAU,P53_MESAU,# & P53_HUMAN,P53_CERAE,P53_CRIGR,P53_FELCA,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (JC6176,JC6193,JH0633,S51648,S06594)# REFERENCES: gnjatic95a,parker96a,zeh94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLGRNSFEV*# SEQUENCE: LLGRNSFEV*# ...# >HUM11C31# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (187-195)# DB REFERENCE: SWISS: (P53_BOVIN,P53_MESAU,P53_HUMAN,P53_CANFA,P53_MOUSE,# & P53_RAT,P53_FELCA,P53_CERAE,P53_MESAU,P53_CERAE,# & P53_MOUSE,P53_FELCA,P53_SHEEP,P53_SHEEP,P53_HUMAN,# & P53_RAT)# & PIR1: (DNHU53,DNMS53)# & PIR2: (JC6193,S51648,S02192,S06594,I46226,JH0633,S38824)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GLAPPQHLI*# SEQUENCE: GLAPPQHLI*# ...# >HUM11C32# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: HLA assembly as./reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (256-264)# DB REFERENCE: SWISS: (P53_MOUSE,P53_HUMAN,P53_CERAE,P53_RAT,P53_MOUSE,P53_RAT,# & P53_CERAE,P53_HUMAN)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S02192,S06594,JC6193,S38824)# REFERENCES: gnjatic95a,zeh94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,TLEDSSGNL*# SEQUENCE: TLEDSSGNL*# ...# >HUM11C33# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (26-35)# DB REFERENCE: SWISS: (P53_HUMAN,P53_CERAE,P53_CERAE,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,LPENNVLSPL*# SEQUENCE: LPENNVLSPL*# ...# >HUM11C34# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (63-73)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,APRMPEAAPPV*# SEQUENCE: APRMPEAAPPV*# ...# >HUM11C35# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (63-73) homologue# DB REFERENCE: PIR1: (DNHU53)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,APRMPEAAPRV*# SEQUENCE: APRMPEAAPRV*# ...# >HUM11C36# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (189-197)# DB REFERENCE: SWISS: (P53_MOUSE,P53_FELCA,P53_HUMAN,P53_SHEEP,P53_CRIGR,# & P53_MESAU,P53_MESAU,P53_BOVIN,P53_CERAE,P53_SHEEP,# & P53_CANFA,P53_MOUSE,P53_RAT,P53_HUMAN,P53_RAT,P53_FELCA,# & P53_CERAE)# & PIR1: (DNHU53,DNMS53)# & PIR2: (I46226,S06594,JH0633,JC6193,S02192,S38824,S51648,# & JC6176)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,APPQHLIRV*# SEQUENCE: APPQHLIRV*# ...# >HUM11C37# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (249-257)# DB REFERENCE: SWISS: (P53_SALIR,P53_MESAU,P53_MOUSE,P53_MESAU,P53_CRIGR,# & P53_SALIR,P53_SHEEP,P53_BOVIN,P53_RAT,P53_CERAE,# & P53_SHEEP,P53_RAT,P53_HUMAN,P53_CERAE,P53_XENLA,# & P53_XENLA,P53_HUMAN,P53_MOUSE,P53_CANFA)# & PIR1: (DNHU53,DNMS53)# & PIR2: (JH0633,JH0631,S06594,S02192,S38824,S51648,JC6176,JC6193,# & A29376)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,RPILTIITL*# SEQUENCE: RPILTIITL*# ...# >HUM11C38# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 (321-330)# DB REFERENCE: SWISS: (P53_CERAE,P53_SHEEP,P53_RAT,P53_BOVIN,P53_MOUSE,# & P53_CERAE,P53_HUMAN,P53_FELCA,P53_MOUSE,P53_HUMAN,# & P53_SHEEP,P53_RAT,P53_FELCA)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S38824,S02192,S51648,S06594)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,KPLDGEYFTL*# SEQUENCE: KPLDGEYFTL*# ...# >HUM11C39# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (135-143)# DB REFERENCE: SWISS: (P53_CANFA,P53_SHEEP,P53_MOUSE,P53_FELCA,P53_SALIR,# & P53_SALIR,P53_CERAE,P53_MOUSE,P53_MESAU,P53_CRIGR,# & P53_HUMAN,P53_FELCA,P53_MESAU,P53_SHEEP,P53_RAT,P53_RAT,# & P53_CERAE,P53_BOVIN,P53_HUMAN)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S02192,JC6176,JC6193,S06594,S51648,JH0631,JH0633)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesl,CQLAKTCPV*# SEQUENCE: CQLAKTCPV*# ...# >HUM11C3A# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (210-218)# DB REFERENCE: SWISS: (P53_FELCA,P53_HUMAN,P53_BOVIN,P53_FELCA,P53_SHEEP,# & P53_CERAE,P53_HUMAN,P53_SHEEP,P53_CERAE,P53_CANFA)# & PIR1: (DNHU53)# & PIR2: (S51648,JC6193,S06594)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesl,NTFRHSVVV*# SEQUENCE: NTFRHSVVV*# ...# >HUM11C3B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (210-218) homologue# ANCHOR POSITIONS:# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesl,NTFRHSLVV*# SEQUENCE: NTFRHSLVV*# ...# >HUM11C3C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 (210-218)# ANCHOR POSITIONS:# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesm,NTFQHSVVV*# SEQUENCE: NTFQHSVVV*# ...# >HUM11C3D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 (375-383)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: gnjatic95a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesl,QSTSRHKKL*# SEQUENCE: QSTSRHKKL*# ...# >HUM11C3E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum circumsporosoite protein CSP# DB REFERENCE: PIR2: (B29795)# REFERENCES: plebanski94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YLKTIQNSL*# SEQUENCE: YLKTIQNSL*# ...# >HUM11C3F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HLA assembly as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum circumsporosoite protein CSP# DB REFERENCE: SWISS: (CSP_PLAFO)# & PIR2: (S05428)# REFERENCES: plebanski94a,blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,YLNKIQNSL*# SEQUENCE: YLNKIQNSL*# ...# >HUM11C40# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum trombospondin related anonymous protein TRAP# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# REFERENCES: plebanski94a# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,KNKEKALII*# SEQUENCE: KNKEKALII*# ...# >HUM11C41# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum liver stage specific antigen-1# DB REFERENCE: PIR2: (A45592)# REFERENCES: plebanski94a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,KPNDKSLY*# SEQUENCE: KPNDKSLY*# ...# >HUM11C42# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: FLU nucleoprotein# ANCHOR POSITIONS:# REFERENCES: plebanski94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,ILRQSVAHK*# SEQUENCE: ILRQSVAHK*# ...# >MUS21C43# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBcAg (120-131)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBVZ,CORA_HPBVT,CORA_HPBV9,CORA_HPBVO,# & CORA_HPBVA,CORA_HPBVJ,CORA_HPBVY,CORA_HPBVF,CORA_HPBV4,# & CORA_HPBVW,CORA_HPBV2)# & PIR1: (NKVLAH,NKVLCP,NKVLJ1,NKVLA3,NKVLA2,NKVLA1,NKVLKS,NKVLA4,# & NKVLBH,NKVLA6,NKVLH3,NKVLJ2)# & PIR2: (S53270,S53232,S35530,S53186,S53279,S01405,S53211,S53274,# & S53169,S53146,S53200,S20755,S53260,S53140,S53202,S53238,# & S53166,S33686,S04570,S53159,S53257,S53207,S53251,S53225,# & S53129,S53137,S53172,S53161,S53163,S53227,S53216,S53181,# & S47405,S53152,S53255,S53204,S53272,S53221,S53267,S53253,# & JQ2227,S53236,S53175,S20746,S53281,S32204,S53149,S53214,# & S53240,S53242,S53229,S53198,S25651,S47409,S53247,S53189,# & S53223)# REFERENCES: altuvia94a,milich95a# COMMENT:# SUMMARY: I-As,actyesu,bindyesu,VSFGVWIRTPPA*# SEQUENCE: VSFGVWIRTPPA*# ...# >MUS21C44# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBcAg (120-131)# DB REFERENCE: SWISS: (CORA_HPBVW,CORA_HPBV2,CORA_HPBVY,CORA_HPBV9,CORA_HPBVF,# & CORA_HPBV4,CORA_HPBVA,CORA_HPBVJ,CORA_HPBVL,CORA_HPBVT,# & CORA_HPBVZ,CORA_HPBVO)# & PIR1: (NKVLA6,NKVLKS,NKVLBH,NKVLJ1,NKVLCP,NKVLH3,NKVLJ2,NKVLA1,# & NKVLA4,NKVLAH,NKVLA2,NKVLA3)# & PIR2: (S53189,S25651,S53238,S53202,S53152,S53214,S20750,S53251,# & S53221,S53253,S53255,S53163,S53172,S53225,S53270,S53198,# & S53169,S53232,S20755,S53242,S53229,S20746,S32204,S53166,# & S53159,S53257,S53207,S33686,S53272,JQ2227,S53204,S04570,# & S53129,S53240,S53279,S35530,S53186,S01405,S53274,S53211,# & S53260,S53140,S53146,S53227,S53161,S53223,S53236,S53194,# & S53175,S53281,S53216,S47405,S53181,S53247,S47409)# REFERENCES: altuvia94a,milich95a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,PPAYRPPNAPIL*# SEQUENCE: PPAYRPPNAPIL*# ...# >HUM11C45# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBNA4# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: khanna95a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesu,AVLLHEESM*# SEQUENCE: AVLLHEESM*# ...# >HUM11C46# MHC MOLECULE: HLA-A23, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: LMP2A# DB REFERENCE: SWISS: (LMP2_EBV)# & PIR1: (WMBELM)# REFERENCES: khanna95a# COMMENT:# SUMMARY: HLA-A23,actyesh,bindyesu,PYLFWLAAI*# SEQUENCE: PYLFWLAAI*# ...# >HUM21C47# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# REFERENCES: khanna95a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesu,TSLYNLRRGTALA*# SEQUENCE: TSLYNLRRGTALA*# ...# >HUM11C48# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBNA4# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# REFERENCES: khanna95a# COMMENT:# SUMMARY: HLA-B44,actyesh,bindyesu,VEITPYKPTW*# SEQUENCE: VEITPYKPTW*# ...# >HUM11C49# MHC MOLECULE: HLA-A29, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBNA3# ANCHOR POSITIONS:# REFERENCES: khanna95a# COMMENT:# SUMMARY: HLA-A29,actyesh,bindyesu,SPGDQLPGVFSDGRAVACAPV*# SEQUENCE: SPGDQLPGVFSDGRAVACAPV*# ...# >HUM11C4A# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Yersinia enterocolitica urease beta subunit (60-68)# DB REFERENCE: SWISS: (URE2_YERPS,URE2_YEREN)# & PIR1: (S31418)# REFERENCES: mertz94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,VRNTGDRPI*# SEQUENCE: VRNTGDRPI*# ...# >HUM11C4B# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Yersinia enterocolitica urease beta subunit (93-101)# DB REFERENCE: SWISS: (URE2_YERPS,URE2_YEREN)# & PIR1: (S31418)# REFERENCES: mertz94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,KRLNISSTT*# SEQUENCE: KRLNISSTT*# ...# >HUM11C4C# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Yersinia enterocolitica urease beta subunit (103-111)# DB REFERENCE: SWISS: (URE2_YEREN,URE2_YERPS)# & PIR1: (S31418)# REFERENCES: mertz94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,IRFEPGDET*# SEQUENCE: IRFEPGDET*# ...# >HUM11C4D# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Yersinia enterocolitica urease beta subunit (153-161)# DB REFERENCE: SWISS: (URE2_YEREN)# & PIR1: (S31418)# REFERENCES: mertz94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,RRAAERGFK*# SEQUENCE: RRAAERGFK*# ...# >HUM11C4E# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Yersinia enterocolitica 50 S ribosomal protein L23 (11-19)# DB REFERENCE: SWISS: (RL23_ECOLI,RL23_YEREN,RL23_ECOLI)# & PIR1: (R5EC23)# REFERENCES: mertz94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,LRAPHVSEK*# SEQUENCE: LRAPHVSEK*# ...# >HUM11C4F# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Yersinia enterocolitica 50 S ribosomal protein L23 (67-75)# DB REFERENCE: SWISS: (RL23_YEREN,RL23_YERPS)# & PIR1: (R5EB23)# REFERENCES: mertz94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,KRHGQRVGR*# SEQUENCE: KRHGQRVGR*# ...# >HUM11C50# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Yersinia enterocolitica 50 S ribosomal protein L23 (75-83)# DB REFERENCE: SWISS: (RL23_ECOLI,RL23_YEREN,RL23_YERPS,RL23_HAEIN,RL23_ACTAC,# & RL23_ECOLI)# & PIR1: (R5EC23,R5EB23)# & PIR2: (G64092)# REFERENCES: mertz94a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,RRSDWKKAY*# SEQUENCE: RRSDWKKAY*# ...# >HUM21C51# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as./competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP p (85-99) homologue# DB REFERENCE: SWISS: (MBP_PANTR,MBP_RAT,MBP_MOUSE,MBP_HUMAN,MBP_BOVIN,# & MBP_CAVPO)# & PIR1: (MBMSB,MBBOB,MBRTS,MBCZB,MBHUB,MBPGB)# & PIR2: (A37246)# REFERENCES: windhagen95a,wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENPVVHFFKNIVTPR*# SEQUENCE: ENPVVHFFKNIVTPR*# ...# >HUM21C52# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: MBP p (85-99) homologue# ANCHOR POSITIONS:# REFERENCES: windhagen95a# COMMENT:# SUMMARY: HLA-DR15,actyesl,bindyesl,ENPVKHFFKNIVTPR*# SEQUENCE: ENPVKHFFKNIVTPR*# ...# >HUM21C53# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as./competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP p (85-99) homologue# ANCHOR POSITIONS:# REFERENCES: windhagen95a,wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENPVVAFFKNIVTPR*# SEQUENCE: ENPVVAFFKNIVTPR*# ...# >HUM21C54# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: MBP p (85-99) homologue# ANCHOR POSITIONS:# REFERENCES: windhagen95a,wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesl,bindyesm,ENPVVDFFKNIVTPR*# SEQUENCE: ENPVVDFFKNIVTPR*# ...# >HUM21C55# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: MBP p (85-99) homologue# ANCHOR POSITIONS:# REFERENCES: windhagen95a# COMMENT:# SUMMARY: HLA-DR15,actyesn,bindyesh,ENPVVKFFKNIVTPR*# SEQUENCE: ENPVVKFFKNIVTPR*# ...# >HUM21C56# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as./competition# ACTIVITY: none# BINDING: yes, high# SOURCE: MBP p (85-99) homologue# ANCHOR POSITIONS:# REFERENCES: windhagen95a,wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesn,bindyesh,ENPVVHAFKNIVTPR*# SEQUENCE: ENPVVHAFKNIVTPR*# ...# >HUM21C57# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as./competition# ACTIVITY: none# BINDING: yes, moderate# SOURCE: MBP p (85-99) homologue# ANCHOR POSITIONS:# REFERENCES: windhagen95a,wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesn,bindyesm,ENPVVHFAKNIVTPR*# SEQUENCE: ENPVVHFAKNIVTPR*# ...# >HUM21C58# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as./competition# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: MBP p (85-99) homologue# ANCHOR POSITIONS:# REFERENCES: windhagen95a,wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesm,bindyesh,ENPVVHFFANIVTPR*# SEQUENCE: ENPVVHFFANIVTPR*# ...# >HUM21C59# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MBP (83-102)# ANCHOR POSITIONS:# REFERENCES: nag94a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,YDENPVVHFFKNIVTPRTPP*# SEQUENCE: YDENPVVHFFKNIVTPRTPP*# ...# >MUS21C5A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,PLIAYLKQATK*# SEQUENCE: PLIAYLKQATK*# ...# >MUS21C5B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,GLIAYLKQATK*# SEQUENCE: GLIAYLKQATK*# ...# >MUS21C5C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,ALIAYLKQATK*# SEQUENCE: ALIAYLKQATK*# ...# >MUS21C5D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesm,VLIAYLKQATK*# SEQUENCE: VLIAYLKQATK*# ...# >MUS21C5E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,LLIAYLKQATK*# SEQUENCE: LLIAYLKQATK*# ...# >MUS21C5F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,ILIAYLKQATK*# SEQUENCE: ILIAYLKQATK*# ...# >MUS21C60# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,MLIAYLKQATK*# SEQUENCE: MLIAYLKQATK*# ...# >MUS21C61# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,FLIAYLKQATK*# SEQUENCE: FLIAYLKQATK*# ...# >MUS21C62# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,WLIAYLKQATK*# SEQUENCE: WLIAYLKQATK*# ...# >MUS21C63# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,YLIAYLKQATK*# SEQUENCE: YLIAYLKQATK*# ...# >MUS21C64# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,HLIAYLKQATK*# SEQUENCE: HLIAYLKQATK*# ...# >MUS21C65# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,RLIAYLKQATK*# SEQUENCE: RLIAYLKQATK*# ...# >MUS21C66# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,KLIAYLKQATK*# SEQUENCE: KLIAYLKQATK*# ...# >MUS21C67# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103)# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: altuvia94a,harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYLKQATK*# SEQUENCE: DLIAYLKQATK*# ...# >MUS21C68# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,NLIAYLKQATK*# SEQUENCE: NLIAYLKQATK*# ...# >MUS21C69# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesh,QLIAYLKQATK*# SEQUENCE: QLIAYLKQATK*# ...# >MUS21C6A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,CLIAYLKQATK*# SEQUENCE: CLIAYLKQATK*# ...# >MUS21C6B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,SLIAYLKQATK*# SEQUENCE: SLIAYLKQATK*# ...# >MUS21C6C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,TLIAYLKQATK*# SEQUENCE: TLIAYLKQATK*# ...# >MUS21C6D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DPIAYLKQATK*# SEQUENCE: DPIAYLKQATK*# ...# >MUS21C6E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DGIAYLKQATK*# SEQUENCE: DGIAYLKQATK*# ...# >MUS21C6F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DAIAYLKQATK*# SEQUENCE: DAIAYLKQATK*# ...# >MUS21C70# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DVIAYLKQATK*# SEQUENCE: DVIAYLKQATK*# ...# >MUS21C71# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DIIAYLKQATK*# SEQUENCE: DIIAYLKQATK*# ...# >MUS21C72# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DMIAYLKQATK*# SEQUENCE: DMIAYLKQATK*# ...# >MUS21C73# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DFIAYLKQATK*# SEQUENCE: DFIAYLKQATK*# ...# >MUS21C74# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DWIAYLKQATK*# SEQUENCE: DWIAYLKQATK*# ...# >MUS21C75# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DYIAYLKQATK*# SEQUENCE: DYIAYLKQATK*# ...# >MUS21C76# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DHIAYLKQATK*# SEQUENCE: DHIAYLKQATK*# ...# >MUS21C77# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DRIAYLKQATK*# SEQUENCE: DRIAYLKQATK*# ...# >MUS21C78# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DKIAYLKQATK*# SEQUENCE: DKIAYLKQATK*# ...# >MUS21C79# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesm,DDIAYLKQATK*# SEQUENCE: DDIAYLKQATK*# ...# >MUS21C7A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesl,DEIAYLKQATK*# SEQUENCE: DEIAYLKQATK*# ...# >MUS21C7B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DNIAYLKQATK*# SEQUENCE: DNIAYLKQATK*# ...# >MUS21C7C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DQIAYLKQATK*# SEQUENCE: DQIAYLKQATK*# ...# >MUS21C7D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DCIAYLKQATK*# SEQUENCE: DCIAYLKQATK*# ...# >MUS21C7E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DSIAYLKQATK*# SEQUENCE: DSIAYLKQATK*# ...# >MUS21C7F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DTIAYLKQATK*# SEQUENCE: DTIAYLKQATK*# ...# >MUS21C80# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLVAYLKQATK*# SEQUENCE: DLVAYLKQATK*# ...# >MUS21C81# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLLAYLKQATK*# SEQUENCE: DLLAYLKQATK*# ...# >MUS21C82# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DLFAYLKQATK*# SEQUENCE: DLFAYLKQATK*# ...# >MUS21C83# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DLWAYLKQATK*# SEQUENCE: DLWAYLKQATK*# ...# >MUS21C84# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesl,DLTAYLKQATK*# SEQUENCE: DLTAYLKQATK*# ...# >MUS21C85# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIGYLKQATK*# SEQUENCE: DLIGYLKQATK*# ...# >MUS21C86# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIVYLKQATK*# SEQUENCE: DLIVYLKQATK*# ...# >MUS21C87# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, little# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesl,DLILYLKQATK*# SEQUENCE: DLILYLKQATK*# ...# >MUS21C88# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIIYLKQATK*# SEQUENCE: DLIIYLKQATK*# ...# >MUS21C89# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIMYLKQATK*# SEQUENCE: DLIMYLKQATK*# ...# >MUS21C8A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIFYLKQATK*# SEQUENCE: DLIFYLKQATK*# ...# >MUS21C8B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIWYLKQATK*# SEQUENCE: DLIWYLKQATK*# ...# >MUS21C8C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIYYLKQATK*# SEQUENCE: DLIYYLKQATK*# ...# >MUS21C8D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIHYLKQATK*# SEQUENCE: DLIHYLKQATK*# ...# >MUS21C8E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIRYLKQATK*# SEQUENCE: DLIRYLKQATK*# ...# >MUS21C8F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIKYLKQATK*# SEQUENCE: DLIKYLKQATK*# ...# >MUS21C90# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIDYLKQATK*# SEQUENCE: DLIDYLKQATK*# ...# >MUS21C91# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIEYLKQATK*# SEQUENCE: DLIEYLKQATK*# ...# >MUS21C92# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLINYLKQATK*# SEQUENCE: DLINYLKQATK*# ...# >MUS21C93# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIQYLKQATK*# SEQUENCE: DLIQYLKQATK*# ...# >MUS21C94# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesm,DLICYLKQATK*# SEQUENCE: DLICYLKQATK*# ...# >MUS21C95# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLISYLKQATK*# SEQUENCE: DLISYLKQATK*# ...# >MUS21C96# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLITYLKQATK*# SEQUENCE: DLITYLKQATK*# ...# >MUS21C97# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAPLKQATK*# SEQUENCE: DLIAPLKQATK*# ...# >MUS21C98# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIAGLKQATK*# SEQUENCE: DLIAGLKQATK*# ...# >MUS21C99# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAALKQATK*# SEQUENCE: DLIAALKQATK*# ...# >MUS21C9A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAVLKQATK*# SEQUENCE: DLIAVLKQATK*# ...# >MUS21C9B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIALLKQATK*# SEQUENCE: DLIALLKQATK*# ...# >MUS21C9C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAILKQATK*# SEQUENCE: DLIAILKQATK*# ...# >MUS21C9D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAMLKQATK*# SEQUENCE: DLIAMLKQATK*# ...# >MUS21C9E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAFLKQATK*# SEQUENCE: DLIAFLKQATK*# ...# >MUS21C9F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAWLKQATK*# SEQUENCE: DLIAWLKQATK*# ...# >MUS21CA0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAHLKQATK*# SEQUENCE: DLIAHLKQATK*# ...# >MUS21CA1# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIARLKQATK*# SEQUENCE: DLIARLKQATK*# ...# >MUS21CA2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIAKLKQATK*# SEQUENCE: DLIAKLKQATK*# ...# >MUS21CA3# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAELKQATK*# SEQUENCE: DLIAELKQATK*# ...# >MUS21CA4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIANLKQATK*# SEQUENCE: DLIANLKQATK*# ...# >MUS21CA5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAQLKQATK*# SEQUENCE: DLIAQLKQATK*# ...# >MUS21CA6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIACLKQATK*# SEQUENCE: DLIACLKQATK*# ...# >MUS21CA7# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIASLKQATK*# SEQUENCE: DLIASLKQATK*# ...# >MUS21CA8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIATLKQATK*# SEQUENCE: DLIATLKQATK*# ...# >MUS21CA9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYGKQATK*# SEQUENCE: DLIAYGKQATK*# ...# >MUS21CAA# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYAKQATK*# SEQUENCE: DLIAYAKQATK*# ...# >MUS21CAB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYVKQATK*# SEQUENCE: DLIAYVKQATK*# ...# >MUS21CAC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYIKQATK*# SEQUENCE: DLIAYIKQATK*# ...# >MUS21CAD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesh,DLIAYMKQATK*# SEQUENCE: DLIAYMKQATK*# ...# >MUS21CAE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesh,DLIAYFKQATK*# SEQUENCE: DLIAYFKQATK*# ...# >MUS21CAF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIAYWKQATK*# SEQUENCE: DLIAYWKQATK*# ...# >MUS21CB0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYYKQATK*# SEQUENCE: DLIAYYKQATK*# ...# >MUS21CB1# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesh,DLIAYHKQATK*# SEQUENCE: DLIAYHKQATK*# ...# >MUS21CB2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIAYRKQATK*# SEQUENCE: DLIAYRKQATK*# ...# >MUS21CB3# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesl,DLIAYKKQATK*# SEQUENCE: DLIAYKKQATK*# ...# >MUS21CB4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYDKQATK*# SEQUENCE: DLIAYDKQATK*# ...# >MUS21CB5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesm,bindyesh,DLIAYEKQATK*# SEQUENCE: DLIAYEKQATK*# ...# >MUS21CB6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYNKQATK*# SEQUENCE: DLIAYNKQATK*# ...# >MUS21CB7# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYQKQATK*# SEQUENCE: DLIAYQKQATK*# ...# >MUS21CB8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DLIAYCKQATK*# SEQUENCE: DLIAYCKQATK*# ...# >MUS21CB9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYSKQATK*# SEQUENCE: DLIAYSKQATK*# ...# >MUS21CBA# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYTKQATK*# SEQUENCE: DLIAYTKQATK*# ...# >MUS21CBB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLPQATK*# SEQUENCE: DLIAYLPQATK*# ...# >MUS21CBC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLGQATK*# SEQUENCE: DLIAYLGQATK*# ...# >MUS21CBD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLAQATK*# SEQUENCE: DLIAYLAQATK*# ...# >MUS21CBE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLVQATK*# SEQUENCE: DLIAYLVQATK*# ...# >MUS21CBF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLLQATK*# SEQUENCE: DLIAYLLQATK*# ...# >MUS21CC0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLIQATK*# SEQUENCE: DLIAYLIQATK*# ...# >MUS21CC1# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLMQATK*# SEQUENCE: DLIAYLMQATK*# ...# >MUS21CC2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLFQATK*# SEQUENCE: DLIAYLFQATK*# ...# >MUS21CC3# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLWQATK*# SEQUENCE: DLIAYLWQATK*# ...# >MUS21CC4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLYQATK*# SEQUENCE: DLIAYLYQATK*# ...# >MUS21CC5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLHQATK*# SEQUENCE: DLIAYLHQATK*# ...# >MUS21CC6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLRQATK*# SEQUENCE: DLIAYLRQATK*# ...# >MUS21CC7# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLDQATK*# SEQUENCE: DLIAYLDQATK*# ...# >MUS21CC8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLEQATK*# SEQUENCE: DLIAYLEQATK*# ...# >MUS21CC9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLNQATK*# SEQUENCE: DLIAYLNQATK*# ...# >MUS21CCA# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLQQATK*# SEQUENCE: DLIAYLQQATK*# ...# >MUS21CCB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIAYLCQATK*# SEQUENCE: DLIAYLCQATK*# ...# >MUS21CCC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLSQATK*# SEQUENCE: DLIAYLSQATK*# ...# >MUS21CCD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLTQATK*# SEQUENCE: DLIAYLTQATK*# ...# >MUS21CCE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesm,DLIAYLKPATK*# SEQUENCE: DLIAYLKPATK*# ...# >MUS21CCF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYLKGATK*# SEQUENCE: DLIAYLKGATK*# ...# >MUS21CD0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYLKAATK*# SEQUENCE: DLIAYLKAATK*# ...# >MUS21CD1# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIAYLKVATK*# SEQUENCE: DLIAYLKVATK*# ...# >MUS21CD2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKMATK*# SEQUENCE: DLIAYLKMATK*# ...# >MUS21CD3# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesl,DLIAYLKRATK*# SEQUENCE: DLIAYLKRATK*# ...# >MUS21CD4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYLKEATK*# SEQUENCE: DLIAYLKEATK*# ...# >MUS21CD5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKNATK*# SEQUENCE: DLIAYLKNATK*# ...# >MUS21CD6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# DB REFERENCE: SWISS: (CYC_HAEIR,CYC_LUCCU,CYC2_DROME,CYC2_DROME,CYC_BOEPE,# & CYC_BOEPE)# & PIR1: (CCFFDM,CCFFCM,CCFHHF,CCHFGB)# & PIR2: (B25506)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYLKSATK*# SEQUENCE: DLIAYLKSATK*# ...# >MUS21CD7# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYLKTATK*# SEQUENCE: DLIAYLKTATK*# ...# >MUS21CD8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQPTK*# SEQUENCE: DLIAYLKQPTK*# ...# >MUS21CD9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQGTK*# SEQUENCE: DLIAYLKQGTK*# ...# >MUS21CDA# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQVTK*# SEQUENCE: DLIAYLKQVTK*# ...# >MUS21CDB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQLTK*# SEQUENCE: DLIAYLKQLTK*# ...# >MUS21CDC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQITK*# SEQUENCE: DLIAYLKQITK*# ...# >MUS21CDD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQMTK*# SEQUENCE: DLIAYLKQMTK*# ...# >MUS21CDE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQFTK*# SEQUENCE: DLIAYLKQFTK*# ...# >MUS21CDF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQWTK*# SEQUENCE: DLIAYLKQWTK*# ...# >MUS21CE0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQYTK*# SEQUENCE: DLIAYLKQYTK*# ...# >MUS21CE1# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQHTK*# SEQUENCE: DLIAYLKQHTK*# ...# >MUS21CE2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQRTK*# SEQUENCE: DLIAYLKQRTK*# ...# >MUS21CE3# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQKTK*# SEQUENCE: DLIAYLKQKTK*# ...# >MUS21CE4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQDTK*# SEQUENCE: DLIAYLKQDTK*# ...# >MUS21CE5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQETK*# SEQUENCE: DLIAYLKQETK*# ...# >MUS21CE6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQNTK*# SEQUENCE: DLIAYLKQNTK*# ...# >MUS21CE7# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQQTK*# SEQUENCE: DLIAYLKQQTK*# ...# >MUS21CE8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesl,DLIAYLKQCTK*# SEQUENCE: DLIAYLKQCTK*# ...# >MUS21CE9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQSTK*# SEQUENCE: DLIAYLKQSTK*# ...# >MUS21CEA# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQTTK*# SEQUENCE: DLIAYLKQTTK*# ...# >MUS21CEB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAPK*# SEQUENCE: DLIAYLKQAPK*# ...# >MUS21CEC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAGK*# SEQUENCE: DLIAYLKQAGK*# ...# >MUS21CED# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAAK*# SEQUENCE: DLIAYLKQAAK*# ...# >MUS21CEE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesh,DLIAYLKQAVK*# SEQUENCE: DLIAYLKQAVK*# ...# >MUS21CEF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQALK*# SEQUENCE: DLIAYLKQALK*# ...# >MUS21CF0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAIK*# SEQUENCE: DLIAYLKQAIK*# ...# >MUS21CF1# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAMK*# SEQUENCE: DLIAYLKQAMK*# ...# >MUS21CF2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAFK*# SEQUENCE: DLIAYLKQAFK*# ...# >MUS21CF3# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAWK*# SEQUENCE: DLIAYLKQAWK*# ...# >MUS21CF4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAYK*# SEQUENCE: DLIAYLKQAYK*# ...# >MUS21CF5# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAHK*# SEQUENCE: DLIAYLKQAHK*# ...# >MUS21CF6# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQARK*# SEQUENCE: DLIAYLKQARK*# ...# >MUS21CF7# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAKK*# SEQUENCE: DLIAYLKQAKK*# ...# >MUS21CF8# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQADK*# SEQUENCE: DLIAYLKQADK*# ...# >MUS21CF9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAEK*# SEQUENCE: DLIAYLKQAEK*# ...# >MUS21CFA# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQANK*# SEQUENCE: DLIAYLKQANK*# ...# >MUS21CFB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQAQK*# SEQUENCE: DLIAYLKQAQK*# ...# >MUS21CFC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIAYLKQACK*# SEQUENCE: DLIAYLKQACK*# ...# >MUS21CFD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQASK*# SEQUENCE: DLIAYLKQASK*# ...# >MUS21CFE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# DB REFERENCE: SWISS: (CYC_COLLI,CYC_CHLRE,CYC_COLLI,CYC_CHLRE)# & PIR1: (CCPY)# & PIR2: (S29514)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesl,bindyesm,DLIAYLKQATA*# SEQUENCE: DLIAYLKQATA*# ...# >MUS21CFF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIAYLKQATV*# SEQUENCE: DLIAYLKQATV*# ...# >MUS21D00# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQATL*# SEQUENCE: DLIAYLKQATL*# ...# >MUS21D01# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQATI*# SEQUENCE: DLIAYLKQATI*# ...# >MUS21D02# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIAYLKQATM*# SEQUENCE: DLIAYLKQATM*# ...# >MUS21D03# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesh,DLIAYLKQATF*# SEQUENCE: DLIAYLKQATF*# ...# >MUS21D04# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesm,DLIAYLKQATY*# SEQUENCE: DLIAYLKQATY*# ...# >MUS21D05# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesh,DLIAYLKQATR*# SEQUENCE: DLIAYLKQATR*# ...# >MUS21D06# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesl,DLIAYLKQATS*# SEQUENCE: DLIAYLKQATS*# ...# >MUS21D07# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as./activation as.# ACTIVITY: none# BINDING: yes, little# SOURCE: moth cytochrome C (93-103) homologue# ANCHOR POSITIONS: 3,8,11# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesn,bindyesl,DLIAYLKQATT*# SEQUENCE: DLIAYLKQATT*# ...# >MUS21D08# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (255-263)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LESIINFEKL*# SEQUENCE: LESIINFEKL*# ...# >MUS21D09# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (64-92)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_CHICK,LYC_SYRRE,LYC_CHICK,LYC_PAVCR,# & LYC_CHRAM,LYC_MELGA,LYC_PHACO,LYC_LOPLE)# & PIR1: (LZTK,LZFER,LZQJE,LZCH)# & PIR2: (JH0212,JH0211,JT0526,JU0178,JQ1033,JU0237,JQ1041)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LSSDITASV*# SEQUENCE: LSSDITASV*# ...# >MUS21D0A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (88-96)# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_MELGA,LYC_SYRRE,LYC_CHICK,LYC_CHICK,# & LYC_PHAVE,LYC_PAVCR,LYC_LOPLE,LYC_PHACO)# & PIR1: (LZCH,LZTK,LZQJE,LZFER)# & PIR2: (JT0526,JQ1041,JU0237,JH0212,JH0211,JU0178,JQ1033)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,ITASVNCAK*# SEQUENCE: ITASVNCAK*# ...# >MUS21D0B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (108-116)# ANCHOR POSITIONS: 1,6,9# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,WYAWRNRCK*# SEQUENCE: WYAWRNRCK*# ...# >MUS21D0C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SWMb (69-77)# DB REFERENCE: SWISS: (MYG_TURTR,MYG_KOGSI,MYG_GLOME,MYG_RABIT,MYG_PHYCA,# & MYG_ORCOR,MYG_PHYCA)# & PIR1: (MYWHL,MYDDBS,MYDD,MYWHW,MYWHP,MYWHT,MYRB)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LTALGAILK*# SEQUENCE: LTALGAILK*# ...# >MUS21D0D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Lambdarep (18-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LKAIYEKKK*# SEQUENCE: LKAIYEKKK*# ...# >MUS21D0E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSVgD (9-17)# DB REFERENCE: SWISS: (VGLD_HSV11,VLGD_HSV1A,VGLD_HSV2,VGLD_HSV1H)# & PIR1: (VGBEDZ,VGBED2,VGBED1,A47627,VGBE33,VGBE17)# & PIR2: (E43674)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LKMADPNRF*# SEQUENCE: LKMADPNRF*# ...# >MUS21D0F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SNase (69-97)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LAYIYADGK*# SEQUENCE: LAYIYADGK*# ...# >MUS21D10# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SNase (125-133)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LRKSEAQAK*# SEQUENCE: LRKSEAQAK*# ...# >MUS21D11# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SNase (104-112)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,VRQGLAKVA*# SEQUENCE: VRQGLAKVA*# ...# >MUS21D12# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TUNA CytC# DB REFERENCE: SWISS: (CYC_KATPE)# & PIR1: (CCBN)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,VAYLKSATS*# SEQUENCE: VAYLKSATS*# ...# >MUS21D13# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MOUSE CytC# DB REFERENCE: SWISS: (CYC_MACGI,CYC_ATESP,CYC_RABIT,CYC_MACMU,CYC_HORSE,# & CYC_MOUSE,CYC_ESCGI,CYC_ESCGI,CYC_BOVIN,CYC_EQUAS,# & CYC_EQUAS,CYC_HUMAN,CYC_ATESP,CYC_HORSE)# & PIR1: (CCGW,CCMQR,CCMKP,CCSH,CCCM,CCHOD,CCCZ,CCHOZ,CCPG,CCRT,# & CCHO,CCKGG,CCMS,CCBO,CCHU,CCWHC,CCRB)# & PIR2: (C04604)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,IAYLKKATNE*# SEQUENCE: IAYLKKATNE*# ...# >MUS21D14# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SWMb (136-146)# DB REFERENCE: SWISS: (MYG_TURTR,MYG_GLOME,MYG_MEGNO,MYG_BALAC,MYG_ZIPCA,# & MYG_INIGE,MYG_PHYCA,MYG_ORCOR,MYG_KOGSI,MYG_CASFI,# & MYG_MESCA,MYG_BALPH,MYG_ESCGI,MYG_PHYCA)# & PIR1: (MYDDAR,MYDDBS,MYWHF,MYWHL,MYWHC,MYWHW,MYWHT,MYWHP,MYWHH,# & MYWHU,MYWHK,MYWHZ,MYDD)# & PIR2: (JN0410)# REFERENCES: harris93e# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,FRKDIAAKY*# SEQUENCE: FRKDIAAKY*# ...# >HUM21D15# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSA-1 (106-121)# DB REFERENCE: SWISS: (ALBU_HUMAN,ALB_MACMU)# & PIR1: (ABHUS)# & PIR2: (A47391)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,ETYGEMADCCAKQEPE*# SEQUENCE: ETYGEMADCCAKQEPE*# ...# >HUM21D16# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSA-1 (105-120)# DB REFERENCE: SWISS: (ALBU_HUMAN,ALB_MACMU)# & PIR1: (ABHUS)# & PIR2: (A47391,G01747)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,RETYGEMADCCAKQEP*# SEQUENCE: RETYGEMADCCAKQEP*# ...# >HUM21D17# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSA-1 (105-121)# DB REFERENCE: SWISS: (ALBU_HUMAN,ALB_MACMU)# & PIR1: (ABHUS)# & PIR2: (A47391)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,RETYGEMADCCAKQEPE*# SEQUENCE: RETYGEMADCCAKQEPE*# ...# >HUM21D18# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSA-1 (104-119)# DB REFERENCE: SWISS: (ALBU_HUMAN,ALB_MACMU)# & PIR1: (ABHUS)# & PIR2: (A47391,G01747)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,LRETYGEMADCCAKQE*# SEQUENCE: LRETYGEMADCCAKQE*# ...# >HUM21D19# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VCAM-1 (448-465)# DB REFERENCE: SWISS: (VCA1_HUMAN,VCA1_HUMAN)# & PIR2: (A41288,B41288)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,ENIEFLEDTDMKSLENKS*# SEQUENCE: ENIEFLEDTDMKSLENKS*# ...# >HUM21D1A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VCAM-1 (448-459)# DB REFERENCE: SWISS: (VCA1_HUMAN,VCA1_HUMAN)# & PIR2: (A41288,B41288)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,ENIEFLEDTDMK*# SEQUENCE: ENIEFLEDTDMK*# ...# >HUM21D1B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSA-2 (443-458)# DB REFERENCE: SWISS: (ALB_MACMU,ALBU_HUMAN)# & PIR1: (ABHUS)# & PIR2: (A47391)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,STPTLVEVSRNLGKVG*# SEQUENCE: STPTLVEVSRNLGKVG*# ...# >HUM21D1C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSA-2 (444-459)# DB REFERENCE: SWISS: (ALBU_HUMAN)# & PIR1: (ABHUS)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,TPTLVEVSRNLGKVGS*# SEQUENCE: TPTLVEVSRNLGKVGS*# ...# >HUM21D1D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSA-2 (444-458)# DB REFERENCE: SWISS: (ALB_MACMU,ALBU_HUMAN)# & PIR1: (ABHUS)# & PIR2: (A47391)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,TPTLVEVSRNLGKVG*# SEQUENCE: TPTLVEVSRNLGKVG*# ...# >HUM21D1E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgG-lambda (134-149)# DB REFERENCE: SWISS: (LAC_HUMAN,I141_HUMAN)# & PIR1: (A33911,L2HU)# & PIR2: (S25746,S25751,S05270,B49444,S25740,S21066,S25750,S12441,# & S25744,S12440,S25742,S25753,S25747,S12442,S29258,S14675,# & S25738,S25752,S03401,S25759,A42193,S25748,S25757,S25749,# & S25754,S25741,S25755,A39949,S25758,S12443,S25745,# & S25756)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,FPPSSEELQANKATLV*# SEQUENCE: FPPSSEELQANKATLV*# ...# >HUM21D1F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L35 (52-72)# DB REFERENCE: SWISS: (RL35_HUMAN,RL35_RAT)# & PIR1: (R5RT35)# & PIR2: (G01477)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,SIARVLTVINQTQKENLRKFY*# SEQUENCE: SIARVLTVINQTQKENLRKFY*# ...# >HUM21D20# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin S (24-39)# DB REFERENCE: SWISS: (CATS_HUMAN)# & PIR2: (A42482)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,LDHHWHLWKKTYGKQY*# SEQUENCE: LDHHWHLWKKTYGKQY*# ...# >HUM21D21# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: E4.1 (374-380)# DB REFERENCE: SWISS: (41_HUMAN)# & PIR1: (MMHUE4)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,VVPKAQK*# SEQUENCE: VVPKAQK*# ...# >HUM21D22# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: HPLC and mass spectrometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L31 (116-125)# DB REFERENCE: SWISS: (RL31_HUMAN,RL31_HUMAN)# & PIR1: (R5HU31,R5RT31)# REFERENCES: gordon95a# COMMENT: self peptide# SUMMARY: HLA-DR4,actunkn,bindyesu,NLQTVNVDEN*# SEQUENCE: NLQTVNVDEN*# ...# >HUM11D23# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Chlamydia trachomatis 57-kDa hsp# DB REFERENCE: PIR2: (A60273)# REFERENCES: rognan95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,KRGIDKAAK*# SEQUENCE: KRGIDKAAK*# ...# >HUM11D24# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Chlamydia trachomatis 57-kDa hsp homologue# ANCHOR POSITIONS:# REFERENCES: rognan95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,KRLIDKAAK*# SEQUENCE: KRLIDKAAK*# ...# >HUM11D25# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: HLA assembly as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Chlamydia trachomatis groEL (117-125) homologue# ANCHOR POSITIONS:# REFERENCES: rognan95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesm,QRLGGGGGK*# SEQUENCE: QRLGGGGGK*# ...# >HUM11D26# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HPLC and mass spectrometry/inhibition as./CTL as./Reference# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: myosin class I# ANCHOR POSITIONS: 2,9# REFERENCES: denhaan95a,engelhard96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,YIGEVLVSV*# SEQUENCE: YIGEVLVSV*# ...# >HUM11D27# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HPLC and mass spectrometry/inhibition as./CTL as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: myosin class I# ANCHOR POSITIONS: 2,9# REFERENCES: denhaan95a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,YLGEVLVSV*# SEQUENCE: YLGEVLVSV*# ...# >HUM11D28# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HPLC and mass spectrometry/inhibition as./CTL as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: myosin class I# ANCHOR POSITIONS: 2,9# REFERENCES: denhaan95a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,YLGEVIVSV*# SEQUENCE: YLGEVIVSV*# ...# >HUM11D29# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBNA-1 (565-574)# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# REFERENCES: wrightham95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLQTHIFAEV*# SEQUENCE: FLQTHIFAEV*# ...# >HUM11D2A# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HTLV-1 pol# DB REFERENCE: SWISS: (POL_HTL1A,POL_HTL1C)# & PIR1: (GNLJGH,GNLJCN)# REFERENCES: schonbach95a,schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,IPLPKQFQPY*# SEQUENCE: IPLPKQFQPY*# ...# >HUM11D2B# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-1 env# DB REFERENCE: SWISS: (ENV_HTL1M,ENV_HTL1F,ENV_HTL1N,ENV_HTL1A)# & PIR1: (VCVWH,VCLJMT)# & PIR2: (S14605,B61547,B41358)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,VPSSSSTPLLY*# SEQUENCE: VPSSSSTPLLY*# ...# >HUM11D2C# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-1 env# DB REFERENCE: SWISS: (ENV_HTL1F,ENV_HTL1N,ENV_HTL1M,ENV_HTL1A)# & PIR1: (VCLJMT,VCVWH)# & PIR2: (S14605,A45714,B61547)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,FPFSLLVDAPGY*# SEQUENCE: FPFSLLVDAPGY*# ...# >HUM11D2D# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-2 gag# DB REFERENCE: SWISS: (GAG_HTLV2)# & PIR1: (FOLJH2)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,EPILRSLAY*# SEQUENCE: EPILRSLAY*# ...# >HUM11D2E# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-1 vprt# DB REFERENCE: SWISS: (VPRT_HTL1C,VPRT_HTL1A)# & PIR1: (PNLJH1,PNLJCN)# & PIR2: (A60720,A61547)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,TPLKNTSVL*# SEQUENCE: TPLKNTSVL*# ...# >HUM11D2F# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-1 gag# DB REFERENCE: SWISS: (GAG_HTL1M,GAG_HTL1C,GAG_HTLV2,GAG_HTL1A)# & PIR1: (FOLJH2,FOLJGH,FOLJCN)# & PIR2: (S06073)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,TPKDKTKVL*# SEQUENCE: TPKDKTKVL*# ...# >HUM11D30# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ENV_HIV2G-15# DB REFERENCE: SWISS: (ENV_HV2G1,ENV_HV2ST,ENV_HV2S2)# & PIR1: (VCLJS4,VCLJGG,VCLJST)# & PIR2: (S53098)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,VPITLMSGL*# SEQUENCE: VPITLMSGL*# ...# >HUM11D31# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ENV_HIV2B-16# DB REFERENCE: SWISS: (ENV_HV2BE)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,LPITLMSGL*# SEQUENCE: LPITLMSGL*# ...# >HUM11D32# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAG_HIV21-17# DB REFERENCE: SWISS: (NEF_HV2D1)# & PIR2: (S12160,S54849,S54865,S54853)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,VPVMPRVPL*# SEQUENCE: VPVMPRVPL*# ...# >HUM11D33# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: NEF_HIV2N-16# DB REFERENCE: SWISS: (NEF_HV2NZ)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPVTPRVPL*# SEQUENCE: FPVTPRVPL*# ...# >HUM11D34# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: EAD_EBV-19# DB REFERENCE: SWISS: (EAD_EBV)# & PIR1: (QQBE13)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPLDLSVIL*# SEQUENCE: LPLDLSVIL*# ...# >HUM11D35# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: KR2_EBV-20# DB REFERENCE: SWISS: (KR2_EBV,KR2_EBV)# & PIR2: (S33033)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPITCEYLL*# SEQUENCE: LPITCEYLL*# ...# >HUM11D36# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TEGU EBV-21# DB REFERENCE: SWISS: (TEGU_EBV)# & PIR1: (QQBE8)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,RPLTSRPEL*# SEQUENCE: RPLTSRPEL*# ...# >HUM11D37# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TEGU_EBV-22# DB REFERENCE: SWISS: (TEGU_EBV)# & PIR1: (QQBE8)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,HPLTNNLPL*# SEQUENCE: HPLTNNLPL*# ...# >HUM11D38# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TEGU_EBV-23# DB REFERENCE: SWISS: (TEGU_EBV)# & PIR1: (QQBE8)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPLQIPIPL*# SEQUENCE: LPLQIPIPL*# ...# >HUM11D39# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: UL52_EBV-24# DB REFERENCE: SWISS: (UL52_EBV)# & PIR1: (QQBE15)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,TPLVELLTL*# SEQUENCE: TPLVELLTL*# ...# >HUM11D3A# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: VIMP_EBV-25# DB REFERENCE: SWISS: (VGLM_EBV)# & PIR1: (QQBE35)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,VPVSETVEL*# SEQUENCE: VPVSETVEL*# ...# >HUM11D3B# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: VIMP_EBV-26# DB REFERENCE: SWISS: (VGLM_EBV)# & PIR1: (QQBE35)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,KPVVTNLYL*# SEQUENCE: KPVVTNLYL*# ...# >HUM11D3C# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: VP40_EBV-27# DB REFERENCE: SWISS: (VP40_EBV)# & PIR1: (QQBE3R)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,DPLTVKSQL*# SEQUENCE: DPLTVKSQL*# ...# >HUM11D3D# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: VTER_EBV-28# DB REFERENCE: SWISS: (VTER_EBV)# & PIR1: (QQBE38)# REFERENCES: schonbach95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,TPVQVQMCL*# SEQUENCE: TPVQVQMCL*# ...# >HUM11D3E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: induction of surface expression/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human GAD65 (114-123)# DB REFERENCE: SWISS: (DCE2_MOUSE,DCE2_RAT,DCE2_HUMAN)# & PIR1: (JH0423,A41292,S38533)# REFERENCES: panina-bordignon95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,VMNILLQYVV*# SEQUENCE: VMNILLQYVV*# ...# >HUM11D3F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HLA expression/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV pol (652-660)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1N5,POL_HV1EL,POL_HV1B5,POL_HV1RH,# & POL_HV1Z2,POL_HV1Y2,POL_HV1BR,POL_HV1OY,POL_HV1PV,# & POL_HV1A2,POL_HV1ND,POL_HV1H2,POL_HV1JR,POL_HV1B1)# & PIR1: (GNVWVL,GNVWH3,GNVWLV,GNLJND,GNVWA2,B44001)# & PIR2: (A47175,S54378,B47175)# & PIR3: (S33980,S11523)# REFERENCES: brander95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ALQDSGLEV*# SEQUENCE: ALQDSGLEV*# ...# >HUM11D40# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HLA expression/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV env (199-207)# ANCHOR POSITIONS: 2,9# REFERENCES: brander95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,KLTSLCNTV*# SEQUENCE: KLTSLCNTV*# ...# >HUM11D41# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HLA expression/cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV env (529-537)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1S1,ENV_HV1Z8,ENV_HV1MN,ENV_SIVCZ,# & ENV_HV1MA,ENV_HV1Z6,ENV_HV1C4,ENV_HV1MF,ENV_HV1Y2,# & ENV_HV1OY,ENV_HV1B1,ENV_HV1W1,ENV_HV1J3,ENV_HV1KB,# & ENV_HV1PV,ENV_HV1Z2,ENV_HV1ND,ENV_HV1H2,ENV_HV1JR,# & ENV_HV1W2,ENV_HV1BR,ENV_HV1H3,ENV_HV1RH,ENV_HV1B8,# & ENV_HV1BN,ENV_HV1A2,ENV_HV1EL,ENV_HV1SC,ENV_HV1S3)# & PIR1: (VCLJSI,VCLJZR,VCLJKB,VCLJKX,VCLJA2,VCLJH4,VCLJSC,H44001,# & VCLJBR,A44963,VCLJND,VCLJLV,VCLJH3,VCLJVL,VCLJ3W,# & VCLJMN)# & PIR2: (C41621,S60549,S60547,S60557,S21998,S70419,S70418,S70420,# & S60550,S60531,S21994,S60692,S60705,S70421,S60524,S70424,# & S60546,S60690,S60553,S70417,S21990,S60541,S60556,S60528,# & S60694,S60554,S25940,S60548,S60522,S60532,S60696,S21992,# & S60558,S22000,S60706,B41621,S60538,S60691,S60693,S22006,# & S60707,S60688,S22002,S21996,S70423,S60687,S60552,S60525,# & S60545,S22004,S70422,S60551,S54384,S60543,A41621,S70425,# & S60526,S60523,S60521)# & PIR3: (S33985,S13288,S13289)# REFERENCES: brander95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,FLGAAGSTM*# SEQUENCE: FLGAAGSTM*# ...# >HUM11D42# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HLA expression# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV env (582-590)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1H3,ENV_HV1ZH,ENV_HV1J3,ENV_HV1PV,# & ENV_HV1H2,ENV_HV1Z2,ENV_HV1C4,ENV_HV1Z6,ENV_HV1B1,# & ENV_HV1EL,ENV_HV1B8,ENV_HV1BR)# & PIR1: (VCLJH4,VCLJLV,VCLJH3,VCLJZR,VCLJVL,A44963)# & PIR2: (S54384,S21996,S70425,S21998,S70422)# & PIR3: (S33985,S13288)# REFERENCES: brander95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,QLQARILAV*# SEQUENCE: QLQARILAV*# ...# >HUM11D43# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: HLA expression/cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV env (821-828)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1MF,ENV_HV1PV,ENV_HV1S3,ENV_HV1KB,# & ENV_HV1BR,ENV_HV1OY,ENV_HV1Y2,ENV_HV1B1,ENV_HV1H3,# & ENV_HV1MN,ENV_HV1B8,ENV_HV1Z8,ENV_HV1JR,ENV_HV1H2)# & PIR1: (VCLJKB,VCLJH3,VCLJLV,H44001,VCLJMN,VCLJBR,VCLJVL)# & PIR2: (S22004,S70420,S22002,S70421,S21998,S70425,S70424,S70418,# & S21992,S22006,S70417,S70419,S21994,S22000)# & PIR3: (S33985,S13289,S13288)# REFERENCES: brander95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesu,LLNATAIAV*# SEQUENCE: LLNATAIAV*# ...# >HUM21D44# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TPO (632-645)# DB REFERENCE: SWISS: (PERT_HUMAN)# & PIR1: (OPHUIT)# REFERENCES: kwok95a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,IDVWLGGLAENFLP*# SEQUENCE: IDVWLGGLAENFLP*# ...# >HUM21D45# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TPO (632-645)# DB REFERENCE: SWISS: (PERT_HUMAN)# & PIR1: (OPHUIT)# REFERENCES: kwok95a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,IDVWLGGLAENFLP*# SEQUENCE: IDVWLGGLAENFLP*# ...# >HUM21D46# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TPO (632-645)# DB REFERENCE: SWISS: (PERT_HUMAN)# & PIR1: (OPHUIT)# REFERENCES: kwok95a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,IDVWLGGLAENFLP*# SEQUENCE: IDVWLGGLAENFLP*# ...# >HUM21D47# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: lambda repressor (12-24)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: kwok95a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,LEDARRLKAIYEK*# SEQUENCE: LEDARRLKAIYEK*# ...# >HUM21D48# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-ala homologue# ANCHOR POSITIONS:# REFERENCES: kwok95a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,AAYAAAAAAKAA*# SEQUENCE: AAYAAAAAAKAA*# ...# >HUM21D49# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: poly-ala homologue# ANCHOR POSITIONS:# REFERENCES: kwok95a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,AAYAAAAAAKAA*# SEQUENCE: AAYAAAAAAKAA*# ...# >HUM21D4A# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: poly-ala homologue# ANCHOR POSITIONS:# REFERENCES: kwok95a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,AAYAAAAAAKAA*# SEQUENCE: AAYAAAAAAKAA*# ...# >HUM11D4B# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# ANCHOR POSITIONS: 3,5,9# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGKKRYKLK*# SEQUENCE: GGKKRYKLK*# ...# >HUM11D4C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# ANCHOR POSITIONS: 3,5,9# REFERENCES: mcadam95a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGRKKYKLK*# SEQUENCE: GGRKKYKLK*# ...# >HUM11D4D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# ANCHOR POSITIONS: 3,5,9# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGRKKYKFK*# SEQUENCE: GGRKKYKFK*# ...# >HUM11D4E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# ANCHOR POSITIONS: 3,5,9# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGRKKYQLK*# SEQUENCE: GGRKKYQLK*# ...# >HUM11D4F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# DB REFERENCE: SWISS: (GAG_HV2BE,GAG_HV1EL,GAG_HV2KR,GAG_HV1W2,GAG_HV1JR,# & GAG_HV1MA,GAG_HV2SB,GAG_HV2RO,GAG_HV2ST,GAG_HV1Z2)# & PIR1: (FOLJG2,FOLJST)# & PIR2: (S54377,S53091)# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGKKKYRLK*# SEQUENCE: GGKKKYRLK*# ...# >HUM11D50# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# ANCHOR POSITIONS: 3,5,9# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesn,bindyesu,GGRKKYRLK*# SEQUENCE: GGRKKYRLK*# ...# >HUM11D51# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# DB REFERENCE: SWISS: (GAG_HV1OY)# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGKKKYQLK*# SEQUENCE: GGKKKYQLK*# ...# >HUM11D52# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# DB REFERENCE: SWISS: (GAG_HV1RH)# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,RGKKRYKLK*# SEQUENCE: RGKKRYKLK*# ...# >HUM11D53# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# DB REFERENCE: SWISS: (GAG_HV1Y2,GAG_HV1C4)# & PIR1: (A44001,FOVWH4)# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGKKQYRLK*# SEQUENCE: GGKKQYRLK*# ...# >HUM11D54# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# ANCHOR POSITIONS: 3,5,9# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGKKKYKLR*# SEQUENCE: GGKKKYKLR*# ...# >HUM11D55# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: HIV gag p17-3 (24-32)# DB REFERENCE: SWISS: (GAG_HV1ND)# & PIR1: (FOLJND)# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesn,bindyesu,GGKKKYALK*# SEQUENCE: GGKKKYALK*# ...# >HUM11D56# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p24-13 (259-216)# DB REFERENCE: SWISS: (GAG_HV1MA)# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GDIYKRWII*# SEQUENCE: GDIYKRWII*# ...# >HUM11D57# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: HLA assembly as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gag p24-20 (329-337)# ANCHOR POSITIONS: 3,5,9# REFERENCES: mcadam95a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,DCRTILKAL*# SEQUENCE: DCRTILKAL*# ...# >HUM21D58# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: birch pollen allergen Bet v 1 (144-153)# DB REFERENCE: SWISS: (BV1E_BETVE,BV1J_BETVE,BV1B_BETVE,BV1L_BETVE,BV1M_BETVE,# & BV1M_BETVE,BV1A_BETVE,BV1G_BETVE,BV1D_BETVE,BV1L_BETVE,# & BV1C_BETVE,BV1F_BETVE,BV1C_BETVE,MPA1_CARBE,MPA2_CARBE,# & BV1A_BETVE,BV1K_BETVE,MPA2_CARBE,BV1D_BETVE,MPA1_CARBE,# & BV1B_BETVE,BV1J_BETVE,BV1E_BETVE,BV1G_BETVE,BV1F_BETVE,# & BV1K_BETVE)# & PIR2: (S05376,B55699,C55699,I55699,G55699,A55699,H55699,A57427,# & D55699,F55699,E55699)# REFERENCES: breiteneder95a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,LRAVESYLLA*# SEQUENCE: LRAVESYLLA*# ...# >HUM21D59# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: birch pollen allergen Bet v 1 (144-153)# DB REFERENCE: SWISS: (BV1A_BETVE,BV1K_BETVE,BV1G_BETVE,BV1D_BETVE,BV1G_BETVE,# & BV1L_BETVE,BV1B_BETVE,MPA1_CARBE,BV1K_BETVE,MPA2_CARBE,# & BV1C_BETVE,BV1F_BETVE,MPA2_CARBE,BV1D_BETVE,BV1A_BETVE,# & MPA1_CARBE,BV1B_BETVE,BV1J_BETVE,BV1E_BETVE,BV1L_BETVE,# & BV1M_BETVE,BV1M_BETVE,BV1E_BETVE,BV1J_BETVE,BV1C_BETVE,# & BV1F_BETVE)# & PIR2: (C55699,G55699,I55699,B55699,A55699,D55699,H55699,A57427,# & S05376,F55699,E55699)# REFERENCES: breiteneder95a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,LRAVESYLLA*# SEQUENCE: LRAVESYLLA*# ...# >HUM21D5A# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: birch pollen allergen Bet v 1 (144-152)# DB REFERENCE: SWISS: (BV1E_BETVE,BV1F_BETVE,MPA2_CARBE,MPA1_CARBE,BV1F_BETVE,# & BV1A_BETVE,BV1J_BETVE,BV1E_BETVE,MPA1_CARBE,BV1L_BETVE,# & BV1C_BETVE,BV1B_BETVE,BV1K_BETVE,BV1D_BETVE,BV1J_BETVE,# & BV1C_BETVE,BV1M_BETVE,BV1G_BETVE,BV1D_BETVE,BV1K_BETVE,# & BV1B_BETVE,MPA2_CARBE,BV1A_BETVE,BV1G_BETVE,BV1M_BETVE,# & BV1L_BETVE)# & PIR2: (H55699,F55699,E55699,G55699,I55699,B55699,A55699,D55699,# & A57427,S05376,C55699)# REFERENCES: breiteneder95a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,LRAVESYLL*# SEQUENCE: LRAVESYLL*# ...# >HUM21D5B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: birch pollen allergen Bet v 1 (144-152)# DB REFERENCE: SWISS: (BV1B_BETVE,BV1C_BETVE,BV1B_BETVE,MPA1_CARBE,BV1J_BETVE,# & BV1A_BETVE,BV1F_BETVE,BV1F_BETVE,BV1J_BETVE,BV1G_BETVE,# & BV1A_BETVE,BV1M_BETVE,BV1G_BETVE,BV1D_BETVE,BV1K_BETVE,# & BV1L_BETVE,BV1M_BETVE,MPA2_CARBE,BV1D_BETVE,BV1C_BETVE,# & BV1K_BETVE,BV1L_BETVE,MPA1_CARBE,BV1E_BETVE,BV1E_BETVE,# & MPA2_CARBE)# & PIR2: (S05376,A55699,B55699,E55699,F55699,H55699,A57427,C55699,# & D55699,I55699,G55699)# REFERENCES: breiteneder95a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,LRAVESYLL*# SEQUENCE: LRAVESYLL*# ...# >HUM11D5C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (63-77)# DB REFERENCE: PIR1: (SAVLBH)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLGWSPQAQGILETL*# SEQUENCE: LLGWSPQAQGILETL*# ...# >HUM11D5D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (141-157)# DB REFERENCE: SWISS: (VMSA_HPBVA)# & PIR1: (SAVLBH,SAVLA1)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,NPVPTTVSPISSIFSRI*# SEQUENCE: NPVPTTVSPISSIFSRI*# ...# >HUM11D5E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (174-193)# DB REFERENCE: SWISS: (VMSA_HPBVN,VMSA_HPBV0,VMSA_HPBVD,VMSA_HPBVP,VMSA_HPBV2,# & VMSA_HPBVZ,VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBV2,# & VMSA_HPBVY,VMSA_HPBV4,VMSA_HPBVS,VMSA_HPBVY,# & VMSA_HPBVW)# & PIR1: (SAVLN1,JQ1575,SAVLA,SAVLAH,SAVLBH,SAVLAJ,JQ1577,SAVLAD,# & SAVLVE,SAVLAR,SAVLHV,SAVLVD)# & PIR2: (S32202,JQ2094,JQ2102,JQ2112,JQ2046,S20753,S36654,JQ2097,# & JQ2075,JQ2068,JQ2079,JQ2065,JQ2053,JQ2095,S47407,S20745,# & JQ2100,JQ2104,JQ2048,JQ2077,JQ2072,JQ2070,JQ2055,JQ2050,# & S41870,JQ2067,JQ2083,JQ2066,JQ2047,JQ2099,S41869,S47411,# & JQ2052,JQ2081,JQ2078,JQ2098,JQ2115,JQ2045,JQ2103,JQ2073,# & JQ2114,JQ2105,JQ2063,JQ2113,S43492,JQ2076,JQ2108,JQ2111,# & JQ2054,JQ2109,S20749,JQ2069,JQ2051,JQ2080,JQ2056,# & S35528)# & PIR4: (S42226)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,PLLVLQAGFFLLTRILTIPQ*# SEQUENCE: PLLVLQAGFFLLTRILTIPQ*# ...# >HUM11D5F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (194-213)# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVA)# & PIR1: (SAVLBH,SAVLAH,SAVLA1,SAVLAJ,JQ1572,JQ1571)# & PIR2: (S20745,JQ2072,JQ2066,JQ2078,S41870,S32202,JQ2068,JQ2065,# & S41871,JQ2076,JQ2063,S20753,S47407,JQ2075,JQ2079,JQ2073,# & JQ2069,JQ2080,S41869,JQ2081,JQ2070,JQ2083,JQ2067,# & JQ2077)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLDSWWTSLNFLGGTTVCLG*# SEQUENCE: SLDSWWTSLNFLGGTTVCLG*# ...# >HUM11D60# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (234-253)# DB REFERENCE: SWISS: (VMSA_HPBV0,VMSA_HPBVD,VMSA_HPBVW,VMSA_HPBVS,VMSA_HPBVL,# & VMSA_HPBVT,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVW,VMSA_HPBV9,# & VMSA_HPBVY,VMSA_HPBVN,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVA,# & VMSA_HPBV4,VMSA_HPBVZ,VMSA_HPBV2,VMSA_HPBVP)# & PIR1: (SAVLCP,JQ1576,JQ1577,SAVLVD,JQ1574,SAVLA,JQ1581,JQ1575,# & JQ1572,JQ1571,JQ1579,SAVLBH,SAVLAH,SAVLAD,SAVLHV,JQ1580,# & SAVLN1,JQ1573,SAVLAJ,SAVLA1,SAVLAR,SAVLKS,JQ1578,# & SAVLVE)# & PIR2: (JQ2048,JQ2055,JQ2100,JQ2069,JQ2047,JQ2099,JQ2080,JQ2081,# & JQ2110,S41869,JQ2089,JQ2052,JQ2085,JQ2045,JQ2098,JQ2103,# & JQ2068,JQ2054,JQ2109,JQ2090,JQ2092,JQ2051,S41870,JQ2066,# & JQ2119,JQ2106,JQ2226,JQ2121,JQ2114,JQ2105,S20745,JQ2072,# & JQ2101,S35528,JQ2070,JQ2083,JQ2087,JQ2097,JQ2077,JQ2067,# & JQ2088,JQ2225,JQ2112,JQ2096,S20753,JQ2113,JQ2079,JQ2075,# & JQ2122,JQ2094,JQ2050,S43492,JQ2063,S47407,JQ2120,JQ2053,# & JQ2095,JQ2102,S36654,JQ2104,JQ2073,JQ2115,S47411,JQ2078,# & JQ2091,S32202,JQ2065,JQ2111,JQ2046,JQ2123,JQ2076,JQ2230,# & JQ2056,JQ2108)# & PIR4: (S42226)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GYRWMCLRRFIIFLFILLLC*# SEQUENCE: GYRWMCLRRFIIFLFILLLC*# ...# >HUM11D61# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (246-265)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBV4,VMSA_HPBVW,VMSA_HPBVZ,# & VMSA_HPBVP,VMSA_HPBVD,VMSA_HPBV0,VMSA_HPBVR,VMSA_HPBVT,# & VMSA_HPBV2,VMSA_HPBVA,VMSA_HPBV9,VMSA_HPBVW,VMSA_HPBV2,# & VMSA_HPBVR,VMSA_HPBVL)# & PIR1: (JQ1571,JQ1572,JQ1579,JQ1573,SAVLA,JQ1581,SAVLVE,SAVLA1,# & SAVLAJ,SAVLVD,JQ1575,SAVLCP,JQ1576,JQ1574,SAVLKS,SAVLAH,# & SAVLBH,SAVLHV,JQ1578,JQ1580,SAVLAD)# & PIR2: (JQ2122,S20753,JQ2077,JQ2083,JQ2070,JQ2094,JQ2056,JQ2053,# & S32202,JQ2080,JQ2045,JQ2054,JQ2092,JQ2065,JQ2091,JQ2072,# & S35528,JQ2114,JQ2105,JQ2098,JQ2103,S41870,JQ2109,JQ2068,# & JQ2087,JQ2097,JQ2088,JQ2079,JQ2112,JQ2100,S47407,JQ2113,# & JQ2096,JQ2075,JQ2110,JQ2067,JQ2225,JQ2081,S41869,JQ2089,# & JQ2055,JQ2069,JQ2047,JQ2099,JQ2108,JQ2123,JQ2076,JQ2046,# & JQ2050,JQ2111,JQ2078,JQ2104,JQ2073,JQ2115,S47411,JQ2230,# & JQ2063,S41871,JQ2102,JQ2095,JQ2121,JQ2226,JQ2120,JQ2101,# & S20745,JQ2119,JQ2066,JQ2090,JQ2085,JQ2052,JQ2106,JQ2116,# & JQ2051)# & PIR4: (S42226)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLFILLLCLIFLLVLLDYQG*# SEQUENCE: FLFILLLCLIFLLVLLDYQG*# ...# >HUM11D62# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (309-328)# DB REFERENCE: SWISS: (VMSA_HPBVA,VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBVY)# & PIR1: (JQ1578,JQ1572,JQ1571,SAVLAH,SAVLBH,SAVLA1,SAVLAJ,# & JQ1573)# & PIR2: (JQ2073,JQ2088,JQ2079,JQ2083,S20753,JQ2077,JQ2070,JQ2072,# & JQ2065,JQ2091,S47407,JQ2092,S20745,JQ2066,S41869,JQ2069,# & JQ2067,JQ2081,JQ2090,JQ2075,JQ2089,S41871,JQ2063,JQ2085,# & JQ2076,JQ2078,JQ2087,JQ2068,S41870,S32202,JQ2080)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,NCTCIPIPSSWAFGKFLWEW*# SEQUENCE: NCTCIPIPSSWAFGKFLWEW*# ...# >HUM11D63# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (328-348)# DB REFERENCE: SWISS: (VMSA_HPBVA,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVZ)# & PIR1: (SAVLBH,SAVLA1,SAVLAJ,JQ1571,SAVLAH,JQ1572,JQ1574)# & PIR2: (JQ2081,JQ2063,JQ2076,JQ2075,JQ2065,S47407,JQ2073,S20745,# & JQ2067,JQ2066,JQ2069,S41869,S32202,JQ2068,JQ2078,S20753,# & JQ2077,JQ2101)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ASARFSWLSLLVPFVQWFVG*# SEQUENCE: ASARFSWLSLLVPFVQWFVG*# ...# >HUM11D64# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV surface Ag (349-358)# DB REFERENCE: SWISS: (VMSA_HPBVJ,VMSA_HPBVR,VMSA_HPBVD,VMSA_HPBVN,VMSA_HPBVS,# & VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBV4,VMSA_HPBVR)# & PIR1: (JQ1578,SAVLAH,JQ1573,JQ1571,SAVLJ1,SAVLAR,JQ1577,SAVLAD,# & JQ1572,JQ1574,JQ1576,JQ1581,SAVLA,SAVLN1,SAVLBH)# & PIR2: (JQ2079,JQ2078,JQ2104,JQ2091,JQ2089,S20745,JQ2098,JQ2109,# & JQ2092,S32202,JQ2050,S35528,JQ2114,JQ2105,S47407,JQ2094,# & JQ2066,JQ2113,JQ2069,JQ2096,JQ2061,JQ2116,JQ2110,JQ2101,# & JQ2108,JQ2106,S20753,JQ2095,JQ2111,JQ2083,JQ2070,JQ2097,# & JQ2085,JQ2112,JQ2073,JQ2075,JQ2087,JQ2065,JQ2067,S41869,# & JQ2099,JQ2090,JQ2063)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LSPTVWLSVIWMMWYWGPSL*# SEQUENCE: LSPTVWLSVIWMMWYWGPSL*# ...# >HUM11D65# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV core Ag (11-27)# DB REFERENCE: SWISS: (CORA_HPBVZ,CORA_HPBVF,CORA_HPBVL,CORA_HPBVA,CORA_HPBVJ,# & CORA_HPBV2,CORA_HPBVW,CORA_HPBV9,CORA_HPBVY)# & PIR1: (NKVLA2,NKVLA1,NKVLH3,NKVLBH,NKVLA6,NKVLKS,NKVLAH,NKVLA3,# & NKVLJ1,NKVLCP)# & PIR2: (S53207,S53270,S47409,S53169,S53229,S53242,S32204,S53255,# & S53200,S01405,S53260,S53267,S53204,S33686,S53272,S53227,# & S53257,S53159,S53240,S20750,S53184,S53251,S53238,S53202,# & S25651,S53232,S53155,S20746,S53181,S47405,S53216,S53225,# & S53163,S53253,S53236,S53281,S53223,S53279,S53211,# & S53274)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ATVELLSFLPSDFFPSV*# SEQUENCE: ATVELLSFLPSDFFPSV*# ...# >HUM11D66# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV core Ag (91-110)# DB REFERENCE: SWISS: (CORA_HPBVA,CORA_HPBVY)# & PIR1: (NKVLA1,NKVLAH,NKVLBH)# & PIR2: (S53216,S47405,S53163,S53175,S53232,S53267,S53157,S53286,# & S53247,S20750,S53251,S53242,S53169,S32204,S53200,S53198,# & S53214,S53270,S53227,S53211,S53274,S53281,S53140,S53223,# & S53146,S53181,S53137,S53194,S53253,S53238,S53255,S20755,# & S53186,S53229,S53221,S53143,S53152,S53189,S53207)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,TNMGLKFRQLLWFHISCLTF*# SEQUENCE: TNMGLKFRQLLWFHISCLTF*# ...# >HUM11D67# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV core Ag (111-125)# ANCHOR POSITIONS:# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GRETVILYLVSEGVW*# SEQUENCE: GRETVILYLVSEGVW*# ...# >HUM21D68# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HBV core Ag (111-125)# ANCHOR POSITIONS:# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,GRETVILYLVSEGVW*# SEQUENCE: GRETVILYLVSEGVW*# ...# >HUM11D69# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 13 (9-24)# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1OY,GAG_HV1N5,GAG_HV1Y2)# & PIR1: (FOVWA2,A44001)# & PIR2: (S24473,S22044)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,QRKTVKCFNCGKEGHI*# SEQUENCE: QRKTVKCFNCGKEGHI*# ...# >HUM11D6A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 13 (25-40)# DB REFERENCE: SWISS: (GAG_HV1EL,GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,AKNCRAPRKKGCWRCG*# SEQUENCE: AKNCRAPRKKGCWRCG*# ...# >HUM11D6B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 13 (57-72)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1BR,GAG_HV1A2,GAG_HV1PV,GAG_HV1JR,# & GAG_HV1H2,GAG_HV1B1)# & PIR1: (FOVWH3,FOVWLV,FOVWA2)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LGKIWPSYKGRPGNFL*# SEQUENCE: LGKIWPSYKGRPGNFL*# ...# >HUM11D6C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 17 (25-40)# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1B1,GAG_HV1BR,GAG_HV1A2,GAG_HV1B5,# & GAG_HV1PV,GAG_HV1J3)# & PIR1: (FOVWH3,FOVWLV,FOVWA2,FOVWVL)# & PIR3: (S33979)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KKKYKLKHIVWASREL*# SEQUENCE: KKKYKLKHIVWASREL*# ...# >HUM11D6D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 17 (113-133)# DB REFERENCE: SWISS: (GAG_HV1A2)# & PIR1: (FOVWA2)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KAQQAAAAAGTGNSSQVSQNY*# SEQUENCE: KAQQAAAAAGTGNSSQVSQNY*# ...# >HUM11D6E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 25 (73-88)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1H2,GAG_HV1B5,GAG_HV1A2,GAG_HV1B1,# & GAG_HV1PV)# & PIR1: (FOVWVL,FOVWH3,FOVWLV,FOVWA2)# & PIR2: (S49086)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,INEEAAEWDRVHPVHA*# SEQUENCE: INEEAAEWDRVHPVHA*# ...# >HUM11D6F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 25 (121-135)# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1MN,GAG_HV1B1,GAG_HV1Y2,GAG_HV1H2,# & GAG_HV1B5,GAG_HV1W2,GAG_HV1JR,GAG_HV1N5,GAG_HV1ND,# & GAG_HV1OY,GAG_HV1BR,GAG_HV1Z2,GAG_HV1PV,GAG_HV1RH,# & GAG_HV1J3)# & PIR1: (A44001,A38068,FOVWLV,FOVWVL,FOVWA2,FOVWH3,FOLJND)# & PIR2: (S60702,S60708,S54377,S60698,S60704,S60697,S60703,# & S60699)# & PIR3: (S33979)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,NPPIPVGEIYKRWIIL*# SEQUENCE: NPPIPVGEIYKRWIIL*# ...# >HUM11D70# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 25 (129-144)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1B5,GAG_HV1OY,GAG_HV1ND,GAG_HV1Y2,# & GAG_HV1Z2,GAG_HV1PV,GAG_HV1B1,GAG_HV1MN,GAG_HV1A2,# & GAG_HV1MA,GAG_HV1H2,GAG_HV1W2,GAG_HV1N5,GAG_HV1BR,# & GAG_HV1J3,GAG_HV1RH,GAG_HV1JR)# & PIR1: (FOLJND,FOVWH3,A44001,FOVWLV,FOVWVL,A38068,FOVWA2,# & FOVWH4)# & PIR2: (S60699,S60697,S60698,S54377,S60703,S60708,S60704,# & S60702)# & PIR3: (S33979)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,IYKRWIILGLNKIVRM*# SEQUENCE: IYKRWIILGLNKIVRM*# ...# >HUM11D71# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gag 25 (153-168)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1H2,GAG_HV1ND,GAG_HV1B1,GAG_HV1MN,# & GAG_HV1Z2,GAG_HV1B5,GAG_HV1MA,GAG_HV1BR,GAG_HV1W2,# & GAG_HV1EL,GAG_HV1RH,GAG_HV1J3,GAG_HV1U4,GAG_SIVCZ,# & GAG_HV1JR,GAG_HV1A2,GAG_HV1OY,GAG_HV1Y2,GAG_HV1C4)# & PIR1: (FOVWLV,FOLJSI,FOLJND,FOVWH3,A44001,A38068,FOVWA2,FOVWVL,# & FOVWH4)# & PIR2: (S60704,S60702,S52929,S60698,S54377,S60708,S60700,S60703,# & S60699)# & PIR3: (S33979)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,IRQGPKEPFRDYVDRF*# SEQUENCE: IRQGPKEPFRDYVDRF*# ...# >HUM11D72# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV latent membrane (41-51)# DB REFERENCE: SWISS: (LMP1_EBV,LMP1_EBVC)# & PIR1: (QQBE50,LABECA)# & PIR2: (G00065,S21660)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YIVMSDWTGGA*# SEQUENCE: YIVMSDWTGGA*# ...# >HUM11D73# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV latent membrane (97-105)# DB REFERENCE: SWISS: (LMP1_EBVR,LMP1_EBVC,LMP1_EBV)# & PIR1: (LABECA,QQBE50,LABERJ)# & PIR2: (S21660,G00065,S24611)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALWNLHGQA*# SEQUENCE: ALWNLHGQA*# ...# >HUM11D74# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human microglobulin beta-2 (49-64)# ANCHOR POSITIONS:# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,VEHSDLSFSNDWSFYL*# SEQUENCE: VEHSDLSFSNDWSFYL*# ...# >HUM11D75# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human microglobulin beta-2 (61-76)# DB REFERENCE: SWISS: (B2MG_HUMAN,B2MG_PONPY)# & PIR1: (MGHUB2)# & PIR2: (I61868,I36963,I37063)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SFYLLYYTEFTPTEKD*# SEQUENCE: SFYLLYYTEFTPTEKD*# ...# >HUM11D76# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human microglobulin beta-2 (85-99)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: sette91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,VTLSQPKIVKWDRDM*# SEQUENCE: VTLSQPKIVKWDRDM*# ...# >HUM11D77# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human histone H3, H3.3 (52-60)# DB REFERENCE: SWISS: (YB21_CAEEL,H33_CAEEL,H3_ENCAL,H31_HUMAN,H33_HUMAN,# & H3_DROME,H3_NEUCR,H3_EMENI,H3_CAEEL,H32_XENLA,H3_STRPU,# & H3_PSAMI,H31_SCHPO,H3_PSAMI,H33_SCHPO,H32_BOVIN,# & H3_ACRFO)# & PIR1: (HSKW3,HSHU33,HSTR3,HSHU3,HSRK3,HSZP3,HSXL31,HSBO3,# & HSEAH3,HSUR3P,HSFI3,HSXL32,HSCH3,HSUR3M)# & PIR2: (I57019,I50244,S32638,I49397,S34185,S01198,S09655,JQ1983,# & S50140,S61218,A56618,S10097,A56654,S01197,JQ1343,JQ0757,# & S61214,JQ1984,S01196,I48092,S20109,JN0687,S10168,S57473,# & S06743,I49395,A02630,S61215,S32621,S04186,I51448,S61220,# & S06755,S07350,S11315,S20678,I50460,JH0304,I50245,S20669,# & JS0690,I49398,A56580)# & PIR3: (S42066,S11938,S42065,A45941)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRYQKSTEL*# SEQUENCE: RRYQKSTEL*# ...# >HUM11D78# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human histone H3, H3.3 homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,ARYQKSTEL*# SEQUENCE: ARYQKSTEL*# ...# >HUM11D79# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human histone H3, H3.3 homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RQYQKSTEL*# SEQUENCE: RQYQKSTEL*# ...# >HUM11D7A# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human Hsp89 beta (195-203)# DB REFERENCE: SWISS: (HS9B_HUMAN,HS9B_HUMAN,HS9B_RAT,HS9B_CHICK,HS9B_MOUSE)# & PIR1: (HHMS84,HHHU84)# & PIR2: (JC1468)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRVKEVVKK*# SEQUENCE: RRVKEVVKK*# ...# >HUM11D7B# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rat 60S ribosomal protein L28 (37-45)# DB REFERENCE: SWISS: (RL28_HUMAN,RL28_RAT,RL28_RAT,RL28_MOUSE)# & PIR1: (R5RT28)# & PIR2: (S55915,I48738)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,FRYNGLIHR*# SEQUENCE: FRYNGLIHR*# ...# >HUM11D7C# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rat 60S ribosomal protein L28 homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,FQYNGLIHR*# SEQUENCE: FQYNGLIHR*# ...# >HUM11D7D# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human ATP-dependant rna helicase (77-85)# DB REFERENCE: SWISS: (P68_MOUSE,P68_HUMAN,P68_HUMAN)# & PIR2: (JC1087,I48385)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRSKEITVR*# SEQUENCE: RRSKEITVR*# ...# >HUM11D7E# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein (yeast/slime mould) (173-181)# DB REFERENCE: SWISS: (RL8_XENLA,RL8_HUMAN,RL8_AEDAL,RL8_HUMAN)# & PIR1: (R5RTL8)# & PIR2: (JN0923,S42725)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRIDKPILK*# SEQUENCE: GRIDKPILK*# ...# >HUM11D7F# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein (yeast/slime mould) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GQIDKPILK*# SEQUENCE: GQIDKPILK*# ...# >HUM11D80# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein (yeast/slime mould) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRIDKPILA*# SEQUENCE: GRIDKPILA*# ...# >HUM11D81# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (314-322)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1BR,ENV_HV1MF,ENV_HV1H3,ENV_HV1B1,# & ENV_HV1B8,ENV_HV1PV)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S13288,S33985)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRAFVTIGK*# SEQUENCE: GRAFVTIGK*# ...# >HUM11D82# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (314-322) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GQAFVTIGK*# SEQUENCE: GQAFVTIGK*# ...# >HUM11D83# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (314-322) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRAFVTIGA*# SEQUENCE: GRAFVTIGA*# ...# >HUM11D84# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA3C (258-266)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015)# REFERENCES: villadangos95a,fruci95a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRIYDLIEL*# SEQUENCE: RRIYDLIEL*# ...# >HUM11D85# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LMP2 (236-244)# DB REFERENCE: SWISS: (LMP2_EBV)# & PIR1: (WMBELM)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRRWRRLTV*# SEQUENCE: RRRWRRLTV*# ...# >HUM11D86# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A nucleoprotein (383-391)# DB REFERENCE: SWISS: (VNUC_IAUSS,VNUC_IAZ41,VNUC_IAB37,VNUC_IAME3,VNUC_IAZH4,# & VNUC_IAMAN,VNUC_IAME6,VNUC_IAZ29,VNUC_IAVI6,VNUC_IAZI1,# & VNUC_IAMEF,VNUC_IAHO1,VNUC_IAS31,VNUC_IAZW1,VNUC_IADM2,# & VNUC_IAWIS,VNUC_IAZI3,VNUC_IAFOW,VNUC_IAPAR,VNUC_IANEJ,# & VNUC_IAZTE,VNUC_IAFOM,VNUC_IAMIN,VNUC_IAWHN,VNUC_IAPUE,# & VNUC_IATEI,VNUC_IAWHP,VNUC_IAFPD,VNUC_IAMEE,VNUC_IAGD7,# & VNUC_IAHMI,VNUC_IAZI2,VNUC_IASE0,VNUC_IAZJ2,VNUC_IAZJA,# & VNUC_IATRT,VNUC_IAZJ3,VNUC_IAZMA,VNUC_IAANN,VNUC_IASH2,# & VNUC_IAANA,VNUC_IATKN,VNUC_IAKIE,VNUC_IAHO2,VNUC_IATX7,# & VNUC_IAZDA,VNUC_IAS11,VNUC_IAHTE,VNUC_IACAL,VNUC_IAHLO,# & VNUC_IAZH1,VNUC_IANT6,VNUC_IASIN,VNUC_IADU2,VNUC_IAZON,# & VNUC_IARUD,VNUC_IAZW2,VNUC_IAOHI,VNUC_IATRS,VNUC_IAANN,# & VNUC_IAMAA,VNUC_IACKP,VNUC_IAMEG,VNUC_IAME4,VNUC_IALEN,# & VNUC_IAFPR,VNUC_IABUD,VNUC_IADE1,VNUC_IATKO,VNUC_IAMEA,# & VNUC_IAUDO,VNUC_IAS06,VNUC_IAMEC,VNUC_IAMEB,VNUC_IABRA,# & VNUC_IAME5,VNUC_IAZH3,VNUC_IAGRE,VNUC_IAWIL,VNUC_IADNZ,# & VNUC_IAZJ1,VNUC_IACKG,VNUC_IADAU,VNUC_IADMA,VNUC_IAHIC,# & VNUC_IAB39,VNUC_IADE2,VNUC_IAEN5,VNUC_IAZOH,VNUC_IADBE)# & PIR1: (VHIVA7,VHIVA3,VHIVX1,VHIVX2,VHIV8H,VHIVX5,VHIVAK,VHIVN8,# & VHIVXL,VHIV68,VHIVX6,VHIVN3,VHIVN7,VHIVN1,VHIVM1,A60028,# & VHIVX4,VHIVX3,VHIVN5,VHIV61,VHIVC1,VHIVN9,VHIV34,# & VHIVA6)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS: 2,9# REFERENCES: rammensee95a,villadangos95a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,SRYWAIRTR*# SEQUENCE: SRYWAIRTR*# ...# >HUM11D87# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV GAG p24 protein (265-276)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1MA,GAG_HV1BR,GAG_HV1Z2,GAG_HV1B1,# & GAG_HV1RH,GAG_HV1Y2,GAG_HV1A2,GAG_HV1JR,GAG_HV1N5,# & GAG_HV1H2,GAG_HV1ND,GAG_HV1W2,GAG_HV1J3,GAG_HV1MN,# & GAG_HV1C4,GAG_HV1OY,GAG_HV1PV)# & PIR1: (FOVWA2,FOVWH4,FOVWLV,A44001,FOLJND,FOVWH3,A38068,# & FOVWVL)# & PIR2: (S60702,S60698,S60708,S60697,S60704,S54377,S60699,# & S60703)# & PIR3: (S33979,S19598)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KRWIILGLN*# SEQUENCE: KRWIILGLN*# ...# >HUM11D88# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human histone H3, H3.3# DB REFERENCE: SWISS: (H31_SCHPO,YB21_CAEEL,H3_PSAMI,H3_DROME,H3_ACRFO,# & H33_SCHPO,H3_PSAMI,H3_EMENI,H3_STRPU,H3_CAEEL,H32_XENLA,# & H3_ENCAL,H31_HUMAN,H33_CAEEL,H33_HUMAN,H3_NEUCR,# & H32_BOVIN)# & PIR1: (HSRK3,HSTR3,HSXL32,HSFI3,HSUR3P,HSBO3,HSKW3,HSXL31,# & HSHU3,HSZP3,HSHU33,HSEAH3,HSCH3,HSUR3M)# & PIR2: (I50244,I57019,A56654,A02630,S57473,JN0687,JH0304,I50460,# & S32621,JQ0757,JQ1343,I49395,JS0690,S20669,S32638,I49397,# & JQ1983,S01198,S09655,S34185,S01197,S61214,S61218,JQ1984,# & S61215,S07350,S06755,S61220,S11315,I51448,S04186,S06743,# & S10168,S01196,S20109,I48092,S20678,I50245,I49398,A56580,# & S10097,A56618,S50140)# & PIR3: (S42066,S11938,A45941,S42065)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRYQKSTEL*# SEQUENCE: RRYQKSTEL*# ...# >HUM11D89# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human histone H3, H3.3 homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,ARYQKSTEL*# SEQUENCE: ARYQKSTEL*# ...# >HUM11D8A# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rat 60S ribosomal protein L28# DB REFERENCE: SWISS: (RL28_RAT,RL28_HUMAN,RL28_RAT,RL28_MOUSE)# & PIR1: (R5RT28)# & PIR2: (S55915,I48738)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,FRYNGLIHR*# SEQUENCE: FRYNGLIHR*# ...# >HUM11D8B# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rat 60S ribosomal protein L28 homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,FQYNGLIHR*# SEQUENCE: FQYNGLIHR*# ...# >HUM11D8C# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human ATP-dependant rna helicase# DB REFERENCE: SWISS: (P68_HUMAN,P68_MOUSE,P68_HUMAN)# & PIR2: (I48385,JC1087)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRSKEITVR*# SEQUENCE: RRSKEITVR*# ...# >HUM11D8D# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein (yeast/slime mould)# DB REFERENCE: SWISS: (RL8_HUMAN,RL8_XENLA,RL8_AEDAL,RL8_HUMAN)# & PIR1: (R5RTL8)# & PIR2: (S42725,JN0923)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRIDKPILK*# SEQUENCE: GRIDKPILK*# ...# >HUM11D8E# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein (yeast/slime mould) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRIDKPILA*# SEQUENCE: GRIDKPILA*# ...# >HUM11D8F# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (314-322)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1H3,ENV_HV1MF,ENV_HV1B1,ENV_HV1B8,# & ENV_HV1H2,ENV_HV1PV)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRAFVTIGK*# SEQUENCE: GRAFVTIGK*# ...# >HUM11D90# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp120 (314-322) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRAFVTIGA*# SEQUENCE: GRAFVTIGA*# ...# >HUM11D91# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBNA3C (258-266)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRIYDLIEL*# SEQUENCE: RRIYDLIEL*# ...# >HUM11D92# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LMP2 (236-244)# DB REFERENCE: SWISS: (LMP2_EBV)# & PIR1: (WMBELM)# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,RRRWRRLTV*# SEQUENCE: RRRWRRLTV*# ...# >HUM11D93# MHC MOLECULE: HLA-B27(B*2703), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza A nucleoprotein (383-391)# DB REFERENCE: SWISS: (VNUC_IAME6,VNUC_IADNZ,VNUC_IAGRE,VNUC_IAZW1,VNUC_IADM2,# & VNUC_IAMEF,VNUC_IAZI1,VNUC_IAB37,VNUC_IAWIS,VNUC_IAZTE,# & VNUC_IAFOM,VNUC_IAWHN,VNUC_IAMEE,VNUC_IAFPD,VNUC_IAWHP,# & VNUC_IAHMI,VNUC_IAGD7,VNUC_IAFOW,VNUC_IANEJ,VNUC_IAPAR,# & VNUC_IATEI,VNUC_IAZMA,VNUC_IAZDA,VNUC_IAZH1,VNUC_IACKP,# & VNUC_IAMEG,VNUC_IAOHI,VNUC_IATRS,VNUC_IAANN,VNUC_IADU2,# & VNUC_IATRT,VNUC_IAZJA,VNUC_IASIN,VNUC_IAANN,VNUC_IASE0,# & VNUC_IAS11,VNUC_IATX7,VNUC_IAS31,VNUC_IAZ29,VNUC_IAMIN,# & VNUC_IAPUE,VNUC_IAUSS,VNUC_IAZ41,VNUC_IAMAN,VNUC_IAZI3,# & VNUC_IAME4,VNUC_IAS06,VNUC_IAMEC,VNUC_IABUD,VNUC_IAB39,# & VNUC_IAHIC,VNUC_IACKG,VNUC_IADMA,VNUC_IAZH3,VNUC_IAME5,# & VNUC_IAMEB,VNUC_IADE2,VNUC_IAZOH,VNUC_IAZJ2,VNUC_IAZW2,# & VNUC_IAANA,VNUC_IAHO2,VNUC_IAKIE,VNUC_IASH2,VNUC_IACAL,# & VNUC_IAHTE,VNUC_IAHO1,VNUC_IAWIL,VNUC_IAME3,VNUC_IADE1,# & VNUC_IAUDO,VNUC_IALEN,VNUC_IAFPR,VNUC_IADAU,VNUC_IAEN5,# & VNUC_IABRA,VNUC_IAZON,VNUC_IAMAA,VNUC_IANT6,VNUC_IADBE,# & VNUC_IATKN,VNUC_IAZJ1,VNUC_IAZI2,VNUC_IARUD,VNUC_IAZJ3,# & VNUC_IAMEA,VNUC_IATKO,VNUC_IAVI6,VNUC_IAZH4,VNUC_IAHLO)# & PIR1: (VHIVX3,VHIVN3,VHIVN8,VHIVC1,VHIVX6,VHIVX1,VHIVX4,VHIVAK,# & VHIVX5,VHIV61,VHIVN9,VHIV34,VHIVA6,VHIVN1,VHIVM1,A60028,# & VHIVN5,VHIVXL,VHIV68,VHIVX2,VHIVN7,VHIV8H,VHIVA3,# & VHIVA7)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS: 2,9# REFERENCES: villadangos95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,SRYWAIRTR*# SEQUENCE: SRYWAIRTR*# ...# >HUM11D94# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MART-1 (22-30)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,TTAEEAAGI*# SEQUENCE: TTAEEAAGI*# ...# >HUM11D95# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MART-1 (29-37)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,GIGILTVIL*# SEQUENCE: GIGILTVIL*# ...# >HUM11D96# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/Competition/Half-time# ACTIVITY: none# BINDING: yes, high# SOURCE: MART-1 (31-39)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95a,van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,GILTVILGV*# SEQUENCE: GILTVILGV*# ...# >HUM11D97# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: MART-1 (33-41)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,LTVILGVLL*# SEQUENCE: LTVILGVLL*# ...# >HUM11D98# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/Competition/Half-time# ACTIVITY: none# BINDING: yes, high# SOURCE: MART-1 (34-42)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95a,van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,TVILGVLLL*# SEQUENCE: TVILGVLLL*# ...# >HUM11D99# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/Half-time# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: MART-1 (35-43)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95a,van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,VILGVLLLI*# SEQUENCE: VILGVLLLI*# ...# >HUM11D9A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/Competition/Half-time/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MART-1 (56-64)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95a,van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,ALMDKSLHV*# SEQUENCE: ALMDKSLHV*# ...# >HUM11D9B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: none# BINDING: yes, little# SOURCE: MART-1 (61-69)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95a,van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,SLHVGTQCA*# SEQUENCE: SLHVGTQCA*# ...# >MUS11D9C# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Alpha-ketoglutarate dehydrogenase homologue# ANCHOR POSITIONS:# REFERENCES: wu95a# COMMENT:# SUMMARY: H-2Ld,actyesl,bindyesu,LSPYPFDI*# SEQUENCE: LSPYPFDI*# ...# >HUM11D9D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./assembly as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: HIV-1 reverse transcriptase (476-484) homologue# ANCHOR POSITIONS:# REFERENCES: pogue95a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesl,FLKEPVHGV*# SEQUENCE: FLKEPVHGV*# ...# >HUM11D9E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./assembly as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: HIV-1 reverse transcriptase (476-484) homologue# ANCHOR POSITIONS:# REFERENCES: pogue95a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesl,YLKEPVHGV*# SEQUENCE: YLKEPVHGV*# ...# >HUM11D9F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./assembly as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HIV-1 reverse transcriptase (476-484) homologue# ANCHOR POSITIONS:# REFERENCES: pogue95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,ILFEPVHGV*# SEQUENCE: ILFEPVHGV*# ...# >HUM11DA0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./assembly as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HIV-1 reverse transcriptase (476-484) homologue# ANCHOR POSITIONS:# REFERENCES: pogue95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,ILYEPVHGV*# SEQUENCE: ILYEPVHGV*# ...# >HUM11DA1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./assembly as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HIV-1 reverse transcriptase (476-484) homologue# ANCHOR POSITIONS:# REFERENCES: pogue95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,ILWEPVHGV*# SEQUENCE: ILWEPVHGV*# ...# >HUM11DA2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./assembly as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: HIV-1 reverse transcriptase (476-484) homologue# ANCHOR POSITIONS:# REFERENCES: pogue95a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesl,ILKSPVHGV*# SEQUENCE: ILKSPVHGV*# ...# >HUM11DA3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: stabilisation as./assembly as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: HIV-1 reverse transcriptase (476-484) homologue# ANCHOR POSITIONS:# REFERENCES: pogue95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,ILKEYVHGV*# SEQUENCE: ILKEYVHGV*# ...# >HUM21DA4# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50)# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,MLEFVVEFDLPGIKA*# SEQUENCE: MLEFVVEFDLPGIKA*# ...# >HUM21DA5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLAFVVEFDLPGIKA*# SEQUENCE: MLAFVVEFDLPGIKA*# ...# >HUM21DA6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLKFVVEFDLPGIKA*# SEQUENCE: MLKFVVEFDLPGIKA*# ...# >HUM21DA7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,MLEFAVEFDLPGIKA*# SEQUENCE: MLEFAVEFDLPGIKA*# ...# >HUM21DA8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVAEFDLPGIKA*# SEQUENCE: MLEFVAEFDLPGIKA*# ...# >HUM21DA9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVVAFDLPGIKA*# SEQUENCE: MLEFVVAFDLPGIKA*# ...# >HUM21DAA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVVEADLPGIKA*# SEQUENCE: MLEFVVEADLPGIKA*# ...# >HUM21DAB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVVEFALPGIKA*# SEQUENCE: MLEFVVEFALPGIKA*# ...# >HUM21DAC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVVEFDAPGIKA*# SEQUENCE: MLEFVVEFDAPGIKA*# ...# >HUM21DAD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVVEFDLAGIKA*# SEQUENCE: MLEFVVEFDLAGIKA*# ...# >HUM21DAE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,MLEFVVEFDLPAIKA*# SEQUENCE: MLEFVVEFDLPAIKA*# ...# >HUM21DAF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVVEFDLPGAKA*# SEQUENCE: MLEFVVEFDLPGAKA*# ...# >HUM21DB0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVVEFDLPGIAA*# SEQUENCE: MLEFVVEFDLPGIAA*# ...# >HUM21DB1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./binding as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Mycobacterium leprae ML (38-50) homologue# ANCHOR POSITIONS: 4# REFERENCES: mcnicholl95a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,MLEFVVEFDLPGIEA*# SEQUENCE: MLEFVVEFDLPGIEA*# ...# >MUS11DB2# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./stabilisation as./CTL induction# ACTIVITY: ?# BINDING: yes, little# SOURCE: human papilloma virus tumour antigen E6 (50-57)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: bauer95a,feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,YDFAFRDL*# SEQUENCE: YDFAFRDL*# ...# >MUS11DB3# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: binding as./stabilisation as./CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: human papilloma virus tumour antigen E7 (48-55)# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: bauer95a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,DRAHYNIV*# SEQUENCE: DRAHYNIV*# ...# >MUS21DB4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as./Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (25-43)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZQJE,LZCH)# & PIR2: (JU0237)# REFERENCES: bauer95a,adorini93a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,LGNWVCAAKFESNFNTQAT*# SEQUENCE: LGNWVCAAKFESNFNTQAT*# ...# >MUS21DB5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (31-43)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZQJE,LZCH)# & PIR2: (JU0237)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,AAKFESNFNTQAT*# SEQUENCE: AAKFESNFNTQAT*# ...# >MUS21DB6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (51-61)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_CHRAM,LYC_MELGA,LYC1_ANAPL,LYC_CHICK,# & LYC_ORTVE,LYC_CHICK,LYC_PHAVE,LYC_PHACO,LYC_LOPLE,# & LYC1_TACAC,LYC_PAVCR)# & PIR1: (LZQJE,LZTK,LZFER,LZCH,LZOVE,LZDK)# & PIR2: (JQ1033,A45660,JC2144,JH0212,JU0178,A61281,JT0526,JQ1041,# & JU0237,JH0211)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,TDYGILQINSR*# SEQUENCE: TDYGILQINSR*# ...# >MUS21DB7# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (101-116)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPLE,LYC_CHICK,LYC_LOPCA,LYC_CHRAM)# & PIR1: (LZCH,LZQJEC)# & PIR2: (JQ1033)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,DGNGMNAWVAWRNRCK*# SEQUENCE: DGNGMNAWVAWRNRCK*# ...# >MUS21DB8# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (105-120)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_PAVCR,LYC_COTJA,LYC_MELGA,LYC3_ANAPL,# & LYC_COLVI,LYC_LOPLE,LYC_CHICK,LYC_CHRAM,LYC_LOPCA,# & LYC_CHICK)# & PIR1: (LZQJEC,LZCH,LZQJE,LZTK,LZDK3)# & PIR2: (JQ1033,JU0237,JT0526,JQ1041)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,MNAWVAWRNRCKGTDV*# SEQUENCE: MNAWVAWRNRCKGTDV*# ...# >MUS21DB9# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (107-129)# ANCHOR POSITIONS:# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,AWVAWRNRCKGTDVQAWIRGARL*# SEQUENCE: AWVAWRNRCKGTDVQAWIRGARL*# ...# >MUS21DBA# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (110-129)# ANCHOR POSITIONS:# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,AWRNRCKGTDVQAWIRGALR*# SEQUENCE: AWRNRCKGTDVQAWIRGALR*# ...# >MUS21DBB# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (112-129)# ANCHOR POSITIONS:# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,RNRCKGTDVQAWIRGALR*# SEQUENCE: RNRCKGTDVQAWIRGALR*# ...# >MUS21DBC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (8-29)# ANCHOR POSITIONS:# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,LAAAMKRHGLDNYRGYSLGINWV*# SEQUENCE: LAAAMKRHGLDNYRGYSLGINWV*# ...# >MUS21DBD# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (25-43)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZQJE,LZCH)# & PIR2: (JU0237)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,LGNWVCAAKFESNFNTQAT*# SEQUENCE: LGNWVCAAKFESNFNTQAT*# ...# >MUS21DBE# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (51-66)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_SYRRE,LYC_LOPLE,LYC_CHICK,LYC_CHRAM,# & LYC_PHACO,LYC_CHICK,LYC_PAVCR,LYC_ORTVE,LYC_MELGA)# & PIR1: (LZCH,LZOVE,LZQJE,LZTK)# & PIR2: (JC2144,JQ1033,JU0178,JU0237,JT0526,JQ1041)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,TDYGILQINSRWWCND*# SEQUENCE: TDYGILQINSRWWCND*# ...# >MUS21DBF# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (94-110)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_CHICK,LYC_PHACO,LYC_LOPLE,LYC_LOPCA,# & LYC_CHRAM,LYC_CHICK)# & PIR1: (LZCH,LZQJEC)# & PIR2: (JC2144,JQ1033)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,CAKKIVSDGNGMNAWVA*# SEQUENCE: CAKKIVSDGNGMNAWVA*# ...# >MUS21DC0# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (101-116)# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_CHICK,LYC_CHRAM,LYC_LOPCA,LYC_CHICK)# & PIR1: (LZCH,LZQJEC)# & PIR2: (JQ1033)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,DGNGMNAWVAWRNRCK*# SEQUENCE: DGNGMNAWVAWRNRCK*# ...# >MUS21DC1# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (105-120)# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_PAVCR,LYC_MELGA,LYC_CHICK,LYC_COLVI,# & LYC_COTJA,LYC_CHICK,LYC_SYRRE,LYC3_ANAPL,LYC_CHRAM,# & LYC_LOPCA)# & PIR1: (LZDK3,LZTK,LZQJEC,LZQJE,LZCH)# & PIR2: (JQ1041,JT0526,JU0237,JQ1033)# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,MNAWVAWRNRCKGTDV*# SEQUENCE: MNAWVAWRNRCKGTDV*# ...# >MUS21DC2# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (107-129)# ANCHOR POSITIONS:# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,AWVAWRNRCKGTDVQAWIRGARL*# SEQUENCE: AWVAWRNRCKGTDVQAWIRGARL*# ...# >MUS21DC3# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (110-129)# ANCHOR POSITIONS:# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,AWRNRCKGTDVQAWIRGALR*# SEQUENCE: AWRNRCKGTDVQAWIRGALR*# ...# >MUS21DC4# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: competitive binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (112-129)# ANCHOR POSITIONS:# REFERENCES: bauer95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,RNRCKGTDVQAWIRGALR*# SEQUENCE: RNRCKGTDVQAWIRGALR*# ...# >MUS21DC5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: human alpha1-antitrypsin hAAT PiM (205-220)# DB REFERENCE: SWISS: (A1AT_HUMAN,A1AT_HUMAN)# & PIR1: (ITHU)# REFERENCES: hagerty95a# COMMENT:# SUMMARY: I-Ak,actyesm,bindyesu,EEDFHVDQVTTVKVPM*# SEQUENCE: EEDFHVDQVTTVKVPM*# ...# >MUS21DC6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: human alpha1-antitrypsin hAAT PiZ (205-220)# DB REFERENCE: SWISS: (A1AT_PAPAN)# & PIR1: (ITBA)# REFERENCES: hagerty95a# COMMENT:# SUMMARY: I-Ak,actyesm,bindyesu,EEDFHVDQATTVKVPM*# SEQUENCE: EEDFHVDQATTVKVPM*# ...# >MUS21DC7# MHC MOLECULE: I-Ar, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Type II collagen CII (604-618)# ANCHOR POSITIONS:# REFERENCES: miyahara95a# COMMENT:# SUMMARY: I-Ar,actyesu,bindyesu,GPPGPAGPAGTAGAR*# SEQUENCE: GPPGPAGPAGTAGAR*# ...# >MUS21DC8# MHC MOLECULE: I-Ar, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Type II collagen CII (607-621)# ANCHOR POSITIONS:# REFERENCES: miyahara95a# COMMENT:# SUMMARY: I-Ar,actyesu,bindyesu,GPAGPAGTAGARGAP*# SEQUENCE: GPAGPAGTAGARGAP*# ...# >MUS21DC9# MHC MOLECULE: I-Ar, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Type II collagen CII (610-624)# ANCHOR POSITIONS:# REFERENCES: miyahara95a# COMMENT:# SUMMARY: I-Ar,actyesu,bindyesu,GPAGTAGARGAPGER*# SEQUENCE: GPAGTAGARGAPGER*# ...# >HUM21DCA# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (1-21)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVT,POLS_RUBVM)# & PIR1: (GNWVR4,GNWV77,GNWVR3)# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,MASTTPITMEDLQKALEAQSR*# SEQUENCE: MASTTPITMEDLQKALEAQSR*# ...# >HUM21DCB# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (1-29)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVM)# & PIR1: (GNWV77,GNWVR3)# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,MASTTPITMEDLQKALEAQSRALRAGLAA*# SEQUENCE: MASTTPITMEDLQKALEAQSRALRAGLAA*# ...# >HUM21DCC# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (1-29)# DB REFERENCE: SWISS: (POLS_RUBVR)# & PIR1: (GNWVRA)# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,MASTTPITMEDLQKALETQSRVLRAGLTA*# SEQUENCE: MASTTPITMEDLQKALETQSRVLRAGLTA*# ...# >HUM21DCD# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (24-41)# DB REFERENCE: SWISS: (POLS_RUBVR)# & PIR1: (GNWVRA)# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RAGLTAGASQSRRPRPPR*# SEQUENCE: RAGLTAGASQSRRPRPPR*# ...# >HUM21DCE# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (90-114)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVR,POLS_RUBVT,POLS_RUBVM)# & PIR1: (GNWV77,GNWVR3,GNWVR4,GNWVRA)# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,QTPAPKPSRAPPQQPQPPRMQTGR*# SEQUENCE: QTPAPKPSRAPPQQPQPPRMQTGR*# ...# >HUM21DCF# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (108-134)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVR,POLS_RUBVM,POLS_RUBVT)# & PIR1: (GNWV77,GNWVR4,GNWVRA,GNWVR3)# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RMQTGRGGSAPRPELGPPTNPFQAAVA*# SEQUENCE: RMQTGRGGSAPRPELGPPTNPFQAAVA*# ...# >HUM21DD0# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (110-127)# ANCHOR POSITIONS:# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NTPPGLEPRPASGGRGTQ*# SEQUENCE: NTPPGLEPRPASGGRGTQ*# ...# >HUM21DD1# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (255-277)# DB REFERENCE: SWISS: (POLS_RUBVM,POLS_RUBVT)# & PIR1: (GNWVR3,GNWVR4)# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,APLPPHTTERIETRSARHPWRIR*# SEQUENCE: APLPPHTTERIETRSARHPWRIR*# ...# >HUM21DD2# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: lymphoproliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus capsid protein RVC (277-300)# DB REFERENCE: SWISS: (POLS_RUBVM,POLS_RUBVH,POLS_RUBVR)# & PIR1: (GNWVRA,GNWV77,GNWVR3)# REFERENCES: mitchell94a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RFGAPQAFLAGLLLAAVAVGTARA*# SEQUENCE: RFGAPQAFLAGLLLAAVAVGTARA*# ...# >HUM21DD3# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (947-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,FNNFTVSFWLRVPKVSASHLE*# SEQUENCE: FNNFTVSFWLRVPKVSASHLE*# ...# >HUM21DD4# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSASHLE*# SEQUENCE: TVSFWLRVPKVSASHLE*# ...# >HUM21DD5# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGITELKKLE*# SEQUENCE: QYIKANSKFIGITELKKLE*# ...# >HUM21DD6# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (830-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,IKANSKFIGITELK*# SEQUENCE: IKANSKFIGITELK*# ...# >HUM21DD7# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (830-839)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,IKANSKFIGI*# SEQUENCE: IKANSKFIGI*# ...# >HUM21DD8# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (831-839)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,KANSKFIGI*# SEQUENCE: KANSKFIGI*# ...# >HUM21DD9# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,AYIKANSKFIGITE*# SEQUENCE: AYIKANSKFIGITE*# ...# >HUM21DDA# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QAIKANSKFIGITE*# SEQUENCE: QAIKANSKFIGITE*# ...# >HUM21DDB# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYAKANSKFIGITE*# SEQUENCE: QYAKANSKFIGITE*# ...# >HUM21DDC# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYIAANSKFIGITE*# SEQUENCE: QYIAANSKFIGITE*# ...# >HUM21DDD# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: TT (828-841)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a,boitel95a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesh,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM21DDE# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, high# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: valmori94a,boitel95a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesh,QYIKAASKFIGITE*# SEQUENCE: QYIKAASKFIGITE*# ...# >HUM21DDF# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: valmori94a,boitel95a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesm,QYIKANAKFIGITE*# SEQUENCE: QYIKANAKFIGITE*# ...# >HUM21DE0# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSAFIGITE*# SEQUENCE: QYIKANSAFIGITE*# ...# >HUM21DE1# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYIKANSKAIGITE*# SEQUENCE: QYIKANSKAIGITE*# ...# >HUM21DE2# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFAGITE*# SEQUENCE: QYIKANSKFAGITE*# ...# >HUM21DE3# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a,boitel95a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesl,QYIKANSKFIAITE*# SEQUENCE: QYIKANSKFIAITE*# ...# >HUM21DE4# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGATE*# SEQUENCE: QYIKANSKFIGATE*# ...# >HUM21DE5# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGIAE*# SEQUENCE: QYIKANSKFIGIAE*# ...# >HUM21DE6# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGITA*# SEQUENCE: QYIKANSKFIGITA*# ...# >HUM21DE7# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,AVSFWLRVPKVSSHLE*# SEQUENCE: AVSFWLRVPKVSSHLE*# ...# >HUM21DE8# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TASFWLRVPKVSSHLE*# SEQUENCE: TASFWLRVPKVSSHLE*# ...# >HUM21DE9# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVAFWLRVPKVSSHLE*# SEQUENCE: TVAFWLRVPKVSSHLE*# ...# >HUM21DEA# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSAWLRVPKVSSHLE*# SEQUENCE: TVSAWLRVPKVSSHLE*# ...# >HUM21DEB# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFALRVPKVSSHLE*# SEQUENCE: TVSFALRVPKVSSHLE*# ...# >HUM21DEC# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWARVPKVSSHLE*# SEQUENCE: TVSFWARVPKVSSHLE*# ...# >HUM21DED# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWLAVPKVSSHLE*# SEQUENCE: TVSFWLAVPKVSSHLE*# ...# >HUM21DEE# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRAPKVSSHLE*# SEQUENCE: TVSFWLRAPKVSSHLE*# ...# >HUM21DEF# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWLRVAKVSSHLE*# SEQUENCE: TVSFWLRVAKVSSHLE*# ...# >HUM21DF0# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPAVSSHLE*# SEQUENCE: TVSFWLRVPAVSSHLE*# ...# >HUM21DF1# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWLRVPKASSHLE*# SEQUENCE: TVSFWLRVPKASSHLE*# ...# >HUM21DF2# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVASHLE*# SEQUENCE: TVSFWLRVPKVASHLE*# ...# >HUM21DF3# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSAHLE*# SEQUENCE: TVSFWLRVPKVSAHLE*# ...# >HUM21DF4# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSSALE*# SEQUENCE: TVSFWLRVPKVSSALE*# ...# >HUM21DF5# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSSHAE*# SEQUENCE: TVSFWLRVPKVSSHAE*# ...# >HUM21DF6# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSSHLA*# SEQUENCE: TVSFWLRVPKVSSHLA*# ...# >HUM21DF7# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (947-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,FNNFTVSFWLRVPKVSASHLE*# SEQUENCE: FNNFTVSFWLRVPKVSASHLE*# ...# >HUM21DF8# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-967)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSASHLE*# SEQUENCE: TVSFWLRVPKVSASHLE*# ...# >HUM21DF9# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-846)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGITELKKLE*# SEQUENCE: QYIKANSKFIGITELKKLE*# ...# >HUM21DFA# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (830-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,IKANSKFIGITELK*# SEQUENCE: IKANSKFIGITELK*# ...# >HUM21DFB# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (830-839)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,IKANSKFIGI*# SEQUENCE: IKANSKFIGI*# ...# >HUM21DFC# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,AYIKANSKFIGITE*# SEQUENCE: AYIKANSKFIGITE*# ...# >HUM21DFD# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QAIKANSKFIGITE*# SEQUENCE: QAIKANSKFIGITE*# ...# >HUM21DFE# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYAKANSKFIGITE*# SEQUENCE: QYAKANSKFIGITE*# ...# >HUM21DFF# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYIAANSKFIGITE*# SEQUENCE: QYIAANSKFIGITE*# ...# >HUM21E00# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM21E01# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYIKAASKFIGITE*# SEQUENCE: QYIKAASKFIGITE*# ...# >HUM21E02# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYIKANAKFIGITE*# SEQUENCE: QYIKANAKFIGITE*# ...# >HUM21E03# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYIKANSAFIGITE*# SEQUENCE: QYIKANSAFIGITE*# ...# >HUM21E04# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,QYIKANSKAIGITE*# SEQUENCE: QYIKANSKAIGITE*# ...# >HUM21E05# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFAGITE*# SEQUENCE: QYIKANSKFAGITE*# ...# >HUM21E06# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIAITE*# SEQUENCE: QYIKANSKFIAITE*# ...# >HUM21E07# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGATE*# SEQUENCE: QYIKANSKFIGATE*# ...# >HUM21E08# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGIAE*# SEQUENCE: QYIKANSKFIGIAE*# ...# >HUM21E09# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (828-841) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,QYIKANSKFIGITA*# SEQUENCE: QYIKANSKFIGITA*# ...# >HUM21E0A# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,AVSFWLRVPKVSSHLE*# SEQUENCE: AVSFWLRVPKVSSHLE*# ...# >HUM21E0B# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TASFWLRVPKVSSHLE*# SEQUENCE: TASFWLRVPKVSSHLE*# ...# >HUM21E0C# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVAFWLRVPKVSSHLE*# SEQUENCE: TVAFWLRVPKVSSHLE*# ...# >HUM21E0D# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSAWLRVPKVSSHLE*# SEQUENCE: TVSAWLRVPKVSSHLE*# ...# >HUM21E0E# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFALRVPKVSSHLE*# SEQUENCE: TVSFALRVPKVSSHLE*# ...# >HUM21E0F# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWARVPKVSSHLE*# SEQUENCE: TVSFWARVPKVSSHLE*# ...# >HUM21E10# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWLAVPKVSSHLE*# SEQUENCE: TVSFWLAVPKVSSHLE*# ...# >HUM21E11# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWLRAPKVSSHLE*# SEQUENCE: TVSFWLRAPKVSSHLE*# ...# >HUM21E12# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWLRVAKVSSHLE*# SEQUENCE: TVSFWLRVAKVSSHLE*# ...# >HUM21E13# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesn,bindyesu,TVSFWLRVPAVSSHLE*# SEQUENCE: TVSFWLRVPAVSSHLE*# ...# >HUM21E14# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKASSHLE*# SEQUENCE: TVSFWLRVPKASSHLE*# ...# >HUM21E15# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVASHLE*# SEQUENCE: TVSFWLRVPKVASHLE*# ...# >HUM21E16# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSAHLE*# SEQUENCE: TVSFWLRVPKVSAHLE*# ...# >HUM21E17# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSSALE*# SEQUENCE: TVSFWLRVPKVSSALE*# ...# >HUM21E18# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSSHAE*# SEQUENCE: TVSFWLRVPKVSSHAE*# ...# >HUM21E19# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: competitive inhibition as./recognition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT (951-963) homologue# ANCHOR POSITIONS:# REFERENCES: valmori94a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,TVSFWLRVPKVSSHLA*# SEQUENCE: TVSFWLRVPKVSSHLA*# ...# >HUM21E1A# MHC MOLECULE: HLA-DQ1, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (140-148)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1PV,GAG_HV1J3,GAG_HV1MN,GAG_HV1N5,# & GAG_HV1H2,GAG_HV1ND,GAG_HV1Y2,GAG_HV1A2,GAG_HV1RH,# & GAG_HV1EL,GAG_HV1B1,GAG_HV1Z2,GAG_SIVCZ,GAG_HV1B5,# & GAG_HV1BR,GAG_HV1W2,GAG_HV1JR)# & PIR1: (A44001,FOVWA2,FOVWH4,A38068,FOLJND,FOVWH3,FOVWVL,FOLJSI,# & FOVWLV)# & PIR2: (S52929,S54377)# REFERENCES: littaua92a# COMMENT:# SUMMARY: HLA-DQ1,actyesu,bindyesu,GQMVHQAIS*# SEQUENCE: GQMVHQAIS*# ...# >HUM21E1B# MHC MOLECULE: HLA-DQ3, CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 gag (140-148)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_SIVCZ,GAG_HV1JR,GAG_HV1EL,GAG_HV1Z2,# & GAG_HV1BR,GAG_HV1RH,GAG_HV1W2,GAG_HV1ND,GAG_HV1A2,# & GAG_HV1Y2,GAG_HV1N5,GAG_HV1H2,GAG_HV1B1,GAG_HV1PV,# & GAG_HV1C4,GAG_HV1J3,GAG_HV1B5)# & PIR1: (FOVWA2,FOVWH3,FOLJND,A44001,FOVWH4,FOLJSI,FOVWVL,FOVWLV,# & A38068)# & PIR2: (S52929,S54377)# REFERENCES: littaua92a# COMMENT:# SUMMARY: HLA-DQ3,actyesu,bindyesu,GQMVHQAIS*# SEQUENCE: GQMVHQAIS*# ...# >MUS21E1C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EMb (102-118)# DB REFERENCE: SWISS: (MYG_MESCA,MYG_HORSE,MYG_HORSE)# & PIR1: (MYHO,MYWHU,MYHOZ)# REFERENCES: villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,KYLEFISDAIIHVLHSK*# SEQUENCE: KYLEFISDAIIHVLHSK*# ...# >MUS21E1D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EMb (131-153)# DB REFERENCE: SWISS: (MYG_HORSE,MYG_HORSE)# & PIR1: (MYHOZ,MYHO)# REFERENCES: villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,MTKALELFRNDIAAKYKELGFQG*# SEQUENCE: MTKALELFRNDIAAKYKELGFQG*# ...# >MUS21E1E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (13-35)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_CHICK,LYC_LOPCA,LYC_NUMME)# & PIR1: (LZQJEC,LZCH,LZUH)# REFERENCES: villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,KRHGLDNYRGYSLGNWVCAAKFE*# SEQUENCE: KRHGLDNYRGYSLGNWVCAAKFE*# ...# >MUS21E1F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (74-96)# DB REFERENCE: SWISS: (LYC_MELGA,LYC_PAVCR,LYC_CHICK,LYC_CHICK)# & PIR1: (LZTK,LZCH,LZQJE)# & PIR2: (JU0237,JT0526)# REFERENCES: villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,NLCNIPCSALLSSDITASVNCAK*# SEQUENCE: NLCNIPCSALLSSDITASVNCAK*# ...# >MUS21E20# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (74-96)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_MELGA,LYC_PAVCR)# & PIR1: (LZCH,LZQJE,LZTK)# & PIR2: (JT0526,JU0237)# REFERENCES: villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,NLCNIPCSALLSSDITASVNCAK*# SEQUENCE: NLCNIPCSALLSSDITASVNCAK*# ...# >MUS21E21# MHC MOLECULE: H-2f, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: cI (73-88)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: villadangos95a,vaysburd95a,smilek90a# COMMENT:# SUMMARY: H-2f,actyesu,bindyesu,VEEFSPSIAREIYEMY*# SEQUENCE: VEEFSPSIAREIYEMY*# ...# >MUS21E22# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: cI (73-88)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: villadangos95a,vaysburd95a,smilek90a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,VEEFSPSIAREIYEMY*# SEQUENCE: VEEFSPSIAREIYEMY*# ...# >MUS21E23# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Flu (111-120)# DB REFERENCE: SWISS: (HEMA_IATAI,HEMA_IAHAR,HEMA_IALEN,HEMA_IACAO,HEMA_IAUSS,# & HEMA_IAKIE,HEMA_IAXIA,HEMA_IAPUE)# & PIR1: (HMIV,HMIVTA,HMIVUR)# & PIR2: (JQ2372,JQ2370,A35788,JQ2371,JQ1437,PQ0321,PQ0319,# & JQ1643)# REFERENCES: villadangos95a,vaysburd95a,smilek90a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,FERFEIFPKE*# SEQUENCE: FERFEIFPKE*# ...# >MUS21E24# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SNase (61-79)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,FTKKMVENAKKIEVEFDKG*# SEQUENCE: FTKKMVENAKKIEVEFDKG*# ...# >MUS21E25# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: 65-kD HSP TB (112-126)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCIT,CH60_MYCVA,CH60_MYCTU,CH60_MYCKA,# & CH60_MYCRH,CH60_MYCAG,CH60_MYCMA,CH60_MYCNO,CH60_MYCPA,# & CH60_MYCGS,CH62_MYCTU,CH60_MYCMR,CH62_STRAL,CH60_MYCGO,# & CH60_MYCAS,CH60_MYCCH,CH60_MYCCI,CH60_MYCAV,CH60_MYCPH,# & CH60_MYCSH,CH60_MYCSC,CH60_MYCXE,CH60_MYCFO,CH60_MYCFA,# & CH60_MYCGN,CH60_MYCPA,CH60_MYCPV)# & PIR2: (S05295,A43509,S05294,S40245,S05292,C41325,S05293,A26950,# & A25902)# REFERENCES: villadangos95a,vaysburd95a,smilek90a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,YEKIGAELVKEVAKK*# SEQUENCE: YEKIGAELVKEVAKK*# ...# >MUS21E26# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: 65-kD HSP TB (112-126)# DB REFERENCE: SWISS: (CH60_MYCPH,CH60_MYCVA,CH60_MYCPV,CH62_MYCTU,CH60_MYCGN,# & CH60_MYCFO,CH62_MYCLE,CH60_MYCIT,CH60_MYCMR,CH60_MYCPA,# & CH60_MYCGS,CH60_MYCNO,CH60_MYCRH,CH60_MYCAS,CH60_MYCFA,# & CH60_MYCSC,CH60_MYCSH,CH60_MYCXE,CH60_MYCAV,CH60_MYCTU,# & CH60_MYCKA,CH62_STRAL,CH60_MYCMA,CH60_MYCAG,CH60_MYCPA,# & CH60_MYCGO,CH60_MYCCH,CH60_MYCCI)# & PIR2: (A43509,A25902,S40245,S05292,S05295,S05294,A26950,C41325,# & S05293)# REFERENCES: villadangos95a,vaysburd95a,smilek90a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,YEKIGAELVKEVAKK*# SEQUENCE: YEKIGAELVKEVAKK*# ...# >MUS21E27# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: 65-kD HSP TB (112-126)# DB REFERENCE: SWISS: (CH62_MYCLE,CH60_MYCGS,CH60_MYCAS,CH60_MYCAV,CH60_MYCSC,# & CH60_MYCSH,CH60_MYCCH,CH60_MYCPA,CH60_MYCMA,CH60_MYCGN,# & CH60_MYCPV,CH60_MYCXE,CH60_MYCFA,CH60_MYCPA,CH60_MYCNO,# & CH60_MYCIT,CH60_MYCCI,CH62_STRAL,CH60_MYCGO,CH62_MYCTU,# & CH60_MYCKA,CH60_MYCMR,CH60_MYCRH,CH60_MYCAG,CH60_MYCTU,# & CH60_MYCFO,CH60_MYCVA,CH60_MYCPH)# & PIR2: (A25902,A26950,C41325,S05294,S05295,A43509,S05293,S05292,# & S40245)# REFERENCES: villadangos95a,vaysburd95a,smilek90a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,YEKIGAELVKEVAKK*# SEQUENCE: YEKIGAELVKEVAKK*# ...# >MUS21E28# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ROIV# ANCHOR POSITIONS:# REFERENCES: villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,AHAAHAAHAAHAAHAA*# SEQUENCE: AHAAHAAHAAHAAHAA*# ...# >MUS21E29# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: RLI# ANCHOR POSITIONS:# REFERENCES: villadangos95a,vaysburd95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,ARRLKARRLKARRLK*# SEQUENCE: ARRLKARRLKARRLK*# ...# >MUS21E2A# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (323-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: villadangos95a,amor96a,lock91a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,ISQAVHAAHAEINEAGR*# SEQUENCE: ISQAVHAAHAEINEAGR*# ...# >MUS21E2B# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EMb (131-153)# DB REFERENCE: SWISS: (MYG_HORSE,MYG_HORSE)# & PIR1: (MYHO,MYHOZ)# REFERENCES: vaysburd95a,lock91a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,MTKALELFRNDIAAKYKELGFQG*# SEQUENCE: MTKALELFRNDIAAKYKELGFQG*# ...# >MUS21E2C# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (13-35)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_NUMME,LYC_LOPCA,LYC_CHICK)# & PIR1: (LZCH,LZUH,LZQJEC)# REFERENCES: vaysburd95a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,KRHGLDNYRGYSLGNWVCAAKFE*# SEQUENCE: KRHGLDNYRGYSLGNWVCAAKFE*# ...# >MUS21E2D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: lambda rep. cI (12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# REFERENCES: vaysburd95a,amor96a,lock91a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >MUS21E2E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SNase (61-79)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: vaysburd95a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,FTKKMVENAKKIEVEFDKG*# SEQUENCE: FTKKMVENAKKIEVEFDKG*# ...# >MUS21E2F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: alpha-1 antitrypsin (148-163)# DB REFERENCE: SWISS: (A1A1_MOUSE)# & PIR2: (I49470,I49474,A25420)# REFERENCES: vaysburd95a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,LSQAVHKAVLTIDETG*# SEQUENCE: LSQAVHKAVLTIDETG*# ...# >MUS21E30# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Laminin b1 chain precursor (1594-1612)# DB REFERENCE: SWISS: (LMB1_HUMAN,LMB1_MOUSE,LMB1_HUMAN,LMB1_MOUSE)# & PIR1: (MMHUB1,MMMSB1)# REFERENCES: vaysburd95a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,MVKEALEEAEKAQVAAEKA*# SEQUENCE: MVKEALEEAEKAQVAAEKA*# ...# >MUS21E31# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as./Reference# ACTIVITY: none# BINDING: yes, ?# SOURCE: PSG-1 (63-76)# DB REFERENCE: SWISS: (PSG1_MOUSE,PSG1_MOUSE)# & PIR1: (S01498)# REFERENCES: vaysburd95a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesn,bindyesu,FENRKRIEPVLIRK*# SEQUENCE: FENRKRIEPVLIRK*# ...# >MUS21E32# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Murine myoglobin (131-153)# DB REFERENCE: SWISS: (MYG_ORYAF,MYG_MOUSE,MYG_MOUSE,MYG_SPAEH,MYG_NYCCO,# & MYG_CTEGU,MYG_TUPGL,MYG_GALCR,MYG_PROGU,MYG_LAGMA,# & MYG_ERIEU)# & PIR1: (MYOL,MYOY,MYHH,MYVJ,MYRTNG,MYKS,MYLR,MYMS)# REFERENCES: vaysburd95a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,MSKALELFRNDIAAKYKELGFQG*# SEQUENCE: MSKALELFRNDIAAKYKELGFQG*# ...# >MUS21E33# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EMb (131-153)# DB REFERENCE: SWISS: (MYG_HORSE,MYG_HORSE)# & PIR1: (MYHO,MYHOZ)# REFERENCES: vaysburd95a,harrison97a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,MTKALELFRNDIAAKYKELGFQG*# SEQUENCE: MTKALELFRNDIAAKYKELGFQG*# ...# >MUS21E34# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EMb (131-153)# DB REFERENCE: SWISS: (MYG_HORSE,MYG_HORSE)# & PIR1: (MYHOZ,MYHO)# REFERENCES: vaysburd95a,lock91a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,MTKALELFRNDIAAKYKELGFQG*# SEQUENCE: MTKALELFRNDIAAKYKELGFQG*# ...# >HUM11E35# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 2# DB REFERENCE: SWISS: (EBN2_EBV)# & PIR2: (S32988)# & PIR3: (S42447,S42442)# REFERENCES: khanna92a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,DTPLIPLTIF*# SEQUENCE: DTPLIPLTIF*# ...# >HUM11E36# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 2# DB REFERENCE: SWISS: (EBN2_EBV)# & PIR2: (S32988)# & PIR3: (S42447,S42442)# REFERENCES: khanna92a# COMMENT:# SUMMARY: HLA-B18,actyesu,bindyesu,PRSPTVFYNIPPMPL*# SEQUENCE: PRSPTVFYNIPPMPL*# ...# >HUM11E37# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 3C (332-346)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (S33015,A31666)# REFERENCES: khanna92a# COMMENT: HLA-A24 or HLA-B44# SUMMARY: HLA-?,actyesu,bindyesu,RGIKEHVIQNAFRKA*# SEQUENCE: RGIKEHVIQNAFRKA*# ...# >HUM11E38# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA 2# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (S33015,S27922,H49034,A31666)# REFERENCES: khanna92a,shi97a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,EENLLDFVRF*# SEQUENCE: EENLLDFVRF*# ...# >MUS11E39# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as./Competition/Half-time# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: OVA (257-264)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: jameson92a,jackson93a,cook96a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,SIINFEKL*# SEQUENCE: SIINFEKL*# ...# >MUS11E3A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,AIINFEKL*# SEQUENCE: AIINFEKL*# ...# >MUS11E3B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,SAINFEKL*# SEQUENCE: SAINFEKL*# ...# >MUS11E3C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,SIANFEKL*# SEQUENCE: SIANFEKL*# ...# >MUS11E3D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actyesn,bindyesh,SIIAFEKL*# SEQUENCE: SIIAFEKL*# ...# >MUS11E3E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesl,SIINAEKL*# SEQUENCE: SIINAEKL*# ...# >MUS11E3F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,SIINFAKL*# SEQUENCE: SIINFAKL*# ...# >MUS11E40# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,SIINFEAL*# SEQUENCE: SIINFEAL*# ...# >MUS11E41# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesl,SIINFEKA*# SEQUENCE: SIINFEKA*# ...# >MUS11E42# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (25-32)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,ENIFYCPI*# SEQUENCE: ENIFYCPI*# ...# >MUS11E43# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (55-62)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,KVVRFDKL*# SEQUENCE: KVVRFDKL*# ...# >MUS11E44# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: stabilisation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (176-183)# ANCHOR POSITIONS:# REFERENCES: jameson92a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,VAIVFKGL*# SEQUENCE: VAIVFKGL*# ...# >MUS21E45# MHC MOLECULE: I-?, CLASS-2, (MOUSE)# METHOD: peptide screening as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bovine collagen alpha (271-282)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C)# & PIR2: (I60384)# REFERENCES: hay93a# COMMENT: important epitope in collagen-induced arthritis# SUMMARY: I-?,actyesu,bindyesu,GEPGIAGFKGEQ*# SEQUENCE: GEPGIAGFKGEQ*# ...# >MUS11E46# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: HPLC/cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Connexin-37# DB REFERENCE: SWISS: (CXA4_RAT,CXA4_MOUSE,CXA4_HUMAN,CXA4_HUMAN,CXA4_PIG,# & CXA4_MOUSE,CXA4_RAT)# & PIR1: (A40548,B42053)# & PIR2: (I55593)# REFERENCES: mandelboim94a# COMMENT:# SUMMARY: H-2Kb,actyesn,bindyesu,FECNTAQP*# SEQUENCE: FECNTAQP*# ...# >HUM21E47# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-106)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_PANTR,MBP_RAT,MBP_BOVIN,MBP_MOUSE,# & MBP_HUMAN)# & PIR1: (MBPGB,MBBOB,MBRTS,MBHUB,MBCZB,MBMSB)# & PIR2: (A37246)# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VVHFFKNIVTPRTPPPSQGKGRGLS*# SEQUENCE: VVHFFKNIVTPRTPPPSQGKGRGLS*# ...# >HUM21E48# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (87-99)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,MBP_RAT,MBP_PANTR,# & MBP_CAVPO)# & PIR1: (MBCZB,MBMSB,MBHUB,MBPGB,MBBOB,MBRTS)# & PIR2: (A37246)# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VVHFFKNIVTPRT*# SEQUENCE: VVHFFKNIVTPRT*# ...# >HUM21E49# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-99)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_BOVIN,MBP_HUMAN,MBP_RAT,MBP_PANTR,# & MBP_MOUSE)# & PIR1: (MBHUB,MBCZB,MBMSB,MBBOB,MBPGB,MBRTS)# & PIR2: (A37246)# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIVTPRT*# SEQUENCE: VHFFKNIVTPRT*# ...# >HUM21E4A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (89-99)# DB REFERENCE: SWISS: (MBP_RAT,MBP_MOUSE,MBP_PANTR,MBP_CAVPO,MBP_HUMAN,# & MBP_BOVIN)# & PIR1: (MBPGB,MBCZB,MBHUB,MBBOB,MBMSB,MBRTS)# & PIR2: (A37246)# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,HFFKNIVTPRT*# SEQUENCE: HFFKNIVTPRT*# ...# >HUM21E4B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_CAVPO,MBP_MOUSE,MBP_PANTR,MBP_RAT,# & MBP_HUMAN)# & PIR1: (MBPGB,MBMSB,MBBOB,MBCZB,MBHUB,MBRTS)# & PIR2: (A37246)# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >HUM21E4C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (91-102)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_MOUSE,MBP_HUMAN,MBP_RAT,MBP_PANTR,# & MBP_BOVIN)# & PIR1: (MBMSB,MBRTS,MBCZB,MBHUB,MBBOB,MBPGB)# & PIR2: (A37246)# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,FKNIVTPRTPPP*# SEQUENCE: FKNIVTPRTPPP*# ...# >HUM21E4D# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,VHFAKNIVTPRTP*# SEQUENCE: VHFAKNIVTPRTP*# ...# >HUM21E4E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHAFKNIVTPRTP*# SEQUENCE: VHAFKNIVTPRTP*# ...# >HUM21E4F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFAKNIVTPRTP*# SEQUENCE: VHFAKNIVTPRTP*# ...# >HUM21E50# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFANIVTPRTP*# SEQUENCE: VHFFANIVTPRTP*# ...# >HUM21E51# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNAVTPRTP*# SEQUENCE: VHFFKNAVTPRTP*# ...# >HUM21E52# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIATPRTP*# SEQUENCE: VHFFKNIATPRTP*# ...# >HUM21E53# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIVTARTP*# SEQUENCE: VHFFKNIVTARTP*# ...# >HUM21E54# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIVTPATP*# SEQUENCE: VHFFKNIVTPATP*# ...# >HUM21E55# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIVTPRAP*# SEQUENCE: VHFFKNIVTPRAP*# ...# >HUM21E56# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHAFKNIVTPRTP*# SEQUENCE: VHAFKNIVTPRTP*# ...# >HUM21E57# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFAKNIVTPRTP*# SEQUENCE: VHFAKNIVTPRTP*# ...# >HUM21E58# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFANIVTPRTP*# SEQUENCE: VHFFANIVTPRTP*# ...# >HUM21E59# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKAIVTPRTP*# SEQUENCE: VHFFKAIVTPRTP*# ...# >HUM21E5A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNAVTPRTP*# SEQUENCE: VHFFKNAVTPRTP*# ...# >HUM21E5B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIATPRTP*# SEQUENCE: VHFFKNIATPRTP*# ...# >HUM21E5C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesu,VHFFKNIVAPRTP*# SEQUENCE: VHFFKNIVAPRTP*# ...# >HUM21E5D# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIVTARTP*# SEQUENCE: VHFFKNIVTARTP*# ...# >HUM21E5E# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIVTPATP*# SEQUENCE: VHFFKNIVTPATP*# ...# >HUM21E5F# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VHFFKNIVTPRAP*# SEQUENCE: VHFFKNIVTPRAP*# ...# >HUM21E60# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_MOUSE,MBP_PANTR,MBP_CAVPO,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBHUB,MBMSB,MBPGB,MBRTS,MBCZB,MBBOB)# & PIR2: (A37246)# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >HUM21E61# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFANIVTPRTP*# SEQUENCE: VHFFANIVTPRTP*# ...# >HUM21E62# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFKAIVTPRTP*# SEQUENCE: VHFFKAIVTPRTP*# ...# >HUM21E63# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFKNAVTPRTP*# SEQUENCE: VHFFKNAVTPRTP*# ...# >HUM21E64# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFKNIATPRTP*# SEQUENCE: VHFFKNIATPRTP*# ...# >HUM21E65# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFKNIVAPRTP*# SEQUENCE: VHFFKNIVAPRTP*# ...# >HUM21E66# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFKNIVTARTP*# SEQUENCE: VHFFKNIVTARTP*# ...# >HUM21E67# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFKNIVTPATP*# SEQUENCE: VHFFKNIVTPATP*# ...# >HUM21E68# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (88-100) homologue# ANCHOR POSITIONS:# REFERENCES: martin92a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,VHFFKNIVTPRAP*# SEQUENCE: VHFFKNIVTPRAP*# ...# >HUM21E69# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP Ii (88-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: sinigaglia95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VSKMRMATPLLMQAL*# SEQUENCE: VSKMRMATPLLMQAL*# ...# >HUM21E6A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: NA+/K+ ATPase# DB REFERENCE: SWISS: (ATN1_PIG,ATN1_HORSE,ATN1_RAT,ATN1_HUMAN,ATN1_CANFA,# & ATN3_PIG,ATN1_HUMAN,ATN1_SHEEP)# & PIR1: (PWSHNA,S04630)# & PIR2: (B24862,S20970,A24639,A24414)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,ADLRIISANGCKV*# SEQUENCE: ADLRIISANGCKV*# ...# >HUM21E6B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,VEYHFLSPYVSPK*# SEQUENCE: VEYHFLSPYVSPK*# ...# >HUM21E6C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine fetuin# DB REFERENCE: SWISS: (A2HS_SHEEP,A2HS_BOVIN,A2HS_SHEEP,A2HS_BOVIN)# & PIR2: (A35714,S22394)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,HTLNQIDSVKVWP*# SEQUENCE: HTLNQIDSVKVWP*# ...# >HUM21E6D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Self-peptide SP3# ANCHOR POSITIONS: 3,6# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LEFRAMAQFSRKT*# SEQUENCE: LEFRAMAQFSRKT*# ...# >HUM21E6E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA A2# DB REFERENCE: SWISS: (1A03_PANTR,1A31_HUMAN,1A43_HUMAN,1A24_HUMAN,1A11_HUMAN,# & 1A04_PANTR,1A03_HUMAN,1A04_GORGO,1A01_PANTR,1A30_HUMAN,# & 1A02_HUMAN,1A69_HUMAN,1A01_PONPY,1A68_HUMAN,1A33_HUMAN,# & 1A02_HUMAN,1A02_GORGO,1A03_GORGO,1A25_HUMAN,1A31_HUMAN,# & 1A36_HUMAN,1A66_HUMAN,1A01_GORGO,1A01_HUMAN,1A26_HUMAN,# & 1A32_HUMAN,1A34_HUMAN,1A29_HUMAN,1A23_HUMAN,1A26_HUMAN,# & 1A74_HUMAN)# & PIR1: (HLHUA3,HLHUAW,HLHU69,HLHU28,HLHU32,HLHUA2)# & PIR2: (I38610,I84487,I54307,I36965,S18198,I38436,I72171,JL0135,# & I83063,I37480,I37476,I38519,I61856,I38443,I54416,I38518,# & I37477,I36966,JH0536,A45847,I84448,I72170,JH0534,S03535,# & I37482,S51099,S01171,A35997,A37028,I54493,S16769,I84432,# & I37542,JH0535,JH0537,I37479,A47636,I37483,I37478,I38441,# & I61857,I37470,I36959,I56039,I61902,I36961)# & PIR3: (S06424)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TQFVRFDSDAASQ*# SEQUENCE: TQFVRFDSDAASQ*# ...# >HUM21E6F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA Cw9# DB REFERENCE: SWISS: (1B39_HUMAN,1CXX_HUMAN,1C01_HUMAN,1C01_PANTR,1B38_HUMAN,# & HA19_CANFA,1C02_HUMAN,1C04_HUMAN,1B36_HUMAN,1C18_HUMAN,# & 1B34_HUMAN,1C11_HUMAN,1C15_HUMAN,1C03_HUMAN,HA1B_BOVIN,# & 1B02_HUMAN,1C16_HUMAN,1C12_HUMAN,1C14_HUMAN,1C01_GORGO,# & 1B20_HUMAN,1C03_GORGO,1C06_HUMAN,1B04_HUMAN,1C07_HUMAN,# & 1B35_HUMAN,1C02_HUMAN,1C17_HUMAN)# & PIR1: (S42102,HLHUC4,HLHUB7)# & PIR2: (S11143,I84431,S48134,JH0546,JH0288,JH0289,I59622,A45849,# & I81231,I68750,I56116,I54418,JH0526,I68701,I61905,A45857,# & I61865,I68749,S52486,I72113,I56149,I67482,S44994,I38507,# & I36958,I37135,I61866,S42823,I46603,JH0543,A45845,I61906,# & I56034,A49411,C37028,JH0544,I59655,JH0292,A60369,I61864,# & B37028,I37527,I54449,B45831,I67483,I38505,I59188,I54430,# & B27638,I46030,JH0290,I81232,JS0262,I37528,S60601,I68712,# & I46604,I37526,I37492,I37523,I59651,A45897,JH0291,I72808,# & I37544,I46049,I37078,I68747,I37529)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,RSWTAADTAAQIT*# SEQUENCE: RSWTAADTAAQIT*# ...# >HUM21E70# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VLA-4# DB REFERENCE: SWISS: (ITA4_HUMAN,ITA4_HUMAN)# & PIR2: (S06046)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SLFVYNITTNKYK*# SEQUENCE: SLFVYNITTNKYK*# ...# >HUM21E71# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Bovine hemoglobin# DB REFERENCE: SWISS: (HBA_BOSGF,HBA_HIPAM,HBA_MEGLY,HBA_BOVIN,HBA_CYNSP,# & HBA_PAPCY,HBA_MACAS,HBA_CTEGU,HBA_BISBO,HBA_MYOVE,# & HBA_CERAE,HBA_ANTPA,HBA_PTEPO,HBA_ODOVI,HBA_CEBCA,# & HBA1_TADBR,HBA_SPECI,HBA_MACGG,HBA1_BOSMU,HBA_TAPGE,# & HBA_TRAST,HBA_ROUAE,HBA3_PANTR,HBA_CAPHI,HBA_MACSI,# & HBA_PROHA,HBA_CALAR,HBA3_GORGO,HBA_CERTO,HBA_HUMAN,# & HBA_MACNE,HBA_NYCCO,HBA_HUMAN,HBA_COLBA,HBA_BOVIN,# & HBA_MACFA,HBA_EULFU,HBA1_GALCR,HBA_SAGFU,HBA_MACAS,# & HBA_MANSP,HBA_RHIUN,HBA_THEGE,HBA_CERSI,HBA_PTEAL,# & HBA_SPEPA,HBA_MACCA,HBA_MARMA,HBA_MACSP,HBA_LORTA,# & HBA_TUPGL,HBA_ATEGE,HBA_GORGO,HBA_TARBA,HBA2_GALCR,# & HBA_CEBAP,HBA2_BOSMU,HBA_RANTA,HBA_PONPY,HBA_TRIIN,# & HBA_PREEN,HBA_SPETO,HBA_MACMU,HBA_ALCAA)# & PIR1: (HAMQC,HAMQP,HABAG,HAGT,HAHU,HALRS,HABTV,HABOKA,HABOG,# & HARTNG,HARNW,HAHXR,HAMKP,HAYA2,HAMQIP,HALRN,HAGO,HACJB,# & HABO,HACZ,HACZP,HABAIM,HASHR2,HASHR1,HAEKN,HAMQF,HAFXB,# & HAMQR,HAMQB,HAMKS,HAEMA,HABAY,HAMQ2P,HAFXG,HAMQA,HAMQJ,# & HAYA1,HASH,HAGT2)# & PIR2: (A25359,S31853,A29702,I78575,S31851,I58217,A29392,B25597,# & B28865,A24690,A25597,A25477,A26543,JU0165,A24693,A25729,# & A29391,S31852,JC1099,C27792,A26640,A25357,B25727,B25126,# & B27792,D60515)# & PIR3: (S20277,B49141,S28934,S20278,S59496,S13481)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,RMFLSFPTTKT*# SEQUENCE: RMFLSFPTTKT*# ...# >HUM21E72# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human hsp# DB REFERENCE: SWISS: (HS70_PLEWA,HS70_ONCTS,HS70_CHICK,HS71_CANAL,HS72_MOUSE,# & HS7C_DICDI,HS71_RAT,HS71_HUMAN,HS72_PICAN,HS7C_ICTPU,# & HS73_BOVIN,HS7C_RAT,HS7C_CRIGR,HS71_HANPO,HS70_ONCMY,# & HS71_YEAST,HS72_HUMAN,HS7C_DICDI,HS71_PIG,HS7C_BOVIN,# & HS7X_PIG,HS7C_RAT,HS71_PIG,HS72_PICAN,HS7C_ICTPU,# & HS76_HUMAN,HS73_BOVIN,HS74_CANAL,HS7T_MOUSE,HS7C_HUMAN,# & HS72_HUMAN,HS7T_MOUSE,HS70_BLAEM,HS71_MOUSE,HS72_MOUSE,# & HS7C_BRARE,HS74_YEAST,HS71_BOVIN,HS7D_DROME,HS71_SCHPO,# & HS71_RAT,HS7H_HUMAN,HS7C_BOVIN,HS72_RAT,HS71_PICAN,# & HS71_MOUSE,HS70_HYDMA,HS72_BOVIN,HS73_RAT,HS76_PIG,# & HS72_YEAST)# & PIR1: (HHBYA1)# & PIR2: (I51344,A27077,A34041,A35922,S31766,S51712,B45871,S10859,# & I46588,A48872,B36590,S09036,S11456,I56574,JC4853,S07197,# & I51129,A55719,A25646,S67431,S31716,S41415,S25585,A36333,# & A48439,I54542,A45935,S08211,S43388,A29160,JH0095,S20139,# & A45871,S27004,S37394,I49761,S41372,S35718)# & PIR3: (S21175)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,DFYTSITRARFEE*# SEQUENCE: DFYTSITRARFEE*# ...# >HUM21E73# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human granulin D# DB REFERENCE: SWISS: (GRN_HUMAN,GRN_CAVPO)# & PIR1: (GYHU)# & PIR2: (I48141)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,AGYTCNVKARSCE*# SEQUENCE: AGYTCNVKARSCE*# ...# >HUM21E74# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human hsp# DB REFERENCE: SWISS: (HS7C_BOVIN,HS7C_RAT,HS7C_ICTPU,HS7C_BOVIN,HS7C_HUMAN,# & HS7C_RAT,HS7C_ICTPU)# & PIR2: (A27077,S11456,S31716,S07197,JC4853,A45935)# REFERENCES: sinigaglia94b# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,NHFIAEFKRKHKK*# SEQUENCE: NHFIAEFKRKHKK*# ...# >HUM21E75# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human PDC-E2 (163-176)# DB REFERENCE: SWISS: (ODP2_RAT,ODP2_HUMAN)# & PIR1: (XXHU)# & PIR2: (I55976,S21766,A40497)# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GDLLAEIETDKATI*# SEQUENCE: GDLLAEIETDKATI*# ...# >HUM21E76# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human PDC-E2 (36-49)# DB REFERENCE: SWISS: (ODP2_HUMAN,ODP2_RAT)# & PIR1: (XXHU)# & PIR2: (A40497,S52490,S21766)# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GDLIAEVETDKATV*# SEQUENCE: GDLIAEVETDKATV*# ...# >HUM21E77# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: E. coli PDC-E2 (31-44)# DB REFERENCE: SWISS: (ODP2_HAEIN,ODP2_ECOLI,ODP2_ECOLI)# & PIR1: (XXECDP)# & PIR2: (I64111)# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,EQSLITVEGDKASM*# SEQUENCE: EQSLITVEGDKASM*# ...# >HUM21E78# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human PDC-E2 (163-176) homologue# ANCHOR POSITIONS:# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GDALAEIETDKATI*# SEQUENCE: GDALAEIETDKATI*# ...# >HUM21E79# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human PDC-E2 (163-176) homologue# ANCHOR POSITIONS:# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GDLAAEIETDKATI*# SEQUENCE: GDLAAEIETDKATI*# ...# >HUM21E7A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human PDC-E2 (163-176) homologue# ANCHOR POSITIONS:# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GDLLSEIETDKATI*# SEQUENCE: GDLLSEIETDKATI*# ...# >HUM21E7B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human PDC-E2 (163-176) homologue# ANCHOR POSITIONS:# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GDLLAAIETDKATI*# SEQUENCE: GDLLAAIETDKATI*# ...# >HUM21E7C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human PDC-E2 (163-176) homologue# ANCHOR POSITIONS:# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GDLLAEAETDKATI*# SEQUENCE: GDLLAEAETDKATI*# ...# >HUM21E7D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: proliferation as./competitive proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human PDC-E2 (163-176) homologue# ANCHOR POSITIONS:# REFERENCES: shimoda95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GDLLAEIEADKATI*# SEQUENCE: GDLLAEIEADKATI*# ...# >MUS21E7E# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >MUS21E7F# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >MUS21E80# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesm,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >MUS21E81# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >MUS21E82# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >MUS21E83# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: I-As,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >MUS21E84# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: I-As,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >MUS21E85# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: I-As,actunkn,bindyesl,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >MUS21E86# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >MUS21E87# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >MUS21E88# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >MUS21E89# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21E8A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >HUM21E8B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21E8C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >HUM21E8D# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >HUM21E8E# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21E8F# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >HUM21E90# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >HUM21E91# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21E92# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >HUM21E93# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition binding as./direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a,sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >HUM21E94# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21E95# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >HUM21E96# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >HUM21E97# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: inhibition binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a,alexander94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21E98# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >HUM21E99# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >HUM21E9A# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: inhibition binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a,alexander94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21E9B# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesl,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >HUM21E9C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >HUM21E9D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: inhibition binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a,alexander94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21E9E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >HUM21E9F# MHC MOLECULE: HLA-DRw53, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mouse Ii (85-101)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DRw53,actunkn,bindyesm,KPVSQMRMATPLLMRPM*# SEQUENCE: KPVSQMRMATPLLMRPM*# ...# >HUM21EA0# MHC MOLECULE: HLA-DRw53, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DRw53,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21EA1# MHC MOLECULE: HLA-DRw53, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human Ii (80-103) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DRw53,actunkn,bindyesm,YLPKPPKPVSKLRLATPLLLQALPL*# SEQUENCE: YLPKPPKPVSKLRLATPLLLQALPL*# ...# >HUM21EA2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: OVA (323-339) reiterative# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YYVRAVRAYLTT*# SEQUENCE: YYVRAVRAYLTT*# ...# >HUM21EA3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ROIV# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,YAHAAHAAHAAHAAHAA*# SEQUENCE: YAHAAHAAHAAHAAHAA*# ...# >HUM21EA4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: inhibition binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PKHVKQNTLKLAT*# SEQUENCE: PKHVKQNTLKLAT*# ...# >HUM21EA5# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human insulin alpha chain (1-14)# DB REFERENCE: SWISS: (INS_BALPH,INS_RABIT,INS_MACFA,INS_PIG,INS_CERAE,# & INS_HUMAN,INS_CANFA,INS_PANTR,INS_HUMAN,INS_PIG)# & PIR1: (INWHP,IPDG,IPPG,INRB,INWHF,IPHU)# & PIR2: (A42179,A53438,JQ0178,B42179)# REFERENCES: naquet88a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,GIVEQCCTSICSLY*# SEQUENCE: GIVEQCCTSICSLY*# ...# >HUM21EA6# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human insulin alpha chain (1-14)# DB REFERENCE: SWISS: (INS_MACFA,INS_PIG,INS_RABIT,INS_BALPH,INS_HUMAN,# & INS_PANTR,INS_HUMAN,INS_CERAE,INS_PIG,INS_CANFA)# & PIR1: (IPDG,IPHU,INWHF,INRB,IPPG,INWHP)# & PIR2: (A42179,JQ0178,B42179,A53438)# REFERENCES: naquet88a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GIVEQCCTSICSLY*# SEQUENCE: GIVEQCCTSICSLY*# ...# >HUM21EA7# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human insulin alpha chain (1-14)# DB REFERENCE: SWISS: (INS_PIG,INS_MACFA,INS_PANTR,INS_HUMAN,INS_CERAE,# & INS_HUMAN,INS_RABIT,INS_CANFA,INS_PIG,INS_BALPH)# & PIR1: (IPPG,INRB,IPDG,IPHU,INWHF,INWHP)# & PIR2: (A53438,B42179,JQ0178,A42179)# REFERENCES: naquet88a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,GIVEQCCTSICSLY*# SEQUENCE: GIVEQCCTSICSLY*# ...# >HUM21EA8# MHC MOLECULE: HLA-DQ3, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human insulin alpha chain (1-14)# DB REFERENCE: SWISS: (INS_HUMAN,INS_CERAE,INS_PIG,INS_CANFA,INS_PANTR,# & INS_HUMAN,INS_RABIT,INS_PIG,INS_BALPH,INS_MACFA)# & PIR1: (IPHU,INWHF,INWHP,IPDG,INRB,IPPG)# & PIR2: (JQ0178,A42179,B42179,A53438)# REFERENCES: naquet88a# COMMENT:# SUMMARY: HLA-DQ3,actyesu,bindyesu,GIVEQCCTSICSLY*# SEQUENCE: GIVEQCCTSICSLY*# ...# >HUM21EA9# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human insulin beta chain (10-25)# DB REFERENCE: SWISS: (INS_ACOCA,INS_PSAOB,INS_AOTTR,INS_CRILO,INS_BALBO,# & INS_SHEEP,INS2_RAT,INS_DIDMA,INS2_MOUSE,INS_CANFA,# & INS_ELEMA,INS_CAMDR,INS_PIG,INS_CAPHI,INS_KATPE,# & INS_MACFA,INS_ANAPL,INS_SELRF,INS1_RAT,INS2_MOUSE,# & INS_FELCA,INS_PIG,INS_CHICK,INS_BALPH,INS_HUMAN,# & INS1_MOUSE,INS_PANTR,INS_ANSAN,INS_CERAE,INS_HUMAN,# & INS_ACOCA,INS_PSESC,INS_HORSE,INS_RABIT,INS_BOVIN,# & INS_SELRF)# & PIR1: (INMKSQ,INRB,INTK,INGS,INCT,INCMA,IPRT1,INEL,INMS1,INWHP,# & A61129,INSH,INOS,IPBO,IPCH,INGT,INWH1S,INWHF,INHY,IPPG,# & IPHU,IPHO,INMS2,IPRT2,IPDG)# & PIR2: (A53438,I48166,JQ0362,A60414,B42179,JQ0178,A42179,# & A39883)# & PIR3: (JQ0363,I51221,S44470)# REFERENCES: naquet88a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,HLVEALYLVCGERGFF*# SEQUENCE: HLVEALYLVCGERGFF*# ...# >HUM21EAA# MHC MOLECULE: HLA-DQ2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human insulin beta chain (10-25)# DB REFERENCE: SWISS: (INS_SELRF,INS_KATPE,INS_PANTR,INS_MACFA,INS_HUMAN,# & INS2_MOUSE,INS_CERAE,INS_AOTTR,INS_CRILO,INS_PSESC,# & INS_ACOCA,INS_PSAOB,INS_ANAPL,INS_SELRF,INS_CHICK,# & INS_PIG,INS_FELCA,INS2_MOUSE,INS_CAMDR,INS_ELEMA,# & INS_PIG,INS_BALPH,INS_CAPHI,INS_SHEEP,INS_DIDMA,# & INS_CANFA,INS_HUMAN,INS2_RAT,INS1_MOUSE,INS_ANSAN,# & INS_ACOCA,INS_HORSE,INS_BOVIN,INS_RABIT,INS_BALBO,# & INS1_RAT)# & PIR1: (INSH,IPDG,INHY,INWHF,IPPG,INCT,INMS1,IPRT1,IPCH,A61129,# & INWH1S,INGT,IPRT2,IPBO,INMS2,IPHU,IPHO,INCMA,INWHP,INOS,# & INEL,INGS,INTK,INMKSQ,INRB)# & PIR2: (A60414,A39883,A42179,JQ0178,B42179,JQ0362,I48166,# & A53438)# & PIR3: (JQ0363,I51221,S44470)# REFERENCES: naquet88a# COMMENT:# SUMMARY: HLA-DQ2,actyesu,bindyesu,HLVEALYLVCGERGFF*# SEQUENCE: HLVEALYLVCGERGFF*# ...# >HUM21EAB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: calreticulin (295-310)# DB REFERENCE: SWISS: (CRTC_HUMAN,CRTC_HUMAN)# & PIR2: (A37047)# REFERENCES: max94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,DNPEYSPDPSIYAYDN*# SEQUENCE: DNPEYSPDPSIYAYDN*# ...# >HUM21EAC# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: calreticulin (295-310)# DB REFERENCE: SWISS: (CRTC_HUMAN,CRTC_HUMAN)# & PIR2: (A37047)# REFERENCES: max94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DNPEYSPDPSIYAYDN*# SEQUENCE: DNPEYSPDPSIYAYDN*# ...# >HUM21EAD# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: calreticulin (295-310)# DB REFERENCE: SWISS: (CRTC_HUMAN,CRTC_HUMAN)# & PIR2: (A37047)# REFERENCES: max94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,DNPEYSPDPSIYAYDN*# SEQUENCE: DNPEYSPDPSIYAYDN*# ...# >HUM21EAE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRSMAAAAA*# SEQUENCE: YRSMAAAAA*# ...# >HUM21EAF# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,VRSMAAAAA*# SEQUENCE: VRSMAAAAA*# ...# >HUM21EB0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,FRSMAAAAA*# SEQUENCE: FRSMAAAAA*# ...# >HUM21EB1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,MRSMAAAAA*# SEQUENCE: MRSMAAAAA*# ...# >HUM21EB2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,IRSMAAAAA*# SEQUENCE: IRSMAAAAA*# ...# >HUM21EB3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,LRSMAAAAA*# SEQUENCE: LRSMAAAAA*# ...# >HUM21EB4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,WRSMAAAAA*# SEQUENCE: WRSMAAAAA*# ...# >HUM21EB5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRSMGAAAA*# SEQUENCE: YRSMGAAAA*# ...# >HUM21EB6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,YRSMAGAAA*# SEQUENCE: YRSMAGAAA*# ...# >HUM21EB7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,YRSMAAGAA*# SEQUENCE: YRSMAAGAA*# ...# >HUM21EB8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRSMLAAAA*# SEQUENCE: YRSMLAAAA*# ...# >HUM21EB9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YRSMAALAA*# SEQUENCE: YRSMAALAA*# ...# >HUM21EBA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,YRSMEAAAA*# SEQUENCE: YRSMEAAAA*# ...# >HUM21EBB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,YRSMAAEAA*# SEQUENCE: YRSMAAEAA*# ...# >HUM21EBC# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,YRSMRAAAA*# SEQUENCE: YRSMRAAAA*# ...# >HUM21EBD# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,YRSMARAAA*# SEQUENCE: YRSMARAAA*# ...# >HUM21EBE# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: artificial peptide# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,YRSMAARAA*# SEQUENCE: YRSMAARAA*# ...# >HUM21EBF# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human cartilage link protein# DB REFERENCE: SWISS: (PLK_PIG,PLK_BOVIN,PLK_HUMAN,PLK_BOVIN,PLK_HUMAN,PLK_PIG,# & PLK_HORSE)# & PIR1: (LKHU)# & PIR2: (S04243,I47145,S42938,A29165)# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,IKWTKLTSDYLKE*# SEQUENCE: IKWTKLTSDYLKE*# ...# >HUM21EC0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human cartilage link protein# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,LGYDRADAGWLAD*# SEQUENCE: LGYDRADAGWLAD*# ...# >HUM21EC1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxoid TT# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PLYKKMEAVKLRD*# SEQUENCE: PLYKKMEAVKLRD*# ...# >HUM21EC2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxoid TT# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,NAFRNVDGSGLVS*# SEQUENCE: NAFRNVDGSGLVS*# ...# >HUM21EC3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tetanus toxoid TT# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,SKYFQDPALLLMH*# SEQUENCE: SKYFQDPALLLMH*# ...# >HUM21EC4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxoid TT# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,TIYQYLYAQKSPT*# SEQUENCE: TIYQYLYAQKSPT*# ...# >HUM21EC5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tetanus toxoid TT# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,IYYRRLYNGLKFI*# SEQUENCE: IYYRRLYNGLKFI*# ...# >HUM21EC6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD65# DB REFERENCE: SWISS: (DCE2_MOUSE,DCE2_HUMAN,DCE2_PIG)# & PIR1: (A41292,S38533)# & PIR2: (JC4064)# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VNYAFLHATDLLP*# SEQUENCE: VNYAFLHATDLLP*# ...# >HUM21EC7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD65# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,QKFTGGIGNKLAA*# SEQUENCE: QKFTGGIGNKLAA*# ...# >HUM21EC8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD65# DB REFERENCE: SWISS: (DCE2_PIG,DCE2_MOUSE,DCE2_HUMAN,DCE2_RAT)# & PIR1: (A41292,JH0423,S38533)# & PIR2: (I67412,JC4064)# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,LDMVGLAADWLTS*# SEQUENCE: LDMVGLAADWLTS*# ...# >HUM21EC9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD65# ANCHOR POSITIONS:# REFERENCES: hammer94c# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GAFDPLLAVADIA*# SEQUENCE: GAFDPLLAVADIA*# ...# >HUM21ECA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBVnc (50-69)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVY,CORA_HPBV2,CORA_HPBVW,# & CORA_HPBVJ)# & PIR1: (NKVLAH,NKVLA3,NKVLJ1,NKVLBH,NKVLA6,NKVLKS)# & PIR2: (S20755,S53238,S53152,S53207,S47409,S01405,S53181,S53149,# & S53200,S20750,S53286,S53169,S32204,S20746,S25651,S53202,# & S53161,S53216,S53157,S53274,S53227,S53140,S53267,S53247,# & S47405,S53272,S53204,S53163,S22318)# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM21ECB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,QYIKANSFIGITE*# SEQUENCE: QYIKANSFIGITE*# ...# >HUM21ECC# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: CS (378-398)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM21ECD# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MT (17-31)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YSGPLKAEIAQRLEDV*# SEQUENCE: YSGPLKAEIAQRLEDV*# ...# >HUM21ECE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21ECF# MHC MOLECULE: HLA-DR2(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBVnc (50-69)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBV2,CORA_HPBVW,CORA_HPBV9,# & CORA_HPBVJ)# & PIR1: (NKVLJ1,NKVLKS,NKVLA6,NKVLAH,NKVLBH,NKVLA3)# & PIR2: (S53149,S53204,S53157,S53216,S20746,S53227,S53140,S53207,# & S53238,S32204,S53200,S20755,S53286,S20750,S25651,S53202,# & S53169,S53161,S53152,S01405,S53181,S53247,S53267,S47405,# & S47409,S53163,S53274,S53272,S22318)# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM21ED0# MHC MOLECULE: HLA-DR2(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: CS (378-398)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM21ED1# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,QYIKANSFIGITE*# SEQUENCE: QYIKANSFIGITE*# ...# >HUM21ED2# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21ED3# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBVnc (50-69)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVJ,CORA_HPBVW,CORA_HPBV2,# & CORA_HPBVY)# & PIR1: (NKVLAH,NKVLA3,NKVLA6,NKVLBH,NKVLJ1,NKVLKS)# & PIR2: (S53216,S53157,S53207,S20755,S32204,S53204,S53274,S20746,# & S53247,S47409,S22318,S53163,S25651,S53169,S53161,S01405,# & S53272,S53238,S53140,S53181,S47405,S53202,S53286,S20750,# & S53200,S53149,S53227,S53267,S53152)# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM21ED4# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: CS (378-398)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM21ED5# MHC MOLECULE: HLA-DR5, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR5,actunkn,bindyesh,QYIKANSFIGITE*# SEQUENCE: QYIKANSFIGITE*# ...# >HUM21ED6# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,QYIKANSFIGITE*# SEQUENCE: QYIKANSFIGITE*# ...# >HUM21ED7# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MT (17-31)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,YSGPLKAEIAQRLEDV*# SEQUENCE: YSGPLKAEIAQRLEDV*# ...# >HUM21ED8# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MT (17-31)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,YSGPLKAEIAQRLEDV*# SEQUENCE: YSGPLKAEIAQRLEDV*# ...# >HUM21ED9# MHC MOLECULE: HLA-DR52(DRB3*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21EDA# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IADH3,HEMA_IADU3,HEMA_IADH4,HEMA_IAZH2,HEMA_IAQU7,# & HEMA_IADHM,HEMA_IANT6,HEMA_IABAN,HEMA_IADH6,HEMA_IAZUK,# & HEMA_IAZCO,HEMA_IAEN7,HEMA_IAUDO,HEMA_IADH1,HEMA_IAME2,# & HEMA_IADH2,HEMA_IAVI7,HEMA_IADH7,HEMA_IAEN6,HEMA_IAAIC,# & HEMA_IAME1)# & PIR1: (HMIVHM,HMIV15,HMIVS3,HMIV98,HMIV80,HMIV89,HMIVH,HMIV77,# & HMIVV,HMIVDU,HMIVHA,HMIV33,HMIV6)# & PIR2: (JQ1156,A92979)# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesl,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM21EDB# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MT (17-31)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesl,YSGPLKAEIAQRLEDV*# SEQUENCE: YSGPLKAEIAQRLEDV*# ...# >HUM21EDC# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21EDD# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBVnc (50-69)# DB REFERENCE: SWISS: (CORA_HPBVW,CORA_HPBV2,CORA_HPBV9,CORA_HPBVJ,# & CORA_HPBVY)# & PIR1: (NKVLAH,NKVLJ1,NKVLA6,NKVLA3,NKVLBH,NKVLKS)# & PIR2: (S53227,S53152,S53267,S53140,S53200,S53149,S53216,S53274,# & S53181,S20750,S32204,S20755,S53247,S01405,S53157,S53238,# & S53272,S53286,S25651,S53161,S20746,S22318,S53163,S53207,# & S53204,S53202,S47405,S53169,S47409)# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM21EDE# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,QYIKANSFIGITE*# SEQUENCE: QYIKANSFIGITE*# ...# >HUM21EDF# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: CS (378-398)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,DIEKKIAKMEKASSVFNVVNS*# SEQUENCE: DIEKKIAKMEKASSVFNVVNS*# ...# >HUM21EE0# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MT (17-31)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,YSGPLKAEIAQRLEDV*# SEQUENCE: YSGPLKAEIAQRLEDV*# ...# >HUM21EE1# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ii (80-103)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMGALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMGALPM*# ...# >HUM21EE2# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (323-336)# DB REFERENCE: SWISS: (OVAL_COTJA,OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesm,ISQAVHAAHAEINE*# SEQUENCE: ISQAVHAAHAEINE*# ...# >HUM21EE3# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (46-61)# DB REFERENCE: SWISS: (LYC1_ANAPL,LYC_CHICK,LYC_SYRRE,LYC_CHRAM,LYC_CHICK,# & LYC_LOPLE,LYC_PHAVE,LYC1_TACAC,LYC_PAVCR,LYC_MELGA,# & LYC_PHACO)# & PIR1: (LZTK,LZCH,LZQJE,LZFER,LZDK)# & PIR2: (JU0237,JQ1041,A45660,JC2144,JU0178,JH0211,JQ1033,JH0212,# & JT0526,A61281)# REFERENCES: alexander94a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >MUS21EE4# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBVnc (128-140)# DB REFERENCE: SWISS: (CORA_HPBVW,CORA_HPBVA,CORA_HPBVY,CORA_HPBVJ,CORA_HPBVF,# & CORA_HPBV9,CORA_HPBV4,CORA_HPBVZ,CORA_HPBVL,CORA_HPBVT,# & CORA_HPBVO,CORA_HPBV2)# & PIR1: (NKVLA2,NKVLKS,NKVLAH,NKVLCP,NKVLA6,NKVLBH,NKVLH3,NKVLA3,# & NKVLA4,NKVLA1,NKVLJ1,NKVLJ2)# & PIR2: (JQ2227,S53159,S53166,S53281,S53223,S53232,S53175,S53274,# & S53279,S32204,S53161,S53172,S53146,S53238,S53140,S01405,# & S53207,S53163,S20746,S53253,S53272,S53186,S53169,S47409,# & S20750,S53236,S53194,S53260,S25651,S53240,S53214,S53270,# & S20755,S35530,S53181,S53225,S53152,S53198,S53189,S53255,# & S53204,S53229,S53221,S47405,S04570,S53129,S33686,S53257,# & S53247,S53211,S53216,S53242,S53227,S53202,S53251)# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesm,TPPAYRPPNAPIL*# SEQUENCE: TPPAYRPPNAPIL*# ...# >MUS21EE5# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: OVA (323-336)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesm,ISQAVHAAHAEINE*# SEQUENCE: ISQAVHAAHAEINE*# ...# >MUS21EE6# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (139-151)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-Ab,actunkn,bindyesl,HSLGKWLGHPDKF*# SEQUENCE: HSLGKWLGHPDKF*# ...# >MUS21EE7# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: HEL (46-61)# DB REFERENCE: SWISS: (LYC1_ANAPL,LYC_CHRAM,LYC_CHICK,LYC_SYRRE,LYC_LOPLE,# & LYC_CHICK,LYC1_TACAC,LYC_PAVCR,LYC_MELGA,LYC_PHACO,# & LYC_PHAVE)# & PIR1: (LZQJE,LZCH,LZDK,LZTK,LZFER)# & PIR2: (JU0237,A45660,JU0178,JQ1033,JH0211,A61281,JH0212,JT0526,# & JQ1041,JC2144)# REFERENCES: alexander94a,feng94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesl,NTDGSTDYGILQINSR*# SEQUENCE: NTDGSTDYGILQINSR*# ...# >MUS21EE8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Lambda rep. (12-26)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,YLEDARRLKAIYEKKK*# SEQUENCE: YLEDARRLKAIYEKKK*# ...# >MUS21EE9# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Lambda rep. (12-26)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesm,YLEDARRLKAIYEKKK*# SEQUENCE: YLEDARRLKAIYEKKK*# ...# >MUS21EEA# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (323-336)# DB REFERENCE: SWISS: (OVAL_COTJA,OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-As,actunkn,bindyesl,ISQAVHAAHAEINE*# SEQUENCE: ISQAVHAAHAEINE*# ...# >MUS21EEB# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (323-336)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,ISQAVHAAHAEINE*# SEQUENCE: ISQAVHAAHAEINE*# ...# >MUS21EEC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (323-336)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK,OVAL_COTJA)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesm,ISQAVHAAHAEINE*# SEQUENCE: ISQAVHAAHAEINE*# ...# >MUS21EED# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Lambda rep. (12-26)# ANCHOR POSITIONS:# REFERENCES: alexander94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesh,YLEDARRLKAIYEKKK*# SEQUENCE: YLEDARRLKAIYEKKK*# ...# >HUM11EEE# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./binding as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: FLU M1 (58-66)# DB REFERENCE: SWISS: (VMT1_IAMAN,VMT1_IAZI1,VMT1_IAFOW,VMT1_IAUSS,VMT1_IAANN,# & VMT1_IAUDO,VMT1_IABAN,VMT1_IACKB,VMT1_IALE2,VMT1_IALE1,# & VMT1_IAWIL,VMT1_IAPUE)# & PIR1: (MFIVC,JN0392,MFIVWS,MFIV61,MFIV1K,MFIV1M,MFIV)# & PIR2: (S14616,S04050,S04054,S04058,S04052,S04056,S07429)# REFERENCES: rivoltini95b,barouch95a,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesh,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM11EEF# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: FLU M1 (58-66)# DB REFERENCE: SWISS: (VMT1_IALE2,VMT1_IAPUE,VMT1_IAUSS,VMT1_IAUDO,VMT1_IACKB,# & VMT1_IAANN,VMT1_IAWIL,VMT1_IALE1,VMT1_IAFOW,VMT1_IAZI1,# & VMT1_IAMAN,VMT1_IABAN)# & PIR1: (MFIV1K,JN0392,MFIV,MFIV61,MFIV1M,MFIVC,MFIVWS)# & PIR2: (S14616,S04050,S04054,S04056,S07429,S04052,S04058)# REFERENCES: rivoltini95b# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesm,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM11EF0# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./binding as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: FLU M1 (58-66)# DB REFERENCE: SWISS: (VMT1_IAWIL,VMT1_IALE1,VMT1_IABAN,VMT1_IAZI1,VMT1_IAMAN,# & VMT1_IAUDO,VMT1_IACKB,VMT1_IALE2,VMT1_IAANN,VMT1_IAFOW,# & VMT1_IAPUE,VMT1_IAUSS)# & PIR1: (MFIV,MFIVC,JN0392,MFIV1K,MFIV1M,MFIV61,MFIVWS)# & PIR2: (S04050,S04056,S04054,S14616,S04058,S04052,S07429)# REFERENCES: rivoltini95b,barouch95a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesm,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM11EF1# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competition# ACTIVITY: none# BINDING: yes, moderate# SOURCE: melanoma antigen MART.1 (27-35)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95b,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM11EF2# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: FLU M1 (58-66)# DB REFERENCE: SWISS: (VMT1_IALE1,VMT1_IAZI1,VMT1_IAANN,VMT1_IAMAN,VMT1_IAUSS,# & VMT1_IAPUE,VMT1_IAFOW,VMT1_IABAN,VMT1_IAWIL,VMT1_IALE2,# & VMT1_IACKB,VMT1_IAUDO)# & PIR1: (MFIVWS,MFIV61,MFIVC,JN0392,MFIV1K,MFIV1M,MFIV)# & PIR2: (S04054,S14616,S04052,S04050,S04056,S04058,S07429)# REFERENCES: rivoltini95b# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesm,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM11EF3# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: GP100 (476-485)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A53668,I38400)# REFERENCES: rivoltini95b,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,VLYRYGSFSV*# SEQUENCE: VLYRYGSFSV*# ...# >HUM11EF4# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: GP100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# REFERENCES: rivoltini95b,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM11EF5# MHC MOLECULE: HLA-A2(A*0209), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: FLU M1 (58-66)# DB REFERENCE: SWISS: (VMT1_IACKB,VMT1_IAUDO,VMT1_IALE2,VMT1_IAPUE,VMT1_IAANN,# & VMT1_IALE1,VMT1_IAWIL,VMT1_IAMAN,VMT1_IAFOW,VMT1_IABAN,# & VMT1_IAZI1,VMT1_IAUSS)# & PIR1: (MFIV1K,MFIV61,MFIV,MFIVC,JN0392,MFIV1M,MFIVWS)# & PIR2: (S04050,S04058,S04054,S07429,S14616,S04052,S04056)# REFERENCES: rivoltini95b,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM11EF6# MHC MOLECULE: HLA-A2(A*0209), CLASS-1, (HUMAN)# METHOD: CTL assays/inhibition/Competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: melanoma antigen MART.1 (27-35)# DB REFERENCE: PIR2: (A55253)# REFERENCES: rivoltini95b,fleischauer96a,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM11EF7# MHC MOLECULE: HLA-A2(A*0209), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: GP100 (476-485)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A53668)# REFERENCES: rivoltini95b,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,VLYRYGSFSV*# SEQUENCE: VLYRYGSFSV*# ...# >HUM11EF8# MHC MOLECULE: HLA-A2(A*0209), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: GP100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A53668)# REFERENCES: rivoltini95b,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >HUM11EF9# MHC MOLECULE: HLA-A2(A*0209), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: GP100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A53668,I38400)# REFERENCES: rivoltini95b,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM21EFA# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (1-19)# DB REFERENCE: PIR1: (MPRTPL,S34792,MPHUPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,MGLLECCARCLVGAPFASLV*# SEQUENCE: MGLLECCARCLVGAPFASLV*# ...# >HUM21EFB# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (30-49)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_BOVIN,MYPR_HUMAN,# & MYPR_RABIT)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,LFCGCGHEALTGTEKLIETY*# SEQUENCE: LFCGCGHEALTGTEKLIETY*# ...# >HUM21EFC# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (40-59)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_RABIT,MYPR_BOVIN,MYPR_CANFA,# & MYPR_HUMAN)# & PIR1: (MPBOPL,MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,TGTEKLIETYFSKNYQDYEY*# SEQUENCE: TGTEKLIETYFSKNYQDYEY*# ...# >HUM21EFD# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (50-69)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT,MYPR_BOVIN,# & MYPR_HUMAN)# & PIR1: (MPRTPL,MPBOPL,MPHUPL,S34792)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,FSKNYQDYEYLINVIHAFQY*# SEQUENCE: FSKNYQDYEYLINVIHAFQY*# ...# >HUM21EFE# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (60-79)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_BOVIN,MYPR_HUMAN,# & MYPR_CANFA)# & PIR1: (MPRTPL,MPHUPL,S34792,MPBOPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,LINVIHAFQYVIYGTASFFF*# SEQUENCE: LINVIHAFQYVIYGTASFFF*# ...# >HUM21EFF# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (70-89)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_CHICK,MYPR_BOVIN,MYPR_CANFA,# & MYPR_HUMAN)# & PIR1: (S34792,MPRTPL,MPHUPL)# & PIR2: (S17600,A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,VIYGTASFFFLYGALLLAEG*# SEQUENCE: VIYGTASFFFLYGALLLAEG*# ...# >HUM21F00# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: proteolipid protein PLP (80-99)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,# & MYPR_POEGU,MYPR_CHICK)# & PIR1: (MPHUPL,S34792,MPRTPL)# & PIR2: (S17600,A43548)# & PIR3: (I51270)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,LYGALLLAEGFYTTGAVRQI*# SEQUENCE: LYGALLLAEGFYTTGAVRQI*# ...# >HUM21F01# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: proteolipid protein PLP (90-109)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_HUMAN,MYPR_RABIT,# & MYPR_BOVIN)# & PIR1: (MPBOPL,MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,FYTTGAVRQIFGDYKTTICG*# SEQUENCE: FYTTGAVRQIFGDYKTTICG*# ...# >HUM21F02# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (130-149)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_HUMAN,MYPR_BOVIN,# & MYPR_CANFA)# & PIR1: (MPRTPL,S34792,MPHUPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,QAHSLERVCHCLGKWLGHPD*# SEQUENCE: QAHSLERVCHCLGKWLGHPD*# ...# >HUM21F03# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (140-159)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_RABIT,MYPR_BOVIN,MYPR_HUMAN,# & MYPR_CANFA)# & PIR1: (MPRTPL,MPHUPL,S34792)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,CLGKWLGHPDKFVGITYALT*# SEQUENCE: CLGKWLGHPDKFVGITYALT*# ...# >HUM21F04# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (160-179)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_BOVIN,MYPR_RABIT,MYPR_HUMAN)# & PIR1: (MPBOPL,MPHUPL,S34792,MPRTPL)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,VVWLLVFACSAVPVYIYFNT*# SEQUENCE: VVWLLVFACSAVPVYIYFNT*# ...# >HUM21F05# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: proteolipid protein PLP (170-189)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CHICK,MYPR_CANFA,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548,S17600)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,AVPVYIYFNTWTTCQSIAFP*# SEQUENCE: AVPVYIYFNTWTTCQSIAFP*# ...# >HUM21F06# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (180-199)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA)# & PIR1: (MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,WTTCQSIAFPSKTSASIGSL*# SEQUENCE: WTTCQSIAFPSKTSASIGSL*# ...# >HUM21F07# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: proteolipid protein PLP (200-219)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_CHICK,MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (MPRTPL,MPBOPL,MPHUPL,S34792)# & PIR2: (S17600,A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,CADARMYGVLPWNAFPGKVC*# SEQUENCE: CADARMYGVLPWNAFPGKVC*# ...# >HUM21F08# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (210-229)# DB REFERENCE: SWISS: (MYPR_CHICK,MYPR_CANFA,MYPR_HUMAN,MYPR_BOVIN,MYPR_RABIT,# & MYPR_POEGU,MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPRTPL,MPBOPL)# & PIR2: (S17600,A43548)# & PIR3: (I51270)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,PWNAFPGKVCGSNLLSICKT*# SEQUENCE: PWNAFPGKVCGSNLLSICKT*# ...# >HUM21F09# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (220-239)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_CANFA,MYPR_HUMAN,# & MYPR_BOVIN)# & PIR1: (MPBOPL,S34792,MPRTPL,MPHUPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,GSNLLSICKTAEFQMTFHLF*# SEQUENCE: GSNLLSICKTAEFQMTFHLF*# ...# >HUM21F0A# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (230-249)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_CANFA,MYPR_HUMAN,MYPR_HUMAN,# & MYPR_RABIT)# & PIR1: (MPHUPL,MPRTPL,S34792,MPBOPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,AEFQMTFHLFIAAFVGAAAT*# SEQUENCE: AEFQMTFHLFIAAFVGAAAT*# ...# >HUM21F0B# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (240-259)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_CANFA,MYPR_CHICK,MYPR_BOVIN,MYPR_HUMAN,# & MYPR_HUMAN)# & PIR1: (MPHUPL,MPRTPL,S34792)# & PIR2: (A43548,S17600)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,IAAFVGAAATLVSLLTFMIA*# SEQUENCE: IAAFVGAAATLVSLLTFMIA*# ...# >HUM21F0C# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (250-269)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_BOVIN,MYPR_HUMAN,MYPR_HUMAN,MYPR_CHICK,# & MYPR_CANFA)# & PIR1: (MPRTPL,MPHUPL,S34792)# & PIR2: (A43548,S17600)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,LVSLLTFMIAATYNFAVLKL*# SEQUENCE: LVSLLTFMIAATYNFAVLKL*# ...# >HUM21F0D# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (260-276)# ANCHOR POSITIONS:# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,MAATYNFAVLKLMGRFTKF*# SEQUENCE: MAATYNFAVLKLMGRFTKF*# ...# >HUM21F0E# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (50-69)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,# & MYPR_BOVIN)# & PIR1: (MPRTPL,MPBOPL,S34792,MPHUPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,FSKNYQDYEYLINVIHAFQY*# SEQUENCE: FSKNYQDYEYLINVIHAFQY*# ...# >HUM21F0F# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (80-99)# DB REFERENCE: SWISS: (MYPR_POEGU,MYPR_BOVIN,MYPR_RABIT,MYPR_HUMAN,MYPR_HUMAN,# & MYPR_CANFA,MYPR_CHICK)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (S17600,A43548)# & PIR3: (I51270)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,LYGALLLAEGFYTTGAVRQI*# SEQUENCE: LYGALLLAEGFYTTGAVRQI*# ...# >HUM21F10# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: proteolipid protein PLP (90-109)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_BOVIN,MYPR_CANFA,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (MPHUPL,MPRTPL,MPBOPL,S34792)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,FYTTGAVRQIFGDYKTTICG*# SEQUENCE: FYTTGAVRQIFGDYKTTICG*# ...# >HUM21F11# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (100-119)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_CANFA,MYPR_BOVIN,MYPR_HUMAN,# & MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPBOPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,FGDYKTTICGKGLSATVTGG*# SEQUENCE: FGDYKTTICGKGLSATVTGG*# ...# >HUM21F12# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (110-129)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,KGLSATVTGGQKGRGYRGQH*# SEQUENCE: KGLSATVTGGQKGRGYRGQH*# ...# >HUM21F13# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (130-149)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_RABIT,MYPR_CANFA,# & MYPR_BOVIN)# & PIR1: (MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,QAHSLERVCHCLGKWLGHPD*# SEQUENCE: QAHSLERVCHCLGKWLGHPD*# ...# >HUM21F14# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (140-159)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,MYPR_BOVIN,# & MYPR_CANFA)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,CLGKWLGHPDKFVGITYALT*# SEQUENCE: CLGKWLGHPDKFVGITYALT*# ...# >HUM21F15# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (180-199)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_HUMAN)# & PIR1: (MPHUPL,S34792,MPRTPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,WTTCQSIAFPSKTSASIGSL*# SEQUENCE: WTTCQSIAFPSKTSASIGSL*# ...# >HUM21F16# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (190-209)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA)# & PIR1: (MPRTPL,S34792,MPHUPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,SKTSASIGSLCADARMYGVL*# SEQUENCE: SKTSASIGSLCADARMYGVL*# ...# >HUM21F17# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (200-219)# DB REFERENCE: SWISS: (MYPR_CHICK,MYPR_CANFA,MYPR_HUMAN,MYPR_HUMAN,MYPR_RABIT,# & MYPR_BOVIN)# & PIR1: (MPHUPL,MPRTPL,S34792,MPBOPL)# & PIR2: (A43548,S17600)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,CADARMYGVLPWNAFPGKVC*# SEQUENCE: CADARMYGVLPWNAFPGKVC*# ...# >HUM21F18# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (210-229)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_POEGU,MYPR_RABIT,MYPR_HUMAN,MYPR_CHICK,# & MYPR_BOVIN,MYPR_HUMAN)# & PIR1: (MPBOPL,MPHUPL,MPRTPL,S34792)# & PIR2: (S17600,A43548)# & PIR3: (I51270)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,PWNAFPGKVCGSNLLSICKT*# SEQUENCE: PWNAFPGKVCGSNLLSICKT*# ...# >HUM21F19# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (220-239)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_BOVIN,MYPR_RABIT,MYPR_HUMAN,# & MYPR_CANFA)# & PIR1: (MPHUPL,MPRTPL,MPBOPL,S34792)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,GSNLLSICKTAEFQMTFHLF*# SEQUENCE: GSNLLSICKTAEFQMTFHLF*# ...# >HUM21F1A# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (240-259)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_CHICK,MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (MPHUPL,S34792,MPRTPL)# & PIR2: (S17600,A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,IAAFVGAAATLVSLLTFMIA*# SEQUENCE: IAAFVGAAATLVSLLTFMIA*# ...# >HUM21F1B# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (250-269)# DB REFERENCE: SWISS: (MYPR_CHICK,MYPR_CANFA,MYPR_RABIT,MYPR_HUMAN,MYPR_HUMAN,# & MYPR_BOVIN)# & PIR1: (S34792,MPRTPL,MPHUPL)# & PIR2: (A43548,S17600)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,LVSLLTFMIAATYNFAVLKL*# SEQUENCE: LVSLLTFMIAATYNFAVLKL*# ...# >HUM21F1C# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: proteolipid protein PLP (260-276)# ANCHOR POSITIONS:# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,MAATYNFAVLKLMGRFTKF*# SEQUENCE: MAATYNFAVLKLMGRFTKF*# ...# >HUM21F1D# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (20-39)# DB REFERENCE: SWISS: (MYPR_POEGU,MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,MYPR_CHICK,# & MYPR_CANFA,MYPR_BOVIN)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (S17600,A43548)# & PIR3: (I51270)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,ATGLCFFGVALFCGCGHEAL*# SEQUENCE: ATGLCFFGVALFCGCGHEAL*# ...# >HUM21F1E# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (120-139)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_BOVIN,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPBOPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QKGRGSRGQHQAHSLERVCH*# SEQUENCE: QKGRGSRGQHQAHSLERVCH*# ...# >HUM21F1F# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (90-109)# ANCHOR POSITIONS:# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,FYYTTGAVRQIFGDYKTTICG*# SEQUENCE: FYYTTGAVRQIFGDYKTTICG*# ...# >HUM21F20# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (80-99)# DB REFERENCE: SWISS: (MYPR_POEGU,MYPR_HUMAN,MYPR_RABIT,MYPR_CHICK,MYPR_HUMAN,# & MYPR_CANFA,MYPR_BOVIN)# & PIR1: (MPHUPL,S34792,MPRTPL)# & PIR2: (A43548,S17600)# & PIR3: (I51270)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,LYGALLLAEGFYTTGAVRQI*# SEQUENCE: LYGALLLAEGFYTTGAVRQI*# ...# >HUM21F21# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (90-109)# ANCHOR POSITIONS:# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,FYYTTGAVRQIFGDYKTTICG*# SEQUENCE: FYYTTGAVRQIFGDYKTTICG*# ...# >HUM21F22# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (170-189)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_RABIT,MYPR_CHICK,# & MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (S17600,A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AVPVYIYFNTWTTCQSIAFP*# SEQUENCE: AVPVYIYFNTWTTCQSIAFP*# ...# >HUM21F23# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (260-276)# ANCHOR POSITIONS:# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,MAATYNFAVLKLMGRGTKF*# SEQUENCE: MAATYNFAVLKLMGRGTKF*# ...# >HUM21F24# MHC MOLECULE: HLA-DRw53, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (80-99)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_BOVIN,MYPR_HUMAN,MYPR_POEGU,MYPR_HUMAN,# & MYPR_CHICK,MYPR_RABIT)# & PIR1: (S34792,MPRTPL,MPHUPL)# & PIR2: (S17600,A43548)# & PIR3: (I51270)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DRw53,actunkn,bindyesl,LYGALLLAEGFYTTGAVRQI*# SEQUENCE: LYGALLLAEGFYTTGAVRQI*# ...# >HUM21F25# MHC MOLECULE: HLA-DRw53, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: proteolipid protein PLP (90-109)# ANCHOR POSITIONS:# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DRw53,actunkn,bindyesh,FYYTTGAVRQIFGDYKTTICG*# SEQUENCE: FYYTTGAVRQIFGDYKTTICG*# ...# >HUM21F26# MHC MOLECULE: HLA-DRw53, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (260-276)# ANCHOR POSITIONS:# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DRw53,actunkn,bindyesl,MAATYNFAVLKLMGRGTKF*# SEQUENCE: MAATYNFAVLKLMGRGTKF*# ...# >HUM21F27# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: proteolipid protein PLP (180-199)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_HUMAN)# & PIR1: (MPRTPL,S34792,MPHUPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,WTTCQSIAFPSKTSASIGSL*# SEQUENCE: WTTCQSIAFPSKTSASIGSL*# ...# >HUM21F28# MHC MOLECULE: HLA-DRw53, CLASS-2, (HUMAN)# METHOD: competitive inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: proteolipid protein PLP (180-199)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA)# & PIR1: (MPHUPL,S34792,MPRTPL)# & PIR2: (A43548)# REFERENCES: markovic-plese95a# COMMENT:# SUMMARY: HLA-DRw53,actunkn,bindyesl,WTTCQSIAFPSKTSASIGSL*# SEQUENCE: WTTCQSIAFPSKTSASIGSL*# ...# >HUM21F29# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human pro-insulin (24-36)# DB REFERENCE: SWISS: (INS_MACFA,INS_PANTR,INS_CERAE,INS_HUMAN,INS_HUMAN)# & PIR1: (IPHU)# & PIR2: (A42179,JQ0178,B42179)# REFERENCES: rudy95# COMMENT: T-cells stimulated in at risk for IDDM individuals# SUMMARY: HLA-D?,actyesu,bindyesu,FFYTPKTRREAED*# SEQUENCE: FFYTPKTRREAED*# ...# >HUM21F2A# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human GAD-65 (506-518)# DB REFERENCE: SWISS: (DCE2_HUMAN)# & PIR1: (A41292)# REFERENCES: rudy95# COMMENT: T-cells stimulated in at risk for IDDM individuals# SUMMARY: HLA-D?,actyesu,bindyesu,FWYIPPSLRTLED*# SEQUENCE: FWYIPPSLRTLED*# ...# >HUM21F2B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (82-96)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,KPPKPVSKMRMATPL*# SEQUENCE: KPPKPVSKMRMATPL*# ...# >HUM21F2C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (83-97)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PPKPVSKMRMATPLL*# SEQUENCE: PPKPVSKMRMATPLL*# ...# >HUM21F2D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (84-98)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PKPVSKMRMATPLLM*# SEQUENCE: PKPVSKMRMATPLLM*# ...# >HUM21F2E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-99)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,KPVSKMRMATPLLMQ*# SEQUENCE: KPVSKMRMATPLLMQ*# ...# >HUM21F2F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (86-100)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PVSKMRMATPLLMQA*# SEQUENCE: PVSKMRMATPLLMQA*# ...# >HUM21F30# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMRMATPLLMQAL*# SEQUENCE: VSKMRMATPLLMQAL*# ...# >HUM21F31# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,KPVSKMRMATPLLMQALP*# SEQUENCE: KPVSKMRMATPLLMQALP*# ...# >HUM21F32# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (86-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PVSKMRMATPLLMQALP*# SEQUENCE: PVSKMRMATPLLMQALP*# ...# >HUM21F33# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMRMATPLLMQALP*# SEQUENCE: VSKMRMATPLLMQALP*# ...# >HUM21F34# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (88-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,SKMRMATPLLMQALP*# SEQUENCE: SKMRMATPLLMQALP*# ...# >HUM21F35# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (90-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,MRMATPLLMQALP*# SEQUENCE: MRMATPLLMQALP*# ...# >HUM21F36# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,KPVSKMRMATPLLMQAL*# SEQUENCE: KPVSKMRMATPLLMQAL*# ...# >HUM21F37# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (85-100)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,KPVSKMRMATPLLMQA*# SEQUENCE: KPVSKMRMATPLLMQA*# ...# >HUM21F38# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (85-98)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,KPVSKMRMATPLLM*# SEQUENCE: KPVSKMRMATPLLM*# ...# >HUM21F39# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,ASKMRMATPLLMQAL*# SEQUENCE: ASKMRMATPLLMQAL*# ...# >HUM21F3A# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VAKMRMATPLLMQAL*# SEQUENCE: VAKMRMATPLLMQAL*# ...# >HUM21F3B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSAMRMATPLLMQAL*# SEQUENCE: VSAMRMATPLLMQAL*# ...# >HUM21F3C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMAMATPLLMQAL*# SEQUENCE: VSKMAMATPLLMQAL*# ...# >HUM21F3D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMRMVTPLLMQAL*# SEQUENCE: VSKMRMVTPLLMQAL*# ...# >HUM21F3E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMRMAAPLLMQAL*# SEQUENCE: VSKMRMAAPLLMQAL*# ...# >HUM21F3F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMRMATALLMQAL*# SEQUENCE: VSKMRMATALLMQAL*# ...# >HUM21F40# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMRMATPALMQAL*# SEQUENCE: VSKMRMATPALMQAL*# ...# >HUM21F41# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMRMATPLAMQAL*# SEQUENCE: VSKMRMATPLAMQAL*# ...# >HUM21F42# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,VSKMRMATPLLAQAL*# SEQUENCE: VSKMRMATPLLAQAL*# ...# >HUM21F43# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,VSKMRMATPLLMAAL*# SEQUENCE: VSKMRMATPLLMAAL*# ...# >HUM21F44# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,VSKMRMATPLLMQVL*# SEQUENCE: VSKMRMATPLLMQVL*# ...# >HUM21F45# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VSKMRMATPLLMQAA*# SEQUENCE: VSKMRMATPLLMQAA*# ...# >HUM21F46# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (83-97)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,PPKPVSKMRMATPLL*# SEQUENCE: PPKPVSKMRMATPLL*# ...# >HUM21F47# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (84-98)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,PKPVSKMRMATPLLM*# SEQUENCE: PKPVSKMRMATPLLM*# ...# >HUM21F48# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-99)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,KPVSKMRMATPLLMQ*# SEQUENCE: KPVSKMRMATPLLMQ*# ...# >HUM21F49# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (86-100)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,PVSKMRMATPLLMQA*# SEQUENCE: PVSKMRMATPLLMQA*# ...# >HUM21F4A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMATPLLMQAL*# SEQUENCE: VSKMRMATPLLMQAL*# ...# >HUM21F4B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (88-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,SKMRMATPLLMQALP*# SEQUENCE: SKMRMATPLLMQALP*# ...# >HUM21F4C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,KPVSKMRMATPLLMQALP*# SEQUENCE: KPVSKMRMATPLLMQALP*# ...# >HUM21F4D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (86-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,PVSKMRMATPLLMQALP*# SEQUENCE: PVSKMRMATPLLMQALP*# ...# >HUM21F4E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,VSKMRMATPLLMQALP*# SEQUENCE: VSKMRMATPLLMQALP*# ...# >HUM21F4F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (89-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,KMRMATPLLMQALP*# SEQUENCE: KMRMATPLLMQALP*# ...# >HUM21F50# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (90-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,MRMATPLLMQALP*# SEQUENCE: MRMATPLLMQALP*# ...# >HUM21F51# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (85-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,KPVSKMRMATPLLMQAL*# SEQUENCE: KPVSKMRMATPLLMQAL*# ...# >HUM21F52# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (85-100)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,KPVSKMRMATPLLMQA*# SEQUENCE: KPVSKMRMATPLLMQA*# ...# >HUM21F53# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,ASKMRMATPLLMQAL*# SEQUENCE: ASKMRMATPLLMQAL*# ...# >HUM21F54# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VAKMRMATPLLMQAL*# SEQUENCE: VAKMRMATPLLMQAL*# ...# >HUM21F55# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSAMRMATPLLMQAL*# SEQUENCE: VSAMRMATPLLMQAL*# ...# >HUM21F56# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMAMATPLLMQAL*# SEQUENCE: VSKMAMATPLLMQAL*# ...# >HUM21F57# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRAATPLLMQAL*# SEQUENCE: VSKMRAATPLLMQAL*# ...# >HUM21F58# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMVTPLLMQAL*# SEQUENCE: VSKMRMVTPLLMQAL*# ...# >HUM21F59# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMAAPLLMQAL*# SEQUENCE: VSKMRMAAPLLMQAL*# ...# >HUM21F5A# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMATALLMQAL*# SEQUENCE: VSKMRMATALLMQAL*# ...# >HUM21F5B# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMATPALMQAL*# SEQUENCE: VSKMRMATPALMQAL*# ...# >HUM21F5C# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMATPLAMQAL*# SEQUENCE: VSKMRMATPLAMQAL*# ...# >HUM21F5D# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMATPLLMAAL*# SEQUENCE: VSKMRMATPLLMAAL*# ...# >HUM21F5E# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMATPLLMQVL*# SEQUENCE: VSKMRMATPLLMQVL*# ...# >HUM21F5F# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VSKMRMATPLLMQAA*# SEQUENCE: VSKMRMATPLLMQAA*# ...# >HUM21F60# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (80-103)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPM*# ...# >HUM21F61# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (84-98)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,PKPVSKMRMATPLLM*# SEQUENCE: PKPVSKMRMATPLLM*# ...# >HUM21F62# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-99)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,KPVSKMRMATPLLMQ*# SEQUENCE: KPVSKMRMATPLLMQ*# ...# >HUM21F63# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (86-100)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,PVSKMRMATPLLMQA*# SEQUENCE: PVSKMRMATPLLMQA*# ...# >HUM21F64# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VSKMRMATPLLMQAL*# SEQUENCE: VSKMRMATPLLMQAL*# ...# >HUM21F65# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (88-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,SKMRMATPLLMQALP*# SEQUENCE: SKMRMATPLLMQALP*# ...# >HUM21F66# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (89-103)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,KMRMATPLLMQALPM*# SEQUENCE: KMRMATPLLMQALPM*# ...# >HUM21F67# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,KPVSKMRMATPLLMQALP*# SEQUENCE: KPVSKMRMATPLLMQALP*# ...# >HUM21F68# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (86-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,PVSKMRMATPLLMQALP*# SEQUENCE: PVSKMRMATPLLMQALP*# ...# >HUM21F69# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VSKMRMATPLLMQALP*# SEQUENCE: VSKMRMATPLLMQALP*# ...# >HUM21F6A# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (89-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,KMRMATPLLMQALP*# SEQUENCE: KMRMATPLLMQALP*# ...# >HUM21F6B# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (90-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,MRMATPLLMQALP*# SEQUENCE: MRMATPLLMQALP*# ...# >HUM21F6C# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,KPVSKMRMATPLLMQAL*# SEQUENCE: KPVSKMRMATPLLMQAL*# ...# >HUM21F6D# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-100)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,KPVSKMRMATPLLMQA*# SEQUENCE: KPVSKMRMATPLLMQA*# ...# >HUM21F6E# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (85-98)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,KPVSKMRMATPLLM*# SEQUENCE: KPVSKMRMATPLLM*# ...# >HUM21F6F# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,ASKMRMATPLLMQAL*# SEQUENCE: ASKMRMATPLLMQAL*# ...# >HUM21F70# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VAKMRMATPLLMQAL*# SEQUENCE: VAKMRMATPLLMQAL*# ...# >HUM21F71# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VSAMRMATPLLMQAL*# SEQUENCE: VSAMRMATPLLMQAL*# ...# >HUM21F72# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VSKMAMATPLLMQAL*# SEQUENCE: VSKMAMATPLLMQAL*# ...# >HUM21F73# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VSKMRMVTPLLMQAL*# SEQUENCE: VSKMRMVTPLLMQAL*# ...# >HUM21F74# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VSKMRMAAPLLMQAL*# SEQUENCE: VSKMRMAAPLLMQAL*# ...# >HUM21F75# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,VSKMRMATALLMQAL*# SEQUENCE: VSKMRMATALLMQAL*# ...# >HUM21F76# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesh,VSKMRMATPALMQAL*# SEQUENCE: VSKMRMATPALMQAL*# ...# >HUM21F77# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,VSKMRMATPLAMQAL*# SEQUENCE: VSKMRMATPLAMQAL*# ...# >HUM21F78# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,VSKMRMATPLLMAAL*# SEQUENCE: VSKMRMATPLLMAAL*# ...# >HUM21F79# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,VSKMRMATPLLMQVL*# SEQUENCE: VSKMRMATPLLMQVL*# ...# >HUM21F7A# MHC MOLECULE: HLA-DR17, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,6,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,VSKMRMATPLLMQAA*# SEQUENCE: VSKMRMATPLLMQAA*# ...# >HUM21F7B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (80-103)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPM*# ...# >HUM21F7C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (83-97)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PPKPVSKMRMATPLL*# SEQUENCE: PPKPVSKMRMATPLL*# ...# >HUM21F7D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (84-98)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKPVSKMRMATPLLM*# SEQUENCE: PKPVSKMRMATPLLM*# ...# >HUM21F7E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-99)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,KPVSKMRMATPLLMQ*# SEQUENCE: KPVSKMRMATPLLMQ*# ...# >HUM21F7F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (86-100)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,PVSKMRMATPLLMQA*# SEQUENCE: PVSKMRMATPLLMQA*# ...# >HUM21F80# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMATPLLMQAL*# SEQUENCE: VSKMRMATPLLMQAL*# ...# >HUM21F81# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (88-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,SKMRMATPLLMQALP*# SEQUENCE: SKMRMATPLLMQALP*# ...# >HUM21F82# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (89-103)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,KMRMATPLLMQALPM*# SEQUENCE: KMRMATPLLMQALPM*# ...# >HUM21F83# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (85-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,KPVSKMRMATPLLMQALP*# SEQUENCE: KPVSKMRMATPLLMQALP*# ...# >HUM21F84# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (86-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,PVSKMRMATPLLMQALP*# SEQUENCE: PVSKMRMATPLLMQALP*# ...# >HUM21F85# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMATPLLMQALP*# SEQUENCE: VSKMRMATPLLMQALP*# ...# >HUM21F86# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (89-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,KMRMATPLLMQALP*# SEQUENCE: KMRMATPLLMQALP*# ...# >HUM21F87# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Invariant chain Ii (90-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,MRMATPLLMQALP*# SEQUENCE: MRMATPLLMQALP*# ...# >HUM21F88# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (85-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,KPVSKMRMATPLLMQAL*# SEQUENCE: KPVSKMRMATPLLMQAL*# ...# >HUM21F89# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (85-100)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,KPVSKMRMATPLLMQA*# SEQUENCE: KPVSKMRMATPLLMQA*# ...# >HUM21F8A# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,ASKMRMATPLLMQAL*# SEQUENCE: ASKMRMATPLLMQAL*# ...# >HUM21F8B# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VAKMRMATPLLMQAL*# SEQUENCE: VAKMRMATPLLMQAL*# ...# >HUM21F8C# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSAMRMATPLLMQAL*# SEQUENCE: VSAMRMATPLLMQAL*# ...# >HUM21F8D# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMAMATPLLMQAL*# SEQUENCE: VSKMAMATPLLMQAL*# ...# >HUM21F8E# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,VSKMRAATPLLMQAL*# SEQUENCE: VSKMRAATPLLMQAL*# ...# >HUM21F8F# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMVTPLLMQAL*# SEQUENCE: VSKMRMVTPLLMQAL*# ...# >HUM21F90# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMAAPLLMQAL*# SEQUENCE: VSKMRMAAPLLMQAL*# ...# >HUM21F91# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMATALLMQAL*# SEQUENCE: VSKMRMATALLMQAL*# ...# >HUM21F92# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMATPALMQAL*# SEQUENCE: VSKMRMATPALMQAL*# ...# >HUM21F93# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMATPLAMQAL*# SEQUENCE: VSKMRMATPLAMQAL*# ...# >HUM21F94# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMATPLLMAAL*# SEQUENCE: VSKMRMATPLLMAAL*# ...# >HUM21F95# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,VSKMRMATPLLMQVL*# SEQUENCE: VSKMRMATPLLMQVL*# ...# >HUM21F96# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: binding inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Invariant chain Ii (87-101)# ANCHOR POSITIONS: 4,12# REFERENCES: geluk95a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,VSKMRMATPLLMQAA*# SEQUENCE: VSKMRMATPLLMQAA*# ...# >MUS21F97# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: direct binding as.# ACTIVITY: none# BINDING: yes, little# SOURCE: mouse myelin basic protein# ANCHOR POSITIONS:# REFERENCES: kumar95a# COMMENT: acetylated N-terminus# SUMMARY: I-Au,actyesn,bindyesl,ASQERPSQR*# SEQUENCE: ASQERPSQR*# ...# >MUS21F98# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: direct binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: mouse myelin basic protein# ANCHOR POSITIONS:# REFERENCES: kumar95a# COMMENT: acetylated N-terminus# SUMMARY: I-Au,actyesn,bindyesm,ASQQRPSQR*# SEQUENCE: ASQQRPSQR*# ...# >MUS21F99# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: direct binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: mouse myelin basic protein# ANCHOR POSITIONS:# REFERENCES: kumar95a# COMMENT: acetylated N-terminus# SUMMARY: I-Au,actyesn,bindyesm,ASQARPSQR*# SEQUENCE: ASQARPSQR*# ...# >MUS21F9A# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: direct binding as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: mouse myelin basic protein# ANCHOR POSITIONS:# REFERENCES: kumar95a# COMMENT: acetylated N-terminus# SUMMARY: I-Au,actyesh,bindyesh,ASQVRPSQR*# SEQUENCE: ASQVRPSQR*# ...# >MUS21F9B# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: direct binding as.# ACTIVITY: none# BINDING: yes, high# SOURCE: mouse myelin basic protein# ANCHOR POSITIONS:# REFERENCES: kumar95a# COMMENT: acetylated N-terminus# SUMMARY: I-Au,actyesn,bindyesh,ASQYRPSQR*# SEQUENCE: ASQYRPSQR*# ...# >MUS21F9C# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: direct binding as.# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: mouse myelin basic protein# ANCHOR POSITIONS:# REFERENCES: kumar95a# COMMENT: acetylated N-terminus# SUMMARY: I-Au,actyesh,bindyesh,ASQMRPSQR*# SEQUENCE: ASQMRPSQR*# ...# >HUM21F9D# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor 2 (267-277)# DB REFERENCE: SWISS: (EF2_MESAU,EF2_RAT,EF2_HUMAN,EF2_CRIGR,EF2_MESAU,EF2_RAT,# & EF2_CRIGR)# & PIR1: (EFHU2,EFRT2)# & PIR2: (A28660,A25440)# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,DPANGKFSKSA*# SEQUENCE: DPANGKFSKSA*# ...# >HUM21F9E# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A11 (143-156)# DB REFERENCE: SWISS: (1A11_HUMAN)# & PIR2: (I83063,A47636,I36959)# & PIR3: (S06424)# REFERENCES: futaki95a,fujisao96a,kobayashi96a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,KRKWEAAHAAEQQR*# SEQUENCE: KRKWEAAHAAEQQR*# ...# >HUM21F9F# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Neuropeptide Y-like receptor (306 - 317)# DB REFERENCE: SWISS: (CCR4_HUMAN,LCR1_HUMAN,CCR4_BOVIN,LCR1_BOVIN)# & PIR2: (S28787,A45747,G00048)# REFERENCES: futaki95a,kobayashi96a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,GAKFKTSAQHAL*# SEQUENCE: GAKFKTSAQHAL*# ...# >HUM21FA0# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (215-230)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: futaki95a,kobayashi96a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,NPGGYVAYSKAATVTG*# SEQUENCE: NPGGYVAYSKAATVTG*# ...# >HUM21FA1# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595)# DB REFERENCE: SWISS: (PLSL_MOUSE,PLSL_HUMAN,PLSL_HUMAN)# & PIR1: (A35836)# & PIR2: (I49445)# REFERENCES: futaki95a,kobayashi96a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,NNAKYAISMARKIGA*# SEQUENCE: NNAKYAISMARKIGA*# ...# >HUM21FA2# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (1585-1598)# ANCHOR POSITIONS:# REFERENCES: futaki95a,kobayashi96a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,NKVDLTFSKQHALL*# SEQUENCE: NKVDLTFSKQHALL*# ...# >HUM21FA3# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,VEKYYAYAENDVEK*# SEQUENCE: VEKYYAYAENDVEK*# ...# >HUM21FA4# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,FPKYYIGSQEKILQ*# SEQUENCE: FPKYYIGSQEKILQ*# ...# >HUM21FA5# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: futaki95a,kobayashi96a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,FPKDYAGAALERL*# SEQUENCE: FPKDYAGAALERL*# ...# >HUM21FA6# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,FSYDYRGSRSAELM*# SEQUENCE: FSYDYRGSRSAELM*# ...# >HUM21FA7# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,SPKYYVLAKAFVYP*# SEQUENCE: SPKYYVLAKAFVYP*# ...# >HUM21FA8# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,KPKAYQLSAINMIQYR*# SEQUENCE: KPKAYQLSAINMIQYR*# ...# >HUM21FA9# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,KPQYVFALPGQL*# SEQUENCE: KPQYVFALPGQL*# ...# >HUM21FAA# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: futaki95a,fujisao96a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,EPKDFVYALNLTQTLNP*# SEQUENCE: EPKDFVYALNLTQTLNP*# ...# >HUM21FAB# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (582-595)# DB REFERENCE: SWISS: (PLSL_HUMAN,PLSL_HUMAN,PLSL_MOUSE)# & PIR1: (A35836)# & PIR2: (I49445)# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,NAKYAISMARKIGA*# SEQUENCE: NAKYAISMARKIGA*# ...# >HUM21FAC# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B-100 (1586-1598)# ANCHOR POSITIONS:# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,KVDLTFSKQHALL*# SEQUENCE: KVDLTFSKQHALL*# ...# >HUM21FAD# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ii (97-116)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQ*# SEQUENCE: LPKPPKPVSKMRMATPLLMQ*# ...# >HUM21FAE# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: HPLC/Edman microsequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ii (97-113)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: futaki95a# COMMENT: Eluted naturally processed peptides# SUMMARY: HLA-DR9,actunkn,bindyesu,LPKPPKPVSKMRMATPL*# SEQUENCE: LPKPPKPVSKMRMATPL*# ...# >HUM11FAF# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,ARIAAAIAK*# SEQUENCE: ARIAAAIAK*# ...# >HUM11FB0# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARIAAAIAL*# SEQUENCE: ARIAAAIAL*# ...# >HUM11FB1# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARIAAAIAF*# SEQUENCE: ARIAAAIAF*# ...# >HUM11FB2# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARIAAAIAY*# SEQUENCE: ARIAAAIAY*# ...# >HUM11FB3# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARIAAAIAK*# SEQUENCE: ARIAAAIAK*# ...# >HUM11FB4# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARIAAAIAR*# SEQUENCE: ARIAAAIAR*# ...# >HUM11FB5# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARIAAAIAA*# SEQUENCE: ARIAAAIAA*# ...# >HUM11FB6# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARIAAAIAL*# SEQUENCE: ARIAAAIAL*# ...# >HUM11FB7# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,ARIAAAIAH*# SEQUENCE: ARIAAAIAH*# ...# >HUM11FB8# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesh,ARIAAAIAF*# SEQUENCE: ARIAAAIAF*# ...# >HUM11FB9# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: class I alpha chain refolding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS: 2,9# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesl,ARIAAAIAY*# SEQUENCE: ARIAAAIAY*# ...# >HUM11FBA# MHC MOLECULE: HLA-B27(B*2702), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA3C# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015)# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRIYDLIEL*# SEQUENCE: RRIYDLIEL*# ...# >HUM11FBB# MHC MOLECULE: HLA-B27(B*2704), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBNA3C# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (S33015,A31666)# REFERENCES: fruci95a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRIYDLIEL*# SEQUENCE: RRIYDLIEL*# ...# >MUS21FBC# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus M protein (146-161)# DB REFERENCE: SWISS: (VMAT_SENDF,VMAT_SEND5,VMAT_SENDZ,VMAT_SENDH)# & PIR1: (MFNZSV,MFNZS,MFNZFU)# REFERENCES: cole95a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,IFNANKVALAPQCLPV*# SEQUENCE: IFNANKVALAPQCLPV*# ...# >MUS21FBD# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Sendai virus M protein (331-346)# DB REFERENCE: SWISS: (VMAT_SENDH,VMAT_SENDZ,VMAT_SENDF,VMAT_SEND5)# & PIR1: (MFNZSV,MFNZS,MFNZFU)# REFERENCES: cole95a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,FRYYPNVVAKNIGRIR*# SEQUENCE: FRYYPNVVAKNIGRIR*# ...# >HUM11FBE# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV adw (1169-1177)# DB REFERENCE: SWISS: (DPOL_HPBVO,DPOL_HPBVI,DPOL_HPBVJ)# & PIR1: (JDVLJ2,JDVLJ1,JDVLJ3)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,LYAAVTNFL*# SEQUENCE: LYAAVTNFL*# ...# >HUM11FBF# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV E2 (719-727)# DB REFERENCE: SWISS: (POLG_HCVBK)# & PIR1: (GNWVTC)# & PIR2: (S19876,S18030,S18032)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,EYVLLLFLL*# SEQUENCE: EYVLLLFLL*# ...# >HUM11FC0# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ayw (368-376)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVZ)# & PIR1: (SAVLAJ,SAVLBH,SAVLAH,JQ1572,JQ1571)# & PIR2: (JQ2078,S20753,JQ2077,JQ2076,JQ2067,JQ2075,S20749,JQ2073,# & JQ2065,JQ2070,S41869,JQ2081,JQ2080,JQ2063,S20745,S32202,# & JQ2072,S47407,JQ2068,JQ2069,S41871)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,LYSILSPFL*# SEQUENCE: LYSILSPFL*# ...# >HUM11FC1# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HPV 18 E6 (33-41)# DB REFERENCE: SWISS: (VE6_HPV18)# & PIR1: (W6WL18)# & PIR2: (I56705)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,VYCKTVLEL*# SEQUENCE: VYCKTVLEL*# ...# >HUM11FC2# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HER-2/neu (440-448)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (A24571,TVRTNU)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,AYSLTLQGL*# SEQUENCE: AYSLTLQGL*# ...# >HUM11FC3# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER-2/neu (63-71)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,TYLPTNASL*# SEQUENCE: TYLPTNASL*# ...# >HUM11FC4# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (512-520)# DB REFERENCE: SWISS: (POL_HV1OY,POL_HV1A2,POL_HV1RH,POL_HV1B5,POL_HV1EL,# & POL_HV1N5,POL_HV1MN,POL_HV1Y2,POL_HV1U4,POL_HV1Z2,# & POL_HV1BR,POL_HV1B1,POL_HV1H2,POL_HV1ND,POL_HV1PV)# & PIR1: (B44001,GNLJND,GNVWLV,GNVWH3,GNVWA2,GNVWVL)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S33980)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,IYQEPFKNL*# SEQUENCE: IYQEPFKNL*# ...# >HUM11FC5# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV NS3 (1296-1294)# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVH,POLG_HCVBK,POLG_HCVTW,POLG_HCVJ6,# & POLG_HCV1)# & PIR1: (GNWVTW,GNWVC3,GNWVTC,GNWVCH)# & PIR2: (PC2219,S18030,S40770,A45573,S21337,JQ1303)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,TYSTYGKFL*# SEQUENCE: TYSTYGKFL*# ...# >HUM11FC6# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HPV 18 E6 (98-106)# DB REFERENCE: SWISS: (VE6_HPV18,VE6_HPV45)# & PIR1: (W6WL18)# & PIR2: (S36561)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,LYNLLIRCL*# SEQUENCE: LYNLLIRCL*# ...# >HUM11FC7# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV ayw (1085-1093)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVA,DPOL_HPBVY)# & PIR1: (S20757,JDVLA1,S47406,JDVLVA,JDVLVB)# & PIR2: (S71785)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,LYQTFGRKL*# SEQUENCE: LYQTFGRKL*# ...# >HUM11FC8# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 18 E6 (85-93)# DB REFERENCE: SWISS: (VE6_HPV18)# & PIR1: (W6WL18)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,VYGDTLEKL*# SEQUENCE: VYGDTLEKL*# ...# >HUM11FC9# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV NS56 (2871-2879)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVBK,POLG_HCVH,POLG_HCVJT,POLG_HCVJA,# & POLG_HCVTW)# & PIR1: (GNWVTC,GNWVCH,GNWVCJ,GNWVTW,GNWVC3)# & PIR2: (PS0104,JQ0880,A45573,D39109,JQ0879,S40770,PS0102)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,CYSIEPLDL*# SEQUENCE: CYSIEPLDL*# ...# >HUM11FCA# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 16 E6 (66-74)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,PYAVCDKCL*# SEQUENCE: PYAVCDKCL*# ...# >HUM11FCB# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HER-2/neu (553-561)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,EYVNARHCL*# SEQUENCE: EYVNARHCL*# ...# >HUM11FCC# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV adr (1067-1075)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBVM,DPOL_HPBVL,DPOL_HPBV4)# & PIR1: (JDVLVR,JDVLCP,JDVLVS,S43491)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,LYKTFGRKL*# SEQUENCE: LYKTFGRKL*# ...# >HUM11FCD# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 16 E6 (82-90)# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,EYRHYCYSL*# SEQUENCE: EYRHYCYSL*# ...# >HUM11FCE# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV adr/adw (578-586)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVR,DPOL_HPBVP,DPOL_HPBV9,DPOL_HPBVJ,# & DPOL_HPBV2,DPOL_HPBV4,DPOL_HPBVL,DPOL_HPBVW,DPOL_HPBVO,# & DPOL_HPBVI)# & PIR1: (S43491,JDVLJ3,JDVLVS,JDVLJ2,JDVLKS,JDVLJ1,JDVLCP,JDVLVD,# & JDVLVR)# & PIR2: (S71785,S35527)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,SYQHFRKLL*# SEQUENCE: SYQHFRKLL*# ...# >HUM11FCF# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Prostate Ca psm (606-614)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,KYADKIYSI*# SEQUENCE: KYADKIYSI*# ...# >HUM11FD0# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (392-401)# DB REFERENCE: SWISS: (DPOL_HPBVZ,DPOM_HPBVY,DPOL_HPBV2,DPOL_HPBVI,DPOL_HPBVA,# & DPOL_HPBVO,DPOL_HPBVY,DPOL_HPBVT,DPOL_HPBVP,DPOL_HPBVM,# & DPOL_HPBVR,DPOL_HPBVJ,DPOL_HPBV4,DPOL_HPBVW)# & PIR1: (JDVLVR,JDVLJ1,S20757,JDVLVD,JDVLJ3,JDVLVS,S43491,JDVLVB,# & JDVLA1,JDVLVH,JDVLVA,S20752,S47406,JQ2229,JDVLJ2)# & PIR2: (S71785,S35527)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,SWPKFAVPNL*# SEQUENCE: SWPKFAVPNL*# ...# >HUM11FD1# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (334-342)# DB REFERENCE: SWISS: (VMSA_HPBVD,VMSA_HPBVI,VMSA_HPBV9,VMSA_HPBVJ,VMSA_HPBV2,# & VMSA_HPBV0,VMSA_HPBVY,VMSA_HPBVR,VMSA_HPBVW,VMSA_HPBV4,# & VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBVS,VMSA_HPBV2,VMSA_HPBVN,# & VMSA_HPBVA,VMSA_HPBVO,VMSA_HPBVR,VMSA_HPBVP,# & VMSA_HPBVW)# & PIR1: (JQ1572,SAVLA1,SAVLVE,SAVLAR,SAVLHV,SAVLAD,SAVLJ1,JQ1578,# & SAVLA,JQ1571,JQ1575,SAVLJ2,JQ1573,SAVLKS,SAVLBH,SAVLAJ,# & JQ1570,SAVLN1,JQ1576,JQ1574,SAVLVD,JQ1577,SAVLAH,# & SAVLJ3)# & PIR2: (JQ2089,JQ2050,JQ2080,JQ2065,JQ2062,JQ2073,JQ2115,JQ2114,# & JQ2105,S35528,JQ2046,JQ2066,JQ2108,S43492,JQ2101,S36654,# & JQ2078,JQ2103,JQ2054,JQ2045,JQ2077,JQ2053,S41870,JQ2116,# & JQ2100,JQ2090,JQ2056,JQ2076,JQ2085,JQ2113,S20753,JQ2072,# & JQ2091,JQ2051,JQ2104,JQ2058,S32202,JQ2057,JQ2052,JQ2055,# & JQ2069,JQ2098,JQ2109,JQ2092,S20745,JQ2048,S47407,JQ2060,# & JQ2047,JQ2061,S20749,JQ2070,JQ2063,JQ2059,JQ2106,JQ2110,# & JQ2083,JQ2112,JQ2111,JQ2097,JQ2087,JQ2102,JQ2068,JQ2079,# & JQ2075,S47411,S41869,JQ2081,JQ2067)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,SWLSLLVPF*# SEQUENCE: SWLSLLVPF*# ...# >HUM11FD2# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBVenv (197-205)# DB REFERENCE: SWISS: (VMSA_HPBVI,VMSA_HPBVJ,VMSA_HPBV2,VMSA_HPBVL,VMSA_HPBVW,# & VMSA_HPBV4,VMSA_HPBVT,VMSA_HPBVA,VMSA_HPBVO,VMSA_HPBV0,# & VMSA_HPBVR,VMSA_HPBVS,VMSA_HPBVN,VMSA_HPBVZ,VMSA_HPBVP,# & VMSA_HPBVR,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVW,VMSA_HPBV2,# & VMSA_HPBVD,VMSA_HPBV9)# & PIR1: (SAVLJ3,SAVLKS,SAVLJ2,JQ1571,JQ1575,JQ1570,JQ1579,JQ1577,# & SAVLN1,JQ1574,JQ1581,SAVLA,SAVLA1,JQ1580,SAVLCP,SAVLJ1,# & JQ1576,SAVLVD,SAVLAH,SAVLAJ,SAVLAD,SAVLHV,SAVLAR,JQ1578,# & SAVLVE,JQ1572,SAVLBH,JQ1573)# & PIR2: (JQ2079,JQ2102,S41871,JQ2055,JQ2096,JQ2053,JQ2059,S20745,# & JQ2068,JQ2110,JQ2112,JQ2047,JQ2109,JQ2116,JQ2077,JQ2090,# & JQ2091,JQ2225,JQ2057,JQ2069,JQ2114,JQ2065,JQ2062,JQ2120,# & JQ2089,JQ2051,S32202,JQ2104,JQ2072,JQ2058,JQ2052,JQ2050,# & JQ2119,JQ2080,JQ2046,S35528,JQ2115,JQ2073,JQ2088,JQ2105,# & JQ2054,JQ2106,JQ2083,JQ2063,JQ2067,JQ2122,JQ2099,S20753,# & JQ2113,JQ2111,JQ2097,JQ2087,S47411,S41869,JQ2081,JQ2075,# & JQ2070,JQ2095,JQ2098,S47407,JQ2048,JQ2092,JQ2061,JQ2060,# & JQ2100,JQ2045,JQ2123,S41870,JQ2085,JQ2230,JQ2056,JQ2076,# & JQ2094,JQ2066,JQ2226,JQ2121,JQ2108,JQ2101,JQ2078,JQ2103,# & S36654)# & PIR4: (S42226)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,SWWTSLNFL*# SEQUENCE: SWWTSLNFL*# ...# >HUM11FD3# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HPV 6b/11 E1 (586-595)# DB REFERENCE: SWISS: (VE1_HPV11,VE1_HPV6B)# & PIR1: (W1WL11,W1WL6)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,TFTFPNPFPF*# SEQUENCE: TFTFPNPFPF*# ...# >HUM11FD4# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HPV 6b/11 E1 (439-447)# ANCHOR POSITIONS: 2,9# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,NKWKPIVQFL*# SEQUENCE: NKWKPIVQFL*# ...# >HUM11FD5# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (686-695)# DB REFERENCE: SWISS: (DPOL_WHV8,DPOL_WHV7,DPOL_HPBVO,DPOL_HPBVY,DPOL_HPBVT,# & DPOL_HPBVM,DPOL_WHV1,DPOL_WHV8I,DPOL_WHV59,DPOL_HPBVZ,# & DPOM_HPBVY,DPOL_HPBV2,DPOL_HPBV9,DPOL_HPBV4,DPOL_HPBVA,# & DPOL_WHVW6,DPOL_HPBVJ,DPOL_HPBGS,DPOL_HPBVL,DPOL_HPBVP,# & DPOL_HPBVR,DPOL_HPBVI)# & PIR1: (JDVLC,JDVL64,JDVLVR,JDVL59,JDVLKS,JDVLS,JDVLJ1,JDVLCP,# & S20757,JDVLVS,JDVLVB,JDVL7,JDVLVA,JDVLW8,JDVLJ3,JDVLVH,# & JDVLA1,S43491,JDVLVD,JDVLC2,JDVLJ2,JQ2229,S47406,# & S20752)# & PIR2: (S71785)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,VFADATPTGW*# SEQUENCE: VFADATPTGW*# ...# >HUM11FD6# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV gag (26-34)# DB REFERENCE: SWISS: (GAG_HTL1M,GAG_HTL1C,GAG_HTL1A,GAG_HTLV2)# & PIR1: (FOLJH2,FOLJCN,FOLJGH)# & PIR2: (S06073,A41358)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,NFLQAAYRL*# SEQUENCE: NFLQAAYRL*# ...# >HUM11FD7# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV env (345-354)# DB REFERENCE: SWISS: (VMSA_HPBVN,VMSA_HPBVR,VMSA_HPBVA,VMSA_HPBVO,VMSA_HPBV9,# & VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBV4,VMSA_HPBVW,VMSA_HPBV2,# & VMSA_HPBVJ,VMSA_HPBVR,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVI,# & VMSA_HPBV0,VMSA_HPBVP)# & PIR1: (SAVLA1,SAVLJ1,JQ1570,JQ1577,JQ1575,JQ1571,SAVLJ3,SAVLN1,# & JQ1581,JQ1574,SAVLA,SAVLKS,SAVLJ2,SAVLBH,SAVLAH,SAVLVD,# & SAVLVE,SAVLHV,JQ1572)# & PIR2: (JQ2067,JQ2113,JQ2062,JQ2069,JQ2112,JQ2047,JQ2100,JQ2048,# & S47407,JQ2103,JQ2066,S20745,JQ2057,JQ2114,JQ2111,S41869,# & JQ2075,JQ2094,JQ2058,JQ2055,JQ2109,JQ2110,JQ2077,S20749,# & JQ2116,S41871,JQ2053,JQ2059,JQ2068,JQ2054,JQ2095,JQ2098,# & JQ2099,JQ2063,JQ2097,S47411,S20753,JQ2065,JQ2045,JQ2076,# & JQ2056,JQ2101,JQ2108,JQ2051,JQ2052,S32202,JQ2050,JQ2046,# & JQ2115,JQ2078,JQ2060,JQ2061,JQ2073)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,WFVGLSPTVW*# SEQUENCE: WFVGLSPTVW*# ...# >HUM11FD8# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b/11 E1 (609-617)# DB REFERENCE: SWISS: (VE1_HPV11,VE1_HPV6B)# & PIR1: (W1WL6,W1WL11)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,NWKCFFERL*# SEQUENCE: NWKCFFERL*# ...# >HUM11FD9# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Prostate Ca psm (624-633)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,TYSVSFDSLF*# SEQUENCE: TYSVSFDSLF*# ...# >HUM11FDA# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (236-245)# DB REFERENCE: SWISS: (VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBVL,VMSA_HPBVN,VMSA_HPBVT,# & VMSA_HPBVA,VMSA_HPBVJ,VMSA_HPBVS,VMSA_HPBV2,VMSA_HPBV4,# & VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBVY,VMSA_HPBVP,VMSA_HPBVO,# & VMSA_HPBV2,VMSA_HPBV9,VMSA_HPBVZ,VMSA_HPBVW,VMSA_HPBV0,# & VMSA_HPBVY,VMSA_HPBVD)# & PIR1: (SAVLA1,SAVLCP,SAVLBH,JQ1570,JQ1581,JQ1572,JQ1578,JQ1573,# & SAVLJ2,SAVLHV,SAVLAH,SAVLVD,JQ1575,JQ1579,JQ1574,SAVLN1,# & SAVLJ3,JQ1577,SAVLAD,SAVLAR,JQ1580,SAVLKS,JQ1576,SAVLVE,# & JQ1571,SAVLJ1,SAVLA,SAVLAJ)# & PIR2: (JQ2060,JQ2105,JQ2114,JQ2111,S41869,JQ2075,JQ2057,JQ2094,# & JQ2096,JQ2079,JQ2102,JQ2069,JQ2067,JQ2090,JQ2112,JQ2103,# & JQ2048,JQ2100,JQ2120,JQ2091,JQ2054,JQ2053,JQ2059,JQ2087,# & JQ2068,JQ2083,S20753,S47411,S41870,JQ2097,JQ2088,JQ2070,# & S43492,JQ2099,JQ2106,JQ2109,JQ2076,JQ2056,JQ2045,S35528,# & JQ2119,S32202,JQ2115,JQ2226,JQ2121,JQ2095,JQ2098,JQ2063,# & JQ2230,JQ2058,JQ2055,S20745,JQ2050,JQ2101,JQ2052,JQ2061,# & JQ2078,JQ2073,JQ2123,JQ2110,JQ2113,S36654,JQ2085,JQ2065,# & JQ2092,JQ2089,JQ2051,JQ2072,JQ2104,JQ2046,JQ2080,JQ2108,# & JQ2062,JQ2047,JQ2066,JQ2225,S47407,JQ2081,JQ2077,# & JQ2122)# & PIR4: (S42226)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,RWMCLRRFII*# SEQUENCE: RWMCLRRFII*# ...# >HUM11FDB# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV tax (164-173)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,TWPLLPHVIF*# SEQUENCE: TWPLLPHVIF*# ...# >HUM11FDC# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV tax (154-163)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547,B45714)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,MYLYQLSPPI*# SEQUENCE: MYLYQLSPPI*# ...# >HUM11FDD# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV tax (164-172)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,TWPLLPHVI*# SEQUENCE: TWPLLPHVI*# ...# >HUM11FDE# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Prostate Ca psm (74-83)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,LYNFTQIPHL*# SEQUENCE: LYNFTQIPHL*# ...# >HUM11FDF# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV tax (229-237)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (B45714,G61547)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,AWQNGLLPF*# SEQUENCE: AWQNGLLPF*# ...# >HUM11FE0# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV tax (249-257)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,TFTDGTPMI*# SEQUENCE: TFTDGTPMI*# ...# >HUM11FE1# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Prostate Ca psm (32-41)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,FFLLGFLFGW*# SEQUENCE: FFLLGFLFGW*# ...# >HUM11FE2# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV tax (301-309)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTLV2)# & PIR1: (TNLJCN,TNLJT2,TNLJH2)# & PIR2: (A48751)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,SFHNLHLLF*# SEQUENCE: SFHNLHLLF*# ...# >HUM11FE3# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV tax (311-319)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547,B45714)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,EYTNIPISL*# SEQUENCE: EYTNIPISL*# ...# >HUM11FE4# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV tax 1 (187-195)# DB REFERENCE: SWISS: (TAT_HTL1A)# & PIR1: (TNLJH1)# & PIR2: (G61547)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,PYKRIEELL*# SEQUENCE: PYKRIEELL*# ...# >HUM11FE5# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (51-59)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVJ,DPOL_HPBVL,DPOL_HPBVP,DPOL_HPBV9,# & DPOL_HPBV2,DPOL_HPBVO,DPOL_HPBVY,DPOL_HPBVT,DPOL_HPBVM,# & DPOL_HPBVI,DPOL_HPBVW,DPOM_HPBVY,DPOL_HPBVZ,DPOL_HPBV4,# & DPOL_HPBVR)# & PIR1: (JDVLJ3,S20752,S43491,JDVLVD,JDVLVR,JDVLCP,S20757,JDVLVS,# & JDVLVB,JDVLVA,S47406,JQ2229,JDVLJ2,JDVLJ1,JDVLKS,JDVLVH,# & JDVLA1)# & PIR2: (S35527,S71785)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,PWTHKVGNF*# SEQUENCE: PWTHKVGNF*# ...# >HUM11FE6# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Prostate Ca psm (448-456)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AYINADSSI*# SEQUENCE: AYINADSSI*# ...# >HUM11FE7# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b/11 E1 (445-454)# DB REFERENCE: SWISS: (VE1_HPV11,VE1_HPV13,VE1_PCPV1,VE1_HPV6B)# & PIR1: (W1WL11,W1WL13,W1WLC1,W1WL6)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,QFLRHQNIEF*# SEQUENCE: QFLRHQNIEF*# ...# >HUM11FE8# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV tax (289-297)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,SFLLSHGLI*# SEQUENCE: SFLLSHGLI*# ...# >HUM11FE9# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b/11 E1 (612-621)# DB REFERENCE: SWISS: (VE1_HPV11,VE1_HPV6B)# & PIR1: (W1WL6,W1WL11)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,CFFERLSSSL*# SEQUENCE: CFFERLSSSL*# ...# >HUM11FEA# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV env (65-73)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBVA,# & VMSA_HPBVY,VMSA_HPBVP,VMSA_HPBVI,VMSA_HPBVJ,VMSA_HPBVW,# & VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBVW)# & PIR1: (SAVLJ3,SAVLVD,SAVLAH,SAVLJ1,SAVLVE,SAVLAJ,SAVLA,SAVLBH,# & SAVLA1)# & PIR2: (S36654,S41871,S47407,S20745,S20753,S32202,S35528,S47411,# & S41870,S41869,S20749)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,GWSPQAQGI*# SEQUENCE: GWSPQAQGI*# ...# >HUM11FEB# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV env (237-246)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBVD,VMSA_HPBVY,VMSA_HPBV9,# & VMSA_HPBVW,VMSA_HPBVZ,VMSA_HPBV0,VMSA_HPBVW,VMSA_HPBVS,# & VMSA_HPBV2,VMSA_HPBV4,VMSA_HPBVJ,VMSA_HPBVO,VMSA_HPBVL,# & VMSA_HPBVA,VMSA_HPBVP,VMSA_HPBVT,VMSA_HPBVY,VMSA_HPBVI,# & VMSA_HPBVN,VMSA_HPBVR)# & PIR1: (SAVLN1,JQ1570,JQ1581,SAVLVE,JQ1573,SAVLA,SAVLJ2,SAVLHV,# & JQ1572,SAVLCP,SAVLAH,SAVLVD,SAVLA1,JQ1576,SAVLBH,SAVLAR,# & SAVLAD,JQ1575,SAVLJ1,JQ1578,SAVLAJ,JQ1574,JQ1580,JQ1577,# & JQ1571,JQ1579,SAVLKS,SAVLJ3)# & PIR2: (JQ2087,JQ2079,JQ2062,JQ2085,S35528,S41870,JQ2052,JQ2101,# & JQ2088,JQ2113,JQ2058,JQ2073,JQ2050,S32202,JQ2095,JQ2097,# & JQ2119,JQ2057,JQ2112,JQ2065,S47411,JQ2047,JQ2066,JQ2081,# & JQ2063,JQ2098,JQ2056,JQ2115,JQ2103,JQ2054,JQ2053,JQ2068,# & S20753,S47407,JQ2091,JQ2046,JQ2072,S43492,JQ2083,JQ2230,# & JQ2121,JQ2226,JQ2076,JQ2045,JQ2225,JQ2055,JQ2078,JQ2061,# & S41869,JQ2122,JQ2070,JQ2106,JQ2109,JQ2099,JQ2123,JQ2110,# & JQ2096,S20745,JQ2102,JQ2069,JQ2090,JQ2067,JQ2059,JQ2100,# & JQ2120,JQ2048,S36654,JQ2077,JQ2092,JQ2080,JQ2108,JQ2051,# & JQ2104,JQ2089,JQ2060,JQ2105,JQ2111,JQ2075,JQ2114,# & JQ2094)# & PIR4: (S42226)# REFERENCES: kondo95a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,WMCLRRFIIF*# SEQUENCE: WMCLRRFIIF*# ...# >HUM21FEC# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct binding/blocking as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ii (95-108)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: vogt95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,TPLLMQALPMGALP*# SEQUENCE: TPLLMQALPMGALP*# ...# >HUM21FED# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct binding/blocking as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ii (101-118)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: vogt95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,ALPMGALPQGPMQNATKY*# SEQUENCE: ALPMGALPQGPMQNATKY*# ...# >HUM21FEE# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct binding/blocking as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ii (111-128)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: vogt95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,PMQNATKYGNMTEDHVMH*# SEQUENCE: PMQNATKYGNMTEDHVMH*# ...# >HUM21FEF# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct binding/blocking as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (81-105)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: vogt95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQALPMG*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPMG*# ...# >HUM21FF0# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: direct binding/blocking as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (85-105)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_MOUSE,MBP_PANTR,MBP_BOVIN,# & MBP_CAVPO)# & PIR1: (MBRTS,MBHUB,MBPGB,MBBOB,MBMSB,MBCZB)# & PIR2: (A37246)# REFERENCES: vogt95a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,PVVHFFKNIVTPRTPPPSQGK*# SEQUENCE: PVVHFFKNIVTPRTPPPSQGK*# ...# >HUM21FF1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: direct binding/blocking as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ii (90-108)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: vogt95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,KMRMATPLLMQALPMGALP*# SEQUENCE: KMRMATPLLMQALPMGALP*# ...# >HUM21FF2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: direct binding/blocking as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (85-105)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_BOVIN,MBP_MOUSE,MBP_PANTR,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBBOB,MBHUB,MBPGB,MBRTS,MBMSB,MBCZB)# & PIR2: (A37246)# REFERENCES: vogt95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PVVHFFKNIVTPRTPPPSQGK*# SEQUENCE: PVVHFFKNIVTPRTPPPSQGK*# ...# >HUM11FF3# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MAGE-1 (161-169)# ANCHOR POSITIONS:# REFERENCES: van_den_eynde95a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A1,actyesu,bindyesu,EADPPTGHSY*# SEQUENCE: EADPPTGHSY*# ...# >HUM11FF4# MHC MOLECULE: HLA-Cw16, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MAGE-1 (230-238)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a,romero96a,farina96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-Cw16,actyesu,bindyesu,SAYGEPRKL*# SEQUENCE: SAYGEPRKL*# ...# >HUM11FF5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MAGE-3 (271-279)# DB REFERENCE: SWISS: (MAGC_HUMAN,MAG3_HUMAN,MAG3_HUMAN,MAGC_HUMAN)# & PIR2: (I54519,JC2362,JC2361)# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A2,actyesu,bindyesu,FLWGPRALV*# SEQUENCE: FLWGPRALV*# ...# >HUM11FF6# MHC MOLECULE: HLA-Cw16, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: BAGE (2-10)# ANCHOR POSITIONS:# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a,romero96a,farina96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-Cw16,actyesu,bindyesu,AARAVFLAL*# SEQUENCE: AARAVFLAL*# ...# >HUM11FF7# MHC MOLECULE: HLA-Cw6, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: GAGE-1,2 (9-16)# ANCHOR POSITIONS:# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a,romero96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-Cw6,actyesu,bindyesu,YRPRPRRY*# SEQUENCE: YRPRPRRY*# ...# >MUS11FF8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: pS3 homologue (232-240)# REFERENCES: van_den_eynde95a# COMMENT: tumor-specific antigen# SUMMARY: H-2Kd,actyesu,bindyesu,KYICNSSCM*# SEQUENCE: KYICNSSCM*# ...# >MUS11FF9# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: reference/stabilization# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: RAS (60-67) homologue (61K)# ANCHOR POSITIONS:# REFERENCES: van_den_eynde95a,skipper93a# COMMENT: tumor-specific antigen# SUMMARY: H-2Kb,actyesu,bindyesu,GKEEYSAM*# SEQUENCE: GKEEYSAM*# ...# >MUS11FFA# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: RAS (61-67) homologue (61L)# ANCHOR POSITIONS:# REFERENCES: van_den_eynde95a# COMMENT: tumor-specific antigen# SUMMARY: H-2Kb,actyesu,bindyesu,LEEYSAM*# SEQUENCE: LEEYSAM*# ...# >HUM11FFB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tyrosinase (1-9)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A2,actyesu,bindyesu,MLLAVLYCL*# SEQUENCE: MLLAVLYCL*# ...# >HUM11FFC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tyrosinase (369-377)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A2,actyesu,bindyesu,YMNGTMSQV*# SEQUENCE: YMNGTMSQV*# ...# >HUM11FFD# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tyrosinase# ANCHOR POSITIONS:# REFERENCES: van_den_eynde95a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A2,actyesu,bindyesu,YMDGTMSQVT*# SEQUENCE: YMDGTMSQVT*# ...# >HUM11FFE# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tyrosinase (192-200)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_MOUSE,TYRO_HUMAN,TYRO_MOUSE)# & PIR1: (YRHU1,YRMSCS)# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-B44,actyesu,bindyesu,SEIWRDIDF*# SEQUENCE: SEIWRDIDF*# ...# >HUM11FFF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pmel17gp100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A2,actyesu,bindyesu,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM12000# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pmel17gp100 (209-217)# ANCHOR POSITIONS:# REFERENCES: van_den_eynde95a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A2,actyesu,bindyesu,ITDQVPGSV*# SEQUENCE: ITDQVPGSV*# ...# >HUM12001# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pmel17gp100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A53668,A41234)# REFERENCES: van_den_eynde95a,parker96a,rosenberg96a,robbins96a# COMMENT: tumor-specific antigen/natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >HUM12002# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pmel17gp100 (457-466)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A53668,A41234)# REFERENCES: van_den_eynde95a,parker96a,rosenberg96a,robbins96a# COMMENT: tumor-specific antigen/natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,LLDGTATLRL*# SEQUENCE: LLDGTATLRL*# ...# >HUM12003# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pmel17gp100 (476-485)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,A41234,I38400)# REFERENCES: van_den_eynde95a,rosenberg96a,robbins96a# COMMENT: tumor-specific antigen# SUMMARY: HLA-A2,actyesu,bindyesu,VLYRYGSFSV*# SEQUENCE: VLYRYGSFSV*# ...# >HUM22004# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p 2 (16-31)# DB REFERENCE: SWISS: (DER2_DERPT,DER2_DERFA)# & PIR2: (A60381)# REFERENCES: verhoef93a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,VLVPGCHGSEPCIIHR*# SEQUENCE: VLVPGCHGSEPCIIHR*# ...# >HUM22005# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p 2 (111-129)# DB REFERENCE: SWISS: (DER2_DERPT,DER2_DERFA)# & PIR2: (A60381)# REFERENCES: verhoef93a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,MGDDGVLACAIATHAKIRD*# SEQUENCE: MGDDGVLACAIATHAKIRD*# ...# >HUM22006# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p 2 (82-100)# DB REFERENCE: SWISS: (DER2_DERPT,DER2_DERFA,DEF2_DERFA,DEF2_DERFA)# & PIR2: (A60381,A61241,JU0394)# REFERENCES: verhoef93a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,KGQQYDIKYTWNVPKIAPK*# SEQUENCE: KGQQYDIKYTWNVPKIAPK*# ...# >HUM22007# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p 2 (22-40)# DB REFERENCE: SWISS: (DER2_DERFA,DER2_DERPT)# & PIR2: (A60381)# REFERENCES: verhoef93a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,HGSEPCIIHRGKPFQLEAV*# SEQUENCE: HGSEPCIIHRGKPFQLEAV*# ...# >HUM22008# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p 2 (22-40)# DB REFERENCE: SWISS: (DER2_DERPT,DER2_DERFA)# & PIR2: (A60381)# REFERENCES: verhoef93a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,HGSEPCIIHRGKPFQLEAV*# SEQUENCE: HGSEPCIIHRGKPFQLEAV*# ...# >HUM22009# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (84-102)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_RAT,MBP_BOVIN,MBP_PANTR,# & MBP_MOUSE)# & PIR1: (MBPGB,MBBOB,MBMSB,MBHUB,MBRTS,MBCZB)# & PIR2: (A37246)# REFERENCES: ota90a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,DENPVVHFFKNIVTPRTPP*# SEQUENCE: DENPVVHFFKNIVTPRTPP*# ...# >HUM2200A# MHC MOLECULE: HLA-DQ5(DQA1*0101xDQB1*0501), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (84-102)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN,MBP_BOVIN,MBP_CAVPO,MBP_RAT,# & MBP_PANTR)# & PIR1: (MBCZB,MBHUB,MBPGB,MBMSB,MBRTS,MBBOB)# & PIR2: (A37246)# REFERENCES: ota90a# COMMENT:# SUMMARY: HLA-DQ5,actyesu,bindyesu,DENPVVHFFKNIVTPRTPP*# SEQUENCE: DENPVVHFFKNIVTPRTPP*# ...# >HUM2200B# MHC MOLECULE: HLA-DR53(DRB4*01011), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (143-168)# ANCHOR POSITIONS:# REFERENCES: ota90a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,FKGVADAQGTLSKIFKLGGRD*# SEQUENCE: FKGVADAQGTLSKIFKLGGRD*# ...# >HUM2200C# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: ho90a# COMMENT: promiscuous recognition on DR or DQ# SUMMARY: HLA-D?,actyesu,bindyesu,NSVDDALINSTKIYSYFPSV*# SEQUENCE: NSVDDALINSTKIYSYFPSV*# ...# >HUM2200D# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TT# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# REFERENCES: ho90a# COMMENT: promiscuous recognition on DR or DQ or DP# SUMMARY: HLA-D?,actyesu,bindyesu,PGINGKAIHLVNNESSE*# SEQUENCE: PGINGKAIHLVNNESSE*# ...# >HUM2200E# MHC MOLECULE: HLA-DQ7, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p 2 (111-129)# DB REFERENCE: SWISS: (DER2_DERFA,DER2_DERPT)# & PIR2: (A60381)# REFERENCES: obrien95a# COMMENT:# SUMMARY: HLA-DQ7,actyesu,bindyesu,MGDDGVLACAIATHAKIRD*# SEQUENCE: MGDDGVLACAIATHAKIRD*# ...# >HUM2200F# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (75-86)# DB REFERENCE: SWISS: (BV1A_BETVE,BV1L_BETVE,BV1D_BETVE,BV1L_BETVE,BV1A_BETVE,# & BV1G_BETVE,BV1D_BETVE,BV1G_BETVE)# & PIR2: (S05376,I55699,C55699,F55699)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DHTNFKYNYSVI*# SEQUENCE: DHTNFKYNYSVI*# ...# >HUM22010# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (75-88)# DB REFERENCE: SWISS: (BV1G_BETVE,BV1A_BETVE,BV1D_BETVE,BV1A_BETVE,BV1L_BETVE,# & BV1D_BETVE,BV1G_BETVE,BV1L_BETVE)# & PIR2: (F55699,S05376,I55699,C55699)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DHTNFKYNYSVIEG*# SEQUENCE: DHTNFKYNYSVIEG*# ...# >HUM22011# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (75-90)# DB REFERENCE: SWISS: (BV1D_BETVE,BV1D_BETVE,BV1G_BETVE,BV1A_BETVE,BV1A_BETVE,# & BV1L_BETVE,BV1G_BETVE,BV1L_BETVE)# & PIR2: (I55699,S05376,C55699,F55699)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DHTNFKYNYSVIEGGP*# SEQUENCE: DHTNFKYNYSVIEGGP*# ...# >HUM22012# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (75-92)# DB REFERENCE: SWISS: (BV1A_BETVE,BV1A_BETVE)# & PIR2: (S05376)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DHTNFKYNYSVIEGGPIG*# SEQUENCE: DHTNFKYNYSVIEGGPIG*# ...# >HUM22013# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (111-122)# DB REFERENCE: SWISS: (BV1K_BETVE,BV1C_BETVE,BV1M_BETVE,BV1M_BETVE,BV1A_BETVE,# & BV1B_BETVE,BV1C_BETVE,BV1B_BETVE,BV1K_BETVE,# & BV1A_BETVE)# & PIR2: (S47251,A55699,H55699,S47250,A57427,S05376,B55699)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GSILKISNKYHT*# SEQUENCE: GSILKISNKYHT*# ...# >HUM22014# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (111-124)# DB REFERENCE: SWISS: (BV1M_BETVE,BV1C_BETVE,BV1A_BETVE,BV1K_BETVE,BV1M_BETVE,# & BV1B_BETVE,BV1A_BETVE,BV1B_BETVE,BV1K_BETVE,# & BV1C_BETVE)# & PIR2: (H55699,S47251,B55699,A55699,A57427,S47250,S05376)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GSILKISNKYHTKG*# SEQUENCE: GSILKISNKYHTKG*# ...# >HUM22015# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (111-126)# DB REFERENCE: SWISS: (BV1B_BETVE,BV1K_BETVE,BV1A_BETVE,BV1K_BETVE,BV1B_BETVE,# & BV1A_BETVE,BV1M_BETVE,BV1M_BETVE)# & PIR2: (A57427,S05376,H55699,A55699)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GSILKISNKYHTKGDH*# SEQUENCE: GSILKISNKYHTKGDH*# ...# >HUM22016# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (141-152)# DB REFERENCE: SWISS: (BV1E_BETVE,BV1J_BETVE,BV1D_BETVE,BV1D_BETVE,BV1E_BETVE,# & BV1A_BETVE,BV1F_BETVE,BV1G_BETVE,BV1L_BETVE,BV1F_BETVE,# & BV1L_BETVE,BV1J_BETVE,BV1G_BETVE,BV1A_BETVE)# & PIR2: (E55699,S05376,G55699,C55699,D55699,I55699,F55699)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ETLLRAVESYLL*# SEQUENCE: ETLLRAVESYLL*# ...# >HUM22017# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (141-154)# DB REFERENCE: SWISS: (BV1J_BETVE,BV1L_BETVE,BV1F_BETVE,BV1F_BETVE,BV1L_BETVE,# & BV1D_BETVE,BV1A_BETVE,BV1G_BETVE,BV1A_BETVE,BV1G_BETVE,# & BV1E_BETVE,BV1J_BETVE,BV1E_BETVE,BV1D_BETVE)# & PIR2: (S05376,I55699,F55699,D55699,C55699,E55699,G55699)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ETLLRAVESYLLAH*# SEQUENCE: ETLLRAVESYLLAH*# ...# >HUM22018# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Bet V 1 (141-156)# DB REFERENCE: SWISS: (BV1E_BETVE,BV1J_BETVE,BV1D_BETVE,BV1A_BETVE,BV1G_BETVE,# & BV1E_BETVE,BV1D_BETVE,BV1G_BETVE,BV1A_BETVE,BV1L_BETVE,# & BV1F_BETVE,BV1F_BETVE,BV1L_BETVE,BV1J_BETVE)# & PIR2: (E55699,C55699,D55699,F55699,S05376,G55699,I55699)# REFERENCES: ebner95a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ETLLRAVESYLLAHSD*# SEQUENCE: ETLLRAVESYLLAHSD*# ...# >HUM12019# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as./reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: tyrosinase (206-214)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: kang95,rosenberg96a,robbins96a,romero96a# COMMENT:# SUMMARY: HLA-A24,actyesh,bindyesu,AFLPWHRLF*# SEQUENCE: AFLPWHRLF*# ...# >HUM1201A# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: tyrosinase (206-215)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: kang95# COMMENT:# SUMMARY: HLA-A24,actyesh,bindyesu,AFLPWHRLFL*# SEQUENCE: AFLPWHRLFL*# ...# >HUM2201B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (304-322)# DB REFERENCE: SWISS: (HEMA_IADH2,HEMA_IAEN6,HEMA_IAAIC,HEMA_IAUDO,HEMA_IAZCO,# & HEMA_IADHM,HEMA_IADH6,HEMA_IAZH2,HEMA_IADH3,HEMA_IADH4,# & HEMA_IABAN,HEMA_IADH1,HEMA_IAME2,HEMA_IAZUK,HEMA_IADU3,# & HEMA_IAVI7,HEMA_IAQU7,HEMA_IANT6,HEMA_IADH7,# & HEMA_IAEN7)# & PIR1: (HMIV15,HMIVH,HMIVS3,HMIVHM,HMIV77,HMIVHA,HMIV33,HMIVV,# & HMIVDU,HMIV89,HMIV80,HMIV6,HMIV98)# & PIR2: (A92979,JQ1156)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GACPKYVKQNTLKLATGMR*# SEQUENCE: GACPKYVKQNTLKLATGMR*# ...# >HUM2201C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (304-319)# DB REFERENCE: SWISS: (HEMA_IABAN,HEMA_IADH3,HEMA_IAME2,HEMA_IAME1,HEMA_IADHM,# & HEMA_IADH6,HEMA_IAZCO,HEMA_IAUDO,HEMA_IAVI7,HEMA_IAEN6,# & HEMA_IADH2,HEMA_IAZUK,HEMA_IAZH2,HEMA_IADH1,HEMA_IAAIC,# & HEMA_IADH7,HEMA_IADU3,HEMA_IANT6,HEMA_IAQU7,HEMA_IAEN7,# & HEMA_IADH4)# & PIR1: (HMIV98,HMIVV,HMIVHM,HMIVDU,HMIV33,HMIV77,HMIV6,HMIVH,# & HMIV15,HMIV89,HMIV80,HMIVS3,HMIVHA)# & PIR2: (JQ1156,A92979)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,GACPKYVKQNTLKLAT*# SEQUENCE: GACPKYVKQNTLKLAT*# ...# >HUM2201D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (304-318)# DB REFERENCE: SWISS: (HEMA_IAZH2,HEMA_IADH3,HEMA_IABAN,HEMA_IAGHK,HEMA_IAME1,# & HEMA_IAQU7,HEMA_IAZUK,HEMA_IAVI7,HEMA_IAEN6,HEMA_IADH6,# & HEMA_IAZCO,HEMA_IAUDO,HEMA_IADHM,HEMA_IADH2,HEMA_IADHL,# & HEMA_IADH7,HEMA_IADU3,HEMA_IANT6,HEMA_IADH4,HEMA_IAEN7,# & HEMA_IAAIC,HEMA_IAME2,HEMA_IADH1)# & PIR1: (HMIV6,HMIV80,HMIVHA,HMIV15,HMIVS3,HMIV98,HMIVH,HMIV77,# & HMIV33,HMIVDU,HMIVV,HMIVHM,HMIV89)# & PIR2: (A92979,JQ1156,JQ1155,JQ1154)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GACPKYVKQNTLKLA*# SEQUENCE: GACPKYVKQNTLKLA*# ...# >HUM2201E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (304-317)# DB REFERENCE: SWISS: (HEMA_IAGHK,HEMA_IADH4,HEMA_IADH3,HEMA_IAQU7,HEMA_IABAN,# & HEMA_IAZH2,HEMA_IAME1,HEMA_IAAIC,HEMA_IANT6,HEMA_IADU3,# & HEMA_IAUDO,HEMA_IAZCO,HEMA_IADH6,HEMA_IADH2,HEMA_IAEN6,# & HEMA_IAEN7,HEMA_IADH7,HEMA_IADHM,HEMA_IADHL,HEMA_IAZUK,# & HEMA_IAVI7,HEMA_IAME2,HEMA_IADH1)# & PIR1: (HMIV80,HMIVV,HMIVS3,HMIVHM,HMIVDU,HMIV89,HMIV15,HMIV77,# & HMIVH,HMIVHA,HMIV6,HMIV33,HMIV98)# & PIR2: (A92979,JQ1156,JQ1155,JQ1154)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,GACPKYVKQNTLKL*# SEQUENCE: GACPKYVKQNTLKL*# ...# >HUM2201F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-322)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IAZUK,HEMA_IADHM,HEMA_IAZCO,HEMA_IAUDO,# & HEMA_IADU3,HEMA_IAEN6,HEMA_IADH2,HEMA_IADH6,HEMA_IAAIC,# & HEMA_IAQU7,HEMA_IABAN,HEMA_IAZH2,HEMA_IADH1,HEMA_IADH7,# & HEMA_IAEN7,HEMA_IAME2,HEMA_IAVI7,HEMA_IADH3,# & HEMA_IANT6)# & PIR1: (HMIVHM,HMIVDU,HMIV33,HMIV6,HMIV98,HMIV15,HMIVH,HMIVV,# & HMIV80,HMIVHA,HMIV89,HMIV77,HMIVS3)# & PIR2: (A92979,JQ1156)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKLATGMR*# SEQUENCE: PKYVKQNTLKLATGMR*# ...# >HUM22020# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (308-322)# DB REFERENCE: SWISS: (HEMA_IADH3,HEMA_IAEN6,HEMA_IAQU7,HEMA_IADH4,HEMA_IADHM,# & HEMA_IAZUK,HEMA_IAZCO,HEMA_IADH1,HEMA_IAME2,HEMA_IAZH2,# & HEMA_IAAIC,HEMA_IABAN,HEMA_IADH7,HEMA_IAEN7,HEMA_IAVI7,# & HEMA_IAUDO,HEMA_IADU3,HEMA_IANT6,HEMA_IADH6,# & HEMA_IADH2)# & PIR1: (HMIVHA,HMIV89,HMIV33,HMIVS3,HMIV80,HMIV98,HMIVV,HMIV77,# & HMIV6,HMIVHM,HMIVDU,HMIV15,HMIVH)# & PIR2: (A92979,JQ1156)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KYVKQNTLKLATGMR*# SEQUENCE: KYVKQNTLKLATGMR*# ...# >HUM22021# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (309-322)# DB REFERENCE: SWISS: (HEMA_IADH3,HEMA_IAAIC,HEMA_IADH1,HEMA_IAME2,HEMA_IADHM,# & HEMA_IABAN,HEMA_IADH6,HEMA_IADH2,HEMA_IANT6,HEMA_IAUDO,# & HEMA_IAME6,HEMA_IAEN7,HEMA_IADH7,HEMA_IAVI7,HEMA_IAZUK,# & HEMA_IADU3,HEMA_IAQU7,HEMA_IADH4,HEMA_IAEN6,HEMA_IAZCO,# & HEMA_IAZH2)# & PIR1: (HMIV98,HMIVH,HMIVDU,HMIV89,HMIVHM,HMIVHA,HMIV15,HMIV6,# & HMIVS3,HMIV33,HMIV86,HMIVV,HMIV77,HMIV80)# & PIR2: (S52187,S52176,JQ2374,S52174,S52195,JQ2377,S52197,S52179,# & S52199,S52178,A92979,S52191,S52185,JQ1156,JQ2378,S52186,# & S52182,S52180,S52189,S52188,S52173,S52183,JQ2375,S52198,# & S52175)# & PIR3: (S38637)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,YVKQNTLKLATGMR*# SEQUENCE: YVKQNTLKLATGMR*# ...# >HUM22022# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (75-98)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_HUMAN)# & PIR1: (MBHUB,MBMSB)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GRTQDENPVVHFFKNIVTPRTPPP*# SEQUENCE: GRTQDENPVVHFFKNIVTPRTPPP*# ...# >HUM22023# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HKYVKQNTLKLAT*# SEQUENCE: HKYVKQNTLKLAT*# ...# >HUM22024# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AKYVKQNTLKLAT*# SEQUENCE: AKYVKQNTLKLAT*# ...# >HUM22025# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KKYVKQNTLKLAT*# SEQUENCE: KKYVKQNTLKLAT*# ...# >HUM22026# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EKYVKQNTLKLAT*# SEQUENCE: EKYVKQNTLKLAT*# ...# >HUM22027# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PHYVKQNTLKLAT*# SEQUENCE: PHYVKQNTLKLAT*# ...# >HUM22028# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52189,S52180,S52188,S52173,JQ2375,S52179,S52185,S52178,# & S52191,JQ2377,S52199,S52186,S52197,S52187,JQ2378,JQ2374,# & S52174,S52176,S52195,S52182,S52183,S52198,S52175)# & PIR3: (S38637)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PRYVKQNTLKLAT*# SEQUENCE: PRYVKQNTLKLAT*# ...# >HUM22029# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PEYVKQNTLKLAT*# SEQUENCE: PEYVKQNTLKLAT*# ...# >HUM2202A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PSYVKQNTLKLAT*# SEQUENCE: PSYVKQNTLKLAT*# ...# >HUM2202B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PAYVKQNTLKLAT*# SEQUENCE: PAYVKQNTLKLAT*# ...# >HUM2202C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKFVKQNTLKLAT*# SEQUENCE: PKFVKQNTLKLAT*# ...# >HUM2202D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKIVKQNTLKLAT*# SEQUENCE: PKIVKQNTLKLAT*# ...# >HUM2202E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKVVKQNTLKLAT*# SEQUENCE: PKVVKQNTLKLAT*# ...# >HUM2202F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYQKQNTLKLAT*# SEQUENCE: PKYQKQNTLKLAT*# ...# >HUM22030# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYHKQNTLKLAT*# SEQUENCE: PKYHKQNTLKLAT*# ...# >HUM22031# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYLKQNTLKLAT*# SEQUENCE: PKYLKQNTLKLAT*# ...# >HUM22032# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYAKQNTLKLAT*# SEQUENCE: PKYAKQNTLKLAT*# ...# >HUM22033# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYKKQNTLKLAT*# SEQUENCE: PKYKKQNTLKLAT*# ...# >HUM22034# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYEKQNTLKLAT*# SEQUENCE: PKYEKQNTLKLAT*# ...# >HUM22035# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVAQNTLKLAT*# SEQUENCE: PKYVAQNTLKLAT*# ...# >HUM22036# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVHQNTLKLAT*# SEQUENCE: PKYVHQNTLKLAT*# ...# >HUM22037# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVSQNTLKLAT*# SEQUENCE: PKYVSQNTLKLAT*# ...# >HUM22038# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVRQNTLKLAT*# SEQUENCE: PKYVRQNTLKLAT*# ...# >HUM22039# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVEQNTLKLAT*# SEQUENCE: PKYVEQNTLKLAT*# ...# >HUM2203A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVVQNTLKLAT*# SEQUENCE: PKYVVQNTLKLAT*# ...# >HUM2203B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKENTLKLAT*# SEQUENCE: PKYVKENTLKLAT*# ...# >HUM2203C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKANTLKLAT*# SEQUENCE: PKYVKANTLKLAT*# ...# >HUM2203D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKHNTLKLAT*# SEQUENCE: PKYVKHNTLKLAT*# ...# >HUM2203E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKLNTLKLAT*# SEQUENCE: PKYVKLNTLKLAT*# ...# >HUM2203F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKTNTLKLAT*# SEQUENCE: PKYVKTNTLKLAT*# ...# >HUM22040# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKNNTLKLAT*# SEQUENCE: PKYVKNNTLKLAT*# ...# >HUM22041# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,PKYVKKNTLKLAT*# SEQUENCE: PKYVKKNTLKLAT*# ...# >HUM22042# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQKTLKLAT*# SEQUENCE: PKYVKQKTLKLAT*# ...# >HUM22043# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQETLKLAT*# SEQUENCE: PKYVKQETLKLAT*# ...# >HUM22044# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQATLKLAT*# SEQUENCE: PKYVKQATLKLAT*# ...# >HUM22045# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQTTLKLAT*# SEQUENCE: PKYVKQTTLKLAT*# ...# >HUM22046# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQHTLKLAT*# SEQUENCE: PKYVKQHTLKLAT*# ...# >HUM22047# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQQTLKLAT*# SEQUENCE: PKYVKQQTLKLAT*# ...# >HUM22048# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQLTLKLAT*# SEQUENCE: PKYVKQLTLKLAT*# ...# >HUM22049# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNVLKLAT*# SEQUENCE: PKYVKQNVLKLAT*# ...# >HUM2204A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IADHK,HEMA_IAZH3)# & PIR1: (HMIVS2)# & PIR2: (JQ1153)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNSLKLAT*# SEQUENCE: PKYVKQNSLKLAT*# ...# >HUM2204B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,PKYVKQNALKLAT*# SEQUENCE: PKYVKQNALKLAT*# ...# >HUM2204C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: 3# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTAKLAT*# SEQUENCE: PKYVKQNTAKLAT*# ...# >HUM2204D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTQKLAT*# SEQUENCE: PKYVKQNTQKLAT*# ...# >HUM2204E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTEKLAT*# SEQUENCE: PKYVKQNTEKLAT*# ...# >HUM2204F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTHKLAT*# SEQUENCE: PKYVKQNTHKLAT*# ...# >HUM22050# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTIKLAT*# SEQUENCE: PKYVKQNTIKLAT*# ...# >HUM22051# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,PKYVKQNTKKLAT*# SEQUENCE: PKYVKQNTKKLAT*# ...# >HUM22052# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLALAT*# SEQUENCE: PKYVKQNTLALAT*# ...# >HUM22053# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLHLAT*# SEQUENCE: PKYVKQNTLHLAT*# ...# >HUM22054# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLLLAT*# SEQUENCE: PKYVKQNTLLLAT*# ...# >HUM22055# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLRLAT*# SEQUENCE: PKYVKQNTLRLAT*# ...# >HUM22056# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLELAT*# SEQUENCE: PKYVKQNTLELAT*# ...# >HUM22057# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLSLAT*# SEQUENCE: PKYVKQNTLSLAT*# ...# >HUM22058# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKAAT*# SEQUENCE: PKYVKQNTLKAAT*# ...# >HUM22059# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKQAT*# SEQUENCE: PKYVKQNTLKQAT*# ...# >HUM2205A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKIAT*# SEQUENCE: PKYVKQNTLKIAT*# ...# >HUM2205B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKHAT*# SEQUENCE: PKYVKQNTLKHAT*# ...# >HUM2205C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKFAT*# SEQUENCE: PKYVKQNTLKFAT*# ...# >HUM2205D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,PKYVKQNTLKKAT*# SEQUENCE: PKYVKQNTLKKAT*# ...# >HUM2205E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKLKT*# SEQUENCE: PKYVKQNTLKLKT*# ...# >HUM2205F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKLFT*# SEQUENCE: PKYVKQNTLKLFT*# ...# >HUM22060# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKLST*# SEQUENCE: PKYVKQNTLKLST*# ...# >HUM22061# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKLHT*# SEQUENCE: PKYVKQNTLKLHT*# ...# >HUM22062# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKLAS*# SEQUENCE: PKYVKQNTLKLAS*# ...# >HUM22063# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PKYVKQNTLKLAH*# SEQUENCE: PKYVKQNTLKLAH*# ...# >HUM22064# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKLAA*# SEQUENCE: PKYVKQNTLKLAA*# ...# >HUM22065# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKLAK*# SEQUENCE: PKYVKQNTLKLAK*# ...# >HUM22066# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PKYVKQNTLKLAY*# SEQUENCE: PKYVKQNTLKLAY*# ...# >HUM22067# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Amylin (6-25)# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TSATQRLANSLVHSSNNFGA*# SEQUENCE: TSATQRLANSLVHSSNNFGA*# ...# >HUM22068# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hu MBP (84-103)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,MBP_CAVPO,MBP_RAT,# & MBP_PANTR)# & PIR1: (MBHUB,MBRTS,MBBOB,MBMSB,MBCZB,MBPGB)# & PIR2: (A37246)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,NPVVHFFKNIVTPRTPPPSQ*# SEQUENCE: NPVVHFFKNIVTPRTPPPSQ*# ...# >HUM22069# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Amylin (16-37)# DB REFERENCE: SWISS: (IAPP_HUMAN)# & PIR1: (TCHUIA)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LVHSSNNFGAILSSTNVGSNTY*# SEQUENCE: LVHSSNNFGAILSSTNVGSNTY*# ...# >HUM2206A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ova (297-316)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LMAMGITDVFSSSANLSGIS*# SEQUENCE: LMAMGITDVFSSSANLSGIS*# ...# >HUM2206B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV S (16-33)# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YQAGFFLLTRILTIPQSLD*# SEQUENCE: YQAGFFLLTRILTIPQSLD*# ...# >HUM2206C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pre S1 (47-63)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBVA,VMSA_HPBVY)# & PIR1: (SAVLBH,SAVLAH,SAVLAJ,SAVLA1)# & PIR2: (S20745,S41871,S41869,S47407,S20753,S41870,S32202)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VGAGAFGLGFTPPHGGL*# SEQUENCE: VGAGAFGLGFTPPHGGL*# ...# >HUM2206D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ach R (257-269)# DB REFERENCE: SWISS: (ACHA_RAT,ACHA_MOUSE,ACHA_MOUSE,ACH2_XENLA,ACHA_TORMA,# & ACH1_XENLA,ACHA_TORCA,ACHA_BOVIN,ACHA_CHICK,# & ACHA_HUMAN)# & PIR1: (ACHUA1,ACCHAN,ACRYA1,ACBOA1)# & PIR2: (A28529,A24383,I50150,I50548,S08162,I49458)# & PIR3: (S13872)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LLVIVELIPSTSS*# SEQUENCE: LLVIVELIPSTSS*# ...# >HUM2206E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ms beta 2m (61-76)# DB REFERENCE: SWISS: (B2MG_RAT,B2MG_MOUSE,B2MG_RAT,B2MG_MOUSE,B2MG_MUSSP)# & PIR1: (A26842,MGMSB2)# & PIR2: (I84730)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SFYILAHTEFTPTETD*# SEQUENCE: SFYILAHTEFTPTETD*# ...# >HUM2206F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pre S1 (33-49)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY)# & PIR1: (SAVLAH)# & PIR2: (S41869)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,NPVLTTASPLSSIFSR*# SEQUENCE: NPVLTTASPLSSIFSR*# ...# >HUM22070# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ova (20-39)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VHHANENIFYCPIAIMSALA*# SEQUENCE: VHHANENIFYCPIAIMSALA*# ...# >HUM22071# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV core (50-69)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVJ,CORA_HPBV9,CORA_HPBV2,# & CORA_HPBVW)# & PIR1: (NKVLA6,NKVLJ1,NKVLAH,NKVLBH,NKVLKS,NKVLA3)# & PIR2: (S53216,S53152,S53274,S53161,S25651,S53200,S53149,S22318,# & S32204,S53204,S47405,S53272,S47409,S53227,S53202,S01405,# & S53207,S53238,S53286,S53157,S53247,S53163,S53169,S20750,# & S20746,S53181,S53267,S20755,S53140)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM22072# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pre S1 (1-17)# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVA,VMSA_HPBVY)# & PIR1: (SAVLAH,SAVLBH,SAVLAJ,SAVLA1)# & PIR2: (S47407,S41869,S41871,S32202,S20749,S20753,S20745)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,MGQNLSTSNPLGFFPDH*# SEQUENCE: MGQNLSTSNPLGFFPDH*# ...# >HUM22073# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: CD4# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YKKSIQFHWKNSNQIKILGNQGSFLTKGPS*# SEQUENCE: YKKSIQFHWKNSNQIKILGNQGSFLTKGPS*# ...# >HUM22074# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ova (15-29)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (I50605)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,DVFKELKVHHANENI*# SEQUENCE: DVFKELKVHHANENI*# ...# >HUM22075# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Lol p1 (80-96)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (A37881,B37881,A37396,B37396)# & PIR3: (S13614)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EDVIPEGWKADTSYSAK*# SEQUENCE: EDVIPEGWKADTSYSAK*# ...# >HUM22076# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (81-96)# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_MELGA,LYC_CHICK,LYC_SYRRE,LYC_CHICK,# & LYC_CHRAM,LYC_PHAVE,LYC_LOPLE,LYC_PHACO)# & PIR1: (LZFER,LZCH,LZQJE,LZTK)# & PIR2: (JQ1033,JT0526,JU0237,JQ1041,JH0212,JH0211,JU0178)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >HUM22077# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hu MBP (13-32)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR,MBP_MOUSE,MBP_CAVPO,MBP_RAT)# & PIR1: (MBHUB,MBRTS,MBMSB,MBCZB)# & PIR2: (A37246)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KYLATASTMDHARHGFLPRH*# SEQUENCE: KYLATASTMDHARHGFLPRH*# ...# >HUM22078# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Nase (111-130)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VAYVYKPNNTHEQHLRKSEA*# SEQUENCE: VAYVYKPNNTHEQHLRKSEA*# ...# >HUM22079# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hu insulin# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AGIVEQSSTSISSLYQLENYSN*# SEQUENCE: AGIVEQSSTSISSLYQLENYSN*# ...# >HUM2207A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ms MBP (131-150)# DB REFERENCE: SWISS: (MBP_MOUSE)# & PIR1: (MBMSB)# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YKSAHKGFKGAYDAQGTLSK*# SEQUENCE: YKSAHKGFKGAYDAQGTLSK*# ...# >HUM2207B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ova (327-332)homologue# ANCHOR POSITIONS:# REFERENCES: sette93b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YKMKMVHAAHAKMKM*# SEQUENCE: YKMKMVHAAHAKMKM*# ...# >HUM1207C# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Dengue virus D4V (464-472)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actyesn,bindyesu,NPAQEDDQY*# SEQUENCE: NPAQEDDQY*# ...# >HUM1207D# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Dengue virus D4V (477-485)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actyesn,bindyesu,DPLKNDEDH*# SEQUENCE: DPLKNDEDH*# ...# >HUM1207E# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V (500-508)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,TPEGIIPTL*# SEQUENCE: TPEGIIPTL*# ...# >HUM1207F# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Dengue virus D4V (505-513)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actyesn,bindyesu,IPTLFGPER*# SEQUENCE: IPTLFGPER*# ...# >HUM12080# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Dengue virus D4V (542-550)# DB REFERENCE: SWISS: (POLG_DEN4,POLG_DEN1S)# & PIR1: (GNWVDF,A42551)# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actyesn,bindyesu,LPVWLSYKV*# SEQUENCE: LPVWLSYKV*# ...# >HUM12081# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: none# BINDING: yes, ?# SOURCE: Dengue virus D4V (603-611)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actyesn,bindyesu,DPMALKDFK*# SEQUENCE: DPMALKDFK*# ...# >HUM12082# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Dengue virus D4V (500-508) homologue# ANCHOR POSITIONS:# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,DPEGIIPTL*# SEQUENCE: DPEGIIPTL*# ...# >HUM12083# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Dengue virus D4V (500-508) homologue# ANCHOR POSITIONS:# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,TPDGIIPTL*# SEQUENCE: TPDGIIPTL*# ...# >HUM12084# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Dengue virus D4V (500-508) homologue# ANCHOR POSITIONS:# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,TPEDIIPTL*# SEQUENCE: TPEDIIPTL*# ...# >HUM12085# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Dengue virus D4V (500-508) homologue# ANCHOR POSITIONS:# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,TPEGDIPTL*# SEQUENCE: TPEGDIPTL*# ...# >HUM12086# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Dengue virus D4V (500-508) homologue# ANCHOR POSITIONS:# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,TPEGIIPDL*# SEQUENCE: TPEGIIPDL*# ...# >HUM12087# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: flow cytometry binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Dengue virus D4V (500-508) homologue# ANCHOR POSITIONS:# REFERENCES: zivny95a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,TPEGIIPTD*# SEQUENCE: TPEGIIPTD*# ...# >HUM12088# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV-1 env (829-837)# DB REFERENCE: SWISS: (ENV_HV1MN)# & PIR1: (VCLJMN)# REFERENCES: dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,RVIEVLQRA*# SEQUENCE: RVIEVLQRA*# ...# >HUM12089# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HIV-1 env (815-824)# ANCHOR POSITIONS:# REFERENCES: dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,LLNATDIAVA*# SEQUENCE: LLNATDIAVA*# ...# >HUM1208A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV-1 env (815-823)# ANCHOR POSITIONS:# REFERENCES: dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLNATDIAV*# SEQUENCE: LLNATDIAV*# ...# >HUM1208B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HIV-1 env (814-823)# ANCHOR POSITIONS:# REFERENCES: dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,SLLNATDIAV*# SEQUENCE: SLLNATDIAV*# ...# >HUM1208C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HIV-1 env (800-808)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1ND,ENV_HV1MF,ENV_HV1H3,ENV_HV1JR,# & ENV_HV1J3,ENV_HV1H2,ENV_HV1OY,ENV_HV1PV,ENV_HV1B8,# & ENV_HV1KB,ENV_HV1B1,ENV_HV1EL,ENV_HV1C4,ENV_HV1BN,# & ENV_HV1RH,ENV_HV1SC,ENV_HV1MN)# & PIR1: (VCLJMN,VCLJH3,VCLJVL,VCLJH4,VCLJSC,VCLJLV,VCLJND,VCLJBR,# & VCLJKB)# & PIR2: (S21994,S21998,S70418,S21996,S70423,S21992,S70425,S70422,# & S22002,S21990,S70424,S70421)# & PIR3: (S33985,S13288,S13289)# REFERENCES: dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,LLQYWSQEL*# SEQUENCE: LLQYWSQEL*# ...# >HUM1208D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HIV-1 env (687-696)# DB REFERENCE: SWISS: (ENV_HV1KB,ENV_HV1J3,ENV_HV1W1,ENV_HV1MN,ENV_HV1A2,# & ENV_HV1H3,ENV_HV1PV,ENV_HV1MF,ENV_HV1BR,ENV_HV1SC,# & ENV_HV1RH,ENV_HV1S1,ENV_HV1B1,ENV_HV1H2,ENV_HV1B8)# & PIR1: (VCLJKB,VCLJLV,VCLJKX,VCLJSC,VCLJH3,VCLJVL,VCLJMN,VCLJA2,# & VCLJ3W)# & PIR2: (S22006,S21992,S70418,S70419,S22000,B41621,S22004,S70420,# & S70417,S70424,S22002)# & PIR3: (S13289,S13288,S33985)# REFERENCES: dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,IMIVGGLVGL*# SEQUENCE: IMIVGGLVGL*# ...# >HUM1208E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: HIV-1 env (679-687)# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1JR,ENV_HV1S1,ENV_HV1Z8,ENV_HV1ZH,# & ENV_HV1Z6,ENV_HV1BR,ENV_HV1EL,ENV_HV1BN,ENV_HV1MF,# & ENV_HV1Z2,ENV_HV1SC,ENV_HV1A2,ENV_HV1C4,ENV_HV1W1,# & ENV_HV1MN,ENV_HV1KB,ENV_HV1W2)# & PIR1: (VCLJA2,VCLJ3W,H44001,VCLJKB,VCLJZR,A44963,VCLJBR,VCLJMN,# & VCLJKX,VCLJSC,VCLJH4,VCLJLV)# & PIR2: (S70422,B41621,S22000,S70420,S21996,S70425,C41621,S22002,# & S22006,S70418,S70419,S21998,S70417,S54384,S22004)# & PIR3: (S13289)# REFERENCES: dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,WLWYIKIFI*# SEQUENCE: WLWYIKIFI*# ...# >HUM1208F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HIV-1 env (120-128)# DB REFERENCE: SWISS: (ENV_HV1J3,ENV_HV1A2,ENV_HV1C4,ENV_HV1W1,ENV_HV1ND,# & ENV_HV1ZH,ENV_HV1Z2,ENV_HV1S3,ENV_HV1MN,ENV_HV1KB,# & ENV_HV1W2,ENV_HV1MA,ENV_HV1SC,ENV_HV1RH,ENV_HV1Y2,# & ENV_HV1Z8,ENV_HV1S1,ENV_HV1EL,ENV_HV1Z6,ENV_HV1BN,# & ENV_HV1OY,ENV_HV1JR,ENV_SIVCZ)# & PIR1: (VCLJZR,VCLJSC,H44001,VCLJSI,VCLJH4,VCLJMN,VCLJKX,VCLJND,# & VCLJ3W,VCLJA2,VCLJKB,A44963)# & PIR2: (S54384,S31493,S25939,S25938,A40218)# & PIR3: (S13289)# REFERENCES: dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,KLTPLCVTL*# SEQUENCE: KLTPLCVTL*# ...# >HUM12090# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HIV-1 env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dupuis95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,IISLWDQSL*# SEQUENCE: IISLWDQSL*# ...# >HUM12091# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: class I stabilisation/reconstitution/cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MUC-1 (9-17)# DB REFERENCE: SWISS: (MUC1_HUMAN)# & PIR2: (S10571,I56024,S10572,A35886,A35887,A35175,PX0066,# & B35175)# & PIR3: (JN0100)# REFERENCES: domenech95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,STAPPAHGV*# SEQUENCE: STAPPAHGV*# ...# >HUM12092# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: class I stabilisation/reconstitution/cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MUC-1 (9-17)# DB REFERENCE: SWISS: (MUC1_HUMAN)# & PIR2: (B35175,I56024,A35175,A35886,S10572,PX0066,S10571,# & A35887)# & PIR3: (JN0100)# REFERENCES: domenech95a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,STAPPAHGV*# SEQUENCE: STAPPAHGV*# ...# >HUM12093# MHC MOLECULE: HLA-A3(A*0302), CLASS-1, (HUMAN)# METHOD: class I stabilisation/reconstitution/cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MUC-1 (9-17)# DB REFERENCE: SWISS: (MUC1_HUMAN)# & PIR2: (S10572,A35887,A35886,A35175,PX0066,S10571,B35175,# & I56024)# & PIR3: (JN0100)# REFERENCES: domenech95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,STAPPAHGV*# SEQUENCE: STAPPAHGV*# ...# >HUM12094# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: class I stabilisation/reconstitution/cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MUC-1 (8-17)# DB REFERENCE: SWISS: (MUC1_HUMAN)# & PIR2: (A35175,B35175,S10572,A35887,A35886,S10571,PX0066,# & I56024)# & PIR3: (JN0100)# REFERENCES: domenech95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,GSTAPPAHGV*# SEQUENCE: GSTAPPAHGV*# ...# >HUM12095# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: class I stabilisation/reconstitution/cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MUC-1 (16-24)# DB REFERENCE: SWISS: (MUC1_HUMAN)# & PIR2: (A36735,B35175,A35886,PX0066,S10571,A35887,S10572,# & A35175)# REFERENCES: domenech95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,GVTSAPDTR*# SEQUENCE: GVTSAPDTR*# ...# >HUM12096# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2 and pos 7 either I or L# SUMMARY: HLA-A2,actunkn,bindyesu,SIPSGGXGV*# SEQUENCE: SIPSGGXGV*# ...# >HUM12097# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (IMO1_HUMAN,IMA2_HUMAN)# & PIR2: (A56516)# REFERENCES: sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GLVPFLVSV*# SEQUENCE: GLVPFLVSV*# ...# >HUM12098# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2 and pos 3 either I or L# SUMMARY: HLA-A2,actunkn,bindyesu,SIXVRALEV*# SEQUENCE: SIXVRALEV*# ...# >HUM12099# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2 and pos 3 either I or L# SUMMARY: HLA-A2,actunkn,bindyesu,SLXVRALEV*# SEQUENCE: SLXVRALEV*# ...# >HUM1209A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVXXI*# SEQUENCE: KINEPVXXI*# ...# >HUM1209B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVXXL*# SEQUENCE: KINEPVXXL*# ...# >HUM1209C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVXXI*# SEQUENCE: KLNEPVXXI*# ...# >HUM1209D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVXXL*# SEQUENCE: KLNEPVXXL*# ...# >HUM1209E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VIXPKXXXI*# SEQUENCE: VIXPKXXXI*# ...# >HUM1209F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VIXPKXXXL*# SEQUENCE: VIXPKXXXL*# ...# >HUM120A0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VLXPKXXXI*# SEQUENCE: VLXPKXXXI*# ...# >HUM120A1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VLXPKXXXL*# SEQUENCE: VLXPKXXXL*# ...# >HUM120A2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,5 and 6 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,EIVDXXEKV*# SEQUENCE: EIVDXXEKV*# ...# >HUM120A3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,5 and 6 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,ELVDXXEKV*# SEQUENCE: ELVDXXEKV*# ...# >HUM120A4# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2 and pos 7 either I or L# SUMMARY: HLA-A2,actunkn,bindyesu,SIPSGGXGV*# SEQUENCE: SIPSGGXGV*# ...# >HUM120A5# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (A43708,S21727)# REFERENCES: sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLDVPTAAV*# SEQUENCE: LLDVPTAAV*# ...# >HUM120A6# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (2AAB_HUMAN,2AAA_DROME,2AAA_HUMAN,2AAB_PIG,2AAA_PEA,# & 2AAA_PIG)# & PIR2: (B34541,C34541,S69215,D34541,S40171,S43776,S51809,S51807,# & S72499,I51631,A43767,S51808,A34541,A36180)# REFERENCES: sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLLPAIVEL*# SEQUENCE: SLLPAIVEL*# ...# >HUM120A7# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVXXI*# SEQUENCE: KINEPVXXI*# ...# >HUM120A8# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,KINEPVXXL*# SEQUENCE: KINEPVXXL*# ...# >HUM120A9# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVXXI*# SEQUENCE: KLNEPVXXI*# ...# >HUM120AA# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVXXL*# SEQUENCE: KLNEPVXXL*# ...# >HUM120AB# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (P68_HUMAN,P68_HUMAN,P68_MOUSE)# & PIR2: (I48385,JC1087)# REFERENCES: sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YLLPAIVHI*# SEQUENCE: YLLPAIVHI*# ...# >HUM120AC# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VIXPKXXXI*# SEQUENCE: VIXPKXXXI*# ...# >HUM120AD# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VIXPKXXXL*# SEQUENCE: VIXPKXXXL*# ...# >HUM120AE# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VLXPKXXXI*# SEQUENCE: VLXPKXXXI*# ...# >HUM120AF# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VLXPKXXXL*# SEQUENCE: VLXPKXXXL*# ...# >HUM120B0# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FIXEGRDAI*# SEQUENCE: FIXEGRDAI*# ...# >HUM120B1# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FIXEGRDAL*# SEQUENCE: FIXEGRDAL*# ...# >HUM120B2# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FLXEGRDAI*# SEQUENCE: FLXEGRDAI*# ...# >HUM120B3# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FLXEGRDAL*# SEQUENCE: FLXEGRDAL*# ...# >HUM120B4# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 3,5,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FVXDXXYRI*# SEQUENCE: FVXDXXYRI*# ...# >HUM120B5# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 3,5,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FVXDXXYRL*# SEQUENCE: FVXDXXYRL*# ...# >HUM120B6# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2 and pos 3 either I or L# SUMMARY: HLA-A2,actunkn,bindyesu,SIXVRALEV*# SEQUENCE: SIXVRALEV*# ...# >HUM120B7# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2 and pos 3 either I or L# SUMMARY: HLA-A2,actunkn,bindyesu,SLXVRALEV*# SEQUENCE: SLXVRALEV*# ...# >HUM120B8# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (2AAA_PIG,2AAA_PEA,2AAB_PIG,2AAA_DROME,2AAB_HUMAN,# & 2AAA_HUMAN)# & PIR2: (S69215,B34541,D34541,S51807,S72499,S43776,I51631,S51808,# & A36180,C34541,A34541,S40171,S51809,A43767)# REFERENCES: sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLLPAIVEL*# SEQUENCE: SLLPAIVEL*# ...# >HUM120B9# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (P68_HUMAN,P68_HUMAN,P68_MOUSE)# & PIR2: (I48385,JC1087)# REFERENCES: sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YLLPAIVHI*# SEQUENCE: YLLPAIVHI*# ...# >HUM120BA# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VIXPKXXXI*# SEQUENCE: VIXPKXXXI*# ...# >HUM120BB# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VIXPKXXXL*# SEQUENCE: VIXPKXXXL*# ...# >HUM120BC# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VLXPKXXXI*# SEQUENCE: VLXPKXXXI*# ...# >HUM120BD# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3,6,7,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VLXPKXXXL*# SEQUENCE: VLXPKXXXL*# ...# >HUM120BE# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FIXEGRDAI*# SEQUENCE: FIXEGRDAI*# ...# >HUM120BF# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FIXEGRDAL*# SEQUENCE: FIXEGRDAL*# ...# >HUM120C0# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FLXEGRDAI*# SEQUENCE: FLXEGRDAI*# ...# >HUM120C1# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FLXEGRDAL*# SEQUENCE: FLXEGRDAL*# ...# >HUM120C2# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,5 and 6 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,EIVDXXEKV*# SEQUENCE: EIVDXXEKV*# ...# >HUM120C3# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,5 and 6 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,ELVDXXEKV*# SEQUENCE: ELVDXXEKV*# ...# >HUM120C4# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 3,5,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FVXDXXYRI*# SEQUENCE: FVXDXXYRI*# ...# >HUM120C5# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 3,5,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,FVXDXXYRL*# SEQUENCE: FVXDXXYRL*# ...# >HUM120C6# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VQXEVFVEI*# SEQUENCE: VQXEVFVEI*# ...# >HUM120C7# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 3 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VQXEVFVEL*# SEQUENCE: VQXEVFVEL*# ...# >HUM120C8# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MVVEKSYAV*# SEQUENCE: MVVEKSYAV*# ...# >HUM120C9# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (INIP_HUMAN)# & PIR2: (S21727,A43708)# REFERENCES: sudo95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLDVPTAAV*# SEQUENCE: LLDVPTAAV*# ...# >HUM120CA# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 1,2,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,XIDSDXERI*# SEQUENCE: XIDSDXERI*# ...# >HUM120CB# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 1,2,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,XIDSDXERL*# SEQUENCE: XIDSDXERL*# ...# >HUM120CC# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 1,2,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,XLDSDXERI*# SEQUENCE: XLDSDXERI*# ...# >HUM120CD# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 1,2,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,XLDSDXERL*# SEQUENCE: XLDSDXERL*# ...# >HUM120CE# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VIDSQXEDI*# SEQUENCE: VIDSQXEDI*# ...# >HUM120CF# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VIDSQXEDL*# SEQUENCE: VIDSQXEDL*# ...# >HUM120D0# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VLDSQXEDI*# SEQUENCE: VLDSQXEDI*# ...# >HUM120D1# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,6 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,VLDSQXEDL*# SEQUENCE: VLDSQXEDL*# ...# >HUM120D2# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 1,2 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,XIDEPFAHI*# SEQUENCE: XIDEPFAHI*# ...# >HUM120D3# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 1,2 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,XIDEPFAHL*# SEQUENCE: XIDEPFAHL*# ...# >HUM120D4# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 1,2 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,XLDEPFAHI*# SEQUENCE: XLDEPFAHI*# ...# >HUM120D5# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 1,2 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,XLDEPFAHL*# SEQUENCE: XLDEPFAHL*# ...# >HUM120D6# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,AIDKATVXI*# SEQUENCE: AIDKATVXI*# ...# >HUM120D7# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,AIDKATVXL*# SEQUENCE: AIDKATVXL*# ...# >HUM120D8# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,ALDKATVXI*# SEQUENCE: ALDKATVXI*# ...# >HUM120D9# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC/edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sudo95a# COMMENT: pos 2,8 and 9 either L or I# SUMMARY: HLA-A2,actunkn,bindyesu,ALDKATVXL*# SEQUENCE: ALDKATVXL*# ...# >MUS220DA# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: IL-2 as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Amb a 5 (27-36)# DB REFERENCE: SWISS: (MP5A_AMBPS,MP5A_AMBPS,MPA5_AMBEL,MPA5_AMBEL)# & PIR1: (ARRA5)# REFERENCES: zhu95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,PWQVVCYESS*# SEQUENCE: PWQVVCYESS*# ...# >MUS220DB# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: IL-2 as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Amb t 5 (24-34)# DB REFERENCE: SWISS: (MPT5_AMBTR,MPT5_AMBTR)# & PIR1: (ARRA5G)# REFERENCES: zhu95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,KYCVCYDSKAI*# SEQUENCE: KYCVCYDSKAI*# ...# >MUS220DC# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse insulin II B chain (9-23)# DB REFERENCE: SWISS: (INS_ANAPL,INS2_MOUSE,INS_FELCA,INS_PIG,INS_CHICK,# & INS_SELRF,INS_BALPH,INS_CAPHI,INS_ELEMA,INS_ACOCA,# & INS_PSESC,INS_CRILO,INS_BALBO,INS_SELRF,INS_ANSAN,# & INS_MACFA,INS2_RAT,INS_HORSE,INS_RABIT,INS_BOVIN,# & INS_HUMAN,INS_SHEEP,INS_CANFA,INS_ACOCA,INS_CAMDR,# & INS_PIG,INS_CERAE,INS_DIDMA,INS2_MOUSE,INS_KATPE,# & INS_HUMAN,INS_PANTR,INS_PSAOB)# & PIR1: (INSH,IPDG,INWHF,A61129,IPPG,INWHP,INTK,INEL,INRB,INMS2,# & IPHO,IPBO,IPHU,INOS,IPRT2,INGT,INWH1S,INGS,INCMA,INCT,# & IPCH,INHY)# & PIR2: (A42179,B42179,I48166,JQ0178,JQ0362,A60414,A53438)# & PIR3: (JQ0363,S44470,I51221)# REFERENCES: daniel95a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,SHLVEALYLVCGERG*# SEQUENCE: SHLVEALYLVCGERG*# ...# >HUM220DD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A01_PONPY,1A30_HUMAN,1A01_PANTR,# & 1A68_HUMAN,1A04_GORGO,1A04_PANTR,1A24_HUMAN,1A31_HUMAN,# & 1A26_HUMAN,1A74_HUMAN,1A33_HUMAN,1A43_HUMAN,1A11_HUMAN,# & 1A03_HUMAN,1A31_HUMAN,1A03_PANTR,1A29_HUMAN,1A23_HUMAN,# & 1A26_HUMAN,1A32_HUMAN,1A01_GORGO,1A66_HUMAN,1A34_HUMAN,# & 1A02_GORGO,1A69_HUMAN,1A03_GORGO,1A25_HUMAN)# & PIR1: (HLHUA2,HLHU32,HLHU28,HLHU69,HLHUAW,HLHUA3)# & PIR2: (JL0135,I72171,I37482,JH0534,A45847,S03535,I36966,I83063,# & I38436,I37480,S51099,S01171,I56039,I36961,I38441,I38610,# & A47636,I84487,I38443,I54416,I37477,I54493,A37028,S16769,# & I37479,JH0537,I84432,I36965,I36959,I54307,JH0536,I84448,# & I61902,I37470,I37542,JH0535,I37483,I61857,A35997,I37476,# & I38519,S18198,I72170)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,DTQFVRFDSDAASQR*# SEQUENCE: DTQFVRFDSDAASQR*# ...# >HUM220DE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DTQFVRVDSDAASQRMEP*# SEQUENCE: DTQFVRVDSDAASQRMEP*# ...# >HUM220DF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A01_GORGO,1A34_HUMAN,1A23_HUMAN,1A29_HUMAN,1A26_HUMAN,# & 1A32_HUMAN,1A03_GORGO,1A03_PANTR,1A11_HUMAN,1A43_HUMAN,# & 1A74_HUMAN,1A31_HUMAN,1A02_HUMAN,1A24_HUMAN,1A30_HUMAN,# & 1A33_HUMAN,1A03_HUMAN,1A26_HUMAN,1A66_HUMAN,1A25_HUMAN,# & 1A04_PANTR,1A04_GORGO,1A68_HUMAN,1A01_PANTR,1A69_HUMAN,# & 1A01_PONPY,1A02_GORGO,1A02_HUMAN,1A31_HUMAN)# & PIR1: (HLHUA2,HLHU69,HLHUAW,HLHU32,HLHU28,HLHUA3)# & PIR2: (I37482,I83063,I54416,I54493,I37476,I72170,S01171,S51099,# & I36961,JH0537,I36959,I84487,I84448,I36966,I38436,A45847,# & I56039,I38519,S18198,A37028,S16769,I37479,I84432,I36965,# & I54307,I38441,A35997,JH0536,I61902,I37470,JH0535,I37542,# & I61857,I37483,I37480,JL0135,I72171,S03535,JH0534,I38443,# & I37477,I38610,A47636)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DTQFVRFDSDAASQRMEPR*# SEQUENCE: DTQFVRFDSDAASQRMEPR*# ...# >HUM220E0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A04_PANTR,1A03_GORGO,1A01_PANTR,1A01_PONPY,1A69_HUMAN,# & 1A68_HUMAN,1A31_HUMAN,1A11_HUMAN,1A24_HUMAN,1A30_HUMAN,# & 1A02_GORGO,1A32_HUMAN,1A04_GORGO,1A02_HUMAN,1A03_HUMAN,# & 1A33_HUMAN,1A26_HUMAN,1A25_HUMAN,1A66_HUMAN,1A02_HUMAN,# & 1A01_GORGO,1A26_HUMAN,1A29_HUMAN,1A23_HUMAN,1A34_HUMAN,# & 1A03_PANTR,1A74_HUMAN,1A43_HUMAN,1A31_HUMAN)# & PIR1: (HLHU28,HLHU32,HLHU69,HLHUA2,HLHUA3,HLHUAW)# & PIR2: (A37028,I37479,S16769,S03535,I72171,I37477,I38610,I36961,# & JH0537,I84487,I36959,I38436,A45847,I72170,I37476,S01171,# & S51099,I37470,A35997,JH0536,I56039,S18198,I37482,JH0535,# & I37542,I37483,I61857,I37480,JH0534,I36966,I84448,I83063,# & I54493,I61902,I54416,I38519,I38441,I84432,JL0135,A47636,# & I54307,I36965,I38443)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQR*# SEQUENCE: VDDTQFVRFDSDAASQR*# ...# >HUM220E1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A66_HUMAN,1A25_HUMAN,1A02_HUMAN,1A33_HUMAN,1A43_HUMAN,# & 1A31_HUMAN,1A74_HUMAN,1A29_HUMAN,1A34_HUMAN,1A32_HUMAN,# & 1A02_GORGO,1A24_HUMAN,1A30_HUMAN,1A01_PONPY,1A69_HUMAN,# & 1A23_HUMAN,1A31_HUMAN,1A02_HUMAN,1A03_HUMAN,1A03_PANTR,# & 1A01_PANTR,1A68_HUMAN,1A03_GORGO,1A01_GORGO,1A26_HUMAN,# & 1A04_PANTR,1A04_GORGO,1A11_HUMAN,1A26_HUMAN)# & PIR1: (HLHU32,HLHUA3,HLHUA2,HLHU69,HLHU28,HLHUAW)# & PIR2: (I37479,I56039,I37477,I72171,S03535,I37470,I37542,I38519,# & I84448,I38436,I84487,A45847,JL0135,JH0534,I83063,I36961,# & I36959,JH0537,I38443,A47636,I54307,I36965,I84432,I38441,# & I37482,JH0535,I37483,I61857,I37480,I37476,I72170,S51099,# & S01171,I61902,I54416,I36966,I54493,A37028,S16769,I38610,# & S18198,A35997,JH0536)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VDDTQFVRFDSDAASQRME*# SEQUENCE: VDDTQFVRFDSDAASQRME*# ...# >HUM220E2# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A29_HUMAN,1A34_HUMAN,1A01_GORGO,1A26_HUMAN,1A03_GORGO,# & 1A68_HUMAN,1A24_HUMAN,1A02_HUMAN,1A04_PANTR,1A26_HUMAN,# & 1A11_HUMAN,1A04_GORGO,1A01_PANTR,1A03_HUMAN,1A69_HUMAN,# & 1A01_PONPY,1A23_HUMAN,1A03_PANTR,1A31_HUMAN,1A43_HUMAN,# & 1A31_HUMAN,1A74_HUMAN,1A02_HUMAN,1A33_HUMAN,1A66_HUMAN,# & 1A25_HUMAN,1A30_HUMAN,1A32_HUMAN,1A02_GORGO)# & PIR1: (HLHU32,HLHUAW,HLHUA3,HLHU69,HLHU28,HLHUA2)# & PIR2: (I36959,S01171,I37476,I37482,I37483,JH0535,I37480,S16769,# & A37028,I38610,S18198,A35997,JH0536,JH0534,JL0135,I83063,# & I38436,A45847,I84487,I61902,I38443,A47636,I37470,I37542,# & I56039,I37479,I72171,I54493,I61857,S03535,I84432,I36966,# & I54416,I84448,I38519,I37477,I36961,I38441,I36965,I54307,# & I72170,S51099,JH0537)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQRMEP*# SEQUENCE: VDDTQFVRFDSDAASQRMEP*# ...# >HUM220E3# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A01_PONPY,1A69_HUMAN,1A03_PANTR,1A31_HUMAN,1A03_HUMAN,# & 1A02_GORGO,1A32_HUMAN,1A33_HUMAN,1A25_HUMAN,1A74_HUMAN,# & 1A02_HUMAN,1A11_HUMAN,1A26_HUMAN,1A04_GORGO,1A01_PANTR,# & 1A04_PANTR,1A02_HUMAN,1A24_HUMAN,1A23_HUMAN,1A30_HUMAN,# & 1A68_HUMAN,1A03_GORGO,1A01_GORGO,1A26_HUMAN,1A29_HUMAN,# & 1A34_HUMAN,1A31_HUMAN,1A43_HUMAN,1A66_HUMAN)# & PIR1: (HLHU32,HLHUA2,HLHU69,HLHU28,HLHUA3,HLHUAW)# & PIR2: (I37470,I38610,S18198,JH0536,I37482,I38441,I54307,I36966,# & I38443,I84432,JH0534,JL0135,I36961,JH0537,S51099,I72170,# & I36965,I37479,I56039,I72171,I37542,I54493,I38436,A45847,# & I84487,I83063,I54416,I37477,I84448,I38519,I61857,S03535,# & I36959,I37476,S01171,I37480,S16769,A37028,A35997,JH0535,# & I37483,A47636,I61902)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAASQRMEPR*# SEQUENCE: VDDTQFVRFDSDAASQRMEPR*# ...# >HUM220E4# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DRB1*0401 beta-chain# DB REFERENCE: SWISS: (HB2H_HUMAN,HB2D_HUMAN)# & PIR2: (A29310,S01441)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VYPEVTVYPAKT*# SEQUENCE: VYPEVTVYPAKT*# ...# >HUM220E5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DRB1*0401 beta-chain# DB REFERENCE: SWISS: (HB2D_HUMAN,HB2H_HUMAN)# & PIR2: (A29310,S01441)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VYPEVTVYPAK*# SEQUENCE: VYPEVTVYPAK*# ...# >HUM220E6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig K variable region# DB REFERENCE: PIR2: (S37506)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,PGQPPRLLIYDASNRATGIPA*# SEQUENCE: PGQPPRLLIYDASNRATGIPA*# ...# >HUM220E7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ig K variable region# DB REFERENCE: PIR2: (S37506)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KPGQPPRLLIYDASNRATGIPA*# SEQUENCE: KPGQPPRLLIYDASNRATGIPA*# ...# >HUM220E8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig K variable region# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,PEPPRLLIYDASNRATGIPA*# SEQUENCE: PEPPRLLIYDASNRATGIPA*# ...# >HUM220E9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig K variable region# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,PEPPRLLIYDASNRATG*# SEQUENCE: PEPPRLLIYDASNRATG*# ...# >HUM220EA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: to rat cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HDYNFVKAINAIQKSW*# SEQUENCE: HDYNFVKAINAIQKSW*# ...# >HUM220EB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Homologous to rat cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,HDYNFVKAINAIQKSWT*# SEQUENCE: HDYNFVKAINAIQKSWT*# ...# >HUM220EC# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha-chain# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,ANIAVDKANLEIMTKR*# SEQUENCE: ANIAVDKANLEIMTKR*# ...# >HUM220ED# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha-chain# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I72480,I56085)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LANIAVDKANLEIMTKR*# SEQUENCE: LANIAVDKANLEIMTKR*# ...# >HUM220EE# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha-chain# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LGALANIAVDKANLE*# SEQUENCE: LGALANIAVDKANLE*# ...# >HUM220EF# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha-chain# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (A53273,I56085,I72480)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,QGALANIAVDKANLEIM*# SEQUENCE: QGALANIAVDKANLEIM*# ...# >HUM220F0# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DR alpha-chain# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I72480,I56085)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,AQGALANIAVDKANLEIMT*# SEQUENCE: AQGALANIAVDKANLEIMT*# ...# >HUM220F1# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B33_HUMAN,1B43_HUMAN,1B04_GORGO,1B38_HUMAN,1B48_HUMAN,# & 1B47_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I37519,I38437,JH0542,I37520,I37492,I61864)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GSHSMRYFHTAMSRPGRG*# SEQUENCE: GSHSMRYFHTAMSRPGRG*# ...# >HUM220F2# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B43_HUMAN,1B47_HUMAN,1B48_HUMAN,1B33_HUMAN,1B38_HUMAN,# & 1B04_GORGO)# & PIR1: (HLHU40)# & PIR2: (I37492,I37519,I38437,JH0542,I37520,I61864)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SHSMRYFHTAMSRPG*# SEQUENCE: SHSMRYFHTAMSRPG*# ...# >HUM220F3# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B04_GORGO,1B48_HUMAN,1B38_HUMAN,1B33_HUMAN,1B43_HUMAN,# & 1B47_HUMAN)# & PIR1: (HLHU40)# & PIR2: (JH0542,I37492,I61864,I37520,I38437,I37519)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SHSMRYFHTAMSRP*# SEQUENCE: SHSMRYFHTAMSRP*# ...# >HUM220F4# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SHSMRYGHTAMSR*# SEQUENCE: SHSMRYGHTAMSR*# ...# >HUM220F5# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B47_HUMAN,1B04_GORGO,1B38_HUMAN,1B48_HUMAN,1B43_HUMAN,# & 1B33_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I38437,I37492,JH0542,I61864,I37519,I37520)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SHSMRYFHTAMS*# SEQUENCE: SHSMRYFHTAMS*# ...# >HUM220F6# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B38_HUMAN,1B04_GORGO,1B43_HUMAN,1B48_HUMAN,1B47_HUMAN,# & 1B33_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I38437,I61864,I37492,I37519,JH0542,I37520)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,HSMRYFHTAMSRPGRG*# SEQUENCE: HSMRYFHTAMSRPGRG*# ...# >HUM220F7# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B38_HUMAN,1B48_HUMAN,1B43_HUMAN,1B33_HUMAN,1B04_GORGO,# & 1B47_HUMAN)# & PIR1: (HLHU40)# & PIR2: (I38437,I37520,I37492,I37519,JH0542,I61864)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SMRYFHTAMSRPGRG*# SEQUENCE: SMRYFHTAMSRPGRG*# ...# >HUM220F8# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1C11_HUMAN,1A04_PANTR,1A01_PANTR,1C04_HUMAN,1C02_HUMAN,# & 1A01_HUMAN,1B34_HUMAN,1A11_HUMAN,1B46_HUMAN,1B33_HUMAN,# & 1A01_PONPY,1C15_HUMAN,1A03_PANTR,1A03_HUMAN,1C03_HUMAN,# & 1A32_HUMAN,1A02_GORGO,1A33_HUMAN,1C13_HUMAN,1C04_GORGO,# & 1B02_HUMAN,1C05_HUMAN,1B38_HUMAN,1CXX_HUMAN,1C01_HUMAN,# & 1C01_PANTR,1A30_HUMAN,1C01_SAGOE,1C16_HUMAN,1A31_HUMAN,# & 1A26_HUMAN,1C18_HUMAN,1A80_HUMAN,1C02_GORGO,1B39_HUMAN,# & 1C03_GORGO,1C06_HUMAN,1B35_HUMAN,1A66_HUMAN,1A43_HUMAN,# & 1C17_HUMAN,HLAH_HUMAN,1C02_HUMAN,1B20_HUMAN,1A74_HUMAN,# & 1B36_HUMAN,1A36_HUMAN,HLAH_HUMAN,1C02_GORGO,1A25_HUMAN,# & 1C01_GORGO,1C12_HUMAN,1A31_HUMAN,1C14_HUMAN,1A01_SAGOE,# & 1A29_HUMAN,1C07_HUMAN,1A03_GORGO,1A01_GORGO,1A26_HUMAN,# & 1B04_HUMAN,1A34_HUMAN)# & PIR1: (HLHU32,HLHUC4,HLHUA3,HLHUW3,HLHU40,HLHU12,HLHUB7,# & S42102)# & PIR2: (I59622,I54307,I54418,JH0526,I68701,I38610,I72113,I56149,# & S44994,I56053,I37477,S11136,A47636,I56034,S42823,A37028,# & A35997,I59655,JH0292,JH0535,I38518,I81232,I72218,I56039,# & I38436,S03535,I72029,A45847,I72170,S11142,S52486,S11140,# & S18198,I37482,S11137,I61906,I37135,I84431,I79640,I72171,# & I37523,I59651,S51102,A45897,I61903,I84487,I68712,I83063,# & I37476,S01171,I36959,JH0545,S16769,B37028,JH0543,I37480,# & I37483,JH0544,A49411,C37028,S11141,I59188,I38505,I54449,# & I37527,I54430,I61856,I37479,I37526,I36958,I61866,S10934,# & I61864,I37478,I81231,I68750,I56116,I36966,JH0288,S48134,# & JH0546,S24438,I84432,I36965,JH0547,I36961,JH0290,I38437,# & JS0262,S51100,JL0135,I37528,S60601,JH0534,S11139,I37078,# & I68747,I38519,S11133,I37529,JH0536,I61865,I68749,I61905,# & A45857,S11134,I38507,I38439,JH0291,I37492,I72808,S11135,# & I37544)# & PIR3: (S06424,G02922)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KDYIALNEDLRS*# SEQUENCE: KDYIALNEDLRS*# ...# >HUM220F9# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A26_HUMAN,1A34_HUMAN,1A01_GORGO,1B04_HUMAN,1C14_HUMAN,# & 1A01_SAGOE,1C12_HUMAN,1C01_GORGO,1A25_HUMAN,1C02_GORGO,# & 1C13_HUMAN,1A32_HUMAN,HLAH_HUMAN,1C11_HUMAN,1C02_GORGO,# & 1A03_GORGO,1B36_HUMAN,1A36_HUMAN,1A74_HUMAN,1B20_HUMAN,# & 1C07_HUMAN,1A31_HUMAN,1A29_HUMAN,1A02_GORGO,1A33_HUMAN,# & 1C05_HUMAN,1C03_GORGO,1C06_HUMAN,1B35_HUMAN,1C16_HUMAN,# & 1A31_HUMAN,1C18_HUMAN,1B39_HUMAN,1C01_PANTR,1A80_HUMAN,# & 1A26_HUMAN,1C02_HUMAN,HLAH_HUMAN,1A43_HUMAN,1C17_HUMAN,# & 1A66_HUMAN,1A11_HUMAN,1B46_HUMAN,1B33_HUMAN,1C04_GORGO,# & 1B02_HUMAN,1A01_PONPY,1C15_HUMAN,1A03_PANTR,1A03_HUMAN,# & 1C03_HUMAN,1C02_HUMAN,1A01_HUMAN,1B34_HUMAN,1C04_HUMAN,# & 1A01_PANTR,1B38_HUMAN,1CXX_HUMAN,1A04_PANTR,1A30_HUMAN,# & 1C01_SAGOE,1C01_HUMAN)# & PIR1: (HLHUW3,S42102,HLHUB7,HLHUA3,HLHU32,HLHU40,HLHU12,# & HLHUC4)# & PIR2: (I61866,I36958,I56039,I38518,I81232,A35997,I59655,JH0292,# & S42823,I56034,A47636,A37028,I84432,S48134,JH0288,I68750,# & I37478,I81231,I61864,I56116,S10934,I37544,I38439,JH0291,# & I61865,A45857,I61905,JH0536,S11134,I61906,S11137,I37135,# & I72113,S44994,I56149,I68701,JH0526,I38610,I59622,I54307,# & I54418,I56053,I61856,I37479,I37526,S03535,S52486,S11140,# & A45847,S11142,S60601,S16769,I54430,I83063,I59651,A45897,# & I84487,I59188,I37476,S01171,I37483,JH0543,I37480,C37028,# & JH0544,A49411,B37028,JH0545,I37527,I54449,S11141,I72808,# & S11139,I68747,I38519,JL0135,JH0290,JH0547,I36965,I36961,# & I72029,I84431,I72170,S18198,I37482,I37528,S51100,I72171,# & I72218,S11136,S11135,S11133,I38437,JS0262,JH0534,I37078,# & I37529,I68749,I38507,I37492,I36959,I38505,I37523,I79640,# & I61903,I68712,S51102,I36966,S24438,JH0546,I38436,I37477,# & JH0535)# & PIR3: (S06424,G02922)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KDYIALNEDLRSWT*# SEQUENCE: KDYIALNEDLRSWT*# ...# >HUM220FA# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A80_HUMAN,HLAH_HUMAN,1C02_HUMAN,1A43_HUMAN,1A66_HUMAN,# & 1C17_HUMAN,1A30_HUMAN,1C01_HUMAN,1A01_HUMAN,1C02_HUMAN,# & 1A01_PANTR,1C04_HUMAN,1B46_HUMAN,1A11_HUMAN,1B33_HUMAN,# & 1C03_HUMAN,1A04_PANTR,1CXX_HUMAN,1B20_HUMAN,1A74_HUMAN,# & 1A36_HUMAN,1A33_HUMAN,1A31_HUMAN,1A02_GORGO,1C06_HUMAN,# & 1B35_HUMAN,1C16_HUMAN,1B39_HUMAN,1B34_HUMAN,1B38_HUMAN,# & 1A31_HUMAN,1C01_PANTR,1C05_HUMAN,1A29_HUMAN,1B36_HUMAN,# & 1A01_GORGO,1C02_GORGO,1C01_GORGO,1A01_SAGOE,1A03_GORGO,# & 1C02_GORGO,HLAH_HUMAN,1C11_HUMAN,1C18_HUMAN,1C07_HUMAN,# & 1C01_SAGOE,1C03_GORGO,1A26_HUMAN,1C15_HUMAN,1A03_PANTR,# & 1A03_HUMAN,1A01_PONPY,1B02_HUMAN,1A32_HUMAN,1C04_GORGO,# & 1C13_HUMAN,1A25_HUMAN,1A34_HUMAN,1A26_HUMAN,1B04_HUMAN,# & 1C12_HUMAN,1C14_HUMAN)# & PIR1: (HLHU12,HLHUB7,HLHU40,HLHUW3,HLHUA3,HLHU32,S42102,# & HLHUC4)# & PIR2: (I36959,I68749,I37078,JS0262,I38436,JH0546,I61906,I68701,# & S11140,I68747,JH0291,I36965,JH0290,I37527,A49411,JH0544,# & I37483,I37480,I54430,I37478,I61905,S10934,S48134,JH0288,# & I81231,I56034,S42823,I81232,I72171,I59188,I54449,JL0135,# & I83063,C37028,S16769,S18198,JH0536,A45857,S11134,I38439,# & I37544,I56116,I61864,I68750,I84432,A45897,I84487,I59651,# & JH0543,S01171,I37476,S11139,JH0547,I36961,I38519,I72808,# & JH0545,B37028,S11141,A37028,I61865,S11137,S11133,S11135,# & S11136,I72218,S11142,S60601,S24438,I36966,JH0535,I37477,# & I37528,S51100,I72170,I37482,I84431,I72029,I38518,A47636,# & I56039,JH0292,I59655,A35997,I36958,I61866,I56053,I38610,# & I59622,JH0526,S44994,I72113,I56149,I54307,I54418,A45847,# & I37135,I37523,I38505,JH0534,I68712,S51102,I79640,I61903,# & I38507,I38437,I37492,I37529,I61856,I37479,I37526,S03535,# & S52486)# & PIR3: (S06424,G02922)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KDYIALNEDLRSWTA*# SEQUENCE: KDYIALNEDLRSWTA*# ...# >HUM220FB# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A25_HUMAN,1A34_HUMAN,1B04_HUMAN,1A26_HUMAN,1A32_HUMAN,# & 1C13_HUMAN,1C04_GORGO,1B02_HUMAN,1C03_HUMAN,1C15_HUMAN,# & 1A03_HUMAN,1B46_HUMAN,1A11_HUMAN,1C02_HUMAN,1A01_HUMAN,# & HLAH_HUMAN,1C17_HUMAN,1C02_GORGO,1A26_HUMAN,1A01_PANTR,# & 1C04_HUMAN,1C01_SAGOE,1C11_HUMAN,1C07_HUMAN,1C18_HUMAN,# & 1C12_HUMAN,1C14_HUMAN,1B33_HUMAN,1A01_PONPY,1C03_GORGO,# & 1C02_GORGO,HA1A_RABIT,1B36_HUMAN,1A66_HUMAN,1A31_HUMAN,# & 1A31_HUMAN,1A29_HUMAN,1C01_PANTR,HA19_CANFA,1C01_GORGO,# & 1A01_GORGO,1B38_HUMAN,1B34_HUMAN,1A03_GORGO,HLAH_HUMAN,# & 1C01_HUMAN,1A43_HUMAN,HA1B_RABIT,1C02_HUMAN,1A04_PANTR,# & 1CXX_HUMAN,1A30_HUMAN,1A80_HUMAN,1B20_HUMAN,1A74_HUMAN,# & 1A36_HUMAN,1A02_GORGO,1A33_HUMAN,1B35_HUMAN,1C16_HUMAN,# & 1C06_HUMAN,1B39_HUMAN)# & PIR1: (HLHUB7,HLHUA3,HLHU40,S42102,HLHUC4,HLHU32,HLRB,HLHU12)# & PIR2: (S11135,S11133,S11136,S11142,S60601,I67482,I36965,I68747,# & JH0291,I37527,I37483,I37480,JH0544,A49411,I54430,I37528,# & I72170,I72029,I37482,I84431,I37477,JH0535,I61856,I37479,# & I37526,I46604,I38437,JH0534,I68712,I79640,I61903,S51102,# & I37523,I36966,I37529,I46030,S18198,I83063,JL0135,I54449,# & I59188,C37028,I46858,I37078,JH0546,I38436,I68701,A45849,# & I61906,S11141,A37028,S11137,I72171,JH0288,I81231,I56034,# & S42823,I81232,S52486,JH0543,B37028,A45831,I84432,I61864,# & S11134,I67483,I37544,A60369,A45897,I84487,I59651,I38519,# & I46603,S11139,JH0547,I36961,A45845,I37135,A45847,S44994,# & I56149,I72113,JH0526,I54418,I36958,I61866,JH0292,A47636,# & S16769,S48134,JH0545,I61865,JH0289,S24438,I38610,I54307,# & I38518,I56039,A35997,I59655,I59622,I38505,I37492,I38507,# & I37476,S01171,I38439,I72808,A45857,JH0536,I68750,I56116,# & I72218,S51100,S11140,JS0262,I36959,I68749,I61905,I37478,# & JH0290)# & PIR3: (G02922,S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DYIALNEDLRSWTAAD*# SEQUENCE: DYIALNEDLRSWTAAD*# ...# >HUM220FC# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A29_HUMAN,1C01_PANTR,1A01_GORGO,1B34_HUMAN,1B38_HUMAN,# & HA19_CANFA,1B39_HUMAN,1A33_HUMAN,1A02_GORGO,1A36_HUMAN,# & 1B20_HUMAN,1A74_HUMAN,1C18_HUMAN,1A66_HUMAN,1C12_HUMAN,# & 1B33_HUMAN,1C03_GORGO,HA1A_RABIT,1B36_HUMAN,1C05_HUMAN,# & 1C01_SAGOE,1C11_HUMAN,1A31_HUMAN,1A80_HUMAN,1A03_GORGO,# & HLAH_HUMAN,1B35_HUMAN,1C16_HUMAN,1C02_GORGO,1A31_HUMAN,# & 1A01_PONPY,HLAH_HUMAN,1A30_HUMAN,1A43_HUMAN,1C02_HUMAN,# & 1C13_HUMAN,1A25_HUMAN,1A32_HUMAN,1C15_HUMAN,1A01_PANTR,# & 1C17_HUMAN,1C02_GORGO,1A26_HUMAN,1C04_HUMAN,1C04_GORGO,# & 1C06_HUMAN,1C07_HUMAN,1B04_HUMAN,1C14_HUMAN,1CXX_HUMAN,# & 1C02_HUMAN,1A03_PANTR,1A01_HUMAN,1A04_PANTR,1B46_HUMAN,# & 1A11_HUMAN,1C03_HUMAN,1A03_HUMAN,1B02_HUMAN,1A34_HUMAN,# & 1A26_HUMAN,1C01_GORGO,1C01_HUMAN,HA1B_RABIT)# & PIR1: (S42102,HLHUC4,HLHUW3,HLHUB7,HLHUA3,HLRB,HLHU12,HLHU32,# & HLHU40)# & PIR2: (I38439,I56116,I37476,I59622,I59655,I38507,JS0262,I36959,# & I68749,I61906,I37078,I81232,JH0292,I36958,I84432,JH0543,# & I37483,JH0544,I68747,S60601,I37477,S11133,I37479,I79640,# & S51102,I36965,S11141,I46858,S16769,I68750,I61905,I38519,# & I38610,JH0289,I61903,I37523,I38437,I37529,I46030,I68712,# & JH0534,I36966,I37526,I61856,I84431,JH0535,I37528,S11135,# & I72170,I72029,I37482,I67483,I61864,A45831,S11139,I36961,# & JH0547,I37544,I46603,I59651,A45897,I84487,A45845,I61866,# & S44994,I72113,I56149,JH0526,I54418,A45847,I46604,I37135,# & A60369,B37028,A47636,S11134,S24438,I54307,S52486,S51100,# & I72218,S11140,I37478,JH0290,JH0545,I61865,S48134,I68701,# & I67482,JH0291,I37527,I37480,A49411,S03535,S11136,S11142,# & I54430,A45849,JH0546,S18198,I38436,I81231,C37028,I59188,# & I54449,JL0135,I83063,S01171,I72808,A45857,JH0536,I37492,# & I38505,I56039,A35997,I38518,A37028,S11137,I72171,JH0288,# & S42823,I56034)# & PIR3: (S06424,G02922)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DYIALNEDLRSWTAA*# SEQUENCE: DYIALNEDLRSWTAA*# ...# >HUM220FD# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-A alpha-chain# DB REFERENCE: SWISS: (1A34_HUMAN,1A26_HUMAN,1B02_HUMAN,1A03_HUMAN,1C03_HUMAN,# & 1A11_HUMAN,1A03_PANTR,1A01_HUMAN,1A04_PANTR,1CXX_HUMAN,# & 1C12_HUMAN,1A32_HUMAN,1A25_HUMAN,1C15_HUMAN,1A31_HUMAN,# & 1C02_HUMAN,1C06_HUMAN,1C04_GORGO,1C02_GORGO,1C07_HUMAN,# & 1B46_HUMAN,1C14_HUMAN,1B04_HUMAN,1C01_HUMAN,HA1B_RABIT,# & 1C01_GORGO,1C13_HUMAN,HA19_CANFA,1B39_HUMAN,1B34_HUMAN,# & 1C11_HUMAN,1B33_HUMAN,1A26_HUMAN,1C04_HUMAN,1C02_GORGO,# & 1A01_PONPY,1A31_HUMAN,HLAH_HUMAN,1A03_GORGO,1B35_HUMAN,# & 1C16_HUMAN,HLAH_HUMAN,1A30_HUMAN,1A01_SAGOE,1A80_HUMAN,# & 1A43_HUMAN,1C02_HUMAN,1A01_PANTR,1C17_HUMAN,1A02_GORGO,# & 1A33_HUMAN,1A36_HUMAN,1A74_HUMAN,1B20_HUMAN,1A01_GORGO,# & 1B38_HUMAN,1A29_HUMAN,1C01_PANTR,1A66_HUMAN,1C18_HUMAN,# & 1C03_GORGO,1B36_HUMAN,HA1A_RABIT,1C05_HUMAN,# & 1C01_SAGOE)# & PIR1: (HLHUW3,HLHUB7,HLHUA3,HLHU12,HLHU32,HLHUC4,HLHU40,HLRB,# & S42102)# & PIR2: (S24438,S52486,I37479,I37477,S11133,JH0544,S60601,I61906,# & I84432,JH0543,I54307,S48134,I37478,S51100,I72218,A37028,# & S42823,I72171,A35997,I38505,I37492,I38610,JH0289,I38519,# & I38439,I37476,I59622,I56116,I38507,JS0262,I36959,I37078,# & A47636,S11134,I46858,I36965,S11141,I68750,I61905,S16769,# & B37028,S01171,A45897,S03535,S11135,I37528,I84431,I72170,# & I37482,I61856,I37523,I37526,I61903,JH0534,I36966,I46603,# & I37544,I61866,I61864,A45847,I46604,I54418,I37135,S44994,# & I72113,I56149,JH0288,I81231,JL0135,I83063,I59188,I56053,# & A45849,JH0546,I38436,S11136,S11142,I54430,I68701,JH0291,# & A45831,I68712,I72029,I84487,A45845,I59655,I68747,I56039,# & I38518,I54449,I37480,I67482,I37527,A49411,I56034,C37028,# & S18198,S11137,A45857,JH0536,I72808,A60369,I59651,JH0526,# & JH0547,I36961,S11139,I67483,I38437,I37529,I46030,JH0535,# & S11140,JH0290,JH0545,I61865,I68749,I81232,I37483,I79640,# & S51102,S10934,JH0292,I36958)# & PIR3: (G02922,S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DYIALNEDLRSWT*# SEQUENCE: DYIALNEDLRSWT*# ...# >HUM220FE# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: Apolipoprotein B# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TPDFIVPLTDLRIPS*# SEQUENCE: TPDFIVPLTDLRIPS*# ...# >HUM220FF# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TPDFIVPLTDLRIP*# SEQUENCE: TPDFIVPLTDLRIP*# ...# >HUM22100# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,PDFIVPLTDLRIP*# SEQUENCE: PDFIVPLTDLRIP*# ...# >HUM22101# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,PDFIVPLTDLRIPSVQ*# SEQUENCE: PDFIVPLTDLRIPSVQ*# ...# >HUM22102# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FIVPLTDLRIPS*# SEQUENCE: FIVPLTDLRIPS*# ...# >HUM22103# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FQTPDFIVPLTDLRIPSVQI*# SEQUENCE: FQTPDFIVPLTDLRIPSVQI*# ...# >HUM22104# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EIKILNIFGVIKGFVEP*# SEQUENCE: EIKILNIFGVIKGFVEP*# ...# >HUM22105# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EIKILNIFGVIKGFVE*# SEQUENCE: EIKILNIFGVIKGFVE*# ...# >HUM22106# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IKILNIFGVIKGFVEPD*# SEQUENCE: IKILNIFGVIKGFVEPD*# ...# >HUM22107# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IKILNIFGVIKGFVEP*# SEQUENCE: IKILNIFGVIKGFVEP*# ...# >HUM22108# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,IKILNIFGVIKGFVE*# SEQUENCE: IKILNIFGVIKGFVE*# ...# >HUM22109# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cytoplasmic actin# DB REFERENCE: SWISS: (ACT_CHLRE,ACT_PHARH,ACT_AJECA,ACT5_DIPDE,ACT2_XENTR,# & ACTE_STRPU,ACT_VOLCA,ACT2_FUGRU,ACT_PUCGR,ACT3_LIMPO,# & ACT1_HELER,ACT3_DROME,ACT1_FUGRU,ACT1_ACACA,ACT2_LYTPI,# & ACT2_ARTSX,ACTF_STRPU,ACT8_DICDI,ACT4_CAEEL,ACTB_HUMAN,# & ACT8_DICDI,ACT2_DIPDE,ACT_CHLRE,ACTB_CRIGR,ACTD_STRPU,# & ACT_THELA,ACT_CANAL,ACT1_SCHMA,ACT_TAESO,ACT3_FUGRU,# & ACT2_BOMMO,ACT2_BACDO,ACT5_XENLA,ACT5_CHICK,ACT5_BACDO,# & ACT_SCHPO,ACT1_PODCA,ACT1_ABSGL,ACT_CYAME,ACTY_LIMPO,# & ACT1_XENLA,ACT3_PODCA,ACTM_APLCA,ACTA_LIMPO,ACT1_DROME,# & ACTC_PISOC,ACTA_LIMPO,ACTM_MOLOC,ACT_MANSE,ACTA_STRPU,# & ACTB_CYPCA,ACTA_PHYPO,ACT3_LIMPO,ACT1_ONCVO,ACTM_STYCL,# & ACTM_HELER,ACT4_ARTSX,ACTA_CHICK,ACT1_STRFN,ACT3_BACDO,# & ACT1_HELER,ACTG_EMENI,ACT1_HALRO,ACTM_PISOC,ACTG_HUMAN,# & ACT_SPOLI,ACT1_CAEEL,ACTM_HELER,ACT2_ECHGR,FGR_FSVGR,# & ACT3_DIPDE,ACT_KLULA,ACTY_LIMPO,ACT6_DROME,ACTM_HELTB,# & ACT1_PNECA,ACT2_DROME,ACT3_DIPDE,ACTM_STRPU,ACTB_STRPU,# & ACT3_BOMMO,ACT2_ABSGL,ACTB_RABIT,ACTC_FUGRU,ACTH_HUMAN,# & ACT5_DIPDE,ACT2_DIPDE,ACT2_LYTPI,ACTS_FUGRU,ACTT_FUGRU,# & ACTM_STYPL,ACT2_HALRO,ACT_HYDAT,ACTM_HELTB,ACT2_XENLA,# & ACTB_XENBO,ACTH_HUMAN,ACT3_XENLA,ACTS_HUMAN,ACT_YEAST,# & ACT2_SCHMA,ACT2_ONCVO,ACT_NEUCR,ACT_SCHPO,ACT_CRYNE,# & ACT1_ARTSX,ACTC_HALRO,ACTC_STRPU,ACTC_HUMAN,ACT_YEAST,# & ACT4_CAEEL,ACTS_CARAU,ACT2_CAEEL,ACT5_DROME,ACTA_HUMAN,# & ACTN_STYCL,ACTS_CYPCA,ACT8_XENLA,ACT1_DICDI,ACT_TRIRE,# & ACTM_MOLOC,ACT1_BOMMO)# & PIR1: (ATBOG,ATCHSM,ATHUSM,ATBOSM,ATCH,A48324,ATRB,ATRTC,# & A24904,A25719,ATRBSM,ATDO,ATAX,ATCHB,ATRT,ATMSB,ATFY,# & ATFF8,ATHUG,A23022,B29686,A43552,TVMVRR,ATBOB,S11222,# & ATHUB,ATMSG,ATRBB,ATBY,ATHUC,ATHU,ATURS,A22224,JS0702)# & PIR2: (S12730,B24848,S21907,A31375,A28258,A24848,JN0833,I49465,# & S16710,S16709,S27135,S09578,JT0385,S07251,S38782,S11450,# & A37431,S43509,S05430,A32788,A55001,S49481,S11453,A26559,# & A48449,B25819,S42103,JQ0154,A26836,S07639,JC1246,S49480,# & C43616,S04538,JS0190,A54728,JC4612,A29664,S09059,S11451,# & S03126,A03000,S03109,A25135,S08596,S07382,A43911,A32798,# & S49479,S14120,A40261,JS0189,A25084,S47897,JC5228,S33387,# & S01077,JN0832,JC5227,S07288,A61043,A29686)# & PIR3: (S70377,S71118,S71126,S71124,S71119,S71120,S71125,S65079,# & A44940)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,MGQKDSYVGDEAQSKR*# SEQUENCE: MGQKDSYVGDEAQSKR*# ...# >HUM2210A# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cytoplasmic actin# DB REFERENCE: SWISS: (ACT3_DICDI,ACT_CRYNE,ACT8_XENLA,ACT_PHARH,ACT4_CAEEL,# & ACT5_CHICK,ACT1_PODCA,ACT1_HELER,ACTC_HALRO,ACTB_CRIGR,# & ACTC_STYPL,ACT_ACHBI,ACTY_LIMPO,ACT3_PODCA,ACT1_PHYIN,# & ACTC_STRPU,ACT2_ONCVO,ACT1_LYTPI,ACT2_CAEEL,ACT1_DICDI,# & ACT_FUCVE,ACT4_CAEEL,ACT2_SCHMA,ACTM_STRPU,ACT5_DIPDE,# & ACTM_HELTB,ACT3_LIMPO,ACT_PUCGR,ACT8_DICDI,ACT8_DICDI,# & ACTM_HELER,ACTA_PHYPO,ACT4_ARTSX,ACT2_DIPDE,ACTF_STRPU,# & ACT1_PLAFA,ACT1_SCHMA,ACT3_FUGRU,ACTD_STRPU,ACT_FUCDI,# & ACT2_PLAFA,ACT_TAESO,ACT1_STRFN,ACT2_DICDI,ACT1_DROME,# & ACTA_LIMPO,ACT5_XENLA,ACTC_PISOC,ACTA_LIMPO,ACTM_APLCA,# & ACTB_CYPCA,ACT3_LIMPO,ACT1_ONCVO,ACT1_HELER,ACT1_ECHGR,# & ACT_TOXGO,ACT2_FUGRU,ACTE_STRPU,ACT1_NAEFO,ACT1_ACACA,# & ACT1_FUGRU,ACT2_DIPDE,ACT_TOXGO,ACT5_DIPDE,ACTB_HUMAN,# & ACT_COSCS,ACTB_XENBO,ACT1_NAEFO,ACT_FUCDI,ACT1_LYTPI,# & ACT_HYDAT,ACTB_RABIT,ACTM_HELTB,ACTY_LIMPO,ACT2_DROME,# & ACT3_DIPDE,ACT3_BOMMO,ACTG_HUMAN,ACT3_DIPDE,FGR_FSVGR,# & ACTM_PISOC,ACTM_HELER,ACT1_CAEEL,ACT2_ECHGR)# & PIR1: (A48324,ATMSG,ATRBB,TVMVRR,A43552,ATBOB,ATHUB,ATCHB,ATDO,# & ATAX,ATRTC,ATBOG,ATURS,S11222,ATHUG,ATFY,ATMSB)# & PIR2: (A29664,S09578,S27135,S16709,S08596,A25135,A03000,S07288,# & JC5227,S43509,S12730,JS0190,S49480,S07251,A48449,S49481,# & S11453,A26559,A54509,B23412,S42103,S24409,JS0189,A25084,# & S12628,S49479,C43616,JC5228,A54496,S05430,S38782,JE0414,# & S01077,JN0832,A55001,JQ0154,S33386,C23412,S24408,A28258,# & JN0833,S16710)# & PIR3: (S49007,S71126,S70377,S71125,S71124,A44940)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,TLKYPIEHGIVTNWDD*# SEQUENCE: TLKYPIEHGIVTNWDD*# ...# >HUM2210B# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cytoplasmic actin# DB REFERENCE: SWISS: (ACT8_DICDI,ACT3_LIMPO,ACT_PUCGR,ACT2_PHYIN,ACT5_DIPDE,# & ACT_ACECL,ACT_KLULA,ACT2_ABSGL,ACTM_STRPU,ACT8_XENLA,# & ACT4_CAEEL,ACT2_SCHMA,ACT2_CAEEL,ACT1_DICDI,ACT_FUCVE,# & ACTY_LIMPO,ACTC_STRPU,ACT_ACHBI,ACTC_STYPL,ACT4_ARTSX,# & ACTA_PHYPO,ACTM_HELER,ACT_YEAST,ACT1_CAEEL,ACT6_DIPDE,# & ACTM_PISOC,ACT_HYDAT,ACT1_LYTPI,ACTB_RABIT,ACT3_DIPDE,# & ACT_VOLCA,ACTG_HUMAN,ACT2_DROME,ACTM_HELTB,ACTY_LIMPO,# & ACT3_FUGRU,ACT2_PLAFA,ACTD_STRPU,ACT_TAESO,ACT1_SCHMA,# & ACT1_STRFN,ACT2_DICDI,ACTF_STRPU,ACT_CHLRE,ACTE_STRPU,# & ACT_LEIMA,ACT1_ECHGR,ACT1_HELER,ACT2_FUGRU,ACT_TOXGO,# & ACT5_DIPDE,ACT_FUCDI,ACT1_NAEFO,ACT2_DIPDE,ACT1_FUGRU,# & ACT1_ACACA,ACTB_HUMAN,ACT1_PLAFA,ACT2_TRYBB,ACT_TOXGO,# & ACT1_NAEFO,ACTB_XENBO,FGR_FSVGR,ACT3_DIPDE,ACT3_BOMMO,# & ACT1_LYTPI,ACT_PHYME,ACT2_DIPDE,ACT8_DICDI,ACT1_PHYIN,# & ACT3_PODCA,ACTM_HELTB,ACT1_TRYBB,ACT_PHARH,ACT4_CAEEL,# & ACT3_DICDI,ACT_CRYNE,ACTC_HALRO,ACTB_CRIGR,ACT1_DROME,# & ACTA_LIMPO,ACTM_APLCA,ACT_TRYCR,ACT_YEAST,ACT1_ONCVO,# & ACT1_HELER,ACT6_DIPDE,ACT3_LIMPO,ACTB_CYPCA,ACT1_ABSGL,# & ACTA_LIMPO,ACTC_PISOC,ACT_CYAME,ACT3_ECHGR,ACT5_XENLA,# & ACT1_PODCA,ACT5_CHICK,ACT_COSCS,ACT_CHLRE,ACTM_HELER,# & ACT2_ECHGR,ACT2_ONCVO,ACT_FUCDI)# & PIR1: (ATBOG,ATCHB,ATHUB,ATBOB,ATMSG,ATHUG,S11222,ATJN,ATDO,# & ATAX,ATRTC,TVMVRR,A43552,ATRBB,ATBY,ATMSB,ATFY,JS0702,# & A48324,ATURS)# & PIR2: (S33386,JE0415,JN0833,A03000,A25135,S07288,A32798,JC5227,# & A54496,S03109,A48449,A26559,JC5228,S14120,S08596,A54509,# & S11453,S49481,B23412,S42103,A25084,S12628,S49479,S24409,# & JS0189,S05430,S38782,B27724,JC4612,A28258,S16710,C23412,# & S24408,C43616,S09578,S27135,S16709,A29664,S12730,S39777,# & S43509,JN0832,S01077,JE0414,A27724,A55001,JQ0154,S49480,# & JS0190,S07251)# & PIR3: (S49007,S71124,S70377,S71126,S65079,S71125,A44940)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YPIEHGIVTNWDDM*# SEQUENCE: YPIEHGIVTNWDDM*# ...# >HUM2210C# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cytoplasmic actin# DB REFERENCE: SWISS: (ACT1_PODCA,ACT6_DIPDE,ACT5_DROME,ACTC_HALRO,ACT3_DIPDE,# & ACTB_XENBO,ACT_TOBAC,ACT8_DICDI,ACT5_DIPDE,ACT3_ARTSX,# & ACT1_STRFN,ACT_TAESO,ACTD_STRPU,ACT5_BACDO,ACT1_SCHMA,# & ACT3_ECHGR,ACTC_ARATH,ACTC_PISOC,ACT1_SORVU,ACT2_PEA,# & ACT3_LIMPO,ACTA_LIMPO,ACT_CHLRE,ACT2_SOLTU,ACT7_ARATH,# & ACT3_LIMPO,ACTB_CYPCA,ACT2_BACDO,ACT5_CHICK,ACT5_XENLA,# & ACT5_SOLTU,ACT_CHERU,ACT_COSCS,ACT3_PEA,ACT1_BOMMO,# & ACTM_HELER,ACT_CHLRE,ACT2_ECHGR,ACT4_ARATH,ACTD_PHYPO,# & ACT2_ONCVO,ACTC_ARATH,FGR_FSVGR,ACT3_PODCA,ACTB_STRPU,# & ACTA_LIMPO,ACT1_NAEFO,ACTB_HUMAN,ACT4_CAEEL,ACT8_XENLA,# & ACT2_LYTPI,ACT4_SOLTU,ACT2_PHYIN,ACTY_LIMPO,ACT_ACHBI,# & ACT1_PEA,ACTM_HELTB,ACT7_ARATH,ACTY_LIMPO,ACT1_DICDI,# & ACT1_NAEFO,ACT2_DIPDE,ACTB_ARATH,ACT2_DROME,ACT2_DAUCA,# & ACT2_CAEEL,ACT_FUCVE,ACT6_DIPDE,ACTM_PISOC,ACT3_DIPDE,# & ACT1_CAEEL,ACTG_HUMAN,ACT_VOLCA,ACT_HYDAT,ACT1_LYTPI,# & ACT_MANSE,ACT1_HELER,ACT1_ECHGR,ACT3_BACDO,ACT1_FUGRU,# & ACT1_ACACA,ACT3_FUGRU,ACTF_STRPU,ACTA_STRPU,ACTE_STRPU,# & ACT_TOXGO,ACT5_DIPDE,ACT2_FUGRU,ACT3_DROME,ACT3_SOLTU,# & ACTM_STRPU,ACT2_LYTPI,ACT4_CAEEL,ACT2_SCHMA,ACTM_HELER,# & ACT4_ARTSX,ACTC_STYPL,ACTA_PHYPO,ACTC_STRPU,ACT1_HELER,# & ACT2_NAEFO,ACT1_ONCVO,ACT1_AEDAE,ACT1_DROME,ACT_CRAVI,# & ACTM_STYPL,ACTB_ARATH,ACT4_ARATH,ACT_PHARH,ACTB_CRIGR,# & ACT2_ARATH,ACT1_PHYIN,ACT2_DIPDE,ACT6_DROME,ACT1_ORYSA,# & ACT8_DICDI,ACTM_HELTB,ACT_PHYME,ACT_SPOLI,ACT1_LYTPI,# & ACT1_SOLTU,ACT3_BOMMO,ACT4_DROME,ACT_TOXGO)# & PIR1: (A43552,S11222,ATHUB,TVMVRR,ATAX,ATHUG,ATFF8,ATRTC,ATRZ1,# & ATMSG,ATCHB,ATBOB,ATBOG,ATURS,A48324,ATFF7,ATFY,ATMSB,# & ATDO,ATJN)# & PIR2: (S38782,JC4612,S68109,S07288,JC5227,A25135,S07003,S16710,# & S24408,S09059,JS0190,JE0414,S33387,JN0832,S01077,S20097,# & A48449,A37431,S20096,A26559,S26435,JC5228,S33386,JN0833,# & JT0596,JS0189,S68107,A03000,S20094,S68108,S14120,S11452,# & B23412,A25084,S11453,S31933,JC1246,S25488,S43509,S27135,# & S09578,A29664,S47090,S24409,S04538,S20098,JQ0154,S16709,# & A55001,S49480,S49479,S49481,S58316,S68110,JE0415,# & S05430)# & PIR3: (S71124,S71126,S70377,S49007,S71125,A44940)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VAPEEHPVLLTEAPLNPKA*# SEQUENCE: VAPEEHPVLLTEAPLNPKA*# ...# >HUM2210D# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cytoplasmic actin# DB REFERENCE: SWISS: (ACTM_HELTB,ACTY_LIMPO,ACTY_LIMPO,ACT8_XENLA,ACT4_CAEEL,# & FGR_FSVGR,ACT5_DROME,ACT3_PODCA,ACTC_FUGRU,ACTH_HUMAN,# & ACTM_HELER,ACT2_ECHGR,ACT2_ONCVO,ACTT_FUGRU,ACT3_LIMPO,# & ACTB_CYPCA,ACT5_CHICK,ACT5_XENLA,ACTS_HUMAN,ACT2_XENLA,# & ACT2_DIPDE,ACT1_AEDAE,ACT1_ONCVO,ACT4_DROME,ACTB_CRIGR,# & ACT6_DROME,ACT2_DIPDE,ACT1_LYTPI,ACT3_DIPDE,ACTM_STYCL,# & ACTM_PISOC,ACTA_CHICK,ACT_HYDAT,ACT2_FUGRU,ACT1_FUGRU,# & ACT3_BACDO,ACTM_MOLOC,ACT2_DROME,ACT2_CAEEL,ACT2_LYTPI,# & ACTC_STYPL,ACTC_STRPU,ACT2_ARTSX,ACT_PHARH,ACT4_CAEEL,# & ACT2_SCHMA,ACTM_HELER,ACT3_DROME,ACT2_BOMMO,ACTB_RABIT,# & ACT1_DROME,ACT1_HELER,ACT_SPOLI,ACT2_XENTR,ACT_CRYNE,# & ACTS_FUGRU,ACTM_HELTB,ACT2_HALRO,ACT3_XENLA,ACTH_HUMAN,# & ACTM_APLCA,ACT2_BACDO,ACTB_STRPU,ACTA_LIMPO,ACTB_HUMAN,# & ACTS_CARAU,ACT5_DIPDE,ACTA_HUMAN,ACTN_STYCL,ACTS_CYPCA,# & ACT1_XENLA,ACT_MANSE,ACTA_STRPU,ACT1_HELER,ACT1_LYTPI,# & ACT3_LIMPO,ACT2_LYTPI,ACT1_PODCA,ACT3_DIPDE,ACTC_HUMAN,# & ACT1_STRFN,ACT1_ARTSX,ACT5_DIPDE,ACT3_FUGRU,ACT5_BACDO,# & ACT_TAESO,ACT1_SCHMA,ACTA_LIMPO,ACT4_ARTSX,ACTM_MOLOC,# & ACTC_HALRO,ACTB_XENBO,ACTC_PISOC,ACTG_HUMAN,ACT1_CAEEL,# & ACTD_STRPU,ACTF_STRPU,ACTE_STRPU)# & PIR1: (ATCHB,ATRT,ATHU,A22224,ATRBB,ATHUC,A24904,ATCH,A25719,# & ATMSB,ATFF7,ATBOG,ATURS,ATHUG,B29686,ATBOB,ATMSG,ATFF8,# & ATRTC,TVMVRR,ATHUSM,A48324,A23022,A43552,S11222,ATHUB,# & ATRB,ATRBSM,ATCHSM,ATBOSM)# & PIR2: (S33386,S11451,JC5228,A48449,A55001,I49465,A24848,A31375,# & S49479,A32788,S27135,S07251,S12730,JC5227,S49481,B25819,# & JS0190,A43911,S01077,JN0832,A40261,S16710,S11453,S08596,# & S43509,S09578,JQ0154,S07382,JN0833,JC1246,A03000,A54728,# & B24848,S21907,S05430,S11450,S04538,S07288,S38782,A61043,# & A29686,A28258,A26559,C43616,S16709,S49480,JS0189)# & PIR3: (S71124,A44940,S71120,S71125,S70377,S71118,S71119,# & S71126)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,AVFPSIVGRPRHQGVMV*# SEQUENCE: AVFPSIVGRPRHQGVMV*# ...# >HUM2210E# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig K variable region# DB REFERENCE: SWISS: (KV1K_HUMAN,KV1W_HUMAN)# & PIR1: (K1HUWK,K1HUKA)# & PIR2: (B49047,S21522,S21528,S11699,S24209,S46376,S34086,S21527,# & S47182,S36264,A27594,S34083,S40367,S34084,S16840,S40331,# & S24206,S42264,S36262,S46377)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KPGKAPKLLIYAASSL*# SEQUENCE: KPGKAPKLLIYAASSL*# ...# >HUM2210F# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig K variable region# DB REFERENCE: SWISS: (KV1W_HUMAN,KV1K_HUMAN)# & PIR1: (K1HUKA,K1HUWK)# & PIR2: (S34083,S40367,A27594,B49047,S36262,S11699,S46376,S24209,# & S36264,S34084,S46377,S16840,S21528,S21522,S47182,S21527,# & S34086,S24206,S42264,S40368,S40331)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,APKLLIYAASSL*# SEQUENCE: APKLLIYAASSL*# ...# >HUM22110# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-B alpha-chain (131-145)# DB REFERENCE: SWISS: (1B32_HUMAN,1B31_HUMAN,1B26_HUMAN)# & PIR2: (I54314,I61904,I59645,I38875,I84488,I54505,I38874,# & I68850)# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GRLLRGHNQFAYDGK*# SEQUENCE: GRLLRGHNQFAYDGK*# ...# >HUM22111# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B26_HUMAN,1B32_HUMAN,1B31_HUMAN)# & PIR2: (I84488,I38875,I68850,I54505,I38874,I54314,I61904,# & I59645)# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GPDGRLLRGHNQFAYDGK*# SEQUENCE: GPDGRLLRGHNQFAYDGK*# ...# >HUM22112# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain (128-146)# DB REFERENCE: SWISS: (1B32_HUMAN,1B31_HUMAN,1B26_HUMAN)# & PIR2: (I68850,I54505,I54314,I38875,I84488,I61904,I59645,# & I38874)# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GPDGRLLRGHNQFAYDGKD*# SEQUENCE: GPDGRLLRGHNQFAYDGKD*# ...# >HUM22113# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B31_HUMAN,1B32_HUMAN,1B26_HUMAN)# & PIR2: (I38875,I68850,I61904,I59645,I38874,I84488,I54505,# & I54314)# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GPDGRLLRGHNQFAYDG*# SEQUENCE: GPDGRLLRGHNQFAYDG*# ...# >HUM22114# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B alpha-chain# DB REFERENCE: SWISS: (1B31_HUMAN,1B32_HUMAN,1B26_HUMAN)# & PIR2: (I84488,I54505,I68850,I61904,I59645,I54314,I38874,# & I38875)# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GPDGRLLRGHNQFAYDGKDY*# SEQUENCE: GPDGRLLRGHNQFAYDGKDY*# ...# >HUM22115# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: Invariant chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,MHHWLLFEMSRHSLE*# SEQUENCE: MHHWLLFEMSRHSLE*# ...# >HUM22116# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,HHWLLFEMSRHSLE*# SEQUENCE: HHWLLFEMSRHSLE*# ...# >HUM22117# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,WLLFEMSRHSLEQKP*# SEQUENCE: WLLFEMSRHSLEQKP*# ...# >HUM22118# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Low-affinity IgE Fc receptor# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SPEEQDFLTKHASHTGSWIG*# SEQUENCE: SPEEQDFLTKHASHTGSWIG*# ...# >HUM22119# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Low-affinity IgE Fc receptor# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EQDFLTKHASHTGSWIG*# SEQUENCE: EQDFLTKHASHTGSWIG*# ...# >HUM2211A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, high# SOURCE: Low-affinity IgE Fc receptor# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,QDFLTKHASHTGSWIG*# SEQUENCE: QDFLTKHASHTGSWIG*# ...# >HUM2211B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD48# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FDQKIVEWDSRKSKYF*# SEQUENCE: FDQKIVEWDSRKSKYF*# ...# >HUM2211C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD48# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FDQKIVEWDSRKSKYFE*# SEQUENCE: FDQKIVEWDSRKSKYFE*# ...# >HUM2211D# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD48# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FDQKIVEWDSRKSKYFES*# SEQUENCE: FDQKIVEWDSRKSKYFES*# ...# >HUM2211E# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD48# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FDQKIVEWDSRKSK*# SEQUENCE: FDQKIVEWDSRKSK*# ...# >HUM2211F# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD48# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DQKIVEWDSRKSKYFE*# SEQUENCE: DQKIVEWDSRKSKYFE*# ...# >HUM22120# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CD48# DB REFERENCE: SWISS: (BCM1_HUMAN,BCM1_HUMAN)# & PIR2: (A53244)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DQKIVEWDSRKSKYF*# SEQUENCE: DQKIVEWDSRKSKYF*# ...# >HUM22121# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glyceraldehyde 3-phosphate dehydrogenase GAPDH (11-23)# DB REFERENCE: SWISS: (G3P_PIG,G3P_BOVIN,G3P_RABIT,G3P2_JACOR,G3P1_JACOR,# & G3P_PIG,G3P2_HUMAN,G3P1_JACOR,G3P_BOVIN,G3P_RABIT,# & G3P2_JACOR,G3P1_HUMAN)# & PIR1: (DEHUG3,DEPGG3)# & PIR2: (A12055,JC4309)# & PIR3: (S62673,S62674)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FGRIGRLVTRAAFN*# SEQUENCE: FGRIGRLVTRAAFN*# ...# >HUM22122# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glyceraldehyde 3-phosphate dehydrogenase# DB REFERENCE: SWISS: (G3P_PIG,G3P_RABIT,G3P2_JACOR,G3P_BOVIN,G3P2_JACOR,# & G3P1_JACOR,G3P2_HUMAN,G3P_PIG,G3P1_HUMAN,G3P_BOVIN,# & G3P_RABIT,G3P1_JACOR)# & PIR1: (DEPGG3,DEHUG3)# & PIR2: (JC4309,A12055)# & PIR3: (S62673,S62674)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FGRIGRLVTRAAFNS*# SEQUENCE: FGRIGRLVTRAAFNS*# ...# >HUM22123# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glyceraldehyde 3-phosphate dehydrogenase GAPDH (11-25)# DB REFERENCE: SWISS: (G3P2_JACOR,G3P_PIG,G3P_BOVIN,G3P1_HUMAN,G3P_BOVIN,# & G3P1_JACOR,G3P2_HUMAN,G3P_RABIT,G3P2_JACOR,G3P1_JACOR,# & G3P_RABIT,G3P_PIG)# & PIR1: (DEHUG3,DEPGG3)# & PIR2: (A12055,JC4309)# & PIR3: (S62673,S62674)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FGRIGRLVTRAAFNSG*# SEQUENCE: FGRIGRLVTRAAFNSG*# ...# >HUM22124# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glyceraldehyde 3-phosphate dehydrogenase GAPDH (10-25)# DB REFERENCE: SWISS: (G3P_RABIT,G3P_BOVIN,G3P1_JACOR,G3P_PIG,G3P_PIG,# & G3P_BOVIN,G3P2_HUMAN,G3P_RABIT,G3P2_JACOR,G3P1_HUMAN,# & G3P1_JACOR,G3P2_JACOR)# & PIR1: (DEHUG3,DEPGG3)# & PIR2: (JC4309,A12055)# & PIR3: (S62674,S62673)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GFGRIGRLVTRAAFNSG*# SEQUENCE: GFGRIGRLVTRAAFNSG*# ...# >HUM22125# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glyceraldehyde 3-phosphate dehydrogenase# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GFGRIGRLVTRAAFNSGR*# SEQUENCE: GFGRIGRLVTRAAFNSGR*# ...# >HUM22126# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: eluted self peptides HPLC/Edman degradation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glyceraldehyde 3-phosphate dehydrogenase# DB REFERENCE: SWISS: (G3P_BOVIN,G3P1_JACOR,G3P1_HUMAN,G3P_PIG,G3P_PIG,# & G3P_RABIT,G3P2_HUMAN,G3P_BOVIN,G3P1_JACOR,G3P_RABIT)# & PIR1: (DEHUG3,DEPGG3)# & PIR2: (JC4309,A12055)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GFGRIGRLVTRAAFNSGKVD*# SEQUENCE: GFGRIGRLVTRAAFNSGKVD*# ...# >HUM22127# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ig K# DB REFERENCE: SWISS: (KV3I_HUMAN)# & PIR1: (K3HUVG)# & PIR2: (S40360,S37516,S37522,S34102,S29627,S11697,PN0537,A56701,# & S16833,S16824,S16837,S16830,S23628,S16829,G44151,S40344,# & S37506,S16826,PL0106)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,LIYDASNRAT*# SEQUENCE: LIYDASNRAT*# ...# >HUM22128# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HIDYNFVKAINAIQKSWT*# SEQUENCE: HIDYNFVKAINAIQKSWT*# ...# >HUM22129# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Cathepsin C# DB REFERENCE: SWISS: (CATC_HUMAN)# & PIR2: (S66504)# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,NFVKAINAIQ*# SEQUENCE: NFVKAINAIQ*# ...# >HUM2212A# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ig K# DB REFERENCE: PIR2: (S37506)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KPGQPPRLLIYDASNRATGIPA*# SEQUENCE: KPGQPPRLLIYDASNRATGIPA*# ...# >HUM2212B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,HIDYNFVKAINAIQKSWT*# SEQUENCE: HIDYNFVKAINAIQKSWT*# ...# >HUM2212C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,HDYNFVKAINAIQKSW*# SEQUENCE: HDYNFVKAINAIQKSW*# ...# >HUM2212D# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ig K# DB REFERENCE: PIR2: (S37506)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KPGQPPRLLIYDASNRATGIPA*# SEQUENCE: KPGQPPRLLIYDASNRATGIPA*# ...# >HUM2212E# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HIDYNFVKAINAIQKSWT*# SEQUENCE: HIDYNFVKAINAIQKSWT*# ...# >HUM2212F# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HDYNFVKAINAIQKSW*# SEQUENCE: HDYNFVKAINAIQKSW*# ...# >HUM22130# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-A# DB REFERENCE: SWISS: (1A01_PANTR,1A66_HUMAN,1A69_HUMAN,1A31_HUMAN,1A01_PONPY,# & 1A03_GORGO,1A30_HUMAN,1A04_GORGO,1A23_HUMAN,1A02_HUMAN,# & 1A24_HUMAN,1A29_HUMAN,1A26_HUMAN,1A02_GORGO,1A25_HUMAN,# & 1A32_HUMAN,1A68_HUMAN,1A74_HUMAN,1A33_HUMAN,1A02_HUMAN,# & 1A03_HUMAN,1A04_PANTR,1A03_PANTR,1A11_HUMAN,1A31_HUMAN,# & 1A34_HUMAN,1A01_GORGO,1A43_HUMAN,1A26_HUMAN)# & PIR1: (HLHUAW,HLHU28,HLHU69,HLHUA2,HLHU32,HLHUA3)# & PIR2: (I54416,JH0537,S51099,I37477,I37479,I84432,I37476,I84448,# & I36959,I61857,JH0536,I37470,S18198,I36965,S16769,A47636,# & I38441,I84487,I56039,I54307,I54493,I72171,I37542,JL0135,# & I61902,A45847,JH0534,S03535,I72170,I37482,I38436,S01171,# & I38443,I37480,A35997,A37028,I83063,I36966,JH0535,I36961,# & I37483,I38610,I38519)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VDDTQFVRFDSDAASQRME*# SEQUENCE: VDDTQFVRFDSDAASQRME*# ...# >HUM22131# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-A# DB REFERENCE: SWISS: (1A03_PANTR,1A04_PANTR,1A03_HUMAN,1A11_HUMAN,1A74_HUMAN,# & 1A33_HUMAN,1A02_HUMAN,1A43_HUMAN,1A26_HUMAN,1A34_HUMAN,# & 1A31_HUMAN,1A01_GORGO,1A68_HUMAN,1A69_HUMAN,1A31_HUMAN,# & 1A26_HUMAN,1A32_HUMAN,1A25_HUMAN,1A02_GORGO,1A29_HUMAN,# & 1A23_HUMAN,1A24_HUMAN,1A02_HUMAN,1A30_HUMAN,1A03_GORGO,# & 1A01_PONPY,1A01_PANTR,1A04_GORGO,1A66_HUMAN)# & PIR1: (HLHUA3,HLHU28,HLHUA2,HLHUAW,HLHU32,HLHU69)# & PIR2: (JH0535,I37483,I36961,I83063,I36966,A35997,I72170,I37482,# & I54307,I37542,S51099,I37476,JH0536,I54493,A45847,JL0135,# & I61902,S03535,JH0534,I72171,JH0537,I54416,I84432,I37479,# & I37477,I61857,I84448,I36959,I37480,I38436,S01171,I38443,# & I38610,I38519,I56039,A37028,I84487,I38441,S18198,I37470,# & A47636,I36965,S16769)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,DTQFVRFDSDAASQR*# SEQUENCE: DTQFVRFDSDAASQR*# ...# >HUM22132# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ig K# DB REFERENCE: PIR2: (S37506)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KPGQPPRLLIYDASNRATGIPA*# SEQUENCE: KPGQPPRLLIYDASNRATGIPA*# ...# >HUM22133# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HIDYNFVKAINAIQKSWT*# SEQUENCE: HIDYNFVKAINAIQKSWT*# ...# >HUM22134# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Cathepsin C# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,HDYNFVKAINAIQKSW*# SEQUENCE: HDYNFVKAINAIQKSW*# ...# >HUM22135# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A# DB REFERENCE: SWISS: (1A30_HUMAN,1A03_GORGO,1A04_GORGO,1A01_PANTR,1A01_PONPY,# & 1A23_HUMAN,1A02_HUMAN,1A24_HUMAN,1A31_HUMAN,1A34_HUMAN,# & 1A02_GORGO,1A29_HUMAN,1A25_HUMAN,1A26_HUMAN,1A43_HUMAN,# & 1A01_GORGO,1A31_HUMAN,1A69_HUMAN,1A68_HUMAN,1A11_HUMAN,# & 1A74_HUMAN,1A33_HUMAN,1A02_HUMAN,1A04_PANTR,1A03_PANTR,# & 1A03_HUMAN,1A66_HUMAN,1A26_HUMAN,1A32_HUMAN)# & PIR1: (HLHUA3,HLHUA2,HLHU69,HLHUAW,HLHU32,HLHU28)# & PIR2: (I37470,S18198,S16769,I38441,I37477,I61857,I36965,I84448,# & S03535,I61902,I56039,A37028,I38610,I38443,S01171,I54307,# & I37542,I72170,I37482,S51099,JH0536,I37480,I83063,A35997,# & I37483,JH0535,I54493,A45847,JL0135,I37476,I38519,I84487,# & A47636,JH0537,I54416,I37479,I84432,I36959,I72171,JH0534,# & I36961,I36966,I38436)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,VDDTQFVRFDSDAASQRME*# SEQUENCE: VDDTQFVRFDSDAASQRME*# ...# >HUM22136# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-A# DB REFERENCE: SWISS: (1A31_HUMAN,1A03_PANTR,1A30_HUMAN,1A03_GORGO,1A01_PANTR,# & 1A04_GORGO,1A66_HUMAN,1A04_PANTR,1A02_HUMAN,1A03_HUMAN,# & 1A32_HUMAN,1A26_HUMAN,1A33_HUMAN,1A11_HUMAN,1A69_HUMAN,# & 1A02_HUMAN,1A25_HUMAN,1A68_HUMAN,1A74_HUMAN,1A31_HUMAN,# & 1A34_HUMAN,1A01_GORGO,1A43_HUMAN,1A29_HUMAN,1A02_GORGO,# & 1A24_HUMAN,1A26_HUMAN,1A01_PONPY,1A23_HUMAN)# & PIR1: (HLHU28,HLHU69,HLHUA3,HLHUA2,HLHUAW,HLHU32)# & PIR2: (I83063,I38441,I56039,I37470,I54307,I84487,JH0534,I84432,# & I36965,I61902,JL0135,I38519,I36966,I36961,I38436,I37476,# & I72171,JH0537,I37479,I54416,I36959,A47636,A45847,I54493,# & A35997,JH0535,I37483,I37542,I37482,I72170,JH0536,S51099,# & I37480,S03535,I37477,I61857,S16769,I84448,S18198,I38443,# & S01171,A37028,I38610)# & PIR3: (S06424)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DTQFVRFDSDAASQR*# SEQUENCE: DTQFVRFDSDAASQR*# ...# >HUM22137# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Apolipoprotein B# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,TPDFIVPLTDLRIPS*# SEQUENCE: TPDFIVPLTDLRIPS*# ...# >HUM22138# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-DR alpha chain# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,LANIAVDKANLEIMTRR*# SEQUENCE: LANIAVDKANLEIMTRR*# ...# >HUM22139# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-DR alpha chain# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,LANIAVDKANLEIMTRR*# SEQUENCE: LANIAVDKANLEIMTRR*# ...# >HUM2213A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Apolipoprotein B# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,TPDFIVPLTDLRIPS*# SEQUENCE: TPDFIVPLTDLRIPS*# ...# >HUM2213B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-DR alpha chain# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,LANIAVDKANLEIMTRR*# SEQUENCE: LANIAVDKANLEIMTRR*# ...# >HUM2213C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Actin# DB REFERENCE: SWISS: (ACT3_LIMPO,ACT_YEAST,ACT_TRYCR,ACT2_TRYBB,ACT1_LYTPI,# & ACT2_SCHMA,ACT1_NAEFO,ACT_CHLRE,ACT5_DIPDE,ACT_CRYNE,# & ACTM_HELTB,ACTB_RABIT,ACT1_DICDI,ACT1_DROME,ACT_ACHBI,# & ACT2_PHYIN,ACT1_TRYBB,ACT1_NAEFO,ACTA_LIMPO,ACTB_HUMAN,# & ACTB_CRIGR,ACT_FUCVE,ACT_FUCDI,ACT_PHARH,ACT6_DIPDE,# & ACT_VOLCA,ACT2_DROME,ACT1_ACACA,ACT2_CAEEL,ACT2_DIPDE,# & ACT1_LYTPI,ACT2_ECHGR,ACT2_ONCVO,ACTM_STRPU,ACTM_HELTB,# & ACTY_LIMPO,ACT3_LIMPO,ACT3_PODCA,ACT2_ABSGL,FGR_FSVGR,# & ACT8_DICDI,ACT_KLULA,ACT_PHYME,ACT4_CAEEL,ACT8_XENLA,# & ACT3_BOMMO,ACT_PUCGR,ACTA_LIMPO,ACT1_STRFN,ACT2_DICDI,# & ACT1_FUGRU,ACT5_DIPDE,ACT1_ECHGR,ACT1_PODCA,ACT_CHLRE,# & ACT3_DIPDE,ACT4_ARTSX,ACTG_HUMAN,ACTF_STRPU,ACTC_PISOC,# & ACTC_HALRO,ACT6_DIPDE,ACTA_PHYPO,ACT1_ONCVO,ACT_LEIMA,# & ACTC_STRPU,ACTC_STYPL,ACT1_PHYIN,ACT_ACECL,ACT_COSCS,# & ACTY_LIMPO,ACT5_CHICK,ACT2_DIPDE,ACTM_APLCA,ACT1_HELER,# & ACTB_XENBO,ACT1_PLAFA,ACT1_HELER,ACTM_HELER,ACT1_SCHMA,# & ACT_CYAME,ACT1_ABSGL,ACT2_FUGRU,ACT2_PLAFA,ACT3_DIPDE,# & ACTM_PISOC,ACT_TOXGO,ACT_HYDAT,ACT_TOXGO,ACT_FUCDI,# & ACT4_CAEEL,ACT3_ECHGR,ACT_TAESO,ACT3_FUGRU,ACTD_STRPU,# & ACTE_STRPU,ACT1_CAEEL,ACT8_DICDI,ACTM_HELER,ACTB_CYPCA,# & ACT5_XENLA,ACT_YEAST,ACT3_DICDI)# & PIR1: (ATMSG,ATAX,ATRTC,ATHUG,TVMVRR,ATRBB,ATFY,ATURS,ATBOB,# & A48324,JS0702,ATHUB,S11222,ATBY,ATDO,ATCHB,ATJN,ATMSB,# & ATBOG,A43552)# & PIR2: (S07288,JE0414,S38782,S39777,A26559,A28258,JN0832,JS0190,# & S16710,S43509,S12628,A25084,A54509,S01077,A27724,JS0189,# & JC4612,S16709,A25135,S05430,S12730,S07251,A03000,B27724,# & A54496,JC5227,JQ0154,JN0833,JC5228,S33386,A55001,S24409,# & S03109,S49481,S42103,S11453,S14120,C23412,S49480,S24408,# & C43616,A29664,S09578,S08596,B23412,S49479,JE0415,A48449,# & A32798,S27135)# & PIR3: (A44940,S71124,S65079,S71125,S71126,S70377,S49007)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YPIEHGIVTNWDDM*# SEQUENCE: YPIEHGIVTNWDDM*# ...# >HUM2213D# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-DR alpha chain# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,LANIAVDKANLEIMTRR*# SEQUENCE: LANIAVDKANLEIMTRR*# ...# >HUM2213E# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-DR alpha chain# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,DKANLEIMTKR*# SEQUENCE: DKANLEIMTKR*# ...# >HUM2213F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ii chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,MHHWLLFEMSRHSLE*# SEQUENCE: MHHWLLFEMSRHSLE*# ...# >HUM22140# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-B# DB REFERENCE: SWISS: (1B32_HUMAN,1B31_HUMAN,1B26_HUMAN)# & PIR2: (I68850,I59645,I61904,I38874,I54505,I84488,I38875,# & I54314)# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GRLLRGHNQFAYDGK*# SEQUENCE: GRLLRGHNQFAYDGK*# ...# >HUM22141# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ii chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,MHHWLLFEMSRHSLE*# SEQUENCE: MHHWLLFEMSRHSLE*# ...# >HUM22142# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-B# DB REFERENCE: SWISS: (1B32_HUMAN,1B26_HUMAN,1B31_HUMAN)# & PIR2: (I84488,I68850,I54314,I38875,I54505,I38874,I61904,# & I59645)# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GRLLRGHNQFAYDGK*# SEQUENCE: GRLLRGHNQFAYDGK*# ...# >HUM22143# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ii chain# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,MHHWLLFEMSRHSLE*# SEQUENCE: MHHWLLFEMSRHSLE*# ...# >HUM22144# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae# DB REFERENCE: SWISS: (18KD_MYCLE)# & PIR2: (A27586)# REFERENCES: kirschmann95a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDLPGIK*# SEQUENCE: EEFVVEFDLPGIK*# ...# >HUM22145# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AEFVVEFDLPGIK*# SEQUENCE: AEFVVEFDLPGIK*# ...# >HUM22146# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EAFVVEFDLPGIK*# SEQUENCE: EAFVVEFDLPGIK*# ...# >HUM22147# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFAVEFDLPGIK*# SEQUENCE: EEFAVEFDLPGIK*# ...# >HUM22148# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVAEFDLPGIK*# SEQUENCE: EEFVAEFDLPGIK*# ...# >HUM22149# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVAFDLPGIK*# SEQUENCE: EEFVVAFDLPGIK*# ...# >HUM2214A# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEADLPGIK*# SEQUENCE: EEFVVEADLPGIK*# ...# >HUM2214B# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEFALPGIK*# SEQUENCE: EEFVVEFALPGIK*# ...# >HUM2214C# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDAPGIK*# SEQUENCE: EEFVVEFDAPGIK*# ...# >HUM2214D# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEFDLAGIK*# SEQUENCE: EEFVVEFDLAGIK*# ...# >HUM2214E# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDLPAIK*# SEQUENCE: EEFVVEFDLPAIK*# ...# >HUM2214F# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDLPGAK*# SEQUENCE: EEFVVEFDLPGAK*# ...# >HUM22150# MHC MOLECULE: HLA-DR4(DRB1*0404), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDLPGIA*# SEQUENCE: EEFVVEFDLPGIA*# ...# >HUM22151# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as./binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae# DB REFERENCE: SWISS: (18KD_MYCLE)# & PIR2: (A27586)# REFERENCES: kirschmann95a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEFDLPGIK*# SEQUENCE: EEFVVEFDLPGIK*# ...# >HUM22152# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,AEFVVEFDLPGIK*# SEQUENCE: AEFVVEFDLPGIK*# ...# >HUM22153# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EAFVVEFDLPGIK*# SEQUENCE: EAFVVEFDLPGIK*# ...# >HUM22154# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFAVEFDLPGIK*# SEQUENCE: EEFAVEFDLPGIK*# ...# >HUM22155# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVAEFDLPGIK*# SEQUENCE: EEFVAEFDLPGIK*# ...# >HUM22156# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVAFDLPGIK*# SEQUENCE: EEFVVAFDLPGIK*# ...# >HUM22157# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEADLPGIK*# SEQUENCE: EEFVVEADLPGIK*# ...# >HUM22158# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEFALPGIK*# SEQUENCE: EEFVVEFALPGIK*# ...# >HUM22159# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,EEFVVEFDAPGIK*# SEQUENCE: EEFVVEFDAPGIK*# ...# >HUM2215A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,EEFVVEFDLAGIK*# SEQUENCE: EEFVVEFDLAGIK*# ...# >HUM2215B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EEFVVEFDLPAIK*# SEQUENCE: EEFVVEFDLPAIK*# ...# >HUM2215C# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,EEFVVEFDLPGAK*# SEQUENCE: EEFVVEFDLPGAK*# ...# >HUM2215D# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae homologue# ANCHOR POSITIONS:# REFERENCES: kirschmann95a,woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEFDLPGIA*# SEQUENCE: EEFVVEFDLPGIA*# ...# >MUS2215E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: CPH (362-382)# DB REFERENCE: SWISS: (CBPH_MOUSE,CBPH_RAT)# & PIR2: (S16383,S12461,A40469)# REFERENCES: carrasco-marin96a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,KNSLINYLEQIHRGVKGFVR*# SEQUENCE: KNSLINYLEQIHRGVKGFVR*# ...# >MUS2215F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: CPH (440-464)# ANCHOR POSITIONS:# REFERENCES: carrasco-marin96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YFSPAVGVDFELESFSERKEEEKEEL*# SEQUENCE: YFSPAVGVDFELESFSERKEEEKEEL*# ...# >MUS22160# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: GAD (524-543)# DB REFERENCE: SWISS: (DCE2_MOUSE,DCE2_HUMAN,DCE2_RAT)# & PIR1: (JH0423,A41292,S38533)# REFERENCES: carrasco-marin96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,SRLSKVAPVIKARMMEYGT*# SEQUENCE: SRLSKVAPVIKARMMEYGT*# ...# >MUS22161# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSP (437-460)# ANCHOR POSITIONS:# REFERENCES: carrasco-marin96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YVLGGGCALLRCIPALDSLTPANED*# SEQUENCE: YVLGGGCALLRCIPALDSLTPANED*# ...# >MUS22162# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA (323-339)# ANCHOR POSITIONS:# REFERENCES: carrasco-marin96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,ISQAVHAAHAEINEAGRY*# SEQUENCE: ISQAVHAAHAEINEAGRY*# ...# >MUS22163# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: OVA homologue# ANCHOR POSITIONS:# REFERENCES: carrasco-marin96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YTYTVHAAHAYTYT*# SEQUENCE: YTYTVHAAHAYTYT*# ...# >MUS22164# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin (55-68)# ANCHOR POSITIONS:# REFERENCES: carrasco-marin96a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,GHNFVTAIRNQQEG*# SEQUENCE: GHNFVTAIRNQQEG*# ...# >HUM22165# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: OVA (258-276)# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,IINFEKLTEWTSSNVMEERY*# SEQUENCE: IINFEKLTEWTSSNVMEERY*# ...# >HUM22166# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (264-276)# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,LTEWTSSNVMEERY*# SEQUENCE: LTEWTSSNVMEERY*# ...# >HUM22167# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (266-274)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,EWTSSNVMEE*# SEQUENCE: EWTSSNVMEE*# ...# >HUM22168# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (266-273)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,EWTSSNVME*# SEQUENCE: EWTSSNVME*# ...# >HUM22169# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMEERY*# SEQUENCE: WTSSNVMEERY*# ...# >HUM2216A# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,ATSSNVMEERY*# SEQUENCE: ATSSNVMEERY*# ...# >HUM2216B# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WASSNVMEERY*# SEQUENCE: WASSNVMEERY*# ...# >HUM2216C# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTASNVMEERY*# SEQUENCE: WTASNVMEERY*# ...# >HUM2216D# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSANVMEERY*# SEQUENCE: WTSANVMEERY*# ...# >HUM2216E# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WTSSAVMEERY*# SEQUENCE: WTSSAVMEERY*# ...# >HUM2216F# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVAEERY*# SEQUENCE: WTSSNVAEERY*# ...# >HUM22170# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMAERY*# SEQUENCE: WTSSNVMAERY*# ...# >HUM22171# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMEEAY*# SEQUENCE: WTSSNVMEEAY*# ...# >HUM22172# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMEERA*# SEQUENCE: WTSSNVMEERA*# ...# >HUM22173# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,AAAAAVAAEAY*# SEQUENCE: AAAAAVAAEAY*# ...# >HUM22174# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMEER*# SEQUENCE: WTSSNVMEER*# ...# >HUM22175# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMEERL*# SEQUENCE: WTSSNVMEERL*# ...# >HUM22176# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,WTSSNVMEERM*# SEQUENCE: WTSSNVMEERM*# ...# >HUM22177# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMEERS*# SEQUENCE: WTSSNVMEERS*# ...# >HUM22178# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNAMEERY*# SEQUENCE: WTSSNAMEERY*# ...# >HUM22179# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNKMEERY*# SEQUENCE: WTSSNKMEERY*# ...# >HUM2217A# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,WTSSNEMEERY*# SEQUENCE: WTSSNEMEERY*# ...# >HUM2217B# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMELRY*# SEQUENCE: WTSSNVMELRY*# ...# >HUM2217C# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMEARY*# SEQUENCE: WTSSNVMEARY*# ...# >HUM2217D# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,WTSSNVMEKRY*# SEQUENCE: WTSSNVMEKRY*# ...# >HUM2217E# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA (267-276) homologue# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WTSSNVMEDRY*# SEQUENCE: WTSSNVMEDRY*# ...# >HUM2217F# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. bovis 65 kDa (243-255)# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,KPLLIIAEDVEGEY*# SEQUENCE: KPLLIIAEDVEGEY*# ...# >HUM22180# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA class I alpha (46-60)# DB REFERENCE: SWISS: (1B59_HUMAN,1B38_HUMAN,1B32_HUMAN,1B63_HUMAN,1B45_HUMAN,# & 1B35_HUMAN,1B57_HUMAN,1B04_HUMAN,1A11_HUMAN,1B40_HUMAN,# & 1A03_PANTR,1A04_PANTR,1B02_HUMAN,1B13_HUMAN,1B41_HUMAN,# & 1B14_HUMAN,1A74_HUMAN,1B29_HUMAN,1A68_HUMAN,1B18_HUMAN,# & 1B53_HUMAN,1B07_HUMAN,1B24_HUMAN,1B27_HUMAN,1B28_HUMAN,# & 1B47_HUMAN,1B36_HUMAN,1B01_GORGO,1A29_HUMAN,1B62_HUMAN,# & 1B03_GORGO,1B54_HUMAN,1A26_HUMAN,1B23_HUMAN,1A24_HUMAN,# & 1B01_PANTR,1A43_HUMAN,1A01_GORGO,1A34_HUMAN,1B19_HUMAN,# & 1A25_HUMAN,1B49_HUMAN,1B43_HUMAN,1B39_HUMAN,1B46_HUMAN,# & 1B08_HUMAN,1B48_HUMAN,1B31_HUMAN,1B58_HUMAN,1A32_HUMAN,# & 1B26_HUMAN,1A69_HUMAN,1B21_HUMAN,1B25_HUMAN,1A33_HUMAN,# & 1B33_HUMAN,1B42_HUMAN,1B34_HUMAN,1A02_HUMAN,1A26_HUMAN,# & 1B02_GORGO,1B15_HUMAN,1A03_HUMAN,1A01_HUMAN,1B11_HUMAN,# & 1A02_PANTR,1A02_HUMAN,1A66_HUMAN,1B02_PANTR,1B22_HUMAN,# & 1A01_PANTR,1B52_HUMAN,1A23_HUMAN,1B56_HUMAN,1A36_HUMAN,# & 1B20_HUMAN)# & PIR1: (HLHUAW,HLHU69,HLHUB7,HLHU28,HLHUB2,HLHUA3,HLHUA2,HLHU32,# & HLHU40,S42102,HLHUB8,HLHUB4)# & PIR2: (I68701,S24434,I37542,S03538,I37482,I37492,I37520,S24437,# & I37480,I59645,I37478,A35997,I56133,I72754,I37483,B30345,# & A45847,JH0540,I36957,I84431,I61859,I68724,I84448,I84488,# & I61856,S16769,I37475,I37477,I61864,I80176,S16789,S01171,# & S03537,I38610,I68850,A37028,I37522,I38860,JH0541,I38441,# & I56116,I36966,I80174,I38436,I54314,S24438,I37515,I54505,# & S52486,A45834,I80168,I72752,I81233,S60601,I72171,I37485,# & I37479,I36959,A47636,I80169,I61860,I54463,I37120,I83063,# & I61865,JL0135,I38442,I61902,I36965,I38509,I37516,I54457,# & S24439,I38518,I36962,I80171,I54298,A45880,I84487,I68747,# & I59655,S24435,JH0534,I61861,I56149,I54308,S24436,I38437,# & I54307,I72755,I68774,I61906,I84490,S24440,I38876,I36956,# & I37470,C35997,I59651,I36961,I38875,I61905,S03535,I61903,# & I37519,S25415,I61907,I54418,I61857,I61904,I59188,I38443,# & I54493,I80170,JH0539,I38874,I72753,S51099,A30345,I59633,# & I54416,I61862)# & PIR3: (S06424,S07113)# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,EPRAPWIEQEGPEYW*# SEQUENCE: EPRAPWIEQEGPEYW*# ...# >HUM22181# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Rabies virus nucleoprotein (11-25)# DB REFERENCE: SWISS: (NCAP_RABVF,NCAP_RABVP,NCAP_RABVA,NCAP_RABVS,# & NCAP_RABVU)# & PIR1: (VHVNRV,VHVNAV,VHVNSB)# & PIR2: (JQ2015,JQ2016)# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,NNQVVSLKPEIIVDQY*# SEQUENCE: NNQVVSLKPEIIVDQY*# ...# >HUM22182# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: DQ alpha 0301 (153-168)# DB REFERENCE: SWISS: (HA26_HUMAN,HA25_HUMAN,HA22_HUMAN,HA21_HUMAN,# & HA26_HUMAN)# & PIR1: (HLHUDX,HLHUD1,HLHUD7,HLHUDC)# & PIR2: (A29312,I54290,I54439,I54444,I68717,I58988,A37044,# & I54437)# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,YLTFLPSADEIYDCKV*# SEQUENCE: YLTFLPSADEIYDCKV*# ...# >HUM22183# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. leprae 18 kDa (31-43)# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,DAVREGEEFVVEF*# SEQUENCE: DAVREGEEFVVEF*# ...# >HUM22184# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Flu nucleoprotein (265-280)# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,IASNENMDAMESSTLY*# SEQUENCE: IASNENMDAMESSTLY*# ...# >HUM22185# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Thyroid peroxidase (632-645)# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,IDVWLGGLAENFLPY*# SEQUENCE: IDVWLGGLAENFLPY*# ...# >HUM22186# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*02), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p21 ras (54-67) homologue 61L# ANCHOR POSITIONS:# REFERENCES: johansen96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,DILDTAGLEEYSAM*# SEQUENCE: DILDTAGLEEYSAM*# ...# >HUM22187# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49)# DB REFERENCE: SWISS: (18KD_MYCLE)# & PIR2: (A27586)# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDLPGIK*# SEQUENCE: EEFVVEFDLPGIK*# ...# >HUM22188# MHC MOLECULE: HLA-DR4(DRB1*0403), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML (37-49)# DB REFERENCE: SWISS: (18KD_MYCLE)# & PIR2: (A27586)# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEFDLPGIK*# SEQUENCE: EEFVVEFDLPGIK*# ...# >HUM22189# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,AEFVVEFDLPGIK*# SEQUENCE: AEFVVEFDLPGIK*# ...# >HUM2218A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EAFVVEFDLPGIK*# SEQUENCE: EAFVVEFDLPGIK*# ...# >HUM2218B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFAVEFDLPGIK*# SEQUENCE: EEFAVEFDLPGIK*# ...# >HUM2218C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVAEFDLPGIK*# SEQUENCE: EEFVAEFDLPGIK*# ...# >HUM2218D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVAFDLPGIK*# SEQUENCE: EEFVVAFDLPGIK*# ...# >HUM2218E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEADLPGIK*# SEQUENCE: EEFVVEADLPGIK*# ...# >HUM2218F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFALPGIK*# SEQUENCE: EEFVVEFALPGIK*# ...# >HUM22190# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEFDAPGIK*# SEQUENCE: EEFVVEFDAPGIK*# ...# >HUM22191# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EEFVVEFDLAGIK*# SEQUENCE: EEFVVEFDLAGIK*# ...# >HUM22192# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDLPAIK*# SEQUENCE: EEFVVEFDLPAIK*# ...# >HUM22193# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDLPGAK*# SEQUENCE: EEFVVEFDLPGAK*# ...# >HUM22194# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EEFVVEFDLPGIA*# SEQUENCE: EEFVVEFDLPGIA*# ...# >HUM22195# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,FAAEFDAAAA*# SEQUENCE: FAAEFDAAAA*# ...# >HUM22196# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EEFVAEFDLPGIK*# SEQUENCE: EEFVAEFDLPGIK*# ...# >HUM22197# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,EEFVVEFALPGIK*# SEQUENCE: EEFVVEFALPGIK*# ...# >HUM22198# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,EEFVVEFDLPAIK*# SEQUENCE: EEFVVEFDLPAIK*# ...# >HUM22199# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ML (37-49) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EEFVVEFDLPGAK*# SEQUENCE: EEFVVEFDLPGAK*# ...# >HUM2219A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,PKEVKQNTLKLAT*# SEQUENCE: PKEVKQNTLKLAT*# ...# >HUM2219B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319)# DB REFERENCE: SWISS: (HEMA_IADH6,HEMA_IAZH2,HEMA_IAAIC,HEMA_IAZUK,HEMA_IADU3,# & HEMA_IAZCO,HEMA_IADH2,HEMA_IADH7,HEMA_IAEN7,HEMA_IAVI7,# & HEMA_IAUDO,HEMA_IABAN,HEMA_IANT6,HEMA_IAME2,HEMA_IADH1,# & HEMA_IADHM,HEMA_IADH3,HEMA_IAQU7,HEMA_IAME1,HEMA_IAEN6,# & HEMA_IADH4)# & PIR1: (HMIV15,HMIV77,HMIV89,HMIVHA,HMIVS3,HMIV33,HMIVH,HMIV6,# & HMIV98,HMIV80,HMIVDU,HMIVV,HMIVHM)# & PIR2: (JQ1156,A92979)# REFERENCES: woulfe95a,raddrizzani97a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,PKYVKQNTLKLAT*# SEQUENCE: PKYVKQNTLKLAT*# ...# >HUM2219C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS:# REFERENCES: woulfe95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,PKEVKQNTLKLAT*# SEQUENCE: PKEVKQNTLKLAT*# ...# >HUM1219D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEPVLLL*# SEQUENCE: KLNEPVLLL*# ...# >HUM1219E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (IMA2_HUMAN,IMO1_HUMAN)# & PIR2: (A56516)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GLVPFLVSV*# SEQUENCE: GLVPFLVSV*# ...# >HUM1219F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLLVRALEV*# SEQUENCE: SLLVRALEV*# ...# >HUM121A0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (COFI_CHICK,COF1_PIG,COF1_RAT,COF2_MOUSE,COF1_PIG,# & COF1_MOUSE,COF1_HUMAN,COF1_HUMAN)# & PIR1: (S12632,B35703,S12584,A29240)# & PIR2: (A53812,S49101)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALYDATYET*# SEQUENCE: ALYDATYET*# ...# >HUM121A1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLPSGGLGV*# SEQUENCE: SLPSGGLGV*# ...# >HUM121A2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SMAPGNTSV*# SEQUENCE: SMAPGNTSV*# ...# >HUM121A3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference/CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VMSA_HPBVI,VMSA_HPBVR,VMSA_HPBVN,VMSA_HPBVJ,VMSA_HPBVY,# & VMSA_HPBVD,VMSA_HPBV2,VMSA_HPBV9,VMSA_HPBVZ,VMSA_HPBVW,# & VMSA_HPBV2,VMSA_HPBVS,VMSA_HPBV4,VMSA_HPBVW,VMSA_HPBVP,# & VMSA_HPBVO,VMSA_HPBVY,VMSA_HPBV0,VMSA_HPBVR,# & VMSA_HPBVA)# & PIR1: (SAVLJ1,SAVLAH,SAVLJ3,SAVLAR,JQ1576,SAVLBH,SAVLAD,JQ1573,# & SAVLVE,SAVLA,JQ1575,JQ1572,SAVLHV,SAVLJ2,JQ1570,JQ1574,# & JQ1571,JQ1577,SAVLVD,SAVLAJ,SAVLA1,JQ1578,SAVLN1,# & SAVLKS)# & PIR2: (JQ2052,S35528,JQ2097,JQ2083,JQ2072,JQ2092,JQ2060,JQ2085,# & JQ2058,S47411,JQ2102,JQ2048,JQ2067,JQ2080,S20749,S41870,# & JQ2055,S32202,JQ2116,JQ2103,JQ2047,JQ2046,JQ2091,S43492,# & JQ2062,JQ2101,JQ2079,JQ2087,JQ2112,JQ2057,S47407,JQ2066,# & JQ2081,JQ2065,S41869,JQ2113,JQ2050,JQ2073,JQ2061,JQ2078,# & JQ2077,JQ2108,JQ2105,S20753,JQ2089,JQ2111,JQ2075,JQ2114,# & JQ2054,JQ2068,JQ2053,JQ2063,JQ2098,JQ2056,JQ2070,JQ2109,# & JQ2106,JQ2110,JQ2090,JQ2069,JQ2059,JQ2100,S36654,JQ2045,# & S20745,JQ2104,JQ2051,JQ2076,JQ2115)# REFERENCES: parker96a,cerny95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,WLSLLVPFV*# SEQUENCE: WLSLLVPFV*# ...# >HUM121A4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVJ6,POLG_HCVTW,POLG_HCVJT,POLG_HCVBK,# & POLG_HCVH,POLG_HCV1)# & PIR1: (GNWVCH,GNWVC3,GNWVTC,GNWVTW,GNWVCJ)# & PIR2: (JQ1303,S40770,A45573)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GLRDLAVAV*# SEQUENCE: GLRDLAVAV*# ...# >HUM121A5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCV1,POLG_HCVBK,POLG_HCVH,POLG_HCVJA,# & POLG_HCVTW)# & PIR1: (GNWVCJ,GNWVTC,GNWVC3,GNWVCH,GNWVTW)# & PIR2: (S32748,PS0326,A54317,S06067,A45573,JQ1366,PC2219,S18030,# & A61196,S40770)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YLVAYQATV*# SEQUENCE: YLVAYQATV*# ...# >HUM121A6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBV9,DPOL_HPBV2,DPOL_HPBVM,# & DPOL_HPBVL)# & PIR1: (JDVLCP,JDVLKS,S43491,JDVLVD,JDVLVS,JDVLVR,S20757)# & PIR2: (S35527)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLYAVSPSV*# SEQUENCE: SLYAVSPSV*# ...# >HUM121A7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,PLTSIISAV*# SEQUENCE: PLTSIISAV*# ...# >HUM121A8# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALSRKVAEL*# SEQUENCE: ALSRKVAEL*# ...# >HUM121A9# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOM_HPBVY,DPOL_HPBVY,DPOL_HPBVZ,DPOL_HPBVR,# & DPOL_HPBVA)# & PIR1: (S47406,S43491,S20752,JDVLVB,JDVLVA,JDVLA1,JDVLVR,# & JDVLVH)# & PIR2: (S71785)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLCKQYLNL*# SEQUENCE: FLCKQYLNL*# ...# >HUM121AA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVH,POLG_HCVJA,POLG_HCVJT,POLG_HCV1,# & POLG_HCVTW)# & PIR1: (GNWVCJ,GNWVCH,GNWVC3,GNWVTW,GNWVTC)# & PIR2: (S40770,A45573,S18030)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YLVTRHADV*# SEQUENCE: YLVTRHADV*# ...# >HUM121AB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVY,DPOL_HPBVI,DPOL_HPBVJ,DPOM_HPBVY,# & DPOL_HPBVT,DPOL_HPBVO)# & PIR1: (S47406,JDVLVA,JDVLJ1,JDVLVB,JDVLJ3,JDVLA1,JQ2229,S20752,# & JDVLJ2)# & PIR2: (S71785)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,SLYADSPSV*# SEQUENCE: SLYADSPSV*# ...# >HUM121AC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1C4)# & PIR1: (FOVWH4)# & PIR2: (S60697)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RMYSPISIL*# SEQUENCE: RMYSPISIL*# ...# >HUM121AD# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVJ,DPOL_HPBVZ,DPOL_HPBV9,DPOL_HPBV2,# & DPOL_HPBVP,DPOL_HPBVT,DPOM_HPBVY,DPOL_HPBVI,DPOL_HPBVW,# & DPOL_HPBVL,DPOL_HPBVY,DPOL_HPBVO)# & PIR1: (JDVLJ3,JDVLKS,JDVLVH,JDVLJ1,JDVLVA,JQ2229,S20757,JDVLCP,# & JDVLA1,JDVLJ2,JDVLVD,JDVLVB,S47406)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GLSRYVARL*# SEQUENCE: GLSRYVARL*# ...# >HUM121AE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,HLYQGCQVV*# SEQUENCE: HLYQGCQVV*# ...# >HUM121AF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVA,VMSA_HPBVZ)# & PIR1: (JQ1572,SAVLBH,SAVLA1,SAVLAJ,SAVLAH,JQ1571)# & PIR2: (JQ2075,JQ2069,S20753,JQ2073,JQ2081,JQ2066,S47407,JQ2070,# & JQ2067,JQ2079,JQ2083,S41871,S41870,S32202,JQ2076,JQ2072,# & JQ2065,S41869,JQ2063,JQ2077,JQ2080,JQ2068,JQ2078,# & S20745)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLGGTTVCL*# SEQUENCE: FLGGTTVCL*# ...# >HUM121B0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,YMLDLQPET*# SEQUENCE: YMLDLQPET*# ...# >HUM121B1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,TLHEYMLDL*# SEQUENCE: TLHEYMLDL*# ...# >HUM121B2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KLPQLCTEL*# SEQUENCE: KLPQLCTEL*# ...# >HUM121B3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LLMGTLGIV*# SEQUENCE: LLMGTLGIV*# ...# >HUM121B4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FAFRDLCIV*# SEQUENCE: FAFRDLCIV*# ...# >HUM121B5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,MLDLQPETT*# SEQUENCE: MLDLQPETT*# ...# >HUM121B6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GTLGIVCPI*# SEQUENCE: GTLGIVCPI*# ...# >HUM121B7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,LQTTIHDII*# SEQUENCE: LQTTIHDII*# ...# >HUM121B8# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AMFQDPQER*# SEQUENCE: AMFQDPQER*# ...# >HUM121B9# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,TLGIVCPIC*# SEQUENCE: TLGIVCPIC*# ...# >HUM121BA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VMT1_IAUDO,VMT1_IAMAN,VMT1_IAUSS,VMT1_IABAN,VMT1_IAFPR,# & VMT1_IAWIL,VMT1_IAPUE,VMT1_IAFPW,VMT1_IACKB,VMT1_IALE2,# & VMT1_IALE1,VMT1_IAFOW,VMT1_IAANN)# & PIR1: (MFIVC,MFIV,B45539,MFIV1K,PN0083,PN0086,JN0392,MFIV61,# & MFIV1F,MFIV1M,MFIVWS)# & PIR2: (S04054,S04050,S07429,S04058,S07945,S04056,S04052,# & S14616)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLTEVETYV*# SEQUENCE: LLTEVETYV*# ...# >HUM121BB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VMT1_IAFOW,VMT1_IAZI1,VMT1_IABAN,VMT1_IAUDO,VMT1_IAANN,# & VMT1_IAPUE,VMT1_IACKB,VMT1_IAMAN,VMT1_IALE1,VMT1_IALE2,# & VMT1_IAUSS,VMT1_IAWIL)# & PIR1: (JN0392,MFIV1M,MFIV1K,MFIVWS,MFIV61,MFIVC,MFIV)# & PIR2: (S04052,S14616,S04058,S04056,S04050,S07429,S04054)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ILSPLTKGI*# SEQUENCE: ILSPLTKGI*# ...# >HUM121BC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VMT1_IAPUE,VMT1_IACAO,VMT1_IAANN,VMT1_IAUSS,VMT1_IAWIL,# & VMT1_IAFPW,VMT1_IAFOW,VMT1_IAZI1,VMT1_IACKB)# & PIR1: (B45539,MFIVWS,JN0392,MFIV,MFIV61,PN0086,PN0083)# & PIR2: (S04052,S14616,S04050,S07945,S07429,S04056)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,QMVTTTNPL*# SEQUENCE: QMVTTTNPL*# ...# >HUM121BD# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RMGATVTTEV*# SEQUENCE: RMGATVTTEV*# ...# >HUM121BE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GMNERPILT*# SEQUENCE: GMNERPILT*# ...# >HUM121BF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GLAPPQHEI*# SEQUENCE: GLAPPQHEI*# ...# >HUM121C0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLGRNSFEM*# SEQUENCE: LLGRNSFEM*# ...# >HUM121C1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference/reconstitution# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (P53_HUMAN,P53_MOUSE,P53_HUMAN,P53_BOVIN,P53_RAT,# & P53_MOUSE,P53_SHEEP,P53_CERAE,P53_FELCA,P53_RAT,# & P53_CERAE,P53_FELCA,P53_SHEEP)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S38824,S06594,S02192,S51648)# REFERENCES: parker96a,zeh94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,PLDGEYFTL*# SEQUENCE: PLDGEYFTL*# ...# >HUM121C2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (P53_CERAE,P53_MOUSE,P53_MESAU,P53_HUMAN,P53_BOVIN,# & P53_CANFA,P53_SALIR,P53_MOUSE,P53_CRIGR,P53_SHEEP,# & P53_SALIR,P53_HUMAN,P53_FELCA,P53_CERAE,P53_FELCA,# & P53_SHEEP,P53_RAT,P53_MESAU,P53_RAT)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S06594,S02192,JC6193,JC6176,JH0631,JH0633,S51648,# & S38824)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,QLAKTCPVQ*# SEQUENCE: QLAKTCPVQ*# ...# >HUM121C3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference/reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN,P53_CERAE,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: parker96a,zeh94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KLLPENNVL*# SEQUENCE: KLLPENNVL*# ...# >HUM121C4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GMNRHPILT*# SEQUENCE: GMNRHPILT*# ...# >HUM121C5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (P53_MESAU,P53_RAT,P53_HUMAN,P53_HUMAN,P53_RAT,P53_MESAU,# & P53_CERAE,P53_SHEEP,P53_SALIR,P53_SALIR,P53_MOUSE,# & P53_CRIGR,P53_CANFA,P53_BOVIN,P53_MOUSE,P53_CERAE,# & P53_CHICK,P53_XENLA,P53_XENLA,P53_SHEEP,P53_CHICK)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S02192,JC6193,S51648,S06594,S02193,A29376,S38824,JH0631,# & JH0633,JC6176)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GMNRRPILT*# SEQUENCE: GMNRRPILT*# ...# >HUM121C6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GMNCRPILT*# SEQUENCE: GMNCRPILT*# ...# >HUM121C7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,GMNKRPILT*# SEQUENCE: GMNKRPILT*# ...# >HUM121C8# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference/reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (P53_HUMAN,P53_MOUSE,P53_MOUSE,P53_CRIGR,P53_CANFA,# & P53_FELCA,P53_SHEEP,P53_CERAE,P53_FELCA,P53_CERAE,# & P53_SHEEP,P53_HUMAN,P53_BOVIN)# & PIR1: (DNHU53,DNMS53)# & PIR2: (JC6176,S51648,S06594,S38824,I46226,JC6193)# REFERENCES: parker96a,zeh94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,HLIRVEGNL*# SEQUENCE: HLIRVEGNL*# ...# >HUM121C9# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,HLIKVEGNL*# SEQUENCE: HLIKVEGNL*# ...# >HUM121CA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hepatitis B sAg# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVN,VMSA_HPBV2,VMSA_HPBVJ,VMSA_HPBV9,# & VMSA_HPBV0,VMSA_HPBVR,VMSA_HPBVO,VMSA_HPBVP,VMSA_HPBVW,# & VMSA_HPBVR,VMSA_HPBVY,VMSA_HPBVI,VMSA_HPBV4,VMSA_HPBVW,# & VMSA_HPBVA,VMSA_HPBVZ,VMSA_HPBVY)# & PIR1: (SAVLJ1,SAVLN1,SAVLBH,SAVLAJ,JQ1574,JQ1570,SAVLHV,SAVLVE,# & SAVLKS,SAVLVD,JQ1577,SAVLJ3,JQ1571,JQ1572,SAVLA1,SAVLAH,# & SAVLJ2,SAVLA,JQ1575)# & PIR2: (JQ2109,JQ2053,JQ2054,JQ2112,JQ2050,JQ2113,JQ2062,JQ2076,# & JQ2099,JQ2048,JQ2078,JQ2068,S41869,JQ2060,JQ2077,JQ2058,# & S47411,JQ2115,JQ2116,S20749,JQ2047,JQ2052,JQ2072,JQ2097,# & JQ2069,JQ2059,JQ2045,S47407,JQ2081,JQ2066,JQ2108,S36654,# & JQ2103,JQ2114,JQ2051,JQ2061,JQ2110,JQ2073,S32202,JQ2067,# & JQ2056,S20753,JQ2100,JQ2111,S20745,JQ2046,JQ2101,JQ2057,# & JQ2055,JQ2063,JQ2098,JQ2065,JQ2075)# REFERENCES: parker96a# COMMENT: natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,LLVPFVQWFV*# SEQUENCE: LLVPFVQWFV*# ...# >HUM121CB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT: natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,ALWGFFPVL*# SEQUENCE: ALWGFFPVL*# ...# >HUM121CC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hepatitis B sAg# DB REFERENCE: SWISS: (VMSA_HPBV2,VMSA_HPBVI,VMSA_HPBVP,VMSA_HPBVJ,VMSA_WHV7,# & VMSA_HPBVW,VMSA_HPBVD,VMSA_HPBV2,VMSA_HPBVN,VMSA_HPBV0,# & VMSA_WHV8I,VMSA_WHV1,VMSA_WHV8,VMSA_HPBVS,VMSA_HPBVO,# & VMSA_HPBVL,VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVA,VMSA_HPBVT,# & VMSA_HPBV4,VMSA_HPBV9,VMSA_WHVW6,VMSA_HPBVR,VMSA_HPBVR,# & VMSA_HPBVY,VMSA_WHV59,VMSA_HPBVW)# & PIR1: (SAVLJ1,SAVLBH,JQ1575,JQ1581,SAVLVD,SAVLW8,SAVLAJ,JQ1578,# & SAVL59,JQ1573,JQ1577,SAVLAD,JQ1576,SAVLKS,SAVL7,SAVLCP,# & SAVLVE,SAVLHV,SAVLAR,JQ1579,SAVLN1,SAVLC,JQ1574,JQ1570,# & SAVLC2,JQ1571,SAVLA1,JQ1572,JQ1580,SAVLJ3,SAVLJ2,SAVL64,# & SAVLA,SAVLAH)# & PIR2: (JQ2108,JQ2114,JQ2098,JQ2092,JQ2063,JQ2088,S35528,JQ2075,# & JQ2094,JQ2119,JQ2095,S20753,JQ2056,JQ2057,JQ2047,JQ2077,# & JQ2072,JQ2052,S47411,S41869,JQ2115,JQ2091,JQ2102,JQ2061,# & JQ2101,S20745,S47407,JQ2230,JQ2059,JQ2226,JQ2225,JQ2062,# & JQ2079,JQ2106,JQ2070,JQ2089,JQ2048,JQ2122,JQ2045,JQ2112,# & JQ2120,JQ2054,JQ2053,JQ2105,JQ2109,JQ2096,JQ2050,JQ2113,# & JQ2069,JQ2121,JQ2090,JQ2081,JQ2066,JQ2065,JQ2080,JQ2046,# & JQ2104,JQ2051,JQ2103,JQ2055,JQ2085,JQ2067,S32202,JQ2073,# & JQ2110,JQ2100,JQ2111,S43492,JQ2058,JQ2060,JQ2123,JQ2087,# & JQ2097,S41871,JQ2083,S41870,S20749,JQ2078,JQ2116,JQ2068,# & JQ2099,JQ2076)# & PIR4: (S42226)# REFERENCES: parker96a# COMMENT: natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,LLCLIFLLV*# SEQUENCE: LLCLIFLLV*# ...# >HUM121CD# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hepatitis B sAg# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBVW,VMSA_HPBVP,# & VMSA_HPBV2,VMSA_HPBV0,VMSA_HPBVD,VMSA_HPBVZ,VMSA_HPBVA,# & VMSA_HPBVT,VMSA_HPBVR,VMSA_HPBVW,VMSA_HPBV9,VMSA_HPBVJ,# & VMSA_HPBV2,VMSA_HPBVL,VMSA_HPBVY,VMSA_HPBV4,# & VMSA_HPBVO)# & PIR1: (JQ1576,SAVLAJ,SAVLBH,SAVLVD,JQ1575,SAVLHV,SAVLVE,SAVLAD,# & JQ1570,SAVLKS,JQ1579,SAVLAH,JQ1572,SAVLJ3,SAVLA1,JQ1580,# & SAVLJ2,SAVLA,JQ1571,SAVLJ1,JQ1581,SAVLCP,JQ1573,JQ1574,# & JQ1578)# & PIR2: (JQ2058,JQ2067,S32202,JQ2073,JQ2110,JQ2111,JQ2100,JQ2065,# & JQ2055,JQ2085,JQ2103,JQ2225,JQ2070,S47407,JQ2062,JQ2089,# & JQ2106,JQ2095,JQ2056,JQ2057,JQ2094,JQ2045,JQ2091,JQ2052,# & JQ2072,JQ2047,JQ2102,JQ2061,JQ2101,JQ2092,JQ2063,JQ2075,# & JQ2088,JQ2114,JQ2053,JQ2120,JQ2054,JQ2109,JQ2121,JQ2069,# & JQ2081,JQ2090,JQ2097,JQ2083,JQ2123,JQ2060,JQ2087,JQ2078,# & JQ2096,JQ2076,S20745,JQ2050,JQ2066,JQ2099,JQ2068,JQ2116,# & S41871,S47411,S41869,JQ2079,JQ2230,JQ2226,JQ2051,JQ2080,# & JQ2059,JQ2077,JQ2115,JQ2108,S41870,JQ2104,JQ2098,S35528,# & JQ2119,S20753,JQ2122,JQ2112,JQ2105)# REFERENCES: parker96a# COMMENT: natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,LLDYQGMLPV*# SEQUENCE: LLDYQGMLPV*# ...# >HUM121CE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Epstein-Barr virus LMP-2# DB REFERENCE: SWISS: (LMP2_EBV)# & PIR1: (WMBELM)# REFERENCES: parker96a# COMMENT: natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,CLGGLLTMV*# SEQUENCE: CLGGLLTMV*# ...# >HUM121CF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: influenza B NP# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT: natural T-cell epitope# SUMMARY: HLA-A2,actyesu,bindyesu,KLGEFYNQMN*# SEQUENCE: KLGEFYNQMN*# ...# >HUM121D1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: myelin basic protein# ANCHOR POSITIONS:# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,SLSRFSWGA3*# SEQUENCE: SLSRFSWGA3*# ...# >HUM121D2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: papillomavirustype 11 E7# DB REFERENCE: SWISS: (VE7_HPV6B)# & PIR1: (W7WL6)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GLHCYEQLV*# SEQUENCE: GLHCYEQLV*# ...# >HUM121D3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: papillomavirus type 11 E7# DB REFERENCE: SWISS: (VE7_HPV11)# & PIR1: (W7WL11)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,RLVTLKDIV*# SEQUENCE: RLVTLKDIV*# ...# >HUM121D4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: acetylcholine receptor# DB REFERENCE: SWISS: (ACHA_RAT,ACHA_MOUSE,ACHA_MOUSE,ACHA_HUMAN)# & PIR1: (ACHUA1)# & PIR2: (A24383,I49458)# & PIR3: (S13872)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,HILLGVFML*# SEQUENCE: HILLGVFML*# ...# >HUM121D5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: papillomavirus type 11 E7# DB REFERENCE: SWISS: (VE7_HPV6B)# & PIR1: (W7WL6)# REFERENCES: parker96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,PLKQHFQIV*# SEQUENCE: PLKQHFQIV*# ...# >MUS221D6# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: hurtenbach93a# COMMENT: peptide tested with D amino acids at ends y- . . -t# SUMMARY: I-Ag7,actunkn,bindyesh,TYTVHAAHAYTY*# SEQUENCE: TYTVHAAHAYTY*# ...# >MUS221D7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: hurtenbach93a# COMMENT: peptide tested with D amino acids at ends y- . . -t# SUMMARY: I-Ad,actunkn,bindyesl,TYTVHAAHAYTY*# SEQUENCE: TYTVHAAHAYTY*# ...# >MUS221D8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: hurtenbach93a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,KMKMVHAAHAKMKM*# SEQUENCE: KMKMVHAAHAKMKM*# ...# >MUS221D9# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: hurtenbach93a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesh,KMKMVHAAHAKMKM*# SEQUENCE: KMKMVHAAHAKMKM*# ...# >MUS221DA# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: inhibition as./reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HSP 60# DB REFERENCE: SWISS: (P60_HUMAN,P60_HUMAN)# & PIR1: (A32800)# & PIR2: (I53042)# REFERENCES: elias96a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,VLGGGCALLRCIPALDSLTPANED*# SEQUENCE: VLGGGCALLRCIPALDSLTPANED*# ...# >HUM121DB# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POL_HTL1C,POL_HTL1A)# & PIR1: (GNLJGH,GNLJCN)# REFERENCES: schonbach95b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,FAFTVPQQCNY*# SEQUENCE: FAFTVPQQCNY*# ...# >HUM121DC# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POL_HTL1A,POL_HTL1C)# & PIR1: (GNLJCN,GNLJGH)# REFERENCES: schonbach95b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,SAVLLLDKY*# SEQUENCE: SAVLLLDKY*# ...# >HUM121DD# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: schonbach95b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPGFDFTPGY*# SEQUENCE: LPGFDFTPGY*# ...# >HUM121DE# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1B5,POL_HV1A2,POL_HV1U4,POL_HV1BR,# & POL_HV1Z2,POL_HV1B1,POL_HV1PV,POL_HV1H2,POL_HV1ND,# & POL_HV1Y2,POL_HV1OY,POL_HV1JR,POL_HV1MN,POL_HV1N5,# & POL_HV1MA,POL_HV1EL)# & PIR1: (GNLJND,GNVWA2,B44001,GNVWVL,GNVWLV,GNVWH3)# & PIR2: (S32068,S63747,S32053,S32058,S32061,S32157,S32072,S63734,# & S32160,S63748,S32092,S32098,S32097,S54378,S32090,S32059,# & S63755,S63732,S63750,S63736,S32051,S32089,S63735,S32119,# & S32093,S32069,A47175,S32086,S32138,S32047,S63741,S32134,# & S63753,S32081,S63737,S63733,S32079,S63746,S32074,S63751,# & S32088,S32082,S32091,S32071,S32139,S32136,S32048,S32077,# & S32159,B47175,S32087,S32118,S32066,S32062,S32094,S32065,# & S32076,S32080,S32135,S32117,S32078,S63745,S63731,S63754,# & S32070,S32126,S32084,S32122,S32049,S32096,S32075,S32137,# & S32067,S32083,S32073,S63742,S32095,S63752,S32050)# & PIR3: (S33980)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,SPIETVPVKL*# SEQUENCE: SPIETVPVKL*# ...# >HUM121DF# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (REV_HV1Z8,REV_HV1BN,REV_HV1PV,REV_HV1Z6,REV_HV1ND,# & REV_HV1MA,REV_HV1J3,REV_HV1W2,REV_HV1SC,REV_HV1S1,# & REV_HV1C4,REV_HV1H2,REV_HV1JR,REV_HV1OY,REV_HV1S3,# & REV_HV1Z2,REV_HV112,REV_HV1A2,REV_HV1B1,REV_HV1BR,# & REV_HV1B8,REV_HV1EL)# & PIR1: (VKLJND,VKLJBR,VKLJH3)# & PIR2: (JC4968,S14607,S54382)# & PIR3: (S33983)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,EPVPLQLPPL*# SEQUENCE: EPVPLQLPPL*# ...# >HUM121E0# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VIF_HV1Y2,VIF_HV1A2,VIF_HV1N5)# & PIR1: (C44001,ASLJO1)# & PIR2: (S42990,S42969,S42980,S42991,S43005,S42944,S42972,S42956,# & S42977,S42951,S42953,S42962,S42952,S42974,S42961)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,IPLGDAKLVI*# SEQUENCE: IPLGDAKLVI*# ...# >HUM121E1# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,EPIDKEIYPL*# SEQUENCE: EPIDKEIYPL*# ...# >HUM121E2# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1OY,GAG_HV1ND,GAG_HV1RH,GAG_HV1Z2,GAG_HV1EL,# & GAG_HV1N5,GAG_HV1Y2,GAG_HV1A2,GAG_HV1W2,GAG_HV1C4,# & GAG_HV1JR)# & PIR1: (FOLJND,FOVWH4,FOVWA2,A44001)# & PIR2: (S54377)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,YPIVQNLQGQM*# SEQUENCE: YPIVQNLQGQM*# ...# >HUM121E3# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: schonbach95b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPFDENGNVY*# SEQUENCE: FPFDENGNVY*# ...# >HUM121E4# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1Z6,ENV_HV1BR,ENV_HV1MF,ENV_HV1SC,# & ENV_HV1B1,ENV_HV1N5,ENV_HV1EL,ENV_HV1OY,ENV_HV1W2,# & ENV_HV1MN,ENV_HV1KB,ENV_HV1Z8,ENV_HV1H2,ENV_HV1Z2,# & ENV_HV1W1,ENV_HV1B8,ENV_HV1Y2,ENV_HV1MA,ENV_HV1C4,# & ENV_HV1H3,ENV_HV1PV,ENV_HV1S1,ENV_HV1RH)# & PIR1: (VCLJA2,VCLJLV,VCLJH3,VCLJKB,VCLJSC,VCLJKX,H44001,VCLJMN,# & VCLJH4,VCLJ3W,VCLJZR,VCLJVL)# & PIR2: (A40218,S25939,S25938,S54384)# & PIR3: (S13288,S33985,S13289)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,VPVWKEATTTL*# SEQUENCE: VPVWKEATTTL*# ...# >HUM121E5# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# REFERENCES: schonbach95b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,RPIVSTQLLL*# SEQUENCE: RPIVSTQLLL*# ...# >HUM121E6# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./Flow cytometry/CTL assays/CTL induction/Reference# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: HIV env (255-263)# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# REFERENCES: schonbach95b,shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesl,RPIVSTQLL*# SEQUENCE: RPIVSTQLL*# ...# >HUM121E7# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1ND,POL_HV1H2,POL_HV1RH,POL_HV1B5,POL_HV1EL,# & POL_HV1U4,POL_HV1Y2,POL_HV1PV,POL_HV1Z2,POL_HV1BR,# & POL_HV1A2,POL_HV1MA,POL_HV1MN,POL_HV1OY,POL_HV1N5,# & POL_HV1JR,POL_HV1B1)# & PIR1: (GNVWH3,GNVWLV,GNVWVL,GNLJND,B44001,GNVWA2)# & PIR2: (S54378,A47175,B47175)# & PIR3: (S33980)# REFERENCES: schonbach95b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,TPPLVKLWYQL*# SEQUENCE: TPPLVKLWYQL*# ...# >HUM121E8# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVH,POLG_HCVTW,POLG_HCVBK,POLG_HCVJT)# & PIR1: (GNWVTW,GNWVTC,GNWVCH,GNWVC3)# & PIR2: (S40770,A45573)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPINALSNSL*# SEQUENCE: LPINALSNSL*# ...# >HUM121E9# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVJA)# & PIR1: (GNWVCJ)# & PIR2: (A45573,S18030)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,IPVESMETTM*# SEQUENCE: IPVESMETTM*# ...# >HUM121EA# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVJA,POLG_HCVBK,POLG_HCVJT,POLG_HCVH,# & POLG_HCV1)# & PIR1: (GNWVTC,GNWVTW,GNWVCH,GNWVCJ,GNWVC3)# & PIR2: (S40770,JQ0880,S18030,A45573,PS0085,JQ0879,PS0102,# & PS0104)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,TPVNSWLGNI*# SEQUENCE: TPVNSWLGNI*# ...# >HUM121EB# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJT,POLG_HCVJ7,POLG_HCVJ8,# & POLG_HCVTW)# & PIR1: (GNWVJ8,GNWVTW,GNWVTC)# & PIR2: (A45573,S18032,S19876)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,YPCTVNFTIF*# SEQUENCE: YPCTVNFTIF*# ...# >HUM121EC# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJT,POLG_HCVHK,POLG_HCVJA,# & POLG_HCVH4)# & PIR1: (GNWVCJ,GNWVTC)# & PIR2: (S21471,S19876,S18030,S18032,JQ1926,S12707,PN0677,PN0011,# & S32741,PS0165,JQ1925,A45573)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,YPGHVSGHRM*# SEQUENCE: YPGHVSGHRM*# ...# >HUM121ED# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVJ5,POLG_HCVJ2,POLG_HCVJA,POLG_HCVJT,POLG_HCVHK,# & POLG_HCVH4,POLG_HCVH,POLG_HCV1,POLG_HCVJ7,POLG_HCVE1,# & POLG_HCVJ8,POLG_HCVBK,POLG_HCVH8,POLG_HCVH7,POLG_HCVTW,# & POLG_HCVJ6)# & PIR1: (GNWVCH,GNWVC3,GNWVTC,GNWVCJ,GNWVTW,GNWVJ8)# & PIR2: (JQ1303,S18032,PC2061,S21471,PC1304,JQ0883,PN0677,JN0265,# & S18031,JQ0881,A44150,PC1305,S19876,JH0711,S18030,PC1284,# & PS0388,S41288,PC1303,S19875,S40770,JQ1584,PC2060,S12707,# & JQ1926,JQ1925,A45573)# & PIR3: (S32740)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,LPGCSFSIFL*# SEQUENCE: LPGCSFSIFL*# ...# >HUM121EE# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVJA,POLG_HCVJT,POLG_HCVBK)# & PIR1: (GNWVTC,GNWVCJ,GNWVTW)# & PIR2: (A45573,S18030)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPYIEQGMQL*# SEQUENCE: LPYIEQGMQL*# ...# >HUM121EF# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVH,POLG_HCV1,POLG_HCVJA,POLG_HCVJT,# & POLG_HCVTW)# & PIR1: (GNWVTW,GNWVC3,GNWVCJ,GNWVCH,GNWVTC)# & PIR2: (PS0326,A45573,S40770)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,NPAIASLMAF*# SEQUENCE: NPAIASLMAF*# ...# >HUM121F0# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJT,POLG_HCVJ6,POLG_HCV1,POLG_HCVJ8,# & POLG_HCVJA,POLG_HCVTW)# & PIR1: (GNWVC3,GNWVTW,GNWVJ8,GNWVTC,GNWVCJ)# & PIR2: (PS0329,A61196,S06067,S40770,A45573,S32748,JQ1303,PS0328,# & PS0326,JQ1366,A54317,PC2219,PS0327)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPVCQDHLEF*# SEQUENCE: LPVCQDHLEF*# ...# >HUM121F1# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,RPLLREDVTF*# SEQUENCE: RPLLREDVTF*# ...# >HUM121F2# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJT,POLG_HCVJA)# & PIR1: (GNWVCJ,GNWVTC)# & PIR2: (A45573)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,HPELIFDITKL*# SEQUENCE: HPELIFDITKL*# ...# >HUM121F3# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVJT)# & PIR1: (GNWVCJ)# & PIR2: (A45573)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,SPLTTQNTLLF*# SEQUENCE: SPLTTQNTLLF*# ...# >HUM121F4# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,TPLQDWAHAGL*# SEQUENCE: TPLQDWAHAGL*# ...# >HUM121F5# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCV1,POLG_HCVJA,POLG_HCVJ8,POLG_HCVJ6,# & POLG_HCVJT,POLG_HCVBK,POLG_HCVTW)# & PIR1: (GNWVTC,GNWVTW,GNWVCJ,GNWVJ8,GNWVCH,GNWVC3)# & PIR2: (A54317,JQ1366,A61196,S06067,PS0328,PS0326,A45573,PS0327,# & JQ1303,PS0329,S40770,S32748,PC2219)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,TPGLPVCQDHL*# SEQUENCE: TPGLPVCQDHL*# ...# >HUM121F6# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVBK,POLG_HCVJT)# & PIR1: (GNWVTC,GNWVCJ)# & PIR2: (PQ0248,PQ0253,PQ0250,S20763,A45573,PQ0251,S10002,PQ0252,# & PQ0254,S18030,PQ0255)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,SPDADLIEANL*# SEQUENCE: SPDADLIEANL*# ...# >HUM121F7# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVHK,POLG_HCVBK,POLG_HCVJT,POLG_HCVH4,POLG_HCVJ2,# & POLG_HCVTW,POLG_HCVJ6,POLG_HCVJ5)# & PIR1: (GNWVTC,GNWVTW)# & PIR2: (JQ1926,S18032,S41357,S41353,S41352,S18031,PC1284,S41350,# & JQ1303,S41354,S41342,S19876,S41349,S41347,A45573,S18030,# & JQ1925,S12707,PN0677,S21471,JQ0881)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,YPWPLYGNEGL*# SEQUENCE: YPWPLYGNEGL*# ...# >HUM121F8# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVJT,POLG_HCVTW)# & PIR1: (GNWVTW,GNWVCJ)# & PIR2: (S18030,A45573,JQ0879)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,TPIPAASQLDL*# SEQUENCE: TPIPAASQLDL*# ...# >HUM121F9# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (S18030,A45573)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,HPITKFIMACM*# SEQUENCE: HPITKFIMACM*# ...# >HUM121FA# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBN3 EBV# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,TPTFVHLQATL*# SEQUENCE: TPTFVHLQATL*# ...# >HUM121FB# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: BRL1 EBV# DB REFERENCE: SWISS: (BRL1_EBV)# & PIR1: (QQBE29)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,SPLTPELNEIL*# SEQUENCE: SPLTPELNEIL*# ...# >HUM121FC# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBN4 EBV# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# & PIR2: (S27921)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,QPLTSPTTSQL*# SEQUENCE: QPLTSPTTSQL*# ...# >HUM121FD# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: YTR1 EBV# DB REFERENCE: SWISS: (YTR1_EBV)# & PIR2: (S33045)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,IPVTVLSSLQL*# SEQUENCE: IPVTVLSSLQL*# ...# >HUM121FE# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBN6 EBV# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (S27922,S33015,A31666)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,QPISHEEQPRY*# SEQUENCE: QPISHEEQPRY*# ...# >HUM121FF# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as./flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: LMP2 EBV# DB REFERENCE: SWISS: (LMP2_EBV)# & PIR1: (WMBELM)# REFERENCES: schonbach95b,schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,QPLGTQDQSLY*# SEQUENCE: QPLGTQDQSLY*# ...# >HUM22200# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: DRB1 HV3 1501# DB REFERENCE: SWISS: (HB2G_HUMAN)# & PIR1: (HLHUWB)# & PIR2: (A27618,C27060,I54287,I59647,I68734,D32526)# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesm,bindyesu,KDILEQARAAVDTYC*# SEQUENCE: KDILEQARAAVDTYC*# ...# >HUM22201# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: DRB1 HV3 1601# DB REFERENCE: SWISS: (HB2I_HUMAN)# & PIR2: (A25324,I59634,B28043,I54309,F27060,I37539,A25239,I68777,# & D25239,S54258,C32526,I54550,B45832,I68733,B27060,B28756,# & I67726,I38898)# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesm,bindyesu,KDFLEDRRAAVDTYC*# SEQUENCE: KDFLEDRRAAVDTYC*# ...# >HUM22202# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: DRB1 HV3 1602# DB REFERENCE: PIR2: (B27618)# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesl,bindyesu,KDLLEDRRAAVDTYC*# SEQUENCE: KDLLEDRRAAVDTYC*# ...# >HUM22203# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: DRB1 HV3 0402# DB REFERENCE: PIR2: (I38899,S54907,S70749,I79421,I56072,A33287,G28043,S03439,# & I72484,H28043,I54291,G01972)# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesh,bindyesu,KDILEDERAAVDTYC*# SEQUENCE: KDILEDERAAVDTYC*# ...# >HUM22204# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: DRB1 HV3 1103# DB REFERENCE: PIR2: (I54448)# ANCHOR POSITIONS:# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesh,bindyesu,KDFLEDERAAVDTYC*# SEQUENCE: KDFLEDERAAVDTYC*# ...# >HUM22205# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: DRB1 HV3 1303# DB REFERENCE: PIR2: (G02057,I72483)# ANCHOR POSITIONS:# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesm,bindyesu,KDILEDKRAAVDTYC*# SEQUENCE: KDILEDKRAAVDTYC*# ...# >HUM22206# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: DRB1 HV3 1403# ANCHOR POSITIONS:# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesl,bindyesu,KDLLEDRRALVDTYC*# SEQUENCE: KDLLEDRRALVDTYC*# ...# >HUM22207# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: DRB1 HV3 0801# DB REFERENCE: PIR2: (I38411,I54304,I54473,A45856,I51875,I59643)# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesm,bindyesu,KDFLEDRRALVDTYC*# SEQUENCE: KDFLEDRRALVDTYC*# ...# >HUM22208# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: DRB1 HV3 0803# DB REFERENCE: PIR2: (I54500,S57512,I68778)# ANCHOR POSITIONS:# REFERENCES: zanelli96a# COMMENT:# SUMMARY: HLA-DQ8,actyesl,bindyesu,KDILEDRRALVDTYC*# SEQUENCE: KDILEDRRALVDTYC*# ...# >HUM22209# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: beta-cell membrane protein 38 kDa (51-70)# ANCHOR POSITIONS:# REFERENCES: neophytou96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,EPEASPSLWEIEFAKQLASV*# SEQUENCE: EPEASPSLWEIEFAKQLASV*# ...# >HUM2220A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: beta-cell membrane protein 38 kDa (58-67)# ANCHOR POSITIONS:# REFERENCES: neophytou96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,LWEIEFAKQL*# SEQUENCE: LWEIEFAKQL*# ...# >HUM2220B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: beta-cell membrane protein 38 kDa (59-68)# ANCHOR POSITIONS:# REFERENCES: neophytou96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,WEIEFAKQLA*# SEQUENCE: WEIEFAKQLA*# ...# >HUM1220C# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ARYDRSGRYL*# SEQUENCE: ARYDRSGRYL*# ...# >HUM1220D# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DRHERITKL*# SEQUENCE: DRHERITKL*# ...# >HUM1220E# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERFTXIXG*# SEQUENCE: ERFTXIXG*# ...# >HUM1220F# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,GRYFRIQEY*# SEQUENCE: GRYFRIQEY*# ...# >HUM12210# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,SRDLRVIXG*# SEQUENCE: SRDLRVIXG*# ...# >HUM12211# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,SGFIGLTQL*# SEQUENCE: SGFIGLTQL*# ...# >HUM12212# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DKYERLVQ*# SEQUENCE: DKYERLVQ*# ...# >HUM12213# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,IFFARIQG*# SEQUENCE: IFFARIQG*# ...# >HUM12214# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DRYIHAVLL*# SEQUENCE: DRYIHAVLL*# ...# >HUM12215# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DRLERITQL*# SEQUENCE: DRLERITQL*# ...# >HUM12216# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DELIGITSL*# SEQUENCE: DELIGITSL*# ...# >HUM12217# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: eluted self peptides HPLC# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,SGVITLNTN*# SEQUENCE: SGVITLNTN*# ...# >HUM12218# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSrn (234-242)# DB REFERENCE: SWISS: (C61A_HUMAN,C61A_MOUSE)# & PIR2: (I38167)# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DAYRRIHSL*# SEQUENCE: DAYRRIHSL*# ...# >HUM12219# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DRYRRIHSL*# SEQUENCE: DRYRRIHSL*# ...# >HUM1221A# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERYPRYNQL*# SEQUENCE: ERYPRYNQL*# ...# >HUM1221B# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DRKLRINSL*# SEQUENCE: DRKLRINSL*# ...# >HUM1221C# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,GRYFRIQEV*# SEQUENCE: GRYFRIQEV*# ...# >HUM1221D# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERTLHLVEL*# SEQUENCE: ERTLHLVEL*# ...# >HUM1221E# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DRYRARHSL*# SEQUENCE: DRYRARHSL*# ...# >HUM1221F# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DRKLARNSL*# SEQUENCE: DRKLARNSL*# ...# >HUM12220# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DRKLAINSL*# SEQUENCE: DRKLAINSL*# ...# >HUM12221# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSrn (234-242) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,DAYRAIHSL*# SEQUENCE: DAYRAIHSL*# ...# >HUM12222# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,GRYFAIQEV*# SEQUENCE: GRYFAIQEV*# ...# >HUM12223# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,AAAARAAAL*# SEQUENCE: AAAARAAAL*# ...# >HUM12224# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ARYARAAAA*# SEQUENCE: ARYARAAAA*# ...# >HUM12225# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ARAARAAAL*# SEQUENCE: ARAARAAAL*# ...# >HUM12226# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,AAYARAAAA*# SEQUENCE: AAYARAAAA*# ...# >HUM12227# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ARAAARAAL*# SEQUENCE: ARAAARAAL*# ...# >HUM12228# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,AAYARAAAL*# SEQUENCE: AAYARAAAL*# ...# >HUM12229# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83)# DB REFERENCE: SWISS: (RS25_HUMAN,RS25_DROME)# & PIR1: (R3RT25)# & PIR2: (JQ1347)# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERLKIRGSL*# SEQUENCE: ERLKIRGSL*# ...# >HUM1222A# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ARLKIRGSL*# SEQUENCE: ARLKIRGSL*# ...# >HUM1222B# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERAKIRGSL*# SEQUENCE: ERAKIRGSL*# ...# >HUM1222C# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERLAIRGSL*# SEQUENCE: ERLAIRGSL*# ...# >HUM1222D# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERLKARGSL*# SEQUENCE: ERLKARGSL*# ...# >HUM1222E# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERLKIAGSL*# SEQUENCE: ERLKIAGSL*# ...# >HUM1222F# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERLKIRASL*# SEQUENCE: ERLKIRASL*# ...# >HUM12230# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERLKIRGAL*# SEQUENCE: ERLKIRGAL*# ...# >HUM12231# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal protein S25 (75-83) homologue# ANCHOR POSITIONS:# REFERENCES: dibrino94b# COMMENT:# SUMMARY: HLA-B14,actunkn,bindyesu,ERLKIRGSA*# SEQUENCE: ERLKIRGSA*# ...# >HUM12232# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,SRYVAIRTK*# SEQUENCE: SRYVAIRTK*# ...# >HUM12233# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,SRYVAIRTL*# SEQUENCE: SRYVAIRTL*# ...# >HUM12234# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,SRYVAIRTR*# SEQUENCE: SRYVAIRTR*# ...# >HUM12235# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRAFVTIGL*# SEQUENCE: GRAFVTIGL*# ...# >HUM12236# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,LRFGYPVYV*# SEQUENCE: LRFGYPVYV*# ...# >HUM12237# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,LQFGYPVYK*# SEQUENCE: LQFGYPVYK*# ...# >HUM12238# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,LQFGYPVYV*# SEQUENCE: LQFGYPVYV*# ...# >HUM12239# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GQLGFVFTK*# SEQUENCE: GQLGFVFTK*# ...# >HUM1223A# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GQLGFVFTL*# SEQUENCE: GQLGFVFTL*# ...# >HUM1223B# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRFGGGGGL*# SEQUENCE: GRFGGGGGL*# ...# >HUM1223C# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRFGGGGGR*# SEQUENCE: GRFGGGGGR*# ...# >HUM1223D# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRFGGGGGK*# SEQUENCE: GRFGGGGGK*# ...# >HUM1223E# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: beta2m dissociation# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: parker94b# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRFGGVGGV*# SEQUENCE: GRFGGVGGV*# ...# >HUM1223F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV LMP2 (421-434)# ANCHOR POSITIONS:# REFERENCES: lee93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GPVFMCLGGLTMV*# SEQUENCE: GPVFMCLGGLTMV*# ...# >HUM12240# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV LMP2 (425-438)# ANCHOR POSITIONS:# REFERENCES: lee93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,MCLGGLTMVAGAV*# SEQUENCE: MCLGGLTMVAGAV*# ...# >HUM12241# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV LMP2 (425-434)# DB REFERENCE: SWISS: (LMP2_EBV)# & PIR1: (WMBELM)# REFERENCES: lee93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,MCLGGLLTMV*# SEQUENCE: MCLGGLLTMV*# ...# >HUM12242# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: EBV LMP2 (426-434)# DB REFERENCE: SWISS: (LMP2_EBV)# & PIR1: (WMBELM)# REFERENCES: van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,CLGGLLTMV*# SEQUENCE: CLGGLLTMV*# ...# >HUM12243# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV LMP2 (426-434) homologue# ANCHOR POSITIONS:# REFERENCES: lee93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,CLGGLITMV*# SEQUENCE: CLGGLITMV*# ...# >HUM12244# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV LMP2 (426-434) homologue# ANCHOR POSITIONS:# REFERENCES: lee93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,SLGGLLTMV*# SEQUENCE: SLGGLLTMV*# ...# >HUM12245# MHC MOLECULE: HLA-B44(B*4402), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./cytotoxic inhibition as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tyrosinase (192-200)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_MOUSE,TYRO_MOUSE,TYRO_HUMAN)# & PIR1: (YRHU1,YRMSCS)# REFERENCES: brichard96a,van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,SEIWRDIDF*# SEQUENCE: SEIWRDIDF*# ...# >HUM12246# MHC MOLECULE: HLA-B44(B*4403), CLASS-1, (HUMAN)# METHOD: cytotoxicity as./cytotoxic inhibition as./reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: tyrosinase (192-200)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_MOUSE,TYRO_HUMAN,TYRO_MOUSE)# & PIR1: (YRHU1,YRMSCS)# REFERENCES: brichard96a,van_der_bruggen96a,romero96a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesh,SEIWRDIDF*# SEQUENCE: SEIWRDIDF*# ...# >HUM12247# MHC MOLECULE: HLA-B44(B*4402), CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tyrosinase (192-200)# ANCHOR POSITIONS:# REFERENCES: brichard96a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,YEIWRDIDF*# SEQUENCE: YEIWRDIDF*# ...# >HUM12248# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HCV NS4# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVH,POLG_HCVTW,POLG_HCV1,POLG_HCVBK,# & POLG_HCVJA)# & PIR1: (GNWVCH,GNWVCJ,GNWVTW,GNWVTC,GNWVC3)# & PIR2: (PS0326,S40770,A45573,S18030)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,LLFNILGGWV*# SEQUENCE: LLFNILGGWV*# ...# >HUM12249# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV POL# DB REFERENCE: SWISS: (DPOL_HPBV9,DPOL_HPBVT,DPOL_HPBVI,DPOL_HPBVY,DPOL_HPBVZ,# & DPOM_HPBVY,DPOL_HPBVJ,DPOL_HPBVO,DPOL_HPBVA,DPOL_HPBVP,# & DPOL_HPBVL,DPOL_HPBVR,DPOL_HPBV2,DPOL_HPBV4,# & DPOL_HPBVM)# & PIR1: (JDVLVS,JDVLA1,JDVLCP,JDVLVD,JDVLJ2,JDVLVB,S20757,S43491,# & JDVLVA,JDVLVR,JDVLVH,JDVLKS,JDVLJ1,JQ2229,S20752,# & JDVLJ3)# & PIR2: (S35527,S71785)# REFERENCES: wentworth96a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,ALMPLYACI*# SEQUENCE: ALMPLYACI*# ...# >HUM1224A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HCV NS1/E2# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCVTW,POLG_HCVBK,POLG_HCV1,POLG_HCVJ7,# & POLG_HCVJT,POLG_HCVJ6,POLG_HCVJA,POLG_HCVJ5)# & PIR1: (GNWVCJ,GNWVTC,GNWVTW,GNWVCH,GNWVC3)# & PIR2: (S19876,A45573,S19875,S40770,S18031,S18030,PN0677,JQ1366,# & S18032,JQ1303)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLLLADARV*# SEQUENCE: FLLLADARV*# ...# >HUM1224B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HCV CORE# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVTH,POLG_HCVJ2,POLG_HCVH7,POLG_HCVH4,# & POLG_HCVH8,POLG_HCVTW,POLG_HCVBK,POLG_HCV1,POLG_HCVJT,# & POLG_HCVE1,POLG_HCVHK,POLG_HCVH)# & PIR1: (GNWVCH,GNWVCJ,GNWVTC,GNWVC3,GNWVTW)# & PIR2: (S12707,JN0265,S21471,S18031,PN0677,JQ1925,A44150,A45573,# & PC2219,PS0388,PC1284,S41288,S18032,PC2061,S18030,JQ1584,# & JH0711,PC2060,JQ1926,S40770,S19875)# & PIR3: (S32740)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,DLMGYIPLV*# SEQUENCE: DLMGYIPLV*# ...# >HUM1224C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HPV 16 E6# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,FAFRDLCIV*# SEQUENCE: FAFRDLCIV*# ...# >HUM1224D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HCV NS4# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVJA,POLG_HCVH,POLG_HCVBK,POLG_HCV1)# & PIR1: (GNWVCH,GNWVTC,GNWVC3,GNWVCJ)# & PIR2: (S18030,S40770,A45573,PS0326)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,ILAGYGAGV*# SEQUENCE: ILAGYGAGV*# ...# >HUM1224E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HCV CORE# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVH,POLG_HCVJ7,POLG_HCVBK,POLG_HCVJA,# & POLG_HCVJ5,POLG_HCVJ8,POLG_HCV1,POLG_HCVJ2,POLG_HCVJ6)# & PIR1: (GNWVCH,GNWVJ8,GNWVTC,GNWVTW,GNWVCJ,GNWVC3)# & PIR2: (JQ0883,S41346,JQ0881,S41368,S41350,S41352,PN0677,S41345,# & S41349,S40770,S41342,PQ0805,A44150,S41363,S41366,S41351,# & S41356,S41370,S41362,PQ0804,S41353,S41371,PS0388,S41355,# & PC1284,S41341,JQ1303,S12707,JN0265,S41347,S41343,S41365,# & JH0711,S41354,S18031,S41364,S21471,S19875,JQ1584,S41369,# & S41357,S18030,S21336,S18032)# & PIR3: (S32740)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,YLLPRRGPRL*# SEQUENCE: YLLPRRGPRL*# ...# >HUM1224F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HBV ENV# DB REFERENCE: SWISS: (VMSA_HPBVJ,VMSA_HPBVP,VMSA_HPBVZ,VMSA_HPBV2,VMSA_HPBVY,# & VMSA_HPBVS,VMSA_HPBVL,VMSA_HPBVO,VMSA_HPBV4,VMSA_HPBVW,# & VMSA_HPBVR,VMSA_HPBVN,VMSA_HPBVW,VMSA_HPBV0,VMSA_HPBVD,# & VMSA_HPBV2,VMSA_HPBVA,VMSA_HPBVR,VMSA_HPBVY)# & PIR1: (JQ1570,SAVLJ1,JQ1573,JQ1578,JQ1575,SAVLN1,SAVLA,SAVLAD,# & SAVLA1,SAVLBH,SAVLAR,SAVLVD,SAVLCP,JQ1581,SAVLJ2,SAVLAJ,# & SAVLAH,JQ1577,SAVLHV,SAVLVE)# & PIR2: (JQ2053,JQ2069,S20749,S32202,JQ2111,JQ2100,JQ2087,JQ2060,# & JQ2113,JQ2097,JQ2054,JQ2115,JQ2077,JQ2059,S41870,JQ2050,# & JQ2066,JQ2076,S20745,JQ2051,JQ2079,S35528,JQ2098,S20753,# & JQ2112,JQ2085,JQ2055,S43492,JQ2070,JQ2114,JQ2088,JQ2092,# & JQ2091,JQ2072,JQ2047,JQ2052,JQ2102,JQ2061,JQ2116,JQ2057,# & S36654,JQ2109,JQ2090,JQ2123,JQ2103,JQ2065,JQ2073,JQ2058,# & S08142,S41869,S47411,JQ2099,JQ2046,JQ2075,JQ2063,JQ2094,# & JQ2056,JQ2045,JQ2048,JQ2078,JQ2083,JQ2081,JQ2108,JQ2104,# & JQ2105,JQ2068,JQ2080,JQ2110,JQ2067,S47407,JQ2095)# & PIR4: (S42226)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,LLVLQAGFFL*# SEQUENCE: LLVLQAGFFL*# ...# >HUM12250# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: BCV NS4# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVTW,POLG_HCVBK,POLG_HCV1,POLG_HCVH,# & POLG_HCVJT)# & PIR1: (GNWVTW,GNWVTC,GNWVC3,GNWVCJ,GNWVCH)# & PIR2: (S40770,A45573,S18030,PS0326)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,ILGGWVAAQL*# SEQUENCE: ILGGWVAAQL*# ...# >HUM12251# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as./competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBV POL# DB REFERENCE: SWISS: (DPOL_HPBV2,DPOL_HPBVM,DPOL_HPBVP,DPOL_HPBVI,DPOM_HPBVY,# & DPOL_HPBV9,DPOL_HPBVZ,DPOL_HPBVY,DPOL_HPBVL,DPOL_HPBVJ,# & DPOL_HPBVA,DPOL_HPBVR,DPOL_HPBV4)# & PIR1: (JDVLVH,JDVLA1,JDVLVB,JDVLCP,S20752,JDVLJ3,JDVLJ1,S20757,# & S43491,JDVLVA,S47406,JDVLVS,JDVLVR,JDVLVD,JDVLKS)# & PIR2: (S71785,S35527)# REFERENCES: wentworth96a,bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,YMDDVVLGA*# SEQUENCE: YMDDVVLGA*# ...# >HUM12252# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HPV 16 E7# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,GTLGIVCPI*# SEQUENCE: GTLGIVCPI*# ...# >HUM12253# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: HCV NS1/E2# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVJA,POLG_HCVTW,POLG_HCVBK,POLG_HCVH,# & POLG_HCV1)# & PIR1: (GNWVCH,GNWVCJ,GNWVTC,GNWVC3,GNWVTW)# & PIR2: (S19875,S40770,S19876,A45573,S18031,S18032,PN0677,# & S18030)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,ALSTGLIHL*# SEQUENCE: ALSTGLIHL*# ...# >HUM12254# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HCV CORE (178-187)# DB REFERENCE: SWISS: (POLG_HCVTH,POLG_HCVH,POLG_HCV1,POLG_HCVH8,POLG_HCVH7,# & POLG_HCVE1)# & PIR1: (GNWVC3,GNWVCH)# & PIR2: (S18032,A44150,JQ1584,S18030,S40770,S19875)# & PIR3: (S32740)# REFERENCES: wentworth96a,van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,LLALLSCLTV*# SEQUENCE: LLALLSCLTV*# ...# >HUM12255# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HCV CORE# DB REFERENCE: SWISS: (POLG_HCVJ2,POLG_HCVJA,POLG_HCVTW,POLG_HCVJT)# & PIR1: (GNWVTW,GNWVCJ)# & PIR2: (S12707,A45573,PC1284,PN0677,S21471,S19876,S18031)# REFERENCES: wentworth96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,LLALLSCLTI*# SEQUENCE: LLALLSCLTI*# ...# >HUM12256# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV NS5# DB REFERENCE: SWISS: (POLG_HCVBK)# & PIR1: (GNWVTC)# REFERENCES: kurokohchi96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,TGAPVTYSTY*# SEQUENCE: TGAPVTYSTY*# ...# >HUM12257# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: Human wild type p53 (25-33)# DB REFERENCE: SWISS: (P53_FELCA,P53_FELCA,P53_CERAE,P53_HUMAN,P53_CANFA,# & P53_CERAE,P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,LLPENNVLS*# SEQUENCE: LLPENNVLS*# ...# >HUM12258# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: Human wild type p53 (31-39)# DB REFERENCE: SWISS: (P53_CERAE,P53_HUMAN,P53_HUMAN,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,VLSPLPSQA*# SEQUENCE: VLSPLPSQA*# ...# >HUM12259# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: Human wild type p53 (31-40)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# & PIR1: (DNHU53)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,VLSPLPSQAM*# SEQUENCE: VLSPLPSQAM*# ...# >HUM1225A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: Human wild type p53 (69-76)# DB REFERENCE: SWISS: (P53_HUMAN,IDUA_HUMAN,P53_HUMAN)# & PIR2: (S53645)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,AAPPVAPA*# SEQUENCE: AAPPVAPA*# ...# >HUM1225B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: Human wild type p53 (69-78)# DB REFERENCE: SWISS: (P53_HUMAN,P53_HUMAN)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,AAPPVAPAPA*# SEQUENCE: AAPPVAPAPA*# ...# >HUM1225C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: Human wild type p53 (78-86)# DB REFERENCE: SWISS: (P53_HUMAN,P53_CERAE,P53_HUMAN,P53_CERAE)# & PIR1: (DNHU53)# & PIR2: (S06594)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,AAPTPAAPA*# SEQUENCE: AAPTPAAPA*# ...# >HUM1225D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: Human wild type p53 (149-157)# DB REFERENCE: SWISS: (P53_HUMAN,P53_RAT,P53_MESAU,P53_CRIGR,P53_RAT,P53_MESAU,# & P53_HUMAN)# & PIR1: (DNHU53)# & PIR2: (JH0633,JC6176,S02192,JC6193)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesl,STPPPGTRV*# SEQUENCE: STPPPGTRV*# ...# >HUM1225E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: Human wild type p53 (210-218)# ANCHOR POSITIONS:# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesm,NTFRHSWV*# SEQUENCE: NTFRHSWV*# ...# >HUM1225F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: Human wild type p53 (255-264)# DB REFERENCE: SWISS: (P53_HUMAN,P53_RAT,P53_RAT,P53_CERAE,P53_MOUSE,P53_MOUSE,# & P53_HUMAN,P53_CERAE)# & PIR1: (DNHU53,DNMS53)# & PIR2: (JC6193,S02192,S06594,S38824)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,ITLEDSSGNL*# SEQUENCE: ITLEDSSGNL*# ...# >HUM12260# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: Human wild type p53 (255-265)# DB REFERENCE: SWISS: (P53_HUMAN,P53_MOUSE,P53_MOUSE,P53_RAT,P53_CERAE,# & P53_HUMAN,P53_RAT,P53_CERAE)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S06594,S02192,S38824,JC6193)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesl,ITLEDSSGNLL*# SEQUENCE: ITLEDSSGNLL*# ...# >HUM12261# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: inhibition as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, high# SOURCE: Mouse wild type p53 (261-269)# DB REFERENCE: SWISS: (P53_MOUSE,P53_RAT,P53_MOUSE,P53_RAT)# & PIR1: (DNMS53)# & PIR2: (S38824,S02192)# REFERENCES: theobald95a# COMMENT:# SUMMARY: HLA-A2,actyesn,bindyesh,LLGRDSFEV*# SEQUENCE: LLGRDSFEV*# ...# >HUM22262# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pf155/RESA (181-195)# DB REFERENCE: SWISS: (RESA_PLAFF)# & PIR2: (A25526)# REFERENCES: fievet# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,LGRSGGDIIKKMQTL*# SEQUENCE: LGRSGGDIIKKMQTL*# ...# >HUM22263# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pf155/RESA (533-551)# DB REFERENCE: SWISS: (RESA_PLAFF,RESA_PLAFN)# & PIR2: (A25526)# REFERENCES: fievet# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NADMNEITERYFKLAENYY*# SEQUENCE: NADMNEITERYFKLAENYY*# ...# >HUM22264# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pf155/RESA (700-714)# DB REFERENCE: SWISS: (RESA_PLAFF,RESA_PLAFN)# & PIR2: (A25526)# REFERENCES: fievet# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,SLRWIFKHVAKTHLK*# SEQUENCE: SLRWIFKHVAKTHLK*# ...# >HUM22265# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pf155/RESA (862-878)# DB REFERENCE: SWISS: (RESA_PLAFF)# & PIR2: (A25526)# REFERENCES: fievet# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IVGYIMHGISTINTEMK*# SEQUENCE: IVGYIMHGISTINTEMK*# ...# >HUM22266# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Pf155/RESA (944-959)# DB REFERENCE: SWISS: (RESA_PLAFF)# & PIR2: (S21342,A25526)# REFERENCES: fievet# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EENVEHDAEENVEHDA*# SEQUENCE: EENVEHDAEENVEHDA*# ...# >MUS22267# MHC MOLECULE: I-Ap, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (I60384)# REFERENCES: fievet# COMMENT:# SUMMARY: I-Ap,actyesu,bindyesu,IAGFKGEQGPK*# SEQUENCE: IAGFKGEQGPK*# ...# >MUS22268# MHC MOLECULE: I-Ap, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (89-101)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_BOVIN,MBP_PANTR,MBP_MOUSE,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBHUB,MBCZB,MBBOB,MBPGB,MBMSB,MBRTS)# & PIR2: (A37246)# REFERENCES: fievet# COMMENT:# SUMMARY: I-Ap,actyesu,bindyesu,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >MUS22269# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_HUMAN,CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# & PIR2: (I60384)# REFERENCES: fievet# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKGEQGPK*# SEQUENCE: IAGFKGEQGPK*# ...# >MUS2226A# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (89-101)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_CAVPO,MBP_PANTR,MBP_MOUSE,MBP_HUMAN,# & MBP_RAT)# & PIR1: (MBHUB,MBBOB,MBPGB,MBCZB,MBMSB,MBRTS)# & PIR2: (A37246)# REFERENCES: fievet# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,VHFFKNIVTPRTP*# SEQUENCE: VHFFKNIVTPRTP*# ...# >MUS2226B# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKAEQGPK*# SEQUENCE: IAGFKAEQGPK*# ...# >MUS2226C# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKGEAGPK*# SEQUENCE: IAGFKGEAGPK*# ...# >MUS2226D# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKGEQAPK*# SEQUENCE: IAGFKGEQAPK*# ...# >MUS2226E# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKGEQGAK*# SEQUENCE: IAGFKGEQGAK*# ...# >MUS2226F# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKGEQGPA*# SEQUENCE: IAGFKGEQGPA*# ...# >MUS22270# MHC MOLECULE: I-Ap, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Ap,actyesu,bindyesu,AAGFKGEQGPK*# SEQUENCE: AAGFKGEQGPK*# ...# >MUS22271# MHC MOLECULE: I-Ap, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Ap,actyesu,bindyesu,IAGFKAEQGPK*# SEQUENCE: IAGFKAEQGPK*# ...# >MUS22272# MHC MOLECULE: I-Ap, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Ap,actyesu,bindyesu,IAGFKGEAGPK*# SEQUENCE: IAGFKGEAGPK*# ...# >MUS22273# MHC MOLECULE: I-Ap, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Ap,actyesu,bindyesu,IAGFKGEQAPK*# SEQUENCE: IAGFKGEQAPK*# ...# >MUS22274# MHC MOLECULE: I-Ap, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Ap,actyesu,bindyesu,IAGFKGEQGAK*# SEQUENCE: IAGFKGEQGAK*# ...# >MUS22275# MHC MOLECULE: I-Ap, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: chick collagen cII (260-270) homologue# ANCHOR POSITIONS:# REFERENCES: fievet# COMMENT:# SUMMARY: I-Ap,actyesu,bindyesu,IAGFKGEQGPA*# SEQUENCE: IAGFKGEQGPA*# ...# >HUM12276# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as./Reference/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV-1 gag p17 (77-85)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1JR,GAG_HV1PV,GAG_HV1B5,GAG_HV1Y2,# & GAG_HV1EL,GAG_HV1H2,GAG_HV1OY,GAG_HV1ND,GAG_HV1A2,# & GAG_HV1BR,GAG_HV1MA,GAG_HV1B1,GAG_HV1MN,GAG_HV1W2)# & PIR1: (FOVWH3,FOVWH4,FOVWVL,FOLJND,A44001,FOVWLV,A38068,# & FOVWA2)# & PIR3: (S33979)# REFERENCES: barouch95a,van_der_burg95a,van_der_burg96a,hivdb97a,goulder97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,SLYNTVATL*# SEQUENCE: SLYNTVATL*# ...# >HUM12277# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 gag p17 (77-85)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1B5,GAG_HV1Y2,GAG_HV1B1,GAG_HV1EL,# & GAG_HV1W2,GAG_HV1PV,GAG_HV1MA,GAG_HV1JR,GAG_HV1MN,# & GAG_HV1OY,GAG_HV1ND,GAG_HV1BR,GAG_HV1H2,GAG_HV1A2)# & PIR1: (FOVWH3,FOVWA2,FOVWVL,FOLJND,A44001,A38068,FOVWLV,# & FOVWH4)# & PIR3: (S33979)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLYNTVATL*# SEQUENCE: SLYNTVATL*# ...# >HUM12278# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 pol (476-484)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1MA,POL_HV1Z2,POL_HV1BR,POL_HV1PV,# & POL_HV1RH,POL_HV1EL,POL_HV1ND,POL_HV1MN,POL_HV1OY,# & POL_HV1JR,POL_HV1B5,POL_HV1Y2,POL_HV1B1,POL_HV1H2)# & PIR1: (GNVWLV,GNVWH3,B44001,GNLJND,GNVWVL)# & PIR2: (B47175,S54378)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM12279# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: nfluenza matrix protein (58-66)# DB REFERENCE: SWISS: (VMT1_IAWIL,VMT1_IABAN,VMT1_IACKB,VMT1_IAMAN,VMT1_IAFOW,# & VMT1_IAUDO,VMT1_IAZI1,VMT1_IAPUE,VMT1_IAANN,VMT1_IAUSS,# & VMT1_IALE1,VMT1_IALE2)# & PIR1: (MFIV,MFIV61,MFIVC,MFIV1K,MFIV1M,JN0392,MFIVWS)# & PIR2: (S14616,S04050,S04058,S04054,S07429,S04056,S04052)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM1227A# MHC MOLECULE: HLA-A69(A*6901), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: nfluenza matrix protein (58-66)# DB REFERENCE: SWISS: (VMT1_IAUDO,VMT1_IAZI1,VMT1_IAPUE,VMT1_IAFOW,VMT1_IALE2,# & VMT1_IALE1,VMT1_IAANN,VMT1_IAUSS,VMT1_IABAN,VMT1_IACKB,# & VMT1_IAWIL,VMT1_IAMAN)# & PIR1: (MFIV1M,MFIV1K,MFIV,JN0392,MFIV61,MFIVWS,MFIVC)# & PIR2: (S04052,S04056,S04054,S04050,S14616,S07429,S04058)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesh,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM1227B# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp90# DB REFERENCE: SWISS: (HS9B_RAT,HS9B_MOUSE,HS9B_HUMAN,HS9B_HUMAN)# & PIR1: (HHMS84,HHHU84)# & PIR2: (I57523)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,AVPDEIPPL*# SEQUENCE: AVPDEIPPL*# ...# >HUM1227C# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human MHC class I alpha# DB REFERENCE: SWISS: (1C04_GORGO,1C02_GORGO,1C02_GORGO,1C12_HUMAN,1B29_HUMAN,# & 1B07_HUMAN,1C03_GORGO,1B31_HUMAN,1B08_HUMAN,1B26_HUMAN,# & 1C11_HUMAN,1C07_HUMAN,1B32_HUMAN,1C14_HUMAN,1B23_HUMAN,# & 1C13_HUMAN)# & PIR1: (S42102)# & PIR2: (I68850,I38874,I79640,JH0545,JH0526,I61862,I37544,I59645,# & I84488,I80166,I54505,I54314,I80168,I80167,JH0546,I56133,# & I61859,I80165,I37135,I38875,C35997,I81232,I68774,S24440,# & S24439,JH0547,I61904,I80170,I54463,JS0262,I37078)# & PIR3: (G02922)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FAYDGKDYI*# SEQUENCE: FAYDGKDYI*# ...# >HUM1227D# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: expressed sequence tag# DB REFERENCE: SWISS: (Y174_HUMAN,Y174_HUMAN)# ANCHOR POSITIONS:# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FVLPELPSV*# SEQUENCE: FVLPELPSV*# ...# >HUM1227E# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: connexin 32# DB REFERENCE: SWISS: (CXB1_HUMAN,CXB1_RAT,CXB1_MOUSE,CXB1_HUMAN,CXB1_RAT,# & CXB1_MOUSE)# & PIR1: (B29005,B49769,GJRT)# & PIR2: (B56601)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,YVISVVFRL*# SEQUENCE: YVISVVFRL*# ...# >HUM1227F# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FQLEINVRL*# SEQUENCE: FQLEINVRL*# ...# >HUM12280# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L35 ribosomal protein# ANCHOR POSITIONS:# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FQLDDLKVEL*# SEQUENCE: FQLDDLKVEL*# ...# >HUM12281# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: bovine hemoglobin# DB REFERENCE: SWISS: (HBA_ROUAE,HBA_PTEAL,HBA_BOVIN,HBA2_BOSMU,HBA_RANTA,# & HBA_BOVIN,HBA_ALCAA,HBA_CYNSP,HBA1_BOSMU)# & PIR1: (HAEKN,HAFXB,HAYA1,HABO,HAYA2,HABTF)# & PIR2: (A29392)# & PIR3: (S13481)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,HLPSDFTPAV*# SEQUENCE: HLPSDFTPAV*# ...# >HUM12282# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 60S ribosomal protein# DB REFERENCE: SWISS: (RL19_HUMAN,RL19_MOUSE)# & PIR1: (R5RT19)# & PIR2: (A48992,A36554)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ILMEHIHKL*# SEQUENCE: ILMEHIHKL*# ...# >HUM12283# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human MHC class I alpha# DB REFERENCE: SWISS: (1C13_HUMAN,1B07_HUMAN,1B23_HUMAN,1C04_GORGO,1C12_HUMAN,# & 1C03_GORGO,1B26_HUMAN,1B29_HUMAN,1B31_HUMAN,1B32_HUMAN,# & 1C07_HUMAN,1C11_HUMAN,1C02_GORGO,1C02_GORGO,1B08_HUMAN,# & 1C14_HUMAN)# & PIR1: (S42102)# & PIR2: (I80166,I54314,I37544,JH0526,JH0545,JH0547,I61859,JH0546,# & I84488,I68774,I80165,I79640,S24440,I54505,I59645,I80170,# & I61904,S24439,I81232,I38875,C35997,I38874,I61862,I68850,# & I37078,JS0262,I54463,I37135,I56133,I80168,I80167)# & PIR3: (G02922)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FAYDGKDYI*# SEQUENCE: FAYDGKDYI*# ...# >HUM12284# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-E precursor# DB REFERENCE: SWISS: (HLAE_HUMAN,HLAE_PONPY)# & PIR2: (I69006,I69005,A28834,A27797,I61867,I68745,I69002,I54551,# & I69004,I69003)# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FAYDGKDYL*# SEQUENCE: FAYDGKDYL*# ...# >HUM12285# MHC MOLECULE: HLA-A2(A*0214), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ubiquitin# ANCHOR POSITIONS:# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,STLHLVRL*# SEQUENCE: STLHLVRL*# ...# >HUM12286# MHC MOLECULE: HLA-A69(A*6901), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: gamma actin# ANCHOR POSITIONS:# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesu,ETFNTPAHYV*# SEQUENCE: ETFNTPAHYV*# ...# >HUM12287# MHC MOLECULE: HLA-A69(A*6901), CLASS-1, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: elongation factor# ANCHOR POSITIONS:# REFERENCES: barouch95a# COMMENT:# SUMMARY: HLA-A69,actunkn,bindyesu,ETVAVGVIKAV*# SEQUENCE: ETVAVGVIKAV*# ...# >MUS12288# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: T cell activation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: malarkannan95b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,ASVVEFSSL*# SEQUENCE: ASVVEFSSL*# ...# >MUS12289# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: T cell activation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: malarkannan95b# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,SVVEFSSL*# SEQUENCE: SVVEFSSL*# ...# >MUS22294# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MCC (91-103)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI,CYC_CHLRE,CYC_CHLRE)# & PIR1: (CCPY)# & PIR2: (S29514)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,RADLIAYLKQATA*# SEQUENCE: RADLIAYLKQATA*# ...# >MUS22295# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IL-2R gamma chain (168-182)# DB REFERENCE: SWISS: (CYRG_MOUSE,CYRG_MOUSE)# & PIR2: (I49280,S37582)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,SQLELRWKSRHIKER*# SEQUENCE: SQLELRWKSRHIKER*# ...# >MUS22296# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IL-2R gamma chain (170-182)# DB REFERENCE: SWISS: (CYRG_MOUSE,CYRG_MOUSE)# & PIR2: (I49280,S37582)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,LELRWKSRHIKER*# SEQUENCE: LELRWKSRHIKER*# ...# >MUS22297# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apo-E prec. (222-236)# DB REFERENCE: SWISS: (APE_BOVIN,APE_BOVIN)# & PIR2: (I45996,S26478)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,ERAEAWRQKLHGRL*# SEQUENCE: ERAEAWRQKLHGRL*# ...# >MUS22298# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apo-E prec. (223-236)# DB REFERENCE: SWISS: (APE_BOVIN,APE_BOVIN)# & PIR2: (S26478,I45996)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,RAEAWRQKLHGRL*# SEQUENCE: RAEAWRQKLHGRL*# ...# >MUS22299# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,AQFMWIIRKRIQLP*# SEQUENCE: AQFMWIIRKRIQLP*# ...# >MUS2229A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: similar to apolipoprotein B (2211-2224)# ANCHOR POSITIONS:# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,SLDEHYHIRVHLVK*# SEQUENCE: SLDEHYHIRVHLVK*# ...# >MUS2229B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: C. elegans cDNA homolog (74-87)# ANCHOR POSITIONS:# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,GQFYFLIRKRIHLR*# SEQUENCE: GQFYFLIRKRIHLR*# ...# >MUS2229C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Actin B 8-# DB REFERENCE: SWISS: (ACT2_BACDO,ACTM_APLCA,ACT1_CAEEL,ACT1_PHYIN,ACT2_BOMMO,# & ACT5_CHICK,ACT1_PODCA,ACT1_ONCVO,ACT1_ECHGR,ACT1_FUGRU,# & ACTA_LIMPO,ACTY_LIMPO,ACT3_BOMMO,ACT3_PODCA,ACT2_DIPDE,# & ACT2_ONCVO,ACT_FUCDI,ACT5_DROME,ACTC_HALRO,ACTA_LIMPO,# & ACT2_SCHMA,ACTB_RABIT,ACT1_DROME,ACT_MANSE,ACTY_LIMPO,# & ACTM_HELER,ACT1_BOMMO,ACT4_ARTSX,ACT6_DIPDE,ACTB_HUMAN,# & ACT1_NAEFO,ACT3_LIMPO,ACT1_NAEFO,ACT_ACHBI,ACTM_HELTB,# & ACTM_HELTB,ACTB_CRIGR,ACT2_ARTSX,ACT4_CAEEL,ACT_TAESO,# & ACT3_FUGRU,ACTB_CYPCA,ACT4_CAEEL,ACTM_PISOC,ACT_HYDAT,# & ACT2_DROME,ACT5_BACDO,ACT1_ARTSX,ACT2_FUGRU,ACT_FUCDI,# & ACT3_DROME,ACTC_STYPL,ACT2_DIPDE,ACT_ENTHI,ACTC_PISOC,# & ACT4_DROME,ACT3_LIMPO,ACT6_DIPDE,ACT3_BACDO,ACT_FUCVE,# & ACTM_HELER)# & PIR1: (ATBOB,ATRBB,ATFF7,ATHUB,ATAXE,ATCHB,ATMSB,A48324)# & PIR2: (JS0190,S43509,S16710,JN0832,S38782,JE0414,A28258,A26559,# & S05430,A61043,JS0189,A25135,JQ0154,JN0833,S24408,S49480,# & S33386,A03000,S04538,S11450,S07382,S11451,S11453,S49481,# & S09059,S07251,JC5227,JC5228,A48449,S27135,S08596,S12730,# & S49479)# & PIR3: (A44940,S71126,S71124,S71125)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,LVVDNGSGMCKAGF*# SEQUENCE: LVVDNGSGMCKAGF*# ...# >MUS2229D# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: carboxypeptidase A (44-54)# DB REFERENCE: SWISS: (CBPC_MOUSE)# & PIR2: (A34487)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,LYVLKIGKKDG*# SEQUENCE: LYVLKIGKKDG*# ...# >MUS2229E# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta2m (42-56)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,HPPHIEIQMLKNGKK*# SEQUENCE: HPPHIEIQMLKNGKK*# ...# >MUS2229F# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: H-2Ld (160-175)# DB REFERENCE: SWISS: (HA1L_MOUSE,HA11_MOUSE,HA11_MOUSE)# & PIR1: (HLMSLD,HLMSDB)# & PIR2: (I54069,JL0059,B60854,I56002,I60188,I55665,JL0058,C60854,# & I70694,I48658)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,EGECVEWLHRYLKNG*# SEQUENCE: EGECVEWLHRYLKNG*# ...# >MUS222A0# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta-actin (286-303)# DB REFERENCE: SWISS: (ACTT_FUGRU,ACTS_HUMAN,ACT1_FUGRU,ACTC_FUGRU,ACT3_FUGRU,# & ACTH_HUMAN,ACT1_HALRO,ACT1_XENLA,ACTA_CHICK,ACT3_LIMPO,# & ACT8_XENLA,ACTB_RABIT,ACT2_ONCVO,ACTM_MOLOC,ACT1_CAEEL,# & ACTB_CRIGR,ACT4_CAEEL,ACTS_CARAU,ACTA_HUMAN,ACTG_HUMAN,# & ACTN_STYCL,ACTS_CYPCA,ACT3_LIMPO,ACTS_PLEWA,ACT2_XENTR,# & ACT4_CAEEL,ACTB_HUMAN,ACT2_HALRO,ACT4_ARTSX,ACTS_FUGRU,# & ACTB_XENBO,ACT3_XENLA,ACT2_CAEEL,ACTM_STYCL,ACT1_DROME,# & ACTH_HUMAN,ACT2_XENLA,ACT5_CHICK,ACTM_MOLOC,ACT4_DROME,# & ACT5_XENLA,ACTC_HUMAN)# & PIR1: (ATBOG,A43552,ATRB,ATRT,ATMSG,A23022,ATCHSM,ATMSB,ATCH,# & B29686,ATHUSM,ATRBB,A25719,A24904,S11222,A22224,ATHU,# & ATHUC,ATBOB,ATFF7,ATCHB,ATBOSM,ATRBSM,ATHUG,ATRTC,# & ATHUB)# & PIR2: (S16710,I46679,I39393,A43911,I46473,A32788,A54728,S49480,# & A26337,S21907,B24848,A55001,A31375,A24848,S27135,B25819,# & S01077,S16709,A29686,S38782,S11453,A26559,A40261)# & PIR3: (S71126,S71124,S71120,S71118,S71119)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,MQKEITALAPSTMKIKII*# SEQUENCE: MQKEITALAPSTMKIKII*# ...# >MUS222A1# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: substance P receptor (255-261)# DB REFERENCE: SWISS: (NK1R_RAT)# & PIR2: (A34357)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,CTFAICWLPFHVFFL*# SEQUENCE: CTFAICWLPFHVFFL*# ...# >MUS222A2# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSP60 (478-492)# DB REFERENCE: SWISS: (P60_HUMAN,P60_HUMAN)# & PIR1: (A32800)# & PIR2: (I53042)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Es,actunkn,bindyesu,EGSLIVEKIMQSSSE*# SEQUENCE: EGSLIVEKIMQSSSE*# ...# >MUS222A3# MHC MOLECULE: I-Es, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MCC (95-103)# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Es,actyesu,bindyesu,IAYLKQATK*# SEQUENCE: IAYLKQATK*# ...# >MUS222A4# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MuLV env protein (454-475)# DB REFERENCE: SWISS: (ENV_MLVAV)# & PIR1: (VCVWEK)# & PIR2: (B43491,A46511,A43491)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Eb,actunkn,bindyesu,SPSYVYHQFERRAKYKREPVSL*# SEQUENCE: SPSYVYHQFERRAKYKREPVSL*# ...# >MUS222A5# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: BSA (141-153)# DB REFERENCE: SWISS: (ALBU_FELCA,ALBU_PIG,ALBU_BOVIN)# & PIR1: (ABBOS,ABPGS)# & PIR2: (S57632,JC4660)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Eb,actunkn,bindyesu,GKYLYEIARRHPYFY*# SEQUENCE: GKYLYEIARRHPYFY*# ...# >MUS222A6# MHC MOLECULE: I-Eb, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MCC (95-103)# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Eb,actyesu,bindyesu,IAYLKQATK*# SEQUENCE: IAYLKQATK*# ...# >HUM122A7# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,S33015,S27922)# REFERENCES: smith95# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,QPRAPIRPI*# SEQUENCE: QPRAPIRPI*# ...# >HUM122A8# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (EBN3_EBV,EBN3_EBV)# & PIR2: (A24938)# REFERENCES: smith95# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,RPPIFIRRL*# SEQUENCE: RPPIFIRRL*# ...# >HUM122A9# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1BN,NEF_HV1BR)# & PIR1: (ASLJBR,ASLJFV)# & PIR2: (S24985,S03247,S03244,S43467)# REFERENCES: smith95# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,TPGPGVRYPL*# SEQUENCE: TPGPGVRYPL*# ...# >MUS122AA# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,AAPGNYPAL*# SEQUENCE: AAPGNYPAL*# ...# >MUS122AB# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,DAPGNYPAL*# SEQUENCE: DAPGNYPAL*# ...# >MUS122AC# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesl,bindyesu,EAPGNYPAL*# SEQUENCE: EAPGNYPAL*# ...# >MUS122AD# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,GAPGNYPAL*# SEQUENCE: GAPGNYPAL*# ...# >MUS122AE# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,HAPGNYPAL*# SEQUENCE: HAPGNYPAL*# ...# >MUS122AF# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,IAPGNYPAL*# SEQUENCE: IAPGNYPAL*# ...# >MUS122B0# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,KAPGNYPAL*# SEQUENCE: KAPGNYPAL*# ...# >MUS122B1# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,LAPGNYPAL*# SEQUENCE: LAPGNYPAL*# ...# >MUS122B2# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,NAPGNYPAL*# SEQUENCE: NAPGNYPAL*# ...# >MUS122B3# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,PAPGNYPAL*# SEQUENCE: PAPGNYPAL*# ...# >MUS122B4# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,QAPGNYPAL*# SEQUENCE: QAPGNYPAL*# ...# >MUS122B5# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,RAPGNYPAL*# SEQUENCE: RAPGNYPAL*# ...# >MUS122B6# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,SAPGNYPAL*# SEQUENCE: SAPGNYPAL*# ...# >MUS122B7# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,VAPGNYPAL*# SEQUENCE: VAPGNYPAL*# ...# >MUS122B8# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,YAPGNYPAL*# SEQUENCE: YAPGNYPAL*# ...# >MUS122B9# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPANYPAL*# SEQUENCE: FAPANYPAL*# ...# >MUS122BA# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPDNYPAL*# SEQUENCE: FAPDNYPAL*# ...# >MUS122BB# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPENYPAL*# SEQUENCE: FAPENYPAL*# ...# >MUS122BC# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPFNYPAL*# SEQUENCE: FAPFNYPAL*# ...# >MUS122BD# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPHNYPAL*# SEQUENCE: FAPHNYPAL*# ...# >MUS122BE# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPLNYPAL*# SEQUENCE: FAPLNYPAL*# ...# >MUS122BF# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPQNYPAL*# SEQUENCE: FAPQNYPAL*# ...# >MUS122C0# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPRNYPAL*# SEQUENCE: FAPRNYPAL*# ...# >MUS122C1# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPSNYPAL*# SEQUENCE: FAPSNYPAL*# ...# >MUS122C2# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesl,bindyesu,FAPTNYPAL*# SEQUENCE: FAPTNYPAL*# ...# >MUS122C3# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,FAPVNYPAL*# SEQUENCE: FAPVNYPAL*# ...# >MUS122C4# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPYNYPAL*# SEQUENCE: FAPYNYPAL*# ...# >MUS122C5# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,FAPGAYPAL*# SEQUENCE: FAPGAYPAL*# ...# >MUS122C6# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,FAPGDYPAL*# SEQUENCE: FAPGDYPAL*# ...# >MUS122C7# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGEYPAL*# SEQUENCE: FAPGEYPAL*# ...# >MUS122C8# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGFYPAL*# SEQUENCE: FAPGFYPAL*# ...# >MUS122C9# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,FAPGGYPAL*# SEQUENCE: FAPGGYPAL*# ...# >MUS122CA# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGHYPAL*# SEQUENCE: FAPGHYPAL*# ...# >MUS122CB# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGIYPAL*# SEQUENCE: FAPGIYPAL*# ...# >MUS122CC# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGKYPAL*# SEQUENCE: FAPGKYPAL*# ...# >MUS122CD# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGLYPAL*# SEQUENCE: FAPGLYPAL*# ...# >MUS122CE# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGPYPAL*# SEQUENCE: FAPGPYPAL*# ...# >MUS122CF# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,FAPGQYPAL*# SEQUENCE: FAPGQYPAL*# ...# >MUS122D0# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,FAPGRYPAL*# SEQUENCE: FAPGRYPAL*# ...# >MUS122D1# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGSYPAL*# SEQUENCE: FAPGSYPAL*# ...# >MUS122D2# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGTYPAL*# SEQUENCE: FAPGTYPAL*# ...# >MUS122D3# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGVYPAL*# SEQUENCE: FAPGVYPAL*# ...# >MUS122D4# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPDL*# SEQUENCE: FAPGNYPDL*# ...# >MUS122D5# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPEL*# SEQUENCE: FAPGNYPEL*# ...# >MUS122D6# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPFL*# SEQUENCE: FAPGNYPFL*# ...# >MUS122D7# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,FAPGNYPGL*# SEQUENCE: FAPGNYPGL*# ...# >MUS122D8# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPHL*# SEQUENCE: FAPGNYPHL*# ...# >MUS122D9# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPIL*# SEQUENCE: FAPGNYPIL*# ...# >MUS122DA# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPKL*# SEQUENCE: FAPGNYPKL*# ...# >MUS122DB# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPLL*# SEQUENCE: FAPGNYPLL*# ...# >MUS122DC# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPPL*# SEQUENCE: FAPGNYPPL*# ...# >MUS122DD# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPNL*# SEQUENCE: FAPGNYPNL*# ...# >MUS122DE# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPQL*# SEQUENCE: FAPGNYPQL*# ...# >MUS122DF# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPRL*# SEQUENCE: FAPGNYPRL*# ...# >MUS122E0# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPSL*# SEQUENCE: FAPGNYPSL*# ...# >MUS122E1# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,FAPGNYPTL*# SEQUENCE: FAPGNYPTL*# ...# >MUS122E2# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: cole95b# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,FAPGNYPYL*# SEQUENCE: FAPGNYPYL*# ...# >MUS122E3# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sykulev95a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesu,LSAFPFDL*# SEQUENCE: LSAFPFDL*# ...# >MUS122E4# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sykulev95a# COMMENT:# SUMMARY: H-2Ld,actyesl,bindyesu,LSPFAFDL*# SEQUENCE: LSPFAFDL*# ...# >MUS122E5# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: sykulev95a# COMMENT:# SUMMARY: H-2Ld,actyesl,bindyesu,LSPFPFDA*# SEQUENCE: LSPFPFDA*# ...# >MUS222E6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (30-49)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_BOVIN,MYPR_RABIT,MYPR_HUMAN,# & MYPR_CANFA)# & PIR1: (MPRTPL,MPHUPL,S34792)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,LFCGCGHEALTGTEKLIETY*# SEQUENCE: LFCGCGHEALTGTEKLIETY*# ...# >MUS222E7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (50-69)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA,MYPR_RABIT,# & MYPR_BOVIN)# & PIR1: (S34792,MPHUPL,MPRTPL,MPBOPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,FSKNYQDYEYLINVIHAFQY*# SEQUENCE: FSKNYQDYEYLINVIHAFQY*# ...# >MUS222E8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (40-59)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_RABIT,MYPR_BOVIN,MYPR_CANFA,# & MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPRTPL,MPBOPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,TGTEKLIETYFSKNYQDYEY*# SEQUENCE: TGTEKLIETYFSKNYQDYEY*# ...# >MUS222E9# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (80-99)# ANCHOR POSITIONS:# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,LYGALLLAYGFYTTGAVRQI*# SEQUENCE: LYGALLLAYGFYTTGAVRQI*# ...# >MUS222EA# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (100-119)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_BOVIN,MYPR_HUMAN,MYPR_CANFA,# & MYPR_RABIT)# & PIR1: (MPRTPL,S34792,MPBOPL,MPHUPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,FGDYKTTICGKGLSATVTGG*# SEQUENCE: FGDYKTTICGKGLSATVTGG*# ...# >MUS222EB# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (120-139)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_HUMAN,MYPR_RABIT,# & MYPR_BOVIN)# & PIR1: (MPBOPL,MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,QKGRGSRGQHQAHSLERVCH*# SEQUENCE: QKGRGSRGQHQAHSLERVCH*# ...# >MUS222EC# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (140-159)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,MYPR_BOVIN,# & MYPR_CANFA)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,CLGKWLGHPDKFVGITYALT*# SEQUENCE: CLGKWLGHPDKFVGITYALT*# ...# >MUS222ED# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PLP (178-191)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_HUMAN,MYPR_RABIT)# & PIR1: (MPRTPL,MPHUPL,S34792)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,NTWTTCQSIAFPSK*# SEQUENCE: NTWTTCQSIAFPSK*# ...# >MUS222EE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PLP (180-199)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_HUMAN)# & PIR1: (MPHUPL,S34792,MPRTPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,WTTCQSIAFPSKTSASIGSL*# SEQUENCE: WTTCQSIAFPSKTSASIGSL*# ...# >MUS222EF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: PLP (190-209)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA)# & PIR1: (MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,SKTSASIGSLCADARMYGVL*# SEQUENCE: SKTSASIGSLCADARMYGVL*# ...# >MUS222F0# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PLP (200-219)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_CHICK,MYPR_HUMAN,MYPR_CANFA,# & MYPR_BOVIN)# & PIR1: (MPBOPL,MPRTPL,S34792,MPHUPL)# & PIR2: (A43548,S17600)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,CADARMYGVLPWNAFPGKVC*# SEQUENCE: CADARMYGVLPWNAFPGKVC*# ...# >MUS222F1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (240-259)# DB REFERENCE: PIR1: (MPBOPL)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,IAAFVGAAATLVSLVTFMIA*# SEQUENCE: IAAFVGAAATLVSLVTFMIA*# ...# >MUS222F2# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (30-49)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,MYPR_CANFA,# & MYPR_BOVIN)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,LFCGCGHEALTGTEKLIETY*# SEQUENCE: LFCGCGHEALTGTEKLIETY*# ...# >MUS222F3# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (40-59)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_BOVIN,MYPR_HUMAN,MYPR_HUMAN,# & MYPR_RABIT)# & PIR1: (MPRTPL,MPBOPL,S34792,MPHUPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,TGTEKLIETYFSKNYQDYEY*# SEQUENCE: TGTEKLIETYFSKNYQDYEY*# ...# >MUS222F4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (90-109)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_BOVIN,MYPR_HUMAN,# & MYPR_CANFA)# & PIR1: (MPHUPL,MPRTPL,MPBOPL,S34792)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,FYTTGAVRQIFGDYKTTICG*# SEQUENCE: FYTTGAVRQIFGDYKTTICG*# ...# >MUS222F5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (120-139)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA,# & MYPR_RABIT)# & PIR1: (MPBOPL,S34792,MPRTPL,MPHUPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,QKGRGSRGQHQAHSLERVCH*# SEQUENCE: QKGRGSRGQHQAHSLERVCH*# ...# >MUS222F6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PLP (178-191)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_CANFA,MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,NTWTTCQSIAFPSK*# SEQUENCE: NTWTTCQSIAFPSK*# ...# >MUS222F7# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (180-199)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,WTTCQSIAFPSKTSASIGSL*# SEQUENCE: WTTCQSIAFPSKTSASIGSL*# ...# >MUS222F8# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (190-209)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,SKTSASIGSLCADARMYGVL*# SEQUENCE: SKTSASIGSLCADARMYGVL*# ...# >MUS222F9# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: PLP (60-79)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_BOVIN,MYPR_HUMAN,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (MPRTPL,S34792,MPBOPL,MPHUPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesh,bindyesl,LINVIHAFQYVIYGTASFFF*# SEQUENCE: LINVIHAFQYVIYGTASFFF*# ...# >MUS222FA# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: PLP (90-109)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT,# & MYPR_HUMAN)# & PIR1: (MPHUPL,MPRTPL,S34792,MPBOPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesl,FYTTGAVRQIFGDYKTTICG*# SEQUENCE: FYTTGAVRQIFGDYKTTICG*# ...# >MUS222FB# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: PLP (100-119)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_CANFA,MYPR_HUMAN,MYPR_HUMAN,# & MYPR_RABIT)# & PIR1: (S34792,MPRTPL,MPHUPL,MPBOPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesl,FGDYKTTICGKGLSATVTGG*# SEQUENCE: FGDYKTTICGKGLSATVTGG*# ...# >MUS222FC# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: PLP (130-149)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_BOVIN,MYPR_CANFA,MYPR_HUMAN,# & MYPR_HUMAN)# & PIR1: (MPRTPL,MPHUPL,S34792)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesh,bindyesl,QAHSLERVCHCLGKWLGHPD*# SEQUENCE: QAHSLERVCHCLGKWLGHPD*# ...# >MUS222FD# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: PLP (139-151)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA,MYPR_POEGU,# & MYPR_RABIT)# & PIR1: (S34792,MPRTPL,MPHUPL)# & PIR2: (A43548)# & PIR3: (I51270)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesh,HCLGKWLGHPDKF*# SEQUENCE: HCLGKWLGHPDKF*# ...# >MUS222FE# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: PLP (140-159)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_CANFA,MYPR_RABIT,MYPR_HUMAN,# & MYPR_BOVIN)# & PIR1: (S34792,MPRTPL,MPHUPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesl,bindyesl,CLGKWLGHPDKFVGITYALT*# SEQUENCE: CLGKWLGHPDKFVGITYALT*# ...# >MUS222FF# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: PLP (170-189)# ANCHOR POSITIONS:# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesl,AVPVYEYFNTWTTCQSIAFP*# SEQUENCE: AVPVYEYFNTWTTCQSIAFP*# ...# >MUS22300# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: PLP (178-191)# DB REFERENCE: SWISS: (MYPR_CANFA,MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesm,NTWTTCQSIAFPSK*# SEQUENCE: NTWTTCQSIAFPSK*# ...# >MUS22301# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: PLP (180-199)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA)# & PIR1: (MPRTPL,S34792,MPHUPL)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesl,WTTCQSIAFPSKTSASIGSL*# SEQUENCE: WTTCQSIAFPSKTSASIGSL*# ...# >MUS22302# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: none# BINDING: yes, little# SOURCE: PLP (190-209)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_HUMAN,MYPR_CANFA)# & PIR1: (MPHUPL,MPRTPL,S34792)# & PIR2: (A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesn,bindyesl,SKTSASIGSLCADARMYGVL*# SEQUENCE: SKTSASIGSLCADARMYGVL*# ...# >MUS22303# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: PLP (200-219)# DB REFERENCE: SWISS: (MYPR_CHICK,MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,MYPR_BOVIN,# & MYPR_CANFA)# & PIR1: (MPHUPL,S34792,MPRTPL,MPBOPL)# & PIR2: (S17600,A43548)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesl,bindyesl,CADARMYGVLPWNAFPGKVC*# SEQUENCE: CADARMYGVLPWNAFPGKVC*# ...# >MUS22304# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: PLP (250-269)# DB REFERENCE: PIR1: (MPBOPL)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesl,LVSLVTFMIAATYNFAVLKL*# SEQUENCE: LVSLVTFMIAATYNFAVLKL*# ...# >MUS22305# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: PLP (260-276)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_CHICK,MYPR_HUMAN,MYPR_BOVIN,MYPR_CANFA,# & MYPR_HUMAN)# & PIR1: (S34792,MPHUPL,MPBOPL,MPRTPL)# & PIR2: (A43548,S17600)# REFERENCES: greer96a# COMMENT:# SUMMARY: I-As,actunkn,bindyesl,ATYNFAVLKLMGRGTKF*# SEQUENCE: ATYNFAVLKLMGRGTKF*# ...# >HUM12306# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,NPYTDPTXGAT*# SEQUENCE: NPYTDPTXGAT*# ...# >HUM12307# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,DVKAPSAKY*# SEQUENCE: DVKAPSAKY*# ...# >HUM12308# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLYKNPAKY*# SEQUENCE: KLYKNPAKY*# ...# >HUM12309# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,AVYXXANXKL*# SEQUENCE: AVYXXANXKL*# ...# >HUM1230A# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,DVYERXEXM*# SEQUENCE: DVYERXEXM*# ...# >HUM1230B# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: E2F related transcription factor (85-93)# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SVKHPGGRK*# SEQUENCE: SVKHPGGRK*# ...# >HUM1230C# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLYLXTANK*# SEQUENCE: KLYLXTANK*# ...# >HUM1230D# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,DWYENVVLKK*# SEQUENCE: DWYENVVLKK*# ...# >HUM1230E# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,ATYPPMRXKQ*# SEQUENCE: ATYPPMRXKQ*# ...# >HUM1230F# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VCAM (144-152)# DB REFERENCE: SWISS: (VCA1_HUMAN,VCA1_HUMAN)# & PIR2: (PH1379,A41288,B41288)# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,VYPFDRLEI*# SEQUENCE: VYPFDRLEI*# ...# >HUM12310# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,ALYEPLVWY*# SEQUENCE: ALYEPLVWY*# ...# >HUM12311# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,DYLDVXLAY*# SEQUENCE: DYLDVXLAY*# ...# >HUM12312# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLFDYXXWTY*# SEQUENCE: KLFDYXXWTY*# ...# >HUM12313# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,GLYDVFEAD*# SEQUENCE: GLYDVFEAD*# ...# >HUM12314# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,KLAPIWLDY*# SEQUENCE: KLAPIWLDY*# ...# >HUM12315# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,GLFERSARX*# SEQUENCE: GLFERSARX*# ...# >HUM12316# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,DTPNVLIVIXL*# SEQUENCE: DTPNVLIVIXL*# ...# >HUM12317# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 nef (188-198)# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesu,SSLAFHHKAR*# SEQUENCE: SSLAFHHKAR*# ...# >HUM12318# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,DPRDNYLYK*# SEQUENCE: DPRDNYLYK*# ...# >HUM12319# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: dbl-proto oncogene (444-454)# DB REFERENCE: SWISS: (DBL_HUMAN)# & PIR1: (TVHUDB)# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,LQYEFDVILSP*# SEQUENCE: LQYEFDVILSP*# ...# >HUM1231A# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,DEYGVARTYLDFEME*# SEQUENCE: DEYGVARTYLDFEME*# ...# >HUM1231B# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,YPYNXINXDN*# SEQUENCE: YPYNXINXDN*# ...# >HUM1231C# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,DPVESNYXY*# SEQUENCE: DPVESNYXY*# ...# >HUM1231D# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CMV like# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,SEYRVKEXK*# SEQUENCE: SEYRVKEXK*# ...# >HUM1231E# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,DEFEFPWV*# SEQUENCE: DEFEFPWV*# ...# >HUM1231F# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV nef (134-142)# DB REFERENCE: SWISS: (NEF_HV1U4,NEF_HV112,NEF_HV1EL,NEF_HV1PV,NEF_HV1BR,# & NEF_HV1B8)# & PIR1: (ASLJFV,ASLJ12,ASLJH3,ASLJVL)# & PIR2: (S03244,S43467,S03247)# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B18,actunkn,bindyesu,YPLTFGWCY*# SEQUENCE: YPLTFGWCY*# ...# >HUM12320# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: bovine serum albumin (55-67)# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,LQQXPFDEHVKLV*# SEQUENCE: LQQXPFDEHVKLV*# ...# >HUM12321# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,GLFEQVRQDNQ*# SEQUENCE: GLFEQVRQDNQ*# ...# >HUM12322# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta2 microglobulin signal peptide (1-12)# DB REFERENCE: SWISS: (B2MG_PONPY)# & PIR2: (I61868)# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,IQRTPKIQVYTR*# SEQUENCE: IQRTPKIQVYTR*# ...# >HUM12323# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: bovine serum albumin (68-80)# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,NELTEFAKTXVAD*# SEQUENCE: NELTEFAKTXVAD*# ...# >HUM12324# MHC MOLECULE: HLA-B?, CLASS-1, (HUMAN)# METHOD: eluted peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: harris95a# COMMENT: HLA-B18 or HLA-B51# SUMMARY: HLA-B?,actunkn,bindyesu,GLVDPEVFAY*# SEQUENCE: GLVDPEVFAY*# ...# >HUM22325# MHC MOLECULE: HLA-DR2(DRB1*1501), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (95-116)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_RABIT,MYPR_HUMAN,MYPR_BOVIN,# & MYPR_CANFA)# & PIR1: (MPBOPL,MPRTPL,S34792,MPHUPL)# & PIR2: (A43548)# REFERENCES: ohashi95a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,AVRQIFGDYKTTICGKGLSATV*# SEQUENCE: AVRQIFGDYKTTICGKGLSATV*# ...# >MUS22326# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: myhcalpha (334-352)# DB REFERENCE: PIR2: (I49464)# ANCHOR POSITIONS:# REFERENCES: donermeyer95a# COMMENT:# SUMMARY: I-Ak,actyesh,bindyesu,DSAFDVLSFTAEEKAGVYK*# SEQUENCE: DSAFDVLSFTAEEKAGVYK*# ...# >MUS22327# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: myhcalpha (334-348)# DB REFERENCE: PIR2: (I49464)# ANCHOR POSITIONS:# REFERENCES: donermeyer95a# COMMENT:# SUMMARY: I-Ak,actyesm,bindyesu,DSAFDVLSFTAEEKA*# SEQUENCE: DSAFDVLSFTAEEKA*# ...# >MUS22328# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: myhcalpha (335-348)# DB REFERENCE: PIR2: (I49464)# ANCHOR POSITIONS:# REFERENCES: donermeyer95a# COMMENT:# SUMMARY: I-Ak,actyesm,bindyesu,SAFDVLSFTAEEKA*# SEQUENCE: SAFDVLSFTAEEKA*# ...# >MUS22329# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: myhcalpha (335-348) homologue# DB REFERENCE: SWISS: (MYSA_RAT)# & PIR1: (S06005)# & PIR2: (I48175)# REFERENCES: donermeyer95a# COMMENT:# SUMMARY: I-Ak,actyesm,bindyesu,SAFDVLGFTAEEKA*# SEQUENCE: SAFDVLGFTAEEKA*# ...# >MUS2232A# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: stimulation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: myhcalpha (335-348) homologue# ANCHOR POSITIONS:# REFERENCES: donermeyer95a# COMMENT:# SUMMARY: I-Ak,actyesl,bindyesu,SAFDVLSFTPEEKA*# SEQUENCE: SAFDVLSFTPEEKA*# ...# >MUS2232B# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: M. tuberculosis 19000 MW# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,VTGSVVCTTAAGNVNIAIGG*# SEQUENCE: VTGSVVCTTAAGNVNIAIGG*# ...# >MUS2232C# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,ATGSVVCTTAAGNVNIAIGA*# SEQUENCE: ATGSVVCTTAAGNVNIAIGA*# ...# >MUS2232D# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ab,actyesm,bindyesu,AAGSVVCTTAAGNVNIAIAA*# SEQUENCE: AAGSVVCTTAAGNVNIAIAA*# ...# >MUS2232E# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,AAASVVCTTAAGNVNIAAAA*# SEQUENCE: AAASVVCTTAAGNVNIAAAA*# ...# >MUS2232F# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,AAAAVVCTTAAGNVNIAAAA*# SEQUENCE: AAAAVVCTTAAGNVNIAAAA*# ...# >MUS22330# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,AAAAAVCTTAAGNVNIAAAA*# SEQUENCE: AAAAAVCTTAAGNVNIAAAA*# ...# >MUS22331# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,AAAAAACTTAAGNVNIAAAA*# SEQUENCE: AAAAAACTTAAGNVNIAAAA*# ...# >MUS22332# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,AAAAAAATTAAGNVNIAAAA*# SEQUENCE: AAAAAAATTAAGNVNIAAAA*# ...# >MUS22333# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. tuberculosis 19000 MW# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,VTGSVVCTTAAGNVNIAIGG*# SEQUENCE: VTGSVVCTTAAGNVNIAIGG*# ...# >MUS22334# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,ATGSVVCTTAAGNVNIAIGA*# SEQUENCE: ATGSVVCTTAAGNVNIAIGA*# ...# >MUS22335# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,AAGSVVCTTAAGNVNIAIAA*# SEQUENCE: AAGSVVCTTAAGNVNIAIAA*# ...# >MUS22336# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,AAASVVCTTAAGNVNIAAAA*# SEQUENCE: AAASVVCTTAAGNVNIAAAA*# ...# >MUS22337# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,AAAAVVCTTAAGNVNIAAAA*# SEQUENCE: AAAAVVCTTAAGNVNIAAAA*# ...# >MUS22338# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,AAAAAVCTTAAGNVNIAAAA*# SEQUENCE: AAAAAVCTTAAGNVNIAAAA*# ...# >MUS22339# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,AAAAAACTTAAGNVNIAAAA*# SEQUENCE: AAAAAACTTAAGNVNIAAAA*# ...# >MUS2233A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,AAAAAAATTAAGNVNIAAAA*# SEQUENCE: AAAAAAATTAAGNVNIAAAA*# ...# >MUS2233B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,AAAAAAAAAAAGNVNIAAAA*# SEQUENCE: AAAAAAAAAAAGNVNIAAAA*# ...# >MUS2233C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: stimulation as./binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: M. tuberculosis 19000 MW homologue# ANCHOR POSITIONS:# REFERENCES: roman95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,AAAAAAAAALAANANIAAAA*# SEQUENCE: AAAAAAAAALAANANIAAAA*# ...# >MUS2233D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,AYVKQNTLKL*# SEQUENCE: AYVKQNTLKL*# ...# >MUS2233E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,CYVKQNTLKL*# SEQUENCE: CYVKQNTLKL*# ...# >MUS2233F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,DYVKQNTLKL*# SEQUENCE: DYVKQNTLKL*# ...# >MUS22340# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,EYVKQNTLKL*# SEQUENCE: EYVKQNTLKL*# ...# >MUS22341# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,FYVKQNTLKL*# SEQUENCE: FYVKQNTLKL*# ...# >MUS22342# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,GYVKQNTLKL*# SEQUENCE: GYVKQNTLKL*# ...# >MUS22343# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,HYVKQNTLKL*# SEQUENCE: HYVKQNTLKL*# ...# >MUS22344# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,IYVKQNTLKL*# SEQUENCE: IYVKQNTLKL*# ...# >MUS22345# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain# DB REFERENCE: SWISS: (HEMA_IADH6,HEMA_IAGHK,HEMA_IAAIC,HEMA_IADH2,HEMA_IAZUK,# & HEMA_IADU3,HEMA_IAZCO,HEMA_IANT6,HEMA_IADHM,HEMA_IADH4,# & HEMA_IADH3,HEMA_IADH7,HEMA_IAEN7,HEMA_IAVI7,HEMA_IABAN,# & HEMA_IADHL,HEMA_IAQU7,HEMA_IAME1,HEMA_IADH1,HEMA_IAZH2,# & HEMA_IAME2,HEMA_IAEN6,HEMA_IAUDO)# & PIR1: (HMIVV,HMIV33,HMIVH,HMIV98,HMIV15,HMIVHM,HMIV80,HMIVDU,# & HMIVHA,HMIVS3,HMIV89,HMIV77,HMIV6)# & PIR2: (A92979,JQ1155,JQ1154,JQ1156)# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKQNTLKL*# SEQUENCE: KYVKQNTLKL*# ...# >MUS22346# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,LYVKQNTLKL*# SEQUENCE: LYVKQNTLKL*# ...# >MUS22347# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,MYVKQNTLKL*# SEQUENCE: MYVKQNTLKL*# ...# >MUS22348# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,NYVKQNTLKL*# SEQUENCE: NYVKQNTLKL*# ...# >MUS22349# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,PYVKQNTLKL*# SEQUENCE: PYVKQNTLKL*# ...# >MUS2234A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,QYVKQNTLKL*# SEQUENCE: QYVKQNTLKL*# ...# >MUS2234B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52185,S52187,JQ2378,S52182,S52198,S52173,S52180,S52191,# & S52199,JQ2374,S52174,S52197,JQ2375,S52179,S52175,S52176,# & S52195,S52186,S52178,S52188,S52183,S52189,JQ2377)# & PIR3: (S38637)# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,RYVKQNTLKL*# SEQUENCE: RYVKQNTLKL*# ...# >MUS2234C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,SYVKQNTLKL*# SEQUENCE: SYVKQNTLKL*# ...# >MUS2234D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,TYVKQNTLKL*# SEQUENCE: TYVKQNTLKL*# ...# >MUS2234E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,VYVKQNTLKL*# SEQUENCE: VYVKQNTLKL*# ...# >MUS2234F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,WYVKQNTLKL*# SEQUENCE: WYVKQNTLKL*# ...# >MUS22350# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,YYVKQNTLKL*# SEQUENCE: YYVKQNTLKL*# ...# >MUS22351# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KAVKQNTLKL*# SEQUENCE: KAVKQNTLKL*# ...# >MUS22352# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KCVKQNTLKL*# SEQUENCE: KCVKQNTLKL*# ...# >MUS22353# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KDVKQNTLKL*# SEQUENCE: KDVKQNTLKL*# ...# >MUS22354# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KEVKQNTLKL*# SEQUENCE: KEVKQNTLKL*# ...# >MUS22355# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KFVKQNTLKL*# SEQUENCE: KFVKQNTLKL*# ...# >MUS22356# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KGVKQNTLKL*# SEQUENCE: KGVKQNTLKL*# ...# >MUS22357# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KHVKQNTLKL*# SEQUENCE: KHVKQNTLKL*# ...# >MUS22358# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KIVKQNTLKL*# SEQUENCE: KIVKQNTLKL*# ...# >MUS22359# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KKVKQNTLKL*# SEQUENCE: KKVKQNTLKL*# ...# >MUS2235A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KLVKQNTLKL*# SEQUENCE: KLVKQNTLKL*# ...# >MUS2235B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KMVKQNTLKL*# SEQUENCE: KMVKQNTLKL*# ...# >MUS2235C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KNVKQNTLKL*# SEQUENCE: KNVKQNTLKL*# ...# >MUS2235D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KPVKQNTLKL*# SEQUENCE: KPVKQNTLKL*# ...# >MUS2235E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KQVKQNTLKL*# SEQUENCE: KQVKQNTLKL*# ...# >MUS2235F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KRVKQNTLKL*# SEQUENCE: KRVKQNTLKL*# ...# >MUS22360# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KSVKQNTLKL*# SEQUENCE: KSVKQNTLKL*# ...# >MUS22361# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KTVKQNTLKL*# SEQUENCE: KTVKQNTLKL*# ...# >MUS22362# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KVVKQNTLKL*# SEQUENCE: KVVKQNTLKL*# ...# >MUS22363# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KWVKQNTLKL*# SEQUENCE: KWVKQNTLKL*# ...# >MUS22364# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYAKQNTLKL*# SEQUENCE: KYAKQNTLKL*# ...# >MUS22365# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYCKQNTLKL*# SEQUENCE: KYCKQNTLKL*# ...# >MUS22366# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYDKQNTLKL*# SEQUENCE: KYDKQNTLKL*# ...# >MUS22367# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYEKQNTLKL*# SEQUENCE: KYEKQNTLKL*# ...# >MUS22368# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYFKQNTLKL*# SEQUENCE: KYFKQNTLKL*# ...# >MUS22369# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYGKQNTLKL*# SEQUENCE: KYGKQNTLKL*# ...# >MUS2236A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYHKQNTLKL*# SEQUENCE: KYHKQNTLKL*# ...# >MUS2236B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# DB REFERENCE: SWISS: (HEMA_IAHNM,HEMA_IAHRO,HEMA_IAHSA,HEMA_IAHFO)# & PIR1: (HMIVE6,HMIVE7,HMIVE8,HMIVE5)# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYIKQNTLKL*# SEQUENCE: KYIKQNTLKL*# ...# >MUS2236C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYKKQNTLKL*# SEQUENCE: KYKKQNTLKL*# ...# >MUS2236D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYLKQNTLKL*# SEQUENCE: KYLKQNTLKL*# ...# >MUS2236E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYMKQNTLKL*# SEQUENCE: KYMKQNTLKL*# ...# >MUS2236F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYNKQNTLKL*# SEQUENCE: KYNKQNTLKL*# ...# >MUS22370# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYPKQNTLKL*# SEQUENCE: KYPKQNTLKL*# ...# >MUS22371# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYQKQNTLKL*# SEQUENCE: KYQKQNTLKL*# ...# >MUS22372# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYRKQNTLKL*# SEQUENCE: KYRKQNTLKL*# ...# >MUS22373# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYSKQNTLKL*# SEQUENCE: KYSKQNTLKL*# ...# >MUS22374# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYTKQNTLKL*# SEQUENCE: KYTKQNTLKL*# ...# >MUS22375# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYWKQNTLKL*# SEQUENCE: KYWKQNTLKL*# ...# >MUS22376# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYYKQNTLKL*# SEQUENCE: KYYKQNTLKL*# ...# >MUS22377# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVAQNTLKL*# SEQUENCE: KYVAQNTLKL*# ...# >MUS22378# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVCQNTLKL*# SEQUENCE: KYVCQNTLKL*# ...# >MUS22379# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVDQNTLKL*# SEQUENCE: KYVDQNTLKL*# ...# >MUS2237A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVEQNTLKL*# SEQUENCE: KYVEQNTLKL*# ...# >MUS2237B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVFQNTLKL*# SEQUENCE: KYVFQNTLKL*# ...# >MUS2237C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVGQNTLKL*# SEQUENCE: KYVGQNTLKL*# ...# >MUS2237D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVHQNTLKL*# SEQUENCE: KYVHQNTLKL*# ...# >MUS2237E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVIQNTLKL*# SEQUENCE: KYVIQNTLKL*# ...# >MUS2237F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVLQNTLKL*# SEQUENCE: KYVLQNTLKL*# ...# >MUS22380# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVMQNTLKL*# SEQUENCE: KYVMQNTLKL*# ...# >MUS22381# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVNQNTLKL*# SEQUENCE: KYVNQNTLKL*# ...# >MUS22382# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVPQNTLKL*# SEQUENCE: KYVPQNTLKL*# ...# >MUS22383# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVQQNTLKL*# SEQUENCE: KYVQQNTLKL*# ...# >MUS22384# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVRQNTLKL*# SEQUENCE: KYVRQNTLKL*# ...# >MUS22385# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVSQNTLKL*# SEQUENCE: KYVSQNTLKL*# ...# >MUS22386# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVTQNTLKL*# SEQUENCE: KYVTQNTLKL*# ...# >MUS22387# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVVQNTLKL*# SEQUENCE: KYVVQNTLKL*# ...# >MUS22388# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVWQNTLKL*# SEQUENCE: KYVWQNTLKL*# ...# >MUS22389# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVYQNTLKL*# SEQUENCE: KYVYQNTLKL*# ...# >MUS2238A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKANTLKL*# SEQUENCE: KYVKANTLKL*# ...# >MUS2238B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKCNTLKL*# SEQUENCE: KYVKCNTLKL*# ...# >MUS2238C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKDNTLKL*# SEQUENCE: KYVKDNTLKL*# ...# >MUS2238D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKENTLKL*# SEQUENCE: KYVKENTLKL*# ...# >MUS2238E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKFNTLKL*# SEQUENCE: KYVKFNTLKL*# ...# >MUS2238F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKGNTLKL*# SEQUENCE: KYVKGNTLKL*# ...# >MUS22390# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKHNTLKL*# SEQUENCE: KYVKHNTLKL*# ...# >MUS22391# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKINTLKL*# SEQUENCE: KYVKINTLKL*# ...# >MUS22392# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKKNTLKL*# SEQUENCE: KYVKKNTLKL*# ...# >MUS22393# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKLNTLKL*# SEQUENCE: KYVKLNTLKL*# ...# >MUS22394# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKMNTLKL*# SEQUENCE: KYVKMNTLKL*# ...# >MUS22395# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKNNTLKL*# SEQUENCE: KYVKNNTLKL*# ...# >MUS22396# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKPNTLKL*# SEQUENCE: KYVKPNTLKL*# ...# >MUS22397# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKRNTLKL*# SEQUENCE: KYVKRNTLKL*# ...# >MUS22398# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKSNTLKL*# SEQUENCE: KYVKSNTLKL*# ...# >MUS22399# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKTNTLKL*# SEQUENCE: KYVKTNTLKL*# ...# >MUS2239A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKVNTLKL*# SEQUENCE: KYVKVNTLKL*# ...# >MUS2239B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKWNTLKL*# SEQUENCE: KYVKWNTLKL*# ...# >MUS2239C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKYNTLKL*# SEQUENCE: KYVKYNTLKL*# ...# >MUS2239D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# DB REFERENCE: SWISS: (HEMA_IADA3)# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQGTLKL*# SEQUENCE: KYVKQGTLKL*# ...# >MUS2239E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQHTLKL*# SEQUENCE: KYVKQHTLKL*# ...# >MUS2239F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQKTLKL*# SEQUENCE: KYVKQKTLKL*# ...# >MUS223A0# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQPTLKL*# SEQUENCE: KYVKQPTLKL*# ...# >MUS223A1# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQQTLKL*# SEQUENCE: KYVKQQTLKL*# ...# >MUS223A2# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQRTLKL*# SEQUENCE: KYVKQRTLKL*# ...# >MUS223A3# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQTTLKL*# SEQUENCE: KYVKQTTLKL*# ...# >MUS223A4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQNPLKL*# SEQUENCE: KYVKQNPLKL*# ...# >MUS223A5# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# DB REFERENCE: SWISS: (HEMA_IAZH3,HEMA_IADHK)# & PIR1: (HMIVS2)# & PIR2: (JQ1153)# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNSLKL*# SEQUENCE: KYVKQNSLKL*# ...# >MUS223A6# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTIKL*# SEQUENCE: KYVKQNTIKL*# ...# >MUS223A7# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTPKL*# SEQUENCE: KYVKQNTPKL*# ...# >MUS223A8# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTTKL*# SEQUENCE: KYVKQNTTKL*# ...# >MUS223A9# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTVKL*# SEQUENCE: KYVKQNTVKL*# ...# >MUS223AA# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQNTYKL*# SEQUENCE: KYVKQNTYKL*# ...# >MUS223AB# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLLL*# SEQUENCE: KYVKQNTLLL*# ...# >MUS223AC# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLML*# SEQUENCE: KYVKQNTLML*# ...# >MUS223AD# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQNTLRL*# SEQUENCE: KYVKQNTLRL*# ...# >MUS223AE# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLYL*# SEQUENCE: KYVKQNTLYL*# ...# >MUS223AF# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLKA*# SEQUENCE: KYVKQNTLKA*# ...# >MUS223B0# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLKC*# SEQUENCE: KYVKQNTLKC*# ...# >MUS223B1# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLKF*# SEQUENCE: KYVKQNTLKF*# ...# >MUS223B2# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLKG*# SEQUENCE: KYVKQNTLKG*# ...# >MUS223B3# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKQNTLKH*# SEQUENCE: KYVKQNTLKH*# ...# >MUS223B4# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLKI*# SEQUENCE: KYVKQNTLKI*# ...# >MUS223B5# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQNTLKK*# SEQUENCE: KYVKQNTLKK*# ...# >MUS223B6# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQNTLKN*# SEQUENCE: KYVKQNTLKN*# ...# >MUS223B7# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQNTLKQ*# SEQUENCE: KYVKQNTLKQ*# ...# >MUS223B8# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KYVKQNTLKS*# SEQUENCE: KYVKQNTLKS*# ...# >MUS223B9# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLKT*# SEQUENCE: KYVKQNTLKT*# ...# >MUS223BA# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KYVKQNTLKV*# SEQUENCE: KYVKQNTLKV*# ...# >MUS223BB# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKQNTLKW*# SEQUENCE: KYVKQNTLKW*# ...# >MUS223BC# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: inflenza H3 HA heavy chain homologue# ANCHOR POSITIONS:# REFERENCES: fahrer95a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KYVKQNTLKY*# SEQUENCE: KYVKQNTLKY*# ...# >HUM223BD# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: D. pteronyssinus Der pI (45-67)# DB REFERENCE: PIR2: (JQ0337)# REFERENCES: yssel92a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,SAYLAHRNQSLDLAEQELVDCAS*# SEQUENCE: SAYLAHRNQSLDLAEQELVDCAS*# ...# >HUM223BE# MHC MOLECULE: HLA-DR11, CLASS-2, (HUMAN)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: D. pteronyssinus Der pI (94-104)# ANCHOR POSITIONS:# REFERENCES: yssel92a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,YAYVAREQSCR*# SEQUENCE: YAYVAREQSCR*# ...# >HUM223BF# MHC MOLECULE: HLA-DR8, CLASS-2, (HUMAN)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: D. pteronyssinus Der pI (94-104)# ANCHOR POSITIONS:# REFERENCES: yssel92a# COMMENT:# SUMMARY: HLA-DR8,actyesu,bindyesu,YAYVAREQSCR*# SEQUENCE: YAYVAREQSCR*# ...# >HUM223C0# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: D. pteronyssinus Der pI (94-104)# ANCHOR POSITIONS:# REFERENCES: yssel92a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,YAYVAREQSCR*# SEQUENCE: YAYVAREQSCR*# ...# >HUM223C1# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: stimulation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: D. pteronyssinus Der pI (117-143)# ANCHOR POSITIONS:# REFERENCES: yssel92a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,QIYPPNANKIREALAQTHSAIAHYWT*# SEQUENCE: QIYPPNANKIREALAQTHSAIAHYWT*# ...# >HUM123C2# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,SEIDLILGY*# SEQUENCE: SEIDLILGY*# ...# >HUM123C3# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,SEIDTVAKY*# SEQUENCE: SEIDTVAKY*# ...# >HUM123C4# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,DEVGIVTKMY*# SEQUENCE: DEVGIVTKMY*# ...# >HUM123C5# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,DEVGIVTKY*# SEQUENCE: DEVGIVTKY*# ...# >HUM123C6# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,AEIPTRVNY*# SEQUENCE: AEIPTRVNY*# ...# >HUM123C7# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,AEIPRTFKY*# SEQUENCE: AEIPRTFKY*# ...# >HUM123C8# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,AEIAAAAAY*# SEQUENCE: AEIAAAAAY*# ...# >HUM123C9# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,AEAPAAAAY*# SEQUENCE: AEAPAAAAY*# ...# >HUM123CA# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,AAIAAVAKY*# SEQUENCE: AAIAAVAKY*# ...# >HUM123CB# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,AEIAAVAKY*# SEQUENCE: AEIAAVAKY*# ...# >HUM123CC# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,AEIAAVAKA*# SEQUENCE: AEIAAVAKA*# ...# >HUM123CD# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,ADIAAVAKY*# SEQUENCE: ADIAAVAKY*# ...# >HUM123CE# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,AEIAAYAKL*# SEQUENCE: AEIAAYAKL*# ...# >HUM123CF# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,AEIAAVAKH*# SEQUENCE: AEIAAVAKH*# ...# >HUM123D0# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,AEIAAVAKF*# SEQUENCE: AEIAAVAKF*# ...# >HUM123D1# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,AEIAAVAKK*# SEQUENCE: AEIAAVAKK*# ...# >HUM123D2# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,AEIAAVAKR*# SEQUENCE: AEIAAVAKR*# ...# >HUM123D3# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,AEIAAAAKY*# SEQUENCE: AEIAAAAKY*# ...# >HUM123D4# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,AEIAAAAAE*# SEQUENCE: AEIAAAAAE*# ...# >HUM123D5# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: NS1 (158-166)*# DB REFERENCE: SWISS: (VNS1_IALE1,VNS1_IADE1,VNS1_IAFOW,VNS1_IALEN,VNS1_IAPI0,# & VNS1_IAFOM,VNS1_IADU3,VNS1_IATRS,VNS1_IAMAN,VNS1_IAAIC,# & VNS1_IACKB,VNS1_IACHI,VNS1_IAPUE,VNS1_IAANN,VNS1_IAMAO,# & VNS1_IAPI2,VNS1_IAUSS,VNS1_IACKJ,VNS1_IAMYN,# & VNS1_IAFPR)# & PIR1: (MNIV61,MNIV1,MNIVA1,MNIV1F,MNIV77,MNIVA3,MNIVX1,MNIVX9,# & MNIVA2,MNIVX5,MNIVC1,MNIV47,MNIVX7,MNIVA4,MNIVX3,# & MNIV14)# & PIR2: (S09648)# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actyesm,bindyesh,GEISPLPSL*# SEQUENCE: GEISPLPSL*# ...# >HUM123D6# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: NP (379-387)*# DB REFERENCE: SWISS: (VNUC_IADNZ,VNUC_IAMIN,VNUC_IAHO1,VNUC_IAZON,VNUC_IADU2,# & VNUC_IADM2,VNUC_IAZW2,VNUC_IACAL,VNUC_IAANA,VNUC_IATRS,# & VNUC_IAMAA,VNUC_IAZH4,VNUC_IARUD,VNUC_IAMEA,VNUC_IAGRE,# & VNUC_IAZOH,VNUC_IAB37,VNUC_IAZW1,VNUC_IAWIS,VNUC_IATEI,# & VNUC_IAFOW,VNUC_IANEJ,VNUC_IAWHP,VNUC_IAME5,VNUC_IATRT,# & VNUC_IAZ41,VNUC_IAUSS,VNUC_IABRA,VNUC_IADAU,VNUC_IAPUE,# & VNUC_IAZ29,VNUC_IAS31,VNUC_IAMAN,VNUC_IAZJA,VNUC_IAGU1,# & VNUC_IASE0,VNUC_IAZCA,VNUC_IAME4,VNUC_IAHIC,VNUC_IADE2,# & VNUC_IAMEB,VNUC_IAS06,VNUC_IACKP,VNUC_IAZMA,VNUC_IAMEG,# & VNUC_IAZH1,VNUC_IAHMI,VNUC_IAGD7,VNUC_IADMA,VNUC_IAMEF,# & VNUC_IAPAR,VNUC_IAFOM,VNUC_IAZTE,VNUC_IAMEE,VNUC_IAFPD,# & VNUC_IASIN,VNUC_IAMEC,VNUC_IABUD,VNUC_IAB39,VNUC_IAZI3,# & VNUC_IAANN,VNUC_IAS11,VNUC_IATX7,VNUC_IADCZ,VNUC_IAZI1,# & VNUC_IAZH3,VNUC_IACKG,VNUC_IAME6,VNUC_IAOHI,VNUC_IAWHN,# & VNUC_IAZDA,VNUC_IAEN5,VNUC_IALEN,VNUC_IAFPR,VNUC_IADE1,# & VNUC_IAUDO,VNUC_IAHPR,VNUC_IAZJ2,VNUC_IAHO2,VNUC_IAHTE,# & VNUC_IAKIE,VNUC_IASH2,VNUC_IADBE,VNUC_IAWIL,VNUC_IAME3,# & VNUC_IANT6,VNUC_IATKN,VNUC_IATKO,VNUC_IAZJ3,VNUC_IAZJ1,# & VNUC_IAHLO,VNUC_IAVI6,VNUC_IAZI2,VNUC_IAANN)# & PIR1: (VHIVN5,VHIV34,VHIVN7,VHIVN9,VHIVA7,VHIVA3,VHIV8H,VHIVM1,# & VHIVN8,VHIV68,VHIVC1,VHIVX1,A60028,VHIVN1,VHIVX2,VHIVA6,# & VHIVX3,VHIVN4,VHIVXL,VHIV61,VHIVX4,VHIVX5,VHIVAK,VHIVX6,# & VHIVN3)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actyesl,bindyesl,LELRSRYWA*# SEQUENCE: LELRSRYWA*# ...# >HUM123D7# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: none# BINDING: yes, little# SOURCE: NP (17-28)*# DB REFERENCE: SWISS: (VNUC_IAMEG,VNUC_IACKP,VNUC_IADM2,VNUC_IAZJ4,VNUC_IAMIN,# & VNUC_IAHO1,VNUC_IABRA,VNUC_IAB37,VNUC_IAGRE,VNUC_IATRT,# & VNUC_IAZOH,VNUC_IAWHP,VNUC_IATEI,VNUC_IATRS,VNUC_IAMAA,# & VNUC_IAMEA,VNUC_IAZNE,VNUC_IAHIC,VNUC_IADMA,VNUC_IAZMA,# & VNUC_IAMEE,VNUC_IAFPD,VNUC_IAPAR,VNUC_IAMAN,VNUC_IAHPR,# & VNUC_IAGUA,VNUC_IADCZ,VNUC_IASIN,VNUC_IAANA,VNUC_IACAL,# & VNUC_IASH2,VNUC_IAKIE,VNUC_IANT6,VNUC_IATKO,VNUC_IAS06,# & VNUC_IAHJI,VNUC_IAZCA,VNUC_IAME4,VNUC_IAGU1,VNUC_IAZJA,# & VNUC_IADE1,VNUC_IAFPR,VNUC_IAEN5,VNUC_IADAU,VNUC_IASE0,# & VNUC_IAPUE,VNUC_IADE2,VNUC_IADHK,VNUC_IAFOM,VNUC_IAHMI,# & VNUC_IATKN,VNUC_IADBE,VNUC_IAWIL,VNUC_IAME3,VNUC_IAHTE,# & VNUC_IAHO2,VNUC_IALEN,VNUC_IAHLO,VNUC_IACKG,VNUC_IAZH3,# & VNUC_IAME6,VNUC_IAB39,VNUC_IAMEC,VNUC_IABUD,VNUC_IAZI1,# & VNUC_IAZDA,VNUC_IAANN,VNUC_IAS11,VNUC_IAMEB,VNUC_IAGD7,# & VNUC_IAUDO,VNUC_IADNZ,VNUC_IAZH1,VNUC_IARUD,VNUC_IAME5,# & VNUC_IAUSS,VNUC_IAS31,VNUC_IAMEF,VNUC_IAZGE,VNUC_IATX7,# & VNUC_IAOHI,VNUC_IAZ29)# & PIR1: (VHIVN3,VHIV61,VHIVM1,VHIVC1,VHIVX1,VHIVX6,VHIVX4,VHIV68,# & VHIVAK,VHIVX5,VHIVN1,A60028,VHIV8H,VHIVA7,VHIVA3,VHIVA6,# & VHIVXL,VHIVX3,VHIVN2,VHIVN4,VHIV34,VHIVN7,VHIVN5,# & VHIVN6)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actyesn,bindyesl,GERQNATEI*# SEQUENCE: GERQNATEI*# ...# >HUM123D8# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: NP (338-346)*# DB REFERENCE: SWISS: (VNUC_IAZH1,VNUC_IAVI6,VNUC_IAHO1,VNUC_IADE1,VNUC_IANT6,# & VNUC_IALEN,VNUC_IAPUE)# & PIR1: (VHIV8H,VHIVN7,VHIV68,VHIVXL,VHIV34)# & PIR2: (B36754)# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actyesm,bindyesl,FEDLRVLSF*# SEQUENCE: FEDLRVLSF*# ...# >HUM123D9# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: beta2 incorporation as./cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: NP (379-388)*# DB REFERENCE: SWISS: (VNUC_IAFPR,VNUC_IAWIL,VNUC_IADE2,VNUC_IAS06,VNUC_IAZCA,# & VNUC_IADE1,VNUC_IAANN,VNUC_IAZDA,VNUC_IAME6,VNUC_IACKG,# & VNUC_IAHO1,VNUC_IAVI6,VNUC_IASH2,VNUC_IAWHN,VNUC_IAZI3,# & VNUC_IAANA,VNUC_IAZJ1,VNUC_IAB37,VNUC_IADMA,VNUC_IAPUE,# & VNUC_IADM2,VNUC_IADNZ,VNUC_IAUSS,VNUC_IAME5,VNUC_IAZH4,# & VNUC_IAMEB,VNUC_IAUDO,VNUC_IAZ41,VNUC_IAS11,VNUC_IAOHI,# & VNUC_IATX7,VNUC_IAS31,VNUC_IADU2,VNUC_IAEN5,VNUC_IADAU,# & VNUC_IAHO2,VNUC_IASE0,VNUC_IAME4,VNUC_IABUD,VNUC_IAMEC,# & VNUC_IAB39,VNUC_IAMEA,VNUC_IAHLO,VNUC_IATKN,VNUC_IAME3,# & VNUC_IADBE,VNUC_IAMIN,VNUC_IAZJ3,VNUC_IAMEE,VNUC_IAFPD,# & VNUC_IAANN,VNUC_IAZMA,VNUC_IAZI2,VNUC_IAZJ2,VNUC_IATEI,# & VNUC_IAGRE,VNUC_IAZOH,VNUC_IATRT,VNUC_IABRA,VNUC_IADCZ,# & VNUC_IANT6,VNUC_IATKO,VNUC_IARUD,VNUC_IACAL,VNUC_IASIN,# & VNUC_IALEN,VNUC_IAMAN,VNUC_IANEJ,VNUC_IAZ29,VNUC_IAZON,# & VNUC_IAZTE,VNUC_IAHPR,VNUC_IAGD7,VNUC_IACKP,VNUC_IAHMI,# & VNUC_IAMEG,VNUC_IAPAR,VNUC_IAZH1,VNUC_IAZW1,VNUC_IAWIS,# & VNUC_IAFOW,VNUC_IAFOM,VNUC_IAMEF,VNUC_IAMAA,VNUC_IATRS,# & VNUC_IAWHP,VNUC_IAZH3,VNUC_IAZI1,VNUC_IAZJA,VNUC_IAGU1,# & VNUC_IAHTE,VNUC_IAKIE,VNUC_IAZW2,VNUC_IAHIC)# & PIR1: (VHIVN3,VHIVAK,VHIVX5,VHIVX1,VHIVX2,VHIVN5,VHIVN1,VHIVC1,# & VHIVX6,VHIVXL,VHIVX4,VHIVN9,VHIVA7,VHIVA6,VHIV61,VHIVM1,# & VHIV34,VHIVN7,VHIV8H,VHIVA3,VHIVN4,VHIVN8,VHIVX3,VHIV68,# & A60028)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS:# REFERENCES: dibrino95a# COMMENT:# SUMMARY: HLA-B44,actyesh,bindyesl,LELRSRYWAI*# SEQUENCE: LELRSRYWAI*# ...# >HUM123DA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDCFPSV*# SEQUENCE: FLPSDCFPSV*# ...# >HUM123DB# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HPV16 E6# ANCHOR POSITIONS:# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,HLDKKKQRFH*# SEQUENCE: HLDKKKQRFH*# ...# >HUM123DC# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,KVFPCALINK*# SEQUENCE: KVFPCALINK*# ...# >HUM123DD# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesm,KLFNIMVTY*# SEQUENCE: KLFNIMVTY*# ...# >HUM123DE# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesm,KLHKQRAKS*# SEQUENCE: KLHKQRAKS*# ...# >HUM123DF# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as./Refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 pol (221-229)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1U4,POL_HV1Y2,POL_HV1H2,POL_HV1BR,# & POL_HV1OY,POL_HV1A2,POL_HV1MN,POL_HV1B1,POL_HV1ND,# & POL_HV1JR,POL_HV1Z2,POL_HV1EL,POL_HV1RH,POL_HV1B5,# & POL_SIVCZ,POL_HV1PV,POL_HV1N5)# & PIR1: (B44001,GNVWVL,GNVWLV,GNVWH3,GNLJND,GNLJSI,GNVWA2)# & PIR2: (S32079,S32134,S32093,S32138,S32097,S32098,S32050,S32092,# & S32073,S32067,C47330,S32137,S54378,S32132,S32068,S32128,# & S32072,S32090,S32127,S32089,S32051,S32070,F47330,S32094,# & S32071,S32091,B47330,S32139,E47330,S32129,S32078,S32133,# & S32152,S32075,S32096,S32080,S32069,S32047,S32136,S32048,# & S32077,S32135,S32131,B47175,A47330,S32049)# REFERENCES: van_der_burg95a,tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,AIKKKDSTK*# SEQUENCE: AIKKKDSTK*# ...# >HUM123E0# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as./Refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 pol (252-260)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1OY,POL_HV1BR,POL_HV1H2,POL_HV1Y2,# & POL_HV1RH,POL_HV1A2,POL_HV1MN,POL_HV1B1,POL_HV1B5,# & POL_SIVA1,POL_HV1N5,POL_HV1MA,POL_HV1ND,POL_HV1JR,# & POL_HV1Z2,POL_HV1PV,POL_SIVCZ)# & PIR1: (GNLJND,GNLJSI,GNVWA2,B44001,GNVWLV,GNVWH3,GNVWVL)# & PIR2: (S32057,S32126,S32063,S32078,S32139,S32053,S32127,S32072,# & S32068,S54378,S32067,S32065,S32087,S32118,S32082,S32064,# & S32129,S32095,A47175,S32054,S32056,S32076,S32069,S32080,# & S32117,S32075,S32097,S32088,S32136,S32135,S32062,S32159,# & S32060,A47330,S32052,S32122,S32084,S32151,S43127,B47175,# & S32085,S32128,S32132,C47330,S32120,S32059,S32070,S32140,# & D47330,S32160,S32157,S32061,S32152,S32133,B47330,S32058,# & S32083,F47330,S32055,S32086,S32081,S32138,S32074,# & S32077)# REFERENCES: van_der_burg95a,tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,GIPHPAGLK*# SEQUENCE: GIPHPAGLK*# ...# >HUM123E1# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 pol (306-313)# DB REFERENCE: SWISS: (POL_SIVCZ,POL_HV1JR,POL_HV1RH,POL_HV1EL,POL_HV1Z2,# & POL_HV1OY,POL_HV1B5,POL_HV1N5,POL_HV1B1,POL_HV1MN,# & POL_HV1A2,POL_HV1MA,POL_HV1U4,POL_HV1PV,POL_HV1ND,# & POL_HV1Y2,POL_SIVGB,POL_HV1H2,POL_HV1BR)# & PIR1: (B44001,GNVWH3,GNVWVL,GNVWA2,GNVWLV,GNLJND,GNLJSI)# & PIR2: (S32074,S32083,S32134,S32081,S32086,S32119,S32090,D47330,# & C47330,S32059,S32072,B47330,S32061,S32160,S32093,S32079,# & S32127,S32088,S32071,S32091,S32075,S32117,S32080,S32069,# & S32060,S32159,S32062,S32135,A47330,S32052,S32122,S32084,# & S43127,B47175,S32151,S32073,S32157,S32053,S32139,S32063,# & S32126,S32057,S32065,S32087,F47330,S32092,S32098,S32096,# & S32095,A47175,S32054,S32129,S32067,S32118,S32048,S32076,# & S32056,S32132,S32120,S32058,S32055,S32050,S32138,S32066,# & S32082,S32047,S32064,S32137,S32152,S32133,S32051,S32140,# & S32070,S32089,S32128,S32077,S32097,E47330,S32085,S32136,# & S32094,S32131,S54378,S32068,S32078,S28081,S32049)# & PIR3: (S33980)# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,NVLPQGWK*# SEQUENCE: NVLPQGWK*# ...# >HUM123E2# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 pol (388-397)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1JR,POL_HV1OY,POL_HV1N5,POL_HV1EL,# & POL_HV1Z2,POL_SIVCZ,POL_HV1MN,POL_HV1A2,POL_HV1B1,# & POL_HV1Y2,POL_HV1BR,POL_HV1H2,POL_HV1PV,POL_HV1U4,# & POL_HV1ND,POL_HV1RH,POL_SIVGB,POL_HV1B5)# & PIR1: (B44001,GNVWVL,GNVWH3,GNLJND,GNLJSI,GNVWLV,GNVWA2)# & PIR2: (A47175,S43127,S28081,S54378,B47175)# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,WMGYELHPDK*# SEQUENCE: WMGYELHPDK*# ...# >HUM123E3# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as./Refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 pol (461-470)# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1MN,POL_HV1RH,POL_HV1B1,POL_HV1PV,# & POL_HV1Z2,POL_HV1EL,POL_HV1JR,POL_HV1MA,POL_HV1N5,# & POL_HV1OY,POL_HV1Y2,POL_HV1BR,POL_HV1H2,POL_HV1B5,# & POL_HV1U4,POL_HV1ND)# & PIR1: (GNVWA2,GNLJND,GNVWH3,GNVWLV,B44001,GNVWVL)# & PIR2: (A49489,S54378,B47175)# & PIR3: (S33980)# REFERENCES: van_der_burg95a,tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ELAENREILK*# SEQUENCE: ELAENREILK*# ...# >HUM123E4# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 pol (781-790)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1N5,POL_HV1H2,POL_HV1ND,POL_HV1A2,# & POL_HV1RH,POL_HV1PV,POL_HV1B1,POL_HV1OY,POL_HV1MA,# & POL_HV1JR,POL_HV1Z2,POL_HV1BR,POL_HV1Y2,POL_HV1U4,# & POL_HV1B5,POL_HV1MN)# & PIR1: (GNVWLV,GNVWH3,GNVWVL,GNVWA2,GNLJND,B44001)# & PIR2: (S54378)# & PIR3: (S33980)# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,QLDCTHLEGK*# SEQUENCE: QLDCTHLEGK*# ...# >HUM123E5# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 pol (795-802)# ANCHOR POSITIONS:# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,AVHHVASGY*# SEQUENCE: AVHHVASGY*# ...# >HUM123E6# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as./Refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 pol (883-892)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1MN,POL_HV1B5,POL_HV1B1,POL_HV1PV,# & POL_HV1H2,POL_HV1N5,POL_HV1EL,POL_HV1Z6,POL_HV1ND,# & POL_HV1OY,POL_HV1Z2,POL_SIVCZ,POL_HV1RH,POL_HV1JR,# & POL_HV1BR,POL_HV1A2)# & PIR1: (GNVWH3,GNVWVL,GNVWA2,B44001,GNLJND,GNLJSI,GNVWLV)# & PIR2: (A26192,S54378)# & PIR3: (S33980)# REFERENCES: van_der_burg95a,tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,QVRDQAEHLK*# SEQUENCE: QVRDQAEHLK*# ...# >HUM123E7# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as./Refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 pol (898-906)# DB REFERENCE: SWISS: (POL_HV1U4,POL_HV1PV,POL_HV1JR,POL_HV1RH,POL_HV1Y2,# & POL_HV1B5,POL_HV1ND,POL_HV1Z6,POL_HV1B1,POL_HV1EL,# & POL_HV1H2,POL_HV1MA,POL_SIVCZ,POL_HV1Z2,POL_HV1BR,# & POL_HV1N5,POL_HV1A2,POL_HV1MN,POL_HV1OY)# & PIR1: (GNVWH3,GNVWVL,GNVWA2,B44001,GNVWLV,GNLJND,GNLJSI)# & PIR2: (S54378,A26192)# & PIR3: (S33980)# REFERENCES: van_der_burg95a,tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,AVFIHNFKR*# SEQUENCE: AVFIHNFKR*# ...# >HUM123E8# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 pol (909-918)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1OY,POL_HV1B1,POL_HV1H2,POL_HV1A2,# & POL_HV1N5,POL_HV1Y2,POL_HV1JR,POL_HV1RH,POL_HV1PV,# & POL_HV1Z6,POL_HV1ND,POL_HV1EL,POL_HV1BR,POL_HV1MN,# & POL_HV1Z2,POL_HV1U4,POL_HV1B5)# & PIR1: (B44001,GNVWH3,GNVWVL,GNLJND,GNVWA2,GNVWLV)# & PIR2: (A26192,S54378)# & PIR3: (S33980)# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,GIGGYSAGER*# SEQUENCE: GIGGYSAGER*# ...# >HUM123E9# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as./Refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 pol (938-946)# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1A2,POL_HV1U4,POL_HV1PV,POL_HV1ND,# & POL_HV1Z6,POL_HV1BR,POL_HV1H2,POL_HV1JR,POL_HV1RH,# & POL_HV1EL,POL_HV1N5,POL_HV1MN,POL_HV1Z2,POL_HV1OY,# & POL_HV1MA,POL_HV1B1,POL_HV1Y2)# & PIR1: (GNLJND,GNVWVL,GNVWH3,GNVWLV,B44001,GNVWA2)# & PIR2: (A26192,S54378,S46347)# & PIR3: (S33980)# REFERENCES: van_der_burg95a,tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,KIQNFRVYY*# SEQUENCE: KIQNFRVYY*# ...# >HUM123EA# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: binding as./competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 pol (938-945)# DB REFERENCE: SWISS: (POL_HV1Z6,POL_HV1BR,POL_HV1EL,POL_HV1ND,POL_HV1A2,# & POL_HV1B5,POL_HV1PV,POL_HV1RH,POL_HV1N5,POL_HV1Z2,# & POL_HV1OY,POL_HV1MA,POL_HV1B1,POL_HV1Y2,POL_HV1JR,# & POL_HV1MN,POL_HV1H2,POL_HV1U4)# & PIR1: (GNVWA2,GNVWLV,B44001,GNVWVL,GNVWH3,GNLJND)# & PIR2: (S46347,S54378,A26192)# & PIR3: (S33980)# REFERENCES: van_der_burg95a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,KIQNFRVY*# SEQUENCE: KIQNFRVY*# ...# >HUM223EB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: bovine collagen type II cII (261-273)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesh,AGFKGEQGPKGEP*# SEQUENCE: AGFKGEQGPKGEP*# ...# >HUM223EC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: bovine collagen type II cII (84-96)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_BOVIN,CA12_MOUSE,CA12_HUMAN,# & CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (B40333,B41182,A41182,A40333)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PGVKGHRGYPGLD*# SEQUENCE: PGVKGHRGYPGLD*# ...# >HUM223ED# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: bovine collagen type II cII (258-270)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (I60384)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PGIAGFKGEQGPK*# SEQUENCE: PGIAGFKGEQGPK*# ...# >HUM223EE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: bovine collagen type II cII (231-243)# ANCHOR POSITIONS:# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,PGPKGARGPPGPT*# SEQUENCE: PGPKGARGPPGPT*# ...# >HUM223EF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: bovine collagen type II cII (462-474)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_BOVIN,CA12_BOVIN,CA12_MOUSE,# & CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (A41182,B41182)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SGFQGLPGPPGPP*# SEQUENCE: SGFQGLPGPPGPP*# ...# >HUM223F0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: bovine collagen type II cII (21-33)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_MOUSE,CA12_HUMAN,CA12_BOVIN,# & CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (B41182,B40333,A41182)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QGFQGNPGEPGEP*# SEQUENCE: QGFQGNPGEPGEP*# ...# >HUM223F1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: bovine collagen type II cII (105-117)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_MOUSE)# & PIR1: (CGHU6C)# & PIR2: (A41182,B41182)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,PGVKGESGSPGEN*# SEQUENCE: PGVKGESGSPGEN*# ...# >HUM223F2# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: bovine collagen type II cII (393-405)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN,CA12_HUMAN,CA12_MOUSE,# & CA12_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (B41182,A40333,B40333,A41182)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,QGARGQPGVMGFP*# SEQUENCE: QGARGQPGVMGFP*# ...# >HUM223F3# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: bovine collagen type II cII (225-237)# DB REFERENCE: SWISS: (CA11_HUMAN,CA11_MOUSE,CA11_HUMAN,CA12_BOVIN,CA11_CHICK,# & CA12_BOVIN,CA11_RAT)# & PIR1: (CGRT1S,CGBO6C,CGCH1S,CGHU1S)# & PIR2: (S21626)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,PGIAGAPGFPGAR*# SEQUENCE: PGIAGAPGFPGAR*# ...# >HUM223F4# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: bovine collagen type II cII (262-273)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesm,GFKGEQGPKGEP*# SEQUENCE: GFKGEQGPKGEP*# ...# >HUM223F5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: bovine collagen type II cII (263-273)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesl,FKGEQGPKGEP*# SEQUENCE: FKGEQGPKGEP*# ...# >HUM223F6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: bovine collagen type II cII (261-272)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (B40333,I60384)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesh,AGFKGEQGPKGE*# SEQUENCE: AGFKGEQGPKGE*# ...# >HUM223F7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: bovine collagen type II cII (261-271)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# & PIR2: (B40333,I60384)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesh,AGFKGEQGPKG*# SEQUENCE: AGFKGEQGPKG*# ...# >HUM223F8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: bovine collagen type II cII (261-270)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_BOVIN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGHU6C,CGBO6C)# & PIR2: (I60384,B40333)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesm,AGFKGEQGPK*# SEQUENCE: AGFKGEQGPK*# ...# >HUM223F9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as./proliferation as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: bovine collagen type II cII (261-269)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_HUMAN,CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (B40333,I60384)# REFERENCES: fugger96a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesm,AGFKGEQGP*# SEQUENCE: AGFKGEQGP*# ...# >HUM123FA# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEVDVEYXY*# SEQUENCE: XEVDVEYXY*# ...# >HUM123FB# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEFDTFESY*# SEQUENCE: XEFDTFESY*# ...# >HUM123FC# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEIELILEYX*# SEQUENCE: XEIELILEYX*# ...# >HUM123FD# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEXPMAEAX*# SEQUENCE: XEXPMAEAX*# ...# >HUM123FE# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEDDQQQALV*# SEQUENCE: XEDDQQQALV*# ...# >HUM123FF# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hsp 90 alpha chain# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEKYIDQEEL*# SEQUENCE: XEKYIDQEEL*# ...# >HUM12400# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEFFPEYYYY*# SEQUENCE: XEFFPEYYYY*# ...# >HUM12401# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEFQEHYEY*# SEQUENCE: XEFQEHYEY*# ...# >HUM12402# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEFQVYLXQ*# SEQUENCE: XEFQVYLXQ*# ...# >HUM12403# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEIQINVQ*# SEQUENCE: XEIQINVQ*# ...# >HUM12404# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEVNNVALL*# SEQUENCE: XEVNNVALL*# ...# >HUM12405# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,PEMSVXXLL*# SEQUENCE: PEMSVXXLL*# ...# >HUM12406# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEIGAGATGA*# SEQUENCE: XEIGAGATGA*# ...# >HUM12407# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ubiquitin# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XESTLHLVL*# SEQUENCE: XESTLHLVL*# ...# >HUM12408# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEFPLVVXL*# SEQUENCE: XEFPLVVXL*# ...# >HUM12409# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: eluted self peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesu,XEFTLXLAY*# SEQUENCE: XEFTLXLAY*# ...# >HUM1240A# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesh,GEFGGGGGGY*# SEQUENCE: GEFGGGGGGY*# ...# >HUM1240B# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesh,GEFGGGGGY*# SEQUENCE: GEFGGGGGY*# ...# >HUM1240C# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesm,GEVGGGGGY*# SEQUENCE: GEVGGGGGY*# ...# >HUM1240D# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesm,GEFGGGGGL*# SEQUENCE: GEFGGGGGL*# ...# >HUM1240E# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesm,GEFGGGGGG*# SEQUENCE: GEFGGGGGG*# ...# >HUM1240F# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesl,GEGGGGGGY*# SEQUENCE: GEGGGGGGY*# ...# >HUM12410# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesh,KEIELILEY*# SEQUENCE: KEIELILEY*# ...# >HUM12411# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesh,KEFQEHYEY*# SEQUENCE: KEFQEHYEY*# ...# >HUM12412# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesh,GEFGGGGGGY*# SEQUENCE: GEFGGGGGGY*# ...# >HUM12413# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesm,GEFGGGGGY*# SEQUENCE: GEFGGGGGY*# ...# >HUM12414# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesl,GEVGGGGGY*# SEQUENCE: GEVGGGGGY*# ...# >HUM12415# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesh,GEFGGGGGL*# SEQUENCE: GEFGGGGGL*# ...# >HUM12416# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesm,GEFGGGGGG*# SEQUENCE: GEFGGGGGG*# ...# >HUM12417# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesl,GEGGGGGGY*# SEQUENCE: GEGGGGGGY*# ...# >HUM12418# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesl,KEFQEHYEY*# SEQUENCE: KEFQEHYEY*# ...# >HUM12419# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,GEFGGGGGGY*# SEQUENCE: GEFGGGGGGY*# ...# >HUM1241A# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,GEFGGGGGY*# SEQUENCE: GEFGGGGGY*# ...# >HUM1241B# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,GEVGGGGGY*# SEQUENCE: GEVGGGGGY*# ...# >HUM1241C# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,GEFGGGGGL*# SEQUENCE: GEFGGGGGL*# ...# >HUM1241D# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Gly homologue# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,GEGGGGGGY*# SEQUENCE: GEGGGGGGY*# ...# >HUM1241E# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human retinal S-Ag (379-387)# DB REFERENCE: SWISS: (ARRS_HUMAN)# & PIR2: (A30357)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesl,FEEFARHNL*# SEQUENCE: FEEFARHNL*# ...# >HUM1241F# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: human retinal S-Ag (379-387)# DB REFERENCE: SWISS: (ARRS_HUMAN)# & PIR2: (A30357)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesh,FEEFARHNL*# SEQUENCE: FEEFARHNL*# ...# >HUM12420# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: human retinal S-Ag (379-387)# DB REFERENCE: SWISS: (ARRS_HUMAN)# & PIR2: (A30357)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,FEEFARHNL*# SEQUENCE: FEEFARHNL*# ...# >HUM12421# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human retinal S-Ag (317-325)# DB REFERENCE: SWISS: (ARRS_CANFA,ARRS_HUMAN)# & PIR2: (A30357)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesm,KEGIDRTVL*# SEQUENCE: KEGIDRTVL*# ...# >HUM12422# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: human retinal S-Ag (317-325)# DB REFERENCE: SWISS: (ARRS_HUMAN,ARRS_CANFA)# & PIR2: (A30357)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesh,KEGIDRTVL*# SEQUENCE: KEGIDRTVL*# ...# >HUM12423# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: human retinal S-Ag (344-352)# DB REFERENCE: SWISS: (ARRS_RAT,ARRS_HUMAN,ARRS_CANFA,ARRS_BOVIN,ARRS_MOUSE)# & PIR2: (A30357,S03960,I46054,JS0066,A28404)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesh,GELTSSEVA*# SEQUENCE: GELTSSEVA*# ...# >HUM12424# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human retinal S-Ag (344-352)# DB REFERENCE: SWISS: (ARRS_CANFA,ARRS_BOVIN,ARRS_RAT,ARRS_HUMAN,ARRS_MOUSE)# & PIR2: (A28404,A30357,S03960,I46054,JS0066)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,GELTSSEVA*# SEQUENCE: GELTSSEVA*# ...# >HUM12425# MHC MOLECULE: HLA-A29(A*2902), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human retinal S-Ag (349-357)# DB REFERENCE: SWISS: (ARRS_MOUSE,ARRS_HUMAN,ARRS_CANFA,ARRS_BOVIN,ARRS_RAT)# & PIR2: (A28404,S03960,JS0066,A30357,I46054)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-A29,actunkn,bindyesm,SEVATEVPF*# SEQUENCE: SEVATEVPF*# ...# >HUM12426# MHC MOLECULE: HLA-B61(B*4002), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human retinal S-Ag (349-357)# DB REFERENCE: SWISS: (ARRS_CANFA,ARRS_HUMAN,ARRS_MOUSE,ARRS_BOVIN,ARRS_RAT)# & PIR2: (A30357,I46054,S03960,JS0066,A28404)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesm,SEVATEVPF*# SEQUENCE: SEVATEVPF*# ...# >HUM12427# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human retinal S-Ag (349-357)# DB REFERENCE: SWISS: (ARRS_MOUSE,ARRS_BOVIN,ARRS_RAT,ARRS_HUMAN,ARRS_CANFA)# & PIR2: (S03960,A28404,A30357,JS0066,I46054)# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,SEVATEVPF*# SEQUENCE: SEVATEVPF*# ...# >HUM12428# MHC MOLECULE: HLA-B61, CLASS-1, (HUMAN)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ubiquitin# ANCHOR POSITIONS:# REFERENCES: boisgerault96a# COMMENT:# SUMMARY: HLA-B61,actunkn,bindyesu,XESTLHLVL*# SEQUENCE: XESTLHLVL*# ...# >HUM12429# MHC MOLECULE: HLA-B44(B*4402), CLASS-1, (HUMAN)# METHOD: cytotoxic inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE3 (90-98)# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG6_HUMAN,MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (G01445,JC2361,JC2360)# REFERENCES: van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,QEEEGPSTF*# SEQUENCE: QEEEGPSTF*# ...# >HUM1242A# MHC MOLECULE: HLA-B44(B*4402), CLASS-1, (HUMAN)# METHOD: cytotoxic inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (167-176)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# REFERENCES: van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,MEVDPIGHLY*# SEQUENCE: MEVDPIGHLY*# ...# >HUM1242B# MHC MOLECULE: HLA-B44(B*4402), CLASS-1, (HUMAN)# METHOD: cytotoxic inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE3 (222-231)# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG3_HUMAN,MAG6_HUMAN,MAG3_HUMAN)# & PIR2: (JC2360,G01445,JC2361)# REFERENCES: van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesl,WEELSVLEVF*# SEQUENCE: WEELSVLEVF*# ...# >HUM1242C# MHC MOLECULE: HLA-B44(B*4402), CLASS-1, (HUMAN)# METHOD: cytotoxic inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (223-231)# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG3_HUMAN,MAG3_HUMAN,MAG6_HUMAN)# & PIR2: (JC2360,G01445,JC2361)# REFERENCES: van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,EELSVLEVF*# SEQUENCE: EELSVLEVF*# ...# >HUM1242D# MHC MOLECULE: HLA-B44(B*4403), CLASS-1, (HUMAN)# METHOD: cytotoxic inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (90-98)# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG3_HUMAN,MAG6_HUMAN,MAG3_HUMAN)# & PIR2: (G01445,JC2361,JC2360)# REFERENCES: van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesm,QEEEGPSTF*# SEQUENCE: QEEEGPSTF*# ...# >HUM1242E# MHC MOLECULE: HLA-B44(B*4403), CLASS-1, (HUMAN)# METHOD: cytotoxic inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (167-176)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# REFERENCES: van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,MEVDPIGHLY*# SEQUENCE: MEVDPIGHLY*# ...# >HUM1242F# MHC MOLECULE: HLA-B44(B*4403), CLASS-1, (HUMAN)# METHOD: cytotoxic inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (222-231)# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG3_HUMAN,MAG6_HUMAN,MAG3_HUMAN)# & PIR2: (G01445,JC2361,JC2360)# REFERENCES: van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,WEELSVLEVF*# SEQUENCE: WEELSVLEVF*# ...# >HUM12430# MHC MOLECULE: HLA-B44(B*4403), CLASS-1, (HUMAN)# METHOD: cytotoxic inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (223-231)# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG3_HUMAN,MAG6_HUMAN,MAG3_HUMAN)# & PIR2: (G01445,JC2361,JC2360)# REFERENCES: van_der_bruggen96a# COMMENT:# SUMMARY: HLA-B44,actunkn,bindyesh,EELSVLEVF*# SEQUENCE: EELSVLEVF*# ...# >HUM22431# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein B (2646-)# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,STPEFTILNTFHIPSFTI*# SEQUENCE: STPEFTILNTFHIPSFTI*# ...# >HUM22432# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP(97-)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQAL*# SEQUENCE: LPKPPKPVSKMRMATPLLMQAL*# ...# >HUM22433# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sialyltransferase (CD75) (288-)# DB REFERENCE: SWISS: (CAG1_HUMAN,CAG1_HUMAN)# & PIR2: (A41734)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,HPNQPFYILKPQMPWELW*# SEQUENCE: HPNQPFYILKPQMPWELW*# ...# >HUM22434# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (CD71) (737-)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LATWTIQGAANALSGDVW*# SEQUENCE: LATWTIQGAANALSGDVW*# ...# >HUM22435# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Tubulin alpha1 chain (391-)# DB REFERENCE: SWISS: (TBA2_DROME,TBA4_CHICK,TBA1_PARLI,TBA2_MOUSE,TBA3_DROME,# & TBA2_CHICK,TBA_PIG,TBA_TETTH,TBA5_CHICK,TBA_OCTDO,# & TBA2_PATVU,TBAT_ONCMY,TBA1_CHLRE,TBA_BOMMO,TBA_XENLA,# & TBA_ONCKE,TBA_TETPY,TBA6_MOUSE,TBA3_CHICK,TBA3_MOUSE,# & TBA1_DROME,TBA1_HUMAN,TBA1_CRIGR,TBA1_RAT,TBA_OCTVU,# & TBA2_CHLRE,TBA_HAECO,TBA1_CHICK,TBA_TORMA,TBA4_HUMAN,# & TBA8_CHICK,TBA2_CHLRE,TBA1_CHLRE,TBA_LYTPI,TBA1_VOLCA)# & PIR1: (UBRTA,UBCHA3,UBURAL,UBCHA5,UBPGA,UBCHA8,UBCHA4,UBCHA)# & PIR2: (A25873,I77427,I77428,I77403,S01767,B26488,A56622,I77424,# & A23035,S52152,C26488,A60671,B53298,A61544,B24903,A48466,# & S42033,A61275,A53298,S04694,I77426,S25004,S43425,JC4133,# & S00253,A24903,A48433,I57601,S11207,I77425,A26724,S43138,# & C24903,A26488,A56635,I57568)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LDHKFDLMYAKRAFVHWY*# SEQUENCE: LDHKFDLMYAKRAFVHWY*# ...# >HUM22436# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,XXPAFYMLKGKLQYXL*# SEQUENCE: XXPAFYMLKGKLQYXL*# ...# >HUM22437# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Alkaline phosphatase (479-)# DB REFERENCE: SWISS: (PPBT_BOVIN,PPBT_BOVIN)# & PIR2: (A29600)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,YIPHVMAYAACIGANRDH*# SEQUENCE: YIPHVMAYAACIGANRDH*# ...# >HUM22438# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (97-)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQAL*# SEQUENCE: LPKPPKPVSKMRMATPLLMQAL*# ...# >HUM22439# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Mannose-6-phosphate receptor (185-)# DB REFERENCE: SWISS: (MPRI_HUMAN,MPRI_HUMAN)# & PIR2: (I37623,A28372)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,DLNPLIKLSGAYLVDDSD*# SEQUENCE: DLNPLIKLSGAYLVDDSD*# ...# >HUM2243A# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ras-related protein Rab-5A (123-)# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SPNIVIALSGKADLANK*# SEQUENCE: SPNIVIALSGKADLANK*# ...# >HUM2243B# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (CD71) (332-)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# & PIR2: (S29548)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,LPNIPVQTISRAAAEKLF*# SEQUENCE: LPNIPVQTISRAAAEKLF*# ...# >HUM2243C# MHC MOLECULE: HLA-DR1(DRB1*0102), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ubiquitin (3-)# DB REFERENCE: SWISS: (UBIQ_HUMAN,UBIQ_HUMAN,UBIQ_STRPU)# & PIR1: (UQHU,UQHY,UQUYSF,UQFFR7,UQHUC,S29853,UQHUR,UQFFM,UQWO7A,# & UQHUB,UQHUR7,UQBO)# & PIR2: (A49768,A26087,I52220,S28203,JC5226,S11248,I50437,I50728,# & S13928,S12583,S11296,I50438,A29584,S10319,S62740,S42750,# & S45359,S21083,I52328,A31560,I51568,I45964,JH0302)# & PIR3: (S46214)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,IFVKTLTGKTITLEVEPS*# SEQUENCE: IFVKTLTGKTITLEVEPS*# ...# >HUM2243D# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle serum albumin (419-)# DB REFERENCE: SWISS: (ALBU_BOVIN)# & PIR1: (ABBOS)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,TPTLVEVSRSLGKVGTRC*# SEQUENCE: TPTLVEVSRSLGKVGTRC*# ...# >HUM2243E# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin D (221-)# DB REFERENCE: SWISS: (CATD_HUMAN)# & PIR1: (KHHUD)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,IGRYYTVFDRDNNRVGFA*# SEQUENCE: IGRYYTVFDRDNNRVGFA*# ...# >HUM2243F# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Coagulation factor V (39-)# DB REFERENCE: SWISS: (FA5_HUMAN,FA5_HUMAN)# & PIR1: (KFHU5)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,TTYKKVVFRKYLDSTFTK*# SEQUENCE: TTYKKVVFRKYLDSTFTK*# ...# >HUM22440# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Granulin D (41-)# DB REFERENCE: SWISS: (GRN_HUMAN)# & PIR1: (GYHU)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,CPAGYTCNVKARSCEKEV*# SEQUENCE: CPAGYTCNVKARSCEKEV*# ...# >HUM22441# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA A2 (103-)# DB REFERENCE: SWISS: (1A02_HUMAN,1A02_HUMAN,1A69_HUMAN)# & PIR1: (HLHU69,HLHUA2)# & PIR2: (I61902,I84448,I37542,I61857,I38443,I38442)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,VGSDWRFLRGYHQYAYDG*# SEQUENCE: VGSDWRFLRGYHQYAYDG*# ...# >HUM22442# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Membrane cofactor protein (315-)# DB REFERENCE: PIR2: (S01896,I57998)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,VPYRYLQRRKKKGKADGG*# SEQUENCE: VPYRYLQRRKKKGKADGG*# ...# >HUM22443# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Nidogen (429-)# DB REFERENCE: SWISS: (NIDO_MOUSE,NIDO_MOUSE,NIDO_HUMAN)# & PIR1: (MMHUND,MMMSND)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,DLHSYVVMNHGRSYTAIS*# SEQUENCE: DLHSYVVMNHGRSYTAIS*# ...# >HUM22444# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribophorin 1(86-)# DB REFERENCE: SWISS: (RIB1_HUMAN,RIB1_HUMAN)# & PIR2: (A26168)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,SGRFFTVKLPVALDPGAK*# SEQUENCE: SGRFFTVKLPVALDPGAK*# ...# >HUM22445# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Serotonin receptor (359-)# DB REFERENCE: SWISS: (5H1A_RAT,5H1A_MOUSE,5H1A_HUMAN)# & PIR2: (I38209,I49375,S07343,S31438)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,LPFFIVALVLPFCESSCH*# SEQUENCE: LPFFIVALVLPFCESSCH*# ...# >HUM22446# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Tubulin aLPHA-chain (220-)# DB REFERENCE: SWISS: (TBA3_MOUSE,TBA2_PATVU,TBA1_RAT,TBA1_PARLI,TBAT_ONCMY,# & TBA3_CHICK,TBA1_DROME,TBA_PIG,TBA1_CHICK,TBA8_CHICK,# & TBA1_HUMAN,TBA3_DROME)# & PIR1: (UBPGA,UBRTA,UBCHA8,UBCHA,UBCHA3)# & PIR2: (I77426,A56622,S42033,A48433,C26488,A60671,A23035,I77424,# & B24903,I57568,A26488,S11207)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,ERPTYTNLNRLIGQIVSS*# SEQUENCE: ERPTYTNLNRLIGQIVSS*# ...# >HUM22447# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein (196-)# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,SPLALIKGMTRPLSTLIS*# SEQUENCE: SPLALIKGMTRPLSTLIS*# ...# >HUM22448# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2-microglobulin (4-)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I37063,I36963)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,TPKIQVYSRHPAENGKSN*# SEQUENCE: TPKIQVYSRHPAENGKSN*# ...# >HUM22449# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle serum albumin (419-)# DB REFERENCE: SWISS: (ALBU_BOVIN)# & PIR1: (ABBOS)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,TPTLVEVSRSLGKVGTRC*# SEQUENCE: TPTLVEVSRSLGKVGTRC*# ...# >HUM2244A# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin D (134-)# DB REFERENCE: SWISS: (CATD_HUMAN)# & PIR1: (KHHUD)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,GPVDEVRELQKAIGAVPL*# SEQUENCE: GPVDEVRELQKAIGAVPL*# ...# >HUM2244B# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Heat shock cognate prot. Mr 71000 (62-)# DB REFERENCE: SWISS: (HS7C_RAT,HS70_SCHMA,HS7C_RAT,HS7C_BOVIN,HS7C_HUMAN,# & HS7C_CRIGR,HS7C_BOVIN)# & PIR2: (JC4853,A35922,A48469,S31716,S07197,A45935,A27077,# & S11456)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,NPTNTVFDAKRLIGRRFD*# SEQUENCE: NPTNTVFDAKRLIGRRFD*# ...# >HUM2244C# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lymphocyte activation antigen (414-)# DB REFERENCE: SWISS: (4F2_HUMAN,4F2_HUMAN)# & PIR1: (SAHU4F)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,DPGSLLSLFRRLSDQRSK*# SEQUENCE: DPGSLLSLFRRLSDQRSK*# ...# >HUM2244D# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Macrophage inflammatory prot. (47-)# DB REFERENCE: SWISS: (MI1A_HUMAN)# & PIR2: (A30574)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,KPGVIFLTKRSRQVCADP*# SEQUENCE: KPGVIFLTKRSRQVCADP*# ...# >HUM2244E# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrin receptor (580-)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,IPELNKVARAAAEVAGQF*# SEQUENCE: IPELNKVARAAAEVAGQF*# ...# >HUM2244F# MHC MOLECULE: HLA-DR11(DRB1*1104), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,EPEITILNvKLQPA*# SEQUENCE: EPEITILNvKLQPA*# ...# >HUM22450# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2-microglobulin (21-)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,TPKIQVYSRHPAENGKSN*# SEQUENCE: TPKIQVYSRHPAENGKSN*# ...# >HUM22451# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA A33 (323-)# DB REFERENCE: SWISS: (1A01_GORGO,1A31_HUMAN,1A32_HUMAN,1A33_HUMAN,1A74_HUMAN,# & 1A04_GORGO,1A29_HUMAN,1A03_GORGO,1A31_HUMAN)# & PIR2: (S18198,A45847,I37482,JH0536,I72171,JH0537,JH0534,I38610,# & I72170)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,AGAVVAAVRWRRKSSDRK*# SEQUENCE: AGAVVAAVRWRRKSSDRK*# ...# >HUM22452# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA B44 (6-)# DB REFERENCE: SWISS: (1B10_HUMAN,1B54_HUMAN,1B56_HUMAN,1B11_HUMAN,1B23_HUMAN,# & 1B12_HUMAN,1B12_HUMAN,1B53_HUMAN,1B58_HUMAN,1B25_HUMAN,# & 1B42_HUMAN,1B41_HUMAN,1B40_HUMAN,1B52_HUMAN,1B62_HUMAN,# & 1B22_HUMAN,1B21_HUMAN,1B05_HUMAN,1B49_HUMAN,1B44_HUMAN,# & 1B26_HUMAN,1B24_HUMAN,1B55_HUMAN,1B28_HUMAN,1B57_HUMAN,# & 1B45_HUMAN,1B60_HUMAN,1B63_HUMAN,1B59_HUMAN,# & 1B61_HUMAN)# & PIR1: (HLHUB4,HLHUB8)# & PIR2: (I59654,I62044,I54442,B30345,I56130,I62042,I62041,S24433,# & I68724,I62043,I61861,S24435,I38421,I54308,I84490,I37521,# & I54314,I72755,S24434,I37522,I38509,D35997,I37120,I54298,# & A45880,I54457,I37516,G01230,I61907,S25415,I68748,I72753,# & I59633,A30345,I61904,I72752,S24027,A45834,I84486,I62045,# & I72754,I61863,A45850,S16789,I56133,S24436,I37475)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,RYFYTAMSRPGRGEPRFI*# SEQUENCE: RYFYTAMSRPGRGEPRFI*# ...# >HUM22453# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DR13 beta chain (43-)# DB REFERENCE: SWISS: (HB2Q_HUMAN,HB2Q_HUMAN,HB2I_HUMAN)# & PIR1: (HLHUS2)# & PIR2: (I38898,A28909,I68798,I81237,I38425,C39247,I54448,S54258,# & I81236,G28043,I59636,I81234,I59641,I59634,A25324,I68751,# & PH0153,S07906,I37537,E30536,S54907,I59637,I38195,# & I68800)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,DVGEFRAVTELGRPDEEY*# SEQUENCE: DVGEFRAVTELGRPDEEY*# ...# >HUM22454# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DR52 beta chain (43-)# DB REFERENCE: PIR2: (I68909,I37539,A42621,I38897,B42621)# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,DVGEYRAVTELGRPDEEY*# SEQUENCE: DVGEYRAVTELGRPDEEY*# ...# >HUM22455# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DQ6 beta chain (53-)# DB REFERENCE: PIR2: (G35056,I36904,D35056)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,TERVRLVTRHIYNREEYV*# SEQUENCE: TERVRLVTRHIYNREEYV*# ...# >HUM22456# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Invariant chain (CD74) (66-)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN,HG2A_RAT)# & PIR1: (HLHUG)# & PIR2: (S04362,JC4796)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,TTAYFLYQQQGRLDKLTV*# SEQUENCE: TTAYFLYQQQGRLDKLTV*# ...# >HUM22457# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? Cathepsin L-like (237-)# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,ESFLXYKKGIY*# SEQUENCE: ESFLXYKKGIY*# ...# >HUM22458# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? Rat Clathrin Heavy Ch.-like (1596-)# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,MPYFITAMK*# SEQUENCE: MPYFITAMK*# ...# >HUM22459# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,xPAFYMLKGKLQYELQY*# SEQUENCE: xPAFYMLKGKLQYELQY*# ...# >HUM2245A# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,TPIFYMYIRXXYR*# SEQUENCE: TPIFYMYIRXXYR*# ...# >HUM2245B# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: B2-microglobulin (21-)# DB REFERENCE: SWISS: (B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I36963,I37063)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,TPKIQVYSRHPAENGKSN*# SEQUENCE: TPKIQVYSRHPAENGKSN*# ...# >HUM2245C# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cattle fetuin (45-)# DB REFERENCE: SWISS: (A2HS_BOVIN,A2HS_SHEEP,A2HS_BOVIN,A2HS_SHEEP)# & PIR2: (A35714,S22394)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,IDSVKVWPRRPTGEVYDI*# SEQUENCE: IDSVKVWPRRPTGEVYDI*# ...# >HUM2245D# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DQB1*0604 (53-)# DB REFERENCE: PIR2: (I36904,D35056,G35056)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,TERVRLVTRHIYNREEYV*# SEQUENCE: TERVRLVTRHIYNREEYV*# ...# >HUM2245E# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DQB1*0604 (123-)# DB REFERENCE: SWISS: (HB25_HUMAN,HB25_HUMAN)# & PIR1: (HLHUC3)# & PIR2: (I67725,I53630,I54432,I68732)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,FYPGQIKVRWFRNDQEET*# SEQUENCE: FYPGQIKVRWFRNDQEET*# ...# >HUM2245F# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Low affin. IgE recept. (CD23) (163-)# DB REFERENCE: SWISS: (FCE2_HUMAN,FCE2_HUMAN)# & PIR1: (LNHUER)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,CPEKWINFQRKCYYFGKG*# SEQUENCE: CPEKWINFQRKCYYFGKG*# ...# >HUM22460# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Sialyltransferase (CD75) (206-)# DB REFERENCE: SWISS: (CAG1_HUMAN,CAG1_HUMAN)# & PIR2: (A41734)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,DAVLRFNGAPTANFQQDV*# SEQUENCE: DAVLRFNGAPTANFQQDV*# ...# >HUM22461# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesu,SPEFILYAR*# SEQUENCE: SPEFILYAR*# ...# >HUM22462# MHC MOLECULE: HLA-DR52(DRB3*0202), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Apolipoprotein (3344-)# DB REFERENCE: SWISS: (APB_HUMAN,APB_HUMAN)# & PIR1: (LPHUB)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,KSSVITLNTNAELFNQSD*# SEQUENCE: KSSVITLNTNAELFNQSD*# ...# >HUM22463# MHC MOLECULE: HLA-DR52(DRB3*0202), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA A1 (119-)# DB REFERENCE: SWISS: (1C02_HUMAN,1B39_HUMAN,1C03_GORGO,1B20_HUMAN,1CXX_HUMAN,# & 1C02_HUMAN,1B46_HUMAN,1B33_HUMAN,1C16_HUMAN,1B34_HUMAN,# & 1C12_HUMAN,1C04_HUMAN,1C04_GORGO,1C18_HUMAN,1C07_HUMAN,# & 1B36_HUMAN,1C01_PANTR,1C17_HUMAN,1C01_GORGO,1C01_HUMAN,# & 1B38_HUMAN,1B35_HUMAN,1C14_HUMAN,1B04_HUMAN,1C02_GORGO,# & 1C02_GORGO,1C06_HUMAN,1C15_HUMAN,1C03_HUMAN,1B02_HUMAN,# & 1C11_HUMAN)# & PIR1: (HLHUC4,S42102,HLHUB7,HLHU40)# & PIR2: (I61865,I38507,I59622,JH0543,I54418,JH0546,I37529,C37028,# & I56034,I59655,I68747,I68701,B37028,I38437,I61906,JH0292,# & I36958,JH0526,I68749,JH0545,JH0290,I61905,I38505,S60601,# & S52486,I81232,I56116,S48134,I61866,I37526,JS0262,JH0288,# & JH0291,I37078,I37492,A45897,I61864,I59651,I61903,I59188,# & I72808,A45857,JH0547,JH0544,I81231,I56149,I68712,I54449,# & I37544,I37527,A49411,I68750,I54430,S42823,S24438,I37528,# & I37523,S44994,I72113,I84431,I37135)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,KDYIALNEDLRSWTAADT*# SEQUENCE: KDYIALNEDLRSWTAADT*# ...# >HUM22464# MHC MOLECULE: HLA-DR52(DRB3*0202), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DR aLPHA chain (33-)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085,I72480)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,IQAEFYLNPDQSGEFMFD*# SEQUENCE: IQAEFYLNPDQSGEFMFD*# ...# >HUM22465# MHC MOLECULE: HLA-DR52(DRB3*0202), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DPw4 BETA chain (25-)# DB REFERENCE: SWISS: (HB2Q_HUMAN,HB2Q_HUMAN)# & PIR1: (HLHUS2)# & PIR2: (I68798,I68793,S07906,I59636,I38195,I68800,I68788,I37298,# & I59624,I59637,E30536,I68792,I81235,D39247,A39247,H30536,# & A28909,D30537,I54483,C39247,I68751,I81238,I68799,# & I68802)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,LERYIYNREEFVRFDSDVGE*# SEQUENCE: LERYIYNREEFVRFDSDVGE*# ...# >HUM22466# MHC MOLECULE: HLA-DR52(DRB3*0202), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Pleckstrin (161-)# DB REFERENCE: SWISS: (P47_HUMAN)# & PIR2: (S00755)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,VIDWLVSNQSVRNRQEGL*# SEQUENCE: VIDWLVSNQSVRNRQEGL*# ...# >HUM22467# MHC MOLECULE: HLA-DR52(DRB3*0202), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ? Haemoglobin-like (124-)# ANCHOR POSITIONS:# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,SLDKFLANVSTVLTGKYR*# SEQUENCE: SLDKFLANVSTVLTGKYR*# ...# >HUM22468# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Elongation factor Tu (342-)# DB REFERENCE: SWISS: (EF13_XENLA,EF11_RHIRA,EF1A_CRIGR,EF11_HUMAN,EF11_HUMAN,# & EF12_RHIRA,EF12_XENLA,EF1A_MOUSE,EF13_RHIRA,EF11_MOUSE,# & EF11_CRIGR)# & PIR1: (EFRB1,EFMS1,EFHU1)# & PIR2: (S13806,A25938,S06300,I50226,JH0530,S35986,I59399,JU0133,# & S21055)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,AQVIILNHPGQISAGYAP*# SEQUENCE: AQVIILNHPGQISAGYAP*# ...# >HUM22469# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA DR alpha chain (110-)# DB REFERENCE: SWISS: (HA2R_HUMAN)# & PIR1: (HLHUDA)# & PIR2: (I56085)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,VPPEVTVLTNSPVELREP*# SEQUENCE: VPPEVTVLTNSPVELREP*# ...# >HUM2246A# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig lambda chain (11-)# DB REFERENCE: SWISS: (LAC_HUMAN,I141_HUMAN)# & PIR1: (A33911,L2HU)# & PIR2: (S12441,S25738,B49444,S25744,S25750,S25753,S25748,S14675,# & S25759,S03401,S25752,A42193,S21066,S25740,S12440,S25747,# & S25742,S25757,S25749,S25756,S29258,S25745,A39949,S12443,# & S25758,S25754,S25755,S25741,S25746,S05270,S25751,# & S12442)# REFERENCES: verreck96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,FPPSSEELQANKATLVCL*# SEQUENCE: FPPSSEELQANKATLVCL*# ...# >HUM2246B# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: analysis of lymphokine production# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p I (61-80)# DB REFERENCE: SWISS: (DER2_DERPT,DER2_DERFA)# & PIR2: (A60381)# REFERENCES: neeno96a# COMMENT:# SUMMARY: HLA-DQ8,actyesu,bindyesu,LEVDVPGIDPNACHYMKCPL*# SEQUENCE: LEVDVPGIDPNACHYMKCPL*# ...# >HUM2246C# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: analysis of lymphokine production# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p I (91-110)# DB REFERENCE: SWISS: (DER2_DERFA,DER2_DERPT)# & PIR2: (A60381)# REFERENCES: neeno96a# COMMENT:# SUMMARY: HLA-DQ8,actyesu,bindyesu,TWNVPKIAPKSENVVVTVKV*# SEQUENCE: TWNVPKIAPKSENVVVTVKV*# ...# >HUM2246D# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: analysis of lymphokine production# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p I (111-129)# DB REFERENCE: SWISS: (DER2_DERFA,DER2_DERPT)# & PIR2: (A60381)# REFERENCES: neeno96a# COMMENT:# SUMMARY: HLA-DQ8,actyesu,bindyesu,MGDDGVLACAIATHAKIRD*# SEQUENCE: MGDDGVLACAIATHAKIRD*# ...# >MUS1246E# MHC MOLECULE: H2-M3(M3wt), CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: mitochondrial peptide# DB REFERENCE: SWISS: (NU5M_MOUSE,NU5M_MOUSE)# & PIR1: (QXMS5M)# REFERENCES: morse96a# COMMENT:# SUMMARY: H2-M3,actyesh,bindyesu,MNIFTTSIL*# SEQUENCE: MNIFTTSIL*# ...# >MUS1246F# MHC MOLECULE: H2-M3(M3wt), CLASS-1, (MOUSE)# METHOD: cytotoxicity as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: mitochondrial peptide# DB REFERENCE: SWISS: (COX1_HORSE,COX1_BOVIN,COX1_MOUSE,COX1_MOUSE,COX1_RHIUN,# & COX1_ORNAN,COX1_CAPHI,COX1_DIDMA,COX1_HORSE,# & COX1_BOVIN)# & PIR1: (ODMS1,ODBO1)# & PIR2: (S42812)# & PIR3: (S47872)# REFERENCES: morse96a# COMMENT:# SUMMARY: H2-M3,actyesm,bindyesu,MFINRWLFS*# SEQUENCE: MFINRWLFS*# ...# >HUM12470# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV1 NS4 (1789-)# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCV1)# & PIR1: (GNWVC3,GNWVCH)# & PIR2: (PS0326,S40770)# REFERENCES: van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLMAFTAAV*# SEQUENCE: SLMAFTAAV*# ...# >HUM12471# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as./Reference# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HIV-1 Pol (267-)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1B5,POL_HV1A2,POL_HV1MA,POL_HV1PV,# & POL_HV1H2,POL_HV1BR,POL_HV1ND,POL_HV1OY,POL_HV1RH,# & POL_HV1B1,POL_HV1MN,POL_HV1U4,POL_HV1JR,POL_HV1Y2,# & POL_HV1N5,POL_HV1EL)# & PIR1: (GNLJND,GNVWVL,GNVWLV,GNVWH3,GNVWA2,B44001)# & PIR2: (S32048,S32118,S32067,S32076,S32120,S32072,S32093,S32047,# & S32082,S32066,S32132,S32055,S32050,S32131,S32068,S32049,# & E47330,S32097,S32094,S32065,S32053,S32139,S32063,S32126,# & S32117,S32071,S32152,S32133,S32137,S32085,S32089,S32054,# & S32096,S32098,S32077,F47330,S32092,S32134,S32086,C47330,# & S32119,D47330,S32122,S32052,A47330,S32135,S32159,S32081,# & S32073,S32127,S32084,S32059,S32078,S54378,S32088,S32087,# & S32058,S32056,S32064,B47175,S32138,S32160,S32061,B47330,# & S32074,S32083,S32090,S32157,S32151,S32062,S32060,S32069,# & S32075,S32091,A47175,S32136,S43127,S32140,S32070,S32128,# & S32095,S32129,S32057)# & PIR3: (S33980)# REFERENCES: van_der_burg96a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,VLDVGDAYFSV*# SEQUENCE: VLDVGDAYFSV*# ...# >HUM12472# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV core (18-)# ANCHOR POSITIONS:# REFERENCES: van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDDFPSV*# SEQUENCE: FLPSDDFPSV*# ...# >HUM12473# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 pol (343-)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1U4,POL_HV1JR,POL_HV1H2,POL_HV1PV,# & POL_HV1B5,POL_HV1A2,POL_SIVCZ,POL_HV1B1,POL_HV1OY,# & POL_HV1MN,POL_HV1Y2,POL_HV1N5,POL_HV1EL,POL_HV1RH,# & POL_HV1MA,POL_HV1ND,POL_HV1BR)# & PIR1: (GNVWA2,GNLJND,GNLJSI,GNVWLV,GNVWVL,GNVWH3,B44001)# & PIR2: (S32049,S32066,E47330,S32050,S32093,S32083,S32060,S32091,# & S43127,S32077,S32137,S32152,S32065,S32117,S32159,S32052,# & D47330,S32084,S32134,S32081,C47330,S32160,S32056,S54378,# & S32096,S32080,S32089,S32126,S32053,S32140,S32151,S32157,# & B47175,S32138,S32122,A47330,S32086,S32139,S32063,S32071,# & S32135,S32119,S32072,S32118,S32048,S32067,S32076,S32051,# & S32090,S32074,S32075,S32069,S32062,S32098,F47330,S32054,# & S32133,S32085,S32068,S32131,S32097,S32094,S32047,S32082,# & S32120,S32132,S32055,S32057,S32095,S32129,A47175,S32136,# & S32070,S32128,B47330,S32061,S32064,S32058,S32059,S32079,# & S32073,S32127,S32088,S32087,S32078)# & PIR3: (S33980)# REFERENCES: van_der_burg96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YMDDLYVGSDL*# SEQUENCE: YMDDLYVGSDL*# ...# >HUM12474# MHC MOLECULE: HLA-Cw6(Cw*0602), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw6,actunkn,bindyesu,YQFTGIKKY*# SEQUENCE: YQFTGIKKY*# ...# >HUM12475# MHC MOLECULE: HLA-Cw6(Cw*0602), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw6,actunkn,bindyesu,VRHDGGNVL*# SEQUENCE: VRHDGGNVL*# ...# >HUM12476# MHC MOLECULE: HLA-Cw6(Cw*0602), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw6,actunkn,bindyesu,FAXXLIXRV*# SEQUENCE: FAXXLIXRV*# ...# >HUM12477# MHC MOLECULE: HLA-Cw6(Cw*0602), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw6,actunkn,bindyesu,XQXTPXAXXYY*# SEQUENCE: XQXTPXAXXYY*# ...# >HUM12478# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CKShs2 (40-48)# DB REFERENCE: SWISS: (CKS2_HUMAN)# & PIR2: (B36670)# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,KYFDEHYEY*# SEQUENCE: KYFDEHYEY*# ...# >HUM12479# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: histone H3.3# DB REFERENCE: SWISS: (H31_SCHPO,H33_CAEEL,H32_BOVIN,H3_CAEEL,H3_CHLRE,# & H3_PSAMI,H32_XENLA,H3_VOLCA,H3_STRPU,H33_HUMAN,# & H31_HUMAN,H3_PSAMI,H3_DROME,H32_MEDSA,H3_ACRFO)# & PIR1: (HSTR3,HSRK3,HSXL32,HSCH3,HSHU33,HSKW3,HSUR3M,HSXL31,# & HSHU3,HSBO3,HSUR3P,HSZP3,HSFI3)# & PIR2: (JN0687,JQ1983,S01197,B61286,S10168,S06743,B38309,S04186,# & S34185,S20109,A61286,JS0690,S20669,S61218,JQ1343,JQ0757,# & I49395,S59581,JQ1984,S51664,S32638,I50460,JH0304,A56580,# & I50245,S20678,S04521,I49398,S61220,S06755,S11315,S24346,# & S61215,A56654,S57473,A02630,S10097,S59123,A56618,S50140,# & I50244,I49397,S61214,S09655,S01198,S59592,S00940,S01196,# & I51448,I57019)# & PIR3: (S42066,A45941,S42065,C61286)# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,RYRPGTVAL*# SEQUENCE: RYRPGTVAL*# ...# >HUM1247A# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Protein synthesis factor eIF-4C (87-95)# DB REFERENCE: SWISS: (IF1A_HUMAN,IF1A_MOUSE,IF1A_RABIT,IF1A_RABIT,# & IF1A_HUMAN)# & PIR2: (B53045,C53045)# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,NKADVILKY*# SEQUENCE: NKADVILKY*# ...# >HUM1247B# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,IYPQNVILY*# SEQUENCE: IYPQNVILY*# ...# >HUM1247C# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: glytamil-tRNA synthetase (343-351)# DB REFERENCE: SWISS: (SYEP_HUMAN,SYEP_HUMAN)# & PIR1: (SYHUQT)# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,IRKPYIWEY*# SEQUENCE: IRKPYIWEY*# ...# >HUM1247D# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human hnRNP A2/B1# ANCHOR POSITIONS:# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,NYGGGNYGSGHSY*# SEQUENCE: NYGGGNYGSGHSY*# ...# >HUM1247E# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,XMPPXLXG*# SEQUENCE: XMPPXLXG*# ...# >HUM1247F# MHC MOLECULE: HLA-Cw7(Cw*0702), CLASS-1, (HUMAN)# METHOD: pool sequencing/individual sequencing# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: falk93c# COMMENT:# SUMMARY: HLA-Cw7,actunkn,bindyesu,FYPPXXY*# SEQUENCE: FYPPXXY*# ...# >HUM12480# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human insulin degrading enzyme (304-313)# DB REFERENCE: SWISS: (IDE_HUMAN,IDE_RAT)# & PIR1: (SNHUIN)# & PIR2: (S29509)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,VPIKDIRNLY*# SEQUENCE: VPIKDIRNLY*# ...# >HUM12481# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV-1 ATK,MT-2,HS35 env-gp46 (67-76)# DB REFERENCE: SWISS: (ENV_HTL1F,ENV_HTL1C,ENV_HTL1A,ENV_HTL1M)# & PIR1: (VCLJMT,VCVWH,VCLJCN)# & PIR2: (S14605,B61547)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,CPNLVSYSSY*# SEQUENCE: CPNLVSYSSY*# ...# >HUM12482# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HPV-18 L2# DB REFERENCE: SWISS: (VL2_HPV18)# & PIR1: (P2WL18)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,IPKKRKRVPY*# SEQUENCE: IPKKRKRVPY*# ...# >HUM12483# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HPV-18 E1# DB REFERENCE: SWISS: (VE1_HPV18)# & PIR1: (W1WL18)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,HPAKDNRWPY*# SEQUENCE: HPAKDNRWPY*# ...# >HUM12484# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HPV-16 L2# DB REFERENCE: SWISS: (VL2_HPV16)# & PIR1: (P2WLHS)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,SPTSINNGLY*# SEQUENCE: SPTSINNGLY*# ...# >HUM12485# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HPV-16 L1# DB REFERENCE: SWISS: (VL1_HPV16)# & PIR1: (P1WLHS)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,EPYGDSLFFY*# SEQUENCE: EPYGDSLFFY*# ...# >HUM12486# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-2 pol# DB REFERENCE: SWISS: (POL_HTLV2)# & PIR1: (GNLJH2)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,IPLPKQYQPY*# SEQUENCE: IPLPKQYQPY*# ...# >HUM12487# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-1 ATK,MT-2 env-gp46# DB REFERENCE: SWISS: (ENV_HTL1N,ENV_HTL1A,ENV_HTL1F,ENV_HTL1M)# & PIR1: (VCVWH,VCLJMT)# & PIR2: (S14605,B41358,B61547)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,VPSSSSTPLL*# SEQUENCE: VPSSSSTPLL*# ...# >HUM12488# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HS35 HS35 env-gp46# DB REFERENCE: SWISS: (ENV_HTL1C)# & PIR1: (VCLJCN)# REFERENCES: schonbach96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,VPSPSSTPLL*# SEQUENCE: VPSPSSTPLL*# ...# >HUM12489# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (1227-1235)# DB REFERENCE: SWISS: (POL_HV1PV,POL_HV1A2,POL_HV1B5,POL_HV1MN,POL_HV1N5,# & POL_HV1Y2,POL_HV1EL,POL_HV1ND,POL_HV1BR,POL_HV1RH,# & POL_HV1OY,POL_HV1B1,POL_HV1Z2,POL_HV1JR,POL_HV1H2)# & PIR1: (GNVWLV,GNVWA2,GNVWVL,GNVWH3,GNLJND,B44001)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S33980,S11523)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,YLAWVPAHK*# SEQUENCE: YLAWVPAHK*# ...# >HUM1248A# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as./Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-2 (299-307)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a,mcintyre96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ISYPPLHER*# SEQUENCE: ISYPPLHER*# ...# >HUM1248B# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (1075-1083)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1Y2,POL_HV1PV,POL_HV1BR,POL_HV1Z2,# & POL_HV1OY,POL_HV1B1,POL_HV1MA,POL_HV1H2,POL_HV1ND,# & POL_HV1RH,POL_HV1B5,POL_SIVCZ,POL_HV1MN)# & PIR1: (GNVWVL,B44001,GNVWLV,GNLJND,GNLJSI,GNVWH3)# & PIR2: (S54378)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,IVIWGKTPK*# SEQUENCE: IVIWGKTPK*# ...# >HUM1248C# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (1434-1442)# DB REFERENCE: SWISS: (POL_SIVCZ,POL_HV1ND,POL_HV1PV,POL_HV1BR,POL_HV1N5,# & POL_HV1Y2,POL_HV1H2,POL_HV1JR,POL_HV1RH,POL_HV1B1,# & POL_HV1U4,POL_HV1B5,POL_HV1MN,POL_HV1Z6,POL_HV1MA,# & POL_HV1EL,POL_HV1OY,POL_HV1Z2,POL_HV1A2)# & PIR1: (GNLJND,GNLJSI,GNVWA2,GNVWLV,B44001,GNVWVL,GNVWH3)# & PIR2: (A26192,S54378)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,AVFIHNFKR*# SEQUENCE: AVFIHNFKR*# ...# >HUM1248D# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ayw (713-721)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVM,DPOL_HPBVA)# & PIR1: (S20752,JDVLA1,JDVLVA,JDVLVS,S47406)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,IMPARFYPK*# SEQUENCE: IMPARFYPK*# ...# >HUM1248E# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (601-609)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOM_HPBVY,DPOL_HPBV4,DPOL_HPBVY,DPOL_HPBVI,# & DPOL_HPBVL,DPOL_HPBVR,DPOL_HPBVO)# & PIR1: (JDVLCP,JDVLVR,JDVLJ2,JDVLVB,JDVLVA,JDVLJ3,S20752,# & JDVLA1)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,RLADEGLNR*# SEQUENCE: RLADEGLNR*# ...# >HUM1248F# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV ade X (1548-1555)# DB REFERENCE: SWISS: (X_HPBV2,X_HPBV2,X_HPBVJ,X_HPBV4,X_HPBVI,X_HPBVT,X_HPBVO,# & X_HPBVY,X_HPBV9,X_HPBVL)# & PIR1: (QQVLD1,QQVLAW,QQVLCP,A48345,QQVLKS,QQVLBH)# & PIR2: (S12542,S53254,S53190,JS0604,S53233,S53132,JS0256,S20756,# & S47404,S32203,S20751,S53130,S35529,S25650,S53162,S53156,# & S33687,JQ2228,JS0603,S53187,S53219)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,KVFVLGGCR*# SEQUENCE: KVFVLGGCR*# ...# >HUM12490# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum TRAP (611-619)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,LACAGLAYK*# SEQUENCE: LACAGLAYK*# ...# >HUM12491# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (621-629)# DB REFERENCE: SWISS: (DPOL_HPBVW,DPOL_HPBVO,DPOL_HPBVL,DPOL_HPBV9,DPOL_HPBVT,# & DPOL_HPBV2,DPOL_HPBVA,DPOL_HPBVP,DPOL_HPBVI,DPOL_HPBVY,# & DPOL_HPBV4,DPOM_HPBVY,DPOL_HPBVZ,DPOL_HPBVM,DPOL_HPBVJ,# & DPOL_HPBVR)# & PIR1: (JDVLVA,JDVLA1,JDVLJ3,JQ2229,S20752,S47406,JDVLVD,JDVLCP,# & JDVLKS,S43491,JDVLVR,JDVLVS,JDVLJ2,S20757,JDVLVH,JDVLVB,# & JDVLJ1)# & PIR2: (S35527,S71785)# REFERENCES: sidney96a,bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,NVSIPWTHK*# SEQUENCE: NVSIPWTHK*# ...# >HUM12492# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as./Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE-1 (96-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a,mcintyre96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,SLFRAVITK*# SEQUENCE: SLFRAVITK*# ...# >HUM12493# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA1 (94-102)# DB REFERENCE: PIR2: (A45592)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,QTNFKSLLR*# SEQUENCE: QTNFKSLLR*# ...# >HUM12494# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (398-406)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVM,DPOL_HPBVR)# & PIR1: (JDVLVS,JDVLVR)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,GSTHVSWPK*# SEQUENCE: GSTHVSWPK*# ...# >HUM12495# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV env (370-378)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1SC,ENV_HV1W2,ENV_HV1H2,ENV_HV1PV,# & ENV_HV1W1)# & PIR1: (VCLJVL,VCLJ3W,VCLJH3,VCLJSC)# & PIR2: (S25940,S35830)# & PIR3: (S33985)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,RAKWNNTLK*# SEQUENCE: RAKWNNTLK*# ...# >HUM12496# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-1 (66-74)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,TTINFTRQR*# SEQUENCE: TTINFTRQR*# ...# >HUM12497# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV X (69-77)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,CALPFTSAR*# SEQUENCE: CALPFTSAR*# ...# >HUM12498# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV adr pol (711-719)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVT,DPOL_HPBVM,DPOL_HPBVR)# & PIR1: (JDVLVR,JDVLVS,JQ2229)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,AVNHYFKTR*# SEQUENCE: AVNHYFKTR*# ...# >HUM12499# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: c-ERB2 (669-677)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,VVFGILIKR*# SEQUENCE: VVFGILIKR*# ...# >HUM1249A# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU A NP (166-174)# DB REFERENCE: SWISS: (VNUC_IATKO,VNUC_IAGU2,VNUC_IACAL,VNUC_IANT6,VNUC_IAME5,# & VNUC_IAUSS,VNUC_IADNZ,VNUC_IABRA,VNUC_IAMIN,VNUC_IAMEE,# & VNUC_IAHJI,VNUC_IADBE,VNUC_IAME4,VNUC_IAZOH,VNUC_IATEI,# & VNUC_IAMEC,VNUC_IADE2,VNUC_IATX7,VNUC_IAOHI,VNUC_IAS11,# & VNUC_IAZ41,VNUC_IAMEB,VNUC_IAZH4,VNUC_IAANA,VNUC_IAZW1,# & VNUC_IAWIS,VNUC_IADMA,VNUC_IAWHN,VNUC_IAZJ1,VNUC_IAPUE,# & VNUC_IAVI6,VNUC_IAB37,VNUC_IAGUA,VNUC_IAANN,VNUC_IAZJ4,# & VNUC_IAUDO,VNUC_IAFPR,VNUC_IAZNE,VNUC_IAZCA,VNUC_IADM2,# & VNUC_IAWIL,VNUC_IAHO1,VNUC_IAME6,VNUC_IACKG,VNUC_IAFOW,# & VNUC_IAGU4,VNUC_IAZI3,VNUC_IAB39,VNUC_IABUD,VNUC_IAGRE,# & VNUC_IAMEA,VNUC_IAEN5,VNUC_IADAU,VNUC_IASE0,VNUC_IAZJ3,# & VNUC_IAZMA,VNUC_IAZI2,VNUC_IADCZ,VNUC_IAZGE,VNUC_IAHPR,# & VNUC_IAPAR,VNUC_IAMEG,VNUC_IACKP,VNUC_IAGU1,VNUC_IAZH1,# & VNUC_IAMEF,VNUC_IAZ29,VNUC_IAGUM,VNUC_IAHIC,VNUC_IAWHP,# & VNUC_IAZDA,VNUC_IAANN,VNUC_IAFPD,VNUC_IAS06,VNUC_IAFOM,# & VNUC_IAKIE,VNUC_IATRS,VNUC_IAGU3,VNUC_IAZTE,VNUC_IAHMI,# & VNUC_IAZJ2,VNUC_IATRT,VNUC_IAHO2,VNUC_IATKN,VNUC_IAME3,# & VNUC_IAHLO,VNUC_IARUD,VNUC_IASIN,VNUC_IALEN,VNUC_IAMAN,# & VNUC_IASH2,VNUC_IADU2,VNUC_IAS31,VNUC_IADE1,VNUC_IAGD7,# & VNUC_IADHK,VNUC_IANEJ,VNUC_IAZON,VNUC_IAGUN,VNUC_IAZW2,# & VNUC_IAZI1,VNUC_IAZH3,VNUC_IAMAA,VNUC_IAZJA,VNUC_IAHTE)# & PIR1: (VHIVN7,VHIVA3,VHIVN6,A60028,VHIVA6,VHIVN4,VHIV34,VHIVX3,# & VHIV68,VHIVX6,VHIVX2,VHIVC1,VHIV8H,VHIVN9,VHIVN1,VHIVN5,# & VHIVA7,VHIVAK,VHIVX5,VHIVN2,VHIVX4,VHIV61,VHIVM1,VHIVX1,# & VHIVXL,VHIVN3,VHIVN8)# & PIR2: (B36754,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,LMQGSTLPR*# SEQUENCE: LMQGSTLPR*# ...# >HUM1249B# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE 2 (66-74)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a,mcyntyre96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,TTINYTLWR*# SEQUENCE: TTINYTLWR*# ...# >HUM1249C# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV ENV (1290-1298)# DB REFERENCE: SWISS: (POLG_HCVE1,POLG_HCVJ2,POLG_HCVH7,POLG_HCVH8,POLG_HCVBK,# & POLG_HCV1,POLG_HCVTW,POLG_HCVHK,POLG_HCVTH,POLG_HCVJA,# & POLG_HCVJT)# & PIR1: (GNWVCJ,GNWVTW,GNWVC3,GNWVTC)# & PIR2: (S18031,JQ1925,S18032,S21471,JN0265,PN0011,PS0165,S12707,# & PC1284,PS0164,A44150,JQ1584,PN0677,S32749,S19876,A45573,# & S19875,S18030,S40770)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,QLFTFSPRR*# SEQUENCE: QLFTFSPRR*# ...# >HUM1249D# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV CORE (51-58)# DB REFERENCE: SWISS: (POLG_HCVJ5,POLG_HCVHK,POLG_HCV1,POLG_HCVH4,POLG_HCVJA,# & POLG_HCVJ2,POLG_HCVJ8,POLG_HCVH,POLG_HCVJT,POLG_HCVJ7,# & POLG_HCVBK,POLG_HCVJ6)# & PIR1: (GNWVC3,GNWVCH,GNWVCJ,GNWVTC,GNWVJ8)# & PIR2: (S41354,S41363,S19875,S19876,S41346,JQ0883,S41358,JQ0881,# & S41367,S41369,S41357,PC2060,S41345,S41352,S44190,PC2219,# & S41341,S12707,S41343,PQ0804,S41362,S21471,S18032,S41347,# & S41351,S41348,PQ0393,PC1284,S41371,PS0388,S41355,S41356,# & JN0265,S41370,A44150,JQ1926,S41353,JQ1584,S21336,A45573,# & S41350,S41368,S40770,S18030,JQ1303,S41344,S41365,JQ1925,# & S41288,S18031,S41366,S41360,S41359,S41364,PN0677,PQ0805,# & S41361,S41342)# & PIR3: (S32740,PQ0398)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,KTSERSQPR*# SEQUENCE: KTSERSQPR*# ...# >HUM1249E# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV adr POL (1257-1265)# DB REFERENCE: PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,HLYPVARQR*# SEQUENCE: HLYPVARQR*# ...# >HUM1249F# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: c-ERB2 (754-762)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,VLRENTSPK*# SEQUENCE: VLRENTSPK*# ...# >HUM124A0# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: c-ERB2 (852-860)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161,A47253,PT0184)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,LVKSPNHVK*# SEQUENCE: LVKSPNHVK*# ...# >HUM124A1# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (1227-1235)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1RH,POL_HV1MN,POL_HV1Z2,POL_HV1OY,# & POL_HV1H2,POL_HV1JR,POL_HV1BR,POL_HV1ND,POL_HV1EL,# & POL_HV1B5,POL_HV1Y2,POL_HV1PV,POL_HV1A2,POL_HV1N5)# & PIR1: (B44001,GNVWA2,GNLJND,GNVWH3,GNVWLV,GNVWVL)# & PIR2: (A47175,S54378,B47175)# & PIR3: (S33980,S11523)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,YLAWVPAHK*# SEQUENCE: YLAWVPAHK*# ...# >HUM124A2# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-2 (299-307)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,ISYPPLHER*# SEQUENCE: ISYPPLHER*# ...# >HUM124A3# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (1075-1083)# DB REFERENCE: SWISS: (POL_HV1B5,POL_SIVCZ,POL_HV1N5,POL_HV1OY,POL_HV1MA,# & POL_HV1Z2,POL_HV1B1,POL_HV1MN,POL_HV1BR,POL_HV1H2,# & POL_HV1ND,POL_HV1Y2,POL_HV1RH,POL_HV1PV)# & PIR1: (B44001,GNLJSI,GNVWVL,GNLJND,GNVWLV,GNVWH3)# & PIR2: (S54378)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,IVIWGKTPK*# SEQUENCE: IVIWGKTPK*# ...# >HUM124A4# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (1434-1442)# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1Z2,POL_HV1MN,POL_HV1B1,POL_HV1OY,# & POL_HV1Z6,POL_HV1EL,POL_HV1B5,POL_HV1N5,POL_SIVCZ,# & POL_HV1ND,POL_HV1Y2,POL_HV1MA,POL_HV1BR,POL_HV1H2,# & POL_HV1JR,POL_HV1U4,POL_HV1PV,POL_HV1A2)# & PIR1: (GNLJND,GNLJSI,GNVWH3,GNVWVL,B44001,GNVWA2,GNVWLV)# & PIR2: (A26192,S54378)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,AVFIHNFKR*# SEQUENCE: AVFIHNFKR*# ...# >HUM124A5# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ayw (713-721)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBVA)# & PIR1: (JDVLA1,JDVLVS,JDVLVA,S47406,S20752)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,IMPARFYPK*# SEQUENCE: IMPARFYPK*# ...# >HUM124A6# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (601-609)# DB REFERENCE: SWISS: (DPOL_HPBVO,DPOM_HPBVY,DPOL_HPBVA,DPOL_HPBVI,DPOL_HPBVY,# & DPOL_HPBV4,DPOL_HPBVL,DPOL_HPBVR)# & PIR1: (JDVLJ3,JDVLVA,JDVLA1,JDVLVB,JDVLCP,JDVLVR,S20752,# & JDVLJ2)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,RLADEGLNR*# SEQUENCE: RLADEGLNR*# ...# >HUM124A7# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV ade X (1548-1555)# DB REFERENCE: SWISS: (X_HPBV2,X_HPBV2,X_HPBVT,X_HPBV9,X_HPBVY,X_HPBVO,X_HPBVL,# & X_HPBV4,X_HPBVJ,X_HPBVI)# & PIR1: (QQVLAW,QQVLD1,QQVLBH,QQVLKS,QQVLCP,A48345)# & PIR2: (JS0604,S20756,S53187,S53130,S53156,S33687,S12542,JQ2228,# & S32203,S53219,S53162,S25650,S35529,S53254,JS0256,JS0603,# & S53190,S53233,S53132,S47404,S20751)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,KVFVLGGCR*# SEQUENCE: KVFVLGGCR*# ...# >HUM124A8# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum TRAP (611-619)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,LACAGLAYK*# SEQUENCE: LACAGLAYK*# ...# >HUM124A9# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as./competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBV adr pol (621-629)# DB REFERENCE: SWISS: (DPOL_HPBV9,DPOL_HPBV4,DPOL_HPBVL,DPOL_HPBVW,DPOL_HPBVR,# & DPOL_HPBVT,DPOL_HPBV2,DPOL_HPBVP,DPOL_HPBVZ,DPOL_HPBVI,# & DPOM_HPBVY,DPOL_HPBVA,DPOL_HPBVO,DPOL_HPBVM,DPOL_HPBVJ,# & DPOL_HPBVY)# & PIR1: (JDVLJ3,JDVLVB,JQ2229,JDVLVS,JDVLJ1,JDVLCP,S20752,JDVLVD,# & JDVLKS,JDVLA1,JDVLVA,S47406,S20757,JDVLVR,S43491,JDVLJ2,# & JDVLVH)# & PIR2: (S35527,S71785)# REFERENCES: sidney96a,bertoni97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesm,NVSIPWTHK*# SEQUENCE: NVSIPWTHK*# ...# >HUM124AA# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE-1 (96-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,SLFRAVITK*# SEQUENCE: SLFRAVITK*# ...# >HUM124AB# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA1 (94-102)# DB REFERENCE: PIR2: (A45592)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,QTNFKSLLR*# SEQUENCE: QTNFKSLLR*# ...# >HUM124AC# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (398-406)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBV4,DPOL_HPBVR)# & PIR1: (JDVLVR,JDVLVS)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,GSTHVSWPK*# SEQUENCE: GSTHVSWPK*# ...# >HUM124AD# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV env (370-378)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1H2,ENV_HV1W1,ENV_HV1PV,ENV_HV1SC,# & ENV_HV1W2)# & PIR1: (VCLJH3,VCLJSC,VCLJ3W,VCLJVL)# & PIR2: (S25940,S35830)# & PIR3: (S33985)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,RAKWNNTLK*# SEQUENCE: RAKWNNTLK*# ...# >HUM124AE# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PSA (299-307)# DB REFERENCE: SWISS: (PROS_HUMAN,KLK2_HUMAN,PROS_HUMAN)# & PIR2: (A32297,A29586,G01551)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,YTKVVHYRK*# SEQUENCE: YTKVVHYRK*# ...# >HUM124AF# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE-1 (66-74)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,TTINFTRQR*# SEQUENCE: TTINFTRQR*# ...# >HUM124B0# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV X (69-77)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,CALPFTSAR*# SEQUENCE: CALPFTSAR*# ...# >HUM124B1# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (711-719)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVR,DPOL_HPBV4,DPOL_HPBVT)# & PIR1: (JDVLVR,JQ2229,JDVLVS)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,AVNHYFKTR*# SEQUENCE: AVNHYFKTR*# ...# >HUM124B2# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (859-867)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1H2,POL_HV1U4,POL_HV1JR,POL_HV1BR,# & POL_HV1ND,POL_HV1A2,POL_HV1OY,POL_SIVCZ,POL_HV1Z2,# & POL_HV1MA,POL_HV1MN,POL_HV1PV,POL_HV1B5,POL_HV1N5)# & PIR1: (GNVWVL,GNLJND,GNLJSI,GNVWLV,GNVWA2)# & PIR2: (S32062,S32118,S32072,S32074,S32129,S32064,S32058,S32061,# & B47330,D47330,S32052,S32159,S32077,S32152,A47175,S32059,# & S32087,S54378,S32078,S32056,S32160,S32084,S32081,S32091,# & S32049,B47175,S32083,A47330,S32138,S32140,S32089,S32126,# & S32096,S32080,S32048,S32069,S32095,S43127,S32131,S32128,# & S32119,S32139,S32063,S32082,S32068,S32132,S32120,S32055,# & S32094,S32085,S32054,S32098,S32134,S32151,S32122,S32157,# & S32053,S32076,S32047,S32051,S32067,S32050,S32066,S32093,# & S32060,S32065,E47330,S32137,S32117,S32127,S32079,S32088,# & S32070,S32136,S32135,S32071,S32086,S32133,S32090,S32057,# & S32075)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,MTKILEPFR*# SEQUENCE: MTKILEPFR*# ...# >HUM124B3# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: c-ERB2 (669-677)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,VVFGILIKR*# SEQUENCE: VVFGILIKR*# ...# >HUM124B4# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate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sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,LMQGSTLPR*# SEQUENCE: LMQGSTLPR*# ...# >HUM124B5# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE 2 (66-74)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,TTINYTLWR*# SEQUENCE: TTINYTLWR*# ...# >HUM124B6# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV ENV (1290-1298)# DB REFERENCE: SWISS: (POLG_HCVH8,POLG_HCVE1,POLG_HCVTH,POLG_HCVHK,POLG_HCVJT,# & POLG_HCVJ2,POLG_HCV1,POLG_HCVJA,POLG_HCVBK,POLG_HCVH7,# & POLG_HCVTW)# & PIR1: (GNWVTW,GNWVC3,GNWVTC,GNWVCJ)# & PIR2: (S12707,S32749,S18032,PS0164,S40770,PS0165,S19875,A44150,# & JQ1584,JN0265,JQ1925,PC1284,S19876,PN0011,S18030,A45573,# & S21471,PN0677,S18031)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,QLFTFSPRR*# SEQUENCE: QLFTFSPRR*# ...# >HUM124B7# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (226-234)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG6_HUMAN,MAG3_HUMAN,MAG6_HUMAN)# & PIR2: (G01445,JC2361,JC2360)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,SVLEVFEGR*# SEQUENCE: SVLEVFEGR*# ...# >HUM124B8# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV CORE (51-58)# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVHK,POLG_HCVJ7,POLG_HCV1,POLG_HCVBK,# & POLG_HCVH,POLG_HCVJ5,POLG_HCVH4,POLG_HCVJ2,POLG_HCVJ8,# & POLG_HCVJ6,POLG_HCVJA)# & PIR1: (GNWVCH,GNWVC3,GNWVJ8,GNWVCJ,GNWVTC)# & PIR2: (PC2060,S41357,S41369,S41358,S19876,S18030,PC2219,S41345,# & S41352,S21471,JQ0881,S41367,JQ1926,S21336,S41363,S41354,# & S41350,S41368,PQ0805,S40770,S41361,JQ1584,A44150,S18031,# & S41362,S41343,S41351,S41365,JQ1303,S41288,S41370,S41356,# & S41371,S41359,S41344,JQ1925,PS0388,S41347,A45573,PQ0393,# & JN0265,S41348,S41360,S41366,S18032,PN0677,PQ0804,S44190,# & S41341,S19875,S41346,JQ0883,PC1284,S41355,S41353,S41342,# & S12707,S41364)# & PIR3: (S32740,PQ0398)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,KTSERSQPR*# SEQUENCE: KTSERSQPR*# ...# >HUM124B9# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV adr POL (1257-1265)# DB REFERENCE: PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,HLYPVARQR*# SEQUENCE: HLYPVARQR*# ...# >HUM124BA# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: c-ERB2 (754-762)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,VLRENTSPK*# SEQUENCE: VLRENTSPK*# ...# >HUM124BB# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: c-ERB2 (852-860)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161,PT0184,A47253)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,LVKSPNHVK*# SEQUENCE: LVKSPNHVK*# ...# >HUM124BC# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (1227-1235)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1PV,POL_HV1B1,POL_HV1BR,POL_HV1EL,# & POL_HV1OY,POL_HV1A2,POL_HV1MN,POL_HV1Z2,POL_HV1RH,# & POL_HV1B5,POL_HV1N5,POL_HV1H2,POL_HV1ND,POL_HV1JR)# & PIR1: (GNVWA2,GNVWH3,GNVWLV,GNVWVL,B44001,GNLJND)# & PIR2: (A47175,B47175,S54378)# & PIR3: (S33980,S11523)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,YLAWVPAHK*# SEQUENCE: YLAWVPAHK*# ...# >HUM124BD# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE-2 (299-307)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,ISYPPLHER*# SEQUENCE: ISYPPLHER*# ...# >HUM124BE# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (1075-1083)# DB REFERENCE: SWISS: (POL_HV1ND,POL_HV1B5,POL_HV1OY,POL_HV1RH,POL_HV1MN,# & POL_HV1Y2,POL_HV1PV,POL_HV1B1,POL_SIVCZ,POL_HV1Z2,# & POL_HV1N5,POL_HV1H2,POL_HV1MA,POL_HV1BR)# & PIR1: (GNLJSI,B44001,GNVWVL,GNVWLV,GNVWH3,GNLJND)# & PIR2: (S54378)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,IVIWGKTPK*# SEQUENCE: IVIWGKTPK*# ...# >HUM124BF# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (1434-1442)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1Z6,POL_HV1Y2,POL_HV1U4,POL_HV1A2,# & POL_HV1Z2,POL_HV1ND,POL_HV1RH,POL_HV1B5,POL_HV1OY,# & POL_HV1MA,POL_HV1BR,POL_HV1PV,POL_HV1MN,POL_HV1EL,# & POL_HV1B1,POL_SIVCZ,POL_HV1N5,POL_HV1JR)# & PIR1: (GNVWLV,GNLJND,GNVWA2,GNVWVL,GNVWH3,B44001,GNLJSI)# & PIR2: (S54378,A26192)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,AVFIHNFKR*# SEQUENCE: AVFIHNFKR*# ...# >HUM124C0# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ayw (713-721)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVY,DPOL_HPBVM)# & PIR1: (S20752,JDVLA1,JDVLVA,S47406,JDVLVS)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,IMPARFYPK*# SEQUENCE: IMPARFYPK*# ...# >HUM124C1# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (601-609)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVI,DPOL_HPBVO,DPOL_HPBVL,DPOL_HPBVR,# & DPOL_HPBV4,DPOL_HPBVY,DPOL_HPBVA)# & PIR1: (JDVLVA,JDVLA1,JDVLVR,JDVLJ2,JDVLVB,JDVLCP,JDVLJ3,# & S20752)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,RLADEGLNR*# SEQUENCE: RLADEGLNR*# ...# >HUM124C2# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ade X (1548-1555)# DB REFERENCE: SWISS: (X_HPBVI,X_HPBV2,X_HPBV2,X_HPBV9,X_HPBVY,X_HPBVO,X_HPBVJ,# & X_HPBV4,X_HPBVT,X_HPBVL)# & PIR1: (QQVLCP,A48345,QQVLAW,QQVLD1,QQVLBH,QQVLKS)# & PIR2: (S33687,S53132,S53233,S20751,S47404,S53219,S53130,S53254,# & JS0603,JS0256,S32203,JQ2228,S53156,S53190,S53187,S20756,# & S35529,S53162,S25650,JS0604,S12542)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,KVFVLGGCR*# SEQUENCE: KVFVLGGCR*# ...# >HUM124C3# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum TRAP (611-619)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,LACAGLAYK*# SEQUENCE: LACAGLAYK*# ...# >HUM124C4# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-1 (96-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,SLFRAVITK*# SEQUENCE: SLFRAVITK*# ...# >HUM124C5# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA1 (94-102)# DB REFERENCE: PIR2: (A45592)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,QTNFKSLLR*# SEQUENCE: QTNFKSLLR*# ...# >HUM124C6# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (398-406)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBV4,DPOL_HPBVM)# & PIR1: (JDVLVS,JDVLVR)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,GSTHVSWPK*# SEQUENCE: GSTHVSWPK*# ...# >HUM124C7# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV env (370-378)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1W1,ENV_HV1B1,ENV_HV1H2,ENV_HV1SC,# & ENV_HV1W2)# & PIR1: (VCLJSC,VCLJH3,VCLJ3W,VCLJVL)# & PIR2: (S35830,S25940)# & PIR3: (S33985)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,RAKWNNTLK*# SEQUENCE: RAKWNNTLK*# ...# >HUM124C8# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: PSA (299-307)# DB REFERENCE: SWISS: (KLK2_HUMAN,PROS_HUMAN,PROS_HUMAN)# & PIR2: (A32297,G01551,A29586)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,YTKVVHYRK*# SEQUENCE: YTKVVHYRK*# ...# >HUM124C9# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE-1 (66-74)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,TTINFTRQR*# SEQUENCE: TTINFTRQR*# ...# >HUM124CA# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV X (69-77)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,CALPFTSAR*# SEQUENCE: CALPFTSAR*# ...# >HUM124CB# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV adr pol (711-719)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVR,DPOL_HPBVM,DPOL_HPBVT)# & PIR1: (JQ2229,JDVLVS,JDVLVR)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,AVNHYFKTR*# SEQUENCE: AVNHYFKTR*# ...# >HUM124CC# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (859-867)# DB REFERENCE: SWISS: (POL_HV1PV,POL_SIVCZ,POL_HV1N5,POL_HV1ND,POL_HV1B5,# & POL_HV1OY,POL_HV1MA,POL_HV1BR,POL_HV1H2,POL_HV1A2,# & POL_HV1U4,POL_HV1Z2,POL_HV1MN,POL_HV1JR,POL_HV1EL)# & PIR1: (GNVWLV,GNVWA2,GNLJND,GNLJSI,GNVWVL)# & PIR2: (D47330,S32077,S32152,S32087,S32078,S32160,S32081,S32084,# & S32126,S32049,S32083,S32056,S32091,S32133,B47175,S32075,# & S32096,S32080,A47330,S32048,S32095,S43127,S32128,S32131,# & S32051,S32067,S32076,S32157,S32053,S32122,S32151,S32060,# & S32093,S32050,S32066,E47330,S32065,S32061,B47330,S32058,# & S32072,S32139,S32068,S32082,S32055,S32098,S32085,S32094,# & S54378,S32138,S32120,S32062,S32129,S32064,S32052,S32159,# & S32059,S32132,S32054,S32119,S32134,S32117,S32127,S32079,# & S32088,S32057,S32086,S32071,S32135,S32140,S32069,S32063,# & S32118,S32089,S32074,A47175,S32047,S32090,S32070,S32136,# & S32137)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,MTKILEPFR*# SEQUENCE: MTKILEPFR*# ...# >HUM124CD# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: c-ERB2 (669-677)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,VVFGILIKR*# SEQUENCE: VVFGILIKR*# ...# >HUM124CE# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU A NP (166-174)# DB REFERENCE: SWISS: (VNUC_IAME4,VNUC_IADCZ,VNUC_IADU2,VNUC_IAZMA,VNUC_IAZJA,# & VNUC_IAANN,VNUC_IADHK,VNUC_IAZOH,VNUC_IAB39,VNUC_IAZJ4,# & VNUC_IAHO2,VNUC_IAZJ2,VNUC_IAGUA,VNUC_IAZJ1,VNUC_IAHPR,# & VNUC_IAMEE,VNUC_IAMAN,VNUC_IASIN,VNUC_IAZH1,VNUC_IAHIC,# & VNUC_IAME6,VNUC_IAZI3,VNUC_IAGU2,VNUC_IADE2,VNUC_IADNZ,# & VNUC_IAHJI,VNUC_IAEN5,VNUC_IAWIL,VNUC_IAFOW,VNUC_IANEJ,# & VNUC_IAGUN,VNUC_IAZI1,VNUC_IATKN,VNUC_IATRS,VNUC_IAZGE,# & VNUC_IAS06,VNUC_IADE1,VNUC_IAOHI,VNUC_IAANN,VNUC_IANT6,# & VNUC_IAB37,VNUC_IAMEC,VNUC_IADBE,VNUC_IAZNE,VNUC_IAZW2,# & VNUC_IAHTE,VNUC_IAMAA,VNUC_IAHLO,VNUC_IADM2,VNUC_IACKP,# & VNUC_IAWHP,VNUC_IAGUM,VNUC_IAPUE,VNUC_IAANA,VNUC_IAVI6,# & VNUC_IAFPD,VNUC_IATRT,VNUC_IASH2,VNUC_IAZDA,VNUC_IATX7,# & VNUC_IAMEF,VNUC_IADAU,VNUC_IAMEG,VNUC_IABUD,VNUC_IAMIN,# & VNUC_IAS31,VNUC_IALEN,VNUC_IARUD,VNUC_IAFOM,VNUC_IAKIE,# & VNUC_IAGU3,VNUC_IAHMI,VNUC_IAZTE,VNUC_IAMEB,VNUC_IAS11,# & VNUC_IAUSS,VNUC_IAZH4,VNUC_IATKO,VNUC_IACAL,VNUC_IAWIS,# & VNUC_IAGU1,VNUC_IAZ29,VNUC_IAMEA,VNUC_IAZJ3,VNUC_IAUDO,# & VNUC_IASE0,VNUC_IAPAR,VNUC_IAZCA,VNUC_IAME3,VNUC_IAZON,# & VNUC_IAFPR,VNUC_IAHO1,VNUC_IACKG,VNUC_IAGU4,VNUC_IAZH3,# & VNUC_IAGD7,VNUC_IAGRE,VNUC_IAZI2,VNUC_IAZW1,VNUC_IADMA,# & VNUC_IAWHN,VNUC_IAME5,VNUC_IAZ41,VNUC_IABRA,VNUC_IATEI)# & PIR1: (VHIVAK,VHIVN8,VHIVN6,VHIVA7,VHIV8H,VHIVM1,VHIVN5,VHIVN3,# & VHIVA6,A60028,VHIV34,VHIVX1,VHIV61,VHIVX5,VHIVC1,VHIVN7,# & VHIVN1,VHIVX2,VHIVX6,VHIVN9,VHIVX3,VHIV68,VHIVX4,VHIVN2,# & VHIVXL,VHIVN4,VHIVA3)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,LMQGSTLPR*# SEQUENCE: LMQGSTLPR*# ...# >HUM124CF# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE 2 (66-74)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,TTINYTLWR*# SEQUENCE: TTINYTLWR*# ...# >HUM124D0# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV ENV (1290-1298)# DB REFERENCE: SWISS: (POLG_HCVH7,POLG_HCV1,POLG_HCVH8,POLG_HCVHK,POLG_HCVJT,# & POLG_HCVE1,POLG_HCVTH,POLG_HCVJ2,POLG_HCVBK,POLG_HCVTW,# & POLG_HCVJA)# & PIR1: (GNWVC3,GNWVTC,GNWVTW,GNWVCJ)# & PIR2: (S40770,PS0165,PN0011,S19875,S12707,JQ1925,S18032,JN0265,# & S18030,S19876,PS0164,PC1284,S32749,JQ1584,A45573,S21471,# & PN0677,A44150,S18031)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,QLFTFSPRR*# SEQUENCE: QLFTFSPRR*# ...# >HUM124D1# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (226-234)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG6_HUMAN,MAG6_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361,JC2360,G01445)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,SVLEVFEGR*# SEQUENCE: SVLEVFEGR*# ...# >HUM124D2# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV CORE (51-58)# DB REFERENCE: SWISS: (POLG_HCVHK,POLG_HCVJ7,POLG_HCVJ8,POLG_HCVJ6,POLG_HCVJA,# & POLG_HCVJ5,POLG_HCVBK,POLG_HCVJT,POLG_HCVH,POLG_HCV1,# & POLG_HCVJ2,POLG_HCVH4)# & PIR1: (GNWVCJ,GNWVC3,GNWVCH,GNWVTC,GNWVJ8)# & PIR2: (S18031,A44150,S41360,JQ1925,S12707,S41354,S18032,S41343,# & JN0265,PC2060,S41358,S41369,S19875,PC2219,S41352,S41367,# & JQ0881,S41359,S41344,JQ1584,S41364,S21471,PQ0804,S44190,# & S41341,S41355,S41350,S19876,S41361,S41288,JQ1303,S41365,# & S41356,S41351,S41371,S41348,S41366,S41342,S41363,S41353,# & PC1284,S41347,PQ0393,PS0388,S41370,A45573,S41346,JQ0883,# & S40770,S41362,S18030,S41368,PQ0805,PN0677,S41345,S41357,# & S21336,JQ1926)# & PIR3: (PQ0398,S32740)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,KTSERSQPR*# SEQUENCE: KTSERSQPR*# ...# >HUM124D3# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr POL (1257-1265)# DB REFERENCE: PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,HLYPVARQR*# SEQUENCE: HLYPVARQR*# ...# >HUM124D4# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: c-ERB2 (754-762)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,VLRENTSPK*# SEQUENCE: VLRENTSPK*# ...# >HUM124D5# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: c-ERB2 (852-860)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161,A47253,PT0184)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,LVKSPNHVK*# SEQUENCE: LVKSPNHVK*# ...# >HUM124D6# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (1227-1235)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1RH,POL_HV1OY,POL_HV1H2,POL_HV1B1,# & POL_HV1N5,POL_HV1EL,POL_HV1Y2,POL_HV1ND,POL_HV1PV,# & POL_HV1BR,POL_HV1A2,POL_HV1B5,POL_HV1MN,POL_HV1JR)# & PIR1: (GNVWLV,GNVWVL,B44001,GNVWA2,GNLJND,GNVWH3)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S33980,S11523)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesh,YLAWVPAHK*# SEQUENCE: YLAWVPAHK*# ...# >HUM124D7# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-2 (299-307)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,ISYPPLHER*# SEQUENCE: ISYPPLHER*# ...# >HUM124D8# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (1075-1083)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1BR,POL_HV1Y2,POL_HV1OY,POL_HV1B1,# & POL_SIVCZ,POL_HV1Z2,POL_HV1RH,POL_HV1PV,POL_HV1B5,# & POL_HV1N5,POL_HV1MA,POL_HV1H2,POL_HV1ND)# & PIR1: (GNLJSI,GNLJND,GNVWH3,GNVWVL,GNVWLV,B44001)# & PIR2: (S54378)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,IVIWGKTPK*# SEQUENCE: IVIWGKTPK*# ...# >HUM124D9# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (1434-1442)# DB REFERENCE: SWISS: (POL_HV1EL,POL_SIVCZ,POL_HV1N5,POL_HV1MA,POL_HV1Z6,# & POL_HV1H2,POL_HV1B1,POL_HV1ND,POL_HV1B5,POL_HV1RH,# & POL_HV1BR,POL_HV1OY,POL_HV1MN,POL_HV1Z2,POL_HV1Y2,# & POL_HV1U4,POL_HV1PV,POL_HV1JR,POL_HV1A2)# & PIR1: (GNVWLV,GNLJSI,GNVWA2,B44001,GNVWVL,GNLJND,GNVWH3)# & PIR2: (S54378,A26192)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,AVFIHNFKR*# SEQUENCE: AVFIHNFKR*# ...# >HUM124DA# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV ayw (713-721)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBVA)# & PIR1: (S20752,JDVLA1,JDVLVS,JDVLVA,S47406)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,IMPARFYPK*# SEQUENCE: IMPARFYPK*# ...# >HUM124DB# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (601-609)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVA,DPOL_HPBVY,DPOL_HPBV4,DPOL_HPBVR,# & DPOL_HPBVL,DPOL_HPBVI,DPOL_HPBVO)# & PIR1: (JDVLVA,JDVLVR,JDVLA1,JDVLCP,S20752,JDVLVB,JDVLJ3,# & JDVLJ2)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,RLADEGLNR*# SEQUENCE: RLADEGLNR*# ...# >HUM124DC# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV ade X (1548-1555)# DB REFERENCE: SWISS: (X_HPBVY,X_HPBVT,X_HPBV2,X_HPBVI,X_HPBV9,X_HPBVL,X_HPBV4,# & X_HPBVO,X_HPBVJ,X_HPBV2)# & PIR1: (QQVLAW,QQVLCP,A48345,QQVLKS,QQVLBH,QQVLD1)# & PIR2: (S20756,S53162,S12542,JS0256,S53254,S53132,S20751,S47404,# & S53219,S53156,JS0604,JS0603,S53130,S35529,JQ2228,S32203,# & S53190,S53187,S25650,S53233,S33687)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,KVFVLGGCR*# SEQUENCE: KVFVLGGCR*# ...# >HUM124DD# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as./competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum TRAP (611-619)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# REFERENCES: sidney96a,doolan97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesm,LACAGLAYK*# SEQUENCE: LACAGLAYK*# ...# >HUM124DE# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (621-629)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBV9,DPOL_HPBVT,DPOL_HPBVZ,DPOL_HPBVR,# & DPOL_HPBVJ,DPOL_HPBVA,DPOL_HPBV2,DPOL_HPBV4,DPOL_HPBVP,# & DPOL_HPBVL,DPOL_HPBVW,DPOL_HPBVY,DPOL_HPBVM,DPOL_HPBVI,# & DPOL_HPBVO)# & PIR1: (JDVLVH,S43491,S20757,JDVLA1,JDVLCP,S20752,JDVLVS,JDVLKS,# & JDVLVB,JDVLVD,JDVLVR,S47406,JDVLVA,JDVLJ1,JDVLJ3,JQ2229,# & JDVLJ2)# & PIR2: (S35527,S71785)# REFERENCES: sidney96a,bertoni97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,NVSIPWTHK*# SEQUENCE: NVSIPWTHK*# ...# >HUM124DF# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-1 (96-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a,threlkeld97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,SLFRAVITK*# SEQUENCE: SLFRAVITK*# ...# >HUM124E0# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as./competition/CTL assays/recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: P. falciparum LSA1 (94-102)# DB REFERENCE: PIR2: (A45592)# REFERENCES: sidney96a,doolan97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesl,QTNFKSLLR*# SEQUENCE: QTNFKSLLR*# ...# >HUM124E1# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (398-406)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVM,DPOL_HPBVR)# & PIR1: (JDVLVR,JDVLVS)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,GSTHVSWPK*# SEQUENCE: GSTHVSWPK*# ...# >HUM124E2# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: PSA (299-307)# DB REFERENCE: SWISS: (PROS_HUMAN,PROS_HUMAN,KLK2_HUMAN)# & PIR2: (A32297,A29586,G01551)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesh,YTKVVHYRK*# SEQUENCE: YTKVVHYRK*# ...# >HUM124E3# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE-1 (66-74)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesh,TTINFTRQR*# SEQUENCE: TTINFTRQR*# ...# >HUM124E4# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV X (69-77)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesh,CALPFTSAR*# SEQUENCE: CALPFTSAR*# ...# >HUM124E5# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV adr pol (711-719)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVR,DPOL_HPBVT,DPOL_HPBV4)# & PIR1: (JDVLVR,JDVLVS,JQ2229)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesh,AVNHYFKTR*# SEQUENCE: AVNHYFKTR*# ...# >HUM124E6# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (859-867)# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1JR,POL_HV1Z2,POL_HV1MN,POL_HV1ND,# & POL_HV1OY,POL_HV1H2,POL_HV1MA,POL_HV1BR,POL_HV1EL,# & POL_HV1U4,POL_HV1B5,POL_HV1N5,POL_HV1PV,POL_SIVCZ)# & PIR1: (GNVWLV,GNLJND,GNLJSI,GNVWVL,GNVWA2)# & PIR2: (B47330,S32087,S32058,S32082,B47175,S32077,S32080,S32083,# & S32160,S32119,S32152,S32064,S32054,S32052,S32075,S32098,# & S32048,S32095,S32128,S43127,S32053,S32157,S32129,S32159,# & S32132,A47330,A47175,S32151,S32093,S32060,S32066,E47330,# & S54378,S32127,S32088,S32140,S32086,S32074,S32118,S32063,# & S32094,S32138,S32120,S32136,S32070,S32047,S32071,S32135,# & S32117,S32079,S32067,S32076,S32065,S32050,S32131,S32134,# & S32051,S32078,S32084,S32096,S32081,S32056,S32072,S32061,# & S32085,S32122,S32133,D47330,S32049,S32126,S32091,S32090,# & S32057,S32059,S32062,S32089,S32137,S32069,S32068,S32055,# & S32139)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,MTKILEPFR*# SEQUENCE: MTKILEPFR*# ...# >HUM124E7# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: c-ERB2 (669-677)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,VVFGILIKR*# SEQUENCE: VVFGILIKR*# ...# >HUM124E8# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: FLU A NP (166-174)# DB REFERENCE: SWISS: (VNUC_IAZNE,VNUC_IAZGE,VNUC_IAZI1,VNUC_IAFOW,VNUC_IATKN,# & VNUC_IANEJ,VNUC_IAGUN,VNUC_IATRS,VNUC_IANT6,VNUC_IAMEC,# & VNUC_IAB37,VNUC_IADM2,VNUC_IAMAA,VNUC_IAFPD,VNUC_IAWHP,# & VNUC_IAGUM,VNUC_IAANA,VNUC_IAVI6,VNUC_IADNZ,VNUC_IABUD,# & VNUC_IAMEF,VNUC_IAMEG,VNUC_IACKG,VNUC_IALEN,VNUC_IARUD,# & VNUC_IAGD7,VNUC_IAHO1,VNUC_IADMA,VNUC_IAWHN,VNUC_IADE1,# & VNUC_IAS06,VNUC_IAZON,VNUC_IAZCA,VNUC_IAPAR,VNUC_IAUDO,# & VNUC_IAZJ3,VNUC_IAMEA,VNUC_IATKO,VNUC_IAMIN,VNUC_IAFOM,# & VNUC_IAS31,VNUC_IAGU3,VNUC_IAZTE,VNUC_IAHMI,VNUC_IAHJI,# & VNUC_IADE2,VNUC_IAEN5,VNUC_IATX7,VNUC_IATRT,VNUC_IAHLO,# & VNUC_IASH2,VNUC_IAZDA,VNUC_IAHTE,VNUC_IAZW2,VNUC_IACKP,# & VNUC_IAANN,VNUC_IAOHI,VNUC_IAKIE,VNUC_IAZI2,VNUC_IAFPR,# & VNUC_IAGU1,VNUC_IAS11,VNUC_IAUSS,VNUC_IAME3,VNUC_IAME5,# & VNUC_IABRA,VNUC_IADU2,VNUC_IADCZ,VNUC_IAME4,VNUC_IAZMA,# & VNUC_IAANN,VNUC_IAZOH,VNUC_IAMAN,VNUC_IASIN,VNUC_IAZI3,# & VNUC_IAHIC,VNUC_IAZH1,VNUC_IAB39,VNUC_IAZJ4,VNUC_IAHPR,# & VNUC_IAZJ1,VNUC_IAGUA,VNUC_IAWIL,VNUC_IAME6,VNUC_IAHO2,# & VNUC_IAZ41,VNUC_IATEI,VNUC_IADHK,VNUC_IAZJA,VNUC_IAZ29,# & VNUC_IAZH4,VNUC_IACAL,VNUC_IAGU4,VNUC_IAGRE,VNUC_IADBE,# & VNUC_IASE0,VNUC_IAPUE,VNUC_IAMEE,VNUC_IAZH3,VNUC_IAMEB,# & VNUC_IAWIS,VNUC_IADAU,VNUC_IAZW1,VNUC_IAZJ2,VNUC_IAGU2)# & PIR1: (VHIVN8,VHIVN1,VHIVN7,VHIV8H,VHIVN6,VHIVN5,VHIVX3,VHIVN9,# & VHIVX4,VHIVN4,A60028,VHIV34,VHIVX1,VHIV61,VHIVXL,VHIVN2,# & VHIV68,VHIVX6,VHIVN3,VHIVA6,VHIVX5,VHIVA7,VHIVX2,VHIVC1,# & VHIVAK,VHIVA3,VHIVM1)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesh,LMQGSTLPR*# SEQUENCE: LMQGSTLPR*# ...# >HUM124E9# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE 2 (66-74)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,TTINYTLWR*# SEQUENCE: TTINYTLWR*# ...# >HUM124EA# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV ENV (1290-1298)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVTW,POLG_HCVH8,POLG_HCVJA,POLG_HCVJ2,# & POLG_HCVE1,POLG_HCVTH,POLG_HCVHK,POLG_HCVBK,POLG_HCVJT,# & POLG_HCVH7)# & PIR1: (GNWVC3,GNWVTC,GNWVCJ,GNWVTW)# & PIR2: (PS0165,S21471,S18032,S19875,PS0164,PN0011,S18031,A44150,# & PC1284,S32749,A45573,S12707,JN0265,JQ1925,S19876,JQ1584,# & PN0677,S40770,S18030)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,QLFTFSPRR*# SEQUENCE: QLFTFSPRR*# ...# >HUM124EB# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (226-234)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG6_HUMAN,MAG6_HUMAN,MAG3_HUMAN)# & PIR2: (JC2360,G01445,JC2361)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesh,SVLEVFEGR*# SEQUENCE: SVLEVFEGR*# ...# >HUM124EC# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV CORE (51-58)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVJA,POLG_HCVH4,POLG_HCVJ7,POLG_HCVH,# & POLG_HCVJ6,POLG_HCVBK,POLG_HCVJ5,POLG_HCVHK,POLG_HCVJ8,# & POLG_HCVJT,POLG_HCVJ2)# & PIR1: (GNWVJ8,GNWVTC,GNWVC3,GNWVCH,GNWVCJ)# & PIR2: (S41356,S41361,S41343,PC2219,S41367,S41352,S41369,JQ1303,# & S41350,S41354,S44190,S41341,PQ0804,S41355,A45573,S19876,# & S41362,PQ0805,PC1284,S41364,S41363,S41353,S41342,S41366,# & S21471,PS0388,PQ0393,S41347,S21336,JQ1926,JQ1584,JQ0883,# & S18030,S41368,PN0677,S41346,S40770,S41345,S41357,S41344,# & S41359,S19875,S41288,S18032,S41351,S41358,JQ0881,PC2060,# & A44150,S41360,S18031,JN0265,S41365,S41348,S41371,S41370,# & S12707,JQ1925)# & PIR3: (S32740,PQ0398)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,KTSERSQPR*# SEQUENCE: KTSERSQPR*# ...# >HUM124ED# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr POL (1257-1265)# DB REFERENCE: PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,HLYPVARQR*# SEQUENCE: HLYPVARQR*# ...# >HUM124EE# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: c-ERB2 (754-762)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,VLRENTSPK*# SEQUENCE: VLRENTSPK*# ...# >HUM124EF# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: c-ERB2 (852-860)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (TVRTNU,A24571)# & PIR2: (PT0184,A47253,I48161)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,LVKSPNHVK*# SEQUENCE: LVKSPNHVK*# ...# >HUM124F0# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (1227-1235)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1OY,POL_HV1PV,POL_HV1MN,POL_HV1Z2,# & POL_HV1A2,POL_HV1BR,POL_HV1ND,POL_HV1B5,POL_HV1N5,# & POL_HV1JR,POL_HV1H2,POL_HV1RH,POL_HV1B1,POL_HV1EL)# & PIR1: (GNVWVL,GNLJND,B44001,GNVWA2,GNVWLV,GNVWH3)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S11523,S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,YLAWVPAHK*# SEQUENCE: YLAWVPAHK*# ...# >HUM124F1# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-2 (299-307)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,ISYPPLHER*# SEQUENCE: ISYPPLHER*# ...# >HUM124F2# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (1075-1083)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1Z2,POL_HV1B5,POL_HV1PV,POL_SIVCZ,# & POL_HV1OY,POL_HV1Y2,POL_HV1ND,POL_HV1RH,POL_HV1B1,# & POL_HV1H2,POL_HV1N5,POL_HV1BR,POL_HV1MA)# & PIR1: (GNVWH3,GNVWVL,B44001,GNLJSI,GNVWLV,GNLJND)# & PIR2: (S54378)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,IVIWGKTPK*# SEQUENCE: IVIWGKTPK*# ...# >HUM124F3# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (1434-1442)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1A2,POL_SIVCZ,POL_HV1EL,POL_HV1Y2,# & POL_HV1Z6,POL_HV1N5,POL_HV1B1,POL_HV1OY,POL_HV1U4,# & POL_HV1ND,POL_HV1PV,POL_HV1MN,POL_HV1Z2,POL_HV1B5,# & POL_HV1RH,POL_HV1H2,POL_HV1JR,POL_HV1BR)# & PIR1: (GNVWLV,GNLJSI,GNVWA2,GNVWH3,GNVWVL,B44001,GNLJND)# & PIR2: (S54378,A26192)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,AVFIHNFKR*# SEQUENCE: AVFIHNFKR*# ...# >HUM124F4# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV ayw (713-721)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVY,DPOL_HPBVM)# & PIR1: (JDVLVA,S47406,JDVLA1,S20752,JDVLVS)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,IMPARFYPK*# SEQUENCE: IMPARFYPK*# ...# >HUM124F5# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV adr pol (601-609)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBVY,DPOM_HPBVY,DPOL_HPBV4,DPOL_HPBVR,# & DPOL_HPBVL,DPOL_HPBVO,DPOL_HPBVA)# & PIR1: (JDVLVB,JDVLVR,JDVLCP,S20752,JDVLA1,JDVLVA,JDVLJ2,# & JDVLJ3)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,RLADEGLNR*# SEQUENCE: RLADEGLNR*# ...# >HUM124F6# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV ade X (1548-1555)# DB REFERENCE: SWISS: (X_HPBVY,X_HPBV4,X_HPBVT,X_HPBV2,X_HPBVJ,X_HPBVO,X_HPBVI,# & X_HPBV2,X_HPBV9,X_HPBVL)# & PIR1: (QQVLBH,QQVLCP,A48345,QQVLKS,QQVLD1,QQVLAW)# & PIR2: (S53156,S53254,S25650,JQ2228,S53162,S53190,S33687,JS0603,# & JS0604,S53132,S20751,S47404,S53219,JS0256,S20756,S12542,# & S53187,S32203,S53233,S53130,S35529)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,KVFVLGGCR*# SEQUENCE: KVFVLGGCR*# ...# >HUM124F7# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum TRAP (611-619)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# REFERENCES: sidney96a,doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,LACAGLAYK*# SEQUENCE: LACAGLAYK*# ...# >HUM124F8# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (621-629)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBV4,DPOL_HPBVZ,DPOL_HPBVR,# & DPOL_HPBVL,DPOL_HPBV2,DPOL_HPBVP,DPOL_HPBVW,DPOL_HPBVT,# & DPOL_HPBVA,DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBV9,DPOL_HPBVO,# & DPOL_HPBVJ)# & PIR1: (JDVLCP,JDVLVB,S20757,JDVLVH,S20752,JDVLJ3,JDVLJ2,JDVLVD,# & JDVLVA,JDVLKS,JDVLVS,S47406,JDVLA1,JDVLVR,JDVLJ1,S43491,# & JQ2229)# & PIR2: (S35527,S71785)# REFERENCES: sidney96a,bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,NVSIPWTHK*# SEQUENCE: NVSIPWTHK*# ...# >HUM124F9# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as./competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MAGE-1 (96-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a,threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesh,SLFRAVITK*# SEQUENCE: SLFRAVITK*# ...# >HUM124FA# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as./competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA1 (94-102)# DB REFERENCE: PIR2: (A45592)# REFERENCES: sidney96a,doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,QTNFKSLLR*# SEQUENCE: QTNFKSLLR*# ...# >HUM124FB# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (398-406)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVM,DPOL_HPBVR)# & PIR1: (JDVLVR,JDVLVS)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,GSTHVSWPK*# SEQUENCE: GSTHVSWPK*# ...# >HUM124FC# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV env (370-378)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1PV,ENV_HV1W1,ENV_HV1W2,ENV_HV1SC,# & ENV_HV1B1)# & PIR1: (VCLJSC,VCLJH3,VCLJ3W,VCLJVL)# & PIR2: (S25940,S35830)# & PIR3: (S33985)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,RAKWNNTLK*# SEQUENCE: RAKWNNTLK*# ...# >HUM124FD# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: PSA (299-307)# DB REFERENCE: SWISS: (KLK2_HUMAN,PROS_HUMAN,PROS_HUMAN)# & PIR2: (A29586,A32297,G01551)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,YTKVVHYRK*# SEQUENCE: YTKVVHYRK*# ...# >HUM124FE# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE-1 (66-74)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,TTINFTRQR*# SEQUENCE: TTINFTRQR*# ...# >HUM124FF# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV X (69-77)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,CALPFTSAR*# SEQUENCE: CALPFTSAR*# ...# >HUM12500# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr pol (711-719)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBV4,DPOL_HPBVM,DPOL_HPBVT)# & PIR1: (JDVLVS,JQ2229,JDVLVR)# & PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,AVNHYFKTR*# SEQUENCE: AVNHYFKTR*# ...# >HUM12501# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (859-867)# DB REFERENCE: SWISS: (POL_HV1U4,POL_HV1EL,POL_HV1MN,POL_SIVCZ,POL_HV1B5,# & POL_HV1ND,POL_HV1OY,POL_HV1PV,POL_HV1MA,POL_HV1N5,# & POL_HV1H2,POL_HV1JR,POL_HV1A2,POL_HV1Z2,POL_HV1BR)# & PIR1: (GNVWA2,GNLJSI,GNVWLV,GNVWVL,GNLJND)# & PIR2: (S54378,A47330,B47330,S32087,S32132,D47330,S32068,S32152,# & S32060,S32151,S32071,S32050,S32067,S32134,S32131,S32069,# & S32139,A47175,S32091,S32049,S32090,S32059,S32057,S32054,# & S32064,S32052,S32061,S32085,S32096,S32081,S32056,S32084,# & S32138,S32047,S32136,S32070,S32095,S32048,S43127,S32128,# & S32157,S32053,S32127,S32088,S32074,S32118,S32129,S32159,# & S32093,S32065,S32072,S32089,S32083,S32058,S32075,S32098,# & B47175,S32137,S32055,S32126,S32133,S32122,S32062,S32119,# & S32082,S32077,S32160,S32080,S32066,E47330,S32086,S32140,# & S32063,S32120,S32094,S32078,S32076,S32051,S32079,S32117,# & S32135)# & PIR3: (S33980)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,MTKILEPFR*# SEQUENCE: MTKILEPFR*# ...# >HUM12502# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: c-ERB2 (669-677)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,VVFGILIKR*# SEQUENCE: VVFGILIKR*# ...# >HUM12503# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FLU A NP (166-174)# DB REFERENCE: SWISS: (VNUC_IAZ29,VNUC_IAZH4,VNUC_IACAL,VNUC_IAZJ2,VNUC_IAGU2,# & VNUC_IAME6,VNUC_IADHK,VNUC_IAZJA,VNUC_IAGRE,VNUC_IASE0,# & VNUC_IAMEE,VNUC_IADAU,VNUC_IAZH3,VNUC_IAMEB,VNUC_IAWIS,# & VNUC_IAZW1,VNUC_IAANN,VNUC_IAS11,VNUC_IAHTE,VNUC_IASH2,# & VNUC_IAHO2,VNUC_IAEN5,VNUC_IAZOH,VNUC_IAME4,VNUC_IAME5,# & VNUC_IAFPR,VNUC_IATKN,VNUC_IAMEC,VNUC_IAZI1,VNUC_IAUDO,# & VNUC_IAS31,VNUC_IAHMI,VNUC_IADM2,VNUC_IAANA,VNUC_IAMEF,# & VNUC_IABUD,VNUC_IAWIL,VNUC_IADNZ,VNUC_IAMEG,VNUC_IAMAA,# & VNUC_IAB37,VNUC_IAZNE,VNUC_IANEJ,VNUC_IAFOW,VNUC_IAGUN,# & VNUC_IATRS,VNUC_IAVI6,VNUC_IAGUM,VNUC_IAHO1,VNUC_IARUD,# & VNUC_IAGU3,VNUC_IAFOM,VNUC_IADMA,VNUC_IATKO,VNUC_IAZJ3,# & VNUC_IAMEA,VNUC_IAPAR,VNUC_IAZON,VNUC_IACKP,VNUC_IAZW2,# & VNUC_IAHLO,VNUC_IATRT,VNUC_IAZDA,VNUC_IATX7,VNUC_IAHJI,# & VNUC_IAUSS,VNUC_IAKIE,VNUC_IAZI2,VNUC_IAOHI,VNUC_IADCZ,# & VNUC_IADU2,VNUC_IAZMA,VNUC_IAANN,VNUC_IAZH1,VNUC_IAZI3,# & VNUC_IAMAN,VNUC_IASIN,VNUC_IAHPR,VNUC_IAZJ4,VNUC_IAGUA,# & VNUC_IAZJ1,VNUC_IACKG,VNUC_IALEN,VNUC_IAB39,VNUC_IAWHP,# & VNUC_IADE1,VNUC_IABRA,VNUC_IADE2,VNUC_IAZ41,VNUC_IATEI,# & VNUC_IAWHN,VNUC_IAZCA,VNUC_IAGD7,VNUC_IAPUE,VNUC_IADBE,# & VNUC_IAGU4,VNUC_IAME3,VNUC_IAGU1,VNUC_IAFPD,VNUC_IAHIC,# & VNUC_IAZTE,VNUC_IAMIN,VNUC_IAZGE,VNUC_IAS06,VNUC_IANT6)# & PIR1: (VHIV68,VHIVN3,VHIVN1,VHIVN7,VHIVN8,VHIVN4,VHIVX6,VHIVXL,# & VHIVA7,A60028,VHIV34,VHIVX2,VHIVX5,VHIVAK,VHIVX4,VHIVN9,# & VHIVN2,VHIV61,VHIVX1,VHIV8H,VHIVX3,VHIVN5,VHIVC1,VHIVN6,# & VHIVA6,VHIVM1,VHIVA3)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS: 9# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,LMQGSTLPR*# SEQUENCE: LMQGSTLPR*# ...# >HUM12504# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE 2 (66-74)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,TTINYTLWR*# SEQUENCE: TTINYTLWR*# ...# >HUM12505# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV ENV (1290-1298)# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVE1,POLG_HCVJA,POLG_HCVTH,POLG_HCVTW,# & POLG_HCVH7,POLG_HCV1,POLG_HCVHK,POLG_HCVJ2,POLG_HCVBK,# & POLG_HCVH8)# & PIR1: (GNWVTC,GNWVCJ,GNWVC3,GNWVTW)# & PIR2: (S21471,S32749,S12707,PS0165,JN0265,S19876,PN0011,A45573,# & PS0164,S18031,S40770,S18030,JQ1584,PC1284,A44150,S18032,# & S19875,JQ1925,PN0677)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,QLFTFSPRR*# SEQUENCE: QLFTFSPRR*# ...# >HUM12506# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (226-234)# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG3_HUMAN,MAG3_HUMAN,MAG6_HUMAN)# & PIR2: (JC2361,JC2360,G01445)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,SVLEVFEGR*# SEQUENCE: SVLEVFEGR*# ...# >HUM12507# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV CORE (51-58)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVJ8,POLG_HCVH,POLG_HCVH4,POLG_HCVBK,# & POLG_HCVHK,POLG_HCVJT,POLG_HCVJA,POLG_HCVJ6,POLG_HCVJ2,# & POLG_HCVJ5,POLG_HCVJ7)# & PIR1: (GNWVCH,GNWVTC,GNWVCJ,GNWVJ8,GNWVC3)# & PIR2: (JQ1584,S41355,S41364,S41354,S41367,S41352,S41343,PC2219,# & S41350,S41342,S41347,PQ0393,JQ1926,PQ0804,S18030,S41366,# & S41288,S41345,S41361,S41356,S41371,A45573,S41369,JQ1303,# & S44190,S41341,PC1284,S40770,S18031,JN0265,S19876,S41346,# & S41357,S41368,S41359,S41344,S21471,S12707,S41370,S41365,# & S41348,S41351,PC2060,JQ0881,S41358,S41360,S41353,S41363,# & S18032,PQ0805,S19875,S41362,A44150,S21336,JQ0883,PN0677,# & PS0388,JQ1925)# & PIR3: (PQ0398,S32740)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,KTSERSQPR*# SEQUENCE: KTSERSQPR*# ...# >HUM12508# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV adr POL (1257-1265)# DB REFERENCE: PIR2: (S35527)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,HLYPVARQR*# SEQUENCE: HLYPVARQR*# ...# >HUM12509# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: c-ERB2 (852-860)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (TVRTNU,A24571)# & PIR2: (PT0184,A47253,I48161)# REFERENCES: sidney96a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,LVKSPNHVK*# SEQUENCE: LVKSPNHVK*# ...# >HUM2250A# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSAY*# SEQUENCE: ANDGATGWVASMSSAY*# ...# >HUM2250B# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,SNDGATGWVASMSSAY*# SEQUENCE: SNDGATGWVASMSSAY*# ...# >HUM2250C# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,AADGATGWVASMSSAY*# SEQUENCE: AADGATGWVASMSSAY*# ...# >HUM2250D# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANAGATGWVASMSSAY*# SEQUENCE: ANAGATGWVASMSSAY*# ...# >HUM2250E# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDSATGWVASMSSAY*# SEQUENCE: ANDSATGWVASMSSAY*# ...# >HUM2250F# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGSTGWVASMSSAY*# SEQUENCE: ANDGSTGWVASMSSAY*# ...# >HUM22510# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGAAGWVASMSSAY*# SEQUENCE: ANDGAAGWVASMSSAY*# ...# >HUM22511# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATSWVASMSSAY*# SEQUENCE: ANDGATSWVASMSSAY*# ...# >HUM22512# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWSASMSSAY*# SEQUENCE: ANDGATGWSASMSSAY*# ...# >HUM22513# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWKASMSSAY*# SEQUENCE: ANDGATGWKASMSSAY*# ...# >HUM22514# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWDASMSSAY*# SEQUENCE: ANDGATGWDASMSSAY*# ...# >HUM22515# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVSSMSSAY*# SEQUENCE: ANDGATGWVSSMSSAY*# ...# >HUM22516# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVKSMSSAY*# SEQUENCE: ANDGATGWVKSMSSAY*# ...# >HUM22517# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVDSMSSAY*# SEQUENCE: ANDGATGWVDSMSSAY*# ...# >HUM22518# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVTSMSSAY*# SEQUENCE: ANDGATGWVTSMSSAY*# ...# >HUM22519# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASKSSAY*# SEQUENCE: ANDGATGWVASKSSAY*# ...# >HUM2251A# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASDSSAY*# SEQUENCE: ANDGATGWVASDSSAY*# ...# >HUM2251B# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMASAY*# SEQUENCE: ANDGATGWVASMASAY*# ...# >HUM2251C# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMKSAY*# SEQUENCE: ANDGATGWVASMKSAY*# ...# >HUM2251D# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMDSAY*# SEQUENCE: ANDGATGWVASMDSAY*# ...# >HUM2251E# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMVSAY*# SEQUENCE: ANDGATGWVASMVSAY*# ...# >HUM2251F# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSAAY*# SEQUENCE: ANDGATGWVASMSAAY*# ...# >HUM22520# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSKAY*# SEQUENCE: ANDGATGWVASMSKAY*# ...# >HUM22521# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSDAY*# SEQUENCE: ANDGATGWVASMSDAY*# ...# >HUM22522# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSVAY*# SEQUENCE: ANDGATGWVASMSVAY*# ...# >HUM22523# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSSY*# SEQUENCE: ANDGATGWVASMSSSY*# ...# >HUM22524# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSKY*# SEQUENCE: ANDGATGWVASMSSKY*# ...# >HUM22525# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSDY*# SEQUENCE: ANDGATGWVASMSSDY*# ...# >HUM22526# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSTY*# SEQUENCE: ANDGATGWVASMSSTY*# ...# >HUM22527# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSAS*# SEQUENCE: ANDGATGWVASMSSAS*# ...# >HUM22528# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSAK*# SEQUENCE: ANDGATGWVASMSSAK*# ...# >HUM22529# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSAD*# SEQUENCE: ANDGATGWVASMSSAD*# ...# >HUM2252A# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVASMSSAG*# SEQUENCE: ANDGATGWVASMSSAG*# ...# >HUM2252B# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGLVASMSSAY*# SEQUENCE: ANDGATGLVASMSSAY*# ...# >HUM2252C# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGFVASMSSAY*# SEQUENCE: ANDGATGFVASMSSAY*# ...# >HUM2252D# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVANMSSAY*# SEQUENCE: ANDGATGWVANMSSAY*# ...# >HUM2252E# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVAAMSSAY*# SEQUENCE: ANDGATGWVAAMSSAY*# ...# >HUM2252F# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVAVMSSAY*# SEQUENCE: ANDGATGWVAVMSSAY*# ...# >HUM22530# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,ANDGATGWVAFMSSAY*# SEQUENCE: ANDGATGWVAFMSSAY*# ...# >HUM22531# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: tetanus toxin# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actyesu,bindyesu,FNNFTVSFWLRVEK*# SEQUENCE: FNNFTVSFWLRVEK*# ...# >HUM22533# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: neuropeptide Y-like receptor (306-317)# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,GAKFKASAQHAL*# SEQUENCE: GAKFKASAQHAL*# ...# >HUM22534# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: eluted self peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: apolipoprotein B-100 (1585-1597)# ANCHOR POSITIONS:# REFERENCES: fujisao96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesu,NKVSLTFSKQVALG*# SEQUENCE: NKVSLTFSKQVALG*# ...# >HUM22535# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HLA-DRB1*0101 beta (1-20)# DB REFERENCE: SWISS: (HB2F_HUMAN,HB2E_HUMAN)# & PIR1: (HLHU1B)# & PIR2: (I56072)# REFERENCES: liu96a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,GDTRPRFLWQLKFECHFFNG*# SEQUENCE: GDTRPRFLWQLKFECHFFNG*# ...# >HUM22536# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HLA-DRB1*0101 beta (11-30)# DB REFERENCE: SWISS: (HB2E_HUMAN,HB2F_HUMAN)# & PIR1: (HLHU1B)# & PIR2: (PH0147,I56072)# REFERENCES: liu96a# COMMENT:# SUMMARY: HLA-DR11,actyesu,bindyesu,LKFECHFFNGTERVRLLERC*# SEQUENCE: LKFECHFFNGTERVRLLERC*# ...# >MUS22537# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (129-139)# ANCHOR POSITIONS:# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,NHNTNGVTAAS*# SEQUENCE: NHNTNGVTAAS*# ...# >MUS22538# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (130-140)# ANCHOR POSITIONS:# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,HNTNGVTAASS*# SEQUENCE: HNTNGVTAASS*# ...# >MUS22539# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (131-141)# ANCHOR POSITIONS:# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,NTNGVTAASSH*# SEQUENCE: NTNGVTAASSH*# ...# >MUS2253A# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (132-142)# ANCHOR POSITIONS:# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,TNGVTAASSHE*# SEQUENCE: TNGVTAASSHE*# ...# >MUS2253B# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (133-143)# ANCHOR POSITIONS:# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,NGVTAASSHEG*# SEQUENCE: NGVTAASSHEG*# ...# >MUS2253C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MYO (105-115)# DB REFERENCE: SWISS: (MYG_RABIT,MYG_PHOSI,MYG_GALCR,MYG_KOGSI,MYG_INIGE,# & MYG_ONDZI,MYG_TACAC,MYG_ORCOR,MYG_PHYCA,MYG_HALGR,# & MYG_ZALCA,MYG_PHOPH,MYG_PERPO,MYG_TURTR,MYG_PHYCA,# & MYG_GLOME,MYG_CASFI)# & PIR1: (MYWHW,PN0126,MYSLG,MYLP,MYPE,MYRB,MYDDBS,MYWHL,MYPED,# & MYWHP,MYWHT,MYZC,MYSLH,MYDD,MYDDAR)# & PIR2: (JN0410,JN0344)# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,EFISEAIIHVL*# SEQUENCE: EFISEAIIHVL*# ...# >MUS2253D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MYO (106-116)# DB REFERENCE: SWISS: (MYG_PHOPH,MYG_GLOME,MYG_PHYCA,MYG_PHOSI,MYG_PHYCA,# & MYG_TURTR,MYG_HALGR,MYG_ORCOR,MYG_INIGE,MYG_KOGSI,# & MYG_RABIT)# & PIR1: (MYWHP,MYDDAR,MYRB,MYPED,MYWHW,MYWHT,MYPE,MYDDBS,MYWHL,# & MYDD,MYSLH,MYSLG)# & PIR2: (JN0344)# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,FISEAIIHVLH*# SEQUENCE: FISEAIIHVLH*# ...# >MUS2253E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MYO (107-117)# DB REFERENCE: SWISS: (MYG_ORCOR,MYG_TURTR,MYG_GLOME,MYG_HALGR,MYG_PHYCA,# & MYG_PHOSI,MYG_KOGSI,MYG_INIGE,MYG_PHOPH,MYG_PHYCA,# & MYG_RABIT)# & PIR1: (MYDDBS,MYWHL,MYDDAR,MYWHP,MYPED,MYRB,MYWHT,MYPE,MYSLH,# & MYDD,MYWHW,MYSLG)# & PIR2: (JN0344)# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,ISEAIIHVLHS*# SEQUENCE: ISEAIIHVLHS*# ...# >MUS2253F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MYO (109-119)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_TURTR,MYG_INIGE,MYG_PHOPH,MYG_KOGSI,# & MYG_PHYCA,MYG_ORCOR,MYG_GLOME)# & PIR1: (MYDDBS,MYWHL,MYWHP,MYDDAR,MYWHT,MYWHW,MYPE,MYDD,MYPED)# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,EAIIHVLHSRH*# SEQUENCE: EAIIHVLHSRH*# ...# >MUS22540# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MYO (110-120)# DB REFERENCE: SWISS: (MYG_ESCGI,MYG_GLOME,MYG_KOGSI,MYG_TURTR,MYG_INIGE,# & MYG_PHYCA,MYG_PHOPH,MYG_MEGNO,MYG_ZIPCA,MYG_BALAC,# & MYG_ORCOR,MYG_BALPH,MYG_PHYCA)# & PIR1: (MYPE,MYWHC,MYDD,MYDDAR,MYWHF,MYWHT,MYWHK,MYWHZ,MYWHW,# & MYPED,MYWHH,MYWHP,MYDDBS,MYWHL)# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,AIIHVLHSRHP*# SEQUENCE: AIIHVLHSRHP*# ...# >MUS22541# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MYO (111-121)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA,MYG_INIGE,MYG_ESCGI)# & PIR1: (MYWHP,MYWHC,MYDDAR)# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,IIHVLHSRHPG*# SEQUENCE: IIHVLHSRHPG*# ...# >MUS22542# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MYO (112-122)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_ESCGI,MYG_INIGE,MYG_PHYCA)# & PIR1: (MYWHP,MYDDAR,MYWHC)# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,IHVLHSRHPGD*# SEQUENCE: IHVLHSRHPGD*# ...# >MUS22543# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HSVgd (245-260)# ANCHOR POSITIONS:# REFERENCES: sette88a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,APYSTLLPPELSETP*# SEQUENCE: APYSTLLPPELSETP*# ...# >MUS22544# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP Ac (9-20)# DB REFERENCE: SWISS: (MBP_RAT,MBP_CAVPO,MBP_PANTR,MBP_HUMAN)# & PIR1: (MBHUB,MBRTS,MBCZB)# & PIR2: (A37246)# REFERENCES: fugger96b# COMMENT: acetylated N-terminus# SUMMARY: I-Au,actunkn,bindyesh,RHGSKYLATAST*# SEQUENCE: RHGSKYLATAST*# ...# >MUS22545# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (11-23)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_RAT,MBP_MOUSE,MBP_PANTR)# & PIR1: (MBCZB,MBHUB,MBMSB,MBRTS)# & PIR2: (A37246)# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,SKYLATASTMDHA*# SEQUENCE: SKYLATASTMDHA*# ...# >MUS22546# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (42-54)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBCZB,MBHUB)# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesl,GRFFGGDRGAPKRG*# SEQUENCE: GRFFGGDRGAPKRG*# ...# >MUS22547# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (68-80)# ANCHOR POSITIONS:# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesl,YGSLPQICSHGRTQ*# SEQUENCE: YGSLPQICSHGRTQ*# ...# >MUS22548# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (141-156)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesl,KGVDAQGTLSKIF*# SEQUENCE: KGVDAQGTLSKIF*# ...# >MUS22549# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (142-167)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesl,KGVDAQGTLSKIFKLGGRDSRSGS*# SEQUENCE: KGVDAQGTLSKIFKLGGRDSRSGS*# ...# >MUS2254A# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ovalbumin (323-339)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,ISQAVHAAHAEINEAGR*# SEQUENCE: ISQAVHAAHAEINEAGR*# ...# >MUS2254B# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: RDP-1# ANCHOR POSITIONS:# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesm,QVVALKPAIAAAA*# SEQUENCE: QVVALKPAIAAAA*# ...# >MUS2254C# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: RDP-3# ANCHOR POSITIONS:# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesl,AAQVKSLKPEKIVDQ*# SEQUENCE: AAQVKSLKPEKIVDQ*# ...# >MUS2254D# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP Ac (1-11) Y4# ANCHOR POSITIONS:# REFERENCES: fugger96b# COMMENT: acetylated N-terminus# SUMMARY: I-Au,actunkn,bindyesm,ASQYRPSQRHG*# SEQUENCE: ASQYRPSQRHG*# ...# >MUS2254E# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: binding as./inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: fugger96b# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,AAVHAAHAAAAAA*# SEQUENCE: AAVHAAHAAAAAA*# ...# >CHI1254F# MHC MOLECULE: Patr-A11, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV E2/NS1 (711-718)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVH)# & PIR1: (GNWVC3,GNWVCH)# & PIR2: (S40770,JQ1366)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-A11,actyesu,bindyesu,SWAIKWEY*# SEQUENCE: SWAIKWEY*# ...# >CHI12550# MHC MOLECULE: Patr-B13, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV E2/NS1 (542-550)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVH)# & PIR1: (GNWVC3,GNWVCH)# & PIR2: (S40770,JQ1366,JQ1584)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B13,actyesu,bindyesu,TRPPLGNWF*# SEQUENCE: TRPPLGNWF*# ...# >CHI12551# MHC MOLECULE: Patr-B13, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV NS3 (1357-1365)# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJT,POLG_HCVJA,POLG_HCV1)# & PIR1: (GNWVTC,GNWVC3,GNWVCJ)# & PIR2: (A45573,S18030,S21337)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B13,actyesu,bindyesu,VPHPNIEEV*# SEQUENCE: VPHPNIEEV*# ...# >CHI12552# MHC MOLECULE: Patr-B01, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV NS3 (1444-1452)# DB REFERENCE: SWISS: (POLG_HCVJ8,POLG_HCVBK,POLG_HCV1,POLG_HCVJT)# & PIR1: (GNWVTC,GNWVC3,GNWVJ8)# & PIR2: (S21337,S18030,A45573,S40770)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B01,actyesu,bindyesu,YTGDFDSVI*# SEQUENCE: YTGDFDSVI*# ...# >CHI12553# MHC MOLECULE: Patr-B16, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV NS3 (1446-1454)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVJA,POLG_HCVTW,POLG_HCVJT,POLG_HCVBK,# & POLG_HCVH,POLG_HCVJ6,POLG_HCVJ8)# & PIR1: (GNWVC3,GNWVJ8,GNWVCJ,GNWVTC,GNWVTW,GNWVCH)# & PIR2: (A45573,PC2219,S40770,S18030,S21337,JQ1303)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B16,actyesu,bindyesu,GDFDSVIDC*# SEQUENCE: GDFDSVIDC*# ...# >CHI12554# MHC MOLECULE: Patr-B16, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV E1 (233-241)# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCVTH,POLG_HCV1)# & PIR1: (GNWVC3,GNWVCH)# & PIR2: (JQ1584)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B16,actyesu,bindyesu,GNASRCWVA*# SEQUENCE: GNASRCWVA*# ...# >CHI12555# MHC MOLECULE: Patr-A04, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCV E2/NS1 (588-596)# DB REFERENCE: SWISS: (POLG_HCV1)# & PIR1: (GNWVC3)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-A04,actyesl,bindyesu,KHPDATYSR*# SEQUENCE: KHPDATYSR*# ...# >CHI12556# MHC MOLECULE: Patr-A04, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HCV E2/NS1 (588-596) homologue# ANCHOR POSITIONS:# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-A04,actyesl,bindyesu,KHPDATYSK*# SEQUENCE: KHPDATYSK*# ...# >CHI12557# MHC MOLECULE: Patr-B13, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV-1# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCV1)# & PIR1: (GNWVC3,GNWVCH)# & PIR2: (S40770,JQ1584,JQ1366)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B13,actyesu,bindyesu,NTRPPLGNWF*# SEQUENCE: NTRPPLGNWF*# ...# >CHI12558# MHC MOLECULE: Patr-B13, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV-1# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVJ6,POLG_HCV1,POLG_HCVJT,POLG_HCVBK)# & PIR1: (GNWVC3,GNWVCJ,GNWVTC)# & PIR2: (S18030,PC2219,A45573,JQ1303,S21337)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B13,actyesu,bindyesu,PHPNIEEVAL*# SEQUENCE: PHPNIEEVAL*# ...# >CHI12559# MHC MOLECULE: Patr-B13, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV-T# DB REFERENCE: SWISS: (POLG_HCVTW)# & PIR1: (GNWVTW)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B13,actyesu,bindyesu,PHPNIEEIAL*# SEQUENCE: PHPNIEEIAL*# ...# >CHI1255A# MHC MOLECULE: Patr-A11, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV-1# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVH)# & PIR1: (GNWVCH,GNWVC3)# & PIR2: (S40770)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-A11,actyesu,bindyesu,SWAIKWEYVV*# SEQUENCE: SWAIKWEYVV*# ...# >CHI1255B# MHC MOLECULE: Patr-B01, CLASS-1, (CHIMPANZEE)# METHOD: cytotoxicity as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV-H77# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCVJ6,POLG_HCVTW,POLG_HCVJA)# & PIR1: (GNWVCH,GNWVCJ,GNWVTW)# & PIR2: (JQ1303,PC2219)# REFERENCES: kowalski96a# COMMENT:# SUMMARY: Patr-B01,actyesu,bindyesu,FTGDFDSVI*# SEQUENCE: FTGDFDSVI*# ...# >MUS2255C# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: conalbumin# DB REFERENCE: SWISS: (TRFE_CHICK,TRFE_CHICK)# & PIR1: (TFCHE)# REFERENCES: santangelo96a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,HRGAIEWEGIESG*# SEQUENCE: HRGAIEWEGIESG*# ...# >MUS2255D# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: huCol IV# ANCHOR POSITIONS:# REFERENCES: santangelo96a# COMMENT:# SUMMARY: I-As,actunkn,bindyesu,EAIQPGCIGGPK*# SEQUENCE: EAIQPGCIGGPK*# ...# >MUS2255E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MSA# ANCHOR POSITIONS:# REFERENCES: santangelo96a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KPKATAEQLKTVNDD*# SEQUENCE: KPKATAEQLKTVNDD*# ...# >MUS2255F# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: D10# ANCHOR POSITIONS:# REFERENCES: santangelo96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,KGTDFQLNQLEGKKG*# SEQUENCE: KGTDFQLNQLEGKKG*# ...# >MUS22560# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: D10# DB REFERENCE: SWISS: (FCE2_MOUSE,FCE2_MOUSE)# & PIR1: (LNMSER)# & PIR2: (S34198)# REFERENCES: santangelo96a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesu,SYLDAWVCEQLAT*# SEQUENCE: SYLDAWVCEQLAT*# ...# >MUS22561# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse MBP (87-101)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_MOUSE,MBP_CAVPO,MBP_BOVIN,MBP_PANTR,# & MBP_RAT)# & PIR1: (MBRTS,MBMSB,MBBOB,MBCZB,MBPGB,MBHUB)# & PIR2: (A37246)# REFERENCES: amor96a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,FKNIVTPRTPPPSQGK*# SEQUENCE: FKNIVTPRTPPPSQGK*# ...# >MUS22562# MHC MOLECULE: H-2q, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse MBP (87-101)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_MOUSE,MBP_CAVPO,MBP_BOVIN,# & MBP_PANTR)# & PIR1: (MBCZB,MBMSB,MBBOB,MBRTS,MBHUB,MBPGB)# & PIR2: (A37246)# REFERENCES: amor96a# COMMENT:# SUMMARY: H-2q,actyesu,bindyesu,FKNIVTPRTPPPSQGK*# SEQUENCE: FKNIVTPRTPPPSQGK*# ...# >MUS22563# MHC MOLECULE: H-2r, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse MBP (87-101)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_BOVIN,MBP_RAT,MBP_CAVPO,MBP_HUMAN,# & MBP_MOUSE)# & PIR1: (MBBOB,MBMSB,MBPGB,MBHUB,MBCZB,MBRTS)# & PIR2: (A37246)# REFERENCES: amor96a# COMMENT:# SUMMARY: H-2r,actyesu,bindyesu,FKNIVTPRTPPPSQGK*# SEQUENCE: FKNIVTPRTPPPSQGK*# ...# >MUS22564# MHC MOLECULE: H-2f, CLASS-2, (MOUSE)# METHOD: reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse MBP (87-101)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_BOVIN,MBP_PANTR,MBP_CAVPO,MBP_RAT,# & MBP_MOUSE)# & PIR1: (MBBOB,MBMSB,MBPGB,MBHUB,MBRTS,MBCZB)# & PIR2: (A37246)# REFERENCES: amor96a# COMMENT:# SUMMARY: H-2f,actyesu,bindyesu,FKNIVTPRTPPPSQGK*# SEQUENCE: FKNIVTPRTPPPSQGK*# ...# >MUS22565# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse MBP (12-26)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_CAVPO,MBP_RAT,MBP_HUMAN,MBP_MOUSE)# & PIR1: (MBRTS,MBCZB,MBHUB,MBMSB)# & PIR2: (A37246)# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YLATASTMDHARHGF*# SEQUENCE: YLATASTMDHARHGF*# ...# >MUS22566# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse MBP (21-35)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_CAVPO,MBP_BOVIN,MBP_MOUSE,MBP_RAT,# & MBP_HUMAN)# & PIR1: (MBBOB,MBRTS,MBCZB,MBPGB,MBHUB,MBMSB)# & PIR2: (A37246)# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,HARHGFLPRHRDTGI*# SEQUENCE: HARHGFLPRHRDTGI*# ...# >MUS22567# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rat MOG (1-15)# ANCHOR POSITIONS:# REFERENCES: amor96a,amor94a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,GQFGVIGPGYPIRAL*# SEQUENCE: GQFGVIGPGYPIRAL*# ...# >MUS22568# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE/reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rat MOG (8-22)# ANCHOR POSITIONS:# REFERENCES: amor96a,amor94a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,PGYPIRALVGDEQED*# SEQUENCE: PGYPIRALVGDEQED*# ...# >MUS22569# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rat MOG (9-23)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,GYPIRALVGDEQEDP*# SEQUENCE: GYPIRALVGDEQEDP*# ...# >MUS2256A# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (54-68)# DB REFERENCE: SWISS: (MYPR_BOVIN,MYPR_HUMAN,MYPR_RABIT,MYPR_CANFA,# & MYPR_HUMAN)# & PIR1: (S34792,MPBOPL,MPHUPL,MPRTPL)# & PIR2: (A43548)# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YQDYEYLINVIHAFQ*# SEQUENCE: YQDYEYLINVIHAFQ*# ...# >MUS2256B# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (55-69)# DB REFERENCE: SWISS: (MYPR_RABIT,MYPR_HUMAN,MYPR_CANFA,MYPR_BOVIN,# & MYPR_HUMAN)# & PIR1: (S34792,MPRTPL,MPHUPL,MPBOPL)# & PIR2: (A43548)# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,QDYEYLINVIHAFQY*# SEQUENCE: QDYEYLINVIHAFQY*# ...# >MUS2256C# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (57-71)# DB REFERENCE: SWISS: (MYPR_HUMAN,MYPR_RABIT,MYPR_CANFA,MYPR_BOVIN,# & MYPR_HUMAN)# & PIR1: (MPRTPL,MPBOPL,MPHUPL,S34792)# & PIR2: (A43548)# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YEYLINVIHAFQYVI*# SEQUENCE: YEYLINVIHAFQYVI*# ...# >MUS2256D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (58-72)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,EYLINVIHAFQYVIG*# SEQUENCE: EYLINVIHAFQYVIG*# ...# >MUS2256E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (59-73)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YLINVIHAFQYVIGT*# SEQUENCE: YLINVIHAFQYVIGT*# ...# >MUS2256F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (60-74)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,LINVIHAFQYVIGTA*# SEQUENCE: LINVIHAFQYVIGTA*# ...# >MUS22570# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (61-75)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,INVIHAFQYVIGTAS*# SEQUENCE: INVIHAFQYVIGTAS*# ...# >MUS22571# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (62-76)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,NVIHAFQYVIGTASF*# SEQUENCE: NVIHAFQYVIGTASF*# ...# >MUS22572# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (60-73)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,LINVIHAFQYVIGT*# SEQUENCE: LINVIHAFQYVIGT*# ...# >MUS22573# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (54-76)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YQDYEYLINVIHAFQYVIGTASF*# SEQUENCE: YQDYEYLINVIHAFQYVIGTASF*# ...# >MUS22574# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as./induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DKEKLINVIHAFQYV*# SEQUENCE: DKEKLINVIHAFQYV*# ...# >MUS22575# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DKEKLINVIHAFQKV*# SEQUENCE: DKEKLINVIHAFQKV*# ...# >MUS22576# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,KKKKYEYLINVIHAFQYV*# SEQUENCE: KKKKYEYLINVIHAFQYV*# ...# >MUS22577# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DKEYLINVIHAFQYV*# SEQUENCE: DKEYLINVIHAFQYV*# ...# >MUS22578# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DKEYKINVIHAFQYV*# SEQUENCE: DKEYKINVIHAFQYV*# ...# >MUS22579# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DKEYLKNVIHAFQYV*# SEQUENCE: DKEYLKNVIHAFQYV*# ...# >MUS2257A# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DYEYLIKVIHAFQYV*# SEQUENCE: DYEYLIKVIHAFQYV*# ...# >MUS2257B# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DYEYLINKIHAFQYV*# SEQUENCE: DYEYLINKIHAFQYV*# ...# >MUS2257C# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DYEYLINVIHAFKYV*# SEQUENCE: DYEYLINVIHAFKYV*# ...# >MUS2257D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DYEYLINVIHAFQKV*# SEQUENCE: DYEYLINVIHAFQKV*# ...# >MUS2257E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DYEYLINVIHAFQYK*# SEQUENCE: DYEYLINVIHAFQYK*# ...# >MUS2257F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,KDYEYLINVIHAFQYVK*# SEQUENCE: KDYEYLINVIHAFQYVK*# ...# >MUS22580# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DDYEYLINVIHAFQYVD*# SEQUENCE: DDYEYLINVIHAFQYVD*# ...# >MUS22581# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70) homologue# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,DDEYLINVIHAFQYVDD*# SEQUENCE: DDEYLINVIHAFQYVDD*# ...# >MUS22582# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MOG (1-23)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,GQFRVIGPGYPIRALVGDEQED*# SEQUENCE: GQFRVIGPGYPIRALVGDEQED*# ...# >MUS22583# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PLP (54-76)# ANCHOR POSITIONS:# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YDYEYLINVIHAFQYVIGASF*# SEQUENCE: YDYEYLINVIHAFQYVIGASF*# ...# >MUS22584# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (12-35)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_MOUSE,MBP_PANTR,MBP_RAT,MBP_HUMAN)# & PIR1: (MBCZB,MBMSB,MBHUB,MBRTS)# & PIR2: (A37246)# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,YLATASTMDHARHGFLPRHRDTGI*# SEQUENCE: YLATASTMDHARHGFLPRHRDTGI*# ...# >MUS22585# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (9-28)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_LOPCA,LYC_NUMME,LYC_CHICK)# & PIR1: (LZQJEC,LZUH,LZCH)# REFERENCES: amor96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,LAAAMKRHGLDNYRGYSLGNW*# SEQUENCE: LAAAMKRHGLDNYRGYSLGNW*# ...# >MUS22586# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rat MOG (43-57)# ANCHOR POSITIONS:# REFERENCES: amor94a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,PFSRWHLYRNGKDQ*# SEQUENCE: PFSRWHLYRNGKDQ*# ...# >MUS22587# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: induction of EAE# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: rat MOG (134-148)# DB REFERENCE: SWISS: (MOG_RAT)# & PIR2: (B47712)# REFERENCES: amor94a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,PMLLLQVSVGLVFLF*# SEQUENCE: PMLLLQVSVGLVFLF*# ...# >HUM22588# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,FTAFGFSEQRTFAER*# SEQUENCE: FTAFGFSEQRTFAER*# ...# >HUM22589# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,SISPGSGLFSPGYTR*# SEQUENCE: SISPGSGLFSPGYTR*# ...# >HUM2258A# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VEGPVYDAVVNMLRR*# SEQUENCE: VEGPVYDAVVNMLRR*# ...# >HUM2258B# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,FGRGPVSITAPMFLN*# SEQUENCE: FGRGPVSITAPMFLN*# ...# >HUM2258C# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,LDGIWSGRVLHTATF*# SEQUENCE: LDGIWSGRVLHTATF*# ...# >HUM2258D# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,HRVASDINLTISFRY*# SEQUENCE: HRVASDINLTISFRY*# ...# >HUM2258E# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,GRSALVRVTYVSPFL*# SEQUENCE: GRSALVRVTYVSPFL*# ...# >HUM2258F# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,LRCSSFRRDSlLLYY*# SEQUENCE: LRCSSFRRDSlLLYY*# ...# >HUM22590# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,QDVDYFRHPPEVSLL*# SEQUENCE: QDVDYFRHPPEVSLL*# ...# >HUM22591# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,RTPGFCYLSLSSALR*# SEQUENCE: RTPGFCYLSLSSALR*# ...# >HUM22592# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PIFPVVSSSGSSSSP*# SEQUENCE: PIFPVVSSSGSSSSP*# ...# >HUM22593# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,WPMCSDYPSVSLCPW*# SEQUENCE: WPMCSDYPSVSLCPW*# ...# >HUM22594# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PSWKRSALVRWALLQ*# SEQUENCE: PSWKRSALVRWALLQ*# ...# >HUM22595# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PLYFRSRTCPSCSPR*# SEQUENCE: PLYFRSRTCPSCSPR*# ...# >HUM22596# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,FEGVYDPSINVSKLV*# SEQUENCE: FEGVYDPSINVSKLV*# ...# >HUM22597# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VASFFFMDPFSLHYR*# SEQUENCE: VASFFFMDPFSLHYR*# ...# >HUM22598# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PGHSLGKLSVLHSFF*# SEQUENCE: PGHSLGKLSVLHSFF*# ...# >HUM22599# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PVRYGFSGPRLAELW*# SEQUENCE: PVRYGFSGPRLAELW*# ...# >HUM2259A# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,GCSALVGFLILLCCM*# SEQUENCE: GCSALVGFLILLCCM*# ...# >HUM2259B# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,LGRGPVSITAPMFLN*# SEQUENCE: LGRGPVSITAPMFLN*# ...# >HUM2259C# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PAVASTSSLIIDGPF*# SEQUENCE: PAVASTSSLIIDGPF*# ...# >HUM2259D# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,LVLLLFIALGFMYGA*# SEQUENCE: LVLLLFIALGFMYGA*# ...# >HUM2259E# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,IVSVVIRGNEGAFWS*# SEQUENCE: IVSVVIRGNEGAFWS*# ...# >HUM2259F# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,PLSGHSSVLAAlSMP*# SEQUENCE: PLSGHSSVLAAlSMP*# ...# >HUM225A0# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,GRFRHYSMLRHHSIR*# SEQUENCE: GRFRHYSMLRHHSIR*# ...# >HUM225A1# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,RSSHHPSFAVSLEPL*# SEQUENCE: RSSHHPSFAVSLEPL*# ...# >HUM225A2# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,LGYVPVWAPSRNGWR*# SEQUENCE: LGYVPVWAPSRNGWR*# ...# >HUM225A3# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PFWNFGCRHRSFLPV*# SEQUENCE: PFWNFGCRHRSFLPV*# ...# >HUM225A4# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,GAGVLTPFTWRRFHM*# SEQUENCE: GAGVLTPFTWRRFHM*# ...# >HUM225A5# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,TRLYVTWSGNTVHDG*# SEQUENCE: TRLYVTWSGNTVHDG*# ...# >HUM225A6# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PKTFQYGGRTVGGLW*# SEQUENCE: PKTFQYGGRTVGGLW*# ...# >HUM225A7# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,DYEGTRVRLLGVGRS*# SEQUENCE: DYEGTRVRLLGVGRS*# ...# >HUM225A8# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PFPRKHVCWNQVRRV*# SEQUENCE: PFPRKHVCWNQVRRV*# ...# >HUM225A9# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PFVVPTASSWALDLP*# SEQUENCE: PFVVPTASSWALDLP*# ...# >HUM225AA# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PPFRIVRCCGWGLGC*# SEQUENCE: PPFRIVRCCGWGLGC*# ...# >HUM225AB# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PVIAIPPSFANMFLF*# SEQUENCE: PVIAIPPSFANMFLF*# ...# >HUM225AC# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,IFYLVSCFTFMVLFA*# SEQUENCE: IFYLVSCFTFMVLFA*# ...# >HUM225AD# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PWTPFQTRVGRPVGA*# SEQUENCE: PWTPFQTRVGRPVGA*# ...# >HUM225AE# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,IPPILPAYTLLGHPR*# SEQUENCE: IPPILPAYTLLGHPR*# ...# >HUM225AF# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,GPLSVRSRGVMLPFF*# SEQUENCE: GPLSVRSRGVMLPFF*# ...# >HUM225B0# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PIYSDGGGAFFPRHF*# SEQUENCE: PIYSDGGGAFFPRHF*# ...# >HUM225B1# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,LSSSFDRDSSPPCCW*# SEQUENCE: LSSSFDRDSSPPCCW*# ...# >HUM225B2# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,SFGVSRFIGGNGYWI*# SEQUENCE: SFGVSRFIGGNGYWI*# ...# >HUM225B3# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,RRSSVAPVANFGVMD*# SEQUENCE: RRSSVAPVANFGVMD*# ...# >HUM225B4# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,LWGCPGSGRSPCAIR*# SEQUENCE: LWGCPGSGRSPCAIR*# ...# >HUM225B5# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,AANLLFYPDLGWFAV*# SEQUENCE: AANLLFYPDLGWFAV*# ...# >HUM225B6# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,LFFSNTHRINRILYL*# SEQUENCE: LFFSNTHRINRILYL*# ...# >HUM225B7# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,GPVWSSGLYRLFYAS*# SEQUENCE: GPVWSSGLYRLFYAS*# ...# >HUM225B8# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PKAFQYGGRAVGGLW*# SEQUENCE: PKAFQYGGRAVGGLW*# ...# >HUM225B9# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,TRWGESDSFAISPPG*# SEQUENCE: TRWGESDSFAISPPG*# ...# >HUM225BA# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,AWNLNFKVAPGHGSV*# SEQUENCE: AWNLNFKVAPGHGSV*# ...# >HUM225BB# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,THRGLRLYRPHSYIR*# SEQUENCE: THRGLRLYRPHSYIR*# ...# >HUM225BC# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,SISHASRLFSPCYTR*# SEQUENCE: SISHASRLFSPCYTR*# ...# >HUM225BD# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,VSSRYNALWNCVTCY*# SEQUENCE: VSSRYNALWNCVTCY*# ...# >HUM225BE# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,AVPTSKPHRGPFFPS*# SEQUENCE: AVPTSKPHRGPFFPS*# ...# >HUM225BF# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,CHRCFHFRRHPVAVF*# SEQUENCE: CHRCFHFRRHPVAVF*# ...# >HUM225C0# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,HRISHFAHRYLARLH*# SEQUENCE: HRISHFAHRYLARLH*# ...# >HUM225C1# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PVRDFPYDAFIYVWN*# SEQUENCE: PVRDFPYDAFIYVWN*# ...# >HUM225C2# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PWTPPIPLNVGRNRA*# SEQUENCE: PWTPPIPLNVGRNRA*# ...# >HUM225C3# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PFVVSDIAFMGLFYD*# SEQUENCE: PFVVSDIAFMGLFYD*# ...# >HUM225C4# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,ARLLMISLLALFFCG*# SEQUENCE: ARLLMISLLALFFCG*# ...# >HUM225C5# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,PISSVFLSSSVVFPS*# SEQUENCE: PISSVFLSSSVVFPS*# ...# >HUM225C6# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,GTGRFSNAAGFTVSK*# SEQUENCE: GTGRFSNAAGFTVSK*# ...# >HUM225C7# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,WVGGSSFRLLPGFWG*# SEQUENCE: WVGGSSFRLLPGFWG*# ...# >HUM225C8# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,HGSRLQRYFLYTIHR*# SEQUENCE: HGSRLQRYFLYTIHR*# ...# >HUM225C9# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,STAFSFSASGSVLYW*# SEQUENCE: STAFSFSASGSVLYW*# ...# >HUM225CA# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,VGFLGLKRGPPGVDA*# SEQUENCE: VGFLGLKRGPPGVDA*# ...# >HUM225CB# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: eluted phage peptides# ACTIVITY: ?# BINDING: yes, ?# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesu,GICGGCGVFPGVSVR*# SEQUENCE: GICGGCGVFPGVSVR*# ...# >HUM225CC# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (163-177)# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,KEPGVSGPMGPRGPPGK*# SEQUENCE: KEPGVSGPMGPRGPPGK*# ...# >HUM225CD# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (265-278)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_BOVIN,CA12_MOUSE,# & CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (A41182,B41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,RTGPAGAAGARGND*# SEQUENCE: RTGPAGAAGARGND*# ...# >HUM225CE# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (313-328)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_BOVIN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (I45876)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,ARGPEGAQGPRGEPGT*# SEQUENCE: ARGPEGAQGPRGEPGT*# ...# >HUM225CF# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (628-643)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_MOUSE)# & PIR1: (CGHU6C)# & PIR2: (A41182,B41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,PRGERGFPGERGSPGA*# SEQUENCE: PRGERGFPGERGSPGA*# ...# >HUM225D0# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (619-637)# DB REFERENCE: SWISS: (CA12_MOUSE,CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (B41182,B40333,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,EAGAPGLVGPRGERGFPGE*# SEQUENCE: EAGAPGLVGPRGERGFPGE*# ...# >HUM225D1# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (676-689)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_MOUSE,CA12_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (B40333,B41182,A40333,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,PPGLQGMPGERGAA*# SEQUENCE: PPGLQGMPGERGAA*# ...# >HUM225D2# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (574-587)# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,PPGPAGERGEQ*# SEQUENCE: PPGPAGERGEQ*# ...# >HUM225D3# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (211-226)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_HUMAN,CA12_MOUSE,# & CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (A41182,B41182,A40333,B40333)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,TPGLPGVKGHRGYPGL*# SEQUENCE: TPGLPGVKGHRGYPGL*# ...# >HUM225D4# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (517-532)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_MOUSE,CA12_BOVIN,CA12_HUMAN,# & CA12_HUMAN)# & PIR1: (CGHU6C,CGBO6C)# & PIR2: (A41182,A40333,B41182,B40333)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,RPGPPGPQGARGQPGV*# SEQUENCE: RPGPPGPQGARGQPGV*# ...# >HUM225D5# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (196-211)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (A40333,B40333)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,ERGPPGPQGARGFPGT*# SEQUENCE: ERGPPGPQGARGFPGT*# ...# >HUM225D6# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (358-376)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,IAGAPGFPGPRGPPDPQGA*# SEQUENCE: IAGAPGFPGPRGPPDPQGA*# ...# >HUM225D7# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (543-556)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,GEPGKAGEKGLPGA*# SEQUENCE: GEPGKAGEKGLPGA*# ...# >HUM225D8# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (640-655)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_MOUSE,CA12_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (A41182,B41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,SPGAQGLQGPRGLPGT*# SEQUENCE: SPGAQGLQGPRGLPGT*# ...# >HUM225D9# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (156-171)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_BOVIN,CA12_HUMAN,CA12_BOVIN,# & CA12_MOUSE)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (B41182,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,GNPGEPGEPGVSGPMG*# SEQUENCE: GNPGEPGEPGVSGPMG*# ...# >HUM225DA# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (120-140)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,EKAGGAQLGVMQGPMGPMGPR*# SEQUENCE: EKAGGAQLGVMQGPMGPMGPR*# ...# >HUM225DB# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (187-202)# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,EAKPGKAGERGPPGPQG*# SEQUENCE: EAKPGKAGERGPPGPQG*# ...# >HUM225DC# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (265-278)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN,CA12_HUMAN,CA12_HUMAN,# & CA12_MOUSE)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (B41182,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,RTGPAGAAGARGND*# SEQUENCE: RTGPAGAAGARGND*# ...# >HUM225DD# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (313-328)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (I45876)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,ARGPEGAQGPRGEPGT*# SEQUENCE: ARGPEGAQGPRGEPGT*# ...# >HUM225DE# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (628-643)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_MOUSE)# & PIR1: (CGHU6C)# & PIR2: (B41182,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,PRGERGFPGERGSPGA*# SEQUENCE: PRGERGFPGERGSPGA*# ...# >HUM225DF# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (619-637)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_MOUSE,CA12_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (B40333,B41182,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,EAGAPGLVGPRGERGFPGE*# SEQUENCE: EAGAPGLVGPRGERGFPGE*# ...# >HUM225E0# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (676-689)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_MOUSE,CA12_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (A40333,B40333,B41182,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,PPGLQGMPGERGAA*# SEQUENCE: PPGLQGMPGERGAA*# ...# >HUM225E1# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (574-587)# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,PPGPAGERGEQ*# SEQUENCE: PPGPAGERGEQ*# ...# >HUM225E2# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: collagen II (211-226)# DB REFERENCE: SWISS: (CA12_MOUSE,CA12_HUMAN,CA12_BOVIN,CA12_HUMAN,# & CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# & PIR2: (A40333,B41182,A41182,B40333)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,TPGLPGVKGHRGYPGL*# SEQUENCE: TPGLPGVKGHRGYPGL*# ...# >HUM225E3# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (517-532)# DB REFERENCE: SWISS: (CA12_MOUSE,CA12_BOVIN,CA12_HUMAN,CA12_HUMAN,# & CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# & PIR2: (B41182,A40333,A41182,B40333)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,RPGPPGPQGARGQPGV*# SEQUENCE: RPGPPGPQGARGQPGV*# ...# >HUM225E4# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (196-211)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_BOVIN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGHU6C,CGBO6C)# & PIR2: (A40333,B40333)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,ERGPPGPQGARGFPGT*# SEQUENCE: ERGPPGPQGARGFPGT*# ...# >HUM225E5# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (358-376)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,IAGAPGFPGPRGPPDPQGA*# SEQUENCE: IAGAPGFPGPRGPPDPQGA*# ...# >HUM225E6# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (640-655)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_MOUSE,CA12_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (A41182,B41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,SPGAQGLQGPRGLPGT*# SEQUENCE: SPGAQGLQGPRGLPGT*# ...# >HUM225E7# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (120-140)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,EKAGGAQLGVMQGPMGPMGPR*# SEQUENCE: EKAGGAQLGVMQGPMGPMGPR*# ...# >HUM225E8# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (187-202)# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,EAKPGKAGERGPPGPQG*# SEQUENCE: EAKPGKAGERGPPGPQG*# ...# >HUM225E9# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,SEGPVYDAVVNMLRR*# SEQUENCE: SEGPVYDAVVNMLRR*# ...# >HUM225EA# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VAGPVYDAVVNMLRR*# SEQUENCE: VAGPVYDAVVNMLRR*# ...# >HUM225EB# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VESPVYDAVVNMLRR*# SEQUENCE: VESPVYDAVVNMLRR*# ...# >HUM225EC# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,VEGSVYDAVVNMLRR*# SEQUENCE: VEGSVYDAVVNMLRR*# ...# >HUM225ED# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,VEGPVSDAVVNMLRR*# SEQUENCE: VEGPVSDAVVNMLRR*# ...# >HUM225EE# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,VEGPVYAAVVNMLRR*# SEQUENCE: VEGPVYAAVVNMLRR*# ...# >HUM225EF# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VEGPVYDSVVNMLRR*# SEQUENCE: VEGPVYDSVVNMLRR*# ...# >HUM225F0# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VEGPVYDASVNMLRR*# SEQUENCE: VEGPVYDASVNMLRR*# ...# >HUM225F1# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,VEGPVYDAVSNMLRR*# SEQUENCE: VEGPVYDAVSNMLRR*# ...# >HUM225F2# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesl,VEGPVYDAVVAMLRR*# SEQUENCE: VEGPVYDAVVAMLRR*# ...# >HUM225F3# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,VEGPVYDAVVNSLRR*# SEQUENCE: VEGPVYDAVVNSLRR*# ...# >HUM225F4# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VEGPVYDAVVNMSRR*# SEQUENCE: VEGPVYDAVVNMSRR*# ...# >HUM225F5# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: random phage# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesm,VEGPVYDAVVNMLRA*# SEQUENCE: VEGPVYDAVVNMLRA*# ...# >HUM225F6# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# DB REFERENCE: PIR2: (S33412,JN0867,PN0667)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VAAAAAAAAR*# SEQUENCE: VAAAAAAAAR*# ...# >HUM225F7# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,SAAAAAAAAR*# SEQUENCE: SAAAAAAAAR*# ...# >HUM225F8# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# DB REFERENCE: SWISS: (ID4_MOUSE,ID4_MOUSE,GAT4_HUMAN,PUM_DROME,ID4_HUMAN,# & TOLA_PSEAE,GAT4_RAT,GAT4_MOUSE,MEM2_CAEEL,HLES_DROME,# & TOLA_PSEAE,HM1D_DROAN,ID4_HUMAN)# & PIR1: (A48099)# & PIR2: (S13367,JN0867,S43260,B39369,S22026,A39369,JC4020,I61183,# & S33412,A44067,G01855,PN0667,A46221,I57561)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,AAAAAAAAR*# SEQUENCE: AAAAAAAAR*# ...# >HUM225F9# MHC MOLECULE: HLA-DQ4(DQA1*0302xDQB1*0401), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala homologue# ANCHOR POSITIONS:# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DQ4,actunkn,bindyesh,VAAAAAAAR*# SEQUENCE: VAAAAAAAR*# ...# >HUM225FA# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen II (1064-1081)# DB REFERENCE: SWISS: (CA12_CHICK,CA12_HUMAN,CA12_HUMAN,CA12_MOUSE)# & PIR1: (CGHU6C)# & PIR2: (B41182,S07133,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,RGFTGLQGLPGPPGPSGD*# SEQUENCE: RGFTGLQGLPGPPGPSGD*# ...# >HUM225FB# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen II (593-610)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_MOUSE)# & PIR1: (CGHU6C)# & PIR2: (B41182,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SGFQGLPGPPGPPGEGGK*# SEQUENCE: SGFQGLPGPPGPPGEGGK*# ...# >HUM225FC# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (429-442)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,GGVGPIGPPGERGA*# SEQUENCE: GGVGPIGPPGERGA*# ...# >HUM225FD# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen II (1064-1081)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_MOUSE,CA12_CHICK)# & PIR1: (CGHU6C)# & PIR2: (S07133,B41182,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,RGFTGLQGLPGPPGPSGD*# SEQUENCE: RGFTGLQGLPGPPGPSGD*# ...# >HUM225FE# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: collagen II (593-610)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_MOUSE,CA12_HUMAN)# & PIR1: (CGHU6C)# & PIR2: (B41182,A41182)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SGFQGLPGPPGPPGEGGK*# SEQUENCE: SGFQGLPGPPGPPGEGGK*# ...# >HUM225FF# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: inhibition as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: collagen II (429-442)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGHU6C)# REFERENCES: matsushita96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,GGVGPIGPPGERGA*# SEQUENCE: GGVGPIGPPGERGA*# ...# >HUM22600# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 homologue (148-166)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,DSTPPPGTRFRAMAIYKQS*# SEQUENCE: DSTPPPGTRFRAMAIYKQS*# ...# >HUM22601# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_MSVNS,RASH_MSVHA,RASH_RRASV)# & PIR1: (TVMVRS,TVMV3H,TVMVNS)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,EYKLVVVGARGVGKSALT*# SEQUENCE: EYKLVVVGARGVGKSALT*# ...# >HUM22602# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASK_XENLA,RASX_XENLA)# & PIR2: (A60192,I52219,S34138,I52688)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM22603# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASK_MSVKI,RASK_MSVKI)# & PIR1: (TVMV2K)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,EYKLVVVGASGVGKSALT*# SEQUENCE: EYKLVVVGASGVGKSALT*# ...# >HUM22604# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (148-166)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,DSTPPPGTRFRAMAIYKQS*# SEQUENCE: DSTPPPGTRFRAMAIYKQS*# ...# >HUM22605# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,MGSMNRRPILT*# SEQUENCE: MGSMNRRPILT*# ...# >HUM22606# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,MGGMNQRPILT*# SEQUENCE: MGGMNQRPILT*# ...# >HUM22607# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,MGGMNWRPILT*# SEQUENCE: MGGMNWRPILT*# ...# >HUM22608# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,MGGMNRSPILT*# SEQUENCE: MGGMNRSPILT*# ...# >HUM22609# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (278-291)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,PGRDWRTEEENLRK*# SEQUENCE: PGRDWRTEEENLRK*# ...# >HUM2260A# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,EYKLVVVGADGVGKSALT*# SEQUENCE: EYKLVVVGADGVGKSALT*# ...# >HUM2260B# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASK_XENLA,RASX_XENLA)# & PIR2: (I52688,I52219,A60192,S34138)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM2260C# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,EYKLVVVGAAGVGKSALT*# SEQUENCE: EYKLVVVGAAGVGKSALT*# ...# >HUM2260D# MHC MOLECULE: HLA-DR15(DRB1*1502), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 homologue (148-166)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DSTPPPGTRFRAMAIYKQS*# SEQUENCE: DSTPPPGTRFRAMAIYKQS*# ...# >HUM2260E# MHC MOLECULE: HLA-DR15(DRB1*1502), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,MGSMNRRPILT*# SEQUENCE: MGSMNRRPILT*# ...# >HUM2260F# MHC MOLECULE: HLA-DR15(DRB1*1502), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,MGGMNQRPILT*# SEQUENCE: MGGMNQRPILT*# ...# >HUM22610# MHC MOLECULE: HLA-DR15(DRB1*1502), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,MGGMNWRPILT*# SEQUENCE: MGGMNWRPILT*# ...# >HUM22611# MHC MOLECULE: HLA-DR15(DRB1*1502), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,MGGMNRSPILT*# SEQUENCE: MGGMNRSPILT*# ...# >HUM22612# MHC MOLECULE: HLA-DR15(DRB1*1502), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASH_MSVNS,RASH_MSVHA,RASH_MSVHA,RASH_RRASV)# & PIR1: (TVMVRS,TVMV3H,TVMVNS)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,EYKLVVVGARGVGKSALT*# SEQUENCE: EYKLVVVGARGVGKSALT*# ...# >HUM22613# MHC MOLECULE: HLA-DR15(DRB1*1502), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,EYKLVVVGADGVGKSALT*# SEQUENCE: EYKLVVVGADGVGKSALT*# ...# >HUM22614# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASK_XENLA,RASX_XENLA)# & PIR2: (S34138,I52219,A60192,I52688)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM22615# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASK_MSVKI,RASK_MSVKI)# & PIR1: (TVMV2K)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,EYKLVVVGASGVGKSALT*# SEQUENCE: EYKLVVVGASGVGKSALT*# ...# >HUM22616# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASH_MSVNS,RASH_RRASV,RASH_MSVHA,RASH_MSVHA)# & PIR1: (TVMV3H,TVMVNS,TVMVRS)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,EYKLVVVGARGVGKSALT*# SEQUENCE: EYKLVVVGARGVGKSALT*# ...# >HUM22617# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,EYKLVVVGADGVGKSALT*# SEQUENCE: EYKLVVVGADGVGKSALT*# ...# >HUM22618# MHC MOLECULE: HLA-DR51(DRB5*0102), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASK_XENLA,RASX_XENLA)# & PIR2: (S34138,A60192,I52219,I52688)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM22619# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (148-166)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,DSTPPPGTRFRAMAIYKQS*# SEQUENCE: DSTPPPGTRFRAMAIYKQS*# ...# >HUM2261A# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,MGSMNRRPILT*# SEQUENCE: MGSMNRRPILT*# ...# >HUM2261B# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesm,MGGMNQRPILT*# SEQUENCE: MGGMNQRPILT*# ...# >HUM2261C# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,MGGMNWRPILT*# SEQUENCE: MGGMNWRPILT*# ...# >HUM2261D# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,MGGMNRSPILT*# SEQUENCE: MGGMNRSPILT*# ...# >HUM2261E# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (278-291)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,PGRDWRTEEENLRK*# SEQUENCE: PGRDWRTEEENLRK*# ...# >HUM2261F# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,EYKLVVVGADGVGKSALT*# SEQUENCE: EYKLVVVGADGVGKSALT*# ...# >HUM22620# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASX_XENLA,RASK_XENLA)# & PIR2: (I52219,S34138,A60192,I52688)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR17,actunkn,bindyesl,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM22621# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_MSVNS,RASH_RRASV,RASH_MSVHA)# & PIR1: (TVMVNS,TVMV3H,TVMVRS)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EYKLVVVGARGVGKSALT*# SEQUENCE: EYKLVVVGARGVGKSALT*# ...# >HUM22622# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASX_XENLA,RASK_XENLA)# & PIR2: (S34138,A60192,I52219,I52688)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM22623# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (148-166)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,DSTPPPGTRFRAMAIYKQS*# SEQUENCE: DSTPPPGTRFRAMAIYKQS*# ...# >HUM22624# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,MGGMNQRPILT*# SEQUENCE: MGGMNQRPILT*# ...# >HUM22625# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_MSVNS,RASH_RRASV,RASH_MSVHA)# & PIR1: (TVMV3H,TVMVNS,TVMVRS)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,EYKLVVVGARGVGKSALT*# SEQUENCE: EYKLVVVGARGVGKSALT*# ...# >HUM22626# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EYKLVVVGADGVGKSALT*# SEQUENCE: EYKLVVVGADGVGKSALT*# ...# >HUM22627# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EYKLVVVGAAGVGKSALT*# SEQUENCE: EYKLVVVGAAGVGKSALT*# ...# >HUM22628# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (148-166)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,DSTPPPGTRFRAMAIYKQS*# SEQUENCE: DSTPPPGTRFRAMAIYKQS*# ...# >HUM22629# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASK_XENLA,RASX_XENLA)# & PIR2: (I52688,S34138,A60192,I52219)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM2262A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,EYKLVVVGAAGVGKSALT*# SEQUENCE: EYKLVVVGAAGVGKSALT*# ...# >HUM2262B# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesl,MGSMNRRPILT*# SEQUENCE: MGSMNRRPILT*# ...# >HUM2262C# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesm,MGGMNQRPILT*# SEQUENCE: MGGMNQRPILT*# ...# >HUM2262D# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASX_XENLA,RASK_XENLA)# & PIR2: (S34138,A60192,I52688,I52219)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesm,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM2262E# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,MGSMNRRPILT*# SEQUENCE: MGSMNRRPILT*# ...# >HUM2262F# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,MGGMNQRPILT*# SEQUENCE: MGGMNQRPILT*# ...# >HUM22630# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,MGGMNRSPILT*# SEQUENCE: MGGMNRSPILT*# ...# >HUM22631# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p53 homologue (278-291)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesm,PGRDWRTEEENLRK*# SEQUENCE: PGRDWRTEEENLRK*# ...# >HUM22632# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesl,EYKLVVVGADGVGKSALT*# SEQUENCE: EYKLVVVGADGVGKSALT*# ...# >HUM22633# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,MGSMNRRPILT*# SEQUENCE: MGSMNRRPILT*# ...# >HUM22634# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,MGGMNQRPILT*# SEQUENCE: MGGMNQRPILT*# ...# >HUM22635# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,EYKLVVVGADGVGKSALT*# SEQUENCE: EYKLVVVGADGVGKSALT*# ...# >HUM22636# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASX_XENLA,RASK_XENLA)# & PIR2: (I52688,A60192,S34138,I52219)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM22637# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: p53 homologue (243-253)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,MGGMNQRPILT*# SEQUENCE: MGGMNQRPILT*# ...# >HUM22638# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASH_RRASV,RASH_MSVHA,RASH_MSVHA,RASH_MSVNS)# & PIR1: (TVMVNS,TVMV3H,TVMVRS)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,EYKLVVVGARGVGKSALT*# SEQUENCE: EYKLVVVGARGVGKSALT*# ...# >HUM22639# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,EYKLVVVGADGVGKSALT*# SEQUENCE: EYKLVVVGADGVGKSALT*# ...# >HUM2263A# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASX_XENLA,RASK_XENLA)# & PIR2: (S34138,A60192,I52688,I52219)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesh,EYKLVVVGAVGVGKSALT*# SEQUENCE: EYKLVVVGAVGVGKSALT*# ...# >HUM2263B# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ras homologue (3-20)# DB REFERENCE: SWISS: (RASK_MSVKI,RASK_MSVKI)# & PIR1: (TVMV2K)# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,EYKLVVVGASGVGKSALT*# SEQUENCE: EYKLVVVGASGVGKSALT*# ...# >HUM2263C# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,EYKLVVVGAAGVGKSALT*# SEQUENCE: EYKLVVVGAAGVGKSALT*# ...# >HUM2263D# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ras homologue (3-20)# ANCHOR POSITIONS:# REFERENCES: murikami96a# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,EYKLVVVGAGDVGKSALT*# SEQUENCE: EYKLVVVGAGDVGKSALT*# ...# >MUS2263E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58)# DB REFERENCE: SWISS: (CYC_DRONO,CYC_COLLI,CYC_DRONO,CYC_ANAPL,CYC_ANAPL,# & CYC_APTPA,CYC_CHICK,CYC_COLLI,CYC_CHICK,CYC_APTPA,# & CYC_STRCA)# & PIR1: (CCOS,CCEU,CCTK,CCPY,CCDK,CCPN,CCCH)# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,AEGFSYTDANKNKGIT*# SEQUENCE: AEGFSYTDANKNKGIT*# ...# >MUS2263F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,AEGRSYTEANKAKGIT*# SEQUENCE: AEGRSYTEANKAKGIT*# ...# >MUS22640# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Ag7,actyesl,bindyesu,AEGASYTEANKAKGIT*# SEQUENCE: AEGASYTEANKAKGIT*# ...# >MUS22641# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Ag7,actyesl,bindyesu,AEGDSYTEANKAKGIT*# SEQUENCE: AEGDSYTEANKAKGIT*# ...# >MUS22642# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a,itoh94a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGRSYTEANKAKGIT*# SEQUENCE: AEGRSYTEANKAKGIT*# ...# >MUS22643# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a,itoh94a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGFSYTEANKAKGIT*# SEQUENCE: AEGFSYTEANKAKGIT*# ...# >MUS22644# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Au,actyesl,bindyesu,AEGRSYTEANKAKGIT*# SEQUENCE: AEGRSYTEANKAKGIT*# ...# >MUS22645# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Au,actyesm,bindyesu,AEGFSYTEANKAKGIT*# SEQUENCE: AEGFSYTEANKAKGIT*# ...# >MUS22646# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Au,actyesl,bindyesu,AEGASYTEANKAKGIT*# SEQUENCE: AEGASYTEANKAKGIT*# ...# >MUS22647# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a,itoh94a# COMMENT:# SUMMARY: I-As,actyesh,bindyesu,AEGFSYTEANKAKGIT*# SEQUENCE: AEGFSYTEANKAKGIT*# ...# >MUS22648# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a,itoh94a# COMMENT:# SUMMARY: I-As,actyesl,bindyesu,AEGASYTEANKAKGIT*# SEQUENCE: AEGASYTEANKAKGIT*# ...# >MUS22649# MHC MOLECULE: I-Av, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Av,actyesm,bindyesu,AEGRSYTEANKAKGIT*# SEQUENCE: AEGRSYTEANKAKGIT*# ...# >MUS2264A# MHC MOLECULE: I-Av, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Av,actyesl,bindyesu,AEGFSYTEANKAKGIT*# SEQUENCE: AEGFSYTEANKAKGIT*# ...# >MUS2264B# MHC MOLECULE: I-Av, CLASS-2, (MOUSE)# METHOD: proliferation as.# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS:# REFERENCES: katoh96a# COMMENT:# SUMMARY: I-Av,actyesl,bindyesu,AEGASYTEANKAKGIT*# SEQUENCE: AEGASYTEANKAKGIT*# ...# >HUM2264C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: tyrosinase (56-70)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesm,QNILLSNAPLGPQFP*# SEQUENCE: QNILLSNAPLGPQFP*# ...# >HUM2264D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,QNFLLSNAPLGPQFP*# SEQUENCE: QNFLLSNAPLGPQFP*# ...# >HUM2264E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QNVLLSNAPLGPQFP*# SEQUENCE: QNVLLSNAPLGPQFP*# ...# >HUM2264F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QNIQLSNAPLGPQFP*# SEQUENCE: QNIQLSNAPLGPQFP*# ...# >HUM22650# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QNIFLSNAPLGPQFP*# SEQUENCE: QNIFLSNAPLGPQFP*# ...# >HUM22651# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,QNIVLSNAPLGPQFP*# SEQUENCE: QNIVLSNAPLGPQFP*# ...# >HUM22652# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QNILQSNAPLGPQFP*# SEQUENCE: QNILQSNAPLGPQFP*# ...# >HUM22653# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,QNILFSNAPLGPQFP*# SEQUENCE: QNILFSNAPLGPQFP*# ...# >HUM22654# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QNILVSNAPLGPQFP*# SEQUENCE: QNILVSNAPLGPQFP*# ...# >HUM22655# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, high# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,QNILLSNVPLGPQFP*# SEQUENCE: QNILLSNVPLGPQFP*# ...# >HUM22656# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QNILLSNAQLGPQFP*# SEQUENCE: QNILLSNAQLGPQFP*# ...# >HUM22657# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,QNILLSNAVLGPQFP*# SEQUENCE: QNILLSNAVLGPQFP*# ...# >HUM22658# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,QNILLSNAPQGPQFP*# SEQUENCE: QNILLSNAPQGPQFP*# ...# >HUM22659# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tyrosinase (56-70) homologue# ANCHOR POSITIONS: 3,8# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,QNILLSNAPVGPQFP*# SEQUENCE: QNILLSNAPVGPQFP*# ...# >HUM2265A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (57-70)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,NILLSNAPLGPQFP*# SEQUENCE: NILLSNAPLGPQFP*# ...# >HUM2265B# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: none# BINDING: yes, moderate# SOURCE: tyrosinase (448-462)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actyesn,bindyesm,DYSYLQDSDPDSFQD*# SEQUENCE: DYSYLQDSDPDSFQD*# ...# >HUM2265C# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (448-462) homologue# ANCHOR POSITIONS: 4,9# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DQSYLQDSDPDSFQD*# SEQUENCE: DQSYLQDSDPDSFQD*# ...# >HUM2265D# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, little# SOURCE: tyrosinase (448-462) homologue# ANCHOR POSITIONS: 4,9# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,DFSYLQDSDPDSFQD*# SEQUENCE: DFSYLQDSDPDSFQD*# ...# >HUM2265E# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (448-462) homologue# ANCHOR POSITIONS: 4,9# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DYSFLQDSDPDSFQD*# SEQUENCE: DYSFLQDSDPDSFQD*# ...# >HUM2265F# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (448-462) homologue# ANCHOR POSITIONS: 4,9# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DYSYQQDSDPDSFQD*# SEQUENCE: DYSYQQDSDPDSFQD*# ...# >HUM22660# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (448-462) homologue# ANCHOR POSITIONS: 4,9# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,DYSYFQDSDPDSFQD*# SEQUENCE: DYSYFQDSDPDSFQD*# ...# >HUM22661# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (449-462)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,YSYLQDSDPDSFQD*# SEQUENCE: YSYLQDSDPDSFQD*# ...# >HUM22662# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (450-462)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SYLQDSDPDSFQD*# SEQUENCE: SYLQDSDPDSFQD*# ...# >HUM22663# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: competitive binding as.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tyrosinase (451-462)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# REFERENCES: topalian96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,YLQDSDPDSFQD*# SEQUENCE: YLQDSDPDSFQD*# ...# >HUM12664# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92)# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_HV1EL,NEF_HV1Z6,NEF_HV1ND,NEF_HV1A2,# & NEF_HV1Y2,NEF_HV1ZH,NEF_HV1OY,NEF_HV1S1,NEF_HV1MA,# & NEF_HV1RH,NEF_HV1Z2,NEF_HV1SC,NEF_HV1U4)# & PIR1: (B44963,ASLJO2,I44001,QQLJND,QQLJZR)# & PIR2: (S54385,S03246,S25937)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPVRPQVPL*# SEQUENCE: FPVRPQVPL*# ...# >HUM12665# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPVRPQVPI*# SEQUENCE: FPVRPQVPI*# ...# >HUM12666# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPVRPQVPV*# SEQUENCE: FPVRPQVPV*# ...# >HUM12667# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPVRPQVPM*# SEQUENCE: FPVRPQVPM*# ...# >HUM12668# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPVRPQVPF*# SEQUENCE: FPVRPQVPF*# ...# >HUM12669# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,FPVRPQVPA*# SEQUENCE: FPVRPQVPA*# ...# >HUM1266A# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,FPVRPQVPW*# SEQUENCE: FPVRPQVPW*# ...# >HUM1266B# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,FPVRPQVPH*# SEQUENCE: FPVRPQVPH*# ...# >HUM1266C# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: competition/flow cytometry/CTL assays# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV nef (84-92)# DB REFERENCE: SWISS: (NEF_HV1EL,NEF_HV1OY,NEF_HV1MA,NEF_HV1S1,NEF_HV1A2,# & NEF_HV1Y2,NEF_HV1U4,NEF_HV1JR,NEF_HV1Z2,NEF_HV1SC,# & NEF_HV1ND,NEF_HV1ZH,NEF_HV1RH,NEF_HV1Z6)# & PIR1: (QQLJND,I44001,QQLJZR,B44963,ASLJO2)# & PIR2: (S54385,S03246,S25937)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b,shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesh,FPVRPQVPL*# SEQUENCE: FPVRPQVPL*# ...# >HUM1266D# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,FAVRPQVPL*# SEQUENCE: FAVRPQVPL*# ...# >HUM1266E# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,FGVRPQVPL*# SEQUENCE: FGVRPQVPL*# ...# >HUM1266F# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,FPVRPQVPI*# SEQUENCE: FPVRPQVPI*# ...# >HUM12670# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,FPVRPQVPV*# SEQUENCE: FPVRPQVPV*# ...# >HUM12671# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPVRPQVPM*# SEQUENCE: FPVRPQVPM*# ...# >HUM12672# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPVRPQVPF*# SEQUENCE: FPVRPQVPF*# ...# >HUM12673# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPVRPQVPA*# SEQUENCE: FPVRPQVPA*# ...# >HUM12674# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPVRPQVPW*# SEQUENCE: FPVRPQVPW*# ...# >HUM12675# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPVRPQVPY*# SEQUENCE: FPVRPQVPY*# ...# >HUM12676# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,FPVRPQVPH*# SEQUENCE: FPVRPQVPH*# ...# >HUM12677# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# DB REFERENCE: SWISS: (NEF_SIVCZ)# & PIR1: (ASLJIK)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,FPVRPQVPT*# SEQUENCE: FPVRPQVPT*# ...# >HUM12678# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,FPVRPQVPQ*# SEQUENCE: FPVRPQVPQ*# ...# >HUM12679# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92)# DB REFERENCE: SWISS: (NEF_HV1EL,NEF_HV1OY,NEF_HV1Z6,NEF_HV1MA,NEF_HV1Y2,# & NEF_HV1U4,NEF_HV1JR,NEF_HV1Z2,NEF_HV1ND,NEF_HV1ZH,# & NEF_HV1SC,NEF_HV1S1,NEF_HV1A2,NEF_HV1RH)# & PIR1: (QQLJZR,I44001,QQLJND,B44963,ASLJO2)# & PIR2: (S25937,S54385,S03246)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPVRPQVPL*# SEQUENCE: FPVRPQVPL*# ...# >HUM1267A# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,FAVRPQVPL*# SEQUENCE: FAVRPQVPL*# ...# >HUM1267B# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,FGVRPQVPL*# SEQUENCE: FGVRPQVPL*# ...# >HUM1267C# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPVRPQVPI*# SEQUENCE: FPVRPQVPI*# ...# >HUM1267D# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPVRPQVPV*# SEQUENCE: FPVRPQVPV*# ...# >HUM1267E# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92)# DB REFERENCE: SWISS: (NEF_HV1A2,NEF_HV1ZH,NEF_HV1RH,NEF_HV1ND,NEF_HV1Z2,# & NEF_HV1U4,NEF_HV1EL,NEF_HV1JR,NEF_HV1OY,NEF_HV1Y2,# & NEF_HV1MA,NEF_HV1Z6,NEF_HV1SC,NEF_HV1S1)# & PIR1: (QQLJND,I44001,B44963,ASLJO2,QQLJZR)# & PIR2: (S25937,S54385,S03246)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,FPVRPQVPL*# SEQUENCE: FPVRPQVPL*# ...# >HUM1267F# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPVRPQVPI*# SEQUENCE: FPVRPQVPI*# ...# >HUM12680# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPVRPQVPM*# SEQUENCE: FPVRPQVPM*# ...# >HUM12681# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPVRPQVPF*# SEQUENCE: FPVRPQVPF*# ...# >HUM12682# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPVRPQVPW*# SEQUENCE: FPVRPQVPW*# ...# >HUM12683# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,FPVRPQVPY*# SEQUENCE: FPVRPQVPY*# ...# >HUM12684# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92)# DB REFERENCE: SWISS: (NEF_HV1S1,NEF_HV1MA,NEF_HV1Y2,NEF_HV1U4,NEF_HV1EL,# & NEF_HV1JR,NEF_HV1Z2,NEF_HV1A2,NEF_HV1Z6,NEF_HV1OY,# & NEF_HV1RH,NEF_HV1SC,NEF_HV1ND,NEF_HV1ZH)# & PIR1: (B44963,ASLJO2,QQLJZR,QQLJND,I44001)# & PIR2: (S54385,S03246,S25937)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPVRPQVPL*# SEQUENCE: FPVRPQVPL*# ...# >HUM12685# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,FAVRPQVPL*# SEQUENCE: FAVRPQVPL*# ...# >HUM12686# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPVRPQVPI*# SEQUENCE: FPVRPQVPI*# ...# >HUM12687# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPVRPQVPV*# SEQUENCE: FPVRPQVPV*# ...# >HUM12688# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPVRPQVPA*# SEQUENCE: FPVRPQVPA*# ...# >HUM12689# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPVRPQVPN*# SEQUENCE: FPVRPQVPN*# ...# >HUM1268A# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (84-92) homologue# DB REFERENCE: SWISS: (NEF_SIVCZ)# & PIR1: (ASLJIK)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPVRPQVPT*# SEQUENCE: FPVRPQVPT*# ...# >HUM1268B# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV nef (84-92) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,FPVRPQVPC*# SEQUENCE: FPVRPQVPC*# ...# >HUM1268C# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Candida 1768 aur (76-84)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPASFFIKL*# SEQUENCE: FPASFFIKL*# ...# >HUM1268D# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ENV (313-321)# DB REFERENCE: SWISS: (VMSA_HPBVD,VMSA_HPBV9,VMSA_HPBVR,VMSA_HPBV4,VMSA_HPBVJ,# & VMSA_HPBVY,VMSA_HPBVA,VMSA_HPBVR,VMSA_HPBVY,VMSA_HPBV2,# & VMSA_HPBVW,VMSA_HPBVN,VMSA_HPBVI,VMSA_HPBVO,VMSA_HPBV0,# & VMSA_HPBVP,VMSA_HPBVZ,VMSA_HPBV2,VMSA_HPBVS,VMSA_HPBVL,# & VMSA_HPBVW)# & PIR1: (SAVLJ1,SAVLN1,SAVLJ3,JQ1572,JQ1575,SAVLAR,SAVLA1,SAVLVD,# & JQ1571,JQ1570,SAVLCP,SAVLAJ,JQ1577,SAVLAH,SAVLBH,SAVLA,# & SAVLHV,JQ1576,JQ1578,JQ1573,SAVLVE,SAVLKS,SAVLAD,SAVLJ2,# & JQ1574,JQ1581)# & PIR2: (JQ2108,JQ2104,JQ2081,JQ2048,S41869,S47411,JQ2099,JQ2094,# & JQ2063,JQ2075,JQ2095,S47407,JQ2110,JQ2080,JQ2096,JQ2109,# & JQ2123,JQ2058,S41871,JQ2065,JQ2073,JQ2103,JQ2059,JQ2077,# & JQ2115,JQ2076,S20745,JQ2066,JQ2057,JQ2062,JQ2106,JQ2089,# & JQ2112,S41870,JQ2079,JQ2098,S35528,JQ2051,JQ2054,JQ2072,# & JQ2052,JQ2055,JQ2085,S43492,JQ2114,JQ2088,JQ2061,JQ2097,# & JQ2100,JQ2105,JQ2078,JQ2068,JQ2069,S32202,JQ2113,JQ2060,# & JQ2053,JQ2083,JQ2067,JQ2102,JQ2092,JQ2087,S20749,JQ2111,# & JQ2091,JQ2070,JQ2047,JQ2116,JQ2045,JQ2090,JQ2046,JQ2101,# & S20753,JQ2050)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b,bertoni97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,IPIPSSWAF*# SEQUENCE: IPIPSSWAF*# ...# >HUM1268E# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE2 (170-178)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,VPISHLYIL*# SEQUENCE: VPISHLYIL*# ...# >HUM1268F# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (196-204)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,MPKAGLLII*# SEQUENCE: MPKAGLLII*# ...# >HUM12690# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Prost. Ca PSM (289-297)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,LPSIPVHPI*# SEQUENCE: LPSIPVHPI*# ...# >HUM12691# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: C. albicans 1768 aur (107-115)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,LPVFTWLAL*# SEQUENCE: LPVFTWLAL*# ...# >HUM12692# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: C albicans 1768 aur (174-182)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,FPFVLAAII*# SEQUENCE: FPFVLAAII*# ...# >HUM12693# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER2/neu (941-949)# DB REFERENCE: SWISS: (EGFR_HUMAN,KERB_AVIER,ERB2_HUMAN,EGFR_HUMAN,XMRK_XIPMA,# & KER2_CHICK,EGFR_MOUSE,KER1_CHICK,NEU_RAT,EGFR_MACMU,# & EGFR_MACMU)# & PIR1: (TVRTNU,GQHUE,TVFVEB,A24571,TVFVLV,TVCHLV,TVYUH)# & PIR2: (I78540,B44776,S13809,S35745,S06142,S13808,A47253,I48161,# & S00727,A53183,S13807)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,LPQPPICTI*# SEQUENCE: LPQPPICTI*# ...# >HUM12694# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV POL (541-549)# DB REFERENCE: SWISS: (DPOL_HPBVO,DPOL_HPBVZ,DPOL_HPBVJ,DPOL_HPBV9,DPOM_HPBVY,# & DPOL_HPBVM,DPOL_HPBVI,DPOL_HPBV2,DPOL_HPBVP,DPOL_HPBVT,# & DPOL_HPBVL,DPOL_HPBVY,DPOL_HPBV4,DPOL_HPBVR,# & DPOL_HPBVA)# & PIR1: (JDVLA1,S47406,JQ2229,JDVLJ2,JDVLVA,JDVLJ3,JDVLVS,JDVLJ1,# & S20757,JDVLVR,S20752,JDVLCP,JDVLVD,JDVLVH,JDVLKS,JDVLVB,# & S43491)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,FPHCLAFSY*# SEQUENCE: FPHCLAFSY*# ...# >HUM12695# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV Core (168-176)# DB REFERENCE: SWISS: (POLG_HCVHK,POLG_HCVH,POLG_HCVJT,POLG_HCVH7,POLG_HCVJ8,# & POLG_HCVTW,POLG_HCVE1,POLG_HCV1,POLG_HCVBK,POLG_HCVJ2,# & POLG_HCVJ5,POLG_HCVJ7,POLG_HCVH4,POLG_HCVJA,POLG_HCVJ6,# & POLG_HCVH8)# & PIR1: (GNWVCJ,GNWVJ8,GNWVTW,GNWVTC,GNWVC3,GNWVCH)# & PIR2: (PC2219,A45573,JQ0881,S18032,PN0677,PS0388,S18030,S12707,# & S21471,JQ1303,PC1304,S40770,PC1305,S41288,PC1303,S18031,# & JH0711,JQ1584,JN0265,S19876,PC2061,PC2060,PC1284,S19875,# & JQ0883,JQ1925,A44150,JQ1926)# & PIR3: (S32740)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,LPGCSFSIF*# SEQUENCE: LPGCSFSIF*# ...# >HUM12696# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV POL (171-179)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1RH,POL_HV1B1,POL_HV1Z2,POL_HV1N5,# & POL_HV1BR,POL_HV1A2,POL_HV1JR,POL_HV1MN,POL_HV1H2,# & POL_HV1EL,POL_HV1U4,POL_HV1Y2,POL_HV1B5,POL_HV1ND,# & POL_HV1PV,POL_HV1OY)# & PIR1: (B44001,GNVWH3,GNLJND,GNVWLV,GNVWVL,GNVWA2)# & PIR2: (S63752,S63737,S63736,S63744,S63735,S54378,S63733,S63732,# & S63747,S63742,S63748,S63734,S63745,S63749,S63739,S63731,# & S63754,S63755,S63750,S63746,S63753,S63751,S63741)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,FPISPIETV*# SEQUENCE: FPISPIETV*# ...# >HUM12697# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: C. albicans 1768 aur (284-292)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,FPRFKFVWV*# SEQUENCE: FPRFKFVWV*# ...# >HUM12698# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER2/neu (65-73)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,LPTNASLSF*# SEQUENCE: LPTNASLSF*# ...# >HUM12699# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HER2/neu(706-714)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,MPNQAQMRI*# SEQUENCE: MPNQAQMRI*# ...# >HUM1269A# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Candida 1768 aur (76-84)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPASFFIKL*# SEQUENCE: FPASFFIKL*# ...# >HUM1269B# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ENV (313-321)# DB REFERENCE: SWISS: (VMSA_HPBVA,VMSA_HPBVS,VMSA_HPBVL,VMSA_HPBVP,VMSA_HPBVI,# & VMSA_HPBVY,VMSA_HPBVW,VMSA_HPBVN,VMSA_HPBVR,VMSA_HPBVO,# & VMSA_HPBV0,VMSA_HPBV2,VMSA_HPBVR,VMSA_HPBVZ,VMSA_HPBV4,# & VMSA_HPBV9,VMSA_HPBVJ,VMSA_HPBVD,VMSA_HPBVY,VMSA_HPBV2,# & VMSA_HPBVW)# & PIR1: (SAVLJ2,JQ1576,SAVLCP,SAVLAJ,SAVLA1,JQ1572,JQ1573,SAVLBH,# & SAVLJ3,SAVLAH,JQ1577,JQ1571,SAVLVD,JQ1570,SAVLN1,SAVLJ1,# & JQ1575,SAVLAR,SAVLHV,JQ1578,SAVLKS,SAVLAD,SAVLVE,SAVLA,# & JQ1574,JQ1581)# & PIR2: (JQ2058,JQ2123,JQ2065,JQ2115,S20745,JQ2076,JQ2063,S47411,# & S41869,JQ2110,JQ2048,JQ2104,JQ2108,JQ2095,JQ2116,JQ2091,# & JQ2102,JQ2092,JQ2083,JQ2097,JQ2046,JQ2045,JQ2101,JQ2050,# & JQ2053,JQ2069,JQ2113,JQ2060,JQ2068,JQ2105,JQ2072,JQ2052,# & S43492,JQ2088,JQ2061,S41870,S35528,JQ2051,JQ2106,S47407,# & S32202,JQ2114,JQ2057,JQ2055,JQ2054,JQ2077,JQ2059,JQ2066,# & JQ2103,JQ2075,JQ2073,JQ2109,JQ2112,JQ2079,JQ2089,JQ2062,# & JQ2090,JQ2047,JQ2070,JQ2099,JQ2080,JQ2096,JQ2067,JQ2078,# & JQ2085,JQ2100,JQ2094,JQ2081,JQ2098,S41871,JQ2111,S20749,# & JQ2087,S20753)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b,bertoni97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,IPIPSSWAF*# SEQUENCE: IPIPSSWAF*# ...# >HUM1269C# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE2 (170-178)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,VPISHLYIL*# SEQUENCE: VPISHLYIL*# ...# >HUM1269D# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Prost. Ca PSM (289-297)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,LPSIPVHPI*# SEQUENCE: LPSIPVHPI*# ...# >HUM1269E# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: C. albicans 1768 aur (107-115)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPVFTWLAL*# SEQUENCE: LPVFTWLAL*# ...# >HUM1269F# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: C albicans 1768 aur (174-182)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPFVLAAII*# SEQUENCE: FPFVLAAII*# ...# >HUM126A0# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV POL (541-549)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVA,DPOL_HPBV4,DPOL_HPBVL,DPOL_HPBVT,# & DPOL_HPBVM,DPOL_HPBVJ,DPOL_HPBV2,DPOL_HPBVR,DPOL_HPBV9,# & DPOL_HPBVO,DPOL_HPBVI,DPOL_HPBVP,DPOM_HPBVY,# & DPOL_HPBVZ)# & PIR1: (JDVLVH,JDVLKS,JDVLVB,JDVLVD,JDVLA1,JDVLVR,S20757,S20752,# & JDVLJ3,JDVLVS,JDVLJ1,JDVLCP,JDVLVA,JQ2229,JDVLJ2,S47406,# & S43491)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPHCLAFSY*# SEQUENCE: FPHCLAFSY*# ...# >HUM126A1# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV Core (168-176)# DB REFERENCE: SWISS: (POLG_HCVHK,POLG_HCVJ5,POLG_HCVH4,POLG_HCVJ6,POLG_HCVJ7,# & POLG_HCVJA,POLG_HCVH8,POLG_HCVH,POLG_HCVTW,POLG_HCVJ2,# & POLG_HCV1,POLG_HCVBK,POLG_HCVE1,POLG_HCVH7,POLG_HCVJ8,# & POLG_HCVJT)# & PIR1: (GNWVTW,GNWVTC,GNWVC3,GNWVCH,GNWVCJ,GNWVJ8)# & PIR2: (A44150,JQ1926,JQ1303,PC1304,S21471,S12707,PC2219,S18032,# & PN0677,JQ0881,S41288,PC1305,PC1303,JN0265,S19875,JQ0883,# & JQ1925,S40770,S19876,PC2061,PC2060,PC1284,PS0388,A45573,# & S18030,JQ1584,S18031,JH0711)# & PIR3: (S32740)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,LPGCSFSIF*# SEQUENCE: LPGCSFSIF*# ...# >HUM126A2# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV E2 (622-630)# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVBK,POLG_HCVJ7,POLG_HCVTW,# & POLG_HCVJ8)# & PIR1: (GNWVTC,GNWVTW,GNWVJ8)# & PIR2: (S19876,S18032,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,YPCTVNFTI*# SEQUENCE: YPCTVNFTI*# ...# >HUM126A3# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV POL (171-179)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1A2,POL_HV1MN,POL_HV1BR,POL_HV1U4,# & POL_HV1JR,POL_HV1RH,POL_HV1B1,POL_HV1N5,POL_HV1Z2,# & POL_HV1H2,POL_HV1EL,POL_HV1Y2,POL_HV1B5,POL_HV1ND,# & POL_HV1OY,POL_HV1PV)# & PIR1: (GNVWA2,B44001,GNVWLV,GNVWVL,GNLJND,GNVWH3)# & PIR2: (S63749,S63748,S63734,S63737,S63736,S63747,S63755,S63750,# & S63753,S63751,S63735,S63733,S63744,S63752,S54378,S63739,# & S63732,S63745,S63742,S63731,S63754,S63741,S63746)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,FPISPIETV*# SEQUENCE: FPISPIETV*# ...# >HUM126A4# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV (1582-1590)# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVH,POLG_HCVTW,POLG_HCVJT)# & PIR1: (GNWVCH,GNWVTW,GNWVTC)# & PIR2: (S06067,PC2219,A61196,A54317,A45573,S40770,S18030)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,FPYLVAYQA*# SEQUENCE: FPYLVAYQA*# ...# >HUM126A5# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER2/neu (65-73)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,LPTNASLSF*# SEQUENCE: LPTNASLSF*# ...# >HUM126A6# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HER2/neu(706-714)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,MPNQAQMRI*# SEQUENCE: MPNQAQMRI*# ...# >HUM126A7# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Candida 1768 aur (76-84)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPASFFIKL*# SEQUENCE: FPASFFIKL*# ...# >HUM126A8# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBV ENV (313-321)# DB REFERENCE: SWISS: (VMSA_HPBVA,VMSA_HPBVS,VMSA_HPBVY,VMSA_HPBVI,VMSA_HPBV2,# & VMSA_HPBVO,VMSA_HPBV9,VMSA_HPBV4,VMSA_HPBVJ,VMSA_HPBVY,# & VMSA_HPBVN,VMSA_HPBVW,VMSA_HPBVP,VMSA_HPBVZ,VMSA_HPBVR,# & VMSA_HPBVD,VMSA_HPBV0,VMSA_HPBVR,VMSA_HPBVL,VMSA_HPBV2,# & VMSA_HPBVW)# & PIR1: (SAVLCP,SAVLA,SAVLKS,SAVLHV,JQ1578,SAVLAD,SAVLVE,SAVLJ2,# & JQ1576,JQ1572,SAVLAR,SAVLAJ,JQ1575,SAVLJ1,SAVLBH,JQ1573,# & SAVLA1,JQ1577,SAVLAH,JQ1570,JQ1571,SAVLVD,JQ1574,JQ1581,# & SAVLN1,SAVLJ3)# & PIR2: (JQ2065,JQ2058,JQ2063,JQ2076,S20745,JQ2115,S47411,S41869,# & JQ2104,JQ2108,JQ2048,JQ2051,JQ2052,JQ2072,S43492,JQ2088,# & JQ2112,JQ2060,JQ2123,JQ2047,JQ2070,JQ2096,JQ2080,JQ2099,# & JQ2067,JQ2085,JQ2100,S20753,JQ2094,JQ2098,S32202,JQ2050,# & JQ2101,JQ2105,JQ2046,JQ2069,JQ2114,JQ2054,JQ2103,JQ2075,# & JQ2077,JQ2089,JQ2091,JQ2095,JQ2110,JQ2061,S41870,S35528,# & JQ2106,JQ2083,JQ2045,JQ2113,JQ2092,JQ2102,JQ2068,JQ2053,# & JQ2057,JQ2062,JQ2073,JQ2078,S20749,S47407,JQ2090,JQ2055,# & JQ2109,JQ2066,JQ2059,JQ2079,S41871,JQ2081,JQ2087,JQ2111,# & JQ2116,JQ2097)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b,bertoni97a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesm,IPIPSSWAF*# SEQUENCE: IPIPSSWAF*# ...# >HUM126A9# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE2 (170-178)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,VPISHLYIL*# SEQUENCE: VPISHLYIL*# ...# >HUM126AA# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (196-204)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,MPKAGLLII*# SEQUENCE: MPKAGLLII*# ...# >HUM126AB# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Prost. Ca PSM (289-297)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPSIPVHPI*# SEQUENCE: LPSIPVHPI*# ...# >HUM126AC# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: C. albicans 1768 aur (107-115)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPVFTWLAL*# SEQUENCE: LPVFTWLAL*# ...# >HUM126AD# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: C albicans 1768 aur (174-182)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPFVLAAII*# SEQUENCE: FPFVLAAII*# ...# >HUM126AE# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HER2/neu (941-949)# DB REFERENCE: SWISS: (ERB2_HUMAN,EGFR_MACMU,XMRK_XIPMA,KER1_CHICK,EGFR_MOUSE,# & NEU_RAT,EGFR_HUMAN,EGFR_HUMAN,EGFR_MACMU,KERB_AVIER,# & KER2_CHICK)# & PIR1: (TVYUH,TVCHLV,TVRTNU,TVFVEB,TVFVLV,A24571,GQHUE)# & PIR2: (A53183,I78540,S06142,S13807,S00727,S13808,S35745,S13809,# & B44776,I48161,A47253)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPQPPICTI*# SEQUENCE: LPQPPICTI*# ...# >HUM126AF# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV Core (168-176)# DB REFERENCE: SWISS: (POLG_HCVJ6,POLG_HCVJA,POLG_HCVH4,POLG_HCVJ8,POLG_HCVBK,# & POLG_HCVHK,POLG_HCVJ5,POLG_HCVH7,POLG_HCVJ2,POLG_HCVJ7,# & POLG_HCV1,POLG_HCVE1,POLG_HCVH8,POLG_HCVJT,POLG_HCVTW,# & POLG_HCVH)# & PIR1: (GNWVJ8,GNWVTW,GNWVTC,GNWVCH,GNWVC3,GNWVCJ)# & PIR2: (JQ1925,JN0265,PC1305,A45573,S41288,S18030,S18031,JH0711,# & PC2219,S12707,S21471,S40770,PC1304,A44150,JQ1926,PS0388,# & PC2060,PC2061,S19876,S18032,JQ0881,PN0677,JQ1584,JQ1303,# & S19875,JQ0883,PC1303,PC1284)# & PIR3: (S32740)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,LPGCSFSIF*# SEQUENCE: LPGCSFSIF*# ...# >HUM126B0# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV E2 (622-630)# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVJ7,POLG_HCVJT,POLG_HCVBK,# & POLG_HCVJ8)# & PIR1: (GNWVTW,GNWVJ8,GNWVTC)# & PIR2: (A45573,S19876,S18032)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,YPCTVNFTI*# SEQUENCE: YPCTVNFTI*# ...# >HUM126B1# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV POL (171-179)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1A2,POL_HV1B1,POL_HV1H2,POL_HV1N5,# & POL_HV1Z2,POL_HV1EL,POL_HV1OY,POL_HV1PV,POL_HV1B5,# & POL_HV1Y2,POL_HV1ND,POL_HV1RH,POL_HV1U4,POL_HV1MN,# & POL_HV1MA,POL_HV1JR)# & PIR1: (GNVWH3,GNVWLV,GNLJND,GNVWVL,GNVWA2,B44001)# & PIR2: (S63748,S63736,S63749,S63751,S63750,S63744,S63752,S54378,# & S63746,S63754,S63732,S63745,S63735,S63737,S63747,S63753,# & S63733,S63731,S63741,S63742,S63755,S63734,S63739)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,FPISPIETV*# SEQUENCE: FPISPIETV*# ...# >HUM126B2# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV (1582-1590)# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCVJT,POLG_HCVTW,POLG_HCVBK)# & PIR1: (GNWVTW,GNWVTC,GNWVCH)# & PIR2: (A54317,S40770,S18030,S06067,PC2219,A61196,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,FPYLVAYQA*# SEQUENCE: FPYLVAYQA*# ...# >HUM126B3# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: C. albicans 1768 aur (284-292)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,FPRFKFVWV*# SEQUENCE: FPRFKFVWV*# ...# >HUM126B4# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HER2/neu (65-73)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,LPTNASLSF*# SEQUENCE: LPTNASLSF*# ...# >HUM126B5# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HER2/neu(706-714)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,MPNQAQMRI*# SEQUENCE: MPNQAQMRI*# ...# >HUM126B6# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Candida 1768 aur (76-84)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPASFFIKL*# SEQUENCE: FPASFFIKL*# ...# >HUM126B7# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV ENV (313-321)# DB REFERENCE: SWISS: (VMSA_HPBVA,VMSA_HPBVW,VMSA_HPBVD,VMSA_HPBVO,VMSA_HPBVL,# & VMSA_HPBV9,VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBV4,VMSA_HPBVS,# & VMSA_HPBVJ,VMSA_HPBVP,VMSA_HPBVN,VMSA_HPBVW,VMSA_HPBVR,# & VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVZ,# & VMSA_HPBV0)# & PIR1: (JQ1581,JQ1574,SAVLAH,JQ1577,JQ1576,SAVLBH,SAVLJ2,JQ1570,# & SAVLN1,SAVLHV,SAVLA,SAVLVD,SAVLJ3,SAVLAR,SAVLAJ,SAVLAD,# & SAVLVE,JQ1578,JQ1573,JQ1571,SAVLA1,JQ1572,SAVLKS,SAVLCP,# & JQ1575,SAVLJ1)# & PIR2: (S43492,JQ2052,JQ2088,JQ2076,JQ2063,S47411,JQ2108,JQ2101,# & JQ2050,JQ2046,JQ2058,JQ2072,S35528,JQ2106,JQ2095,JQ2091,# & JQ2094,S20753,JQ2099,JQ2103,JQ2077,JQ2089,JQ2054,JQ2067,# & JQ2100,JQ2098,JQ2085,JQ2070,JQ2096,JQ2083,JQ2045,JQ2053,# & JQ2102,JQ2092,JQ2078,JQ2062,S20749,S47407,JQ2112,JQ2060,# & JQ2087,JQ2081,S41871,JQ2079,JQ2090,JQ2116,JQ2097,JQ2105,# & JQ2069,JQ2075,JQ2114,S41869,JQ2104,JQ2065,S20745,JQ2051,# & JQ2115,JQ2057,JQ2113,JQ2068,JQ2110,S41870,JQ2080,JQ2059,# & JQ2066,JQ2111,JQ2055,JQ2048,JQ2123,S32202,JQ2047,JQ2109,# & JQ2061,JQ2073)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b,bertoni97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,IPIPSSWAF*# SEQUENCE: IPIPSSWAF*# ...# >HUM126B8# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE2 (170-178)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,VPISHLYIL*# SEQUENCE: VPISHLYIL*# ...# >HUM126B9# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (196-204)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,MPKAGLLII*# SEQUENCE: MPKAGLLII*# ...# >HUM126BA# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Prost. Ca PSM (289-297)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,LPSIPVHPI*# SEQUENCE: LPSIPVHPI*# ...# >HUM126BB# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: C. albicans 1768 aur (107-115)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,LPVFTWLAL*# SEQUENCE: LPVFTWLAL*# ...# >HUM126BC# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: C albicans 1768 aur (174-182)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPFVLAAII*# SEQUENCE: FPFVLAAII*# ...# >HUM126BD# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HER2/neu (941-949)# DB REFERENCE: SWISS: (EGFR_MOUSE,ERB2_HUMAN,EGFR_HUMAN,EGFR_MACMU,EGFR_HUMAN,# & XMRK_XIPMA,KER1_CHICK,KER2_CHICK,KERB_AVIER,EGFR_MACMU,# & NEU_RAT)# & PIR1: (TVFVEB,TVFVLV,GQHUE,TVYUH,TVCHLV,TVRTNU,A24571)# & PIR2: (A47253,S35745,B44776,S13808,A53183,S13807,I78540,S06142,# & S00727,I48161,S13809)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,LPQPPICTI*# SEQUENCE: LPQPPICTI*# ...# >HUM126BE# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV POL (541-549)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBVZ,DPOL_HPBVL,DPOL_HPBVR,# & DPOL_HPBV9,DPOL_HPBVJ,DPOL_HPBVM,DPOL_HPBVA,DPOL_HPBVO,# & DPOL_HPBV2,DPOL_HPBVT,DPOL_HPBVI,DPOL_HPBV4,# & DPOL_HPBVY)# & PIR1: (JDVLJ1,JDVLVS,JDVLCP,JDVLKS,JDVLVH,JDVLVB,JDVLVD,JDVLJ3,# & S47406,JDVLA1,S20752,S20757,JDVLVR,JDVLVA,JQ2229,S43491,# & JDVLJ2)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPHCLAFSY*# SEQUENCE: FPHCLAFSY*# ...# >HUM126BF# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV Core (168-176)# DB REFERENCE: SWISS: (POLG_HCVE1,POLG_HCVBK,POLG_HCVJ8,POLG_HCVJ6,POLG_HCVJ5,# & POLG_HCVH7,POLG_HCVJT,POLG_HCVH,POLG_HCVJ7,POLG_HCVH8,# & POLG_HCVJ2,POLG_HCV1,POLG_HCVTW,POLG_HCVH4,POLG_HCVHK,# & POLG_HCVJA)# & PIR1: (GNWVCH,GNWVC3,GNWVJ8,GNWVCJ,GNWVTW,GNWVTC)# & PIR2: (PC2061,PN0677,JN0265,S12707,S41288,S19875,JQ1584,S18030,# & JQ0881,JH0711,A45573,S18031,S21471,S19876,A44150,JQ1926,# & PS0388,S40770,JQ1303,JQ0883,PC1303,PC1284,PC2219,PC1305,# & PC2060,PC1304,JQ1925,S18032)# & PIR3: (S32740)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,LPGCSFSIF*# SEQUENCE: LPGCSFSIF*# ...# >HUM126C0# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV E2 (622-630)# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJ8,POLG_HCVTW,POLG_HCVJ7,# & POLG_HCVJT)# & PIR1: (GNWVJ8,GNWVTC,GNWVTW)# & PIR2: (A45573,S19876,S18032)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,YPCTVNFTI*# SEQUENCE: YPCTVNFTI*# ...# >HUM126C1# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV POL (171-179)# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1EL,POL_HV1ND,POL_HV1Y2,POL_HV1B1,# & POL_HV1Z2,POL_HV1OY,POL_HV1MN,POL_HV1MA,POL_HV1JR,# & POL_HV1RH,POL_HV1H2,POL_HV1PV,POL_HV1N5,POL_HV1U4,# & POL_HV1BR,POL_HV1A2)# & PIR1: (GNVWLV,GNLJND,GNVWVL,GNVWA2,B44001,GNVWH3)# & PIR2: (S63735,S63737,S63742,S63734,S63731,S63752,S63744,S63732,# & S63736,S63750,S63749,S63751,S63733,S63746,S63745,S63755,# & S63753,S63739,S63748,S63747,S63741,S63754,S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,FPISPIETV*# SEQUENCE: FPISPIETV*# ...# >HUM126C2# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV (1582-1590)# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVBK,POLG_HCVH,POLG_HCVTW)# & PIR1: (GNWVTC,GNWVTW,GNWVCH)# & PIR2: (A54317,A61196,PC2219,A45573,S40770,S06067,S18030)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,FPYLVAYQA*# SEQUENCE: FPYLVAYQA*# ...# >HUM126C3# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: C. albicans 1768 aur (284-292)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,FPRFKFVWV*# SEQUENCE: FPRFKFVWV*# ...# >HUM126C4# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HER2/neu (65-73)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,LPTNASLSF*# SEQUENCE: LPTNASLSF*# ...# >HUM126C5# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HER2/neu(706-714)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,MPNQAQMRI*# SEQUENCE: MPNQAQMRI*# ...# >HUM126C6# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Candida 1768 aur (76-84)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPASFFIKL*# SEQUENCE: FPASFFIKL*# ...# >HUM126C7# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV ENV (313-321)# DB REFERENCE: SWISS: (VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBV0,# & VMSA_HPBV2,VMSA_HPBV4,VMSA_HPBVI,VMSA_HPBVR,VMSA_HPBVW,# & VMSA_HPBVN,VMSA_HPBVP,VMSA_HPBVS,VMSA_HPBVO,VMSA_HPBVL,# & VMSA_HPBVW,VMSA_HPBVJ,VMSA_HPBVR,VMSA_HPBV9,VMSA_HPBVD,# & VMSA_HPBVA)# & PIR1: (JQ1574,SAVLAH,SAVLHV,SAVLCP,SAVLKS,JQ1575,JQ1573,SAVLJ3,# & SAVLA1,JQ1576,SAVLJ2,SAVLBH,SAVLAD,SAVLVE,JQ1578,SAVLA,# & JQ1577,JQ1581,JQ1570,SAVLN1,JQ1571,SAVLVD,SAVLAR,SAVLAJ,# & SAVLJ1,JQ1572)# & PIR2: (S43492,JQ2063,JQ2108,JQ2046,JQ2067,JQ2098,JQ2100,JQ2085,# & JQ2096,JQ2077,JQ2089,JQ2070,JQ2050,JQ2088,JQ2058,JQ2073,# & JQ2109,S32202,JQ2072,JQ2068,JQ2048,JQ2123,JQ2066,JQ2059,# & JQ2055,JQ2111,JQ2045,JQ2083,JQ2062,S47407,JQ2095,S35528,# & S20753,S41871,JQ2081,JQ2097,JQ2112,JQ2060,JQ2114,JQ2080,# & JQ2075,JQ2069,JQ2104,JQ2115,S20745,JQ2051,S41869,JQ2105,# & JQ2110,JQ2113,S41870,JQ2061,S20749,JQ2079,JQ2099,JQ2047,# & JQ2052,JQ2101,S47411,JQ2076,JQ2087,JQ2090,JQ2116,JQ2078,# & JQ2102,JQ2092,JQ2053,JQ2057,JQ2065,JQ2106,JQ2091,JQ2094,# & JQ2103,JQ2054)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b,bertoni97a# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,IPIPSSWAF*# SEQUENCE: IPIPSSWAF*# ...# >HUM126C8# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE2 (170-178)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,VPISHLYIL*# SEQUENCE: VPISHLYIL*# ...# >HUM126C9# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (196-204)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,MPKAGLLII*# SEQUENCE: MPKAGLLII*# ...# >HUM126CA# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Prost. Ca PSM (289-297)# DB REFERENCE: SWISS: (PSM_HUMAN)# & PIR2: (A56881)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,LPSIPVHPI*# SEQUENCE: LPSIPVHPI*# ...# >HUM126CB# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: C. albicans 1768 aur (107-115)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,LPVFTWLAL*# SEQUENCE: LPVFTWLAL*# ...# >HUM126CC# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: C albicans 1768 aur (174-182)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPFVLAAII*# SEQUENCE: FPFVLAAII*# ...# >HUM126CD# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HER2/neu (941-949)# DB REFERENCE: SWISS: (XMRK_XIPMA,EGFR_MACMU,EGFR_MACMU,NEU_RAT,EGFR_HUMAN,# & KER1_CHICK,ERB2_HUMAN,KERB_AVIER,KER2_CHICK,EGFR_HUMAN,# & EGFR_MOUSE)# & PIR1: (TVCHLV,A24571,GQHUE,TVFVLV,TVRTNU,TVFVEB,TVYUH)# & PIR2: (A47253,S13808,S35745,I78540,S06142,A53183,S13809,I48161,# & S13807,S00727,B44776)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,LPQPPICTI*# SEQUENCE: LPQPPICTI*# ...# >HUM126CE# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV POL (541-549)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBVT,DPOL_HPBVL,DPOL_HPBVM,DPOL_HPBV9,# & DPOL_HPBVR,DPOL_HPBVZ,DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBVJ,# & DPOL_HPBVA,DPOL_HPBVO,DPOL_HPBV2,DPOL_HPBV4,# & DPOL_HPBVY)# & PIR1: (JDVLVH,JDVLKS,S20757,S20752,JQ2229,JDVLJ2,S43491,JDVLVR,# & JDVLA1,JDVLVD,JDVLVB,JDVLVS,JDVLJ3,JDVLJ1,JDVLVA,S47406,# & JDVLCP)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,FPHCLAFSY*# SEQUENCE: FPHCLAFSY*# ...# >HUM126CF# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV E2 (622-630)# DB REFERENCE: SWISS: (POLG_HCVJ7,POLG_HCVJT,POLG_HCVJ8,POLG_HCVBK,# & POLG_HCVTW)# & PIR1: (GNWVJ8,GNWVTW,GNWVTC)# & PIR2: (S19876,S18032,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,YPCTVNFTI*# SEQUENCE: YPCTVNFTI*# ...# >HUM126D0# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV POL (171-179)# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1Y2,POL_HV1ND,POL_HV1B5,POL_HV1H2,# & POL_HV1A2,POL_HV1BR,POL_HV1MN,POL_HV1JR,POL_HV1Z2,# & POL_HV1OY,POL_HV1B1,POL_HV1N5,POL_HV1PV,POL_HV1U4,# & POL_HV1EL,POL_HV1MA)# & PIR1: (B44001,GNLJND,GNVWVL,GNVWLV,GNVWA2,GNVWH3)# & PIR2: (S63755,S63735,S63742,S54378,S63750,S63751,S63741,S63746,# & S63749,S63732,S63736,S63754,S63753,S63739,S63745,S63733,# & S63731,S63744,S63752,S63747,S63748,S63737,S63734)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPISPIETV*# SEQUENCE: FPISPIETV*# ...# >HUM126D1# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV (1582-1590)# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVJT,POLG_HCVH,POLG_HCVBK)# & PIR1: (GNWVTW,GNWVTC,GNWVCH)# & PIR2: (S18030,A45573,S40770,A61196,PC2219,S06067,A54317)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPYLVAYQA*# SEQUENCE: FPYLVAYQA*# ...# >HUM126D2# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: C. albicans 1768 aur (284-292)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPRFKFVWV*# SEQUENCE: FPRFKFVWV*# ...# >HUM126D3# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER2/neu(706-714)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,MPNQAQMRI*# SEQUENCE: MPNQAQMRI*# ...# >HUM126D4# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (208-214)# DB REFERENCE: SWISS: (TYRO_MOUSE,TYRO_HUMAN,TYRO_HUMAN,TYRO_MOUSE)# & PIR1: (YRMSCS,YRHU1)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,LPWHRLFLL*# SEQUENCE: LPWHRLFLL*# ...# >HUM126D5# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-I tax (165-173)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,WPLLPHVIF*# SEQUENCE: WPLLPHVIF*# ...# >HUM126D6# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: PAP (277-285)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,IPSYKKLIM*# SEQUENCE: IPSYKKLIM*# ...# >HUM126D7# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (156-164)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,LPFRNCPRF*# SEQUENCE: LPFRNCPRF*# ...# >HUM126D8# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp100 (198-206)# DB REFERENCE: SWISS: (PM17_BOVIN,PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A49179,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,VPLAHSSSA*# SEQUENCE: VPLAHSSSA*# ...# >HUM126D9# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b E1 (455-463)# DB REFERENCE: SWISS: (VE1_HPV6B)# & PIR1: (W1WL6)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,IPFLTKFKL*# SEQUENCE: IPFLTKFKL*# ...# >HUM126DA# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: PSA (184-192)# DB REFERENCE: SWISS: (PROS_HUMAN,PROS_HUMAN)# & PIR2: (A31567,A32297,G01551)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,HPQKVTKFM*# SEQUENCE: HPQKVTKFM*# ...# >HUM126DB# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b E1 (641-649)# DB REFERENCE: SWISS: (VE1_HPV6B,VE1_HPV07)# & PIR1: (W1WL6)# & PIR2: (S36586)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,VPGTVVRTL*# SEQUENCE: VPGTVVRTL*# ...# >HUM126DC# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: GCDFP-15 (11-19)# DB REFERENCE: SWISS: (SABP_HUMAN)# & PIR1: (SQHUAC)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,SPATLLLVL*# SEQUENCE: SPATLLLVL*# ...# >HUM126DD# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp100 (401-409)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,A41234,I38400)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,TPAEVSIVV*# SEQUENCE: TPAEVSIVV*# ...# >HUM126DE# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tyrosinase (164-162)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_CANFA,TYRO_HUMAN,TYRO_MOUSE,TYRO_MOUSE,# & TYRO_CANFA)# & PIR1: (YRHU1,YRMSCS)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,TPMFNDINI*# SEQUENCE: TPMFNDINI*# ...# >HUM126DF# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tyrosinase (264-272)# DB REFERENCE: SWISS: (TYRO_TRISI,TYRO_CHICK,TYRO_HUMAN,TYRO_CANFA,TYRO_COTJA,# & TYRO_CHICK,TYRO_HUMAN,TYRO_MOUSE,TYRO_RANNI,TYRO_CANFA,# & TYRO_COTJA,TYRO_MOUSE)# & PIR1: (YRHU1,YRMSCS)# & PIR2: (JC1392,I51169,PC4153,I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,SPASFFSSW*# SEQUENCE: SPASFFSSW*# ...# >HUM126E0# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 11 E1 (93-101)# DB REFERENCE: SWISS: (VE1_HPV11)# & PIR1: (W1WL11)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,SPISNVANA*# SEQUENCE: SPISNVANA*# ...# >HUM126E1# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HPV 6b/11 E1 (468-476)# DB REFERENCE: SWISS: (VE1_HPV6B,VE1_HPV13,VE1_HPV11,VE1_PCPV1)# & PIR1: (W1WL11,W1WL13,W1WL6,W1WLC1)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,TPKKNCIAI*# SEQUENCE: TPKKNCIAI*# ...# >HUM126E2# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HPV16 E1 (107-115)# DB REFERENCE: SWISS: (VE1_HPV35,VE1_HPV31)# & PIR1: (W1WL31,W1WL35)# & PIR2: (S36523)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,SPRLKAICI*# SEQUENCE: SPRLKAICI*# ...# >HUM126E3# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (160-168)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547,B45714)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,SPPITWPLL*# SEQUENCE: SPPITWPLL*# ...# >HUM126E4# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (348-356)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,SPSCPLERF*# SEQUENCE: SPSCPLERF*# ...# >HUM126E5# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (261-269)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547,B45714)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,CPKDGQPSL*# SEQUENCE: CPKDGQPSL*# ...# >HUM126E6# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MART1 (1-9)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,MPREDAHFI*# SEQUENCE: MPREDAHFI*# ...# >HUM126E7# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-I tax (213-221)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,LPTTLFQPV*# SEQUENCE: LPTTLFQPV*# ...# >HUM126E8# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp100 (520-528)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,I38400,A41234)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,LPKEACMEI*# SEQUENCE: LPKEACMEI*# ...# >HUM126E9# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-I tax (101-109)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,IPPSFLQAM*# SEQUENCE: IPPSFLQAM*# ...# >HUM126EA# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tyrosinase (430-438)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_MOUSE,TYRO_MOUSE,TYRO_HUMAN)# & PIR1: (YRHU1,YRMSCS)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,IPLYRNGDF*# SEQUENCE: IPLYRNGDF*# ...# >HUM126EB# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (351-359)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,CPLERFAEL*# SEQUENCE: CPLERFAEL*# ...# >HUM126EC# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp100 (282-290)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A53668,I38400)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,EPGPVTAQV*# SEQUENCE: EPGPVTAQV*# ...# >HUM126ED# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HPV18 El (97-105)# DB REFERENCE: SWISS: (VE1_HPV18)# & PIR1: (W1WL18)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,SPLGERLEV*# SEQUENCE: SPLGERLEV*# ...# >HUM126EE# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (284-292)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN,PM17_BOVIN)# & PIR2: (A49179,A53668,I38400,A41234)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,GPVTAQVVL*# SEQUENCE: GPVTAQVVL*# ...# >HUM126EF# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b/11 E1 (118-126)# DB REFERENCE: SWISS: (VE1_HPV6B,VE1_HPV11)# & PIR1: (W1WL6,W1WL11)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,QPKKVKRRL*# SEQUENCE: QPKKVKRRL*# ...# >HUM126F0# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,IPIPSSWAI*# SEQUENCE: IPIPSSWAI*# ...# >HUM126F1# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,FPHCLAFSI*# SEQUENCE: FPHCLAFSI*# ...# >HUM126F2# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPIPSSWAI*# SEQUENCE: FPIPSSWAI*# ...# >HUM126F3# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV core (168-176) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPGCSFSIF*# SEQUENCE: FPGCSFSIF*# ...# >HUM126F4# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE2 (170-178) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,FPISHLYIL*# SEQUENCE: FPISHLYIL*# ...# >HUM126F5# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,FPKAGLLII*# SEQUENCE: FPKAGLLII*# ...# >HUM126F6# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,MPFAGLLI*# SEQUENCE: MPFAGLLI*# ...# >HUM126F7# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (208-214)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_MOUSE,TYRO_HUMAN,TYRO_MOUSE)# & PIR1: (YRMSCS,YRHU1)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPWHRLFLL*# SEQUENCE: LPWHRLFLL*# ...# >HUM126F8# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-I tax (165-173)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,WPLLPHVIF*# SEQUENCE: WPLLPHVIF*# ...# >HUM126F9# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (277-285)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,IPSYKKLIM*# SEQUENCE: IPSYKKLIM*# ...# >HUM126FA# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (156-164)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,LPFRNCPRF*# SEQUENCE: LPFRNCPRF*# ...# >HUM126FB# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (124-132)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,FPPEGVSIW*# SEQUENCE: FPPEGVSIW*# ...# >HUM126FC# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PSA (184-192)# DB REFERENCE: SWISS: (PROS_HUMAN,PROS_HUMAN)# & PIR2: (G01551,A32297,A31567)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,HPQKVTKFM*# SEQUENCE: HPQKVTKFM*# ...# >HUM126FD# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GCDFP-15 (11-19)# DB REFERENCE: SWISS: (SABP_HUMAN)# & PIR1: (SQHUAC)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,SPATLLLVL*# SEQUENCE: SPATLLLVL*# ...# >HUM126FE# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp100 (401-409)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,I38400,A41234)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,TPAEVSIVV*# SEQUENCE: TPAEVSIVV*# ...# >HUM126FF# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tyrosinase (264-272)# DB REFERENCE: SWISS: (TYRO_MOUSE,TYRO_HUMAN,TYRO_RANNI,TYRO_CHICK,TYRO_HUMAN,# & TYRO_CANFA,TYRO_COTJA,TYRO_TRISI,TYRO_CHICK,TYRO_MOUSE,# & TYRO_COTJA,TYRO_CANFA)# & PIR1: (YRMSCS,YRHU1)# & PIR2: (PC4153,I49736,I51169,JC1392)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,SPASFFSSW*# SEQUENCE: SPASFFSSW*# ...# >HUM12700# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (348-356)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,SPSCPLERF*# SEQUENCE: SPSCPLERF*# ...# >HUM12701# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (261-269)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (B45714,G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,CPKDGQPSL*# SEQUENCE: CPKDGQPSL*# ...# >HUM12702# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MART1 (1-9)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,MPREDAHFI*# SEQUENCE: MPREDAHFI*# ...# >HUM12703# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (213-221)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,LPTTLFQPV*# SEQUENCE: LPTTLFQPV*# ...# >HUM12704# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-I tax (101-109)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,IPPSFLQAM*# SEQUENCE: IPPSFLQAM*# ...# >HUM12705# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (351-359)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,CPLERFAEL*# SEQUENCE: CPLERFAEL*# ...# >HUM12706# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PSA (78-86)# DB REFERENCE: SWISS: (PROS_HUMAN,PROS_HUMAN)# & PIR2: (B31567,A31567,A32297,I52712,G01551)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,HPEDTGQVF*# SEQUENCE: HPEDTGQVF*# ...# >HUM12707# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,IPIPSSWAI*# SEQUENCE: IPIPSSWAI*# ...# >HUM12708# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPHCLAFSI*# SEQUENCE: FPHCLAFSI*# ...# >HUM12709# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPIPSSWAI*# SEQUENCE: FPIPSSWAI*# ...# >HUM1270A# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV core (168-176) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPGCSFSIF*# SEQUENCE: FPGCSFSIF*# ...# >HUM1270B# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE2 (170-178) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPISHLYIL*# SEQUENCE: FPISHLYIL*# ...# >HUM1270C# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,FPKAGLLII*# SEQUENCE: FPKAGLLII*# ...# >HUM1270D# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPFCLAFSY*# SEQUENCE: FPFCLAFSY*# ...# >HUM1270E# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,MPFAGLLI*# SEQUENCE: MPFAGLLI*# ...# >HUM1270F# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (208-214)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_MOUSE,TYRO_HUMAN,TYRO_MOUSE)# & PIR1: (YRMSCS,YRHU1)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPWHRLFLL*# SEQUENCE: LPWHRLFLL*# ...# >HUM12710# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-I tax (165-173)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,WPLLPHVIF*# SEQUENCE: WPLLPHVIF*# ...# >HUM12711# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (277-285)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,IPSYKKLIM*# SEQUENCE: IPSYKKLIM*# ...# >HUM12712# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: PAP (156-164)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPFRNCPRF*# SEQUENCE: LPFRNCPRF*# ...# >HUM12713# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp100 (198-206)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_BOVIN,PM17_HUMAN)# & PIR2: (A53668,A41234,A49179,I38400)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,VPLAHSSSA*# SEQUENCE: VPLAHSSSA*# ...# >HUM12714# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: PAP (124-132)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPPEGVSIW*# SEQUENCE: FPPEGVSIW*# ...# >HUM12715# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HPV 6b E1 (455-463)# DB REFERENCE: SWISS: (VE1_HPV6B)# & PIR1: (W1WL6)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,IPFLTKFKL*# SEQUENCE: IPFLTKFKL*# ...# >HUM12716# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PSA (184-192)# DB REFERENCE: SWISS: (PROS_HUMAN,PROS_HUMAN)# & PIR2: (G01551,A32297,A31567)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,HPQKVTKFM*# SEQUENCE: HPQKVTKFM*# ...# >HUM12717# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp100 (97-105)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,I38400,A41234)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPDGQVIWV*# SEQUENCE: LPDGQVIWV*# ...# >HUM12718# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b E1 (641-649)# DB REFERENCE: SWISS: (VE1_HPV6B,VE1_HPV07)# & PIR1: (W1WL6)# & PIR2: (S36586)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,VPGTVVRTL*# SEQUENCE: VPGTVVRTL*# ...# >HUM12719# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GCDFP-15 (11-19)# DB REFERENCE: SWISS: (SABP_HUMAN)# & PIR1: (SQHUAC)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,SPATLLLVL*# SEQUENCE: SPATLLLVL*# ...# >HUM1271A# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp100 (401-409)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,TPAEVSIVV*# SEQUENCE: TPAEVSIVV*# ...# >HUM1271B# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (164-162)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_CANFA,TYRO_MOUSE,TYRO_CANFA,TYRO_HUMAN,# & TYRO_MOUSE)# & PIR1: (YRMSCS,YRHU1)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,TPMFNDINI*# SEQUENCE: TPMFNDINI*# ...# >HUM1271C# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b/11 E1 (468-476)# DB REFERENCE: SWISS: (VE1_HPV13,VE1_HPV6B,VE1_HPV11,VE1_PCPV1)# & PIR1: (W1WL6,W1WL13,W1WLC1,W1WL11)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,TPKKNCIAI*# SEQUENCE: TPKKNCIAI*# ...# >HUM1271D# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (160-168)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547,B45714)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,SPPITWPLL*# SEQUENCE: SPPITWPLL*# ...# >HUM1271E# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (348-356)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,SPSCPLERF*# SEQUENCE: SPSCPLERF*# ...# >HUM1271F# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (261-269)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (B45714,G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,CPKDGQPSL*# SEQUENCE: CPKDGQPSL*# ...# >HUM12720# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MART1 (1-9)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,MPREDAHFI*# SEQUENCE: MPREDAHFI*# ...# >HUM12721# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV-I tax (213-221)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPTTLFQPV*# SEQUENCE: LPTTLFQPV*# ...# >HUM12722# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp100 (520-528)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,A41234,I38400)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPKEACMEI*# SEQUENCE: LPKEACMEI*# ...# >HUM12723# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp100 (545-553)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A53668,A41234)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPSPACQLV*# SEQUENCE: LPSPACQLV*# ...# >HUM12724# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HPV18 E1 (263-271)# DB REFERENCE: SWISS: (VE1_HPV18)# & PIR1: (W1WL18)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,QPFILYAHI*# SEQUENCE: QPFILYAHI*# ...# >HUM12725# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (101-109)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,IPPSFLQAM*# SEQUENCE: IPPSFLQAM*# ...# >HUM12726# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (146-154)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,VPLSEDQLL*# SEQUENCE: VPLSEDQLL*# ...# >HUM12727# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tyrosinase (456-464)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,DPDSFQDYI*# SEQUENCE: DPDSFQDYI*# ...# >HUM12728# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: PAP (351-359)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,CPLERFAEL*# SEQUENCE: CPLERFAEL*# ...# >HUM12729# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp100 (282-290)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,EPGPVTAQV*# SEQUENCE: EPGPVTAQV*# ...# >HUM1272A# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PSA (78-86)# DB REFERENCE: SWISS: (PROS_HUMAN,PROS_HUMAN)# & PIR2: (B31567,I52712,A32297,A31567,G01551)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,HPEDTGQVF*# SEQUENCE: HPEDTGQVF*# ...# >HUM1272B# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (74-82)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,GPTLIGANA*# SEQUENCE: GPTLIGANA*# ...# >HUM1272C# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Tyrosinase (383-391)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_MOUSE,TYRO_ORYLA,TYRO_MOUSE,# & TYRO_HUMAN)# & PIR1: (YRMSCS,YRHU1)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,DPIFLLHHA*# SEQUENCE: DPIFLLHHA*# ...# >HUM1272D# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (284-292)# DB REFERENCE: SWISS: (PM17_BOVIN,PM17_HUMAN,PM17_HUMAN)# & PIR2: (A49179,A53668,A41234,I38400)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,GPVTAQVVL*# SEQUENCE: GPVTAQVVL*# ...# >HUM1272E# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 11 E1 (512-520)# DB REFERENCE: SWISS: (VE1_HPV11)# & PIR1: (W1WL11)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,QPLTDAKVA*# SEQUENCE: QPLTDAKVA*# ...# >HUM1272F# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b/11 E1 (118-126)# DB REFERENCE: SWISS: (VE1_HPV6B,VE1_HPV11)# & PIR1: (W1WL11,W1WL6)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,QPKKVKRRL*# SEQUENCE: QPKKVKRRL*# ...# >HUM12730# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,IPIPSSWAI*# SEQUENCE: IPIPSSWAI*# ...# >HUM12731# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPHCLAFSI*# SEQUENCE: FPHCLAFSI*# ...# >HUM12732# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,FPIPSSWAI*# SEQUENCE: FPIPSSWAI*# ...# >HUM12733# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV core (168-176) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,FPGCSFSIF*# SEQUENCE: FPGCSFSIF*# ...# >HUM12734# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE2 (170-178) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPISHLYIL*# SEQUENCE: FPISHLYIL*# ...# >HUM12735# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPKAGLLII*# SEQUENCE: FPKAGLLII*# ...# >HUM12736# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPFCLAFSY*# SEQUENCE: FPFCLAFSY*# ...# >HUM12737# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,MPFAGLLI*# SEQUENCE: MPFAGLLI*# ...# >HUM12738# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (208-214)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN,TYRO_MOUSE,TYRO_MOUSE)# & PIR1: (YRHU1,YRMSCS)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,LPWHRLFLL*# SEQUENCE: LPWHRLFLL*# ...# >HUM12739# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (165-173)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,WPLLPHVIF*# SEQUENCE: WPLLPHVIF*# ...# >HUM1273A# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (277-285)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,IPSYKKLIM*# SEQUENCE: IPSYKKLIM*# ...# >HUM1273B# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (156-164)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,LPFRNCPRF*# SEQUENCE: LPFRNCPRF*# ...# >HUM1273C# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: PAP (124-132)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPPEGVSIW*# SEQUENCE: FPPEGVSIW*# ...# >HUM1273D# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b E1 (455-463)# DB REFERENCE: SWISS: (VE1_HPV6B)# & PIR1: (W1WL6)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,IPFLTKFKL*# SEQUENCE: IPFLTKFKL*# ...# >HUM1273E# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp100 (97-105)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,A41234,I38400)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,LPDGQVIWV*# SEQUENCE: LPDGQVIWV*# ...# >HUM1273F# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: GCDFP-15 (11-19)# DB REFERENCE: SWISS: (SABP_HUMAN)# & PIR1: (SQHUAC)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,SPATLLLVL*# SEQUENCE: SPATLLLVL*# ...# >HUM12740# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tyrosinase (164-162)# DB REFERENCE: SWISS: (TYRO_MOUSE,TYRO_HUMAN,TYRO_MOUSE,TYRO_HUMAN,TYRO_CANFA,# & TYRO_CANFA)# & PIR1: (YRMSCS,YRHU1)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,TPMFNDINI*# SEQUENCE: TPMFNDINI*# ...# >HUM12741# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (264-272)# DB REFERENCE: SWISS: (TYRO_MOUSE,TYRO_HUMAN,TYRO_RANNI,TYRO_COTJA,TYRO_COTJA,# & TYRO_CANFA,TYRO_CANFA,TYRO_TRISI,TYRO_HUMAN,TYRO_CHICK,# & TYRO_MOUSE,TYRO_CHICK)# & PIR1: (YRMSCS,YRHU1)# & PIR2: (PC4153,JC1392,I49736,I51169)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,SPASFFSSW*# SEQUENCE: SPASFFSSW*# ...# >HUM12742# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (348-356)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,SPSCPLERF*# SEQUENCE: SPSCPLERF*# ...# >HUM12743# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MART1 (1-9)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,MPREDAHFI*# SEQUENCE: MPREDAHFI*# ...# >HUM12744# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (146-154)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,VPLSEDQLL*# SEQUENCE: VPLSEDQLL*# ...# >HUM12745# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (351-359)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,CPLERFAEL*# SEQUENCE: CPLERFAEL*# ...# >HUM12746# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PSA (78-86)# DB REFERENCE: SWISS: (PROS_HUMAN,PROS_HUMAN)# & PIR2: (I52712,A31567,A32297,G01551,B31567)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,HPEDTGQVF*# SEQUENCE: HPEDTGQVF*# ...# >HUM12747# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,IPIPSSWAI*# SEQUENCE: IPIPSSWAI*# ...# >HUM12748# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPHCLAFSI*# SEQUENCE: FPHCLAFSI*# ...# >HUM12749# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPIPSSWAI*# SEQUENCE: FPIPSSWAI*# ...# >HUM1274A# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HCV core (168-176) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPGCSFSIF*# SEQUENCE: FPGCSFSIF*# ...# >HUM1274B# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE2 (170-178) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPISHLYIL*# SEQUENCE: FPISHLYIL*# ...# >HUM1274C# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,FPKAGLLII*# SEQUENCE: FPKAGLLII*# ...# >HUM1274D# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,FPFCLAFSY*# SEQUENCE: FPFCLAFSY*# ...# >HUM1274E# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesh,MPFAGLLI*# SEQUENCE: MPFAGLLI*# ...# >HUM1274F# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (208-214)# DB REFERENCE: SWISS: (TYRO_MOUSE,TYRO_HUMAN,TYRO_HUMAN,TYRO_MOUSE)# & PIR1: (YRHU1,YRMSCS)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,LPWHRLFLL*# SEQUENCE: LPWHRLFLL*# ...# >HUM12750# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-I tax (165-173)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,WPLLPHVIF*# SEQUENCE: WPLLPHVIF*# ...# >HUM12751# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PAP (156-164)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,LPFRNCPRF*# SEQUENCE: LPFRNCPRF*# ...# >HUM12752# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp100 (198-206)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN,PM17_BOVIN)# & PIR2: (A49179,I38400,A53668,A41234)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,VPLAHSSSA*# SEQUENCE: VPLAHSSSA*# ...# >HUM12753# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (124-132)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,FPPEGVSIW*# SEQUENCE: FPPEGVSIW*# ...# >HUM12754# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b E1 (455-463)# DB REFERENCE: SWISS: (VE1_HPV6B)# & PIR1: (W1WL6)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,IPFLTKFKL*# SEQUENCE: IPFLTKFKL*# ...# >HUM12755# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp100 (97-105)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,LPDGQVIWV*# SEQUENCE: LPDGQVIWV*# ...# >HUM12756# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp100 (401-409)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,TPAEVSIVV*# SEQUENCE: TPAEVSIVV*# ...# >HUM12757# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HPV 11 E1 (93-101)# DB REFERENCE: SWISS: (VE1_HPV11)# & PIR1: (W1WL11)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,SPISNVANA*# SEQUENCE: SPISNVANA*# ...# >HUM12758# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 6b/11 E1 (468-476)# DB REFERENCE: SWISS: (VE1_HPV11,VE1_PCPV1,VE1_HPV6B,VE1_HPV13)# & PIR1: (W1WL11,W1WL6,W1WLC1,W1WL13)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,TPKKNCIAI*# SEQUENCE: TPKKNCIAI*# ...# >HUM12759# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HTLV-I tax (160-168)# DB REFERENCE: SWISS: (TAT_HTL1C,TAT_HTL1A)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (B45714,G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,SPPITWPLL*# SEQUENCE: SPPITWPLL*# ...# >HUM1275A# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MART1 (1-9)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,MPREDAHFI*# SEQUENCE: MPREDAHFI*# ...# >HUM1275B# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HTLV-I tax (213-221)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,LPTTLFQPV*# SEQUENCE: LPTTLFQPV*# ...# >HUM1275C# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp100 (520-528)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,LPKEACMEI*# SEQUENCE: LPKEACMEI*# ...# >HUM1275D# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp100 (545-553)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,LPSPACQLV*# SEQUENCE: LPSPACQLV*# ...# >HUM1275E# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV18 E1 (263-271)# DB REFERENCE: SWISS: (VE1_HPV18)# & PIR1: (W1WL18)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,QPFILYAHI*# SEQUENCE: QPFILYAHI*# ...# >HUM1275F# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HTLV-I tax (101-109)# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,IPPSFLQAM*# SEQUENCE: IPPSFLQAM*# ...# >HUM12760# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (433-441)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A53668,I38400)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,IPEPEGPDA*# SEQUENCE: IPEPEGPDA*# ...# >HUM12761# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PAP (351-359)# DB REFERENCE: SWISS: (PPAP_HUMAN)# & PIR1: (JH0610)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,CPLERFAEL*# SEQUENCE: CPLERFAEL*# ...# >HUM12762# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp100 (282-290)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A53668,I38400)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,EPGPVTAQV*# SEQUENCE: EPGPVTAQV*# ...# >HUM12763# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (74-82)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,GPTLIGANA*# SEQUENCE: GPTLIGANA*# ...# >HUM12764# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (383-391)# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_MOUSE,TYRO_HUMAN,TYRO_ORYLA,# & TYRO_MOUSE)# & PIR1: (YRHU1,YRMSCS)# & PIR2: (I49736)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,DPIFLLHHA*# SEQUENCE: DPIFLLHHA*# ...# >HUM12765# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HPV 11 E1 (512-520)# DB REFERENCE: SWISS: (VE1_HPV11)# & PIR1: (W1WL11)# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,QPLTDAKVA*# SEQUENCE: QPLTDAKVA*# ...# >HUM12766# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,IPIPSSWAI*# SEQUENCE: IPIPSSWAI*# ...# >HUM12767# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPHCLAFSI*# SEQUENCE: FPHCLAFSI*# ...# >HUM12768# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV env (313-321) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,FPIPSSWAI*# SEQUENCE: FPIPSSWAI*# ...# >HUM12769# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV core (168-176) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,FPGCSFSIF*# SEQUENCE: FPGCSFSIF*# ...# >HUM1276A# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE2 (170-178) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPISHLYIL*# SEQUENCE: FPISHLYIL*# ...# >HUM1276B# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,FPKAGLLII*# SEQUENCE: FPKAGLLII*# ...# >HUM1276C# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (541-549) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,FPFCLAFSY*# SEQUENCE: FPFCLAFSY*# ...# >HUM1276D# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE3 (196-204) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: sidney96b# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,MPFAGLLII*# SEQUENCE: MPFAGLLII*# ...# >HUM1276E# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1JR,POL_HV1MN,POL_HV1BR,POL_HV1A2,# & POL_HV1Y2,POL_HV1ND,POL_HV1RH,POL_HV1H2,POL_HV1MA,# & POL_HV1PV,POL_HV1N5,POL_HV1U4,POL_SIVCZ,POL_HV1B5,# & POL_HV1Z2,POL_HV1OY,POL_HV1EL)# & PIR1: (GNVWA2,GNLJND,GNVWVL,GNVWH3,GNLJSI,GNVWLV,B44001)# & PIR2: (S32081,S32056,S32050,S32138,S32091,S32049,S32131,S32134,# & S32071,S32119,S32064,S32057,A47175,S32083,C47330,S32098,# & S32137,S32055,S32126,S32062,S32122,S32079,S54378,S32065,# & S32072,S32089,S32093,S32152,S32151,S32060,S32068,S32132,# & S32139,S32048,S32095,F47330,S32074,S32097,S32088,S32127,# & S32159,S32051,S32063,S32087,S32053,S32157,S32129,B47175,# & S32133,B47330,A47330,D47330,S32058,S32075,S32082,S32076,# & S32078,S32117,S32135,S32061,S32084,S32070,S32085,S32136,# & S32047,S32096,S43127,S32128,S32118,S32077,S32080,S32160,# & E47330,S32066,S32086,S32140,S32120,S32094,S32054,S32052,# & S32073,S32090,S32059,S32069,S32067)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,LYVGSDLEI*# SEQUENCE: LYVGSDLEI*# ...# >HUM1276F# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,LFVGSDLEI*# SEQUENCE: LFVGSDLEI*# ...# >HUM12770# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,LWVGSDLEI*# SEQUENCE: LWVGSDLEI*# ...# >HUM12771# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,LYVGSDLEF*# SEQUENCE: LYVGSDLEF*# ...# >HUM12772# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,LYVGSDLEW*# SEQUENCE: LYVGSDLEW*# ...# >HUM12773# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,LYVGSDLEL*# SEQUENCE: LYVGSDLEL*# ...# >HUM12774# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 gp41 (583-591)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1S1,ENV_HV1EL,ENV_HV1Z2,ENV_HV1J3,# & ENV_HV1OY,ENV_HV1Z6,ENV_HV1C4,ENV_HV1H3,ENV_HV1B1,# & ENV_HV1B8,ENV_HV1ZH,ENV_HV1BR,ENV_HV1MF,ENV_HV1H2,# & ENV_HV1MN,ENV_HV1BN)# & PIR1: (VCLJH3,VCLJBR,VCLJMN,VCLJH4,VCLJZR,VCLJLV,A44963,# & VCLJVL)# & PIR2: (S70417,S21992,S70421,S70424,S21994,S70419,S54384,S70418,# & S70422,S22000,S21998,S22002,S21990,S22006,S70420,S70425,# & S70423,S21996,S22004,B41621)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,RYLKDQQLL*# SEQUENCE: RYLKDQQLL*# ...# >HUM12775# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: Tyrosinase (206-214)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,AFLDWHRLF*# SEQUENCE: AFLDWHRLF*# ...# >HUM12776# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Tyrosinase (206-215)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AFLDWHRLFL*# SEQUENCE: AFLDWHRLFL*# ...# >HUM12777# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJ8,POLG_HCVBK,POLG_HCVJA,POLG_HCV1)# & PIR1: (GNWVTC,GNWVJ8,GNWVCJ,GNWVC3)# & PIR2: (S40770)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AYMSKAHGI*# SEQUENCE: AYMSKAHGI*# ...# >HUM12778# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (TAT_HV1A2,TAT_HV1A2)# & PIR2: (S02462)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,CFTRKGLGI*# SEQUENCE: CFTRKGLGI*# ...# >HUM12779# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1RH,POL_HV1Y2,POL_HV1ND,POL_HV1MA,# & POL_HV1MN,POL_HV1N5,POL_HV1B1,POL_HV1EL,POL_HV1B5,# & POL_HV1OY,POL_HV1JR,POL_HV1Z2,POL_HV1H2,POL_HV1U4,# & POL_HV1PV,POL_HV1A2,POL_SIVCZ)# & PIR1: (GNVWVL,GNVWLV,B44001,GNLJSI,GNVWH3,GNLJND,GNVWA2)# & PIR2: (S32050,S32057,S32092,S32064,S32097,S32048,S32095,S32139,# & E47330,S32080,S32140,S32094,S32069,S32054,S32090,S32047,# & S32060,S32068,S32132,S32065,S32126,S32135,S32133,B47175,# & B47330,A47330,S32159,S32118,S32066,S32056,S32062,S32098,# & S32055,S54378,S43127,S32136,S32067,S32152,S32151,S32072,# & S32089,S32079,S32093,S32083,S32122,S32119,D47330,S32120,# & S32077,S32160,S32086,S32052,S32073,S32059,S32058,S32075,# & S32076,S32078,S32117,S32070,S32061,S32085,S32084,S32063,# & S32051,S32053,S32157,S32134,S32138,S32081,S32074,S32127,# & A47175,S32091,S32088,F47330,S32082,S32087,S32049,S32071,# & C47330)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,DFWEVQLGI*# SEQUENCE: DFWEVQLGI*# ...# >HUM1277A# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573,PN0677)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,EYIVLLFLL*# SEQUENCE: EYIVLLFLL*# ...# >HUM1277B# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1RH)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,FFYCNTTQL*# SEQUENCE: FFYCNTTQL*# ...# >HUM1277C# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1RH)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,FYCNTTQLF*# SEQUENCE: FYCNTTQLF*# ...# >HUM1277D# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: PIR2: (PC1185,PC1187,S24106,S18030,PC1196,PC1190,PC1189,PC1188,# & S24070,PC1184,S32742,PC1192,PC1193,S24077,S24094,PC1186,# & S18032,PC1191,S24105,PC1195,PC1182,PC1194)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,HYAPQPCGI*# SEQUENCE: HYAPQPCGI*# ...# >HUM1277E# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573,S24069,S24107,S24073,B48776)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,HYAPRQCGI*# SEQUENCE: HYAPRQCGI*# ...# >HUM1277F# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1OY,POL_HV1U4,POL_HV1H2,POL_HV1A2,# & POL_SIVCZ,POL_HV1PV,POL_HV1Z2,POL_HV1JR,POL_HV1B5,# & POL_HV1B1,POL_HV1BR,POL_HV1ND,POL_HV1RH,POL_HV1MA,# & POL_HV1EL)# & PIR1: (GNLJSI,GNVWLV,GNVWH3,GNVWA2,GNLJND,GNVWVL)# & PIR2: (S32136,S32048,B47330,S32098,S32066,S32074,S32049,S32047,# & E47330,S32096,S32160,S32072,S32067,D47330,S32137,S43127,# & S32089,S32152,S32075,S32076,S32078,S32070,S32157,S32051,# & S32092,S32128,S32050,S32139,A47330,S32135,S32129,S32159,# & S32133,B47175,S32090,S32069,S32132,S32068,S32126,S54378,# & S32091,A47175,S32071,S32093,S32079,S32131,S32134,S32138,# & S32080)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,IFQSSMTKI*# SEQUENCE: IFQSSMTKI*# ...# >HUM12780# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VPR_HV1BR,VPR_HV1JR,VPR_HV1B1,VPR_HV1RH,VPR_HV1B5,# & VPR_HV1N5,VPR_HV1SC,VPR_HV1Z2,VPR_HV1Y2,VPR_HV1EL,# & VPR_HV1OY,VPR_HV1MN,VPR_HV1MA,VPR_HV1A2)# & PIR1: (D44001)# & PIR2: (S54380)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,IYETYGDTW*# SEQUENCE: IYETYGDTW*# ...# >HUM12781# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,IYIGPGRAF*# SEQUENCE: IYIGPGRAF*# ...# >HUM12782# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV2CA,GAG_HV1H2,GAG_HV2NZ,GAG_HV1B5,# & GAG_HV1J3,GAG_HV1BR,GAG_HV1A2,GAG_HV1PV)# & PIR1: (FOVWH3,FOLJCA,FOVWLV,FOVWA2,FOVWVL)# & PIR3: (S33979)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,KYKLKHIVW*# SEQUENCE: KYKLKHIVW*# ...# >HUM12783# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,LYKYKVIKI*# SEQUENCE: LYKYKVIKI*# ...# >HUM12784# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVJA,POLG_HCVBK,POLG_HCVJT,POLG_HCV1)# & PIR1: (GNWVCJ,GNWVTW,GNWVC3,GNWVTC)# & PIR2: (S40770,A45573,S18030)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,MYTNVDQDL*# SEQUENCE: MYTNVDQDL*# ...# >HUM12785# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1N5,ENV_HV1Y2,ENV_HV1C4,ENV_HV1S3,ENV_HV1A2)# & PIR1: (H44001,VCLJH4,VCLJA2)# & PIR2: (S35843,A41621,B41621,S35823,S35868,C41621,S35844,# & A46410)# & PIR3: (S13289)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,NFTNNAKTI*# SEQUENCE: NFTNNAKTI*# ...# >HUM12786# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1JR)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,NYTNTIYTL*# SEQUENCE: NYTNTIYTL*# ...# >HUM12787# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1Y2,POL_HV1A2,POL_HV1B1,POL_HV1Z2,# & POL_HV1JR,POL_HV1RH,POL_HV1MN,POL_HV1OY,POL_HV1H2,# & POL_HV1U4,POL_HV1B5,POL_HV1N5,POL_HV1PV,POL_HV1EL,# & POL_SIVCZ,POL_HV1MA,POL_HV1ND)# & PIR1: (GNVWA2,GNLJND,GNLJSI,GNVWLV,GNVWVL,GNVWH3,B44001)# & PIR2: (S43127,B47175,A47175,S54378)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,PFLWMGYEL*# SEQUENCE: PFLWMGYEL*# ...# >HUM12788# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1JR,GAG_HV1U4,GAG_HV1MN,GAG_HV1ND,# & GAG_HV1W2,GAG_HV1B5,GAG_HV1RH,GAG_HV1MA,GAG_HV1C4,# & GAG_SIVCZ,GAG_HV1H2,GAG_HV1Z2,GAG_HV1OY,GAG_HV1J3,# & GAG_HV1A2,GAG_HV1BR,GAG_HV1EL,GAG_HV1B1,GAG_HV1Y2)# & PIR1: (A44001,FOVWH4,FOVWLV,FOVWA2,A38068,FOLJSI,FOLJND,FOVWVL,# & FOVWH3)# & PIR2: (S60699,S60698,S52929,S60700,S60697,S60702,S60708,S60703,# & S54377,S60704)# & PIR3: (S33979)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,PFRDYVDRF*# SEQUENCE: PFRDYVDRF*# ...# >HUM12789# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVTW,POLG_HCVJT,POLG_HCVJA)# & PIR1: (GNWVTC,GNWVTW,GNWVCJ)# & PIR2: (A45573,S18030)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,PYIEQGMQL*# SEQUENCE: PYIEQGMQL*# ...# >HUM1278A# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VPR_HV1Z2,VPR_HV1JR,VPR_HV1RH,VPR_HV1N5,VPR_HV1SC,# & VPR_HV1A2,VPR_HV1OY)# & PIR2: (S54380)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,PYNEWTLEL*# SEQUENCE: PYNEWTLEL*# ...# >HUM1278B# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1B1,POL_HV1JR,POL_HV1BR,POL_HV1Y2,# & POL_HV1A2,POL_SIVAI,POL_HV1OY,POL_HV1N5,POL_HV1MN,# & POL_HV1PV,POL_HV1MA,POL_HV1H2,POL_HV1U4,POL_HV1B5)# & PIR1: (GNVWA2,GNVWH3,GNVWLV,GNVWVL,B44001)# & PIR2: (S32072,S32134,S32081,S32137,D47330,S32122,S32119,S32152,# & S32089,S32082,S32074,S32050,S32093,S46347,S32085,S32084,# & S46354,S32117,S32058,S32091,S32071,S32095,S32097,S32051,# & A47175,S32151,S32128,S32139,S32092,S32120,S32090,S32086,# & S32069,S32059,S32135,S32159,S32080,S32087,C47330,S32088,# & S32048,S32118,S32136,S32062,S32094,S32047,S32140,S32049,# & S32066,S32098,F47330,S32138,S32131,S32126,B47175,S32132,# & S32160,S32067,S32096,B47330,S32065,E47330,S32063,S32061,# & S32073,S32068,S32133,S32129,A47330,S32079,S32127,S32083,# & S32070,S32078,S32076,S32075,S32157)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,PYNTPVFAI*# SEQUENCE: PYNTPVFAI*# ...# >HUM1278C# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1A2)# & PIR1: (GNVWA2)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,QYDQIPVEI*# SEQUENCE: QYDQIPVEI*# ...# >HUM1278D# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVJ8,POLG_HCVH,POLG_HCVJT,POLG_HCV1,# & POLG_HCVJ6,POLG_HCVBK,POLG_HCVJA)# & PIR1: (GNWVC3,GNWVTC,GNWVCJ,GNWVCH,GNWVTW,GNWVJ8)# & PIR2: (PS0326,S40770,S18030,JQ1303,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,QYLAGLSTL*# SEQUENCE: QYLAGLSTL*# ...# >HUM1278E# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VIF_HV1B5,VIF_HV1ND,VIF_HV1N5,VIF_HV1OY,VIF_HV1B1,# & VIF_HV1A2,VIF_HV1NA)# & PIR1: (ASLJND,ASLJNA,ASLJO1,ASLJS3)# & PIR2: (S42997,S43005,S42941,S42977,S42946,S42975,S42998,S42969,# & S42954,S42958,S42964,S42944,S42952,S42957,S42974,S42995,# & S42945,S43006,S42959,S42973,S42949,S42942,S42960,S42990,# & S42953)# & PIR3: (S33981)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,QYLALAALI*# SEQUENCE: QYLALAALI*# ...# >HUM1278F# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1OY,POL_HV1Y2,POL_SIVCZ,POL_HV1U4,POL_HV1A2,# & POL_HV1MN,POL_HV1EL,POL_HV1H2,POL_HV1BR,POL_HV1B1,# & POL_HV1B5,POL_HV1PV,POL_HV1Z2,POL_HV1N5,POL_HV1JR,# & POL_HV1RH,POL_HV1ND,POL_HV1MA)# & PIR1: (GNVWVL,GNLJND,GNVWH3,GNLJSI,B44001,GNVWA2,GNVWLV)# & PIR2: (S43127,S32070,S32054,S32060,S32129,S32133,S32062,S32094,# & S32049,S32097,S32091,S32135,S32090,S32069,S32128,S32051,# & S32134,S32137,F47330,S32131,B47330,S32126,D47330,S32160,# & S32138,S32061,S32078,S32079,S32084,S32059,A47175,S32095,# & S32136,S32048,S32118,S32088,S32080,S32082,S32050,S32072,# & S32093,S32074,B47175,S32132,S32055,S32065,S32067,S32096,# & E47330,A47330,S32073,S32068,S32063,S32098,S32087,C47330,# & S32053,S32064,S32157,S32075,S32076,S32057,S32083,S32127,# & S54378,S32117,S32071,S32052,S32047,S32140,S32066,S32058,# & S32077,S32056,S32092,S32151,S32139,S32159,S32085,S32120,# & S32086,S32089,S32152,S32119,S32122,S32081)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,QYNVLPQGW*# SEQUENCE: QYNVLPQGW*# ...# >HUM12790# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1N5,GAG_HV1A2,GAG_HV1BR,GAG_HV1W2,# & GAG_HV1PV,GAG_HV1H2,GAG_HV1B5,GAG_HV1JR,GAG_HV1C4)# & PIR1: (FOVWA2,FOVWVL,FOVWLV,FOVWH3,FOVWH4)# & PIR3: (S33979)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,RFAVNPGLL*# SEQUENCE: RFAVNPGLL*# ...# >HUM12791# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJT)# & PIR1: (GNWVTC)# & PIR2: (PQ0250,PQ0251,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,RYAPACRPL*# SEQUENCE: RYAPACRPL*# ...# >HUM12792# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1S3,ENV_HV1A2,ENV_HV1RH,ENV_HV1W1,ENV_HV1ND,# & ENV_HV1W2,ENV_HV1Y2,ENV_HV1SC)# & PIR1: (H44001,VCLJ3W,VCLJND,VCLJSC,VCLJA2)# & PIR2: (C41621,A41621)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,RYLRDQQLL*# SEQUENCE: RYLRDQQLL*# ...# >HUM12793# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1S3,ENV_HV1MA)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,SFNCRGEFF*# SEQUENCE: SFNCRGEFF*# ...# >HUM12794# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1EL,POL_HV1BR,POL_HV1PV,POL_HV1B5,# & POL_HV1JR,POL_HV1A2)# & PIR1: (GNVWVL,GNVWA2,GNVWLV,GNVWH3)# & PIR2: (S63733,S63755,S63742,S63738,S63744,S63735,S63756)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,SFNFPQITL*# SEQUENCE: SFNFPQITL*# ...# >HUM12795# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# & PIR2: (S22004,S70419,S22006,S70420)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,SYRRLRDLL*# SEQUENCE: SYRRLRDLL*# ...# >HUM12796# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVJT,POLG_HCVTW,POLG_HCVBK)# & PIR1: (GNWVTW,GNWVCJ,GNWVTC)# & PIR2: (S18030,A45573,S40770)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,SYTWTGALI*# SEQUENCE: SYTWTGALI*# ...# >HUM12797# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1OY,POL_HV1EL,POL_HV1Y2,POL_HV1A2,POL_HV1PV,# & POL_HV1B1,POL_HV1H2,POL_HV1RH,POL_HV1BR,POL_HV1MN,# & POL_HV1B5,POL_HV1U4,POL_HV1Z2,POL_HV1N5,POL_HV1ND)# & PIR1: (GNVWH3,GNVWLV,GNVWA2,GNLJND,GNVWVL,B44001)# & PIR2: (A47175,B47175,S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,TYQIYQEPF*# SEQUENCE: TYQIYQEPF*# ...# >HUM12798# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1S1,ENV_HV1MN,ENV_HV1W1,ENV_HV1EL,ENV_HV1W2,# & ENV_HV1Y2,ENV_HV1SC,ENV_HV1Z2,ENV_HV1JR,ENV_HV1KB,# & ENV_HV1MF,ENV_HV1BR,ENV_HV1A2,ENV_HV1Z8,ENV_HV1Z6,# & ENV_HV1C4,ENV_HV1ZH,ENV_HV1BN)# & PIR1: (VCLJKB,VCLJMN,VCLJKX,A44963,VCLJ3W,VCLJH4,VCLJLV,VCLJZR,# & H44001,VCLJA2,VCLJBR,VCLJSC)# & PIR2: (B41621,S54384,S21996,S22004,S70417,S70418,S22002,S70422,# & S22000,S70419,S22006,S21998,S70425,S70420)# & PIR3: (S13289)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,WYIKIFIMI*# SEQUENCE: WYIKIFIMI*# ...# >HUM12799# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1PV,POL_HV1EL,POL_HV1A2,POL_HV1JR,# & POL_HV1B1,POL_HV1ND,POL_HV1H2,POL_HV1RH,POL_HV1MN,# & POL_HV1Z2,POL_HV1N5,POL_HV1BR,POL_HV1B5)# & PIR1: (GNLJND,GNVWH3,GNVWVL,B44001,GNVWA2,GNVWLV)# & PIR2: (A47175,S54378,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,WYQLEKEPI*# SEQUENCE: WYQLEKEPI*# ...# >HUM1279A# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJA)# & PIR1: (GNWVTC,GNWVCJ)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,YYKVFLARL*# SEQUENCE: YYKVFLARL*# ...# >HUM1279B# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1A2)# & PIR1: (GNVWA2)# ANCHOR POSITIONS: 2,9# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,YYRDNKDPL*# SEQUENCE: YYRDNKDPL*# ...# >HUM1279C# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: 2,8# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,RYPLTEGW*# SEQUENCE: RYPLTEGW*# ...# >HUM1279D# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (NEF_HV1S1,NEF_HV1JR,NEF_HV1Y2,NEF_HV1A2,NEF_HV1BN,# & NEF_HV1S3,NEF_HV1MA,NEF_HV1RH,NEF_HV1MN)# & PIR1: (I44001,ASLJBR,ASLJO2)# & PIR2: (S03246,S25937,S24985)# ANCHOR POSITIONS: 2,8# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,TFGWCFKL*# SEQUENCE: TFGWCFKL*# ...# >HUM1279E# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1RH,POL_HV1PV,POL_HV1A2,POL_HV1Y2,# & POL_HV1JR,POL_HV1ND,POL_HV1H2,POL_HV1B5,POL_HV1BR,# & POL_HV1U4,POL_HV1EL,POL_HV1OY,POL_HV1Z2,POL_HV1N5,# & POL_HV1B1)# & PIR1: (GNLJND,B44001,GNVWLV,GNVWVL,GNVWA2,GNVWH3)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,8# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,EFVNTPPL*# SEQUENCE: EFVNTPPL*# ...# >HUM1279F# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,10# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,KYWWSLLQYW*# SEQUENCE: KYWWSLLQYW*# ...# >HUM127A0# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1MA,GAG_HV1ND,GAG_HV1MN,GAG_HV1C4,GAG_HV1U4,# & GAG_HV1PV,GAG_HV1W2,GAG_HV1OY,GAG_HV1H2,GAG_HV1Z2,# & GAG_HV1BR,GAG_HV1EL,GAG_HV1A2,GAG_HV1N5,GAG_HV1Y2,# & GAG_HV1B5,GAG_HV1J3,GAG_HV1RH,GAG_SIVCZ,GAG_HV1B1,# & GAG_HV1JR)# & PIR1: (FOVWH3,A44001,FOVWH4,FOLJND,FOVWA2,FOVWLV,A38068,FOLJSI,# & FOVWVL)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: 2,10# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AFSPEVIPMF*# SEQUENCE: AFSPEVIPMF*# ...# >HUM127A1# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# & PIR2: (S60538)# ANCHOR POSITIONS: 2,10# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesl,QFGNNKTIVF*# SEQUENCE: QFGNNKTIVF*# ...# >HUM127A2# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1OY,POL_HV1N5,POL_HV1Z2,POL_HV1B5,POL_HV1BR,# & POL_HV1U4,POL_HV1H2,POL_HV1JR,POL_HV1MA,POL_SIVCZ,# & POL_HV1B1,POL_HV1PV,POL_HV1RH,POL_HV1A2,POL_HV1EL,# & POL_HV1Y2,POL_HV1ND)# & PIR1: (GNVWLV,GNVWVL,GNVWA2,GNVWH3,GNLJND,GNLJSI,B44001)# & PIR2: (A47175,S54378,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,11# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesh,EYWQATWIPEW*# SEQUENCE: EYWQATWIPEW*# ...# >HUM127A3# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1A2,POL_HV1N5,POL_HV1Y2,POL_HV1PV,# & POL_SIVCZ,POL_HV1B1,POL_HV1ND,POL_HV1H2,POL_HV1JR,# & POL_HV1MN,POL_HV1BR,POL_HV1B5)# & PIR1: (GNVWA2,GNVWH3,GNLJSI,GNLJND,B44001,GNVWLV,GNVWVL)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,11# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,AYFLLKLAGRW*# SEQUENCE: AYFLLKLAGRW*# ...# >HUM127A4# MHC MOLECULE: HLA-A24(A*2402), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VIF_HV1A2)# & PIR1: (ASLJO1)# ANCHOR POSITIONS: 2,11# REFERENCES: ibe96a# COMMENT:# SUMMARY: HLA-A24,actunkn,bindyesm,CFSESAIKNAI*# SEQUENCE: CFSESAIKNAI*# ...# >HUM127A5# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA4# DB REFERENCE: SWISS: (EBN4_EBV)# & PIR1: (QQBE24)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,AVFDRKSDAK*# SEQUENCE: AVFDRKSDAK*# ...# >HUM127A6# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV BARF1# DB REFERENCE: SWISS: (BRF1_EBV)# & PIR1: (QQBE48)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,VAVDLSLPK*# SEQUENCE: VAVDLSLPK*# ...# >HUM127A7# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,GVFVYGGSK*# SEQUENCE: GVFVYGGSK*# ...# >HUM127A8# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HPV16 E6# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,LLIRCINCQK*# SEQUENCE: LLIRCINCQK*# ...# >HUM127A9# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HPV18 E6# DB REFERENCE: SWISS: (VE6_HPV18)# & PIR1: (W6WL18)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,SVYGDTLEK*# SEQUENCE: SVYGDTLEK*# ...# >HUM127AA# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HPV18 E6# DB REFERENCE: SWISS: (VE6_HPV18)# & PIR1: (W6WL18)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,SIPHAACHK*# SEQUENCE: SIPHAACHK*# ...# >HUM127AB# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/Competition/CTL assays# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1JR,POL_HV1PV,POL_HV1RH,POL_HV1ND,POL_HV1A2,# & POL_HV1OY,POL_HV1BR,POL_HV1Z2,POL_HV1MN,POL_HV1H2,# & POL_HV1EL,POL_HV1MA,POL_HV1B5,POL_HV1B1)# & PIR1: (GNLJND,GNVWLV,GNVWVL,GNVWH3,GNVWA2)# & PIR2: (B47175,S32160,S32092,S32070,S43127,S32134,S32137,S32051,# & S32090,S32076,S32157,S32047,S32066,S32050,S32093,S32072,# & S32074,S32096,S32067,S32091,S32069,S32135,S32075,S32068,# & A47175,E47330,S32098,S32049,D47330,B47330,S32126,S32136,# & S32048,S32080,S32138,S32078,S32079,S32159,S32139,S32071,# & S54378,A47330,S32089)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a,threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesh,AIFQSSMTK*# SEQUENCE: AIFQSSMTK*# ...# >HUM127AC# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: p53# DB REFERENCE: SWISS: (P53_RAT,P53_BOVIN,P53_MESAU,P53_HUMAN,P53_RAT,P53_MOUSE,# & P53_SHEEP,P53_HUMAN,P53_MESAU,P53_MOUSE,P53_CERAE,# & P53_CERAE,P53_CRIGR,P53_SHEEP)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S51648,JH0633,S02192,JC6176,S06594,S38824,JC6193)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,RVRAMAIYK*# SEQUENCE: RVRAMAIYK*# ...# >HUM127AD# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: p53# DB REFERENCE: SWISS: (P53_MESAU,P53_RAT,P53_CERAE,P53_CRIGR,P53_CERAE,# & P53_MOUSE,P53_RAT,P53_MESAU,P53_HUMAN,P53_HUMAN,# & P53_MOUSE,P53_FELCA,P53_FELCA)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S06594,S38824,JC6193,JH0633,JC6176,S02192)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,ELNEALELK*# SEQUENCE: ELNEALELK*# ...# >HUM127AE# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: alpha2m# DB REFERENCE: SWISS: (A2MG_HUMAN)# & PIR1: (MAHU)# & PIR2: (JC5143)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,TITKLSFVK*# SEQUENCE: TITKLSFVK*# ...# >HUM127AF# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: actin binding protein# DB REFERENCE: SWISS: (ABP2_HUMAN,ABP2_HUMAN)# & PIR2: (A37098)# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,SVFVDSLTK*# SEQUENCE: SVFVDSLTK*# ...# >HUM127B0# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,AVTDFSVIK*# SEQUENCE: AVTDFSVIK*# ...# >HUM127B1# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,IATDFSVIK*# SEQUENCE: IATDFSVIK*# ...# >HUM127B2# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/cytotoxicity# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,IVADFSVIK*# SEQUENCE: IVADFSVIK*# ...# >HUM127B3# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,IVTAFSVIK*# SEQUENCE: IVTAFSVIK*# ...# >HUM127B4# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,IVTDASVIK*# SEQUENCE: IVTDASVIK*# ...# >HUM127B5# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesu,IVTDFAVIK*# SEQUENCE: IVTDFAVIK*# ...# >HUM127B6# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,IVTDFSAIK*# SEQUENCE: IVTDFSAIK*# ...# >HUM127B7# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,IVTDFSVAK*# SEQUENCE: IVTDFSVAK*# ...# >HUM127B8# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,AAFDRKSDAK*# SEQUENCE: AAFDRKSDAK*# ...# >HUM127B9# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,AVADRKSDAK*# SEQUENCE: AVADRKSDAK*# ...# >HUM127BA# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,AVFARKSDAK*# SEQUENCE: AVFARKSDAK*# ...# >HUM127BB# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,AVFDAKSDAK*# SEQUENCE: AVFDAKSDAK*# ...# >HUM127BC# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,AVFDRASDAK*# SEQUENCE: AVFDRASDAK*# ...# >HUM127BD# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: refolding/CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,AVFDRKADAK*# SEQUENCE: AVFDRKADAK*# ...# >HUM127BE# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,AVFDRKSAAK*# SEQUENCE: AVFDRKSAAK*# ...# >HUM127BF# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EBV EBNA4 homologue# ANCHOR POSITIONS: ?# REFERENCES: zhang96a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,AVFDRKSDAA*# SEQUENCE: AVFDRKSDAA*# ...# >HUM127C0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: Infl. MP (58-68) homologue K62# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GILGFVKTLTV*# SEQUENCE: GILGFVKTLTV*# ...# >HUM127C1# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CS (1-20)# DB REFERENCE: SWISS: (CSP_PLAFO,CSP_PLARE,CSP_PLAFT,CSP_PLAFW,CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (A54533,S05428,A54529,A39756)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,MMRKLAILSVSSFLFVEALF*# SEQUENCE: MMRKLAILSVSSFLFVEALF*# ...# >HUM127C2# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum CS (6-25)# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLAFO,CSP_PLAFW,CSP_PLAFT,CSP_PLARE)# & PIR1: (OZZQAF)# & PIR2: (A54529,A54533,A39756,S05428)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AILSVSSFLFVEALFQEYQC*# SEQUENCE: AILSVSSFLFVEALFQEYQC*# ...# >HUM127C3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CS (46-65)# DB REFERENCE: SWISS: (CSP_PLARE,CSP_PLAFW,CSP_PLAFT,CSP_PLAFL,CSP_PLAFA,# & CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (S05428,A54529,B29795,A29795,A54533,A39756)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,NLYNELEMNYYGKQENWYSL*# SEQUENCE: NLYNELEMNYYGKQENWYSL*# ...# >HUM127C4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CS (56-75)# DB REFERENCE: SWISS: (CSP_PLAFL,CSP_PLAFW,CSP_PLAFT,CSP_PLAFO,CSP_PLAFA,# & CSP_PLARE)# & PIR1: (OZZQAF)# & PIR2: (A54529,S05428,A29795,A39756,B29795,A54533)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YGKQENWYSLKKNSRSLGEN*# SEQUENCE: YGKQENWYSLKKNSRSLGEN*# ...# >HUM127C5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CS (333-352)# DB REFERENCE: SWISS: (CSP_PLAFA)# & PIR1: (OZZQAF)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,QYLKKIKNSISTEWSPCSVT*# SEQUENCE: QYLKKIKNSISTEWSPCSVT*# ...# >HUM127C6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CS (1-10)# DB REFERENCE: SWISS: (CSP_PLAFO,CSP_PLAFT,CSP_PLAFW,CSP_PLAFA,CSP_PLARE)# & PIR1: (OZZQAF)# & PIR2: (A54529,A39756,S05428,A54533)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,MMRKLAILSV*# SEQUENCE: MMRKLAILSV*# ...# >HUM127C7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum CS (1-9)# DB REFERENCE: SWISS: (CSP_PLARE,CSP_PLAFA,CSP_PLAFW,CSP_PLAFT,CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (A54529,S05428,A54533,A39756)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,MMRKLAILS*# SEQUENCE: MMRKLAILS*# ...# >HUM127C8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum CS (54-65)# DB REFERENCE: SWISS: (CSP_PLAFW,CSP_PLAFT,CSP_PLAFO,CSP_PLAFA,CSP_PLARE,# & CSP_PLAFL)# & PIR1: (OZZQAF)# & PIR2: (B29795,A54529,A54533,S05428,A29795,A39756)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,NYYGKQENWYSL*# SEQUENCE: NYYGKQENWYSL*# ...# >HUM127C9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CS (55-65)# DB REFERENCE: SWISS: (CSP_PLAFT,CSP_PLAFW,CSP_PLAFL,CSP_PLAFA,CSP_PLARE,# & CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (B29795,A54533,S05428,A29795,A39756,A54529)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YYGKQENWYSL*# SEQUENCE: YYGKQENWYSL*# ...# >HUM127CA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CS (56-65)# DB REFERENCE: SWISS: (CSP_PLAFW,CSP_PLARE,CSP_PLAFL,CSP_PLAFA,CSP_PLAFO,# & CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (A54533,A54529,B29795,A29795,S05428,A39756)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,YGKQENWYSL*# SEQUENCE: YGKQENWYSL*# ...# >HUM127CB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CS (333-342)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,QYLKKIKNSL*# SEQUENCE: QYLKKIKNSL*# ...# >HUM127CC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CS (333-342)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KYLKKIKNSL*# SEQUENCE: KYLKKIKNSL*# ...# >HUM127CD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CS (334-342)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,YLKKIKNSL*# SEQUENCE: YLKKIKNSL*# ...# >HUM127CE# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CS (333-342)# DB REFERENCE: SWISS: (CSP_PLAFO)# & PIR2: (S05428)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,EYLNKIQNSL*# SEQUENCE: EYLNKIQNSL*# ...# >HUM127CF# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CS (334-342)# DB REFERENCE: SWISS: (CSP_PLAFT,CSP_PLAFW)# & PIR2: (A54529,A54533,D60657,E60657)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,YLKKIQNSL*# SEQUENCE: YLKKIQNSL*# ...# >HUM127D0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CS (64-72)# DB REFERENCE: SWISS: (CSP_PLAFW,CSP_PLARE,CSP_PLAFT,CSP_PLAFL,CSP_PLAFA,# & CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (S05428,A39756,A54529,A29795,B29795,A54533)# ANCHOR POSITIONS: ?# REFERENCES: blum-tirouvanziam95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLKKNSRSL*# SEQUENCE: SLKKNSRSL*# ...# >HUM127D1# MHC MOLECULE: HLA-B44(B*4402), CLASS-1, (HUMAN)# METHOD: LDA/CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV# DB REFERENCE: PIR2: (E49253,D49253)# ANCHOR POSITIONS: ?# REFERENCES: burrows94a# COMMENT:# SUMMARY: HLA-B44,actyesu,bindyesu,FLRGRAYGL*# SEQUENCE: FLRGRAYGL*# ...# >HUM127D2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV core (131-140)# DB REFERENCE: SWISS: (POLG_HCVH8,POLG_HCVJ2,POLG_HCVHK,POLG_HCVH4,POLG_HCVTW,# & POLG_HCVJT,POLG_HCVH,POLG_HCV1,POLG_HCVTH,POLG_HCVH7,# & POLG_HCVBK,POLG_HCVE1,POLG_HCVJA)# & PIR1: (GNWVC3,GNWVTC,GNWVCH,GNWVCJ,GNWVTW)# & PIR2: (PN0677,JQ1584,S19875,S40770,JH0711,PC2060,JQ1925,S41288,# & S18032,S12707,JN0265,S18030,PC2061,PC2219,S18031,PS0388,# & A45573,PC1284,JQ1926,A44150,S21471)# & PIR3: (S32740)# ANCHOR POSITIONS: ?# REFERENCES: cerny95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ADLMGYIPLV*# SEQUENCE: ADLMGYIPLV*# ...# >HUM127D3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV core (178-187)# DB REFERENCE: SWISS: (POLG_HCVE1,POLG_HCVTH,POLG_HCV1,POLG_HCVH,POLG_HCVH7,# & POLG_HCVH8)# & PIR1: (GNWVCH,GNWVC3)# & PIR2: (S40770,S18032,S18030,JQ1584,S19875,A44150)# & PIR3: (S32740)# ANCHOR POSITIONS: ?# REFERENCES: cerny95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,LLALLSCLTV*# SEQUENCE: LLALLSCLTV*# ...# >HUM127D4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV NS3 (1406-1415)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVH)# & PIR1: (GNWVCH,GNWVC3)# ANCHOR POSITIONS: ?# REFERENCES: cerny95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,KLVALGINAV*# SEQUENCE: KLVALGINAV*# ...# >HUM127D5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV NS4 (1789-1797)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVH)# & PIR1: (GNWVCH,GNWVC3)# & PIR2: (S40770,PS0326)# ANCHOR POSITIONS: ?# REFERENCES: cerny95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,SLMAFTAAV*# SEQUENCE: SLMAFTAAV*# ...# >HUM127D6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HCV NS3 (1073-1081)# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCV1,POLG_HCVTW)# & PIR1: (GNWVTW,GNWVC3,GNWVCH)# & PIR2: (S40770)# ANCHOR POSITIONS: ?# REFERENCES: cerny95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,CINGVCWTV*# SEQUENCE: CINGVCWTV*# ...# >HUM127D7# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1/LAI nef (73-82)# DB REFERENCE: SWISS: (NEF_HV1RH,NEF_HV1ZH)# & PIR1: (B44963)# & PIR2: (S03246)# ANCHOR POSITIONS: ?# REFERENCES: couillin95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,QVPLRPMTFK*# SEQUENCE: QVPLRPMTFK*# ...# >HUM127D8# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1/LAI nef (73-82)# ANCHOR POSITIONS: ?# REFERENCES: couillin95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,QVPLRPMTSK*# SEQUENCE: QVPLRPMTSK*# ...# >HUM127D9# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Stabilization/Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV-1/LAI nef (84-92)# DB REFERENCE: SWISS: (NEF_HV1SC,NEF_HV1Z6,NEF_HV1BR,NEF_HV1PV,NEF_HV1B8,# & NEF_HV1RH,NEF_HV1BN,NEF_HV1H2,NEF_HV1B1,NEF_HV1ND,# & NEF_HV112)# & PIR1: (ASLJH3,QQLJND,ASLJ12,ASLJVL,ASLJFV,QQLJZR,ASLJBR)# & PIR2: (S03246,S03244,S43467,S24985,S03245,S03247)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: couillin95a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,AVDLSHFLK*# SEQUENCE: AVDLSHFLK*# ...# >HUM127DA# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1/LAI nef (84-92)# DB REFERENCE: SWISS: (NEF_HV1Z2,NEF_HV1S1,NEF_HV1EL,NEF_HV1OY,NEF_HV1S3,# & NEF_HV1MN)# & PIR2: (S54385)# ANCHOR POSITIONS: ?# REFERENCES: couillin95a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,ALDLSHFLK*# SEQUENCE: ALDLSHFLK*# ...# >HUM127DB# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: falk95a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPPEVNRQL*# SEQUENCE: IPPEVNRQL*# ...# >HUM127DC# MHC MOLECULE: HLA-B52(B*5201), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: falk95a# COMMENT:# SUMMARY: HLA-B52,actunkn,bindyesu,HMYIFLHTV*# SEQUENCE: HMYIFLHTV*# ...# >HUM127DD# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HSP89 alpha (201-209)# DB REFERENCE: SWISS: (HS9A_CHICK,HS9A_MOUSE,HS9A_CRIGR,HS9A_MOUSE,# & HS9A_HUMAN)# & PIR1: (HHHU86,HHCH90,HHMS86)# ANCHOR POSITIONS: 2,9# REFERENCES: fruci93b# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,RRIKEIVKK*# SEQUENCE: RRIKEIVKK*# ...# >HUM127DE# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (173-181)# DB REFERENCE: SWISS: (P53_CERAE,P53_MOUSE,P53_HUMAN,P53_BOVIN,P53_MOUSE,# & P53_HUMAN,P53_CHICK,P53_FELCA,P53_FELCA,P53_CHICK,# & P53_CANFA,P53_MESAU,P53_RAT,P53_RAT,P53_MESAU,P53_CERAE,# & P53_CRIGR)# & PIR1: (DNHU53,DNMS53)# & PIR2: (S51648,S06594,S38824,S02192,S02193,JH0633,I46226,JC6176,# & JC6193)# ANCHOR POSITIONS: 2,9# REFERENCES: fruci93b# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,VRRCPHHER*# SEQUENCE: VRRCPHHER*# ...# >HUM127DF# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, high# SOURCE: P53 (272-280)# DB REFERENCE: SWISS: (P53_CANFA,P53_SHEEP,P53_RAT,P53_MOUSE,P53_FELCA,# & P53_CHICK,P53_FELCA,P53_HUMAN,P53_XENLA,P53_XENLA,# & P53_MOUSE,P53_CERAE,P53_SALIR,P53_RAT,P53_SHEEP,# & P53_HUMAN,P53_CHICK,P53_BOVIN,P53_SALIR,P53_CERAE)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S02193,S06594,JH0631,A29376,S02192,S38824,S51648,# & JC6193)# ANCHOR POSITIONS: 2,9# REFERENCES: fruci93b# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,VRVCACPGR*# SEQUENCE: VRVCACPGR*# ...# >HUM127E0# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, little# SOURCE: P53 (334-342)# DB REFERENCE: SWISS: (P53_RAT,P53_FELCA,P53_HUMAN,P53_FELCA,P53_CERAE,# & P53_CERAE,P53_HUMAN,P53_RAT)# & PIR1: (DNHU53)# & PIR2: (S06594,S02192,JC6193)# ANCHOR POSITIONS: 2,9# REFERENCES: fruci93b# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,GRERFEMFR*# SEQUENCE: GRERFEMFR*# ...# >HUM127E1# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: Alpha chain refolding# ACTIVITY: ?# BINDING: yes, little# SOURCE: HSP89 alpha (201-209)# DB REFERENCE: SWISS: (HS9A_CRIGR,HS9A_MOUSE,HS9A_HUMAN,HS9A_CHICK,# & HS9A_MOUSE)# & PIR1: (HHHU86,HHMS86,HHCH90)# ANCHOR POSITIONS: 2,9# REFERENCES: fruci93b# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,RRIKEIVKK*# SEQUENCE: RRIKEIVKK*# ...# >HUM127E2# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: CTL assays/Competition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MAGE-3 (161-169)# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,EVDPIGHSY*# SEQUENCE: EVDPIGHSY*# ...# >HUM127E3# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-1 (161-169) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,AADPTGHSY*# SEQUENCE: AADPTGHSY*# ...# >HUM127E4# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-1 (161-169) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EADATGHSY*# SEQUENCE: EADATGHSY*# ...# >HUM127E5# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-1 (161-169) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EADPAGHSY*# SEQUENCE: EADPAGHSY*# ...# >HUM127E6# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-1 (161-169) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EADPTAHSY*# SEQUENCE: EADPTAHSY*# ...# >HUM127E7# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-1 (161-169) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EADPTGASY*# SEQUENCE: EADPTGASY*# ...# >HUM127E8# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-1 (161-169) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EADPTGHAY*# SEQUENCE: EADPTGHAY*# ...# >HUM127E9# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-2 (161-169)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889,PH1294)# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EVVPISHLY*# SEQUENCE: EVVPISHLY*# ...# >HUM127EA# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-4b (161-169)# DB REFERENCE: SWISS: (MAG4_HUMAN,MAG4_HUMAN)# & PIR2: (G01446,JC2359)# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EVDPTSNTY*# SEQUENCE: EVDPTSNTY*# ...# >HUM127EB# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-5 (161-169)# DB REFERENCE: PIR2: (PH1300,PH1299)# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EADPTSNTY*# SEQUENCE: EADPTSNTY*# ...# >HUM127EC# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MAGE-6 (161-169)# DB REFERENCE: SWISS: (MAG6_HUMAN,MAG6_HUMAN)# & PIR2: (G01445,JC2360)# ANCHOR POSITIONS: 2,9# REFERENCES: gaugler94a# COMMENT:# SUMMARY: HLA-A1,actunkn,bindyesu,EVDPIGHVY*# SEQUENCE: EVDPIGHVY*# ...# >HUM127ED# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (182-198)# DB REFERENCE: SWISS: (NEF_HV1Y2,NEF_HV112,NEF_HV1PV,NEF_HV1BR)# & PIR1: (ASLJ12,ASLJVL,ASLJFV,I44001)# & PIR2: (S03245,S03244,S43467)# & PIR3: (JQ1620,S33986)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a,hivdb97a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,EWRFDSRLAFHHVAREL*# SEQUENCE: EWRFDSRLAFHHVAREL*# ...# >HUM127EE# MHC MOLECULE: HLA-A25, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (182-198)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1BR,NEF_HV1Y2,NEF_HV112)# & PIR1: (ASLJFV,I44001,ASLJVL,ASLJ12)# & PIR2: (S03245,S43467,S03244)# & PIR3: (JQ1620,S33986)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a,hivdb97a# COMMENT:# SUMMARY: HLA-A25,actyesu,bindyesu,EWRFDSRLAFHHVAREL*# SEQUENCE: EWRFDSRLAFHHVAREL*# ...# >HUM127EF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (182-198)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1PV,NEF_HV112,NEF_HV1Y2)# & PIR1: (ASLJ12,ASLJVL,I44001,ASLJFV)# & PIR2: (S43467,S03244,S03245)# & PIR3: (S33986,JQ1620)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,EWRFDSRLAFHHVAREL*# SEQUENCE: EWRFDSRLAFHHVAREL*# ...# >HUM127F0# MHC MOLECULE: HLA-B52, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (182-198)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV112,NEF_HV1Y2,NEF_HV1PV)# & PIR1: (ASLJVL,I44001,ASLJFV,ASLJ12)# & PIR2: (S03244,S03245,S43467)# & PIR3: (S33986,JQ1620)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a# COMMENT:# SUMMARY: HLA-B52,actyesu,bindyesu,EWRFDSRLAFHHVAREL*# SEQUENCE: EWRFDSRLAFHHVAREL*# ...# >HUM127F1# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (182-198)# DB REFERENCE: SWISS: (NEF_HV1Y2,NEF_HV1PV,NEF_HV112,NEF_HV1BR)# & PIR1: (ASLJVL,ASLJFV,I44001,ASLJ12)# & PIR2: (S03244,S03245,S43467)# & PIR3: (S33986,JQ1620)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,EWRFDSRLAFHHVAREL*# SEQUENCE: EWRFDSRLAFHHVAREL*# ...# >HUM127F2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (190-198)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1BR,NEF_HV1Y2,NEF_HV1PV)# & PIR1: (ASLJVL,I44001,ASLJ12,ASLJFV)# & PIR2: (S43467,S03245,S03244)# & PIR3: (JQ1620,S33986)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a,brander95b# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,AFHHVAREL*# SEQUENCE: AFHHVAREL*# ...# >HUM127F3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (190-198)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1PV,NEF_HV1Y2,NEF_HV112)# & PIR1: (ASLJFV,I44001,ASLJ12,ASLJVL)# & PIR2: (S03244,S43467,S03245)# & PIR3: (S33986,JQ1620)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,AFHHVAREL*# SEQUENCE: AFHHVAREL*# ...# >HUM127F4# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (190-198)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV112,NEF_HV1Y2,NEF_HV1BR)# & PIR1: (ASLJVL,I44001,ASLJ12,ASLJFV)# & PIR2: (S03244,S03245,S43467)# & PIR3: (S33986,JQ1620)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,AFHHVAREL*# SEQUENCE: AFHHVAREL*# ...# >HUM127F5# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (190-198)# DB REFERENCE: SWISS: (NEF_HV1Y2,NEF_HV1PV,NEF_HV112,NEF_HV1BR)# & PIR1: (I44001,ASLJVL,ASLJFV,ASLJ12)# & PIR2: (S03245,S03244,S43467)# & PIR3: (JQ1620,S33986)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,AFHHVAREL*# SEQUENCE: AFHHVAREL*# ...# >HUM127F6# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (190-198) homologue# DB REFERENCE: SWISS: (NEF_HV1RH)# & PIR2: (S03246)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,AFHHVAREK*# SEQUENCE: AFHHVAREK*# ...# >HUM127F7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 LAI nef (190-198) homologue# DB REFERENCE: SWISS: (NEF_HV1BN,NEF_HV1S1,NEF_HV1A2,NEF_HV1B8)# & PIR1: (ASLJBR,ASLJO2,ASLJH3)# & PIR2: (S03247)# ANCHOR POSITIONS: ?# REFERENCES: hadida95a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,AFHHMAREL*# SEQUENCE: AFHHMAREL*# ...# >HUM127F8# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HTLV-1 tax# DB REFERENCE: SWISS: (TAT_HTL1A)# & PIR1: (TNLJH1)# & PIR2: (G61547)# ANCHOR POSITIONS: ?# REFERENCES: koenig93a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,VPYKRIEEL*# SEQUENCE: VPYKRIEEL*# ...# >HUM127F9# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HTLV-1 tax# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJCN,TNLJH1)# & PIR2: (G61547)# ANCHOR POSITIONS: ?# REFERENCES: koenig93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FGYPVYV*# SEQUENCE: FGYPVYV*# ...# >HUM127FA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HTLV-1 tax# DB REFERENCE: SWISS: (TAT_HTL1A,TAT_HTL1C)# & PIR1: (TNLJH1,TNLJCN)# & PIR2: (G61547)# ANCHOR POSITIONS: ?# REFERENCES: koenig93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,LFGYPVYV*# SEQUENCE: LFGYPVYV*# ...# >HUM127FB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HTLV-1 tax homologue# ANCHOR POSITIONS: ?# REFERENCES: koenig93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FGYAVYV*# SEQUENCE: FGYAVYV*# ...# >HUM127FC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HTLV-1 tax homologue# ANCHOR POSITIONS: ?# REFERENCES: koenig93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FGYPVYA*# SEQUENCE: FGYPVYA*# ...# >HUM127FD# MHC MOLECULE: HLA-A30, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 Gp160 (844-863)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1B8,ENV_HV1B1,ENV_HV1PV)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: lieberman92a# COMMENT:# SUMMARY: HLA-A30,actyesu,bindyesu,YRAIRHIPRRIRQGLERILL*# SEQUENCE: YRAIRHIPRRIRQGLERILL*# ...# >HUM127FE# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 Gp160 (788-809)# DB REFERENCE: SWISS: (ENV_HV1J3,ENV_HV1W1,ENV_HV1RH,ENV_HV1SC,ENV_HV1MF,# & ENV_HV1B1,ENV_HV1PV,ENV_HV1B8,ENV_HV1H3,ENV_HV1H2,# & ENV_HV1BR,ENV_HV1W2)# & PIR1: (VCLJVL,VCLJH3,VCLJLV,VCLJ3W,VCLJSC)# & PIR2: (S70417,S70424,S21992,S21990,S70423)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: lieberman92a,hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,IVELLGRRGWEALKYWWNLLQY*# SEQUENCE: IVELLGRRGWEALKYWWNLLQY*# ...# >HUM127FF# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 Gp160 (844-863)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1B1,ENV_HV1PV,ENV_HV1H3)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: lieberman92a,hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,YRAIRHIPRRIRQGLERILL*# SEQUENCE: YRAIRHIPRRIRQGLERILL*# ...# >HUM12800# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella capsid protein (9-22)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVM,POLS_RUBVT)# & PIR1: (GNWV77,GNWVR4,GNWVR3)# ANCHOR POSITIONS: ?# REFERENCES: lovett93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,MEDLQKALEAQSRA*# SEQUENCE: MEDLQKALEAQSRA*# ...# >HUM12801# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface antigen HBsAg (334-343)# DB REFERENCE: SWISS: (VMSA_HPBV9,VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVD,VMSA_HPBVW,# & VMSA_HPBVR,VMSA_HPBVJ,VMSA_HPBVO,VMSA_HPBVA,VMSA_HPBVP,# & VMSA_HPBVR,VMSA_HPBV0,VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVS,# & VMSA_HPBV2,VMSA_HPBVW,VMSA_HPBVN,VMSA_HPBV4,# & VMSA_HPBVI)# & PIR1: (JQ1571,SAVLN1,JQ1572,SAVLAR,JQ1577,SAVLAH,SAVLKS,SAVLJ3,# & JQ1570,SAVLBH,SAVLA,SAVLVE,JQ1578,JQ1573,SAVLA1,JQ1575,# & SAVLHV,JQ1574,SAVLJ1,SAVLAJ,SAVLVD,SAVLAD,JQ1576,# & SAVLJ2)# & PIR2: (JQ2087,JQ2078,JQ2065,JQ2053,JQ2102,JQ2077,JQ2063,JQ2089,# & S43492,JQ2114,JQ2112,JQ2060,S41869,S41870,S47411,JQ2062,# & JQ2097,JQ2115,JQ2101,JQ2116,JQ2056,JQ2052,JQ2072,JQ2046,# & S47407,JQ2083,JQ2045,S35528,S20753,JQ2108,JQ2085,JQ2098,# & JQ2067,JQ2100,JQ2057,JQ2090,JQ2076,JQ2047,JQ2061,JQ2058,# & JQ2113,JQ2110,JQ2105,S20749,JQ2079,JQ2050,JQ2070,JQ2080,# & JQ2075,JQ2069,JQ2051,JQ2104,S20745,JQ2081,JQ2048,JQ2111,# & JQ2055,JQ2059,JQ2066,JQ2068,JQ2109,JQ2073,S32202,JQ2054,# & JQ2103,JQ2106,JQ2091,JQ2092,S36654)# ANCHOR POSITIONS: ?# REFERENCES: nayersina93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,SWLSLLVPFV*# SEQUENCE: SWLSLLVPFV*# ...# >HUM12802# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hepatitis B surface antigen HBsAg (335-344)# DB REFERENCE: SWISS: (VMSA_HPBVW,VMSA_HPBV4,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBVA,# & VMSA_HPBVI,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVZ,VMSA_HPBV0,# & VMSA_HPBV9,VMSA_HPBVO,VMSA_HPBVP,VMSA_HPBV2,VMSA_HPBVW,# & VMSA_HPBVD,VMSA_HPBVJ,VMSA_HPBVN,VMSA_HPBV2,# & VMSA_HPBVS)# & PIR1: (SAVLBH,SAVLAH,SAVLKS,JQ1577,JQ1572,JQ1571,JQ1576,SAVLJ2,# & SAVLAD,SAVLVD,SAVLHV,SAVLJ1,SAVLAJ,JQ1573,JQ1574,JQ1575,# & SAVLVE,JQ1578,JQ1570,SAVLA,SAVLA1,SAVLAR,SAVLN1,# & SAVLJ3)# & PIR2: (JQ2089,JQ2063,JQ2112,JQ2105,JQ2079,S20749,JQ2110,JQ2061,# & JQ2050,JQ2070,JQ2057,JQ2073,S32202,JQ2054,JQ2092,JQ2046,# & JQ2072,JQ2115,JQ2097,JQ2056,JQ2116,JQ2101,S41869,S41870,# & S47411,JQ2087,JQ2078,JQ2102,JQ2053,S47407,JQ2045,S20753,# & JQ2098,S20745,JQ2080,JQ2075,JQ2069,JQ2111,JQ2055,JQ2059,# & JQ2066,JQ2048,JQ2106,S43492,JQ2091,JQ2051,JQ2062,JQ2052,# & S35528,JQ2085,JQ2108,S36654,JQ2109,JQ2103,JQ2068,JQ2081,# & JQ2104,JQ2100,JQ2067,JQ2083,JQ2114,JQ2060,JQ2077,JQ2065,# & JQ2047,JQ2076,JQ2090,JQ2113,JQ2058)# ANCHOR POSITIONS: ?# REFERENCES: nayersina93a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,WLSLLVPFVQ*# SEQUENCE: WLSLLVPFVQ*# ...# >HUM12803# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Hepatitis B surface antigen HBsAg (201-210)# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_HPBVA,VMSA_HPBVY,VMSA_HPBVY)# & PIR1: (SAVLBH,JQ1572,JQ1571,SAVLAH,SAVLA1,SAVLAJ)# & PIR2: (S41869,JQ2065,JQ2077,JQ2067,S20745,S47407,JQ2070,JQ2080,# & JQ2075,JQ2073,JQ2063,S32202,S20753,JQ2069,JQ2066,JQ2076,# & JQ2079,S41871,JQ2078,S41870,JQ2072,JQ2068,JQ2083,# & JQ2081)# ANCHOR POSITIONS: ?# REFERENCES: nayersina93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SLNFLGGTTV*# SEQUENCE: SLNFLGGTTV*# ...# >HUM12804# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: CTL/Stabilization/Elution# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: poindexter95a# COMMENT: kidney-specific peptide# SUMMARY: HLA-A3,actyesu,bindyesh,GPPGVTIVK*# SEQUENCE: GPPGVTIVK*# ...# >HUM12805# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: poindexter95a# COMMENT: kidney-specific peptide# SUMMARY: HLA-A3,actunkn,bindyesu,KVFPAYALINK*# SEQUENCE: KVFPAYALINK*# ...# >HUM12806# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1/2 nef (75-82)# DB REFERENCE: SWISS: (NEF_HV1B1,NEF_HV1OY,NEF_HV1EL,NEF_HV1ND,NEF_HV1JR,# & NEF_HV1H2,NEF_HV1U4,NEF_HV1Z2,NEF_HV112,NEF_HV1B8,# & NEF_HV1SC,NEF_HV1PV,NEF_HV1A2,NEF_HV1MA,NEF_HV1S1,# & NEF_HV2D2,NEF_HV1BR,NEF_HV1BN,NEF_HV1MN,NEF_HV1Z6,# & NEF_HV1S3)# & PIR1: (ASLJFV,QQLJZR,ASLJ12,ASLJH3,ASLJO2,ASLJBR,QQLJND,# & ASLJVL)# & PIR2: (S24985,S03244,S54385,S03245,S24572,S25937,S43467)# & PIR3: (S33986)# ANCHOR POSITIONS: 2# REFERENCES: rowland-jones95a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,VPLRPMTY*# SEQUENCE: VPLRPMTY*# ...# >HUM12807# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 pol (329-337)# DB REFERENCE: SWISS: (POL_HV1U4)# ANCHOR POSITIONS: 2# REFERENCES: rowland-jones95a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,HPDIVIYQY*# SEQUENCE: HPDIVIYQY*# ...# >HUM12808# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-2 pol (329-337)# DB REFERENCE: SWISS: (POL_HV2D1,POL_HV2BE,POL_HV2G1)# & PIR1: (GNLJGG)# & PIR2: (S12153)# ANCHOR POSITIONS: 2# REFERENCES: rowland-jones95a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,NPDVILIQY*# SEQUENCE: NPDVILIQY*# ...# >HUM12809# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p24 (260-269)# DB REFERENCE: SWISS: (GAG_HV1MA,GAG_HV1U4)# ANCHOR POSITIONS: 2# REFERENCES: rowland-jones95a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,PPIPVGDIY*# SEQUENCE: PPIPVGDIY*# ...# >HUM1280A# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-2 p24 (260-269)# ANCHOR POSITIONS: 2# REFERENCES: rowland-jones95a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,NPVPVGDIY*# SEQUENCE: NPVPVGDIY*# ...# >HUM1280B# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 p17 (130-138)# DB REFERENCE: SWISS: (GAG_HV1J3)# ANCHOR POSITIONS: 2# REFERENCES: rowland-jones95a,brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,NSSKVSQNY*# SEQUENCE: NSSKVSQNY*# ...# >HUM1280C# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-2 p17 (130-138)# DB REFERENCE: SWISS: (GAG_HV2CA,GAG_SIVSP)# & PIR1: (FOLJCA)# ANCHOR POSITIONS: 2# REFERENCES: rowland-jones95a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,PPSGKGGNY*# SEQUENCE: PPSGKGGNY*# ...# >HUM1280D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Hepatitis C virus HCV# DB REFERENCE: SWISS: (POLG_HCVHK,POLG_HCVH4,POLG_HCVTW,POLG_HCVJT,POLG_HCV1,# & POLG_HCVH,POLG_HCVE1,POLG_HCVTH,POLG_HCVJA,POLG_HCVH8,# & POLG_HCVBK,POLG_HCVJ2,POLG_HCVH7)# & PIR1: (GNWVTW,GNWVCJ,GNWVC3,GNWVTC,GNWVCH)# & PIR2: (S12707,PS0388,PC2219,S21471,JQ1926,PC2061,JQ1584,S19875,# & S40770,S41288,JH0711,JQ1925,S18032,S18030,A45573,JN0265,# & S18031,PC1284,A44150,PN0677,PC2060)# & PIR3: (S32740)# ANCHOR POSITIONS: ?# REFERENCES: shirai95a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,DLMGYIPL*# SEQUENCE: DLMGYIPL*# ...# >HUM1280E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Hepatitis C virus HCV# DB REFERENCE: SWISS: (POLG_HCVH8,POLG_HCVE1,POLG_HCVH,POLG_HCV1)# & PIR1: (GNWVCH,GNWVC3)# & PIR2: (S32749,PC2061,PC1303,PC2060,S40770,S41288)# ANCHOR POSITIONS: ?# REFERENCES: shirai95a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,ILHTPGCV*# SEQUENCE: ILHTPGCV*# ...# >HUM1280F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Hepatitis C virus HCV# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVHK,POLG_HCVH8,POLG_HCVJA,POLG_HCVH,# & POLG_HCVTW,POLG_HCVH7,POLG_HCVTH,POLG_HCVE0,POLG_HCVJ2,# & POLG_HCV1)# & PIR1: (GNWVC3,GNWVCH,GNWVTW,GNWVCJ)# & PIR2: (S25123,PN0011,S40770,PS0164,A44150,S18030,S32741,A45573,# & PS0165,PS0104,S12707,S19876,JH0711,JQ1925,S18032,JQ1366,# & PS0102,S32743,S18031,PC1284,JQ1584,S19875,S32745,PN0677,# & S32749)# ANCHOR POSITIONS: ?# REFERENCES: shirai95a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,SMVGNWAKV*# SEQUENCE: SMVGNWAKV*# ...# >HUM12810# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Hepatitis C virus HCV# DB REFERENCE: SWISS: (POLG_HCV1)# & PIR1: (GNWVC3)# & PIR2: (PS0104)# ANCHOR POSITIONS: ?# REFERENCES: shirai95a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,SLLAPGAKQNV*# SEQUENCE: SLLAPGAKQNV*# ...# >HUM12811# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLYERVPQL*# SEQUENCE: FLYERVPQL*# ...# >HUM12812# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLYEAVPQL*# SEQUENCE: FLYEAVPQL*# ...# >HUM12813# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLWEFPHDL*# SEQUENCE: FLWEFPHDL*# ...# >HUM12814# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FMLDWFPTI*# SEQUENCE: FMLDWFPTI*# ...# >HUM12815# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MMQDIDFYL*# SEQUENCE: MMQDIDFYL*# ...# >HUM12816# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KLNEILWSI*# SEQUENCE: KLNEILWSI*# ...# >HUM12817# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,WLNEILWSI*# SEQUENCE: WLNEILWSI*# ...# >HUM12818# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLWAIMHTE*# SEQUENCE: FLWAIMHTE*# ...# >HUM12819# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLLPSFAPD*# SEQUENCE: FLLPSFAPD*# ...# >HUM1281A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FLWTLEGDV*# SEQUENCE: FLWTLEGDV*# ...# >HUM1281B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,LLYDWDFGL*# SEQUENCE: LLYDWDFGL*# ...# >HUM1281C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,MLWEGFTYI*# SEQUENCE: MLWEGFTYI*# ...# >HUM1281D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FMFDLAAEL*# SEQUENCE: FMFDLAAEL*# ...# >HUM1281E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,FMFESPWNV*# SEQUENCE: FMFESPWNV*# ...# >HUM1281F# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,TPRFLNSPI*# SEQUENCE: TPRFLNSPI*# ...# >HUM12820# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRVVQMPL*# SEQUENCE: APRVVQMPL*# ...# >HUM12821# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,LPRNVTFAV*# SEQUENCE: LPRNVTFAV*# ...# >HUM12822# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APRGGMYHV*# SEQUENCE: APRGGMYHV*# ...# >HUM12823# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,KPRGFVPMN*# SEQUENCE: KPRGFVPMN*# ...# >HUM12824# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,LPFKRGGSL*# SEQUENCE: LPFKRGGSL*# ...# >HUM12825# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,APYGFVKIF*# SEQUENCE: APYGFVKIF*# ...# >HUM12826# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,RPRPVSHMW*# SEQUENCE: RPRPVSHMW*# ...# >HUM12827# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,LXRGSMXGL*# SEQUENCE: LXRGSMXGL*# ...# >HUM12828# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,IPMGRRGGI*# SEQUENCE: IPMGRRGGI*# ...# >HUM12829# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,RPRGAYGDL*# SEQUENCE: RPRGAYGDL*# ...# >HUM1282A# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Combinatorial peptide libraries/Pepscan# ACTIVITY: ?# BINDING: yes, ?# SOURCE: combinatorial libraries# ANCHOR POSITIONS: ?# REFERENCES: smith94b# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesu,MPRQXGAXI*# SEQUENCE: MPRQXGAXI*# ...# >HUM1282B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBV EBNA2# DB REFERENCE: SWISS: (EBN2_EBV)# & PIR2: (S32988)# & PIR3: (S42442,S42447)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,SAMRMLWMANYIVRQSRGDR*# SEQUENCE: SAMRMLWMANYIVRQSRGDR*# ...# >HUM1282C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV EBNA2# DB REFERENCE: SWISS: (EBN2_EBV)# & PIR2: (S32988)# & PIR3: (S42442,S42447)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,SGPPWWPPICDPPQPSKTQG*# SEQUENCE: SGPPWWPPICDPPQPSKTQG*# ...# >HUM1282D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR1: (QQBE27)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,SQAPLPCVLWPVL*# SEQUENCE: SQAPLPCVLWPVL*# ...# >HUM1282E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR1: (QQBE27)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,AYAAPQLFPVSDITQ*# SEQUENCE: AYAAPQLFPVSDITQ*# ...# >HUM1282F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR1: (QQBE27)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QQTNQAGGEAPQPGD*# SEQUENCE: QQTNQAGGEAPQPGD*# ...# >HUM12830# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR1: (QQBE27)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,TVQTAAAVVFACPGA*# SEQUENCE: TVQTAAAVVFACPGA*# ...# >HUM12831# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR1: (QQBE27)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FACPGANQGQQLADI*# SEQUENCE: FACPGANQGQQLADI*# ...# >HUM12832# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,CDSELEIKRYKNRVA*# SEQUENCE: CDSELEIKRYKNRVA*# ...# >HUM12833# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,RYKNRVASRKCRAKF*# SEQUENCE: RYKNRVASRKCRAKF*# ...# >HUM12834# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,NIAEGLRAL*# SEQUENCE: NIAEGLRAL*# ...# >HUM12835# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALAIPQCRL*# SEQUENCE: ALAIPQCRL*# ...# >HUM12836# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FMVFLQTHI*# SEQUENCE: FMVFLQTHI*# ...# >HUM12837# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,VLKDAIKDL*# SEQUENCE: VLKDAIKDL*# ...# >HUM12838# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gp41 (653-664)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,IEESQNQQEKNEC*# SEQUENCE: IEESQNQQEKNEC*# ...# >HUM12839# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 pol (150-162)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1U4,POL_HV1Y2,POL_HV1B1,POL_HV1Z2,# & POL_HV1MA,POL_HV1EL,POL_HV1H2,POL_HV1JR,POL_HV1PV,# & POL_HV1MN,POL_HV1A2,POL_HV1RH,POL_HV1ND,POL_HV1BR,# & POL_HV1B5,POL_HV1OY)# & PIR1: (GNVWLV,B44001,GNLJND,GNVWVL,GNVWA2,GNVWH3)# & PIR2: (S63749,S63744,S63736,S63732,S63745,S63755,S63748,S63747,# & S63733,S63737,S63734,S63753,S63739,S63742,S63750,S54378,# & S63746,S63741,S63735,S63752,S63731,S63738,S63751,# & S63754)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GCTLNFPISPIET*# SEQUENCE: GCTLNFPISPIET*# ...# >HUM1283A# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,TWVAGVFVYGGSKTSLYNLR*# SEQUENCE: TWVAGVFVYGGSKTSLYNLR*# ...# >HUM1283B# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,GMAPGPGPQPGPLRESIVCY*# SEQUENCE: GMAPGPGPQPGPLRESIVCY*# ...# >HUM1283C# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,GPLRESIVCYFMVFLQTHIF*# SEQUENCE: GPLRESIVCYFMVFLQTHIF*# ...# >HUM1283D# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,FMVFLQTHIFAEVLKDAIKD*# SEQUENCE: FMVFLQTHIFAEVLKDAIKD*# ...# >HUM1283E# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,LVMTKPAPTCNIRVTVCSFD*# SEQUENCE: LVMTKPAPTCNIRVTVCSFD*# ...# >HUM1283F# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,NIRVTVCSFDDGVDLPPWFP*# SEQUENCE: NIRVTVCSFDDGVDLPPWFP*# ...# >HUM12840# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBV EBNA1# DB REFERENCE: SWISS: (EBN1_EBV)# & PIR1: (QQBE31)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,RPQKRPSCIGCKGTHGGTGA*# SEQUENCE: RPQKRPSCIGCKGTHGGTGA*# ...# >HUM12841# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV EBNA2# DB REFERENCE: SWISS: (EBN2_EBV)# & PIR2: (S32988)# & PIR3: (S42447,S42442)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,GYDVGHGPLASAMRMLWMAN*# SEQUENCE: GYDVGHGPLASAMRMLWMAN*# ...# >HUM12842# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: EBV EBNA2# DB REFERENCE: SWISS: (EBN2_EBV)# & PIR2: (S32988)# & PIR3: (S42442,S42447)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,RPTTLPPTPLLTVLQRPTEL*# SEQUENCE: RPTTLPPTPLLTVLQRPTEL*# ...# >HUM12843# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR1: (QQBE27)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,SQAPLPCVLWPVL*# SEQUENCE: SQAPLPCVLWPVL*# ...# >HUM12844# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR1: (QQBE27)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,PVSDITQNQQTNQAG*# SEQUENCE: PVSDITQNQQTNQAG*# ...# >HUM12845# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR1: (QQBE27)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,TVQTAAAVVFACPGA*# SEQUENCE: TVQTAAAVVFACPGA*# ...# >HUM12846# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,CDSELEIKRYKNRVA*# SEQUENCE: CDSELEIKRYKNRVA*# ...# >HUM12847# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: EBV BZLF-1# DB REFERENCE: SWISS: (BZLF_EBV)# & PIR3: (S03634)# ANCHOR POSITIONS: ?# REFERENCES: stuber95a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,DVDSIIPRTPDVLHE*# SEQUENCE: DVDSIIPRTPDVLHE*# ...# >HUM22848# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MVF PhoE (453-464)# DB REFERENCE: SWISS: (VGLF_MEASY,VGLF_MEASE,VGLF_MEASE,VGLF_MEASI)# & PIR1: (VGNZMV,JU0274)# & PIR2: (PQ0376,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: verjans95a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,PPISLERLDVGT*# SEQUENCE: PPISLERLDVGT*# ...# >HUM12849# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MVF PhoE (437-447)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASY,VGLF_MEASE)# & PIR1: (E48556,JU0274,VGNZMV)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: verjans95a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,SRRYPDAVYLH*# SEQUENCE: SRRYPDAVYLH*# ...# >HUM1284A# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-1 (161-169)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: zeh94a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,EADPTGHSY*# SEQUENCE: EADPTGHSY*# ...# >HUM1284B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: human p53 (129-137)# ANCHOR POSITIONS: ?# REFERENCES: zeh94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALNKFMCQL*# SEQUENCE: ALNKFMCQL*# ...# >HUM1284C# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: human p53 (186-196)# DB REFERENCE: SWISS: (P53_MOUSE,P53_HUMAN,P53_MESAU,P53_MOUSE,P53_CERAE,# & P53_FELCA,P53_RAT,P53_CANFA,P53_SHEEP,P53_HUMAN,# & P53_SHEEP,P53_BOVIN,P53_FELCA,P53_MESAU,P53_RAT,# & P53_CERAE)# & PIR1: (DNMS53,DNHU53)# & PIR2: (S38824,JH0633,I46226,JC6193,S06594,S51648,S02192)# ANCHOR POSITIONS: ?# REFERENCES: zeh94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,DGLAPPQHLIR*# SEQUENCE: DGLAPPQHLIR*# ...# >HUM1284D# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VPEIYKRWI*# SEQUENCE: VPEIYKRWI*# ...# >HUM1284E# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VPRNLLTQI*# SEQUENCE: VPRNLLTQI*# ...# >HUM1284F# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPCTLNFPI*# SEQUENCE: IPCTLNFPI*# ...# >HUM12850# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,YPLASLKSF*# SEQUENCE: YPLASLKSF*# ...# >HUM12851# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,EPIVGAETI*# SEQUENCE: EPIVGAETI*# ...# >HUM12852# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPKLPGVPI*# SEQUENCE: LPKLPGVPI*# ...# >HUM12853# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1B5,GAG_HV1Y2,GAG_HV1JR,GAG_HV1B1,# & GAG_HV1RH,GAG_HV1J3,GAG_HV1A2,GAG_HV1N5,GAG_HV1BR,# & GAG_HV1ND,GAG_HV1MN,GAG_HV1W2,GAG_HV1H2,GAG_HV1Z2,# & GAG_HV1OY,GAG_HV1EL)# & PIR1: (FOVWA2,A38068,FOVWVL,FOVWH3,A44001,FOVWLV,FOLJND)# & PIR2: (S44993,S54377,S60699,S60698,S60702,S60708,S60703,S60704,# & S49086,S60697)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NPPIPVGEI*# SEQUENCE: NPPIPVGEI*# ...# >HUM12854# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1MA,GAG_HV1MN,GAG_HV1ND)# & PIR1: (FOLJND,A38068)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPLASLKSL*# SEQUENCE: YPLASLKSL*# ...# >HUM12855# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1OY,POL_HV1MN,POL_HV1BR,POL_HV1Z2,POL_HV1JR,# & POL_HV1Y2,POL_HV1B1,POL_HV1MA,POL_HV1H2,POL_HV1U4,# & POL_HV1B5,POL_HV1PV,POL_HV1ND,POL_HV1RH,POL_HV1EL,# & POL_HV1A2,POL_HV1N5)# & PIR1: (B44001,GNVWVL,GNVWA2,GNVWLV,GNVWH3,GNLJND)# & PIR2: (S63732,S63734,S63737,S63733,S63753,S63742,S63739,S63754,# & S63751,S63752,S63750,S63745,S63744,S63749,S63731,S63748,# & S63747,S63755,S63736,S63746,S63741,S54378,S63735)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a,sakaguchi97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,FPISPIETV*# SEQUENCE: FPISPIETV*# ...# >HUM12856# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1A2,POL_HV1N5,POL_SIVCZ,POL_HV1Z2,# & POL_HV1ND,POL_HV1RH,POL_HV1H2,POL_HV1MA,POL_HV1BR,# & POL_HV1EL,POL_HV1PV,POL_HV1MN,POL_HV1Y2,POL_HV1B1,# & POL_HV1JR,POL_HV1OY)# & PIR1: (GNLJND,GNVWLV,GNLJSI,GNVWH3,GNVWA2,B44001,GNVWVL)# & PIR2: (S32136,S32079,S32126,S32066,B47175,S32137,S32051,S32086,# & S32050,S32093,S32074,S32073,S32091,S32067,S32096,S32048,# & S32157,S32076,S63747,S32159,S63734,S32081,S32059,S32088,# & S32061,S32092,S63748,S32053,S32087,S32072,S32135,S63752,# & S32049,S63751,S32082,S32138,S32065,S32078,S63754,S32080,# & S63731,S32084,S32118,S32077,S32058,S32160,S63743,S32090,# & S32070,S32062,S32094,S63746,S63741,S54378,S32098,S32117,# & S32075,S32068,S32085,S63753,S63737,S63733,S32071,S32122,# & S32139,S32119,S63732,S32134,S32083,S32089,S32069,A47175,# & S63750,S32047,S32097)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a,sakaguchi97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VPVKLKPGM*# SEQUENCE: VPVKLKPGM*# ...# >HUM12857# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1OY,POL_HV1MN,POL_HV1N5,POL_HV1BR,# & POL_HV1PV,POL_HV1Y2,POL_HV1JR,POL_HV1RH,POL_HV1B1,# & POL_HV1A2,POL_HV1U4,POL_HV1H2)# & PIR1: (GNVWVL,GNVWLV,GNVWH3,GNVWA2,B44001)# & PIR2: (S43127,A47175,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPEKDSWTV*# SEQUENCE: LPEKDSWTV*# ...# >HUM12858# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (NEF_HV1Z6,NEF_HV1Y2,NEF_HV1S1,NEF_HV1U4,NEF_HV1OY,# & NEF_HV1ND,NEF_HV1ZH,NEF_HV1RH,NEF_HV1A2,NEF_HV1EL,# & NEF_HV1MA,NEF_HV1Z2,NEF_HV1JR,NEF_HV1SC)# & PIR1: (I44001,QQLJND,QQLJZR,ASLJO2,B44963)# & PIR2: (S54385,S03246,S25937)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,FPVRPQVPL*# SEQUENCE: FPVRPQVPL*# ...# >HUM12859# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (REV_HV1MA,REV_HV1PV,REV_HV1RH,REV_HV1Y2,REV_HV1B1,# & REV_HV1A2,REV_HV1B8,REV_HV1BR,REV_HV1H2,REV_HV1J3,# & REV_HV1W2,REV_HV1C4,REV_HV1SC,REV_HV1BN,REV_HV1JR,# & REV_HV112)# & PIR1: (VKLJBR,F44001,VKLJH3)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPLERLTL*# SEQUENCE: LPPLERLTL*# ...# >HUM1285A# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1PV,GAG_HV1B5,GAG_HV1BR,GAG_HV1H2,# & GAG_HV1OY,GAG_HV1B1,GAG_HV1JR)# & PIR1: (FOVWH3,FOVWA2,FOVWLV)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a,sakaguchi97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,YPLTSLRSL*# SEQUENCE: YPLTSLRSL*# ...# >HUM1285B# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1A2,POL_HV1PV,POL_HV1Z2,POL_HV1H2,# & POL_HV1Y2,POL_HV1OY,POL_HV1B5,POL_HV1N5,POL_HV1EL,# & POL_HV1U4,POL_HV1RH,POL_HV1BR,POL_HV1ND)# & PIR1: (GNVWVL,GNVWLV,B44001,GNLJND,GNVWH3,GNVWA2)# & PIR2: (S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a,sakaguchi97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,LPPVVAKEI*# SEQUENCE: LPPVVAKEI*# ...# >HUM1285C# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1S1,ENV_HV1S3,ENV_HV1Z3,ENV_HV1Z6,# & ENV_HV1RH,ENV_HV1ZH,ENV_HV1H3,ENV_HV1C4,ENV_HV1PV,# & ENV_HV1N5,ENV_HV1SC,ENV_HV1B1,ENV_HV1A2,ENV_HV1JR,# & ENV_HV1Y2,ENV_HV1EL,ENV_HV1Z2,ENV_HV1B8,ENV_HV1BR,# & ENV_HV1KB,ENV_HV1W2,ENV_HV1H2)# & PIR1: (VCLJKB,VCLJSC,VCLJH4,VCLJLV,H44001,VCLJA2,VCLJVL,VCLJZR,# & A44963,VCLJKX,VCLJH3)# & PIR2: (S25938,S25939,S54384,A53034)# & PIR3: (S33985,S49197,S13288)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,CPKVSFEPI*# SEQUENCE: CPKVSFEPI*# ...# >HUM1285D# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1MA,ENV_HV1JR,ENV_HV1W2,ENV_HV1B8,# & ENV_HV1J3,ENV_HV1B1,ENV_HV1C4,ENV_HV1H2,ENV_HV1Z8,# & ENV_HV1W1,ENV_HV1BN,ENV_HV1S3,ENV_HV1S1,ENV_HV1A2)# & PIR1: (VCLJ3W,VCLJA2,H44001,VCLJH4,VCLJBR,VCLJH3)# & PIR2: (C41621,A40218,S25940,S60538)# & PIR3: (S33985)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a,sakaguchi97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,LPCRIKQII*# SEQUENCE: LPCRIKQII*# ...# >HUM1285E# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJ7,POLG_HCVTW,POLG_HCVBK,POLG_HCVJT,# & POLG_HCVJ8)# & PIR1: (GNWVTC,GNWVJ8,GNWVTW)# & PIR2: (S19876,A45573,S18032)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPCTVNFTI*# SEQUENCE: YPCTVNFTI*# ...# >HUM1285F# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVBK,POLG_HCVTW,POLG_HCVJT,POLG_HCVH,# & POLG_HCV1)# & PIR1: (GNWVC3,GNWVTW,GNWVCJ,GNWVTC,GNWVCH)# & PIR2: (S18030,S19876,S18031,S19875,S18032,PN0677,A45573,# & S40770)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPALSTGLI*# SEQUENCE: LPALSTGLI*# ...# >HUM12860# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573,S18030)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,CPSGHAVGI*# SEQUENCE: CPSGHAVGI*# ...# >HUM12861# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPTSGDVVI*# SEQUENCE: IPTSGDVVI*# ...# >HUM12862# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPTTGPPI*# SEQUENCE: LPPTTGPPI*# ...# >HUM12863# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVH,POLG_HCV1,POLG_HCVJA,POLG_HCVBK,# & POLG_HCVJT)# & PIR1: (GNWVCJ,GNWVCH,GNWVTW,GNWVC3,GNWVTC)# & PIR2: (A45573,PS0085,PS0104,S18030,JQ0880,S40770,PS0102)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,APTLWARMI*# SEQUENCE: APTLWARMI*# ...# >HUM12864# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVBK,POLG_HCVJA,POLG_HCVJT)# & PIR1: (GNWVTW,GNWVCJ,GNWVTC)# & PIR2: (A45573,S18030,PS0102,JQ0879)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,EPLDLPQII*# SEQUENCE: EPLDLPQII*# ...# >HUM12865# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1BR,GAG_HV1B5,GAG_HV1Z2,GAG_HV1B1,# & GAG_HV1C4,GAG_HV1OY,GAG_HV1EL,GAG_HV1N5,GAG_HV1RH,# & GAG_HV1JR,GAG_HV1J3,GAG_HV1PV,GAG_HV1MA,GAG_HV1A2,# & GAG_HV1W2,GAG_HV1H2,GAG_HV1MN,GAG_HV1Y2)# & PIR1: (FOVWH4,A44001,FOVWLV,FOVWA2,FOVWVL,FOVWH3,A38068,# & FOLJND)# & PIR2: (S60703,S60699,S60698,S60700,S60708,S60704,S54377)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NANPDCKTI*# SEQUENCE: NANPDCKTI*# ...# >HUM12866# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1PV,POL_HV1H2,POL_HV1RH,POL_HV1Z2,# & POL_HV1EL,POL_SIVCZ,POL_HV1OY,POL_HV1B1,POL_HV1Y2,# & POL_HV1MA,POL_HV1Z6,POL_HV1A2,POL_HV1JR,POL_HV1B5,# & POL_HV1N5,POL_HV1ND,POL_HV1U4)# & PIR1: (GNLJND,B44001,GNLJSI,GNVWH3,GNVWA2,GNVWLV,GNVWVL)# & PIR2: (S54378,A26192)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,TAVQMAVFI*# SEQUENCE: TAVQMAVFI*# ...# >HUM12867# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1W1,ENV_HV1A2)# & PIR1: (VCLJ3W,VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YAPPIGGQI*# SEQUENCE: YAPPIGGQI*# ...# >HUM12868# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VAQRAYRAI*# SEQUENCE: VAQRAYRAI*# ...# >HUM12869# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1A2,POL_HV1Z2,POL_HV1MA,POL_HV1BR,# & POL_HV1H2,POL_HV2D1,POL_HV2BE,POL_HV1B5,POL_SIVM1,# & POL_HV1PV,POL_HV2SB,POL_HV2G1,POL_HV1B1,POL_HV2CA,# & POL_HV1Y2,POL_HV1MN,POL_HV2ST,POL_HV2NZ,POL_HV1EL,# & POL_HV1OY,POL_SIVSP,POL_SIVM1,POL_HV1ND,POL_HV1JR,# & POL_HV2KR,POL_SIVS4,POL_SIVMK,POL_HV1N5,POL_HV2RO)# & PIR1: (GNLJG2,GNLJGG,GNVWH3,GNLJG5,GNLJCA,GNVWLV,GNVWVL,B44001,# & GNLJST,GNLJG3,GNVWA2,GNLJND)# & PIR2: (S32048,S32096,S32157,S32076,S32069,S32089,A47330,S43127,# & S32056,S12153,S32136,S30484,S32054,B47175,S32060,S32159,# & S32081,S32061,F47330,S32092,S32059,S30483,S32082,S32080,# & S32078,D47330,S32160,S32063,S32094,S32062,S32077,A47175,# & S53092,S32050,S32093,S32073,S32127,S32135,S32098,S32097,# & S32079,S32086,S32075,S32119,S32139,S32085,S32072,S32052,# & E47330,S32140,S32087,C47330,S32120,S32151,S32071,S32117,# & S32083,S32134,S32126,S32051,S32066,S54378,S32074,S32090,# & S32118,S32058,S32122,S32068,S32047,S32088,S32095,S32091,# & S32067,S32137,S32064,S32057,S32065,S32138,S32049,S32053,# & S32055,S32084,S32070)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,QGWKGSPAI*# SEQUENCE: QGWKGSPAI*# ...# >HUM1286A# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VGCLVGLRI*# SEQUENCE: VGCLVGLRI*# ...# >HUM1286B# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a,sakaguchi97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,DARAYDTEV*# SEQUENCE: DARAYDTEV*# ...# >HUM1286C# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NALFRNLDV*# SEQUENCE: NALFRNLDV*# ...# >HUM1286D# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VIF_HV1N5,VIF_HV1A2,VIF_HV1Y2)# & PIR1: (C44001,ASLJO1)# & PIR2: (S42944,S42952,S42953,S42991,S42974,S42956,S42951,S42962,# & S42990,S42977,S42969,S42992,S42941,S42972,S43005,S42999,# & S42980,S43004,S42961)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPLGDAKLV*# SEQUENCE: IPLGDAKLV*# ...# >HUM1286E# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1MN,GAG_HV1Z2,GAG_HV1B1,GAG_HV1B5,# & GAG_HV1A2,GAG_HV1EL,GAG_HV1N5,GAG_HV1J3,GAG_HV1RH,# & GAG_HV1H2,GAG_HV1W2,GAG_HV1Y2,GAG_HV1BR,GAG_HV1OY,# & GAG_HV1PV,GAG_HV1JR)# & PIR1: (FOLJND,FOVWVL,FOVWLV,A38068,FOVWH3,A44001,FOVWA2)# & PIR2: (S60703,S54377,S44993,S60704,S60699,S49086,S60698,S60708,# & S60697,S60702)# & PIR3: (S33979,S19598)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NPPIPVGEI*# SEQUENCE: NPPIPVGEI*# ...# >HUM1286F# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1ND,GAG_HV1MN,GAG_HV1MA)# & PIR1: (FOLJND,A38068)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPLASLKSL*# SEQUENCE: YPLASLKSL*# ...# >HUM12870# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1JR,POL_HV1N5,POL_HV1OY,POL_HV1B1,POL_HV1EL,# & POL_HV1MN,POL_HV1H2,POL_HV1BR,POL_HV1B5,POL_HV1U4,# & POL_HV1PV,POL_HV1Z2,POL_HV1MA,POL_HV1A2,POL_HV1RH,# & POL_HV1Y2,POL_HV1ND)# & PIR1: (GNVWH3,GNVWA2,GNLJND,GNVWVL,GNVWLV,B44001)# & PIR2: (S63748,S63734,S63731,S63752,S63754,S54378,S63745,S63739,# & S63742,S63753,S63732,S63737,S63733,S63736,S63747,S63755,# & S63751,S63741,S63746,S63735,S63749,S63744,S63750)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,FPISPIETV*# SEQUENCE: FPISPIETV*# ...# >HUM12871# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1PV,POL_HV1ND,POL_HV1EL,POL_HV1A2,# & POL_SIVCZ,POL_HV1JR,POL_HV1RH,POL_HV1MA,POL_HV1N5,# & POL_HV1MN,POL_HV1OY,POL_HV1B1,POL_HV1B5,POL_HV1BR,# & POL_HV1H2,POL_HV1Z2)# & PIR1: (GNVWA2,GNLJSI,B44001,GNVWVL,GNVWLV,GNLJND,GNVWH3)# & PIR2: (S63747,S32079,S32135,S32097,S32084,S32070,S32065,S32049,# & S32067,S32068,S32053,S32047,S32088,S32091,S32058,S32051,# & S32081,S32059,A47175,S32093,S32087,S32071,S32083,S32134,# & S32096,S32048,S32076,S32089,S63750,S63748,S32092,S32085,# & S63737,S32119,S32094,S32080,S32082,S32160,S63741,S32075,# & S32074,S32126,S54378,S32066,S32118,S63754,S63743,S32061,# & B47175,S32136,S32069,S32157,S63746,S63751,S32050,S32073,# & S32077,S63732,S63753,S63733,S32078,S32062,S32159,S32122,# & S32137,S32117,S32090,S63752,S32138,S63731,S63734,S32072,# & S32139,S32086,S32098)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VPVKLKPGM*# SEQUENCE: VPVKLKPGM*# ...# >HUM12872# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1U4,POL_HV1N5,POL_HV1B5,POL_HV1BR,# & POL_HV1A2,POL_HV1JR,POL_HV1PV,POL_HV1Y2,POL_HV1B1,# & POL_HV1H2,POL_HV1OY,POL_HV1MN)# & PIR1: (GNVWLV,B44001,GNVWH3,GNVWVL,GNVWA2)# & PIR2: (A47175,S43127,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPEKDSWTV*# SEQUENCE: LPEKDSWTV*# ...# >HUM12873# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_HV1MA,NEF_HV1Z2,NEF_HV1RH,NEF_HV1SC,# & NEF_HV1Z6,NEF_HV1S1,NEF_HV1ZH,NEF_HV1EL,NEF_HV1OY,# & NEF_HV1A2,NEF_HV1U4,NEF_HV1ND,NEF_HV1Y2)# & PIR1: (QQLJND,I44001,B44963,ASLJO2,QQLJZR)# & PIR2: (S25937,S03246,S54385)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,FPVRPQVPL*# SEQUENCE: FPVRPQVPL*# ...# >HUM12874# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (REV_HV1BN,REV_HV1JR,REV_HV1B8,REV_HV1W2,REV_HV1C4,# & REV_HV1H2,REV_HV1Y2,REV_HV1SC,REV_HV1PV,REV_HV1RH,# & REV_HV1BR,REV_HV112,REV_HV1MA,REV_HV1J3,REV_HV1B1,# & REV_HV1A2)# & PIR1: (VKLJBR,VKLJH3,F44001)# & PIR2: (S14607,JC4968)# & PIR3: (S33983)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPLERLTL*# SEQUENCE: LPPLERLTL*# ...# >HUM12875# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1JR,GAG_HV1OY,GAG_HV1PV,GAG_HV1A2,# & GAG_HV1B5,GAG_HV1B1,GAG_HV1H2)# & PIR1: (FOVWA2,FOVWLV,FOVWH3)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPLTSLRSL*# SEQUENCE: YPLTSLRSL*# ...# >HUM12876# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1PV,POL_HV1ND,POL_HV1A2,POL_HV1RH,POL_HV1B5,# & POL_HV1Z2,POL_HV1U4,POL_HV1BR,POL_HV1Y2,POL_HV1H2,# & POL_HV1EL,POL_HV1OY,POL_HV1N5,POL_HV1B1)# & PIR1: (GNVWA2,GNLJND,B44001,GNVWLV,GNVWVL,GNVWH3)# & PIR2: (S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPVVAKEI*# SEQUENCE: LPPVVAKEI*# ...# >HUM12877# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1N5,ENV_HV1JR,ENV_HV1Z3,ENV_HV1B8,ENV_HV1Z2,# & ENV_HV1MF,ENV_HV1S3,ENV_HV1S1,ENV_HV1Z6,ENV_HV1Y2,# & ENV_HV1SC,ENV_HV1PV,ENV_HV1EL,ENV_HV1W2,ENV_HV1KB,# & ENV_HV1BR,ENV_HV1A2,ENV_HV1C4,ENV_HV1ZH,ENV_HV1H2,# & ENV_HV1H3,ENV_HV1RH,ENV_HV1B1)# & PIR1: (VCLJH4,VCLJKX,A44963,H44001,VCLJSC,VCLJH3,VCLJKB,VCLJZR,# & VCLJVL,VCLJLV,VCLJA2)# & PIR2: (S25939,A53034,S54384,S25938)# & PIR3: (S49197,S13288,S33985)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,CPKVSFEPI*# SEQUENCE: CPKVSFEPI*# ...# >HUM12878# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1Z8,ENV_HV1S3,ENV_HV1S1,ENV_HV1J3,ENV_HV1B1,# & ENV_HV1W2,ENV_HV1MA,ENV_HV1C4,ENV_HV1Y2,ENV_HV1B8,# & ENV_HV1BN,ENV_HV1JR,ENV_HV1H2,ENV_HV1A2,ENV_HV1W1)# & PIR1: (VCLJH4,VCLJ3W,VCLJBR,VCLJH3,H44001,VCLJA2)# & PIR2: (S60538,S25940,C41621,A40218)# & PIR3: (S33985)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPCRIKQII*# SEQUENCE: LPCRIKQII*# ...# >HUM12879# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJ8,POLG_HCVTW,POLG_HCVJ7,POLG_HCVBK,# & POLG_HCVJT)# & PIR1: (GNWVTW,GNWVJ8,GNWVTC)# & PIR2: (S18032,S19876,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPCTVNFTI*# SEQUENCE: YPCTVNFTI*# ...# >HUM1287A# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCV1,POLG_HCVJT,POLG_HCVH,POLG_HCVTW,# & POLG_HCVJA)# & PIR1: (GNWVCJ,GNWVCH,GNWVTW,GNWVC3,GNWVTC)# & PIR2: (S18031,S19875,PN0677,S19876,A45573,S18030,S18032,# & S40770)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPALSTGLI*# SEQUENCE: LPALSTGLI*# ...# >HUM1287B# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (S18030,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,CPSGHAVGI*# SEQUENCE: CPSGHAVGI*# ...# >HUM1287C# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPTSGDVVI*# SEQUENCE: IPTSGDVVI*# ...# >HUM1287D# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPTTGPPI*# SEQUENCE: LPPTTGPPI*# ...# >HUM1287E# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCV1,POLG_HCVBK,POLG_HCVTW,POLG_HCVJT,# & POLG_HCVJA)# & PIR1: (GNWVCJ,GNWVCH,GNWVTW,GNWVTC,GNWVC3)# & PIR2: (A45573,PS0085,PS0102,PS0104,S40770,S18030,JQ0880)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,APTLWARMI*# SEQUENCE: APTLWARMI*# ...# >HUM1287F# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVBK,POLG_HCVJT,POLG_HCVJA,POLG_HCVTW)# & PIR1: (GNWVTW,GNWVCJ,GNWVTC)# & PIR2: (S18030,JQ0879,A45573,PS0102)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,EPLDLPQII*# SEQUENCE: EPLDLPQII*# ...# >HUM12880# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_HV1MA,GAG_HV1B5,GAG_HV1B1,GAG_HV1J3,# & GAG_HV1EL,GAG_HV1Y2,GAG_HV1Z2,GAG_HV1A2,GAG_HV1C4,# & GAG_HV1PV,GAG_HV1OY,GAG_HV1BR,GAG_HV1JR,GAG_HV1N5,# & GAG_HV1W2,GAG_HV1ND,GAG_HV1RH,GAG_HV1H2)# & PIR1: (FOVWH4,FOVWVL,FOVWH3,FOVWLV,A38068,FOVWA2,FOLJND,# & A44001)# & PIR2: (S60708,S60704,S60698,S60703,S54377,S60700,S60699)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NANPDCKTI*# SEQUENCE: NANPDCKTI*# ...# >HUM12881# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1Y2,POL_SIVCZ,POL_HV1OY,POL_HV1Z2,POL_HV1A2,# & POL_HV1JR,POL_HV1U4,POL_HV1BR,POL_HV1B5,POL_HV1N5,# & POL_HV1B1,POL_HV1H2,POL_HV1Z6,POL_HV1EL,POL_HV1PV,# & POL_HV1ND,POL_HV1RH,POL_HV1MA)# & PIR1: (GNVWVL,GNLJSI,GNLJND,GNVWH3,B44001,GNVWA2,GNVWLV)# & PIR2: (A26192,S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,TAVQMAVFI*# SEQUENCE: TAVQMAVFI*# ...# >HUM12882# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1W1,ENV_HV1A2)# & PIR1: (VCLJ3W,VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YAPPIGGQI*# SEQUENCE: YAPPIGGQI*# ...# >HUM12883# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VAQRAYRAI*# SEQUENCE: VAQRAYRAI*# ...# >HUM12884# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV2SB,POL_HV1N5,POL_HV1Z2,POL_HV2G1,POL_HV2D1,# & POL_HV1JR,POL_HV1BR,POL_SIVM1,POL_HV1ND,POL_HV2CA,# & POL_HV1MA,POL_SIVMK,POL_HV2KR,POL_HV1H2,POL_HV1MN,# & POL_HV1A2,POL_HV1B1,POL_HV2BE,POL_HV2NZ,POL_HV1EL,# & POL_HV2RO,POL_SIVS4,POL_HV1RH,POL_HV1B5,POL_SIVSP,# & POL_SIVM1,POL_HV2ST,POL_HV1PV,POL_HV1OY,POL_HV1Y2)# & PIR1: (GNLJG3,B44001,GNVWLV,GNLJG2,GNVWH3,GNLJGG,GNLJCA,GNLJST,# & GNLJND,GNLJG5,GNVWVL,GNVWA2)# & PIR2: (S43127,S32078,S32151,S32067,S32056,S32088,S30484,S32091,# & S32059,S32096,S32076,S32119,S32075,S32080,S32089,S32093,# & S32117,S32140,S54378,S32137,S32090,S32064,S32055,S32139,# & S32092,S32122,S32062,S32057,S32118,S32066,S32074,S32126,# & S32061,S32069,S32157,S32086,S32098,A47175,S32072,S32095,# & S32138,B47175,S32058,S32051,S32060,S32054,S32047,S32049,# & S32134,S32083,S32087,S53092,S32048,S32120,S32052,E47330,# & C47330,S32077,S32073,S32136,S32050,S32097,S32084,S32065,# & S32070,A47330,S12153,S32079,S32159,F47330,S32068,S32053,# & S32135,S32071,S30483,S32127,S32094,S32063,D47330,S32081,# & S32160,S32082,S32085)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,QGWKGSPAI*# SEQUENCE: QGWKGSPAI*# ...# >HUM12885# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VGCLVGLRI*# SEQUENCE: VGCLVGLRI*# ...# >HUM12886# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,DARAYDTEV*# SEQUENCE: DARAYDTEV*# ...# >HUM12887# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NALFRNLDV*# SEQUENCE: NALFRNLDV*# ...# >HUM12888# MHC MOLECULE: HLA-B51(B*5102), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VIF_HV1Y2,VIF_HV1A2,VIF_HV1N5)# & PIR1: (ASLJO1,C44001)# & PIR2: (S42977,S42969,S42991,S42990,S42956,S42951,S42962,S42952,# & S43005,S42972,S42944,S42953,S42974,S42980,S42961,S43004,# & S42941,S42992,S42999)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPLGDAKLV*# SEQUENCE: IPLGDAKLV*# ...# >HUM12889# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1Z2,GAG_HV1ND,GAG_HV1H2,GAG_HV1BR,# & GAG_HV1W2,GAG_HV1JR,GAG_HV1A2,GAG_HV1Y2,GAG_HV1PV,# & GAG_HV1B5,GAG_HV1B1,GAG_HV1MN,GAG_HV1J3,GAG_HV1EL,# & GAG_HV1RH,GAG_HV1OY)# & PIR1: (FOVWH3,FOVWA2,FOLJND,FOVWVL,FOVWLV,A38068,A44001)# & PIR2: (S60708,S60703,S54377,S60702,S60699,S60698,S49086,S44993,# & S60697,S60704)# & PIR3: (S33979,S19598)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NPPIPVGEI*# SEQUENCE: NPPIPVGEI*# ...# >HUM1288A# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1MA,GAG_HV1ND,GAG_HV1MN,GAG_HV1RH)# & PIR1: (A38068,FOLJND)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPLASLKSL*# SEQUENCE: YPLASLKSL*# ...# >HUM1288B# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1PV,POL_HV1Y2,POL_HV1N5,POL_HV1JR,# & POL_HV1MN,POL_HV1A2,POL_HV1B1,POL_HV1ND,POL_HV1H2,# & POL_HV1BR,POL_HV1OY,POL_HV1B5,POL_HV1RH,POL_HV1Z2,# & POL_HV1EL,POL_HV1U4)# & PIR1: (GNVWLV,GNLJND,B44001,GNVWA2,GNVWVL,GNVWH3)# & PIR2: (S63741,S63732,S63752,S63742,S63737,S63733,S63735,S63744,# & S63750,S63747,S63751,S63753,S63731,S63734,S54378,S63748,# & S63736,S63755,S63745,S63739,S63749,S63746,S63754)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,FPISPIETV*# SEQUENCE: FPISPIETV*# ...# >HUM1288C# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1RH,POL_SIVCZ,POL_HV1EL,POL_HV1Z2,# & POL_HV1BR,POL_HV1MA,POL_HV1B1,POL_HV1Y2,POL_HV1MN,# & POL_HV1ND,POL_HV1JR,POL_HV1PV,POL_HV1H2,POL_HV1N5,# & POL_HV1B5,POL_HV1OY)# & PIR1: (B44001,GNVWVL,GNVWA2,GNVWLV,GNLJND,GNVWH3,GNLJSI)# & PIR2: (S32096,S32075,S32072,S32062,S32157,S32069,S32118,S32122,# & S32160,S32048,S32081,S32085,S63752,S32050,S32136,S32084,# & S32097,S32070,S32083,S63737,S63732,A47175,S63754,S32078,# & S32059,S32159,S32071,S32135,S32053,S32068,S32117,S32093,# & S32089,S32137,S32090,S32092,S32088,S32091,S63743,S32067,# & S63746,S32080,S63748,S54378,S63747,S32079,S63751,S63753,# & S32077,S32086,S32138,S32098,S63734,S63731,S32061,S32126,# & S32074,S32066,S32139,S32076,S32094,S63733,S32051,S32073,# & S32119,S63741,S32082,B47175,S32087,S32134,S63750,S32049,# & S32065,S32047,S32058)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VPVKLKPGM*# SEQUENCE: VPVKLKPGM*# ...# >HUM1288D# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1N5,POL_HV1B5,POL_HV1OY,POL_HV1PV,# & POL_HV1JR,POL_HV1Y2,POL_HV1B1,POL_HV1RH,POL_HV1MN,# & POL_HV1U4,POL_HV1BR,POL_HV1H2)# & PIR1: (GNVWH3,B44001,GNVWLV,GNVWA2,GNVWVL)# & PIR2: (S43127,A47175,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPEKDSWTV*# SEQUENCE: LPEKDSWTV*# ...# >HUM1288E# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_HV1RH,NEF_HV1ND,NEF_HV1Y2,NEF_HV1MA,# & NEF_HV1SC,NEF_HV1A2,NEF_HV1OY,NEF_HV1EL,NEF_HV1ZH,# & NEF_HV1Z2,NEF_HV1U4,NEF_HV1S1,NEF_HV1Z6)# & PIR1: (ASLJO2,B44963,I44001,QQLJND,QQLJZR)# & PIR2: (S54385,S25937,S03246)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,FPVRPQVPL*# SEQUENCE: FPVRPQVPL*# ...# >HUM1288F# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (REV_HV1SC,REV_HV1A2,REV_HV1MA,REV_HV112,REV_HV1BR,# & REV_HV1H2,REV_HV1RH,REV_HV1JR,REV_HV1BN,REV_HV1C4,# & REV_HV1B8,REV_HV1J3,REV_HV1B1,REV_HV1W2,REV_HV1PV,# & REV_HV1Y2)# & PIR1: (VKLJBR,VKLJH3,F44001)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPLERLTL*# SEQUENCE: LPPLERLTL*# ...# >HUM12890# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1B1,GAG_HV1A2,GAG_HV1JR,GAG_HV1B5,# & GAG_HV1OY,GAG_HV1BR,GAG_HV1PV)# & PIR1: (FOVWA2,FOVWLV,FOVWH3)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPLTSLRSL*# SEQUENCE: YPLTSLRSL*# ...# >HUM12891# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1PV,POL_HV1A2,POL_HV1N5,POL_HV1EL,POL_HV1Z2,# & POL_HV1U4,POL_HV1BR,POL_HV1B1,POL_HV1B5,POL_HV1OY,# & POL_HV1ND,POL_HV1Y2,POL_HV1RH,POL_HV1H2)# & PIR1: (GNVWLV,GNLJND,GNVWVL,GNVWH3,B44001,GNVWA2)# & PIR2: (S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPVVAKEI*# SEQUENCE: LPPVVAKEI*# ...# >HUM12892# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1N5,ENV_HV1ZH,ENV_HV1BR,ENV_HV1EL,ENV_HV1Y2,# & ENV_HV1Z3,ENV_HV1Z6,ENV_HV1B8,ENV_HV1MF,ENV_HV1JR,# & ENV_HV1A2,ENV_HV1W2,ENV_HV1B1,ENV_HV1KB,ENV_HV1S1,# & ENV_HV1S3,ENV_HV1RH,ENV_HV1Z2,ENV_HV1H2,ENV_HV1C4,# & ENV_HV1SC,ENV_HV1PV,ENV_HV1H3)# & PIR1: (VCLJLV,VCLJA2,H44001,VCLJKX,VCLJSC,VCLJH4,VCLJH3,VCLJZR,# & VCLJVL,A44963,VCLJKB)# & PIR2: (A53034,S54384,S25939,S25938)# & PIR3: (S49197,S33985,S13288)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,CPKVSFEPI*# SEQUENCE: CPKVSFEPI*# ...# >HUM12893# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1MA,ENV_HV1C4,ENV_HV1Z8,ENV_HV1JR,# & ENV_HV1Y2,ENV_HV1B8,ENV_HV1S1,ENV_HV1S3,ENV_HV1W1,# & ENV_HV1H2,ENV_HV1A2,ENV_HV1W2,ENV_HV1J3,ENV_HV1BN)# & PIR1: (VCLJBR,VCLJA2,VCLJH4,VCLJ3W,H44001,VCLJH3)# & PIR2: (A40218,S25940,C41621,S60538)# & PIR3: (S33985)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPCRIKQII*# SEQUENCE: LPCRIKQII*# ...# >HUM12894# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVJ8,POLG_HCVBK,POLG_HCVJ7,# & POLG_HCVTW)# & PIR1: (GNWVTC,GNWVTW,GNWVJ8)# & PIR2: (A45573,S19876,S18032)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YPCTVNFTI*# SEQUENCE: YPCTVNFTI*# ...# >HUM12895# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCVTW,POLG_HCVH,POLG_HCVBK,POLG_HCV1,# & POLG_HCVJT)# & PIR1: (GNWVC3,GNWVCJ,GNWVCH,GNWVTW,GNWVTC)# & PIR2: (S18030,S40770,PN0677,S19876,S18032,S18031,A45573,# & S19875)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPALSTGLI*# SEQUENCE: LPALSTGLI*# ...# >HUM12896# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (S18030,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,CPSGHAVGI*# SEQUENCE: CPSGHAVGI*# ...# >HUM12897# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPTSGDVVI*# SEQUENCE: IPTSGDVVI*# ...# >HUM12898# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT)# & PIR2: (A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,LPPTTGPPI*# SEQUENCE: LPPTTGPPI*# ...# >HUM12899# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVTW,POLG_HCVJA,POLG_HCV1,POLG_HCVJT,POLG_HCVH,# & POLG_HCVBK)# & PIR1: (GNWVCH,GNWVC3,GNWVTC,GNWVCJ,GNWVTW)# & PIR2: (PS0104,PS0102,S40770,A45573,PS0085,S18030,JQ0880)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,APTLWARMI*# SEQUENCE: APTLWARMI*# ...# >HUM1289A# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POLG_HCVJT,POLG_HCVTW,POLG_HCVBK,POLG_HCVJA)# & PIR1: (GNWVCJ,GNWVTW,GNWVTC)# & PIR2: (JQ0879,PS0102,S18030,A45573)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,EPLDLPQII*# SEQUENCE: EPLDLPQII*# ...# >HUM1289B# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1RH,GAG_HV1ND,GAG_HV1C4,GAG_HV1MN,# & GAG_HV1B1,GAG_HV1EL,GAG_HV1J3,GAG_HV1H2,GAG_HV1N5,# & GAG_HV1PV,GAG_HV1B5,GAG_HV1OY,GAG_HV1W2,GAG_HV1JR,# & GAG_HV1Y2,GAG_HV1Z2,GAG_HV1A2,GAG_HV1MA)# & PIR1: (FOVWA2,A38068,FOVWH4,FOLJND,FOVWH3,FOVWLV,A44001,# & FOVWVL)# & PIR2: (S60700,S60703,S60698,S60699,S60704,S54377,S60708)# & PIR3: (S33979,S19598)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NANPDCKTI*# SEQUENCE: NANPDCKTI*# ...# >HUM1289C# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1RH,POL_HV1Y2,POL_HV1PV,POL_HV1U4,# & POL_HV1B1,POL_HV1B5,POL_HV1OY,POL_HV1Z6,POL_HV1BR,# & POL_HV1EL,POL_HV1N5,POL_HV1A2,POL_SIVCZ,POL_HV1H2,# & POL_HV1ND,POL_HV1JR,POL_HV1Z2)# & PIR1: (B44001,GNVWH3,GNLJND,GNVWLV,GNVWVL,GNLJSI,GNVWA2)# & PIR2: (S54378,A26192)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,TAVQMAVFI*# SEQUENCE: TAVQMAVFI*# ...# >HUM1289D# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1W1,ENV_HV1A2)# & PIR1: (VCLJ3W,VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,YAPPIGGQI*# SEQUENCE: YAPPIGGQI*# ...# >HUM1289E# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VAQRAYRAI*# SEQUENCE: VAQRAYRAI*# ...# >HUM1289F# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1B1,POL_SIVMK,POL_HV2ST,POL_HV1Z2,POL_HV2NZ,# & POL_SIVS4,POL_HV2SB,POL_SIVM1,POL_HV1PV,POL_HV1A2,# & POL_HV1EL,POL_HV2D1,POL_HV1H2,POL_HV1BR,POL_HV2KR,# & POL_HV1B5,POL_HV1OY,POL_HV2RO,POL_HV2BE,POL_HV1RH,# & POL_HV1JR,POL_HV1ND,POL_HV1Y2,POL_HV1N5,POL_SIVM1,# & POL_HV2G1,POL_HV2CA,POL_HV1MN,POL_HV1MA,POL_SIVSP)# & PIR1: (GNLJST,GNLJG3,GNVWH3,GNVWA2,GNLJG2,B44001,GNLJGG,GNVWLV,# & GNLJND,GNVWVL,GNLJCA,GNLJG5)# & PIR2: (S32056,S32075,S32118,S32062,S32072,S32096,S32055,S32064,# & S32078,S32059,S32076,S32051,S32073,F47330,S32120,A47330,# & S32092,S32093,S32090,S32137,S43127,S32088,S32067,A47175,# & S32057,S32089,S32117,S32159,S32053,S32135,S32097,S30484,# & S32136,S32050,S32083,S32085,S54378,S32081,S32087,S32058,# & S32134,S32063,S32054,S32098,S32138,S32061,S32077,S53092,# & S32079,S32049,E47330,S32071,B47175,S32086,S32060,S32126,# & S12153,C47330,S32052,D47330,S32047,S32082,S32119,S32048,# & S32070,S32084,S32157,S32069,S32068,S32140,S32127,S32160,# & S32122,S32151,S32091,S32080,S32066,S32074,S32095,S32065,# & S30483,S32139,S32094)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,QGWKGSPAI*# SEQUENCE: QGWKGSPAI*# ...# >HUM128A0# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,VGCLVGLRI*# SEQUENCE: VGCLVGLRI*# ...# >HUM128A1# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,DARAYDTEV*# SEQUENCE: DARAYDTEV*# ...# >HUM128A2# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,NALFRNLDV*# SEQUENCE: NALFRNLDV*# ...# >HUM128A3# MHC MOLECULE: HLA-B51(B*5103), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (VIF_HV1Y2,VIF_HV1A2,VIF_HV1N5)# & PIR1: (C44001,ASLJO1)# & PIR2: (S42961,S42969,S42977,S42952,S42990,S42956,S42992,S42941,# & S42999,S43005,S42962,S42951,S42991,S42974,S42980,S43004,# & S42944,S42953,S42972)# ANCHOR POSITIONS: 2,9# REFERENCES: kikuchi96a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesu,IPLGDAKLV*# SEQUENCE: IPLGDAKLV*# ...# >HUM128A4# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-1 (108-116)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 37 deg C# SUMMARY: HLA-A3,actunkn,bindyesm,DLVGFLLLK*# SEQUENCE: DLVGFLLLK*# ...# >HUM128A5# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-1 (109-117)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 37 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,LVGFLLLKY*# SEQUENCE: LVGFLLLKY*# ...# >HUM128A6# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE-1 (128-136)# DB REFERENCE: SWISS: (MAG8_HUMAN,MAG8_HUMAN,MAG1_HUMAN,MAG9_HUMAN,MAG1_HUMAN,# & MAG9_HUMAN)# & PIR2: (JC2358,I38668,I38667)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 37 deg C# SUMMARY: HLA-A3,actunkn,bindyesh,MLESVIKNY*# SEQUENCE: MLESVIKNY*# ...# >HUM128A7# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-1 (171-179)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAGC_HUMAN,MAGC_HUMAN,MAG8_HUMAN,MAG8_HUMAN,# & MAG2_HUMAN,MAG4_HUMAN,MAG1_HUMAN,MAG4_HUMAN,# & MAG1_HUMAN)# & PIR2: (JC2359,I54519,G01446,I68889,JC2362,I38661,I38667,# & JC2358)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 37 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,LVTCLGLSY*# SEQUENCE: LVTCLGLSY*# ...# >HUM128A8# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-1 (243-251)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 37 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,LVQEKYLEY*# SEQUENCE: LVQEKYLEY*# ...# >HUM128A9# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-1 (97-105)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesm,LFRAVITKK*# SEQUENCE: LFRAVITKK*# ...# >HUM128AA# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-1 (109-117)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesm,LVGFLLLKY*# SEQUENCE: LVGFLLLKY*# ...# >HUM128AB# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-1 (270-278)# DB REFERENCE: SWISS: (MAG4_HUMAN,MAG1_HUMAN,MAG1_HUMAN,MAG4_HUMAN)# & PIR2: (I38661,JC2358,G01446,JC2359)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,ALAETSYVK*# SEQUENCE: ALAETSYVK*# ...# >HUM128AC# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-2 (104-112)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN)# & PIR2: (I68889)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,EFQAAISRK*# SEQUENCE: EFQAAISRK*# ...# >HUM128AD# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-2/3 (115-123)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAGC_HUMAN,MAG3_HUMAN,MAG2_HUMAN,MAG3_HUMAN,# & MAGC_HUMAN)# & PIR2: (JC2361,I68889,I54519,JC2362)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesm,ELVHFLLLK*# SEQUENCE: ELVHFLLLK*# ...# >HUM128AE# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MAGE-2 (236-244)# DB REFERENCE: SWISS: (MAG2_HUMAN,MAG2_HUMAN,MAGC_HUMAN,MAGC_HUMAN)# & PIR2: (JC2362,I54519,I68889)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesm,DSVFAHPRK*# SEQUENCE: DSVFAHPRK*# ...# >HUM128AF# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-3 (69-77)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN,MAG6_HUMAN,MAG6_HUMAN)# & PIR2: (JC2360,G01445,JC2361)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,SSLPTTMNY*# SEQUENCE: SSLPTTMNY*# ...# >HUM128B0# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-3 (145-153)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG6_HUMAN,MAG6_HUMAN,MAG3_HUMAN)# & PIR2: (JC2360,G01445,JC2361)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,YFFPVIFSK*# SEQUENCE: YFFPVIFSK*# ...# >HUM128B1# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-3 (168-176)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,EVDPIGHLY*# SEQUENCE: EVDPIGHLY*# ...# >HUM128B2# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE-3 (293-301)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2362,JC2361)# ANCHOR POSITIONS: ?# REFERENCES: mcintyre96a# COMMENT: tested at 26 deg C# SUMMARY: HLA-A3,actunkn,bindyesl,ISGGPHISY*# SEQUENCE: ISGGPHISY*# ...# >HUM128B3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: gp100# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_BOVIN,PM17_MOUSE,PM17_HUMAN)# & PIR2: (S53871,A41234,A49179,I38400,A53668)# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a,robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,ITDQVPFSV*# SEQUENCE: ITDQVPFSV*# ...# >HUM128B4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MART-l/Melan-A# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ILTVIILGVL*# SEQUENCE: ILTVIILGVL*# ...# >HUM128B5# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: TRP-1 gp75# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a,robbins96a,romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A31,actyesu,bindyesu,MSLQRQFLR*# SEQUENCE: MSLQRQFLR*# ...# >HUM228B6# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tyrosinase# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,QNIILSNAPLGPQFP*# SEQUENCE: QNIILSNAPLGPQFP*# ...# >HUM228B7# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tyrosinase# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a,robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-DR4,actyesu,bindyesu,SYLQDSDPDSFQD*# SEQUENCE: SYLQDSDPDSFQD*# ...# >HUM128B8# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Beta-Catenin# DB REFERENCE: SWISS: (CTNB_XENLA,CTNB_MOUSE,CTNB_HUMAN,CTNB_MOUSE)# & PIR2: (S35091,S35099,A38973)# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,SYLDSGIH*# SEQUENCE: SYLDSGIH*# ...# >HUM128B9# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MUM-1# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a,robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-B44,actyesu,bindyesu,EEKLIVVLF*# SEQUENCE: EEKLIVVLF*# ...# >HUM128BA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: cdk4# DB REFERENCE: PIR2: (S52841)# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a,robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,ACDPHSGHFV*# SEQUENCE: ACDPHSGHFV*# ...# >HUM128BB# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p15# DB REFERENCE: PIR2: (I38927)# ANCHOR POSITIONS: ?# REFERENCES: rosenberg96a,robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-A24,actyesu,bindyesu,AYGLDFYIL*# SEQUENCE: AYGLDFYIL*# ...# >HUM128BC# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: CTL assays/inhibition/competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Melan-A/MART-1 (27-35)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: fleischauer96a,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesh,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM128BD# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: CTL assays/inhibition# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: Melan-A/MART-1 (27-35)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: fleischauer96a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesh,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM128BE# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: CTL assays/Competition# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Melan-A/MART-1 (27-35)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: fleischauer96a,rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesl,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM128BF# MHC MOLECULE: HLA-A69(A*6901), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Melan-A/MART-1 (27-35)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: fleischauer96a# COMMENT:# SUMMARY: HLA-A69,actyesl,bindyesu,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM128C0# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reference/Competition/Half-time# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MAGE-3 (271-279)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAGC_HUMAN,MAG3_HUMAN,MAGC_HUMAN)# & PIR2: (JC2361,I54519,JC2362)# ANCHOR POSITIONS: ?# REFERENCES: fleischauer96a,kawakami96a,romero96a,van-elsas96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesh,FLWGPRALV*# SEQUENCE: FLWGPRALV*# ...# >HUM128C1# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MAGE-1 (271-279)# DB REFERENCE: SWISS: (MAGC_HUMAN,MAG3_HUMAN,MAGC_HUMAN,MAG3_HUMAN)# & PIR2: (JC2362,JC2361,I54519)# ANCHOR POSITIONS: ?# REFERENCES: fleischauer96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FLWGPRALV*# SEQUENCE: FLWGPRALV*# ...# >HUM128C2# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MAGE-1 (271-279)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAGC_HUMAN,MAGC_HUMAN,MAG3_HUMAN)# & PIR2: (JC2362,I54519,JC2361)# ANCHOR POSITIONS: ?# REFERENCES: fleischauer96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FLWGPRALV*# SEQUENCE: FLWGPRALV*# ...# >HUM128C3# MHC MOLECULE: HLA-A2(A*0209), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MAGE-1 (271-279)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN,MAGC_HUMAN,MAGC_HUMAN)# & PIR2: (I54519,JC2361,JC2362)# ANCHOR POSITIONS: ?# REFERENCES: fleischauer96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FLWGPRALV*# SEQUENCE: FLWGPRALV*# ...# >HUM128C4# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL assays/CTL induction/Reference# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (587-595)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1JR,POL_HV1H2,POL_HV1B5,POL_HV1BR,# & POL_HV1PV,POL_HV1A2,POL_HV1MA,POL_HV1B1)# & PIR1: (GNVWVL,GNVWLV,GNVWH3,GNVWA2)# & PIR2: (B47175,A47175)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesh,EPIVGAETF*# SEQUENCE: EPIVGAETF*# ...# >HUM128C5# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (804-814)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1H2,POL_HV1B1,POL_HV1A2,POL_HV1Z2,# & POL_HV1U4,POL_HV1MA,POL_HV1Y2,POL_HV1ND,POL_HV1JR,# & POL_HV1EL,POL_HV1OY,POL_HV1B5,POL_HV1BR,POL_SIVCZ,# & POL_HV1PV,POL_HV1RH,POL_HV1MN)# & PIR1: (GNVWVL,GNVWH3,GNLJND,B44001,GNVWA2,GNLJSI,GNVWLV)# & PIR2: (S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,IPAETGQETAY*# SEQUENCE: IPAETGQETAY*# ...# >HUM128C6# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV nef (133-140)# DB REFERENCE: SWISS: (NEF_HV1EL,NEF_HV1A2,NEF_HV1ND,NEF_HV1MN,NEF_HV1PV,# & NEF_HV1S1,NEF_HV112,NEF_HV1OY,NEF_HV1Z6,NEF_HV1U4)# & PIR1: (ASLJ12,ASLJH3,QQLJND,ASLJVL,ASLJO2,QQLJZR)# & PIR2: (S03245,S25937)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,TPGPGIRY*# SEQUENCE: TPGPGIRY*# ...# >HUM128C7# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV env (413-421)# DB REFERENCE: SWISS: (ENV_HV1Z8,ENV_HV1B8,ENV_HV1BN,ENV_HV1A2,ENV_HV1W2,# & ENV_HV1J3,ENV_HV1H2,ENV_HV1B1,ENV_HV1C4,ENV_HV1MA,# & ENV_HV1Y2,ENV_HV1JR,ENV_HV1W1,ENV_HV1S1,ENV_HV1S3)# & PIR1: (VCLJH3,VCLJA2,VCLJH4,VCLJ3W,H44001,VCLJBR)# & PIR2: (S60538,A40218,S25940,C41621)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,LPCRIKQII*# SEQUENCE: LPCRIKQII*# ...# >HUM128C8# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV gag (486-494)# DB REFERENCE: SWISS: (GAG_HV1JR,GAG_HV1OY,GAG_HV1H2,GAG_HV1BR,GAG_HV1B1,# & GAG_HV1A2,GAG_HV1B5,GAG_HV1PV)# & PIR1: (FOVWH3,FOVWLV,FOVWA2)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,YPLTSLRSL*# SEQUENCE: YPLTSLRSL*# ...# >HUM128C9# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (574-582)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1JR,POL_HV1ND,POL_HV1EL,POL_SIVAG,# & POL_HV1A2,POL_HV1B1,POL_HV1N5,POL_HV1B5,POL_HV1BR,# & POL_HV1Z2,POL_HV1MA,POL_HV1U4,POL_HV1Y2,POL_HV1MN,# & POL_HV1OY,POL_SIVCZ,POL_HV1PV,POL_HV1RH)# & PIR1: (GNVWA2,GNVWH3,GNLJND,GNVWVL,GNVWLV,GNLJSI,B44001)# & PIR2: (S54378,A47175,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,TPPLVKLWY*# SEQUENCE: TPPLVKLWY*# ...# >HUM128CA# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV gag (459-467)# DB REFERENCE: SWISS: (GAG_HV1JR,GAG_HV1N5,GAG_HV1MN,GAG_HV1J3,GAG_HV1A2,# & GAG_HV1C4,GAG_HV1RH)# & PIR1: (A38068,FOVWH4,FOVWA2)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,APPEESFRF*# SEQUENCE: APPEESFRF*# ...# >HUM128CB# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL assays/CTL induction/Reference# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HIV pol (448-456)# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1OY,POL_HV1MN,POL_HV1B1,POL_HV1Y2,# & POL_HV1H2,POL_HV1BR,POL_HV1A2,POL_HV1EL,POL_HV1Z2,# & POL_HV1PV)# & PIR1: (GNVWA2,GNVWLV,GNVWVL,B44001,GNVWH3)# & PIR2: (S54378,B47175,A49489)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesm,IPLTEEAEL*# SEQUENCE: IPLTEEAEL*# ...# >HUM128CC# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL assays/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: HIV env (77-85)# DB REFERENCE: SWISS: (ENV_HV1JR,ENV_HV1PV,ENV_HV1SC,ENV_HV1H3,ENV_HV1J3,# & ENV_HV1BR,ENV_HV1B8,ENV_HV1N5,ENV_HV1KB,ENV_HV1B1,# & ENV_HV1H2,ENV_HV1OY,ENV_HV1S3,ENV_HV1A2)# & PIR1: (VCLJSC,VCLJA2,VCLJH3,VCLJKB,VCLJKX,VCLJVL,VCLJLV)# & PIR3: (S33985,S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actyesm,bindyesm,DPNPQEVVL*# SEQUENCE: DPNPQEVVL*# ...# >HUM128CD# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL assays/CTL induction/Reference# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: HIV pol (587-596)# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1PV,POL_HV1JR,POL_HV1MN,POL_HV1H2,# & POL_HV1B1,POL_HV1MA,POL_HV1BR,POL_HV1A2)# & PIR1: (GNVWA2,GNVWVL,GNVWH3,GNVWLV)# & PIR2: (A47175,B47175)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesm,bindyesl,EPIVGAETFY*# SEQUENCE: EPIVGAETFY*# ...# >HUM128CE# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag (255-264)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_HV1Y2,GAG_HV1OY,GAG_HV1H2,GAG_HV1N5,# & GAG_HV1ND,GAG_HV1BR,GAG_HV1A2,GAG_HV1PV,GAG_HV1W2,# & GAG_HV1JR,GAG_HV1B1,GAG_HV1EL,GAG_HV1B5,GAG_HV1J3,# & GAG_HV1Z2,GAG_HV1RH)# & PIR1: (FOVWH3,FOVWVL,A44001,A38068,FOVWLV,FOLJND,FOVWA2)# & PIR2: (S54377,S60708,S60703,S60702,S60697,S49086,S60699,S44993,# & S60704,S60698)# & PIR3: (S33979,S19598)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,NPPIPVGEIY*# SEQUENCE: NPPIPVGEIY*# ...# >HUM128CF# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL assays/Reference# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: HIV nef (139-147)# DB REFERENCE: SWISS: (NEF_HV1A2,NEF_HV1MN,NEF_HV1Z6,NEF_HV1S1,NEF_HV1RH,# & NEF_HV1BN,NEF_HV1ND)# & PIR1: (QQLJND,ASLJO2,QQLJZR,ASLJBR)# & PIR2: (S03246,S25937,S24985)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesl,YPLTFGWCF*# SEQUENCE: YPLTFGWCF*# ...# >HUM128D0# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL assays/CTL induction/Reference# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: HIV pol (330-338)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1H2,POL_HV1MN,POL_HV1N5,POL_HV1B5,# & POL_HV1PV,POL_HV1OY,POL_HV1BR,POL_HV1A2)# & PIR1: (GNVWLV,GNVWA2,GNVWVL,GNVWH3)# & PIR2: (S32117,S32062,S32120,A47330,S32137,S32067,S32054,S32138,# & S32079,S32134,D47330,S32064,S32055,B47330,S32056,S32075,# & S32118,S32072,S32135,S32159,S32097,F47330,S32076,B47175,# & C47330,S32052,S32119,S32140,S32127,S32160,S32151,S32122,# & S32071,S32139,S32065,S32069,S32095,S32066,S32074,S32058,# & S32063,S32061,E47330,S32068,S32070,S32157,S32080,S32136,# & S32073,S32057,S32053,S32077,S32096,S32059,S32078,S32129,# & S32060,S32126)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesm,bindyesl,NPDIVIYQY*# SEQUENCE: NPDIVIYQY*# ...# >HUM128D1# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/Reference# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV nef (78-85)# DB REFERENCE: SWISS: (NEF_HV1ND,NEF_HV1U4,NEF_HV1JR,NEF_HV112,NEF_HV2D2,# & NEF_HV1EL,NEF_HV1S3,NEF_HV1B8,NEF_HV1BN,NEF_HV1Z2,# & NEF_HV1MN,NEF_HV1B1,NEF_HV1Z6,NEF_HV1OY,NEF_HV1A2,# & NEF_HV1H2,NEF_HV1S1,NEF_HV1MA,NEF_HV1SC,NEF_HV1BR,# & NEF_HV1PV)# & PIR1: (QQLJND,ASLJH3,ASLJ12,QQLJZR,ASLJBR,ASLJO2,ASLJVL,# & ASLJFV)# & PIR2: (S54385,S24572,S25937,S43467,S24985,S03245,S03244)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,VPLRPMTY*# SEQUENCE: VPLRPMTY*# ...# >HUM128D2# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag (293-303)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1ND,GAG_HV1OY,GAG_HV1H2,GAG_HV1N5,# & GAG_HV1MN,GAG_HV1W2,GAG_HV1J3,GAG_HV1RH,GAG_HV1B5,# & GAG_HV1EL,GAG_SIVCZ,GAG_HV1Z2,GAG_HV1B1,GAG_HV1JR,# & GAG_HV1A2,GAG_HV1C4,GAG_HV1Y2)# & PIR1: (FOVWH4,FOLJND,FOVWA2,FOVWLV,A44001,A38068,FOVWVL,FOVWH3,# & FOLJSI)# & PIR2: (S60703,S60699,S60704,S54377,S60708,S52929,S60700,S60697,# & S60698,S60702)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,EPFRDYVDRFY*# SEQUENCE: EPFRDYVDRFY*# ...# >HUM128D3# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (379-387)# DB REFERENCE: SWISS: (POL_HV1BR,POL_SIVCZ,POL_HV1H2,POL_HV1PV,POL_HV1Z2,# & POL_HV1N5,POL_HV1ND,POL_HV1JR,POL_HV1B5,POL_HV1A2,# & POL_HV1Y2,POL_HV1OY,POL_HV1B1,POL_HV1RH,POL_HV1MA,# & POL_HV1U4,POL_HV1MN,POL_HV1EL)# & PIR1: (GNVWH3,GNVWVL,GNLJSI,GNLJND,GNVWA2,B44001,GNVWLV)# & PIR2: (S43127,S54378,A47175,B47175)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,EPPFLWMGY*# SEQUENCE: EPPFLWMGY*# ...# >HUM128D4# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (500-510)# DB REFERENCE: SWISS: (POL_HV1U4,POL_HV1RH,POL_HV1B1,POL_HV1A2,POL_HV1Z2,# & POL_HV1N5,POL_HV1ND,POL_HV1JR,POL_HV1H2,POL_HV1B5,# & POL_HV1Y2,POL_HV1MN,POL_HV1EL,POL_HV1BR,POL_HV1PV,# & POL_HV1OY)# & PIR1: (B44001,GNVWA2,GNVWLV,GNLJND,GNVWVL,GNVWH3)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,EPFKNLKTGKY*# SEQUENCE: EPFKNLKTGKY*# ...# >HUM128D5# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag (340-348)# DB REFERENCE: SWISS: (GAG_HV1Y2,GAG_HV1JR,GAG_HV1J3,GAG_HV1MN,GAG_HV1W2,# & GAG_HV1OY,GAG_HV1C4,GAG_HV1A2,GAG_HV1RH,GAG_HV1B5,# & GAG_HV1PV,GAG_HV1H2,GAG_HV1BR,GAG_HV1B1)# & PIR1: (A44001,FOVWA2,FOVWH4,FOVWVL,FOVWLV,A38068,FOVWH3)# & PIR2: (S60703,S60699,S60697,S60704,S60700)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,GPAATLEEM*# SEQUENCE: GPAATLEEM*# ...# >HUM128D6# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL assays/CTL induction/Reference# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: HIV pol (311-319)# DB REFERENCE: SWISS: (POL_HV1ND,POL_HV1A2,POL_HV1MA,POL_HV1H2,POL_HV1Y2,# & POL_HV1B5,POL_HV1BR,POL_HV1RH,POL_HV1B1,POL_HV1JR,# & POL_HV1EL,POL_HV1Z2,POL_HV1OY,POL_HV1PV,POL_HV1MN)# & PIR1: (GNVWLV,GNVWA2,GNVWH3,GNVWVL,GNLJND,B44001)# & PIR2: (S32097,S32159,S32089,S32092,S32075,B47175,S32134,S32080,# & S32096,S32050,S32072,A47330,S32068,S32157,S32091,S32136,# & S54378,S32073,S32066,S32074,E47330,S32048,S32078,S32051,# & S32071,S43127,F47330,S32076,C47330,S32069,S32139,D47330,# & S32137,S32138,S32079,S32093,S32135,S32047,S32126,S32160,# & S32067,S32098,S32049,S32070,A47175,S32090)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesl,SPAIFQSSM*# SEQUENCE: SPAIFQSSM*# ...# >HUM128D7# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV gag (479-486)# DB REFERENCE: SWISS: (GAG_HV1Y2,GAG_HV1JR,GAG_HV1H2,GAG_HV1N5,GAG_HV1PV,# & GAG_HV1BR,GAG_HV1B1,GAG_HV1B5,GAG_HV1A2)# & PIR1: (FOVWA2,FOVWH3,A44001,FOVWLV)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,EPIDKELY*# SEQUENCE: EPIDKELY*# ...# >HUM128D8# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (467-474)# DB REFERENCE: SWISS: (POL_HV1A2)# & PIR1: (GNVWA2)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,EPVHEVYY*# SEQUENCE: EPVHEVYY*# ...# >HUM128D9# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL assays/CTL induction# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: HIV pol (273-282)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1Z2,POL_HV1N5,POL_HV1JR,POL_HV1A2,# & POL_HV1OY)# & PIR1: (GNVWA2)# & PIR2: (S32076,S32056,S32052,S32136,S32078,S32160,S32077,S32053,# & S32058,S32157,S32065,S32133,S32135,S32128,C47330,S32055,# & S32152,S32075,S32134,E47330,S32066,S32074,S43127,S32071,# & S32137,D47330,S32132,S54378,S32073,S32059,S32060,S32129,# & S32063,S32061,S32067,S32131,S32095,S32070,S32096,S32072,# & A47330,S32062,S32057,S32138,S32054,S32159,S32097,S32139,# & S32064,B47330,F47330)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesl,VPLDKDFRKY*# SEQUENCE: VPLDKDFRKY*# ...# >HUM128DA# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry/CTL induction/Reference# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: HIV nef (75-85)# DB REFERENCE: SWISS: (NEF_HV1MA,NEF_HV1A2,NEF_HV1OY,NEF_HV1Z2,NEF_HV1JR,# & NEF_HV1Z6,NEF_HV1S1,NEF_HV1SC,NEF_HV1EL,NEF_HV1U4,# & NEF_HV1ND)# & PIR1: (QQLJND,QQLJZR,ASLJO2)# & PIR2: (S54385,S25937)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesl,RPQVPLRPMTY*# SEQUENCE: RPQVPLRPMTY*# ...# >HUM128DB# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV nef (75-83)# DB REFERENCE: SWISS: (NEF_HV1OY,NEF_HV1Z6,NEF_HV1Y2,NEF_HV1Z2,NEF_HV1U4,# & NEF_HV1JR,NEF_HV1A2,NEF_HV1EL,NEF_HV1ZH,NEF_HV1ND,# & NEF_HV1MA,NEF_HV1SC,NEF_HV1S1,NEF_HV1RH)# & PIR1: (B44963,QQLJZR,QQLJND,ASLJO2,I44001)# & PIR2: (S25937,S54385,S03246)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,RPQVPLRPM*# SEQUENCE: RPQVPLRPM*# ...# >HUM128DC# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV rev (75-83)# DB REFERENCE: SWISS: (REV_HV1BR,REV_HV1H2,REV_HV1SC,REV_HV1MA,REV_HV1BN,# & REV_HV1B8,REV_HV1C4,REV_HV1J3,REV_HV1W2,REV_HV1Y2,# & REV_HV1PV,REV_HV1B1,REV_HV1JR,REV_HV1RH,REV_HV112,# & REV_HV1A2)# & PIR1: (F44001,VKLJH3,VKLJBR)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,LPPLERLTL*# SEQUENCE: LPPLERLTL*# ...# >HUM128DD# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV pol# DB REFERENCE: SWISS: (POL_HV1PV,POL_HV1B5,POL_HV1JR,POL_HV1H2,POL_HV1B1,# & POL_HV1MN,POL_HV1BR,POL_HV1MA,POL_HV1A2)# & PIR1: (GNVWH3,GNVWVL,GNVWA2,GNVWLV)# & PIR2: (B47175,A47175)# & PIR3: (S11523,S33980)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B51,actyesl,bindyesu,EPIVGAETF*# SEQUENCE: EPIVGAETF*# ...# >HUM128DE# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: CTL assays/CTL induction/Reference# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV RT (448-456)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1A2,POL_HV1EL,POL_HV1OY,POL_HV1PV,# & POL_HV1MN,POL_HV1Y2,POL_HV1H2,POL_HV1B5,POL_HV1BR,# & POL_HV1Z2)# & PIR1: (B44001,GNVWLV,GNVWA2,GNVWH3,GNVWVL)# & PIR2: (A49489,S54378,B47175)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a,hivdb97a# COMMENT:# SUMMARY: HLA-B51,actyesm,bindyesu,IPLTEEAEL*# SEQUENCE: IPLTEEAEL*# ...# >HUM128DF# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1EL,NEF_HV1ND,NEF_HV1SC,NEF_HV1Z2,NEF_HV1U4,# & NEF_HV1JR,NEF_HV1A2,NEF_HV1MA,NEF_HV1OY,NEF_HV1Z6,# & NEF_HV1S1)# & PIR1: (ASLJO2,QQLJND,QQLJZR)# & PIR2: (S25937,S54385)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B51,actyesl,bindyesu,RPQVPLRPMTY*# SEQUENCE: RPQVPLRPMTY*# ...# >HUM128E0# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: CTL assays/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV env# DB REFERENCE: SWISS: (ENV_HV1JR,ENV_HV1B1,ENV_HV1OY,ENV_HV1H2,ENV_HV1N5,# & ENV_HV1B8,ENV_HV1KB,ENV_HV1J3,ENV_HV1SC,ENV_HV1PV,# & ENV_HV1H3,ENV_HV1S3,ENV_HV1A2,ENV_HV1BR)# & PIR1: (VCLJA2,VCLJKX,VCLJVL,VCLJLV,VCLJKB,VCLJSC,VCLJH3)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: shiga96a# COMMENT:# SUMMARY: HLA-B51,actyesm,bindyesu,DPNPQEVVL*# SEQUENCE: DPNPQEVVL*# ...# >HUM128E1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,DLERXGXAKVG*# SEQUENCE: DLERXGXAKVG*# ...# >HUM128E2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,KLDGSXXXLG*# SEQUENCE: KLDGSXXXLG*# ...# >HUM128E3# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,KLDQGVRXAX*# SEQUENCE: KLDQGVRXAX*# ...# >HUM128E4# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,VLKGQXWLYA*# SEQUENCE: VLKGQXWLYA*# ...# >HUM128E5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Integrin VLA3 alpha# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,NLRDKLRPL*# SEQUENCE: NLRDKLRPL*# ...# >HUM128E6# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,XLAERSXXXIX*# SEQUENCE: XLAERSXXXIX*# ...# >HUM128E7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,DLDENYFEY*# SEQUENCE: DLDENYFEY*# ...# >HUM128E8# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,KLAPXXXKQX*# SEQUENCE: KLAPXXXKQX*# ...# >HUM128E9# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,KLDGVXXXXA*# SEQUENCE: KLDGVXXXXA*# ...# >HUM128EA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glucose transporter 2 (249-257)# DB REFERENCE: SWISS: (GTR2_HUMAN)# & PIR2: (A31318)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,KLDEEVKAK*# SEQUENCE: KLDEEVKAK*# ...# >HUM128EB# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,XLDDSNRYG*# SEQUENCE: XLDDSNRYG*# ...# >HUM128EC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,GLDDLXVMKL*# SEQUENCE: GLDDLXVMKL*# ...# >HUM128ED# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: c-src proto-oncogene# DB REFERENCE: SWISS: (SRC_RSVSR,SRC_CHICK,SRC_HUMAN,SRC_AVISS,FYN_HUMAN,# & SRC2_XENLA,SRC_RSVPA,YES_AVISY,YES_XIPHE,SRC_RSVH1,# & SRCN_MOUSE,SRC_AVIST,FYN_MOUSE,FYN_XIPHE,YES_MOUSE,# & YES_CHICK,FYN_XENLA,SRC_AVIS2,YES_HUMAN,SRC1_XENLA,# & SRC_RSVP,SRC_HUMAN,SRC_AVISR,FYN_CHICK,SRC_CHICK,# & YES_XENLA,FYN_MOUSE)# & PIR1: (TVHUSR,TVFVPR,TVFVR,TVHUYS,TVHUSC,TVCHS,TVCHYS,TVFVMT,# & TVHUSY,TVFV60,TVFVS1,TVFVS2,TVFVG9,OKFVYR)# & PIR2: (B34104,S31645,S20808,A43610,S15582,S26420,A43806,A49114,# & A44991,A45501,S33568,A34104,PT0199)# & PIR3: (I51592,I51593)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,ALYGRFTIKS*# SEQUENCE: ALYGRFTIKS*# ...# >HUM128EE# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,ALDEARKRKGF*# SEQUENCE: ALDEARKRKGF*# ...# >HUM128EF# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,XLDKTIAVY*# SEQUENCE: XLDKTIAVY*# ...# >HUM128F0# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,YLTAEXXXKS*# SEQUENCE: YLTAEXXXKS*# ...# >HUM128F1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-A2,actunkn,bindyesu,XLSASPXKS*# SEQUENCE: XLSASPXKS*# ...# >HUM128F2# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,XENSAFLVKXY*# SEQUENCE: XENSAFLVKXY*# ...# >HUM128F3# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: colligin Hsp 47 (247-255)# DB REFERENCE: SWISS: (HS47_HUMAN,HS47_RAT)# & PIR1: (A40968,S20608)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,DEKEKLQLV*# SEQUENCE: DEKEKLQLV*# ...# >HUM128F4# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,KEKXSNXSXS*# SEQUENCE: KEKXSNXSXS*# ...# >HUM128F5# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,KEVSDLERSK*# SEQUENCE: KEVSDLERSK*# ...# >HUM128F6# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,KEKERNYXKAE*# SEQUENCE: KEKERNYXKAE*# ...# >HUM128F7# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,XEDDHNWNK*# SEQUENCE: XEDDHNWNK*# ...# >HUM128F8# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,XEDERPNXXK*# SEQUENCE: XEDERPNXXK*# ...# >HUM128F9# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PGI-PLD (128-135)# DB REFERENCE: SWISS: (PHL1_HUMAN,PHLD_HUMAN,PHL2_HUMAN)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,GEDGRVYV*# SEQUENCE: GEDGRVYV*# ...# >HUM128FA# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 5-HT 1F receptor (142-150)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B18,actunkn,bindyesu,XEYARKXT*# SEQUENCE: XEYARKXT*# ...# >HUM128FB# MHC MOLECULE: HLA-Cw7, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-Cw7,actunkn,bindyesu,KPGXSGXSGS*# SEQUENCE: KPGXSGXSGS*# ...# >HUM128FC# MHC MOLECULE: HLA-Cw7, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-Cw7,actunkn,bindyesu,XFYGASXXAS*# SEQUENCE: XFYGASXXAS*# ...# >HUM128FD# MHC MOLECULE: HLA-Cw7, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-Cw7,actunkn,bindyesu,IFRWEVQFASF*# SEQUENCE: IFRWEVQFASF*# ...# >HUM128FE# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Predicted from eluted peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-B7,actunkn,bindyesu,XSIRKIQXXK*# SEQUENCE: XSIRKIQXXK*# ...# >HUM128FF# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,DLERXGXAKVG*# SEQUENCE: DLERXGXAKVG*# ...# >HUM12900# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KLDGSXXXLG*# SEQUENCE: KLDGSXXXLG*# ...# >HUM12901# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KLDQGVRXAX*# SEQUENCE: KLDQGVRXAX*# ...# >HUM12902# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,VLKGQXWLYA*# SEQUENCE: VLKGQXWLYA*# ...# >HUM12903# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Integrin VLA3 alpha# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,NLRDKLRPL*# SEQUENCE: NLRDKLRPL*# ...# >HUM12904# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XLAERSXXXIX*# SEQUENCE: XLAERSXXXIX*# ...# >HUM12905# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,DLDENYFEY*# SEQUENCE: DLDENYFEY*# ...# >HUM12906# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KLAPXXXKQX*# SEQUENCE: KLAPXXXKQX*# ...# >HUM12907# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KLDGVXXXXA*# SEQUENCE: KLDGVXXXXA*# ...# >HUM12908# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Glucose transporter 2 (249-257)# DB REFERENCE: SWISS: (GTR2_HUMAN)# & PIR2: (A31318)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KLDEEVKAK*# SEQUENCE: KLDEEVKAK*# ...# >HUM12909# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XLDDSNRYG*# SEQUENCE: XLDDSNRYG*# ...# >HUM1290A# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,GLDDLXVMKL*# SEQUENCE: GLDDLXVMKL*# ...# >HUM1290B# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: c-src proto-oncogene# DB REFERENCE: SWISS: (SRC_RSVSR,SRC_AVIST,FYN_MOUSE,SRCN_MOUSE,SRC_RSVPA,# & YES_CHICK,SRC1_XENLA,YES_XENLA,SRC_CHICK,FYN_CHICK,# & SRC_AVISR,SRC_AVISS,SRC_HUMAN,FYN_HUMAN,SRC2_XENLA,# & YES_AVISY,YES_XIPHE,SRC_HUMAN,SRC_RSVP,FYN_XENLA,# & SRC_AVIS2,YES_HUMAN,FYN_XIPHE,SRC_CHICK,YES_MOUSE,# & FYN_MOUSE,SRC_RSVH1)# & PIR1: (TVFVG9,TVHUSC,TVCHS,TVFV60,TVFVS1,TVFVR,TVHUYS,TVFVPR,# & TVHUSR,TVHUSY,TVFVMT,TVCHYS,OKFVYR,TVFVS2)# & PIR2: (B34104,A43610,S15582,S20808,S31645,S26420,A43806,S33568,# & A44991,A49114,A34104,PT0199,A45501)# & PIR3: (I51592,I51593)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,ALYGRFTIKS*# SEQUENCE: ALYGRFTIKS*# ...# >HUM1290C# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,ALDEARKRKGF*# SEQUENCE: ALDEARKRKGF*# ...# >HUM1290D# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XLDKTIAVY*# SEQUENCE: XLDKTIAVY*# ...# >HUM1290E# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,YLTAEXXXKS*# SEQUENCE: YLTAEXXXKS*# ...# >HUM1290F# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XLSASPXKS*# SEQUENCE: XLSASPXKS*# ...# >HUM12910# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XENSAFLVKXY*# SEQUENCE: XENSAFLVKXY*# ...# >HUM12911# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: colligin Hsp 47 (247-255)# DB REFERENCE: SWISS: (HS47_RAT,HS47_HUMAN)# & PIR1: (A40968,S20608)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,DEKEKLQLV*# SEQUENCE: DEKEKLQLV*# ...# >HUM12912# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KEKXSNXSXS*# SEQUENCE: KEKXSNXSXS*# ...# >HUM12913# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KEVSDLERSK*# SEQUENCE: KEVSDLERSK*# ...# >HUM12914# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KEKERNYXKAE*# SEQUENCE: KEKERNYXKAE*# ...# >HUM12915# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XEDDHNWNK*# SEQUENCE: XEDDHNWNK*# ...# >HUM12916# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XEDERPNXXK*# SEQUENCE: XEDERPNXXK*# ...# >HUM12917# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PGI-PLD (128-135)# DB REFERENCE: SWISS: (PHL2_HUMAN,PHL1_HUMAN,PHLD_HUMAN)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,GEDGRVYV*# SEQUENCE: GEDGRVYV*# ...# >HUM12918# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 5-HT 1F receptor (142-150)# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XEYARKXT*# SEQUENCE: XEYARKXT*# ...# >HUM12919# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,KPGXSGXSGS*# SEQUENCE: KPGXSGXSGS*# ...# >HUM1291A# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XFYGASXXAS*# SEQUENCE: XFYGASXXAS*# ...# >HUM1291B# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,IFRWEVQFASF*# SEQUENCE: IFRWEVQFASF*# ...# >HUM1291C# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: papadopulos96a# COMMENT: extracted from pancreatic beta-cell line# SUMMARY: HLA-?,actunkn,bindyesu,XSIRKIQXXK*# SEQUENCE: XSIRKIQXXK*# ...# >HUM1291D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: HER-2 (5-13)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ALCRWGLLL*# SEQUENCE: ALCRWGLLL*# ...# >HUM1291E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/CTL assays/Reference# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HER-2 (369-377)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a,romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesh,KIFGSLAFL*# SEQUENCE: KIFGSLAFL*# ...# >HUM1291F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: HER-2 (391-399)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,PLQPEQLQV*# SEQUENCE: PLQPEQLQV*# ...# >HUM12920# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER-2 (402-410)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,TLEEITGYL*# SEQUENCE: TLEEITGYL*# ...# >HUM12921# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: HER-2 (457-465)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,SLRELGSGL*# SEQUENCE: SLRELGSGL*# ...# >HUM12922# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER-2 (466-474)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALIHHNTHL*# SEQUENCE: ALIHHNTHL*# ...# >HUM12923# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER-2 (689-697)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,RLLQETELV*# SEQUENCE: RLLQETELV*# ...# >HUM12924# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/CTL assays/CTL induction# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HER-2 (789-797)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (TVRTNU,A24571)# & PIR2: (I48161)# ANCHOR POSITIONS: 2,9# REFERENCES: fisk95a,disis94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,CLTSTVQLV*# SEQUENCE: CLTSTVQLV*# ...# >HUM12925# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HER-2 (851-859)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (TVRTNU,A24571)# & PIR2: (PT0184,A47253,I48161)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a,disis94a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,VLVKSPNHV*# SEQUENCE: VLVKSPNHV*# ...# >HUM12926# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: HER-2 (971-979)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ELVSEVSKV*# SEQUENCE: ELVSEVSKV*# ...# >HUM12927# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: Folate-binding protein(112-120)# DB REFERENCE: SWISS: (FOL2_MOUSE,FOL1_HUMAN,FOL2_HUMAN,FOL2_HUMAN,# & FOL1_MOUSE)# & PIR2: (A33417,A45753,B40969,A40969)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,NLGPWIQQV*# SEQUENCE: NLGPWIQQV*# ...# >HUM12928# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HER-2 (971-979)# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# ANCHOR POSITIONS: ?# REFERENCES: fisk95a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ELVSEFSRM*# SEQUENCE: ELVSEFSRM*# ...# >HUM12929# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: Flu matrix (128-135)# DB REFERENCE: SWISS: (VMT1_IAFPR,VMT1_IAZI1,VMT1_IAUDO,VMT1_IAFOW,VMT1_IALE1,# & VMT1_IAANN,VMT1_IACKB,VMT1_IABAN,VMT1_IAUSS,VMT1_IAPUE,# & VMT1_IALE2,VMT1_IAFPW,VMT1_IAWIL)# & PIR1: (MFIVWS,MFIV1F,MFIV,PN0086,MFIVC,JN0392,MFIV61,B45539,# & PN0083,MFIV1K)# & PIR2: (S07945,S04056,S04054,S07429,S04050,S04058,S04052,# & S14616)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesl,ASCMGLIY*# SEQUENCE: ASCMGLIY*# ...# >HUM1292A# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesh,DSCMGLIY*# SEQUENCE: DSCMGLIY*# ...# >HUM1292B# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesm,bindyesh,NSCMGLIY*# SEQUENCE: NSCMGLIY*# ...# >HUM1292C# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesm,bindyesh,APCMGLIY*# SEQUENCE: APCMGLIY*# ...# >HUM1292D# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesm,bindyesm,ASCKGLIY*# SEQUENCE: ASCKGLIY*# ...# >HUM1292E# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesh,bindyesh,ASCIGLIY*# SEQUENCE: ASCIGLIY*# ...# >HUM1292F# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesm,bindyesm,ASCMGLLY*# SEQUENCE: ASCMGLLY*# ...# >HUM12930# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,ASCMGLRY*# SEQUENCE: ASCMGLRY*# ...# >HUM12931# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesl,bindyesl,ASCMGLIH*# SEQUENCE: ASCMGLIH*# ...# >HUM12932# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Stabilization/LDA# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: Flu matrix homologue (128-135)# ANCHOR POSITIONS: ?# REFERENCES: dong96a# COMMENT:# SUMMARY: HLA-B35,actyesl,bindyesm,ASCMGLIF*# SEQUENCE: ASCMGLIF*# ...# >HUM12933# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE:?# DB REFERENCE: SWISS: (ENV_HV1OY,ENV_HV1ND,ENV_HV1ZH,ENV_HV1RH,ENV_HV1KB)# & PIR1: (VCLJND,A44963,VCLJKB,VCLJKX)# & PIR2: (S60526,S60525,S60558,A41621)# ANCHOR POSITIONS: 2# REFERENCES: sakaguchi97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,LPCRIKQIV*# SEQUENCE: LPCRIKQIV*# ...# >HUM12934# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1PV,GAG_HV1OY,GAG_HV1H2,GAG_HV1JR,# & GAG_HV1BR,GAG_HV1B1,GAG_HV1A2)# & PIR1: (FOVWA2,FOVWLV,FOVWH3)# ANCHOR POSITIONS: 2# REFERENCES: sakaguchi97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,YPLTSLRSLF*# SEQUENCE: YPLTSLRSLF*# ...# >HUM12935# MHC MOLECULE: HLA-B46(B*4601), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-B46,actunkn,bindyesu,FIKDGSSTY*# SEQUENCE: FIKDGSSTY*# ...# >HUM12936# MHC MOLECULE: HLA-B46(B*4601), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-B46,actunkn,bindyesu,SIRDGVRAY*# SEQUENCE: SIRDGVRAY*# ...# >HUM12937# MHC MOLECULE: HLA-B46(B*4601), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human HSC70/HSP70 (126-134)# DB REFERENCE: SWISS: (HS7C_RAT,HS7C_RAT,HS7C_PETHY,HS73_BOVIN,HS70_PLEWA,# & HS72_MOUSE,HS73_BOVIN,HS7C_BOVIN,HS71_RAT,HS70_MAIZE,# & HS71_HUMAN,HS72_HUMAN,HS70_ONCMY,HS7C_CRIGR,HS7C_BOVIN,# & HS7E_SPIOL,HS7C_ICTPU,HS72_HUMAN,HS72_MOUSE,HS7C_BRARE,# & HS71_RAT,HS71_BOVIN,HS7C_ICTPU,HS72_RAT,HS71_MOUSE,# & HS72_BOVIN,HS70_CHICK,HS7C_HUMAN,HS71_MOUSE)# & PIR2: (S03250,S43388,A42582,I54542,A25646,A25089,A35922,JC4853,# & S07197,A45871,A27077,A45935,A55719,I51129,I56574,JH0095,# & S08211,S11456,S10859,JC4610,S31716,A29160)# & PIR3: (S21175)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-B46,actunkn,bindyesu,KMKEIAEAY*# SEQUENCE: KMKEIAEAY*# ...# >HUM12938# MHC MOLECULE: HLA-B46(B*4601), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human proteasome subunit C8 (150-159)# DB REFERENCE: SWISS: (PRC8_RAT,PRC8_HUMAN,PRC8_RAT,PRC8_HUMAN)# & PIR1: (SNRTC8,SNHUC8)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-B46,actunkn,bindyesu,YMIDPSGVSY*# SEQUENCE: YMIDPSGVSY*# ...# >HUM12939# MHC MOLECULE: HLA-B46(B*4601), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-B46,actunkn,bindyesu,YVIPHVHAF*# SEQUENCE: YVIPHVHAF*# ...# >HUM1293A# MHC MOLECULE: HLA-B46(B*4601), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human cyclin B (269-277)# DB REFERENCE: SWISS: (CGB1_HUMAN)# & PIR2: (A32992)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-B46,actunkn,bindyesu,FAFVTDNTY*# SEQUENCE: FAFVTDNTY*# ...# >HUM1293B# MHC MOLECULE: HLA-B62(B*1501), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human ribosome protein L8 (7-16)# DB REFERENCE: SWISS: (RL8_XENLA,RL8_HUMAN,RL8_HUMAN)# & PIR1: (R5RTL8)# & PIR2: (JN0923,S42725)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-B62,actunkn,bindyesu,GQRKGAGSVF*# SEQUENCE: GQRKGAGSVF*# ...# >HUM1293C# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (SEP2_HUMAN)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-Cw1,actunkn,bindyesu,IAPTGHSL*# SEQUENCE: IAPTGHSL*# ...# >HUM1293D# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human granulin (162-170)# DB REFERENCE: SWISS: (GRN_HUMAN)# & PIR1: (GYHU)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-Cw1,actunkn,bindyesu,ITPTGTHPL*# SEQUENCE: ITPTGTHPL*# ...# >HUM1293E# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human HSP27 (69-77)# DB REFERENCE: SWISS: (HS27_HUMAN,HS27_CANFA)# & PIR1: (HHHU27)# & PIR2: (JC4244)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-Cw1,actunkn,bindyesu,AAPAYSRAL*# SEQUENCE: AAPAYSRAL*# ...# >HUM1293F# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-Cw1,actunkn,bindyesu,FAPYNKPSL*# SEQUENCE: FAPYNKPSL*# ...# >HUM12940# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-Cw1,actunkn,bindyesu,HLPETKFSEL*# SEQUENCE: HLPETKFSEL*# ...# >HUM12941# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human butyryl cholinesterase (228-236)# DB REFERENCE: SWISS: (CHLE_HUMAN)# & PIR1: (ACHU)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-Cw1,actunkn,bindyesu,NAPWAVTSL*# SEQUENCE: NAPWAVTSL*# ...# >HUM12942# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human tissue inhibitor of metalloproteinase (66-74)# DB REFERENCE: SWISS: (TIM1_HUMAN,TIM1_HUMAN,TIM1_PAPCY)# & PIR1: (ZYHUEP)# & PIR2: (JC4303)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-Cw1,actunkn,bindyesu,VAPWNSLSL*# SEQUENCE: VAPWNSLSL*# ...# >HUM12943# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human nucleic acid-binding protein (53-61)# DB REFERENCE: SWISS: (ROX_MOUSE)# & PIR2: (S58529,S65678,S43489,I48281,S42472,S65679,S42471)# ANCHOR POSITIONS: ?# REFERENCES: barber96a# COMMENT:# SUMMARY: HLA-Cw1,actunkn,bindyesu,NCPERIITL*# SEQUENCE: NCPERIITL*# ...# >HUM12944# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Elution/Competition/CTL assays/CTL induction# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: human vinculin (358-366)# DB REFERENCE: SWISS: (VINC_HUMAN)# & PIR1: (A35955)# & PIR2: (A60965)# ANCHOR POSITIONS: ?# REFERENCES: dimarzoveronese96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,GLDVLTAKV*# SEQUENCE: GLDVLTAKV*# ...# >HUM12945# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Elution/Competition/CTL assays/CTL induction# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: human vinculin (823-831)# DB REFERENCE: SWISS: (VINC_CHICK,VINC_HUMAN)# & PIR1: (A35955,A29997)# ANCHOR POSITIONS: ?# REFERENCES: dimarzoveronese96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,RILGAVAKV*# SEQUENCE: RILGAVAKV*# ...# >HUM12946# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human vinculin (983-991)# DB REFERENCE: SWISS: (VINC_PIG,VINC_CHICK,VINC_HUMAN,VINC_XENLA)# & PIR1: (A29997,A35955)# & PIR2: (S29508,S29507)# ANCHOR POSITIONS: ?# REFERENCES: dimarzoveronese96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,QVCERIPTI*# SEQUENCE: QVCERIPTI*# ...# >HUM12947# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HER-2/neu(1172-1180)# DB REFERENCE: SWISS: (NEU_RAT,ERB2_HUMAN)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# ANCHOR POSITIONS: 2,9# REFERENCES: disis94a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,TLSPGKNGV*# SEQUENCE: TLSPGKNGV*# ...# >HUM12948# MHC MOLECULE: HLA-G, CLASS-1, (HUMAN)# METHOD: Elution/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-G,actunkn,bindyesu,KLPAQFYIL*# SEQUENCE: KLPAQFYIL*# ...# >HUM12949# MHC MOLECULE: HLA-G, CLASS-1, (HUMAN)# METHOD: Elution/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-G,actunkn,bindyesu,RLPKDFRIL*# SEQUENCE: RLPKDFRIL*# ...# >HUM1294A# MHC MOLECULE: HLA-G, CLASS-1, (HUMAN)# METHOD: Elution/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: histone H2A# DB REFERENCE: SWISS: (H2A2_MOUSE,H2A3_LYTPI,H2A_URECA,H2AX_HUMAN,H2A4_MOUSE,# & H2A3_STRPU,H2A1_YEAST,H2A2_HUMAN,H2A1_HUMAN,H2A_SIPNU,# & H2A3_CHICK,H2A2_SCHPO,H2AX_MOUSE,H2A5_HUMAN,H2AX_HUMAN,# & H2A1_PSAMI,H2A_ONCMY,H2A1_XENLA,H2A_DROME,H2AT_RAT,# & H2A_SEPOF,H2A1_MOUSE,H2A_ACRFO,H2A_EMENI,H2A1_SCHPO,# & H2A_PLADU,H2A1_RAT,H2A4_PSAMI,H2A3_PSAMI,H2A_CAIMO,# & H2A_CHITH,H2AO_CHITH,H2A_STRPU,H2A3_CHICK,H2A_PARLI,# & H2AL_STRPU,H2A3_MOUSE,H2A4_CHICK,H2A2_YEAST,H2A2_PSAMI,# & H2A1_YEAST)# & PIR1: (HSIN21,HSURH2,HSRT2A,HSBYA2,HSURA1,HSUR9M,HSZPA2,HSZPA3,# & HSHUA1,HSFF2,HSOO2,HSTR21,HSBYA1,HSXLA2,HSUR7M,HSHUA5,# & HSCH2A,HSBO2A,HSUR9P,HSURA2,HSXLA1,HSURH9)# & PIR2: (C56612,I50457,A25077,S19241,A27332,S11314,S45110,JC1523,# & S21938,I48406,I49394,S26188,I50657,JH0303,C56580,A36322,# & S06754,S18004,S06742,S21849,S04565,S07631,B56618,I48091,# & G40335,S40435)# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-G,actunkn,bindyesu,RIIPRHLQL*# SEQUENCE: RIIPRHLQL*# ...# >HUM1294B# MHC MOLECULE: HLA-G, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1B1,POL_HV1Z2,POL_HV1RH,POL_HV1EL,# & POL_HV1B5,POL_HV1PV,POL_HV1OY,POL_HV1H2,POL_HV1MN,# & POL_HV1BR,POL_HV1N5,POL_HV1JR,POL_HV1Y2,POL_HV1ND)# & PIR1: (B44001,GNVWVL,GNVWLV,GNVWH3,GNLJND)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-G,actunkn,bindyesu,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM1294C# MHC MOLECULE: HLA-G, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-G,actunkn,bindyesu,KIPAQFYIL*# SEQUENCE: KIPAQFYIL*# ...# >HUM1294D# MHC MOLECULE: HLA-G, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-G,actunkn,bindyesl,KGGAQFYIL*# SEQUENCE: KGGAQFYIL*# ...# >HUM1294E# MHC MOLECULE: HLA-G, CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-G,actunkn,bindyesu,KGPAQFYIL*# SEQUENCE: KGPAQFYIL*# ...# >HUM1294F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KLPAQFYIL*# SEQUENCE: KLPAQFYIL*# ...# >HUM12950# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RLPKDFRIL*# SEQUENCE: RLPKDFRIL*# ...# >HUM12951# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: histone H2A# DB REFERENCE: SWISS: (H2A4_MOUSE,H2A_URECA,H2A3_LYTPI,H2A2_MOUSE,H2A_ONCMY,# & H2A1_PSAMI,H2A_STRPU,H2A5_HUMAN,H2AX_HUMAN,H2AX_MOUSE,# & H2A4_PSAMI,H2A1_RAT,H2A1_SCHPO,H2A_PLADU,H2A_ACRFO,# & H2AT_RAT,H2A1_MOUSE,H2A_DROME,H2A_CAIMO,H2A3_PSAMI,# & H2A2_SCHPO,H2A3_CHICK,H2A1_HUMAN,H2A2_HUMAN,H2A_SEPOF,# & H2A_PARLI,H2A_CHITH,H2AX_HUMAN,H2A4_CHICK,H2A3_MOUSE,# & H2A1_YEAST,H2A2_PSAMI,H2A3_STRPU,H2A1_YEAST,H2A2_YEAST,# & H2AO_CHITH,H2A3_CHICK,H2A_SIPNU,H2AL_STRPU,H2A1_XENLA,# & H2A_EMENI)# & PIR1: (HSCH2A,HSURH9,HSUR9M,HSZPA2,HSURA1,HSUR9P,HSBO2A,HSUR7M,# & HSBYA1,HSOO2,HSFF2,HSTR21,HSBYA2,HSHUA5,HSXLA2,HSURH2,# & HSIN21,HSRT2A,HSZPA3,HSHUA1,HSURA2,HSXLA1)# & PIR2: (S21849,S06742,S06754,S19241,I50457,I50657,JH0303,C56580,# & I48091,S04565,S07631,G40335,S21938,C56612,S11314,S45110,# & S40435,B56618,JC1523,A36322,S18004,I49394,S26188,A27332,# & I48406,A25077)# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,RIIPRHLQL*# SEQUENCE: RIIPRHLQL*# ...# >HUM12952# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (RL36_RAT)# & PIR2: (JN0483)# ANCHOR POSITIONS: 2,9# REFERENCES: diehl96a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,GRLTKHTKF*# SEQUENCE: GRLTKHTKF*# ...# >HUM12953# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 env# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1BR,ENV_HV1H2,ENV_HV1B8,ENV_HV1PV,# & ENV_HV1H3,ENV_HV1B1)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: alexander-miller96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >HUM12954# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays/Reconstitution# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 env# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1H3,ENV_HV1B8,ENV_HV1PV,ENV_HV1BR,# & ENV_HV1MF,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR2: (S65399)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: alexander-miller96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,RGPGRAFVTI*# SEQUENCE: RGPGRAFVTI*# ...# >HUM12955# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HIV-1 env# ANCHOR POSITIONS: ?# REFERENCES: alexander-miller96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,AGPGRAFVTI*# SEQUENCE: AGPGRAFVTI*# ...# >HUM12956# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HIV-1 env# ANCHOR POSITIONS: ?# REFERENCES: alexander-miller96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,RAPGRAFVTI*# SEQUENCE: RAPGRAFVTI*# ...# >HUM12957# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 env# ANCHOR POSITIONS: ?# REFERENCES: alexander-miller96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RGPGRGFVTI*# SEQUENCE: RGPGRGFVTI*# ...# >HUM12958# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 env# ANCHOR POSITIONS: ?# REFERENCES: alexander-miller96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RGPGRAAVTI*# SEQUENCE: RGPGRAAVTI*# ...# >HUM12959# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 env# ANCHOR POSITIONS: ?# REFERENCES: alexander-miller96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,RGPGRAFVAI*# SEQUENCE: RGPGRAFVAI*# ...# >HUM1295A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 env# ANCHOR POSITIONS: ?# REFERENCES: alexander-miller96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,RGPGRAFVTA*# SEQUENCE: RGPGRAFVTA*# ...# >HUM1295B# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: CTL assays/Elution# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Pmel-17 gp 100# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A53668,A41234)# ANCHOR POSITIONS: ?# REFERENCES: skipper96a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesu,ALLAVGATK*# SEQUENCE: ALLAVGATK*# ...# >HUM1295C# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Pmel-17 gp 100# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A53668,I38400)# ANCHOR POSITIONS: ?# REFERENCES: skipper96a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,LLAVGATK*# SEQUENCE: LLAVGATK*# ...# >HUM1295D# MHC MOLECULE: HLA-B73(B*7301), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human ribosomal protein L8 (162-170)# DB REFERENCE: SWISS: (RL8_HUMAN,RL8_HUMAN)# & PIR1: (R5RTL8)# & PIR2: (JN0923)# ANCHOR POSITIONS: 2,9# REFERENCES: barber96b# COMMENT:# SUMMARY: HLA-B73,actunkn,bindyesu,NRAVVGVVA*# SEQUENCE: NRAVVGVVA*# ...# >HUM1295E# MHC MOLECULE: HLA-B73(B*7301), CLASS-1, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human ribosomal protein S30 (113-121)# DB REFERENCE: SWISS: (RS30_HUMAN,RS30_HUMAN)# & PIR2: (S38383,JC1278,A47416,I48346)# ANCHOR POSITIONS: 2,9# REFERENCES: barber96b# COMMENT:# SUMMARY: HLA-B73,actunkn,bindyesu,NRRFVNVVP*# SEQUENCE: NRRFVNVVP*# ...# >HUM1295F# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (1C04_HUMAN,1C18_HUMAN)# & PIR2: (I37523,I37527,I37544,I61866)# ANCHOR POSITIONS: ?# REFERENCES: smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,RVMAPRTLL*# SEQUENCE: RVMAPRTLL*# ...# >HUM12960# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,AVMAPRTVL*# SEQUENCE: AVMAPRTVL*# ...# >HUM12961# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reconstitution# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: smith96a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,RVMAPRTVL*# SEQUENCE: RVMAPRTVL*# ...# >HUM12962# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/Recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,IMDQVPFSV*# SEQUENCE: IMDQVPFSV*# ...# >HUM12963# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,IIDQVPFSV*# SEQUENCE: IIDQVPFSV*# ...# >HUM12964# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FTDQVPFSV*# SEQUENCE: FTDQVPFSV*# ...# >HUM12965# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,WTDQVPFSV*# SEQUENCE: WTDQVPFSV*# ...# >HUM12966# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YTDQVPFSV*# SEQUENCE: YTDQVPFSV*# ...# >HUM12967# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ITWQVPFSV*# SEQUENCE: ITWQVPFSV*# ...# >HUM12968# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ITFQVPFSV*# SEQUENCE: ITFQVPFSV*# ...# >HUM12969# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ITYQVPFSV*# SEQUENCE: ITYQVPFSV*# ...# >HUM1296A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ITAQVPFSV*# SEQUENCE: ITAQVPFSV*# ...# >HUM1296B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ITMQVPFSV*# SEQUENCE: ITMQVPFSV*# ...# >HUM1296C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ITSQVPFSV*# SEQUENCE: ITSQVPFSV*# ...# >HUM1296D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILAQVPFSV*# SEQUENCE: ILAQVPFSV*# ...# >HUM1296E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILMQVPFSV*# SEQUENCE: ILMQVPFSV*# ...# >HUM1296F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILSQVPFSV*# SEQUENCE: ILSQVPFSV*# ...# >HUM12970# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/Recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,WLDQVPFSV*# SEQUENCE: WLDQVPFSV*# ...# >HUM12971# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/inhibition# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: gp 100 (280-288) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesl,YLEPGPVTV*# SEQUENCE: YLEPGPVTV*# ...# >HUM12972# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/Recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: gp 100 (280-288) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,YLEPGPVTL*# SEQUENCE: YLEPGPVTL*# ...# >HUM12973# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/Recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: gp 100 (280-288) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,YLEPGPVTI*# SEQUENCE: YLEPGPVTI*# ...# >HUM12974# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/Recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: gp 100 (280-288) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesl,FLEPGPVTA*# SEQUENCE: FLEPGPVTA*# ...# >HUM12975# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (280-288) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,WLEPGPVTA*# SEQUENCE: WLEPGPVTA*# ...# >HUM12976# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,FLDQVPFSV*# SEQUENCE: FLDQVPFSV*# ...# >HUM12977# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,ILDQVPFSV*# SEQUENCE: ILDQVPFSV*# ...# >HUM12978# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: gp 100 (209-217) homologue# ANCHOR POSITIONS: ?# REFERENCES: parkhurst96a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,YLDQVPFSV*# SEQUENCE: YLDQVPFSV*# ...# >HUM12979# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: CDK4# DB REFERENCE: PIR2: (S52841)# ANCHOR POSITIONS: ?# REFERENCES: kawakami96a,romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,ACDPHSGHFV*# SEQUENCE: ACDPHSGHFV*# ...# >HUM1297A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Other biochemical# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza MA (57-73)# ANCHOR POSITIONS: ?# REFERENCES: reyes91a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,KGILGFVFTLTVPSERY*# SEQUENCE: KGILGFVFTLTVPSERY*# ...# >HUM1297B# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: Other biochemical# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Influenza NP (336-354)# ANCHOR POSITIONS: ?# REFERENCES: reyes91a# COMMENT:# SUMMARY: HLA-B37,actunkn,bindyesu,AAFEDLRVLSFIRGTKVSPRY*# SEQUENCE: AAFEDLRVLSFIRGTKVSPRY*# ...# >HUM1297C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reference/CTL assays/Competition# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: Tyrosinase# ANCHOR POSITIONS: ?# REFERENCES: engelhard96a,romero96a,skipper96b,van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesh,YMDGTMSQV*# SEQUENCE: YMDGTMSQV*# ...# >HUM1297D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MART-1/MelanA# ANCHOR POSITIONS: ?# REFERENCES: robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,MGIGILTV*# SEQUENCE: MGIGILTV*# ...# >HUM1297E# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MART-1/MelanA# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,ILTVILGVL*# SEQUENCE: ILTVILGVL*# ...# >HUM2297F# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Tyrosinase# DB REFERENCE: SWISS: (TYRO_HUMAN,TYRO_HUMAN)# & PIR1: (YRHU1)# ANCHOR POSITIONS: ?# REFERENCES: robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-DR4,actyesu,bindyesu,QNILLSNAPLGPQFP*# SEQUENCE: QNILLSNAPLGPQFP*# ...# >HUM12980# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: N-acetylglucosaminyltransferase-V# ANCHOR POSITIONS: ?# REFERENCES: robbins96a,romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,VLPDVFIRC*# SEQUENCE: VLPDVFIRC*# ...# >HUM12981# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Beta-catenin (23-32)# ANCHOR POSITIONS: ?# REFERENCES: robbins96a,romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A24,actyesu,bindyesu,SYLDSGIHF*# SEQUENCE: SYLDSGIHF*# ...# >HUM12982# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HER-2/neu# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: ?# REFERENCES: robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,IISAVVGIL*# SEQUENCE: IISAVVGIL*# ...# >HUM12983# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HER-2/neu# DB REFERENCE: SWISS: (ERB2_HUMAN,NEU_RAT)# & PIR1: (A24571,TVRTNU)# & PIR2: (I48161)# ANCHOR POSITIONS: ?# REFERENCES: robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,KIFGSLAFL*# SEQUENCE: KIFGSLAFL*# ...# >HUM12984# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Human papillomavirus-E6, E7# DB REFERENCE: SWISS: (VE7_HPV16)# & PIR1: (W7WLHS)# & PIR3: (S12367)# ANCHOR POSITIONS: ?# REFERENCES: robbins96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,YMLDLQPETT*# SEQUENCE: YMLDLQPETT*# ...# >HUM12985# MHC MOLECULE: HLA-B44, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MAGE-3 (167-176)# DB REFERENCE: SWISS: (MAG3_HUMAN,MAG3_HUMAN)# & PIR2: (JC2361)# ANCHOR POSITIONS: ?# REFERENCES: romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-B44,actyesu,bindyesu,MEVDPIGHLY*# SEQUENCE: MEVDPIGHLY*# ...# >HUM12986# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: RAGE (11-20)# ANCHOR POSITIONS: ?# REFERENCES: romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-B7,actyesu,bindyesu,SPSSNRIRT*# SEQUENCE: SPSSNRIRT*# ...# >HUM12987# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: CEA (571-579)# DB REFERENCE: SWISS: (CCEM_HUMAN,CCEM_HUMAN)# & PIR2: (A36319)# ANCHOR POSITIONS: ?# REFERENCES: romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,YLSGANLNL*# SEQUENCE: YLSGANLNL*# ...# >HUM12988# MHC MOLECULE: HLA-B44(B*4402), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MUM-1# ANCHOR POSITIONS: ?# REFERENCES: romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-B44,actyesu,bindyesu,EEKLIVVLF*# SEQUENCE: EEKLIVVLF*# ...# >HUM12989# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HER-2/neu (654-662)# DB REFERENCE: SWISS: (ERB2_HUMAN)# & PIR1: (A24571)# ANCHOR POSITIONS: ?# REFERENCES: romero96a# COMMENT: cancer related antigens# SUMMARY: HLA-A2,actyesu,bindyesu,IISAVVGIL*# SEQUENCE: IISAVVGIL*# ...# >HUM1298A# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: X-ray cristallography/Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-2 gag# DB REFERENCE: SWISS: (GAG_SIVSP,GAG_SIVA1,GAG_SIVS4,GAG_HV2ST,GAG_HV2BE,# & GAG_SIVMS,GAG_HV2KR,GAG_HV2G1,GAG_HV2NZ,GAG_HV2SB,# & GAG_SIVAG,GAG_HV2CA,GAG_SIVAT,GAG_SIVMK,GAG_HV2D1,# & GAG_HV2D2,GAG_HV2RO)# & PIR1: (FOLJG5,FOLJST,FOLJG4,FOLJTM,FOLJCA,FOLJG2,FOLJGG)# & PIR2: (S12152,S08435,S03070,S53091,S04237)# ANCHOR POSITIONS: ?# REFERENCES: smith96b# COMMENT:# SUMMARY: HLA-B53,actyesu,bindyesu,TPYDINQML*# SEQUENCE: TPYDINQML*# ...# >HUM1298B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: skipper96b# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ALWGFFPVL*# SEQUENCE: ALWGFFPVL*# ...# >HUM1298C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: GnT-V# ANCHOR POSITIONS: ?# REFERENCES: guilloux96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,VLPDVFIRCV*# SEQUENCE: VLPDVFIRCV*# ...# >HUM1298D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: GnT-V# ANCHOR POSITIONS: ?# REFERENCES: guilloux96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,VLPDVFIRC*# SEQUENCE: VLPDVFIRC*# ...# >HUM1298E# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBVc homologue (18-27)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM1298F# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBVc homologue (18-27)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM12990# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBVc homologue (18-27)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM12991# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBVc homologue (18-27)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM12992# MHC MOLECULE: HLA-A2(A*0209), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBVc homologue (18-27)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM12993# MHC MOLECULE: HLA-A2(A*0210), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBVc homologue (18-27)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM12994# MHC MOLECULE: HLA-A2(A*0211), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBVc homologue (18-27)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDYFPSV*# SEQUENCE: FLPSDYFPSV*# ...# >HUM12995# MHC MOLECULE: HLA-A2(A*0210), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MART-1 (27-35)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM12996# MHC MOLECULE: HLA-A2(A*0211), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: MART-1 (27-35)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,AAGIGILTV*# SEQUENCE: AAGIGILTV*# ...# >HUM12997# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: gp 100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A53668)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >HUM12998# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: gp 100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A53668,A41234)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >HUM12999# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,A41234,I38400)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >HUM1299A# MHC MOLECULE: HLA-A2(A*0210), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,A53668,I38400)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >HUM1299B# MHC MOLECULE: HLA-A2(A*0211), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: gp 100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A53668)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >HUM1299C# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,I38400,A41234)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM1299D# MHC MOLECULE: HLA-A2(A*0204), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,A41234,I38400)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM1299E# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A41234,I38400,A53668)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM1299F# MHC MOLECULE: HLA-A2(A*0210), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: gp 100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (A53668,I38400,A41234)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM129A0# MHC MOLECULE: HLA-A2(A*0211), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: gp 100 (154-162)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KTWGQYWQV*# SEQUENCE: KTWGQYWQV*# ...# >HUM129A1# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: gp 100 (280-288)# DB REFERENCE: SWISS: (PM17_HUMAN,PM17_HUMAN)# & PIR2: (I38400,A41234,A53668)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,YLEPGPVTA*# SEQUENCE: YLEPGPVTA*# ...# >HUM129A2# MHC MOLECULE: HLA-A2(A*0211), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Flu M1 (58-66)# DB REFERENCE: SWISS: (VMT1_IABAN,VMT1_IAFOW,VMT1_IAZI1,VMT1_IAANN,VMT1_IAWIL,# & VMT1_IAPUE,VMT1_IAUSS,VMT1_IAUDO,VMT1_IAMAN,VMT1_IACKB,# & VMT1_IALE2,VMT1_IALE1)# & PIR1: (MFIV1M,MFIV61,MFIV1K,MFIVWS,MFIVC,JN0392,MFIV)# & PIR2: (S14616,S04052,S04054,S04058,S04050,S04056,S07429)# ANCHOR POSITIONS: ?# REFERENCES: rivoltini96a# COMMENT:# SUMMARY: HLA-A2,actyesm,bindyesu,GILGFVFTL*# SEQUENCE: GILGFVFTL*# ...# >HUM129A3# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Melan-A/MART-1 (26-35)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,EAAGTGILTV*# SEQUENCE: EAAGTGILTV*# ...# >HUM129A4# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: Melan-A/MART-1 (29-36)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GIGILTVI*# SEQUENCE: GIGILTVI*# ...# >HUM129A5# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: Melan-A/MART-1 (32-42)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILTVILGVLLL*# SEQUENCE: ILTVILGVLLL*# ...# >HUM129A6# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Melan-A/MART-1 (32-41)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ILTVILGVLL*# SEQUENCE: ILTVILGVLL*# ...# >HUM129A7# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/Competition/Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: Melan-A/MART-1 (32-39)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ILTVILGV*# SEQUENCE: ILTVILGV*# ...# >HUM129A8# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/Competition/Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: Melan-A/MART-1 (57-64)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LMDKSLHV*# SEQUENCE: LMDKSLHV*# ...# >HUM129A9# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, little# SOURCE: Melan-A/MART-1 (87-96)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,SLQEKNCEPV*# SEQUENCE: SLQEKNCEPV*# ...# >HUM129AA# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Melan-A/MART-1 (55-64)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RALMDKSLHV*# SEQUENCE: RALMDKSLHV*# ...# >HUM129AB# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Melan-A/MART-1 (61-70)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,SLHVGTQCAL*# SEQUENCE: SLHVGTQCAL*# ...# >HUM129AC# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: Melan-A/MART-1 (27-34)# DB REFERENCE: PIR2: (A55253)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,AAGIGILT*# SEQUENCE: AAGIGILT*# ...# >HUM129AD# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: Melan-A/MART-1 (36-43)# DB REFERENCE: SWISS: (CYB_CAPMR,CYB_SPERI,CYB_LAMGU)# & PIR2: (A55253,S43267)# & PIR3: (A53077)# ANCHOR POSITIONS: ?# REFERENCES: van-elsas96a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ILGVLLLI*# SEQUENCE: ILGVLLLI*# ...# >HUM129AE# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: 2# REFERENCES: schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,YPNQNLQGQM*# SEQUENCE: YPNQNLQGQM*# ...# >HUM129AF# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VE1_HPV33,VE12_HPV16)# & PIR1: (W1WLHS,W1WL33)# ANCHOR POSITIONS: 2# REFERENCES: schonbach96b# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPFDENGNPVY*# SEQUENCE: FPFDENGNPVY*# ...# >HUM129B0# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference/Stabilization# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV nef (90-97)# DB REFERENCE: SWISS: (NEF_SIVA1,NEF_HV1B8,NEF_SIVCZ,NEF_HV1H2,NEF_HV1MN,# & NEF_HV1U4,NEF_HV1PV,NEF_HV1BR,NEF_HV1MA,NEF_SIVAG,# & NEF_HV1Y2,NEF_HV1A2,NEF_HV1JR,NEF_HV1B1,NEF_HV1BN,# & NEF_HV1ZH,NEF_HV112,NEF_HV1Z6,NEF_HV1OY,NEF_HV1EL,# & NEF_HV1S3,NEF_HV1ND,NEF_SIVAT,NEF_HV1S1,NEF_HV1RH)# & PIR1: (ASLJH3,ASLJIK,QQLJZR,QQLJND,ASLJ12,I44001,ASLJM4,ASLJO2,# & B44963,ASLJBR,ASLJVL,ASLJFV)# & PIR2: (S03244,S24985,S03245,S03246,S03247,S43467,S46353)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: price97a,brander95b,hivdb97a,goulder97a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesh,FLKEKGGL*# SEQUENCE: FLKEKGGL*# ...# >HUM129B1# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV nef (90-97)# ANCHOR POSITIONS: ?# REFERENCES: price97a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,LLKEKGGL*# SEQUENCE: LLKEKGGL*# ...# >HUM129B2# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV nef (90-97)# ANCHOR POSITIONS: ?# REFERENCES: price97a# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,SLKEKGGL*# SEQUENCE: SLKEKGGL*# ...# >HUM129B3# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays/Stabilization# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: HIV nef (90-97)# ANCHOR POSITIONS: ?# REFERENCES: price97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesh,FLKDKGGL*# SEQUENCE: FLKDKGGL*# ...# >HUM129B4# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays/Stabilization# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: HIV nef (90-97)# DB REFERENCE: SWISS: (NEF_HV1SC)# ANCHOR POSITIONS: ?# REFERENCES: price97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesl,FLKEQGGL*# SEQUENCE: FLKEQGGL*# ...# >HUM129B5# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV nef (90-97)# ANCHOR POSITIONS: ?# REFERENCES: price97a# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,FLKENGGL*# SEQUENCE: FLKENGGL*# ...# >HUM129B6# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV nef (90-97)# ANCHOR POSITIONS: ?# REFERENCES: price97a# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,FLKEEGGL*# SEQUENCE: FLKEEGGL*# ...# >HUM129B7# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,VIYQTMDDL*# SEQUENCE: VIYQTMDDL*# ...# >HUM129B8# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,SLLNATDIAV*# SEQUENCE: SLLNATDIAV*# ...# >HUM129B9# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (18-26)# DB REFERENCE: SWISS: (GAG_HV2ST,GAG_HV1H2,GAG_HV1Z2,GAG_HV1MN,GAG_HV1B1,# & GAG_SIVSP,GAG_HV1OY,GAG_HV2KR,GAG_HV2NZ,GAG_HV2SB,# & GAG_HV1B5,GAG_SIVM1,GAG_HV1MA,GAG_HV1J3,GAG_HV1Y2,# & GAG_HV1W2,GAG_HV1A2,GAG_HV1EL,GAG_HV1C4,GAG_HV1JR,# & GAG_SIVMK,GAG_HV1PV,GAG_HV1BR,GAG_HV1N5)# & PIR1: (FOLJST,FOVWA2,A38068,FOLJG3,FOVWH3,FOVWH4,FOLJG5,FOVWLV,# & A44001,FOVWVL)# & PIR2: (S03070,S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,KIRLRPGGK*# SEQUENCE: KIRLRPGGK*# ...# >HUM129BA# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1EL,GAG_HV1MN,GAG_HV1MA,GAG_HV2ST,# & GAG_HV1H2,GAG_HV1BR,GAG_HV2RO,GAG_HV2SB,GAG_HV1OY,# & GAG_HV2BE,GAG_SIVMK,GAG_HV1JR,GAG_HV1PV,GAG_HV2KR,# & GAG_HV2NZ,GAG_HV1ND,GAG_HV1B1,GAG_HV2CA,GAG_HV1Z2,# & GAG_HV2D2,GAG_HV1J3,GAG_SIVM1,GAG_HV1W2,GAG_SIVMS,# & GAG_HV1A2)# & PIR1: (FOLJTM,FOLJG5,FOLJG3,FOVWVL,FOVWLV,FOLJCA,FOLJG2,FOLJND,# & FOVWH3,FOVWA2,A38068,FOLJST)# & PIR2: (S53091,S03070,S08435,S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,RLRPGGKKK*# SEQUENCE: RLRPGGKKK*# ...# >HUM129BB# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Reference/Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV env (49-57)# DB REFERENCE: SWISS: (ENV_HV1OY,ENV_HV1Z2,ENV_HV1B1,ENV_HV1S3,ENV_HV1A2,# & ENV_HV1MA,ENV_HV1Z3,ENV_HV1C4,ENV_HV1MF,ENV_HV1BR,# & ENV_HV1SC,ENV_HV1Z6,ENV_HV1N5,ENV_HV1J3,ENV_HV1RH,# & ENV_HV1PV,ENV_HV1W1,ENV_HV1BN,ENV_HV1EL,ENV_HV1W2,# & ENV_HV1H3,ENV_HV1KB,ENV_HV1H2,ENV_HV1Y2,ENV_HV1S1,# & ENV_HV1JR,ENV_HV1MN,ENV_HV1Z8,ENV_HV1ZH)# & PIR1: (VCLJ3W,VCLJH3,VCLJKX,VCLJMN,H44001,VCLJA2,VCLJH4,VCLJLV,# & VCLJSC,A44963,VCLJZR,VCLJBR,VCLJKB,VCLJVL)# & PIR2: (A40218,S54384)# & PIR3: (S13288,S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a,threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,TVYYGVPVWK*# SEQUENCE: TVYYGVPVWK*# ...# >HUM129BC# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1B1,GAG_HV1BR,GAG_HV1H2,GAG_HV1MA,# & GAG_HV1J3,GAG_HV1A2,GAG_HV1W2,GAG_HV1PV,GAG_HV1C4,# & GAG_HV1JR)# & PIR1: (FOVWH4,FOVWH3,FOVWA2,FOVWVL,FOVWLV)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,TLYCVHQRI*# SEQUENCE: TLYCVHQRI*# ...# >HUM129BD# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1PV,POL_HV1OY,POL_HV1A2,POL_HV1BR,# & POL_HV1Z2,POL_HV1B5,POL_HV1ND,POL_HV1U4,POL_HV1MN,# & POL_HV1Y2,POL_HV1N5,POL_HV1H2,POL_HV1RH,POL_HV1EL)# & PIR1: (GNVWH3,GNVWLV,GNVWVL,GNVWA2,B44001,GNLJND)# & PIR2: (A47175,S54378,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,IYQEPFKNLK*# SEQUENCE: IYQEPFKNLK*# ...# >HUM129BE# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1S3,NEF_HV1ND,NEF_HV1BR,NEF_HV1Z2,NEF_HV1H2,# & NEF_HV1SC,NEF_HV1A2,NEF_HV1EL,NEF_HV1OY,NEF_HV2D2,# & NEF_HV1MA,NEF_HV1MN,NEF_HV1U4,NEF_HV1PV,NEF_HV1B8,# & NEF_HV1JR,NEF_HV112,NEF_HV1Z6,NEF_HV1S1,NEF_HV1BN,# & NEF_HV1B1)# & PIR1: (QQLJZR,QQLJND,ASLJH3,ASLJFV,ASLJ12,ASLJO2,ASLJBR,# & ASLJVL)# & PIR2: (S43467,S24572,S54385,S25937,S03244,S03245,S24985)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,PLRPMTYK*# SEQUENCE: PLRPMTYK*# ...# >HUM129BF# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120# DB REFERENCE: SWISS: (ENV_HV1ND,ENV_HV1H3,ENV_HV1W2,ENV_HV1BR,ENV_HV1J3,# & ENV_HV1N5,ENV_HV1MF,ENV_HV1ZH,ENV_HV1B8,ENV_HV1S1,# & ENV_HV1MN,ENV_HV1H2,ENV_HV1B1,ENV_HV1S3,ENV_HV1C4,# & ENV_HV1Z3,ENV_HV1BN,ENV_HV1Y2,ENV_HV1SC,ENV_HV1KB,# & ENV_HV1JR,ENV_HV1PV,ENV_HV1W1)# & PIR1: (VCLJH3,VCLJKX,VCLJMN,VCLJH4,VCLJLV,VCLJ3W,H44001,VCLJVL,# & VCLJKB,VCLJND,VCLJBR,A44963,VCLJSC)# & PIR2: (S25939,S25938,A40218)# & PIR3: (S13288,S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,LFCASDAKAY*# SEQUENCE: LFCASDAKAY*# ...# >HUM129C0# MHC MOLECULE: HLA-A25, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24# DB REFERENCE: SWISS: (GAG_HV1Y2,GAG_HV1A2,GAG_HV1ND,GAG_HV1Z2,GAG_HV1B5,# & GAG_HV1N5,GAG_HV1EL,GAG_HV1MN,GAG_HV1W2,GAG_HV1PV,# & GAG_HV1J3,GAG_HV1C4,GAG_HV1JR,GAG_HV1RH,GAG_HV1H2,# & GAG_SIVCZ,GAG_HV1MA,GAG_HV1B1,GAG_HV1BR)# & PIR1: (FOVWH3,FOVWH4,A44001,FOLJSI,A38068,FOVWA2,FOVWVL,FOVWLV,# & FOLJND)# & PIR2: (S54377)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-A25,actyesu,bindyesu,QAISPRTLNAW*# SEQUENCE: QAISPRTLNAW*# ...# >HUM129C1# MHC MOLECULE: HLA-A25, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (203-212)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1EL,GAG_HV1Z2,GAG_HV1OY,GAG_HV1B1,# & GAG_HV1RH,GAG_HV1PV,GAG_HV1J3,GAG_HV1JR,GAG_HV1C4,# & GAG_HV1Y2,GAG_HV1W2,GAG_HV1A2,GAG_HV1MN,GAG_HV1H2,# & GAG_HV1BR,GAG_HV1B5)# & PIR1: (FOVWH3,FOVWVL,A38068,FOVWH4,FOVWLV,FOVWA2,A44001)# & PIR2: (S44993,S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-A25,actyesu,bindyesu,ETINEEAAEW*# SEQUENCE: ETINEEAAEW*# ...# >HUM129C2# MHC MOLECULE: HLA-A32, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1EL,POL_HV1MN,POL_HV1H2,POL_HV1Y2,# & POL_HV1PV,POL_HV1B1,POL_HV1JR,POL_HV1ND,POL_HV1BR,# & POL_HV1Z2)# & PIR1: (GNVWLV,GNLJND,B44001,GNVWH3,GNVWVL)# & PIR2: (S54378,B47175)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-A32,actyesu,bindyesu,PIQKETWETW*# SEQUENCE: PIQKETWETW*# ...# >HUM129C3# MHC MOLECULE: HLA-A32, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1H3,ENV_HV1PV,ENV_HV1BR)# & PIR1: (VCLJVL,VCLJLV)# & PIR3: (S13289,S13288)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-A32,actyesu,bindyesu,RIKQFINMW*# SEQUENCE: RIKQFINMW*# ...# >HUM129C4# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (333-341)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1RH,ENV_SIVML,ENV_HV1BR,ENV_HV1PV,# & ENV_HV1H3,ENV_SIVMK,ENV_HV1W2,ENV_HV1H2,ENV_HV1B1,# & ENV_HV1BN,ENV_HV1B8,ENV_SIVM1,ENV_HV1ZH,ENV_SIVCZ,# & ENV_SIVSP,ENV_HV1EL,ENV_HV1OY,ENV_HV2D2,ENV_HV1W1,# & ENV_SIVS4)# & PIR1: (VCLJG3,VCLJBR,VCLJH3,VCLJS2,VCLJ3W,A44963,VCLJSI,VCLJVL,# & VCLJG5,VCLJLV)# & PIR2: (A45713,S21990,S70420,S70418,S22000,S22006,S24571,S04322,# & S55072,S22002,S70417,S55073,S03068,S70423,A53034)# & PIR3: (S49197,S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,IPRRIRQGL*# SEQUENCE: IPRRIRQGL*# ...# >HUM129C5# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (51-59)# DB REFERENCE: SWISS: (GAG_HV1J3,GAG_HV1BR,GAG_HV1H2,GAG_HV1Y2,GAG_HV1A2,# & GAG_HV1W2,GAG_HV1ND,GAG_HV1EL,GAG_HV1N5,GAG_HV1Z2,# & GAG_HV1RH,GAG_HV1JR,GAG_HV1B1,GAG_HV1OY,GAG_HV1MN,# & GAG_HV1PV,GAG_HV1C4,GAG_HV1B5)# & PIR1: (A44001,FOVWA2,FOVWH4,FOLJND,FOVWVL,FOVWH3,A38068,# & FOVWLV)# & PIR2: (S54377,S49086)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,DLNTMLNTV*# SEQUENCE: DLNTMLNTV*# ...# >HUM129C6# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (166-174)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,DRFWKTLRA*# SEQUENCE: DRFWKTLRA*# ...# >HUM129C7# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B18,actyesu,bindyesu,YPLTIGWCY*# SEQUENCE: YPLTIGWCY*# ...# >HUM129C8# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1H3,ENV_HV1KB,ENV_HV1Z2,ENV_HV1B1,# & ENV_HV1ZH,ENV_HV1H2,ENV_HV1BN,ENV_HV1C4,ENV_HV1OY,# & ENV_HV1PV,ENV_HV1MN,ENV_HV1S1,ENV_HV1Z6,ENV_HV1B8,# & ENV_HV1EL,ENV_HV1BR,ENV_HV1J3,ENV_HV1JR)# & PIR1: (VCLJVL,VCLJBR,VCLJKB,VCLJLV,VCLJKX,A44963,VCLJZR,VCLJMN,# & VCLJH4,VCLJH3)# & PIR2: (S21996,S21994,S70424,S22000,S21998,S21990,S70425,S70421,# & S70422,S70420,S70419,S70418,S70417,S70423,S21992,S54384,# & S22006,S22002,S22004,B41621)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RYLKDQQL*# SEQUENCE: RYLKDQQL*# ...# >HUM129C9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41# DB REFERENCE: SWISS: (ENV_HV1SC,ENV_HV1ND,ENV_HV1Z2,ENV_HV1H2,ENV_HV1J3,# & ENV_HV1Z6,ENV_HV1S1,ENV_HV1H3,ENV_HV1B8,ENV_HV1W1,# & ENV_HV1PV,ENV_HV1BR,ENV_HV1B1,ENV_HV1MF,ENV_HV1MA,# & ENV_HV1W2,ENV_HV1RH)# & PIR1: (VCLJSC,VCLJ3W,VCLJLV,VCLJND,VCLJZR,VCLJH3,VCLJVL)# & PIR2: (S54384,S21992,S70423,S22000,S21990,S22002,S70418,S70417,# & S70424)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,GRRGWEALKY*# SEQUENCE: GRRGWEALKY*# ...# >HUM129CA# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1U4,NEF_HV1PV,NEF_HV1MA,NEF_HV112,NEF_HV1B1,# & NEF_HV1JR,NEF_HV1Z2,NEF_HV1OY,NEF_HV1A2,NEF_HV1H2,# & NEF_HV1BR,NEF_HV1SC,NEF_HV1EL,NEF_HV1B8,NEF_HV1Z6,# & NEF_HV1MN,NEF_HV1BN,NEF_HV1S1,NEF_HV1ND,NEF_HV1S3)# & PIR1: (ASLJ12,ASLJVL,QQLJZR,ASLJH3,ASLJO2,ASLJFV,QQLJND,# & ASLJBR)# & PIR2: (S24985,S43467,S03244,S54385,S25937,S03245)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,QVPLRPMTYK*# SEQUENCE: QVPLRPMTYK*# ...# >HUM129CB# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1RH,NEF_HV1U4,NEF_HV1ND,NEF_HV1B8,NEF_HV1BN,# & NEF_HV1EL,NEF_HV1Z6,NEF_HV1S1,NEF_HV1A2,NEF_HV1BR,# & NEF_HV112,NEF_HV1PV,NEF_HV1MN)# & PIR1: (ASLJH3,ASLJFV,QQLJND,ASLJ12,ASLJBR,ASLJO2,QQLJZR,# & ASLJVL)# & PIR2: (S03245,S03246,S25937,S03247,S03244,S24985,S43467)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RYPLTFGW*# SEQUENCE: RYPLTFGW*# ...# >HUM129CC# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1MA,ENV_HV1RH,ENV_HV1PV,ENV_HV1OY,# & ENV_HV1SC,ENV_HV1S1,ENV_HV1B1,ENV_HV1N5,ENV_HV1A2,# & ENV_HV1Z6,ENV_HV1Y2,ENV_HV1H2,ENV_HV1EL,ENV_HV1Z2,# & ENV_HV1MN,ENV_HV1H3,ENV_HV1C4,ENV_HV1B8,ENV_HV1W1,# & ENV_HV1BR,ENV_HV1Z8,ENV_HV1KB,ENV_HV1W2)# & PIR1: (VCLJZR,VCLJ3W,VCLJLV,VCLJA2,VCLJKX,VCLJSC,VCLJVL,VCLJH4,# & VCLJMN,H44001,VCLJKB,VCLJH3)# & PIR2: (S54384,A40218,S25939,S25938)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,VPVWKEATTTL*# SEQUENCE: VPVWKEATTTL*# ...# >HUM129CD# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (96-104)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1PV,ENV_HV1B1,ENV_HV1B8,ENV_HV1BR,# & ENV_HV1H3,ENV_HV1H2,ENV_HV1A2,ENV_HV1BN,ENV_HV1J3,# & ENV_HV1C4,ENV_HV1S1)# & PIR1: (VCLJBR,VCLJA2,VCLJLV,VCLJH4,VCLJVL,VCLJH3)# & PIR2: (S70418,S70423,B41621,A41621,S21990,S22002)# & PIR3: (S33985,S13289,S13288)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,TAVPWNASW*# SEQUENCE: TAVPWNASW*# ...# >HUM129CE# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1BN,NEF_HV1Y2,NEF_HV1MA,NEF_HV1JR,NEF_HV1OY,# & NEF_HV1S1,NEF_HV1BR,NEF_HV1RH,NEF_HV1S3,NEF_HV1A2,# & NEF_HV1PV,NEF_HV1B8,NEF_HV112,NEF_HV1MN)# & PIR1: (ASLJ12,ASLJFV,I44001,ASLJO2,ASLJVL,ASLJBR)# & PIR2: (S03247,S03246,S03245,S43467)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,YFPDWQNYT*# SEQUENCE: YFPDWQNYT*# ...# >HUM129CF# MHC MOLECULE: HLA-B39, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24# DB REFERENCE: SWISS: (GAG_HV1U4,GAG_HV1B1,GAG_HV1C4,GAG_HV1J3,GAG_HV1MA,# & GAG_HV1N5,GAG_HV1A2,GAG_HV1Y2,GAG_HV1BR,GAG_HV1H2,# & GAG_HV1ND,GAG_HV1Z2,GAG_HV1EL,GAG_HV1W2,GAG_HV1PV,# & GAG_HV1RH,GAG_HV1MN,GAG_HV1B5,GAG_HV1OY,GAG_HV1JR)# & PIR1: (FOVWH3,FOVWLV,FOVWVL,FOVWH4,FOLJND,A44001,A38068,# & FOVWA2)# & PIR2: (S49086,S54377,S44993)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B39,actyesu,bindyesu,GHQAAMQML*# SEQUENCE: GHQAAMQML*# ...# >HUM129D0# MHC MOLECULE: HLA-B55, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (41-50)# DB REFERENCE: SWISS: (ENV_HV1RH,ENV_HV1N5,ENV_HV1H2,ENV_HV1MN,ENV_HV1A2,# & ENV_HV1EL,ENV_HV1KB,ENV_HV1Z6,ENV_HV1W2,ENV_HV1B1,# & ENV_HV1PV,ENV_HV1MF,ENV_HV1Z8,ENV_HV1BR,ENV_HV1Z2,# & ENV_HV1H3,ENV_HV1Y2,ENV_HV1B8,ENV_HV1W1,ENV_HV1S1,# & ENV_HV1SC,ENV_HV1OY,ENV_HV1C4,ENV_HV1MA)# & PIR1: (VCLJKX,VCLJ3W,VCLJLV,H44001,VCLJVL,VCLJSC,VCLJKB,VCLJMN,# & VCLJH3,VCLJZR,VCLJH4,VCLJA2)# & PIR2: (S25938,S25939,S54384,A40218)# & PIR3: (S13288,S33985,S13289)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B55,actyesu,bindyesu,VPVWKEATTT*# SEQUENCE: VPVWKEATTT*# ...# >HUM129D1# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (108-117)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1MN,GAG_HV1W2,GAG_HV1A2,GAG_SIVCZ,# & GAG_HV1N5,GAG_HV1C4,GAG_HV1MA,GAG_HV1OY,GAG_HV1B5,# & GAG_HV1J3,GAG_HV1Y2,GAG_HV1BR,GAG_HV1H2,GAG_HV1RH,# & GAG_HV1JR,GAG_HV1B1)# & PIR1: (A44001,A38068,FOVWH4,FOVWVL,FOVWH3,FOVWLV,FOVWA2,# & FOLJSI)# & PIR2: (S60702,S60699,S60708,S60698,S60703,S49086)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,TSTLQEQIGW*# SEQUENCE: TSTLQEQIGW*# ...# >HUM129D2# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1A2,NEF_HV1RH,NEF_HV1S1,NEF_HV1B8,NEF_HV112,# & NEF_HV1MN,NEF_HV1BR,NEF_HV1S3,NEF_HV1OY,NEF_HV1JR,# & NEF_HV1PV,NEF_HV1MA,NEF_HV1Y2,NEF_HV1BN)# & PIR1: (ASLJVL,ASLJO2,I44001,ASLJFV,ASLJBR,ASLJ12)# & PIR2: (S03247,S24985,S03245,S43467,S03246)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,HTQGYFPDWQ*# SEQUENCE: HTQGYFPDWQ*# ...# >HUM129D3# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1MN,NEF_HV1S1,NEF_HV1PV,NEF_HV1Y2,NEF_HV1BR,# & NEF_HV1S3,NEF_HV1BN,NEF_HV1MA,NEF_HV1RH,NEF_HV1B8,# & NEF_HV112,NEF_HV1JR,NEF_HV1OY,NEF_HV1A2)# & PIR1: (ASLJFV,ASLJBR,ASLJ12,ASLJO2,ASLJVL,I44001)# & PIR2: (S03245,S43467,S03247,S03246)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,YFPDWQNYT*# SEQUENCE: YFPDWQNYT*# ...# >HUM129D4# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (136-145)# DB REFERENCE: SWISS: (GAG_HV1Z2,GAG_HV1J3,GAG_HV1RH,GAG_HV1B5,GAG_HV1MN,# & GAG_HV1H2,GAG_HV1BR,GAG_HV1Y2,GAG_HV1ND,GAG_HV1C4,# & GAG_HV1W2,GAG_HV1JR,GAG_HV1A2,GAG_HV1PV,GAG_HV1U4,# & GAG_HV1N5,GAG_HV1MA,GAG_HV1OY,GAG_HV1B1)# & PIR1: (A44001,FOVWVL,FOLJND,FOVWA2,FOVWLV,A38068,FOVWH3,# & FOVWH4)# & PIR2: (S60708,S54377,S60698,S60697,S60699,S60703,S60704,# & S60702)# & PIR3: (S33979,S19598)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,LGLNKIVRMY*# SEQUENCE: LGLNKIVRMY*# ...# >HUM129D5# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (464-473)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1N5,POL_HV1JR,POL_HV1OY,POL_HV1PV,# & POL_HV1H2,POL_HV1B1,POL_HV1Z2,POL_HV1RH,POL_HV1ND,# & POL_HV1BR,POL_HV1Y2,POL_HV1B5,POL_HV1MA,POL_HV1EL)# & PIR1: (GNVWH3,GNVWVL,GNLJND,B44001,GNVWLV)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,ILKEPVHGVY*# SEQUENCE: ILKEPVHGVY*# ...# >HUM129D6# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1Z6,NEF_HV1BR,NEF_HV1B8,NEF_HV112,# & NEF_HV1RH,NEF_HV1ND,NEF_HV1BN,NEF_HV1H2,NEF_HV1SC,# & NEF_HV1B1)# & PIR1: (ASLJFV,QQLJND,ASLJ12,ASLJBR,ASLJVL,ASLJH3,QQLJZR)# & PIR2: (S43467,S24985,S03246,S03244,S03247,S03245)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: brander95b# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,AVDLSHFL*# SEQUENCE: AVDLSHFL*# ...# >HUM129D7# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: Reference/CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV nef# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV112,NEF_HV1B8,NEF_HV1A2,NEF_HV1OY,# & NEF_HV1PV,NEF_HV1S3,NEF_HV1Y2,NEF_HV1MN,NEF_HV1S1,# & NEF_HV1BN,NEF_HV1MA,NEF_HV1RH,NEF_HV1JR)# & PIR1: (ASLJFV,I44001,ASLJ12,ASLJBR,ASLJO2,ASLJVL)# & PIR2: (S03245,S03246,S03247,S43467)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,goulder97a# COMMENT:# SUMMARY: HLA-B62,actyesl,bindyesu,TQGYFPDWQNY*# SEQUENCE: TQGYFPDWQNY*# ...# >HUM129D8# MHC MOLECULE: HLA-Cw4, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (379-387)# DB REFERENCE: SWISS: (ENV_HV1W1,ENV_HV1Z8,ENV_HV1PV,ENV_HV1S1,ENV_HV1BN,# & ENV_HV1W2,ENV_HV1EL,ENV_HV1C4,ENV_HV1OY,ENV_HV1SC,# & ENV_HV1Z2,ENV_HV1BR,ENV_HV1H3,ENV_HV1Y2,ENV_HV1B8,# & ENV_HV1J3,ENV_HV1RH,ENV_HV1H2,ENV_HV1MN,ENV_HV1N5,# & ENV_HV1Z6,ENV_HV1ZH,ENV_HV1MF,ENV_HV1B1,ENV_HV1JR)# & PIR1: (VCLJZR,H44001,VCLJSC,VCLJBR,VCLJMN,A44963,VCLJVL,VCLJH3,# & VCLJH4,VCLJLV,VCLJ3W)# & PIR2: (S60545,S60546,S60529,S60521,S60535,S54384,S60557,S60523,# & S60525,A40218,S60555,S31493,S60548,S60528,S60541,S60547,# & S60549,S60550,S60524,S60522,S60556,A41621)# & PIR3: (S13289,S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: brander95b,hivdb97a# COMMENT:# SUMMARY: HLA-Cw4,actyesu,bindyesu,SFNCGGEFF*# SEQUENCE: SFNCGGEFF*# ...# >HUM129D9# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (18-27)# DB REFERENCE: SWISS: (GAG_HV2KR,GAG_HV2NZ,GAG_HV1Z2,GAG_HV2ST,GAG_HV1J3,# & GAG_SIVMK,GAG_HV1OY,GAG_HV1PV,GAG_HV1MA,GAG_HV1N5,# & GAG_HV1B1,GAG_HV2SB,GAG_HV1B5,GAG_HV1MN,GAG_HV1Y2,# & GAG_HV1EL,GAG_HV1BR,GAG_HV1C4,GAG_HV1JR,GAG_HV1A2,# & GAG_HV1W2,GAG_SIVSP,GAG_HV1H2,GAG_SIVM1)# & PIR1: (FOVWLV,FOLJST,FOVWA2,FOVWH4,A44001,FOLJG5,FOVWH3,FOLJG3,# & FOVWVL,A38068)# & PIR2: (S03070,S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KIRLRPGGKK*# SEQUENCE: KIRLRPGGKK*# ...# >HUM129DA# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (18-26)# DB REFERENCE: SWISS: (GAG_SIVSP,GAG_HV1J3,GAG_HV2NZ,GAG_HV1JR,GAG_HV1EL,# & GAG_HV1BR,GAG_HV2KR,GAG_HV2SB,GAG_HV1N5,GAG_HV1MA,# & GAG_HV1OY,GAG_HV1B5,GAG_HV1Y2,GAG_HV2ST,GAG_SIVM1,# & GAG_HV1C4,GAG_HV1H2,GAG_HV1Z2,GAG_SIVMK,GAG_HV1PV,# & GAG_HV1W2,GAG_HV1MN,GAG_HV1A2,GAG_HV1B1)# & PIR1: (FOLJG3,FOVWA2,FOVWLV,FOLJST,FOVWH3,A38068,FOVWH4,FOVWVL,# & FOLJG5,A44001)# & PIR2: (S03070,S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a,goulder97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,KIRLRPGGK*# SEQUENCE: KIRLRPGGK*# ...# >HUM129DB# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (18-42)# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1H2,GAG_HV1PV,GAG_HV1BR,GAG_HV1J3,# & GAG_HV1B1,GAG_HV1B5)# & PIR1: (FOVWVL,FOVWH3,FOVWA2,FOVWLV)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,KIRLRPGGKKKYKLKHIVWASRELE*# SEQUENCE: KIRLRPGGKKKYKLKHIVWASRELE*# ...# >HUM129DC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (19-27)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV2ST,GAG_HV1N5,GAG_HV1MA,GAG_HV1B1,# & GAG_HV1H2,GAG_HV2RO,GAG_HV1PV,GAG_HV1A2,GAG_SIVM1,# & GAG_HV1J3,GAG_HV1MN,GAG_HV1BR,GAG_HV2NZ,GAG_SIVSP,# & GAG_HV1EL,GAG_HV1Y2,GAG_HV1Z2,GAG_HV1C4,GAG_HV1OY,# & GAG_HV1B5,GAG_HV2KR,GAG_HV1W2,GAG_SIVMK,GAG_HV2SB,# & GAG_HV1JR)# & PIR1: (FOLJND,FOLJST,FOVWVL,FOVWH3,FOLJG2,FOVWLV,A38068,FOVWH4,# & FOLJG5,FOLJG3,FOVWA2,A44001)# & PIR2: (S03070,S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,IRLRPGGKK*# SEQUENCE: IRLRPGGKK*# ...# >HUM129DD# MHC MOLECULE: HLA-B42, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (20-29)# DB REFERENCE: SWISS: (GAG_HV1MA,GAG_HV2SB,GAG_HV1MN,GAG_HV1ND,GAG_HV2BE,# & GAG_HV1B5,GAG_SIVM1,GAG_HV2CA,GAG_HV2ST,GAG_HV1A2,# & GAG_HV1BR,GAG_HV2NZ,GAG_HV1Z2,GAG_HV2KR,GAG_HV1JR,# & GAG_HV1W2,GAG_SIVMK,GAG_HV1EL,GAG_HV1OY,GAG_HV2RO,# & GAG_HV1H2,GAG_SIVMS,GAG_HV1PV,GAG_HV2D2,GAG_HV1B1,# & GAG_HV1J3)# & PIR1: (FOLJCA,FOVWH3,FOVWLV,FOLJND,FOLJST,FOLJG3,FOLJTM,FOVWA2,# & FOVWVL,A38068,FOLJG2,FOLJG5)# & PIR2: (S53091,S08435,S54377,S03070)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B42,actyesu,bindyesu,RLRPGGKKKY*# SEQUENCE: RLRPGGKKKY*# ...# >HUM129DE# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (20-29)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_SIVMS,GAG_HV1H2,GAG_HV2RO,GAG_HV2D2,# & GAG_HV1J3,GAG_HV1JR,GAG_HV1OY,GAG_SIVM1,GAG_HV1BR,# & GAG_HV1A2,GAG_HV2NZ,GAG_HV1Z2,GAG_HV2SB,GAG_HV2ST,# & GAG_HV2CA,GAG_HV1W2,GAG_HV1MN,GAG_HV1ND,GAG_HV1B5,# & GAG_SIVMK,GAG_HV2KR,GAG_HV1EL,GAG_HV1B1,GAG_HV1MA,# & GAG_HV2BE)# & PIR1: (FOVWVL,FOLJG5,FOLJG2,FOLJTM,FOVWH3,FOLJG3,FOVWA2,A38068,# & FOVWLV,FOLJCA,FOLJND,FOLJST)# & PIR2: (S03070,S08435,S54377,S53091)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,RLRPGGKKKY*# SEQUENCE: RLRPGGKKKY*# ...# >HUM129DF# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (24-35)# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1B1,GAG_HV1B5,GAG_HV1BR,GAG_HV1PV,# & GAG_HV1H2,GAG_HV2CA,GAG_HV2NZ,GAG_HV1J3)# & PIR1: (FOLJCA,FOVWH3,FOVWVL,FOVWLV,FOVWA2)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,GGKKKYKLKHIV*# SEQUENCE: GGKKKYKLKHIV*# ...# >HUM129E0# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (28-36)# DB REFERENCE: SWISS: (GAG_HV2CA,GAG_HV1PV,GAG_HV1H2,GAG_HV1B5,GAG_HV1A2,# & GAG_HV1B1,GAG_HV1BR,GAG_HV1J3,GAG_HV2NZ)# & PIR1: (FOVWH3,FOLJCA,FOVWVL,FOVWA2,FOVWLV)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,KYKLKHIVW*# SEQUENCE: KYKLKHIVW*# ...# >HUM129E1# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (36-44)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1ND,GAG_HV1J3,GAG_HV1B5,GAG_HV1MA,# & GAG_HV1BR,GAG_HV1RH,GAG_HV1Y2,GAG_HV1A2,GAG_HV1OY,# & GAG_HV1W2,GAG_HV1Z2,GAG_HV1B1,GAG_HV1MN,GAG_HV1H2,# & GAG_SIVCZ,GAG_HV1JR,GAG_HV1N5)# & PIR1: (FOVWVL,FOVWH3,FOVWA2,FOVWLV,A44001,FOLJSI,FOLJND,# & A38068)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,WASRELERF*# SEQUENCE: WASRELERF*# ...# >HUM129E2# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (69-93)# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1W2,GAG_HV1BR,GAG_HV1B5,GAG_HV1C4,# & GAG_HV1PV,GAG_HV1B1)# & PIR1: (FOVWLV,FOVWH4,FOVWH3,FOVWVL)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,QTGSEELRSLYNTVATLYCVHQRIE*# SEQUENCE: QTGSEELRSLYNTVATLYCVHQRIE*# ...# >HUM129E3# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (71-79)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1N5,GAG_HV1PV,GAG_HV1B1,GAG_HV1A2,# & GAG_HV1Y2,GAG_HV1B5,GAG_HV1W2,GAG_HV1BR,GAG_HV1H2)# & PIR1: (FOVWVL,FOVWH4,FOVWA2,FOVWH3,FOVWLV,A44001)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,GSEELRSLY*# SEQUENCE: GSEELRSLY*# ...# >HUM129E4# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference/CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV p17 (74-82)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1B5,GAG_HV1C4,GAG_HV1PV,GAG_HV1B1,# & GAG_HV1U4,GAG_HV1A2,GAG_HV1W2,GAG_HV1EL,GAG_HV1Y2,# & GAG_HV1H2)# & PIR1: (FOVWH4,FOVWH3,A44001,FOVWLV,FOVWVL,FOVWA2)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a,goulder97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,ELRSLYNTV*# SEQUENCE: ELRSLYNTV*# ...# >HUM129E5# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (88-115)# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1PV,GAG_HV1B5,GAG_HV1BR,GAG_HV1B1)# & PIR1: (FOVWLV,FOVWH3,FOVWVL)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,VHQRIEIKDTKEALDKIEEEQNKSKKKA*# SEQUENCE: VHQRIEIKDTKEALDKIEEEQNKSKKKA*# ...# >HUM129E6# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (121-132)# DB REFERENCE: SWISS: (GAG_HV1H2)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesu,DTGHSNQVSQNY*# SEQUENCE: DTGHSNQVSQNY*# ...# >HUM129E7# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (15-23)# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1OY,GAG_HV1Z2,GAG_HV1MN,GAG_HV1B5,# & GAG_HV1PV,GAG_HV1JR,GAG_HV1C4,GAG_SIVCZ,GAG_HV1A2,# & GAG_HV1BR,GAG_HV1J3,GAG_HV1Y2,GAG_HV1ND,GAG_HV1H2,# & GAG_HV1B1,GAG_HV1MA,GAG_HV1W2,GAG_HV1EL,GAG_HV1N5)# & PIR1: (FOLJSI,FOVWH3,A44001,FOVWVL,FOVWA2,FOVWLV,A38068,FOLJND,# & FOVWH4)# & PIR2: (S54377)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,ISPRTLNAW*# SEQUENCE: ISPRTLNAW*# ...# >HUM129E8# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (30-40)# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1C4,GAG_HV1N5,GAG_HV1OY,GAG_HV1B5,# & GAG_HV1MN,GAG_HV1U4,GAG_HV1RH,GAG_HV1JR,GAG_HV1PV,# & GAG_HV1EL,GAG_HV1Z2,GAG_SIVCZ,GAG_HV1MA,GAG_HV1H2,# & GAG_HV1W2,GAG_HV1BR,GAG_HV1B1,GAG_HV1Y2,GAG_HV1ND,# & GAG_HV1J3)# & PIR1: (FOVWH3,FOVWLV,A38068,FOVWVL,FOLJSI,FOVWA2,FOVWH4,FOLJND,# & A44001)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,KAFSPEVIPMF*# SEQUENCE: KAFSPEVIPMF*# ...# >HUM129E9# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (31-50)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1JR,GAG_HV1EL,GAG_HV1Z2,GAG_HV1ND,# & GAG_HV1MA,GAG_HV1W2,GAG_HV1B1,GAG_HV1Y2,GAG_HV1B5,# & GAG_HV1A2,GAG_HV1N5,GAG_HV1BR,GAG_HV1H2,GAG_HV1MN,# & GAG_HV1U4,GAG_HV1RH,GAG_HV1J3)# & PIR1: (FOVWVL,FOVWH3,A44001,FOVWA2,FOLJND,FOVWLV,A38068)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,AFSPEVIPMFSALSEGATPQ*# SEQUENCE: AFSPEVIPMFSALSEGATPQ*# ...# >HUM129EA# MHC MOLECULE: HLA-A26, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (31-50)# DB REFERENCE: SWISS: (GAG_HV1U4,GAG_HV1RH,GAG_HV1BR,GAG_HV1H2,GAG_HV1MN,# & GAG_HV1N5,GAG_HV1ND,GAG_HV1Y2,GAG_HV1B1,GAG_HV1MA,# & GAG_HV1W2,GAG_HV1J3,GAG_HV1EL,GAG_HV1JR,GAG_HV1PV,# & GAG_HV1Z2,GAG_HV1B5,GAG_HV1A2)# & PIR1: (FOVWA2,FOVWH3,FOVWVL,A38068,FOVWLV,FOLJND,A44001)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A26,actyesu,bindyesu,AFSPEVIPMFSALSEGATPQ*# SEQUENCE: AFSPEVIPMFSALSEGATPQ*# ...# >HUM129EB# MHC MOLECULE: HLA-A26, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (35-43)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1MN,GAG_HV1MA,GAG_HV1N5,GAG_HV1EL,# & GAG_HV1A2,GAG_HV1Z2,GAG_HV1U4,GAG_HV1RH,GAG_HV1OY,# & GAG_HV1JR,GAG_SIVCZ,GAG_HV1H2,GAG_HV1Y2,GAG_HV1B1,# & GAG_HV1W2,GAG_HV1BR,GAG_HV1B5,GAG_HV1PV,GAG_HV1J3)# & PIR1: (FOVWVL,A44001,A38068,FOLJSI,FOVWLV,FOVWH3,FOLJND,# & FOVWA2)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A26,actyesu,bindyesu,EVIPMFSAL*# SEQUENCE: EVIPMFSAL*# ...# >HUM129EC# MHC MOLECULE: HLA-Cw1(Cw*0102), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (36-43)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1Z2,GAG_HV1OY,GAG_HV1B1,GAG_HV1MN,# & GAG_HV1MA,GAG_HV1N5,GAG_HV1W2,GAG_HV1BR,GAG_HV1B5,# & GAG_HV1J3,GAG_HV1A2,GAG_HV1EL,GAG_HV1ND,GAG_HV1H2,# & GAG_HV1Y2,GAG_HV1JR,GAG_SIVCZ,GAG_HV1U4,GAG_HV1RH)# & PIR1: (FOVWH3,A44001,FOVWA2,FOVWVL,FOLJSI,FOVWLV,FOLJND,# & A38068)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-Cw1,actyesu,bindyesu,VIPMFSAL*# SEQUENCE: VIPMFSAL*# ...# >HUM129ED# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (47-55)# DB REFERENCE: SWISS: (GAG_HV1J3,GAG_HV1W2,GAG_HV1BR,GAG_HV1Z2,GAG_HV1B1,# & GAG_HV1PV,GAG_HV1MN,GAG_HV1N5,GAG_HV1JR,GAG_HV1RH,# & GAG_HV1Y2,GAG_HV1H2,GAG_HV1ND,GAG_HV1C4,GAG_HV1A2,# & GAG_HV1EL,GAG_HV1OY,GAG_HV1B5)# & PIR1: (FOVWVL,FOVWA2,A38068,FOVWH4,FOLJND,FOVWLV,FOVWH3,# & A44001)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,ATPQDLNTM*# SEQUENCE: ATPQDLNTM*# ...# >HUM129EE# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (47-55)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,APPQDLNTM*# SEQUENCE: APPQDLNTM*# ...# >HUM129EF# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (48-56)# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1W2,GAG_HV1Z2,GAG_HV1J3,GAG_HV1H2,# & GAG_HV1ND,GAG_HV1RH,GAG_HV1MN,GAG_HV1N5,GAG_HV1BR,# & GAG_HV1OY,GAG_HV1EL,GAG_HV1C4,GAG_HV1PV,GAG_HV1Y2,# & GAG_HV1B5,GAG_HV1JR,GAG_HV1B1)# & PIR1: (A44001,FOVWH3,FOVWVL,FOLJND,FOVWH4,FOVWA2,FOVWLV,# & A38068)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,TPQDLNTML*# SEQUENCE: TPQDLNTML*# ...# >HUM129F0# MHC MOLECULE: HLA-B52, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (62-70)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1Z2,GAG_HV1W2,GAG_HV1MA,GAG_HV1U4,# & GAG_HV1EL,GAG_HV1OY,GAG_HV1RH,GAG_HV1C4,GAG_HV1BR,# & GAG_HV1N5,GAG_HV1H2,GAG_HV1J3,GAG_HV1MN,GAG_HV1A2,# & GAG_HV1JR,GAG_HV1B1,GAG_HV1Y2,GAG_HV1PV,GAG_HV1B5)# & PIR1: (A38068,FOVWH3,FOLJND,FOVWH4,FOVWLV,FOVWA2,FOVWVL,# & A44001)# & PIR2: (S54377,S44993,S49086)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B52,actyesu,bindyesu,HQAAMQMLK*# SEQUENCE: HQAAMQMLK*# ...# >HUM129F1# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (61-71)# DB REFERENCE: SWISS: (GAG_HV1Z2,GAG_HV1A2,GAG_HV1J3,GAG_HV1H2,GAG_HV1OY,# & GAG_HV1EL,GAG_HV1C4,GAG_HV1BR,GAG_HV1N5,GAG_HV1W2,# & GAG_HV1Y2,GAG_HV1PV,GAG_HV1B1,GAG_HV1B5,GAG_HV1JR,# & GAG_HV1MN,GAG_HV1ND,GAG_HV1RH)# & PIR1: (FOVWVL,FOLJND,FOVWLV,FOVWH4,FOVWH3,A44001,A38068,# & FOVWA2)# & PIR2: (S54377,S44993)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GHQAAMQMLKE*# SEQUENCE: GHQAAMQMLKE*# ...# >HUM129F2# MHC MOLECULE: HLA-B55, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (83-92)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1H2,GAG_HV1A2,GAG_HV1B1,GAG_HV1B5,# & GAG_HV1PV)# & PIR1: (FOVWVL,FOVWA2,FOVWLV,FOVWH3)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B55,actyesu,bindyesu,VHPVHAGPIA*# SEQUENCE: VHPVHAGPIA*# ...# >HUM129F3# MHC MOLECULE: HLA-B58(B*5801), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (108-117)# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1PV,GAG_HV1B5,GAG_HV1B1,GAG_HV1MA,# & GAG_HV1A2,GAG_HV1OY,GAG_HV1C4,GAG_HV1Y2,GAG_HV1H2,# & GAG_HV1JR,GAG_HV1J3,GAG_HV1MN,GAG_HV1N5,GAG_HV1RH,# & GAG_HV1BR,GAG_SIVCZ)# & PIR1: (FOVWVL,FOVWH4,FOVWA2,A44001,A38068,FOVWH3,FOVWLV,# & FOLJSI)# & PIR2: (S49086,S60698,S60708,S60702,S60703,S60699)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B58,actyesu,bindyesu,TSTLQEQIGW*# SEQUENCE: TSTLQEQIGW*# ...# >HUM129F4# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (121-140)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1BR,GAG_HV1RH,GAG_HV1ND,GAG_HV1H2,# & GAG_HV1A2,GAG_HV1B5,GAG_HV1Z2,GAG_HV1OY,GAG_HV1W2,# & GAG_HV1B1,GAG_HV1MN,GAG_HV1Y2,GAG_HV1JR,GAG_HV1J3,# & GAG_HV1PV)# & PIR1: (FOLJND,FOVWVL,FOVWH3,FOVWA2,A44001,FOVWLV,A38068)# & PIR2: (S60697,S60699,S60708,S60702,S60703,S54377,S60704,# & S60698)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,NPPIPVGEIYKRWIILGLNK*# SEQUENCE: NPPIPVGEIYKRWIILGLNK*# ...# >HUM129F5# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (122-130)# DB REFERENCE: SWISS: (GAG_HV1J3,GAG_HV1Y2,GAG_HV1OY,GAG_HV1Z2,GAG_HV1W2,# & GAG_HV1B1,GAG_HV1MN,GAG_HV1JR,GAG_HV1B5,GAG_HV1EL,# & GAG_HV1ND,GAG_HV1PV,GAG_HV1BR,GAG_HV1RH,GAG_HV1H2,# & GAG_HV1A2,GAG_HV1N5)# & PIR1: (FOVWLV,A38068,FOVWH3,FOLJND,FOVWA2,A44001,FOVWVL)# & PIR2: (S60702,S60708,S49086,S60698,S54377,S44993,S60703,S60704,# & S60697,S60699)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,PPIPVGEIY*# SEQUENCE: PPIPVGEIY*# ...# >HUM129F6# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (130-140)# DB REFERENCE: SWISS: (GAG_SIVMS,GAG_HV2D2,GAG_SIVSP,GAG_SIVM1,GAG_SIVS4)# & PIR1: (FOLJG3,FOLJTM)# & PIR2: (S08435,S04237)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRWIQLGLQK*# SEQUENCE: RRWIQLGLQK*# ...# >HUM129F7# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (130-148)# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1A2,GAG_HV1B5,GAG_HV1OY,GAG_HV1W2,# & GAG_HV1B1,GAG_HV1PV,GAG_HV1BR,GAG_HV1N5,GAG_HV1Y2)# & PIR1: (A44001,FOVWVL,FOVWLV,FOVWH3,FOVWA2)# & PIR2: (S60702,S60703,S60704,S60699)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,YKRWIILGLNKIVRMYSPT*# SEQUENCE: YKRWIILGLNKIVRMYSPT*# ...# >HUM129F8# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (131-150)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1BR,GAG_HV1Y2,GAG_HV1OY,GAG_HV1B1,# & GAG_HV1N5,GAG_HV1H2,GAG_HV1W2,GAG_HV1B5,GAG_HV1A2)# & PIR1: (FOVWH3,A44001,FOVWA2,FOVWLV,FOVWVL)# & PIR2: (S60703,S60699,S60704,S60702)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,KRWIILGLNKIVRMYSPTSI*# SEQUENCE: KRWIILGLNKIVRMYSPTSI*# ...# >HUM129F9# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (131-145)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesu,KRWIILGLNKIVMRY*# SEQUENCE: KRWIILGLNKIVMRY*# ...# >HUM129FA# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (131-145)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRWIILGLNKIVMRY*# SEQUENCE: KRWIILGLNKIVMRY*# ...# >HUM129FB# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV p24 (131-142)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1A2,GAG_HV1C4,GAG_HV1B1,GAG_HV1ND,# & GAG_HV1N5,GAG_HV1JR,GAG_HV1H2,GAG_HV1RH,GAG_HV1J3,# & GAG_HV1MA,GAG_HV1Z2,GAG_HV1MN,GAG_HV1Y2,GAG_HV1OY,# & GAG_HV1BR,GAG_HV1PV,GAG_HV1W2)# & PIR1: (FOVWA2,A44001,A38068,FOVWVL,FOVWH3,FOVWH4,FOVWLV,# & FOLJND)# & PIR2: (S60699,S60704,S60698,S60703,S60708,S60697,S60702,# & S54377)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actunkn,bindyesu,KRWIILGLNKIV*# SEQUENCE: KRWIILGLNKIV*# ...# >HUM129FC# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (131-140)# DB REFERENCE: PIR2: (S60700)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRWIIMGLNK*# SEQUENCE: KRWIIMGLNK*# ...# >HUM129FD# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (131-139)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,KRWIIMGNK*# SEQUENCE: KRWIIMGNK*# ...# >HUM129FE# MHC MOLECULE: HLA-B52, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (143-150)# DB REFERENCE: SWISS: (GAG_HV1W2,GAG_HV1B5,GAG_HV1A2,GAG_HV1N5,GAG_HV1B1,# & GAG_HV1BR,GAG_HV1PV,GAG_HV1OY,GAG_HV1H2,GAG_HV1Y2)# & PIR1: (A44001,FOVWA2,FOVWH3,FOVWLV,FOVWVL)# & PIR2: (S60704,S60702,S60699,S60703)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B52,actyesu,bindyesu,RMYSPTSI*# SEQUENCE: RMYSPTSI*# ...# >HUM129FF# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (166-174)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1JR,GAG_HV1BR,GAG_HV1H2,GAG_HV1OY,# & GAG_HV1Y2,GAG_HV1J3,GAG_HV1N5,GAG_HV1Z2,GAG_HV1B1,# & GAG_HV1EL,GAG_HV1PV,GAG_HV1MN,GAG_HV1A2,GAG_SIVCZ,# & GAG_HV1W2,GAG_HV1RH,GAG_HV1B5,GAG_HV1C4)# & PIR1: (A44001,FOLJND,FOVWA2,FOVWLV,FOVWH3,FOVWH4,A38068,FOLJSI,# & FOVWVL)# & PIR2: (S60698,S52929,S60704,S54377,S60697,S60703,S60708,S60702,# & S60699,S60700)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,DRFYKTLRA*# SEQUENCE: DRFYKTLRA*# ...# >HUM12A00# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (166-174)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,DRFYKILRA*# SEQUENCE: DRFYKILRA*# ...# >HUM12A01# MHC MOLECULE: HLA-Cw8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (173-181)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_SIVCZ,GAG_HV1B5,GAG_HV1C4,GAG_HV1MN,# & GAG_HV1Y2,GAG_HV1PV,GAG_HV1BR,GAG_HV1H2,GAG_HV1J3,# & GAG_HV1N5,GAG_HV1Z2)# & PIR1: (FOVWVL,A44001,FOVWH4,FOLJSI,FOVWLV,A38068,FOVWH3)# & PIR2: (S60699,S54377,S60697,S60700,S60708)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-Cw8,actyesu,bindyesu,RAEQASQEV*# SEQUENCE: RAEQASQEV*# ...# >HUM12A02# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (173-181)# DB REFERENCE: SWISS: (GAG_SIVCZ,GAG_HV1PV,GAG_HV1BR,GAG_HV1N5,GAG_HV1Z2,# & GAG_HV1MN,GAG_HV1C4,GAG_HV1B5,GAG_HV1Y2,GAG_HV1B1,# & GAG_HV1H2,GAG_HV1J3)# & PIR1: (A38068,FOVWLV,FOLJSI,A44001,FOVWH4,FOVWVL,FOVWH3)# & PIR2: (S54377,S60699,S60700,S60697,S60708)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,RAEQASQEV*# SEQUENCE: RAEQASQEV*# ...# >HUM12A03# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (176-184)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1H2,GAG_HV1J3,GAG_HV1Y2,GAG_HV1B1,# & GAG_HV1PV,GAG_SIVCZ,GAG_HV1N5,GAG_HV1C4,GAG_HV1B5,# & GAG_HV1MN)# & PIR1: (FOVWLV,FOVWVL,FOLJSI,FOVWH3,A38068,FOVWH4,A44001)# & PIR2: (S60697,S60700,S60699,S60708)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,QASQEVKNW*# SEQUENCE: QASQEVKNW*# ...# >HUM12A04# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (181-190)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1U4,GAG_HV1B5,GAG_HV1MN,GAG_HV1JR,# & GAG_HV1H2,GAG_HV1W2,GAG_HV1A2,GAG_HV1ND,GAG_HV1B1,# & GAG_HV1Y2,GAG_HV1J3,GAG_HV1N5,GAG_HV1EL,GAG_HV1OY,# & GAG_HV1MA,GAG_HV1BR,GAG_HV1C4)# & PIR1: (A38068,FOVWH3,FOVWA2,FOVWH4,A44001,FOVWVL,FOLJND,# & FOVWLV)# & PIR2: (S60697,S60708,S60704,S60702,S60699,S60698,S60703,# & S60700)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,VKNWMTETLL*# SEQUENCE: VKNWMTETLL*# ...# >HUM12A05# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (193-201)# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1N5,GAG_HV1BR,GAG_HV1PV,GAG_HV1H2,# & GAG_HV1EL,GAG_HV1C4,GAG_HV1MA,GAG_HV1OY,GAG_HV1MN,# & GAG_HV1Z2,GAG_HV1JR,GAG_HV1Y2,GAG_HV1ND,GAG_HV1B1,# & GAG_HV1A2,GAG_HV1J3,GAG_HV1B5,GAG_HV1W2)# & PIR1: (FOVWH4,A38068,FOVWH3,FOVWVL,FOLJND,A44001,FOVWLV,# & FOVWA2)# & PIR2: (S60700,S60708,S60699,S60698,S60703,S54377,S60704)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesu,NANPDCKTI*# SEQUENCE: NANPDCKTI*# ...# >HUM12A06# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (211-230)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1W2,GAG_HV1C4,GAG_HV1MN,GAG_HV1U4,# & GAG_HV1OY,GAG_HV1Y2,GAG_HV1J3,GAG_HV1A2,GAG_HV1B1,# & GAG_HV1JR,GAG_HV1H2,GAG_HV1N5,GAG_HV1B5,GAG_HV1PV,# & GAG_HV1BR)# & PIR1: (FOVWLV,FOLJND,FOVWVL,FOVWH4,A38068,FOVWH3,A44001,# & FOVWA2)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,LEEMMTACQGVGGPGHKARV*# SEQUENCE: LEEMMTACQGVGGPGHKARV*# ...# >HUM12A07# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (217-227)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1JR,GAG_HV1PV,GAG_HV1A2,GAG_HV1U4,# & GAG_HV1B1,GAG_HV1Y2,GAG_HV1OY,GAG_HV1B5,GAG_HV1N5,# & GAG_HV1H2,GAG_HV1J3,GAG_HV1ND,GAG_HV1W2,GAG_HV1MN,# & GAG_HV1C4)# & PIR1: (FOVWLV,FOVWH4,FOVWVL,A38068,A44001,FOVWA2,FOLJND,# & FOVWH3)# & PIR2: (S60702,S60697,S60708,S60703,S60699)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,ACQGVGGPGHK*# SEQUENCE: ACQGVGGPGHK*# ...# >HUM12A08# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference/CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV p24 (223-231)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1J3,GAG_HV1B1,GAG_HV1U4,GAG_HV1BR,# & GAG_HV1OY,GAG_HV1Y2,GAG_HV1B5,GAG_HV1ND,GAG_HV1MN,# & GAG_HV1C4,GAG_HV1H2,GAG_HV1W2,GAG_HV1A2,GAG_HV1JR,# & GAG_HV1PV)# & PIR1: (FOVWVL,FOVWLV,A44001,FOVWH4,FOVWH3,A38068,FOVWA2,# & FOLJND)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a,goulder97a# COMMENT:# SUMMARY: HLA-B7,actyesm,bindyesu,GPGHKARVL*# SEQUENCE: GPGHKARVL*# ...# >HUM12A09# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p15 (69-83)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1PV,GAG_HV1B5,GAG_HV1B1)# & PIR1: (FOVWH3)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GNFLQSRPEPTAPPF*# SEQUENCE: GNFLQSRPEPTAPPF*# ...# >HUM12A0A# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (59-67)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1N5,POL_HV1A2,POL_HV1U4,POL_HV1B5,# & POL_HV1EL,POL_HV1Y2,POL_HV1ND,POL_HV1Z2,POL_HV1PV,# & POL_HV1BR,POL_HV1J3,POL_HV1JR)# & PIR1: (GNVWH3,GNVWA2,GNVWLV,GNLJND,GNVWVL,B44001)# & PIR2: (S63747,S63743,S63731,S63734,S63745,S63738,S63708,S63742,# & S63750,S63735,S63751,S63753,S63737,S63739,S63749,S63744,# & S63741,S63752,S63755,S63746,S63748,S63733,S63754,S63740,# & S63756,S54378,S63732,S63736)# & PIR3: (S34484)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,ITLWQRPLV*# SEQUENCE: ITLWQRPLV*# ...# >HUM12A0B# MHC MOLECULE: HLA-A74(A*7401), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (59-67)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1B5,POL_HV1A2,POL_HV1BR,POL_HV1Z2,# & POL_HV1ND,POL_HV1Y2,POL_HV1J3,POL_HV1JR,POL_HV1PV,# & POL_HV1U4,POL_HV1EL,POL_HV1B1)# & PIR1: (GNVWA2,GNVWVL,GNVWLV,GNLJND,GNVWH3,B44001)# & PIR2: (S63708,S63738,S63731,S63734,S63752,S63732,S63747,S63733,# & S63754,S63740,S63756,S63751,S63735,S63744,S63736,S63741,# & S63739,S63749,S63753,S63745,S63743,S63742,S63748,S63746,# & S63755,S63750,S63737,S54378)# & PIR3: (S34484)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A74,actyesu,bindyesu,ITLWQRPLV*# SEQUENCE: ITLWQRPLV*# ...# >HUM12A0C# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (86-94)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1OY,POL_HV1RH,POL_HV1Z2,POL_HV1Y2,# & POL_HV1A2,POL_HV1N5)# & PIR1: (B44001,GNVWA2)# & PIR2: (S63734,S54378,S63733,S63739,S63745,S63738,S63740,S63756,# & S63754,S63735,S63736,S63749,S63753)# & PIR3: (S34484)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesu,DTVLEEMNL*# SEQUENCE: DTVLEEMNL*# ...# >MUS12A0D# MHC MOLECULE: H-2k, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (193-207)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1Y2,POL_HV1MN,POL_HV1JR,POL_HV1PV,# & POL_HV1B5,POL_HV1N5,POL_HV1RH,POL_HV1H2,POL_HV1A2,# & POL_HV1B1)# & PIR1: (GNVWLV,GNVWVL,GNVWA2,B44001,GNVWH3)# & PIR2: (A47175,S32135,S32117,S32120,S32057,S32056,S32136,S32053,# & S32119,S32095,S32060,B47175,S32059,S32127,S32122,S32062,# & S32063,S32064,S32065,B47330,S32139,S32058,F47330,S32052,# & S32055,S32118,S32054,S32126,S32134,S32061,S32151,# & S32140)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,CTEMEKEGKISKIGP*# SEQUENCE: CTEMEKEGKISKIGP*# ...# >HUM12A0E# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (262-270)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV2D1,POL_HV2RO,POL_HV1OY,POL_HV1Y2,# & POL_HV1JR,POL_HV2G1,POL_HV1PV,POL_HV2CA,POL_HV1Z2,# & POL_HV1B5,POL_HV1BR,POL_HV2SB,POL_SIVS4,POL_SIVAT,# & POL_SIVCZ,POL_HV1N5,POL_HV1A2,POL_HV1RH,POL_HV1ND,# & POL_HV1MN,POL_HV2ST,POL_HV1B1,POL_HV1U4,POL_HV1H2,# & POL_HV1MA,POL_SIVSP,POL_HV2NZ)# & PIR1: (GNLJST,GNVWA2,GNLJG4,GNVWH3,GNVWLV,B44001,GNLJG2,GNVWVL,# & GNLJND,GNLJGG,GNLJSI,GNLJCA)# & PIR2: (S32091,S32072,S32096,S32057,S32067,S32131,S32048,S32086,# & C47330,S32058,S32084,S32159,S32062,S30484,S32066,S32088,# & S43127,S32085,S32129,S32120,S32079,S32082,S32151,S32061,# & S32160,S53092,S32063,S32050,S32049,S32098,F47330,S32092,# & S32089,S32139,B47330,S32119,S32071,B47175,S32069,S32095,# & S32074,S32054,S32087,S32134,S32093,S32097,E47330,S32060,# & S32059,S32117,A47330,S32068,S32053,S32136,S12153,S32075,# & S32152,S32135,A47175,S32070,S32056,D47330,S32137,S32081,# & S32083,S32127,S32122,S32073,S32132,S32051,S32055,S32077,# & S32052,S32090,S32118,S32078,S32065,S32080,S32138,S32064,# & S32047,S32128,S32126,S32133,S54378,S32157,S32140,S32094,# & S32076,S30483)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,TVLDVGDAY*# SEQUENCE: TVLDVGDAY*# ...# >HUM12A0F# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (273-282)# DB REFERENCE: SWISS: (POL_HV1ND,POL_HV1PV,POL_HV1MA,POL_HV1H2,POL_HV1B1,# & POL_HV1BR,POL_HV1B5,POL_HV1EL)# & PIR1: (GNLJND,GNVWVL,GNVWLV,GNVWH3)# & PIR2: (S32084,S32086,S32085,S32068,S32069,S32082,A47175,S32083,# & S32081,B47175,S32087,S32088)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,VPLDEDFRKY*# SEQUENCE: VPLDEDFRKY*# ...# >HUM12A10# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (296-304)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1MA,POL_HV1N5,POL_HV1A2,POL_HV1ND,# & POL_HV1JR,POL_HV1Z2,POL_HV1MN,POL_HV1PV,POL_HV1H2,# & POL_HV1EL,POL_HV1B1,POL_HV1OY)# & PIR1: (GNVWA2,GNVWLV,GNVWH3,GNVWVL,GNLJND)# & PIR2: (S32066,S32058,S32048,S32126,S32076,S32118,S32138,S32078,# & S32082,S32054,S32073,S32071,S32081,S32051,S32068,D47330,# & S32152,S32053,S32079,S32061,S32097,S32069,S32060,S32139,# & S32074,S32083,S32134,S32159,S32052,S32133,S32084,S32047,# & S32157,S32140,S32135,S32119,S32132,S32095,S32092,S32089,# & B47175,B47330,S32127,S32070,S32056,A47175,S32137,S32136,# & S32077,S43127,C47330,S32128,S32117,A47330,S32075,S32094,# & S32086,S54378,S32087,S32062,S32055,S32090,S32085,S32064,# & S32065,S32080,S32129,S32120,S32160,S32151,S32059,S32093,# & S32088,S32072,S32057,S32096,S32067,S32091,S32050,S32063,# & S32049,S32098)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,GIRYQYNVL*# SEQUENCE: GIRYQYNVL*# ...# >HUM12A11# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (296-304)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,KIKYQYNVL*# SEQUENCE: KIKYQYNVL*# ...# >HUM12A12# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (283-290)# DB REFERENCE: SWISS: (POL_HV1BR,POL_EIAV9,POL_HV1OY,POL_HV1Z2,POL_HV1B5,# & POL_EIAVC,POL_HV1A2,POL_HV1U4,POL_HV1B1,POL_HV1MN,# & POL_HV1PV,POL_HV1JR,POL_HV1H2,POL_HV1RH,POL_SIVCZ,# & POL_HV1ND,POL_HV1Y2,POL_EIAVY,POL_HV1N5,POL_HV1MA)# & PIR1: (GNLJ22,GNLJND,GNLJSI,B44001,GNVWA2,GNVWLV,GNLJEW,GNVWVL,# & GNLJEV,GNVWH3)# & PIR2: (F47330,S32061,S32060,C47330,S32128,A47175,S43127,E47330,# & S32159,S32052,S32157,S32047,S32059,S32129,S32120,S32160,# & S32082,S32054,S32091,S32057,S32050,S32098,S32049,S32062,# & S32055,S32081,S32089,S32092,S32118,S32051,S54378,S32086,# & S32127,S32152,S32094,S32063,S32131,S32048,B47175,S32133,# & S32084,S32083,S32064,S32087,S32122,S32117,S32090,S32085,# & S32056,S32132,S32095,S32151,S32093,S32088,S32126,S32058,# & S32053,D47330)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesu,TAFTIPSI*# SEQUENCE: TAFTIPSI*# ...# >HUM12A13# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (308-320)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1ND,POL_HV1Y2,POL_HV1MA,POL_HV1B1,# & POL_HV1B5,POL_HV1A2,POL_HV1JR,POL_HV1RH,POL_HV1MN,# & POL_HV1Z2,POL_HV1PV,POL_HV1OY,POL_HV1EL,POL_HV1BR)# & PIR1: (GNVWVL,GNVWH3,B44001,GNLJND,GNVWLV,GNVWA2)# & PIR2: (S32090,S32126,S32093,S32096,S32159,S32070,S32050,S32074,# & S32139,S32069,S32079,S32135,S32066,S32138,S32048,S32091,# & B47175,S54378,S32049,A47330,S32089,S32047,S32098,S43127,# & S32075,S32067,S32160,S32080,S32072,S32071,S32068,S32073,# & S32157,E47330,A47175,C47330,S32136,S32051,S32137,S32092,# & S32134,S32078,S32076,D47330)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,WKGSPAIFQSSMT*# SEQUENCE: WKGSPAIFQSSMT*# ...# >HUM12A14# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (313-321)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1OY,POL_HV1A2,POL_HV1ND,POL_HV1PV,# & POL_HV1EL,POL_HV1JR,POL_HV1RH,POL_HV1MN,POL_HV1BR,# & POL_HV1MA,POL_HV1H2,POL_HV1B5,POL_HV1B1)# & PIR1: (GNVWA2,GNVWLV,GNVWVL,GNVWH3,GNLJND)# & PIR2: (S32090,S32126,S32093,S32096,S32139,S32089,S32098,S32047,# & S43127,S32067,S32091,S32048,S32092,S32136,S32078,S32076,# & D47330,S32134,E47330,S32157,S32068,S32075,A47330,S32159,# & S32160,S32080,S54378,S32072,S32071,S32135,S32074,S32069,# & S32079,S32138,S32066,S32049,A47175,B47330,B47175,S32051,# & S32137,S32050,S32070)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,AIFQSSMTK*# SEQUENCE: AIFQSSMTK*# ...# >HUM12A15# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (313-321)# DB REFERENCE: PIR2: (C47330)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,AIFQSSMTR*# SEQUENCE: AIFQSSMTR*# ...# >HUM12A16# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (313-321)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,AIFLSSMTK*# SEQUENCE: AIFLSSMTK*# ...# >HUM12A17# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Reference/Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV RT (313-321)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1JR,POL_HV1RH,POL_HV1BR,POL_HV1H2,# & POL_HV1OY,POL_HV1ND,POL_HV1Z2,POL_HV1B1,POL_HV1EL,# & POL_HV1A2,POL_HV1PV,POL_HV1B5,POL_HV1MA)# & PIR1: (GNVWA2,GNLJND,GNVWVL,GNVWLV,GNVWH3)# & PIR2: (S32136,D47330,S54378,S32080,S32137,S32050,S32067,S32160,# & S32159,S32075,A47330,S32092,S32091,S32090,E47330,S32076,# & S32134,S32157,B47330,S32068,S32078,S32139,S32096,S32126,# & S32093,S43127,S32098,S32047,S32089,S32048,B47175,A47175,# & S32135,S32074,S32069,S32079,S32072,S32071,S32138,S32066,# & S32049,S32051,S32070)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a,threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesh,bindyesh,AIFQSSMTK*# SEQUENCE: AIFQSSMTK*# ...# >HUM12A18# MHC MOLECULE: HLA-A33, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (313-321)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1RH,POL_HV1ND,POL_HV1EL,POL_HV1BR,# & POL_HV1B5,POL_HV1MA,POL_HV1B1,POL_HV1Z2,POL_HV1A2,# & POL_HV1PV,POL_HV1MN,POL_HV1JR,POL_HV1OY)# & PIR1: (GNVWH3,GNVWA2,GNVWVL,GNVWLV,GNLJND)# & PIR2: (S32050,S32067,S32160,S32159,A47330,S32075,S32091,S32068,# & S32136,S32080,S32069,S32079,S32135,S32049,S32138,B47175,# & S32048,S32098,S32047,S32139,A47175,S32134,E47330,S32076,# & S32051,S32096,S32126,D47330,S32092,S32078,B47330,S32157,# & S32090,S32071,S32074,S32070,S32072,S32066,S32137,S54378,# & S32093,S43127,S32089)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesu,AIFQSSMTK*# SEQUENCE: AIFQSSMTK*# ...# >HUM12A19# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (334-342)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1N5,POL_HV1OY,POL_HV1Y2,POL_HV1EL,# & POL_HV1U4,POL_HV1RH,POL_HV1PV,POL_HV1A2,POL_HV1Z2,# & POL_HV1BR,POL_HV1B5,POL_HV1H2,POL_HV1MN,POL_HV1ND,# & POL_HV1MA)# & PIR1: (GNVWH3,GNVWLV,GNVWA2,GNVWVL,GNLJND,B44001)# & PIR2: (S32065,S32054,S32069,S32073,S32049,S32047,S32076,S32070,# & S32061,S32060,F47330,S32160,A47330,D47330,S32084,S32086,# & S32081,S32152,S32131,S32097,B47330,S32157,S32064,C47330,# & S32095,S32122,S32074,S32062,S32059,S32127,S32119,S32134,# & S32138,S32057,S32048,S32055,S32098,B47175,S32132,S32056,# & S32088,S32071,S32083,E47330,S32129,S32079,S32135,S32120,# & S32082,S32080,S32136,S32159,S32075,S32050,S32067,S32091,# & S32052,S32068,S32128,S32117,S32089,S32087,S32093,S32085,# & A47175,S32118,S32077,S32139,S32063,S32140,S32051,S32096,# & S32126,S32094,S32092,S32078,S32133,S32090,S54378,S32151,# & S32072,S32066,S32137,S32058,S32053)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,VIYQYMDDL*# SEQUENCE: VIYQYMDDL*# ...# >HUM12A1A# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (415-426)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1A2,POL_HV1ND,POL_HV1U4,POL_HV1Y2,# & POL_HV1Z2,POL_HV1RH,POL_HV1OY,POL_HV1JR,POL_HV1N5,# & POL_HV1PV,POL_HV1MN,POL_HV1H2,POL_HV1BR,POL_HV1B5,# & POL_HV1B1)# & PIR1: (GNVWA2,GNVWH3,B44001,GNLJND,GNVWVL,GNVWLV)# & PIR2: (S46347,S43127,A47175,S54378,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,LVGKLNWASQIY*# SEQUENCE: LVGKLNWASQIY*# ...# >HUM12A1B# MHC MOLECULE: HLA-B42, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (426-434)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B42,actyesu,bindyesu,YPGIQKVRQL*# SEQUENCE: YPGIQKVRQL*# ...# >HUM12A1C# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (495-507)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1B5,POL_HV1OY,POL_HV1N5,POL_HV1Z2,# & POL_HV1A2,POL_HV1ND,POL_HV1U4,POL_HV1PV,POL_HV1BR,# & POL_HV1EL,POL_HV1H2,POL_HV1MN,POL_HV1RH,POL_HV1Y2)# & PIR1: (GNVWA2,B44001,GNVWLV,GNVWH3,GNVWVL,GNLJND)# & PIR2: (A47175,B47175,S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,QIYQEPFKNLKTG*# SEQUENCE: QIYQEPFKNLKTG*# ...# >HUM12A1D# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (495-505)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1MN,POL_HV1A2,POL_HV1B1,POL_HV1RH,# & POL_HV1PV,POL_HV1BR,POL_HV1EL,POL_HV1H2,POL_HV1ND,# & POL_HV1U4,POL_HV1OY,POL_HV1N5,POL_HV1B5,POL_HV1Z2)# & PIR1: (GNVWLV,GNLJND,GNVWVL,GNVWH3,B44001,GNVWA2)# & PIR2: (A47175,S54378,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,QIYQEPFKNLK*# SEQUENCE: QIYQEPFKNLK*# ...# >HUM12A1E# MHC MOLECULE: HLA-A28, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (519-527)# DB REFERENCE: SWISS: (POL_HV1U4)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A28,actyesu,bindyesu,DVKQLTEVV*# SEQUENCE: DVKQLTEVV*# ...# >HUM12A1F# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (547-556)# DB REFERENCE: SWISS: (POL_HV1JR,POL_HV1B1,POL_HV1H2,POL_HV1BR,POL_HV1B5,# & POL_HV1Y2,POL_HV1MN,POL_HV1PV,POL_HV1EL,POL_HV1Z2,# & POL_HV1ND)# & PIR1: (B44001,GNVWH3,GNVWVL,GNVWLV,GNLJND)# & PIR2: (S54378,B47175)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B53,actyesu,bindyesu,PIQKETWETW*# SEQUENCE: PIQKETWETW*# ...# >HUM12A20# MHC MOLECULE: HLA-B53, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (547-556)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B53,actyesu,bindyesu,PIQKEAWETW*# SEQUENCE: PIQKEAWETW*# ...# >HUM12A21# MHC MOLECULE: HLA-Cw2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (547-556)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1MN,POL_HV1EL,POL_HV1B5,POL_HV1Y2,# & POL_HV1PV,POL_HV1ND,POL_HV1Z2,POL_HV1JR,POL_HV1BR,# & POL_HV1B1)# & PIR1: (GNVWLV,GNVWVL,GNVWH3,B44001,GNLJND)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-Cw2,actyesu,bindyesu,PIQKETWETW*# SEQUENCE: PIQKETWETW*# ...# >HUM12A22# MHC MOLECULE: HLA-Cw2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (547-556)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-Cw2,actyesu,bindyesu,PIQKEAWETW*# SEQUENCE: PIQKEAWETW*# ...# >HUM12A23# MHC MOLECULE: HLA-B45, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (591-600)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1BR,POL_HV1PV,POL_HV1H2,POL_HV1JR,# & POL_HV1OY,POL_HV1Z2,POL_HV1B5,POL_HV1A2,POL_HV1EL,# & POL_HV1N5,POL_HV1Y2,POL_HV1ND,POL_HV1MN,POL_HV1RH,# & POL_HV1B1,POL_HV1U4)# & PIR1: (GNVWVL,B44001,GNVWLV,GNVWA2,GNLJND,GNVWH3)# & PIR2: (S54378,B47175,A47175)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B45,actyesu,bindyesu,GAETFYVDGA*# SEQUENCE: GAETFYVDGA*# ...# >HUM12A24# MHC MOLECULE: HLA-B45, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (591-600)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B45,actyesu,bindyesu,GVETFYVDGA*# SEQUENCE: GVETFYVDGA*# ...# >HUM12A25# MHC MOLECULE: HLA-A28, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (592-602)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1JR,POL_HV1H2,POL_HV1PV,POL_HV1OY,# & POL_HV1Z2,POL_HV1EL,POL_HV1ND,POL_HV1RH,POL_HV1A2,# & POL_HV1Y2,POL_HV1MN,POL_HV1U4,POL_HV1N5,POL_HV1B1)# & PIR1: (B44001,GNLJND,GNVWH3,GNVWVL,GNVWA2)# & PIR2: (B47175,S54378,A47175)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A28,actyesu,bindyesu,AETFYVDGAAN*# SEQUENCE: AETFYVDGAAN*# ...# >HUM12A26# MHC MOLECULE: HLA-A26, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (593-603)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1N5,POL_HV1OY,POL_HV1Z2,POL_HV1H2,# & POL_HV1ND,POL_HV1U4,POL_HV1MA,POL_HV1MN,POL_HV1RH,# & POL_HV1PV,POL_HV1JR,POL_HV1A2,POL_HV1Y2,POL_HV1B1)# & PIR1: (GNVWA2,GNVWH3,B44001,GNLJND,GNVWVL)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A26,actyesu,bindyesu,ETFYVDGAANR*# SEQUENCE: ETFYVDGAANR*# ...# >HUM12A27# MHC MOLECULE: HLA-A26, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (593-603)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A26,actyesu,bindyesu,ETYYVNGAANR*# SEQUENCE: ETYYVNGAANR*# ...# >HUM12A28# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (636-660)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1B1,POL_HV1Y2,POL_HV1PV)# & PIR1: (B44001,GNVWVL,GNVWH3)# & PIR3: (S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,AIYLALQDSGLEVNIVTDSQYALGI*# SEQUENCE: AIYLALQDSGLEVNIVTDSQYALGI*# ...# >HUM12A29# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (636-660)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1PV,POL_HV1Y2,POL_HV1B1)# & PIR1: (GNVWH3,GNVWVL,B44001)# & PIR3: (S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,AIYLALQDSGLEVNIVTDSQYALGI*# SEQUENCE: AIYLALQDSGLEVNIVTDSQYALGI*# ...# >HUM12A2A# MHC MOLECULE: HLA-B14, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (640-660)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B14,actyesu,bindyesu,ALQDSGLEVVTDSQYALGI*# SEQUENCE: ALQDSGLEVVTDSQYALGI*# ...# >HUM12A2B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV RT (640-648)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1B1,POL_HV1Z2,POL_HV1A2,POL_HV1JR,# & POL_HV1RH,POL_HV1BR,POL_HV1EL,POL_HV1PV,POL_HV1B5,# & POL_HV1Y2,POL_HV1OY,POL_HV1N5,POL_HV1H2,POL_HV1ND)# & PIR1: (B44001,GNVWH3,GNVWVL,GNVWLV,GNLJND,GNVWA2)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S11523,S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesu,ALQDSGLEV*# SEQUENCE: ALQDSGLEV*# ...# >HUM12A2C# MHC MOLECULE: HLA-Cw8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (651-660)# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1H2,POL_HV1Y2,POL_HV1ND,POL_HV1B5,# & POL_HV1RH,POL_HV1Z2,POL_HV1EL,POL_HV1N5,POL_HV1OY,# & POL_HV1BR,POL_HV1PV,POL_HV1JR,POL_HV1MN,POL_HV1U4,# & POL_HV1B1,POL_HV1MA)# & PIR1: (GNVWH3,B44001,GNVWLV,GNVWVL,GNLJND,GNVWA2)# & PIR2: (S54378,B47175,A47175)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-Cw8,actyesu,bindyesu,VTDSQYALGI*# SEQUENCE: VTDSQYALGI*# ...# >HUM12A2D# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV rev (9-23)# DB REFERENCE: SWISS: (REV_HV1H2)# & PIR2: (JC4968)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,DEELIRTVRLIKLLY*# SEQUENCE: DEELIRTVRLIKLLY*# ...# >HUM12A2E# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV rev (25-39)# DB REFERENCE: SWISS: (REV_HV1H2,REV_HV1BR,REV_HV112,REV_HV1PV,REV_HV1B1,# & REV_HV1OY)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,SNPPPNPEGTRQARR*# SEQUENCE: SNPPPNPEGTRQARR*# ...# >HUM12A2F# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV rev (33-48)# DB REFERENCE: SWISS: (REV_HV1S3,REV_HV1SC,REV_HV112,REV_HV1W2,REV_HV1Y2,# & REV_HV1C4,REV_HV1A2,REV_HV1JR,REV_HV1OY,REV_HV1RH,# & REV_HV1B1,REV_HV1PV,REV_HV1MN,REV_HV1BR,REV_HV1H2,# & REV_HV1S1,REV_HV1B8)# & PIR1: (F44001,VKLJH3)# & PIR2: (S14607,JC4968)# & PIR3: (S33983)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,GTRQARRNRRRRWRER*# SEQUENCE: GTRQARRNRRRRWRER*# ...# >HUM12A30# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV rev (41-56)# DB REFERENCE: SWISS: (REV_HV1S3,REV_HV1B8,REV_HV1B1,REV_HV1PV,REV_HV1BR,# & REV_HV112,REV_HV1H2)# & PIR1: (VKLJH3)# & PIR2: (S14607,JC4968)# & PIR3: (S33983)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,RRRRWRERQRQIHSIS*# SEQUENCE: RRRRWRERQRQIHSIS*# ...# >HUM12A31# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (2-10)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B1,ENV_HV1H2,ENV_HV1PV,ENV_HV1BR,# & ENV_HV1B8,ENV_HV1H3)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,RVKEKYQHL*# SEQUENCE: RVKEKYQHL*# ...# >HUM12A32# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (30-54)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1A2,ENV_HV1H3,ENV_HV1H2,ENV_HV1PV,# & ENV_HV1BR,ENV_HV1MN)# & PIR1: (VCLJMN,VCLJH3,VCLJLV,VCLJVL,VCLJA2)# & PIR2: (A40218)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,TEKLWVTVYYGVPVWKEATTTLFCA*# SEQUENCE: TEKLWVTVYYGVPVWKEATTTLFCA*# ...# >HUM12A33# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (30-54)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1BR,ENV_HV1MN,ENV_HV1H2,ENV_HV1PV,# & ENV_HV1A2,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJA2,VCLJVL,VCLJMN,VCLJLV)# & PIR2: (A40218)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B18,actyesu,bindyesu,TEKLWVTVYYGVPVWKEATTTLFCA*# SEQUENCE: TEKLWVTVYYGVPVWKEATTTLFCA*# ...# >HUM12A34# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (32-41)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1JR,ENV_HV1PV,ENV_HV1A2,ENV_HV1BR,# & ENV_HV1B1,ENV_HV1BN,ENV_HV1MN,ENV_HV1H3,ENV_HV1S1)# & PIR1: (VCLJVL,VCLJA2,VCLJMN,VCLJBR,VCLJH3,VCLJLV)# & PIR2: (A40218)# & PIR3: (S13289,S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,KLWVTVYYGV*# SEQUENCE: KLWVTVYYGV*# ...# >HUM12A35# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (41-60)# DB REFERENCE: SWISS: (ENV_HV1SC,ENV_HV1H3,ENV_HV1W2,ENV_HV1S1,ENV_HV1MN,# & ENV_HV1C4,ENV_HV1MF,ENV_HV1N5,ENV_HV1B8,ENV_HV1B1,# & ENV_HV1KB,ENV_HV1Y2,ENV_HV1H2,ENV_HV1W1,ENV_HV1BR,# & ENV_HV1PV)# & PIR1: (VCLJKB,VCLJH3,VCLJH4,VCLJKX,VCLJSC,VCLJVL,H44001,VCLJ3W,# & VCLJLV,VCLJMN)# & PIR2: (S25939,S25938,A40218)# & PIR3: (S13288,S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,VPVWKEATTTLFCASDAKAY*# SEQUENCE: VPVWKEATTTLFCASDAKAY*# ...# >HUM12A36# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (51-70)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,LFCASDAKAYDTEVHINVWAT*# SEQUENCE: LFCASDAKAYDTEVHINVWAT*# ...# >HUM12A37# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (51-60)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1JR,ENV_HV1BR,ENV_HV1MN,ENV_HV1PV,# & ENV_HV1N5,ENV_HV1C4,ENV_HV1S3,ENV_HV1Y2,ENV_HV1ND,# & ENV_HV1Z3,ENV_HV1KB,ENV_HV1ZH,ENV_HV1W1,ENV_HV1H2,# & ENV_HV1J3,ENV_HV1B8,ENV_HV1B1,ENV_HV1H3,ENV_HV1W2,# & ENV_HV1S1,ENV_HV1SC,ENV_HV1MF)# & PIR1: (VCLJH3,VCLJKB,VCLJH4,H44001,VCLJLV,VCLJMN,VCLJND,VCLJSC,# & VCLJBR,VCLJKX,VCLJVL,A44963,VCLJ3W)# & PIR2: (S25938,A40218,S25939)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,LFCASDAKAY*# SEQUENCE: LFCASDAKAY*# ...# >HUM12A38# MHC MOLECULE: HLA-B38, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (51-60)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B38,actyesu,bindyesu,LFCASCAKAY*# SEQUENCE: LFCASCAKAY*# ...# >HUM12A39# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (77-85)# DB REFERENCE: SWISS: (ENV_HV1OY,ENV_HV1B1,ENV_HV1KB,ENV_HV1H2,ENV_HV1PV,# & ENV_HV1JR,ENV_HV1S3,ENV_HV1B8,ENV_HV1J3,ENV_HV1H3,# & ENV_HV1SC,ENV_HV1BR,ENV_HV1N5,ENV_HV1A2)# & PIR1: (VCLJA2,VCLJKB,VCLJH3,VCLJSC,VCLJKX,VCLJLV,VCLJVL)# & PIR3: (S33985,S13289,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,DPNPQEVVL*# SEQUENCE: DPNPQEVVL*# ...# >HUM12A3A# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (77-85)# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1PV,ENV_HV1H3,ENV_HV1BR,ENV_HV1N5,# & ENV_HV1H2,ENV_HV1OY,ENV_HV1KB,ENV_HV1J3,ENV_HV1SC,# & ENV_HV1B8,ENV_HV1S3,ENV_HV1JR,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJKB,VCLJKX,VCLJVL,VCLJLV,VCLJA2,VCLJSC)# & PIR3: (S33985,S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesu,DPNPQEVVL*# SEQUENCE: DPNPQEVVL*# ...# >HUM12A3B# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (103-118)# DB REFERENCE: SWISS: (ENV_HV1OY,ENV_HV1A2)# & PIR1: (VCLJA2)# & PIR2: (A40218,A53034)# & PIR3: (S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,MQEDIISLWDQSLKPC*# SEQUENCE: MQEDIISLWDQSLKPC*# ...# >HUM12A3C# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (104-116)# DB REFERENCE: SWISS: (ENV_HV1S1,ENV_HV1W2,ENV_HV1BN,ENV_HV1EL,ENV_HV1PV,# & ENV_HV1Z2,ENV_HV1H2,ENV_HV1C4,ENV_HV1MN,ENV_HV1N5,# & ENV_HV1RH,ENV_HV1MA,ENV_HV1Y2,ENV_HV1J3,ENV_HV1SC,# & ENV_HV1Z6,ENV_HV1MF,ENV_HV1W1,ENV_HV1Z3,ENV_SIVCZ,# & ENV_HV1BR,ENV_HV1ND,ENV_HV1B8,ENV_HV1H3,ENV_HV1B1)# & PIR1: (VCLJLV,H44001,VCLJ3W,VCLJND,VCLJH3,VCLJSI,VCLJMN,VCLJVL,# & VCLJBR,VCLJSC,VCLJH4,VCLJZR)# & PIR2: (S25939,S25938,S31493,S54384)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >HUM12A3D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (120-128)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,KTLPLCVTL*# SEQUENCE: KTLPLCVTL*# ...# >HUM12A3E# MHC MOLECULE: HLA-Cw8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (160-169)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1PV,ENV_HV1H2,ENV_HV1B1,ENV_HV1H3,# & ENV_HV1BR)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-Cw8,actyesu,bindyesu,NCSFNISTSI*# SEQUENCE: NCSFNISTSI*# ...# >HUM12A3F# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (192-311)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1B8,ENV_HV1H3,ENV_HV1PV,ENV_HV1BR)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,TTSYTLTSCNTSVITQACPK*# SEQUENCE: TTSYTLTSCNTSVITQACPK*# ...# >HUM12A40# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (196-204)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,KLTSCNTSV*# SEQUENCE: KLTSCNTSV*# ...# >HUM12A41# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (206-225)# DB REFERENCE: SWISS: (ENV_HV1JR,ENV_HV1B1,ENV_HV1Z6,ENV_HV1N5,ENV_HV1BR,# & ENV_HV1PV,ENV_HV1Z3,ENV_HV1MF,ENV_HV1H2,ENV_HV1ZH,# & ENV_HV1B8,ENV_HV1H3,ENV_HV1Y2,ENV_HV1EL,ENV_HV1Z2,# & ENV_HV1S1,ENV_HV1W2)# & PIR1: (VCLJLV,A44963,H44001,VCLJVL,VCLJZR,VCLJH3)# & PIR2: (S25938,A53034,S54384,S25939)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,TQACPKVSFEPIPIHYCAPA*# SEQUENCE: TQACPKVSFEPIPIHYCAPA*# ...# >HUM12A42# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (216-235)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1B8,ENV_HV1H3,ENV_HV1B1,ENV_HV1JR,# & ENV_HV1BR,ENV_HV1PV,ENV_HV1H2,ENV_HV1S3)# & PIR1: (VCLJVL,VCLJLV,VCLJBR,VCLJH3)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,PIPIHYCAPAGFAILKCNNK*# SEQUENCE: PIPIHYCAPAGFAILKCNNK*# ...# >HUM12A43# MHC MOLECULE: HLA-Cw8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (243-251)# DB REFERENCE: SWISS: (ENV_HV1SC,ENV_HV1J3,ENV_HV1H3,ENV_HV1OY,ENV_HV1C4,# & ENV_HV1W1,ENV_HV1N5,ENV_HV1BR,ENV_HV1PV,ENV_HV1S3,# & ENV_HV1Y2,ENV_HV1EL,ENV_HV1Z2,ENV_HV1BN,ENV_HV1W2,# & ENV_HV1S1,ENV_HV1MF,ENV_HV1H2,ENV_HV1B1,ENV_HV1A2,# & ENV_HV1B8,ENV_HV1Z6)# & PIR1: (VCLJH3,VCLJZR,VCLJSC,H44001,VCLJBR,VCLJLV,VCLJH4,VCLJVL,# & VCLJ3W,VCLJA2)# & PIR2: (S25939,S54384,S25938)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-Cw8,actyesu,bindyesu,CTNVSTVQC*# SEQUENCE: CTNVSTVQC*# ...# >HUM12A44# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (246-265)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1B1,ENV_HV1Z3,ENV_HV1MF,ENV_HV1S1,# & ENV_HV1BN,ENV_HV1RH,ENV_HV1H2,ENV_HV1B8,ENV_HV1Z6,# & ENV_HV1BR,ENV_HV1ND,ENV_HV1ZH,ENV_HV1KB,ENV_HV1EL,# & ENV_HV1Z2,ENV_HV1H3,ENV_HV1C4,ENV_HV1W1,ENV_HV1Z8,# & ENV_HV1JR,ENV_HV1MN,ENV_HV1W2,ENV_HV1Y2)# & PIR1: (VCLJH4,VCLJKX,VCLJVL,VCLJND,VCLJZR,VCLJH3,VCLJ3W,VCLJMN,# & VCLJBR,H44001,VCLJKB,VCLJLV,A44963)# & PIR2: (S25939,S54384)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,VSTVQCTHGIRPVVSTQLLL*# SEQUENCE: VSTVQCTHGIRPVVSTQLLL*# ...# >HUM12A45# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (256-275)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1MN,ENV_HV1RH,ENV_HV1BN,ENV_HV1BR,# & ENV_HV1PV,ENV_HV1B1,ENV_HV1B8,ENV_HV1H2,ENV_HV1C4)# & PIR1: (VCLJH3,VCLJVL,VCLJBR,VCLJMN,VCLJLV,VCLJH4)# & PIR3: (S33985,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,RPVVSTQLLLNGSLAEEEVV*# SEQUENCE: RPVVSTQLLLNGSLAEEEVV*# ...# >MUS12A46# MHC MOLECULE: H-2d, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1H2,ENV_HV1H3,ENV_HV1PV,ENV_HV1B1,# & ENV_HV1B8,ENV_HV1MF)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >MUS12A47# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1MN)# & PIR1: (VCLJMN)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,RIHIGPGRAFYTTKN*# SEQUENCE: RIHIGPGRAFYTTKN*# ...# >MUS12A48# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (313-322)# DB REFERENCE: SWISS: (ENV_HV1MN,ENV_HV1J3,ENV_HV1JR)# & PIR1: (VCLJMN)# & PIR2: (S35815,D46410,S35862,S35809,S35820,S35858,PC2295,S35859,# & S35819,A41621,S35816,S35808,A46410,S35807,S35857,S35849,# & S60549,S60550,C41621,S35848,S35821,S35861)# & PIR3: (S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,IGPGRAFYTT*# SEQUENCE: IGPGRAFYTT*# ...# >HUM12A49# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1B1,ENV_HV1PV,ENV_HV1H2,ENV_HV1H3,# & ENV_HV1MF,ENV_HV1BR)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >HUM12A4A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H3,ENV_HV1MF,ENV_HV1BR,ENV_HV1B1,# & ENV_HV1B8,ENV_HV1H2)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >MUS12A4B# MHC MOLECULE: H-2p, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1B8,ENV_HV1BR,ENV_HV1MF,ENV_HV1PV,# & ENV_HV1B1,ENV_HV1H3)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2p,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >MUS12A4C# MHC MOLECULE: H-2u, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H3,ENV_HV1B1,ENV_HV1B8,ENV_HV1H2,# & ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2u,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >MUS12A4D# MHC MOLECULE: H-2q, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1BR,ENV_HV1MF,ENV_HV1PV,ENV_HV1H3,# & ENV_HV1H2,ENV_HV1B8)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2q,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >HUM12A4E# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1H3,ENV_HV1B1,ENV_HV1BR,ENV_HV1H2,# & ENV_HV1MF,ENV_HV1PV)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >HUM12A4F# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1PV,ENV_HV1BR,ENV_HV1B1,ENV_HV1H2,# & ENV_HV1H3,ENV_HV1B8)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >HUM12A50# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1MN)# & PIR1: (VCLJMN)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,RIHIGPGRAFYTTKN*# SEQUENCE: RIHIGPGRAFYTTKN*# ...# >MUS12A51# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1RH)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,SITKGPGRVIYATGQ*# SEQUENCE: SITKGPGRVIYATGQ*# ...# >HUM12A52# MHC MOLECULE: HLA-B15, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (379-387)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1ZH,ENV_HV1BR,ENV_HV1H2,ENV_HV1OY,# & ENV_HV1RH,ENV_HV1N5,ENV_HV1PV,ENV_HV1EL,ENV_HV1W2,# & ENV_HV1H3,ENV_HV1C4,ENV_HV1S1,ENV_HV1MF,ENV_HV1Z8,# & ENV_HV1Z2,ENV_HV1Y2,ENV_HV1MN,ENV_HV1BN,ENV_HV1Z6,# & ENV_HV1J3,ENV_HV1B8,ENV_HV1SC,ENV_HV1JR,ENV_HV1W1)# & PIR1: (VCLJZR,VCLJVL,VCLJH4,VCLJBR,VCLJSC,VCLJMN,H44001,VCLJLV,# & A44963,VCLJ3W,VCLJH3)# & PIR2: (S60555,S60549,S60550,S31493,S60547,S60541,S60557,S60535,# & A41621,S60528,A40218,S60525,S60545,S60556,S60522,S54384,# & S60529,S60523,S60546,S60524,S60548,S60521)# & PIR3: (S13288,S33985,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B15,actyesu,bindyesu,SFNCGGEFF*# SEQUENCE: SFNCGGEFF*# ...# >HUM12A53# MHC MOLECULE: HLA-B15, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (379-387)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B15,actyesu,bindyesu,SSTCGGEFF*# SEQUENCE: SSTCGGEFF*# ...# >HUM12A54# MHC MOLECULE: HLA-B15, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (379-387)# DB REFERENCE: PIR2: (S60553,S60554,S60552,S60532,S60531,S60551)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B15,actyesu,bindyesu,SFTCGGEFF*# SEQUENCE: SFTCGGEFF*# ...# >HUM12A55# MHC MOLECULE: HLA-A29, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (380-388)# DB REFERENCE: SWISS: (ENV_HV1N5,ENV_HV1W1,ENV_HV1OY,ENV_HV1MF,ENV_HV1W2,# & ENV_HV1H2,ENV_HV1ZH,ENV_HV1SC,ENV_HV1Z8,ENV_HV1S1,# & ENV_HV1B8,ENV_HV1B1,ENV_HV1EL,ENV_HV1JR,ENV_HV1Z3,# & ENV_HV1J3,ENV_HV1C4,ENV_HV1Z2,ENV_HV1Z6,ENV_HV1MN,# & ENV_HV1Y2,ENV_HV1RH,ENV_HV1PV,ENV_HV1BR,ENV_SIVCZ,# & ENV_HV1KB,ENV_HV1H3)# & PIR1: (VCLJKX,H44001,VCLJLV,VCLJSI,VCLJVL,VCLJSC,VCLJH4,VCLJKB,# & VCLJH3,VCLJMN,VCLJ3W,VCLJZR,A44963)# & PIR2: (S60521,S60524,S60538,S60546,B41621,S60526,S60529,S54384,# & A41621,S60535,S60522,S60548,S60558,S60525,A40218,S60541,# & S60549,S60550,S60545,S60547,S60557,S60523,S60555,S60556,# & S31493,S60528,C41621)# & PIR3: (S13289,S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A29,actyesu,bindyesu,FNCGGEFFY*# SEQUENCE: FNCGGEFFY*# ...# >HUM12A56# MHC MOLECULE: HLA-A29, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (380-388)# DB REFERENCE: SWISS: (ENV_HV1S3,ENV_HV1A2,ENV_HV1MA)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A29,actyesu,bindyesu,FNCRGEFFY*# SEQUENCE: FNCRGEFFY*# ...# >MUS12A57# MHC MOLECULE: H-2a, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1J3,ENV_HV1JR,ENV_HV1S3,ENV_HV1MN,# & ENV_HV1BN,ENV_HV1A2,ENV_HV1B1,ENV_HV1B8)# & PIR1: (VCLJA2,H44001,VCLJMN,VCLJH3,VCLJBR)# & PIR2: (S25940,A40218,C41621,S60538)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2a,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS12A58# MHC MOLECULE: H-2b, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1S3,ENV_HV1JR,ENV_HV1BN,ENV_HV1A2,ENV_HV1MN,# & ENV_HV1Y2,ENV_HV1J3,ENV_HV1B8,ENV_HV1B1)# & PIR1: (VCLJA2,H44001,VCLJMN,VCLJBR,VCLJH3)# & PIR2: (A40218,C41621,S60538,S25940)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS12A59# MHC MOLECULE: H-2f, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1JR,ENV_HV1BN,ENV_HV1MN,ENV_HV1A2,ENV_HV1B1,# & ENV_HV1B8,ENV_HV1Y2,ENV_HV1J3,ENV_HV1S3)# & PIR1: (VCLJA2,VCLJBR,VCLJMN,H44001,VCLJH3)# & PIR2: (S60538,C41621,S25940,A40218)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2f,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >HUM12A5A# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1S3,ENV_HV1JR,ENV_HV1BN,ENV_HV1A2,ENV_HV1B1,# & ENV_HV1B8,ENV_HV1J3,ENV_HV1MN,ENV_HV1Y2)# & PIR1: (H44001,VCLJBR,VCLJA2,VCLJH3,VCLJMN)# & PIR2: (S25940,A40218,C41621,S60538)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >HUM12A5B# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-436)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H3,ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJLV,VCLJVL)# & PIR3: (S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,KQFINMWQEVGKAMY*# SEQUENCE: KQFINMWQEVGKAMY*# ...# >MUS12A5C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (435-444)# DB REFERENCE: SWISS: (ENV_HV1W1,ENV_HV1A2)# & PIR1: (VCLJ3W,VCLJA2)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,MYAPPIGGQI*# SEQUENCE: MYAPPIGGQI*# ...# >HUM12A5D# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (47-55)# DB REFERENCE: SWISS: (ENV_HV1RH,ENV_HV1A2,ENV_HV1ZH,ENV_HV1H2,ENV_HV1W1,# & ENV_HV1B1,ENV_HV1Z6,ENV_HV1ND,ENV_HV1S3,ENV_HV1PV,# & ENV_HV1MA,ENV_HV1S1,ENV_HV1H3,ENV_HV1OY,ENV_HV1BR,# & ENV_HV1MF,ENV_HV1Z2,ENV_HV1Y2,ENV_HV1SC,ENV_HV1EL)# & PIR1: (VCLJZR,A44963,VCLJ3W,VCLJA2,VCLJSC,H44001,VCLJND,VCLJVL,# & VCLJH3,VCLJLV)# & PIR2: (S60691,S60538,S60706,S60529,S54384,S60705,S60693,S70419,# & S60547,S60545,S60687,S60531,S60532,S60523,S60689,S60552,# & S21994,S60556,S60554,S70421,S60524,S22000,B41621,S60694,# & S70420,S60528,S21996,S60553,S22002,S60707,S60557,S60525,# & A41621,S60690,S60548,S70422,S60696,S60522,S60535,S22004,# & S60695,S22006,C41621,S70418,S60521,S60551,S60546,# & S70417)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,RAIEAQQHL*# SEQUENCE: RAIEAQQHL*# ...# >HUM12A5E# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (47-55)# DB REFERENCE: SWISS: (ENV_HV1W2,ENV_HV1KB)# & PIR1: (VCLJKB,VCLJKX)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,RAIDAQQHL*# SEQUENCE: RAIDAQQHL*# ...# >HUM12A5F# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (47-55)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,RVIEAQQHL*# SEQUENCE: RVIEAQQHL*# ...# >HUM12A60# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (47-55)# DB REFERENCE: SWISS: (ENV_HV1ND,ENV_HV1S3,ENV_HV1MA,ENV_HV1PV,ENV_HV1W1,# & ENV_HV1Y2,ENV_HV1EL,ENV_HV1H3,ENV_HV1B1,ENV_HV1OY,# & ENV_HV1SC,ENV_HV1Z2,ENV_HV1S1,ENV_HV1BR,ENV_HV1MF,# & ENV_HV1Z6,ENV_HV1H2,ENV_HV1ZH,ENV_HV1A2,ENV_HV1RH)# & PIR1: (VCLJA2,VCLJSC,H44001,A44963,VCLJZR,VCLJH3,VCLJVL,VCLJND,# & VCLJ3W,VCLJLV)# & PIR2: (S60551,S70418,S22006,S22004,S60523,S60689,S60531,S60532,# & S60547,S22000,S70420,S60538,S60529,S21994,S70421,S60521,# & S60525,S60548,S60522,S60695,S60687,S60545,S60552,S60554,# & S60556,S60694,S21996,S60553,S60528,C41621,S60546,S70417,# & S22002,S60557,S60707,A41621,S70422,S60696,S60690,S70419,# & B41621,S60693,S60535,S60524,S54384,S60706,S60705,# & S60691)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesu,RAIEAQQHL*# SEQUENCE: RAIEAQQHL*# ...# >HUM12A61# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (74-82)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1PV,ENV_HV1KB,ENV_HV1B8,ENV_HV1EL,# & ENV_HV1H3,ENV_HV1BR,ENV_HV1OY,ENV_HV1ZH,ENV_HV1MN,# & ENV_HV1B1,ENV_HV1Z2,ENV_HV1H2,ENV_HV1MF,ENV_HV1S1,# & ENV_HV1Z6,ENV_HV1JR,ENV_HV1J3,ENV_HV1C4)# & PIR1: (VCLJH4,VCLJH3,VCLJZR,VCLJLV,VCLJKB,VCLJMN,VCLJVL,A44963,# & VCLJBR,VCLJKX)# & PIR2: (S70423,S21996,B41621,S70421,S21998,S22004,S21992,S70419,# & S70420,S22000,S21994,S70424,S21990,S54384,S70422,S22002,# & S70417,S70425,S70418,S22006)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,ERYLKDQQL*# SEQUENCE: ERYLKDQQL*# ...# >HUM12A62# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (96-104)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1S1,ENV_HV1MF,ENV_HV1BR,ENV_HV1B8,# & ENV_HV1PV,ENV_HV1BN,ENV_HV1H3,ENV_HV1J3,ENV_HV1B1,# & ENV_HV1A2,ENV_HV1C4)# & PIR1: (VCLJBR,VCLJA2,VCLJH3,VCLJVL,VCLJLV,VCLJH4)# & PIR2: (A41621,S70418,S22002,B41621,S21990,S70423)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,TAVPWNASW*# SEQUENCE: TAVPWNASW*# ...# >HUM12A63# MHC MOLECULE: HLA-A32, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (191-210)# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1W1,ENV_HV1RH,ENV_HV1PV,ENV_HV1W2,# & ENV_HV1BR,ENV_HV1B8,ENV_HV1H2,ENV_HV1MF)# & PIR1: (VCLJ3W,VCLJVL,H44001,VCLJLV)# & PIR2: (S22006,S70419,S70420,S22004)# & PIR3: (S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A32,actyesu,bindyesu,VLSIVNRVRQGYSPLSFQTH*# SEQUENCE: VLSIVNRVRQGYSPLSFQTH*# ...# >HUM12A64# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (259-267)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1MA,ENV_HV1BR,ENV_HV1H2,ENV_HV1MF,# & ENV_HV1W2,ENV_HV1H3,ENV_HV1SC,ENV_HV1B1,ENV_HV1Y2,# & ENV_HV1KB,ENV_HV1C4,ENV_HV1PV,ENV_HV1W1,ENV_HV1J3,# & ENV_HV1RH,ENV_HV1BN)# & PIR1: (H44001,VCLJH4,VCLJ3W,VCLJVL,VCLJLV,VCLJH3,VCLJSC,VCLJBR,# & VCLJKB)# & PIR2: (S70418,S22002,S21996,S70423,S70417,S70421,S22000,S21998,# & S70425,S21990,S70422,S21994,S70424,S21992)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,HRLRDLLLI*# SEQUENCE: HRLRDLLLI*# ...# >HUM12A65# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (271-292)# DB REFERENCE: SWISS: (ENV_HV1RH,ENV_HV1PV,ENV_HV1W1,ENV_HV1J3,ENV_HV1B1,# & ENV_HV1H3,ENV_HV1SC,ENV_HV1B8,ENV_HV1MF,ENV_HV1H2,# & ENV_HV1BR,ENV_HV1W2)# & PIR1: (VCLJVL,VCLJ3W,VCLJLV,VCLJSC,VCLJH3)# & PIR2: (S21992,S70417,S21990,S70423,S70424)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,IVELLGRRGWEALKYWWNLLQY*# SEQUENCE: IVELLGRRGWEALKYWWNLLQY*# ...# >HUM12A66# MHC MOLECULE: HLA-B27, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (276-284)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,GRRRGWEALK*# SEQUENCE: GRRRGWEALK*# ...# >HUM12A67# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (285-306)# DB REFERENCE: SWISS: (ENV_HV1B8)# & PIR3: (S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,YWWNLLQYWSQELKNSAVNLLN*# SEQUENCE: YWWNLLQYWSQELKNSAVNLLN*# ...# >HUM12A68# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (304-312)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,LLNATDIAV*# SEQUENCE: LLNATDIAV*# ...# >HUM12A69# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (327-346)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1H3,ENV_HV1PV,ENV_HV1B8)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,YRAIRHIPRRIRQGLERILL*# SEQUENCE: YRAIRHIPRRIRQGLERILL*# ...# >HUM12A6A# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (327-346)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1H3,ENV_HV1PV,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJVL)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,YRAIRHIPRRIRQGLERILL*# SEQUENCE: YRAIRHIPRRIRQGLERILL*# ...# >MUS12A6B# MHC MOLECULE: H-2d, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (317-331)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1B1,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >MUS12A6C# MHC MOLECULE: H-2p, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (317-331)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1PV,ENV_HV1B1)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2p,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >MUS12A6D# MHC MOLECULE: H-2u, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (317-331)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2u,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >MUS12A6E# MHC MOLECULE: H-2q, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (317-331)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B1,ENV_HV1PV)# & PIR1: (VCLJH3,VCLJVL)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2q,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >HUM12A6F# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (317-331)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >HUM12A70# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (318-326)# DB REFERENCE: SWISS: (ENV_HV1MN)# & PIR1: (VCLJMN)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,RVIEVLQRA*# SEQUENCE: RVIEVLQRA*# ...# >HUM12A71# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (320-344)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,IEVVQGAYRAIIRHIPRRIRQGLERI*# SEQUENCE: IEVVQGAYRAIIRHIPRRIRQGLERI*# ...# >HUM12A72# MHC MOLECULE: HLA-A30, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (335-346)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1H3,ENV_HV1B8,ENV_HV1PV,ENV_HV1BR,# & ENV_HV1H2)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A30,actyesu,bindyesu,RRIRQGLERILL*# SEQUENCE: RRIRQGLERILL*# ...# >HUM12A73# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (335-346)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1PV,ENV_HV1BR,ENV_HV1H3,ENV_HV1B1,# & ENV_HV1B8)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,RRIRQGLERILL*# SEQUENCE: RRIRQGLERILL*# ...# >HUM12A74# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (335-346)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1B1,ENV_HV1BR,ENV_HV1H2,ENV_HV1PV,# & ENV_HV1H3)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,RRIRQGLERILL*# SEQUENCE: RRIRQGLERILL*# ...# >HUM12A75# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference/CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV nef (13-20)# DB REFERENCE: SWISS: (NEF_HV1SC,NEF_HV1MN,NEF_HV1BR,NEF_HV1Y2)# & PIR1: (I44001,ASLJFV)# & PIR2: (S03244,S25937,S24985)# & PIR3: (S07344)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a,goulder97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesu,WPTVRERM*# SEQUENCE: WPTVRERM*# ...# >HUM12A76# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (60-79)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1B8,NEF_HV1B1,NEF_HV1H2)# & PIR1: (ASLJFV,ASLJH3)# & PIR2: (S43467,S03244,S24985)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,EEEEVGFPVTPQVPLRPMTY*# SEQUENCE: EEEEVGFPVTPQVPLRPMTY*# ...# >HUM12A77# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (64-78)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,VGFPVTPQVPLRMT*# SEQUENCE: VGFPVTPQVPLRMT*# ...# >HUM12A78# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (64-78)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,VGFPVTPQVPLRMT*# SEQUENCE: VGFPVTPQVPLRMT*# ...# >HUM12A79# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (66-75)# DB REFERENCE: SWISS: (NEF_HV1B1,NEF_HV1PV,NEF_HV112,NEF_HV1B8,NEF_HV1BR,# & NEF_HV1H2)# & PIR1: (ASLJFV,ASLJVL,ASLJ12,ASLJH3)# & PIR2: (S24985,S03245,S43467,S03244)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,FPVTPQVPLR*# SEQUENCE: FPVTPQVPLR*# ...# >HUM12A7A# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (71-80)# DB REFERENCE: SWISS: (NEF_HV1B1,NEF_HV1SC,NEF_HV1MA,NEF_HV112,NEF_HV1MN,# & NEF_HV1BR,NEF_HV1H2,NEF_HV1OY,NEF_HV1B8,NEF_HV1EL,# & NEF_HV1PV,NEF_HV1S3,NEF_HV1ND,NEF_HV1A2,NEF_HV1BN,# & NEF_HV1Z6,NEF_HV1JR,NEF_HV1S1,NEF_HV1Z2,NEF_HV1U4)# & PIR1: (ASLJO2,ASLJH3,ASLJBR,ASLJVL,ASLJFV,ASLJ12,QQLJZR,# & QQLJND)# & PIR2: (S25937,S43467,S54385,S03244,S03245,S24985)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,QVPLRPMTYK*# SEQUENCE: QVPLRPMTYK*# ...# >HUM12A7B# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (72-79)# DB REFERENCE: SWISS: (NEF_HV1BN,NEF_HV1S1,NEF_HV1Z2,NEF_HV1B1,NEF_HV1ND,# & NEF_HV1H2,NEF_HV1A2,NEF_HV1OY,NEF_HV1B8,NEF_HV1MN,# & NEF_HV2D2,NEF_HV1SC,NEF_HV112,NEF_HV1MA,NEF_HV1BR,# & NEF_HV1EL,NEF_HV1PV,NEF_HV1S3,NEF_HV1Z6,NEF_HV1JR,# & NEF_HV1U4)# & PIR1: (ASLJH3,ASLJO2,QQLJND,QQLJZR,ASLJ12,ASLJFV,ASLJVL,# & ASLJBR)# & PIR2: (S54385,S25937,S43467,S24985,S03244,S24572,S03245)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,VPLRPMTY*# SEQUENCE: VPLRPMTY*# ...# >HUM12A7C# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (84-98)# DB REFERENCE: SWISS: (NEF_HV1BN,NEF_SIVCZ,NEF_HV112,NEF_HV1BR,NEF_HV1S3,# & NEF_HV1EL,NEF_HV1Z6,NEF_HV1JR,NEF_HV1Y2,NEF_HV1B8,# & NEF_HV1H2,NEF_HV1OY,NEF_HV1PV,NEF_HV1ND,NEF_HV1B1,# & NEF_HV1S1)# & PIR1: (ASLJH3,QQLJND,ASLJVL,ASLJ12,ASLJIK,ASLJFV,ASLJBR,QQLJZR,# & I44001)# & PIR2: (S43467,S03245,S03247,S24985,S03244)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,DLSHFLKEKGGLEGL*# SEQUENCE: DLSHFLKEKGGLEGL*# ...# >HUM12A7D# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (84-98)# DB REFERENCE: SWISS: (NEF_HV1H2,NEF_HV1B8,NEF_HV1OY,NEF_HV1S3,NEF_HV1EL,# & NEF_HV1BR,NEF_HV1S1,NEF_HV1BN,NEF_HV112,NEF_HV1JR,# & NEF_HV1Z6,NEF_HV1Y2,NEF_SIVCZ,NEF_HV1B1,NEF_HV1ND,# & NEF_HV1PV)# & PIR1: (ASLJFV,ASLJVL,ASLJ12,ASLJIK,I44001,QQLJZR,ASLJBR,QQLJND,# & ASLJH3)# & PIR2: (S03244,S24985,S03247,S43467,S03245)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,DLSHFLKEKGGLEGL*# SEQUENCE: DLSHFLKEKGGLEGL*# ...# >HUM12A7E# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (84-92)# DB REFERENCE: SWISS: (NEF_HV1OY,NEF_HV1Z2,NEF_HV1S3,NEF_HV1Y2,NEF_HV1BR,# & NEF_HV1PV,NEF_HV1ND,NEF_HV1MA,NEF_HV112,NEF_HV1JR,# & NEF_HV1BN,NEF_HV1MN,NEF_HV1B1,NEF_HV1S1,NEF_HV1EL,# & NEF_HV1RH,NEF_HV1B8,NEF_HV1Z6,NEF_SIVCZ,NEF_HV1H2)# & PIR1: (ASLJ12,ASLJIK,ASLJFV,ASLJVL,QQLJZR,ASLJBR,QQLJND,ASLJH3,# & I44001)# & PIR2: (S43467,S03245,S03247,S03246,S54385,S03244,S24985)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,DLSHFLKEK*# SEQUENCE: DLSHFLKEK*# ...# >HUM12A7F# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (100-114)# DB REFERENCE: SWISS: (NEF_HV1B1,NEF_HV112,NEF_HV1PV,NEF_HV1BR,NEF_HV1H2)# & PIR1: (ASLJ12,ASLJFV,ASLJH3,ASLJVL)# & PIR2: (S43467,S03247,S03245,S03244)# & PIR3: (S33986,S07344)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesu,HSQRRQDILDLWIYH*# SEQUENCE: HSQRRQDILDLWIYH*# ...# >HUM12A80# MHC MOLECULE: HLA-B27(B*2705), CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (103-112)# DB REFERENCE: SWISS: (NEF_HV1H2,NEF_HV1PV,NEF_HV112,NEF_HV1B8,NEF_HV1BR,# & NEF_HV1B1)# & PIR1: (ASLJH3,ASLJVL,ASLJFV,ASLJ12)# & PIR2: (S43467,S03245,S03247,S03244)# & PIR3: (S07344,S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B27,actyesu,bindyesu,RRQDILDLWI*# SEQUENCE: RRQDILDLWI*# ...# >HUM12A81# MHC MOLECULE: HLA-B13, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (101-125)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV112,NEF_HV1BR)# & PIR1: (ASLJVL,ASLJ12,ASLJFV)# & PIR2: (S03247,S03245,S43467)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B13,actyesu,bindyesu,SQRRQDILDLWIYHTQGYFPDWQNY*# SEQUENCE: SQRRQDILDLWIYHTQGYFPDWQNY*# ...# >HUM12A82# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (110-131)# DB REFERENCE: SWISS: (NEF_HV1S3,NEF_HV1BR)# & PIR1: (ASLJFV)# & PIR2: (S03247,S43467)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,LWIYHTQGYFPDWQNYTPGPGV*# SEQUENCE: LWIYHTQGYFPDWQNYTPGPGV*# ...# >HUM12A83# MHC MOLECULE: HLA-A1, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (111-126)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1JR,NEF_HV1S3,NEF_HV1BR,NEF_HV1A2,# & NEF_HV1PV)# & PIR1: (ASLJFV,ASLJO2,ASLJVL,ASLJ12)# & PIR2: (S43467,S03245,S03247)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A1,actyesu,bindyesu,WIYHTQGYFPDWQNYT*# SEQUENCE: WIYHTQGYFPDWQNYT*# ...# >HUM12A84# MHC MOLECULE: HLA-B17, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (111-123)# DB REFERENCE: SWISS: (NEF_HV1JR,NEF_HV1S3,NEF_HV1BR,NEF_HV1PV,NEF_HV1A2,# & NEF_HV112)# & PIR1: (ASLJFV,ASLJO2,ASLJ12,ASLJVL)# & PIR2: (S24985,S03245,S43467,S03247)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B17,actyesu,bindyesu,WIYHTQGYFPDWQ*# SEQUENCE: WIYHTQGYFPDWQ*# ...# >HUM12A85# MHC MOLECULE: HLA-B17, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (113-123)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B17,actyesu,bindyesu,YHTQGYFPQWQ*# SEQUENCE: YHTQGYFPQWQ*# ...# >HUM12A86# MHC MOLECULE: HLA-B17, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (115-126)# DB REFERENCE: SWISS: (NEF_HV1RH,NEF_HV1JR,NEF_HV1B8,NEF_HV1PV,NEF_HV112,# & NEF_HV1Y2,NEF_HV1OY,NEF_HV1BN,NEF_HV1MA,NEF_HV1S3,# & NEF_HV1BR,NEF_HV1S1,NEF_HV1MN,NEF_HV1A2)# & PIR1: (ASLJ12,ASLJBR,I44001,ASLJFV,ASLJO2,ASLJVL)# & PIR2: (S03246,S03245,S03247,S43467)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B17,actyesu,bindyesu,TQGYFPDWQNYT*# SEQUENCE: TQGYFPDWQNYT*# ...# >HUM12A87# MHC MOLECULE: HLA-B37, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (115-126)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1JR,NEF_HV1OY,NEF_HV1MN,NEF_HV1Y2,# & NEF_HV1MA,NEF_HV1A2,NEF_HV1S3,NEF_HV1RH,NEF_HV1S1,# & NEF_HV1BR,NEF_HV1B8,NEF_HV1BN,NEF_HV1PV)# & PIR1: (I44001,ASLJ12,ASLJVL,ASLJBR,ASLJO2,ASLJFV)# & PIR2: (S03247,S03245,S03246,S43467)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,TQGYFPDWQNYT*# SEQUENCE: TQGYFPDWQNYT*# ...# >HUM12A88# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (116-125)# DB REFERENCE: SWISS: (NEF_HV1MA,NEF_HV1JR,NEF_HV1Y2,NEF_HV1RH,NEF_HV1PV,# & NEF_HV1OY,NEF_HV1BR,NEF_HV1A2,NEF_HV112,NEF_HV1MN,# & NEF_HV1S1,NEF_HV1S3,NEF_HV1B8,NEF_HV1BN)# & PIR1: (ASLJ12,ASLJBR,I44001,ASLJO2,ASLJFV,ASLJVL)# & PIR2: (S03245,S03247,S43467,S03246)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B62,actyesu,bindyesu,QGYFPDWQNY*# SEQUENCE: QGYFPDWQNY*# ...# >HUM12A89# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (118-126)# DB REFERENCE: SWISS: (NEF_HV1Y2,NEF_HV1RH,NEF_HV1PV,NEF_HV1A2,NEF_HV1MN,# & NEF_HV1S1,NEF_HV112,NEF_HV1B8,NEF_HV1BR,NEF_HV1S3,# & NEF_HV1BN,NEF_HV1JR,NEF_HV1OY,NEF_HV1MA)# & PIR1: (ASLJO2,ASLJ12,ASLJFV,ASLJVL,ASLJBR,I44001)# & PIR2: (S03246,S03247,S43467,S03245)# & PIR3: (S33986)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,YFPDWQNYT*# SEQUENCE: YFPDWQNYT*# ...# >HUM12A8A# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (118-126)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,FFPDWKNYT*# SEQUENCE: FFPDWKNYT*# ...# >HUM12A8B# MHC MOLECULE: HLA-A24, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (118-142)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1PV)# & PIR1: (ASLJVL,ASLJ12)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A24,actyesu,bindyesu,YFPDWQNYTPGPGIRYPLTFGWCYK*# SEQUENCE: YFPDWQNYTPGPGIRYPLTFGWCYK*# ...# >HUM12A8C# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (121-135)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,QWQNYTPGPGVRYPL*# SEQUENCE: QWQNYTPGPGVRYPL*# ...# >HUM12A8D# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (121-135)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,FFPDYTPGPGTRFPL*# SEQUENCE: FFPDYTPGPGTRFPL*# ...# >HUM12A8E# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (121-135)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,FFPDYKPGPGTRFPL*# SEQUENCE: FFPDYKPGPGTRFPL*# ...# >HUM12A8F# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (128-141)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1BR)# & PIR1: (ASLJFV)# & PIR2: (S03247,S43467,S03244)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,GPGVRYPLTFGWCY*# SEQUENCE: GPGVRYPLTFGWCY*# ...# >HUM12A90# MHC MOLECULE: HLA-B57, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (131-146)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1B8)# & PIR1: (ASLJFV)# & PIR2: (S03244,S03247,S43467)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B57,actyesu,bindyesu,VRYPLTFGWCYKLVPV*# SEQUENCE: VRYPLTFGWCYKLVPV*# ...# >HUM12A91# MHC MOLECULE: HLA-B18, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (132-142)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1B8,NEF_HV1PV,NEF_HV1U4,NEF_HV112)# & PIR1: (ASLJFV,ASLJVL,ASLJ12,ASLJH3)# & PIR2: (S03247,S03244,S43467)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B18,actyesu,bindyesu,RYPLTFGWCYK*# SEQUENCE: RYPLTFGWCYK*# ...# >HUM12A92# MHC MOLECULE: HLA-?, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (160-179)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV112,NEF_HV1BR,NEF_HV1B8)# & PIR1: (ASLJFV,ASLJVL,ASLJ12,ASLJH3)# & PIR2: (S43467,S03245,S03244,S03247)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-?,actyesu,bindyesu,TSLLHPVSLHGMDDPEREVL*# SEQUENCE: TSLLHPVSLHGMDDPEREVL*# ...# >HUM12A93# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (178-187)# DB REFERENCE: SWISS: (NEF_HV1B8,NEF_HV1PV,NEF_HV112,NEF_HV1BR)# & PIR1: (ASLJ12,ASLJH3,ASLJVL,ASLJFV)# & PIR2: (S25937,S43467,S03245,S03244,S03247)# & PIR3: (S33986,JQ1620)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,VLEWRFDSRL*# SEQUENCE: VLEWRFDSRL*# ...# >HUM12A94# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (184-191)# DB REFERENCE: SWISS: (NEF_HV112,NEF_HV1PV,NEF_HV1Y2,NEF_HV1RH,NEF_HV1S1,# & NEF_HV1B8,NEF_HV1BN,NEF_HV1BR)# & PIR1: (I44001,ASLJVL,ASLJFV,ASLJ12,ASLJBR,ASLJH3)# & PIR2: (S24985,S03247,S03246,S03245,S43467,S03244)# & PIR3: (S33986,JQ1620)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,DSRLAFHH*# SEQUENCE: DSRLAFHH*# ...# >HUM12A95# MHC MOLECULE: HLA-B52, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef (186-194)# DB REFERENCE: SWISS: (NEF_HV1PV,NEF_HV1Y2,NEF_HV1BR,NEF_HV1RH,NEF_HV112)# & PIR1: (ASLJFV,ASLJVL,ASLJ12,I44001)# & PIR2: (S03244,S43467,S03246,S03245)# & PIR3: (S33986,JQ1620)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-B52,actyesu,bindyesu,RLAFHHVAR*# SEQUENCE: RLAFHHVAR*# ...# >HUM22A96# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (14-21)# DB REFERENCE: SWISS: (GAG_HV1J3,GAG_HV1PV,GAG_HV1JR,GAG_HV1C4,GAG_HV1H2,# & GAG_HV1B5,GAG_HV1B1,GAG_HV1MN,GAG_HV1BR)# & PIR1: (FOVWVL,A38068,FOVWH4,FOVWH3,FOVWLV)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DRWEKIRL*# SEQUENCE: DRWEKIRL*# ...# >HUM22A97# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (33-47)# DB REFERENCE: SWISS: (GAG_HV1RH,GAG_HV1BR,GAG_HV1J3,GAG_HV1B1,GAG_HV1W2,# & GAG_HV1A2,GAG_HV1PV,GAG_HV1N5,GAG_HV1JR,GAG_HV1H2,# & GAG_HV1B5)# & PIR1: (FOVWH3,FOVWLV,FOVWA2,FOVWVL)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,HIVWASRELERFAVN*# SEQUENCE: HIVWASRELERFAVN*# ...# >HUM22A98# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (93-107)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1B5,GAG_HV1PV,GAG_HV1H2,GAG_HV1BR)# & PIR1: (FOVWLV,FOVWVL,FOVWH3)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EIKDTKEALDKIEEE*# SEQUENCE: EIKDTKEALDKIEEE*# ...# >HUM22A99# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p17 (118-132)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1BR,GAG_HV1B1,GAG_HV1B5)# & PIR1: (FOVWVL,FOVWH3,FOVWLV)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,AAADTGHSSQVSQNY*# SEQUENCE: AAADTGHSSQVSQNY*# ...# >HUM22A9A# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (1-15)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_HV1B5,GAG_HV1BR,GAG_HV1J3,GAG_HV1B1,# & GAG_HV1H2,GAG_HV1PV)# & PIR1: (FOVWH3,FOVWVL,A38068,FOVWLV)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PIVQNIQGQMVHQAI*# SEQUENCE: PIVQNIQGQMVHQAI*# ...# >HUM22A9B# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (76-90)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1B5,GAG_HV1BR,GAG_HV1A2,GAG_HV1B1,# & GAG_HV1H2)# & PIR1: (FOVWA2,FOVWVL,FOVWH3,FOVWLV)# & PIR2: (S49086)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EAAEWDRVHPVHAGP*# SEQUENCE: EAAEWDRVHPVHAGP*# ...# >RHE22A9C# MHC MOLECULE: Mamu-?, CLASS-2, (RHESUS MACAQUE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (81-95)# DB REFERENCE: SWISS: (GAG_HV1PV,GAG_HV1BR,GAG_HV1B5,GAG_HV1A2,GAG_HV1H2,# & GAG_HV1B1)# & PIR1: (FOVWA2,FOVWH3,FOVWLV,FOVWVL)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: Mamu-?,actyesu,bindyesu,DRVHPVHAGPIAPGQ*# SEQUENCE: DRVHPVHAGPIAPGQ*# ...# >MUS22A9D# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (87-101)# DB REFERENCE: SWISS: (GAG_HV1Y2,GAG_HV1OY,GAG_HV1Z2,GAG_HV1PV,GAG_HV1RH,# & GAG_HV1H2,GAG_HV1C4,GAG_HV1B5,GAG_HV1BR,GAG_HV1A2,# & GAG_HV1JR,GAG_HV1B1,GAG_HV1W2,GAG_HV1MN,GAG_HV1EL,# & GAG_HV1N5)# & PIR1: (FOVWVL,FOVWH4,FOVWH3,FOVWA2,A38068,A44001,FOVWLV)# & PIR2: (S54377)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,HAGPIAPGQMREPRG*# SEQUENCE: HAGPIAPGQMREPRG*# ...# >HUM22A9E# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (88-95)# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1W2,GAG_HV1BR,GAG_HV1PV,GAG_HV1B1,# & GAG_HV1A2,GAG_HV1JR,GAG_HV1Z2,GAG_HV1RH,GAG_SIVCZ,# & GAG_HV1N5,GAG_HV1J3,GAG_HV1OY,GAG_HV1Y2,GAG_HV1C4,# & GAG_HV1B5,GAG_HV1MN,GAG_HV1EL)# & PIR1: (FOVWA2,FOVWH3,FOVWLV,A38068,A44001,FOVWVL,FOVWH4,# & FOLJSI)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,AGPIAPGQ*# SEQUENCE: AGPIAPGQ*# ...# >HUM22A9F# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (96-110)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,MREPRGSKIAGTTST*# SEQUENCE: MREPRGSKIAGTTST*# ...# >RHE22AA0# MHC MOLECULE: Mamu-?, CLASS-2, (RHESUS MACAQUE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (101-115)# DB REFERENCE: SWISS: (GAG_HV1Z2,GAG_HV1RH,GAG_HV1ND,GAG_SIVCZ,GAG_HV1N5,# & GAG_HV1Y2,GAG_HV1EL,GAG_HV1H2,GAG_HV1BR,GAG_HV1W2,# & GAG_HV1OY,GAG_HV1MN,GAG_HV1MA,GAG_HV1A2,GAG_HV1JR,# & GAG_HV1B1,GAG_HV1J3,GAG_HV1PV,GAG_HV1B5,GAG_HV1C4)# & PIR1: (FOVWH3,FOLJND,A38068,FOVWA2,A44001,FOLJSI,FOVWH4,FOVWVL,# & FOVWLV)# & PIR2: (S60698,S60703,S60700,S54377,S60704,S60702,S49086,S60699,# & S60708)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: Mamu-?,actyesu,bindyesu,GSDIAGTTSTLQEQI*# SEQUENCE: GSDIAGTTSTLQEQI*# ...# >RHE22AA1# MHC MOLECULE: Mamu-?, CLASS-2, (RHESUS MACAQUE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (265-279)# DB REFERENCE: SWISS: (GAG_HV1ND,GAG_HV1H2,GAG_HV1OY,GAG_HV1Z2,GAG_HV1B5,# & GAG_HV1C4,GAG_HV1PV,GAG_HV1J3,GAG_HV1RH,GAG_HV1N5,# & GAG_HV1Y2,GAG_HV1BR,GAG_HV1W2,GAG_HV1MA,GAG_HV1MN,# & GAG_HV1B1,GAG_HV1JR,GAG_HV1A2)# & PIR1: (FOVWA2,FOLJND,A38068,A44001,FOVWVL,FOVWH4,FOVWLV,# & FOVWH3)# & PIR2: (S60708,S60702,S60704,S60697,S60699,S60698,S60703,# & S54377)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: Mamu-?,actyesu,bindyesu,KRWIILGLNKIVRMY*# SEQUENCE: KRWIILGLNKIVRMY*# ...# >HUM22AA2# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (142-161)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VRMYSPTSILNIRQGPKEPF*# SEQUENCE: VRMYSPTSILNIRQGPKEPF*# ...# >HUM22AA3# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (146-160)# DB REFERENCE: SWISS: (GAG_HV1OY,GAG_HV1PV,GAG_HV1N5,GAG_HV1Y2,GAG_HV1W2,# & GAG_HV1B1,GAG_HV1A2,GAG_HV1H2,GAG_HV1BR,GAG_HV1B5)# & PIR1: (FOVWVL,A44001,FOVWH3,FOVWLV,FOVWA2)# & PIR2: (S60702,S60703,S60704,S60699)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,SPTSILDIRQGPKEP*# SEQUENCE: SPTSILDIRQGPKEP*# ...# >HUM22AA4# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p24 (156-170)# DB REFERENCE: SWISS: (GAG_HV1J3,GAG_HV1BR,GAG_HV1W2,GAG_HV1N5,GAG_HV1JR,# & GAG_HV1MN,GAG_HV1OY,GAG_SIVCZ,GAG_HV1B1,GAG_HV1A2,# & GAG_HV1EL,GAG_HV1RH,GAG_HV1H2,GAG_HV1C4,GAG_HV1B5,# & GAG_HV1Z2,GAG_HV1ND,GAG_HV1Y2)# & PIR1: (A44001,FOVWH4,FOVWH3,FOLJSI,FOVWA2,A38068,FOVWVL,FOLJND,# & FOVWLV)# & PIR2: (S60697,S60700,S60702,S60699,S60708,S60704,S60703,S52929,# & S60698,S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GPKEPFRDYVDRFYK*# SEQUENCE: GPKEPFRDYVDRFYK*# ...# >HUM22AA5# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p15 (16-30)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1H2,GAG_HV1PV)# & PIR1: (FOVWH3,FOVWVL)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,FNCGKEGHTARNCRA*# SEQUENCE: FNCGKEGHTARNCRA*# ...# >HUM22AA6# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p15 (41-55)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1MA,GAG_HV1PV,GAG_HV1N5,GAG_HV1B1,# & GAG_HV1U4,GAG_HV1BR,GAG_HV1Y2,GAG_HV1MN,GAG_HV1H2)# & PIR1: (FOVWLV,FOVWH3,A44001,A38068,FOVWVL)# & PIR2: (S24471,S24478)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,KEGHQMKDCTERQAN*# SEQUENCE: KEGHQMKDCTERQAN*# ...# >HUM22AA7# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p15 (46-60)# DB REFERENCE: SWISS: (GAG_HV1N5,GAG_HV1C4,GAG_HV1A2,GAG_HV1B5,GAG_HV1ND,# & GAG_HV1MN,GAG_HV1Y2,GAG_HV1H2,GAG_HV1B1,GAG_HV1U4,# & GAG_HV1BR,GAG_HV1PV,GAG_HV1OY,GAG_HV1MA)# & PIR1: (FOVWA2,FOLJND,FOVWVL,A38068,A44001,FOVWLV,FOVWH4,# & FOVWH3)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,MKDCTERQANFLGKI*# SEQUENCE: MKDCTERQANFLGKI*# ...# >HUM22AA8# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p15 (54-61)# DB REFERENCE: SWISS: (GAG_HV1B1,GAG_HV1RH,GAG_HV1BR,GAG_HV1Y2,GAG_HV1ND,# & GAG_HV1J3,GAG_HV1H2,GAG_HV1N5,GAG_HV1C4,GAG_HV1A2,# & GAG_HV1B5,GAG_HV1Z2,GAG_HV1MN,GAG_HV1U4,GAG_HV1OY,# & GAG_HV1MA,GAG_HV1JR,GAG_HV1PV)# & PIR1: (A44001,A38068,FOLJND,FOVWH4,FOVWLV,FOVWH3,FOVWA2)# & PIR2: (S54377)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ANFLGKIW*# SEQUENCE: ANFLGKIW*# ...# >MUS22AA9# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p15 (69-83)# DB REFERENCE: SWISS: (GAG_HV1MA,GAG_HV1EL,GAG_HV1ND,GAG_HV1Z2)# & PIR1: (FOLJND)# & PIR2: (S54377)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,GNFLQSRPEPTAPPA*# SEQUENCE: GNFLQSRPEPTAPPA*# ...# >HUM22AAA# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p15 (81-88)# DB REFERENCE: SWISS: (GAG_HV1BR,GAG_HV1PV,GAG_HV1B5,GAG_HV1H2,GAG_HV1B1)# & PIR1: (FOVWLV,FOVWH3)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PPEESFRS*# SEQUENCE: PPEESFRS*# ...# >HUM22AAB# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV p15 (84-98)# DB REFERENCE: SWISS: (GAG_HV1H2,GAG_HV1B5,GAG_HV1PV,GAG_HV1B1)# & PIR1: (FOVWH3)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ESFRSGVETTTPPQK*# SEQUENCE: ESFRSGVETTTPPQK*# ...# >HUM22AAC# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV vpr (66-80)# DB REFERENCE: SWISS: (VPR_HV1MN,VPR_HV1SC,VPR_HV1BR,VPR_HV1N5,VPR_HV1JR)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,QLLFIHFRIGCRHSR*# SEQUENCE: QLLFIHFRIGCRHSR*# ...# >MUS22AAD# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV vpr (66-80)# DB REFERENCE: SWISS: (VPR_HV1JR,VPR_HV1BR,VPR_HV1SC,VPR_HV1MN,VPR_HV1N5)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,QLLFIHFRIGCRHSR*# SEQUENCE: QLLFIHFRIGCRHSR*# ...# >HUM22AAE# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (191-207)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1RH,POL_HV1N5,POL_HV1JR,POL_HV1PV,# & POL_HV1A2,POL_HV1H2,POL_HV1Y2,POL_HV1MN,POL_HV1B5,# & POL_HV1B1)# & PIR1: (GNVWA2,GNVWH3,GNVWLV,GNVWVL,B44001)# & PIR2: (S32139,S32063,S32065,S32054,S32058,S32052,S32122,B47330,# & S32062,S32059,S32061,S32060,S32135,S32120,S32134,S32119,# & S32127,B47175,S32056,S32117,F47330,A47175,S32064,S32053,# & S32057,S32055,S32095,S32151,S32126,S32118,S32136)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EICTEMEKEGKISKIGP*# SEQUENCE: EICTEMEKEGKISKIGP*# ...# >MUS22AAF# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (193-207)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1MN,POL_HV1B5,POL_HV1PV,POL_HV1JR,# & POL_HV1RH,POL_HV1N5,POL_HV1BR,POL_HV1A2,POL_HV1Y2,# & POL_HV1H2)# & PIR1: (GNVWA2,GNVWLV,GNVWVL,B44001,GNVWH3)# & PIR2: (S32052,B47175,S32122,S32061,S32151,S32126,S32118,S32135,# & S32119,S32062,S32055,S32136,S32127,S32134,S32120,S32058,# & S32095,S32057,S32053,A47175,S32064,F47330,S32056,S32117,# & S32063,S32139,S32065,S32054,S32060,S32140,S32059,# & B47330)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,CTEMEKEGKISKIGP*# SEQUENCE: CTEMEKEGKISKIGP*# ...# >MUS22AB0# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (203-217)# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1PV,POL_HV1B1,POL_HV1A2,POL_HV1N5,# & POL_HV1MN,POL_HV1Y2,POL_HV1H2,POL_HV1JR,POL_HV1RH,# & POL_HV1BR,POL_HV1U4)# & PIR1: (GNVWLV,GNVWA2,B44001,GNVWVL,GNVWH3)# & PIR2: (S32092,S32094,S32117,S32069,S32061,S32073,S32047,B47175,# & S32076,S32072,S32137,S32090,S32078,S32096,S32087,S32089,# & S32085,B47330,S32140,S32129,S32071,S32088,S32083,C47330,# & S32136,S32074,S32131,S32157,S32062,S32135,S32119,S32081,# & S32152,S32160,S32122,S32151,S32118,S32126,S32050,S32067,# & S32159,S32075,S32079,S32139,S32082,S32080,S32134,S32058,# & S32086,S32127,S32049,S32070,S32095,S32133,S32093,S32068,# & S32128,S32091,S32098,S32132,S32097,S32084,D47330,A47330,# & S32066,F47330,S32051,A47175,S32120,S32048,S32063,S32138,# & S32065,S32059)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,SKIGPENPYNTPVFA*# SEQUENCE: SKIGPENPYNTPVFA*# ...# >MUS22AB1# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (217-232)# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1MN,POL_HV1ND,POL_HV1Z2,POL_HV1BR,# & POL_HV1U4,POL_HV1JR,POL_SIVCZ,POL_HV1A2,POL_HV1OY,# & POL_HV1N5,POL_HV1EL,POL_HV1B5,POL_HV1B1,POL_HV1H2,# & POL_HV1Y2,POL_HV1PV)# & PIR1: (GNVWA2,GNVWVL,GNLJSI,GNVWH3,GNVWLV,GNLJND,B44001)# & PIR2: (S32137,S32139,S32129,A47330,S32138,S32048,S32093,S32091,# & S32049,E47330,S32067,S32096,S54378,S32090,S32072,B47175,# & S32073,S32127,S32080,S32050,S32134,S32075,S32079,S32089,# & B47330,S32078,S32094,F47330,S32051,S32098,S32097,S32133,# & S32128,S32068,S32070,S32092,S32069,S32047,S32135,S32152,# & S32077,S32071,S32136,S32131,C47330)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,AIKKKDSTKWRKLVDF*# SEQUENCE: AIKKKDSTKWRKLVDF*# ...# >MUS22AB2# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (288-302)# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1OY,POL_HV1ND,POL_HV1H2,POL_HV1PV,# & POL_HV1BR,POL_HV1N5,POL_HV1MA,POL_HV1MN,POL_HV1JR,# & POL_HV1Z2,POL_HV1B1)# & PIR1: (GNLJND,GNVWLV,GNVWVL,GNVWH3,GNVWA2)# & PIR2: (S32064,S32056,S32128,S32053,S32133,S32088,S32083,S32120,# & S32063,S32081,S32057,S32118,S43127,C47330,S32055,S54378,# & S32090,D47330,S32091,S32132,A47175,S32084,S32152,S32092,# & S32087,S32054,S32159,S32094,S32082,S32089,S32160,S32085,# & B47175,S32061,S32151,S32062,S32059,S32058,S32095,S32093,# & S32049,S32052,S32048,S32129,S32157,S32051,S32126,S32098,# & S32050,S32086,S32060,S32047)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,PSINNETPGIRYQYN*# SEQUENCE: PSINNETPGIRYQYN*# ...# >HUM22AB3# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (350-364)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1PV,POL_HV1H2,POL_HV1B5,POL_HV1JR,# & POL_HV1A2,POL_HV1B1,POL_HV1BR,POL_HV1N5,POL_HV1OY)# & PIR1: (GNVWH3,GNVWVL,GNVWA2,B44001,GNVWLV)# & PIR2: (S32138,S32052,B47175,S32065,S32122,S32118,S32135,S32089,# & S32136,S32159,S32160,S32054,S32140,C47330,S32134,A47330,# & S32157,S32098,S32126,S32127,S32064,S32056,S32117,S32063,# & D47330,F47330,A47175,S32139,S32137,S32055)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IGQHRTKIEELRQHL*# SEQUENCE: IGQHRTKIEELRQHL*# ...# >HUM22AB4# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (404-418)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,KDSWTWNDIQKLVGK*# SEQUENCE: KDSWTWNDIQKLVGK*# ...# >HUM22AB5# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (413-427)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,QKLWGKLNWASQIYP*# SEQUENCE: QKLWGKLNWASQIYP*# ...# >HUM22AB6# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (430-445)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,WRQLCKLLRGTKALT*# SEQUENCE: WRQLCKLLRGTKALT*# ...# >HUM22AB7# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (440-454)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1EL,POL_HV1Y2,POL_HV1Z2,POL_HV1OY,# & POL_HV1B1,POL_HV1A2,POL_HV1B5,POL_HV1H2,POL_HV1BR,# & POL_HV1PV)# & PIR1: (GNVWLV,B44001,GNVWH3,GNVWVL,GNVWA2)# & PIR2: (S54378,B47175)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GTKALTEVIPLTEEA*# SEQUENCE: GTKALTEVIPLTEEA*# ...# >HUM22AB8# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (449-463)# DB REFERENCE: SWISS: (POL_HV1PV,POL_HV1H2,POL_HV1OY,POL_HV1EL,POL_HV1A2,# & POL_HV1B5,POL_HV1B1,POL_HV1Z2,POL_HV1Y2,POL_HV1ND,# & POL_HV1MN,POL_HV1BR,POL_HV1N5)# & PIR1: (GNVWH3,GNVWA2,B44001,GNVWLV,GNLJND,GNVWVL)# & PIR2: (A49489,B47175,S54378)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PLTEEAELELAENRE*# SEQUENCE: PLTEEAELELAENRE*# ...# >HUM22AB9# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (457-472)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1EL,POL_HV1PV,POL_HV1OY,POL_HV1RH,# & POL_HV1H2,POL_HV1B5,POL_HV1ND,POL_HV1Y2,POL_HV1MN,# & POL_HV1MA,POL_HV1B1,POL_HV1Z2,POL_HV1JR,POL_HV1N5)# & PIR1: (GNVWH3,GNVWVL,B44001,GNVWLV,GNLJND)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,LAENREILKEPVHGV*# SEQUENCE: LAENREILKEPVHGV*# ...# >HUM22ABA# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (539-553)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1H2,POL_HV1ND,POL_HV1B1,POL_HV1BR,# & POL_HV1PV,POL_HV1OY,POL_HV1B5,POL_HV1N5,POL_HV1RH)# & PIR1: (GNVWVL,GNVWH3,GNLJND,B44001,GNVWLV)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GKTPKFKLPIQKETW*# SEQUENCE: GKTPKFKLPIQKETW*# ...# >HUM22ABB# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (583-598)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1A2,POL_HV1MN,POL_HV1PV,POL_HV1JR,# & POL_HV1B5,POL_HV1H2,POL_HV1B1)# & PIR1: (GNVWA2,GNVWH3,GNVWLV,GNVWVL)# & PIR2: (B47175,A47175)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,LEKEPIVGAETFYVD*# SEQUENCE: LEKEPIVGAETFYVD*# ...# >MUS22ABC# MHC MOLECULE: H-2f, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (683-698)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1A2,POL_HV1B5,POL_HV1ND,POL_HV1N5,# & POL_HV1OY,POL_HV1MN,POL_HV1EL,POL_HV1BR,POL_HV1RH,# & POL_HV1H2,POL_HV1JR,POL_HV1Y2,POL_HV1Z2)# & PIR1: (GNVWVL,B44001,GNVWLV,GNVWH3,GNLJND,GNVWA2)# & PIR2: (B47175,S54378,A47175)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2f,actyesu,bindyesu,KEKVYLAWVPAHKGIG*# SEQUENCE: KEKVYLAWVPAHKGIG*# ...# >MUS22ABD# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (683-698)# DB REFERENCE: SWISS: (POL_HV1B5,POL_HV1N5,POL_HV1B1,POL_HV1RH,POL_HV1OY,# & POL_HV1H2,POL_HV1Z2,POL_HV1Y2,POL_HV1EL,POL_HV1JR,# & POL_HV1BR,POL_HV1MN,POL_HV1A2,POL_HV1ND)# & PIR1: (GNVWLV,GNVWA2,GNLJND,GNVWVL,GNVWH3,B44001)# & PIR2: (A47175,S54378,B47175)# & PIR3: (S11523,S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KEKVYLAWVPAHKGIG*# SEQUENCE: KEKVYLAWVPAHKGIG*# ...# >MUS22ABE# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (683-698)# DB REFERENCE: SWISS: (POL_HV1A2,POL_HV1OY,POL_HV1BR,POL_HV1B5,POL_HV1MN,# & POL_HV1Y2,POL_HV1H2,POL_HV1EL,POL_HV1JR,POL_HV1Z2,# & POL_HV1N5,POL_HV1B1,POL_HV1RH,POL_HV1ND)# & PIR1: (GNVWH3,GNVWA2,GNLJND,B44001,GNVWLV,GNVWVL)# & PIR2: (B47175,A47175,S54378)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,KEKVYLAWVPAHKGIG*# SEQUENCE: KEKVYLAWVPAHKGIG*# ...# >HUM22ABF# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (720-730)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1RH,POL_HV1BR,POL_HV1PV,POL_HV1B1)# & PIR1: (GNVWLV,GNVWH3,GNVWVL)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IDKAQDEHEKY*# SEQUENCE: IDKAQDEHEKY*# ...# >HUM22AC0# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (899-913)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1OY,POL_HV1Z2,POL_HV1PV,POL_HV1N5,# & POL_HV1Z6,POL_HV1ND,POL_HV1A2,POL_HV1RH,POL_HV1H2,# & POL_HV1U4,POL_HV1B5,POL_HV1MN,POL_HV1B1,POL_HV1Y2,# & POL_HV1BR,POL_HV1JR)# & PIR1: (GNVWLV,B44001,GNVWVL,GNVWH3,GNLJND,GNVWA2)# & PIR2: (A26192,S54378)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NFKRKGGIGGYSAGE*# SEQUENCE: NFKRKGGIGGYSAGE*# ...# >HUM22AC1# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (923-937)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1Y2,POL_HV1MN,POL_HV1JR,POL_HV1Z2,# & POL_HV1OY,POL_HV1B5,POL_HV1B1,POL_HV1BR,POL_HV1Z6,# & POL_HV1N5,POL_HV1RH,POL_HV1A2,POL_HV1PV,POL_HV1MA)# & PIR1: (GNVWVL,B44001,GNVWLV,GNVWA2,GNVWH3)# & PIR2: (S54378,A26192)# & PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IQTKELQKQITKIQN*# SEQUENCE: IQTKELQKQITKIQN*# ...# >HUM22AC2# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV RT (942-954)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,YRNSRNPLWKGPA*# SEQUENCE: YRNSRNPLWKGPA*# ...# >HUM22AC3# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV rev (9-23)# DB REFERENCE: SWISS: (REV_HV1H2)# & PIR2: (JC4968)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DEELIRTVRLIKLLY*# SEQUENCE: DEELIRTVRLIKLLY*# ...# >HUM22AC4# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV rev (25-39)# DB REFERENCE: SWISS: (REV_HV112,REV_HV1H2,REV_HV1PV,REV_HV1OY,REV_HV1B1,# & REV_HV1BR)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,SNPPPNPEGTRQARR*# SEQUENCE: SNPPPNPEGTRQARR*# ...# >HUM22AC5# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV rev (33-48)# DB REFERENCE: SWISS: (REV_HV1B8,REV_HV1B1,REV_HV1C4,REV_HV1OY,REV_HV1MN,# & REV_HV1Y2,REV_HV1RH,REV_HV1A2,REV_HV1W2,REV_HV1SC,# & REV_HV112,REV_HV1H2,REV_HV1PV,REV_HV1S3,REV_HV1S1,# & REV_HV1BR,REV_HV1JR)# & PIR1: (F44001,VKLJH3)# & PIR2: (S14607,JC4968)# & PIR3: (S33983)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GTRQARRNRRRRWRER*# SEQUENCE: GTRQARRNRRRRWRER*# ...# >HUM22AC6# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV rev (41-56)# DB REFERENCE: SWISS: (REV_HV1PV,REV_HV1H2,REV_HV1S3,REV_HV1B8,REV_HV112,# & REV_HV1B1,REV_HV1BR)# & PIR1: (VKLJH3)# & PIR2: (JC4968,S14607)# & PIR3: (S33983)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RRRRWRERQRQIHSIS*# SEQUENCE: RRRRWRERQRQIHSIS*# ...# >HUM22AC7# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (66-77)# DB REFERENCE: SWISS: (ENV_HV1S3,ENV_HV1A2,ENV_HV1Y2,ENV_HV1J3,ENV_HV1ZH,# & ENV_HV1W2,ENV_HV1B1,ENV_HV1B8,ENV_HV1OY,ENV_HV1PV,# & ENV_HV1H2,ENV_HV1JR,ENV_HV1S1,ENV_HV1BR,ENV_HV1KB,# & ENV_HV1BN,ENV_HV1N5)# & PIR1: (A44963,H44001,VCLJA2,VCLJKX,VCLJVL,VCLJH3,VCLJBR,VCLJLV,# & VCLJKB)# & PIR2: (S25939,A40218,S25938)# & PIR3: (S13288,S33985,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NVWATHACVPTD*# SEQUENCE: NVWATHACVPTD*# ...# >HUM22AC8# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (100-111)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1MF,ENV_HV1BR,ENV_HV1N5,ENV_HV1EL,# & ENV_HV1Y2,ENV_HV1MN,ENV_HV1MA,ENV_HV1Z2,ENV_HV1C4,# & ENV_HV1Z3,ENV_HV1Z8,ENV_HV1S1,ENV_HV1H2,ENV_HV1ND,# & ENV_HV1B8,ENV_HV1SC,ENV_HV1W1,ENV_HV1PV,ENV_HV1B1,# & ENV_HV1RH,ENV_HV1J3,ENV_HV1BN,ENV_HV1W2)# & PIR1: (VCLJND,VCLJ3W,VCLJH4,VCLJSC,VCLJMN,VCLJLV,VCLJBR,H44001,# & VCLJVL,VCLJH3)# & PIR2: (S54384,S31493,S25938,S25939)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VEQMHEDIISLW*# SEQUENCE: VEQMHEDIISLW*# ...# >MUS22AC9# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (104-116)# DB REFERENCE: SWISS: (ENV_HV1ND,ENV_HV1H2,ENV_HV1EL,ENV_HV1S1,ENV_HV1B1,# & ENV_HV1BN,ENV_HV1Z6,ENV_HV1W1,ENV_HV1C4,ENV_SIVCZ,# & ENV_HV1SC,ENV_HV1PV,ENV_HV1Z2,ENV_HV1N5,ENV_HV1BR,# & ENV_HV1RH,ENV_HV1H3,ENV_HV1MF,ENV_HV1Z3,ENV_HV1MN,# & ENV_HV1Y2,ENV_HV1MA,ENV_HV1J3,ENV_HV1W2,ENV_HV1B8)# & PIR1: (VCLJMN,VCLJZR,VCLJH4,VCLJ3W,VCLJSC,VCLJND,VCLJBR,VCLJVL,# & VCLJLV,VCLJH3,H44001,VCLJSI)# & PIR2: (S25938,S54384,S31493,S25939)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2s,actyesu,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >HUM22ACA# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (104-116)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1SC,ENV_HV1ND,ENV_HV1H2,ENV_HV1BN,# & ENV_HV1EL,ENV_HV1MA,ENV_HV1C4,ENV_HV1Z6,ENV_HV1J3,# & ENV_HV1N5,ENV_HV1H3,ENV_HV1W2,ENV_HV1B8,ENV_HV1Y2,# & ENV_HV1MF,ENV_HV1Z3,ENV_HV1W1,ENV_HV1Z2,ENV_HV1RH,# & ENV_HV1S1,ENV_HV1BR,ENV_HV1MN,ENV_HV1B1,ENV_SIVCZ)# & PIR1: (VCLJND,VCLJ3W,VCLJH4,VCLJSI,VCLJMN,VCLJH3,VCLJVL,VCLJLV,# & VCLJBR,H44001,VCLJSC,VCLJZR)# & PIR2: (S25939,S25938,S54384,S31493)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >RHE22ACB# MHC MOLECULE: Mamu-?, CLASS-2, (RHESUS MACAQUE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (104-116)# DB REFERENCE: SWISS: (ENV_SIVCZ,ENV_HV1N5,ENV_HV1Z2,ENV_HV1MN,ENV_HV1BN,# & ENV_HV1MF,ENV_HV1Y2,ENV_HV1B8,ENV_HV1W2,ENV_HV1RH,# & ENV_HV1Z6,ENV_HV1H3,ENV_HV1S1,ENV_HV1MA,ENV_HV1SC,# & ENV_HV1PV,ENV_HV1H2,ENV_HV1EL,ENV_HV1Z3,ENV_HV1J3,# & ENV_HV1C4,ENV_HV1ND,ENV_HV1BR,ENV_HV1B1,ENV_HV1W1)# & PIR1: (VCLJVL,VCLJBR,VCLJMN,VCLJND,VCLJH4,H44001,VCLJSC,VCLJLV,# & VCLJSI,VCLJ3W,VCLJZR,VCLJH3)# & PIR2: (S25938,S31493,S25939,S54384)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: Mamu-?,actyesu,bindyesu,HEDIISLWDQSLK*# SEQUENCE: HEDIISLWDQSLK*# ...# >HUM22ACC# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (107-118)# DB REFERENCE: SWISS: (ENV_SIVCZ,ENV_HV1N5,ENV_HV1MN,ENV_HV1Z2,ENV_HV1J3,# & ENV_HV1H3,ENV_HV1SC,ENV_HV1MA,ENV_HV1Y2,ENV_HV1BR,# & ENV_HV1W1,ENV_HV1B1,ENV_HV1C4,ENV_HV1Z3,ENV_HV1ND,# & ENV_HV1KB,ENV_HV1BN,ENV_HV1B8,ENV_HV1MF,ENV_HV1RH,# & ENV_HV1W2,ENV_HV1EL,ENV_HV1H2,ENV_HV1PV,ENV_HV1Z6,# & ENV_HV1S1,ENV_HV1OY,ENV_HV1A2)# & PIR1: (VCLJVL,VCLJSI,VCLJH3,VCLJND,VCLJH4,VCLJKX,VCLJLV,H44001,# & VCLJSC,VCLJZR,VCLJKB,VCLJ3W,VCLJMN,VCLJBR,VCLJA2)# & PIR2: (S54384,A40218,S25939,S31493,S25938,A53034)# & PIR3: (S33985,S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IISLWDQSLKPC*# SEQUENCE: IISLWDQSLKPC*# ...# >HUM22ACD# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (224-239)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PAGFAILKCNNKTFNY*# SEQUENCE: PAGFAILKCNNKTFNY*# ...# >HUM22ACE# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (225-236)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1A2,ENV_HV1B1,ENV_HV1H2,ENV_HV1PV,# & ENV_HV1BR,ENV_HV1H3,ENV_HV1JR)# & PIR1: (VCLJLV,VCLJH3,VCLJVL,VCLJA2)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,AGFAILKCNNKT*# SEQUENCE: AGFAILKCNNKT*# ...# >HUM22ACF# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (234-249)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NKTFNGKGPCTNVSTY*# SEQUENCE: NKTFNGKGPCTNVSTY*# ...# >HUM22AD0# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (244-258)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TNVSTVQCTHGRPIY*# SEQUENCE: TNVSTVQCTHGRPIY*# ...# >HUM22AD1# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (254-269)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GIRPIVSTQLLLNGSC*# SEQUENCE: GIRPIVSTQLLLNGSC*# ...# >HUM22AD2# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (273-287)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1B1,ENV_HV1PV)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EVVIRSANFTDNAKT*# SEQUENCE: EVVIRSANFTDNAKT*# ...# >HUM22AD3# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (273-289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VVIRSDNFTNNAKTIC*# SEQUENCE: VVIRSDNFTNNAKTIC*# ...# >HUM22AD4# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (278-292)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1BR,ENV_HV1MF,ENV_HV1B1)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,SANFTDNAKTIIVQL*# SEQUENCE: SANFTDNAKTIIVQL*# ...# >HUM22AD5# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (284-299)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NAKTIIVQLNESVAIC*# SEQUENCE: NAKTIIVQLNESVAIC*# ...# >HUM22AD6# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (324-339)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RIIGDIRKAHCNISRY*# SEQUENCE: RIIGDIRKAHCNISRY*# ...# >HUM22AD7# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (288-297)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1BR)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR2: (S35812,S35847)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IIVQLNQSVE*# SEQUENCE: IIVQLNQSVE*# ...# >HUM22AD8# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (293-301)# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1Z2,ENV_HV1Z6)# & PIR1: (VCLJA2,VCLJZR)# & PIR2: (S54384)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NESVAINCT*# SEQUENCE: NESVAINCT*# ...# >MUS22AD9# MHC MOLECULE: H-2?, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (294-299)# DB REFERENCE: SWISS: (ENV_HV1MN,APLP_MANSE)# & PIR1: (VCLJMN)# & PIR2: (C41621,S42902)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2?,actyesu,bindyesu,ESVQIN*# SEQUENCE: ESVQIN*# ...# >GOA22ADA# MHC MOLECULE: ?, CLASS-2, (GOAT)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (300-316)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1MF,ENV_HV1B1,ENV_HV1BR)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR3: (S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: ?,actyesu,bindyesu,CTRPNNNTRKSIRIQRGPG*# SEQUENCE: CTRPNNNTRKSIRIQRGPG*# ...# >MUS22ADB# MHC MOLECULE: H-2?, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (306-317)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1B1,ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2?,actyesu,bindyesu,NTRKSIRIQRGPGR*# SEQUENCE: NTRKSIRIQRGPGR*# ...# >HUM22ADC# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (311-325)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EQRGPGRAFVTIGKI*# SEQUENCE: EQRGPGRAFVTIGKI*# ...# >MUS22ADD# MHC MOLECULE: H-2Ad, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1B1,ENV_HV1H2,ENV_HV1PV,ENV_HV1H3,# & ENV_HV1B8,ENV_HV1BR)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2Ad,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >HUM22ADE# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1PV,ENV_HV1H3,ENV_HV1BR,ENV_HV1B8,# & ENV_HV1H2,ENV_HV1MF)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-DR?,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >HUM22ADF# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1MF,ENV_HV1BR,ENV_HV1H3,ENV_HV1B8,# & ENV_HV1B1,ENV_HV1PV)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RIQRGPGRAFVTIGK*# SEQUENCE: RIQRGPGRAFVTIGK*# ...# >HUM22AE0# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-324)# DB REFERENCE: SWISS: (ENV_HV1MN)# & PIR1: (VCLJMN)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RIHIGPGRAFYTTKN*# SEQUENCE: RIHIGPGRAFYTTKN*# ...# >MUS22AE1# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (310-323)# DB REFERENCE: SWISS: (ENV_HV1MN,ENV_HV1J3)# & PIR1: (VCLJMN)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,RIHIGPGRAFYTTK*# SEQUENCE: RIHIGPGRAFYTTK*# ...# >HUM22AE2# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (316-331)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1PV,ENV_HV1H3,ENV_HV1BR,ENV_HV1B1,# & ENV_HV1H2,ENV_HV1MF)# & PIR1: (VCLJLV,VCLJH3,VCLJVL)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GRAFVTIGKIGNMRQ*# SEQUENCE: GRAFVTIGKIGNMRQ*# ...# >MUS22AE3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (330-344)# DB REFERENCE: SWISS: (ENV_HV1W2,ENV_HV1H2,ENV_HV1W1,ENV_HV1PV,ENV_HV1B1,# & ENV_HV1SC)# & PIR1: (VCLJ3W,VCLJH3,VCLJVL,VCLJSC)# & PIR2: (S25940)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,RQAHCNISRAKWNNT*# SEQUENCE: RQAHCNISRAKWNNT*# ...# >HUM22AE4# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (334-348)# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,CNISRAQWNNTLEQI*# SEQUENCE: CNISRAQWNNTLEQI*# ...# >MUS22AE5# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (338-352)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,RAKWNNTLKQICSKL*# SEQUENCE: RAKWNNTLKQICSKL*# ...# >HUM22AE6# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (344-359)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TLEQIVKKLREQFGNC*# SEQUENCE: TLEQIVKKLREQFGNC*# ...# >HUM22AE7# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (347-360)# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,QIVKKLREQFGNNK*# SEQUENCE: QIVKKLREQFGNNK*# ...# >HUM22AE8# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (368-382)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,SSGGKPEIVTHSFNC*# SEQUENCE: SSGGKPEIVTHSFNC*# ...# >HUM22AE9# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (360-369)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1B1,ENV_HV1PV,ENV_HV1B8,ENV_HV1H2,# & ENV_HV1H3)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NKTIIFKQSS*# SEQUENCE: NKTIIFKQSS*# ...# >HUM22AEA# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (373-387)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H2,ENV_HV1B1,ENV_HV1B8,ENV_HV1BR,# & ENV_HV1Y2,ENV_HV1W1,ENV_HV1H3,ENV_HV1MF,ENV_HV1W2)# & PIR1: (H44001,VCLJ3W,VCLJVL,VCLJH3,VCLJLV)# & PIR2: (A40218)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PEIVTHSFNCGGEFF*# SEQUENCE: PEIVTHSFNCGGEFF*# ...# >HUM22AEB# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (385-399)# DB REFERENCE: SWISS: (ENV_HV1A2)# & PIR1: (VCLJA2)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EFFYCNTTQLFNNTW*# SEQUENCE: EFFYCNTTQLFNNTW*# ...# >HUM22AEC# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (395-410)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,FNNTWRLNHTEGTKGC*# SEQUENCE: FNNTWRLNHTEGTKGC*# ...# >HUM22AED# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (398-412)# DB REFERENCE: SWISS: (ENV_HV1B1)# & PIR1: (VCLJH3)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TWFNSTWSTKGSNNT*# SEQUENCE: TWFNSTWSTKGSNNT*# ...# >HUM22AEE# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (398-412)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1B1)# & PIR1: (VCLJH3)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TWSTKGSNNTEGSDT*# SEQUENCE: TWSTKGSNNTEGSDT*# ...# >HUM22AEF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (410-430)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1H3,ENV_HV1BR,ENV_HV1PV)# & PIR1: (VCLJVL,VCLJLV)# & PIR3: (S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,GSDTITLPCRIKQFINMWQE*# SEQUENCE: GSDTITLPCRIKQFINMWQE*# ...# >HUM22AF0# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (417-432)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,LPCRIKQIINMWQEVY*# SEQUENCE: LPCRIKQIINMWQEVY*# ...# >HUM22AF1# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (425-439)# DB REFERENCE: SWISS: (ENV_HV1S3,ENV_HV1BR,ENV_HV1PV,ENV_HV1BN,ENV_HV1JR,# & ENV_HV1MN,ENV_HV1A2,ENV_HV1MF,ENV_HV1J3,ENV_HV1B8,# & ENV_HV1H3,ENV_HV1SC,ENV_HV1Y2,ENV_HV1B1)# & PIR1: (VCLJMN,VCLJA2,VCLJVL,H44001,VCLJSC,VCLJBR,VCLJLV,# & VCLJH3)# & PIR2: (A40218,C41621,S25940,S60538)# & PIR3: (S13288,S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,INMWQEVGKAMYAPP*# SEQUENCE: INMWQEVGKAMYAPP*# ...# >HUM22AF2# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1B1,ENV_HV1S3,ENV_HV1B8,ENV_HV1BN,# & ENV_HV1JR,ENV_HV1MN,ENV_HV1A2,ENV_HV1J3)# & PIR1: (VCLJH3,VCLJMN,H44001,VCLJBR,VCLJA2)# & PIR2: (S25940,A40218,S60538,C41621)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >GOA22AF3# MHC MOLECULE: ?, CLASS-2, (GOAT)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1A2,ENV_HV1S3,ENV_HV1Y2,ENV_HV1B1,# & ENV_HV1J3,ENV_HV1MN,ENV_HV1JR,ENV_HV1BN)# & PIR1: (VCLJH3,H44001,VCLJA2,VCLJMN,VCLJBR)# & PIR2: (S60538,S25940,A40218,C41621)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: ?,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS22AF4# MHC MOLECULE: H-2?, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1A2,ENV_HV1BN,ENV_HV1B8,ENV_HV1S3,ENV_HV1Y2,# & ENV_HV1B1,ENV_HV1JR,ENV_HV1J3,ENV_HV1MN)# & PIR1: (H44001,VCLJA2,VCLJMN,VCLJH3,VCLJBR)# & PIR2: (C41621,S60538,A40218,S25940)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2?,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >CHI22AF5# MHC MOLECULE: Patr-?, CLASS-2, (CHIMPANZEE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1MN,ENV_HV1JR,ENV_HV1J3,ENV_HV1S3,# & ENV_HV1A2,ENV_HV1B8,ENV_HV1BN,ENV_HV1Y2)# & PIR1: (VCLJA2,VCLJBR,H44001,VCLJH3,VCLJMN)# & PIR2: (S25940,C41621,A40218,S60538)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: Patr-?,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >MUS22AF6# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-445)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,KQIIMNWQEVGKAMYAPPISGQIR*# SEQUENCE: KQIIMNWQEVGKAMYAPPISGQIR*# ...# >HUM22AF7# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (422-437)# DB REFERENCE: SWISS: (ENV_HV1Y2,ENV_HV1JR,ENV_HV1B1,ENV_HV1B8,ENV_HV1MN,# & ENV_HV1A2,ENV_HV1BN,ENV_HV1J3,ENV_HV1S3)# & PIR1: (VCLJA2,VCLJMN,H44001,VCLJBR,VCLJH3)# & PIR2: (A40218,S60538,S25940,C41621)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-DR?,actyesu,bindyesu,KQIINMWQEVGKAMYA*# SEQUENCE: KQIINMWQEVGKAMYA*# ...# >HUM22AF8# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (427-442)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,MWQEVGKAMYAPPIGC*# SEQUENCE: MWQEVGKAMYAPPIGC*# ...# >HUM22AF9# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (437-452)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,APPIGGQISCSSNITY*# SEQUENCE: APPIGGQISCSSNITY*# ...# >HUM22AFA# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (447-462)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,SSNITGLLLTRDGGTC*# SEQUENCE: SSNITGLLLTRDGGTC*# ...# >HUM22AFB# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (457-472)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RDGGTNVTNDTEVFRC*# SEQUENCE: RDGGTNVTNDTEVFRC*# ...# >HUM22AFC# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (460-475)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1B8)# & PIR1: (VCLJH3)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GNSNNESEIFRPGGG*# SEQUENCE: GNSNNESEIFRPGGG*# ...# >HUM22AFD# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (470-485)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1Z6,ENV_HV1JR,ENV_HV1SC,ENV_HV1MN,# & ENV_HV1PV,ENV_HV1Y2,ENV_HV1B8,ENV_HV1C4,ENV_HV1B1,# & ENV_HV1A2,ENV_HV1H3,ENV_HV1S1,ENV_HV1ZH,ENV_HV1Z2,# & ENV_HV1EL,ENV_HV1MF,ENV_HV1KB)# & PIR1: (H44001,A44963,VCLJVL,VCLJMN,VCLJH4,VCLJLV,VCLJA2,VCLJZR,# & VCLJSC,VCLJKX,VCLJKB,VCLJH3)# & PIR2: (S60535,S60524,S60531,S60556,A41621,S60552,S60528,S60555,# & S60551,S60523,S60532,C41621,S31493,S60521,S60545,S60522,# & S54384,S60529,S60548,S60546,S60547,S60550,S60554,# & S60553)# & PIR3: (S33985,S13289,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,FRPGGGDMRDNWRSEL*# SEQUENCE: FRPGGGDMRDNWRSEL*# ...# >HUM22AFE# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (476-490)# DB REFERENCE: SWISS: (ENV_HV1ND,ENV_HV1B8,ENV_HV1Y2,ENV_HV1H3,ENV_HV1B1,# & ENV_HV1S1,ENV_HV1MF,ENV_HV1EL,ENV_HV1OY,ENV_HV1C4,# & ENV_HV1BR,ENV_HV1Z6,ENV_HV1PV,ENV_HV1MN,ENV_HV1ZH,# & ENV_HV1Z2,ENV_HV1KB,ENV_HV1H2,ENV_HV1JR,ENV_HV1SC,# & ENV_HV1A2)# & PIR1: (VCLJND,VCLJA2,VCLJSC,VCLJH3,H44001,A44963,VCLJVL,VCLJMN,# & VCLJKB,VCLJH4,VCLJLV,VCLJKX,VCLJZR)# & PIR2: (S60522,S60545,S60528,S60532,S60523,S60551,S60535,S60531,# & A41621,S60553,S60554,C41621,S31493,B41621,S60521,S60555,# & S60529,S60547,S60546,S60524,S60548,S54384,S60550,# & S60552)# & PIR3: (S33985,S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DMRDNWRSELYKYKV*# SEQUENCE: DMRDNWRSELYKYKV*# ...# >MUS22AFF# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (478-492)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1BR,ENV_HV1W1,ENV_HV1MF,ENV_HV1ND,# & ENV_HV1H3,ENV_HV1B8,ENV_HV1OY,ENV_HV1J3,ENV_HV1B1,# & ENV_HV1Z2,ENV_HV1ZH,ENV_HV1SC,ENV_HV1BN,ENV_HV1KB,# & ENV_HV1Y2,ENV_HV1S1,ENV_HV1H2,ENV_HV1JR,ENV_HV1Z6,# & ENV_HV1C4)# & PIR1: (VCLJBR,VCLJVL,H44001,VCLJND,VCLJKX,VCLJZR,VCLJH4,VCLJH3,# & VCLJ3W,VCLJKB,VCLJSC,VCLJLV,A44963)# & PIR2: (S60553,S60529,S60535,S60531,S60552,S60551,A40218,C41621,# & S25940,S60548,S60547,S60546,S60524,S60522,S60528,S60545,# & S60532,S60523,S54384,S60555,S60554,S60521)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,RDNWRSELYKYKVVK*# SEQUENCE: RDNWRSELYKYKVVK*# ...# >HUM22B00# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (486-500)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1Z2,ENV_HV1Y2,ENV_HV1Z6,ENV_HV1H2,# & ENV_HV1H3,ENV_HV1B8,ENV_HV1B1,ENV_HV1OY,ENV_HV1C4,# & ENV_HV1BN,ENV_HV1SC,ENV_HV1JR,ENV_HV1S3,ENV_HV1W1,# & ENV_HV1BR,ENV_HV1PV,ENV_HV1S1,ENV_HV1KB)# & PIR1: (VCLJSC,VCLJH4,VCLJ3W,VCLJZR,VCLJKB,VCLJH3,VCLJVL,H44001,# & VCLJBR,VCLJLV,VCLJKX,A44963)# & PIR2: (S60547,S60558,S25940,S60546,S60541,S60545,S60531,S60552,# & S60551,S60526,A40218,S60548,S60543,S60554,S60553,S60555,# & S54384,S60535,S60524,S60528,S60532,S60538,C41621,# & S60529)# & PIR3: (S13288,S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,YKYKVVKIEPLGVAP*# SEQUENCE: YKYKVVKIEPLGVAP*# ...# >HUM22B01# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (487-502)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,KYKVIKIEPLGIAPTC*# SEQUENCE: KYKVIKIEPLGIAPTC*# ...# >MUS22B02# MHC MOLECULE: H-2?, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp120 (489-51)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2?,actyesu,bindyesu,KVVKIEPLGVAPTKAKRRVVQREKRC*# SEQUENCE: KVVKIEPLGVAPTKAKRRVVQREKRC*# ...# >HUM22B03# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (37-51)# DB REFERENCE: SWISS: (ENV_HV1W1,ENV_HV1Z6,ENV_HV1EL,ENV_HV1MF,ENV_HV1A2,# & ENV_HV1S1,ENV_HV1Y2,ENV_HV1B1,ENV_HV1Z2,ENV_HV1ZH,# & ENV_HV1S3,ENV_HV1MA,ENV_HV1PV,ENV_HV1BR,ENV_HV1JR,# & ENV_HV1SC,ENV_HV1H2,ENV_HV1RH,ENV_HV1OY,ENV_HV1H3,# & ENV_HV1MN,ENV_HV1Z8)# & PIR1: (VCLJMN,VCLJH3,VCLJA2,VCLJZR,H44001,VCLJLV,VCLJVL,VCLJ3W,# & A44963,VCLJSC)# & PIR2: (S21990,S21998,S60694,S60538,S60705,S60706,S60689,A41621,# & S70421,S70418,S22002,B41621,S54384,S70425,S21994,S22006,# & S70417,S70422,S25940,S60690,S60696,C41621,S60691,S60525,# & S21996,S70420,S70423,S22004,S60695,S60707,S70419,# & S22000)# & PIR3: (S33985,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GIVQQQNNLLRAIEA*# SEQUENCE: GIVQQQNNLLRAIEA*# ...# >HUM22B04# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (52-66)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1H2,ENV_HV1PV,ENV_HV1BR,ENV_HV1OY,# & ENV_HV1C4,ENV_HV1Z2,ENV_HV1B1,ENV_HV1MA,ENV_HV1S3,# & ENV_HV1J3,ENV_HV1Y2,ENV_HV1S1,ENV_HV1A2,ENV_HV1ND,# & ENV_HV1H3,ENV_HV1SC,ENV_HV1W2,ENV_HV1Z6,ENV_HV1KB,# & ENV_HV1W1,ENV_HV1MF,ENV_HV1RH,ENV_HV1EL)# & PIR1: (VCLJVL,VCLJSC,VCLJH4,VCLJH3,VCLJND,VCLJA2,VCLJKB,H44001,# & VCLJKX,VCLJZR,VCLJLV,VCLJ3W)# & PIR2: (S70418,S22006,S70422,S70420,A41621,S22002,S70419,S70421,# & S22004,C41621,S21996,S54384,S70417,S21994,B41621,# & S22000)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,QQHLLQLTVWGIKQL*# SEQUENCE: QQHLLQLTVWGIKQL*# ...# >HUM22B05# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (62-87)# DB REFERENCE: SWISS: (ENV_HV1Z2,ENV_HV1H2,ENV_HV1EL,ENV_HV1MF,ENV_HV1BR,# & ENV_HV1ZH,ENV_HV1Z6,ENV_HV1H3,ENV_HV1B8,ENV_HV1PV,# & ENV_HV1B1,ENV_HV1J3)# & PIR1: (VCLJH3,A44963,VCLJZR,VCLJVL,VCLJLV)# & PIR2: (S21998,S70425,S21996,S54384,S70422)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GIKQLQARILAVERYLKDQQLLGIWG*# SEQUENCE: GIKQLQARILAVERYLKDQQLLGIWG*# ...# >MUS22B06# MHC MOLECULE: H-2?, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (68-98)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1B8,ENV_HV1BR,ENV_HV1MF,ENV_HV1B1,# & ENV_HV1H2,ENV_HV1J3)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR2: (S21996,S70422)# & PIR3: (S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2?,actyesu,bindyesu,ARILAVERYLKDQQLLGIWGCSGKLICTTAV*# SEQUENCE: ARILAVERYLKDQQLLGIWGCSGKLICTTAV*# ...# >HUM22B07# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (84-94)# DB REFERENCE: SWISS: (ENV_HV1J3,ENV_HV1PV,ENV_HV1B8,ENV_HV1S1,ENV_HV1RH,# & ENV_HV1Z2,ENV_HV1OY,ENV_HV1Y2,ENV_HV1BN,ENV_HV1MF,# & ENV_HV1H2,ENV_HV1W1,ENV_HV1B1,ENV_HV1SC,ENV_HV1W2,# & ENV_HV1A2,ENV_HV1Z6,ENV_HV1BR,ENV_HV1JR,ENV_HV1S3)# & PIR1: (VCLJVL,VCLJA2,VCLJBR,VCLJZR,VCLJH3,VCLJSC,VCLJLV,H44001,# & VCLJ3W)# & PIR2: (S70420,A41621,S21996,S70424,C41621,S70419,S22004,S70421,# & S21992,B41621,S21998,S70422,S21994,S70425,S22006,# & S54384)# & PIR3: (S13289,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GIWGCSGKLIC*# SEQUENCE: GIWGCSGKLIC*# ...# >MUS22B08# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (83-94)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,LGLWGCSGKLIC*# SEQUENCE: LGLWGCSGKLIC*# ...# >HUM22B09# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (83-94)# DB REFERENCE: SWISS: (ENV_HV1SC,ENV_HV1A2,ENV_HV1W2,ENV_HV1H2,ENV_HV1W1,# & ENV_HV1BR,ENV_HV1Y2,ENV_HV1BN,ENV_HV1J3,ENV_HV1Z2,# & ENV_HV1OY,ENV_HV1Z6,ENV_HV1PV,ENV_HV1B8,ENV_HV1S1,# & ENV_HV1S3,ENV_HV1B1,ENV_HV1RH,ENV_HV1MF)# & PIR1: (VCLJH3,VCLJLV,H44001,VCLJZR,VCLJ3W,VCLJBR,VCLJSC,VCLJA2,# & VCLJVL)# & PIR2: (S22004,S21992,S21998,S70425,S70419,S70424,C41621,S21994,# & A41621,S70420,S21996,S22006,S54384,S70421,B41621,# & S70422)# & PIR3: (S13289,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,LGIWGCSGKLIC*# SEQUENCE: LGIWGCSGKLIC*# ...# >HUM22B0A# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (81-92)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ELLGIWGCSGKL*# SEQUENCE: ELLGIWGCSGKL*# ...# >HUM22B0B# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (87-98)# DB REFERENCE: SWISS: (ENV_HV1C4,ENV_HV1H2,ENV_HV1B1,ENV_HV1MF,ENV_HV1BR,# & ENV_HV1J3,ENV_HV1B8,ENV_HV1PV,ENV_HV1S1,ENV_HV1JR,# & ENV_HV1A2,ENV_HV1BN)# & PIR1: (VCLJBR,VCLJVL,VCLJH4,VCLJA2,VCLJH3,VCLJLV)# & PIR2: (S22006,C41621,B41621,A41621,S21996,S70422,S70420)# & PIR3: (S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GCSGKLICTTAV*# SEQUENCE: GCSGKLICTTAV*# ...# >HUM22B0C# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (99-106)# DB REFERENCE: SWISS: (ENV_HV1S1,ENV_HV1W2,ENV_HV1BN,ENV_HV1A2,ENV_HV1W1,# & ENV_HV1MN,ENV_HV1BR,ENV_HV1OY,ENV_HV1B1,ENV_HV1MF,# & ENV_HV1J3,ENV_HV1C4,ENV_HV1H3,ENV_HV1B8,ENV_HV1RH,# & ENV_HV1PV,ENV_HV1H2)# & PIR1: (VCLJBR,VCLJVL,VCLJH3,VCLJH4,VCLJMN,VCLJ3W,VCLJLV,# & VCLJA2)# & PIR2: (S21998,B41621,A41621,S70417,S22002,S21990,S70418,S70425,# & S22000,S70423)# & PIR3: (S13288,S33985,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PWNASWSN*# SEQUENCE: PWNASWSN*# ...# >HUM22B0D# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (104-119)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,WSNKSLEDIWDNMTWC*# SEQUENCE: WSNKSLEDIWDNMTWC*# ...# >HUM22B0E# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (124-139)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EIDNYTNTIYTLLEEC*# SEQUENCE: EIDNYTNTIYTLLEEC*# ...# >HUM22B0F# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (137-151)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1BR,ENV_HV1OY,ENV_HV1H3,ENV_HV1B8,# & ENV_HV1H2,ENV_HV1S3,ENV_HV1RH,ENV_HV1W1,ENV_HV1SC,# & ENV_HV1J3,ENV_HV1B1,ENV_HV1S1,ENV_HV1A2)# & PIR1: (VCLJVL,VCLJSC,VCLJH3,VCLJA2,VCLJ3W,VCLJLV)# & PIR2: (S22004,S21994,S21996,C41621,S70420,S22006,S70421,S70422,# & S70419)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,EESQNQQEKNEQELL*# SEQUENCE: EESQNQQEKNEQELL*# ...# >HUM22B10# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (133-145)# DB REFERENCE: SWISS: (ENV_HV1B8,ENV_HV1H2,ENV_HV1B1,ENV_HV1H3,ENV_HV1PV,# & ENV_HV1BR)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,HSLIEESQNQQEK*# SEQUENCE: HSLIEESQNQQEK*# ...# >HUM22B11# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (157-171)# DB REFERENCE: SWISS: (ENV_HV1H3,ENV_HV1BN,ENV_HV1MF,ENV_HV1B1,ENV_HV1SC,# & ENV_HV1H2,ENV_HV1BR,ENV_HV1B8)# & PIR1: (VCLJBR,VCLJH3,VCLJLV,VCLJSC)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ASLWNWFNITNWLWY*# SEQUENCE: ASLWNWFNITNWLWY*# ...# >HUM22B12# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (172-186)# DB REFERENCE: SWISS: (ENV_HV1B1,ENV_HV1H2,ENV_HV1H3,ENV_HV1PV,ENV_HV1B8)# & PIR1: (VCLJH3,VCLJVL)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IKLFIMIVGGLVGLR*# SEQUENCE: IKLFIMIVGGLVGLR*# ...# >HUM22B13# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (215-227)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1H2,ENV_HV1JR,ENV_HV1B1,ENV_HV1Z8,# & ENV_HV1Z2,ENV_HV1BN,ENV_HV1KB,ENV_HV1B8,ENV_HV1S1,# & ENV_HV1MN,ENV_HV1J3,ENV_HV1H3,ENV_HV1SC,ENV_HV1OY,# & ENV_HV1W2)# & PIR1: (VCLJH3,VCLJBR,VCLJMN,VCLJKB,VCLJLV,VCLJSC)# & PIR2: (S70420,S21994,S21990,S21998,S70423,S54384,S22004,JT0954,# & S70425,S21996,JU0266,S22006,S70421,S70419,S70422)# & PIR3: (S13288,S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RGPDRPEGIEEEG*# SEQUENCE: RGPDRPEGIEEEG*# ...# >MUS22B14# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (270-284)# DB REFERENCE: SWISS: (ENV_HV1S1,ENV_HV1PV,ENV_HV1MF,ENV_HV1RH,ENV_HV1SC,# & ENV_HV1B8,ENV_HV1H3,ENV_HV1J3,ENV_HV1BR,ENV_HV1W1,# & ENV_HV1H2,ENV_HV1ND,ENV_HV1B1,ENV_HV1MA,ENV_HV1Z6,# & ENV_HV1Z2,ENV_HV1W2)# & PIR1: (VCLJLV,VCLJND,VCLJ3W,VCLJSC,VCLJVL,VCLJZR,VCLJH3)# & PIR2: (S22002,S70423,S21992,S54384,S21990,S70417,S70418,# & S70424)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,RIVELLGRRGWEALK*# SEQUENCE: RIVELLGRRGWEALK*# ...# >MUS22B15# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (270-284)# DB REFERENCE: SWISS: (ENV_HV1W2,ENV_HV1B1,ENV_HV1H2,ENV_HV1BR,ENV_HV1H3,# & ENV_HV1MA,ENV_HV1Z2,ENV_HV1MF,ENV_HV1PV,ENV_HV1B8,# & ENV_HV1J3,ENV_HV1ND,ENV_HV1W1,ENV_HV1S1,ENV_HV1SC,# & ENV_HV1RH,ENV_HV1Z6)# & PIR1: (VCLJND,VCLJH3,VCLJLV,VCLJ3W,VCLJSC,VCLJVL,VCLJZR)# & PIR2: (S70418,S70417,S21992,S54384,S21990,S22002,S70423,# & S70424)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,RIVELLGRRGWEALK*# SEQUENCE: RIVELLGRRGWEALK*# ...# >MUS22B16# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (284-298)# DB REFERENCE: SWISS: (ENV_HV1C4,ENV_HV1BN,ENV_HV1PV,ENV_HV1MF,ENV_HV1B8,# & ENV_HV1J3,ENV_HV1BR,ENV_HV1H2,ENV_HV1B1,ENV_HV1H3,# & ENV_HV1JR,ENV_HV1RH,ENV_HV1OY,ENV_HV1MN)# & PIR1: (VCLJVL,VCLJH4,VCLJBR,VCLJMN,VCLJH3,VCLJLV)# & PIR2: (S70421,S70422,S21992,S21994,S70424,S21996)# & PIR3: (S33985,S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KYWWNLLQYWSQELK*# SEQUENCE: KYWWNLLQYWSQELK*# ...# >MUS22B17# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (289-303)# DB REFERENCE: SWISS: (ENV_HV1C4,ENV_HV1RH,ENV_HV1MF,ENV_HV1BN,ENV_HV1KB,# & ENV_HV1JR,ENV_HV1H2,ENV_HV1B1,ENV_HV1BR,ENV_HV1H3,# & ENV_HV1PV,ENV_HV1J3)# & PIR1: (VCLJKB,VCLJH4,VCLJBR,VCLJH3,VCLJLV,VCLJVL)# & PIR2: (S70425,S70422,S21996,S21992,S21998,S70424)# & PIR3: (S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,LLQYWSQELKNSAVS*# SEQUENCE: LLQYWSQELKNSAVS*# ...# >MUS22B18# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (289-303)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1PV,ENV_HV1J3,ENV_HV1JR,ENV_HV1RH,# & ENV_HV1BR,ENV_HV1H2,ENV_HV1C4,ENV_HV1H3,ENV_HV1BN,# & ENV_HV1KB,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJVL,VCLJBR,VCLJH4,VCLJLV,VCLJKB)# & PIR2: (S70422,S21992,S21996,S70425,S21998,S70424)# & PIR3: (S33985,S13289)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,LLQYWSQELKNSAVS*# SEQUENCE: LLQYWSQELKNSAVS*# ...# >HUM22B19# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (304-319)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,WLNATAIAVTEGTDRC*# SEQUENCE: WLNATAIAVTEGTDRC*# ...# >MUS22B1A# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (317-325)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1PV,ENV_HV1B1,ENV_HV1BR,ENV_HV1MF)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,DRVIEVVQG*# SEQUENCE: DRVIEVVQG*# ...# >RHE22B1B# MHC MOLECULE: Mamu-?, CLASS-2, (RHESUS MACAQUE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (317-331)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1MF,ENV_HV1B1)# & PIR1: (VCLJH3,VCLJVL)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: Mamu-?,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >HUM22B1C# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (317-331)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1PV,ENV_HV1B1)# & PIR1: (VCLJVL,VCLJH3)# & PIR3: (S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DRVIEVVQGAYRAIR*# SEQUENCE: DRVIEVVQGAYRAIR*# ...# >MUS22B1D# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (329-338)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1BR,ENV_HV1MF,ENV_HV1H2,ENV_HV1H3,# & ENV_HV1B8,ENV_HV1B1)# & PIR1: (VCLJVL,VCLJLV,VCLJH3)# & PIR2: (S70418,S22002)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,AIRHIPRRIR*# SEQUENCE: AIRHIPRRIR*# ...# >HUM22B1E# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV gp41 (332-346)# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1B1,ENV_HV1B8,ENV_HV1H3,ENV_HV1H2,# & ENV_HV1PV)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,HIPRRIRQGLERILL*# SEQUENCE: HIPRRIRQGLERILL*# ...# >RAT22B1F# MHC MOLECULE: ?, CLASS-2, (RAT)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef(45-67)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1H2)# & PIR1: (ASLJFV)# & PIR2: (S03247,S24985,S03244)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: ?,actyesu,bindyesu,SSNTAATNAACAWLEAQEEEEVGFP*# SEQUENCE: SSNTAATNAACAWLEAQEEEEVGFP*# ...# >CHI22B20# MHC MOLECULE: Patr-?, CLASS-2, (CHIMPANZEE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV nef(45-67)# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1H2)# & PIR1: (ASLJFV)# & PIR2: (S24985,S03247,S03244)# ANCHOR POSITIONS: ?# REFERENCES: hivdb97a# COMMENT:# SUMMARY: Patr-?,actyesu,bindyesu,SSNTAATNAACAWLEAQEEEEVGFP*# SEQUENCE: SSNTAATNAACAWLEAQEEEEVGFP*# ...# >HUM12B21# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: human actin binding protein (2532-2540)# DB REFERENCE: SWISS: (ABP2_HUMAN,ABP2_HUMAN)# & PIR2: (A37098)# ANCHOR POSITIONS: ?# REFERENCES: gavioli96a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesu,SVFVDSLTK*# SEQUENCE: SVFVDSLTK*# ...# >HUM12B22# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV EBNA6 (98-106)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR1: (QQBE25)# & PIR2: (A31666)# ANCHOR POSITIONS: ?# REFERENCES: gavioli96a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,LPPHDITPY*# SEQUENCE: LPPHDITPY*# ...# >HUM12B23# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: EBV EBNA4 (399-408)# ANCHOR POSITIONS: ?# REFERENCES: levitsky96a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesu,AVFDRKSVAK*# SEQUENCE: AVFDRKSVAK*# ...# >HUM12B24# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesh,QYDDAVYKL*# SEQUENCE: QYDDAVYKL*# ...# >HUM12B25# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesh,SYDDAVYKL*# SEQUENCE: SYDDAVYKL*# ...# >HUM12B26# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesm,QYDAAVYKL*# SEQUENCE: QYDAAVYKL*# ...# >HUM12B27# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesm,QYDDRVYKL*# SEQUENCE: QYDDRVYKL*# ...# >HUM12B28# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesm,QYDDAGYKL*# SEQUENCE: QYDDAGYKL*# ...# >HUM12B29# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesh,QYDDAVAKL*# SEQUENCE: QYDDAVAKL*# ...# >HUM12B2A# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesm,QYDDAVEKL*# SEQUENCE: QYDDAVEKL*# ...# >HUM12B2B# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesm,QYDDAVYHL*# SEQUENCE: QYDDAVYHL*# ...# >HUM12B2C# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesh,QYDDAVYFL*# SEQUENCE: QYDDAVYFL*# ...# >HUM12B2D# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesm,QYDDAVYSL*# SEQUENCE: QYDDAVYSL*# ...# >HUM12B2E# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesh,QYDDAVYRL*# SEQUENCE: QYDDAVYRL*# ...# >HUM12B2F# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesh,QYDDAVYEL*# SEQUENCE: QYDDAVYEL*# ...# >HUM12B30# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesh,QYDDAVYDL*# SEQUENCE: QYDDAVYDL*# ...# >HUM12B31# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: Stabilization/HLA assembly# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: rajagopalan97a# COMMENT:# SUMMARY: HLA-Cw4,actunkn,bindyesm,QYDDAVYKF*# SEQUENCE: QYDDAVYKF*# ...# >HUM12B32# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p24 gag (302-320)# DB REFERENCE: SWISS: (GAG_HV1B5,GAG_HV1MN,GAG_HV1BR,GAG_HV1C4,GAG_HV1N5,# & GAG_HV1PV,GAG_HV1B1,GAG_HV1J3,GAG_HV1Y2,GAG_HV1H2)# & PIR1: (FOVWLV,A44001,FOVWVL,A38068,FOVWH3,FOVWH4)# & PIR2: (S60708,S60697,S60699,S60700)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: buseyne97a# COMMENT:# SUMMARY: HLA-Cw4,actyesl,bindyesu,KTLRAEQASQEVKNWMTET*# SEQUENCE: KTLRAEQASQEVKNWMTET*# ...# >HUM12B33# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p24 gag (308-320)# DB REFERENCE: SWISS: (GAG_HV1MN,GAG_HV1Y2,GAG_HV1B1,GAG_HV1J3,GAG_HV1B5,# & GAG_HV1H2,GAG_HV1PV,GAG_HV1BR,GAG_HV1N5,GAG_HV1C4)# & PIR1: (FOVWVL,FOVWH4,FOVWLV,A38068,A44001,FOVWH3)# & PIR2: (S60699,S60708,S60697,S60700)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: buseyne97a# COMMENT:# SUMMARY: HLA-Cw4,actyesm,bindyesu,QASQEVKNWMTET*# SEQUENCE: QASQEVKNWMTET*# ...# >HUM12B34# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p24 gag (308-317)# DB REFERENCE: SWISS: (GAG_HV1C4,GAG_HV1MN,GAG_HV1Y2,GAG_HV1J3,GAG_HV1B1,# & GAG_HV1B5,GAG_HV1PV,GAG_HV1N5,GAG_HV1BR,GAG_SIVCZ,# & GAG_HV1H2)# & PIR1: (FOVWVL,FOVWH4,A44001,FOVWH3,A38068,FOLJSI,FOVWLV)# & PIR2: (S60699,S60708,S60697,S60700)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: buseyne97a# COMMENT:# SUMMARY: HLA-Cw4,actyesm,bindyesu,QASQEVKNWM*# SEQUENCE: QASQEVKNWM*# ...# >HUM12B35# MHC MOLECULE: HLA-Cw4(Cw*0401), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p24 gag (308-316)# DB REFERENCE: SWISS: (GAG_SIVCZ,GAG_HV1PV,GAG_HV1B5,GAG_HV1BR,GAG_HV1N5,# & GAG_HV1H2,GAG_HV1C4,GAG_HV1Y2,GAG_HV1B1,GAG_HV1J3,# & GAG_HV1MN)# & PIR1: (FOVWH3,A44001,A38068,FOLJSI,FOVWH4,FOVWLV,FOVWVL)# & PIR2: (S60697,S60700,S60708,S60699)# & PIR3: (S33979)# ANCHOR POSITIONS: ?# REFERENCES: buseyne97a# COMMENT:# SUMMARY: HLA-Cw4,actyesm,bindyesu,QASQEVKNW*# SEQUENCE: QASQEVKNW*# ...# >HUM12B36# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1H2,NEF_HV1B1,NEF_HV1PV,NEF_HV112)# & PIR1: (ASLJFV,ASLJH3,ASLJVL,ASLJ12)# & PIR2: (S03244,S03247,S03245,S43467)# & PIR3: (S33986,S07344)# ANCHOR POSITIONS: ?# REFERENCES: goulder97a# COMMENT:# SUMMARY: HLA-B7,actyesm,bindyesu,HSQRRQDILDLWIY*# SEQUENCE: HSQRRQDILDLWIY*# ...# >HUM12B37# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: goulder97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,TVYGVPVWK*# SEQUENCE: TVYGVPVWK*# ...# >HUM12B38# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HIV p17 gag (77-85)# DB REFERENCE: SWISS: (GAG_HV1N5)# ANCHOR POSITIONS: ?# REFERENCES: goulder97a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesu,SLYNTIAVL*# SEQUENCE: SLYNTIAVL*# ...# >HUM12B39# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV p17 gag (77-85)# DB REFERENCE: SWISS: (GAG_HV1Z2,GAG_HV1J3)# & PIR2: (S54377)# ANCHOR POSITIONS: ?# REFERENCES: goulder97a# COMMENT:# SUMMARY: HLA-A2,actyesl,bindyesu,SLFNTVATL*# SEQUENCE: SLFNTVATL*# ...# >HUM12B3A# MHC MOLECULE: HLA-B62, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HIV p24# DB REFERENCE: SWISS: (GAG_HV1Y2,GAG_HV1MN,GAG_HV1U4,GAG_HV1B5,GAG_HV1W2,# & GAG_HV1EL,GAG_HV1MA,GAG_HV1C4,GAG_HV1PV,GAG_HV1Z2,# & GAG_HV1ND,GAG_HV1J3,GAG_HV1JR,GAG_HV1H2,GAG_HV1OY,# & GAG_HV1A2,GAG_HV1N5,GAG_HV1B1,GAG_HV1BR,GAG_HV1RH)# & PIR1: (FOVWA2,FOLJND,FOVWVL,A38068,A44001,FOVWH3,FOVWH4,# & FOVWLV)# & PIR2: (S60704,S60698,S60699,S60697,S54377,S60702,S60708,# & S60703)# & PIR3: (S33979,S19598)# ANCHOR POSITIONS: ?# REFERENCES: goulder97a# COMMENT:# SUMMARY: HLA-B62,actyesh,bindyesu,GLNKIVRMY*# SEQUENCE: GLNKIVRMY*# ...# >HUM12B3B# MHC MOLECULE: HLA-A62, CLASS-1, (HUMAN)# METHOD: CTL assays/Reference# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV pol (476-484)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1MA,POL_HV1BR,POL_HV1PV,POL_HV1B5,# & POL_HV1B1,POL_HV1Z2,POL_HV1Y2,POL_HV1JR,POL_HV1N5,# & POL_HV1H2,POL_HV1MN,POL_HV1RH,POL_HV1ND,POL_HV1OY)# & PIR1: (GNLJND,B44001,GNVWH3,GNVWVL,GNVWLV)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: ?# REFERENCES: goulder97a# COMMENT:# SUMMARY: HLA-A62,actyesl,bindyesu,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >HUM12B3C# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference/CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (GAG_HV1Z2,GAG_HV1EL,GAG_HV1MN,GAG_HV1C4,GAG_HV1RH,# & GAG_HV1W2,GAG_HV1B5,GAG_HV1Y2,GAG_HV1PV,GAG_HV1A2,# & GAG_HV1ND,GAG_HV1H2,GAG_HV1N5,GAG_HV1BR,GAG_HV1B1,# & GAG_HV1OY,GAG_HV1J3,GAG_HV1JR)# & PIR1: (A44001,FOVWVL,FOVWLV,A38068,FOVWH3,FOLJND,FOVWA2,# & FOVWH4)# & PIR2: (S60699,S60697,S60703,S54377,S60702,S60708,S60700,S60704,# & S60698)# & PIR3: (S19598,S33979)# ANCHOR POSITIONS: ?# REFERENCES: goulder97a,goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,EIYKRWII*# SEQUENCE: EIYKRWII*# ...# >HUM12B3D# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Molecular modeling# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV-1 gag# ANCHOR POSITIONS: ?# REFERENCES: goulder97b# COMMENT:# SUMMARY: HLA-B8,actunkn,bindyesu,GGRKKYKL*# SEQUENCE: GGRKKYKL*# ...# >HUM12B3E# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HIV-1 gp41# DB REFERENCE: SWISS: (ENV_HV1BR,ENV_HV1S1,ENV_HV1JR,ENV_HV1J3,ENV_HV1OY,# & ENV_HV1B8,ENV_HV1KB,ENV_HV1MN,ENV_HV1Z8,ENV_HV1MF,# & ENV_HV1ZH,ENV_HV1Z6,ENV_HV1PV,ENV_HV1BN,ENV_HV1Z2,# & ENV_HV1H2,ENV_HV1EL,ENV_HV1H3,ENV_HV1C4,ENV_HV1B1)# & PIR1: (VCLJMN,VCLJH3,VCLJKB,VCLJH4,VCLJKX,VCLJLV,VCLJBR,VCLJVL,# & A44963,VCLJZR)# & PIR2: (S21990,S70417,S70422,S70421,B41621,S70418,S22002,S70423,# & S22006,S22000,S70420,S70425,S70424,S21998,S21994,S21996,# & S70419,S54384,S22004,S21992)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesu,bindyesu,YLKDQQL*# SEQUENCE: YLKDQQL*# ...# >HUM12B3F# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 nef# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1SC)# & PIR1: (ASLJFV)# & PIR3: (S07344)# ANCHOR POSITIONS: ?# REFERENCES: goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,VVGWPTVRERM*# SEQUENCE: VVGWPTVRERM*# ...# >HUM12B40# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 nef# DB REFERENCE: SWISS: (NEF_HV1SC,NEF_HV1MN,NEF_HV1Y2,NEF_HV1BR)# & PIR1: (I44001,ASLJFV)# & PIR2: (S03244,S24985,S25937)# & PIR3: (S07344)# ANCHOR POSITIONS: ?# REFERENCES: goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,GWPTVRERMR*# SEQUENCE: GWPTVRERMR*# ...# >HUM12B41# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 nef# DB REFERENCE: SWISS: (NEF_HV1BR,NEF_HV1Y2,NEF_HV1MN)# & PIR1: (ASLJFV,I44001)# & PIR2: (S25937,S24985,S03244)# & PIR3: (S07344)# ANCHOR POSITIONS: ?# REFERENCES: goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,WPTVRERMRR*# SEQUENCE: WPTVRERMRR*# ...# >HUM12B42# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 nef# DB REFERENCE: SWISS: (NEF_HV1SC,NEF_HV1Y2,NEF_HV1BR,NEF_HV1MN)# & PIR1: (ASLJFV,I44001)# & PIR2: (S24985,S25937,S03244)# & PIR3: (S07344)# ANCHOR POSITIONS: ?# REFERENCES: goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,GWPTVRERM*# SEQUENCE: GWPTVRERM*# ...# >HUM12B43# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV-1 nef# DB REFERENCE: SWISS: (NEF_HV1SC,NEF_HV1MN,NEF_HV1BR,NEF_HV1Y2)# & PIR1: (ASLJFV,I44001)# & PIR2: (S03244,S24985,S25937)# & PIR3: (S07344)# ANCHOR POSITIONS: ?# REFERENCES: goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesl,bindyesu,WPTVRERMR*# SEQUENCE: WPTVRERMR*# ...# >HUM12B44# MHC MOLECULE: HLA-B8, CLASS-1, (HUMAN)# METHOD: CTL assays/Stabilization# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: HIV-1 nef# DB REFERENCE: SWISS: (NEF_HV2NZ,NEF_SIVM1,NEF_SIVML,NEF_HV2CA,NEF_HV2BE,# & NEF_SIVSP,NEF_SIVMK,NEF_SIVGB,NEF_SIVMA,NEF_HV2D1,# & NEF_SIVS4)# & PIR1: (ASLJCZ,ASLJM3,ASLJMA,ASLJM5,ASLJRT)# & PIR2: (S54851,S54853,S54865,S54866,S54867,S12160,S03069,S03071,# & S53099,S07993,S54852,S54859,S54849,S28085)# ANCHOR POSITIONS: ?# REFERENCES: goulder97b# COMMENT:# SUMMARY: HLA-B8,actyesm,bindyesm,FIKEKGGL*# SEQUENCE: FIKEKGGL*# ...# >HUM12B45# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (14-23)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLIFFDLFLV*# SEQUENCE: FLIFFDLFLV*# ...# >HUM12B46# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (80-88)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,VLAGLLGNV*# SEQUENCE: VLAGLLGNV*# ...# >HUM12B47# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum CSP (394-403)# DB REFERENCE: SWISS: (CSP_PLAFO,CSP_PLAFA,CSP_PLAFT,CSP_PLARE,CSP_PLAFW)# & PIR1: (OZZQAF)# & PIR2: (A54533,A54529,A39756,S05428)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,GLIMVLSFL*# SEQUENCE: GLIMVLSFL*# ...# >HUM12B48# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (2-10)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,KILSVFFLA*# SEQUENCE: KILSVFFLA*# ...# >HUM12B49# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (83-91)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,GLLGNVSTV*# SEQUENCE: GLLGNVSTV*# ...# >HUM12B4A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum Exp-1 (91-100)# DB REFERENCE: SWISS: (EXP1_PLAFA,CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780,A26769)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,VLLGGVGLVL*# SEQUENCE: VLLGGVGLVL*# ...# >HUM12B4B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum CSP (7-16)# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLAFO,CSP_PLAFT,CSP_PLARE,CSP_PLAFW)# & PIR1: (OZZQAF)# & PIR2: (S05428,A39756,A54529,A54533)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,ILSVSSFLFV*# SEQUENCE: ILSVSSFLFV*# ...# >HUM12B4C# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (14-23)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLIFFDLFLV*# SEQUENCE: FLIFFDLFLV*# ...# >HUM12B4D# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (80-88)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,VLAGLLGNV*# SEQUENCE: VLAGLLGNV*# ...# >HUM12B4E# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CSP (394-403)# DB REFERENCE: SWISS: (CSP_PLAFO,CSP_PLAFW,CSP_PLAFT,CSP_PLARE,CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (S05428,A54529,A54533,A39756)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLIMVLSFL*# SEQUENCE: GLIMVLSFL*# ...# >HUM12B4F# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum Exp-1 (2-10)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,KILSVFFLA*# SEQUENCE: KILSVFFLA*# ...# >HUM12B50# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (83-91)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GLLGNVSTV*# SEQUENCE: GLLGNVSTV*# ...# >HUM12B51# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum CSP (7-16)# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLARE,CSP_PLAFO,CSP_PLAFW,CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (A54529,A54533,A39756,S05428)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILSVSSFLFV*# SEQUENCE: ILSVSSFLFV*# ...# >HUM12B52# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (14-23)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLIFFDLFLV*# SEQUENCE: FLIFFDLFLV*# ...# >HUM12B53# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (80-88)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,VLAGLLGNV*# SEQUENCE: VLAGLLGNV*# ...# >HUM12B54# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CSP (394-403)# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLARE,CSP_PLAFO,CSP_PLAFT,CSP_PLAFW)# & PIR1: (OZZQAF)# & PIR2: (A54529,A54533,A39756,S05428)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLIMVLSFL*# SEQUENCE: GLIMVLSFL*# ...# >HUM12B55# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (2-10)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KILSVFFLA*# SEQUENCE: KILSVFFLA*# ...# >HUM12B56# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (83-91)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLLGNVSTV*# SEQUENCE: GLLGNVSTV*# ...# >HUM12B57# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (91-100)# DB REFERENCE: SWISS: (CRA_PLAFA,EXP1_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A26769,A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,VLLGGVGLVL*# SEQUENCE: VLLGGVGLVL*# ...# >HUM12B58# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CSP (7-16)# DB REFERENCE: SWISS: (CSP_PLAFW,CSP_PLAFA,CSP_PLAFO,CSP_PLAFT,CSP_PLARE)# & PIR1: (OZZQAF)# & PIR2: (A54533,A39756,A54529,S05428)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ILSVSSFLFV*# SEQUENCE: ILSVSSFLFV*# ...# >HUM12B59# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (14-23)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLIFFDLFLV*# SEQUENCE: FLIFFDLFLV*# ...# >HUM12B5A# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (80-88)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,VLAGLLGNV*# SEQUENCE: VLAGLLGNV*# ...# >HUM12B5B# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CSP (394-403)# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLAFW,CSP_PLAFO,CSP_PLAFT,CSP_PLARE)# & PIR1: (OZZQAF)# & PIR2: (S05428,A54533,A39756,A54529)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GLIMVLSFL*# SEQUENCE: GLIMVLSFL*# ...# >HUM12B5C# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (2-10)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,KILSVFFLA*# SEQUENCE: KILSVFFLA*# ...# >HUM12B5D# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (83-91)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLLGNVSTV*# SEQUENCE: GLLGNVSTV*# ...# >HUM12B5E# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum Exp-1 (91-100)# DB REFERENCE: SWISS: (CRA_PLAFA,EXP1_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A26769,A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,VLLGGVGLVL*# SEQUENCE: VLLGGVGLVL*# ...# >HUM12B5F# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum CSP (7-16)# DB REFERENCE: SWISS: (CSP_PLAFT,CSP_PLAFW,CSP_PLARE,CSP_PLAFO,CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (A54533,A54529,S05428,A39756)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ILSVSSFLFV*# SEQUENCE: ILSVSSFLFV*# ...# >HUM12B60# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (14-23)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,FLIFFDLFLV*# SEQUENCE: FLIFFDLFLV*# ...# >HUM12B61# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (80-88)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,VLAGLLGNV*# SEQUENCE: VLAGLLGNV*# ...# >HUM12B62# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum CSP (394-403)# DB REFERENCE: SWISS: (CSP_PLAFT,CSP_PLAFW,CSP_PLAFA,CSP_PLARE,CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (S05428,A54533,A39756,A54529)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,GLIMVLSFL*# SEQUENCE: GLIMVLSFL*# ...# >HUM12B63# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum CSP (7-16)# DB REFERENCE: SWISS: (CSP_PLAFT,CSP_PLARE,CSP_PLAFO,CSP_PLAFW,CSP_PLAFA)# & PIR1: (OZZQAF)# & PIR2: (A54529,S05428,A39756,A54533)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,ILSVSSFLFV*# SEQUENCE: ILSVSSFLFV*# ...# >HUM12B64# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (94-102)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,QTNFKSLLR*# SEQUENCE: QTNFKSLLR*# ...# >HUM12B65# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (523-531)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesm,LACAGLAYK*# SEQUENCE: LACAGLAYK*# ...# >HUM12B66# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (10-18)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,ALFFIIFNK*# SEQUENCE: ALFFIIFNK*# ...# >HUM12B67# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (522-531)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,LLACAGLAYK*# SEQUENCE: LLACAGLAYK*# ...# >HUM12B68# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (105-113)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesm,GVSENIFLK*# SEQUENCE: GVSENIFLK*# ...# >HUM12B69# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (59-68)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesm,HVLSHNSYEK*# SEQUENCE: HVLSHNSYEK*# ...# >HUM12B6A# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (11-20)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesl,FILVNLLIFH*# SEQUENCE: FILVNLLIFH*# ...# >HUM12B6B# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (49-57)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,RINEEKHEK*# SEQUENCE: RINEEKHEK*# ...# >HUM12B6C# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (2-10)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,KILSVFFLA*# SEQUENCE: KILSVFFLA*# ...# >HUM12B6D# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (1855-1863)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,SLYDEHIKK*# SEQUENCE: SLYDEHIKK*# ...# >HUM12B6E# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (60-68)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,VLSHNSYEK*# SEQUENCE: VLSHNSYEK*# ...# >HUM12B6F# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum Exp-1 (28-36)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,GTGSGVSSK*# SEQUENCE: GTGSGVSSK*# ...# >HUM12B70# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (111-119)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,FLKENKLNK*# SEQUENCE: FLKENKLNK*# ...# >HUM12B71# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (522-530)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,LLACAGLAY*# SEQUENCE: LLACAGLAY*# ...# >HUM12B72# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CSP (85-93)# DB REFERENCE: SWISS: (CSP_PLAFL,CSP_PLAFW,CSP_PLAFA,CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (B29795,S05428,A54529,A29795)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,KLRKPKHKK*# SEQUENCE: KLRKPKHKK*# ...# >HUM12B73# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (102-111)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,RLHSDASKNK*# SEQUENCE: RLHSDASKNK*# ...# >HUM12B74# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum Exp-1 (99-107)# DB REFERENCE: SWISS: (CRA_PLAFA,EXP1_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780,A26769)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,VLYNTEKGR*# SEQUENCE: VLYNTEKGR*# ...# >HUM12B75# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (100-109)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,IIRLHSDASK*# SEQUENCE: IIRLHSDASK*# ...# >HUM12B76# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (521-530)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,ALLACAGLAY*# SEQUENCE: ALLACAGLAY*# ...# >HUM12B77# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (16-24)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,LLIFHINGK*# SEQUENCE: LLIFHINGK*# ...# >HUM12B78# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (1854-1863)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,KSLYDEHIKK*# SEQUENCE: KSLYDEHIKK*# ...# >HUM12B79# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (28-37)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,GTGSGVSSKK*# SEQUENCE: GTGSGVSSKK*# ...# >HUM12B7A# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum SSP2 (120-128)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,SLLSTNLPY*# SEQUENCE: SLLSTNLPY*# ...# >HUM12B7B# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (94-102)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,QTNFKSLLR*# SEQUENCE: QTNFKSLLR*# ...# >HUM12B7C# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (523-531)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,LACAGLAYK*# SEQUENCE: LACAGLAYK*# ...# >HUM12B7D# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CSP (344-353)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,VTCGNGIQVP*# SEQUENCE: VTCGNGIQVP*# ...# >HUM12B7E# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (10-18)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,ALFFIIFNK*# SEQUENCE: ALFFIIFNK*# ...# >HUM12B7F# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (522-531)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,LLACAGLAYK*# SEQUENCE: LLACAGLAYK*# ...# >HUM12B80# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (105-113)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,GVSENIFLK*# SEQUENCE: GVSENIFLK*# ...# >HUM12B81# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (59-68)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,HVLSHNSYEK*# SEQUENCE: HVLSHNSYEK*# ...# >HUM12B82# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (11-20)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,FILVNLLIFH*# SEQUENCE: FILVNLLIFH*# ...# >HUM12B83# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (49-57)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,RINEEKHEK*# SEQUENCE: RINEEKHEK*# ...# >HUM12B84# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (2-10)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,KILSVFFLA*# SEQUENCE: KILSVFFLA*# ...# >HUM12B85# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (1855-1863)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,SLYDEHIKK*# SEQUENCE: SLYDEHIKK*# ...# >HUM12B86# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (60-68)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,VLSHNSYEK*# SEQUENCE: VLSHNSYEK*# ...# >HUM12B87# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Exp-1 (28-36)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,GTGSGVSSK*# SEQUENCE: GTGSGVSSK*# ...# >HUM12B88# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (111-119)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,FLKENKLNK*# SEQUENCE: FLKENKLNK*# ...# >HUM12B89# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum SSP2 (522-530)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,LLACAGLAY*# SEQUENCE: LLACAGLAY*# ...# >HUM12B8A# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum SSP2 (102-111)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,RLHSDASKNK*# SEQUENCE: RLHSDASKNK*# ...# >HUM12B8B# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (99-107)# DB REFERENCE: SWISS: (CRA_PLAFA,EXP1_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A26769,A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,VLYNTEKGR*# SEQUENCE: VLYNTEKGR*# ...# >HUM12B8C# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum SSP2 (521-530)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,ALLACAGLAY*# SEQUENCE: ALLACAGLAY*# ...# >HUM12B8D# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (16-24)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,LLIFHINGK*# SEQUENCE: LLIFHINGK*# ...# >HUM12B8E# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (1854-1863)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,KSLYDEHIKK*# SEQUENCE: KSLYDEHIKK*# ...# >HUM12B8F# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum Exp-1 (28-37)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,GTGSGVSSKK*# SEQUENCE: GTGSGVSSKK*# ...# >HUM12B90# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (120-128)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,SLLSTNLPY*# SEQUENCE: SLLSTNLPY*# ...# >HUM12B91# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (1854-1863)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,KSLYDEHIK*# SEQUENCE: KSLYDEHIK*# ...# >HUM12B92# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (307-315)# DB REFERENCE: PIR2: (A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,RGDNFAVEK*# SEQUENCE: RGDNFAVEK*# ...# >HUM12B93# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (94-102)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,QTNFKSLLR*# SEQUENCE: QTNFKSLLR*# ...# >HUM12B94# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum CSP (344-353)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,VTCGNGIQVP*# SEQUENCE: VTCGNGIQVP*# ...# >HUM12B95# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (10-18)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,ALFFIIFNK*# SEQUENCE: ALFFIIFNK*# ...# >HUM12B96# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum SSP2 (522-531)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,LLACAGLAYK*# SEQUENCE: LLACAGLAYK*# ...# >HUM12B97# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (105-113)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,GVSENIFLK*# SEQUENCE: GVSENIFLK*# ...# >HUM12B98# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (11-20)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,FILVNLLIFH*# SEQUENCE: FILVNLLIFH*# ...# >HUM12B99# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (49-57)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,RINEEKHEK*# SEQUENCE: RINEEKHEK*# ...# >HUM12B9A# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum CSP (85-93)# DB REFERENCE: SWISS: (CSP_PLAFO,CSP_PLAFA,CSP_PLAFL,CSP_PLAFW)# & PIR1: (OZZQAF)# & PIR2: (B29795,A54529,S05428,A29795)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,KLRKPKHKK*# SEQUENCE: KLRKPKHKK*# ...# >HUM12B9B# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum CSP (344-353)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesm,VTCGNGIQVP*# SEQUENCE: VTCGNGIQVP*# ...# >HUM12B9C# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (10-18)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesl,ALFFIIFNK*# SEQUENCE: ALFFIIFNK*# ...# >HUM12B9D# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: P. falciparum SSP2 (522-531)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesl,LLACAGLAYK*# SEQUENCE: LLACAGLAYK*# ...# >HUM12B9E# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (11-20)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesm,FILVNLLIFH*# SEQUENCE: FILVNLLIFH*# ...# >HUM12B9F# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (111-119)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,FLKENKLNK*# SEQUENCE: FLKENKLNK*# ...# >HUM12BA0# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (99-107)# DB REFERENCE: SWISS: (CRA_PLAFA,EXP1_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A26769,A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,VLYNTEKGR*# SEQUENCE: VLYNTEKGR*# ...# >HUM12BA1# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum CSP (344-353)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,VTCGNGIQVP*# SEQUENCE: VTCGNGIQVP*# ...# >HUM12BA2# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum Exp-1 (10-18)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,ALFFIIFNK*# SEQUENCE: ALFFIIFNK*# ...# >HUM12BA3# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (522-531)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,LLACAGLAYK*# SEQUENCE: LLACAGLAYK*# ...# >HUM12BA4# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum LSA-1 (105-113)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,GVSENIFLK*# SEQUENCE: GVSENIFLK*# ...# >HUM12BA5# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (59-68)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,HVLSHNSYEK*# SEQUENCE: HVLSHNSYEK*# ...# >HUM12BA6# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (11-20)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,FILVNLLIFH*# SEQUENCE: FILVNLLIFH*# ...# >HUM12BA7# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (1855-1863)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,SLYDEHIKK*# SEQUENCE: SLYDEHIKK*# ...# >HUM12BA8# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum LSA-1 (60-68)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,VLSHNSYEK*# SEQUENCE: VLSHNSYEK*# ...# >HUM12BA9# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (28-36)# DB REFERENCE: SWISS: (CRA_PLAFA)# & PIR2: (A25780)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,GTGSGVSSK*# SEQUENCE: GTGSGVSSK*# ...# >HUM12BAA# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (111-119)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,FLKENKLNK*# SEQUENCE: FLKENKLNK*# ...# >HUM12BAB# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum SSP2 (522-530)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,LLACAGLAY*# SEQUENCE: LLACAGLAY*# ...# >HUM12BAC# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum Exp-1 (99-107)# DB REFERENCE: SWISS: (EXP1_PLAFA,CRA_PLAFA)# & PIR1: (YAZQ51)# & PIR2: (A25780,A26769)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,VLYNTEKGR*# SEQUENCE: VLYNTEKGR*# ...# >HUM12BAD# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum LSA-1 (16-24)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,LLIFHINGK*# SEQUENCE: LLIFHINGK*# ...# >HUM12BAE# MHC MOLECULE: HLA-B7(B*0701), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: P. falciparum Pfs16 (77-86)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesm,MPLETCILAI*# SEQUENCE: MPLETCILAI*# ...# >HUM12BAF# MHC MOLECULE: HLA-B7(B*0701), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (539-548)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesh,TPYAGEPAPF*# SEQUENCE: TPYAGEPAPF*# ...# >HUM12BB0# MHC MOLECULE: HLA-B7(B*0701), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (305-313)# DB REFERENCE: PIR2: (A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B7,actyesu,bindyesh,RPRGDNFAV*# SEQUENCE: RPRGDNFAV*# ...# >HUM12BB1# MHC MOLECULE: HLA-B7(B*0701), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (206-214)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,HPSDGKCNL*# SEQUENCE: HPSDGKCNL*# ...# >HUM12BB2# MHC MOLECULE: HLA-B7(B*0701), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (303-311)# DB REFERENCE: PIR2: (A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,QPRPRGDNF*# SEQUENCE: QPRPRGDNF*# ...# >HUM12BB3# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum Pfs16 (77-86)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesh,MPLETCILAI*# SEQUENCE: MPLETCILAI*# ...# >HUM12BB4# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (539-548)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (A46283,S04531)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesh,TPYAGEPAPF*# SEQUENCE: TPYAGEPAPF*# ...# >HUM12BB5# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Pfs16 (77-86)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,MPLETCILAI*# SEQUENCE: MPLETCILAI*# ...# >HUM12BB6# MHC MOLECULE: HLA-B51(B*5101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum SSP2 (539-548)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesh,TPYAGEPAPF*# SEQUENCE: TPYAGEPAPF*# ...# >HUM12BB7# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: P. falciparum Pfs16 (77-86)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B53,actyesu,bindyesh,MPLETCILAI*# SEQUENCE: MPLETCILAI*# ...# >HUM12BB8# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. falciparum SSP2 (539-548)# DB REFERENCE: SWISS: (TRAP_PLAFA)# & PIR2: (S04531,A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,TPYAGEPAPF*# SEQUENCE: TPYAGEPAPF*# ...# >HUM12BB9# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. falciparum Pfs16 (77-86)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,MPLETCILAI*# SEQUENCE: MPLETCILAI*# ...# >HUM12BBA# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. falciparum SSP2 (305-313)# DB REFERENCE: PIR2: (A46283)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,RPRGDNFAV*# SEQUENCE: RPRGDNFAV*# ...# >HUM12BBB# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CSP (344-353)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesu,VTCGNGIQVP*# SEQUENCE: VTCGNGIQVP*# ...# >HUM12BBC# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum LSA-1 (105-113)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesu,GVSENIFLK*# SEQUENCE: GVSENIFLK*# ...# >HUM12BBD# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: CTL assays/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum LSA-1 (59-68)# DB REFERENCE: PIR2: (A45592)# ANCHOR POSITIONS: ?# REFERENCES: doolan97a# COMMENT:# SUMMARY: HLA-A33,actyesu,bindyesu,HVLSHNSYEK*# SEQUENCE: HVLSHNSYEK*# ...# >HUM12BBE# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: CTL assays/Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HCV NS4 (1863-1872)# DB REFERENCE: SWISS: (POLG_HCVJA,POLG_HCV1,POLG_HCVBK,POLG_HCVJT,POLG_HCVTW,# & POLG_HCVH)# & PIR1: (GNWVTW,GNWVTC,GNWVCH,GNWVCJ,GNWVC3)# & PIR2: (PS0326,S40770,A45573,S18030)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,GVAGALVAFK*# SEQUENCE: GVAGALVAFK*# ...# >HUM12BBF# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: CTL assays/Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HCV NS4 (1863-1872)# DB REFERENCE: SWISS: (POLG_HCVH,POLG_HCV1,POLG_HCVTW,POLG_HCVJA,POLG_HCVJT,# & POLG_HCVBK)# & PIR1: (GNWVCJ,GNWVC3,GNWVTW,GNWVTC,GNWVCH)# & PIR2: (A45573,S40770,PS0326,S18030)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,GVAGALVAFK*# SEQUENCE: GVAGALVAFK*# ...# >HUM12BC0# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (150-159)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBVW,DPOL_HPBV9,DPOL_HPBVR,# & DPOL_HPBV2,DPOL_HPBVO,DPOL_HPBVI,DPOL_HPBVY,DPOL_HPBVM,# & DPOL_HPBVJ,DPOL_HPBV4,DPOL_HPBVT)# & PIR1: (S20757,S20752,S47406,JQ2229,JDVLVS,JDVLVA,JDVLKS,JDVLVR,# & S43491,JDVLJ2,JDVLVD,JDVLVB,JDVLJ1,JDVLJ3)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,TLWKAGILYK*# SEQUENCE: TLWKAGILYK*# ...# >HUM12BC1# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV env (48-57)# DB REFERENCE: SWISS: (ENV_HV1C4,ENV_HV1H2,ENV_HV1B1,ENV_HV1EL,ENV_HV1W1,# & ENV_HV1OY,ENV_HV1ZH,ENV_HV1S3,ENV_HV1MN,ENV_HV1S1,# & ENV_HV1BR,ENV_HV1JR,ENV_HV1J3,ENV_HV1W2,ENV_HV1H3,# & ENV_HV1Z2,ENV_HV1Z6,ENV_HV1N5,ENV_HV1RH,ENV_HV1MA,# & ENV_HV1PV,ENV_HV1Z3,ENV_HV1KB,ENV_HV1BN,ENV_HV1A2,# & ENV_HV1SC,ENV_HV1Z8,ENV_HV1Y2,ENV_HV1MF)# & PIR1: (VCLJSC,VCLJA2,VCLJBR,VCLJH4,A44963,VCLJVL,VCLJZR,VCLJ3W,# & VCLJKB,VCLJH3,VCLJMN,VCLJKX,VCLJLV,H44001)# & PIR2: (S54384,A40218)# & PIR3: (S33985,S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,VTVYYGVPVWK*# SEQUENCE: VTVYYGVPVWK*# ...# >HUM12BC2# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MAGE 1 (96-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,SLFRAVITK*# SEQUENCE: SLFRAVITK*# ...# >HUM12BC3# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE 1 (95-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ESLFRAVITK*# SEQUENCE: ESLFRAVITK*# ...# >HUM12BC4# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (150-159)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVM,DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBVP,# & DPOL_HPBVO,DPOL_HPBVR,DPOL_HPBVW,DPOL_HPBV9,DPOL_HPBVJ,# & DPOL_HPBV4,DPOL_HPBVT,DPOL_HPBV2)# & PIR1: (JDVLJ3,S20752,JDVLVR,JQ2229,JDVLVS,S20757,JDVLKS,JDVLJ2,# & S43491,S47406,JDVLVA,JDVLJ1,JDVLVB,JDVLVD)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,TLWKAGILYK*# SEQUENCE: TLWKAGILYK*# ...# >HUM12BC5# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV env (49-57)# DB REFERENCE: SWISS: (ENV_HV1ZH,ENV_HV1J3,ENV_HV1B1,ENV_HV1C4,ENV_HV1H2,# & ENV_HV1EL,ENV_HV1S3,ENV_HV1OY,ENV_HV1W1,ENV_HV1JR,# & ENV_HV1PV,ENV_HV1MA,ENV_HV1Z6,ENV_HV1N5,ENV_HV1Z2,# & ENV_HV1W2,ENV_HV1S1,ENV_HV1H3,ENV_HV1Z3,ENV_HV1KB,# & ENV_HV1MN,ENV_HV1BR,ENV_HV1SC,ENV_HV1MF,ENV_HV1A2,# & ENV_HV1Z8,ENV_HV1Y2,ENV_HV1RH,ENV_HV1BN)# & PIR1: (VCLJBR,VCLJA2,VCLJKB,VCLJVL,VCLJZR,VCLJKX,VCLJMN,VCLJSC,# & VCLJLV,VCLJH4,H44001,A44963,VCLJ3W,VCLJH3)# & PIR2: (A40218,S54384)# & PIR3: (S13288,S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,TVYYGVPVWK*# SEQUENCE: TVYYGVPVWK*# ...# >HUM12BC6# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HIV env (48-57)# DB REFERENCE: SWISS: (ENV_HV1J3,ENV_HV1ZH,ENV_HV1A2,ENV_HV1BR,ENV_HV1MN,# & ENV_HV1MA,ENV_HV1Z2,ENV_HV1W2,ENV_HV1W1,ENV_HV1S3,# & ENV_HV1C4,ENV_HV1B1,ENV_HV1H2,ENV_HV1JR,ENV_HV1OY,# & ENV_HV1N5,ENV_HV1Z6,ENV_HV1PV,ENV_HV1SC,ENV_HV1Y2,# & ENV_HV1Z8,ENV_HV1MF,ENV_HV1RH,ENV_HV1BN,ENV_HV1KB,# & ENV_HV1Z3,ENV_HV1H3,ENV_HV1EL,ENV_HV1S1)# & PIR1: (VCLJSC,VCLJKX,H44001,VCLJLV,VCLJH4,VCLJA2,VCLJBR,VCLJZR,# & VCLJH3,A44963,VCLJ3W,VCLJMN,VCLJKB,VCLJVL)# & PIR2: (A40218,S54384)# & PIR3: (S33985,S13289,S13288)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,VTVYYGVPVWK*# SEQUENCE: VTVYYGVPVWK*# ...# >HUM12BC7# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: MAGE 1 (96-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,SLFRAVITK*# SEQUENCE: SLFRAVITK*# ...# >HUM12BC8# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE 1 (95-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,ESLFRAVITK*# SEQUENCE: ESLFRAVITK*# ...# >HUM12BC9# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (150-159)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVO,DPOL_HPBVJ,DPOL_HPBVT,DPOL_HPBV4,# & DPOL_HPBVR,DPOL_HPBVP,DPOM_HPBVY,DPOL_HPBVW,DPOL_HPBVY,# & DPOL_HPBV9,DPOL_HPBVI,DPOL_HPBV2)# & PIR1: (JDVLVB,JDVLJ1,JDVLVD,S47406,JDVLVS,JDVLKS,JDVLJ2,JDVLVA,# & JQ2229,JDVLJ3,S20752,S43491,JDVLVR,S20757)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a,bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,TLWKAGILYK*# SEQUENCE: TLWKAGILYK*# ...# >HUM12BCA# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HCV NS4 (1863-1872)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVTW,POLG_HCVJA,POLG_HCVH,POLG_HCVJT,# & POLG_HCVBK)# & PIR1: (GNWVCH,GNWVCJ,GNWVTC,GNWVC3,GNWVTW)# & PIR2: (S40770,A45573,S18030,PS0326)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,GVAGALVAFK*# SEQUENCE: GVAGALVAFK*# ...# >HUM12BCB# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV env (49-57)# DB REFERENCE: SWISS: (ENV_HV1N5,ENV_HV1PV,ENV_HV1C4,ENV_HV1B1,ENV_HV1OY,# & ENV_HV1H2,ENV_HV1MF,ENV_HV1H3,ENV_HV1Z3,ENV_HV1KB,# & ENV_HV1SC,ENV_HV1Z8,ENV_HV1Y2,ENV_HV1BN,ENV_HV1MA,# & ENV_HV1ZH,ENV_HV1J3,ENV_HV1Z2,ENV_HV1W2,ENV_HV1S1,# & ENV_HV1EL,ENV_HV1JR,ENV_HV1S3,ENV_HV1RH,ENV_HV1BR,# & ENV_HV1A2,ENV_HV1W1,ENV_HV1MN,ENV_HV1Z6)# & PIR1: (A44963,VCLJH3,VCLJKB,VCLJMN,VCLJKX,VCLJVL,VCLJLV,H44001,# & VCLJA2,VCLJZR,VCLJBR,VCLJ3W,VCLJH4,VCLJSC)# & PIR2: (A40218,S54384)# & PIR3: (S13288,S13289,S33985)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,TVYYGVPVWK*# SEQUENCE: TVYYGVPVWK*# ...# >HUM12BCC# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HIV env (48-57)# DB REFERENCE: SWISS: (ENV_HV1W1,ENV_HV1MA,ENV_HV1N5,ENV_HV1PV,ENV_HV1Z3,# & ENV_HV1Z2,ENV_HV1A2,ENV_HV1H3,ENV_HV1Y2,ENV_HV1KB,# & ENV_HV1C4,ENV_HV1H2,ENV_HV1OY,ENV_HV1MN,ENV_HV1Z6,# & ENV_HV1S3,ENV_HV1RH,ENV_HV1BR,ENV_HV1EL,ENV_HV1JR,# & ENV_HV1S1,ENV_HV1J3,ENV_HV1ZH,ENV_HV1W2,ENV_HV1BN,# & ENV_HV1Z8,ENV_HV1SC,ENV_HV1B1,ENV_HV1MF)# & PIR1: (VCLJVL,VCLJ3W,VCLJLV,A44963,VCLJMN,VCLJH4,VCLJSC,VCLJBR,# & VCLJKX,VCLJKB,VCLJH3,VCLJZR,VCLJA2,H44001)# & PIR2: (A40218,S54384)# & PIR3: (S13289,S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actyesu,bindyesm,VTVYYGVPVWK*# SEQUENCE: VTVYYGVPVWK*# ...# >HUM12BCD# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE 1 (95-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,ESLFRAVITK*# SEQUENCE: ESLFRAVITK*# ...# >HUM12BCE# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (150-159)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBV2,DPOL_HPBVM,DPOL_HPBVR,DPOL_HPBVJ,# & DPOL_HPBVT,DPOL_HPBV4,DPOL_HPBVI,DPOL_HPBV9,DPOM_HPBVY,# & DPOL_HPBVP,DPOL_HPBVO,DPOL_HPBVW)# & PIR1: (JDVLJ3,JDVLVR,S20752,JQ2229,S47406,JDVLVA,JDVLVD,JDVLJ2,# & JDVLJ1,JDVLKS,JDVLVS,S20757,S43491,JDVLVB)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a,bertoni97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,TLWKAGILYK*# SEQUENCE: TLWKAGILYK*# ...# >HUM12BCF# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HCV NS4 (1863-1872)# DB REFERENCE: SWISS: (POLG_HCV1,POLG_HCVJA,POLG_HCVH,POLG_HCVJT,POLG_HCVBK,# & POLG_HCVTW)# & PIR1: (GNWVC3,GNWVCH,GNWVTC,GNWVCJ,GNWVTW)# & PIR2: (S40770,S18030,PS0326,A45573)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,GVAGALVAFK*# SEQUENCE: GVAGALVAFK*# ...# >HUM12BD0# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV env (49-57)# DB REFERENCE: SWISS: (ENV_HV1BN,ENV_HV1ZH,ENV_HV1W2,ENV_HV1W1,ENV_HV1MA,# & ENV_HV1B1,ENV_HV1N5,ENV_HV1PV,ENV_HV1Z2,ENV_HV1Z3,# & ENV_HV1BR,ENV_HV1S3,ENV_HV1RH,ENV_HV1JR,ENV_HV1S1,# & ENV_HV1EL,ENV_HV1Z8,ENV_HV1SC,ENV_HV1MF,ENV_HV1J3,# & ENV_HV1Z6,ENV_HV1MN,ENV_HV1C4,ENV_HV1H2,ENV_HV1OY,# & ENV_HV1Y2,ENV_HV1A2,ENV_HV1H3,ENV_HV1KB)# & PIR1: (VCLJA2,H44001,VCLJSC,VCLJH3,VCLJMN,VCLJZR,VCLJKB,VCLJH4,# & VCLJBR,VCLJVL,VCLJLV,A44963,VCLJKX,VCLJ3W)# & PIR2: (S54384,A40218)# & PIR3: (S13289,S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,TVYYGVPVWK*# SEQUENCE: TVYYGVPVWK*# ...# >HUM12BD1# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV env (48-57)# DB REFERENCE: SWISS: (ENV_HV1Z8,ENV_HV1SC,ENV_HV1MF,ENV_HV1H3,ENV_HV1W2,# & ENV_HV1ZH,ENV_HV1BN,ENV_HV1PV,ENV_HV1N5,ENV_HV1Z3,# & ENV_HV1W1,ENV_HV1EL,ENV_HV1J3,ENV_HV1Z6,ENV_HV1BR,# & ENV_HV1S1,ENV_HV1S3,ENV_HV1MN,ENV_HV1Y2,ENV_HV1A2,# & ENV_HV1KB,ENV_HV1JR,ENV_HV1RH,ENV_HV1OY,ENV_HV1H2,# & ENV_HV1C4,ENV_HV1B1,ENV_HV1Z2,ENV_HV1MA)# & PIR1: (VCLJH4,VCLJBR,VCLJ3W,VCLJKX,VCLJZR,VCLJKB,H44001,VCLJA2,# & VCLJH3,VCLJVL,VCLJMN,A44963,VCLJLV,VCLJSC)# & PIR2: (A40218,S54384)# & PIR3: (S33985,S13288,S13289)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,VTVYYGVPVWK*# SEQUENCE: VTVYYGVPVWK*# ...# >HUM12BD2# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MAGE 1 (96-104)# DB REFERENCE: SWISS: (MAG1_HUMAN,MAG1_HUMAN)# & PIR2: (JC2358)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,SLFRAVITK*# SEQUENCE: SLFRAVITK*# ...# >HUM12BD3# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,GIFQSSMTK*# SEQUENCE: GIFQSSMTK*# ...# >HUM12BD4# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesh,bindyesh,AAFQSSMTK*# SEQUENCE: AAFQSSMTK*# ...# >HUM12BD5# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,AIAQSSMTK*# SEQUENCE: AIAQSSMTK*# ...# >HUM12BD6# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesh,AIFASSMTK*# SEQUENCE: AIFASSMTK*# ...# >HUM12BD7# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# DB REFERENCE: PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesh,AIFQASMTK*# SEQUENCE: AIFQASMTK*# ...# >HUM12BD8# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesh,bindyesh,AIFQSAMTK*# SEQUENCE: AIFQSAMTK*# ...# >HUM12BD9# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesh,AIFQSSATK*# SEQUENCE: AIFQSSATK*# ...# >HUM12BDA# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesh,AIFQSSMAK*# SEQUENCE: AIFQSSMAK*# ...# >HUM12BDB# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,AIFQSSMTA*# SEQUENCE: AIFQSSMTA*# ...# >HUM12BDC# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesh,bindyesh,FIFQSSMTK*# SEQUENCE: FIFQSSMTK*# ...# >HUM12BDD# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesl,ANFQSSMTK*# SEQUENCE: ANFQSSMTK*# ...# >HUM12BDE# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesl,AYFQSSMTK*# SEQUENCE: AYFQSSMTK*# ...# >HUM12BDF# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesh,AIFQSSMTY*# SEQUENCE: AIFQSSMTY*# ...# >HUM12BE0# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1U4,POL_SIVCZ)# & PIR1: (GNLJSI)# & PIR2: (S32132,S32129,S32152,S32128)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesh,bindyesh,SIFQSSMTK*# SEQUENCE: SIFQSSMTK*# ...# >HUM12BE1# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1N5)# & PIR2: (S32064,S32056,S32087,S32054,S32082,S32140,S32119,S32117,# & S32063,S32120,S32052,S32095,S32085,S32062,S32118,S32122,# & S32059,S32084,S32055,S32077,S32060,S32086,S32127,S32088,# & S32083,S32053,S32057,S32065,S32061,S32151,S32081)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesh,AIFQCSMTK*# SEQUENCE: AIFQCSMTK*# ...# >HUM12BE2# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: PIR2: (C47330)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesh,bindyesh,AIFQSSMTR*# SEQUENCE: AIFQSSMTR*# ...# >HUM12BE3# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,AILQSSMTR*# SEQUENCE: AILQSSMTR*# ...# >HUM12BE4# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesm,bindyesh,AIFQRSMTR*# SEQUENCE: AIFQRSMTR*# ...# >HUM12BE5# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesh,GIFQSSMTK*# SEQUENCE: GIFQSSMTK*# ...# >HUM12BE6# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesh,AAFQSSMTK*# SEQUENCE: AAFQSSMTK*# ...# >HUM12BE7# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesh,AIAQSSMTK*# SEQUENCE: AIAQSSMTK*# ...# >HUM12BE8# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesh,AIFASSMTK*# SEQUENCE: AIFASSMTK*# ...# >HUM12BE9# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# DB REFERENCE: PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesh,AIFQASMTK*# SEQUENCE: AIFQASMTK*# ...# >HUM12BEA# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesh,AIFQSAMTK*# SEQUENCE: AIFQSAMTK*# ...# >HUM12BEB# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesh,AIFQSSATK*# SEQUENCE: AIFQSSATK*# ...# >HUM12BEC# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,AIFQSSMAK*# SEQUENCE: AIFQSSMAK*# ...# >HUM12BED# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesm,AIFQSSMTA*# SEQUENCE: AIFQSSMTA*# ...# >HUM12BEE# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,FIFQSSMTK*# SEQUENCE: FIFQSSMTK*# ...# >HUM12BEF# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,ANFQSSMTK*# SEQUENCE: ANFQSSMTK*# ...# >HUM12BF0# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, little# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesl,AYFQSSMTK*# SEQUENCE: AYFQSSMTK*# ...# >HUM12BF1# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesh,AIFQSSMTY*# SEQUENCE: AIFQSSMTY*# ...# >HUM12BF2# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_SIVCZ,POL_HV1U4)# & PIR1: (GNLJSI)# & PIR2: (S32152,S32132,S32128,S32129)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesh,SIFQSSMTK*# SEQUENCE: SIFQSSMTK*# ...# >HUM12BF3# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1N5)# & PIR2: (S32118,S32122,S32088,S32056,S32087,S32119,S32086,S32060,# & S32052,S32059,S32065,S32057,S32063,S32082,S32077,S32084,# & S32054,S32140,S32053,S32055,S32064,S32085,S32062,S32083,# & S32127,S32095,S32081,S32117,S32120,S32061,S32151)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesh,AIFQCSMTK*# SEQUENCE: AIFQCSMTK*# ...# >HUM12BF4# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: PIR2: (C47330)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesh,bindyesh,AIFQSSMTR*# SEQUENCE: AIFQSSMTR*# ...# >HUM12BF5# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,AILQSSMTR*# SEQUENCE: AILQSSMTR*# ...# >HUM12BF6# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesh,AIFQRSMTR*# SEQUENCE: AIFQRSMTR*# ...# >HUM12BF7# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,AIFASSMTK*# SEQUENCE: AIFASSMTK*# ...# >HUM12BF8# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,AIFQSSATK*# SEQUENCE: AIFQSSATK*# ...# >HUM12BF9# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,AYFQSSMTK*# SEQUENCE: AYFQSSMTK*# ...# >HUM12BFA# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1N5)# & PIR2: (S32084,S32095,S32127,S32082,S32088,S32122,S32140,S32053,# & S32064,S32059,S32065,S32061,S32062,S32086,S32056,S32087,# & S32081,S32117,S32055,S32052,S32063,S32060,S32118,S32057,# & S32120,S32083,S32085,S32054,S32077,S32119,S32151)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,AIFQCSMTK*# SEQUENCE: AIFQCSMTK*# ...# >HUM12BFB# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333)# DB REFERENCE: PIR2: (C47330)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,AIFQSSMTR*# SEQUENCE: AIFQSSMTR*# ...# >HUM12BFC# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,AILQSSMTR*# SEQUENCE: AILQSSMTR*# ...# >HUM12BFD# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesh,AIFQRSMTR*# SEQUENCE: AIFQRSMTR*# ...# >HUM12BFE# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesh,AIFQRSMTR*# SEQUENCE: AIFQRSMTR*# ...# >HUM12BFF# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1Z2,POL_HV1MA,POL_HV1BR,POL_HV1JR,# & POL_HV1ND,POL_HV1OY,POL_HV1EL,POL_HV1PV,POL_HV1MN,# & POL_HV1H2,POL_HV1A2,POL_HV1B5,POL_HV1B1)# & PIR1: (GNVWLV,GNVWA2,GNVWVL,GNLJND,GNVWH3)# & PIR2: (A47175,S32078,S32092,S32134,S32093,S32072,S32135,S32157,# & S32126,S32096,S32051,S32098,S32070,S32048,S54378,S32075,# & S32076,D47330,S32090,S32068,S32074,S32050,S32066,S32047,# & S32071,S32139,S32137,S32091,A47330,S32159,S32160,S32136,# & S32089,S32138,S32049,E47330,S32067,B47330,S43127,S32069,# & B47175,S32079,S32080)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,AIFQSSMTK*# SEQUENCE: AIFQSSMTK*# ...# >HUM12C00# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,GIFQSSMTK*# SEQUENCE: GIFQSSMTK*# ...# >HUM12C01# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,AAFQSSMTK*# SEQUENCE: AAFQSSMTK*# ...# >HUM12C02# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,AIAQSSMTK*# SEQUENCE: AIAQSSMTK*# ...# >HUM12C03# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,AIFASSMTK*# SEQUENCE: AIFASSMTK*# ...# >HUM12C04# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333) homologue# DB REFERENCE: PIR3: (S33980)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,AIFQASMTK*# SEQUENCE: AIFQASMTK*# ...# >HUM12C05# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,AIFQSAMTK*# SEQUENCE: AIFQSAMTK*# ...# >HUM12C06# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,AIFQSSATK*# SEQUENCE: AIFQSSATK*# ...# >HUM12C07# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,AIFQSSMAK*# SEQUENCE: AIFQSSMAK*# ...# >HUM12C08# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,FIFQSSMTK*# SEQUENCE: FIFQSSMTK*# ...# >HUM12C09# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,ANFQSSMTK*# SEQUENCE: ANFQSSMTK*# ...# >HUM12C0A# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_SIVCZ,POL_HV1U4)# & PIR1: (GNLJSI)# & PIR2: (S32129,S32132,S32128,S32152)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,SIFQSSMTK*# SEQUENCE: SIFQSSMTK*# ...# >HUM12C0B# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1N5)# & PIR2: (S32095,S32061,S32086,S32056,S32151,S32054,S32077,S32085,# & S32122,S32052,S32117,S32140,S32060,S32057,S32082,S32062,# & S32083,S32065,S32059,S32064,S32053,S32088,S32120,S32118,# & S32084,S32119,S32055,S32063,S32087,S32081,S32127)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,AIFQCSMTK*# SEQUENCE: AIFQCSMTK*# ...# >HUM12C0C# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333)# DB REFERENCE: PIR2: (C47330)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,AIFQSSMTR*# SEQUENCE: AIFQSSMTR*# ...# >HUM12C0D# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,AILQSSMTR*# SEQUENCE: AILQSSMTR*# ...# >HUM12C0E# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV pol (325-333)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,AIFQRSMTR*# SEQUENCE: AIFQRSMTR*# ...# >HUM12C0F# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,AKFQSSMTK*# SEQUENCE: AKFQSSMTK*# ...# >HUM12C10# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1Y2)# & PIR1: (B44001)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A3,actyesl,bindyesu,AIFQSSMTT*# SEQUENCE: AIFQSSMTT*# ...# >HUM12C11# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HIV pol (325-333) homologue# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesl,bindyesu,AKFQSSMTK*# SEQUENCE: AKFQSSMTK*# ...# >HUM12C12# MHC MOLECULE: HLA-A11(A*1101), CLASS-1, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HIV pol (325-333)# DB REFERENCE: SWISS: (POL_HV1Y2)# & PIR1: (B44001)# ANCHOR POSITIONS: ?# REFERENCES: threlkeld97a# COMMENT:# SUMMARY: HLA-A11,actyesm,bindyesu,AIFQSSMTT*# SEQUENCE: AIFQSSMTT*# ...# >HUM12C13# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV EBNA-3C (284-293)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,H49034,S33015,S27922)# ANCHOR POSITIONS: ?# REFERENCES: shi97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,LLDFVRFMGV*# SEQUENCE: LLDFVRFMGV*# ...# >HUM12C14# MHC MOLECULE: HLA-B37(B*3701), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EBV EBNA-3C (285-293)# DB REFERENCE: SWISS: (EBN6_EBV)# & PIR2: (A31666,H49034,S33015,S27922)# ANCHOR POSITIONS: ?# REFERENCES: shi97a# COMMENT:# SUMMARY: HLA-B37,actyesu,bindyesu,LDFVRFMGV*# SEQUENCE: LDFVRFMGV*# ...# >HUM12C15# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: burrows97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,MPEATVYGL*# SEQUENCE: MPEATVYGL*# ...# >HUM12C16# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: burrows97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,IPIAPVYGM*# SEQUENCE: IPIAPVYGM*# ...# >HUM12C17# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (PYRG_HUMAN,PYRG_MOUSE)# & PIR1: (SYHUTP)# ANCHOR POSITIONS: ?# REFERENCES: burrows97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,KPSPPYFGL*# SEQUENCE: KPSPPYFGL*# ...# >HUM12C18# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: SWISS: (CPCA_HUMAN,CPCI_HUMAN,CPC9_HUMAN)# & PIR2: (D28951,A61269,B38462)# ANCHOR POSITIONS: ?# REFERENCES: burrows97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,KPIVVLHGY*# SEQUENCE: KPIVVLHGY*# ...# >HUM12C19# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: PIR2: (D49253,E49253)# ANCHOR POSITIONS: ?# REFERENCES: burrows97a# COMMENT: Dual specificity B35/B7 of the same T cell clone# SUMMARY: HLA-B35,actyesu,bindyesu,FLRGRAYGL*# SEQUENCE: FLRGRAYGL*# ...# >HUM12C1A# MHC MOLECULE: HLA-B7, CLASS-1, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: PIR2: (E49253,D49253)# ANCHOR POSITIONS: ?# REFERENCES: burrows97a# COMMENT: Dual specificity B35/B7 of the same T cell clone# SUMMARY: HLA-B7,actyesu,bindyesu,FLRGRAYGL*# SEQUENCE: FLRGRAYGL*# ...# >HUM22C1B# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesh,AAFAAAATLKAAA*# SEQUENCE: AAFAAAATLKAAA*# ...# >HUM22C1C# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AKFAAAATLKAAA*# SEQUENCE: AKFAAAATLKAAA*# ...# >HUM22C1D# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AAFAKAATLKAAA*# SEQUENCE: AAFAKAATLKAAA*# ...# >HUM22C1E# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AKFAKANTLKAAA*# SEQUENCE: AKFAKANTLKAAA*# ...# >HUM22C1F# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: alexander93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AKFVKAATLKAAA*# SEQUENCE: AKFVKAATLKAAA*# ...# >HUM22C20# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: poly-Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: alexander93a# COMMENT:# SUMMARY: HLA-DR1,actyesh,bindyesh,AKFVKANTLKAAA*# SEQUENCE: AKFVKANTLKAAA*# ...# >HUM22C21# MHC MOLECULE: HLA-DR52(DRB3*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TT (830-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# ANCHOR POSITIONS: ?# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR52,actunkn,bindyesu,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM22C22# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKFIG*# SEQUENCE: YIKANSKFIG*# ...# >HUM22C23# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,AIKANSKFIG*# SEQUENCE: AIKANSKFIG*# ...# >HUM22C24# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,EIKANSKFIG*# SEQUENCE: EIKANSKFIG*# ...# >HUM22C25# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,SIKANSKFIG*# SEQUENCE: SIKANSKFIG*# ...# >HUM22C26# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YVKANSKFIG*# SEQUENCE: YVKANSKFIG*# ...# >HUM22C27# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIAANSKFIG*# SEQUENCE: YIAANSKFIG*# ...# >HUM22C28# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YISANSKFIG*# SEQUENCE: YISANSKFIG*# ...# >HUM22C29# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIIANSKFIG*# SEQUENCE: YIIANSKFIG*# ...# >HUM22C2A# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIRANSKFIG*# SEQUENCE: YIRANSKFIG*# ...# >HUM22C2B# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKKNSKFIG*# SEQUENCE: YIKKNSKFIG*# ...# >HUM22C2C# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKFNSKFIG*# SEQUENCE: YIKFNSKFIG*# ...# >HUM22C2D# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKSNSKFIG*# SEQUENCE: YIKSNSKFIG*# ...# >HUM22C2E# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesm,YIKANAKFIG*# SEQUENCE: YIKANAKFIG*# ...# >HUM22C2F# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANQKFIG*# SEQUENCE: YIKANQKFIG*# ...# >HUM22C30# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSAFIG*# SEQUENCE: YIKANSAFIG*# ...# >HUM22C31# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSEFIG*# SEQUENCE: YIKANSEFIG*# ...# >HUM22C32# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSRFIG*# SEQUENCE: YIKANSRFIG*# ...# >HUM22C33# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKAIG*# SEQUENCE: YIKANSKAIG*# ...# >HUM22C34# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKSIG*# SEQUENCE: YIKANSKSIG*# ...# >HUM22C35# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKYIG*# SEQUENCE: YIKANSKYIG*# ...# >HUM22C36# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKFAG*# SEQUENCE: YIKANSKFAG*# ...# >HUM22C37# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKFKG*# SEQUENCE: YIKANSKFKG*# ...# >HUM22C38# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKFQG*# SEQUENCE: YIKANSKFQG*# ...# >HUM22C39# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKFVG*# SEQUENCE: YIKANSKFVG*# ...# >HUM22C3A# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (831-840) homologue# ANCHOR POSITIONS: 2,4# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,YIKANSKFIA*# SEQUENCE: YIKANSKFIA*# ...# >HUM22C3B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,TYIKANSKFIGITE*# SEQUENCE: TYIKANSKFIGITE*# ...# >HUM22C3C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,LYIKANSKFIGITE*# SEQUENCE: LYIKANSKFIGITE*# ...# >HUM22C3D# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,NYIKANSKFIGITE*# SEQUENCE: NYIKANSKFIGITE*# ...# >HUM22C3E# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QEIKANSKFIGITE*# SEQUENCE: QEIKANSKFIGITE*# ...# >HUM22C3F# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QSIKANSKFIGITE*# SEQUENCE: QSIKANSKFIGITE*# ...# >HUM22C40# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QFIKANSKFIGITE*# SEQUENCE: QFIKANSKFIGITE*# ...# >HUM22C41# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYVKANSKFIGITE*# SEQUENCE: QYVKANSKFIGITE*# ...# >HUM22C42# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYISANSKFIGITE*# SEQUENCE: QYISANSKFIGITE*# ...# >HUM22C43# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIIANSKFIGITE*# SEQUENCE: QYIIANSKFIGITE*# ...# >HUM22C44# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIRANSKFIGITE*# SEQUENCE: QYIRANSKFIGITE*# ...# >HUM22C45# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKKNSKFIGITE*# SEQUENCE: QYIKKNSKFIGITE*# ...# >HUM22C46# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKFNSKFIGITE*# SEQUENCE: QYIKFNSKFIGITE*# ...# >HUM22C47# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKSNSKFIGITE*# SEQUENCE: QYIKSNSKFIGITE*# ...# >HUM22C48# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKALSKFIGITE*# SEQUENCE: QYIKALSKFIGITE*# ...# >HUM22C49# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKAQSKFIGITE*# SEQUENCE: QYIKAQSKFIGITE*# ...# >HUM22C4A# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANYKFIGITE*# SEQUENCE: QYIKANYKFIGITE*# ...# >HUM22C4B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANQKFIGITE*# SEQUENCE: QYIKANQKFIGITE*# ...# >HUM22C4C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSSFIGITE*# SEQUENCE: QYIKANSSFIGITE*# ...# >HUM22C4D# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,QYIKANSRFIGITE*# SEQUENCE: QYIKANSRFIGITE*# ...# >HUM22C4E# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,QYIKANSKEIGITE*# SEQUENCE: QYIKANSKEIGITE*# ...# >HUM22C4F# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKSIGITE*# SEQUENCE: QYIKANSKSIGITE*# ...# >HUM22C50# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKYIGITE*# SEQUENCE: QYIKANSKYIGITE*# ...# >HUM22C51# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKFKGITE*# SEQUENCE: QYIKANSKFKGITE*# ...# >HUM22C52# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKFQGITE*# SEQUENCE: QYIKANSKFQGITE*# ...# >HUM22C53# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKFVGITE*# SEQUENCE: QYIKANSKFVGITE*# ...# >HUM22C54# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,QYIKANSKFIQITE*# SEQUENCE: QYIKANSKFIQITE*# ...# >HUM22C55# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,QYIKANSKFIGQTE*# SEQUENCE: QYIKANSKFIGQTE*# ...# >HUM22C56# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,QYIKANSKFIGKTE*# SEQUENCE: QYIKANSKFIGKTE*# ...# >HUM22C57# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKFIGLTE*# SEQUENCE: QYIKANSKFIGLTE*# ...# >HUM22C58# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,QYIKANSKFIGIKE*# SEQUENCE: QYIKANSKFIGIKE*# ...# >HUM22C59# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKFIGIFE*# SEQUENCE: QYIKANSKFIGIFE*# ...# >HUM22C5A# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKFIGISE*# SEQUENCE: QYIKANSKFIGISE*# ...# >HUM22C5B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKFIGITK*# SEQUENCE: QYIKANSKFIGITK*# ...# >HUM22C5C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,QYIKANSKFIGITD*# SEQUENCE: QYIKANSKFIGITD*# ...# >HUM22C5D# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,11# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,QYIKANSKFIGITV*# SEQUENCE: QYIKANSKFIGITV*# ...# >HUM22C5E# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM22C5F# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,AYIKANSKFIGITE*# SEQUENCE: AYIKANSKFIGITE*# ...# >HUM22C60# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,LYIKANSKFIGITE*# SEQUENCE: LYIKANSKFIGITE*# ...# >HUM22C61# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,NYIKANSKFIGITE*# SEQUENCE: NYIKANSKFIGITE*# ...# >HUM22C62# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGATE*# SEQUENCE: QYIKANSKFIGATE*# ...# >HUM22C63# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGKTE*# SEQUENCE: QYIKANSKFIGKTE*# ...# >HUM22C64# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGQTE*# SEQUENCE: QYIKANSKFIGQTE*# ...# >HUM22C65# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGIAE*# SEQUENCE: QYIKANSKFIGIAE*# ...# >HUM22C66# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGIKE*# SEQUENCE: QYIKANSKFIGIKE*# ...# >HUM22C67# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGISE*# SEQUENCE: QYIKANSKFIGISE*# ...# >HUM22C68# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesh,bindyesu,QYIKANSKFIGITA*# SEQUENCE: QYIKANSKFIGITA*# ...# >HUM22C69# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGITV*# SEQUENCE: QYIKANSKFIGITV*# ...# >HUM22C6A# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGITK*# SEQUENCE: QYIKANSKFIGITK*# ...# >HUM22C6B# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIGITD*# SEQUENCE: QYIKANSKFIGITD*# ...# >HUM22C6C# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QAIKANSKFIGITE*# SEQUENCE: QAIKANSKFIGITE*# ...# >HUM22C6D# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QEIKANSKFIGITE*# SEQUENCE: QEIKANSKFIGITE*# ...# >HUM22C6E# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QSIKANSKFIGITE*# SEQUENCE: QSIKANSKFIGITE*# ...# >HUM22C6F# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QFIKANSKFIGITE*# SEQUENCE: QFIKANSKFIGITE*# ...# >HUM22C70# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYAKANSKFIGITE*# SEQUENCE: QYAKANSKFIGITE*# ...# >HUM22C71# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYQKANSKFIGITE*# SEQUENCE: QYQKANSKFIGITE*# ...# >HUM22C72# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYKKANSKFIGITE*# SEQUENCE: QYKKANSKFIGITE*# ...# >HUM22C73# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYVKANSKFIGITE*# SEQUENCE: QYVKANSKFIGITE*# ...# >HUM22C74# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKSNSKFIGITE*# SEQUENCE: QYIKSNSKFIGITE*# ...# >HUM22C75# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKAASKFIGITE*# SEQUENCE: QYIKAASKFIGITE*# ...# >HUM22C76# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKALSKFIGITE*# SEQUENCE: QYIKALSKFIGITE*# ...# >HUM22C77# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKAQSKFIGITE*# SEQUENCE: QYIKAQSKFIGITE*# ...# >HUM22C78# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANAKFIGITE*# SEQUENCE: QYIKANAKFIGITE*# ...# >HUM22C79# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANSAFIGITE*# SEQUENCE: QYIKANSAFIGITE*# ...# >HUM22C7A# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANSEFIGITE*# SEQUENCE: QYIKANSEFIGITE*# ...# >HUM22C7B# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSRFIGITE*# SEQUENCE: QYIKANSRFIGITE*# ...# >HUM22C7C# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKYIGITE*# SEQUENCE: QYIKANSKYIGITE*# ...# >HUM22C7D# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANSKFAGITE*# SEQUENCE: QYIKANSKFAGITE*# ...# >HUM22C7E# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANSKFKGITE*# SEQUENCE: QYIKANSKFKGITE*# ...# >HUM22C7F# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANSKFQGITE*# SEQUENCE: QYIKANSKFQGITE*# ...# >HUM22C80# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFVGITE*# SEQUENCE: QYIKANSKFVGITE*# ...# >HUM22C81# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesm,bindyesu,QYIKANSKFIAITE*# SEQUENCE: QYIKANSKFIAITE*# ...# >HUM22C82# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANSKFIYITE*# SEQUENCE: QYIKANSKFIYITE*# ...# >HUM22C83# MHC MOLECULE: HLA-DR13(DRB1*1302), CLASS-2, (HUMAN)# METHOD: Recognition# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: TT (830-843) homologue# ANCHOR POSITIONS: 3,6# REFERENCES: boitel95a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesu,QYIKANSKFIQITE*# SEQUENCE: QYIKANSKFIQITE*# ...# >HUM12C84# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 nef(73-82)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,QVPLRPHTYK*# SEQUENCE: QVPLRPHTYK*# ...# >HUM12C85# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 RT (245-254)# DB REFERENCE: SWISS: (POL_HV1MN,POL_HV1JR,POL_HV1Y2,POL_HV1H2,POL_HV1B5,# & POL_HV1B1,POL_HV1BR,POL_HV1PV,POL_HV1N5,POL_HV1RH)# & PIR1: (B44001,GNVWLV,GNVWVL,GNVWH3)# & PIR2: (A47175,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,VLPEKDSWTV*# SEQUENCE: VLPEKDSWTV*# ...# >HUM12C86# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 RT (308-317)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1Y2,POL_HV1H2,POL_HV1MA,POL_HV1MN,# & POL_HV1OY,POL_HV1JR,POL_HV1ND,POL_HV1EL,POL_HV1BR,# & POL_HV1RH,POL_HV1PV,POL_HV1N5,POL_HV1B5,POL_HV1B1)# & PIR1: (GNLJND,GNVWLV,B44001,GNVWH3,GNVWVL)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,EILKEPVHGV*# SEQUENCE: EILKEPVHGV*# ...# >HUM12C87# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 RT (286-295)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1Y2,POL_HV1JR,POL_HV1OY,POL_HV1EL,# & POL_HV1A2,POL_HV1MN,POL_HV1BR,POL_HV1H2,POL_HV1PV,# & POL_HV1B5,POL_HV1B1)# & PIR1: (GNVWLV,GNVWH3,GNVWVL,GNVWA2,B44001)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,TKALTEVIPL*# SEQUENCE: TKALTEVIPL*# ...# >HUM12C88# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 RT (108-417)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1RH,POL_HV1B5,POL_HV1BR,POL_HV1OY,# & POL_HV1MA,POL_HV1ND,POL_HV1Y2,POL_HV1N5,POL_HV1EL,# & POL_HV1JR,POL_HV1H2,POL_HV1PV,POL_HV1A2,POL_HV1U4,# & POL_HV1B1)# & PIR1: (B44001,GNVWH3,GNVWA2,GNVWVL,GNLJND,GNVWLV)# & PIR2: (B47175,S54378,A47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ATWIPEWEFV*# SEQUENCE: ATWIPEWEFV*# ...# >HUM12C89# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 RT (410-429)# DB REFERENCE: SWISS: (POL_HV1Z2,POL_HV1RH,POL_HV1B5,POL_HV1BR,POL_HV1B1,# & POL_HV1A2,POL_HV1PV,POL_HV1U4,POL_HV1JR,POL_HV1EL,# & POL_HV1ND,POL_HV1MA,POL_HV1OY,POL_HV1N5,POL_HV1H2,# & POL_HV1Y2)# & PIR1: (GNVWLV,B44001,GNVWVL,GNLJND,GNVWA2,GNVWH3)# & PIR2: (B47175,S54378,A47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,WIPEWEFVNT*# SEQUENCE: WIPEWEFVNT*# ...# >HUM12C8A# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 RT (83-92)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1JR,POL_HV1B5,POL_HV1ND,POL_HV1U4,# & POL_HV1A2,POL_HV1MA,POL_HV1PV,POL_HV1RH,POL_HV1BR,# & POL_HV1Z2,POL_HV1N5,POL_HV1OY,POL_HV1EL,POL_HV1H2,# & POL_SIVCZ,POL_HV1Y2)# & PIR1: (GNVWH3,GNLJSI,GNVWA2,GNVWVL,GNLJND,B44001,GNVWLV)# & PIR2: (S32057,C47330,S32092,S32062,S32078,S32093,S32048,S32077,# & S32096,S32051,S32052,S32157,S32079,S32080,S32066,S32050,# & S32053,S32064,S32065,S32059,S32133,S32074,S32049,A47175,# & S32097,S32055,E47330,S32075,S32152,S32095,S32056,S32086,# & S32160,S32132,S32094,S54378,S32071,S32068,A47330,S43127,# & S32081,B47330,S32082,S32069,S32087,S32091,S32088,F47330,# & S32047,S32083,S32159,S32084,S32063,S32067,S32076,D47330,# & S32061,B47175,S32070,S32054,S32085,S32073,S32058,S32060,# & S32072,S32098,S32090,S32089)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,RTQDFWEVQL*# SEQUENCE: RTQDFWEVQL*# ...# >HUM12C8B# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 RT (524-533)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1JR,POL_HV1B5,POL_HV1ND,POL_HV1BR,# & POL_HV1MN,POL_HV1RH,POL_HV1Y2,POL_HV1N5,POL_HV1H2,# & POL_HV1OY,POL_HV1Z2,POL_HV1A2,POL_HV1EL)# & PIR1: (GNVWLV,GNVWH3,GNVWA2,GNVWVL,GNLJND,B44001)# & PIR2: (S54378,B47175)# & PIR3: (S11523)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,QLIKKEKVYL*# SEQUENCE: QLIKKEKVYL*# ...# >HUM12C8C# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 RT (130-139)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1Y2,POL_HV1PV,POL_HV1A2,POL_HV1MA,# & POL_HV1MN,POL_HV1RH,POL_HV1N5,POL_SIVCZ,POL_HV1B1,# & POL_HV1JR,POL_HV1B5,POL_HV1ND,POL_HV1H2,POL_HV1Z2,# & POL_HV1U4,POL_HV1OY)# & PIR1: (GNLJND,GNVWH3,B44001,GNLJSI,GNVWA2,GNVWLV,GNVWVL)# & PIR2: (D47330,S32151,S32085,S32054,S32159,S32084,S32063,S32060,# & S32094,S32126,S32089,S32157,S32120,S54378,S32052,S32051,# & S32087,S32057,B47175,S32131,S32160,S32086,S32133,S32049,# & S32132,S43127,E47330,S32048,S32056,S32047,S32118,S32055,# & S32064,S32050,S32095,S32091,S32058,S32090,S32098,S32059,# & S32061,S32088,F47330,S32083,S32062,S32092,C47330,S32093,# & S32129,S32128,S32152,A47175,S32053,S32082,S32081)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FTIPSINNET*# SEQUENCE: FTIPSINNET*# ...# >HUM12C8D# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (91-100)# DB REFERENCE: SWISS: (POL_HV2G1,POL_HV1RH,POL_HV1N5,POL_HV2D1,POL_HV2RO,# & POL_SIVAT,POL_HV2SB,POL_HV1H2,POL_HV1PV,POL_HV2ST,# & POL_HV1BR,POL_HV1Y2,POL_HV1EL,POL_SIVSP,POL_SIVS4,# & POL_HV1Z2,POL_SIVM1,POL_SIVM1,POL_HV1MA,POL_HV2KR,# & POL_HV1B5,POL_SIVCZ,POL_HV1B1,POL_HV1MN,POL_SIVA1,# & POL_HV2BE,POL_SIVAI,POL_HV2CA,POL_HV1JR,POL_HV1ND,# & POL_HV1OY,POL_HV1A2,POL_HV2NZ)# & PIR1: (GNLJST,B44001,GNVWVL,GNVWLV,GNVWA2,GNLJG4,GNLJND,GNLJGG,# & GNLJCA,GNLJG3,GNLJG2,GNVWH3,GNLJSI)# & PIR2: (S32127,B47330,S32068,S32057,S32063,S12153,S32087,S54378,# & S32052,S32085,S32060,S32151,S32078,S46347,A47175,F47330,# & S32061,S32070,S32062,S32067,S32132,S32065,S32133,S32056,# & S32135,S32064,S32159,S32077,S32053,S32069,S32058,S32081,# & S32138,S32084,S32097,B47175,S32160,S32074,S32086,S32139,# & A47330,S32152,S32075,S46354,S32120,S32157,D47330,S32054,# & S32082,S30484,S32122,S32126,S32080,S32136,S32140,S32118,# & S32095,S32055,S32117,S32072,S43127,S32059,S53092,C47330,# & S32083,S32076,S32088)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QLGIPHPAGL*# SEQUENCE: QLGIPHPAGL*# ...# >HUM12C8E# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (158-167)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1ND,POL_HV1MN,POL_HV1B1,POL_HV1B5,# & POL_HV1RH,POL_HV1H2,POL_HV1EL,POL_HV1PV,POL_HV1MA,# & POL_HV1OY,POL_HV1A2,POL_HV1JR,POL_HV1Z2)# & PIR1: (GNLJND,GNVWVL,GNVWH3,GNVWLV,GNVWA2)# & PIR2: (A47175,S32070,S32093,S32078,S32134,S32098,E47330,S32048,# & S32138,S32069,S32047,S32135,S32089,S32096,B47330,S32068,# & S32076,S32080,B47175,S32139,D47330,S32137,S32079,S43127,# & A47330,S32126,S32159,S32067,S32160,S32091,S32090,S32050,# & S32092,S54378,S32072,S32051,S32136,S32075,S32066,S32157,# & S32049,S32071,S32074)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,AIFQSSMTKI*# SEQUENCE: AIFQSSMTKI*# ...# >HUM12C8F# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (281-290)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1PV,POL_HV1B1,POL_HV1Z2,POL_HV1N5,# & POL_HV1JR,POL_HV1B5,POL_HV1Y2,POL_HV1A2,POL_HV1H2,# & POL_HV1ND,POL_HV1MN,POL_HV1OY,POL_HV1RH,POL_HV1BR)# & PIR1: (GNLJND,B44001,GNVWH3,GNVWVL,GNVWLV,GNVWA2)# & PIR2: (B47175,A47175,S54378)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KLLRGTKALT*# SEQUENCE: KLLRGTKALT*# ...# >HUM12C90# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (49-58)# DB REFERENCE: SWISS: (POL_HV1RH,POL_SIVCZ,POL_HV1PV,POL_HV1MA,POL_HV1Y2,# & POL_HV1B5,POL_HV1B1,POL_HV1N5,POL_HV1JR,POL_HV1MN,# & POL_HV1BR,POL_HV1U4,POL_HV1A2,POL_HV1H2)# & PIR1: (GNVWVL,B44001,GNVWH3,GNVWLV,GNVWA2,GNLJSI)# & PIR2: (F47330,S32060,S32085,S32072,S32050,S32133,S32065,S32132,# & S32056,S32067,S32159,S32064,S32126,S32058,A47330,S32053,# & S32137,S32070,S32093,S32119,S32098,S32134,S32059,S32068,# & S32082,B47175,S32063,S32129,S32128,S32087,S32136,S32052,# & S32051,S32057,S32135,S32118,S32117,S32048,S32066,S32088,# & S32095,A47175,S32054,S32076,S32120,S32080,S32086,D47330,# & S32097,S32075,S32139,S32152,S32131,S32089,S32096,C47330,# & S32140,S32094,S32047,S32055,S32078,S32071,S32074,S32127,# & S32049,S32157,S32151,S32061,S32090,S32160,S32091,S32081,# & S32084,S32079,S32062,S32092,S32073,B47330,S32122,S32083,# & S32138,S32069)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,KIGPENPYNT*# SEQUENCE: KIGPENPYNT*# ...# >HUM12C91# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (494-503)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1JR,POL_HV1H2,POL_HV1EL,POL_HV1PV,# & POL_HV1OY,POL_HV1ND,POL_HV1A2,POL_HV1Z2,POL_HV1RH,# & POL_HV1MN,POL_HV1BR,POL_HV1U4,POL_HV1B5,POL_HV1B1,# & POL_HV1N5,POL_HV1MA)# & PIR1: (GNVWA2,GNVWLV,GNLJND,B44001,GNVWVL,GNVWH3)# & PIR2: (A47175,B47175,S54378)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,NIVTDSQYAL*# SEQUENCE: NIVTDSQYAL*# ...# >HUM12C92# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (340-349)# DB REFERENCE: SWISS: (POL_HV1OY,POL_HV1B1,POL_HV1N5,POL_HV1BR,POL_HV1Y2,# & POL_HV1PV,POL_HV1ND,POL_HV1EL,POL_HV1H2,POL_HV1U4,# & POL_HV1B5,POL_HV1A2,POL_HV1MN,POL_HV1Z2,POL_HV1RH)# & PIR1: (GNLJND,B44001,GNVWH3,GNVWA2,GNVWVL,GNVWLV)# & PIR2: (B47175,S54378,A47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QIYQEPFKNL*# SEQUENCE: QIYQEPFKNL*# ...# >HUM12C93# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (273-282)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1BR,POL_HV1PV,POL_HV1N5,POL_HV1B1,# & POL_HV1Z2,POL_HV1H2,POL_HV1Y2,POL_HV1B5)# & PIR1: (GNVWLV,GNVWVL,GNVWH3,B44001)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GIKVRQLCKL*# SEQUENCE: GIKVRQLCKL*# ...# >HUM12C94# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (1-10)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1H2,POL_HV1MA,POL_HV1B5,POL_HV1Z2,# & POL_HV1ND,POL_HV1N5,POL_HV1B1,POL_HV1JR,POL_HV1A2,# & POL_HV1MN,POL_HV1U4,POL_HV1BR,POL_HV1OY,POL_HV1PV,# & POL_HV1EL,POL_HV1RH)# & PIR1: (GNLJND,GNVWA2,GNVWLV,B44001,GNVWH3,GNVWVL)# & PIR2: (S32068,S63750,S32128,S54378,S32119,S32070,S32134,S63732,# & S32082,S32076,S32097,S32086,S32078,S32072,S63753,S63749,# & S32050,S32048,S32118,S32135,S63747,S32087,S63736,S32053,# & S63735,S63737,S63731,S32067,S32159,S63748,S32096,S63733,# & S32066,S32095,S32122,S32077,S32083,S32138,S63742,S32081,# & S32084,S32079,S32160,S32091,S63745,S32140,S32094,S63734,# & S32049,S32127,S32080,S32139,S32051,S32136,S63752,S32098,# & S32059,S32117,S32090,S32061,S32071,S32047,B47175,S32152,# & S32089,S32126,S32065,S32137,S63746,S63755,S32074,S32157,# & S63741,A47175,S32133,S32132,S32088,S63751,S63754,S32092,# & S32062,S32073,S32069)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,PISPIETVPV*# SEQUENCE: PISPIETVPV*# ...# >HUM12C95# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (516-525)# DB REFERENCE: SWISS: (POL_HV1BR,POL_HV1B5,POL_HV1H2,POL_HV1PV,POL_HV1EL,# & POL_HV1B1)# & PIR1: (GNVWH3,GNVWLV,GNVWVL)# & PIR3: (S11523)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,ELVNQIIEQL*# SEQUENCE: ELVNQIIEQL*# ...# >HUM12C96# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (252-261)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1RH,POL_HV2CA,POL_HV1Z2,POL_HV1B1,# & POL_HV2RO,POL_HV1BR,POL_HV2G1,POL_HV2SB,POL_SIVAT,# & POL_HV2D1,POL_SIVSP,POL_HV1H2,POL_HV1B5,POL_SIVM1,# & POL_HV1PV,POL_HV1JR,POL_SIVM1,POL_SIVS4,POL_HV1U4,# & POL_HV1A2,POL_HV2BE,POL_HV1ND,POL_HV2KR,POL_HV1Y2,# & POL_SIVMK,POL_HV2NZ,POL_HV1MN,POL_HV2ST,POL_HV1MA,# & POL_HV1OY)# & PIR1: (GNLJG5,GNLJCA,GNLJG2,GNLJND,GNLJST,GNVWVL,GNVWLV,GNLJG4,# & GNVWA2,B44001,GNVWH3,GNLJG3,GNLJGG)# & PIR2: (S53092,S46347,S30483,B47175,A47175,S43127,S54378,S12153,# & S30484)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,WTVNDIQKLV*# SEQUENCE: WTVNDIQKLV*# ...# >HUM12C97# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (367-376)# DB REFERENCE: SWISS: (POL_HV1H2,POL_HV1PV,POL_HV1BR,POL_HV1B5,POL_HV1OY,# & POL_HV1B1)# & PIR1: (GNVWH3,GNVWVL,GNVWLV)# & PIR2: (B47175,A47175)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QLTEAVQKIT*# SEQUENCE: QLTEAVQKIT*# ...# >HUM12C98# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (258-267)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1MN,POL_HV1OY,POL_SIVAT,POL_HV1B1,# & POL_HV1N5,POL_HV1RH,POL_SIVGB,POL_SIVA1,POL_HV1A2,# & POL_HV1B5,POL_HV1Y2,POL_HV1Z2,POL_HV1H2,POL_HV1JR,# & POL_HV1U4,POL_HV1ND,POL_HV1PV,POL_HV1BR)# & PIR1: (GNLJND,GNLJG4,B44001,GNVWLV,GNVWA2,GNVWH3,GNVWVL)# & PIR2: (S54378,S46347,S28081,S43127,A47175,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,QKLVGKLNWA*# SEQUENCE: QKLVGKLNWA*# ...# >HUM12C99# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (433-442)# DB REFERENCE: SWISS: (POL_HV1JR,POL_HV1A2,POL_HV1B1,POL_HV1BR,POL_HV1PV,# & POL_HV1MA,POL_HV1MN,POL_HV1OY,POL_HV1H2,POL_HV1B5)# & PIR1: (GNVWLV,GNVWVL,GNVWA2,GNVWH3)# & PIR2: (B47175,A47175)# & PIR3: (S33980,S11523)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,PIVGAETFYV*# SEQUENCE: PIVGAETFYV*# ...# >HUM12C9A# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 RT (73-82)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1BR,POL_HV1PV,POL_HV1Z2,POL_HV1H2,# & POL_SIVCZ,POL_HV1ND,POL_HV1A2,POL_HV1U4,POL_HV1MN,# & POL_HV1EL,POL_HV1RH,POL_HV1B1,POL_HV1OY,POL_HV1Y2)# & PIR1: (GNLJSI,GNLJND,GNVWLV,GNVWA2,B44001,GNVWVL,GNVWH3)# & PIR2: (S32098,S32117,S32059,S32051,S43127,S32126,S32066,S32122,# & S32081,S32127,S32091,S32067,S32053,S32052,S32057,S32063,# & S32129,S32072,S32135,S32048,S32093,S32075,S32076,S32132,# & S32157,S32074,S32131,S32096,F47330,S32095,S32133,B47175,# & S32092,S32120,S32128,S32068,S32078,A47175,S32089,S32151,# & S32071,S32047,S32061,S32090,S32055,S32065,S32152,S32069,# & S32062,S32073,S32088,E47330,A47330,S32058,S32064,S32083,# & S32138,S32136,C47330,S32139,S32080,S32049,S32140,S32085,# & S32060,S32094,S32160,S32084,S32079,S32056,S32159,S54378,# & B47330,D47330,S32097,S32054,S32119,S32134,S32118,S32082,# & S32087,S32050,S32070,S32077,S32086)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,KLVDFRELNK*# SEQUENCE: KLVDFRELNK*# ...# >HUM12C9B# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 RT (11-20)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,KLKPGMDCPK*# SEQUENCE: KLKPGMDCPK*# ...# >HUM12C9C# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 RT (381 -390)# DB REFERENCE: SWISS: (POL_HV1N5,POL_HV1PV,POL_HV1H2,POL_HV1B1,POL_HV1OY,# & POL_HV1Y2,POL_HV1B5,POL_HV1BR,POL_HV1RH,POL_HV1ND)# & PIR1: (GNVWLV,GNVWH3,GNLJND,GNVWVL,B44001)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesh,VIWGKTPKFK*# SEQUENCE: VIWGKTPKFK*# ...# >HUM12C9D# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 RT (179-188)# DB REFERENCE: SWISS: (POL_HV1Y2,POL_HV1U4,POL_HV1MN,POL_HV1MA,POL_HV1B5,# & POL_HV1BR,POL_HV1Z2,POL_HV1H2,POL_HV1N5,POL_HV1PV,# & POL_HV1A2,POL_HV1RH,POL_HV1ND,POL_HV1B1,POL_HV1OY,# & POL_HV1EL)# & PIR1: (GNVWH3,GNVWLV,GNVWA2,B44001,GNVWVL,GNLJND)# & PIR2: (S32076,S32053,S32137,S32065,A47330,S32085,S32049,S32160,# & S32097,S32070,S32084,S32079,S32056,S32140,S32159,S32119,# & S32082,S32134,S32054,S32064,S32138,C47330,S32139,S32062,# & S32152,S32055,A47175,S32089,S32151,S32047,S32048,S32075,# & S32052,S32057,S32072,S32067,S32078,S32120,B47175,S32133,# & S32092,S32066,S32122,S32127,S32126,S32117,S32059,S32098,# & S32077,S32131,S32132,S32095,S32096,S32118,S32086,S32157,# & F47330,S32128,S32071,S32090,S32136,S32083,S54378,S32094,# & S32060,S32129,S32091,S32051,S32074,S32087,S32050,D47330,# & B47330,S32080,S32058,E47330,S32061,S32088,S32073,S32069,# & S32068,S32081,S32063,S32093,S32135)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,VIYQYMDDLY*# SEQUENCE: VIYQYMDDLY*# ...# >HUM12C9E# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HIV-1 RT (240-249)# DB REFERENCE: SWISS: (POL_HV1RH,POL_HV1MN,POL_HV1JR,POL_HV1B1,POL_HV1BR,# & POL_HV1Y2,POL_HV1N5,POL_HV1H2,POL_HV1PV)# & PIR1: (B44001,GNVWVL,GNVWLV,GNVWH3)# & PIR2: (B47175,A47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,TVQPIVLPEK*# SEQUENCE: TVQPIVLPEK*# ...# >HUM12C9F# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (278-287)# DB REFERENCE: SWISS: (POL_HV1B1,POL_HV1A2,POL_HV1MN,POL_HV1RH,POL_HV1H2,# & POL_HV1Z2,POL_HV1Y2,POL_HV1ND,POL_HV1BR,POL_HV1N5,# & POL_HV1PV,POL_HV1JR,POL_HV1B5,POL_HV1EL)# & PIR1: (GNVWH3,GNVWVL,B44001,GNVWLV,GNLJND,GNVWA2)# & PIR2: (B47175,S54378,A47175)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,QLCKLLRGTK*# SEQUENCE: QLCKLLRGTK*# ...# >HUM12CA0# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (275-284)# DB REFERENCE: SWISS: (POL_HV1PV,POL_HV1B5,POL_HV1Y2,POL_HV1H2,POL_HV1Z2,# & POL_HV1EL,POL_HV1BR,POL_HV1B1,POL_HV1N5)# & PIR1: (GNVWH3,GNVWLV,GNVWVL,B44001)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,KVRQLCKLLR*# SEQUENCE: KVRQLCKLLR*# ...# >HUM12CA1# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (229-238)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,WMGYELHPPK*# SEQUENCE: WMGYELHPPK*# ...# >HUM12CA2# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (93-102)# DB REFERENCE: SWISS: (POL_HV1OY,POL_HV1JR,POL_HV1PV,POL_HV1H2,POL_HV1Z2,# & POL_HV1MN,POL_HV1RH,POL_SIVA1,POL_HV1B1,POL_HV1EL,# & POL_HV1Y2,POL_SIVCZ,POL_HV1A2,POL_HV1MA,POL_HV1B5,# & POL_HV1BR,POL_HV1ND)# & PIR1: (B44001,GNLJND,GNVWA2,GNVWVL,GNVWLV,GNLJSI,GNVWH3)# & PIR2: (S32117,S32075,S32057,S32067,S32078,S32077,S32095,S32058,# & D47330,B47330,S32118,F47330,S32063,S32081,S43127,S32061,# & S32069,S32136,S32128,S32074,S32070,S32065,A47330,S32085,# & S32076,S32053,S32062,S54378,S32152,S32055,S32064,S32139,# & S32054,S32082,S32140,S32056,A47175,S32160,S32159,S32151,# & S32072,S32059,S32127,S32138,S32052,C47330,B47175,S32087,# & S32080,S32088,S32068,S32135,S32120,S32126,S32083,S32122,# & S32133,S32132,S32129,S32157,S32060,S32086,S32097,# & S32084)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,GIPHPAGLKK*# SEQUENCE: GIPHPAGLKK*# ...# >HUM12CA3# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (422-431)# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1U4,POL_HV1B1,POL_HV1JR,POL_HV1N5,# & POL_HV1MN,POL_HV1Z2,POL_HV1OY,POL_HV1PV,POL_HV1H2,# & POL_HV1RH,POL_HV1A2,POL_HV1Y2,POL_HV1ND,POL_HV1BR,# & POL_HV1B5)# & PIR1: (GNVWLV,B44001,GNLJND,GNVWH3,GNVWVL,GNVWA2)# & PIR2: (S54378,A47175,B47175)# & PIR3: (S33980)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,LVKLWYQLEK*# SEQUENCE: LVKLWYQLEK*# ...# >HUM12CA4# MHC MOLECULE: HLA-A3(A*0301), CLASS-1, (HUMAN)# METHOD: Refolding with competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 RT (309-318)# DB REFERENCE: SWISS: (POL_HV1MA,POL_HV1B1,POL_HV1ND,POL_HV1H2,POL_HV1PV,# & POL_HV1RH,POL_HV1OY,POL_HV1Y2,POL_HV1N5,POL_HV1B5,# & POL_HV1MN,POL_HV1JR,POL_HV1Z2,POL_HV1EL,POL_HV1BR)# & PIR1: (GNVWVL,GNVWH3,B44001,GNVWLV,GNLJND)# & PIR2: (B47175,S54378)# ANCHOR POSITIONS: 2,10# REFERENCES: tan97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,ILKEPVHGVY*# SEQUENCE: ILKEPVHGVY*# ...# >HUM12CA5# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV env (183-191)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBVN,VMSA_HPBVZ,VMSA_HPBVP,# & VMSA_HPBV9,VMSA_HPBVW,VMSA_HPBVD,VMSA_HPBVW,VMSA_HPBV4,# & VMSA_HPBV2,VMSA_HPBVS,VMSA_HPBVY,VMSA_HPBV0,VMSA_HPBVR,# & VMSA_HPBVY)# & PIR1: (JQ1575,SAVLVE,SAVLHV,SAVLAD,JQ1577,SAVLKS,SAVLA,SAVLAJ,# & SAVLN1,SAVLBH,SAVLAR,SAVLVD,SAVLAH)# & PIR2: (JQ2075,JQ2052,JQ2055,JQ2098,JQ2045,JQ2063,S41870,JQ2076,# & JQ2099,JQ2051,JQ2108,JQ2103,JQ2102,JQ2046,JQ2070,JQ2104,# & JQ2094,S20745,S41871,JQ2068,JQ2081,JQ2083,JQ2096,JQ2066,# & JQ2053,S47411,JQ2050,JQ2072,JQ2105,S20749,JQ2112,JQ2100,# & S47407,JQ2109,S36654,JQ2097,JQ2115,JQ2056,JQ2067,JQ2077,# & JQ2065,JQ2047,S41869,JQ2113,JQ2080,JQ2073,S43492,JQ2114,# & S35528,S20753,JQ2111,JQ2079,JQ2048,S32202,JQ2069,JQ2095,# & JQ2054,JQ2078)# & PIR4: (S42226)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,FLLTRILTI*# SEQUENCE: FLLTRILTI*# ...# >HUM12CA6# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (642-650)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBV4,DPOL_HPBVJ,DPOL_HPBVM,DPOL_HPBVL,# & DPOL_HPBV2,DPOL_HPBVY,DPOL_HPBVI,DPOL_HPBV9,DPOL_HPBVT,# & DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBVO,DPOL_HPBVA,# & DPOL_HPBVZ)# & PIR1: (JQ2229,JDVLKS,JDVLVD,JDVLVB,JDVLJ3,JDVLA1,JDVLJ2,JDVLVA,# & JDVLVH,JDVLVS,JDVLJ1,JDVLCP,S20757,S20752,JDVLVR,# & S43491)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALMPLYACI*# SEQUENCE: ALMPLYACI*# ...# >HUM12CA7# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBV pol (455-463)# DB REFERENCE: SWISS: (DPOL_HPBVZ,DPOL_HPBVW,DPOL_HPBVA,DPOL_HPBVP,DPOL_HPBVT,# & DPOL_HPBVI,DPOL_HPBV2,DPOL_HPBVY,DPOL_HPBVL,DPOL_HPBV9,# & DPOL_HPBVJ,DPOL_HPBVO,DPOM_HPBVY)# & PIR1: (S20757,JDVLVB,S47406,JQ2229,JDVLKS,JDVLVA,JDVLA1,JDVLVH,# & JDVLVD,JDVLJ2,JDVLJ3,JDVLCP,JDVLJ1)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesm,GLSRYVARL*# SEQUENCE: GLSRYVARL*# ...# >HUM12CA8# MHC MOLECULE: HLA-A2(A*0202), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (575-583)# DB REFERENCE: SWISS: (DPOL_HPBVZ,DPOL_HPBVR,DPOL_HPBVI,DPOL_HPBVM,DPOM_HPBVY,# & DPOL_HPBV2,DPOL_HPBVY,DPOL_HPBVL,DPOL_HPBV9,DPOL_HPBVJ,# & DPOL_HPBVP,DPOL_HPBV4,DPOL_HPBVO,DPOL_HPBVA)# & PIR1: (JDVLVS,JDVLJ1,JDVLVH,JDVLJ2,JDVLCP,JDVLJ3,JDVLVD,S20752,# & S47406,JDVLKS,JDVLVB,JDVLVA,JDVLA1,S20757,JDVLVR)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,FLLSLGIHL*# SEQUENCE: FLLSLGIHL*# ...# >HUM12CA9# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV core (18-29)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVA,CORA_HPBVJ,CORA_HPBVT,CORA_HPBVW,# & CORA_HPBVZ,CORA_HPBVO,CORA_HPBV2,CORA_HPBV9,CORA_HPBVL,# & CORA_HPBVF)# & PIR1: (NKVLAH,NKVLJ1,NKVLJ2,NKVLA6,NKVLH3,NKVLCP,NKVLA2,NKVLKS,# & NKVLA3,NKVLA1,NKVLBH)# & PIR2: (S53211,S53152,S20750,S53178,S53255,S53189,S53288,S53181,# & JQ2227,S53159,S53216,S53143,S53169,S53163,S53251,S25651,# & S53242,S53274,S20746,S53253,S53272,S47409,S53221,S53227,# & S53202,S53137,S53232,S53279,S53223,S32204,S53260,S53204,# & S53270,S53214,S53207,S53238,S43490,S53257,S53240,S53225,# & S53200,S53129,S53229,S53155,S01405,S53175,S53281,S47405,# & S53184,S33686,S53286,S53236,S53267)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLPSDFFPSV*# SEQUENCE: FLPSDFFPSV*# ...# >HUM12CAA# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV env (183-191)# DB REFERENCE: SWISS: (VMSA_HPBVZ,VMSA_HPBVP,VMSA_HPBV0,VMSA_HPBVW,VMSA_HPBVR,# & VMSA_HPBVY,VMSA_HPBV2,VMSA_HPBV9,VMSA_HPBVW,VMSA_HPBVD,# & VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBV4,VMSA_HPBVN,VMSA_HPBVY,# & VMSA_HPBVS)# & PIR1: (SAVLA,SAVLN1,SAVLAJ,SAVLVE,JQ1577,JQ1575,SAVLVD,SAVLAH,# & SAVLBH,SAVLAR,SAVLAD,SAVLKS,SAVLHV)# & PIR2: (JQ2051,JQ2055,JQ2045,JQ2075,JQ2105,JQ2095,JQ2077,JQ2104,# & JQ2076,JQ2108,JQ2080,S41871,JQ2046,JQ2102,JQ2112,JQ2072,# & JQ2050,S47407,JQ2079,JQ2113,JQ2047,S41869,JQ2067,JQ2065,# & JQ2073,JQ2056,JQ2109,S36654,JQ2100,JQ2096,JQ2066,JQ2068,# & JQ2081,JQ2083,JQ2103,JQ2099,S41870,JQ2114,S43492,S35528,# & JQ2052,JQ2063,JQ2094,JQ2070,JQ2098,S47411,JQ2115,S20753,# & S20745,JQ2069,S20749,JQ2078,JQ2054,JQ2048,JQ2111,S32202,# & JQ2053,JQ2097)# & PIR4: (S42226)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,FLLTRILTI*# SEQUENCE: FLLTRILTI*# ...# >HUM12CAB# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV cnv (335-343)# DB REFERENCE: SWISS: (VMSA_HPBVW,VMSA_HPBV0,VMSA_HPBVY,VMSA_HPBVI,VMSA_HPBVP,# & VMSA_HPBVJ,VMSA_HPBVN,VMSA_HPBVO,VMSA_HPBV4,VMSA_HPBVS,# & VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBVD,VMSA_HPBVA,VMSA_HPBVY,# & VMSA_HPBVZ,VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBV9,# & VMSA_HPBV2)# & PIR1: (SAVLAD,JQ1578,SAVLAR,JQ1576,JQ1571,JQ1573,SAVLA1,SAVLAH,# & SAVLAJ,SAVLVE,JQ1575,SAVLN1,SAVLA,JQ1572,JQ1570,SAVLBH,# & SAVLJ2,SAVLVD,JQ1574,SAVLKS,SAVLJ1,SAVLHV,JQ1577,# & SAVLJ3)# & PIR2: (JQ2073,JQ2113,JQ2100,S36654,JQ2111,S32202,JQ2054,JQ2053,# & JQ2059,JQ2097,JQ2048,JQ2092,JQ2060,JQ2102,JQ2058,JQ2105,# & JQ2055,JQ2062,JQ2045,JQ2051,JQ2098,S47411,JQ2115,JQ2076,# & S20753,JQ2104,JQ2090,S47407,JQ2112,JQ2079,JQ2072,S43492,# & JQ2114,S41870,JQ2101,JQ2116,JQ2081,JQ2052,JQ2087,JQ2070,# & S20749,JQ2078,S20745,JQ2066,JQ2083,JQ2089,JQ2110,JQ2056,# & JQ2047,S41869,JQ2109,JQ2067,JQ2080,JQ2046,JQ2050,JQ2103,# & S35528,JQ2085,JQ2075,JQ2063,JQ2061,JQ2068,JQ2057,JQ2065,# & JQ2069,JQ2106,JQ2108,JQ2077,JQ2091)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,WLSLLVPFV*# SEQUENCE: WLSLLVPFV*# ...# >HUM12CAC# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (642-650)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVR,DPOL_HPBV9,DPOL_HPBV2,DPOL_HPBVI,# & DPOL_HPBVZ,DPOM_HPBVY,DPOL_HPBVY,DPOL_HPBV4,DPOL_HPBVO,# & DPOL_HPBVP,DPOL_HPBVT,DPOL_HPBVL,DPOL_HPBVA,# & DPOL_HPBVJ)# & PIR1: (JDVLJ1,JQ2229,JDVLVD,JDVLVS,JDVLJ3,JDVLVA,JDVLJ2,JDVLCP,# & JDVLVH,JDVLVB,JDVLA1,S43491,JDVLKS,JDVLVR,S20752,# & S20757)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,ALMPLYACI*# SEQUENCE: ALMPLYACI*# ...# >HUM12CAD# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (455-463)# DB REFERENCE: SWISS: (DPOL_HPBV9,DPOL_HPBV2,DPOL_HPBVL,DPOL_HPBVW,DPOL_HPBVT,# & DPOL_HPBVO,DPOM_HPBVY,DPOL_HPBVZ,DPOL_HPBVP,DPOL_HPBVI,# & DPOL_HPBVA,DPOL_HPBVY,DPOL_HPBVJ)# & PIR1: (S20757,JDVLVB,JDVLA1,JDVLKS,JDVLJ2,JDVLVH,JDVLCP,S47406,# & JDVLVD,JQ2229,JDVLJ1,JDVLJ3,JDVLVA)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,GLSRYVARL*# SEQUENCE: GLSRYVARL*# ...# >HUM12CAE# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (575-583)# DB REFERENCE: SWISS: (DPOL_HPBV9,DPOL_HPBV2,DPOL_HPBVO,DPOL_HPBVL,DPOL_HPBVR,# & DPOL_HPBVA,DPOL_HPBVM,DPOL_HPBVP,DPOM_HPBVY,DPOL_HPBV4,# & DPOL_HPBVZ,DPOL_HPBVI,DPOL_HPBVJ,DPOL_HPBVY)# & PIR1: (S47406,S20757,JDVLVB,JDVLVD,JDVLVS,JDVLVA,JDVLJ3,JDVLJ1,# & JDVLJ2,JDVLCP,JDVLVH,JDVLVR,S20752,JDVLKS,JDVLA1)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,FLLSLGIHL*# SEQUENCE: FLLSLGIHL*# ...# >HUM12CAF# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV env (62-70)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVZ,VMSA_HPBVT,VMSA_HPBVA,VMSA_HPBVR,# & VMSA_HPBVY,VMSA_HPBVJ,VMSA_HPBVO,VMSA_HPBV4,VMSA_HPBVY,# & VMSA_HPBVI)# & PIR1: (SAVLJ1,SAVLJ3,SAVLAJ,SAVLBH,SAVLAH,SAVLA,SAVLA1,# & SAVLJ2)# & PIR2: (S41869,JQ2230,S32202,S41870,S20753,S47407,S43492,S20745,# & S20749,S35528,S41871)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,GLLGWSPQA*# SEQUENCE: GLLGWSPQA*# ...# >HUM12CB0# MHC MOLECULE: HLA-A2(A*0203), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (538-546)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVP,DPOL_HPBVA,DPOL_HPBVR,DPOM_HPBVY,# & DPOL_HPBV9,DPOL_HPBVI,DPOL_HPBVJ,DPOL_HPBVZ,DPOL_HPBV4,# & DPOL_HPBVL,DPOL_HPBVM,DPOL_HPBV2)# & PIR1: (JDVLA1,S20757,JDVLVB,JDVLVD,JDVLVA,S47406,JDVLJ3,JDVLJ1,# & JDVLVS,JDVLCP,JDVLVH,S20752,JDVLVR,S43491,JDVLKS)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,YMDDVVLGA*# SEQUENCE: YMDDVVLGA*# ...# >HUM12CB1# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV core (18-29)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBVL,CORA_HPBV2,CORA_HPBVZ,CORA_HPBVW,# & CORA_HPBVT,CORA_HPBVO,CORA_HPBVF,CORA_HPBVY,CORA_HPBVJ,# & CORA_HPBVA)# & PIR1: (NKVLBH,NKVLA6,NKVLAH,NKVLJ2,NKVLJ1,NKVLCP,NKVLH3,NKVLA3,# & NKVLA1,NKVLA2,NKVLKS)# & PIR2: (S53207,S43490,S53204,S53211,S53232,S53152,S53255,S53253,# & S53129,S53267,S53236,S53281,S53175,S33686,S53184,S53189,# & S53159,JQ2227,S53178,S53181,S53251,S53274,S20746,S53202,# & S53227,S53221,S47409,S53272,S53223,S53163,S53143,S53155,# & S53229,S53225,S53200,S53240,S25651,S53242,S53169,S20750,# & S53260,S53270,S53137,S53279,S47405,S53288,S53216,S53214,# & S53238,S32204,S01405,S53257,S53286)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLPSDFFPSV*# SEQUENCE: FLPSDFFPSV*# ...# >HUM12CB2# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV env (183-191)# DB REFERENCE: SWISS: (VMSA_HPBVD,VMSA_HPBVN,VMSA_HPBV2,VMSA_HPBVP,VMSA_HPBVS,# & VMSA_HPBV0,VMSA_HPBVW,VMSA_HPBVW,VMSA_HPBV9,VMSA_HPBVY,# & VMSA_HPBVR,VMSA_HPBVZ,VMSA_HPBVY,VMSA_HPBVR,VMSA_HPBV4,# & VMSA_HPBV2)# & PIR1: (JQ1577,SAVLVD,SAVLKS,SAVLAJ,SAVLBH,SAVLVE,SAVLAR,SAVLAH,# & JQ1575,SAVLN1,SAVLA,SAVLAD,SAVLHV)# & PIR2: (JQ2070,JQ2079,JQ2104,JQ2053,JQ2077,JQ2096,S20749,S20745,# & S32202,JQ2111,JQ2113,S36654,JQ2115,JQ2066,JQ2078,JQ2050,# & JQ2051,JQ2055,JQ2105,JQ2094,S41871,JQ2102,S35528,JQ2072,# & JQ2112,JQ2114,JQ2076,JQ2099,S47411,JQ2098,JQ2056,JQ2109,# & JQ2047,JQ2048,S20753,JQ2063,JQ2065,JQ2068,JQ2075,JQ2108,# & JQ2095,JQ2069,JQ2103,S41869,JQ2046,JQ2080,S47407,JQ2083,# & JQ2097,JQ2045,S41870,JQ2073,JQ2100,S43492,JQ2081,JQ2052,# & JQ2054,JQ2067)# & PIR4: (S42226)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLLTRILTI*# SEQUENCE: FLLTRILTI*# ...# >HUM12CB3# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV env (335-343)# DB REFERENCE: SWISS: (VMSA_HPBVS,VMSA_HPBV9,VMSA_HPBVY,VMSA_HPBVY,VMSA_HPBV4,# & VMSA_HPBV2,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBVA,# & VMSA_HPBV2,VMSA_HPBV0,VMSA_HPBVW,VMSA_HPBVO,VMSA_HPBVP,# & VMSA_HPBVN,VMSA_HPBVD,VMSA_HPBVJ,VMSA_HPBVW,# & VMSA_HPBVZ)# & PIR1: (SAVLJ1,JQ1577,JQ1570,SAVLHV,JQ1571,SAVLJ2,JQ1572,SAVLBH,# & SAVLVD,SAVLKS,JQ1576,SAVLN1,SAVLAH,SAVLAJ,JQ1575,JQ1578,# & SAVLAR,JQ1573,SAVLA,SAVLVE,SAVLA1,JQ1574,SAVLAD,# & SAVLJ3)# & PIR2: (JQ2087,JQ2055,JQ2072,JQ2112,S43492,JQ2052,S41870,JQ2100,# & JQ2078,JQ2081,JQ2050,JQ2115,JQ2106,JQ2077,JQ2085,JQ2079,# & JQ2057,JQ2070,JQ2061,JQ2104,JQ2045,JQ2097,JQ2092,JQ2067,# & JQ2110,JQ2089,S20745,JQ2113,S36654,JQ2111,S20753,JQ2068,# & JQ2063,JQ2101,JQ2076,JQ2116,JQ2047,JQ2090,JQ2058,S41869,# & JQ2060,JQ2046,JQ2065,JQ2069,JQ2108,JQ2066,S20749,JQ2048,# & JQ2075,JQ2080,JQ2054,JQ2098,S47411,JQ2056,JQ2109,JQ2114,# & S35528,JQ2051,JQ2105,JQ2091,JQ2053,JQ2059,JQ2073,S47407,# & JQ2083,S32202,JQ2062,JQ2103,JQ2102)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,WLSLLVPFV*# SEQUENCE: WLSLLVPFV*# ...# >HUM12CB4# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (642-650)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBVZ,DPOL_HPBVY,DPOL_HPBVR,DPOL_HPBVJ,# & DPOL_HPBV4,DPOL_HPBV2,DPOL_HPBVL,DPOL_HPBVM,DPOL_HPBV9,# & DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBVA,# & DPOL_HPBVO)# & PIR1: (JDVLKS,JDVLJ2,S43491,JDVLVR,JDVLVH,JDVLJ3,JDVLJ1,S20752,# & S20757,JDVLVB,JDVLVS,JDVLA1,JDVLVD,JQ2229,JDVLVA,# & JDVLCP)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesm,ALMPLYACI*# SEQUENCE: ALMPLYACI*# ...# >HUM12CB5# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (575-583)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBVP,DPOL_HPBVA,DPOM_HPBVY,DPOL_HPBV9,# & DPOL_HPBVI,DPOL_HPBVO,DPOL_HPBV2,DPOL_HPBVL,DPOL_HPBVY,# & DPOL_HPBVM,DPOL_HPBVZ,DPOL_HPBVJ,DPOL_HPBV4)# & PIR1: (S20752,JDVLKS,JDVLA1,JDVLVD,S47406,JDVLVB,JDVLVS,JDVLVH,# & JDVLJ3,JDVLJ1,JDVLCP,JDVLVA,JDVLJ2,JDVLVR,S20757)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesh,FLLSLGIHL*# SEQUENCE: FLLSLGIHL*# ...# >HUM12CB6# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV env (62-70)# DB REFERENCE: SWISS: (VMSA_HPBVJ,VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBVZ,VMSA_HPBVR,# & VMSA_HPBVY,VMSA_HPBVT,VMSA_HPBV4,VMSA_HPBVY,VMSA_HPBVO,# & VMSA_HPBVA)# & PIR1: (SAVLJ2,SAVLJ1,SAVLBH,SAVLA,SAVLJ3,SAVLAH,SAVLAJ,# & SAVLA1)# & PIR2: (S47407,S32202,S35528,S20745,S20753,S41870,S41869,S43492,# & S41871,S20749,JQ2230)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,GLLGWSPQA*# SEQUENCE: GLLGWSPQA*# ...# >HUM12CB7# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV core (18-29)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVO,CORA_HPBVY,CORA_HPBVF,CORA_HPBV2,# & CORA_HPBVL,CORA_HPBVT,CORA_HPBVA,CORA_HPBVZ,CORA_HPBV9,# & CORA_HPBVW)# & PIR1: (NKVLKS,NKVLAH,NKVLA6,NKVLA3,NKVLA1,NKVLCP,NKVLJ1,NKVLBH,# & NKVLA2,NKVLH3,NKVLJ2)# & PIR2: (S53240,S53225,S53169,S53270,S53175,S33686,JQ2227,S43490,# & S53207,S53143,S53163,S53272,S53223,S20746,S53281,S53221,# & S53214,S32204,S53288,S53202,S53227,S47409,S53204,S53211,# & S53152,S53274,S53251,S53236,S53267,S53129,S53260,S53279,# & S53137,S53184,S53189,S53159,S53178,S53181,S20750,S53257,# & S53238,S53286,S01405,S53253,S53255,S53232,S53216,S47405,# & S25651,S53242,S53229,S53155,S53200)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,FLPSDFFPSV*# SEQUENCE: FLPSDFFPSV*# ...# >HUM12CB8# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV cnv (335-343)# DB REFERENCE: SWISS: (VMSA_HPBVO,VMSA_HPBVW,VMSA_HPBV9,VMSA_HPBV2,VMSA_HPBVY,# & VMSA_HPBVZ,VMSA_HPBVW,VMSA_HPBVP,VMSA_HPBVR,VMSA_HPBV4,# & VMSA_HPBVJ,VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVN,VMSA_HPBVS,# & VMSA_HPBVA,VMSA_HPBVI,VMSA_HPBVD,VMSA_HPBV0,# & VMSA_HPBVR)# & PIR1: (SAVLKS,SAVLHV,JQ1570,SAVLA1,SAVLAJ,JQ1571,JQ1577,SAVLAR,# & JQ1573,SAVLJ2,SAVLN1,SAVLVE,SAVLVD,SAVLA,SAVLBH,JQ1572,# & SAVLJ3,SAVLAH,JQ1575,JQ1578,SAVLJ1,SAVLAD,JQ1576,# & JQ1574)# & PIR2: (S20749,JQ2048,JQ2080,JQ2091,JQ2083,JQ2078,JQ2102,JQ2103,# & JQ2062,JQ2067,JQ2092,JQ2104,S32202,JQ2061,JQ2085,JQ2109,# & S47411,JQ2114,JQ2105,JQ2051,JQ2054,JQ2115,JQ2050,JQ2077,# & JQ2106,S47407,JQ2057,JQ2070,JQ2063,JQ2089,S35528,JQ2110,# & JQ2113,S36654,JQ2100,S41870,JQ2072,JQ2112,JQ2055,JQ2052,# & JQ2087,S20753,S20745,JQ2060,JQ2058,JQ2046,JQ2108,JQ2069,# & JQ2073,JQ2059,JQ2053,S41869,JQ2081,JQ2097,JQ2111,JQ2047,# & JQ2090,JQ2116,JQ2101,JQ2076,JQ2065,JQ2068,S43492,JQ2045,# & JQ2079,JQ2056,JQ2098,JQ2075,JQ2066)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,WLSLLVPFV*# SEQUENCE: WLSLLVPFV*# ...# >HUM12CB9# MHC MOLECULE: HLA-A68(A*6802), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (642-650)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBVR,DPOL_HPBVO,DPOL_HPBV2,# & DPOM_HPBVY,DPOL_HPBV9,DPOL_HPBVI,DPOL_HPBVA,DPOL_HPBVP,# & DPOL_HPBV4,DPOL_HPBVJ,DPOL_HPBVZ,DPOL_HPBVL,# & DPOL_HPBVT)# & PIR1: (JDVLVR,S20752,JQ2229,JDVLKS,JDVLVA,JDVLCP,JDVLVB,JDVLVD,# & JDVLVS,S43491,JDVLJ1,JDVLJ2,S20757,JDVLA1,JDVLVH,# & JDVLJ3)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,ALMPLYACI*# SEQUENCE: ALMPLYACI*# ...# >HUM12CBA# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (149-159)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBV2,DPOL_HPBV9,DPOL_HPBVY,DPOL_HPBVW,# & DPOL_HPBVT,DPOL_HPBVR,DPOL_HPBVO,DPOM_HPBVY,DPOL_HPBVP,# & DPOL_HPBVM,DPOL_HPBV4,DPOL_HPBVJ)# & PIR1: (JDVLVS,JDVLVB,JQ2229,JDVLJ3,JDVLJ1,JDVLVD,S47406,JDVLKS,# & S20757,JDVLVA,S43491,JDVLVR,JDVLJ2,S20752)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,HTLWKAGILYK*# SEQUENCE: HTLWKAGILYK*# ...# >HUM12CBB# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV core (141-151)# DB REFERENCE: SWISS: (CORA_HPBVA,CORA_HPBV9,CORA_HPBVO,CORA_HPBVJ,CORA_HPBVY,# & CORA_HPBV4,CORA_HPBVF,CORA_HPBVL,CORA_HPBV2,CORA_HPBVZ,# & CORA_HPBVT,CORA_HPBVW)# & PIR1: (NKVLA3,NKVLA4,NKVLJ2,NKVLA2,NKVLA1,NKVLCP,NKVLBH,NKVLH3,# & NKVLAH,NKVLA6,NKVLKS,NKVLJ1)# & PIR2: (S35530,S53129,S53279,S53159,S53204,S53227,S53225,S53146,# & S53270,JQ2227,S53223,S53166,S01405,S25651,S53200,S53238,# & S53194,S53236,S53257,S53155,S53207,S53172,S53140,S53221,# & S53251,S53198,S53202,S47409,S53260,S53184,S53178,S20750,# & S53181,S53216,S47405,S53229,S53242,S53157,S53272,S53163,# & S53255,S04570,S53232,S53253,S53281,S20746,S53152,S53211,# & S32204,S53175,S33686,S53240,S53169)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,STLPETTVVRR*# SEQUENCE: STLPETTVVRR*# ...# >HUM12CBC# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBV pol (654-663)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBVO,DPOL_HPBV2,DPOL_HPBVL,DPOL_HPBV4,# & DPOL_HPBVJ,DPOL_HPBVM,DPOL_HPBVP,DPOL_HPBVR,DPOL_HPBVA,# & DPOM_HPBVY,DPOL_HPBVY,DPOL_HPBV9,DPOL_HPBVZ)# & PIR1: (S20752,S47406,S43491,JDVLJ2,JDVLVR,JDVLVS,JDVLA1,JDVLCP,# & JDVLJ3,JDVLVA,JDVLVD,JDVLJ1,JDVLVH,JDVLVB,JDVLKS,# & S20757)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesm,QAFTFSPTYK*# SEQUENCE: QAFTFSPTYK*# ...# >HUM12CBD# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: HBV pol (520-528)# DB REFERENCE: SWISS: (DPOL_HPBVP,DPOL_HPBVM,DPOL_HPBV4,DPOL_HPBVJ,DPOL_HPBVL,# & DPOL_HPBVI,DPOL_HPBVR,DPOL_HPBVA,DPOL_HPBVY,DPOL_HPBVZ,# & DPOL_HPBV2,DPOL_HPBV9,DPOL_HPBVT,DPOM_HPBVY,# & DPOL_HPBVO)# & PIR1: (JDVLKS,JQ2229,JDVLVB,JDVLVR,JDVLJ1,JDVLVA,JDVLA1,S20752,# & JDVLJ2,S47406,JDVLVH,S20757,JDVLVD,JDVLCP,JDVLJ3,# & JDVLVS)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesl,SAICSVVRR*# SEQUENCE: SAICSVVRR*# ...# >HUM12CBE# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (55-63)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVR,DPOL_HPBVZ,DPOL_HPBVP,DPOL_HPBV2,# & DPOL_HPBVL,DPOL_HPBVI,DPOL_HPBVO,DPOM_HPBVY,DPOL_HPBV4,# & DPOL_HPBVJ,DPOL_HPBVM,DPOL_HPBVW,DPOL_HPBVY,DPOL_HPBV9,# & DPOL_HPBVT)# & PIR1: (JDVLA1,JDVLVA,JDVLVB,JQ2229,JDVLKS,JDVLVS,JDVLVR,JDVLCP,# & S20757,JDVLVH,JDVLJ2,JDVLJ1,S43491,JDVLVD,JDVLJ3,# & S47406)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,KVGNFTGLY*# SEQUENCE: KVGNFTGLY*# ...# >HUM12CBF# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (150-159)# DB REFERENCE: SWISS: (DPOL_HPBV2,DPOL_HPBVI,DPOL_HPBVM,DPOL_HPBVW,DPOL_HPBVY,# & DPOL_HPBVT,DPOL_HPBV9,DPOL_HPBVR,DPOL_HPBVP,DPOL_HPBVJ,# & DPOM_HPBVY,DPOL_HPBVO,DPOL_HPBV4)# & PIR1: (JDVLVD,S20757,S20752,JQ2229,JDVLVS,JDVLVR,JDVLVB,JDVLKS,# & JDVLVA,S43491,JDVLJ3,S47406,JDVLJ1,JDVLJ2)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actyesu,bindyesh,TLWKAGILYK*# SEQUENCE: TLWKAGILYK*# ...# >HUM12CC0# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (358-367)# DB REFERENCE: SWISS: (DPOL_HPBV2,DPOL_HPBVZ,DPOL_HPBVY,DPOL_HPBVJ,DPOL_HPBVM,# & DPOL_HPBV4,DPOL_HPBVA,DPOL_HPBVI,DPOL_HPBVW,DPOL_HPBV9,# & DPOL_HPBVT,DPOL_HPBVL,DPOM_HPBVY,DPOL_HPBVO,DPOL_HPBVR,# & DPOL_HPBVP)# & PIR1: (JDVLJ3,S43491,JDVLVH,JDVLVD,JDVLA1,JDVLJ1,S47406,JDVLVA,# & JDVLKS,JDVLVB,JQ2229,JDVLVR,JDVLVS,S20752,S20757,JDVLJ2,# & JDVLCP)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,VTGGVFLVDK*# SEQUENCE: VTGGVFLVDK*# ...# >HUM12CC1# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (612-620)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVI,DPOL_HPBVT,DPOL_HPBV2,DPOL_HPBVP,# & DPOL_HPBVL,DPOL_HPBVA,DPOL_HPBVJ,DPOM_HPBVY,DPOL_HPBVO,# & DPOL_HPBV9,DPOL_HPBVM)# & PIR1: (JDVLA1,JDVLJ1,S47406,JDVLVD,S20757,JQ2229,JDVLVB,JDVLKS,# & S20752,JDVLJ3,S43491,JDVLJ2,JDVLCP,JDVLVS)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,PVNRPIDWK*# SEQUENCE: PVNRPIDWK*# ...# >HUM12CC2# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (149-158)# DB REFERENCE: SWISS: (DPOL_HPBVP,DPOL_HPBVO,DPOL_HPBVY,DPOL_HPBV9,DPOL_HPBV4,# & DPOL_HPBVR,DPOL_HPBVM,DPOL_HPBVW,DPOM_HPBVY,DPOL_HPBVI,# & DPOL_HPBVT,DPOL_HPBV2,DPOL_HPBVJ)# & PIR1: (S20757,JQ2229,JDVLVB,JDVLVD,JDVLVS,JDVLVR,JDVLKS,S20752,# & JDVLJ3,S43491,JDVLJ2,S47406,JDVLVA,JDVLJ1)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,HTLWKAGILY*# SEQUENCE: HTLWKAGILY*# ...# >HUM12CC3# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (538-547)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVL,DPOL_HPBVR,DPOL_HPBV4,DPOM_HPBVY,# & DPOL_HPBV2,DPOL_HPBVJ,DPOL_HPBVI,DPOL_HPBVY,DPOL_HPBVP,# & DPOL_HPBV9,DPOL_HPBVZ,DPOL_HPBVM)# & PIR1: (JDVLA1,S43491,JDVLJ3,JDVLVS,JDVLCP,S20752,JDVLVR,JDVLVA,# & JDVLJ1,S20757,JDVLVB,S47406,JDVLKS,JDVLVH,JDVLVD)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,YMDDVVLGAK*# SEQUENCE: YMDDVVLGAK*# ...# >HUM12CC4# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (150-158)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBV4,DPOL_HPBVO,DPOL_HPBVR,DPOM_HPBVY,# & DPOL_HPBVJ,DPOL_HPBV2,DPOL_HPBVW,DPOL_HPBVI,DPOL_HPBVY,# & DPOL_HPBV9,DPOL_HPBVP,DPOL_HPBVT)# & PIR1: (JQ2229,JDVLVS,JDVLKS,S47406,JDVLVD,S43491,JDVLJ3,JDVLVA,# & JDVLJ1,S20752,JDVLVR,S20757,JDVLVB,JDVLJ2)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,TLWKAGILY*# SEQUENCE: TLWKAGILY*# ...# >HUM12CC5# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (735-745)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBVM,DPOL_HPBVZ,DPOM_HPBVY,DPOL_HPBV2,# & DPOL_HPBV9,DPOL_HPBVI,DPOL_HPBVO,DPOL_HPBVL,DPOL_HPBVA,# & DPOL_HPBVY,DPOL_HPBVR,DPOL_HPBVJ)# & PIR1: (S20757,JDVLVB,JDVLKS,S47406,JDVLCP,JDVLVD,JDVLJ1,S43491,# & JDVLJ2,JDVLA1,S20752,JDVLVH,JDVLVS,JDVLVA,JDVLJ3,JQ2229,# & JDVLVR)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,GTDNSVVLSRK*# SEQUENCE: GTDNSVVLSRK*# ...# >HUM12CC6# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (357-367)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVJ,DPOL_HPBVT,DPOL_HPBVM,DPOL_HPBVZ,# & DPOL_HPBVW,DPOL_HPBVP,DPOM_HPBVY,DPOL_HPBV9,DPOL_HPBVO,# & DPOL_HPBVI,DPOL_HPBVR,DPOL_HPBVY,DPOL_HPBV4,DPOL_HPBV2,# & DPOL_HPBVA)# & PIR1: (JDVLVA,JDVLA1,S20752,S20757,JDVLJ3,JQ2229,JDVLVR,JDVLVB,# & JDVLJ2,JDVLJ1,S43491,JDVLVH,JDVLVS,JDVLKS,S47406,JDVLCP,# & JDVLVD)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesl,RVTGGVFLVDK*# SEQUENCE: RVTGGVFLVDK*# ...# >HUM12CC7# MHC MOLECULE: HLA-A3, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV env (360-369)# DB REFERENCE: SWISS: (VMSA_HPBVD,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVW,VMSA_HPBVP,# & VMSA_HPBV4,VMSA_HPBVN,VMSA_HPBVS,VMSA_HPBV2,VMSA_HPBVJ,# & VMSA_HPBVY,VMSA_HPBV9,VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVZ,# & VMSA_HPBVW)# & PIR1: (SAVLA,JQ1573,SAVLAJ,JQ1577,JQ1571,JQ1581,SAVLN1,JQ1575,# & SAVLJ1,SAVLVD,SAVLAR,JQ1576,SAVLAD,JQ1572,SAVLVE,SAVLBH,# & SAVLAH,JQ1578,SAVLKS)# & PIR2: (JQ2052,S20753,JQ2063,JQ2108,JQ2089,S35528,JQ2094,JQ2050,# & S47407,JQ2070,JQ2061,JQ2048,JQ2088,S36654,JQ2111,S47411,# & JQ2051,JQ2054,JQ2067,JQ2085,JQ2099,JQ2104,S32202,JQ2083,# & JQ2096,JQ2103,JQ2098,JQ2075,JQ2045,JQ2053,S41869,JQ2081,# & JQ2055,JQ2072,S41870,JQ2097,JQ2079,JQ2059,JQ2073,S20749,# & JQ2110,JQ2105,JQ2112,JQ2087,S20745,JQ2069,JQ2114,JQ2109,# & JQ2080,JQ2092,JQ2115,JQ2106,JQ2113,JQ2095,JQ2091,JQ2078,# & JQ2116,JQ2047,JQ2090,JQ2065,JQ2056,JQ2066)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A3,actunkn,bindyesm,MMWYWGPSLY*# SEQUENCE: MMWYWGPSLY*# ...# >HUM12CC8# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (149-159)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBVM,DPOL_HPBV2,DPOL_HPBVY,DPOL_HPBV4,# & DPOL_HPBVR,DPOL_HPBV9,DPOL_HPBVP,DPOL_HPBVO,DPOL_HPBVW,# & DPOL_HPBVJ,DPOL_HPBVI,DPOM_HPBVY)# & PIR1: (S20757,S20752,JDVLKS,JDVLVA,JDVLVS,JDVLJ1,JDVLVB,JDVLJ2,# & S43491,S47406,JDVLVD,JDVLVR,JQ2229,JDVLJ3)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,HTLWKAGILYK*# SEQUENCE: HTLWKAGILYK*# ...# >HUM12CC9# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV core (141-151)# DB REFERENCE: SWISS: (CORA_HPBVT,CORA_HPBVW,CORA_HPBVL,CORA_HPBVF,CORA_HPBVJ,# & CORA_HPBVO,CORA_HPBVY,CORA_HPBV4,CORA_HPBV9,CORA_HPBVA,# & CORA_HPBV2,CORA_HPBVZ)# & PIR1: (NKVLBH,NKVLH3,NKVLAH,NKVLKS,NKVLCP,NKVLA4,NKVLJ1,NKVLJ2,# & NKVLA3,NKVLA1,NKVLA2,NKVLA6)# & PIR2: (S53216,S53242,S53181,S20750,S53184,S53198,S53223,S53260,# & S53155,S53236,S53207,S53172,S53140,S01405,S53200,S25651,# & S53238,S53270,JQ2227,S53225,S53166,S53152,S53211,S35530,# & S53227,S32204,S53175,S53169,S53240,S53255,S53253,S53146,# & S53129,S53204,S20746,S53281,S33686,S53157,S53178,S47405,# & S53229,S53232,S53163,S53251,S53202,S47409,S53221,S53257,# & S53272,S04570,S53194,S53159,S53279)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,STLPETTVVRR*# SEQUENCE: STLPETTVVRR*# ...# >HUM12CCA# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (654-663)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVY,DPOL_HPBVJ,DPOL_HPBVI,DPOL_HPBVP,# & DPOL_HPBVO,DPOL_HPBVZ,DPOL_HPBV4,DPOL_HPBVR,DPOL_HPBVM,# & DPOL_HPBV2,DPOL_HPBVA,DPOL_HPBV9,DPOM_HPBVY)# & PIR1: (S20752,S43491,JDVLJ1,S20757,JDVLVB,JDVLKS,JDVLA1,JDVLVS,# & JDVLVA,JDVLVR,JDVLJ3,JDVLVH,JDVLJ2,S47406,JDVLVD,# & JDVLCP)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,QAFTFSPTYK*# SEQUENCE: QAFTFSPTYK*# ...# >HUM12CCB# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (520-528)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBVO,DPOL_HPBVT,DPOL_HPBVI,# & DPOL_HPBVJ,DPOL_HPBVL,DPOL_HPBVZ,DPOL_HPBVM,DPOL_HPBV2,# & DPOL_HPBVA,DPOL_HPBV9,DPOL_HPBVR,DPOL_HPBV4,# & DPOL_HPBVY)# & PIR1: (S47406,JDVLVD,JDVLVH,JDVLVR,JDVLVA,JDVLA1,JDVLKS,JDVLJ1,# & S20757,JDVLVB,JDVLJ3,JDVLCP,JDVLJ2,JDVLVS,JQ2229,# & S20752)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,SAICSVVRR*# SEQUENCE: SAICSVVRR*# ...# >HUM12CCC# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (377-386)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBVT,DPOL_HPBVO,DPOL_HPBVP,DPOL_HPBVZ,# & DPOL_WHV59,DPOL_HPBVA,DPOL_HPBVL,DPOL_HPBVJ,DPOL_HPBGS,# & DPOL_HPBVW,DPOL_HPBVM,DPOL_HPBV2,DPOL_WHV8I,DPOL_HPBVY,# & DPOL_WHV1,DPOL_HPBV4,DPOL_HPBVR,DPOL_WHV7,DPOL_HPBV9,# & DPOM_HPBVY,DPOL_WHVW6)# & PIR1: (JDVLJ2,JDVLVD,JDVLVR,JDVLW8,JDVLKS,S47406,JDVLA1,JDVLCP,# & JDVLJ3,JDVLVB,JDVLVS,JQ2229,S43491,S20752,JDVLJ1,S20757,# & JDVL7,JDVLS,JDVLVA,JDVLC,JDVL64,JDVLVH,JDVL59)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,LVVDFSQFSR*# SEQUENCE: LVVDFSQFSR*# ...# >HUM12CCD# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: HBV pol (55-63)# DB REFERENCE: SWISS: (DPOL_HPBV2,DPOL_HPBVR,DPOL_HPBVT,DPOL_HPBVZ,DPOL_HPBVI,# & DPOL_HPBV9,DPOL_HPBVA,DPOL_HPBVL,DPOL_HPBVM,DPOL_HPBVY,# & DPOL_HPBVW,DPOM_HPBVY,DPOL_HPBV4,DPOL_HPBVJ,DPOL_HPBVO,# & DPOL_HPBVP)# & PIR1: (JDVLVH,JDVLVA,JDVLJ1,S20757,JDVLVB,S43491,JDVLVS,JDVLVD,# & JDVLVR,JDVLKS,JDVLJ2,JDVLA1,JQ2229,JDVLCP,JDVLJ3,# & S47406)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesm,KVGNFTGLY*# SEQUENCE: KVGNFTGLY*# ...# >HUM12CCE# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV pol (150-159)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVT,DPOL_HPBV9,DPOL_HPBVR,DPOL_HPBV2,# & DPOL_HPBVI,DPOL_HPBVY,DPOL_HPBVJ,DPOL_HPBVO,DPOL_HPBVP,# & DPOM_HPBVY,DPOL_HPBVW,DPOL_HPBVM)# & PIR1: (S47406,S43491,JDVLJ2,JDVLJ1,JDVLJ3,JQ2229,JDVLKS,S20752,# & JDVLVD,JDVLVR,S20757,JDVLVB,JDVLVS,JDVLVA)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actyesu,bindyesh,TLWKAGILYK*# SEQUENCE: TLWKAGILYK*# ...# >HUM12CCF# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (358-367)# DB REFERENCE: SWISS: (DPOL_HPBVO,DPOL_HPBVL,DPOM_HPBVY,DPOL_HPBV4,DPOL_HPBVT,# & DPOL_HPBV9,DPOL_HPBVR,DPOL_HPBVI,DPOL_HPBVA,DPOL_HPBVY,# & DPOL_HPBVP,DPOL_HPBVM,DPOL_HPBVW,DPOL_HPBVZ,DPOL_HPBVJ,# & DPOL_HPBV2)# & PIR1: (JDVLVA,JDVLVB,JDVLVS,S20752,JDVLKS,JDVLVD,JDVLVR,JDVLJ3,# & JQ2229,JDVLCP,JDVLJ1,S43491,S47406,JDVLVH,S20757,JDVLA1,# & JDVLJ2)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,VTGGVFLVDK*# SEQUENCE: VTGGVFLVDK*# ...# >HUM12CD0# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (378-386)# DB REFERENCE: SWISS: (DPOL_HPBVW,DPOL_WHV1,DPOL_HPBVR,DPOL_HPBV4,DPOL_WHV7,# & DPOL_HPBVO,DPOL_HPBVL,DPOM_HPBVY,DPOL_HPBVT,DPOL_HPBVI,# & DPOL_HPBVA,DPOL_HPBGS,DPOL_WHV59,DPOL_HPBVM,DPOL_HPBVZ,# & DPOL_HPBVJ,DPOL_HPBV2,DPOL_WHVW6,DPOL_WHV8I,DPOL_HPBV9,# & DPOL_HPBVY,DPOL_HPBVP)# & PIR1: (S43491,JDVLVB,JDVLVA,JDVLVD,JDVLW8,JDVL59,JDVLJ2,S20757,# & JDVLVH,JDVLA1,JDVLCP,S47406,JDVLJ3,JDVLJ1,JDVLVR,JQ2229,# & JDVLKS,JDVLS,S20752,JDVL7,JDVLC,JDVL64,JDVLVS)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,VVDFSQFSR*# SEQUENCE: VVDFSQFSR*# ...# >HUM12CD1# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV nuc (170-179)# DB REFERENCE: SWISS: (CORA_HPBV4,CORA_HPBVL,CORA_HPBVY,CORA_HPBV2,CORA_HPBVT,# & CORA_HPBVJ,CORA_HPBVF,CORA_HPBVW,CORA_HPBV9,CORA_HPBVO,# & CORA_HPBVA,CORA_HPBVZ)# & PIR1: (NKVLH3,NKVLJ1,NKVLKS,NKVLJ2,NKVLA4,NKVLA6,NKVLCP,NKVLA2,# & NKVLA1,NKVLAH,NKVLA3,NKVLBH)# & PIR2: (S53221,S53129,S20746,S53281,S53159,S53194,S53272,S53223,# & S53260,S53225,S53152,S53227,S35530,S53155,S53172,S53251,# & S53202,S53178,S53163,S33686,S53157,S53229,S47405,S53184,# & S53198,S53240,S53169,S53253,S53204,S53211,S53216,S53279,# & S53288,S53257,S47409,S04570,S32204,S53166,S43490,S53232,# & S53146,S01405,S53238,S53270,JQ2227,S53236,S53207,S53140,# & S20750,S53181,S53242,S25651,S53200,S53175,S53255)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,STLPETTVVR*# SEQUENCE: STLPETTVVR*# ...# >HUM12CD2# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV nuc (171-180)# DB REFERENCE: SWISS: (CORA_HPBVA,CORA_HPBVO,CORA_HPBVT,CORA_HPBVY,CORA_HPBVL,# & CORA_HPBV2,CORA_HPBVF,CORA_HPBVW,CORA_HPBVZ,CORA_HPBV9,# & CORA_HPBV4,CORA_HPBVJ)# & PIR1: (NKVLCP,NKVLAH,NKVLA2,NKVLH3,NKVLBH,NKVLA3,NKVLA1,NKVLA6,# & NKVLA4,NKVLJ2,NKVLKS,NKVLJ1)# & PIR2: (S53152,S53225,S47405,S53253,S53240,S53198,S53272,S53223,# & S53281,S53238,S53255,S53155,S53202,S53175,S53181,S53216,# & S53279,S32204,S53166,S53184,S53211,S53227,S53169,S53242,# & S53274,S35530,S01405,S53200,S25651,S20750,S53159,S53194,# & S53260,S53178,S53251,S53229,S53157,S53163,S33686,S53172,# & S53221,S53129,S20746,S53204,S04570,S53207,S53140,S53236,# & JQ2227,S53270,S53232,S53146,S53257,S47409)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,TLPETTVVRR*# SEQUENCE: TLPETTVVRR*# ...# >HUM12CD3# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (612-620)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBV4,DPOL_HPBVO,DPOL_HPBVL,DPOL_HPBVT,# & DPOL_HPBV2,DPOM_HPBVY,DPOL_HPBVJ,DPOL_HPBV9,DPOL_HPBVP,# & DPOL_HPBVA,DPOL_HPBVM)# & PIR1: (JDVLJ3,S20757,JDVLJ2,JDVLKS,S20752,JQ2229,S43491,JDVLVB,# & S47406,JDVLA1,JDVLJ1,JDVLCP,JDVLVS,JDVLVD)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,PVNRPIDWK*# SEQUENCE: PVNRPIDWK*# ...# >HUM12CD4# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (735-744)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVT,DPOL_HPBVA,DPOL_HPBVR,DPOL_HPBVZ,# & DPOL_HPBVO,DPOL_HPBVJ,DPOL_HPBV2,DPOM_HPBVY,DPOL_HPBV9,# & DPOL_HPBVM,DPOL_HPBVI,DPOL_HPBVY)# & PIR1: (JDVLCP,JDVLVS,JDVLKS,JQ2229,JDVLJ3,JDVLVA,JDVLJ1,JDVLA1,# & S47406,JDVLVD,JDVLVR,S20752,S43491,JDVLVB,JDVLVH,S20757,# & JDVLJ2)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,GTDNSVVLSR*# SEQUENCE: GTDNSVVLSR*# ...# >HUM12CD5# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (538-547)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVJ,DPOL_HPBVA,DPOL_HPBVR,DPOL_HPBV9,# & DPOL_HPBVZ,DPOL_HPBV2,DPOM_HPBVY,DPOL_HPBVM,DPOL_HPBV4,# & DPOL_HPBVL,DPOL_HPBVP,DPOL_HPBVI)# & PIR1: (S43491,JDVLVB,JDVLVH,JDVLVA,JDVLJ1,S47406,JDVLVD,JDVLA1,# & JDVLVR,S20752,S20757,JDVLCP,JDVLKS,JDVLVS,JDVLJ3)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesl,YMDDVVLGAK*# SEQUENCE: YMDDVVLGAK*# ...# >HUM12CD6# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (735-745)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBVR,DPOL_HPBVA,DPOL_HPBV9,DPOL_HPBVO,# & DPOM_HPBVY,DPOL_HPBV2,DPOL_HPBVM,DPOL_HPBVL,DPOL_HPBVY,# & DPOL_HPBVJ,DPOL_HPBVI,DPOL_HPBVZ)# & PIR1: (JQ2229,JDVLVB,JDVLVH,S43491,JDVLJ2,JDVLVR,S20757,S20752,# & JDVLVS,JDVLCP,JDVLJ3,JDVLVA,JDVLJ1,S47406,JDVLA1,JDVLVD,# & JDVLKS)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesh,GTDNSVVLSRK*# SEQUENCE: GTDNSVVLSRK*# ...# >HUM12CD7# MHC MOLECULE: HLA-A11, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (357-367)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBV2,DPOM_HPBVY,DPOL_HPBVZ,DPOL_HPBVT,# & DPOL_HPBVP,DPOL_HPBVW,DPOL_HPBVR,DPOL_HPBVA,DPOL_HPBVY,# & DPOL_HPBVJ,DPOL_HPBVM,DPOL_HPBVO,DPOL_HPBV4,DPOL_HPBVL,# & DPOL_HPBV9)# & PIR1: (S20757,JDVLVS,JDVLCP,JDVLJ3,JDVLVB,JDVLVH,S43491,JDVLJ2,# & JDVLVD,JDVLA1,S47406,JDVLKS,JDVLVA,JDVLJ1,JDVLVR,S20752,# & JQ2229)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A11,actunkn,bindyesm,RVTGGVFLVDK*# SEQUENCE: RVTGGVFLVDK*# ...# >HUM12CD8# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (149-159)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBV9,DPOL_HPBVT,DPOL_HPBVW,DPOL_HPBVP,# & DPOL_HPBVY,DPOL_HPBVR,DPOL_HPBV4,DPOL_HPBVJ,DPOL_HPBVM,# & DPOL_HPBVO,DPOL_HPBV2,DPOM_HPBVY)# & PIR1: (JDVLVS,S20757,JDVLVR,JDVLJ1,JDVLJ3,JDVLVD,S47406,JDVLJ2,# & S43491,JDVLKS,JDVLVB,S20752,JDVLVA,JQ2229)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesm,HTLWKAGILYK*# SEQUENCE: HTLWKAGILYK*# ...# >HUM12CD9# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (520-528)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVP,DPOL_HPBVJ,DPOL_HPBV4,DPOL_HPBVM,# & DPOL_HPBVO,DPOL_HPBVI,DPOL_HPBV9,DPOL_HPBVT,DPOL_HPBVY,# & DPOL_HPBVA,DPOL_HPBV2,DPOL_HPBVZ,DPOL_HPBVR,# & DPOM_HPBVY)# & PIR1: (JDVLVA,JDVLVB,S20752,S20757,JDVLJ1,JDVLVR,JDVLKS,S47406,# & JDVLVD,JDVLJ2,JDVLA1,JDVLJ3,JDVLCP,JDVLVS,JQ2229,# & JDVLVH)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,SAICSVVRR*# SEQUENCE: SAICSVVRR*# ...# >HUM12CDA# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (377-386)# DB REFERENCE: SWISS: (DPOL_WHVW6,DPOL_HPBVW,DPOL_HPBVL,DPOL_HPBVT,DPOL_HPBVZ,# & DPOL_HPBV4,DPOL_HPBVO,DPOL_HPBVJ,DPOL_HPBVP,DPOL_WHV1,# & DPOL_HPBVI,DPOL_WHV7,DPOL_HPBV9,DPOL_HPBVY,DPOL_HPBVR,# & DPOM_HPBVY,DPOL_HPBGS,DPOL_WHV8I,DPOL_WHV59,DPOL_HPBV2,# & DPOL_HPBVA,DPOL_HPBVM)# & PIR1: (JDVLA1,JDVLCP,JDVLC,JDVLJ2,JDVLVR,JDVLKS,JDVLVS,S20757,# & S20752,JDVLVA,JDVLVB,JDVLS,JDVL7,S43491,S47406,JDVLJ3,# & JDVL64,JDVLJ1,JDVLW8,JQ2229,JDVLVD,JDVLVH,JDVL59)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,LVVDFSQFSR*# SEQUENCE: LVVDFSQFSR*# ...# >HUM12CDB# MHC MOLECULE: HLA-A31(A*3101), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV nuc (170-179)# DB REFERENCE: SWISS: (CORA_HPBVF,CORA_HPBV4,CORA_HPBVY,CORA_HPBVO,CORA_HPBVA,# & CORA_HPBVT,CORA_HPBVW,CORA_HPBV2,CORA_HPBVZ,CORA_HPBVL,# & CORA_HPBV9,CORA_HPBVJ)# & PIR1: (NKVLKS,NKVLAH,NKVLJ1,NKVLJ2,NKVLA3,NKVLBH,NKVLA6,NKVLCP,# & NKVLH3,NKVLA2,NKVLA1,NKVLA4)# & PIR2: (S53169,S53242,S53175,S53181,S53202,S53155,S32204,S53216,# & S53279,S53211,S53288,S53255,S53272,S53223,S53236,S53140,# & S53257,S53159,S53260,S25651,S01405,S20750,S53253,S53198,# & S53281,S35530,S20746,S53178,S53157,S33686,S53172,S53200,# & S53240,S53227,S53184,S53238,S53166,S53229,S53146,S47409,# & S53204,S53152,S47405,S53225,S43490,S53207,S53232,S04570,# & JQ2227,S53270,S53194,S53221,S53129,S53163,S53251)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A31,actunkn,bindyesl,STLPETTVVR*# SEQUENCE: STLPETTVVR*# ...# >HUM12CDC# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (149-159)# DB REFERENCE: SWISS: (DPOL_HPBV2,DPOL_HPBVJ,DPOL_HPBV9,DPOL_HPBVI,DPOL_HPBVR,# & DPOL_HPBVY,DPOM_HPBVY,DPOL_HPBVO,DPOL_HPBV4,DPOL_HPBVP,# & DPOL_HPBVW,DPOL_HPBVT,DPOL_HPBVM)# & PIR1: (S47406,S43491,S20757,JDVLVS,S20752,JDVLKS,JDVLJ2,JQ2229,# & JDVLVA,JDVLVB,JDVLJ1,JDVLVR,JDVLJ3,JDVLVD)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,HTLWKAGILYK*# SEQUENCE: HTLWKAGILYK*# ...# >HUM12CDD# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV core (141-151)# DB REFERENCE: SWISS: (CORA_HPBVL,CORA_HPBVJ,CORA_HPBVW,CORA_HPBV2,CORA_HPBVZ,# & CORA_HPBVY,CORA_HPBVT,CORA_HPBVO,CORA_HPBVA,CORA_HPBV9,# & CORA_HPBV4,CORA_HPBVF)# & PIR1: (NKVLJ2,NKVLAH,NKVLCP,NKVLA6,NKVLA2,NKVLA3,NKVLBH,NKVLH3,# & NKVLA4,NKVLA1,NKVLKS,NKVLJ1)# & PIR2: (S53169,S53181,S53175,JQ2227,S53221,S53253,S53198,S53281,# & S53255,S53272,S53223,S53216,S53279,S53211,S53232,S53146,# & S53204,S53166,S53240,S53200,S53163,S53260,S53257,S53178,# & S53129,S53157,S53202,S33686,S53172,S20750,S25651,S53140,# & S53159,S20746,S53242,S53155,S32204,S53152,S53225,S47405,# & S04570,S53251,S53194,S53207,S53270,S01405,S53236,S53229,# & S53227,S53184,S47409,S53238,S35530)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,STLPETTVVRR*# SEQUENCE: STLPETTVVRR*# ...# >HUM12CDE# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (520-528)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVP,DPOL_HPBVO,DPOL_HPBVJ,DPOL_HPBV9,# & DPOL_HPBVT,DPOL_HPBVZ,DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBVY,# & DPOL_HPBV2,DPOL_HPBVL,DPOL_HPBVM,DPOL_HPBV4,# & DPOL_HPBVR)# & PIR1: (JDVLVR,JQ2229,JDVLVD,JDVLVH,S47406,JDVLA1,JDVLCP,S20752,# & JDVLJ2,JDVLKS,JDVLVB,JDVLVA,JDVLVS,S20757,JDVLJ1,# & JDVLJ3)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,SAICSVVRR*# SEQUENCE: SAICSVVRR*# ...# >HUM12CDF# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (377-386)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBGS,DPOL_HPBVO,DPOL_HPBVJ,DPOL_HPBV9,# & DPOL_WHVW6,DPOL_HPBVA,DPOL_HPBVP,DPOL_HPBVT,DPOL_HPBVY,# & DPOL_HPBVI,DPOL_WHV1,DPOL_HPBVL,DPOL_HPBVM,DPOL_HPBVW,# & DPOL_WHV7,DPOL_HPBVZ,DPOL_HPBV2,DPOL_WHV59,DPOL_HPBVR,# & DPOL_WHV8I,DPOL_HPBV4)# & PIR1: (JDVL64,S43491,JDVLJ2,JDVLC,JDVLVH,JDVLVD,JDVLVR,JDVLVS,# & JDVLKS,S20757,S20752,JDVLA1,JDVLCP,JDVLW8,JDVLVA,JDVLVB,# & JDVLS,JDVL7,JQ2229,JDVL59,JDVLJ1,JDVLJ3,S47406)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesm,LVVDFSQFSR*# SEQUENCE: LVVDFSQFSR*# ...# >HUM12CE0# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (378-386)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOM_HPBVY,DPOL_HPBV9,DPOL_HPBVT,DPOL_WHVW6,# & DPOL_HPBVR,DPOL_HPBVP,DPOL_HPBVA,DPOL_HPBVJ,DPOL_HPBVI,# & DPOL_HPBVL,DPOL_HPBVW,DPOL_WHV7,DPOL_HPBVM,DPOL_HPBVZ,# & DPOL_WHV59,DPOL_WHV8I,DPOL_HPBV2,DPOL_WHV1,DPOL_HPBV4,# & DPOL_HPBGS,DPOL_HPBVO)# & PIR1: (S20757,JDVLA1,JDVLVB,JDVLC,S47406,JDVL7,JDVLS,JDVLVA,# & JDVLKS,JDVLVS,S20752,JDVL64,JDVLVR,JQ2229,JDVLW8,JDVLCP,# & JDVLVH,JDVLVD,JDVLJ1,JDVLJ3,JDVL59,S43491,JDVLJ2)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,VVDFSQFSR*# SEQUENCE: VVDFSQFSR*# ...# >HUM12CE1# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV nuc (170-179)# DB REFERENCE: SWISS: (CORA_HPBV9,CORA_HPBV4,CORA_HPBVF,CORA_HPBVT,CORA_HPBVO,# & CORA_HPBVA,CORA_HPBVZ,CORA_HPBVY,CORA_HPBVL,CORA_HPBVJ,# & CORA_HPBVW,CORA_HPBV2)# & PIR1: (NKVLJ2,NKVLCP,NKVLKS,NKVLA3,NKVLA1,NKVLJ1,NKVLH3,NKVLBH,# & NKVLA4,NKVLA6,NKVLAH,NKVLA2)# & PIR2: (JQ2227,S53181,S53288,S53159,S53140,S53204,S53146,S53166,# & S53200,S53129,S33686,S53172,S53163,S53229,S53236,S01405,# & S32204,S53155,S53251,S53194,S53207,S47405,S53152,S53225,# & S43490,S53238,S53260,S53279,S53255,S53211,S53216,S53178,# & S53272,S53198,S25651,S20746,S35530,S53223,S53281,S53169,# & S53175,S53232,S20750,S53242,S53270,S53184,S04570,S53240,# & S53257,S53157,S53202,S53227,S47409,S53253,S53221)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,STLPETTVVR*# SEQUENCE: STLPETTVVR*# ...# >HUM12CE2# MHC MOLECULE: HLA-A33(A*3301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV nuc (171-180)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBV2,CORA_HPBVL,CORA_HPBVT,CORA_HPBV9,# & CORA_HPBVA,CORA_HPBVZ,CORA_HPBVJ,CORA_HPBVF,CORA_HPBV4,# & CORA_HPBVO,CORA_HPBVW)# & PIR1: (NKVLH3,NKVLJ2,NKVLKS,NKVLJ1,NKVLA4,NKVLAH,NKVLA3,NKVLCP,# & NKVLA2,NKVLA1,NKVLA6,NKVLBH)# & PIR2: (S33686,S53229,S47405,S53184,S53281,S53175,S35530,S25651,# & S53216,S53255,S53129,S53163,S53236,S01405,S53194,S53207,# & S53225,S53169,S53140,S53200,S53279,S53260,S53181,JQ2227,# & S53155,S53251,S53274,S53178,S53211,S20750,S47409,S53157,# & S53202,S53257,S53253,S53242,S53270,S04570,S53227,S53240,# & S53221,S53198,S53272,S20746,S53172,S53223,S53232,S53152,# & S32204,S53238,S53204,S53146,S53166,S53159)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A33,actunkn,bindyesl,TLPETTVVRR*# SEQUENCE: TLPETTVVRR*# ...# >HUM12CE3# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (149-159)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVI,DPOL_HPBVP,DPOL_HPBVJ,DPOL_HPBVW,# & DPOL_HPBVM,DPOL_HPBV2,DPOL_HPBVT,DPOM_HPBVY,DPOL_HPBV9,# & DPOL_HPBVR,DPOL_HPBVO,DPOL_HPBV4)# & PIR1: (S43491,JQ2229,JDVLVR,JDVLJ3,JDVLVS,S20752,S20757,JDVLVB,# & JDVLJ2,JDVLVD,JDVLKS,JDVLVA,JDVLJ1,S47406)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,HTLWKAGILYK*# SEQUENCE: HTLWKAGILYK*# ...# >HUM12CE4# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (654-663)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBV4,DPOL_HPBVL,DPOL_HPBVJ,DPOL_HPBVZ,# & DPOL_HPBVO,DPOL_HPBV9,DPOL_HPBVR,DPOM_HPBVY,DPOL_HPBVA,# & DPOL_HPBV2,DPOL_HPBVI,DPOL_HPBVP,DPOL_HPBVY)# & PIR1: (JDVLCP,JDVLKS,JDVLVA,JDVLVD,JDVLA1,JDVLJ1,S20752,JDVLVR,# & JDVLJ3,JDVLVH,S20757,JDVLVB,JDVLJ2,S43491,S47406,# & JDVLVS)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,QAFTFSPTYK*# SEQUENCE: QAFTFSPTYK*# ...# >HUM12CE5# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (520-528)# DB REFERENCE: SWISS: (DPOL_HPBVP,DPOL_HPBVI,DPOL_HPBVT,DPOM_HPBVY,DPOL_HPBV2,# & DPOL_HPBVO,DPOL_HPBV9,DPOL_HPBVR,DPOL_HPBVZ,DPOL_HPBV4,# & DPOL_HPBVJ,DPOL_HPBVL,DPOL_HPBVM,DPOL_HPBVA,# & DPOL_HPBVY)# & PIR1: (JDVLCP,JDVLJ1,JDVLVD,JDVLVA,JDVLJ2,S20757,JDVLVB,JQ2229,# & S20752,JDVLVR,JDVLVH,JDVLVS,S47406,JDVLJ3,JDVLKS,# & JDVLA1)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,SAICSVVRR*# SEQUENCE: SAICSVVRR*# ...# >HUM12CE6# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (377-386)# DB REFERENCE: SWISS: (DPOL_HPBVW,DPOL_HPBVP,DPOL_WHV1,DPOL_HPBV9,DPOL_HPBVA,# & DPOL_HPBVY,DPOL_WHVW6,DPOL_HPBGS,DPOL_HPBV4,DPOL_WHV59,# & DPOL_WHV8I,DPOL_HPBVZ,DPOL_HPBVL,DPOL_HPBVJ,DPOL_HPBVM,# & DPOL_WHV7,DPOM_HPBVY,DPOL_HPBVO,DPOL_HPBVR,DPOL_HPBVI,# & DPOL_HPBVT,DPOL_HPBV2)# & PIR1: (JQ2229,JDVL64,S43491,JDVLKS,JDVLJ3,JDVLVH,JDVLVR,S20757,# & JDVLVB,JDVLW8,JDVLJ2,JDVL7,JDVLS,S20752,JDVLVD,JDVLVA,# & JDVL59,S47406,JDVLVS,JDVLJ1,JDVLCP,JDVLA1,JDVLC)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesh,LVVDFSQFSR*# SEQUENCE: LVVDFSQFSR*# ...# >HUM12CE7# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (358-367)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVI,DPOL_HPBVW,DPOL_HPBVJ,DPOL_HPBVZ,# & DPOL_HPBVR,DPOL_HPBVY,DPOL_HPBVT,DPOL_HPBV9,DPOL_HPBVP,# & DPOL_HPBV4,DPOL_HPBVM,DPOL_HPBVL,DPOL_HPBVA,DPOL_HPBV2,# & DPOL_HPBVO)# & PIR1: (JDVLVR,S43491,S47406,JDVLJ3,S20752,JDVLVD,JDVLJ2,S20757,# & JQ2229,JDVLA1,JDVLCP,JDVLJ1,JDVLVB,JDVLVH,JDVLVA,JDVLKS,# & JDVLVS)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesl,VTGGVFLVDK*# SEQUENCE: VTGGVFLVDK*# ...# >HUM12CE8# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (378-386)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVW,DPOL_HPBVI,DPOL_HPBV9,DPOL_WHVW6,# & DPOL_HPBVT,DPOL_HPBVM,DPOL_WHV1,DPOL_HPBVO,DPOL_HPBV2,# & DPOL_HPBV4,DPOL_HPBVA,DPOL_HPBVP,DPOL_HPBGS,DPOL_WHV8I,# & DPOL_HPBVY,DPOL_HPBVZ,DPOL_HPBVR,DPOL_HPBVJ,DPOL_WHV7,# & DPOL_WHV59,DPOL_HPBVL)# & PIR1: (JQ2229,JDVLVR,JDVLVA,JDVLVH,JDVL64,JDVLKS,JDVLVD,JDVLW8,# & JDVLJ2,S47406,JDVL59,S43491,JDVLJ3,JDVLA1,JDVLCP,JDVLJ1,# & S20752,S20757,JDVLVS,JDVLVB,JDVLC,JDVLS,JDVL7)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,VVDFSQFSR*# SEQUENCE: VVDFSQFSR*# ...# >HUM12CE9# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV nuc (170-179)# DB REFERENCE: SWISS: (CORA_HPBV4,CORA_HPBVZ,CORA_HPBVA,CORA_HPBVJ,CORA_HPBVF,# & CORA_HPBV9,CORA_HPBVL,CORA_HPBV2,CORA_HPBVY,CORA_HPBVT,# & CORA_HPBVO,CORA_HPBVW)# & PIR1: (NKVLJ1,NKVLKS,NKVLJ2,NKVLBH,NKVLA6,NKVLH3,NKVLA1,NKVLA2,# & NKVLCP,NKVLAH,NKVLA4,NKVLA3)# & PIR2: (S53211,S53146,S32204,S53166,S53204,S53238,S53288,S53152,# & S53159,S43490,S53255,S53257,S53253,S53202,S53242,S53270,# & S53227,S47409,S53223,S53172,S53200,S53279,S53260,S53272,# & S20746,S53221,S35530,S25651,S53129,S53163,S53207,S53155,# & S53251,JQ2227,S53181,S53229,S53178,S53184,S53175,S53281,# & S33686,S47405,S53216,S53198,S53232,S20750,S53140,S53169,# & S53225,S53194,S53236,S01405,S04570,S53240,S53157)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,STLPETTVVR*# SEQUENCE: STLPETTVVR*# ...# >HUM12CEA# MHC MOLECULE: HLA-A68(A*6801), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV nuc (171-180)# DB REFERENCE: SWISS: (CORA_HPBV4,CORA_HPBVJ,CORA_HPBVZ,CORA_HPBVO,CORA_HPBV2,# & CORA_HPBVL,CORA_HPBVW,CORA_HPBV9,CORA_HPBVF,CORA_HPBVY,# & CORA_HPBVT,CORA_HPBVA)# & PIR1: (NKVLBH,NKVLH3,NKVLKS,NKVLJ2,NKVLAH,NKVLA3,NKVLA1,NKVLCP,# & NKVLA2,NKVLA4,NKVLA6,NKVLJ1)# & PIR2: (S53251,S53178,S53140,S53225,S01405,S53169,S53146,S53272,# & S53207,S53221,S53200,S20746,S53172,JQ2227,S53232,S53281,# & S32204,S53152,S53216,S53198,S53255,S53159,S53274,S53240,# & S04570,S53157,S53236,S53194,S47405,S33686,S53229,S53184,# & S53175,S53155,S20750,S53181,S53279,S53260,S53129,S53163,# & S25651,S35530,S53253,S53211,S53227,S47409,S53270,S53242,# & S53257,S53202,S53223,S53238,S53204,S53166)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A68,actunkn,bindyesm,TLPETTVVRR*# SEQUENCE: TLPETTVVRR*# ...# >HUM12CEB# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (530-539)# DB REFERENCE: SWISS: (DPOL_HPBV2,DPOL_HPBVZ,DPOL_HPBVO,DPOL_HPBVA,DPOL_HPBV4,# & DPOL_HPBVP,DPOM_HPBVY,DPOL_HPBVI,DPOL_HPBVM,DPOL_HPBVT,# & DPOL_HPBVY,DPOL_HPBV9,DPOL_HPBVR,DPOL_HPBVL,# & DPOL_HPBVJ)# & PIR1: (S20757,JQ2229,S20752,JDVLVD,JDVLKS,JDVLVR,JDVLCP,JDVLA1,# & JDVLVA,JDVLJ1,S43491,JDVLJ3,S47406,JDVLVS,JDVLVB,JDVLVH,# & JDVLJ2)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,FPHCLAFSYM*# SEQUENCE: FPHCLAFSYM*# ...# >HUM12CEC# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV core (19-27)# DB REFERENCE: SWISS: (CORA_HPBVW,CORA_HPBV2,CORA_HPBVO,CORA_HPBVL,CORA_HPBVZ,# & CORA_HPBVJ,CORA_HPBVT,CORA_HPBVY,CORA_HPBV9,CORA_HPBVA,# & CORA_HPBVF)# & PIR1: (NKVLAH,NKVLCP,NKVLA1,NKVLA2,NKVLA6,NKVLH3,NKVLA3,NKVLJ2,# & NKVLBH,NKVLKS,NKVLJ1)# & PIR2: (S53163,S53202,S53257,S53242,S47409,S53288,S47405,S33686,# & S53137,S53240,S53189,S53155,S53181,S20750,S53184,S53229,# & S53175,S53255,S53274,S53159,S53216,S53272,S53143,S53232,# & S53214,S53152,S01405,S53169,S53225,S53251,S53178,S53211,# & S43490,JQ2227,S20746,S53200,S53253,S53270,S53281,S32204,# & S53260,S53279,S53129,S53221,S53207,S25651,S53267,S53238,# & S53204,S53227,S53223,S53286,S53236)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesl,LPSDFFPSV*# SEQUENCE: LPSDFFPSV*# ...# >HUM12CED# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (429-437)# DB REFERENCE: SWISS: (DPOL_HPBVO,DPOL_HPBV4,DPOL_HPBVA,DPOL_HPBVP,DPOM_HPBVY,# & DPOL_HPBVT,DPOL_HPBVY,DPOL_HPBVW,DPOL_HPBVJ,DPOL_HPBVL,# & DPOL_HPBV9,DPOL_HPBVI,DPOL_HPBVM,DPOL_HPBVR,DPOL_HPBV2,# & DPOL_HPBVZ)# & PIR1: (S20757,JDVLJ3,JQ2229,JDVLVB,JDVLVS,JDVLVR,JDVLKS,JDVLVA,# & JDVLJ1,S43491,S47406,JDVLCP,JDVLA1,JDVLVH,JDVLJ2,S20752,# & JDVLVD)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,HPAAMPHLL*# SEQUENCE: HPAAMPHLL*# ...# >HUM12CEE# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (640-648)# DB REFERENCE: SWISS: (DPOL_HPBVP,DPOL_HPBV2,DPOL_HPBVM,DPOL_HPBV9,DPOL_HPBVL,# & DPOL_HPBVJ,DPOL_HPBVO,DPOL_HPBVA,DPOL_HPBV4,DPOL_HPBVI,# & DPOL_HPBVZ,DPOL_HPBVY,DPOL_HPBVT,DPOM_HPBVY,# & DPOL_HPBVR)# & PIR1: (JDVLVB,JDVLVA,JDVLVR,S20752,S20757,JQ2229,JDVLJ3,JDVLKS,# & S43491,JDVLCP,JDVLA1,JDVLJ1,JDVLVS,JDVLJ2,JDVLVH,# & JDVLVD)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,YPALMPLYA*# SEQUENCE: YPALMPLYA*# ...# >HUM12CEF# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (354-363)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVI,DPOL_HPBVZ,DPOL_HPBV4,DPOL_HPBVP,# & DPOL_HPBV9,DPOL_HPBVM,DPOL_HPBV2,DPOL_HPBVT,DPOM_HPBVY,# & DPOL_HPBVW,DPOL_HPBVL,DPOL_HPBVJ,DPOL_HPBVO,# & DPOL_HPBVR)# & PIR1: (JDVLJ3,JDVLKS,JDVLJ2,JQ2229,S20757,S20752,JDVLVH,JDVLCP,# & JDVLA1,JDVLJ1,S47406,S43491,JDVLVS,JDVLVR,JDVLVB,# & JDVLVD)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesh,TPARVTGGVF*# SEQUENCE: TPARVTGGVF*# ...# >HUM12CF0# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (429-438)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVJ,DPOL_HPBVL,DPOL_HPBVT,DPOL_HPBVR,# & DPOL_HPBV4,DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBVI,DPOL_HPBVZ,# & DPOL_HPBVO,DPOM_HPBVY)# & PIR1: (JDVLVA,JDVLJ2,JDVLJ1,JDVLA1,JDVLCP,S47406,JDVLVR,JDVLVH,# & JDVLVS,S43491,S20757,JQ2229,S20752,JDVLVB,JDVLJ3)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,HPAAMPHLLV*# SEQUENCE: HPAAMPHLLV*# ...# >HUM12CF1# MHC MOLECULE: HLA-B7(B*0702), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (778-786)# DB REFERENCE: SWISS: (DPOL_HPBVO,DPOL_HPBVY,DPOL_HPBVI,DPOL_HPBVM,DPOL_HPBVL,# & DPOL_HPBVJ,DPOL_HPBV2,DPOL_HPBVR,DPOL_HPBVA,DPOM_HPBVY,# & DPOL_HPBVT,DPOL_HPBV9)# & PIR1: (JDVLA1,JDVLVA,JDVLVB,JDVLVD,JDVLJ2,JDVLVS,S20752,JQ2229,# & S20757,S43491,JDVLKS,JDVLJ3,JDVLJ1,JDVLCP,S47406,# & JDVLVR)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B7,actunkn,bindyesm,DPSRGRLGL*# SEQUENCE: DPSRGRLGL*# ...# >HUM12CF2# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (530-539)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBVZ,DPOL_HPBVO,DPOM_HPBVY,DPOL_HPBVT,# & DPOL_HPBV9,DPOL_HPBVA,DPOL_HPBVP,DPOL_HPBVL,DPOL_HPBVJ,# & DPOL_HPBV2,DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBV4,# & DPOL_HPBVI)# & PIR1: (JDVLVH,JDVLCP,JDVLJ1,JDVLVD,JDVLJ2,JDVLA1,JDVLVB,JDVLVS,# & JQ2229,S20757,S20752,JDVLKS,JDVLVR,JDVLJ3,JDVLVA,S47406,# & S43491)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesh,FPHCLAFSYM*# SEQUENCE: FPHCLAFSYM*# ...# >HUM12CF3# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV core (19-27)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVT,CORA_HPBVJ,CORA_HPBV2,CORA_HPBVW,# & CORA_HPBVF,CORA_HPBV9,CORA_HPBVA,CORA_HPBVL,CORA_HPBVO,# & CORA_HPBVZ)# & PIR1: (NKVLA3,NKVLAH,NKVLA1,NKVLA6,NKVLA2,NKVLJ2,NKVLH3,NKVLBH,# & NKVLCP,NKVLJ1,NKVLKS)# & PIR2: (S33686,S53137,S53175,S53184,S53189,S20750,S53279,S53257,# & S53204,S53214,S53152,S53251,S53169,S01405,S53225,S53216,# & S53255,S25651,S53267,S53238,S53227,S20746,S43490,S53253,# & S53286,S53281,S53129,S53221,S53207,S53270,S53260,S32204,# & S47409,S53181,S53143,S53232,S53178,S53200,JQ2227,S53211,# & S53236,S53223,S53163,S53229,S53202,S53242,S53288,S47405,# & S53240,S53155,S53272,S53159,S53274)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,LPSDFFPSV*# SEQUENCE: LPSDFFPSV*# ...# >HUM12CF4# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (429-437)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBVR,DPOL_HPBVW,DPOL_HPBVY,DPOL_HPBV4,# & DPOL_HPBV9,DPOL_HPBVO,DPOM_HPBVY,DPOL_HPBV2,DPOL_HPBVL,# & DPOL_HPBVP,DPOL_HPBVJ,DPOL_HPBVM,DPOL_HPBVA,DPOL_HPBVZ,# & DPOL_HPBVI)# & PIR1: (JDVLJ2,JDVLJ1,JDVLVH,JDVLVD,JDVLKS,JDVLJ3,JDVLVB,S20757,# & JDVLA1,S47406,JDVLVR,S20752,JQ2229,JDVLVA,JDVLVS,S43491,# & JDVLCP)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,HPAAMPHLL*# SEQUENCE: HPAAMPHLL*# ...# >HUM12CF5# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (640-648)# DB REFERENCE: SWISS: (DPOL_HPBVI,DPOL_HPBVY,DPOL_HPBV4,DPOL_HPBVP,DPOM_HPBVY,# & DPOL_HPBVL,DPOL_HPBV2,DPOL_HPBVT,DPOL_HPBVR,DPOL_HPBVJ,# & DPOL_HPBVA,DPOL_HPBVM,DPOL_HPBVZ,DPOL_HPBV9,# & DPOL_HPBVO)# & PIR1: (JDVLKS,JDVLVR,JQ2229,S20752,JDVLA1,JDVLVH,JDVLVD,JDVLJ1,# & JDVLJ2,JDVLVA,JDVLCP,JDVLVB,S20757,JDVLJ3,JDVLVS,# & S43491)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,YPALMPLYA*# SEQUENCE: YPALMPLYA*# ...# >HUM12CF6# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (354-363)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBV4,DPOL_HPBVP,DPOL_HPBVI,DPOL_HPBVW,# & DPOL_HPBVO,DPOL_HPBV9,DPOL_HPBVZ,DPOL_HPBVM,DPOL_HPBVJ,# & DPOL_HPBVA,DPOM_HPBVY,DPOL_HPBVR,DPOL_HPBV2,# & DPOL_HPBVL)# & PIR1: (JDVLJ1,JDVLA1,JDVLVS,S43491,JDVLJ3,JDVLVB,S20757,JDVLVH,# & JDVLVD,JDVLJ2,JDVLVR,S20752,JDVLKS,JDVLCP,JQ2229,# & S47406)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesm,TPARVTGGVF*# SEQUENCE: TPARVTGGVF*# ...# >HUM12CF7# MHC MOLECULE: HLA-B35(B*3501), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (429-438)# DB REFERENCE: SWISS: (DPOM_HPBVY,DPOL_HPBVL,DPOL_HPBVI,DPOL_HPBVY,DPOL_HPBVM,# & DPOL_HPBVT,DPOL_HPBVZ,DPOL_HPBVO,DPOL_HPBVR,DPOL_HPBVJ,# & DPOL_HPBVA,DPOL_HPBV4)# & PIR1: (S20752,S47406,JQ2229,JDVLVR,JDVLJ2,JDVLVH,JDVLJ3,JDVLVB,# & S20757,S43491,JDVLVS,JDVLCP,JDVLVA,JDVLJ1,JDVLA1)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesl,HPAAMPHLLV*# SEQUENCE: HPAAMPHLLV*# ...# >HUM12CF8# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (530-539)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVO,DPOL_HPBVZ,DPOL_HPBVR,DPOL_HPBV9,# & DPOL_HPBVI,DPOL_HPBVM,DPOL_HPBVY,DPOL_HPBVT,DPOL_HPBVJ,# & DPOL_HPBVA,DPOL_HPBVP,DPOL_HPBV2,DPOM_HPBVY,# & DPOL_HPBVL)# & PIR1: (S47406,JDVLKS,JDVLVR,JDVLVA,JDVLJ1,JDVLA1,JDVLCP,JDVLVB,# & S20757,JDVLJ3,JDVLVD,S43491,JDVLJ2,JDVLVH,JQ2229,JDVLVS,# & S20752)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,FPHCLAFSYM*# SEQUENCE: FPHCLAFSYM*# ...# >HUM12CF9# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: HBV core (19-27)# DB REFERENCE: SWISS: (CORA_HPBV2,CORA_HPBVT,CORA_HPBVF,CORA_HPBVZ,CORA_HPBVY,# & CORA_HPBVW,CORA_HPBVJ,CORA_HPBV9,CORA_HPBVA,CORA_HPBVL,# & CORA_HPBVO)# & PIR1: (NKVLCP,NKVLA3,NKVLAH,NKVLA6,NKVLA2,NKVLBH,NKVLH3,NKVLJ1,# & NKVLKS,NKVLJ2,NKVLA1)# & PIR2: (S53163,S53229,S53202,S47405,S53240,S53272,S53207,S43490,# & S53281,S53286,S53253,S53129,S53143,S53232,S53204,S53236,# & JQ2227,S53178,S53181,S32204,S53184,S53175,S53189,S53169,# & S53211,S53279,S53257,S53137,S20750,S53267,S25651,S53227,# & S53238,S53255,S20746,S53251,S53225,S53214,S53242,S53288,# & S53155,S53274,S53200,S53221,S53152,S01405,S53159,S53223,# & S53260,S33686,S53216,S53270,S47409)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesh,LPSDFFPSV*# SEQUENCE: LPSDFFPSV*# ...# >HUM12CFA# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (429-437)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBVA,DPOL_HPBV9,DPOL_HPBVO,DPOL_HPBVZ,# & DPOL_HPBVW,DPOL_HPBVY,DPOL_HPBVP,DPOL_HPBV2,DPOM_HPBVY,# & DPOL_HPBVJ,DPOL_HPBVI,DPOL_HPBVM,DPOL_HPBV4,DPOL_HPBVR,# & DPOL_HPBVL)# & PIR1: (JQ2229,JDVLVS,JDVLVR,JDVLJ2,JDVLVH,JDVLVA,JDVLJ1,JDVLA1,# & JDVLCP,JDVLKS,S47406,JDVLJ3,JDVLVD,S43491,S20752,S20757,# & JDVLVB)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,HPAAMPHLL*# SEQUENCE: HPAAMPHLL*# ...# >HUM12CFB# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (640-648)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBVL,DPOL_HPBVZ,DPOL_HPBV9,DPOL_HPBVT,# & DPOL_HPBVA,DPOL_HPBVP,DPOL_HPBVJ,DPOL_HPBVO,DPOL_HPBVY,# & DPOL_HPBV4,DPOL_HPBV2,DPOM_HPBVY,DPOL_HPBVM,# & DPOL_HPBVI)# & PIR1: (S20757,JDVLVD,S43491,JDVLCP,JDVLA1,JQ2229,JDVLVS,JDVLKS,# & JDVLVR,JDVLJ3,JDVLJ1,JDVLVA,JDVLJ2,JDVLVH,JDVLVB,# & S20752)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesm,YPALMPLYA*# SEQUENCE: YPALMPLYA*# ...# >HUM12CFC# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (429-438)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBVL,DPOL_HPBVJ,DPOL_HPBVT,DPOL_HPBVO,# & DPOL_HPBVY,DPOL_HPBVI,DPOL_HPBVZ,DPOL_HPBV4,DPOL_HPBVM,# & DPOM_HPBVY,DPOL_HPBVA)# & PIR1: (JDVLJ3,JDVLVA,JDVLJ1,JDVLVR,JQ2229,JDVLVH,S20757,JDVLJ2,# & JDVLVS,S47406,S20752,S43491,JDVLCP,JDVLA1,JDVLVB)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B51,actunkn,bindyesl,HPAAMPHLLV*# SEQUENCE: HPAAMPHLLV*# ...# >HUM12CFD# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (530-539)# DB REFERENCE: SWISS: (DPOL_HPBV2,DPOL_HPBVO,DPOL_HPBVZ,DPOL_HPBV4,DPOL_HPBVA,# & DPOL_HPBVY,DPOL_HPBVR,DPOL_HPBVL,DPOL_HPBVJ,DPOL_HPBVT,# & DPOL_HPBVI,DPOL_HPBV9,DPOM_HPBVY,DPOL_HPBVP,# & DPOL_HPBVM)# & PIR1: (JDVLVD,JDVLJ2,JDVLA1,S43491,JDVLCP,JDVLKS,S47406,S20757,# & S20752,JDVLVS,JDVLVA,JDVLJ3,JDVLJ1,JDVLVR,JDVLVB,JQ2229,# & JDVLVH)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,FPHCLAFSYM*# SEQUENCE: FPHCLAFSYM*# ...# >HUM12CFE# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV core (19-27)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVW,CORA_HPBVJ,CORA_HPBVA,CORA_HPBVO,# & CORA_HPBV2,CORA_HPBVT,CORA_HPBVF,CORA_HPBVZ,CORA_HPBVL,# & CORA_HPBV9)# & PIR1: (NKVLA3,NKVLA6,NKVLBH,NKVLA2,NKVLAH,NKVLCP,NKVLH3,NKVLKS,# & NKVLJ1,NKVLA1,NKVLJ2)# & PIR2: (S43490,S53286,S53253,S53129,S53189,S53169,S53163,S53202,# & S53229,S53178,S53240,S53181,JQ2227,S32204,S53236,S53143,# & S53232,S53279,S25651,S53238,S53251,S53255,S53225,S20746,# & S20750,S53257,S53270,S47409,S53216,S33686,S53221,S53274,# & S53288,S53211,S01405,S53159,S53223,S53152,S53260,S53227,# & S47405,S53204,S53200,S53155,S53242,S53267,S53214,S53137,# & S53281,S53272,S53207,S53175,S53184)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,LPSDFFPSV*# SEQUENCE: LPSDFFPSV*# ...# >HUM12CFF# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (429-437)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVT,DPOL_HPBV9,DPOL_HPBVO,DPOL_HPBV2,# & DPOL_HPBVM,DPOL_HPBVI,DPOL_HPBVW,DPOL_HPBVR,DPOL_HPBVJ,# & DPOL_HPBVA,DPOL_HPBVY,DPOL_HPBVZ,DPOL_HPBV4,DPOM_HPBVY,# & DPOL_HPBVP)# & PIR1: (JDVLVS,S47406,JDVLKS,JDVLA1,JDVLCP,S20752,S43491,JDVLVB,# & JDVLVH,S20757,JQ2229,JDVLJ2,JDVLVD,JDVLJ3,JDVLJ1,JDVLVA,# & JDVLVR)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesm,HPAAMPHLL*# SEQUENCE: HPAAMPHLL*# ...# >HUM12D00# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (640-648)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVT,DPOL_HPBVM,DPOL_HPBVI,DPOL_HPBV4,# & DPOL_HPBVA,DPOL_HPBVY,DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBV9,# & DPOL_HPBVO,DPOL_HPBV2,DPOL_HPBVZ,DPOL_HPBVR,# & DPOL_HPBVJ)# & PIR1: (JDVLJ2,JDVLVA,JDVLVR,S43491,JDVLCP,JDVLA1,JDVLVH,JDVLVB,# & S20757,JQ2229,JDVLJ3,JDVLJ1,JDVLVD,JDVLKS,JDVLVS,# & S20752)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,YPALMPLYA*# SEQUENCE: YPALMPLYA*# ...# >HUM12D01# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (354-363)# DB REFERENCE: SWISS: (DPOL_HPBVM,DPOL_HPBVA,DPOL_HPBV4,DPOL_HPBVL,DPOL_HPBVJ,# & DPOL_HPBV2,DPOL_HPBVT,DPOL_HPBVW,DPOL_HPBV9,DPOL_HPBVO,# & DPOM_HPBVY,DPOL_HPBVP,DPOL_HPBVZ,DPOL_HPBVR,# & DPOL_HPBVI)# & PIR1: (S20752,S47406,JDVLVS,JDVLVB,JQ2229,S20757,S43491,JDVLVR,# & JDVLJ1,JDVLKS,JDVLVD,JDVLJ2,JDVLCP,JDVLJ3,JDVLVH,# & JDVLA1)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,TPARVTGGVF*# SEQUENCE: TPARVTGGVF*# ...# >HUM12D02# MHC MOLECULE: HLA-B53(B*5301), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (429-438)# DB REFERENCE: SWISS: (DPOL_HPBVO,DPOL_HPBVM,DPOL_HPBVA,DPOL_HPBVL,DPOL_HPBVY,# & DPOM_HPBVY,DPOL_HPBVJ,DPOL_HPBV4,DPOL_HPBVT,DPOL_HPBVR,# & DPOL_HPBVZ,DPOL_HPBVI)# & PIR1: (JDVLCP,JDVLA1,JDVLJ3,JDVLVH,S20757,JDVLVB,S43491,JDVLVR,# & JDVLVA,JDVLJ2,JDVLJ1,S20752,S47406,JDVLVS,JQ2229)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B53,actunkn,bindyesl,HPAAMPHLLV*# SEQUENCE: HPAAMPHLLV*# ...# >HUM12D03# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HBV pol (530-539)# DB REFERENCE: SWISS: (DPOL_HPBVO,DPOL_HPBVY,DPOL_HPBVL,DPOL_HPBVM,DPOL_HPBVA,# & DPOL_HPBVP,DPOM_HPBVY,DPOL_HPBVT,DPOL_HPBVJ,DPOL_HPBV2,# & DPOL_HPBV4,DPOL_HPBVI,DPOL_HPBVR,DPOL_HPBVZ,# & DPOL_HPBV9)# & PIR1: (S20752,S47406,JDVLJ3,JDVLVH,JDVLJ2,JDVLVA,JDVLVR,JDVLJ1,# & JQ2229,JDVLA1,JDVLVD,JDVLKS,JDVLVB,S20757,S43491,JDVLVS,# & JDVLCP)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesm,FPHCLAFSYM*# SEQUENCE: FPHCLAFSYM*# ...# >HUM12D04# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV core (19-27)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVA,CORA_HPBV2,CORA_HPBVF,CORA_HPBVZ,# & CORA_HPBV9,CORA_HPBVY,CORA_HPBVO,CORA_HPBVW,CORA_HPBVT,# & CORA_HPBVL)# & PIR1: (NKVLBH,NKVLJ2,NKVLAH,NKVLJ1,NKVLH3,NKVLA1,NKVLKS,NKVLCP,# & NKVLA6,NKVLA2,NKVLA3)# & PIR2: (S53238,S53229,S47409,S53274,S53175,S53184,S53242,S53214,# & S53227,S53204,S20750,S53255,S53181,JQ2227,S53200,S53223,# & S53270,S33686,S53216,S53202,S53163,S53240,S53178,S53236,# & S43490,S53286,S53129,S53253,S53137,S32204,S53288,S53257,# & S53279,S53232,S53143,S53251,S53225,S20746,S25651,S53221,# & S01405,S53211,S53159,S53207,S53281,S53272,S53189,S53169,# & S47405,S53267,S53155,S53152,S53260)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,LPSDFFPSV*# SEQUENCE: LPSDFFPSV*# ...# >HUM12D05# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (429-437)# DB REFERENCE: SWISS: (DPOL_HPBVP,DPOL_HPBVL,DPOL_HPBV9,DPOL_HPBVA,DPOL_HPBVW,# & DPOM_HPBVY,DPOL_HPBVI,DPOL_HPBVT,DPOL_HPBVZ,DPOL_HPBVR,# & DPOL_HPBV4,DPOL_HPBVJ,DPOL_HPBV2,DPOL_HPBVO,DPOL_HPBVM,# & DPOL_HPBVY)# & PIR1: (JDVLJ2,JDVLVA,JDVLJ3,JDVLVH,JDVLKS,JDVLVB,S20757,S43491,# & JDVLVR,S20752,S47406,JDVLVD,JDVLVS,JDVLA1,JQ2229,JDVLJ1,# & JDVLCP)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,HPAAMPHLL*# SEQUENCE: HPAAMPHLL*# ...# >HUM12D06# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HBV pol (640-648)# DB REFERENCE: SWISS: (DPOL_HPBVT,DPOL_HPBVY,DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBV9,# & DPOL_HPBVP,DPOL_HPBVL,DPOL_HPBVA,DPOL_HPBVZ,DPOL_HPBV4,# & DPOL_HPBVO,DPOL_HPBV2,DPOL_HPBVJ,DPOL_HPBVM,# & DPOL_HPBVR)# & PIR1: (JDVLVD,JQ2229,S20752,JDVLJ1,JDVLCP,JDVLA1,JDVLVA,JDVLKS,# & JDVLJ2,JDVLVR,JDVLJ3,JDVLVH,JDVLVB,S20757,S43491,# & JDVLVS)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesh,YPALMPLYA*# SEQUENCE: YPALMPLYA*# ...# >HUM12D07# MHC MOLECULE: HLA-B54(B*5401), CLASS-1, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HBV pol (429-438)# DB REFERENCE: SWISS: (DPOL_HPBVY,DPOL_HPBVR,DPOL_HPBVT,DPOL_HPBVA,DPOL_HPBVO,# & DPOL_HPBV4,DPOL_HPBVJ,DPOL_HPBVZ,DPOL_HPBVL,DPOL_HPBVM,# & DPOL_HPBVI,DPOM_HPBVY)# & PIR1: (JDVLCP,JDVLJ1,JDVLVS,JDVLJ2,JDVLVR,JDVLVH,JDVLVB,S43491,# & S20757,JDVLJ3,JQ2229,S47406,JDVLVA,JDVLA1,S20752)# & PIR2: (S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B54,actunkn,bindyesl,HPAAMPHLLV*# SEQUENCE: HPAAMPHLLV*# ...# >HUM12D08# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV env (183-191)# DB REFERENCE: SWISS: (VMSA_HPBVS,VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVZ,VMSA_HPBVP,# & VMSA_HPBVW,VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBVD,VMSA_HPBV9,# & VMSA_HPBV2,VMSA_HPBVY,VMSA_HPBVW,VMSA_HPBVN,VMSA_HPBV0,# & VMSA_HPBV4)# & PIR1: (SAVLAJ,SAVLAH,SAVLAD,SAVLBH,SAVLA,SAVLVE,SAVLAR,SAVLVD,# & SAVLKS,SAVLN1,JQ1577,JQ1575,SAVLHV)# & PIR2: (JQ2108,S35528,S47407,JQ2104,JQ2046,S41871,JQ2077,JQ2083,# & JQ2067,JQ2054,JQ2099,S32202,JQ2072,JQ2096,JQ2094,S20749,# & JQ2073,JQ2100,JQ2048,JQ2111,JQ2112,JQ2066,JQ2065,JQ2078,# & JQ2080,JQ2114,JQ2115,JQ2069,JQ2076,S20745,S43492,S41870,# & JQ2055,JQ2102,JQ2081,S41869,JQ2045,JQ2075,JQ2098,JQ2097,# & JQ2056,JQ2047,JQ2068,JQ2113,S47411,JQ2051,JQ2103,S20753,# & JQ2063,JQ2105,JQ2079,JQ2070,JQ2050,JQ2052,S36654,JQ2095,# & JQ2109,JQ2053)# & PIR4: (S42226)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FLLTRILTI*# SEQUENCE: FLLTRILTI*# ...# >HUM12D09# MHC MOLECULE: HLA-A31, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV pol (520-528)# DB REFERENCE: SWISS: (DPOL_HPBVL,DPOL_HPBVA,DPOL_HPBVI,DPOM_HPBVY,DPOL_HPBV4,# & DPOL_HPBVP,DPOL_HPBVO,DPOL_HPBVJ,DPOL_HPBV2,DPOL_HPBV9,# & DPOL_HPBVM,DPOL_HPBVR,DPOL_HPBVY,DPOL_HPBVT,# & DPOL_HPBVZ)# & PIR1: (JDVLVD,JDVLA1,JDVLCP,JDVLVA,JDVLVH,JDVLVR,JDVLVB,S47406,# & S20752,S20757,JDVLJ2,JDVLVS,JQ2229,JDVLJ3,JDVLKS,# & JDVLJ1)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A31,actyesu,bindyesu,SAICSVVRR*# SEQUENCE: SAICSVVRR*# ...# >HUM12D0A# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV pol (354-363)# DB REFERENCE: SWISS: (DPOL_HPBVA,DPOL_HPBVJ,DPOL_HPBVI,DPOL_HPBV4,DPOL_HPBVM,# & DPOL_HPBV9,DPOL_HPBV2,DPOL_HPBVR,DPOL_HPBVO,DPOL_HPBVW,# & DPOL_HPBVZ,DPOL_HPBVL,DPOL_HPBVP,DPOL_HPBVT,# & DPOM_HPBVY)# & PIR1: (JDVLKS,JDVLJ2,JDVLVR,JDVLVH,S20757,S47406,JDVLVS,JDVLJ1,# & JDVLJ3,JQ2229,JDVLVB,S43491,JDVLCP,JDVLVD,JDVLA1,# & S20752)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B35,actyesu,bindyesu,TPARVTGGVF*# SEQUENCE: TPARVTGGVF*# ...# >HUM12D0B# MHC MOLECULE: HLA-B51, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV pol (354-363)# DB REFERENCE: SWISS: (DPOL_HPBV4,DPOL_HPBVL,DPOL_HPBV2,DPOL_HPBV9,DPOL_HPBVJ,# & DPOL_HPBVI,DPOL_HPBVR,DPOL_HPBVO,DPOL_HPBVZ,DPOL_HPBVP,# & DPOM_HPBVY,DPOL_HPBVW,DPOL_HPBVT,DPOL_HPBVM,# & DPOL_HPBVA)# & PIR1: (JDVLJ1,JDVLJ3,JQ2229,JDVLVS,JDVLVD,JDVLA1,JDVLCP,S43491,# & JDVLVR,JDVLVH,S47406,JDVLJ2,JDVLVB,JDVLKS,S20752,# & S20757)# & PIR2: (S35527,S71785)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-B51,actyesu,bindyesu,TPARVTGGVF*# SEQUENCE: TPARVTGGVF*# ...# >HUM12D0C# MHC MOLECULE: HLA-A2(A*0207), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV core (18-27)# DB REFERENCE: SWISS: (CORA_HPBVJ,CORA_HPBVT,CORA_HPBVL,CORA_HPBVW,CORA_HPBV2,# & CORA_HPBV9,CORA_HPBVA,CORA_HPBVF,CORA_HPBVZ,CORA_HPBVY,# & CORA_HPBVO)# & PIR1: (NKVLA1,NKVLCP,NKVLJ2,NKVLAH,NKVLBH,NKVLKS,NKVLJ1,NKVLH3,# & NKVLA2,NKVLA6,NKVLA3)# & PIR2: (S53178,S53129,S43490,S53286,S53257,S53279,S25651,S53240,# & S53238,S53211,S53281,S53267,S53260,S47405,S53169,S53189,# & JQ2227,S53181,S53255,S20750,S53223,S53270,S53216,S33686,# & S53200,S53227,S53137,S32204,S53214,S53274,S01405,S53207,# & S53229,S47409,S53288,S53236,S53202,S53163,S53143,S53242,# & S53184,S53175,S53204,S53253,S53232,S53221,S20746,S53251,# & S53225,S53272,S53159,S53152,S53155)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FLPSDFFPSV*# SEQUENCE: FLPSDFFPSV*# ...# >HUM12D0D# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV pol (575-583)# DB REFERENCE: SWISS: (DPOL_HPBVR,DPOL_HPBV9,DPOL_HPBVM,DPOL_HPBVA,DPOL_HPBVP,# & DPOL_HPBVY,DPOL_HPBVZ,DPOL_HPBVI,DPOL_HPBV2,DPOL_HPBVJ,# & DPOL_HPBVL,DPOL_HPBV4,DPOL_HPBVO,DPOM_HPBVY)# & PIR1: (JDVLJ3,JDVLVS,JDVLVA,S47406,JDVLVH,JDVLJ1,JDVLJ2,JDVLVR,# & JDVLKS,JDVLCP,JDVLVD,JDVLA1,S20757,JDVLVB,S20752)# & PIR2: (S71785,S35527)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,FLLSLGIHL*# SEQUENCE: FLLSLGIHL*# ...# >HUM12D0E# MHC MOLECULE: HLA-A2(A*0205), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV pol (455-463)# DB REFERENCE: SWISS: (DPOL_HPBVZ,DPOL_HPBVW,DPOM_HPBVY,DPOL_HPBV2,DPOL_HPBV9,# & DPOL_HPBVI,DPOL_HPBVY,DPOL_HPBVP,DPOL_HPBVA,DPOL_HPBVJ,# & DPOL_HPBVO,DPOL_HPBVT,DPOL_HPBVL)# & PIR1: (JDVLCP,JDVLA1,JDVLVA,JDVLJ3,S20757,JDVLKS,JDVLVB,JDVLVH,# & S47406,JDVLJ1,JDVLJ2,JQ2229,JDVLVD)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GLSRYVARL*# SEQUENCE: GLSRYVARL*# ...# >HUM12D0F# MHC MOLECULE: HLA-A2(A*0206), CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBV pol (455-463)# DB REFERENCE: SWISS: (DPOL_HPBV9,DPOL_HPBVL,DPOL_HPBVW,DPOL_HPBVZ,DPOL_HPBV2,# & DPOL_HPBVA,DPOL_HPBVY,DPOM_HPBVY,DPOL_HPBVT,DPOL_HPBVO,# & DPOL_HPBVJ,DPOL_HPBVI,DPOL_HPBVP)# & PIR1: (JDVLJ3,JDVLJ2,S20757,JDVLKS,JDVLVB,JQ2229,S47406,JDVLA1,# & JDVLJ1,JDVLVA,JDVLVH,JDVLCP,JDVLVD)# ANCHOR POSITIONS: ?# REFERENCES: bertoni97a# COMMENT:# SUMMARY: HLA-A2,actyesu,bindyesu,GLSRYVARL*# SEQUENCE: GLSRYVARL*# ...# >HUM22D10# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (37-59)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,KSNGYKGDWYVQQLRMLNRDLEQ*# SEQUENCE: KSNGYKGDWYVQQLRMLNRDLEQ*# ...# >HUM22D11# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (400-420)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,ANSKLAALERLNKELEESKKL*# SEQUENCE: ANSKLAALERLNKELEESKKL*# ...# >HUM22D12# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (165-187)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesh,bindyesh,KQKVLSLEQQLAVTKENAKKDFE*# SEQUENCE: KQKVLSLEQQLAVTKENAKKDFE*# ...# >HUM22D13# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (128-151)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,RHKQEIAEKENVISKLNGELQPLK*# SEQUENCE: RHKQEIAEKENVISKLNGELQPLK*# ...# >HUM22D14# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (73-96)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,LGKLGIDNADLKAKITELEKSVEE*# SEQUENCE: LGKLGIDNADLKAKITELEKSVEE*# ...# >HUM22D15# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (15-36)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,LGQKFERLRQRSELYLQQYYDN*# SEQUENCE: LGQKFERLRQRSELYLQQYYDN*# ...# >HUM22D16# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (269-292)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,QAKKATEAELNNLKAELAKVTEQK*# SEQUENCE: QAKKATEAELNNLKAELAKVTEQK*# ...# >HUM22D17# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (389-409)# DB REFERENCE: SWISS: (M5_STRPY,M24_STRPY,M6_STRPY,PAM_STRPY,M12_STRPY)# & PIR2: (S54871,S34978,S30284,A28616,JC1419,A28549,S43554,A26297,# & S35401,A44643,A60115,S43556,S30283,A49545)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,AKKQVEKALEEANSKLAALEK*# SEQUENCE: AKKQVEKALEEANSKLAALEK*# ...# >HUM22D18# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (301-325)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,GTARDLEAVRKAKAQVEAALKQLEE*# SEQUENCE: GTARDLEAVRKAKAQVEAALKQLEE*# ...# >HUM22D19# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (112-136)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesh,bindyesh,EKDIQFGREVHAADLLRHKQEIAEK*# SEQUENCE: EKDIQFGREVHAADLLRHKQEIAEK*# ...# >HUM22D1A# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Proliferation/Competition# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (441-460)# DB REFERENCE: SWISS: (SPH_STRPY,M5_STRPY,M12_STRPY,M6_STRPY)# & PIR2: (S34978,A43528,A60115,A44643,A28616,A26297)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesl,bindyesh,EQLAKQAEELAKLRAGKASD*# SEQUENCE: EQLAKQAEELAKLRAGKASD*# ...# >HUM22D1B# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Proliferation/Competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (421-440)# DB REFERENCE: SWISS: (M5_STRPY,M24_STRPY,M6_STRPY,PAM_STRPY,M12_STRPY)# & PIR2: (S30284,A44643,S43554,A60115,A28549,JC1419,A49545,A26297,# & S30283,A28616,S43556,S54871)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesh,bindyesh,TEKEKAELQAKLEAEAKALK*# SEQUENCE: TEKEKAELQAKLEAEAKALK*# ...# >HUM22D1C# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (190-212)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,ALGHQLADKEYNAKIAELESKLA*# SEQUENCE: ALGHQLADKEYNAKIAELESKLA*# ...# >HUM22D1D# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry/Proliferation/Competition# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (431-451)# DB REFERENCE: SWISS: (M21_STRPY,M12_STRPY,M6_STRPY,PAM_STRPY,SPH_STRPY,# & MRP4_STRPY,M5_STRPY)# & PIR2: (A26297,A43528,S23325,A60115,S57835,S52536,S52537,A46173,# & S49550,A44643,S30283,A49545,S57834,A33939,A28616,# & S34978)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesh,bindyesh,KLEAEAKALKEQLAKQAEELA*# SEQUENCE: KLEAEAKALKEQLAKQAEELA*# ...# >HUM22D1E# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (316-340)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesm,VEAALKQLEEQNKISEASRKGLRRD*# SEQUENCE: VEAALKQLEEQNKISEASRKGLRRD*# ...# >HUM22D1F# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (97-120)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesm,KNDVLSQIKKELEEAEKDIQFGRE*# SEQUENCE: KNDVLSQIKKELEEAEKDIQFGRE*# ...# >HUM22D20# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (327-346)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesm,NKISEASRKGLRRDLDTSRE*# SEQUENCE: NKISEASRKGLRRDLDTSRE*# ...# >HUM22D21# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (177-200)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesm,VTKENAKKDFELAALGHQLADKEY*# SEQUENCE: VTKENAKKDFELAALGHQLADKEY*# ...# >HUM22D22# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (357-378)# DB REFERENCE: SWISS: (M6_STRPY,M12_STRPY,PAM_STRPY)# & PIR2: (A49545,A60115,S57835,A26297,S34978,S30284,S35401,# & A44643)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesm,NLTAELDKVKEEKQISDASRQG*# SEQUENCE: NLTAELDKVKEEKQISDASRQG*# ...# >HUM22D23# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (347-367)# DB REFERENCE: SWISS: (M12_STRPY,PAM_STRPY,M6_STRPY)# & PIR2: (A60115,A44643,S35401,S43556,S57835,A26297,S43554,S54871,# & JC1419,A49545,S30284,S34978)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesm,AKKQVEKDLANLTAELDKVKE*# SEQUENCE: AKKQVEKDLANLTAELDKVKE*# ...# >HUM22D24# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (410-430)# DB REFERENCE: SWISS: (PAM_STRPY,M5_STRPY,M6_STRPY,M24_STRPY)# & PIR2: (S35401,A44643,A28616,S43556,A26297,A28549,S30284,A49545,# & S43554,S30283,JC1419,S54871)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesm,LNKELEESKKLTEKEKAELQA*# SEQUENCE: LNKELEESKKLTEKEKAELQA*# ...# >HUM22D25# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (243-266)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,IKQLEEQKQILDASRKGTARDLEA*# SEQUENCE: IKQLEEQKQILDASRKGTARDLEA*# ...# >HUM22D26# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (202-225)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,AKIAELESKLADAKKDFELAALGH*# SEQUENCE: AKIAELESKLADAKKDFELAALGH*# ...# >HUM22D27# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (26-46)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115,S61073)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,SELYLQQYYDNKSNGYKGDWY*# SEQUENCE: SELYLQQYYDNKSNGYKGDWY*# ...# >HUM22D28# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (50-72)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,LKMLNRDLEQAYNELSGEAHKDA*# SEQUENCE: LKMLNRDLEQAYNELSGEAHKDA*# ...# >HUM22D29# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (368-388)# DB REFERENCE: SWISS: (M12_STRPY,M6_STRPY,PAM_STRPY)# & PIR2: (S30284,A49545,S30283,S34978,S35401,A26297,A44643,A60115,# & S57835)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,EKQISDASRQGLRRDLDASRE*# SEQUENCE: EKQISDASRQGLRRDLDASRE*# ...# >HUM22D2A# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (216-239)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,KDFELAALGHQHAHNEYQAKLAEK*# SEQUENCE: KDFELAALGHQHAHNEYQAKLAEK*# ...# >HUM22D2B# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (86-107)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,KITELEKSVEEKNDVLSQIKKE*# SEQUENCE: KITELEKSVEEKNDVLSQIKKE*# ...# >HUM22D2C# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (229-253)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,HNEYQAKLAEKDGQIKQLEEQKQIL*# SEQUENCE: HNEYQAKLAEKDGQIKQLEEQKQIL*# ...# >HUM22D2D# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (1-25)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (S61073,A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,DHSDLVAEKQRLEDLGQKFERLKQR*# SEQUENCE: DHSDLVAEKQRLEDLGQKFERLKQR*# ...# >HUM22D2E# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (62-83)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesl,NELSGEAHKDALGKLGIDNADL*# SEQUENCE: NELSGEAHKDALGKLGIDNADL*# ...# >HUM22D2F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Streptococcal wall Ag M 12 (347-367)# DB REFERENCE: SWISS: (PAM_STRPY,M12_STRPY,M6_STRPY)# & PIR2: (S34978,S43556,S43554,A60115,A26297,S35401,S54871,S57835,# & S30284,A49545,JC1419,A44643)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DR4,actyesm,bindyesu,AKKQVEKDLANLTAELDKVKE*# SEQUENCE: AKKQVEKDLANLTAELDKVKE*# ...# >HUM22D30# MHC MOLECULE: HLA-DQ6(DQA1*0103xDQB1*0601), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Streptococcal wall Ag M 12 (347-367)# DB REFERENCE: SWISS: (PAM_STRPY,M12_STRPY,M6_STRPY)# & PIR2: (A44643,S43554,S35401,S54871,JC1419,S43556,S34978,S57835,# & A60115,S30284,A49545,A26297)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DQ6,actyesh,bindyesu,AKKQVEKDLANLTAELDKVKE*# SEQUENCE: AKKQVEKDLANLTAELDKVKE*# ...# >HUM22D31# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (112-128)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesm,EKDIQFGREVHAADLLR*# SEQUENCE: EKDIQFGREVHAADLLR*# ...# >HUM22D32# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (114-128)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,DIQFGREVHAADLLR*# SEQUENCE: DIQFGREVHAADLLR*# ...# >HUM22D33# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation/Competition# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (116-128)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesh,QFGREVHAADLLR*# SEQUENCE: QFGREVHAADLLR*# ...# >HUM22D34# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (118-128)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,GREVHAADLLR*# SEQUENCE: GREVHAADLLR*# ...# >HUM22D35# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (112-125)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,EKDIQFGREVHAAD*# SEQUENCE: EKDIQFGREVHAAD*# ...# >HUM22D36# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (113-125)# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,KDIQFGREVHAAD*# SEQUENCE: KDIQFGREVHAAD*# ...# >HUM22D37# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (431-442)# DB REFERENCE: SWISS: (SPH_STRPY,MRP4_STRPY,M6_STRPY,PAM_STRPY,M12_STRPY,# & M5_STRPY,M21_STRPY)# & PIR2: (S23325,A44643,S52537,A28616,S49550,A49545,S35760,A46173,# & S30283,A26297,A43528,S52536,S57834,S57835,A33939,A60115,# & S34978)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,KLEAEAKALKEQ*# SEQUENCE: KLEAEAKALKEQ*# ...# >HUM22D38# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (441-453)# DB REFERENCE: SWISS: (ARP4_STRPY,M49_STRPY,SPH_STRPY,PAM_STRPY,M12_STRPY,# & M6_STRPY,MRP4_STRPY,M21_STRPY,M5_STRPY)# & PIR2: (S05568,S54858,A44643,S49550,S49551,S52537,S37046,S34978,# & S57834,A33939,S57835,A60115,S52536,B54128,A43528,A26297,# & S30283,A49545,A46173,A43715,A28616,S23325)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,EQLAKQAEELAKL*# SEQUENCE: EQLAKQAEELAKL*# ...# >HUM22D39# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Streptococcal wall Ag M 12 (442-453)# DB REFERENCE: SWISS: (M21_STRPY,M49_STRPY,M5_STRPY,M6_STRPY,MRP4_STRPY,# & PAM_STRPY,M12_STRPY,SPH_STRPY,ARP4_STRPY)# & PIR2: (A46173,S54858,A43528,B54128,S52536,S57834,A60115,S57835,# & S34978,A44643,S49550,S49551,S05568,A28616,S30283,A49545,# & A26297,A43715,S52537,S37046,S23325,A33939)# & PIR3: (S46489)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actunkn,bindyesh,QLAKQAEELAKL*# SEQUENCE: QLAKQAEELAKL*# ...# >HUM22D3A# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Proliferation/Competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (116-128) homologue# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesm,QFGKEVHAADLLR*# SEQUENCE: QFGKEVHAADLLR*# ...# >HUM22D3B# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Proliferation/Competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: Streptococcal wall Ag M 12 (441-453) homologue# DB REFERENCE: SWISS: (M24_STRPY)# & PIR2: (JC1419,A28549,S30284,S43556,S43554,S54871)# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesm,EKLAKQAEELAKL*# SEQUENCE: EKLAKQAEELAKL*# ...# >HUM22D3C# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Proliferation/Competition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (441-453) homologue# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,ETLAKQAEELAKL*# SEQUENCE: ETLAKQAEELAKL*# ...# >HUM22D3D# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Proliferation/Competition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (441-453) homologue# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,EELAKQAEELAKL*# SEQUENCE: EELAKQAEELAKL*# ...# >HUM22D3E# MHC MOLECULE: HLA-DP9(DPA1*0201xDPB1*0901), CLASS-2, (HUMAN)# METHOD: Proliferation/Competition# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: Streptococcal wall Ag M 12 (441-453) homologue# ANCHOR POSITIONS: ?# REFERENCES: dong95a# COMMENT:# SUMMARY: HLA-DP9,actyesu,bindyesl,EALAKQAEELAKL*# SEQUENCE: EALAKQAEELAKL*# ...# >HUM22D3F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MIF (33-48)# ANCHOR POSITIONS: ?# REFERENCES: kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KPPQYIAVHWPDQLM*# SEQUENCE: KPPQYIAVHWPDQLM*# ...# >HUM22D40# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MIF (33-47)# ANCHOR POSITIONS: ?# REFERENCES: kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KPPQYIAVHWPDQL*# SEQUENCE: KPPQYIAVHWPDQL*# ...# >HUM22D41# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Elution/Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MIF (33-46)# ANCHOR POSITIONS: ?# REFERENCES: kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,KPPQYIAVHWPDQ*# SEQUENCE: KPPQYIAVHWPDQ*# ...# >HUM22D42# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Transferrinin (89-ND)# DB REFERENCE: SWISS: (TRFE_BOVIN)# ANCHOR POSITIONS: ?# REFERENCES: kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,NPQTHYYAVAVVKKDTD*# SEQUENCE: NPQTHYYAVAVVKKDTD*# ...# >HUM22D43# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Flow cytometry# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta2m (85-98)# DB REFERENCE: SWISS: (B2MG_PONPY,B2MG_HUMAN)# & PIR1: (MGHUB2)# & PIR2: (I61868,I36963,I37063)# ANCHOR POSITIONS: ?# REFERENCES: kinouchi94a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LYYTEFTPTEKDEY*# SEQUENCE: LYYTEFTPTEKDEY*# ...# >HUM22D44# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-102)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_BOVIN,MBP_PANTR,MBP_MOUSE,MBP_RAT,# & MBP_HUMAN)# & PIR1: (MBMSB,MBPGB,MBCZB,MBHUB,MBRTS,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DENPVVHFFKNIVTPRTPP*# SEQUENCE: DENPVVHFFKNIVTPRTPP*# ...# >HUM22D45# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DENPVVHFFKNIVTRPTPPY*# SEQUENCE: DENPVVHFFKNIVTRPTPPY*# ...# >HUM22D46# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-102,Y93R)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DENPVVHFFRNIVTPRTPPY*# SEQUENCE: DENPVVHFFRNIVTPRTPPY*# ...# >HUM22D47# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (85-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,ENPVVHFFKNIVTPRTPPY*# SEQUENCE: ENPVVHFFKNIVTPRTPPY*# ...# >HUM22D48# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (86-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,NPVVHFFKNIVTPRTPPY*# SEQUENCE: NPVVHFFKNIVTPRTPPY*# ...# >HUM22D49# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (87-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,PVVHFFKNIVTPRTPPY*# SEQUENCE: PVVHFFKNIVTPRTPPY*# ...# >HUM22D4A# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (88-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,VVHFFKNIVTPRTPPY*# SEQUENCE: VVHFFKNIVTPRTPPY*# ...# >HUM22D4B# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (89-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,VHFFKNIVTPRTPPY*# SEQUENCE: VHFFKNIVTPRTPPY*# ...# >HUM22D4C# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (90-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,HFFKNIVTPRTPPY*# SEQUENCE: HFFKNIVTPRTPPY*# ...# >HUM22D4D# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-100)# DB REFERENCE: SWISS: (MBP_RAT,MBP_PANTR,MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,# & MBP_CAVPO)# & PIR1: (MBHUB,MBRTS,MBCZB,MBPGB,MBBOB,MBMSB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DENPVVHFFKNIVTPRT*# SEQUENCE: DENPVVHFFKNIVTPRT*# ...# >HUM22D4E# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-99)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_PANTR,MBP_BOVIN,MBP_HUMAN,MBP_MOUSE,# & MBP_RAT)# & PIR1: (MBPGB,MBHUB,MBMSB,MBCZB,MBRTS,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DENPVVHFFKNIVTPR*# SEQUENCE: DENPVVHFFKNIVTPR*# ...# >HUM22D4F# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-97)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_HUMAN,MBP_BOVIN,MBP_MOUSE,MBP_PANTR,# & MBP_RAT)# & PIR1: (MBPGB,MBCZB,MBRTS,MBHUB,MBMSB,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DENPVVHFFKNIVT*# SEQUENCE: DENPVVHFFKNIVT*# ...# >HUM22D50# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-96)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN,MBP_CAVPO,MBP_BOVIN,MBP_MOUSE,# & MBP_RAT)# & PIR1: (MBRTS,MBHUB,MBCZB,MBMSB,MBBOB,MBPGB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DENPVVHFFKNIV*# SEQUENCE: DENPVVHFFKNIV*# ...# >HUM22D51# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-95)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_PANTR,MBP_MOUSE,MBP_HUMAN,MBP_CAVPO,# & MBP_RAT)# & PIR1: (MBPGB,MBHUB,MBBOB,MBRTS,MBMSB,MBCZB)# & PIR2: (I53256,A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,DENPVVHFFKNI*# SEQUENCE: DENPVVHFFKNI*# ...# >HUM22D52# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (84-94)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_RAT,MBP_HUMAN,MBP_BOVIN,MBP_MOUSE,# & MBP_PANTR)# & PIR1: (MBHUB,MBBOB,MBRTS,MBPGB,MBMSB,MBCZB)# & PIR2: (A37246,I53256)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,DENPVVHFFKN*# SEQUENCE: DENPVVHFFKN*# ...# >HUM22D53# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (85-98,98A)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,ENPVVHFFKNIVTA*# SEQUENCE: ENPVVHFFKNIVTA*# ...# >HUM22D54# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (86-99)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR,MBP_MOUSE,MBP_BOVIN,MBP_CAVPO,# & MBP_RAT)# & PIR1: (MBHUB,MBPGB,MBCZB,MBBOB,MBRTS,MBMSB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,NPVVHFFKNIVTPR*# SEQUENCE: NPVVHFFKNIVTPR*# ...# >HUM22D55# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (86-98,98A)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,NPVVHFFKNIVTA*# SEQUENCE: NPVVHFFKNIVTA*# ...# >HUM22D56# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (87-99)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_MOUSE,MBP_PANTR,MBP_HUMAN,MBP_RAT,# & MBP_BOVIN)# & PIR1: (MBPGB,MBRTS,MBCZB,MBMSB,MBHUB,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,PVVHFFKNIVTPR*# SEQUENCE: PVVHFFKNIVTPR*# ...# >HUM22D57# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (87-98,98A)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,PVVHFFKNIVTA*# SEQUENCE: PVVHFFKNIVTA*# ...# >HUM22D58# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (89-99)# DB REFERENCE: SWISS: (MBP_BOVIN,MBP_RAT,MBP_HUMAN,MBP_PANTR,MBP_CAVPO,# & MBP_MOUSE)# & PIR1: (MBRTS,MBPGB,MBHUB,MBBOB,MBCZB,MBMSB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesl,VHFFKNIVTPR*# SEQUENCE: VHFFKNIVTPR*# ...# >HUM22D59# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP Y(80-103)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,YGRTQDENPVVHFFKNIVTPRTPP*# SEQUENCE: YGRTQDENPVVHFFKNIVTPRTPP*# ...# >HUM22D5A# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,85A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ANPVVHFFKNIVTPR*# SEQUENCE: ANPVVHFFKNIVTPR*# ...# >HUM22D5B# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,86A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,EAPVVHFFKNIVTPR*# SEQUENCE: EAPVVHFFKNIVTPR*# ...# >HUM22D5C# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,87A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENAVVHFFKNIVTPR*# SEQUENCE: ENAVVHFFKNIVTPR*# ...# >HUM22D5D# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (85-99,88A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,ENPAVHFFKNIVTPR*# SEQUENCE: ENPAVHFFKNIVTPR*# ...# >HUM22D5E# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (85-99,89A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesm,ENPVAHFFKNIVTPR*# SEQUENCE: ENPVAHFFKNIVTPR*# ...# >HUM22D5F# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,94A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENPVVHFFKAIVTPR*# SEQUENCE: ENPVVHFFKAIVTPR*# ...# >HUM22D60# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,95A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENPVVHFFKNAVTPR*# SEQUENCE: ENPVVHFFKNAVTPR*# ...# >HUM22D61# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,96A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENPVVHFFKNIATPR*# SEQUENCE: ENPVVHFFKNIATPR*# ...# >HUM22D62# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,97A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENPVVHFFKNIVAPR*# SEQUENCE: ENPVVHFFKNIVAPR*# ...# >HUM22D63# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,98A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENPVVHFFKNIVTAR*# SEQUENCE: ENPVVHFFKNIVTAR*# ...# >HUM22D64# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: MBP (85-99,99A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesh,bindyesh,ENPVVHFFKNIVTPA*# SEQUENCE: ENPVVHFFKNIVTPA*# ...# >HUM22D65# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (Y80-103)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actunkn,bindyesh,YGRTQDENPVVHFFKNIVTPRTPPP*# SEQUENCE: YGRTQDENPVVHFFKNIVTPRTPPP*# ...# >HUM22D66# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (84-102)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_PANTR,MBP_CAVPO,MBP_BOVIN,# & MBP_MOUSE)# & PIR1: (MBRTS,MBCZB,MBMSB,MBHUB,MBPGB,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,DENPVVHFFKNIVTPRTPP*# SEQUENCE: DENPVVHFFKNIVTPRTPP*# ...# >HUM22D67# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (84-102,Y93R)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,DENPVVHFFRNIVTPRTPPY*# SEQUENCE: DENPVVHFFRNIVTPRTPPY*# ...# >HUM22D68# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPVVHFFKNIVTPRTPPY*# SEQUENCE: ENPVVHFFKNIVTPRTPPY*# ...# >HUM22D69# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (86-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,NPVVHFFKNIVTPRTPPY*# SEQUENCE: NPVVHFFKNIVTPRTPPY*# ...# >HUM22D6A# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (87-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,PVVHFFKNIVTPRTPPY*# SEQUENCE: PVVHFFKNIVTPRTPPY*# ...# >HUM22D6B# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (88-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,VVHFFKNIVTPRTPPY*# SEQUENCE: VVHFFKNIVTPRTPPY*# ...# >HUM22D6C# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (89-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,VHFFKNIVTPRTPPY*# SEQUENCE: VHFFKNIVTPRTPPY*# ...# >HUM22D6D# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (90-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,HFFKNIVTPRTPPY*# SEQUENCE: HFFKNIVTPRTPPY*# ...# >HUM22D6E# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (91-102Y)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,FFKNIVTPRTPPY*# SEQUENCE: FFKNIVTPRTPPY*# ...# >HUM22D6F# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (84-100)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_CAVPO,MBP_RAT,MBP_HUMAN,MBP_PANTR,# & MBP_BOVIN)# & PIR1: (MBBOB,MBMSB,MBRTS,MBCZB,MBPGB,MBHUB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,DENPVVHFFKNIVTPRT*# SEQUENCE: DENPVVHFFKNIVTPRT*# ...# >HUM22D70# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (84-99)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_RAT,MBP_MOUSE,MBP_BOVIN,MBP_CAVPO,# & MBP_PANTR)# & PIR1: (MBMSB,MBBOB,MBHUB,MBRTS,MBCZB,MBPGB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,DENPVVHFFKNIVTPR*# SEQUENCE: DENPVVHFFKNIVTPR*# ...# >HUM22D71# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (84-97)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_HUMAN,MBP_PANTR,MBP_MOUSE,MBP_RAT,# & MBP_BOVIN)# & PIR1: (MBBOB,MBPGB,MBHUB,MBCZB,MBRTS,MBMSB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,DENPVVHFFKNIVT*# SEQUENCE: DENPVVHFFKNIVT*# ...# >HUM22D72# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (84-96)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_BOVIN,MBP_PANTR,MBP_HUMAN,MBP_RAT,# & MBP_CAVPO)# & PIR1: (MBPGB,MBCZB,MBHUB,MBRTS,MBMSB,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,DENPVVHFFKNIV*# SEQUENCE: DENPVVHFFKNIV*# ...# >HUM22D73# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition/Reference# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: MBP (85-99)# DB REFERENCE: SWISS: (MBP_CAVPO,MBP_HUMAN,MBP_BOVIN,MBP_RAT,MBP_MOUSE,# & MBP_PANTR)# & PIR1: (MBBOB,MBMSB,MBRTS,MBHUB,MBPGB,MBCZB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actyesu,bindyesl,ENPVVHFFKNIVTPR*# SEQUENCE: ENPVVHFFKNIVTPR*# ...# >HUM22D74# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (86-99)# DB REFERENCE: SWISS: (MBP_RAT,MBP_HUMAN,MBP_PANTR,MBP_MOUSE,MBP_CAVPO,# & MBP_BOVIN)# & PIR1: (MBMSB,MBHUB,MBPGB,MBCZB,MBRTS,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,NPVVHFFKNIVTPR*# SEQUENCE: NPVVHFFKNIVTPR*# ...# >HUM22D75# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (89-99)# DB REFERENCE: SWISS: (MBP_MOUSE,MBP_PANTR,MBP_RAT,MBP_BOVIN,MBP_HUMAN,# & MBP_CAVPO)# & PIR1: (MBRTS,MBMSB,MBBOB,MBCZB,MBPGB,MBHUB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,VHFFKNIVTPR*# SEQUENCE: VHFFKNIVTPR*# ...# >HUM22D76# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: TT(830-843)# DB REFERENCE: SWISS: (TETX_CLOTE)# & PIR1: (BTCLTN)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,QYIKANSKFIGITE*# SEQUENCE: QYIKANSKFIGITE*# ...# >HUM22D77# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (85-99,85A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,ANPVVHFFKNIVTPR*# SEQUENCE: ANPVVHFFKNIVTPR*# ...# >HUM22D78# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,86A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,EAPVVHFFKNIVTPR*# SEQUENCE: EAPVVHFFKNIVTPR*# ...# >HUM22D79# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,87A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENAVVHFFKNIVTPR*# SEQUENCE: ENAVVHFFKNIVTPR*# ...# >HUM22D7A# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,88A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPAVHFFKNIVTPR*# SEQUENCE: ENPAVHFFKNIVTPR*# ...# >HUM22D7B# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,89A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPVAHFFKNIVTPR*# SEQUENCE: ENPVAHFFKNIVTPR*# ...# >HUM22D7C# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,90A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPVVAFFKNIVTPR*# SEQUENCE: ENPVVAFFKNIVTPR*# ...# >HUM22D7D# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,91A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPVVHAFKNIVTPR*# SEQUENCE: ENPVVHAFKNIVTPR*# ...# >HUM22D7E# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,93A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPVVHFFANIVTPR*# SEQUENCE: ENPVVHFFANIVTPR*# ...# >HUM22D7F# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (85-99,94A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,ENPVVHFFKAIVTPR*# SEQUENCE: ENPVVHFFKAIVTPR*# ...# >HUM22D80# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,95A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPVVHFFKNAVTPR*# SEQUENCE: ENPVVHFFKNAVTPR*# ...# >HUM22D81# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,96A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPVVHFFKNIATPR*# SEQUENCE: ENPVVHFFKNIATPR*# ...# >HUM22D82# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MBP (85-99,97A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesh,ENPVVHFFKNIVAPR*# SEQUENCE: ENPVVHFFKNIVAPR*# ...# >HUM22D83# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MBP (85-99,98A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesm,ENPVVHFFKNIVTAR*# SEQUENCE: ENPVVHFFKNIVTAR*# ...# >HUM22D84# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MBP (85-99,99A) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actunkn,bindyesl,ENPVVHFFKNIVTPA*# SEQUENCE: ENPVVHFFKNIVTPA*# ...# >HUM22D85# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MBP (85-99) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesm,bindyesu,ENPVVHYFKNIVTPR*# SEQUENCE: ENPVVHYFKNIVTPR*# ...# >HUM22D86# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: MBP (85-99) homologue# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesm,bindyesu,ENPVVHFFRNIVTPR*# SEQUENCE: ENPVVHFFRNIVTPR*# ...# >HUM22D87# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (86-105)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_CAVPO,MBP_BOVIN,MBP_MOUSE,MBP_PANTR,# & MBP_RAT)# & PIR1: (MBRTS,MBPGB,MBCZB,MBHUB,MBMSB,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,VVHFFKNIVTPRTPPPSQGK*# SEQUENCE: VVHFFKNIVTPRTPPPSQGK*# ...# >HUM22D88# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (131-145)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,ASDYKSAHKGFKGVD*# SEQUENCE: ASDYKSAHKGFKGVD*# ...# >HUM22D89# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (139-153)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,KGFKGVDAQGTLSKI*# SEQUENCE: KGFKGVDAQGTLSKI*# ...# >HUM22D8A# MHC MOLECULE: HLA-DR15(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (76-91)# DB REFERENCE: SWISS: (MBP_HUMAN)# & PIR1: (MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,SHGRTQDENPVVHFFK*# SEQUENCE: SHGRTQDENPVVHFFK*# ...# >HUM22D8B# MHC MOLECULE: HLA-DR51(DRB5*0101), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (148-162)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN,MBP_CAVPO,MBP_MOUSE,MBP_BOVIN)# & PIR1: (MBPGB,MBHUB,MBCZB,MBMSB,MBBOB)# & PIR2: (A37246)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig94a# COMMENT:# SUMMARY: HLA-DR51,actyesu,bindyesu,GTLSKIFKLGGRDSR*# SEQUENCE: GTLSKIFKLGGRDSR*# ...# >HUM22D8C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (15-34)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,YDPNLRPAERDSDVVNVSLK*# SEQUENCE: YDPNLRPAERDSDVVNVSLK*# ...# >HUM22D8D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (30-49)# DB REFERENCE: SWISS: (ACHG_RAT,ACHG_MOUSE,ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (A23261,I45847,S13874,I56566)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,NVSLKLTLTNLISLNEREEA*# SEQUENCE: NVSLKLTLTNLISLNEREEA*# ...# >HUM22D8E# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (45-64)# DB REFERENCE: SWISS: (ACHG_RAT,ACHG_HUMAN,ACHG_BOVIN,ACHG_MOUSE)# & PIR2: (I56566,A23261,S13874,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,EREEALTTNVWIEMQWCDYR*# SEQUENCE: EREEALTTNVWIEMQWCDYR*# ...# >HUM22D8F# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (90-109)# DB REFERENCE: SWISS: (ACHG_MOUSE,ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (A23261,I56566,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,IVLENNVDGVFEVALYCNVL*# SEQUENCE: IVLENNVDGVFEVALYCNVL*# ...# >HUM22D90# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (105-124)# DB REFERENCE: SWISS: (ACHG_MOUSE,ACHG_RAT,ACHG_HUMAN)# & PIR2: (A23261,I56566,S13874)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,YCNVLVSPDGCIYWLPPAIF*# SEQUENCE: YCNVLVSPDGCIYWLPPAIF*# ...# >HUM22D91# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (135-154)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_MOUSE,ACHG_HUMAN)# & PIR2: (A23261,I56566,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,FPFDWQNCSLIFQSQTYST*# SEQUENCE: FPFDWQNCSLIFQSQTYST*# ...# >HUM22D92# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (150-169)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,TYSTNEIDLQLSQEDGQTIE*# SEQUENCE: TYSTNEIDLQLSQEDGQTIE*# ...# >HUM22D93# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (180-202)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,ENGEWAIQHRPAKMLLDPAAPAQ*# SEQUENCE: ENGEWAIQHRPAKMLLDPAAPAQ*# ...# >HUM22D94# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (190-209)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PAKMLLDPAAPAQEAGHQKV*# SEQUENCE: PAKMLLDPAAPAQEAGHQKV*# ...# >HUM22D95# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (203-222)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,EAGHQKVVFYILIQRKPLFY*# SEQUENCE: EAGHQKVVFYILIQRKPLFY*# ...# >HUM22D96# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (218-237)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN,ACHG_MOUSE)# & PIR2: (I56566,I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,KPLFYVINIIAPCVLISSVA*# SEQUENCE: KPLFYVINIIAPCVLISSVA*# ...# >HUM22D97# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (233-252)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,ISSVAILIHFLPAKAGGQKC*# SEQUENCE: ISSVAILIHFLPAKAGGQKC*# ...# >HUM22D98# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (263-273)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_RAT,ACHG_MOUSE)# & PIR2: (S13874,I56566,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,TVFLFLVAKKV*# SEQUENCE: TVFLFLVAKKV*# ...# >HUM22D99# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (284-303)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (A23261,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,SKYLTFLLVVTILIVVNAV*# SEQUENCE: SKYLTFLLVVTILIVVNAV*# ...# >HUM22D9A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (297-312)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_HUMAN)# & PIR2: (A23261,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,IVVNAVVVLNVSLRSP*# SEQUENCE: IVVNAVVVLNVSLRSP*# ...# >HUM22D9B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (306-325)# DB REFERENCE: SWISS: (ACHG_RAT,ACHG_BOVIN,ACHG_HUMAN)# & PIR2: (S13874,A23261,I56566,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,NVSLRSPHTHSMARGVRKVF*# SEQUENCE: NVSLRSPHTHSMARGVRKVF*# ...# >HUM22D9C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (321-340)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_HUMAN)# & PIR2: (I45847,A23261,I56566)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,VRKVFLRLLPQLLRMHVRPL*# SEQUENCE: VRKVFLRLLPQLLRMHVRPL*# ...# >HUM22D9D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (336-355)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,VRPLAPAAVQDTQSRLQNG*# SEQUENCE: VRPLAPAAVQDTQSRLQNG*# ...# >HUM22D9E# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (351-370)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,RLQNGSSGWSITTGEEVALC*# SEQUENCE: RLQNGSSGWSITTGEEVALC*# ...# >HUM22D9F# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (386-405)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,LVAAALEKLEKGPELGLSQF*# SEQUENCE: LVAAALEKLEKGPELGLSQF*# ...# >HUM22DA0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (396-415)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,KGPELGLSQFCGSLKQAAPA*# SEQUENCE: KGPELGLSQFCGSLKQAAPA*# ...# >HUM22DA1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (411-430)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,QAAPAIQACVEACNLIACAR*# SEQUENCE: QAAPAIQACVEACNLIACAR*# ...# >HUM22DA2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (454-473)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_MOUSE,ACHG_RAT)# & PIR2: (S13874,I56566,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,CFLAMLSLFICGTAGIFLMA*# SEQUENCE: CFLAMLSLFICGTAGIFLMA*# ...# >HUM22DA3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (470-489)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,FLMAHYNRVPALPFPGDPRP*# SEQUENCE: FLMAHYNRVPALPFPGDPRP*# ...# >HUM22DA4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (476-495)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,NRVPALPFPGDPRPYLPSPD*# SEQUENCE: NRVPALPFPGDPRPYLPSPD*# ...# >HUM22DA5# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (15-34)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,YDPNLRPAERDSDVVNVSLK*# SEQUENCE: YDPNLRPAERDSDVVNVSLK*# ...# >HUM22DA6# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (30-49)# DB REFERENCE: SWISS: (ACHG_MOUSE,ACHG_BOVIN,ACHG_RAT,ACHG_HUMAN)# & PIR2: (A23261,I45847,I56566,S13874)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,NVSLKLTLTNLISLNEREEA*# SEQUENCE: NVSLKLTLTNLISLNEREEA*# ...# >HUM22DA7# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (45-64)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN,ACHG_MOUSE,ACHG_RAT)# & PIR2: (I45847,I56566,A23261,S13874)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,EREEALTTNVWIEMQWCDYR*# SEQUENCE: EREEALTTNVWIEMQWCDYR*# ...# >HUM22DA8# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (60-79)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,WCDYRLRWDPRDYEGLWVLR*# SEQUENCE: WCDYRLRWDPRDYEGLWVLR*# ...# >HUM22DA9# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (75-94)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (A23261,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,LWVLRVPSTMVWRPDIVLEN*# SEQUENCE: LWVLRVPSTMVWRPDIVLEN*# ...# >HUM22DAA# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (90-109)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_MOUSE,ACHG_BOVIN)# & PIR2: (I45847,I56566,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,IVLENNVDGVFEVALYCNVL*# SEQUENCE: IVLENNVDGVFEVALYCNVL*# ...# >HUM22DAB# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (180-202)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,ENGEWAIQHRPAKMLLDPAAPAQ*# SEQUENCE: ENGEWAIQHRPAKMLLDPAAPAQ*# ...# >HUM22DAC# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (190-209)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,PAKMLLDPAAPAQEAGHQKV*# SEQUENCE: PAKMLLDPAAPAQEAGHQKV*# ...# >HUM22DAD# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (203-222)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,EAGHQKVVFYILIQRKPLFY*# SEQUENCE: EAGHQKVVFYILIQRKPLFY*# ...# >HUM22DAE# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (233-252)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,ISSVAILIHFLPAKAGGQKC*# SEQUENCE: ISSVAILIHFLPAKAGGQKC*# ...# >HUM22DAF# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (263-273)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_RAT,ACHG_MOUSE)# & PIR2: (I56566,S13874,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,TVFLFLVAKKV*# SEQUENCE: TVFLFLVAKKV*# ...# >HUM22DB0# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (284-303)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (A23261,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,SKYLTFLLVVTILIVVNAV*# SEQUENCE: SKYLTFLLVVTILIVVNAV*# ...# >HUM22DB1# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (297-312)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_HUMAN)# & PIR2: (I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,IVVNAVVVLNVSLRSP*# SEQUENCE: IVVNAVVVLNVSLRSP*# ...# >HUM22DB2# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (306-325)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_RAT,ACHG_BOVIN)# & PIR2: (I56566,S13874,A23261,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,NVSLRSPHTHSMARGVRKVF*# SEQUENCE: NVSLRSPHTHSMARGVRKVF*# ...# >HUM22DB3# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (321-340)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (I45847,A23261,I56566)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,VRKVFLRLLPQLLRMHVRPL*# SEQUENCE: VRKVFLRLLPQLLRMHVRPL*# ...# >HUM22DB4# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (381-400)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesm,WQRQGLVAAALEKLEKGPEL*# SEQUENCE: WQRQGLVAAALEKLEKGPEL*# ...# >HUM22DB5# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (386-405)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,LVAAALEKLEKGPELGLSQF*# SEQUENCE: LVAAALEKLEKGPELGLSQF*# ...# >HUM22DB6# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (396-415)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesh,KGPELGLSQFCGSLKQAAPA*# SEQUENCE: KGPELGLSQFCGSLKQAAPA*# ...# >HUM22DB7# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (411-430)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,QAAPAIQACVEACNLIACAR*# SEQUENCE: QAAPAIQACVEACNLIACAR*# ...# >HUM22DB8# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (426-445)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,IACARHQQSHFDNGNEEWFL*# SEQUENCE: IACARHQQSHFDNGNEEWFL*# ...# >HUM22DB9# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (454-473)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_RAT,ACHG_MOUSE)# & PIR2: (S13874,I56566,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,CFLAMLSLFICGTAGIFLMA*# SEQUENCE: CFLAMLSLFICGTAGIFLMA*# ...# >HUM22DBA# MHC MOLECULE: HLA-DR2(DRB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (470-489)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesl,FLMAHYNRVPALPFPGDPRP*# SEQUENCE: FLMAHYNRVPALPFPGDPRP*# ...# >HUM22DBB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (1-20)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,RNQEERLLADLMQNYDPNLR*# SEQUENCE: RNQEERLLADLMQNYDPNLR*# ...# >HUM22DBC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (15-34)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,YDPNLRPAERDSDVVNVSLK*# SEQUENCE: YDPNLRPAERDSDVVNVSLK*# ...# >HUM22DBD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (30-49)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN,ACHG_MOUSE,ACHG_RAT)# & PIR2: (S13874,I56566,I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,NVSLKLTLTNLISLNEREEA*# SEQUENCE: NVSLKLTLTNLISLNEREEA*# ...# >HUM22DBE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (45-64)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_MOUSE,ACHG_HUMAN,ACHG_RAT)# & PIR2: (A23261,I45847,I56566,S13874)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EREEALTTNVWIEMQWCDYR*# SEQUENCE: EREEALTTNVWIEMQWCDYR*# ...# >HUM22DBF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (60-79)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,WCDYRLRWDPRDYEGLWVLR*# SEQUENCE: WCDYRLRWDPRDYEGLWVLR*# ...# >HUM22DC0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (75-94)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,LWVLRVPSTMVWRPDIVLEN*# SEQUENCE: LWVLRVPSTMVWRPDIVLEN*# ...# >HUM22DC1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (90-109)# DB REFERENCE: SWISS: (ACHG_MOUSE,ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (A23261,I56566,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,IVLENNVDGVFEVALYCNVL*# SEQUENCE: IVLENNVDGVFEVALYCNVL*# ...# >HUM22DC2# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (105-124)# DB REFERENCE: SWISS: (ACHG_RAT,ACHG_MOUSE,ACHG_HUMAN)# & PIR2: (S13874,A23261,I56566)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,YCNVLVSPDGCIYWLPPAIF*# SEQUENCE: YCNVLVSPDGCIYWLPPAIF*# ...# >HUM22DC3# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (120-139)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PPAIFRSACSISVTYFPFDW*# SEQUENCE: PPAIFRSACSISVTYFPFDW*# ...# >HUM22DC4# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (135-154)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_HUMAN,ACHG_MOUSE)# & PIR2: (A23261,I45847,I56566)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,FPFDWQNCSLIFQSQTYST*# SEQUENCE: FPFDWQNCSLIFQSQTYST*# ...# >HUM22DC5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (150-169)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,TYSTNEIDLQLSQEDGQTIE*# SEQUENCE: TYSTNEIDLQLSQEDGQTIE*# ...# >HUM22DC6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (180-202)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,ENGEWAIQHRPAKMLLDPAAPAQ*# SEQUENCE: ENGEWAIQHRPAKMLLDPAAPAQ*# ...# >HUM22DC7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (190-209)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,PAKMLLDPAAPAQEAGHQKV*# SEQUENCE: PAKMLLDPAAPAQEAGHQKV*# ...# >HUM22DC8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (203-222)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,EAGHQKVVFYILIQRKPLFY*# SEQUENCE: EAGHQKVVFYILIQRKPLFY*# ...# >HUM22DC9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (218-237)# DB REFERENCE: SWISS: (ACHG_MOUSE,ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (I56566,I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KPLFYVINIIAPCVLISSVA*# SEQUENCE: KPLFYVINIIAPCVLISSVA*# ...# >HUM22DCA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (233-252)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,ISSVAILIHFLPAKAGGQKC*# SEQUENCE: ISSVAILIHFLPAKAGGQKC*# ...# >HUM22DCB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (248-267)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,GGQKCTVAINVLLAQTVFLF*# SEQUENCE: GGQKCTVAINVLLAQTVFLF*# ...# >HUM22DCC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (263-273)# DB REFERENCE: SWISS: (ACHG_MOUSE,ACHG_RAT,ACHG_BOVIN)# & PIR2: (S13874,I45847,I56566)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,TVFLFLVAKKV*# SEQUENCE: TVFLFLVAKKV*# ...# >HUM22DCD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (269-288)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,LAKKVPETSQAVPLISKYLT*# SEQUENCE: LAKKVPETSQAVPLISKYLT*# ...# >HUM22DCE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (284-303)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SKYLTFLLVVTILIVVNAV*# SEQUENCE: SKYLTFLLVVTILIVVNAV*# ...# >HUM22DCF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (297-312)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,IVVNAVVVLNVSLRSP*# SEQUENCE: IVVNAVVVLNVSLRSP*# ...# >HUM22DD0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (306-325)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_RAT,ACHG_HUMAN)# & PIR2: (A23261,I45847,I56566,S13874)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,NVSLRSPHTHSMARGVRKVF*# SEQUENCE: NVSLRSPHTHSMARGVRKVF*# ...# >HUM22DD1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (321-340)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (I56566,A23261,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,VRKVFLRLLPQLLRMHVRPL*# SEQUENCE: VRKVFLRLLPQLLRMHVRPL*# ...# >HUM22DD2# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (336-355)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,VRPLAPAAVQDTQSRLQNG*# SEQUENCE: VRPLAPAAVQDTQSRLQNG*# ...# >HUM22DD3# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (351-370)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,RLQNGSSGWSITTGEEVALC*# SEQUENCE: RLQNGSSGWSITTGEEVALC*# ...# >HUM22DD4# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (366-385)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,EVALCLPRSELLFQQWQRQG*# SEQUENCE: EVALCLPRSELLFQQWQRQG*# ...# >HUM22DD5# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (381-400)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,WQRQGLVAAALEKLEKGPEL*# SEQUENCE: WQRQGLVAAALEKLEKGPEL*# ...# >HUM22DD6# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (386-405)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,LVAAALEKLEKGPELGLSQF*# SEQUENCE: LVAAALEKLEKGPELGLSQF*# ...# >HUM22DD7# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (396-415)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KGPELGLSQFCGSLKQAAPA*# SEQUENCE: KGPELGLSQFCGSLKQAAPA*# ...# >HUM22DD8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (411-430)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,QAAPAIQACVEACNLIACAR*# SEQUENCE: QAAPAIQACVEACNLIACAR*# ...# >HUM22DD9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (426-445)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,IACARHQQSHFDNGNEEWFL*# SEQUENCE: IACARHQQSHFDNGNEEWFL*# ...# >HUM22DDA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (438-457)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,NGNEEWFLVGRVLDRVCFLA*# SEQUENCE: NGNEEWFLVGRVLDRVCFLA*# ...# >HUM22DDB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (454-473)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_MOUSE,ACHG_RAT)# & PIR2: (I56566,S13874,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,CFLAMLSLFICGTAGIFLMA*# SEQUENCE: CFLAMLSLFICGTAGIFLMA*# ...# >HUM22DDC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (470-489)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,FLMAHYNRVPALPFPGDPRP*# SEQUENCE: FLMAHYNRVPALPFPGDPRP*# ...# >HUM22DDD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (476-495)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,NRVPALPFPGDPRPYLPSPD*# SEQUENCE: NRVPALPFPGDPRPYLPSPD*# ...# >HUM22DDE# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (1-20)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,RNQEERLLADLMQNYDPNLR*# SEQUENCE: RNQEERLLADLMQNYDPNLR*# ...# >HUM22DDF# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (15-34)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,YDPNLRPAERDSDVVNVSLK*# SEQUENCE: YDPNLRPAERDSDVVNVSLK*# ...# >HUM22DE0# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (30-49)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_RAT,ACHG_MOUSE,ACHG_BOVIN)# & PIR2: (I56566,A23261,I45847,S13874)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,NVSLKLTLTNLISLNEREEA*# SEQUENCE: NVSLKLTLTNLISLNEREEA*# ...# >HUM22DE1# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (45-64)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN,ACHG_MOUSE,ACHG_RAT)# & PIR2: (A23261,I56566,S13874,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,EREEALTTNVWIEMQWCDYR*# SEQUENCE: EREEALTTNVWIEMQWCDYR*# ...# >HUM22DE2# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (60-79)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,WCDYRLRWDPRDYEGLWVLR*# SEQUENCE: WCDYRLRWDPRDYEGLWVLR*# ...# >HUM22DE3# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (90-109)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_MOUSE,ACHG_BOVIN)# & PIR2: (I45847,I56566,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,IVLENNVDGVFEVALYCNVL*# SEQUENCE: IVLENNVDGVFEVALYCNVL*# ...# >HUM22DE4# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (105-124)# DB REFERENCE: SWISS: (ACHG_RAT,ACHG_HUMAN,ACHG_MOUSE)# & PIR2: (A23261,I56566,S13874)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,YCNVLVSPDGCIYWLPPAIF*# SEQUENCE: YCNVLVSPDGCIYWLPPAIF*# ...# >HUM22DE5# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (120-139)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PPAIFRSACSISVTYFPFDW*# SEQUENCE: PPAIFRSACSISVTYFPFDW*# ...# >HUM22DE6# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (135-154)# DB REFERENCE: SWISS: (ACHG_MOUSE,ACHG_BOVIN,ACHG_HUMAN)# & PIR2: (I56566,I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,FPFDWQNCSLIFQSQTYST*# SEQUENCE: FPFDWQNCSLIFQSQTYST*# ...# >HUM22DE7# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (150-169)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,TYSTNEIDLQLSQEDGQTIE*# SEQUENCE: TYSTNEIDLQLSQEDGQTIE*# ...# >HUM22DE8# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (180-202)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,ENGEWAIQHRPAKMLLDPAAPAQ*# SEQUENCE: ENGEWAIQHRPAKMLLDPAAPAQ*# ...# >HUM22DE9# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (190-209)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PAKMLLDPAAPAQEAGHQKV*# SEQUENCE: PAKMLLDPAAPAQEAGHQKV*# ...# >HUM22DEA# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (203-222)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,EAGHQKVVFYILIQRKPLFY*# SEQUENCE: EAGHQKVVFYILIQRKPLFY*# ...# >HUM22DEB# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: H AChR gamma (218-237)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_MOUSE,ACHG_BOVIN)# & PIR2: (I56566,A23261,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,KPLFYVINIIAPCVLISSVA*# SEQUENCE: KPLFYVINIIAPCVLISSVA*# ...# >HUM22DEC# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (233-252)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,ISSVAILIHFLPAKAGGQKC*# SEQUENCE: ISSVAILIHFLPAKAGGQKC*# ...# >HUM22DED# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (248-267)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_HUMAN)# & PIR2: (I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,GGQKCTVAINVLLAQTVFLF*# SEQUENCE: GGQKCTVAINVLLAQTVFLF*# ...# >HUM22DEE# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (263-273)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_RAT,ACHG_MOUSE)# & PIR2: (I45847,I56566,S13874)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,TVFLFLVAKKV*# SEQUENCE: TVFLFLVAKKV*# ...# >HUM22DEF# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (269-288)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,LAKKVPETSQAVPLISKYLT*# SEQUENCE: LAKKVPETSQAVPLISKYLT*# ...# >HUM22DF0# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (284-303)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_HUMAN)# & PIR2: (I45847,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,SKYLTFLLVVTILIVVNAV*# SEQUENCE: SKYLTFLLVVTILIVVNAV*# ...# >HUM22DF1# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (297-312)# DB REFERENCE: SWISS: (ACHG_BOVIN,ACHG_HUMAN)# & PIR2: (A23261,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,IVVNAVVVLNVSLRSP*# SEQUENCE: IVVNAVVVLNVSLRSP*# ...# >HUM22DF2# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (306-325)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN,ACHG_RAT)# & PIR2: (A23261,S13874,I56566,I45847)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,NVSLRSPHTHSMARGVRKVF*# SEQUENCE: NVSLRSPHTHSMARGVRKVF*# ...# >HUM22DF3# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (321-340)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_BOVIN)# & PIR2: (A23261,I45847,I56566)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,VRKVFLRLLPQLLRMHVRPL*# SEQUENCE: VRKVFLRLLPQLLRMHVRPL*# ...# >HUM22DF4# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (336-355)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,VRPLAPAAVQDTQSRLQNG*# SEQUENCE: VRPLAPAAVQDTQSRLQNG*# ...# >HUM22DF5# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (351-370)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,RLQNGSSGWSITTGEEVALC*# SEQUENCE: RLQNGSSGWSITTGEEVALC*# ...# >HUM22DF6# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (366-385)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,EVALCLPRSELLFQQWQRQG*# SEQUENCE: EVALCLPRSELLFQQWQRQG*# ...# >HUM22DF7# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (381-400)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,WQRQGLVAAALEKLEKGPEL*# SEQUENCE: WQRQGLVAAALEKLEKGPEL*# ...# >HUM22DF8# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (396-415)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,KGPELGLSQFCGSLKQAAPA*# SEQUENCE: KGPELGLSQFCGSLKQAAPA*# ...# >HUM22DF9# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (411-430)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,QAAPAIQACVEACNLIACAR*# SEQUENCE: QAAPAIQACVEACNLIACAR*# ...# >HUM22DFA# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (426-445)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,IACARHQQSHFDNGNEEWFL*# SEQUENCE: IACARHQQSHFDNGNEEWFL*# ...# >HUM22DFB# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (438-457)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,NGNEEWFLVGRVLDRVCFLA*# SEQUENCE: NGNEEWFLVGRVLDRVCFLA*# ...# >HUM22DFC# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (454-473)# DB REFERENCE: SWISS: (ACHG_HUMAN,ACHG_RAT,ACHG_MOUSE)# & PIR2: (S13874,I56566,A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,CFLAMLSLFICGTAGIFLMA*# SEQUENCE: CFLAMLSLFICGTAGIFLMA*# ...# >HUM22DFD# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: H AChR gamma (470-489)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,FLMAHYNRVPALPFPGDPRP*# SEQUENCE: FLMAHYNRVPALPFPGDPRP*# ...# >HUM22DFE# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: H AChR gamma (476-495)# DB REFERENCE: SWISS: (ACHG_HUMAN)# & PIR2: (A23261)# ANCHOR POSITIONS: ?# REFERENCES: yuen96a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,NRVPALPFPGDPRPYLPSPD*# SEQUENCE: NRVPALPFPGDPRPYLPSPD*# ...# >HUM22DFF# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (144-163)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,MKLGTWTYDGSWAINPESD*# SEQUENCE: MKLGTWTYDGSWAINPESD*# ...# >HUM22E00# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (138-167)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesu,DEQNCSMKLGTWTYDGSWAINPESDQPDL*# SEQUENCE: DEQNCSMKLGTWTYDGSWAINPESDQPDL*# ...# >HUM22E01# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (138-167)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,DEQNCSMKLGTWTYDGSWAINPESDQPDL*# SEQUENCE: DEQNCSMKLGTWTYDGSWAINPESDQPDL*# ...# >HUM22E02# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (138-167)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,DEQNCSMKLGTWTYDGSWAINPESDQPDL*# SEQUENCE: DEQNCSMKLGTWTYDGSWAINPESDQPDL*# ...# >HUM22E03# MHC MOLECULE: HLA-DR10, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (62-90)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR10,actyesu,bindyesu,DYNLRWNPDDYGGVKKIHIPSEKIWRPDL*# SEQUENCE: DYNLRWNPDDYGGVKKIHIPSEKIWRPDL*# ...# >HUM22E04# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (75-115)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,VKKIHIPSERIWRPDLVLYNNADGDFAIVKFTKVLLQYTGH*# SEQUENCE: VKKIHIPSERIWRPDLVLYNNADGDFAIVKFTKVLLQYTGH*# ...# >HUM22E05# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (75-115)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,VKKIHIPSERIWRPDLVLYNNADGDFAIVKFTKVLLQYTGH*# SEQUENCE: VKKIHIPSERIWRPDLVLYNNADGDFAIVKFTKVLLQYTGH*# ...# >HUM22E06# MHC MOLECULE: HLA-DR10, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (138-167)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR10,actyesu,bindyesu,DEQNCSMKLGTWTYDGSWAINPESDQPDL*# SEQUENCE: DEQNCSMKLGTWTYDGSWAINPESDQPDL*# ...# >HUM22E07# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (309-344)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,PNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTE*# SEQUENCE: PNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTE*# ...# >HUM22E08# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (309-344)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR3,actyesu,bindyesu,PNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTE*# SEQUENCE: PNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTE*# ...# >HUM22E09# MHC MOLECULE: HLA-DR15, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (309-344)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DR15,actyesu,bindyesu,PNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTE*# SEQUENCE: PNWVRKVFIDTIPNIMFFSTMKRPSREKQDKKIFTE*# ...# >HUM22E0A# MHC MOLECULE: HLA-DQw5, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: AChR (338-369)# DB REFERENCE: SWISS: (ACHA_BOVIN,ACHA_HUMAN)# & PIR1: (ACHUA1,ACBOA1)# ANCHOR POSITIONS: ?# REFERENCES: matsuo95a# COMMENT:# SUMMARY: HLA-DQw5,actyesu,bindyesu,DKKIFTEDIDISDISGKPGPPPMGFHSPLIKH*# SEQUENCE: DKKIFTEDIDISDISGKPGPPPMGFHSPLIKH*# ...# >HUM22E0B# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: DG (190-204)# DB REFERENCE: SWISS: (DSG3_HUMAN,DSG3_HUMAN)# & PIR1: (IJHUG3)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig95a# COMMENT:# SUMMARY: HLA-DR4,actyesh,bindyesu,LNSKIAFKIVSQEPA*# SEQUENCE: LNSKIAFKIVSQEPA*# ...# >HUM22E0C# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: DG (206-220)# DB REFERENCE: SWISS: (DSG3_HUMAN,DSG3_HUMAN)# & PIR1: (IJHUG3)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig95a# COMMENT:# SUMMARY: HLA-DR?,actyesu,bindyesu,TPMFLLSRNTGEVRT*# SEQUENCE: TPMFLLSRNTGEVRT*# ...# >HUM22E0D# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: DG (251-265)# DB REFERENCE: SWISS: (DSG3_HUMAN,DSG3_HUMAN)# & PIR1: (IJHUG3)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig95a# COMMENT:# SUMMARY: HLA-DR?,actyesu,bindyesu,CECNIKVKDVNDNFP*# SEQUENCE: CECNIKVKDVNDNFP*# ...# >HUM22E0E# MHC MOLECULE: HLA-DR?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: DG (762-786)# DB REFERENCE: SWISS: (DSG3_HUMAN,DSG3_HUMAN)# & PIR1: (IJHUG3)# ANCHOR POSITIONS: ?# REFERENCES: wucherpfennig95a# COMMENT:# SUMMARY: HLA-DR?,actyesu,bindyesu,QSGTMRTRHSTGGTN*# SEQUENCE: QSGTMRTRHSTGGTN*# ...# >HUM22E0F# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Class 1 (153-166)# DB REFERENCE: SWISS: (1C18_HUMAN,1C03_GORGO,1CXX_HUMAN,1C02_HUMAN,1C01_PANTR,# & 1B36_HUMAN,1C07_HUMAN,1C17_HUMAN,1C12_HUMAN,1B33_HUMAN,# & 1B46_HUMAN,1B34_HUMAN,1C16_HUMAN,1C06_HUMAN,1B04_HUMAN,# & 1C14_HUMAN,1B35_HUMAN,1B38_HUMAN,1C01_HUMAN,1C01_GORGO,# & 1B02_HUMAN,1C04_HUMAN,1C11_HUMAN,1C15_HUMAN,HA19_CANFA,# & 1C03_HUMAN,HLAG_HUMAN,1B20_HUMAN,1C02_HUMAN,# & 1B39_HUMAN)# & PIR1: (HLHUC4,HLHUB7,HLHU40,S42102)# & PIR2: (I59188,I72808,A45857,I59651,JH0544,I61903,I68750,A49411,# & S11143,I68712,I56149,I81231,I59655,JH0546,I54418,JH0290,# & I68749,JH0526,I61905,I36958,JH0289,I38437,I61906,B37028,# & I68701,I67482,I46030,S24438,S42823,I54430,I84431,I72113,# & I37135,I56071,I61865,A39953,I59622,I38507,JH0291,I37078,# & JS0262,JH0288,I81232,S52486,A45897,I46603,JH0543,I67483,# & A60369,I37544,I37527,I61864,I61866,I46604,S60601,I38505,# & A45849,I54449,A45845,S48134,I56116,B45831,I37492,I37526,# & C37028,I56034,I37529,I37523,I68747,I37528,S44994,# & JH0292)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLRSWTAADTAAQI*# SEQUENCE: DLRSWTAADTAAQI*# ...# >HUM22E10# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA Class 1 (153-168)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,DLKSWTAADTAAQITQ*# SEQUENCE: DLKSWTAADTAAQITQ*# ...# >HUM22E11# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA Class 1 (154-167)# DB REFERENCE: SWISS: (1B20_HUMAN,1C03_HUMAN,1B34_HUMAN,1B39_HUMAN,1C02_HUMAN,# & HA19_CANFA,1C15_HUMAN,1C11_HUMAN,1C04_HUMAN,1B02_HUMAN,# & 1C14_HUMAN,1B38_HUMAN,1B35_HUMAN,1B04_HUMAN,1C06_HUMAN,# & 1C01_HUMAN,1C01_GORGO,1C17_HUMAN,1C16_HUMAN,1C12_HUMAN,# & 1C18_HUMAN,1C03_GORGO,1C07_HUMAN,1C01_PANTR,1B36_HUMAN,# & HA1B_BOVIN,1CXX_HUMAN,1C02_HUMAN)# & PIR1: (HLHUC4,HLHUB7,S42102)# & PIR2: (I68750,I56149,I46049,I59651,I37492,I37529,I37523,I56034,# & I68747,S44994,I67482,B27638,I59622,I38507,I46604,I38505,# & I37544,A60369,I37078,I46603,I54418,I72113,I56116,I37528,# & I61865,I81232,JH0291,JS0262,JH0288,S52486,JH0526,I68749,# & I36958,I61905,JH0289,JH0290,JH0546,I59655,I37526,B45831,# & S48134,C37028,A45857,I72808,JH0544,I59188,S11143,I68712,# & I81231,A49411,I84431,I37135,I54430,I46030,S42823,I61906,# & B37028,I68701,S60601,A45849,I61866,I61864,A45845,I54449,# & JH0292,I67483,I37527,A45897,JH0543)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LRSWTAADTAAQIT*# SEQUENCE: LRSWTAADTAAQIT*# ...# >HUM22E12# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Class 1 (5-ND)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,MRYFYTAVSRPC*# SEQUENCE: MRYFYTAVSRPC*# ...# >HUM22E13# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-Class 1 (28-41)# DB REFERENCE: SWISS: (1A31_HUMAN,1C02_HUMAN,1A03_HUMAN,1B11_HUMAN,1B07_HUMAN,# & 1B01_GORGO,1C16_HUMAN,1C15_HUMAN,1B21_HUMAN,HA19_CANFA,# & 1B61_HUMAN,1B62_HUMAN,1A24_HUMAN,1A01_PONPY,1A23_HUMAN,# & 1A29_HUMAN,1A01_GORGO,1B24_HUMAN,1B55_HUMAN,1B26_HUMAN,# & 1A26_HUMAN,1B56_HUMAN,1A04_GORGO,1A01_PANTR,1A03_GORGO,# & 1C07_HUMAN,1A36_HUMAN,1B54_HUMAN,1C03_GORGO,1A66_HUMAN,# & 1A01_HUMAN,1A02_HUMAN,1A02_HUMAN,1A31_HUMAN,1B31_HUMAN,# & 1B46_HUMAN,1B04_HUMAN,1A43_HUMAN,1C01_HUMAN,1A32_HUMAN,# & 1C06_HUMAN,1C01_SAGOE,1A69_HUMAN,1B39_HUMAN,1A68_HUMAN,# & 1A33_HUMAN,HA1A_RABIT,1B49_HUMAN,1C11_HUMAN,1B32_HUMAN,# & 1B57_HUMAN,1C02_GORGO,1C02_GORGO,1B59_HUMAN,1B60_HUMAN,# & 1A25_HUMAN,1B63_HUMAN,1A01_SAGOE,1C02_HUMAN,1A11_HUMAN,# & 1B58_HUMAN,1B25_HUMAN,1B01_SAGOE,1B53_HUMAN,1A74_HUMAN,# & 1A02_GORGO,1C01_GORGO,1B27_HUMAN,1C04_HUMAN,1C04_GORGO,# & 1B02_HUMAN,1A03_PANTR,1C03_HUMAN,1B12_HUMAN,1B22_HUMAN,# & 1A04_PANTR,1B52_HUMAN,1B08_HUMAN,HA1B_RABIT,1B02_GORGO,# & 1A26_HUMAN,1B12_HUMAN,1CXX_HUMAN,1C18_HUMAN,1C01_PANTR,# & 1B23_HUMAN,1B29_HUMAN,1B28_HUMAN,1A34_HUMAN,1B44_HUMAN,# & 1C17_HUMAN,1B03_GORGO,1A30_HUMAN,1B10_HUMAN,1B01_PANTR)# & PIR1: (HLHUB7,S42102,HLHUB8,HLHUAW,HLHUA2,HLRB,HLHU32,HLHU69,# & HLHUC4,HLHU28,HLHUA3)# & PIR2: (S24436,I37475,I72113,I62041,I84488,I68774,I37528,S24433,# & I54307,JH0547,I84432,I36961,I59651,I62042,S10934,I37470,# & I37523,I68747,I56034,S44994,I38505,I37544,I38519,I37078,# & G01230,I54457,JH0544,I54298,A45857,I59188,A45880,S24438,# & S48134,I38443,I59645,I37526,I83063,C37028,JH0541,I72753,# & S11133,I37521,I61862,I54314,JH0545,I54449,I54308,I84490,# & S60601,I36965,I68850,I61866,JL0135,I38421,S24435,A45845,# & JH0534,I37476,I84487,I37527,I46858,I72755,S11134,S24434,# & JH0543,I54416,I59654,S11137,S51099,I72170,JH0539,I38507,# & I56039,B30345,S33355,I62044,I84448,B37028,S24439,I54430,# & JH0537,I84431,I36959,S42823,A47636,I81233,I38442,D35997,# & I72218,I38436,C35997,JH0535,S03537,I61863,S16789,I72217,# & I36957,S16769,JS0262,I72754,I61865,A37028,I62045,A45847,# & I84486,S11136,S01171,I56053,JH0536,I61904,I72752,A45834,# & I37480,S11142,I72171,I37478,I37483,I68749,JH0540,S03535,# & I56133,I61859,I54418,I37522,S24440,I81231,I36966,I80169,# & I61903,S18198,S11135,I59308,I61902,I80165,I62043,A35997,# & I54463,JH0526,S24437,S24027,JH0546,I61856,I37477,I80168,# & I80167,I37482,I54505,I38441,I61857,I61907,I68748,A30345,# & I59633,I37120,I68712,A49411,I38509,I37479,I80170,I56130,# & I80166,S52290,I37529,I54493,I67482,I38610,I37542,I59622,# & I80171,S11141,I38518,S11138)# & PIR3: (S06424,S07113,G02922)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,VDDTQFVRFDSDAA*# SEQUENCE: VDDTQFVRFDSDAA*# ...# >HUM22E14# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cathepsin C (rat) homologue# DB REFERENCE: SWISS: (CATC_HUMAN)# & PIR2: (S66504)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YDHNFVKAINAIQKS*# SEQUENCE: YDHNFVKAINAIQKS*# ...# >HUM22E15# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: PGSG (27-ND)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,YPTQRARYQWYRCNPDSNS*# SEQUENCE: YPTQRARYQWYRCNPDSNS*# ...# >HUM22E16# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ig kappa chain precursor (93-ND)# DB REFERENCE: SWISS: (KV3E_HUMAN,KV3G_HUMAN,KV3L_HUMAN,KV3D_HUMAN,# & KV3C_HUMAN)# & PIR1: (K3HUGO,K3HUNG,K3HUTI,K3HUHA)# & PIR2: (S37513,S49532,S20635,S37520,S44120,D30601,A25521,S37518,# & S16843,E30607,S37517,G30607,S16842,S46369,S33988,S38643,# & S37514,PH0964,F30607,S37528,S40327,S37508,H30601,A30608,# & S37524,S40380,S20636,S37503,C30601,S67940,JH0429,S20637,# & C27594,B30601,C30608,G30601,H44151,B27594,A23746,S34096,# & S37526,S20633,S37507,PH0963,E30609,S46375,B25521,A32274,# & S37505,A30601,PH0965)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SGTDFTLTISRLEPE*# SEQUENCE: SGTDFTLTISRLEPE*# ...# >HUM22E17# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IgM m chain# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,GPTTYKVTSSLQIKE*# SEQUENCE: GPTTYKVTSSLQIKE*# ...# >HUM22E18# MHC MOLECULE: HLA-DR4(DRB1*0407), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# DB REFERENCE: PIR2: (G02476)# ANCHOR POSITIONS: ?# REFERENCES: davenport97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,LPSYEEALSLPSKT*# SEQUENCE: LPSYEEALSLPSKT*# ...# >HUM22E19# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: MHC-1 alpha (46-59)# DB REFERENCE: SWISS: (1A26_HUMAN,1B02_GORGO,1B27_HUMAN,1B01_PANTR,1B03_GORGO,# & 1B29_HUMAN,1A34_HUMAN,1B28_HUMAN,1B23_HUMAN,1A03_PANTR,# & 1B40_HUMAN,1B42_HUMAN,1A03_HUMAN,1B22_HUMAN,1B20_HUMAN,# & 1B52_HUMAN,1B43_HUMAN,1B45_HUMAN,1B58_HUMAN,1B25_HUMAN,# & 1A25_HUMAN,1B63_HUMAN,1B59_HUMAN,1B14_HUMAN,1B57_HUMAN,# & 1A33_HUMAN,1B47_HUMAN,1A69_HUMAN,1B39_HUMAN,1A32_HUMAN,# & 1B04_HUMAN,1A68_HUMAN,1B35_HUMAN,1B33_HUMAN,1B49_HUMAN,# & 1B18_HUMAN,1B32_HUMAN,1B38_HUMAN,1A11_HUMAN,1B48_HUMAN,# & 1B53_HUMAN,1B02_HUMAN,1B34_HUMAN,1B13_HUMAN,1B41_HUMAN,# & 1B62_HUMAN,1B15_HUMAN,1B01_GORGO,1B21_HUMAN,1B19_HUMAN,# & 1A01_PANTR,1A23_HUMAN,1B54_HUMAN,1A02_HUMAN,1B08_HUMAN,# & 1A04_PANTR,1B11_HUMAN,1A74_HUMAN,1B07_HUMAN,1A66_HUMAN,# & 1B31_HUMAN,1A02_HUMAN,1B56_HUMAN,1A01_HUMAN,1A02_PANTR,# & 1B02_PANTR,1A26_HUMAN,1B26_HUMAN,1A01_GORGO,1A24_HUMAN,# & 1B36_HUMAN,1A36_HUMAN,1A29_HUMAN,1A43_HUMAN,1B24_HUMAN,# & 1B46_HUMAN)# & PIR1: (HLHUB7,HLHU40,HLHU32,HLHUB2,HLHU28,HLHU69,HLHUAW,HLHUB4,# & HLHUA2,HLHUB8,S42102,HLHUA3)# & PIR2: (I68724,I38518,I56149,I80171,I54493,I38610,I36956,I80169,# & S24440,I37522,I61903,I38876,I56116,I54418,I56133,I84487,# & I37516,B30345,S25415,I84448,I38860,I54416,JH0539,I59651,# & I36961,I61860,I68747,I54505,I38441,A30345,I80170,A35997,# & I54463,I80168,I61856,S24436,I54307,I36962,I38874,I84488,# & I68774,S03537,S16789,S16769,I61865,S01171,I37480,I80176,# & I37483,I59655,I36959,A47636,I37520,I38436,I61905,S24439,# & I37515,I61906,I54298,C35997,I36965,I84490,I54308,S60601,# & JL0135,S24435,I80174,I61862,JH0541,I72753,I83063,I68701,# & A45880,S24437,I37479,I38437,I59645,I38443,S24438,I37470,# & I61864,I72171,A45847,I72754,I84431,S03535,I61902,I61859,# & I36966,I81233,S03538,I38442,I59188,I36957,S52486,A37028,# & A45834,I72752,I61904,I37478,JH0540,S51099,I72755,S24434,# & I68850,JH0534,I54314,I54457,I37485,I38875,I37542,I37492,# & I59633,I61907,I61857,I38509,I37120,I37482,I37519,I37477,# & I37475,I61861)# & PIR3: (S06424,S07113)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,EPRAPWIEQEGPEY*# SEQUENCE: EPRAPWIEQEGPEY*# ...# >HUM22E1A# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Elution/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (46-63)# DB REFERENCE: SWISS: (1A32_HUMAN,1A01_HUMAN,1A36_HUMAN,1A74_HUMAN,1A03_HUMAN,# & 1A03_PANTR,1A11_HUMAN)# & PIR1: (HLHUA3,HLHU32)# & PIR2: (I38518,I37482,A47636,I36959,I83063,I37478,I61856,I54307,# & S03535,I36966)# & PIR3: (S06424)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,EPRAPWIEQEGPEYWDQE*# SEQUENCE: EPRAPWIEQEGPEYWDQE*# ...# >HUM22E1B# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: li chain (80-99)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,LPKPPKPVSKMRMATPLLMQ*# SEQUENCE: LPKPPKPVSKMRMATPLLMQ*# ...# >HUM22E1C# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: li chain (91-107)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,RMATPLLMQALPMGALPQ*# SEQUENCE: RMATPLLMQALPMGALPQ*# ...# >HUM22E1D# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: li chain (92-105)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,MATPLLMQALPMGAL*# SEQUENCE: MATPLLMQALPMGAL*# ...# >HUM22E1E# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: li chain (92-107)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,MATPLLMQALPMGALPQ*# SEQUENCE: MATPLLMQALPMGALPQ*# ...# >HUM22E1F# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: li chain (92-104)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesu,MATPLLMQALPMGA*# SEQUENCE: MATPLLMQALPMGA*# ...# >HUM22E20# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: li chain (Y80-102)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,YLPKPPKPVSKMRMATPLLMQALP*# SEQUENCE: YLPKPPKPVSKMRMATPLLMQALP*# ...# >HUM22E21# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: li chain (91-102)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,RMATPLLMQALPMGALP*# SEQUENCE: RMATPLLMQALPMGALP*# ...# >HUM22E22# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Mycobacterium bovis 65 kD (243-255)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,KPLLIIAEDVEGEY*# SEQUENCE: KPLLIIAEDVEGEY*# ...# >HUM22E23# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Mycobacterium leprae 18kD (Y31-43)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,YDAWREGEEFVVEF*# SEQUENCE: YDAWREGEEFVVEF*# ...# >HUM22E24# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MHC-1 alpha (48-58)# DB REFERENCE: SWISS: (1A26_HUMAN,1B02_GORGO,1B60_HUMAN,1B45_HUMAN,1B25_HUMAN,# & 1A03_PANTR,1B05_HUMAN,1B58_HUMAN,1B14_HUMAN,1B59_HUMAN,# & 1A25_HUMAN,1B63_HUMAN,1A68_HUMAN,1A33_HUMAN,1A69_HUMAN,# & 1B16_HUMAN,1B39_HUMAN,1B57_HUMAN,1B40_HUMAN,1A11_HUMAN,# & 1B42_HUMAN,1B52_HUMAN,1B20_HUMAN,1B28_HUMAN,1B29_HUMAN,# & 1A34_HUMAN,1B23_HUMAN,1B03_GORGO,1B01_PANTR,1B62_HUMAN,# & 1A74_HUMAN,1B21_HUMAN,1B01_GORGO,1B15_HUMAN,1B12_HUMAN,# & 1A36_HUMAN,1A01_PANTR,1B19_HUMAN,1B44_HUMAN,1B10_HUMAN,# & 1A23_HUMAN,1B13_HUMAN,1B02_HUMAN,1B07_HUMAN,1B12_HUMAN,# & 1B41_HUMAN,1A03_HUMAN,1B48_HUMAN,1B34_HUMAN,1B54_HUMAN,# & 1A02_HUMAN,1B27_HUMAN,1B43_HUMAN,1B61_HUMAN,1A04_PANTR,# & 1B08_HUMAN,1B02_PANTR,1A02_PANTR,1A01_HUMAN,1A26_HUMAN,# & 1B36_HUMAN,1B24_HUMAN,1B47_HUMAN,1B33_HUMAN,1B38_HUMAN,# & 1B46_HUMAN,1B31_HUMAN,1A66_HUMAN,1B22_HUMAN,1B53_HUMAN,# & 1A29_HUMAN,1B11_HUMAN,1A02_HUMAN,1A24_HUMAN,1A01_GORGO,# & 1B26_HUMAN,1A32_HUMAN,1A43_HUMAN,1B04_HUMAN,1B35_HUMAN,# & 1B32_HUMAN,1B49_HUMAN,1B18_HUMAN,1B56_HUMAN)# & PIR1: (HLHUB2,HLHU32,HLHU69,HLHUA3,HLHUAW,HLHUB4,HLHUA2,HLHU40,# & HLHUB8,S42102,HLHUB7,HLHU28)# & PIR2: (I62043,I61902,I61859,I72754,I72171,A45847,I59645,I37492,# & I37482,I37542,I37519,I37120,I38509,I61857,I59633,I61861,# & I37479,S24437,I61864,I38443,S24438,I38437,I37470,I38874,# & I68774,I80168,A35997,I54463,I37478,I62044,I54505,A30345,# & I36956,I56149,I62042,I68724,I37522,S03535,I36966,A47636,# & I72752,A45834,JH0540,S03538,I38442,S24027,I81233,I54442,# & I59188,A37028,I36957,I37485,I54457,I38875,I54314,I72755,# & JH0534,I38518,I68748,I38876,I61903,S24440,I80169,I62041,# & S24433,I54418,I80174,JH0541,I61862,S24435,I54308,I36965,# & I84490,I54298,C35997,I37520,I84486,A45850,I62045,I80176,# & S03537,I37480,S01171,I61863,I84487,I37516,G01230,I36961,# & JH0539,B30345,I61856,I68747,I37521,I38421,S16769,I38436,# & S60601,I84448,I59655,S24439,I68701,D35997,I84431,I54493,# & I56133,I38860,I36962,I38441,I36959,S52486,I61904,S51099,# & I54289,I37477,I61907,I83063,I61905,I37515,I61906,A45880,# & I37483,I61865,I54307,JL0135,I72753,S16789,I54416,S25415,# & I61860,I59651,S24436,I84488,I80170,I59654,I37475,I68850,# & S24434,I80171,I38610,I56116)# & PIR3: (S06424,S07113)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,RAPWIEQEGPE*# SEQUENCE: RAPWIEQEGPE*# ...# >HUM22E25# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MHC-1 alpha (49-59)# DB REFERENCE: SWISS: (1B23_HUMAN,1B63_HUMAN,1A25_HUMAN,1B14_HUMAN,1A68_HUMAN,# & 1B35_HUMAN,1B39_HUMAN,1A32_HUMAN,1B04_HUMAN,1B26_HUMAN,# & 1A01_GORGO,1B22_HUMAN,1A02_HUMAN,1A26_HUMAN,1B12_HUMAN,# & 1B56_HUMAN,1B59_HUMAN,1B18_HUMAN,1B32_HUMAN,1B49_HUMAN,# & 1A69_HUMAN,1A33_HUMAN,1A43_HUMAN,1A24_HUMAN,1B53_HUMAN,# & 1A29_HUMAN,1B11_HUMAN,1B58_HUMAN,1B45_HUMAN,1B15_HUMAN,# & 1B01_GORGO,1B48_HUMAN,1A36_HUMAN,1B13_HUMAN,1B41_HUMAN,# & 1B61_HUMAN,1B38_HUMAN,1B43_HUMAN,1B27_HUMAN,1B34_HUMAN,# & 1B54_HUMAN,1A02_HUMAN,1B24_HUMAN,1B36_HUMAN,1A26_HUMAN,# & 1B47_HUMAN,1B33_HUMAN,1B02_PANTR,1A02_PANTR,1A01_HUMAN,# & 1B46_HUMAN,1A04_PANTR,1B08_HUMAN,1A66_HUMAN,1B31_HUMAN,# & 1B44_HUMAN,1A23_HUMAN,1B10_HUMAN,1A01_PANTR,1B19_HUMAN,# & 1B62_HUMAN,1B02_HUMAN,1A03_HUMAN,1B07_HUMAN,1B12_HUMAN,# & 1B02_GORGO,1B57_HUMAN,1B05_HUMAN,1B60_HUMAN,1B25_HUMAN,# & 1A03_PANTR,1B29_HUMAN,1A34_HUMAN,1B28_HUMAN,1B01_PANTR,# & 1B03_GORGO,1A11_HUMAN,1B42_HUMAN,1B52_HUMAN,1B20_HUMAN,# & 1B40_HUMAN,1A74_HUMAN,1B21_HUMAN)# & PIR1: (HLHUB8,HLHU28,HLHUB7,HLHU40,HLHUA2,S42102,HLHUB4,HLHU32,# & HLHUB2,HLHUA3,HLHU69,HLHUAW)# & PIR2: (I37519,I37492,I61859,I72171,S24438,I38610,I84488,I83063,# & I61906,I37515,JL0135,I68850,S24434,I68748,I38518,I38875,# & I37485,S24027,S03538,I54442,A47636,I72752,I61903,I62042,# & I36956,A30345,S03537,S16769,B30345,I38874,I80176,I37520,# & I54298,I54308,I84490,S24435,I61904,A37028,I59188,I56149,# & I37478,I68701,I38860,G01230,I36965,I61862,I80174,I61863,# & I37480,I62043,I36966,S03535,I37522,S24440,I68724,I80168,# & I62044,A35997,I54463,I54505,I68774,I62045,I84486,A45850,# & S01171,C35997,JH0541,I84487,I38421,I68747,I37521,JH0539,# & I36961,I37516,I61856,I37470,I61864,I38437,I37479,S24437,# & I80170,I80171,I59654,S24436,I61860,I59651,I54416,S25415,# & I61865,S16789,I54307,I72753,A45880,I37483,I61905,I38443,# & I59645,A45847,I72754,I61861,I37482,I37542,I61902,I37120,# & I38509,I59633,I61857,I72755,I54314,JH0534,JH0540,I81233,# & I38442,I54457,A45834,I36957,I38876,I62041,I80169,I54418,# & S24433,I54493,I38441,I36962,I56133,S52486,I36959,S51099,# & I61907,I37477,I38436,I84448,S60601,I56116,I37475,D35997,# & I59655,S24439,I84431)# & PIR3: (S07113,S06424)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,APWIEQEGPEY*# SEQUENCE: APWIEQEGPEY*# ...# >HUM22E26# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (50-60)# DB REFERENCE: SWISS: (1B12_HUMAN,1B07_HUMAN,1B02_HUMAN,1A03_HUMAN,1B44_HUMAN,# & 1A23_HUMAN,1A01_PANTR,1B19_HUMAN,1B40_HUMAN,1A11_HUMAN,# & 1B29_HUMAN,1A34_HUMAN,1B28_HUMAN,1B01_PANTR,1B03_GORGO,# & 1A03_PANTR,1B02_GORGO,1A74_HUMAN,1B21_HUMAN,1B52_HUMAN,# & 1B04_GORGO,1B62_HUMAN,1B34_HUMAN,1B11_HUMAN,1B54_HUMAN,# & 1A02_HUMAN,1A04_PANTR,1B08_HUMAN,1B31_HUMAN,1A66_HUMAN,# & 1B46_HUMAN,1B47_HUMAN,1B33_HUMAN,1A01_HUMAN,1A26_HUMAN,# & 1B27_HUMAN,1B56_HUMAN,1B53_HUMAN,1A29_HUMAN,1A24_HUMAN,# & 1B59_HUMAN,1A43_HUMAN,1B18_HUMAN,1B49_HUMAN,1A33_HUMAN,# & 1A69_HUMAN,1B58_HUMAN,1B45_HUMAN,1B38_HUMAN,1B43_HUMAN,# & 1B48_HUMAN,1A36_HUMAN,1B01_GORGO,1B41_HUMAN,1B61_HUMAN,# & 1B15_HUMAN,1B32_HUMAN,1B13_HUMAN,1B02_PANTR,1B24_HUMAN,# & 1B42_HUMAN,1B22_HUMAN,1B12_HUMAN,1A26_HUMAN,1B26_HUMAN,# & 1B35_HUMAN,1B63_HUMAN,1B60_HUMAN,1B23_HUMAN,1B36_HUMAN,# & 1A02_PANTR,1B10_HUMAN,1B39_HUMAN,1B20_HUMAN,1A02_HUMAN,# & 1A32_HUMAN,1A01_GORGO,1B04_HUMAN,1A68_HUMAN,1A25_HUMAN,# & 1B14_HUMAN,1B05_HUMAN,1B25_HUMAN,1B57_HUMAN)# & PIR1: (HLHUAW,HLHU32,HLHUA3,HLHUB7,HLHUB2,S42102,HLHUA2,HLHU28,# & HLHUB4,HLHU69,HLHUB8,HLHU40)# & PIR2: (I68701,I38860,I37480,I36965,I61862,I80174,I37478,S24434,# & I68850,I38610,I84488,I83063,I37515,I61859,S24438,I37519,# & I62043,I61904,I56149,I59188,I37470,I61864,S24437,I37479,# & S16789,I61905,I54307,I72753,A45880,I59651,I80171,I80170,# & S24436,I56116,S24439,D35997,I54308,I84490,S24435,B30345,# & S03537,I37520,I62042,I36956,I61903,I72752,I68748,I38518,# & S03538,I38875,I38436,S60601,I36962,I54493,I38441,I56133,# & S52486,I37477,S51099,I62044,I54505,A35997,I36966,I36960,# & S24440,I38876,S03535,I68774,JH0539,I61856,I36961,I84487,# & I37516,A45850,JH0534,I72755,I61861,I38442,I54457,I81233,# & JH0540,A45834,I72754,A45847,I38437,I59645,I37120,I37542,# & I61902,I38421,I61865,I84486,I62045,C35997,JH0541,I80168,# & I62041,G01230,I61863,A37028,I36957,I54314,I38443,I61857,# & I59633,S25415,I37483,A47636,S16769,I37521,I68747,I80169,# & I37522,I68724,I54463,JH0542,S01171,I54418,S24433,I37482,# & I38509,I54416,I59654,I61860,I61906,JL0135,I37492,I72171,# & I38874,I80176,I54298,A30345,S24027,I54442,I37485,I59655,# & I84431,I37475,I61907,I36959,I84448)# & PIR3: (S07115,S07113,S06424)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,PWIEQEGPEYW*# SEQUENCE: PWIEQEGPEYW*# ...# >HUM22E27# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-61)# DB REFERENCE: SWISS: (1A11_HUMAN,1B29_HUMAN,1A34_HUMAN,1B28_HUMAN,1A03_PANTR,# & 1B25_HUMAN,1B02_GORGO,1B14_HUMAN,1A25_HUMAN,1A68_HUMAN,# & 1A01_GORGO,1B04_HUMAN,1B12_HUMAN,1B52_HUMAN,1A02_HUMAN,# & 1B49_HUMAN,1B56_HUMAN,1B41_HUMAN,1A26_HUMAN,1B24_HUMAN,# & 1B57_HUMAN,1B05_HUMAN,1B01_PANTR,1B03_GORGO,1A32_HUMAN,# & 1B20_HUMAN,1B10_HUMAN,1B39_HUMAN,1B36_HUMAN,1A02_PANTR,# & 1B44_HUMAN,1B47_HUMAN,1A01_HUMAN,1B33_HUMAN,1A66_HUMAN,# & 1A29_HUMAN,1B34_HUMAN,1B18_HUMAN,1B32_HUMAN,1B13_HUMAN,# & 1B63_HUMAN,1B02_PANTR,1B15_HUMAN,1A02_HUMAN,1B42_HUMAN,# & 1B35_HUMAN,1B60_HUMAN,1B26_HUMAN,1B12_HUMAN,1B23_HUMAN,# & 1A36_HUMAN,1B01_GORGO,1A33_HUMAN,1A69_HUMAN,1A24_HUMAN,# & 1A43_HUMAN,1B59_HUMAN,1B58_HUMAN,1B45_HUMAN,1B53_HUMAN,# & 1B38_HUMAN,1B43_HUMAN,1B48_HUMAN,1B61_HUMAN,1B22_HUMAN,# & 1A04_PANTR,1B08_HUMAN,1B31_HUMAN,1B46_HUMAN,1B07_HUMAN,# & 1B02_HUMAN,1A74_HUMAN,1B21_HUMAN,1B62_HUMAN,1B40_HUMAN,# & 1B04_GORGO,1B19_HUMAN,1A23_HUMAN,1A01_PANTR,1A03_HUMAN,# & 1A26_HUMAN,1B27_HUMAN,1B54_HUMAN,1B11_HUMAN)# & PIR1: (HLHU40,HLHUB4,HLHUA2,S42102,HLHU69,HLHU32,HLHUA3,HLHUB2,# & HLHUB7,HLHU28,HLHUAW,HLHUB8)# & PIR2: (I37515,I61862,I36965,I37480,I59654,I37521,I54463,I80176,# & I37492,I38518,I38875,I37520,I54308,I84490,I56133,I38441,# & I56116,I61905,A45850,I36960,JH0539,I37516,I84487,S16769,# & G01230,S24435,I72752,S24438,S52486,S16789,I72753,I38610,# & I37483,I59645,I37542,I62044,I81233,I80168,I72754,I61856,# & D35997,I36962,S24439,A45880,I54307,I59651,I80171,I80170,# & S24436,S24437,I37479,I68774,I36961,I54505,A35997,I38876,# & S24440,I36966,S03535,A45847,I61864,I37470,I38437,I61902,# & I37120,I38442,I54457,I72755,JH0534,I61861,JH0540,A45834,# & I61904,I59188,I62043,I61860,I54416,I37482,I38509,S01171,# & I68747,JH0542,S24433,I54418,I68724,I37522,I80169,I80174,# & I37478,I56149,I38860,I68701,I61859,I83063,I84488,S24434,# & I68850,S03538,I37519,I68748,I62042,I36956,I61903,B30345,# & S03537,I38436,S60601,I54493,S51099,I37477,S25415,I54314,# & I59633,I61857,I38443,A47636,I38421,I61865,I37475,I84431,# & I59655,I61907,I36959,I84448,I54298,I38874,A30345,S24027,# & I54442,I37485,I72171,JL0135,I61906,I36957,I62041,I84486,# & I62045,C35997,JH0541,I61863,A37028)# & PIR3: (S07115,S06424,S07113)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEGPEYWD*# SEQUENCE: WIEQEGPEYWD*# ...# >HUM22E28# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MHC-1 alpha (52-62)# DB REFERENCE: SWISS: (1A32_HUMAN,1A01_HUMAN,1A36_HUMAN,1A03_PANTR,1A74_HUMAN,# & 1A11_HUMAN,1A03_HUMAN)# & PIR1: (HLHUA3,HLHU32)# & PIR2: (I61856,I36959,I38518,A47636,S03535,I36966,I37478,I83063,# & I54307,I37482)# & PIR3: (S06424)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,IEQEGPEYWDQ*# SEQUENCE: IEQEGPEYWDQ*# ...# >HUM22E29# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60)# DB REFERENCE: SWISS: (1A01_PANTR,1A03_HUMAN,1B40_HUMAN,1B21_HUMAN,1B04_GORGO,# & 1B25_HUMAN,1A11_HUMAN,1B02_GORGO,1A34_HUMAN,1B28_HUMAN,# & 1A68_HUMAN,1A03_PANTR,1A01_GORGO,HA12_MOUSE,HA15_MOUSE,# & 1B35_HUMAN,1B36_HUMAN,1B02_PANTR,1B29_HUMAN,1B33_HUMAN,# & 1A66_HUMAN,1B44_HUMAN,1B03_GORGO,1B05_HUMAN,HA12_MOUSE,# & 1B57_HUMAN,1B10_HUMAN,1B20_HUMAN,1B39_HUMAN,1A02_PANTR,# & 1B32_HUMAN,1B13_HUMAN,1B63_HUMAN,1A29_HUMAN,1B34_HUMAN,# & 1B22_HUMAN,1B12_HUMAN,1B43_HUMAN,1B48_HUMAN,1B61_HUMAN,# & 1A24_HUMAN,1A43_HUMAN,1B45_HUMAN,1B01_GORGO,1B27_HUMAN,# & 1A26_HUMAN,1B46_HUMAN,1B07_HUMAN,1B02_HUMAN,1A04_PANTR,# & 1B08_HUMAN,1B31_HUMAN,1B11_HUMAN,1B53_HUMAN,1A02_HUMAN,# & 1B15_HUMAN,1B42_HUMAN,1A32_HUMAN,1A01_HUMAN,1B01_PANTR,# & 1B47_HUMAN,1B18_HUMAN,1B60_HUMAN,1B26_HUMAN,1B23_HUMAN,# & 1B38_HUMAN,1B59_HUMAN,1A69_HUMAN,1A33_HUMAN,1B58_HUMAN,# & 1B54_HUMAN,1B49_HUMAN,1B41_HUMAN,1A26_HUMAN,1B24_HUMAN,# & 1B52_HUMAN,1A02_HUMAN,1A36_HUMAN,1B12_HUMAN,1B56_HUMAN,# & HA1Y_MOUSE,1B04_HUMAN,1A74_HUMAN,1A25_HUMAN,1B14_HUMAN,# & 1A23_HUMAN,1B19_HUMAN,1B62_HUMAN)# & PIR1: (HLHUB7,HLHUB2,HLMS37,HLHU69,HLHU40,HLMS1,HLHUAW,HLHUB4,# & S42102,HLHUA2,HLHU32,HLHU28,HLHUB8,HLHUA3)# & PIR2: (I38509,I54416,S01171,I68724,I61859,S03538,S03537,I80174,# & I36966,A35997,I38442,JH0540,I37470,I83063,I80170,D35997,# & S51099,I61862,I37515,I37516,I84487,A45850,I54308,I56116,# & I38441,I62045,I38443,I38874,I84448,I61906,A30345,I37485,# & I49712,I54493,I72755,S24440,S52486,I59645,S16789,I54298,# & I36957,I38436,I37519,I80176,I37480,I84488,I36959,S24434,# & I68850,I56149,I68701,I38860,I37477,S60601,I61903,I68748,# & I36956,I62042,B30345,I38876,I36961,I68774,S03535,I61902,# & I38437,I61864,A45847,I54457,JH0534,A45834,I61861,I37120,# & A45880,S24437,I37479,I80171,S24436,I59651,I36962,I37478,# & S24439,I54505,S25415,I38421,I61856,I61865,I38875,I37482,# & I84490,I37520,I61905,I56133,I36960,JH0539,I84431,I37475,# & I61907,I59655,JL0135,S24027,I54442,I72171,A37028,I61863,# & I54314,I59633,I61857,I62041,JH0541,C35997,I84486,A47636,# & I59188,I61904,I62043,JH0542,I68747,S24433,I80169,I54418,# & I37522,I49713,I38518,I61860,I72754,I81233,I80168,G01230,# & S16769,I72753,S24435,I72752,S24438,I38610,I37483,I62044,# & I37542,I54307,I37492,I59654,I37521,I54463,I36965)# & PIR3: (S07115,S07113,S06424)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEGPEYW*# SEQUENCE: WIEQEGPEYW*# ...# >HUM22E2A# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MHC-1 alpha (52-60)# DB REFERENCE: SWISS: (1B31_HUMAN,1B53_HUMAN,1B25_HUMAN,1A34_HUMAN,HA12_MOUSE,# & HA15_MOUSE,1B29_HUMAN,1B36_HUMAN,1B02_PANTR,1B35_HUMAN,# & 1B45_HUMAN,1A24_HUMAN,1A01_HUMAN,1B15_HUMAN,HA12_MOUSE,# & 1B05_HUMAN,1B32_HUMAN,HA1Y_MOUSE,1B01_PANTR,1B38_HUMAN,# & 1B19_HUMAN,1B04_HUMAN,1B14_HUMAN,1B33_HUMAN,1A29_HUMAN,# & 1B34_HUMAN,1A66_HUMAN,1B57_HUMAN,1B13_HUMAN,1B12_HUMAN,# & 1B43_HUMAN,1B22_HUMAN,1B11_HUMAN,1A43_HUMAN,1B01_GORGO,# & 1B61_HUMAN,1B42_HUMAN,1A32_HUMAN,1A02_PANTR,1B39_HUMAN,# & 1B20_HUMAN,1B10_HUMAN,1A02_HUMAN,1B58_HUMAN,1B23_HUMAN,# & 1B60_HUMAN,1B47_HUMAN,1B18_HUMAN,1B49_HUMAN,1B56_HUMAN,# & 1B41_HUMAN,1B12_HUMAN,1B52_HUMAN,1A36_HUMAN,1B24_HUMAN,# & 1A74_HUMAN,1A23_HUMAN,1B62_HUMAN,1A25_HUMAN,1B54_HUMAN,# & 1A69_HUMAN,1A33_HUMAN,1B48_HUMAN,1B28_HUMAN,1B44_HUMAN,# & 1B63_HUMAN,1A02_HUMAN,1A26_HUMAN,1B03_GORGO,1B26_HUMAN,# & 1B59_HUMAN,1A01_GORGO,1A11_HUMAN,1A03_PANTR,1A68_HUMAN,# & 1A01_PANTR,1B21_HUMAN,1A03_HUMAN,1B40_HUMAN,1B04_GORGO,# & 1B02_GORGO,1B07_HUMAN,1B08_HUMAN,1A04_PANTR,1B02_HUMAN,# & 1A26_HUMAN,1B46_HUMAN,1B27_HUMAN)# & PIR1: (HLHUB8,HLHU69,HLHU40,S42102,HLHU32,HLHU28,HLHUA3,HLHUA2,# & HLHUB4,HLMS37,HLMS1,HLHUB7,HLHUB2,HLHUAW)# & PIR2: (I62045,I38443,I61906,I37485,A30345,I38874,I84448,I84487,# & I37516,I56116,I37515,I54308,I38441,I61862,I72755,I54493,# & I49712,I38436,S24440,S52486,I59645,S16789,I36957,I54298,# & I37519,I80176,I37480,I54505,I37482,I38875,I56133,I38421,# & I61856,S25415,I37542,I37483,I37492,I38442,JH0540,I37470,# & I83063,S03538,I61859,I68724,I54416,I81233,I80168,I72754,# & I72752,S24438,I38610,S24435,S16769,I54463,I61905,S01171,# & G01230,I56149,I59188,I84488,S24434,I68701,I62042,I36959,# & B30345,I80171,I59651,S24436,A45880,S24439,I36962,I37477,# & I38876,A45834,JH0534,S03535,I61864,I38437,A45847,I37479,# & S24437,I61902,I61861,JH0542,S24433,I80169,I37522,I54418,# & I38518,I84431,I37475,I49713,I61860,I62043,A47636,A37028,# & I54314,I62041,I61857,JH0541,C35997,JL0135,I54442,I72171,# & I61907,I36961,D35997,S03537,I80174,S24027,I61863,I84486,# & I37520,I36960,I62044,I37120,I54457,I68748,I59654,I37521,# & I36965,I72753,I54307,I38509,I36966,A35997,I80170,S51099,# & A45850,I38860,I68850,I36956,I61903,I37478,S60601,I68774,# & I59633,I61904,I59655,I68747,JH0539,I84490,I61865)# & PIR3: (S07113,S06424,S07115)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,IEQEGPEYW*# SEQUENCE: IEQEGPEYW*# ...# >HUM22E2B# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,AIEQEGPEYW*# SEQUENCE: AIEQEGPEYW*# ...# >HUM22E2C# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,KIEQEGPEYW*# SEQUENCE: KIEQEGPEYW*# ...# >HUM22E2D# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,YIEQEGPEYW*# SEQUENCE: YIEQEGPEYW*# ...# >HUM22E2E# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIAQEGPEYW*# SEQUENCE: WIAQEGPEYW*# ...# >HUM22E2F# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIKQEGPEYW*# SEQUENCE: WIKQEGPEYW*# ...# >HUM22E30# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIDQEGPEYW*# SEQUENCE: WIDQEGPEYW*# ...# >HUM22E31# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIWQEGPEYW*# SEQUENCE: WIWQEGPEYW*# ...# >HUM22E32# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEAEGPEYW*# SEQUENCE: WIEAEGPEYW*# ...# >HUM22E33# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# DB REFERENCE: PIR2: (I46049)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEKEGPEYW*# SEQUENCE: WIEKEGPEYW*# ...# >HUM22E34# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIENEGPEYW*# SEQUENCE: WIENEGPEYW*# ...# >HUM22E35# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEAPEYW*# SEQUENCE: WIEQEAPEYW*# ...# >HUM22E36# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEKPEYW*# SEQUENCE: WIEQEKPEYW*# ...# >HUM22E37# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEGPEAW*# SEQUENCE: WIEQEGPEAW*# ...# >HUM22E38# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEGPEKW*# SEQUENCE: WIEQEGPEKW*# ...# >HUM22E39# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEGPEFW*# SEQUENCE: WIEQEGPEFW*# ...# >HUM22E3A# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesl,WAEQEGPEYW*# SEQUENCE: WAEQEGPEYW*# ...# >HUM22E3B# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MHC-1 alpha (51-60) homologue# DB REFERENCE: PIR2: (S35940)# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WLEQEGPEYW*# SEQUENCE: WLEQEGPEYW*# ...# >HUM22E3C# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQAGPEYW*# SEQUENCE: WIEQAGPEYW*# ...# >HUM22E3D# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQDGPEYW*# SEQUENCE: WIEQDGPEYW*# ...# >HUM22E3E# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WIEQWGPEYW*# SEQUENCE: WIEQWGPEYW*# ...# >HUM22E3F# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEGAEYW*# SEQUENCE: WIEQEGAEYW*# ...# >HUM22E40# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WIEQEGPAYW*# SEQUENCE: WIEQEGPAYW*# ...# >HUM22E41# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEGPDYW*# SEQUENCE: WIEQEGPDYW*# ...# >HUM22E42# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WIEQEGPWYW*# SEQUENCE: WIEQEGPWYW*# ...# >HUM22E43# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesm,WIEQEGPEYA*# SEQUENCE: WIEQEGPEYA*# ...# >HUM22E44# MHC MOLECULE: HLA-DQ2(DQA1*0501xDQB1*0201), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MHC-1 alpha (51-60) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-de-wal96a# COMMENT:# SUMMARY: HLA-DQ2,actunkn,bindyesh,WIEQEGPEYY*# SEQUENCE: WIEQEGPEYY*# ...# >HUM22E45# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Elution/Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IE1 (162-175)# DB REFERENCE: SWISS: (VIE1_HCMVT,VIE1_HCMVA)# & PIR1: (EDBEIC,EDBEM5)# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesm,bindyesu,DKREMWMACIKELH*# SEQUENCE: DKREMWMACIKELH*# ...# >HUM22E46# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Predicted from longer peptide# ACTIVITY: ?# BINDING: yes, ?# SOURCE: IE1 (164-173)# DB REFERENCE: SWISS: (VIE1_HCMVA,VIE1_HCMVT)# & PIR1: (EDBEM5,EDBEIC)# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,REMWMACIKE*# SEQUENCE: REMWMACIKE*# ...# >HUM22E47# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IE1 (156-175)# DB REFERENCE: SWISS: (VIE1_HCMVA,VIE1_HCMVT)# & PIR1: (EDBEIC,EDBEM5)# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesm,bindyesu,NYIVPEDKREMWMACIKELH*# SEQUENCE: NYIVPEDKREMWMACIKELH*# ...# >HUM22E48# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IE1 (157-175)# DB REFERENCE: SWISS: (VIE1_HCMVT,VIE1_HCMVA)# & PIR1: (EDBEIC,EDBEM5)# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesm,bindyesu,YIVPEDKREMWMACIKELH*# SEQUENCE: YIVPEDKREMWMACIKELH*# ...# >HUM22E49# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IE1 (158-175)# DB REFERENCE: SWISS: (VIE1_HCMVA,VIE1_HCMVT)# & PIR1: (EDBEM5,EDBEIC)# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesm,bindyesu,IVPEDKREMWMACIKELH*# SEQUENCE: IVPEDKREMWMACIKELH*# ...# >HUM22E4A# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IE1 (160-175)# DB REFERENCE: SWISS: (VIE1_HCMVA,VIE1_HCMVT)# & PIR1: (EDBEIC,EDBEM5)# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesl,bindyesu,PEDKREMWMACIKELH*# SEQUENCE: PEDKREMWMACIKELH*# ...# >HUM22E4B# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IE1 (158-175) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesl,bindyesu,IVPEDKREMWMACIKEAA*# SEQUENCE: IVPEDKREMWMACIKEAA*# ...# >HUM22E4C# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IE1 (158-175) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesl,bindyesu,IVPEDKREMWMACIAALH*# SEQUENCE: IVPEDKREMWMACIAALH*# ...# >HUM22E4D# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: IE1 (158-175) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesh,bindyesu,IVPEDKREMWMAAAKELH*# SEQUENCE: IVPEDKREMWMAAAKELH*# ...# >HUM22E4E# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: IE1 (158-175) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesl,bindyesu,IVPEDKREMWAACIKELH*# SEQUENCE: IVPEDKREMWAACIKELH*# ...# >HUM22E4F# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IE1 (158-175) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesm,bindyesu,IVPEAAREMWMACIKELH*# SEQUENCE: IVPEAAREMWMACIKELH*# ...# >HUM22E50# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: IE1 (158-175) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesm,bindyesu,IVAADKREMWMACIKELH*# SEQUENCE: IVAADKREMWMACIKELH*# ...# >HUM22E51# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: IE1 (158-175) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautier96a# COMMENT:# SUMMARY: HLA-DR8,actyesh,bindyesu,AAPEDKREMWMACIKELH*# SEQUENCE: AAPEDKREMWMACIKELH*# ...# >HUM22E52# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-B7 (150-161)# DB REFERENCE: SWISS: (1A33_HUMAN,1A80_HUMAN,1B01_SAGOE,1A74_HUMAN,HLAH_HUMAN,# & 1OKO_GORGO,1C02_GORGO,1A36_HUMAN,1B34_HUMAN,1A66_HUMAN,# & 1B33_HUMAN,1C14_HUMAN,1C06_HUMAN,1C01_SAGOE,HA1A_RABIT,# & 1B20_HUMAN,1B39_HUMAN,1A02_GORGO,1C01_GORGO,1C01_PANTR,# & 1C17_HUMAN,1B35_HUMAN,1B36_HUMAN,1A01_HUMAN,1C04_HUMAN,# & 1C04_GORGO,HA1B_RABIT,1C02_HUMAN,1B38_HUMAN,1B04_HUMAN,# & HLAF_HUMAN,1A11_HUMAN,1C01_HUMAN,1A43_HUMAN,1C28_PANTR,# & HA19_CANFA,1A26_HUMAN,1C16_HUMAN,1C15_HUMAN,1A31_HUMAN,# & 1C13_HUMAN,HLAF_HUMAN,1A25_HUMAN,HLAH_HUMAN,1CXX_HUMAN,# & 1C02_GORGO,HLAF_MACMU,1A29_HUMAN,1C02_HUMAN,1A34_HUMAN,# & 1A30_HUMAN,HLAG_HUMAN,1C03_HUMAN,1C11_HUMAN,1A31_HUMAN,# & 1C12_HUMAN,1C07_HUMAN,1A01_PANTR,1A01_PONPY,1B02_HUMAN,# & 1A04_PANTR,1B46_HUMAN,1C03_GORGO,1A03_HUMAN,1A03_GORGO,# & 1A01_GORGO,1C18_HUMAN,1A32_HUMAN,1A26_HUMAN)# & PIR1: (HLHUB7,HLHUC4,HLHU12,HLHUA3,HLRB,S42102,HLHU32,HLHU40)# & PIR2: (JH0538,S01171,I81231,S11141,S11140,S11138,I54307,I67482,# & S51102,I59622,I46604,A60369,I79640,A45831,S18198,I72029,# & S11135,I46603,I37480,I37528,I72113,I67483,A45897,I68750,# & I36965,I61865,A49411,I68712,I61903,S60601,S44994,I37523,# & I56034,I56116,I38439,I38519,I37544,I38505,S52486,I37078,# & A45849,S24438,I37527,I46858,I38610,I72808,I37476,S16769,# & S11134,JH0543,S11137,JH0292,B45831,I38507,I83063,S33355,# & S18197,S51100,I37492,JH0545,I54449,S11143,A45845,A45857,# & I61856,I37482,C37028,I46030,I37526,I81232,S11142,S11136,# & JH0534,JH0291,I37479,I61864,I38437,JH0288,I59188,I36959,# & I54430,B37028,I84431,JH0290,A39953,S42823,I46860,I56071,# & A37028,JH0535,S29990,I36958,JH0544,JH0289,I46859,I37135,# & I61866,I59651,I72217,I36961,A60384,I61906,I56039,I72170,# & S11133,I37483,A47636,JH0536,I68749,I37477,I38518,I72218,# & I54418,JL0135,I72171,A35997,I36966,I37529,JH0526,JH0546,# & I37478,I68747,I38436,I84487,I84432,JH0547,I56149,I68701,# & A45847,JS0262,I61905,S48134,I59655,S11139)# & PIR3: (G02922,S07114,S06424)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,LNEDLRSWTAAD*# SEQUENCE: LNEDLRSWTAAD*# ...# >HUM22E53# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta2-microglobulin (91-104)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,TPTEKDEYCARVNH*# SEQUENCE: TPTEKDEYCARVNH*# ...# >HUM22E54# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Competition/Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HLA-DRB1*0402 (99-108)# DB REFERENCE: PIR2: (S70749,I56072,I38899,G28043,A33287,H28043,I54448,S03439,# & G01972,S54907,I54291,I72484,I79421)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,DERAAVDTYC*# SEQUENCE: DERAAVDTYC*# ...# >HUM22E55# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: p21 ras (61-89)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,CLLDILDTAGLEEYSAMRD*# SEQUENCE: CLLDILDTAGLEEYSAMRD*# ...# >HUM22E56# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum CP (379-395)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,IEKKIAKMEKASSVFNV*# SEQUENCE: IEKKIAKMEKASSVFNV*# ...# >HUM22E57# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: thyroid peroxidase (632-641)# DB REFERENCE: SWISS: (PERT_MOUSE,PERT_HUMAN,PERT_PIG,PERT_RAT)# & PIR1: (OPHUIT,OPPGIT)# & PIR2: (JN0550,S07047)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,IDVWLGGLAE*# SEQUENCE: IDVWLGGLAE*# ...# >HUM22E58# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Reference/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV-2 VP-16 (433-445)# DB REFERENCE: SWISS: (ATIN_HSV2H,ATIN_HSV23)# & PIR1: (IXBE33)# & PIR2: (JS0689)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a,buckner96a,kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,DMTPADALDDFDL*# SEQUENCE: DMTPADALDDFDL*# ...# >HUM22E59# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Reference/direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: transferrin receptor (332-347)# DB REFERENCE: SWISS: (TRSR_HUMAN,TRSR_HUMAN)# & PIR1: (JXHU)# & PIR2: (S29548)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a,kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,IPVQTISRAAAEKLFG*# SEQUENCE: IPVQTISRAAAEKLFG*# ...# >HUM22E5A# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: BPRP (1-16)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,GPPEKPQGPPQQEGNN*# SEQUENCE: GPPEKPQGPPQQEGNN*# ...# >HUM22E5B# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ribosomal L18 protein (17-42)# DB REFERENCE: SWISS: (RL18_MOUSE,RL18_RAT,RL18_HUMAN)# & PIR1: (R5RT81,JN0779)# & PIR2: (S38352)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,EPKSQDIYLRLLVKLYRFLARRTNST*# SEQUENCE: EPKSQDIYLRLLVKLYRFLARRTNST*# ...# >HUM22E5C# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-B7 (150-164)# DB REFERENCE: SWISS: (1B46_HUMAN,1B02_HUMAN,1B33_HUMAN,1B35_HUMAN,1C17_HUMAN,# & 1C01_HUMAN,1C03_HUMAN,HLAG_HUMAN,1CXX_HUMAN,HA19_CANFA,# & 1C15_HUMAN,1C16_HUMAN,1C02_HUMAN,HA1B_RABIT,1B38_HUMAN,# & 1C02_HUMAN,1C01_PANTR,1C01_GORGO,1C04_GORGO,1C04_HUMAN,# & 1C02_GORGO,1B39_HUMAN,1B20_HUMAN,1B34_HUMAN,1B36_HUMAN,# & 1C18_HUMAN,1C02_GORGO,1C07_HUMAN,1C12_HUMAN,1C14_HUMAN,# & 1C06_HUMAN,1C03_GORGO,HA1A_RABIT,1C11_HUMAN,# & 1B04_HUMAN)# & PIR1: (HLHUC4,HLHUB7,HLHU40,S42102,HLRB)# & PIR2: (I61865,A49411,I68712,S60601,I37528,I67483,A45831,A60369,# & I59622,I67482,I54418,I68749,I81231,I59655,S48134,I59651,# & I61866,I61905,I56149,JS0262,JH0526,I68747,JH0546,I37529,# & JH0547,I38507,JH0543,I38505,I37544,S52486,A45849,S44994,# & I37523,I56034,I56116,I37527,A45845,S11143,I54449,I37492,# & JH0545,I37526,JH0290,A39953,I36958,I54430,I56071,JH0544,# & A45857,JH0289,JH0288,I61864,B37028,I46858,I72808,I46604,# & I46603,I61906,I84431,S42823,S24438,I46030,C37028,I38437,# & I72113,I37078,B45831,JH0292,I61903,I68750,I68701,I37135,# & JH0291,I81232,I59188,A45897)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,LNEDLRSWTAADTAA*# SEQUENCE: LNEDLRSWTAADTAA*# ...# >HUM22E5D# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-B7 (150-159)# DB REFERENCE: SWISS: (HLAG_HUMAN,1B20_HUMAN,1C14_HUMAN,1A31_HUMAN,1B34_HUMAN,# & 1C12_HUMAN,1A04_PANTR,1A01_PANTR,1A03_PANTR,1A03_HUMAN,# & 1A03_GORGO,1A01_GORGO,HLAH_HUMAN,HA1B_RABIT,1A26_HUMAN,# & HA1A_BOVIN,HLAE_PONPY,1C03_GORGO,1B39_HUMAN,1C15_HUMAN,# & 1C16_HUMAN,1C02_HUMAN,1A33_HUMAN,1C04_GORGO,1C04_HUMAN,# & 1A01_SAGOE,1A80_HUMAN,1C01_GORGO,1OKO_GORGO,1A66_HUMAN,# & 1C01_SAGOE,1C02_GORGO,1A36_HUMAN,1B36_HUMAN,HLAH_HUMAN,# & 1A01_HUMAN,1A02_GORGO,1C02_HUMAN,1C03_HUMAN,1A31_HUMAN,# & 1C13_HUMAN,1CXX_HUMAN,1B46_HUMAN,1C28_PANTR,HLAF_HUMAN,# & HA15_MOUSE,HLAE_HUMAN,1A29_HUMAN,1B35_HUMAN,HLAF_MACMU,# & HLAF_HUMAN,1A25_HUMAN,1C01_HUMAN,1A34_HUMAN,1A43_HUMAN,# & 1B02_HUMAN,1A11_HUMAN,1B33_HUMAN,1A30_HUMAN,1C17_HUMAN,# & HA19_CANFA,1B38_HUMAN,1C05_HUMAN,1B01_SAGOE,1C01_PANTR,# & 1A74_HUMAN,1A01_PONPY,1C06_HUMAN,1C07_HUMAN,HA1A_RABIT,# & 1C11_HUMAN,1B04_HUMAN,1C02_GORGO,1A26_HUMAN,1A32_HUMAN,# & 1C18_HUMAN)# & PIR1: (HLMS37,HLHUW3,HLHUC4,HLHUB7,HLHUA3,HLHU32,HLRB,S42102,# & HLHU40,HLHU12)# & PIR2: (S11138,I54307,I83063,S60601,I68747,I38437,I38518,I46030,# & I72170,I81232,I56071,A45845,I38507,S44994,I37528,S11136,# & I61864,JH0288,S18197,I46859,JH0291,S11139,I36965,I61867,# & I68712,S11134,B53250,A45831,I59622,I67482,I37479,S51100,# & I67483,I56116,I37523,I38505,I56053,JH0535,A37028,I54430,# & JH0290,I84487,A60384,I37078,S42823,A35997,I46603,I46604,# & JS0262,S51102,JH0534,I36958,I36961,S18198,I37526,A45840,# & A45857,JH0544,JH0289,A39953,I36959,B37028,S11142,I54449,# & JH0545,I37492,S11143,I37527,I46860,S29990,JH0543,I61856,# & I37482,I37544,S52486,I56034,I38610,A28834,A45849,I38439,# & I81231,I38519,A60369,S16769,I37476,S33355,A27797,A49411,# & S11137,I61865,S03535,I84432,I56198,I38436,I36966,I37478,# & I61906,A45847,I59188,I37135,I68701,I72217,I46858,I72808,# & A45897,I59655,I59651,JH0538,I61866,S01171,I84431,JH0536,# & I46608,I37477,A47636,C37028,I72218,I72171,JL0135,S24438,# & JH0292,B45831,S11133,I37483,I72113,I68750,I61903,I56039,# & JH0526,JH0546,S10934,I37529,JH0547,S11141,S11140,I79640,# & I61905,S11135,I56149,I72029,S48134,I37480,I68745,I68749,# & I54418,A27638)# & PIR3: (G02922,S07114,S06424)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,LNEDLRSWTA*# SEQUENCE: LNEDLRSWTA*# ...# >HUM22E5E# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-B7 (151-160)# DB REFERENCE: SWISS: (1C03_GORGO,1B39_HUMAN,HA1B_RABIT,1A26_HUMAN,HLAH_HUMAN,# & HLAG_HUMAN,1A01_PANTR,1A03_HUMAN,1A03_PANTR,1C16_HUMAN,# & 1A32_HUMAN,1A34_HUMAN,1A43_HUMAN,1B01_SAGOE,1C02_GORGO,# & HA1A_RABIT,1C11_HUMAN,1A11_HUMAN,1B02_HUMAN,1B33_HUMAN,# & 1C17_HUMAN,1A30_HUMAN,HA19_CANFA,1C05_HUMAN,1B38_HUMAN,# & 1B04_HUMAN,1A26_HUMAN,1A01_PONPY,1C06_HUMAN,1A74_HUMAN,# & 1C01_PANTR,1C01_HUMAN,1C18_HUMAN,1C28_PANTR,1B46_HUMAN,# & 1A29_HUMAN,HLAF_HUMAN,1B35_HUMAN,HLAF_MACMU,1A25_HUMAN,# & HLAF_HUMAN,1C15_HUMAN,1C02_HUMAN,1A36_HUMAN,1B36_HUMAN,# & 1C04_GORGO,1A33_HUMAN,1C04_HUMAN,1C01_GORGO,1A80_HUMAN,# & HLAH_HUMAN,1OKO_GORGO,1CXX_HUMAN,1A02_GORGO,1A01_HUMAN,# & 1C02_HUMAN,1C03_HUMAN,1C13_HUMAN,1A01_GORGO,1A31_HUMAN,# & 1C07_HUMAN,1A03_GORGO,1A04_PANTR,1A04_GORGO,1C12_HUMAN,# & 1A31_HUMAN,1C14_HUMAN,1B20_HUMAN,1A66_HUMAN,1B34_HUMAN,# & 1C02_GORGO,1C01_SAGOE)# & PIR1: (HLRB,HLHUW3,HLHU32,HLHUC4,HLHUA3,HLHU12,HLHU40,S42102,# & HLHUB7)# & PIR2: (I68750,I61903,I56039,I37483,C37028,I72218,I72171,JL0135,# & A47636,B45831,I37477,I84431,JH0536,I59655,JH0538,I61866,# & S01171,I59188,A45847,I37135,I68701,I84432,I37478,I61906,# & A45831,I68712,I67482,I67483,I56116,I37523,I38505,S51100,# & A37028,JH0535,JH0290,I37479,I46858,I72808,I72217,A45897,# & I83063,S11138,I54307,I38437,I46030,I38518,I72170,I81232,# & JH0534,I36958,S18198,I37526,JH0291,I46859,JH0288,S18197,# & A45845,I38507,S44994,I37528,S60601,A60384,I84487,I37078,# & S42823,I46603,A35997,S51102,S03535,S11140,I54418,I68749,# & I37480,I79640,I61905,I56149,JH0526,JH0547,S11141,I37529,# & I81231,I38519,A60369,S11137,I61865,A49411,S16769,JH0537,# & S33355,I56034,JH0543,I38610,A45849,I37476,I37544,S52486,# & JH0544,S11142,B37028,I36959,JH0289,S29990,I46860,I37492,# & JH0545,S11143,I38436,I36966,JS0262,S11134,I59622,I36965,# & A45857,A39953,I61856,I37527,I54449,I37482,I38439,JH0546,# & I72029,S48134,JH0292,I72113,I59651,I68747,I36961,I61864,# & S11136,I56071,S11139,I54430,I46604,S11135,S24438,# & S11133)# & PIR3: (S07114,S06424,G02922)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,NEDLRSWTAA*# SEQUENCE: NEDLRSWTAA*# ...# >HUM22E5F# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-B7 (152-161)# DB REFERENCE: SWISS: (1A36_HUMAN,1B36_HUMAN,1A66_HUMAN,1C04_HUMAN,1C04_GORGO,# & 1C01_GORGO,1A80_HUMAN,HLAH_HUMAN,1B34_HUMAN,1C02_GORGO,# & 1C01_SAGOE,1B20_HUMAN,1A31_HUMAN,1C14_HUMAN,1A04_GORGO,# & 1A04_PANTR,1A03_GORGO,1C01_PANTR,1C07_HUMAN,1A68_HUMAN,# & 1C02_GORGO,1A26_HUMAN,1A29_HUMAN,HLAF_HUMAN,HLAF_MACMU,# & 1B46_HUMAN,1C28_PANTR,1A25_HUMAN,1C01_HUMAN,1CXX_HUMAN,# & 1A02_GORGO,1A01_HUMAN,1C02_HUMAN,1C15_HUMAN,1OKO_GORGO,# & 1C02_HUMAN,1C03_HUMAN,1A02_HUMAN,1C13_HUMAN,1B04_HUMAN,# & 1B38_HUMAN,1A01_PONPY,1A23_HUMAN,1A30_HUMAN,1B33_HUMAN,# & 1B02_HUMAN,1A11_HUMAN,1C17_HUMAN,1A01_PANTR,1A03_HUMAN,# & 1B39_HUMAN,1C03_GORGO,HA1B_RABIT,1AXX_HUMAN,1A34_HUMAN,# & HA1A_RABIT,1A32_HUMAN,1A43_HUMAN,1B01_SAGOE,HLAG_HUMAN,# & HLAH_HUMAN,1A26_HUMAN,1A24_HUMAN,1C16_HUMAN,1C11_HUMAN,# & 1C06_HUMAN,HA19_CANFA,1A69_HUMAN,1A74_HUMAN,1B35_HUMAN,# & HLAF_HUMAN,1C18_HUMAN,1C12_HUMAN,1A33_HUMAN,1A02_HUMAN,# & 1A31_HUMAN,1A01_GORGO)# & PIR1: (HLHUA3,HLHU32,HLHUAW,HLHU69,HLHUA2,HLHU12,HLHU40,S42102,# & HLHU10,HLHUC4,HLHUB7,HLRB)# & PIR2: (I38442,I59188,I61903,S42823,I46859,I61864,S11139,I37492,# & I54418,I38610,I54416,S51102,S51100,I56116,A45847,I37478,# & JH0538,B45831,C37028,JH0536,I72218,I56039,I59655,I56149,# & S11137,I81231,I56034,S52486,I37476,A45849,I46860,I61902,# & S11142,S48134,I37482,A39953,I54449,I36966,I59622,I84487,# & A60384,I37078,I38507,S60601,JH0291,I38518,S11138,I36959,# & I68749,S18197,I37544,S16769,JH0545,S29990,JH0544,JH0289,# & JH0543,I38519,A60369,I37480,S33355,A49411,JH0537,I61865,# & S11140,S11141,JH0547,I79640,I37529,JH0526,I61857,I61905,# & I61906,I84432,A45897,I37542,I37135,I68701,I61866,S01171,# & I84431,A47636,I37477,I37483,I72171,JL0135,I68750,B37028,# & JS0262,S11134,I36965,S11136,I56071,I36961,I68747,S11143,# & I46604,I54430,I54412,S11133,S24438,S11135,I54307,I46030,# & I38437,I72170,I56009,I81232,I36958,JH0534,S18198,I37526,# & A45857,I37527,I61856,I38439,JH0546,I72029,JH0292,I72113,# & I38436,I59651,I46603,I38441,A35997,I38443,JH0288,A45845,# & I83063,S44994,I54493,I37528,I68700,I46858,I72808,I72217,# & JH0290,I37479,I67483,JH0535,A37028,I37470,I38505,I37523,# & I67482,I68712,A45831,I84448)# & PIR3: (S07114,G02922,S06424)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,EDLRSWTAAD*# SEQUENCE: EDLRSWTAAD*# ...# >HUM22E60# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-B7 (153-162)# DB REFERENCE: SWISS: (1C02_GORGO,1C01_GORGO,1C04_HUMAN,1C01_PANTR,1C07_HUMAN,# & 1B02_HUMAN,HLAF_HUMAN,1B46_HUMAN,HLAF_HUMAN,1C16_HUMAN,# & 1C11_HUMAN,HLAG_HUMAN,HA19_CANFA,1C06_HUMAN,1B35_HUMAN,# & 1C18_HUMAN,1C12_HUMAN,HA1A_RABIT,1C01_HUMAN,1B04_HUMAN,# & 1CXX_HUMAN,1C03_HUMAN,1C28_PANTR,HLAF_MACMU,1B33_HUMAN,# & 1C17_HUMAN,1B38_HUMAN,1B39_HUMAN,1C03_GORGO,HA1B_RABIT,# & 1B20_HUMAN,1B34_HUMAN,1C14_HUMAN,1C02_GORGO,1B36_HUMAN,# & 1C02_HUMAN,1C04_GORGO,1C15_HUMAN,1C02_HUMAN)# & PIR1: (HLHUC4,HLHU40,S42102,HLHUB7,HLRB)# & PIR2: (JH0292,I72113,A45857,I46030,I38437,I37526,I68747,I56116,# & B45831,I59655,S52486,A45849,I81231,S11143,I46604,S24438,# & I59188,I61903,S42823,I37492,I54449,A39953,I59622,I37078,# & A60384,I38507,JH0289,S29990,B37028,I38505,I68712,I37523,# & I46858,I72808,S44994,I37528,A45845,I46603,I37135,A45897,# & I61906,I61866,JH0547,JH0543,A60369,I61865,I81232,I54430,# & I56071,JS0262,S48134,I61864,JH0291,S60601,I56034,C37028,# & JH0544,JH0545,A49411,I61905,I37529,I68701,I68750,I67482,# & JH0288,I37527,JH0546,I59651,I36958,JH0526,I84431,I37544,# & I68749,I54418,A45831,JH0290,I67483,I56149)# & PIR3: (S07114)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,DLRSWTAADT*# SEQUENCE: DLRSWTAADT*# ...# >HUM22E61# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-B7 (154-163)# DB REFERENCE: SWISS: (1C12_HUMAN,1C02_HUMAN,1CXX_HUMAN,1C03_HUMAN,1B36_HUMAN,# & 1C14_HUMAN,1C04_GORGO,1C01_GORGO,1B46_HUMAN,1C02_GORGO,# & 1C02_GORGO,1C15_HUMAN,1C01_HUMAN,1C17_HUMAN,HA1B_BOVIN,# & HA1A_RABIT,1B38_HUMAN,1B04_HUMAN,1B33_HUMAN,1C03_GORGO,# & 1B39_HUMAN,HA1B_RABIT,1C16_HUMAN,HLAG_HUMAN,1C18_HUMAN,# & 1B35_HUMAN,1C06_HUMAN,1C04_HUMAN,1C07_HUMAN,1C01_PANTR,# & 1B02_HUMAN,HA19_CANFA,1C11_HUMAN,1C02_HUMAN,1B20_HUMAN,# & 1B34_HUMAN)# & PIR1: (HLHUC4,S42102,HLHU40,HLRB,HLHUB7)# & PIR2: (I68701,I59188,A39953,I84431,JH0290,I37544,I56149,B37028,# & I38437,S52486,I59655,A45857,I38505,I37528,I46030,JH0289,# & JH0288,I37527,A49411,I37529,I61903,I37492,JH0547,I61866,# & A60369,I61865,I61906,A45897,I37135,I72808,I46858,I68712,# & I37523,I46603,S44994,A45845,I68747,I37526,I72113,JH0292,# & JH0543,JS0262,I56071,I54430,S60601,S48134,I61864,I56034,# & C37028,JH0291,JH0526,I68749,I54418,I67483,A45831,I81232,# & S42823,I61905,I68750,JH0544,JH0545,I67482,B27638,I59651,# & JH0546,I36958,I38507,I46049,I54449,I59622,S24438,S11143,# & I46604,A45849,I81231,B45831,I56116,I37078)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,LRSWTAADTA*# SEQUENCE: LRSWTAADTA*# ...# >HUM22E62# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HLA-B7 (155-164)# DB REFERENCE: SWISS: (1C04_GORGO,1B38_HUMAN,1B33_HUMAN,1B36_HUMAN,1CXX_HUMAN,# & 1B46_HUMAN,1C02_GORGO,1C02_GORGO,1C15_HUMAN,1C01_HUMAN,# & 1C17_HUMAN,1C04_HUMAN,1C16_HUMAN,1C06_HUMAN,1C02_HUMAN,# & 1B34_HUMAN,1C11_HUMAN,HA1B_BOVIN,1B20_HUMAN,1B02_HUMAN,# & 1C01_PANTR,1C07_HUMAN,HA1B_RABIT,1B39_HUMAN,1C03_GORGO,# & HLAG_HUMAN,1C18_HUMAN,1B35_HUMAN,1C01_GORGO,HA1A_RABIT,# & 1C02_HUMAN,1C12_HUMAN,HA19_CANFA,1C03_HUMAN,1B04_HUMAN,# & 1C14_HUMAN)# & PIR1: (HLHUC4,HLHU40,HLRB,S42102,HLHUB7)# & PIR2: (JS0262,I59651,I36958,I67482,I61905,S42823,I61864,JH0291,# & S60601,I54430,I67483,A45831,S52486,I59655,A45857,I46030,# & I37528,I38505,I81232,A39953,I59188,I68701,I84431,JH0290,# & I37544,I56149,I38437,JH0288,I37527,A49411,I37529,I37492,# & I61865,JH0543,I37078,S11143,I46604,I59622,I46049,I38507,# & I68747,JH0292,I37526,S44994,A45845,I46603,JH0547,A60369,# & I61866,I72808,A45897,I37135,I81231,I61906,JH0289,B37028,# & JH0526,I54418,I68749,S48134,C37028,I56034,I61903,S24438,# & I72113,I68712,I46858,A45849,I56116,I54449,I68750,JH0544,# & B27638,JH0546,I37523,B45831,I56071,JH0545)# ANCHOR POSITIONS: ?# REFERENCES: godkin97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,RSWTAADTAA*# SEQUENCE: RSWTAADTAA*# ...# >HUM22E63# MHC MOLECULE: HLA-DR14(DRB1*1405), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: BCGap (84-100)# ANCHOR POSITIONS: ?# REFERENCES: matsushita97a# COMMENT:# SUMMARY: HLA-DR14,actyesu,bindyesu,EEYLILSARLVLAVVSK*# SEQUENCE: EEYLILSARLVLAVVSK*# ...# >HUM22E64# MHC MOLECULE: HLA-DR14(DRB1*1405), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: BCGap (84-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: matsushita97a# COMMENT:# SUMMARY: HLA-DR14,actyesu,bindyesu,EEYLILSAREVLAVVSK*# SEQUENCE: EEYLILSAREVLAVVSK*# ...# >HUM22E65# MHC MOLECULE: HLA-DR14(DRB1*1405), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: BCGap (84-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: matsushita97a# COMMENT:# SUMMARY: HLA-DR14,actyesu,bindyesu,EEYLILSARHVLAVVSK*# SEQUENCE: EEYLILSARHVLAVVSK*# ...# >HUM22E66# MHC MOLECULE: HLA-DR14(DRB1*1405), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: BCGap (84-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: matsushita97a# COMMENT:# SUMMARY: HLA-DR14,actyesu,bindyesu,EEYLILSARYVLAVVSK*# SEQUENCE: EEYLILSARYVLAVVSK*# ...# >HUM22E67# MHC MOLECULE: HLA-DR53, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HV3# DB REFERENCE: SWISS: (HB2K_HUMAN)# & PIR2: (I79423,I54514,I71905,PT0168,B28031,A45870,I68828,A45873,# & PH0157,PT0162,I59092,I54494,B33287,S03440,I38897)# ANCHOR POSITIONS: ?# REFERENCES: dorak94a# COMMENT:# SUMMARY: HLA-DR53,actyesu,bindyesu,DLLERRRAEV*# SEQUENCE: DLLERRRAEV*# ...# >HUM22E68# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: p21 ras (1-25)# DB REFERENCE: SWISS: (RASH_MSVNS,RASH_MSVHA,RASH_RRASV,RASH_MSVHA)# & PIR1: (TVMV3H,TVMVNS,TVMVRS)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,MTEYKLVVVGARGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGARGVGKSALTIQLIQ*# ...# >HUM22E69# MHC MOLECULE: HLA-DQ7(DQB1*0301), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: p21 ras (1-25)# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_MSVHA,RASH_RRASV,RASH_MSVNS)# & PIR1: (TVMVNS,TVMVRS,TVMV3H)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DQ7,actyesh,bindyesu,MTEYKLVVVGARGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGARGVGKSALTIQLIQ*# ...# >HUM22E6A# MHC MOLECULE: HLA-DP3(DPB1*0301), CLASS-2, (HUMAN)# METHOD: Reference# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: p21 ras (1-25)# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_MSVHA,RASH_MSVNS,RASH_RRASV)# & PIR1: (TVMVNS,TVMV3H,TVMVRS)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DP3,actyesh,bindyesu,MTEYKLVVVGARGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGARGVGKSALTIQLIQ*# ...# >HUM22E6B# MHC MOLECULE: HLA-DP3(DPB1*0301), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: p21 ras (1-25)# DB REFERENCE: SWISS: (RAS_CARAU,RAS1_DROME,RASN_RAT,RASH_CHICK,RASN_CAVPO,# & RAS1_DROME,RASK_HUMAN,RASN_MOUSE,RASK_MELGA,RASN_HUMAN,# & RASL_HUMAN,RASK_MOUSE,RASH_RAT,RASK_RAT,RASH_HUMAN,# & RASH_HUMAN,RASL_MOUSE,RASH_RAT,RASK_RAT,RASL_MOUSE,# & RASL_RAT,RASN_MOUSE,RASL_RAT,RASL_HUMAN,RASK_MONDO,# & RASH_MESAU,RASH_MOUSE,RASN_HUMAN)# & PIR1: (TVMSK,TVCHRS,TVHUH,TVFF85,TVHU2K,TVHURA,TVHUK,TVMSNS,# & TVGPRT,TVGPRS)# & PIR2: (JC5154,I59498,S05483,S06217,A37355,A43808,B54321,S26621,# & B25229,PC4098,S02054,A46134,A25229,S57718,S31720,I59500,# & I58402,I52205,A54321,A48088,I37096,PC4097,A43816)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DP3,actyesh,bindyesu,MTEYKLVVVGAGGVGKSALTIQLIQ*# SEQUENCE: MTEYKLVVVGAGGVGKSALTIQLIQ*# ...# >HUM22E6C# MHC MOLECULE: HLA-DP3(DPB1*0301), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p21 ras (8-21)# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_RRASV,RASH_MSVNS,RASH_MSVHA)# & PIR1: (TVMV3H,TVMVRS,TVMVNS)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DP3,actyesm,bindyesu,VVGARGVGKSALTI*# SEQUENCE: VVGARGVGKSALTI*# ...# >HUM22E6D# MHC MOLECULE: HLA-DP3(DPB1*0301), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p21 ras (8-20)# DB REFERENCE: SWISS: (RASH_MSVNS,RASH_MSVHA,RASH_MSVHA,RASH_RRASV)# & PIR1: (TVMVRS,TVMV3H,TVMVNS)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DP3,actyesl,bindyesu,VVGARGVGKSALT*# SEQUENCE: VVGARGVGKSALT*# ...# >HUM22E6E# MHC MOLECULE: HLA-DQ7(DPQ1*0301), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: p21 ras (8-21)# DB REFERENCE: SWISS: (RASH_MSVNS,RASH_RRASV,RASH_MSVHA,RASH_MSVHA)# & PIR1: (TVMVNS,TVMV3H,TVMVRS)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DQ7,actyesh,bindyesu,VVGARGVGKSALTI*# SEQUENCE: VVGARGVGKSALTI*# ...# >HUM22E6F# MHC MOLECULE: HLA-DQ7(DPQ1*0301), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p21 ras (8-20)# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_MSVHA,RASH_RRASV,RASH_MSVNS)# & PIR1: (TVMV3H,TVMVNS,TVMVRS)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DQ7,actyesm,bindyesu,VVGARGVGKSALT*# SEQUENCE: VVGARGVGKSALT*# ...# >HUM22E70# MHC MOLECULE: HLA-DQ7(DPQ1*0301), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p21 ras (9-21)# DB REFERENCE: SWISS: (RASH_MSVHA,RASH_MSVNS,RASH_MSVHA,RASH_RRASV)# & PIR1: (TVMVNS,TVMVRS,TVMV3H)# ANCHOR POSITIONS: ?# REFERENCES: fossum93a# COMMENT:# SUMMARY: HLA-DQ7,actyesm,bindyesu,VGARGVGKSALTI*# SEQUENCE: VGARGVGKSALTI*# ...# >HUM22E71# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBsAg (1-28)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBV4)# & PIR1: (SAVLA)# & PIR2: (S35528,S43492)# ANCHOR POSITIONS: ?# REFERENCES: mann88a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,MGGWSSKPRQGMGTNLSVPNPLGFFPDH*# SEQUENCE: MGGWSSKPRQGMGTNLSVPNPLGFFPDH*# ...# >HUM22E72# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBsAg (12-32)# DB REFERENCE: SWISS: (VMSA_HPBV9,VMSA_HPBVR,VMSA_HPBVI,VMSA_HPBVJ,VMSA_HPBVP,# & VMSA_HPBV2,VMSA_HPBV2,VMSA_HPBVR,VMSA_HPBVO,# & VMSA_HPBV4)# & PIR1: (SAVLJ1,SAVLVD,SAVLJ2,SAVLA,SAVLJ3,SAVLKS)# & PIR2: (S35528,S43492,S36654,S47411)# ANCHOR POSITIONS: ?# REFERENCES: mann88a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,MGTNLSVPNPLGFFPDHQLDP*# SEQUENCE: MGTNLSVPNPLGFFPDHQLDP*# ...# >HUM22E73# MHC MOLECULE: HLA-DR7, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HBsAg (21-47)# DB REFERENCE: SWISS: (VMSA_HPBVR,VMSA_HPBVR,VMSA_HPBV2,VMSA_HPBVP,# & VMSA_HPBV2)# & PIR1: (SAVLVD,SAVLA)# & PIR2: (S47411,S35528,S43492,S36654)# ANCHOR POSITIONS: ?# REFERENCES: mann88a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,PLGFFPDHQLDPAFGANSNNPDWDFNP*# SEQUENCE: PLGFFPDHQLDPAFGANSNNPDWDFNP*# ...# >HUM22E74# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,AKYVKQNTLKLAT*# SEQUENCE: AKYVKQNTLKLAT*# ...# >HUM22E75# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,KKYVKQNTLKLAT*# SEQUENCE: KKYVKQNTLKLAT*# ...# >HUM22E76# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,EKYVKQNTLKLAT*# SEQUENCE: EKYVKQNTLKLAT*# ...# >HUM22E77# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52189,JQ2377,S52179,S52183,S52178,S52186,S52176,S52199,# & S52191,S52180,S52195,S52198,JQ2374,S52197,JQ2378,S52173,# & S52188,JQ2375,S52175,S52174,S52182,S52187,S52185)# & PIR3: (S38637)# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesm,PRYVKQNTLKLAT*# SEQUENCE: PRYVKQNTLKLAT*# ...# >HUM22E78# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PEYVKQNTLKLAT*# SEQUENCE: PEYVKQNTLKLAT*# ...# >HUM22E79# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PSYVKQNTLKLAT*# SEQUENCE: PSYVKQNTLKLAT*# ...# >HUM22E7A# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PAYVKQNTLKLAT*# SEQUENCE: PAYVKQNTLKLAT*# ...# >HUM22E7B# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKVVKQNTLKLAT*# SEQUENCE: PKVVKQNTLKLAT*# ...# >HUM22E7C# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesl,bindyesm,PKYLKQNTLKLAT*# SEQUENCE: PKYLKQNTLKLAT*# ...# >HUM22E7D# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYKKQNTLKLAT*# SEQUENCE: PKYKKQNTLKLAT*# ...# >HUM22E7E# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,PKYQKQNTLKLAT*# SEQUENCE: PKYQKQNTLKLAT*# ...# >HUM22E7F# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYEKQNTLKLAT*# SEQUENCE: PKYEKQNTLKLAT*# ...# >HUM22E80# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVRQNTLKLAT*# SEQUENCE: PKYVRQNTLKLAT*# ...# >HUM22E81# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVEQNTLKLAT*# SEQUENCE: PKYVEQNTLKLAT*# ...# >HUM22E82# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVSQNTLKLAT*# SEQUENCE: PKYVSQNTLKLAT*# ...# >HUM22E83# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVAQNTLKLAT*# SEQUENCE: PKYVAQNTLKLAT*# ...# >HUM22E84# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesh,PKYVKNNTLKLAT*# SEQUENCE: PKYVKNNTLKLAT*# ...# >HUM22E85# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesh,PKYVKLNTLKLAT*# SEQUENCE: PKYVKLNTLKLAT*# ...# >HUM22E86# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesh,PKYVKTNTLKLAT*# SEQUENCE: PKYVKTNTLKLAT*# ...# >HUM22E87# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKKNTLKLAT*# SEQUENCE: PKYVKKNTLKLAT*# ...# >HUM22E88# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQCTLKLAT*# SEQUENCE: PKYVKQCTLKLAT*# ...# >HUM22E89# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQTTLKLAT*# SEQUENCE: PKYVKQTTLKLAT*# ...# >HUM22E8A# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQLTLKLAT*# SEQUENCE: PKYVKQLTLKLAT*# ...# >HUM22E8B# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQATLKLAT*# SEQUENCE: PKYVKQATLKLAT*# ...# >HUM22E8C# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HA (307-319) homologue# DB REFERENCE: SWISS: (HEMA_IADHK,HEMA_IAZH3)# & PIR1: (HMIVS2)# & PIR2: (JQ1153)# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesh,PKYVKQNSLKLAT*# SEQUENCE: PKYVKQNSLKLAT*# ...# >HUM22E8D# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNELKLAT*# SEQUENCE: PKYVKQNELKLAT*# ...# >HUM22E8E# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,PKYVKQNVLKLAT*# SEQUENCE: PKYVKQNVLKLAT*# ...# >HUM22E8F# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNKLKLAT*# SEQUENCE: PKYVKQNKLKLAT*# ...# >HUM22E90# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesh,PKYVKQNTIKLAT*# SEQUENCE: PKYVKQNTIKLAT*# ...# >HUM22E91# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesl,PKYVKQNTKKLAT*# SEQUENCE: PKYVKQNTKKLAT*# ...# >HUM22E92# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTQKLAT*# SEQUENCE: PKYVKQNTQKLAT*# ...# >HUM22E93# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNTEKLAT*# SEQUENCE: PKYVKQNTEKLAT*# ...# >HUM22E94# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLRLAT*# SEQUENCE: PKYVKQNTLRLAT*# ...# >HUM22E95# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLELAT*# SEQUENCE: PKYVKQNTLELAT*# ...# >HUM22E96# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLSLAT*# SEQUENCE: PKYVKQNTLSLAT*# ...# >HUM22E97# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLALAT*# SEQUENCE: PKYVKQNTLALAT*# ...# >HUM22E98# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesh,PKYVKQNTLKIAT*# SEQUENCE: PKYVKQNTLKIAT*# ...# >HUM22E99# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNTLKKAT*# SEQUENCE: PKYVKQNTLKKAT*# ...# >HUM22E9A# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNTLKQAT*# SEQUENCE: PKYVKQNTLKQAT*# ...# >HUM22E9B# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesl,PKYVKQNTLKAAT*# SEQUENCE: PKYVKQNTLKAAT*# ...# >HUM22E9C# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,PKYVKQNTLKLST*# SEQUENCE: PKYVKQNTLKLST*# ...# >HUM22E9D# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,PKYVKQNTLKLFT*# SEQUENCE: PKYVKQNTLKLFT*# ...# >HUM22E9E# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,PKYVKQNTLKLKT*# SEQUENCE: PKYVKQNTLKLKT*# ...# >HUM22E9F# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,PKYVKQNTLKLAS*# SEQUENCE: PKYVKQNTLKLAS*# ...# >HUM22EA0# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,PKYVKQNTLKLAK*# SEQUENCE: PKYVKQNTLKLAK*# ...# >HUM22EA1# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesm,PKYVKQNTLKLAY*# SEQUENCE: PKYVKQNTLKLAY*# ...# >HUM22EA2# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesm,PKYVKQNTLKLAA*# SEQUENCE: PKYVKQNTLKLAA*# ...# >HUM22EA3# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HA (307-319) homologue# ANCHOR POSITIONS: ?# REFERENCES: krieger91a# COMMENT:# SUMMARY: HLA-DR7,actyesh,bindyesu,PKFVKQNTLKLAT*# SEQUENCE: PKFVKQNTLKLAT*# ...# >HUM22EA4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: IM (19-31)# DB REFERENCE: SWISS: (VMT1_IAWIL,VMT1_IAMAN,VMT1_IACKB,VMT1_IALE1,VMT1_IAFOW,# & VMT1_IAFPW,VMT1_IABAN,VMT1_IAUSS,VMT1_IAPUE,VMT1_IAUDO,# & VMT1_IAFPR,VMT1_IALE2,VMT1_IAANN)# & PIR1: (MFIV1K,MFIV1F,JN0392,MFIV1M,MFIV61,B45539,MFIV,MFIVC,# & MFIVWS)# & PIR2: (S04058,S04056,S04050,S07945,S07429,S04054,S04052,# & S14616)# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PLKAEIAQRLEDV*# SEQUENCE: PLKAEIAQRLEDV*# ...# >HUM22EA5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: IM (19-30)# DB REFERENCE: SWISS: (VMT1_IAFPR,VMT1_IAANN,VMT1_IAFOW,VMT1_IAUSS,VMT1_IAWIL,# & VMT1_IALE2,VMT1_IAPUE,VMT1_IAUDO,VMT1_IABAN,VMT1_IALE1,# & VMT1_IACKB,VMT1_IAFPW,VMT1_IAMAN)# & PIR1: (JN0392,MFIV1F,B45539,MFIV1M,MFIV1K,MFIVC,MFIV61,MFIVWS,# & MFIV)# & PIR2: (S07945,S04052,S04056,S14616,S04054,S04050,S04058,# & S07429)# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PLKAEIAQRLED*# SEQUENCE: PLKAEIAQRLED*# ...# >HUM22EA6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: IM (19-29)# DB REFERENCE: SWISS: (VMT1_IABAN,VMT1_IAFPW,VMT1_IACKB,VMT1_IAMAN,VMT1_IAUDO,# & VMT1_IAPUE,VMT1_IALE2,VMT1_IAFPR,VMT1_IALE1,VMT1_IAWIL,# & VMT1_IAANN,VMT1_IAFOW,VMT1_IAUSS)# & PIR1: (MFIV1M,B45539,MFIV1K,MFIVC,MFIV,MFIVWS,MFIV61,JN0392,# & MFIV1F)# & PIR2: (S07429,S04058,S04052,S04056,S07945,S04050,S14616,# & S04054)# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PLKAEIAQRLE*# SEQUENCE: PLKAEIAQRLE*# ...# >HUM22EA7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: IM (19-28)# DB REFERENCE: SWISS: (VMT1_IAUSS,VMT1_IAANN,VMT1_IABAN,VMT1_IACKB,VMT1_IAMAN,# & VMT1_IAUDO,VMT1_IAFOW,VMT1_IALE1,VMT1_IAWIL,VMT1_IAFPW,# & VMT1_IALE2,VMT1_IAPUE,VMT1_IAFPR)# & PIR1: (MFIV1M,MFIV61,MFIV1F,MFIVC,B45539,MFIV1K,MFIV,MFIVWS,# & JN0392)# & PIR2: (S04052,S04056,S04054,S14616,S07429,S07945,S04050,# & S04058)# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PLKAEIAQRL*# SEQUENCE: PLKAEIAQRL*# ...# >HUM22EA8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: IM (20-31)# DB REFERENCE: SWISS: (VMT1_IAWIL,VMT1_IAPUE,VMT1_IABAN,VMT1_IAMAN,VMT1_IACKB,# & VMT1_IAUSS,VMT1_IAANN,VMT1_IAFOW,VMT1_IAFPW,VMT1_IALE2,# & VMT1_IAFPR,VMT1_IALE1,VMT1_IAUDO)# & PIR1: (MFIVC,B45539,MFIV,MFIV61,MFIV1F,MFIV1M,JN0392,MFIV1K,# & MFIVWS)# & PIR2: (S04054,S04056,S04050,S07429,S14616,S04058,S04052,# & S07945)# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,LKAEIAQRLEDV*# SEQUENCE: LKAEIAQRLEDV*# ...# >HUM22EA9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: IM (19-31) homologue# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PKKAEIAQRLEDV*# SEQUENCE: PKKAEIAQRLEDV*# ...# >HUM22EAA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: IM (19-31) homologue# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PIKAEIAQRLEDV*# SEQUENCE: PIKAEIAQRLEDV*# ...# >HUM22EAB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: IM (19-31) homologue# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PVKAEIAQRLEDV*# SEQUENCE: PVKAEIAQRLEDV*# ...# >HUM22EAC# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: IM (19-31) homologue# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PWKAEIAQRLEDV*# SEQUENCE: PWKAEIAQRLEDV*# ...# >HUM22EAD# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: IM (19-31) homologue# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PYKAEIAQRLEDV*# SEQUENCE: PYKAEIAQRLEDV*# ...# >HUM22EAE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: IM (19-31) homologue# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,PFKAEIAQRLEDV*# SEQUENCE: PFKAEIAQRLEDV*# ...# >HUM22EAF# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: IM (19-31) homologue# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PLKAEIGQRLEDV*# SEQUENCE: PLKAEIGQRLEDV*# ...# >HUM22EB0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: IM (19-31) homologue# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PLKAEISQRLEDV*# SEQUENCE: PLKAEISQRLEDV*# ...# >HUM22EB1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: li (80-104)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: max93a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,LPKPPKPVSKMRMATPLLMQALPMG*# SEQUENCE: LPKPPKPVSKMRMATPLLMQALPMG*# ...# >HUM22EB2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p-II (29-42)# DB REFERENCE: SWISS: (DER2_DERFA,DER2_DERPT)# & PIR2: (A60381)# ANCHOR POSITIONS: ?# REFERENCES: vanneerven93a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,EIKKVLVPGCHGSE*# SEQUENCE: EIKKVLVPGCHGSE*# ...# >HUM22EB3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Der p-II (116-129)# DB REFERENCE: SWISS: (DER2_DERFA,DER2_DERPT)# & PIR2: (A60381)# ANCHOR POSITIONS: ?# REFERENCES: vanneerven93a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,PKSENVVVTVKVMG*# SEQUENCE: PKSENVVVTVKVMG*# ...# >HUM22EB4# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HA (306-320)# DB REFERENCE: SWISS: (HEMA_IANT6,HEMA_IAAIC,HEMA_IAZCO,HEMA_IADH3,HEMA_IAEN7,# & HEMA_IAVI7,HEMA_IADH4,HEMA_IADU3,HEMA_IAQU7,HEMA_IABAN,# & HEMA_IADHM,HEMA_IADH6,HEMA_IADH1,HEMA_IAEN6,HEMA_IAZH2,# & HEMA_IAUDO,HEMA_IADH7)# & PIR1: (HMIVS3,HMIV77,HMIV89,HMIVHA,HMIVDU,HMIVV,HMIV15,HMIV98,# & HMIV33,HMIVH,HMIV6)# & PIR2: (JQ1156,A92979)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actyesh,bindyesu,CPKYVKQNTLKLATGMRNVPEKQT*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQT*# ...# >HUM22EB5# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HA (306-320)# DB REFERENCE: SWISS: (HEMA_IAEN6,HEMA_IADHM,HEMA_IAUDO,HEMA_IADU3,HEMA_IAAIC,# & HEMA_IADH7,HEMA_IAEN7,HEMA_IAVI7,HEMA_IABAN,HEMA_IADH6,# & HEMA_IADH4,HEMA_IAQU7,HEMA_IAZH2,HEMA_IANT6,HEMA_IAZCO,# & HEMA_IADH3,HEMA_IADH1)# & PIR1: (HMIVS3,HMIVH,HMIVDU,HMIVV,HMIV89,HMIVHA,HMIV77,HMIV15,# & HMIV6,HMIV98,HMIV33)# & PIR2: (A92979,JQ1156)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actyesl,bindyesu,CPKYVKQNTLKLATGMRNVPEKQT*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQT*# ...# >HUM22EB6# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HA (306-320)# DB REFERENCE: SWISS: (HEMA_IADH4,HEMA_IADH6,HEMA_IABAN,HEMA_IAQU7,HEMA_IAZCO,# & HEMA_IAZH2,HEMA_IADH1,HEMA_IAEN6,HEMA_IAUDO,HEMA_IADHM,# & HEMA_IANT6,HEMA_IAVI7,HEMA_IADH7,HEMA_IADU3,HEMA_IAEN7,# & HEMA_IAAIC,HEMA_IADH3)# & PIR1: (HMIVDU,HMIV89,HMIVHA,HMIV77,HMIVH,HMIVS3,HMIV33,HMIV98,# & HMIV6,HMIVV,HMIV15)# & PIR2: (JQ1156,A92979)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actyesm,bindyesu,CPKYVKQNTLKLATGMRNVPEKQT*# SEQUENCE: CPKYVKQNTLKLATGMRNVPEKQT*# ...# >HUM22EB7# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,FYVKQNTLKL*# SEQUENCE: FYVKQNTLKL*# ...# >HUM22EB8# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52195,S52173,JQ2378,S52188,S52175,S52176,S52186,S52189,# & JQ2377,S52185,S52191,S52174,S52183,S52179,S52178,JQ2375,# & JQ2374,S52187,S52180,S52199,S52198,S52197,S52182)# & PIR3: (S38637)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,RYVKQNTLKL*# SEQUENCE: RYVKQNTLKL*# ...# >HUM22EB9# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,AYVKQNTLKL*# SEQUENCE: AYVKQNTLKL*# ...# >HUM22EBA# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,HYVKQNTLKL*# SEQUENCE: HYVKQNTLKL*# ...# >HUM22EBB# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,DYVKQNTLKL*# SEQUENCE: DYVKQNTLKL*# ...# >HUM22EBC# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KFVKQNTLKL*# SEQUENCE: KFVKQNTLKL*# ...# >HUM22EBD# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KRVKQNTLKL*# SEQUENCE: KRVKQNTLKL*# ...# >HUM22EBE# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYFKQNTLKL*# SEQUENCE: KYFKQNTLKL*# ...# >HUM22EBF# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYRKQNTLKL*# SEQUENCE: KYRKQNTLKL*# ...# >HUM22EC0# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYHKQNTLKL*# SEQUENCE: KYHKQNTLKL*# ...# >HUM22EC1# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYAKQNTLKL*# SEQUENCE: KYAKQNTLKL*# ...# >HUM22EC2# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVFQNTLKL*# SEQUENCE: KYVFQNTLKL*# ...# >HUM22EC3# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVRQNTLKL*# SEQUENCE: KYVRQNTLKL*# ...# >HUM22EC4# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVHQNTLKL*# SEQUENCE: KYVHQNTLKL*# ...# >HUM22EC5# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVAQNTLKL*# SEQUENCE: KYVAQNTLKL*# ...# >HUM22EC6# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,KYVKFNTLKL*# SEQUENCE: KYVKFNTLKL*# ...# >HUM22EC7# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKRNTLKL*# SEQUENCE: KYVKRNTLKL*# ...# >HUM22EC8# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKHNTLKL*# SEQUENCE: KYVKHNTLKL*# ...# >HUM22EC9# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKANTLKL*# SEQUENCE: KYVKANTLKL*# ...# >HUM22ECA# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQFTLKL*# SEQUENCE: KYVKQFTLKL*# ...# >HUM22ECB# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQATLKL*# SEQUENCE: KYVKQATLKL*# ...# >HUM22ECC# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQRTLKL*# SEQUENCE: KYVKQRTLKL*# ...# >HUM22ECD# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQHTLKL*# SEQUENCE: KYVKQHTLKL*# ...# >HUM22ECE# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQDTLKL*# SEQUENCE: KYVKQDTLKL*# ...# >HUM22ECF# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNRLKL*# SEQUENCE: KYVKQNRLKL*# ...# >HUM22ED0# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNALKL*# SEQUENCE: KYVKQNALKL*# ...# >HUM22ED1# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNHLKL*# SEQUENCE: KYVKQNHLKL*# ...# >HUM22ED2# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNFLKL*# SEQUENCE: KYVKQNFLKL*# ...# >HUM22ED3# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTAKL*# SEQUENCE: KYVKQNTAKL*# ...# >HUM22ED4# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTRKL*# SEQUENCE: KYVKQNTRKL*# ...# >HUM22ED5# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTFKL*# SEQUENCE: KYVKQNTFKL*# ...# >HUM22ED6# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTHKL*# SEQUENCE: KYVKQNTHKL*# ...# >HUM22ED7# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLRL*# SEQUENCE: KYVKQNTLRL*# ...# >HUM22ED8# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLHL*# SEQUENCE: KYVKQNTLHL*# ...# >HUM22ED9# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLAL*# SEQUENCE: KYVKQNTLAL*# ...# >HUM22EDA# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLFL*# SEQUENCE: KYVKQNTLFL*# ...# >HUM22EDB# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTLDL*# SEQUENCE: KYVKQNTLDL*# ...# >HUM22EDC# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKA*# SEQUENCE: KYVKQNTLKA*# ...# >HUM22EDD# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKR*# SEQUENCE: KYVKQNTLKR*# ...# >HUM22EDE# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKH*# SEQUENCE: KYVKQNTLKH*# ...# >HUM22EDF# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKF*# SEQUENCE: KYVKQNTLKF*# ...# >HUM22EE0# MHC MOLECULE: HLA-DR11(DRB3*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTLKD*# SEQUENCE: KYVKQNTLKD*# ...# >HUM22EE1# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52174,S52191,S52185,S52189,S52176,S52198,JQ2378,S52179,# & S52183,S52178,JQ2374,S52186,JQ2377,S52199,S52180,S52197,# & S52195,S52173,S52188,S52175,S52182,JQ2375,S52187)# & PIR3: (S38637)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,RYVKQNTLKL*# SEQUENCE: RYVKQNTLKL*# ...# >HUM22EE2# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,AYVKQNTLKL*# SEQUENCE: AYVKQNTLKL*# ...# >HUM22EE3# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,HYVKQNTLKL*# SEQUENCE: HYVKQNTLKL*# ...# >HUM22EE4# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,FYVKQNTLKL*# SEQUENCE: FYVKQNTLKL*# ...# >HUM22EE5# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,DYVKQNTLKL*# SEQUENCE: DYVKQNTLKL*# ...# >HUM22EE6# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KHVKQNTLKL*# SEQUENCE: KHVKQNTLKL*# ...# >HUM22EE7# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KFVKQNTLKL*# SEQUENCE: KFVKQNTLKL*# ...# >HUM22EE8# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KRVKQNTLKL*# SEQUENCE: KRVKQNTLKL*# ...# >HUM22EE9# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KAVKQNTLKL*# SEQUENCE: KAVKQNTLKL*# ...# >HUM22EEA# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KDVKQNTLKL*# SEQUENCE: KDVKQNTLKL*# ...# >HUM22EEB# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYFKQNTLKL*# SEQUENCE: KYFKQNTLKL*# ...# >HUM22EEC# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYRKQNTLKL*# SEQUENCE: KYRKQNTLKL*# ...# >HUM22EED# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYAKQNTLKL*# SEQUENCE: KYAKQNTLKL*# ...# >HUM22EEE# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYDKQNTLKL*# SEQUENCE: KYDKQNTLKL*# ...# >HUM22EEF# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYHKQNTLKL*# SEQUENCE: KYHKQNTLKL*# ...# >HUM22EF0# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVFQNTLKL*# SEQUENCE: KYVFQNTLKL*# ...# >HUM22EF1# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVHQNTLKL*# SEQUENCE: KYVHQNTLKL*# ...# >HUM22EF2# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVRQNTLKL*# SEQUENCE: KYVRQNTLKL*# ...# >HUM22EF3# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVAQNTLKL*# SEQUENCE: KYVAQNTLKL*# ...# >HUM22EF4# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVDQNTLKL*# SEQUENCE: KYVDQNTLKL*# ...# >HUM22EF5# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKFNTLKL*# SEQUENCE: KYVKFNTLKL*# ...# >HUM22EF6# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKANTLKL*# SEQUENCE: KYVKANTLKL*# ...# >HUM22EF7# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKHNTLKL*# SEQUENCE: KYVKHNTLKL*# ...# >HUM22EF8# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKRNTLKL*# SEQUENCE: KYVKRNTLKL*# ...# >HUM22EF9# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKDNTLKL*# SEQUENCE: KYVKDNTLKL*# ...# >HUM22EFA# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQFTLKL*# SEQUENCE: KYVKQFTLKL*# ...# >HUM22EFB# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQATLKL*# SEQUENCE: KYVKQATLKL*# ...# >HUM22EFC# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQRTLKL*# SEQUENCE: KYVKQRTLKL*# ...# >HUM22EFD# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQHTLKL*# SEQUENCE: KYVKQHTLKL*# ...# >HUM22EFE# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQDTLKL*# SEQUENCE: KYVKQDTLKL*# ...# >HUM22EFF# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNALKL*# SEQUENCE: KYVKQNALKL*# ...# >HUM22F00# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNFLKL*# SEQUENCE: KYVKQNFLKL*# ...# >HUM22F01# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNHLKL*# SEQUENCE: KYVKQNHLKL*# ...# >HUM22F02# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNRLKL*# SEQUENCE: KYVKQNRLKL*# ...# >HUM22F03# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNDLKL*# SEQUENCE: KYVKQNDLKL*# ...# >HUM22F04# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTAKL*# SEQUENCE: KYVKQNTAKL*# ...# >HUM22F05# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTHKL*# SEQUENCE: KYVKQNTHKL*# ...# >HUM22F06# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTFKL*# SEQUENCE: KYVKQNTFKL*# ...# >HUM22F07# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTDKL*# SEQUENCE: KYVKQNTDKL*# ...# >HUM22F08# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTRKL*# SEQUENCE: KYVKQNTRKL*# ...# >HUM22F09# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLFL*# SEQUENCE: KYVKQNTLFL*# ...# >HUM22F0A# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLAL*# SEQUENCE: KYVKQNTLAL*# ...# >HUM22F0B# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLHL*# SEQUENCE: KYVKQNTLHL*# ...# >HUM22F0C# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLRL*# SEQUENCE: KYVKQNTLRL*# ...# >HUM22F0D# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTLDL*# SEQUENCE: KYVKQNTLDL*# ...# >HUM22F0E# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKA*# SEQUENCE: KYVKQNTLKA*# ...# >HUM22F0F# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKH*# SEQUENCE: KYVKQNTLKH*# ...# >HUM22F10# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKR*# SEQUENCE: KYVKQNTLKR*# ...# >HUM22F11# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKF*# SEQUENCE: KYVKQNTLKF*# ...# >HUM22F12# MHC MOLECULE: HLA-DR11(DRB3*1104), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTLKD*# SEQUENCE: KYVKQNTLKD*# ...# >HUM22F13# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,AYVKQNTLKL*# SEQUENCE: AYVKQNTLKL*# ...# >HUM22F14# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,DYVKQNTLKL*# SEQUENCE: DYVKQNTLKL*# ...# >HUM22F15# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (S52178,S52179,S52183,JQ2375,S52187,S52174,S52191,S52185,# & S52188,S52186,JQ2377,S52197,S52199,JQ2374,S52198,S52182,# & S52195,JQ2378,S52175,S52180,S52173,S52189,S52176)# & PIR3: (S38637)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,RYVKQNTLKL*# SEQUENCE: RYVKQNTLKL*# ...# >HUM22F16# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,HYVKQNTLKL*# SEQUENCE: HYVKQNTLKL*# ...# >HUM22F17# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,FYVKQNTLKL*# SEQUENCE: FYVKQNTLKL*# ...# >HUM22F18# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KFVKQNTLKL*# SEQUENCE: KFVKQNTLKL*# ...# >HUM22F19# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KDVKQNTLKL*# SEQUENCE: KDVKQNTLKL*# ...# >HUM22F1A# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KHVKQNTLKL*# SEQUENCE: KHVKQNTLKL*# ...# >HUM22F1B# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KRVKQNTLKL*# SEQUENCE: KRVKQNTLKL*# ...# >HUM22F1C# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYRKQNTLKL*# SEQUENCE: KYRKQNTLKL*# ...# >HUM22F1D# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYHKQNTLKL*# SEQUENCE: KYHKQNTLKL*# ...# >HUM22F1E# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYFKQNTLKL*# SEQUENCE: KYFKQNTLKL*# ...# >HUM22F1F# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYDKQNTLKL*# SEQUENCE: KYDKQNTLKL*# ...# >HUM22F20# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYAKQNTLKL*# SEQUENCE: KYAKQNTLKL*# ...# >HUM22F21# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVFQNTLKL*# SEQUENCE: KYVFQNTLKL*# ...# >HUM22F22# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVRQNTLKL*# SEQUENCE: KYVRQNTLKL*# ...# >HUM22F23# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVAQNTLKL*# SEQUENCE: KYVAQNTLKL*# ...# >HUM22F24# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVHQNTLKL*# SEQUENCE: KYVHQNTLKL*# ...# >HUM22F25# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKRNTLKL*# SEQUENCE: KYVKRNTLKL*# ...# >HUM22F26# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKHNTLKL*# SEQUENCE: KYVKHNTLKL*# ...# >HUM22F27# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKANTLKL*# SEQUENCE: KYVKANTLKL*# ...# >HUM22F28# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKFNTLKL*# SEQUENCE: KYVKFNTLKL*# ...# >HUM22F29# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKDNTLKL*# SEQUENCE: KYVKDNTLKL*# ...# >HUM22F2A# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQRTLKL*# SEQUENCE: KYVKQRTLKL*# ...# >HUM22F2B# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQHTLKL*# SEQUENCE: KYVKQHTLKL*# ...# >HUM22F2C# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQDTLKL*# SEQUENCE: KYVKQDTLKL*# ...# >HUM22F2D# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQATLKL*# SEQUENCE: KYVKQATLKL*# ...# >HUM22F2E# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNALKL*# SEQUENCE: KYVKQNALKL*# ...# >HUM22F2F# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNHLKL*# SEQUENCE: KYVKQNHLKL*# ...# >HUM22F30# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNFLKL*# SEQUENCE: KYVKQNFLKL*# ...# >HUM22F31# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNRLKL*# SEQUENCE: KYVKQNRLKL*# ...# >HUM22F32# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNDLKL*# SEQUENCE: KYVKQNDLKL*# ...# >HUM22F33# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTRKL*# SEQUENCE: KYVKQNTRKL*# ...# >HUM22F34# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTHKL*# SEQUENCE: KYVKQNTHKL*# ...# >HUM22F35# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTFKL*# SEQUENCE: KYVKQNTFKL*# ...# >HUM22F36# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTAKL*# SEQUENCE: KYVKQNTAKL*# ...# >HUM22F37# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTDKL*# SEQUENCE: KYVKQNTDKL*# ...# >HUM22F38# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,KYVKQNTLAL*# SEQUENCE: KYVKQNTLAL*# ...# >HUM22F39# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLFL*# SEQUENCE: KYVKQNTLFL*# ...# >HUM22F3A# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLRL*# SEQUENCE: KYVKQNTLRL*# ...# >HUM22F3B# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLHL*# SEQUENCE: KYVKQNTLHL*# ...# >HUM22F3C# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLDL*# SEQUENCE: KYVKQNTLDL*# ...# >HUM22F3D# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKF*# SEQUENCE: KYVKQNTLKF*# ...# >HUM22F3E# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKA*# SEQUENCE: KYVKQNTLKA*# ...# >HUM22F3F# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKD*# SEQUENCE: KYVKQNTLKD*# ...# >HUM22F40# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKH*# SEQUENCE: KYVKQNTLKH*# ...# >HUM22F41# MHC MOLECULE: HLA-DR11(DRB3*1103), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTLKR*# SEQUENCE: KYVKQNTLKR*# ...# >HUM22F42# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,DYVKQNTLKL*# SEQUENCE: DYVKQNTLKL*# ...# >HUM22F43# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,FYVKQNTLKL*# SEQUENCE: FYVKQNTLKL*# ...# >HUM22F44# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,AYVKQNTLKL*# SEQUENCE: AYVKQNTLKL*# ...# >HUM22F45# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# DB REFERENCE: SWISS: (HEMA_IAME6)# & PIR1: (HMIV86)# & PIR2: (JQ2374,S52176,S52187,S52197,S52179,JQ2378,S52186,JQ2377,# & S52188,JQ2375,S52180,S52175,S52173,S52178,S52183,S52191,# & S52174,S52185,S52198,S52189,S52182,S52195,S52199)# & PIR3: (S38637)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,RYVKQNTLKL*# SEQUENCE: RYVKQNTLKL*# ...# >HUM22F46# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,HYVKQNTLKL*# SEQUENCE: HYVKQNTLKL*# ...# >HUM22F47# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KFVKQNTLKL*# SEQUENCE: KFVKQNTLKL*# ...# >HUM22F48# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KHVKQNTLKL*# SEQUENCE: KHVKQNTLKL*# ...# >HUM22F49# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KAVKQNTLKL*# SEQUENCE: KAVKQNTLKL*# ...# >HUM22F4A# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KDVKQNTLKL*# SEQUENCE: KDVKQNTLKL*# ...# >HUM22F4B# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYAKQNTLKL*# SEQUENCE: KYAKQNTLKL*# ...# >HUM22F4C# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYFKQNTLKL*# SEQUENCE: KYFKQNTLKL*# ...# >HUM22F4D# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYHKQNTLKL*# SEQUENCE: KYHKQNTLKL*# ...# >HUM22F4E# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYDKQNTLKL*# SEQUENCE: KYDKQNTLKL*# ...# >HUM22F4F# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYRKQNTLKL*# SEQUENCE: KYRKQNTLKL*# ...# >HUM22F50# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVHQNTLKL*# SEQUENCE: KYVHQNTLKL*# ...# >HUM22F51# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVAQNTLKL*# SEQUENCE: KYVAQNTLKL*# ...# >HUM22F52# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVRQNTLKL*# SEQUENCE: KYVRQNTLKL*# ...# >HUM22F53# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVFQNTLKL*# SEQUENCE: KYVFQNTLKL*# ...# >HUM22F54# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVDQNTLKL*# SEQUENCE: KYVDQNTLKL*# ...# >HUM22F55# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKFNTLKL*# SEQUENCE: KYVKFNTLKL*# ...# >HUM22F56# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKANTLKL*# SEQUENCE: KYVKANTLKL*# ...# >HUM22F57# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKHNTLKL*# SEQUENCE: KYVKHNTLKL*# ...# >HUM22F58# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKRNTLKL*# SEQUENCE: KYVKRNTLKL*# ...# >HUM22F59# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKDNTLKL*# SEQUENCE: KYVKDNTLKL*# ...# >HUM22F5A# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQFTLKL*# SEQUENCE: KYVKQFTLKL*# ...# >HUM22F5B# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQHTLKL*# SEQUENCE: KYVKQHTLKL*# ...# >HUM22F5C# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQDTLKL*# SEQUENCE: KYVKQDTLKL*# ...# >HUM22F5D# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQATLKL*# SEQUENCE: KYVKQATLKL*# ...# >HUM22F5E# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQRTLKL*# SEQUENCE: KYVKQRTLKL*# ...# >HUM22F5F# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNHLKL*# SEQUENCE: KYVKQNHLKL*# ...# >HUM22F60# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNALKL*# SEQUENCE: KYVKQNALKL*# ...# >HUM22F61# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNFLKL*# SEQUENCE: KYVKQNFLKL*# ...# >HUM22F62# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNDLKL*# SEQUENCE: KYVKQNDLKL*# ...# >HUM22F63# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNRLKL*# SEQUENCE: KYVKQNRLKL*# ...# >HUM22F64# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTAKL*# SEQUENCE: KYVKQNTAKL*# ...# >HUM22F65# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTFKL*# SEQUENCE: KYVKQNTFKL*# ...# >HUM22F66# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTHKL*# SEQUENCE: KYVKQNTHKL*# ...# >HUM22F67# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTRKL*# SEQUENCE: KYVKQNTRKL*# ...# >HUM22F68# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTDKL*# SEQUENCE: KYVKQNTDKL*# ...# >HUM22F69# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLFL*# SEQUENCE: KYVKQNTLFL*# ...# >HUM22F6A# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLAL*# SEQUENCE: KYVKQNTLAL*# ...# >HUM22F6B# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLHL*# SEQUENCE: KYVKQNTLHL*# ...# >HUM22F6C# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLRL*# SEQUENCE: KYVKQNTLRL*# ...# >HUM22F6D# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,KYVKQNTLKA*# SEQUENCE: KYVKQNTLKA*# ...# >HUM22F6E# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTLKD*# SEQUENCE: KYVKQNTLKD*# ...# >HUM22F6F# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTLKF*# SEQUENCE: KYVKQNTLKF*# ...# >HUM22F70# MHC MOLECULE: HLA-DR11(DRB3*1102), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (308-317) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski93a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesl,KYVKQNTLKH*# SEQUENCE: KYVKQNTLKH*# ...# >HUM22F71# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F72# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F73# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,SKAAAATPLLMQA*# SEQUENCE: SKAAAATPLLMQA*# ...# >HUM22F74# MHC MOLECULE: HLA-DR2(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F75# MHC MOLECULE: HLA-DR2(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F76# MHC MOLECULE: HLA-DR2(DRB1*1501), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR2,actunkn,bindyesu,SKAAAATPLLMQA*# SEQUENCE: SKAAAATPLLMQA*# ...# >HUM22F77# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F78# MHC MOLECULE: HLA-DR3(DRB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F79# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F7A# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F7B# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F7C# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F7D# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F7E# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR7,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F7F# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F80# MHC MOLECULE: HLA-DR8(DRB1*0801), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR8,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F81# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F82# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F83# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,SKAAAATPLLMQA*# SEQUENCE: SKAAAATPLLMQA*# ...# >HUM22F84# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,SKAAAATPAAAQA*# SEQUENCE: SKAAAATPAAAQA*# ...# >HUM22F85# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,SKAAAAAAAAAQA*# SEQUENCE: SKAAAAAAAAAQA*# ...# >HUM22F86# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (91-98)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_RAT,HG2A_HUMAN,HG2A_MOUSE)# & PIR1: (HLHUG,HLHMSG)# & PIR2: (S04362)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,MRMATPLL*# SEQUENCE: MRMATPLL*# ...# >HUM22F87# MHC MOLECULE: HLA-DQ9(DQA1*0201xDQB1*0303), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesu,SKMRMATPLLMQA*# SEQUENCE: SKMRMATPLLMQA*# ...# >HUM22F88# MHC MOLECULE: HLA-DQ9(DQA1*0201xDQB1*0303), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesu,SKMAAATPLLMQA*# SEQUENCE: SKMAAATPLLMQA*# ...# >HUM22F89# MHC MOLECULE: HLA-DQ9(DQA1*0201xDQB1*0303), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesu,SKAAAATPLLMQA*# SEQUENCE: SKAAAATPLLMQA*# ...# >HUM22F8A# MHC MOLECULE: HLA-DQ9(DQA1*0201xDQB1*0303), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesu,SKAAAATPAAAQA*# SEQUENCE: SKAAAATPAAAQA*# ...# >HUM22F8B# MHC MOLECULE: HLA-DQ9(DQA1*0201xDQB1*0303), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (89-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesu,SKAAAAAAAAAQA*# SEQUENCE: SKAAAAAAAAAQA*# ...# >HUM22F8C# MHC MOLECULE: HLA-DQ9(DQA1*0201xDQB1*0303), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP (91-98)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_MOUSE,HG2A_HUMAN,HG2A_RAT)# & PIR1: (HLHUG,HLHMSG)# & PIR2: (S04362)# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesu,MRMATPLL*# SEQUENCE: MRMATPLL*# ...# >HUM22F8D# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,AAAAAAAA*# SEQUENCE: AAAAAAAA*# ...# >HUM22F8E# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,GFKAAAAAAA*# SEQUENCE: GFKAAAAAAA*# ...# >HUM22F8F# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,AAAAA*# SEQUENCE: AAAAA*# ...# >HUM22F90# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,AAAAAA*# SEQUENCE: AAAAAA*# ...# >HUM22F91# MHC MOLECULE: HLA-DQ7(DQA1*0501xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,AAAAAAA*# SEQUENCE: AAAAAAA*# ...# >HUM22F92# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesu,GFKAAAAAAA*# SEQUENCE: GFKAAAAAAA*# ...# >HUM22F93# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYRQMSAPTLG*# SEQUENCE: GYRQMSAPTLG*# ...# >HUM22F94# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 3# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GNWRALRGALG*# SEQUENCE: GNWRALRGALG*# ...# >HUM22F95# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYQQMGARLMG*# SEQUENCE: GYQQMGARLMG*# ...# >HUM22F96# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYGKLRGGTLG*# SEQUENCE: GYGKLRGGTLG*# ...# >HUM22F97# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYRGMSAFRAG*# SEQUENCE: GYRGMSAFRAG*# ...# >HUM22F98# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYKPLWGQMTG*# SEQUENCE: GYKPLWGQMTG*# ...# >HUM22F99# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYRHAQAYGVG*# SEQUENCE: GYRHAQAYGVG*# ...# >HUM22F9A# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYRMQSNHVSG*# SEQUENCE: GYRMQSNHVSG*# ...# >HUM22F9B# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 3# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GSWRHIQTRVG*# SEQUENCE: GSWRHIQTRVG*# ...# >HUM22F9C# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 3# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GTYRGMAGFRG*# SEQUENCE: GTYRGMAGFRG*# ...# >HUM22F9D# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 3# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GRFTQMMAVAG*# SEQUENCE: GRFTQMMAVAG*# ...# >HUM22F9E# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYRQMWVNRAG*# SEQUENCE: GYRQMWVNRAG*# ...# >HUM22F9F# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYKPMLASVGG*# SEQUENCE: GYKPMLASVGG*# ...# >HUM22FA0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GFSAIRNRILG*# SEQUENCE: GFSAIRNRILG*# ...# >HUM22FA1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYQALRAYWQG*# SEQUENCE: GYQALRAYWQG*# ...# >HUM22FA2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 3# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GTWNSLRGRLG*# SEQUENCE: GTWNSLRGRLG*# ...# >HUM22FA3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYAAMRGGQIG*# SEQUENCE: GYAAMRGGQIG*# ...# >HUM22FA4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GWKGLQGALSG*# SEQUENCE: GWKGLQGALSG*# ...# >HUM22FA5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GFERARSRLLG*# SEQUENCE: GFERARSRLLG*# ...# >HUM22FA6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYRAMQTTLSG*# SEQUENCE: GYRAMQTTLSG*# ...# >HUM22FA7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GYKLLRATQMG*# SEQUENCE: GYKLLRATQMG*# ...# >HUM22FA8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 3# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GPWQAMRGWLG*# SEQUENCE: GPWQAMRGWLG*# ...# >HUM22FA9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 2# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GFHQLRGGSLG*# SEQUENCE: GFHQLRGGSLG*# ...# >HUM22FAA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: phage library peptide# ANCHOR POSITIONS: 3# REFERENCES: raddrizzani97a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,GRFTQMGALAG*# SEQUENCE: GRFTQMGALAG*# ...# >HUM22FAB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (34-53)# DB REFERENCE: SWISS: (OMPE_CHLTR,OMPA_CHLTR,OMPF_CHLTR,OMPA_CHLTR,# & OMPB_CHLTR)# & PIR1: (MMCWTE,MMCWTB,MMCWTF)# & PIR2: (S12799,S11006,S11009)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,DAISMRMGYYGDFVFDRVLK*# SEQUENCE: DAISMRMGYYGDFVFDRVLK*# ...# >HUM22FAC# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (157-175)# DB REFERENCE: SWISS: (OMPE_CHLTR)# & PIR1: (MMCWTE)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,DQSVVELYTDTAFSWSVGA*# SEQUENCE: DQSVVELYTDTAFSWSVGA*# ...# >HUM22FAD# MHC MOLECULE: HLA-DR7(DRB1*0701), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (249-260)# DB REFERENCE: SWISS: (OMP3_CHLPS,OMPE_CHLTR)# & PIR1: (MMCWTE)# & PIR2: (A40371)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DR7,actyesu,bindyesu,VELYTDTAFSWSVGA*# SEQUENCE: VELYTDTAFSWSVGA*# ...# >HUM22FAE# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (251-262)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,LYTDTAFSWSVGADA*# SEQUENCE: LYTDTAFSWSVGADA*# ...# >HUM22FAF# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (253-265)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,TDTAFSWSVGADASID*# SEQUENCE: TDTAFSWSVGADASID*# ...# >HUM22FB0# MHC MOLECULE: HLA-DR13, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (250-261)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DR13,actyesu,bindyesu,ELYTDTAFSWSVGAD*# SEQUENCE: ELYTDTAFSWSVGAD*# ...# >HUM22FB1# MHC MOLECULE: HLA-DR17(DRB1*0301), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (253-261)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DR17,actyesu,bindyesu,TDTAFSWSVGAD*# SEQUENCE: TDTAFSWSVGAD*# ...# >HUM22FB2# MHC MOLECULE: HLA-DR52, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (89-105)# DB REFERENCE: SWISS: (OMPE_CHLTR,OMPB_CHLTR)# & PIR1: (MMCWTB,MMCWTE)# & PIR2: (B60333,S11009,B60756,JC1432)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DR52,actyesu,bindyesu,RHMQDAEMFTNAACMAL*# SEQUENCE: RHMQDAEMFTNAACMAL*# ...# >HUM22FB3# MHC MOLECULE: HLA-DQ3(DQA1*05xDQB1*0301), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Chlamydia trachomatis MOMP (89-105)# DB REFERENCE: SWISS: (OMPE_CHLTR,OMPB_CHLTR)# & PIR1: (MMCWTB,MMCWTE)# & PIR2: (B60333,S11009,JC1432,B60756)# ANCHOR POSITIONS: ?# REFERENCES: ortiz96a# COMMENT:# SUMMARY: HLA-DQ3,actyesu,bindyesu,RHMQDAEMFTNAACMAL*# SEQUENCE: RHMQDAEMFTNAACMAL*# ...# >HUM22FB4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (11-25)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASY,VGLF_MEASA,VGLF_MEASE,# & VGLF_MEASE)# & PIR1: (E48556,JU0274,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,FMAVLLTLQTPTGQI*# SEQUENCE: FMAVLLTLQTPTGQI*# ...# >HUM22FB5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_MEASA,VGLF_MEASI)# & PIR1: (VGNZMV,E48556)# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNITLL*# SEQUENCE: HQSLVIKLMPNITLL*# ...# >HUM22FB6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (56-70)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASA,VGLF_MEASI,VGLF_MEASE)# & PIR1: (VGNZMV,E48556)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,IKLMPNITLLNNCTR*# SEQUENCE: IKLMPNITLLNNCTR*# ...# >HUM22FB7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (66-80)# DB REFERENCE: SWISS: (VGLF_MEASY,VGLF_MEASE,VGLF_MEASI,VGLF_MEASA,# & VGLF_MEASE)# & PIR1: (JU0274,VGNZMV,E48556)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,NNCTRVEIAEYRRLL*# SEQUENCE: NNCTRVEIAEYRRLL*# ...# >HUM22FB8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (71-85)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASA,VGLF_MEASE,VGLF_MEASE,# & VGLF_MEASY)# & PIR1: (E48556,VGNZMV,JU0274)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,VEIAEYRRLLRTVLE*# SEQUENCE: VEIAEYRRLLRTVLE*# ...# >HUM22FB9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (76-90)# DB REFERENCE: SWISS: (VGLF_MEASY,VGLF_MEASE,VGLF_MEASE,VGLF_MEASA,# & VGLF_MEASI)# & PIR1: (E48556,VGNZMV,JU0274)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,YRRLLRTVLEPIRDA*# SEQUENCE: YRRLLRTVLEPIRDA*# ...# >HUM22FBA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (126-140)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_RINDR,VGLF_MEASY,VGLF_MEASI,VGLF_CDVO,# & VGLF_MEASA,VGLF_RINDB,VGLF_RINDL,VGLF_RINDK,# & VGLF_MEASE)# & PIR1: (VGNZRK,VGNZRL,VGNZMV,E48556,VGNZCD,JU0274)# & PIR2: (PQ0868,JQ2223,PQ0869,PQ0871,S47299,S47300,PQ0867,PQ0873,# & S47305,PQ0866)# & PIR3: (S47034,S21382)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,ATAAQITAGIALHQS*# SEQUENCE: ATAAQITAGIALHQS*# ...# >HUM22FBB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (171-185)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASI,VGLF_RINDK,VGLF_RINDB,VGLF_MEASE,# & VGLF_MEASE,VGLF_MEASY,VGLF_RINDR)# & PIR1: (E48556,VGNZMV,VGNZRK,JU0274)# & PIR2: (S47305,S47299,PQ0869,PQ0868,S47300,PQ0871,PQ0873,# & PQ0867)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,MILAVQGVQDYINNE*# SEQUENCE: MILAVQGVQDYINNE*# ...# >HUM22FBC# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (181-195)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASA,VGLF_MEASY,VGLF_MEASE,# & VGLF_MEASI)# & PIR1: (VGNZMV,E48556,JU0274)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,YINNELIPSMNQLSC*# SEQUENCE: YINNELIPSMNQLSC*# ...# >HUM22FBD# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (211-225)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_RINDR,VGLF_MEASE,VGLF_MEASA,VGLF_MEASY,# & VGLF_MEASE,VGLF_RINDK)# & PIR1: (VGNZRK,VGNZMV,JU0274,E48556)# & PIR2: (S47305)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,TEILSLFGPSLRDPI*# SEQUENCE: TEILSLFGPSLRDPI*# ...# >HUM22FBE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (221-235)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASE,VGLF_MEASA,VGLF_MEASY,VGLF_MEASE,# & VGLF_RINDR,VGLF_PHODV,VGLF_RINDK)# & PIR1: (VGNZRK,VGNZPD,A48346,E48556,JU0274,VGNZMV)# & PIR2: (S47305,JQ2223)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,LRDPISAEISIQALS*# SEQUENCE: LRDPISAEISIQALS*# ...# >HUM22FBF# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (226-240)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_PHODV,VGLF_RINDB,VGLF_MEASI,VGLF_MEASE,# & VGLF_MEASA,VGLF_RINDR,VGLF_RINDK)# & PIR1: (A48346,E48556,VGNZMV,VGNZPD,VGNZRK)# & PIR2: (S47305,S47299,JQ2223,S47300)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,SAEISIQALSYALGG*# SEQUENCE: SAEISIQALSYALGG*# ...# >HUM22FC0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (256-270)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_MEASA,VGLF_MEASI,# & VGLF_MEASY)# & PIR1: (E48556,JU0274,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,LLGILESRGIKARIT*# SEQUENCE: LLGILESRGIKARIT*# ...# >HUM22FC1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (271-285)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_MEASI,VGLF_MEASY)# & PIR1: (VGNZMV,JU0274)# & PIR2: (PQ0376,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HVDTESYFIVLSIAY*# SEQUENCE: HVDTESYFIVLSIAY*# ...# >HUM22FC2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (276-290)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASE,VGLF_MEASY,VGLF_MEASE)# & PIR1: (VGNZMV,JU0274)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,SYFIVLSIAYPTLSE*# SEQUENCE: SYFIVLSIAYPTLSE*# ...# >HUM22FC3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (281-295)# DB REFERENCE: SWISS: (VGLF_MEASY,VGLF_MEASE,VGLF_MEASE,VGLF_MEASA)# & PIR1: (VGNZMV,E48556,JU0274)# & PIR2: (PQ0388,S55386,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,LSIAYPTLSEIKGVI*# SEQUENCE: LSIAYPTLSEIKGVI*# ...# >HUM22FC4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (286-300)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_MEASY,VGLF_MEASA)# & PIR1: (JU0274,VGNZMV,E48556)# & PIR2: (PQ0376,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,PTLSEIKGVIVHRLE*# SEQUENCE: PTLSEIKGVIVHRLE*# ...# >HUM22FC5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (291-305)# DB REFERENCE: SWISS: (VGLF_RINDB,VGLF_MEASA,VGLF_MEASE,VGLF_MEASE,# & VGLF_MEASY)# & PIR1: (VGNZMV,E48556,JU0274)# & PIR2: (PQ0388,PQ0376,S47300)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,IKGVIVHRLEGVSYN*# SEQUENCE: IKGVIVHRLEGVSYN*# ...# >HUM22FC6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (316-330)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASY,VGLF_MEASE,# & VGLF_MEASI)# & PIR1: (JU0274,VGNZMV,E48556)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,PKYVATQGYLISNFD*# SEQUENCE: PKYVATQGYLISNFD*# ...# >HUM22FC7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (331-345)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASY,VGLF_MEASE,VGLF_MEASA,# & VGLF_MEASE)# & PIR1: (VGNZMV,E48556,JU0274)# & PIR2: (PQ0376,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,ESSCTFMPEGTVCSQ*# SEQUENCE: ESSCTFMPEGTVCSQ*# ...# >HUM22FC8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (346-360)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_MEASI,VGLF_MEASA,# & VGLF_MEASY)# & PIR1: (JU0274,VGNZMV,E48556)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,NALYPMSPLLQECLR*# SEQUENCE: NALYPMSPLLQECLR*# ...# >HUM22FC9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (376-390)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_MEASA,VGLF_MEASY,# & VGLF_MEASI)# & PIR1: (E48556,VGNZMV,JU0274)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,GNRFILSQGNLIANC*# SEQUENCE: GNRFILSQGNLIANC*# ...# >HUM22FCA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (381-395)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASY,VGLF_MEASE,VGLF_MEASE,# & VGLF_MEASI)# & PIR1: (JU0274,E48556,VGNZMV)# & PIR2: (PQ0376,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,LSQGNLIANCASILC*# SEQUENCE: LSQGNLIANCASILC*# ...# >HUM22FCB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (401-415)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASE)# & PIR1: (VGNZMV,E48556)# & PIR2: (PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,GTIINQDPDKILTYI*# SEQUENCE: GTIINQDPDKILTYI*# ...# >HUM22FCC# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (466-480)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASY,VGLF_MEASE,VGLF_MEASE,# & VGLF_MEASI)# & PIR1: (E48556,VGNZMV,JU0274)# & PIR2: (PQ0376,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AIAKLEDAKELLESS*# SEQUENCE: AIAKLEDAKELLESS*# ...# >HUM22FCD# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (481-495)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASE,VGLF_MEASE,VGLF_MEASY)# & PIR1: (VGNZMV,JU0274)# & PIR2: (PQ0376,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,DQILRSMKGLSSTSI*# SEQUENCE: DQILRSMKGLSSTSI*# ...# >HUM22FCE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (496-510)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASI,VGLF_MEASA,VGLF_MEASE,# & VGLF_MEASY)# & PIR1: (VGNZMV,JU0274,E48556)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,VYILIAVCLGGLIGI*# SEQUENCE: VYILIAVCLGGLIGI*# ...# >HUM22FCF# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (501-515)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASA,VGLF_MEASE,VGLF_MEASE,# & VGLF_MEASY)# & PIR1: (VGNZMV,E48556,JU0274)# & PIR2: (PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,AVCLGGLIGIPALIC*# SEQUENCE: AVCLGGLIGIPALIC*# ...# >HUM22FD0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSDDIKLMPNITLL*# SEQUENCE: HQSDDIKLMPNITLL*# ...# >HUM22FD1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSDVIKLMPNITLL*# SEQUENCE: HQSDVIKLMPNITLL*# ...# >HUM22FD2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,HQSLDIKLMPNITLL*# SEQUENCE: HQSLDIKLMPNITLL*# ...# >HUM22FD3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,HQSLVIELMPNITLL*# SEQUENCE: HQSLVIELMPNITLL*# ...# >HUM22FD4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,HQSLVIDLMPNITLL*# SEQUENCE: HQSLVIDLMPNITLL*# ...# >HUM22FD5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIRLMPNITLL*# SEQUENCE: HQSLVIRLMPNITLL*# ...# >HUM22FD6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HQSLVIYLMPNITLL*# SEQUENCE: HQSLVIYLMPNITLL*# ...# >HUM22FD7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HQSLVIFLMPNITLL*# SEQUENCE: HQSLVIFLMPNITLL*# ...# >HUM22FD8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIHLMPNITLL*# SEQUENCE: HQSLVIHLMPNITLL*# ...# >HUM22FD9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKSMPNITLL*# SEQUENCE: HQSLVIKSMPNITLL*# ...# >HUM22FDA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKRMPNITLL*# SEQUENCE: HQSLVIKRMPNITLL*# ...# >HUM22FDB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLYPNITLL*# SEQUENCE: HQSLVIKLYPNITLL*# ...# >HUM22FDC# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLEPNITLL*# SEQUENCE: HQSLVIKLEPNITLL*# ...# >HUM22FDD# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLRPNITLL*# SEQUENCE: HQSLVIKLRPNITLL*# ...# >HUM22FDE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HQSLVIKLMWNITLL*# SEQUENCE: HQSLVIKLMWNITLL*# ...# >HUM22FDF# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HQSLVIKLMFNITLL*# SEQUENCE: HQSLVIKLMFNITLL*# ...# >HUM22FE0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPRITLL*# SEQUENCE: HQSLVIKLMPRITLL*# ...# >HUM22FE1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,HQSLVIKLMPWITLL*# SEQUENCE: HQSLVIKLMPWITLL*# ...# >HUM22FE2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,HQSLVIKLMPNDTLL*# SEQUENCE: HQSLVIKLMPNDTLL*# ...# >HUM22FE3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNITTL*# SEQUENCE: HQSLVIKLMPNITTL*# ...# >HUM22FE4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNITHL*# SEQUENCE: HQSLVIKLMPNITHL*# ...# >HUM22FE5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesm,HQSLVIKLMPNITEL*# SEQUENCE: HQSLVIKLMPNITEL*# ...# >HUM22FE6# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNITLK*# SEQUENCE: HQSLVIKLMPNITLK*# ...# >HUM22FE7# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNITLE*# SEQUENCE: HQSLVIKLMPNITLE*# ...# >HUM22FE8# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,AQSLVIKLMPNITLL*# SEQUENCE: AQSLVIKLMPNITLL*# ...# >HUM22FE9# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HASLVIKLMPNITLL*# SEQUENCE: HASLVIKLMPNITLL*# ...# >HUM22FEA# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQALVIKLMPNITLL*# SEQUENCE: HQALVIKLMPNITLL*# ...# >HUM22FEB# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSAVIKLMPNITLL*# SEQUENCE: HQSAVIKLMPNITLL*# ...# >HUM22FEC# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVAKLMPNITLL*# SEQUENCE: HQSLVAKLMPNITLL*# ...# >HUM22FED# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIALMPNITLL*# SEQUENCE: HQSLVIALMPNITLL*# ...# >HUM22FEE# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKAMPNITLL*# SEQUENCE: HQSLVIKAMPNITLL*# ...# >HUM22FEF# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLAPNITLL*# SEQUENCE: HQSLVIKLAPNITLL*# ...# >HUM22FF0# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMANITLL*# SEQUENCE: HQSLVIKLMANITLL*# ...# >HUM22FF1# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesl,HQSLVIKLMPAITLL*# SEQUENCE: HQSLVIKLMPAITLL*# ...# >HUM22FF2# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNATLL*# SEQUENCE: HQSLVIKLMPNATLL*# ...# >HUM22FF3# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNIALL*# SEQUENCE: HQSLVIKLMPNIALL*# ...# >HUM22FF4# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNITAL*# SEQUENCE: HQSLVIKLMPNITAL*# ...# >HUM22FF5# MHC MOLECULE: HLA-DR1(DRB1*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Measles virus fusion protein MVFP (51-65) homologue# ANCHOR POSITIONS: 6,10# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-DR1,actunkn,bindyesh,HQSLVIKLMPNITLA*# SEQUENCE: HQSLVIKLMPNITLA*# ...# >HUM22FF6# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (51-65)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_MEASA,VGLF_MEASI)# & PIR1: (E48556,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,HQSLVIKLMPNITLL*# SEQUENCE: HQSLVIKLMPNITLL*# ...# >HUM22FF7# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (56-70)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASE,VGLF_MEASE,VGLF_MEASA)# & PIR1: (E48556,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IKLMPNITLLNNCTR*# SEQUENCE: IKLMPNITLLNNCTR*# ...# >HUM22FF8# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (61-75)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASI,VGLF_MEASE)# & PIR1: (E48556,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,NITLLNNCTRVEIAE*# SEQUENCE: NITLLNNCTRVEIAE*# ...# >HUM22FF9# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (121-135)# DB REFERENCE: SWISS: (VGLF_RINDR,VGLF_RINDK,VGLF_MEASA,VGLF_MEASE,VGLF_RINDL,# & VGLF_RINDB,VGLF_MEASE,VGLF_MEASI,VGLF_MEASY)# & PIR1: (E48556,VGNZRL,JU0274,VGNZMV,VGNZRK)# & PIR2: (PQ0873,PQ0871,JQ2223,S47305,PQ0869,PQ0868,S47299,PQ0867,# & S47300,PQ0866)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,AALGVATAAQITAGI*# SEQUENCE: AALGVATAAQITAGI*# ...# >HUM22FFA# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (181-195)# DB REFERENCE: SWISS: (VGLF_MEASY,VGLF_MEASE,VGLF_MEASE,VGLF_MEASA,# & VGLF_MEASI)# & PIR1: (E48556,VGNZMV,JU0274)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,YINNELIPSMNQLSC*# SEQUENCE: YINNELIPSMNQLSC*# ...# >HUM22FFB# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (186-200)# DB REFERENCE: SWISS: (VGLF_MEASY,VGLF_MEASA,VGLF_MEASE,VGLF_MEASE,# & VGLF_MEASI)# & PIR1: (E48556,JU0274,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,LIPSMNQLSCDLIGQ*# SEQUENCE: LIPSMNQLSCDLIGQ*# ...# >HUM22FFC# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (196-210)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASA,VGLF_MEASE,VGLF_MEASY,# & VGLF_MEASE)# & PIR1: (JU0274,E48556,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,DLIGQKLGLKLLRYY*# SEQUENCE: DLIGQKLGLKLLRYY*# ...# >HUM22FFD# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (206-220)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_RINDL,VGLF_MEASY,VGLF_RINDB,# & VGLF_RINDR,VGLF_MEASA,VGLF_MEASI,VGLF_RINDK)# & PIR1: (VGNZMV,VGNZRL,E48556,VGNZRK,JU0274)# & PIR2: (S47300,S47305,S47299)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,LLRYYTEILSLFGPS*# SEQUENCE: LLRYYTEILSLFGPS*# ...# >HUM22FFE# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (211-225)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASI,VGLF_RINDK,VGLF_MEASE,VGLF_MEASY,# & VGLF_RINDR,VGLF_MEASA)# & PIR1: (VGNZMV,JU0274,VGNZRK,E48556)# & PIR2: (S47305)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TEILSLFGPSLRDPI*# SEQUENCE: TEILSLFGPSLRDPI*# ...# >HUM22FFF# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (231-245)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASI,VGLF_MEASE)# & PIR1: (E48556,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,IQALSYALGGDINKV*# SEQUENCE: IQALSYALGGDINKV*# ...# >HUM23000# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (236-250)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASE,VGLF_MEASI)# & PIR1: (E48556,VGNZMV)# & PIR3: (S47034)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,YALGGDINKVLEKLG*# SEQUENCE: YALGGDINKVLEKLG*# ...# >HUM23001# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MVFP (261-275)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASY,VGLF_MEASE,VGLF_MEASE,# & VGLF_MEASA)# & PIR1: (JU0274,VGNZMV,E48556)# ANCHOR POSITIONS: ?# REFERENCES: muller96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ESRGIKARITHVDTE*# SEQUENCE: ESRGIKARITHVDTE*# ...# >HUM23002# MHC MOLECULE: HLA-DR4, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (276-290)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVR,POLS_RUBVM,POLS_RUBVT)# & PIR1: (GNWVR3,GNWVRA,GNWV77,GNWVR4)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,WVTPVIGSQARKCGL*# SEQUENCE: WVTPVIGSQARKCGL*# ...# >HUM23003# MHC MOLECULE: HLA-DR2, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (276-290)# DB REFERENCE: SWISS: (POLS_RUBVT,POLS_RUBVR,POLS_RUBVH,POLS_RUBVM)# & PIR1: (GNWVR4,GNWVRA,GNWVR3,GNWV77)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-DR2,actyesu,bindyesu,WVTPVIGSQARKCGL*# SEQUENCE: WVTPVIGSQARKCGL*# ...# >HUM23004# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (277-289)# DB REFERENCE: SWISS: (POLS_RUBVM,POLS_RUBVT,POLS_RUBVR,POLS_RUBVH)# & PIR1: (GNWVR3,GNWV77,GNWVR4,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VTPVIGSQARKCG*# SEQUENCE: VTPVIGSQARKCG*# ...# >HUM23005# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (277-288)# DB REFERENCE: SWISS: (POLS_RUBVT,POLS_RUBVR,POLS_RUBVH,POLS_RUBVM)# & PIR1: (GNWVRA,GNWVR3,GNWV77,GNWVR4)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VTPVIGSQARKC*# SEQUENCE: VTPVIGSQARKC*# ...# >HUM23006# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (278-289)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVM,POLS_RUBVT,POLS_RUBVH)# & PIR1: (GNWV77,GNWVRA,GNWVR4,GNWVR3)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TPVIGSQARKCG*# SEQUENCE: TPVIGSQARKCG*# ...# >HUM23007# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (277-287)# DB REFERENCE: SWISS: (POLS_RUBVT,POLS_RUBVM,POLS_RUBVR,POLS_RUBVH)# & PIR1: (GNWVR4,GNWVRA,GNWV77,GNWVR3)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VTPVIGSQARK*# SEQUENCE: VTPVIGSQARK*# ...# >HUM23008# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (279-289)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVH,POLS_RUBVT,POLS_RUBVM)# & PIR1: (GNWVR4,GNWVR3,GNWV77,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PVIGSQARKCG*# SEQUENCE: PVIGSQARKCG*# ...# >HUM23009# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (278-288)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVT,POLS_RUBVM,POLS_RUBVR)# & PIR1: (GNWVR4,GNWVR3,GNWVRA,GNWV77)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TPVIGSQARKC*# SEQUENCE: TPVIGSQARKC*# ...# >HUM2300A# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (280-289)# DB REFERENCE: SWISS: (POLS_RUBVT,POLS_RUBVH,POLS_RUBVR,POLS_RUBVM)# & PIR1: (GNWVR4,GNWVRA,GNWVR3,GNWV77)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VIGSQARKCG*# SEQUENCE: VIGSQARKCG*# ...# >HUM2300B# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (278-287)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVM,POLS_RUBVR,POLS_RUBVT)# & PIR1: (GNWVRA,GNWVR4,GNWVR3,GNWV77)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TPVIGSQARK*# SEQUENCE: TPVIGSQARK*# ...# >HUM2300C# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (279-288)# DB REFERENCE: SWISS: (POLS_RUBVM,POLS_RUBVT,POLS_RUBVH,POLS_RUBVR)# & PIR1: (GNWV77,GNWVR3,GNWVR4,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PVIGSQARKC*# SEQUENCE: PVIGSQARKC*# ...# >HUM2300D# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (280-287)# DB REFERENCE: SWISS: (POLS_RUBVM,POLS_RUBVH,POLS_RUBVR,POLS_RUBVT)# & PIR1: (GNWVR4,GNWVR3,GNWV77,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VIGSQARKC*# SEQUENCE: VIGSQARKC*# ...# >HUM2300E# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (279-286)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVM,POLS_RUBVT,POLS_RUBVH)# & PIR1: (GNWVR3,GNWV77,GNWVRA,GNWVR4)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PVIGSQARK*# SEQUENCE: PVIGSQARK*# ...# >HUM2300F# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (280-287)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVH,POLS_RUBVM,POLS_RUBVT)# & PIR1: (GNWV77,GNWVR3,GNWVR4,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VIGSQARK*# SEQUENCE: VIGSQARK*# ...# >HUM23010# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (381-395)# DB REFERENCE: SWISS: (POLS_RUBVT)# & PIR1: (GNWVR4)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,VPPGKFVTAALLNTP*# SEQUENCE: VPPGKFVTAALLNTP*# ...# >HUM23011# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (382-394)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVH,POLS_RUBVT,POLS_RUBVM)# & PIR1: (GNWVR4,GNWVRA,GNWV77,GNWVR3)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PPGKFVTAALLNT*# SEQUENCE: PPGKFVTAALLNT*# ...# >HUM23012# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (383-394)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVM,POLS_RUBVR,POLS_RUBVT)# & PIR1: (GNWV77,GNWVR4,GNWVRA,GNWVR3)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PGKFVTAALLNT*# SEQUENCE: PGKFVTAALLNT*# ...# >HUM23013# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (382-392)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVT,POLS_RUBVM,POLS_RUBVH)# & PIR1: (GNWV77,GNWVR3,GNWVR4,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PPGKFVTAALL*# SEQUENCE: PPGKFVTAALL*# ...# >HUM23014# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (384-394)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVT,POLS_RUBVM,POLS_RUBVH)# & PIR1: (GNWVR3,GNWV77,GNWVR4,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GKFVTAALLNT*# SEQUENCE: GKFVTAALLNT*# ...# >HUM23015# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (383-393)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVM,POLS_RUBVR,POLS_RUBVT)# & PIR1: (GNWVR4,GNWV77,GNWVR3,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,PGKFVTAALLN*# SEQUENCE: PGKFVTAALLN*# ...# >HUM23016# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (385-394)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVM,POLS_RUBVH,POLS_RUBVT)# & PIR1: (GNWVR4,GNWV77,GNWVR3,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,KFVTAALLNT*# SEQUENCE: KFVTAALLNT*# ...# >HUM23017# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (384-393)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVM,POLS_RUBVH,POLS_RUBVT)# & PIR1: (GNWVRA,GNWVR3,GNWV77,GNWVR4)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,GKFVTAALLN*# SEQUENCE: GKFVTAALLN*# ...# >HUM23018# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (385-393)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVT,POLS_RUBVM,POLS_RUBVR)# & PIR1: (GNWVRA,GNWV77,GNWVR3,GNWVR4)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,KFVTAALLN*# SEQUENCE: KFVTAALLN*# ...# >HUM23019# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (410-420)# DB REFERENCE: SWISS: (POLS_RUBVT)# & PIR2: (A24309)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TARVIDPAAQS*# SEQUENCE: TARVIDPAAQS*# ...# >HUM2301A# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (410-419)# DB REFERENCE: SWISS: (POLS_RUBVT)# & PIR2: (A24309)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,TARVIDPAAQ*# SEQUENCE: TARVIDPAAQ*# ...# >HUM2301B# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (411-420)# DB REFERENCE: SWISS: (POLS_RUBVT,POLS_RUBVH,POLS_RUBVR)# & PIR1: (GNWV77,GNWVR4,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ARVIDPAAQS*# SEQUENCE: ARVIDPAAQS*# ...# >HUM2301C# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (412-420)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVR,POLS_RUBVT)# & PIR1: (GNWVR4,GNWVRA,GNWV77)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RVIDPAAQS*# SEQUENCE: RVIDPAAQS*# ...# >HUM2301D# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (411-419)# DB REFERENCE: SWISS: (POLS_RUBVH,POLS_RUBVR,POLS_RUBVT)# & PIR1: (GNWVR4,GNWV77,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,ARVIDPAAQ*# SEQUENCE: ARVIDPAAQ*# ...# >HUM2301E# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rubella virus E1 glycoprotein (412-419)# DB REFERENCE: SWISS: (POLS_RUBVR,POLS_RUBVT,POLS_RUBVH)# & PIR1: (GNWVR4,GNWV77,GNWVRA)# & PIR2: (A24309)# & PIR3: (A32270)# ANCHOR POSITIONS: ?# REFERENCES: marttila96a# COMMENT:# SUMMARY: HLA-D?,actyesu,bindyesu,RVIDPAAQ*# SEQUENCE: RVIDPAAQ*# ...# >HUM2301F# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HA (306-320) homologue# DB REFERENCE: SWISS: (HEMA_IAZCO,HEMA_IAZH2,HEMA_IAQU7,HEMA_IADH4,HEMA_IADH6,# & HEMA_IAZUK,HEMA_IAEN6,HEMA_IADHM,HEMA_IAUDO,HEMA_IADH2,# & HEMA_IADU3,HEMA_IAME2,HEMA_IANT6,HEMA_IAAIC,HEMA_IADH7,# & HEMA_IAEN7,HEMA_IADH3,HEMA_IADH1,HEMA_IABAN,# & HEMA_IAVI7)# & PIR1: (HMIVHM,HMIV15,HMIV89,HMIV80,HMIV6,HMIV33,HMIVS3,HMIVDU,# & HMIVV,HMIVH,HMIVHA,HMIV98,HMIV77)# & PIR2: (A92979,JQ1156)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR11,actyesh,bindyesh,CPKYVKQNTLKLATG*# SEQUENCE: CPKYVKQNTLKLATG*# ...# >HUM23020# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,CPKYAKQNTLKLATG*# SEQUENCE: CPKYAKQNTLKLATG*# ...# >HUM23021# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesm,CPKYVAQNTLKLATG*# SEQUENCE: CPKYVAQNTLKLATG*# ...# >HUM23022# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR11,actyesl,bindyesm,CPKYVKANTLKLATG*# SEQUENCE: CPKYVKANTLKLATG*# ...# >HUM23023# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR11,actyesh,bindyesh,CPKYVKQATLKLATG*# SEQUENCE: CPKYVKQATLKLATG*# ...# >HUM23024# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR11,actyesh,bindyesh,CPKYVKQNALKLATG*# SEQUENCE: CPKYVKQNALKLATG*# ...# >HUM23025# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR11,actyesm,bindyesh,CPKYVKQNTAKLATG*# SEQUENCE: CPKYVKQNTAKLATG*# ...# >HUM23026# MHC MOLECULE: HLA-DR11(DRB1*1101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR11,actunkn,bindyesh,CPKYVKQNTLALATG*# SEQUENCE: CPKYVKQNTLALATG*# ...# >HUM23027# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# DB REFERENCE: SWISS: (HEMA_IADH2,HEMA_IADHM,HEMA_IAEN7,HEMA_IADH1,HEMA_IAZCO,# & HEMA_IAZH2,HEMA_IABAN,HEMA_IAVI7,HEMA_IANT6,HEMA_IAQU7,# & HEMA_IADH6,HEMA_IAZUK,HEMA_IADH7,HEMA_IAME2,HEMA_IAAIC,# & HEMA_IADH3,HEMA_IADU3,HEMA_IAEN6,HEMA_IADH4,# & HEMA_IAUDO)# & PIR1: (HMIVHM,HMIV89,HMIVHA,HMIV15,HMIV6,HMIV80,HMIVDU,HMIVH,# & HMIVV,HMIV33,HMIVS3,HMIV77,HMIV98)# & PIR2: (JQ1156,A92979)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actyesh,bindyesm,CPKYVKQNTLKLATG*# SEQUENCE: CPKYVKQNTLKLATG*# ...# >HUM23028# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actyesh,bindyesl,CPKAVKQNTLKLATG*# SEQUENCE: CPKAVKQNTLKLATG*# ...# >HUM23029# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesm,CPKYAKQNTLKLATG*# SEQUENCE: CPKYAKQNTLKLATG*# ...# >HUM2302A# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesm,CPKYVAQNTLKLATG*# SEQUENCE: CPKYVAQNTLKLATG*# ...# >HUM2302B# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesm,CPKYVKANTLKLATG*# SEQUENCE: CPKYVKANTLKLATG*# ...# >HUM2302C# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesm,CPKYVKQATLKLATG*# SEQUENCE: CPKYVKQATLKLATG*# ...# >HUM2302D# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition,CTL induction# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesm,CPKYVKQNALKLATG*# SEQUENCE: CPKYVKQNALKLATG*# ...# >HUM2302E# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesm,CPKYVKQNTAKLATG*# SEQUENCE: CPKYVKQNTAKLATG*# ...# >HUM2302F# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actunkn,bindyesl,CPKYVKQNTLALATG*# SEQUENCE: CPKYVKQNTLALATG*# ...# >HUM23030# MHC MOLECULE: HLA-DR13(DRB1*1301), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR13,actyesl,bindyesm,CPKYVKQNTLKAATG*# SEQUENCE: CPKYVKQNTLKAATG*# ...# >HUM23031# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# DB REFERENCE: SWISS: (HEMA_IAME2,HEMA_IADU3,HEMA_IAAIC,HEMA_IAZH2,HEMA_IABAN,# & HEMA_IADH1,HEMA_IAQU7,HEMA_IAZUK,HEMA_IANT6,HEMA_IADH7,# & HEMA_IADH6,HEMA_IAZCO,HEMA_IAEN6,HEMA_IAUDO,HEMA_IADH4,# & HEMA_IAEN7,HEMA_IADH2,HEMA_IADHM,HEMA_IADH3,# & HEMA_IAVI7)# & PIR1: (HMIVHM,HMIVHA,HMIVDU,HMIV77,HMIV33,HMIV15,HMIV80,HMIV6,# & HMIVH,HMIV98,HMIVS3,HMIVV,HMIV89)# & PIR2: (JQ1156,A92979)# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actyesm,bindyesm,CPKYVKQNTLKLATG*# SEQUENCE: CPKYVKQNTLKLATG*# ...# >HUM23032# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actyesh,bindyesm,CPKAVKQNTLKLATG*# SEQUENCE: CPKAVKQNTLKLATG*# ...# >HUM23033# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,CPKYAKQNTLKLATG*# SEQUENCE: CPKYAKQNTLKLATG*# ...# >HUM23034# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,CPKYVAQNTLKLATG*# SEQUENCE: CPKYVAQNTLKLATG*# ...# >HUM23035# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,CPKYVKANTLKLATG*# SEQUENCE: CPKYVKANTLKLATG*# ...# >HUM23036# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,CPKYVKQATLKLATG*# SEQUENCE: CPKYVKQATLKLATG*# ...# >HUM23037# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,CPKYVKQNALKLATG*# SEQUENCE: CPKYVKQNALKLATG*# ...# >HUM23038# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,CPKYVKQNTAKLATG*# SEQUENCE: CPKYVKQNTAKLATG*# ...# >HUM23039# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,CPKYVKQNTLALATG*# SEQUENCE: CPKYVKQNTLALATG*# ...# >HUM2303A# MHC MOLECULE: HLA-DR4(DRB1*0402), CLASS-2, (HUMAN)# METHOD: Competition/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: HA (306-320) homologue# ANCHOR POSITIONS: ?# REFERENCES: zeliszewski96a# COMMENT:# SUMMARY: HLA-DR4,actyesm,bindyesh,CPKYVKQNTLKAATG*# SEQUENCE: CPKYVKQNTLKAATG*# ...# >HUM2303B# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595)# DB REFERENCE: SWISS: (PLSL_MOUSE,PLSL_HUMAN,PLSL_HUMAN)# & PIR1: (A35836)# & PIR2: (I49445)# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,NNAKYAISMARKIGA*# SEQUENCE: NNAKYAISMARKIGA*# ...# >HUM2303C# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,AAAKAAIAAARKIAA*# SEQUENCE: AAAKAAIAAARKIAA*# ...# >HUM2303D# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,AAAKAAIAAARAIAA*# SEQUENCE: AAAKAAIAAARAIAA*# ...# >HUM2303E# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) Ala homologue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,AAAKAAIAAAAKIAA*# SEQUENCE: AAAKAAIAAAAKIAA*# ...# >HUM2303F# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,ANAKYAISMARKIGA*# SEQUENCE: ANAKYAISMARKIGA*# ...# >HUM23040# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,NAAKYAISMARKIGA*# SEQUENCE: NAAKYAISMARKIGA*# ...# >HUM23041# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesl,NNAAYAISMARKIGA*# SEQUENCE: NNAAYAISMARKIGA*# ...# >HUM23042# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,NNAKAAISMARKIGA*# SEQUENCE: NNAKAAISMARKIGA*# ...# >HUM23043# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesl,NNAKYAASMARKIGA*# SEQUENCE: NNAKYAASMARKIGA*# ...# >HUM23044# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,NNAKYAIAMARKIGA*# SEQUENCE: NNAKYAIAMARKIGA*# ...# >HUM23045# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,NNAKYAISAARKIGA*# SEQUENCE: NNAKYAISAARKIGA*# ...# >HUM23046# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesl,NNAKYAISMARAIGA*# SEQUENCE: NNAKYAISMARAIGA*# ...# >HUM23047# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesl,NNAKYAISMARKAGA*# SEQUENCE: NNAKYAISMARKAGA*# ...# >HUM23048# MHC MOLECULE: HLA-DR53(DRB4*0101), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: L plastin (581-595) analogue# ANCHOR POSITIONS: ?# REFERENCES: kobayashi96a# COMMENT:# SUMMARY: HLA-DR53,actunkn,bindyesu,NNAKYAISMARKIAA*# SEQUENCE: NNAKYAISMARKIAA*# ...# >HUM23049# MHC MOLECULE: DR52, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Rye grass allergen Lol p1 (191-210)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPL1_LOLPR)# & PIR2: (A37881,B37881)# & PIR3: (S13614)# ANCHOR POSITIONS: ?# REFERENCES: perez90a# COMMENT:# SUMMARY: DR52,actyesu,bindyesu,ESWGAVWRIDTPDKLTGPFT*# SEQUENCE: ESWGAVWRIDTPDKLTGPFT*# ...# >HUM2304A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Competition/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesh,bindyesm,NRDLAQAYNELSGEA*# SEQUENCE: NRDLAQAYNELSGEA*# ...# >HUM2304B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDVEQAYNELSGEA*# SEQUENCE: NRDVEQAYNELSGEA*# ...# >HUM2304C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# DB REFERENCE: SWISS: (M12_STRPY)# & PIR2: (A60115)# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELSGEA*# SEQUENCE: NRDLEQAYNELSGEA*# ...# >HUM2304D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDIEQAYNELSGEA*# SEQUENCE: NRDIEQAYNELSGEA*# ...# >HUM2304E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDFEQAYNELSGEA*# SEQUENCE: NRDFEQAYNELSGEA*# ...# >HUM2304F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDMEQAYNELSGEA*# SEQUENCE: NRDMEQAYNELSGEA*# ...# >HUM23050# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLDQAYNELSGEA*# SEQUENCE: NRDLDQAYNELSGEA*# ...# >HUM23051# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLQQAYNELSGEA*# SEQUENCE: NRDLQQAYNELSGEA*# ...# >HUM23052# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLENAYNELSGEA*# SEQUENCE: NRDLENAYNELSGEA*# ...# >HUM23053# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLETAYNELSGEA*# SEQUENCE: NRDLETAYNELSGEA*# ...# >HUM23054# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLECAYNELSGEA*# SEQUENCE: NRDLECAYNELSGEA*# ...# >HUM23055# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEAAYNELSGEA*# SEQUENCE: NRDLEAAYNELSGEA*# ...# >HUM23056# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEVAYNELSGEA*# SEQUENCE: NRDLEVAYNELSGEA*# ...# >HUM23057# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLELAYNELSGEA*# SEQUENCE: NRDLELAYNELSGEA*# ...# >HUM23058# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEIAYNELSGEA*# SEQUENCE: NRDLEIAYNELSGEA*# ...# >HUM23059# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEMAYNELSGEA*# SEQUENCE: NRDLEMAYNELSGEA*# ...# >HUM2305A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQTYNELSGEA*# SEQUENCE: NRDLEQTYNELSGEA*# ...# >HUM2305B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQSYNELSGEA*# SEQUENCE: NRDLEQSYNELSGEA*# ...# >HUM2305C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQCYNELSGEA*# SEQUENCE: NRDLEQCYNELSGEA*# ...# >HUM2305D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQVYNELSGEA*# SEQUENCE: NRDLEQVYNELSGEA*# ...# >HUM2305E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQIYNELSGEA*# SEQUENCE: NRDLEQIYNELSGEA*# ...# >HUM2305F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAFNELSGEA*# SEQUENCE: NRDLEQAFNELSGEA*# ...# >HUM23060# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAMNELSGEA*# SEQUENCE: NRDLEQAMNELSGEA*# ...# >HUM23061# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYDELSGEA*# SEQUENCE: NRDLEQAYDELSGEA*# ...# >HUM23062# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYTELSGEA*# SEQUENCE: NRDLEQAYTELSGEA*# ...# >HUM23063# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYAELSGEA*# SEQUENCE: NRDLEQAYAELSGEA*# ...# >HUM23064# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYVELSGEA*# SEQUENCE: NRDLEQAYVELSGEA*# ...# >HUM23065# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYIELSGEA*# SEQUENCE: NRDLEQAYIELSGEA*# ...# >HUM23066# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNHLSGEA*# SEQUENCE: NRDLEQAYNHLSGEA*# ...# >HUM23067# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNDLSGEA*# SEQUENCE: NRDLEQAYNDLSGEA*# ...# >HUM23068# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNQLSGEA*# SEQUENCE: NRDLEQAYNQLSGEA*# ...# >HUM23069# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNALSGEA*# SEQUENCE: NRDLEQAYNALSGEA*# ...# >HUM2306A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNMLSGEA*# SEQUENCE: NRDLEQAYNMLSGEA*# ...# >HUM2306B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNERSGEA*# SEQUENCE: NRDLEQAYNERSGEA*# ...# >HUM2306C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNEKSGEA*# SEQUENCE: NRDLEQAYNEKSGEA*# ...# >HUM2306D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNEHSGEA*# SEQUENCE: NRDLEQAYNEHSGEA*# ...# >HUM2306E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNEESGEA*# SEQUENCE: NRDLEQAYNEESGEA*# ...# >HUM2306F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNETSGEA*# SEQUENCE: NRDLEQAYNETSGEA*# ...# >HUM23070# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNEGSGEA*# SEQUENCE: NRDLEQAYNEGSGEA*# ...# >HUM23071# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNEVSGEA*# SEQUENCE: NRDLEQAYNEVSGEA*# ...# >HUM23072# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNEISGEA*# SEQUENCE: NRDLEQAYNEISGEA*# ...# >HUM23073# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNEYSGEA*# SEQUENCE: NRDLEQAYNEYSGEA*# ...# >HUM23074# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELRGEA*# SEQUENCE: NRDLEQAYNELRGEA*# ...# >HUM23075# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELKGEA*# SEQUENCE: NRDLEQAYNELKGEA*# ...# >HUM23076# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELHGEA*# SEQUENCE: NRDLEQAYNELHGEA*# ...# >HUM23077# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELTGEA*# SEQUENCE: NRDLEQAYNELTGEA*# ...# >HUM23078# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELGGEA*# SEQUENCE: NRDLEQAYNELGGEA*# ...# >HUM23079# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELAGEA*# SEQUENCE: NRDLEQAYNELAGEA*# ...# >HUM2307A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELVGEA*# SEQUENCE: NRDLEQAYNELVGEA*# ...# >HUM2307B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELIGEA*# SEQUENCE: NRDLEQAYNELIGEA*# ...# >HUM2307C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNELMGEA*# SEQUENCE: NRDLEQAYNELMGEA*# ...# >HUM2307D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLNQAYNELSGEA*# SEQUENCE: NRDLNQAYNELSGEA*# ...# >HUM2307E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLVQAYNELSGEA*# SEQUENCE: NRDLVQAYNELSGEA*# ...# >HUM2307F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLLQAYNELSGEA*# SEQUENCE: NRDLLQAYNELSGEA*# ...# >HUM23080# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLIQAYNELSGEA*# SEQUENCE: NRDLIQAYNELSGEA*# ...# >HUM23081# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLFQAYNELSGEA*# SEQUENCE: NRDLFQAYNELSGEA*# ...# >HUM23082# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLMQAYNELSGEA*# SEQUENCE: NRDLMQAYNELSGEA*# ...# >HUM23083# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLWQAYNELSGEA*# SEQUENCE: NRDLWQAYNELSGEA*# ...# >HUM23084# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLYQAYNELSGEA*# SEQUENCE: NRDLYQAYNELSGEA*# ...# >HUM23085# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEHAYNELSGEA*# SEQUENCE: NRDLEHAYNELSGEA*# ...# >HUM23086# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEDAYNELSGEA*# SEQUENCE: NRDLEDAYNELSGEA*# ...# >HUM23087# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEGAYNELSGEA*# SEQUENCE: NRDLEGAYNELSGEA*# ...# >HUM23088# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEFAYNELSGEA*# SEQUENCE: NRDLEFAYNELSGEA*# ...# >HUM23089# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEWAYNELSGEA*# SEQUENCE: NRDLEWAYNELSGEA*# ...# >HUM2308A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEYAYNELSGEA*# SEQUENCE: NRDLEYAYNELSGEA*# ...# >HUM2308B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQLYNELSGEA*# SEQUENCE: NRDLEQLYNELSGEA*# ...# >HUM2308C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQMYNELSGEA*# SEQUENCE: NRDLEQMYNELSGEA*# ...# >HUM2308D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQARNELSGEA*# SEQUENCE: NRDLEQARNELSGEA*# ...# >HUM2308E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAQNELSGEA*# SEQUENCE: NRDLEQAQNELSGEA*# ...# >HUM2308F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQANNELSGEA*# SEQUENCE: NRDLEQANNELSGEA*# ...# >HUM23090# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQATNELSGEA*# SEQUENCE: NRDLEQATNELSGEA*# ...# >HUM23091# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQASNELSGEA*# SEQUENCE: NRDLEQASNELSGEA*# ...# >HUM23092# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQACNELSGEA*# SEQUENCE: NRDLEQACNELSGEA*# ...# >HUM23093# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAGNELSGEA*# SEQUENCE: NRDLEQAGNELSGEA*# ...# >HUM23094# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAANELSGEA*# SEQUENCE: NRDLEQAANELSGEA*# ...# >HUM23095# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAVNELSGEA*# SEQUENCE: NRDLEQAVNELSGEA*# ...# >HUM23096# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAWNELSGEA*# SEQUENCE: NRDLEQAWNELSGEA*# ...# >HUM23097# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYSELSGEA*# SEQUENCE: NRDLEQAYSELSGEA*# ...# >HUM23098# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNRLSGEA*# SEQUENCE: NRDLEQAYNRLSGEA*# ...# >HUM23099# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNKLSGEA*# SEQUENCE: NRDLEQAYNKLSGEA*# ...# >HUM2309A# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNSLSGEA*# SEQUENCE: NRDLEQAYNSLSGEA*# ...# >HUM2309B# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNCLSGEA*# SEQUENCE: NRDLEQAYNCLSGEA*# ...# >HUM2309C# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNVLSGEA*# SEQUENCE: NRDLEQAYNVLSGEA*# ...# >HUM2309D# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNLLSGEA*# SEQUENCE: NRDLEQAYNLLSGEA*# ...# >HUM2309E# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNILSGEA*# SEQUENCE: NRDLEQAYNILSGEA*# ...# >HUM2309F# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNFLSGEA*# SEQUENCE: NRDLEQAYNFLSGEA*# ...# >HUM230A0# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNWLSGEA*# SEQUENCE: NRDLEQAYNWLSGEA*# ...# >HUM230A1# MHC MOLECULE: HLA-DR4(DRB1*0406), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemolytic streptococcal strain 12 M (54-68) homologue# ANCHOR POSITIONS: ?# REFERENCES: chen96a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,NRDLEQAYNYLSGEA*# SEQUENCE: NRDLEQAYNYLSGEA*# ...# >HUM230A2# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Unknown# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Coxsackie virus 2C# DB REFERENCE: SWISS: (POLG_COXB5,POLG_COXA9,POLG_SVDVU,POLG_SVDVH,POLG_COXB1,# & POLG_COXB3,POLG_EC11G,POLG_COXB4,POLG_CXA9)# & PIR1: (GNNYA9,GNNYSH,GNNYB4,GNNYB1,JQ2021,GNNYBT,GNNYEC,GNNYSV,# & GNNYB3)# ANCHOR POSITIONS: ?# REFERENCES: desouza97a# COMMENT:# SUMMARY: HLA-DQ8,actyesu,bindyesu,WLKVKILPEV*# SEQUENCE: WLKVKILPEV*# ...# >HUM230A3# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: Unknown# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Human GAD 65# DB REFERENCE: SWISS: (DCE2_PIG,DCE2_HUMAN)# & PIR1: (A41292)# & PIR2: (JC4064)# ANCHOR POSITIONS: ?# REFERENCES: desouza97a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,IARFKMFPE*# SEQUENCE: IARFKMFPE*# ...# >HUM230A4# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 34P3A# ANCHOR POSITIONS: ?# REFERENCES: buckner96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,IARAKMFPAVAEK*# SEQUENCE: IARAKMFPAVAEK*# ...# >HUM230A5# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 34P3A# ANCHOR POSITIONS: ?# REFERENCES: buckner96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,IARAKMFPAVAEK*# SEQUENCE: IARAKMFPAVAEK*# ...# >HUM230A6# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV10a# ANCHOR POSITIONS: ?# REFERENCES: buckner96a,kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,DMTPADALDAFDL*# SEQUENCE: DMTPADALDAFDL*# ...# >HUM230A7# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: lambda repressor# ANCHOR POSITIONS: ?# REFERENCES: buckner96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,LEDARRAKALYAK*# SEQUENCE: LEDARRAKALYAK*# ...# >HUM230A8# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: lambda repressor# ANCHOR POSITIONS: ?# REFERENCES: buckner96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,LEDARRAKALYAK*# SEQUENCE: LEDARRAKALYAK*# ...# >HUM230A9# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: buckner96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,VSKMRMATPLLMQAL*# SEQUENCE: VSKMRMATPLLMQAL*# ...# >HUM230AA# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CLIP Inv (104-118)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: buckner96a,kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,VSKMRMATPLLMQAL*# SEQUENCE: VSKMRMATPLLMQAL*# ...# >HUM230AB# MHC MOLECULE: HLA-DQ9(DQA1*0301xDQB1*0303), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV-2 (433-445) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesu,DMTPADALDAFDL*# SEQUENCE: DMTPADALDAFDL*# ...# >HUM230AC# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV-2 (433-445) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,DLTPADALDDFDL*# SEQUENCE: DLTPADALDDFDL*# ...# >HUM230AD# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV-2 (433-445) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,DLTPADALDEFDL*# SEQUENCE: DLTPADALDEFDL*# ...# >HUM230AE# MHC MOLECULE: HLA-DQ9(DQA1*0301xDQB1*0303), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: HSV-2 (433-445) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesl,DLTPADALDEFDL*# SEQUENCE: DLTPADALDEFDL*# ...# >HUM230AF# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV-2 (433-445) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,DMTPADALDLFDL*# SEQUENCE: DMTPADALDLFDL*# ...# >HUM230B0# MHC MOLECULE: HLA-DQ9(DQA1*0301xDQB1*0303), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSV-2 (433-445) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesu,DMTPADALDLFDL*# SEQUENCE: DMTPADALDLFDL*# ...# >HUM230B1# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: CLIP (81-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,LPKPPKPVSKMRMDTPLLMQALPM*# SEQUENCE: LPKPPKPVSKMRMDTPLLMQALPM*# ...# >HUM230B2# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (89-104)# DB REFERENCE: SWISS: (HG2A_HUMAN,HG2A_HUMAN)# & PIR1: (HLHUG)# ANCHOR POSITIONS: ?# REFERENCES: van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,SKMRMATPLLMQALPM*# SEQUENCE: SKMRMATPLLMQALPM*# ...# >HUM230B3# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (81-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,SKMRMATKLLMQALPM*# SEQUENCE: SKMRMATKLLMQALPM*# ...# >HUM230B4# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: CLIP (81-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,SKMRMDTKLLMQALPM*# SEQUENCE: SKMRMDTKLLMQALPM*# ...# >HUM230B5# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: Apolipoprotein B (2877-2894)# ANCHOR POSITIONS: ?# REFERENCES: van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,ISNQLTLDSNIKYFHKLN*# SEQUENCE: ISNQLTLDSNIKYFHKLN*# ...# >HUM230B6# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Apolipoprotein B (2877-2894) homologue# ANCHOR POSITIONS: ?# REFERENCES: van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesm,ISNQLTLASNIKYFHKLN*# SEQUENCE: ISNQLTLASNIKYFHKLN*# ...# >HUM230B7# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: HAChR alpha (312-325)# DB REFERENCE: SWISS: (ACHA_BOVIN,ACHA_HUMAN,ACHA_RAT,ACHA_MOUSE,ACHA_MOUSE)# & PIR1: (ACBOA1,ACHUA1)# & PIR2: (I49458,A24383)# & PIR3: (S13872)# ANCHOR POSITIONS: ?# REFERENCES: van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,VRKVFIDTIPNIMF*# SEQUENCE: VRKVFIDTIPNIMF*# ...# >HUM230B8# MHC MOLECULE: HLA-DR3, CLASS-2, (HUMAN)# METHOD: Half-time# ACTIVITY: ?# BINDING: yes, high# SOURCE: MOMP (251-265)# DB REFERENCE: SWISS: (OMPB_CHLTR,OMPM_CHLTR,OMPA_CHLTR,OMPN_CHLTR,OMPC_CHLTR,# & OMPE_CHLTR,OMPL_CHLTR,OMPH_CHLTR,OMPA_CHLTR)# & PIR1: (MMCWTH,MMCWTB,MMCWTE,MMCWTC)# & PIR2: (S11006,JT0947,S12799,B60756,S11007,S11012,JC1432,JE0413,# & S11009,I40741,S06259,S16034)# ANCHOR POSITIONS: ?# REFERENCES: van-ham96a# COMMENT:# SUMMARY: HLA-DR3,actunkn,bindyesh,QASLALSYRLNMFTP*# SEQUENCE: QASLALSYRLNMFTP*# ...# >HUM230B9# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (81-94)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,LIGFRKEIGRMLNI*# SEQUENCE: LIGFRKEIGRMLNI*# ...# >HUM230BA# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (81-93)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,LIGFRKEIGRMLN*# SEQUENCE: LIGFRKEIGRMLN*# ...# >HUM230BB# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (81-92)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,LIGFRKEIGRML*# SEQUENCE: LIGFRKEIGRML*# ...# >HUM230BC# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (82-95)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,IGFRKEIGRMLNIL*# SEQUENCE: IGFRKEIGRMLNIL*# ...# >HUM230BD# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (83-95)# DB REFERENCE: SWISS: (POLG_DEN26,POLG_DEN2P,POLG_DEN2J,POLG_DEN4,POLG_DEN2N,# & POLG_DEN27)# & PIR1: (GNWVDF,GNWVJA,GNWVDP,GNWV26,GNWV16)# & PIR2: (A47666,A48644,S09220,S09222,JS0219)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,GFRKEIGRMLNIL*# SEQUENCE: GFRKEIGRMLNIL*# ...# >HUM230BE# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (84-91)# DB REFERENCE: SWISS: (POLG_DEN26,POLG_DEN2J,POLG_DEN4,POLG_DEN27,POLG_DEN2P,# & POLG_DEN2N)# & PIR1: (GNWVJA,GNWVDF,GNWV16,GNWV26,GNWVDP)# & PIR2: (A47666,A48644,S09222,S09220,JS0219)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,FRKEIGRM*# SEQUENCE: FRKEIGRM*# ...# >HUM230BF# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (81-94)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,LIGFRKEIGRMLNI*# SEQUENCE: LIGFRKEIGRMLNI*# ...# >HUM230C0# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (81-93)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,LIGFRKEIGRMLN*# SEQUENCE: LIGFRKEIGRMLN*# ...# >HUM230C1# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (81-92)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,LIGFRKEIGRML*# SEQUENCE: LIGFRKEIGRML*# ...# >HUM230C2# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (81-91)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,LIGFRKEIGRM*# SEQUENCE: LIGFRKEIGRM*# ...# >HUM230C3# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (82-95)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,IGFRKEIGRMLNIL*# SEQUENCE: IGFRKEIGRMLNIL*# ...# >HUM230C4# MHC MOLECULE: HLA-DR1, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (84-91)# DB REFERENCE: SWISS: (POLG_DEN27,POLG_DEN2N,POLG_DEN2J,POLG_DEN26,POLG_DEN4,# & POLG_DEN2P)# & PIR1: (GNWVDP,GNWVJA,GNWVDF,GNWV26,GNWV16)# & PIR2: (A48644,S09220,A47666,S09222,JS0219)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DR1,actyesu,bindyesu,FRKEIGRM*# SEQUENCE: FRKEIGRM*# ...# >HUM230C5# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (43-55)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# & PIR2: (A47666)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,PLRMVLAFITFLR*# SEQUENCE: PLRMVLAFITFLR*# ...# >HUM230C6# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (46-55)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# & PIR2: (A47666)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,MVLAFITFLR*# SEQUENCE: MVLAFITFLR*# ...# >HUM230C7# MHC MOLECULE: HLA-DP4, CLASS-2, (HUMAN)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Dengue virus D4V capsid protein (47-55)# DB REFERENCE: SWISS: (POLG_DEN4)# & PIR1: (GNWVDF)# & PIR2: (A47666)# ANCHOR POSITIONS: ?# REFERENCES: gagnon96a# COMMENT:# SUMMARY: HLA-DP4,actyesu,bindyesu,VLAFITFLR*# SEQUENCE: VLAFITFLR*# ...# >HUM230C8# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (111-129)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,LSRFSWGAEGQRPGFGYGG*# SEQUENCE: LSRFSWGAEGQRPGFGYGG*# ...# >HUM230C9# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (112-129)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBHUB,MBCZB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,SRFSWGAEGQRPGFGYGG*# SEQUENCE: SRFSWGAEGQRPGFGYGG*# ...# >HUM230CA# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (113-129)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,RFSWGAEGQRPGFGYGG*# SEQUENCE: RFSWGAEGQRPGFGYGG*# ...# >HUM230CB# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (114-129)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBCZB,MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,FSWGAEGQRPGFGYGG*# SEQUENCE: FSWGAEGQRPGFGYGG*# ...# >HUM230CC# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (115-129)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBCZB,MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,SWGAEGQRPGFGYGG*# SEQUENCE: SWGAEGQRPGFGYGG*# ...# >HUM230CD# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (116-129)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBCZB,MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,WGAEGQRPGFGYGG*# SEQUENCE: WGAEGQRPGFGYGG*# ...# >HUM230CE# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (111-128)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBHUB,MBCZB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,LSRFSWGAEGQRPGFGYG*# SEQUENCE: LSRFSWGAEGQRPGFGYG*# ...# >HUM230CF# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (111-127)# DB REFERENCE: SWISS: (MBP_HUMAN,MBP_PANTR)# & PIR1: (MBCZB,MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,LSRFSWGAEGQRPGFGY*# SEQUENCE: LSRFSWGAEGQRPGFGY*# ...# >HUM230D0# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (111-126)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,LSRFSWGAEGQRPGFG*# SEQUENCE: LSRFSWGAEGQRPGFG*# ...# >HUM230D1# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (111-125)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,LSRFSWGAEGQRPGF*# SEQUENCE: LSRFSWGAEGQRPGF*# ...# >HUM230D2# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (111-124)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBCZB,MBHUB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,LSRFSWGAEGQRPG*# SEQUENCE: LSRFSWGAEGQRPG*# ...# >HUM230D3# MHC MOLECULE: HLA-DR4(DRB1*0401), CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MBP (111-123)# DB REFERENCE: SWISS: (MBP_PANTR,MBP_HUMAN)# & PIR1: (MBHUB,MBCZB)# ANCHOR POSITIONS: ?# REFERENCES: muraro97a# COMMENT:# SUMMARY: HLA-DR4,actyesu,bindyesu,LSRFSWGAEGQRP*# SEQUENCE: LSRFSWGAEGQRP*# ...# >HUM230D4# MHC MOLECULE: HLA-DQ6(DQA1*0101xDQB1*0602), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: GAD 65 (253-265)# DB REFERENCE: SWISS: (DCE2_HUMAN,DCE2_PIG)# & PIR1: (A41292)# & PIR2: (JC4064)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ6,actunkn,bindyesl,IARFKMFPEVKEK*# SEQUENCE: IARFKMFPEVKEK*# ...# >HUM230D5# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265)# DB REFERENCE: SWISS: (DCE2_HUMAN,DCE2_PIG)# & PIR1: (A41292)# & PIR2: (JC4064)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARFKMFPEVKEK*# SEQUENCE: IARFKMFPEVKEK*# ...# >HUM230D6# MHC MOLECULE: HLA-DQ9(DQA1*0301xDQB1*0303), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: GAD 65 (253-265)# DB REFERENCE: SWISS: (DCE2_HUMAN,DCE2_PIG)# & PIR1: (A41292)# & PIR2: (JC4064)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesl,IARFKMFPEVKEK*# SEQUENCE: IARFKMFPEVKEK*# ...# >HUM230D7# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARFKMFPEVFEK*# SEQUENCE: IARFKMFPEVFEK*# ...# >HUM230D8# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,IARFKMFPERKEK*# SEQUENCE: IARFKMFPERKEK*# ...# >HUM230D9# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,IARFKMFREVKEK*# SEQUENCE: IARFKMFREVKEK*# ...# >HUM230DA# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,IARFKMRPEVKEK*# SEQUENCE: IARFKMRPEVKEK*# ...# >HUM230DB# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,IARFKRFPEVKEK*# SEQUENCE: IARFKRFPEVKEK*# ...# >HUM230DC# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARFFMFPEVKEK*# SEQUENCE: IARFFMFPEVKEK*# ...# >HUM230DD# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IAFFKMFPEVKEK*# SEQUENCE: IAFFKMFPEVKEK*# ...# >HUM230DE# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,IRRFKMFPEVKEK*# SEQUENCE: IRRFKMFPEVKEK*# ...# >HUM230DF# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,TARFKMFPEVKEK*# SEQUENCE: TARFKMFPEVKEK*# ...# >HUM230E0# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,QARFKMFPEVKEK*# SEQUENCE: QARFKMFPEVKEK*# ...# >HUM230E1# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,FARFKMFPEVKEK*# SEQUENCE: FARFKMFPEVKEK*# ...# >HUM230E2# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,DARFKMFPEVKEK*# SEQUENCE: DARFKMFPEVKEK*# ...# >HUM230E3# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,AARFKMFPEVKEK*# SEQUENCE: AARFKMFPEVKEK*# ...# >HUM230E4# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,IARTKMFPEVKEK*# SEQUENCE: IARTKMFPEVKEK*# ...# >HUM230E5# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARLKMFPEVKEK*# SEQUENCE: IARLKMFPEVKEK*# ...# >HUM230E6# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARAKMFPEVKEK*# SEQUENCE: IARAKMFPEVKEK*# ...# >HUM230E7# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARFKTFPEVKEK*# SEQUENCE: IARFKTFPEVKEK*# ...# >HUM230E8# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,IARFKDFPEVKEK*# SEQUENCE: IARFKDFPEVKEK*# ...# >HUM230E9# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARFKAFPEVKEK*# SEQUENCE: IARFKAFPEVKEK*# ...# >HUM230EA# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,IARFKMFPETKEK*# SEQUENCE: IARFKMFPETKEK*# ...# >HUM230EB# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,IARFKMFPELKEK*# SEQUENCE: IARFKMFPELKEK*# ...# >HUM230EC# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,IARFKMFPEAKEK*# SEQUENCE: IARFKMFPEAKEK*# ...# >HUM230ED# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-263)# DB REFERENCE: SWISS: (DCE2_HUMAN,DCE2_PIG)# & PIR1: (A41292)# & PIR2: (JC4064)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARFKMFPEVK*# SEQUENCE: IARFKMFPEVK*# ...# >HUM230EE# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-263) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesh,IARAKMFPEVK*# SEQUENCE: IARAKMFPEVK*# ...# >HUM230EF# MHC MOLECULE: HLA-DQ9(DQA1*0301xDQB1*0303), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-263) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesh,IARFKMFPAVK*# SEQUENCE: IARFKMFPAVK*# ...# >HUM230F0# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-263) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesh,IARAKMFPAVK*# SEQUENCE: IARAKMFPAVK*# ...# >HUM230F1# MHC MOLECULE: HLA-DQ9(DQA1*0301xDQB1*0303), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: GAD 65 (253-263) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ9,actunkn,bindyesh,IARAKMFPAVK*# SEQUENCE: IARAKMFPAVK*# ...# >HUM230F2# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: lambda repressor (12-24)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,LEDARRLKAIYEK*# SEQUENCE: LEDARRLKAIYEK*# ...# >HUM230F3# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: lambda repressor (12-24)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,LEDARRAKAIYAK*# SEQUENCE: LEDARRAKAIYAK*# ...# >HUM230F4# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, high# SOURCE: lambda repressor (12-24)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesh,LEDARRAKAIYAK*# SEQUENCE: LEDARRAKAIYAK*# ...# >HUM230F5# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: lambda repressor (12-24)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesl,LEDARRLKAIYAK*# SEQUENCE: LEDARRLKAIYAK*# ...# >HUM230F6# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, little# SOURCE: lambda repressor (12-24)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesl,LEDARRLKAIYAK*# SEQUENCE: LEDARRLKAIYAK*# ...# >HUM230F7# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: p21 ras (55-64) 61L# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,ILDTAGLEEY*# SEQUENCE: ILDTAGLEEY*# ...# >HUM230F8# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Rabies virus nucleoprotein rN (11-25)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,NQVVSLVPEIIVDR*# SEQUENCE: NQVVSLVPEIIVDR*# ...# >HUM230F9# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: AYK# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,AAYAAAAAAKAA*# SEQUENCE: AAYAAAAAAKAA*# ...# >HUM230FA# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: DQ alpha (75-87)# DB REFERENCE: SWISS: (HA24_HUMAN,HA21_HUMAN)# & PIR1: (HLHUDC,HLHUDQ)# & PIR2: (I68551,A29312)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesu,IVIKRSNSTAATN*# SEQUENCE: IVIKRSNSTAATN*# ...# >HUM230FB# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Lol p1 (101-120)# DB REFERENCE: SWISS: (MPL1_LOLPR,MPH1_HOLLA,MPH1_HOLLA,MPA1_PHAAQ,# & MPL1_LOLPR)# & PIR2: (S38581,B37881,A37881)# & PIR3: (S13614)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,APYHFDLSGHAFGSMAKKGE*# SEQUENCE: APYHFDLSGHAFGSMAKKGE*# ...# >HUM230FC# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Staphylococcus nuclease St (101-120)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,EALVRQGLAKVAYVYKPNNT*# SEQUENCE: EALVRQGLAKVAYVYKPNNT*# ...# >HUM230FD# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: CS (332-398)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,KIAKMEKASSVFNVVNS*# SEQUENCE: KIAKMEKASSVFNVVNS*# ...# >HUM230FE# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: 19K MT (1-15)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,YEHRVKRGLTVAVAGA*# SEQUENCE: YEHRVKRGLTVAVAGA*# ...# >HUM230FF# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hepatitis B core HBC (1-20)# DB REFERENCE: SWISS: (CORA_HPBV2,CORA_HPBV9,CORA_HPBVW,CORA_HPBVZ,CORA_HPBVA,# & CORA_HPBVL,CORA_HPBVJ,CORA_HPBVY)# & PIR1: (NKVLCP,NKVLA3,NKVLKS,NKVLA2,NKVLA6,NKVLBH,NKVLJ1,NKVLAH,# & NKVLA1)# & PIR2: (S53202,S53260,S53211,S53257,S53279,S53240,S53267,S25651,# & S53163,S20746,S53272,S53200,S53270,S33686,S53216,S20750,# & S53255,S53181,S53169,S53253,S53159,S32204,S53274,S53198,# & S53236,S53204,S53184,S47409,S53186,S53229,S01405,S53207,# & S53238,S53172,S53247,S53242,S53227,S53281,S53140,S53155,# & S53225,S47405,S53251,S53232,S53223)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,MDIDPYKEFGATVELLSFLP*# SEQUENCE: MDIDPYKEFGATVELLSFLP*# ...# >HUM23100# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Hepatitis B core HBC (50-69)# DB REFERENCE: SWISS: (CORA_HPBVY,CORA_HPBVW,CORA_HPBVJ,CORA_HPBV9,# & CORA_HPBV2)# & PIR1: (NKVLA3,NKVLA6,NKVLAH,NKVLJ1,NKVLBH,NKVLKS)# & PIR2: (S53157,S53207,S20755,S47405,S53200,S53149,S53216,S53286,# & S53202,S53267,S53163,S25651,S53161,S53272,S20746,S53227,# & S53140,S53152,S47409,S53238,S32204,S53274,S22318,S53204,# & S53247,S01405,S53169,S53181,S20750)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,PHHTALRQAILCWGELMTLA*# SEQUENCE: PHHTALRQAILCWGELMTLA*# ...# >HUM23101# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HIV gp13 (57-72)# DB REFERENCE: SWISS: (GAG_HV1A2,GAG_HV1PV,GAG_HV1B5,GAG_HV1BR,GAG_HV1JR,# & GAG_HV1B1,GAG_HV1H2)# & PIR1: (FOVWH3,FOVWLV,FOVWA2)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,LGKIWPSYKGRPGNFL*# SEQUENCE: LGKIWPSYKGRPGNFL*# ...# >HUM23102# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ova (323-336)# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_COTJA,OVAL_CHICK)# & PIR1: (OACH)# & PIR2: (S11433)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,ISQAVHAAHAEINE*# SEQUENCE: ISQAVHAAHAEINE*# ...# >HUM23103# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: EBV LMP (372-386)# DB REFERENCE: SWISS: (LMP1_EBVR,LMP1_EBVC,LMP1_EBV)# & PIR1: (LABECA,LABERJ,QQBE50)# & PIR2: (S24611,G00065,S21660)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,DDDDPHGPVQLSYYD*# SEQUENCE: DDDDPHGPVQLSYYD*# ...# >HUM23104# MHC MOLECULE: HLA-DQ7(DQA1*0301xDQB1*0301), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, ?# SOURCE: beta2 microglobulin (91-106)# DB REFERENCE: SWISS: (B2MG_MOUSE,B2MG_MOUSE)# & PIR1: (MGMSB2)# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ7,actunkn,bindyesu,ACRVKHDSMAEPKTVY*# SEQUENCE: ACRVKHDSMAEPKTVY*# ...# >HUM23105# MHC MOLECULE: HLA-DQ8(DQA1*0301xDQB1*0302), CLASS-2, (HUMAN)# METHOD: direct binding# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: GAD 65 (253-265) homologue# ANCHOR POSITIONS: ?# REFERENCES: kwok96a# COMMENT:# SUMMARY: HLA-DQ8,actunkn,bindyesm,IAAAAMFPEVKEK*# SEQUENCE: IAAAAMFPEVKEK*# ...# >MUS23106# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: aggrecan G 1 global domain# DB REFERENCE: SWISS: (PGCA_HUMAN,PGCA_HUMAN)# & PIR2: (A39086)# ANCHOR POSITIONS: ?# REFERENCES: zhang97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,ATEGRVRVNSAYQDK*# SEQUENCE: ATEGRVRVNSAYQDK*# ...# >MUS23107# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: aggrecan G 1 global domain# DB REFERENCE: SWISS: (PGCA_RABIT,PGCA_RAT,PGCA_RAT,PGCA_HUMAN,PGCA_MOUSE,# & PGCA_HUMAN)# & PIR2: (A39086,A55182,A28453,S29139,A28452)# ANCHOR POSITIONS: ?# REFERENCES: zhang97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,DRAQRACLQNSAIIATPEQL*# SEQUENCE: DRAQRACLQNSAIIATPEQL*# ...# >MUS23108# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine link protein# DB REFERENCE: SWISS: (PLK_PIG,PLK_PIG,PLK_BOVIN,PLK_BOVIN,PLK_RAT,PLK_RAT)# & PIR1: (LKRT2)# & PIR2: (A28654,S04243,I47145)# ANCHOR POSITIONS: ?# REFERENCES: zhang97a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,NDGAQIAKVGQIFAAWKLLGYDR*# SEQUENCE: NDGAQIAKVGQIFAAWKLLGYDR*# ...# >RAT23109# MHC MOLECULE: RT1, CLASS-2, (RAT Lewis)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine aggrecan G1 domain# ANCHOR POSITIONS: ?# REFERENCES: zhang97a# COMMENT:# SUMMARY: RT1,actyesu,bindyesu,RVLLGSSLTIPCYFIDPMHPVTTAPS*# SEQUENCE: RVLLGSSLTIPCYFIDPMHPVTTAPS*# ...# >RAT2310A# MHC MOLECULE: RTn, CLASS-2, (RAT BN)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine link protein# DB REFERENCE: SWISS: (PLK_BOVIN,PLK_BOVIN)# ANCHOR POSITIONS: ?# REFERENCES: zhang97a# COMMENT:# SUMMARY: RTn,actyesu,bindyesu,PRRRCSPSEAAVRFVGFPDKKHKLY*# SEQUENCE: PRRRCSPSEAAVRFVGFPDKKHKLY*# ...# >MUS2310B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (112-124)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH)# ANCHOR POSITIONS: ?# REFERENCES: adorini93a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,RNRCKGTDVQAWI*# SEQUENCE: RNRCKGTDVQAWI*# ...# >MUS2310C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Reference/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (1-18)# ANCHOR POSITIONS: ?# REFERENCES: adorini93a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,KVFGRCELMAMKRHGLD*# SEQUENCE: KVFGRCELMAMKRHGLD*# ...# >MUS2310D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (108-116)# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_SYRRE,LYC_PAVCR,LYC_CHICK,LYC_CHRAM,# & LYC_MELGA,LYC3_ANAPL,LYC_COLVI,LYC_COTJA,LYC_CHICK,# & LYC_LOPCA)# & PIR1: (LZQJE,LZCH,LZTK,LZQJEC,LZDK3)# & PIR2: (JU0237,JQ1041,JT0526,JQ1033)# ANCHOR POSITIONS: ?# REFERENCES: adorini93a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,WVAWRNRCK*# SEQUENCE: WVAWRNRCK*# ...# >MUS2310E# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (116-129)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZCH)# ANCHOR POSITIONS: ?# REFERENCES: adorini93a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,KGTDVQAWIRGCRL*# SEQUENCE: KGTDVQAWIRGCRL*# ...# >MUS2310F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (108-116)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_PAVCR,LYC3_ANAPL,LYC_COTJA,LYC_CHRAM,# & LYC_SYRRE,LYC_LOPLE,LYC_COLVI,LYC_MELGA,LYC_CHICK,# & LYC_CHICK)# & PIR1: (LZQJE,LZQJEC,LZCH,LZDK3,LZTK)# & PIR2: (JQ1033,JT0526,JU0237,JQ1041)# ANCHOR POSITIONS: ?# REFERENCES: adorini93a,guery92a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,WVAWRNRCK*# SEQUENCE: WVAWRNRCK*# ...# >MUS13110# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays/Stabilization# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: SV (206-214)# DB REFERENCE: SWISS: (TALA_SV40)# & PIR1: (TVVPT4)# ANCHOR POSITIONS: ?# REFERENCES: alsheikly94a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesl,SAINNYAQK*# SEQUENCE: SAINNYAQK*# ...# >MUS13111# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays/Stabilization# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: SV (492-500)# DB REFERENCE: SWISS: (TALA_SV40,TALA_POVHA)# & PIR1: (TVVPTH,TVVPT4)# & PIR3: (PH1378,PH1377)# ANCHOR POSITIONS: ?# REFERENCES: alsheikly94a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesm,NNLDNLRDY*# SEQUENCE: NNLDNLRDY*# ...# >RAT23112# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (91-100)# DB REFERENCE: SWISS: (CH60_MYCFO,CH60_MYCPH,CH60_MYCPA,CH60_MYCAV,CH62_STRAL,# & CH61_STRAL,CH60_MYCPA,CH60_MYCPV,CH61_STRCO,CH60_MYCFA,# & CH60_MYCIT,CH60_MYCVA,CH62_MYCTU,CH60_MYCRH,CH60_MYCTU,# & CH60_MYCAG,CH60_MYCCI)# & PIR2: (B41325,C41325,A26950,S05293,S05292,S05294,S05295,S37566,# & A43509,S40245)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesl,bindyesu,DGTTTATVLAQALVR*# SEQUENCE: DGTTTATVLAQALVR*# ...# >RAT23113# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (176-190)# DB REFERENCE: SWISS: (CH60_MYCCH,CH60_MYCTU,CH60_MYCFO,CH60_MYCPA,CH60_MYCAV,# & CH60_MYCPA,CH62_MYCLE,CH62_MYCTU,CH60_MYCMR)# & PIR2: (A26950,A43509,A25902,S40245)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesh,bindyesu,EESNTFGLQLELTEG*# SEQUENCE: EESNTFGLQLELTEG*# ...# >RAT23114# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (216-225)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU)# & PIR2: (A43509,A26950)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesh,bindyesu,AVLEDPYILLVSSKV*# SEQUENCE: AVLEDPYILLVSSKV*# ...# >RAT23115# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (226-235)# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCTU)# & PIR2: (A43509,A26950)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesh,bindyesu,STVKDLLPLLEKVIG*# SEQUENCE: STVKDLLPLLEKVIG*# ...# >RAT23116# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (256-265)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_MYCLE,CH60_MYCTU,CH60_MYCPA,CH62_STRAL,# & CH62_MYCTU)# & PIR2: (A26950,S40245,C41325,A43509,A25902)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesl,bindyesu,ALSTLVVNKIRGTFK*# SEQUENCE: ALSTLVVNKIRGTFK*# ...# >RAT23117# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (386-400)# DB REFERENCE: SWISS: (CH60_MYCPA,CH62_STRAL,CH60_MYCTU,CH62_MYCLE,CH60_MYCPA,# & CH62_MYCTU)# & PIR2: (C41325,A25902,A26950,A43509,S40245)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesl,bindyesu,ELKERKHRIEDAVRN*# SEQUENCE: ELKERKHRIEDAVRN*# ...# >RAT23118# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (396-405)# DB REFERENCE: SWISS: (CH62_MYCTU,CH60_MYCTU,CH60_MYCPA,CH62_STRAL,CH60_MYCPA,# & CH62_MYCLE)# & PIR2: (S40245,A25902,C41325,A43509,A26950)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesl,bindyesu,DAVRNAKAAVEEGIV*# SEQUENCE: DAVRNAKAAVEEGIV*# ...# >RAT23119# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (446-455)# DB REFERENCE: SWISS: (CH60_MYCTU,CH62_MYCTU)# & PIR2: (A26950,A43509)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesl,bindyesu,APLKQIAFNSGLEPG*# SEQUENCE: APLKQIAFNSGLEPG*# ...# >RAT2311A# MHC MOLECULE: RT1.Bl, CLASS-2, (RAT Lewis)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis Mt hsp65 (511-520)# ANCHOR POSITIONS: ?# REFERENCES: anderton94a# COMMENT:# SUMMARY: RT1.Bl,actyesl,bindyesu,FLTTEAVVADKPERE*# SEQUENCE: FLTTEAVVADKPERE*# ...# >MUS2311B# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (283-297)# DB REFERENCE: SWISS: (CA11_MOUSE,CA11_HUMAN,CA11_HUMAN,CA12_HUMAN,CA11_RAT,# & CA12_MOUSE,CA12_BOVIN,CA12_BOVIN,CA12_HUMAN,# & CA11_CHICK)# & PIR1: (CGHU1S,CGHU6C,CGBO6C,CGCH1S,CGRT1S)# & PIR2: (S21626,B41182,B40333,A40333,A41182)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,GPAGEEGKRGARGEP*# SEQUENCE: GPAGEEGKRGARGEP*# ...# >MUS2311C# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (286-300)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN,CA12_MOUSE)# & PIR1: (CGBO6C)# & PIR2: (B41182,A41182)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,GEEGKRGARGEPGGA*# SEQUENCE: GEEGKRGARGEPGGA*# ...# >MUS2311D# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (289-303)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,GKRGARGEPGGAGPA*# SEQUENCE: GKRGARGEPGGAGPA*# ...# >MUS2311E# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (252-266)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,KGQTGEPGIAGFKGE*# SEQUENCE: KGQTGEPGIAGFKGE*# ...# >MUS2311F# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (253-267)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,GQTGEPGIAGFKGEQ*# SEQUENCE: GQTGEPGIAGFKGEQ*# ...# >MUS23120# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (254-268)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,QTGEPGIAGFKGEQG*# SEQUENCE: QTGEPGIAGFKGEQG*# ...# >MUS23121# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (255-269)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,TGEPGIAGFKGEQGP*# SEQUENCE: TGEPGIAGFKGEQGP*# ...# >MUS23122# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (256-270)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,GEPGIAGFKGEQGPK*# SEQUENCE: GEPGIAGFKGEQGPK*# ...# >MUS23123# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (257-271)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,EPGIAGFKGEQGPKG*# SEQUENCE: EPGIAGFKGEQGPKG*# ...# >MUS23124# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (258-272)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_BOVIN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGHU6C,CGBO6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,PGIAGFKGEQGPKGE*# SEQUENCE: PGIAGFKGEQGPKGE*# ...# >MUS23125# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (259-273)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,GIAGFKGEQGPKGEP*# SEQUENCE: GIAGFKGEQGPKGEP*# ...# >MUS23126# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (260-274)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_HUMAN,CA12_BOVIN)# & PIR1: (CGHU6C,CGBO6C)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKGEQGPKGEPG*# SEQUENCE: IAGFKGEQGPKGEPG*# ...# >MUS23127# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (259-268)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_BOVIN,CA12_HUMAN,CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,GIAGFKGEQG*# SEQUENCE: GIAGFKGEQG*# ...# >MUS23128# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (259-267)# DB REFERENCE: SWISS: (CA12_HUMAN,CA12_HUMAN,CA12_BOVIN,CA12_BOVIN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,GIAGFKGEQ*# SEQUENCE: GIAGFKGEQ*# ...# >MUS23129# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (260-267)# DB REFERENCE: SWISS: (CA12_BOVIN,CA12_HUMAN,CA12_BOVIN,CA12_HUMAN)# & PIR1: (CGBO6C,CGHU6C)# & PIR2: (I60384)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKGEQ*# SEQUENCE: IAGFKGEQ*# ...# >MUS2312A# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: bovine collagen CII (260-267)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesl,bindyesu,AAGFKGEQ*# SEQUENCE: AAGFKGEQ*# ...# >MUS2312B# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (260-267)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IGGFKGEQ*# SEQUENCE: IGGFKGEQ*# ...# >MUS2312C# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: bovine collagen CII (260-267)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesl,bindyesu,IAAFKGEQ*# SEQUENCE: IAAFKGEQ*# ...# >MUS2312D# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: bovine collagen CII (260-267)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesl,bindyesu,IAGAKGEQ*# SEQUENCE: IAGAKGEQ*# ...# >MUS2312E# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: bovine collagen CII (260-267)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesl,bindyesu,IAGFAGEQ*# SEQUENCE: IAGFAGEQ*# ...# >MUS2312F# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (260-267)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKAEQ*# SEQUENCE: IAGFKAEQ*# ...# >MUS23130# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: bovine collagen CII (260-267)# ANCHOR POSITIONS: ?# REFERENCES: brand94a# COMMENT:# SUMMARY: I-Aq,actyesu,bindyesu,IAGFKGEA*# SEQUENCE: IAGFKGEA*# ...# >MUS23131# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Elution/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HA (110-120)# DB REFERENCE: SWISS: (HEMA_IALEN,HEMA_IAXIA,HEMA_IAKIE,HEMA_IATAI,HEMA_IAPUE,# & HEMA_IACAO,HEMA_IAUSS,HEMA_IAHAR)# & PIR1: (HMIVTA,HMIV,HMIVUR)# & PIR2: (JQ2370,JQ1643,PQ0321,A35788,JQ1437,PQ0319,JQ2372,# & JQ2371)# ANCHOR POSITIONS: ?# REFERENCES: brumenau93a,zaghouani93a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,SFERFEIFPKE*# SEQUENCE: SFERFEIFPKE*# ...# >MUS23132# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HA (110-117)# DB REFERENCE: SWISS: (HEMA_IAZIN,HEMA_IATAI,HEMA_IAHAR,HEMA_IAZNJ,HEMA_IALEN,# & HEMA_IAKIE,HEMA_IAXIA,HEMA_IAUSS,HEMA_IACAO,# & HEMA_IAPUE)# & PIR1: (HMIVTA,HMIV,HMIVUR,HMIVN1,HMIV17)# & PIR2: (A35788,PQ0321,JQ2372,JQ2370,PQ0319,JQ1437,JQ1643,# & JQ2371)# & PIR3: (S69886,S69889,S69888)# ANCHOR POSITIONS: ?# REFERENCES: brumenau93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,SFERFEIF*# SEQUENCE: SFERFEIF*# ...# >MUS23133# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: brumenau93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,XKPNAAEDPGLAXQAAK*# SEQUENCE: XKPNAAEDPGLAXQAAK*# ...# >MUS23134# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: BSA# ANCHOR POSITIONS: ?# REFERENCES: brumenau93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,VDEPQNLIKQNXDQFEKLG*# SEQUENCE: VDEPQNLIKQNXDQFEKLG*# ...# >MUS23135# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: brumenau93a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,XRPNAGEDPGLARQAPK*# SEQUENCE: XRPNAGEDPGLARQAPK*# ...# >MUS23136# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Vesicular stomatitis virus VSV-Ind (52-71)# DB REFERENCE: SWISS: (VGLG_VSVIG)# ANCHOR POSITIONS: ?# REFERENCES: burkhart94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,LIGTGLQVKMPKSHKAIQAD*# SEQUENCE: LIGTGLQVKMPKSHKAIQAD*# ...# >MUS23137# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Vesicular stomatitis virus VSV-Ind (316-335)# DB REFERENCE: SWISS: (VGLG_VSVSJ,VGLG_VSVIG)# & PIR1: (VGVN)# ANCHOR POSITIONS: ?# REFERENCES: burkhart94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,VDLSYLAPKNPGTGPAFTII*# SEQUENCE: VDLSYLAPKNPGTGPAFTII*# ...# >MUS23138# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Vesicular stomatitis virus VSV-Ind (415-433)# DB REFERENCE: SWISS: (VGLG_VSVSJ,VGLG_VSVIG,VGLG_VSVO)# & PIR1: (VGVN)# ANCHOR POSITIONS: ?# REFERENCES: burkhart94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,SSKAQVFEHPHIQDAASQL*# SEQUENCE: SSKAQVFEHPHIQDAASQL*# ...# >MUS23139# MHC MOLECULE: I-A?, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: I-E alpha chain# DB REFERENCE: SWISS: (HA23_MOUSE,HA21_MOUSE,HA21_MOUSE,HA22_MOUSE,# & HA2R_HUMAN)# & PIR1: (HLHUDA,HLMSEA,HLMSED)# & PIR2: (S06316,I56085,I55971,I72480,I54426,A46505)# ANCHOR POSITIONS: ?# REFERENCES: burroughs92a# COMMENT:# SUMMARY: I-A?,actunkn,bindyesu,ASFEAQGALANIAVDKA# SEQUENCE: ASFEAQGALANIAVDKA*# ...# >MUS1313A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. yoelli CS (280-288)# ANCHOR POSITIONS: 2,9# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,SYVPSAEKI*# SEQUENCE: SYVPSAEKI*# ...# >MUS1313B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza HA (202-212)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# ANCHOR POSITIONS: 2,9# REFERENCES: eberl93a,maryanski91a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,RTLYQNVGTYV*# SEQUENCE: RTLYQNVGTYV*# ...# >MUS1313C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza HA (211-221)# DB REFERENCE: SWISS: (HEMA_IAJAP)# & PIR1: (HMIV2)# & PIR2: (PL0161)# ANCHOR POSITIONS: ?# REFERENCES: eberl93a,maryanski91a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,YVSVGTSTLNK*# SEQUENCE: YVSVGTSTLNK*# ...# >MUS1313D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza HA (535-545)# ANCHOR POSITIONS: ?# REFERENCES: eberl93a,maryanski91a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,VYQILAIYATVAGSLSLIAMMAG*# SEQUENCE: VYQILAIYATVAGSLSLIAMMAG*# ...# >MUS1313E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Listeria monocytogenes listeriolysin O LLO (91-99)# DB REFERENCE: SWISS: (TACY_LISMO)# & PIR2: (A43505,S24231)# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesu,GYKDGNEYIV*# SEQUENCE: GYKDGNEYIV*# ...# >MUS1313F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference/CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: P91 A (12-20) homologue# ANCHOR POSITIONS: 2,9# REFERENCES: eberl93a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesu,IYTQNRRAL*# SEQUENCE: IYTQNRRAL*# ...# >MUS13140# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. berghei CS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,YIPNAEKI*# SEQUENCE: YIPNAEKI*# ...# >MUS13141# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. berghei CS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,YIPLAEKI*# SEQUENCE: YIPLAEKI*# ...# >MUS13142# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. berghei CS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,YIPAAEKI*# SEQUENCE: YIPAAEKI*# ...# >MUS13143# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. berghei CS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YIPVAEKI*# SEQUENCE: YIPVAEKI*# ...# >MUS13144# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. berghei CS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YIPQAEKI*# SEQUENCE: YIPQAEKI*# ...# >MUS13145# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. berghei CS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YIPIAEKI*# SEQUENCE: YIPIAEKI*# ...# >MUS13146# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. berghei CS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YIPDAEKI*# SEQUENCE: YIPDAEKI*# ...# >MUS13147# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. berghei CS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,YIPFAEKI*# SEQUENCE: YIPFAEKI*# ...# >MUS13148# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,SYIPNAEKI*# SEQUENCE: SYIPNAEKI*# ...# >MUS13149# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,SYIPAAEKI*# SEQUENCE: SYIPAAEKI*# ...# >MUS1314A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,SYIPLAEKI*# SEQUENCE: SYIPLAEKI*# ...# >MUS1314B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,SYIPIAEKI*# SEQUENCE: SYIPIAEKI*# ...# >MUS1314C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,SYIPDAEKI*# SEQUENCE: SYIPDAEKI*# ...# >MUS1314D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,SYIPQAEKI*# SEQUENCE: SYIPQAEKI*# ...# >MUS1314E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,SYIPFAEKI*# SEQUENCE: SYIPFAEKI*# ...# >MUS1314F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,SYIPEAEKI*# SEQUENCE: SYIPEAEKI*# ...# >MUS13150# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P. berghei CS (252-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,SYIPKAEKI*# SEQUENCE: SYIPKAEKI*# ...# >MUS13151# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza NP (147-155) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,TYQRNRALV*# SEQUENCE: TYQRNRALV*# ...# >MUS13152# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza NP (147-155) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,TYQRARALV*# SEQUENCE: TYQRARALV*# ...# >MUS13153# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza NP (147-155) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,TYQRERALV*# SEQUENCE: TYQRERALV*# ...# >MUS13154# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza NP (147-155) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,TYQRFRALV*# SEQUENCE: TYQRFRALV*# ...# >MUS13155# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HLA-Cw3 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RYLKAGKETL*# SEQUENCE: RYLKAGKETL*# ...# >MUS13156# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HLA-Cw3 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: eberl93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYLKEGKETL*# SEQUENCE: RYLKEGKETL*# ...# >MUS13157# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Reference/Stabilization/Competition# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: LCMV GP (33-41)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a,martin96a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesm,KAVYNFATM*# SEQUENCE: KAVYNFATM*# ...# >MUS13158# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE5_HPV16)# & PIR1: (W5WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesm,IIFVYIPL*# SEQUENCE: IIFVYIPL*# ...# >MUS13159# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (P53_MOUSE,P53_RAT,P53_MOUSE,P53_RAT)# & PIR1: (DNMS53)# & PIR2: (S38824,JC6193,S02192)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,AIYKKSQHM*# SEQUENCE: AIYKKSQHM*# ...# >MUS1315A# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (P53_MOUSE,P53_MOUSE)# & PIR1: (DNMS53)# & PIR2: (S38824)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,VMCTYSPPL*# SEQUENCE: VMCTYSPPL*# ...# >MUS1315B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VE6_HPV16)# & PIR1: (W6WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,EVYDFAFRDL*# SEQUENCE: EVYDFAFRDL*# ...# >MUS1315C# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (GAG_MSVFR,GAG_MLVRD,GAG_MLVAV,GAG_FRSFV)# & PIR1: (FOMVGV,FOVW5S,A40831,FOMVRV,FOMVFB)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,RSALYPAL*# SEQUENCE: RSALYPAL*# ...# >MUS1315D# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (ENV_MLVCB,ENV_MLVFP,ENV_MLVMO,ENV_MCFF,ENV_MSVFB,# & ENV_MLVFF,ENV_MLVKI,ENV_MLVF5,ENV_MCFF3,ENV_MLVAV,# & ENV_RMCFV)# & PIR1: (VCMVRV,VCVWEK,VCVWM1,VCMVCB,VCVWEM,VCVWFS,VCVWM2,# & VCMVPV)# & PIR2: (A03986,A43491,A46511,A03985,B43491,S22805)# & PIR3: (S70395)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,ATQQFQQL*# SEQUENCE: ATQQFQQL*# ...# >MUS1315E# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (E1BL_ADE12)# & PIR1: (ERAD24)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,YKYSFEQL*# SEQUENCE: YKYSFEQL*# ...# >MUS1315F# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE12_HPV16)# & PIR1: (W1WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,WPYLHNRL*# SEQUENCE: WPYLHNRL*# ...# >MUS13160# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE5_HPV16)# & PIR1: (W5WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,SVSTYTSL*# SEQUENCE: SVSTYTSL*# ...# >MUS13161# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (E1BL_ADE12)# & PIR1: (ERAD24)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,AIKAFAKL*# SEQUENCE: AIKAFAKL*# ...# >MUS13162# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (ENV_MLVRD,ENV_FENV1,ENV_RMCFV,ENV_MCFF,ENV_MSVFB,# & ENV_MLVFP,ENV_MLVMO,ENV_MLVCB,ENV_MCFF3,ENV_MLVAV,# & ENV_MLVHO,ENV_MLVF5,ENV_MLVFF,ENV_MLVRK,ENV_MLVKI,# & ENV2_MOUSE)# & PIR1: (VCVWM1,VCVWEK,VCMVRV,VCVWEM,VCVWM2,VCMVKA,VCVWFS,VCMVVR,# & VCMVCE,VCMVPV,VCMVHL,VCMVCB)# & PIR2: (B43491,A03985,S22805,S15464,A43491,A46511,A25483,# & A03986)# & PIR3: (S70395)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,LTQQYHQL*# SEQUENCE: LTQQYHQL*# ...# >MUS13163# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL assays# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: HPV16 E1 (590-583)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesl,NPFTFVVL*# SEQUENCE: NPFTFVVL*# ...# >MUS13164# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (VE4_HPV16)# & PIR1: (W4WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,AATKYPLL*# SEQUENCE: AATKYPLL*# ...# >MUS13165# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,ENAAFVLL*# SEQUENCE: ENAAFVLL*# ...# >MUS13166# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (CD20_MOUSE,CD20_MOUSE)# & PIR2: (A30558)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,ISAFFQKL*# SEQUENCE: ISAFFQKL*# ...# >MUS13167# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,VALLIRPLLL*# SEQUENCE: VALLIRPLLL*# ...# >MUS13168# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (ENV_MLVRD,ENV_MLVRK,ENV_MLVAV)# & PIR1: (VCMVKA,VCMVVR,VCVWEK)# & PIR2: (S22805,B43491,A46511,A43491)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,PSYVYHQF*# SEQUENCE: PSYVYHQF*# ...# >MUS13169# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (KACA_RAT,KAC_MOUSE,KACB_RAT)# & PIR1: (K1RTB,K1RTA,K1MS)# & PIR2: (S37484,S68241,S06084,S38865,S16112,S52028,S14237,S42772,# & I54782,PC4203,S01320,JL0029,A56169,A31790)# & PIR3: (S25058)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,STYSMSSTL*# SEQUENCE: STYSMSSTL*# ...# >MUS1316A# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (E1BL_ADE05)# & PIR1: (Q1AD55)# & PIR2: (S77553)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,VAELYPEL*# SEQUENCE: VAELYPEL*# ...# >MUS1316B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (CD19_MOUSE,CD19_HUMAN,CD19_CAVPO)# & PIR2: (I48142,I49580,B45808,A44441)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,ILYAAPQL*# SEQUENCE: ILYAAPQL*# ...# >MUS1316C# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (VE12_HPV16)# & PIR1: (W1WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,RTWSRLSL*# SEQUENCE: RTWSRLSL*# ...# >MUS1316D# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (GAG_MLVDU,GAG_MLVCB,GAG_MLVHO,GAG_MLVRD,GAG_MLVBM,# & GAG_MLVDE,GAG_MLVAV)# & PIR1: (FOMVHL,FOMVGV,FOMVMB,FOMVME,FOMVDU,FOMVRV)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,HLVLYRQL*# SEQUENCE: HLVLYRQL*# ...# >MUS1316E# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (P53_MOUSE,P53_FELCA,P53_MOUSE,P53_FELCA)# & PIR1: (DNMS53)# & PIR2: (S38824)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,TYSPPLNKL*# SEQUENCE: TYSPPLNKL*# ...# >MUS1316F# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,LTTDYAVL*# SEQUENCE: LTTDYAVL*# ...# >MUS13170# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (RASN_MOUSE,RASN_MOUSE)# & PIR1: (TVMSNS)# & PIR2: (S02054)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,RQYRLKKL*# SEQUENCE: RQYRLKKL*# ...# >MUS13171# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,SAPANASVA*# SEQUENCE: SAPANASVA*# ...# >MUS13172# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,SAINNAQKL*# SEQUENCE: SAINNAQKL*# ...# >MUS13173# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,VNIRCCYI*# SEQUENCE: VNIRCCYI*# ...# >MUS13174# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (CD20_MOUSE,CD20_MOUSE)# & PIR2: (A30558)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,SQPKNEEEI*# SEQUENCE: SQPKNEEEI*# ...# >MUS13175# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VE2_HPV16)# & PIR1: (W2WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,FKHINHQVV*# SEQUENCE: FKHINHQVV*# ...# >MUS13176# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (RAS_CARAU,RASH_MSV,RASH_CHICK,RASH_HUMAN,RASK_MELGA,# & RASH_HUMAN,RASL_HUMAN,RASK_MOUSE,RASH_RAT,RASK_RAT,# & RASL_MOUSE,RASH_RAT,RASK_MSVKI,RASH_MSVNS,RASK_MSVKI,# & RASK_HUMAN,RASH_MOUSE,RASK_MONDO,RASH_RRASV,RASH_MSVHA,# & RASL_RAT,RASL_MOUSE,RASH_MESAU,RASK_RAT,RASH_MSVHA,# & RASL_HUMAN,RASL_RAT)# & PIR1: (TVHU2K,TVHUK,TVMV3H,TVHUH,TVMVNS,TVMSK,TVMVB,TVCHRS,# & TVMVRS,TVMV2K)# & PIR2: (I59431,A25229,S57718,S31720,JC5154,I80324,I58402,A43816,# & I51971,A37355,A54321,I52205,S05483,S34138)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,FAINNTKSF*# SEQUENCE: FAINNTKSF*# ...# >MUS13177# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (RASN_MOUSE,RASN_HUMAN,RASN_RAT,RASN_MOUSE,RASN_HUMAN,# & RASN_CAVPO)# & PIR1: (TVHURA,TVMSNS,TVGPRS,TVGPRT)# & PIR2: (S02054,A48088,I38149,S26621)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,FAINNSKSF*# SEQUENCE: FAINNSKSF*# ...# >MUS13178# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (ENV_MLVAV)# & PIR1: (VCVWEK)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,LGGVNPVTL*# SEQUENCE: LGGVNPVTL*# ...# >MUS13179# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (GAG_MLVAV,GAG_MSVMO,GAG_MLVFP,GAG_MLVRD,GAG_MLVDU,# & GAG_MLVCB,GAG_MLVFF,GAG_MSVMT,GAG_MLVHO,GAG_MLVBM,# & GAG_MLVDE,GAG_MLVMO,GAG_MLVF5)# & PIR1: (FOMVDU,FOMVME,FOMVGV,FOMVHL,FOMVMB,FOMVM,FOMV1M,FOMVRV,# & FOMVMU)# & PIR2: (A46311)# & PIR3: (S70394,S35474)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,RSPTNLAKV*# SEQUENCE: RSPTNLAKV*# ...# >MUS1317A# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (CD2R_HUMAN,CD20_HUMAN)# & PIR1: (A30586)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,SQPKNEEDI*# SEQUENCE: SQPKNEEDI*# ...# >MUS1317B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (VE2_HPV16,VE2_HPV52)# & PIR1: (W2WLHS)# & PIR2: (S36576)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,GQVDYYGL*# SEQUENCE: GQVDYYGL*# ...# >MUS1317C# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# DB REFERENCE: SWISS: (VE2_HPV16)# & PIR1: (W2WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,THTKAVAL*# SEQUENCE: THTKAVAL*# ...# >MUS1317D# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VE12_HPV16)# & PIR1: (W1WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,FTFPNEFPF*# SEQUENCE: FTFPNEFPF*# ...# >MUS1317E# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VE2_HPV35,VE2_HPV16)# & PIR1: (W2WLHS,W2WL35)# & PIR2: (S36524)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,MHYTNWTHI*# SEQUENCE: MHYTNWTHI*# ...# >MUS1317F# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# DB REFERENCE: SWISS: (VE2_HPV16)# & PIR1: (W2WLHS)# ANCHOR POSITIONS: ?# REFERENCES: feltkamp94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,SQYSNEKWTL*# SEQUENCE: SQYSNEKWTL*# ...# >MUS13180# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VSV nucleoprotein (52-59) homologue# ANCHOR POSITIONS: ?# REFERENCES: hogquist93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,RGIVYQGL*# SEQUENCE: RGIVYQGL*# ...# >MUS13181# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, ?# SOURCE: VSV nucleoprotein (52-59) homologue# ANCHOR POSITIONS: ?# REFERENCES: hogquist93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,SGIVYQGL*# SEQUENCE: SGIVYQGL*# ...# >MUS13182# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Histone H2B (39-46)# DB REFERENCE: SWISS: (H2B_HUMAN,H2B_RAT,H2B2_MOUSE,H2B1_MOUSE)# & PIR1: (HSBO22,HSHUB2)# & PIR2: (S26185,I48375,I48401,A37363,F40335,E40335)# & PIR3: (B45945)# ANCHOR POSITIONS: ?# REFERENCES: hogquist93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,SVYVYKVL*# SEQUENCE: SVYVYKVL*# ...# >MUS13183# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Primase p49 (249-304)# DB REFERENCE: SWISS: (PRI1_MOUSE,PRI1_HUMAN)# & PIR2: (D46642,S45630,A33269)# ANCHOR POSITIONS: ?# REFERENCES: hogquist93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesu,LQYCFPRL*# SEQUENCE: LQYCFPRL*# ...# >MUS13184# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: VSV-7# DB REFERENCE: SWISS: (NCAP_VSVIG,NCAP_VSVSJ)# & PIR1: (VHVNV4,VHVNN)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,GYVYQGL*# SEQUENCE: GYVYQGL*# ...# >MUS13185# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: VSV-9N# DB REFERENCE: SWISS: (NCAP_VSVIG,NCAP_VSVSJ)# & PIR1: (VHVNV4,VHVNN)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,LRGYVYQGL*# SEQUENCE: LRGYVYQGL*# ...# >MUS13186# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: VSV-10N# DB REFERENCE: SWISS: (NCAP_VSVIG,NCAP_VSVSJ)# & PIR1: (VHVNN,VHVNV4)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,DLRGYVYQGL*# SEQUENCE: DLRGYVYQGL*# ...# >MUS13187# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: VSV-9C# DB REFERENCE: SWISS: (NCAP_VSVSJ,NCAP_VSVIG)# & PIR1: (VHVNV4,VHVNN)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RGYVYQGLK*# SEQUENCE: RGYVYQGLK*# ...# >MUS13188# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: VSV-10C# DB REFERENCE: SWISS: (NCAP_VSVIG,NCAP_VSVSJ)# & PIR1: (VHVNN,VHVNV4)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RGYVYQGLKS*# SEQUENCE: RGYVYQGLKS*# ...# >MUS13189# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA-9N# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,LSIINFEKL*# SEQUENCE: LSIINFEKL*# ...# >MUS1318A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: OVA-10N# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,LESIINFEKL*# SEQUENCE: LESIINFEKL*# ...# >MUS1318B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: OVA-9C# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,SIINFEKLT*# SEQUENCE: SIINFEKLT*# ...# >MUS1318C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: OVA-10C# DB REFERENCE: SWISS: (OVAL_CHICK,OVAL_CHICK)# & PIR1: (OACH)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,SIINFEKLTE*# SEQUENCE: SIINFEKLTE*# ...# >MUS1318D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: SEV-9# DB REFERENCE: SWISS: (NCAP_SENDF,NCAP_PI1HA,NCAP_SENDE,NCAP_PI1HC,NCAP_PI1HW,# & NCAP_SEND5,NCAP_SENDZ,NCAP_PI3B)# & PIR1: (VHNZSV,VHNZP1,VHNZB3,A48341,VHNZT1)# & PIR2: (S72316,S72317,S13778)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,FAPGNYPAL*# SEQUENCE: FAPGNYPAL*# ...# >MUS1318E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P1# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,AKYQAVTTTL*# SEQUENCE: AKYQAVTTTL*# ...# >MUS1318F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV Pol# DB REFERENCE: SWISS: (POL_HV1EL,POL_HV1Y2,POL_HV1RH,POL_HV1N5,POL_HV1ND,# & POL_HV1MA,POL_HV1MN,POL_HV1PV,POL_HV1Z2,POL_HV1BR,# & POL_HV1B1,POL_HV1B5,POL_HV1JR,POL_HV1OY,POL_HV1H2)# & PIR1: (GNVWLV,B44001,GNLJND,GNVWH3,GNVWVL)# & PIR2: (S54378,B47175)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,ILKEPVHGV*# SEQUENCE: ILKEPVHGV*# ...# >MUS13190# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Histone H3# DB REFERENCE: SWISS: (H32_XENLA,H3_STRPU,H33_SCHPO,H33_HUMAN,H3_ENCAL,# & H31_HUMAN,H3_PSAMI,H3_DROME,H3_EMENI,H3_CAEEL,H3_ACRFO,# & H3_NEUCR,H3_PSAMI,YB21_CAEEL,H31_SCHPO,H33_CAEEL,# & H32_BOVIN)# & PIR1: (HSUR3M,HSZP3,HSFI3,HSXL31,HSHU3,HSXL32,HSHU33,HSKW3,# & HSRK3,HSTR3,HSUR3P,HSBO3,HSCH3,HSEAH3)# & PIR2: (A02630,S01197,I48092,S11315,S06755,I50245,JQ1343,JS0690,# & JQ1984,I51448,S09655,S32621,S06743,S04186,S61220,JQ1983,# & S10168,I49398,S20678,A56580,S61215,JQ0757,S32638,I50460,# & JH0304,S07350,S57473,A56654,A56618,S10097,S50140,S20669,# & S61218,I49395,S01198,S01196,S34185,JN0687,S20109,I50244,# & I49397,S61214,I57019)# & PIR3: (S42066,S11938,A45941,S42065)# ANCHOR POSITIONS: ?# REFERENCES: jackson93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RRYQKSTEL*# SEQUENCE: RRYQKSTEL*# ...# >MUS13191# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KQNPIAHQL*# SEQUENCE: KQNPIAHQL*# ...# >MUS13192# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,ALAELPHEI*# SEQUENCE: ALAELPHEI*# ...# >MUS13193# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KQNPTVHHL*# SEQUENCE: KQNPTVHHL*# ...# >MUS13194# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,AGLLGMRSGL*# SEQUENCE: AGLLGMRSGL*# ...# >MUS13195# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KLIKVYHSL*# SEQUENCE: KLIKVYHSL*# ...# >MUS13196# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,VQNXTMHPI*# SEQUENCE: VQNXTMHPI*# ...# >MUS13197# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,RSNGQVHML*# SEQUENCE: RSNGQVHML*# ...# >MUS13198# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Cofilin# DB REFERENCE: SWISS: (COF1_MOUSE,COF1_HUMAN,COF1_PIG,COF1_PIG,COF1_RAT,# & COF1_HUMAN)# & PIR1: (A29240,S12584,S12632)# & PIR2: (S49101)# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KLTGIKHEL*# SEQUENCE: KLTGIKHEL*# ...# >MUS13199# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,AMLATYHKL*# SEQUENCE: AMLATYHKL*# ...# >MUS1319A# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,GQLXVXHKL*# SEQUENCE: GQLXVXHKL*# ...# >MUS1319B# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ribosomal L19# DB REFERENCE: SWISS: (RL19_MOUSE,RL19_HUMAN)# & PIR1: (R5RT19)# & PIR2: (A48992,A36554)# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,ILMEHIHKL*# SEQUENCE: ILMEHIHKL*# ...# >MUS1319C# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,AQNPVLYQI*# SEQUENCE: AQNPVLYQI*# ...# >MUS1319D# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,SMIKTVREM*# SEQUENCE: SMIKTVREM*# ...# >MUS1319E# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KLLPVEHNL*# SEQUENCE: KLLPVEHNL*# ...# >MUS1319F# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,KQLIVTYHL*# SEQUENCE: KQLIVTYHL*# ...# >MUS131A0# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,SVLDDLALL*# SEQUENCE: SVLDDLALL*# ...# >MUS131A1# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,YESPLMXFL*# SEQUENCE: YESPLMXFL*# ...# >MUS131A2# MHC MOLECULE: H-2Qa-2, CLASS-1, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: joyce94a# COMMENT:# SUMMARY: H-2Qa-2,actunkn,bindyesu,DLLGTLHNL*# SEQUENCE: DLLGTLHNL*# ...# >MUS131A3# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, little# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,CPHFMPTNL*# SEQUENCE: CPHFMPTNL*# ...# >MUS131A4# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YPHCMPTNL*# SEQUENCE: YPHCMPTNL*# ...# >MUS131A5# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,YPHFCPTNL*# SEQUENCE: YPHFCPTNL*# ...# >MUS131A6# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YPHFMCTNL*# SEQUENCE: YPHFMCTNL*# ...# >MUS131A7# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YPHFMPCNL*# SEQUENCE: YPHFMPCNL*# ...# >MUS131A8# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YPHFMPTCL*# SEQUENCE: YPHFMPTCL*# ...# >MUS131A9# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, high# SOURCE: OVA (257-264) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,SIICFEKL*# SEQUENCE: SIICFEKL*# ...# >HUM131AA# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, little# SOURCE: HIV-1 gp160 (318-327) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesl,RGPGRAFCTI*# SEQUENCE: RGPGRAFCTI*# ...# >MUS131AB# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, high# SOURCE: HIV-1 gp160 (318-327) homologue# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesh,RGPGRAFCTI*# SEQUENCE: RGPGRAFCTI*# ...# >HUM131AC# MHC MOLECULE: HLA-A2, CLASS-1, (HUMAN)# METHOD: Plasmon res.# ACTIVITY: ?# BINDING: yes, high# SOURCE: IP30 signal# ANCHOR POSITIONS: ?# REFERENCES: khilko93a# COMMENT:# SUMMARY: HLA-A2,actunkn,bindyesh,LLDCPTAAV*# SEQUENCE: LLDCPTAAV*# ...# >MUS131AD# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: CTL induction# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MN virus V3 loop (314-323)# DB REFERENCE: SWISS: (ENV_HV1MN,ENV_HV1JR,ENV_HV1J3)# & PIR1: (VCLJMN)# & PIR2: (S35820,S35807,A46410,S35848,S35857,S60549,S35862,D46410,# & S35808,PC2295,A41621,S35815,C41621,S35858,S35821,S35861,# & S35809,S35849,S35819,S35816,S60550,S35859)# & PIR3: (S13289)# ANCHOR POSITIONS: ?# REFERENCES: li93a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,IGPGRAFYTT*# SEQUENCE: IGPGRAFYTT*# ...# >MUS131AE# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization/In vivo response# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: human papilloma virus type 16 E6 protein (50-57) homologue# ANCHOR POSITIONS: ?# REFERENCES: lipford95a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,YIFAFRDL*# SEQUENCE: YIFAFRDL*# ...# >MUS131AF# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: P91 A (12-24)# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,ISTQNHRALDLVA*# SEQUENCE: ISTQNHRALDLVA*# ...# >MUS131B0# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p198 (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,AYQAVTTTLEE*# SEQUENCE: AYQAVTTTLEE*# ...# >MUS131B1# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p198 (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,KYAAVTTTLEE*# SEQUENCE: KYAAVTTTLEE*# ...# >MUS131B2# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: p198 (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesm,KYQAATTTLEE*# SEQUENCE: KYQAATTTLEE*# ...# >MUS131B3# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p198 (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,KYQAVATTLEE*# SEQUENCE: KYQAVATTLEE*# ...# >MUS131B4# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition,CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: p198 (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesm,KYQAVTTALEE*# SEQUENCE: KYQAVTTALEE*# ...# >MUS131B5# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: p198 (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesm,KYQAVTTTAEE*# SEQUENCE: KYQAVTTTAEE*# ...# >MUS131B6# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: p198 (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesm,KYQAVTTTLAE*# SEQUENCE: KYQAVTTTLAE*# ...# >MUS131B7# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: p198 (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesm,KYQAVTTTLEA*# SEQUENCE: KYQAVTTTLEA*# ...# >MUS131B8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YPHFMPTNA*# SEQUENCE: YPHFMPTNA*# ...# >MUS131B9# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,YPHFMPTAL*# SEQUENCE: YPHFMPTAL*# ...# >MUS131BA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YPHFMPANL*# SEQUENCE: YPHFMPANL*# ...# >MUS131BB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YPHFMATNL*# SEQUENCE: YPHFMATNL*# ...# >MUS131BC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YPHFAPTNL*# SEQUENCE: YPHFAPTNL*# ...# >MUS131BD# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YPHAMPTNL*# SEQUENCE: YPHAMPTNL*# ...# >MUS131BE# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,YPAFMPTNL*# SEQUENCE: YPAFMPTNL*# ...# >MUS131BF# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YAHFMPTNL*# SEQUENCE: YAHFMPTNL*# ...# >MUS131C0# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,APHFMPTNL*# SEQUENCE: APHFMPTNL*# ...# >MUS131C1# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RYPHFMPTNL*# SEQUENCE: RYPHFMPTNL*# ...# >MUS131C2# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition/Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,YPHFMPTNA*# SEQUENCE: YPHFMPTNA*# ...# >MUS131C3# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YPHFMPTAL*# SEQUENCE: YPHFMPTAL*# ...# >MUS131C4# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition/Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,YPHFMPANL*# SEQUENCE: YPHFMPANL*# ...# >MUS131C5# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YPHFMATNL*# SEQUENCE: YPHFMATNL*# ...# >MUS131C6# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,YPHFAPTNL*# SEQUENCE: YPHFAPTNL*# ...# >MUS131C7# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YPHAMPTNL*# SEQUENCE: YPHAMPTNL*# ...# >MUS131C8# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a,robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YPAFMPTNL*# SEQUENCE: YPAFMPTNL*# ...# >MUS131C9# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski91a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,RYPHFMPTNL*# SEQUENCE: RYPHFMPTNL*# ...# >MUS131CA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P91A (11-21) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,KYSTQNRRALD*# SEQUENCE: KYSTQNRRALD*# ...# >MUS131CB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/CTL assays# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: P91A (11-21) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,IYTQNRRALDL*# SEQUENCE: IYTQNRRALDL*# ...# >MUS131CC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P91A (11-21) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,SYQNRRALDLV*# SEQUENCE: SYQNRRALDLV*# ...# >MUS131CD# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P91A (11-21) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,TYNRRALDLVA*# SEQUENCE: TYNRRALDLVA*# ...# >MUS131CE# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P91A (13-23) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,SYQNRRALDLV*# SEQUENCE: SYQNRRALDLV*# ...# >MUS131CF# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P91A (14-24) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,TYNRRALDLVA*# SEQUENCE: TYNRRALDLVA*# ...# >MUS131D0# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: P91A (15-25) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,QYRRALDLVAA*# SEQUENCE: QYRRALDLVAA*# ...# >MUS131D1# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P91A (16-26) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,NYRALDLVAAK*# SEQUENCE: NYRALDLVAAK*# ...# >MUS131D2# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,AYLENGKETL*# SEQUENCE: AYLENGKETL*# ...# >MUS131D3# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,RYAENGKETL*# SEQUENCE: RYAENGKETL*# ...# >MUS131D4# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RYLANGKETL*# SEQUENCE: RYLANGKETL*# ...# >MUS131D5# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RYLEAGKETL*# SEQUENCE: RYLEAGKETL*# ...# >MUS131D6# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RYLENAKETL*# SEQUENCE: RYLENAKETL*# ...# >MUS131D7# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RYLENGAETL*# SEQUENCE: RYLENGAETL*# ...# >MUS131D8# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RYLENGKATL*# SEQUENCE: RYLENGKATL*# ...# >MUS131D9# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,RYLENGKEAL*# SEQUENCE: RYLENGKEAL*# ...# >MUS131DA# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: A24 (170-179) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,RYLENGKETA*# SEQUENCE: RYLENGKETA*# ...# >MUS131DB# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: PbCS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,YAPSAEKI*# SEQUENCE: YAPSAEKI*# ...# >MUS131DC# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PbCS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YIASAEKI*# SEQUENCE: YIASAEKI*# ...# >MUS131DD# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PbCS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YIPSAAKI*# SEQUENCE: YIPSAAKI*# ...# >MUS131DE# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: PbCS (253-260) homologue# ANCHOR POSITIONS: ?# REFERENCES: maryanski93a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,YIPSAEAI*# SEQUENCE: YIPSAEAI*# ...# >MUS131DF# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus MT (162-176)# DB REFERENCE: SWISS: (TAMI_POVMA,TASM_POVMA,TAMI_POVMC,TAMI_POVM3)# & PIR1: (TVVPMP,TVVPA,TVVPM)# & PIR2: (S22562,S22561)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,TRDVLNLYADFIASM*# SEQUENCE: TRDVLNLYADFIASM*# ...# >MUS131E0# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: polyoma virus MT (380-395)# DB REFERENCE: SWISS: (TAMI_POVMC,TAMI_POVMA,TAMI_POVM3)# & PIR1: (TVVPMP,TVVPM)# & PIR2: (S22561)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,RAHSMQRHLRRLGRTL*# SEQUENCE: RAHSMQRHLRRLGRTL*# ...# >MUS131E1# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus MT (162-176)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,TRDVLDLFADFIASM*# SEQUENCE: TRDVLDLFADFIASM*# ...# >MUS131E2# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus MT (162-176)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,TRDVLNLFADFIASM*# SEQUENCE: TRDVLNLFADFIASM*# ...# >MUS131E3# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus MT (162-176)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,TRDVLQLFADFIASM*# SEQUENCE: TRDVLQLFADFIASM*# ...# >MUS131E4# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus LT (516-535)# DB REFERENCE: SWISS: (TALA_POVMA,TALA_POVM3,TALA_POVMC)# & PIR1: (TVVPCP,TVVPT)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,LQQSLLRLKELGSSDALLYL*# SEQUENCE: LQQSLLRLKELGSSDALLYL*# ...# >MUS131E5# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus LT (634-651)# DB REFERENCE: SWISS: (TALA_POVMA)# & PIR1: (TVVPT)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,PGMGVANLDNLRTTWNGS*# SEQUENCE: PGMGVANLDNLRTTWNGS*# ...# >MUS131E6# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus MT (162-176)# DB REFERENCE: SWISS: (TAMI_POVM3,TAMI_POVMA,TASM_POVMA,TAMI_POVMC)# & PIR1: (TVVPMP,TVVPA,TVVPM)# & PIR2: (S22561,S22562)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,TRDVLNLYADFIASM*# SEQUENCE: TRDVLNLYADFIASM*# ...# >MUS131E7# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus MT (380-395)# DB REFERENCE: SWISS: (TAMI_POVMA,TAMI_POVM3,TAMI_POVMC)# & PIR1: (TVVPM,TVVPMP)# & PIR2: (S22561)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,RAHSMQRHLRRLGRTL*# SEQUENCE: RAHSMQRHLRRLGRTL*# ...# >MUS131E8# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: polyoma virus LT (496-512)# DB REFERENCE: SWISS: (TALA_POVMC,TALA_POVM3,TALA_POVMA)# & PIR1: (TVVPT,TVVPCP)# & PIR2: (S22560)# ANCHOR POSITIONS: ?# REFERENCES: reinholdsson-ljunggren93a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesl,LASRRLKLVECTRSQLL*# SEQUENCE: LASRRLKLVECTRSQLL*# ...# >MUS131E9# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: horse cyt c (41-49)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_MACGI,CYC_HORSE)# & PIR1: (CCHO,CCKGG)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,GQAPGFTYT*# SEQUENCE: GQAPGFTYT*# ...# >MUS131EA# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: horse cyt c (41-48)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_MACGI,CYC_HORSE)# & PIR1: (CCKGG,CCHO)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,GQAPGFTY*# SEQUENCE: GQAPGFTY*# ...# >MUS131EB# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: horse cyt c (42-48)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_MACGI,CYC_HORSE)# & PIR1: (CCKGG,CCHO)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Kb,actyesl,bindyesu,QAPGFTY*# SEQUENCE: QAPGFTY*# ...# >MUS131EC# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: horse cyt c (43-48)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_MACGI,CYC_HORSE)# & PIR1: (CCKGG,CCHO)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Kb,actyesl,bindyesu,APGFTY*# SEQUENCE: APGFTY*# ...# >MUS131ED# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: bovine cyt c (40-49)# DB REFERENCE: SWISS: (CYC2_MOUSE,CYC_SCHGR,CYC_ENTTR,CYC_MIRLE,CYC_MINSC,# & CYC2_RAT,CYC_CYPCA,CYC_ENTTR,CYC_EQUAS,CYC_CANFA,# & CYC_EQUAS,CYC2_RAT,CYC_CANFA,CYC_BOVIN,CYC2_MOUSE,# & CYC_CYPCA)# & PIR1: (CCHOZ,CCMST,CCSLE,CCBTS,CCHOD,CCBO,CCLQ,CCLM,CCPG,CCSH,# & CCDG,CCCA,CCRTT)# & PIR3: (S30377)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Kb,actyesm,bindyesu,TGQAPGFSYT*# SEQUENCE: TGQAPGFSYT*# ...# >MUS131EE# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: horse cyt c (41-49)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_HORSE,CYC_MACGI)# & PIR1: (CCKGG,CCHO)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,GQAPGFTYT*# SEQUENCE: GQAPGFTYT*# ...# >MUS131EF# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: horse cyt c (41-48)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_MACGI,CYC_HORSE)# & PIR1: (CCKGG,CCHO)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesu,GQAPGFTY*# SEQUENCE: GQAPGFTY*# ...# >MUS131F0# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: horse cyt c (42-48)# DB REFERENCE: SWISS: (CYC_MACGI,CYC_HORSE,CYC_HORSE)# & PIR1: (CCKGG,CCHO)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,QAPGFTY*# SEQUENCE: QAPGFTY*# ...# >MUS131F1# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: horse cyt c (43-48)# DB REFERENCE: SWISS: (CYC_HORSE,CYC_MACGI,CYC_HORSE)# & PIR1: (CCHO,CCKGG)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Db,actyesl,bindyesu,APGFTY*# SEQUENCE: APGFTY*# ...# >MUS131F2# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: bovine cyt c (40-49)# DB REFERENCE: SWISS: (CYC2_MOUSE,CYC2_RAT,CYC2_MOUSE,CYC_MIRLE,CYC_ENTTR,# & CYC_CYPCA,CYC_MINSC,CYC_BOVIN,CYC2_RAT,CYC_CANFA,# & CYC_SCHGR,CYC_ENTTR,CYC_EQUAS,CYC_CANFA,CYC_EQUAS,# & CYC_CYPCA)# & PIR1: (CCRTT,CCCA,CCDG,CCPG,CCSH,CCSLE,CCBTS,CCHOD,CCHOZ,CCMST,# & CCBO,CCLM,CCLQ)# & PIR3: (S30377)# ANCHOR POSITIONS: ?# REFERENCES: sheil94a# COMMENT:# SUMMARY: H-2Db,actyesm,bindyesu,TGQAPGFSYT*# SEQUENCE: TGQAPGFSYT*# ...# >MUS131F3# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ras (60-67)# DB REFERENCE: SWISS: (LT60_CAEEL,RASK_MSVKI,RASL_NEUCR,RASK_MONDO,RAS1_DROME,# & RASH_MSVHA,RAS1_DROME,RASH_RAT,RASK_RAT,RAS2_YEAST,# & RASL_MOUSE,RAS_CARAU,RASH_CHICK,RASH_MSV,RASL_RAT,# & RAS1_YEAST,RASN_MOUSE,RASX_XENLA,RASK_RAT,RAS1_NEUCR,# & RASH_MESAU,RAS2_PHYPO,RASC_DICDI,RAS3_RHIRA,RASH_MOUSE,# & RASH_RRASV,RASN_RAT,RAS1_YEAST,RAS1_HYDMA,RASK_HUMAN,# & RASH_MSVNS,RAS_SCHPO,RASL_RAT,RASH_HUMAN,RAS1_PHYPO,# & RASK_MELGA,RASA_DICDI,RAS2_RHIRA,RASH_RAT,RASK_XENLA,# & RASC_DICDI,RASK_MSVKI,RASN_MOUSE,RAS1_RHIRA,RASH_HUMAN,# & RASD_DICDI,RASL_HUMAN,RASK_MOUSE,RASN_HUMAN,RASN_CAVPO,# & RASN_HUMAN,RASL_MOUSE,RASL_HUMAN,RAS_ARTSA,RASH_MSVHA,# & RASG_DICDI)# & PIR1: (TVHUH,TVMVNS,TVBYR2,TVCHRS,TVGPRS,TVBYR1,TVMSK,TVMV3H,# & TVBYSR,TVMSNS,TVHU2K,TVDORS,TVMV2K,TVBYPR,TVMVB,TVMVRS,# & TVGPRT,TVHURA,TVFF85,TVDORA,TVHUK)# & PIR2: (S26621,A54321,A36290,A53778,A60192,A43816,I38149,A43808,# & S31720,I58402,PC4097,S35097,S31985,S05483,S12892,B54321,# & I51971,A36365,I57484,A48088,S02054,S34138,B25229,C36365,# & A37355,JC5154,B36365,I80324,PC4098,A25229,S57718,# & A43640)# & PIR3: (S33796,I46914,S38362,S58220)# ANCHOR POSITIONS: ?# REFERENCES: skipper93a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,GQEEYSAM*# SEQUENCE: GQEEYSAM*# ...# >MUS131F4# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Ras (152-)# DB REFERENCE: SWISS: (RASN_MOUSE,RASN_CAVPO,RASH_HUMAN,RASK_HUMAN,RASH_MSVNS,# & RASH_HUMAN,RASH_RRASV,RASN_RAT,RASN_HUMAN,RASK_MSVKI,# & RASH_RAT,RASH_CHICK,RASH_MSVHA,RASK_MOUSE,RASN_HUMAN,# & RASK_MSVKI,RASH_RAT,RASH_MOUSE,RASN_MOUSE,RAS_CARAU,# & RASH_MSVHA,RASH_MSV)# & PIR1: (TVMVRS,TVMSNS,TVMV3H,TVHUH,TVMVNS,TVMSK,TVHUK,TVHURA,# & TVMVB,TVMV2K,TVCHRS,TVGPRS)# & PIR2: (S57718,A25229,A37355,A48088,A43816,S05483,S26621,# & S02054)# ANCHOR POSITIONS: ?# REFERENCES: skipper93a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,VEDAFYTL*# SEQUENCE: VEDAFYTL*# ...# >MUS131F5# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Recognition# ACTIVITY: ?# BINDING: yes, little# SOURCE: p18IIIB (316-327)# DB REFERENCE: SWISS: (ENV_HV1H2,ENV_HV1MF,ENV_HV1BR,ENV_HV1B8,ENV_HV1PV,# & ENV_HV1B1,ENV_HV1H3)# & PIR1: (VCLJLV,VCLJVL,VCLJH3)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesl,IQRGPGRAFVTI*# SEQUENCE: IQRGPGRAFVTI*# ...# >MUS131F6# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: p18IIIB (317-327)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1BR,ENV_HV1H3,ENV_HV1B1,ENV_HV1B8,# & ENV_HV1H2,ENV_HV1MF)# & PIR1: (VCLJH3,VCLJVL,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: H-2Dd,actyesh,bindyesu,QRGPGRAFVTI*# SEQUENCE: QRGPGRAFVTI*# ...# >MUS131F7# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: p18IIIB (316-325)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H3,ENV_HV1H2,ENV_HV1B1,ENV_HV1BR,# & ENV_HV1MF,ENV_HV1B8)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: H-2Dd,actyesh,bindyesu,IQRGPGRAFV*# SEQUENCE: IQRGPGRAFV*# ...# >MUS131F8# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: p18IIIB (317-325)# DB REFERENCE: SWISS: (ENV_HV1PV,ENV_HV1H2,ENV_HV1B1,ENV_HV1H3,ENV_HV1MF,# & ENV_HV1B8,ENV_HV1BR)# & PIR1: (VCLJH3,VCLJLV,VCLJVL)# & PIR3: (S13288,S33985)# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: H-2Dd,actyesh,bindyesu,QRGPGRAFV*# SEQUENCE: QRGPGRAFV*# ...# >MUS131F9# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Competition/Recognition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p18IIIB (318-327) homologue# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesm,RAPGRAFVTI*# SEQUENCE: RAPGRAFVTI*# ...# >MUS131FA# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: p18IIIB (318-327) homologue# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesl,RGAGRAFVTI*# SEQUENCE: RGAGRAFVTI*# ...# >MUS131FB# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: p18IIIB (318-327) homologue# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesh,RGPGRAFVTA*# SEQUENCE: RGPGRAFVTA*# ...# >MUS131FC# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Recognition# ACTIVITY: ?# BINDING: yes, high# SOURCE: p18IIIB (318-327) homologue# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: H-2Dd,actunkn,bindyesh,RGPGRAFATI*# SEQUENCE: RGPGRAFATI*# ...# >MUS231FD# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: p18IIIB (315-327)# DB REFERENCE: SWISS: (ENV_HV1MF,ENV_HV1BR,ENV_HV1PV,ENV_HV1H2,ENV_HV1H3,# & ENV_HV1B1,ENV_HV1B8)# & PIR1: (VCLJVL,VCLJH3,VCLJLV)# & PIR3: (S33985,S13288)# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,RIQRGPGRAFVTI*# SEQUENCE: RIQRGPGRAFVTI*# ...# >MUS231FE# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p18IIIB (315-329) homologue# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,RIQRGPARAFVTIGK*# SEQUENCE: RIQRGPARAFVTIGK*# ...# >MUS231FF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p18IIIB (315-329) homologue# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,RIQRGPGRAFYTIGK*# SEQUENCE: RIQRGPGRAFYTIGK*# ...# >MUS23200# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p18IIIB (315-329) homologue# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,RIQRGPGRAFVAIGK*# SEQUENCE: RIQRGPGRAFVAIGK*# ...# >MUS23201# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: p18IIIB (315-329) homologue# ANCHOR POSITIONS: ?# REFERENCES: takeshita95a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,RIQRGPGRAFVTIAK*# SEQUENCE: RIQRGPGRAFVTIAK*# ...# >MUS13202# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays/Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Adenovirus early protein# ANCHOR POSITIONS: ?# REFERENCES: toes95a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesh,SGPSNIPPEI*# SEQUENCE: SGPSNIPPEI*# ...# >MUS13203# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays/Stabilization# ACTIVITY: yes, ?# BINDING: yes, high# SOURCE: Adenovirus early protein# ANCHOR POSITIONS: ?# REFERENCES: toes95a# COMMENT:# SUMMARY: H-2Db,actyesu,bindyesh,SGPSNTPSEI*# SEQUENCE: SGPSNTPSEI*# ...# >MUS13204# MHC MOLECULE: H-2k, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CS# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLAFT)# & PIR1: (OZZQAF)# & PIR2: (A54533)# ANCHOR POSITIONS: ?# REFERENCES: udhayakumar94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KPKDELDYENDIEKKICKMEKCS*# SEQUENCE: KPKDELDYENDIEKKICKMEKCS*# ...# >MUS13205# MHC MOLECULE: H-2k, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CS# DB REFERENCE: SWISS: (CSP_PLAFW)# & PIR2: (A54529)# ANCHOR POSITIONS: ?# REFERENCES: udhayakumar94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KPKDQLDYENDIEKKICKMEKCS*# SEQUENCE: KPKDQLDYENDIEKKICKMEKCS*# ...# >MUS13206# MHC MOLECULE: H-2k, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CS# ANCHOR POSITIONS: ?# REFERENCES: udhayakumar94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KSKDELDYENDIEKKICKMEKCS*# SEQUENCE: KSKDELDYENDIEKKICKMEKCS*# ...# >MUS13207# MHC MOLECULE: H-2k, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CS# ANCHOR POSITIONS: ?# REFERENCES: udhayakumar94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KPKDELDYENDIEKKICKMVKCS*# SEQUENCE: KPKDELDYENDIEKKICKMVKCS*# ...# >MUS13208# MHC MOLECULE: H-2k, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: P. falciparum CS# ANCHOR POSITIONS: ?# REFERENCES: udhayakumar94a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,KPKDQLNYENDIEKKICKMEKCS*# SEQUENCE: KPKDQLNYENDIEKKICKMEKCS*# ...# >MUS13209# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Reference/Stabilization/CTL induction# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: influenza A/Puerto/Rico/8/34 HA (533-541)# DB REFERENCE: SWISS: (HEMA_IAZNJ,HEMA_IAZIN,HEMA_IAUSS,HEMA_IACKP,HEMA_IAWIL,# & HEMA_IATKO,HEMA_IACKQ,HEMA_IAKIE,HEMA_IALEN,HEMA_IATKW,# & HEMA_IACKS,HEMA_IADIR,HEMA_IAPUE,HEMA_IATKI,# & HEMA_IADA4)# & PIR1: (HMIVTW,HMIV17,HMIVUR,HMIV,HMIVD1,HMIVD8,HMIVC2,HMIV5,# & HMIVT8,HMIVN1)# & PIR3: (S69888,S69887)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesh,IYSTVASSL*# SEQUENCE: IYSTVASSL*# ...# >MUS1320A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL induction# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: influenza A/Puerto/Rico/8/34 HA (462-470)# DB REFERENCE: SWISS: (HEMA_IALEN,HEMA_IAKIE,HEMA_IAWIL,HEMA_IADA4,# & HEMA_IAPUE)# & PIR1: (HMIV,HMIV5,HMIVD1)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actyesl,bindyesh,LYEKVKSQL*# SEQUENCE: LYEKVKSQL*# ...# >MUS1320B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, high# SOURCE: influenza A/Puerto/Rico/8/34 NP (39-47)# DB REFERENCE: SWISS: (VNUC_IAB37,VNUC_IAGUM,VNUC_IAMAA,VNUC_IAUSS,VNUC_IAZW2,# & VNUC_IAHJI,VNUC_IADHK,VNUC_IAZW1,VNUC_IAZI1,VNUC_IAWIL,# & VNUC_IAFPR,VNUC_IACKG,VNUC_IAHO1,VNUC_IARUD,VNUC_IATKO,# & VNUC_IAFOM,VNUC_IAZJ3,VNUC_IAZCA,VNUC_IAMIN,VNUC_IAMEC,# & VNUC_IAME5,VNUC_IAZNE,VNUC_IAME3,VNUC_IALEN,VNUC_IADMA,# & VNUC_IAZ41,VNUC_IATEI,VNUC_IADE2,VNUC_IABRA,VNUC_IAWHN,# & VNUC_IADE1,VNUC_IAWHP,VNUC_IAB39,VNUC_IAGU3,VNUC_IAHIC,# & VNUC_IAFPD,VNUC_IAPUE,VNUC_IAGD7,VNUC_IAZTE,VNUC_IAS06,# & VNUC_IANT6,VNUC_IAZGE,VNUC_IAMEF,VNUC_IATKN,VNUC_IAZOH,# & VNUC_IAME4,VNUC_IADBE,VNUC_IAANN,VNUC_IAEN5,VNUC_IAS31,# & VNUC_IAUDO,VNUC_IAZJ2,VNUC_IAZ29,VNUC_IAMEB,VNUC_IAWIS,# & VNUC_IAKIE,VNUC_IAZI2,VNUC_IATX7,VNUC_IAME6,VNUC_IAZI3,# & VNUC_IAZJ4,VNUC_IAHPR,VNUC_IAZJ1,VNUC_IAVI6,VNUC_IAFOW,# & VNUC_IAZON,VNUC_IAMEA,VNUC_IAPAR,VNUC_IAS11,VNUC_IAHO2,# & VNUC_IASH2,VNUC_IAGU4,VNUC_IADM2,VNUC_IAANA,VNUC_IAZH4,# & VNUC_IACAL,VNUC_IAGU2,VNUC_IAZH3,VNUC_IAMEE,VNUC_IASE0,# & VNUC_IADAU,VNUC_IAMAN,VNUC_IASIN,VNUC_IAZH1,VNUC_IAANN,# & VNUC_IADCZ,VNUC_IADU2,VNUC_IAZMA,VNUC_IAZDA,VNUC_IAZJA,# & VNUC_IACKP,VNUC_IATRT,VNUC_IAOHI,VNUC_IAGUN,VNUC_IANEJ,# & VNUC_IATRS,VNUC_IAMEG,VNUC_IADNZ,VNUC_IAGUA)# & PIR1: (VHIVN7,VHIVN6,VHIVN4,VHIVC1,VHIVM1,VHIV8H,VHIVN2,VHIVN5,# & VHIV68,VHIVN1,VHIVN9,VHIVN8,VHIVX4,VHIVX1,VHIVX3,VHIVAK,# & VHIVX6,A60028,VHIVA3,VHIVA6,VHIV61,VHIVXL,VHIVX2,VHIV34,# & VHIVA7,VHIVX5)# & PIR2: (B36754,PQ0417,A42757)# & PIR3: (S34418)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesh,FYIQMCTEL*# SEQUENCE: FYIQMCTEL*# ...# >MUS1320C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: influenza A/Puerto/Rico/8/34 NA (323-331)# DB REFERENCE: SWISS: (NRAM_IAPUE)# & PIR1: (NMIV)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,VYVDGANGV*# SEQUENCE: VYVDGANGV*# ...# >MUS1320D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: influenza A/Puerto/Rico/8/34 HA (114-122)# DB REFERENCE: SWISS: (HEMA_IAKIE,HEMA_IACAO,HEMA_IAWIL,HEMA_IAUSS,HEMA_IADA4,# & HEMA_IATAI,HEMA_IAHAR,HEMA_IAXIA,HEMA_IAPUE,# & HEMA_IALEN)# & PIR1: (HMIVUR,HMIVD1,HMIVTA,HMIV,HMIV5)# & PIR2: (JQ1643,A35788,JQ1437,PQ0321,PQ0319,S16785)# & PIR3: (S69887)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesh,DYEELREQL*# SEQUENCE: DYEELREQL*# ...# >MUS1320E# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL induction# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: influenza A/Puerto/Rico/8/34 NP (218-226)# DB REFERENCE: SWISS: (VNUC_IAHO2,VNUC_IAANA,VNUC_IAGRE,VNUC_IASIN,VNUC_IAZH1,# & VNUC_IADAU,VNUC_IACAL,VNUC_IAGU2,VNUC_IACKG,VNUC_IAPAR,# & VNUC_IAZ41,VNUC_IAWHN,VNUC_IAB37,VNUC_IAHJI,VNUC_IAZW1,# & VNUC_IAMIN,VNUC_IAMEC,VNUC_IAGUN,VNUC_IATRS,VNUC_IADMA,# & VNUC_IATRT,VNUC_IADCZ,VNUC_IAVI6,VNUC_IAZJ3,VNUC_IAFOM,# & VNUC_IAMAA,VNUC_IAGUA,VNUC_IABUD,VNUC_IAMEA,VNUC_IATKO,# & VNUC_IAHO1,VNUC_IAZH4,VNUC_IAS11,VNUC_IAME3,VNUC_IALEN,# & VNUC_IAWIL,VNUC_IAGU1,VNUC_IAFPR,VNUC_IAZI1,VNUC_IAUSS,# & VNUC_IAZW2,VNUC_IADHK,VNUC_IAGUM,VNUC_IARUD,VNUC_IAZCA,# & VNUC_IAZNE,VNUC_IAME5,VNUC_IATEI,VNUC_IABRA,VNUC_IAB39,# & VNUC_IAFPD,VNUC_IAZJ4,VNUC_IAHPR,VNUC_IAFOW,VNUC_IAGU3,# & VNUC_IAME4,VNUC_IAANN,VNUC_IATKN,VNUC_IAUDO,VNUC_IADBE,# & VNUC_IAMEB,VNUC_IAZJ2,VNUC_IAZ29,VNUC_IAZI3,VNUC_IAKIE,# & VNUC_IATX7,VNUC_IAME6,VNUC_IAZH3,VNUC_IAGU4,VNUC_IASH2,# & VNUC_IAHLO,VNUC_IAMEG,VNUC_IAMAN,VNUC_IADU2,VNUC_IADM2,# & VNUC_IAMEE,VNUC_IASE0,VNUC_IAZJA,VNUC_IAZDA,VNUC_IAZMA,# & VNUC_IACKP,VNUC_IAOHI,VNUC_IAANN,VNUC_IADNZ,VNUC_IANEJ,# & VNUC_IADE2,VNUC_IAHMI,VNUC_IAZON,VNUC_IADE1,VNUC_IAWHP,# & VNUC_IAZGE,VNUC_IANT6,VNUC_IAHIC,VNUC_IAS06,VNUC_IAZTE,# & VNUC_IAGD7,VNUC_IAPUE,VNUC_IAZI2,VNUC_IAZJ1,VNUC_IAWIS,# & VNUC_IAHTE,VNUC_IAEN5,VNUC_IAMEF,VNUC_IAZOH,VNUC_IAS31)# & PIR1: (VHIVC1,VHIV61,VHIVA6,VHIV68,VHIVN8,VHIVN9,VHIVN4,VHIVX4,# & VHIVN1,VHIVX5,VHIVX2,VHIVX3,VHIVN3,VHIVX6,A60028,VHIVA3,# & VHIVX1,VHIVN6,VHIVAK,VHIVXL,VHIV34,VHIVA7,VHIVM1,VHIVN2,# & VHIV8H,VHIVN5,VHIVN7)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesm,AYERMCNIL*# SEQUENCE: AYERMCNIL*# ...# >MUS1320F# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: influenza A/Puerto/Rico/8/34 PB1 (81-89)# DB REFERENCE: SWISS: (RRP1_IAPUE,RRP1_IAZTF,RRP1_IAWIS,RRP1_IAWIL,RRP1_IAGU2,# & RRP1_IASIN,RRP1_IALE3,RRP1_IAKIE,RRP1_IANT6,RRP1_IAVI7,# & RRP1_IAKOR,RRP1_IALE1,RRP1_IABEI,RRP1_IAANN,RRP1_IAHLO,# & RRP1_IAHTE,RRP1_IAKOR,RRP1_IAMAN,RRP1_IAME8,RRP1_IATKM,# & RRP1_IALE2,RRP1_IAZON,RRP1_IAZH3)# & PIR1: (P1IV68,P1IV34,A60008,P1IV33,P1IV61,B60011)# & PIR2: (S06212)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,GYAQTDCVL*# SEQUENCE: GYAQTDCVL*# ...# >MUS13210# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: influenza A/Puerto/Rico/8/34 PA (686-694)# DB REFERENCE: SWISS: (RRP2_IAPUE,RRP2_IALE1,RRP2_IADH2,RRP2_IATKM,RRP2_IAZH2,# & RRP2_IARUD,RRP2_IALE2,RRP2_IAKOR,RRP2_IAWIL,RRP2_IAVI7,# & RRP2_IAGU2,RRP2_IAMAN,RRP2_IAZH3,RRP2_IASIN,RRP2_IAANN,# & RRP2_IAPI0,RRP2_IANT6)# & PIR1: (P2IVWS,P2IV68,P2IV61,C60008,C60011,P2IV34)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,LYEAIEECL*# SEQUENCE: LYEAIEECL*# ...# >MUS13211# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: influenza A/Puerto/Rico/8/34 PB1 (598-606)# DB REFERENCE: SWISS: (RRP1_IAHLO,RRP1_IAZTF,RRP1_IACAO,RRP1_IANT6,RRP1_IAVI7,# & RRP1_IALE3,RRP1_IALE1,RRP1_IAKIE,RRP1_IAPUE,RRP1_IAWIS,# & RRP1_IAWIL,RRP1_IALE2,RRP1_IAKOR,RRP1_IAMAN,RRP1_IAGU2,# & RRP1_IATKM,RRP1_IAZH3,RRP1_IAHTE,RRP1_IAME8,RRP1_IADUN,# & RRP1_IAKOR,RRP1_IAZON,RRP1_IASIN,RRP1_IAANN)# & PIR1: (P1IV68,P1IV33,A60008,P1IV34,B60011,P1IV61)# & PIR2: (S06212)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,LYNIRNLHI*# SEQUENCE: LYNIRNLHI*# ...# >MUS13212# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: influenza A/Puerto/Rico/8/34 PB2 (657-665)# DB REFERENCE: SWISS: (RRP3_IAHLO,RRP3_IATKM,RRP3_IAPUE,RRP3_IAGU2,RRP3_IAHK6,# & RRP3_IARUD,RRP3_IASE2,RRP3_IAGUA,RRP3_IAFPW,RRP3_IAMAN,# & RRP3_IABUD,RRP3_IAFPR)# & PIR1: (P3IV34,P3IV2A,A60011)# & PIR2: (JN0435)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,NYNKATKRL*# SEQUENCE: NYNKATKRL*# ...# >MUS13213# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: influenza A/Puerto/Rico/8/34 M2 (99-107)# DB REFERENCE: SWISS: (VMT1_IAFPW,VMT1_IALE2,VMT1_IAANN,VMT1_IAUSS,VMT1_IAFPR,# & VMT1_IABAN,VMT1_IAMAN,VMT1_IAPUE,VMT1_IAWIL,VMT1_IALE1,# & VMT1_IAUDO,VMT1_IAFOW)# & PIR1: (MFIVC,MFIVWS,MFIV,MFIV61,MFIV1F,MFIV1K,JN0392,MFIV1M)# & PIR2: (S04054,S04058,S07945,S04056,S04050,S04052,S07429,# & S14616)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,LYRKLKREI*# SEQUENCE: LYRKLKREI*# ...# >MUS13214# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: influenza A/Puerto/Rico/8/34 HA (208-216)# DB REFERENCE: SWISS: (HEMA_IAPUE)# & PIR1: (HMIV)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,IYQNENAYV*# SEQUENCE: IYQNENAYV*# ...# >MUS13215# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: influenza A/Puerto/Rico/8/34 NA (154-162)# DB REFERENCE: SWISS: (NRAM_IAPUE,NRAM_IACHI,NRAM_IAWIL,NRAM_IALEN,NRAM_IAPAR,# & NRAM_IAUSS,NRAM_IAKIE)# & PIR1: (NMIVAK,NMIVXL,NMIVU7,NMIV,NMIV3)# & PIR2: (S04801)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,PYNSRFESV*# SEQUENCE: PYNSRFESV*# ...# >MUS13216# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: influenza A/Puerto/Rico/8/34 PB2 (204-212)# DB REFERENCE: SWISS: (RRP3_IAGUA,RRP3_INBAC,RRP3_IAHK6,RRP3_IAHLO,RRP3_IALE1,# & RRP3_IAKIE,RRP3_IARUD,RRP3_IANT6,RRP3_IAWIL,RRP3_IAPUE,# & RRP3_IAANN,RRP3_IALE2,RRP3_IACHI,RRP3_IAMAN,RRP3_IAFPR,# & RRP3_IABUD,RRP3_IAZTE,RRP3_INBAD,RRP3_IATKM,RRP3_IAGU2,# & RRP3_IASIN,RRP3_IAHPR,RRP3_IALE3,RRP3_IAKOR,RRP3_IAZI1,# & RRP3_IAME8,RRP3_IASE2,RRP3_IAVI7)# & PIR1: (P3IV34,B60008,P3IVBW,P3IV61,P3IVBC,A60011,P3IV33,P3IV2A,# & P3IVAK,P3IV68)# & PIR2: (S04930)# ANCHOR POSITIONS: ?# REFERENCES: deng97a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesl,AYMLERELV*# SEQUENCE: AYMLERELV*# ...# >RAT13217# MHC MOLECULE: RT1.Al, CLASS-1, (RAT Lewis)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hnRNP A2 (281-790)# DB REFERENCE: SWISS: (ROA2_HUMAN,RO21_XENLA,ROA2_HUMAN,RO22_XENLA)# & PIR2: (B34504,S40776,S40775)# ANCHOR POSITIONS: ?# REFERENCES: reizis97a# COMMENT:# SUMMARY: RT1.Al,actunkn,bindyesu,GGYGGGYDNY*# SEQUENCE: GGYGGGYDNY*# ...# >RAT13218# MHC MOLECULE: RT1.Al, CLASS-1, (RAT Lewis)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hnRNP F (238-246)# ANCHOR POSITIONS: ?# REFERENCES: reizis97a# COMMENT:# SUMMARY: RT1.Al,actunkn,bindyesu,AGYGGYEEY*# SEQUENCE: AGYGGYEEY*# ...# >RAT13219# MHC MOLECULE: RT1.Al, CLASS-1, (RAT Lewis)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: hnRNP A1 (257-265)# DB REFERENCE: SWISS: (ROA1_MACMU,ROA1_MOUSE,ROA1_RAT,ROA1_HUMAN,ROA1_HUMAN,# & ROA1_RAT,ROA1_MOUSE)# & PIR1: (DDRT)# & PIR2: (S04617,S30192,A44485,S02061)# ANCHOR POSITIONS: ?# REFERENCES: reizis97a# COMMENT:# SUMMARY: RT1.Al,actunkn,bindyesu,GSYNDFGNY*# SEQUENCE: GSYNDFGNY*# ...# >RAT1321A# MHC MOLECULE: RT1.Al, CLASS-1, (RAT Lewis)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: reizis97a# COMMENT:# SUMMARY: RT1.Al,actunkn,bindyesu,SAFRNVTSF*# SEQUENCE: SAFRNVTSF*# ...# >RAT1321B# MHC MOLECULE: RT1.Al, CLASS-1, (RAT Lewis)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: TFIIB (116-124)# DB REFERENCE: SWISS: (TF2B_HUMAN,TF2B_RAT)# & PIR1: (TWHU2B)# & PIR2: (S26299)# ANCHOR POSITIONS: ?# REFERENCES: reizis97a# COMMENT:# SUMMARY: RT1.Al,actunkn,bindyesu,NAFKEITTM*# SEQUENCE: NAFKEITTM*# ...# >RAT1321C# MHC MOLECULE: RT1.Al, CLASS-1, (RAT Lewis)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Unknown# ANCHOR POSITIONS: ?# REFERENCES: reizis97a# COMMENT:# SUMMARY: RT1.Al,actunkn,bindyesu,AAFFNKTEF*# SEQUENCE: AAFFNKTEF*# ...# >RAT1321D# MHC MOLECULE: RT1.Al, CLASS-1, (RAT Lewis)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HSP90 beta (24-32)# DB REFERENCE: SWISS: (HS83_DROSI,HS83_DROPS,HS9C_DICDI,HS9A_RABIT,HS9B_MOUSE,# & HS83_DROME,HS9B_RAT,HS9A_HUMAN,HS83_LEIAM,HS83_DROVI,# & HS9B_HUMAN,HS9A_MOUSE,HS9B_HUMAN,HS9C_DICDI,HS9A_CHICK,# & HS83_TRYBB,HS9A_MOUSE,HS83_DROME,HS9B_CHICK,HS85_TRYCR,# & HS9A_CRIGR)# & PIR1: (HHFF83,HHMS84,HHHU84,HHHU86,HHCH90,HHMS86)# & PIR2: (JC1468,S08119,A26125,C24827,S49155,S57415,D24827,A44983,# & A44943,B24827)# & PIR3: (JQ0129)# ANCHOR POSITIONS: ?# REFERENCES: reizis97a# COMMENT:# SUMMARY: RT1.Al,actunkn,bindyesu,MSLIINTFY*# SEQUENCE: MSLIINTFY*# ...# >RAT1321E# MHC MOLECULE: RT1.Al, CLASS-1, (RAT Lewis)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: LDH M chain (115-122)# DB REFERENCE: SWISS: (LDHM_RABIT,LDHM_RAT,LDHM_BOVIN,LDHM_RABIT,LDHM_PIG,# & LDHM_CHICK,LDHM_PIG,LDHM_MOUSE,LDHM_SQUAC,LDHM_HUMAN,# & LDHM_BOVIN,LDHA_XENLA,LDHM_MOUSE,LDH_PETMA)# & PIR1: (DECHLM,DEDFLM,DEPGLM,DEHULM,DEMSLM)# & PIR2: (A32957,I51656,S12151,A38231,A23083,JQ2222)# ANCHOR POSITIONS: ?# REFERENCES: reizis97a# COMMENT:# SUMMARY: RT1.Al,actunkn,bindyesu,NIFKFIIP*# SEQUENCE: NIFKFIIP*# ...# >MUS1321F# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL assays/Proliferation# ACTIVITY: yes, ?# BINDING: yes, moderate# SOURCE: 8-4 tum- (15-22)# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# ANCHOR POSITIONS: ?# REFERENCES: gillanders96a,mccormick96a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesm,QNHRALDL*# SEQUENCE: QNHRALDL*# ...# >MUS13220# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Elution/CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: MuLV gp70 (423-431)# DB REFERENCE: SWISS: (ENV_MLVAV,ENV_MLVRD,ENV_MLVRK)# & PIR1: (VCMVVR,VCVWEK,VCMVKA)# & PIR2: (B43491,S22805,A43491,A46511)# ANCHOR POSITIONS: ?# REFERENCES: huang96a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesu,SPSYVYHQF*# SEQUENCE: SPSYVYHQF*# ...# >MUS13221# MHC MOLECULE: H-2Dd, CLASS-1, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza NP (366-374)# DB REFERENCE: SWISS: (VNUC_IAFPD,VNUC_IAGU3,VNUC_IATEI,VNUC_IADE2,VNUC_IAWHN,# & VNUC_IAZ41,VNUC_IAANA,VNUC_IAGUA,VNUC_IADM2,VNUC_IATKO,# & VNUC_IAGU2,VNUC_IACKG,VNUC_IADMA,VNUC_IADNZ,VNUC_IAZI2,# & VNUC_IADE1,VNUC_IAZJA,VNUC_IAMAN,VNUC_IADU2,VNUC_IAWIL,# & VNUC_IAZI1,VNUC_IAFPR,VNUC_IALEN,VNUC_IAZNE,VNUC_IARUD,# & VNUC_IAZCA,VNUC_IADHK,VNUC_IATKN,VNUC_IADBE,VNUC_IAZJ4,# & VNUC_IAZ29,VNUC_IASH2,VNUC_IAGU4,VNUC_IAZH3,VNUC_IADCZ,# & VNUC_IATRT,VNUC_IAMAA,VNUC_IAPAR,VNUC_IAGRE,VNUC_IADAU,# & VNUC_IAGUN,VNUC_IAMIN,VNUC_IAHJI,VNUC_IAZI3,VNUC_IAGU1,# & VNUC_IAGUM,VNUC_IAZOH,VNUC_IAHMI,VNUC_IAPUE,VNUC_IAZGE,# & VNUC_IASE0,VNUC_IAZMA)# & PIR1: (VHIVN4,VHIVXL,VHIV34,VHIVX1,VHIVA3,VHIVN2,VHIVN9,VHIVN6,# & VHIVC1,VHIVN3,VHIVN1,A60028,VHIVM1,VHIVA6)# & PIR2: (A42757,B36754)# & PIR3: (S34418)# ANCHOR POSITIONS: ?# REFERENCES: huang96a# COMMENT:# SUMMARY: H-2Dd,actyesu,bindyesu,ASNENMETM*# SEQUENCE: ASNENMETM*# ...# >MUS13222# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Competition/Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,KAVYNFATM*# SEQUENCE: KAVYNFATM*# ...# >MUS13223# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,KAGYNFATM*# SEQUENCE: KAGYNFATM*# ...# >MUS13224# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesh,KALYNFATM*# SEQUENCE: KALYNFATM*# ...# >MUS13225# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,KAVGNFATM*# SEQUENCE: KAVGNFATM*# ...# >MUS13226# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,KAVFNFATM*# SEQUENCE: KAVFNFATM*# ...# >MUS13227# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,KAGYNFATM*# SEQUENCE: KAGYNFATM*# ...# >MUS13228# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesl,KALYNFATM*# SEQUENCE: KALYNFATM*# ...# >MUS13229# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,KAVGNFATM*# SEQUENCE: KAVGNFATM*# ...# >MUS1322A# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: LCMV gp (33-41)# ANCHOR POSITIONS: ?# REFERENCES: martin96a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesh,KAVFNFATM*# SEQUENCE: KAVFNFATM*# ...# >MUS1322B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Influenza HA (A/Japan/305/57) (202-221)# ANCHOR POSITIONS: ?# REFERENCES: hahn96a# COMMENT:# SUMMARY: H-2Kd,actyesm,bindyesu,RTLYQNVGTHVSVGTSTLNK*# SEQUENCE: RTLYQNVGTHVSVGTSTLNK*# ...# >MUS1322C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza HA (A/Japan/305/57) (202-221)# ANCHOR POSITIONS: ?# REFERENCES: hahn96a# COMMENT:# SUMMARY: H-2Kd,actyesl,bindyesu,RTLYQNVGTAVSVGTSTLNK*# SEQUENCE: RTLYQNVGTAVSVGTSTLNK*# ...# >MUS1322D# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Influenza HA (A/Japan/305/57) (202-221)# ANCHOR POSITIONS: ?# REFERENCES: hahn96a# COMMENT:# SUMMARY: H-2Kd,actyesl,bindyesu,RTLYQNVGTTVSVGTSTLNK*# SEQUENCE: RTLYQNVGTTVSVGTSTLNK*# ...# >MUS1322E# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mouse hepatitis virus surface glycoprotein (510-518)# DB REFERENCE: SWISS: (VGL2_CVM4,VGL2_CVMJC)# & PIR1: (JQ1534,VGIHJ2)# ANCHOR POSITIONS: ?# REFERENCES: castro95a# COMMENT:# SUMMARY: H-2Db,actyesh,bindyesu,CSLWNGPHL*# SEQUENCE: CSLWNGPHL*# ...# >MUS1322F# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mouse hepatitis virus surface glycoprotein (598-605)# DB REFERENCE: SWISS: (VGL2_CVMJH,VGL2_CVMA5,VGL2_CVM4)# & PIR1: (VGIHMJ,VGIH59,VGIHJ2)# ANCHOR POSITIONS: ?# REFERENCES: castro95a# COMMENT:# SUMMARY: H-2Kb,actyesh,bindyesu,RCQIFANI*# SEQUENCE: RCQIFANI*# ...# >MUS13230# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization/CTL assays# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Influenza HA (210-219)# ANCHOR POSITIONS: ?# REFERENCES: cao95a# COMMENT:# SUMMARY: H-2Kd,actyesh,bindyesm,TYVSVGTSTI*# SEQUENCE: TYVSVGTSTI*# ...# >MUS13231# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MV NP (280-292)# ANCHOR POSITIONS: ?# REFERENCES: beauverger96a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,MYPALGLHGFDGE*# SEQUENCE: MYPALGLHGFDGE*# ...# >MUS13232# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MV NP (280-292) mutant# ANCHOR POSITIONS: ?# REFERENCES: beauverger96a# COMMENT:# SUMMARY: H-2Ld,actyesu,bindyesu,MYPALGLHGSDGE*# SEQUENCE: MYPALGLHGSDGE*# ...# >MUS13233# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MV NP (280-292) mutant# ANCHOR POSITIONS: ?# REFERENCES: beauverger96a# COMMENT:# SUMMARY: H-2Kk,actyesu,bindyesu,MYPALGLHGSDGE*# SEQUENCE: MYPALGLHGSDGE*# ...# >MUS13234# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,YQNHRALDL*# SEQUENCE: YQNHRALDL*# ...# >MUS13235# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TPNHRALDL*# SEQUENCE: TPNHRALDL*# ...# >MUS13236# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TQNQRALDL*# SEQUENCE: TQNQRALDL*# ...# >MUS13237# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,TQNERALDL*# SEQUENCE: TQNERALDL*# ...# >MUS13238# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,TQNLRALDL*# SEQUENCE: TQNLRALDL*# ...# >MUS13239# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TQNKRALDL*# SEQUENCE: TQNKRALDL*# ...# >MUS1323A# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TQNHQALDL*# SEQUENCE: TQNHQALDL*# ...# >MUS1323B# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TQNHEALDL*# SEQUENCE: TQNHEALDL*# ...# >MUS1323C# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TQNHKALDL*# SEQUENCE: TQNHKALDL*# ...# >MUS1323D# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TQNHRGLDL*# SEQUENCE: TQNHRGLDL*# ...# >MUS1323E# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,TQNHRLLDL*# SEQUENCE: TQNHRLLDL*# ...# >MUS1323F# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TQNHRSLDL*# SEQUENCE: TQNHRSLDL*# ...# >MUS13240# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,TQNHRVLDL*# SEQUENCE: TQNHRVLDL*# ...# >MUS13241# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,TQNHRAGDL*# SEQUENCE: TQNHRAGDL*# ...# >MUS13242# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,TQNHRAFDL*# SEQUENCE: TQNHRAFDL*# ...# >MUS13243# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,TQNHRATDL*# SEQUENCE: TQNHRATDL*# ...# >MUS13244# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,TQNHRALNL*# SEQUENCE: TQNHRALNL*# ...# >MUS13245# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,TQNHRALEL*# SEQUENCE: TQNHRALEL*# ...# >MUS13246# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,TQNHRALPL*# SEQUENCE: TQNHRALPL*# ...# >MUS13247# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,TQNHRALDM*# SEQUENCE: TQNHRALDM*# ...# >MUS13248# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: tum- (14-22) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,TQNHRALDF*# SEQUENCE: TQNHRALDF*# ...# >MUS13249# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: MCMV pp89 (168-176) homologue# ANCHOR POSITIONS: ?# REFERENCES: robinson96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesl,YAHFMPTNL*# SEQUENCE: YAHFMPTNL*# ...# >MUS1324A# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: ras (4-12)# DB REFERENCE: SWISS: (RASX_XENLA,RASK_XENLA)# & PIR2: (S34138,I52688,I57624,I52219,A60192)# ANCHOR POSITIONS: ?# REFERENCES: abrams96a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesl,YKLVVVGAV*# SEQUENCE: YKLVVVGAV*# ...# >MUS1324B# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Competition/CTL assays# ACTIVITY: yes, ?# BINDING: yes, little# SOURCE: ras (3-12)# DB REFERENCE: SWISS: (RASK_XENLA,RASX_XENLA)# & PIR2: (A60192,I57624,S34138,I52688,I52219)# ANCHOR POSITIONS: ?# REFERENCES: abrams96a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesl,EYKLVVVGAV*# SEQUENCE: EYKLVVVGAV*# ...# >MUS1324C# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: Stabilization/Half-time# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: p2Ca# DB REFERENCE: SWISS: (ODO1_HUMAN,ODO1_MOUSE)# & PIR2: (A41911,B38234)# ANCHOR POSITIONS: ?# REFERENCES: cook96a# COMMENT:# SUMMARY: H-2Kd,actunkn,bindyesm,LSPFPFDL*# SEQUENCE: LSPFPFDL*# ...# >MUS1324D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,AESTGNLI*# SEQUENCE: AESTGNLI*# ...# >MUS1324E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,DESTGNLI*# SEQUENCE: DESTGNLI*# ...# >MUS1324F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,EESTGNLI*# SEQUENCE: EESTGNLI*# ...# >MUS13250# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,GESTGNLI*# SEQUENCE: GESTGNLI*# ...# >MUS13251# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,HESTGNLI*# SEQUENCE: HESTGNLI*# ...# >MUS13252# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,IESTGNLI*# SEQUENCE: IESTGNLI*# ...# >MUS13253# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,KESTGNLI*# SEQUENCE: KESTGNLI*# ...# >MUS13254# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,LESTGNLI*# SEQUENCE: LESTGNLI*# ...# >MUS13255# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,MESTGNLI*# SEQUENCE: MESTGNLI*# ...# >MUS13256# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,NESTGNLI*# SEQUENCE: NESTGNLI*# ...# >MUS13257# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,PESTGNLI*# SEQUENCE: PESTGNLI*# ...# >MUS13258# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,QESTGNLI*# SEQUENCE: QESTGNLI*# ...# >MUS13259# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,RESTGNLI*# SEQUENCE: RESTGNLI*# ...# >MUS1325A# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,SESTGNLI*# SEQUENCE: SESTGNLI*# ...# >MUS1325B# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,TESTGNLI*# SEQUENCE: TESTGNLI*# ...# >MUS1325C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,VESTGNLI*# SEQUENCE: VESTGNLI*# ...# >MUS1325D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,WESTGNLI*# SEQUENCE: WESTGNLI*# ...# >MUS1325E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,YESTGNLI*# SEQUENCE: YESTGNLI*# ...# >MUS1325F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FASTGNLI*# SEQUENCE: FASTGNLI*# ...# >MUS13260# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FDSTGNLI*# SEQUENCE: FDSTGNLI*# ...# >MUS13261# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FGSTGNLI*# SEQUENCE: FGSTGNLI*# ...# >MUS13262# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesl,FISTGNLI*# SEQUENCE: FISTGNLI*# ...# >MUS13263# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FLSTGNLI*# SEQUENCE: FLSTGNLI*# ...# >MUS13264# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FMSTGNLI*# SEQUENCE: FMSTGNLI*# ...# >MUS13265# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesl,FNSTGNLI*# SEQUENCE: FNSTGNLI*# ...# >MUS13266# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FPSTGNLI*# SEQUENCE: FPSTGNLI*# ...# >MUS13267# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FQSTGNLI*# SEQUENCE: FQSTGNLI*# ...# >MUS13268# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FSSTGNLI*# SEQUENCE: FSSTGNLI*# ...# >MUS13269# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FTSTGNLI*# SEQUENCE: FTSTGNLI*# ...# >MUS1326A# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FVSTGNLI*# SEQUENCE: FVSTGNLI*# ...# >MUS1326B# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# DB REFERENCE: SWISS: (HEMA_IADA4,HEMA_IAWIL)# & PIR1: (HMIVD1,HMIV5)# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEATGNLI*# SEQUENCE: FEATGNLI*# ...# >MUS1326C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEDTGNLI*# SEQUENCE: FEDTGNLI*# ...# >MUS1326D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEETGNLI*# SEQUENCE: FEETGNLI*# ...# >MUS1326E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEFTGNLI*# SEQUENCE: FEFTGNLI*# ...# >MUS1326F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEGTGNLI*# SEQUENCE: FEGTGNLI*# ...# >MUS13270# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEHTGNLI*# SEQUENCE: FEHTGNLI*# ...# >MUS13271# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEITGNLI*# SEQUENCE: FEITGNLI*# ...# >MUS13272# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEKTGNLI*# SEQUENCE: FEKTGNLI*# ...# >MUS13273# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FELTGNLI*# SEQUENCE: FELTGNLI*# ...# >MUS13274# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEMTGNLI*# SEQUENCE: FEMTGNLI*# ...# >MUS13275# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FENTGNLI*# SEQUENCE: FENTGNLI*# ...# >MUS13276# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEPTGNLI*# SEQUENCE: FEPTGNLI*# ...# >MUS13277# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEQTGNLI*# SEQUENCE: FEQTGNLI*# ...# >MUS13278# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FERTGNLI*# SEQUENCE: FERTGNLI*# ...# >MUS13279# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FETTGNLI*# SEQUENCE: FETTGNLI*# ...# >MUS1327A# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEVTGNLI*# SEQUENCE: FEVTGNLI*# ...# >MUS1327B# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEWTGNLI*# SEQUENCE: FEWTGNLI*# ...# >MUS1327C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FEYTGNLI*# SEQUENCE: FEYTGNLI*# ...# >MUS1327D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESAGNLI*# SEQUENCE: FESAGNLI*# ...# >MUS1327E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESDGNLI*# SEQUENCE: FESDGNLI*# ...# >MUS1327F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESEGNLI*# SEQUENCE: FESEGNLI*# ...# >MUS13280# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESFGNLI*# SEQUENCE: FESFGNLI*# ...# >MUS13281# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESGGNLI*# SEQUENCE: FESGGNLI*# ...# >MUS13282# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESHGNLI*# SEQUENCE: FESHGNLI*# ...# >MUS13283# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESIGNLI*# SEQUENCE: FESIGNLI*# ...# >MUS13284# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESKGNLI*# SEQUENCE: FESKGNLI*# ...# >MUS13285# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESLGNLI*# SEQUENCE: FESLGNLI*# ...# >MUS13286# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESMGNLI*# SEQUENCE: FESMGNLI*# ...# >MUS13287# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESNGNLI*# SEQUENCE: FESNGNLI*# ...# >MUS13288# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESPGNLI*# SEQUENCE: FESPGNLI*# ...# >MUS13289# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESQGNLI*# SEQUENCE: FESQGNLI*# ...# >MUS1328A# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESRGNLI*# SEQUENCE: FESRGNLI*# ...# >MUS1328B# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESSGNLI*# SEQUENCE: FESSGNLI*# ...# >MUS1328C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESVGNLI*# SEQUENCE: FESVGNLI*# ...# >MUS1328D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESWGNLI*# SEQUENCE: FESWGNLI*# ...# >MUS1328E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESYGNLI*# SEQUENCE: FESYGNLI*# ...# >MUS1328F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTANLI*# SEQUENCE: FESTANLI*# ...# >MUS13290# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTDNLI*# SEQUENCE: FESTDNLI*# ...# >MUS13291# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTENLI*# SEQUENCE: FESTENLI*# ...# >MUS13292# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTFNLI*# SEQUENCE: FESTFNLI*# ...# >MUS13293# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTHNLI*# SEQUENCE: FESTHNLI*# ...# >MUS13294# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTINLI*# SEQUENCE: FESTINLI*# ...# >MUS13295# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTKNLI*# SEQUENCE: FESTKNLI*# ...# >MUS13296# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTLNLI*# SEQUENCE: FESTLNLI*# ...# >MUS13297# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTMNLI*# SEQUENCE: FESTMNLI*# ...# >MUS13298# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTNNLI*# SEQUENCE: FESTNNLI*# ...# >MUS13299# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTPNLI*# SEQUENCE: FESTPNLI*# ...# >MUS1329A# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTQNLI*# SEQUENCE: FESTQNLI*# ...# >MUS1329B# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTRNLI*# SEQUENCE: FESTRNLI*# ...# >MUS1329C# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTSNLI*# SEQUENCE: FESTSNLI*# ...# >MUS1329D# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTTNLI*# SEQUENCE: FESTTNLI*# ...# >MUS1329E# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTVNLI*# SEQUENCE: FESTVNLI*# ...# >MUS1329F# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTWNLI*# SEQUENCE: FESTWNLI*# ...# >MUS132A0# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTYNLI*# SEQUENCE: FESTYNLI*# ...# >MUS132A1# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGALI*# SEQUENCE: FESTGALI*# ...# >MUS132A2# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGDLI*# SEQUENCE: FESTGDLI*# ...# >MUS132A3# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGELI*# SEQUENCE: FESTGELI*# ...# >MUS132A4# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGFLI*# SEQUENCE: FESTGFLI*# ...# >MUS132A5# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGGLI*# SEQUENCE: FESTGGLI*# ...# >MUS132A6# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGHLI*# SEQUENCE: FESTGHLI*# ...# >MUS132A7# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGILI*# SEQUENCE: FESTGILI*# ...# >MUS132A8# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGKLI*# SEQUENCE: FESTGKLI*# ...# >MUS132A9# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGLLI*# SEQUENCE: FESTGLLI*# ...# >MUS132AA# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGMLI*# SEQUENCE: FESTGMLI*# ...# >MUS132AB# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGPLI*# SEQUENCE: FESTGPLI*# ...# >MUS132AC# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGQLI*# SEQUENCE: FESTGQLI*# ...# >MUS132AD# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGRLI*# SEQUENCE: FESTGRLI*# ...# >MUS132AE# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGSLI*# SEQUENCE: FESTGSLI*# ...# >MUS132AF# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGTLI*# SEQUENCE: FESTGTLI*# ...# >MUS132B0# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGVLI*# SEQUENCE: FESTGVLI*# ...# >MUS132B1# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGWLI*# SEQUENCE: FESTGWLI*# ...# >MUS132B2# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGYLI*# SEQUENCE: FESTGYLI*# ...# >MUS132B3# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNAI*# SEQUENCE: FESTGNAI*# ...# >MUS132B4# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNDI*# SEQUENCE: FESTGNDI*# ...# >MUS132B5# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNEI*# SEQUENCE: FESTGNEI*# ...# >MUS132B6# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# DB REFERENCE: SWISS: (HEMA_IACKP,HEMA_IACKQ)# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGNFI*# SEQUENCE: FESTGNFI*# ...# >MUS132B7# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNGI*# SEQUENCE: FESTGNGI*# ...# >MUS132B8# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGNHI*# SEQUENCE: FESTGNHI*# ...# >MUS132B9# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNII*# SEQUENCE: FESTGNII*# ...# >MUS132BA# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNKI*# SEQUENCE: FESTGNKI*# ...# >MUS132BB# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNMI*# SEQUENCE: FESTGNMI*# ...# >MUS132BC# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNNI*# SEQUENCE: FESTGNNI*# ...# >MUS132BD# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNPI*# SEQUENCE: FESTGNPI*# ...# >MUS132BE# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNQI*# SEQUENCE: FESTGNQI*# ...# >MUS132BF# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGNRI*# SEQUENCE: FESTGNRI*# ...# >MUS132C0# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNSI*# SEQUENCE: FESTGNSI*# ...# >MUS132C1# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNTI*# SEQUENCE: FESTGNTI*# ...# >MUS132C2# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNVI*# SEQUENCE: FESTGNVI*# ...# >MUS132C3# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGNWI*# SEQUENCE: FESTGNWI*# ...# >MUS132C4# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGNYI*# SEQUENCE: FESTGNYI*# ...# >MUS132C5# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNLA*# SEQUENCE: FESTGNLA*# ...# >MUS132C6# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesh,FESTGNLF*# SEQUENCE: FESTGNLF*# ...# >MUS132C7# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNLL*# SEQUENCE: FESTGNLL*# ...# >MUS132C8# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesl,FESTGNLM*# SEQUENCE: FESTGNLM*# ...# >MUS132C9# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesl,FESTGNLN*# SEQUENCE: FESTGNLN*# ...# >MUS132CA# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNLS*# SEQUENCE: FESTGNLS*# ...# >MUS132CB# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNLT*# SEQUENCE: FESTGNLT*# ...# >MUS132CC# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNLV*# SEQUENCE: FESTGNLV*# ...# >MUS132CD# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesm,FESTGNLW*# SEQUENCE: FESTGNLW*# ...# >MUS132CE# MHC MOLECULE: H-2Kk, CLASS-1, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Influenza HA 2 (255-262) homologue# ANCHOR POSITIONS: ?# REFERENCES: stryhn96a# COMMENT:# SUMMARY: H-2Kk,actunkn,bindyesl,FESTGNLY*# SEQUENCE: FESTGNLY*# ...# >MUS132CF# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Other functional# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MMTV env# DB REFERENCE: SWISS: (ENV_MMTVG,ENV_MMTVB)# & PIR1: (VCMVM,VCMVMM)# & PIR2: (S26388)# ANCHOR POSITIONS: ?# REFERENCES: malarkannan96a# COMMENT:# SUMMARY: H-2Kb,actyesu,bindyesu,ANYDFICV*# SEQUENCE: ANYDFICV*# ...# >MUS132D0# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, high# SOURCE: P91A tum- homologue# DB REFERENCE: SWISS: (DXA2_MOUSE,DXA2_MOUSE)# & PIR2: (I49504)# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesh,QNHRALDLVA*# SEQUENCE: QNHRALDLVA*# ...# >MUS132D1# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: P91A tum- homologue# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesm,ANHRALDLVA*# SEQUENCE: ANHRALDLVA*# ...# >MUS132D2# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization/Proliferation# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: P91A tum- homologue# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesh,QAHRALDLVA*# SEQUENCE: QAHRALDLVA*# ...# >MUS132D3# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization/Proliferation# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: P91A tum- homologue# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actyesm,bindyesm,QNARALDLVA*# SEQUENCE: QNARALDLVA*# ...# >MUS132D4# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: P91A tum- homologue# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actunkn,bindyesm,QNHAALDLVA*# SEQUENCE: QNHAALDLVA*# ...# >MUS132D5# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization/Proliferation# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: P91A tum- homologue# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesl,QNHRALDAVA*# SEQUENCE: QNHRALDAVA*# ...# >MUS132D6# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: P91A tum- homologue# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesm,QNHRALDLAA*# SEQUENCE: QNHRALDLAA*# ...# >MUS132D7# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Stabilization/Proliferation# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: P91A tum- homologue# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actyesh,bindyesm,QNHRALDLVI*# SEQUENCE: QNHRALDLVI*# ...# >MUS132D8# MHC MOLECULE: H-2Ld, CLASS-1, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: P91A tum- homologue# ANCHOR POSITIONS: ?# REFERENCES: mccormick96a# COMMENT:# SUMMARY: H-2Ld,actyesl,bindyesu,QNHRAADLVA*# SEQUENCE: QNHRAADLVA*# ...# >MUS232D9# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: hsp65 (153-171)# DB REFERENCE: SWISS: (CH60_MYCCH,CH60_MYCMA,CH60_MYCAV,CH60_MYCSC,CH60_MYCAS,# & CH60_MYCGN,CH60_MYCMR,CH60_MYCPA,CH60_MYCTU,CH60_MYCGO,# & CH60_MYCPH,CH62_MYCLE,CH60_MYCIT,CH60_MYCFO,CH60_MYCPA,# & CH62_MYCTU,CH60_MYCKA,CH60_MYCSH,CH60_MYCGS)# & PIR2: (A43509,S05295,S05294,S40245,S05293,S05292,A26950,# & A25902)# ANCHOR POSITIONS: ?# REFERENCES: de-velasco95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,DQSIGDLIAEAMDKVGNEG*# SEQUENCE: DQSIGDLIAEAMDKVGNEG*# ...# >MUS232DA# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Hemagglutinin (111-120)# DB REFERENCE: SWISS: (HEMA_IAXIA,HEMA_IAHAR,HEMA_IAKIE,HEMA_IAPUE,HEMA_IACAO,# & HEMA_IAUSS,HEMA_IATAI,HEMA_IALEN)# & PIR1: (HMIV,HMIVUR,HMIVTA)# & PIR2: (PQ0321,A35788,JQ2370,JQ2371,JQ1643,PQ0319,JQ2372,# & JQ1437)# ANCHOR POSITIONS: ?# REFERENCES: de-velasco95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,FERFEIFPKE*# SEQUENCE: FERFEIFPKE*# ...# >MUS232DB# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: CLIP (86-104)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,KPVSQMRMATPLLMRPMSM*# SEQUENCE: KPVSQMRMATPLLMRPMSM*# ...# >MUS232DC# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,KPVSQARMATPLLMRPMSM*# SEQUENCE: KPVSQARMATPLLMRPMSM*# ...# >MUS232DD# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,KPVSQMRAATPLLMRPMSM*# SEQUENCE: KPVSQMRAATPLLMRPMSM*# ...# >MUS232DE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,KPVSQMRMATALLMRPMSM*# SEQUENCE: KPVSQMRMATALLMRPMSM*# ...# >MUS232DF# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,KPVSQMRMATPALMRPMSM*# SEQUENCE: KPVSQMRMATPALMRPMSM*# ...# >MUS232E0# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,KPVSQMRMATPLLARPMSM*# SEQUENCE: KPVSQMRMATPLLARPMSM*# ...# >MUS232E1# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (86-104)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,KPVSQMRMATPLLMRPMSM*# SEQUENCE: KPVSQMRMATPLLMRPMSM*# ...# >MUS232E2# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,KPVSQARMATPLLMRPMSM*# SEQUENCE: KPVSQARMATPLLMRPMSM*# ...# >MUS232E3# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,KPVSQMAMATPLLMRPMSM*# SEQUENCE: KPVSQMAMATPLLMRPMSM*# ...# >MUS232E4# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,KPVSQMRAATPLLMRPMSM*# SEQUENCE: KPVSQMRAATPLLMRPMSM*# ...# >MUS232E5# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,KPVSQMRMATALLMRPMSM*# SEQUENCE: KPVSQMRMATALLMRPMSM*# ...# >MUS232E6# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesm,KPVSQMRMATPALMRPMSM*# SEQUENCE: KPVSQMRMATPALMRPMSM*# ...# >MUS232E7# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesh,KPVSQMRMATPLLARPMSM*# SEQUENCE: KPVSQMRMATPLLARPMSM*# ...# >MUS232E8# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: CLIP (86-104)# DB REFERENCE: SWISS: (HG2A_MOUSE)# & PIR1: (HLHMSG)# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Au,actunkn,bindyesl,KPVSQMRMATPLLMRPMSM*# SEQUENCE: KPVSQMRMATPLLMRPMSM*# ...# >MUS232E9# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,KPVSQMRAATPLLMRPMSM*# SEQUENCE: KPVSQMRAATPLLMRPMSM*# ...# >MUS232EA# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: CLIP (86-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: gautam95a# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,KPVSQMRMATPLLARPMSM*# SEQUENCE: KPVSQMRMATPLLARPMSM*# ...# >MUS232EB# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP1 (211-230)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,SVVTNDMGTICSRIVTERQR*# SEQUENCE: SVVTNDMGTICSRIVTERQR*# ...# >MUS232EC# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HRV capsid VP2 (101-120)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,LGRSGYTHHVQCNASKFNQG*# SEQUENCE: LGRSGYTHHVQCNASKFNQG*# ...# >MUS232ED# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP3 (161-180)# DB REFERENCE: SWISS: (POLG_HRV1A)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,STISLVVPWVSASHFRLTAD*# SEQUENCE: STISLVVPWVSASHFRLTAD*# ...# >MUS232EE# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HRV capsid VP3 (181-200)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,NKYSMAGYITCWYQTXLVVP*# SEQUENCE: NKYSMAGYITCWYQTXLVVP*# ...# >MUS232EF# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP1 (51-70)# DB REFERENCE: SWISS: (POLG_HRV1A)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,IETRYVITSQTRDEMSIESF*# SEQUENCE: IETRYVITSQTRDEMSIESF*# ...# >MUS232F0# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HRV capsid VP1 (111-130)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesh,bindyesu,RRFELFTYVRFDESITLVPC*# SEQUENCE: RRFELFTYVRFDESITLVPC*# ...# >MUS232F1# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP1 (121-140)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,FDESITLVPCIAGRGDDIGH*# SEQUENCE: FDESITLVPCIAGRGDDIGH*# ...# >MUS232F2# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HRV capsid VP1 (131-150)# DB REFERENCE: SWISS: (POLG_HRV1A)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesh,bindyesu,IAGRGDDIGHIVMQYMYVPP*# SEQUENCE: IAGRGDDIGHIVMQYMYVPP*# ...# >MUS232F3# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP1 (241-260)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,HRARHTKAWCPRPPRAVPYT*# SEQUENCE: HRARHTKAWCPRPPRAVPYT*# ...# >MUS232F4# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP2 (21-40)# DB REFERENCE: SWISS: (POLG_HRV1B)# & PIR1: (GNNY1B)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,STITSQDVANAVVGYGVWPH*# SEQUENCE: STITSQDVANAVVGYGVWPH*# ...# >MUS232F5# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HRV capsid VP2 (101-120)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,LGRSGYTHHVQCNASKFNQG*# SEQUENCE: LGRSGYTHHVQCNASKFNQG*# ...# >MUS232F6# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HRV capsid VP2 (121-140)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,TLLVAMIPEHQLASARHGSV*# SEQUENCE: TLLVAMIPEHQLASARHGSV*# ...# >MUS232F7# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP3 (41-60)# DB REFERENCE: SWISS: (POLG_HRV1A)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,KNLIEMCQVDTLIPVNNVGN*# SEQUENCE: KNLIEMCQVDTLIPVNNVGN*# ...# >MUS232F8# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP3 (201-220)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,PSTPQTADMLCFVSACRDFC*# SEQUENCE: PSTPQTADMLCFVSACRDFC*# ...# >MUS232F9# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: HRV capsid VP2 (31-50)# DB REFERENCE: SWISS: (POLG_HRV1B,POLG_HRV1A)# & PIR1: (GNNY1B)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2b,actyesm,bindyesu,AVVGYGVWPHYLTPQDATAI*# SEQUENCE: AVVGYGVWPHYLTPQDATAI*# ...# >MUS232FA# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP2 (91-110)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2b,actyesl,bindyesu,IFGENMYYHFLGRSGYTHHV*# SEQUENCE: IFGENMYYHFLGRSGYTHHV*# ...# >MUS232FB# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: HRV capsid VP2 (201-220)# DB REFERENCE: SWISS: (POLG_HRV1B,POLG_HRV1A)# & PIR1: (GNNY1B)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2b,actyesh,bindyesu,LIVPYVNAVPMDSMLRHNNW*# SEQUENCE: LIVPYVNAVPMDSMLRHNNW*# ...# >MUS232FC# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP2 (211-230)# DB REFERENCE: SWISS: (POLG_HRV1A)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2b,actyesl,bindyesu,MDSMLRHNNWCLVIIPISPL*# SEQUENCE: MDSMLRHNNWCLVIIPISPL*# ...# >MUS232FD# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP2 (221-240)# DB REFERENCE: SWISS: (POLG_HRV1A)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2b,actyesl,bindyesu,CLVIIPISPLRSETTSSNIV*# SEQUENCE: CLVIIPISPLRSETTSSNIV*# ...# >MUS232FE# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: HRV capsid VP3 (121-140)# ANCHOR POSITIONS: ?# REFERENCES: hastings93a# COMMENT:# SUMMARY: H-2b,actyesl,bindyesu,LGRSGYTHHVQCNASKFNQG*# SEQUENCE: LGRSGYTHHVQCNASKFNQG*# ...# >MUS232FF# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: lambda repressor cI (12-26)# ANCHOR POSITIONS: ?# REFERENCES: feng94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,LEDARRLKAITEKKK*# SEQUENCE: LEDARRLKAITEKKK*# ...# >MUS23300# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: lambda repressor cI (12-26)# ANCHOR POSITIONS: ?# REFERENCES: feng94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LEDARRLKAITEKKK*# SEQUENCE: LEDARRLKAITEKKK*# ...# >MUS23301# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: lambda repressor cI (84-98)# ANCHOR POSITIONS: ?# REFERENCES: feng94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,IYEMYEAVSMQKPSLR*# SEQUENCE: IYEMYEAVSMQKPSLR*# ...# >MUS23302# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: pigeon cytochrome c (81-104)# ANCHOR POSITIONS: ?# REFERENCES: feng94a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,IFAGIKKKERADLIAYL*# SEQUENCE: IFAGIKKKERADLIAYL*# ...# >MUS23303# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: pigeon cytochrome c (81-104)# ANCHOR POSITIONS: ?# REFERENCES: feng94a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,IFAGIKKKERADLIAYL*# SEQUENCE: IFAGIKKKERADLIAYL*# ...# >MUS23304# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: lambda repressor cI (73-88)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# ANCHOR POSITIONS: ?# REFERENCES: feng94a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,EEFSPSIAREIYEMY*# SEQUENCE: EEFSPSIAREIYEMY*# ...# >MUS23305# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Ad-alpha (1-17)# DB REFERENCE: SWISS: (HA2D_MOUSE)# & PIR1: (HLMSA2)# ANCHOR POSITIONS: ?# REFERENCES: feng94a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,EDDIEADHVGFYGTTVY*# SEQUENCE: EDDIEADHVGFYGTTVY*# ...# >MUS23306# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ad-beta (75-94)# DB REFERENCE: SWISS: (HB2D_MOUSE)# & PIR1: (HLMSAB)# ANCHOR POSITIONS: ?# REFERENCES: feng94a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesl,VDTACRHNYEGPETSTSLRR*# SEQUENCE: VDTACRHNYEGPETSTSLRR*# ...# >MUS23307# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: TMEV capsid protein (74-86)# DB REFERENCE: SWISS: (POLG_TMEVG,POLG_TMEVB,POLG_TMEVD)# & PIR1: (GNNYTN,GNNYTP,GNNYTM)# & PIR3: (S13554)# ANCHOR POSITIONS: ?# REFERENCES: gerety94a# COMMENT:# SUMMARY: I-As,actyesh,bindyesu,QEAFSHIRIPLPH*# SEQUENCE: QEAFSHIRIPLPH*# ...# >MUS23308# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: EMCV capsid protein (74-86)# DB REFERENCE: SWISS: (POLG_EMCVB,POLG_ENMGO,POLG_EMCVD,POLG_ENMG3)# & PIR1: (GNNYMV,GNNYED,GNNYEB)# & PIR2: (S55401,S35961)# ANCHOR POSITIONS: ?# REFERENCES: gerety94a# COMMENT:# SUMMARY: I-As,actyesl,bindyesu,QKPFEYIRIPLPH*# SEQUENCE: QKPFEYIRIPLPH*# ...# >MUS23309# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Reference/Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (112-129)# ANCHOR POSITIONS: ?# REFERENCES: guery92a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,RNRCKGTDVQAWIRGARL*# SEQUENCE: RNRCKGTDVQAWIRGARL*# ...# >MUS2330A# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (45-64)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2b,actyesm,bindyesu,GAASGPKVVIDGKDQNVTGS*# SEQUENCE: GAASGPKVVIDGKDQNVTGS*# ...# >MUS2330B# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (45-64)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S11234,S02753)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,GAASGPKVVIDGKDQNVTGS*# SEQUENCE: GAASGPKVVIDGKDQNVTGS*# ...# >MUS2330C# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (45-64)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,GAASGPKVVIDGKDQNVTGS*# SEQUENCE: GAASGPKVVIDGKDQNVTGS*# ...# >MUS2330D# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (45-64)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2s,actyesh,bindyesu,GAASGPKVVIDGKDQNVTGS*# SEQUENCE: GAASGPKVVIDGKDQNVTGS*# ...# >MUS2330E# MHC MOLECULE: H-2f, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (45-64)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2f,actyesm,bindyesu,GAASGPKVVIDGKDQNVTGS*# SEQUENCE: GAASGPKVVIDGKDQNVTGS*# ...# >MUS2330F# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (61-80)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2b,actyesh,bindyesu,VTGSVVCTTAAGNVNIAIGG*# SEQUENCE: VTGSVVCTTAAGNVNIAIGG*# ...# >MUS23310# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (61-80)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,VTGSVVCTTAAGNVNIAIGG*# SEQUENCE: VTGSVVCTTAAGNVNIAIGG*# ...# >MUS23311# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (61-80)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S11234,S02753)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2d,actyesh,bindyesu,VTGSVVCTTAAGNVNIAIGG*# SEQUENCE: VTGSVVCTTAAGNVNIAIGG*# ...# >MUS23312# MHC MOLECULE: H-2s, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (61-80)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2s,actyesl,bindyesu,VTGSVVCTTAAGNVNIAIGG*# SEQUENCE: VTGSVVCTTAAGNVNIAIGG*# ...# >MUS23313# MHC MOLECULE: H-2f, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (61-80)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S02753,S11234)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: H-2f,actyesl,bindyesu,VTGSVVCTTAAGNVNIAIGG*# SEQUENCE: VTGSVVCTTAAGNVNIAIGG*# ...# >HUM23314# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (45-64)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S11234,S02753)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: HLA-D?,actyesh,bindyesu,GAASGPKVVIDGKDQNVTGS*# SEQUENCE: GAASGPKVVIDGKDQNVTGS*# ...# >HUM23315# MHC MOLECULE: HLA-D?, CLASS-2, (HUMAN)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 19-kDa Ag (61-80)# DB REFERENCE: SWISS: (19KD_MYCTU)# & PIR2: (S11234,S02753)# ANCHOR POSITIONS: ?# REFERENCES: harris93e# COMMENT:# SUMMARY: HLA-D?,actyesm,bindyesu,VTGSVVCTTAAGNVNIAIGG*# SEQUENCE: VTGSVVCTTAAGNVNIAIGG*# ...# >MUS23316# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Ad,actyesh,bindyesu,AEGASYTEANKAKGIT*# SEQUENCE: AEGASYTEANKAKGIT*# ...# >MUS23317# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,AEGFSYTEANKAKGIT*# SEQUENCE: AEGFSYTEANKAKGIT*# ...# >MUS23318# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# DB REFERENCE: SWISS: (CYC_CHESE,CYC_CHESE)# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Aq,actyesm,bindyesu,AEGFSYTEANKNKGIT*# SEQUENCE: AEGFSYTEANKNKGIT*# ...# >MUS23319# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Aq,actyesl,bindyesu,AEGRSYTEANKAKGIT*# SEQUENCE: AEGRSYTEANKAKGIT*# ...# >MUS2331A# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Aq,actyesl,bindyesu,AEGASYTEANKAKGIT*# SEQUENCE: AEGASYTEANKAKGIT*# ...# >MUS2331B# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# DB REFERENCE: SWISS: (CYC_CHESE,CYC_CHESE)# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-As,actyesm,bindyesu,AEGFSYTEANKNKGIT*# SEQUENCE: AEGFSYTEANKNKGIT*# ...# >MUS2331C# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-As,actyesl,bindyesu,AEGRSYTEANKAKGIT*# SEQUENCE: AEGRSYTEANKAKGIT*# ...# >MUS2331D# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Ad,actyesh,bindyesu,AEGFSYTVANKAKGIT*# SEQUENCE: AEGFSYTVANKAKGIT*# ...# >MUS2331E# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Ad,actyesm,bindyesu,AEGASYTVANKAKGIT*# SEQUENCE: AEGASYTVANKAKGIT*# ...# >MUS2331F# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Ad,actyesl,bindyesu,AEGRSYTVANKAKGIT*# SEQUENCE: AEGRSYTVANKAKGIT*# ...# >MUS23320# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,AEGFSYTVANKAKGIT*# SEQUENCE: AEGFSYTVANKAKGIT*# ...# >MUS23321# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Aq,actyesm,bindyesu,AEGFSYTVANKNKGIT*# SEQUENCE: AEGFSYTVANKNKGIT*# ...# >MUS23322# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Aq,actyesm,bindyesu,AEGRSYTVANKAKGIT*# SEQUENCE: AEGRSYTVANKAKGIT*# ...# >MUS23323# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-Aq,actyesm,bindyesu,AEGASYTVANKAKGIT*# SEQUENCE: AEGASYTVANKAKGIT*# ...# >MUS23324# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-As,actyesh,bindyesu,AEGFSYTVANKAKGIT*# SEQUENCE: AEGFSYTVANKAKGIT*# ...# >MUS23325# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-As,actyesh,bindyesu,AEGFSYTVANKNKGIT*# SEQUENCE: AEGFSYTVANKNKGIT*# ...# >MUS23326# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-As,actyesh,bindyesu,AEGASYTVANKAKGIT*# SEQUENCE: AEGASYTVANKAKGIT*# ...# >MUS23327# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: pigeon cytochrome c (43-58) homologue# ANCHOR POSITIONS: ?# REFERENCES: itoh94a# COMMENT:# SUMMARY: I-As,actyesm,bindyesu,AEGRSYTVANKAKGIT*# SEQUENCE: AEGRSYTVANKAKGIT*# ...# >MUS23328# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mouse cytochrome c (93-104)# DB REFERENCE: SWISS: (CYC2_MOUSE,CYC2_MOUSE)# & PIR1: (CCMST)# ANCHOR POSITIONS: ?# REFERENCES: kelner92a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,DLIKYLKQATSS*# SEQUENCE: DLIKYLKQATSS*# ...# >MUS23329# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mouse cytochrome c (93-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: kelner92a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,DLIAYLKQATSS*# SEQUENCE: DLIAYLKQATSS*# ...# >MUS2332A# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mouse cytochrome c (95-104) homologue# ANCHOR POSITIONS: ?# REFERENCES: kelner92a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,IAYLKQATSS*# SEQUENCE: IAYLKQATSS*# ...# >MUS2332B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mt cyt (93-104)# DB REFERENCE: SWISS: (CYC2_MOUSE,CYC2_MOUSE)# & PIR1: (CCMST)# ANCHOR POSITIONS: ?# REFERENCES: kelner92a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,IKYLKQATSS*# SEQUENCE: IKYLKQATSS*# ...# >MUS2332C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (136-145)# DB REFERENCE: SWISS: (MYG_ESCGI,MYG_MEGNO,MYG_MESCA,MYG_BALAC,MYG_GLOME,# & MYG_TURTR,MYG_CASFI,MYG_ORCOR,MYG_BALPH,MYG_INIGE,# & MYG_PHYCA,MYG_KOGSI,MYG_ZIPCA,MYG_PHYCA)# & PIR1: (MYWHW,MYDD,MYWHP,MYWHH,MYDDAR,MYWHF,MYWHT,MYWHK,MYWHL,# & MYWHU,MYWHC,MYDDBS,MYWHZ)# & PIR2: (JN0410)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,ELFRKDIAAK*# SEQUENCE: ELFRKDIAAK*# ...# >MUS2332D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (136-144)# DB REFERENCE: SWISS: (MYG_BALPH,MYG_BALAC,MYG_ZIPCA,MYG_KOGSI,MYG_MEGNO,# & MYG_TURTR,MYG_ORCOR,MYG_CASFI,MYG_PHYCA,MYG_PHYCA,# & MYG_INIGE,MYG_MESCA,MYG_GLOME,MYG_ESCGI)# & PIR1: (MYWHF,MYWHC,MYWHT,MYWHP,MYWHH,MYDDBS,MYWHZ,MYDD,MYWHK,# & MYWHL,MYWHU,MYWHW,MYDDAR)# & PIR2: (JN0410)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,ELFRKDIAA*# SEQUENCE: ELFRKDIAA*# ...# >MUS2332E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (137-146)# DB REFERENCE: SWISS: (MYG_MEGNO,MYG_BALAC,MYG_ESCGI,MYG_ZIPCA,MYG_ORCOR,# & MYG_KOGSI,MYG_BALPH,MYG_TURTR,MYG_PHYCA,MYG_PHYCA,# & MYG_INIGE,MYG_GLOME,MYG_MESCA,MYG_CASFI)# & PIR1: (MYDDAR,MYWHW,MYWHC,MYWHZ,MYWHU,MYWHK,MYWHP,MYWHF,MYDD,# & MYWHL,MYDDBS,MYWHT,MYWHH)# & PIR2: (JN0410)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,LFRKDIAAKY*# SEQUENCE: LFRKDIAAKY*# ...# >MUS2332F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (137-145)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_CASFI,MYG_BALAC,MYG_MEGNO,MYG_ZIPCA,# & MYG_ORCOR,MYG_ESCGI,MYG_BALPH,MYG_MESCA,MYG_GLOME,# & MYG_INIGE,MYG_PHYCA,MYG_TURTR,MYG_KOGSI)# & PIR1: (MYDD,MYWHT,MYWHL,MYWHZ,MYWHW,MYDDBS,MYWHH,MYWHU,MYWHC,# & MYWHP,MYWHF,MYDDAR,MYWHK)# & PIR2: (JN0410)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,LFRKDIAAK*# SEQUENCE: LFRKDIAAK*# ...# >MUS23330# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,AALELFRKDIAAKY*# SEQUENCE: AALELFRKDIAAKY*# ...# >MUS23331# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,RALELFRKDIAAKY*# SEQUENCE: RALELFRKDIAAKY*# ...# >MUS23332# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,EALELFRKDIAAKY*# SEQUENCE: EALELFRKDIAAKY*# ...# >MUS23333# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALALFRKDIAAKY*# SEQUENCE: KALALFRKDIAAKY*# ...# >MUS23334# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALDLFRKDIAAKY*# SEQUENCE: KALDLFRKDIAAKY*# ...# >MUS23335# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KALKLFRKDIAAKY*# SEQUENCE: KALKLFRKDIAAKY*# ...# >MUS23336# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KALEAFRKDIAAKY*# SEQUENCE: KALEAFRKDIAAKY*# ...# >MUS23337# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALEVFRKDIAAKY*# SEQUENCE: KALEVFRKDIAAKY*# ...# >MUS23338# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALEFFRKDIAAKY*# SEQUENCE: KALEFFRKDIAAKY*# ...# >MUS23339# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALELYRKDIAAKY*# SEQUENCE: KALELYRKDIAAKY*# ...# >MUS2333A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KALELFEKDIAAKY*# SEQUENCE: KALELFEKDIAAKY*# ...# >MUS2333B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# DB REFERENCE: SWISS: (MYG_HALGR,MYG_SPAEH,MYG_ELEMA,MYG_HORSE,MYG_ROUAE,# & MYG_LEPMU,MYG_LAGMA,MYG_CANFA,MYG_ZALCA,MYG_MELME,# & MYG_PROGU,MYG_TUPGL,MYG_CTEGU,MYG_LYCPI,MYG_VULCH,# & MYG_HORSE,MYG_ORYAF,MYG_LOXAF,MYG_ERIEU,MYG_NYCCO,# & MYG_GALCR,MYG_MOUSE,MYG_PERPO,MYG_MOUSE)# & PIR1: (MYVJ,MYOY,MYOL,MYHH,MYSLG,MYSLH,MYHOZ,MYRTNG,MYLR,MYELI,# & MYELA,MYLP,MYHO,MYKS,MYMS)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KALELFRNDIAAKY*# SEQUENCE: KALELFRNDIAAKY*# ...# >MUS2333C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation/Competition# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesm,KALELFRKDAAAKY*# SEQUENCE: KALELFRKDAAAKY*# ...# >MUS2333D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALELFRKDVAAKY*# SEQUENCE: KALELFRKDVAAKY*# ...# >MUS2333E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation/Competition# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesm,KALELFRKDITAKY*# SEQUENCE: KALELFRKDITAKY*# ...# >MUS2333F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# DB REFERENCE: SWISS: (MYG_PHOPH)# & PIR1: (MYPE,MYPED)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KALELFRKDIATKY*# SEQUENCE: KALELFRKDIATKY*# ...# >MUS23340# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALELFRKDIAQKY*# SEQUENCE: KALELFRKDIAQKY*# ...# >MUS23341# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KALELFRKDIAAAY*# SEQUENCE: KALELFRKDIAAAY*# ...# >MUS23342# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALELFRKDIAARY*# SEQUENCE: KALELFRKDIAARY*# ...# >MUS23343# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesl,bindyesu,KALELFRKDIAAEY*# SEQUENCE: KALELFRKDIAAEY*# ...# >MUS23344# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALELFRKDIAAKA*# SEQUENCE: KALELFRKDIAAKA*# ...# >MUS23345# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesm,bindyesu,KALELFRKDIAAKF*# SEQUENCE: KALELFRKDIAAKF*# ...# >MUS23346# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actyesh,bindyesu,KALELFRKDIAAKI*# SEQUENCE: KALELFRKDIAAKI*# ...# >MUS23347# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesh,KALELARKDIAAKY*# SEQUENCE: KALELARKDIAAKY*# ...# >MUS23348# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesh,KALELIRKDIAAKY*# SEQUENCE: KALELIRKDIAAKY*# ...# >MUS23349# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,KALELFKKDIAAKY*# SEQUENCE: KALELFKKDIAAKY*# ...# >MUS2334A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesh,KALELFRRDIAAKY*# SEQUENCE: KALELFRRDIAAKY*# ...# >MUS2334B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,KALELFRKKIAAKY*# SEQUENCE: KALELFRKKIAAKY*# ...# >MUS2334C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesl,KALELFRKDFAAKY*# SEQUENCE: KALELFRKDFAAKY*# ...# >MUS2334D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,KALELFRKDILAKY*# SEQUENCE: KALELFRKDILAKY*# ...# >MUS2334E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesh,KALELFRKDIQAKY*# SEQUENCE: KALELFRKDIQAKY*# ...# >MUS2334F# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Myoglobin (133-146)# ANCHOR POSITIONS: ?# REFERENCES: kurata90a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesm,KALELFRKDIALKY*# SEQUENCE: KALELFRKDIALKY*# ...# >MUS23350# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesh,bindyesu,GRGLAYIYADGKMVN*# SEQUENCE: GRGLAYIYADGKMVN*# ...# >MUS23351# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,GLGLAYIYADGKMVN*# SEQUENCE: GLGLAYIYADGKMVN*# ...# >MUS23352# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,GRGLLYIYADGKMVN*# SEQUENCE: GRGLLYIYADGKMVN*# ...# >MUS23353# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,GRGLAFIYADGKMVN*# SEQUENCE: GRGLAFIYADGKMVN*# ...# >MUS23354# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,GRGLAYIFADGKMVN*# SEQUENCE: GRGLAYIFADGKMVN*# ...# >MUS23355# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,GRGLAYIYLDGKMVN*# SEQUENCE: GRGLAYIYLDGKMVN*# ...# >MUS23356# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesh,bindyesu,GRGLAYIYANGKMVN*# SEQUENCE: GRGLAYIYANGKMVN*# ...# >MUS23357# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,GRGLAYIYADGLMVN*# SEQUENCE: GRGLAYIYADGLMVN*# ...# >MUS23358# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesh,bindyesu,GRGLAYIYADGKLVN*# SEQUENCE: GRGLAYIYADGKLVN*# ...# >MUS23359# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (86-100) homologue# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: H-2k,actyesm,bindyesu,GRGLAYIYADGKMVD*# SEQUENCE: GRGLAYIYADGKMVD*# ...# >MUS2335A# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (91-110)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,YIYADGKMVNEALVRQGLAK*# SEQUENCE: YIYADGKMVNEALVRQGLAK*# ...# >MUS2335B# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staphilococcus aureus nuclease NASE (100-120)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# ANCHOR POSITIONS: ?# REFERENCES: liu93a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,NEALVRQGLAKVAYVYKPNNT*# SEQUENCE: NEALVRQGLAKVAYVYKPNNT*# ...# >MUS2335C# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staphylococcal nuclease (61-79)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# ANCHOR POSITIONS: ?# REFERENCES: lock91a,smilek90a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,FTKKMVENAKKIEVEFDK*# SEQUENCE: FTKKMVENAKKIEVEFDK*# ...# >MUS2335D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Staphylococcal nuclease (61-79)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# ANCHOR POSITIONS: ?# REFERENCES: lock91a,harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,FTKKMVENAKKIEVEFDK*# SEQUENCE: FTKKMVENAKKIEVEFDK*# ...# >MUS2335E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Recognition/In vivo response# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: ribosomal protein L9(34-58)# DB REFERENCE: SWISS: (RL9_HUMAN,RL9_MOUSE,RL9_RAT)# & PIR1: (R5RT9)# & PIR2: (G01436,S65792,S42106,G01705)# ANCHOR POSITIONS: ?# REFERENCES: monach95a# COMMENT:# SUMMARY: I-Ek,actyesh,bindyesu,LRRDFNHINVELSLLGKKKKRLRVD*# SEQUENCE: LRRDFNHINVELSLLGKKKKRLRVD*# ...# >MUS2335F# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (1-15)# DB REFERENCE: SWISS: (LACB_BOVIN,LACB_BOVIN)# & PIR1: (LGBO)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,LIVTQTMKGLDIQKV*# SEQUENCE: LIVTQTMKGLDIQKV*# ...# >MUS23360# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (22-36)# DB REFERENCE: SWISS: (LACB_CAPHI,LACB_CAPHI,LACB_BOVIN,LACB_SHEEP,LACB_BOVIN,# & LACB_BUBAR,LACB_BUBAR)# & PIR1: (LGBUI,LGBO,LGSH,LGGT)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,LAMAASDISLLDAQS*# SEQUENCE: LAMAASDISLLDAQS*# ...# >MUS23361# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (42-56)# DB REFERENCE: SWISS: (LACB_BUBAR,LACB_BOVIN,LACB_BOVIN,LACB_BUBAR)# & PIR1: (LGBO,LGBUI)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesh,bindyesu,YVEELKPTPEGDLEI*# SEQUENCE: YVEELKPTPEGDLEI*# ...# >MUS23362# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (52-66)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,GDLEILLQKWENGEA*# SEQUENCE: GDLEILLQKWENGEA*# ...# >MUS23363# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (62-76)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesh,bindyesu,ENDEAAQKKIIAEKT*# SEQUENCE: ENDEAAQKKIIAEKT*# ...# >MUS23364# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (72-86)# DB REFERENCE: SWISS: (LACB_BUBAR,LACB_BOVIN,LACB_CAPHI,LACB_BUBAR,LACB_BOVIN,# & LACB_SHEEP,LACB_CAPHI)# & PIR1: (LGGT,LGBO,LGSH,LGBUI)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,IAEKTKIPAVFKIDA*# SEQUENCE: IAEKTKIPAVFKIDA*# ...# >MUS23365# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (82-95)# DB REFERENCE: SWISS: (LACB_BOVIN,LACB_CAPHI,LACB_BUBAR,LACB_BOVIN,LACB_BUBAR,# & LACB_SHEEP,LACB_CAPHI)# & PIR1: (LGGT,LGBO,LGSH,LGBUI)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,FKIDALNENKVLVL*# SEQUENCE: FKIDALNENKVLVL*# ...# >MUS23366# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (91-104)# DB REFERENCE: SWISS: (LACB_BOVIN,LACB_BUBAR,LACB_BUBAR,LACB_CAPHI,LACB_SHEEP,# & LACB_CAPHI,LACB_BOVIN)# & PIR1: (LGSH,LGBO,LGGT,LGBUI)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,KVLVLDTDYKKYLL*# SEQUENCE: KVLVLDTDYKKYLL*# ...# >MUS23367# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (100-113)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,KKYLLFAMENSAEP*# SEQUENCE: KKYLLFAMENSAEP*# ...# >MUS23368# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (109-123)# DB REFERENCE: SWISS: (LACB_BUBAR,LACB_BOVIN,LACB_BUBAR,LACB_CAPHI,LACB_CAPHI,# & LACB_SHEEP,LACB_BOVIN)# & PIR1: (LGSH,LGBUI,LGGT,LGBO)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,NSAEPEQSLACQCLV*# SEQUENCE: NSAEPEQSLACQCLV*# ...# >MUS23369# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (119-133)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,AQALVRTPEVDDEAL*# SEQUENCE: AQALVRTPEVDDEAL*# ...# >MUS2336A# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (129-143)# DB REFERENCE: SWISS: (LACB_BOVIN,LACB_BUBAR,LACB_BOVIN,LACB_BUBAR)# & PIR1: (LGBUI,LGBO)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,DDEALEKFDKALKAL*# SEQUENCE: DDEALEKFDKALKAL*# ...# >MUS2336B# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (139-153)# DB REFERENCE: SWISS: (LACB_BOVIN,LACB_BUBAR,LACB_BUBAR,LACB_BOVIN)# & PIR1: (LGBUI,LGBO)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesh,bindyesu,ALKALPMHIRLSFNP*# SEQUENCE: ALKALPMHIRLSFNP*# ...# >MUS2336C# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (149-162)# DB REFERENCE: SWISS: (LACB_BOVIN,LACB_BOVIN)# & PIR1: (LGBO)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,LSFNPTQLEEQCHI*# SEQUENCE: LSFNPTQLEEQCHI*# ...# >MUS2336D# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (11-26)# DB REFERENCE: SWISS: (LACB_BUBAR,LACB_CAPHI,LACB_BOVIN,LACB_CAPHI,LACB_BUBAR,# & LACB_BOVIN)# & PIR1: (LGGT,LGBO,LGBUI)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2b,actyesh,bindyesu,DIQKVAGTWYSLAMAA*# SEQUENCE: DIQKVAGTWYSLAMAA*# ...# >MUS2336E# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (72-86)# DB REFERENCE: SWISS: (LACB_SHEEP,LACB_BOVIN,LACB_BUBAR,LACB_CAPHI,LACB_BUBAR,# & LACB_BOVIN,LACB_CAPHI)# & PIR1: (LGGT,LGBUI,LGBO,LGSH)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2b,actyesh,bindyesu,IAEKTKIPAVFKIDA*# SEQUENCE: IAEKTKIPAVFKIDA*# ...# >MUS2336F# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (100-113)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2b,actyesh,bindyesu,KKYLLFAMENSAEP*# SEQUENCE: KKYLLFAMENSAEP*# ...# >MUS23370# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (119-133)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2b,actyesh,bindyesu,AQALVRTPEVDDEAL*# SEQUENCE: AQALVRTPEVDDEAL*# ...# >MUS23371# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (32-46)# DB REFERENCE: SWISS: (LACB_BUBAR,LACB_CAPHI,LACB_SHEEP,LACB_BOVIN,LACB_BOVIN,# & LACB_CAPHI,LACB_BUBAR)# & PIR1: (LGGT,LGSH,LGBO,LGBUI)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2b,actyesl,bindyesu,LDAQSAPLRVYVEEL*# SEQUENCE: LDAQSAPLRVYVEEL*# ...# >MUS23372# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (42-56)# DB REFERENCE: SWISS: (LACB_BOVIN,LACB_BUBAR,LACB_BOVIN,LACB_BUBAR)# & PIR1: (LGBO,LGBUI)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2b,actyesl,bindyesu,YVEELKPTPEGDLEI*# SEQUENCE: YVEELKPTPEGDLEI*# ...# >MUS23373# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (72-86)# DB REFERENCE: SWISS: (LACB_BUBAR,LACB_SHEEP,LACB_BOVIN,LACB_CAPHI,LACB_BOVIN,# & LACB_BUBAR,LACB_CAPHI)# & PIR1: (LGSH,LGBUI,LGGT,LGBO)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2k,actyesh,bindyesu,IAEKTKIPAVFKIDA*# SEQUENCE: IAEKTKIPAVFKIDA*# ...# >MUS23374# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (129-143)# DB REFERENCE: SWISS: (LACB_BOVIN,LACB_BOVIN,LACB_BUBAR,LACB_BUBAR)# & PIR1: (LGBO,LGBUI)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2k,actyesh,bindyesu,DDEALEKFDKALKAL*# SEQUENCE: DDEALEKFDKALKAL*# ...# >MUS23375# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (139-153)# DB REFERENCE: SWISS: (LACB_BUBAR,LACB_BUBAR,LACB_BOVIN,LACB_BOVIN)# & PIR1: (LGBO,LGBUI)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2k,actyesh,bindyesu,ALKALPMHIRLSFNP*# SEQUENCE: ALKALPMHIRLSFNP*# ...# >MUS23376# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (82-95)# DB REFERENCE: SWISS: (LACB_BUBAR,LACB_CAPHI,LACB_SHEEP,LACB_CAPHI,LACB_BOVIN,# & LACB_BOVIN,LACB_BUBAR)# & PIR1: (LGBO,LGSH,LGGT,LGBUI)# & PIR2: (S00132)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,FKIDALNENKVLVL*# SEQUENCE: FKIDALNENKVLVL*# ...# >MUS23377# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Bovine beta-lactoglobulin (119-133)# ANCHOR POSITIONS: ?# REFERENCES: tsuji93a# COMMENT:# SUMMARY: H-2k,actyesl,bindyesu,AQALVRTPEVDDEAL*# SEQUENCE: AQALVRTPEVDDEAL*# ...# >MUS23378# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (49-61)# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_CHICK,LYC_PAVCR,LYC_MELGA,LYC_CHICK,# & LYC_PHACO,LYC_ORTVE,LYC1_TACAC,LYC_LOPLE,LYC_SYRRE,# & LYC1_ANAPL,LYC_PHAVE)# & PIR1: (LZTK,LZOVE,LZCH,LZQJE,LZDK,LZFER)# & PIR2: (JU0237,A61281,A45660,JQ1041,JQ1033,JT0526,JH0211,JH0212,# & JU0178,JC2144)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actyesu,bindyesu,GSTDYGILQINSR*# SEQUENCE: GSTDYGILQINSR*# ...# >MUS23379# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (48-61)# DB REFERENCE: SWISS: (LYC1_TACAC,LYC_PHACO,LYC_PHAVE,LYC_LOPLE,LYC_CHRAM,# & LYC_PAVCR,LYC_CHICK,LYC_CHICK,LYC1_ANAPL,LYC_SYRRE,# & LYC_MELGA)# & PIR1: (LZFER,LZDK,LZQJE,LZCH,LZTK)# & PIR2: (JU0178,A61281,JU0237,JQ1033,JT0526,A45660,JQ1041,JH0211,# & JH0212,JC2144)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actyesu,bindyesu,DGSTDYGILQINSR*# SEQUENCE: DGSTDYGILQINSR*# ...# >MUS2337A# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (52-66)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_PHACO,LYC_CHICK,LYC_CHRAM,LYC_PAVCR,# & LYC_LOPLE,LYC_MELGA,LYC_SYRRE,LYC_ORTVE,LYC_CHICK)# & PIR1: (LZTK,LZCH,LZOVE,LZQJE)# & PIR2: (JU0178,JQ1033,JQ1041,JU0237,JT0526,JC2144)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,DYGILQINSRWWCND*# SEQUENCE: DYGILQINSRWWCND*# ...# >MUS2337B# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (49-64)# DB REFERENCE: SWISS: (LYC_MELGA,LYC_ORTVE,LYC_CHICK,LYC1_ANAPL,LYC_PHACO,# & LYC_CHICK,LYC_PHAVE,LYC_SYRRE,LYC_PAVCR,LYC_CHRAM,# & LYC_LOPLE)# & PIR1: (LZQJE,LZCH,LZOVE,LZTK,LZDK)# & PIR2: (JU0237,JQ1041,JQ1033,JC2144,JT0526,JU0178)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,GSTDYGILQINSRWWC*# SEQUENCE: GSTDYGILQINSRWWC*# ...# >MUS2337C# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (40-67)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH,LZQJE)# & PIR2: (JU0237)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,TQATNRNTDGSTDYGILQINSRWWCNDG*# SEQUENCE: TQATNRNTDGSTDYGILQINSRWWCNDG*# ...# >MUS2337D# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (43-62)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_PHAVE,LYC1_ANAPL,LYC_PHACO,LYC_PAVCR,# & LYC_CHRAM,LYC_LOPLE,LYC_MELGA,LYC_SYRRE,LYC_CHICK)# & PIR1: (LZQJE,LZTK,LZDK,LZCH)# & PIR2: (JQ1033,JQ1041,JT0526,JU0178,JC2144,JU0237)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,TNRNTDGSTDYGILQINSRW*# SEQUENCE: TNRNTDGSTDYGILQINSRW*# ...# >MUS2337E# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (45-68)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_PHAVE,LYC_PAVCR,LYC_CHRAM,LYC_PHACO,# & LYC_CHICK,LYC_CHICK,LYC_MELGA)# & PIR1: (LZQJE,LZCH,LZTK)# & PIR2: (JQ1041,JU0237,JT0526,JC2144,JU0178)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,RNTDGSTDYGILQINSRWWCNDGR*# SEQUENCE: RNTDGSTDYGILQINSRWWCNDGR*# ...# >MUS2337F# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (50-69)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_ORTVE,LYC_CHICK,LYC_SYRRE,LYC_CHRAM,# & LYC_PAVCR,LYC_PHAVE,LYC_PHACO,LYC_MELGA)# & PIR1: (LZTK,LZOVE,LZCH,LZQJE)# & PIR2: (JU0237,JU0178,JC2144,JT0526,JQ1041)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,STDYGILQINSRWWCNDGRT*# SEQUENCE: STDYGILQINSRWWCNDGRT*# ...# >MUS23380# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (49-62)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPLE,LYC_SYRRE,LYC_PHACO,LYC_CHRAM,# & LYC_CHICK,LYC1_ANAPL,LYC_ORTVE,LYC_PAVCR,LYC_MELGA,# & LYC_PHAVE)# & PIR1: (LZTK,LZDK,LZQJE,LZCH,LZOVE)# & PIR2: (JQ1033,JU0237,JT0526,JC2144,JU0178,JQ1041)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actyesu,bindyesu,GSTDYGILQINSRW*# SEQUENCE: GSTDYGILQINSRW*# ...# >MUS23381# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (48-62)# DB REFERENCE: SWISS: (LYC_CHRAM,LYC_PHACO,LYC_CHICK,LYC_MELGA,LYC_PAVCR,# & LYC_CHICK,LYC_SYRRE,LYC_LOPLE,LYC_PHAVE,LYC1_ANAPL)# & PIR1: (LZCH,LZDK,LZTK,LZQJE)# & PIR2: (JC2144,JU0178,JU0237,JQ1041,JQ1033,JT0526)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actyesu,bindyesu,DGSTDYGILQINSRW*# SEQUENCE: DGSTDYGILQINSRW*# ...# >MUS23382# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (44-66)# DB REFERENCE: SWISS: (LYC_LOPLE,LYC_CHICK,LYC_CHRAM,LYC_PAVCR,LYC_MELGA,# & LYC_PHAVE,LYC_CHICK,LYC_PHACO,LYC_SYRRE)# & PIR1: (LZCH,LZTK,LZQJE)# & PIR2: (JQ1033,JQ1041,JT0526,JU0178,JC2144,JU0237)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,NRNTDGSTDYGILQINSRWWCND*# SEQUENCE: NRNTDGSTDYGILQINSRWWCND*# ...# >MUS23383# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (44-62)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_PHAVE,LYC_CHRAM,LYC_MELGA,LYC_PAVCR,# & LYC_SYRRE,LYC1_ANAPL,LYC_LOPLE,LYC_PHACO,LYC_CHICK)# & PIR1: (LZTK,LZCH,LZDK,LZQJE)# & PIR2: (JU0237,JU0178,JC2144,JQ1033,JQ1041,JT0526)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,NRNTDGSTDYGILQINSRW*# SEQUENCE: NRNTDGSTDYGILQINSRW*# ...# >MUS23384# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (41-68)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK)# & PIR1: (LZQJE,LZCH)# & PIR2: (JU0237)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,QATNRNTDGSTDYGILQINSRWWCNDGR*# SEQUENCE: QATNRNTDGSTDYGILQINSRWWCNDGR*# ...# >MUS23385# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (46-69)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_SYRRE,LYC_PAVCR,LYC_CHRAM,LYC_MELGA,# & LYC_CHICK,LYC_CHICK,LYC_PHACO)# & PIR1: (LZTK,LZCH,LZQJE)# & PIR2: (JU0237,JT0526,JQ1041,JC2144,JU0178)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,NTDGSTDYGILQINSRWWCNDGRT*# SEQUENCE: NTDGSTDYGILQINSRWWCNDGRT*# ...# >MUS23386# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (43-69)# DB REFERENCE: SWISS: (LYC_PHACO,LYC_PAVCR,LYC_CHICK,LYC_LOPLE,LYC_MELGA,# & LYC_CHICK,LYC_CHRAM,LYC_SYRRE,LYC_PHAVE)# & PIR1: (LZQJE,LZCH,LZTK)# & PIR2: (JU0178,JQ1041,JU0237,JQ1033,JT0526,JC2144)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,TNRNTDGSTDYGILQINSRWWCN*# SEQUENCE: TNRNTDGSTDYGILQINSRWWCN*# ...# >MUS23387# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (48-69)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_CHICK,LYC_MELGA,LYC_CHICK,LYC_PHACO,# & LYC_PAVCR,LYC_PHAVE,LYC_CHRAM)# & PIR1: (LZTK,LZCH,LZQJE)# & PIR2: (JU0178,JC2144,JU0237,JT0526,JQ1041)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,DGSTDYGILQINSRWWCNDGRT*# SEQUENCE: DGSTDYGILQINSRWWCNDGRT*# ...# >MUS23388# MHC MOLECULE: H-2Ak, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (47-68)# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_PHAVE,LYC_CHRAM,LYC_PHACO,LYC_CHICK,# & LYC_SYRRE,LYC_CHICK,LYC_MELGA)# & PIR1: (LZQJE,LZTK,LZCH)# & PIR2: (JT0526,JQ1041,JU0237,JC2144,JU0178)# ANCHOR POSITIONS: ?# REFERENCES: vignali93a# COMMENT:# SUMMARY: H-2Ak,actunkn,bindyesu,TDGSTDYGILQINSRWWCNDGR*# SEQUENCE: TDGSTDYGILQINSRWWCNDGR*# ...# >MUS23389# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Listeria monocytogenes listeriolysin LLO (215-226)# DB REFERENCE: SWISS: (TACY_LISMO,TACY_LISSE)# & PIR2: (S22340,A43505,S24231)# ANCHOR POSITIONS: ?# REFERENCES: verma95a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,SQLIAKFGTAFK*# SEQUENCE: SQLIAKFGTAFK*# ...# >MUS2338A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference/Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Listeria monocytogenes listeriolysin LLO (215-226)# DB REFERENCE: SWISS: (TACY_LISMO,TACY_LISSE)# & PIR2: (S22340,S24231,A43505)# ANCHOR POSITIONS: ?# REFERENCES: verma95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,SQLIAKFGTAFK*# SEQUENCE: SQLIAKFGTAFK*# ...# >MUS2338B# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (85-97)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_LOPLE,LYC_CHICK,LYC_CHICK,LYC_PHACO,# & LYC_PHAVE,LYC_CHRAM,LYC_MELGA,LYC_PAVCR)# & PIR1: (LZCH,LZQJE,LZTK)# & PIR2: (JU0178,JU0237,JT0526,JQ1041,JQ1033)# ANCHOR POSITIONS: ?# REFERENCES: viner94a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,SSDITASVNCAKK*# SEQUENCE: SSDITASVNCAKK*# ...# >MUS2338C# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Elution/In vivo response# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (84-96)# DB REFERENCE: SWISS: (LYC_SYRRE,LYC_MELGA,LYC_LOPLE,LYC_CHICK,LYC_PAVCR,# & LYC_PHACO,LYC_PHAVE,LYC_CHRAM,LYC_CHICK)# & PIR1: (LZTK,LZFER,LZQJE,LZCH)# & PIR2: (JQ1041,JQ1033,JU0178,JU0237,JH0211,JH0212,JT0526)# ANCHOR POSITIONS: ?# REFERENCES: viner94a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,LSSDITASVNCAK*# SEQUENCE: LSSDITASVNCAK*# ...# >MUS2338D# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (84-97)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_SYRRE,LYC_MELGA,LYC_PHAVE,LYC_CHRAM,# & LYC_LOPLE,LYC_PAVCR,LYC_PHACO,LYC_CHICK)# & PIR1: (LZTK,LZCH,LZQJE)# & PIR2: (JQ1041,JU0178,JU0237,JT0526,JQ1033)# ANCHOR POSITIONS: ?# REFERENCES: viner94a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,LSSDITASVNCAKK*# SEQUENCE: LSSDITASVNCAKK*# ...# >MUS2338E# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (84-98)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_SYRRE,LYC_CHRAM,LYC_CHICK,LYC_CHICK,# & LYC_PHACO,LYC_PAVCR,LYC_LOPLE,LYC_MELGA)# & PIR1: (LZCH,LZTK,LZQJE)# & PIR2: (JU0237,JU0178,JT0526,JQ1033,JQ1041)# ANCHOR POSITIONS: ?# REFERENCES: viner94a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,LSSDITASVNCAKKI*# SEQUENCE: LSSDITASVNCAKKI*# ...# >MUS2338F# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (84-99)# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_PHACO,LYC_LOPLE,LYC_CHICK,LYC_CHICK,# & LYC_CHRAM,LYC_SYRRE,LYC_PHAVE)# & PIR1: (LZCH,LZQJE)# & PIR2: (JU0237,JU0178,JQ1033,JQ1041,JT0526)# ANCHOR POSITIONS: ?# REFERENCES: viner94a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,LSSDITASVNCAKKIV*# SEQUENCE: LSSDITASVNCAKKIV*# ...# >MUS23390# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: HEL (84-100)# DB REFERENCE: SWISS: (LYC_PAVCR,LYC_CHICK,LYC_CHRAM,LYC_CHICK,LYC_PHAVE,# & LYC_SYRRE,LYC_LOPLE,LYC_PHACO)# & PIR1: (LZQJE,LZCH)# & PIR2: (JU0237,JU0178,JT0526,JQ1041,JQ1033)# ANCHOR POSITIONS: ?# REFERENCES: viner94a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesu,LSSDITASVNCAKKIVS*# SEQUENCE: LSSDITASVNCAKKIVS*# ...# >MUS23391# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 16000 MW Ag (31-40)# DB REFERENCE: SWISS: (14KD_MYCTU,14KD_MYCTU)# & PIR2: (A42651)# ANCHOR POSITIONS: ?# REFERENCES: vordermeier93a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,LRPTFDTRLM*# SEQUENCE: LRPTFDTRLM*# ...# >MUS23392# MHC MOLECULE: H-2b, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 16000 MW Ag (71-91)# DB REFERENCE: SWISS: (14KD_MYCTU,14KD_MYCTU)# & PIR2: (A42651)# ANCHOR POSITIONS: ?# REFERENCES: vordermeier93a# COMMENT:# SUMMARY: H-2b,actyesu,bindyesu,RDGQLTIKAERTEQKDFDGRS*# SEQUENCE: RDGQLTIKAERTEQKDFDGRS*# ...# >MUS23393# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 16000 MW Ag (31-40)# DB REFERENCE: SWISS: (14KD_MYCTU,14KD_MYCTU)# & PIR2: (A42651)# ANCHOR POSITIONS: ?# REFERENCES: vordermeier93a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,LRPTFDTRLM*# SEQUENCE: LRPTFDTRLM*# ...# >MUS23394# MHC MOLECULE: H-2k, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mycobacterium tuberculosis 16000 MW Ag (71-91)# DB REFERENCE: SWISS: (14KD_MYCTU,14KD_MYCTU)# & PIR2: (A42651)# ANCHOR POSITIONS: ?# REFERENCES: vordermeier93a# COMMENT:# SUMMARY: H-2k,actyesu,bindyesu,RDGQLTIKAERTEQKDFDGRS*# SEQUENCE: RDGQLTIKAERTEQKDFDGRS*# ...# >MUS23395# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (181-195)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASI,VGLF_MEASA,VGLF_MEASE,# & VGLF_MEASY)# & PIR1: (E48556,VGNZMV,JU0274)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,YINNELIPSMNQLSC*# SEQUENCE: YINNELIPSMNQLSC*# ...# >MUS23396# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (221-235)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_PHODV,VGLF_MEASY,VGLF_MEASE,VGLF_RINDK,# & VGLF_MEASI,VGLF_RINDR,VGLF_MEASA)# & PIR1: (E48556,VGNZPD,A48346,VGNZRK,VGNZMV,JU0274)# & PIR2: (JQ2223,S47305)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,LRDPISAEISIQALS*# SEQUENCE: LRDPISAEISIQALS*# ...# >MUS23397# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (256-270)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASA,VGLF_MEASE,VGLF_MEASI,# & VGLF_MEASY)# & PIR1: (E48556,VGNZMV,JU0274)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,LLGILESRGIKARIT*# SEQUENCE: LLGILESRGIKARIT*# ...# >MUS23398# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (261-275)# DB REFERENCE: SWISS: (VGLF_MEASY,VGLF_MEASI,VGLF_MEASE,VGLF_MEASA,# & VGLF_MEASE)# & PIR1: (E48556,VGNZMV,JU0274)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,ESRGIKARITHVDTE*# SEQUENCE: ESRGIKARITHVDTE*# ...# >MUS23399# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (271-285)# DB REFERENCE: SWISS: (VGLF_MEASA)# & PIR1: (E48556)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,HVDTESYLIVLSIAY*# SEQUENCE: HVDTESYLIVLSIAY*# ...# >MUS2339A# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (276-290)# DB REFERENCE: SWISS: (VGLF_MEASA)# & PIR1: (E48556)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,SYLIVLSIAYPTLSE*# SEQUENCE: SYLIVLSIAYPTLSE*# ...# >MUS2339B# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, little# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (281-295)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASE,VGLF_MEASY)# & PIR1: (JU0274,E48556,VGNZMV)# & PIR2: (PQ0388,PQ0376,S55386)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesl,bindyesu,LSIAYPTLSEIKGVI*# SEQUENCE: LSIAYPTLSEIKGVI*# ...# >MUS2339C# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (421-436)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_RINDB,VGLF_MEASA,VGLF_MEASE,VGLF_MEASY,# & VGLF_MEASE)# & PIR1: (JU0274,E48556,VGNZMV)# & PIR2: (PQ0388,PQ0376,S47300)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesh,bindyesu,PVVEVNGVTIQVGSR*# SEQUENCE: PVVEVNGVTIQVGSR*# ...# >MUS2339D# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (511-526)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASA,VGLF_MEASI,VGLF_MEASE)# & PIR1: (E48556,VGNZMV)# & PIR2: (PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,PALICCCRGRCNKKG*# SEQUENCE: PALICCCRGRCNKKG*# ...# >MUS2339E# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (51-65)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASE,VGLF_MEASA,VGLF_MEASE)# & PIR1: (E48556,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,HQSLVIKLMPNITLL*# SEQUENCE: HQSLVIKLMPNITLL*# ...# >MUS2339F# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (156-170)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASI,VGLF_MEASE,VGLF_MEASE)# & PIR1: (E48556,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,TTNQAIEAIRQAGQE*# SEQUENCE: TTNQAIEAIRQAGQE*# ...# >MUS233A0# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (226-240)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_RINDB,VGLF_RINDK,VGLF_PHODV,VGLF_MEASE,# & VGLF_MEASI,VGLF_RINDR,VGLF_MEASA)# & PIR1: (VGNZMV,VGNZRK,A48346,VGNZPD,E48556)# & PIR2: (S47300,JQ2223,S47305,S47299)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,SAEISIQALSYALGG*# SEQUENCE: SAEISIQALSYALGG*# ...# >MUS233A1# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (266-280)# DB REFERENCE: SWISS: (VGLF_MEASA)# & PIR1: (E48556)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,KARITHVDTESYLIV*# SEQUENCE: KARITHVDTESYLIV*# ...# >MUS233A2# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (286-300)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASY,VGLF_MEASE)# & PIR1: (JU0274,VGNZMV,E48556)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,PTLSEIKGVIVHRLE*# SEQUENCE: PTLSEIKGVIVHRLE*# ...# >MUS233A3# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (291-305)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASE,VGLF_RINDB,# & VGLF_MEASY)# & PIR1: (VGNZMV,JU0274,E48556)# & PIR2: (PQ0376,S47300,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,IKGVIVHRLEGVSYN*# SEQUENCE: IKGVIVHRLEGVSYN*# ...# >MUS233A4# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (316-330)# DB REFERENCE: SWISS: (VGLF_MEASA,VGLF_MEASE,VGLF_MEASI,VGLF_MEASY,# & VGLF_MEASE)# & PIR1: (VGNZMV,E48556,JU0274)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,PKYVATQGYLISNFD*# SEQUENCE: PKYVATQGYLISNFD*# ...# >MUS233A5# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (321-335)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASA,VGLF_MEASY,VGLF_MEASI,# & VGLF_MEASE)# & PIR1: (VGNZMV,E48556,JU0274)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,TQGYLISNFDESSCT*# SEQUENCE: TQGYLISNFDESSCT*# ...# >MUS233A6# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (326-340)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASY,VGLF_MEASE,VGLF_MEASI,# & VGLF_MEASA)# & PIR1: (VGNZMV,E48556,JU0274)# & PIR2: (PQ0376,PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,ISNFDESSCTFMPEG*# SEQUENCE: ISNFDESSCTFMPEG*# ...# >MUS233A7# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (346-360)# DB REFERENCE: SWISS: (VGLF_MEASI,VGLF_MEASE,VGLF_MEASY,VGLF_MEASE,# & VGLF_MEASA)# & PIR1: (VGNZMV,JU0274,E48556)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,NALYPMSPLLQECLR*# SEQUENCE: NALYPMSPLLQECLR*# ...# >MUS233A8# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (381-396)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASA,VGLF_MEASE,VGLF_MEASI,# & VGLF_MEASY)# & PIR1: (E48556,JU0274,VGNZMV)# & PIR2: (PQ0388,PQ0376)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,LSQGNLIANCASILC*# SEQUENCE: LSQGNLIANCASILC*# ...# >MUS233A9# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (396-410)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASE,VGLF_MEASA,VGLF_MEASY)# & PIR1: (E48556,JU0274,VGNZMV)# & PIR2: (PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,KCYTTGTIINQDPDK*# SEQUENCE: KCYTTGTIINQDPDK*# ...# >MUS233AA# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: Proliferation# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (401-416)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASA,VGLF_MEASE)# & PIR1: (E48556,VGNZMV)# & PIR2: (PQ0388)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesu,bindyesu,GTIINQDPDKILTYI*# SEQUENCE: GTIINQDPDKILTYI*# ...# >MUS233AB# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Pigeon cytochrome c homologue# ANCHOR POSITIONS: ?# REFERENCES: la-face97a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesh,KAERADLIAYLRQATAK*# SEQUENCE: KAERADLIAYLRQATAK*# ...# >MUS233AC# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Pigeon cytochrome c homologue# ANCHOR POSITIONS: ?# REFERENCES: la-face97a# COMMENT:# SUMMARY: I-Ek,actunkn,bindyesh,KAERADLIAYLKQATGK*# SEQUENCE: KAERADLIAYLKQATGK*# ...# >MUS233AD# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,AGSTDYGILQINSR*# SEQUENCE: AGSTDYGILQINSR*# ...# >MUS233AE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DASTDYGILQINSR*# SEQUENCE: DASTDYGILQINSR*# ...# >MUS233AF# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGATDYGILQINSR*# SEQUENCE: DGATDYGILQINSR*# ...# >MUS233B0# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSADYGILQINSR*# SEQUENCE: DGSADYGILQINSR*# ...# >MUS233B1# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDAGILQINSR*# SEQUENCE: DGSTDAGILQINSR*# ...# >MUS233B2# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDYAILQINSR*# SEQUENCE: DGSTDYAILQINSR*# ...# >MUS233B3# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDYGALQINSR*# SEQUENCE: DGSTDYGALQINSR*# ...# >MUS233B4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDYGIAQINSR*# SEQUENCE: DGSTDYGIAQINSR*# ...# >MUS233B5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDYGILAINSR*# SEQUENCE: DGSTDYGILAINSR*# ...# >MUS233B6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDYGILQANSR*# SEQUENCE: DGSTDYGILQANSR*# ...# >MUS233B7# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDYGILQIASR*# SEQUENCE: DGSTDYGILQIASR*# ...# >MUS233B8# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDYGILQINAR*# SEQUENCE: DGSTDYGILQINAR*# ...# >MUS233B9# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTDYGILQINSA*# SEQUENCE: DGSTDYGILQINSA*# ...# >MUS233BA# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AAAADAAAAAAAAAA*# SEQUENCE: AAAADAAAAAAAAAA*# ...# >MUS233BB# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AAAADYAAAAA*# SEQUENCE: AAAADYAAAAA*# ...# >MUS233BC# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AAAADYAAAAAA*# SEQUENCE: AAAADYAAAAAA*# ...# >MUS233BD# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AAAADYAAAAAAA*# SEQUENCE: AAAADYAAAAAAA*# ...# >MUS233BE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AAAADYAAAAAAAA*# SEQUENCE: AAAADYAAAAAAAA*# ...# >MUS233BF# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AAAADYAAAAAAAAA*# SEQUENCE: AAAADYAAAAAAAAA*# ...# >MUS233C0# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AAADYAAAAAAAAA*# SEQUENCE: AAADYAAAAAAAAA*# ...# >MUS233C1# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AADYAAAAAAAAA*# SEQUENCE: AADYAAAAAAAAA*# ...# >MUS233C2# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,ADYAAAAAAAAA*# SEQUENCE: ADYAAAAAAAAA*# ...# >MUS233C3# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DYAAAAAAAAA*# SEQUENCE: DYAAAAAAAAA*# ...# >MUS233C4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTAYGILQINSR*# SEQUENCE: DGSTAYGILQINSR*# ...# >MUS233C5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Hsp70 (28-41) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,IIANAQGNRTTPSY*# SEQUENCE: IIANAQGNRTTPSY*# ...# >MUS233C6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Ryudocan (84-101)# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,EPLVPLDNHIPENAQPGY*# SEQUENCE: EPLVPLDNHIPENAQPGY*# ...# >MUS233C7# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Ryudocan (84-101) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,EPLVPLANHIPENAQPGY*# SEQUENCE: EPLVPLANHIPENAQPGY*# ...# >MUS233C8# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: mIL-1 Rec. (185-199)# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AILLDKGNKEFLSAGY*# SEQUENCE: AILLDKGNKEFLSAGY*# ...# >MUS233C9# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: mIL-1 Rec. (185-199) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AILLAKGNKEFLSAGY*# SEQUENCE: AILLAKGNKEFLSAGY*# ...# >MUS233CA# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: DNA-B (92-108)# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,DPFKGDDENEENPTEPSY*# SEQUENCE: DPFKGDDENEENPTEPSY*# ...# >MUS233CB# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: DNA-B (92-108) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,DPFKGDAENEENPTLPSY*# SEQUENCE: DPFKGDAENEENPTLPSY*# ...# >MUS233CC# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: DNA-B (92-108) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DPFKGADENEENPTLPSY*# SEQUENCE: DPFKGADENEENPTLPSY*# ...# >MUS233CD# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53)# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVGEERAVTELY*# SEQUENCE: FVRFDSDVGEERAVTELY*# ...# >MUS233CE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,FVRFASDVGEERAVTELY*# SEQUENCE: FVRFASDVGEERAVTELY*# ...# >MUS233CF# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b,nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,FVAFDSAVGAARAVTELY*# SEQUENCE: FVAFDSAVGAARAVTELY*# ...# >MUS233D0# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: Transferrin rec. (103-117)# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,KGTDFQLNQLEGKKGY*# SEQUENCE: KGTDFQLNQLEGKKGY*# ...# >MUS233D1# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Transferrin rec. (103-117) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,KGTAFQLNQLEGKKGY*# SEQUENCE: KGTAFQLNQLEGKKGY*# ...# >MUS233D2# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Cathepsin H (77-92)# DB REFERENCE: SWISS: (CATH_RAT)# & PIR1: (KHRTH)# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,YILYNKGIMGEDSYPY*# SEQUENCE: YILYNKGIMGEDSYPY*# ...# >MUS233D3# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Cathepsin H (77-92) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,YILYAKGIMGEDSYPY*# SEQUENCE: YILYAKGIMGEDSYPY*# ...# >MUS233D4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: FcE Rec. II (298-310)# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,SFLDAWVCEQLATY*# SEQUENCE: SFLDAWVCEQLATY*# ...# >MUS233D5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: MB1 (177-193)# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,EDENLYEGINLDDCSMY*# SEQUENCE: EDENLYEGINLDDCSMY*# ...# >MUS233D6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: MB1 (177-193) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96b# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,EDEALYEGLNLDDCSMY*# SEQUENCE: EDEALYEGLNLDDCSMY*# ...# >MUS133D7# MHC MOLECULE: H-2Kd, CLASS-1, (MOUSE)# METHOD: CTL assays# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: artificial construct# ANCHOR POSITIONS: ?# REFERENCES: sauzet96a# COMMENT:# SUMMARY: H-2Kd,actyesu,bindyesu,RYLENGKETLQRTDAPLEDARRLKAIYEKKK*# SEQUENCE: RYLENGKETLQRTDAPLEDARRLKAIYEKKK*# ...# >MUS233D8# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: artificial construct# ANCHOR POSITIONS: ?# REFERENCES: sauzet96a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,RYLENGKETLQRTDAPLEDARRLKAIYEKKK*# SEQUENCE: RYLENGKETLQRTDAPLEDARRLKAIYEKKK*# ...# >MUS233D9# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: artificial construct# ANCHOR POSITIONS: ?# REFERENCES: sauzet96a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,RYLENGKETLQRTDAPLEDARRLKAIYEKKK*# SEQUENCE: RYLENGKETLQRTDAPLEDARRLKAIYEKKK*# ...# >MUS233DA# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Influenza A NP (365-379)# DB REFERENCE: SWISS: (VNUC_IANT6,VNUC_IAHO2,VNUC_IAHO1)# & PIR1: (VHIVN5,VHIV8H,VHIV68)# ANCHOR POSITIONS: ?# REFERENCES: sauzet96a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,IASNENMDAMESSTL*# SEQUENCE: IASNENMDAMESSTL*# ...# >MUS233DB# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: lambda repressor phage (12-26)# DB REFERENCE: SWISS: (RPC1_LAMBD)# & PIR1: (RPBPL)# ANCHOR POSITIONS: ?# REFERENCES: sauzet96a# COMMENT:# SUMMARY: I-Ak,actyesu,bindyesu,LEDARRLKAIYEKKK*# SEQUENCE: LEDARRLKAIYEKKK*# ...# >MUS233DC# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,DGSTEYGILQINSR*# SEQUENCE: DGSTEYGILQINSR*# ...# >MUS233DD# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,DGSTCYGILQINSR*# SEQUENCE: DGSTCYGILQINSR*# ...# >MUS233DE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,DGSTSYGILQINSR*# SEQUENCE: DGSTSYGILQINSR*# ...# >MUS233DF# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTRYGILQINSR*# SEQUENCE: DGSTRYGILQINSR*# ...# >MUS233E0# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTNYGILQINSR*# SEQUENCE: DGSTNYGILQINSR*# ...# >MUS233E1# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTQYGILQINSR*# SEQUENCE: DGSTQYGILQINSR*# ...# >MUS233E2# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTHYGILQINSR*# SEQUENCE: DGSTHYGILQINSR*# ...# >MUS233E3# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTTYGILQINSR*# SEQUENCE: DGSTTYGILQINSR*# ...# >MUS233E4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTLYGILQINSR*# SEQUENCE: DGSTLYGILQINSR*# ...# >MUS233E5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTPYGILQINSR*# SEQUENCE: DGSTPYGILQINSR*# ...# >MUS233E6# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: SDS-PAGE# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (48-61) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,DGSTGYGILQINSR*# SEQUENCE: DGSTGYGILQINSR*# ...# >MUS233E7# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,AVRFDSDVGEFRAVTELY*# SEQUENCE: AVRFDSDVGEFRAVTELY*# ...# >MUS233E8# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FARFDSDVGEFRAVTELY*# SEQUENCE: FARFDSDVGEFRAVTELY*# ...# >MUS233E9# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, high# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesh,FVAFDSDVGEFRAVTELY*# SEQUENCE: FVAFDSDVGEFRAVTELY*# ...# >MUS233EA# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRADSDVGEFRAVTELY*# SEQUENCE: FVRADSDVGEFRAVTELY*# ...# >MUS233EB# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesl,FVRFDADVGEFRAVTELY*# SEQUENCE: FVRFDADVGEFRAVTELY*# ...# >MUS233EC# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSAVGEFRAVTELY*# SEQUENCE: FVRFDSAVGEFRAVTELY*# ...# >MUS233ED# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDAGEFRAVTELY*# SEQUENCE: FVRFDSDAGEFRAVTELY*# ...# >MUS233EE# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVAEFRAVTELY*# SEQUENCE: FVRFDSDVAEFRAVTELY*# ...# >MUS233EF# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition/SDS-PAGE# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVGAFRAVTELY*# SEQUENCE: FVRFDSDVGAFRAVTELY*# ...# >MUS233F0# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVGEARAVTELY*# SEQUENCE: FVRFDSDVGEARAVTELY*# ...# >MUS233F1# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVGEFAAVTELY*# SEQUENCE: FVRFDSDVGEFAAVTELY*# ...# >MUS233F2# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVGEFRAATELY*# SEQUENCE: FVRFDSDVGEFRAATELY*# ...# >MUS233F3# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVGEFRAVAELY*# SEQUENCE: FVRFDSDVGEFRAVAELY*# ...# >MUS233F4# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVGEFRAVTALY*# SEQUENCE: FVRFDSDVGEFRAVTALY*# ...# >MUS233F5# MHC MOLECULE: I-Ak, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: A-beta-k (37-53) homologue# ANCHOR POSITIONS: ?# REFERENCES: nelson96c# COMMENT:# SUMMARY: I-Ak,actunkn,bindyesm,FVRFDSDVGEFRAVTEAY*# SEQUENCE: FVRFDSDVGEFRAVTEAY*# ...# >MUS233F6# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Competition/Recognition# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: Collagen II CII (257-270)# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesl,ELGIAGFKGEQGPK*# SEQUENCE: ELGIAGFKGEQGPK*# ...# >MUS233F7# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,ALGIAGFKGEQGPK*# SEQUENCE: ALGIAGFKGEQGPK*# ...# >MUS233F8# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,EAGIAGFKGEQGPK*# SEQUENCE: EAGIAGFKGEQGPK*# ...# >MUS233F9# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,ELAIAGFKGEQGPK*# SEQUENCE: ELAIAGFKGEQGPK*# ...# >MUS233FA# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Competition/Recognition# ACTIVITY: yes, little# BINDING: yes, little# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesl,bindyesl,ELGIAAFKGEQGPK*# SEQUENCE: ELGIAAFKGEQGPK*# ...# >MUS233FB# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,ELGIAGFKAEQGPK*# SEQUENCE: ELGIAGFKAEQGPK*# ...# >MUS233FC# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,ELGIAGFKGEQAPK*# SEQUENCE: ELGIAGFKGEQAPK*# ...# >MUS233FD# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,ELGIAGFKGEQGAK*# SEQUENCE: ELGIAGFKGEQGAK*# ...# >MUS233FE# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesu,ELGIAGFKGEQGPA*# SEQUENCE: ELGIAGFKGEQGPA*# ...# >MUS233FF# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actunkn,bindyesh,ELGAIGFKGEQGPK*# SEQUENCE: ELGAIGFKGEQGPK*# ...# >MUS23400# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actunkn,bindyesl,ELGIIFKGEQGPK*# SEQUENCE: ELGIIFKGEQGPK*# ...# >MUS23401# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actunkn,bindyesh,ELGIAGAKGEQGPK*# SEQUENCE: ELGIAGAKGEQGPK*# ...# >MUS23402# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Competition/Recognition# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesl,ELGIAGFAGEQGPK*# SEQUENCE: ELGIAGFAGEQGPK*# ...# >MUS23403# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Competition/Recognition# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesh,bindyesl,ELGIAGFKGEAGPK*# SEQUENCE: ELGIAGFKGEAGPK*# ...# >MUS23404# MHC MOLECULE: I-Aq, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Collagen II CII (257-270) homologue# ANCHOR POSITIONS: ?# REFERENCES: rosloniec96a# COMMENT:# SUMMARY: I-Aq,actyesm,bindyesu,ELGIAGFKGAQGPK*# SEQUENCE: ELGIAGFKGAQGPK*# ...# >MUS23405# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Elution# ACTIVITY: ?# BINDING: yes, ?# SOURCE: apolipoprotein B (2211-2224)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actunkn,bindyesu,SLDAHYHIRVHLVK*# SEQUENCE: SLDAHYHIRVHLVK*# ...# >MUS23406# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MCC (91-103)# DB REFERENCE: SWISS: (CYC_MANSE)# & PIR1: (CCWOT)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,RADLIAYLKQATK*# SEQUENCE: RADLIAYLKQATK*# ...# >MUS23407# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: PCC (91-104)# DB REFERENCE: SWISS: (CYC_COLLI,CYC_COLLI)# & PIR1: (CCPY)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,RADLIAYLKQATAK*# SEQUENCE: RADLIAYLKQATAK*# ...# >MUS23408# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SWMb (66-78)# DB REFERENCE: SWISS: (MYG_PHYCA,MYG_PHYCA,MYG_KOGSI)# & PIR1: (MYWHP,MYWHW)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,VTVLTALGAILKK*# SEQUENCE: VTVLTALGAILKK*# ...# >MUS23409# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: Mo/Eq Mb (69-77)# DB REFERENCE: SWISS: (MYG_BOVIN,MYG_LAGMA,MYG_CANFA,MYG_NYCCO,MYG_PONPY,# & MYG_SAISC,MYG_HYLAG,MYG_BALPH,MYG_MELME,MYG_PHOPH,# & MYG_ESCGI,MYG_ZIPCA,MYG_VULCH,MYG_LOXAF,MYG_PHOSI,# & MYG_BOVIN,MYG_SPAEH,MYG_PIG,MYG_HALGR,MYG_HUMAN,# & MYG_LUTLU,MYG_SHEEP,MYG_ELEMA,MYG_CEREL,MYG_GORBE,# & MYG_PERPO,MYG_ERIEU,MYG_PANTR,MYG_ORYAF,MYG_HORSE,# & MYG_GALCR,MYG_HORSE,MYG_MEGNO,MYG_BALAC,MYG_LYCPI,# & MYG_MESCA,MYG_LAGLA,MYG_CEBAP,MYG_AOTTR,MYG_ZALCA,# & MYG_INIGE,MYG_ONDZI,MYG_CALJA,MYG_LEPMU,MYG_ROUAE,# & MYG_PROGU,MYG_PAPAN,MYG_MACFA)# & PIR1: (MYWHZ,MYELA,MYELI,MYZC,MYOT,MYKS,MYLR,MYGO,MYMQHL,MYHO,# & MYBO,MYSLG,MYWHU,MYBD,MYOY,MYHH,MYWHC,MYHOZ,MYWHF,MYOG,# & MYMQW,MYMQN,MYGI,MYCJ,MYSLH,MYBAO,MYVJ,MYOL,MYDDAR,# & MYWHK,MYCZ,MYMQIM,MYMQC,MYHU,MYMQRG,MYPG,MYDE,MYLP,MYPE,# & MYPED,MYWHH,MYSH,MYMQS,PN0126)# & PIR2: (JN0344)# & PIR3: (A61366)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,LTALGGILK*# SEQUENCE: LTALGGILK*# ...# >MUS2340A# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: MoHb (68-76)# DB REFERENCE: SWISS: (HBB2_MOUSE,HBB2_MOUSE)# & PIR1: (HBMSN1)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,ITAFNEGLK*# SEQUENCE: ITAFNEGLK*# ...# >MUS2340B# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (1-18)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_COLVI,LYC_NUMME,LYC_CHICK,LYC_CHICK)# & PIR1: (LZUH,LZCH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,KVFGRCELAAAMKRHGLD*# SEQUENCE: KVFGRCELAAAMKRHGLD*# ...# >MUS2340C# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (81-96)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPLE,LYC_CHICK,LYC_MELGA,LYC_SYRRE,# & LYC_PAVCR,LYC_CHRAM,LYC_PHACO,LYC_PHAVE)# & PIR1: (LZTK,LZCH,LZFER,LZQJE)# & PIR2: (JT0526,JQ1033,JQ1041,JH0212,JH0211,JU0237,JU0178)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,SALLSSDITASVNCAK*# SEQUENCE: SALLSSDITASVNCAK*# ...# >MUS2340D# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: SNase (81-100)# DB REFERENCE: SWISS: (NUC_STAAU)# & PIR1: (NCSAF)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,RTDKYGRGLAYIYADGKMVN*# SEQUENCE: RTDKYGRGLAYIYADGKMVN*# ...# >MUS2340E# MHC MOLECULE: I-Ed, CLASS-2, (MOUSE)# METHOD: Reference/Elution# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: LLO (218-226)# DB REFERENCE: SWISS: (TACY_LISSE,TACY_LISMO)# & PIR2: (S24231,S22340,A43505)# ANCHOR POSITIONS: ?# REFERENCES: schild95a# COMMENT:# SUMMARY: I-Ed,actyesu,bindyesu,IAKFGTAFK*# SEQUENCE: IAKFGTAFK*# ...# >MUS2340F# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: flu HA1 (186-205)# DB REFERENCE: SWISS: (HEMA_IANT6,HEMA_IAQU7,HEMA_IAME1,HEMA_IAX31,HEMA_IAAIC,# & HEMA_IAEN6)# & PIR1: (HMIVH,HMIVHA)# & PIR2: (A93233)# ANCHOR POSITIONS: ?# REFERENCES: thomas96a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,STNQEQTSLYVQASGRVTVS*# SEQUENCE: STNQEQTSLYVQASGRVTVS*# ...# >MUS23410# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: I-Ad beta (1-14)# DB REFERENCE: SWISS: (HB2D_MOUSE)# & PIR1: (HLMSAB)# ANCHOR POSITIONS: ?# REFERENCES: rider96a# COMMENT:# SUMMARY: I-Ad,actunkn,bindyesu,GNSERHFVVQFKGE*# SEQUENCE: GNSERHFVVQFKGE*# ...# >MUS23411# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: S. mansoni calpain (339-354)# DB REFERENCE: SWISS: (CAN_SCHMA)# & PIR2: (A39343)# ANCHOR POSITIONS: ?# REFERENCES: jankovic96a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,WGDSHEWKGAWCDGS*# SEQUENCE: WGDSHEWKGAWCDGS*# ...# >MUS23412# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: S. mansoni calpain (344-358)# DB REFERENCE: SWISS: (CAN_SCHMA)# & PIR2: (A39343)# ANCHOR POSITIONS: ?# REFERENCES: jankovic96a# COMMENT:# SUMMARY: I-Ab,actyesh,bindyesu,EWKGAWCDGSPQWRE*# SEQUENCE: EWKGAWCDGSPQWRE*# ...# >MUS23413# MHC MOLECULE: I-Au, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, high# SOURCE: Ac (1-11) homologue# ANCHOR POSITIONS: ?# REFERENCES: smilek90a# COMMENT:# SUMMARY: I-Au,actunkn,bindyesh,ASAARPSQRHG*# SEQUENCE: ASAARPSQRHG*# ...# >MUS23414# MHC MOLECULE: I-Ad, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: EQM (102-118)# ANCHOR POSITIONS: ?# REFERENCES: smilek90a# COMMENT:# SUMMARY: I-Ad,actyesu,bindyesu,KYLEFISDAIIHVLIISK*# SEQUENCE: KYLEFISDAIIHVLIISK*# ...# >MUS23415# MHC MOLECULE: I-Ek, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (74-96)# DB REFERENCE: SWISS: (LYC_PHAVE,LYC_CHRAM,LYC_PAVCR,LYC_CHICK,LYC_MELGA,# & LYC_LOPLE,LYC_CHICK,LYC_PHACO)# & PIR1: (LZCH,LZQJE,LZFER,LZTK)# & PIR2: (JU0178,JH0211,JT0526,JH0212,JQ1033,JU0237)# ANCHOR POSITIONS: ?# REFERENCES: smilek90a# COMMENT:# SUMMARY: I-Ek,actyesu,bindyesu,IPCSALLSSDITASVNCA*# SEQUENCE: IPCSALLSSDITASVNCA*# ...# >MUS23416# MHC MOLECULE: I-Ab, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (74-96)# DB REFERENCE: SWISS: (LYC_MELGA,LYC_PHAVE,LYC_PHACO,LYC_CHRAM,LYC_LOPLE,# & LYC_CHICK,LYC_CHICK,LYC_PAVCR)# & PIR1: (LZQJE,LZCH,LZTK,LZFER)# & PIR2: (JH0212,JQ1033,JT0526,JU0237,JH0211,JU0178)# ANCHOR POSITIONS: ?# REFERENCES: smilek90a# COMMENT:# SUMMARY: I-Ab,actyesu,bindyesu,IPCSALLSSDITASVNCA*# SEQUENCE: IPCSALLSSDITASVNCA*# ...# >MUS23417# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition/direct binding# ACTIVITY: yes, high# BINDING: yes, high# SOURCE: human Ac receptor alpha (195-212)# DB REFERENCE: SWISS: (ACHA_HUMAN)# & PIR1: (ACHUA1)# ANCHOR POSITIONS: ?# REFERENCES: kirshner96a# COMMENT:# SUMMARY: I-As,actyesh,bindyesh,DTPYLDITYHFVMQRLPL*# SEQUENCE: DTPYLDITYHFVMQRLPL*# ...# >MUS23418# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: human Ac receptor alpha (195-212) homologue# ANCHOR POSITIONS: ?# REFERENCES: kirshner96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesu,DTPYLKITYHFVMQRLPL*# SEQUENCE: DTPYLKITYHFVMQRLPL*# ...# >MUS23419# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition/Competition# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: human Ac receptor alpha (195-212) homologue# ANCHOR POSITIONS: ?# REFERENCES: kirshner96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesm,DTPYLDITYGFVMQRLPL*# SEQUENCE: DTPYLDITYGFVMQRLPL*# ...# >MUS2341A# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: human Ac receptor alpha (195-212) homologue# ANCHOR POSITIONS: ?# REFERENCES: kirshner96a# COMMENT:# SUMMARY: I-As,actyesh,bindyesu,DTPYLDITYHFVMDRLPL*# SEQUENCE: DTPYLDITYHFVMDRLPL*# ...# >MUS2341B# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition# ACTIVITY: yes, high# BINDING: yes, ?# SOURCE: human Ac receptor alpha (195-212) homologue# ANCHOR POSITIONS: ?# REFERENCES: kirshner96a# COMMENT:# SUMMARY: I-As,actyesh,bindyesu,DTPYLDITYHFVMNRLPL*# SEQUENCE: DTPYLDITYHFVMNRLPL*# ...# >MUS2341C# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Proliferation/Recognition/direct binding# ACTIVITY: yes, high# BINDING: yes, little# SOURCE: human Ac receptor alpha (195-212) homologue# ANCHOR POSITIONS: ?# REFERENCES: kirshner96a# COMMENT:# SUMMARY: I-As,actyesh,bindyesl,DTPYLDITYHFVMQKLPL*# SEQUENCE: DTPYLDITYHFVMQKLPL*# ...# >MUS2341D# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: Recognition/direct binding# ACTIVITY: yes, moderate# BINDING: yes, moderate# SOURCE: human Ac receptor alpha (195-212) homologue# ANCHOR POSITIONS: ?# REFERENCES: kirshner96a# COMMENT:# SUMMARY: I-As,actyesm,bindyesm,DTPYLDITFHFVMQRLPL*# SEQUENCE: DTPYLDITFHFVMQRLPL*# ...# >MUS2341E# MHC MOLECULE: I-As, CLASS-2, (MOUSE)# METHOD: direct binding/Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: human Ac receptor alpha (195-212) homologue# ANCHOR POSITIONS: ?# REFERENCES: kirshner96a# COMMENT:# SUMMARY: I-As,actunkn,bindyesh,DTPYLDITYHFVAQRLPL*# SEQUENCE: DTPYLDITYHFVAQRLPL*# ...# >HUM2341F# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,APGTGAYYVLLN*# SEQUENCE: APGTGAYYVLLN*# ...# >HUM23420# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SSGTGAYYVLLN*# SEQUENCE: SSGTGAYYVLLN*# ...# >HUM23421# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPSTGAYYVLLN*# SEQUENCE: SPSTGAYYVLLN*# ...# >HUM23422# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPGAGAYYVLLN*# SEQUENCE: SPGAGAYYVLLN*# ...# >HUM23423# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPGTSAYYVLLN*# SEQUENCE: SPGTSAYYVLLN*# ...# >HUM23424# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPGTGSYYVLLN*# SEQUENCE: SPGTGSYYVLLN*# ...# >HUM23425# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPGTGAWYVLLN*# SEQUENCE: SPGTGAWYVLLN*# ...# >HUM23426# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPGTGALYVLLN*# SEQUENCE: SPGTGALYVLLN*# ...# >HUM23427# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPGTGAMYVLLN*# SEQUENCE: SPGTGAMYVLLN*# ...# >HUM23428# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,SPGTGAYSVLLN*# SEQUENCE: SPGTGAYSVLLN*# ...# >HUM23429# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SPGTGAYYSLLN*# SEQUENCE: SPGTGAYYSLLN*# ...# >HUM2342A# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,SPGTGAYYVLSN*# SEQUENCE: SPGTGAYYVLSN*# ...# >HUM2342B# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesl,SPGTGAYYVLLA*# SEQUENCE: SPGTGAYYVLLA*# ...# >HUM2342C# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesh,KYYVLLN*# SEQUENCE: KYYVLLN*# ...# >HUM2342D# MHC MOLECULE: HLA-DR4(DRB1*0405), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# DB REFERENCE: SWISS: (NUPL_HUMAN,NUPL_HUMAN)# & PIR2: (S58887,A57088)# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR4,actunkn,bindyesm,KYAALAN*# SEQUENCE: KYAALAN*# ...# >HUM2342E# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesh,KWAASAAAAA*# SEQUENCE: KWAASAAAAA*# ...# >HUM2342F# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,KWAASAAAA*# SEQUENCE: KWAASAAAA*# ...# >HUM23430# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesm,KWAASAAA*# SEQUENCE: KWAASAAA*# ...# >HUM23431# MHC MOLECULE: HLA-DR9(DRB1*0901), CLASS-2, (HUMAN)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: ?# ANCHOR POSITIONS: ?# REFERENCES: matsushita97b# COMMENT:# SUMMARY: HLA-DR9,actunkn,bindyesl,KWAASAA*# SEQUENCE: KWAASAA*# ...# >MUS23432# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (9-27)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_LOPCA,LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZUH,LZCH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AAAMKRHGLDNYRGYSLGN*# SEQUENCE: AAAMKRHGLDNYRGYSLGN*# ...# >MUS23433# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (10-27)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_NUMME,LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZCH,LZQJEC,LZUH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AAMKRHGLDNYRGYSLGN*# SEQUENCE: AAMKRHGLDNYRGYSLGN*# ...# >MUS23434# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (11-27)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_NUMME,LYC_CHICK,LYC_CHICK,LYC_LOPCA)# & PIR1: (LZCH,LZUH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AMKRHGLDNYRGYSLGN*# SEQUENCE: AMKRHGLDNYRGYSLGN*# ...# >MUS23435# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (12-27)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_LOPCA,LYC_COLVI,LYC_CHICK,LYC_CHICK)# & PIR1: (LZQJEC,LZUH,LZCH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,MKRHGLDNYRGYSLGN*# SEQUENCE: MKRHGLDNYRGYSLGN*# ...# >MUS23436# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (13-27)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_NUMME,LYC_CHICK,LYC_CHICK,LYC_COLVI)# & PIR1: (LZQJEC,LZCH,LZUH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,KRHGLDNYRGYSLGN*# SEQUENCE: KRHGLDNYRGYSLGN*# ...# >MUS23437# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (14-27)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,RHGLDNYKGYSLGN*# SEQUENCE: RHGLDNYKGYSLGN*# ...# >MUS23438# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (15-27)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_COLVI,LYC_LOPCA,LYC_NUMME)# & PIR1: (LZUH,LZQJEC,LZCH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,HGLDNYRGYSLGN*# SEQUENCE: HGLDNYRGYSLGN*# ...# >MUS23439# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (9-26)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_LOPCA,LYC_NUMME,LYC_CHICK,LYC_CHICK)# & PIR1: (LZCH,LZUH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AAAMKRHGLDNYRGYSLG*# SEQUENCE: AAAMKRHGLDNYRGYSLG*# ...# >MUS2343A# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (9-25)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_LOPCA,LYC_CHICK,LYC_COLVI,LYC_CHICK)# & PIR1: (LZCH,LZQJEC,LZUH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AAAMKRHGLDNYRGYSL*# SEQUENCE: AAAMKRHGLDNYRGYSL*# ...# >MUS2343B# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (9-24)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_NUMME,LYC_CHICK,LYC_COLVI,LYC_CHICK)# & PIR1: (LZUH,LZCH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,AAAMKRHGLDNYRGYS*# SEQUENCE: AAAMKRHGLDNYRGYS*# ...# >MUS2343C# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (9-22)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPCA,LYC_NUMME,LYC_CHICK,LYC_COLVI)# & PIR1: (LZUH,LZQJEC,LZCH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AAAMKRHGLDNYRG*# SEQUENCE: AAAMKRHGLDNYRG*# ...# >MUS2343D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (9-21)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_CHICK,LYC_COLVI,LYC_CHICK,LYC_NUMME)# & PIR1: (LZQJEC,LZUH,LZCH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AAAMKRHGLDNYR*# SEQUENCE: AAAMKRHGLDNYR*# ...# >MUS2343E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (9-2O)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_NUMME,LYC_CHICK,LYC_COLVI,LYC_LOPCA)# & PIR1: (LZCH,LZUH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,AAAMKRHGLDNY*# SEQUENCE: AAAMKRHGLDNY*# ...# >MUS2343F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (9-19)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_NUMME,LYC_CHICK,LYC_LOPCA)# & PIR1: (LZCH,LZUH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,AAAMKRHGLDN*# SEQUENCE: AAAMKRHGLDN*# ...# >MUS23440# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: yes, little# BINDING: yes, high# SOURCE: HEL (12-23)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_NUMME,LYC_CHICK,LYC_LOPCA)# & PIR1: (LZCH,LZUH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesl,bindyesh,MKRHGLDNYRGY*# SEQUENCE: MKRHGLDNYRGY*# ...# >MUS23441# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: HEL (12-22)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_CHICK,LYC_CHICK,LYC_COLVI,LYC_LOPCA)# & PIR1: (LZQJEC,LZCH,LZUH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,MKRHGLDNYRG*# SEQUENCE: MKRHGLDNYRG*# ...# >MUS23442# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: yes, little# BINDING: yes, moderate# SOURCE: HEL (12-21)# DB REFERENCE: SWISS: (LYC_NUMME,LYC_CHICK,LYC_LOPCA,LYC_COLVI,LYC_CHICK)# & PIR1: (LZUH,LZCH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesl,bindyesm,MKRHGLDNYR*# SEQUENCE: MKRHGLDNYR*# ...# >MUS23443# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (12-20)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_COLVI,LYC_NUMME,LYC_CHICK,LYC_LOPCA)# & PIR1: (LZQJEC,LZCH,LZUH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,MKRHGLDNY*# SEQUENCE: MKRHGLDNY*# ...# >MUS23444# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (13-23)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_CHICK,LYC_CHICK,LYC_COLVI,LYC_NUMME)# & PIR1: (LZCH,LZUH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,KRHGLDNYRGY*# SEQUENCE: KRHGLDNYRGY*# ...# >MUS23445# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: HEL (13-22)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_CHICK,LYC_NUMME,LYC_LOPCA,LYC_COLVI)# & PIR1: (LZUH,LZCH,LZQJEC)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,KRHGLDNYRG*# SEQUENCE: KRHGLDNYRG*# ...# >MUS23446# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (13-21)# DB REFERENCE: SWISS: (LYC_COLVI,LYC_NUMME,LYC_CHICK,LYC_LOPCA,LYC_CHICK)# & PIR1: (LZCH,LZQJEC,LZUH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,KRHGLDNYR*# SEQUENCE: KRHGLDNYR*# ...# >MUS23447# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: HEL (14-22)# DB REFERENCE: SWISS: (LYC_LOPCA,LYC_CHICK,LYC_COLVI,LYC_NUMME,LYC_CHICK)# & PIR1: (LZQJEC,LZCH,LZUH)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,RHGLDNYRG*# SEQUENCE: RHGLDNYRG*# ...# >MUS23448# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,KAAALAAYA*# SEQUENCE: KAAALAAYA*# ...# >MUS23449# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,KAAAAAAYA*# SEQUENCE: KAAAAAAYA*# ...# >MUS2344A# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,AAAALAAYA*# SEQUENCE: AAAALAAYA*# ...# >MUS2344B# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,AAAAYAALA*# SEQUENCE: AAAAYAALA*# ...# >MUS2344C# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,AAALAAAYA*# SEQUENCE: AAALAAAYA*# ...# >MUS2344D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,AAAAALAYA*# SEQUENCE: AAAAALAYA*# ...# >MUS2344E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,AAAAALAAY*# SEQUENCE: AAAAALAAY*# ...# >MUS2344F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,AAAALAAY*# SEQUENCE: AAAALAAY*# ...# >MUS23450# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# DB REFERENCE: SWISS: (VSI2_TRYBB)# & PIR2: (S18447)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AAALAAYA*# SEQUENCE: AAALAAYA*# ...# >MUS23451# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,AAALAAYAA*# SEQUENCE: AAALAAYAA*# ...# >MUS23452# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,AALAAYAA*# SEQUENCE: AALAAYAA*# ...# >MUS23453# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala# DB REFERENCE: SWISS: (VSI2_TRYBB,HMCT_BOMMO,HMCT_BOMMO)# & PIR2: (S18447,S52093)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,AALAAYA*# SEQUENCE: AALAAYA*# ...# >MUS23454# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Poly-Ala# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,ALAAYAAAA*# SEQUENCE: ALAAYAAAA*# ...# >MUS23455# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (1-15)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,FVNQHLAGSHLVEAL*# SEQUENCE: FVNQHLAGSHLVEAL*# ...# >MUS23456# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human proinsulin (9-23)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,SHLVEALYLVAGERG*# SEQUENCE: SHLVEALYLVAGERG*# ...# >MUS23457# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (13-27)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,EALYLVAGERGFFYT*# SEQUENCE: EALYLVAGERGFFYT*# ...# >MUS23458# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human proinsulin (21-35)# DB REFERENCE: SWISS: (INS_HUMAN,INS_MACFA,INS_CERAE,INS_PANTR,INS_HUMAN)# & PIR1: (IPHU)# & PIR2: (A42179,JQ0178,B42179)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,ERGFFYTPKTRREAE*# SEQUENCE: ERGFFYTPKTRREAE*# ...# >MUS23459# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human proinsulin (25-39)# DB REFERENCE: SWISS: (INS_HUMAN,INS_PANTR,INS_HUMAN)# & PIR1: (IPHU)# & PIR2: (A42179)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,FYTPKTRREAEDLQV*# SEQUENCE: FYTPKTRREAEDLQV*# ...# >MUS2345A# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (29-43)# DB REFERENCE: SWISS: (INS_HUMAN,INS_AOTTR,INS_PANTR,INS_HUMAN)# & PIR1: (IPHU)# & PIR2: (A39883,A42179)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,KTRREAEDLQVGQVE*# SEQUENCE: KTRREAEDLQVGQVE*# ...# >MUS2345B# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (41-55)# DB REFERENCE: SWISS: (INS_CERAE,INS_HUMAN,INS_MACFA,INS_HUMAN,INS_PANTR)# & PIR1: (IPHU)# & PIR2: (JQ0178,B42179,A42179)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,QVELGGGPGAGSLQP*# SEQUENCE: QVELGGGPGAGSLQP*# ...# >MUS2345C# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, high# SOURCE: Human proinsulin (45-59)# DB REFERENCE: SWISS: (INS_CERAE,INS_HUMAN,INS_MACFA,INS_PANTR,INS_HUMAN)# & PIR1: (IPHU)# & PIR2: (JQ0178,A42179,B42179)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesh,GGGPGAGSLQPLALE*# SEQUENCE: GGGPGAGSLQPLALE*# ...# >MUS2345D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human proinsulin (49-63)# DB REFERENCE: SWISS: (INS_MACFA,INS_HUMAN,INS_CERAE,INS_HUMAN,INS_PANTR)# & PIR1: (IPHU)# & PIR2: (JQ0178,A42179,B42179)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,GAGSLQPLALEGSLQ*# SEQUENCE: GAGSLQPLALEGSLQ*# ...# >MUS2345E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (53-67)# DB REFERENCE: SWISS: (INS_CERAE,INS_HUMAN,INS_HUMAN,INS_PANTR,INS_MACFA)# & PIR1: (IPHU)# & PIR2: (JQ0178,B42179,A42179)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,LQPLALEGSLQKRGI*# SEQUENCE: LQPLALEGSLQKRGI*# ...# >MUS2345F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (57-71)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,ALEGSLQKRGIVEQA*# SEQUENCE: ALEGSLQKRGIVEQA*# ...# >MUS23460# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (61-75)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,SLQKRGIVEQAATSI*# SEQUENCE: SLQKRGIVEQAATSI*# ...# >MUS23461# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: Human proinsulin (65-79)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesm,RGIVEQAATSIASLY*# SEQUENCE: RGIVEQAATSIASLY*# ...# >MUS23462# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (69-83)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,EQAATSIASLYQLEN*# SEQUENCE: EQAATSIASLYQLEN*# ...# >MUS23463# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Competition# ACTIVITY: ?# BINDING: yes, little# SOURCE: Human proinsulin (73-86)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesl,TSIASLYQLENYAN*# SEQUENCE: TSIASLYQLENYAN*# ...# >MUS23464# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (9-29)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,AAAMKRHCLDITYRGYSLGNW*# SEQUENCE: AAAMKRHCLDITYRGYSLGNW*# ...# >MUS23465# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: HEL (90-104)# DB REFERENCE: SWISS: (LYC_CHICK,LYC_LOPLE,LYC_CHRAM,LYC_CHICK,LYC_PHACO)# & PIR1: (LZCH)# & PIR2: (JQ1033,JC2144)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,SVNCAKKIVSDGNGM*# SEQUENCE: SVNCAKKIVSDGNGM*# ...# >MUS23466# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: human GAD65 (509-528)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,IPPLRYLLDNEERMSRLSK*# SEQUENCE: IPPLRYLLDNEERMSRLSK*# ...# >MUS23467# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: yes, ?# BINDING: yes, ?# SOURCE: human GAD65 (247-266)# DB REFERENCE: SWISS: (DCE2_HUMAN)# & PIR1: (A41292)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actyesu,bindyesu,NMYAMMIARFKMFPEVKEKG*# SEQUENCE: NMYAMMIARFKMFPEVKEKG*# ...# >MUS23468# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse PLP (56-70)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,DYEYLINVIIIAFQYV*# SEQUENCE: DYEYLINVIIIAFQYV*# ...# >MUS23469# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse MBP (12-35)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,YAATASTMDHARHGFLPRHRDTGI*# SEQUENCE: YAATASTMDHARHGFLPRHRDTGI*# ...# >MUS2346A# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: Carboxypeptidase H (440-464)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,FSPAVDFELESFSERKEEEKEEL*# SEQUENCE: FSPAVDFELESFSERKEEEKEEL*# ...# >MUS2346B# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse myoglobin (131-153)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,MSKALELFRNDIAAKYKLGFQG*# SEQUENCE: MSKALELFRNDIAAKYKLGFQG*# ...# >MUS2346C# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse TCR Vbeta8.2 (38-60)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,DTGHGLRLITIYSYGAGSTEKGDI*# SEQUENCE: DTGHGLRLITIYSYGAGSTEKGDI*# ...# >MUS2346D# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse TCR Vbeta6 (38-60)# DB REFERENCE: SWISS: (TVB4_MOUSE)# & PIR1: (RWMSLB)# & PIR2: (H27577,I71939)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,DSGKGLRLIYYSITENDLQKGDL*# SEQUENCE: DSGKGLRLIYYSITENDLQKGDL*# ...# >MUS2346E# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse myoglobin (110-121)# DB REFERENCE: SWISS: (MYG_MOUSE,MYG_MOUSE)# & PIR1: (MYMS)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,IIIEVLKKRHSG*# SEQUENCE: IIIEVLKKRHSG*# ...# >MUS2346F# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse myoglobin (69-78)# DB REFERENCE: SWISS: (MYG_MOUSE,MYG_MOUSE)# & PIR1: (MYMS)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,LTALGTILKK*# SEQUENCE: LTALGTILKK*# ...# >MUS23470# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: ribosomal S30 peptide (75-96)# DB REFERENCE: SWISS: (RS30_HUMAN,RS30_HUMAN)# & PIR2: (I48346,JC1278,A47416)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,KVHGSLARAGKVRGQTPKVAKQ*# SEQUENCE: KVHGSLARAGKVRGQTPKVAKQ*# ...# >MUS23471# MHC MOLECULE: I-Ag7, CLASS-2, (MOUSE)# METHOD: Reference# ACTIVITY: ?# BINDING: yes, ?# SOURCE: mouse MOG (35-55)# ANCHOR POSITIONS: ?# REFERENCES: harrison97a# COMMENT:# SUMMARY: I-Ag7,actunkn,bindyesu,MEVGWYRSPFSRVVHLVRNGK*# SEQUENCE: MEVGWYRSPFSRVVHLVRNGK*# ...# >HUM13472# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum CS (368-375)# DB REFERENCE: SWISS: (CSP_PLAFA,CSP_PLAFT,CSP_PLAFO)# & PIR1: (OZZQAF)# & PIR2: (S05428,A38869,A54533,C60657,B60657)# ANCHOR POSITIONS: ?# REFERENCES: udhayakumar97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,KPKDELDY*# SEQUENCE: KPKDELDY*# ...# >HUM13473# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum CS (368-375)# ANCHOR POSITIONS: ?# REFERENCES: udhayakumar97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,KPKDELNY*# SEQUENCE: KPKDELNY*# ...# >HUM13474# MHC MOLECULE: HLA-B35, CLASS-1, (HUMAN)# METHOD: CTL assays# ACTIVITY: ?# BINDING: yes, ?# SOURCE: P. falciparum CS (368-375)# ANCHOR POSITIONS: ?# REFERENCES: udhayakumar97a# COMMENT:# SUMMARY: HLA-B35,actunkn,bindyesu,KPKDQLGY*# SEQUENCE: KPKDQLGY*# ...# >HUM13475# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/Stabilization/Recognition# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Melan-A/MART-1 (26-35) homologue# ANCHOR POSITIONS: ?# REFERENCES: romero97a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,YAAGIGILTV*# SEQUENCE: YAAGIGILTV*# ...# >HUM13476# MHC MOLECULE: HLA-A2(A*0201), CLASS-1, (HUMAN)# METHOD: Competition/Stabilization/Recognition# ACTIVITY: yes, high# BINDING: yes, moderate# SOURCE: Melan-A/MART-1 (26-35) homologue# ANCHOR POSITIONS: ?# REFERENCES: romero97a# COMMENT:# SUMMARY: HLA-A2,actyesh,bindyesm,FAAGIGILTV*# SEQUENCE: FAAGIGILTV*# ...# >MUS13477# MHC MOLECULE: H-2Db, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: SV (493-501)# DB REFERENCE: SWISS: (TALA_POVHA,TALA_POVM3,TALA_SV40,TALA_POVMC)# & PIR3: (PH1377,PH1378)# ANCHOR POSITIONS: ?# REFERENCES: alsheikly94a# COMMENT:# SUMMARY: H-2Db,actunkn,bindyesm,NLDNLRDYL*# SEQUENCE: NLDNLRDYL*# ...# >MUS13478# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: SV (206-214)# DB REFERENCE: SWISS: (TALA_SV40)# ANCHOR POSITIONS: ?# REFERENCES: alsheikly94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,SAINNYAQK*# SEQUENCE: SAINNYAQK*# ...# >MUS13479# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, moderate# SOURCE: SV (223-231)# DB REFERENCE: SWISS: (TALA_SV40,TALA_POVBA,TALA_POVBK,TALA_POVJC)# ANCHOR POSITIONS: ?# REFERENCES: alsheikly94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesm,CKGVNKEYL*# SEQUENCE: CKGVNKEYL*# ...# >MUS1347A# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: SV (489-497)# DB REFERENCE: SWISS: (TALA_SV40,TALA_POVMK)# & PIR3: (PH1377)# ANCHOR POSITIONS: ?# REFERENCES: alsheikly94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,QGINNLDNL*# SEQUENCE: QGINNLDNL*# ...# >MUS1347B# MHC MOLECULE: H-2Kb, CLASS-1, (MOUSE)# METHOD: Stabilization# ACTIVITY: ?# BINDING: yes, little# SOURCE: SV (492-500)# DB REFERENCE: SWISS: (TALA_SV40,TALA_POVHA)# ANCHOR POSITIONS: ?# REFERENCES: alsheikly94a# COMMENT:# SUMMARY: H-2Kb,actunkn,bindyesl,NNLDNLRDY*# SEQUENCE: NNLDNLRDY*# ...# >MUS2347C# MHC MOLECULE: H-2d, CLASS-2, (MOUSE)# METHOD: In vivo response# ACTIVITY: yes, moderate# BINDING: yes, ?# SOURCE: Measles virus fusion protein MV-F (91-105)# DB REFERENCE: SWISS: (VGLF_MEASE,VGLF_MEASA)# & PIR1: (E48556,VGNZMV)# ANCHOR POSITIONS: ?# REFERENCES: muller95a# COMMENT:# SUMMARY: H-2d,actyesm,bindyesu,LNAMTQNIRPVQSVA*# SEQUENCE: LNAMTQNIRPVQSVA*# ...#